https://www.biopharmawatch.com/news/AZTR/azitra-announces-q3-2025-results-business-updates2025-11-12T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-q3-2025-financial-results-update2025-11-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-phase-2-trial-results2025-10-20T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-positive-data-phase-1-2-trial-ide397-trodelvy2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-hengrui-positive-phase-1-data-ide849-sclc2025-09-07T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-q3-2025-results-novartis-merger2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-2025-financial-guidance-and-reports-results2025-08-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-q1-2025-financial-results2025-05-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-phase-2-trial-lti-03-ipf2025-10-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q3-2025-financial-results-update2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-q3-20252025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q3-2025-financial-results2025-11-06T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-q3-2025-financial-results2025-11-10T21:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-jefferies-global-healthcare-conference-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-investor-conferences-20252025-08-20T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-bge-102-phase-1-trial-obesity2025-08-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-preclinical-data-apj-agonism-diabetic-obesity2025-06-21T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-expands-drug-discovery-platform2025-06-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-business-update-progress-h1-20252025-08-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-year-end-2024-financial-results2025-04-07T21:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-research-annamycin-pancreatic-cancer2025-11-12T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-phase-3-miracle-trial-acute-leukemia-meeting2025-10-30T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-expands-global-ip-portfolio-anamycin-patent2025-10-29T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-canadian-patent-annamycin2025-09-25T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-eu-patient-phase-3-miracle-trial-aml2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-warrant-exercise-6-million2025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-positive-aml-survival-data2025-08-27T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-webull-financial-webinar2025-08-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-q3-2025-results-update2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-investor-conference-participation2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-inducement-grants-nasdaq-rule-56352025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-q3-2025-results2025-11-04T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-second-milestone-payment-kyowa-kirin2025-11-03T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-kyowa-ash-2025-ziftomenib-data-presentation2025-11-03T14:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-30-million-milestone-ziftomenib-aml2025-10-24T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-esmo-2025-data2025-10-18T07:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-kyowa-kin-launch-clinical-trial-aml2025-10-01T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-q3-2025-results-share-repurchase2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-positive-topline-phase-1-2-results-shingles-vaccine2025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-q2-2025-financial-results2025-08-07T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-q1-2025-results-update2025-05-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-reschedules-q1-2025-results-release-and-call2025-05-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q3-2025-results2025-10-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-q3-2025-financial-results-business-update2025-11-06T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-leadership-transition-plan2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fda-pdufa-date-lnth-2501-pet-imaging-kit2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fda-acceptance-mk-6240-alzheimers-imaging-agent2025-10-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-third-quarter-2025-earnings-call2025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-ge-healthcare-licensing-agreement-pylaryfiy-japan2025-09-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-morgan-stanley-healthcare-conference-20252025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fda-acceptance-nda-psma-pet-imaging-agent2025-08-06T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-ptk7-target-aacr-nci-eortc2025-10-24T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-reports-q1-2025-financial-results2025-05-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-third-quarter-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-preliminary-q2-2025-results2025-01-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-q2-2025-financial-results2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-q3-2025-update2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-investor-conferences-20252025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-arid1b-cbp-ep300-updates2025-10-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-arid1b-degrader-progress-summit2025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-citizens-life-sciences-conference2025-05-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-board-appointments2025-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-q1-2025-results-ayvakit-guidance2025-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-q4-2024-results2025-02-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-2025-outlook-growth-strategy2025-01-12T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-third-quarter-2025-results-update2025-11-13T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-q3-2025-financial-results-business-update2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-presentation-hc-wainwright-conference2025-08-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-acquisition-novartis-q1-2025-results2025-05-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-q3-2025-financial-results2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-denifanstat-posters-aasld-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/denifanstat-phase-3-acne-trial-results-china2025-10-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-investor-conferences-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-aasld-2025-presentation2025-10-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-phase-1-trial-denifanstat-resmetirom2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-fierce-biotech-week-panel2025-09-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/positive-phase-3-results-denifanstat-acne-eadv-20252025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-mash-summit-20252025-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-first-quarter-results-20252025-05-13T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-closes-public-offering-senior-notes2025-09-29T12:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-pricing-euro-1-5-billion-senior-notes2025-09-15T21:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-q3-2025-financial-results2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/transcon-pth-renal-function-improvements-hypoparathyroidism2025-11-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-submits-maa-transcon-cnp-achondroplasia2025-10-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-endocrinology-rare-disease-data-asbmr-20252025-09-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-2025-wells-fargo-conference2025-08-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/fda-approves-skytrofa-growth-hormone-deficiency2025-07-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-ks101-apex-study-week-20-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-ksi-101-apex-study-results2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q2-2025-results-highlights2025-08-13T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-first-patient-arcevo-lsa-artizen-trial2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-participate-stifel-2025-healthcare-conference2025-10-29T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-q3-2025-financial-results-teleconference2025-10-23T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-amds-persevere-protect-trials-eacts-presentation2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-participate-morgan-stanley-healthcare-conference2025-09-05T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-participate-upcoming-investor-conferences2025-07-30T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-new-executive-committee-members-leadership-expansion2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-us-government-obesity-medicines-access2025-11-06T18:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-eloralintide-phase-2-results-weight-loss2025-11-06T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-new-european-manufacturing-facility2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-q3-2025-financial-results2025-10-30T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-inversion-puerto-rico-capacidad-manufactura2025-10-29T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-invests-1-2-billion-puerto-rico-manufacturing2025-10-29T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-q3-2025-financial-results2025-11-05T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-q3-2025-results-corporate-update2025-11-06T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-q3-2025-results-and-progress2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-financing-support-growth-sentry-trial2025-10-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2025-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-q3-2025-financial-results2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-data-asds-20252025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-q3-2025-financial-results2025-10-31T11:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-phase-3-results-upadacitinib-vitiligo2025-10-29T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-superiority-humira-rheumatoid-arthritis-study2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-acquires-gilgamesh-bretisilocin2025-10-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-updated-indication-rinvoq2025-10-13T14:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-esmo-2025-targeted-therapies2025-10-13T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-q3-2025-financial-results-merger-divestment-plan2025-10-16T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-second-quarter-2025-financial-results2025-08-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-first-quarter-2025-results-divestment-plan2025-05-15T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q3-2025-financial-results2025-11-06T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q1-2025-financial-results-update2025-04-30T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-q3-2025-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-presents-ap-sa02-idweek-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-q3-2025-results2025-11-05T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-appoints-core-ir-for-investor-relations2025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-us-patent-endoxifen-formulations2025-04-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-smart-2-0-study-breast-cancer2025-04-29T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-2024-financial-results-update2025-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fourth-quarter-2024-results2025-03-20T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-metastatic-breast-cancer-endoxifen2025-03-11T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-congratulates-dr-tessa-cigler-cdc-grant2025-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-responds-ptab-ruling-patent-issuance2025-01-30T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-2024-accomplishments-outlook-20252025-01-23T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-abstracts-z-endoxifen-sabcs-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-q3-2025-financial-results-updates2025-11-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-participate-d-boral-conference2025-05-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-q1-2025-financial-results2025-05-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-q1-2025-earnings-release-webcast2025-04-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-fireside-chat-november-20252025-10-30T17:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-q1-fy2026-results-corporate-update2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-investor-conferences-2025-ash2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-update-q3-2025-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-cln-049-ash-20252025-11-03T14:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-cln-978-preclinical-data-acr-20252025-10-25T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-fireside-chat-stifel-2025-forum2025-09-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-licenses-velinotamig-autoimmune-diseases2025-06-04T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-2025-asco-jefferies-conference2025-05-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-taiho-positive-results-rezilient1-trial2025-05-22T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-first-half-2025-results2025-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-phase-2-study-opaganib-darolutamide2025-07-01T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-reports-record-q3-2025-results-im8-growth2025-11-10T12:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q3-2025-financial-results-earnings-call2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-record-revenue-october-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-acquires-100-bitcoin-im8-reaches-100m-arr2025-10-31T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-dual-engine-revolution-manifesto2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-closes-44-million-equity-offering2025-10-28T18:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-48-million-equity-offering-im8-expansion2025-10-27T14:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-global-limited-public-offering2025-10-25T00:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-launches-daily-ultimate-longevity-supplement2025-10-08T12:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-q3-2025-results-financial-guidance2025-11-06T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q3-2025-results-business-updates2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-presentation-td-cowen-summit2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-september-2025-investor-conferences2025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-closes-underwriters-option2025-08-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-public-offering-pricing2025-08-07T03:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-public-offering-20252025-08-06T20:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-hypoimmune-modified-islet-cells2025-08-04T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-positive-results-type-1-diabetes2025-06-23T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-ada-scientific-sessions-20252025-06-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-q3-2025-financial-results-highlights-milestones2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-jefferies-2025-london-healthcare-conference2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-100-million-offering-common-stock2025-11-06T11:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-positive-data-phase-1-2-prism-trial-wet-amd2025-11-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-licensing-agreement-otsuka-pharmaceutical2025-10-31T03:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-employment-inducement-grants2025-10-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-chardan-genetic-medicines-conference2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-advances-4d-710-phase-2-funding-cystic-fibrosis-foundation2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-leadership-expansion-bla-readiness2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-felzartamab-asn-kidney-week-20252025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/health-canada-authorization-leqembi-lecanemab2025-10-26T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-licenses-c5ar1-antagonist-vanqua-bio2025-10-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-dapirolizumab-pegol-acr-convergence-20252025-10-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-iqlik-best-inventions-20252025-10-13T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stoke-new-data-zorevunersen-dravet-syndrome2025-10-09T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-iqlik-launch-alzheimers-treatment2025-10-06T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-iv-maintenance-dosing-china2025-09-28T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-alzheimers-treatment-australia2025-09-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-regulatory-update-nusinersen-high-dose-regimen2025-09-23T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reschedules-q2-2025-results-release2025-08-13T22:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-fast-track-nrx-1002025-08-11T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-nrxp-dura-medical-acquisition-clearance2025-08-08T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-citizen-petition-benzethonium-chloride2025-08-04T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fireside-chat-btig-conference-20252025-07-29T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-nrxp-acquires-cohen-associates2025-06-26T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-files-cnpv-application-nrx-1002025-06-23T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-investor-partnership2025-06-16T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-hc-wainwright-conference2025-06-12T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-files-anda-preservative-free-ketamine2025-06-05T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-q3-2025-results-guidance-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-third-quarter-2025-earnings-call2025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-investor-conferences-september-20252025-08-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-q1-2025-results2025-05-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-needham-healthcare-conference-20252025-03-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-participate-keybanc-healthcare-forum2025-03-07T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-fourth-quarter-2024-results-guidance2025-02-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-present-investor-conferences2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-first-quarter-fiscal-2026-results2025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-nov-20252025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-conference-call-november-20252025-10-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-q3-2025-financial-results2025-11-10T11:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-q3-2025-results-corporate-update2025-11-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-revenue-growth2025-11-04T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q3-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-2101-abstracts-aes-20252025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-third-quarter-financial-results-november-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/medicare-advantage-plan-rewalk-7-exoskeleton2025-09-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ce-mark-approval-rewalk-7-exoskeleton2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ltd-q2-2025-financial-results2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-appoints-almog-adar-cfo2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-expands-distribution-partnership-uae-gcc2025-08-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-closes-2-6-million-public-offering2025-06-26T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-2-6-million-public-offering2025-06-25T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-exoskeleton-medicare-coverage2025-06-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-q3-2025-financial-results2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-q1-2025-financial-results2025-05-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-q3-2025-results-business-update2025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-ceo-transition-plan-growth2025-11-05T11:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-participate-investor-conferences2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-report-q2-2025-results-august-52025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-acquires-rev102-enpp1-inhibitor-hpp2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/mit-recursion-boltz-2-ai-model-binding-affinity2025-06-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/duncan-regional-hospital-bd-alaris-emr-interoperability2025-11-13T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-purewick-portable-solution-urinary-incontinence2025-11-12T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-fiscal-2025-financial-results2025-11-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-dividend-increase-54th-year2025-11-06T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-agility-study-revello-stent-pad2025-11-04T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-fda-clearance-ce-certification-enteric-panels2025-11-03T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-simplifies-at-home-hpv-testing2025-10-22T10:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-enabled-solutions-healthcare2025-10-20T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-manufacturing-excellence-broken-bow-anniversary2025-10-16T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-cfo-transition-plan2025-10-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-alphaledger-t12-fund-investment2025-10-29T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-update-ptsd-drug-development2025-10-23T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-bitcoin-purchase-strategic-growth2025-10-08T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-acquires-researchcoin-support-decentralized-science2025-10-06T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-closes-2-5-million-offering2025-10-01T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-fireblocks-strategic-agreement2025-09-29T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-cryptocurrency-treasury-strategy2025-09-16T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-japanese-patent-ptsd-drug2025-09-09T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-inducement-awards2025-11-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-q3-2025-financial-results-update2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-positive-phase-1-results-spy0032025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-upcoming-investor-conferences-november-20252025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-acr-convergence-20252025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-public-offering-316-million2025-10-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-public-offering-pricing2025-10-14T01:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-public-offering-common-stock2025-10-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-poster-presentations-uegw-20252025-10-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q2-2025-financial-results2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-third-quarter-2025-financial-results2025-11-05T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/hifi-solves-consortium-publishes-study-pacbio2025-11-05T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-berry-genomics-regulatory-approval-china2025-11-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-revio-vega-advancements-lower-genome-cost2025-10-14T10:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-hifi-technology-south-korea-pangenome-project2025-10-13T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-hifi-sequencing-longevity-study2025-10-08T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-expands-partnership-seqwell-long-read-sample-prep2025-10-07T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-high-throughput-carrier-screening-assay2025-09-22T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-epicypher-partner-fiber-seq-workflow2025-09-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-regulatory-clearance-art100-uae2025-11-06T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-bites-ai-strategic-alliance2025-10-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-appoints-new-vp-and-board-member2025-10-21T19:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-h1-2025-results-business-update2025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-hyla-blood-sensor-us-elsoconference2025-09-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-hyla-blood-sensor-fda-submission2025-09-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspiratechnologies-expands-art100-lung-transplant2025-09-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-patent-approval-art500-technology2025-08-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-secures-27-million-order-art100-systems2025-08-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-q3-2025-results-update2025-11-13T02:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-snda-fda-filspari-fsgs2025-03-17T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-inducement-grants-nasdaq-rule-56352025-03-12T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-investor-conferences-march-20252025-02-24T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-q4-2024-financial-results2025-02-20T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-2025-outlook-update2025-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-jp-morgan-conference-20252025-01-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-ipo-submission-aspi2025-11-12T22:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-private-placement-convertible-notes2025-11-07T14:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-quantum-leap-energy-engagement-uk-regulators2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-acquires-one-30-seven-assets2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-public-offering-pricing2025-10-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-business-updates-october-20252025-10-13T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-institutional-investor-event-south-africa-20252025-10-10T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-purchase-order-enriched-barium-1372025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-executive-management-changes-october-20252025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-financial-results-q2-20252025-05-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-annual-general-meeting-results2025-03-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q2-2025-financial-results2025-08-08T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q1-2025-financial-results2025-05-06T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-reports-fiscal-q3-2025-results2025-08-12T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-q3-2025-results2025-11-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-q3-2025-results-update2025-11-05T21:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-biospace-best-places-to-work2025-11-04T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-jefferies-conference-20252025-11-03T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-scientific-conferences-20252025-10-09T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-share-repurchase-program2025-10-01T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-investor-conferences-20252025-08-28T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-settlement-firdapse-patent-litigation2025-08-26T23:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-modeyso-h3-k27m-glioma-sno-20252025-11-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-q3-2025-financial-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/fda-approves-zepzelca-atezolizumab-combination-therapy2025-10-02T22:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-phase-4-data-xywav2025-09-22T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-q2-2025-financial-results2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-q3-2025-financial-results2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-annual-meeting-results-20252025-08-11T20:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-q2-results-pelareorep-plans2025-08-08T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-jefferies-global-healthcare-conference-20252025-11-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/fda-accepts-biomarin-palynziq-adolescents-pku2025-10-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-third-quarter-2025-results-update2025-10-27T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-q3-2025-financial-results-call2025-10-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-voxzogo-bone-health-asbmr-20252025-09-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-positive-phase-3-data-palynziq-adolescents-pku2025-09-06T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-participate-investor-conferences-september2025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-reports-strong-q2-2025-results2025-08-04T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-ian-clark-board-directors2025-08-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-2025-revenue-surges-703-percent2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q3-2025-financial-results2025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-rezolve-ad-phase-2b-study-20252025-09-18T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-cld-401-sitc-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-investor-event-sitc-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-scientific-advisory-board-cld-4012025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-oncology-summit-boston2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-public-offering-august-20252025-08-21T22:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-public-offering-pricing2025-08-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q2-2025-results2025-08-08T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-fda-fast-track-cld-201-sarcoma2025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q4-full-year-2024-results2025-03-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-q2-2025-results-bausch-acquisition-update2025-08-12T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-reports-q1-2025-results-business-update2025-05-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-q4-2024-financial-results2025-03-19T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-presentation-oppenheimer-conference-20252025-02-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-q3-2025-results2025-10-23T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-q2-2025-results-dividend-guidance-update2025-07-24T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-pipeline-progress-q3-2025-results2025-10-30T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-reports-third-quarter-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/storm-pe-trial-results-cavt-anticoagulation2025-11-03T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/storm-pe-trial-cavt-superior-anticoagulation2025-10-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-investor-conferences-20252025-08-20T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-presents-canaccord-genuity-conference-20252025-07-30T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-storm-pe-trial-enrollment-completion2025-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-q3-2025-financial-results2025-11-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-q2-2025-financial-results2025-08-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-q3-2025-financial-results2025-11-12T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-q3-2025-financial-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q3-2025-financial-results2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-tender-offer-repurchase-shares2025-10-20T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-capital-return-plan2025-10-15T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-ker-065-asbmr-20252025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-healthcare-conferences-20252025-08-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-fda-orphan-drug-designation-ker-065-dmd2025-08-20T13:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-prioritizes-clinical-advancement-of-ker-0652025-08-06T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-phase-3-renew-trial-elritercept2025-07-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-return-375-million-excess-capital-stockholders2025-06-09T10:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-third-quarter-2025-financial-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/imprimisrx-leadership-changes-hrow2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-acquire-melt-pharmaceuticals2025-09-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-access-for-all-launch2025-09-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-investor-analyst-day-agenda-september-20252025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-pricing-250-million-offering-senior-notes2025-09-08T21:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-presents-hc-wainwright-ophthalmology-conference2025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-hybrite-ctcl-therapy-advancement2025-08-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-hybrite-ctcl-treatment2025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-dr-ellen-kim-hybrite-clinical-trials2025-06-06T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-postpones-earnings-release-audit2025-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-report-q4-full-year-2024-results2025-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-strengthens-balance-sheet-warrants-exercise2025-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-strengthens-balance-sheet-rights-offering2025-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-expands-dubai-sales-subsidiary2025-01-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-q1-2025-results-business-updates2025-05-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-q3-2025-financial-results2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-ash-2025-presentations2025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-xyngari-phase-3-trial-results2025-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-jefferies-london-healthcare-conference2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-cantor-global-healthcare-conference2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q3-results-business-update2025-11-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q2-2025-financial-results-conference-call2025-07-24T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-fiscal-2026-first-quarter-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-q3-2025-results2025-10-22T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-cfo-dan-brennan-retires-jon-monson-succeeds2025-04-23T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-new-ceo-noam-band2025-04-07T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-reports-q2-2025-financial-results2025-08-08T10:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-second-quarter-2025-results-announcement2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/serb-pharmaceuticals-acquires-y-mabs-therapeutics2025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-virtual-radiopharmaceutical-rd-update2025-05-28T10:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-gd2-sada-prit-trial-poster-anr-meeting2025-05-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-virtual-radiopharmaceutical-rd-update-may-20252025-05-13T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/naxitamab-danyelza-nccn-guidelines-update2025-05-07T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-presents-cd38-sada-aacr-20252025-04-27T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-closes-1-1-million-offering2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-registered-direct-offering2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-nasdaq-extension-compliance-notice2025-10-21T00:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-acquires-renal-anti-fibrotic-program-vectus2025-10-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-investor-webinar-september-20252025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-initiates-ind-preparation-xorlo-gout-program2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-completes-private-placement-1145002025-08-08T23:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-corporate-update-2025-20262025-08-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-completes-private-placement-units2025-07-22T23:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-third-quarter-conference-call-november-20252025-10-08T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-aldo-denti-cco2025-10-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-retains-wellspect-healthcare2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-participate-investor-conferences2025-08-26T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-daniel-scavilla-ceo2025-07-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-prices-550-million-junior-subordinated-notes2025-06-05T21:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-matthew-garth-cfo2025-05-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q3-2025-results2025-10-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/ingrezza-post-hoc-analysis-tardive-dyskinesia-remission2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-osavampator-phase-2-study-results2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-reports-q3-2025-results2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-lava-amendment-purchase-agreement2025-10-17T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-extends-tender-offer-lava-therapeutics2025-10-02T20:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends2025-09-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-closes-tender-offer-hillevax2025-09-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-presentation-hc-wainwright-conference2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/mural-oncology-acquisition-xoma-royalty2025-08-20T12:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-closing-tender-offer-turnstone-biologics2025-08-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-lava-therapeutics-agreement2025-08-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-distribution-agreement-tianjin-merrill-youli2025-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-share-repurchase-program-1-million2025-06-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-launch-tea-pigment-health-products2025-05-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-launch-postbiotic-hypoglycemic-ingredient-series2025-05-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-reverse-stock-split2025-05-15T10:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-launches-broccoli-derived-sleep-health-products2025-05-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-nasdaq-delisting-notifications2025-05-02T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-apple-polyphenol-commercial-order2025-04-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-broccoli-nutritional-power-delivery-system2025-04-08T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-breakthrough-bio-manufacturing-tea-pigments2025-04-07T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-pipeline-business-updates-q3-20252025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-phase-2-data-vilastobart-sitc-20252025-11-07T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-sitc-40th-annual-meeting2025-11-07T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-inducement-grants-nasdaq-rule-56352025-11-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-sitc-2025-presentations2025-10-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-phase-2-trial-efarindodekin-alfa2025-09-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-guggenheim-healthcare-conference-20252025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-q3-2025-financial-results-update2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-public-offering-155-million2025-10-27T23:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-135-million-offering2025-10-24T04:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-public-offering-mavorixafor2025-10-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-restructuring-business-operations2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-08-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-85-million-private-placement2025-08-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-60-million-financing-management-changes2025-08-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-positive-phase-2-trial-data-eha2025-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-q2-2025-results-update2025-11-12T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-q1-2025-results-update2025-08-13T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-reports-q3-2025-financial-results2025-11-07T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/burixafor-clinical-data-ash-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-burixafor-phase-2-trial-update2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-present-upcoming-investor-conferences2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-reports-q3-2025-results-business-update2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-report-q3-2025-financial-results2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-appoints-tucker-kelly-cfo2025-10-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-10-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-investor-webinar-early-stage-ion-channel-programs2025-09-25T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fiscal-q2-2026-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-secures-32-million-growth2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-schedules-q2-2026-financial-results-call2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-participate-roth-healthcare-conference2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-exercise-warrants-3-25-million2025-09-08T19:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/neuronos-fda-orphan-drug-designation-glioblastoma2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-hc-wainwright-conference-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-lungfit-ph-distribution-agreements-japan2025-08-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q3-2025-financial-results-update2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-investor-conferences-november-20252025-11-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-lifesciences-wve-007-obesity-preclinical-data2025-11-05T01:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-positive-data-inlight-trial-wve-0072025-10-30T02:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-research-day-october-20252025-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-lifesci-positive-update-restoration-2-trial-wve-0062025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q2-2025-financial-results-webcast2025-07-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-gempharmatech-service-contract2025-11-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-investment-neologics-bioscience2025-10-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-reverse-stock-split-october-20252025-10-16T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-delisting-nasdaq2025-10-14T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-nasdaq-compliance-extension2025-10-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-offering2025-09-25T17:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-partners-hong-kong-web3-standardization2025-09-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-partners-wuxi-hospital-ai-healthcare2025-09-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-closes-offering2025-05-22T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-offering-pricing2025-05-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-epic-study-imaavy-gmg2025-10-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/psoriasis-unmet-needs-oral-treatments2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-crohns-disease-remission2025-10-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-phase-2b-results-ulcerative-colitis2025-10-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-sjogren-disease-phase-2-results2025-10-24T22:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-long-term-results-psoriasis2025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/subcutaneous-amivantamab-head-neck-cancer-results2025-10-19T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-q3-2025-results-business-update2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-phase-2b-trial-repibresib-results2025-07-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-vyn202-program-update2025-07-02T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-update-vyn202-program2025-04-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-hc-wainwright-conference-20252025-03-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-march-investor-conferences2025-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-phase-1b-trial-vyn202-plaque-psoriasis2025-02-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-ce-mark-locket2025-05-27T13:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-engages-pcg-advisory-investor-relations2025-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-special-meeting-adjournment-20252025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-nasdaq-extension-compliance2025-08-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-q3-2025-results2025-11-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/transition-bio-voyager-collaboration-tdp-43-als-ftd2025-11-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-investor-conferences2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-alzheimers-program-apoe-targeting2025-07-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-presents-hc-wainwright-neuro-perspectives-conference2025-06-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-alpl-blood-brain-barrier-aav-capsids2025-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-next-generation-cns-capsids-asgct-20252025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-preclinical-data-tau-targeting-gene-therapy2025-03-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-clinical-data-adhd-improvement2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-clinical-trial-results-pediatric-osa2025-09-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-q2-2025-financial-results-update2025-08-19T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-q2-2025-financial-results2025-08-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-management-expansion-growth2025-07-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-medicare-approval-vidasleep2025-07-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-acquisition-sleep-center-nevada2025-06-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-q3-2025-financial-results-update2025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-new-scientific-advisory-board-appointments2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-innodia-symposium-easd-20252025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-september-investor-conferences2025-09-03T20:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-80-million-private-placement2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtvt-uspto-allowance-cadisegliatin-patent2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-catt1-phase-3-trial-cadisegliatin2025-08-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-hcw-home-series-20252025-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-appoints-cfo-reinitiates-phase-3-trial2025-05-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-q3-2025-results2025-11-06T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-phase-2-study-results-vtx32322025-10-22T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-investor-conferences-20252025-08-27T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-positive-phase-2a-results-vtx3232-parkinsons2025-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-jefferies-global-healthcare-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-expands-sab-nlrp3-experts2025-04-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-phase-2-trial-vtx958-crohns-disease2025-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-acquisition-msd-approved-high-court2025-10-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-merck-acquisition-approval2025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-phase-3-enhance-studies-ers-congress-20252025-09-16T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-june-2025-investor-conference2025-05-21T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-q1-2025-financial-results-update2025-04-29T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-amended-financing-oaktree-omerset2025-03-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-public-offering-100-million2025-11-11T02:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/telitacicept-phase-3-study-iga-nephropathy2025-11-08T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-participate-investor-conferences2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-jeremy-sokolove-cmo2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-inducement-grants-nasdaq-rule-5635c42025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/telitacicept-phase-3-gmg-data2025-10-29T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-webcast-phase-3-telitacicept-data-sjogrens2025-10-22T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-phase-3-iga-nephropathy-study-asn-20252025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-telitacicept-phase-3-study-lupus2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-phase-2-vp-315-basal-cell-carcinoma-data2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-positive-feedback-ema-approval-ycanth-eu2025-10-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-approval-ycanth-japan2025-09-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-hc-wainwright-conference-20252025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q2-2025-financial-results2025-08-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-strong-growth-ycanth-q2-20252025-07-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-amendment-collaboration-license-agreement-torii2025-07-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-jefferies-conference-20252025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-delisting-nasdaq2025-04-17T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-termination-merger-wind-down2025-04-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-business-update-q4-2024-results2025-03-27T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-qumulusai-merger-intent2025-03-18T12:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reverse-merger-termination-strategic-alternatives2025-02-28T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-oqory-promising-data-oqy-32582025-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reverse-stock-split2025-01-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-iluzanebart-phase-2-update-alsp2025-06-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-merger-agreement-sanofi2025-05-21T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-q1-2025-results-updates2025-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-vg-3927-ad-pd-20252025-04-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-stifel-2025-cns-forum2025-03-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-guggenheim-conference-20252025-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-vg-3927-phase-1-trial-results2025-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-2024-achievements-2025-milestones2025-01-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-abstracts-obesityweek-20252025-10-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-pricing-public-offering2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-proposed-public-offering2025-10-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fda-meeting-enobosarm-regulatory-clarity-obesity2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2025-third-quarter-results2025-08-12T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-enobosarm-chronic-weight-loss-management2025-08-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-reverse-stock-split2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-2025-q3-results-conference-call2025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-participate-2025-btig-virtual-biotech-conference2025-07-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-positive-results-phase-2b-quality-study2025-06-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-third-quarter-2025-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-debt-equity-exchange2025-10-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-q3-2025-financial-results-release2025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-closes-3-45-million-offering2025-06-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-3-45-million-offering-nasdaq2025-06-06T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-sells-hair-business-20-million2025-06-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-td-cowen-summit-20252025-11-10T12:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-atacicept-fda-application-iga-nephropathy2025-11-07T23:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inducement-grants-nasdaq-rule-56352025-11-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-origins-phase-3-data-atacicept-igan2025-11-06T14:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-q3-2025-results2025-11-05T12:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-investor-call-origins-update-november-20252025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-origins-atacicept-asn-kidney-week-20252025-10-17T13:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-investor-conferences-20252025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-pepinemab-immunotherapy-head-neck-cancer-asco-20252025-05-27T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-report-clinical-data-pepinemab-aacr-20252025-04-21T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-delists-common-stock-nasdaq2025-03-07T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-q3-2025-financial-results2025-11-06T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-presents-wells-fargo-healthcare-conference-20252025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-second-quarter-2025-financial-results2025-07-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-truist-securities-medtech-conference-20252025-06-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-q1-2025-results-profitability-guidance2025-05-08T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-presents-bank-america-healthcare-conference-20252025-05-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-upcoming-investor-conferences2025-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-merger-cara-therapeutics2025-04-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-business-update-q3-2025-results2025-11-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-closes-common-stock-offering2025-10-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-common-stock-offering-pricing2025-10-26T23:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-presentation-thinkequity-conference-20252025-10-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-withdraws-cortigent-spin-off-date2025-10-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-emerging-growth-conference-20252025-09-24T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-spin-off-cortigent-neuromodulation2025-09-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-npm-139-semaglutide-implant-update2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-ceo-presentation-hc-wainwright-conference2025-08-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-business-update-equity-financing-q2-20252025-08-13T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-positive-phase-1-results-zika-vaccine2025-11-04T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-phase-1-trial-zika-vaccine-results2025-11-04T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investor-conferences-us-europe2025-10-27T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investor-meetings-healthcare-conferences2025-10-27T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-refinances-debt-pharmakon-advisors2025-10-06T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-refinances-debt-pharmakon-advisors-business-updates2025-10-06T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-q3-2025-financial-results-zusduri-launch2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-phase-3-utopia-trial-results-ugm-1032025-11-06T12:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-guggenheim-conference-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-third-quarter-2025-results2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/cms-assigns-j-code-for-zusduri-20262025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/zusduri-clinical-review-bladder-cancer2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-inducement-grants-nasdaq-rule-5635c42025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-investor-conferences-september-20252025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-launches-zusduri-q2-2025-results2025-08-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-zusduris-24-month-response-phase-3-trial2025-08-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-reports-q3-2025-results-progress2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-november-investor-conferences2025-10-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-verekitug-ers-congress-20252025-09-30T08:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-stifel-2025-forum2025-09-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-vibrant-trial-results2025-09-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-trial-verekitug-copd2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/verekitug-potency-tslp-receptor-eaaci-congress2025-06-15T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-presents-verekitug-eaaci-20252025-06-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-aspire-phase-2b-study-results2025-05-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-arvo-2025-presentation2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-ubx1325-dme-vision-improvements2025-04-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-q1-2025-financial-results2025-04-22T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-virtual-investor-event-ubx13252025-03-23T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-appoints-yehia-hashad-board2025-03-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-employment-inducement-award2025-01-07T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-appoints-federico-grossi-cmo2025-01-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-expands-hla-coverage-precision-t-cell-therapy2025-11-05T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-clarifies-financials-capital-efficiency-low-cash-burn2025-11-03T19:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-engages-business-community-leaders-progress2025-10-29T16:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-updates-tvgn-489-long-covid-interest2025-10-15T19:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-initiative-t-cell-therapy-enhancement2025-09-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-tvgn-489-long-covid-viral-reservoirs2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-hhs-long-covid-impact-tvgn-4892025-09-19T19:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-cio-joins-startup-forum-databricks-tour-boston2025-09-10T15:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-5-year-revenue-forecast-liver-cancer-prevention2025-09-09T19:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-tvgn-489-clinical-product-valuation2025-09-08T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-private-placement-preferred-stock2025-06-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-business-combination-filing2025-06-03T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q3-2025-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-regains-rights-tsha-102-rett-syndrome2025-10-16T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reveal-phase-1-2-trials-tsha-1022025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-inducement-grant-nasdaq-rule-56352025-10-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-q1-2025-financial-results2025-05-08T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-explores-strategic-alternatives2025-02-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-acquisition-by-novartis2025-09-09T05:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-phase-2-tranquility-trial-data-esc-20252025-08-31T14:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-q2-2025-results-business-highlights2025-08-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-phase-2-tranquility-trial-results2025-05-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-leerink-partners-conference-20252025-03-03T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-guggenheim-conference-20252025-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-appoints-dr-paul-ridker-advisory-board2025-01-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-debt-equity-conversion2025-10-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-regains-nasdaq-compliance2025-09-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-appoints-paul-tivnan-director2025-08-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-offshore-manufacturing-hiv-test2025-08-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-preclara-preeclampsia-testing-approval2025-08-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-cgm-sensor-trial-results2025-08-12T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-launches-cgm-ai-native-platform2025-07-24T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-profitability-inflection-point2025-07-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-investor-conferences-20252025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-dreams-grant-recipients2025-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-inducement-grants-nasdaq-rule-56352025-09-02T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-appoints-maha-radhakrishnan2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-elevate-45-201-eu-authorization2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-q3-2025-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-ratutrelvir-phase-2-covid-studies2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-appoints-john-leaman-and-key-executives2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-phase-2-covid-studies-ratutrelvir2025-08-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-q2-2025-financial-results2025-08-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-advances-antiviral-pipeline-regulatory-submissions2025-06-30T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-rigosertib-efficacy-rdeb-scc2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-fda-guidance-tivoxavir-marboxil2025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-q3-2025-results-business-update2025-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-clearance-pivotal-trial-amezalpat-hcc-china2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-4-6-million-offering2025-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-orphan-drug-designation-amezalpat-hcc2025-06-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-amezalpat-moa-data-aacr-20252025-04-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-orphan-drug-designation-tpst-1495-fap2025-04-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-explores-strategic-alternatives-oncology-assets2025-04-09T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-q3-2025-results2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-response-unusual-market-action2025-10-24T18:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-warrant-incentive-operation2025-10-16T19:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-warrant-inducement-transaction2025-10-16T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-upcoming-congress-presentations2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-upcoming-presentations-esmo-idweek2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn-12-esgct-presentation2025-10-06T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn12-esgct-presentation2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-q2-2025-financial-results2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-q3-2025-financial-results-update2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-mypeak-1-phase-1b-2a-trial-results2025-11-08T16:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-tn-201-clinical-data-aha-20252025-11-04T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-hc-wainwright-conference-20252025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-october-investor-conferences2025-10-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-inducement-grants-nasdaq-rule-56352025-09-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-morgan-stanley-conference-20252025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-myclimb-study-esc-20252025-08-31T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-canaccord-genuity-conference-20252025-08-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-third-quarter-2025-results2025-11-10T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-stifel-2025-healthcare-conference2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-collaboration-mgh-tnx-1500-trial2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presentation-bio-europe-20252025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-acr-20252025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-focus-study-avp-d2025-10-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-poster-acr-20252025-10-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-801-mpox-vaccine-data2025-10-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-1500-update-japan-congress2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-world-vaccine-congress-20252025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-jefferies-conference-20252025-11-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-bio-europe-20252025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-invited-life-sciences-innovation-forum-20252025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-advances-tzls-501-il-6r-monoclonal-antibody2025-09-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ectrims-presentation-foralumab2025-09-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/dod-grant-tiziana-life-sciences-intranasal-therapy-sci2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ceo-share-purchase2025-09-09T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-phase-2a-trial-foralumab-msa2025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2025-financial-results2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-report-first-quarter-2025-results2025-04-24T23:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-pluristyx-plurifreeze-cryopreservation-system2025-03-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-pluristyx-collaboration-cell-therapies2025-03-11T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-acquisition-future-pak2025-09-25T17:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-acquisition-completion-future-pak2025-09-25T17:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-court-approval-acquisition-future-pak2025-09-16T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-final-court-approval-acquisition-future-pak2025-09-16T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-shareholders-approve-acquisition-plan2025-09-12T15:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-shareholders-approve-acquisition-future-pak2025-09-12T15:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-egrifta-wrmc-availability-hiv-lipodystrophy2025-09-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-egrifta-wr-availability-hiv-lipodystrophy2025-09-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-vote-favor-arrangement-future-pak2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-shareholder-vote-arrangement-future-pak2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-q3-2025-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-immuneonco-presentation-2510-nsclc-wclc-20252025-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/immuneonco-imm2510-nsclc-clinical-trial-results2025-07-31T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-fda-clearance-axn-2510-ind-phase-1-trial2025-07-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-appoints-john-maraganore-board-role2025-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-appoints-jamie-freedman-cmo2025-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-jefferies-global-healthcare-conference-20252025-05-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-immuneonco-investor-breakfast-2025-asco2025-05-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/imm2510-phase-2-trial-nsclc-enrollment-update2025-05-22T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-liquidation-thb335-update2025-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-liquidation-dissolution-plan2025-04-14T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-q4-2024-financial-results2025-03-27T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-phase-1-results-thb335-update2025-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-td-cowen-summit-participation2025-11-10T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-q3-2025-financial-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-conference-call-q3-20252025-10-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-phase-3-enhance-trial-briumvi2025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/briumvi-six-year-data-relapsing-ms2025-09-24T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-data-presentations-ectrims-20252025-09-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-phase-3-trial-briumvi-enrollment-commenced2025-09-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-hc-wainwright-conference-20252025-09-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-share-repurchase-authorization2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-cantor-global-healthcare-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend2025-11-06T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-third-quarter-results-2025-outlook2025-11-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-q3-2025-earnings-conference-call-details2025-10-16T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/first-patient-enrolled-dubstent-diabetes-trial2025-09-11T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-presentation-morgan-stanley-healthcare-conference2025-08-26T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-barrigel-rectal-spacer-launch-japan2025-08-19T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-second-quarter-2025-earnings-call2025-07-17T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-acquires-biotronik-vascular-intervention-business2025-07-01T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-q3-2025-financial-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-inducement-grants-employees2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-positive-clinical-data-tern-701-cml-ash-meeting2025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-phase-2-trial-tern-601-obesity-results2025-10-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-webinar-tern-701-phase-1-data2025-08-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-phase-1-study-tern-6012025-06-23T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-june-investor-conferences2025-05-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-guggenheim-smid-cap-biotech-conference2025-01-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-appoints-gillian-andor-vp-clinical-operations2025-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-q3-2025-financial-results-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-guggenheim-healthcare-innovation-conference2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-fda-agreement-pivotal-study-design2025-11-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-acr-convergence-2025-presentations2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-investor-conferences-20252025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presentation-jefferies-conference2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presentation-asgct-20252025-04-28T20:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-needham-conference-20252025-03-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-third-quarter-2025-financial-results2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-william-plovanic-board-directors2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-board-update-betty-jo-rocchio2025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-inducement-grants-nasdaq-rule-5635c42025-08-08T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-participate-canaccord-genuity-conference2025-07-23T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-european-launch-ovitex-ingual2025-06-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-jeffrey-blizard-president2025-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-2-million-offering2025-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-participate-investor-conference-november-20252025-11-05T22:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-q3-2025-financial-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-third-quarter-2025-financial-results-webcast2025-10-28T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-q3-2025-results-update2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-best-places-to-work-20262025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inducement-grants-nasdaq-rule-56352025-10-01T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-investor-conferences-20252025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-russell-3000-index-addition2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-appoints-william-conkling-cco2025-06-02T20:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-q3-2025-results2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-third-quarter-fiscal-year-2025-results2025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-host-investor-day-november-20252025-08-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-participate-2025-wells-fargo-healthcare-conference2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-quarterly-dividend-increase2025-08-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-participate-bank-america-healthcare-conference-20252025-04-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesia-infection-negative2025-10-15T11:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/b-free-chronic-babesiosis-study-sxtp2025-10-09T11:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-webcast-hc-wainwright-conference2025-09-03T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharma-mount-sinai-phase-ii-trial-tafenoquine2025-08-19T12:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-q2-2025-results2025-08-13T20:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-tulane-research-agreement-tafenoquine2025-07-17T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-closes-10-million-offering2025-07-16T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-public-offering-pricing2025-07-15T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-arakoda-babesiosis-market-size2025-07-15T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-chmp-opinion-nirogacestat-desmoid-tumors2025-06-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-chmp-positive-opinion-mirdametinib2025-05-24T23:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-mirdametinib-nf1-pn-approval2025-05-24T23:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-regains-nasdaq-compliance2025-03-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-share-consolidation2025-02-21T17:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-participate-2025-jefferies-healthcare-conference2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-third-quarter-2025-financial-results2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-q3-2025-results-conference-call2025-10-21T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-september-investor-conferences2025-08-27T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-acquisition-sage-therapeutics2025-07-31T12:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-expiration-hsr-waiting-period-sage-acquisition2025-07-28T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-acquires-sage-therapeutics-neuropsychiatry2025-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2025-third-quarter-results2025-11-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/genesisx-robotic-navigation-fda-clearance2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-launch-synchrony-system-eu-fda-submission2025-10-15T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-cardiofocus-robotic-pfa-collaboration2025-10-13T11:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/erasmus-medical-center-genesis-robotic-system2025-09-22T11:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/first-us-commercial-robotic-hd-mapping-procedures2025-09-02T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-investor-conferences-september-20252025-09-02T11:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-technology-featured-hrx-20252025-08-28T11:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-q3-2025-financial-results2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-wedbush-securities-panel-20252025-10-02T11:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-closes-103-million-private-placement2025-08-26T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-ind-sl-325-inflammatory-bowel-disease2025-08-21T14:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-private-placement-103-million2025-08-05T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-leerink-partners-therapeutics-forum2025-07-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-participation-needham-conference-20252025-04-02T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-q3-2025-results-ceo-transition2025-11-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/tricare-west-expands-neurostar-tms-coverage-adolescents2025-11-12T15:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inducement-grant-nasdaq-rule-56352025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/new-york-medicaid-expands-tms-therapy-coverage2025-09-17T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neurostar-publication-jaacap-open-treatment-efficacy2025-07-30T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-next-gen-adc-innovation2025-11-12T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-exclusive-partnership-elite-dna-behavioral-health2025-10-30T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-q3-2025-financial-results-conference-call2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-presentation-canaccord-growth-conference2025-08-04T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-q3-2025-results2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-virtual-rd-day-november-20252025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-world-adc-conference-20252025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-operational-restructuring-cash-runway2025-09-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-fda-collaboration-advancing-adc-standards2025-07-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-appoints-greg-chow-cfo2025-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-investor-conferences-may-20252025-05-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-fiscal-2026-second-quarter-results2025-11-05T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-dividend-0-63-per-share2025-10-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-conference-call-fiscal-2026-results2025-10-21T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-cfo-transition-michael-tokich-karen-burton2025-08-06T20:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/cms-recognition-expanded-cpt-codes-sskn2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-q3-2025-financial-results-update2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-cofepris-clearance-theraclear-mexico2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-market-leadership-litigation-milestones2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/excimer-laser-promising-results-cutaneous-lymphoma-sskn2025-10-14T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/eczema-awareness-month-strata-skin-sciences-xtrac-laser2025-10-03T14:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-xtrac-laser-study-psoriasis2025-09-30T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/combination-therapy-vitiligo-strata-sskn2025-09-22T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-2-42-million-offering2025-09-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-elevate-360-growth-partnerships2025-09-04T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-first-telesurgery-ssii2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-reports-q3-2025-financial-results2025-10-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-upcoming-investor-conferences2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-us-regulatory-update-ssi-mantra2025-10-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-appoints-naveen-kumar-amara-cfo2025-09-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-first-pediatric-pyeloplasty-telesurgery2025-09-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-first-robotic-telesurgery-mantram-bus2025-09-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-intercontinental-robotic-cardiac-telesurgery2025-07-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-stock-option-grant-cfo2025-11-12T22:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-q3-2025-results-business-update2025-11-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-healthcare-investor-conference2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-patent-antibody-wnt-pathway2025-05-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-q3-2025-financial-results-neffy2025-11-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/get-neffy-on-us-program-launch2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharma-neffy-presentation-acaa-meeting-20252025-11-03T19:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-conference-call-q3-20252025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-european-patent-decision-neffy2025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-secures-loan-facility-neffy-commercialization2025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/neffy-epinephrine-nasal-spray-approval-japan2025-09-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/real-world-evidence-neffy-anaphylaxis2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-investor-conferences-september-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q3-2025-financial-results-update2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/pivotal-phase-3-data-tebipenem-hbr-cuti2025-10-21T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-tebipenem-hbr-idweek-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-gsk-pivot-po-phase-3-study-tebibenem-hbr2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-esther-rajavelu-ceo-appointment2025-04-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquisition-neurothera-labs2025-10-24T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-sale-mitocarex-n2off-cancer-therapies2025-10-23T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-quantum-3d-protein-modeling-initiative2025-10-23T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-patent-binge-behavior-disorders2025-10-20T11:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquisition-miza-ventures2025-10-15T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-merger-termination-autotmax-agreement2025-10-06T10:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/n2off-shareholders-approve-scisparc-merger-mitocarex2025-09-29T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-autotmax-merger-approval2025-08-28T13:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-shareholders-approve-merger-automax2025-08-28T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-q3-2025-financial-results2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-partners-cm-sales-arkansas2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-third-quarter-2025-earnings2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-focusfactor-pharmacist-recommendation-2025-20262025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expansion-kroger-pricesmart-wakefern2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expands-focusfactor-new-england2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-leadership-changes-strategic-partnerships2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-partners-alabev-launch-focusfactor-beverages2025-09-17T13:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-closes-public-offering-4-375-million2025-08-27T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-pricing-public-offering2025-08-26T01:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q3-fy2025-financial-results2025-11-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-conference-call-november-20252025-11-03T21:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/cms-final-rule-2026-physician-fee-schedule-ultramist2025-11-03T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-q3-2025-revenue-results2025-10-06T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-strategic-debt-refinancing-jp-morgan2025-09-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-presentation-canaccord-conference-20252025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-dustin-libby-evp2025-06-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-updated-clinical-results-senti-202-ash-20252025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-present-chardan-genetic-medicines-conference2025-10-16T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-presentation-biojapan-20252025-10-06T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-medinvest-conference-presentation2025-09-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-presentation-hc-wainwright-conference-20252025-09-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-webull-webinar-20252025-08-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-phase-2-dose-selection-senti-2022025-08-12T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-q2-2025-results-phase-1-senti-202-update2025-08-07T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-phase-2-dose-senti-202-aml2025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-virtual-investor-conference2025-07-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-strategic-review-shareholder-value2025-10-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-solnerstotug-esmo-2025-results2025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-kol-event-solnerstotug-october-20252025-09-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-hc-wainwright-conference-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-q2-2025-results-update2025-08-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-esmo-congress-20252025-07-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reverse-stock-split2025-06-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-participate-canaccord-genuity-conference2025-04-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-2024-financial-results-clinical-update2025-03-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-pico-snpwt-study-wound-dehiscence2025-10-27T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-ufc-partnership-extension2025-10-22T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-new-cpt-code-cartilage-repair-implant2025-10-09T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-allevyn-complete-care-dressing-data2025-10-03T15:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-coriograph-pre-op-services-shoulder2025-10-01T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-regneten-implant-updates2025-09-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-launches-centrio-prp-system2025-09-03T14:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-q-fix-knotless-anchor-launch2025-07-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-sponsors-players-wimbledon-20252025-06-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-trigen-max-tibia-nailing-system-launch2025-06-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-q3-2025-financial-results2025-11-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-sil204-pan-kras-activity2025-09-30T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-regains-nasdaq-compliance2025-09-25T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-public-offering-pricing2025-09-11T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-positive-preclinical-data-sil2042025-09-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-phase-2-3-trials-sil2042025-09-04T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-presentation-hc-wainwright-conference2025-09-02T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-warrants-exercise-1-8-million2025-08-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-preclinical-data-sil2042025-07-31T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-q3-2025-financial-results2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-ash-investor-event-december-20252025-11-03T14:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-niktimvo-ash-20252025-11-03T14:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-november-investor-conferences2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-third-quarter-2025-financial-results-conference-call2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-fda-approval-revuforj-npm1-aml2025-10-24T17:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-nccn-guidelines-aml2025-09-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-q3-2025-financial-results2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-strategic-realignment-surgical-business2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-ceo-transition2025-09-02T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-presentation-cantor-healthcare-conference-20252025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-launches-tissue-health-plus-pilot-program2025-07-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-regains-nasdaq-compliance2025-10-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reverse-stock-split2025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-extension-nasdaq-compliance2025-07-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-seclidemstat-inhibiting-lsd1-studies2025-07-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/decoy-therapeutics-langer-scientific-advisory-board2025-04-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/decoy-therapeutics-promising-antiviral-measles2025-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-merger-decoy-therapeutics-update2025-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-resumes-enrollment-phase-1-2-trial2025-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-decoy-merger-agreement2025-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-q3-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-sls009-phase-2-data-ash-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-warrant-exercise-31-million2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-jp-morgan-forum-20252025-10-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-sls009-esmo-20252025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-rd-day-october-2025-aml-trial-update2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-regal-trial-positive-recommendation2025-08-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-phase-2-trial-sls009-aml-fda-guidance2025-07-15T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-100-million-share-repurchase2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-q3-2025-results-vykat-launch2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-november-conferences2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-q3-2025-financial-results2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-appoints-mark-hahn-board2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-public-offering-200-million2025-07-10T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alumis-merger-approval2025-05-13T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-iss-recommends-vote-for-alumis-merger2025-05-06T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alumis-merger-vote-20252025-05-01T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/alumis-acelyrin-amended-merger-agreement2025-04-21T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-limited-duration-stockholder-rights-plan2025-03-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alumis-merger-strategic-rationale2025-03-04T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-concentra-biosciences-merger-update2025-03-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-receives-acquisition-interest-from-concentra2025-02-21T02:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/alumis-acelyrin-merger-immune-diseases2025-02-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-announces-phase-2-data-lonigutamab-ted2025-01-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-health-canada-approval-epsolay2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-q2-2025-results-and-updates2025-08-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-first-quarter-2025-results2025-05-23T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reverse-share-split2025-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-mayne-pharma-epsolay-twyneo-purchase-agreement2025-04-17T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-investor-conferences-20252025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-innovation-passport-sgt-0032025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-inducement-grants-nasdaq-rule-56352025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-q3-2025-results-insPIRE-duchenne-update2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-scientific-meetings-20252025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-presents-at-neuromuscular-study-group-meeting2025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-licensing-agreement-kinea-bio-aav-slb1012025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-q3-2025-results-update2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-obesityweek-2025-nimacimab2025-11-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-nimacimab-phase-2a-data2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-phase-1b-nimacimab-easd-meeting2025-09-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-nimacimab-weight-loss-combination-therapy2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-completes-26-week-treatment-phase-cbeyond-study2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-kol-event-cbeyond-phase-2a-data2025-08-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-investment-medical-conferences2025-08-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-q3-2025-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-investor-conferences-november-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-phase-1-data-nacfc-20252025-10-24T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-precision-cf-phase-2a-trial2025-10-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-nacfc-2025-presentation2025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-appoints-caroline-stark-beer-cbo2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-phase-1-trial-sion-451-cystic-fibrosis2025-08-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-preclinical-data-cftr-correction2025-06-06T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-september-20252025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-november-20252025-10-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-special-cash-dividend-20252025-04-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-appoints-general-john-keane-board2025-03-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-reports-q3-2025-results-and-guidance2025-11-10T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-third-quarter-2025-results2025-10-20T20:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-presents-morgan-stanley-healthcare-conference-20252025-08-26T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-present-canaccord-growth-conference-20252025-07-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-truist-securities-medtech-conference-20252025-06-04T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-goldman-sachs-conference-20252025-05-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-bofa-securities-2025-healthcare-conference2025-05-06T20:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-executes-loi-with-molecule-ai2025-10-10T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-enter-ai-pharmaceutical-market2025-10-09T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-q2-2025-update2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-4-25-million-private-placement2025-06-24T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-private-placement-425-million2025-06-20T19:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-reverse-stock-split-june-20252025-06-12T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-reverse-stock-split-nasdaq-compliance2025-06-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-george-scorsis-chairman-board2025-06-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-corporate-update-may-20252025-05-15T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-fda-orphan-drug-phase-2-trial2025-05-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-secondary-offering-common-stock2025-11-06T21:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-strong-q3-2025-results2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-third-quarter-2025-earnings-release2025-10-21T21:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-progress-q3-2025-financial-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-participate-upcoming-investor-conferences2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-appoints-keith-gottesdiener-board-directors2025-09-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-phase-1-trial-sep-631-mrgprx22025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-jefferies-healthcare-conference2025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-corporate-overview-q4-2024-results2025-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-td-cowen-health-care-conference2025-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/omni-surgical-system-trusync-technology-glaucoma2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-third-quarter-2025-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-appoints-new-coo-cfo2025-11-06T21:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-investor-conferences-20252025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-third-quarter-2025-financial-results2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-tearcare-fee-schedule-announcement2025-10-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-omni-surgical-system-review2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-omni-unitedhealthcare-coverage2025-09-09T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-tearcare-tfos-dews-iii-guidelines2025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-presentation-morgan-stanley-conference2025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-hupo-2025-proteomics-data2025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-third-quarter-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-participate-november-investor-conferences2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-proteomics-genomics-precision-medicine-ashg-20252025-10-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-isaac-ro-board-directors2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-participate-morgan-stanley-healthcare-conference2025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-q2-2025-financial-results2025-08-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-participate-canaccord-genuity-growth-conference2025-07-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-report-second-quarter-2025-results2025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-q3-2025-results-corporate-update2025-11-05T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-gsk-phase-3-mario-study-resolution2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-positive-results-phase-1-scy-2472025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-sc247-timm-12-presentations2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-hc-wainwright-conference-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-resumes-patient-dosing-phase-3-mario-study2025-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-present-preclinical-data-scy-247-escmid2025-04-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-appeal-nyse-delisting2025-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-engages-alliance-global-partners2025-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-kalocyte-erythromer-manufacturing2025-01-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-cancels-reverse-stock-split2025-01-17T20:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/mannkind-acquisition-scpharmaceuticals-revenue-growth2025-10-07T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/mannkind-acquires-scpharmaceuticals-patient-centric-leader2025-08-25T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-patent-allowances-scp-1112025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-q2-2025-financial-results-update2025-08-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-q2-2025-financial-results-announcement2025-07-31T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-participation-investor-conferences2025-05-01T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-financial-results-conference-call-20252025-03-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-reports-q3-2025-financial-results2025-11-13T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-arbli-losartan-formulary-expansion2025-11-04T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-launches-arbli-commercial-sales2025-10-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scientures-arbli-first-fda-approved-liquid-losartan2025-10-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-repayment-conversion-debentures2025-10-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-secures-gpo-agreements-arbli-expanding-market-access2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-expands-access-arbli-losartan-rebate-agreement2025-09-16T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-announces-3-9-million-offering2025-08-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-arbli-launch-quantities-shipment2025-08-13T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-secures-bridge-funding2025-07-24T21:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-distribution-dream-bowl-meme-coin2025-11-11T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-announces-exclusive-license-datavault-ai-tokenization2025-11-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-sponsors-dream-bowl-2026-shareholder-meme-coin2025-11-03T14:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-completes-first-tranche-oramed-warrant-repurchase2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-closes-initial-tranche-investment-datavault-ai2025-09-26T19:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-bitcoin-investment-datavault-ai2025-09-25T19:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-closes-200-million-bitcoin-transaction2025-09-25T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-biconomy-mou-cryptocurrency-strategies2025-09-24T14:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-signs-securities-purchase-agreement-bitcoin2025-09-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-semnur-denali-business-combination2025-09-22T19:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-reports-q3-2025-financials-business-update2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-appoints-dawn-bir-board2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-hc-wainwright-conference-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-appoints-dr-joseph-hulihan-cmo2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-simufilam-preclinical-study-tsc-epilepsy2025-08-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-simufilam-preclinical-data-tsc-alliance-meeting2025-06-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-appoints-bordey-enhance-preclinical-program2025-05-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-announces-retirement-of-cmo-and-new-svp2025-04-21T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-presents-sab-142-data-at-ispad-conference2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-participate-investor-conferences-nov-dec-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-easd-presentations-sab-1422025-09-19T11:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-presentations-easd-20252025-09-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-q2-2025-financial-results2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-oversubscribed-private-placement-175-million2025-07-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-q1-2025-financial-results-updates2025-05-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-full-year-2024-results2025-03-31T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-phase-1-results-sab-142-t1d-therapy2025-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inducement-grant-nasdaq-listing-rule2025-11-10T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-fiscal-2026-results-business-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-virtual-investor-event-ersodetug-development2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-participate-investor-conferences2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-fda-alignment-phase-3-trial-ersodetug2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-appoints-sunil-karnawat-cfo2025-08-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-participate-btig-virtual-biotechnology-conference2025-07-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-obesityweek-2025-presentations2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-fda-review-extension-imcivree2025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-imcivree-reimbursement-canada2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q3-2025-results-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-investor-conferences-20252025-08-27T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-fda-acceptance-setmelanotide2025-08-20T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q2-2025-results-report2025-07-22T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-brilaroxazine-presentation-neuroscience-20252025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-european-patent-brilaroxazine-pulmonary-fibrosis2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-participate-spartan-capital-investor-conference2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-present-negative-symptom-data-brilaroxazine-cns-summit-20252025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-participate-kol-webinar-alliance-global-partners2025-10-07T20:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-participate-roth-healthcare-conference-20252025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-participate-lytham-partners-fall-2025-investor-conference2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-9-million-public-offering2025-09-19T01:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-proposed-public-offering2025-09-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-q2-2025-financial-results2025-08-14T20:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q3-2025-financial-results-update2025-11-05T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-investor-conferences-november-20252025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q3-2025-financial-results-webcast2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/daraxonrasib-fda-orphan-drug-designation-pancreatic-cancer2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-elironrasib-data-presentation2025-10-22T16:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-daraxonrasib-voucher-fda2025-10-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-leadership-additions-alan-sandler2025-09-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-daraxonrasib-phase-3-trial2025-09-10T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-q2-2025-business-update2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-priovant-positive-phase-3-valor-study-results2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-best-workplaces-bio-pharma-20252025-09-11T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-batoclimab-graves-disease-remission-data2025-09-03T17:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-priovant-investor-conference-brepocitinib-dermatomyositis2025-06-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-strengthens-scientific-advisory-board-timothy-donahue2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-canaccord-forum-20252025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-q3-2025-financial-results-conference-call2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-expands-advisory-board-thierry-de-baere2025-10-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-panther-study-progress-first-procedure2025-09-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-presentation-investment-conference-20252025-09-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-expands-commercialization-efforts-renovocath2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-employment-inducement-grants2025-10-30T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-carsten-brunn-chairman2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-investor-conferences-september-20252025-08-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-phase-3-aurora-trial-descartes-082025-05-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-hc-wainwright-bioconnect-conference2025-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-q1-fiscal-year-2026-results2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-q1-fiscal-2026-earnings-report2025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-participation-bank-america-healthcare-conference-20252025-09-16T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-launches-sleep-institute-global-priority2025-09-03T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/obstructive-sleep-apnea-77-million-us-adults-20502025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-innovation-leadership-red-dot-awards-patents2025-08-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-board-election-nicole-mowad-nassar2025-08-18T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-official-sleep-partner-lions-tour-20252025-05-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q3-2025-financial-results2025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-100-million-offering2025-11-04T12:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-fda-feedback-ndv-01-nmibc2025-11-04T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-max-kates-clinical-advisory-board2025-10-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-regains-compliance-nasdaq-minimum-bid-price2025-09-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-mid-year-ceo-letter-shareholders2025-09-10T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q2-2025-results-ndv-01-data2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-yair-lotan-chair-cab2025-07-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-raj-pruthi-cmo-urology2025-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-investor-conferences-november2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q2-2025-results-announcement2025-07-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-appoints-claire-mazumdar2025-06-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-updated-data-rly-2608-asco-20252025-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-november-conferences2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-q3-2025-financial-results-guidance-update2025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-third-quarter-2025-financial-results2025-10-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-novasign-partnership-bioprocessing-digitalization2025-07-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-2024-corporate-sustainability-report2025-05-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-william-blair-growth-conference2025-05-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-may-investor-conferences2025-05-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-sitc-2025-rp1-abstract2025-11-07T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fiscal-q2-2026-results-corporate-update2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fda-acceptance-bla-rp1-advanced-melanoma2025-10-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-acral-melanoma-data-esmo-20252025-10-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-update-type-a-meeting-fda2025-09-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fda-type-a-meeting-rp12025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fda-complete-response-rp1-melanoma2025-07-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-inducement-grants-nasdaq-rule-5635c42025-07-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-secures-us-patent-ai-drug-discovery2025-06-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-expedited-trial-predictive-oncology-merger2025-05-22T19:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-expedited-trial-lawsuit-predictive-oncology2025-05-22T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-launches-augusta-ai-precision-neurology-platform2025-05-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-amsterdam-umc-collaboration-blood-platelet-rna-diagnostics2025-05-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-nebul-partnership-accelerate-biomarker-discovery2025-04-22T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-biosciences-biosymetrics-merger-ai-drug-discovery2025-04-09T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-update-predictive-oncology-agreement2025-04-04T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-completes-first-milestone-payment-predictive-oncology2025-03-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-progress-ash-2025-multiple-myeloma-lymphoma2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-phase-2-trials-factor-xi-antibodies2025-11-08T15:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-afrs-trial-results-fda-review2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-investor-conference-presentations2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-wins-2025-prix-galien-award2025-10-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-q3-2025-results2025-10-28T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-eu-approval-cscc-treatment2025-10-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-esmo-2025-advances-oncology-pipeline2025-10-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/db-oto-results-hearing-speech-perception-children2025-10-12T14:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-approval-adjuvant-cscc-treatment2025-10-08T18:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-investor-webinar-briefing2025-11-09T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-third-quarter-2025-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/recell-system-standard-of-care-acute-wound-treatment2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avitamedical-recell-burns-australia2025-10-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-ceo-transition2025-10-16T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/cms-ntap-recell-access-non-burn-wounds2025-10-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-receives-ce-mark-recell-go-europe2025-09-14T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/recell-system-reduces-hospital-stay-avita-medical2025-09-04T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-september-investor-conference-participation2025-08-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-q3-2025-financial-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-sale-north-american-royalties-crysvita2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-first-patient-dosed-aurora-study-gtx-1022025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-conference-call-q3-2025-update2025-10-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-inducement-grant-nasdaq-rule-56352025-10-24T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-evkeeza-approval-aifa-hofh2025-10-08T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-eric-olson-cbo2025-09-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-positive-data-phase-3-dtx401-gsdia2025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-q3-2025-results-highlights2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-investor-conferences-november-20252025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-prestige-phase-2b-trial-azureprubart-food-allergies2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-public-offering-pricing2025-10-22T03:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-positive-topline-data-rpt9042025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-fda-clearance-ind-phase-2b-trial-rpt9042025-09-29T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-q3-2025-financials-update2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-investor-conferences-20252025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-td-cowen-summit-participation2025-09-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-announces-pricing-public-offering-common-stock2025-09-10T01:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-public-offering-common-stock2025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-positive-results-rap-219-phase-2a-trial2025-09-08T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-investor-analyst-day-updates2025-06-02T18:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-participate-jefferies-goldman-sachs-conferences2025-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-q3-2025-results-update2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-obesityweek-2025-semaglutide2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-board-appointments2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-closes-60-million-private-placement2025-10-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-chugai-collaboration-1-billion2025-10-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-3-million-offering2025-07-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-endo-2025-presentation-bioequivalence2025-07-14T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-chugai-research-agreement2025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-q3-2025-financial-results-update2025-11-10T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-third-quarter-2025-financial-results2025-11-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-regulatory-update-amt-130-huntingtons-disease2025-11-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-upsized-public-offering-closure2025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-pricing-upsized-public-offering2025-09-26T03:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-200-million-public-offering2025-09-24T20:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-refinancing-debt-funding-amts-130-launch2025-09-24T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-positive-results-amd-130-huntingtons-disease2025-09-24T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-amt-191-phase-i-ii-data-fabry-disease2025-09-05T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-q3-2025-results2025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-corporate-update-october-20252025-10-31T23:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-unbuzzd-webinar-alcohol-metabolism2025-10-23T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-warrant-expiration-cvr-distribution2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-responds-to-allegations2025-10-14T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-whistleblower-reward-stock-manipulation2025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-special-dividend-cvrs-litigation-settlement2025-10-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-phase-2-clinical-trial-update2025-10-02T11:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-dr-jack-antel-clinical-advisor-lucid-ms2025-10-01T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-agm-results-20252025-09-29T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-achieves-rapamycin-target-loadings2025-11-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-update-q3-2025-results2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-syndrome-study-update2025-10-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-fda-orphan-drug-designation-qrx0032025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-private-placement-financing2025-10-10T13:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video-fasanella-sisters2025-09-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-campaign-milestone2025-08-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-new-cfo-commercialization-strategy2025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video-series2025-08-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-rebrand-aixcrypto-stockholder-meeting-november-20252025-10-28T03:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-bitgo-partnership-treasury-allocation2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-launches-c10-cryptocurrency-asset-treasury2025-10-13T01:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-leadership-changes2025-10-06T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-closes-41-million-pipe-financing2025-09-30T11:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/faraday-future-invests-41-million-in-qualigen-therapeutics2025-09-19T22:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-nasdaq-update-compliance-status2025-07-28T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-4-5-million-private-placement2025-07-28T16:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-granted-new-patents-covering-25-countries2025-07-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-nasdaq-deficiency-notification2025-05-19T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-investor-conferences-november-20252025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-business-update-q3-2025-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-micvo-data-presentation-esmo-aacr-nci-eortc2025-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-appoints-alex-kane-investor-relations2025-10-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-inducement-grants-nasdaq-rule-56352025-09-30T20:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q3-2025-results2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-d-plex-1800-wins-biotech-breakthrough-award2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-phase-3-shield-ii-results-acs-20252025-09-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-presents-lytham-roth-conferences-20252025-09-17T12:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-gmp-inspection-success-d-plex18002025-09-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-participate-hc-wainwright-conference-20252025-09-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-presentation-israel-controlled-release-society-conference2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-appoints-dr-nurit-tweezer-zaks-cmo2025-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q3-2025-financial-results-update2025-11-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-stifel-2025-healthcare-conference2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-qtorn-pitavastatin-dsap2025-11-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/fda-awards-funding-palvella-phase-3-selva-trial2025-10-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-expands-qtorin-development2025-09-24T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-rapamycin-venous-malformations2025-09-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-phase-2-toiva-trial-enrollment-complete2025-09-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-leadership-appointment-david-osborne2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-investor-conferences-20252025-08-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-japan-patent-modified-stilbenoid2025-07-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q3-2025-financial-results2025-11-13T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-acquires-xepi-financing2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-moms-against-molluscum2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-september-investor-conferences2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-wells-fargo-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q2-2025-financial-results-update2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-launches-zelsuvmi-topical-gel2025-07-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-merger-channel-therapeutics2025-07-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/channel-therapeutics-reverse-stock-split-merger-pelthos2025-06-27T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-respect-lm-trial-results-sitc-meeting2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-q3-2025-results-business-highlights2025-10-30T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-cnside-diagnostic-platform-launch2025-10-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-unitedhealthcare-cnsid-assay-agreement2025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-cprit-advance-payment2025-09-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-cnside-diagnostics-accreditation2025-09-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-hc-wainwright-conference-20252025-09-02T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-compliance-nasdaq-listing-criteria2025-08-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-respect-lm-trial-results-reyobiq2025-08-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-stockholders-equity-compliance2025-08-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/alphaton-capital-closes-financing-ton-token-acquisition2025-09-25T18:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/alphaton-capital-launches-ton-digital-asset-strategy2025-09-03T16:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-fiscal-year-results-20252025-07-25T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-compliance-nasdaq-requirements2025-06-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-compedica-stock-exchange2025-06-09T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-preclinical-results-mesothelioma-port-72025-04-28T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-resumes-enrollment-port-6-adport-6012025-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-nasdaq-compliance-extension2025-02-12T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-private-financing-completion2025-01-30T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-q3-2025-results-axiomer-study-initiation2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-cta-authorization-ax-0810-investor-event2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-participate-investor-conferences-october-20252025-10-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-presentation-rna-editing-summit-20252025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-cta-submission-phase-1-study-ax-0810-ntcp2025-06-26T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-upcoming-scientific-presentations-asgct-tides2025-05-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-webcast-presentation-citizens-life-sciences-conference2025-05-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-general-meeting-shareholders-20252025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-be-smart-esophageal-cancer-study2025-10-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-engages-redchip-investor-relations2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-thinkequity-conference-20252025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-crown-medical-collections-bankruptcy2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-explores-crypto-treasury-strategy2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-stockholders-approve-proposals-september-20252025-09-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-virtual-roadshow-september-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-special-meeting-shareholders-20252025-08-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-financial-results-june-20252025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-q3-2025-results-regulatory-updates2025-11-10T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-phase-2-regeneration-trial-results2025-11-06T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-participate-upcoming-conferences2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-abstracts-asn-kidney-week-20252025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-fda-accelerated-approval-rilparencel2025-07-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-participate-hc-wainwright-kidney-conference2025-07-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-domestication-delaware2025-07-01T16:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-exclusive-distribution-agreement2025-11-13T09:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-distribution-agreement-getz-healthcare2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-exclusive-distribution-agreement-saudi-arabia2025-11-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-tulsa-pro-canada-distribution-rights2025-11-10T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-busch-center-500th-tulsa-procedure2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-stifel-2025-healthcare-conference2025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-record-revenue-q3-20252025-10-07T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/texas-prostate-dallas-medical-center-tulsa-program2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-lake-street-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-q2-2025-financial-results2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-q3-2025-financial-results-update2025-11-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-strategic-business-update2025-11-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incyte-jak2v617f-agreement2025-11-04T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-ash-2025-abstracts2025-11-03T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-appoints-katina-dorton-board2025-10-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-upcoming-healthcare-conferences2025-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-citizens-life-sciences-conference2025-05-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-announces-presentations-aacr-annual-meeting-20252025-04-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-jefferies-global-healthcare-conference2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-q3-2025-financial-results2025-11-07T15:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-q3-2025-financial-results2025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-appoints-matthew-hawryluk-cbo2025-11-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-virtual-kol-event-wilsons-disease-strategy2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-participate-investor-conferences2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-public-offering-august-20252025-08-01T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-public-offering-pricing2025-07-31T01:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q3-2025-financial-results2025-11-04T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-ceo-transition-larry-wood2025-07-24T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/water-iv-trial-aquablation-therapy-prostate-cancer2025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q2-2025-financial-results2025-07-21T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/aquablation-therapy-category-i-code-medicare-20262025-07-15T01:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-investor-conferences-may-june-20252025-04-29T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-aquablation-therapy-aua-20252025-04-24T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inducement-grants-nasdaq-rule-56352025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-investor-conferences2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-update-q3-2025-results2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-accelerated-development-relutrigine-fda-feedback2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-public-offering2025-10-17T03:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-ulixacaltamide-phase-3-results-essential-tremor2025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-borescope-development-jet-engines2025-11-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-ar-systems-fighter-pilots2025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-conference-call-november-20252025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-lytham-partners-fall-2025-conference2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-q4-fy-2025-results2025-09-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-expands-facilities-backlog2025-06-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-leadership-additions-digital-asset-strategy2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-closes-private-placements-digital-assets2025-10-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-private-placements-athir-tokens2025-09-29T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-reverse-stock-split2025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-every-cure-drug-repurposing-collaboration2025-09-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-q2-2025-results-update2025-08-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-shareholder-letter-chemo-fx-expansion2025-07-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-yorkville-partnership-ai-drug-discovery2025-07-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-3d-organoid-models-labcorp2025-06-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/court-denies-renovaro-motion-expedited-trial-july2025-05-27T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-reports-q3-2025-results2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-rezatapopt-pynacle-trial-update2025-10-24T15:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-rezatapopt-presentation-aacr-nci-eortc-20252025-10-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-investor-conferences-20252025-05-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-acquires-kokomodo-cultivated-cacao-agfoodtech2025-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-expansion-intellectual-property-3d-immune-cells2025-04-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-collaboration-hemafund-ukraine-radiation-preparedness2025-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-secures-3-5-million-investment-shareholder2025-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-secures-investment-enters-cacao-market2025-01-23T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q3-2025-results2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-guggenheim-healthcare-conference2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-board-appointment-slanix-alex2025-10-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-phase-1b-alzheimers-trial-update2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-showcase-preciad-trial-design2025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-private-placement-financing2025-07-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-0-8-million-offering2025-07-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-fast-track-pmn310-alzheimers2025-07-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-corporate-update-q3-2025-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-update-beacon-ipf2025-06-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-ats-2025-conference-data2025-05-21T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-strategic-realignment-workforce2025-05-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-ats-2025-conference-presentations2025-04-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-pln-101095-phase-1-data2025-03-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-stockholder-rights-agreement2025-03-13T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-viral-blocking-formulation-results2025-11-06T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-positive-preclinical-results-pl14-allergen-blocking2025-10-06T12:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-submits-pre-sub-fda-pl-14-allergy-blocker2025-09-19T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-intranasal-delivery-pl14-allergy-blocker-study2025-09-12T11:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-regains-nasdaq-compliance2025-08-14T12:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-nasdaq-listing-hearings-panel2025-07-15T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-intranasal-delivery-results-cns-therapeutics2025-06-12T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-nasdaq-delisting-notice2025-05-23T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-positive-preclinical-data-nasal-protection2025-05-21T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-q3-2025-results-business-update2025-11-12T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-deucrictibant-acaa-2025-presentation2025-11-10T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-present-clinical-data-acaa-2025-meeting2025-10-23T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-closes-201-2-million-public-offering2025-07-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-pricing-175-million-offering2025-07-23T01:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-public-offering-ordinary-shares2025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-topline-data-update-rapide-3-study2025-07-10T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-clinical-trial-data-deucrictibant-hae-summit-20252025-06-27T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-deucrictibant-eaaci-congress-20252025-06-16T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-third-quarter-2025-financial-results2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-positive-fda-feedback-bx011-phage-cocktail2025-11-04T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-bx004-fda-feedback-update2025-10-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-ceo-presentation-hc-wainwright-conference2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-bx004-phase-2b-trial-update2025-08-19T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-phase-1b-2a-bx004-cystic-fibrosis-results2025-07-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-phase-2-study-voquezna-eoe2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-investor-conferences-20252025-11-03T12:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q3-2025-results-update2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-voquezna-phase-3-study-results2025-10-25T13:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-highlight-voquezna-acg-20252025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-appoints-sanjeev-narula-cfo2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-clarifies-shareholder-ownership-changes2025-08-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-q3-2025-financial-results-growth2025-11-06T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-fireside-chat-jefferies-conference-20252025-10-30T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-third-quarter-2025-financial-results2025-10-23T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-2025-acaa-meeting-abstracts2025-10-20T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-g-and-a-expense-reduction-update2025-10-06T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-fda-acceptance-leniolisib-apds-children2025-10-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-promoted-euronext-amx-index2025-09-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-hc-wainwright-conference-20252025-09-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-appoints-kenneth-lynard-cfo2025-09-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-investor-conference-august-20252025-08-04T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-q3-2025-results-clinical-update2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-11-1-million-offering2025-11-11T20:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-sitc-2025-immunotherapy-data2025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-conference-call-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-sitc-2025-presentation2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-expedited-approval-pds0101-hpv16-cancer2025-10-29T12:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-head-neck-cancer-trial-results2025-09-18T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-versatile-002-phase-2-trial-results2025-08-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-q3-2025-financial-results-vax-24-update2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-fill-finish-manufacturing-north-carolina2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-advances-vax-31-infant-phase-2-study2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-q2-2025-results-vax-31-update2025-08-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-first-quarter-2025-financial-results-update2025-05-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-dr-olivier-brandicourt-board2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-positive-results-vax-24-infant-phase-2-study2025-03-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-webcast-conference-call-vax-24-results2025-03-30T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-report-fourth-quarter-full-year-2024-results2025-02-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-poster-presentation-pcs499-asn-kidney-week-20252025-11-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-secures-strategic-investment2025-08-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-portfolio-business-update2025-07-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-pricing-public-offering2025-06-17T16:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-intact-therapeutics-license-gastroparesis2025-06-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-bio-international-convention-20252025-06-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-asco-2025-abstracts2025-05-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-dr-david-young-presentation-orphan-drug-congress2025-04-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-medinvest-conference-20252025-03-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-2025-bio-ceo-investor-conference2025-02-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-fireside-chat-healthcare-conferences2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-q3-2025-financial-results2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-phase-2-study-pcrx-201-osteoarthritis2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-license-agreement-amacathera2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-third-quarter-2025-financial-results2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-pcrx-201-gene-therapy-data2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-qilu-pharmaceutical-anda-filing2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-exparel-data-amcp-nexus-20252025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-whiteoak-application-exparel2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-establishes-ibogaine-operations-africa2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-phase-iib-study-adjustment-disorder2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-investment-psylabs-35000002025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-presentation-hc-wainwright-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-corporate-update-august-20252025-08-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-psylabs-ibogaine-production2025-07-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-dr-garcia-romeu-scientific-advisory-board2025-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-q3-2025-financial-results-highlights2025-11-10T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-guggenheim-healthcare-innovation-conference2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-participate-chardan-genetic-medicines-conference2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-hc-wainwright-investment-conference-20252025-08-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reverse-stock-split-20252025-07-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-uplift-d-study-update2025-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-investor-conferences-20252025-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-sharon-skare-clinical-operations2025-10-28T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-phase-1b-pali-2108-crohns-disease2025-10-20T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-canadian-patent-pali-21082025-10-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-cancels-special-meeting-stockholders2025-10-09T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-closes-138-million-offering2025-10-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-pricing-120-million-offering2025-10-01T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-special-meeting-adjourned-quorum2025-09-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-positive-pali-2108-phase-1b-data2025-09-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-phase-1b-trial-pali-2108-fscd2025-09-05T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-leadership-succession-business-updates2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-private-placement-175-million2025-10-03T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-positive-results-ov329-gaba-inhibitor2025-10-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-business-updates-q2-2025-results2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-btig-virtual-biotech-conference2025-07-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-immedica-ganaxolone-royalties-agreement2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-investor-media-event-june-20252025-06-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-needham-conference-20252025-04-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-acceptance-ons-5010-wet-amd2025-11-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-resubmits-bla-ons-50102025-11-03T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-type-a-meeting-update2025-09-29T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-euretina-innovation-spotlight-20252025-09-03T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-type-a-meeting2025-09-02T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-update-ons-5010-lytenava2025-08-28T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-q3-2025-financial-results-update2025-08-14T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-ophthalmology-innovation-summit-20252025-07-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-virtual-investor-conference2025-07-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-appoints-bob-jahr-ceo2025-07-01T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-q3-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-third-quarter-2025-financial-results-earnings-call2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-steven-boyd-board-directors2025-10-28T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-appoints-anne-messing-as-cco2025-08-04T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-launches-novel-blood-collection-device2025-07-10T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-40-million-stock-repurchase-program2025-03-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-q3-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-november-investor-conferences2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-180-million-private-placement2025-09-17T05:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-positive-interim-phase-1-results-orka-0012025-09-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/orka-001-phase-2a-trial-clearance2025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-promotes-laura-sandler-coo2025-07-01T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-jefferies-conference-20252025-05-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-phase-1-trial-orka-0022025-05-20T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-inducement-grants-nasdaq-rule-5635c42025-11-07T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-enozertinib-publication-cancer-research2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-investor-conferences-november-20252025-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-eortc-nci-aacr-conference-20252025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-appoints-kevin-brodbeck-cto2025-08-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-q2-2025-financial-results2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-cms-payment-reform-20262025-11-03T18:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-inducement-grants-nasdaq-rule-56352025-10-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-update-second-phase-3-renu-study2025-09-25T20:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-investor-conferences-september2025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-q2-fy2025-results2025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-cms-skin-substitute-payment-reform2025-07-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-q4-full-year-2024-results2025-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-cancels-earnings-call-acquisition-paratek2025-03-20T01:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-preliminary-q4-2024-revenue2025-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-corporate-update-settlement-leadership-changes2025-08-18T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-discontinues-wet-amd-trials2025-03-31T04:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-coast-phase-3-trial-results2025-03-24T04:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-phase-2b-wet-amd-publication2025-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-half-year-results-business-updates2025-02-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-drug-product-ppq-campaign-completed2025-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-coast-final-week-52-patient-visit2025-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-presentation-oppenheimer-healthcare-conference2025-02-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-wet-amd-data-macula-society-meeting2025-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-investor-days-new-york-australia2025-01-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-financing-private-placement-debt-settlement2025-09-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-ocuvex-terminate-merger-agreement2025-09-26T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-proteomedix-immunovia-pancreasure-license-agreement2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-ocuvex-merger-agreement2025-07-16T12:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-positive-decision-nasdaq-hearings-panel2025-06-16T12:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-reverse-stock-split-special-meeting-results2025-06-11T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-receives-nasdaq-delisting-notice2025-05-22T20:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-ocuvex-business-combination2025-04-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-proclarix-clinical-validation-danish-cohort2025-03-24T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-business-update-fxr-program-sale2025-03-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-fxr-program-acquisition-eli-lilly2025-02-25T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-acquisition-deerfield-management2025-02-21T14:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-third-quarter-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/insourced-dialysis-service-line-outset-medical2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-2025-stifel-healthcare-conference2025-11-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-third-quarter-2025-results2025-10-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/northwest-kidney-centers-outset-medical-collaboration2025-09-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-presents-morgan-stanley-conference2025-08-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-q2-2025-results-revenue-growth2025-08-06T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-names-first-chief-nursing-officer2025-07-30T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-goldman-sachs-healthcare-conference-20252025-06-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-q3-2025-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-inducement-grants-nasdaq-rule-56352025-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-investor-conferences-20252025-11-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-phase-3-opera-02-trial-sabcs-20252025-10-30T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-phase-1b-2-trial-palazestrant-ribociclib2025-10-18T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-clinical-trial-agreement-pfizer2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-present-bio-europe-2025-vienna2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-chairman-acquires-shares2025-10-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-urcosimod-clinical-trial-ncp2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-funding-urcosimod-neuropathic-corneal-pain2025-07-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-presentation-bio-international-convention2025-06-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-gpcrs-summit-presentation-urcosimod2025-05-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/fda-fast-track-urcosimod-neuropathic-corneal-pain2025-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-urcosimod-long-term-stability2025-03-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-q2-2025-shareholder-update2025-08-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-southern-star-research-onp-002-phase-iia-trial2025-07-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-drug-manufacturing-agreement-onp-0022025-07-16T12:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-completes-16-5-million-offering2025-07-02T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-public-offering-preferred-stock-warrants2025-07-01T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-presents-bio-convention-neurotrauma-symposium-20252025-06-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-one-for-thirty-reverse-stock-split2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-phase-ii-concussion-drug-trial-australia2025-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-webinar-on-concussion-treatment-onp-0022025-05-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-participate-traumatic-brain-injury-conference2025-04-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q3-2025-results-business-update2025-11-06T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-investor-conferences2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-investor-conferences-20252025-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-first-quarter-2025-results-release2025-05-07T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-participate-needham-healthcare-conference2025-04-02T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-successful-2024-sets-stage-2025-catalysts2025-03-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-btig-conference-20252025-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-prices-29-million-equity-offering2025-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-appoints-dr-paul-billings-cmo2025-01-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-expands-vitagraft-kidney-market-opportunity2025-01-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-conferences-november-december-20252025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inducement-grant-nasdaq-rule-5635c42025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-q3-2025-results2025-11-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-achieves-randomization-in-sol-r2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-participate-scientific-conferences-october-20252025-10-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-underwritten-offering-common-stock2025-09-30T11:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-day-axpaxli-progress2025-09-30T10:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-day-september-20252025-09-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-q3-2025-financial-results-update2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-financial-results-and-milestones-20252025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-participate-november-investor-conferences2025-11-05T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-110-million-financing-privosegtor-development2025-10-30T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-raises-110-million-for-privosegtor-development2025-10-30T08:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-late-stage-pipeline-eyecelerator-aao-20252025-10-14T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-business-update-q3-2025-results2025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-webcast-november-2025-business-updates2025-10-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-present-industry-investor-conferences-october-20252025-10-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-kwangdong-license-agreement-ocu4002025-09-15T10:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-participate-hc-wainwright-global-investment-conference2025-09-02T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-positive-scientific-advice-ema-ocu410st2025-08-13T10:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-20-million-offering-20252025-08-12T19:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-new-appointments-retina-advisory-board-leadership2025-07-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-expands-energy-digital-assets2025-04-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-patent-bispecific-antibodies-china2025-03-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-egfr-mutant-lung-cancer-fda-alignment2025-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-malaria-vaccine-research-funding2025-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-stifel-healthcare-conference-20252025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-participate-stifel-2025-healthcare-conference2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-q3-2025-financial-results-release2025-10-30T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-first-commercial-patients-genio-system-us2025-10-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-first-us-commercial-patients-genio-system2025-10-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-transparency-notification-vestal-point-capital2025-10-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-expansion-middle-east-genio2025-09-23T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-expands-middle-east-presence2025-09-23T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-upcoming-investor-conferences2025-11-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-q3-2025-results2025-11-10T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-business-update-call-november-20252025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-terumo-30-million-agreements2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-virtue-sab-trial-enrollment2025-10-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-georgia-innovation-summit2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-clinical-data-hrx-20252025-09-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-clinical-data-publication2025-08-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-private-placement-common-stock2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-business-update-q3-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-simcere-expansion-phase-1-trial-sim05052025-10-16T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-hc-wainwright-conference-20252025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-nc605-osteogenesis-imperfecta-preclinical-data2025-07-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-simcere-partnership-antibody-drug-conjugate2025-06-16T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-ligachembio-lnc74-asco-20252025-05-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-needham-healthcare-conference2025-04-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-fda-q-submission-gen-2-sync-alzheimers-dementia2025-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-regulatory-approval-gen-2-sync-israel2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-difs-neurostimulation-alzheimers-dementia-improvements2025-10-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-dr-robert-rothstein-appointment2025-10-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-maxim-growth-summit-20252025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-gen-2-sync-alzheimers-clinical-results2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-us-patent-halo-clarity-device2025-09-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-live-investor-webinar-september-92025-08-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-appoints-justin-van-fleet-cfo2025-08-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-reports-q3-2025-results2025-11-04T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp900-poster-presentation-highlights2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-appoints-juan-sanchez-board2025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-hc-wainwright-investment-conference2025-09-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-phase-1b-nxp900-initiation2025-08-11T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp800-nxp900-update-ovarian-cancer2025-07-31T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp900-drug-drug-interaction-study2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-fda-meeting-aversafentanyl2025-10-28T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ceo-return-gareth-sheridan2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-brand-institute-fentanyl-patch2025-10-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-files-provisional-patent-aversat-technology2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-presentation-noble-capital-markets-conference2025-10-08T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-present-microcap-rodeo-conference2025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-quarterly-report-revenue-aversa-fentanyl2025-09-10T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-announces-warrant-exercise-6-432025-09-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-emerging-growth-conference-20252025-08-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-positive-phase-1-data-nexiguran-amyloidosis2025-11-10T20:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-lonvoguran-ziclumeran-positive-data2025-11-08T22:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-q3-2025-results-updates2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-update-magnitude-trials-nexiguran2025-10-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-nasdaq-rule-56352025-10-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-nexiguran-phase-1-trial-data-presentation2025-09-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-q3-2025-financial-results2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-peter-soukas-cmo2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inducement-grants-nasdaq-rule-56352025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-dan-dearen-board-directors2025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-presentation-hc-wainwright-conference2025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-raymond-cohen-board-directors2025-07-31T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-combined-financings-58-million2025-07-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-new-medical-coverage-michigan2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-strong-third-quarter-2025-results2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-q3-2025-results-update-call2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-fda-clearance-functional-dyspepsia-treatment2025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-participate-lytham-partners-fall-2025-conference2025-09-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-new-medical-policy-coverage-700k-lives2025-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-achieves-milestone-fap-ibs-guidelines2025-06-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-roger-dansey-board2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-nx-1607-sitc-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-ash-annual-meeting-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-investor-conferences2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-250-million-offering2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-daybreak-pivotal-study-bexobrutideg-cll2025-10-22T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-nx-1607-esmo-congress-20252025-10-18T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-q3-2025-financial-results-update2025-10-09T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-gs-6791-preclinical-data-eadv-20252025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-q2-2025-financial-results-guidance2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-cms-reimbursement-epilepsy-rns-system2025-08-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-strategic-cfo-transition2025-06-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-secures-75-million-debt-financing2025-06-04T20:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-nautilus-study-results-20252025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-update-tariff-status2025-04-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-rns-system-data-2025-aan-meeting2025-04-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-presentation-aan-20252025-04-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-sidoti-small-cap-conference-20252025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-fda-clearance-onerf-trigeminal-nerve-ablation-system2025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-q3-fy2025-results-revenue-growth2025-08-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-third-quarter-fiscal-results-20252025-07-31T16:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-receives-notice-of-allowance-for-patent2025-07-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-patient-seizure-freedom-onerf-ablation-system2025-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-appoints-emily-johns-general-counsel2025-06-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medinvest-conference-20252025-05-29T17:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-funding-compliance-reporting-obligations2025-07-16T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-third-quarter-2025-financial-results2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-november-investor-conferences2025-10-30T17:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-poster-presentation-acr-convergence-20252025-10-22T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-hcw-home-series2025-07-23T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-appoints-shawn-rose-cmo-autoimmune-focus2025-06-06T12:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-april-investor-conference2025-04-01T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-q3-2025-financial-results-update2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-conferences-november2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-phase-1-study-nmra-8982025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-nmra-215-weight-loss-preclinical-results2025-10-27T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-host-virtual-rd-day-october-272025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-strategic-review-maximize-stockholder-value2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-stockholder-rights-plan2025-10-27T20:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-affirms-bnc210-trial-update2025-10-20T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-fiscal-year-end-2025-results2025-09-29T20:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-presentation-hc-wainwright-conference2025-08-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-presentation-ascp-2025-annual-meeting2025-05-27T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-first-quarter-2025-business-updates2025-05-20T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-review-2024-highlights-2025-plans2025-04-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-nasdaq-opening-bell-20252025-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-q3-2025-financial-results2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-financing-roluperidone-phase-3-trial2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-jefferies-london-healthcare-conference-20252025-11-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-jefferies-london-healthcare-conference2025-11-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-investor-conferences-november-20252025-11-03T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-healthcare-royalty-agreement-funding2025-10-31T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-royalty-monetization-agreement2025-10-31T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-clinical-updates-jnj-1900-nbtxr32025-10-24T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-updates-jnj-1900-clinical-program2025-10-24T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-field-evaluation-unit-buck-institute2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q3-2025-financial-results2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-september-investor-conferences2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-agreement-allen-institute-alzheimers-research2025-07-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-goldman-sachs-conference-20252025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq-rule-56352025-11-07T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-corporate-update-q3-20252025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-medical-meeting-investor-conferences-november2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-stifel-2025-forum2025-09-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-ema-marketing-authorization-obicetrapib2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-broadway-trial-alzheimers-biomarkers2025-07-30T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-positive-alzheimers-data-broadway-trial2025-06-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-showcases-cancer-detection-solutions-medica-20252025-11-12T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-attend-garps-20252025-11-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-attend-2025-maxim-growth-summit2025-10-15T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-pancreatic-cancer-biomarker-study-results2025-10-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-colorectal-cancer-screening-presentation2025-09-30T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-launch-coloalert-switzerland2025-09-23T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-coloalert-registration-uk2025-09-02T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-swiss-approval-coloalert2025-08-13T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-follow-on-offering-20252025-08-04T14:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-care-cooperation-agreement2025-07-23T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-investor-healthcare-conferences2025-11-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-myrisk-cancer-test-expansion2025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-2025-nsgc-conference-advancements2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q3-2025-financial-results2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/genesight-results-depression-treatment-analysis2025-10-31T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-adds-f8-fxn-genes-foresight-panel2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-sophia-genetics-liquid-biopsy-collaboration2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-precise-mrd-clinical-data-lancet-oncology2025-09-04T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/genesight-test-improves-depression-response-rates2025-09-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-proxy-statement-acquisition-details2025-09-23T23:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-q2-2025-financial-results-update2025-08-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-securities-issue2025-05-19T19:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-explores-strategic-alternatives2025-04-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-phase-3-artistry-7-trial-update2025-03-25T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-q4-2024-results-clinical-milestones2025-03-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-presents-td-cowen-conference-20252025-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-cfo-transition-20262025-11-12T21:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-q3-2025-financial-results2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-q3-2025-financial-results-release2025-10-08T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-moonlight-bio-t-cell-therapies2025-10-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-operational-restructuring-costs-profitability2025-09-22T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-platform-license-agreement-adicet-bio2025-08-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-strategic-license-agreement-anocca-tcr-t-therapy2025-07-31T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-positive-phase-2b-results-met-097i2025-09-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-next-generation-obesity-portfolio-easd-20252025-09-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-september-investor-conferences2025-08-27T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-reports-q2-2025-results-progress2025-07-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-goldman-sachs-healthcare-conference-20252025-06-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-positive-phase-1-data-amylin-candidate-met-233i2025-06-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-research-obesity-portfolio-ada-20252025-06-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-present-bank-america-2025-healthcare-conference2025-05-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-new-board-members2025-03-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-acquisition-preferred-stock-dr-smith2025-02-13T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-evelyn-dan-board2025-02-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-nyse-noncompliance-notice2025-01-10T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-q2-2025-financial-results2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-call-august-20252025-07-28T21:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-appoints-rajesh-asarpota-cfo2025-06-25T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-appoints-bernd-brust-ceo2025-06-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-2024-sustainability-report2025-05-21T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-postpones-earnings-release2025-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-mcrc-clinical-data2025-10-25T09:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-colorectal-cancer-data2025-10-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-aacr-nci-eortc-conference2025-10-14T18:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-abstract-petosemtamab-aacr-conference-20252025-10-13T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-2025-wells-fargo-healthcare-conference2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-q2-2025-results-business-update2025-08-07T19:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-q2-2025-financial-results2025-08-07T19:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-present-canaccord-genuity-growth-conference2025-08-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/day-one-biopharmaceuticals-acquire-mersana-therapeutics2025-11-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-third-quarter-2025-conference-call2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-business-update-q2-2025-results2025-08-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-reverse-stock-split2025-07-24T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-emile-phase-1-data-asco-20252025-06-02T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-investor-conferences2025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-business-update-q1-2025-results2025-05-15T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-restructuring-plan-emi-le-breast-cancer2025-05-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-emile-presentations-asco-20252025-04-23T14:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-kathryn-penkus-corzo-board-appointment2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-ash-2025-mt-601-presentations2025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-first-patient-ots-program2025-10-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-hc-wainwright-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-phase-1-apollo-study-update2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-fireside-chat-canaccord-conference2025-07-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-cellipont-collaboration-mt-6012025-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-lymphodepletion-mar-t-cells2025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-mar-t-cells-webcast2025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-canaccord-genuity-conference2025-04-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-new-data-dll3-targeting-mp07122025-11-12T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-phase-1-2a-trial-mp0533-ash-20252025-11-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-sitc-2025-data-presentation2025-11-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-q3-2025-results-clinical-progress2025-10-30T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-h1-2025-financial-results2025-08-25T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-appoints-martin-steegmaier-cso2025-08-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-orano-med-preclinical-data-mp07262025-06-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-positive-data-phase-1-2a-trial-mp05332025-06-11T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-operational-efficiencies-cash-runway2025-06-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-investor-conferences-20252025-05-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-q3-2025-financial-results2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-fireside-chat-leerink-conference2025-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-update-clinical-programs2025-01-12T16:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-presentation-jp-morgan-conference-20252025-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-contract-research-development-award-20252025-11-06T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-completes-enrollment-mn-001-clinical-trial2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-atherosclerosis-therapeutic-approach2025-10-30T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-presentation-ld-micro-conference-20252025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-completes-enrollment-combat-als-trial2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-combat-als-poster-presentation-symposium2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-shareholder-update-key-developments2025-09-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-presentation-hc-wainwright-conference-20252025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-combat-als-trial-enrollment2025-08-26T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-signs-standby-equity-purchase-agreement2025-07-31T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-q3-2025-financial-results2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-new-data-copper-balance-wilson-disease2025-11-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-abstract-accepted-aasld-liver-meeting-20252025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-135-million-offering2025-09-24T03:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-alxn1840-copper-balance-wilson-disease2025-09-24T03:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-alxn1840-ana-2025-presentation2025-09-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-abstract-accepted-ana-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-expanded-access-program-mnpr-1012025-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-russell-3000-2000-inclusion2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presentation-jefferies-global-healthcare-conference2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-phase-3-icon-1-trial-update2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-launches-al-mann-scholarship-diabetes2025-11-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-reports-q3-2025-financial-results2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-third-quarter-financial-results-call-20252025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-fda-review-afrezza-children-diabetes2025-10-13T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-appoints-dr-ajay-ahuja-cmo2025-09-29T10:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-investor-conferences-september-20252025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-expansion-united-therapeutics-collaboration2025-08-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-wrapsody-trial-results2025-11-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-24-month-efficacy-results-wave-trial2025-11-03T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-q3-2025-results-guidance-update2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-pentax-c2-cryoballoon-technology2025-10-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-q3-2025-results-announcement2025-10-03T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-scout-milestone-750000-patients2025-10-01T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-embosphere-ce-mark-knee-osteoarthritis2025-09-12T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/first-patient-enrolled-merit-medical-wrapsody-registry2025-08-18T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-prelude-wave-launch-snapfix-technology2025-08-07T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-autonomous-robotic-knee-surgery2025-07-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRM/zimmer-biomet-acquires-monogram-technologies2025-07-14T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-q1-2025-financial-results2025-05-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-offering-pricing2025-11-05T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-q3-2025-results-sonelokimab-data2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-velas-phase-3-results-sonelokimab2025-09-28T16:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-q2-2025-update2025-08-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-capital-markets-day-april-20252025-04-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-secures-500-million-financing-clinical-updates2025-04-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-initiates-new-clinical-trials-sonelokimab2025-01-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q3-2025-financial-results-update2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/lorundrostat-asn-kidney-week-20252025-11-07T23:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-investor-conferences2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-phase-2-explore-ckd-trial-asn-kidney-week-20252025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-phase-2-explore-osa-trial2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-launch-htn-trial-lorundrostat-hypertension2025-09-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-upsized-public-offering2025-09-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-pricing-public-offering2025-09-03T01:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-public-offering-common-stock2025-09-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-growth-initiatives-new-leadership2025-10-14T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-nyse-compliance-notification2025-10-14T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-appoints-dawood-sayed-board2025-09-22T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-revenue-increase-q2-20252025-08-14T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-q2-2025-results-call2025-08-13T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-appoints-jason-papes-sales-marketing2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-appoints-eric-hines-ceo2025-08-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-compuflo-sales-painless-center2025-07-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-appoints-shanth-thiyagalingam-board2025-05-19T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-reports-revenue-business-update-q1-20252025-05-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-investor-conferences-20252025-11-12T20:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-second-quarter-results-20252025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-second-quarter-results-november-20252025-10-03T15:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend2025-10-03T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-strategic-financing-plan2025-08-18T18:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-fy25-results2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-third-quarter-2025-update2025-11-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-etrapamil-nasal-spray-psvt2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-etriapamil-aha-20252025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-conference-presentation-20252025-08-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-public-offering-20252025-07-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-proposed-public-offering2025-07-11T10:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-fda-acceptance-cardamyst-response2025-07-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-fda-response-cardamyst-etripamil2025-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-q3-2025-results-pipeline-prioritization2025-11-11T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-mgx-001-hemophilia-a-preclinical-data2025-11-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-business-updates-q2-2025-results2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-appoints-laurence-reid-board-directors2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-advancements-next-gen-genome-editing-asgct-20252025-05-14T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-present-scientific-meetings-20252025-05-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-publication-nature-communications-cast-systems2025-03-13T10:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-presents-td-cowens-45th-health-care-conference2025-02-11T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-affordable-access-zepbound-wegovy2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-mgx-0024-avian-flu-defense2025-05-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-entry-high-growth-pouch-industry2025-04-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-expands-diabetes-market-diabetinol2025-03-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-launches-peachesrx-womens-telehealth2025-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-advances-avian-flu-research2025-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-h1n1-h5n1-research-advancement2025-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-exclusive-distribution-agreement-dermytol2025-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ME/23andme-sale-agreement-ttam-research-institute2025-06-13T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ME/23andme-voluntary-delist-nasdaq-deregister-sec2025-05-27T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ME/regeneron-acquires-23andme-court-supervised-sale2025-05-19T11:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-fda-meeting-rexlemestrocel-opioid-cessation2025-11-04T23:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-net-revenues-increase-q2-20252025-10-19T23:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-j-code-medicare-medicaid-services2025-10-03T01:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-cell-therapy-us-origin-tariffs2025-09-26T05:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/successful-launch-ryoncil-meso2025-09-15T01:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-convertible-notes-50-million2025-09-04T01:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/banner-year-mesoblast-fda-approval-ryoncil2025-08-29T00:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-20252025-08-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/successful-commercial-launch-of-ryoncil2025-07-18T00:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-reports-q3-2025-results-update2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-stifel-2025-healthcare-conference2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presentation-hc-wainwright-conference2025-09-02T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-second-quarter-2025-financial-results2025-08-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-appoints-eric-risser-ceo2025-08-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-sagard-royalty-purchase-agreement2025-06-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-goldman-sachs-healthcare-conference-20252025-06-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-q1-2025-financial-results-release2025-05-06T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-participate-investor-conference2025-05-01T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q3-results-20252025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-third-quarter-2025-financial-results-release2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-closes-exosome-diagnostics-acquisition2025-09-15T21:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-q2-2025-results-acquisition-bio-techne2025-08-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-appoints-michael-holder-management-change2025-07-03T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q1-2025-results2025-05-14T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-q4-full-year-2024-results2025-02-26T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-fourth-quarter-full-year-2024-results2025-02-12T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-2024-revenues-2025-guidance2025-01-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-update-epieffect-randomized-controlled-trial2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-participate-upcoming-investor-conferences2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-comments-cy-2026-medicare-physician-fee-schedule2025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-record-revenue-third-quarter-20252025-10-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-third-quarter-2025-results-conference-call2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-launches-epiexpress2025-10-06T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-sponsor-attend-sawc-fall-symposium2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-record-q2-2025-results2025-07-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-vaporox-strategic-collaboration2025-07-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-third-quarter-2025-financial-results2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-gmp-manufacturing-facility-nexobrid2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-30-million-offering-ordinary-shares2025-09-29T12:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-nexobrid-approval-australia2025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-nexobrid-european-burns-association-congress2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-presents-hc-wainwright-investment-conference2025-08-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-q2-2025-results-update2025-08-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/medi-wound-escharex-phase-ii-data-wound-closure2025-08-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-positive-interim-analysis-sknjct-0032025-03-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-phase-2-clinical-design-uae-bcc2025-02-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-update-sknjct-003-phase-2-study2025-02-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-standby-equity-agreement-delisting-tsxv2025-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-mash-cirrhosis-data2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-equity-awards-nasdaq-rule-56352025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q3-2025-financial-results2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-new-data-mash-program-aasld-20252025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-morgan-stanley-conference-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-q3-2025-financial-results2025-11-11T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2025-q3-financial-results2025-10-28T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-raises-7-6-million-growth-capital2025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-time-healthtech-companies-20252025-09-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/deepview-system-european-burns-association-congress2025-09-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-submission-fda-deepview-system2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/deepview-system-british-burn-association-conference2025-06-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-appoints-stanley-micek-coo2025-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-q3-2025-financial-results-updates2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-carb-x-funding-ser-1552025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-155-idweek-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-fda-feedback-ser-155-phase-22025-09-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-hc-wainwright-conference-20252025-08-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-leadership-transition2025-07-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-155-asco-20252025-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-q3-2025-financial-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-november-investor-conferences2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-stifel-2025-forum2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-upsized-public-offering2025-09-25T01:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-proposed-public-offering2025-09-22T20:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-canvuparatide-phase-2-trial-results2025-09-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-phase-2-trial-results-canvuparatide2025-09-19T20:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-phase-1-trial-mbx-4291-obesity2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-andreas-moraitis2025-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-orphan-drug-designation-mb-1012025-07-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-regains-compliance-nasdaq-requirement2025-03-05T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-sale-fixed-assets-exit-facility2025-02-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-regains-nasdaq-compliance2025-02-11T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-closes-8-million-public-offering2025-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-public-offering-pricing2025-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reverse-stock-split2025-01-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-endovascular-robotic-system-release2025-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-system-debut-symposium2025-10-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-logistics-partner-liberty-system2025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-final-closing-preferred-investment-options2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-patent-japan-global-ip-portfolio2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-fda-clearance-liberty-robotic-system2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-preferred-investment-options-exercise2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-fda-clearance-liberty-system-conference2025-09-09T12:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-q3-2025-financial-results2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-asn-kidney-week-20252025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-investor-conferences-20252025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-appoints-herve-hoppenot-chairman2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-oversubscribed-private-placement-150-million2025-09-11T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-positive-phase-1-results-mze7822025-09-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-appoints-misbah-tahir-cfo2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-jefferies-2025-conference2025-05-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-101-trial-progress-aacr-20252025-10-27T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-2-nsclc-trial-results2025-10-23T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-private-placement-funding-phase-ii-trial2025-10-13T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-digital-asset-treasury-strategy2025-10-07T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-101-phase-2-trial-grant2025-09-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-101-phase-2-trial-nsclc2025-09-11T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-abstract-poster-presentation-2025-iaslc2025-09-05T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-interim-clinical-data-publication2025-08-27T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-european-patent-telomere-targeting-agents2025-08-13T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-phase-3-trial-update2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-clinical-plan-lyr-210-enlighten-22025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-15-million-offering2025-06-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-enlighten-2-phase-3-trial-results2025-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-q3-2025-results2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-acquires-lyl273-car-t-cell-therapy2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-phase-1-2-ronde-cel-ash-meeting2025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-phase-3-car-t-cell-trial-aggressive-lymphoma2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-september-investor-conferences2025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-private-placement-funding2025-07-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-hcw-home-series-participation2025-06-23T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-phase-1-2-lyl314-data2025-06-17T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-strengthens-leadership-team2025-06-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q3-2025-financial-results2025-11-05T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-public-offering-private-placement2025-10-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-offering-common-stock2025-10-16T20:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-fda-accelerated-approval-lx20062025-10-07T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-fda-breakthrough-therapy-lx20062025-07-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-partnership-advance-cardiac-rna-therapeutics2025-06-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-80-million-financing-genetic-medicines2025-05-27T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-jefferies-2025-conference2025-11-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-hfpef-data-aha-20252025-11-08T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q3-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-benefits-patient-populations-ahead-of-sessions-20252025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-pilavapadin-phase-3-development2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-roundtable-chronic-pain-policy2025-10-08T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-update-fda-zynquista2025-09-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/pilavapadin-dpn-pain-reduction-easd-neurodiab2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-pilavapadin-clinical-data-presentations2025-09-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-therapeutics-tender-offer-delisting-nasdaq2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-therapeutics-shareholders-tender-shares-xoma-royalty2025-11-10T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-therapeutics-egm-rescheduled-november-20252025-09-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-reports-q2-2025-results-corporate-update2025-08-13T20:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-therapeutics-full-waiver-rvo-payment-obligation2025-04-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-evaluation-strategic-options-shareholder-value2025-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-doses-first-patient-phase-1-lava-1266-study2025-01-10T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-q3-2025-financial-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-nomlabofusp-friedreichs-ataxia-study2025-09-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-conference-call-nomlabofusp2025-09-28T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-public-offering-20252025-07-31T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-public-offering-pricing2025-07-30T03:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-public-offering2025-07-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-nonclinical-data-nomlabofusp-friedreichs-ataxia2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-fda-recommendations-nomlabofusp2025-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-q3-2025-financial-results-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-bio-pharma-award-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-preclinical-data-certepetide-adc2025-11-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-catalent-adc-license-agreement2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-cendifox-trial-results2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-warpnine-ilsta-trial-enrollment-update2025-07-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-q3-2025-results-business-update2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-inducement-grants-nasdaq-listing-rule-5635c42025-09-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/alcon-acquires-lensar-merger-agreement2025-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-fourth-quarter-full-year-2024-results2025-02-19T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-upcoming-investor-conferences2025-11-12T21:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-third-quarter-2025-earnings-announcement2025-10-09T21:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-presents-bank-america-healthcare-conference-20252025-05-05T20:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-present-needham-virtual-healthcare-conference2025-04-01T19:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-spartan-capital-conference-20252025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-q4-2025-priorities-lb-100-acquisition-plans2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-board-appointments-cfo2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-corporate-update2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-1-5-million-offering2025-07-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-5-million-private-placement2025-07-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-us-patent-stem-cell-therapy-aging-frailty2025-11-12T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-third-quarter-2025-financial-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-dr-joshua-hare-npr-interview-hlhs-therapy2025-10-27T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-participate-roth-healthcare-conference-20252025-10-06T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/george-paletta-elected-longeveron-board2025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-attend-alliance-regenerative-medicine-meeting2025-09-22T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-leadership-updates2025-09-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-presents-hc-wainwright-investment-conference2025-08-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-positive-results-phase-2a-lp-10-oral-lichen-planus2025-09-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-delisting-nasdaq-capital-market2025-06-20T19:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-us-patent-diagnostic-technology2025-06-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-collaboration-cook-myosite-lp-3102025-06-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-phase-2a-data-lp-310-oral-lichen-planus2025-05-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-lp-10-oral-lichen-planus-presentation2025-04-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-positive-phase-2a-results-lp-310-oral-lichen-planus2025-04-22T09:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-phase-2a-trial-lp-310-oral-lichen-planus2025-04-08T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-podcast-michael-chancellor2025-03-31T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-third-quarter-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-participate-november-investor-conferences2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-investor-day-december-20252025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-sq-innovation-fda-approval-lasix-onyu2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-closes-convertible-senior-notes-offering2025-08-14T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-pricing-convertible-senior-notes-offering2025-08-12T03:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-investor-conferences-20252025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-financial-results-september-20252025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-commercial-manufacturing-partner2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-polypeptide-collaboration-peptide-manufacturing2025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-industry-events2025-10-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-inducement-grant-nasdaq-rule-56352025-09-23T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-contract-pharma-conference2025-09-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q3-2025-financial-results2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-vizz-commercial-availability2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-investor-medical-conferences2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-fda-approval-vizz-presbyopia-treatment2025-07-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-nmpa-submission-lnz100-presbyopia2025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-thea-license-agreement-lnz100-canada2025-07-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-lotus-pharmaceutical-license-agreement2025-05-09T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-q3-2025-results-highlights2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-ash-annual-meeting-20252025-11-03T16:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q3-2025-results2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-morgan-stanley-conference-20252025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-appoints-carlos-santos-cfo2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-5-year-survival-data-asco-20252025-06-03T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-oncologic-hematologic-developments-asco-eha-asgct2025-05-22T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-event-asco-20252025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-reports-q3-2025-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-precise-sg100k-proteomics-collaboration2025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-q2-earnings-call-20252025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotech-sale-somalogic-illumina2025-06-23T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-proteomics-roundtable-webcast-series2025-05-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-new-product-innovations-aacr-20252025-04-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q3-2025-results-business-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-november-investor-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-579-preclinical-data-acr-meeting2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-eadv-ers-congresses2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-brian-adams-appointment2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-public-offering-250-million2025-06-27T03:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-activates-clinical-trial-site-uab2025-11-04T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-phase-1-1b-trial-update2025-09-08T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-presentation-update-hc-wainwright-conference2025-08-29T12:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-dr-james-lee-advisory-board2025-06-11T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-updated-interim-data-pas-004-asco-20252025-06-02T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-preclinical-data-pas-004-inhibits-ets22025-05-20T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q3-2025-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-fda-designation-hsv1-kb8012025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-fda-approval-vyjuvek-label-update2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-presents-cantor-global-healthcare-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-kb707-oncology-update2025-08-21T16:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-vyjuvek-approval-japan-deb2025-07-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/jeune-positive-results-phase-1-kb304-wrinkles2025-07-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-q3-results-updates-on-krro-1102025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-participate-investor-scientific-conferences-september-20252025-09-02T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-q2-2025-financial-results-updates2025-08-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-receives-ema-orphan-drug-designation-krro-1102025-07-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-appoints-loic-vincent-cso2025-04-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-full-year-2024-financial-results2025-03-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/krro-110-orphan-drug-designation-aatd2025-03-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-present-td-cowen-health-care-conference2025-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-jefferies-conference-20252025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q3-2025-results2025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-orphan-drug-designation-kpl-387-pericarditis2025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-investor-conferences-september2025-08-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q2-2025-financial-results2025-07-24T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-phase-2-3-trial-kpl-387-recurrent-pericarditis2025-06-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-carly-pearce-life-disrupted-campaign2025-04-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/largest-real-world-study-wearable-defibrillators-kmts2025-11-10T14:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-ace-pas-trial-results-aha-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-stifel-2025-conference2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-appoints-timothy-moran-chief-business-officer2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-cardiac-recovery-system-hfsa-20252025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-dr-elizabeth-kwo-appointment2025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-q1-fiscal-2026-results2025-09-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-top-workplaces-20252025-07-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-financial-results-q3-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-cytogam-cmv-kidney-transplant-trial2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-q3-financial-results-november-20252025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-present-stifel-2025-healthcare-conference2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-participate-september-investor-conferences2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-fda-approval-plasma-collection-center-houston2025-08-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-q2-results-20252025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-global-operations-products-availability2025-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-expands-specialty-bracing-portfolio2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-participate-upcoming-conferences2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-q3-2025-financial-results2025-10-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-fda-approval-3p-pediatric-plating-platform2025-10-28T20:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-q3-2025-revenue-guidance2025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-verteglide-first-procedures-eos2025-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-my01-distribution-agreement2025-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-appoints-kelly-fischer-board2025-08-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-chase-phase-2b-trial-results2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-presentation-hc-wainwright-conference2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-appoints-todd-bazemore-ceo2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-q2-2025-results-and-update2025-08-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-presents-hc-wainwright-ophthalmology-conference2025-08-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-kol-event-kpi-012-pced-treatment2025-07-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-presentation-jefferies-global-healthcare-conference2025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-fda-clearance-ind-phase-2a-trial2025-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-financing-parkinsons-trial2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-names-jean-fallacara-brand-ambassador2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-launch-pre-orders2025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-chris-webber-nugevia-ambassador2025-08-19T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-mnd-launch2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-jotrol-advancement2025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-regains-nasdaq-compliance2025-07-10T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-pwr-launch2025-06-30T19:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-glo-launch2025-06-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-preclinical-safety-profile-jade1012025-11-08T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-participate-upcoming-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-new-data-jaDE101-asn-kidney-week-20252025-10-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jadebiosciences-jade201-autoimmune-diseases2025-10-07T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-135-million-private-placement2025-10-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-phase-1-trial-jade1012025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-q2-2025-financial-results-update2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-investor-conferences-20252025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-appoints-brad-dahms-cfo2025-07-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-q3-2025-update2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-investor-conferences-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-30-million-offering2025-09-19T04:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-public-offering-briquilimab2025-09-18T20:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-corporate-reorganization-cost-cutting2025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-briquilimab-update-csu2025-07-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-briquilimab-eaaci-congress-20252025-06-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-q3-2025-financial-results2025-11-06T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-third-quarter-2025-financial-results-call2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-webcast-revolution-clinical-program-vyd23112025-10-28T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-us-ind-clearance-vyd2311-covid2025-10-06T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-paul-b-bolno-to-board2025-09-24T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-kristie-kuhl-communications-officer2025-09-17T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/spear-study-group-long-covid-antibody-study-design2025-09-04T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-participate-upcoming-investor-conferences2025-08-27T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-closing-57-5-million-public-offering2025-08-22T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-50-million-public-offering2025-08-21T03:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-temporary-suspension-euronext-paris2025-11-13T07:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-temporary-trading-halt-euronext-paris2025-11-13T07:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-public-offering-phase-3-trial-funding2025-11-12T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-launch-public-offering-125-million2025-11-12T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/assemblee-generale-mixte-inventiva-novembre-20252025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/combined-general-meeting-november-2025-documents2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-at-the-market-offering-iva2025-10-14T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-new-atm-program-100-million2025-10-14T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-acquisition-concentra-biosciences2025-07-21T11:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-wind-down-operations2025-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/galaxies-lung-201-results-belrestotug-dostarlimab2025-05-13T20:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/galaxies-lung-201-results-itos2025-05-13T20:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/galaxies-lung-201-results-belrestotug-dostarlimab-itos2025-05-13T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-financial-results-q1-20252025-04-29T21:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-q1-2025-financial-results2025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-preclinical-data-eos-215-aacr-20252025-03-26T15:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-q4-2024-results2025-02-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITCI/johnson-johnson-acquires-intra-cellular-therapies2025-01-13T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-settles-caplyta-patent-litigation2025-01-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-jp-morgan-conference-20252025-01-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-third-quarter-2025-financial-results2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-rally-mf-phase-2-trial-ash-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-investor-conferences-20252025-10-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-upsized-public-offering-250-million2025-10-21T04:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-public-offering-common-stock2025-10-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-update-hematology-portfolio-objectives2025-10-20T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-phase-1b-trial-data-asn-kidney-week-20252025-10-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-fda-national-priority-voucher-bitopertin-epp2025-10-16T21:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-nda-bitopertin-epp2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings2025-10-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-ai-advanced-imaging-ion-system2025-10-08T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-real-time-surgical-insights-da-vinci-52025-09-12T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-demonstrates-telesurgery-capabilities2025-07-16T13:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/vessel-sealer-curved-fda-clearance2025-07-10T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitives-da-vinci-5-surgical-system-ce-mark2025-07-02T13:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/dan-larson-robotic-surgery-success-story2025-05-27T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-ceo-transition-announcement-20252025-05-15T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-fda-clearance-da-vinci-single-port2025-05-01T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-americas-growth-leaders-20262025-11-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-reports-third-quarter-2025-results2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-third-quarter-2025-financial-results-call2025-10-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-board-transition-anthony-vuoto-retires-joe-kiani-appointed2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-participate-wells-fargo-healthcare-conference-20252025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-fda-clearance-mridium-3870-infusion-pump2025-05-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-first-quarter-2025-financial-results2025-05-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-first-quarter-2025-financial-results-call2025-04-28T13:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-third-quarter-2025-financial-results2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-nasdaq-listing-compliance2025-09-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-second-quarter-2025-financial-results2025-07-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-dame-trial-first-patient-enrolled2025-06-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-preliminary-results-q1-20252025-04-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-strategic-vision-call-april-20252025-04-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-opgx-best1-phase-1-2-trial2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-financial-results-q3-2025-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-fda-meeting-opgx-lca5-advancement2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-23-million-offering2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-inducement-grant-nasdaq-rule-56352025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-gma-spotlight-gene-therapy2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-chardan-genetic-medicines-conference-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-present-october-2025-conferences2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-positive-pediatric-data-opgx-lca5-trial2025-09-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-q3-2025-update2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-new-beta-islet-program-type-1-diabetes2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-presentation-chardan-conference2025-10-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-hc-wainwright-conference-20252025-08-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-eular-2025-presentations2025-05-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-asgct-2025-presentations2025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-fireside-chat-preclinical-programs2025-04-15T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-lifileucel-nsclc-clinical-data2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-third-quarter-2025-financial-results-webcast2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-inducement-grants-nasdaq-rule-56352025-10-17T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-conference-presentations2025-08-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-amtagvi-health-canada-approval-advanced-melanoma2025-08-18T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-financial-results-q2-20252025-08-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-participation-investor-conferences2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-preclinical-data-sitc-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-phase-3-results-cylembio-keytruda-esmo-20252025-10-20T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-update-pre-bla-meeting-fda2025-09-29T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-esmo-2025-abstract-presentation2025-09-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-q2-2025-financial-results-business-highlights2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/iobiotech-cylembio-keytruda-phase-3-trial-results2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-participation-cowen-jefferies-conferences2025-05-20T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-postpones-2025-annual-meeting2025-06-20T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-energy-3-trial-results2025-05-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-enpp1-deficiency-publication-impact2025-04-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-participate-needham-healthcare-conference2025-03-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-enpp1-deficiency-pivotal-program-update2025-03-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-td-cowen-conference-20252025-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-inz-701-enpp1-deficiency-presentation-chop-20252025-02-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-q3-2025-results-business-update2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-maxim-growth-summit-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-phase-2-mindful-trial-results-alzheimers2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-cordstrom-manufacturing-success2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-carepctrial-results2025-08-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-minful-trial-findings-video-release2025-07-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-agent-797-sitc-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q3-2025-results-and-clinical-highlights2025-11-05T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-agent-797-sitc-presentation2025-10-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-appoints-dr-holcomb-board2025-09-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-dr-jennifer-buell-car-tcr-summit2025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-appoints-dr-terese-hammond2025-09-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q2-2025-results2025-08-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-corporate-update-q2-20252025-07-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-inkts-solid-tumor-therapy2025-07-15T12:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-complete-remission-testicular-cancer2025-07-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-q3-2025-financial-results2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-clinical-update-decoy202025-09-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-hc-wainwright-conference-20252025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-additional-sale-private-placement2025-07-01T12:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reverse-stock-split2025-06-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-phase-1b-2-trial-decoy20-tislelizumab2025-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-dr-newman-cytokine-summit2025-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-q3-2025-results-business-highlights2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-inb-100-phase-1-trial-expansion-ohio-state2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-inb-619-b-cell-depletion-autoimmune2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-inb-200-four-years-remission-glioblastoma-trial2025-06-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-phase-1-inb-200-gbm-data2025-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-preclinical-data-inb-619-asgct-20252025-05-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-isct-2025-gamma-delta-t-cell-manufacturing2025-05-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-present-clinical-preclinical-data-gamma-delta-t-cell-platform2025-04-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-corporate-updates-financial-results-q2-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-batoclimab-six-month-remission-graves-disease2025-09-03T16:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-next-phase-growth-leadership-changes2025-04-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-positive-results-batoclimab-mg-cidp-studies2025-03-19T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-investor-webcast-batoclimab-results2025-03-18T20:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-q3-20242025-02-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-450-million-private-placement2025-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-q3-2025-financial-results-updates2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-discusses-overall-survival-data-phase-2a-trial2025-09-26T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-announces-175-million-offering-sanofi2025-09-25T04:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-public-offering-sanofi-investment2025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-appoints-dr-thomas-schall-chairman-board2025-09-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-closes-25-million-private-placement2025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-clinical-supply-agreement-lilly-atebimetinib2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-imm-529-fda-approval-phase-2-trial2025-11-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-clinical-trial-update-imm-529-travelan2025-10-31T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-q1-fy26-sales-growth2025-10-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-shareholder-update-projects-progress2025-10-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-partners-with-investorhub2025-08-27T02:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-fy25-global-sales-exceed-projection2025-07-17T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-highest-sales-history2025-04-10T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-calmino-ibs-treatment-launch2025-03-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-clinical-proof-of-concept-tcr-bispecifics2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-amie-krause-chief-people-officer2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/anzu-cel-prame-cell-therapy-esmo-20252025-10-20T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-venkat-ramanan-cfo2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-q2-2025-financial-results-update2025-08-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima203-prame-cell-therapy-asco-20252025-05-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima203-asco-2025-presentation2025-04-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-q3-2025-financial-results-business-update2025-11-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-webcast-ovarian-cancer-immunotherapy2025-11-10T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-immunotherapy-ovarian-cancer2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-ovarian-cancer-treatment2025-11-07T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-third-quarter-2025-conference-call2025-11-06T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-ovation-3-study-update2025-11-04T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-ovation-3-advanced-ovarian-cancer2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-2-ovation-2-sitc-presentation2025-10-23T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-ovation-3-study-advanced-ovarian-cancer2025-10-20T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-present-placcine-technology-vaccine-conferences2025-10-17T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-appoints-chief-commercial-officer-nxc-201-launch2025-11-12T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nxc-201-ash-2025-presentation2025-11-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-guggenheim-healthcare-conference-20252025-10-14T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-ash-2025-abstract-presentation2025-10-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-presents-piper-sandler-conference2025-10-01T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nexicart-2-enrollment-milestone2025-09-18T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/nancy-chang-joins-immix-biopharma-board2025-09-11T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-goose-capital-investment2025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-stifel-2025-healthcare-conference2025-08-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-other-serious-diseases-strategy2025-08-06T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/eftisarc-neo-phase-ii-results-ctos-20252025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-rd-tax-incentive-france2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q1-fy262025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/primary-endpoint-met-eftisarc-neo-phase-ii-immp2025-10-20T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-esmo-congress-2025-nsclc-treatment2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-fda-project-optimus-completion2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-tacti-004-phase-iii-update-nsclc2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-phase-ii-trial-neoadjuvant-efti-breast-cancer2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-eftisarc-neo-phase-ii-ctos-20252025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-positive-fda-feedback-efti-head-neck-cancer2025-08-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-q3-2025-results-progress-2026-launch2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-third-quarter-2025-results-webinar-conference2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-new-vp-marketing-transplant-assay-launch2025-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-reports-kidney-transplant-immune-reset-therapy2025-10-06T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/insight-molecular-diagnostics-kidney-transplant-conferences2025-09-24T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/insight-molecular-diagnostics-positive-strategic-update2025-09-08T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-enrolls-first-patient-graftassuredx-trial2025-09-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-participate-nyc-investment-conferences-september-20252025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-q2-2025-results-graftassuredx-launch2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-release-q2-2025-results-needham-conference2025-08-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-investor-conferences-november-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-data-hepatitis-b-aasld2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-q3-2025-financial-results-update2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-q2-2025-financial-results-call2025-07-31T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-2025-jefferies-global-healthcare-conference2025-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-hiv-functional-cure-croi-20252025-03-10T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-appoints-timothy-pigot2025-08-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-q2-2025-results2025-08-14T20:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-appoints-david-mcintyre-cfo2025-04-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-expansion-senior-leadership-team2025-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-appoints-mark-iwicki-ceo-growth2025-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-acquisition-concentra-biosciences2025-07-01T12:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-strategic-update-autoimmunity-pipeline2025-01-09T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-positive-phase-2a-data-inf904-hidradenitis-csu2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-guggenheim-healthcare-conference2025-10-21T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-regains-compliance-nasdaq-minimum-bid-price2025-09-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-september-investor-conferences2025-08-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-q2-2025-results-business-update2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-report-second-quarter-2025-results2025-07-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-nasdaq-deficiency-notice-minimum-bid-price2025-07-11T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-vilobelimab-phase-3-trial-outcome2025-05-28T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participate-investor-conferences-20252025-05-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-third-quarter-results-november-20252025-11-05T15:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-quellimmune-therapy-results2025-09-29T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-neutralize-aki-trial-update2025-09-24T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-hc-wainwright-conference-20252025-09-04T22:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-quellimmune-health-economic-study2025-09-02T12:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-neutralize-aki-trial-enrollment-milestone2025-08-06T12:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-4-4-million-offering2025-07-31T19:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-new-ceo-management-changes2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-preliminary-sales-results-q3-20252025-10-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-new-ceo-olivier-te-boekhorst2025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-bank-debt-refinancing2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-ceo-succession-planning2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-virtual-annual-meeting-20252025-06-05T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-radnet-acquisition-vote-recommendation2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-q1-2025-financial-results2025-05-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-microsoft-collaboration-mammography-solutions2025-04-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-appoints-mark-koeniguer-cco2025-04-08T14:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-fourth-quarter-full-year-2024-results2025-03-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-ramsoft-partnership-ai-mammography-solutions2025-03-05T19:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/koios-medical-icad-partner-breast-cancer-detection-ecr-20252025-02-26T19:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-ai-research-ecr-20252025-02-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-pre-announces-estimated-q4-2024-revenue2025-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-q2-2025-results2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-fda-clearance-cusa-clarity2025-11-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-q3-2025-financial-results2025-10-30T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-q3-2025-results-call2025-10-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-neurosurgical-portfolio-cns-meeting2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-new-cmo2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-leadership-presentation-conferences2025-08-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acclarent-aera-pediatric-registry2025-07-02T20:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-veithsymposium-2025-presentations2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-q3-2025-financial-results-business-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-phase-3-trial-results-kidney-week-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-q3-financial-results-november-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-symvess-autologous-vein-comparison2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-60-million-oversubscribed-offering2025-10-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-symvess-ukraine-combat-results2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-expansion-intellectual-property-bioengineered-esophagus2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-ctev-coronary-bypass-graft-preclinical-data2025-09-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-symvess-patients-outcomes-publication2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-business-update-fq1-2026-results2025-09-11T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-conference-participation-investor-webinar2025-08-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-fda-breakthrough-device-aortic-stenosis2025-06-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-patent-granted-ecg-assessment2025-06-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-signs-first-myovista-insights-customer2025-05-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-ceo-andrew-simpson-emerging-growth-conference-822025-05-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-investor-webinar-may-14-20252025-05-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-adds-key-advisors-scientific-board2025-05-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-launch-myo-vista-insights-platform2025-05-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-sitc-2025-presentation2025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-q3-2025-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-fast-track-wtx-1242025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-sitc-2025-poster-presentations2025-10-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-kidneycan-summit-20252025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-bio-international-convention-20252025-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-jefferies-conference-20252025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-q2-2025-financial-results2025-08-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-acquisition-xoma-royalty2025-08-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-2024-financial-results2025-03-28T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-delisting-notification-nasdaq2025-05-12T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-new-day-diagnostics-partnership2025-05-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-reverse-stock-split2025-03-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-9-million-public-offering2025-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-immune-checkpoint-inhibitor-sitc20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-preclinical-data-tce-program-sitc-20252025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-participates-virtual-investor-segment2025-10-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-participate-maxim-growth-summit-20252025-10-16T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-poster-presentations-sitc-20252025-10-16T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-virtual-investor-tcell-engager-program2025-09-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-congratulates-wugen-equity-financing2025-09-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-trbc-pembrolizumab-immune-checkpoint-inhibitor2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-positive-results-tcell-engager-study2025-09-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-second-generation-immune-checkpoint-inhibitor2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q3-2025-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q3-2025-earnings-call2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-expands-distribution-agreement-fisher-scientific2025-09-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-stephen-denelsky-board2025-09-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-ceo-succession-plan-appointment-directors2025-07-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-john-duke-board-appointment2025-06-02T20:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-q3-2025-financial-results-update2025-11-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-phase-3-trial-pirfenidone-pneumoconiosis2025-10-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-hydronidone-phase-3-results-aasld-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-hc-wainwright-conference-20252025-09-05T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-appoints-dan-weng-board2025-08-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-first-dosing-phase-1-trial-f230-pah-china2025-06-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-public-offering-closure2025-05-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-pricing-public-offering2025-05-23T00:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-public-offering-common-stock2025-05-22T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-q3-2025-results-revita-momentum2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-q3-2025-financial-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-rjva-002-preclinical-results-obesity2025-10-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-60-million-offering2025-09-26T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-revita-weight-loss-maintenance2025-09-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-expands-board-of-directors2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-closes-23-million-public-offering2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-20-million-public-offering2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-enrollment-update-gtb-3650-phase-1-trial2025-10-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-centurion-bahamas-summit-20252025-10-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-hc-wainwright-conference-20252025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-q2-2025-financial-results2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-advances-cohort-3-gtb-3650-phase-1-trial2025-08-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-appoints-new-board-member2025-06-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-advances-gtb-3650-phase-1-trial2025-05-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-ipf-study-interim-results2025-09-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-presentation-hc-wainwright-conference2025-09-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-webull-financial-webinar-20252025-08-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-ceo-participates-virtual-investor-segment2025-07-31T17:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-virtual-investor-conference-20252025-07-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-study-gr-0621-ipf-enrollment-complete2025-07-01T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-gr0621-inflammation-fibrosis-data2025-05-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-virtual-investor-closing-bell-series2025-05-21T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-q2-2026-financial-results-update2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-abstract-accepted-svin-meeting2025-11-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-secures-funding-fda-review-gtx-1042025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-strive-on-trial-results-20252025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-us-patent-iv-dosing-regimen-gtx-1042025-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-presentation-hc-wainwright-conference2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-gtx-104-fda-review2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-q3-2025-results-highlights2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-upcoming-healthcare-investor-conferences2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-ada-poster-presentations-accg-26712025-06-20T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-reports-q3-2025-financial-results2025-11-05T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-participate-fireside-chat-hc-wainwright-conference2025-09-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-appoints-eric-groen-executive-team2025-07-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-fireside-chat-citizens-conference-20252025-05-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-pricing-offering-common-stock2025-03-25T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-fda-approval-pathway-olvi-vec2025-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-newsoara-positive-phase-1b-2-data-olvi-vec2025-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-q3-2025-results2025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-third-quarter-earnings-release2025-10-16T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-anthem-elbow-fracture-system2025-10-14T20:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-jury-verdict-life-spine2025-08-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-leadership-transitions-q2-2025-sales-results2025-07-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-durapro-navigation-system-launch2025-07-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-share-repurchase-program2025-05-15T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-private-offering-senior-notes-acquisition-merus2025-11-10T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-fireside-chat-jefferies-conference-london2025-11-05T17:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-epcoritamab-ash-20252025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-tender-offer-merus-shares2025-10-21T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-endometrial-cancer-data2025-10-18T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-darzalex-sales-q3-20252025-10-14T10:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-acquires-merus-late-stage-pipeline2025-09-29T05:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-stock-units-warrants-grant-employees2025-09-25T23:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-q3-2025-results2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-highlight-gb3226-program-ash-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-full-year-2024-financial-results2025-03-19T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-participate-upcoming-investor-conferences2025-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-mrt-8102-preclinical-data-aha-20252025-11-08T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-q3-2025-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-investor-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-mrt-6160-acr-convergence-20252025-10-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-novartis-collaboration-degraders-immune-diseases2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-phase-1-study-mrt-8102-inflammation2025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-science-publication-molecular-glue-degraders2025-07-03T18:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-austria-expansion2025-10-09T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-expansion-belgium2025-10-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-portugal-flamingo-01-trial2025-09-30T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-trial-ireland2025-09-18T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-glsi-100-fda-fast-track2025-09-10T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/noble-capital-markets-initiates-research-coverage-glsi2025-08-20T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-internal-clinical-operations2025-08-19T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-romania-expansion2025-08-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-ceo-interviews-update2025-08-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-update2025-04-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-financial-results-update-november-20252025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-financial-results-business-update-20252025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-new-data-glpg5101-ash-20252025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-board-changes-business-development-focus2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-board-changes-strategic-focus2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/glpg3667-differentiation-tyk2-inhibitors-acr-20252025-10-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-glpg3667-acr-convergence-2025-data2025-10-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-cell-therapy-activities-reduction2025-10-21T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-wind-down-cell-therapy-business2025-10-21T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-novel-therapies-symposium-2025-ecnp2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-global-pivotal-program-plans2025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-ind-hold-response-fda2025-06-20T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-presentation-ascp-20252025-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-pricing-150-million-public-offering2025-02-05T01:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-public-offering2025-02-03T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-executive-leadership-transitions2025-10-13T20:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-inducement-grants-nasdaq-rule-56352025-09-18T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-preclinical-trial-oily-drug-delivery2025-10-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-new-product-development-agreement-melbourne-health2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-technology-us-product-launches-nutraceuticals2025-09-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-preclinical-trial-gel-based-antihistamine2025-09-05T15:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-agreement-idt-australia-manufacturing-facility2025-07-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-expands-us-operations-healthy-extracts-partner2025-06-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-sportsgel-sponsor-pickleball-tour-australia-new-zealand2025-02-27T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-launches-sportsgel-distribution-agreement-wpic2025-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-appoints-matthew-jones-head-sports-performance2025-01-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-third-quarter-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-ceo-transition2025-10-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-ctlnp-delivery-system-data-q2-2025-results2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reverse-stock-split2025-07-18T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-inducement-grant-nasdaq-rule-56352025-07-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-presentation-jefferies-conference-20252025-05-28T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-q1-2025-results2025-05-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-needham-conference-20252025-04-02T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-td-cowen-conference-20252025-02-24T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-shareholders-vote-november-20252025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-appoints-dr-usman-latif-advisory-team2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-participate-q3-virtual-investor-summit2025-09-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reports-q2-2025-financial-results2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-expands-clinical-advisory-team-hirsh2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-exhibit-adces-20252025-07-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-repurchases-series-a-warrants2025-07-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-continuous-blood-glucose-monitor-results2025-06-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reverse-stock-split-nasdaq-requirements2025-06-12T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-q3-2025-results-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-neuroscience-2025-presentation2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-attend-2025-maxim-growth-summit2025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-virtual-kol-event-gt-02287-parkinsons2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-gt-02287-parkinsons-phase-1b-study2025-10-06T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-drug-discovery-innovation-programme-20252025-09-23T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-gt-02287-phase-1b-extension-study2025-09-18T11:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-phase-1b-dosing-extension2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-btig-conference-20252025-07-24T12:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-navigate-trial-results-aasld-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-hc-wainwright-mash-conference2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-q2-2025-financial-results-update2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-new-credit-line-20252025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-kol-event-belapectin-mash-cirrhosis2025-06-10T12:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inducement-grants-nasdaq-rule-5635c42025-11-07T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-pioneer-trial-data-ash-20252025-11-03T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-q3-2025-highlights2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-q3-2025-results-call2025-10-22T12:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-preclinical-data-esmo-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-investor-meetings-20252025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-q3-2025-financial-results2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-investor-conferences-november-20252025-10-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/new-four-year-data-pombiliti-opfolda-iciem2025-09-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-approval-pombiliti-opfolda-japan2025-06-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/new-analysis-pombiliti-opfolda-muscle-nerve2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-q3-2025-financial-results-business-update2025-11-10T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-phase-2-trial-fg-3246-mcrpc2025-09-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-sale-china-astrazeneca-220-million2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-presents-hc-wainwright-investment-conference2025-08-27T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-approval-sale-china-astrazeneca2025-08-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-positive-fda-feedback-roxadustat-lr-mds2025-08-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reverse-stock-split-20252025-06-12T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-q3-2025-results-corporate-update2025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-present-bio-europe-20252025-10-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-present-2025-thinkequity-conference2025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presentation-2025-cell-gene-meeting2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibroblast-cells-therapeutic-advantages2025-09-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-positive-ind-updates-psoriasis-treatment2025-09-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-bone-marrow-organoid-advancements2025-09-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presentation-hc-wainwright-conference2025-08-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-multipotent-cells2025-07-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q2-2025-financial-results2025-08-14T10:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-annual-meeting2025-06-03T20:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-launch-pedmarqsi-germany2025-02-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-urica-therapeutics-phase-3-trials-dotinurad2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-urica-therapeutics-crystalys-financing2025-10-01T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-update-nda-cutx-1012025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-hc-wainwright-conference-20252025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-q2-2025-financial-results2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-sale-checkpoint-therapeutics2025-05-30T14:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/partex-fortress-biotech-ai-collaboration2025-03-17T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-q3-2025-results-and-corporate-developments2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-participation-investor-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-third-quarter-2025-financial-results2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-inducement-grants-nasdaq-rule-5635c42025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-pricing-public-offering2025-10-15T02:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-public-offering-common-stock2025-10-14T20:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-phase-3-duravyu-dme-trials2025-10-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-q3-2025-results-updates2025-11-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-awards-nasdaq-rule-56352025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft819-sle-acr-convergence-20252025-10-26T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-kamal-adawi-cfo2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-investor-conferences-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-q3-2025-financial-results-update2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-acquisition-qol-medical2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-eversana-gimoti-access-expansion2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-gimoti-patent-fda-orange-book2025-08-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-gimoti-patent-exclusivity-20382025-08-06T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-gimoti-patent-allowance-20362025-07-09T12:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-td-incidence-metoclopramide-ddw-20252025-04-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-2026-financial-calendar2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-phase-2-trial-evx-01-data2025-11-07T22:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-q3-2025-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-expands-rd-pipeline-ai-designed-cancer-vaccine2025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-raises-7-2-million-cash-runway-20272025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-appoints-dr-helen-tayton-martin-ceo2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-phase-2-trial-results-evx-012025-10-17T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-phase-2-trial-esmo-congress-20252025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-craig-hallum-conference-20252025-11-12T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-participate-2025-wells-fargo-conference2025-08-20T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-fda-acceptance-et-600-nda2025-07-08T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-addition-russell-indexes2025-06-27T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-fda-approval-khindivi-hydrocortisone-solution2025-05-28T21:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-investor-conferences-20252025-05-14T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-agreement-acquired-roche2025-09-18T05:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inducement-grants-nasdaq-listing-rule-56352025-09-05T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-investor-conferences-september-20252025-08-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-q2-2025-financial-results-updates2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-participate-goldman-sachs-healthcare-conference2025-06-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-clear-outcomes-data-aha-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-inducement-grants-nasdaq-rule-5635c42025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-q3-2025-financial-results-update2025-11-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-john-harlow-cfo2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-jefferies-global-healthcare-conference-20252025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-hosts-virtual-kol-event-statin-intolerance2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-clear-outcomes-aha-scientific-sessions-20252025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-nominates-esp-2001-preclinical-development-candidate2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-pricing-public-offering-common-stock2025-10-08T01:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-present-cell-20252025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-reports-strong-quarterly-performance2025-11-10T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-cellipont-partnership-ovarian-cancer2025-11-06T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-presentation-cell-gene-meeting2025-10-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-ceo-panel-ipsc-summit2025-09-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-aacr-conference-20252025-09-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-operational-update-20252025-09-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-presentation-hc-wainwright-conference2025-09-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-nasdaq-compliance2025-07-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-advisory-board-expansion2025-06-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-q3-2025-business-updates2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-us-patent-eras-00152025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-upcoming-conferences-november-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-morgan-stanley-healthcare-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-ind-clearance-eras-40012025-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-investor-conferences-june-20252025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-clinical-advancement-rastargeting-franchise2025-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-bank-america-health-care-conference2025-05-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-participate-upcoming-investor-conferences2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-inducement-grants-nasdaq-rule-56352025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-kol-event-ulcerative-colitis-november-20252025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-leadership-corporate-updates2025-10-06T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-q3-2025-financial-results2025-11-04T21:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-positive-data-resolve-trial-eosinophilic-esophagitis2025-09-29T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-public-offering-80-million2025-09-24T12:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-70-million-offering2025-09-23T02:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-proposed-public-offering2025-09-22T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/resolve-trial-results-eosinophilic-esophagitis-eprx2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-investor-conferences-20252025-07-22T21:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-doses-first-patient-phase-2b-eo-e-trial2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-annual-meeting-results2025-06-02T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-q3-fiscal-2025-results2025-06-16T22:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-strategic-alternatives-review2025-04-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-voluntarily-delist-nyse-otcqx2025-03-28T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-nyse-non-compliance-notice2025-01-14T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-eb613-phase-2-trial-results2025-10-23T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-phase-2-eb613-nams-20252025-10-16T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-positive-pk-data-oral-glp2-tablet2025-09-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-eb613-positive-effects-asbmr-20252025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-clinical-data-september-conferences2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-q2-2025-financial-results2025-08-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-fda-agreement-bmd-eb613-phase-3-study2025-07-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/opko-enterabio-oral-glp2-tablet-2025-espen-congress2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/opko-enterabio-endo-2025-presentation2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTO/entero-therapeutics-appoints-richard-paolone-ceo2025-02-14T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTO/entero-therapeutics-secures-loan-appoints-board-members2025-02-07T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-phase-iia-allocetra-acr-convergence-20252025-10-28T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-kol-webinar-knee-osteoarthritis-insights2025-09-29T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-strategic-roadmap-positive-phase-iia-results2025-09-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-patent-allocetra-osteoarthritis2025-09-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-positive-data-allocetra-knee-osteoarthritis2025-08-18T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-phase-ii-knee-osteoarthritis-webinar2025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-phase-ii-topline-data-announcement-20252025-07-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-allocetra-eular-congress-20252025-06-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-presentation-israeli-biomed-2025-conference2025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-allocetra-osteoarthritis-oarsi-20252025-04-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-third-quarter-2025-results2025-11-06T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-conference-call-q3-2025-results2025-10-24T20:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-sells-dr-comfort-business-60-million2025-10-08T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-time-change-baird-2025-conference2025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-participate-upcoming-investor-conferences2025-08-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-second-quarter-2025-results-conference-call2025-07-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-reports-q3-2025-results-bioenvelope-sale2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-third-quarter-2025-financial-results2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-presents-ld-micro-main-event-xix-conference2025-10-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-appoints-guido-neels-board-directors2025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-bioenvelope-sale-boston-scientific2025-10-01T12:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-biologic-envelopes-cied-stabilization2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-exhibit-elupro-antibiotic-eluting-bioenvelope2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-participate-upcoming-investor-conferences2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-robust-growth-elupro-market-adoption2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-el002-7p-trial-results-sitc-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-sitc-2025-presentation2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-phase-2-amplify-7p-trial-results2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-phase-1-trial-eli-002-7p-pancreatic-cancer2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-inducement-grants2025-09-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-eli-002-7p-trial-results2025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-eli-002-amplify-201-phase-1-data2025-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-q2-2025-financial-results2025-08-07T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-eli-002-phase-2-study-update2025-08-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-virtual-kol-event-eli-0022025-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-50-million-offering2025-11-12T12:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-phase-2-bestow-trial-results-tegoprubart2025-11-06T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-guggenheim-conference-20252025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-presentation-ix-congress-20252025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-cantor-global-healthcare-conference-20252025-08-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-q2-2025-results2025-08-14T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-conference-call-tegoprubart-kidney-transplantation2025-07-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-upcoming-conference-schedule2025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-positive-results-phase-3-study2025-10-28T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-fiscal-3rd-quarter-2025-results2025-08-08T20:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-bloom-burton-conference-20242025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-cfo-transition2025-04-04T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-15-million-private-placement2025-02-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-q3-2025-results-updates2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-edit-401-poster-presentation-aha-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-proof-of-concept-edit-401-esgct-20252025-10-09T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-esgct-congress-presentation-investor-conferences2025-10-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-nominates-edit-401-lead-candidate2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-webinar-lead-in-vivo-candidate2025-08-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-investor-conferences-september-20252025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-targeted-lipid-nanoparticle-delivery2025-06-12T06:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-eha-2025-congress-presentation2025-05-14T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-reports-third-quarter-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-presents-jefferies-global-healthcare-conference-london2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-participate-ubs-global-healthcare-conference2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-announces-q3-2025-financial-results2025-10-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-secures-euro36-million-credit-facility-eib2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/focal-one-prostate-cancer-awareness-campaign2025-09-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/focal-one-hifu-innovation-award-edap2025-09-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-hifu-reimbursement-prostate-cancer-france2025-09-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-reports-strong-q2-2025-hifu-results2025-08-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-euro-credit-facility-growth-expansion2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-participate-canaccord-genuity-forum2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-q3-2025-financial-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-q3-2025-results-webinar2025-10-23T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inducement-grant-nasdaq-listing-rule2025-10-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/ecor-gammacore-nvns-improves-post-concussion-symptoms2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-reimbursement-approval-gammacore-belgium2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-truvaga-plus-best-relaxation-gadget2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-board-changes-cuneo-errico2025-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-partners-greg-buttle-truvaga-plus2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-q3-2025-results-business-highlights2025-11-05T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-investor-conferences2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-phase-1-2-achieve-trial-data2025-10-06T22:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-brian-posner-board2025-10-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-orphan-drug-designation-dyne-2512025-09-29T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-fda-breakthrough-dyne-251-dmd2025-08-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-public-offering-closure2025-07-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-200-million-offering2025-07-01T01:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-dr-sullivan-retirement2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q3-2025-financial-results2025-10-29T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-survey-biological-threats-preparedness2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-opioid-poisoning-awareness-naloxone2025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-29-million-orders2025-09-19T12:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-17-million-contract-tembexa2025-09-15T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-acam2000-contract-modification2025-09-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-cyfendus-anthrax-vaccine-contract2025-09-02T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-naloxone-awareness-campaign2025-08-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-ceo-engage-investors-maxim-growth-summit2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-bva-technology-medaxiom-transforum-fall-252025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-fda-cleared-bva-analyzer-hfsa2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-next-gen-bva-analyzer-hfsa-meeting2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-blood-volume-analysis-covid-sepsis-study2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-presentation-hc-wainwright-conference2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-mid-year-update-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-nasdaq-closing-bell-ceremony-replay2025-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-fda-clearance-blood-volume-analyzer2025-08-07T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-blood-volume-analysis-technology-expansion2025-07-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-q3-2025-results2025-11-06T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-secures-license-for-sp162025-09-29T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-hc-wainwright-conference-20252025-09-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-halneuron-phase-2b-trial-enrollment2025-08-07T17:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-sidoti-conference-20252025-06-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-nasdaq-compliance2025-04-11T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-dt-818-dosing-plans-20262025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-appoints-justin-gover-board2025-09-10T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-2025-cantor-global-healthcare-conference2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-progress-genetac-programs-q2-20252025-08-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-friedreich-ataxia-dosing-trial2025-06-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-2025-jefferies-global-healthcare-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-2025-rbc-healthcare-conference2025-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-phase-1-data-dt-168-fuchs-dystrophy2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-phase-1-data-fuchs-dystrophy-eyecelerator2025-04-21T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-prader-willi-syndrome-program2025-11-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-upcoming-conferences2025-10-30T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-201-preclinical-results2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-2025-jefferies-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-epilepsy-rd-day-20252025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-101-study-results2025-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-rd-day-20252025-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-expands-scientific-advisory-board2025-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-healthcare-conferences-march-20252025-02-24T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-jefferies-global-healthcare-conference-20252025-11-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alphatau-radioactive-material-license-new-hampshire2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-first-patient-pancreatic-cancer-trial2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-participate-investor-conferences-september-20252025-08-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-q2-2025-results-corporate-update2025-08-11T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-presentation-jefferies-global-healthcare-conference2025-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-appoints-nadav-kidron-board-directors2025-05-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-closes-36-9-million-offering-oramed-alliance2025-04-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-q3-financial-results2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-investor-conferences-november2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-claseprubart-2025-aanem2025-10-29T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-license-agreement-dnth2122025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-288-million-offering2025-09-11T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-upsized-public-offering2025-09-10T02:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-claseprubart-phase-2-magic-trial-results2025-09-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q3-2025-financial-results2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-board-executive-leadership-updates2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-fda-review-extension-tividenofusp-alfa-mps-ii2025-10-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q1-2025-results-bla-submission2025-05-06T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-phase-1-2-study-hunter-syndrome2025-02-06T16:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-worlsymposium-2025-presentations2025-01-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-q3-2025-results2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-emrosi-phase-3-results-derm2025-10-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-october-2025-investor-conferences2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-emerging-growth-conference-20252025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-nasdaq-closing-bell-august-112025-08-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-announces-q2-2025-results2025-08-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-expands-emrosi-coverage2025-07-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-phase-3-vitesse-trial-completion2025-11-12T04:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbvt-vitesse-phase-3-trial-completion2025-11-12T04:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-guggenheim-healthcare-conference-20252025-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-guggenheim-healthcare-conference2025-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-appoints-kevin-trapp-cfo2025-11-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-appoints-kevin-trapp-cco2025-11-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-acquires-mersana-therapeutics2025-11-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-ojemda-tovorafenib-sno-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-third-quarter-2025-results2025-11-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-report-q3-2025-financial-results2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-report-second-quarter-2025-results2025-07-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-appoints-michael-vasconcelles-head-research-development2025-06-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-report-first-quarter-2025-results2025-04-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-launch-dare-to-play-sildenafil-cream2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-q3-2025-financial-results-conference-call2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-gates-foundation-funding-assessment2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-funding-smart-drug-delivery-device2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-funding-preeclampsia-research2025-09-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-q2-2025-financial-results-update2025-08-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-rosy-wellness-sildenafil-cream-campaign2025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-webinar-sildenafil-cream2025-07-21T17:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-maple-hcm-data-presentation-20252025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-q3-2025-financial-results-update2025-11-05T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-investor-conferences-november-20252025-11-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-upcoming-presentations-hcm-sessions-20252025-10-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-third-quarter-results-november-20252025-10-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inducement-grants-nasdaq-listing-rule2025-10-17T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-aficamten-hfsa-20252025-09-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-communications-grant-program-20252025-09-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-present-stifel-2025-forum2025-09-23T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/bio-green-med-acquisition-fitters-sdn-bhd2025-09-12T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-q2-2025-financial-results2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-preclinical-data-plogosertib-biliary-tract-cancer2025-08-04T22:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-comments-stock-price-volatility2025-07-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-amendment-exchange-agreement2025-07-07T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-plogosertib-fibrolamellar-carcinoma-data2025-07-07T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-announces-stock-split2025-07-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-private-placement-offering2025-06-20T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-regains-nasdaq-compliance-minimum-bid-price2025-06-03T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-q3-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-presents-jefferies-global-healthcare-conference-london2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-presents-canaccord-growth-conference-20252025-07-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-second-quarter-2025-results-conference-call2025-07-21T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-positive-news-outpatient-payment-barostim2025-07-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-present-william-blair-growth-stock-conference2025-05-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-signs-mou-singapore-biowaste-solutions2025-10-27T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-skyline-signature-series-presentation-october-20252025-10-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-secures-exclusive-medical-waste-recycling-technology2025-09-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-commitment-shareholders-patients-stock-activity2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-dr-sherman-fda-maggot-license2025-07-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-update-research-studies-education-institutes2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-lab-supply-medifly-therapy-mena-region2025-06-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-ipo-over-allotment-option2025-05-08T17:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-ivf-media-facility-certification2025-05-05T16:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-closing-initial-public-offering2025-05-05T16:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-q3-2025-results2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-immunoscape-collaboration-cell-therapy2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-leadership-transition-growth-strategies2025-09-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-fireside-chat-cantor-conference2025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-cue-102-glioblastoma-trial2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-phase-1-trial-cue-101-pembrolizumab2025-07-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-cue-101-update-hawaii-summit2025-07-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-fda-feedback-pre-ind-cue-4012025-06-24T20:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-jefferies-london-healthcare-conference2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-q3-2025-financial-results-update2025-11-06T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-cx-801-phase-1-data-sitc-20252025-11-04T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-rachael-lester-cbo2025-10-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-september-investor-conferences2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-cx-2051-phase-1-update2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-growth-leaders-20262025-11-12T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-muse-micro-analyzer-award-20252025-11-06T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-investor-conferences-20252025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-q3-2025-financial-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-flow-cytometry-access-initiative2025-10-29T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-expands-european-presence-amsterdam2025-10-15T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-full-spectrum-cell-analysis-conferences2025-09-10T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-piper-sandler-conference-20252025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2025-results2025-11-03T21:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-launches-advancead-tx-atopic-dermatitis2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-investor-conferences-20252025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/tissuecypher-risk-insights-acg-20252025-10-26T19:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/decisiondx-melanoma-risk-stratification-fall-conference2025-10-24T08:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2025-financial-results-conference-call2025-10-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/derek-maetzold-ceo-of-the-year-cstl2025-10-01T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-top-workplaces-20252025-09-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-americas-greatest-companies-20252025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-q2-2025-results-strategic-update2025-08-14T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-2025-shareholder-meeting-results2025-06-30T22:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-board-reconstitution-shareholders2025-05-30T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-director-nominations-goodwood2025-05-26T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-appoints-anna-biehn-ceo2025-04-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-management-cease-trade-order2025-04-01T23:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-delay-year-end-reporting2025-03-19T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q3-20252025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-phase-1-trial-data-ash-20252025-11-03T14:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-guggenheim-healthcare-conference2025-10-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-ciforadenant-esmo-20252025-10-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-appoints-david-moore-board2025-10-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-ind-approval-soquelitinib-china2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-eular-20252025-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-q3-2025-financial-results-corporate-updates2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-fda-registration-path-neflamapimod-dementia2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-appoints-david-quigley-board2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-emerging-growth-conference-presentation2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-phase-2b-trial-neflamapimod-dementia2025-10-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-appoints-matthew-winton-as-cbo2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-participate-roth-healthcare-conference2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-dementia-lewy-bodies-ana-conference2025-09-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-participate-investor-conferences-september-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-business-update-q3-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-positive-phase-1-data-ctx3102025-11-08T14:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-ctx460-preclinical-data-aatd2025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-esgct-2025-presentation2025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-sirius-phase-2-srsd107-thromboembolic-disorders2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-aha-scientific-sessions-20252025-09-09T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-investor-conferences-september-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-time-most-influential-20252025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-phase-1-data-update-ctx3102025-06-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-q3-2025-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-limited-edition-spinach-green-apple-products-fall2025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2025-q3-earnings-call2025-10-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-launches-sourz-spinach-multipacks2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-expands-peace-naturals-switzerland2025-07-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2025-annual-meeting-results2025-06-23T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-td-cowen-consumer-conference-20252025-06-02T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-november-2025-inducement-grants2025-11-10T21:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-q3-2025-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-neuroendocrine-tumor-research-nanets-20252025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-fda-approval-palsonify-acromegaly2025-09-25T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-fda-orphan-drug-designation-atmelnant-cah2025-08-21T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-q3-2025-financial-results-guidance-update2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-defencath-innovative-technology-designation2025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-q3-2025-results-guidance2025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-completes-enrollment-phase-iii-respect-trial2025-09-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-investment-talphera-niaid2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-acquisition-melinta-therapeutics-leadership2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-participate-investor-conferences2025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-acquires-melinta-therapeutics2025-08-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-q3-2025-results-business-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-investor-conferences-november-20252025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-positive-data-ras-mutated-mcrc-trial2025-07-29T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-dr-roger-sidhu-appointment-crdf-004-update2025-06-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-positive-data-onvansertib-paclitaxel-trial2025-06-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-second-patent-onvansertib-mcrc2025-04-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-q3-2025-financial-results-update2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-investor-conferences-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-public-offering-pricing2025-10-31T06:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-proposed-public-offering2025-10-30T20:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-crb-701-esmo252025-10-18T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-crb-701-esmo-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-piper-sandler-symposium2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-esmo-2025-kol-event2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/fda-fast-track-corbus-pharmaceuticals-crb-7012025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-fourth-quarter-full-year-2025-release2025-11-04T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-share-repurchase-program-increase2025-09-17T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-third-quarter-2025-results2025-08-27T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-participate-wells-fargo-healthcare-conference2025-08-14T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-2024-sustainability-report2025-05-20T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-participate-william-blair-conference2025-05-08T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-appoints-barbara-carbone-board2025-04-30T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-participate-upcoming-investor-conferences2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-q3-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/paris-hilton-collaborates-collegium-pharmaceutical-adhd2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-report-q3-2025-financial-results2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-poster-presentations-aacap-nei-conferences2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-nasdaq-opening-bell-anniversary2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-present-nine-posters-painweek-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-q2-2025-financial-results2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-public-offerings-20252025-11-12T04:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-phase-3-trial-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-q3-2025-results2025-11-03T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-ash-meeting-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-kras-poster-presentation-20252025-10-24T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-fda-breakthrough-designation-bezuclastinib2025-10-20T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-inducement-grants-nasdaq-rule-56352025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-participation-citi-biopharma-conference2025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-extinguishes-convertible-note-yorkville2025-07-22T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-filing-registration-statement-merger-z-squared2025-06-26T12:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/monarch-snap-biosciences-licensing-agreement2025-05-28T12:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-nexgenai-india-hub-launch2025-04-17T12:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-geartm-cell-therapy-platform2025-03-11T12:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-nexgenai-nuburu-partnership-innovation2025-03-07T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-nexgenai-arketyp-valu-partnership2025-02-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-marketleverage-ai-affiliate-marketing-partnership2025-02-20T12:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-private-placement-investment2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-nih-sbir-award-influenza-program2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-noble-capital-markets-conference2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-13-million-offering2025-09-15T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-cdi-988-norovirus-conference2025-09-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-fda-ind-clearance-cdi-988-norovirus-study2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-hc-wainwright-conference-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-q2-2025-financial-results2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-phase-1-results-cdi-9882025-08-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-ct-95-ct-202-sitc-20252025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-q3-2025-results2025-11-05T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-investor-conferences-20252025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-sitc-40th-annual-meeting2025-10-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-inducement-grant-nasdaq-rule-56352025-10-03T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-ctim-76-trial-presentation-asco-20252025-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-appoints-dr-karen-chagin-cmo2025-05-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-q3-2025-results-update2025-11-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-rademikibart-ers-congress-20252025-09-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presentations-ers-congress-20252025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-terminates-adr-program-and-lists-on-nasdaq2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-investor-conferences-september-20252025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-asthma-education-expansion2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-appoints-jim-schoeneck-board2025-07-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-btig-virtual-biotechnology-conference2025-07-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-public-offering-250-million2025-11-12T01:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-public-offering-ads2025-11-11T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-investor-conferences-20252025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-ox2r-agoinst-update-q3-20252025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-morgan-stanley-conference-20252025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-q2-2025-results2025-08-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-ind-clearance-orx1422025-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-q4-2024-financial-results2025-03-21T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-inducement-grants-nasdaq-rule-56352025-03-07T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/jazz-pharmaceuticals-acquire-chimerix-oncology-portfolio2025-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-fda-acceptance-dordaviprone-h3-k27m-glioma2025-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-jonestrading-precision-medicine-symposium2025-01-29T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-speak-white-house-cancer-moonshot-forum2025-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-q3-2025-financial-results-update2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-preclinical-data-ctx-10726-sitc-20252025-11-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-november-investor-events2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-pricing-public-offering2025-08-13T02:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-proposed-public-offering2025-08-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-jefferies-global-healthcare-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-patent-publication-depression-treatment2025-11-12T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-phase-i-ii-trial-alcohol-use-disorder2025-11-10T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-nasdaq-notification-stockholders-equity2025-11-06T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-ip-protection-meai-depression-south-korea2025-11-05T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-meai-cocaine-addiction-patent2025-10-31T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-ceo-dr-adi-zuloff-shani-webinar2025-10-28T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-appoints-gifford-global-impact2025-10-27T13:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-nebokitug-aasld-2025-presentations2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-hc-wainwright-conference-20252025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-q2-2025-financial-results-corporate-update2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-nebokitug-phase-2-data-bsg-live-20252025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-positive-fda-feedback-nebokitug-phase-32025-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-new-patents-nebokitug-psc2025-06-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-nebokitug-clinical-data-conferences2025-04-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-q3-2025-results-and-updates2025-11-06T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-investor-conferences-20252025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-appoints-adam-villa-ashley-jones2025-10-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-presents-data-asn-kidney-week-20252025-10-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-appoints-susan-altschuller-cfo2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-clym116-preclinical-data-ig-an-therapeutic2025-09-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-webcast-clym116-igan-opportunity2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-euretina-congress-20252025-08-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-xipere-approval-canada2025-07-23T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-strategic-alternatives-scs-platform2025-07-17T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-summit-meeting-presentations2025-06-17T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-fireside-chat-stifel-ophthalmology-forum2025-05-21T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-phase-3-program-update2025-05-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-arvo-2025-presentations2025-05-09T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-fireside-chat-citizens-conference2025-05-01T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-fireside-chat-needham-conference2025-04-01T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-third-quarter-2025-update2025-11-13T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-rare-pediatric-designation-iopofosine2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-preclinical-data-aacr-conference2025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-raises-5-8-million2025-10-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-ema-cma-iopofosine2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-aacr-pediatric-cancer-conference2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-evestia-partnership-tnbc-trial2025-09-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-itm-actinium-225-supply-agreement2025-09-11T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-oppenheimer-summit-20252025-09-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-q3-2025-financial-results2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-emerging-growth-conference-presentation2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-participate-maxim-growth-summit2025-10-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-cnmau8-ectrims-2025-data2025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-preclinical-data-cnm-au8-parkinsons-disease2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-presentation-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-present-canaccord-growth-conference-20252025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-regulatory-update-fda-meeting-neurofilament-analysis2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-financial-results-q3-20252025-11-07T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-q3-2025-results-business-update2025-11-07T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-ash-2025-eti-cel-advancements2025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-development-update-eti-cel-ash-20252025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-q3-financial-results-november-20252025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-rd-day-lasme-cel-potential-b-cell-leukemia2025-10-16T19:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-rd-day-lasme-cel-potential-unmet-need2025-10-16T19:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-q3-2025-financial-results-update2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-appoints-terri-lawver-as-cco2025-11-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-upcoming-investor-conferences2025-11-07T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-phase-2-results-cold-urticaria-sd2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-csu-phase-2-data2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-phase-1-trial-cdx-622-results2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-chronic-spontaneous-urticaria-eadv-20252025-09-17T09:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-morgan-stanley-healthcare-conference2025-09-09T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-phase-2-barzolvolimab-eosinophilic-esophagitis-results2025-08-19T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-reports-q3-2025-results-update2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-names-bryan-downey-cco-ctxt-1301-launch2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-phase-3-results-ctxt-1301-adult-adhd2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-ct-1301-aacap-podium-presentation2025-10-23T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/fda-accepts-cingulate-cth-1301-adhd-nda2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-exclusive-manufacturing-partnership-bend-bio-sciences2025-09-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-management-team-update2025-08-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-submits-nda-ctx-1301-fda2025-08-06T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-fda-waiver-ctxt-1301-approval2025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-sitc-chs-114-biomarker-data2025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-q3-2025-financial-results-update2025-11-06T21:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/arvind-sood-joins-coherus-oncology2025-11-06T18:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-investor-conferences-20252025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-poster-sitc-20252025-10-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-strategic-transformation-cancer-therapeutics2025-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-phase-2-study-zervimesine-alzheimers2025-11-13T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-q3-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-30-million-offering-zervimesine2025-09-02T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-30-million-offering2025-08-28T00:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-regains-nasdaq-compliance2025-08-26T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-zervimesine-data-aaic-20252025-07-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-zervimesine-alzheimers-study2025-07-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-bond-003-cohort-c-results2025-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-completes-enrollment-pivot-0062025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-executive-leadership-investor-conferences2025-08-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-q2-2025-financial-results-business-updates2025-08-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-jury-verdict-no-royalties-ani-pharmaceuticals2025-07-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-goldman-sachs-healthcare-conference2025-06-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-2025-rbc-capital-markets-conference2025-05-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-nmibc-research-fellowship-20252025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-bond-003-cretostimogene-data-aau-20252025-04-26T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-biodefense-initiative-veterans2025-10-30T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-warrants-exercise-agreements2025-10-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-shareholder-letter-20252025-10-27T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-nobel-laureates-regulatory-t-cells2025-10-07T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/celz-fda-fast-track-designation-celz-201-ddt2025-08-13T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-type-1-diabetes-patent2025-07-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-immcelz-heart-failure2025-07-11T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/celz-fda-clearance-expanded-dose-escalation-trial2025-03-20T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-ivf-access-initiative2025-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-q3-2025-results-corporate-update2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-third-quarter-2025-financial-results-webcast2025-11-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-stifel-2025-healthcare-conference2025-11-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-update-viktoria-1-trial-pik3ca-mutant-cohort2025-10-18T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-updated-data-esmo-2025-gedatolisib-darolutamide2025-10-18T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/gedatolisib-phase-3-viktoria-1-trial-results2025-10-18T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-viktoria-1-trial-esmo-congress-20252025-09-22T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-gedatolisib-nda-submission-fda-review2025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-corporate-update-q3-2025-results2025-11-06T21:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-november-investor-conferences2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-cd388-eswi-conference-20252025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-phase-2b-data-id-week-20252025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-eswi-influenza-conference-20252025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-fda-breakthrough-therapy-cd388-influenza2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-barda-award-cd388-manufacturing-development2025-10-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-phase-3-anchor-trial-cd3882025-09-25T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDMO/avid-stockholders-approve-gho-ampersand-transaction2025-01-30T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDMO/avid-reminds-stockholders-vote-transaction-gho-ampersand2025-01-22T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDMO/avid-recommends-stockholders-vote-for-gho-ampersand-transaction2025-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-investor-presentation-gho-ampersand2025-01-08T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-125-million-offering2025-10-16T11:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-pfizer-collaboration-cemsidomide-elranatamab2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-phase-1-results2025-09-20T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-biogen-ind-acceptance2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-phase-1-trial-cemsidomide-ims-meeting2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-march-investor-conferences2025-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-participate-canaccord-genuity-forum2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-reports-third-quarter-2025-financial-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/erica-rogers-joins-ceribell-board2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-participate-canaccord-genuity-conference2025-07-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-report-q2-2025-financial-results2025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-files-complaints-against-natus-medical2025-07-07T20:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-participate-william-blair-growth-conference2025-05-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-q3-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-investor-conferences-november2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-cr-001-sitc-2025-presentation2025-11-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-appoints-jan-pinkas-cso2025-07-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-merger-glycomimetics-private-placement2025-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-jefferies-conference-20252025-05-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-appoints-david-lubner-board2025-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-appoints-new-ceo-and-leadership-team2025-04-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q3-2025-financial-results-update2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-deramiocel-study-biomedicines2025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-deramiocel-regulatory-update2025-09-25T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-responds-fda-complete-response-letter-deramiocel2025-09-09T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-phase-1-exosome-vaccine-trial2025-08-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-fda-type-a-meeting2025-08-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-webinar-deramiocel-dmd2025-07-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-esophageal-varices-resolution2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-h1-2025-financial-results-clinical-update2025-08-28T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-phase-2a-enrollment-milestone2025-07-30T11:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-public-offering-15-million2025-07-28T16:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/uclas-study-piclidenoson-vascular-dementia2025-07-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-phase-iia-pancreatic-cancer-study-bio-20252025-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-raises-175-million-phase-3-trials2025-05-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/fda-approval-namodenoson-pancreatic-cancer2025-04-17T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-3-million-offering2025-04-14T18:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-685m-future-revenues-partnerships2025-04-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-reports-q3-2025-results-and-highlights2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-glp-toxicology-studies-cmp-syngap-012025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-oversubscribed-private-placement-syngap1-treatment2025-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-translational-data-syngap1-urea-cycle-disorders2025-05-16T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-preclinical-data-asgct-20252025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-reports-full-year-2024-financial-results2025-03-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-appoints-industry-veterans-board2025-03-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-participate-upcoming-investor-conferences2025-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-q3-2025-financial-results2025-11-13T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-immunotherapy-sitc-20252025-11-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-jefferies-conference-20252025-11-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-bali-pulendran2025-10-16T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-130-million-loan-trinity-capital2025-10-14T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-positive-data-can-3110-glioblastoma2025-10-14T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-sitc-2025-annual-meeting2025-10-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-phase-3-trial-can-2409-prostate-cancer2025-09-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-carl-h-june2025-09-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-third-quarter-2025-update2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-investor-conferences-november-december2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-rese-cel-acr-convergence-20252025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-appoints-steve-gavel-cco2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reset-pv-data-esgct-20252025-10-09T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-public-offering-pricing2025-06-11T13:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-rese-cel-data-eular-20252025-06-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-q3-2025-results-corporate-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-q2-2025-financial-results-update2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-plinabulin-clinical-study-ici-failure2025-07-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-phase-2-study-pembrolizumab-plinabulin-docetaxel2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-poster-presentation-2025-asco2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2024-annual-report2025-03-27T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-2024-financial-results-clinical-highlights2025-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-sells-equity-seed-therapeutics-plinabulin-trials2025-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-q3-2025-financial-results2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-q3-fy2025-financial-results-report2025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-presentation-morgan-stanley-healthcare-conference2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-canaccord-genuity-conference-20252025-08-07T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-new-400-million-credit-agreement2025-08-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-fda-clearances-pns-products2025-07-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-clinical-update-20252025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-expands-global-patent-portfolio2025-02-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPTH/biopath-holdings-phase-1b-trial-update-bp10022025-02-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-q3-2025-financial-results2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-japanese-patent-thermostem2025-10-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-appoints-crystal-romano-global-operations2025-10-22T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-maxim-growth-summit-20252025-10-15T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-ceo-lance-alstodt-interview-big-biz-show2025-10-07T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-registered-direct-offering2025-10-06T18:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-q2-2025-results-conference-call2025-08-05T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-benzinga-show-bRTX-100-update2025-06-18T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-q3-2025-results-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-serenity-at-home-study-results2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-nasdaq-closing-bell-october-20252025-10-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-regains-nasdaq-compliance2025-09-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-serenity-at-home-phase-3-trial-results2025-09-10T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-hc-wainwright-conference-20252025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-serenity-trial-update2025-08-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-q3-2025-financial-results2025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-clywedog-merger-metabolic-autoimmune-diseases2025-09-30T13:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-strategic-focus-immunology-inflammation2025-01-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-q3-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-update-bdc-4182-cash-runway-20272025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-kol-conference-call-bdc-3042-phase-1-results2025-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/boltbody-isacs-preclinical-results-aacr-20252025-04-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-bdc-3042-phase-1-results-aacr-20252025-04-25T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-march-conferences2025-02-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-q3-2025-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-presentation-aacr-nci-eortc-20252025-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-goldman-sachs-healthcare-conference2025-06-05T20:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-portfolio-prioritization-runway-extension2025-05-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-needham-virtual-healthcare-conference2025-04-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-leerink-global-healthcare-conference2025-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-robert-doebele-cmo-appointment2025-02-03T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q3-2025-results-business-update2025-11-03T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q3-2025-financial-results-update2025-11-03T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-innovation-series-day-november-20252025-10-28T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-hosts-rd-day-november-11-20252025-10-28T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q3-2025-results-conference-call2025-10-27T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-public-exchange-offer-curevac-shares2025-10-22T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-public-exchange-offer-curevac2025-10-22T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-ai-day-october-20252025-09-23T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-hosts-second-ai-day-october-20252025-09-23T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-100-million-offering2025-11-06T05:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-public-offering-november-20252025-11-05T21:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-bb301-clinical-trial-results-fda-fast-track2025-11-03T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-appoints-sharon-mates-board2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-phase-1b-2a-update-bb-301-opmd2025-11-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-full-year-2025-results-update2025-09-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-operational-updates2025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-positive-results-bb-301-opmd2025-03-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-targeted-rna-seq-leukemia2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-report-q3-2025-financial-results2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-ashg-2025-conference2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-participate-hc-wainwright-home-event2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-closes-10-million-public-offering2025-09-17T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-10-million-offering2025-09-16T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-chromoanagenesis-cancer-research2025-09-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/cms-preliminary-payment-determination-ogm-cpt-code2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-present-hc-wainwright-investment-conference2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-q2-2025-results-business-progress2025-08-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-jefferies-london-healthcare-conference2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-preclinical-advances-bmf-650-icovamenib2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-q3-2025-results-highlights2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-poster-presentations-obesityweek-20252025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-bmf-650-phase-i-trial2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-citi-biotech-fireside-chat2025-10-21T23:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-public-offering-pricing2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-positive-results-phase-ii-covalent-1112025-10-06T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inducement-grant-nasdaq-rule-56352025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-corporate-update-clinical-milestones2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-closes-4-5-million-private-placement2025-10-10T21:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-sanyo-seiko-partnership-symphony-platform2025-10-09T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-q2-2025-update2025-08-07T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-abstract-presentation-saem-20252025-04-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-warrant-inducement-transaction2025-04-07T21:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-expands-cdmo-services-market-demand2025-11-06T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-henry-schein-marketing-agreement-ibs-test2025-10-16T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-fiscal-2026-results2025-10-15T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/gary-huff-appointed-biomerica-board2025-10-08T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-launches-ai-infoods-ibs-navigator2025-09-09T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/uae-approves-biomerica-fortel-kidney-test-home-use2025-09-03T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/uae-approves-biomerica-fortel-ulcer-test-home-use2025-08-14T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/infoods-ibs-cpt-code-biomerica2025-07-02T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/scott-madel-joins-biomerica-as-cco2025-06-26T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-q3-2025-financial-results-update2025-11-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-sells-xepi-license-pelthos-therapeutics2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-closes-purchase-us-assets2025-10-23T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-participate-lytham-partners-fall-2025-conference2025-09-26T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-engages-lytham-partners-investor-relations2025-09-23T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-phase-3-study-ameluz-completion2025-09-16T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-phase-2b-study-acne-vulgaris2025-08-25T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-appoints-george-jones-cco2025-08-11T20:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-q3-2025-financial-results-update2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-webcast-november-2025-financial-results2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-conditional-marketing-authorization-tinlarebant2025-11-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-deutsche-bank-adr-investor-conference2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-participate-maxim-growth-summit-20252025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-nmpa-priority-review-tinlarebant-stargardt2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-dragon-trial-completion-tinlarebant2025-09-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-private-placement-financing-275-million2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-investor-conferences-20252025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-investor-conferences2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-q3-2025-results-update2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-jefferies-conference-20252025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/servier-black-diamond-licensing-agreement-bdtx-49332025-03-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-host-live-investor-webinar-october-82025-09-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-phase-2-trial-bezisterim-long-covid2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-closes-12-million-public-offering2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-pricing-public-offering2025-08-08T00:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-age-deceleration-alzheimers-conference2025-07-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-appoints-industry-veterans-to-board2025-07-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-aging-neurodegeneration-conference2025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-sunrise-pd-trial-atmrd-congress2025-06-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-phase-2-sunrise-pd-trial-presentation2025-06-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-clinical-trial-bezisterim-long-covid2025-05-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-approval-cta-phase-3-serenta-trial-fap2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-symposium-fap-mechanisms-chemoprevention-trial-issues2025-10-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-interim-results-june-20252025-09-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-enrolment-first-patients-serenta-trial-fap2025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-adr-ratio-change-effective2025-07-31T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-filing-cta-phase-3-serenta-trial-fap2025-07-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-annual-general-meeting-results2025-06-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-serenta-phase-3-study-fap2025-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-new-data-acaa-highlight-hae-burden-pediatric-patients2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-inducement-grants-nasdaq-rule-56352025-11-05T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presentation-jefferies-conference-20252025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-q3-2025-financial-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pediatric-hae-data-acaa-meeting-20252025-10-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-acquires-astria-therapeutics-hair-portfolio2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-sale-european-orladeyo-business2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-anti-cancer-activity-sitc-20252025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-anti-cancer-activity-bria-ots2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-dsmb-positive-recommendation-phase-3-study2025-10-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-clinical-sites-phase-3-study2025-10-21T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-collaboration-msk-accelerator-breast-cancer2025-10-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-3-clinical-biomarker-data-esmo-20252025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-preclinical-data-sitc-20252025-10-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-bria-ots-mechanism-action-validation2025-08-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-nci-grant-bria-pros-prostate-cancer2025-08-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-q3-2025-results2025-11-12T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-first-patient-phase-3-trial2025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-q3-2025-update-financial-results-call2025-11-06T00:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-phase-3-cardiamp-hf-ii-trial-enrollment2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-regains-compliance-nasdaq-listing-requirements2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-positive-consultation-pmda-cell-therapy2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-12-million-public-offering2025-09-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-cardiamp-trial-results-improved-exercise-tolerance2025-09-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-ceo-peter-altman-hc-wainwright-conference-20252025-09-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-cart-tech-partnership-heart3d-imaging2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q3-2025-financial-results-update2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-ficerafusp-alfa-fda-designation2025-10-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-investor-conferences2025-08-27T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-goldman-sachs-conference-20252025-06-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-ficerafusp-alfa-asco-20252025-06-01T17:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-ficerafusp-alfa-aacr-20252025-04-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-mecbotamab-vedotin-survival-sarcomas2025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-q3-2025-financial-results2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-ozuriftamab-vedotin-opscc-ipvs-conference2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-phase-1-trial-ba3182-esmo-20252025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-present-clinical-data-mecbotamab-vedotin-sitc-20252025-10-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-regulatory-update-ozuriftamab-vedotin-opscc2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-q2-2025-financial-results-progress2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-upcoming-presentation-esmo-tat-asia-20252025-07-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-ba3182-esmo-20252025-07-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-investor-conferences-20252025-11-03T21:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-q3-2025-financial-results2025-10-28T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-third-quarter-2025-results2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-presentation-bank-america-conference2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/acoramidis-reduces-mortality-attr-cm-populations2025-11-08T15:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-participate-november-investor-conferences2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-presents-attribute-cm-data-aha-20252025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-q3-2025-financial-results2025-10-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-positive-phase-3-encaleret-results2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-phase-3-encaleret-results-october-29-20252025-10-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-phase-3-results-bbp-418-lgmd2i-r92025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-inducement-grants-nasdaq-rule-56352025-10-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/acoramidis-reduces-cardiovascular-outcomes-attr-cm2025-09-28T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-acquires-gaba-a-receptor-modulator-azd73252025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q3-2025-financial-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-november-20252025-10-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-mental-illness-awareness-week2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-psych-congress-20252025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-rd-day-cns-pipeline2025-07-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-nasdaq-opening-bell2025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-upcoming-investor-conferences2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-q3-2025-financial-results2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-fda-review-timeline-avance-nerve-graft2025-08-25T10:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-canaccord-genuity-conference2025-07-29T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-goldman-sachs-healthcare-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-blarcamesine-alzheimers-trial-results2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-presentation-alzheimer-europe-conference2025-10-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-successful-once-daily-tablet-anavex3-712025-10-02T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-phase-2-results-anavex3-71-schizophrenia2025-10-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/oral-blarcamesine-phase-iiib-iii-alzheimers-trial2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-hc-wainwright-conference-20252025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-blarcamesine-autophagy-mechanism-publication2025-08-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-blarcamesine-alzheimers-prevention-study2025-08-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-fiscal-2025-q3-results2025-08-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-third-quarter-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-investor-conferences-20252025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-completes-enrollment-lotus-trial-avtx-0092025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-leadership-expansion-appointments2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalon-therapeutics-appoints-kevin-lind-board2025-09-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-q2-2025-financial-results-business-updates2025-08-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-appointment-of-rita-jain-to-board2025-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-announces-third-quarter-results-20252025-11-12T22:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/fda-approves-anteris-duravr-thv-paradigm-trial2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-duravr-thv-positive-outcomes-small-annuli2025-10-28T22:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-duravr-thv-clinical-outcomes-tct-20252025-10-27T12:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-european-regulatory-clearance-paradigm-trial2025-10-15T13:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-special-meeting-adjourned2025-09-19T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-postpones-stockholders-meeting2025-09-11T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/ateapharma-q3-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/ateas-bemnifosbuvir-ruzavir-hcv-treatment-data2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-virtual-hcv-kol-panel-november-20252025-10-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-morgan-stanley-conference-20252025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-q2-2025-financial-results-call2025-07-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/ateapharma-advancement-global-phase-3-hcv-program2025-06-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-q3-2025-results-update2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-jazz-pharmaceuticals-global-settlement2025-10-22T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-grant-inducement-awards-nasdaq-rule-56352025-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-five-years-sleep-research2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-lumryz-world-sleep-2025-data2025-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-valiloxybate-license2025-09-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-investor-conferences-20252025-08-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-appoints-brent-rice-cco2025-09-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-firmonertinib-phase-1b-study-egfr-nsclc2025-09-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-q2-2025-financial-results2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/furvent-phase-3-firmonertinib-nsclc-data-20262025-07-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-announces-pricing-75-million-offering2025-07-02T03:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-investor-event-firmonertinib-nsclc2025-06-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-q3-2025-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-hc-wainwright-conference-20252025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-public-offering-pricing2025-05-15T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-investor-conferences-20252025-05-01T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-teresa-bitetti-appointment2025-04-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/positive-data-phase-1-trial-bel-sar-nmibc-eau-congress2025-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-piper-sandler-conference-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-third-quarter-2025-results-update2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-phase-3-efzo-fit-study-ers-congress-20252025-09-30T09:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-phase-3-efzo-fit-study-results2025-09-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inducement-grants-nasdaq-rule-56352025-09-05T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-added-russell-indexes2025-06-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-phase-2-efzo-connect-study-findings2025-06-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-investor-conferences-may-june-20252025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-bell-potter-conference-20252025-11-12T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ath434-msa-symposium2025-11-10T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q1-fy26-cash-flow-report2025-10-31T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-positive-data-ath434-phase-2-trial2025-10-09T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-2025-parkinsons-congress2025-10-02T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ath434-phase-2-data-ana-meeting2025-09-15T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-raises-20-million-strategic-placement2025-09-08T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-biotech-showcase-presentation2025-09-02T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q4-fy25-cash-flow-report2025-07-30T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-positive-data-ath434-msa2025-07-28T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-q3-2025-results-business-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reverse-stock-split2025-09-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-ath-1105-phase-1-trial-results2025-08-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-ath-1105-phase-1-trial-data2025-05-13T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-2024-financial-results-pipeline-updates2025-02-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-leadership-transition2025-10-28T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-real-world-study-sympazan-clobazam2025-09-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-present-new-data-sympazan-ana20252025-09-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-participate-hc-wainwright-lake-street-conferences2025-09-03T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-q2-2025-financial-results2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-participate-alliance-global-partners-showcase2025-05-19T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-q1-2025-results-webcast2025-05-05T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-participate-iaccess-alpha-conference-20252025-03-20T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-q3-2025-financial-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-positive-phase-1b-data-abi-43342025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-investor-conference-participation2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-hsv-inhibitor-abi-5366-data-iusti2025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-pricing-175-million-equity-financing2025-08-08T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-positive-results-abi-53662025-08-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-phase-1a-data-abi-6250-hdv2025-08-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-genital-herpes-data-presentation2025-07-26T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-phase-1b-abi-1179-trial2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-third-quarter-2025-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-preclinical-data-arv-393-ash-20252025-11-03T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-participate-investor-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-third-quarter-2025-financial-results-webcast2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-arv-806-preclinical-data-aacr-nci-eortc-20252025-10-24T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-arv-806-presentation-aacr-nci-eortc-20252025-10-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/vepdegestrant-veritac-2-trial-results2025-10-20T08:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-vepdegestrant-esmo-congress-20252025-10-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-arv-102-positive-phase-1-data-mds-20252025-10-05T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-allonk-autoimmune-disease-data2025-11-12T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-q3-2025-financial-results2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-virtual-event-allonk-data2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-investor-conferences-november-20252025-10-30T20:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-refractory-ra-lead-indication2025-10-16T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-cantor-healthcare-conference-20252025-08-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-jefferies-global-healthcare-conference2025-05-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-phase-1-2-data-allonk-rituximab-b-nhl2025-05-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-business-update-q3-20252025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-fabp3-cancer-publication2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-appoints-mark-spring-cfo2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-expanded-clinical-data-art26-12-art27-132025-10-15T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-closes-2-million-public-offering2025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-public-offering-20252025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-public-offering2025-09-29T23:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-positive-phase-2-cares-data2025-09-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art12-11-efficacy-depression-anxiety2025-09-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-integument-infant-phase-2-study-zoryve-cream2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-inducement-grants-nasdaq-rule-56352025-11-07T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-safety-efficacy-seborrheic-dermatitis2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/free-to-be-me-campaign-arcutis2025-10-30T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-strategy-sustainable-growth-q3-2025-results2025-10-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-present-investor-conferences2025-10-27T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-atopic-dermatitis-conference-20252025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/fda-approves-arcutis-zoryve-cream-atopic-dermatitis-children2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-pharmaceuticals-ipo-closing2025-05-12T21:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-pharmaceuticals-ipo-pricing-announcement2025-05-08T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-q3-2025-financial-results-business-update2025-10-30T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-vyvgart-data-aanem-mgfa-20252025-10-29T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-2025-aanem-mgfa-meeting-data2025-10-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-extraordinary-general-meeting-november-20252025-10-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-investor-conferences-september-20252025-08-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-adapt-seron-study-results-vyvgart2025-08-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-rd-webinar-argx-119-september-20252025-08-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-monica-seles-myastenia-gravis-awareness2025-08-12T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aqst-q3-2025-financial-results-business-update2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-leadership-expansion-growth2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-fireside-chat-piper-sandler2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-acaa-meeting-20252025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q3-2025-results-conference-call2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-patent-broadening2025-10-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-fda-update2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-september-investor-conferences2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-85-million-offering2025-08-14T10:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-funding-anaphylm-launch2025-08-14T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/xphozah-tenapanor-patient-satisfaction-serum-phosphate-reduction2025-11-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-jefferies-global-healthcare-conference-20252025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-ceo-participate-wedbush-asn-2025-conference2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-q3-2025-financial-results-update2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-ibrela-acg-2025-meeting2025-10-28T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-abstracts-american-society-nephrology-kidney-week2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-third-quarter-2025-financial-results-call2025-10-13T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-appoints-sue-hohenleitner-cfo2025-10-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-participate-investor-conferences2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-executive-leadership-changes2025-08-04T20:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-upcoming-investor-conferences-november-20252025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-fda-510k-ayons-power-liposuction2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-virtual-kol-event-ayon-launch2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-inducement-grant-nasdaq-rule-56352025-08-07T20:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-participate-canaccord-growth-conference2025-07-30T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-launch-renuvion-china2025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-q3-2025-results-clinical-update2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-clinical-update-acesot-1051-trial2025-10-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-phase-2-dose-atrn-119-combination-therapies2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-eortc-nci-aacr-conference-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-hc-wainwright-conference-20252025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-reports-apr-1051-clinical-data-hpv-hnscc2025-06-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-hpv-head-neck-cancer-trial2025-03-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-q3-2025-financial-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-update-fda-meeting2025-09-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-leadership-appointments2025-06-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-govorestat-insPIRE-trial-results2025-05-18T11:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-late-breaking-abstract-pns-20252025-05-09T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-files-form-12b-25-sec2025-03-31T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-appoints-todd-baumgartner-cro2025-03-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-5-year-gale-data-syfovre-geographic-atrophy2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-stifel-2025-healthcare-conference2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-third-quarter-2025-results2025-10-30T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/new-data-reinforcing-efficacy-of-empaveli2025-10-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-conference-call-october-20252025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-investor-conferences-20252025-08-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/fda-approves-apellis-empaveli-c3g-ic-mpgm-treatment2025-07-28T23:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-abstracts-asrs-meeting-syfovre2025-07-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-nasdaq-listing-announcement2025-10-16T16:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-nasdaq-listing-update2025-10-16T16:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-advances-clinical-development-aplm2025-10-15T16:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-company-operational-update2025-10-14T01:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-reports-2024-financial-results-clinical-updates2025-04-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-launxp-agreement-vebreltinib2025-03-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pipeline-progress-q3-2025-results2025-11-10T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-positive-phase-1-results-apg3332025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-upcoming-conferences2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-public-offering-345-million2025-10-10T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pricing-300-million-offering2025-10-09T01:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-public-offering2025-10-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-apg777-eadv-2025-presentation2025-09-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-stifel-2025-forum2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-phase-2-apex-trial-results2025-07-07T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-corporate-updates-q3-2025-results2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-phase-3-alzheimers-program-progress2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-3-4-million-stock-offering2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-closes-6-million-stock-offering2025-10-15T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-biomarker-data-buntanetap-alzheimers2025-10-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-appoints-mark-guerin-cfo2025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-buntanetap-pharmacokinetics-publication2025-09-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-presents-hc-wainwright-investment-conference2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-pricing-public-offering-common-stock2025-11-13T03:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-q3-2025-results-and-milestones2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-september-investor-conferences2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-inducement-grant-new-employee2025-08-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-ema-product-development-coordinator-pilot-vonaprument2025-08-07T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-phase-3-archer-ii-trial-completion2025-07-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-appoints-dr-clark-amd-trial-advances2025-06-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-jefferies-global-healthcare-conference2025-05-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-q3-2025-financial-results2025-11-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-hyalofast-pma-filing2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-inducement-grants-nasdaq-rule-56352025-09-05T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-hyalofast-phase-iii-study-results2025-07-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-second-quarter-2025-financial-results2025-07-16T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-jefferies-global-healthcare-conference2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q3-2025-financial-results2025-11-07T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q3-2025-results-conference-call2025-10-24T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-new-day-trial-results-aao-20252025-10-16T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-investor-conferences-20252025-08-25T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-new-day-trial-results-iluvien-dme2025-07-23T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-leerink-partners-therapeutics-forum-20252025-07-02T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-preclinical-data-cortrophin-gel2025-06-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-phase-2-trial-rosnilimab-results2025-11-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-announces-q3-2025-financial-results-business-update2025-11-04T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-participation-november-investor-conferences2025-11-04T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-positive-phase-2b-trial-rosnilimab-ra2025-10-29T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-phase-2b-rosnilimab-acr-convergence-20252025-10-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-separation-biopharma-royalty-assets-20262025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-overview-anb033-virtual-event-october-142025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-positive-rosnilimab-data-phase-2b-trial-ra2025-06-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-q3-2025-financial-results2025-10-30T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-tentative-approval-beclomethasone-inhaler2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-launches-brekiya-dhe-autoinjector-migraine-cluster-headaches2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-third-quarter-2025-results-webcast2025-09-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-bla-submission-biosimilar-xolair2025-09-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-bimatoprost-ophthalmic-solution2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-sodium-oxybate-solution2025-09-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-risperidone-injectable-suspension2025-09-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-refinancing-credit-agreement-offering-notes2025-07-21T11:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/reduce-it-aspirin-analysis-aha-scientific-sessions-20252025-11-09T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-presents-new-analyses-reduce-it-aha-20252025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-q3-2025-financial-results2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-supports-fda-revision-fenofibrate-labeling2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-third-quarter-2025-financial-results-conference-call2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-hls-therapeutics-ccc-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-epa-mechanistic-insights-esc-20252025-08-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/reduce-it-analyses-esc-2025-vascepa2025-08-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/new-analyses-reduce-it-esc-congress-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-tct-2025-presentations2025-10-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-highlight-nerve-sensing-platform-maxim-summit2025-10-16T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-patent-nerve-targeted-therapies2025-10-09T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-ceo-corner-segment-release2025-10-02T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-glp-study-sensing-rf-ablation-system2025-09-29T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-abstract-cirse-20252025-09-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-virtual-investor-segment2025-09-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-pain-reduction-study2025-09-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-presentation-hc-wainwright-conference2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-european-patent-catheter-technology2025-08-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-presentation-military-health-symposium-20252025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-2025-financial-results-clinical-update2025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-closing-5-million-private-placement2025-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-phase-ii-trial-al0012025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-reverse-stock-split2025-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-qmenta-ai-imaging-phase-ii-trials2025-05-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-phase-ii-trial-al001-alzheimers2025-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-phase-ii-trial-al001-mdd2025-03-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-q3-2025-financial-results-update2025-11-07T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-q3-2025-results-sitc-presentation2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx2004-preclinical-data-phase-1-trial-progress2025-10-23T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-phase-2-aspen-06-trial-sitc-20252025-10-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-barbara-klencke-interim-cmo2025-09-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-investor-conferences-september-20252025-08-29T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-phase-1-trial-alx2004-egfr-tumors2025-08-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-jefferies-2025-conference2025-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-q3-20252025-11-12T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-results-business-update-20252025-11-12T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-court-ruling-avt06-eylea2025-11-10T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/uk-high-court-rules-alvotech-avt06-eylea-biosimilar2025-11-10T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-advanz-marketing-authorizations-gobivaz2025-11-06T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-q3-2025-earnings-announcement2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-impact-phase-2b-trial-data-lancet2025-11-11T13:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-pemvidutide-liver-fibrosis-aasld-20252025-11-07T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-q3-2025-financial-results-business-updates2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-participate-investor-conferences2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-reclaim-phase-2-trial-pemvidutide-aud2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-phase-2b-impact-data-pemvidutide-mash-aasld-20252025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-christophe-arbet-engels-cmo2025-09-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-linda-richardson-cfo2025-09-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-participate-november-investor-conferences2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-reports-q2-2025-results-and-corporate-update2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-lumus-phase-2b-trial-esk-001-sle-enrollment2025-07-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-promotes-sanam-pangali-chief-legal-officer2025-07-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-presentation-jefferies-global-healthcare-conference2025-05-29T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-completes-enrollment-phase-3-esk-0012025-05-29T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-merger-acelyrin-completed2025-05-21T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-stockholders-approve-merger-acelyrin2025-05-13T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-phase-2-data-stenoparib2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-ceo-presents-biomarkers-precision-medicine-20252025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-fda-fast-track-stenoparib-ovarian-cancer2025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-q2-2025-update-clinical-progress2025-08-15T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-licensing-agreement-drp-platform2025-07-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-jeff-ervin-cfo-appointment2025-07-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-australian-patent-acceptance-stenoparib2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-doses-second-patient-phase-2-trial2025-06-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-board-changes2025-06-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-research-collaboration-indiana-biosciences2025-06-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-investor-conferences-20252025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q3-2025-results-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-alpha3-trial-poster-ash-20252025-11-03T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-alpha3-trial-cema-cel-lymphodepletion2025-08-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-phase-1-data-allocation-3162025-06-01T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-agreement-acquired-concentra-biosciences2025-04-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-business-update-q4-2024-results2025-03-12T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-phase-1-trial-results-ak006-csu2025-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-liver-meeting-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-q3-2025-financial-results2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-investor-conferences-20252025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-third-quarter-2025-results2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-inducement-grants-nasdaq-rule-56352025-10-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-pevifoscorvir-sodium-approval2025-10-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-hc-wainwright-liver-conference-20252025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-liver-meeting-2025-abstracts2025-10-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-preclinical-presentations-hbv-meeting-20252025-09-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-hc-wainwright-conference-20252025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-q1-2025-financial-results2025-05-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-expands-biopharma-service-portfolio2025-04-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-enable-medicine-single-cell-spatial-atlas2025-04-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-super-study-cancer-immunophenotyping2025-04-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-pheno-cycler-fusion-cancer-equity2025-04-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-fourth-quarter-2024-financial-results2025-03-17T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ph1-adc-data-sitc-20252025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-abstract-sitc-meeting-20252025-11-04T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-scientific-advisory-board-dr-hurvitz2025-10-30T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ceo-corner-launch2025-10-22T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-2-5-million-offering2025-10-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-files-patents-immuno-oncology-adc-platform2025-10-09T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-sitc-presentation-20252025-10-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-preclinical-data-ph1-adc2025-09-24T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-hc-wainwright-conference-20252025-09-05T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-efruxifermin-aasld-20252025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-acquired-novo-nordisk-5-2-billion2025-10-09T10:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-morgan-stanley-conference-20252025-08-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-efruxifermin-harmony-trial-results2025-08-14T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-q2-2025-results-business-update2025-08-08T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-histoindex-easl-20252025-05-11T07:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-q3-2025-financial-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/vadadustat-post-hoc-analysis-asn-kidney-week-20252025-11-06T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-investor-conferences-november-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inducement-grants-nasdaq-rule-56352025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-vafseo-update-non-dialysis2025-10-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-asn-kidney-week-2025-presentations2025-10-20T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-launches-a-perfusctm-3d-cell-culture-platform2025-09-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-ip-offering-6-56-million2025-03-07T17:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-upmc-abstract-advanced-ovarian-cancer2025-11-10T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-sitc-presentation-20252025-11-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-european-patent-ampligen-long-covid2025-11-03T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-2025-maxim-growth-summit2025-10-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-approval-20392025-09-25T18:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-patent-japan-cancer-therapy2025-09-25T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-interferon-alpha-tumor-growth2025-09-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-conference-poland2025-09-04T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ceo-corner-segment-release2025-08-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-q2-2025-financial-results-update2025-08-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-q3-2025-financial-results2025-11-12T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-healingmaps-partnership2025-09-05T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-clear-platform-launch2025-08-26T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-commercial-agreement-fda-cleared-bna-platform2025-07-14T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-added-russell-microcap-index2025-06-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-objective-measurement-alzheimers2025-06-20T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-acquires-evoke-neuroscience2025-05-06T01:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-warrant-exercise-funds2025-02-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-nvidia-connect-program2025-02-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-mitapivat-data-ash-20252025-11-03T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-q3-2025-results-business-update2025-10-30T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-positive-chmp-opinion-thalassemia2025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-third-quarter-2025-financial-results-webcast2025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-update-pdufa-goal-date-pyrukynd-thalassemia2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-approval-thalassemia-saudi-arabia2025-08-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-dr-jay-backstrom-board-directors2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-goldman-sachs-healthcare-conference-20252025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-nasdaq-delisting-notice2025-05-14T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-insolvency-proceedings-filing2025-05-13T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-afm24-response-rates-aacr-20252025-04-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-abstracts-asco-20252025-04-23T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-receives-nasdaq-deficiency-notice2025-04-21T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-afm24-abstract-aacr-20252025-03-25T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-present-leerink-partners-healthcare-conference-20252025-03-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inducement-grants-nyse-american2025-05-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-aegis-capital-conference-20252025-05-19T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-first-quarter-2025-results-update2025-05-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-nyse-american-compliance-plan2025-04-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-appoints-rob-bancroft-ceo2025-04-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-ceo-transition2025-03-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-leerink-global-healthcare-conference2025-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reverse-stock-split2025-02-24T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-treasury-shares2025-10-29T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-2025-financial-results-update2025-09-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-appoints-bny-mellon-as-depositary-bank2025-09-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-resolutions-annual-meeting2025-06-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-q1-2025-financial-results2025-06-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-gabab-pam-candidate-anti-tussive-activity2025-06-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-positive-gabab-pam-chronic-cough-data-presentation2025-06-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-completes-screening-artemis-trial-ixo-vec2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inducement-grants-nasdaq-rule-56352025-09-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-q2-2025-results-pipeline-highlights2025-08-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-hc-wainwright-ophthalmology-conference2025-08-06T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-2025-rbc-ophthalmology-conference2025-03-31T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-investor-conferences-20252025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q3-2025-financial-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-morgan-stanley-conference-20252025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-flatiron-integration-clonoseq2025-07-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-clonoseq-mrd-assessment-asco-eha-20252025-05-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-q3-2025-financial-results-update2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fda-approval-yield-enhancement-process2025-04-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-statement-on-tariffs2025-04-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-raymond-james-conference-20252025-02-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-ceo-big-biz-show2025-10-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-partners-genomind-precision-medicine-testing2025-10-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-business-update-fda-eop2-meeting-ad042025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-nasdaq-extension-compliance2025-09-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-senate-support-clinical-trial-endpoints2025-08-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-q2-2025-financial-results-update2025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-eop2-fda-meeting-success2025-08-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-regains-nasdaq-compliance2025-07-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-pct-patent-application-20452025-07-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-manufacturing-agreements-cambrex-thermo-fisher2025-06-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-licensing-agreement-third-arc-bio2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-phase-2-muzastotug-keytruda-colorectal-cancer2025-10-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-expands-safebody-collaboration-exelixis2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-adg126-csco-meeting-20252025-09-05T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-appoints-axel-hoos-executive-advisor2025-09-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-investor-conferences-september-20252025-08-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-six-months-2025-financial-results2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-regulatory-update-muzastotug-fda-meeting2025-07-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-conjugatebio-partner-develop-antibody-drug-conjugate2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-sanofi-investment-muzastotug2025-07-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-fda-updated-data-elraglusib2025-09-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-public-offering-20252025-09-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-public-offering-15-million2025-09-10T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-public-offering2025-09-09T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-clinical-trial-advanced-pancreatic-cancer2025-08-06T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-ewing-sarcoma-phase-1-trial2025-07-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-2-trial-results2025-06-24T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-trial-asco-20252025-06-20T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-russell-index-inclusion2025-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-2-data2025-06-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-q3-2025-financial-results-update2025-11-06T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-november-healthcare-conferences2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-rd-day-2025-new-york2025-09-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-ati-2138-eadv-20252025-09-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-phase-2a-trial-results-ati-21382025-07-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-leadership-transition2025-07-28T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-russell-indexes-inclusion2025-06-30T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-hc-wainwright-conference-20252025-06-26T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-present-jefferies-2025-london-healthcare-conference2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-q3-2025-results-corporate-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-appoints-catherine-mummery-chair-cab2025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/aci-19626-tdp-43-pet-tracer-nature-communications2025-10-24T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/aci-35-030-phase-1b-2a-trial-results2025-09-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-pipeline-focus-operational-efficiencies2025-09-04T07:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-phase-2-trial-results-parkinsons2025-04-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-ad-pd-2025-symposium2025-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-update-q3-20252025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-nda-milestones2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q3-2025-results-conference-call2025-10-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-erik-atkisson-appointment2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-fda-voucher-cytisinicline2025-10-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-new-hire-inducement-awards2025-10-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-smoking-cessation2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-promotes-craig-donnelly-coo2025-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-dr-mark-rubinstein-cmo2025-09-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-fda-acceptance-cytisinicline-nda2025-09-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHL/achilles-therapeutics-voluntary-nasdaq-delisting2025-02-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-phase-3-trials-ulcerative-colitis2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-abtect-trial-results-ulcerative-colitis2025-10-06T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-abtect-trial-results-safety-data2025-10-05T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-acceptance-late-breaking-abstract-ueg-20252025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-ueg-presentation-20252025-09-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-first-half-2025-financial-results2025-09-08T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-q3-2025-results-corporate-update2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-abstracts-aasld-20252025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reacquires-china-rights-imdusiran2025-06-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-clinical-trial-data-easl-20252025-05-07T06:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-present-imdusiran-ab-101-easl-congress-20252025-04-23T06:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/genevant-arbutus-patent-infringement-modena2025-03-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-board-changes-lindsay-androski-ceo2025-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-q3-2025-results2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-appoints-george-golumbeski-chairman2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-stifel-healthcare-conference2025-11-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-investor-conferences-20252025-08-26T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-pTau217-assay-utility2025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-jcr-collaboration-alzheimers-therapy2025-07-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-aaic-2025-cost-savings-sabirnetug2025-07-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-q3-2025-results2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-employee-inducement-grants2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-j-code-zevaskyn2025-10-30T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-james-gow2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-ab0-503-fda-rdea-pilot-program2025-10-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-children-hospital-colorado-zevaskyn2025-10-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-investor-conferences-september-20252025-08-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-inducement-grant-nasdaq-rule-56352025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-obesityweek-2025-data2025-11-04T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-investor-conferences-november2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-obesityweek-2025-presentation2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-fda-protocol-amendment-phase-3-hero-trial2025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-stifel-2025-forum2025-09-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-q2-2025-results-pipeline-updates2025-08-13T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-lisaftoclax-ash-20252025-11-04T01:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-olverembatinib-ash-20252025-11-04T01:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-investor-conferences-november-20252025-10-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-2025-interim-financial-results2025-08-20T23:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-glora-4-phase-iii-study-lisaftoclax2025-08-17T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-evercore-china-biotech-summit2025-08-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-btig-conference-20252025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-tradipitant-glp1-nausea-vomiting-results2025-11-17T23:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-second-winds-film-blood-cancer2025-11-14T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-robert-huffines-jacqueline-wright-board2025-11-17T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-onclarity-hpv-assay-who-prequalification2025-11-17T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/ziihera-phase-3-results-her2-targeted-agent2025-11-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-positive-topline-data-neladalkib-advanced-nsclc2025-11-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-rezlidhia-five-year-data-publication2025-11-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-inhibits-structural-damage-psa2025-11-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-gateway-labs-philadelphia-opening2025-11-19T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-financial-results-september-20252025-11-19T13:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-financial-results-20252025-11-20T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-nine-month-2025-financial-results2025-11-20T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-advanz-pharma-gobivaz-approval-europe2025-11-20T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-advanz-pharma-gobivaz-market-authorization2025-11-20T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-q3-2025-financial-results2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-evercore-isi-healthcare-conference2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-piper-sandler-healthcare-conference-20252025-11-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-evercore-healthcare-conference2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-lecanemab-data-ctad-conference2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-december-investor-conferences2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-piper-sandler-healthcare-conference-20252025-11-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-patent-application-depression-treatment2025-11-20T11:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-q3-2025-results-corporate-updates2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-humana-cnsid-assay-coverage2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-ibogaine-supply-breakthrough2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-presents-noblecon21-emerging-growth-conference2025-11-20T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-piper-sandler-healthcare-conference-20252025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-q3-2025-results-corporate-update2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-2-thio-101-study-romania2025-11-20T13:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-investment-conferences-20252025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-mink-215-anti-tumor-activity2025-11-20T16:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-noblecon21-investor-conference2025-11-20T14:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-atev-positive-results-veithsymposium2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-gt-02287-neuroscience-20252025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-hrec-approval-phase-1-2-cywc628-trial2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-positive-data-cmv-vaccine-program2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-fda-clearance-focal-one-hifu2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-fda-approved-alcohol-use-disorder-trial2025-11-20T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-q3-2025-financial-results-update2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-participate-benchmark-investor-conference2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fites-cf602-erectile-dysfunction-patent-brazil2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receptor-ai-collaboration-cancer-therapeutics2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-december-20252025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-corporate-updates2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-agreements-22-5-million-financing2025-11-21T05:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-announces-stock-repurchase-plan-100-million2025-11-21T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-litigation-tesaro-gsk2025-11-21T08:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-acquires-lava-therapeutics2025-11-21T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/b-free-chronic-babesiosis-study-open-enrollment2025-11-21T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-otsuka-launches-nexletol-japan2025-11-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-evercore-healthcare-conference-20252025-11-21T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inducement-grants-nasdaq-rule-5635c42025-11-21T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-ateganosine-clinical-program-sitc-20252025-11-21T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-positive-pas-004-pk-data2025-11-21T17:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-reports-long-term-survival-trends-gbm-trial2025-11-24T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-warrant-exercise-20-million2025-11-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-positive-six-month-data-knee-osteoarthritis2025-11-24T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-avt03-marketing-authorization-europe2025-11-24T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-approval-avt03-biosimilar-prolia-xgeva2025-11-24T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-hematology-investor-event2025-11-24T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-ash-2025-hematology-pipeline-advancements2025-11-24T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-vby329-rsv-antibody-development2025-11-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-advances-veterinary-partnerships-biofit-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-evercore-healthcare-conference2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-piper-sandler-conference-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-investor-conferences-december-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-piper-sandler-conference-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-phase-1-trial-update2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-piper-sandler-conference2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-helios-3-axpaxli-npdr2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-december-investor-conferences2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-investor-conferences2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-december-investor-conferences2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-fda-ind-clearance-phase-2-study2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-dlb-ctad-conference2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-completes-senior-notes-tender-offer2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-good-supply-vaping-products-quebec2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-good-supply-vapes-quebec-launch2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-piper-sandler-conference-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-vepdegestrant-sabcs-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-participation-upcoming-investor-conferences2025-11-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-evercore-healthcare-conference2025-11-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-fda-leqembi-subcutaneous-application2025-11-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-azetukalner-aes-2025-data2025-11-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-presents-piper-sandler-conference2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-investor-conferences-december2025-11-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-8-35-million-offering2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-nasal-foralumab-phase-2-trial-accepted2025-11-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-participate-evercore-healthcare-conference2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approval-chronic-spontaneous-urticaria-eu2025-11-25T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-phase-2a-data-rap-219-seizures2025-11-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-upcoming-conference-participation2025-11-25T13:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-sil204-toxicology-studies-phase-2-3-trial2025-11-25T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-phase-2-results-lyme-vaccine2025-11-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-positive-phase-2-results-lyme-vaccine2025-11-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-genio-therapy-medicare-reimbursement-20262025-11-26T06:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-genio-therapy-medicare-reimbursement-increases2025-11-26T06:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-bank-of-america-transparency-declarations2025-11-26T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-transparency-notifications-bank-of-america2025-11-26T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-priority-review-sonrotoclax-mcl-treatment2025-11-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVLT/scilex-closes-second-tranche-investment-datavault-ai2025-11-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-piper-sandler-conference-20252025-11-26T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-participate-evercore-healthconx-conference2025-11-26T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-evercore-healthcare-conference2025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquire-patents-endoscopy-systems2025-11-26T12:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-participate-citi-2025-global-healthcare-conference2025-11-26T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-participate-piper-sandler-conference-20252025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-citi-2025-healthcare-conference2025-11-26T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-investor-webinar-december-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/enlivex-closes-212-million-private-placement2025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-warrant-inducement-transaction2025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-participate-piper-sandler-healthcare-conference2025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-piper-sandler-conference-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-investor-conferences-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-evercore-healthcare-conference-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-curevac-exchange-offer-update2025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-exchange-offer-curevac-shares-expiration2025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-blarcamesine-ctad-conference-20252025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-piper-sandler-healthcare-conference-20252025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-presents-evercore-healthcare-conference-20252025-11-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-pipeline-presentation-noblecon212025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-emperor-total-artificial-heart-ismcs-20252025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-piper-sandler-conference2025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-presents-piper-sandler-healthcare-conference2025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-board-transition-christina-rossi2025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/emory-hospital-adopts-liberty-endovascular-robotic-system2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-payoff-outstanding-debt2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-ceo-corner-strategic-growth2025-11-26T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-reverse-stock-split2025-11-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-acquisition-xoma-royalty2025-11-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-custom-integration-pipeline2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-virtual-investor-closing-bell-series2025-11-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-lawsuit-stock-manipulation-w52025-11-26T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-ph80-menopausal-hot-flashes-findings2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-evm401-patent-allowance2025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-pristina-recon-dl-mammography2025-11-26T12:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-participation-december-investor-conferences2025-11-26T15:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-consolidates-operations-france2025-11-26T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-consolidate-operations-france2025-11-26T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-webinar-french-shareholders-december-20252025-11-27T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-fiba-award-20252025-11-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/illuccix-available-france-official-journal2025-11-28T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-shares-voting-rights-november-20252025-11-28T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-general-assembly-vote-results-november-20252025-11-28T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-shareholders-meeting-results-november-20252025-11-28T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inducement-grants-nasdaq-rule-56352025-11-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-recommendation-reimbursement-skyrizi-colitis2025-11-28T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/skyrizi-positive-reimbursement-canada-ulcerative-colitis2025-11-28T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-regulatory-update-tradipitant-motion-sickness2025-11-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-evercore-healthcare-conference-20252025-11-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-launch-ai-bph-module-rsna-suo2025-11-28T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inducement-grant-nasdaq-rule-56352025-11-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-nasdaq-notification-letter2025-11-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-public-offering-60-million2025-11-28T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-piper-sandler-healthcare-conference-20252025-11-28T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-stock-manipulation-lawsuit2025-11-28T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-acquires-family-beginnings-clinic2025-11-28T18:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/deephealth-next-gen-imaging-ai-rsna-20252025-11-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-next-generation-signa-mri-technology2025-11-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-rsna-2025-innovation2025-11-30T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-verida-launch-ai-spectral-ct2025-11-30T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-blueseal-horizon-helium-free-mri-platform2025-11-30T16:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-q3-2025-financial-results2025-12-01T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-agm-december-20252025-12-01T09:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eclipse-phase-3-atogepant-migraine-data2025-12-01T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/deephealth-breast-suite-launch-ai-cancer-detection2025-12-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-phase-3-dragon-trial-results2025-12-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-ind-clearance-ide034-bispecific-adc2025-12-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-board-transition2025-12-01T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-alzheimers-candidates-ctad-20252025-12-01T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-sells-complement-inhibitor-adx-0972025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-participate-piper-sandler-healthcare-conference2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-fda-fast-track-cln-0492025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-regains-nasdaq-compliance2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-piper-sandler-conference-20252025-12-01T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-evercore-healthcare-conference2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-proteograph-platform-genetic-signals-drug-targets2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-tessera-develop-tsra-196-gene-therapy2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-respect-phase-1-results-sabcs-20252025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-plasma-ptau-alzheimers-trials2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-evercore-healthcare-conference2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-va-contract-functional-abdominal-pain2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-webcast-phase-1-btx-degrader-bexobrutideg2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-apoc3-ionis-nature-conference-20252025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-public-offering2025-12-01T12:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-q2-fy26-results2025-12-01T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-secures-investment-and-new-ceo2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-evercore-healthcare-conference-20252025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-piper-sandler-conference-20252025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-phase-3-zervimesine-alzheimers-ctad2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-phase-1b-ficerafusp-alfa-data-esmo-asia2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-ceo-transition-succession-plan2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-rare-kidney-disease-pipeline2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-tender-offer-lilly-expiration2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-biogen-presentations-2025-aes-meeting2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-fda-breakthrough-olesarsen-severe-hypertriglyceridemia2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-notice-allowance-xp-8121-patent2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-frank-leonard-ceo-appointment2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bmy-ash-2025-hematology-pipeline-data2025-12-01T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-appoints-carolyn-bonner-cfo2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dyadic-brig-bio-animal-free-alpha-lactalbumin-agreement2025-12-01T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-appoints-margaret-dugan-cmo2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-ceo-letter-shareholders2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-noble-capital-markets-conference-20252025-12-01T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stoke-presentations-2025-aes-meeting2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-webinar-tupelo-phase-1b-2-trial2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-appoints-nick-tressler-cfo2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-closes-novo-nordisk-agreement-zaltenibart2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-bloom-phase-2-study-fragile-x2025-12-01T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-appoints-richard-hoffman-general-counsel2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-21-cfr-part-11-compliance-software-xcelligence-rtca-esight2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reverse-stock-split2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-enters-gerd-device-market-acquisition2025-12-01T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-collaborate-texas-biomed-influenza-study2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-fda-rare-pediatric-disease-sgt-2122025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-presentation-iaccess-alpha-conference2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-participate-evercore-healthcare-conference2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-piper-sandler-conference-20252025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-breast-cancer-sabcs2025-12-01T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-launches-lymphir-cancer-immunotherapy2025-12-01T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eclipse-phase-3-data-european-headache-congress2025-12-01T17:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inducement-grants-nasdaq-rule-56352025-12-01T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-inducement-grants-nasdaq-listing-rule-5635c42025-12-01T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-sale-coflex-assets-companion-spine2025-12-01T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-inducement-plan-grants2025-12-01T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-inducement-grants-nasdaq-rule-56352025-12-01T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/2025-sabcs-breast-cancer-index-test-utility2025-12-02T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-phase-3-argus-trial-data-20252025-12-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-pari-european-patent-molbreevi-nebulizer2025-12-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-innovation-webcast-rd-leadership2025-12-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engens-detalimogene-fda-manufacturing-pilot-program2025-12-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-fda-breakthrough-therapy-plozasiran2025-12-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-fda-breakthrough-therapy-zilganersen-alexander-disease2025-12-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-investor-conferences-december-20252025-12-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-appoints-dr-winer-advisory-board2025-12-02T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-fda-type-c-meeting-scheduled2025-12-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/doctorbox-adds-mainz-biomed-coloalert2025-12-02T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-albuterol-sulfate-aerosol2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-futurevision-advisory-council2025-12-02T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-nine-month-2025-results-cdmo-growth2025-12-02T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/who-approval-olastrocel-celz-2012025-12-02T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-fda-approval-trial-locally-recurrent-prostate-cancer2025-12-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-winnie-harlow-vitiligo-awareness-campaign2025-12-02T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-nvidia-imaging-solutions-rsna-20252025-12-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-ai-powered-care-aes-20252025-12-02T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-signatera-datasets-sabcs-20252025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-aws-strategic-collaboration-ai-platform2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-appoints-lucile-blaise-global-head-commercialization2025-12-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDY/aurigene-phase-1-study-aur112-lymphoid-malignancies2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-grants-40th-us-patent2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-2-phase-3-data-sabcs-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-corporate-update-call-december-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-appoints-alicia-secor-board2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-manufacturing-upscaling-nasal-spray-platform2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-spinout-il-6-asset2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-briquilimab-asthma-study-results2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-dr-petra-kaufmann-cmo2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reveal-1-results-glp-1-weight-maintenance2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-closes-60-million-offering2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-dlb-biomarker-data2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-positive-results-pedmark-japan2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-clinical-corporate-updates2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-evercore-healthcare-conference-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-virtual-fireside-chat-titan-partners2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-acquires-sommaplast-oral-dosing-packaging2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLP/simulations-plus-fourth-quarter-fiscal-2025-results2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-phase-1-trial-results-janz007-mcrpc2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-new-employee-inducement-grants-december-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMCL/omnicell-innovation-update-ashp-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-december-2025-conferences2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-webinar-preliminary-data-etesian-study2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-leadership-presentation-citi-2025-conference2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-cyclosporine-ophthalmic-emulsion2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eclipse-study-atogepant-migraine-results2025-12-02T04:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eclipse-study-atogepant-migraine-relief2025-12-02T08:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/lecanemab-pharmacological-effect-csad-conference-20252025-12-02T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-positive-preclinical-data-pegph202009-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-roche-phase-1-clinical-trial-enhanze-technology2009-01-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-presents-jp-morgan-healthcare-conference2009-01-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-grant-cdmo-business2023-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-nasdaq-compliance-update2023-11-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/eib-considering-extension-financial-facility-scini2023-10-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-q3-2023-financial-results2023-10-31T12:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-bio-europe-20232023-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-showcase-cgmp-biologics-cdmo-cphi-barcelona-20232023-10-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-1-33-million-offering2023-09-19T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-psoriasis-nanoabs-preclinical-results2023-09-13T20:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-investment-conferences-20232023-09-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-lti-03-ipf-study2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-fda-clearance-phase-2-trial-lti-03-ipf2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-lti-03-ipf-data-publication2025-09-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-ipf-summit-20252025-08-14T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-financing-agreements-21-million2025-07-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/ailerons-positive-phase-1b-trial-results-lti-032024-05-15T21:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/ailerons-upcoming-investor-conferences2024-05-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/ailerons-20-million-offering-closed2024-05-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/zircon-x-study-tlx250-cdx-clinical-decision-making2025-11-19T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-participate-ubs-jefferies-healthcare-conferences2025-11-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/tlx250-cdx-included-in-international-guidelines2025-10-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-doses-first-patient-solace-trial-bone-pain2025-10-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-206m-revenue-fy-2025-guidance-upgraded2025-10-14T06:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/cms-grants-tpt-status-gozellix2025-09-23T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-first-patient-phase-3-bipass-trial-prostate-cancer2025-09-09T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-presents-morgan-stanley-hc-wainwright-conferences2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-2025-half-year-results-commercial-performance2025-08-21T00:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-h1-2025-results-investor-webcast-notification2025-07-29T22:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-morgan-stanley-healthcare-conference2021-08-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-ubs-genomics-summit2021-08-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-q2-2021-financial-results2021-08-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-bio-rad-patent-agreement2021-07-27T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-chromium-x-series-launch2021-07-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-visium-assay-ffpe-tissues2021-06-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-june-investor-conferences2021-05-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-bofa-securities-2021-conference2021-04-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-launch-simpligraft-simplimax-wound-care2024-04-30T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-record-revenue-20232024-04-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-fourth-quarter-results-20232024-03-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-increases-credit-facility-midcap-financial2024-03-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-present-td-cowen-conference2024-02-26T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-investor-conferences-20242024-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-acquires-nanoss-production-operations2023-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-nasdaq-ipo-closing2021-10-18T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-ipo-pricing-announcement2021-10-14T02:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-new-employee-stock-options2024-10-02T11:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-grants-inducement-plan2024-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-investor-conferences-september-20242024-09-03T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q2-2024-financial-results2024-08-06T22:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adct-lot7-phase-1b-trial-updates2025-12-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reverse-stock-split2024-11-29T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-private-placement2024-11-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-open-letter-shareholders2024-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-nasdaq-extension-compliance2024-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1-ttx-mc138-trial-update2024-10-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1-trial-ttx-mc1382024-10-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-study-ttx-mc138-metastatic-cancer2024-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-nih-grant-ttx-mc1382024-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/catalent-brainstorm-partnership-nurown-als-therapy2020-10-23T15:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/catalent-brainstorm-partnership-nurown-therapy2020-10-23T15:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/catalent-brainstorm-partnership-nurown-manufacture2020-10-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-present-scientific-conferences-september2020-09-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-appoints-anthony-waclawski-regulatory-affairs2020-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-nurown-exosome-treatment-covid-19-ards2020-07-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-sme-status-ema2020-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-financial-results-q1-2020-update2020-05-07T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-leases-cleanroom-facility-tel-aviv2020-05-07T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-nurown-immunomodulation-neurology2020-05-04T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-piper-sandler-conference-20252025-11-25T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-miracle-trial-update-aml2025-11-13T13:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-virtual-investor-event-ash-20252025-12-03T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/first-us-commercial-sale-komzifti-kura-oncology2025-12-02T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/komzifti-nccn-guidelines-aml2025-11-25T22:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/komzifti-fda-approval-npm1-mutated-aml2025-11-13T15:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-hc-wainwright-conference-20202020-08-31T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-grant-cpg-1018-adjuvant-capacity-covid-192020-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-q2-2020-financial-results2020-08-06T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/trisalus-acquires-dynavax-sd-101-oncology-program2020-08-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-report-q2-2020-financial-results2020-07-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-medigen-collaboration-covid19-vaccine2020-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-new-board-members2020-07-21T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-mount-sinai-universal-influenza-vaccine2020-07-16T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-phase-1-trial-medicagos-covid-19-vaccine2020-07-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-presentation-american-society-hematology-20172017-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-q3-2017-financial-results2017-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-presents-sitc-32nd-annual-meeting-cowen-io-next-summit2017-11-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-q3-2017-financial-results-conference-call2017-11-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-presentation-cantor-fitzgerald-conference2017-09-22T15:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-pricing-public-offering-common-stock2017-09-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-aurigene-ca-170-update-esmo-20172017-09-11T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-presentation-baird-2017-healthcare-conference2017-09-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-ca-170-poster-esmo-20172017-08-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-florbetaben-f18-ctad-2025-presentation2025-11-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-hcwainwright-hbv-conference2023-10-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-abstracts-aasld-20232023-10-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-business-update-q3-20232023-10-05T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-barda-funding-antibody-platform2023-10-03T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-1-trial-hiv-vaccine2023-09-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-investor-healthcare-conferences-september-20232023-08-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-sasha-damouni-ellis2023-06-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-inducement-grants-nasdaq-rule-5635c42018-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-board-changes-elizabeth-anderson2018-11-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presents-three-november-conferences2018-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-q3-2018-financial-results-business-update2018-10-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-third-quarter-2018-financial-results-conference-call2018-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-new-data-idweek-chest-20182018-10-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-patent-protection-japan-20332018-10-04T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-fda-approval-arikayce-mac-lung-disease2018-09-28T21:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/convert-study-alis-ntm-lung-disease2018-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-q4-2022-financial-results-2023-objectives2023-03-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-conference-call-svb-cash-holdings2023-03-11T16:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-data-sgo-20232023-02-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-corporate-update-financial-report-20222023-02-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-participate-february-investor-conferences2023-01-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-balstilimab-mss-crc-asco-gi2023-01-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-participate-b-riley-2023-virtual-oncology-conference2023-01-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-data-asco-gi-presentation2022-12-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-balstilimab-advanced-sarcoma2022-11-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-criminal-investigation-update2024-12-13T00:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-pika-rabies-vaccine-application-pakistan2024-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-deutsche-bank-health-care-conference2009-05-15T13:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-presents-bank-america-healthcare-conference-20092009-05-12T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-present-sequire-investor-summit-puerto-rico2023-04-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launch-minimed-780g-system-instinct-sensor2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-pre-ind-submission-sublingual-aspirin2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-expands-okaidx-testing-cancer-detection2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-fda-approval-trial-recurrent-prostate-cancer2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-canadian-patent-stem-cell-treatment2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-hemopurifier-long-covid2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-new-data-ash-2025-blood-cancers2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-investor-event-pioneer-trial-data2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-receipt-anda-ketafree2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-fda-type-c-meeting-20252025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-snda-ameluz-pdt-sbcc-treatment2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-james-izanec-vp-clinical-development2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-patent-mpar-overdose-technology2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-synthetic-halneuron-ip-filing2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-iovera-results-chronic-low-back-pain2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-new-data-aipac-003-phase-ii-sabcs-20252025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-q2-2025-financial-results2025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-cancels-conference-call-svb-deposit-access2023-03-13T00:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-2-peninsula-trial-results2023-07-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-fda-review-extension-transcon-cnp-achondroplasia2025-11-25T23:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/cosibelimab-results-esmo-congress-20242024-09-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-presentation-hc-wainwright-conference2024-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-cosibelimab-fda-acceptance2024-07-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/gc-cell-checkpoint-therapeutics-cancer-research2024-07-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-12-million-offering2024-07-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-cryoablation-superior-drug-therapy-af2020-08-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-first-quarter-financial-results-20212020-08-25T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-appoints-kevin-lofton-director2020-08-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-fy2021-q22020-08-24T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evolut-tavr-updated-labeling-bicuspid-as2020-08-21T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-financial-results-q1-fy20212020-08-11T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-acquires-companion-medical-smart-insulin-pen2020-08-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-interstim-micro-neurostimulator2020-08-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-orphan-drug-designation-sclc2023-09-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapy-lung-cancer2019-09-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-biotech-strength-potential2019-08-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-jaypirca-cll-sll-indication2025-12-03T17:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-fda-approval-unloxcyt2024-12-13T23:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/approach-trial-transcon-cnp-achondroplasia-results2025-11-17T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/fda-accepts-karyopharm-snda-xpovio-multiple-myeloma2020-07-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-nci-partnership-xpovio-research2020-07-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-xpovio-q2-2020-sales-update2020-07-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-inducement-grants-nasdaq-rule-5635c42020-07-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-xpovio-phase-2b-sadal-study-results2020-06-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-fda-approval-xpovio-dlbcl2020-06-22T15:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-eha-2020-presentation-selinexor-eltanexor2020-06-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-selinexor-phase-1-2-glioblastoma-study2020-06-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-positive-phase-3-boston-data-asco-20202020-05-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-elites-study-interstim-micro-system2020-08-20T14:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-hugo-robotic-surgery-fda-clearance2025-12-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-milestone-achievements-biotech-growth2019-08-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapy-cancer-treatment2019-05-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapy-breakthroughs2019-05-30T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapies-cancer-treatment2019-05-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapy-programs2019-04-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-ceo-discusses-partnerships-and-developments2017-09-19T18:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-pre-nds-meeting-health-canada-april-20262025-12-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-presentations-sabcs-20252025-12-04T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-positive-interim-phase-1-data-bge-1022025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-new-use-patents-aramchol-rezdiffra-mash2025-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-nu-q-nets-sepsis-detection-france2025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-nuq-assay-detection-sepsis-france2025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-strategy-sustainable-growth2025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-academy-launch-education-platform2025-12-04T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endras-taeus-liver-matches-mri-pdff-performance2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-advances-starlight-1-trial-phase-ii2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-launches-new-plasmid-preps2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-presentation-sachs-forum-20262025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-tender-results-senior-notes-2026-20272025-12-04T12:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-fda-clearance-omnipod-5-enhancements2025-12-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-releases-skintuition-report-20252025-12-04T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-presentation-asco-20262025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-mesenchymal-drift-chronic-diseases2025-12-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-appoints-spencer-stiles-president-coo2025-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-wins-injunction-merck-keytruda-germany2025-12-04T18:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/fda-lifts-partial-hold-tradipitant-motion-sickness2025-12-04T21:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-presentation-dawson-james-conference-20232023-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/eazy-testing-aditxtscore-covid-19-monitoring2021-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-appoints-dolly-tyan-senior-vp-clinical-development2021-01-29T14:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-secures-financing-scale-aditxtscore2021-01-26T13:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxtscore-immune-monitoring-launch-february-20212021-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-distribution-agreement-todos-medical2020-12-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-present-ld-micro-conference-20202020-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxtscore-covid19-event-dr-drew2020-11-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-appoints-anthony-voorhies-business-development2020-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-secures-clia-certification-and-launches-covid-19-test2020-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q3-2022-results2022-10-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-updates-sleep-society-meetings2022-09-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-wells-fargo-conference-20222022-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-appoints-ezgi-yagci-vp-investor-relations2022-08-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-stock-offering-pricing2022-08-12T01:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q2-2022-results2022-08-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-new-independent-directors2022-08-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-fda-approval-full-body-mri-compatibility2022-07-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-presentation-lake-street-conference-20192019-09-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-presentation-dougherty-conference2019-09-03T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q2-2019-update2019-08-13T20:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-intellisight-conference-20192019-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/interim-results-phase-1b-dm199-chronic-kidney-disease2019-06-19T20:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-presentation-craig-hallum-conference-20192019-05-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-scientific-advisory-board-kidney-disease2019-05-21T12:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q1-2019-financials-update2019-05-06T12:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/tac-stim-performance-improvements-air-force2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-human-health-innovation-conference2021-06-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-jefferies-conference-20212021-05-27T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-buyback-equity-spin-off-hanxin-subsidiary2021-05-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q1-2021-financial-results2021-05-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-fda-approval-morphine-sulfate-injection2021-05-03T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q1-2021-earnings-call2021-04-29T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-needham-conference-20212021-04-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-fda-approval-dextrose-injection2021-03-29T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-third-quarter-2025-results2025-11-14T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-needham-conference-20212021-04-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q4-2020-financial-results2021-03-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-svb-leerink-conference-20212021-02-18T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-appoints-william-forbes-cdo2021-02-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q3-2020-financial-results2020-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-key-talent-hiring2020-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-presents-piper-sandler-healthcare-conference2025-11-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-nasdaq-notification-mvp2023-08-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-share-consolidation2023-07-27T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-nasdaq-notification-minimum-bid-price2023-03-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-covid-19-catalogue-inclusion2022-12-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-partnership-lian-ou-health2022-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-authorized-international-branch2022-03-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-fiscal-year-2021-results2022-01-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-strategic-alliance-jiangxi-imm2022-01-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-inducement-grants-nasdaq-rule-56352025-12-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-dr-lori-kunkel-appointment2024-04-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-90-million-financing-updates2024-03-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-q4-2023-financial-results2024-03-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-narcan-nasal-spray-anniversary2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-march-investor-conferences2023-02-21T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-ocs-heart-fda-advisory-panel-postponement2020-09-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-ipo-closing-additional-shares2022-02-08T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-pricing-initial-public-offering2022-02-04T06:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-third-quarter-2016-results2016-11-02T11:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-ceo-transition-damien-mcdonald2016-11-02T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-credit-suisse-healthcare-conference-20162016-10-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-conference-call-q3-2016-results2016-10-04T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-participation-eacts-annual-meeting2016-09-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-launches-next-gen-icd-crt-d-devices2016-09-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-growth-new-facility-adoptions-bva-analyzer2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-capital-efficiency-q3-20252025-11-14T19:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-piper-sandler-conference-20252025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-partners-akeso-ivonescimab2022-12-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-dr-cesano-appointment2022-11-17T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-financial-results-q3-20222022-11-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-ridinilazole-idweek-20222022-10-20T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-dr-robert-booth2022-10-03T20:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-100-million-rights-offering2022-08-09T17:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-lab-capabilities-expansion2025-12-03T13:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-completes-clinical-study-hyla-blood-sensor2025-11-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-appoints-executives-global-sales-board2025-10-21T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/paul-mann-returns-ceo-aspi2025-12-02T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-quarterly-update-call-november-20252025-11-17T21:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-public-offering-common-stock2025-10-14T20:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-q3-2025-financial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-q2-2025-results-call2025-08-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-phase-2-data-silevertinib2025-12-03T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-silevertinib-webcast-phase-2-results2025-12-02T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inducement-grants-new-employees2025-11-17T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp900-phase-1b-meeting2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/crest-2-study-carotid-artery-stenting-benefits2025-11-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-piper-sandler-healthcare-conference-20252025-11-19T21:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/prostact-global-phase-3-first-patient-dosed2025-12-08T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-oppenheimer-summit-20252025-12-08T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-atalanta-1-cell-therapy-data-ash-20252025-12-08T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-development-plan-ash-20252025-12-08T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-eti-cel-nhl-response-rate-ash-20252025-12-08T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inducement-grants-nasdaq-rule-56352025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-inducement-grants-nasdaq-rule-5635c42025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inducement-grants-december-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-inlexzo-gemcitabine-nmibc-study-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-inducement-grants-december-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-december-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-phase-1b-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-inducement-awards-december-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-ipo-closing2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-warrant-inducement-5-million2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-closes-10-million-offering2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/gallop-oncology-lyt-200-phase-1b-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-amx0114-als-lumina-trial-data2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/zorevunersen-dravet-syndrome-aes-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-bcr-abl1-panel-2025-ash-meeting2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-private-placement-warrant-inducement2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-rap-219-seizures-data-analysis2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-mural-oncology2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/freenome-perceptive-capital-business-combination2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cretostimogene-potential-backbone-therapy-nmibc2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-adipose-distribution-presentation-cvct-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-advancing-rare-disease-therapies2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-epcoritamab-clinical-trials-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-bexobrutideg-phase-1-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/bezuclastinib-summit-results-nonadvanced-systemic-mastocytosis2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-agreement-monetize-equity-biocon-biologics2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-clonoseq-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-rally-mf-phase-2-trial-data2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APTO/aptose-tuspetinib-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-ficerafusp-alfa-data-phase-1b2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-preclinical-data-arv-393-glofitamab-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-enozertinib-esmo-asia-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-ultramist-healogics-gpo2025-12-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-phase-2-3-trial-update-als2025-12-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-enrollment-completion2025-12-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-deliver-trial-results2025-12-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-updated-bexmab-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/spago-nanomedical-nomination-committee-2026-agm2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-end-of-phase-2-fda-deupirfenidone-ipf2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVO/evotec-sale-toulouse-site-sandoz2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/sonrotoclax-data-ash-2025-b-cell-malignancies2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ash-2025-ascentage-pharma-lisaftoclax-data2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-phase-2-data-sls009-aza-ven-aml-mr-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-positive-phase-2-nxc-201-results-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-100-million-offering2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-access-clinical-program-aleniglipron2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-pirtobrutinib-phase-3-study-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-ronde-cel-clinical-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/lynozyfic-linvoseltamab-multiple-myeloma-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/hemgenix-long-term-durability-safety-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-updated-data-phase-1b-study-r289-lower-risk-mds2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-data-inc033989-myelofibrosis-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-inca033989-breakthrough-therapy-fda2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-investor-conference-call-deliver-trial2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/yescarta-safety-efficacy-quality-life-benefits-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-evorpacept-phase-2-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-pm359-cgd-clinical-data-publication2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-epkinly-phase-3-data-follicular-lymphoma2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-china-national-reimbursement-drug-list-updates2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/onco-innovations-nasdaq-cross-listing-equity-offering2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/hympavzi-reduced-bleeds-hemophilia-a-b2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-positive-data-alloha-phase-1-trial2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-pociredir-sickle-cell-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/kite-bicistronic-car-t-cell-therapies-phase-1-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/kite-anito-cel-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-oncoc4-gotistobart-sqnsclc-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-new-data-evx-04-cancer-vaccine-ash-meeting2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-takeda-rusfertide-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-ash-2025-presentation2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-casgevys-first-data-children-5-11-ash-meeting2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-dor-target-cancer-therapy2025-12-08T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cretostimogene-grenadenorepvec-nmibc-data2025-12-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-annamycin-collaboration-brain-tumors2025-12-08T13:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-abstract-hep-dart-20252025-12-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-abstracts-naclc-lung-cancer2025-12-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-baird-biotech-discovery-series2025-12-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-gene-editing-hscs-fusogen-technology2025-12-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-injection-j-code-reimbursement-update2025-12-08T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-jp-morgan-healthcare-conference2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/positive-phase-1b-2-results-rec-4881-tupelo-trial2025-12-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lingo-android-glucose-monitor2025-12-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-expands-leadership-ambassador-jamie-mccourt2025-12-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-positive-data-phase-1-inlight-trial2025-12-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-ss-mantra-fda-submission2025-12-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-ash-2025-leadership2025-12-08T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-showcase-aav-slb101-cardiac-gene-therapy2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-presents-sab-142-at-atted-asia-conference2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-fda-clearance-smart-comfort-cpap-therapy2025-12-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-aes-wrap-up-best-in-class-potential-epilepsies2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-fda-pre-submission-meeting-pl-142025-12-08T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-discontinues-phase-2b-bx004-trial2025-12-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-accelerates-nda-submission-axpaxli2025-12-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-virtue-sab-ici-meeting2025-12-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-bexobrutideg-phase-1-trial-ash-20252025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-iss-recommends-white-proxy-card2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/carolyn-bertozzi-returns-lilly-board2025-12-08T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-phase-3-trial-vax-312025-12-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-kyowa-combination-data-ziftomenib-venetoclax-azacitidine2025-12-08T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-cln-049-ash-meeting2025-12-08T15:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-first-quarter-2026-dividend2025-12-08T19:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-cosara-participate-virocon-20252025-12-08T17:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/jim-lang-elected-halozyme-board-directors2025-12-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-fda-fast-track-st-503-sfn-treatment2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-varian-theranostics-ebrt-collaboration2025-12-11T09:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-pricing-550-million-financing2025-12-11T06:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-2025-rd-update-ash-data-review2025-12-11T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-amends-at-the-market-offering-agreement2025-12-11T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-ffrct-analysis-cost-savings2025-12-11T08:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-appoints-jon-resnick-ceo2025-12-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-late-breaking-preclinical-data-bbo-10203-sabcs2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-enrollment-phase-2-3-trial-darovasertib2025-12-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-exercise-warrants-68-million2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/fda-renews-canalevia-ca1-approval-jagx2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-orders-high-performance-nmr-systems-europe2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-fda-clearance-cable-free-ecg2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-water-tower-research-fireside-chat2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-ctdna-research-sabcs-20252025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/tukysa-first-line-maintenance-therapy-her2-positive-breast-cancer2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-positive-phase-2-results-chikungunya-vaccine2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-share-repurchase-program-20252025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-telomere-targeting-approach-nsclc2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-fda-clearance-da-vinci-sp-indications2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DLHC/dlh-reports-fiscal-2025-fourth-quarter-results2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-ipf-study-results2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-hero-trial-prader-willi-syndrome2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-preliminary-data-setmelanotide-pws2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-december-2025-inducement-grants2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-fda-response-ser-2522025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-positive-ragistomig-phase-1-data-esmo-io2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-18-million-offering-lymphir-launch2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-inducement-grant-new-employee2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-inducement-awards-nasdaq-rule-56352025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-retatrutide-phase-3-trial-results2025-12-11T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1510-esmo-2025-data2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-wyss-center-3d-multiomics-technology2025-12-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-wyss-center-biologie-spatiale2025-12-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-announces-10-million-cash-dividend2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-phase-3-sunrize-study-results2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-expands-cnside-assay-california2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-scientific-advisory-board-radiotherapeutics2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-fda-fast-track-kt-6212025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-jp-morgan-2026-conference2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-micropulse-glaucoma-retreatment-study2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima203cd8-prame-cell-therapy-data-esmo-io-20252025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-izicopan-international-name2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-ceo-transition-orexin-strategy2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-phase-1a-study-results-crb-913-obesity2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-dublin-3-phase-3-study-plinabulin-docetaxel2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-positive-phase-2-data-parkinsons-disease2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-new-treatment-center-texas2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/broadwood-partners-opposes-staar-surgical-alcon-sale2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-refinancing-convertible-notes2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-partial-repurchase-convertible-senior-notes-20272025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/fda-priority-review-opdivo-hodgkin-lymphoma2025-12-11T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-pipeline-progress-outlook-investor-day-20252025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-setmelanotide-pws-trial-results2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-new-us-patent-emp-012025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/redecans-amped-live-resin-vapes-launch2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-acsl5-preclinical-data-lx98512025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-application-fibroblast-platform2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-year-2025-financial-results-call2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-launches-nanoss-strata-synthetic-bone-graft2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-present-two-posters-sabcs-20252025-12-11T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-corporate-update-financing2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fda-designation-endoxifen-dmd2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-arakoda-expansion-20262025-12-11T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-quarterly-dividend-increase-20252025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-relutrigine-nda-filing-20262025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-intranasal-naloxone-hydrogel-advancement2025-12-11T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-urcosimod-phase-2-results2025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-leadership-insider-buying-trial-data-signals-potential2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-upgrade-myvista-insights-platform-launch2025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-strategic-restructuring-plan2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-antigen-spreading-AMPLIFY-7P-trial2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-advances-optical-genome-mapping-amp-20252025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-egyptian-drug-authority-authorization2025-12-11T13:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-hep-dart-20252025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-smart-infusion-pump-emr-integration2025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-european-patent-molbreevi-liquid-formulation2025-12-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-appoints-sean-salmon-board2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-104-phase-3-trial2025-12-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-partners-vugene-ai-drug-discovery2025-12-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-water-institute-launch-education2025-12-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-acceptance-clinical-data-abstract-asco-20262025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-lumee-technology-presentation-linc-20262025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-senior-notes-offering2025-12-11T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-acquires-vlx-1005-hit-treatment2025-12-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-emrosi-clinical-trial-results2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-new-ceo-development-phase2025-12-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-public-offering-pricing2025-12-11T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staars-go-shop-process-alcon-merger2025-12-11T14:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-first-patients-dual-energy-platform2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-acquisition-proposal-silvercape-investments2025-12-11T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-issues-second-tranche-bonds-eur-10-million2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-2026-financial-calendar2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/otr-therapeutics-zealand-pharma-collaboration-metabolic-diseases2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-private-placement-update2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-inducement-grants-nasdaq-elvn2025-12-11T21:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-jp-morgan-conference-20262025-12-11T22:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-positive-phase-1-breast-cancer-vaccine2025-12-11T23:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-uplizna-generalized-myasthenia-gravis2025-12-11T23:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-public-offering-pricing2025-12-12T05:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-merus-tender-offer-completion2025-12-12T06:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-investor-conference-20262025-12-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/revuforj-revumenib-best-new-drug-scrip-awards-20252025-12-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-preclinical-data-sabcs-20252025-12-12T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-increases-quarterly-dividend-54th-year2025-12-12T15:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-inluriyo-imlunestrant-ember-3-study-results2025-12-12T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approves-akeega-brca2-mcspc2025-12-13T01:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-uplighted-studies-update-efgartigimod-sc2025-12-15T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-integrates-cac-mid-60-sbf-120-euronext2025-12-15T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-joins-cac-mid-60-sbf-120-indices2025-12-15T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-acquires-spectrawave-advancing-coronary-imaging2025-12-15T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-concludes-legacy-doj-matter2025-11-20T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-participate-piper-sandler-healthcare-conference2025-11-19T14:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-amcp-nexus-2025-sublocade-evidence2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-q3-2025-financial-results-guidance2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-participate-stifel-2025-healthcare-conference2025-10-28T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-third-quarter-2025-financial-results-webcast2025-10-16T21:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/rapid-induction-sublocade-improves-retention-opioid-treatment2025-10-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-proposes-new-corporate-structure-us-domiciliation2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-q2-2025-financial-results-guidance-raise2025-07-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-cancellation-london-listing-nasdaq-maintained2025-07-25T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-virtual-kol-event-neuroimmunology2025-07-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-new-cfo-appointment2025-06-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jefferies-conference-20252025-05-28T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-business-update-q1-2025-results2025-05-13T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-leerink-partners-conference-20252025-03-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-naji-gehchan-appointment2025-01-21T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jp-morgan-healthcare-conference-20252025-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-leadership-growth-appointments2024-12-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-private-placement-funding2025-11-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-addresses-false-report-sale-securities2025-11-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-positive-preclinical-data-atr-01-ichthyosis-vulgaris2025-10-20T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-participate-dermatologic-rare-disease-panel2025-10-15T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-nyse-american-non-compliance-notice2025-10-03T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-presentation-hc-wainwright-conference-20252025-09-04T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-first-patient-phase-1-2-trial-atr-042025-08-27T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-reverse-stock-split2025-08-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-third-quarter-2025-financial-results2025-11-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-presentation-hc-wainwright-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-sale-lavie-bio-icl-completion2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-generative-ai-foundation-model-completion2025-06-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-innovation-authority-grant-fill-finish-capabilities2025-10-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-six-month-2025-financial-results2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-pc111-disease-modifying-therapy-pemphigus-sjs-ten2025-07-29T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-pc111-award-italian-dermatology2025-06-26T12:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-funding-cdmo-growth-bio-convention-20252025-06-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-acquisition-pincell-clearance2025-06-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-q1-2025-financial-results2025-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-announces-annual-financial-results-20242025-05-07T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-pincell-webinar-pc111-rare-skin-diseases2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-adjourns-annual-meeting-stockholders2025-06-24T15:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-first-patient-renew-trial-lti-03-ipf2025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-ats-2025-conference-lti-03-ipf2025-05-19T21:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-q1-2025-results-business-update2025-05-15T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-presentation-citizens-conference-20252025-04-30T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-abstract-accepted-ats-20252025-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-patents-lti-03-respiratory-diseases2025-04-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-lti-2355-ipf-pasc-f-publication2025-04-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-avadel-bid-counteroffer-lundbeck2025-11-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/lundbeck-bids-for-avadel-pharmaceuticals2025-11-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-narcolepsy-program-phase-iii2025-11-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-spin-out-oncology-business2022-11-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/managing-multigenerational-post-pandemic-workforce2022-08-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-oncology-asco-22-nemvaleukin2022-06-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/kinaset-ceo-robert-clarke-asthma-patients2022-01-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/biopharma-clinical-report-2q20212021-07-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-lybalvi-fda-approval-schizophrenia-drug2021-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-participate-evercore-healthcare-conference2025-11-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-acquires-elektrofi-drug-delivery-expansion2025-11-18T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/fda-approves-darzalex-faspro-high-risk-smoldering-multiple-myeloma2025-11-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-pricing-convertible-senior-notes-offering2025-11-07T04:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-2025-financial-guidance-q3-results2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-third-quarter-2025-results2025-10-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-opens-tms-yokohama-japan2025-11-21T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/zircon-x-study-tlx250-cdx-impact-clinical-decision-making2025-11-20T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/opalescence-trial-tlx250-cdx-breast-cancer2025-11-12T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-solace-trial-bone-pain-treatment2025-10-23T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-injunction-parse-biosciences-atac-products2025-03-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-5000-plex-gene-panel2024-05-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-q1-2024-financial-results2024-04-30T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-visium-hd-spatial-assay2024-03-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-expands-xenium-menu-cell-segmentation-immuno-oncology2024-03-21T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-begins-commercial-shipments-gem-x-products2024-03-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-td-cowen-conference-20242024-02-20T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-gem-x-technology2024-02-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-ind-submission-ide574-cancer2025-12-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-december-2025-investor-events2025-11-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-positive-phase-2-data-darovasertib2025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-managed-access-program-del-zota-dmd442025-11-19T14:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-acquisition-novartis-ag2025-10-26T18:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-investor-conference-participation2025-10-16T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-positive-pre-bla-meeting-fda-del-zota2025-10-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-explore44-data-wms-congress2025-10-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-upsized-public-offering2025-09-15T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-public-offering-common-stock2025-09-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-del-zota-disease-progression-reversal2025-09-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-launches-collagenx-surgical-wound-closure2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-hc-wainwright-conference-20252025-09-04T13:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-cg-annual-growth-conference-20252025-08-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-q2-2025-financial-results-announcement2025-08-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-fda-clearance-phase-3-trial-primec-als2025-11-24T14:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-investor-webinar-december-20252025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-primec-alzheimers-biomarkers-reduction2025-10-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-primec-alzheimers-trial-results2025-09-10T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-private-placement-premium2025-09-04T13:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-live-podcast-als-science-commercialization2025-07-22T13:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-primec-commercial-manufacturing-scale-up2025-05-07T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-shareholder-letter-clinical-progress2025-04-24T14:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-nasdaq-extension-compliance2025-12-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-4-million-offering2025-10-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-int230-6-clinical-results-ebio-medicine2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-invincible-4-update2025-09-10T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-fireside-chat-hc-wainwright-conference2025-09-02T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-regains-nasdaq-compliance2025-08-12T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/fda-review-nurown-evidence-treatment-effectiveness2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-nurown-als-survival-data2025-06-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-manufacturing-partnership-minaris-nurown-phase-3b2025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-fda-clearance-phase-3b-trial-nurown-als2025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-appoints-dr-michel-janicot2025-11-17T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-study-ttx-mc1382025-10-14T13:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-acquires-polynoma-funding2025-10-08T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-dr-phillip-zamore-appointment2025-05-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-trial-update2025-05-08T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-trial-progress2025-05-01T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-special-meeting-adjournment2025-04-21T21:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-lotis-7-update-webcast2025-12-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q3-2025-financial-results-call2025-11-03T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-november-investor-conferences2025-10-27T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-60-million-private-placement2025-10-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-cantor-global-healthcare-conference-20252025-08-27T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-esophageal-precancer-detection-data2025-12-09T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-genomeweb-best-places-to-work2025-11-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-participate-canaccord-forum2025-11-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-conference-call-november-20252025-10-29T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-maxim-growth-summit-20252025-10-15T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-john-palumbo-board-appointment2025-09-25T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-appoints-danielle-scelfo-market-access2025-09-16T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-public-offering-closure2025-09-11T14:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-public-offering-pricing2025-09-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-participate-evercore-healthcare-conference2025-11-19T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-exclusive-license-vaxart-oral-covid-vaccine2025-11-05T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-third-quarter-2025-financial-results-conference-call2025-10-22T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-phase-1-2-trial-shingles-vaccine2025-10-21T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-participate-2025-wells-fargo-healthcare-conference2025-08-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-stockholders-elect-director-nominees-20252025-06-11T16:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-kol-investor-event-ampreloxetine2025-11-20T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-investor-conferences-december-20252025-11-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-ampreloxetine-symposium-presentation2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-yupelri-copd-chest-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-hc-wainwright-conference-20252025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-phase-3-cypress-study-enrollment-completed2025-08-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-q2-2025-financial-results2025-07-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-stifel-2025-healthcare-conference2025-11-05T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fda-collaboration-framework2025-10-01T22:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-hetlioz-insomnia-study-publication2025-09-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-september-2025-investor-conferences2025-08-28T22:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-virtual-investor-conference-20252025-03-11T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-at-roth-conference-20252025-03-10T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-annamycin-patent-allowances2025-03-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-abstract-accepted-isalxix-symposium2025-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-3-5-million-offering2025-02-25T17:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-warrant-exercise-5-8-million2025-02-13T18:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-fda-guidance-miracle-trial-aml2025-02-13T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-approval-miracle-phase-3-trial2025-02-11T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-participates-in-virtual-investor-segment2025-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-annamycin-phase-3-trial-update2025-01-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-q3-2025-financial-results-webcast2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-appoints-joe-todisco-board-directors2025-10-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-private-placement-financing-29-million2025-09-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-nephro-crrt-trial-enrollment-milestone2025-08-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-piper-sandler-conference-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-jefferies-conference-20252025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-investor-conferences2025-09-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-btig-conference-20252025-07-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-hcw-home-series2025-06-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-third-quarter-earnings-release-date2025-03-20T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/nrlb-withdraws-labor-claim-neogen2025-02-18T21:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-igenity-bchf-bovine-heart-health2025-01-21T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-mda2-quantitative-salmonella-assay2025-01-16T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-participate-upcoming-investor-conferences2025-01-07T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-second-quarter-earnings-release-change2025-01-02T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-petrifilm-bacillus-cereus-count-plate2024-12-17T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-participate-piper-sandler-healthcare-conference2024-11-27T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-q3-2025-results-update2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-top-line-results-am-001-study-aramchol2025-11-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-top-line-results-oncology-moa-studies2025-11-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-digital-asset-management-strategy2025-08-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-biomarker-signature-aramchol-expansion-potential2025-05-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-ayvakit-efficacy-eha-eaaci-20252025-06-12T23:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-q1-2025-financial-results2025-04-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-needham-conference-20252025-03-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-mast-cell-therapies-2025-aaaai2025-02-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-jp-morgan-conference-20252024-12-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-ash-2024-ayvakit-advancements2024-12-07T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-signal-aa-phase-2a-trial-enrollment-completed2025-10-21T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-participate-2025-wells-fargo-healthcare-conference2025-08-28T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-appoints-adrien-sipos-interim-cmo2025-06-25T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-fda-fast-track-bempikibart-alopecia-areata2025-04-30T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-transparency-update-equity-financing2025-07-31T17:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-strategic-update-woori-io2025-07-30T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-acquires-woori-io-glucose-monitoring2025-07-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-appoints-dr-andreas-niethammer-cmo-vaximm2025-07-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-security-token-offering-roadmap2025-07-09T15:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-bcm-europe-taekwondo-token-launch2025-05-22T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/darnatein-presents-bmp-conference-20252025-05-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-tyra-300-proof-of-concept-data2024-10-24T23:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-q2-2023-results-highlights2023-08-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-preclinical-data-tyra-200-symposium2022-10-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-september-2022-investor-conferences2022-09-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-2021-jefferies-london-conference2021-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-announces-ipo-closing-and-underwriters-option2021-09-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-divests-clinical-services-business-audax-private-equity2024-08-16T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-launches-responsible-supplier-program2023-06-21T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-rebrands-tao-synergies-taox2025-06-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-tao-acquisition-crypto-strategy2025-06-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-crypto-strategy-ai-token-tao2025-06-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-special-committee-value-creation2024-12-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-5-million-financing2024-09-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-collaboration-lsu-health-spinal-cord-injury2024-07-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-fda-ind-bryostatin-1-ms-trial2024-06-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-dea-cannabis-reclassification-benefits2024-05-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-regains-nasdaq-compliance2024-04-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-increases-stake-psilocybin-drug-discovery2024-04-09T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-inducement-grants-nasdaq-rule-56352025-12-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/european-commission-approves-brinsupribrensocatib-ncfb2025-11-18T16:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-global-day-of-good-20252025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-present-november-december-2025-investor-conferences2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-science-top-employers-20252025-10-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-phase-3-aspen-study-presentation-chest-20252025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-third-quarter-2025-financial-results-conference-call2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-first-sale-nuq-cancer-assays-clinical-use2025-11-25T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-first-sales-contract-nuq-cancer-tests2025-11-25T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-q3-2025-financial-results-update2025-11-13T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-schedules-q3-2025-earnings-call2025-11-10T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-donates-nuq-vet-cancer-tests-hope-dogs2025-10-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-pricing-public-offering-common-stock2025-10-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-15-6-million-offering2025-12-09T14:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-reports-q3-2025-results-update2025-11-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-dor-targeting-mdscs-ash-meeting2025-11-03T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inclusion-russell-indexes2025-07-01T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-acquisition-kineta2025-06-30T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-phase-3-trial-ifx-2-0-keytruda-mcc2025-06-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-inducement-grants-nasdaq2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-appoints-christopher-martin-board2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-new-cfo-michael-noffi2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-investor-conferences-20252025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-sevasemten-wms-congress-20252025-10-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-jefferies-global-healthcare-conference2025-11-11T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-launch-charged-aerosol-detector-empower-software2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-q3-2025-financial-results2025-11-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-rd-day-december-20252025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-q3-2025-financial-results2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-investor-conferences-20252025-10-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-conference-call-q3-2025-results2025-10-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-vatiquinone-crl-fda2025-08-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-novartis-acquisition-agreement2025-04-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-2025-oppenheimer-summit2025-04-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-phase-1b-trial-farabursen-adpkd2025-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-leerink-partners-2025-conference2025-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-oppenheimer-conference-20252025-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-adpkd-farabursen-updates2025-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-investor-conferences-20242024-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-acceptance-denifanstat-acne-nmpa2025-12-10T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-inducement-grants-nasdaq-5635c42025-12-09T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q3-2025-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-investor-conferences-20252025-11-12T22:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-participate-scientific-conferences-ksi-1012025-09-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-presentation-american-chemical-society-20252025-08-19T19:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-investor-rd-day-july-20252025-07-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-ksi-101-presentation-iois-20252025-06-25T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-2025-jefferies-conference2025-05-30T02:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-regains-nasdaq-compliance2024-10-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-extraordinary-general-meeting-20242024-09-11T02:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-fy-2024-financial-results2024-08-16T02:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-cash-dividend-q3-fy20262025-12-04T21:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-q2-fiscal-2026-financial-results2025-11-18T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-q2-fy2026-financial-results2025-11-05T22:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-symplicity-spyral-coverage-finalized2025-10-28T23:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/spyral-htn-on-med-results-blood-pressure-reductions2025-10-26T22:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-brainsense-adaptive-deep-brain-stimulation2025-10-09T15:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-hugo-robotic-surgery-study-gynecology2025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-builds-6-billion-facility-alabama2025-12-09T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-adverum-acquisition-tender-offer-expiration2025-12-09T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-improves-survival-cll-sll2025-12-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-progress-breast-cancer-symposium-20252025-11-24T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-phase-3-ash-20252025-11-24T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-attend-morgan-stanley-conference2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-strategic-review-infant-formula-business2025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-attend-jefferies-consumer-conference2025-11-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend2025-10-29T16:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-third-quarter-2025-financial-results-release2025-10-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/opill-chill-collaboration-launch2025-10-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-attend-barclays-consumer-staples-conference2025-08-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-complete-response-mrd-patient2025-06-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-transition-nasdaq-otc-markets2025-03-21T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-bio-pharm-outsourcing-initiatives-reducing-burn-rate2025-03-18T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-acquires-ophthalmic-pharmaceutical-company2025-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-bio-pharm-ceo-cancer-progress-panel-european-forum2025-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-achieve-clinical-trial-cohort-a-completion2025-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-achieve-clinical-trial-patient-dosing-completion2025-02-10T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-bio-pharm-ads-ratio-change2025-02-05T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-h5n1-proof-of-concept-studies2025-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-water-tower-research-chat-20252025-12-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-who-approval-liraltagene-autoleucel2025-11-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-patent-20252025-11-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-data-transfer-agreement-cleveland-clinic2025-11-05T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-spartan-capital-conference-20252025-10-23T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-chinese-patent-breast-cancer-vaccine2025-10-20T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-trial2025-10-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-results-sabcs-20252025-09-22T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-inc-reverse-stock-split2025-12-02T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-phase-2a-data-vanoglipel-mash-aasld-20252025-11-07T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-phase-1-preclinical-data-da-1726-obesityweek-20252025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-poster-presentation-vanoglipel-aasld-20252025-10-27T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-da-1726-obesityweek-20252025-10-20T15:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-presentation-hc-wainwright-liver-conference2025-10-14T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-present-upcoming-investor-industry-conferences2025-08-26T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-phase-1-trial-da-1726-obesity-8-weeks2025-08-06T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-third-quarter-2025-financial-results2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-sentry-trial-enrollment-completion2025-09-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-acclaim-1-phase-1-gene-therapy-data2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-adds-clinical-trial-site-acclaim-lung-cancer2025-11-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-patent-reqorsa-gene-therapy-pd-l1-antibodies2025-11-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-10-million-offering-nasdaq2025-10-28T16:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-positive-preclinical-data-reqorsa-gene-therapy2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-september-investor-conferences2025-09-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gene-therapy-lung-cancer2019-09-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-pipeline-update-clinical-progress2025-12-03T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-nvidia-connect-program2025-11-20T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-gdnf-weight-loss-therapy-study2025-10-27T12:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-fda-orphan-drug-ht-kit2025-10-21T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-expands-ai-initiative-nvidia-platform2025-10-08T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ceo-presentation-bio-europe-20252025-10-07T12:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-patent-expansion2025-09-24T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-shareholder-update-ht-001-ht-kit2025-09-16T13:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ema-submission-ht-001-cancer2025-09-10T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-whole-genome-sequencing-genetic-signals2025-11-12T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-webcast-upcoming-investor-conference2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-protein-prep-precision-ngs-proteomics2025-11-10T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-responds-chinese-ministry-commerce-updates2025-11-05T22:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-5-base-solution-multiomic-discovery2025-10-15T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-constellation-mapped-read-technology-genedx-pilot2025-10-15T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-third-quarter-2025-financial-results2025-10-14T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-advances-personalized-cancer-care-partnerships2025-09-23T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-q3-2025-results-release2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-com701-phase-1-trials-esmo-20252025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-present-sitc-20252025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-research-single-cell-genomics-2025-conference2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-hc-wainwright-investment-conference2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-q3-2025-financial-results2025-11-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-third-quarter-2025-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-acquires-quantum-computing-bio-data-company2025-10-23T14:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-board-changes-strategic-decision2025-09-16T11:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-regains-nasdaq-compliance2025-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-warrant-amendments-registration-filing2025-08-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-covid-19-vaccine-development2020-03-24T15:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-eczema-market-growth2020-01-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-acne-eczema-asthma-research2020-01-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-emerging-markets-report2019-12-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-eczema-therapy-market2019-12-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-adds-dr-adam-friedman-advisory-board2019-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-initial-public-offering2019-02-20T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-third-quarter-2024-results-update2024-11-08T15:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-cross-license-agreement-mannkind2024-05-29T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-pur3100-clinical-results-migraine2024-05-15T14:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-piper-sandler-healthcare-conference-20252025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-fda-approval-epkinly-lymphoma2025-11-18T17:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-migraine-career-catalyst-award-recipients-20252025-11-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NLSP/nls-pharmaceutics-kadimastem-equity-financing2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-closes-18-2-million-offering2025-11-12T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-upsized-public-offering2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-abj-mathew-center-biopreservation2025-11-20T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-investor-conferences-nov-dec-20252025-11-17T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-sale-savsu-subsidiary2025-10-07T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-invests-in-pluristyx2025-07-28T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q2-2025-financial-results-update2025-07-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-earnings-call-update2025-05-08T21:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-webinar-s-aureus-bacteremia2025-11-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-cgmp-manufacturing-facility-los-angeles2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-phase-2a-disarm-study-results2025-10-22T16:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-structural-biology-publication2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-hc-wainwright-conference-20252025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-positive-topline-data-phase-1b-2a-disarm-study2025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-preclinical-data-crac-channel-inhibitor-pah2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-auxora-preclinical-data-asn-kidney-week-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-telperian-ai-collaboration-clinical-trials2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-hc-wainwright-investment-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-hc-wainwright-kidney-conference-20252025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-phase-2-kourage-trial-auxora-aki2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-symposium-vicenza-course-aki-crrt-ebpt2025-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fda-strategy-endoxifen-breast-cancer2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/insilico-atossa-endoxifen-glioblastoma-study2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-endoxifen-duchenne-muscular-dystrophy-opportunity2025-11-17T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-third-quarter-2025-update2025-11-12T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-recast-trial-update2025-10-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-maxim-growth-summit-20252025-10-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-appoints-mark-daniel-cfo-commercial-readiness2025-10-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-carpo-trial-auxora-expansion2023-08-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-relisting-nasdaq2023-06-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-merger-graybug-vision2023-03-20T20:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/graybug-name-symbol-change-calciMedica2023-03-20T17:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/graybug-calimedica-merger-agreement2022-11-21T23:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-financial-results-september-20222022-11-10T21:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-investor-day-sustainable-growth-strategy2025-12-09T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-credeliotm-cat-eua-new-world-screwworm2025-11-21T18:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-participate-upcoming-investor-conferences2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-expands-credelio-labels-lyme-disease-ticks2025-10-27T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-credelio-fda-eua-new-world-screwworm2025-10-24T21:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-host-investor-day-december-9-20252025-10-16T21:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-third-quarter-2025-financial-results2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-fda-approves-zenrelia-label-update2025-09-23T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-innovation-credilio-quattro-blockbuster-status2025-09-08T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-east-africa-growth-accelerator-socio-economic-value2020-02-17T14:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-presentation-pcr-platform-ai-integration2025-12-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-tuberculosis-test-adoption-implementation2025-11-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-clinical-evaluations-fda-submission2025-11-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-q3-2025-results2025-11-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-jv-announcement-saudi-arabia2025-11-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-maxim-group-spac-transaction-india2025-11-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-ai-business-unit-co-dx-primer-ai2025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-third-quarter-2025-earnings-release2025-10-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-cosara-launch-ivd-products-india2020-01-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-expansion-ghana2019-10-29T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-zdc-launch2019-10-10T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-liquid-biopsy-conference-corfu2019-10-03T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-launch-vector-control-products-opma2019-09-19T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-lgc-expand-license-agreement-coprimer2019-09-04T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-presentation-rodman-renshaw-conference-20192019-08-28T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q2-2025-financial-results-im8-growth2025-09-13T04:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-fourth-quarter-full-year-2024-results2025-03-06T03:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-collaboration-mayo-clinic-supplements2024-12-20T03:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-space-experiment-aging-longevity-iss2024-12-06T03:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-december-2025-investor-conferences2025-11-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-appoints-kristian-humer-cfo2025-11-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-new-employment-inducement-grants2025-11-14T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-executives-share-purchases-1-45-million2025-11-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/cantor-fitzgerald-reiterates-overweight-rating-prenetics2025-11-14T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk5211-clinical-trial-hip-fracture2015-09-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q2-2015-financial-results-update2015-08-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-phase-2-trial-vk28092015-07-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-agreement-monetize-equity-stake-biocon2025-12-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-participate-upcoming-investor-conferences2025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/study-on-antibiotic-prices-and-scarcity-europe2025-11-20T19:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/study-reveals-antibiotic-access-issues-europe2025-11-20T19:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/study-highlights-urgent-reforms-antibiotic-access-vtrs2025-11-20T00:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/study-reveals-price-decrease-cost-increase-shortages-vtrs2025-11-20T00:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/european-study-shows-declining-prices-rising-costs2025-11-20T00:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/european-study-falling-prices-rising-costs-shortages2025-11-19T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-thinkequity-conference-20242024-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-report-q2-2021-results2021-08-11T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-otsuka-joint-venture-iv-solutions2025-05-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-introduces-new-infusion-devices-fda-clearance2025-04-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-fda-clearance-plum-duo-infusion-pump2023-08-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-plum-360-best-in-klas-smart-pump2023-02-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-acquires-smiths-medical2022-01-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-recalls-amino-acid-injection2021-09-03T19:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-new-york-supreme-court-judgment2025-11-04T17:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-talicia-investment-partnership2025-10-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-talicia-middle-east-deal2025-10-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-wins-ny-supreme-court-appeal-kukbo2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-legal-costs-award2025-08-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-talicia-licensing-payments2025-08-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-positive-fda-feedback-rhb-204-crohns-disease2025-07-21T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-china-commercial-insurance-list2025-12-08T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stoke-zorevunersen-dravet-syndrome-aes-20252025-12-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-leqembi-data-ctad-conference-20252025-12-03T23:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-submits-new-drug-application-leqembi-japan2025-11-28T00:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-dayra-collaboration-oral-macrocyclic-peptides2025-11-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stoke-dravet-syndrome-study-publication2025-11-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ibuprofen-approval-mexico2025-10-01T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/tabuk-launches-vibativ-antibiotic-saudi-arabia2025-09-29T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-vizient-contract-vibativ-starter-pak2025-08-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q2-2025-results-update2025-07-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-presentation-german-equity-forum-20202020-11-16T14:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-german-equity-forum-20202020-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-q3-2020-results-talicia-growth2020-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-q3-financial-results-webcast2020-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-patent-allowance-opaganib-rhb-1072020-11-04T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-talicia-phase-3-acg-20202020-10-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-production-expansion2020-10-15T05:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-manufacturing-partnerships2020-10-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-covid19-collaboration2020-10-14T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-1154-phase-3-trial-update2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-2401-obesityweek-presentation2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-presents-hc-wainwright-investment-conference2025-09-05T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-virtual-rd-event-lpcn-1154-postpartum-depression2025-06-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-filing-new-drug-submission-tlando-canada2025-06-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-enhanced-leo-system-protein-analysis2025-12-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-present-upcoming-investor-conferences2025-11-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-licenses-ai-designed-novobody-duo-molecules2025-11-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/ai-spatial-biology-biomarker-discovery-melanoma2025-11-04T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-reimbursement-coverage-rewalk-7-exoskeleton2025-12-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/unitedhealthcare-medicare-advantage-approval-rewalk-72025-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ltd-reports-q3-2025-results2025-11-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/fda-extends-review-tlando-lpcn2017-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-usppto-decision-interference-clarus2017-09-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-fda-advisory-meeting-tlando2017-09-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-presentation-ladenburg-thalmann-conference-20172017-09-19T19:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-presentation-rodman-renshaw-conference-20172017-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-fda-acknowledgement-tlando-nda-resubmission2017-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-resubmits-nda-lpcn-1021-hypogonadism2017-08-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q2-20172017-08-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-endometriosis-drug-discontinued-failure2025-07-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-layoffs-new-jersey-workforce-cuts2025-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/mercks-singulair-linked-mental-health-issues2024-11-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/roivant-sells-dermavant-to-organon-deal-value-1-2b2024-09-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/humira-biosimilars-launch-us2023-07-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/fda-weekly-review-daewoong-novavax-preceptis2022-08-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-international-womens-day-holiday2022-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/merck-spinout-organon-launch-global-womens-health2021-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/biopharma-leadership-changes-october-20232018-09-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-participate-evercore-isi-healthcare-conference2025-11-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-participate-industry-investor-conferences-november2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-vidofludimus-calcium-ectrims-20252025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-vidofludimus-calcium-patent-allowance2025-09-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-positive-data-phase-2-emphasis-trial2025-06-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-phase-3-ensure-trials-enrollment-completed2025-06-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-upsized-public-offering-200m2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-pricing-public-offering-common-shares2025-11-12T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-proposed-public-offering-common-shares2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/fda-complete-response-biohaven-vyglxia-spinocerebellar-ataxia2025-11-05T01:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-phase-2-3-trial-parkinsons-disease2025-05-29T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-trap-degrader-innovation-rd-day2025-05-28T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-oncology-program-updates-20252025-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-positive-phase-1-results2025-06-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-phase-1-results-webcast2025-06-16T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-investor-conferences-june-20252025-05-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-q1-2025-financial-results2025-05-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-poster-presentations-ddw-20252025-05-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-phase-1-trial-spy0032025-03-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-acquisition-concentra-biosciences2025-06-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-preclinical-data-eo-1022-aacr-20252025-04-25T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-discontinues-eo-3021-advances-eo-10222025-03-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-investor-conferences-march-20252025-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-updates-adr-programs-milestones2025-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-nominates-eo-1022-her3-adc2024-12-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-preclinical-data-20242024-12-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/haleon-appoints-carl-haney-chief-rd-officer2025-06-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/haleon-joe-sta-romana-chief-customer-officer2024-12-02T12:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/haleon-eroxon-launch-fda-cleared-gel-ed2024-09-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/centrum-silver-memory-benefits-older-adults2024-01-24T19:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-first-quarter-dividend2025-12-09T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-citi-global-healthcare-conference-20252025-11-24T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-present-evercore-healthconx-conference2025-11-24T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-imdelltra-small-cell-lung-cancer2025-11-19T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-repatha-cuts-cardiovascular-risk-trial-results2025-11-08T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-repatha-phase-3-data-aha-20252025-10-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-webcast-2025-third-quarter-results2025-10-29T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-investor-scientific-conferences2020-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-preclinical-covid-vaccine2020-09-04T14:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-supply-agreement-israel2020-08-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-phase-1-2-covid-19-vaccine2020-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q2-2020-financial-results-update2020-08-10T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-appoints-lance-kurata-clo2020-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-public-offering-20202020-07-31T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-public-offering-173-million2020-07-29T04:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-public-offering-common-stock2020-07-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-david-hastings-cfo-appointment2025-12-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q3-2025-financial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-stifel-2025-healthcare-conference2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-chest-2025-abstracts2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-phase-2a-river-trial-ers-congress-20252025-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-september-conferences2025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-prosense-cryoablation-rsna-20252025-12-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-patent-allowance-china-cryoablation2025-12-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecures-prosense-cancer-treatment-approval-switzerland2025-11-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-nasdaq-minimum-bid-price-notification2025-11-14T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-q3-2025-results-report2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-promotes-shay-levav-coo-commercial-traction2025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecures-cryoablation-system-nsclc-survival-rate2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-prosense-tme-fall-summit-breast-cancer2025-10-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-maxim-growth-summit-20252025-10-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/university-wisconsin-wins-abbott-big-ten-blood-competition2025-12-07T01:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-ensure-max-protein-shakes2025-12-04T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-acquires-exact-sciences-cancer-diagnostics2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-heartmates-holiday-movie-hallmark2025-11-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-third-quarter-2025-results-guidance2025-10-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/diabete-et-prejuges-campagne-abbott2025-10-15T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-third-quarter-earnings-conference-call2025-09-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-completes-acquisition-xenotherapeutics2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-securityholders-approve-acquisition-xenotherapeutics2025-10-06T22:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-acquired-xenotherapeutics2025-07-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-corporate-update-financial-results-20242024-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-terminates-phase-2-study-masofaniten-enzalutamide2024-11-01T01:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-masofaniten-esmo-20242024-09-13T22:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presentation-2024-cantor-conference2024-09-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-clinical-trial-updates-haduvio2020-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-chemoglo-hazardous-drug-testing2025-12-04T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-new-cell-analyzer-configurations2025-12-03T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-surgiphor-surgical-wound-irrigation-europe2025-11-24T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-regains-compliance-nasdaq2024-01-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-15-million-private-placement-nasdaq-listing2021-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-pyxis-es-system-dod-medication-safety2017-03-01T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-rights-offering-expiration2022-08-02T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-dr-maky-zanganeh-co-ceo-president2022-07-26T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-upcoming-investor-conferences2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-allucent-fda-ind-application-ptsd2025-11-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-installation-art100-system2025-03-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-showcase-amsect-conference-20252025-03-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-ceo-update-respiratory-care2025-03-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-nasdaq-notification-minimum-bid-requirement2025-03-13T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-2024-financial-results2025-03-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-hyla-blood-sensor-results2025-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-positive-results-bloodstream-infections2025-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxygenation-indicator-hyla-sensor2025-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-art100-advanced-features-support2025-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-life-support-systems-deployment2025-01-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-patent-japan-dual-lumen-cannula2025-12-09T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-cml-data-ash-20252025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-soho-2025-annual-meeting2025-08-25T23:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-public-offering-closure2025-06-16T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-public-offering-pricing2025-06-13T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-phase-1-trial-data2025-06-13T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-nol-preservation-plan2025-08-15T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-capital-restructuring-growth2025-08-08T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-reschedules-q2-2025-earnings-call2025-08-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-settlement-mylan-cinvanti-aponvie2025-05-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-appoints-mark-hensley-coo2025-04-28T23:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q4-2024-results2025-02-27T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/darioiq-launch-ai-integration-hypertension2025-12-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-digital-health-platform-blood-pressure-improvements2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-new-client-target-exceeded-20252025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-study-cost-savings-digital-health-platform2025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-significant-reduction-medical-costs2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-third-quarter-2025-results-conference-call2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dario-signs-new-employer-clients-value-based-care2025-10-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-onestep-strategic-collaboration-fall-risk-assessment2025-10-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-strategic-review-unsolicited-inquiries2025-09-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-phase-1-trial-update2024-09-28T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-phase-1a-data-presentation2024-09-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-investor-conferences-june-20242024-05-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-proof-of-concept-data2024-03-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-ccs-medical-partnership2017-07-24T13:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-fda-clearance-android-devices2017-07-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-first-choice-uk-diabetes2017-07-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-18-million-offering2025-12-10T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-expands-lymphir-distribution-turkey-gcc2025-12-04T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-ash-annual-meeting-20252025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-launch-verix-ai2025-11-21T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-mckesson-distribution-agreement-lymphir2025-10-20T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-eversana-commercialization-agreement2025-10-16T13:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-named-patient-programs2025-10-07T13:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-closes-9-million-offering2025-09-10T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-bank-america-conference-20252025-11-24T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-fastest-growing-company-20252025-11-19T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-citi-global-healthcare-conference2025-11-18T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-epidiolex-aes-20252025-12-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-present-phase-3-results-ziihera2025-12-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-citi-2025-healthcare-conference2025-11-18T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-appoints-ted-love-board2025-10-28T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-third-quarter-results-november-20252025-10-22T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-live-investor-webinar-november-20252025-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q3-2025-results2025-11-13T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-chapter-11-assets-sale2025-05-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-fda-510k-clearance-wave-system2025-03-21T18:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q4-2024-results2025-01-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q3-results-call-20242024-10-25T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-fda-clearance-accelerate-arc-system2024-09-30T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-wave-pre-clinical-trial-success2024-08-08T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-third-quarter-2025-financial-results2025-11-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-participation-scientific-conferences2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-positive-topline-results-ozekibart-chondrosarcoma2025-10-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-biosciences-leadership-changes2025-04-01T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-phase-1-trial-ozekibart-colorectal-cancer2025-01-21T22:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-biosciences-loan-agreement-oxford-finance2025-01-13T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-piper-sandler-healthcare-conference-20252025-11-18T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-inducement-grants-nasdaq-rule-56352025-10-31T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-mercedes-benz-organ-transportation-network-italy2025-09-22T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-september-investor-conferences2025-08-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-fda-ide-approval-next-gen-ocs-heart-trial2025-08-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-breast-cancer-findings2025-12-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-private-placement-equity-securities2025-12-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-immune-complete-response-tnbc-update2025-11-18T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-fda-type-c-meeting-gbm-paxalisib2025-10-27T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-pd-l1-degrader-agreement2025-10-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-tumor-reduction-paxalisib-tnbc2025-10-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-ai-driven-therapy-dipg-dmg2025-10-01T14:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-her2-positive-breast-cancer2025-09-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-2-million-private-placement2025-08-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-trial-results2025-07-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-anal-cancer-data2025-10-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-shareholder-meeting-nevada-jurisdiction2025-10-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pancreatic-cancer-study-update2025-09-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-goblet-study-update-us-expansion2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-mcrc-regulatory-pathway2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-safety-data-update2025-09-02T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-investor-conferences-september-20252025-08-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-voluntary-delisting-tsx2025-08-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-phase-3-trial-vosoritide-achondroplasia2016-12-12T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-q3-2016-financial-results2016-10-27T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-vosoritide-data-ashg-20162016-10-19T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/uk-regulatory-agency-approves-biomarin-bmn-270-study2016-10-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-patent-interference-update2016-09-21T12:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-ema-validation-brineura-cerliponase-alfa2016-09-15T12:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-ssieme-2016-presentations2016-09-08T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-update-brineura-cerliponase-alfa-cln2-disease2016-09-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-review-q2-2018-results2018-07-19T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-william-blair-conference-20182018-06-05T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q1-2018-financial-results2018-05-09T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-eccmid-2018-data-release2018-04-21T07:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-convertible-notes-offering2018-03-23T06:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q4-full-year-results-20172018-02-15T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q4-earnings-call-20182018-02-08T22:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-ce-ivd-milestone-revenue-growth2018-01-10T12:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-global-healthcare-conference-20202020-09-01T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-q2-2020-financial-results2020-08-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-canaccord-40th-annual-growth-conference2020-07-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-public-offering-pricing2020-05-26T22:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-proposed-public-offering-common-stock2020-05-26T11:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-positive-results-ocs-liver-protect-trial2020-05-26T11:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-first-patient-treated-study-pelareorep2018-12-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-presentation-ash-20182018-12-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appoints-rita-laeufle-cmo2018-11-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-phase-2-study-pelareorep-keytruda2018-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-2018-q3-financial-results-update2018-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-presentation-sitc-20182018-11-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-conference-call-q3-results2018-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-ash-annual-meeting2018-11-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-at-the-market-facility2018-10-25T00:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/bausch-health-acquires-durect-corporation-liver-disease2025-09-11T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-larsucosterol-phase-2b-results-publication2025-01-28T15:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-sells-alzet-product-line-lafayette-instrument2024-11-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-inducement-grants-nasdaq-rule-56352025-12-05T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezolve-ad-study-rezpegaldesleukin-acaa-20252025-11-08T22:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-jefferies-conference-20252025-10-30T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-q3-financial-results-call2025-10-28T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-investor-conferences-september-20252025-09-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/japanese-pharmas-ma-us-eu2025-12-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/fda-probing-patient-death-takeda-therapy2025-11-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/top-biopharma-companies-hiring-november-20242025-11-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/biospace-2026-best-places-to-work2025-11-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/regulatory-jobs-biopharma-hiring2025-10-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-partners-innovent-cancer-assets2025-10-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/q3-earnings-novo-buys-akero-takeda-exits-cell-therapy2025-10-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-nabla-ai-partnership-early-pipeline2025-10-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/oncology-job-opportunities-growth2025-10-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-healthcare-conferences-20232010-09-07T22:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-raises-1-4-billion-20252025-10-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-nyse-underwriting-approval2025-10-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-tim-ledwick-interim-cfo2025-09-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-appoints-brian-parsley-board2025-09-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-american-bitcoin-nasdaq-debut2025-09-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-files-2-billion-shelf-registration2025-08-28T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-crypto-advisory-board-expansion2025-08-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-quarterly-dividend-20252025-12-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-synchrony-prefillable-syringe-launch-cphi2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-third-quarter-2025-conference-call2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-participate-investor-conferences-september-20252025-08-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-robert-mcmahon-cfo-appointment2025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-annual-financial-results-march-20242024-03-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-exclusive-license-agreement-motixafortide-asia2023-10-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-motixafortide-phase-2-trial-results2023-09-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-q2-2023-results-and-updates2023-08-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-genesis-phase-3-trial-data-publication2023-04-17T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-participate-investor-conference2025-11-25T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-completes-enrollment-duchenne-gene-therapy2025-10-30T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-conference-call-november-20252025-10-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presentation-american-academy-ophthalmology-20252025-10-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-completes-enrollment-pivotal-trials-wet-amd2025-10-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presentation-world-muscle-society2025-09-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-positive-data-rgx-121-mps-ii-trial2025-09-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRS/precigen-syros-zhiyi-agile-capital-raises2022-07-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRS/biotech-gender-equality-tipping-point2021-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRS/2021-biotech-ipos-roaring-start2021-01-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRS/ash-2020-crispr-vertex-sickle-cell-cure2020-12-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-q4-2024-results-update2025-03-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-100-million-pipe-financing2025-03-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-special-meeting-stockholders-approval2025-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-td-cowen-healthcare-conference-20252025-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-appoints-david-dornan-cso2025-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-proxy-statement-special-meeting-20252025-02-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-adc-portfolio-sale-pipe-financing2024-12-19T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-q3-2024-financial-results2024-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-precision1-trial-update2024-08-20T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-phase-1-trial-rgx-314-wet-amd2018-02-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-enhances-gene-therapy-manufacturing-capabilities2018-01-23T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-avexis-expansion-license-agreement-sma2018-01-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-year-end-2017-update2018-01-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-ind-active-phase-i-ii-trial-rgx-1212017-12-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-presents-piper-sandler-healthcare-conference2025-11-19T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-investor-event-tct-conference-october-20252025-10-08T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-shruthi-narayan-president-promotion2025-08-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-second-quarter-2025-earnings-call2025-07-01T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-appoints-ron-squarer-board-directors2025-12-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-piper-sandler-healthcare-conference-20252025-11-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-public-offering-closing-nuvl2025-11-24T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-fda-acceptance-zidesamtinib-nsclc2025-11-19T21:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-public-offering-common-stock2025-11-19T04:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-arros-1-trial-zidesamtinib-presentation-20252025-11-04T22:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-piper-sandler-healthcare-conference2025-11-18T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-wolfe-research-healthcare-conference2025-11-04T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-325-million-private-placement-financing2025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-oxford-symplify-study-galleri-test-edcc2025-10-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-pathfinder-2-results-galleri-cancer-detection2025-10-18T10:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/samsung-grail-collaboration-galleri-test-asia2025-10-16T13:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-galleri-data-esmo-edcc-20252025-09-23T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-december-investor-conferences2025-11-18T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-pricing-public-offering-25-million2025-11-11T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-proposed-public-offering2025-11-10T23:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-bla-submission-accelerated-approval-ino-31072025-11-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-inducement-grant-2022-plan2025-10-31T21:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-stephens-biotechnology-conference2025-10-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/clinical-proof-of-concept-dmabs-nature-medicine2025-10-21T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-q3-2025-results-update2025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-expands-rhcollagen-distribution-north-america2025-10-27T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-collagen-bioink-study-results2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/first-humanized-3d-bioprinted-skin-model-collplant2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-positive-results-dermal-filler2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-expands-vergenixstr-distribution-europe2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-presentation-biofabrication-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-participate-hc-wainwright-conference-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-settlement-stockholder-derivative-actions2023-06-23T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-phase-2-trial-hpv-cancers2018-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-dmab-technology-clinical-trials-20192018-11-27T02:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-dmab-phase-1-trial-preparation2018-11-27T02:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-dna-monoclonal-antibody-trial-results2018-11-27T02:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-dmab-platform-preclinical-results-clinical-trial-20192018-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-leadership-appointments-commercialization2018-11-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-q3-2018-results2018-11-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-investment-conferences-20182018-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-closes-35-million-direct-offering2021-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-35-million-ads-offering2021-02-12T04:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-tender-offer-results2025-11-20T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-appoints-eliot-forster-chairman-board2023-09-12T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bio-therapeutics-worlsymposium-20232023-02-21T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-q3-2022-results2022-11-14T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bio-appoints-dr-shmuel-ben-zvi2022-06-30T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-fireside-chat-june-30-20212021-06-28T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bio-deficiency-letter-nyse-american2019-08-30T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-strategic-alternatives2019-08-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/shlomo-yanai-resigns-chairman-protalix-biotherapeutics2019-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-q2-2019-conference-call2019-07-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bioappoints-eyal-rubin-cfo2019-07-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bright-trial-phase-iii-completion2019-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bio-therapeutics-new-ceo-dror-bashan2019-05-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-defiance-study-esmo-20252025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-private-placement-digital-assets2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-private-placement-winklevoss-capital2025-10-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-q2-2025-financial-results2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-sirexatamab-colorectal-cancer-update2025-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-virtual-fireside-chat-december-20252025-12-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-presentation-jefferies-global-healthcare-conference2025-11-17T22:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-q3-2025-results-business-update2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/dr-robert-hawes-bartlett-obituary-ctso2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-showcase-cardiac-surgery-data-eacts-20252025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-drugsorb-atr-regulatory-update2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-webinar-sepsis-septic-shock2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-presentation-hc-wainwright-conference2025-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-merck-pfizer-collaboration-trx5182018-07-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presentation-jmp-conference-20182018-06-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-dkn-01-aacr-20182018-04-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-public-offering-closing2018-03-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-public-offering-pricing2018-03-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-public-offering-common-stock2018-03-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presentation-needham-conference-20182018-03-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-dkn-01-update-aacr-20182018-03-14T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-q4-2024-revenue-report2025-01-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-rights-offering-begins2024-12-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-investor-meetings-jp-morgan-conference2024-12-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-piper-sandler-healthcare-conference-20242024-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-enrollment-milestone-hybrite-ctcl-trial2025-11-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-recent-accomplishments-q3-2025-results2025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-expands-european-medical-advisory-board-ctcl2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-closes-7-5-million-public-offering2025-09-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-pricing-public-offering-7-5-million2025-09-26T11:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-tomas-philipson-strategic-advisor2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-thermovax-ebola-vaccine-stability2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-presentation-hc-wainwright-conference-20252025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-orphan-drug-designation-behcets-disease2025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-kombucha-product-sales-agreement-qingshengyuan2025-12-10T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-next-gen-tea-pigment-digestive-health-products2025-11-25T14:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-cooperation-agreement-apple-series-health-products2025-09-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-weight-managing-compounds-ai-drug-rd2025-09-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-nasdaq-compliance-letter2025-08-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-launches-ai-powered-drug-research-development2025-07-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-distribution-agreement-weight-loss-products2025-07-21T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-nasdaq-compliance2025-07-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-breakthrough-order-gut-health-products2025-07-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-expansion-project-update2022-09-30T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-q3-2025-results-business-updates2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-third-quarter-2025-financial-results2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-papzimeos-long-term-results-rrp2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-125-million-financing2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-virtual-fireside-chats-cantor-hc-wainwright2025-08-25T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-fda-approval-papzimeos-therapy2025-08-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-rrp-awareness-day-20252025-04-16T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-full-year-2024-results-business-updates2025-03-19T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-full-year-2024-results-call2025-03-13T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-us-marketing-authorization-transfer-sanofi2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-site-consolidation-cost-reduction-strategy2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-sanofi-partnership-nuvaxovid-eu-transfer2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-progress-sanofi-agreement2025-09-30T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-approval-japan-takeda-payment2025-09-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-2025-2026-fda-approval2025-08-27T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-innovative-treatment-ctcl2025-12-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-present-thinkequity-conference-20242024-10-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-hc-wainwright-conference-fireside-chat2021-03-08T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-takeda-covid-19-vaccine-trial-japan2021-03-01T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-takeda-license-agreement-covid-vaccine-japan2021-02-26T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-completes-enrollment-prevent-19-trial2021-02-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gavi-mou-covax-supply-1-1-billion-doses2021-02-18T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-conference-call-fourth-quarter-results2021-02-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-sk-bioscience-collaboration-covid-19-vaccine2021-02-16T01:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-swiss-government-covid-vaccine-agreement2021-02-04T22:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-rolling-review-covid-vaccine-authorization2021-02-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reports-fiscal-third-quarter-2025-results2025-11-17T13:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-declares-dividend-distribution2025-11-17T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-shareholder-letter-insulin-program-investment-growth2025-10-23T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-investment-alpha-tau-collaboration2025-04-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-shareholder-letter-20252025-03-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-joint-venture-accelerate-oral-insulin2025-02-11T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-restructuring-scilex-debt2024-10-07T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-letter-to-shareholders-update2024-06-26T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-stock-buy-back-program2024-06-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-custom-tools-digital-pcr-ngs-panels2024-11-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-mcgill-university-microbiome-research2024-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-q3-2024-growth-outlook-increased2024-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-meningitis-encephalitis-panel2024-11-04T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-fda-approval-qiastat-dx-meningitis-panel2024-11-04T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-fda-approval-qiastat-dx-mini-panel-respiratory-infections2024-10-29T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-mini-panel2024-10-29T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-updates-phase-1b-study-r289-lower-risk-mds2025-12-07T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-presents-piper-sandler-healthcare-conference2025-11-26T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-presents-jefferies-global-healthcare-conference2025-11-12T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q3-2025-results2025-10-29T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-r289-phase-1b-mds-trial-update2025-10-08T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-10-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-participate-september-investor-conferences2025-08-26T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-sabcs-20252025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-participate-stephens-biotechnology-chat2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-atnm-400-lung-cancer-aacr-conference2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-efficacy-data-pcf-retreat2025-10-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-nsclc-data-aacr-conference2025-10-13T17:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-atnm-400-preclinical-data-prostate-cancer2025-10-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-atnm-400-prostate-cancer-summit-20252025-07-31T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-atnm-400-prostate-cancer-efficacy-snmm-meeting2025-06-23T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-iomab-act-trial-enrollment-utsw2025-05-06T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-ata-annual-meeting-20242024-10-14T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-preliminary-financial-results-20242024-10-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-nasdaq-listing2024-10-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-participate-roths-healthcare-conference2024-10-08T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-delisting-nasdaq-sec-deregistration2025-12-05T16:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-corporate-updates2025-03-31T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-hc-wainwright-conference-20252025-02-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-oppenheimer-conference-20252025-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-strategic-restructuring-pipeline2024-12-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-evercore-healthconx-conference-20242024-11-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-engineered-macrophages-liver-fibrosis2024-11-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-preclinical-data-gpc3-car-m-therapy-hcc2024-11-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-q3-2024-results-business-highlights2024-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-inducement-award-nasdaq-listing-rules2025-10-31T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-first-quarter-fiscal-2026-results2025-10-28T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-transformation-leadership-appointments2025-10-20T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-melbourne-launch2025-10-08T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-university-wisconsin-madison-mou-advance-radiotherapy2025-09-30T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-launches-advanced-radiotherapy-solution2025-09-26T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-host-analyst-event-astro-meeting-20252025-09-11T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-completes-last-visit-phase-3-trial-acne2025-03-04T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-nuclear-medicine-advisory-board-iomab-b2018-07-17T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-webcast-actimab-a-mrd-trial-july-20182018-07-09T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-new-clinical-trial-actimab-a-mrd-aml2018-06-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-sierra-trial-enrollment-update2018-06-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-update-snmmi-annual-meeting2018-06-25T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-phase-1-trial-actimab-a-clag-m2018-06-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-bioequity-europe-conference-20182018-05-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-dr-jeffrey-chell2018-05-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-strengthens-clinical-team2018-04-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-awe-technology-showcase-aacr-20182018-04-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-present-jp-morgan-healthcare-conference2014-12-16T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-brean-capital-2014-life-science-conference2014-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-q1-fiscal-2015-results2014-10-29T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-financial-results-q1-fiscal-20152014-10-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-signs-exclusive-radiation-therapy-contract2014-09-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-financial-results-fy-2014-guidance2014-08-21T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-presentation-morgan-stanley-healthcare-conference2014-08-19T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-financial-results-q4-fiscal-20142014-08-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-presentation-goldman-sachs-conference-20142014-06-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-presentation-goldman-sachs-healthcare-conference-20142014-05-28T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-q4-2019-financial-results2020-02-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inducement-grants-nasdaq-rule2020-02-21T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-investor-conferences-march-20202020-02-20T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-q4-2019-results-announcement2020-02-19T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-kristin-yarema-cco2020-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-2020-milestones-jp-morgan-conference2020-01-12T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-tab-cel-ebv-ptld-results-ash-20192019-12-09T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-evercore-isi-healthconx-conference2019-11-26T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-investor-conference-schedule2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-acquires-nalu-medical2025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-investor-day-20252025-09-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-farapulse-fda-approval2025-07-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-conference-call-q2-2025-results2025-07-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/advantage-af-trial-results-farapulse-system2025-04-24T20:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-darzalex-faspro-phase-3-results-multiple-myeloma2025-12-09T12:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/carvykti-treatment-free-remissions-multiple-myeloma2025-12-06T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-inlexzo-gemcitabine-bladder-cancer-study-results2025-12-05T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approval-caplyta-lumateperone-mdd2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acxp-health-holland-grant-dna-pol-iiic-inhibitors2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-publication-nature-communications-dna-pol-iiic2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-new-data-dna-pol-iiic-inhibitor-antibiotics-idweek-20252025-10-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q3-2025-financial-results-call2025-10-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-australian-patent-dna-polymerase-iiic-inhibitors2025-10-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-positive-opinion-ema-ibezapolstat-cdi-children2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-regains-nasdaq-compliance2025-09-03T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-reverse-stock-split2025-07-31T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-acquisition-social-proxy-private-placement2024-08-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-acquires-the-social-proxy-ai-web-data2024-06-05T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-to-acquire-the-social-proxy2024-03-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-nasdaq-notification-minimum-bid-price2023-10-20T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-business-operations-israel2023-10-20T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-rd-day-december-20252025-12-09T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-ingrezza-review-tardive-dyskinesia2025-11-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-investor-conferences-20252025-11-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-update-phase-2-nbi-10707702025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-kinect-4-analysis-ingrezza-efficacy2025-10-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q3-2025-financial-results2025-10-07T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-mike-sibley2025-10-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-ingrezza-huntingtons-disease-data2025-10-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-hemopurifier-long-covid-data2025-12-02T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-second-quarter-results-november-20252025-11-07T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-hemopurifier-oncology-trial-australia2025-10-07T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-pricing-public-offering2025-09-04T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-hemopurifier-patents-long-covid-cac2025-09-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-dsmb-recommendation-advance-trial2025-07-15T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-acquires-mural-oncology2025-12-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-financial-results-conference-call-20202020-02-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-public-offering-pricing2020-02-12T00:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-public-offering-shares2020-02-10T21:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-inducement-grants-nasdaq-rule-5635c42019-12-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-business-update-investor-conference2019-11-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-third-quarter-2019-results2019-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-appoints-mark-thierer-board2019-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-investor-webinar-aes-2025-data2025-12-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-reports-q1-2025-financial-results2025-05-13T10:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-cfo-transition2025-11-26T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-second-quarter-conference-call-20252025-07-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-phase-2-data-burixafor-multiple-myeloma-ash-20252025-12-08T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-350-million-public-offering2025-12-10T02:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-250-million-offering2025-12-08T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-inlight-trial-wve-007-obesity-data2025-12-07T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-revenue-growth-q3-20252025-11-19T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-q3-2025-financial-results2025-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-imaging-manufacturing-day-event2017-10-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-imaging-participate-cjs-securities-conference2017-06-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-imaging-ecr-exhibit-20172017-02-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-imaging-investor-conferences-20172017-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-novartis-immunology-acquisition-strategies2025-11-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-new-products-dim-analysts-eye-kidney-portfolio2025-11-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/mid-cap-biopharma-ma-opportunities2025-10-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/biospace-40-under-40-winners-impact-industry-grit2025-10-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-enlaza-autoimmune-disease-pact2025-09-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/fda-leadership-changes-drug-pricing-negotiations2025-08-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-vx993-trial-failure-q2-earnings2025-08-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/biotechs-to-watch-q2-2025-earnings2025-07-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-participate-maxim-group-2022-conference2022-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-q3-financial-results-update2022-02-10T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-q3-2022-financial-results2022-02-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-jefferies-london-healthcare-conference2021-11-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-phase-2a-trial-ph94b2021-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-ph94b-preclinical-data-anti-anxiety2021-10-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-advances-palisade-phase-3-program-ph94b2021-09-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-baird-global-healthcare-conference2021-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-q1-2023-update2023-05-09T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-partnership-enable-injections2023-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-inducement-grants-nasdaq-rule-56352023-05-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-webcast-q1-2023-results2023-05-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-arvo-2023-presentations2023-04-20T17:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-appoints-tony-casciano-cco2023-04-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-q3-2025-financial-results-update2025-11-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-merger-oqory2024-12-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-year-2025-results-conference-call2025-12-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-presents-sarcopenia-cachexia-conference-20252025-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-james-meyers-board2025-11-26T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-private-placement-financing-50-million2025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-present-stephens-investment-conference-november-20252025-11-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-regains-nasdaq-compliance2022-11-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-investor-conferences-november-20242024-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-delisting-notification-nasdaq2024-12-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-q3-2024-financial-results-corporate-update2024-11-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-activmab-update-project-deals-sitc-presentation2024-11-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-pepinemab-immunity-clinical-benefit-sitc2024-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-signal-ad-trial-pepinemab-alzheimers-update2024-10-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-exercise-warrants-6-2-million2024-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-donates-shares-to-police-association2025-12-11T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-dr-curtis-patton-yale-honor2025-12-09T19:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-recognized-njbiz-power-list-20252025-12-08T19:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-phase-2-results-chikungunya-vaccine-children2025-12-10T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-secures-regulatory-approval-uni-gold-hiv-test2025-11-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-epicapture-prostate-cancer-test2025-11-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-nasdaq-notice-compliance2024-11-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-merger-agreement-ke-sdn-bhd2024-08-19T20:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-nasdaq-compliance2024-01-25T21:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-reverse-stock-split-20232023-12-28T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-board-appointments2023-10-16T20:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-sale-proneura-assets2023-07-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-q2-2025-financial-results-progress2025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-acquires-dual-car-t-programs-factor2025-11-19T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/novo-nordisk-thermo-fisher-wegovy-demand2023-08-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/week-in-review-novo-nordisk-novavax-nektar-lawsuit2023-08-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/ultragenyx-sued-henrietta-lacks-family-hela-cells2023-08-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-cuts-88-jobs-san-diego-layoffs2023-06-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-grant-program-innovation2023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/importance-of-validated-processes-in-mrna-production2023-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/ai-potential-in-pharmaceutical-industry2023-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/sonoma-thermo-fisher-jobs-seattle-plainville2022-08-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-q4-2024-financial-results2025-03-29T01:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-preclinical-data-sitc-20242024-11-05T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-strategic-restructuring-portfolio2024-10-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-positive-data-tidal-01-trial2024-08-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-presentation-bank-america-conference2024-05-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-proposed-public-offering2025-12-11T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-lifts-clinical-hold-mypeak-1-trial2025-12-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-positive-data-ridge-1-trial2025-12-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-piper-jaffray-conference2015-11-13T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-stifel-2015-healthcare-conference2015-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q3-2015-earnings-call2015-10-13T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-conference-presentations2015-08-26T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-wedbush-pacgrow-conference-20152015-07-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-cowen-conference-20152015-02-27T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-q2-2025-results2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-spinout-il6-asset2025-12-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-irina-ishak-general-counsel2025-12-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-fibromyalgia-treatment2025-11-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-sale-acute-care-interventional-urology-oem-businesses2025-12-09T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-presentation-jefferies-global-healthcare-conference2025-11-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-evercore-healthconx-conference2024-11-25T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-investor-conferences-november2024-11-07T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-closes-public-offering-747-million2025-12-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-upsized-public-offering-650-million2025-12-10T04:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-proposed-public-offering2025-12-09T11:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-phase-1-data-tern-701-cml-ash-meeting2025-12-08T19:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-jefferies-conference-20252025-11-14T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-deloitte-fast-500-20252025-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-q3-2024-financial-results-update2024-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-guggenheim-healthcare-conference-20242024-10-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-closes-100-million-private-placement2024-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-100-million-private-placement2024-08-06T11:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-levosimendan-patent-ph-hfpef2024-04-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-kol-event-levosimendan-phase-3-level-study2024-04-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-ceo-passing-changes-board2024-08-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-russell-indexes-membership2024-07-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-dia-2024-panel-participation2024-06-17T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-pivotal-milestones-telomir-12024-05-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-preclinical-data-telomir-12024-04-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-preclinical-data-presentation2024-04-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-collaboration-argenta-osteoarthritis2024-03-29T20:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-preclinical-data-global-longevity-conference2024-03-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-ai-telomir-1-potential2024-03-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-piper-sandler-37th-healthcare-conference2025-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-inducement-grants-nasdaq-rule-56352025-11-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-q3-2025-financial-results2025-11-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-kol-event-alloha-phase-1-trial2025-12-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-q3-2023-results-phase-1-data2023-11-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-presentation-hawaii-summit2023-06-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-tcr-t-library-phase-1-2-trial-asco2023-05-25T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-asco-2023-poster-presentation2023-04-26T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-appoints-dr-robert-hofmeister2023-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-investor-conferences-april-20232023-03-29T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-participate-upcoming-investor-conference2025-11-24T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-q3-2025-results2025-11-13T18:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-chmp-positive-mirdametinib-nf1-pn2025-05-24T23:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-chmp-advies-mirdametinib-nf1-pn2025-05-24T23:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-nasdaq-notification-bid-price-deficiency2024-10-07T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-reverse-stock-split2023-10-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-nasdaq-extension2023-05-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/sxt-pharmaceuticals-convertible-promissory-note2022-03-15T02:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-4-1-million-offering2022-01-20T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-update-impala-avail-clinical-studies2019-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-optima-clinical-study-results-molgradex-ntm2018-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-evercore-healthconx-conference-20182018-11-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-q3-2018-results-business-update2018-11-07T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-third-quarter-2018-financial-results-conference-call2018-11-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-completes-enrollment-molgradex-impala-study2018-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-enrollment-update-molgradex-clinical-studies2018-09-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-pap-foundation-partnership2018-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-piper-sandler-healthcare-conference-20252025-11-24T13:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-phase-1-trial-stro-0042025-12-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-showcases-xtrac-theraclearx-teracilad-20252025-12-09T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-q3-2025-financial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-bank-america-cns-conference-20252025-12-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-raises-dividend-to-0-63-per-share2025-07-30T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-declares-dividend-0-57-per-share2025-05-07T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-announces-pricing-75-million-public-offering2025-12-05T03:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-phase-2-advanced-2-trial-update2025-12-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-positive-results-tara-002-trial2025-11-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-advanced-2-trial-data-presentation2025-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-q2-2025-results2025-07-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-upcoming-healthcare-investor-conferences2025-11-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-q2-2025-financial-results2025-08-07T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/pompano-veterinary-oncology-sensus-healthcare-srt2024-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q3-2024-financial-results2024-11-18T01:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-third-quarter-2024-conference-call2024-10-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-sells-srt-system-providence-swedish-hospital2024-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q2-2024-conference-call2024-08-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-srt-100-veterinary-use-tel-aviv2024-05-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-first-srt-100-vision-sale-asia2024-05-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-srk-015-sma-europe-congress2020-02-06T12:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-corporate-update-rd-priorities-20202020-01-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-gilead-fibrosis-collaboration-milestone2020-01-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-added-to-nasdaq-biotechnology-index2019-12-19T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-topaz-phase-2-trial-srk-015-sma2019-11-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-q3-2019-results-business-progress2019-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-presentation-jefferies-london-conference2019-11-08T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-srk-015-world-muscle-society-congress2019-10-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-appoints-george-nomikos-vp-medical-research2019-09-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-upcoming-healthcare-conferences2019-09-04T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inducement-grants-nasdaq-rule-5635c42023-01-31T23:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q4-2022-revenue-report2023-01-09T18:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-jp-morgan-conference-20232023-01-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-fda-accepts-srp-9001-application2022-11-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-evercore-healthconx-conference2022-11-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q3-2022-results2022-11-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/fda-committee-recommends-praluent-approval2015-06-09T22:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-elixa-study-results-lixisenatide2015-03-19T06:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-regeneron-odyssey-long-term-trial-results2015-03-15T15:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-mannkind-global-licensing-agreement-afrezza2014-08-11T05:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/first-ever-dengue-vaccine-efficacy-asia2014-07-10T23:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-regeneron-positive-results-dupilumab-study2014-07-09T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-positive-phase-3-results-toujeo2014-06-14T17:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q3-2025-results-business-update2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q1-2025-financial-results-update2025-05-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/neurothera-labs-acquires-quantum-bio-data-company2025-12-02T14:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expands-focusfactor-distribution-ten-states2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-q3-2025-results2025-11-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-senti-202-phase-1-trial-results2025-12-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-fda-rmat-designation-senti-202-aml2025-12-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-conference-call-senti-202-data-ash-20252025-12-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-phase-1-senti-202-study-ash-meeting2025-11-13T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-participate-jp-morgan-healthcare-conference2025-12-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-assets-microsafe-group2020-02-27T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-q3-fy2020-financial-results2020-02-14T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-maxim-group-strategic-opportunities2020-01-23T21:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-closes-public-offering2019-11-29T21:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-public-offering-1-6-million2019-11-26T15:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-public-offering-common-stock2019-11-26T00:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-management-changes2019-10-01T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-regains-nasdaq-compliance2019-07-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-receives-positive-feedback-phase-2-3-trial2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-errors-sp-capq-platform-merger2025-11-19T19:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-decoy-merger-completion2025-11-13T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-biomimetic-innovations-osstic-update2025-12-10T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-piper-sandler-conference-20252025-11-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-passing-board-member-harris2025-12-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-piper-sandler-conference-20252025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-nasdaq-compliance-extension2024-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-andelyn-biosciences-licensing-agreement2025-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/lilly-sangamo-licensing-deal-1-4b2025-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-pfizer-hemophilia-gene-therapy-termination2025-01-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-fabry-gene-therapy-fda-approval2024-10-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-genentech-deal-alzheimers-1-9b2024-08-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-hemophilia-gene-therapy-financial-challenges2024-07-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/novartis-biogen-scrap-gene-regulation-partnerships-sangamo2023-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/clinical-trial-updates-labor-day-weekend2022-09-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/clinical-trial-updates-covid-19-eua-cyton-dyn2022-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-sanofi-scd-program-update2022-01-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-piper-sandler-conference-20252025-11-18T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-ventures-launch-biotech-innovation2024-11-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-q3-2024-results2024-11-14T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-brexafemme-nda-transfer-gsk2025-11-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-federal-funding-collaboration-hackensack-johns-hopkins2025-11-17T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-closes-5-million-private-placement2023-05-16T13:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-private-placement-announcement2023-05-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-blinkrx-collaboration-arbli-launch2025-12-10T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-participate-iaccess-alpha-investment-conference-20252025-12-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-exercise-warrants-20-million2025-11-25T19:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-dream-bowl-2026-meme-coin-distribution2025-11-21T20:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-layoffs-75-percent2025-02-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/roche-returns-camonsertib-repare-therapy2024-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/roche-repare-1-2b-deal-cancer-therapy2022-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/aacr-bms-repare-investisbio-data2022-04-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/canada-biotech-talent-growth2021-08-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/valence-repare-ai-precision-oncology2021-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/bms-repare-65-million-collaboration2020-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-secures-funding-synthetic-lethality2017-06-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-reports-third-quarter-results-business-highlights2025-11-13T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-presents-sage-547-data-aan-20162016-03-03T21:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-cowen-health-care-conference-20162016-02-29T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-q4-2015-results2016-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-presentation-leerink-conference-20162016-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-public-offering-pricing2016-01-07T02:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-jp-morgan-conference-20162016-01-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-updates-phase-3-status-trial-results2015-12-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-q3-2025-results-and-business-highlights2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-descartes-08-phase-2-trial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inducement-grant-nasdaq-rule-5635c42025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q2-2025-financial-results-update2025-08-06T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q2-2025-financial-results2025-07-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-ndv-01-phase-2-data-presentation2025-12-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q3-2025-results2025-11-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q2-2025-financial-results2025-07-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-poster-presentation-nhia-20222022-03-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inducement-grant-nasdaq-rule-56352022-02-14T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-triferic-dialysate-approval-south-korea2022-01-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-triferic-avnu-approval-south-korea2022-01-13T13:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-presentation-hc-wainwright-bioconnect-20222022-01-07T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-fda-feedback-phase-2-trial2021-12-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-fpc-heparin-interaction-study2021-11-16T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q3-2021-update2021-11-15T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-financial-results-june-20222022-08-15T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-5-million-offering2022-07-29T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-public-offering-5-million2022-07-26T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-phase-1b-clear-study-results2022-07-22T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-revtx-99b-allergic-rhinitis2022-05-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-conference-call-update2022-04-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-phase-2b-study-results2022-03-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-casdatifan-kidney-cancer-merck-challenge2025-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/checkpoint-inhibitors-at-a-crossroads2025-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/tigit-therapeutics-esmo-20242024-10-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/gilead-expands-arcus-collaboration-320m-investment2024-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/gilead-arcus-phase-ii-upper-gi-cancers2023-11-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/biopharma-companies-stock-investments2023-09-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/asco-gilead-arcus-cancer-immunotherapy-scrutiny2023-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-gilead-amend-phase-iii-nsclc-trial2022-11-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/iteos-gsk-anti-tigit-candidate-future2022-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-presentation-agp-showcase2025-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-third-quarter-2025-financial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-fda-approval-rvo-treatment2025-11-19T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-approval-eu-adjuvant-cscc-treatment2025-11-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-piper-sandler-conference-20252025-11-24T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-investor-conferences-december-20252025-11-24T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-rap-219-clinical-response-seizures2025-12-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-biosciences-biosymetrics-merger-ai-biomarkers2025-02-26T18:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-evercore-healthcare-conference-20252025-11-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-rebrands-aixcrypto-holdings2025-11-16T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-bla-submission-imsidolimab-gpp2025-12-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-releases-cvr-kintara-safety-endpoint2025-12-15T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-proposed-public-offering2025-12-15T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-transfer-ind-breast-cancer-vaccine2025-12-15T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-z-endoxifen-updates-sabcs-20252025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-results-cll2025-12-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-bd-max-system-with-new-viasure-assays2025-12-15T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-1-8-million-offering-equity-financing2025-12-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-conference-call-rezolve-aa-results2025-12-15T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-jp-morgan-conference-20262025-12-15T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-jp-morgan-healthcare-conference-20252025-12-15T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-transformation-plan-operational-efficiency2025-12-15T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-quarterly-cash-dividend2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-fireside-chat-december-20252025-12-15T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-150-million-private-placement2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-global-rollout-hba1c-testing-solution2025-12-15T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-withdraws-public-offering2025-12-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-inducement-grants-nasdaq-rule-5635c42025-12-15T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expands-focusfactor-distribution-maine-pennsylvania2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-fda-meeting-renu-knee-osteoarthritis2025-12-15T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-jp-morgan-conference-20262025-12-15T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-phase-2-clinical-study-bcc2025-12-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-presentation-jp-morgan-healthcare-conference2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-private-placement-45-million2025-12-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-phase-1-2-trial-outcomes2025-12-15T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-q2-2026-results-business-update2025-12-15T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-fda-510k-submission-myovista-wavecg-device2025-12-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-calls-tranche-a-warrants-december-20252025-12-15T22:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-mrt-2359-phase-1-2-results2025-12-15T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/xoma-acquires-generation-bio-merger-agreement2025-12-15T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/roxadustat-orphan-drug-designation-mds2025-12-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-1-7-million-offering-nasdaq2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-fda-acceptance-cutx-101-nda2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-arbitration-decision-servier2025-12-15T21:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-arbitral-decision-servier-dispute2025-12-15T21:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-presentation-jp-morgan-20262025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-servier-arbitration-cellectis2025-12-15T22:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-pfizer-immune-receptor-agreements2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-ii-data2025-12-15T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-mohamad-tabrizi-cbo2025-12-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-licenses-tnx-4900-neuropathic-pain2025-12-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-jp-morgan-conference2025-12-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-mrt-2359-enzalutamide-cancer2025-12-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-stock-options-inducement-grants-nasdaq2025-12-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presentation-jp-morgan-conference-20252025-12-18T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-cypath-lung-test-american-cancer-society2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-influenza-co-primers-analysis-h3n22025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-partnering-investor-meetings-jpmorgan-20262025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-public-offering-100-million2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/celz-adapt-trial-enrollment-completion2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-level-study-assessment2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-shareholders-nomination-board2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CG/acentra-health-appoints-meghan-harris-board-directors2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-phase-1-study-accg-2671-obesity2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-positive-results-phase-1-wp1066-trial2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-phase-2-alzheimers-trial2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-wins-excellence-award-20252025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-jp-morgan-healthcare-conference2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-presentation-jp-morgan-conference2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sabs-positive-phase-1-results-sab-142-t1d2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-phase-2a-sgx302-results-psoriasis2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-present-jp-morgan-healthcare-conference2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-phase-2-breast-cancer-update2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-yarrow-merger-agreement2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-influenza-co-primers-analysis2025-12-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-positive-interim-data-4d-710-phase-1-trial2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/extended-release-buprenorphine-reduces-opioid-use2025-12-17T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-signs-lungfit-ph-distribution-agreements2025-12-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-expands-rewalk-distribution-internationally2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-record-sales-fda-clearance-prosense2025-12-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-tapi-global-license-agreement-resmetirom2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-investor-events-20262025-12-17T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-regains-nasdaq-compliance2025-12-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-business-review-20252025-12-17T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-clinical-business-update-brensocatib-ins11482025-12-17T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-nyse-compliance-plan-acceptance2025-12-17T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-ratutrelvir-positive-interim-data2025-12-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-phase-1-sab-142-results2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-astrazeneca-royalties-agreement2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-wins-2025-award-precision-therapy2025-12-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-presents-jp-morgan-healthcare-conference-20262025-12-17T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approval-rybrevant-faspro-johnson-johnson2025-12-17T23:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-year-2025-results-clinical-progress2025-12-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-update-phase-1b-sgt-210-darier-disease2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-launch-genio-therapy-netherlands2025-12-17T06:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-genio-launch-netherlands2025-12-17T06:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-phase-1b-study-nxp900-osimertinib-nsclc2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-closing-bell-nasdaq2025-12-17T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-acquisition-renergen-approvals2025-12-17T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-jp-morgan-healthcare-conference-20262025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-jp-morgan-conference-20262025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-jp-morgan-conference-20262025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-convertible-bonds-sale-108-million2025-12-17T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-jp-morgan-conference-20262025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-jp-morgan-healthcare-conference-20262025-12-17T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-presents-jp-morgan-healthcare-conference-20262025-12-17T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-us-patent-female-sexual-dysfunction2025-12-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-presentation-jp-morgan-healthcare-conference2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/celz-adapt-trial-enrollment-completed2025-12-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-nmpa-approval-myorzo-aficamten-china2025-12-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-decisiondx-um-prame-study2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-jp-morgan-healthcare-conference-20262025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-debt-refinancing-growth-package2025-12-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-cdmo-agreement2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-phase-3-trial-atebimetinib-pancreatic-cancer2025-12-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-jp-morgan-2026-conference2025-12-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-jp-morgan-2026-healthcare-conference2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-ecco-2026-abstracts2025-12-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLUE/impactful-ma-deals-20252025-12-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-participate-investor-conferences-20262025-12-17T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-european-commission-approval-minjuvi-follicular-lymphoma2025-12-17T16:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staars-stockholders-vote-alcon-merger2025-12-17T15:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-palisade-3-fasedienol-results-social-anxiety2025-12-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-regulatory-approval-swoop-india2025-12-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-clinical-trials-award-advanced-prostate-cancer2025-12-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-participation-jp-morgan-healthcare-conference2025-12-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-files-pma-supplement-ige-indication2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-invest-250-million-manufacturing-expansion2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-participate-jp-morgan-healthcare-conference2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-launches-gobivaz-biosimilar-simponi-europe2025-12-22T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-launches-gobivaz-simponi-europe2025-12-22T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/destiny-endometrial02-phase-3-trial-enhertu2025-12-22T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/enhertu-breakthrough-therapy-designation-breast-cancer2025-12-22T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/precision-medicine-update-tlx-china-phase-3-study2025-12-22T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-shares-voting-rights-december-20252025-12-22T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-launches-blaze-trial-immunotherapy-resistance2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inducement-grants-nasdaq-rule-56352025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bms-agreement-us-government-affordability-access-medicines2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/samsung-biologics-acquires-human-genome-sciences-gsk2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-agreement-us-government-access-medicines2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-inducement-grants-nasdaq-listing-rule-56352025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-us-government-agreement-lower-drug-costs2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-ipo-registration-diabetes-business-minimed2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-fda-approval-myqorzo-obstructive-hcm2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-nasdaq-biotechnology-index2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-convertible-bonds-issuance2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-appoints-bob-marshall-chairman-board2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-inducement-grants-nasdaq-rule-56352025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-jp-morgan-healthcare-conference-20262025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-annual-meeting-adjournment2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-acquisition-executive-chairman2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-private-placement-tcgx2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-lowers-medicine-costs-us-government2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-precision-oncology-alliance-welcomes-providence-swedish2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-acquire-amicus-therapeutics-4-8-billion2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-private-placement-gamma-delta-t-cell-engager2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-public-offering-pricing2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-fda-update-belapectin-funding2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-tebipenem-hbr-nda-resubmission-fda2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fiscal-year-2025-results2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-update-msd-collaboration-gonorrhea-vaccine2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-inducement-grants-nasdaq-rule-56352025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-pemvidutide-impact-phase-2b-results2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-included-in-sp-smallcap-6002025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-sephience-approval-japan2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-dividends2025-12-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-launches-rezenopy-naloxone-nasal-spray2025-12-22T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-nasdaq-extension-compliance2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-lawsuit-stock-manipulation2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-jp-morgan-healthcare-conference2025-12-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-positive-update-imp761-phase-i-study2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-symvess-long-term-safety-efficacy-results2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-updates-strategy2025-12-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/first-patient-dosed-alpaccca-trial-firmonertinib2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/ateapharma-completes-enrollment-phase-3-trial-hcv2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-acquires-nicotinamide-riboside-patents2025-12-22T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-resubmits-bla-molbreevi-autoimmune-pap2025-12-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-participate-jp-morgan-healthcare-conference2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-licenses-assembly-biosciences-herpes-programs2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-appoints-senior-executives-commercialization2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-livechain-acquire-humanyze-note2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-presentation-jp-morgan-conference-20262025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-landmark-nature-study-alzheimers-disease2025-12-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-bla-acceptance-veligrotug2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-presents-jp-morgan-healthcare-conference-20262025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-approval-ekterly-japan-hereditary-angioedema2025-12-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-zugo-cel-update-autoimmune-hematologic2025-12-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-present-jp-morgan-healthcare-conference-20262025-12-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-eb612-long-acting-pth-tablet2025-12-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-ceo-2025-shareholder-letter2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-impact-proenzymes-pancreatic-cancer2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-q2-fiscal-2026-results-announcement2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-appoints-jack-stover-board2025-12-22T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-regains-compliance-nasdaq-minimum-bid-price2025-12-22T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-volt-pfa-system-fda-approval-afib2025-12-22T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/sanofi-acquire-dynavax-hepatitis-b-shingles-vaccine2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/fda-approves-agios-aqvesme-thalassemia-treatment2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-phase-1-study-update2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-appoints-andrew-einhorn-board2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-fy-2025-financial-results-update2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-fiscal-year-2025-update2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reverse-split-ads-ratio-change2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-acquires-acera-surgical2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-nasdaq-extension2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-leaders-board-directors2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-initiates-blas-for-renu-knee-arthritis2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-jp-morgan-healthcare-conference-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/fda-approves-edwards-sapien-m3-mitral-valve-system2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-jp-morgan-healthcare-conference-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-balstilimab-ovarian-cancer-results2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-cta-acceptance-alstars-trial-als2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-fiscal-2026-q2-results-report2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-approval-cobenfy-first-class-therapy-schizophrenia2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-january-2026-events2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-inducement-awards-december-20252025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-jp-morgan-healthcare-conference-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-jp-morgan-conference-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-fda-qualification-bmd-osteoporosis2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-gmp-manufacturing-aktx-1012025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-expanding-ip-strategy2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-agreements-capital-structure-growth2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-expand-ovarian-cancer-trial2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-announces-survival-data-phase-2a-trial2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-regulatory-update-brilaroxazine-schizophrenia2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-rhnell-1-shelf-life-extension2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-appoints-walter-rosebrough-director2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-investor-webinar-january-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-participate-jp-morgan-healthcare-conference2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-cms-medicare-payment-rate-infoods-ibs-test2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-gilead-acquisition-rp-34672025-12-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-edg-7500-cirrushcm-phase-2-results2025-12-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-phase-2-update-bhv-7000-depression2025-12-24T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-nda-resubmission-tebipenem-hbr-fda2025-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-psilocybin-phase-iib-trial-approval2025-12-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-announces-2-5-million-placements2025-12-19T15:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-partnership-cube-group-solana-digital-assets2025-12-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-zasocitinib-phase-iii-psoriasis-data2025-12-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-financing-announcement-20252025-12-19T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-medical-coverage-policy-milestone2025-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-publication-journal-inflammation-immunomodulatory-effects2025-12-19T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-donates-shares-fire-department2025-12-19T16:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fy-2025-financial-results2025-12-19T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-first-tranche-convertible-bonds2025-12-19T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-nasdaq-opening-bell-20252025-12-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reverse-merger-abl2025-12-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-teva-avt06-sale-agreement-20262025-12-19T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-teva-us-settlement-avt06-biosimilar-eylea2025-12-19T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-regulatory-update-fda-response2025-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-bempedoic-acid-acc-recommendation-20252025-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-brazilian-patent-sexual-dysfunction2025-12-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reverse-stock-split2025-12-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-earnings-conference-call-january-20262025-12-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-ceo-comments-cms-withdrawal-skin-substitutes2025-12-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-termination-roosevelt-resources2025-12-26T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-quarterly-dividend-announcement2025-12-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-lockup-extension-20262025-12-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-ask-pharm-license-agreement-an90252025-12-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-yartemlea-approval-conference-call2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inducement-grants-nasdaq-rule-56352025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-employment-inducement-grants2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-earnings-conference-call-20262025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-ceo-comments-cms-withdrawal-lcds2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reverse-stock-split2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-termination-notice-roosevelt-resources2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/fda-review-inovios-bla-ino-3107-rrp2025-12-29T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-positive-ema-advice-phase-3-trial-vcn-012025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-ema-approval-phase-iii-trial2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-annual-safety-report-intranasal-foralumab-fda2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-20-million-offering2025-12-29T12:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-4800-lyme-disease-updates2025-12-29T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/neffy-epinephrine-nasal-spray-approval-china2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-presents-sachs-neuroscience-forum2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-fda-breakthrough-ulixacaltamide-essential-tremor2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-explores-revenue-generating-opportunities2025-12-29T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-private-placement-financing2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-6-million-securities-purchase-agreement2025-12-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-portfolio-prioritization-update2025-12-29T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-il-6-antibody-production2025-12-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-fda-approval-motiva-implants2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-acquires-halda-therapeutics-cancer-treatment2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-investor-conference-20262025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-phase-3-regal-trial-update-gps-aml2025-12-29T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-phase-3-orbit-cosmic-results-setrusumab2025-12-29T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-phase-3-orbit-cosmic-results-setrusumab2025-12-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRM/medirom-partners-world-proof-human-japan2025-12-29T13:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/babesia-infection-chronic-fatigue-study-nc-state2025-12-29T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-jp-morgan-conference-20262025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-distribution-agreement-miplyffa-npc2025-12-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-sponsor-mash-tag-2026-conference2025-12-29T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-australian-patent-codx-pcr-platform2025-12-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-exclusive-distribution-ai-analyzer2025-12-29T14:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-ai-blood-analyzer-approval2025-12-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-sells-majority-stake-pocono-pharmaceutical2025-12-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-startup-health-alzheimers-moonshot-participation2025-12-29T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-dr-soon-shiong-influential-oncology-20252025-12-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVM/celsci-reports-fiscal-2025-results2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-patent-issuance2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-rebuilding-anticoagulation-therapy2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-2025-clinical-advances-20262025-12-29T16:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-presents-jp-morgan-healthcare-conference2025-12-29T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-rd-transformation-innovation2025-12-16T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-participate-jp-morgan-healthcare-conference2025-12-16T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezolve-aa-phase-2b-study-rezpegaldesleukin-alopecia2025-12-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-ppd-phase-3-study-enrollment-milestone2025-12-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-biosciences-inbrx-106-ozekibart-updates2025-12-16T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-fiscal-year-2025-results2025-12-23T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-jp-morgan-conference-20262025-12-23T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-present-2026-jp-morgan-healthcare-conference2025-12-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-jp-morgan-conference-20252025-12-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-present-jp-morgan-healthcare-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-participate-jp-morgan-healthcare-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-jp-morgan-conference-20262025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-ramp-203-update-kras-g12c-trial2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-presents-jp-morgan-healthcare-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-private-placement-12-4-million2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-presentation-jp-morgan-healthcare-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-appoints-dr-olga-nissan-vp-business-development2025-12-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-us-market-entry-trump-order2025-12-30T12:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-capital-allocation-update-im8-focus2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-allucent-phase-1-clinical-development2025-12-30T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-takeda-royalty-sharing-transaction2025-12-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-appoints-dan-moorhead-cfo2025-12-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-phase-3-data-update-vilobelimab-pyoderma-gangrenosum2025-12-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-private-placement-funding2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/phase-1-2-study-tividenofusp-alfa-hunter-syndrome2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-nda-submission2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-closes-980-million-credit-facility2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-european-patent-nerve-targeted-therapies2025-12-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-webcast-conference-call-q4-2025-results2025-12-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-japanese-patent-pali-21082025-12-30T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-7-million-direct-offering2025-12-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-invests-10-million-digital-assets2025-12-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-patent-opioid-technology2025-12-30T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INNV/innovage-participation-jp-morgan-healthcare-conference2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-ceo-elected-azbio-board2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-restructures-convertible-notes2025-12-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-nasdaq-opening-bell-20262025-12-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reverse-stock-split2025-12-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-2025-shareholder-letter2025-12-30T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-sells-hong-kong-subsidiary2025-12-30T15:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-present-jp-morgan-2026-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-appoints-john-kenny-board-directors2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-jp-morgan-healthcare-conference-20262025-12-30T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ceo-letter-shareholders-20252025-12-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-gatc-health-40-million-spv-ozuriftamab-vedotin2025-12-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-fda-axs-05-alzheimers-agitation-review2025-12-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-fda-pre-nda-meeting-ax12-narcolepsy2025-12-31T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-ceo-letter-20252025-12-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-jp-morgan-conference-20262025-12-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-focus-study-subgroup-analyses2025-12-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-complete-response-letter-relacorilant2025-12-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-presentation-jp-morgan-conference-20262025-12-31T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-files-ind-application-cyps317-psoriasis2025-12-31T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-expands-european-network-with-medsell2025-12-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-regains-nasdaq-compliance2025-12-31T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-present-jp-morgan-healthcare-conference2025-12-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-manufacturing-partnership2025-12-31T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-usda-approval-befrena-canine-dermatitis2025-12-31T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-nasdaq-extension-compliance2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-gatc-health-ozuriftamab-vedotin-trial2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inducement-grants-nasdaq-rule-56352026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-research-genome-wide-pathways-gout-update2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-private-placement-10-million2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-secures-term-loan-facility-100-million2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-focus-study-subgroup-analyses2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presentation-jp-morgan-healthcare-conference-20262026-01-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-spect-business-sale-shine-technologies2026-01-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-oncology-dermatology-ip-platform2026-01-02T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-jp-morgan-healthcare-conference-20262026-01-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-appoints-jason-litten-cmo2026-01-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-nasal-spray-flu-protection2026-01-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-achondroplasia-investor-webinar-january-20262026-01-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-fourth-quarter-2025-results2026-01-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-quarterly-dividend-q1-20262026-01-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-fy-2026-financial-guidance2026-01-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-jp-morgan-conference-20262026-01-02T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-engages-njs-foresight-bio-advisory2026-01-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-appoints-kasowitz-llp-counsel2026-01-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-fourth-quarter-2025-earnings-report2026-01-02T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-employee-inducement-grant2026-01-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-inducement-grants-nasdaq-rule-56352026-01-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-trial-representation-clinical-research2026-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/clinical-readouts-h1-20262026-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-leadership-transition-growth2026-01-05T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-founder-purchase-ads2026-01-05T06:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-palsonify-update-phase-2-results2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-nasdaq-notification-late-filing-report2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-inducement-grants-nasdaq-rule-56352026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-closes-private-placement2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-new-employee-inducement-grant2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-nasdaq-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-ind-status-gh0012026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-fourth-quarter-2025-results-conference-call2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-fourth-quarter-2025-earnings-call2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-fda-grant-canalevia-ca12026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ON/innocan-pharma-anticipates-nyse-listing-offering2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-jp-morgan-healthcare-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVO/evotec-appoints-dr-sarah-fakih-evp-communications2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-board-changes-leadership-roles2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-participation-jp-morgan-conference2026-01-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-update-convertible-debt-capital-structure2026-01-05T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-2026-pipeline-strategy2026-01-05T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-nmra-511-phase-1b-results-alzheimers-agitation2026-01-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-product-agreement-extension-20262026-01-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-skye-bioscience-nimacimab-enhanze-obesity2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presentation-jp-morgan-healthcare-conference-20262026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-rhb-102-gi-indications-glp-1-therapy2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-voluntary-warrant-exchange-update2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-first-phasix-hernia-prevention-case-greece2026-01-05T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-advocacy-scholars-summit-20262026-01-05T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/permanent-j-code-zusduritreatment-access2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-presentation-jp-morgan-conference2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-fda-designations-tara-0022026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-financial-results-q4-full-year-20252026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-presentation-jp-morgan-healthcare-conference2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-vykat-xr-study-results2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-acquires-xeglyze-head-lice-treatment2026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-submits-ct-ng-self-test-colli-pee-fda-review2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-appoints-robert-dempsey-ceo2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-jp-morgan-healthcare-conference-20252026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-jp-morgan-healthcare-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/baylor-college-medicine-multi-antigen-targeted-t-cells2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-biotech-showcase-2026-skinject-phase-22026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-lunatus-partnership-vizz-middle-east2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-presents-jp-morgan-healthcare-conference2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-2026-objectives-strategy-pipeline2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-us-commercial-launch-graftassuredx2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-plans-marketing-authorization-israel2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-hydronidone-approval-pathway2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-2026-strategic-outlook2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-olvi-vec-lung-cancer-trials-interim-data2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-presentation-jp-morgan-healthcare-conference2026-01-05T12:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-fda-lifts-clinical-hold-gh0012026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-participate-jp-morgan-healthcare-conference2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-phase-1-results-january-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-jp-morgan-conference-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-palsonify-launch-atmelnant-trial-results2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-jp-morgan-conference-20262026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-leadership-appointments2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-fda-breakthrough-device-lvo-stroke2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/fiona-sharp-appointed-cfo-biodexa-pharmaceuticals2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-participate-jp-morgan-healthcare-conference2026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-fda-breakthrough-therapy-pemvidutide-mash2026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-jp-morgan-healthcare-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-presentation-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-positive-preclinical-results-fsdc-therapy2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABR/caring-brands-exclusive-license-emesyl2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYOJ/ryojbaba-shareholder-letter-2025-highlights-2026-priorities2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-jp-morgan-conference-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-presents-jp-morgan-healthcare-conference-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-jp-morgan-conference-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WW/weight-watchers-glp1-platform-wegovy-pill2026-01-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-expands-collaboration-novo-nordisk-wegovy-pill2026-01-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jp-morgan-2026-conference2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-appoints-hyunsu-jung-ceo2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-phase-3-indigo-trial-obexelimab-results2026-01-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-mollo-xmg-cannabis-beverages-dry-january2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-fast-track-designation-alzheimers2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-participate-jp-morgan-healthcare-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-presentation-jp-morgan-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-protagonist-rusfertide-nda-polycythemia-vera2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-jp-morgan-conference-20242026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-launches-21-gene-fetal-focus-nipt2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-jp-morgan-2026-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-participate-jp-morgan-healthcare-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-participate-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-global-regulatory-submissions-influenza-vaccine2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-ind-clearances-cr-001-cr-0032026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-appoints-sung-lee-board2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-neurocare-therapy-depression-ptsd2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-phase-1b-trial-da-1726-results2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-appoints-alon-dayan-board-directors2026-01-05T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-libre-assist-app-feature-diabetes-food-decisions2026-01-05T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-acquisition-liquid-biopsy-diagnostics2026-01-05T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-preclinical-results-pl14-allergen-blocking2026-01-05T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-ngc-cap-interim-analysis2026-01-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-achieves-ibogaine-production-milestone2026-01-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-2025-highlights-review2026-01-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-submits-pre-market-approval-module-fda2026-01-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-tagmokitug-pharmacology-publication2026-01-05T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-manufacturing-agreement-pathmuscle2026-01-05T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-limited-2026-clinical-commercial-roadmap2026-01-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-first-half-2026-outlook2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-leadership-appointments2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-8-million-offering2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-leads-rare-disease-genomics-20252026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-fda-acceptance-ind-coya-302-ftd2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-q4-2025-results-announcement2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-jp-morgan-healthcare-conference-20242026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-presents-jp-morgan-healthcare-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-health-canada-approval-redeemplo-fcs2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-results-tafasitamab-dlbcl-trial2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-participate-jp-morgan-healthcare-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-participate-jp-morgan-healthcare-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-telomir-1-tumor-growth-reduction2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-fast-track-designation-ml-007c-ma2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-acquisition-liquid-biopsy-technology-investment2026-01-05T15:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-sung-lee-board-appointment2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-ceo-speak-jp-morgan-healthcare-conference2026-01-05T21:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-fourth-quarter-earnings-conference-call2026-01-05T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-presents-jp-morgan-healthcare-conference-20262026-01-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-jp-morgan-conference-20262026-01-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presentation-jp-morgan-healthcare-conference2026-01-06T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-altaur-trial-asco-gi-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/lecanemab-subcutaneous-formulation-china-approval2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-presents-jp-morgan-healthcare-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-jp-morgan-conference-20242026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-conference-call-onward-data-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-presents-jp-morgan-healthcare-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-bmb-101-phase-2-results-announcement2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-inducement-grants-nasdaq-rule-56352026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-participation-january-2026-conference2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-present-jp-morgan-healthcare-conference2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-wind-down-cell-therapy-activities2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-medsteer-phase-2-study-cyc-1262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-conference-call-phase-1b-trial2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-public-offering-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-employee-inducement-awards2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-board-changes-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-44th-jp-morgan-healthcare-conference2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-appoints-oliver-engert-ca-officer2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-inducement-grants-nasdaq-56352026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-privosegtor-fda-breakthrough-therapy-designation2026-01-06T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-present-biotech-showcase-jp-morgan-conference2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-ceo-amir-reichman-bio-manufacturing-roundtable2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-unravel-collaboration-neurological-damage-therapy2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-clinical-update-diabetes-gene-therapy2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-2025-earnings-conference-call2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-company-update-development-milestones-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-presentation-jp-morgan-healthcare-conference-20262026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-2025-accomplishments-upcoming-milestones2026-01-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-board-development-phase-32026-01-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-acquisition-renergen2026-01-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-18-million-payment-scilex-holdings2026-01-07T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-presents-jp-morgan-healthcare-conference-20262026-01-07T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-jp-morgan-healthcare-conference2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-phase-3-ycanthe-vp-102-common-warts2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-fda-priority-review-atacicept-igAN2026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-phase-3-thrive-3-trial-choline-chloride2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-jp-morgan-conference-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-woda-launch-access-program-revuforj2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-changes-name-decoy-therapeutics2026-01-07T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-jp-morgan-healthcare-conference-20262026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-appoints-new-chair-and-director2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-phase-3-sunrize-study-insights-hyperinsulinism2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-rap-219-phase-3-program-epilepsy-portfolio2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-leadership-appointment-vimal-patel2026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-jp-morgan-conference-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-jp-morgan-conference-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-strategic-investment-crohns-colitis-foundation2026-01-07T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-jp-morgan-conference-20262026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-jp-morgan-conference-20262026-01-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-2026-guidance-revenue-ebitda-growth2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presentation-jp-morgan-healthcare-conference2026-01-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-2026-milestones2026-01-07T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-conference-call-strategic-change-focus2026-01-07T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-positive-phase-1-data-mrt-81022026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-partners-anthropic-ai-research-development2026-01-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-conference-participation-jpm-week2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-ceo-letter-shareholders-20252026-01-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-rebrands-kyntra-bio-focus-oncology-rare-diseases2026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-jp-morgan-healthcare-conference-20262026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-jp-morgan-conference-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-pipeline-commercial-overview-jp-morgan-conference2026-01-09T01:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investors-jp-morgan-healthcare-conference-20262026-01-09T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investors-jp-morgan-healthcare-conference2026-01-09T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-inducement-grant-nasdaq-56352026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-jp-morgan-conference-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-everett-cunningham-ceo-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-inducement-grants-nasdaq-rule-56352026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-ekterly-launch-update-2025-revenue2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLP/simulations-plus-q1-fiscal-2026-results2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/octave-bioscience-kirk-stockwood-appointment2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-sales-increase-december-quarter2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-delivery-order-anthrax-vaccine2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-2026-strategy-catalysts2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-leadership-appointments2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-2025-revenue-estimates2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presentation-jp-morgan-conference-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-reports-fourth-quarter-full-year-2025-revenues2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-kb407-coral-1-update2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-eversense-365-twiist-aid-launch2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-preliminary-q4-2025-results2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-presents-phase-2-revert-ipf-data2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-preliminary-sales-results-q4-20252026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-2026-outlook2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-inducement-awards-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-second-quarter-fiscal-2026-earnings-report2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-appoints-mark-wilson-chief-legal-officer2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-taltz-zepbound-phase-3b-trial-results2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/visby-engages-quest-labcorp-consumer-access-sti-test2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-ip-strategy-update2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-phase-1-clinical-trial-agent-7972026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-jp-morgan-healthcare-conference-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-komodo-health-partnership-rare-disease-dataset2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-abstracts-2026-asco-gastrointestinal-symposium2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-q4-2025-financial-results-release2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-jp-morgan-conference-update2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-appoints-lara-ramsburg-chief-officer2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-cifi-long-read-3c-method2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-ceo-transition-barbara-weber-retirement2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-public-offering-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-biotech-showcase-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/namsa-acquires-labcorp-medical-device-testing-assets2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VEEV/veeva-biomarin-strategic-partnership2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-webcast-acquisition-cdmo-assets2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-clinical-data-asco-gi-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-advances-clinical-trials-evorpacept-alx20042026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-q4-2025-revenue-record2026-01-09T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-presentation-jp-morgan-healthcare-conference-20262026-01-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-agreement-lower-medicine-costs-us2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-2025-revenue-outlook-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-corporate-updates-milestones2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-2026-program-defining-year2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-business-update-jp-morgan-healthcare-conference2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-neuroscience-innovation-forum-20262026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q4-2025-revenue-milestones2026-01-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-progress-outlook-20262026-01-09T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-fda-type-a-meeting-amts-1302026-01-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-2026-outlook-advancing-pipeline2026-01-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-jp-morgan-2026-conference2026-01-09T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-2025-achievements-2026-priorities2026-01-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-expands-mash-pipeline-ervogastat-license-agreement2026-01-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-2026-strategic-priorities-jp-morgan-conference2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-global-bioinnovation-forum-nxt-41x-program2026-01-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-strategic-initiatives-20262026-01-09T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-name-change-leonabio-lona2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-regulatory-update2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-vascepa-therapies-elevated-triglycerides2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-registered-direct-offering-over-28-million2026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-relief-chronic-pain2026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-jp-morgan-conference-20262026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-2026-strategic-priorities2026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-pivot-006-phase-3-data-timeline2026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-phase-2-results-timing-update2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-change-jurisdiction-nevada2026-01-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-biotech-showcase-20262026-01-09T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-fda-alignment-pfs-primary-endpoint2026-01-09T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-poc-study-pain-relief-pancreatic-cancer2026-01-09T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ceo-corner-2025-progress2026-01-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-launches-ng-tube-comfort-program2026-01-09T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-preliminary-2025-revenue-guidance2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-lilly-ai-drug-discovery-collaboration2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-private-placement-80-8-million2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APVO/aptevotherapeutics-secures-60-million-equity-line2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-lilly-tunelab-livedesign-partnership2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-appoints-maria-sainz-board-directors2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZR/kezar-regulatory-update-zetomipzomib-autoimmune-hepatitis2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-fourth-quarter-full-year-2025-results2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-acquires-vivasure-medical-limited2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-clinical-studies-data-locks-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-closing-public-offering2026-01-09T16:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-updated-presentation-time-jp-morgan-conference2026-01-09T16:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-biobeat-collaboration-wearable-defibrillator2026-01-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-fda-acceptance-vyvgart-seronegative-gmg2026-01-13T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-global-oncology-leadership-jp-morgan-conference2026-01-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-strengthens-balance-sheet-cash-runway-20282026-01-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-nasdaq-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-update-2026-outlook2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-business-updates2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-regains-nasdaq-compliance2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-earnings-call-february-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-employee-inducement-grants-nasdaq-rule-56352026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inducement-grant-nasdaq-rule-56352026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-arpit-dave-chief-digital-officer2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-virtual-2026-annual-meeting-shareholders2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-virtual-fireside-chat-titan-partners2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-nasdaq-notification-minimum-equity-non-compliance2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-inducement-grants-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-preliminary-results-q4-2025-revenue-guidance-q1-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-inducement-grant-new-employees2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-fda-orphan-drug-sgt-2122026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-reports-preliminary-fourth-quarter-full-year-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-phase-2-trial-abcl635-menopause2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-european-commission-approval-spinraza-high-dose2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-update-2025-2026-priorities2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-2025-results-commercial-growth2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-preliminary-results-q4-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/us-saudi-biotech-alliance-summit-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-commercial-progress-program-updates-2026-milestones2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATEC/atec-theradaptive-partnership-regenerative-technology2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/cosara-regional-conferences-distributor-relationships2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-fda-clearance-minimed-go-smart-mdi-system2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/ai-driven-immuno-oncology-initiative-10x-genomics2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-advance-research-diagnostic-applications2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-study-autoimmune-disease-diagnostics2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-manufacturing-scale-up-entolimod2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-phase-1-study-update-cid-1032026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-vivasure-acquisition-haemonetics2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-platform-scalability-t-cell-pipeline-expansion-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-mark-bezjak-vice-president2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-atezolizumab-anal-cancer2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-bge-102-phase-1-data-hscrp-reduction2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-preliminary-revenue-q4-full-year-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-preliminary-fourth-quarter-full-year-2025-revenue2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-hifi-sequencing-sudc-research2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMDA/omada-health-preliminary-revenue-q4-fy-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-collaboration-n-lorem-esperare-precision-therapies2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-jp-morgan-conference-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-preliminary-results-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-2026-milestones2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-q4-2025-results2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-corporate-name-change-mgx-therapeutics2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-cnm-au8-fda-meeting-biomarker-data2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-operational-highlights-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/syncardia-hydrix-development-collaboration-emperor-heart2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q4-2025-results-guidance-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-upcoming-milestones-jp-morgan-healthcare-conference2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-2025-milestones-2026-priorities2026-01-13T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-2026-priorities2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-phase-3-study-ap-sa022026-01-13T12:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-strategic-investment-partnership-oramed2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-invests-110-million-us-pharmaceutical-supply-chain2026-01-13T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-lifeward-strategic-transaction2026-01-13T12:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-leadership-depression-acnp-20262026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-donald-zurbay-board2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/xtl-biopharmaceuticals-acquires-neuronos-autism-market2026-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-tivoxavir-marboxil-ind-application2026-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-preliminary-revenue-q4-20252026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquires-patents-endoscope-market2026-01-13T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-q4-2025-financial-highlights2026-01-13T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-simufilam-phase-3-results-alzheimers-publication2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-pre-jp-morgan-update-2025-growth-outlook2026-01-13T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-secures-loan-facility-horizon-finance2026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-lg-chem-exparel-asian-markets2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-webcast-ocu410-phase-2-trial-data2026-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-2026-objectives-strategy2026-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-outlook-pas-004-clinical-programs2026-01-13T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/zycubo-fda-approval-menkes-disease2026-01-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-expands-ai-immunology-autoimmune-diseases2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-record-fourth-quarter-revenues-20252026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-complete-resolution-lung-metastasis2026-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-access-ad-initiative-alzheimers-disease2026-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-james-hassard-cfo2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-announces-ceo-succession2026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-nsclc-checkpoint-inhibitors2026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-mrd-risk-stratification-ai-model2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-strategic-priorities-global-pipeline-progress2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-acnp-2026-presentations2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-q4-2025-results-and-2026-outlook2026-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/tropion-lung17-phase-3-trial-datroway-nsclc2026-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-positive-preclinical-results-cannabinoid-absorption2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-syncardia-cruxx-medtech-podcast-launch2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-supports-decentralized-transplant-monitoring2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-partnership-refuah-health-center-femaseed2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-preliminary-2025-financial-results2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-annamycin-cardiotoxicity-assessment2026-01-13T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-shareholder-update-20262026-01-13T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-explores-investment-opportunities-high-growth-sectors2026-01-13T13:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-2026-update-shareholder-feedback2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/treace-preliminary-fourth-quarter-full-year-2025-revenue2026-01-13T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-50-percent-enrollment-maveric-trial2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-achievements-business-objectives-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-financing-phase-2b-halneuron2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-accelerates-outlook-2026-pivotal-trial-unblinding2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-strategic-priorities-2026-milestones2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-2-trial-data2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-billion-cell-atlas-ai-drug-discovery2026-01-13T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-preliminary-financial-results-q4-fy20252026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-acquires-neuronos-autism-market2026-01-13T14:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-positive-data-adapt-trial2026-01-13T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMCL/omnicell-q4-2025-financial-results-release2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GDRX/surescripts-goodrx-partnership-price-transparency2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-new-data-acnp-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-fy-2025-results-outlook-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/definium-therapeutics-new-nasdaq-ticker-dftx2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-oncology-leadership-jp-morgan-conference2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSCR/oscar-health-2025-earnings-conference-call2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-global-access-commitment-agreement2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-mrd-testing-breast-lung-colon-cancer2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-lifenet-health-collaboration-drug-discovery2026-01-13T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-jp-morgan-conference-20242026-01-13T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-erica-wheeler-cervical-cancer-screening2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-business-pipeline-updates-jp-morgan-conference2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-dynamo-series-smart-stretcher-launch2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-business-pipeline-updates-jp-morgan2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-nasal-vaccine-delivery-castlevax-phase-ii-trial2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-2025-guidance-2026-outlook2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-preliminary-q4-2025-net-sales-guidance2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-appoints-dr-orrin-devinsky-head-clinical-strategy2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-participate-lytham-partners-2026-summit2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bridgebio-oncology-inducement-grants-20262026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-50-million-financing2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-2026-outlook-neuromuscular-cardiac-pipeline2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q4-2025-revenue2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-2025-revenue-guidance-and-milestones2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-fda-review-extension-filspari2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-positive-results-nsclc2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPAA/minovia-therapeutics-new-us-patents-mitochondrial-therapy2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-upsized-public-offering-15-million2026-01-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-shawn-bevec-svp-investor-relations2026-01-14T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-patterson-dental-partnership-renewal2026-01-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-patent-rezenopy-naloxone-spray2026-01-14T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-strategic-milestones2026-01-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-launches-make-it-vizzable-campaign2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/saudi-fda-accelerated-approval-anktiva-nsclc2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/saudi-fda-approval-immunitybio-anktiva-bladder-cancer2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-validates-platform-precision-tdp43-discovery2026-01-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-patent-alto-207-depression2026-01-14T12:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-present-sequire-investor-summit-20262026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-private-placement-nasdaq2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-53-growth-medicare-advantage-membership2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-launches-otc-enfit-syringes2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-updated-guidance-2025-20262026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-expands-sls009-clinical-program-europe2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-participate-alphanorth-capital-event-20262026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSPT/sl-bio-horizon-space-acquisition-business-combination2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-expands-europe-distribution-engagement2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/emjx-ceo-eric-jackson-fireside-chat-treasury-strategy2026-01-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-approval-nrx-100-ketamine2026-01-14T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-public-offering-pricing2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-partnership-refuah-health-femaseed-access2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appoints-john-mcadory-yujun-wu2026-01-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-aml-data-ash-meeting2026-01-14T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-difs-neurostimulation-adhd-study2026-01-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-present-results-pancreatic-cancer-study-aacr-20262026-01-14T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-preliminary-fourth-quarter-full-year-2025-results2026-01-14T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-trial-cmnd-1002026-01-14T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/emergency-care-holdings-acquires-philips-emergency-care2026-01-14T15:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddys-launches-olopatadine-hydrochloride-ophthalmic-solution2026-01-14T13:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAT/j-star-signs-mou-with-pssb-battery-resins2026-01-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-nasdaq-extension-compliance-bid-price2026-01-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OR/os-therapies-filing-form-s1-os-animal-health2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-broad-spectrum-antivirals-influenza-wave2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-jpm26-yeztugo-hiv-numbers2026-01-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-analyst-coverage-valuation-zacks2026-01-14T16:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-record-q4-2025-revenues2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-secures-50-million-loan-facility2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-monotherapy-phase-3-study-results2026-01-14T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/big-pharma-manufacturing-job-opportunities-20262026-01-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-gemini-presentation-aki-crrt-20262026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-patent-application-ad042026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-preliminary-results-q4-full-year-20252026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-aacr-2026-pancreatic-cancer-study2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-virtual-investor-ceo-connect-ash2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-expands-sls009-europe2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-reverse-stock-split2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-upsized-public-offering2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-strategic-milestones-20262026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-ox2r-against-neuropsychiatric-indications2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/ajovy-reduces-migraine-days-children-adolescents2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-q2-fiscal-2026-results2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-debt-management-convertible-notes-offering2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONQ/katie-arrington-joins-ionq-as-cio2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/saudi-fda-approves-immunitybio-anktiva-bladder-cancer2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-tdp43-discovery-neurodegenerative-disease2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-alto-207-patent-depression2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/mount-sinai-first-metro-new-york-tulsa-pro2026-01-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-positive-phase-2-data-ocu410-gene-therapy2026-01-15T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-fda-clearance-encor-encompass-breast-biopsy-system2026-01-15T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-eu-regulatory-inflection-ht-0012026-01-15T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-preliminary-financial-update-20252026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-acquires-penumbra2026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-reverse-stock-split2026-01-15T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-present-real-world-data-apsard-20262026-01-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-forward-phase-3-trial-axs-14-fibromyalgia2026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-ind-submission-gtb-55502026-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staarsurgical-broadwood-cooperation-agreement2026-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-sales-momentum-20252026-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-swoop-system-contrast-study-enrollment2026-01-15T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-imagevue-dr50-plus-launch2026-01-15T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-closes-141m-collaboration-zydus-lifesciences2026-01-15T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-veterinary-cancer-care-mast-cell-tumor-testing2026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABP/abpro-abp-102-jp-morgan-healthcare-conference2026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-expands-hsa-fsa-access-tru-niagen2026-01-15T13:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-pancreatic-cancer-impact2026-01-15T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-ai-initiative-tcm-supply-chain2026-01-15T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/ingrezza-vs-austedo-vmat2-occupancy-comparison2026-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-clean-balance-sheet-steps2026-01-15T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-sidoti-conference-20262026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-submission-ketamine-suicidal-depression2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-prices-550-million-convertible-notes2026-01-16T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTV/asp-ultra-gi-cycle-ce-mark-approval2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-global-innovation-strategy-jp-morgan-conference2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-medical-reverse-stock-split2026-01-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-special-meeting-results-20262026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-fourth-quarter-2025-results2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-closing-public-offering2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-sales-momentum-113-million-revenue2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-approval-clinical-trial-cid-1032026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/ingrezza-vs-austedo-vmat2-occupancy2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/zydus-lifesciences-acquires-agenus-biologics-facilities2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-eu-regulatory-inflection-ht-001-trial2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-positive-phase-2-data-ocu410-geographic-atrophy2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-webcast-conference-call-q4-2025-results2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-preliminary-update-fourth-quarter-full-year-20252026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABP/abpro-abp-102-celltrion-jpmorgan-conference2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-warrant-exercise-4-64-million2026-01-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-offering-17-6-million2026-01-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-inducement-grants-nasdaq-rule-56352026-01-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-pali-2108-ibd-conferences-20262026-01-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-invests-in-opendoor-technologies2026-01-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-launches-lumee-tissue-oxygen-monitoring2026-01-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-2025-annual-meeting-date2026-01-16T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-lock-up-agreement2026-01-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-acnp-meeting-20262026-01-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-sponsors-symposium-veterinary-meeting-expo2026-01-16T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-real-world-data-delivery-1-5m-patients2026-01-16T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-bought-deal-financing2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-cd19-car-nk-therapy-waldenstrom-lymphoma2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-advances-bcg-naive-nmibc-program2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/protagonist-decision-rusfertide-takeda2026-01-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-topline-results-epcoritamab-phase-3-trial2026-01-16T18:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/first-us-patient-dosed-bipass-phase-3-study2026-01-17T09:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/next-gen-alzheimers-treatment-candidates2026-01-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-continued-sales-growth2026-01-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/genflow-biosciences-directorate-change2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/harbour-biomed-acquires-spruce-biosciences-stock2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/fda-acknowledges-rexlemestrocel-l-back-pain-efficacy2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-employment-inducement-grants-january-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-fda-approval-nexplanon-extension2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-inducement-grants-nasdaq-listing-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/repare-shareholders-approve-acquisition-xenotherapeutics2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-inducement-grants-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-employment-inducement-grant-january-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-inducement-grants-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-inducement-grants-nasdaq-listing-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fda-orphan-drug-designation-endoxifen-dmd2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-inducement-grants-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HKPD/cellyan-biotechnology-nasdaq-bid-price-deficiency2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-inducement-grants-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-atopic-dermatitis-trial-results2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-inducement-grants-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-inducement-grant-nasdaq-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-inducement-grant-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-8-8-million-offering2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-epcoritamab-phase-3-results-dlbcl-trial2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-topline-results-epcoritamab-phase-3-trial2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/vaximm-appoints-sebastien-wieckowski-cso2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-emerging-growth-conference-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/precision-platforms-disrupt-2026-tumor-landscape2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-warrants-exercise-4-64-million2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-inducement-grants-january-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-release-results-q4-2025-webcast2026-01-19T14:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/enhertu-pertuzumab-eu-validation-first-line-treatment2026-01-19T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-merck-collaboration-oncology-therapies2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-chikungunya-vaccine-update2026-01-19T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-update-chikungunya-vaccine-ixchiq2026-01-19T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/nmpa-accepts-illuccix-application-prostate-cancer2026-01-20T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-fy-2025-guidance-gozellix-launch2026-01-20T21:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-fda-resubmission-ankteva-bladder-cancer2026-01-20T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-achieves-fy-2025-guidance-revenue-growth2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-orphan-drug-designation-ipf2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sofetabart-mipitecan-fda-breakthrough-designation2026-01-20T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-launches-inpefa-sotagliflozin-uae2026-01-20T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-conference-call-february-20262026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-phase-3-trial-lpcn-1154-postpartum-depression2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-synchrony-s1-prefillable-syringe-launch2026-01-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/new-consensus-recommends-papzimeos-first-line-treatment2026-01-20T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-license-agreement-pfizer-matrix-m2026-01-20T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-postpones-reverse-stock-split2026-01-20T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-merck-long-term-survival-mrna-keytruda-combo2026-01-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-nasdaq-anniversary-opening-bell-20262026-01-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-dealflow-discovery-conference-20262026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-analyst-day-january-20262026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-phase-2-study-vyd2311-long-covid2026-01-20T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-preliminary-full-year-2025-business-update2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-orphan-drug-designation-japan-dyne-1012026-01-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-atopic-dermatitis-trial2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-nda-bezuclastinib-rtor2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-fda-gedatolisib-advanced-breast-cancer2026-01-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-phase-2a-pancreatic-cancer-study2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-igalmi-label-expansion2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-advances-bbi-940-kinesin-degrader2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-neuro-pmr-study-results-portable-mri2026-01-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-ceo-letter-stockholders2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-presentation-dealflow-discovery-conference2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-lp-284-fda-orphan-drug-designation2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-preliminary-financial-results-20252026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-fourth-quarter-full-year-2025-results2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-microsoft-ai-lung-cancer-detection2026-01-20T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-fetal-focus-nipt-smfm-presentation2026-01-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q4-2025-financial-results2026-01-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-expands-renovocath-adoption-cancer-centers2026-01-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-breakthrough-designation-qrx0032026-01-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presentation-dealflow-discovery-conference2026-01-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-corporation-live-earnings-webcast2026-01-20T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-health-appoints-adnan-mansour-cdo2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-phase-2-results-ns0022026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-open-market-purchases-fu-wei2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-nasdaq-closing-bell-20262026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-merck-five-year-data-intismeran-keytruda2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-bge-102-indication-expansion-dme-trial-20262026-01-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-extends-access-nuq-vet-cancer-test2026-01-20T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-cms-reimbursement-trusight-oncology2026-01-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ce-mark-tactiflex-duo-ablation-catheter2026-01-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inducement-grants-nasdaq-listing-rule2026-01-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-ateganosine-cancer-treatment-2026-milestones2026-01-20T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-customer-growth-robotic-expansion2026-01-20T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-secures-uk-ces-contract-steraMist2026-01-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-new-patent-application2026-01-20T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRNS/transcat-third-quarter-fiscal-year-2026-conference-call2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-presentation-dealflow-conference-20262026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-fourth-quarter-2025-financial-results2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-gelrinc-cartilage-regeneration-mri-results2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-sublingual-alprazolam-patent2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-patent-acne-treatment-australia2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-fourth-quarter-full-year-2025-results2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-fetal-focus-sgnipt-smfm-presentation2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-fda-resubmission-anktiva-bladder-cancer2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-q4-2025-earnings-call2026-01-20T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-advances-ateganosine-cancer-treatment2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ce-mark-tactiflex-duo-ablation-catheter-afib2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-200-million-public-offering2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-host-first-2026-stakeholder-webcast2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engn-expands-debt-facility-hercules-capital2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-fourth-quarter-full-year-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-webcast-fiscal-2026-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-announces-fourth-quarter-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-ceo-emerging-growth-conference-20262026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-warrant-exercise-proceeds2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-dividend-distribution-warrants2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-investor-day-recap-20262026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inducement-grants-nasdaq-listing-rule-56352026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-public-offering-20262026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-proposed-public-offering-150-million2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-announces-proposed-public-offering2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-200-million-offering-medtronic-investment2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-fourth-quarter-full-year-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-lupus-optimal-care-initiative-grants2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-intranasal-foralumab-publication2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-granted-patent-alzheimers-treatment2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-va-contract-esoguard2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-patent-ht-kit-cancer-program2026-01-21T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-ypsomed-partnership-biologics-market2026-01-21T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-advances-budgetary-validation-purchase-orders2026-01-21T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dario-health-surpasses-100-scientific-studies2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-burixafor-phase-2-trial-tandem-meetings-20262026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-voluntary-delist-nasdaq2026-01-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/california-k12-schools-neffy-program-epinephrine2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-poster-keystone-obesity-conference2026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-fda-qidp-fast-track-scy-2472026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-appoints-david-robinson-cfo2026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-pricing-22-5-million-offering-common-stock2026-01-21T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-end-of-phase-2-fda-pilavapadin2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-acquired-kuva-labs2026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/good-health-summit-morehouse-college2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-data-tandem-meetings-20262026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-explores-strategic-alternatives2026-01-21T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-net-sales-darzalex-20252026-01-21T11:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-q1-2026-priorities-pipeline-outlook2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/acacia-clinics-vagus-nerve-study-ecor2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-shareholder-letter-2026-objectives2026-01-21T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/concerns-topical-steroids-chronic-skin-conditions2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-tandem-meetings-20262026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-phase-2-b-supreme-study-update2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-1-2-trial2026-01-21T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-appoints-sandeep-kulkarni-ceo2026-01-21T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-jama-study-alzheimers-risk-profiling2026-01-21T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-expands-medical-affairs-infrastructure-botensilimab-balstilimab2026-01-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-q4-full-year-2025-results2026-01-21T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-latitude-tissue-free-mrd-test-validation2026-01-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/nivf-appoints-joshua-chu-tokenization-strategy2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-appoints-marc-waldman-vp-commercial2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-appoints-minako-pazdera-general-counsel2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-fiscal-q2-2026-results2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-clarivate-top-100-global-innovator-20262026-01-21T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/dawnzera-approval-eu-hereditary-angioedema2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-fourth-quarter-full-year-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-report-q4-full-year-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/fluoguide-ind-submission-fg001-registration-trial2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-exxua-launch-major-depression-treatment2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/interpace-biosciences-2025-revenue-guidance2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inducement-grants-nasdaq-listing-rule-56352026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-fourth-quarter-2025-financial-results2026-01-21T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-ceo-named-top-healthcare-technology-ceo2026-01-21T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-coimmunity-initiative-grants-vaccination-gaps2026-01-21T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/dawnzera-approved-eu-hereditary-angioedema2026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-fortune-most-admired-companies-20262026-01-21T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-gazi-university-collaboration2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-acquires-integrity-orthopaedics-shoulder-repair2026-01-21T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-science-talent-search-2026-finalists2026-01-21T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-expands-medical-affairs-infrastructure-bot-bal2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-q4-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-conference-call-q4-2025-results2026-01-21T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-second-quarter-fiscal-2026-results2026-01-21T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/companies-hiring-rd-professionals2026-01-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-fda-approves-gp2-flamingo-012026-01-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-medical-italia-launch-expansion-portfolio2026-01-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-upsized-public-offering-124-million2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-upsized-public-offering2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-fourth-quarter-2025-financial-results-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/trodelvy-keytruda-phase-3-ascent-04-results2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q4-2025-earnings-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inducement-grants-nasdaq-rule-56352026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATXS/astria-stockholders-approve-acquisition-biocryst2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-advance-conversation-early-car-t-access2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/biostem-technologies-acquisition-biotissue-wound-care2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q4-2025-results-webcast2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-fiscal-2026-first-quarter-conference-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inducement-award-20262026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-fda-bpd-type-2a-meeting-shareholder-approval2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-q4-2025-results-conference-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-expands-belgian-manufacturing-capacity2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-proposed-public-offering-common-stock2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-business-update-conference-call-20262026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-acquisition-integrity-orthopaedics2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-gemini-fda-approval-pathway-aki2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-22-5-million-offering2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-clinical-trial-results2026-01-22T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-financial-results-conference-call-20252026-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-full-year-2025-results2026-01-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-cortigent-orion-system-nans-20262026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-phase-2-advanced-2-trial-asco-20262026-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharma-partnership-runway-health-arakoda2026-01-22T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reyobiq-cnsid-commercialization-update2026-01-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-amendment-lifearc-license-teverelix2026-01-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-laurie-stelzer-board-appointment2026-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-lindsey-vonn-antibodies-education2026-01-22T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-phase-3-rosella-trial-relacorilant-ovarian-cancer2026-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-gammagard-liquid-erc-us-availability2026-01-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/initiate-study-pathogen-inactivated-platelets-cerus2026-01-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-bms-collaboration-tumor-therapeutic2026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-appoints-kevin-tracey-board2026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-appoints-bryan-humbarger-cfo2026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-q4-2025-results-conference-call2026-01-22T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAT/j-star-complaints-against-pwc-aicpa-pcaob2026-01-22T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-fda-clearance-ai-scada-brainct-ich2026-01-22T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-us-patent-pds01012026-01-22T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/sweetwater-launches-big-trip-double-ipa2026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-webcast-q4-2025-conference-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-nasdaq-hearings-panel-grants-listing2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-elects-ellen-cooper-board-directors2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-usability-study-nasarix-allergy-blocker2026-01-22T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-medical-italia-launch-therapeutic-cannabis2026-01-22T14:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-medical-italia-expansion-portfolio2026-01-22T14:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-phase-2b-ipf-cough-trial-results2026-01-22T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-quarterly-dividend-2026-meeting-details2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-report-full-year-2025-results2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-advances-vax-31-pneumococcal-vaccine-programs2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-eu-mdr-certification-navigation-software2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-q4-2025-financial-results-report2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-report-q4-2025-results-investor-conference2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-closing-public-offering2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-medtronic-tavr-investment-320-million2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fourth-quarter-earnings2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-phase-2-3-trial-atmelnant-cah2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inducement-awards-20262026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q4-2025-financial-results2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-benefit-hf-trial-barostim-heart-failure2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIR/mirion-earnings-release-conference-call-20252026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-fda-approval-guardant360-cdx-braftovi2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-fda-clearance-ai-software2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-new-us-patent-pds01012026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-clinical-response2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-laurie-stelzer-audit-chair2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-advanced-2-trial-data-asco-symposium2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-sphere-360-catheter-ce-mark-ide-trial2026-01-23T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-research-cloud-ai-panel-design2026-01-23T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-preliminary-financial-results-20252026-01-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/fda-approves-compassionate-use-urcosimod-neuropathic-corneal-pain2026-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-closes-22-5-million-offering2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-business-update-20262026-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-phase-iii-vaccine-trials-skepticism2026-01-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-nasdaq-closing-bell-anniversary2026-01-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-fourth-quarter-full-year-2025-results-call2026-01-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-voluntary-delisting-tase2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-phase-1b-data-tegoprubart-kidney-transplant2026-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-9-million-offering2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-business-update-2026-objectives2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-launches-s540md-slide-scanner-system2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-2-results-glioblastoma-anktiva2026-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-fourth-quarter-2025-earnings-call2026-01-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/20-million-patients-benefit-da-vinci-surgery2026-01-23T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-acquisition-astria-therapeutics2026-01-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-financing-14-million2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-partnership-runway-health-arakoda2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-fda-approval-afrezza-label-update2026-01-26T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/prospera-test-lung-transplant-study-ntra2026-01-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/fda-accepts-leqembi-iqlik-sbla-subcutaneous-dosing2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-boswick-symposium-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-report-3-year-data-embark-study-elevidys2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAFF/moolec-science-nasdaq-exception-compliance-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-upsized-public-offering-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-q3-2025-financial-results-business-update2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-upsized-public-offering-common-stock2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inducement-grant-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-receives-nasdaq-notification-stockholders-equity-deficiency2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-business-update-february-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-exercise-warrants-11-million2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-key-dates-terms2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-s540md-slide-scanner-launch2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-2-results-recurrent-glioblastoma2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-acquisition-astria-therapeutics-hae2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-red-c-phase-3-trials-update2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/enlivex-therapeutics-nasdaq-trading2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CM/daxor-corporation-9-million-offering2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-reports-financial-results-20252026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-affera-sphere-360-ce-mark-ide-trial2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-phase-1b-data-tegoprubart-kidney-transplant2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-private-offering-senior-notes-amicus-acquisition2026-01-26T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquisition-ip-portfolio-gerd-device2026-01-26T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-kol-event-roluperidone2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/baylor-pancreatic-cancer-study-marker-therapeutics2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-cardamyst-etripamil-launch2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-secures-new-us-patent-novel-compound-structures2026-01-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-portfolio-update-rain-token-whitebit2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-gist-therapy2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-terminates-agreement-kowa-promotion-zoryve2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-fourth-quarter-2025-financial-results-call2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-positive-embark-results-elevidys-duchenne2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-acquisition-bluejay-therapeutics-hdv2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-phase-1-miroliverelap-results2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-patent-adc-program-aktx-1022026-01-26T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-ratutrelvir-influenza-treatment2026-01-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-phase-2-illuminate-1-trial-bipolar-depression2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-presentation-miplyffa-worlsymposium2026-01-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-redomiciliation-completion-us2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-2-nbi-1065890-tardive-dyskinesia2026-01-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-fda-type-c-meeting-hlhs-trial2026-01-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/da-vinci-5-cleared-cardiac-procedures2026-01-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-funds-note-purchase-agreements2026-01-26T21:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-api-stockpile-deals-details2026-01-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-hyft-technology-functional-adjacency2026-01-27T05:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-transformation-biotech-defense-industrial-consolidator2026-01-27T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-update-financing-strategy2026-01-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-ati-2138-hair-regrowth2026-01-27T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-participation-investor-conferences2026-01-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-presentation-jefferies-global-healthcare-conference2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-appoints-william-sharbaugh-board-directors2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-acquires-bluejay-therapeutics-hdv-treatment2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-positive-three-year-embark-results-elevidys2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KODK/kodak-expands-pharmaceuticals-portfolio-products2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-fourth-quarter-2025-results2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-inducement-grant-nasdaq-rule-56352026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-q4-2025-results-report2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-survival-rate-sr-agvhd-treatment-update2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-nuq-nets-indication-hidradenitis-suppurativa2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-mexican-patent-breast-cancer-vaccine2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-phase-1b-study-paxalisib-tnbc2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-data-presentations-actrims-20262026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expands-focusfactor-distribution-canada2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-orphan-drug-designation-japan2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-fda-lifts-hold-magnitude-2-trial2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-leadership-appointments-cardiovascular-expertise2026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-terminates-license-agreement-qilu2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-gene-therapy-trial-mertk-retinitis-pigmentosa2026-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-selected-for-japan-entry-acceleration-program2026-01-27T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-on-track-with-hcm-awareness2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-myqorzo-available-us-treatment-ohcm2026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-positive-update-onvansertib-trial2026-01-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-leadership-changes-late-stage-development2026-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-fda-meeting-zervimesine-dlb2026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-reverse-stock-split2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-dragon-ii-trial-enrollment-completed2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-2-survival-data-bctx2026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q4-2025-financial-results2026-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fourth-quarter-full-year-2025-results2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-advances-mrd-commercialization-timeline2026-01-27T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-ip-momentum-patent-application2026-01-27T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-capital-allocation-digital-assets2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-share-repurchase-program-benchmark2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-forte-huntingtons-disease-awareness2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/sweetwater-420-fest-2026-lineup2026-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICLR/icon-accellacare-expands-oncology-research-capabilities2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-fourth-quarter-full-year-2025-results2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-bexmarilimab-phase-i-ii-trial-sarcoma2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/strong-divitum-tka-results-jco-precision-oncology2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/biotech-veteran-virologist-joins-cancervax2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-terminates-promotion-agreement-kowa2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-miplyffa-worlsymposium-20262026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-fourth-quarter-2025-financial-results2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-redomiciliation-us-completion2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-financial-results-conference-call-20252026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-private-offering-senior-notes-acquisition2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/prospera-guided-care-lung-transplant-study2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-files-patent-aktx-102-ceacam52026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-secures-us-patent-novel-compound-structures2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-ratutrelvir-tivoxavir-marboxil-update2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-2-study-nbi-1065890-tardive-dyskinesia2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-fda-type-c-meeting-elpis-ii-hlhs2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/da-vinci-5-cleared-for-cardiac-procedures2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-positive-results-phase-1-miroliverelap2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-reverse-stock-split-20262026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-expands-ai-program-alcohol-use-disorder2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-shareholders-approve-bd-combination2026-01-27T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-financial-results-fiscal-20262026-01-27T14:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-spin-off-biosciences-diagnostic-solutions2026-01-27T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/next-generation-tablo-hemodialysis-fda-clearance-launch2026-01-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-2025-milestones-2026-strategic-initiatives2026-01-27T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-first-quarter-2026-earnings-release2026-01-27T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-tender-offer-results2026-01-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-first-commercial-sales-yartemlea2026-01-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-fourth-quarter-fiscal-year-2025-earnings-release2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-swoop-system-stroke-detection-data2026-01-27T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-btig-conference-participation2026-01-27T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-amendment-hercules-capital-debt-facility-fda-approval2026-01-27T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-fourth-quarter-2025-financial-results2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-vt-1953-phase-3-study-valuation2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNBX/bnb-plus-corp-presents-digital-asset-investor-conference2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-fourth-quarter-year-end-2025-results2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-declares-dividend-share-repurchase-authorization2026-01-27T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-quadruplet-regimen-approval2026-01-27T20:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-revenue-estimates-and-guidance2026-01-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-ultrasensitive-assays-ella-platform2026-01-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-glp1-users2026-01-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-abstracts-tpip-pvri-2026-congress2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-imcas-2026-data-facial-injectables2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-discontinues-phase-2-kourage-trial2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-litifilimab-fda-breakthrough-therapy-designation2026-01-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-asbrs-breast-cancer-treatment-guidelines2026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-shareholder-letter-20252026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-update-20262026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-regulatory-update-ultra-rare-mps-programs2026-01-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-matt-skelton-cco2026-01-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-castanospermine-purification-license2026-01-28T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-sc247-imari-presentation-antifungal-activity2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-acceptance-clinical-data-abstract-sio-20262026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-promotes-alireza-javadi-cto2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-q4-2025-results-report2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-samit-hirawat2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-successful-type-c-fda-meeting2026-01-28T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-parkinsons-research-collaboration2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/roche-obesity-moderna-vaccine-sarepta-data2026-01-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-gene-expression-ipf2026-01-28T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-appoints-kylie-jimenez-cpo2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-appoints-kylie-jimenez-chief-people-officer2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-patients-show-tumor-regression-immune-activation2026-01-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/first-patient-dosed-accel-phase-3-study-ibsrela2026-01-28T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-pain-mitigation-pancreatic-cancer-sio-20262026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-data-presentations-worlsymposium-20262026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-completes-enrollment-aces-emb-trial-heart-transplantation2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-1-5-million-offering2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-launches-vitagard-mrd-infrastructure-asean-market2026-01-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-partnership-u-deliver-distribution2026-01-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-report-fourth-quarter-full-year-2025-results2026-01-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-fda-breakthrough-therapy-nxc-2012026-01-28T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-phase-2-study-results-il-12-immunocytokine2026-01-28T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-submission2026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-fourth-quarter-full-year-2025-results-webcast2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-half-year-results-updates2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-pivot-to-growth-strategy-2025-results2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-acquires-woori-io-strategic-review2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-shareholder-letter-20262026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-japanese-mhlw-orphan-drug-designation2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-accelerates-ip-momentum2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-selected-for-jeap2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-sublingual-clopidogrel-patent2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-dragon-ii-trial-enrollment-complete2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-fda-lifts-clinical-hold-magnitude-2-trial2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-report-fourth-quarter-full-year-2025-results2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-fda-approval-idose-tr-re-administration2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-refutes-misleading-claims2026-01-28T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-75-million-offering2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-financial-results-february-20262026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-q4-2025-financial-results-release2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-q2-2026-dividend2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-changes2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-upcoming-investor-events2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-quadruplet-regimen-approval-multiple-myeloma2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-declares-dividend-authorizes-share-repurchases2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-q2-results-report2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-investor-conferences-20262026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-fourth-quarter-2025-financial-results2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-amendment-hercules-capital-debt-facility2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-fourth-quarter-full-year-2025-results2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-fourth-quarter-year-end-2025-financial-results2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-phase-1-2a-study-arodimer-pa2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-webcast-2025-financial-results2026-01-28T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-tlx591-px-prostate-cancer-japan2026-01-29T13:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/it-professionals-hiring-biopharma-20262026-01-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-regeneron-bayer-eylea-agreement2026-01-29T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-settlement-agreement-eylea-biosimilar2026-01-29T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-q3-fy2025-results-vyvanse-generics-impact2026-01-29T06:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-data-presentations-worldsymposium-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-quarterly-dividend-april-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-metastatic-breast-cancer-resistance2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-barda-entolimod-radiation-syndrome-discussion2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-shareholder-letter-revenue-20252026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-fda-breakthrough-nxc-2012026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-phase-2-results-pds01adc-prostate-cancer2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-new-data-imcas-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-update-key-value-drivers-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-samit-hirawat-board2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-enrollment-update-pf614-phase-3-trial2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-q4-full-year-2025-results2026-01-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/bexmarilimab-clever-1-inhibition-cancer-immunotherapy2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-veterinary-recall-hycoat-solution2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-safety-data-children-ataxia-telangiectasia2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-inducement-grant-nasdaq-rule-56352026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-btig-conference-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-ryoncil-revenue-increase-q2-20252026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-board-appointments2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-q4-fiscal-year-2025-results2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-btig-conference-participation-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-pharmaceuticals-added-to-sp-600-index2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-fda-clearance-ser-252-parkinsons2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-envetec-recycling-solution-laboratory-plastics2026-01-29T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-renergen-helium-project-update2026-01-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-fourth-quarter-full-year-2025-conference-call2026-01-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-nimacimab-keystone-obesity-conference2026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-breadth-phase-2b-asthma-trial-kt-6212026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q2-fy262026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-february-investor-conferences2026-01-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-revita-weight-maintenance-data2026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-uspto-patents-cbgm-platform2026-01-29T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-participation-apao-20262026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-btig-conference-participation-20262026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-conference-call-q4-2025-results2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-collaboration-totec-pharma2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-boehringer-ingelheim-data-collaboration2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-fourth-quarter-full-year-2025-results2026-01-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/fda-acceptance-ivonescimab-summit-therapeutics2026-01-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/satellos-appoints-antoinette-paone-cdo-regulatory-affairs2026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-tender-offer-extension2026-01-29T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-announces-q4-2025-financial-results-call2026-01-29T13:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-participate-upcoming-conferences2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INNV/innovage-expands-board-appointment-directors2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-positive-us-study-results-linc-20262026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/terrapin-beer-co-brand-refresh-20262026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-love-in-mind-migraine-impact-relationships2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/art100-completes-clinical-evaluation-budgeted-procurement2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-ibd-experts-clinical-advisory-board2026-01-29T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-japan-patent-potency-assay-methods2026-01-29T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-noble-capital-conference-20262026-01-29T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/cibolo-health-endorses-heartsciences-myoVista-insights2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-shareholder-letter-2026-trials-milestones2026-01-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-analyst-day-february-20262026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-early-clinical-proof-concept-apr-10512026-01-29T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-private-placement-5-6-million2026-01-29T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-fourth-quarter-full-year-2025-results2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-acquires-safe-save-medical-cell-sciences2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-warrant-inducement-7-5-million2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-report-q4-full-year-2025-results2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-expanding-phase-iii-gelrinc-clinical-sites2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-agreement-microsize-sublingual-aspirin2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-positive-results-phase-iii-denifanstat-acne2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-fourth-quarter-2025-financial-results2026-01-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pricing-private-offering-senior-notes2026-01-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-fda-approval-galleri-multi-cancer-test2026-01-30T00:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pricing-public-offering-private-placement2026-01-30T07:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-manufacturing-consolidation-20262026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-public-offering-common-stock2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-worldsymposium-2026-data-presentations2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-eversense-365-european-approval2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-update-on-recent-developments2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-q2-fiscal-year-2026-results2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-fourth-quarter-2025-results-conference-call2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-stock-units-warrants-employees-20262026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALK/alk-receives-positive-recommendation-eurne2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-550-million-public-offering2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-q4-2025-financial-results2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-fda-clearance-rystiggo-freedomedge-infusion2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-seanobi-study-100-patients-enrolled2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-phase-3-neat-trial-results2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-closes-75-million-offering-common-stock2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-recordati-collaboration-mrna-3927-commercialization2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-phase-3-resilient-data-tonmya2026-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-fourth-quarter-full-year-2025-results2026-01-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-annual-shareholder-meeting-summary-20262026-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-rd-leadership-evolution2026-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q2-fy26-cash-flow-report2026-01-30T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-guggenheim-biotech-summit-20262026-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-reimbursement-submission-nuq-cancer-assays2026-01-30T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-acquisition-somalogic-completes2026-01-30T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-preclinical-data-nd2l2026-01-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-invests-20-million-in-quantum-scan-holdings2026-01-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-resubmits-bla-ux111-sanfilippo-syndrome2026-01-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-recordati-mrna-therapy-partnership2026-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-sale-somalogic-illumina2026-01-30T14:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-corporate-update-strategic-alternatives2026-01-30T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-pricing-underwritten-offering2026-01-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/cd47-expression-predicts-response-evorpacept-advanced-breast-cancer2026-01-30T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-chmp-opinion-zynyz-scac-treatment2026-01-30T14:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-private-placement-11-million2026-01-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-phase-ii-clinical-data-mcs-82026-01-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-pennsylvania-manufacturing-facility2026-01-30T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-urcosimod-ascrs-presentation-20262026-01-30T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-nasdaq-minimum-bid-price-notification2026-01-30T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-fda-complete-response-letter-leniolisib-apds2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXT/sensient-announces-conference-call-january-20262026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-departure-cfo-shane-kovacs2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presentation-imaging-dosimetry-data-mp07122026-02-02T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-sandoz-biosimilars-canada-australia-new-zealand2026-02-02T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-supply-commercialization-agreements-biosimilars2026-02-02T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-investor-relations-events-february-20262026-02-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-expands-3d-stem-cell-organoid-culture-portfolio2026-02-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-q4-full-year-2025-results2026-02-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-signatera-cdx-fda-approval-submission2026-02-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-financial-results-q4-full-year-20252026-02-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-licenses-rare-disease-product2026-02-02T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-ultrasensitive-ctdna-monitoring-cancer-immunotherapy2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-fda-orphan-drug-ifx-2-0-melanoma2026-02-02T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-inducement-grants-nasdaq-rules2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-nexus-triomphe-amds-persevere-trials2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-positive-52-week-data-asc40-acne-trial2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-reaffirms-2025-revenue-guidance-strong-growth2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-new-patent-dna-polymerase-inhibitors2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-accelerate-regulatory-engagement-wve-0062026-02-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-amends-license-agreement-newsoara2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-goodrx-arakoda-partnership2026-02-02T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/eurneffy-adrenaline-nasal-spray-eu-approval2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-patent-cannabinoid-technology2026-02-02T13:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-positive-cbeyond-phase-2a-results-nimacimab2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-injection-angiogenesis-20262026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-statins-porokeratosis2026-02-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-fda-fast-track-sonelokimab-ppp2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-15-year-anniversary-epifix-amniofix2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-financial-results-webcast-20262026-02-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-national-burn-awareness-week-20262026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-relocates-headquarters-san-jose2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-participate-conferences-february-20262026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-phase-2b-trial-halneuron2026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-webcast-enzyme-transportvehicle-programs2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-share-repurchase-program2026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-positive-results-integument-infant-trial-zoryve2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-fda-complete-response-anaphylm2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-btig-conference-participation-20262026-02-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-fda-accepts-nda-zanzalintinib-mcrc2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-allia-moveo-fda-clearance-ce-mark2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-fiscal-2026-q1-results2026-02-02T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-td-cowen-conference-20262026-02-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-interim-co-ceos-appointment2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-funds-vt-1953-phase-3-study2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-2-car-nk-cell-therapy-trial2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-sale-short-read-sequencing-assets2026-02-02T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-peer-reviewed-research-difs-technology2026-02-02T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-scope-summit-2026-concussion-treatment2026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/polaryx-therapeutics-nasdaq-listing-plyx2026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DLHC/dlh-fiscal-2026-first-quarter-results2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-nasdaq-bell-ringing-20262026-02-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GROUP/astrazeneca-begins-trading-nyse2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/ambry-genetics-one-millionth-test-rna-diagnostic-accuracy2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-pharma-bio-neuroscience-conference-amsterdam2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-car-t-therapy-approval2026-02-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-diabetes-expands-insulin-delivery-solutions2026-02-02T14:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-precision7-contact-lens-canada2026-02-02T14:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-bla-filing-ost-her2-osteosarcoma2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGC/igc-pharma-phase-2-calma-trial-enrollment2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/sparrow-appoints-carlo-incerti-board-directors2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/fruzaqla-reimbursement-ontario-mcrc2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-novartis-partnership-mayzent-ms-canada2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-grants-new-employees-inducement-plan2026-02-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-inducement-grants-nasdaq-rule-56352026-02-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-spin-off-record-date2026-02-03T02:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-instituto-butantan-chikungunya-vaccine-brazil2026-02-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-instituto-butantan-pilot-vaccination-brazil2026-02-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-2026-financial-guidance-rare-disease-pipeline2026-02-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/biontech-multi-modality-vs-moderna-mrna-pipeline2026-02-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-preclinical-data-mglu7-nams-anxiety-treatment2026-02-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/datroway-priority-review-tnbc-treatment2026-02-03T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/preciseonco-consortium-awarded-eur-14-9-million-ihi-grant2026-02-03T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/osrx-licensing-availability-compounded-ophthalmic-medications2026-02-03T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-inducement-grants-nasdaq-rule-56352026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-closes-632-million-public-offering2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-inducement-grants-nasdaq-rule-5635c42026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inducement-grants-february-20262026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-flow-cytometry-mrd-myeloma-test2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-us-names-approval-car-t-therapy2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-diabetes-expands-access-insulin-delivery-solutions2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-acquires-wylie-oaks-texas2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-acquires-timber-ridge-wisconsin2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-expands-arizona-operations2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-acquires-northwest-radiology-indiana2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-webinar-february-20262026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-source-healthcare-nociscan-growth2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-trofinetide-rett-syndrome-update2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/definium-therapeutics-employee-inducement-grants2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-fourth-quarter-full-year-2025-results2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-zovegalisib-fda-breakthrough-designation2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-interim-ceo-appointment2026-02-03T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-guggenheim-biotech-summit-20262026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-guggenheim-biotech-summit-20262026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-expands-enabling-technology-market2026-02-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-fda-liberty-phase-3-trial-vyd23112026-02-03T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-fiscal-2026-first-quarter-results2026-02-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-participate-btig-medtech-conference-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-investor-conferences-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-meai-veterans-access-therapies2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-late-breaking-results-cardiamp-hf-trial2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-fda-meeting-efzofitimod-pulmonary-sarcoidosis2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-allohome-clinical-validation-2026-tandem-meetings2026-02-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-earnings-conference-call-february-20262026-02-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-inducement-grants-nasdaq-rule-56352026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-leadership-transitions-oncology-pipeline2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-cardiac-catheter-af-symposium2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-fourth-quarter-full-year-2025-results2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-change-the-target-cardiovascular-care2026-02-03T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-full-year-2025-results-2026-guidance2026-02-03T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-ultra-long-acting-glp-1-ra-weight-loss-phase-2b2026-02-03T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-fourth-quarter-full-year-2025-results2026-02-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-phase-2-trial-enrollment-open2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-commercial-update-arbli-launch2026-02-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn-01-retinoblastoma-apao-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-third-quarter-results-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-worlsymposium-2026-data2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-present-investor-scientific-conferences-february2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-appoints-mayo-pujols-cto2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fiscal-q3-2026-results-update2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-phase-1-vcn-01-retinoblastoma-apao-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-guggenheim-summit-20262026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-140-million-private-placement-financing2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LONA/leonabio-appoints-mark-kubik-cbo2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-championship-sunday-events2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-announces-revenues-and-earnings2026-02-03T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-announces-revenues-earnings-february-20262026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-neurorestore-acd856-adpd-20262026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/wuxi-vertex-tcell-engager-agreement2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-td-cowen-health-care-conference-20262026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-first-quarter-fiscal-year-2026-results2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-fourth-quarter-2025-results2026-02-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-leadership-team-expansion2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-phase-1-starlight-1-data-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-cardiovascular-scientific-forum-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-fda-clearance-tap2d-image-enhancement2026-02-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-acquires-cathworks-innovation-strategy2026-02-03T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-san-diego-zoo-frozen-zoo-sequencing2026-02-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-fda-clearance-prt123962026-02-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/faces-of-natrelle-testimonial-program-launch2026-02-03T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-fda-ema-applications-upadacitinib-vitiligo2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-appoints-matthew-maletta-chief-legal-officer2026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-hyla-blood-sensor-validation2026-02-03T14:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-appoints-michael-p-miller-board-directors2026-02-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-healthcare-conference-taipei-20262026-02-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-fda-clearance-gtb-5550-trike2026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-fda-pre-ind-meeting2026-02-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-new-patent-tenapanor2026-02-03T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/cycle-pharmaceuticals-acquires-applied-therapeutics2026-02-03T13:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-fda-submission-alzheimers-blood-test2026-02-03T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-presentation-spie-medical-imaging-20262026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-neuroplasticity-psychiatric-disease2026-02-03T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-reduces-short-position-crypto2026-02-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-expands-european-commercial-footprint-switzerland2026-02-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-underwritten-offering-pricing2026-02-03T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-soteria-trial-launch-worlsymposium-20262026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-duck-flats-partnership-fda-ind-readiness2026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABR/caring-brands-secures-new-patents-hair-technology2026-02-03T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-ketamir-2-phase-1-study-update2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXAS/oncotype-dx-breast-recurrence-score-test-milestone2026-02-03T14:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-partnership-mounjaro-discounted-therapy2026-02-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-full-year-2025-results2026-02-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-report-q4-full-year-2025-results-investor-event2026-02-03T21:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-full-year-results-2025-webcast-notification2026-02-04T11:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/biotech-ipos-2021-current-status2026-02-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/mapi-pharma-ga-depot-ppms-actrims-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-full-year-2025-results-guidance-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-ultra-long-acting-glp-1-ra-weight-loss-phase-2b-trial2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-leadership-transitions-innovation-oncology2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-presentation-healthcare-conference-taipei-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-pricing-offering2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-expands-european-commercial-footprint2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-neuroplasticity-psychiatric-treatment2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/twist-bioscience-inducement-grants-nasdaq-rule-56352026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-leadership-changes-regulatory-clinical2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-fourth-quarter-2025-financial-results2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-showcases-qiasprint-connect-slas-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-investor-conferences-february-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-fourth-quarter-full-year-2025-results-investor-event2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-btig-conference-participation2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-q2-results2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-staar-study-fabry-disease2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-investor-conference-february-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reverse-stock-split-nasdaq-compliance2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-awards-february-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-upsized-ipo-pricing-announcement2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-inkt-ipf-data-keystone-symposia2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-phase-2-calliper-trial-data-actrims-20262026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-february-20262026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-q2-fiscal-2026-results2026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-q4-2025-results2026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-participate-guggenheim-biotech-summit2026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-reports-q4-full-year-2025-results2026-02-04T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-fiscal-2026-first-quarter-results-conference-call2026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/final-apex-phase-1b-results-kodiaks-ksi-1012026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-q4-2025-financial-results-2026-guidance2026-02-04T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/devote-study-nusinersen-sma-results2026-02-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-investor-conferences-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-guggenheim-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-participate-guggenheim-biotech-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-acquires-stake-arrow-aviation2026-02-04T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-guggenheim-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-guggenheim-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-presents-oppenheimer-healthcare-conference-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-february-investor-conferences2026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-guggenheim-biotech-summit-20262026-02-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-guggenheim-biotech-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-investor-conferences-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-february-healthcare-conferences2026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-2025-revenue-business-updates2026-02-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-participate-guggenheim-biotech-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-publication-ultralow-temperature-ablation-vt2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/kasey-keller-lymphoma-journey-breyanzi2026-02-04T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-genomic-alterations-gene-editing2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-cancer-phase-1-data-aacr-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-institutional-volatility-income-vault2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-locket-device-hospital-approvals2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/breckenridge-distillery-romano-beverage-distribution-illinois2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-guggenheim-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/opko-enterabio-partnership-oral-pth-tablet2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-guggenheim-biotech-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-guggenheim-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-quarterly-dividend-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-february-conferences-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-miplyffa-npc-worldsymposium2026-02-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-presentation-guggenheim-summit-20262026-02-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-guggenheim-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-cc-pharma-top-100-innovator-germany2026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-fourth-quarter-2025-results2026-02-04T12:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-positive-ai-modeling-results-syntekabio-collaboration2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-third-quarter-results-conference-call2026-02-04T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-2026-first-quarter-results2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-clinical-data-sio-2026-meeting2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-2025-financial-results-clinical-highlights2026-02-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/opko-enterabio-partnership-oral-pth-tablet2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-exclusive-license-otsukas-opb-171775-gist2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-eugene-kennedy-cmo2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-stelo-smart-meal-logging-enhancements2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srp-1005-clinical-trial-approval2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-fy2026-q3-results-conference-call2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-fda-approval-aptima-hpv-assay2026-02-04T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-next-generation-automated-solutions-slas20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-presentation-guggenheim-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-shareholder-letter-growth-outlook2026-02-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-participate-investor-conferences-february-20262026-02-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-fda-fast-track-pelareorep-colorectal-cancer2026-02-04T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-evident-capital-tokenized-bond-launch2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-sponsors-symposium-european-hidradenitis-suppurativa2026-02-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-fda-fast-track-ifetroban-dmd2026-02-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-congressional-directive-alternative-endpoints-aud2026-02-04T14:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-anito-cel-tandem-presentation-20262026-02-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-exclusive-distribution-agreement-summit-products2026-02-04T15:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-fiscal-2026-q2-financial-results2026-02-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q4-2025-results-announcement2026-02-04T23:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-medical-regains-nasdaq-compliance2026-02-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-anito-cel-late-breaking-presentation-tandem-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-fiscal-year-2026-q3-results-update2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-presents-guggenheim-biotech-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-ultralow-temperature-ablation-vt2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-quarterly-dividend-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-fourth-quarter-2025-revenue-updates2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/pharosai-10x-genomics-cancer-research-ai-spatial-biology2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/ambrys-contributions-to-maves-support-patient-reclassifications2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/lumicell-appoints-cheryl-blanchard-board-directors2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-investor-conferences-february-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-fiscal-2026-first-quarter-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-q4-2025-financial-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-pivot-insulin-patch-pump-milestone2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-appoints-ori-gon-cfo2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-clinical-data-tamp-therapy-sio-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-eugene-kennedy-chief-medical-advisor2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reiterates-full-year-2025-financial-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/acarix-eu-mdr-certification-cadscor-system2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-q3-results-conference-call-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-canada-pr-ajovy-pediatric-migraine-approval2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-avt80-entivio-study-results2026-02-05T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-positive-results-avt80-biosimilar-entivio2026-02-05T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-q4-2025-financial-results-release2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-inducement-awards-nasdaq-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-guggenheim-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-fiscal-2026-q3-results-earnings-call2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-participation-february-2026-investor-conferences2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-q4-2025-results-growth-pillars2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-q4-2025-financial-results-call2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q4-2025-results-announcement2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-inducement-grant-nasdaq-rule-56352026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-guggenheim-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fourth-quarter-2025-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-acquisition-update-renal-therapeutic-program2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-fiscal-2026-q3-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-investor-conferences-february-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-acquires-dual-targeting-car-t-assets2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-guggenheim-biotech-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-report-2025-results-business-update2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inducement-grants-february-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-attend-health-care-conferences2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-q4-full-year-2025-financial-results-call2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-guggenheim-biotech-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-guggenheim-biotech-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-guggenheim-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPO/enpro-fourth-quarter-year-end-2025-earnings-release2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-participate-guggenheim-biotech-summit-20262026-02-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-q4-2025-results2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-investor-conferences-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-burixafor-stem-cell-mobilization-multiple-myeloma2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-guggenheim-biotech-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-investor-conferences-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-2026-shareholder-letter2026-02-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/spago-nanomedical-year-end-report-20252026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-2a-ind-amendment-ttx-mc1382026-02-05T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-guggenheim-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-fourth-quarter-full-year-2025-results-call2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-fourth-quarter-2025-results2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-fourth-quarter-2025-financial-results2026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-addresses-market-rumor-no-crypto-assets2026-02-05T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-endoxifen-duchenne-muscular-dystrophy2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-fireside-chat-guggenheim-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-fourth-quarter-2025-earnings-call2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-475-million-offering-nasdaq-iinn2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-2-million-offering2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-guggenheim-biotech-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-appoints-richard-kyle-board2026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-guggenheim-biotech-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-appoints-mark-voll-cfo2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/pro-familia-profound-medical-sonalleve-procedures2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-guggenheim-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-oppenheimer-conference-20262026-02-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-launches-neurocare-ai-virtual-clinic2026-02-05T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-announces-q4-2025-results2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-oncology-conference-20262026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-investor-conferences-february-20262026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-ovarian-cancer-study-update2026-02-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/uwe-heartsciences-ecg-education-center2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-canadian-patent-cachexia-treatment2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-guggenheim-biotech-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-present-upcoming-conferences-february-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-guggenheim-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q4-2025-financial-results-conference-call2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-extends-access-program-zervimesine2026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-liver-transplant-success2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-participate-guggenheim-biotech-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-fourth-quarter-2025-financial-results2026-02-05T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-inducement-grants-nasdaq-rule-56352026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-report-financial-results-february-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-guggenheim-biotech-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-participate-february-investor-conferences2026-02-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-investor-conferences-20262026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-positive-year-end-interim-clinical-progress2026-02-05T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-health-canada-authorization-livmarli-tablet2026-02-05T13:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-health-canada-authorization-livmarli-pfic2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-launches-discovery-platforms-slas20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-q4-2025-earnings-release-webcast2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q4-2025-results-conference-call2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-pert-consortium-research-fund-pulmonary-embolism2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-participate-investor-conferences2026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-launches-omnipod-5-middle-east2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-full-year-2025-results2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-q4-full-year-2025-results2026-02-05T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-soundhealth-collaboration2026-02-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INNV/innovage-senior-care-capitol-advocacy2026-02-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-proenzyme-therapy-pancreatic-cancer2026-02-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-board-appointments-20262026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fiscal-q2-2026-revenue-growth2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-q4-2025-results-conference-call2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/locket-suture-retention-device-scripps-conference-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-reverse-stock-split-february-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-announces-private-placement-funding2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-guggenheim-summit-20262026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-bitgo-collaboration-solana-strategy2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-epigenetic-modulation-cancer-aging2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-health-canada-approval-enflonsia-rsv-prevention2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-q3-fiscal-2026-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-participate-webinar-webull-financial2026-02-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-supports-mikaela-naylon-act-reauthorization2026-02-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-webinar-participation-webull-financial2026-02-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-webinar-participation2026-02-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/fda-accelerates-oncolytics-biotech-cancer-treatment2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMCL/omnicell-fy-2025-financial-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-q4-2025-earnings-date-revenue-growth2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-financial-results-q4-fy-20252026-02-05T21:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-launches-cost-savings-program-trumprx2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-cardiac-catheter-study2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-reports-fourth-quarter-annual-2025-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-ipo-pricing-announcement2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-announces-pricing-initial-public-offering2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-fiscal-2026-first-quarter-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/tralesinidase-alfa-potential-treatment-sanfilippo-syndrome2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-quarterly-preferred-stock-dividend2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-ipo-closing-additional-shares2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-ind-clearance-btk-degrader-apg-32882026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/amtagvi-real-world-data-advanced-melanoma2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-shareholder-approval-z-squared-merger2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-report-fourth-quarter-full-year-2025-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-investor-conferences-february-20262026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-investor-conferences-march-20262026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-conference-call-q4-full-year-20252026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-guggenheim-biotech-summit-20262026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q4-2025-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-fourth-quarter-full-year-2025-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-launches-eden-study-preeclampsia-risk-assessment2026-02-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-inducement-grants-nasdaq-rule-5635c42026-02-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-actrims-20262026-02-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-guggenheim-summit-20262026-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-positive-phase-2-brepocitinib-cutanous-sarcoidosis2026-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/priovant-positive-phase-2-results-brepocitinib-cs2026-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-clearmind-intranasal-formulation-development2026-02-06T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-corporate-updates-financial-results-q3-20252026-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-tacti-004-phase-iii-trial-enrolment2026-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-development-agreement-intranasal-meai2026-02-06T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/fda-priority-review-hympavzi-hemophilia-treatment2026-02-06T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-presents-guggenheim-biotech-summit2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-guggenheim-biotech-summit-20262026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ablation-catheters-afib-symposium-20262026-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-piper-sandler-symposium-20262026-02-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-pricing-public-offering2026-02-06T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-webinar-participation-february-20262026-02-06T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-voluntary-delist-nasdaq2026-02-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q4-2025-financial-results2026-02-06T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/fda-approves-yescarta-label-update-pcnsl2026-02-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-eventhorizoniq-launch2026-02-06T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-milestone-2-system-integration-marketplace-activation2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-rapid-procurement-influenza-research2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-special-meeting-adjournment-reconvened-meeting2026-02-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biologics-license-application-lecanemab-china-priority-review2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-closes-94-million-offering-private-placement2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inducement-grants-nasdaq-rule-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-inducement-grants-nasdaq-rule-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-inducement-awards-february-20262026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inducement-grant-nasdaq-rule-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inducement-grants-nasdaq-listing-rule-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/pendopharm-yorvipath-approval-hypoparathyroidism2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q4-2025-financial-results-call2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-q4-2025-financial-results2026-02-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-first-quarter-fiscal-2026-results2026-02-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-inhale-1st-study-afrezza-pediatric-diabetes2026-02-09T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-fourth-quarter-2025-results-call2026-02-09T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-rita-johnson-greene-cfo2026-02-09T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-canadian-patent-namodenoson-obesity-therapy2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-upcoming-conferences-20262026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-adam-rogers-ceo-appointment2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-q1-fy-2026-financial-results-update2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-appoints-scientific-advisory-board2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ovarian-cancer-car-t-trial-update2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-completes-enrollment-4front-1-phase-3-trial2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-secures-vendor-approval-clalit-health-services2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-fda-ide-approval-ocs-heart-trial2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-presents-upcoming-investor-conferences2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-launch-ychant-japan-molluscum-contagiosum2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/klinikum-fuerth-robotic-heart-arrhythmia-program2026-02-09T13:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-fda-feedback-sgt-003-duchenne2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-board-composition-changes-20262026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-inducement-grants-nasdaq-rule-56352026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-rmat-designation-kb707-nsclc2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-promotes-kate-rochlin-president-coo2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-dod-funding-bioengineered-blood-vessels2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-quellimmune-therapy-pediatric-akd2026-02-09T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-appoints-geno-germano-chairman-board2026-02-09T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-communications-grant-recipients-20262026-02-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-investor-conferences-20262026-02-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-positive-safety-results-cmnd-1002026-02-09T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-participate-immuno-oncology-360-conference2026-02-09T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-fiscal-2026-q1-results-update2026-02-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-guggenheim-biotech-summit-20262026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-appoints-michael-stansky-board-directors2026-02-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-sponsors-nad-health-conference2026-02-09T13:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-launches-readyfix-fleet-management-solution2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-appoints-experts-advisory-board2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-presentation-td-cowen-oppenheimer-conferences2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-phase-3-trial-vdphl01-hair-loss2026-02-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-eb103-presentation-tandem-meetings2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/chemspeed-sciy-self-driving-laboratory-platform2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-positive-results-phase-3-ameluz-pdt2026-02-09T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-advances-in-ogm2026-02-09T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-piper-sandler-symposium-20262026-02-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMDA/omada-health-q4-2025-results-conference-call2026-02-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-advances-onp-002-concussion-therapy2026-02-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGPU/axe-compute-appoints-christopher-miglino-ceo2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obexelimab-phase-2-moonstone-trial-results2026-02-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-acquire-orna-therapeutics-cell-therapies2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-expands-global-ip-protection-australian-patent2026-02-09T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-completes-combination-bd-biosciences-diagnostic-solutions2026-02-09T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-biosciences-diagnostic-solutions-spin-off2026-02-09T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-acquisition-generation-bio2026-02-09T14:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-phase-3-sigma-trial-safusidenib2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-completes-combination-bd-biosciences-diagnostics2026-02-09T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-planned-departure-cfo-key-milestones2026-02-09T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-conference-call-rezolve-ad-results2026-02-09T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-regulatory-update-rgx-121-mps-ii2026-02-09T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-nyse-american-non-compliance-notice2026-02-09T22:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-full-year-2025-growth-acceleration2026-02-10T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-reappoints-ceo-roy-jakobs2026-02-10T05:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-board-appointment2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-mako-handheld-robotics-release2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-closes-acquisition-generation-bio2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-eb103-tandem-meetings-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-fda-accepts-oveporexton-narcolepsy-nt12026-02-10T08:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLP/simulations-plus-extensions-fda-niehs-collaborations2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-conference-call-february-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-closes-public-offering-usd57-2-million2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMTM/amentum-reports-q1-fy2026-results-guidance2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-barclays-healthcare-conference-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MEDP/medpace-holdings-reports-q4-full-year-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-conference-call-q4-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-fiscal-q1-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-investor-meetings-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-guggenheim-summit-participation2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-frontier-space-partnership-life-sciences-research2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-q4-2025-results-investor-conferences2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-closes-initial-public-offering2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-ipo-closing2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-fourth-quarter-2025-earnings-call2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-fourth-quarter-2025-financial-results-earnings-call2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-new-data-aacr-io-biomarkers-bot-bal2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-launches-unity-fetal-antigen-nipts2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-appoints-dr-ben-porter-brown-cmo2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-expanding-immunology-portfolio-aaaaai-20262026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-conference-call-fy2025-results2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-report-fourth-quarter-full-year-2025-results2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotoos-q4-2025-results-announcement2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-110-million-offering2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-clinical-data-aaaaai-20262026-02-10T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-oveporexton-fda-priority-review-narcolepsy2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-google-cloud-ai-agents-chemistry2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-mbl-distributor-nuq-discover-japan2026-02-10T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-patent-reqorsa-gene-therapy-cancer2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-gdnf-results-semaglutide-comparison2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezolve-ad-maintenance-data-rezpegaldesleukin2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-hba1c-analyser-ifcc-gold-classification2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-showcase-neffy-aaaaai-20262026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-phase-1-sep-631-aaaa-meeting-20262026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-establishes-renovocath-medical-advisory-board2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-report-fourth-quarter-full-year-2025-results2026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-launch-orquick-hiv-self-test-canada2026-02-10T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-appoints-flavio-mantelli-cmo2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-appoints-david-sandoval2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-fda-clearance-teverelix-phase-2b-study2026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-vincent-capone-ceo-appointment2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-fourth-quarter-2025-results2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-record-financial-results-20252026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-cordstrom-uk-marketing-authorization2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q4-2025-results-outlook-20262026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-ceo-pete-oheeron-hspan-summit-20262026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-portfolio-update-rain-token-kraken2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-transition-securities-exchange-act2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-report-fourth-quarter-full-year-2025-results2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-summit-posters-2026-aaaai2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-completes-patient-enrollment-bRTX-1002026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-fda-submission-amended-trial-protocol2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-presents-glioblastoma-summit-20262026-02-10T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-fourth-quarter-full-year-2025-results2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q4-2025-financial-results2026-02-10T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-govramp-tx-ramp-certifications2026-02-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-webinar-als-drug-development2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-launches-library-preparation-kits2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-report-q4-2025-results2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-duke-collaboration-obesity-research2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-q4-2025-financial-results-announcement2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-phase-2a-evo301-atopic-dermatitis-results2026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-edp-978-presentation-2026-aaaai2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-participate-upcoming-investor-conferences2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-fourth-quarter-full-year-2025-results2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-participate-guggenheim-biotech-summit-20262026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-fda-pre-submission-helix-catheter2026-02-10T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-achieves-second-who-inn-milestone2026-02-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-aprevo-lumbar-fusion-procedure2026-02-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WW/weight-watchers-pvolve-partnership-strength-workouts2026-02-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDXS/codexis-achieves-iso-9001-certification2026-02-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-preclinical-data-soteria-trial2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-receives-12-2-million-new-jersey-nols2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-chairmans-letter-20262026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-michael-cola-ceo2026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-fourth-quarter-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-financial-results-march-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QSI/quantum-si-fourth-quarter-2025-financial-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-duke-collaboration-clinical-research-obesity2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOYG/starlab-auxilium-biotechnologies-microgravity-research2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-evo301-phase-2a-results-atopic-dermatitis2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-edp-978-aaaai-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ON/astrazeneca-results-fy-q4-20252026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-q4-full-year-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-participate-guggenheim-securities-biotech-summit-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-regains-nasdaq-compliance2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-q4-2025-financial-results-guidance-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopervision-launches-misight-1-day-japan2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-long-term-agreement-mexico2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-fourth-quarter-full-year-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-dividend-increase-share-repurchase-authorization2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-warrant-inducement-transaction-3-4-million2026-02-10T18:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-tender-offers-debt-securities2026-02-10T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-fourth-quarter-full-year-2025-results2026-02-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-q4-2025-financial-results2026-02-10T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-proposed-public-offering2026-02-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-report-financial-results-february-20262026-02-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-february-20262026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-private-placement-15-million2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-pricing-public-offering-275-million2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-fourth-quarter-fiscal-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-increases-dividend-20262026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-webcast-phase-2-valiant-trial-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-refusal-to-file-fda-mrna-10102026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-vitesse-phase-3-study-presentation2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-preliminary-financial-results-q4-20252026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-q3-2026-financial-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-public-offering-common-preferred-stock2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-european-summit-20262026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-report-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-inducement-grant-nasdaq-rule-56352026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-regulatory-approval-upstream-manufacturing2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-presentation-glioblastoma-summit-20262026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-q4-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/boston-life-sciences-job-openings2026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-expands-mash-pipeline-licensing-agreement2026-02-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/seismic-consortium-secures-ih-grant-minimally-invasive-brain-treatments2026-02-11T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-2025-accomplishments-2026-outlook2026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q4-2025-financial-results-earnings-call2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-leadership-changes-20262026-02-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-shero-imaging-breast-cancer-cryoablation-missouri2026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-expands-lymphir-distribution-europe2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-fourth-quarter-2025-results2026-02-11T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-2026-q1-results-clinical-progress2026-02-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-valiant-trial-results2026-02-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-strategic-plan-dual-targeting-car-t-assets2026-02-11T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-phase-1-trial-senti-202-aml2026-02-11T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-q4-2025-results-call2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q4-2025-results2026-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-meeting-request-crl-response2026-02-11T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-2025-financial-results2026-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/fda-refuses-review-moderna-mrna-flu-vaccine2026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-investor-conferences-20262026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-announces-26-million-registered-direct-offering2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-proactive-disciplined-deals-ma-not-urgent2026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-fourth-quarter-2025-financial-results2026-02-11T12:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-healthy-extracts-partnership-gel-nutrition2026-02-11T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-board-members-stock-purchases2026-02-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/telehealth-available-dare-to-play-sildenafil-cream2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-glioblastoma-summit-20262026-02-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-positive-fda-outcome-btx-1002026-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-fda-filing-ameluz-sbcc2026-02-11T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-new-hae-data-aaai-20262026-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-fourth-quarter-full-year-2025-results-conference-call2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-expands-adc-pipeline2026-02-11T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-20262026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/astrazeneca-awards-3-4-million-healthcare-access2026-02-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q4-2025-results-announcement2026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-first-patient-dosed-stk-002-phase-12026-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-fourth-quarter-2025-financial-results-webcast2026-02-11T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-fda-clearance-pbgene-dmd2026-02-11T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q4-2025-results-webcast2026-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-orphan-drug-status-vt-19532026-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-approval-ovarian-cancer-treatment2026-02-11T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-fda-approval-pd-l1-ihc-22c3-pharmdx-eoc2026-02-11T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-fourth-quarter-full-year-2025-results2026-02-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-settlement-shareholder-litigation2026-02-11T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-patent-issuance-invocell-device2026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-novel-serotonergic-agonists-20262026-02-11T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-names-michael-cola-ceo-growth2026-02-11T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-ceo-and-advances-clinical-trials2026-02-11T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-ceo-appointment-michael-cola2026-02-11T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-antibody-drug-conjugate-data-sot-meeting2026-02-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-redeems-preferred-stock-cancels-shares2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-heartways-program-chap-certification2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-unite2fight-paralysis-symposium-20262026-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-upsized-public-offering-78-million2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-boehringer-ingelheim-impact-award2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-21-million-private-placement2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-launches-fda-cleared-blood-test-alzheimers2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-transition-atm-equity-offering-leerink-partners2026-02-11T15:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/biopharma-job-market-layoff-decline-20262026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-fourth-quarter-2025-earnings-announcement2026-02-11T14:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-increases-share-capital2026-02-11T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-flu-vaccine-rejection-fda2026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-q3-fy2026-results2026-02-11T18:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q4-2025-financial-results2026-02-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q4-2025-financial-results2026-02-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-upsized-public-offering2026-02-12T03:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-fourth-quarter-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-q4-2025-financial-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q4-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bridgebio-oncology-inducement-grants-nasdaq-rule-56352026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-3-phase-3-trial-vax-312026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-investor-conference-presentations-february-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q4-2025-results-update2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-q3-2026-financial-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/astrazeneca-health-equity-funding-20232026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-announces-pricing-public-offering2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-underwritten-offering-pricing2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/fda-approves-novocure-optune-pax-pancreatic-cancer2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-lokahi-fda-type-c-meeting-lt-100-apitox2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-inducement-awards-february-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-investor-conferences-march-april-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-conference-call-fy-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-fourth-quarter-year-end-results-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/high-survival-rates-ryoncil-eind-program-sr-agvhd2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-board-chair-transition-freire-dorsa2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q4-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-fourth-quarter-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-fourth-quarter-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-virtual-kol-event-tx2100-hht2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-fourth-quarter-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-fourth-quarter-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-phase-1-trial-an90252026-02-12T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/divitum-tka-prognostic-associations-breast-cancer2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fourth-quarter-2025-earnings-call2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-oppenheimer-conference-20262026-02-12T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-q4-2025-results2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-signs-supply-agreement-qkine2026-02-12T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-appoints-michele-holcomb-board-directors2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-us-notice-allowance-exon-skipping-therapy2026-02-12T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-uplizna-approval-generalized-myasthenia-gravis2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-grant-inducement-awards-nasdaq-listing-rules2026-02-12T12:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-joins-ihope-initiative-genomic-sequencing2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-q4-full-year-2025-results2026-02-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-redtail-platform-aacr-io-20262026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-scientific-investor-conferences2026-02-12T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-progress-upcoming-milestones-20262026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-fourth-quarter-full-year-2025-results2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-appoints-chris-chapman-cco2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-investor-conferences-20262026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-q4-2025-financial-results-release2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-mount-logan-award-tulsa-procedure2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-nopain-act-survey-data2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-acquires-realbotix-ai-humanoid-robotics2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/hhs-backs-prasad-moderna-flu-shot-blowback2026-02-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-corporate-updates-inflammatory-immune-diseases2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-endovascular-robotic-system-iest2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-phase-3-car-t-cell-trial-lyl3142026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-report-fourth-quarter-full-year-2025-results2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-fda-alignment-phase-2b-3-xpro1595-alzheimers2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-third-quarter-2026-update2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-appoints-david-horn-board-directors2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q4-2025-financial-results-call2026-02-12T14:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/digital-pathology-ai-her2-cancer-treatment2026-02-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-appoints-lucinda-warren-cfbo2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2025-earnings-conference-call2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-oppenheimer-conference-20262026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-report-q4-full-year-2025-results2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-igalmi-market-assessment2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-q2-2026-results-update2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-abstracts-accepted-american-college-psychiatrists2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-positive-phase-3-results-infigratinib-achondroplasia2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-randy-teel-ceo2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-global-patent-portfolio-expansion2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-dsmb-approval-phase-3-trial-buntanetap-alzheimers2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-virtual-investor-closing-bell-event2026-02-12T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-full-year-2025-results2026-02-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-new-subsidiary-ardia2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-leadership-appointments2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-fourth-quarter-full-year-2025-results2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-earnings-call-february-20262026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-q4-2025-results2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-acquires-avadel-pharmaceuticals-sleep-medicine2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-reports-fourth-quarter-results-20252026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-management-investor-conferences2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-fourth-quarter-2025-results2026-02-12T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-allohome-ai-powered-ngs-surveillance-aml-mds2026-02-12T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-full-year-2025-results2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-ekterly-data-2026-aaai-meeting2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-reports-fourth-quarter-full-year-2025-results2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-advances-bladder-kidney-cancers-asco-20262026-02-12T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-great-place-to-work-fourth-year2026-02-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-record-bookings-2025-subscription-transition2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-inkspace-imaging-snuggle-pediatric-mri-coil2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-successful-heart-transplant-ucsf2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-phase-ii-trial-results-mcs-82026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-reports-record-revenue-growth2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-expands-gamefilm-registry-nba-nhl-alumni2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-q4-2025-financial-results-report2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-secures-financing-accelerate-growth2026-02-12T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-expands-uk-pharmaceutical-access-smartway-agreement2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-report-q4-full-year-2025-results2026-02-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-fourth-quarter-full-year-2025-results2026-02-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-announces-q4-2025-financial-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNVC/mpox-orphan-drug-designation-nv-387-nanoviricides2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-patent-sublingual-ondansetron2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-pantracer-pro-solid-tumor-therapy2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-update-2025-earnings-investigation2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INM/inmed-reports-q2-fiscal-2026-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-fourth-quarter-2025-earnings-call2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-reports-q4-full-year-results-20252026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-investor-conferences-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-ekterly-presentation-2026-aaai-meeting2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-allohome-ai-ngs-surveillance-aml-mds2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-advances-bladder-kidney-cancer-treatment-asco-gu-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-flu-vaccine-rejection-breakeven-plans2026-02-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-withdraws-translarna-nda2026-02-12T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-fourth-quarter-full-year-2025-results2026-02-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-uplizna-approval-myasthenia-gravis2026-02-12T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-closes-private-offering-senior-notes2026-02-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-q3-2026-results-update2026-02-12T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-present-march-2026-investor-conferences2026-02-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-fda-clearance-stealth-axis-surgical-system2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/ollie-bearman-joins-prenetics-im8-health2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-private-placement-commercial-stage2026-02-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-reports-first-revenue-from-lymphir2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-td-cowen-health-care-conference-20262026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-q3-2026-results-corporate-update2026-02-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-investor-conferences-20262026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-kidney-franchise-journavx-sales2026-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-private-placement-funding2026-02-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-wy-biotech-trimmune-financing2026-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-fourth-quarter-full-year-2025-results2026-02-13T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-chi-mei-feasibility-study-apercus2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-inducement-grants-nasdaq-rule-56352026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-launches-ceo-corner-platform2026-02-13T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-mayo-clinic-oxygen-monitoring-collaboration2026-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-expands-puerto-rico-water-filtration-solutions2026-02-13T13:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-closes-15-million-private-placement2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-q3-2026-financial-results2026-02-13T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-new-board-member-phillip-balatsos2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/breztri-phase-iii-trials-asthma-results2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXT/sensient-technologies-q4-2025-results2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-fourth-quarter-fiscal-year-2025-results2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALK/alk-annual-report-presentation-20252026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reverse-stock-split2026-02-13T13:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-fourth-quarter-fiscal-year-2025-results2026-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-global-patent-protection-da-17262026-02-13T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-board-of-directors-updates2026-02-13T14:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-uplizna-amgen-gmg-treatment2026-02-13T14:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-investor-webinar-20262026-02-13T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-q2-fiscal-year-2026-conference-call2026-02-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-first-digital-asset-treasury-borrowing2026-02-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-phase-2-study-alto-101-enrollment-completed2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-citi-2026-oncology-summit2026-02-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-uplizna-approval-europe-generalized-mg2026-02-13T19:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-closes-460-million-offering2026-02-13T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-ella-platform-ce-ivd-marking2026-02-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-retevmo-event-free-survival-lung-cancer2026-02-16T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-discuss-2025-results-march-20262026-02-16T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-mrna-flu-shot-efficacy-wait2026-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-phase-3-trials-data-release2026-02-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-participate-td-cowen-health-care-conference2026-02-16T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-q4-2025-financial-results2026-02-16T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-oppenheimer-conference-20262026-02-17T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-appoints-katie-kazem-chief-legal-officer2026-02-17T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-preliminary-2025-fiscal-results2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-full-year-2025-results-guidance-march-20262026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-phase-1-study-janx0112026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-bispecific-antibody-licensing-agreement2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-financial-results-q4-20252026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-participate-investor-conferences2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/fda-accepts-iberdomide-application-bmy2026-02-17T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-braftovi-regimen-improves-survival-colorectal-cancer2026-02-17T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-comp360-phase-3-trial-success2026-02-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-fourth-quarter-2025-earnings-call2026-02-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-regulatory-engagement-saudia-arabia2026-02-17T11:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-fireside-chat-leerink-conference2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-investor-conferences2026-02-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-expands-global-ip-estate2026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-q1-2026-results-update2026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-report-q4-2025-results2026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-nasal-epinephrine-powder-aaai-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-oppenheimer-conference-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-pociredir-sickle-cell-trial-data2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-oppenheimer-conference-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-closes-12-million-private-placement2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q4-2025-financial-results-update2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-preclinical-data-cue-4012026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-upcoming-investor-conferences2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q4-2025-results-call2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-kol-event-vonaprument-geographic-atrophy2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-2025-financial-results2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-sale-insighta-tencent-70-million2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-fourth-quarter-full-year-2025-results-call2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-rewalk-exoskeleton-aetna-coverage-expansion2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/vtak-acquires-strategic-stake-flyte2026-02-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-private-placement-strategic-update2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/briumvi-long-term-efficacy-relapsing-ms2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-spl026-phase-2a-trial-results2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-fourth-quarter-full-year-2025-results2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-european-commission-approval-myorzo2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-centurion-one-capital-conference-20262026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/brainsway-change-ads-ratio2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-fourth-quarter-2025-earnings-release2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-launches-spinach-pufferz-vape2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-td-cowen-conference-20262026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-oppenheimer-conference-20262026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-proliant-launch-recombinant-human-albumin2026-02-17T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-great-place-to-work-certification-20262026-02-17T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-dcat-week-20262026-02-17T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-oppenheimer-conference-20262026-02-17T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-obesity-breakthrough2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-positive-results-sol-1-trial2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-participate-investor-conferences-march-20262026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-elevate-44-201-study-dose-escalation2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-path-new-drug-application-nrx-1002026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-cyc-126-phase-2-study-update2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-launches-pharmapack-kits2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-settles-sunosi-patent-litigation2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-fourth-quarter-full-year-2025-results-webcast2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-present-upcoming-investor-conference2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q4-2025-results2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-expands-executive-team-appointments2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-investor-conferences-20262026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-symon-ii-study-enrollment-20262026-02-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-fourth-quarter-2025-financial-results-call2026-02-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-q4-2025-results-business-update2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/duvakitug-phase-2b-maintenance-results-uc-cd2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-barda-expansion-ai-ultrasound2026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-fourth-quarter-full-year-results-20252026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-successful-primate-study-oncotox-aml2026-02-17T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-investor-call-february-20262026-02-17T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-hiv-treatment-prevention-data-croi-20262026-02-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-td-cowen-conference-20262026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-fda-approval-wakix-pediatric-narcolepsy2026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-total30-multifocal-toric-lens2026-02-17T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-acquired-by-danaher-for-180-per-share2026-02-17T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-fourth-quarter-full-year-2025-results2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/clinical-utility-bioaffinity-technologies-cypath-lung-test2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/viiv-healthcare-hiv-innovation-croi-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-investor-conferences-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-positive-data-rlyb116-phase-1-study2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/scribe-therapeutics-lilly-collaboration-milestone2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-participate-investor-conferences-20262026-02-17T14:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-phase-1-database-lock-ameluz2026-02-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-shareholder-meeting-results2026-02-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-ceo-marc-hertz-virtual-investor-segment2026-02-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-oppenheimer-conference-20262026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-brian-piper-appointment-cfo2026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDXS/codexis-td-cowen-health-care-conference-20262026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LITS/lite-strategy-fiscal-2026-q2-results2026-02-17T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-bram-verstockt-clinical-advisory-board2026-02-17T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-public-offering-pricing2026-02-17T13:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-japanese-patent-annamycin2026-02-17T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-selects-cro-soteria-phase-2-trial2026-02-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-key-executive-appointments2026-02-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-308-nm-excimer-laser-psoriasis2026-02-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-arc-ecr-2026-showcase-ai-capabilities2026-02-17T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/danaher-acquire-masimo-corporation2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approves-rybrevant-faspro-monthly-dosing2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-next-gen-microflow-lc-columns2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-td-cowen-conference-20262026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-sublingual-meclizine-patent2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGC/igc-pharma-secures-composition-protection-igc-ad12026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-investor-conferences-march-20262026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-dr-robert-redfield-advisor2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-q4-full-year-2025-financial-results2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-tumor-cell-mortality-tnbc2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-appoints-key-executives-strategic-transformation2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-q2-fy2026-results-corporate-update2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-participation-investor-conferences-20262026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-q3-fiscal-2026-results2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-2025-fourth-quarter-results2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-ucsf-collaboration-nktr-0165-ms2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-eu-authorization-mnexspike-vaccine2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-leerink-partners-conference-20262026-02-18T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-follow-on-offering-pricing2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-fourth-quarter-2025-call2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-150-million-public-offering2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-fourth-quarter-2025-results2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-oppenheimer-conference-participation2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/fda-expands-evo-icl-age-indication2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-td-cowen-healthcare-conference-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q4-fy2025-results-update2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-fourth-quarter-financial-results-20252026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-participate-td-cowen-health-care-conference2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-inducement-grants-nasdaq-listing-rule-56352026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-report-fourth-quarter-full-year-2025-results2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-financial-results-webcast-time-change2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-presents-td-cowen-health-care-conference-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-submits-european-marketing-authorization-tlx101-px2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-share-repurchase-program2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-financial-results-business-update-march-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-closing-private-placement-financing2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-first-patient-phase-2-givastomig-gastric-cancer2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-investor-conferences-february-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-leerink-2026-conference2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-q4-2025-financial-results-guidance-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-investor-day-march-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-public-offering-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-share-buy-back-program-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-phase-1a-results-zp98302026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-investor-conferences-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presentation-leerink-conference-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-licenses-syn-020-rasayana-therapeutics2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-citizens-life-sciences-conference-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-appoints-sidney-braun-ceo-liora2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-inducement-grants-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-investor-conferences-20262026-02-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-ascend-phase-1-2-trial-cr-0012026-02-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-participation-barclays-global-healthcare-conference2026-02-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-carlsberg-exclusive-brewing-partnership2026-02-18T12:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-conference-call-march-20262026-02-18T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-2025-financial-results-update2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-citi-2026-oncology-summit2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-oppenheimer-conference-20262026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-report-fourth-quarter-2025-results2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-appoints-dr-greenhawt-cmo2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-q4-2025-results-investor-conferences2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-announces-reverse-stock-split2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-report-fourth-quarter-year-end-2025-results2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-appoints-michael-campbell-cco2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-fourth-quarter-2025-financial-results-call2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-experts-als-platform2026-02-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-participate-march-2026-investor-conferences2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-oppenheimer-conference-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-executive-appointments2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-pbgene-dmd-presentation-mda-conference2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-virtual-kol-event-sat-3247-dmd2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-fourth-quarter-full-year-2025-results2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q4-2025-results-guidance-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-positive-fda-meetings-ta-ert-sanfilippo2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-ekterly-first-line-therapy-pediatric-hae2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-mayo-clinic-ai-drug-discovery-collaboration2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPO/enpro-reports-fourth-quarter-full-year-2025-results2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-fda-review-influenza-vaccine2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVM/celsci-fiscal-first-quarter-2026-results2026-02-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-positive-preclinical-results-uveitis2026-02-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-authorization-europe-bladder-cancer2026-02-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-reports-q4-2025-financial-results2026-02-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-financial-services-launch2026-02-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-us-patent-zunveyl-dosing-regimens2026-02-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-acquires-faeth-therapeutics2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-arexvy-rsv-risk-reduction-study2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-investor-conferences2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-td-cowen-health-care-conference2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-investor-conferences2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-raymond-james-conference-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q4-fy-2025-results-im8-revenue-growth2026-02-18T14:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-biocom-conference-20262026-02-18T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-fourth-quarter-full-year-2025-results2026-02-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-corporate-update-half-year-results2026-02-18T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-20252026-02-18T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-appoints-david-pyott-board2026-02-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-notice-allowance-japan-spc-152026-02-18T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-miracle-trial-preliminary-results2026-02-18T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/vietnam-approves-biomericas-ez-detect-nationwide-distribution2026-02-18T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/johns-hopkins-dermatology-xtrac-laser2026-02-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-phase-2-trial-sclc2026-02-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/pluri-china-patent-immune-cell-expansion2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-great-place-to-work-certification-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-oppenheimer-conference-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-investor-conferences2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-apr-1051-clinical-activity-update2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-ecco-congress-spy003-presentations2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-participate-upcoming-conferences2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-special-stock-dividend2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-barda-discussions-entolimod-march-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-inducement-grants-nasdaq-rule-56352026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q4-2025-results-call2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-patent-expansion2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-oppenheimer-conference-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-patent-claims-australia2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-fda-breakthrough-designation-head-neck-cancer2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/fluo-guide-webcast-february-20262026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-phase-ii-beam-x-trial-bexmarilimab-aml2026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-q4-fy2025-results-march-20262026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-financial-results-20252026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-2025-revenue-outlook-20262026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-licenses-phase-1-drug-candidate-otsuka-gist2026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-upcoming-conferences-march-20262026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-fy-2025-results2026-02-20T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-venclexta-acalabrutinib-combination-cll2026-02-20T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-prefunded-warrants-exercised2026-02-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-leerink-partners-conference-20262026-02-20T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALK/henriette-mersebach-steps-down-alk-rd2026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-public-offering-pricing2026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-participate-oppenheimer-td-cowen-conferences2026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-reverse-share-split2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-redtail-platform-bites-aacr-io-20262026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/high-dose-inhaled-nitric-oxide-antimicrobial-therapy2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-phase-3-versatile-003-trial-amendment2026-02-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-20262026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-pedmark-head-neck-cancers2026-02-20T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-data-2026-aaaai2026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-fourth-quarter-full-year-2025-results2026-02-20T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-td-cowen-health-care-conference2026-02-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-launches-anktiva-saudi-arabia2026-02-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-pricing-public-offering2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-participate-upcoming-investor-conferences2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-td-cowen-conference-20262026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-presentation-td-cowen-conference2026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/calquence-venetoclax-approval-chronic-lymphocytic-leukemia2026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-cell-gene-live-event-20262026-02-20T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/2020-biolabs-virtual-investor-webinar-february-20262026-02-20T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-acquires-strategic-stake-in-sarborg2026-02-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-nyse-warning-letter2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-investor-conferences-20262026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-virtual-investor-day-march-20262026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-compliance-nasdaq-requirements2026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-fourth-quarter-earnings-conference-call2026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-share-transactions-managerial-employees2026-02-20T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-virtual-investor-closing-bell2026-02-20T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-opendoor-ownership-increase2026-02-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-participate-upcoming-investor-conferences-february-20262026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALK/annual-general-meeting-alk-abello-20262026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-409th-consecutive-quarterly-dividend2026-02-20T16:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-fda-approval-bysanti-milsaperidone2026-02-20T22:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-ecco-20262026-02-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-ulcerative-colitis-long-term-data2026-02-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/sickle-cell-gene-therapies-casgevy-lyfgenia-traction2026-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presentation-td-cowen-healthcare-conference2026-02-23T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquires-arcellx-anito-cel-potential2026-02-23T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-biocidal-product-approvals2026-02-23T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-bexmarilimab-poster-presentation-bsh-20262026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-dr-theodora-ross-cdo2026-02-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-amended-healthcare-royalty-agreement2026-02-23T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-appoints-ryan-maynard-cfo2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-patents-reqorsa-gene-therapy-cancer2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-fda-qidp-designation-ap-sa022026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-testing-capabilities-diagnostic-accuracy2026-02-23T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-participate-upcoming-investor-conferences2026-02-23T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-quantum-leap-energy-necsa-collaboration2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-launches-bioflex-3d-bioprinting-kit2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-board-directors-election2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-emerging-growth-conference-20262026-02-23T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-participate-46th-annual-td-cowen-health-care-conference2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-td-cowen-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-q4-2025-financial-results2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-conference-call-q4-2025-results2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-conference-call-webcast-2025-results2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-march-investor-conferences2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-investor-conferences-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-investor-conferences-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-2025-financial-results-announcement2026-02-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-oppenheimer-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-oppenheimer-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-investor-conferences-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-sol-1-data-macula-society-meeting2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-march-investor-conferences2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-investor-conferences-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-fda-clearance-ind-phase-2-dare-hpv2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-presentations-aaaai-20262026-02-23T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-td-cowen-health-care-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-participate-march-conferences2026-02-23T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-phase-2-momentum-trial-cemsidomide2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-bb-301-abstract-acceptance2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-webcast-financial-results-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-investor-webinar-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-participate-march-investor-conferences2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q4-2025-results-update2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-dr-paeger-board-directors2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-presents-at-healthcare-investor-conferences2026-02-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-participate-upcoming-investor-conferences2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-oppenheimer-conference-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-td-cowen-conference-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-american-heart-month-prioritize-therapies-cvd2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-croi-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-seralutinib-phase-3-prosera-results2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-business-update2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-licenses-miudella-hormone-free-iud2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-refinance-senior-secured-debt2026-02-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-agbt-2026-spatial-biology-advancements2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-td-cowen-conference-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-700-percent-revenue-growth-anktiva2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-investor-conferences-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-advances-functional-proteomics-timsomni-mass-spectrometry2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-phase-2-luspatercept-results2026-02-23T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-evolves-human-health-structure2026-02-23T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-appoints-dr-eisner-dr-nirula-board2026-02-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-oppenheimer-conference-20262026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-compuflo-advisor-program-launch2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-participation-world-adc-summit2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-nasdaq-extension-compliance2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYOJ/ryojbaba-participation-guardian-girls-aikido-project2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-governance-restructuring2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-fda-acceptance-dtx401-gsdia2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-sells-prv-205-million2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-investor-conferences-20262026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-fda-policy-reduction-trial-burden2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-investor-conferences-20262026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-congressional-support-deep-brain-neurostimulation2026-02-23T13:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-leerink-partners-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/syncardia-total-artificial-heart-training-houston2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-fourth-quarter-2025-financial-results2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-present-march-investor-conferences2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-adjourn-special-meeting-stockholders2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-preclinical-testing-rig-i-immunotherapy2026-02-23T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/zepbound-tirzepatide-multi-dose-kwikpen-available2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-dr-conejo-garcia-keynote-sctr-retreat2026-02-23T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-novaseq-x-advancements-data-quality-output2026-02-23T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-launches-im8-daily-ultimate-essentials-pro2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-highres-lightning-talk-nvidia-gtc2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ice-secret-trial-results2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-pali-2108-ecco-20262026-02-23T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-amends-financing-agreement2026-02-23T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-webinar-xpro1595-alzheimers-strategy2026-02-23T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquires-arcellx-car-t-therapy2026-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-prv-sale2026-02-23T14:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-investor-conferences-march-20262026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-investor-conferences-20262026-02-23T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-olga-anczukow-sab2026-02-23T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-phase-2-trial-ampligen-durvalumab2026-02-23T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-td-cowen-health-care-conference2026-02-23T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-webcast-healthcare-conference-20262026-02-23T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-fda-approval-smart-capsule2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-investor-conferences2026-02-23T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-reimbursement-milestone-ama-cpt-code2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAT/j-star-exclusive-distribution-agreement-pssb2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-pacific-backbone-infrastructure2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-ama-cpt-code-femaseed-intratubal-insemination2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-reports-q4-2025-results-guidance-20262026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-td-cowen-health-care-conference2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/avenue-therapeutics-exclusive-license-atx-04-pompe-disease2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-scientific-industry-events2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-march-2026-investor-conferences2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-neo-conference-20242026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-announces-quarterly-dividend-20262026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-expands-collaboration-pathai-digital-pathology2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-invest-380-million-north-chicago-manufacturing2026-02-23T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-td-cowen-health-care-conference2026-02-23T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-presents-barclays-global-healthcare-conference-20262026-02-23T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-reports-fourth-quarter-full-year-2025-results2026-02-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-abstracts-aacr-annual-meeting-20262026-02-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/successful-readout-sinergy-trial-signatera-mrd-treatment2026-02-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-participate-investor-conferences2026-02-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-corporate-update-q4-2025-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-1-results-vir-5500-prostate-cancer2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-casdatifan-hif-2a-inhibitor-kidney-cancer-data2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-presentation-leerink-partners-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-td-cowen-conference-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-dr-soon-shiong-milken-summit-cancer-20352026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-presents-td-cowen-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-participate-td-cowen-health-care-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-financial-results-q4-20252026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-fourth-quarter-2025-earnings-call2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-investor-conferences-march-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-participate-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-pauses-enrollment-linnet-trial2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-conference-call-selva-trial-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/tara-002-complete-response-rate-bladder-cancer2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-fg-3246-enzalutamide-asco-gu-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-investor-conferences-march-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-inducement-grant-nasdaq-rule-56352026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-si-bone-distribution-agreement2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-fda-clearance-nexsys-pcs-persona-plus2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-full-year-2025-financial-results-update2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-oppenheimer-conference-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-francois-nader-appointment2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-participate-2026-canaccord-genuity-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-updated-earnings-call-dates2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-q4-full-year-2025-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-report-fourth-quarter-full-year-2025-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-q4-2025-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q4-2025-financial-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-presentation-td-cowen-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-investor-conferences-march-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-reports-record-financial-results-q4-20252026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-march-investor-conferences2026-02-24T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-investor-conferences-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-td-cowen-health-care-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-q4-2025-results2026-02-24T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-investor-conferences-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-investor-conferences-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-presents-bio-investment-growth-summit2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-investor-conferences-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-revenue-growth-2026-outlook2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-q4-2025-results-and-2026-guidance2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-positive-results-phase-3-selva-study-qtorin-rapamycin2026-02-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-march-investor-conferences2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-halo-clarity-trial-fda-submission-insomnia2026-02-24T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-investor-conferences-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-voyager-platform-launch-us-hupo-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-presentation-ddw-20262026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-expert-dtx-launch-accelerate-discovery2026-02-24T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-td-cowen-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-fda-breakthrough-designation-nomlabofusp2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q4-2025-results2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-march-investor-conferences2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-td-cowen-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q4-2025-results2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-covid-19-antibody-protection-study2026-02-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q4-fy25-results-updates2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-positive-results-til-cell-therapy-sarcomas2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-present-td-cowen-health-care-conference2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-updated-clinical-data-mrt-2359-enzalutamide2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-business-highlights-financial-results-20252026-02-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-phase-1b-pioneer-trial-results2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-fourth-quarter-full-year-2025-results2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-us-patent-pan-kras-inhibitor-eras-40012026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-outpatient-bva-diagnostic-program-tennessee2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-td-cowen-conference-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-stockholder-letter-cnmau8-2026-catalysts2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-td-cowen-conference-20262026-02-24T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-td-cowen-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q4-2025-results-and-update2026-02-24T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-report-fourth-quarter-full-year-2025-results2026-02-24T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-advancements-in-hemato-malignancies2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-clarity-phase-3-trial-solriamfetol2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-fourth-quarter-full-year-2025-results2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-at-587-hepatitis-e-croi-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-q4-2025-results-corporate-update2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-thad-huston-cfo-appointment2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-business-update-clinical-progress2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q4-2025-results-conference-call2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-lpga-partnership-digestive-health2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-q4-2025-results2026-02-24T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-march-conferences2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-td-cowen-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-investor-conferences-20262026-02-24T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-phase-1b-trial-ati-052-asthma2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-phase-1-trial-nlrp3-inhibitor2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-raymond-james-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-q4-2025-results-2026-guidance2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/livechain-acquires-humanyze-ai-hr-analytics2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-participate-citizens-life-sciences-conference2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-leadership-transition-growth2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-2025-financial-results2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-march-2026-events2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZOM/diality-appoints-peter-donato-cfo2026-02-24T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-investor-conferences2026-02-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNBX/bnb-plus-corp-new-orders-lineadna-genetic-medicine2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/ttfields-therapy-coverage-bc-cancer2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-investor-conferences-march2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-q4-2025-results-and-2026-guidance2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-upcoming-presentations-mda-conference-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-noetik-collaboration-tissue-models2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-td-cowen-46th-annual-health-care-conference2026-02-24T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-td-cowen-healthcare-conference-20262026-02-24T11:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-strategic-progress-diversification-fuels-success2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-investor-conferences-20262026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/tampa-general-hospital-adopts-liberty-robotic-system2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-phase-2-results-cad-1005-hit2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-global-protection-thermostem2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-patent-notice-allowance-feeding-tube2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-sarborg-expansion-bacteria-agrochemicals2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-barclays-healthcare-conference-20262026-02-24T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGPU/axe-compute-explores-strategic-options-helomics-business2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-fda-fast-track-aky-11892026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-board-appointments2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-freda-lewis-hall2026-02-24T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/treace-new-product-innovations-acfas-20262026-02-24T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-participate-upcoming-investor-conferences2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-financial-results-20252026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/acd440-orphan-drug-status-eu2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VMD/viemed-healthcare-year-end-2025-earnings-call2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-fda-approval-ipratropium-bromide-hfa2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-participate-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-md-anderson-clinical-trial-atr-042026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-present-march-2026-investor-conferences2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/minimed-launches-ipo-roadshow2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-dnastack-global-federated-hifi-dataset2026-02-24T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-participate-investor-conferences-march2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-registration-programs-scac-crc2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q4-2025-results2026-02-24T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-presentation-td-cowen-conference2026-02-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-expands-us-operations-greenwood-indiana2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-2026-asco-gu-conference2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-3-ateganosine-nsclc2026-02-24T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-nosedives-late-stage-failure-pah-program-uncertainty2026-02-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-positive-results-phase-3-paridiprubart-study2026-02-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-japanese-marketing-approval-alphadart2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-mda-conference-20262026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/max-homa-arcutis-free-to-be-me-campaign2026-02-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-oppenheimer-conference-20262026-02-24T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-march-investor-conferences2026-02-24T14:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-exercises-warrants-3-million2026-02-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-launch-elevidys-japan2026-02-24T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-decipher-data-asco-gu-symposium-20262026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q4-2025-results-call2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-participate-bank-america-animal-health-summit2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-td-cowen-conference2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-exclusive-distribution-agreement-rmr-ortho2026-02-24T15:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approved-allergic-fungal-rhinosinusitis2026-02-24T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/dentsply-sirona-burkhart-dental-partnership-expansion2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XGN/exagen-announces-q4-2025-financial-results2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-risorius-eeg-digital-biomarkers-partnership2026-02-24T13:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-bouygues-uk-drug-testing2026-02-24T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-launches-synchfix-evt-syndesmotic-fixation2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-launches-ai-insights-breast-cancer-signature2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-trupath-genome-genomic-insight2026-02-24T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-td-cowen-health-care-conference2026-02-24T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-td-cowen-health-care-conference2026-02-24T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-fda-approval-imaavy-waiha-treatment2026-02-24T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-investor-conferences-march2026-02-24T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-investor-conferences-20262026-02-24T22:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-accelerates-ht-001-trial-enrollment2026-02-24T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-2025-financial-results-update2026-02-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-2025-financial-results-guidance2026-02-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-fourth-quarter-full-year-2025-results2026-02-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-investor-conferences-march-20262026-02-24T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-present-leerink-partners-healthcare-conference2026-02-25T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-prices-private-placement-convertible-notes2026-02-25T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/fluoguide-annual-report-fiscal-year-20252026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/fluoguide-q4-2025-report2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-pricing-public-offering2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-proposed-public-offering2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-q4-2025-results-update2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-full-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-march-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-td-cowen-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-reports-fourth-quarter-full-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-td-cowen-health-care-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-share-repurchase-program2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/fda-approves-pfizer-braftovi-colorectal-cancer2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-phase-2-results-business-update2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-new-board-members2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-investor-conferences-march-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-td-cowen-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-full-year-2025-financial-results-update2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-participate-raymond-james-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-fourth-quarter-2025-financial-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-td-cowen-health-care-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-q4-2025-results-and-2026-outlook2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-public-offering-common-stock2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-fourth-quarter-full-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-q4-2025-results-guidance-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-record-financial-results-20252026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-proposed-public-offering2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-q4-2025-results-business-update2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-td-cowen-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-investor-conferences-march-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-ser-252-parkinsons-trial2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-td-cowen-health-care-conference2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-march-2026-investor-conferences2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-march-2026-investor-conferences2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-strategic-alternatives2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-q4-full-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-fourth-quarter-fiscal-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q4-2025-results-announcement2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZVRA/transpire-bio-appoints-laduane-clifton-cfo2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-capital-increase-employee-warrant-exercise2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-hy26-results-strategic-reset2026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-q4-full-year-2025-results-2026-guidance2026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-inducement-grants-nasdaq-rule-56352026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-q4-2025-financial-results2026-02-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-reports-fourth-quarter-full-year-2025-results2026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-investor-conferences-march-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-launches-elevidys-gene-therapy-japan2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-phase-1-trial-ide0342026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-fda-acceptance-imsiidolimab-gpp2026-02-25T12:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-investor-conferences-20262026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/fda-accepts-viatris-snda-mr-141-presbyopia2026-02-25T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/joint-commercialization-redhill-talicia-launch2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-launches-talicia-promotion2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-early-tender-results-upsize-offer-cap2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-acquires-ai-powered-exoskeleton-for-stroke-recovery2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-conference-call-march-20262026-02-25T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-march-investor-conferences2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-redeem-1-trial-results-tpst-20032026-02-25T12:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-investor-conferences-march-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-nasal-foralumab-biomarker-data2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-td-cowen-conference-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-march-investor-conferences2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-new-cpt-code-reyobiq2026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-upcoming-investor-conferences2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-investor-conferences-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-investor-conferences-march-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-td-cowen-conference-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-fda-acceptance-phentolamine-presbyopia2026-02-25T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-investor-conferences-march2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-q4-2025-financial-results-update2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-td-cowen-conference-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-q4-2025-financial-results2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-fourth-quarter-full-year-2025-results2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-td-cowen-conference-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-investor-conferences-20262026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-financial-results-conference-call2026-02-25T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-phase-3-barzolvolimab-chronic-spontaneous-urticaria2026-02-25T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-ogm-impact-oncology-therapy2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-march-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-td-cowen-conference-20262026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-investor-conferences-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-td-cowen-conference-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-march-investor-conferences2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-q4-2025-financial-results2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-ceo-corner-publication-strategy2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-investor-dinner-mar-a-lago2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-leerink-partners-2026-healthcare-conference2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-investor-conferences-20262026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-yc-biotech-partnership-dual-core-regulatory-platform2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CURX/curanex-operational-update-regulatory-milestones2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-citizens-life-sciences-conference2026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-reports-fourth-quarter-full-year-2025-results2026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-inducement-grants-nasdaq-56352026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-participate-investor-conferences2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-expands-robotic-filling-platform-support2026-02-25T13:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-ceo-letter-shareholders-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-participate-canaccord-genuity-conference2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-commercial-momentum-multi-pillar-execution2026-02-25T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launch-minimed-go-smart-mdi-system2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-multiomics-cancer-breakthroughs2026-02-25T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-secures-financing-commitment2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-participation-investor-conferences-march-20262026-02-25T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-q4-2025-financial-results-release2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-extends-rights-offering-subscription-period2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-study-bamc2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-participate-leerink-partners-healthcare-conference2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-withdrawal-petition-patent2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-2025-results-outlook2026-02-25T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-financial-results-q4-20252026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-investor-conferences2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-q4-2025-financial-results2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-cellscape-xr-launch-spatial-proteomics2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-acquires-drug-discovery-assets-charles-river2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-ceo-succession-plan-announcement2026-02-25T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-fourth-quarter-2025-results2026-02-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-125-million-public-offering2026-02-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-2025-revenues-increase-30-percent2026-02-25T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-the-tie-collaboration-solana2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDXS/codexis-fourth-quarter-fiscal-year-2025-results2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-first-readers-shipped2026-02-25T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/2020-biolabs-launch-onetest-longevity-blood-test2026-02-25T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-strategic-alternatives-review2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-aaos-2026-annual-meeting2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-td-cowen-conference2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-reports-fourth-quarter-full-year-2025-results2026-02-25T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-tender-offers-pricing-announcement2026-02-25T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-td-cowen-conference-20262026-02-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-q4-2025-financial-results-update2026-02-26T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-eckert-ziegler-development-agreement2026-02-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-investor-conferences-2025-results2026-02-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-validation-study-cypath-lung2026-02-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-full-year-2025-financial-results2026-02-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-adapt-oculus-trial-results2026-02-26T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-fourth-quarter-2025-results-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-reports-fourth-quarter-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-75-million-offering2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-record-fourth-quarter-full-year-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-vykat-xr-launch-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-participate-march-2026-investor-conferences2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-fourth-quarter-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-record-financial-results-20252026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-march-2026-investor-conferences2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-at-march-2026-healthcare-conference2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-fourth-quarter-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-reports-fourth-quarter-2025-results-guidance2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-presentation-td-cowen-health-care-conference2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-record-financial-results-20252026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-investor-conferences-march-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-fourth-quarter-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-phase-3-trials-doravirine-islatravir-hiv2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-fda-approval-desmoda2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-q4-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-phase-2b-trial-results-stem-cell-therapy2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-participate-td-cowen-healthcare-conference2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-participate-march-2026-investor-conferences2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-march-2026-conference-presentation2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-beacon-study-enrollment2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-leerink-2026-conference2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-year-end-report-20252026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-public-offering-pricing2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-upsized-public-offering2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-upsized-public-offering2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/fda-approves-numelvi-jak-inhibitor-dogs2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-increases-quarterly-dividend2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTMD/biote-fourth-quarter-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-reports-fourth-quarter-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-fourth-quarter-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q4-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-q4-2025-financial-results-pipeline-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-q1-fiscal-year-2026-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-4-million-icls-sold2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-q4-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-fourth-quarter-year-end-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-financial-results-2025-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-update-pending-acquisition-alcon2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-upcoming-conferences-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/viiv-healthcare-lotivibart-hiv-treatment-data2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/viiv-healthcare-pipeline-data-hiv-treatment-therapies2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-bictegravir-lenacapavir-hiv-treatment2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-third-quarter-results-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-participate-investor-conferences-march-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-tender-offers-pricing2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-q4-2025-results-corporate-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-q4-full-year-2025-financial-results-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-td-cowen-conference-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-participate-march-2026-investor-conferences2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-launches-radar-st-mrd-testing2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-2025-results-outlook2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/immuno-oncology-investments-accelerate-pipeline-catalysts-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-q4-2025-results-guidance2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-fourth-quarter-full-year-2025-results2026-02-26T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q4-fy-2025-results-release2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-financial-results-2025-update2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-q4-2025-financial-results2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-fourth-quarter-2025-earnings-release2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-q4-full-year-2025-results-guidance-20262026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-fourth-quarter-full-year-2025-results2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-reports-q4-2025-results-guidance-20262026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-fourth-quarter-2025-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-investor-conferences-20262026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-fourth-quarter-full-year-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-q4-2025-results-muscular-dystrophy2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-orforglipron-superior-blood-sugar-control2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-fy2025-financial-results2026-02-26T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-fourth-quarter-full-year-2025-results2026-02-26T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-dividend-policy-2026-quarterly-announcement2026-02-26T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-year-end-2025-results-corporate-update2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-pipeline-progress-milestones-financial-results2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-korean-patent-photocurable-dermal-filler2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-positive-opinion-orphan-drug-sgx9452026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-q4-2025-financial-results2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q4-2025-results-update2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-2025-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-full-year-2025-results2026-02-26T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-vibrant-trial-aaaai-20262026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-q4-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-reports-q4-2025-results-briumvi-guidance2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-phase-1-allohatrial-fda-clearance2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-james-mackaness-retirement-jennifer-fulk2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q4-2025-results-update2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-2026-investor-day-strategic-plan2026-02-26T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/rezatapopt-phase-1-results-published-nejm2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q4-2025-results-guidance2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-q4-2025-results-updates2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q4-fiscal-year-2025-results2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-reports-fourth-quarter-full-year-2025-results2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-td-cowen-conference-20262026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-fourth-quarter-full-year-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q4-2025-financial-results-update2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-presentation-upcoming-conferences2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-leerink-partners-healthcare-conference2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q4-2025-earnings-call2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-remains-1-pivotal-cohort-completion2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-merck-hiv-pills-phase-3-data2026-02-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-leerink-partners-2026-conference2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-reports-2025-results2026-02-26T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-fourth-quarter-full-year-2025-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-financial-results-20252026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-day-3-highlights2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-infoods-ibs-real-world-data2026-02-26T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-2025-financial-results-business-update2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-conference-call-march-20262026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-full-year-2025-results2026-02-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-fourth-quarter-2025-financial-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-4th-quarter-2025-results-announcement2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-q4-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-q4-2025-results-update2026-02-26T11:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-mda-conference-20262026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-introduces-sensus-link-advanced-capabilities2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-reports-fourth-quarter-results-20252026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endras-taeus-liver-device-consistency-clinical-study2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-enrollment-pivotal-trial-anktiva-bcg2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-sells-chromadex-business-lgc2026-02-26T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-progress-financial-results-20252026-02-26T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-acquisition-celyn-therapeutics-assets2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/olezarsen-fda-priority-review-severe-hypertriglyceridemia2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-q4-2025-financial-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/systimmune-bms-positive-phase-iii-results-iza-bren2026-02-26T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-2025-financial-results-outlook-20262026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-q4-2025-financial-results2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-warrant-exercise-funding2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-2026-sir-annual-meeting-abstract-acceptance2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/netherton-now-recognizes-rare-disease-day2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-present-bio-investment-growth-summit2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-fourth-quarter-2025-results2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-financial-results-business-update2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-phase-1-trial-scy-2472026-02-26T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-naloxone-formulation-study-results2026-02-26T13:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-training-day-tht-20262026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLSN/yoolie-park-joins-solesence-as-vp-brand-partnerships2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-leerink-healthcare-conference-20262026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-reports-q4-2025-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JYNT/joint-corp-report-2025-results-conference-call2026-02-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/good-supply-cannabis-spring-lineup-canada2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-reports-fourth-quarter-full-year-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-phase-2a-results-emp-01-social-anxiety2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-nominates-cunniff-burke-board2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-evaluates-acquisition-sciometrix-digital-care-management2026-02-26T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-q4-2025-results2026-02-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/us-patent-office-sun-pharma-patent-unpatentable2026-02-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-prafulla-gokhale2026-02-26T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-participate-investor-conferences-march-20262026-02-26T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-report-q4-full-year-2025-results2026-02-26T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-fembloc-mdsap-certification-global-access2026-02-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-partners-viuhealth-autoimmune-dataset2026-02-26T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-investor-conferences-march-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-benjamin-beauvalot-appointment2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/lineage-cell-therapeutics-q4-2025-results-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-year-end-fourth-quarter-2025-results2026-02-26T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-pasritamig-docetaxel-prostate-cancer-study-results2026-02-26T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-mda-conference-2026-presentations2026-02-26T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-2026-citizens-conference2026-02-26T21:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q4-2025-financial-results2026-02-26T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-financial-results-q4-2025-announcement2026-02-26T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-investor-conferences2026-02-26T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/jpm26-conference-insights-san-francisco2026-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-march-2026-investor-conferences2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GENB/generate-biomedicines-ipo-pricing-announcement2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-profits-substantial-growth-pipeline2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-investor-conferences-march-20262026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-report-q4-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-financial-results-20252026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/definium-therapeutics-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-fda-breakthrough-therapy-ngn-401-rett-syndrome2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-q4-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-achieve-1-study-interim-readout2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-reports-2025-financial-results-corporate-update2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-participate-march-2026-investor-conferences2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-participate-march-2026-investor-conferences2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-transformation-saentra-forge-strategic-expansion2026-02-27T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inducement-grants-nasdaq-rule-5635c42026-02-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-investor-conferences-20262026-02-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-fourth-quarter-full-year-2025-results2026-02-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-closing-144-million-public-offering2026-02-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-q4-2025-results2026-02-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-q4-2025-financial-results-business-update2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGNY/progyny-fourth-quarter-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-university-hospital-essen-promise-pet-collaboration2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-regains-nasdaq-compliance2026-02-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-tax-valuation-allowance-impact-q4-results2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-eu-approval-chronic-spontaneous-urticaria2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-march-investor-conferences2026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-highlights-advancements-ogm2026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-financial-results-20252026-02-27T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-q4-2025-results-and-update2026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-vtama-phase-3-atopic-dermatitis-sleep-improvement2026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-business-update-fy-20252026-02-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-dawnzera-data-2026-aaaai-meeting2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-2025-financial-results-business-updates2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-rare-disease-day-commitment2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/zusduri-achieves-complete-responses-eortc-risk-groups2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-advancing-renovocath-adoption-cancer-centers2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-participate-upcoming-investor-conferences2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRM/medirom-partnership-tools-for-humanity-expansion2026-02-27T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-jefferies-biotech-summit-20262026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/treace-medical-concepts-q4-full-year-2025-results2026-02-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-positive-opinion-ema-mavorixafor2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-olumiant-chmp-approval-adolescents-alopecia-areata2026-02-27T13:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-whole-genome-sequencing-rare-disease-testing-florida2026-02-27T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-opgx-best1-gene-therapy-phase-1-2-data2026-02-27T15:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-update-expiration-20262026-02-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-paclitaxel-bevacizumab-ovarian-cancer2026-02-27T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/signatera-mrd-data-asco-gu-bladder-preservation2026-02-27T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/padcev-keytruda-bladder-cancer-trial-results2026-02-27T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-padcev-improves-survival-muscle-invasive-bladder-cancer2026-02-27T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-route-79-duchenne-scholarship-program-20262026-02-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-withdraws-s1-registration-statement-offering2026-02-27T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-commercial-launch-rwd-platform-palantir2026-02-27T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-mcombriax-positive-opinion-ema2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-full-year-2025-results-business-updates2026-02-27T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/fda-approves-biomarin-palynziq-adolescents-pku2026-02-28T01:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-summit-trial-aaaai-20262026-02-28T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-welireg-adjuvant-therapy-rcc-results2026-02-28T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/welireg-lenvima-advanced-renal-cell-carcinoma-results2026-02-28T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-verekitug-phase-2-vibrant-trial-results2026-03-01T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-positive-phase-1-data-sep-6312026-03-01T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-positive-data-aaaai-20262026-03-01T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/investor-education-webinar-tlx2026-03-02T12:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-protagonist-fda-accepts-rusfertide-nda2026-03-02T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-phase-3-transcend-trial-data2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-vibrant-trial-verekitug-aaaai-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-phase-3-vitesse-study-aaaai-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-welireg-adjuvant-therapy-rcc-trial-results2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/welireg-lenvima-advanced-renal-cell-carcinoma-trial-results2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/biocytogen-first-patient-dosed-phase-1-trial-ide0342026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/fda-approves-biomarins-palynziq-for-adolescents-with-pku2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-participate-2026-leerink-healthcare-conference2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-share-repurchase-plan-announcement2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inducement-grants-nasdaq-rule-5635c42026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/fda-approves-yuviwel-achondroplasia-treatment2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inducement-grants-nasdaq-rule-56352026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-nasdaq-delist-hearing-request2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-management-td-cowen-health-care-conference2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-phase-3-hero-trial-pause2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-q4-2025-results-update2026-03-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-acquires-cl-273-celyn-therapeutics2026-03-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/ralinepag-reduces-clinical-worsening-risk-pah2026-03-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-aln1003-preclinical-data-obesity2026-03-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-royalty-pharma-250-million-financing2026-03-02T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-corporate-update-financial-results-20252026-03-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-fourth-quarter-2025-results2026-03-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-acquires-gleamer-radiology-ai-solutions2026-03-02T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-city-of-hope-phase-ii-trial-bexmarilimab2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VACH/veraxa-biotech-merger-approval-vach2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-full-year-2025-results2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-terminates-merger-cullgen-alternative-opportunities2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-collaboration-shirley-ryan-abilitylab-rewalk2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-surgiphor-1000ml-fda-clearance-surgical-safety2026-03-02T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-participate-investor-conferences2026-03-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-leerink-partners-conference-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-zusduri-launch-financial-results-20252026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-refinanced-term-loan-agreement-pharmakon2026-03-02T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-reverse-share-split-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-q4-2025-financial-results2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-present-upcoming-investor-conferences2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-2025-financial-results-company-updates2026-03-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-upsized-public-offering-20262026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/deucrictibant-data-aaaai-20262026-03-02T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-igor-studies-aaos-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-phase-3-limelight-enrollment-completion-ocu4002026-03-02T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-fda-lift-clinical-hold-magnitude-trial2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-amber-faust-appointment2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-appoints-susan-rodriguez-cso2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-bio-summit-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-expands-investment-footprint-europe2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-participate-investor-conferences-march-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-regains-nasdaq-compliance2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-reports-full-year-2025-financial-results2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-leerink-partners-2026-healthcare-conference2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-first-patients-dosed-phase-3-duravyu-dme2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-financial-results-20252026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-acquires-us-rights-to-hemangeol2026-03-02T12:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-appoints-pete-ligotti-cco-nxt-41x-launch2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-q4-2025-financial-results2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-participate-investor-conferences2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-advancing-zervimesine-dlb-psychosis2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-leerink-global-healthcare-conference2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-evaluates-strategic-options-shareholder-value2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-msa-awareness-month-20262026-03-02T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-mikael-dolsten-board-directors2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pipeline-progress-2025-results2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/icosapent-ethyl-reduce-it-hospitalizations-death2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-investor-conferences-20262026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-present-leerink-partners-healthcare-conference2026-03-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-approved-thalassemia-uae2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-125-million-share-repurchase-initiative2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-candid-merger-agreement2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-tg-therapeutics-azer-cel-milestone2026-03-02T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-acquires-neogen-animal-genomics-business2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-sale-genomics-business-zoetis2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-sebetralstat-patient-satisfaction-data2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-record-performance-2025-guidance-20262026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-optune-lua-reimbursement-approval-japan2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-investor-conferences-20262026-03-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-signs-mou-women-web3-hong-kong-health-initiative2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-fourth-quarter-full-year-2025-results-update2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q4-2025-results-update2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-barostim-outcomes-tht-20262026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-us-patent-fibroblast-cell-therapy-osteoporosis2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-fourth-quarter-2025-results-conference-call2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-leadership-artificial-heart-therapy2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-12-lox-inhibitor-expansion2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-march-investor-conferences2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-q4-2025-financial-results-call2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-march-conferences-20262026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-inzymes-non-animal-dairy-enzyme-commercialization-20262026-03-02T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-present-leerink-partners-2026-conference2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-appoints-prof-joshua-brown-cmo2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-appoints-drew-hykes-board2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-march-2026-investor-conferences2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-2025-results2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-egm-results-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-restricted-stock-units-warrants-grant-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-phase-2-data-aaaai-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-investor-conferences-march-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-signs-amendment-pincell-option-agreement-feng-application2026-03-02T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-finalizes-companion-spine-transactions2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-50-percent-enrollment-nephro-crrt-trial2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fda-tentative-approval-pnt20032026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-2026-annual-meeting-corporate-update2026-03-02T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-td-cowen-health-care-conference2026-03-02T13:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-positive-results-phase-3-affirm-study-skyrizi2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-prosense-cryoablation-breast-fibroadenomas-study2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-launches-colorectal-cancer-study2026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-participate-investor-conferences-march-20262026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-investor-conferences-march-20262026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-share-buyback-program-20262026-03-02T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-phase-3-trial-ampligen-pancreatic-cancer2026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/lucent-diagnostics-life-line-screening-partnership2026-03-02T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-q3-fy-2026-results-call2026-03-02T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-foundation-12-million-hiv-prevention-initiative2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-appeal-nyse-delisting-compliance-plan2026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-acquires-brewdog-global-craft-beverage-platform2026-03-02T15:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-financial-results-march-20262026-03-02T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-investor-conferences2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/alan-walshe-appointed-general-manager-takeda-canada2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-positive-recommendation-amvuttra-reimbursement2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-appoints-lynne-kelley-cmo2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-acquires-cullgen-targeted-protein-degradation2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-participate-investor-conferences-march-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-appoints-prof-joshua-brown2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-aln1003-obesity-treatment-data2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-participation-scientific-conference2026-03-02T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-business-developments-financial-results-20252026-03-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-global-sleep-survey-20262026-03-03T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/sherpa-research-consortium-ai-assistive-technologies2026-03-03T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-pricing-public-offering2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-cfo-speak-barclays-global-healthcare-conference2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-investor-conference-call-april-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-dividend-march-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-ceo-speak-leerink-partners-2026-healthcare-conference2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-re-examination-trofinetide-rett-syndrome2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-investor-conferences-march-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-full-year-fourth-quarter-2025-results2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-financial-results-q4-full-year-20252026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-presentation-2026-citizens-conference2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-public-offering-common-stock2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-correction-announcement-march-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-business-developments-q4-2025-results2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-fourth-quarter-2025-results-update2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-participate-march-2026-investor-conferences2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-investor-conferences-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-q4-2025-financial-results2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inducement-grants-nasdaq-rule-56352026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-presentation-leerink-healthcare-conference2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-q4-2025-financial-results-guidance2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-leerink-partners-conference-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-q4-2025-results-guidance-share-repurchase2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-appointment-richard-kender-ceo2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-q4-2025-financial-results-conference-call2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-rotator-cuff-repair-aaos-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-participate-march-2026-investor-conferences2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-uplisting-nasdaq-global-select-market2026-03-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-q3-2026-results2026-03-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-acquires-corstasis-enbumyst-nasal-spray2026-03-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q4-2025-financial-results-call2026-03-03T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-sevasemten-mda-conference-20262026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-present-leerink-partners-healthcare-conference2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-2025-financial-results-clinical-updates2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-executives-open-market-share-purchases2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-investor-conferences-march-20262026-03-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dario-health-oral-glp1-therapy-support2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-phase-3-trial-triesence-cataract-surgery2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-fda-fast-track-sle2026-03-03T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-diagnostic-platform-asthma-therapy2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-participate-upcoming-investor-conferences2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-regulatory-update-tabelecleucel2026-03-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-chopin-trial-results-lancet-oncology2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-reports-q4-2025-results-outlook-20262026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-leerink-conference-20262026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q4-2025-results2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-citizens-life-sciences-conference2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-fourth-quarter-full-year-2025-results2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-leerink-global-healthcare-conference-20262026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-march-investor-conferences2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-tumor-growth-inhibition2026-03-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-wisconsin-clinic-progyny-network2026-03-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-investor-conferences-20262026-03-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-partners-with-total-clean-air2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-shareholder-update-20262026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-present-multiple-investor-conferences2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-leerink-partners-conference2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYOJ/ryojbaba-global-labor-support-agreement2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-fourth-quarter-2025-results-conference-call2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-molteni-collaboration-ad04-europe2026-03-03T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-appoints-raghunathan-global-sales-vp2026-03-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-showcase-alzheimers-treatment-20262026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-2025-fiscal-year-results2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardias-late-breaking-results-cardiamp-hf-trial2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-leerink-partners-2026-conference2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/insight-molecular-diagnostics-graftassuredx-fda-submission2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-presentations-adpd-2026-conference2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-john-fowler-appointment2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-march-investor-conferences2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-2025-financial-results2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-investor-conferences-march-20262026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-phase-1a-1b-arq-234-atopic-dermatitis2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-simcyp-simulator-asciminib-cml-trials2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-potential-impact2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-keybanc-forum-presentation2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-distribution-agreement-imperial-imaging2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/embrace-your-sparkle-paris-hilton-campaign-coll2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-participate-roth-conference-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-financial-results-conference-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-citizens-conference-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-keybanc-healthcare-forum2026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-leerink-global-healthcare-conference2026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-q4-2025-financial-results-report2026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-march-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-lonvoguran-ziclumeran-aaaai-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-secondary-offering-class-a-common-stock2026-03-03T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/brepocitinib-fda-acceptance-priority-review-dermatomyositis2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-q4-2025-results-business-highlights2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-leerink-partners-2026-conference2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-2026-leerink-partners-conference2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-phase-3-bpl-003-trd2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-investor-conferences-march-20262026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-phase-3-cypress-study-failure2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-secures-royalty-free-license-oncolytic-immunotherapy2026-03-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-fda-hearing-hetlioz-jet-lag-disorder2026-03-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-leerink-partners-2026-conference2026-03-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-export-npx-5-australia-phase-iib-trial2026-03-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-operational-stability-geopolitical-event2026-03-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presents-leerink-partners-conference2026-03-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-diagnostic-platform-asthma-therapy2026-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-business-update-call-phase-2a-data-vis-1012026-03-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XGN/exagen-participate-investor-conferences2026-03-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-microsize-sublingual-alprazolam2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-mpar-technology-publication2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-leerink-partners-conference-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/sherpa-consortium-ai-technologies-brain-cancer-treatments2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-cfo-thierry-pieton-investor-conferences2026-03-03T15:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-q4-full-year-2025-results-business-update2026-03-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-oppenheimer-conference-participation-20262026-03-03T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-presentation-ubs-global-consumer-retail-conference2026-03-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-2025-revenue-growth2026-03-03T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-financial-results-20252026-03-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-q4-2025-financial-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QSI/quantum-si-reports-q4-full-year-2025-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-appoints-jonathan-poole-board2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-presentation-leerink-conference-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-2025-financial-results-business-update2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-fy-2025-results-pipeline-progress2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-inducement-grants-nasdaq-listing-rule-56352026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-advances-oral-epetraborole-phase-2-study2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-2025-financial-results-business-highlights2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-blackstone-400-million-agreement-duvakitug2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-poster-aapm-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-grand-opening-new-headquarters2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-fourth-quarter-2025-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-webcast-citizens-life-sciences-conference-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-q4-2025-financial-results-update2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-upcoming-conference-calls-2025-update2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inducement-grants-nasdaq-rule2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-march-2026-investor-conferences2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-leerink-partners-2026-conference2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q4-2025-financial-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-q4-2025-financial-results-update2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-leerink-partners-conference-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-update-business-separation-financial-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-aaos-2026-showcase-robotics2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-colorectal-cancer-screening-success2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-2025-financial-results-announcement2026-03-04T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-fourth-quarter-full-year-2025-results2026-03-04T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-acquisition-gleamer-conference-call2026-03-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-rembra-ct-ecr-2026-launch2026-03-04T09:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-pharma-presentation-stora-aktiedagarna2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-financial-statements-20252026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-annual-report-20252026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-leerink-conference-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presentations-mda-conference-20262026-03-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-present-leerink-2026-healthcare-conference2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-fireside-chat-leerink-conference2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-fda-approval-new-manufacturing-facility2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-announces-reverse-stock-split2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-q4-2025-financial-results-update2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-participate-citizens-life-sciences-conference2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-fireside-chat-barclays-conference2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-citizens-life-sciences-conference2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-win-covid-19-patent-spat-roivant2026-03-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-participate-march-investor-conferences2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-fiscal-year-fourth-quarter-2025-results2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-ai-infrastructure-biotech2026-03-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-inducement-grants-nasdaq-rule-56352026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-collaboration-tampa-general-hospital2026-03-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-regains-compliance-nasdaq-listing-requirements2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-announces-q4-full-year-2025-results2026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-report-financial-results-march-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-phase-3-trial-neflamapimod-dementia-lewy-bodies2026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-clinical-trial-approval2026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-financial-results-20252026-03-04T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fites-namodenoson-phase-2a-pancreatic-cancer-study2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-shareholder-letter-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-present-additional-data-fortify-trial-20262026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-appoints-daniel-claassen2026-03-04T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-participate-investor-conferences-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-progresses-development-commercial-launch-foundation-model2026-03-04T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-srnt-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-investor-conferences-20262026-03-04T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/radoff-jec-group-open-letter-seer-independent-directors2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-clearcardio-partnership-12-lead-ecg-technology2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-delisting-notice-nyse2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-inducement-grants-nasdaq-rule-5635c42026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-vybrance-north-american-meeting2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-revenue-growth-fiscal-year-20252026-03-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-positions-transformational-growth2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-inducement-grant-nasdaq-rule-56352026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-ama-policy-radiation-protection2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-first-payer-cms-aligned-network2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-phase-3-protocol-eb613-osteoporosis2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-business-update-q4-full-year-2025-results2026-03-04T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-jefferies-biotech-summit-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-appoints-new-leaders2026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-fermbox-launch-recombinant-dnase-i2026-03-04T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/deephealth-comprehensive-ai-solutions-ecr-20262026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-q4-full-year-2025-results2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-phase-1-ketamir-2-dosing-completed2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-highlight-obesity-metabolic-therapies-forum2026-03-04T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-openai-api-ht-kit-oncology2026-03-04T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-phase-1-data-lymphir-carl-t-therapy2026-03-04T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-participate-investor-conferences2026-03-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-top-abstract-crt-20262026-03-04T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-results2026-03-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-dr-mary-yamashita-medical-advisor2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-exercise-warrants-4-million-proceeds2026-03-04T15:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-gallup-award-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/akeso-inovio-clinical-collaboration-gbm-therapy2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-systems-ceo-appointment2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-ama-session-growth-plans2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-conference-call-fy-2025-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-q2-dividend2026-03-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-secondary-offering-pricing2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-fourth-quarter-year-end-2025-financial-report2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-participation-2026-citizens-life-sciences-conference2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-fourth-quarter-year-end-2025-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-fourth-quarter-full-year-2025-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-regulatory-updates-freedom22026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-reports-2025-financial-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q4-2025-financial-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-ultomiris-royalty-revenue-forecast-change2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inducement-grants-nasdaq2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-citizens-life-sciences-conference2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/zorevunersen-dravet-syndrome-potential-modification2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VMD/viemed-healthcare-record-2025-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-march-2026-investor-conferences2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-ss0-2026-decisiondx-melanoma2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-second-quarter-dividend2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-closes-30-million-offering2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inducement-grants-march-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q4-2025-financial-results-update2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-business-highlights-financial-results-20252026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inducement-grants-march-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-indomo-acne-treatment-agreement2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-leerink-partners-2026-conference2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-investor-conferences-march-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-reports-q4-2025-results-raises-guidance2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-2025-financial-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-q4-2025-financial-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-march-2026-investor-events2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-employee-inducement-awards-march-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-2025-financial-results-update2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-advances-iliac-artery-treatment-eu2026-03-05T07:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-participate-upcoming-investor-conferences2026-03-05T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-employer-connect-launch-obesity-coverage-options2026-03-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-coffee-microcaps2026-03-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-q4-2025-financial-results2026-03-05T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-q4-2025-financial-results2026-03-05T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-sma-data-mda-sma-europe-conferences2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-appoints-nate-salpeter-cto2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-q4-full-year-2025-results2026-03-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-report-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-annual-special-meeting-shareholders-20262026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-financial-results-update-march-20262026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-2025-financial-results-update2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-march-conferences-20262026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-launch-amniofix-thyroid-shields2026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-phase-2-sknjct-003-results2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q4-2025-financial-results2026-03-05T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-q4-2025-financial-results-declaration-trial-updates2026-03-05T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-michael-mina-cmo2026-03-05T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-full-year-2025-financial-results-update2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-2025-financial-results-business-update2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-2025-annual-report-delay2026-03-05T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-participate-investor-conferences-march-20262026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-q4-2025-financial-results-update2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-present-new-real-world-data-painconnect-20262026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-2025-financial-results-update2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-participate-be-well-show-20262026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-bxcl501-opioid-withdrawal-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-mhra-registration-hp-detect-commercial-sales2026-03-05T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-business-progress-q4-2025-results2026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-symposium-parkinsons-disease-adpd-20262026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-alnylam-research-collaboration-cardiovascular-disease2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-wve-006-ats-conference-presentation2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-appoints-chris-gibson-board-directors2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-sarborg-us-provisional-patent-ai-signature-agent2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-phase-1-2-trial-cywc628-diabetic-foot-ulcers2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-fda-enrollment-save-registry2026-03-05T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CURX/curanex-forms-scientific-advisory-board2026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-phase-2-results-hlp004-gad2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-appoints-justin-renz-cfo2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-fourth-quarter-2025-financial-results-call2026-03-05T12:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-tango-clinical-collaboration-eras-00152026-03-05T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-q4-2025-financial-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/alliance-genomic-discovery-expansion-regeneron2026-03-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-christopher-hite-board2026-03-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-2025-results2026-03-05T14:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-promotion-mas-matsuda-executive-vice-president2026-03-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-tenaya-genetic-heart-disease-targets2026-03-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-time-lapse-incubation-technology-wisconsin2026-03-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-best-innovation-competition-crt-20262026-03-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-board-transition-hezi-levy2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHIO/phio-participates-renmark-virtual-roadshow2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-march-2026-investor-conference2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-ai-digital-leadership-himss-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/hls-therapeutics-launches-nilemdo-canada2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-participate-march-2026-investor-conferences2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-cfo-transition-britt-vitalone-kenny-cheung2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-business-achievements-2025-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-azure-clinical-program-update2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-phase-2-study-dm199-preeclampsia2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-oppenheimer-conference-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-first-patient-enrollments-heart-attack-study2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-tibusure-study-design-presentation2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/hls-therapeutics-launches-nilemdotm-canada2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/herantis-pharma-2025-report-release2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-annual-report-2025-correction2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-present-leerink-partners-2026-healthcare-conference2026-03-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-revello-stent-ce-marking-eu2026-03-05T19:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-fda-approval-tecvayli-darzalex-multiple-myeloma2026-03-05T20:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-cancels-special-meeting-stockholders2026-03-05T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-cash-dividend-fy-20262026-03-05T21:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-investor-conferences-20262026-03-05T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-report-fourth-quarter-full-year-2025-results2026-03-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/minimed-announces-ipo-pricing2026-03-06T00:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-presents-pharma-discovery-bio-europe-spring-20262026-03-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-ares-g3-rheometer-launch2026-03-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-korean-patent-breast-cancer-vaccine2026-03-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-positive-results-phase-1-abbv-295-study2026-03-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/asbrs-resource-guide-cryotherapy-breast-cancer-iccm2026-03-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-scientific-conferences2026-03-09T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-collaboration-als-trial2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-rinvatercept-data-mda-conference2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-ibezapolstat-clinical-trial-recurrent-cdi2026-03-09T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/first-ever-dental-dedicated-mri-fda-clearance2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-positive-topline-data-phase-3-x-tole2-study2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-phase-2b-plateau-clinical-trial-enobosarm-semaglutide2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-leadership-diversified-growth-strategy2026-03-09T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-tn-301-preclinical-data-mda-20262026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/briumvi-reduces-relapse-mri-activity-ms2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-completes-private-placement-growth2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-neffy-commercialization-update-20252026-03-09T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-2025-financial-results-update2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-160-million-private-placement2026-03-09T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-phase-2-ndv-01-bladder-cancer-data2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/olatorepatide-obesity-treatment-phase-3-results2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-tenacia-collaboration-rap-2192026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q4-2025-financial-results2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-investor-call-captain-trial-outcomes2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-q4-full-year-2025-results2026-03-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-afrezza-data-at-atted-20262026-03-09T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q4-2025-financial-results2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-positive-phase-2-skincare-study2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-phase-3-development-plan-canvuparatide2026-03-09T14:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-closes-50-million-tranche-appointment2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-oversubscribed-private-placement2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-share-buyback-program-update2026-03-09T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-name-change-damora-therapeutics-blood-disorders2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-q4-2025-results-updates2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-participate-iaccess-virtual-alpha-conference-20262026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-financial-results-webinar-march-20262026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-phase-3-captivate-trial-update2026-03-09T11:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-go-decision-captiavate-trial-claseprubart2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-present-new-data-cue-401-wirm-20262026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/decisiondx-melanoma-i31-slnb-study-results2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-q4-2025-financial-results2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-phase-1b-study-cdi-988-norovirus2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-financial-results-march-20262026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-presents-new-data-aua-20262026-03-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-q4-full-year-2025-results2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-positive-phase-2b-results-acne2026-03-09T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-supports-lifes-a-polyp-foundation-fap2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-bell-potter-summit-20262026-03-09T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-ras-inhibitors-research2026-03-09T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-zevaskyn-commercial-launch-update2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-ns002-phase-2-study-presentation2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-eventhorizoniq-subscription-launch2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-advances-bla-submission-fabry-disease2026-03-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-expands-skin-health-ecosystem2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-appoints-robert-lenz-board-directors2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-presentation-life-sciences-investor-forum2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-private-lending-pool-hyperlend2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-bim-iol-system-phase-1-2-results2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-end-of-phase-2-fda-meeting-ipf-cough2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-opens-palm-beach-clinic2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-fourth-quarter-full-year-2025-results2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-acmg-2026-abstracts-presentation2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-2025-financial-results-updates2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-fda-fast-track-pbgene-dmd2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-board-changes-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-vybrance-thyroid-nodule-study2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-40-million-private-placement-financing2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-appoints-dale-hooks-cco2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-stock-repurchase-authorization2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-q1-2026-financial-results-business-update2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-successor-2-mezigdomide-results2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-phase-2-study-tilrekimig-atopic-dermatitis2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-ai-insights-pancreatic-cancer-therapy2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/koselugo-approved-canada-plexiform-neurofibromas-nf12026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-ost-her2-type-b-pre-bla-meeting2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INM/inmed-update-pharmaceutical-development-programs2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-resubmission-sbla-fda-anktiva-bcg-nmibc2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-visara-positive-results-vis-101-phase-2a-study2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/chiesi-protalix-elfabrio-eu-approval-four-week-dosing2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-acquires-biocare-medical-pathology-solutions2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/enhertu-priority-review-her2-positive-breast-cancer2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-deliver-trial-results-dmd2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-phase-3-harmonia-trial-z-basivarsen-dm12026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/fda-approves-sotyktu-for-active-psoriatic-arthritis2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-zymyz-approval-advanced-scac2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-closing-rights-offering2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-regulatory-update-molbreevi-autoimmune-pap2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-acquisition-kuva-labs2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-inducement-grants-nasdaq-rule-56352026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq-5635c42026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-nasdaq-ntla2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reverse-stock-split-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-grants-inducement-awards2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-inducement-awards-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-announces-bbo-11818-preclinical-data-cancer-discovery2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGNY/progyny-executives-investor-conferences-march-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-presents-mda-conference-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/servier-day-one-acquisition-oncology-portfolio2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-240-million-private-placement2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-david-ramsay-interim-cfo2026-03-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-conference-call-20252026-03-12T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-q4-2025-financial-results2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-water-tower-research-podcast2026-03-12T15:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-global-patent-expansion-vanoglipel2026-03-12T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-clinical-trial-update-endoxifen2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-japanese-patent-codx-pcr-platform2026-03-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/freestyle-libre-technology-type-2-diabetes-management2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/freestyle-libre-technology-improves-glucose-management2026-03-12T08:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-voxzogo-early-treatment-achondroplasia2026-03-12T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-manufacturing-process-cld-4012026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/los-angeles-life-sciences-growth2026-03-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-maxim-group-strategic-opportunities2026-03-12T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-fourth-quarter-full-year-2025-results2026-03-12T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-reverse-stock-split2026-03-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-financial-results-conference-call2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-rollout-glucose-monitoring-system-brazil2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-full-year-2025-results2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-clearmind-patent-weight-loss-therapy2026-03-12T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-sls009-aml-trial-enrollment2026-03-12T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-fourth-quarter-2025-results2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-positive-phase-3-dtx301-otc-deficiency2026-03-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-presents-roth-conference-20262026-03-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-year-end-2025-results2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-hydros-robotic-system-launch2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-2025-financial-results2026-03-12T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-2025-financial-results-update2026-03-12T12:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-fourth-quarter-2025-results-update-call2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-stifel-2026-cns-forum2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-financial-results-march-20262026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-q4-2025-financial-results2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-q4-2025-financial-results2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-2025-financial-results-conference-call2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-2025-financial-results2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-report-full-year-2025-results-march-19-20262026-03-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q4-full-year-2025-results2026-03-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-financial-results-business-update-20252026-03-12T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-ad-pd-2026-fda-update2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-advances-burn-treatment-fibroblast-spheroid-technology2026-03-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-fda-clearance-ind-dare-hpv2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-presentations-adpd-2026-conference2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-2025-financial-results-highlights2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-hope-3-data-2026-mda-conference2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-q4-2025-financial-results2026-03-12T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-abstract-adpd-20262026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-abstract-accepted-saem-20262026-03-12T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q4-2025-financial-results2026-03-12T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-q4-full-year-2025-results2026-03-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-ceo-retirement-and-successor-appointment2026-03-12T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CURX/curanex-expands-scientific-advisory-board2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-report-2025-financial-results-conference-call2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-fourth-quarter-full-year-2025-results-call2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-deramiocel-dmd-mda-conference-20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-expands-global-reach-argentina-clearance2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/extraordinary-general-meeting-izafe-group2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-saentra-forge-ceo-appointment-italian-academy2026-03-13T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q4-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-q4-year-end-2025-update-call2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-fourth-quarter-2025-results-conference-call2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-ceo-retirement-and-new-appointment2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-report-financial-results-q4-20252026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-fourth-quarter-full-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-reports-revenue-growth-fy20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q4-2025-financial-results-update2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-public-offering-747-million2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-q4-full-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-719-million-offering2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q4-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-q4-full-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-fourth-quarter-full-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-fourth-quarter-year-end-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-q4-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-q4-2025-financial-results-update2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-annual-business-update-20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capso-vision-financial-results-release-march-20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q4-2025-financial-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-q4-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-2025-financial-results-updates2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-q4-full-year-2025-financial-results-report2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-q4-2025-financial-results-update2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-fourth-quarter-fiscal-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-2025-results-2026-milestones2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZR/enodia-therapeutics-acquisition-kezar-assets2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-reports-financial-results-20252026-03-13T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-recommends-shareholders-vote-for-consolidation2026-03-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-financial-results-20252026-03-13T10:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-2025-financial-results2026-03-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-ticker-change-nasdaq-qucy2026-03-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-total-artificial-heart-btv2026-03-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-q4-2025-financial-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-prices-upsized-convertible-senior-notes-offering2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-march-20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-keybanc-virtual-healthcare-forum2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-ceo-transition2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-stifel-2026-cns-forum2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-revenue-growth-20252026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-financial-results-20252026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-type-1-diabetes-study-results2026-03-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-shareholder-approval-oramed-partnership2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/tacti-004-phase-iii-study-discontinued2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/graftassure-assay-superiority-study-imdx2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-financing-ra-capital-management2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-inducement-awards-nasdaq-rule-56352026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-hong-kong-patent-depression-therapy2026-03-13T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-2025-financial-results2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-2025-revenue-cypath-lung2026-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-strategic-progress-clinical-development2026-03-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-new-brain-wave-biomarkers-adhd2026-03-13T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/captain-trial-tulsa-vs-robotic-prostatectomy2026-03-13T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-q4-full-year-2025-results2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-acquires-ignite-proteomics-cancer-care2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-fourth-quarter-year-end-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-participation-stifel-2026-cns-forum2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-eu-mdr-certification-freedom60-infusion-pump2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-nk-cell-production-milestone2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-reports-2025-financial-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-zervimesine-dlb-adpd-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-q3-2026-results-update2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-q4-full-year-2025-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-inducement-awards-nasdaq-rule-56352026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-public-offering-common-stock2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-financial-results-20252026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-participate-38th-annual-roth-conference2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/reduce-it-data-acc-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-participate-roth-conference-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-upcoming-investor-meetings2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-corporate-updates-fiscal-year-2025-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-participate-roth-conference-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-clearmind-patent-depression-therapy2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/new-data-approach-trial-transcon-cnp-achondroplasia2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-speak-38th-roth-conference2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-phase-ii-covalent-111-results-diabetes2026-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-regulatory-milestone-saudi-arabia2026-03-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-lsi-usa-26-summit-presentation2026-03-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYPH/cypherpunk-reports-full-year-2025-financial-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-veritas-genetics-preventive-genomics-consortium2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-ai-insights-platinum-resistance-ovarian-cancer2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-2025-annual-results-conference-call2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/fda-approves-tecvayli-darzalex-faspro-multiple-myeloma2026-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-conference-call-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-q4-2025-financial-results-update2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-bioequivalence-ketamine-application2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-update-recurrence-rate2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-q4-2025-earnings-call2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q4-2025-financial-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRFS/grifols-chronos-platform-parkinsons-disease2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-agreement-global-preclinical-cro2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-nsclc-trial-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-appoints-henry-brem2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-launches-sancuso-website2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-sonicare-world-oral-health-night2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-fda-response-reproxalap-dry-eye2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-appoints-kevin-lobo-board-directors2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-ai-platform-launch-nvidia2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-patents-psychedelic-therapies2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-fourth-quarter-full-year-2025-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-appoints-vivek-jayaraman-ceo2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-financial-results-20252026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-cfo-transition2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-enrollment-endeavor-cohort-8-elevidys-gene-therapy2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-successful-debt-refinancing2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-corporate-update-fiscal-2025-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-new-data-cardio-pulmonary-pipeline-acc262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-phase-3-results-20252026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-120-million-financing2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-sidoti-small-cap-conference-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-2025-financial-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-business-progress-financial-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-accelerates-cardiac-catheter-program2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-positive-topline-phase-2-results-atirmociclib2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-at-roth-conference-20262026-03-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/transcon-hgh-turner-syndrome-trial-results2026-03-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/imc-strategic-entry-cyber-drone-interception2026-03-17T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-q4-2025-earnings-release-webcast2026-03-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-2025-financial-operational-results2026-03-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-reports-q4-2025-results2026-03-17T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-osa-study-oral-anatomy-correlation2026-03-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-q4-2025-results2026-03-17T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-dan-reuvers-ceo2026-03-17T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-fda-pdufa-fee-waiver-d-plex100-nda2026-03-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/quantum-cyber-strategy-trump-administration-cybersecurity2026-03-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-roth-conference-participation2026-03-17T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-financial-results-webcast-march-20262026-03-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-financial-results-platform-expansion2026-03-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-submits-marketing-authorization-symvess-israel2026-03-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-license-hcw11-006-trimmune2026-03-17T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-nmpa-priority-review-hydronidone2026-03-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-q4-2025-results2026-03-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-clear-outcomes-acc-20262026-03-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-phase-1b-2a-resolve-trial-eosinophilic-esophagitis2026-03-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/national-survey-correctional-facilities-opioid-treatment2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-gardasil-eurogin-congress-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/clinical-utility-signatera-anal-rectal-cancers2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-fourth-quarter-2025-earnings-call2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-q3-fiscal-2026-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-lawsuit-clarity-ventures2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-andrew-ratz-cto2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-q4-2025-results-corporate-update2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-q4-2025-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNNN/anbio-biotechnology-keybanc-capital-markets-forum2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-presents-new-data-aacr-annual-meeting2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-aacr-2026-posters2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-aacr-2026-adc-portfolio2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-muzastotug-aacr-2026-presentations2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-aacr-annual-meeting-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-prt13722-aacr-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-inducement-grants-nasdaq-rule-56352026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ads-ratio-change2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1-5-billion-women-missing-screenings-holx2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-aacr-2026-presentations2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-aacr-2026-oncology-candidates2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-aacr-presentation-cldn18-22026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-aacr-2026-botensilimab-balstilimab-colorectal-cancer2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1500-millones-mujeres-pruebas-preventivas-holx2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-aacr-annual-meeting-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-rinzimetostat-aacr-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-transparency-notification-bank-of-america2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-bank-of-america-transparency-declaration2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrrivent-preclinical-posters-aacr-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-aacr-2026-presentation-kinesin-degrader2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-zidesamtinib-aacr-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1-5-billion-women-missing-preventive-tests-holx2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1-5-billion-women-lack-essential-screenings2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1-5-billion-women-lack-essential-screenings-holx2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-aacr-2026-abstracts2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-aacr-2026-presentations2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-rd-day-april-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/nccn-guidelines-update-anktiva-bcg-nmibc2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-research-agreements-nad-plus2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-aacr-annual-meeting-20262026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-abstracts-sgo-2026-avutometinib-defactinib2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-250-million-offering2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-poster-presentations-aacr-20262026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-new-data-aacr-annual-meeting2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-kimmtrak-2026-aacr-presentation2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNNN/anbio-biotechnology-keybanc-healthcare-forum2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-2026-aacr-annual-meeting-atebimetinib-data2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-operational-progress-altai-capital2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-full-year-2025-financial-results2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-pricing-public-offering-common-stock2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-aacr-annual-meeting-20262026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-aacr-2026-preclinical-data2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-announces-gael-touya-ceo-transition2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/aarvik-therapeutics-aacr-2026-adc-molecules2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-abstracts-sgo-2026-ovarian-cancer2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-acquisition-bako-stratadx2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-aacr-2026-mrd-mced-data2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-q4-2025-financial-results-update2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inducement-grants-nasdaq-rules2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-10-million-public-offering2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-q4-2025-financial-results2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-20252026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-bio-europe-spring-20262026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-full-year-2025-results-highlights-milestones2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-announces-presentations-aacr-annual-meeting-20262026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-barda-funding-deepview-system2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-appoints-kathy-turner-board2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-full-year-2025-results2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-participate-38th-annual-roth-conference2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/red-light-holland-kala-bio-pex010-clinical-development2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-abstracts-ascrs-2026-annual-meeting2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-university-buffalo-sjogrens-syndrome2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-report-q4-2025-results2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-virtual-investor-event-niyad-crrt2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-labcorp-collaboration-precision-oncology-testing2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-glp1-obesity-program-irb-approval-phase-12026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-iba-cyclotron-manufacturing-expansion2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-choisit-cyclone-kiube-iba-production-us2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-2025-financial-results-conference-call2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-2025-financial-results-business-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-financial-results-q4-2025-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-presents-roth-conference-20262026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q4-2025-results-business-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-board-constitution-restricted-stock-units-warrants2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-annual-general-meeting-20262026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-20-million-offering2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-phase-i-study-lag-3-agonist-autoimmune-diseases2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-gtx-104-presentation-data-asah2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q4-2025-financial-results2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-2025-results-miracle-trial-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fda-action-animal-testing2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-q4-fiscal-year-2025-results2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-fourth-quarter-2025-business-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-launches-national-chemical-defense-consortium2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-hybrite-clinical-summary-expert-opinion2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-hotswap-launch-aferetica-partnership-isicem-20262026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/woori-io-signs-nda-sinopharm-china-market2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-cardamyst-launch-update2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-new-roles-20262026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-kol-webinar-ras-mutated-colorectal-cancer2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/deucrictibant-efficacy-safety-h%20hereditary-angioedema2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-financial-results-conference-call-20262026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-fourth-quarter-2025-results-needham-conference2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/autophagy-failure-alzheimers-disease-avxl2026-03-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-lung-nodule-biomarker-study2026-03-20T12:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capsovision-announces-14-million-private-placement-financing2026-03-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-next-gen-emperor-heart-technology-acc-20262026-03-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-iba-cyclone-manufacturing-expansion-us2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardias-2025-financial-results-conference-call2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptars-unidose-nasal-delivery-phase-ii-study-inna0512026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-full-year-2025-results-business-update2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-quantiFERON-tb-prevention-data2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-full-year-2025-financial-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-fda-approval-imcivree-acquired-obesity2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-q4-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-releases-q1-2026-aide-memoire2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-conference-call-first-quarter-2026-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-roth-conference-20262026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-reports-q4-full-year-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-report-financial-results-march-20262026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLSN/solesence-fourth-quarter-full-year-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-closes-85-million-offering2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-2025-earnings-call2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-virtual-rd-day-kidney-disease-pipeline2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-2025-financial-results-update2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-q4-2025-financial-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-year-end-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-year-end-2025-financial-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-q4-full-year-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-q4-2025-financial-results-conference-call2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-gpsai-study-improving-cancer-diagnosis2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-expands-south-asia-distribution2026-03-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-acquisition-exact-sciences-march-20262026-03-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezpegaldesleukin-phase-2b-studies-aad-20262026-03-20T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-quarterly-dividend-announcement2026-03-20T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-gpsai-study-misdiagnosis-cancer2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-form-20-f-annual-report-filing-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-present-new-ekterly-data-angioedema-conference2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/pantherx-selected-exclusive-pharmacy-imcivree-expansion2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/real-world-leqembi-treatment-persistence-adpd-20262026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/lecanemab-long-term-treatment-persistence-adpd-20262026-03-20T16:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-ads-ratio-change2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/danaher-first-quarter-2026-earnings-call2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-investor-events-darovasertib-results2026-03-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-conference-call-apex-trial-data2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-investor-relations-events-darovasertib-results2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-data-parkinsons-alzheimers-adpd-20262026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-presentation-ebmt-2026-ta-tma-treatment2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-opdivo-approval-hodgkin-lymphoma2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-inducement-grants-nasdaq-rule-5635c42026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-cfo-inducement-grant2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-annual-general-meeting-may-20262026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inducement-grants-nasdaq-rule-56352026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-approval-macau-nmibc2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-report-2025-financial-results-conference-call2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-webcast-phase-2-trial-data-ocu4102026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-2025-financial-results-business-updates2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-approves-effexor-japan-generalized-anxiety-disorder2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/new-data-long-term-treatment-lecanemab-2026-ad-pd-congress2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-fourth-quarter-full-year-2025-results2026-03-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-enrollment-milestone-miracle-trial2026-03-23T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-positive-results-phase-3b-encore-arikayce2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/craig-tendler-leads-tuhura-vista-program-aml2026-03-23T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-omniasecure-fda-approval-defibrillation-lead2026-03-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-phase-1-renergen-helium-project-drilling-completed2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-pipeline-business-updates-2025-results2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-phase-3-trial-fda-approval2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-epicapture-prostate-cancer-test-results2026-03-23T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-private-placement-funding2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tp-03-approval-china-demodex-blepharitis-tars2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-share-reclassification2026-03-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-senti-202-innate-killer-conference2026-03-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-closes-10-million-offering2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-closing-10-million-private-placement2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-unbuzzd-clinical-trial-publication2026-03-23T12:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-business-update-q4-2025-results2026-03-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-leadership-appointment-jennifer-mcdonough2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/eau-guidelines-upgrade-aquablation-therapy-bph2026-03-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-1-opus-2-phase-3-trials2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-reverse-stock-split-20262026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-2026-acc-presentations2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-parmeet-ahuja-cfo2026-03-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-annual-general-meeting-20262026-03-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-launch-choriofix-advanced-wound-care2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-novo-nordisk-phase-1-study-lx98512026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-commercial-site-transfer-agreement2026-03-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-2025-financial-results-update2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/national-viagra-day-women-claim-turn2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-q4-2025-results2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-q4-2025-results-business-update2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-global-early-access-erapa-fap-patients2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q4-2025-results-update2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-attr-cm-acc-presentation-20262026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-valneva-lyme-disease-vaccine-phase-3-results2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-treatment-results-us-cutaneous-lymphoma-workshop2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-aacr-2026-presentations2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-300-million-offering2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-annual-meeting-shareholders-20262026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-public-offering2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-board-departure2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-pricing-oversubscribed-offering2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-zilganersen-fda-priority-review-alexander-disease2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-valneva-lyme-disease-vaccine-efficacy-phase-32026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-joenja-approval-japan-apds2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-photonova-spectra-fda-clearance2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-fourth-quarter-2025-results2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/insitro-bristol-myers-squibb-collaboration-expansion2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-initiates-coverage-zacks2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquires-ouro-medicines-t-cell-engager2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approval-bullous-pemphigoid-japan2026-03-24T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-medtech-leader-european-patent-office-20252026-03-24T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-evolving-into-saentra-forge-strategic-options2026-03-24T07:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-q1-2026-aide-memoire-availability2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approval-japan-bullous-pemphigoid2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-q4-fiscal-year-2025-results-webcast2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-gilead-collaboration-t-cell-engager-autoimmune2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-2025-financial-results-presentation2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-world-vaccine-congress-20262026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-q4-2025-financial-results2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-fourth-quarter-full-year-2025-results2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-2025-financial-results-highlights2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-q4-2025-results-business-update2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-2025-results2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-elcc-2026-lung-cancer-portfolio2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-elcc-2026-lung-cancer-data2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-pricing-public-offering2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-2025-results-regulatory-progress2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-reports-q4-2025-results-and-guidance2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/usana-cellsentials-consumerlab-approval2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-private-placement-ra-capital2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-full-year-2025-results-call2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-advances-attr-cm-care-collaboration-viz-ai2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-q4-full-year-2025-results2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-reports-full-year-2025-results2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-phase-2-armada-trial-results-ocu4102026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-ip-patent-portfolio2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-phase-3-sentry-trial-myelofibrosis-results2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-partners-with-mlb-striking-out-cancer2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/john-stamos-jodie-sweetin-cologuard-campaign2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-quantum-leap-bristol-laser-facility2026-03-24T11:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-usclc-workshop-2026-lymphir2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-partnership-avance-clinical-australia2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-advances-final-cohort-oncology-trial2026-03-24T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-update-congenital-hyperinsulinism-fda-meeting2026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-investor-summit-conference-20262026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-jeffrey-munsie-appointment2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-sotagliflozin-presentations-acc-20262026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q4-2025-financial-results2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-fast-company-innovative-companies-20262026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-year-end-2025-results-update2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-2025-financial-results-conference-call2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquires-ouro-medicines-galapagos-partnership2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q4-2025-financial-results2026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-appoints-michael-maclean-board-directors2026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q4-2025-results-business-updates2026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/2020-biolabs-rokit-healthcare-ckd-prediction-agreement2026-03-24T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-debt-financing-rain-token-updates2026-03-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-robotic-system-publication2026-03-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-dairy-industry-mexico2026-03-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-add-on-offering-senior-unsecured-notes2026-03-24T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-expands-presence-michigan-health-system2026-03-24T12:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-adc-toxicity-detection-models2026-03-24T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-haus-agreement-silhouette2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMS/ams-financial-results-conference-call-20252026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-compliance-nasdaq-filing-requirement2026-03-24T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-joins-crsp-index-s-p-benchmark-indices2026-03-24T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-roth-conference-20262026-03-24T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/spago-nanomedical-tumorad-abstract-presentation2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-superpower-supplementation-partnership2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-advances-key-regulatory-milestones2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-dpyd-testing-colorectal-cancer-awareness2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-appoints-meir-peleg-cfo2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMD/inmode-presentation-needham-healthcare-conference-20262026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-webcast-may-5-conference-call2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-receives-uae-regulatory-clearance2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-acquisition-clario-holdings2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-pre-clinical-results-catheter2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-merit-medical-agreement-viaverte-system2026-03-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-positive-data2026-03-24T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-phase-2-3-trial-sil2042026-03-24T13:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-acquire-20-percent-colugo-stake2026-03-24T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-investor-summit-conference-20262026-03-24T15:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-ceo-pay-bump-20252026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-congress-bipartisan-legislation-aud2026-03-24T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-2026-hfma-map-award-revenue-cycle-excellence2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-research-collaboration-spain2026-03-24T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-2025-financial-results-highlights2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-conference-call-2025-results2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-q4-full-year-results-20252026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-2025-business-highlights-financial-results2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-nasdaq-minimum-bid-requirement2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-clinical-data-sirna-pipeline-fshd1-dm12026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-financing-avenue-capital2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-shareholders-approved-share-consolidation2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-pricing-50-million-offering-senior-notes2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-employment-inducement-grants2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-public-offering-350-million2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pricing-public-offering2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-employment-inducement-grants-march-20262026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MEDP/medpace-holdings-first-quarter-2026-results2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-q4-2025-results2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-fourth-quarter-full-year-2025-results2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-q4-2025-results-and-2026-guidance2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-fourth-quarter-results-20252026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-2025-financial-results2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-join-cac-mid-60-sbf-120-indices2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-ana-sodium-reduction-initiative2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-addresses-short-seller-report2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-acquire-terns-pharmaceuticals-hematology-pipeline2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/merck-acquire-terns-pharmaceuticals-hematology-pipeline2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-fiscal-year-2025-results-update2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-withdraws-blarcamesine-eu-application2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-geekwire-deal-of-the-year2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-virtual-investor-event-april-20262026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-announces-reverse-stock-split2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-q4-2025-financial-results-announcement2026-03-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-ships-diagnostic-materials-india-tuberculosis-studies2026-03-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-expands-comet-suite-spatial-biology2026-03-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-vicki-goodman-cmo2026-03-25T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-jane-wright-mitchell-clo2026-03-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-full-year-2025-results2026-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-reports-q4-2025-results-highlights2026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-phase-2-horizon-trial-mze8292026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-2-data-ovarian-cancer2026-03-25T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-myvista-insights-epic-toolbox-designation2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-ouro-buy-johnson-johnson-approval2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-reports-record-hifu-revenue-20252026-03-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-phase-1b-trial-cemsidomide-elranatamab2026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-2025-financial-results2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APUS/inscobee-apimeds-new-board-appointment2026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-binary-ionization-technology-approval2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-reports-full-year-2025-results2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-reverse-stock-split-march-20262026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-fda-update-qrx003-netherton-syndrome2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-fda-feedback-abp-450-biosimilar2026-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/flyte-hops-vision-jet-private-aviation2026-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-nova-2-trial-lb-102-schizophrenia2026-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-media-speculation2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-declaration-rumeur-medias2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-oncology-studies-aacr-20262026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-abstracts-aki-crrt-20262026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-jessica-chutter-board2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-showcase-cardiology-portfolio-acc262026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-first-quarter-2026-results-announcement2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-strategic-alternatives-review2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-reports-2025-financial-results2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-detection-early-stage-cancers2026-03-25T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-positive-results-icesecret-study-kidney-cancer2026-03-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/new-york-life-sciences-job-opportunities2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-realbotix-ericsson-6g-trial2026-03-25T16:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-phase-2b-results-mebufotenin-trd2026-03-25T15:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-fda-approval-avlayah-hunter-syndrome2026-03-25T15:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-webinar2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-hedges-defi-portfolio-investment-gold2026-03-25T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-advances-ns002-pivotal-study2026-03-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-glaucoma-market-expansion2026-03-25T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-full-year-2025-financial-results2026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-third-quarter-results-april-20262026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-intrasight-plus-launch-coronary-interventions2026-03-25T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-executive-leadership-appointments2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-new-contracts-for-smallpox2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-closes-public-offering2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-fourth-quarter-full-year-2025-results2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-q4-2025-results-corporate-update2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-announces-executive-team-appointments2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-ernennung-von-fuehrungspersonal2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-announces-executive-appointments2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/fda-approves-corcepts-lifyorli-ovarian-cancer2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-fiscal-year-2025-earnings-call2026-03-25T21:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-q4-2025-financial-results2026-03-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q4-2025-financial-results-update2026-03-25T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-q4-2025-results-and-highlights2026-03-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-2025-financial-results-business-updates2026-03-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-2025-financial-results-business-updates2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-share-consolidation2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-files-annual-report-fiscal-year-20252026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-appoints-jesper-hoiland-head-strategy2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2025-annual-report-10-k2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2025-financial-results2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-annual-meeting-stockholders-virtual-format2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-new-executive-appointments2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-nominations-haute-direction2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-full-year-2025-results-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-annual-meeting-2026-virtual-format2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-receives-audit-opinion-going-concern2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q4-2025-financial-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-files-annual-report-20252026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/glyphallo-first-triglyceride-mimetic-prodrug2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-full-year-2025-results-update2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reverse-stock-split-nasdaq-compliance2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2025-annual-report2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-jesper-hoiland-strategy-appointment2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-financial-results-20252026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-fourth-quarter-full-year-2025-results-webinar2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-q4-full-year-2025-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-full-year-2025-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-q4-full-year-2025-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-greg-madison-cco2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-first-quarter-2026-results-conference-call2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-roluperidone-olanzapine-trial-sirs-20262026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-fourth-quarter-2025-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-q4-2025-results-eq504-update2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-strategic-partnership-oramed2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-new-contracts-smallpox2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-2025-financial-results-business-highlights2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-expand-personalized-nutrition-acquisition-bioniq2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-fda-approval-plasma-collection-center-san-antonio2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-q4-2025-financial-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-financial-results-20252026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-financial-results-corporate-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-phase-3-vanquish-2-trial-completion2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-investor-analyst-day-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-phase-2-panova-4-trial-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-orphan-drug-designation-sgx945-behcets-disease2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-appoints-ron-andrews-board2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-pivotal-trial-anktiva-bcg-nmibc2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-blood-volume-analysis-validated-sccm-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-2026-aspire-higher-scholarship-program2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-4-million-offering2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-fda-approval-pd-l1-ihc-22c3-esophageal-cancer2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-openclaw-ai-drug-discovery2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-ai-insights-brain-metastases-risk2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-2025-financial-results-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-rain-update-ai-agent-interface-prediction-market2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-eu-consortium-cardio-oncology2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-acquires-bbb-delivery-technology2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-fourth-quarter-full-year-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-securities-fraud-lawsuit2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-first-quarter-2026-earnings-call2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-chmp-positive-opinion-imcivree2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-q4-2025-results2026-03-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-vitiligo-program-update-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-abstract-risk-stratification-lung-cancer-elcc2026-03-26T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-glow2-phase-3-results-diabetic-retinopathy2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-year-end-2025-financial-results2026-03-26T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-consensus-recommendations-tardive-dyskinesia2026-03-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-positive-phase-1-data-wve-0072026-03-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-insurance-coverage-nevada2026-03-26T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-3-development-strategy-verekitug2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-phase-1-study-tnx-19002026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-phase-iii-tiger-pac-trial-milestone2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-phase-2-clinical-trial-lucid-ms2026-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q4-20252026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-launches-security-subsidiary-israel-investment2026-03-26T12:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-business-update-skinject-study2026-03-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/emory-healthcare-robotic-endovascular-procedures2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-expands-business-development-team2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-new-agreements2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-appoints-rick-mcelheny-business-development2026-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-appoints-new-board-members2026-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-virtual-rd-day-april-20262026-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-year-end-2025-results-update2026-03-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-partnership-department-war-ptsd-tbi2026-03-26T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-receptor-selectivity2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/fda-clears-philips-ai-solution-heart-valve-repair2026-03-26T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-q4-fy2025-results-conference-call2026-03-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-european-ip-patent-grant2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-expands-tapinarof-ip-portfolio-patent-filings2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-reports-2025-financial-results2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-popsicle-adult-beverages-launch2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-us-patent-agmb-447-ipf-treatment2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q4-2025-results-guidance-20262026-03-26T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-new-cto-appointment2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/fda-approves-lifyorli-relacorilant-cort2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-participate-world-vaccine-congress-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-participation-world-vaccine-congress-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-leadership-eu-consortium-cardio-oncology2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-strategic-cro-evaluation-clinical-research2026-03-26T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-2025-highlights-update2026-03-26T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-leads-eu-ihi-consortium-cardio-oncology2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2025-financial-results-clinical-progress2026-03-26T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-vinia-no-1-resveratrol-brand-us2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-leads-eu-funded-ihi-consortium2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-role-consortium-cardio-oncology-eu2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-2025-annual-report-shareholders-meetings2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-2025-annual-report-and-general-meetings2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-public-offering-403-million2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-full-year-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-offerings-convertible-notes-common-stock2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-public-offering-common-stock2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-reports-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-reports-q4-2025-earnings-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q4-2025-results-business-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-graftassuredx-fda-review-q4-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-ceo-resignation-appointment-robert-goodman2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capso-vision-reports-q4-full-year-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-fiscal-2025-results-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-phase-3-apollo-trial-bitopertin-epp2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-share-consolidation-delay2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-host-march-2026-webcast-bot-bal2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-results-annual-special-meeting-shareholders2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-concurrent-public-offerings-20262026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-positive-chmp-opinion-joenja-apds-treatment2026-03-27T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-march-2026-stakeholder-webcast-bot-bal2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLP/simulations-plus-q2-fiscal-2026-earnings-call2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-corporate-update-20252026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-record-revenues-financial-results-q4-20252026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LONA/leonabio-reports-2025-financial-results-business-update2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-2025-annual-report-filing2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-phase-3-apollo-trial-bitopertin2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/eisai-nuvation-bio-taletrectinib-ema-approval2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-concurrent-public-offerings2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-2025-financial-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-2025-financial-results-business-update2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-nominates-gino-santini-board-directors2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-business-update-q4-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capsovision-q4-full-year-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-fourth-quarter-full-year-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-submits-graftassuredx-fda-review-q4-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-reports-financial-results-20252026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-financial-results-20252026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-fourth-quarter-full-year-2025-earnings2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-submission-marketing-authorization-brazil-palsonify2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-2025-financial-results-updates2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-q4-2025-financial-update2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-reports-q4-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-annual-general-meeting-2026-resolutions2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-advances-cro-evaluation-revenue-growth2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-compass-consortium-cardio-oncology2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-fda-approval-pd-l1-ihc-22c3-esophageal-carcinoma2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-quilt-2-005-trial-results-20262026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-first-oncology-injectable-self-administration2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-reports-2025-financial-results-progress2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-broad-institute-patent-decision2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-fda-approval-kresladi-pediatric-lad-i2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-upsized-public-offering2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-patent-india-psychedelic-compounds2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/irenic-letter-teleflex-board-acquirors2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-texas-prostate-100th-tulsa-procedure2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-75-million-private-placement-tcgx2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-reports-financial-results-20252026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-lawsuit-skincure-oncology2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-q4-full-year-2025-results2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/ivonescimab-phase-iii-studies-elcc-20262026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-mcs2-clinical-benefits2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/york-space-systems-new-contract-update2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/first-tracks-biotherapeutics-secures-145-million-private-placement2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-spin-off-first-tracks-biotherapeutics2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-announces-stock-repurchase-plan-business-update2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-q4-full-year-2025-results2026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-fda-approval-neffy-age-requirement2026-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-2025-financial-results2026-03-27T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-rinzimetostat-phase-1b-trial-data2026-03-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-150-million-private-placement2026-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-fourth-quarter-year-end-2025-results2026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-financial-results-20252026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-fda-ide-filing-q2-20262026-03-27T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-igalmi-approval-outpatient-setting2026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-refutes-culper-research-allegations2026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGPU/axe-compute-annual-report-conference-call2026-03-27T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/maryland-fire-departments-cancer-screenings-onetest2026-03-27T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-signs-binding-offer-sophia-high-tech2026-03-27T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-medical-2025-financial-results-envee-system2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/fda-clearance-ind-star-001-pediatric-cns-trial2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-fda-approval-kresladi-leukocyte-adhesion2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-reports-fourth-quarter-full-year-2025-results2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-commitment-value-maximizing-strategies2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ebglyss-lebrikizumab-atopic-dermatitis-results2026-03-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-aad-2026-immune-mediated-skin-diseases2026-03-27T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-2026-dermatology-meeting2026-03-27T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-positive-data-phase-2-urticaria-studies2026-03-27T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-private-placement-11-million2026-03-27T14:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-ati-2138-aad-2026-results2026-03-27T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-nova-1-trial-results-sirs-20262026-03-27T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-mhra-ema-australian-tga-meetings2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/ivonescimab-data-phase-iii-elcc-20262026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-vtama-cream-atopic-dermatitis-analysis2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-open-strategic-alternatives2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-2026-annual-meeting-date2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-financial-results-update-20252026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-2025-financial-results-update2026-03-27T21:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-data-acc-20232026-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-momentum-trial-presentation-acc-20232026-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-litifilimab-phase-2-results-cle2026-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-phase-3-sonelokimab-hidradenitis-suppurativa-results2026-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezpegaldesleukin-phase-2b-results-aad-20262026-03-28T17:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/icotyde-one-year-results-plaque-psoriasis2026-03-28T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/champion-af-study-watchman-flx-device2026-03-28T15:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/hi-peitho-trial-boston-scientific-ekos-superior-treatment2026-03-28T15:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-povorcitinib-hidradenitis-supurativa-aad-20262026-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-data-povorcitinib-hidradenitis-suppurativa2026-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-povorcitinib-hidradenitis-suppurativa-aad-20262026-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-securities-fraud-lawsuit2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-lawsuit-securities-violations2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-presents-phase-2-data-nbtxr3-lung-cancer2026-03-30T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bms-phase-3-scout-hcm-trial-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-winrevair-phase-2-cadence-trial-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-zasocitinib-psoriasis-phase-3-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-momentum-trial-acc-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-cuts-risk-major-cardiovascular-events2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/taltz-zepbound-superior-efficacy-psoriatic-arthritis-obesity2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-phase-3-sonelokimab-results-hidradenitis-suppurativa2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/valor-trial-brepocitinib-dermatomyositis-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-envudeucitinib-phase-3-trials-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-hypertriglyceridemia-data2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezpegaldesleukin-phase-2b-rezolve-ad-rezolve-aa-data-aad-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/hi-peitho-trial-ekos-superior-treatment-pulmonary-embolism2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/champion-af-study-watchman-flx-device-stroke-risk-reduction2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-amlitelimab-phase-3-results-atopic-dermatitis2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-broadening-data-aad-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-phase-2-results-atopic-dermatitis-infants2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-icotyde-phase-3-data-aad-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/cobenfy-switch-study-symptom-stability2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-financial-results-20252026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-2026-annual-meeting-date-announcement2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-full-year-2025-financial-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inducement-grants-march-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-ceo-transition-lucinda-warren2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q4-full-year-2025-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-lb-102-cognitive-performance-sirs-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-ceo-emerging-growth-conference-april-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-positive-phase-2-data-barzolvolimab-aad-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-2026-aad-meeting2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ebglyss-lebrikizumab-atopic-dermatitis-study-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/decisiondx-melanoma-test-improves-risk-prediction2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-fda-fast-track-zw191-ovarian-cancer2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-fda-clearance-asurys-fluid-management-system2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-emobot-partnership-ai-depression-thermometer2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-fda-anaphylm-meeting2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACB/aurora-executive-gender-diversity-globe-mail2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-elegrobart-phase-3-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-teton-1-study-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-positive-phase-3-data-kid-trial2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-stat6-inhibitor-immunology20262026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/fda-approves-high-dose-spinraza-nusinersen-sma2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-plinabulin-aacr-2026-poster-presentation2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-vilobelimab-pyoderma-gangrenosum-aad-20262026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-full-year-2025-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-reports-q4-full-year-2025-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-ai-polio-vaccine-world-congress2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-exparel-cost-care-ors-20262026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-apr-1051-clinical-trial-update2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-conference-call-q1-2026-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-oversubscribed-private-placement2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-fda-clearance-blind-sweep-ai-tool2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-third-quarter-fy-2026-results-release2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-ema-validation-marketing-authorization-application2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-fireside-chat-hc-wainwright-march-312026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-settles-debt2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-introduces-iv-verify-line-labeling-system2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/koppers-closing-bell-20th-anniversary2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ovarian-cancer-car-t-therapy-presentation2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-evoque-system-two-year-data2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-phase-1-combination-study-ide849-ide1612026-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-precision-oncology-flatiron-integration2026-03-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-dr-robert-walker-rd-lead2026-03-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-q4-2025-financial-results-update2026-03-30T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-first-patient-phase-3-upstream-sjd-trial2026-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/envision-trial-results-zusduri-urogen2026-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-year-end-2025-financial-results2026-03-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-expands-global-opportunity-ss-mantra-approval2026-03-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-alcon-patent-infringement-verdict2026-03-30T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-patent-upheld-nano-micro-particle-enrichment2026-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-reports-year-end-2025-financial-results2026-03-30T12:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-full-year-2025-financial-results2026-03-30T10:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-fda-clearance-ux016-gne-myopathy2026-03-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-allucent-phase-2-trial-ms2026-03-30T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-scientific-publication-vascular-anomalies2026-03-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-adds-former-mossad-deputy-advisory-board2026-03-30T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-2025-financial-results-update-pds0101-phase-32026-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-q4-2025-financial-results2026-03-30T10:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-skinject-phase-2-validation2026-03-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-bionic-intelligence-research-agent-launch2026-03-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nexicart-2-trial-enrollment-complete2026-03-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-positive-data-quellimmune-save-registry2026-03-30T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-new-data-clear-outcomes-acc-20262026-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio2026-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-private-placement-financing2026-03-30T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/rademikibart-phase-3-atopic-dermatitis-results2026-03-30T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-positive-topline-data-rademikibart2026-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-clinical-trial-cmnd-1002026-03-30T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-vetbiolix-phase-2-osteoarthritis-study-dogs2026-03-30T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/new-data-acc26-vutrisiran-zilebesiran2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-fda-clearance-ak-2519-business-updates2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-needham-healthcare-conference-20262026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-presentation-world-vaccine-congress-washington2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-q4-2025-financial-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-sale-priority-review-voucher2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-freedom2-study-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-full-year-2025-financial-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INGN/inogen-inc-inducement-grants-nasdaq-listing-rule2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-financial-results-20252026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-2025-results-business-update2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-first-quarter-2026-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-fda-approval-vascade-mvp-xl2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-q4-2025-results-update2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-full-year-2025-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-date-change-earnings-call2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-publishes-2025-annual-report2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-annual-report-20252026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-files-annual-report-sec-20252026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-2025-financial-report-20-f2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-privosegtor-prime-designation-optic-neuritis2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-inducement-grants-nasdaq-rule-56352026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/signatera-mrd-breast-cancer-surgery2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-appoints-jon-congleton-board2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-fourth-quarter-full-year-2025-results2026-03-31T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-gilead-collaboration-gamgertamig-autoimmune2026-03-31T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPO/onward-medical-2025-results-commercial-performance-pipeline-milestones2026-03-31T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-2025-annual-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-updates-withholding-tax-cash-dividend2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-phase-1-data-lyme-disease2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-acquire-apellis-immunology-portfolio2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-first-quarter-2026-results-announcement2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-phase-2-trial-epetraborole2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-resubmits-bla-apitegromab-sma2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/poxel-sale-pxl770-scynexis-196-million2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q4-2025-results-phase-2-advancements2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-raymond-james-2026-symposium2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-recent-accomplishments-financial-results-20252026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-financing-global-expansion-immunotherapy2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-2025-financial-results-business-updates2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp900-aacr-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-annual-report-20252026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inducement-grants-nasdaq-rule-56352026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-2025-financial-results-update2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-buntanetap-historical-review-scientist2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-first-quarter-2026-earnings-call2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-needham-virtual-healthcare-conference-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-2025-financial-results-antiviral-updates2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-chinese-patent-cancer-technology2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-arrows-clinical-trial-data-pralsetinib-nsclc2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-coolmonth-2026-offers2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-needham-healthcare-conference-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-participate-needham-virtual-healthcare-conference2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-new-us-patent-evm301-drug-candidates2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-phase-2-trial-lyme-disease-prevention2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-cruise-ship-clinic-partnership2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-strategic-partnership-tigerbone-group-health-initiatives2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/cost-impact-model-sublocade-correctional-facilities2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-launch-update2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-presentation-ddw-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-financial-results-20252026-03-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-year-end-2025-financial-results2026-03-31T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-funding-belgium2026-03-31T13:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-2025-results-revenue-growth2026-03-31T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-acquires-apellis-immunology-portfolio2026-03-31T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-terminates-equity-facilities2026-03-31T12:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-2025-revenue-surges-487-percent2026-03-31T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-names-nick-mead-vice-president-investor-relations2026-03-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-expands-dublin-facility-injectable-therapies2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-emerging-growth-conference-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-2025-annual-report-highlights2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-share-consolidation2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-briaPro-asset-purchase-soluble-cd802026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-25th-annual-needham-conference2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-participate-needham-healthcare-conference2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-q4-full-year-2025-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-inducement-grants-nasdaq-rule-56352026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-reports-2025-financial-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-q4-2025-financial-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-2025-results-update2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-manufactures-cywc628-drug-product2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-annual-report-20252026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-rejects-mini-tender-offer-potemkin2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-q4-2025-financial-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGPU/axe-compute-reports-full-year-2025-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q4-2025-results-highlights2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/tanner-pharma-biodexa-global-access-program-paf2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/tanner-pharma-biodexa-early-access-program-fap2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/tanner-pharma-biodexa-early-access-fap-patients2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/tanner-pharma-biodexa-access-program-fap2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-q4-2025-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-achieve-1-study-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-pricing-public-offering2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-2-million-euros-funding-belgium2026-04-01T01:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-enabled-medication-dispensing-europe2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-orbis-investment-shareholder-announcement2026-04-01T07:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-2025-financial-results-updates2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACI/albertsons-fiscal-2025-earnings-release-conference-call2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-reports-fourth-quarter-year-end-2025-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-business-highlights-q4-2025-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-q4-2025-financial-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-inducement-awards-nasdaq-rule-56352026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-ceo-letter-shareholders2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-first-quarter-results-april-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-management-present-needham-conference2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-q4-2025-results-business-update2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-2025-financial-results-business-update2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-inducement-grants-cfo-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-simcere-sim0505-abstract-asco-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-financial-results-corporate-update-20252026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-q4-2025-financial-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-phase-3-trial-roluperidone2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-2025-financial-results-highlights2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-rinzimetostat-darolutamide-phase-3-trial2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-participate-needham-healthcare-conference2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-share-consolidation-april-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-financial-results-q4-20252026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-business-update-full-year-2025-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-manufacturing-cywc628-diabetic-foot-ulcer-trial2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-oral-showcase-respiratory-innovation-summit2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-coolmonth-announcement-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-kristin-stafford-cfo2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-regains-nasdaq-compliance-bid-price2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-completes-dosing-phase-2-3-trial-ocu410st2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-rap-219-phase-2-data-2026-aan2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-present-additional-sol-1-data-april-20262026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-phase-3-brilliance-studies-alixorexton-narcolepsy2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-thierry-bernard-board-directors2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-first-quarter-2026-financial-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-q1-2026-financial-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/usana-ceo-calls-for-daily-health-routines2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-first-quarter-2026-results-announcement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-korsana-merger-agreement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-abstract-ats-2026-conference2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-skinject-phase-2-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-full-year-2025-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-first-patient-global-phase-3-battman-trial2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-global-clinical-trial-collaboration2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-fda-approval-alyftrek-trikafta-cf2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-q4-2025-financial-results-update2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/rajani-dinavahi-appointed-cmo-ardelyx2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-q1-2026-financial-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-nvns-benefits-mtbi-ptsd2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-nda-gist2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-reports-q4-2025-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-bofa-securities-conference-20262026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-cfo-transition-announcement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-development-candidate-nomination2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-biotek-cytation-9-launch2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-fulcrum-vt-study-results-hrs-20262026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/incision-free-mri-guided-prostate-treatment-sir-20262026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-announces-4-million-public-offering2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hungary-approves-ht-001-trial-expansion2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-sir-2026-meeting2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-breast-imaging-software-update2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-logic-gated-car-design2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-phase-22026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-domicile-change-nevada2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-expands-commercial-access-lungfit-ph2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-view-point-medical2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/renuvion-wins-newbeauty-award-minimally-invasive-skin-tightener2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-enabled-medication-dispensing-system-europe2026-04-01T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-aacr-2026-presentation2026-04-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-nasal-anti-cd3-cognition-aging2026-04-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ind-application-lucid-ms2026-04-01T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-scientific-conference2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-share-consolidation-effective-date2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-based-medication-distribution-europe2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-medication-dispensing-europe2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-european-medication-dispensing-ai-system2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-2-million-offering2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-hirc-member-choice-awards-supply-chain-achievement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-third-quarter-fiscal-2026-earnings-release2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-philip-vickers-appointment2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-ascrs-2026-presentations2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-proposed-public-offering-common-stock2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-participate-needham-healthcare-conference2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-extends-tender-offer-acquire-arcellx2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-q1-2026-results-announcement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-us-patent-alpha-1062-traumatic-brain-injury2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-phase-2-alto-101-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-inducement-grants-nasdaq-rule-56352026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-inducement-grant-nasdaq-rule-5635c42026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-2-million-euro-funding-belgium2026-04-01T16:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-foundayo-glp1-pill-weight-loss2026-04-01T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-appoints-david-gill-non-executive-director2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-pricing-300-million-public-offering2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-battman-phase-3-study-first-patient-enrolled2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-batman-trial-success2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-battman-trial-success-mss-pmmr-cancer2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-battman-phase-3-study-enrollment2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-3-battman-study-enrollment2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-3-battman-trial-bot-bal-cancer2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-first-patient-battman-trial2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-iii-battman-trial-recruitment2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-brepocitinib-lpp-phase-2b-3-trial2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-phase-3-batoclimab-thyroid-eye-disease-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-fiscal-year-2026-q3-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/priovant-brepocitinib-lpp-phase-2b-3-trial2026-04-02T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-q4-2025-results-business-update2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-2025-annual-report-filing2026-04-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-phase-2b-3-trial-mk-87482026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/european-commission-approves-keytruda-ovarian-carcinoma2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-sales-growth-q1-20262026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-pricing-public-offering-70-million2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-agent-797-asgct-20262026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-patent-buntanetap-neurological-injuries2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/positive-results-hybrite-comparative-study-ctcl2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-raymond-james-symposium-20262026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-outperforms-traditional-methods-multiple-myeloma2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-international-preparedness-conferences2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-fda-fast-track-cdi-988-norovirus2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-board-transition-mark-pavao2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-strengthens-executive-team2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-new-treatment-center-zevaskyn-new-york2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-chromoseq-launch-myeloid-malignancies2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-ceo-early-breast-cancer-detection2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-first-quarter-2026-earnings-release2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-webcast-conference-call-q1-2026-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-private-placement-bvf-partners2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-public-offering-pricing2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-regains-nasdaq-compliance2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-board-changes-david-king-nomination2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-fda-accelerated-approval-cardiamp-system2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/comira-manufacturing-facility-saudia-arabia2026-04-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-giannis-antetokounmpo-partnership2026-04-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-1154-postpartum-depression-results2026-04-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-highmark-coverage-cnside-assay2026-04-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-realbotix-ai-humanoid-robot-delivery-update2026-04-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/pfizer-biontech-halt-covid-vaccine-trial-slow-enrollment2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-sponsor-advanced-wound-care-conferences2026-04-02T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-barda-award-nexobrid-development2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-closes-3-million-public-offering2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-closing-2-million-offering2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-zovegalisib-vascular-anomalies-issva-20262026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-inducement-grants-nasdaq-rule-5635c42026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-award-nasdaq-rule-56352026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-announces-first-quarter-2026-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-inducement-grants-nasdaq-rule-56352026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-needham-virtual-healthcare-conference2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q1-2026-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-inducement-awards-nasdaq-rule-56352026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-q1-2026-results-announcement2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-nasdaq-minimum-bid-price-notification2026-04-02T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-foundayo-orforglipron-lly2026-04-02T17:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-kempen-life-sciences-conference2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-needham-conference-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-inducement-grants-nasdaq-listing-rule-56352026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-quarterly-dividend-april-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-april-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/trinetx-regeneron-collaboration-health-records-research2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inducement-grants-nasdaq-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-award-april-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-leadership-transition-jim-oconnor2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-zovegalisib-vascular-anomalies-presentation2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-participate-needham-healthcare-conference2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-nyse-american-compliance-plan2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/medi-wound-barda-contract-vericel-nexobrid2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-phase-ii-study-agent-797-aacr-20262026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-ii-study-bot-bal-aacr-20262026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-inducement-grant-karen-basbaum2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-first-quarter-2026-earnings-report2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/trump-tariff-drugmakers-impact-gsk2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-inducement-grants-nasdaq-rule-5635c42026-04-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-board-changes2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-dnl593-grn-ftd2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-nasdaq-notifications-minimum-bid-price2026-04-03T15:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-inducement-grants-nasdaq-ikt2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBO/impact-biomedical-going-concern-audit-opinion-20252026-04-03T17:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-golden-cone-safety-award-20262026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-inducement-grants-nasdaq-listing-rule2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-expands-precision-diagnostics-panomics-platform2026-04-06T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-presentation-fueling-mash-symposium2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-labeling-alignment-ketamine2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-needham-conference-20262026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-strategic-reorganization-cdmo-platform2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-scientific-abstracts-ascrs-20262026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-first-quarter-2026-results2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-reports-fy-2026-q1-results2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-fda-correspondence-advertising-compliance2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-participate-needham-healthcare-conference2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q1-2026-financial-results2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-needham-conference-20262026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-annual-shareholder-update-20262026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-phase-2-clinical-data-aacr-20262026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-participate-needham-virtual-conference2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-chemosat-guidelines-uveal-melanoma2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-q1-2026-revenue-growth2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-puraply-am-trial-results2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-derick-elliott-appointment2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-participate-needham-healthcare-conference2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-fda-meeting-pelareorep-anal-cancer2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/strategic-review-sale-tms-business-stim2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-launches-pick-pack-pro-fulfillment-technology2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-brazilian-patent-primec-composition2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ceo-smart-money-circle-interview2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-positive-phase-3-results-tepezza-ted2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/nyse-content-update-humanx-ai-event2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-paul-miele-cfo2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-first-quarter-2026-results2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-announces-q1-2026-financial-results2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-kol-webinar-mrgprx2-inhibition-migraine2026-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-april-investor-conferences2026-04-07T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-successful-first-year-launch-meso2026-04-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-achieves-primary-endpoint-puraply-am-trial2026-04-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-revaccination-data-escmid-20262026-04-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-cfo-transition-announcement2026-04-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-orphan-drug-exclusivity-yuviwel-launch2026-04-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inducement-grants-nasdaq-rule-56352026-04-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-present-needham-healthcare-conference2026-04-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-update-patent-claims-gp2-market-potential2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/20-abstracts-aacr-natera-oncology-platform2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-nda-neladalkib-advanced-alk-positive-nsclc2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-symon-ii-trial-enrollment-update2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-new-day-trial-results2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-fda-approval-nexus-aortic-arch-system2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-antibodies-for-any-body-campaign2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-raymond-james-symposium-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-glp-1-summit-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-investor-conference-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-response-pointillist-family-office2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-regains-nasdaq-compliance2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-zelicapavir-escmid-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-nanopulse-af-clinical-study2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-invests-photothermal-afm-ir-semiconductor-research2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-needham-conference-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-needham-conference-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/palvella-therapeutics-kent-taylor-appointment2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-fda-alignment-restor-phase-3-study2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-amanda-garofalo-appointment2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-phase-2-trial-extension-evx-012026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-vertex-collaboration-hypercon-technology2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-fast-track-sim0505-ovarian-cancer2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-needham-conference-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-improve-pah-phase-3-study-ikt-0012026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-first-patient-enrollment-ptsd-study2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-needham-conference-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-donation-parkinsons-awareness-month2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-announces-3-5-million-offering2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-investor-meetings-raymond-james-symposium2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-announces-name-change-to-engene-therapeutics2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-five-million-motiva-devices2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-mhra-accepts-maa-autoimmune-pap2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-highlight-phase-3-x-tole2-data-2026-aan2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-keith-goldan-appointment2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-participate-needham-healthcare-conference2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-needham-conference-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-financing-agreement-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquire-tubulis-oncology-pipeline2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-dispute-resolution-lytenava2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/slno-shareholder-alert-class-action-lawsuit2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-secures-defense-collaboration2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-begins-tender-offer-acquire-terns-pharmaceuticals2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-daybue-trofinetide-rett-syndrome-availability2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-appoints-richard-marshall-cmo2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-full-year-2025-financial-results-update2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-inducement-grants-nasdaq-rule-56352026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-needham-virtual-healthcare-conference-20262026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-presents-needham-healthcare-conference2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-aacr-2026-partnering-event2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-inducement-grants-nasdaq-rule-56352026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-appoints-clare-kahn-phd2026-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-aacr-2026-presentation2026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-fda-clearance-ryoncil-dmd-trial2026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-employee-inducement-grants-april-20262026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-reports-full-year-2025-financial-results2026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-galleri-test-epic-integration2026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-report-first-quarter-2026-results2026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-grants-inducement-awards2026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-eyeprogpo-partnership-retina-laser-technology2026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-needham-virtual-healthcare-conference-20252026-04-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-bpl-003-phase-2a-results2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-needham-virtual-healthcare-conference-20262026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-fda-approval-isosorbide-mononitrate-launch2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-liverty-tips-stent-graft-portal-hypertension-eu2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-needham-conference-20262026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-first-quarter-2026-results2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-webcast-budoprutug-cd19-opportunity2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-participate-needham-healthcare-conference2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-needham-conference-20232026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-needham-conference2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-fda-designation-miroliverelap2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-first-quarter-2026-financial-results2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-preclinical-milestone-boehringer-ingelheim2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-needham-conference-20262026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/acc-scientific-sessions-2026-icosapent-ethyl2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-fireside-chat-needham-conference2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-expands-customer-footprint-bva-program-ohio2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-partnership-ginkgo-bioworks-ai-advisory-board2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-participate-needham-virtual-healthcare-conference2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-kcc2-rd-event-april-14-20262026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-ide-approval-vclas-system2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-eq504-poster-presentations-immunology20262026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-appoints-david-mcguire-cfo2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/ondo-global-markets-tokenizes-enlivex-ordinary-shares2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-ai-powered-molecular-insight-nsclc2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-sir-2026-presentation2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-first-quarter-2026-results-report2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-strengthens-board-director-appointments2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-closes-3-5-million-funding2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inducement-grant-nasdaq-rule-56352026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-q1-2026-financial-results2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-q1-2026-sales-increase2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-presentation-needham-conference-20262026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-present-needham-healthcare-conference2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-2025-registration-document-annual-report2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-initiates-thetis-study-nereus-glp-1-vomiting2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVST/envista-first-quarter-2026-earnings-call2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-pricing-public-offering2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-first-quarter-2026-financial-results-call2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/cosette-pharmaceuticals-acquisition-sympazan2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-agreement-acquired-garda-therapeutics2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-proposed-public-offering2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-inducement-grants-nasdaq-listing-rule2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-preliminary-net-sales-q1-20262026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-needham-conference-20232026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-2026-q1-financial-results2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-first-quarter-2026-earnings-release2026-04-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-first-quarter-2026-conference-call2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-royalty-mrd-patents-update2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-participate-scientific-medical-conferences-april2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-governance-updates2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-purewick-urine-collection-system-study2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-first-quarter-2026-financial-results-webcast2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/oxford-biotherapeutics-collaboration-bristol-myers-squibb2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-revolution-program-measles-antibody-vms0632026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-appoints-dr-sara-kenkare-mitra2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-presents-bloom-burton-healthcare-conference2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-presentation-carb-x-investor-day2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-needham-virtual-healthcare-conference2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-participate-needham-healthcare-conference2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-strengthens-leadership-team2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-realigns-spine-leadership-focus-execution2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-investor-conferences-20262026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-q1-2026-earnings-call2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-izicopan-c5ar-inhibitor-data2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/goodrx-expands-access-foundayo-zepbound-pharmacies2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-record-revenue-q1-20262026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-needham-conference-20262026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/amazon-pharmacy-eli-lilly-foundayo-delivery2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-conference-call-20262026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-q1-2026-results-conference-call2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-top-workplaces-20262026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q1-2026-financial-results2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q1-2026-financial-results2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-400mg-azenosertib-ovarian-cancer2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-fireside-chat-needham-conference2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-preci-sg100k-collaboration2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-signals-bio-design-launch-biologic-research2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-als-biomarker-study2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-10-million-offering-common-stock-warrants2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-usp-monograph-nrcl2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/americans-believe-chronic-diseases-preventable-healthcare-survey2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/weight-watchers-launches-eli-lilly-foundayo2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-participate-investor-conferences-20262026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-2026-annual-meeting-shareholders-webcast2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fda-withdraw-proposal-20272026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-threshold-of-life-memorial2026-04-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-brain-penetrating-aramchol-formulation2026-04-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-darlifarnib-cabozantinib-ikcs-europe-20262026-04-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/foundayo-lilly-oral-glp1-weight-loss-available-us2026-04-09T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-preclinical-data-aacr-20262026-04-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-redchip-conference-20262026-04-09T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-advantage-collar-launch2026-04-09T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-research-2026-aan-meeting2026-04-09T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/regeneten-bioinductive-implant-recovery-times-halved2026-04-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-precision-health-research-collaboration-proteomics2026-04-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-appoints-eric-daniels-cdo2026-04-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-realbotix-vinci-ai-robot-launch2026-04-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-peer-reviewed-study-difs-technology2026-04-09T11:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-sgo-annual-meeting-data-presentations2026-04-09T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-deepview-system-american-burn-association-meeting2026-04-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-gilead-sciences-kt-200-license2026-04-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-jefferies-global-healthcare-conference2026-04-09T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-roche-collaboration-dacs2026-04-09T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-phase-1b-data-escmid-20262026-04-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-launches-bimatoprost-ophthalmic-solution2026-04-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-partners-with-wuxi-xdc2026-04-09T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WW/weight-watchers-board-committee-appointments2026-04-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-presentation-needham-conference2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-report-q1-2026-results2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-vp-315-abstract-sid-20262026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/rick-byrd-retire-bd2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-sir-2026-presentation2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-appoints-madelene-gani-coo2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-financial-results-q2-fiscal-20262026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-narcan-nasal-spray-bc-program2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-first-quarter-2026-financial-results2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/fda-accepts-nda-tlx101-px-pixclara2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-leadership-appointments-growth2026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-vp315-abstract-sid-20262026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q1-2026-financial-results2026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-report-q1-2026-financial-results2026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-aacr-2026-presentation-data2026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-gilead-collaboration-oncology-rd2026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-biomarkers-als-study2026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-first-quarter-2026-financial-results2026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-q1-2026-revenue-growth2026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-redchip-biotech-conference-20262026-04-10T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-top-workplaces-20262026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-data-presentations-ascrs-20262026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-avmapki-fakzynja-data-sgo-20262026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-first-quarter-2026-results-conference-call2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-participate-investor-conferences2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-earnings-call-may-5-20262026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lifemd-offering-eli-lilly-foundayo-weight-management2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-closes-10-million-offering-phase-3-alzheimers2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-first-patient-higher-dose-phase-1-study-da-17262026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-inducement-grant-nasdaq-rule-56352026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-conference-call-spy001-results2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-alpha3-trial-update2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-participate-needham-healthcare-conference2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-topline-results-phase-2-3-trial2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PNTG/pennant-acquires-arbor-rose-senior-living2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/imc-receives-nasdaq-minimum-bid-notification2026-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEM/select-medical-announces-q1-2026-results2026-04-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/haisca-abbvie-license-agreement-pain-medicines2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-financial-results-q4-fiscal-year-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-aacr-2026-ultrasensitive-ctdna2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-regeneron-radiopharma-collaboration2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-launch-carbamazepine-capsules2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-report-first-quarter-2026-results2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-appoints-glenn-tyson-cco2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-announces-30-million-private-placement2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-letter-to-shareholders-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMD/inmode-q1-2026-financial-results-conference-call2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-phase-1-trial-edp-978-urticaria2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-nmr-products-workflow-solutions-enc-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/ifinatamab-deruxtecan-priority-review-small-cell-lung-cancer2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-alpha3-trial-cema-cel-results2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-hcw-home-bloom-burton-conference-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-acquires-amplitude-vascular-systems2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-investor-conferences-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-q1-2026-results2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-essential3-positive-phase-3-program-aan-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-refinancing-credit-facility2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/radoff-jec-group-acquire-seer2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-positive-interim-analysis-allogene-alph3-trial2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-expands-biomanufacturing-infrastructure2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-1-trial-vir-55002026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-credit-agreement-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-chop-collaboration-pediatric-diagnostics2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-present-logic-gated-cell-therapies-aacr-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/storm-pe-data-cavt-anticoagulation-pulmonary-embolism2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-showcases-innovations-aorn-conference-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-bevacizumab-ovarian-cancer2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-servier-positive-results-phase-2-3-trial-darovasertib2026-04-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-dilon-technologies-distribution-agreement2026-04-13T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-venetoclax-cll-trial-results2026-04-13T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-skyline-trial-results-spy001-ulcerative-colitis2026-04-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-business-update-20262026-04-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dario-appoints-john-palumbo-board-directors2026-04-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-ame-technology-implementation2026-04-13T12:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/optum-expands-neurostar-tms-coverage-nurse-practitioners2026-04-13T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-phase-1-trial-sep-479-hypoparathyroidism2026-04-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approval-eu-chronic-spontaneous-urticaria2026-04-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-phase-3-shield-ii-data-escmid-20262026-04-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-appoints-john-d-doux2026-04-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-acquires-dfsl-defense-technology2026-04-13T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-exparel-lower-healthcare-costs-outpatient-surgeries2026-04-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-axpaxli-wet-amd-trial-data2026-04-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expert-consensus-chronic-wound-debridement2026-04-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-full-market-release-liberty-system2026-04-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/favorable-results-ovarian-cancer-study-lxt2026-04-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-fda-fast-track-kt-621-asthma2026-04-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-appoints-timothy-williams-executive-vice-president2026-04-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-jeff-knight-cdo2026-04-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-phase-1-trial-akb-90902026-04-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-eeg-erp-repository-milestone2026-04-13T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-patent-infringement-lawsuit-cleerly2026-04-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-phase-iia-trial-onp-002-concussion2026-04-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-distribution-agreement-digital-x-ray-imaging-arkansas2026-04-13T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-vivo-study-accepted-publication2026-04-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-robert-langer-advisor2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-nobel-science-skin-cancer-chat2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-el32-manufacturing-optimization2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-aacr-annual-meeting-2026-research2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/edp-978-phase-1-trial-urticaria2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/ifinatamab-deruxtecan-priority-review-es-sclc2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-aacr-2026-ctdna-data-therapy-resistance2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-health-notice-of-results2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-shares-voting-rights-april-20262026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-annual-general-meeting-20262026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/beckman-coulter-ce-mark-access-memed-bv-assay2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/haisco-abbvie-license-agreement-pain-medicines2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-mirvetuximab-phase-2-data-sgo-20262026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-trastuzumab-pamirtecan-endometrial-cancer-efficacy2026-04-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-rosetta-trial-results-sgo-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-rosella-study-sgo-conference-lifyorli2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-rosetta-trial-results-ovarian-cancer2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-rosella-study-lifyorli-overall-survival2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-phase-iii-rosella-study-results2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-investor-conference-april-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-offering-common-stock-notes2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-public-offering-175-million2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMED/minimed-financial-results-q4-fiscal-year-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-first-quarter-2026-financial-results2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-first-quarter-2026-results-announcement2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-first-quarter-2026-results2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-needham-conference-20262026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cema-cel-trial-interim-data-cellectis2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cema-cel-alph3-trial-results-cellectis2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-innovation-strategy-board-appointments2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-proposed-public-offering2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-setdb1-inhibitor-drug-development2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-gdnf-mafld-obesity-data2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-third-quarter-fiscal-2026-results2026-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-refinances-convertible-bonds2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-fda-approval-filspari-fsgs2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMCL/omnicell-first-quarter-2026-financial-results2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-april-20262026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-gdnf-positive-data-mafld-obesity2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-acquisition-vectus-kidney-asset2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-innovation-strategy-appointments-board2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-public-offering-april-20262026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMED/minimed-announces-financial-results-q4-fy20262026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-april-2026-investor-conference2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bridgebio-oncology-inducement-grants-april-20262026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-mayo-clinic-collaboration-sc4512026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-innovations-aorn-global-surgical-conference-20262026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-1-trial-vir-5500-prostate-cancer2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/lineage-forms-scientific-advisory-board2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-allogene-alpha3-trial-results2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-bevacizumab-advanced-ovarian-cancer2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-aacr-annual-meeting-20262026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-jeff-knight-coo2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-expands-biomanufacturing-infrastructure-testing-facility2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/ai-platforms-enhance-jaguar-health-crofelemer-development2026-04-14T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-financing-update2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-acquisition-american-industrial-partners2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-dividend-increase-20232026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-q1-2026-results-outlook2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-us-grant-program-comp360-training2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inducement-grants-nasdaq-rule-56352026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-adds-peter-lebowitz-advisory-board2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-first-quarter-2026-financial-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-conference-call-may-20262026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-ai-powered-data-platform-alzheimers-research2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-advanced-therapies-community-care2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/findings-long-term-analysis-lybalvi-schizophrenia2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-cmnd-100-phase-i-ii-trial-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-q1-2026-results-report2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-2026-bloom-burton-conference2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-launches-respiratory-inhalation-products-us2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-strive-on-phase-3-trial-results-aan-20262026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-abstract-accepted-2026-aan-meeting2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-report-first-quarter-2026-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-appoints-andrew-fang-head-business-development2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/real-world-evidence-industry-momentum-imdx-graftassure-assay2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-biafine-launch-online-ordering2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-q1-2026-results-update2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-appoints-glenn-reicin-cfo2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-new-data-ats-2026-conference2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-proposed-offering-senior-secured-notes2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-first-quarter-2026-financial-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-investor-webinar-april-21-20262026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-launches-withzeta-ai-for-cancer-drug-discovery2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-first-quarter-financial-results-report2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-webinar-osteoporosis-treatment-eb6132026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-pancreatic-cancer-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/openloop-health-at-home-sleep-apnea-test2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-acquires-crossbridge-bio2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-data-driven-discovery-pediatric-cancer2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-mychoice-test-prostate-cancer-japan2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-2-billion-offerings2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-pricing-public-offering2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-public-offering-pricing2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-acquires-car-platform-technology2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-first-patient-phase-3-ipax-bright-trial2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2026-earnings-announcement2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-shareholder-vote-april-20262026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-phase-2-b-supreme-study-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-appoints-matthew-lang-coo2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-inducement-grant-nasdaq-rule-56352026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-prices-upsizes-convertible-bonds-600-million2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-first-quarter-earnings-report-20262026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-appoints-jorge-santos-vp-sales2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q1-2026-conference-call2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/logicare3pl-selected-distribution-partner-harrow2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-first-quarter-2026-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CON/concentra-chief-medical-officer-retirement2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/first-patients-dosed-cabaletta-bio-rese-cel2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-bloodstream-infection-testing2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-first-quarter-2026-financial-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-q1-2026-earnings-release-call2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-report-first-quarter-2026-results2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/pepfar-global-fund-investment-gilead-lenacapavir2026-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-cancer-dx-test-lymphoma-dogs-germany2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-phase-3-ipax-bright-trial-tlx101-tx2026-04-15T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-prices-upsizes-convertible-bonds-offering2026-04-15T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-omnidawn-mals-detector-launch2026-04-15T02:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-diagnostic-case-study2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-inducement-grants-april-20262026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-q1-2026-financial-results-release2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-first-quarter-2026-financial-results2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-first-quarter-2026-earnings-announcement2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q1-2026-financial-results2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-inducement-grant-april-20262026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-phase-2-b-supreme-study-results2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-system-release-needham-conference2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-lenacapavir-hiv-prevention-investment2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/galera-obsidian-merger-agreement-private-placement2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOVT/novanta-first-quarter-2026-earnings-release2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QSI/quantum-si-single-molecule-protein-sequencing-cancer2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-aacr-2026-abstracts-presentation2026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-new-data-ats-conference-20262026-04-15T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q1-2026-financial-results-webcast2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-report-first-quarter-2026-results2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-advances-robotic-tms-therapy2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-acquires-safari-flower-company2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-eliminate-b-trial-expansion2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/usana-schedules-first-quarter-2026-earnings-release2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-first-quarter-2026-financial-results-webcast2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-appoints-charles-morris-cmo2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-positive-dsm-recommendation-cmnd-100-trial2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-kol-event-ath434-msa2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/boehringer-ingelheim-zai-lab-dll3-collaboration2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-d-boral-capital-global-conference-20262026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-entolimod-radiation-countermeasure-presentation2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-dr-sudha-rao-appointment2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-cancer-research-solutions-aacr-20262026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-fda-orphan-drug-designation-eftilagimod-alfa2026-04-15T12:19:55.161Zmonthly0.5https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-simufilam-preclinical-data-publication2026-04-15T12:20:17.488Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-announces-letter-to-shareholders2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-allocation-allo-329-autoimmune-diseases2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-private-placement-financing2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-q1-2026-financial-results-release2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-first-quarter-2026-financial-results-conference-call2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-rit-solution-expands-access-oncology-trials2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUNA/auna-reporting-dates-q1-20262026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-content-innovation-engine-aacr-20262026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-corp-securities-fraud-lawsuit2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-securities-fraud-lawsuit2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-geneial-loi-rare-disease-cohorts2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-pinnacle-award-20262026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-first-quarter-2026-results2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q1-2026-financial-results2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-first-quarter-2026-financial-results2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-fda-agreement-outpatient-dosing-nkx0192026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-redomiciliation-united-states2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-preliminary-revenue-update-q1-20262026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-q1-2026-financial-results-report2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-inducement-grants-nasdaq-rule-56352026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-pricing-senior-secured-notes-offering2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-top-100-global-innovator2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-divest-lab-products-eurobio-scientific2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-first-quarter-2026-results-announcement2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-participate-bank-america-healthcare-conference2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-first-quarter-2026-results2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-permanent-j-code-epioxa2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-fda-review-extension-molgramostim2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGI/organigram-acquisition-sanity-group-financing2026-04-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/biopharma-layoffs-slow-q1-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-2026-agm-announcement2026-04-16T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-divests-lab-products-business-eurobio-scientific2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-bank-america-2026-healthcare-conference2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q1-2026-results-announcement2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-q1-2026-financial-results2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-preliminary-revenue-q1-2026-update2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-report-q1-2026-results-conference-call2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-full-year-2025-results-highlights2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q1-2026-results2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-2025-financial-results2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/neutrolis-appoints-caren-deardorf-cbso2026-04-16T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-exclusive-license-amoytop-pevifoscorvir-china2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-first-quarter-2026-financial-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-honors-transparency-resiliency-partnership2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-compact-crispr-nuclease-publication2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-private-placement-financing2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-vibrance-1-phase-2-study-presentation-aan-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-2025-sustainability-report-release2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-earnings-conference-call-april-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-aan-presentation-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-cheryl-blanchard2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-presentations-scientific-conferences2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-dr-ken-kramer-medical-affairs2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-first-quarter-2026-financial-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-appoints-glenn-gormley-board-directors2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-preclinical-data-aacr-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-appoints-svetlana-makhni-cfo2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-report-first-quarter-2026-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-7-1-million-offering2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-asells-prostate-cancer-collaboration2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-q1-2026-financial-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-present-argus-trial-data-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medicals-ulta-technology-heart-rhythm-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-first-quarter-2026-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-conference-call-q1-2026-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-first-quarter-2026-financial-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/hca-healthcare-hospitals-modern-healthcare-top-1002026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-q1-2026-results-conference-call2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/cms-permanent-reimbursement-j-code-yartemlea2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/city-of-hope-evaluate-quest-diagnostics-haystack-mrd2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-issues-stockholder-letter-corporate-update2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-israeli-market-entry-fertility-portfolio2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft839-aacr-presentation2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-expands-caldolor-indication2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/achieve-4-foundayo-phase-3-results2026-04-16T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-first-quarter-2026-financial-results-call2026-04-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-streamlined-brand-architecture2026-04-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-q1-2026-results-acquisition-exact-sciences2026-04-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-iopidine-j-code-announcement2026-04-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-intranasal-foralumab-long-covid2026-04-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-poster-presentation-ddw-20262026-04-16T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-restructuring-cost-reduction-initiative2026-04-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-cfo-succession-plan2026-04-16T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-announces-q1-2026-financial-results2026-04-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-medicare-claim-review-infoods-ibs2026-04-16T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-first-quarter-2026-financial-results2026-04-16T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-pricing-offering-common-stock2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-first-quarter-earnings-release2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-public-offering-463-million2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-first-quarter-2026-earnings-call2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-public-offering-common-stock2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-first-quarter-financial-results-april-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q1-2026-financial-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-first-quarter-2026-financial-results-call2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-jones-trading-fireside-chat2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-symbotic-ai-robotics-partnership2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-first-quarter-2026-results-conference-call2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHAB/enhabit-stockholder-meeting-may-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-first-quarter-2026-financial-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-expands-mammography-collaboration2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-first-quarter-2026-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-showcase-sample-insight-solutions-aacr-20262026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-first-quarter-2026-earnings-release2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-first-quarter-2026-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-first-quarter-2026-financial-results2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-phase-1-study-janx0142026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-first-quarter-2026-financial-results-announcement2026-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-launches-mygenuis-pro-escmid-20262026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-vibrant-trial-data-ats-20262026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-host-analyst-event-april-20262026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ann-cunningham-appointment2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-opens-training-innovation-center-breda2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-voluntary-delisting-nasdaq2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-appoints-habib-dable-board2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALPS/alps-group-appoints-hee-lee-board-directors2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-precision-oncology-ucsf-joining-alliance2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUNA/auna-preliminary-key-performance-indicators-q1-20262026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquisition-arcellx-regulatory-approvals2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/aidabreast-multi-omic-assay-clinical-oncology2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/nyse-content-update-aevex-public-debut2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-darlifarnib-cabozantinib-ccrcc-results2026-04-17T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-orphan-drug-designation-skinject-gorlin-syndrome2026-04-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-data-aan-annual-meeting2026-04-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-sales-growth-q3-20262026-04-17T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-aacr-annual-meeting-20262026-04-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-spatial-biology-aacr-20262026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-virtual-event-igalmi-launch-plan2026-04-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-submission-update2026-04-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-emjx-shareholder-update2026-04-17T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-expands-maldi-biotyper-ir-biotyper-workflows2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-private-placement-13-9-million2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-john-bertrand-board2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-ipo-pricing2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-2026-aan-meeting2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-expands-mammography-collaboration-deephealth2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-showcase-oncology-solutions-aacr-20262026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-q1-2026-financial-results2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-next-gen-heart-platform-ishlt-20262026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-q1-2026-earnings-release2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-closing-7-1-million-offering2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-jones-trading-aacr-chat2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-inducement-awards-april-20262026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-200-million-offering2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-report-first-quarter-2026-results2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-refinances-term-loan-increases-flexibility2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-q1-2026-financial-results2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QSI/quantum-si-first-quarter-2026-financial-results2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIR/mirion-earnings-release-conference-call-q1-20262026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-asstellas-collaboration-prostate-cancer2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-phase-3-argus-trial-data-presentation2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-conference-call-first-quarter-2026-results2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-ulta-technology-heart-rhythm-20262026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q1-2026-earnings-release2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-q1-2026-financial-results2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-announces-q1-2026-financial-results2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-first-quarter-2026-results-conference-call2026-04-17T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-aacr-2026-presentation2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-phase-3-data-alxn1840-wilson-disease2026-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-azetukalner-phase-3-study-results-2026-aan2026-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-1-data-zoldonrasib-aacr-20262026-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-nasdaq-notice-late-form-10k-filing2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-ai-immunology-cancer-vaccine-trial-results2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-ai-immunology-glioblastoma-vaccine2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-azenosertib-preclinical-data-aacr-20262026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-q1-2026-earnings-release-details2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/advancements-in-cancerguard-multi-cancer-detection2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-secondary-public-offering2026-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/prame-directed-cell-therapy-pediatric-nephroblastoma2026-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-second-public-offering2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-phase-3-diamond-program-ocs-01-completion2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-completes-follow-up-phase-3-diamond-trial-ocs-012026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-secondary-public-offering-price2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-trial-data-aacr-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-first-quarter-2026-financial-results2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSCR/meet-lucie-new-way-shop-healthcare2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-pricing-90-million-offering2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-needham-virtual-psychedelics-forum2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-presents-data-ishlt-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-fda-approval-pimozide-launch2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/deucrictibant-ir-xr-combined-use-evidence-ciic-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/fda-priority-review-keytruda-bladder-cancer2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-appoints-andreas-grauer-cmo2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-psychedelic-medications-approval2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-chairman-marc-elia-politico-summit2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-technology-heart-rhythm-society-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-nuzefatide-update-aacr-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-introduces-alloseq-nano-efi-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-acquisition-lex-diagnostics2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-positive-results-cmnd-100-aud-trial2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2026-q1-earnings-call2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-positive-phase-3-data-aacr-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-agreement-tj-biopharma-felzartamab-china2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-appoints-christy-shafer-cfo2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-updates-presentation-type-1-diabetes-program2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-andreas-grauer-cmo-appointment2026-04-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-reqorsa-gene-therapy-lung-cancer-aacr-20262026-04-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-advances-ptsd-treatment-psychedelics2026-04-20T10:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prl13722-preclinical-data-aacr-20262026-04-20T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-uplift-d-trial-updates2026-04-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-phase-3-diamond-program-completion-ocs-012026-04-20T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-nanoprimer-lnp-dna-immunotherapy2026-04-20T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-155-data-escmid-20262026-04-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-rare-pediatric-disease-designation-nf12026-04-20T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-aacr-2026-molecular-glue-degrader2026-04-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-acquires-cathworks-cardiovascular-care2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-launches-pimozide-tablets-fda-approval2026-04-20T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WW/weight-watchers-appoints-heather-thiltgen-board2026-04-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-qtorin-rapamycin-results-issva-20262026-04-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-phase-1-heat-trial-20262026-04-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-appoints-kyle-lynch-cgo2026-04-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-ishtl-2026-data-presentation2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-phase-ib-study-acd856-completed2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-aacr-2026-preclinical-studies2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-pricing-34-million-offering2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-preclinical-data-aacr-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/ttp-group-sale-lex-diagnostics2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-aacr-2026-adc-data2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-azetukalner-phase-3-study-results-aan-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-long-term-incentive-programs-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-share-transactions-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-1-data-zoldonrasib-nsclc-aacr-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-conference-call-rezolve-aa-results-april-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-pmda-align-cardiamp-approval2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q1-2026-financial-results-update2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-atera-spatial-biology-platform2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-elevate-pd-results-crexont-parkinsons2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-pln-101095-aacr-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-q1-2026-financial-results-call2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-zl-1503-preclinical-data-itich-relief2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-appoints-felecia-ettenberg-chief-legal-officer2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-ordinary-shares-nasdaq2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-vyvgart-2026-aan-meeting2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q1-2026-financial-results-call2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-private-placement-closing2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inducement-grant-april-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GDRX/goodrx-q1-2026-earnings-release-conference-call2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-zocilurtatug-pelitecan-data-es-sclc2026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-matisse-phase-2-results-aacr-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-lp-300-lung-cancer-data2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-apollo-funds-agreement-medical-surgical-solutions2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-bbi-940-aacr-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-preclinical-data-aacr-20262026-04-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-supports-executive-order-psychedelic-research2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/dana-farber-cancer-institute-ignite-proteomics-study2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-first-quarter-2026-financial-results2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-aacr-2026-advancements2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/advancing-drug-pipelines-driving-valuation-biotech2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-q1-2026-financial-results2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-dividend-dream-bowl-tokens-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-white-house-executive-order-mental-health2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-invests-ambulatory-surgery-centers2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-completes-spin-off-first-tracks-biotherapeutics2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-leadership-cannabis-commitment-advancing-care2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-q1-2026-earnings-release2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-secundaria-oferta-acoes2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-preisfestsetzung-zweitplatzierung-aktien2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-secundaria-oferta-acciones2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-pricing-secondary-offering2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbcm-offerta-pubblica-secondaria-prezzo2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-launches-rnuq-webshop-broadening-product-range2026-04-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dario-improves-workplace-function-productivity2026-04-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezolve-aa-results-rezpegaldesleukin-alopecia-areata2026-04-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-trump-executive-order-psychedelic-innovation2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-compliant-nasdaq-requirements2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-report-first-quarter-2026-results2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-closes-173-million-offering2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-oppenheimer-2026-event2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-q1-2026-financial-results-report2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-q1-2026-financial-results-update2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-public-offering-common-stock2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-conference-call-may-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-annual-meeting-stockholders-20262026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-first-quarter-2026-financial-results2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-q1-2026-earnings-call2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-nominates-michael-dale-board-directors2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-board-appointment-bethany-sensenig2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-webcast-ozekibart-colorectal-cancer-update2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-osprey-clinical-study-results2026-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-inducement-grants-nasdaq-rule-56352026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-public-offering-pricing2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-inducement-grants-nasdaq-rule-5635c42026-04-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-appoints-bethany-sensenig-board2026-04-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/definium-therapeutics-inducement-grants-april-20262026-04-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-canadian-approval-navigation-system2026-04-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-stockholder-meeting-approval2026-04-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KLRA/kailera-closes-initial-public-offering2026-04-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMWL/amwell-reports-q1-2026-results2026-04-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-report-q1-2026-results-may-112026-04-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/danaher-first-quarter-2026-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-aacr-2026-ultrasensitive-ctdna-monitoring2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNH/unitedhealth-group-q1-2026-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-osmind-collaboration-psychedelic-treatments2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-webcast-q1-2026-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q1-2026-financial-results-update2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q1-2026-results-conference-call2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-first-quarter-2026-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-phase-1b-2a-resolve-trial-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-nasdaq-compliance-requirements2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/foundation-medicine-bmy-collaboration-mtap-deletion2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-first-quarter-2026-financial-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-zilganersen-alexander-disease-aan-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-regains-nasdaq-compliance2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-bria-ots-positive-data-aacr-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-available-saudi-arabia2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-closes-preferred-stock-transaction-merger2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q1-2026-financial-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-phase-3-peak-trial-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-q1-2026-financial-results-call2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-bap-pharma-global-partner-bot-bal-access2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OABI/omniab-report-first-quarter-2026-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-fiscal-2026-q2-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-phase-2b-trial-alto-207-trd2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-effectiveness-vcgs-toxicology2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-panel-discussion-needham-forum2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-appoints-arun-nagdev-cmo-pocus2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-q1-2026-results-conference-call2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-expands-alpha3-trial-south-korea-australia2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-closing-transaction-nexgel2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-abstract-accepted-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-first-quarter-2026-financial-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-first-quarter-2026-financial-results-conference-call2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/uipath-five-year-anniversary-nyse2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-class-action-lawsuit2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSTM/healthstream-first-quarter-2026-earnings-call2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-150-million-offering2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-presents-data-asco-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-daraxonrasib-aacr-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-phase-1-data-zw191-aacr-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-presentation-aky-2519-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/prostact-global-phase-3-late-breaking-abstract-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-first-quarter-earnings-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-redemption-convertible-senior-notes-20282026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-first-quarter-2026-financial-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-redomiciliation-us2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-silevertinib-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-asco-2026-oral-presentations2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-onvansertib-phase-2-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-rally-mf-phase-2-trial-asco-presentation2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-q1-2026-financial-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-upsized-public-offering-325-million2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-board-leadership-transition-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-first-quarter-results-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-interphex-2026-award-cellseal-cryocase2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-clinical-update-ozekibart-colorectal-cancer2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-asco-2026-optimum-02-trial-data2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-secondary-public-offering-completed2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-secondary-offering-completion2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-bap-pharma-global-partnership-bot-bal2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-bap-pharma-global-partner-bot-bal2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-bap-pharma-partnership-bot-bal-access2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-bap-pharma-partnership-bot-bal-access-programs2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-bap-pharma-partnership-innovative-therapies2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-update-garda-therapeutics-tender-process2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-appoints-kola-otitoju-chief-officer2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-2026-rbc-capital-markets-conference2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-q1-2026-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-first-quarter-2026-financial-results2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-first-quarter-financial-results-may-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-conference-call-q1-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presentation-abstracts-ishlt-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-secondary-public-offering-3-1-million-shares2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-public-offering-success2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/fda-approves-merck-idvynso-doravirine-islatravir2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-phase-3-rosetta-trial-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-asco-2026-presentations2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-phase-3-ringside-data-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-2-botensilimab-data-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-ndas-tinlarebant-stargardt-disease2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-q1-2026-financial-results-announcement2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-q1-2026-results-guidance2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/kashiv-biosciences-acquisition-amneal-pharmaceuticals2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-q1-2026-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-phase-3-results-tafasitamab-asco-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-tafasitamab-phase-3-asco-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-phase-3-study-tafasitamab-asco-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-phase-iii-tafasitamab-asco-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-tafasitamab-phase-3-study-asco-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-ddw-2026-presentation2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-first-quarter-2026-financial-results-announcement2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-positive-fda-feedback-ketamine2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-appoints-edward-conner-cmo2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-fda-approved-companion-diagnostic-keytruda2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/positive-clinical-data-biomarkers-reqorsa-gene-therapy2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-presents-pivotal-data-alkove-1-trial-2026-asco2026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-appoints-mark-hagler-president-corporate-strategy2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-pbgene-hbv-easl-congress-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q1-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-data-ahn-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-50-million-credit-facility2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-first-quarter-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q1-2026-results-webcast2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-first-quarter-2026-results-conference-call2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-abstract-presentation-asco-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-abstracts-asco-2026-crb-7012026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-key-manufacturing-milestone-tpst-20032026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-innovation-hrs-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-first-quarter-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-google-cloud-ai-partnership2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-conference-call-q1-2026-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-quarterly-dividend-declaration2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-filing-form-20-f-fiscal-year-20252026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q1-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-deepview-system-american-burn-association-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUTL/advancing-drug-pipelines-drive-biotech-valuations2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-first-quarter-2026-financial-results-release2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reverse-stock-split2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-fda-study-may-proceed-refisolone-phase-22026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-first-quarter-2026-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-present-long-term-pain-data-ecio-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q1-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-pricing-225-million-public-offering2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-nasdaq-notice-late-form-10-k2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-proposed-public-offering-securities2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-q1-2026-conference-call2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-q1-2026-results-conference-call2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-first-quarter-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-first-quarter-2026-financial-results-earnings-call2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-lb-102-jama-psychiatry-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-hope-3-results-aan-20262026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-strengthens-leadership-team-phase-3-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-report-q1-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/danaher-prices-euro-denominated-senior-notes-offering2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-dr-charles-duncan2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q1-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-cookeville-rehabilitation-hospital2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-retirement-david-reese2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-third-quarter-fiscal-2026-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-q1-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-first-quarter-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-tender-offer-notes2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-declares-second-quarter-2026-dividend2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-first-quarter-2026-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USPH/us-physical-therapy-q1-2026-earnings-release2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-dt120-clinical-advancements2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-neurosterix-phase-1-ntx-253-schizophrenia2026-04-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-presents-2026-asco-annual-meeting2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTMD/biote-first-quarter-2026-financial-results-release2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGC/igc-pharma-adds-kerwin-medical-center-calma-trial2026-04-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-stock-offering-announcement2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/emerging-growth-research-report-immuron-price-target2026-04-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-completes-public-offering-310-million-shares2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-abstract-accepted-asco-20262026-04-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbcm-offerta-pubblica-secondaria-chiusura2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-cierre-venta-secundaria-acciones2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-announces-stock-repurchase-plan2026-04-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-cloture-offre-publique-secondaire2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-updated-guidelines-liberty-system2026-04-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-second-quarter-2026-earnings-release2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q1-2026-results-webcast2026-04-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/prospera-evidence-heart-lung-transplantation-ishlt2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-present-long-term-pain-mitigation-data2026-04-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-oncology-innovation-asco-20262026-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-2026-first-quarter-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-abstract-accepted-asco-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-first-quarter-2026-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-q1-2026-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-first-quarter-2026-earnings-release2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-q1-2026-earnings-call-info2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-present-april-2026-investor-conferences2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-first-quarter-2026-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-inducement-grant-nasdaq-rule-56352026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/brewdog-usa-innovation-spring-summer-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-first-quarter-2026-financial-results-call2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-hcp-perspectives-burden-tpn-sbs-ddw-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNBX/bnb-plus-corp-completes-historic-1-2-million-lineadna-order2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-manufacturing-spectronrx-reyobiq2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-appoints-andrew-chan2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-strengthens-advisory-board2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-q1-2026-financial-results2026-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-q1-2026-financial-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-first-quarter-2026-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-tweed-summer-campaign2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-ibs-c-treatment-patterns-ddw-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-report-q1-2026-financial-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-documentary-vagus-nerve-stimulation2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-q1-2026-financial-results-release2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-fireside-chat-brilaroxazine-neuropsychiatric-indications2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-obesity-day-may-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-participate-investor-conferences2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-milestone-payment-bms2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reverse-stock-split-april-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q1-2026-results-report2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-q1-2026-financial-results-announcement2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-launches-zoranex-ai-platform2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-upcoming-investor-conferences-may2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-18-million-offering2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-first-quarter-2026-financial-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-first-quarter-2026-earnings-call2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-participate-ntsad-conference2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-phase-iia-allocetra-oarsi-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-q1-2026-earnings-call2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-treats-first-pancreatic-cancer-patient-europe2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-apotex-integration2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATEC/atec-report-first-quarter-2026-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/understanding-addressing-syphilis-trends2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-inducement-grants-nasdaq-rule-56352026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-5-million-offering2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-may-events-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-report-q1-2026-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-q1-2026-financial-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-appoints-jessica-chutter-board2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q1-2026-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-ludovic-brellier-executive-vice-president2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-bofa-securities-2026-conference2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-first-quarter-2026-earnings-release2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-q1-2026-financial-results-teleconference-details2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-public-offering-373-8-million2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q1-2026-results-update2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q1-2026-results-conference-call2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-bank-america-2026-conference2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-q1-2026-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-appoints-david-duckworth-interim-cfo2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-first-quarter-results-conference-call2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-q1-2026-financial-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-conference-call-q1-20262026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-first-quarter-2026-financial-results2026-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-agreement-lower-drug-costs-gene-therapy-free2026-04-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/median-technologies-2025-financial-results-q1-2026-highlights2026-04-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGNY/progyny-q1-2026-results-report2026-04-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-regulatory-update-gtx-1042026-04-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/otarmeni-gene-therapy-fda-approval-regeneron2026-04-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/orchestra-biomed-avim-therapy-hrs-20262026-04-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-vascade-mvp-xl-study-safety-efficacy2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-positive-chmp-opinion-redepmplo2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-first-quarter-2026-results2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-expiration-hsr-waiting-period-acquire-terns-pharmaceuticals2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-q1-2026-results-conference-call2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/radoff-jec-group-acquisition-proposal-seer2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/hca-healthcare-first-quarter-2026-results2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-q1-2026-earnings-release-webcast2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-inducement-awards-nasdaq-rule-56352026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/aetna-progress-prior-authorization-simplification2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-private-placement-financing2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OABI/omniab-participate-upcoming-investor-conferences2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-oral-presentation-gba1-meeting-20262026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-first-quarter-2026-financial-results2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-earnings-report-may-20262026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-presentation-bofa-goldman-sachs-conferences2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-report-first-quarter-2026-results2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-2025-annual-report2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-conference-call-week-16-data-orka-0012026-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-phase-3-haelo-trial-lonvoguran-ziclumeran2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/delaware-court-rules-anaptys-tesaro-breach-claim2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-heart-rhythm-2026-data2026-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-webcast-2026-first-quarter-results2026-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/sun-pharma-acquires-organon2026-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-conference-call-phase-2-3-study-vdphl012026-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-positive-results-vclas-system2026-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-cardiac-catheter-heart-rhythm-20262026-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-psy-pan-silver-award-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMM/global-food-beverage-disinfection-cleaning-market-outlook-2025-20352026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-josh-lehrer-board2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-inset-i-135rfx-launch2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-positive-phase-3-results-lonvo-z-hai2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-kol-webinar-on-onvansertib2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-may-conferences-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/usana-glow-skin-supplement-launch2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-vdphl01-positive-phase-2-3-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-pricing-offering-series-a-common-stock2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-positive-fda-feedback-ath4342026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-clinical-data-presentations-asco-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-appoints-keith-vendola-cfo2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-first-quarter-2026-financial-results-call2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-first-quarter-2026-financial-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-clinical-evidence-leadership-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-q1-2026-results-announcement2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-fda-acceptance-zanidatamab2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-nccn-guidelines-taletrectinib2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-first-quarter-2026-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-stenoparib-drp-test-patent-allowance2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-promotes-birgitte-rono-coo-cso2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-virtual-kol-event-phase-2-bezisterim-parkinsons2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-report-first-quarter-2026-financial-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-full-year-2025-financial-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-virtual-kol-event-atev-hemodialysis2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-oral-presentation-retinal-therapeutics-summit2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-fda-application-infants-atopic-dermatitis2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-presents-asco-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-dr-moore-appointment-research-agreement2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-sells-microbiology-business-astorg2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-four-year-supply-agreement-intercept-blood-system2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-investor-conferences-may-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/redhill-biopharma-full-year-2025-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/hca-announces-proposed-public-offering-senior-notes2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-first-quarter-2026-financial-results-conference-call2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-ridge-1-phase-1b-2-trial-asgct-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-announces-registered-direct-offering2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XGN/exagen-announces-q1-2026-financial-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AHG/ahg-brain-computer-interface-rd-program2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-participation-upcoming-conferences2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-european-patent-application-drug-delivery2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/haleon-appoints-richard-manso-cmo2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-strategic-corporate-updates2026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-fda-application-skyrizi-crohns-disease2026-04-27T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-appoints-daniel-gilmer-board2026-04-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/sun-pharma-acquires-organon-11-75b2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-acquisition-amicus-therapeutics2026-04-27T13:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-fda-pivotal-anal-cancer-study2026-04-27T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-first-quarter-2026-financial-results2026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-priority-review-imaavy-nipocalimab-waiha2026-04-27T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/ligand-acquire-xoma-royalty-accelerate-profit-growth2026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-ridge-1-trial-asgct-20262026-04-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-fda-breakthrough-therapy-tern-7012026-04-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-rejects-radoff-jec-group-proposal2026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-zovegalisib-atirmociclib-breast-cancer2026-04-27T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-filing-european-patent-drug-delivery-platform2026-04-27T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/exparel-reduces-opioid-use-medical-costs-hip-surgery2026-04-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-positive-week-16-data-orka-0012026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-fda-application-lonvo-z2026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-positive-phase-3-results-lonvo-z2026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ceo-lawmakers-energy-commerce2026-04-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-participate-medical-conferences-may-20262026-04-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-t-cell-engager-update2026-04-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-business-highlights-q1-20262026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-josh-lehrer-board-appointment2026-04-27T10:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-clinical-study-et-7002026-04-27T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-conference-call-phase-1-data-eras-00152026-04-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-presentation-pancreatic-cancer-asco-20262026-04-27T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-rezafungin-phase-iii-results2026-04-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/tovecimig-significant-benefit-companion-002-biliary-cancer2026-04-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-evaluates-meai-fda-breakthrough-designation2026-04-27T11:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-virtual-kol-event-bezisterim-parkinsons-disease2026-04-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-fda-snda-zoryve-atopic-dermatitis-infants2026-04-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-abstract-presentation-nkf-spring-meetings2026-04-27T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-reports-2025-financial-results-clinical-updates2026-04-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-closes-225-million-public-offering2026-04-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-proposed-public-offering-common-stock2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-wins-gold-silver-stevie-awards-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-discontinuation-janx008-development2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-first-quarter-update-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-q1-2026-financial-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-aleniglipron-ada-sessions2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-advanced-2-trial-update2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-first-quarter-2026-financial-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-prices-senior-notes-offering2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-presents-bank-america-health-care-conference2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-500-million-offering2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-q1-2026-financial-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-q1-2026-results-revenue-trends2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-preliminary-q1-2026-results-sales-trends2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-appoints-tim-orourke-ceo2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-preclinical-data-edit-401-hyperlipidemia2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-asgct-presentation-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-report-q1-2026-results-conference-call2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-epigenetic-editing-asgct-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-preclinical-data-asgct-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACS/pacs-group-appoints-carey-hendrickson-cfo2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACS/pac-group-announces-retirement-cfo-mark-hancock2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-bernstein-conference-participation2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-first-quarter-2026-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-regulatory-change-brazil2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-upcoming-presentations-asgct-20262026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/hca-healthcare-cynthia-cifuentes-finkel-appointment2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-launch-public-offering2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-phase-2-covalent-112-trial-results2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/new-study-targets-brain-metastasis-mn-1662026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/educational-webinar-psma-therapy-tlx2026-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/bepirovirsen-priority-review-fda2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-first-quarter-2026-earnings-call2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-first-quarter-2026-financial-results-call2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-secures-cms-reimbursement-paradigm-trial2026-04-28T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-appoints-daniel-keefe-commercial-director2026-04-28T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/gsk-bepirovirsen-priority-review-fda2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/survodutide-phase-3-trial-results-weight-loss2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-launches-public-offering2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-bernstein-conference-20262026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-advances-clinical-translation-brain-metastasis2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-q1-2026-results-sales-outlook2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-fast-track-designation-coramitug-attr-cardiomyopathy2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-discontinues-janx008-development2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q1-2026-financial-results2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-positive-results-phase-2-trial-icovamenib2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-eu-approval-palsonify-acromegaly2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-asgct-2026-presentations2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-preclinical-data-tsha-102-rett-syndrome2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-sg293-asgct-2026-presentation2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-epigenetic-editing-platform-asgct-annual-meeting2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-first-quarter-2026-results-conference-call2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-cns-gene-therapies-asgct-20262026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-force-platform-cns-activity-asgct-20262026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-clinical-update-april-20262026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-positive-phase-1-data-eras-00152026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-public-offering-common-stock-20262026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-adeniglipron-ada-20262026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-predictcell-training-commercial-readiness2026-04-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-playing-with-heart-program-ldl-c-awareness2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-announces-110-million-private-placement2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-investor-conferences-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-first-quarter-2026-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-milestone-buyout-agreement2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-q1-2026-financial-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-preclinical-data-diabetes-gene-therapy-asgct-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-asgct-2026-presentation2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/fda-accepts-zipalertinib-nda-nsclc-treatment2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-bofa-securities-2026-health-care-conference2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-sale-priority-review-voucher2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-bofa-securities-2026-conference2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-phase-3-flash2-trial-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-participate-barclays-leveraged-finance-conference2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presentations-european-society-cardiology-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-tara-mind-veteran-mental-health2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-icv-delivery-cns-gene-therapy-presentation2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-subsitipharm-manufacturing-partnership-je-vaccine2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-market-movers-investor-summit-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q1-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-medaxiom-cv-transforum-spring-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-phase-2-3-alzheimers-trial-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-japanese-patent-heart3d-fusion-imaging2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-first-quarter-2026-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cellares-cabaletta-bio-commercial-supply-agreement2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q1-2026-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-participate-2026-bank-america-conference2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-letter-shareholders-2026-meeting2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-science-machine-collaboration2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-market-access-strategy-botanical-drugs2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-olympia-pharmaceuticals-partnership2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-launches-sport-performance-eyewear2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-nominates-kofi-amoo-gottfried-board2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquisition-arcellx-anito-cel-launch2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-ultrasome-knee-osteoarthritis2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-investor-alert-false-claims2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-pivot-hd-results-webcast2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-settlement-agreements-vyndamax-patent2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-poster-presentation-asgct-2026-atr-01-ichthyosis-vulgaris2026-04-28T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-fda-application-upadacitinib-alopecia-areata2026-04-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-appoints-michael-panzara-cmo2026-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-fda-clearance-ultreon-3-0-ai-imaging-platform2026-04-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-secures-390k-order-quantum-research2026-04-28T12:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-participate-upcoming-investor-conferences2026-04-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-first-quarter-2026-results2026-04-28T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q1-2026-financial-results-update2026-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-phase-2-3-clinical-trial-application-germany2026-04-28T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-orphan-drug-designation-sgt-0032026-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-first-quarter-2026-financial-results2026-04-28T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-clinical-regulatory-update-qrx0092026-04-28T16:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-shield-ii-trial-data-presentation2026-04-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-blue-shield-california-coverage-cnside-assay2026-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-peer-reviewed-publication-chronic-insomnia2026-04-28T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/aacr-2026-combo-therapies-moderna-marengo-skin-breast-cancer2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q1-2026-financial-results2026-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-regains-nasdaq-compliance-minimum-bid-price2026-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q1-2026-earnings-call2026-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-ultrasome-knee-osteoarthritis-breakthrough2026-04-28T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-regulatory-rna-profiling-study2026-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-cellares-commercial-supply-agreement-rese-cel2026-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-phase-1b-2a-results-asgct-20262026-04-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-present-upcoming-investor-conferences2026-04-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-launches-health-education-attr-cm2026-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-first-quarter-2026-results2026-04-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-milestone-buyout-option2026-04-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-buntanetap-phase-2-3-alzheimers-results2026-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-phase-1a-results-ati-052-ati-21382026-04-28T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-insider-led-pipe-financing2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-inducement-grant-nasdaq-rule-5635c42026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-participate-investor-conferences-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-shareholders-approve-resolutions-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-shareholder-meeting-2026-approvals2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q1-2026-results-update2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-acquires-naveris-viral-cancer-testing2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-q1-2026-financial-results-call2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-investor-conferences-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-q1-2026-financial-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRC/nrc-health-first-quarter-2026-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-first-quarter-fiscal-year-2026-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-2026-first-quarter-financial-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q1-2026-earnings-call-date2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-april-20262026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-announces-q2-fy2026-results-may-272026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-fy-2025-financial-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-report-q1-2026-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEM/select-medical-expiration-hart-scott-rodino2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-q1-2026-financial-results2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-imsiidolimab-publication-nejm-evidence2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-upsized-public-offering-700-million2026-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-positive-results-pivot-hd-study2026-04-28T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-set-oximetry-accuracy-newborns-study2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-set-pulsoximetrie-nauwkeurig-gehospitaliseerde-pasgeborenen2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-set-accuracy-study-neonates2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-phase-3-trial-chronic-low-back-pain2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-bofa-conference-20262026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-priority-review-beone-medicines-tevimbra2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-executive-team-updates-innovation-growth2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-first-quarter-2026-financial-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-centrovena-one-insertion-system-launch2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-elrexfio-improves-pfs-multiple-myeloma2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-davis-schneider-narcan-awareness2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-pricing-public-offering2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-report-first-quarter-2026-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-conference-call-may-20262026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-first-clinical-trial-site-function-dmd2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-q1-2026-financial-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-q1-2026-earnings-release2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-professor-dwek-retirement2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-annual-report-fiscal-year-20252026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2026-annual-meeting-shareholders2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-cancels-first-quarter-earnings-call2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-ndas-varegacestat-desmoid-tumors2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-emergency-authorization-new-world-screwworm2026-04-29T00:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-eu-approval-xolremdi-mavorixafor2026-04-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-phase-2-lyme-disease-study2026-04-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-sab-biotherapeutics-sab-142-contract2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-q1-2026-financial-results2026-04-29T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-ceo-cso-present-scientific-conferences-may2026-04-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-sol-x-trial-axpaxli-wet-amd2026-04-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2026-financial-results2026-04-29T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-2026-first-quarter-financial-results2026-04-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-first-quarter-2026-financial-results-update2026-04-29T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-gabab-pam-candidate-antitussive-activity-ipf-cough2026-04-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/chiesi-acquires-kalvista-pharmaceuticals-rare-disease2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-first-quarter-2026-results2026-04-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-connected-ai-claims-intelligence-caremc2026-04-29T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-q1-2026-results-innovative-portfolio-growth2026-04-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-acquires-emalex-biosciences-ecopipam2026-04-29T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-annual-results-20252026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVO/evotec-se-first-quarter-2026-results-announcement2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-first-quarter-2026-results2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-may-2026-investor-conferences2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-completes-bla-submission-renu2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-el-22-patent-application2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-q1-2026-results-business-updates2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-participate-investor-conferences-april-20262026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-inducement-grant-nasdaq-rule-56352026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q1-2026-financial-results-update2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-first-quarter-2026-financial-results2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-q1-2026-results2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-first-quarter-2026-financial-results2026-04-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/chiesi-acquires-kalvista-pharmaceuticals-rare-diseases2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-advance-dual-targeting-car-t-platform-update2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q1-2026-results-conference-call2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-q1-2026-financial-results-webinar2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-pricing-underwritten-offering2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-conference-call-q1-2026-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-bofa-conference-20262026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-agp-healthcare-showcase2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-bofa-securities-2026-conference2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-bofa-securities-2026-conference2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/radoff-jec-group-responds-seer-rejection2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-ai-insights-temozolomide-glioblastoma2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-q1-2026-financial-results-conference-call2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-fda-priority-review-bictegravir-lenacapavir2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-abstract-acceptance-ddw-20262026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-predictbbb-ai-evolves-lqm2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-new-laboratory-germany2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-new-testing-laboratory-germany2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/optimal-psma-trial-tlx597-tx-prostate-cancer2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-report-first-quarter-2026-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-presents-bank-america-healthcare-conference2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-present-upcoming-investor-conferences2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-first-quarter-2026-financial-results-report2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-report-first-quarter-2026-financial-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q1-2026-results-announcement2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q1-2026-financial-results-webcast2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-report-q1-2026-financial-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-nasdaq-notification-late-filing-annual-report2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q1-2026-financial-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-first-quarter-2026-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-bofa-securities-2026-healthcare-conference2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/european-commission-approves-poherdy-pertuzumab2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-first-quarter-2026-financial-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-upsized-public-offering-private-placement2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-set-oximetry-accuracy-newborns-skin-tones2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-set-pulse-oximetry-study-newborns2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-set-pulse-oximetry-accuracy-study2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-first-quarter-2026-financial-results-update2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-webcast-q3-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-garda-tender-offer-deadline-extension2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-completes-senior-secured-refinancing2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-q1-2026-results-stock-repurchase2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-q1-2026-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-q1-2026-financial-results-report2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-first-quarter-2026-financial-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-investor-conferences-20262026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-migraine-care-program-launch2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-success-reserved-offering-84-million-euros2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-successful-reserved-offering-euro84-million2026-04-30T05:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-reports-2025-financial-results-corporate-update2026-04-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-form-10-k-update2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-investor-medical-conferences-may-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-participate-bank-america-health-care-conference2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-appoints-jason-weidman-ceo2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-first-quarter-2026-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-achieves-excellence-employee-well-being2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q1-2026-financial-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-2026-bank-america-healthcare-conference2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-q1-2026-financial-results-guidance2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-first-quarter-2026-results-may-82026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-present-may-2026-investor-conferences2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-first-quarter-2026-financial-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-q1-2026-financial-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-q1-2026-financial-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-set-pulse-oximetry-study-results2026-04-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-q1-2026-financial-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-first-quarter-2026-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-first-quarter-2026-financial-results-update2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-may-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-q1-2026-financial-results-update2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-participate-milken-institute-conference2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q1-2026-financial-results-update2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-reimagine-campaign-kras-ovarian-cancer2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-q1-2026-results-revenue-decline2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-acam2000-mpox-approval2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-nominates-dr-lykke-hinsch-gylvin-board2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-present-scientific-conferences-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-first-quarter-2026-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presentation-bank-america-conference2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-first-quarter-2026-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-tac-stim-named-semifinalist-safety-challenge2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q3-fy262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-nasdaq-bid-price-deficiency2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-q1-2026-results-presentation2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-darren-snellgrove-cfo2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-patent-grant-israel-reqorsa-pd1-antibodies2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-q1-2026-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-nuvalent-strategic-collaboration2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-appoints-ryan-koors-investor-relations2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-nda-darovasertib-rtor2026-04-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-q1-2026-financial-results-guidance2026-04-30T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-rhb-204-map-crohn-disease-development2026-04-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-conference-call-q1-20262026-04-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-asgct-2026-presentations2026-04-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-q1-2026-financial-results2026-04-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-successful-uk-mhra-pre-submission-meeting-amt-1302026-04-30T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q1-2026-financial-results-update2026-04-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-fortify-phase-1b-trial-pln-1010952026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q1-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-poster-presentation-sid-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-first-quarter-2026-update2026-04-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-small-business-innovator-award-texas2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-q1-2026-business-update-call2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-alector-nivisnebart-alzheimers-failure2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q1-2026-financial-results-update2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q3-fy26-update2026-04-30T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-cd47-biomarker-data-esmo-breast-cancer-20262026-04-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-q1-2026-financial-updates2026-04-30T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-phase-1b-2-abate-trial-alzheimers2026-04-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-financial-results-2025-type-1-diabetes-update2026-04-30T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-asgct-annual-meeting-20262026-04-30T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/bioreference-launches-direct-platform-access-testing2026-04-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/banner-health-advancement-total-artificial-heart-technology2026-04-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/sweetwater-salt-life-livin-salty-launch2026-04-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-q1-2026-results-nociscan-growth2026-04-30T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-refinances-credit-facility2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft819-sle-data-presentation-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-reverse-stock-split-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/fda-grants-orchestra-biomed-additional-breakthrough-device-designation2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/ibrx-lawsuit-alleges-chairman-overstated-drug-capabilities2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-q1-2026-earnings-release-webcast2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-philanthropic-effort-skin-cancer-awareness2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-annual-report-fiscal-year-20242026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-pricing-50-million-offering2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-limited-reports-full-year-2025-financial-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/tlx101-px-maa-accepted-europe2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-change-executive-team2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-management-change2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-special-meeting-adjourned2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-frataxin-skin-surrogate2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-release-q1-2026-financial-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-report-q1-2026-results-business-update2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-cfo-brett-sandercock-retires-aaron-bloomer-successor2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-q1-2026-operating-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-q3-fiscal-year-2026-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-release-date-second-quarter-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-presents-bofa-securities-2026-healthcare-conference2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capso-vision-first-quarter-2026-results-release2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-first-quarter-2026-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/hca-healthcare-presentation-may-conference2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-q1-2026-financial-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-board-declares-quarterly-dividend2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-dazucorilant-als-survival-benefit2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-pipeline-791-chronic-pain-trial2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-q1-2026-investor-update-call2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-elizabeth-thompson-retirement2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-webcast-q1-2026-updates2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-q1-2026-financial-results-update2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-first-quarter-2026-results2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-aao-2026-innovations2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/european-commission-approves-poherdy-pertuzumab-ogn2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/eu-approval-poherdy-biosimilar-perjeta-ogn2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-priority-review-tevimbra-beone-medicines2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-priority-review-tevimbra-her2-cancer2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-approval-beone-medicines-tevimabra-her2-cancer2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-priority-review-tevimbra-her2-plus-gea2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-priority-review-tevimabra-beone-medicines2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/ec-approves-poherdy-pertuzumab-henlius-ogn2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-set-pulse-oximetry-neonates-skin-pigmentation2026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-first-quarter-results-may-20262026-04-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-pipeline-advances-ks101-data-conferences2026-05-01T05:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-first-quarter-2026-financial-results2026-05-01T00:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-upsized-ipo-pricing2026-05-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/truqap-capivasertib-fda-recommendation-prostate-cancer2026-05-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-public-offering-80-million2026-05-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-reports-first-quarter-2026-results2026-05-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALC/alcon-2026-annual-general-meeting-results2026-05-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-report-first-quarter-2026-results2026-05-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-ipo-pricing-announcement2026-05-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-arvo-2026-presentation2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-q1-2026-results-guidance2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-investor-conferences-20262026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-200-million-repurchase2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-relaunches-hemangeol2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-zephyr-phase-2-trial-enrollment-completed2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-acog-2026-low-dose-estrogen-patch2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-first-quarter-2026-financial-results2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-present-investor-conferences-20262026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-auvelity-fda-approval-event2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-imcivree-authorization-europe2026-05-01T10:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-phase-1-mp0317-data-nature-cancer2026-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-acquired-by-archimed2026-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-report-first-quarter-2026-results2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-redepmplo-approval-australia2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/kevin-guest-smile-leaders-urge2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-voquezna-ddw-20262026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-q1-2026-results-conference-call2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-participate-bank-america-healthcare-conference-20262026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-inducement-grants-nasdaq-rule-56352026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PNTG/pennant-acquires-senior-living-communities2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-inducement-grant-nasdaq-rule-56352026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-appoints-dr-jeymi-tambiah-cmo2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-first-quarter-earnings-call-20262026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-first-quarter-results-may-20262026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-interview-bloomberg-tv2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-conference-call-may-20262026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-nereus-tradipitant-motion-sickness2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-fda-approval-jakafi-xr2026-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-fda-approval-jakafi-xr-myeloid-disorders2026-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/ten-year-pivotal-data-edwards-lifesciences-resilia-tissue2026-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-web3-strategic-layout2026-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-dll3-targeting-radio-darpin-conferences2026-05-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-investor-call-vistas-study-results2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-new-data-voxzogo-achondroplasia-20262026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-fda-approval-jakafi-xr-treatment2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-inducement-grants-nasdaq-rule-56352026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inducement-grants-nasdaq-listing-rule-56352026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-inducement-grant-nasdaq-rule-56352026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-phase-3-viktoria-1-trial-results2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-filing-form-10-k-nasdaq-compliance-strategic-transformation2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq-nams2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-crenessity-data-pediatric-cah2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVLN/avalyn-closes-initial-public-offering-ipo2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-employee-inducement-award-may-20262026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-voluntary-recall-cguard-prime-135-cm2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-fda-approval-cguardians-iii-study2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-dividend-dream-bowl-tokens-may-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-public-offering-common-stock2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-150-million-offering2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fda-approval-asceniv-pediatric-patients2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-175-million-accelerated-share-repurchase2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-first-quarter-2026-results-release2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-present-bank-america-healthcare-conference2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-simcere-dose-optimization-sim0505-gynecologic-cancers2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-presentation-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-business-updates-q1-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-2026-virtual-annual-meeting-stockholders2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-survey-findings-ddw-2026-tpn-short-bowel-syndrome2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-expands-clonal-genes-offering2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-ats-2026-presentation-arikayce-results2026-05-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-anthony-bazarko-cfo2026-05-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-acoramidis-data-esc-heart-failure-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-izicopan-reactive-metabolite-profile2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-1-study-nbip-2118-obesity2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-603-ibd-preclinical-data-ddw-20262026-05-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q1-2026-results2026-05-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-appoints-kartik-krishnan-cmo2026-05-04T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-european-licensing-agreement-navenibart2026-05-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q1-2026-financial-results2026-05-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-ceo-transition-phase-3-trial-update2026-05-04T10:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-may-2026-events2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/centrum-adults-50-complete-multivitamin-launch2026-05-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/10-barrel-brewing-launches-clean-slate-salty-sips2026-05-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-appoints-timothy-healey-cco2026-05-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVO/evotec-preclinical-development-candidate-dermatology2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q1-2026-results-investor-conference2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-fda-accelerated-approval-als2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-investor-conferences-may2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-new-data-setmelanotide-pes-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-general-meeting-shareholders-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-q1-2026-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-bernstein-conference-call-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-commercial-leadership-appointments2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-amended-merger-agreement-garda-therapeutics2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-investor-conference-call-aglatimagene2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-fda-approval-guardant360-cdx2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-phase-2a-data-alto-2072026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-webcast-xmab942-xmab412-ddw2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-names-michael-buckner-chief-legal-officer2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fda-rare-pediatric-disease-designation2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-cywc628-phase-1-2-trial2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q1-2026-results-update2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-hc-wainwright-conference-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-first-quarter-financial-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-lifesciences-moldx-approval-chromoseq-genomic-profiling2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-report-q1-2026-results-may-132026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-vutrisiran-heart-failure-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-upcoming-investor-conferences2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-launches-niagen-plus-telehealth-platform2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-us-patent-expansion-intranasal-drug-delivery2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-asgct-2026-presentations2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-additional-300-million-manufacturing-investment2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-260-million-offering2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-shareholders-approve-acquisition-danaher2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-first-quarter-2026-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-20-million-preferred-issuance2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-second-quarter-2026-dividend2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q1-2026-financial-results2026-05-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-rewalk-data-asia-2026-conference2026-05-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-announces-cash-dividend2026-05-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-colorectal-cancer2026-05-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-dna-pol-iiic-inhibitors-escmid-20262026-05-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/caplyta-lumateperone-efficacy-mdd-meta-analysis2026-05-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-tardive-dyskinesia-survey-results2026-05-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-smart-view-detect-ai-diagnostic-aid2026-05-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-participate-bofa-health-care-conference2026-05-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-phase-2-lotu-trial-qtorin-rapamycin2026-05-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-sagard-expanded-royalty-agreement2026-05-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-expands-scientific-advisory-expertise2026-05-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-acquisition-cullgen2026-05-04T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-100-local-disease-control-rate-ddw-20262026-05-04T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-vadadustat-post-hoc-analysis-publication2026-05-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/flyte-increases-capacity-hiring-initiative-spirit-airlines-shutdown2026-05-04T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-fiscal-year-2025-results-update2026-05-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-amended-loan-agreement-hercules-140-million2026-05-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-appoints-nadia-dac-cco2026-05-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-distribution-agreement-nuviodx-nanox-arc2026-05-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-participate-may-2026-investor-conferences2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNVC/nv-387-orphan-drug-designation-fda2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-launches-mpower-supply-chain-technology2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/opregen-3-year-results-geographic-atrophy2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-positive-results-tak-881-pid-trial2026-05-04T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q1-2026-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-private-offering-convertible-senior-notes2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-preclinical-data-burn-wound-healing2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-report-q1-2026-results-investor-conference2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-reports-first-quarter-2026-financial-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-phase-1b-trial-aky-2519-mcrpc2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-bank-america-conference-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-first-quarter-2026-financial-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staaar-surgical-first-quarter-2026-earnings-call2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-inducement-grants-nasdaq-rule-56352026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-hc-wainwright-conference-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-appoints-paul-keel-board-directors2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-first-quarter-2026-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-q1-2026-financial-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-cfo-transition-paul-campbell2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-first-quarter-financial-results-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-q1-financial-results-may-20262026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-business-update-q1-2026-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-benefit-hf-trial-first-patient-enrollment2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-first-quarter-2026-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSTM/healthstream-first-quarter-2026-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-first-quarter-2026-financial-report-update2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-appointment-cfo2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-announces-strong-q1-results2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/tlx250-px-potential-in-diagnosing-kidney-cancers2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-expands-distribution-agreement-atlanta-dental2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-predictt-clinical-trial-liver-tumors2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-protocol-amendment-nanoray-312-study2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-amendment-nanoray-312-study-protocol2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-upcoming-investor-conferences2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-q1-2026-results-and-business-developments2026-05-04T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-first-quarter-2026-results2026-05-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PNTG/pennant-announces-first-quarter-2026-earnings-release2026-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-heart-failure-2026-vutrisiran-analyses2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-heart-failure-congress-2026-vutrisiran2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/dme-aware-delphi-study-arvo-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-q1-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-q1-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACS/pacs-group-first-quarter-2026-earnings-release2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-financial-results-q1-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-first-quarter-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-first-quarter-results-2026-guidance2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-quarterly-dividend2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-first-quarter-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-first-quarter-2026-financial-results-webcast2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-ndv-01-aua20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-first-quarter-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-q1-2026-financial-results-update2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-commercial-manufacturing-ketamine2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-reports-eref-data-resolve-trial-eoe2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-eco-2026-poster-presentations2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-q1-2026-results-update2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-q1-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-expanded-access-program-post-bariatric-hypoglycemia2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-q1-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-2025-sustainability-report2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-first-quarter-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-q1-2026-financial-results-update2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-present-results-phase-3-calibrate-trial-ece-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-q1-2026-results-guidance2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-q1-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-piktor-trial-breast-cancer2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-presentation-bladder-cancer-aau2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-q1-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-present-may-conferences2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q1-2026-financial-results-update2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-bank-america-conference-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-investor-conferences-may-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-aspennova-phase-3-trial-azenosertib2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-bank-america-health-care-conference2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-adds-clinical-stage-sirna-asset-targeting-pnpla32026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-new-data-ibd-2026-ddw2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-caremark-biosimilar-adoption-formulary-updates2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-d-boral-capital-conference2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-eb-003-ptsd-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-madrigal-license-pnpla32026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-pricing-convertible-senior-notes2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q1-2026-results-conference-call2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-q1-2026-financial-results-update2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-q1-2026-financial-results-update2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-q1-2026-financial-results-conference-call2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-mi-clarity-ai-breast-cancer-recurrence-risk2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-host-investor-day-may-14-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-7-million-offering-common-stock2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-acquisition-terns-pharmaceuticals2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-european-patent-ptsd-treatment2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-bank-america-health-care-conference-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-fertility-treatment-femaseed-launch2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-bank-america-health-care-conference-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-garda-postpone-tender-offer2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-q1-2026-financial-results-update2026-05-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-q1-2026-financial-results2026-05-05T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-omvoh-durable-disease-clearance-ulcerative-colitis2026-05-05T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-wellstar-medication-management-ai2026-05-05T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-q1-2026-financial-results-update2026-05-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-prosense-cryoablation-asbrs-20262026-05-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-4804-ibd-clinical-efficacy2026-05-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-efficacy-perianal-fistulizing-crohns-disease2026-05-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-q1-2026-renal-evolution2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-10500-surgeries-ssi-mantra2026-05-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-q1-2026-results-outlook2026-05-05T11:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-leadership-transition2026-05-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-first-quarter-2026-results-conference-call2026-05-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-investor-conferences-may-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-eosinophilic-esophagitis-phase-4-trial-results2026-05-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-q1-2026-financial-results-updates2026-05-05T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-receives-follow-on-order-ophthalmic-program2026-05-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-phase-1a-b-data-ulcerative-colitis2026-05-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-q1-2026-financial-results2026-05-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-business-update-q1-2026-results2026-05-05T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-q1-2026-financial-results-webcast2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-financial-results-web-conference-may-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-acquisition-acea-pharma-phoenix2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-launches-wound-care-products-ewma-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-announces-fourth-quarter-results-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-phase-2-lotus-trial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-proposed-public-offering2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HQY/healthequity-first-quarter-earnings-release2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-first-quarter-results-may-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-anthony-nolan-collaboration-expansion2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-first-quarter-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-public-offering-common-stock2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-q1-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-first-quarter-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-bofa-securities-2026-conference2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q1-2026-financial-results-update2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-participate-investor-conferences2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-q1-2026-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-investor-conferences-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-proposed-public-offering-common-stock2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-european-authorization-ht-001-trial2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-sustainable-solutions-platform2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-participate-upcoming-investor-conferences2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-bank-america-healthcare-conference-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATEC/atec-refinances-existing-debt-bank-facility2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-first-quarter-financial-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-record-first-quarter-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-q1-2026-results-pipeline-update2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-convertible-senior-notes-offering2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/danaher-announces-quarterly-dividend2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-quarterly-dividend2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-quarterly-dividend-increase2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q1-2026-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-first-quarter-2026-results-conference-call2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-closes-299-million-offering2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-icovamenib-ada-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-q1-2026-financial-results2026-05-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-q1-2026-financial-results2026-05-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-first-quarter-2026-financial-results2026-05-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q1-2026-results2026-05-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-secures-funding-lymphir-commercialization2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-tak-881-phase-2-3-trial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-tak-881-phase-2-3-study-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-tak-881-phase-2-3-results-pid2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-positive-results-tak-881-clinical-trial2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-positive-results-tak-881-phase-2-3-study2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-positive-results-phase-2-3-tak-881-pid2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-phase-2-3-trial-tak-881-idp-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/lbl-047-prioritized-clinical-development-sjogrens-lupus-dermatomyositis2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-pricing-public-offering2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-conference-call-q1-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-q1-2026-performance-outlook2026-05-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-first-quarter-2026-financial-results2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-q1-2026-financial-results-update2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-participate-may-2026-investor-conferences2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVLN/avalyn-patient-centered-research-ats-20262026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-inducement-grants-nasdaq-rule-5635c42026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-reports-first-quarter-2026-financial-results2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-q1-2026-results2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-q1-2026-results2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-q1-2026-financial-results-update2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-q1-2026-financial-results-update2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q1-2026-financial-results2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q1-2026-financial-results2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-participate-may-2026-investor-conferences2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-bofa-securities-2026-healthcare-conference2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q1-2026-financial-results2026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-phase-2-data-abscopal-effects-vp-3152026-05-06T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-first-quarter-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-q1-results-web-conference-may-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-first-quarter-2026-results-guidance2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-q1-2026-financial-results-business-update2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-fiscal-2026-q2-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-q1-2026-results-and-developments2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-investor-conferences-may-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-clinical-update-isct-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-eoe-histology-scoring-data-resolve-trial2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-public-offering-pricing2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q1-2026-results-conference-call2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMD/inmode-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-webcast-topline-results-rgx-2022026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-casgevy-reimbursement-agreement-germany2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-pediatric-limb-reconstruction-innovation-posna-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-acquires-nirlab-ag-narcotics-detection2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-participate-bank-america-healthcare-conference2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-expands-pre-roll-portfolio-spinach-stix2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-fda-clearance-bria-bres-clinical-study2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-first-quarter-financial-results-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-reports-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-may-investor-conferences2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-first-quarter-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-participation-needham-conference2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-ligand-investment-15-million2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-present-bank-america-health-care-conference-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-bofa-securities-conference-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q1-2026-results-update2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-q1-2026-results-announcement2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-bank-america-conference-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-medtronic-funding-backbeat-trial2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-reports-zusduri-revenue-growth-q1-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-first-quarter-2026-results-report2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-conference-call-q1-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-bank-america-healthcare-conference2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-tender-offer-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/lucent-diagnostics-tempus-alzheimers-biomarker-testing2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THC/tenet-participate-bofa-health-care-conference2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-public-offerings2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-first-quarter-results-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-advancement-izicopan-anca-associated-vasculitis2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-rbc-capital-markets-conference-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presentation-bank-america-conference-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-pricing-150-million-offering2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-report-fiscal-2026-q2-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-first-quarter-results-update2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-q1-2026-results-report2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-q1-2026-conference-call-details2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-expands-navy-mental-health-support2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/jito-foundation-solana-strategic-partnership-apac2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-4-5-billion-investment-indiana-manufacturing2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-us-patent-atr-12-program2026-05-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-launches-trivium-shaped-bone-graft2026-05-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/tissue-dynamics-galmed-cardiac-fibrosis-platform2026-05-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-nu-q-vet-cancer-test-cats2026-05-06T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-first-quarter-2026-financial-results2026-05-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-first-quarter-2026-results2026-05-06T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-karisma-endoxifen-trial-results2026-05-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-aprovacao-anvisa-valvula-epic-max2026-05-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-appoints-dr-peter-fiske2026-05-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-snmmi-2026-presentations2026-05-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-glucocorticoid-dose-reduction-recommendations2026-05-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-q1-2026-financial-results2026-05-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-q1-2026-financial-results-update2026-05-06T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-coverage-35-million-patients2026-05-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-q1-2026-financial-results-briumvi-guidance2026-05-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-q1-2026-financial-results-update2026-05-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-third-patent-arbli-losartan-suspension2026-05-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-ralinepag-dpi-pulmonary-hypertension2026-05-06T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q1-2026-financial-results-update2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-participate-investor-conferences-may-june2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/transcon-cnp-growth-outcomes-achondroplasia-trial2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVST/envista-reports-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2026-third-quarter-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q1-2026-results-announcement2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-third-quarter-conference-call-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-reports-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-first-quarter-2026-results-webinar2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-q1-2026-results-revenue-guidance2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/danaher-presentation-bank-america-conference2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-announces-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-q1-2026-sales-growth2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q1-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-erstes-quartal-2026-ergebnisse2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-full-results-q1-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-q1-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-corporate-update-q1-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-participate-2026-jefferies-global-healthcare2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-financial-results-q1-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-cfo-speak-bank-america-health-care-conference-20262026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-q1-2026-financial-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-q1-2026-earnings-report2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presentation-bofa-securities-2026-conference2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-participate-bank-america-2026-healthcare-conference2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-leadership-transition-al-luderer2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-q3-results-financial-guidance2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-first-quarter-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-bank-of-america-2026-conference2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-acquired-knox-lane-437-million2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q1-2026-financial-results2026-05-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-ty-pennington-bronchiectasis-awareness2026-05-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inducement-awards-nasdaq-rule-5635c42026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-upsized-convertible-senior-notes-offering2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-upsized-public-offering-common-stock2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-presentations-cis-2026-leniolisib-data2026-05-07T05:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-q1-2026-results-joenja-expansion2026-05-07T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-first-quarter-2026-financial-results2026-05-07T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-q1-2026-financial-results-update2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-ceo-appointment-karen-massey2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-participate-bank-america-healthcare-conference2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-first-quarter-2026-results2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-q1-2026-financial-results2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-q1-2026-financial-results-update2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-q1-2026-financial-results-update2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-q1-2026-financial-results2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-reports-q1-2026-financial-results2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reports-first-quarter-2026-results2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-first-quarter-2026-results2026-05-07T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-fda-special-protocol-assessment-privosegtor2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-reports-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-q1-2026-financial-results-updates2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-quantiFERON-test-automation-ai-risk-stratification2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-automated-sample-insight-latent-tb-testing2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GENB/generate-biomedicines-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-vitor-roque-cfo2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-q1-2026-financial-results-outlook2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-q1-2026-revenue-growth2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q1-2026-results-report2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-mental-health-month-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-mark-soued-appointment-cco2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-q1-2026-financial-results-update2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-first-quarter-2026-financial-results-call2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-asgct-2026-presentations2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-new-data-percutaneous-hepatic-perfusion2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-updated-results-phase-2-legend-trial2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/usana-people-first-culture-top-workplaces2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-conferences-may-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-q1-2026-update2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-ceo-presents-multi-protein-model-alzheimers-fierce-biotech2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-nyu-langone-health-clinical-site-phase-3-study2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-bank-america-securities-conference2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-first-quarter-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-spectrum-therapeutics-softgel-expansion2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-record-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-q1-2026-financial-results-updates2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-q1-2026-financial-results-business-update2026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-q1-2026-update2026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-q1-2026-financial-results-business-update2026-05-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-fda-fast-track-ap-sa022026-05-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-q1-2026-update2026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-first-quarter-2026-financial-results2026-05-07T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-q2-fiscal-2026-results2026-05-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-firdapse-patent-settlement2026-05-07T06:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-pipeline-progress-milestones-q1-2026-results2026-05-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/biotech-rd-job-market-growth-20252026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-q1-2026-financial-results2026-05-07T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-elevate-44-201-results2026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-q1-2026-financials-update2026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-reports-liquidity-reduction-cash-burn-q1-20262026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-conference-call-q1-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-ind-clearance-arr-002-ovarian-endometrial-cancers2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-q1-2026-financial-results2026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-q1-2026-financial-results-updates2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-corporate-update-q1-results2026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-q1-2026-results-update2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-q1-2026-financial-results-webcast2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-q1-2026-financial-results-conference-call2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-clearance-clinical-trial-nrx-1012026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-first-quarter-2026-financial-results2026-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-xphozah-long-term-safety-analysis-nkf-meetings2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-bofa-securities-2026-health-care-conference2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-investor-conferences-may-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-presentation-bank-america-conference2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-q1-2026-results-business-highlights2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-presentations-investor-conferences2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-declares-dividend-common-stock2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-phase-3-true-ad4-trial-opzelura-data2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-treats-first-pancreatic-cancer-patient-italy2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-gsk-collaboration-oncology-targets2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/goss-securities-fraud-lawsuit-prospera-study-failure2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-zeta-ai-roadmap-launch2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LONA/leonabio-board-appointments-fred-callori-natalie-holles-silverman2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-health-group-secondary-public-offering2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-inducement-grants-nasdaq-rule-56352026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-presentation-bank-america-healthcare-conference2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-participate-upcoming-investor-conferences2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-health-secondary-public-offering2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-appoints-pierre-boulud-board-directors2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-q1-2026-financial-results-update2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-business-update-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-q1-2026-financial-results-highlights-milestones2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-first-quarter-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q1-2026-results-business-highlights2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-acquisition-amplitude-vascular-systems2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-may-2026-investor-conferences2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-presents-bank-america-securities-2026-conference2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-550000-in-convertible-note-financings2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q1-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-first-quarter-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-investor-conferences-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-q1-2026-results-divestiture-biosecurity2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-bofa-securities-2026-health-care-conference2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-at-bofa-healthcare-conference2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-participate-bofa-health-care-conference-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-phase-3-true-ad4-opzelura-data2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-long-term-data-opzelura-trial2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-phase-3-true-ad4-study-opzelura2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-announces-long-term-data-opzelura-study2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-share-repurchase-authorization-increase2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-bank-america-conference2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CON/concentra-group-holdings-q1-results-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-fiscal-2026-results-guidance2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-first-quarter-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-first-quarter-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-announces-quarterly-dividend2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-financial-results-q2-fy-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-investor-conferences-may2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-2026-stifel-virtual-forum2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-first-quarter-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-q1-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-fiscal-2026-q2-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q1-2026-results-pipeline-progress2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-first-quarter-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-scientists-publish-landmark-paper-biocatalytic-synthesis2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-financial-results-q1-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-q1-2026-results-updates2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/tak-881-phase-2-3-trial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/fda-review-leqembi-early-alzheimers2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOBI/mobia-medical-ipo-pricing-announcement2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-investor-conferences-20262026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYO/myomo-first-quarter-2026-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OWLT/owlet-announces-q1-2026-financial-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-q1-2026-financial-results-business-highlights2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QSI/quantum-si-first-quarter-2026-results-proteus-milestones2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-q1-2026-financial-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-investor-conferences-may-june-20262026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-may-20262026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-q1-2026-financial-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-arvo-2026-pipeline-advancement2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-inducement-grants-nasdaq-listing-rule-56352026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q1-2026-financial-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q1-2026-financial-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-financial-results-q1-20262026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-bank-america-conference-20262026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-q1-2026-results-business-update2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-q1-2026-results-highlights2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGNY/progyny-announces-first-quarter-2026-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q1-20262026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-q1-2026-results-and-milestones2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-q1-20262026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-first-quarter-2026-financial-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-q1-2026-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-q1-2026-financial-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-reports-q1-2026-financial-results2026-05-08T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-prices-115-million-offering2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-nasdaq-listing-determination2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q1-2026-financial-results2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-investor-conferences-20262026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-bofa-securities-2026-healthcare-conference2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-cristiano-ronaldo-fuel-like-ronaldo-campaign2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-q1-2026-results-img-007-update2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-advances-hantavirus-clinical-candidates2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-updates-q1-2026-results2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-palisade-4-fasedienol-social-anxiety2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-fda-helix-delivery-catheter-clearance2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-2026-q1-financial-results2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-bofa-securities-2026-conference2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-garda-delay-tender-offer2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-appoints-caroll-neubauer-board2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-closes-150-million-offering-ordinary-shares2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-q1-2026-results-business-update2026-05-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-dow-jones-best-in-class-index-20262026-05-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reyobiq-clinical-data-aans-20262026-05-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-launch-g4derm-plus2026-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-q1-2026-financial-results-business-updates2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-first-quarter-2026-results2026-05-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-investor-conferences2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-yeztugo-sales-projections-20262026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-q1-2026-financial-results2026-05-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-300-million-offering2026-05-08T10:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-q1-2026-results2026-05-08T10:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-positive-clinical-data-allonk-rheumatoid-arthritis2026-05-08T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-first-quarter-2026-results2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-q1-2026-financial-results-update2026-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-q1-2026-financial-results2026-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/treace-medical-concepts-first-quarter-2026-results2026-05-08T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-public-offering-20262026-05-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q1-2026-financial-results-update2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/hawkeye-360-soars-31-percent-trading-debut2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/codx-comira-manufacturing-facility-saudi-arabia2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-participate-investor-conferences2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-bank-america-healthcare-conference-20262026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-closes-public-offering-805-million2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-q1-2026-results2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-q1-2026-results-business-updates2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-q1-2026-financial-results-updates2026-05-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-secures-hong-kong-patent-annamycin2026-05-08T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q1-2026-financial-results-earnings-call2026-05-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-q1-2026-financial-results-conference-call2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-webcast-clinical-update-inbrx-106-hexagon-study2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-inducement-grants-nasdaq-rule-5635c42026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-ny-health-authorization2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q1-2026-financial-results2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-first-half-2025-results2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-presentation-ld-micro-invitational-20262026-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-private-placement-2-5-million2026-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-positive-fda-pre-bla-meeting-sonelokimab2026-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-first-quarter-financial-results-20262026-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-fda-inspection-reykjavik-facility2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/fda-inspection-alvotech-manufacturing-facility2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-presents-data-ats-20262026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACH/accendra-health-q1-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-evaluates-covid-monoclonal-antibody-tolerability2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-q1-2026-financial-results-update2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-fda-clearance-elraglusib2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-fda-fast-track-zocilurtatug-pelitecan2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-q1-2026-results-updates2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-first-quarter-2026-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-fda-clearance-power-liposuction2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-bofa-2026-health-care-conference2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-navigate-phase-2b-trial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-upcoming-scientific-conference-presentations2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-first-quarter-results-conference-call2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-accelerates-digital-pathology-ai-workflow2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/cns-drug-delivery-breakthroughs-biotech-opportunities2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/future-of-intoxication-detection-voice2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/next-generation-glp-1-revolution2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-q1-2026-financial-results-update2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-chop-treatment-center-zevaskyn2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-da-1726-easl-congress-20262026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-launch-estyme-in-europe2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-investor-conferences-may-20262026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-first-quarter-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/eli-lilly-150-years-scientific-innovation2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-q1-2026-results-update2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-next-gen-signa-mr-technology2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-appoints-chris-murphy-cfo-owen-hughes-board2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-novabioplus-biological-data-ai2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-report-q1-2026-results-may-152026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-first-quarter-2026-earnings-call2026-05-11T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-fasn-inhibitors-acne-sid-20262026-05-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-lira-cel-phase-1-trial-update2026-05-11T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacb-hifi-solves-subfertility-consortium-study2026-05-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-strategic-direction-value-creation2026-05-11T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-mou-european-nuclear-company2026-05-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-phase-2-data-inbrx-106-hnscc2026-05-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-advances-neuropsychiatry-apa-ascp2026-05-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-q1-2026-financial-results2026-05-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-interim-results-us-trial-glioblastoma2026-05-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-q1-2026-results2026-05-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q1-2026-financial-results-update2026-05-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/acoramidis-demonstrates-disease-modifying-effects-attr-cm2026-05-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-qsm-biomarker-ms2026-05-11T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pipeline-progress-q1-2026-results2026-05-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-ats-2026-presentations-nodify-lung-testing2026-05-11T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-virtual-investor-ovarian-cancer2026-05-11T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-phase-2b-hlhs-trial-update2026-05-11T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLSN/solesence-launches-new-skin-health-technologies2026-05-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/cruise-ship-virus-outbreaks-demand-tomi-steraMist2026-05-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft819-sle-asgct-20262026-05-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-fibroblast-treatment-hantavirus2026-05-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XGN/exagen-inc-reports-first-quarter-2026-results2026-05-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-webinar-insights-cmnd-100-trial2026-05-11T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-first-in-human-trial-rjva-0012026-05-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q1-2026-financial-results2026-05-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-obesity-portfolio-update-phase-1-data2026-05-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-merck-clinical-trial-collaboration-eras-00152026-05-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-myqorzo-aficamten-esc-heart-failure-20262026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-wes-tumor-mutational-burden-study2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-q1-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-q1-2026-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-q1-2026-financial-results-update2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-reports-q1-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-q1-2026-financial-results-update2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-first-quarter-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-q1-2026-financial-results-update2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-presents-rbc-healthcare-conference2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-first-quarter-2026-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-q1-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-q1-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-business-update-may-20262026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-q1-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASTH/physician-association-california-astrana-health-collaboration2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-first-quarter-results-20262026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-first-quarter-2026-results-release2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-closes-132-million-offering2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-participate-jefferies-global-healthcare-conference2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-first-quarter-2026-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-participation-hc-wainwright-bioconnect-conference2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-dismissal-2021-qui-tam-suit2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-q1-2026-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-ats-2026-conference-posters2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-health-first-quarter-2026-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inducement-grant-nasdaq2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-financial-results-q2-20262026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-q1-2026-financial-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-participate-may-investor-conferences2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-fiscal-2026-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-post-falls-rehabilitation-hospital2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACS/pacs-group-first-quarter-2026-results2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-goldman-sachs-healthcare-conference2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-q1-2026-results-highlights2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-q1-2026-financial-results-conference-call2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-q1-2026-results-guidance2026-05-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-data-breach-investigation2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-appoints-dr-colpan-honorary-chairman2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-dr-metin-colpan-honorary-chairman2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/vutrisiran-heart-failure-2026-clinical-benefits2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-icv-delivery-asgct-meeting2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q1-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVM/celsci-corporation-public-offering-pricing2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMTM/amentum-reports-q2-fy2026-results2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-q1-2026-results-report2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-participate-jefferies-global-healthcare-conference-20262026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-q1-2026-results-abcl635-phase-1-data2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inducement-grant-nasdaq-rules2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-investor-conferences-20262026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-participate-upcoming-may-2026-investor-conferences2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-sells-gmp-manufacturing-operations-bora2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q1-2026-results-highlights2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-q1-2026-financial-results2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-q1-2026-financial-results2026-05-12T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-asco-2026-oncology-portfolio-advancements2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-q1-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-first-quarter-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-q1-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-hc-wainwright-bioconnect-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-present-hc-wainwright-bioconnect-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-q1-2026-results-pipeline-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-q1-2026-financial-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-investor-conferences-may-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-business-updates-q1-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-q1-2026-results-highlights2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q1-2026-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-advancead-tx-award-genomics-innovation2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-presents-at-bofa-and-rbc-healthcare-conferences2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-participate-2026-stifel-oncology-forum2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-first-patient-dosed-ascend-study2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/atm-equity-purchases-pulse-biosciences2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-revitalyz-phase-3-results-lumryz2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-presentation-rbc-healthcare-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-participation-upcoming-investor-conferences2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-q1-2026-results-updates2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-3-bria-abc-study-enrollment2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-participate-william-blair-growth-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-may-investor-events2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-participate-investor-conferences-may-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-first-quarter-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-investor-conferences2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-fast-track-als-treatment2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-positive-data-fasedienol-social-anxiety2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-q1-2026-financial-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-q1-2026-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-investor-conferences-may-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-q1-2026-financial-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-presentation-rbc-capital-markets-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-q1-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-hc-wainwright-bioconnect-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/real-world-pedd-study-published2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-hc-wainwright-bioconnect2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-deal-imptis-biosciences-57b-opportunity2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-q1-2026-results-clinical-progress2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-backbeat-trial-enrollment-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-presents-hc-wainwright-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/dr-barry-roseman-senior-medical-advisor-qti2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-ai-solutions-precision-care2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-sales-growth-april-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-eha2026-presentations2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-first-quarter-2026-financial-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-investor-conferences-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-investor-conferences-may-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-q1-2026-financial-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-first-quarter-2026-financial-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q1-2026-financial-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-q3-fiscal-2026-results-business-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q1-2026-financial-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-q1-2026-financial-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-q1-2026-financial-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-bexobrutideg-eha-congress-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-refinances-debt-oaktree2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-q1-2026-results-clinical-progress2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-first-quarter-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-barclays-leveraged-finance-conference-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-investor-conferences-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-appoints-interim-national-medical-director2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-150th-anniversary-food-initiative2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-first-quarter-2026-business-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-2026-rbc-capital-markets-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-2026-rbc-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-first-quarter-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-q1-2026-results-highlights2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-first-quarter-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-q1-2026-financial-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-first-quarter-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-first-quarter-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-first-quarter-financial-results-update2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-first-quarter-2026-financial-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-planned-transition-cfo2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-q1-2026-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/vutrisiran-clinical-benefits-heart-failure-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-q1-2026-financial-results-updates2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-financial-results-q1-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-first-quarter-2026-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-abi-6250-easl-congress-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-easl-congress-2026-abstracts2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-fy2025-results-fy2026-outlook2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/highest-paid-pharma-ceos-20252026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-abstracts-easl-congress-20262026-05-13T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-convertible-notes-offering2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-q1-2026-results-paradigm-trial-update2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/lineage-cell-therapeutics-q1-2026-results-update2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-convertible-senior-notes-offering2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-foundayo-zepbound-weight-loss-maintenance-trials2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-time-most-impactful-companies-20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-revenues-financial-results-q1-fy20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-inducement-awards-may-20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBV/dbv-technologies-hc-wainwright-bioconnect-conference2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-first-quarter-2026-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-participate-2026-rbc-healthcare-conference2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-stockholder-letter-20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-investor-conferences-may-20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-bla-submission-sps2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-q1-2026-update2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-nmpa-acceptance-f3512026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-hc-wainwright-bioconnect-conference-20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-q1-2026-financial-results-business-update2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-investor-conferences-20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-2026-rbc-healthcare-conference2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-cdmo-live-europe2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-sg293-preclinical-data-asgct-20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-healthcare-investor-conference-20262026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-present-hc-wainwright-conference2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-q1-2026-financial-results-update2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-first-quarter-2026-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-q1-2026-financial-results-updates2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-q1-2026-results-pali-2108-progress2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/orchestra-biomed-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-q1-2026-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-medicare-coverage-next-personal-immunotherapy2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-q1-2026-financial-results-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-q1-2026-results-corporate-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-q1-2026-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/european-commission-approves-pfizers-hympavzi2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-present-real-world-evidence-pediatric-hae-ispor-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-easl-2026-abstracts2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-hc-wainwright-bioconnect-conference2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-q1-2026-financial-results-guidance2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-rbc-capital-markets-conference-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-2026-jefferies-conference2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-q1-2026-results-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-may-conferences-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-q1-2026-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-penn-medicine-clinical-site-phase-3-study2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-expands-leadership-team2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-first-quarter-2026-results2026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-first-quarter-2026-results2026-05-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-q1-revenue-increases-395-percent2026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-vy1706-alzheimers-gene-therapy-update2026-05-13T10:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-2026-q2-results-phase-2b-trial-update2026-05-13T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-private-placement-financing2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-q1-2026-financial-results2026-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-patent-infringement-lawsuit-nanomics2026-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-uplisting-nasdaq-global-market2026-05-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q1-2026-results2026-05-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-q1-2026-financial-results-update2026-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-2026-rbc-capital-markets-conference2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-presentation-rbc-capital-markets-conference2026-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-q1-2026-financial-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-q1-2026-financial-results-update2026-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-hc-wainwright-bioconnect-conference2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-fireside-chats-healthcare-conferences2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-quell-fibromyalgia-therapy-study2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-phase-2b-namodenoson-immunotherapy2026-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-leadership-change-donn-casale2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-q1-2026-financial-results-update2026-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICLR/icon-expands-us-research-capabilities2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-q1-2026-financial-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-q1-2026-financial-results-business-update2026-05-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-pemvidutide-easl-congress-20262026-05-13T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-q1-2026-results-corporate-update2026-05-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-q1-2026-results-pipeline-update2026-05-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-phase-1-trial-zb0212026-05-13T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-q1-2026-financial-results-update2026-05-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-investor-conferences-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-acquired-zydus-worldwide-23-50-per-share2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-ip-patent-psychiatric-disorders2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-reports-first-quarter-2026-revenue2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-inducement-grant-sarchi2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/next-generation-glp-1-innovation-healthcare-opportunities2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/real-time-intoxication-detection-platforms-healthcare-opportunities2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/cns-drug-delivery-alzheimers-biodefense-research2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMD/inmode-upcoming-investor-conferences-events2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-new-data-easl-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/global-medical-response-ipo-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-presentation-rbc-global-healthcare-conference2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-hats-on-campaign-actinic-keratosis-awareness2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-preserve-trial-nanoknife-ire-outcomes2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-nasatrix-allergy-blocker-clinical-trial2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-2026-rbc-conference2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-abstracts-eha-congress-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-2026-eha-congress-abstracts-acceptance2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-abstracts-eha-2026-congress2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-abstracts-eha-conference-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-eha-congress-2026-abstracts2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-beqalzi-fda-approval-mcl2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-q1-2026-results-business-updates2026-05-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-miracle-trial-unblinding-20262026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-fiscal-q3-2026-results-business-update2026-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-asgct-conference-boston2026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-shareholder-letter-update2026-05-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-q1-2026-financial-results-update2026-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/zusduri-envision-trial-results-bladder-cancer2026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-q1-2026-financial-results-update2026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-q1-2026-financial-results2026-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-initiates-gmp-manufacturing-phase-2-3-trial2026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-q1-2026-progress-proclarix-validation-study2026-05-13T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-foundation-member-abia-biotech-alliance2026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-q1-2026-results-updates2026-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-bempedoic-acid-eas-congress-20262026-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-preclinical-data-isct-20262026-05-13T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-appoints-susan-knight-stephen-denaro-board2026-05-13T12:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-femhsg-catheter-ce-mark-approval2026-05-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-invests-astro-capital2026-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-q3-revenue-growth2026-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LITS/lite-strategy-fiscal-2026-q3-results2026-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-1q26-business-update2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-q1-2026-financial-results2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-pharma-redeye-investor-forum-may-212026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SOPH/sophia-genetics-synnovis-partnership-cancer-testing-uk2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-saffron-development-completion2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-pharma-abg-investor-days-may-212026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLCD/anaveon-appoints-thomas-mathers-chair-board2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-bexmab-eha-2026-presentation2026-05-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/heart-failure-2026-vutrisiran-clinical-benefits2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/vutrisiran-heart-failure-2026-congress2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-q1-2026-financial-results-regulatory-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q1-2026-results-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-q1-2026-financial-results-business-transformation2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q1-2026-financial-results-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-webcast-financial-results-may-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-q1-2026-financial-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/omnicare-court-approval-sale-genierx2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-first-quarter-2026-financial-results-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-first-quarter-2026-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-q1-2026-financial-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staaar-surgical-first-quarter-2026-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-2026-rbc-healthcare-conference2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-q1-2026-results-graftassure-commercialization-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-first-quarter-2026-financial-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q1-2026-results-business-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q1-2026-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-presentation-rbc-capital-markets2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-kexing-biopharm-biosimilar-development-ai2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-corp-q1-2026-financial-results2026-05-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-q1-2026-results-update2026-05-13T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-nasdaq-extension-compliance2026-05-13T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-q1-2026-financial-results-business-highlights2026-05-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-q1-2026-financial-results2026-05-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-reverse-stock-split-nasdaq2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-investor-day-june-20262026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-rbc-capital-markets-conference-20262026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACB/aurora-plant-breeders-rights-cannabis-science2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-q1-2026-financial-results-business-highlights2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-q1-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-ispor-2026-fibromyalgia-analysis2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-public-offering-5-million2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-q1-2026-results-guidance2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-q1-2026-financial-results-update2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-budoprutug-eha-2026-congress2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-q1-2026-update2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYPH/cypherpunk-technologies-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-presents-preclinical-data-pbgene-dmd2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/biogen-phase-2-celia-study-diranersen-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-fireside-chat-hc-wainwright-20262026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-telix-collaboration-hifu-theranostics2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-zervimesine-expanded-access-program2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-completes-manufacturing-bria-pros-prostate-cancer2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-q1-2026-financial-results-update2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-bioconnect-investor-conference-20262026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-ai-workforce-intelligence-optim%C3%A92026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-poster-presentations-vdphl01-2026-symposium2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-fda-fast-track-xpro1595-alzheimers2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-investor-conferences-20262026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-humana-medicare-advantage-barostim-therapy2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-appoints-brent-pfeiffenberger2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-investor-conferences-20262026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-first-quarter-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q1-2026-results-im8-revenue-growth2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-renuvion-liposuction-study2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-wgu-online-pre-pharmacy-degree-program2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-ghp-award-20262026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-presents-2026-rbc-capital-markets-conference2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-fujifilm-partnership-synapse-imaging2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-taeus-liver-device-validation2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/radoff-jec-group-third-proposal-acquire-seer2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-reverse-stock-split-may-20262026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-presentation-hc-wainwright-conference2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-john-cena-demodex-blepharitis-awareness2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-kol-event-z-endoxifen-breast-cancer2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-acquisition-apellis-pharmaceuticals2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-private-offering-senior-notes2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-q1-2026-report-update2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-fiscal-2nd-quarter-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-q1-2026-results-highlights2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-first-quarter-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capsovision-first-quarter-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-limited-duration-stockholder-rights-plan2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-q1-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-partial-redemption-senior-notes-20282026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-pricing-senior-notes-20342026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-first-quarter-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-prices-3-billion-senior-unsecured-notes2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbcmg-first-quarter-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-q1-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-q1-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-stifel-conference-2026-investor-day2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-first-quarter-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-first-quarter-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-governance-enhancements-2026-investor-day2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-participate-upcoming-investor-events2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-fireside-chat-jefferies-conference2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beqalzi-fda-approval-bcl2-inhibitor2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beqalzi-fda-approval-bcl2-inhibitor-mantle-cell-lymphoma2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beqalzi-fda-approval-bcl2-inhibitor-mcl2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-approves-beqalzi-sonrotoclax-onc2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beqalzi-sonrotoclax-fda-approval-mantle-cell-lymphoma2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-collaborations-psma-pet-imaging-prostate-cancer2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-reports-q1-2026-financial-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-q1-2026-financial-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-q1-2026-financial-results-webcast2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-900-million-meals-donated-child-nutrition2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-business-highlights-q1-2026-results2026-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-ridge-1-phase-1b-2-trial-results2026-05-15T10:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-q1-2026-financial-results-update2026-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-tara-002-nmibc-trial-data2026-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-q1-2026-financial-results-update2026-05-15T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ai-wellness-products-ecrm-conference2026-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-presentations-sid-ats2026-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-business-update-q1-2026-results2026-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-expands-pipeline-ovarian-cancer-immunotherapy2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-corporate-updates-q1-2026-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-q1-2026-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-nasdaq-capital-market-listing-transfer2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-q1-2026-financial-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-phase-2-mindful-trial-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-business-update-q1-2026-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/life-md-investor-conferences-20262026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-q1-2026-results-and-highlights2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-presentation-fundus-disease-forum-20262026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-q1-2026-financial-results-update2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-2026-stifel-oncology-forum2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-investor-webcast-restore-fa-trial2026-05-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-shareholders-approve-agenda-items-agm-20262026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-shareholders-approve-agenda-20262026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-nasdaq-minimum-bid-price-notification2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-phase-3-trial-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-q1-2026-financial-results-highlights2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomeds-us-strategic-engagement-initiative2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-q1-2026-financial-results-update2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-files-annual-report-fiscal-year-20252026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-q1-2026-financial-results-update2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-fiscal-q2-2026-results-update2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-lookback-program-clinical-value-comprehensive-testing2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-first-quarter-2026-financial-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-roundtable-oral-therapies-dermatology-summit2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-university-wisconsin-madison-research-agreement2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-research-access-value-ispor-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-ispor-2026-conference-presentation2026-05-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-advance-outcomes-study-ats-20262026-05-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-imaging-study-milestone2026-05-18T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-hospital-at-home-care-stockholm2026-05-18T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-investment-mirus-tavr2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/peter-menziuso-named-evp-president-bd-interventional2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-2-billion-share-repurchase-agreement2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-q1-2026-financial-results-update2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-poster-presentation-asco-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-acquisition-endospan-ltd2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-q1-2026-financial-results2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-endospan-acquisition-fda-approval-nexus-system2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-launches-exchange-offer-debt-elimination2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-reports-q1-2026-financial-results-business-updates2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-convertible-senior-notes-offering2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-flex-launch-germany2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-us-patents-anktiva-bcg-cancer-treatment2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-appoints-mamata-gokhale-regulatory-affairs2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-goldman-sachs-conference-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-phase-2b-trial-allocetra-knee-osteoarthritis2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-presents-agp-healthcare-showcase-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/fda-accepts-viatris-fast-acting-meloxicam-nda2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-q1-2026-financial-results2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-appoints-dr-hahn-lead2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-participate-agp-annual-healthcare-conference2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-oral-fibroblast-therapeutics2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-obesity-data-ada-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-q1-2026-financial-results-growth-update2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/the-biology-came-first2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-meai-tirzepatide-research-agreement2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-euroPCR-2026-abstracts2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-sfda-approval-acam20002026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-closes-57-5-million-offering2026-05-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PNTG/pennant-group-2026-rbc-global-healthcare-conference2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PNTG/pennant-acquisition-senior-living-arizona2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/ipax-2-study-tlx101-tx-glioblastoma-enrolment-completes2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-cln-978-eular-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-lytham-partners-spring-2026-conference2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-2026-jefferies-conference2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-inducement-grants-new-employees-nasdaq-rule2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-phase-2-study-lam-001-pah-ph-ild2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNCX/quince-acquires-orphai-private-placement-pulmonary-pipeline2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-autostore-installation-aurora-colorado2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-participate-bernstein-strategic-decisions-conference2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-health-convertible-notes-offering2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-new-studies-access-value-ispor-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-inducement-grants-nasdaq-rule-5635c42026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-teton-1-study-tyvaso2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-closing-public-offering2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-2-solstice-trial-easl-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-freedomedge-infusion-system-congress2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-jefferies-global-healthcare-conference2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-new-exercise-capacity-data-impala-22026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-orphan-drug-status-tinlarebant-stargardt-disease2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-amplitude-acquisition-michigan-medtech2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-reverse-share-split2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-appoints-gerard-porreca-executive-vice-president2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-q3-2026-results2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-appoints-michael-bonney-chair-board2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/fracture-ide-trial-boston-scientific-seismi-q-4ce-catheter2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-closes-5-million-public-offering2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-selects-krro-111-treatment-aatd2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-2026-rbc-capital-markets-conference2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LABT/lakewood-amendex-nu-3-phase-2-trial2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-fda-type-c-meeting-harmonic-phase-22026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-comparative-effectiveness-data-aua-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-fda-orphan-drug-designation-cln-0492026-05-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-positive-clinical-data-foralumab-ms2026-05-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-zovegalisib-clinical-data2026-05-19T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-expands-scientific-advisory-board-marta-sacchetti2026-05-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ath434-phase-3-msa2026-05-19T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-ephemeral-ai-oncology-partnership2026-05-19T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-phase-3-indigo-trial-results-eular-20262026-05-19T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-pharma-live-seminar-trka-nam-acd1372026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/anaveon-strengthens-leadership-team-appointments2026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/spago-nanomedical-annual-report-20252026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-jefferies-global-healthcare-conference2026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/avacta-preliminary-results-fy252026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-participate-jefferies-global-healthcare-conference-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-fireside-chat-agp-healthcare-showcase2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-nmibc-research-fellowship-recipients2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-1154-phase-3-data-ascp-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-jefferies-global-healthcare-conference-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-goldman-sachs-healthcare-conference-june2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-positive-preclinical-results-eb-0032026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-merck-phase-3-stellar-316-trial2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-jefferies-global-healthcare-conference2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-patent-transvascular-monitoring-systems2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-presentation-alliance-global-partners-showcase2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-participate-jefferies-global-healthcare-conference2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/hca-healthcare-volunteers-annual-days-of-service2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-2025-corporate-responsibility-report2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-appoints-angel-s-angelov-cmo2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/three-trike-candidates-in-clinic-nk-cell-engager2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-elects-scott-ward-board2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-paridiprubart-era-congress-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-ispor-2026-research-access-benefits2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/oligon-ispor-2026-access-value-research2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-institutional-support-brain-cancer2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/cest-la-biologie-imposee-en-premier2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-data-presentation-2026-asco-meeting2026-05-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-restructures-as-rocket-one-ai-semiconductors2026-05-19T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-ebola-assay-strategy-outbreak-alert2026-05-19T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-appoints-dr-keith-d-rose-cmo2026-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-prosense-reports-recurrence-free-rate-kidney-cancer2026-05-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-rebrands-as-qtrex-quantum2026-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-layoffs-may-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-oura-partner-sleep-health-education2026-05-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-acquires-ai-digital-health-platform-halo-clarity2026-05-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-commercial-agreement-north-shore-health2026-05-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-webcast-phase-2-silevertinib2026-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-appoints-diego-miralles2026-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-stockholder-equity-increase-20262026-05-19T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-applied-biosolutions-sidoti-conference-20262026-05-19T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-steraMist-technology-ebola2026-05-19T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-showcase-navigation-platform-aacn-nti-20262026-05-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-european-cdmo-gmp-production-prp2026-05-19T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-sidoti-conference-may-20262026-05-19T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/blank-bio-seed-financing-pacbio-collaboration2026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLNE/cosette-pharmaceuticals-appoints-david-bell-cco2026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-goldman-sachs-global-healthcare-conference-20262026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-edison-scientific-kosmos-ai-collaboration2026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INM/inmed-mentari-merger-migraine-prevention2026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INM/inmed-pharmaceuticals-amends-preferred-investment-options2026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/herantis-pharma-indivi-partnership-her-096-trial2026-05-19T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-intelligent-eyewear-design2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-impala-2-phase-3-data-molgramostim2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALPS/alps-group-nasdaq-notification-minimum-bid-price2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-participation-william-blair-conference-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-eular-2026-congress-data-presentations2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-proposed-public-offering2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-td-cowen-oncology-summit-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-present-william-blair-conference2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-retirement-cfo-peter-griffith2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-presents-stifel-2026-ophthalmology-forum2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-public-offering-buntanetap2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-advance-ai-drug-discovery-nvidia2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-participate-upcoming-investor-conferences2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-2026-annual-meeting-results2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-expands-rare-disease-portfolio-impavido-commercialization2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-lytham-partners-conference-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-2025-corporate-responsibility-report2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-quarterly-cash-dividend2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-ars-briefing2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-agp-virtual-healthcare-conference2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-inducement-grants-nasdaq-rule-56352026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-phase-2-study-alxn1840-wilson-disease2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-1q26-financial-results2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-fda-acceptance-supplemental-bla-ankteva2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-private-placement-3-million2026-05-20T03:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-participate-june-2026-investor-conferences2026-05-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGC/igc-pharma-q1-2026-financial-results-calma-phase-22026-05-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-investor-conferences-20262026-05-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-inducement-grants-nasdaq-20262026-05-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-public-offering-common-stock2026-05-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-pediatric-pneumococcal-vaccine-phase-2-results2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-q1-2026-financial-results2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-launches-cancer-care-campaign2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-secures-medicare-coverage-breast-cancer2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-upcoming-investor-conferences2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-participate-upcoming-conferences2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-biopharma-eilon-elmalem-appointment-yavne-cdmo2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMD/inmode-appoints-dr-shlomo-nass-and-moshik-itzkovich2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-corporate-updates-financial-results-q4-fy20262026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-fy-2026-business-update2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-participate-june-2026-investor-conferences2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-report-q1-2026-results-may-272026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/expand-trial-natera-fetal-focus-nipt-enrollment2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-participation-william-blair-conference2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-2025-corporate-sustainability-report2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-investor-conferences-20262026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-vonoprazan-research-ddw-20262026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-td-cowen-oncology-summit-20262026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-public-offering-common-stock-warrants2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-easl-2026-data2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-participate-td-cowen-summit2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-peer-reviewed-publication-vanoglipel-mash2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-2026-jefferies-conference2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/fda-approves-guardant360-liquid-cdx-largest-panel2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/pharmala-biotech-licenses-ala-002-jupiter-neurosciences2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-new-biomarker-data-impala-2-trial2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-support-military-community2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-participate-craig-hallum-conference2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-goldman-sachs-healthcare-conference-20262026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-enrollment-milestone-remedy2-trial2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-appoints-celine-martin-jeff-mirviss-board2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/monthly-injectable-buprenorphine-relapse-reduction2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-acquires-spr-therapeutics-chronic-pain2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-reverse-stock-split2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-public-offering-pricing2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-global-follow-on-offering-launch2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-global-offering-launch2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-shareholders-meeting-june-20262026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-general-assembly-june-20262026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-present-william-blair-growth-conference2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-investor-conferences-june2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-2-million-offering2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-expands-animal-health-portfolio-surgical-packs2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-cancer-awareness-campaign-tim-howard2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-launches-awareness-campaign-tim-howard2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-launches-global-cancer-awareness-campaign2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-global-awareness-campaign-tim-howard2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-one-save-changes-everything-campaign2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-tim-howard-cancer-awareness-campaign2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-tim-howard-global-cancer-initiative2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-third-quarter-2026-dividend2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-qia-agent-ai-guidance2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-financial-conferences2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-participate-upcoming-investor-conferences2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-global-cancer-awareness-campaign2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-trading-halt-euronext-paris2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-temporary-suspension-euronext-paris2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-announces-quarterly-dividend2026-05-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-participate-june-2026-investor-conferences2026-05-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-inducement-grants-nasdaq-20262026-05-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-positive-phase-3-study-results-voxzogo-hypochondroplasia2026-05-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-reports-q1-2026-financials2026-05-21T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-who-expand-collaboration-visceral-leishmaniasis2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-oncology-asco-eha-2026-abstracts2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-extension-deadline-special-cash-dividend2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-clinical-data-urolift-barrigel2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-delivers-kidney-stone-care-elyra-thulium-fiber-laser2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-presentation-jefferies-global-healthcare-conference2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-2026-jefferies-conference2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-investor-webcast-eliminate-b-trial2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-presentations-international-myotonic-dystrophy-consortium2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-expansion-austin-largest-sequencing-facility2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-data-psychiatry-sleep-research-spring-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-pact-award-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-june-investor-conferences2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-bcan-raise-awareness-utuc2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-ebola-outbreak-preparedness2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-presentation-jefferies-conference2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-names-nishant-saxena-cbo2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVLN/avalyn-ap01-eular-2026-presentation2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-investor-events-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-investor-conferences-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-launches-1290-infinity-iii-fluorescence-detector2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-fda-approval-vclas-system2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-private-placement-offering2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-2026-asco-eular-presentations2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMED/consistent-glycemic-outcomes-minimed-780g-system2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-upcoming-investor-conferences2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-participate-craig-hallum-conference-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-affordable-housing-williamstown-new-jersey2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-expands-glp-1-offering-canada-generic-semaglutide2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-generic-semaglutide-canada2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-participate-lytham-partners-spring-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-hdfn-podcast-episode-582026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-appoints-stefano-folli-lead-cardiopulmonary-unit2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-trading-resumption-euronext-paris2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-resumes-trading-euronext-paris2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-acquisition-tubulis-oncology-portfolio2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-announces-60-million-public-offering2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-upsized-secondary-offering-pricing2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-nasdaq-delisting-notification2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-asco-2026-clinical-data2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-denali-update-phase-2b-luma-study-biib1222026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-phase-1b-muir-trial-data-asco-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-aky-2519-clinical-data-asco-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-positive-phase-2-results-silevertinib2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-annamycin-cardiac-safety-asco-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-rejects-unsolicited-proposal-radoff-jec-group2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-presentations-asco-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-investor-conferences-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-jefferies-global-healthcare-conference-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-changes-senior-leadership2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-investor-conferences-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-presents-35-studies-at-asco2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-fid-007-asco-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-oncology-portfolio-asco-eha-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-kite-oncology-advancements-asco-eha-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-ascos-2026-presentations-tumor-studies2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-noetik-asco-2026-ai-analysis-tumor-pathology2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-duravelo-2-data-asco-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-2-bot-bal-melanoma-data-asco-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-2026-invisalign-ortho-summit2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-oncology-asco-eha-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-asco-eha-2026-abstracts2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-updated-fiscal-year-2026-financial-outlook2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-stifel-jaws-paws-conference2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-william-blair-growth-stock-conference2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-participation-investor-conferences2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-2026-agm-outcome2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-leadership-changes-may-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/optima-trial-results-asco-2026-prosigna-guided-decisions2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-asco-2026-data2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-asco-2026-oncology-pipeline-data2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-research-pedmark-asco-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presentation-asco-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-ascend-study-cr-001-asco-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-showcase-oncology-portfolio-asco-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-expands-adc-pipeline-cpt1132026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-2026-asco-eha-congress-presentations2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-median-overall-survival-pancreatic-cancer2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/ficerafusp-alfa-pembrolizumab-hnscc-survival-data2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-phase-1-data-ctx-8371-asco-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-phase-1-op-3136-clinical-data-asco-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-webcast-phase-2-crdf-004-data2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-preclinical-data-aktx-101-kras-inhibition2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-abstracts-asco-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/lynozyfic-linvoseltamab-phase-1-2-trial-results2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-2026-asco-abstracts2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-closing-2-million-offering2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presentation-2026-jefferies-global-healthcare-conference2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-publishes-2025-esg-report2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/positive-topline-results-phase-3-trial-vgx-31002026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-presents-2026-jefferies-global-healthcare-conference2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-announces-public-offering-securities2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-mint-commercialization-timeline-update2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-host-investor-conference-call-positive-rasolute-results2026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-presentation-jefferies-conference-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-inducement-grant-nasdaq-rule-56352026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inducement-awards-nasdaq-rule-56352026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-participate-jefferies-global-healthcare-conference-20262026-05-22T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-showcase-late-stage-oncology-pipeline-asco-20262026-05-22T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/otarmeni-ema-filing-acceptance-hearing-loss2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-hemispherian-glix1-asco-20262026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-100-million-offering2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-william-blair-conference-20262026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-positive-clinical-data-asco-20262026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-health-economic-analysis-anktiva-bcg2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-patient-survey-nmibc-bladder-preservation2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-chmp-positive-opinion-trodelvy-triple-negative-breast-cancer2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-positive-eu-chmp-opinion-keytruda-padcev-bladder-cancer2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-nasdaq-delinquency-notification2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-william-daniel-chairman-board2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-investor-call-june-2026-asco-findings2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-positive-chmp-opinion-maviret-hepatitis-c2026-05-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-mrna-flu-vaccine-fda-advisory-committee2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-yuhan-api-supply-deal2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-preclinical-data-psoriasis-20262026-05-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-expands-abi-6250-development2026-05-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/aci-19626-phase-1-data-als2026-05-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/2020-biolabs-emergency-planning-ebola-hantavirus-testing2026-05-22T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/ebola-outbreak-spreading-alarming-speed-tomz2026-05-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-blez-asia-opening-aesthetic-dermatology-bangkok2026-05-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMS/annual-shareholder-meeting-american-shared-hospital-services2026-05-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-expedited-discovery-naked-short-sellers2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/datroway-approval-trop2-antibody-drug-conjugate2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-approval-eu-thalassaemia2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-share-consolidation-20262026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-asco-20262026-05-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-approval-thalassemia-eu2026-05-22T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-announces-dividend-semnur-stock2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/fda-accelerated-approval-gilead-hepcludex-hdv2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-2026-asco-eha-conferences2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inducement-grant-new-employee2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-jefferies-conference-20262026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACH/accendra-health-offers-consent-solicitations2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-receives-nasdaq-delist-notice2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-expands-global-operations-hyderabad2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-global-offering-proceeds-100-million2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-global-offering-100-million2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-nasdaq-notice-late-form-10-q2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-avanzanite-pyrukynd-approval-thalassemia-eu2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-avanzanite-eu-authorization-pyrukynd-thalassemia2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-avanzanite-eu-approval-pyrukynd-thalassemia2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-authorization-eu-thalassemia2026-05-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-nasdaq-debut-regenerative-medicine2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-advances-oncology-abstracts-asco-eha-20262026-05-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-verve-102-phase-1b-results2026-05-25T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-closes-150-million-offering2026-05-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-quarterly-dividend-q2-20262026-05-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reverse-stock-split-20262026-05-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-medical-cannabis-europa-london-20262026-05-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-2026-jefferies-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-darlifarnib-adagrasib-trial-results2026-05-26T10:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-edit-401-preclinical-data-eas-congress2026-05-26T10:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-goldman-sachs-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/biovica-expanded-work-order-cdk-inhibitor2026-05-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-next-personal-ctdna-asco-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-launch-enhanced-panorama-nipt2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-proposed-public-offering2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-jefferies-global-healthcare-conference-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-phase-2-juniper-trial-jade1012026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-crb-701-phase-1-2-data2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-fda-de-novo-clearance-deepview-system2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-auvelity-data-ascp-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-presents-clym116-budoprutug-era-congress-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-showcase-leadership-psychiatry-orexin-biology2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-positive-gait-analyses-nvg-291-phase-1b-2a-study2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRAX/virax-immune-long-covid-clinical-data2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-phase-1b-trial-expansion-paxalisib2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/suitability-vaccine-platform-bundibugyo-virus-ebola-outbreak2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-data-presentations-cmsc-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-q1-2026-financial-results-report2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-appoints-michael-bailey-board2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-participation-goldman-sachs-healthcare-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-jefferies-2026-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-largest-ogm-study-t-cell-leukemia2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-pan-viral-inhibitors-hantavirus-bunyavirus-influenza2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-nih-funding-dare-hpv2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-expands-hypertension-program-solera-health2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-continuous-blood-glucose-monitoring-ada-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-regains-nyse-listing-compliance2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-participate-jp-morgan-goldman-sachs-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-launches-mam-solution-biopharma-quality-control2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-brad-pentelute-scientific-advisory-board2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-johns-hopkins-irb-approval-cmnd-1002026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-oppenheimer-conference-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-behind-the-diagnosis-campaign2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMED/minimed-participate-goldman-sachs-healthcare-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-ebola-pcr-assay-development2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/aetna-ai-claims-processing-improvement2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-public-offering-319-million2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-jefferies-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-completes-last-patient-visit-mn-001-trial2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-closes-global-offering-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-global-offering-completion2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-phase-1-trial-jade2012026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-goldman-sachs-healthcare-conference-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-investor-conferences-june-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-closing-offering-common-stock2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LKFT/lakefront-transparency-notification-bank-of-america2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LKFT/lakefront-bank-of-america-transparency-declaration2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-investor-conferences-june-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-goldman-sachs-conference-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-investor-conferences-june-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-goldman-sachs-healthcare-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-pangea-plate-system-launch-europe2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-launches-pangea-plating-system-europe2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-ceo-speak-jefferies-global-healthcare-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-goldman-sachs-healthcare-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-participate-goldman-sachs-healthcare-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-voluntary-medical-device-correction-omnipod2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-asco-2026-trials-abstracts2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-inducement-grants-nasdaq-rule-5635c42026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-positive-clinical-data-eas-congress2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-theft-scrapped-product-notification2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-goldman-sachs-healthcare-conference2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/phase-3-assure-interim-data-livdelzi-gild2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-easl-congress-2026-positive-data2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-pbgene-hbv-data-easl-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/highest-paid-pharma-ceos-20252026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-announces-results-annual-general-meeting2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-investor-conferences-june-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-2026-jefferies-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LONA/leonabio-participate-medical-industry-meetings-june2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-presents-william-blair-growth-stock-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-participate-william-blair-jefferies-conferences2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-orphan-drug-designation-imsidolimab-japan2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presents-goldman-sachs-healthcare-conference-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-appoints-eva-boratto-cfo2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-investor-conferences-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-participate-upcoming-investor-events2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-fireside-chat-jefferies-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-new-hae-data-eaaci-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-presentation-2026-jefferies-global-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-zeta-tms-deployment2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-june-investor-conferences2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-presentation-jefferies-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-arow-inhbe-easl-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-participation-investor-conferences-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-presentation-jefferies-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-jefferies-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-presentation-topline-results-vdphl012026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/american-cancer-society-recommends-guardant-health-shield-test2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-pre-ind-fda-ncel-101-type-1-diabetes2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-june-2026-investor-conferences2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-participate-2026-jefferies-global-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-easl-2026-belapectin-mash-cirrhosis2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-participate-june-investor-conferences2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVLN/avalyn-participate-jefferies-global-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-investor-webinar-june-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-participation-jefferies-conference-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/reduce-it-analysis-eas-congress-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-2026-jefferies-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-easl-congress-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-update-rain-protocol-liquidity2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-jefferies-global-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-jefferies-global-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LABT/lakewood-amendex-expands-global-ip-portfolio-nu-32026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-announces-private-placement-financing2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-presentation-jefferies-global-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-2a-ttx-mc138-trial2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-peer-reviewed-publication-gx-032026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-pandemic-response-platform-hyft2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-jefferies-global-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-presentation-goldman-sachs-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-joins-russell-microcap-index2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-alstars-trial-summit2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-resubmit-new-drug-application-relacorilant2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-william-blair-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-participate-goldman-sachs-health-care-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-easl-2026-denifanstat-resmetirom2026-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-positive-clinical-data-graves-iga-nephropathy2026-05-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-appoints-erik-lundgren-ceo2026-05-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-leadership-noninvasive-colorectal-cancer-screening2026-05-27T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-key-program-business-updates2026-05-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-orphan-drug-exclusivity-papzimeos2026-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-2026-jefferies-conference2026-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-1500-phase-1-data-publication2026-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-phase-3-enhance-trial-results2026-05-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-qtorin-patent-20432026-05-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/exparel-use-reduces-opioid-use-healthcare-costs2026-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/lilly-acquisitions-moderna-hantavirus-asco-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-fiscal-year-2026-results2026-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/medi%20wound-first-quarter-2026-results-update2026-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-goldman-sachs-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-phase-2a-reset-trial-parkinsons2026-05-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-presentation-2026-jefferies-conference2026-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-regains-rights-hcw9206-hcw92012026-05-27T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/germany-biotech-winners-europe-support2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-erna-101-ind-preparation-milestones2026-05-27T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-fda-acceptance-priority-review-bbp-418-lgmd2i-r92026-05-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-bemnifosbuvir-ruzavir-easl-20262026-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-blackstone-financing-zumilokibart2026-05-27T10:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/impact-phase-2b-data-pemvidutide-mash-easl-20262026-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-announces-canadian-patent-azd5904-male-infertility2026-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/brewdog-underdog-summer-campaign-football2026-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/sharps-technology-rebrands-skyai-global-south-finance2026-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-goldman-sachs-healthcare-conference2026-05-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-2026-jefferies-conference2026-05-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/ember-lifesciences-strategic-investments-series-a-27m2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMED/minimed-showcase-flex-go-ada-scientific-sessions2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-participate-jefferies-healthcare-conference-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-goldman-sachs-healthcare-conference-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-june-investor-conferences2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-investor-conferences-june-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-presentation-jefferies-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-participate-william-blair-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-strengthens-commercial-leadership-appointments2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-investor-conferences-june-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-2026-jefferies-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-goldman-sachs-conference-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-participate-goldman-sachs-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-presents-jefferies-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/body-by-apyx-miami-swim-week-showcase2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-herizon-gea-data2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/hca-healthcare-acquires-college-health-care-professions2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-jefferies-global-healthcare-conference-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/radoff-jec-group-calls-seer-acquisition-proposal-review2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-investor-conference-call-q2-results2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-investor-conferences-june2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-participation-2026-jefferies-global-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-q2-fy-2026-results2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-participate-william-blair-growth-stock-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-goldman-sachs-healthcare-conference-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-patent-allowance-filspari-iga-nephropathy2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-participate-conferences-june2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-webcast-healthcare-conference2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/fda-approves-linzess-pediatric-functional-constipation2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-host-myostitis-rd-webinar-june-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/new-jersey-life-sciences-job-opportunities2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/gsk-bepirovirsen-functional-cure-hepatitis-b2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ce-mark-dual-glucose-ketone-sensing-technology2026-05-28T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-participate-upcoming-june-2026-investor-conferences2026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-full-year-2025-results2026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-decnupaz-bpdcne-treatment2026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-investor-conference-call-q2-20262026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-june-20262026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-signal-er-101-breast-cancer-study2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-elects-kathleen-tregoning2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-caremark-expands-glp-1-coverage-options2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/foundayo-zepbound-coverage-expansion2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-emobot-emocare-validation-ascp-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-presentation-2026-jefferies-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-serenity-phase-3-trial-agitation-bipolar-schizophrenia2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-jefferies-global-healthcare-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-expanded-dpyd-test-cancer-patients2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-fiscal-year-2026-conference-call2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-jefferies-global-healthcare-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-new-data-injectable-treatment-children2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-june-investor-conferences-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-june-investor-events2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-2026-jefferies-global-healthcare-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-investor-conferences-june-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-retirement-senior-secured-debentures2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-2026-jefferies-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-bardet-biedl-syndrome-algorithm2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-2026-jefferies-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-jefferies-conference-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-q1-2026-financial-results-corporate-updates2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-update-rain-holdings-advisory-board2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-presentation-jefferies-conference-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-jefferies-conference-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/systemic-immune-activation-eftilagimod-alfa-cancer2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-openlab-sync-digital-execution-laboratory2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-participation-baird-conference-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-holdings-first-quarter-2026-results2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-jefferies-conference-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-2026-asco-abstracts2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-appoints-andrew-miller2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-10-million-financing-soteria-trial2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-2026-jefferies-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-participate-jefferies-healthcare-conference-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-participate-investor-conferences2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-ceo-presentation-jefferies-conference-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/neurothera-labs-acquisition-cliniquantum-approval2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/enteras-eb613-oral-pth-anabolic-osteoporosis-endo-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-phase-2-calliper-trial-data-cmsc-20262026-05-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-jefferies-conference-20262026-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-jefferies-global-healthcare-conference-20262026-05-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-fda-orphan-drug-designation-oxaliplatin2026-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-water-iv-study-enrollment-completion2026-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/hinge-health-shares-up-72-percent-ipo2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-22-million-financing2026-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-ionis-hepatitis-b-functional-cure-results2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-fda-acceptance-bezuclastinib-ndas2026-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-cdmo-master-services-agreement-ivd-development2026-05-28T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-pmda-regulatory-submission-cardiamp-therapy2026-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-2026-jefferies-conference2026-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-2026-jefferies-conference2026-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-acquires-k25-ai-agency-rights-apac2026-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-successful-debt-repricing2026-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-scripps-hantavirus-antibody-vaccine-development2026-05-28T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/first-patient-dosed-phase-2-trial-agent-7972026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-bla-submission-obexelimab-igg4-rd2026-05-28T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-launches-vibativ-china2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTMD/biote-bob-peterson-interim-ceo2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-launches-cherry-ztripez-cannabis-summer2026-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-mens-health-webinar-june-20262026-05-28T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-jefferies-conference-20262026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-jefferies-global-healthcare-conference-20262026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-investment-conferences-june-20262026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VACH/veraxa-biotech-financial-strengthening2026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/divitum-tka-biological-response-breast-cancer2026-05-28T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-brainstorm-parkinsons-epilepsy-ai-collaboration2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-upsized-secondary-offering-class-a-stock2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/glass-lewis-recommends-pacira-director-nominees2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-equity-receives-nasdaq-deficiency-letter2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-participate-2026-jefferies-healthcare-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-updated-presentation-time-investor-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-june-conferences2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investor-conferences-june-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-june-conferences-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-investor-conference-presentations2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-investor-conferences-june-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approves-tremfya-label-expansion-joint-damage2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/innovent-pfizer-global-collaboration-oncology2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-2026-jefferies-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GENB/generate-biomedicines-goldman-sachs-conference-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-solta-medical-thermage-trademark-china2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-jefferies-2026-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/aetna-mental-health-on-demand-launch2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illuminas-fireflygo-automation-platform-oncology-research2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-innovent-global-strategic-collaboration-oncology2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-june-investor-conferences2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-jefferies-global-healthcare-conference2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-supports-bundibugyo-ebola-research2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-supports-ebola-research-bundibugyo2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-data-presentation-mps-symposium2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-investor-conferences-june2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-nanoknife-ire-expansion-medicare-coverage2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-herizon-gea-phase-3-results2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-herizon-gea-phase-3-data2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-herizon-gea-data-asco-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-herizon-gea-trial-data-asco-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-expands-benefits-new-partners2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-ceo-succession2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-investor-conferences-june-20262026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-jefferies-global-healthcare-conference-20262026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-investor-conferences-june-20262026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-jefferies-conference-20262026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-opioid-use-fibromyalgia-2026-ascp2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-participate-june-2026-investor-conferences2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-solta-medical-thermage-trademark-certification-china2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-ebola-antibody-who-recommendation2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-bat-contract-modification2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-june-2026-conferences2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-inducement-grants-nasdaq-rule-5635c42026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-collaboration-diakonos-oncology-signatera-melanoma2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-brukinsa-cll-asco-20262026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/fda-breakthrough-therapy-calderasib-nsclc2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-investor-conferences-june-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-present-clinical-data-eaaci-congress-20262026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-q1-2026-financial-results2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-relaunches-tweed-germany-cannabis-strains2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-ai-impact-award-20262026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-fourth-quarter-fiscal-year-2026-results2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-endo-2026-abstracts2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-jefferies-global-healthcare-conference-20262026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-warrant-exercise-2-million2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-rp1-bla-resubmission-fda-discussion2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-ceo-fda-pathway-global-strategy2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-bridgeport-rehabilitation-hospital2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/longest-progression-free-survival-nsclc-pfizer-lorbrena2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-fda-approval-ecog-assistant2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-responsive-neuromodulation-assfn-20262026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-japanese-patent-filing-depression-treatment2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-malaysia-china-biotechnology-cooperation2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-immune-system-cancer-hunt2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTHI/ai-revolution-drug-delivery-nthi2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-prime-vendor-expansion-canada2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-annamycin-asco-2026-cardiotoxicity-data2026-05-29T12:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-european-commission-authorization-venclxto2026-05-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/qtrex-announces-10-million-private-placement2026-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-phase-3-study-results-multiple-myeloma2026-05-29T13:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-files-itc-complaint-against-nanomics2026-05-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-present-data-sab-142-ada-focis-20262026-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-rebrands-to-focaltherics-new-ticker-symbol-focl2026-05-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-update-phase-2b-trial-tebapivat-lower-risk-mds2026-05-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/clonoseq-mrd-testing-asco-eha-20262026-05-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-fda-approval-afrezza-inhaled-insulin-children2026-05-29T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-invests-in-uber-technologies2026-05-29T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYA/skyai-appoints-arthur-levine-cfo2026-05-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTH/optimi-health-psychedelic-therapy-access-australia2026-05-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-shareholder-letter-20262026-05-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bmy-mezigdomide-reduces-risk-multiple-myeloma2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-publication-articles-ost-her2-osteosarcoma2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-us-patent-coronavirus-treatment2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-multi-institution-trial-genetic-testing-colorectal-cancer2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-2026-jefferies-conference2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-investor-events-june-20262026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-june-2026-investor-conference2026-05-29T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-reverse-stock-split-nasdaq-hearing2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-afrezza-pediatric-approval-conference-call2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-long-term-control-llc-brukinsa-asco-20262026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-standard-disease-control-llc-brukinsa-asco-20262026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-diamond-phase-3-trials-results-ocs-012026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-lazcluze-atypical-egfr-nsclc2026-05-29T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-phase-3-diamond-results-ocs-012026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-conference-call-phase-1-results2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-presents-jefferies-global-healthcare-conference2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-jefferies-global-healthcare-conference2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-nasdaq-notification-late-filing-2025-report2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-asco-2026-lifyorli-overall-survival-data2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-nasdaq-notice-form-10-q2026-05-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-patent-allowances-actimab-iomab2026-05-29T22:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-update-snmmi-20262026-05-29T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-3-year-survival-analysis-ignyte-trial2026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima203cd8-prame-cell-therapy-asco-20262026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-phase-3-ringside-data-varegacestat-asco-20262026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/encouraging-global-phase-ii-ivonescimab-data-asco-20262026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-nhs-galleri-trial-results-asco-20262026-05-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-asco-snmmi-2026-dll3-targeting-mp07122026-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-sunitinib-gist-trial-results2026-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-cabometyx-cabinet-trial-results-asco-20262026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-phase-3-launch-htn-trial-data2026-05-30T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-asco-2026-presentation2026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-sez6-target-sclc-asco-20262026-05-30T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-papzimeos-long-term-durability-data-asco-20262026-05-30T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/frontmind-study-incyte-tafasitamab-results2026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-frontmind-trial-tafasitamab-results2026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/frontmind-study-tafasitamab-progressione-sopravvivenza2026-05-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-rp2-asco-2026-presentation2026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-braftovi-regimen-colorectal-cancer-results2026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/j-j-erleada-phase-3-prostate-cancer-study2026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima401-magea4-8-bispecific-asco-20262026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/ivonescimab-vs-tislelizumab-squamous-nsclc-study2026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/retevmo-reduction-risk-lung-cancer2026-05-31T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-pathfinder-2-results-cancer-detection-asco-20262026-05-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-amivantamab-head-neck-cancer-results2026-05-31T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/j-j-phase-3-prostate-cancer-study-erleada2026-05-31T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-3-rasolute-302-trial-results2026-05-31T12:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-brenetafusp-phase-1-data-melanoma2026-05-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-brukinsa-2026-asco-presentation2026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-new-standard-chronic-lymphocytic-leukemia2026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-brukinsa-asco-20262026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-olverembatinib-asco-20262026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-alrizomadlin-asco-20262026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/updated-clinical-data-olverembatinib-cml-asco-20262026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-offering-pricing2026-05-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/ucb-biogen-dapirolizumab-pegol-phase-3-results2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-frontmind-trial-results-dlbcl2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/talzenna-xtandi-improves-survival-prostate-cancer2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-preview-bridging-diagnostic-time-gap2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/enzamet-trial-decipher-prostate-test-chemotherapy-benefits2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/optima-trial-prosigna-test-breast-cancer2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-inducement-grants-nasdaq-rule-56352026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-jefferies-global-healthcare-conference-20262026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-june-2026-investor-conferences2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-multimodal-foundation-model-results-oncology2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-islandsbanki-market-making-agreement2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-iceland-bank-renew-market-making-agreement2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-exclusive-license-agreement-cevidoplenib2026-06-01T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-next-gen-lens-ai-platform-oncology-drug-development2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-retevmo-reduction-risk-lung-cancer2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-solid-tumor-pipeline-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-easl-liver-congress-2026-data2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-bms-pumitamig-nsclc-rosetta-trial-results2026-06-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-declaration-trial-vyd2311-enrollment-completed2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-positive-phase-1-results-jade1012026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-phase-2-alxn1840-easl-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-fda-approval-rabies-testing-laboratory2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-headache-alliance-migraine-awareness2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-rd-day-late-stage-programs-july-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-hvivo-partnership-d-mav-clinic2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-advances-4d-proteomics-insights-disease-biology2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/kevin-guest-prioritize-wellness-professional-month2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-investor-conferences-june-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-phase-3-haelo-data-eaaci-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-jefferies-global-healthcare-conference-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-investor-conference-call-sentry-trial2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-private-offering-senior-notes-20322026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/anzu-cel-prame-cell-therapy-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-strategic-alternatives-shareholder-value2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-sim0505-phase-1-data-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-participate-goldman-sachs-healthcare-conference-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-participate-goldman-sachs-healthcare-conference2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/allocetra-efficacy-knee-osteoarthritis-eular-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-virtual-investor-event-canjuparatide-endo-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-phase-1-data-apr-1051-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-nasdaq-hearing-panel-decision2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-avenzo-merger-oncology-therapies2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTMD/biote-appoints-komal-bajaj-cmo2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-fda-acceptance-povetacicept-iga-nephropathy2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-appoints-anton-nikodemus-coo2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-appoints-jeffrey-busch-ceo2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-long-term-control-llc-brukinsa2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/expanded-access-bitopertin-epp-patients2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-conference-call-viktoria-1-results2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-phase-2-gx-03-trial-findings2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-resubmission-fda-ons-50102026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-patent-ovarian-cancer-vaccine2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-sale-arkansas-hospitals2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/tlx591-tx-phase-3-data-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-goldman-sachs-conference-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-jefferies-global-healthcare-conference2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-lb2102-carvykti-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-iss-recommendation-director-nominees2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-michel-lagarde-ceo2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inducement-grant-nasdaq-rule2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-board-transition2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-updated-fid-007-data-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-pricing-senior-notes-offering2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-investor-conferences2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-2026-goldman-sachs-conference2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-funding-universities-orthodontic-research2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-avances-tumores-solidos-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-advancement-solid-tumor-pipeline-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-accelerates-solid-tumor-pipeline2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-clinical-data-lung-bladder-cancer-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-participate-upcoming-investor-conferences2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-frontmind-studie-tafasitamab-ergebnisse2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-joins-euronext-tech-leaders-index2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-cyclic-ims-p20-ms-launch-20262026-06-02T02:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-xevo-mrt-p10-ms-launch-multiomics-research2026-06-02T02:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-fireside-chat-jefferies-conference-20262026-06-02T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVO/evotec-appoints-rui-wang-head-global-ai2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-june-2026-investor-conferences2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-inducement-grant-nasdaq-rule-56352026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-goldman-sachs-healthcare-conference-20262026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-2026-jefferies-healthcare-conference2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-present-planet-microcap-conference-20262026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-receives-nasdaq-delinquency-notice-filing-10-q2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-goldman-sachs-conference-20262026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-jefferies-global-healthcare-conference-20262026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-phase-3-abtect-trial-results-obefazimod-uc2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-discontinues-pociredir-sickle-cell2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-acquires-noctrix-health-sleep-health-portfolio2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-scientific-advisory-board-roluperidone2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-vormatrigine-program-update2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-leaf-patient-monitoring-system-launch2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-participate-june-2026-investor-conferences2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/idt-illumina-oncology-research-workflows2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-servier-optimum-02-trial-data-asco-20262026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-share-buyback-week-22-20262026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-clinical-availability-xh-assay2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIMS/hims-eucalyptus-acquisition-consumer-health-platform2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-approves-aquipta-migraine-treatment-eu2026-06-02T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-portfolio-pipeline-endo-20262026-06-02T08:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-ceo-keynote-address-granada2026-06-02T09:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-exchange-ratio-2025-dividend2026-06-02T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-acquires-iowa-facility2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-acquires-memory-care-facility-california2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-colorectal-cancer-recurrence-detection-asco-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-argonaut-partnership2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-participate-june-investor-industry-conferences2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-goldman-sachs-healthcare-conference-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-phase-2-study-update-nsclc-asco-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-united-imaging-theranostics-collaboration2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACB/aurora-supports-veterans-canada2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-cfo-east-coast-ideas-conference-june-112026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-2026-jefferies-conference2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-exclusive-licensing-agreement2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-acquisition-family-first-homecare2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-goldman-sachs-conference-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-2026-jefferies-conference2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-appoints-james-levine-cfo2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-june-2026-events2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-present-planet-microcap-las-vegas-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-appoints-mike-pinder-marketing-vp2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-year-end-results-conference-call2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-goldman-sachs-healthcare-conference-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-prostate-cancer-data2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-rally-mf-phase-2-trial-asco-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-goldman-sachs-healthcare-conference-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-strategic-investment-apollo-funds2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-extension-early-tender-date2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-ind-enabling-genotoxicity-studies-eb-0032026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-fiscal-year-2025-results2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reverse-share-split-nasdaq-compliance2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-renames-research-program2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-livdelzi-phase-3-trial-pbc2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-launches-tpx-hd-power-tool-orthopaedic-procedures2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gtbiopharma-third-drug-clinic2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-lumea-ipl-9000-sonicare-6400-beauty-awards2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-q2-2026-earnings-release2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-phase-1-study-bmc128-nivolumab2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-late-breaking-eha-2026-lb2501-data2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/ziftomenib-combination-venetoclax-azacitidine-aml2026-06-02T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-lnth-2513-pet-ct-image-of-the-year2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/tissue-dynamics-galmed-cardiac-fibrosis-pathway2026-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-sentry-trial-results-asco-20262026-06-02T13:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-advance-ebola-pcr-test-development2026-06-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-ebola-outbreak2026-06-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/phase-3-proteus-study-erleada-prostate-cancer2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/janj-proteus-study-erleada-prostate-cancer2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-launches-tims-mrms-mass-spectrometry-platform2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-hematology-portfolio-eha-20262026-06-02T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-sentry-trial-eha-2026-presentation2026-06-02T15:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-ifetroban-cancer-metastasis-prevention2026-06-02T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/rise-american-drone-industry-domh2026-06-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appointments-and-promotions2026-06-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-fda-atacicept-approval-igane2026-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-agreement-patent-litigation-jelmyto2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-elevate-45-201-study-cohort-2-initiation2026-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-goldman-sachs-healthcare-conference-20262026-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-tms-research-ctmss-20262026-06-02T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-receives-patent-rezenopy-naloxone-spray2026-06-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-positive-interim-data-upLIFT-study-ersodetug2026-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-engages-stocks-news-for-investor-relations2026-06-02T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-ind-application-qrx003-peeling-skin-syndrome2026-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-kenneth-locke-cto2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-us-commercial-launch-cellav-regenerative-products2026-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-appoints-prof-gabby-sarusi-strategic-advisor2026-06-02T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-day-june-20262026-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-raj-jampa-cto2026-06-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-mrna-melanoma-vaccine-asco-20232026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-system-north-carolina2026-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-open-market-purchases-ceo-director2026-06-02T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-agreement-ophthalmic-customer2026-06-02T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-orphan-drug-designation-pas-004-als2026-06-02T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-trading-resumption-euronext-paris2026-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-capital-structure-optimization-phase-3-readout2026-06-02T12:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-rd-science-forum-june-20262026-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-launches-myovista-insights-ai-ecg-marketplace2026-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-patent-remote-blood-volume-monitor2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-phase-2-trial-onvansertib-results2026-06-02T13:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-complete-response-letter-ctxt-13012026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-positive-clinical-observation-namodenoson2026-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-private-placement-nasdaq2026-06-02T16:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-webinar-cypath-lung-cancer-test2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-real-time-data-ilet-bionic-pancreas2026-06-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-ai-evoke-system-ptsd-biomarker-discovery2026-06-02T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-board-appointments2026-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-fda-clearance-elevate-plus-ai-ultrasound2026-06-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-expansion-food-safety2026-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-study2026-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKIN/hydrafacial-introduces-hydrascalp-keravive-scalp-health2026-06-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-balance-sheet-update-eib-financing2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-proof-of-talk-2026-presentation2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-2025-impact-report2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-distribution-agreement-peru2026-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTH/optimi-health-psilocybin-production-treatment-resistant-depression2026-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-35-years-nasdaq-innovation-growth2026-06-02T11:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-harmonic-trial-lp-300-data2026-06-02T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-acceleration-pipeline-solid-tumors2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-2026-asco-presentation2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-asco-2026-pipeline-solid-tumors2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-proposed-public-offering2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inducement-grants-nasdaq-rule-5635c42026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-inducement-grants-nasdaq-rule-56352026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-fiscal-2026-financial-results2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-closing-offering2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-investor-conferences-june-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-fda-approval-pd-l1-ihc-22c3-expansion2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-appoints-dave-caspers-ceo2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-q1-2026-update2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-update-q1-2026-financials2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-investor-conferences-june-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-investment-conferences-june-20262026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-robert-greene-svp-sales2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-virtual-2026-annual-shareholders-meeting2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-nasdaq-notification-late-filing2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-attend-jefferies-global-healthcare-conference2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-preclinical-data-dengue-hyft2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-reduces-sle-disease-activity-phase-2-study2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-nipocalimab-sjogrens-disease-data-eular-20262026-06-03T05:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-efgartigimod-eular-20262026-06-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOW/sanofi-snowflake-ai-drug-development2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-goldman-sachs-conference-20262026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-offering-senior-notes2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-thrive-phase-2-study-viaskin-peanut-patch2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-indigo-trial-obexelimab-ig4-rd2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMCL/omnicell-present-goldman-sachs-healthcare-conference-20262026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-cyto-2026-innovations2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-mypeak-1-trial-data-announcement2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-goldman-sachs-conference-20262026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-inducement-grants-nasdaq-rule-56352026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inducement-grants-nasdaq-56352026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-asco-2026-data2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-board-transition-new-directors2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-phase-1-study-vax-a1-group-a-strep2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-awards-june-20262026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-june-2026-investor-conferences2026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-pricing-offering-common-stock2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-agreement-capital-structure-growth2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-fiscal-2026-results-highest-revenue-growth2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMED/minimed-expand-sensor-portfolio-dual-glucose-ketone-sensors2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-strategic-investments-cardiac-ablation2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-dr-anna-greka-board2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-appoints-james-sapirstein-ceo2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-settlement-sunosi-patent-litigation2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-goldman-sachs-conference-20262026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PNTG/pennant-expands-senior-living-california-community2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNH/unitedhealth-group-annual-shareholder-meeting-update2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-public-offering-convertible-notes-20322026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-research-pet-spending-budget-item2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-kidney-presentations-european-american-congresses2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-launches-mobile-phlebotomy-south-florida2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-roche-collaboration-mtap-deleted-cancer2026-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-darlifarnib-development-strategy2026-06-03T10:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-hugo-robotic-surgery-expansion2026-06-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-snmmi-20262026-06-03T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-mypeak-1-trial-interim-data2026-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-positive-results-phase-1-trial-briumvi2026-06-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-fda-pre-nda-qtorin-rapamycin2026-06-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-nominates-patricia-gauthier-board2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/asco-2023-revmed-moderna-lilly-china2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-nintedanib-dpi-ipf-trial-progress2026-06-03T10:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-repurchase-royalty-obligations-financing2026-06-03T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-achieve-trial-enrollment-completion2026-06-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-rese-cel-data-eular-20262026-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/sweetwater-brewing-atlanta-soccer-celebration-20262026-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVLN/avalyn-reports-q1-2026-financial-results2026-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-nla-2026-presentations2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-research-collaboration-university-leicester2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-institute-neuro-innovation-nociscan-growth2026-06-03T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-goldman-sachs-conference-20262026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-senior-notes-offering-june-20262026-06-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-goldman-sachs-conference-20262026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-proposed-200-million-term-loan-growth2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-trial-results2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-participate-goldman-sachs-healthcare-conference2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-casdatifan-kidney-cancer-trial2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-early-tender-results-exchange-offer2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-appoints-oncology-leaders-board2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-public-offering-pricing2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/platform-biotech-models-investor-eyes-drug-delivery-markets2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-saudi-arabia-fda-clearance2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-refinancing-credit-agreement-20322026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-east-coast-ideas-conference2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-us-subsidiary-global-expansion2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/cellares-tscan-agreement-automated-manufacturing2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-3x-roi-study2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-public-offering-pricing2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-upsized-public-offering-convertible-notes2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-secondary-offering-share-repurchase2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-virtual-2026-annual-shareholders-meeting2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-participate-goldman-sachs-healthcare-conference2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-annual-general-meeting-20262026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-ceo-letter-shareholders-20262026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adct-lot5-phase-3-results-zynlonta-rituximab2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-webcast-phase-1-elvn-001-data-eha-20262026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-webcast-endometrial-cancer-june-20262026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-shareholders-meeting-results2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-inceptive-ai-collaboration-rnai-therapeutics2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-named-2026-usa-today-most-trusted-brands2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-goldman-sachs-healthcare-conference2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-goldman-sachs-healthcare-conference2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-goldman-sachs-healthcare-conference-june-102026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-proposed-public-offering2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/eular-2026-dapirolizumab-pegol-sle2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-annual-general-meeting-documentation-20262026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-agm-documentation-20262026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-investor-call-sl-325-phase-1-data2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-public-offering-172-million2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-positive-data-paridiprubart-aki2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrxp-iv-ketamine-vs-nasal-esketamine-study2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/fda-confirms-premarket-approval-support-cardiamp2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-inducement-grants-nasdaq-rule-56352026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquisition-cliniquantum2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-q2-2026-results2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-truist-securities-medtech-conference-20262026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PNTG/pennant-hartford-healthcare-home-care-collaboration2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/astrazeneca-largest-transfer-nyse-history2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/am-best-affirms-credit-ratings-cvs-health-aetna2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-2025-financial-results-report2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-new-data-alyftrek-european-cystic-fibrosis-conference2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-appoints-anne-liddy-chief-legal-officer2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/robust-phase-2b-efficacy-favorable-tolerability-berobenatide2026-06-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-connect-study-cgm-benefits-type-2-diabetes2026-06-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-new-data-ada-glp1-type2-diabetes2026-06-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/roche-nurix-collaboration-bexobrutideg2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-fda-acceptance-avt16-biosimilar-entyvio2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/fda-accepts-alvotech-avt16-market-application2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-expansion-manufacturing-slovakia-europe2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-expands-production-capacity-slovakia2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-expansion-slovakia-europe-growth2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-expands-manufacturing-slovakia-growth-europe2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-phase-1-results-sl-3252026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-lyl273-update-phase-1-2-expansion2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-deora-pen-injector-diabetes-weight-management2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/fda-approves-pfizer-hympavzi-hemophilia-treatment2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-vibrant-trial-efficacy-data-eaaci-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-enforcement-11-million-judgment-kukbo2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-participate-jones-trading-fireside-chat2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-appoints-ludwig-hantson-board-directors2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-vaccine-funding-bundibugyo-ebola2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-completes-dosing-embolden-trial-ngn-4012026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-first-patient-cguardians-iii-study2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-guidance-usdh-felix-markets2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-patent-allowance-mn-166-glioblastoma2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-ma-fatima-francisco-appointment2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-rd-webcast-june-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-new-data-eha-2026-blood-cancer2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-ceo-hvivo-capital-markets-day-london2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-alstars-trial-extension-phase2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-acquires-firefly-bio-oncology-pipeline2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-preclinical-characterization-sep-479-endo-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/ignite-proteomics-oncology-registry-evaluation2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cor-medix-minocin-patent-victory2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-share-repurchase-program2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-new-debt-facility-110-million2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-investor-conferences2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-secures-three-us-sites-nasarix-trial2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-goldman-sachs-healthcare-conference2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LKFT/lakefront-appoints-eric-hedrick-cmo2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-500-million-public-offering2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-public-offering-common-stock-warrants2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-goldman-sachs-conference-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/cnty-813-preclinical-data-glucose-control-immune-evasion2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-chief-financial-officer-transition2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-tralesinidase-alfa-data-mps-iiib2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-reports-may-2026-occupancy2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-leadership-transition2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-gilead-phase-3-keynote-d46-evoke-03-update2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-merck-positive-results-islatravir-lenacapavir2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-advances-treatment-rare-endocrine-diseases-endo-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-vopimetostat-daraxonrasib-pancreatic-cancer2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-penny-carlson2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-small-cap-showcase-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/genfit-nashnext-launch-labcorp-ondemand2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-manufacturing-regulatory-progress-cxu2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-financing-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-new-publication-seizure-burden-outcomes2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-private-placement-23-7-million2026-06-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-patent-dynamic-frequency-stimulation2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-surgical-oncology-meeting-highlights2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XGN/exagen-avise-lupus-systematic-review-performance2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-joint-venture-hss-outpatient-imaging-new-york2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-ingrezza-tardive-dyskinesia-data2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-stratamap-spatial-solution-launch2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-late-breaking-obesity-data-ada-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-ingrezza-data-tardive-dyskinesia2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-acquires-colospan-gi-focused-platform2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-supports-livestock-pet-owners-new-world-screwworm2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-poster-presentations-endo-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/rejuvenate-bio-merck-animal-health-collaboration2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-frosted-flyers-award-expansion2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-q1-2026-financial-results2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-acquire-vega-therapeutics-hematology-portfolio2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-positive-phase-1-trial-glyphago2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/mariska-hargitay-bms-investigating-myeloma-campaign2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-nmpa-approval-tivdak-cervical-cancer2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-q1-2026-financial-results2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-300-million-offering2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-first-patient-predict-1-trial-licaminlimab2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/convatec-lilly-foundation-partners-health-funding2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/ai-moves-from-promise-to-practice-philips-report2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-global-biopharma-support-specimen-kits2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/four-year-biomag-i-study-results-europcr2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-liberty-phase-3-trial-vyd23112026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-pria-healthcare-nociscan-partnership2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-westgene-licensing-agreement-car-t-therapy2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-phase-1-trial-kt-4852026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-chief-financial-officer-transition2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-phase-1-data-briumvi-myasthenia-gravis2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-investment-angel-pharma-soquelitinib2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/elraglusib-beacon2-trial-pediatric-neuroblastoma2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-ignite-proteomics-agreement-150-million2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-warrant-exercise-financial-update2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/cervical-nvns-activates-vagus-nerve-review-article2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-coin-cell-dsc-battery-safety-testing2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-ubs-virtual-cns-day2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-beacon-study-results-zunveyl-alzheimers2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-rezenopy-formulary-coverage-expansion2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appointment-jason-faessler-cfo2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-launches-ai-training-platform2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-presentation-2026-truist-securities-medtech-conference2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-fda-update-bitopertin-erythropoietic-protoporphyria2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-system-adoption-michigan2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-headquarters-new-york-expansion2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-ich-safety-exposure-fasedienol-social-anxiety2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-tee-ai-agent-mental-health2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-ovarian-cancer-erna-1012026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-pali-2108-fibrostenotic-crohns-disease2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-acquires-proteintech-genomics2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-japanese-patent-primec2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/lung-cancer-research-azn-proposals-sclc2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCSG/tevogen-healthcare-services-initiative2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-inaugurates-capsule-production-line2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LKFT/lakefront-announces-e50-million-stock-repurchase-program2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LKFT/lakefront-share-buyback-program-50-million2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imd-explores-in-house-transplant-testing-opportunity2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-present-planet-microcap-las-vegas-2026-conference2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-investor-day-guidance2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-participate-upcoming-conferences2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-present-planet-microcap-las-vegas-20262026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-proposed-public-offering2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-fda-rmat-designation-lasme-cel2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-rmat-status-lasm-cel-fda2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-fda-application-entyvio-pediatric-ulcerative-colitis2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-proposed-public-offering2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-stockholders-director-nominees-elected2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-ebglyss-eight-week-dose2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-appoints-darlene-deptula-hicks2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-pricing-600-million-offering2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-public-offering-pricing2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/first-patient-enrolled-study-predicting-flare-ups-atopic-dermatitis2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-participate-investor-industry-scientific-conferences-june2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACH/accendra-health-early-results-offers-consent-solicitations2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMGL/bmgl-reverse-share-split-june-20262026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-relaunches-verkazia-pediatric-eyecare2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-hc-wainwright-summit-20262026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-present-planet-microcap-las-vegas-20262026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-redemption-warrants2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-private-placement-neflamapimod-phase-32026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-clinical-data-t-cell-engagers2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-fda-approval-tofidence-cytokine-release-syndrome2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art26-12-metabolite-data2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-european-patent-mucoadhesive-nasal-drug-delivery2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/genesis-pharma-alnylam-partnership-nordic-region2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-q1-2026-financial-results-corporate-update2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-urges-stockholders-to-vote-for-proposals2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-tender-offer-kuva-labs2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-vafseo-patent-portfolio2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-shareholder-meeting-vote-proposals-20262026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-virtual-kol-event-liver-cancer2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/danaher-acquisition-masimo-corporation2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-ceo-letter-shareholders-ai-healthcare-platform2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-collaboration-sleep-apnea-treatment2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-ceo-corner-global-recognition2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMGL/qingsong-health-basel-medical-ai-healthcare-southeast-asia2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-clinical-trial-results-brazil2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-launches-reefiq-ai-drug-discovery2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-integrated-musculoskeletal-care2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-verisfield-contract-manufacturing-agreement2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presentations-eaaci-20262026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-apex-phase-2-trial-enrollment-complete2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-atev-superiority-phase-3-study2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-nasdaq-notice-minimum-equity-requirement2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-fiscal-year-results2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-public-offering-common-stock2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-closes-public-offering-345-million2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-closing-underwritten-public-offering2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-cloture-offre-public2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-singular-research-conference-20262026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-secures-250-million-loan-growth-opportunities2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-timothy-coughlin-board2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-participate-2026-truist-securities-medtech-conference2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-inducement-awards-nasdaq-rule-5635c42026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-year-end-results-20262026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-wins-illinois-medicaid-contract2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-inducement-grant-nasdaq-rule-5635c42026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-launches-reefiq-drug-discovery-ai2026-06-10T22:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-public-offering-pricing2026-06-11T01:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/genesis-pharma-alnylam-partnership-scandinavia2026-06-11T02:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/genesis-pharma-expands-collaboration-alnylam-scandinavia2026-06-11T02:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-preclinical-data-evx-04-aml-vaccine2026-06-11T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-casgevy-data-eha-congress2026-06-11T06:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/genesis-pharma-alnylam-partnership-scandinavian-countries2026-06-11T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-final-phase-1-results-lasme-cel-eti-cel-eha-20262026-06-11T06:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-phase-1-results-eha-20262026-06-11T06:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-present-privosegtor-clinical-trials-summit-20262026-06-11T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-annual-general-meeting-shareholders-20262026-06-11T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-animal-health-acquire-targan2026-06-11T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-michael-quirk-senior-advisor2026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-phase-1-data-eha-2026-cemsidomide2026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/brewdog-rolls-back-pint-prices-scotland-bank-holiday2026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-btig-infectious-disease-day-20262026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-phase-1b-data-budoprutug-itp-eha-20262026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-updated-phase-1a-b-results-bexobrutideg2026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-grant-for-aci-7104-parkinsons2026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-fiscal-2026-results2026-06-11T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-appoints-hubert-chen-cmo2026-06-11T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-maia-ovarian-trial-poster-esmo-20262026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-private-exchange-convertible-notes2026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-zasocitinib-head-to-head-phase-3-study2026-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-phase-3-data-cll-patients-eha-20262026-06-11T11:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-initiates-precision-e2-study-teverelix-endometriosis2026-06-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-hc-wainwright-neuro-conference-20262026-06-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-phase-1-trial-im-1617-advanced-solid-tumors2026-06-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-divesiran-eha-20262026-06-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VBIO/valion-bio-us-house-armed-services-committee-initiative2026-06-11T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-tecnis-puresee-iol-expansion2026-06-11T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-fda-clearance-urine-collection-kit2026-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-phase-2-renew-trial-uk-expansion2026-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-cguard-prime-30-day-results-tcar2026-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-phase-1-data-fda-alignment2026-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-registered-direct-offering-16-5-million2026-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-rrp-awareness-day-20262026-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharma-patent-license-australian-chestnut-extract2026-06-11T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-kyowa-encouraging-results-ziftomenib-aml2026-06-11T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-td-cowen-growth-call-20262026-06-11T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-poster-presentations-sleep-20262026-06-11T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-rights-offering-registration2026-06-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/european-patent-granted-ecg-assessment-diastolic-function2026-06-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-authorizes-share-repurchase-program2026-06-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-intra-arterial-gemcitabine-delivery-lapc2026-06-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/chiesi-group-acquires-kalvista-pharmaceuticals2026-06-11T12:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-board-directors-appointments2026-06-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-latin-american-commercialization-strategy2026-06-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-immunotherapy-presentations-symposium2026-06-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-announces-private-placement-3-5-million2026-06-11T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-nasdaq-extension-bid-price-compliance2026-06-11T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/rejuvenate-bio-merck-financing-collaboration2026-06-11T13:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-epcore-fl-1-data-epcoritamab2026-06-11T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-acquires-azora-therapeutics-financing2026-06-11T15:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/jette-nygaard-andersen-livanova-board-director2026-06-11T17:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-phase-3-data-cll-eha-20262026-06-11T18:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-phase-3-data-brukinsa-cll-eha-20262026-06-11T18:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-historical-phase-3-data-cll-eha-20262026-06-11T18:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-acquires-doc-pharma2026-06-11T19:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-presents-hc-wainwright-neuro-conference2026-06-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-nasdaq-rule2026-06-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-public-offering-common-stock2026-06-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-thunderbolt-fda-clearance-stroke-technology2026-06-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-roxadustat-transfusion-independence-lr-mds2026-06-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNH/unitedhealth-group-announces-earnings-release-date2026-06-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-hc-wainwright-summit-20262026-06-11T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-graftassure-assay-kidney-transplant-screening2026-06-11T20:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-patent-allowance-keveyis2026-06-11T20:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-present-planet-microcap-las-vegas2026-06-11T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-private-placement-4-million2026-06-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-upsized-public-offering2026-06-12T02:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-prix-galien-uk-award-digital-health-solution2026-06-12T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eha-2026-venetoclax-cll14-trial-results2026-06-12T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-b-cell-cancer-innovation-eha-20262026-06-12T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-phase-3-data-eha-2026-brukinsa2026-06-12T10:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-eha-2026-brukinsa-cll-patients2026-06-12T10:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-canvuparatide-one-year-data2026-06-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-phase-1-data-jda-meeting2026-06-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-participate-hc-wainwright-summit2026-06-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-confirm-dividend-payment-date-june-20262026-06-12T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-jak2-inhibitor-eha-20262026-06-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-wells-fargo-2026-medtech-spotlight2026-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-ce-mark-review-lumee-oxygen-platform2026-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-dr-nigam-shah-board2026-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/bezuclastinib-apex-trial-results-eha-20262026-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-zepzelca-lagoon-trial-update2026-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-positive-clinical-updates-eha-20262026-06-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-wound-healing-awareness-month2026-06-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-acquires-nomad-power-systems2026-06-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-regains-nasdaq-compliance2026-06-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-host-tenth-rnai-roundtable-webcast2026-06-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-ceo-jennifer-bath-jones-ai-day-panel2026-06-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-eha-2026-brukinsa-results-cll2026-06-12T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-annualized-sales-eu-expansion2026-06-12T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-private-placement-offering2026-06-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCTI/wallachbeth-capital-closes-hcti-private-placement-offering2026-06-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-acquisition-scientia-vascular-neurovascular-care2026-06-12T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-veterinary-palatability-trials-kemin2026-06-12T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-rondecabtagene-autoleucel-eha-20262026-06-12T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-shareholders-vote-avoid-costly-adjournment2026-06-12T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-hematology-innovation-eha-20262026-06-12T18:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-410th-consecutive-quarterly-dividend2026-06-12T18:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-b-cell-oncology-eha-20262026-06-12T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-eha-2026-hematological-malignancies2026-06-12T18:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-b-cell-cancer-eha-20262026-06-12T18:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-ceo-jennifer-bath-jones-ai-day2026-06-12T18:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-eha-2026-phase-3-data-brukinsa2026-06-12T19:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-new-contract-manufacturing-orders2026-06-12T19:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-phase-2-results-setmelanotide-pws2026-06-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-repayment-eib-loans-warrants-issuance2026-06-12T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDRE/inventiva-repayment-bei-loans-bonds-issuance2026-06-12T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-board-changes2026-06-12T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-employment-inducement-grant2026-06-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-quarterly-preferred-stock-dividend-redemption-announcement2026-06-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-new-employment-inducement-grant2026-06-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-voluntary-delist-tsx-venture-exchange2026-06-12T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-regulatory-update-influenza-program2026-06-12T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/hematology-product-line-beone-medicines-eha-20262026-06-13T00:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-eha-2026-innovation-b-cell-cancer2026-06-13T00:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-nda-submission-tinlarebant-stargardt-disease2026-06-13T01:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-closes-4-million-private-placement2026-06-13T02:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-phase-3-frontmind-trial-results-eha-20262026-06-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-positive-phase-3-results-lonvo-z-hae2026-06-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-setmelanotide-pws-phase-2-trial2026-06-13T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-present-initial-clinical-data-jak2-inhibitor2026-06-13T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-data-eha-2026-inca0339892026-06-13T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-epcoritamab-dlbcl-response-rates2026-06-13T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/transcon-pth-phase-3-results-hypoparathyroidism2026-06-13T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-lb2501-proof-of-concept-b-nhl2026-06-14T07:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-positive-phase-1-results-cdx-622-eaaci-meeting2026-06-14T09:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-heart-failure-biomarkers-endo-20262026-06-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-verekitug-phase-2-vibrant-trial-eaaci-20262026-06-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-results-angioedema-eaaci-20262026-06-14T14:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-incyte-positive-results-zilurgisertib-fop2026-06-14T20:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-phase-1-data-zw191-esmo-20262026-06-14T22:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-eha2026-clinical-updates2026-06-14T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/harbour-biomed-victory-amgen-patent-case2026-06-15T00:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-qiacuity-gene-expression-portfolio2026-06-15T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-qiacuity-portfolio-gene-expression2026-06-15T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/bio-usawa-appoints-dr-aida-habtezion-board2026-06-15T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-minimal-impact-royalty-revenue-20352026-06-15T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-phase-1-ide892-clinical-trial2026-06-15T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-regained-compliance-nasdaq-listing-requirements2026-06-15T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-invests-1-billion-vision-manufacturing2026-06-15T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-ctim-76-phase-1-results2026-06-15T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/data-supporting-deucrictibant-hae-management-eaaci-20262026-06-15T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-amplify-7p-phase-2-results2026-06-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-sleep-medicine-sleep-20262026-06-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-sunrise-fa-2-trial-update2026-06-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-corporate-update-mika-grasso-co-ceo2026-06-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-executive-chairman-share-purchase2026-06-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-convertible-notes-offering-20262026-06-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-agreement-global-pharmaceutical2026-06-15T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-exhibit-nf-conference-20262026-06-15T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-orphan-drug-designations-alixorexton2026-06-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-q4-fy2026-financial-results2026-06-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-fda-submission-skinject-gorlin-syndrome2026-06-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-files-ind-application-tbs-20252026-06-15T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-phase-3-koastal-update2026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-appoints-shannon-trevino-general-counsel2026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/opko-biologics-opk8801001-acromegaly-endo-20262026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRFS/grifols-launches-fesilty-fibrinogen-human-chmt-us2026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-australian-patent-allocetra-osteoarthritis2026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-atev-phase-3-results-dialysis2026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-nasarix-human-study-nasal-residence-time2026-06-15T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-vice-president-appointments2026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/radoff-jec-group-seer-inc-history-value-destruction2026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-pramipexole-anhedonia2026-06-15T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-webinar-repetitive-head-trauma2026-06-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-name-change-faeth-therapeutics2026-06-15T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-2026-truist-securities-medtech-conference2026-06-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-laura-hamill-board2026-06-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-peer-reviewed-study-stem-cell-technology2026-06-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-launches-phase-2a-csa-aki-trial2026-06-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-cretenessity-data-endo-20262026-06-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-webcast-annual-meeting-shareholders2026-06-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-cremessity-data-endo-20262026-06-15T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XBIT/xbiotech-phase-ii-vilamakitug-trial-axial-spondyloarthritis2026-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XBIT/xbiotech-phase-ii-vilamakitug-spondylarthritis2026-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XBIT/xbiotech-phase-ii-study-vilamakitug-spondyloarthritis2026-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-fda-clearance-medigfly-maggots2026-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-update-us-portfolio-18-series-products2026-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-thunderbolt-ce-mark-europe-stroke2026-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/wiley-iqvia-ai-report-healthcare-value-chain2026-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-q2-2026-results-business-update2026-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCR/intercure-strategic-review-us-cannabis-opportunities2026-06-15T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALC/alcon-unitymd-cs-sco-2026-surgical-innovation2026-06-15T13:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-unity-cs-cos-2026-surgical-innovation2026-06-15T13:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-chronic-care-support2026-06-15T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incy-frontmind-phase-3-study-results-eha-20262026-06-15T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/results-phase-3-frontmind-incyte-eha-20262026-06-15T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-phase-3-study-results-eha-congress2026-06-15T15:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/results-frontend-mind-phase-3-trial-incy2026-06-15T15:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-eha-2026-positive-data-inc0339892026-06-15T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-data-eha-20262026-06-15T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-eha-2026-positive-data-inca0339892026-06-15T15:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-eha-2026-positive-results-inc0339892026-06-15T15:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-oveporexton-narcolepsy-study-data2026-06-15T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-endo-2026-data-presentations2026-06-15T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-125-million-public-offering-private-placement2026-06-15T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-public-offering-125-million2026-06-15T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-increases-stock-repurchase-authorization2026-06-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-cremessity-case-series-endo-20262026-06-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-genio-wins-prix-galien-uk-2026-award2026-06-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-genio-therapy-galien-uk-2026-award2026-06-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-convertible-notes-offering2026-06-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-investor-conference-call-target-d2026-06-15T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-new-inducement-grants2026-06-15T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-separation-plan-mrd-immune-medicine2026-06-15T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-announces-samantha-hammock-chro2026-06-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-fiscal-year-2026-results-update2026-06-15T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/fda-accepts-gilead-yeztugo-application2026-06-15T20:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogenomics-proposed-offering-convertible-senior-notes2026-06-15T21:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-pricing-public-offering-152-million2026-06-16T03:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-public-offering-152-million2026-06-16T03:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-completes-enrollment-phase-3-liberty-trial2026-06-16T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-ultrafiltration-technology-microplastic-risk2026-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-expands-pipeline-avtx-0102026-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-positive-results-phase-1-trial-hcw93022026-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-amendments-nf1-clinical-trial2026-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-fda-fast-track-givastomig-gastric-cancer2026-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-positive-phase-2-trial-results2026-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-tissuecypher-test-100k-orders2026-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluristyx-patent-allowance-synthetic-mrna-technology-japan2026-06-16T11:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-ema-orphan-drug-zocilurtatug-pelitecan2026-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-nominates-ebd-candidates-alzheimers2026-06-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-new-patent-zervimesine-ct18122026-06-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-rejects-forward-industries-proposal2026-06-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-trial-completion2026-06-16T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-dream-bowl-token-biconomy-exchange2026-06-16T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-quell-cv-phase-2-trial-bge-1022026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-sleep-2026-predictor-study2026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-q2-2026-guidance-update2026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-first-us-patent-cth-13012026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-expands-leadership-team-financing2026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-ibezapolstat-led3-conference-results2026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LABT/lakewood-amedev-biotherapeutics-presentation-life-sciences-forum2026-06-16T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-acceptance-ons-5010-lytenava2026-06-16T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-distribution-licensing-agreement-xacduro2026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/protillion-biosciences-drug-discovery-merck2026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-veteran-lung-health2026-06-16T12:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-clinical-study-fda-clearance2026-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-equity-announces-debt-update-new-loan-facility2026-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-expands-access-veterans-military-patients2026-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-dual-listing-nyse-texas2026-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diaMedica-fda-feedback-dm199-preeclampsia2026-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-resolve-phase-4-study-zunveyl2026-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/trilink-gmp-enzyme-manufacturing-facility2026-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-ceo-european-cdmo-gmp-production-prp-phase-1b2026-06-16T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/nyse-partner-reindustrialize-summit-detroit2026-06-16T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-advances-project-phoenix2026-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-reverse-stock-split-june-20262026-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-new-patent-pelareorep-20442026-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-2025-corporate-responsibility-report2026-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-nyc-neuromodulation-conference-20262026-06-16T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-participation-bio-international-convention2026-06-16T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/jetstream-venture-fund-invests-rejuvenate-bio-merck2026-06-16T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-osprey-study-obstructive-sleep-apnea2026-06-16T14:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-brain-cancer-data-season-abu-dhabi-ind2026-06-16T17:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-closes-licensing-agreement-veppanu2026-06-16T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-investor-conference-participation2026-06-16T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/favorable-head-to-head-data-imdx-graftassure2026-06-16T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-gene-therapy-programs-ird2026-06-16T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-target-d-201-trial-kras-g12d2026-06-16T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-second-koar-analysis-journal-american-society-nephrology2026-06-16T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-share-repurchase-program-extension-tsx2026-06-16T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MEDP/medpace-holdings-q2-2026-financial-results2026-06-16T20:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-bio-international-convention-20262026-06-16T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-merger-zydus-lifesciences-completion2026-06-16T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-retirement-chief-research-officer2026-06-16T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-prices-convertible-senior-notes-offering2026-06-17T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-yujiro-hata-chairman-board2026-06-17T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogenomics-pricing-offering-convertible-senior-notes2026-06-17T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-appoints-mayada-al-ahmad-gulf-countries2026-06-17T10:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/challenges-treating-allergic-skin-disease-dogs2026-06-17T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-ersodetug-hyperinsulinism-endo-meeting2026-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-june-july-event-schedule2026-06-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-expands-debt-facility-hercules-capital2026-06-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-ramp-205-results-pancreatic-cancer2026-06-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-eli-002-7p-complete-responses2026-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-participate-iaccess-alpha-conference2026-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-final-tender-results-exchange-offer2026-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-launches-next-generation-nucleus-solution2026-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-us-patent-mucoadhesive-drug-delivery2026-06-17T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-corporate-update-clinical-trials-pharmaceutical-pipeline2026-06-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-intercept-blood-system-isbt-congress2026-06-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-fda-approval-relief-study-nanoknife2026-06-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-erna-101-clinical-stage-biotech2026-06-17T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-day-fda-alignment-axpaxli-nda2026-06-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-joins-russell-indexes2026-06-17T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-phase-2-seabreeze-stat-asthma-study2026-06-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-participate-bio-international-convention-20262026-06-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-cleveland-clinic-bladder-cancer-research2026-06-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-q2-2026-financial-results-release2026-06-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMED/minimed-smallest-app-controlled-insulin-pump-us-launch2026-06-17T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDRE/vahaticor-recruits-first-american-patient-serra-i-study2026-06-17T13:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-ceo-letter-shareholders2026-06-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-global-expansion-abu-dhabi-ind-approval2026-06-17T13:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-pharmex-contract-manufacturing-agreement2026-06-17T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-announces-pricing-offering2026-06-17T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-affordable-housing-investment2026-06-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-3-2-million-offering2026-06-17T14:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/cystic-fibrosis-merck-manuals-patient-guide2026-06-17T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-donates-genesee-county-habitat2026-06-17T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/jcr-pharmaceuticals-acumen-alzheimers-development2026-06-17T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/utezbi-tebipenem-pivoxil-approval-cuti2026-06-17T16:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-5-5-million-private-placement2026-06-17T17:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-enters-global-skincare-market2026-06-17T19:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-lx2006-friedreich-ataxia-jama-publication2026-06-17T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-receives-eib-funding-for-genio-launch2026-06-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-receives-15-million-eib-funding2026-06-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-bla-submission-amt-130-huntingtons-disease2026-06-17T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-trinscreen-hiv-orders-q1-2026-results2026-06-16T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-pricing-offering-convertible-senior-notes2026-06-17T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-q1-2026-results-update2026-06-17T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-vibrance-2-alixorexton-narcolepsy-sleep-20262026-06-17T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-dividend2026-06-17T20:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/utezbi-approved-cuti-treatment-gsk2026-06-17T20:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-ceo-retirement-dr-andrea-pfeifer2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ceo-corner-asco-20262026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-aktx-101-asco-abstract-acceptance2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-agp-healthcare-showcase-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-european-patent-rna-splicing-modulator2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-resubmits-nda-relacorilant-cushings-syndrome2026-06-17T20:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-fda-phase-3-program-ath4342026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-prix-galien-award-20262026-06-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-investor-conferences-20262026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-asco-2026-clinical-data-update2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-trial-full-enrollment2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-phase-2-sunrise-pd-trial-completion2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-proposed-public-offering2026-06-17T20:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-asco-2026-pipeline-progress2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-new-ads-repurchase-program2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BWAY/brainsway-swift-deep-tms-12-month-durability-data2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BWAY/brainsway-invests-hopemark-health2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BWAY/brainsway-q1-2026-financial-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-present-clinical-data-eha-20262026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-q1-2026-results-update2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-goldman-sachs-conference-update2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-vitesse-thrive-eaaci-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-goldman-sachs-healthcare-conference-20262026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-2026-general-meeting-results2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbvt-thrive-phase-2-study-viaskin-peanut-patch2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-hc-wainwright-bioconnect-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-q1-2026-results2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-present-new-data-evx-04-eha-2026-congress2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-global-offering-pricing-announcement2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-phase-2-trial-nbtxr3-lung-cancer-data2026-05-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-appoints-ian-webster-cfo2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-first-quarter-2026-financial-results-update2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVO/novo-nordisk-share-repurchase-programme-20262026-06-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVO/novo-nordisk-it-security-incident2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVO/wegovy-pill-approval-uk-nvo2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVO/novo-nordisk-cardiovascular-inflammation-study2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-appoints-john-gallagher-cfo2026-06-17T20:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVO/novo-nordisk-chmp-approves-wegovy-7-2-mg-eu2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVO/wegovy-pill-chmp-approval-eu2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVO/novo-nordisk-semaglutide-mash-easl-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVO/novo-nordisk-insider-trading-disclosure2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVS/novartis-rhapsido-targeted-therapy-cindu2026-06-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVS/novartis-del-brax-phase-i-ii-fshd-study-results2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVS/novartis-rhapsido-eaaci-congress-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVS/novartis-igan-data-lancet-kidney-function-vanrafia2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVS/novartis-cosentyx-pmr-data-efficacy2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-pricing-95-million-offering2026-06-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-proposed-offering-ordinary-shares2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-leadership-transition-us-ceo2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-flemish-investors-federation-q1-2026-results2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-managerial-transactions-notification2026-06-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-2026-annual-general-meeting-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-declaration-shares-voting-rights-may-20262026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-declaration-shares-voting-rights-april-20262026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-q1-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-q1-2026-financial-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-unchained-phase-3-closes-tonight2026-06-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-unchained-ai-utility-layer-engagement2026-06-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-unchained-ai-crypto-project-launch2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-q1-2026-financial-results-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-fda-acceptance-snda-joenja-apds2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-2026-agm-results2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-q1-2026-financial-results-update2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-present-positive-interim-phase-i-data-imp7612026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/andrew-gengos-joins-immuneering-as-cfo2026-06-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-im1240-eacr-2026-preclinical-data2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPBT/purple-biotech-q1-2026-financial-results2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-reports-q1-2026-financial-results2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-jefferies-global-healthcare-conference-20262026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-easl-congress-2026-abstracts2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-20-million-offering2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-q1-2026-financial-results-update2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-hc-wainwright-bioconnect-conference2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-goldman-sachs-healthcare-conference2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-investor-conferences-may-20262026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-q1-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-sme-status-ema2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-present-bio-international-convention-20262026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-stockholder-letter-strategy-20262026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-2026-first-quarter-financial-results-update2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-fda-type-c-meeting-elpis-ii-trial-hlhs2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-report-2026-q1-results-conference-call2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-board-of-directors-shareholder-letter-20262026-06-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-definitive-proxy-materials-stockholders2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-ai-driven-multi-cancer-screening-asms-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-cori-xt-handheld-robotics-platform2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-voting-rights-shares-may-20262026-06-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-bioscience-annual-meeting-results-20262026-06-17T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-q1-2026-financial-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-present-planet-microcap-showcase-20262026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-first-quarter-2026-results-nxt-41x-progress2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-presentation-ld-micro-invitational-20262026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-q1-2026-results-obefazimod-ulcerative-colitis2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-results-may-2026-annual-general-meeting2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-repurchase-royalty-certificates-45m-offering2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-participate-british-burn-association-conference2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-annual-meeting-voting-results-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-q1-2026-financial-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-fda-approval-vyvgart-gmg-expansion2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-nasdaq-notification-minimum-bid-price2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-warrant-exercise-transaction2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-merger-innocsai-oncology-cell-therapy2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/cenplacel-l-investigational-use-florida2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-appoints-rick-gonzalez-cfo2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-q1-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOCO/gohealth-restructuring-chapter-11-aep-20262026-06-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-reverse-share-split2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-6-5-million-offering2026-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-growth-strategy-new-bookings-20262026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-surpasses-90-million-patient-journeys2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTA/strata-critical-medical-expiration-warrants2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTA/strata-critical-medical-q1-2026-results2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-q3-fiscal-2026-results2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-phase-3-transportnpc-study-completion2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-offering-pricing-20262026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-q1-2026-financial-results2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-acquires-raythera-immunology-pipeline2026-06-17T22:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-public-offering-pricing2026-06-18T01:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-public-offering-165-million2026-06-18T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-samsung-bioepis-agreement-pyzchiva-canada2026-06-18T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-organ-health-leadership-american-transplant-congress2026-06-18T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-cfo-transition-announcement2026-06-18T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-virtual-investor-event-beyond-filtration2026-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-new-patent-neflamapimod-dementia-lewy-bodies2026-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-brain-health-awareness2026-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-maia-ovarian-trial-esmo-20262026-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-zelicapavir-rsv-development2026-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-phase-3-trident-trial-glioblastoma-data2026-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-q2-2026-results-report2026-06-18T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-precision-medicine-diagnostics-american-transplant-congress2026-06-18T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-ventures-launch-25-million-commitment2026-06-18T11:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/imc-cannabis-sells-european-assets-debt-reduction2026-06-18T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-webinar-cardiometabolic-pipeline2026-06-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-us-patent-binge-behavior-regulators2026-06-18T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-esmo-gynaecological-cancers-congress-20262026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-sells-priority-review-voucher2026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-new-zealand-clearance-pm577a-wilson-disease2026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-letter-stockholders-2026-priorities2026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-67-percent-growth-esgh-20262026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-fiscal-year-end-results-20262026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/gandeeva-zymeworks-cryo-em-antibody-discovery2026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-private-placement-19-million2026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-expands-arbli-payor-coverage-access2026-06-18T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-alstars-trial-encals-20262026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-lilly-tunelab-ai-ml-platform2026-06-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-midjourney-ultrasound-scanner2026-06-18T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-regains-nasdaq-compliance2026-06-18T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-swoop-system-scan-volume-record-milestones2026-06-18T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-fda-orphan-drug-designation-gr-0621-ipf2026-06-18T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LITS/lite-strategy-invests-in-litvm-zero-knowledge-platform2026-06-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-japanese-subsidiary-qrx0032026-06-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-nomad-acquisition-update2026-06-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-recells-first-uk-clinical-experience2026-06-18T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-helping-ranchers-fight-new-world-screwworm2026-06-18T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/study-finds-drug-resistant-bacteria-urgent-health-issue2026-06-18T12:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-fda-rare-pediatric-disease-tecarfarin-kawasaki2026-06-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-co-mira-manufacturing-line-unveiling2026-06-18T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/stackadapt-iqvia-mediaos-healthcare-advertising2026-06-18T14:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-phase-2-duripanc-study-milestone2026-06-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-regains-nyse-compliance2026-06-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-financing-nyse-american2026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-positive-mid-year-update-phase-2-study2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-ebola-preparedness-video2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-phase-2-duripanc-enrollment-milestone2026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-defense-technology-update-growth-strategy2026-06-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ebola-ampligen-opportunity2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-announces-financing-offering2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-global-emjx-acquisition-ai-platform-launch2026-06-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-data2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-2-trial-ateganosine2026-06-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-exercise-warrants-4-2-million2026-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-proof-of-concept-bitac-adc-technology2026-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-phase-2-trial-ovarian-cancer-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-asaio-2026-presentations2026-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-bio-pharma-bio-international-convention-20262026-06-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-nyse-american-compliance-plan-accepted2026-06-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-meningioma-phase-1-2a-study2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-phase-i-results-vcn-01-hnscc2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn-01-phase-1-results-hnscc2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-q1-2026-highlights-results2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-investor-update-phase-ii-clinical-trial2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-license-cardiodialysis-technology-sigyn2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-101-trial-enrollment2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-3-nsclc-trial-update2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-fda-clearance-thio-101-trial-expansion2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-104-asco-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-abp-450-botox-biosimilarity-presentation2026-06-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-q1-2026-financial-results-update2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-record-first-quarter-2026-financial-results2026-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-first-quarter-2026-results-update-call2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-reports-revenue-growth-flyte-acquisition2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-ai-security-must-move-beyond-detection2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-appoints-roy-timor-rousso-cbo2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-zorronet-ai-command-control-app-launch2026-05-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-positive-pre-ind-feedback-fda2026-06-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-investor-webinar-june-20262026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-abstracts-asco-20262026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-nyse-american-disclosure2026-05-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-acquires-smartkem2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-emjx-invest-optimi-health-ipo2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-dividend-astro-investment2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-fiscal-q2-2026-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q1-2026-financial-results2026-05-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-positive-results-preclinical-study-ns0032026-06-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-virtual-kol-event-june-20262026-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-emperor-tah-preclinical-studies2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-first-quarter-2026-results2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-announces-pricing-of-5-million-offering2026-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-exclusive-quantum-antenna-license-agreement2026-06-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-terminates-at-the-market-facility2026-06-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-advanced-filament-manufacturing2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-acquires-manufacturing-facility-drone-production2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-investor-presentation-ai-defense-platform2026-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-expands-bp-united-agreement-manufacturing2026-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-us-defense-manufacturing-complex2026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-patent-coaxial-rocket-motor2026-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-financing-debt-free2026-05-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-patent-autonomous-defense-vehicles2026-05-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-patent-scout-ax6-guardian2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-patent-application-emp-shielding-filament2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-patent-autonomous-naval-mine-countermeasure2026-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-drones-corporation-launch-defense-initiatives2026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-sof-week-20262026-05-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-launches-quantum-cyber-ai2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-launches-new-website-defense-technology2026-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-secures-exclusive-drone-platform2026-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDEV/stablecoin-development-corporation-q1-2026-results2026-05-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRML/greenland-mines-skaergaard-palladium-grades-increase2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRML/greenland-mines-skaergaard-pdeq-grade-uplift2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-first-quarter-2026-results2026-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NHC/national-healthcare-properties-preliminary-results-tender-offers2026-06-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTH/optimi-health-launches-microdose-psilocybin-products2026-06-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTH/optimi-health-psilocybin-export-uk-phase-2-trial2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTH/optimi-health-secures-ibogaine-supply-development2026-06-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-ipo-closing2026-06-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-upsized-ipo-pricing2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-public-trading-cancer-therapies2026-06-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-financial-strengthening-20262026-05-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-10-million-stock-offering2026-06-18T16:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-new-chief-sales-officer2026-06-18T17:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEPP/amazfit-helio-strap-pro-hyrox-training2026-06-18T17:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-closing-3-2-million-offering2026-06-18T17:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmofarm-record-q2-2026-revenue-expansion2026-06-18T19:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-quarterly-dividend-declared2026-06-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-announces-reverse-stock-split2026-06-18T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-board-leadership-transition2026-06-19T01:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-japan-approval-minjuvi-tafasitamab-dlbcl2026-06-19T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-mba-life-sciences-scholarship-launch2026-06-19T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-sarclisa-sc-approval-japan-multiple-myeloma2026-06-19T10:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-phase-i-ii-a-trial-amt-260-epilepsy2026-06-19T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LITS/lite-strategy-panel-litecoin-summit-amsterdam2026-06-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEPP/amazfit-introduces-helio-strap-pro-hyrox-training2026-06-19T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-japan-approval-minjuvi-dlbcl2026-06-19T16:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-japan-approves-minjuvi-dlbcl-treatment2026-06-19T16:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-japan-approval-minjuvi-tafasitamab2026-06-19T16:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-annual-meeting-results-20262026-06-19T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-inducement-grants-nasdaq-rule-56352026-06-19T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/new-5w-ai-visibility-index-pharma-dtc-ads2026-06-19T22:27:08.176Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-co-inc-rahway-n-j-usa-announces-first-quarter-2026-financial-results-highlights-sign-mrk-20260430monthly0.5https://www.biopharmawatch.com/news/MRK/merck-co-inc-rahway-n-j-usa-announces-fourth-quarter-and-full-year-2025-financial-results--mrk-20260203monthly0.5https://www.biopharmawatch.com/news/MRK/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2025-financial-results-total-worldwide-mrk-20251030monthly0.5https://www.biopharmawatch.com/news/MRK/merck-co-inc-rahway-n-j-usa-announces-second-quarter-2025-financial-results-total-worldwid-mrk-20250729monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-first-quarter-2025-financial-results-total-worldwide-sales-were-15-5-billi-mrk-20250424monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-fourth-quarter-and-full-year-2024-financial-results-fourth-quarter-worldwi-mrk-20250204monthly0.5https://www.biopharmawatch.com/news/MRK/surendralal-karsanbhai-elected-to-merck-board-of-directors-rahway-n-j-mrk-20241122monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-third-quarter-2024-financial-results-total-worldwide-sales-were-16-7-billi-mrk-20241031monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-second-quarter-2024-financial-results-total-worldwide-sales-were-16-1-bill-mrk-20240730monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-first-quarter-2024-financial-results-sales-reflect-continued-strong-growth-mrk-20240425monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-fourth-quarter-and-full-year-2023-financial-results-fourth-quarter-and-ful-mrk-20240201monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-third-quarter-2023-financial-results-sales-reflect-sustained-growth-partic-mrk-20231026monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-second-quarter-2023-financial-results-sales-reflect-sustained-underlying-g-mrk-20230801monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-first-quarter-2023-financial-results-first-quarter-2023-reflected-continue-mrk-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-fourth-quarter-and-full-year-2022-financial-results-fourth-quarter-and-ful-mrk-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-third-quarter-2022-financial-results-mrk-20221027monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-second-quarter-2022-financial-results-merck-delivers-robust-sales-growth-a-mrk-20220728monthly0.5https://www.biopharmawatch.com/news/MRK/melissa-moody-investor-contacts-peter-dannenbaum-215-407-3536-908-740-1037-johanna-herrman-mrk-20220428monthly0.5https://www.biopharmawatch.com/news/MRK/merck-co-inc-2021-quarterly-and-annual-gaap-to-non-gaap-reconciliations-continuing-operati-mrk-20220421monthly0.5https://www.biopharmawatch.com/news/MRK/melissa-moody-215-407-3536-investor-contacts-peter-dannenbaum-908-740-1037-johanna-herrman-mrk-20220203monthly0.5https://www.biopharmawatch.com/news/MRK/patrick-ryan-investor-contacts-peter-dannenbaum-973-275-7075-908-740-1037-melissa-moody-ra-mrk-20211028monthly0.5https://www.biopharmawatch.com/news/MRK/patrick-ryan-investor-contacts-peter-dannenbaum-973-275-7075-908-740-1037-melissa-moody-21-mrk-20210820monthly0.5https://www.biopharmawatch.com/news/MRK/patrick-ryan-investor-contacts-peter-dannenbaum-973-275-7075-908-740-1037-melissa-moody-21-mrk-20210729monthly0.5https://www.biopharmawatch.com/news/MRK/merck-co-inc-consolidated-statement-of-income-gaap-amounts-in-millions-except-per-share-fi-mrk-20210602monthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-first-quarter-2021-financial-results-mrk-20210429monthly0.5https://www.biopharmawatch.com/news/MRK/patrick-ryan-investor-contacts-peter-dannenbaum-973-275-7075-908-740-1037-michael-decarbo--mrk-20210204monthly0.5https://www.biopharmawatch.com/news/MRK/patrick-ryan-investor-contacts-peter-dannenbaum-973-275-7075-908-740-1037-michael-decarbo--mrk-20210201monthly0.5https://www.biopharmawatch.com/news/MRK/pamela-eisele-investor-contacts-peter-dannenbaum-267-305-3558-908-740-1037-patrick-ryan-mi-mrk-20201027monthly0.5https://www.biopharmawatch.com/news/MRK/pamela-eisele-investor-contacts-peter-dannenbaum-267-305-3558-908-740-1037-patrick-ryan-mi-mrk-20200731monthly0.5https://www.biopharmawatch.com/news/MRK/jennifer-mauer-investor-contacts-peter-dannenbaum-908-740-1801-908-740-1037-pamela-eisele--mrk-20200428monthly0.5https://www.biopharmawatch.com/news/MRK/jennifer-mauer-investor-contacts-peter-dannenbaum-908-740-1801-908-740-1037-pamela-eisele--mrk-20200205monthly0.5https://www.biopharmawatch.com/news/MRK/jennifer-mauer-investor-contact-peter-dannenbaum-908-740-1801-908-740-1037-dr-christine-se-mrk-20200131monthly0.5https://www.biopharmawatch.com/news/MRK/jennifer-mauer-investor-contacts-peter-dannenbaum-908-740-1801-908-740-1037-pamela-eisele--mrk-20191029monthly0.5https://www.biopharmawatch.com/news/MRK/jessica-fine-investor-contacts-teri-loxam-908-740-1707-908-740-1986-pamela-eisele-michael--mrk-20190730monthly0.5https://www.biopharmawatch.com/news/MRK/jennifer-mauer-investor-contacts-teri-loxam-908-740-1801-908-740-1986-pamela-eisele-michae-mrk-20190430monthly0.5https://www.biopharmawatch.com/news/MRK/jennifer-mauer-investor-contacts-teri-loxam-908-740-1801-908-740-1986-claire-gillespie-mic-mrk-20190201monthly0.5https://www.biopharmawatch.com/news/MRK/claire-gillespie-investor-contacts-teri-loxam-267-305-0932-908-740-1986-michael-decarbo-90-mrk-20181025monthly0.5https://www.biopharmawatch.com/news/MRK/claire-gillespie-267-305-0932-investor-contacts-teri-loxam-908-740-1986-peter-dannenbaum-9-mrk-20180926monthly0.5https://www.biopharmawatch.com/news/MRK/tracy-ogden-investor-contacts-teri-loxam-908-740-1747-908-740-1986-claire-gillespie-267-30-mrk-20180727monthly0.5https://www.biopharmawatch.com/news/MRK/tracy-ogden-investor-contacts-teri-loxam-908-740-1747-908-740-1986-claire-gillespie-267-30-mrk-20180501monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-third-quarter-2025-results-and-raises-full-year-2025-e-unh-20251028monthly0.5https://www.biopharmawatch.com/news/UNH/unitedhealth-group-announces-changes-to-leadership-team-unh-20250731monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-re-establishes-full-year-outlook-and-reports-second-quarter-20-unh-20250729monthly0.5https://www.biopharmawatch.com/news/UNH/document-press-release-unitedhealth-group-announces-leadership-transition-stephen-j-hemsle-unh-20250513monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-first-quarter-2025-results-and-revises-full-year-guida-unh-20250417monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-2024-results-revenues-of-400-3-billion-grew-8-year-ove-unh-20250116monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-statement-on-today-s-events-unh-20241204monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-third-quarter-2024-results-revenues-of-100-8-billion-g-unh-20241015monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-second-quarter-2024-results-revenues-of-98-9-billion-g-unh-20240716monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-first-quarter-2024-results-revenues-of-99-8-billion-gr-unh-20240416monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-2023-results-revenues-of-371-6-billion-grew-15-year-ov-unh-20240112monthly0.5https://www.biopharmawatch.com/news/UNH/document-charlie-baker-joins-unitedhealth-group-s-board-of-directors-unh-20231103monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-third-quarter-2023-results-revenues-of-92-4-billion-gr-unh-20231013monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-second-quarter-2023-results-revenues-of-92-9-billion-g-unh-20230714monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-first-quarter-2023-results-revenues-of-91-9-billion-gr-unh-202304142023-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-2022-results-revenues-of-324-2-billion-grew-13-year-ov-unh-202301132023-01-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNH/document-kristen-gil-joins-unitedhealth-group-board-of-directors-minnetonka-minn-dec-12-20-unh-20221212monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-third-quarter-2022-results-revenues-of-80-9-billion-gr-unh-20221014monthly0.5https://www.biopharmawatch.com/news/UNH/optum-and-change-healthcare-complete-combination-unh-20221003monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-second-quarter-2022-results-revenues-of-80-3-billion-g-unh-20220715monthly0.5https://www.biopharmawatch.com/news/UNH/document-unitedhealth-group-reports-first-quarter-2022-results-revenues-of-80-1-billion-gr-unh-20220414monthly0.5https://www.biopharmawatch.com/news/UNH/draft-as-of-march-28-7-pm-ct-optum-and-lhc-group-to-combine-advancing-abilities-to-extend--unh-20220329monthly0.5https://www.biopharmawatch.com/news/UNH/document-n-e-w-s-r-e-l-e-a-s-e-for-immediate-release-unitedhealth-group-reports-2021-resul-unh-20220119monthly0.5https://www.biopharmawatch.com/news/UNH/document-n-e-w-s-r-e-l-e-a-s-e-for-immediate-release-unitedhealth-group-reports-third-quar-unh-20211014monthly0.5https://www.biopharmawatch.com/news/UNH/document-n-e-w-s-r-e-l-e-a-s-e-for-immediate-release-unitedhealth-group-reports-second-qua-unh-20210715monthly0.5https://www.biopharmawatch.com/news/UNH/document-n-e-w-s-r-e-l-e-a-s-e-for-immediate-release-unitedhealth-group-reports-first-quar-unh-20210415monthly0.5https://www.biopharmawatch.com/news/UNH/document-n-e-w-s-r-e-l-e-a-s-e-for-immediate-release-unitedhealth-group-reports-fourth-qua-unh-20210120monthly0.5https://www.biopharmawatch.com/news/UNH/optuminsight-and-change-healthcare-combine-to-advance-a-more-modern-information-and-techno-unh-20210106monthly0.5https://www.biopharmawatch.com/news/UNH/document-n-e-w-s-r-e-l-e-a-s-e-for-immediate-release-unitedhealth-group-reports-third-quar-unh-20201014monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20260519monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20260422monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20231214monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-20231006monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-20230901monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-202305162023-05-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-inc-recast-of-2021-non-gaap-financial-information-as-reported-to-reflect-updated-non-amgn-202301312023-01-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-amgn-20221212monthly0.5https://www.biopharmawatch.com/news/AMGN/not-for-release-publication-or-distribution-directly-or-indirectly-in-whole-or-in-part-in--amgn-20221202monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-inc-recast-of-2021-non-gaap-financial-information-as-reported-to-reflect-updated-non-amgn-20221103monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20221020monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-inc-recast-of-2021-non-gaap-financial-information-as-reported-to-reflect-updated-non-amgn-20220804monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-chemocentryx-for-4-billion-in-cash-acquisition-includes-tavneos-avacopan--amgn-20220804monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-20220803monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-inc-recast-of-2021-non-gaap-financial-information-as-reported-to-reflect-updated-non-amgn-20220427monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20211102monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20210803monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-20210729monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-privately-held-teneobio-for-900-million-in-cash-with-future-contingent-mi-amgn-20210727monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20210601monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20210427monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20210416monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash-acquisition-includes-bema-amgn-20210304monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20210202monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20201028monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20200813monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20200730monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20200728monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20200430monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-update-regarding-covid-19-for-media-amgn-20200331monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20200130monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-20200102monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-20191121monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20191031monthly0.5https://www.biopharmawatch.com/news/AMGN/david-meline-amgen-s-chief-financial-officer-to-retire-peter-griffith-to-assume-cfo-role-i-amgn-20191022monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-20190826monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20190730monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20190430monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20190129monthly0.5https://www.biopharmawatch.com/news/AMGN/third-quarter-product-and-pipeline-update-amgn-20181030monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-ne-amgn-20180726monthly0.5https://www.biopharmawatch.com/news/AMGN/one-amgen-center-drive-thousand-oaks-ca-91320-1799-telephone-805-447-1000-www-amgen-com-am-amgn-20180726monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-first-quarter-financial-results-product-sales-excluding-gild-20260507monthly0.5https://www.biopharmawatch.com/news/GILD/ashleigh-koss-media-public-affairs-gilead-com-jacquie-ross-investors-investor-relations-gi-gild-20260428monthly0.5https://www.biopharmawatch.com/news/GILD/gilead-ashleigh-koss-media-public-affairs-gilead-com-jacquie-ross-investors-investor-relat-gild-20260223monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results-pro-gild-20260210monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-third-quarter-2025-financial-results-product-sales-excl-gild-20251030monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-second-quarter-2025-financial-results-product-sales-exc-gild-20250807monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-first-quarter-2025-financial-results-product-sales-excl-gild-20250424monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results-pro-gild-20250211monthly0.5https://www.biopharmawatch.com/news/GILD/ashleigh-koss-media-public-affairs-gilead-com-jacquie-ross-investors-investor-relations-gi-gild-20241212monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-third-quarter-2024-financial-results-product-sales-excl-gild-20241106monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-second-quarter-2024-financial-results-product-sales-exc-gild-20240808monthly0.5https://www.biopharmawatch.com/news/GILD/ashleigh-koss-media-public-affairs-gilead-com-jacquie-ross-investors-investor-relations-gi-gild-20240717monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-first-quarter-2024-financial-results-product-sales-excl-gild-20240425monthly0.5https://www.biopharmawatch.com/news/GILD/investors-jacquie-ross-investor-relations-gilead-com-media-ashleigh-koss-public-affairs-gi-gild-20240322monthly0.5https://www.biopharmawatch.com/news/GILD/gilead-investors-jacquie-ross-investor-relations-gilead-com-media-ashleigh-koss-public-aff-gild-20240212monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-fourth-quarter-and-full-year-2023-financial-results-pro-gild-20240206monthly0.5https://www.biopharmawatch.com/news/GILD/gilead-contacts-jacquie-ross-investors-investor-relations-gilead-com-ashleigh-koss-media-p-gild-20240201monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-third-quarter-2023-financial-results-product-sales-excl-gild-20231107monthly0.5https://www.biopharmawatch.com/news/GILD/byoung-chul-cho-yonsei-cancer-center-republic-of-korea-1-draft-sacituzumab-govitecan-pembr-gild-20230816monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-second-quarter-2023-financial-results-product-sales-exc-gild-20230803monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-first-quarter-2023-financial-results-product-sales-excl-gild-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-fourth-quarter-and-full-year-2022-financial-results-pro-gild-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-third-quarter-2022-financial-results-product-sales-excl-gild-20221027monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-second-quarter-2022-financial-results-biktarvy-sales-in-gild-20220802monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-first-quarter-2022-financial-results-biktarvy-sales-inc-gild-20220428monthly0.5https://www.biopharmawatch.com/news/GILD/jacquie-ross-investors-investor-relations-gilead-com-nathan-kaiser-u-s-media-650-522-1853--gild-20220307monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-fourth-quarter-and-full-year-2021-financial-results-bik-gild-20220201monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-third-quarter-2021-financial-results-2-million-patients-gild-20211028monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-second-quarter-2021-financial-results-second-quarter-20-gild-20210729monthly0.5https://www.biopharmawatch.com/news/GILD/document-gilead-sciences-announces-first-quarter-2021-financial-results-first-quarter-2021-gild-20210429monthly0.5https://www.biopharmawatch.com/news/GILD/document-contacts-investors-media-jacquie-ross-amy-flood-650-574-3000-650-522-5643-for-imm-gild-20210204monthly0.5https://www.biopharmawatch.com/news/GILD/document-contacts-investors-media-monica-tellado-amy-flood-650-574-3000-650-522-5643-for-i-gild-20210111monthly0.5https://www.biopharmawatch.com/news/GILD/douglas-maffei-phd-investors-650-522-2739-marni-kottle-media-650-522-5388-for-immediate-re-gild-20201208monthly0.5https://www.biopharmawatch.com/news/GILD/document-contacts-investors-media-adam-levy-mba-ph-d-amy-flood-650-574-3000-650-522-5643-d-gild-20201028monthly0.5https://www.biopharmawatch.com/news/GILD/douglas-maffei-phd-investors-650-522-2739-amy-flood-media-650-522-5643-gilead-sciences-com-gild-20201023monthly0.5https://www.biopharmawatch.com/news/GILD/gilead-contacts-immunomedics-contacts-douglas-maffei-phd-investors-dr-chau-cheng-650-522-2-gild-20200913monthly0.5https://www.biopharmawatch.com/news/GILD/document-contacts-investors-media-adam-levy-mba-ph-d-amy-flood-650-574-3000-650-522-5643-d-gild-20200730monthly0.5https://www.biopharmawatch.com/news/GILD/douglas-maffei-phd-investors-650-522-2739-marni-kottle-media-650-522-5388-for-immediate-re-gild-20200616monthly0.5https://www.biopharmawatch.com/news/GILD/exhibit-contacts-investors-media-andrew-dickinson-amy-flood-650-524-0862-650-522-5643-doug-gild-20200430monthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-inc-forty-seven-inc-douglas-maffei-phd-investors-hannah-deresiewicz-invest-gild-20200302monthly0.5https://www.biopharmawatch.com/news/GILD/corporate-product-and-pipeline-updates-for-the-fourth-quarter-including-the-announcement-o-gild-20200204monthly0.5https://www.biopharmawatch.com/news/GILD/douglas-maffei-investors-650-522-2739-amy-flood-media-650-522-5643-for-immediate-release-s-gild-20200130monthly0.5https://www.biopharmawatch.com/news/GILD/corporate-highlights-including-the-announcement-of-gild-20191024monthly0.5https://www.biopharmawatch.com/news/GILD/sung-lee-investors-650-524-7792-marni-kottle-media-650-522-5388-for-immediate-release-gile-gild-20191015monthly0.5https://www.biopharmawatch.com/news/GILD/gilead-galapagos-sung-lee-investors-elizabeth-goodwin-investors-650-524-7792-781-460-1784--gild-20190823monthly0.5https://www.biopharmawatch.com/news/GILD/corporate-highlights-including-the-announcement-of-gild-20190730monthly0.5https://www.biopharmawatch.com/news/GILD/gilead-galapagos-sung-lee-investors-elizabeth-goodwin-investors-650-524-7792-781-460-1784--gild-20190714monthly0.5https://www.biopharmawatch.com/news/GILD/sung-lee-investors-650-524-7792-amy-flood-media-650-522-5643-for-immediate-release-gilead--gild-20190717monthly0.5https://www.biopharmawatch.com/news/GILD/sung-lee-investors-650-524-7792-marni-kottle-media-650-522-5388-for-immediate-release-gile-gild-20190529monthly0.5https://www.biopharmawatch.com/news/GILD/corporate-highlights-including-the-announcement-of-gild-20190502monthly0.5https://www.biopharmawatch.com/news/GILD/sung-lee-investors-650-524-7792-amy-flood-media-650-522-5643-for-immediate-release-gilead--gild-20190430monthly0.5https://www.biopharmawatch.com/news/GILD/product-pipeline-updates-announced-by-gilead-during-the-fourth-quarter-of-2018-include-gild-20190204monthly0.5https://www.biopharmawatch.com/news/GILD/sung-lee-investors-650-524-7792-for-immediate-release-amy-flood-media-650-522-5643-gilead--gild-20181210monthly0.5https://www.biopharmawatch.com/news/GILD/product-and-pipeline-updates-announced-by-gilead-during-the-third-quarter-of-2018-include-gild-20181025monthly0.5https://www.biopharmawatch.com/news/GILD/sung-lee-investors-650-524-7792-amy-flood-media-650-522-5643-for-immediate-release-gilead--gild-20180725monthly0.5https://www.biopharmawatch.com/news/GILD/product-and-pipeline-updates-announced-by-gilead-during-the-second-quarter-of-2018-include-gild-20180725monthly0.5https://www.biopharmawatch.com/news/GILD/sung-lee-investors-650-524-7792-michele-rest-media-650-577-6935-gild-20180509monthly0.5https://www.biopharmawatch.com/news/GILD/product-and-pipeline-updates-announced-by-gilead-during-the-first-quarter-of-2018-include-gild-20180501monthly0.5https://www.biopharmawatch.com/news/GILD/product-pipeline-updates-announced-by-gilead-during-the-fourth-quarter-of-2017-include-gild-20180206monthly0.5https://www.biopharmawatch.com/news/GILD/sung-lee-investors-650-524-7792-michele-rest-media-650-577-6935-for-immediate-release-jacq-gild-20180201monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-for-immediate--jnj-20260414monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-for-immediate--jnj-20260121monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-for-immediate--jnj-20251014monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-for-immediate--jnj-20250908monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-for-immediate--jnj-20250716monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-for-immediate--jnj-20250610monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-for-immediate--jnj-20250415monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-for-immediate--jnj-20250122monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-johnson-johnso-jnj-20241015monthly0.5https://www.biopharmawatch.com/news/JNJ/media-relations-its-jnj-com-investor-contact-investor-relations-its-jnj-com-the-plan-enabl-jnj-20240920monthly0.5https://www.biopharmawatch.com/news/JNJ/joshina-kapoor-media-relations-its-jnj-com-for-immediate-release-johnson-johnson-s-executi-jnj-20240826monthly0.5https://www.biopharmawatch.com/news/JNJ/tesia-williams-media-relations-its-jnj-com-investor-contact-jessica-moore-investor-relatio-jnj-20240717monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-subsidiaries-condensed-consolidated-statement-of-earnings-unaudited-in-jnj-20240501monthly0.5https://www.biopharmawatch.com/news/JNJ/tesia-williams-media-relations-its-jnj-com-investor-contact-jessica-moore-investor-relatio-jnj-20240416monthly0.5https://www.biopharmawatch.com/news/JNJ/tesia-williams-media-relations-its-jnj-com-investor-contact-jessica-moore-investor-relatio-jnj-20240123monthly0.5https://www.biopharmawatch.com/news/JNJ/addition-there-will-be-risks-and-uncertainties-related-to-the-ability-of-the-johnson-johns-jnj-20231130monthly0.5https://www.biopharmawatch.com/news/JNJ/document-media-contacts-tesia-williams-media-relations-its-jnj-com-investor-relations-jess-jnj-20231023monthly0.5https://www.biopharmawatch.com/news/JNJ/tesia-williams-media-relations-its-jnj-com-investor-contact-jessica-moore-investor-relatio-jnj-20231017monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-updated-financials-and-2023-guidance-following-completion-of-the-jnj-20230830monthly0.5https://www.biopharmawatch.com/news/JNJ/the-following-are-certain-preliminary-results-of-selected-unaudited-financial-and-other-in-jnj-20230724monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2023-second-quarter-results-2023-second-quarter-reported-sales-gro-jnj-20230720monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2023-first-quarter-results-2023-first-quarter-reported-sales-growt-jnj-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/copies-of-these-filings-are-available-online-at-www-sec-gov-www-jnj-com-or-on-request-from-jnj-202304042023-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2022-fourth-quarter-and-full-year-results-2022-fourth-quarter-repo-jnj-202301242023-01-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-completes-acquisition-of-abiomed-broadens-medtech-portfolio-with-world-lea-jnj-20221222monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-acquire-abiomed-strengthens-johnson-johnson-s-medtech-business-with-the-jnj-20221101monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2022-third-quarter-results-reported-sales-growth-of-1-9-to-23-8-bi-jnj-20221018monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2022-second-quarter-results-total-sales-growth-of-3-0-to-24-0-bill-jnj-20220719monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2022-first-quarter-results-total-sales-growth-of-5-0-to-23-4-billi-jnj-20220419monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2021-fourth-quarter-and-full-year-results-2021-fourth-quarter-sale-jnj-20220125monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2021-third-quarter-results-total-sales-growth-of-10-7-to-23-3-bill-jnj-20211019monthly0.5https://www.biopharmawatch.com/news/JNJ/alex-gorsky-to-serve-as-executive-chairman-and-transition-role-of-chief-executive-officer--jnj-20210820monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2021-second-quarter-results-strong-sales-growth-of-27-1-to-23-3-bi-jnj-20210721monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2021-first-quarter-results-2021-first-quarter-sales-of-22-3-billio-jnj-20210420monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2020-fourth-quarter-and-full-year-results-2020-fourth-quarter-sale-jnj-20210126monthly0.5https://www.biopharmawatch.com/news/JNJ/press-contact-kim-montagnino-631-375-8779-kmontag-its-jnj-com-investor-contact-christopher-jnj-20201203monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2020-third-quarter-results-sales-of-21-1-billion-reflecting-an-ove-jnj-20201013monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2020-second-quarter-results-sales-of-18-3-billion-reflecting-a-dec-jnj-20200716monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2020-first-quarter-results-sales-of-20-7-billion-reflecting-strong-jnj-20200414monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2019-fourth-quarter-and-full-year-results-2019-fourth-quarter-sale-jnj-20200122monthly0.5https://www.biopharmawatch.com/news/JNJ/kellie-mclaughlin-mobile-609-468-8356-investor-contacts-lesley-fishman-chris-delorefice-of-jnj-20191230monthly0.5https://www.biopharmawatch.com/news/JNJ/press-contacts-ernie-knewitz-cristal-downing-732-524-1090-732-524-3283-media-relations-its-jnj-20191205monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-subsidiaries-condensed-consolidated-statement-of-earnings-unaudited-in-jnj-20191023monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2019-third-quarter-results-sales-of-20-7-billion-reflecting-growth-jnj-20191015monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-appeal-flawed-opioid-judgment-in-oklahoma-company-did-not-cause-opioid--jnj-20190826monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2019-second-quarter-results-sales-of-20-6-billion-reflecting-a-dec-jnj-20190716monthly0.5https://www.biopharmawatch.com/news/JNJ/press-contacts-ernie-knewitz-cristal-downing-732-524-6623-732-524-3283-917-697-2318-m-908--jnj-20190425monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2019-first-quarter-results-sales-of-20-0-billion-reflecting-growth-jnj-20190416monthly0.5https://www.biopharmawatch.com/news/JNJ/global-media-relations-ernie-knewitz-732-524-6623-investor-relations-matt-stuckley-732-524-jnj-20190401monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2018-fourth-quarter-results-2018-fourth-quarter-sales-of-20-4-bill-jnj-20190122monthly0.5https://www.biopharmawatch.com/news/JNJ/ernie-knewitz-donna-lorenson-732-524-6623-410-258-8571-917-697-2318-m-dlorens-its-jnj-com--jnj-20190117monthly0.5https://www.biopharmawatch.com/news/JNJ/ernie-knewitz-cristal-downing-732-524-6623-732-524-3283-917-697-2318-m-908-616-8833-invest-jnj-20181217monthly0.5https://www.biopharmawatch.com/news/JNJ/ernie-knewitz-donna-lorenson-732-524-6623-410-258-8571-917-697-2318-m-dlorens-its-jnj-com--jnj-20181023monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2018-third-quarter-results-2018-third-quarter-sales-of-20-3-billio-jnj-20181016monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2018-second-quarter-results-2018-second-quarter-sales-of-20-8-bill-jnj-20180717monthly0.5https://www.biopharmawatch.com/news/JNJ/press-contacts-ernie-knewitz-732-524-6623-917-697-2318-m-investor-contacts-joseph-j-wolk-l-jnj-20180622monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2018-first-quarter-results-2018-first-quarter-sales-of-20-0-billio-jnj-20180417monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-new-chief-commercial-and-marketing-officer-taylor-patton-current-chief-isrg-20260528monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20260421monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20260122monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-intuitive-announces-preliminary-fourth-quarter-and-full-ye-isrg-20260114monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20251021monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20250722monthly0.5https://www.biopharmawatch.com/news/ISRG/global-public-affairs-1-202-997-7373-intuitive-announces-ceo-transition-effective-isrg-20250515monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20250422monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20250123monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-intuitive-announces-preliminary-fourth-quarter-and-full-ye-isrg-20250115monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20241017monthly0.5https://www.biopharmawatch.com/news/ISRG/global-public-affairs-1-202-997-7373-intuitive-president-david-j-rosa-appointed-to-intuiti-isrg-20240725monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20240718monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20240418monthly0.5https://www.biopharmawatch.com/news/ISRG/global-public-affairs-1-202-997-7373-intuitive-announces-fda-clearance-of-fifth-generation-isrg-20240314monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20240123monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-intuitive-announces-preliminary-fourth-quarter-and-full-ye-isrg-20240109monthly0.5https://www.biopharmawatch.com/news/ISRG/global-public-affairs-1-202-997-7373-intuitive-appoints-sreelakshmi-kolli-to-its-board-of--isrg-20231031monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20231019monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20230720monthly0.5https://www.biopharmawatch.com/news/ISRG/global-public-affairs-1-202-997-7373-intuitive-announces-executive-leadership-changes-dave-isrg-202305162023-05-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-202301242023-01-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-intuitive-announces-preliminary-fourth-quarter-and-full-ye-isrg-202301112023-01-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20221018monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20220721monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20220421monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20220120monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-intuitive-announces-preliminary-fourth-quarter-and-full-ye-isrg-20220112monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20211019monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-board-of-directors-approves-a-three-for-one-isrg-20210805monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20210720monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-appoints-dr-monica-p-reed-to-its-board-of-directors-isrg-20210426monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20210420monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20210121monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-intuitive-announces-preliminary-fourth-quarter-and-full-ye-isrg-20210113monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20201015monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20200721monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-appoints-joseph-c-beery-to-its-board-of-directors-isrg-20200427monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20200416monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-preliminary-first-quarter-results-provides-update-on-covid-19-impact-isrg-20200408monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-retirement-of-board-chair-lonnie-m-smith-dr-craig-h-barratt-succeeds-s-isrg-20200203monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-isrg-20200123monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-intuitive-announces-preliminary-fourth-quarter-and-full-ye-isrg-20200109monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-i-ntuitive-a-nnounces-t-hird-q-uarter-e-isrg-20191017monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-appoints-amy-l-ladd-m-d-to-its-board-of-directors-isrg-20190729monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-i-ntuitive-a-nnounces-s-econd-q-uarter-e-isrg-20190718monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-transition-of-chief-operating-officer-sal-brogna-after-two-decades-of--isrg-20190711monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-i-ntuitive-a-nnounces-f-irst-q-uarter-e-isrg-20190418monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-i-ntuitive-s-urgical-a-nnounces-f-ourth-q-uarter-e-isrg-20190124monthly0.5https://www.biopharmawatch.com/news/ISRG/investor-relations-408-523-2161-intuitive-surgical-announces-preliminary-fourth-quarter-an-isrg-20190109monthly0.5https://www.biopharmawatch.com/news/ABT/in-the-united-states-district-court-for-the-northern-district-of-illinois-eastern-division-abt-20260417monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-exact-sciences-establishes-abbott-as-a-leader-in-fast-grow-abt-20260323monthly0.5https://www.biopharmawatch.com/news/ABT/by-laws-of-abbott-laboratories-adopted-by-the-board-of-directors-of-abbott-laboratories-at-abt-20251212monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-p-abt-20251120monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2022-results-and-raises-full-year-eps-guidance-sales-growth--abt-20220720monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2022-results-sales-growth-of-13-8-percent-organic-sales-growt-abt-20220420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-strong-fourth-quarter-2021-results-issues-2022-forecast-fourth-quarter-sale-abt-20220126monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-names-robert-b-ford-chairman-of-the-board-miles-d-white-to-retire-as-executive-chai-abt-20211210monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2021-results-achieves-strong-double-digit-earnings-growth-and-abt-20211020monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2021-results-sales-growth-of-39-5-percent-organic-sales-grow-abt-20210722monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-issues-updated-2021-outlook-updated-outlook-reflects-lower-recent-and-projected-dem-abt-20210601monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2021-results-abt-20210420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-2020-results-issues-strong-double-digit-growth-forecast-for--abt-20210127monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2020-results-achieves-strong-double-digit-earnings-growth-and-abt-20201021monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2020-results-exceeds-analysts-expectations-worldwide-sales-o-abt-20200716monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2020-results-first-quarter-sales-growth-of-2-5-percent-organi-abt-20200416monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-2019-results-announces-strong-forecast-for-2020-fourth-quart-abt-20200122monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-robert-b-abt-20191113monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2019-results-third-quarter-sales-growth-of-5-5-percent-organi-abt-20191016monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2019-results-accelerated-and-sustainable-growth-driven-by-st-abt-20190717monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2019-results-sales-and-eps-growth-exceed-guidance-projects-st-abt-20190417monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-2018-results-and-issues-strong-forecast-for-2019-full-year-2018-sales-growt-abt-20190123monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2018-results-third-quarter-reported-sales-growth-of-12-1-perc-abt-20181017monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2018-results-second-quarter-reported-sales-growth-of-17-0-pe-abt-20180718monthly0.5https://www.biopharmawatch.com/news/PFE/g-pfizer-reports-strong-first-quarter-results-and-reaffirms-2026-guidance-earnings-driven--pfe-20260505monthly0.5https://www.biopharmawatch.com/news/PFE/g-pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance-focused-executio-pfe-20260203monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides-full-year-2026-guidance-continue-pfe-20251216monthly0.5https://www.biopharmawatch.com/news/PFE/g-pfizer-reports-solid-third-quarter-2025-results-raises-and-narrows-2025-eps-guidance-foc-pfe-20251104monthly0.5https://www.biopharmawatch.com/news/PFE/g-pfizer-reports-strong-second-quarter-2025-results-and-raises-2025-eps-guidance-strengthe-pfe-20250805monthly0.5https://www.biopharmawatch.com/news/PFE/g-pfizer-reports-solid-first-quarter-2025-results-and-reaffirms-2025-guidance-delivers-rob-pfe-20250429monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-strong-full-year-2024-results-and-reaffirms-2025-guidance-full-year-2024-re-pfe-20250204monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-provides-full-year-2025-guidance-and-reaffirms-full-year-2024-guidance-pfe-20241217monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-strong-third-quarter-2024-results-and-raises-2024-guidance-third-quarter-pe-pfe-20241029monthly0.5https://www.biopharmawatch.com/news/PFE/for-immediate-release-pfe-20241015monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-strong-second-quarter-2024-results-and-raises-2024-guidance-second-quarter--pfe-20240730monthly0.5https://www.biopharmawatch.com/news/PFE/dear-colleague-on-wednesday-july-24-the-compensation-committee-of-the-board-of-directors-a-pfe-20240726monthly0.5https://www.biopharmawatch.com/news/PFE/for-immediate-release-pfe-20240701monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-first-quarter-2024-results-solid-first-quarter-results-reflect-continued-gr-pfe-20240501monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-full-year-2023-results-and-reaffirms-full-year-2024-financial-guidance-2023-pfe-20240130monthly0.5https://www.biopharmawatch.com/news/PFE/for-immediate-release-pfe-20240110monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-completes-acquisition-of-seagen-pfe-20231214monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-receives-all-required-regulatory-approvals-to-complete-the-acquisition-of-seagen-pfe-20231212monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-third-quarter-2023-results-third-quarter-2023-revenues-of-13-2-billion-expe-pfe-20231013monthly0.5https://www.biopharmawatch.com/news/PFE/updates-full-year-2023-guidance-pfe-20231013monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-second-quarter-2023-results-second-quarter-2023-revenues-of-12-7-billion-ex-pfe-20230801monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-first-quarter-2023-results-first-quarter-2023-revenues-of-18-3-billion-expe-pfe-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-invests-43-billion-to-battle-cancer-pfizer-to-acquire-seagen-for-229-per-seagen-sha-pfe-202303132023-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-record-full-year-2022-results-and-provides-full-year-2023-financial-guidanc-pfe-202301312023-01-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-strong-third-quarter-2022-results-and-raises-2022-outlook-solid-third-quart-pfe-20221101monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-second-quarter-2022-results-second-quarter-2022-revenues-of-27-7-billion-re-pfe-20220728monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-to-acquire-biohaven-pharmaceuticals-pfe-20220510monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-first-quarter-2022-results-first-quarter-2022-revenues-of-25-7-billion-refl-pfe-20220503monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-fourth-quarter-and-full-year-2021-results-full-year-2021-revenues-of-81-3-b-pfe-20220208monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-announces-retirement-of-chief-financial-officer-pfe-20211117monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-third-quarter-2021-results-third-quarter-2021-revenues-of-24-1-billion-refl-pfe-20211102monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-second-quarter-2021-results-second-quarter-2021-revenues-of-19-0-billion-re-pfe-20210728monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-strong-first-quarter-2021-results-first-quarter-2021-revenues-of-14-6-billi-pfe-20210504monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-fourth-quarter-and-full-year-2020-results-and-releases-5-year-pipeline-metr-pfe-20210202monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-first-quarter-2026-financial-results-reports-first-q-abbv-20260429monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20260331monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-full-year-and-fourth-quarter-2025-financial-results--abbv-20260204monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20251231monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-third-quarter-2025-financial-results-reports-third-q-abbv-20251031monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20250930monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-second-quarter-2025-financial-results-reports-second-abbv-20250731monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20250630monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-first-quarter-2025-financial-results-reports-first-q-abbv-20250425monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20250331monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-appoints-ceo-robert-a-michael-as-chairman-of-the-board-of-directors-richard-a-gonza-abbv-20250214monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-full-year-and-fourth-quarter-2024-financial-results--abbv-20250131monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20241231monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-third-quarter-2024-financial-results-reports-third-q-abbv-20241030monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20240930monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-second-quarter-2024-financial-results-reports-second-abbv-20240725monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20240630monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-first-quarter-2024-financial-results-reports-first-q-abbv-20240426monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20240331monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-appointment-of-robert-a-michael-as-chief-executive-officer-richard-a-gonz-abbv-20240220monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-full-year-and-fourth-quarter-2023-financial-results--abbv-20240202monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20231231monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-cerevel-therapeutics-in-transformative-transaction-to-strengthen-neurosc-abbv-20231206monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-immunogen-including-its-flagship-cancer-therapy-elahere-mirvetuximab-sor-abbv-20231130monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-third-quarter-2023-financial-results-reports-third-q-abbv-20231027monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20230930monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-second-quarter-2023-financial-results-reports-second-abbv-20230727monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20230630monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-first-quarter-2023-financial-results-reports-first-q-abbv-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-202303312023-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-full-year-and-fourth-quarter-2022-financial-results--abbv-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/j-p-morgan-healthcare-conference-abbv-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20221231monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-third-quarter-2022-financial-results-reports-third-q-abbv-20221028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-vice-chairman-of-external-affairs-and-chief-legal-officer-laura-schumacher-to-retir-abbv-20221017monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20220930monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-second-quarter-2022-financial-results-reports-second-abbv-20220729monthly0.5https://www.biopharmawatch.com/news/ABBV/document-abbvie-inc-guidance-including-the-impact-of-acquired-ipr-d-and-milestones-expense-abbv-20220630monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-first-quarter-2022-financial-results-reports-first-q-abbv-20220429monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-reconciliation-of-reported-gaap-and-non-gaap-results-to-revised-non-gaap-result-abbv-20220421monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-full-year-and-fourth-quarter-2021-financial-results--abbv-20220202monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-third-quarter-2021-financial-results-reports-third-q-abbv-20211029monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-second-quarter-2021-financial-results-reports-second-abbv-20210730monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-first-quarter-2021-financial-results-reports-first-q-abbv-20210430monthly0.5https://www.biopharmawatch.com/news/ABBV/notice-of-redemption-to-the-holders-of-abbvie-inc-0-500-senior-notes-due-2021-cusip-no-002-abbv-20210420monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-full-year-and-fourth-quarter-2020-financial-results--abbv-20210203monthly0.5https://www.biopharmawatch.com/news/ABBV/rgan-healthcare-conference-richard-gonzalez-chairman-and-chief-executive-officer-abbv-20210112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-expiration-and-final-results-of-registered-exchange-offers-abbv-20201118monthly0.5https://www.biopharmawatch.com/news/ABBV/document-press-release-abbvie-reports-third-quarter-2020-financial-results-reports-third-q-abbv-20201030monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-commencement-of-registered-exchange-offers-abbv-20201019monthly0.5https://www.biopharmawatch.com/news/ABBV/unaudited-pro-forma-condensed-combined-financial-information-dollar-amounts-presented-in-m-abbv-20201002monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2020-financial-results-abbv-20200731monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-key-product-revenues-quarterly-trend-analysis-unaudited-in-millions-1q19-2q19-3-abbv-20200729monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-final-results-of-exchange-offers-for-allergan-notes-abbv-20200513monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-transformative-acquisition-of-allergan-creates-biopharmaceutical-company--abbv-20200508monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-allergan-receive-clearance-from-u-s-federal-trade-commission-for-abbvie-s-acqui-abbv-20200505monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20200427monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20200420monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20200406monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20200323monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20200309monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20200224monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20200127monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20191220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbv-20191118monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-prices-30-billion-of-senior-unsecured-notes-abbv-20191112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-results-of-early-participation-in-exchange-offers-and-consent-solicitatio-abbv-20191107monthly0.5https://www.biopharmawatch.com/news/ABBV/to-abbvie-s-current-report-on-form-8-k-filed-abbv-20191107monthly0.5https://www.biopharmawatch.com/news/ABBV/sources-and-uses-of-funds-and-pro-forma-debt-the-table-below-sets-forth-the-estimated-sour-abbv-20191106monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2019-financial-results-abbv-20191101monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-commencement-of-exchange-offers-and-consent-solicitations-for-allergan-no-abbv-20191025monthly0.5https://www.biopharmawatch.com/news/ABBV/the-directors-abbvie-inc-1-north-waukegan-road-north-chicago-il-60064-united-states-morgan-abbv-20190916monthly0.5https://www.biopharmawatch.com/news/ABBV/index-to-consolidated-financial-statements-page-reports-of-independent-registered-public-a-abbv-20190916monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2019-financial-results-abbv-20190726monthly0.5https://www.biopharmawatch.com/news/ABBV/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-abbv-20190624monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2019-financial-results-reports-first-quarter-diluted-eps-of-1-abbv-20190425monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2018-financial-results-abbv-20190125monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-executive-leadership-changes-abbv-20181217monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2018-financial-results-reports-third-quarter-diluted-eps-of-1-abbv-20181102monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2018-financial-results-reports-second-quarter-diluted-eps-of-abbv-20180727monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2018-financial-results-reports-first-quarter-diluted-eps-of-1-abbv-20180426monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2017-financial-results-reports-full-year-dilut-abbv-20180126monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2017-financial-results-reports-third-quarter-diluted-eps-of-1-abbv-20171027monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2017-financial-results-reports-second-quarter-diluted-eps-of-abbv-20170728monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2017-financial-results-reports-first-quarter-diluted-eps-of-1-abbv-20170427monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-first-quarter-2026-financial-results-total-revenue-of-2-99-billion-vrtx-20260504monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-fourth-quarter-and-full-year-2025-financial-results-full-year-tota-vrtx-20260212monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-third-quarter-2025-financial-results-total-revenue-of-3-08-billion-vrtx-20251103monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-second-quarter-2025-financial-results-total-revenue-of-2-96-billio-vrtx-20250804monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-first-quarter-2025-financial-results-total-revenue-of-2-77-billion-vrtx-20250505monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-prod-vrtx-20250210monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-third-quarter-2024-financial-results-product-revenue-of-2-77-billi-vrtx-20241104monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-second-quarter-2024-financial-results-product-revenue-of-2-65-bill-vrtx-20240801monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-first-quarter-2024-financial-results-product-revenue-of-2-69-billi-vrtx-20240506monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-fourth-quarter-and-full-year-2023-financial-results-full-year-prod-vrtx-20240205monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-third-quarter-2023-financial-results-product-revenue-of-2-48-billi-vrtx-20231106monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-second-quarter-2023-financial-results-product-revenue-of-2-49-bill-vrtx-20230801monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-first-quarter-2023-financial-results-product-revenue-of-2-37-billi-vrtx-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-fourth-quarter-and-full-year-financial-2022-results-full-year-prod-vrtx-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-third-quarter-2022-financial-results-product-revenue-of-2-33-billi-vrtx-20221027monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-second-quarter-2022-financial-results-product-revenues-of-2-20-bil-vrtx-20220804monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-to-acquire-viacyte-with-the-goal-of-accelerating-its-potentially-curative--vrtx-20220711monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-first-quarter-2022-financial-results-product-revenues-of-2-10-bill-vrtx-20220505monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-fourth-quarter-2021-and-full-year-financial-results-full-year-prod-vrtx-20220126monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-third-quarter-2021-financial-results-product-revenues-of-1-98-bill-vrtx-20211102monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-second-quarter-2021-financial-results-product-revenues-of-1-79-bil-vrtx-20210729monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-first-quarter-2021-financial-results-product-revenues-of-1-72-bill-vrtx-20210429monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-full-year-and-fourth-quarter-2020-financial-results-full-year-2020-vrtx-20210201monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-third-quarter-2020-financial-results-product-revenues-of-1-54-bill-vrtx-20201029monthly0.5https://www.biopharmawatch.com/news/VRTX/document-vertex-reports-second-quarter-2020-financial-results-product-revenues-of-1-52-bil-vrtx-20200730monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2025-operating-results-and-2026-outlook-portage-michigan-syk-20260129monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-way-portage-mi-49002-www-stryker-com-syk-20251204monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2025-operating-results-portage-michigan-syk-20250501monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-the-retirement-of-glenn-s-boehnlein-and-the-promotion-of-preston-wells-t-syk-20250128monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2024-operating-results-and-2025-outlook-portage-michigan-syk-20250128monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2024-operating-results-portage-michigan-syk-20241029monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2024-operating-results-portage-michigan-syk-20240730monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2024-operating-results-portage-michigan-syk-20240430monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2023-operating-results-and-2024-outlook-portage-michigan-syk-20240130monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2023-operating-results-kalamazoo-michigan-syk-20231102monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2023-operating-results-kalamazoo-michigan-syk-20230803monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2023-operating-results-kalamazoo-michigan-syk-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2022-operating-results-and-2023-outlook-kalamazoo-michigan-syk-202301312023-01-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2022-operating-results-kalamazoo-michigan-syk-20221031monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2022-operating-results-kalamazoo-michigan-syk-20220726monthly0.5https://www.biopharmawatch.com/news/SYK/document-2825-airview-boulevard-kalamazoo-mi-49002-press-release-date-syk-20220505monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2022-operating-results-kalamazoo-michigan-syk-20220428monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2021-operating-results-and-2022-outlook-kalamazoo-michigan-syk-20220127monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-unaudited-millions-of-dollars-supplemental-product-sales-information-2-syk-20220114monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2021-operating-results-kalamazoo-michigan-syk-20211028monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2021-operating-results-kalamazoo-michigan-syk-20210727monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2021-operating-results-kalamazoo-michigan-syk-20210427monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2020-operating-results-and-2021-outlook-kalamazoo-michigan-syk-20210127monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2020-operating-results-kalamazoo-michigan-syk-20201029monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2020-operating-results-kalamazoo-michigan-syk-20200730monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2020-operating-results-kalamazoo-michigan-syk-20200430monthly0.5https://www.biopharmawatch.com/news/SYK/airview-boulevard-kalamazoo-mi-49002-press-release-stryker-announces-nomination-of-new-dir-syk-20200225monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2019-results-and-2020-outlook-kalamazoo-michigan-syk-20200128monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2019-operating-results-kalamazoo-michigan-syk-20191029monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2019-operating-results-kalamazoo-michigan-syk-20190725monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2019-operating-results-kalamazoo-michigan-syk-20190423monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2018-results-and-2019-outlook-kalamazoo-michigan-syk-20190129monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-k2m-kalamazoo-michigan-syk-20181109monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2018-operating-results-reported-net-sales-increased-7-9-to-3-syk-20181025monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-k2m-kalamazoo-michigan-syk-20180830monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2018-operating-results-reported-net-sales-increased-10-3-to-syk-20180724monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2018-operating-results-reported-net-sales-increased-9-7-to-3-syk-20180426monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2017-results-and-2018-outlook-kalamazoo-michigan-syk-20180130monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-provides-2017-preliminary-net-sales-results-kalamazoo-michigan-syk-20180109monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-nomination-of-two-new-directors-sheri-s-mccoy-and-rajeev-suri-kalamazoo--syk-20180108monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-mr-howard-e-cox-jr-will-retire-from-board-of-directors-kalamazoo-michiga-syk-20171212monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2017-results-kalamazoo-michigan-syk-20171026monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2017-results-kalamazoo-michigan-syk-20170727monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2017-results-kalamazoo-michigan-syk-20170425monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20260427monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20260424monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20260127monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-20251027monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20251024monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20250725monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20250711monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20250425monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-20250218monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20250124monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20241025monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20240723monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20240426monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20240130monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20231109monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20231024monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20230727monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-20230710monthly0.5https://www.biopharmawatch.com/news/HCA/hca-healthcare-inc-index-to-consolidated-financial-statements-page-report-of-independent-r-hca-20230526monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-202304212023-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-202301272023-01-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-20221025monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-hca-20221021monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-for-immediate-release-media-contact-frank-morgan-harlow-sumerford-615-344-hca-20220722monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-for-immediate-release-media-contact-frank-morgan-harlow-sumerford-615-344-hca-20220422monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-frank-morgan-harlow-sumerford-615-344-2688-615-344-1851-hca-20220302monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contacts-media-contact-mark-kimbrough-frank-morgan-harlow-sumerford-615-344-2688--hca-20220127monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20211022monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-mark-kimbrough-615-344-2688-media-contact-harlow-sumerford-615-344-1851-h-hca-20210727monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20210720monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20210422monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20210202monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20201026monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20201008monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20200722monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20200421monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-hca-20200211monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-harlow-sumerford-615-344-2688-615-344-1851-h-hca-20200128monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-ed-fishbough-615-344-2688-615-344-2810-hca-r-hca-20191029monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-ed-fishbough-615-344-2688-615-344-2810-hca-r-hca-20190730monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-ed-fishbough-615-344-2688-615-344-2810-hca-r-hca-20190430monthly0.5https://www.biopharmawatch.com/news/HCA/news-for-immediate-release-investor-contact-mark-kimbrough-615-344-2688-media-contact-ed-f-hca-20190221monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-ed-fishbough-615-344-2688-615-344-2810-hca-r-hca-20190129monthly0.5https://www.biopharmawatch.com/news/HCA/hca-announces-proposed-public-offering-of-senior-notes-nashville-tenn-business-wire-hca-he-hca-20190117monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-ed-fishbough-615-344-2688-615-344-2810-hca-r-hca-20181030monthly0.5https://www.biopharmawatch.com/news/HCA/news-for-immediate-release-investor-contact-media-contact-mark-kimbrough-ed-fishbough-615--hca-20180910monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-ed-fishbough-615-344-2688-615-344-2810-hca-r-hca-20180725monthly0.5https://www.biopharmawatch.com/news/HCA/investor-contact-media-contact-mark-kimbrough-ed-fishbough-615-344-2688-615-344-2810-hca-r-hca-20180501monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2026-financial-results-re-bmy-20260430monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-built-for-growth-44th-annual-j-p-morgan-healthcare-conference-christo-bmy-20260112monthly0.5https://www.biopharmawatch.com/news/BMY/about-bristol-myers-squibb-transforming-patients-lives-through-science-at-bristol-myers-sq-bmy-20251118monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-cash-tender-offers-to-purchase-certain-notes-princeton-n-j-bmy-20251103monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-third-quarter-financial-results-for-2025-performance-marked-b-bmy-20251030monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-for-2025-performance-undersc-bmy-20250731monthly0.5https://www.biopharmawatch.com/news/BMY/cristian-massacesi-m-d-joins-bristol-myers-squibb-as-executive-vice-president-chief-medica-bmy-20250725monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2025-results-reflect-cont-bmy-20250424monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2024-perfo-bmy-20250206monthly0.5https://www.biopharmawatch.com/news/BMY/rd-annual-j-p-morgan-healthcare-conference-january-13th-2025-christopher-boerner-ph-d-boar-bmy-20250113monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-third-quarter-financial-results-for-2024-performance-reflects-bmy-20241031monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-for-2024-results-underscore--bmy-20240726monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-elects-michael-r-mcmullen-to-board-of-directors-princeton-n-j-bmy-20240618monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2024-performance-reflects-bmy-20240425monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-completes-acquisition-of-karuna-therapeutics-strengthening-neuroscien-bmy-20240318monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-recommends-stockholders-reject-mini-tender-offer-by-tutanota-llc-prin-bmy-20240214monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2023-resul-bmy-20240202monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna-therape-bmy-20231222monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-third-quarter-financial-results-for-2023-reports-third-quarte-bmy-20231026monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-for-2023-reports-second-quar-bmy-20230727monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2023-reports-first-quarte-bmy-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2022-repor-bmy-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022-reports-third-quarte-bmy-20221025monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-for-2022-reports-second-quar-bmy-20220727monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-elects-deepak-l-bhatt-m-d-m-p-h-to-board-of-directors-bmy-20220615monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2022-reports-first-quarte-bmy-20220429monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-earnings-from-operations-unaudited-dollars-and-shares-in-mill-bmy-20220418monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-early-participation-results-upsizing-and-early-settlement-o-bmy-20220301monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-prices-6-billion-of-senior-unsecured-notes-bmy-20220215monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-tender-offers-for-an-aggregate-purchase-price-of-up-to-4-0--bmy-20220215monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2021-repor-bmy-20220204monthly0.5https://www.biopharmawatch.com/news/BMY/investor-event-bmy-20211116monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-third-quarter-financial-results-for-2021-reports-third-quarte-bmy-20211027monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-for-2021-reports-second-quar-bmy-20210728monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-elects-manuel-hidalgo-medina-m-d-ph-d-to-board-of-directors-bmy-20210520monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-for-2021-reports-first-quarte-bmy-20210429monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-early-participation-results-and-early-settlement-of-tender--bmy-20210218monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-tender-offers-for-an-aggregate-purchase-price-of-up-to-4-0--bmy-20210204monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2020-repor-bmy-20210204monthly0.5https://www.biopharmawatch.com/news/BMY/investor-presentation-of-bristol-myers-squibb-company-j-p-morgan-healthcare-conference-bmy-20210111monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-provides-update-on-status-of-contingent-value-rights-princeton-n-j-bmy-20210101monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-prices-7-billion-of-senior-unsecured-notes-bmy-20201109monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-third-quarter-2020-financial-results-reports-third-quarter-re-bmy-20201105monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-to-acquire-myokardia-for-13-1-billion-in-cash-mavacamten-is-a-potenti-bmy-20201005monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-second-quarter-2020-financial-results-reports-second-quarter--bmy-20200806monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-board-elects-two-new-independent-directors-bmy-20200730monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-expiration-and-final-results-of-registered-exchange-offers--bmy-20200716monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-commencement-of-registered-exchange-offers-princeton-n-j-bmy-20200616monthly0.5https://www.biopharmawatch.com/news/BMY/unaudited-pro-forma-condensed-combined-financial-information-the-following-unaudited-pro-f-bmy-20200519monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-strong-first-quarter-2020-financial-results-reports-first-qua-bmy-20200507monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-virtual-2020-annual-meeting-of-shareholders-bmy-20200414monthly0.5https://www.biopharmawatch.com/news/BMY/as-of-3-25-2020-investor-fact-sheet-related-to-covid-19-contents-manufacturing-and-supply--bmy-20200324monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2019-repor-bmy-20200206monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-final-results-of-exchange-offers-for-celgene-corpor-bmy-20191121monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-completes-acquisition-of-celgene-creating-a-leading-biopharma-company-bmy-20191120monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-receives-clearance-from-u-s-federal-trade-commission-for-celgene-acqu-bmy-20191115monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20191115monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20191112monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20191107monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20191105monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20191101monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-third-quarter-financial-results-increases-third-quarter-reven-bmy-20191031monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20191030monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20191018monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20191008monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20190923monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-board-announces-election-of-three-new-directors-mr-michael-bonney-dr--bmy-20190911monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-agreement-between-celgene-and-amgen-to-divest-otezla-for-13-bmy-20190826monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-second-quarter-financial-results-increases-second-quarter-rev-bmy-20190725monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-completes-divestment-of-upsa-new-york-bmy-20190701monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20190628monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-provides-update-on-pending-merger-with-celgene-bmy-20190624monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-post-closing-leadership-team-experienced-leadership-team-an-bmy-20190605monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-extension-of-the-expiration-date-for-exchange-offer-bmy-20190524monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-prices-19-billion-of-senior-unsecured-notes-bmy-20190507monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-results-of-early-participation-in-exchange-offers-a-bmy-20190501monthly0.5https://www.biopharmawatch.com/news/BMY/sources-and-uses-of-funds-and-pro-forma-capitalization-the-table-below-sets-forth-the-esti-bmy-20190501monthly0.5https://www.biopharmawatch.com/news/BMY/celgene-corporation-and-subsidiaries-consolidated-statements-of-income-unaudited-dollars-i-bmy-20190501monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-reports-first-quarter-financial-results-increases-first-quarter-reven-bmy-20190425monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-company-announces-commencement-of-exchange-offers-and-consent-solicit-bmy-20190417monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-shareholders-approve-celgene-acquisition-transaction-on-track-to-clos-bmy-20190412monthly0.5https://www.biopharmawatch.com/news/BSX/document-boston-scientific-chief-financial-officer-cfo-dan-brennan-to-retire-jon-monson-se-bsx-20250423monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-pricing-of-1-5-billion-of-senior-notes-bsx-20250221monthly0.5https://www.biopharmawatch.com/news/BSX/who-made-a-books-and-records-demand-on-boston-scientific-pursuant-to-8-del-c-220-iv-indivi-bsx-20250116monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-axonics-inc-bsx-20241115monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-david-habiger-to-board-of-directors-marlborough-mass-bsx-20240730monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-dr-cheryl-pegus-to-board-of-directors-marlborough-mass-bsx-20240508monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-pricing-of-2-0-billion-of-senior-notes-bsx-20240222monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-early-results-of-its-cash-tender-offer-for-its-outstanding-deb-bsx-20220316monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-pricing-of-3-0-billion-of-senior-notes-bsx-20220303monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-cash-tender-offer-for-up-to-2-5-billion-of-its-outstanding-deb-bsx-20220302monthly0.5https://www.biopharmawatch.com/news/BSX/document-boston-scientific-closes-acquisition-of-baylis-medical-company-inc-bsx-20220215monthly0.5https://www.biopharmawatch.com/news/BSX/document-boston-scientific-announces-agreement-to-acquire-baylis-medical-company-inc-acqui-bsx-20211006monthly0.5https://www.biopharmawatch.com/news/BSX/document-boston-scientific-announces-agreement-to-acquire-devoro-medical-inc-company-to-ad-bsx-20210921monthly0.5https://www.biopharmawatch.com/news/BSX/document-bsx-20210901monthly0.5https://www.biopharmawatch.com/news/BSX/document-for-immediate-release-boston-scientific-elects-david-s-wichmann-to-board-of-direc-bsx-20210624monthly0.5https://www.biopharmawatch.com/news/BSX/document-boston-scientific-exercises-option-to-acquire-farapulse-inc-acquisition-complemen-bsx-20210624monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-lumenis-ltd-surgical-business-from-baring-bsx-20210303monthly0.5https://www.biopharmawatch.com/news/BSX/issued-by-boston-scientific-corporation-document-boston-scientific-announces-agreement-to--bsx-20210121monthly0.5https://www.biopharmawatch.com/news/BSX/dated-december-1-2020-document-boston-scientific-signs-definitive-agreement-to-divest-btg--bsx-20201201monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-announces-fourth-quarter-fiscal-2026-mck-20260306monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-announces-planned-cfo-transition-britt-vitalone-announces-retirement-kenny-cheung-mck-20260305monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-reports-fiscal-2026-mck-20260204monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-reports-fiscal-2026-mck-20251105monthly0.5https://www.biopharmawatch.com/news/MCK/losses-not-covered-by-insurance-or-indemnification-we-are-subject-to-frequently-changing-e-mck-20250923monthly0.5https://www.biopharmawatch.com/news/MCK/supplemental-historical-segment-financial-information-mckesson-corporation-the-company-we--mck-20250918monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-reports-fiscal-2026-mck-20250806monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-4-650-notes-due-2030-4-950-notes-due-2032-5-250-notes-due-2035-underw-mck-20250520monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2025-fourth-quarter-and-full-year-results-and-provides-fiscal-2026-mck-20250508monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-reports-fiscal-2025-mck-20250205monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-reports-fiscal-2025-mck-20241106monthly0.5https://www.biopharmawatch.com/news/MCK/execution-version-mckesson-corporation-4-250-notes-due-2029-underwriting-agreement-mck-20240905monthly0.5https://www.biopharmawatch.com/news/MCK/cautionary-statements-except-for-historical-information-statements-in-this-press-release-r-mck-20240826monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-reports-fiscal-2025-first-quarter-results-first-quarter-highlights-co-mck-20240807monthly0.5https://www.biopharmawatch.com/news/MCK/rachel-rodriguez-469-260-0556-investors-rachel-rodriguez-mckesson-com-media-relations-medi-mck-20240603monthly0.5https://www.biopharmawatch.com/news/MCK/document-mckesson-corporation-reports-fiscal-2024-fourth-quarter-and-full-year-results-fou-mck-20240507monthly0.5https://www.biopharmawatch.com/news/MCK/document-mckesson-corporation-reports-fiscal-2024-third-quarter-results-and-raises-full-ye-mck-20240207monthly0.5https://www.biopharmawatch.com/news/MCK/these-risk-factors-include-but-are-not-limited-to-we-experience-costly-and-disruptive-lega-mck-20240109monthly0.5https://www.biopharmawatch.com/news/MCK/document-mckesson-corporation-reports-fiscal-2024-second-quarter-results-and-raises-full-y-mck-20231101monthly0.5https://www.biopharmawatch.com/news/MCK/document-mckesson-corporation-reports-fiscal-2024-first-quarter-results-first-quarter-high-mck-20230802monthly0.5https://www.biopharmawatch.com/news/MCK/execution-version-mckesson-corporation-4-900-notes-due-2028-5-100-notes-due-2033-underwrit-mck-20230607monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-commences-tender-offer-for-any-and-all-3-796-notes-due-2024-mck-20230607monthly0.5https://www.biopharmawatch.com/news/MCK/document-mckesson-corporation-reports-fiscal-2023-fourth-quarter-and-full-year-results-and-mck-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-5-250-notes-due-2026-underwriting-agreement-mck-202302132023-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/document-mckesson-corporation-reports-fiscal-2023-third-quarter-results-and-raises-full-ye-mck-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-reports-fiscal-2023-second-quarter-results-and-raises-full-year-guida-mck-20221101monthly0.5https://www.biopharmawatch.com/news/MCK/about-mckesson-corporation-mckesson-corporation-is-a-diversified-healthcare-services-leade-mck-20220913monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-reports-fiscal-2023-first-quarter-results-first-quarter-highlights-to-mck-20220803monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2022-fourth-quarter-and-full-year-results-fourth-quarter-highlight-mck-20220505monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-s-board-of-directors-elects-w-roy-dunbar-as-new-director-mck-20220401monthly0.5https://www.biopharmawatch.com/news/MCK/list-of-states-and-territories-that-have-agreed-to-the-opioids-related-settlement-alaska-m-mck-20220225monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2022-third-quarter-results-third-quarter-highlights-year-over-year-mck-20220113monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-s-board-of-directors-elects-james-h-hinton-and-kathleen-wilson-thompson-as-new-di-mck-20220118monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2022-second-quarter-results-second-quarter-highlights-year-over-ye-mck-20211101monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-s-board-of-directors-elects-dr-richard-h-carmona-as-new-independent-director-mck-20210907monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-1-300-notes-due-2026-underwriting-agreement-mck-20210809monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2022-first-quarter-results-first-quarter-highlights-year-over-year-mck-20210804monthly0.5https://www.biopharmawatch.com/news/MCK/registered-certified-mail-regular-mail-or-courier-in-person-by-hand-only-elavon-financial--mck-20210702monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2021-fourth-quarter-and-full-year-results-fourth-quarter-and-full--mck-20210506monthly0.5https://www.biopharmawatch.com/news/MCK/notice-of-director-decision-to-not-stand-for-re-election-document-press-release-mckesson-a-mck-20210419monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2021-third-quarter-results-third-quarter-highlights-year-over-year-mck-20210202monthly0.5https://www.biopharmawatch.com/news/MCK/execution-version-mckesson-corporation-0-900-notes-due-2025-underwriting-agreement-mck-20201130monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2021-second-quarter-results-second-quarter-highlights-year-over-ye-mck-20201101monthly0.5https://www.biopharmawatch.com/news/MCK/board-of-directors-appoints-linda-mantia-document-press-release-mckesson-s-board-of-direct-mck-20201019monthly0.5https://www.biopharmawatch.com/news/MCK/supplemental-historical-segment-financial-information-mckesson-corporation-the-company-we--mck-20200922monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2021-first-quarter-results-first-quarter-highlights-year-over-year-mck-20200803monthly0.5https://www.biopharmawatch.com/news/MCK/7-1-2020-exhibit-mckesson-realigns-organizational-structure-to-better-serve-customers-and--mck-20200701monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2020-fourth-quarter-and-full-year-results-fourth-quarter-highlight-mck-20200520monthly0.5https://www.biopharmawatch.com/news/MCK/exhibit-mckesson-updates-fiscal-2020-guidance-following-completion-of-change-healthcare-sp-mck-20200317monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-mck-20200310monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-sets-final-exchange-ratio-of-11-4086-mck-20200305monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-launches-exchange-offer-to-split-off-its-interest-in-change-healthcare-mck-20200210monthly0.5https://www.biopharmawatch.com/news/MCK/1-13-20-exhibit-mckesson-to-present-at-the-38-th-annual-j-p-morgan-healthcare-conference-mck-20200113monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reaffirms-fiscal-2020-mck-20191218monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-selected-by-department-of-veterans-affairs-as-prime-pharmaceutical-provider-pharm-mck-20191212monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2020-second-quarter-results-total-revenues-of-57-6-billion-reflect-mck-20191030monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-s-board-of-directors-appoints-maria-martinez-as-new-independent-director-mck-20191018monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2020-first-quarter-results-first-quarter-fiscal-2020-revenues-of-5-mck-20190731monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-s-board-of-directors-elects-dr-ken-washington-as-new-independent-director-irving--mck-20190617monthly0.5https://www.biopharmawatch.com/news/MCK/correcting-and-replacing-mckesson-reports-fourth-quarter-and-full-year-2019-results-correc-mck-20190508monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2019-fourth-quarter-and-full-year-results-fourth-quarter-fiscal-20-mck-20190508monthly0.5https://www.biopharmawatch.com/news/MCK/investors-and-financial-media-holly-weiss-972-969-9174-holly-weiss-mckesson-com-general-an-mck-20190426monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2019-third-quarter-results-revenues-of-56-2-billion-for-the-third--mck-20190131monthly0.5https://www.biopharmawatch.com/news/MCK/execution-version-mckesson-corporation-3-650-notes-due-2020-4-750-notes-due-2029-underwrit-mck-20181128monthly0.5https://www.biopharmawatch.com/news/MCK/john-hammergren-announces-retirement-brian-tyler-to-become-mckesson-s-mck-20181101monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2019-second-quarter-results-revenues-of-53-1-billion-for-the-secon-mck-20181025monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-mck-20180913monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2019-first-quarter-results-revenues-of-52-6-billion-for-the-first--mck-20180726monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reaffirms-fiscal-2019-mck-20180628monthly0.5https://www.biopharmawatch.com/news/MCK/supplemental-historical-segment-financial-information-we-are-furnishing-to-investors-suppl-mck-20180524monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2018-fourth-quarter-and-full-year-results-revenues-of-51-6-billion-mck-20180524monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-craig-mercer-415-983-8391-investors-and-financial-media-craig-mercer--mck-20180430monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-launches-multi-year-strategic-growth-initiative-reaffirms-fiscal-2018-outlook-and-mck-20180425monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-corporation-floating-rate-notes-due-2020-1-625-notes-due-2026-underwriting-agreem-mck-20180207monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2018-third-quarter-results-revenues-of-53-6-billion-for-the-third--mck-20180201monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-announces-departure-of-james-beer-evp-and-cfo-appoints-internal-successor-britt-v-mck-20171218monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2018-second-quarter-results-revenues-of-52-1-billion-for-the-secon-mck-20171026monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2018-first-quarter-results-revenues-of-51-1-billion-for-the-first--mck-20170727monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reaffirms-fiscal-2018-mck-20170628monthly0.5https://www.biopharmawatch.com/news/MCK/in-the-first-quarter-of-fiscal-2018-mckesson-corporation-mckesson-the-company-or-we-and-ot-mck-20170518monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2017-fourth-quarter-and-full-year-results-revenues-of-48-7-billion-mck-20170518monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-and-change-healthcare-complete-the-creation-of-new-healthcare-information-technol-mck-20170302monthly0.5https://www.biopharmawatch.com/news/MCK/execution-version-mckesson-corporation-0-625-notes-due-2021-1-500-notes-due-2025-underwrit-mck-20170213monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2017-third-quarter-results-revenues-of-50-1-billion-for-the-third--mck-20170125monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-and-change-healthcare-announce-termination-of-hart-scott-rodino-act-waiting-perio-mck-20161221monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2017-second-quarter-results-and-revised-fiscal-2017-outlook-revenu-mck-20161027monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2017-first-quarter-results-revenues-of-49-7-billion-for-the-first--mck-20160727monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-and-change-healthcare-to-form-new-healthcare-information-technology-company-new-e-mck-20160705monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-updates-fiscal-2017-mck-20160629monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2016-fourth-quarter-and-full-year-results-revenues-of-46-7-billion-mck-20160504monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2016-third-quarter-results-revenues-of-47-9-billion-for-the-third--mck-20160127monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-announces-fiscal-2016-earnings-update-and-preliminary-fiscal-2017-outlook-revised-mck-20160111monthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-reports-fiscal-2016-second-quarter-results-revenues-of-48-8-billion-for-the-secon-mck-20151029monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-fourth-quarter-and-full-year-fiscal-2026-results-delivers-highest-annual-mdt-20260603monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-statement-on-unauthorized-system-access-mdt-20260424monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-strong-third-quarter-fiscal-2026-results-with-highest-enterprise-revenue-mdt-20260217monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-strong-second-quarter-fiscal-2026-financial-results-enterprise-growth-dr-mdt-20251118monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-first-quarter-fiscal-2026-financial-results-11-th-quarter-in-a-row-of-mi-mdt-20250819monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20250623monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-resul-mdt-20250521monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20250218monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20250121monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20241119monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20240820monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20240626monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20240523monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20240220monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20231121monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20230822monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20230626monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20230525monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20221122monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20220823monthly0.5https://www.biopharmawatch.com/news/MDT/document-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-76-mdt-20220627monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20220526monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20220222monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-pamela-reese-ryan-weispfenning-public-relations-investor-re-mdt-20211215monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20211123monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20210824monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20210625monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20210527monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20210223monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-marguerite-copel-ryan-weispfenning-public-relations-investo-mdt-20201214monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20201124monthly0.5https://www.biopharmawatch.com/news/MDT/document-news-release-contacts-erika-winkels-ryan-weispfenning-public-relations-investor-r-mdt-20200825monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20200521monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20200421monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20200218monthly0.5https://www.biopharmawatch.com/news/MDT/erika-winkels-ryan-weispfenning-public-relations-investor-relations-1-763-526-8478-1-763-5-mdt-20191119monthly0.5https://www.biopharmawatch.com/news/MDT/francesca-demartino-ryan-weispfenning-public-relations-investor-relations-1-763-505-2029-1-mdt-20190820monthly0.5https://www.biopharmawatch.com/news/MDT/francesca-demartino-public-relations-1-763-505-2029-ryan-weispfenning-investor-relations-1-mdt-20190710monthly0.5https://www.biopharmawatch.com/news/MDT/francesca-demartino-ryan-weispfenning-public-relations-investor-relations-1-763-505-2029-1-mdt-20190625monthly0.5https://www.biopharmawatch.com/news/MDT/francesca-demartino-ryan-weispfenning-public-relations-investor-relations-1-763-505-2029-1-mdt-20190523monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20190314monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20190307monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20190304monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20190220monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20181120monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20180821monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20180524monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20180220monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20171219monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20171121monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20171108monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20170822monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20170525monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20170221monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20161122monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20160825monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20160531monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20160504monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20160414monthly0.5https://www.biopharmawatch.com/news/MDT/fernando-vivanco-ryan-weispfenning-public-relations-investor-relations-1-763-505-3780-1-76-mdt-20160331monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-corporation-reports-fourth-quarter-and-full-year-2025-results-fourth-quarter-hi-cvs-20260210monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-updates-financial-guidance-highlights-strength-of-businesses-and-announces-stra-cvs-20251209monthly0.5https://www.biopharmawatch.com/news/CVS/woonsocket-ri-cvs-20251120monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-corporation-reports-third-quarter-2025-results-and-updates-full-year-2025-guida-cvs-20251029monthly0.5https://www.biopharmawatch.com/news/CVS/omnicare-initiates-voluntary-chapter-11-process-company-intends-to-use-process-to-implemen-cvs-20250922monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-corporation-reports-second-quarter-2025-results-and-updates-full-year-2025-guid-cvs-20250731monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-corporation-reports-first-quarter-2025-results-and-updates-full-year-2025-guida-cvs-20250501monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-announces-chief-financial-officer-transition-plan-appoints-chief-medical-office-cvs-20250408monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-corporation-reports-fourth-quarter-and-full-year-2024-results-fourth-quarter-hi-cvs-20250212monthly0.5https://www.biopharmawatch.com/news/CVS/investor-larry-mcgrath-media-ethan-slavin-contact-executive-vice-president-contact-860-273-cvs-20241216monthly0.5https://www.biopharmawatch.com/news/CVS/investor-larry-mcgrath-media-ethan-slavin-contact-executive-vice-president-chief-strategy--cvs-20241209monthly0.5https://www.biopharmawatch.com/news/CVS/investor-larry-mcgrath-media-ethan-slavin-contact-executive-vice-president-contact-860-273-cvs-20241206monthly0.5https://www.biopharmawatch.com/news/CVS/investor-larry-mcgrath-media-ethan-slavin-contact-executive-vice-president-contact-860-273-cvs-20241202monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-announces-board-appointments-cvs-health-board-of-directors-appoints-four-new-me-cvs-20241118monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-announces-leadership-appointments-prem-shah-named-group-president-cvs-health-st-cvs-20241106monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-corporation-reports-third-quarter-2024-results-financial-highlights-third-quart-cvs-20241106monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-appoints-david-joyner-president-and-chief-executive-officer-roger-farah-named-e-cvs-20241018monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-corporation-reports-second-quarter-2024-results-and-revises-full-year-2024-guid-cvs-20240807monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-corporation-reports-first-quarter-2024-results-and-revises-full-year-2024-guida-cvs-20240501monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-fourth-quarter-and-full-year-2023-results-woonsocket-cvs-20240207monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-announces-leadership-appointments-thomas-f-cowhey-named-chief-financial-officer-cvs-20240105monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-highlights-path-to-accelerating-long-term-growth-through-building-a-world-of-he-cvs-20231205monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-third-quarter-results-woonsocket-cvs-20231101monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-announces-cfo-shawn-guertin-to-take-leave-of-absence-due-to-family-health-reaso-cvs-20231016monthly0.5https://www.biopharmawatch.com/news/CVS/eighty-seven-87-percent-of-aetna-medicare-advantage-members-in-4-star-plans-or-higher-for--cvs-20231013monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-launches-cordavis-new-business-will-bring-high-quality-biosimilar-products-to-m-cvs-20230823monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-second-quarter-results-woonsocket-cvs-20230802monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-first-quarter-results-completes-acquisitions-of-signify-health-and-oak--cvs-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-completes-acquisition-of-oak-street-health-woonsocket-r-i-cvs-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/form-of-voting-and-support-agreement-this-voting-and-support-agreement-dated-as-of-februar-cvs-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-strong-fourth-quarter-and-full-year-2022-results-woonsocket-cvs-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-to-acquire-oak-street-health-acquisition-further-advances-cvs-health-s-care-del-cvs-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-names-david-joyner-head-of-pharmacy-services-amy-bricker-becomes-chief-product--cvs-202301232023-01-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-third-quarter-results-woonsocket-cvs-20221102monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-to-acquire-signify-health-advances-long-term-strategy-by-providing-platform-for-cvs-20220905monthly0.5https://www.biopharmawatch.com/news/CVS/voting-agreement-voting-agreement-dated-as-of-cvs-20220902monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-strong-second-quarter-results-raises-2022-full-year-eps-and-cash-flow-f-cvs-20220803monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-strong-first-quarter-results-woonsocket-cvs-20220504monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reaches-opioid-settlement-agreement-with-state-of-florida-woonsocket-r-i-cvs-20220330monthly0.5https://www.biopharmawatch.com/news/CVS/charter-2-ss850270-ex9901-htm-press-release-cvs-health-announces-changes-to-board-of-direc-cvs-20220310monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-strong-fourth-quarter-and-full-year-2021-results-confirms-2022-full-yea-cvs-20220209monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-presents-strategy-for-revolutionizing-consumer-health-experience-while-driving--cvs-20211209monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-announces-steps-to-accelerate-omnichannel-health-strategy-prem-shah-to-become-c-cvs-20211118monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-reports-strong-third-quarter-results-key-financial-data-third-quarter-highlight-cvs-20211103monthly0.5https://www.biopharmawatch.com/news/CVS/investor-susie-lisa-cfa-media-t-j-crawford-contact-senior-vice-president-contact-vice-pres-cvs-20210823monthly0.5https://www.biopharmawatch.com/news/CVS/investor-susie-lisa-media-t-j-crawford-contact-senior-vice-president-contact-vice-presiden-cvs-20210809monthly0.5https://www.biopharmawatch.com/news/CVS/investor-susie-lisa-cfa-media-t-j-crawford-contact-senior-vice-president-contact-vice-pres-cvs-20210804monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-appoints-shawn-guertin-chief-financial-officer-woonsocket-r-i-cvs-20210518monthly0.5https://www.biopharmawatch.com/news/CVS/investor-katie-durant-media-t-j-crawford-contact-senior-director-contact-vice-president-in-cvs-20210504monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20210216monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20201221monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20201207monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-announces-ceo-transition-effective-february-2021-karen-s-lynch-named-the-next-p-cvs-20201106monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20201106monthly0.5https://www.biopharmawatch.com/news/CVS/stockholder-presentation-fall-2020-stockholder-engagement-2-cautionary-statement-concernin-cvs-20200925monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20200826monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20200812monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20200805monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20200506monthly0.5https://www.biopharmawatch.com/news/CVS/to-the-company-s-current-report-on-form-8-k-filed-with-the-sec-on-cvs-20200212monthly0.5https://www.biopharmawatch.com/news/CVS/forward-looking-statements-the-private-securities-litigation-reform-act-of-1995-provides-a-cvs-20200203monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20191106monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20190821monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20190819monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20190815monthly0.5https://www.biopharmawatch.com/news/CVS/investor-valerie-haertel-media-t-j-crawford-contact-senior-vice-president-contact-vice-pre-cvs-20190808monthly0.5https://www.biopharmawatch.com/news/CVS/of-cvs-health-s-current-report-on-form-8-k-or-any-of-the-company-s-other-sec-filings-in-ac-cvs-20190808monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-outlines-strategy-to-accelerate-growth-significant-expansion-of-healthhubs-will-cvs-20190604monthly0.5https://www.biopharmawatch.com/news/CVS/investor-joe-krocheski-media-t-j-crawford-contact-vice-president-contact-vice-president-in-cvs-20190501monthly0.5https://www.biopharmawatch.com/news/CVS/investor-mike-mcguire-media-t-j-crawford-contact-senior-vice-president-contact-vice-presid-cvs-20190220monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-completes-acquisition-of-aetna-marking-the-start-of-transforming-the-consumer-h-cvs-20181128monthly0.5https://www.biopharmawatch.com/news/CVS/investor-mike-mcguire-media-carolyn-castel-contact-senior-vice-president-contact-vice-pres-cvs-20181106monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-names-james-clark-senior-vice-president-and-chief-accounting-officer-upon-closi-cvs-20181022monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-provides-update-to-board-and-management-roles-upon-closing-of-aetna-acquisition-cvs-20181010monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-acquisition-of-aetna-moving-forward-on-agreement-with-u-s-department-of-justice-cvs-20181010monthly0.5https://www.biopharmawatch.com/news/CVS/investor-mike-mcguire-media-carolyn-castel-contact-senior-vice-president-contact-vice-pres-cvs-20180808monthly0.5https://www.biopharmawatch.com/news/CVS/forms-a-part-or-to-reflect-the-occurrence-of-unanticipated-events-even-in-the-event-that-a-cvs-20180725monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-announces-management-team-for-combined-company-following-close-of-aetna-acquisi-cvs-20180606monthly0.5https://www.biopharmawatch.com/news/CVS/investor-mike-mcguire-media-carolyn-castel-contact-senior-vice-president-contact-vice-pres-cvs-20180502monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-stockholders-approve-aetna-acquisition-transaction-expected-to-close-in-second--cvs-20180313monthly0.5https://www.biopharmawatch.com/news/CVS/to-this-current-report-on-form-8-k-for-a-discussion-of-the-risks-related-to-operating-glob-cvs-20180306monthly0.5https://www.biopharmawatch.com/news/CVS/to-this-current-report-on-form-8-k-for-a-description-of-share-repurchases-80-cvs-20180228monthly0.5https://www.biopharmawatch.com/news/CVS/investor-mike-mcguire-media-carolyn-castel-contact-senior-vice-president-contact-vice-pres-cvs-20180208monthly0.5https://www.biopharmawatch.com/news/CVS/cvs-health-provides-2018-outlook-expect-adjusted-consolidated-operating-profit-growth-of-1-cvs-20180104monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-first-quarter-2026-results-q1-gaap-sales-of-6-0-billion-up-1-3-operating-margin--mmm-20260421monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-fourth-quarter-and-full-year-2025-results-initiates-full-year-2026-financial-gui-mmm-20260120monthly0.5https://www.biopharmawatch.com/news/MMM/m-delivers-strong-third-quarter-results-increases-full-year-margin-and-eps-guidance-gaap-s-mmm-20251021monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-second-quarter-2025-results-increases-full-year-eps-guidance-gaap-sales-of-6-3-b-mmm-20250718monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-first-quarter-2025-results-gaap-sales-of-6-0-billion-down-1-0-yoy-operating-marg-mmm-20250422monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-fourth-quarter-and-full-year-2024-results-initiates-full-year-2025-financial-gui-mmm-20250121monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-third-quarter-results-raises-full-year-2024-earnings-guidance-sales-of-6-3-billi-mmm-20241022monthly0.5https://www.biopharmawatch.com/news/MMM/m-delivers-strong-second-quarter-results-company-updates-full-year-2024-earnings-guidance--mmm-20240726monthly0.5https://www.biopharmawatch.com/news/MMM/m-transfers-a-portion-of-u-s-pension-payment-obligations-st-paul-minn-mmm-20240613monthly0.5https://www.biopharmawatch.com/news/MMM/m-first-quarter-results-driven-by-strong-operational-performance-company-initiates-full-ye-mmm-20240430monthly0.5https://www.biopharmawatch.com/news/MMM/m-completes-spin-off-of-solventum-mmm-20240401monthly0.5https://www.biopharmawatch.com/news/MMM/combat-arms-earplugs-settlement-set-to-exceed-98-participation-milestone-3m-has-elected-to-mmm-20240129monthly0.5https://www.biopharmawatch.com/news/MMM/m-delivers-strong-fourth-quarter-results-improves-operational-performance-and-exceeds-earn-mmm-20240123monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-third-quarter-2023-results-company-increases-full-year-adjusted-earnings-and-cas-mmm-20231024monthly0.5https://www.biopharmawatch.com/news/MMM/m-announces-combat-arms-settlement-st-paul-minn-mmm-20230829monthly0.5https://www.biopharmawatch.com/news/MMM/bryan-hanson-named-ceo-of-3m-s-health-care-business-group-carrie-cox-industry-veteran-to-s-mmm-20230822monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-second-quarter-2023-results-proactive-initiatives-drive-strong-quarterly-financi-mmm-20230725monthly0.5https://www.biopharmawatch.com/news/MMM/m-resolves-claims-by-public-water-suppliers-supports-drinking-water-solutions-for-vast-maj-mmm-20230622monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-first-quarter-2023-results-company-announces-restructuring-actions-mmm-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMM/divestiture-costs-these-include-costs-related-to-separating-and-divesting-substantially-an-mmm-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMM/anne-chow-and-pedro-pizarro-elected-to-3m-board-of-directors-mmm-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-fourth-quarter-and-full-year-2022-results-mmm-202301242023-01-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMM/m-to-exit-pfas-manufacturing-by-the-end-of-2025-st-paul-mn-3m-nyse-mmm-today-announced-it--mmm-20221220monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-third-quarter-2022-results-third-quarter-highlights-company-reports-gaap-earning-mmm-20221025monthly0.5https://www.biopharmawatch.com/news/MMM/m-announces-final-proration-factor-of-7-346065-percent-for-shares-tendered-in-split-off-ex-mmm-20220906monthly0.5https://www.biopharmawatch.com/news/MMM/m-announces-preliminary-results-of-split-off-exchange-offer-intends-to-accept-tendered-sha-mmm-20220901monthly0.5https://www.biopharmawatch.com/news/MMM/m-sets-final-exchange-ratio-in-split-off-exchange-offer-in-connection-with-neogen-transact-mmm-20220829monthly0.5https://www.biopharmawatch.com/news/MMM/m-statement-regarding-bankruptcy-court-decision-3m-separation-of-food-safety-business-rema-mmm-20220826monthly0.5https://www.biopharmawatch.com/news/MMM/to-the-current-report-on-form-8-k-to-which-this-document-is-attached-as-an-exhibit-the-sum-mmm-20220812monthly0.5https://www.biopharmawatch.com/news/MMM/m-commences-split-off-mmm-20220804monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-second-quarter-2022-results-second-quarter-highlights-aearo-technologies-takes-a-mmm-20220706monthly0.5https://www.biopharmawatch.com/news/MMM/press-statement-wednesday-july-6th-2022-12h40-gmt-1-cabinet-of-the-flemish-minister-of-jus-mmm-20220706monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-first-quarter-2022-results-mmm-20220426monthly0.5https://www.biopharmawatch.com/news/MMM/operating-income-income-before-taxes-provision-for-income-taxes-effective-tax-rate-net-inc-mmm-20220426monthly0.5https://www.biopharmawatch.com/news/MMM/m-advances-actions-for-environmental-stewardship-in-zwijndrecht-mmm-20220330monthly0.5https://www.biopharmawatch.com/news/MMM/disaggregated-revenue-information-updated-basis-non-gaap-measure-year-ended-december-31-ne-mmm-20220211monthly0.5https://www.biopharmawatch.com/news/MMM/suzan-kereere-elected-to-3m-board-of-directors-mmm-20220209monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-fourth-quarter-and-full-year-2021-results-fourth-quarter-highlights-sales-of-8-6-mmm-20220125monthly0.5https://www.biopharmawatch.com/news/MMM/execution-version-agreement-and-plan-of-merger-dated-as-of-december-13-2021-by-and-among-3-mmm-20211213monthly0.5https://www.biopharmawatch.com/news/MMM/joint-announcement-press-release-neogen-to-combine-3m-s-food-safety-business-with-its-exis-mmm-20211214monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-third-quarter-2021-results-third-quarter-highlights-sales-of-8-9-billion-up-7-1--mmm-20211026monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-second-quarter-2021-results-second-quarter-highlights-sales-of-8-9-billion-up-24-mmm-20210727monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-first-quarter-2021-results-first-quarter-highlights-sales-of-8-9-billion-up-9-6--mmm-20210427monthly0.5https://www.biopharmawatch.com/news/MMM/this-current-report-on-form-8-k-includes-supplemental-unaudited-historical-business-segmen-mmm-20210322monthly0.5https://www.biopharmawatch.com/news/MMM/jim-fitterling-elected-to-3m-board-of-directors-mmm-20210202monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-fourth-quarter-and-full-year-2020-results-provides-full-year-2021-guidance-fourt-mmm-20210126monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-sales-information-for-month-of-november-2020-mmm-20201214monthly0.5https://www.biopharmawatch.com/news/MMM/m-to-advance-operating-model-improve-cost-structure-and-accelerate-innovation-enhanced-ope-mmm-20201203monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-sales-information-for-month-of-october-2020-mmm-20201113monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-third-quarter-2020-results-third-quarter-highlights-sales-of-8-4-billion-up-4-5--mmm-20201027monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-sales-information-for-month-of-august-2020-summary-sales-of-2-7-billion-up-2-per-mmm-20200915monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-sales-information-for-month-of-july-2020-july-summary-sales-of-2-8-billion-up-6--mmm-20200813monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-second-quarter-2020-results-strong-execution-and-cash-flow-in-uncertain-environm-mmm-20200728monthly0.5https://www.biopharmawatch.com/news/MMM/m-reports-sales-information-for-month-of-may-2020-may-summary-sales-of-2-2-billion-down-20-mmm-20200615monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-sales-information-for-month-of-april-2020-mmm-20200514monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-first-quarter-2020-results-first-quarter-highlights-sales-of-8-1-billion-up-2-7-mmm-20200428monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-fourth-quarter-and-full-year-2019-results-implements-new-global-operating-model-mmm-20200128monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-third-quarter-2019-results-third-quarter-highlights-sales-of-8-0-billion-down-2-mmm-20191024monthly0.5https://www.biopharmawatch.com/news/MMM/m-completes-acquisition-of-acelity-inc-acquisition-expands-presence-in-advanced-and-surgic-mmm-20191011monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-second-quarter-2019-results-second-quarter-summary-sales-of-8-2-billion-down-2--mmm-20190725monthly0.5https://www.biopharmawatch.com/news/MMM/this-current-report-on-form-8-k-includes-supplemental-unaudited-historical-business-segmen-mmm-20190530monthly0.5https://www.biopharmawatch.com/news/MMM/m-to-acquire-acelity-inc-acquisition-expands-presence-in-advanced-and-surgical-wound-care--mmm-20190502monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-first-quarter-2019-results-company-initiates-restructuring-first-quarter-summar-mmm-20190425monthly0.5https://www.biopharmawatch.com/news/MMM/3m-announces-new-business-segments-and-leadership-appointments-new-structure-increases-cus-mmm-20190318monthly0.5https://www.biopharmawatch.com/news/MMM/this-current-report-on-form-8-k-includes-supplemental-unaudited-historical-business-segmen-mmm-20190308monthly0.5https://www.biopharmawatch.com/news/MMM/3m-leadership-announcement-mmm-20190206monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-fourth-quarter-2018-results-fourth-quarter-highlights-sales-of-7-9-billion-down-mmm-20190129monthly0.5https://www.biopharmawatch.com/news/MMM/m-ceo-introduces-priorities-for-the-future-sets-five-year-financial-targets-3m-also-releas-mmm-20181115monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-third-quarter-2018-results-third-quarter-highlights-sales-of-8-2-billion-down-0-mmm-20181023monthly0.5https://www.biopharmawatch.com/news/MMM/dr-dambisa-f-moyo-elected-to-3m-board-of-directors-mmm-20180813monthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-second-quarter-2018-results-second-quarter-highlights-sales-of-8-4-billion-up-7-mmm-20180724monthly0.5https://www.biopharmawatch.com/news/MMM/m-announces-new-leadership-appointment-mmm-20180509monthly0.5https://www.biopharmawatch.com/news/MMM/m-company-annual-report-on-form-10-k-updated-by-this-current-report-on-form-8-k-for-the-ye-mmm-20180508monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2026-financial-and-operating-results-first-quarter-2026-re-regn-20260429monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-fourth-regn-20260130monthly0.5https://www.biopharmawatch.com/news/REGN/j-a-n-u-a-r-y-1-2-2-0-2-6-j-p-morgan-healthcare-conference-this-non-promotional-presentati-regn-20251231monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2025-financial-and-operating-results-third-quarter-2025-re-regn-20251028monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2025-financial-and-operating-results-second-quarter-2025--regn-20250801monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2025-financial-and-operating-results-first-quarter-2025-re-regn-20250429monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-initia-regn-20250204monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-business-updates-and-highlights-from-broad-clinical-pipeline-at-the-43--regn-20250113monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2024-financial-and-operating-results-third-quarter-2024-re-regn-20241031monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2024-financial-and-operating-results-second-quarter-2024--regn-20240801monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2024-financial-and-operating-results-first-quarter-2024-re-regn-20240502monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-fourth-regn-20240202monthly0.5https://www.biopharmawatch.com/news/REGN/j-p-morgan-healthcare-conference-january-8-2024-this-non-promotional-presentation-contains-regn-20240108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2023-financial-and-operating-results-third-quarter-2023-re-regn-20231102monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2023-financial-and-operating-results-second-quarter-2023--regn-20230803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2023-financial-and-operating-results-first-quarter-2023-re-regn-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results-fourth-regn-202302032023-02-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/j-p-morgan-healthcare-conference-regn-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2022-financial-and-operating-results-third-quarter-2022-re-regn-20221103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2022-financial-and-operating-results-second-quarter-2022--regn-20220803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2022-financial-and-operating-results-first-quarter-2022-re-regn-20220504monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2021-financial-and-operating-results-fourth-regn-20220204monthly0.5https://www.biopharmawatch.com/news/REGN/jp-morgan-healthcare-conference-2022-january-2022-this-non-promotional-presentation-is-int-regn-20220110monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2021-financial-and-operating-results-third-quarter-2021-re-regn-20211104monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2021-financial-and-operating-results-second-quarter-2021--regn-20210805monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2021-financial-and-operating-results-first-quarter-2021-re-regn-20210506monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2020-financial-and-operating-results-fourth-regn-20210205monthly0.5https://www.biopharmawatch.com/news/REGN/leonard-s-schleifer-md-p-h-d-president-ceo-george-d-yancopoulos-md-p-h-d-president-cso-jp--regn-20210111monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2020-financial-and-operating-results-third-quarter-2020-re-regn-20201105monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2020-financial-and-operating-results-second-quarter-2020--regn-20200805monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2020-financial-and-operating-results-first-quarter-2020-re-regn-20200505monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2019-financial-and-operating-results-fourth-regn-20200206monthly0.5https://www.biopharmawatch.com/news/REGN/leonard-s-schleifer-md-p-h-d-president-ceo-george-d-yancopoulos-md-p-h-d-president-cso-jp--regn-20200113monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2019-financial-and-operating-results-third-quarter-2019-re-regn-20191105monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2019-financial-and-operating-results-second-quarter-2019--regn-20190806monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2019-financial-and-operating-results-first-quarter-2019-re-regn-20190507monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2018-financial-and-operating-results-fourth-regn-20190206monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-update-on-commercial-and-pipeline-progress-at-j-p-morgan-healthcare-con-regn-20190107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2018-financial-and-operating-results-third-quarter-2018-ey-regn-20181106monthly0.5https://www.biopharmawatch.com/news/REGN/supreme-court-of-the-state-of-new-york-county-of-new-york-part-39-x-public-employees-retir-regn-20181012monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2018-financial-and-operating-results-second-quarter-2018--regn-20180802monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2018-financial-and-operating-results-first-quarter-2018-ga-regn-20180503monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2017-financial-and-operating-results-fourth-regn-20180208monthly0.5https://www.biopharmawatch.com/news/REGN/jp-morgan-2018-leonard-s-schleifer-md-phd-president-ceo-george-d-yancopoulos-md-phd-presid-regn-20180108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2017-financial-and-operating-results-third-quarter-2017-ey-regn-20171108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2017-financial-and-operating-results-second-quarter-2017--regn-20170803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2017-financial-and-operating-results-first-quarter-2017-ey-regn-20170504monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2016-financial-and-operating-results-fourth-regn-20170209monthly0.5https://www.biopharmawatch.com/news/NVS/t-j-novartis-b-proposed-spin-off-of-alcon-important-information-this-information-brochure--nvs-20190130monthly0.5https://www.biopharmawatch.com/news/NVS/in-the-report-on-form-6-k-of-novartis-ag-furnished-to-the-securities-and-exchange-commissi-nvs-20151029monthly0.5https://www.biopharmawatch.com/news/NVS/in-the-report-on-form-6-k-of-novartis-ag-furnished-to-the-securities-and-exchange-commissi-nvs-20120918monthly0.5https://www.biopharmawatch.com/news/ELV/e-a-r-n-i-n-g-s-r-e-l-e-a-s-e-elevance-health-reports-third-quarter-2025-results-executing-elv-20251021monthly0.5https://www.biopharmawatch.com/news/ELV/earnings-release-elevance-health-reports-first-quarter-2024-results-1q-2024-operating-reve-elv-20240418monthly0.5https://www.biopharmawatch.com/news/ELV/e-a-r-n-i-n-g-s-r-e-l-e-a-s-e-elevance-health-reports-results-for-fourth-quarter-and-full--elv-20240124monthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-reports-third-quarter-2023-results-third-quarter-gaap-net-income-was-5-45--elv-20231018monthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-announces-john-gallina-to-retire-as-cfo-mark-kaye-named-executive-vice-pre-elv-20230808monthly0.5https://www.biopharmawatch.com/news/ELV/p-r-e-s-s-r-e-l-e-a-s-e-elevance-health-reports-second-quarter-2023-results-second-quarter-elv-20230719monthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-reports-first-quarter-2023-results-first-quarter-gaap-net-income-was-8-30--elv-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-reports-fourth-quarter-and-full-year-2022-results-fourth-quarter-and-full--elv-202301252023-01-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-board-welcomes-deanna-strable-as-new-director-indianapolis-elv-20221025monthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-reports-third-quarter-2022-results-raises-full-year-outlook-third-quarter--elv-20221019monthly0.5https://www.biopharmawatch.com/news/ELV/elevance-health-reports-second-quarter-2022-results-raises-full-year-outlook-second-quarte-elv-20220720monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-first-quarter-2022-results-reflecting-strong-momentum-across-all-divisions--elv-20220420monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-fourth-quarter-and-full-year-2021-results-fourth-quarter-gaap-net-income-wa-elv-20220126monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-third-quarter-2021-results-raises-full-year-outlook-third-quarter-gaap-net--elv-20211020monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-s-board-welcomes-susan-dodson-devore-as-new-director-indianapolis-elv-20210804monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-second-quarter-2021-results-raises-full-year-outlook-second-quarter-gaap-ne-elv-20210721monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-first-quarter-2021-results-raises-full-year-outlook-first-quarter-gaap-net--elv-20210421monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-fourth-quarter-and-full-year-2020-results-indianapolis-ind-elv-20210127monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-third-quarter-results-reaffirms-commitment-to-stakeholders-during-covid-19--elv-20201028monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-second-quarter-results-reaffirms-commitment-to-stakeholders-during-covid-19-elv-20200729monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-provides-nationwide-coordinated-response-to-covid-19-indianapolis-ind-elv-20200429monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-fourth-quarter-and-full-year-2019-results-reflecting-solid-performance-four-elv-20200129monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-third-quarter-2019-results-third-quarter-net-income-was-4-55-per-share-incl-elv-20191023monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-s-board-welcomes-ryan-schneider-as-new-director-indianapolis-elv-20191001monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-second-quarter-2019-results-raises-full-year-outlook-second-quarter-net-inc-elv-20190724monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-first-quarter-2019-results-raises-full-year-outlook-first-quarter-net-incom-elv-20190424monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-fourth-quarter-and-full-year-2018-results-reflecting-strong-core-performanc-elv-20190130monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-third-quarter-2018-results-reflecting-strengthening-operating-performance-t-elv-20181031monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-second-quarter-2018-results-reflecting-strong-overall-enterprise-wide-execu-elv-20180725monthly0.5https://www.biopharmawatch.com/news/ELV/chief-operating-officer-deepti-jain-to-lead-ingeniorx-indianapolis-elv-20180510monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-first-quarter-2018-results-reflecting-strong-medical-cost-performance-first-elv-20180425monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-fourth-quarter-and-full-year-2017-results-reflecting-balanced-performance-a-elv-20180131monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-s-board-welcomes-antonio-neri-as-new-director-indianapolis-elv-20171207monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-announces-results-of-its-tender-offer-for-notes-due-2034-2036-2037-2040-and-2044-an-elv-20171129monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-announces-pricing-of-its-tender-offer-for-any-and-all-of-its-7-000-notes-due-2019-i-elv-20171120monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-launches-cash-tender-offers-for-certain-outstanding-debt-securities-indianapolis-bu-elv-20171114monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-inc-announces-key-management-changes-board-elects-gail-k-boudreaux-chief-executive--elv-20171106monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-third-quarter-2017-results-net-income-was-2-80-per-share-including-net-posi-elv-20171025monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-second-quarter-2017-results-net-income-was-3-16-per-share-including-net-neg-elv-20170726monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-comments-on-decision-of-the-delaware-court-of-chancery-on-acquisition-of-cigna-term-elv-20170512monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-files-petition-for-a-writ-of-certiorari-with-the-u-s-supreme-court-regarding-acquis-elv-20170505monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-responds-to-u-s-court-of-appeals-decision-on-acquisition-of-cigna-indianapolis-elv-20170428monthly0.5https://www.biopharmawatch.com/news/ELV/p-r-e-s-s-r-e-l-e-a-s-e-anthem-reports-first-quarter-2017-results-net-income-was-3-73-per--elv-20170426monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-files-suit-against-cigna-seeking-a-temporary-restraining-order-to-enjoin-cigna-from-elv-20170215monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-responds-to-u-s-district-court-s-elv-20170209monthly0.5https://www.biopharmawatch.com/news/ELV/p-r-e-s-s-r-e-l-e-a-s-e-anthem-reports-fourth-quarter-and-full-year-2016-results-net-incom-elv-20170201monthly0.5https://www.biopharmawatch.com/news/ELV/p-r-e-s-s-r-e-l-e-a-s-e-anthem-reports-third-quarter-2016-results-net-income-was-2-30-per--elv-20161102monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-second-quarter-2016-results-net-income-was-2-91-per-share-including-net-neg-elv-20160727monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-statement-regarding-action-by-the-department-of-justice-indianapolis-elv-20160721monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-names-john-gallina-chief-financial-officer-wayne-deveydt-to-step-down-due-to-family-elv-20160504monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-first-quarter-2016-results-net-income-was-2-63-per-share-including-net-nega-elv-20160427monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-files-suit-against-pharmacy-benefit-manager-to-recover-damages-for-pricing-and-oper-elv-20160321monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-fourth-quarter-and-full-year-2015-results-net-income-was-0-68-per-share-inc-elv-20160127monthly0.5https://www.biopharmawatch.com/news/ELV/p-r-e-s-s-r-e-l-e-a-s-e-anthem-announces-shareholder-approval-in-connection-with-cigna-acq-elv-20151203monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-third-quarter-2015-results-net-income-was-2-43-per-share-including-net-nega-elv-20151028monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-second-quarter-2015-results-net-income-was-3-13-per-share-including-net-gai-elv-20150729monthly0.5https://www.biopharmawatch.com/news/ELV/filed-by-anthem-inc-commission-file-no-001-16751-pursuant-to-rule-425-under-the-securities-elv-20150724monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reiterates-commitment-to-184-per-share-proposal-for-cigna-corporation-schedules-cal-elv-20150622monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-inc-announces-retirement-of-ken-goulet-executive-vice-president-and-president-comme-elv-20150526monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-first-quarter-2015-results-net-income-was-3-09-per-share-including-net-loss-elv-20150429monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-inc-completes-acquisition-of-simply-healthcare-holdings-inc-indianapolis-elv-20150218monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-reports-fourth-quarter-2014-results-net-income-was-1-80-per-share-including-net-gai-elv-20150128monthly0.5https://www.biopharmawatch.com/news/ELV/anthem-inc-to-acquire-simply-healthcare-holdings-inc-acquisition-of-medicaid-and-medicare--elv-20141222monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-reports-third-quarter-2014-results-net-income-was-2-22-per-share-including-net-l-elv-20141029monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-reports-second-quarter-2014-results-net-income-was-2-56-per-share-including-net--elv-20140730monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-announces-appointment-of-thomas-c-zielinski-as-executive-vice-president-and-gene-elv-20140430monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-reports-first-quarter-2014-results-net-income-was-2-40-per-share-including-net-g-elv-20140430monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-raises-2014-financial-outlook-company-now-expects-earnings-per-share-to-be-great-elv-20140321monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-reports-fourth-quarter-and-full-year-2013-results-fourth-quarter-net-income-was--elv-20140129monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-enters-agreement-to-divest-of-1-800-contacts-subsidiary-indianapolis-in-elv-20140107monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-reports-third-quarter-2013-results-net-income-was-2-16-per-share-including-incom-elv-20131023monthly0.5https://www.biopharmawatch.com/news/ELV/wellpoint-s-board-welcomes-john-short-and-elizabeth-tallett-as-new-directors-indianapolis--elv-20130917monthly0.5https://www.biopharmawatch.com/news/MDLN/document-mdln-20260506monthly0.5https://www.biopharmawatch.com/news/MDLN/document-medline-reports-fourth-quarter-and-full-year-2025-results-delivered-strong-full-y-mdln-20260225monthly0.5https://www.biopharmawatch.com/news/COR/to-the-company-s-current-report-on-form-8-k-dated-cor-20260506monthly0.5https://www.biopharmawatch.com/news/COR/cencora-to-expand-retina-consultants-of-america-through-acquisition-of-eyesouth-partners-r-cor-20260323monthly0.5https://www.biopharmawatch.com/news/COR/cencora-announces-financial-leadership-transition-cencora-reaffirms-fiscal-2026-financial--cor-20260317monthly0.5https://www.biopharmawatch.com/news/COR/confidential-press-release-covetrus-and-mwi-animal-health-to-merge-combination-of-companio-cor-20260218monthly0.5https://www.biopharmawatch.com/news/COR/cencora-closes-3-0-cor-20260213monthly0.5https://www.biopharmawatch.com/news/COR/cencora-prices-500-million-3-950-senior-notes-due-2029-500-million-4-250-senior-notes-due--cor-20260210monthly0.5https://www.biopharmawatch.com/news/COR/to-the-company-s-current-report-on-form-8-k-dated-cor-20260204monthly0.5https://www.biopharmawatch.com/news/COR/press-release-cor-20260122monthly0.5https://www.biopharmawatch.com/news/COR/cencora-accelerates-oneoncology-acquisition-extending-solutions-offering-for-community-onc-cor-20251215monthly0.5https://www.biopharmawatch.com/news/COR/to-the-company-s-form-8-k-dated-cor-20251105monthly0.5https://www.biopharmawatch.com/news/COR/in-the-court-of-chancery-of-the-state-of-delaware-lebanon-county-employees-retirement-fund-cor-20250815monthly0.5https://www.biopharmawatch.com/news/COR/press-release-cor-20250827monthly0.5https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2025-third-quarter-results-revenue-of-80-7-billion-for-the-third-qu-cor-20250806monthly0.5https://www.biopharmawatch.com/news/COR/press-release-cor-20250528monthly0.5https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2025-second-quarter-results-revenue-of-75-5-billion-for-the-second--cor-20250507monthly0.5https://www.biopharmawatch.com/news/COR/press-release-cor-20250206monthly0.5https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2025-first-quarter-results-revenue-of-81-5-billion-for-the-first-qu-cor-20250205monthly0.5https://www.biopharmawatch.com/news/COR/cencora-completes-acquisition-of-retina-consultants-of-america-acquisition-advances-specia-cor-20250102monthly0.5https://www.biopharmawatch.com/news/COR/cencora-closes-1-8-cor-20241209monthly0.5https://www.biopharmawatch.com/news/COR/cencora-prices-500-million-4-625-senior-notes-due-2027-600-million-4-850-senior-notes-due--cor-20241204monthly0.5https://www.biopharmawatch.com/news/COR/confidential-press-release-cencora-advances-specialty-leadership-through-acquisition-of-re-cor-20241106monthly0.5https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2024-fourth-quarter-and-year-end-results-revenue-of-79-1-billion-fo-cor-20241106monthly0.5https://www.biopharmawatch.com/news/COR/press-release-cor-20240815monthly0.5https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2024-third-quarter-results-revenue-of-74-2-billion-for-the-third-qu-cor-20240731monthly0.5https://www.biopharmawatch.com/news/COR/cencora-announces-common-share-repurchase-from-walgreens-boots-alliance-and-raises-fiscal--cor-20240522monthly0.5https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2024-second-quarter-results-revenue-of-68-4-billion-for-the-second--cor-20240501monthly0.5https://www.biopharmawatch.com/news/COR/cencora-announces-leadership-succession-plan-ceo-steven-h-collis-to-transition-to-executiv-cor-20240312monthly0.5https://www.biopharmawatch.com/news/COR/cencora-closes-500-cor-20240207monthly0.5https://www.biopharmawatch.com/news/COR/final-form-cencora-prices-500-million-5-125-senior-notes-due-2034-conshohocken-pa-cor-20240205monthly0.5https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2024-first-quarter-results-revenue-of-72-3-billion-for-the-first-qu-cor-20240131monthly0.5https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2023-fourth-quarter-and-year-end-results-revenue-of-68-9-billion-fo-cor-20231102monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-becomes-cencora-in-alignment-with-the-company-s-growing-global-footprint-cor-20230830monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-cor-20230815monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20230802monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-tpg-and-amerisourc-cor-20230609monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/tpg-and-amerisourcebergen-to-acquire-leading-specialty-practice-network-oneoncology-from-g-cor-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-announces-intent-to-change-name-to-cencora-unified-corporate-identity-re-cor-202301242023-01-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20221116monthly0.5https://www.biopharmawatch.com/news/COR/explanatory-note-amerisourcebergen-corporation-the-company-or-amerisourcebergen-is-filing--cor-20221107monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20221103monthly0.5https://www.biopharmawatch.com/news/COR/document-press-release-amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-1-cor-20220927monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20220912monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20220803monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20220504monthly0.5https://www.biopharmawatch.com/news/COR/list-of-states-and-territories-that-have-agreed-to-the-opioids-related-settlement-states-a-cor-20220225monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20220202monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-summary-segment-information-in-thousands-unaudited-the-follo-cor-20211104monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20211104monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20210804monthly0.5https://www.biopharmawatch.com/news/COR/distributors-announce-proposed-opioid-settlement-agreement-conshohocken-pa-dublin-oh-and-i-cor-20210721monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20210602monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-1-west-first-avenue-conshohocken-pa-19428-amerisourcebergen--cor-20210505monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-closes-1-cor-20210330monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-prices-1-525-billion-0-737-senior-notes-due-2023-cor-20210326monthly0.5https://www.biopharmawatch.com/news/COR/deloitte-touche-llp-111-s-wacker-drive-chicago-il-60606-usa-tel-1-312-486-1000-fax-1-312-2-cor-20210323monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20210204monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-and-walgreens-boots-alliance-announce-strategic-transaction-amerisourceb-cor-20210106monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-announce-cor-20210106monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20201105monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20200805monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-closes-500-cor-20200519monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-prices-500-million-2-800-senior-notes-due-2030-cor-20200512monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20200507monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20200130monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-cor-20200102monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20191107monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20190801monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20190502monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20190131monthly0.5https://www.biopharmawatch.com/news/COR/amerisourcebergen-corporation-p-o-box-959-valley-forge-pa-19482-amerisourcebergen-reports--cor-20181106monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20260423monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20260210monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-250-2500-ww-ew-20251030monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20251030monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20250724monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20250423monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20250211monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20241024monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20240724monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-250-2500-ww-ew-20240603monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20240425monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20240206monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20231025monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20230726monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-202301312023-01-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-250-2500-fa-ew-20221208monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-250-2500-ww-ew-20221101monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20221027monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20220728monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20220426monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20220126monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20211027monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20210729monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-250-2500-fa-ew-20210505monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20210420monthly0.5https://www.biopharmawatch.com/news/EW/document-edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-25-ew-20210127monthly0.5https://www.biopharmawatch.com/news/EW/third-quarter-highlights-and-outlook-ew-20201021monthly0.5https://www.biopharmawatch.com/news/EW/second-quarter-highlights-and-outlook-ew-20200723monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-250-2500-fa-ew-20200715monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-250-2500-fa-ew-20200713monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-one-edwards-way-irvine-ca-usa-92614-phone-949-250-2500-fa-ew-20200507monthly0.5https://www.biopharmawatch.com/news/EW/forward-looking-statements-involve-risks-and-uncertainties-that-could-cause-actual-results-ew-20200423monthly0.5https://www.biopharmawatch.com/news/EW/forward-looking-statements-involve-risks-and-uncertainties-that-could-cause-actual-results-ew-20200130monthly0.5https://www.biopharmawatch.com/news/EW/third-quarter-and-recent-highlights-ew-20191023monthly0.5https://www.biopharmawatch.com/news/EW/second-quarter-and-recent-highlights-ew-20190723monthly0.5https://www.biopharmawatch.com/news/EW/first-quarter-and-recent-highlights-ew-20190423monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-third-quarter-fiscal-year-2026-results-and-raises-outlook-revenue--cah-20260430monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-second-quarter-fiscal-year-2026-results-and-raises-outlook-revenue-cah-20260205monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-first-quarter-fiscal-year-2026-results-and-raises-outlook-revenue--cah-20251030monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-fourth-quarter-and-fiscal-year-2025-results-and-raises-fiscal-year-cah-20250812monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-third-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-cah-20250501monthly0.5https://www.biopharmawatch.com/news/CAH/robert-musslewhite-and-sudhakar-ramakrishna-to-join-cardinal-health-board-of-directors-cah-20250310monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-second-quarter-fiscal-year-2025-results-and-raises-fiscal-year-202-cah-20250130monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-announces-two-strategic-additions-to-its-portfolio-acquisition-of-a-majori-cah-20241111monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-first-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-cah-20241101monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-fourth-quarter-and-fiscal-year-2024-results-and-raises-fiscal-year-cah-20240814monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-third-quarter-fiscal-year-2024-results-and-raises-fiscal-year-2024-cah-20240502monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-inc-and-subsidiaries-segment-information-fiscal-year-2022-fiscal-year-2023-cah-20240423monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reaffirms-fiscal-2024-non-gaap-eps-guidance-and-long-term-targets-amidst-n-cah-20240422monthly0.5https://www.biopharmawatch.com/news/CAH/bob-azelby-to-join-cardinal-health-board-of-directors-cah-20240228monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-second-quarter-fiscal-2024-results-and-raises-fiscal-2024-outlook--cah-20240201monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-announces-progress-on-business-and-portfolio-review-and-fiscal-2024-outloo-cah-20240101monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-first-quarter-fiscal-2024-results-and-raises-fiscal-2024-outlook-r-cah-20231103monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-fourth-quarter-and-full-year-results-for-fiscal-year-2023-at-high--cah-20230815monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-investor-day-to-highlight-long-term-value-creation-narrowing-fiscal-year-2-cah-20230608monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-third-quarter-fiscal-year-2023-results-and-raises-fiscal-year-2023-cah-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-second-quarter-fiscal-year-2023-results-and-raises-fiscal-year-202-cah-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-first-quarter-fiscal-2023-results-revenue-increased-13-to-49-6-bil-cah-20221104monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-announces-pharmaceutical-segment-organizational-changes-victor-crawford-wi-cah-20220908monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-announces-governance-enhancements-and-shareholder-value-creation-initiativ-cah-20220906monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-fourth-quarter-and-full-year-results-for-fiscal-year-2022-revenue--cah-20220811monthly0.5https://www.biopharmawatch.com/news/CAH/united-states-district-court-for-the-southern-district-of-ohio-eastern-division-in-re-card-cah-20220722monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-third-quarter-fiscal-2022-results-revenue-increased-14-to-44-8-bil-cah-20220505monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-second-quarter-fiscal-2022-results-revenue-increased-9-to-45-5-bil-cah-20220203monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-first-quarter-fiscal-2022-results-revenue-increased-13-to-44-0-bil-cah-20211109monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-fourth-quarter-and-full-year-results-for-fiscal-year-2021-revenue--cah-20210805monthly0.5https://www.biopharmawatch.com/news/CAH/distributors-announce-proposed-opioid-settlement-agreement-07-21-2021-conshohocken-pa-dubl-cah-20210722monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-third-quarter-results-for-fiscal-year-2021-revenue-was-flat-at-39--cah-20210506monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-signs-definitive-agreement-to-sell-its-cordis-business-to-hellman-friedman-cah-20210312monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-second-quarter-results-for-fiscal-year-2021-revenue-increased-5-to-cah-20210205monthly0.5https://www.biopharmawatch.com/news/CAH/cardinal-health-reports-first-quarter-fiscal-2021-results-revenue-increased-5-to-39-1-bill-cah-20201105monthly0.5https://www.biopharmawatch.com/news/CAH/media-sarah-shew-investors-kevin-moran-614-553-3401-614-757-7942-sarah-shew-cardinalhealth-cah-20200831monthly0.5https://www.biopharmawatch.com/news/CAH/media-sarah-shew-investors-kevin-moran-614-553-3401-614-757-7942-sarah-shew-cardinalhealth-cah-20200806monthly0.5https://www.biopharmawatch.com/news/CAH/media-sarah-shew-investors-kevin-moran-614-553-3401-614-757-7942-sarah-shew-cardinalhealth-cah-20200511monthly0.5https://www.biopharmawatch.com/news/CAH/media-erica-lewis-investors-kevin-moran-614-787-0087-614-757-7924-erica-lewis-cardinalheal-cah-20200319monthly0.5https://www.biopharmawatch.com/news/CAH/media-erica-lewis-investors-kevin-moran-614-787-0087-614-757-7942-erica-lewis-cardinalheal-cah-20200206monthly0.5https://www.biopharmawatch.com/news/CAH/media-erica-lewis-614-787-0087-erica-lewis-cardinalhealth-com-investors-kevin-moran-614-75-cah-20200130monthly0.5https://www.biopharmawatch.com/news/CAH/media-brandi-martin-investors-kevin-moran-614-757-3383-614-757-7942-brandi-martin-cardinal-cah-20191107monthly0.5https://www.biopharmawatch.com/news/CAH/media-brandi-martin-investors-lisa-capodici-614-757-3383-614-757-5035-brandi-martin-cardin-cah-20190808monthly0.5https://www.biopharmawatch.com/news/CAH/media-brandi-martin-investors-lisa-capodici-614-757-3383-614-757-5035-brandi-martin-cardin-cah-20190716monthly0.5https://www.biopharmawatch.com/news/CAH/media-brandi-martin-investors-lisa-capodici-614-757-3383-614-757-5035-brandi-martin-cardin-cah-20190509monthly0.5https://www.biopharmawatch.com/news/CAH/media-brandi-martin-investors-lisa-capodici-614-757-3383-614-757-5035-brandi-martin-cardin-cah-20190207monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20181207monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20181108monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20180806monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20180503monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20180308monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20180208monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20171106monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20170802monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20170501monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-614-553-3858-ellen-barry-cardinalhealth-com-investors-sally-curley-614-7-cah-20170418monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20170207monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-lisa-capodici-614-553-3858-614-757-5035-ellen-barry-cardinalhe-cah-20161031monthly0.5https://www.biopharmawatch.com/news/CAH/media-ellen-barry-investors-sally-curley-614-553-3858-614-757-7115-ellen-barry-cardinalhea-cah-20160802monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-investors-sally-curley-614-757-6225-614-757-7115-debbie-mitchell-car-cah-20160428monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-investors-sally-curley-614-757-6225-614-757-7115-debbie-mitchell-car-cah-20160201monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-investors-sally-curley-614-757-6225-614-757-7115-debbie-mitchell-car-cah-20151102monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-investors-sally-curley-614-757-6225-614-757-7115-debbie-mitchell-car-cah-20150730monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-614-757-6225-debbie-mitchell-cardinalhealth-com-investors-sally-curl-cah-20150605monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-614-757-6225-debbie-mitchell-cardinalhealth-com-investors-sally-curl-cah-20150430monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-investors-sally-curley-614-757-6225-614-757-7115-debbie-mitchell-car-cah-20150302monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-614-757-6225-debbie-mitchell-cardinalhealth-com-investors-sally-curl-cah-20150129monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-614-757-6225-debbie-mitchell-cardinalhealth-com-investors-sally-curl-cah-20141030monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-614-757-6225-debbie-mitchell-cardinalhealth-com-investors-sally-curl-cah-20140804monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-614-757-6225-debbie-mitchell-cardinalhealth-com-investors-sally-curl-cah-20140501monthly0.5https://www.biopharmawatch.com/news/CAH/media-debbie-mitchell-614-757-6225-debbie-mitchell-cardinalhealth-com-investors-sally-curl-cah-20140130monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-announces-ceo-succession-michael-erickson-phd-to-succeed-jay-mazelsky-as-president-a-idxx-20260113monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-achieves-third-quarter-revenue-growth-o-idxx-20251103monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-elects-karen-peacock-to-board-of-directors-idxx-20251007monthly0.5https://www.biopharmawatch.com/news/IDXX/john-ravis-investor-relations-1-207-556-8155-idexx-laboratories-announces-second-quarter-r-idxx-20250804monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-elects-joseph-l-jay-hooley-to-board-of-directors-idxx-20250710monthly0.5https://www.biopharmawatch.com/news/IDXX/john-ravis-investor-relations-1-207-556-8155-idexx-laboratories-announces-first-quarter-re-idxx-20250501monthly0.5https://www.biopharmawatch.com/news/IDXX/john-ravis-investor-relations-1-207-556-8155-idexx-laboratories-announces-fourth-quarter-a-idxx-20250203monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-increase-in-share-repurchase-program-authorization-idxx-20241209monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-announces-cfo-transition-brian-mckeon-to-retire-from-idexx-in-june-2025-andrew-emers-idxx-20241121monthly0.5https://www.biopharmawatch.com/news/IDXX/via-diligent-messenger-idxx-20241108monthly0.5https://www.biopharmawatch.com/news/IDXX/john-ravis-investor-relations-1-207-556-8155-idexx-laboratories-announces-third-quarter-re-idxx-20241031monthly0.5https://www.biopharmawatch.com/news/IDXX/john-ravis-investor-relations-1-207-556-8155-idexx-laboratories-announces-second-quarter-r-idxx-20240806monthly0.5https://www.biopharmawatch.com/news/IDXX/john-ravis-investor-relations-1-207-556-8155-idexx-laboratories-announces-first-quarter-re-idxx-20240501monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-announces-fourth-quarter-and-full-year-results-achieves-fourth-quarter-revenue-growt-idxx-20240205monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-achieves-third-quarter-revenue-growth-o-idxx-20231101monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-records-second-quarter-revenue-growth--idxx-20230801monthly0.5https://www.biopharmawatch.com/news/IDXX/i-dexx-laboratories-elects-irene-chang-britt-to-board-of-directors-idxx-20230712monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-achieves-first-quarter-revenue-growth-o-idxx-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-and-full-year-2022-results-achieves-fourth-qua-idxx-202302062023-02-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-achieves-third-quarter-revenue-growth-o-idxx-20221101monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-achieves-second-quarter-revenue-growth-idxx-20220802monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-achieves-first-quarter-revenue-growth-o-idxx-20220504monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-and-full-year-2021-results-idxx-20220202monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-idxx-20211102monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-idxx-20210730monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-idxx-20210504monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-and-full-year-2020-results-idxx-20210202monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-elects-dr-asha-s-collins-to-board-of-directors-idxx-20201112monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-idxx-20201029monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-idxx-20200731monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-idxx-20200430monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-and-full-year-2019-results-idxx-20200131monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-idxx-20191031monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-leadership-changes-jay-mazelsky-appointed-president-and-chief-idxx-20191024monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-idxx-20190801monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-elects-sam-samad-to-board-of-directors-idxx-20190718monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-chairman-president-and-chief-executive-officer-jonathan-ayers-taking-me-idxx-20190701monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-idxx-20190501monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-and-full-year-2018-results-idxx-20190201monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-idxx-20181101monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-idxx-20180801monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-idxx-20180504monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-and-full-year-2017-results-idxx-20180201monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-estimated-impact-of-u-s-tax-reform-idxx-20180105monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-idxx-20171031monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-achieves-revenue-growth-of-9-on-a-repo-idxx-20170801monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-elects-stuart-m-essig-to-board-of-directors-idxx-20170717monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-increase-in-share-repurchase-program-idxx-20170503monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-reports-revenue-growth-of-11-on-both-a--idxx-20170428monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-and-full-year-2016-results-achieves-q4-revenue-idxx-20170202monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-idxx-20161101monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-elects-lawrence-d-kingsley-to-board-of-directors-idxx-20161019monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-overall-revenues-increase-13-driven-by-idxx-20160802monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-achieves-11-organic-growth-for-total-co-idxx-20160429monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-and-full-year-2015-results-achieves-11-normali-idxx-20160129monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-third-quarter-results-achieves-12-normalized-organic-revenue--idxx-20151028monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-second-quarter-results-catalyst-instrument-placements-at-all--idxx-20150730monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-elects-bruce-l-claflin-to-board-of-directors-idxx-20150714monthly0.5https://www.biopharmawatch.com/news/IDXX/execution-copy-idexx-laboratories-inc-50-000-000-3-32-series-a-senior-notes-due-idxx-20150624monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-two-for-one-stock-split-and-increase-in-share-repurchase-prog-idxx-20150506monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-first-quarter-results-premium-instrument-placements-increase--idxx-20150428monthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-announces-fourth-quarter-results-achieves-full-year-normalized-organic--idxx-20150130monthly0.5https://www.biopharmawatch.com/news/IDXX/execution-version-idexx-laboratories-inc-75-000-000-3-25-series-a-senior-notes-due-idxx-20141229monthly0.5https://www.biopharmawatch.com/news/TAK/net-debt-and-adjusted-net-debt-takeda-defines-net-debt-as-the-book-value-of-bonds-and-loan-tak-20260605monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-and-explanation-of-non-ifrs--tak-20260513monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-and-explanation-of-non-ifrs--tak-20260129monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-and-explanation-of-non-ifrs--tak-20251030monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-and-explanation-of-non-ifrs--tak-20250730monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-and-explanation-of-non-ifrs--tak-20250508monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-and-explanation-of-non-ifrs--tak-20250130monthly0.5https://www.biopharmawatch.com/news/TAK/reason-for-submitting-the-extraordinary-report-the-company-has-submitted-the-extraordinary-tak-20241218monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-and-explanation-of-non-ifrs--tak-20241031monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-and-explanation-of-non-ifrs--tak-20240731monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-of-core-financial-measures-c-tak-20240509monthly0.5https://www.biopharmawatch.com/news/TAK/document-financial-appendix-definition-of-non-ifrs-measures-definition-of-core-financial-m-tak-20240201monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-of-core-financial-measures-c-tak-20231026monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-of-core-financial-measures-c-tak-20230727monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-of-core-financial-measures-c-tak-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/the-following-is-the-translation-of-the-articles-of-incorporation-of-takeda-pharmaceutical-tak-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-of-core-financial-measures-c-tak-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/attachment-news-release-takeda-to-acquire-late-stage-potential-best-in-class-oral-alloster-tak-20221213monthly0.5https://www.biopharmawatch.com/news/TAK/financial-appendix-definition-of-non-ifrs-measures-definition-of-core-financial-measures-c-tak-20221027monthly0.5https://www.biopharmawatch.com/news/TAK/2-notwithstanding-the-provisions-of-the-preceding-paragraph-article-14-of-the-pre-amendmen-tak-20220629monthly0.5https://www.biopharmawatch.com/news/TAK/article-31-lapse-of-the-rights-on-dividends-if-any-year-end-dividends-or-interim-dividends-tak-20210818monthly0.5https://www.biopharmawatch.com/news/TAK/etokyorddayallslidesfina-takeda-r-d-investor-day-2019-tokyo-japan-tak-20191121monthly0.5https://www.biopharmawatch.com/news/TAK/final-111519-realizing-the-potential-of-plasma-derived-therapies-investor-relations-day-co-tak-20191115monthly0.5https://www.biopharmawatch.com/news/TAK/rddayallslides20191112nn-takeda-r-d-investor-day-2019-tak-20191114monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-successful-upsizing-and-pricing-of-2-300-000-000-equivalent-senior-notes-pr-teva-20250522monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-appointment-of-matthew-shields-to-executive-vice-president-teva-20240515monthly0.5https://www.biopharmawatch.com/news/TEVA/for-an-accessible-version-of-this-press-release-please-visit-www-tevapharm-com-teva-report-teva-20240508monthly0.5https://www.biopharmawatch.com/news/TEVA/the-following-tables-present-revenues-expenses-and-profit-for-each-segment-for-the-years-e-teva-20240418monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-growth-in-fourth-quarter-and-full-year-2023-2023-revenues-of-15-8-billion-ref-teva-20240131monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-third-quarter-2023-financial-results-and-increases-revenue-guidance-2023-reve-teva-20231108monthly0.5https://www.biopharmawatch.com/news/TEVA/sanofi-and-teva-announce-exclusive-collaboration-to-deliver-inflammatory-bowel-disease-tre-teva-20231004monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-changes-to-executive-management-team-tel-aviv-israel-parsippany-n-j-teva-20230928monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-settles-price-fixing-charges-with-u-s-doj-tel-aviv-israel-parsippany-n-j-teva-20230821monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-second-quarter-2023-financial-results-revenues-of-3-9-billion-gaap-loss-per-s-teva-20230802monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-concludes-nationwide-opioids-settlement-agreement-settles-with-all-50-states-and-99-p-teva-20230608monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-first-quarter-2023-financial-results-and-reaffirms-2023-non-gaap-outlook-tel--teva-202305102023-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-successful-upsize-and-pricing-of-2-490-000-000-equivalent-sustainability-li-teva-202303032023-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-fourth-quarter-and-full-year-2022-financial-results-tel-aviv-israel-business--teva-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-appointment-of-richard-francis-as-president-and-ceo-k-re-schultz-to-retire--teva-20221121monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-third-quarter-2022-financial-results-key-financial-highlights-and-outlook-rev-teva-20221103monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-second-quarter-2022-financial-results-teva-has-reached-agreement-in-principle-teva-20220726monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-first-quarter-2022-financial-results-revenues-of-3-7-billion-gaap-diluted-los-teva-20220503monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-fourth-quarter-and-full-year-2021-financial-results-tel-aviv-israel-business--teva-20220209monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-successful-upsize-of-sustainability-linked-senior-notes-offering-and-pricin-teva-20211102monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-third-quarter-2021-financial-results-revenues-of-3-9-billion-gaap-diluted-eps-teva-20211027monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-second-quarter-2021-financial-results-revenues-of-3-9-billion-gaap-diluted-ep-teva-20210728monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-changes-to-executive-management-team-tel-aviv-israel-parsippany-n-j-busines-teva-20210721monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-first-quarter-2021-financial-results-revenues-of-4-0-billion-gaap-diluted-eps-teva-20210428monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-fourth-quarter-and-full-year-2020-financial-results-tel-aviv-israel-business--teva-20210210monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-third-quarter-2020-financial-results-revenues-of-4-0-billion-gaap-diluted-los-teva-20201105monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-second-quarter-2020-financial-results-revenues-of-3-9-billion-gaap-diluted-ep-teva-20200805monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-first-quarter-2020-financial-results-revenues-of-4-4-billion-gaap-diluted-eps-teva-20200507monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-fourth-quarter-and-full-year-2019-financial-results-tel-aviv-israel-business--teva-20200212monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-appointment-of-new-chief-financial-officer-jerusalem-business-wire-teva-20191107monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-third-quarter-2019-financial-results-revenues-of-4-3-billion-gaap-diluted-los-teva-20191107monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-settles-track-1-opioid-cases-and-reaches-agreement-on-framework-to-settle-remaining-l-teva-20191021monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-second-quarter-2019-financial-results-revenues-of-4-3-billion-gaap-diluted-lo-teva-20190807monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-first-quarter-2019-financial-results-revenues-of-4-3-billion-gaap-diluted-los-teva-20190502monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-fourth-quarter-and-full-year-2018-financial-results-jerusalem-business-wire-teva-20190213monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-third-quarter-2018-financial-results-revenues-of-4-5-billion-free-cash-flow-o-teva-20181101monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-second-quarter-2018-financial-results-revenues-of-4-7-billion-free-cash-flow--teva-20180802monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-first-quarter-2018-financial-results-revenues-of-5-1-billion-free-cash-flow-o-teva-20180503monthly0.5https://www.biopharmawatch.com/news/TEVA/selected-financial-data-by-segment-unaudited-north-america-segment-year-ended-december-31--teva-20180427monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-2017-full-year-and-fourth-quarter-financial-results-jerusalem-business-wire-teva-20180208monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-completes-amendment-to-credit-facilities-jerusalem-feb-1-2018-teva-pharmaceutical-ind-teva-20180201monthly0.5https://www.biopharmawatch.com/news/TEVA/webcast-alert-for-immediate-release-teva-to-present-at-the-36-th-annual-j-p-morgan-healthc-teva-20180104monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-launch-of-an-authorized-generic-of-estrace-cream-in-the-united-states-jerus-teva-20180102monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-announces-restructuring-plan-and-additional-measures-to-improve-its-business-and-fina-teva-20171214monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-third-quarter-2017-financial-results-revenues-of-5-6-billion-cash-flow-from-o-teva-20171102monthly0.5https://www.biopharmawatch.com/news/TEVA/execution-version-amendment-to-senior-unsecured-revolving-credit-agreement-this-amendment--teva-20170918monthly0.5https://www.biopharmawatch.com/news/TEVA/teva-reports-second-quarter-2017-financial-results-revenues-of-5-7-billion-gaap-eps-loss-o-teva-20170803monthly0.5https://www.biopharmawatch.com/news/TEVA/celltrion-and-teva-announce-u-s-fda-acceptance-of-biologics-license-application-for-propos-teva-20170731monthly0.5https://www.biopharmawatch.com/news/AZN/securities-and-exchange-commission-azn-20260224monthly0.5https://www.biopharmawatch.com/news/AZN/no-2723534-the-companies-act-2006-public-company-limited-by-shares-articles-of-association-azn-20251103monthly0.5https://www.biopharmawatch.com/news/AZN/securities-and-exchange-commission-azn-20250218monthly0.5https://www.biopharmawatch.com/news/AZN/securities-and-exchange-commission-azn-20240220monthly0.5https://www.biopharmawatch.com/news/AZN/no-2723534-the-companies-act-2006-public-company-limited-by-shares-articles-of-association-azn-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/securities-and-exchange-commission-azn-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-vitor-roque-chief-financial-officer-franklin-lakes-n-j-bdx-20260507monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-shawn-bevec-svp-investo-bdx-20260507monthly0.5https://www.biopharmawatch.com/news/BDX/non-gaap-financial-measures-included-in-the-financial-tables-the-unaudited-financial-infor-bdx-20260402monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-shawn-bevec-svp-investo-bdx-20260209monthly0.5https://www.biopharmawatch.com/news/BDX/non-gaap-financial-measures-included-in-the-financial-tables-these-revenue-schedules-inclu-bdx-20260205monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-vp-investor-bdx-20251106monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-vp-investor-bdx-20251015monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-sr-director-bdx-20250807monthly0.5https://www.biopharmawatch.com/news/BDX/waters-and-bd-s-biosciences-diagnostic-solutions-business-to-combine-creating-a-life-scien-bdx-20250714monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-sr-director-bdx-20250501monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-sr-director-bdx-20250205monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-sr-director-bdx-20241107monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-sr-director-bdx-20240801monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-sr-director-bdx-20240502monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-sr-director-bdx-20240201monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-adam-reiffe-sr-director-bdx-20231109monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-francesca-demartino-svp-bdx-20230803monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-francesca-demartino-svp-bdx-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-francesca-demartino-svp-bdx-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-francesca-demartino-svp-bdx-20221110monthly0.5https://www.biopharmawatch.com/news/BDX/bdpressreleaseaugus-news-release-for-immediate-release-bd-promotes-two-senior-executives-t-bdx-20220825monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-announces-early-tender-results-and-upsizing-of-offer-subcap-bdx-20220822monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-announces-tender-offers-for-outstanding-debt-securities-bdx-20220808monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contacts-investors-francesca-demartino-svp-bdx-20220804monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-condensed-consolidated-income-statements-unaudited-amounts-in-bdx-20220531monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-investors-francesca-demartino-svp--bdx-20220505monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-condensed-consolidated-income-statements-unaudited-amounts-in-bdx-20220414monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-completion-of-embecta-corp-spinoff-franklin-lakes-n-j-bdx-20220401monthly0.5https://www.biopharmawatch.com/news/BDX/alberto-mas-announces-intent-to-retire-from-bd-at-end-of-fiscal-year-franklin-lakes-n-j-bdx-20220331monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-bd-provides-update-regarding-the-planned-s-bdx-20220321monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-investors-francesca-demartino-svp--bdx-20220203monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-investors-nadia-goncalves-bd-inves-bdx-20211104monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-announces-early-tender-results-bdx-20210819monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-upsizing-of-tender-offers-franklin-lakes-nj-bdx-20210810monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-announces-tender-offers-for-outstanding-debt-securities-bdx-20210805monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-investors-kristen-m-stewart-cfa-sv-bdx-20210805monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-two-future-directors-for-diabetes-care-spinoff-company-david-f-melcher-to-be--bdx-20210712monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-investors-kristen-m-stewart-cfa-sv-bdx-20210506monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-kristen-m-stewart-cfa-strategy-inv-bdx-20210204monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-kristen-m-stewart-cfa-strategy-inv-bdx-20210112monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-kristen-m-stewart-cfa-strategy-inv-bdx-20201105monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20200806monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20200507monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20200206monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20191105monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20190806monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-early-tender-results-bdx-20190603monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-announces-tender-offers-for-outstanding-debt-securities-bdx-20190520monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20190509monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20190205monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20190117monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20181106monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20180802monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20180503monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-of-offer-to-repurchase-its-3-000-notes-due-2026-bdx-20180302monthly0.5https://www.biopharmawatch.com/news/BDX/becton-drive-franklin-lakes-nj-07417-www-bd-com-contact-monique-n-dolecki-investor-relatio-bdx-20180206monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-supplemental-information-reconciliation-of-reported-revenue-t-bdx-20180205monthly0.5https://www.biopharmawatch.com/news/BDX/troy-kirkpatrick-monique-n-dolecki-bd-public-relations-bd-investor-relations-858-617-2361--bdx-20171229monthly0.5https://www.biopharmawatch.com/news/NVO/securities-and-exchange-commission-nvo-20260327monthly0.5https://www.biopharmawatch.com/news/NVO/securities-and-exchange-commission-nvo-20250227monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broader-vyvgar-argx-20260418monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-argx-20260320monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-new-data-at-2026-aan-annual-meeting-that-continue-to-transform-patient-o-argx-20260306monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-2026-strategic-priorities-reported-4-15-billion-yoy-growth-of-90-in-prel-argx-20260112monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-extraordinary-general-meeting-of-shareholders-argx-20251118monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presents-new-data-at-aanem-and-mgfa-highlighting-the-strength-and-broad-benefit-of--argx-20251101monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-advances-clinical-development-of-argx-119-in-congenital-myasthenic-syndromes-phase--argx-20250630monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-european-commission-approval-of-vyvgart-subcutaneous-injection-for-chroni-argx-20250620monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presents-new-efgartigimod-data-at-eular-2025-highlighting-positive-phase-2-proof-of-argx-20250611monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-of-shareholders-argx-20250528monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-positive-chmp-opinion-for-vyvgart-efgartigimod-alfa-subcutaneous-injectio-argx-20250428monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-argx-20250414monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-fda-approval-of-vyvgart-hytrulo-prefilled-syringe-for-self-injection-in-g-argx-20250410monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-vyvgart-data-at-aan-2025-setting-new-standard-in-sustained-efficacy-and--argx-20250408monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-fcrn-leadership-with-long-term-data-and-transformational-patient-outcome-argx-20250307monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-2025-strategic-priorities-reported-2-2-billion-in-preliminary-full-year--argx-20250113monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-in-japan-for-argx-20241227monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-advances-clinical-development-of-efgartigimod-sc-in-idiopathic-inflammatory-myopath-argx-20241120monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-and-zai-lab-announce-approval-of-vyvgart-hytrulo-for-chronic-inflammatory-demyelina-argx-20241111monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-data-showing-patient-impact-across-multiple-immunology-programs-at-2024--argx-20241015monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-in-the-lancet-neurology-of-pivotal-adhere-study-data-in-chron-argx-20240919monthly0.5https://www.biopharmawatch.com/news/ARGX/ex-reflects-cash-cash-equivalents-and-current-financial-assets-hibit-99-1-argenx-reports-h-argx-20240716monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-and-zai-lab-announce-approval-of-efgartigimod-alfa-injection-subcutaneous-injection-argx-20240716monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-breadth-of-autoimmune-pipeline-with-new-multifocal-motor-neuropathy-data-argx-20240625monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-fda-approval-of-vyvgart-hytrulo-for-chronic-inflammatory-demyelinating-po-argx-20240621monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-unveil-its-vision-2030-taking-breakthrough-science-to-50-000-patients-during-its-argx-20240617monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2024-financial-results-and-provides-business-update-398-milli-argx-20240509monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-of-shareholders-argx-20240507monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-data-highlight-evidence-that-vyvgart-and-vyvgart-hytrulo-drive-transformative-outco-argx-20240416monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-advances-clinical-development-of-efgartigimod-in-primary-sjogren-s-disease-rho-stud-argx-20240327monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-argx-20240327monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-approval-of-vyvgart-efgartigimod-alfa-in-japan-for-adults-with-primary-im-argx-20240326monthly0.5https://www.biopharmawatch.com/news/ARGX/annualreport2023-disclaimer-pdf-print-x2013-this-document-is-only-a-x201c-printed-version--argx-20240321monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-delivers-on-promise-to-transform-patient-expectations-in-autoimmunity-at-american-a-argx-20240307monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-full-year-2023-financial-results-and-provides-fourth-quarter-business-updat-argx-20240229monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-fda-acceptance-of-supplemental-biologics-license-application-with-priorit-argx-20240220monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-injection-fo-argx-20240118monthly0.5https://www.biopharmawatch.com/news/ARGX/e-xhibit-99-1-argenx-highlights-2024-strategic-priorities-reported-1-2-billion-in-prelimin-argx-20240108monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-topline-results-from-address-study-of-efgartigimod-sc-in-pemphigus-address--argx-20231220monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-topline-results-from-advance-sc-study-of-vyvgart-hytrulo-in-primary-immune--argx-20231128monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-european-commission-approval-of-subcutaneous-vyvgart-efgartigimod-alfa-fo-argx-20231116monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-data-evaluating-vyvgart-in-neuromuscular-autoimmune-disease-at-aanem-and-argx-20231101monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2023-financial-results-and-provides-business-update-329-milli-argx-20231031monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-vyvgart-efgartigimod-alfa-authorized-for-sale-by-health-canada-for-genera-argx-20230921monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-half-year-2023-financial-results-and-provides-second-quarter-business-updat-argx-20230727monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-inside-information-argenx-announces-launch-of-proposed-global-offeri-argx-20230717monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-positive-topline-data-from-adhere-study-of-vyvgart-hytrulo-in-patients-with-argx-20230717monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-and-zai-lab-announce-approval-of-vyvgart-efgartigimod-alfa-injection-for-generalize-argx-20230630monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-initiates-second-cohort-of-phase-2-arda-study-of-empasiprubart-in-multifocal-motor--argx-20230620monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2023-financial-results-and-provides-business-update-218-milli-argx-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-of-shareholders-argx-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-demonstrates-commitment-to-redefining-treatment-goals-for-generalized-myasthenia-gr-argx-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-and-genmab-enter-partnership-to-advance-antibody-therapies-in-immunology-and-oncolo-argx-202304172023-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-uk-mhra-approval-of-vyvgart-for-the-treatment-of-generalized-myasthenia-g-argx-202303162023-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-planned-transition-of-chief-operating-officer-karen-massey-appointed-as-c-argx-202303022023-03-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-extraordinary-general-meeting-of-shareholders-on-argx-202301302023-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-notification-of-pdufa-date-extension-for-sc-efgartigimod-argx-202301272023-01-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-2023-strategic-priorities-across-immunology-pipeline-reported-402-millio-argx-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-pivotal-advance-trial-data-during-ash-plenary-session-highlighting-vyvga-argx-20221210monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-enters-into-agreement-to-acquire-priority-review-voucher-amsterdam-the-netherlands-argx-20221130monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-u-s-fda-acceptance-of-biologics-license-application-for-subcutaneous-efga-argx-20221122monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2022-financial-results-and-provides-business-update-131-milli-argx-20221027monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-submits-biologics-license-application-to-u-s-food-and-drug-administration-for-subcu-argx-20220921monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-appoints-camilla-sylvest-to-board-of-directors-argx-20220908monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-european-commission-approval-of-vyvgart-efgartigimod-alfa-fcab-for-the-tr-argx-20220811monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-half-year-2022-financial-results-and-provides-second-quarter-business-updat-argx-20220728monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-positive-chmp-opinion-for-efgartigimod-for-the-treatment-of-adult-patients-argx-20220624monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-of-translational-data-of-efgartigimod-in-autoimmune-skin-blis-argx-20220519monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2022-financial-results-and-provides-business-update-21-2-mill-argx-20220505monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-inside-information-argenx-announces-launch-of-proposed-global-offeri-argx-20220322monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-positive-topline-phase-3-data-from-adapt-sc-study-evaluating-subcutaneous-argx-20220322monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-full-year-2021-financial-results-and-provides-fourth-quarter-business-updat-argx-20220303monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-vyvgart-approval-in-japan-for-the-treatment-of-generalized-myasthenia-gra-argx-20220120monthly0.5https://www.biopharmawatch.com/news/ARGX/together-we-discover-j-p-morgan-healthcare-conference-argx-20220110monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-strategic-priorities-for-2022-initiated-global-vyvgart-efgartigimod-alfa-argx-20220107monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-u-s-food-and-drug-administration-fda-approval-of-vyvgart-ocirc-efgartigim-argx-20211217monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-half-year-2021-financial-results-and-provides-second-quarter-business-updat-argx-20210729monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-regain-global-rights-to-cusatuzumab-argx-20210607monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-appoints-karl-gubitz-as-chief-financial-officer-argx-20210601monthly0.5https://www.biopharmawatch.com/news/ARGX/securities-and-exchange-commission-argx-20210514monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-of-shareholders-argx-20210511monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-argx-20210330monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-inside-information-argenx-announces-launch-of-proposed-global-offeri-argx-20210201monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-2021-corporate-priorities-and-highlights-recent-achievements-across-immun-argx-20210108monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-and-zai-lab-announce-strategic-collaboration-for-efgartigimod-in-greater-china-coll-argx-20210106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-enters-into-agreement-to-acquire-priority-review-voucher-argx-20201123monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2020-financial-results-and-provides-business-update-biologics-argx-20201022monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presents-additional-efgartigimod-data-from-global-phase-3-adapt-trial-at-the-myasth-argx-20201005monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-half-year-2020-financial-results-and-provides-second-quarter-business-updat-argx-20200730monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-inside-information-argenx-announces-launch-of-proposed-global-offeri-argx-20200526monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2020-financial-results-and-provides-business-update-topline-d-argx-20200514monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-of-shareholders-argx-20200512monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-argx-20200331monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-full-year-2019-financial-results-and-provides-fourth-quarter-business-updat-argx-20200227monthly0.5https://www.biopharmawatch.com/news/ARGX/jp-morgan-healthcare-conference-january-2020-san-francisco-forward-looking-statements-this-argx-20200113monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-provides-strategic-outlook-advancing-late-stage-pipeline-towards-argenx-2021-vision-argx-20200109monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-receipt-of-first-milestone-payment-under-janssen-collaboration-and-provid-argx-20191207monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-inside-information-argenx-announces-launch-of-proposed-global-offeri-argx-20191106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-data-at-upcoming-61st-american-society-of-hematology-ash-annual-meeting-argx-20191106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2019-financial-results-and-provides-business-update-enrollmen-argx-20191024monthly0.5https://www.biopharmawatch.com/news/ARGX/invitation-to-the-extraordinary-shareholders-meeting-argx-20191014monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-half-year-2019-financial-results-and-second-quarter-business-update-xb7-enr-argx-20190801monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-of-efgartigimod-phase-2-myasthenia-gravis-trial-results-in-ne-argx-20190528monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-pipeline-expansion-and-argenx-2021-vision-to-build-integrated-immunology--argx-20190522monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2019-financial-results-and-provides-business-update-argx-20190509monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-of-shareholders-argx-20190507monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-argx-20190326monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-receive-first-clinical-milestone-payment-for-product-candidate-developed-under-o-argx-20190314monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-fourth-quarter-business-update-and-full-year-2018-financial-results-argx-20190228monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze-technolog-argx-20190204monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-exclusive-global-collaboration-and-license-agreement-for-cusat-argx-20190118monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-provides-detailed-data-from-phase-2-clinical-trial-of-efgartigimod-in-immune-thromb-argx-20181203monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-x2014-inside-information-argenx-enters-exclusive-global-collaboratio-argx-20181203monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-inside-information-argenx-announces-new-cusatuzumab-argx-110-aml-dat-argx-20181101monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2018-financial-results-and-provides-business-update-argx-20181025monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-awarded-2-6-million-vlaio-grant-to-explore-new-applications-of-abdeg-technology-argx-20181009monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-inside-information-argenx-announces-launch-of-proposed-public-offeri-argx-20180917monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-positive-topline-results-from-phase-2-proof-of-concept-trial-of-efgartigimo-argx-20180917monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-doses-first-patient-in-global-phase-3-registration-trial-of-efgartigimod-for-the-tr-argx-20180906monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-feedback-from-japan-s-pmda-on-phase-3-clinical-trial-and-regulatory-pathwa-argx-20180829monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-that-abbvie-has-exercised-its-exclusive-option-to-license-argx-115-a-nove-argx-20180822monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-second-quarter-business-update-and-half-year-2018-financial-results-managem-argx-20180802monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-of-full-data-from-phase-1-healthy-volunteer-study-of-efgartig-argx-20180724monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-milestone-payment-from-strategic-collaboration-with-shire-argx-20180717monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-second-preclinical-milestone-payment-under-its-development-agreement-with--argx-20180628monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-interim-data-from-first-cohort-of-phase-2-proof-of-concept-clinical-trial-o-argx-20180620monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-data-from-phase-1-study-of-efgartigimod-argx-113-subcutaneous-formulation-argx-20180614monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-selected-for-bel-20-index-argx-20180605monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-of-shareholders-argx-20180508monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-complete-data-from-the-phase-2-proof-of-concept-trial-of-efgartigimod-ar-argx-20180424monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-receive-third-preclinical-milestone-payment-from-collaboration-with-leo-pharma-m-argx-20180412monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-appoints-keith-woods-as-chief-operating-officer-argx-20180409monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-orphan-drug-designation-for-argx-113-for-the-treatment-of-myasthenia-grav-argx-20180326monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-expansion-of-its-pipeline-with-addition-of-complement-targeted-argx-117-f-argx-20180322monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-awarded-2-5-million-vlaio-grant-to-identify-novel-therapeutic-antibodies-grant-to-f-argx-20180316monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-fourth-quarter-business-update-and-full-year-2017-financial-results-managem-argx-20180301monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-positive-topline-results-from-phase-2-proof-of-concept-trial-of-argx-113-ef-argx-20171211monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-extraordinary-shareholders-meeting-2017-argx-20171107monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-launches-phase-i-trial-with-subcutaneous-formulation-of-argx-113-subcutaneous-formu-argx-20171030monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2017-financial-results-and-provides-business-update-argx-20171026monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-launches-phase-ii-proof-of-concept-clinical-trial-of-argx-113-for-the-treatment-of--argx-20170926monthly0.5https://www.biopharmawatch.com/news/ARGX/non-regulated-information-argenx-announces-orphan-drug-designation-for-argx-113-for-the-tr-argx-20170925monthly0.5https://www.biopharmawatch.com/news/ARGX/invitation-to-the-extraordinary-shareholders-meeting-argx-20170922monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reaches-50-enrollment-in-phase-2-clinical-trial-of-argx-113-in-immune-thrombocytope-argx-20170920monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-second-quarter-business-update-and-half-year-2017-financial-results-managem-argx-20170824monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-in-nature-medicine-of-preclinical-data-supporting-the-therape-argx-20170823monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presents-full-data-from-argx-111-phase-ib-study-in-patients-with-advanced-cancers-o-argx-20170707monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-second-preclinical-milestone-payment-in-collaboration-with-leo-pharma-argx-20170620monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presents-update-on-phase-i-data-from-argx-110-expansion-study-in-patients-with-cuta-argx-20170614monthly0.5https://www.biopharmawatch.com/news/ARGX/regulated-information-inside-information-argenx-announces-full-exercise-of-underwriters-op-argx-20170517monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-akinc-investors-and-media-1-617-682-4340-josh-brodsk-alny-20260111monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-akinc-investors-and-media-617-682-4340-josh-brodsky--alny-20251203monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-announces-proposed-offering-of-500-million-convertible-senior-notes-alny-20250908monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-akinc-investors-and-media-1-617-682-4340-josh-brodsk-alny-20250618monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20250305monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20250112monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-hi-alny-20240215monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20240107monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2023-financial-results-and-highlights-recent-alny-20231102monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-1-617-682-4340--alny-20231009monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20230803monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-1-617-682-4340--alny-20230724monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-1-617-682-4340--alny-20230630monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2023-financial-results-and-highlights-recent-alny-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-hi-alny-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-202301082023-01-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-1-617-682-4340--alny-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2022-financial-results-and-highlights-recent-alny-20221027monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-1-617-682-4340--alny-20220912monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-second-quarter-2022-financial-results-and-highlights-recen-alny-20220728monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20220614monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2022-financial-results-and-highlights-recent-alny-20220428monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20220405monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-hi-alny-20220210monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20220109monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20220104monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20211028monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20210803monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2021-financial-results-and-highlights-recent-alny-20210429monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-hi-alny-20210211monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20210110monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2020-financial-results-and-highlights-recent-alny-20201105monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-second-quarter-2020-financial-results-and-highlights-recen-alny-20200806monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2020-financial-results-and-highlights-recent-alny-20200506monthly0.5https://www.biopharmawatch.com/news/ALNY/blackstone-and-alnylam-enter-into-2-billion-strategic-financing-collaboration-to-accelerat-alny-20200413monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-1-617-682-4340--alny-20200406monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and-hi-alny-20200206monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20200112monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20191120monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2019-financial-results-and-highlights-recent-alny-20191031monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-second-quarter-2019-financial-results-and-highlights-recen-alny-20190806monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20190711monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2019-financial-results-and-highlights-recent-alny-20190501monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20190408monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-hi-alny-20190207monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20190114monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20190107monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2018-financial-results-and-highlights-recent-alny-20181107monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20180810monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-second-quarter-2018-financial-results-and-highlights-recen-alny-20180802monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2018-financial-results-and-highlights-recent-alny-20180503monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20180420monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results-and-hi-alny-20180208monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20180107monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20171113monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2017-financial-results-and-highlights-recent-alny-20171107monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20170907monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-second-quarter-2017-financial-results-and-highlights-recen-alny-20170809monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20170524monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20170509monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2017-financial-results-and-highlights-recent-alny-20170505monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2016-financial-results-and-hi-alny-20170208monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2016-financial-results-and-highlights-recent-alny-20161102monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20161005monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20160919monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-second-quarter-2016-financial-results-and-highlights-recen-alny-20160804monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2016-financial-results-and-highlights-recent-alny-20160502monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2015-financial-results-and-hi-alny-20160211monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-christine-regan-lindenboom-investors-and-media-617-682-4340-jo-alny-20160111monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2015-financial-results-and-highlights-from-r-alny-20151109monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-second-quarter-2015-financial-results-and-highlights-recen-alny-20150806monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-michael-mason-vice-president-finance-and-treasurer-617-551-832-alny-20150608monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-first-quarter-2015-financial-results-and-highlights-recent-alny-20150507monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2014-financial-results-and-hi-alny-20150212monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-cynthia-clayton-vice-president-investor-relations-and-corporat-alny-20150120monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-inc-cynthia-clayton-vice-president-investor-relations-and-corporat-alny-20150108monthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-reports-third-quarter-2014-financial-results-and-highlights-recent-alny-20141105monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-enters-into-2-billion-flexible-funding-agreement-with-royalty-pharma--rvmd-20250624monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-first-quarter-2025-financial-results-and-update-on-corporate--rvmd-20250507monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-fourth-quarter-and-full-year-2024-financial-results-and-updat-rvmd-20250226monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-third-quarter-2024-financial-results-and-update-on-corporate--rvmd-20241106monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-second-quarter-2024-financial-results-and-update-on-corporate-rvmd-20240807monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-first-quarter-2024-financial-results-and-update-on-corporate--rvmd-20240508monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-fourth-quarter-and-full-year-2023-financial-results-and-updat-rvmd-20240226monthly0.5https://www.biopharmawatch.com/news/RVMD/on-target-to-outsmart-cancer-rvmd-20240109monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-third-quarter-2023-financial-results-and-update-on-corporate--rvmd-20231106monthly0.5https://www.biopharmawatch.com/news/RVMD/leading-independent-proxy-advisory-firms-iss-and-glass-lewis-recommend-revolution-medicine-rvmd-20231101monthly0.5https://www.biopharmawatch.com/news/RVMD/on-target-to-outsmart-cancer-rvmd-20231022monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-second-quarter-2023-financial-results-and-update-on-corporate-rvmd-20230808monthly0.5https://www.biopharmawatch.com/news/RVMD/form-of-parent-stockholder-voting-agreement-this-voting-agreement-this-agreement-is-made-a-rvmd-20230731monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-first-quarter-2023-financial-results-and-update-on-corporate--rvmd-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-fourth-quarter-and-full-year-2022-financial-results-and-updat-rvmd-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/on-target-to-outsmart-cancer-tm-rvmd-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-third-quarter-2022-financial-results-and-update-on-corporate--rvmd-20221107monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-second-quarter-2022-financial-results-and-update-on-corporate-rvmd-20220809monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-first-quarter-2022-financial-results-and-update-on-corporate--rvmd-20220509monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-fourth-quarter-and-year-end-2021-financial-results-and-update-rvmd-20220228monthly0.5https://www.biopharmawatch.com/news/RVMD/on-target-to-outsmart-cancertm-legal-disclaimer-this-presentation-contains-forward-looking-rvmd-20220111monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-third-quarter-financial-results-and-update-on-corporate-progr-rvmd-20211110monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-second-quarter-financial-results-and-update-on-corporate-prog-rvmd-20210811monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-first-quarter-financial-results-and-update-on-corporate-progr-rvmd-20210510monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-fourth-quarter-and-year-end-2020-financial-results-and-update-rvmd-20210302monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-third-quarter-2020-financial-results-and-update-on-corporate--rvmd-20201112monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-second-quarter-2020-financial-results-and-provides-update-on--rvmd-20200810monthly0.5https://www.biopharmawatch.com/news/RVMD/legal-disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning--rvmd-20200622monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-first-quarter-2020-financial-results-and-continued-corporate--rvmd-20200514monthly0.5https://www.biopharmawatch.com/news/A/agilent-names-michael-buckner-as-chief-legal-officer-a-20260504monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-fourth-quarter-fiscal-year-2025-financial-results-delivers-solid-results-i-a-20251124monthly0.5https://www.biopharmawatch.com/news/A/agilent-names-adam-s-elinoff-as-chief-financial-officer-a-20251027monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2025-financial-results-agilent-delivers-strong-r-a-20250827monthly0.5https://www.biopharmawatch.com/news/A/agilent-announces-cfo-transition-a-20250715monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-second-quarter-fiscal-year-2025-financial-results-agilent-delivers-strong--a-20250528monthly0.5https://www.biopharmawatch.com/news/A/pascal-soriot-and-judy-gawlik-brown-named-to-agilent-board-of-directors-global-life-scienc-a-20250521monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-first-quarter-fiscal-year-2025-financial-results-delivers-solid-q1-results-a-20250226monthly0.5https://www.biopharmawatch.com/news/A/document-agilent-technologies-inc-life-sciences-and-diagnostics-markets-segment-unaudited--a-20241213monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-fourth-quarter-fiscal-year-2024-financial-results-delivers-solid-results-i-a-20241125monthly0.5https://www.biopharmawatch.com/news/A/agilent-announces-new-organizational-structure-to-support-its-market-focused-strategy-a-20241125monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2024-financial-results-delivers-better-than-expe-a-20240821monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-second-quarter-fiscal-year-2024-financial-results-full-year-outlook-revise-a-20240529monthly0.5https://www.biopharmawatch.com/news/A/agilent-announces-hans-e-bishop-has-stepped-down-from-board-of-directors-a-20240523monthly0.5https://www.biopharmawatch.com/news/A/padraig-mcdonnell-assumes-agilent-ceo-role-a-20240501monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-first-quarter-fiscal-year-2024-financial-results-revenue-and-earnings-exce-a-20240227monthly0.5https://www.biopharmawatch.com/news/A/ceo-he-led-agilent-s-transformation-into-a-market-leading-life-sciences-and-diagnostics-co-a-20240221monthly0.5https://www.biopharmawatch.com/news/A/document-agilent-technologies-inc-life-sciences-and-applied-markets-segment-unaudited-all--a-20240105monthly0.5https://www.biopharmawatch.com/news/A/agilent-makes-strategic-updates-to-organizational-structure-a-20231220monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-fourth-quarter-fiscal-year-2023-financial-results-revenue-at-the-high-end--a-20231120monthly0.5https://www.biopharmawatch.com/news/A/agilent-names-philip-binns-to-lead-life-sciences-and-applied-markets-group-a-20230905monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2023-financial-results-delivers-on-q3-adjusts-fu-a-20230815monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-second-quarter-fiscal-year-2023-financial-results-delivers-solid-results-a-a-20230523monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-first-quarter-fiscal-year-2023-financial-results-delivers-excellent-start--a-202302282023-02-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-authorizes-2-billion-share-repurchase-program-a-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-fourth-quarter-and-fiscal-year-2022-financial-results-outstanding-fourth-q-a-20221121monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2022-financial-results-delivers-excellent-result-a-20220816monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-second-quarter-fiscal-year-2022-financial-results-delivers-solid-results-i-a-20220524monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-first-quarter-fiscal-year-2022-financial-results-strong-start-to-2022-rais-a-20220222monthly0.5https://www.biopharmawatch.com/news/A/document-agilent-technologies-inc-life-sciences-and-applied-markets-segment-unaudited-all--a-20220105monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-fourth-quarter-and-fiscal-year-2021-financial-results-fourth-quarter-caps--a-20211122monthly0.5https://www.biopharmawatch.com/news/A/dr-otis-brawley-named-to-agilent-board-of-directors-leading-authority-on-cancer-research-j-a-20211118monthly0.5https://www.biopharmawatch.com/news/A/dr-mikael-dolsten-named-to-agilent-board-of-directors-pfizer-executive-brings-strong-scien-a-20210923monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2021-financial-results-delivers-very-strong-resu-a-20210817monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-second-quarter-fiscal-year-2021-financial-results-delivers-strong-broad-ba-a-20210525monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-announces-pricing-of-850-million-of-senior-notes-a-20210303monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-first-quarter-fiscal-year-2021-financial-results-strong-start-to-2021-rais-a-20210216monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-fourth-quarter-and-fiscal-year-2020-financial-results-initiates-fiscal-202-a-20201123monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2020-financial-results-highlights-revenue-of-1-2-a-20200818monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-announces-pricing-of-500-million-of-senior-notes-a-20200601monthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-second-quarter-fiscal-year-2020-financial-results-highlights-revenue-of-1--a-20200521monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-provides-update-on-covid-19-impact-sets-second-quarter-earnings-call--a-20200414monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-to-adjourn-annual-meeting-until-a-20200318monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-first-quarter-fiscal-year-2020-financial-results-highlights-r-a-20200218monthly0.5https://www.biopharmawatch.com/news/A/agilent-announces-crosslab-group-leadership-transition-mark-doak-to-retire-may-1-padraig-m-a-20200123monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-fourth-quarter-and-fiscal-year-2019-financial-results-highlig-a-20191125monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-announces-pricing-of-500-million-of-senior-notes-a-20190905monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-third-quarter-fiscal-year-2019-financial-results-highlights-r-a-20190814monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-second-quarter-fiscal-year-2019-financial-results-highlights--a-20190514monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-first-quarter-fiscal-year-2019-financial-results-strong-start-a-20190220monthly0.5https://www.biopharmawatch.com/news/A/exhibit-agilent-technologies-inc-condensed-consolidated-statement-of-operations-in-million-a-20190125monthly0.5https://www.biopharmawatch.com/news/A/mala-anand-to-join-agilent-s-board-of-directors-sap-se-executive-brings-deep-knowledge-of--a-20190116monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-fourth-quarter-fiscal-year-2018-financial-results-agilent-del-a-20181119monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-third-quarter-fiscal-year-2018-financial-results-company-tops-a-20180814monthly0.5https://www.biopharmawatch.com/news/A/agilent-announces-cfo-transition-didier-hirsch-to-retire-oct-31-robert-w-mcmahon-to-become-a-20180731monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-inc-life-sciences-and-applied-markets-group-unaudited-in-millions-exc-a-20180718monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-second-quarter-fiscal-year-2018-financial-results-strong-quar-a-20180514monthly0.5https://www.biopharmawatch.com/news/A/agilent-announces-departure-of-patrick-kaltenbach-a-20180416monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-first-quarter-fiscal-year-2018-financial-results-excellent-st-a-20180214monthly0.5https://www.biopharmawatch.com/news/A/dow-r-wilson-to-join-agilent-s-board-of-directors-ceo-of-varian-medical-systems-brings-dee-a-20180118monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-fourth-quarter-fiscal-year-2017-financial-results-agilent-cap-a-20171120monthly0.5https://www.biopharmawatch.com/news/A/investor-contact-alicia-rodriguez-1-408-345-8948-alicia-rodriguez-agilent-com-editorial-co-a-20170815monthly0.5https://www.biopharmawatch.com/news/A/hans-e-bishop-to-join-agilent-s-board-of-directors-ceo-of-juno-therapeutics-brings-deep-kn-a-20170718monthly0.5https://www.biopharmawatch.com/news/A/investor-contact-alicia-rodriguez-1-408-345-8948-alicia-rodriguez-agilent-com-editorial-co-a-20170522monthly0.5https://www.biopharmawatch.com/news/A/agilent-technologies-reports-first-quarter-2017-results-strong-start-to-2017-increasing-co-a-20170214monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20260520monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-first-quarter-2026-results-revenue-of-2-3-billion-growing-3-and-net-incom-zts-20260507monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20260205monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20251211monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-third-quarter-2025-results-reports-revenue-of-2-4-billion-growing-1-and-n-zts-20251104monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20251028monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20251009monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-second-quarter-2025-results-raises-full-year-2025-outlook-reports-revenue-zts-20250805monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20250522monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-first-quarter-2025-results-reports-revenue-of-2-2-billion-growing-1-and-n-zts-20250506monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-reports-fourth-quarter-and-full-year-2024-results-reports-revenue-of-2-3-billion-gr-zts-20250213monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-973-945-4333-o-1-973-822-7141-o-jennifer-a-zts-20250206monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-973-945-4333-o-1-973-822-7141-o-jennifer-a-zts-20241212monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20241111monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-third-quarter-2024-results-reports-revenue-of-2-4-billion-growing-11-and--zts-20241104monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20241010monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-second-quarter-2024-results-reports-revenue-of-2-4-billion-growing-8-and--zts-20240806monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jennifer-albano-steve-frank-1-862-399-0810-o-1-973-822-7141-o-jennifer-a-zts-20240801monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jenielle-alonso-steve-frank-1-973-945-4333-o-1-973-822-7141-o-jenielle-a-zts-20240522monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-first-quarter-2024-results-reports-revenue-of-2-2-billion-growing-10-and--zts-20240502monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jenielle-alonso-steve-frank-1-973-945-4333-o-1-973-822-7141-o-jenielle-a-zts-20240401monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-reports-fourth-quarter-and-full-year-2023-results-for-fourth-quarter-2023-zoetis-re-zts-20240213monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-jenielle-alonso-steve-frank-1-973-945-9333-o-1-973-822-7141-o-jenielle-a-zts-20240206monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-bill-price-steve-frank-1-973-443-2742-o-1-973-822-7141-o-william-price-z-zts-20231207monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-third-quarter-2023-results-reports-revenue-of-2-2-billion-growing-7-and-n-zts-20231102monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-bill-price-steve-frank-1-973-443-2742-o-1-973-822-7141-o-william-price-z-zts-20231012monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-second-quarter-2023-results-reports-revenue-of-2-2-billion-growing-6-and--zts-20230808monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-bill-price-steve-frank-1-973-443-2742-o-1-973-822-7141-o-william-price-z-zts-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-first-quarter-2023-results-reports-revenue-of-2-0-billion-growing-1-and-n-zts-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-reports-fourth-quarter-and-full-year-2022-results-for-fourth-quarter-2022-zoetis-re-zts-202302142023-02-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-bill-price-steve-frank-1-973-443-2742-o-1-973-822-7141-o-william-price-z-zts-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-bill-price-steve-frank-1-973-443-2742-o-1-973-822-7141-o-william-price-z-zts-20221208monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-third-quarter-2022-results-reports-revenue-of-2-0-billion-growing-1-and-n-zts-20221103monthly0.5https://www.biopharmawatch.com/news/ZTS/document-media-contacts-investor-contacts-bill-price-steve-frank-1-973-443-2742-o-1-973-82-zts-20221013monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-second-quarter-2022-results-reports-revenue-of-2-1-billion-growing-5-and--zts-20220804monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-first-quarter-2022-results-reports-revenue-of-2-0-billion-growing-6-and-n-zts-20220505monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-reports-fourth-quarter-and-full-year-2021-results-for-fourth-quarter-2021-zoetis-re-zts-20220215monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-third-quarter-2021-results-reports-revenue-of-2-0-billion-growing-11-and--zts-20211104monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-bill-price-steve-frank-1-973-443-2742-o-1-973-822-7141-o-william-price-z-zts-20211018monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-second-quarter-2021-results-reports-revenue-of-1-9-billion-growing-26-and-zts-20210805monthly0.5https://www.biopharmawatch.com/news/ZTS/investor-contacts-bill-price-steve-frank-1-973-443-2742-o-1-973-822-7141-o-william-price-z-zts-20210511monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-first-quarter-2021-results-reports-revenue-of-1-9-billion-growing-22-and--zts-20210506monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-reports-fourth-quarter-and-full-year-2020-results-for-fourth-quarter-2020-zoetis-re-zts-20210216monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-third-quarter-2020-results-reports-revenue-of-1-8-billion-growing-13-and--zts-20201105monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-second-quarter-2020-results-reports-flat-revenue-of-1-5-billion-and-net-i-zts-20200806monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-announces-first-quarter-2020-results-reports-revenue-of-1-5-billion-growing-5-and-n-zts-20200506monthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-reports-fourth-quarter-and-full-year-2019-results-for-fourth-quarter-2019-zoetis-re-zts-20200213monthly0.5https://www.biopharmawatch.com/news/ZTS/underlying-assumptions-prove-to-be-incorrect-actual-results-may-differ-materially-from-tho-zts-20200211monthly0.5https://www.biopharmawatch.com/news/RPRX/henry-fernandez-steps-down-from-royalty-pharma-s-rprx-20250813monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-second-quarter-2025-results-portfolio-receipts-growth-of-20-to-727--rprx-20250806monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-appoints-carole-ho-and-elizabeth-weatherman-to-the-company-s-board-of-direc-rprx-20250717monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-first-quarter-2025-results-portfolio-receipts-growth-of-17-to-839-m-rprx-20250508monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-appoints-vlad-coric-m-d-to-the-company-s-rprx-20250408monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-q4-and-full-year-2024-results-portfolio-receipts-of-742-million-in--rprx-20250211monthly0.5https://www.biopharmawatch.com/news/RPRX/j-p-morgan-healthcare-conference-january-2025-2-forward-looking-statements-this-presentati-rprx-20250113monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-announces-transformative-step-in-company-s-evolution-with-acquisition-of-it-rprx-20250110monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-to-highlight-accomplishments-and-provide-business-update-at-43rd-annual-j-p-rprx-20250110monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-third-quarter-2024-results-portfolio-receipts-growth-of-15-to-735-m-rprx-20241106monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-second-quarter-2024-results-portfolio-receipts-growth-of-12-to-608--rprx-20240808monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-first-quarter-2024-results-royalty-receipts-growth-of-14-driving-po-rprx-20240509monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-highlights-accomplishments-and-provides-business-update-at-42nd-annual-j-p--rprx-20240108monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-raises-full-year-2023-guidance-royalty-pharma-now-expects-2023-adjusted-cas-rprx-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-highlights-accomplishments-and-provides-business-update-at-41st-annual-j-p--rprx-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-agrees-to-acquire-royalty-interest-in-trelegy-ellipta-from-theravance-and-i-rprx-20220713monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-investor-day-highlights-stronger-growth-outlook-and-the-power-of-its-unique-rprx-20220517monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-highlights-accomplishments-and-provides-business-update-at-40th-annual-j-p--rprx-20220110monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-announces-2-025-billion-strategic-funding-partnership-with-morphosys-royalt-rprx-20210602monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-q4-2020-and-full-year-results-double-digit-growth-in-net-cash-provi-rprx-20210217monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-third-quarter-2020-results-double-digit-growth-in-net-cash-provided-rprx-20201110monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-announces-closing-of-6-0-rprx-20200902monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-announces-launch-of-senior-notes-offering-new-york-ny-rprx-20200819monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-reports-second-quarter-2020-results-strong-double-digit-growth-in-net-cash--rprx-20200812monthly0.5https://www.biopharmawatch.com/news/RPRX/royalty-pharma-appoints-henry-a-fernandez-and-ted-w-love-m-d-to-the-company-s-board-of-dir-rprx-20200803monthly0.5https://www.biopharmawatch.com/news/RPRX/pre-quarterly-results-communication-new-york-ny-us-rprx-20200714monthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-technologies-inc-prices-secondary-offering-of-13-281-302-shares-gehc-20241107monthly0.5https://www.biopharmawatch.com/news/GEHC/are-supplemental-measures-of-our-performance-that-we-believe-will-help-investors-understan-gehc-20241030monthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-technologies-inc-prices-upsized-secondary-offering-of-15-000-000-shares-gehc-20240912monthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-technologies-inc-prices-upsized-secondary-offering-of-14-000-000-shares-gehc-20240312monthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-technologies-inc-commences-secondary-offering-of-13-000-000-shares-gehc-20240215monthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-names-james-saccaro-vice-president-and-chief-financial-officer-chicago-il-gehc-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/forward-looking-statements-this-release-contains-forward-looking-statements-these-forward--gehc-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-completes-spin-off-and-begins-trading-on-nasdaq-a-leader-in-precision-care-f-gehc-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-3448-waters-corporation-nyse-wat-reports-f-wat-20260505monthly0.5https://www.biopharmawatch.com/news/WAT/index-to-condensed-combined-financial-statements-item-page-condensed-combined-statements-o-wat-20260316monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-3448-waters-corporation-nyse-wat-reports-f-wat-20260209monthly0.5https://www.biopharmawatch.com/news/WAT/forward-looking-statements-non-gaap-financial-measures-forward-looking-statements-this-pre-wat-20260112monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-3448-waters-corporation-nyse-wat-reports-t-wat-20251104monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-3448-waters-corporation-nyse-wat-reports-s-wat-20250804monthly0.5https://www.biopharmawatch.com/news/WAT/waters-and-bd-s-biosciences-diagnostic-solutions-business-to-combine-creating-a-life-scien-wat-20250714monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-f-wat-20250506monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-f-wat-20250212monthly0.5https://www.biopharmawatch.com/news/WAT/j-p-morgan-43rd-annual-healthcare-conference-udit-batra-ph-d-president-ceo-wat-20250113monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-t-wat-20241101monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-appoints-heather-knight-to-board-of-directors-wat-20240814monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-s-wat-20240731monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-f-wat-20240507monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-f-wat-20240206monthly0.5https://www.biopharmawatch.com/news/WAT/j-p-morgan-42nd-annual-healthcare-conference-udit-batra-ph-d-president-ceo-wat-20240108monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-t-wat-20231107monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-announces-business-unit-leadership-transition-jonathan-pratt-to-step-do-wat-20231024monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-s-wat-20230802monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-completes-acquisition-of-light-scattering-leader-wyatt-technology-milfo-wat-202305162023-05-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-f-wat-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-appoints-richard-fearon-to-board-of-directors-wat-202303282023-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-f-wat-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/j-p-morgan-41st-annual-healthcare-conference-udit-batra-ph-d-president-ceo-wat-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-appoints-dan-brennan-and-mark-vergnano-to-board-of-directors-wat-20221123monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-t-wat-20221101monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-head-of-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports-s-wat-20220802monthly0.5https://www.biopharmawatch.com/news/WAT/analyst-investor-day-wat-20220519monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-director-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports--wat-20220503monthly0.5https://www.biopharmawatch.com/news/WAT/caspar-tudor-director-investor-relations-508-482-2429-waters-corporation-nyse-wat-reports--wat-20220201monthly0.5https://www.biopharmawatch.com/news/WAT/this-presentation-contains-forward-looking-statements-regarding-future-results-and-events--wat-20220110monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-508-482-2314-caspar-tudor-manager-investor-relations-5-wat-20211102monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-appoints-john-m-ballbach-to-board-of-directors-dr-michael-j-berendt-to--wat-20211006monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-508-482-2314-caspar-tudor-manager-investor-relations-5-wat-20210803monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-appoints-wei-jiang-to-board-of-directors-wat-20210624monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20210505monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-continues-transformation-with-planned-leadership-transitions-news-summa-wat-20210421monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20210202monthly0.5https://www.biopharmawatch.com/news/WAT/this-presentation-may-contain-forward-looking-statements-regarding-future-results-and-even-wat-20210112monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-appoints-pearl-s-huang-to-board-of-directors-wat-20201210monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-announces-cfo-transition-sherry-buck-to-step-down-as-wat-20201203monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20201027monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20200728monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-names-udit-batra-president-and-chief-executive-officer-announces-prelim-wat-20200715monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-announces-ceo-succession-plan-wat-20200617monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20200428monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20200204monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20191029monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20190730monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20190423monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20190123monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20181023monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20180724monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20180424monthly0.5https://www.biopharmawatch.com/news/WAT/bryan-brokmeier-cfa-senior-director-investor-relations-508-482-3448-waters-corporation-nys-wat-20180123monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-corporation-wat-20171024monthly0.5https://www.biopharmawatch.com/news/WAT/doug-berthiaume-to-retire-as-chairman-of-the-board-of-waters-corporation-chris-o-connell-e-wat-20171019monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-corporation-wat-20170725monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-corporation-wat-20170425monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-fou-wat-20170124monthly0.5https://www.biopharmawatch.com/news/WAT/john-e-lynch-vice-president-of-investor-relations-508-482-2314-waters-corporation-announce-wat-20161208monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-thi-wat-20161025monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-sec-wat-20160726monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-fir-wat-20160426monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-fou-wat-20160126monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-expands-executive-team-waters-division-president-to-retire-key-leaders--wat-20160125monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-thi-wat-20151027monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-sec-wat-20150728monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-announces-christopher-j-o-connell-as-chief-executive-officer-milford-ma-wat-20150625monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-fir-wat-20150428monthly0.5https://www.biopharmawatch.com/news/WAT/john-lynch-vice-president-treasurer-and-investor-relations-508-482-2314-waters-reports-fou-wat-20150126monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-salli-schwartz-brad-lotterman-salli-schwartz-resmed-com-brad-lotte-rmd-20260430monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-221-3304-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20260430monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-221-3304-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20260129monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-221-3304-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20251030monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5971-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20250818monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20250731monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20250423monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20250130monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20241024monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5971-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20240815monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20240801monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20240425monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-619-510-1281-investorrelations-resmed-com-news-re-rmd-20240124monthly0.5https://www.biopharmawatch.com/news/RMD/for-media-1-858-836-6798-news-resmed-com-for-investors-1-858-836-5000-investorrelations-re-rmd-20231109monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-858-289-7272-investorrelations-resmed-com-news-re-rmd-20231026monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-1-858-836-5000-1-858-289-7272-investorrelations-resmed-com-news-re-rmd-20230803monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-1-858-836-5000-investorrelations-resmed-com-for-media-1-858-836-6798-news-re-rmd-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/for-media-for-investors-news-resmed-com-investorrelations-resmed-com-1-858-836-6798-1-858--rmd-202303302023-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-202301262023-01-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20221027monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20220811monthly0.5https://www.biopharmawatch.com/news/RMD/for-media-for-investors-jayme-rubenstein-amy-wakeham-1-858-836-6798-1-858-836-5000-news-re-rmd-20220628monthly0.5https://www.biopharmawatch.com/news/RMD/for-media-for-media-jayme-rubenstein-laura-willig-1-858-836-6798-49-51-21-28-29-1-808-news-rmd-20220614monthly0.5https://www.biopharmawatch.com/news/RMD/for-media-for-investors-jayme-rubenstein-amy-wakeham-1-858-836-6798-1-858-836-5000-news-re-rmd-20220505monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20220428monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20220127monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20211028monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20210805monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20210429monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20210128monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20201029monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20200805monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20200430monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20200130monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20191024monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20190725monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20190502monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-for-media-amy-wakeham-jayme-rubenstein-1-858-836-5000-1-858-836-6798-investo-rmd-20190124monthly0.5https://www.biopharmawatch.com/news/RMD/for-media-jayme-rubenstein-1-858-836-6798-news-resmed-com-for-investors-amy-wakeham-1-858--rmd-20181114monthly0.5https://www.biopharmawatch.com/news/RMD/for-media-for-investors-jayme-rubenstein-amy-wakeham-1-858-836-6798-1-858-836-5000-news-re-rmd-20181105monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-amy-wakeham-o-858-836-5000-investorrelations-resmed-com-for-media-jayme-rube-rmd-20181025monthly0.5https://www.biopharmawatch.com/news/RMD/for-investors-amy-wakeham-o-858-836-5000-investorrelations-resmed-com-for-media-jayme-rube-rmd-20180802monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-announces-strong-preliminary-fourth-quarter-and-2025-financial-results-driven-by-re-ntra-20260113monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-acquires-foresight-diagnostics-ntra-20251205monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-third-quarter-2025-financial-results-ntra-20251106monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-second-quarter-2025-financial-results-ntra-20250807monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-first-quarter-2025-financial-results-ntra-20250508monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-fourth-quarter-and-full-year-2024-financial-results-ntra-20250227monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-announces-preliminary-fourth-quarter-and-full-year-results-for-2024-2024-revenues-a-ntra-20250115monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-third-quarter-2024-financial-results-ntra-20241112monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-second-quarter-2024-financial-results-ntra-20240808monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-first-quarter-2024-financial-results-ntra-20240509monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-fourth-quarter-and-full-year-2023-financial-results-ntra-20240228monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-acquires-reproductive-health-assets-from-invitae-ntra-20240122monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-announces-preliminary-fourth-quarter-and-full-year-2023-revenues-2023-revenues-are--ntra-20240109monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-third-quarter-2023-financial-results-ntra-20231108monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-launches-proposed-follow-on-offering-ntra-20230906monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-second-quarter-2023-financial-results-ntra-20230803monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-first-quarter-2023-financial-results-ntra-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-fourth-quarter-and-full-year-2022-financial-results-ntra-202302282023-02-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-launches-proposed-follow-on-offering-ntra-20221115monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-third-quarter-2022-financial-results-ntra-20221108monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-second-quarter-2022-financial-results-ntra-20220804monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-first-quarter-2022-financial-results-ntra-20220505monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-executives-and-board-to-take-pay-in-stock-instead-of-cash-leadership-board-to-excha-ntra-20220314monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-fourth-quarter-and-full-year-2021-financial-results-ntra-20220224monthly0.5https://www.biopharmawatch.com/news/NTRA/natera-reports-third-quarter-2021-financial-results-ntra-20211104monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-first-quarter-2026-financial-results-silver-spring-uthr-20260506monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-announces-2-billion-stock-repurchase-authorization-and-ent-uthr-20260309monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2025-financial-result-uthr-20260225monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-record-third-quarter-2025-financial-results-silver-uthr-20251029monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-announces-teton-2-pivotal-study-of-tyvaso-meets-primary-en-uthr-20250902monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-announces-1-billion-accelerated-share-repurchase-program-r-uthr-20250801monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-record-second-quarter-2025-financial-results-recor-uthr-20250730monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-first-quarter-2025-financial-results-silver-spring-uthr-20250430monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2024-financial-result-uthr-20250226monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-enabling-inspiration-j-p-morgan-healthcare-conference-january-13-2025--uthr-20250113monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-third-quarter-2024-financial-results-silver-spring-uthr-20241030monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-second-quarter-2024-financial-results-silver-sprin-uthr-20240731monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-announces-election-of-jan-malcolm-to-its-board-of-director-uthr-20240627monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-first-quarter-2024-financial-results-silver-spring-uthr-20240501monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-announces-1-billion-accelerated-share-repurchase-program-r-uthr-20240325monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2023-financial-result-uthr-20240221monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-third-quarter-2023-financial-results-silver-spring-uthr-20231101monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-second-quarter-2023-financial-results-silver-sprin-uthr-20230802monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-wins-appeal-in-dry-powder-inhaler-patent-litigation-silver-spring-md-a-uthr-20230724monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-first-quarter-2023-financial-results-silver-spring-uthr-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2022-financial-result-uthr-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/uthr-a-public-benefit-corporation-january-2023-1-united-therapeutics-enabling-inspiration--uthr-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/dewey-steadman-phone-202-919-4097-email-ir-unither-com-united-therapeutics-corporation-rep-uthr-20221102monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-announces-first-patient-enrolled-in-phase-3-teton-2-study-of-tyvaso-in-uthr-20221011monthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-prevails-in-dry-powder-inhaler-patent-litigation-silver-spring-md-and-uthr-20220831monthly0.5https://www.biopharmawatch.com/news/UTHR/dewey-steadman-phone-202-919-4097-email-ir-unither-com-united-therapeutics-corporation-rep-uthr-20220803monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20260429monthly0.5https://www.biopharmawatch.com/news/BIIB/tender-and-support-agreement-this-tender-and-support-agreement-this-agreement-dated-as-of-biib-20260331monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20260206monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20251030monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20250731monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20250501monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20250212monthly0.5https://www.biopharmawatch.com/news/BIIB/michael-mcdonnell-executive-vice-president-and-chief-financial-officer-to-retire-in-februa-biib-20241028monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20241030monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20240801monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20240424monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20240213monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20231108monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-completes-acquisition-of-reata-pharmaceuticals-reata-acquisition-bolsters-biogen-s--biib-20230926monthly0.5https://www.biopharmawatch.com/news/BIIB/confidential-biib-20230728monthly0.5https://www.biopharmawatch.com/news/BIIB/document-press-release-cambridge-mass-biib-20230725monthly0.5https://www.biopharmawatch.com/news/BIIB/document-strong-progress-toward-three-potential-launches-in-2023-company-reports-first-qua-biib-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-advances-significant-potential-growth-drivers-company-reports-full-year-20-biib-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-names-christopher-viehbacher-president-and-chief-executive-officer-distinguished-in-biib-20221110monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-third-quarter-2022-results-third-quarter-revenue-2-508-million-gaa-biib-20221025monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-second-quarter-2022-results-second-quarter-revenue-2-589-million-g-biib-20220720monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-first-quarter-2022-results-first-quarter-revenue-2-532-million-gaa-biib-20220503monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-fourth-quarter-and-full-year-2021-results-revenue-fourth-quarter-2-biib-20220203monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-nancy-leaming-and-brian-posner-to-retire-from-board-of-directors-biib-20220131monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-alfred-w-sandrock-jr-to-retire-as-head-of-research-development-biib-20211115monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-third-quarter-2021-results-third-quarter-revenue-2-779-million-gaa-biib-20211020monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-second-quarter-2021-results-second-quarter-revenue-2-775-million-g-biib-20210722monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-first-quarter-2021-results-first-quarter-revenue-2-694-million-gaa-biib-20210422monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-announces-two-new-nominees-for-election-to-board-of-directors-nominees-bri-biib-20210409monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-private-exchange-offer-for-5-200-senior-notes-due-2045-open-to-certain-in-biib-20210204monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-fourth-quarter-and-full-year-2020-results-revenue-fourth-quarter-2-biib-20210203monthly0.5https://www.biopharmawatch.com/news/BIIB/document-biogen-reports-q3-2020-results-third-quarter-revenue-3-376-million-gaap-diluted-e-biib-20201021monthly0.5https://www.biopharmawatch.com/news/BIIB/other-financial-highlights-biib-20200722monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-names-michael-mcdonnell-as-executive-vice-president-and-chief-financial-officer-biib-20200721monthly0.5https://www.biopharmawatch.com/news/BIIB/other-financial-highlights-biib-20200422monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-matt-fearer-ph-1-781-464-3260-public-affairs-biogen-com-investor-contact-biogen-mat-biib-20171121monthly0.5https://www.biopharmawatch.com/news/BIIB/jason-glashow-1-781-464-3260-public-affairs-biogen-com-investor-contact-matt-calistri-1-61-biib-20170613monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-completes-separation-of-global-hemophilia-business-bioverativ-biib-20170201monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-media-contact-biogen-investor-contact-jason-glashow-matt-calistri-biogen-inc-biogen-biib-20170117monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-first-quarter-2026-financial-results-san-diego-business-wire-dxcm-20260430monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-appoints-rick-osterloh-to-board-of-directors-san-diego-business-wire-dxcm-20260226monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-fourth-quarter-and-fiscal-year-2025-financial-results-san-diego-business-wi-dxcm-20260212monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-enters-next-era-of-continued-innovation-with-jake-leach-as-president-and-chief-exec-dxcm-20260107monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-third-quarter-2025-financial-results-and-updates-full-year-2025-guidance-sa-dxcm-20251030monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-appoints-euan-ashley-to-board-of-directors-san-diego-business-wire-dxcm-20251027monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-second-quarter-2025-financial-results-updates-full-year-2025-guidance-and-a-dxcm-20250730monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-announces-promotion-of-jake-leach-to-the-expanded-role-of-president-and-coo-san-die-dxcm-20250513monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-first-quarter-2025-financial-results-and-announces-750-million-share-repurc-dxcm-20250501monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-appoints-ren-e-gal-to-board-of-directors-san-diego-business-wire-dxcm-20250310monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-fourth-quarter-and-fiscal-year-2024-financial-results-san-diego-business-wi-dxcm-20250213monthly0.5https://www.biopharmawatch.com/news/DXCM/dealer-name-and-address-may-2023-to-dexcom-inc-6340-sequence-drive-san-diego-ca-92121-atte-dxcm-202305052023-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-prices-upsized-offering-of-1-1-billion-of-0-375-convertible-senior-notes-due-2028-s-dxcm-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-announces-proposed-offering-of-1-0-billion-of-convertible-senior-notes-san-diego-ca-dxcm-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-preliminary-unaudited-revenue-for-the-fourth-quarter-2021-and-summary-data--dxcm-20220110monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-preliminary-unaudited-revenue-for-the-fourth-quarter-and-fiscal-year-2020-a-dxcm-20210111monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-announces-retirement-of-rick-doubleday-and-pre-announcement-of-third-quarter-2020-r-dxcm-20201026monthly0.5https://www.biopharmawatch.com/news/DXCM/document-dexcom-appoints-kyle-malady-to-board-of-directors-san-diego-business-wire-dxcm-20201013monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-appoints-karen-dahut-to-board-of-directors-san-diego-business-wire-dxcm-20200812monthly0.5https://www.biopharmawatch.com/news/DXCM/notice-of-full-redemption-dexcom-inc-dxcm-20200629monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-prices-offering-of-upsized-1-05-billion-of-0-25-convertible-senior-notes-san-diego--dxcm-20200512monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-announces-proposed-offering-of-850-0-million-of-convertible-senior-notes-san-diego--dxcm-20200511monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-record-preliminary-unaudited-revenue-for-the-fourth-quarter-and-fiscal-year-dxcm-20200113monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-appoints-bridgette-heller-to-board-of-directors-dxcm-20190917monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-reports-record-preliminary-unaudited-revenue-for-the-fourth-quarter-and-fiscal-year-dxcm-20190107monthly0.5https://www.biopharmawatch.com/news/DXCM/dealer-header-jpmorgan-chase-bank-national-association-london-branch-25-bank-street-canary-dxcm-20181127monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-prices-offering-of-750-0-million-of-0-75-convertible-senior-notes-san-diego-ca-busi-dxcm-20181128monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-announces-proposed-offering-of-750-million-of-convertible-senior-notes-san-diego-ca-dxcm-20181126monthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-inc-the-issuer-has-filed-a-registration-statement-including-a-prospectus-with-the-u-dxcm-20181120monthly0.5https://www.biopharmawatch.com/news/ONC/reconciliation-of-gaap-operating-income-guidance-to-non-gaap-operating-income-guidance-for-onc-20260506monthly0.5https://www.biopharmawatch.com/news/ONC/fourth-quarter-full-year-2025-2024-2025-2024-free-cash-flow-non-gaap-net-cash-provided-by--onc-20260226monthly0.5https://www.biopharmawatch.com/news/ONC/three-months-ended-september-30-nine-months-ended-onc-20251106monthly0.5https://www.biopharmawatch.com/news/ONC/three-months-ended-june-30-six-months-ended-onc-20250806monthly0.5https://www.biopharmawatch.com/news/ONC/reconciliation-of-gaap-to-adjusted-eps-basic-gaap-earnings-loss-per-share-basic-0-00-0-19--onc-20250507monthly0.5https://www.biopharmawatch.com/news/ONC/reconciliation-of-selected-gaap-measures-to-non-gaap-measures-amounts-in-thousands-of-u-s--onc-20250227monthly0.5https://www.biopharmawatch.com/news/ONC/reconciliation-of-selected-gaap-measures-to-non-gaap-measures-amounts-in-thousands-of-u-s--onc-20241112monthly0.5https://www.biopharmawatch.com/news/ONC/reconciliation-of-selected-gaap-measures-to-non-gaap-measures-in-thousands-except-per-shar-onc-20240807monthly0.5https://www.biopharmawatch.com/news/ONC/reconciliation-of-selected-gaap-measures-to-non-gaap-measures-in-thousands-except-per-shar-onc-20240508monthly0.5https://www.biopharmawatch.com/news/ONC/financial-information-on-onc-20240426monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-receives-european-commission-approval-for-tislelizumab-as-treatment-for-non-small--onc-20240423monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-receives-fda-approval-for-tevimbra-for-the-treatment-of-advanced-or-metastatic-eso-onc-20240314monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-oncology-company-that-is-discovering-and-developing-inno-onc-20240226monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-biotechnology-company-that-is-discovering-and-developing-onc-20231109monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-biotechnology-company-that-is-discovering-and-developing-onc-20230802monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-biotechnology-company-that-is-discovering-and-developing-onc-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-biotechnology-company-that-is-developing-and-commerciali-onc-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-biotechnology-company-that-is-developing-and-commerciali-onc-20221109monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment--onc-20221102monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-positive-topline-results-from-final-progression-free-survival-analysis-o-onc-20221012monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-receives-positive-chmp-opinion-for-brukinsa-zanubrutinib-for-the-treatment-of-adul-onc-20220919monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-data-presentations-at-esmo-2022-including-late-breaking-oral-presentatio-onc-20220910monthly0.5https://www.biopharmawatch.com/news/ONC/financial-information-on-onc-20220830monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-acceptance-of-11th-regulatory-submission-for-pd-1-inhibitor-tislelizumab-onc-20220823monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-positive-global-phase-3-trial-results-for-pd-1-inhibitor-tislelizumab-in-onc-20220809monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-biotechnology-company-that-is-developing-and-commerciali-onc-20220804monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-provides-regulatory-update-on-the-u-s-biologics-license-application-bla-for-pd-1-i-onc-20220714monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-late-breaking-data-at-esmo-gi-showing-overall-survival-benefit-for-tisle-onc-20220630monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-acceptance-of-supplemental-biologics-license-application-in-china-for-an-onc-20220621monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-highlights-growing-portfolio-and-pipeline-targeting-hematologic-malignancies-at-eu-onc-20220610monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-clinical-data-presentations-at-2022-asco-annual-meeting-demonstrate-mature-and-gro-onc-20220526monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-onc-20220505monthly0.5https://www.biopharmawatch.com/news/ONC/financial-information-on-onc-20220428monthly0.5https://www.biopharmawatch.com/news/ONC/china-nmpa-approves-tislelizumab-for-patients-with-second-line-esophageal-squamous-cell-ca-onc-20220420monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-european-medicines-agency-acceptance-of-marketing-authorization-applicat-onc-20220406monthly0.5https://www.biopharmawatch.com/news/ONC/china-nmpa-approves-tislelizumab-for-patients-with-microsatellite-instability-high-or-mism-onc-20220311monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-onc-20220225monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-european-medicines-agency-acceptance-of-applications-for-brukinsa-zanubr-onc-20220222monthly0.5https://www.biopharmawatch.com/news/ONC/drs-margaret-dugan-and-alessandro-riva-appointed-to-beigene-board-of-directors-industry-le-onc-20220201monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-acceptance-of-a-supplemental-new-drug-application-in-china-for-brukinsa--onc-20220120monthly0.5https://www.biopharmawatch.com/news/ONC/china-nmpa-approves-tislelizumab-as-second-or-third-line-treatment-for-patients-with-local-onc-20220110monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-expands-collaboration-with-novartis-to-develop-and-commercialize-beigene-s-tigit-i-onc-20211220monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-closing-of-its-rmb22-2-billion-us-3-5-billion-initial-public-offering-on-onc-20211215monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-presents-results-from-phase-3-trial-of-tislelizumab-in-nasopharyngeal-cancer-at-es-onc-20211210monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-pricing-of-its-rmb22-2-billion-us-3-5-billion-initial-public-offering-on-onc-20211206monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-launches-proposed-initial-public-offering-on-the-star-market-in-china-cambridge-ma-onc-20211123monthly0.5https://www.biopharmawatch.com/news/ONC/financial-information-beigene-ltd-the-company-previously-submitted-a-listing-application-f-onc-20211116monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-onc-20211104monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-and-nanolek-announce-approval-in-russia-for-brukinsa-zanubrutinib-for-treatment-of-onc-20211020monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-first-regulatory-approval-in-australia-for-brukinsa-zanubrutinib-for-tre-onc-20211007monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-receives-positive-chmp-opinion-for-brukinsa-zanubrutinib-for-the-treatment-of-adul-onc-20210917monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-u-s-fda-acceptance-of-biologics-license-application-for-tislelizumab-in--onc-20210913monthly0.5https://www.biopharmawatch.com/news/ONC/u-s-fda-grants-brukinsa-zanubrutinib-approval-in-waldenstr-m-s-macroglobulinemia-this-mark-onc-20210901monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for--onc-20210822monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-and-eusa-pharma-announce-china-nmpa-approval-of-qarziba-dinutuximab-beta-for-patie-onc-20210817monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-onc-20210805monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-approval-in-canada-of-brukinsa-zanubrutinib-for-the-treatment-of-patient-onc-20210726monthly0.5https://www.biopharmawatch.com/news/ONC/financial-information-beigene-ltd-the-company-previously-submitted-a-listing-application-f-onc-20210728monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for--onc-20210707monthly0.5https://www.biopharmawatch.com/news/ONC/financial-information-beigene-ltd-the-company-previously-submitted-a-listing-application-a-onc-20210630monthly0.5https://www.biopharmawatch.com/news/ONC/china-nmpa-approves-tislelizumab-in-non-small-cell-lung-cancer-and-hepatocellular-carcinom-onc-20210623monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-china-nmpa-approval-of-brukinsa-zanubrutinib-for-the-treatment-of-patien-onc-20210618monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-first-patient-dosed-in-global-phase-3-trial-of-anti-tigit-antibody-ocipe-onc-20210617monthly0.5https://www.biopharmawatch.com/news/ONC/shoreline-biosciences-and-beigene-announce-strategic-worldwide-collaboration-to-develop-an-onc-20210609monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-presents-clinical-data-from-two-pivotal-trials-of-tislelizumab-at-the-2021-asco-an-onc-20210604monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-u-s-fda-acceptance-and-priority-review-of-supplemental-new-drug-applicat-onc-20210519monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-ltd-the-company-previously-submitted-a-listing-application-the-listing-application-onc-20210514monthly0.5https://www.biopharmawatch.com/news/ONC/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated-advanced-onc-20210507monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-science-driven-biotechnology-company-focused-on-developi-onc-20210506monthly0.5https://www.biopharmawatch.com/news/ONC/brukinsa-zanubrutinib-demonstrates-superior-objective-response-rate-by-investigator-assess-onc-20210428monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-presents-clinical-data-on-sitravatinib-in-combination-with-tislelizumab-at-the-aac-onc-20210411monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-first-commercial-manufacturing-approval-for-its-state-of-the-art-biologi-onc-20210407monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-new-chief-financial-officer-julia-wang-current-cfo-and-chief-strategy-of-onc-20210330monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-initiates-phase-1-clinical-trial-for-hpk1-inhibitor-bgb-15025-cambridge-mass-beiji-onc-20210310monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for--onc-20210305monthly0.5https://www.biopharmawatch.com/news/ONC/health-canada-approves-brukinsa-zanubrutinib-for-the-treatment-of-waldenstr-m-s-macroglobu-onc-20210302monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-closing-of-collaboration-with-novartis-to-develop-and-commercialize-anti-onc-20210226monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-onc-20210225monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-u-s-fda-acceptance-of-supplemental-new-drug-application-for-brukinsa-zan-onc-20210217monthly0.5https://www.biopharmawatch.com/news/ONC/financial-information-beigene-ltd-the-company-submitted-a-listing-application-the-listing--onc-20210129monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-positive-topline-results-for-global-phase-3-trial-of-tislelizumab-in-eso-onc-20210127monthly0.5https://www.biopharmawatch.com/news/ONC/eusa-pharma-and-beigene-announce-acceptance-of-a-biologics-license-application-for-sylvant-onc-20210125monthly0.5https://www.biopharmawatch.com/news/ONC/china-national-medical-products-administration-approves-tislelizumab-in-combination-with-c-onc-20210113monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-collaboration-with-novartis-to-develop-and-commercialize-anti-pd-1-antib-onc-20210111monthly0.5https://www.biopharmawatch.com/news/ONC/disclosures-certain-statements-contained-in-this-presentation-and-in-the-accompanying-oral-onc-20210111monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-inclusion-of-three-innovative-oncology-products-in-china-national-reimbu-onc-20201227monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-data-on-brukinsa-zanubrutinib-from-phase-2-trial-in-marginal-zone-lympho-onc-20201206monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-launches-proposed-public-offering-by-selling-shareholders-cambridge-mass-and-beiji-onc-20201201monthly0.5https://www.biopharmawatch.com/news/ONC/document-beigene-announces-the-approval-of-xgeva-denosumab-in-china-for-the-prevention-of--onc-20201119monthly0.5https://www.biopharmawatch.com/news/ONC/document-beigene-announces-that-rationale-303-trial-of-tislelizumab-in-non-small-cell-lung-onc-20201117monthly0.5https://www.biopharmawatch.com/news/ONC/document-eusa-pharma-and-beigene-announce-acceptance-of-a-biologics-license-application-fo-onc-20201109monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-onc-20201105monthly0.5https://www.biopharmawatch.com/news/ONC/bioatla-and-beigene-revise-global-development-and-commercialization-agreement-for-novel-co-onc-20201006monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-acceptance-and-priority-review-by-health-canada-of-new-drug-submission-f-onc-20200909monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-onc-20200827monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-appoints-corsee-sanders-ph-d-to-its-board-of-directors-cambridge-mass-and-onc-20200825monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-onc-20200806monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-pricing-of-approximately-2-08-billion-registered-direct-offering-cambrid-onc-20200712monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-begins-commercializing-xgeva-denosumab-in-china-beijing-china-and-onc-20200630monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-european-medicines-agency-acceptance-of-its-marketing-authorization-appl-onc-20200618monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-biotechnology-company-focused-on-discov-onc-20200511monthly0.5https://www.biopharmawatch.com/news/ONC/exhibit-china-national-medical-products-administration-approves-beigene-s-tislelizumab-for-onc-20200410monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-supply-update-for-abraxane-in-china-onc-20200325monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-research-based-biotechnology-company-fo-onc-20200302monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-reports-third-quarter-2019-financial-results-onc-20191112monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-research-based-biotechnology-company-fo-onc-20190808monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-regains-full-global-rights-to-its-investigational-anti-pd-1-antibody-tislelizumab--onc-20190617monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-research-based-biotechnology-company-fo-onc-20190509monthly0.5https://www.biopharmawatch.com/news/ONC/about-beigene-beigene-is-a-global-commercial-stage-research-based-biotechnology-company-fo-onc-20190227monthly0.5https://www.biopharmawatch.com/news/ONC/corporate-presentation-january-6-2019-onc-20190107monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-announces-acceptance-of-new-drug-application-for-anti-pd-1-antibody-tislelizumab-i-onc-20180831monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-ltd-beigene-initiates-new-phase-3-trial-of-anti-pd-1-antibody-tislelizumab-combine-onc-20180809monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-ltd-beigene-announces-pricing-of-its-hk-7-08-billion-us-903-million-hong-kong-init-onc-20180802monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-ltd-beigene-announces-proposed-hong-kong-initial-public-offering-and-global-offeri-onc-20180727monthly0.5https://www.biopharmawatch.com/news/ONC/beigene-ltd-beigene-announces-plan-to-pursue-accelerated-approval-in-the-u-s-of-btk-inhibi-onc-20180722monthly0.5https://www.biopharmawatch.com/news/ONC/business-overview-we-are-a-commercial-stage-biotechnology-company-focused-on-developing-an-onc-20180720monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-launches-2026-global-employee-stock-purchase-plan-paris-sny-20260604monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-venglustat-accepted-for-priority-review-in-the-us-to-treat-type-3-gaucher-disease-sny-20260528monthly0.5https://www.biopharmawatch.com/news/SNY/ats-phase-2-data-demonstrate-the-superiority-of-efdoralprin-alfa-over-a-standard-of-care-a-sny-20260518monthly0.5https://www.biopharmawatch.com/news/SNY/annual-general-meeting-of-sny-20260429monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-2-3-billion-of-bond-issue-paris-sny-20260424monthly0.5https://www.biopharmawatch.com/news/SNY/escmid-sanofi-s-nuvaxovid-covid-19-vaccine-showed-better-tolerability-than-mnexspike-in-he-sny-20260418monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-sny-20260407monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-s-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat--sny-20260324monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-venglustat-earns-breakthrough-therapy-designation-in-the-us-for-type-3-gaucher-di-sny-20260318monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-rilzabrutinib-earns-orphan-drug-designation-in-japan-for-igg4-related-disease-des-sny-20260302monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-s-dupixent-approved-in-the-us-as-the-first-and-only-medicine-for-alle-sny-20260224monthly0.5https://www.biopharmawatch.com/news/SNY/beyfortus-study-published-in-the-lancet-infectious-diseases-shows-benefit-for-infants-beyo-sny-20260216monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-rilzabrutinib-designated-breakthrough-therapy-in-the-us-and-orphan-drug-in-japan--sny-20260209monthly0.5https://www.biopharmawatch.com/news/SNY/bel-n-garijo-to-become-chief-executive-officer-of-sanofi-paris-sny-20260212monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-completes-the-acquisition-of-dynavax-paris-sny-20260210monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-rezurock-recommended-for-eu-approval-by-the-chmp-to-treat-chronic-graft-vs-host-d-sny-20260130monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-amlitelimab-confirms-its-potential-in-atopic-dermatitis-in-the-shore-phase-3-stud-sny-20260123monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-teizeild-approved-in-the-eu-for-patients-with-stage-2-type-1-diabetes-approval-ba-sny-20260112monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-tzield-accepted-for-priority-review-in-the-us-for-young-children-with-stage-2-typ-sny-20260105monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-dynavax-adding-a-marketed-adult-hepatitis-b-vaccine-and-phase-1-2-shingl-sny-20251224monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-wayrilz-approved-in-the-eu-as-the-first-btk-inhibitor-to-treat-immune-thrombocyto-sny-20251223monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-provides-update-on-tolebrutinib-regulatory-submission-in-non-relapsing-secondary-pr-sny-20251224monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-efdoralprin-alfa-earns-orphan-designation-in-the-eu-for-alpha-1-antitrypsin-defic-sny-20251217monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-reaches-agreement-with-the-us-government-to-lower-medicine-costs-while-strengthenin-sny-20251219monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-provides-update-on-tolebrutinib-regulatory-submission-in-non-relapsing-secondary-pr-sny-20251215monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-completes-acquisition-of-vicebio-paris-sny-20251204monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-s-dupixent-approved-as-the-first-targeted-medicine-in-the-eu-in-over--sny-20251125monthly0.5https://www.biopharmawatch.com/news/SNY/acaai-sanofi-and-regeneron-s-dupixent-pivotal-study-met-all-primary-and-secondary-endpoint-sny-20251118monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-efdoralprin-alfa-met-all-primary-and-key-secondary-endpoints-in-alpha-1-antitryps-sny-20251022monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-usd-3-billion-of-bond-issue-paris-france-sny-20251028monthly0.5https://www.biopharmawatch.com/news/SNY/condensed-half-year-consolidated-financial-statements-b-22-information-related-to-opella-p-sny-20251027monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-provides-update-on-regulatory-review-in-the-eu-for-rezurock-to-treat-chronic-graft--sny-20251017monthly0.5https://www.biopharmawatch.com/news/SNY/alphamedix-tm-212-pb-dotamtate-achieved-all-primary-efficacy-endpoints-in-phase-2-study-de-sny-20251008monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-sar446268-earns-us-fast-track-designation-for-the-treatment-of-non-congenital-myo-sny-20250923monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-s-dupixent-to-treat-chronic-spontaneous-urticaria-advances-in-eu-with-sny-20250922monthly0.5https://www.biopharmawatch.com/news/SNY/tzield-approved-in-china-as-first-disease-modifying-therapy-for-adult-and-pediatric-patien-sny-20250910monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-amlitelimab-met-all-primary-and-key-secondary-endpoints-in-the-coast-1-phase-3-st-sny-20250904monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-wayrilz-approved-in-us-as-first-btk-inhibitor-for-immune-thrombocytopenia-novel-t-sny-20250829monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-rilzabrutinib-earns-orphan-designation-in-the-eu-for-igg4-related-disease-data-fr-sny-20250814monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-completes-the-acquisition-of-vigil-neuroscience-inc-paris-sny-20250806monthly0.5https://www.biopharmawatch.com/news/SNY/half-year-management-report-4-responsibility-statement-of-the-certifying-officer-half-year-sny-20250731monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-sarclisa-approved-in-the-eu-for-the-treatment-of-transplant-eligible-newly-diagno-sny-20250725monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-sar446597-earns-fast-track-designation-in-the-us-for-geographic-atrophy-due-to-ag-sny-20250716monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-completes-acquisition-of-blueprint-medicines-paris-sny-20250718monthly0.5https://www.biopharmawatch.com/news/SNY/riliprubart-earns-orphan-drug-designation-in-the-us-for-antibody-mediated-rejection-in-sol-sny-20250625monthly0.5https://www.biopharmawatch.com/news/SNY/eaaci-dupixent-demonstrated-superiority-over-xolair-omalizumab-in-chronic-rhinosinusitis-w-sny-20250615monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-1-5-billion-bond-issue-paris-sny-20250617monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-accelerates-global-shipping-of-beyfortus-to-prepare-healthcare-providers-months-ahe-sny-20250609monthly0.5https://www.biopharmawatch.com/news/SNY/rilzabrutinib-granted-orphan-drug-designation-in-the-us-for-sickle-cell-disease-fourth-orp-sny-20250603monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-blueprint-medicines-expanding-portfolio-in-rare-immunological-disease-an-sny-20250602monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-completes-acquisition-of-dr-0201-paris-sny-20250527monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-vigil-neuroscience-inc-adding-a-new-investigational-medicine-to-treat-al-sny-20250522monthly0.5https://www.biopharmawatch.com/news/SNY/annual-general-meeting-of-sny-20250430monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-cd-r-close-opella-transaction-create-global-consumer-healthcare-leader-paris-sny-20250430monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-approved-in-the-us-as-the-first-new-targeted-therapy-in-over-a-decade-for-chronic-sny-20250418monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-respiratory-pipeline-advances-with-new-data-in-asthma-and-plans-for-new-clinical--sny-20250415monthly0.5https://www.biopharmawatch.com/news/SNY/tolebrutinib-phase-3-data-published-in-nejm-demonstrate-benefit-on-disability-progression--sny-20250408monthly0.5https://www.biopharmawatch.com/news/SNY/rilzabrutinib-granted-orphan-drug-designation-in-the-us-for-two-rare-diseases-with-no-appr-sny-20250403monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-approved-as-the-first-ever-biologic-medicine-in-japan-for-patients-with-copd-foll-sny-20250328monthly0.5https://www.biopharmawatch.com/news/SNY/tolebrutinib-regulatory-submission-accepted-for-priority-review-in-the-us-for-patients-wit-sny-20250325monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-dren-bio-s-bispecific-myeloid-cell-engager-for-deep-b-cell-depletion-bro-sny-20250320monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-late-breaking-positive-pivotal-data-in-bullous-pemphigoid-presented-at-aad-five-t-sny-20250308monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-eur-1-5-billion-of-bond-issue-paris-sny-20250305monthly0.5https://www.biopharmawatch.com/news/SNY/ecco-2025-new-duvakitug-data-reinforce-best-in-class-potential-in-ulcerative-colitis-and-c-sny-20250222monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-sbla-accepted-for-fda-priority-review-for-the-targeted-treatment-of-bullous-pemph-sny-20250220monthly0.5https://www.biopharmawatch.com/news/SNY/update-on-extraintestinal-pathogenic-e-coli-vaccine-phase-3-clinical-study-independent-int-sny-20250213monthly0.5https://www.biopharmawatch.com/news/SNY/execution-of-a-share-buyback-agreement-for-up-to-2-billion-paris-sny-20250207monthly0.5https://www.biopharmawatch.com/news/SNY/sarclisa-is-the-first-anti-cd38-treatment-in-combination-with-standard-of-care-vrd-approve-sny-20250113monthly0.5https://www.biopharmawatch.com/news/SNY/opella-reaches-study-milestone-for-cialis-paris-sny-20250121monthly0.5https://www.biopharmawatch.com/news/SNY/new-sarclisa-subcutaneous-formulation-met-co-primary-endpoints-in-the-iraklia-phase-3-stud-sny-20250109monthly0.5https://www.biopharmawatch.com/news/SNY/jean-paul-kress-to-join-sanofi-s-board-of-directors-paris-sny-20241219monthly0.5https://www.biopharmawatch.com/news/SNY/tolebrutinib-designated-breakthrough-therapy-by-the-fda-for-non-relapsing-secondary-progre-sny-20241213monthly0.5https://www.biopharmawatch.com/news/SNY/availability-of-the-profit-and-loss-information-of-sanofi-excluding-opella-paris-france-sny-20241206monthly0.5https://www.biopharmawatch.com/news/SNY/sarclisa-recommended-for-eu-approval-by-the-chmp-to-treat-transplant-ineligible-newly-diag-sny-20241114monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young-children-with-eosinop-sny-20241106monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous-urticaria-to-be-presen-sny-20241024monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-orano-join-forces-to-develop-next-generation-radioligand-medicines-paris-sny-20241017monthly0.5https://www.biopharmawatch.com/news/SNY/new-beyfortus-data-featured-at-idweek-reinforce-real-world-effectiveness-against-rsv-disea-sny-20241009monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-copd-appr-sny-20240927monthly0.5https://www.biopharmawatch.com/news/SNY/tolebrutinib-demonstrated-a-31-delay-in-time-to-onset-of-confirmed-disability-progression--sny-20240920monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-is-the-first-and-only-biologic-to-achieve-significant-improvements-in-disease-rem-sny-20240911monthly0.5https://www.biopharmawatch.com/news/SNY/tolebrutinib-meets-primary-endpoint-in-hercules-phase-3-study-the-first-and-only-to-show-r-sny-20240902monthly0.5https://www.biopharmawatch.com/news/SNY/sarclisa-induction-treatment-demonstrated-significantly-improved-progression-free-survival-sny-20240808monthly0.5https://www.biopharmawatch.com/news/SNY/table-of-contents-2-half-year-management-report-37-a-significant-events-of-the-first-half--sny-20240725monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-approved-in-the-eu-as-the-first-ever-targeted-therapy-for-patients-with-copd-firs-sny-20240703monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-biovac-spearhead-polio-vaccine-manufacturing-capabilities-in-africa-paris-sny-20240620monthly0.5https://www.biopharmawatch.com/news/SNY/update-on-fda-priority-review-of-dupixent-for-the-treatment-of-copd-patients-with-type-2-i-sny-20240531monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-completes-acquisition-of-inhibrx-inc-paris-sny-20240530monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-novavax-announce-co-exclusive-licensing-agreement-to-co-commercialize-covid-19--sny-20240510monthly0.5https://www.biopharmawatch.com/news/SNY/new-48-week-frexalimab-phase-2-data-support-potential-for-high-sustained-efficacy-in-multi-sny-20240417monthly0.5https://www.biopharmawatch.com/news/SNY/new-phase-2b-results-for-amlitelimab-support-potential-for-best-in-class-maintenance-of-re-sny-20240311monthly0.5https://www.biopharmawatch.com/news/SNY/phase-2-data-published-in-nejm-show-potential-of-frexalimab-as-high-efficacy-therapy-in-re-sny-20240215monthly0.5https://www.biopharmawatch.com/news/SNY/peer-support-flexible-work-arrangements-salary-for-a-year-sanofi-launches-global-program-f-sny-20240205monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-fda-approved-as-first-and-only-treatment-indicated-for-children-aged-1-year-and-o-sny-20240125monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-inhibrx-inc-adding-potential-best-in-class-rare-disease-asset-for-alpha--sny-20240123monthly0.5https://www.biopharmawatch.com/news/SNY/brian-foard-appointed-head-of-specialty-care-global-business-unit-member-of-sanofi-executi-sny-20240117monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-end-of-program-evaluating-tusamitamab-ravtansine-after-a-2l-nsclc-phase-3-sny-20231221monthly0.5https://www.biopharmawatch.com/news/SNY/r-d-day-sanofi-pipeline-transformation-to-accelerate-growth-driven-by-record-number-of-pot-sny-20231206monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-significantly-reduced-copd-exacerbations-in-second-positive-phase-3-trial-acceler-sny-20231127monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-enters-next-chapter-of-play-to-win-strategy-increases-investments-in-its-pipeline-t-sny-20231027monthly0.5https://www.biopharmawatch.com/news/SNY/media-update-sanofi-and-regeneron-provide-update-on-dupixent-dupilumab-sbla-for-chronic-sp-sny-20231020monthly0.5https://www.biopharmawatch.com/news/SNY/late-breaking-amlitelimab-phase-2b-data-presented-at-eadv-show-potential-best-in-class-pro-sny-20231013monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-agreement-for-potential-first-in-class-vaccine-against-extraintestinal-pa-sny-20231003monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-supporting-vulnerable-communities-as-part-of-commitment-to-social-impact-and-fight--sny-20230919monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-changes-to-its-executive-committee-paris-august-31-st-2023-sanofi-announc-sny-20230905monthly0.5https://www.biopharmawatch.com/news/SNY/u-s-cdc-advisory-committee-unanimously-recommends-routine-use-of-beyfortus-nirsevimab-alip-sny-20230803monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-qunol-a-fast-growing-u-s-brand-in-the-healthy-aging-segment-transaction--sny-20230728monthly0.5https://www.biopharmawatch.com/news/SNY/table-of-contents-2-half-year-management-report-38-a-significant-events-of-the-first-half--sny-20230728monthly0.5https://www.biopharmawatch.com/news/SNY/fda-approves-beyfortus-nirsevimab-alip-to-protect-infants-against-rsv-disease-beyfortus-is-sny-20230717monthly0.5https://www.biopharmawatch.com/news/SNY/altuviiio-late-breaking-data-at-isth-demonstrates-highly-effective-bleed-protection-in-chi-sny-20230625monthly0.5https://www.biopharmawatch.com/news/SNY/fda-advisory-committee-unanimously-recommends-nirsevimab-as-first-immunization-against-rsv-sny-20230608monthly0.5https://www.biopharmawatch.com/news/SNY/annual-general-meeting-of-sny-20230525monthly0.5https://www.biopharmawatch.com/news/SNY/nirsevimab-delivers-83-reduction-in-rsv-infant-hospitalizations-in-a-real-world-clinical-t-sny-202305122023-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-completes-acquisition-of-provention-bio-inc-paris-april-27-2023-sanofi-announced-to-sny-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/nirsevimab-sanofi-astrazeneca-and-sobi-simplify-contractual-agreements-modification-of-exi-sny-202304112023-04-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/two-fitusiran-phase-3-studies-published-in-the-lancet-and-the-lancet-haematology-highlight-sny-202304042023-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-cuts-u-s-list-price-of-lantus-its-most-prescribed-insulin-by-78-and-caps-out-of-poc-sny-202303162023-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in-adult-sny-202303072023-03-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-provention-bio-adding-to-portfolio-tzield-the-first-disease-modifying-tr-sny-202303132023-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/completed-xtend-kids-phase-3-study-strengthens-potential-of-altuviiio-tm-to-redefine-expec-sny-202303022023-03-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/fda-approves-once-weekly-altuviiio-a-new-class-of-factor-viii-therapy-for-hemophilia-a-tha-sny-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-change-in-r-d-leadership-paris-sny-202302132023-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/nejm-publishes-once-weekly-efanesoctocog-alfa-phase-3-data-demonstrating-its-potential-to--sny-202301252023-01-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/positive-dupixent-dupilumab-phase-3-results-in-adults-and-adolescents-with-eosinophilic-es-sny-202301172023-01-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-sny-20221215monthly0.5https://www.biopharmawatch.com/news/SNY/acoziborole-investigational-single-dose-oral-treatment-raises-hope-for-elimination-of-slee-sny-20221130monthly0.5https://www.biopharmawatch.com/news/SNY/european-commission-approves-enjaymo-sutimlimab-for-treatment-of-hemolytic-anemia-in-adult-sny-20221117monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-gsk-s-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-the--sny-20221110monthly0.5https://www.biopharmawatch.com/news/SNY/european-commission-grants-first-approval-worldwide-of-beyfortus-nirsevimab-for-prevention-sny-20221104monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-dupilumab-late-breaking-phase-3-data-presented-at-ueg-week-2022-showed-significan-sny-20221011monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-dupilumab-approved-by-fda-as-the-first-and-only-treatment-indicated-for-prurigo-n-sny-20220928monthly0.5https://www.biopharmawatch.com/news/SNY/chmp-recommends-approval-of-beyfortus-nirsevimab-for-prevention-of-rsv-disease-in-infants--sny-20220916monthly0.5https://www.biopharmawatch.com/news/SNY/evolution-of-the-board-of-directors-paris-sny-20220905monthly0.5https://www.biopharmawatch.com/news/SNY/fda-grants-priority-review-to-efanesoctocog-alfa-for-people-with-hemophilia-a-the-fda-deci-sny-20220902monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-provides-update-on-amcenestrant-clinical-development-program-paris-sny-20220817monthly0.5https://www.biopharmawatch.com/news/SNY/media-update-paris-sny-20220811monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-innovent-biologics-enter-strategic-collaboration-to-accelerate-development-of-o-sny-20220804monthly0.5https://www.biopharmawatch.com/news/SNY/table-of-contents-2-half-year-management-report-40-a-significant-events-of-the-first-half--sny-20220728monthly0.5https://www.biopharmawatch.com/news/SNY/dupixent-dupilumab-phase-3-trial-shows-positive-results-in-children-1-to-11-years-of-age-w-sny-20220714monthly0.5https://www.biopharmawatch.com/news/SNY/fitusiran-prophylaxis-reduced-bleeds-by-61-in-people-with-hemophilia-a-or-b-with-or-withou-sny-20220710monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-global-health-launches-nonprofit-impact-brand-for-30-medicines-in-low-income-countr-sny-20220704monthly0.5https://www.biopharmawatch.com/news/SNY/media-update-patient-enrollment-of-phase-iii-tolebrutinib-trials-paused-in-the-u-s-paris-sny-20220630monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-gsk-first-to-report-a-successful-efficacy-study-against-omicron-with-covid-19-beta--sny-20220624monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-gsk-next-generation-covid-19-booster-delivers-strong-immune-response-against-varian-sny-20220613monthly0.5https://www.biopharmawatch.com/news/SNY/fda-approves-dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-months-to-5-sny-20220607monthly0.5https://www.biopharmawatch.com/news/SNY/fda-grants-efanesoctocog-alfa-breakthrough-therapy-designation-for-hemophilia-a-efanesocto-sny-20220601monthly0.5https://www.biopharmawatch.com/news/SNY/update-on-cialis-rx-to-otc-switch-actual-use-trial-paris-sny-20220530monthly0.5https://www.biopharmawatch.com/news/SNY/fda-approves-dupixent-dupilumab-as-first-treatment-for-adults-and-children-aged-12-and-old-sny-20220520monthly0.5https://www.biopharmawatch.com/news/SNY/new-nirsevimab-data-analyses-reinforce-efficacy-against-rsv-a-prespecified-pooled-analysis-sny-20220511monthly0.5https://www.biopharmawatch.com/news/SNY/q1-2022-change-ifrs-net-sales-reported-9-674m-12-6-ifrs-net-income-reported-2-009m-28-3-if-sny-20220516monthly0.5https://www.biopharmawatch.com/news/SNY/annual-general-meeting-of-sny-20220503monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-teams-up-with-mclaren-racing-to-accelerate-industrial-excellence-paris-sny-20220426monthly0.5https://www.biopharmawatch.com/news/SNY/positive-phase-1-2-study-results-of-rilzabrutinib-in-people-with-immune-thrombocytopenia-p-sny-20220414monthly0.5https://www.biopharmawatch.com/news/SNY/fda-accepts-dupixent-dupilumab-for-priority-review-in-patients-aged-12-years-and-older-wit-sny-20220404monthly0.5https://www.biopharmawatch.com/news/SNY/information-statement-distribution-of-shares-of-euroapi-to-the-shareholders-of-sanofi-this-sny-20220331monthly0.5https://www.biopharmawatch.com/news/SNY/euroapi-listing-on-euronext-paris-expected-on-sny-20220401monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-priced-an-inaugural-sustainability-linked-bond-indexed-on-access-to-me-sny-20220331monthly0.5https://www.biopharmawatch.com/news/SNY/late-breaking-phase-3-data-at-aad-2022-show-dupixent-dupilumab-significantly-improved-sign-sny-20220326monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-seagen-announce-collaboration-to-develop-and-commercialize-multiple-novel-antib-sny-20220316monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-recognized-by-s-p-as-one-of-the-most-sustainability-committed-companies-paris-sny-20220308monthly0.5https://www.biopharmawatch.com/news/SNY/late-breaking-phase-3-data-at-2022-aaaai-annual-meeting-show-dupixent-dupilumab-significan-sny-20220226monthly0.5https://www.biopharmawatch.com/news/SNY/update-on-ongoing-dupixent-dupilumab-chronic-spontaneous-urticaria-phase-3-program-in-a-ph-sny-20220218monthly0.5https://www.biopharmawatch.com/news/SNY/fda-approves-enjaymo-sutimlimab-jome-first-treatment-for-use-in-patients-with-cold-aggluti-sny-20220204monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-chmp-recommends-approval-of-dupixent-dupilumab-for-c-sny-20220131monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-second-positive-phase-3-dupixent-dupilumab-trial-con-sny-20220119monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-exscientia-and-sanofi-establish-strategic-research-c-sny-20220107monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-gilles-schnepp-takes-over-as-chairman-of-the-appoint-sny-20211216monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-vaccines-investor-event-sanofi-reiterates-confidence-sny-20211201monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-invests-180-million-equity-in-owkin-s-artificial-intelligence-and-federated-learnin-sny-20211118monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-completes-acquisition-of-kadmon-paris-sny-20211109monthly0.5https://www.biopharmawatch.com/news/SNY/second-dupixent-dupilumab-phase-3-eosinophilic-esophagitis-trial-to-demonstrate-significan-sny-20211025monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-new-long-term-data-reinforcing-promising-safety-and--sny-20211013monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-new-late-breaking-data-at-eadv-highlights-emerging-c-sny-20210930monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-positive-phase-1-2-study-interim-results-for-its-first-mrna-based-vaccine-sny-20210928monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-new-dupixent-dupilumab-data-in-patients-as-young-as--sny-20210921monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-completes-acquisition-of-translate-bio-accele-sny-20210914monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-provides-update-on-phase-3-study-evaluating-r-sny-20210909monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-approves-nexviazyme-avalglucosidase-alfa-ngpt-an-sny-20210806monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-acquire-translate-bio-advances-deployment--sny-20210803monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-online-availability-of-sanofi-s-half-year-financial--sny-20210729monthly0.5https://www.biopharmawatch.com/news/SNY/table-of-contents-half-year-management-report-operating-and-financial-review-and-prospects-sny-20210730monthly0.5https://www.biopharmawatch.com/news/SNY/table-of-contents-2-half-year-management-report-40-a-significant-events-of-the-first-half--sny-20210729monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-announces-paris-2024-premium-partnership-for--sny-20210716monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-launches-dedicated-vaccines-mrna-center-of-ex-sny-20210629monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-european-commission-approves-aubagio-teriflunomide-a-sny-20210618monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-new-pivotal-data-at-eha-2021-reinforces-sutimlimab-a-sny-20210611monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-launches-its-new-global-employee-share-owners-sny-20210607monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-provides-update-on-venglustat-clinical-progra-sny-20210602monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-showcase-data-from-its-transformative-onco-sny-20210519monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-establishes-three-year-collaboration-with-sta-sny-20210506monthly0.5https://www.biopharmawatch.com/news/SNY/q1-2021-sales-increase-driven-by-growth-drivers-dupixent-and-vaccines-specialty-care-sales-sny-20210511monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-annual-general-meeting-of-sny-20210430monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-european-commission-approves-second-indication-of-sa-sny-20210419monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-invest-in-a-leading-edge-production-site-i-sny-20210412monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-approves-sarclisa-isatuximab-in-combination-with-sny-20210331monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-phase-3-trial-of-libtayo-cemiplimab-monotherapy-in-a-sny-20210315monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-filing-of-the-2020-u-s-form-20-f-and-french-document-sny-20210304monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-approves-libtayo-cemiplimab-rwlc-monotherapy-for-sny-20210222monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-the-lancet-publishes-libtayo-cemiplimab-data-showing-sny-20210212monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-approves-libtayo-cemiplimab-rwlc-as-first-immuno-sny-20210209monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-unveils-euroapi-as-the-name-of-the-new-indust-sny-20210119monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-acquire-kymab-adding-ky1005-to-its-pipelin-sny-20210111monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-renews-partnership-with-the-who-to-fight-negl-sny-20201215monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-gsk-announce-a-delay-in-their-adjuvanted--sny-20201211monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-dupixent-dupilumab-approved-by-european-commission-a-sny-20201130monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-european-commission-approves-menquadfi-the-latest-in-sny-20201125monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-european-commission-approves-supemtek-quadrivalent-r-sny-20201118monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-offers-to-acquire-kiadis-a-clinical-stage-com-sny-20201102monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-european-patent-office-rules-in-favor-of-sanofi-and--sny-20201029monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-dupixent-dupilumab-late-breaking-pivotal-data-showin-sny-20201026monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-translate-bio-mrna-covid-19-vaccine-candi-sny-20201015monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-ema-accepts-regulatory-submission-for-avalglucosidas-sny-20201002monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-gsk-sign-agreements-with-the-government-o-sny-20200922monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-completes-principia-biopharma-inc-acquisition-sny-20200928monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-grants-dupixent-dupilumab-breakthrough-therapy-d-sny-20200914monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-gsk-initiate-phase-1-2-clinical-trial-of--sny-20200903monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-acquire-principia-biopharma-further-streng-sny-20200817monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-gsk-in-advanced-discussions-with-european-sny-20200731monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-online-availability-of-sanofi-s-half-year-financial--sny-20200729monthly0.5https://www.biopharmawatch.com/news/SNY/document-2-half-year-management-report-a-significant-events-of-the-first-half-of-2020-a-1--sny-20200729monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-regeneron-provide-update-on-kevzara-saril-sny-20200702monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-s-virtual-r-d-day-event-to-highlight-capabili-sny-20200623monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-s-investigational-enzyme-replacement-therapy--sny-20200616monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-present-growth-opportunities-and-developme-sny-20200611monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-launch-action-2020-a-worldwide-employee-st-sny-20200603monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-announces-pricing-of-regeneron-stock-offering-sny-20200526monthly0.5https://www.biopharmawatch.com/news/SNY/response-to-covid-19-global-health-crisis-sanofi-showed-resilience-and-maintained-full-bus-sny-20200522monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-grants-priority-review-of-sutimlimab-potential-f-sny-20200514monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-libtayo-cemiplimab-shows-clinically-meaningful-and-d-sny-20200505monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-annual-general-meeting-of-sny-20200428monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-present-phase-2-detailed-results-of-its-br-sny-20200417monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-gsk-to-join-forces-in-unprecedented-vacci-sny-20200415monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-finalizes-praluent-alirocumab-restructuring-w-sny-20200406monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-information-on-sanofi-s-shareholder-s-general-meetin-sny-20200402monthly0.5https://www.biopharmawatch.com/news/SNY/first-patient-outside-u-s-treated-in-global-kevzara-sarilumab-clinical-trial-program-for-p-sny-20200330monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-filing-of-the-2019-u-s-form-20-f-and-french-document-sny-20200305monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-to-create-new-industry-leading-european-compa-sny-20200224monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-accepts-for-priority-review-dupixent-dupilumab-f-sny-20200128monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-completes-acquisition-of-synthorx-inc-synthor-sny-20200123monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-regeneron-announce-intent-to-restructure--sny-20191210monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-to-acquire-synthorx-to-bolster-its-immuno-oncol-sny-20191209monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-announces-settlement-agreement-related-to-con-sny-20191031monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-opens-its-first-digitally-enabled-continuous--sny-20191015monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-u-s-district-court-invalidates-amgen-patent-claims-t-sny-20190828monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-dupixent-dupilumab-showed-positive-topline-results-i-sny-20190806monthly0.5https://www.biopharmawatch.com/news/SNY/half-year-financial-report-table-of-contents-1-condensed-half-year-consolidated-financial--sny-20190729monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-signs-strategic-deal-for-exclusive-us-over-th-sny-20190723monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-to-review-isatuximab-as-a-potential-treatment-fo-sny-20190710monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-google-to-develop-new-healthcare-innovati-sny-20190618monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-communication-from-the-board-of-directors-paul-hudso-sny-20190607monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-phase-3-trial-of-isatuximab-combination-therapy-show-sny-20190602monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-fda-approves-praluent-alirocumab-to-prevent-heart-at-sny-20190426monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-praluent-alirocumab-now-approved-in-european-union-t-sny-20190315monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-regeneron-strongly-disagree-with-verdict--sny-20190225monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-chmp-recommends-approval-of-praluent-alirocumab-to-r-sny-20190204monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nasdaq-sny-sanofi-and-regeneron-restructure-immuno-oncology-col-sny-20190107monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-to-transfer-u-s-stock-exchange-listing-to-nasda-sny-20181218monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-odyssey-outcomes-investigators-highlight-at-aha-that-p-sny-20181111monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-fda-grants-priority-review-for-dupixent-dupilumab-as-p-sny-20181106monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-fda-approves-asthma-indication-for-dupixent-dupilumab--sny-20181022monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-completes-divestiture-of-zentiva-to-advent-pari-sny-20181001monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-to-refocus-two-global-business-units-appoints-d-sny-20180913monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-reaches-civil-settlement-with-us-sec-paris-sny-20180904monthly0.5https://www.biopharmawatch.com/news/SNY/condensed-half-year-consolidated-financial-statements-contents-1-condensed-half-year-conso-sny-20180731monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-head-of-human-resources-roberto-pucci-to-retire-sny-20180726monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-chmp-recommends-approval-of-cablivi-caplacizumab-first-sny-20180629monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-appoints-jean-baptiste-chasseloup-de-chatillon--sny-20180619monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-successfully-prices-usd-2-billion-bond-issue-pa-sny-20180613monthly0.5https://www.biopharmawatch.com/news/SNY/information-on-q1-2018-financial-results-q1-2018-change-change-at-constant-exchange-rates--sny-20180612monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-launches-action-2018-a-worldwide-employee-stock-sny-20180611monthly0.5https://www.biopharmawatch.com/news/SNY/information-on-q1-2018-financial-results-q1-2018-change-change-at-constant-exchange-rates--sny-20180607monthly0.5https://www.biopharmawatch.com/news/SNY/information-on-q1-2018-financial-results-q1-2018-change-change-at-constant-exchange-rates--sny-20180605monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-new-england-journal-of-medicine-publishes-two-positive-sny-20180521monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-annual-general-shareholders-meeting-of-sny-20180502monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-head-of-global-r-d-elias-zerhouni-to-retire-com-sny-20180424monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-to-invest-350-million-in-canadian-vaccine-facil-sny-20180412monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-ema-to-review-cemiplimab-as-a-potential-treatment-for--sny-20180403monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-ema-to-review-sotagliflozin-as-potential-treatment-for-sny-20180329monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-successfully-prices-eur-8-billion-of-bond-issue-sny-20180315monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-and-regeneron-announce-plans-to-make-praluent-m-sny-20180310monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-completes-acquisition-of-bioverativ-inc-bioverativ-inc-is-a-fully-owned-subsidiary--sny-20180308monthly0.5https://www.biopharmawatch.com/news/SNY/sources-sanofi-euronext-san-nyse-sny-evotec-and-sanofi-in-exclusive-talks-to-create-an-evo-sny-20180308monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-s-board-of-directors-proposes-appointment-of-em-sny-20180306monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-fda-to-review-dupixent-dupilumab-as-potential-treatmen-sny-20180302monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-ablynx-for-3-9-billion-strengthens-sanofi-s-r-d-strategy-with-innovative-sny-20180129monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-to-acquire-bioverativ-for-11-6-billion-expands--sny-20180122monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-appoints-dominique-carouge-executive-vice-presi-sny-20180119monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-and-regeneron-to-accelerate-and-expand-investme-sny-20180108monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-alnylam-submit-marketing-authorization-application-to-the-european-medicines-ag-sny-20171218monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-presents-r-d-strategy-and-innovative-pipeline-r-sny-20171213monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-s-toujeo-met-main-objective-in-head-to-head-stu-sny-20171204monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-sanofi-principia-agree-to-develop-multiple-sclerosis-d-sny-20171109monthly0.5https://www.biopharmawatch.com/news/SNY/source-sanofi-euronext-san-nyse-sny-dupilumab-significantly-reduced-steroid-use-asthma-att-sny-20171031monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-files-suit-in-the-u-s-to-defend-its-patent-rights-on-lantus-and-lantus-solostar-par-sny-20171024monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-positive-phase-2-study-results-for-dupilumab-in-patients-wit-sny-20171016monthly0.5https://www.biopharmawatch.com/news/SNY/appellate-court-orders-a-new-trial-and-vacates-permanent-injunction-in-ongoing-patent-case-sny-20171005monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-appoints-stefan-oelrich-executive-vice-president-diabetes-cardiovascular-and-member-sny-20171002monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-positive-study-results-for-dupixent-dupilumab-in-patients-wi-sny-20170916monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-that-cemiplimab-regn2810-has-received-fda-breakthrough-thera-sny-20170908monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-files-suit-in-the-u-s-to-defend-its-patent-rights-on-lantus-paris-france-sny-20170808monthly0.5https://www.biopharmawatch.com/news/SNY/h-alf-y-ear-f-inancial-r-eport-contents-1-condensed-half-year-consolidated-financial-state-sny-20170731monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-receive-positive-chmp-opinion-for-dupixent-dupilumab-to-treat-adult-p-sny-20170721monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-approval-of-kevzara-sarilumab-to-treat-adult-patients-with-m-sny-20170627monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-positive-results-from-first-dedicated-studies-evaluating-pra-sny-20170611monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-receives-chmp-recommendation-for-approval-of-insulin-lispro-biosimilar-positive-opi-sny-20170519monthly0.5https://www.biopharmawatch.com/news/SNY/information-on-q1-2017-financial-results-q1-2017-change-change-at-cer-ifrs-net-sales-repor-sny-20170516monthly0.5https://www.biopharmawatch.com/news/SNY/annual-general-shareholders-meeting-of-sny-20170510monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-appoints-bill-sibold-executive-vice-president-sanofi-genzyme-and-member-of-the-exec-sny-20170428monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-fda-approval-of-dupixent-dupilumab-the-first-targeted-biolog-sny-20170328monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-lonza-enter-into-a-strategic-partnership-to-establish-a-large-scale-biologics-p-sny-20170227monthly0.5https://www.biopharmawatch.com/news/SNY/appeals-court-grants-stay-of-permanent-injunction-for-praluent-alirocumab-during-appeals-p-sny-20170208monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-xyzal-allergy-24hr-approved-for-over-the-counter-use-in-the-united-states-paris-f-sny-20170201monthly0.5https://www.biopharmawatch.com/news/SNY/suliqua-tm-approved-in-the-european-union-for-the-treatment-of-adults-with-type-2-diabetes-sny-20170117monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-soliqua-100-33-now-available-in-the-u-s-paris-france-sny-20170104monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-boehringer-ingelheim-confirm-closing-of-business-swap-on-january-1st-2017-both--sny-20170103monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-receives-fda-approval-of-soliqua-100-33-for-the-treatment-of-adults-with-type-2-dia-sny-20161227monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-receive-complete-response-letter-from-fda-for-sarilumab-an-investigat-sny-20161028monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-positive-dupixent-dupilumab-phase-3-atopic-dermatitis-data-p-sny-20161001monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-verily-life-sciences-announce-launch-of-onduo-a-joint-venture-to-develop-compre-sny-20160912monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-eur-3-billion-bond-issue-paris-france-sny-20160906monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-provides-update-on-new-drug-application-for-investigational-once-daily-fixed-ratio--sny-20160819monthly0.5https://www.biopharmawatch.com/news/SNY/h-alf-y-ear-f-inancial-r-eport-contents-1-condensed-half-year-consolidated-financial-state-sny-20160729monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-enters-into-confidentiality-agreement-with-medivation-and-will-be-provided-due-dili-sny-20160705monthly0.5https://www.biopharmawatch.com/news/SNY/status-of-cvr-product-sales-milestone-1-as-of-sny-20160630monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-that-dupilumab-used-with-topical-corticosteroids-tcs-was-sup-sny-20160627monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-expiration-of-hart-scott-rodino-waiting-period-regarding-proposed-acquisi-sny-20160614monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-files-definitive-consent-solicitation-to-remove-and-replace-medivation-s-board-mail-sny-20160613monthly0.5https://www.biopharmawatch.com/news/SNY/this-presentation-contains-forward-looking-statements-as-defined-in-the-private-securities-sny-20160608monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-requests-record-date-for-consent-solicitation-to-remove-and-replace-medivation-s-bo-sny-20160601monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-changes-to-executive-committee-aligned-to-its-strategic-roadmap-2020-pari-sny-20160523monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-files-consent-solicitation-to-remove-and-replace-medivation-s-board-paris-france-sny-20160525monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-files-for-hart-scott-rodino-notification-regarding-proposed-acquisition-of-medivati-sny-20160512monthly0.5https://www.biopharmawatch.com/news/SNY/annual-general-shareholder-meeting-of-sny-20160504monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-sends-letter-to-medivation-s-board-of-directors-paris-sny-20160505monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-comments-on-medivation-s-rejection-of-proposal-reiterates-commitment-to-consummatin-sny-20160429monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-offers-to-acquire-medivation-for-52-50-per-share-in-cash-proposal-would-provide-imm-sny-20160428monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-dice-molecules-announce-research-collaboration-to-discover-potential-therapeuti-sny-20160411monthly0.5https://www.biopharmawatch.com/news/SNY/capitalization-and-indebtedness-the-following-table-sets-forth-our-cash-and-cash-equivalen-sny-20160315monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-pasteur-and-msd-known-as-merck-in-the-united-states-and-canada-announce-intent-to-e-sny-20160308monthly0.5https://www.biopharmawatch.com/news/SNY/filing-of-the-2015-u-s-form-20-f-and-french-document-de-r-f-rence-containing-the-annual-fi-sny-20160304monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20160209monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-pasteur-s-dengue-vaccine-approved-in-the-philippines-dengvaxia-s-first-approval-in--sny-20160201monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-boehringer-ingelheim-enter-exclusive-negotiations-on-business-swap-sanofi-would-sny-20151215monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-sets-out-strategic-roadmap-for-long-term-growth-sales-cagr-1-between-3-and-4-at-cer-sny-20151106monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20151029monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-evotec-enter-new-research-collaboration-to-discover-and-develop-novel-diabetes-ther-sny-20151006monthly0.5https://www.biopharmawatch.com/news/SNY/half-year-financial-report-contents-condensed-half-year-consolidated-financial-statements--sny-20150731monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20150730monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-new-basal-insulin-lantus-xr-known-as-toujeo-in-the-u-s-and-europe-approved-in-jap-sny-20150729monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-positive-topline-results-from-phase-3-studies-with-sarilumab-sny-20150521monthly0.5https://www.biopharmawatch.com/news/SNY/annual-general-shareholder-meeting-of-sny-20150504monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20150430monthly0.5https://www.biopharmawatch.com/news/SNY/shantha-will-provide-up-to-37-million-doses-of-shan5-shan5-pentavalent-pediatric-vaccine-w-sny-20150317monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-receives-fda-approval-of-once-daily-basal-insulin-toujeo-paris-france-sny-20150226monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-appoints-olivier-brandicourt-as-chief-executive-officer-tenure-as-ceo-will-commence-sny-20150220monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20150205monthly0.5https://www.biopharmawatch.com/news/SNY/european-chmp-adopts-positive-opinion-for-genzyme-s-cerdelga-eliglustat-capsules-paris-sny-20150126monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-that-dupilumab-has-received-fda-breakthrough-therapy-designa-sny-20141120monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-nominates-professor-bonnie-l-bassler-to-its-board-of-directors-paris-france-sny-20141118monthly0.5https://www.biopharmawatch.com/news/SNY/statement-from-sanofi-board-of-directors-paris-france-sny-20141029monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20141028monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-pasteur-s-dengue-vaccine-candidate-successfully-completes-final-landmark-phase-iii--sny-20140903monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-to-present-results-from-four-phase-3-alirocumab-trials-in-hot-line-se-sny-20140825monthly0.5https://www.biopharmawatch.com/news/SNY/half-year-financial-report-2014-contents-condensed-half-year-consolidated-financial-statem-sny-20140801monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20140731monthly0.5https://www.biopharmawatch.com/news/SNY/fda-accepts-sanofi-s-new-drug-application-for-basal-insulin-toujeo-toujeo-dossier-already--sny-20140708monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-new-detailed-data-from-positive-sarilumab-phase-3-rheumatoid-sny-20140612monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-lilly-announce-licensing-agreement-for-cialis-tadalafil-otc-companies-anticipat-sny-20140528monthly0.5https://www.biopharmawatch.com/news/SNY/annual-general-shareholder-meeting-of-sny-20140505monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20140429monthly0.5https://www.biopharmawatch.com/news/SNY/the-world-s-first-large-scale-dengue-vaccine-efficacy-study-successfully-achieved-its-prim-sny-20140428monthly0.5https://www.biopharmawatch.com/news/SNY/genzyme-to-resubmit-lemtrada-tm-application-for-fda-review-paris-france-sny-20140407monthly0.5https://www.biopharmawatch.com/news/SNY/filing-of-the-2013-u-s-form-20-f-and-french-document-de-r-f-rence-containing-the-annual-fi-sny-20140307monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20140206monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-files-suit-in-the-u-s-to-defend-its-patent-rights-on-lantus-and-lantus-solostar-par-sny-20140130monthly0.5https://www.biopharmawatch.com/news/SNY/status-of-cvr-product-sales-milestone-1-as-of-sny-20140116monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-report-positive-results-with-sarilumab-in-first-phase-3-rheumatoid-ar-sny-20131231monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-eur-1-billion-bond-issue-paris-france-sny-20131107monthly0.5https://www.biopharmawatch.com/news/SNY/data-show-sanofi-s-lyxumia-added-to-basal-insulin-lowered-blood-sugar-especially-when-fast-sny-20130924monthly0.5https://www.biopharmawatch.com/news/SNY/european-commission-approves-genzyme-s-multiple-sclerosis-treatment-lemtrada-alemtuzumab-f-sny-20130917monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-provides-update-on-lixisenatide-new-drug-application-in-u-s-paris-france-sny-20130912monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-eur-1-billion-bond-issue-paris-france-sny-20130829monthly0.5https://www.biopharmawatch.com/news/SNY/half-year-financial-report-contents-condensed-half-year-consolidated-financial-statements--sny-20130802monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20130801monthly0.5https://www.biopharmawatch.com/news/SNY/genzyme-receives-positive-chmp-opinion-for-lemtrada-alemtuzumab-in-europe-chmp-also-recomm-sny-20130628monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-provides-update-on-phase-3-studies-of-two-investigational-compounds-paris-france-sny-20130603monthly0.5https://www.biopharmawatch.com/news/SNY/combined-general-shareholder-meeting-of-sny-20130503monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-usd-1-5-billion-bond-issue-paris-france-sny-20130404monthly0.5https://www.biopharmawatch.com/news/SNY/effect-of-genzyme-s-lemtrada-maintained-in-patients-beyond-two-year-pivotal-ms-studies-in--sny-20130321monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-report-positive-proof-of-concept-data-for-dupilumab-an-il-4r-alpha-an-sny-20130302monthly0.5https://www.biopharmawatch.com/news/SNY/capitalization-and-indebtedness-the-following-table-sets-forth-our-cash-and-cash-equivalen-sny-20130311monthly0.5https://www.biopharmawatch.com/news/SNY/genzyme-announces-positive-new-data-from-two-phase-3-studies-for-oral-eliglustat-tartrate--sny-20130215monthly0.5https://www.biopharmawatch.com/news/SNY/p-roduct-s-ales-s-tatement-for-the-p-roduct-s-ales-m-easuring-p-eriod-ended-d-ecember-31-2-sny-20130208monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20130207monthly0.5https://www.biopharmawatch.com/news/SNY/genzyme-and-isis-announce-fda-approval-of-kynamro-mipomersen-sodium-injection-for-the-trea-sny-20130129monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-s-chattem-acquires-over-the-counter-antacid-rolaids-product-acquisition-further-str-sny-20130129monthly0.5https://www.biopharmawatch.com/news/SNY/merial-to-acquire-animal-health-division-of-dosch-pharmaceuticals-in-india-paris-france-sny-20121220monthly0.5https://www.biopharmawatch.com/news/SNY/zaltrap-aflibercept-receives-chmp-positive-opinion-in-the-european-union-for-previously-tr-sny-20121116monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-announce-publication-of-phase-2-results-with-ldl-cholesterol-lowering-sny-20121031monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20121025monthly0.5https://www.biopharmawatch.com/news/SNY/new-data-from-origin-shows-lantus-use-is-about-3-times-more-likely-to-achieve-and-sustain--sny-20121005monthly0.5https://www.biopharmawatch.com/news/SNY/genzyme-phase-3-study-of-oral-compound-eliglustat-tartrate-for-gaucher-disease-meets-prima-sny-20121002monthly0.5https://www.biopharmawatch.com/news/SNY/fda-approves-genzyme-s-aubagio-teriflunomide-a-once-daily-oral-treatment-for-relapsing-mul-sny-20120912monthly0.5https://www.biopharmawatch.com/news/SNY/u-s-fda-approves-zaltrap-ziv-aflibercept-after-priority-review-for-previously-treated-meta-sny-20120828monthly0.5https://www.biopharmawatch.com/news/SNY/t-a-b-l-e-o-f-c-o-n-t-e-n-t-s-2012-half-year-financial-report-translation-of-the-french-la-sny-20120727monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20120726monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-pasteur-s-6-in-1-pediatric-vaccine-hexaxim-receives-positive-opinion-from-european--sny-20120725monthly0.5https://www.biopharmawatch.com/news/SNY/lantus-initiation-after-metformin-achieved-superior-glycemic-control-versus-sitagliptin-in-sny-20120609monthly0.5https://www.biopharmawatch.com/news/SNY/combined-general-shareholder-meeting-of-sny-20120504monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20120427monthly0.5https://www.biopharmawatch.com/news/SNY/significant-improvement-in-disability-scores-observed-in-multiple-sclerosis-patients-who-r-sny-20120424monthly0.5https://www.biopharmawatch.com/news/SNY/phase-3-extension-study-highlights-long-term-safety-and-efficacy-in-sny-20120329monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-to-acquire-pluromed-inc-expanding-its-presence-in-biosurgery-sanofi-to-commercializ-sny-20120316monthly0.5https://www.biopharmawatch.com/news/SNY/genzyme-begins-shipping-fabrazyme-from-newly-approved-framingham-manufacturing-plant-paris-sny-20120301monthly0.5https://www.biopharmawatch.com/news/SNY/genzyme-announces-fda-approval-of-framingham-manufacturing-plant-paris-france-sny-20120124monthly0.5https://www.biopharmawatch.com/news/SNY/genzyme-announces-european-approval-of-framingham-manufacturing-plant-paris-france-sny-20120118monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-reports-positive-results-for-once-daily-lyxumia-lixisenatide-in-combination-with-la-sny-20111206monthly0.5https://www.biopharmawatch.com/news/SNY/statement-regarding-authorization-to-purchase-outstanding-contingent-value-rights-cvrs-san-sny-20111117monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-and-regeneron-report-positive-preliminary-phase-2-program-results-for-anti-pcsk9-an-sny-20111110monthly0.5https://www.biopharmawatch.com/news/SNY/net-sales-up-10-1-and-business-net-income-1-up-4-1-at-cer-2-performance-driven-by-growth-p-sny-20111103monthly0.5https://www.biopharmawatch.com/news/SNY/investigational-oral-multiple-sclerosis-therapy-teriflunomide-aubagio-significantly-reduce-sny-20111005monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-successfully-prices-usd-1-billion-bond-issue-paris-france-sny-20110928monthly0.5https://www.biopharmawatch.com/news/SNY/european-medicines-agency-ema-confirms-positive-benefit-risk-balance-for-multaq-european-p-sny-20110922monthly0.5https://www.biopharmawatch.com/news/SNY/first-half-condensed-consolidated-financial-statements-for-the-six-months-ended-sny-20110927monthly0.5https://www.biopharmawatch.com/news/SNY/lyxumia-lixisenatide-one-step-regimen-as-effective-as-two-step-regimen-in-improving-glycem-sny-20110912monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-new-long-term-objectives-commenting-on-the-group-s-outlook-sanofi-ceo-chr-sny-20110906monthly0.5https://www.biopharmawatch.com/news/SNY/table-of-contents-free-translation-of-the-french-language-original-condensed-half-year-con-sny-20110729monthly0.5https://www.biopharmawatch.com/news/SNY/press-release-paris-sny-20110728monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-divests-dermik-dermatology-unit-to-valeant-pharmaceuticals-international-inc-strate-sny-20110711monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-announces-positive-results-from-the-all-to-target-study-evaluating-two-lantus-and-a-sny-20110624monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-getgo-al-program-on-lyxumia-as-an-add-on-to-basal-insulin-shows-significant-positiv-sny-20110531monthly0.5https://www.biopharmawatch.com/news/SNY/fda-licenses-sanofi-pasteur-s-new-influenza-vaccine-delivered-by-intradermal-microinjectio-sny-20110510monthly0.5https://www.biopharmawatch.com/news/SNY/combined-general-shareholder-meeting-of-sny-20110506monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-and-regeneron-report-positive-phase-iii-results-with-zaltrap-aflibercept-in-sny-20110426monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-genzyme-isis-media-contact-media-contact-media-contact-marisol-p-ron-erin-e-sny-20110405monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-merck-media-contact-media-contact-jean-marc-podvin-david-caouette-33-1-53-7-sny-20110322monthly0.5https://www.biopharmawatch.com/news/SNY/ratio-of-earnings-to-fixed-charges-the-following-table-shows-the-ratios-of-our-earnings-to-sny-20110322monthly0.5https://www.biopharmawatch.com/news/SNY/composition-of-the-board-of-directors-of-sanofi-aventis-paris-france-sny-20110309monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-announces-positive-top-line-lixisenatide-phase-iii-results-paris-france-sny-20110202monthly0.5https://www.biopharmawatch.com/news/SNY/jevtana-cabazitaxel-for-prostate-cancer-recommended-for-approval-in-the-european-union-the-sny-20110121monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-and-merck-kgaa-sign-agreement-to-jointly-investigate-novel-combinations-aga-sny-20110114monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-announces-wayne-pisano-s-retirement-and-appoints-olivier-charmeil-senior-vi-sny-20101210monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-pasteur-s-dengue-vaccine-in-final-stage-of-clinical-development-first-phase-3-study-sny-20101130monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-to-acquire-bmp-sunstone-creating-a-strong-consumer-healthcare-platform-in-c-sny-20101028monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-announces-expiration-of-hart-scott-rodino-waiting-period-for-acquisition-of-sny-20101020monthly0.5https://www.biopharmawatch.com/news/SNY/final-results-from-phase-ii-study-confirm-bsi-201-iniparib-prolongs-survival-in-metastatic-sny-20101010monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-commences-tender-offer-to-acquire-all-outstanding-shares-of-genzyme-for-69--sny-20101004monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-comments-on-injunctive-relief-hearing-regarding-lovenox-paris-france-sny-20101001monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-announces-non-binding-offer-to-acquire-genzyme-69-per-share-all-cash-offer--sny-20100829monthly0.5https://www.biopharmawatch.com/news/SNY/table-of-contents-table-of-contents-free-translation-of-the-french-language-original-conde-sny-20100730monthly0.5https://www.biopharmawatch.com/news/SNY/jevtana-cabazitaxel-injection-now-available-in-the-u-s-jevtana-plus-prednisone-is-the-firs-sny-20100719monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-expresses-concern-over-the-approval-of-another-version-of-enoxaparin-sodium-sny-20100723monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-and-us-biopharmaceutical-company-ascenta-therapeutics-sign-license-agreemen-sny-20100719monthly0.5https://www.biopharmawatch.com/news/SNY/change-in-sanofi-aventis-executive-committee-paris-france-sny-20100601monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-announces-court-decision-resolving-eloxatin-u-s-patent-litigation-eloxatin--sny-20100423monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-announces-settlement-of-eloxatin-u-s-patent-litigation-paris-france-sny-20100401monthly0.5https://www.biopharmawatch.com/news/SNY/media-sanofi-aventis-bristol-myers-squibb-ingrid-g-rg-armbrecht-carmel-hogan-33-153-774-62-sny-20100324monthly0.5https://www.biopharmawatch.com/news/SNY/capitalization-and-indebtedness-the-following-table-sets-forth-our-current-and-long-term-l-sny-20100315monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-pasteur-s-a-h1n1-vaccine-humenza-recommended-by-european-medicines-agency-lyon-fran-sny-20100219monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-signs-agreements-to-establish-new-consumer-healthcare-joint-venture-in-chin-sny-20100129monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-aventis-provides-an-r-d-pipeline-update-chmp-positive-opinion-for-duoplavin-in-card-sny-20100115monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-pricing-of-senior-notes-iqv-20260604monthly0.5https://www.biopharmawatch.com/news/IQV/kerri-joseph-iqvia-investor-relations-kerri-joseph-iqvia-com-1-973-541-3558-alissa-maupin--iqv-20260507monthly0.5https://www.biopharmawatch.com/news/IQV/kerri-joseph-iqvia-investor-relations-kerri-joseph-iqvia-com-1-973-541-3558-alissa-maupin--iqv-20251105monthly0.5https://www.biopharmawatch.com/news/IQV/kerri-joseph-iqvia-investor-relations-kerri-joseph-iqvia-com-1-973-541-3558-alissa-maupin--iqv-20250902monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-offering-of-senior-notes-iqv-20250602monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-first-quarter-2024-results-revenue-of-3-737-million-gaap-net-income-of-288-m-iqv-20240502monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-and-full-year-2023-results-issues-full-year-2024-guidance-rev-iqv-20240214monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-offering-of-senior-secured-notes-iqv-20231114monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-third-quarter-2023-results-revenue-of-3-736-million-grew-4-9-percent-year-ov-iqv-20231101monthly0.5https://www.biopharmawatch.com/news/IQV/news-contact-nick-childs-iqvia-investor-relations-nick-childs-iqvia-com-1-973-316-3828-tre-iqv-20230925monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-second-quarter-2023-results-revenue-of-3-728-million-grew-5-3-percent-year-o-iqv-20230801monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-offering-of-senior-secured-notes-and-senior-notes-iqv-20230518monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-first-quarter-2023-results-reaffirms-full-year-2023-guidance-revenue-of-3-65-iqv-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-and-full-year-2022-results-issues-full-year-2023-guidance-rev-iqv-202302102023-02-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-third-quarter-2022-results-revenue-of-3-562-million-grew-5-0-percent-year-ov-iqv-20221026monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-second-quarter-2022-results-revenue-of-3-541-million-grew-3-0-percent-year-o-iqv-20220721monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-first-quarter-2022-results-revenue-of-3-568-million-increased-4-7-percent-ye-iqv-20220427monthly0.5https://www.biopharmawatch.com/news/IQV/news-contact-nick-childs-iqvia-investor-relations-nick-childs-iqvia-com-1-973-316-3828-tor-iqv-20220314monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-and-full-year-2021-results-raises-full-year-2022-profit-guida-iqv-20220215monthly0.5https://www.biopharmawatch.com/news/IQV/nick-childs-iqvia-investor-relations-nick-childs-iqvia-com-1-973-316-3828-tor-constantino--iqv-20220124monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-third-quarter-2021-results-and-raises-full-year-2021-guidance-revenue-of-3-3-iqv-20211021monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-second-quarter-2021-results-and-raises-full-year-2021-guidance-revenue-of-3--iqv-20210727monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-first-quarter-results-raises-full-year-2021-guidance-revenue-of-3-409-millio-iqv-20210422monthly0.5https://www.biopharmawatch.com/news/IQV/andrew-markwick-iqvia-investor-relations-andrew-markwick-iqvia-com-1-973-257-7144-tor-cons-iqv-20210401monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-pricing-of-offering-of-senior-notes-iqv-20210217monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-offering-of-senior-notes-iqv-20210216monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-and-full-year-2020-results-raises-full-year-2021-guidance-rev-iqv-20210210monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-third-quarter-2020-results-raises-full-year-2020-guidance-and-provides-2021--iqv-20201020monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-second-quarter-2020-results-and-raises-full-year-2020-guidance-second-quarte-iqv-20200722monthly0.5https://www.biopharmawatch.com/news/IQV/tor-constantino-iqvia-media-relations-tor-constantino-iqvia-com-1-484-567-6732-andrew-mark-iqv-20200721monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-pricing-of-offering-of-senior-notes-iqv-20200610monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-offering-of-senior-notes-iqv-20200609monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-first-quarter-2020-results-issues-second-quarter-2020-guidance-and-updates-f-iqv-20200428monthly0.5https://www.biopharmawatch.com/news/IQV/andrew-markwick-iqvia-investor-relations-andrew-markwick-iqvia-com-1-973-257-7144-tor-cons-iqv-20200403monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-and-full-year-2019-results-issues-first-quarter-and-full-year-iqv-20200212monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-third-quarter-2019-results-third-quarter-revenue-2-769-million-adjusted-ebit-iqv-20191030monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-pricing-of-offering-of-senior-notes-danbury-conn-research-triangle-park-n--iqv-20190730monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-offering-of-senior-notes-danbury-conn-research-triangle-park-n-c-business--iqv-20190729monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-second-quarter-2019-results-raises-full-year-revenue-and-adjusted-diluted-ep-iqv-20190724monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-announces-offering-of-senior-notes-iqv-20190507monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-first-quarter-2019-results-reaffirms-full-year-guidance-first-quarter-revenu-iqv-20190501monthly0.5https://www.biopharmawatch.com/news/IQV/tor-constantino-iqvia-media-relations-tor-constantino-iqvia-com-1-484-567-6732-andrew-mark-iqv-20190221monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-and-full-year-2018-results-issues-first-quarter-and-full-year-iqv-20190214monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-third-quarter-2018-results-and-updates-full-year-2018-guidance-revenue-2-594-iqv-20181022monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-second-quarter-2018-results-and-raises-full-year-2018-revenue-and-profit-gui-iqv-20180724monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-first-quarter-2018-results-and-raises-full-year-2018-revenue-guidance-revenu-iqv-20180502monthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-and-full-year-2017-results-issues-first-quarter-and-full-year-iqv-20180214monthly0.5https://www.biopharmawatch.com/news/IQV/andrew-markwick-iqvia-investor-relations-andrew-markwick-iqvia-com-1-973-257-7144-tor-cons-iqv-20171106monthly0.5https://www.biopharmawatch.com/news/IQV/quintilesims-reports-third-quarter-2017-results-revenue-2-019-million-adjusted-ebitda-512--iqv-20171026monthly0.5https://www.biopharmawatch.com/news/IQV/andrew-markwick-quintilesims-investor-relations-andrew-markwick-quintilesims-com-1-973-257-iqv-20170911monthly0.5https://www.biopharmawatch.com/news/IQV/quintilesims-reports-second-quarter-2017-results-gaap-revenue-1-969-million-1-971-million--iqv-20170803monthly0.5https://www.biopharmawatch.com/news/IQV/quintilesims-contacts-tor-constantino-quintilesims-media-relations-tor-constantino-quintil-iqv-20170725monthly0.5https://www.biopharmawatch.com/news/IQV/ims-health-holdings-inc-table-of-contents-page-condensed-consolidated-statements-of-financ-iqv-20170524monthly0.5https://www.biopharmawatch.com/news/IQV/quintilesims-reports-first-quarter-2017-results-and-raises-full-year-2017-adjusted-diluted-iqv-20170503monthly0.5https://www.biopharmawatch.com/news/IQV/andrew-markwick-quintilesims-investor-relations-andrew-markwick-quintilesims-com-1-973-257-iqv-20170223monthly0.5https://www.biopharmawatch.com/news/IQV/quintilesims-reports-fourth-quarter-and-full-year-2016-results-issues-first-quarter-and-fu-iqv-20170214monthly0.5https://www.biopharmawatch.com/news/IQV/quintilesims-announces-executive-leadership-changes-richard-staub-iii-named-president-rese-iqv-20161130monthly0.5https://www.biopharmawatch.com/news/IQV/quintilesims-reports-third-quarter-2016-results-combined-company-guidance-and-additional-m-iqv-20161102monthly0.5https://www.biopharmawatch.com/news/IQV/news-for-immediate-release-contacts-tor-constantino-quintilesims-media-relations-tor-const-iqv-20161003monthly0.5https://www.biopharmawatch.com/news/IQV/ims-health-announces-pricing-on-upsized-offering-of-senior-notes-in-connection-with-quinti-iqv-20160914monthly0.5https://www.biopharmawatch.com/news/IQV/ims-health-announces-offering-of-senior-notes-in-connection-with-quintiles-ims-merger-danb-iqv-20160912monthly0.5https://www.biopharmawatch.com/news/IQV/ims-health-and-quintiles-announce-key-officers-for-merged-company-danbury-conn-research-tr-iqv-20160829monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-2nd-quarter-2016-results-8-6-service-revenue-growth-7-9-at-constant-currency-com-iqv-20160727monthly0.5https://www.biopharmawatch.com/news/IQV/news-for-immediate-release-contacts-tor-constantino-ims-health-media-relations-1-484-567-6-iqv-20160503monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-1st-quarter-2016-results-agreement-to-merge-with-ims-health-in-all-stock-transac-iqv-20160503monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-4th-quarter-and-full-year-2015-results-and-2016-guidance-9-4-constant-currency-s-iqv-20160211monthly0.5https://www.biopharmawatch.com/news/IQV/phil-bridges-media-relations-phil-bridges-quintiles-com-1-919-998-1653-office-1-919-457-63-iqv-20151105monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-3rd-quarter-2015-results-8-3-constant-currency-service-revenue-growth-compared-t-iqv-20151028monthly0.5https://www.biopharmawatch.com/news/IQV/phil-bridges-media-relations-phil-bridges-quintiles-com-1-919-998-1653-office-1-919-457-63-iqv-20151019monthly0.5https://www.biopharmawatch.com/news/IQV/annie-hai-yuan-lo-elected-to-quintiles-transnational-holdings-inc-board-of-directors-resea-iqv-20150928monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-announces-closing-of-secondary-public-offering-research-triangle-park-nc-iqv-20150805monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-2nd-quarter-2015-results-9-8-constant-currency-service-revenue-growth-compared-t-iqv-20150729monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-announces-closing-of-secondary-public-offering-and-repurchase-of-common-stock-re-iqv-20150519monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-announces-completion-of-refinancing-iqv-20150512monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-announces-pricing-of-800-million-senior-notes-offering-research-triangle-park-n--iqv-20150506monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-announces-proposed-offering-of-800-million-of-senior-notes-research-triangle-par-iqv-20150501monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-announces-proposed-refinancing-of-existing-indebtedness-research-triangle-park-n-iqv-20150429monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-1st-quarter-2015-results-1-35-billion-of-net-new-business-representing-a-1-31-bo-iqv-20150429monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-4th-quarter-2014-results-and-2015-guidance-22-2-growth-in-net-new-business-compa-iqv-20150212monthly0.5https://www.biopharmawatch.com/news/IQV/phil-bridges-media-relations-phil-bridges-quintiles-com-1-919-998-1653-office-1-919-457-63-iqv-20150206monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-reports-3rd-quarter-2014-results-13-8-consolidated-service-revenue-growth-integr-iqv-20141030monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-reports-2nd-quarter-2014-results-9-7-consolidated-service-revenue-growth-integra-iqv-20140731monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-reports-first-quarter-2014-results-over-1-0-billion-of-service-revenues-represen-iqv-20140501monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-reports-fourth-quarter-2013-results-1-0-billion-of-service-revenues-in-the-fourt-iqv-20140213monthly0.5https://www.biopharmawatch.com/news/IQV/richard-relyea-elected-to-the-quintiles-transnational-holdings-inc-board-of-directors-rese-iqv-20131217monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-reports-third-quarter-2013-results-net-new-business-wins-over-1-3-billion-up-29--iqv-20131031monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-president-coo-john-ratliff-to-leave-company-at-end-of-2013-research-triangle-par-iqv-20131031monthly0.5https://www.biopharmawatch.com/news/IQV/quintiles-reports-second-quarter-2013-results-and-full-year-2013-guidance-net-new-business-iqv-20130801monthly0.5https://www.biopharmawatch.com/news/ILMN/document-illumina-announces-changes-to-board-of-directors-david-p-king-nominated-to-suppor-ilmn-20260402monthly0.5https://www.biopharmawatch.com/news/ILMN/document-illumina-completes-acquisition-of-somalogic-deeply-expands-leadership-in-proteomi-ilmn-20260130monthly0.5https://www.biopharmawatch.com/news/ILMN/document-investors-conor-mcnamara-1-858-291-6421-ir-illumina-com-media-christine-douglass--ilmn-20260113monthly0.5https://www.biopharmawatch.com/news/ILMN/document-illumina-appoints-dr-eric-green-as-chief-medical-officer-veteran-genomics-leader--ilmn-20260108monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-acquire-somalogic-accelerating-its-proteomics-business-and-advancing-the-compa-ilmn-20250623monthly0.5https://www.biopharmawatch.com/news/ILMN/document-illumina-board-of-directors-elects-dr-scott-gottlieb-chair-keith-meister-to-join--ilmn-20250325monthly0.5https://www.biopharmawatch.com/news/ILMN/document-investors-salli-schwartz-1-858-291-6421-ir-illumina-com-media-bonny-fowler-1-740--ilmn-20250310monthly0.5https://www.biopharmawatch.com/news/ILMN/document-investors-salli-schwartz-1-858-291-6421-ir-illumina-com-media-bonny-fowler-1-740--ilmn-20250114monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-completes-the-divestiture-of-grail-grail-spin-off-complete-grail-to-begin-regular-ilmn-20240624monthly0.5https://www.biopharmawatch.com/news/ILMN/for-release-ilmn-20240409monthly0.5https://www.biopharmawatch.com/news/ILMN/document-investors-salli-schwartz-1-858-291-6421-ir-illumina-com-media-david-mcalpine-1-34-ilmn-20240109monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-s-board-appoints-jacob-thaysen-ph-d-as-its-new-chief-executive-officer-ilmn-20230905monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-ceo-transition-plan-ilmn-20230611monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-preliminary-results-of-annual-meeting-illumina-shareholders-re-elect-ei-ilmn-20230525monthly0.5https://www.biopharmawatch.com/news/ILMN/document-illumina-appoints-joydeep-goswami-chief-financial-officer-ilmn-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/document-corporate-participants-francis-a-desouza-illumina-inc-ceo-director-joydeep-goswam-ilmn-202301112023-01-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-intends-to-appeal-european-commission-s-decision-in-grail-deal-ilmn-20220906monthly0.5https://www.biopharmawatch.com/news/ILMN/transcript2022-c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-francis-a-desouza-illumina-inc-ce-ilmn-20220111monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-appoints-bob-ragusa-as-chief-executive-officer-ceo-of-grail-ragusa-succeeds-hans--ilmn-20211014monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-acquires-grail-to-accelerate-patient-access-to-life-saving-multi-cancer-early-det-ilmn-20210818monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-board-changes-jay-flatley-to-step-down-from-the-board-john-w-thompson-t-ilmn-20210318monthly0.5https://www.biopharmawatch.com/news/ILMN/grail-audited-consolidated-financial-statements-for-the-years-ended-december-31-2019-and-2-ilmn-20210312monthly0.5https://www.biopharmawatch.com/news/ILMN/document-the-following-is-a-transcript-of-a-webcast-presented-by-illumina-inc-the-company--ilmn-20210111monthly0.5https://www.biopharmawatch.com/news/ILMN/llumina-to-acquire-grail-to-launch-new-era-of-cancer-detection-accelerates-commercializati-ilmn-20200921monthly0.5https://www.biopharmawatch.com/news/ILMN/document-dr-scott-gottlieb-former-us-fda-commissioner-joins-illumina-s-board-of-directors-ilmn-20200206monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-pacific-biosciences-announce-termination-of-merger-agreement-ilmn-20200102monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-preliminary-revenue-for-second-quarter-of-fiscal-year-2019-ilmn-20190711monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-names-susan-e-ilmn-20190205monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2025-results-columbus-ohio-usa-mtd-20260507monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2025-results-columbus-ohio-usa-mtd-20260205monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2025-results-columbus-ohio-usa-mtd-20251106monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2025-results-columbus-ohio-usa-mtd-20250731monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2025-results-columbus-ohio-usa-mtd-20250501monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2024-results-columbus-ohio-usa-mtd-20241107monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2024-results-columbus-ohio-usa-mtd-20240801monthly0.5https://www.biopharmawatch.com/news/MTD/brian-shepherd-joins-mettler-toledo-board-of-directors-columbus-ohio-usa-mtd-20240626monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2024-results-columbus-ohio-usa-mtd-20240509monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2023-results-columbus-ohio-usa-mtd-20240208monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-provides-update-on-fourth-quarter-2023-financial-results--mtd-20240104monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-mettler-toledo-announces-upcoming-retirement-of-board-cha-mtd-20231214monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2023-results-columbus-ohio-usa-mtd-20231109monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-wolfgang-wienand-to-join-mettler-toledo-board-of-director-mtd-20230801monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2023-results-columbus-ohio-usa-mtd-20230727monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2023-results-columbus-ohio-usa-mtd-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2022-results-columbus-ohio-usa-mtd-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-mettler-toledo-announces-change-to-board-of-directors-col-mtd-20221123monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-ingrid-zhang-to-join-mettler-toledo-board-of-directors-co-mtd-20221107monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2022-results-columbus-ohio-usa-mtd-20221103monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-roland-diggelmann-joins-mettler-toledo-board-of-directors-mtd-20220801monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2022-results-columbus-ohio-usa-mtd-20220728monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2022-results-columbus-ohio-usa-mtd-20220505monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2021-results-columbus-ohio-usa-mtd-20220210monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2021-results-columbus-ohio-usa-mtd-20211104monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2021-results-columbus-ohio-usa-mtd-20210729monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2021-results-columbus-ohio-usa-mtd-20210506monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-announces-acquisition-of-pendotech-columbus-ohio-usa-mtd-20210324monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2020-results-columbus-ohio-usa-mtd-20210204monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-announces-ceo-transition-patrick-kaltenbach-to-become-ceo-mtd-20201215monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2020-results-columbus-ohio-usa-mtd-20201105monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2020-results-columbus-ohio-usa-mtd-20200730monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2020-results-columbus-ohio-usa-mtd-20200507monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-provides-business-update-columbus-ohio-usa-mtd-20200413monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2019-results-columbus-ohio-usa-mtd-20200206monthly0.5https://www.biopharmawatch.com/news/MTD/director-announcement-exhibit-for-immediate-release-mettler-toledo-international-inc-annou-mtd-20191125monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2019-results-columbus-ohio-usa-mtd-20191107monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2019-results-columbus-ohio-usa-mtd-20190801monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2019-results-columbus-ohio-usa-mtd-20190509monthly0.5https://www.biopharmawatch.com/news/MTD/dated-mtd-20190208monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2018-results-excellent-sales-growt-mtd-20190207monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2018-results-very-good-sales-growth-mtd-20181108monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2018-results-very-good-sales-growt-mtd-20180726monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2018-results-strong-adjusted-eps-gr-mtd-20180503monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2017-results-good-sales-growth-con-mtd-20180208monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2017-results-good-sales-growth-stro-mtd-20171102monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2017-results-very-strong-sales-gro-mtd-20170727monthly0.5https://www.biopharmawatch.com/news/MTD/exhibit-for-immediate-release-mettler-toledo-mtd-20170705monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2017-results-excellent-sales-growth-mtd-20170504monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2016-results-strong-sales-growth-c-mtd-20170202monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2016-results-very-strong-sales-grow-mtd-20161103monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2016-results-strong-sales-growth-s-mtd-20160728monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2016-results-continued-solid-earnin-mtd-20160505monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2015-results-strong-margin-expansi-mtd-20160204monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2015-results-strong-margin-expansio-mtd-20151105monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2015-results-strong-margin-expansi-mtd-20150730monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-announces-connie-harvey-to-join-board-of-directors-columb-mtd-20150522monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2015-results-solid-local-currency-s-mtd-20150507monthly0.5https://www.biopharmawatch.com/news/MTD/second-amendment-to-the-credit-agreement-exhibit991amendmentno2toca2011-conformed-copy-ame-mtd-20150424monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2014-results-solid-sales-and-earni-mtd-20150205monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2014-results-strong-sales-and-earni-mtd-20141106monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-second-quarter-2014-results-solid-earnings-growth-mtd-20140724monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-first-quarter-2014-results-solid-earnings-growth--mtd-20140508monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-fourth-quarter-2013-results-solid-earnings-growth-mtd-20140205monthly0.5https://www.biopharmawatch.com/news/MTD/mettler-toledo-international-inc-reports-third-quarter-2013-results-market-conditions-impr-mtd-20131107monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-genevant-sciences-and-arbutus-biopharma-s-2-25-billion-global-settlement-roiv-20260303monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-first-quarter-ended-roiv-20250811monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-roiv-20250529monthly0.5https://www.biopharmawatch.com/news/ROIV/immunovant-announces-next-phase-of-growth-with-roivant-including-changes-to-its-leadership-roiv-20250421monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-positive-results-for-batoclimab-myasthenia-gravis-mg-and-chronic-inflamm-roiv-20250319monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-third-quarter-ended-roiv-20250210monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-topline-results-from-phase-2-resolve-lung-study-of-namilumab-in-chronic--roiv-20241203monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-second-quarter-ended-roiv-20241112monthly0.5https://www.biopharmawatch.com/news/ROIV/organon-completes-acquisition-of-dermavant-including-innovative-dermatologic-therapy-vtama-roiv-20241028monthly0.5https://www.biopharmawatch.com/news/ROIV/organon-to-acquire-dermavant-including-its-innovative-dermatologic-therapy-vtama-tapinarof-roiv-20240918monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-unveils-new-pipeline-program-mosliciguat-a-potential-first-in-class-and-best-in-ca-roiv-20240910monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-provides-update-on-graves-disease-development-program-high-dose-batoclimab-achieve-roiv-20240909monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-first-quarter-ended-roiv-20240808monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-roiv-20240530monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-positive-neptune-study-results-for-brepocitinib-in-niu-as-well-as-board--roiv-20240402monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-third-quarter-ended-roiv-20240213monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-positive-initial-phase-2-results-for-batoclimab-in-graves-disease-roiv-20231220monthly0.5https://www.biopharmawatch.com/news/ROIV/roche-completes-acquisition-of-telavant-from-roivant-including-rights-to-novel-tl1a-direct-roiv-20231214monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-positive-imvt-1402-initial-600-mg-mad-results-that-confirm-best-in-class-roiv-20231128monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-and-priovant-announce-results-from-phase-2-study-of-oral-brepocitinib-in-systemic--roiv-20231127monthly0.5https://www.biopharmawatch.com/news/ROIV/roche-enters-into-a-definitive-agreement-to-acquire-telavant-including-rights-to-novel-tl1-roiv-20231023monthly0.5https://www.biopharmawatch.com/news/ROIV/immunovant-announces-positive-initial-imvt-1402-phase-1-sad-and-300-mg-subcutaneous-mad-re-roiv-20230926monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-completion-of-redemption-of-its-outstanding-warrants-basel-switzerland-a-roiv-20230911monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-redemption-fair-market-value-in-connection-with-redemption-of-its-outsta-roiv-20230817monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-first-quarter-ended-roiv-20230814monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-redemption-of-outstanding-warrants-basel-switzerland-and-london-and-new--roiv-20230802monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-roiv-20230628monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-chronic-period-data-for-rvt-3101-from-the-tuscany-2-phase-2b-study-in-ulce-roiv-20230622monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-positive-topline-results-from-adoring-1-the-second-atopic-dermatitis-phase-roiv-20230516monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-positive-topline-results-from-adoring-2-atopic-dermatitis-phase-3-trial-of-roiv-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-reports-financial-results-for-the-third-quarter-ended-roiv-202302132023-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-announces-pricing-of-upsized-public-offering-of-common-shares-roiv-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-statistically-significant-and-clinically-meaningful-results-from-the-ind-roiv-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-and-pfizer-form-new-vant-company-focused-on-developing-tl1a-drug-candidate-for-inf-roiv-20221201monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-reports-financial-results-for-the-second-quarter-ended-roiv-20221114monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-announces-pricing-of-primary-and-secondary-public-equity-offering-basel-s-roiv-20221108monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-announces-proposed-public-equity-offering-basel-switzerland-london-new-yo-roiv-20221107monthly0.5https://www.biopharmawatch.com/news/ROIV/immunovant-announces-imvt-1402-a-next-generation-anti-fcrn-in-animal-studies-deep-igg-lowe-roiv-20220928monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-reports-financial-results-for-the-first-quarter-ended-roiv-20220815monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-roiv-20220628monthly0.5https://www.biopharmawatch.com/news/ROIV/fda-approves-dermavant-s-vtama-tapinarof-cream-1-for-the-treatment-of-plaque-psoriasis-in--roiv-20220524monthly0.5https://www.biopharmawatch.com/news/ROIV/forward-looking-statements-this-presentation-contains-forward-looking-statements-for-the-p-roiv-20220330monthly0.5https://www.biopharmawatch.com/news/ROIV/genevant-sciences-and-arbutus-biopharma-file-patent-infringement-lawsuit-against-moderna-c-roiv-20220228monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-reports-financial-results-for-the-quarter-ended-roiv-20220214monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-reports-financial-results-for-the-quarter-ended-roiv-20211115monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-announces-close-of-business-combination-with-montes-archimedes-acquisitio-roiv-20211001monthly0.5https://www.biopharmawatch.com/news/ROIV/statement-of-limitations-1-2-the-following-is-a-series-of-presentations-the-presentation-p-roiv-20210928monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-reports-first-fiscal-quarter-2021-financial-results-and-provides-business-roiv-20210921monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-clinical-update-on-phase-2b-cedar-study-study-did-not-meet-primary-or-seco-insm-20260407monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-u-insm-20260219monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-clinical-and-business-update-phase-2b-birch-study-of-brensocatib-in-crssnp-insm-20251217monthly0.5https://www.biopharmawatch.com/news/INSM/fda-approves-brinsupri-brensocatib-as-the-first-and-only-treatment-for-non-cystic-fibrosis-insm-20250812monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2025-financial-results-and-provides-business-update-arikayce-insm-20250807monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-proposed-650-million-public-offering-of-common-stock-bridgewater-n-j-insm-20250611monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-positive-topline-results-from-phase-2b-study-of-treprostinil-palmitil-inh-insm-20250610monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2025-financial-results-and-provides-business-update-arikayce--insm-20250508monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-redemption-of-all-569-5-million-of-remaining-outstanding-0-75-convertible-insm-20250424monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-that-fda-does-not-currently-plan-to-hold-advisory-committee-meeting-to-di-insm-20250224monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-u-insm-20250220monthly0.5https://www.biopharmawatch.com/news/INSM/fda-grants-priority-review-to-insmed-s-brensocatib-for-treatment-of-bronchiectasis-with-pd-insm-20250206monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-business-update-at-43rd-annual-j-p-morgan-healthcare-conference-arikayce-a-insm-20250110monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2024-financial-results-and-provides-business-update-arikayce--insm-20241031monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2024-financial-results-and-provides-business-update-arikayce-insm-20240808monthly0.5https://www.biopharmawatch.com/news/INSM/additional-positive-data-from-pivotal-aspen-study-of-brensocatib-in-patients-with-bronchie-insm-20240703monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-redemption-of-all-225-million-of-outstanding-1-75-convertible-senior-note-insm-20240627monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-incorporated-commercial-presentation-insm-20240604monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-proposed-500-million-public-offering-of-common-stock-bridgewater-n-j-insm-20240528monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-positive-topline-results-from-landmark-aspen-study-of-brensocatib-in-pati-insm-20240528monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2024-financial-results-and-provides-business-update-arikayce--insm-20240509monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-u-insm-20240222monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-business-update-at-42nd-annual-j-p-morgan-healthcare-conference-arikayce-a-insm-20240105monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2023-financial-results-and-provides-business-update-arikayce--insm-20231026monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-positive-topline-results-from-phase-3-arise-study-of-arikayce-amikacin-li-insm-20230905monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2023-financial-results-and-provides-business-update-arikayce-insm-20230803monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-unveils-new-research-platforms-and-capabilities-at-investor-and-analyst-event-the-f-insm-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2023-financial-results-and-provides-business-update-enrollmen-insm-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-u-insm-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2022-financial-results-and-provides-business-update-arikayce--insm-20221027monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-strategic-financings-totaling-775-million-500-million-secured-in-non-dilu-insm-20221019monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2022-financial-results-and-provides-business-update-arikayce-insm-20220804monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-names-drayton-wise-chief-commercial-officer-bridgewater-n-j-insm-20220523monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2022-financial-results-and-provides-business-update-arikayce--insm-20220505monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business-a-insm-20220217monthly0.5https://www.biopharmawatch.com/news/INSM/this-presentation-contains-forward-looking-statements-that-involve-substantial-risks-and-u-insm-20220110monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2021-financial-results-and-provides-business-update-arikayce--insm-20211028monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2021-financial-results-and-provides-business-update-arikayce-insm-20210805monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-closing-of-public-offerings-of-common-stock-and-convertible-senior-notes--insm-20210513monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-proposed-concurrent-public-offerings-of-common-stock-and-convertible-seni-insm-20210510monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2021-financial-results-and-provides-business-update-arikayce--insm-20210506monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-u-insm-20210225monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-topline-results-from-phase-1-study-of-treprostinil-palmitil-inhalation-po-insm-20210219monthly0.5https://www.biopharmawatch.com/news/INSM/promising-therapies-inspired-by-urgent-unmet-patient-needs-forward-looking-statements-this-insm-20210111monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2020-financial-results-and-provides-business-update-arikayce--insm-20201029monthly0.5https://www.biopharmawatch.com/news/INSM/european-commission-grants-marketing-authorization-for-arikayce-liposomal-590-mg-nebuliser-insm-20201028monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-highlights-progress-across-portfolio-and-outlines-growth-strategy-at-r-d-day-initia-insm-20200930monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2020-financial-results-and-provides-business-update-arikayce-insm-20200806monthly0.5https://www.biopharmawatch.com/news/INSM/final-insmed-receives-positive-chmp-opinion-for-arikayce-liposomal-590-mg-nebuliser-disper-insm-20200724monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwrit-insm-20200507monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-proposed-public-offering-of-common-stock-bridgewater-nj-insm-20200504monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2020-financial-results-and-provides-business-update-company-s-insm-20200430monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-carol-a-schafer-to-its-board-of-directors-bridgewater-n-j-insm-20200402monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-business-update-company-submits-new-drug-application-in-japan-for-arikayce-insm-20200316monthly0.5https://www.biopharmawatch.com/news/INSM/investor-presentation-february-2020-not-for-promotional-use-this-presentation-contains-for-insm-20200225monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-insm-20200225monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-positive-top-line-results-from-phase-2-willow-study-of-ins1007-in-patient-insm-20200203monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-sara-bonstein-as-chief-financial-officer-bridgewater-n-j-insm-20200130monthly0.5https://www.biopharmawatch.com/news/INSM/investor-presentation-january-2020-not-for-promotional-use-this-presentation-contains-forw-insm-20200113monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-dr-clarissa-desjardins-to-its-board-of-directors-and-names-roger-adsett-ch-insm-20191114monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2019-financial-insm-20191030monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2019-financial-results-and-provides-business-update-arikayce-insm-20190801monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-closing-of-public-offering-of-common-stock-bridgewater-nj-insm-20190524monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-proposed-public-offering-of-common-stock-bridgewater-nj-insm-20190520monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2019-financial-results-and-provides-business-update-arikayce--insm-20190507monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-update-on-arikayce-amikacin-liposome-inhalation-suspension-u-s-launch-arik-insm-20190408monthly0.5https://www.biopharmawatch.com/news/INSM/final-insmed-announces-management-changes-bridgewater-n-j-insm-20190327monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-business-u-insm-20190222monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-update-on-arikayce-amikacin-liposome-inhalation-suspension-u-s-launch-and--insm-20190104monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2018-financial-results-and-provides-business-update-pdufa-pr-insm-20180802monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-leo-lee-to-its-board-of-directors-pharmaceutical-executive-brings-insights-insm-20180517monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-fda-acceptance-for-filing-of-new-drug-application-for-alis-in-ntm-lung-di-insm-20180516monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2018-financial-results-and-provides-business-update-insm-20180502monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-submits-new-drug-application-to-fda-for-alis-in-ntm-lung-disease-caused-by-mac-alis-insm-20180329monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-business-u-insm-20180223monthly0.5https://www.biopharmawatch.com/news/INSM/investor-presentation-safe-harbor-statement-2-this-presentation-contains-forward-looking-s-insm-20180214monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-closing-of-public-offering-bridgewater-nj-insm-20180126monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-proposed-public-offering-of-convertible-senior-notes-bridgewater-nj-insm-20180122monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-additional-data-from-alis-amikacin-liposome-inhalation-suspension-phase-3-insm-20180103monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2017-financial-results-and-provides-business-update-during-th-insm-20171102monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-closing-of-public-offering-bridgewater-nj-insm-20170911monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-proposed-public-offering-of-common-stock-bridgewater-nj-insm-20170905monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-positive-top-line-results-from-phase-3-convert-study-of-alis-amikacin-lip-insm-20170905monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2017-financial-results-and-provides-business-update-on-track-insm-20170803monthly0.5https://www.biopharmawatch.com/news/INSM/welcome-opening-remarks-will-lewis-president-and-chief-executive-officer-ntm-and-the-unmet-insm-20170719monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-key-additions-to-its-executive-management-team-paolo-tombesi-named-as-chi-insm-20170515monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2017-financial-results-and-provides-business-update-advancing-insm-20170503monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-2016-financial-results-and-provides-business-update-on-track-insm-20170223monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2016-financial-results-and-provides-business-update-enrollmen-insm-20161103monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2026-first-quarter-total-revenue-from-contin-ste-20250806monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2025-fourth-quarter-and-full-year-full-year--ste-20250514monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2025-third-quarter-total-revenue-from-contin-ste-20250205monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2025-second-quarter-total-revenue-from-conti-ste-20241106monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2025-first-quarter-total-revenue-from-contin-ste-20240806monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2024-fourth-quarter-and-full-year-total-fisc-ste-20240508monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-sell-dental-segment-to-an-affiliate-of-peak-rock-capital-transaction-expected-to-ste-20240411monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2024-third-quarter-third-quarter-revenue-inc-ste-20240207monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2024-second-quarter-second-quarter-revenue-g-ste-20231107monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2024-first-quarter-first-quarter-revenue-gro-ste-20230801monthly0.5https://www.biopharmawatch.com/news/STE/steris-expands-healthcare-products-offering-with-acquisition-of-surgical-instrumentation-a-ste-20230620monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2023-fourth-quarter-and-full-year-fourth-qua-ste-202305102023-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-appoints-esther-m-alegria-ph-d-to-board-of-directors-dublin-ireland-ste-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2023-third-quarter-as-reported-revenue-incre-ste-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2023-second-quarter-as-reported-revenue-was--ste-20221109monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2023-first-quarter-first-quarter-revenue-inc-ste-20220802monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2022-fourth-quarter-and-full-year-fourth-qua-ste-20220511monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2022-third-quarter-third-quarter-revenue-inc-ste-20220208monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2022-second-quarter-second-quarter-revenue-i-ste-20211102monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2022-first-quarter-first-quarter-revenue-inc-ste-20210809monthly0.5https://www.biopharmawatch.com/news/STE/unaudited-pro-forma-condensed-combined-financial-data-the-following-unaudited-condensed-co-ste-20210608monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2021-fourth-quarter-and-full-year-fourth-qua-ste-20210518monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-changes-to-board-of-directors-david-b-lewis-to-retire-at-the-company-s-20-ste-20210511monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-preliminary-financial-results-for-fiscal-2021-company-expects-to-close-th-ste-20210427monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-leadership-succession-plan-walt-rosebrough-to-step-down-as-ceo-at-the-upc-ste-20210203monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2021-third-quarter-third-quarter-revenue-inc-ste-20210202monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-definitive-agreement-to-acquire-cantel-medical-complementary-to-steris-s--ste-20210112monthly0.5https://www.biopharmawatch.com/news/STE/privileged-and-confidential-steris-completes-acquisition-of-key-surgical-dublin-ireland-ste-20201118monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2021-second-quarter-second-quarter-revenue-i-ste-20201102monthly0.5https://www.biopharmawatch.com/news/STE/steris-expands-healthcare-consumables-offering-with-acquisition-of-key-surgical-for-approx-ste-20201006monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2021-first-quarter-first-quarter-revenue-dec-ste-20200803monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2020-fourth-quarter-and-full-year-strong-fou-ste-20200513monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2020-third-quarter-third-quarter-revenue-gro-ste-20200210monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2020-second-quarter-second-quarter-revenue-g-ste-20191104monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2020-first-quarter-first-quarter-revenue-gro-ste-20190805monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-financial-results-for-fiscal-2019-fourth-quarter-and-full-year-strong-fou-ste-20190513monthly0.5https://www.biopharmawatch.com/news/WST/west-reports-first-quarter-2026-results-wst-20260423monthly0.5https://www.biopharmawatch.com/news/WST/west-reports-fourth-quarter-and-full-year-2025-results-wst-20260212monthly0.5https://www.biopharmawatch.com/news/WST/west-reports-third-quarter-2025-results-wst-20251023monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2025-results-and-fourth-quarter-2025-dividend-updates-full-y-wst-20250724monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2025-results-increases-adjusted-diluted-eps-guidance-and-decl-wst-20250424monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2024-results-wst-20250213monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-john-sweeney-cfa-michele-polinsky-vice-president-investor-r-wst-20241211monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2024-results-increases-fiscal-year-2024-guidance-and-declares-wst-20241024monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2024-results-conference-call-scheduled-for-9-a-m-edt-today-e-wst-20240725monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2024-results-and-declares-third-quarter-2024-dividend-confere-wst-20240425monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2023-results-conference-call-scheduled-for-9-a-wst-20240215monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2023-results-updates-full-year-2023-guidance-and-declares-fou-wst-20231026monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2023-results-wst-20230727monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2023-results-and-wst-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2022-results-wst-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2022-results-updates-full-year-2022-guidance-and-declares-fou-wst-20221027monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2022-results-wst-20220728monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-quintin-lai-michele-polinsky-vice-president-investor-relati-wst-20220727monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-quintin-lai-michele-polinsky-vice-president-investor-relati-wst-20220512monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2022-results-and-declares-third-quarter-2022-dividend-wst-20220428monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2021-results-conference-call-scheduled-for-9-a-wst-20220217monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2021-results-and-declares-fourth-quarter-2021-dividend-confer-wst-20211028monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-quintin-lai-michele-pelkowski-vice-president-investor-relat-wst-20210823monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2021-results-wst-20210729monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2021-results-wst-20210429monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2020-results-wst-20210218monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2021-dividend-2021-share-repurchase-program-and-participation-wst-20201209monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-kimberly-banks-mackay-as-senior-vice-president-general-counsel-and-corporate-wst-20201109monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-increase-to-fourth-quarter-2020-dividend-wst-20201028monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2020-results-wst-20201022monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2020-results-wst-20200723monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2020-dividend-wst-20200715monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2020-results-wst-20200423monthly0.5https://www.biopharmawatch.com/news/WST/west-elects-new-director-to-the-board-wst-20200218monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2019-results-wst-20200213monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-quintin-lai-emily-denney-vice-president-investor-relations--wst-20191213monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2019-results-wst-20191024monthly0.5https://www.biopharmawatch.com/news/WST/west-increases-equity-stake-in-daikyo-seiko-ltd-wst-20191016monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2019-results-and-wst-20190725monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2019-results-wst-20190425monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-quintin-lai-emily-denney-vice-president-investor-relations--wst-20190221monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2018-results-wst-20190214monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2018-results-wst-20181025monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2018-results-wst-20180726monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-quintin-lai-emily-denney-vice-president-investor-relations--wst-20180621monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-participation-in-upcoming-june-investor-conferences-wst-20180524monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-dividend-increase-to-fourth-quarter-dividend-and-participatio-wst-20180503monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2018-results-wst-20180426monthly0.5https://www.biopharmawatch.com/news/WST/west-chief-financial-officer-william-federici-announces-plans-to-retire-wst-20180302monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2017-results-and-wst-20180215monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-upcoming-investor-conference-wst-20171115monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2017-results-wst-20171026monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2017-results-wst-20170727monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-quintin-lai-emily-denney-vice-president-investor-relations--wst-20170720monthly0.5https://www.biopharmawatch.com/news/WST/investor-contact-media-contact-quintin-lai-emily-denney-vice-president-investor-relations--wst-20170601monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-and-participation-in-upcoming-investor-conferences-wst-20170517monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2017-results-wst-20170428monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2016-results-and-wst-20170216monthly0.5https://www.biopharmawatch.com/news/WST/investor-and-media-contact-west-quintin-lai-investor-relations-1-610-594-3318-quintin-lai--wst-20161214monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2016-results-wst-20161027monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-david-a-wst-20160926monthly0.5https://www.biopharmawatch.com/news/WST/west-elects-new-director-and-announces-increase-to-quarterly-dividend-wst-20160912monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2016-results-wst-20160728monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2016-results-wst-20160428monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-inc-in-millions-except-per-share-data-presented-as-if-2016-re-wst-20160304monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2015-results-wst-20160218monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-new-organizational-structure-wst-20160112monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-and-share-repurchase-program-wst-20151217monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-george-l-wst-20151120monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2015-results-wst-20151029monthly0.5https://www.biopharmawatch.com/news/WST/general-media-inquiries-investors-and-financial-media-emily-denney-senior-director-communi-wst-20150910monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2015-results-wst-20150730monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2015-results-wst-20150430monthly0.5https://www.biopharmawatch.com/news/WST/eric-green-appointed-chief-executive-officer-of-west-pharmaceutical-services-exton-pa-wst-20150415monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2014-results-wst-20150219monthly0.5https://www.biopharmawatch.com/news/WST/west-michael-a-anderson-vice-president-and-treasurer-610-594-3345-investors-and-financial--wst-20141201monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2014-results-wst-20141030monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-announces-ceo-retirement-and-succession-plan-wst-20141015monthly0.5https://www.biopharmawatch.com/news/WST/west-names-new-president-of-pharmaceutical-packaging-systems-wst-20141007monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-plans-for-a-new-pharmaceutical-component-wst-20141002monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2014-results-wst-20140731monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-10-increase-in-quarterly-dividend-wst-20140717monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-to-acquire-vega-therapeutics-a-wholly-owned-subsidiary-of-star-therapeutics-expandi-incy-20260608monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-first-quarter-2026-financial-results-and-provides-business-updates-incy-20260428monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-announces-executive-leadership-appointments-incy-20260326monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-fourth-quarter-and-full-year-2025-financial-results-incy-20260210monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-third-quarter-2025-financial-results-and-provides-business-updates-incy-20251028monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2025-second-quarter-financial-results-and-provides-updates-incy-20250729monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2025-first-quarter-financial-results-and-provides-updates-incy-20250429monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2024-fourth-quarter-and-year-end-financial-results-incy-20250210monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2024-third-quarter-financial-results-and-provides-updates-incy-20241029monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2024-second-quarter-financial-results-and-provides-updates-incy-20240730monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-announces-intention-to-buy-back-up-to-2-0-billion-of-its-common-stock-incyte-commen-incy-20240513monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2024-first-quarter-financial-results-and-provides-updates-incy-20240430monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2023-fourth-quarter-and-year-end-financial-results-incy-20240213monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2023-third-quarter-financial-results-and-provides-updates-incy-20231031monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2023-second-quarter-financial-results-and-provides-updates-incy-20230801monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2023-first-quarter-financial-results-and-incy-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2022-fourth-quarter-and-year-end-financial-results-incy-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2022-third-quarter-financial-results-and-provides-updates-on-key-incy-20221101monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2022-second-quarter-financial-results-and-provides-updates-on-key-clinical--incy-20220802monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2022-first-quarter-financial-results-and-provides-updates-on-key-clinical-p-incy-20220503monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2021-fourth-quarter-and-year-end-financial-results-and-provides-2022-financ-incy-20220208monthly0.5https://www.biopharmawatch.com/news/INCY/corporate-statement-regarding-opzelura-ruxolitinib-cream-incy-20211102monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2021-third-quarter-financial-results-and-provides-updates-on-key-clinical-p-incy-20211102monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2021-second-quarter-financial-results-and-provides-updates-on-key-clinical--incy-20210803monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2021-first-quarter-financial-results-and-provides-updates-on-key-clinical-p-incy-20210504monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2020-fourth-quarter-and-year-end-financial-results-provides-2021-financial--incy-20210209monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2020-third-quarter-financial-results-and-provides-updates-on-key-clinical-p-incy-20201105monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2020-second-quarter-financial-results-and-provides-updates-on-key-clinical--incy-20200804monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2020-first-quarter-financial-results-and-provides-updates-on-key-clinical-p-incy-20200505monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2019-fourth-quarter-and-year-end-financial-results-and-provides-2020-financ-incy-20200213monthly0.5https://www.biopharmawatch.com/news/INCY/planegg-munich-germany-and-wilmington-delaware-u-s-incy-20200113monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2019-third-quarter-financial-results-and-provides-updates-on-key-clinical-p-incy-20191029monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2019-second-quarter-financial-results-and-provides-updates-on-key-clinical--incy-20190730monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2019-first-quarter-financial-results-and-provides-updates-on-key-clinical-p-incy-20190430monthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-2018-fourth-quarter-and-year-end-financial-results-provides-2019-financial--incy-20190214monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-first-quarter-2026-results-first-quarter-2026-1-strong-rev-uls-20260505monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-broadens-portfolio-with-agreement-to-acquire-eurofins-scientific-s-electr-uls-20260413monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-fourth-quarter-and-full-year-2025-results-announces-2026-g-uls-20260219monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-third-quarter-2025-results-third-quarter-2025-1-strong-rev-uls-20251104monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-announces-executive-leadership-changes-new-leadership-roles-position-the-comp-uls-20250814monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-second-quarter-2025-results-second-quarter-2025-1-strong-r-uls-20250805monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-first-quarter-2025-results-first-quarter-2025-comparisons--uls-20250506monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-fourth-quarter-and-full-year-2024-results-fourth-quarter-2-uls-20250220monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-announces-updates-to-board-of-directors-northbrook-illinois-uls-20250214monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-names-chief-business-operations-and-innovation-officer-alex-dadakis-to-join-u-uls-20241205monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-third-quarter-2024-results-third-quarter-2024-comparisons--uls-20241105monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-second-quarter-2024-results-second-quarter-2024-comparison-uls-20240731monthly0.5https://www.biopharmawatch.com/news/ULS/ul-solutions-inc-reports-strong-first-quarter-2024-results-first-quarter-2024-comparisons--uls-20240520monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-first-quarter-2026-financial-results-delivers-total-revenues-of-3-vtrs-20260507monthly0.5https://www.biopharmawatch.com/news/VTRS/forward-looking-statements-this-press-release-includes-statements-that-constitute-forward--vtrs-20260504monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-fourth-quarter-and-full-year-2025-financial-results-reports-fourt-vtrs-20260226monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-third-quarter-2025-results-and-updates-2025-financial-guidance-de-vtrs-20251106monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-second-quarter-2025-results-and-reiterates-2025-financial-guidanc-vtrs-20250807monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-appointment-of-david-simmons-to-the-company-s-board-of-directors-pittsbu-vtrs-20250805monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-first-quarter-2025-results-and-reaffirms-2025-outlook-delivers-to-vtrs-20250508monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-appointments-of-frank-d-amelio-and-michael-severino-m-d-to-the-company-s-vtrs-20250505monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides--vtrs-20250227monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-third-quarter-financial-results-for-2024-total-revenues-of-3-8-bi-vtrs-20241107monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-cash-tender-offers-for-certain-outstanding-notes-1-pittsburgh-vtrs-20240904monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-second-quarter-financial-results-for-2024-strong-results-demonstr-vtrs-20240808monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-appoints-rogerio-vivaldi-coelho-m-d-to-board-of-directors-pittsburgh-vtrs-20240603monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-first-quarter-2024-financial-results-and-reaffirms-2024-fi-vtrs-20240509monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides--vtrs-20240228monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-continues-its-preparations-for-phase-2-of-its-strategic-plan-by-announcing-the-app-vtrs-20231215monthly0.5https://www.biopharmawatch.com/news/VTRS/robert-j-coury-remarks-at-the-2023-viatris-annual-meeting-of-shareholders-the-end-of-one-e-vtrs-20231215monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-financial-and-operational-results-for-the-third-quarter-20-vtrs-20231107monthly0.5https://www.biopharmawatch.com/news/VTRS/rajiv-malik-to-retire-as-president-of-viatris-effective-vtrs-20231020monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-agreements-on-remaining-planned-divestitures-upon-closing-would-achieve--vtrs-20231001monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-financial-and-operational-results-for-second-quarter-2023--vtrs-20230807monthly0.5https://www.biopharmawatch.com/news/VTRS/robert-j-coury-to-transition-from-executive-chairman-of-viatris-to-chairman-emeritus-and-s-vtrs-20230522monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-financial-and-operational-results-for-first-quarter-2023-a-vtrs-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-appointment-of-scott-a-smith-as-ceo-effective-vtrs-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-fourth-quarter-and-full-year-2022-financial-results-and-pr-vtrs-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-appointments-of-scott-a-smith-and-elisha-w-finney-to-the-company-s-board-vtrs-20221229monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-completes-biosimilars-transaction-with-biocon-biologics-receives-a-2-billion-cash--vtrs-20221129monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-two-acquisitions-to-create-what-it-expects-to-be-a-leading-ophthalmology-vtrs-20221107monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-third-quarter-2022-results-reaffirms-2022-guidance-ranges--vtrs-20221107monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-second-quarter-2022-results-reports-total-revenues-of-4-12-vtrs-20220808monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-first-quarter-2022-results-first-quarter-2022-results-refl-vtrs-20220509monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-fourth-quarter-and-full-year-2021-financial-results-and-is-vtrs-20220228monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-reports-strong-second-quarter-results-board-of-directors-declares-quarter-vtrs-20210809monthly0.5https://www.biopharmawatch.com/news/VTRS/document-viatris-inc-reports-strong-first-quarter-2021-financial-results-reaffirms-2021-gu-vtrs-20210510monthly0.5https://www.biopharmawatch.com/news/VTRS/to-upjohn-s-current-report-on-form-8-k-filed-on-vtrs-20210222monthly0.5https://www.biopharmawatch.com/news/VTRS/upjohn-a-business-unit-of-pfizer-inc-combined-financial-statements-as-of-vtrs-20200529monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-first-quarter-2026-financial-results-and-provides-business-updates-reports-mrna-20260501monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-provides-business-and-pipeline-updates-at-44th-annual-j-p-morgan-healthcare-confer-mrna-20260112monthly0.5https://www.biopharmawatch.com/news/MRNA/document-mrna-20260105monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-analyst-day-highlights-pipeline-progress-and-business-strategy-updates-announces-t-mrna-20251120monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-third-quarter-2025-financial-results-and-provides-business-updates-reports-mrna-20251106monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-second-quarter-2025-financial-results-and-provides-business-updates-report-mrna-20250801monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-first-quarter-2025-financial-results-and-provides-business-updates-reports-mrna-20250501monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-busines-mrna-20250214monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-provides-business-and-pipeline-updates-at-43rd-annual-j-p-morgan-healthcare-confer-mrna-20250113monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-third-quarter-2024-financial-results-and-provides-business-updates-reports-mrna-20241107monthly0.5https://www.biopharmawatch.com/news/MRNA/abbas-hussain-joins-moderna-s-board-of-directors-hussain-brings-more-than-35-years-of-comm-mrna-20241002monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-r-d-day-highlights-progress-and-strategic-priorities-focuses-on-ten-product-approv-mrna-20240912monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-second-quarter-2024-financial-results-and-provides-business-updates-report-mrna-20240801monthly0.5https://www.biopharmawatch.com/news/MRNA/david-rubenstein-joins-moderna-s-board-of-directors-co-founder-and-co-chairman-of-the-carl-mrna-20240723monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-first-quarter-2024-financial-results-and-provides-business-updates-reports-mrna-20240502monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-provides-busines-mrna-20240222monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-provides-business-and-pipeline-updates-at-42-nd-annual-j-p-morgan-healthcare-confe-mrna-20240108monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-third-quarter-2023-financial-results-and-provides-business-updates-third-q-mrna-20231102monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-and-immatics-announce-strategic-multi-platform-collaboration-to-develop-innovative-mrna-20230911monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-second-quarter-2023-financial-results-and-provides-business-updates-second-mrna-20230803monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-first-quarter-2023-financial-results-and-provides-business-updates-first-q-mrna-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and-provides-busines-mrna-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-announces-advances-across-mrna-pipeline-and-provides-business-update-covid-19-vacc-mrna-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vacc-mrna-20221213monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-creates-new-executive-committee-role-ahead-of-new-product-launches-juan-andres-app-mrna-20220929monthly0.5https://www.biopharmawatch.com/news/MRNA/james-mock-joins-moderna-as-chief-financial-officer-cambridge-ma-accesswire-mrna-20220817monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-second-quarter-2022-financial-results-and-provides-business-updates-second-mrna-20220803monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-first-quarter-2022-financial-results-and-provides-business-updates-first-q-mrna-20220504monthly0.5https://www.biopharmawatch.com/news/MRNA/jorge-gomez-joins-moderna-as-chief-financial-officer-cambridge-mass-access-wire-mrna-20220411monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-fourth-quarter-and-fiscal-year-2021-financial-results-and-provides-busines-mrna-20220224monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-announces-advances-across-its-industry-leading-mrna-pipeline-and-provides-business-mrna-20220110monthly0.5https://www.biopharmawatch.com/news/MRNA/document-mrna-20220104monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-third-quarter-fiscal-year-2021-financial-results-and-provides-business-upd-mrna-20211104monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-second-quarter-fiscal-year-2021-financial-results-and-provides-business-up-mrna-20210805monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-reports-first-quarter-fiscal-year-2021-financial-results-and-provides-business-upd-mrna-20210506monthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-provides-clinical-and-supply-updates-on-covid-19-vaccine-program-ahead-of-2-nd-ann-mrna-20210413monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-first-quarter-2026-financial-results-raises-revenue-and-eps-guid-dgx-20260421monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-elects-timothy-wentworth-former-ceo-of-walgreens-boots-alliance-evernort-dgx-20260312monthly0.5https://www.biopharmawatch.com/news/DGX/driving-sustainable-growth-delivering-long-term-value-jim-davis-chairman-ceo-and-president-dgx-20260112monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-third-quarter-2025-financial-results-raises-guidance-for-full-ye-dgx-20251021monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-second-quarter-2025-financial-results-raises-guidance-for-full-y-dgx-20250722monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-first-quarter-2025-financial-results-reaffirms-revenue-and-adjus-dgx-20250422monthly0.5https://www.biopharmawatch.com/news/DGX/investor-day-presentation-davis-investor-day-2025-quest-diagnostics-driving-sustainable-gr-dgx-20250319monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-to-highlight-strategic-priorities-to-drive-sustainable-growth-and-delive-dgx-20250319monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-fourth-quarter-and-full-year-2024-financial-results-provides-gui-dgx-20250130monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-third-quarter-2024-financial-results-updates-guidance-for-full-y-dgx-20241022monthly0.5https://www.biopharmawatch.com/news/DGX/dgx082320248-kex991-dgx-20240829monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-prices-1-85-billion-of-senior-notes-secaucus-nj-dgx-20240815monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-second-quarter-2024-financial-results-raises-guidance-for-full-y-dgx-20240723monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-to-acquire-lifelabs-from-omers-enhancing-diagnostic-services-for-canadia-dgx-20240703monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-elects-robert-b-carter-cio-of-fedex-corporation-to-board-of-directors-se-dgx-20240516monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-first-quarter-2024-financial-results-raises-guidance-for-full-ye-dgx-20240423monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-fourth-quarter-and-full-year-2023-financial-results-provides-gui-dgx-20240201monthly0.5https://www.biopharmawatch.com/news/DGX/government-investigations-lawsuits-or-private-actions-the-competitive-environment-the-comp-dgx-20231101monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-third-quarter-2023-financial-results-updates-guidance-for-full-y-dgx-20231024monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-second-quarter-2023-financial-results-updates-guidance-for-full--dgx-20230726monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-first-quarter-2023-financial-results-updates-guidance-for-full-y-dgx-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-to-discuss-strategic-priorities-to-drive-growth-and-create-shareholder-v-dgx-202303172023-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-board-of-directors-elects-james-e-davis-chairman-of-the-board-secaucus-n-dgx-202303072023-03-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-fourth-quarter-and-full-year-2022-financial-results-provides-gui-dgx-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-completes-leadership-succession-as-jim-davis-becomes-ceo-and-president-j-dgx-20221101monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-third-quarter-2022-financial-results-raises-guidance-for-full-ye-dgx-20221020monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-second-quarter-2022-financial-results-raises-guidance-for-full-y-dgx-20220721monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-names-sam-samad-executive-vice-president-and-chief-financial-officer-sec-dgx-20220609monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-first-quarter-2022-financial-results-raises-guidance-for-full-ye-dgx-20220421monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-announces-leadership-succession-plan-chairman-and-ceo-steve-rusckowski-t-dgx-20220203monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-fourth-quarter-and-full-year-2021-financial-results-provides-gui-dgx-20220203monthly0.5https://www.biopharmawatch.com/news/DGX/document-quest-diagnostics-announces-preliminary-fourth-quarter-and-full-year-2021-dgx-20220112monthly0.5https://www.biopharmawatch.com/news/DGX/document-quest-diagnostics-reports-third-quarter-2021-financial-results-raises-outlook-for-dgx-20211021monthly0.5https://www.biopharmawatch.com/news/DGX/document-ex-99-1-quest-diagnostics-elects-tracey-c-doi-to-board-of-directors-secaucus-n-j-dgx-20210817monthly0.5https://www.biopharmawatch.com/news/DGX/document-quest-diagnostics-reports-second-quarter-2021-financial-results-establishes-full--dgx-20210722monthly0.5https://www.biopharmawatch.com/news/DGX/document-quest-diagnostics-reports-first-quarter-2021-financial-results-announces-plan-for-dgx-20210422monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-updates-strategic-growth-drivers-and-provides-long-term-outlook-at-2021--dgx-20210311monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-announces-board-leadership-changes-daniel-c-stanzione-to-retire-from-boa-dgx-20210223monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-fourth-quarter-and-full-year-2020-financial-results-establishes--dgx-20210204monthly0.5https://www.biopharmawatch.com/news/DGX/document-quest-diagnostics-raises-outlook-for-full-year-2020-revenues-for-full-year-2020-e-dgx-20201216monthly0.5https://www.biopharmawatch.com/news/DGX/document-quest-diagnostics-reports-third-quarter-2020-financial-results-reflecting-continu-dgx-20201022monthly0.5https://www.biopharmawatch.com/news/DGX/document-quest-diagnostics-updates-outlook-for-full-year-2020-revenues-for-full-year-2020--dgx-20200910monthly0.5https://www.biopharmawatch.com/news/DGX/document-quest-diagnostics-reports-second-quarter-2020-financial-results-second-quarter-re-dgx-20200723monthly0.5https://www.biopharmawatch.com/news/DGX/secaucus-n-j-dgx-20200511monthly0.5https://www.biopharmawatch.com/news/DGX/fourth-amended-and-restated-receivables-sales-agreement-execution-version-fourth-amended-a-dgx-20200504monthly0.5https://www.biopharmawatch.com/news/DGX/on-march-31-2020-quest-diagnostics-filed-a-current-report-on-form-8-k-with-the-securities--dgx-20200422monthly0.5https://www.biopharmawatch.com/news/DGX/letter-to-quest-colleagues-an-email-to-colleagues-about-our-business-from-steve-rusckowski-dgx-20200413monthly0.5https://www.biopharmawatch.com/news/DGX/exhibit-quest-diagnostics-elects-wright-lassiter-iii-to-board-of-directors-secaucus-n-j-dgx-20200312monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-prices-800-million-of-senior-notes-dgx-20191209monthly0.5https://www.biopharmawatch.com/news/DGX/changes-in-government-regulations-changing-relationships-with-customers-payers-suppliers-o-dgx-20191022monthly0.5https://www.biopharmawatch.com/news/DGX/management-s-current-estimates-projections-expectations-or-beliefs-and-which-involve-risks-dgx-20190723monthly0.5https://www.biopharmawatch.com/news/DGX/changes-in-government-regulations-changing-relationships-with-customers-payers-suppliers-o-dgx-20190423monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-prices-500-million-of-senior-notes-dgx-20190307monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-elects-denise-morrison-to-board-of-directors-secaucus-n-j-dgx-20190219monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-fourth-quarter-and-full-year-2018-financial-results-provides-gui-dgx-20190214monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-to-discuss-strategic-growth-drivers-and-financial-outlook-at-2018-invest-dgx-20181128monthly0.5https://www.biopharmawatch.com/news/DGX/the-statements-in-this-press-release-which-are-not-historical-facts-may-be-forward-looking-dgx-20181023monthly0.5https://www.biopharmawatch.com/news/DGX/actual-results-and-outcomes-to-be-materially-different-dgx-20180724monthly0.5https://www.biopharmawatch.com/news/DGX/exhibit-unitedhealthcare-establishes-long-term-strategic-partnership-with-quest-diagnostic-dgx-20180525monthly0.5https://www.biopharmawatch.com/news/DGX/the-statements-in-this-press-release-which-are-not-historical-facts-may-be-forward-looking-dgx-20180419monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-fourth-quarter-and-full-year-2017-financial-results-provides-gui-dgx-20180201monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-provides-update-on-impact-of-final-2018-medicare-payment-rates-for-clini-dgx-20171120monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-provides-update-on-impact-to-third-quarter-financial-results-from-hurric-dgx-20170927monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-second-quarter-2017-financial-results-raises-2017-financial-outl-dgx-20170725monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-first-quarter-2017-financial-results-raises-2017-financial-outlo-dgx-20170420monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-fourth-quarter-and-full-year-2016-financial-results-provides-gui-dgx-20170126monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-board-of-directors-elects-stephen-h-rusckowski-chairman-of-the-board-dan-dgx-20161215monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-raises-revenue-growth-outlook-increases-dividend-at-2016-investor-day-re-dgx-20161111monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-third-quarter-2016-financial-results-revenues-of-1-89-billion-up-dgx-20160930monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-reports-second-quarter-2016-financial-results-q2-2016-revenues-of-1-91-b-dgx-20160630monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-announces-proposed-senior-notes-offering-dgx-20160523monthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-completes-effort-to-refocus-on-diagnostic-information-services-updates-2-dgx-20160518monthly0.5https://www.biopharmawatch.com/news/PHG/not-for-release-publication-or-distribution-in-or-into-or-to-any-person-resident-and-or-lo-phg-20220505monthly0.5https://www.biopharmawatch.com/news/PHG/press-information-phg-20220428monthly0.5https://www.biopharmawatch.com/news/PHG/nonqualified-stock-purchase-plan-appendix-a-plan-specifications-for-koninklijke-philips-el-phg-20080319monthly0.5https://www.biopharmawatch.com/news/PHG/annual-report-exv99w1-table-of-contents-a-new-approach-to-annual-reporting-philips-is-stri-phg-20050223monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-first-quarter-2026-financial-results-and-increases-2026-r-gh-20260507monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-fourth-quarter-and-full-year-2025-financial-results-and-p-gh-20260219monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-preliminary-fourth-quarter-and-full-year-2025-results-fourth-qua-gh-20260111monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-pricing-of-upsized-public-offering-of-common-stock-gh-20251105monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-third-quarter-2025-financial-results-and-increases-2025-r-gh-20251029monthly0.5https://www.biopharmawatch.com/news/GH/alex-m-azar-ii-joins-guardant-health-board-of-directors-gh-20250915monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-second-quarter-2025-financial-results-and-increases-2025--gh-20250730monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-first-quarter-2025-financial-results-and-increases-2025-r-gh-20250430monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-fourth-quarter-and-full-year-2024-financial-results-and-p-gh-20250220monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-debt-exchange-transactions-gh-20250207monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-preliminary-fourth-quarter-and-full-year-2024-results-full-year--gh-20250113monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-third-quarter-2024-financial-results-and-increases-2024-r-gh-20241106monthly0.5https://www.biopharmawatch.com/news/GH/roberto-a-mignone-joins-guardant-health-board-of-directors-palo-alto-calif-gh-20241024monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-second-quarter-2024-financial-results-and-increases-2024--gh-20240807monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-s-shield-tm-blood-test-approved-by-fda-as-a-primary-screening-option-clear-gh-20240729monthly0.5https://www.biopharmawatch.com/news/GH/dr-manuel-hidalgo-medina-joins-guardant-health-board-of-directors-palo-alto-calif-gh-20240718monthly0.5https://www.biopharmawatch.com/news/GH/fda-advisory-committee-panel-strongly-recommends-approval-of-shield-blood-test-for-colorec-gh-20240523monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-first-quarter-2024-financial-results-and-increases-2024-r-gh-20240509monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-fourth-quarter-and-full-year-2023-financial-results-and-p-gh-20240222monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-preliminary-fourth-quarter-and-full-year-2023-results-full-year--gh-20240108monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-90-7-million-registered-direct-offering-with-baillie-gifford-gh-20231221monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-tentative-date-of-fda-advisory-panel-review-of-shield-blood-test-gh-20231219monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-to-appeal-federal-district-court-verdict-palo-alto-calif-business-wire-gh-20231115monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-third-quarter-2023-financial-results-and-increases-revenu-gh-20231106monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-second-quarter-2023-financial-results-and-increases-reven-gh-20230803monthly0.5https://www.biopharmawatch.com/news/GH/guardant-resolves-pending-litigation-with-illumina-and-enters-into-new-agreement-to-advanc-gh-20230801monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-first-quarter-2023-financial-results-q1-revenue-increased-gh-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-presents-additional-information-from-eclipse-study-at-2023-digestive-disea-gh-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-additions-to-leadership-team-ines-dahne-steuber-named-as-chief-o-gh-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/musa-tariq-joins-guardant-health-board-of-directors-gh-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-fourth-quarter-and-full-year-2022-financial-results-and-p-gh-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-announces-preliminary-fourth-quarter-and-full-year-2022-results-f-gh-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-announces-positive-results-from-pivotal-eclipse-study-evaluating--gh-20221215monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-third-quarter-2022-financial-results-q3-clinical-and-biop-gh-20221103monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-second-quarter-2022-financial-results-q2-clinical-and-bio-gh-20220804monthly0.5https://www.biopharmawatch.com/news/GH/steve-e-krognes-joins-guardant-health-board-of-directors-gh-20220707monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-completes-purchase-of-guardant-health-amea-joint-venture-gh-20220613monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-first-quarter-2022-financial-results-q1-clinical-and-biop-gh-20220505monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-fourth-quarter-2021-financial-results-and-provides-2022-o-gh-20220223monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-and-foundation-medicine-reach-settlement-in-digital-sequencing-technology--gh-20220107monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-third-quarter-2021-financial-results-achieved-record-reve-gh-20211104monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-appoints-myrtle-potter-to-its-board-of-directors-gh-20211020monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-announces-new-leadership-structure-aligned-with-strategic-growth-objective-gh-20210805monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-second-quarter-2021-financial-results-achieved-revenue-of-gh-20210805monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-first-quarter-2021-financial-results-achieved-revenue-of--gh-20210506monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-fourth-quarter-and-full-year-2020-financial-results-and-p-gh-20210224monthly0.5https://www.biopharmawatch.com/news/GH/j-p-morgan-healthcare-conference-gh-20210111monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-names-michael-bell-as-new-chief-financial-officer-gh-20201211monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-inc-announces-proposed-convertible-senior-notes-offering-redwood-city-cali-gh-20201116monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-third-quarter-2020-financial-results-q3-2020-revenue-incr-gh-20201105monthly0.5https://www.biopharmawatch.com/news/GH/document-guardant-health-reports-second-quarter-2020-financial-results-q2-2020-revenue-inc-gh-20200806monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-reports-first-quarter-2020-financial-results-gh-20200507monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-f-gh-20200224monthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-reports-third-quarter-2019-financial-results-and-raises-2019-revenue-guida-gh-20191107monthly0.5https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-increases-share-repurchase-expectations-x2014-up-to-1-billion-by-year-end-wa-zbh-20260512monthly0.5https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-announces-chief-financial-officer-transition-suketu-upadhyay-to-depart-paul--zbh-20260428monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-troy-kirkpatrick-david-demartino-614-284-1926-646-531-6115-troy-kirkpatric-zbh-20260428monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-troy-kirkpatrick-david-demartino-614-284-1926-646-531-6115-troy-kirkpatric-zbh-20260210monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-troy-kirkpatrick-david-demartino-614-284-1926-646-531-6115-troy-kirkpatric-zbh-20251105monthly0.5https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-completes-acquisition-of-monogram-technologies-transaction-creates-the-broad-zbh-20251007monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-kristen-cardillo-david-demartino-925-786-4913-646-531-6115-kristen-cardill-zbh-20250807monthly0.5https://www.biopharmawatch.com/news/ZBH/disclaimer-cautionary-note-regarding-forward-looking-statements-this-presentation-contains-zbh-20250714monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-heather-zoumas-lubeski-davi-zbh-20250527monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-heather-zoumas-lubeski-david-demartino-445-248-0577-646-531-6115-heather-z-zbh-20250505monthly0.5https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-media-heather-zoumas-lubeski-445-248-0577-heather-zoumaslubeski-zimmerbiomet-zbh-20250421monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-heather-zoumas-lubeski-davi-zbh-20250225monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-heather-zoumas-lubeski-david-demartino-445-248-0577-646-531-6115-heather-z-zbh-20250206monthly0.5https://www.biopharmawatch.com/news/ZBH/execution-version-voting-agreement-this-voting-agreement-this-agreement-dated-as-of-zbh-20250128monthly0.5https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-media-investors-heather-zoumas-lubeski-445-248-0577-heather-zoumaslubeski-zi-zbh-20250128monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-heather-zoumas-lubeski-david-demartino-445-248-0577-646-531-6115-heather-z-zbh-20241030monthly0.5https://www.biopharmawatch.com/news/ZBH/can-be-found-in-management-s-discussion-and-analysis-of-financial-condition-and-results-of-zbh-20240807monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-heather-zoumas-lubeski-zach-weiner-445-248-0577-908-591-6955-heather-zouma-zbh-20240807monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-heather-zoumas-lubeski-zach-weiner-445-248-0577-908-591-6955-heather-zouma-zbh-20240620monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-heather-zoumas-lubeski-zach-weiner-445-248-0577-908-591-6955-heather-zouma-zbh-20240502monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-heather-zoumas-lubeski-zach-weiner-445-248-0577-908-591-6955-heather-zouma-zbh-20240208monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-heather-zoumas-lubeski-zach-zbh-20240105monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-zach-weiner-703-346-3127-908-591-6955-meredith-weissman--zbh-20231107monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-meredith-weissman-keri-matt-zbh-20230822monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-zach-weiner-703-346-3127-908-591-6955-meredith-weissman--zbh-20230801monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-202302032023-02-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20221102monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20220802monthly0.5https://www.biopharmawatch.com/news/ZBH/should-be-read-in-conjunction-with-the-2021-form-10-k-and-subsequent-filings-with-the-sec--zbh-20220622monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-meredith-weissman-keri-matt-zbh-20220516monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20220503monthly0.5https://www.biopharmawatch.com/news/ZBH/as-previously-announced-on-zbh-20220428monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-meredith-weissman-keri-matt-zbh-20220301monthly0.5https://www.biopharmawatch.com/news/ZBH/investor-day-zbh-20220207monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-meredith-weissman-keri-matt-zbh-20220207monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-meredith-weissman-keri-matt-zbh-20211130monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-meredith-weissman-keri-matt-zbh-20211115monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20211104monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20210803monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20210504monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-contacts-media-meredith-weissman-703-346-31-zbh-20210319monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-meredith-weissman-keri-matt-zbh-20210222monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20210205monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20201106monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-meredith-weissman-keri-mattox-703-346-3127-215-275-2431-meredith-weissman--zbh-20200804monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-keri-mattox-574-373-2095-215-275-2431-monica-kendrick-zimm-zbh-20200511monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-keri-mattox-574-373-2095-215-275-2431-monica-kendrick-zimm-zbh-20200408monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-keri-mattox-574-373-2095-215-275-2431-monica-kendrick-zimm-zbh-20200204monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-wendy-wilson-cole-lannum-cfa-574-373-3798-508-409-9366-wendy-wilson-zimmer-zbh-20191105monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-wendy-wilson-cole-lannum-cfa-574-373-3798-574-371-9480-wendy-wilson-zimmer-zbh-20190726monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-contacts-media-investors-wendy-wilson-cole--zbh-20190619monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-wendy-wilson-cole-lannum-cfa-574-373-3798-574-371-9480-wendy-wilson-zimmer-zbh-20190426monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-coleman-lannum-574-372-4989-574-371-9480-monica-kendrick-z-zbh-20190201monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-coleman-lannum-574-372-4989-574-371-9480-monica-kendrick-z-zbh-20181026monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-contacts-media-investors-monica-kendrick-57-zbh-20180803monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-coleman-lannum-574-372-4989-574-371-9480-monica-kendrick-z-zbh-20180727monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-coleman-lannum-574-372-4989-574-371-9480-monica-kendrick-z-zbh-20180426monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-cole-lannum-574-372-4989-574-371-9480-monica-kendrick-zimm-zbh-20180406monthly0.5https://www.biopharmawatch.com/news/ZBH/calculation-agent-agreement-this-calculation-agent-agreement-this-agreement-is-entered-int-zbh-20180319monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-contacts-media-investors-monica-kendrick-de-zbh-20180308monthly0.5https://www.biopharmawatch.com/news/ZBH/media-investors-monica-kendrick-derek-davis-574-372-4989-574-372-4250-monica-kendrick-zimm-zbh-20180130monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-contacts-monica-kendrick-derek-davis-574-37-zbh-20171219monthly0.5https://www.biopharmawatch.com/news/ZBH/e-main-st-warsaw-in-46580-www-zimmerbiomet-com-media-investors-monica-kendrick-matt-aberne-zbh-20171101monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-completes-acquisition-of-soleno-therapeutics-strengthens-neurocrine-nbix-20260518monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-por-nbix-20260406monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-dr-sanjay-keswani-as-chief-medical-officer-accomplished-ph-nbix-20250404monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-amendment-to-strategic-collaboration-with-takeda-to-devel-nbix-20250127monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-commercial-availability-of-crenessity-crinecerfont-for-ch-nbix-20241220monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-positive-phase-2-data-for-nbi-1117568-in-adults-with-schizo-nbix-20240828monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-phase-3-pediatric-study-results-of-crinecerfont-in-childr-nbix-20231005monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-positive-top-line-data-from-phase-3-study-of-crinecerfont-nbix-20230912monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-voyager-therapeutics-enter-strategic-collaboration-for-developm-nbix-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-repurchase-of-convertible-notes-nbix-20220524monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2022-financial-results-and-reiterates-2022-fi-nbix-20220504monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2021-financial-results-and-provid-nbix-20220211monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-preliminary-fourth-quarter-and-full-year-2021-net-product--nbix-20220106monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-sosei-heptares-announce-collaboration-to-develop-novel-muscarin-nbix-20211122monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2021-financial-results-ingrezza-valbenazine-t-nbix-20211101monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2021-financial-results-ingrezza-valbenazine--nbix-20210803monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2021-financial-results-ingrezza-valbenazine-f-nbix-20210505monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-full-year-2020-financial-results-total-a-nbix-20210204monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-preliminary-fourth-quarter-and-full-year-2020-net-product--nbix-20210108monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-repurchase-of-convertible-notes-nbix-20201119monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2020-financial-results-ingrezza-valbenazine-t-nbix-20201109monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-at-citi-15-th-annual-biopharma-virtual-conference-nbix-20200909monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-takeda-announce-collaboration-to-develop-and-commercialize-pote-nbix-20200616monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2020-financial-results-ingrezza-valbenazine-f-nbix-20200506monthly0.5https://www.biopharmawatch.com/news/NBIX/thomson-reuters-streetevents-edited-transcript-nbix-q4-2019-neurocrine-biosciences-inc-ear-nbix-20200205monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-full-year-2019-financial-results-ingrezz-nbix-20200204monthly0.5https://www.biopharmawatch.com/news/NBIX/benefits-of-the-agreements-with-our-collaboration-partners-may-never-be-realized-risks-tha-nbix-20200113monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2019-financial-results-ingrezza-valbenazine-t-nbix-20191104monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2019-financial-results-ingrezza-valbenazine--nbix-20190729monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-2011-equity-incentive-plan-adopted-by-the-board-of-directors-fe-nbix-20190522monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2019-financial-results-ingrezza-valbenazine-f-nbix-20190429monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-year-end-2018-financial-results-ingrezza-nbix-20190205monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-voyager-therapeutics-form-strategic-development-and-commerciali-nbix-20190129monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-preliminary-fourth-quarter-and-full-year-2018-net-product--nbix-20190106monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-topline-data-from-phase-iib-t-force-gold-study-demonstrat-nbix-20181212monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2018-financial-results-ingrezza-valbenazine-t-nbix-20181105monthly0.5https://www.biopharmawatch.com/news/NBIX/corrected-transcript-31-jul-2018-neurocrine-biosciences-inc-nbix-q2-2018-earnings-call-1-8-nbix-20180803monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2018-financial-results-ingrezza-valbenazine--nbix-20180731monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-2011-equity-incentive-plan-adopted-by-the-board-of-directors-fe-nbix-20180530monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2018-financial-results-ingrezza-valbenazine-f-nbix-20180430monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-will-file-new-drug-application-for-opicapone-for-parkinson-s-diseas-nbix-20180214monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-year-end-2017-financial-results-and-prov-nbix-20180213monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-preliminary-fourth-quarter-and-full-year-2017-sales-result-nbix-20180108monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2017-results-ingrezza-valbenazine-net-product-nbix-20171101monthly0.5https://www.biopharmawatch.com/news/ALC/communique-aux-medias-medienmitteilung-alcon-to-acquire-aerie-pharmaceuticals-inc-enhancin-alc-20220822monthly0.5https://www.biopharmawatch.com/news/ALC/document-alcon-announces-executive-committee-changes-geneva-alc-20210628monthly0.5https://www.biopharmawatch.com/news/ALC/document-alcon-to-acquire-u-s-commercialization-rights-to-ophthalmic-eye-drop-simbrinza-ex-alc-20210428monthly0.5https://www.biopharmawatch.com/news/ALC/glossy-pages-to-annual-report-exhibit-1-alcon-annual-report-2019-2-alcon-annual-report-201-alc-20200225monthly0.5https://www.biopharmawatch.com/news/ALC/communique-aux-medias-medienmitteilung-alcon-introduces-acrysof-iq-panoptix-trifocal-iol-i-alc-20190827monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-reports-first-quarter-2019-trading-update-first-quarter-sales-of-1-8-billion-flat-to-alc-20190515monthly0.5https://www.biopharmawatch.com/news/ALC/april-2019-novartis-ag-alcon-inc-separation-and-distribution-agreement-contents-clause-pag-alc-20190409monthly0.5https://www.biopharmawatch.com/news/ALC/south-freeway-fort-worth-texas-76134-2099-http-www-alcon-com-media-release-communique-aux--alc-20190402monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-shareholders-approve-merger-with-novartis-alc-20110407monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-continuing-our-vision-2010-annual-report-alcon-is-dedicated-to-discovering-developin-alc-20110318monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-date-of-annual-general-meeting-alc-20110228monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-b-sch-69-p-o-box-62-h-nenberg-switzerland-2010-business-report-2-alcon-inc-2010--alc-20110215monthly0.5https://www.biopharmawatch.com/news/ALC/statuten-der-alcon-inc-vom-20-januar-2011-articles-of-association-of-alcon-inc-as-of-alc-20110120monthly0.5https://www.biopharmawatch.com/news/ALC/merger-agreement-of-alc-20101214monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-and-novartis-agree-to-merger-terms-novartis-to-pay-total-merger-consideration-valued-alc-20101215monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-notes-change-in-alcon-chairmanship-o-no-change-in-com-alc-20101024monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-board-elects-new-chairman-dr-daniel-vasella-elected-chairman-cary-rayment-will-serve-alc-20101024monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20101021monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-introduces-new-systane-balance-lubricant-eye-drops-for-dry-eye-patients-with-meibomi-alc-20101011monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-names-new-chief-financial-officer-alc-20101004monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-stands-firm-in-commitment-to-minority-shareholders-o--alc-20100930monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-tobradex-st-suspension-new-product-targets-inflammatory-eye-conditions-such-alc-20100922monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-acrysof-iq-restor-toric-intraocular-lens-outside-the-united-states-alc-20100903monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-notes-closing-of-novartis-acquisition-of-nestl-s-stak-alc-20100826monthly0.5https://www.biopharmawatch.com/news/ALC/novartis-completes-purchase-from-nestl-of-majority-interest-in-alcon-h-u-alc-20100826monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-notes-results-of-shareholder-vote-voting-minority-sha-alc-20100816monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-shareholders-conditionally-elect-novartis-designated-directors-h-u-alc-20100816monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-notes-riskmetrics-group-s-and-glass-lewis-opposition--alc-20100802monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-commends-alcon-on-stronger-than-expected-q2-earnings--alc-20100726monthly0.5https://www.biopharmawatch.com/news/ALC/of-foreign-private-issuer-pursuant-to-rule-13a-16-or-15d-16-under-the-securities-alc-20100727monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20100727monthly0.5https://www.biopharmawatch.com/news/ALC/invitation-to-an-extraordinary-general-meeting-of-alcon-inc-monday-alc-20100719monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-announces-meeting-with-minority-shareholders-h-u-alc-20100714monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-to-acquire-lensx-lasers-inc-developer-of-femtosecond-laser-technology-for-increased--alc-20100706monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-announces-creation-and-funding-of-litigation-trust-o--alc-20100708monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-responds-to-notice-of-alcon-egm-to-put-forth-novartis-alc-20100630monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-shareholder-meeting-to-effect-previously-agreed-conditional-replacement-of-alc-20100630monthly0.5https://www.biopharmawatch.com/news/ALC/swiss-corporate-governance-expert-supports-alcon-independent-director-committee-s-position-alc-20100628monthly0.5https://www.biopharmawatch.com/news/ALC/statuten-der-alcon-inc-vom-20-mai-2010-articles-of-association-of-alcon-inc-as-of-alc-20100520monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-shareholders-approve-dividend-elect-directors-alc-20100520monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-notes-that-novartis-grossly-inadequate-merger-proposa-alc-20100427monthly0.5https://www.biopharmawatch.com/news/ALC/securities-and-exchange-commission-alc-20100427monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20100427monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-b-sch-69-p-o-box-62-h-nenberg-switzerland-2009-financial-report-2-alcon-inc-2009-alc-20100408monthly0.5https://www.biopharmawatch.com/news/ALC/invitation-to-the-annual-general-meeting-of-alcon-inc-thursday-alc-20100408monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-completes-acquisition-of-durezol-and-zyclorin-from-sirion-alc-20100329monthly0.5https://www.biopharmawatch.com/news/ALC/exhbit-99-1-execution-copy-alcon-inc-p-o-box-62-b-sch-69ch-6331-h-nenberg-switzerland-alc-20100311monthly0.5https://www.biopharmawatch.com/news/ALC/group-questions-adequacy-and-legality-of-novartis-merger-proposal-to-alcon-s-alc-20100218monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-says-company-s-q4-fy-2009-financial-results-underscor-alc-20100216monthly0.5https://www.biopharmawatch.com/news/ALC/of-foreign-private-issuer-pursuant-to-rule-13a-16-or-15d-16-under-the-securities-alc-20100212monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20100212monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-determines-novartis-merger-proposal-to-minority-share-alc-20100120monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-to-purchase-ophthalmic-pharmaceutical-assets-from-sirion-alc-20100118monthly0.5https://www.biopharmawatch.com/news/ALC/for-immediate-release-alc-20100104monthly0.5https://www.biopharmawatch.com/news/ALC/novartis-announces-option-exercise-and-merger-proposal-alc-20100104monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-independent-director-committee-reviewing-novartis-merger-proposal-alc-20100104monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-to-enter-surgical-glaucoma-market-by-acquiring-optonol-acquisition-reflects-increasi-alc-20091214monthly0.5https://www.biopharmawatch.com/news/ALC/securities-and-exchange-commission-alc-20091028monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20091028monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-to-acquire-swiss-biotechnology-firm-esbatech-ag-company-gains-access-to-proprietary--alc-20090914monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-and-astrazeneca-to-collaborate-on-eye-drug-development-alc-20090723monthly0.5https://www.biopharmawatch.com/news/ALC/securities-and-exchange-commission-alc-20090723monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20090723monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-breaks-ground-in-singapore-on-first-asian-pharmaceutical-manufacturing-plant-ceremon-alc-20090526monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-achieves-required-ownership-in-wavelight-ag-to-initiate-squeeze-out-alc-20090512monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-shareholders-approve-dividend-increase-and-elect-new-members-to-the-board-alc-20090505monthly0.5https://www.biopharmawatch.com/news/ALC/of-foreign-private-issuer-pursuant-to-rule-13a-16-or-15d-16-under-the-securities-alc-20090423monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20090423monthly0.5https://www.biopharmawatch.com/news/ALC/invitation-to-the-annual-general-meeting-of-alcon-inc-tuesday-alc-20090401monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-b-sch-69-p-o-box-62-h-nenberg-switzerland-2008-financial-report-2-alcon-inc-2008-alc-20090401monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-signs-contract-with-lca-vision-for-75-allegretto-wave-excimer-lasers-lasik-chain-sta-alc-20090310monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-executive-deferred-compensation-plan-effective-date-alc-20090305monthly0.5https://www.biopharmawatch.com/news/ALC/statuten-der-alcon-inc-vom-13-februar-2009-articles-of-association-of-alcon-inc-as-of-alc-20090213monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-february-2009-alcon-inc-board-of-d-alc-20090210monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20090212monthly0.5https://www.biopharmawatch.com/news/ALC/of-foreign-private-issuer-pursuant-to-rule-13a-16-or-15d-16-under-the-securities-alc-20090212monthly0.5https://www.biopharmawatch.com/news/ALC/kevin-buehler-appointed-president-and-ceo-of-alcon-cary-rayment-to-continue-as-chairman-of-alc-20090108monthly0.5https://www.biopharmawatch.com/news/ALC/fda-approves-alcon-s-acrysof-iq-restor-3-0-d-intraocular-lens-new-lens-corrects-for-catara-alc-20081223monthly0.5https://www.biopharmawatch.com/news/ALC/azarga-ophthalmic-suspension-approved-for-treatment-of-patients-with-glaucoma-or-ocular-hy-alc-20081202monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-aao-presentation-alc-20081107monthly0.5https://www.biopharmawatch.com/news/ALC/of-foreign-private-issuer-pursuant-to-rule-13a-16-or-15d-16-under-the-securities-alc-20081023monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20081023monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-two-agreements-designed-to-expand-its-future-drug-portfolio-h-alc-20081014monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-plans-to-expand-manufacturing-facility-in-west-virginia-h-alc-20080919monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-new-acrysof-restor-intraocular-lens-for-presbyopia-outside-the-alc-20080915monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-expands-refractive-surgery-options-with-the-introduction-of-the-acrysof-phakic-intra-alc-20080912monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-plans-to-repurchase-up-to-one-million-shares-h-alc-20080908monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-second-quarter-sales-rise-17-9-percent-net-earnings-increase-26-3-percent-alc-20080723monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20080724monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-terminates-the-development-of-anecortave-acetate-in-age-related-macular-degeneration-alc-20080711monthly0.5https://www.biopharmawatch.com/news/ALC/novartis-completes-purchase-of-minority-interest-in-alcon-alc-20080708monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-enters-into-patent-cross-licensing-agreement-with-alc-20080624monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-shareholders-approve-increased-dividend-and-elect-new-members-to-the-board-h-alc-20080506monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20080424monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-first-quarter-sales-rise-16-2-percent-net-income-increases-24-0-percent-alc-20080423monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-patanase-nasal-spray-approved-by-fda-for-treatment-of-nasal-allergy-symptoms-alc-20080415monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-plans-to-build-pharmaceutical-manufacturing-plant-in-singapore-huenenberg--alc-20080414monthly0.5https://www.biopharmawatch.com/news/ALC/novartis-to-acquire-25-percent-minority-stake-in-alcon-from-nestl-alc-20080407monthly0.5https://www.biopharmawatch.com/news/ALC/invitation-to-the-annual-general-meeting-of-alcon-inc-tuesday-alc-20080402monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-b-sch-69-p-o-box-62-h-nenberg-switzerland-2007-financial-report-alcon-inc-2007-f-alc-20080328monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-leadership-change-to-research-and-development-organization-alc-20080310monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-presents-clinical-trial-data-on-anecortave-acetate-for-glaucoma-washington-dc-alc-20080306monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-february-2008-alcon-inc-board-of-d-alc-20080303monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20080207monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-fourth-quarter-sales-rise-20-0-percent-alc-20080206monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-december-2007-alcon-inc-board-of-d-alc-20080204monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-december-2007-alcon-inc-board-of-d-alc-20071205monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-new-share-repurchase-program-alc-20071205monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-receives-fda-approval-of-triesence-injectable-triamcinolone-suspension-for-use-in-ey-alc-20071130monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-gains-all-regulatory-clearances-for-acquisition-of-wavelight-alc-20071106monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-third-quarter-sales-rise-11-0-percent-alc-20071025monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20071025monthly0.5https://www.biopharmawatch.com/news/ALC/public-takeover-period-of-wavelight-ag-ends-alc-20071018monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-amends-nda-for-patanase-nasal-spray-alc-20071010monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-gains-76-9-percent-of-wavelight-shares-and-will-move-forward-with-acquisition-alc-20070928monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-receives-fda-decision-on-retaane-suspension-for-wet-alc-20070924monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-stake-in-wavelight-ag-at-73-5-percent-alc-20070921monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-exceeds-70-percent-stake-in-wavelight-alc-20070917monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-waives-minimum-acceptance-condition-for-wavelight-alc-20070910monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-september-2007-alcon-inc-board-of--alc-20070907monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-expansion-of-swiss-operations-alc-20070910monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-confirms-that-carl-zeiss-meditec-ag-will-tender-all-wavelight-ag-shares-alc-20070907monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-tender-offer-endorsed-by-wavelight-ag-s-executive-committee-and-supervisory-board-alc-20070820monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-tender-offer-for-wavelight-ag-approved-by-german-federal-financial-supervisory-aut-alc-20070810monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-treatment-of-glaucoma-and-ocular-hypertension-travatanz-solution-approved-in-japan-alc-20070731monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-second-quarter-sales-rise-12-3-percent-alc-20070725monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20070726monthly0.5https://www.biopharmawatch.com/news/ALC/anecortave-acetate-clinical-trial-data-for-glaucoma-presented-at-world-congress-of-glaucom-alc-20070717monthly0.5https://www.biopharmawatch.com/news/ALC/richard-croarkin-appointed-cfo-of-alcon-alc-20070716monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-offer-for-wavelight-alc-20070716monthly0.5https://www.biopharmawatch.com/news/ALC/jacqualyn-fouse-to-leave-alcon-for-new-position-alc-20070626monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-may-2007-alcon-inc-board-of-direct-alc-20070509monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-shareholders-approve-dividend-and-elect-a-new-member-to-the-board-h-alc-20070509monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-first-quarter-sales-rise-14-3-percent-alc-20070425monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20070426monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-invitation-to-the-annual-general-meeting-of-alcon-inc-wednesday-alc-20070405monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-b-sch-69-p-o-box-62-h-nenberg-switzerland-2006-financial-report-alcon-inc-2006-f-alc-20070321monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-fourth-quarter-sales-rise-16-1-percent-alc-20070207monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20070208monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-acrysof-restor-apodized-diffractive-aspheric-intraocular-lens-approved-by-alc-20070201monthly0.5https://www.biopharmawatch.com/news/ALC/cms-ruling-provides-medicare-beneficiaries-access-to-astigmatism-correcting-intraocular-le-alc-20070122monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-third-quarter-sales-rise-12-4-percent-alc-20061023monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20061024monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-travatan-z-solution-approved-by-fda-for-treatment-of-glaucoma-and-ocular-hypertens-alc-20060921monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-licenses-novel-anti-infective-compounds-for-eye-ear-and-sinus-infections-from-novaca-alc-20060918monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-increases-share-repurchase-program-alc-20060908monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-presentation-alc-20060911monthly0.5https://www.biopharmawatch.com/news/ALC/organizational-regulations-alc-20060911monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-presentation-alc-20060810monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-eye-allergy-drug-patanol-ophthalmic-solution-approved-in-japan-alc-20060726monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-second-quarter-sales-rise-11-8-percent-alc-20060724monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20060725monthly0.5https://www.biopharmawatch.com/news/ALC/for-release-immediately-refer-to-317-276-5795-terra-fox-lilly-817-551-8974-doug-machatton--alc-20060721monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-and-advanced-medical-optics-settle-all-pending-patent-litigation-alc-20060710monthly0.5https://www.biopharmawatch.com/news/ALC/acrysof-iq-iol-designated-as-a-new-technology-intraocular-lens-alc-20060521monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-gains-fda-approval-for-ladar6000-excimer-laser-and-wavefront-guided-hyperopia-alc-20060508monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-shareholders-approve-dividend-and-elect-two-new-members-to-the-board-h-alc-20060502monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-and-amgen-sign-collaboration-agreement-to-develop-and-commercialize-innovative-thera-alc-20060425monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-first-quarter-sales-rise-8-1-percent-net-earnings-increase-18-5-percent-alc-20060424monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20060425monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-files-patent-infringement-suit-against-teva-pharmaceuticals-alc-20060405monthly0.5https://www.biopharmawatch.com/news/ALC/invitation-to-the-annual-general-meeting-of-alcon-inc-tuesday-alc-20060403monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-and-allergan-reach-agreement-on-brimonidine-0-15-patent-litigation-alc-20060309monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-withdraws-european-application-for-retaane-suspension-alc-20060303monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-presentation-alc-20060303monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-receives-positive-opinion-for-duotrav-eye-drops-solution-from-alc-20060224monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20060209monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-fourth-quarter-sales-rise-10-7-percent-alc-20060208monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-will-appeal-ruling-in-patent-case-alc-20051216monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-uk-operations-resume-after-oil-depot-explosion-alc-20051215monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-receives-approval-of-retaane-suspension-in-australia-alc-20051212monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-announces-wolfgang-reichenberger-to-leave-board-alc-20051206monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-presents-new-clinical-data-and-provides-regulatory-update-on-patanase-nasal-spray-alc-20051107monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-third-quarter-earnings-rise-52-2-percent-on-11-8-percent-sales-growth-alc-20051019monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20051020monthly0.5https://www.biopharmawatch.com/news/ALC/safety-of-alcon-s-retaane-suspension-confirmed-at-24-months-data-supports-clinical-equival-alc-20051013monthly0.5https://www.biopharmawatch.com/news/ALC/fda-approves-alcon-s-opti-free-replenish-alc-20051012monthly0.5https://www.biopharmawatch.com/news/ALC/fda-approves-alcon-s-acrysof-toric-intraocular-lens-alc-20050920monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-september-2005-alcon-inc-board-of--alc-20050908monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-nevanac-suspension-receives-fda-approval-for-treatment-of-pain-and-inflammation-as-alc-20050823monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-second-quarter-sales-increase-12-8-percent-alc-20050727monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20050728monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-receives-approvable-letter-from-fda-for-retaane-suspension-alc-20050524monthly0.5https://www.biopharmawatch.com/news/ALC/cms-ruling-provides-medicare-patients-access-to-alcon-s-acrysof-restor-alc-20050510monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-will-challenge-verdict-in-patent-case-alc-20050506monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-alc-20050506monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-shareholders-approve-dividend-and-elect-board-members-cary-rayment-named-chairman-of-alc-20050503monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-acrysof-restor-apodized-diffractive-iol-revolutionary-apodized-diffractive--alc-20050425monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-s-first-quarter-earnings-rise-30-6-percent-on-11-1-percent-sales-growth-alc-20050421monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20050422monthly0.5https://www.biopharmawatch.com/news/ALC/for-release-alc-20050417monthly0.5https://www.biopharmawatch.com/news/ALC/invitation-to-the-annual-general-meeting-of-alcon-inc-tuesday-alc-20050406monthly0.5https://www.biopharmawatch.com/news/ALC/fda-approves-alcon-s-acrysof-restor-intraocular-lens-alc-20050323monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-new-retaane-clinical-study-data-reported-at-macula-society-mee-alc-20050225monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20050210monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-s-fourth-quarter-earnings-rise-39-9-percent-on-11-9-perc-alc-20050209monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-submits-retaane-drug-applications-to-u-s-and-european-re-alc-20041216monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-for-alcon-inc-s-clinical-information-presentation-at-the-american-ac-alc-20041022monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-for-alcon-inc-s-company-information-presentation-at-the-american-aca-alc-20041022monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-presents-more-retaane-clinical-information-to-retinal-sp-alc-20041021monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-s-third-quarter-earnings-rise-26-9-percent-on-16-5-perce-alc-20041020monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20041021monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-announces-anecortave-acetate-clinical-results-h-nenberg--alc-20041013monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-september-2004-alcon-inc-board-of--alc-20040930monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-alcon-receives-approvable-letter-for-extravan-fort-worth-tx-alc-20040917monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-statement-re-the-times-of-london-article-of-august-28-2004-alc-20040830monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-s-second-quarter-earnings-rise-67-9-percent-on-12-3-perc-alc-20040728monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20040729monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-provides-estimate-of-second-quarter-earnings-h-nenberg-s-alc-20040713monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-tim-sear-to-retire-as-alcon-president-ceo-cary-rayment-elected-alc-20040712monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-retaane-15mg-depot-clinical-update-presented-at-association-fo-alc-20040520monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-receives-fda-approval-for-a-supplementallist-of-suscepti-alc-20040426monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-slides-used-during-the-alcon-inc-conference-call-alc-20040421monthly0.5https://www.biopharmawatch.com/news/ALC/guarantee-fee-and-commercial-paper-program-services-agreement-this-agreement-among-nestl-s-alc-20040422monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-s-first-quarter-earningsrise-46-7-percent-on19-4-percent-alc-20040420monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-will-not-appeal-court-s-decision-h-nenberg-switzerland-alc-20040331monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-releases-clinical-results-on-new-nasal-allergy-spray-for-alc-20040321monthly0.5https://www.biopharmawatch.com/news/ALC/prentation-cowen-healthcare-conference-3-10-04-alcon-inc-alcon-inc-slides-to-be-used-at-th-alc-20040310monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-reports-additional-clinical-data-on-potential-new-glauco-alc-20040307monthly0.5https://www.biopharmawatch.com/news/ALC/q4-2003-webcast-slides-alcon-inc-alcon-inc-2003-operating-results-webcast-slides-alc-20040212monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-q4-2004-operating-results-press-release-alcon-for-immediate-release-alcon-s-fourth-q-alc-20040211monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-views-amo-patent-lawsuit-as-meritless-fort-worth-texas-alc-20031216monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-new-gallup-poll-shows-lasik-fears-remain-that-recent-technolog-alc-20031117monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-to-initiate-new-anecortave-acetate-clinical-trials-for-a-alc-20031113monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-inc-subsidiary-announces-closing-onsale-of-madrid-spain--alc-20031106monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-and-subsidiaries-condensed-consolidated-statements-of-earnings-unaudited-usd-in--alc-20031024monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-affiliate-receives-fda-approvalof-generic-glaucoma-medic-alc-20030916monthly0.5https://www.biopharmawatch.com/news/ALC/anecortave-acetate-demonstrates-significant-long-term-efficacy-in-wet-age-related-macular--alc-20030818monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-analyst-conference-call-7-31-03-presentation-the-following-slides-were-provided--alc-20030731monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-alcon-inc-b-sch-69-p-o-box-62-6331-h-nenberg-switzerland-for-immediate-release-alcon-alc-20030730monthly0.5https://www.biopharmawatch.com/news/ALC/a-for-immediate-release-alcon-receives-fda-approval-for-novel-combination-ear-infection-tr-alc-20030721monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-for-immediate-release-alcon-inc-subsidiary-announces-agreement-tosell-madrid-spain-m-alc-20030717monthly0.5https://www.biopharmawatch.com/news/ALC/a-for-immediate-release-alcon-announces-fda-approval-of-its-acrysof-natural-single-piece-i-alc-20030630monthly0.5https://www.biopharmawatch.com/news/ALC/a-alcon-inc-b-sch-69-p-o-box-62-6331-h-nenberg-switzerland-for-immediate-release-thomas-g--alc-20030520monthly0.5https://www.biopharmawatch.com/news/ALC/a-for-immediate-release-alcon-presents-new-study-results-on-patanol-solution-at-arvo-meeti-alc-20030507monthly0.5https://www.biopharmawatch.com/news/ALC/invitation-to-the-annual-general-meeting-of-alcon-inc-tuesday-alc-20030505monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-2002-annual-report-part-1-of-3-alc-20030505monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-october-march-20032-alcon-inc-boar-alc-20030430monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-alc-20030424monthly0.5https://www.biopharmawatch.com/news/ALC/a-alcon-inc-b-sch-69-p-o-box-62-6331-h-nenberg-switzerland-for-immediate-release-alcon-s-f-alc-20030422monthly0.5https://www.biopharmawatch.com/news/ALC/a-for-immediate-release-alcon-s-newest-antibiotic-vigamox-ophthalmic-solution-proves-safe--alc-20030416monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-introduces-infiniti-vision-system-a-revolutionary-cataract-removal-system-fort-worth-alc-20030415monthly0.5https://www.biopharmawatch.com/news/ALC/alcon-inc-board-of-directors-organizational-regulations-october-2002-2-18-alcon-inc-board--alc-20021210monthly0.5https://www.biopharmawatch.com/news/ALC/articles-of-association-of-alcon-inc-as-of-alc-20020723monthly0.5https://www.biopharmawatch.com/news/ALC/corporate-report-alc-20020717monthly0.5https://www.biopharmawatch.com/news/ALC/a-alcon-inc-bosch-69-p-o-box-62-6331-hunenberg-switzerland-for-release-alc-20020610monthly0.5https://www.biopharmawatch.com/news/ALC/1-txt-press-release-alcon-logo-alcon-research-ltd-6201-south-freeway-fort-worth-76134-for--alc-20020505monthly0.5https://www.biopharmawatch.com/news/ALC/1-txt-press-release-alcon-inc-bosch-69-p-o-box-62-6331-hunenberg-switzerland-for-immediate-alc-20020503monthly0.5https://www.biopharmawatch.com/news/ALC/articles-of-association-of-alcon-inc-as-of-alc-20020418monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-racquel-white-dewey-steadman-media-labcorp--lh-20260527monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-dewey-steadman-investors-racquel-white-media-invest-lh-20260430monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-racquel-white-dewey-steadman-media-labcorp--lh-20260409monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investor-relations-neil-hirsch-dewey-steadman-media-l-lh-20260331monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-neil-hirsch-christin-o-donnell-media-labcor-lh-20260217monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-neil-hirsch-media-christin-o-donnell-investors-media-labcor-lh-20260209monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investor-relations-neil-hirsch-christin-o-donnell-med-lh-20260115monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-media-labcorp-com-investor-labcorp-com-labc-lh-20260114monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investor-relations-media-labcorp-com-investor-labcorp-lh-20251230monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investor-relations-neil-hirsch-christin-o-donnell-med-lh-20251210monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-neil-hirsch-media-media-labcorp-com-christin-o-donn-lh-20251124monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-neil-hirsch-christin-o-donnell-media-labcor-lh-20251028monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-neil-hirsch-christin-o-donnell-media-labcor-lh-20251008monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investor-relations-neil-hirsch-christin-o-donnell-med-lh-20250925monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-neil-hirsch-christin-o-donnell-media-labcor-lh-20250827monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-neil-hirsch-christin-o-donnell-media-labcor-lh-20250724monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-neil-hirsch-christin-o-donnell-media-labcor-lh-20250710monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investor-relations-neil-hirsch-christin-o-donnell-med-lh-20250626monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-neil-hirsch-christin-odonnell-media-labcorp-lh-20250429monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-media-labcorp-com-investor-labcorp-com-labc-lh-20250410monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investor-relations-neil-hirsch-nickolo-russo-media-la-lh-20250331monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-media-labcorp-com-investor-labcorp-com-labc-lh-20250206monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-media-labcorp-com-investor-labcorp-com-labc-lh-20250110monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-media-investors-media-labcorp-com-investor-labcorp-com-lh-20250108monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-christin-o-donnell-investors-investor-labcorp-com-k-lh-20241119monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-christin-o-donnell-investors-investor-labcorp-com-k-lh-20241024monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-christin-o-donnell-336-436-5076--lh-20241010monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-investors-kimbrel-arculeo-christin-o-lh-20240924monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-kimbrel-arculeo-336-436-8263-media-labcorp-com-investors-christin-o-lh-20240916monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-kimbrel-arculeo-336-436-8263-media-l-lh-20240903monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-christin-o-donnell-investors-336-436-5076-investor--lh-20240801monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-christin-o-donnell-336-436-5076--lh-20240725monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-investors-kimbrel-arculeo-christin-o-lh-20240701monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-christin-o-donnell-336-436-5076--lh-20240528monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-christin-o-donnell-investors-336-436-5076-investor--lh-20240425monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-christin-o-donnell-336-436-5076--lh-20240411monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-kimbrel-arculeo-336-436-8263-media-l-lh-20240327monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-christin-o-donnell-investors-336-436-5076-investor--lh-20240215monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-christin-o-donnell-336-436-5076--lh-20240116monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-christin-o-donnell-336-436-5076--lh-20240112monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-kimbrel-arculeo-336-436-8263-media-l-lh-20240102monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-christin-o-donnell-investors-336-436-5076-investor--lh-20231026monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-christin-o-donnell-336-436-5076--lh-20231012monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-christin-o-donnell-investors-336-436-5076--lh-20230929monthly0.5https://www.biopharmawatch.com/news/LH/document-labcorp-contacts-christin-o-donnell-investors-336-436-5076-investor-labcorp-com-k-lh-20230914monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-christin-o-donnell-investors-336-436-5076--lh-20230731monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-20230727monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20230713monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20230703monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20230629monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20230612monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20230609monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-rachael-valdez-336-436-8263-media-la-lh-20230608monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-202303312023-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-202301182023-01-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-202301122023-01-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-brandi-martin-336-436-8263-media-lab-lh-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20221031monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-20221027monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-rachael-valdez-336-436-8263-media-la-lh-20221013monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20221012monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-rachael-valdez-336-436-8263-media-la-lh-20221003monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20220927monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20220906monthly0.5https://www.biopharmawatch.com/news/LH/chas-cook-investors-336-436-5076-investor-labcorp-com-christopher-allman-bradshaw-media-33-lh-20220728monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20220714monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20220517monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-20220428monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20220407monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20220328monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-20220210monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-michele-mazur-336-436-8263-media-lab-lh-20220209monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20220110monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20220104monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20211209monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20211102monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-20211028monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20210928monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-chris-allman-bradshaw-336-436-8263-m-lh-20210913monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20210908monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-chris-allman-bradshaw-336-436-8263-m-lh-20210812monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-20210729monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20210702monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20210518monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-christopher-allman-bradshaw-336-436-8263-media-labcorp-com-investor-lh-20210514monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-christopher-allman-bradshaw-336-436-8263-media-labcorp-com-investor-lh-20210512monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-chas-cook-investors-336-436-5076-investor-labcorp-c-lh-20210429monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20210330monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-media-chris-allman-bradshaw-336-436-8263-m-lh-20210326monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20210319monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-chas-cook-336-436-5076-investor--lh-20210223monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-clarissa-willett-investors-336-436-5076-investor-la-lh-20210211monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-clarissa-willett-336-436-5076-in-lh-20210108monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-clarissa-willett-336-436-5076-in-lh-20210105monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-clarissa-willett-336-436-5076-in-lh-20201125monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-clarissa-willett-336-436-5076-in-lh-20201102monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-clarissa-willett-investors-336-436-5076-investor-la-lh-20201027monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-clarissa-willett-investors-336-4-lh-20200928monthly0.5https://www.biopharmawatch.com/news/LH/document-labcorp-contacts-media-donald-von-hagen-336-436-8263-media-labcorp-com-investors--lh-20200910monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-labcorp-contacts-investors-clarissa-willett-336-436-5076-in-lh-20200901monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-clarissa-willett-investors-336-436-5076-investor-la-lh-20200728monthly0.5https://www.biopharmawatch.com/news/LH/document-for-immediate-release-contact-clarissa-willett-investors-336-436-5076-investor-la-lh-20200706monthly0.5https://www.biopharmawatch.com/news/LH/this-press-release-contains-forward-looking-statements-including-but-not-limited-to-statem-lh-20200506monthly0.5https://www.biopharmawatch.com/news/LH/this-press-release-contains-forward-looking-statements-including-but-not-limited-to-statem-lh-20200505monthly0.5https://www.biopharmawatch.com/news/LH/the-company-has-no-obligation-to-provide-any-updates-to-these-forward-looking-statements-e-lh-20200429monthly0.5https://www.biopharmawatch.com/news/LH/this-press-release-contains-forward-looking-statements-including-but-not-limited-to-statem-lh-20200406monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-investors-clarissa-willett-336-436-5076-investor-labcorp-com-media-pattie-lh-20200302monthly0.5https://www.biopharmawatch.com/news/LH/the-company-has-no-obligation-to-provide-any-updates-to-these-forward-looking-statements-e-lh-20200213monthly0.5https://www.biopharmawatch.com/news/LH/this-press-release-contains-forward-looking-statements-including-but-not-limited-to-statem-lh-20200113monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-investors-clarissa-willett-336-436-5076-investor-labcorp-com-media-pattie-lh-20200106monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-investors-clarissa-willett-336-436-5076-investor-labcorp-com-media-pattie-lh-20191203monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-pattie-kushner-336-436-8263-media-labcorp-com-investors-clarissa-wi-lh-20191126monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-pattie-kushner-336-436-8263-media-labcorp-com-investors-clarissa-wi-lh-20191119monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-investors-clarissa-willett-336-436-5076-investor-labcorp-com-media-pattie-lh-20191118monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-pattie-kushner-336-436-8263-media-labcorp-com-investors-clarissa-wi-lh-20191106monthly0.5https://www.biopharmawatch.com/news/LH/the-company-has-no-obligation-to-provide-any-updates-to-these-forward-looking-statements-e-lh-20191024monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-donald-von-hagen-336-436-8263-media-labcorp-com-investors-clarissa--lh-20191022monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-pattie-kushner-336-436-8263-media-labcorp-com-investors-clarissa-wi-lh-20191015monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-pattie-kushner-336-436-8263-media-labcorp-com-investors-clarissa-wi-lh-20191003monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-pattie-kushner-336-436-8263-media-labcorp-com-investors-clarissa-wi-lh-20190911monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-pattie-kushner-336-436-8263-media-labcorp-com-investors-clarissa-wi-lh-20190829monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-sue-maynard-336-436-8263-media-labcorp-com-investors-clarissa-wille-lh-20190829monthly0.5https://www.biopharmawatch.com/news/LH/clarissa-willett-investors-336-436-5076-investor-labcorp-com-pattie-kushner-media-336-436--lh-20190725monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-don-von-hagen-media-1-336-436-8263-media-labcorp-com-clarissa-willett-inv-lh-20190722monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-clarissa-willett-investors-1-336-436-5076-investor-labcorp-com-pattie-kus-lh-20190701monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-don-von-hagen-media-1-336-436-8263-media-labcorp-com-clarissa-willett-inv-lh-20190625monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-don-von-hagen-media-1-336-436-8263-media-labcorp-com-clarissa-willet-inve-lh-20190618monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-don-von-hagen-media-1-336-436-8263-media-labcorp-com-clarissa-willett-inv-lh-20190607monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-pattie-kushner-336-436-8263-media-labcorp-com-investors-clarissa-wi-lh-20190605monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-media-sue-maynard-1-336-436-8263-media-labcorp-com-envigo-contact-oscar-p-lh-20190603monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-donald-von-hagen-media-1-336-436-8263-media-labcorp-com-clarissa-willet-i-lh-20190510monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-clarissa-willett-investors-1-336-436-5076-investor-labcorp-com-pattie-kus-lh-20190502monthly0.5https://www.biopharmawatch.com/news/LH/clarissa-willett-investors-336-436-5076-investor-labcorp-com-pattie-kushner-media-336-436--lh-20190430monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-envigo-contact-media-sue-maynard-1-336-436-8263-paul-surdez-1-732-873-668-lh-20190417monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-clarissa-willett-investors-1-336-436-5076-investor-labcorp-com-pattie-kus-lh-20190401monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-clarissa-willet-investors-1-336-436-5076-investor-labcorp-com-pattie-kush-lh-20190328monthly0.5https://www.biopharmawatch.com/news/LH/pattie-kushner-media-1-336-436-8263-media-labcorp-com-clarissa-willett-investors-1-336-436-lh-20190311monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-clarissa-willet-investors-1-336-436-5076-investor-labcorp-com-pattie-kush-lh-20190305monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-don-von-hagen-media-1-336-436-8263-media-labcorp-com-clarissa-willet-inve-lh-20190219monthly0.5https://www.biopharmawatch.com/news/LH/scott-frommer-investors-336-436-5076-investor-labcorp-com-pattie-kushner-media-336-436-826-lh-20190207monthly0.5https://www.biopharmawatch.com/news/LH/pattie-kushner-media-1-336-436-8263-media-labcorp-com-scott-frommer-investors-1-336-436-50-lh-20190122monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-scott-frommer-investors-1-336-436-5076-investor-labcorp-com-pattie-kushne-lh-20190116monthly0.5https://www.biopharmawatch.com/news/LH/pattie-kushner-media-1-336-436-8263-media-labcorp-com-scott-frommer-investors-1-336-436-50-lh-20190103monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contacts-scott-frommer-investors-genfit-contacts-naomi-eichenbaum-investors-1-336--lh-20190103monthly0.5https://www.biopharmawatch.com/news/LH/scott-frommer-investors-1-336-436-5076-investor-labcorp-com-pattie-kushner-media-1-336-436-lh-20190102monthly0.5https://www.biopharmawatch.com/news/LH/sue-maynard-media-1-336-436-8263-media-labcorp-com-scott-frommer-investors-1-336-436-5076--lh-20181207monthly0.5https://www.biopharmawatch.com/news/LH/pattie-kushner-media-1-336-436-8263-media-labcorp-com-scott-frommer-investors-1-336-436-50-lh-20181130monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contact-donald-von-hagen-media-walgreens-contact-scott-goldberg-1-336-436-8263-1-8-lh-20181128monthly0.5https://www.biopharmawatch.com/news/LH/labcorp-contact-pattie-kushner-media-1-336-436-8263-media-labcorp-com-scott-frommer-invest-lh-20181108monthly0.5https://www.biopharmawatch.com/news/LH/donald-von-hagen-media-1-336-436-8263-media-labcorp-com-scott-frommer-investors-1-336-436--lh-20181101monthly0.5https://www.biopharmawatch.com/news/LH/donald-von-hagen-media-1-336-436-8263-media-labcorp-com-scott-frommer-investors-1-336-436--lh-20181029monthly0.5https://www.biopharmawatch.com/news/LH/scott-frommer-investors-336-436-5076-investor-labcorp-com-pattie-kushner-media-336-436-826-lh-20181024monthly0.5https://www.biopharmawatch.com/news/JAZZ/january-2026-44th-annual-j-p-morgan-healthcare-conference-redefining-possibilities-in-rare-jazz-20251231monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-names-renee-gala-as-president-and-chief-executive-officer-selection-f-jazz-20250710monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-acquisition-of-chimerix-addition-of-dordaviprone-strengthen-jazz-20250421monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-acquire-chimerix-further-diversifying-oncology-portfolio-dordavipr-jazz-20250305monthly0.5https://www.biopharmawatch.com/news/JAZZ/january-2025-rd-43-annual-j-p-morgan-healthcare-conference-innovating-to-transform-the-liv-jazz-20241231monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatm-jazz-20241121monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-private-offering-of-850-million-of-exchangeable-senior-note-jazz-20240903monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-appoints-philip-johnson-as-chief-financial-officer-mr-johnson-brings--jazz-20240221monthly0.5https://www.biopharmawatch.com/news/JAZZ/transforming-lives-redefining-possibilities-caution-concerning-forward-looking-statements--jazz-20221231monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-zymeworks-announce-jazz-has-confirmed-opt-in-and-advances-partner-jazz-20221221monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-zymeworks-announce-exclusive-license-agreement-to-develop-and-com-jazz-20221019monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-sumitomo-pharma-announce-exclusive-license-agreement-to-develop-a-jazz-20220504monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-werewolf-therapeutics-announce-exclusive-global-license-and-colla-jazz-20220407monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-agreement-to-divest-sunosi-solriamfetol-to-axsome-therapeut-jazz-20220328monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-vision-2025-to-deliver-sustainable-growth-and-enhanced-valu-jazz-20220110monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-u-s-fda-approval-of-rylaze-asparaginase-erwinia-chrysanthem-jazz-20210630monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-acquisition-of-gw-pharmaceuticals-plc-dublin-jazz-20210505monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-closing-of-senior-secured-notes-offering-dublin-jazz-20210429monthly0.5https://www.biopharmawatch.com/news/JAZZ/gw-pharmaceuticals-shareholders-approve-acquisition-by-jazz-pharmaceuticals-london-and-dub-jazz-20210423monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-prices-1-5-billion-million-senior-secured-notes-offering-dublin-jazz-20210422monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-proposed-private-offering-of-senior-secured-notes-dublin-jazz-20210420monthly0.5https://www.biopharmawatch.com/news/JAZZ/forward-looking-statements-safe-harbor-statement-under-the-private-securities-litigation-r-jazz-20210322monthly0.5https://www.biopharmawatch.com/news/JAZZ/forward-looking-statements-safe-harbor-statement-under-the-private-securities-litigation-r-jazz-20210204monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-acquire-gw-pharmaceuticals-plc-creating-an-innovative-high-growth--jazz-20210203monthly0.5https://www.biopharmawatch.com/news/JAZZ/relevant-portion-of-the-transcript-of-the-oral-presentation-by-jazz-pharmaceuticals-plc-at-jazz-20210111monthly0.5https://www.biopharmawatch.com/news/JAZZ/relevant-portion-of-the-transcript-of-the-oral-presentation-by-jazz-pharmaceuticals-plc-at-jazz-20200113monthly0.5https://www.biopharmawatch.com/news/JAZZ/relevant-portion-of-the-transcript-of-the-oral-presentation-by-jazz-pharmaceuticals-plc-at-jazz-20190107monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-new-pdufa-goal-date-for-solriamfetol-for-excessive-daytime-s-jazz-20181221monthly0.5https://www.biopharmawatch.com/news/JAZZ/relevant-portion-of-the-transcript-of-the-oral-presentation-by-jazz-pharmaceuticals-plc-at-jazz-20180108monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-completion-of-offering-and-exercise-in-full-of-initial-purc-jazz-20170901monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-offering-of-500-million-of-exchangeable-senior-notes-due-20-jazz-20170817monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-reaches-settlement-with-hikma-pharmaceuticals-related-to-xyrem-patent-jazz-20170405monthly0.5https://www.biopharmawatch.com/news/JAZZ/relevant-portion-of-the-transcript-of-the-oral-presentation-by-jazz-pharmaceuticals-plc-at-jazz-20170109monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-283-227-6409-l-morris-medpace-com-for-immediate-release-med-medp-20260422monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-283-227-6409-l-morris-medpace-com-for-immediate-release-med-medp-20260209monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-283-227-6409-l-morris-medpace-com-for-immediate-release-med-medp-20251022monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20250721monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20250421monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20250210monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20241021monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20240722monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20240422monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20240212monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20231023monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20230724monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-202302132023-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20221024monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-for-immediate-rele-medp-20220725monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-co-m-for-immediate-rel-medp-20220425monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-co-m-for-immediate-rel-medp-20220214monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-co-m-for-immediate-rel-medp-20211025monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-media-contact-juli-medp-20210726monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-media-contact-juli-medp-20210426monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-media-contact-juli-medp-20210215monthly0.5https://www.biopharmawatch.com/news/MEDP/investor-contact-lauren-morris-513-579-9911-x11994-l-morris-medpace-com-media-contact-juli-medp-20201026monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20200727monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20200428monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20200224monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20191028monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20190729monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20190429monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20190225monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20181029monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20180730monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20180430monthly0.5https://www.biopharmawatch.com/news/MEDP/julie-hopkins-medpace-holdings-inc-513-579-9911-x12627-j-hopkins-medpace-com-investor-cont-medp-20180226monthly0.5https://www.biopharmawatch.com/news/MEDP/mary-kuramoto-medpace-holdings-inc-513-579-9911-x12523-m-kuramoto-medpace-com-investor-con-medp-20171030monthly0.5https://www.biopharmawatch.com/news/MEDP/mary-kuramoto-medpace-holdings-inc-513-579-9911-x12523-m-kuramoto-medpace-com-for-immediat-medp-20170816monthly0.5https://www.biopharmawatch.com/news/MEDP/mary-kuramoto-medpace-holdings-inc-513-579-9911-x12523-m-kuramoto-medpace-com-investor-con-medp-20170731monthly0.5https://www.biopharmawatch.com/news/MEDP/mary-kuramoto-medpace-holdings-inc-513-579-9911-x12523-m-kuramoto-medpace-com-investor-con-medp-20170501monthly0.5https://www.biopharmawatch.com/news/MEDP/mary-kuramoto-medpace-holdings-inc-513-579-9911-x2523-m-kuramoto-medpace-com-investor-cont-medp-20170227monthly0.5https://www.biopharmawatch.com/news/MEDP/mary-kuramoto-medpace-holdings-inc-513-579-9911-x2523-m-kuramoto-medpace-com-investor-cont-medp-20161103monthly0.5https://www.biopharmawatch.com/news/MEDP/mary-kuramoto-medpace-holdings-inc-513-579-9911-x2523-m-kuramoto-medpace-com-investor-cont-medp-20160816monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-first-quarter-2026-results-net-income-available-to-common-shareholder-thc-20260430monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-fourth-quarter-and-fy-2025-results-provides-2026-financial-outlook-ne-thc-20260211monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-accretive-transaction-and-previews-strong-2025-results-tenet-completes-tra-thc-20260202monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-private-offerings-of-senior-secured-notes-and-senior-notes-to-refinance-2--thc-20251103monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-third-quarter-2025-results-raises-2025-financial-outlook-net-income-a-thc-20251028monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-second-quarter-2025-results-raises-2025-financial-outlook-net-income--thc-20250722monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-first-quarter-2025-results-net-income-available-to-common-shareholder-thc-20250429monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-fourth-quarter-and-fy-2024-results-provides-2025-financial-outlook-ne-thc-20250212monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-third-quarter-2024-results-raises-2024-financial-outlook-net-income-a-thc-20241029monthly0.5https://www.biopharmawatch.com/news/THC/tenet-healthcare-to-sell-five-birmingham-hospitals-to-orlando-health-tenet-announces-agree-thc-20240805monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-second-quarter-2024-results-raises-2024-financial-outlook-net-income--thc-20240724monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-first-quarter-2024-results-well-in-excess-of-guidance-raises-2024-financial--thc-20240430monthly0.5https://www.biopharmawatch.com/news/THC/tenet-completes-sale-of-six-hospitals-in-california-dallas-thc-20240401monthly0.5https://www.biopharmawatch.com/news/THC/tenet-to-sell-two-hospitals-and-enter-into-a-revenue-cycle-services-partnership-with-adven-thc-20240229monthly0.5https://www.biopharmawatch.com/news/THC/tenet-calls-for-full-redemption-of-4-875-senior-secured-first-lien-notes-due-2026-dallas-thc-20240216monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-fourth-quarter-and-fy-2023-results-provides-2024-financial-outlook-net-incom-thc-20240131monthly0.5https://www.biopharmawatch.com/news/THC/tenet-healthcare-corporation-unaudited-pro-forma-condensed-consolidated-financial-statemen-thc-20240201monthly0.5https://www.biopharmawatch.com/news/THC/tenet-advances-portfolio-transformation-and-previews-strong-2023-results-tenet-completes-s-thc-20240201monthly0.5https://www.biopharmawatch.com/news/THC/tenet-healthcare-to-sell-three-south-carolina-hospitals-to-novant-health-dallas-tx-thc-20231117monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-third-quarter-2023-results-raises-2023-outlook-net-income-from-continuing-op-thc-20231030monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-second-quarter-2023-results-raises-2023-outlook-net-income-from-continuing-o-thc-20230731monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-chief-financial-officer-transition-dallas-thc-20230623monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-1-350-billion-private-offering-of-senior-secured-notes-dallas-thc-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-first-quarter-2023-results-raises-2023-outlook-net-income-from-continuing-op-thc-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-fourth-quarter-and-fy-2022-results-provides-2023-financial-outlook-net-incom-thc-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THC/tenet-anticipates-beating-midpoint-of-latest-2022-outlook-announces-key-leadership-updates-thc-202301192023-01-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-third-quarter-2022-results-announces-1-billion-share-repurchase-program-net--thc-20221020monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-second-quarter-2022-results-reaffirms-2022-adjusted-ebitda-outlook-net-incom-thc-20220630monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-1-800-billion-private-offering-of-senior-secured-notes-dallas-thc-20220601monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-first-quarter-2022-results-retired-over-800-million-of-debt-to-date-in-2022--thc-20220420monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-amendment-to-its-credit-agreement-dallas-thc-20220317monthly0.5https://www.biopharmawatch.com/news/THC/conifer-to-remain-part-of-tenet-with-strong-path-forward-conference-call-scheduled-for-tod-thc-20220301monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-strong-fourth-quarter-and-fy-2021-results-announces-plan-to-retire-700-milli-thc-20220207monthly0.5https://www.biopharmawatch.com/news/THC/tenet-and-uspi-complete-transaction-to-acquire-thc-20211222monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-1-450-billion-private-offering-of-senior-secured-notes-dallas-nov-16-2021--thc-20211116monthly0.5https://www.biopharmawatch.com/news/THC/tenet-and-uspi-to-acquire-surgcenter-development-and-establish-long-term-development-partn-thc-20211108monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-third-quarter-2021-results-raises-2021-financial-guidance-net-income-from-co-thc-20211020monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-leadership-transition-saum-sutaria-appointed-chief-executive-officer-ron-r-thc-20210809monthly0.5https://www.biopharmawatch.com/news/THC/tenet-completes-sale-of-five-hospitals-in-the-miami-dade-southern-broward-area-dallas-thc-20210802monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-second-quarter-2021-results-raises-2021-financial-guidance-net-income-from-c-thc-20210721monthly0.5https://www.biopharmawatch.com/news/THC/steward-health-care-to-acquire-five-hospitals-in-the-miami-dade-southern-broward-area-from-thc-20210616monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-1-4-billion-private-offering-of-senior-secured-notes-dallas-thc-20210518monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-first-quarter-2021-results-raises-2021-financial-guidance-net-income-from-co-thc-20210420monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-fourth-quarter-2020-results-announces-plan-to-retire-478-million-of-debt-pro-thc-20210209monthly0.5https://www.biopharmawatch.com/news/THC/tenet-to-acquire-portfolio-of-surgery-centers-from-surgcenter-development-expands-uspi-amb-thc-20201210monthly0.5https://www.biopharmawatch.com/news/THC/t-enet-reports-third-quarter-2020-results-and-provides-update-on-effects-of-covid-19-net-l-thc-20201020monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-2-5-billion-private-offering-of-senior-notes-dallas-thc-20200901monthly0.5https://www.biopharmawatch.com/news/THC/t-enet-reports-results-for-the-second-quarter-ended-thc-20200803monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-600-million-private-offering-of-senior-secured-notes-dallas-thc-20200602monthly0.5https://www.biopharmawatch.com/news/THC/t-enet-reports-results-for-the-first-quarter-ended-thc-20200504monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-500-million-private-offering-of-senior-secured-notes-dallas-thc-20200402monthly0.5https://www.biopharmawatch.com/news/THC/tenet-provides-business-and-financial-update-related-to-covid-19-dallas-thc-20200402monthly0.5https://www.biopharmawatch.com/news/THC/t-enet-reports-results-for-the-fourth-quarter-and-year-ended-thc-20200224monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-definitive-agreement-to-divest-memphis-area-hospitals-and-operations-dalla-thc-20191213monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-third-quarter-ended-thc-20191104monthly0.5https://www.biopharmawatch.com/news/THC/tenet-appoints-nadja-west-m-d-as-new-independent-director-surgeon-general-of-the-u-s-army--thc-20190819monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-pricing-of-its-private-offering-of-senior-secured-notes-to-refinance-4-2-b-thc-20190812monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-private-offering-of-senior-secured-notes-to-refinance-4-2-billion-in-outst-thc-20190812monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-second-quarter-ended-thc-20190805monthly0.5https://www.biopharmawatch.com/news/THC/tenet-concludes-conifer-strategic-review-process-and-plans-to-complete-a-tax-free-spin-off-thc-20190724monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-first-quarter-ended-thc-20190429monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-fourth-quarter-and-year-ended-thc-20190225monthly0.5https://www.biopharmawatch.com/news/THC/unaudited-pro-forma-financial-statements-the-following-unaudited-pro-forma-financial-state-thc-20190129monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-third-quarter-ended-thc-20181105monthly0.5https://www.biopharmawatch.com/news/THC/unaudited-pro-forma-financial-statements-the-following-unaudited-pro-forma-financial-state-thc-20180820monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-second-quarter-ended-thc-20180806monthly0.5https://www.biopharmawatch.com/news/THC/tenet-board-appoints-two-independent-directors-dallas-thc-20180529monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-first-quarter-ended-thc-20180430monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reaches-agreement-with-glenview-implements-additional-governance-enhancements-dallas-thc-20180326monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-governance-enhancements-dallas-thc-20180305monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-fourth-quarter-ended-thc-20180226monthly0.5https://www.biopharmawatch.com/news/THC/tenet-completes-sale-of-philadelphia-area-hospitals-and-related-operations-dallas-thc-20180111monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-process-to-explore-a-potential-sale-of-conifer-provides-updates-on-cost-re-thc-20171219monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-third-quarter-ended-thc-20171107monthly0.5https://www.biopharmawatch.com/news/THC/tenet-releases-preliminary-results-for-the-third-quarter-of-2017-announces-150-million-cos-thc-20171027monthly0.5https://www.biopharmawatch.com/news/THC/tenet-ceo-trevor-fetter-departs-company-as-part-of-previously-announced-leadership-transit-thc-20171023monthly0.5https://www.biopharmawatch.com/news/THC/tenet-and-paladin-healthcare-reach-definitive-agreement-to-transfer-ownership-of-tenet-s-p-thc-20170901monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-ceo-transition-commencement-of-board-refreshment-process-and-implementatio-thc-20170831monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-second-quarter-ended-thc-20170807monthly0.5https://www.biopharmawatch.com/news/THC/tenet-completes-sale-of-houston-area-acute-care-hospitals-and-related-operations-to-thc-20170801monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-pricing-of-its-private-offering-of-senior-secured-and-unsecured-notes-to-r-thc-20170605monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-private-offering-of-senior-secured-and-unsecured-notes-to-refinance-3-541--thc-20170605monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-first-quarter-ended-thc-20170501monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-fourth-quarter-ended-thc-20170227monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-completion-of-its-private-offering-of-senior-secured-second-lien-notes-dal-thc-20161201monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-upsizing-and-pricing-of-its-private-offering-of-senior-secured-second-lien-thc-20161116monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-private-offering-of-senior-secured-second-lien-notes-dallas-thc-20161116monthly0.5https://www.biopharmawatch.com/news/THC/tenet-healthcare-board-appoints-two-new-independent-directors-new-directors-bring-signific-thc-20161104monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-third-quarter-ended-thc-20161031monthly0.5https://www.biopharmawatch.com/news/THC/tenet-healthcare-finalizes-previously-disclosed-agreement-to-resolve-clinica-de-la-mama-in-thc-20161003monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-second-quarter-ended-thc-20160801monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-first-quarter-ended-thc-20160502monthly0.5https://www.biopharmawatch.com/news/THC/tenet-completes-sale-of-atlanta-area-hospitals-and-related-operations-to-wellstar-dallas-thc-20160401monthly0.5https://www.biopharmawatch.com/news/THC/tenet-appoints-eric-evans-president-of-hospital-operations-dallas-thc-20160322monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-fourth-quarter-ended-thc-20160222monthly0.5https://www.biopharmawatch.com/news/THC/tenet-board-adds-two-new-independent-directors-addition-of-randy-simpson-and-matt-ripperge-thc-20160119monthly0.5https://www.biopharmawatch.com/news/THC/tenet-and-wellstar-reach-definitive-agreement-for-sale-of-tenet-s-atlanta-area-hospitals-a-thc-20151201monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-third-quarter-ended-thc-20151102monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reaffirms-adjusted-ebitda-outlook-for-the-third-quarter-ended-thc-20151023monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-results-for-the-second-quarter-ended-thc-20150803monthly0.5https://www.biopharmawatch.com/news/THC/tenet-healthcare-corporation-completes-united-surgical-partners-international-and-aspen-he-thc-20150616monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-upsizing-and-pricing-of-private-offering-of-senior-secured-notes-and-prici-thc-20150602monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-private-offering-of-senior-secured-and-unsecured-notes-dallas-thc-20150602monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-adjusted-ebitda-of-529-million-for-the-quarter-ended-thc-20150504monthly0.5https://www.biopharmawatch.com/news/THC/baylor-scott-white-health-and-tenet-to-partner-on-five-north-texas-hospitals-partnership-w-thc-20150323monthly0.5https://www.biopharmawatch.com/news/THC/tenet-united-surgical-partners-international-and-welsh-carson-to-create-the-nation-s-large-thc-20150323monthly0.5https://www.biopharmawatch.com/news/THC/tenet-healthcare-names-tammy-romo-to-board-of-directors-dallas-thc-20150312monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-adjusted-ebitda-of-646-million-for-the-quarter-ended-thc-20150223monthly0.5https://www.biopharmawatch.com/news/THC/tenet-releases-2015-outlook-previews-2014-results-strong-volume-growth-sustained-in-quarte-thc-20141231monthly0.5https://www.biopharmawatch.com/news/THC/tenet-healthcare-names-dr-freda-c-lewis-hall-to-board-of-directors-dallas-thc-20141204monthly0.5https://www.biopharmawatch.com/news/THC/tenet-reports-adjusted-ebitda-of-459-million-for-the-quarter-ended-thc-20141103monthly0.5https://www.biopharmawatch.com/news/THC/tenet-announces-private-offering-of-senior-notes-dallas-thc-20140924monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-closing-of-registered-direct-offering-of-o-rgc-20260522monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-registered-direct-offering-of-ordinary-sha-rgc-20260519monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-first-half-2026-management-financial-resul-rgc-20260508monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-at-the-market-offering-of-ordinary-shares-rgc-20260330monthly0.5https://www.biopharmawatch.com/news/RGC/form-of-fifth-extension-of-letter-of-lock-up-undertaking-date-from-the-optionee-to-regence-rgc-20260213monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-first-half-2025-management-financial-resul-rgc-20250630monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-the-forward-stock-split-is-effected-rgc-20250617monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-forward-stock-split-rgc-20250602monthly0.5https://www.biopharmawatch.com/news/RGC/form-of-forth-extension-of-letter-of-lock-up-undertaking-date-from-the-optionee-to-regence-rgc-20250115monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-first-half-2024-financial-results-rgc-20240620monthly0.5https://www.biopharmawatch.com/news/RGC/form-of-letter-of-lock-up-undertaking-date-from-the-optionee-to-regencell-bioscience-holdi-rgc-20231215monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-first-half-2023-management-financial-resul-rgc-20230615monthly0.5https://www.biopharmawatch.com/news/RGC/second-extension-of-letter-of-lock-up-undertaking-date-from-the-optionee-to-regencell-bios-rgc-20230605monthly0.5https://www.biopharmawatch.com/news/RGC/letter-of-lock-up-undertaking-date-from-the-optionee-to-regencell-bioscience-holdings-limi-rgc-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-s-standardized-formulae-are-shown-to-reduce-adhd-and-asd-symptoms-in--rgc-20220912monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-first-half-2022-management-financial-resul-rgc-20220602monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-announces-additional-earth-efficacy-trial-results-corroborating-effec-rgc-20220518monthly0.5https://www.biopharmawatch.com/news/RGC/form-of-letter-of-lock-up-undertaking-date-rgc-20220506monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-s-investigational-liquid-formula-rgc-cov19-tm-shows-effectiveness-thr-rgc-20220217monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-appoints-dr-william-wing-yan-lo-jp-to-its-board-of-d-rgc-20211213monthly0.5https://www.biopharmawatch.com/news/RGC/joint-venture-agreement-this-joint-venture-agreement-the-agreement-is-made-and-entered-and-rgc-20210902monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-partial-exercise-of-underwriter-s-over-all-rgc-20210820monthly0.5https://www.biopharmawatch.com/news/RGC/regencell-bioscience-holdings-limited-announces-pricing-of-approximately-21-9-million-init-rgc-20210715monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20260505monthly0.5https://www.biopharmawatch.com/news/BNTX/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-bntx-20260310monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-this-presentation-contains-for-bntx-20260114monthly0.5https://www.biopharmawatch.com/news/BNTX/convenience-translation-the-german-version-is-authoritative-articles-of-association-of-bio-bntx-20260106monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-closes-acquisition-of-curevac-n-v-including-subsequent-offering-period-to-strengt-bntx-20251218monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-achieves-minimum-condition-in-curevac-exchange-offer-the-minimum-condition-for-th-bntx-20251203monthly0.5https://www.biopharmawatch.com/news/BNTX/introductory-remarks-douglas-maffei-phd-vice-president-strategy-and-investor-relations-1-3-bntx-20251112monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20251103monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-this-presentation-contains-for-bntx-20251001monthly0.5https://www.biopharmawatch.com/news/BNTX/first-disclosure-of-global-interim-phase-2-data-for-biontech-and-bristol-myers-squibb-pd-l-bntx-20250908monthly0.5https://www.biopharmawatch.com/news/BNTX/certain-information-in-this-document-has-been-omitted-from-this-exhibit-because-it-is-both-bntx-20250908monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20250804monthly0.5https://www.biopharmawatch.com/news/BNTX/execution-version-purchase-agreement-dated-as-of-bntx-20250612monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-strategic-transaction-to-acquire-curevac-in-public-exchange-offer-acqui-bntx-20250611monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20250505monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-quarter-2025-financ-ial-results-and-corporate-update-continued-on-bntx-20250505monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-appointment-of-ram-n-zapata-to-management-board-as-chief-financial-offi-bntx-20250505monthly0.5https://www.biopharmawatch.com/news/BNTX/english-convenience-translation-the-german-language-version-is-decisive-biontech-se-mainz--bntx-20250404monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-this-presentation-contains-for-bntx-20250310monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20241104monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-highlights-ai-capabilities-and-r-d-use-cases-at-inaugural-ai-day-provides-updates-bntx-20241001monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-u-s-fda-approval-authorization-for-omicron-kp-2-adapted-covid--bntx-20240822monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-update-on-mrna-based-combination-vaccine-program-against-influ-bntx-20240816monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20240805monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-2-this-presentation-contains-f-bntx-20240805monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-jn-1-adapted-covid-19-vaccin-bntx-20240627monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-dualitybio-receive-fda-fast-track-designation-for-antibody-drug-conjugate-can-bntx-20240624monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-cepi-expand-partnership-to-strengthen-africa-s-mrna-vaccine-ecosystem-biontec-bntx-20240529monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2024-bntx-20240517monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20240506monthly0.5https://www.biopharmawatch.com/news/BNTX/document-biontech-se-mainz-wkn-a0v9bc-isin-de000a0v9bc4-wkn-a2psr2-isin-us09075v1026-invit-bntx-20240408monthly0.5https://www.biopharmawatch.com/news/BNTX/three-year-phase-1-follow-up-data-for-mrna-based-individualized-immunotherapy-candidate-sh-bntx-20240407monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-2-this-presentation-contains-f-bntx-20240320monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-appointment-of-annemarie-hanekamp-to-management-board-as-chief-commerci-bntx-20240320monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20231106monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-expands-management-board-by-appointing-james-ryan-as-chief-legal-officer-bntx-20230814monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20230807monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-second-quarter-2023-financial-results-and-corporate-update-significant--bntx-20230807monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-completes-acquisition-of-instadeep-acquisition-aims-to-strengthen-biontech-s-pion-bntx-20230731monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-update-on-covid-19-vaccine-supply-agreement-with-the-european--bntx-20230526monthly0.5https://www.biopharmawatch.com/news/BNTX/changes-in-the-supervisory-board-of-biontech-se-and-voting-results-from-the-annual-general-bntx-20230525monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-quarter-2023-financial-results-and-corporate-update-covid-19-vacc-bntx-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/the-german-language-invitation-is-decisive-biontech-se-mainz-wkn-a0v9bc-isin-de000a0v9bc4--bntx-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-new-ads-repurchase-program-bntx-202303282023-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/document-biontech-announces-fourth-quarter-and-full-year-2022-financial-results-and-corpor-bntx-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-oncoc4-announce-strategic-collaboration-to-co-develop-and-commercialize-novel-bntx-202303202023-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-u-s-emergency-use-authorization-of-omicron-ba-4-ba-5-adapted-b-bntx-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-for-u-s-emergency-use-authorization-of-omicron-ba-4-ba-5-adapte-bntx-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-supplemental-biologics-license-application-for-u-s-fda-approval-bntx-202302242023-02-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-acquire-instadeep-to-strengthen-pioneering-position-in-the-field-of-ai-powered-bntx-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-fosun-pharma-provide-covid-19-vaccine-doses-for-vaccination-of-german-expatri-bntx-20221222monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-u-s-fda-fast-track-designation-for-single-dose-mrna-based-vacc-bntx-20221209monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-u-s-fda-emergency-use-authorization-for-omicron-ba-4-ba-5-adap-bntx-20221208monthly0.5https://www.biopharmawatch.com/news/BNTX/disclosure-of-share-buyback-program-pursuant-to-art-5-1-lit-a-of-regulation-eu-no-596-2014-bntx-20221208monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-application-to-u-s-fda-for-emergency-use-authorization-of-omicr-bntx-20221205monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-ryvu-therapeutics-enter-into-global-collaboration-to-develop-and-commercializ-bntx-20221130monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-report-new-data-on-omicron-ba-4-ba-5-adapted-bivalent-booster-demonstr-bntx-20221118monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-advance-next-generation-covid-19-vaccine-strategy-with-study-start-of--bntx-20221116monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-ba-4-ba-5-adapted-bivalent-c-bntx-20221110monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20221107monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-updated-clinical-data-for-omicron-ba-4-ba-5-adapted-bivalent--bntx-20221104monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-comirnaty-in-children-6-months-to-le-bntx-20221019monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-positive-early-data-from-clinical-trial-of-omicron-ba-4-ba-5--bntx-20221013monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-u-s-fda-emergency-use-authorization-for-omicron-ba-4-ba-5-adap-bntx-20221012monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-application-to-u-s-fda-for-emergency-use-authorization-of-omicr-bntx-20220926monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-conversion-of-comirnaty-conditional--bntx-20220916monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-ba-4-ba-5-adapted-bivalent-c-bntx-20220912monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-presents-encouraging-phase-1-2-follow-up-data-for-car-t-candidate-bnt211-in-hard--bntx-20220909monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-ba-1-adapted-bivalent-covid--bntx-20220901monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-granted-fda-emergency-use-authorization-of-omicron-ba-4-ba-5-adapted-b-bntx-20220831monthly0.5https://www.biopharmawatch.com/news/BNTX/statement-on-patent-infringement-lawsuit-filed-by-moderna-biontech-is-aware-of-reports-tha-bntx-20220826monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-complete-submission-to-european-medicines-agency-for-omicron-ba-4-ba-5-bntx-20220826monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-updated-covid-19-vaccine-data-supporting-efficacy-in-children-bntx-20220823monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-application-to-u-s-fda-for-emergency-use-authorization-of-omicr-bntx-20220822monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20220808monthly0.5https://www.biopharmawatch.com/news/BNTX/document-biontech-and-genmab-expand-global-strategic-collaboration-to-develop-and-commerci-bntx-20220805monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-advance-covid-19-vaccine-strategy-with-study-start-of-next-generation--bntx-20220727monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-complete-submission-to-european-medicines-agency-for-omicron-ba-1-adap-bntx-20220719monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-a-variation-to-ema-for-the-vaccination-of-children-ages-6-month-bntx-20220708monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-u-s-fda-approval-of-their-covid-19-vaccine-comirnaty-for-adol-bntx-20220708monthly0.5https://www.biopharmawatch.com/news/BNTX/statement-on-patent-infringement-lawsuit-in-germany-biontech-values-and-respects-valid-int-bntx-20220706monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-new-agreement-with-u-s-government-to-provide-additional-doses-bntx-20220629monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-omicron-adapted-covid-19-vaccine-candidates-demonstrate-high--bntx-20220625monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-receives-priority-medicines-prime-designation-from-ema-for-enhanced-regulatory-su-bntx-20220623monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use-authorization-for-children-6-m-bntx-20220617monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-update-on-rolling-submission-to-european-medicines-agency-for--bntx-20220615monthly0.5https://www.biopharmawatch.com/news/BNTX/positive-phase-1-data-from-mrna-based-individualized-neoantigen-specific-immunotherapy-in--bntx-20220605monthly0.5https://www.biopharmawatch.com/news/BNTX/voting-results-from-biontech-s-annual-general-meeting-2022-shareholders-reappointed-helmut-bntx-20220601monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune-response-high-efficacy-and-fav-bntx-20220523monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-granted-u-s-emergency-use-authorization-for-booster-dose-of-their-covi-bntx-20220517monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-update-on-covid-19-vaccine-supply-agreement-with-european-comm-bntx-20220516monthly0.5https://www.biopharmawatch.com/news/BNTX/unaudited-interim-condensed-consolidated-financial-statements-interim-condensed-consolidat-bntx-20220509monthly0.5https://www.biopharmawatch.com/news/BNTX/disclosure-of-share-buyback-program-pursuant-to-art-5-1-lit-a-of-regulation-eu-no-596-2014-bntx-20220506monthly0.5https://www.biopharmawatch.com/news/BNTX/disclosure-of-share-buyback-program-pursuant-to-art-5-1-lit-a-of-regulation-eu-no-596-2014-bntx-20220502monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-application-for-u-s-emergency-use-authorization-for-a-covid-19--bntx-20220426monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-data-demonstrating-high-immune-response-following-a-booster-d-bntx-20220414monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-presents-positive-preliminary-phase-1-2-data-for-first-in-class-car-t-program-bnt-bntx-20220411monthly0.5https://www.biopharmawatch.com/news/BNTX/b-iontech-granted-pandemic-preparedness-contract-by-german-federal-ministry-of-health-main-bntx-20220408monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-ads-repurchase-program-mainz-germany-march-31-2022-biontech-or-the-comp-bntx-20220331monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-expanded-u-s-emergency-use-authorization-for-an-additional-cov-bntx-20220329monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-for-u-s-emergency-use-authorization-of-an-additional-booster-do-bntx-20220315monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-regeneron-expand-strategic-collaboration-to-advance-clinical-development-of-f-bntx-20220308monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-covid-19-vaccine-booster-in-adolesce-bntx-20220224monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-medigene-announce-global-collaboration-to-advance-t-cell-receptor-immunothera-bntx-20220221monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-introduces-first-modular-mrna-manufacturing-facility-to-promote-scalable-vaccine--bntx-20220216monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-update-on-rolling-submission-for-emergency-use-authorization-o-bntx-20220211monthly0.5https://www.biopharmawatch.com/news/BNTX/the-curious-case-of-the-biontech-priority-review-voucher-zachary-brennan-bntx-20220202monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-initiate-rolling-submission-for-emergency-use-authorization-of-their-c-bntx-20220201monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-initiate-study-to-evaluate-omicron-based-covid-19-vaccine-in-adults-18-bntx-20220125monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-publish-data-from-two-laboratory-studies-on-covid-19-vaccine-induced-a-bntx-20220124monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-instadeep-developed-and-successfully-tested-early-warning-system-to-detect-po-bntx-20220111monthly0.5https://www.biopharmawatch.com/news/BNTX/titelmasterformat-durch-klicken-bearbeiten-this-slide-presentation-includes-forward-lookin-bntx-20220111monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-crescendo-biologics-announce-global-collaboration-to-develop-multi-specific-p-bntx-20220110monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-sign-new-global-collaboration-agreement-to-develop-first-mrna-based-sh-bntx-20220105monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-u-s-fda-emergency-use-authorization-of-covid-19-vaccine-booste-bntx-20220103monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-provide-european-union-more-than-200-million-additional-doses-of-co-bntx-20211220monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-update-on-ongoing-studies-of-covid-19-vaccine-new-york-usa-and-bntx-20211217monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-supplemental-biologics-license-application-for-u-s-fda-approval-bntx-20211217monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-u-s-fda-emergency-use-authorization-of-covid-19-vaccine-booste-bntx-20211209monthly0.5https://www.biopharmawatch.com/news/BNTX/k-1-ex991bnt-presseventxupda-htm-6-k-ex991bnt-presseventxupda-omicron-variant-b-1-1-529-bntx-20211208monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-update-on-omicron-variant-preliminary-laboratory-studies-demon-bntx-20211208monthly0.5https://www.biopharmawatch.com/news/BNTX/omicron-unlikely-to-cause-severe-illness-in-vaccinated-people-biontech-founder-says-by-boj-bntx-20211201monthly0.5https://www.biopharmawatch.com/news/BNTX/nov-26-2021-13-24-biontech-will-take-two-weeks-to-assess-vaccine-against-latest-covid-vari-bntx-20211126monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-comirnaty-in-children-5-to-under-12--bntx-20211126monthly0.5https://www.biopharmawatch.com/news/BNTX/follow-up-data-from-phase-3-trial-of-pfizer-biontech-covid-19-vaccine-support-safety-and-h-bntx-20211122monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-expanded-u-s-fda-emergency-use-authorization-of-covid-19-vacci-bntx-20211119monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-receives-fda-fast-track-designation-for-its-fixvac-candidate-bnt111-in-advanced-m-bntx-20211119monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-request-to-amend-u-s-fda-emergency-use-authorization-of-their-c-bntx-20211109monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-quarterly-report-for-the-three-and-nine-months-ended-bntx-20211109monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-first-u-s-fda-emergency-use-authorization-of-a-covid-19-vaccin-bntx-20211029monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-provide-u-s-government-an-additional-50-million-pediatric-doses-of--bntx-20211028monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-plans-to-initiate-the-construction-of-an-mrna-vaccine-manufacturing-facility-in-a-bntx-20211026monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-andbiontech-announce-phase-3-trial-data-showing-high-efficacy-of-a-covid-19-vaccine-bntx-20211021monthly0.5https://www.biopharmawatch.com/news/BNTX/new-formulation-of-comirnaty-receives-positive-opinion-from-chmp-new-york-usa-and-mainz-ge-bntx-20211018monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submitted-data-to-ema-for-the-vaccination-of-children-5-to-less-than-1-bntx-20211015monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-chmp-positive-opinion-for-covid-19-vaccine-booster-in-the-euro-bntx-20211004monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-expands-clinical-oncology-portfolio-with-first-patient-dosed-in-phase-2-trial-of--bntx-20211001monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-initial-data-to-u-s-fda-from-pivotal-trial-of-covid-19-vaccine--bntx-20210928monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-first-u-s-fda-emergency-use-authorization-of-a-covid-19-vaccin-bntx-20210922monthly0.5https://www.biopharmawatch.com/news/BNTX/p-fizer-and-biontech-expand-collaboration-with-u-s-to-provide-500-million-additional-covid-bntx-20210922monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-a-variation-to-ema-with-the-data-in-support-of-a-booster-dose-o-bntx-20210920monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-a-variation-to-ema-with-the-data-in-support-of-a-booster-dose-o-bntx-20210906monthly0.5https://www.biopharmawatch.com/news/BNTX/joint-communiqu-biontech-evaluates-mrna-vaccine-manufacturing-solutions-in-rwanda-and-sene-bntx-20210827monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-collaboration-with-brazil-s-eurofarma-to-manufacture-covid-19-bntx-20210823monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-initiate-rolling-submission-of-supplemental-biologics-license-applicat-bntx-20210823monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-biontech-covid-19-vaccine-comirnaty-receives-full-u-s-fda-approval-for-individuals--bntx-20210823monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-submission-of-initial-data-to-u-s-fda-to-support-booster-dose-bntx-20210816monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-quarterly-report-for-the-three-and-six-months-ended-bntx-20210809monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-second-quarter-2021-financial-results-and-corporate-update-more-than-on-bntx-20210721monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-completes-acquisition-of-kite-s-neoantigen-tcr-cell-therapy-r-d-platform-and-manu-bntx-20210719monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-provides-update-on-plans-to-develop-sustainable-solutions-to-address-infectious-d-bntx-20210726monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-u-s-government-with-an-additional-200-million-doses-of-covid-bntx-20210723monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-update-on-booster-program-in-light-of-the-delta-variant-as-par-bntx-20210708monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-mainz-germany-annual-general-meeting-in-munich-germany-22-june-2021-voting-res-bntx-20210622monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mrna-based-bnt111-in-p-bntx-20210618monthly0.5https://www.biopharmawatch.com/news/BNTX/financial-times-10-06-2021-biontech-prepares-expansion-into-africa-alongside-eu-by-erika-s-bntx-20210610monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-provide-500-million-doses-of-covid-19-vaccine-to-u-s-government-for-bntx-20210610monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-first-authorization-in-european-union-for-covid-19-vaccine-in--bntx-20210528monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-publishes-first-sustainability-report-and-receives-prime-rating-by-iss-esg-bionte-bntx-20210521monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-sign-agreement-for-additional-supply-to-turkey-of-60-million-doses-of--bntx-20210520monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-the-european-union-with-up-to-1-8-billion-additional-doses-o-bntx-20210520monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-broadens-management-board-by-appointing-jens-holstein-as-cfo-mainz-germany-18-may-bntx-20210518monthly0.5https://www.biopharmawatch.com/news/BNTX/update-on-stability-of-comirnaty-more-flexible-storage-conditions-on-bntx-20210517monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-first-u-s-authorization-for-emergency-use-of-covid-19-vaccine--bntx-20210511monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-quarterly-report-for-the-three-months-ended-bntx-20210510monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-quarter-2021-financial-results-and-corporate-update-more-than-450-bntx-20210506monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-establish-regional-headquarters-for-south-east-asia-and-first-mrna-manufacturi-bntx-20210510monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-initiate-rolling-submission-of-biologics-license-application-for-u-s-f-bntx-20210507monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-provide-covid-19-vaccine-doses-for-olympic-athletes-at-the-2020-tok-bntx-20210506monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-request-to-expand-conditional-marketing-authorization-of-comirn-bntx-20210430monthly0.5https://www.biopharmawatch.com/news/BNTX/europe-will-reach-herd-immunity-this-summer-biontech-chief-the-hill-changing-america-by-ad-bntx-20210428monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-the-european-union-with-100-million-additional-doses-of-comi-bntx-20210419monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-request-regulatory-agencies-expand-emergency-use-of-their-covid-19-vac-bntx-20210409monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-confirm-high-efficacy-and-no-serious-safety-concerns-through-up-to-six-bntx-20210401monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-biontech-announce-positive-topline-results-of-pivotal-covid-19-vaccine-study-in-ado-bntx-20210331monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-full-year-2020-financial-results-and-corporate-update-bnt162b2-vaccine--bntx-20210323monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210326monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210311monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210304monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210225monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210219monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210217monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210212monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210210monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210208monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210202monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210128monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210125monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210120monthly0.5https://www.biopharmawatch.com/news/BNTX/statement-on-european-upscaling-as-well-as-impact-on-deliveries-pfizer-and-biontech-have-d-bntx-20210115monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-forward-looking-statements-var-bntx-20210111monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20210108monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20201229monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20201223monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-forward-looking-statements-var-bntx-20201222monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20201214monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20201211monthly0.5https://www.biopharmawatch.com/news/BNTX/statement-regarding-cyber-attack-on-european-medicines-agency-bntx-20201209monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20201202monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20201120monthly0.5https://www.biopharmawatch.com/news/BNTX/to-its-current-report-on-form-6-k-filed-with-the-sec-on-november-10-which-is-available-on--bntx-20201118monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-quarterly-report-for-the-three-and-nine-months-ended-bntx-20201112monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-third-quarter-2020-financial-results-and-corporate-progress-x2022-bnt16-bntx-20201110monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-pro-forma-financial-information-biontech-se-pro-forma-financial-information-in-bntx-20201110monthly0.5https://www.biopharmawatch.com/news/BNTX/duobody-pd-l1-4-1bb-gen1046-induces-superior-immune-cell-activation-cytokine-production-an-bntx-20201109monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-vaccine-candidate-against-covid-19-achieved-success-in-first--bntx-20201109monthly0.5https://www.biopharmawatch.com/news/BNTX/an-open-letter-from-pfizer-chairman-and-ceo-albert-bourla-as-we-get-closer-to-an-important-bntx-20201016monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-pfizer-initiate-rolling-submission-to-european-medicines-agency-for-sars-cov--bntx-20201006monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-acquire-gmp-manufacturing-site-to-expand-covid-19-vaccine-production-capacity--bntx-20200917monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-receive-up-to-375m-in-funding-from-german-federal-ministry-of-education-and-re-bntx-20200915monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-contacts-media-relations-amy-rose-1-646-592-3157-amy-rose-pfizer-com-investor-relat-bntx-20200914monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-data-from-preclinical-studies-of-mrna-based-vaccine-candidate-bntx-20200909monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-potentially-supply-the-eu-with-200-million-doses-of-mrna-based-vacc-bntx-20200909monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-share-positive-early-data-on-lead-mrna-vaccine-candidate-bnt162b2-agai-bntx-20200820monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-publication-of-peer-reviewed-data-from-ongoing-phase-1-2-stud-bntx-20200812monthly0.5https://www.biopharmawatch.com/news/BNTX/of-the-form-6-k-of-which-this-exhibit-forms-a-part-operating-results-overview-biontech-was-bntx-20200811monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-canada-with-their-bnt162-mrna-based-vaccine-candidate-x2022--bntx-20200805monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-fosun-pharma-announce-start-of-clinical-trial-of-mrna-based-covid-19-vaccine--bntx-20200805monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-strategic-collaboration-with-regeneron-to-advance-fixvac-and-libtayo-ce-bntx-20200731monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-japan-with-120-million-doses-of-their-bnt162-mrna-based-vacc-bntx-20200731monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-publishes-data-from-mrna-based-bnt111-fixvac-melanoma-trial-in-nature-x2022-preli-bntx-20200730monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against-covid-19-and-commence-pivot-bntx-20200727monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-closing-of-512-million-underwritten-offering-of-american-depositary-sha-bntx-20200727monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-pricing-of-upsized-underwritten-offering-and-terms-of-rights-offering-bntx-20200722monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-an-agreement-with-u-s-government-for-up-to-600-million-doses--bntx-20200722monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-proposed-public-offerings-bntx-20200721monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-early-positive-update-from-german-phase-1-2-covid-19-vaccine--bntx-20200720monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-agreement-with-the-united-kingdom-for-30-million-doses-of-mrn-bntx-20200720monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-granted-fda-fast-track-designation-for-two-investigational-mrna-based--bntx-20200713monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-early-positive-data-from-an-ongoing-phase-1-2-study-of-mrna-b-bntx-20200701monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-raise-usd-250-million-in-private-placement-bntx-20200629monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-mainz-germany-annual-general-meeting-in-munich-germany-26-june-2020-voting-res-bntx-20200626monthly0.5https://www.biopharmawatch.com/news/BNTX/dr-lopez-has-the-following-relationships-to-disclose-research-grant-funding-roche-genentec-bntx-20200623monthly0.5https://www.biopharmawatch.com/news/BNTX/dr-braiteh-has-the-following-relationships-to-disclose-honoraria-from-abbott-nutrition-amg-bntx-20200623monthly0.5https://www.biopharmawatch.com/news/BNTX/the-investments-we-have-made-to-develop-our-vaccine-platform-over-the-past-12-years-have-b-bntx-20200611monthly0.5https://www.biopharmawatch.com/news/BNTX/of-the-form-6-k-of-which-this-exhibit-forms-a-part-operating-results-overview-biontech-was-bntx-20200512monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-completes-acquisition-of-neon-therapeutics-mainz-germany-and-cambridge-usa-bntx-20200506monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-dose-first-participants-in-the-u-s-as-part-of-global-covid-19-mrna-vac-bntx-20200505monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-pfizer-announce-completion-of-dosing-for-first-cohort-of-phase-1-2-trial-of-c-bntx-20200429monthly0.5https://www.biopharmawatch.com/news/BNTX/jpt-launches-broad-spectrum-of-covid-19-peptide-tools-for-immune-monitoring-vaccine-diagno-bntx-20200422monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-media-relations-jasmina-alatovic-senior-manager-global-external-communications-te-bntx-20200422monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-further-details-on-collaboration-to-accelerate-global-covid-1-bntx-20200409monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-full-year-2019-financial-results-and-corporate-update-x2022-bnt111-fixv-bntx-20200331monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-co-develop-potential-covid-19-vaccine-x2022-companies-will-jointly--bntx-20200317monthly0.5https://www.biopharmawatch.com/news/BNTX/partnerships-to-develop-mrna-vaccines-for-infectious-diseases-including-with-pfizer-the-un-bntx-20200316monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-fosun-pharma-form-covid-19-vaccine-strategic-alliance-in-china-x2022-biontech-bntx-20200316monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-commencement-of-public-offering-of-american-depositary-shares-mainz-ger-bntx-20200203monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-forward-looking-statements-var-bntx-20200127monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-acquire-neon-to-strengthen-global-leadership-position-in-t-cell-therapies-furt-bntx-20200116monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-forward-looking-statements-var-bntx-20200112monthly0.5https://www.biopharmawatch.com/news/BNTX/this-slide-presentation-includes-forward-looking-statements-forward-looking-statements-var-bntx-20191231monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-appoints-ryan-richardson-as-chief-strategy-officer-to-support-its-continued-globa-bntx-20200113monthly0.5https://www.biopharmawatch.com/news/BNTX/press-release-bntx-20200102monthly0.5https://www.biopharmawatch.com/news/BNTX/joint-press-release-17-december-2019-european-investment-bank-provides-funding-of-50-milli-bntx-20191217monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-provides-update-on-corporate-progress-and-third-quarter-2019-financial-results-bntx-20191114monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2025-financial-results-pen-20250729monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2025-financial-results-pen-20250423monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2024-financial-results-pen-20250218monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2024-financial-results-pen-20241030monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2024-financial-results-pen-20240730monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2024-financial-results-pen-20240507monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2023-financial-results-pen-20240222monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2023-financial-results-pen-20231102monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2023-financial-results-pen-20230801monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2023-financial-results-pen-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2022-financial-results-pen-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2022-financial-results-pen-20221103monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2022-financial-results-pen-20220804monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2022-financial-results-pen-20220503monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2021-financial-results-alameda-ca-pen-20220222monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2021-financial-results-pen-20211103monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2021-financial-results-pen-20210809monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2021-financial-results-pen-20210504monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2020-financial-results-alameda-ca-pen-20210223monthly0.5https://www.biopharmawatch.com/news/PEN/document-penumbra-announces-preliminary-unaudited-revenue-for-the-fourth-quarter-and-full--pen-20210111monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-announces-penumbra-jet-7-reperfusion-catheter-with-xtra-flex-technology-voluntary-pen-20201215monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-responds-to-false-allegations-from-short-sellers-seeking-to-manipulate-company-st-pen-20201208monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2020-financial-results-pen-20201028monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2020-financial-results-pen-20200803monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-announces-management-transition-sri-kosaraju-will-transition-from-his-role-as-pre-pen-20200512monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2020-financial-results-pen-20200507monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-provides-update-on-covid-19-response-and-impact-pen-20200406monthly0.5https://www.biopharmawatch.com/news/PEN/maggie-yuen-appointed-chief-financial-officer-of-penumbra-following-the-promotion-of-sri-k-pen-20191125monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2019-financial-results-pen-20191107monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2019-financial-results-pen-20190806monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2019-financial-results-pen-20190507monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2018-financial-results-alameda-ca-pen-20190226monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2018-financial-results-pen-20181105monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2018-financial-results-pen-20180807monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2018-financial-results-pen-20180508monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2017-financial-results-alameda-ca-pen-20180227monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2017-financial-results-pen-20171107monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2017-financial-results-pen-20170808monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2017-financial-results-pen-20170509monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2016-financial-results-alameda-ca-pen-20170228monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2016-financial-results-pen-20161103monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-second-quarter-2016-financial-results-pen-20160809monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-first-quarter-2016-financial-results-pen-20160509monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2015-financial-results-pen-20160308monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-pen-20151112monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-andrew-exel-20260505monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-andrew-exel-20260210monthly0.5https://www.biopharmawatch.com/news/EXEL/investor-contacts-andrew-peters-svp-strategy-and-investor-relations-exelixis-inc-650-837-7-exel-20260111monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20251104monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20250728monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20250513monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20250220monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20250211monthly0.5https://www.biopharmawatch.com/news/EXEL/investor-contacts-susan-hubbard-evp-public-affairs-investor-relations-exelixis-inc-650-837-exel-20250112monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-varant-exel-20241029monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20240806monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-varant-exel-20240430monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20240206monthly0.5https://www.biopharmawatch.com/news/EXEL/document-investor-contacts-susan-hubbard-evp-public-affairs-investor-relations-exelixis-in-exel-20240107monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20231101monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20230801monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/investor-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-202305072023-05-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/investor-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-202303202023-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20221101monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20220809monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20220510monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20220217monthly0.5https://www.biopharmawatch.com/news/EXEL/document-investor-contacts-susan-hubbard-evp-public-affairs-investor-relations-exelixis-in-exel-20220109monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20211102monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20210805monthly0.5https://www.biopharmawatch.com/news/EXEL/chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-exelixis-com-susan--exel-20210506monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20210210monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20201105monthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-files-second-complaint-in-patent-infringement-lawsuit-against-msn-pharmaceuticals-exel-20200806monthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-partner-takeda-pharmaceutical-company-limited-takeda-receives-approval-in-japan-f-exel-20200505monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20200225monthly0.5https://www.biopharmawatch.com/news/EXEL/document-exelixis-outlines-key-priorities-and-anticipated-milestones-for-2020-21-announces-exel-20200102monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20191030monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20190731monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20190501monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20190212monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20181101monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20180801monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20180502monthly0.5https://www.biopharmawatch.com/news/EXEL/document-contacts-chris-senner-chief-financial-officer-exelixis-inc-650-837-7240-csenner-e-exel-20180226monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-submits-nda-to-fda-for-encaleret-for-individuals-living-with-adh1-phase-3-calibr-bbio-20260512monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-submits-nda-to-fda-for-bbp-418-for-individuals-living-with-lgmd2i-r9-comprehensi-bbio-20260330monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-commercial-updat-bbio-20260220monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-continues-long-term-debt-management-strategy-and-announces-proposed-offering-of--bbio-20260121monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-commercial-progress-program-updates-and-2026-milestones-at-the-44-th-a-bbio-20251231monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-third-quarter-2025-financial-results-and-business-updates-120-7-million--bbio-20251025monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-forward-looking-statements-this-press-release-contains-forward-looking-statement-bbio-20251027monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-second-quarter-2025-financial-results-and-business-updates-as-of-bbio-20250801monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-first-quarter-2025-financial-results-and-business-updates-36-7-million-i-bbio-20250425monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-cfo-succession-bbio-20250317monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-initiates-long-term-debt-management-strategy-and-announces-proposed-offering-of--bbio-20250224monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-fourth-quarter-and-full-year-2024-financial-results-and-commercia-bbio-20250217monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-commercial-progress-program-updates-and-2025-milestones-remarkable-ear-bbio-20250113monthly0.5https://www.biopharmawatch.com/news/BBIO/attruby-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-reduce-cardiovascu-bbio-20241122monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-third-quarter-2024-financial-results-and-business-update-patients-bbio-20241112monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-topline-results-from-phase-1-2-trial-of-investigational-gene-ther-bbio-20240910monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-second-quarter-2024-financial-results-and-business-update-acorami-bbio-20240801monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-appointment-of-thomas-trimarchi-ph-d-as-president-and-chief-operating--bbio-20240723monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-durable-month-12-and-18-phase-2-cohort-5-results-of-oral-infigratinib--bbio-20240604monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-first-quarter-2024-financial-results-and-business-update-presente-bbio-20240502monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-proposed-public-offering-of-common-stock-bbio-20240304monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-fourth-quarter-and-full-year-2023-financial-results-and-business--bbio-20240222monthly0.5https://www.biopharmawatch.com/news/BBIO/jpm-presentation-2024-forward-looking-statement-and-disclaimer-the-presentation-may-contai-bbio-20240108monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update-presente-bbio-20231102monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-250-million-private-placement-equity-financing-250-million-fina-bbio-20230925monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-second-quarter-2023-financial-results-and-business-update-announc-bbio-20230803monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-consistently-positive-results-from-phase-3-attribute-cm-study-of-acora-bbio-20230717monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-first-quarter-2023-financial-results-and-business-update-phase-3--bbio-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-proposed-public-offering-of-common-stock-bbio-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia-de-bbio-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-fourth-quarter-and-full-year-2022-financial-results-and-business--bbio-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update-repo-bbio-20221103monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update-rep-bbio-20220804monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-sells-rare-pediatric-disease-priority-review-voucher-for-110-million-and--bbio-20220513monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-exclusive-license-agreement-with-bristol-myers-squibb-to-develop-and-c-bbio-20220512monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-first-quarter-2022-financial-results-and-business-update-complete-bbio-20220505monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-fourth-quarter-and-full-year-2021-financial-results-and-business--bbio-20220224monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-month-12-topline-results-from-phase-3-attribute-cm-study-attribut-bbio-20211227monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-secures-up-to-750-million-in-non-dilutive-debt-financing-innovative-f-bbio-20211118monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update-topline--bbio-20211104monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-appoints-pioneering-national-leader-in-genomics-and-workforce-diversi-bbio-20211025monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-appoints-finance-and-pharmaceutical-leaders-fred-hassan-andrea-ellis--bbio-20210818monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-second-quarter-2021-financial-results-and-business-update-rec-bbio-20210813monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-first-quarter-2021-financial-results-and-business-update-rece-bbio-20210514monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-fourth-quarter-and-full-year-2020-financial-results-and-busin-bbio-20210226monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-announces-launch-of-secondary-offering-of-common-stock-11-02-2021-at--bbio-20210211monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-announces-proposed-offering-of-400-million-convertible-senior-notes-bbio-20210125monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-announces-completion-of-merger-with-eidos-therapeutics-inc-bbio-20210126monthly0.5https://www.biopharmawatch.com/news/BBIO/stockholders-of-bridgebio-pharma-inc-and-eidos-therapeutics-inc-approve-bridgebio-pharma-i-bbio-20210119monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-third-quarter-2020-financial-results-and-business-update-merg-bbio-20201105monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-eidos-therapeutics-announce-merger-agreement-bridgebio-to-acquire-all-bbio-20201005monthly0.5https://www.biopharmawatch.com/news/BBIO/forward-looking-statements-and-disclaimer-statements-in-this-presentation-that-are-not-sta-bbio-20200929monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-second-quarter-2020-financial-results-and-business-update-ini-bbio-20200811monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-appoints-biotech-trailblazers-brent-saunders-and-randy-scott-and-reno-bbio-20200624monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-first-quarter-2020-financial-results-and-business-update-ende-bbio-20200513monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-announces-proposed-offering-of-350-million-convertible-senior-notes-0-bbio-20200304monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlight-bbio-20200302monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-third-quarter-2019-financial-results-and-highlights-portfolio-pro-bbio-20191226monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-appoints-industry-leader-jennifer-cook-as-new-board-member-genentech--bbio-20191216monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-and-eidos-present-data-from-phase-2-open-label-extension-suggesting-long-term-to-bbio-20191116monthly0.5https://www.biopharmawatch.com/news/BBIO/alexion-and-bridgebio-announce-japanese-license-agreement-for-eidos-transthyretin-amyloido-bbio-20190912monthly0.5https://www.biopharmawatch.com/news/IONS/final-ionis-announces-appointment-of-ludwig-hantson-ph-d-to-board-of-directors-ions-20260608monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-changes-to-board-of-directors-lynne-parshall-and-joseph-wender-to-retire-a-ions-20260309monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-well-positioned-for-continued-momentum-and-substantial-value-creation-in-2026-with-t-ions-20260112monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-partner-gsk-announces-positive-topline-results-from-b-well-1-and-b-well-2-phase-3-st-ions-20260107monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-proposed-convertible-offering-to-refinance-2026-convertible-notes-refinanc-ions-20251111monthly0.5https://www.biopharmawatch.com/news/IONS/groundbreaking-pivotal-study-results-of-olezarsen-for-severe-hypertriglyceridemia-shtg-pre-ions-20251108monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-third-quarter-2025-financial-results-and-highlights-progress-on-key-programs-ions-20251029monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-topline-results-from-pivotal-study-of-zilganersen-in-alexander-di-ions-20250922monthly0.5https://www.biopharmawatch.com/news/IONS/olezarsen-significantly-reduces-triglycerides-and-acute-pancreatitis-events-in-landmark-pi-ions-20250902monthly0.5https://www.biopharmawatch.com/news/IONS/dawnzera-donidalorsen-approved-in-the-u-s-as-first-and-only-rna-targeted-prophylactic-trea-ions-20250821monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-second-quarter-2025-financial-results-and-highlights-progress-on-key-program-ions-20250730monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-dr-richard-geary-chief-development-officer-to-retire-dr-holly-kordasiewicz-ions-20250612monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-topline-results-from-essence-study-of-olezarsen-in-people-with-mo-ions-20250519monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-first-quarter-2025-financial-results-encouraging-start-to-first-independent--ions-20250430monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-and-ono-announce-global-license-agreement-for-sapablursen-in-polycythemia-vera-carls-ions-20250311monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-fourth-quarter-and-full-year-2024-financial-results-first-independent-launch-ions-20250219monthly0.5https://www.biopharmawatch.com/news/IONS/tryngolza-olezarsen-approved-in-u-s-as-first-ever-treatment-for-adults-living-with-familia-ions-20241219monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-third-quarter-2024-financial-results-wainua-tm-u-s-launch-progressing-well-a-ions-20241106monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-second-quarter-2024-financial-results-wainua-tm-u-s-launch-progressing-well--ions-20240801monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-expanded-licensing-agreement-with-otsuka-in-asia-pacific-for-investigation-ions-20240618monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-presents-positive-results-from-oasis-hae-and-oasisplus-studies-of-investigational-me-ions-20240531monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-first-quarter-2024-financial-results-wainua-tm-launch-on-track-eu-and-canada-ions-20240507monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-presents-positive-results-from-phase-3-balance-study-of-olezarsen-for-familial-chylo-ions-20240407monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-fourth-quarter-and-full-year-2023-financial-results-wainua-tm-approved-with--ions-20240221monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-topline-results-from-phase-3-oasis-hae-study-of-investigational-d-ions-20240122monthly0.5https://www.biopharmawatch.com/news/IONS/wainua-eplontersen-granted-regulatory-approval-in-the-u-s-for-the-treatment-of-adults-with-ions-20231221monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-european-licensing-agreement-with-otsuka-for-donidalorsen-in-hereditary-an-ions-20231218monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-the-appointment-of-michael-yang-to-board-of-directors-ions-20231214monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-third-quarter-2023-financial-results-olezarsen-phase-3-data-showed-significa-ions-20231102monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-enters-agreement-with-roche-for-two-novel-rna-targeted-programs-for-alzheimer-s-dise-ions-20230927monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-olezarsen-topline-results-from-phase-3-study-in-people-with-famil-ions-20230926monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-second-quarter-2023-financial-results-reported-phase-3-data-showing-eplonter-ions-20230809monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-enters-collaboration-to-advance-next-generation-program-targeting-lp-a-for-cardiovas-ions-20230803monthly0.5https://www.biopharmawatch.com/news/IONS/eplontersen-continued-to-show-improvement-in-attrv-pn-through-85-weeks-topline-phase-3-neu-ions-20230710monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-prices-private-placement-of-convertible-senior-notes-ions-20230608monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-proposed-private-placement-of-convertible-notes-ions-20230606monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-first-quarter-2023-financial-results-qalsody-approved-for-sod1-als-maa-under-ions-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/fda-approves-qalsody-tofersen-as-the-first-treatment-targeting-a-genetic-cause-of-als-acce-ions-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/eplontersen-halted-attrv-pn-disease-progression-and-improved-neuropathy-impairment-and-qua-ions-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-positive-topline-66-week-results-of-eplontersen-phase-3-study-for-patients-w-ions-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-fourth-quarter-and-full-year-2022-financial-results-eplontersen-nda-submitte-ions-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-third-quarter-financial-results-advanced-key-priorities-initiated-manufactur-ions-20221109monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-second-quarter-financial-results-and-recent-business-achievements-reported-p-ions-20220809monthly0.5https://www.biopharmawatch.com/news/IONS/in-the-court-of-chancery-of-the-state-of-delaware-leo-shumacher-derivatively-on-behalf-of--ions-20220719monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-partner-licenses-rare-kidney-disease-treatment-and-will-advance-into-phase-3-clinica-ions-20220711monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-eplontersen-met-co-primary-and-secondary-endpoints-in-interim-analysis-of--ions-20220621monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-first-quarter-financial-results-and-recent-business-achievements-on-track-to-ions-20220504monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-business-achi-ions-20220224monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-and-astrazeneca-to-develop-and-commercialize-eplontersen-collaboration-expected-to-e-ions-20211207monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-that-pfizer-reports-topline-results-from-phase-2b-clinical-study-of-vupano-ions-20211124monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-third-quarter-2021-financial-results-and-recent-business-achievements-olezar-ions-20211103monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-partner-biogen-provides-update-on-tofersen-phase-3-valor-study-in-sod1-als-in-the-ph-ions-20211017monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-second-quarter-2021-financial-results-and-recent-business-achievements-key-p-ions-20210804monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-changes-to-its-board-of-directors-at-annual-meeting-of-stockholders-joseph-ions-20210602monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-first-quarter-2021-financial-results-and-recent-business-achievements-on-tra-ions-20210505monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-proposed-private-placement-of-convertible-notes-ions-20210406monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-partner-provides-update-on-clinical-studies-evaluating-tominersen-ionis-htt-rx-dosin-ions-20210322monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-business-achi-ions-20210224monthly0.5https://www.biopharmawatch.com/news/IONS/stanley-t-crooke-ph-d-m-d-to-retire-from-ionis-to-focus-on-his-scientific-interests-and-n--ions-20201217monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-highlights-achievements-commercial-strategy-and-technology-advancements-at-investor--ions-20201208monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-completes-acquisition-of-akcea-therapeutics-ions-20201012monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-to-acquire-remaining-stake-in-akcea-therapeutics-ionis-to-acquire-re-ions-20200831monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-second-quarter-2020-financial-results-and-recent-business-achievements-on-tr-ions-20200805monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-first-quarter-2020-financial-results-and-recent-business-achievements-on-tra-ions-20200506monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-provides-fourth-quarter-and-full-year-2019-financial-results-2019-revenues-nearly-do-ions-20200226monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-appoints-walter-m-rosebrough-jr-to-its-board-of-directors-enters-into-coop-coo-20251223monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-appoints-cynthia-lucchese-to-board-of-directors-coo-20221003monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-to-acquire-cook-medical-s-reproductive-health-business-acquisition-will-en-coo-20220207monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-completes-acquisition-of-generate-life-sciences-coo-20211217monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-to-acquire-generate-life-sciences-for-1-6-billion-acquisition-will-expand--coo-20211110monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-elects-maria-rivas-md-to-board-of-directors-coo-20210512monthly0.5https://www.biopharmawatch.com/news/COO/a-thomas-bender-and-allan-e-rubenstein-m-d-to-retire-from-coopercompanies-board-coo-20201210monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-elects-teresa-s-madden-to-board-of-directors-coo-20201112monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-appoints-holly-sheffield-as-president-coopersurgical-and-announces-robert--coo-20200706monthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-announces-2-14-billion-senior-credit-facility-and-amendment-of-500-million-coo-20200401monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-the-cooper-companies-inc-ir-cooperco-com-6140-coo-20180423monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-the-cooper-companies-inc-ir-cooperco-com-6140-coo-20171101monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-the-cooper-companies-inc-ir-cooperco-com-6140-coo-20171010monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-the-cooper-companies-inc-ir-cooperco-com-6140-coo-20170911monthly0.5https://www.biopharmawatch.com/news/COO/obligations-increased-leverage-and-lack-of-access-to-available-financing-including-financi-coo-20170302monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-sui-coo-20161208monthly0.5https://www.biopharmawatch.com/news/COO/stoneridge-mall-road-suite-590-pleasanton-ca-94588-925-460-3663-www-coopercos-com-news-rel-coo-20161106monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-sui-coo-20160901monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-sui-coo-20160602monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-suite-590-pleasanton-ca-94588-925-460-3663-www-coopercos-com-con-coo-20160404monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-contact-suite-590-kim-duncan-pleasanton-ca-94588-vice-president--coo-20160303monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-sui-coo-20151203monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-suite-590-pleasanton-ca-94588-925-460-3663-www-coopercos-com-con-coo-20150903monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-contact-kim-duncan-vice-president-investor-relations-ir-cooperco-coo-20150604monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-sui-coo-20150305monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-vice-president-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-sui-coo-20141204monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20140904monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-suite-590-pleasanton-ca-94588-925-460-3663-www-coopercos-com-con-coo-20140806monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-suite-590-pleasanton-ca-94588-925-460-3663-www-coopercos-com-con-coo-20140630monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20140605monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20140306monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-suite-590-pleasanton-ca-94588-925-460-3663-www-coopercos-com-con-coo-20140123monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20131212monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20131205monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20131107monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20131030monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-contact-suite-590-pleasanton-ca-94588-kim-duncan-925-460-3663-se-coo-20130916monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20130905monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20130606monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20130531monthly0.5https://www.biopharmawatch.com/news/COO/6140-stoneridge-mall-road-contact-suite-590-kim-duncan-pleasanton-ca-94588-senior-director-coo-20130307monthly0.5https://www.biopharmawatch.com/news/COO/kim-duncan-senior-director-investor-relations-ir-cooperco-com-6140-stoneridge-mall-road-su-coo-20130125monthly0.5https://www.biopharmawatch.com/news/ALGN/about-non-gaap-gross-margin-and-non-gaap-operating-margin-as-part-of-our-investor-day-on-t-algn-20250506monthly0.5https://www.biopharmawatch.com/news/ALGN/document-investor-relations-contact-press-contact-madelyn-homick-shannon-mangum-henderson--algn-20210503monthly0.5https://www.biopharmawatch.com/news/ALGN/press-contact-yin-cantor-shannon-mangum-henderson-408-470-1044-678-261-7803-ycantor-alignt-algn-20180305monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-record-third-quarter-2017-results-san-jose-ca-marketwired-algn-20171026monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-record-second-quarter-2017-results-san-jose-ca-marketwired-algn-20170727monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-50-algn-20170503monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-record-first-quarter-2017-results-san-jose-ca-marketwired-algn-20170427monthly0.5https://www.biopharmawatch.com/news/ALGN/press-contact-shirley-stacy-shannon-mangum-henderson-align-technology-inc-ethos-communicat-algn-20170314monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-fourth-quarter-and-year-ended-2016-results-san-jose-ca-marketwi-algn-20170131monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-third-quarter-2016-results-san-jose-ca-marketwired-algn-20161107monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-retirement-of-cfo-david-l-white-and-names-john-f-morici-as-new--algn-20161107monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-second-quarter-2016-results-san-jose-ca-marketwired-algn-20160728monthly0.5https://www.biopharmawatch.com/news/ALGN/shirley-stacy-align-technology-inc-408-470-1150-sstacy-aligntech-com-press-contact-ethos-c-algn-20160725monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-50-million-accelerated-stock-repurchase-program-and-a-10b5-1-algn-20160504monthly0.5https://www.biopharmawatch.com/news/ALGN/press-contact-shirley-stacy-shannon-mangum-henderson-align-technology-inc-ethos-communicat-algn-20151022monthly0.5https://www.biopharmawatch.com/news/ALGN/corporate-participants-shirley-stacy-align-technology-inc-vp-corporate-communications-and--algn-20150724monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-second-quarter-2015-results-san-jose-ca-marketwired-algn-20150723monthly0.5https://www.biopharmawatch.com/news/ALGN/2015-align-technology-announces-10b5-1-stock-repurchase-plan-algn-20150504monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-second-quarter-2014-results-record-revenues-of-192-5-million-up-algn-20140724monthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-announces-first-quarter-fiscal-2014-results-san-jose-ca-marketwired-algn-20140423monthly0.5https://www.biopharmawatch.com/news/ALGN/of-align-technology-issued-october-28-2013-ex-99-1-press-release-10-28-13-investor-relatio-algn-20131028monthly0.5https://www.biopharmawatch.com/news/ALGN/announcing-the-appointment-of-andrea-l-saia-ex-99-1-bod-investor-relations-contact-press-c-algn-20130730monthly0.5https://www.biopharmawatch.com/news/ALGN/announcing-the-appointment-of-mr-white-and-mr-graham-ex-99-1-align-technology-inc-2560-orc-algn-20130718monthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-completes-spin-off-of-pennant-group-ensg-20191001monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-reports-fourth-quarter-2025-financial-results-and-introduces-2026-full-year-guid-solv-20260226monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-reports-third-quarter-2025-financial-results-r-eported-sales-increased-0-7-organ-solv-20251106monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-pricing-of-its-upsized-2-billion-note-tender-offers-solv-20250908monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-completes-sale-of-its-purification-filtration-business-to-thermo-fisher-scientif-solv-20250902monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-1-75-billion-note-tender-offers-solv-20250822monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-pricing-of-secondary-offering-of-common-stock-solv-20250813monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-corporation-unaudited-pro-forma-condensed-consolidated-financial-statements-on-solv-20250813monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-reports-second-quarter-2025-financial-results-reported-sales-increased-3-9-organ-solv-20250807monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-reports-first-quarter-2025-financial-results-reported-sales-increased-2-6-organi-solv-20250508monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-reports-fourth-quarter-2024-financial-results-and-introduces-2025-full-year-guid-solv-20250227monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-reports-third-quarter-2024-financial-results-and-raises-full-year-guidance-repor-solv-20241107monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-reports-second-quarter-2024-financial-results-and-raises-full-year-guidance-sepa-solv-20240808monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-reports-first-quarter-2024-financial-results-and-capital-allocation-update-compl-solv-20240509monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-begins-trading-on-the-new-york-stock-exchange-formerly-3m-health-care-business-s-solv-20240401monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-raises-500-million-in-private-placement-fundraise-led-by-leading-bioph-smmt-20251022monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-raises-235-million-fundraise-led-by-insiders-leading-biopharma-institu-smmt-20240912monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-raises-200-million-also-expands-license-territories-for-ivonescimab-200-million-in--smmt-20240603monthly0.5https://www.biopharmawatch.com/news/SMMT/presented-by-dr-li-zhang-asco-2024-presented-by-dr-li-zhang-asco-2024-presented-by-dr-li-z-smmt-20240603monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-bolsters-its-board-of-directors-with-seasoned-regulatory-clinical-rese-smmt-20211103monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-prominent-biotech-attorney-and-advisor-kenneth-a-clark-to-its-smmt-20211008monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-second-quar-smmt-20210811monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-provides-update-on-ri-codify-trials-cambridge-massachusetts-based-on-a-smmt-20210811monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-we-summit-or-the-company-summit-therapeutics-announces-closing-of--smmt-20210512monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-we-summit-or-the-company-summit-therapeutics-rights-offering-neari-smmt-20210505monthly0.5https://www.biopharmawatch.com/news/SMMT/the-terms-and-conditions-of-the-rights-offering-are-set-forth-in-the-company-s-prospectus--smmt-20210421monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-summit-or-the-company-summit-therapeutics-announces-rights-offerin-smmt-20210326monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-summit-the-company-or-the-group-summit-therapeutics-appoints-dr-ma-smmt-20201123monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20201116monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-summit-or-the-company-summit-announces-closing-of-private-placemen-smmt-20201106monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-summit-or-the-company-summit-announces-agreement-for-a-fundraising-smmt-20201002monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20200929monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-announces-u-k-court-appr-smmt-20200918monthly0.5https://www.biopharmawatch.com/news/SMMT/this-document-is-important-and-requires-your-immediate-attention-this-document-includes-a--smmt-20200727monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20200430monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-appoints-robert-w-duggan-as-chief-exe-smmt-20200414monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-appoints-robert-w-duggan-as-executive-smmt-20200226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-to-receive-1-0-million-m-smmt-20200206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-announces-management-update-oxford-uk-smmt-20200127monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-announces-barda-expands-ridinilazole--smmt-20200123monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-therapeutics-or-the-company-completion-of-50-million-subscr-smmt-20191226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-therapeutics-or-the-company-result-of-general-meeting-admis-smmt-20191223monthly0.5https://www.biopharmawatch.com/news/SMMT/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-smmt-20191206monthly0.5https://www.biopharmawatch.com/news/SMMT/this-announcement-including-the-appendix-and-the-information-contained-herein-is-restricte-smmt-20191206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-result-of-annual-general-meeting-oxford-uk-a-smmt-20190619monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-announces-barda-increases-award-for-r-smmt-20190618monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-publication-of-uk-annual-report-and-notice-o-smmt-20190514monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-award-of-share-options-oxford-uk-and-cambrid-smmt-20190401monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-doses-first-patient-in-phase-3-clinic-smmt-20190213monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-therapeutics-or-the-company-award-of-restricted-stock-units-smmt-20190114monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-therapeutics-or-the-company-completion-of-25-million-subscr-smmt-20190110monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-therapeutics-or-the-company-result-of-general-meeting-oxfor-smmt-20190104monthly0.5https://www.biopharmawatch.com/news/SMMT/this-announcement-including-the-appendices-and-the-information-contained-herein-is-restric-smmt-20181217monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-announces-departure-of-c-smmt-20181217monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-award-of-share-options-oxford-uk-and-cambrid-smmt-20181022monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-surrender-of-share-options-oxford-uk-and-cam-smmt-20181009monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-nominates-new-mechanism-antibiotic-sm-smmt-20180905monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-awarded-additional-12-million-by-bard-smmt-20180816monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-director-pdmr-share-dealing-oxford-uk-cambri-smmt-20180717monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-director-pdmr-share-dealing-oxford-smmt-20180716monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-awarded-up-to-4-5-million-grant-from--smmt-20180710monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-announces-phaseout-dmd-did-not-meet-p-smmt-20180627monthly0.5https://www.biopharmawatch.com/news/SMMT/discuva-limited-index-to-financial-statements-statement-of-financial-position-as-at-smmt-20180515monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-publication-of-uk-annual-report-and-notice-o-smmt-20180503monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-award-of-share-options-and-restricted-stock--smmt-20180424monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20180411monthly0.5https://www.biopharmawatch.com/news/SMMT/this-announcement-is-not-for-release-publication-or-distribution-directly-or-indirectly-in-smmt-20180327monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-announces-new-analysis-showing-ezutro-smmt-20180226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-ezutromid-significantly-reduced-muscle-damag-smmt-20180125monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-obtains-innovative-antibiotic-discove-smmt-20171226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-enters-into-licence-and-commercialisa-smmt-20171221monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20171206monthly0.5https://www.biopharmawatch.com/news/SMMT/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-smmt-20170918monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-announces-proposed-publi-smmt-20170914monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-therapeutics-summit-or-the-company-summit-awarded-barda-con-smmt-20170911monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-announces-positive-top-line-data-from-smmt-20170905monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20170831monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-grant-of-share-options-to-directors-pdmrs-an-smmt-20170720monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-result-of-annual-general-meeting-oxford-uk-1-smmt-20170718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20170614monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-completes-enrolment-of-phaseout-dmd-a-smmt-20170515monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-publication-of-uk-annual-report-2016-17-and--smmt-20170425monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-grant-of-share-options-to-director-smmt-20170413monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20170329monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-summit-outlines-phase-3-programme--smmt-20170201monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-company-or-the-group-summit-appoints-dr-david-roblin-as-chi-smmt-20170118monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-the-company-or-the-group-summit-therapeutics-reports-financ-smmt-20161215monthly0.5https://www.biopharmawatch.com/news/SMMT/sarepta-therapeutics-and-summit-enter-into-exclusive-license-and-collaboration-agreement-f-smmt-20161004monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-receives-rare-pediatric-disease-desig-smmt-20160928monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-receives-fast-track-designation-from--smmt-20160926monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-reports-financial-result-smmt-20160908monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-reports-positive-phase-1-new-formulat-smmt-20160809monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-result-of-annual-general-meeting-oxford-uk-1-smmt-20160718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-award-of-share-options-oxford-uk-24-june-201-smmt-20160624monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-publication-of-uk-annual-report-and-notice-o-smmt-20160617monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-reports-financial-result-smmt-20160602monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-reports-financial-result-smmt-20160510monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-announces-further-us-patent-granted-f-smmt-20160429monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-s-ind-cleared-by-fda-allowing-expansi-smmt-20160426monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-positive-results-from-summit-s-phase-2-codif-smmt-20160412monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-to-present-additional-data-from-phase-smmt-20160330monthly0.5https://www.biopharmawatch.com/news/SMMT/march-2016-dear-shareholder-notification-to-shareholders-regarding-parent-company-financia-smmt-20160323monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-announces-ridinilazole-preserves-the--smmt-20160307monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-granted-key-european-pat-smmt-20160122monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-reports-financial-result-smmt-20151217monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-announces-first-mileston-smmt-20151202monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-announces-novel-antibiot-smmt-20151123monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-and-the-university-of-ox-smmt-20151120monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-presents-additional-data-smmt-20151001monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-completes-targeted-enrol-smmt-20150914monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-appoints-ralf-rosskamp-m-smmt-20150903monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-reports-financial-result-smmt-20150827monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-to-report-second-quarter-smmt-20150825monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-announces-phase-1b-modif-smmt-20150817monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-result-of-annual-general-meeting-oxford-uk-2-smmt-20150730monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-annual-general-meeting-statement-oxford-uk-1-smmt-20150716monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-granted-key-patent-by-eu-smmt-20150708monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-director-share-dealing-oxford-uk-22-june-201-smmt-20150623monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-award-of-share-options-oxford-uk-17-june-201-smmt-20150617monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-reports-first-quarter-re-smmt-20150611monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-to-report-first-quarter--smmt-20150605monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-publication-of-uk-annual-report-and-notice-o-smmt-20150601monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-reports-financial-result-smmt-20150507monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-granted-key-patent-for-n-smmt-20150504monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-summit-or-the-company-summit-therapeutics-announces-exercise-of-ov-smmt-20150318monthly0.5https://www.biopharmawatch.com/news/MDGL/document-madrigal-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provide-mdgl-20260506monthly0.5https://www.biopharmawatch.com/news/MDGL/document-madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-resu-mdgl-20260219monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-enters-into-exclusive-global-license-agreement-for-oral-glp-1-rec-mdgl-20250730monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-secures-500-million-in-senior-secured-credit-from-blue-owl-manage-mdgl-20250722monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-corpora-mdgl-20250501monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-appoints-jacqualyn-a-fouse-ph-d-to-its-board-of-directors-fred-craves-ph-d-to-ret-mdgl-20250311monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-a-mdgl-20250226monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2024-net-sales-mdgl-20250115monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-corpora-mdgl-20241031monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-corpor-mdgl-20240807monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corpora-mdgl-20240507monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-fda-approval-of-rezdiffra-resmetirom-for-the-treatment--mdgl-20240314monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-corporate-updates-and-reports-fourth-quarter-and-full-ye-mdgl-20240228monthly0.5https://www.biopharmawatch.com/news/MDGL/forward-looking-statements-madrigal-pharmaceuticals-this-presentation-includes-forward-loo-mdgl-20240108monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-corporate-updates-and-reports-third-quarter-2023-financi-mdgl-20231106monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-nda-acceptance-and-priority-review-of-the-new-drug-appl-mdgl-20230913monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-corporate-updates-and-reports-second-quarter-2023-financ-mdgl-20230808monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-completes-submission-of-new-drug-application-seeking-accelerated--mdgl-20230717monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-rolling-submission-of-new-drug-application-to-u-s-fda-s-mdgl-20230630monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-corporate-updates-and-reports-first-quarter-2023-financi-mdgl-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-corporate-updates-and-reports-2022-fourth-quarter-and-fu-mdgl-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-300-million-in-financing-events-to-advance-resmetirom-p-mdgl-20221221monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-an-overview-of-upcoming-resmetirom-data-presentations-an-mdgl-20221103monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-clinical-and-business-updates-and-reports-2022-second-qu-mdgl-20220804monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-clinical-and-business-updates-and-reports-2022-first-qua-mdgl-20220509monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-business-and-clinical-updates-and-reports-2021-fourth-qu-mdgl-20220224monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-provides-corporate-update-and-reports-2021-third-quarter-financia-mdgl-20211104monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2021-second-quarter-financial-results-and-provides-corpor-mdgl-20210805monthly0.5https://www.biopharmawatch.com/news/MDGL/alex-howarth-joins-madrigal-pharmaceuticals-as-chief-financial-officer-mdgl-20210518monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2021-first-quarter-financial-results-and-highlights-mdgl-20210506monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2020-fourth-quarter-and-full-year-financial-results-and-h-mdgl-20210225monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-completion-of-enrollment-in-phase-3-maestro-nafld-1-tri-mdgl-20201105monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2020-second-quarter-financial-results-and-highlights-cons-mdgl-20200806monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2020-first-quarter-financial-results-and-highlights-consh-mdgl-20200507monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2019-fourth-quarter-and-full-year-financial-results-and-h-mdgl-20200226monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2019-third-quarter-financial-results-and-highlights-consh-mdgl-20191106monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2019-second-quarter-financial-results-and-highlights-phas-mdgl-20190807monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2019-first-quarter-financial-results-and-highlights-consh-mdgl-20190508monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2018-fourth-quarter-and-full-year-financial-results-and-h-mdgl-20190227monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2018-third-quarter-financial-results-and-highlights-upcom-mdgl-20181106monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2018-second-quarter-financial-results-and-reviews-key-cli-mdgl-20180807monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-s-mgl-3196-achieves-liver-biopsy-endpoints-in-patients-with-non-alcoholic-steatoh-mdgl-20180531monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2018-first-quarter-financial-results-and-reviews-key-clin-mdgl-20180508monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2017-fourth-quarter-and-year-end-financial-results-review-mdgl-20180313monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2017-third-quarter-financial-results-top-line-results-fro-mdgl-20171109monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2017-second-quarter-financial-results-completed-patient-e-mdgl-20170810monthly0.5https://www.biopharmawatch.com/news/MDGL/not-for-immediate-release-madrigal-pharmaceuticals-announces-35-million-private-placement--mdgl-20170621monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2017-first-quarter-financial-results-phase-2-clinical-stu-mdgl-20170511monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-2016-fourth-quarter-and-year-end-financial-results-review-mdgl-20170403monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-reports-third-quarter-2016-financial-results-successfully-completed-merger-and-tr-mdgl-20161114monthly0.5https://www.biopharmawatch.com/news/MDGL/richard-s-levy-m-d-appointed-to-madrigal-board-of-directors-mdgl-20160811monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-completes-merger-with-synta-to-create-leading-cardiovascular-meta-mdgl-20160722monthly0.5https://www.biopharmawatch.com/news/MDGL/the-new-madrigal-pharmaceuticals-nasdaq-snta-corporate-presentation-june-2016-forward-look-mdgl-20160608monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-to-present-at-upcoming-investor-conferences-in-june-mdgl-20160602monthly0.5https://www.biopharmawatch.com/news/MDGL/the-new-madrigal-pharmaceuticals-nasdaq-snta-may-2016-1-forward-looking-statements-any-sta-mdgl-20160503monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-madrigal-pharmaceuticals-merger-announcement-date-mdgl-20160414monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-and-madrigal-announce-merger-agreement-to-create-leading-cardiovascular-metabolic-di-mdgl-20160414monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20151105monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20151020monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20150427monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-closes-public-offering-of-common-stock-lexington-mass-business-wire-mdgl-20150406monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-prices-public-offering-of-common-stock-lexington-mass-business-wire-mdgl-20150331monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20150205monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20141204monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20140806monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20140721monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-nasdaq-snta-galaxy-1-final-results-mdgl-20140508monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20140414monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20140320monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20140303monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20131220monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20131212monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20131118monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20131113monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20131026monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20130912monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20130910monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20130729monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20130603monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7213-fax-781--mdgl-20130313monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20121213monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20120929monthly0.5https://www.biopharmawatch.com/news/MDGL/overview-we-are-a-biopharmaceutical-company-focused-on-discovering-developing-and-commerci-mdgl-20120726monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-nasdaq-snta-galaxy-trial-interim-results-june-27-2012-conference-cal-mdgl-20120628monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20120111monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20120106monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20110604monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20110415monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20110404monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20110226monthly0.5https://www.biopharmawatch.com/news/MDGL/multiple-myeloma-research-foundation-mmrf-and-synta-pharmaceuticals-enter-into-joint-colla-mdgl-20110112monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20101111monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-pharmaceuticals-corp-45-hartwell-avenue-lexington-ma-02421-tel-781-541-7125-fax-781--mdgl-20100930monthly0.5https://www.biopharmawatch.com/news/MDGL/synta-announces-expansion-of-phase-2-trial-for-sta-9090-in-non-small-cell-lung-cancer-base-mdgl-20100913monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2026-results-audubon-pa-gmed-20260507monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-board-departure-audubon-pa-gmed-20260323monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-record-fourth-quarter-and-full-year-sales-results-audub-gmed-20260107monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-third-quarter-2025-results-xfeff-audubon-pa-november-6--gmed-20251106monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-second-quarter-2025-results-xfeff-audubon-pa-august-7-2-gmed-20250807monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-announces-leadership-transitions-and-preliminary-second-quarter-gmed-20250721monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-announce-s-500-m-illion-share-repurchase-program-xfeff-audubon--gmed-20250515monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-first-quarter-2025-results-xfeff-audubon-pa-may-8-202-5-gmed-20250508monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-completes-acquisition-of-nevro-corp-audubon-pa-gmed-20250403monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-fourth-quarter-and-full-year-2024-results-xfeff-audubon-gmed-20250220monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-acquire-nevro-corp-to-expand-treatment-options-for-patients-audubon-pa-a-gmed-20250206monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-preliminary-record-fourth-quarter-and-full-year-sales-r-gmed-20250108monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-third-quarter-202-4-results-xfeff-audubon-pa-november-5-gmed-20241105monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-second-quarter-202-4-results-xfeff-audubon-pa-gmed-20240806monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-first-quarter-202-4-results-xfeff-audubon-pa-may-7-202--gmed-20240507monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-fourth-quarter-and-full-year-20-2-3-results-xfeff-audub-gmed-20240220monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-promotes-keith-pfeil-to-chief-operating-officer-and-chief-finan-gmed-20240205monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-preliminary-record-fourth-quarter-and-full-year-sales-r-gmed-20240110monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-third-quarter-2023-results-xfeff-audubon-pa-november-7--gmed-20231107monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-completes-merger-with-nuvasive-creates-leading-global-musculoskeletal-compa-gmed-20230901monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-second-quarter-2023-results-xfeff-audubon-pa-gmed-20230803monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-first-quarter-2023-results-xfeff-audubon-pa-gmed-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-shareholders-approve-share-issuance-for-merger-with-nuvasive-audubon-pa-gmed-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-fourth-quarter-and-full-year-20-2-2-results-xfeff-audub-gmed-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/legal-disclaimers-no-offer-or-solicitation-this-communication-is-for-informational-purpose-gmed-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-third-quarter-20-2-2-results-xfeff-audubon-pa-gmed-20221108monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-second-quarter-20-2-2-results-xfeff-audubon-pa-august-4-gmed-20220804monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-first-quarter-20-2-2-results-xfeff-audubon-pa-may-1-0-2-gmed-20220510monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-ceo-transition-and-preliminary-first-quarter-2022-sales-gmed-20220421monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-announces-the-expansion-of-its-share-repurchase-program-xfeff-a-gmed-20220304monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-fourth-quarter-and-full-year-20-2-1-results-xfeff-audub-gmed-20220217monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-third-quarter-2021-results-xfeff-audubon-pa-gmed-20211104monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-second-quarter-2021-results-xfeff-audubon-pa-gmed-20210804monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-first-quarter-2021-results-xfeff-audubon-pa-may-4-2021--gmed-20210504monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-fourth-quarter-and-full-year-20-20-results-xfeff-audubo-gmed-20210217monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-third-quarter-2020-results-xfeff-audubon-pa-gmed-20201028monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-second-quarter-2020-results-xfeff-audubon-pa-gmed-20200805monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-first-quarter-2020-results-xfeff-audubon-pa-gmed-20200507monthly0.5https://www.biopharmawatch.com/news/GMED/stock-repurchase-globus-medical-announces-200-million-share-repurchase-program-xfeff-audub-gmed-20200312monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-fourth-quarter-and-full-year-2019-results-xfeff-audubon-gmed-20200220monthly0.5https://www.biopharmawatch.com/news/GMED/sales-release-xfeff-xfeff-globus-medical-reports-preliminary-record-fourth-quarter-and-ful-gmed-20200108monthly0.5https://www.biopharmawatch.com/news/GMED/director-change-globus-medical-announces-board-of-director-addition-and-departure-xfeff-au-gmed-20191213monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-third-quarter-2019-results-xfeff-audubon-pa-november-6--gmed-20191106monthly0.5https://www.biopharmawatch.com/news/GMED/xfeff-xfeff-globus-medical-reports-second-quarter-2019-results-xfeff-audubon-pa-august-1-2-gmed-20190801monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-appoints-keith-pfeil-as-senior-vice-president-and-cfo-gmed-20190627monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2019-results-audubon-pa-gmed-20190502monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-full-year-and-fourth-quarter-2018-results-audubon-pa-gmed-20190221monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-record-fourth-quarter-and-full-year-sales-results-audub-gmed-20190108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2018-results-audubon-pa-gmed-20181108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2018-results-audubon-pa-gmed-20180801monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-full-year-and-fourth-quarter-2017-results-audubon-pa-gmed-20180221monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-fourth-quarter-and-full-year-sales-results-audubon-pa-gmed-20180109monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2017-results-audubon-pa-gmed-20171108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-appoints-david-m-demski-as-ceo-david-c-paul-to-continue-as-executive-chairm-gmed-20170829monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-fda-510-k-clearance-for-excelsius-gps-excelsius-gps-robotic-traje-gmed-20170817monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2017-results-audubon-pa-gmed-20170802monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2017-results-audubon-pa-gmed-20170503monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-full-year-and-fourth-quarter-2016-results-audubon-pa-gmed-20170227monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-fourth-quarter-and-full-year-sales-results-audubon-pa-gmed-20170110monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2016-results-audubon-pa-gmed-20161108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-completes-acquisition-of-alphatec-s-international-business-audubon-pa-gmed-20160901monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-the-acquisition-of-alphatec-s-international-business-audubon-pa-gmed-20160726monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2016-results-audubon-pa-gmed-20160726monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2016-results-audubon-pa-gmed-20160503monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-full-year-and-fourth-quarter-2015-results-record-sales-and-profits--gmed-20160224monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-litigation-settlement-agreement-audubon-pa-gmed-20160119monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-fourth-quarter-and-full-year-record-sales-results-audub-gmed-20160106monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2015-results-reports-record-quarterly-sales-and-incre-gmed-20151103monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-key-executive-changes-dave-demski-named-group-president-emerging--gmed-20150908monthly0.5https://www.biopharmawatch.com/news/GMED/james-r-tobin-former-ceo-of-boston-scientific-joins-globus-medical-board-of-directors-audu-gmed-20150831monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2015-results-reports-record-quarterly-sales-and-incr-gmed-20150730monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2015-results-audubon-pa-gmed-20150505monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-appoints-daniel-scavilla-as-senior-vice-president-and-cfo-audubon-pa-gmed-20150423monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-full-year-and-fourth-quarter-2014-results-record-sales-and-profits--gmed-20150225monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-fourth-quarter-and-full-year-sales-results-audubon-pa-gmed-20150106monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2014-third-quarter-results-record-sales-and-profits-audubon-pa-gmed-20141030monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-acquisition-of-transplant-technologies-of-texas-audubon-pa-gmed-20141023monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2014-second-quarter-results-audubon-pa-gmed-20140805monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2014-first-quarter-results-audubon-pa-gmed-20140429monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-full-year-and-fourth-quarter-2013-results-audubon-pa-gmed-20140226monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-fourth-quarter-and-full-year-sales-results-audubon-pa-gmed-20140114monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-acquisition-of-robotics-developer-excelsius-surgical-audubon-pa-gmed-20140108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2013-third-quarter-results-record-quarterly-sales-audubon-pa-gmed-20131030monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2013-second-quarter-results-record-quarterly-sales-audubon-pa-gmed-20130801monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-jury-verdict-in-patent-infringement-lawsuit-audubon-pa-gmed-20130617monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2013-first-quarter-results-audubon-pa-gmed-20130502monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-full-year-and-fourth-quarter-2012-results-record-revenue-and-earnin-gmed-20130227monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-year-end-sales-results-audubon-pa-gmed-20130115monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2012-third-quarter-results-audubon-pa-gmed-20121101monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-its-first-pma-approval-for-the-secure-c-cervical-artificial-disc--gmed-20120928monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2012-second-quarter-results-audubon-pa-gmed-20120821monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-first-quarter-2026-financial-results-q1-2026-revenue-of-197-millio-asnd-20260507monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2026-notice-is-hereby-given-that-the-annual-gener-asnd-20260223monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-fourth-quarter-and-full-year-2025-financial-results-q4-2025-produc-asnd-20260211monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-third-quarter-2025-financial-results-q3-2025-revenue-of-143-1-mill-asnd-20251112monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-second-quarter-2025-financial-results-q2-2025-revenue-of-103-0-mil-asnd-20250807monthly0.5https://www.biopharmawatch.com/news/ASND/coach-trial-interim-topline-week-26-data-asnd-20250609monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-first-quarter-2025-financial-results-q1-2025-revenue-of-44-7-milli-asnd-20250501monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2025-notice-is-hereby-given-that-the-annual-gener-asnd-20250429monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-fourth-quarter-and-full-year-2024-financial-results-strong-early-u-asnd-20250207monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-j-p-morgan-healthcare-conference-san-francisco-january-2025-for-invest-asnd-20250113monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-third-quarter-2024-financial-results-yorvipath-launching-in-u-s-wi-asnd-20241114monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20240916monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-second-quarter-2024-financial-results-yorvipath-approved-by-u-s-fo-asnd-20240903monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-first-quarter-2024-financial-results-rollout-of-yorvipath-initiate-asnd-20240502monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2024-notice-is-hereby-given-that-the-annual-gener-asnd-20240502monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-fourth-quarter-and-full-year-2023-results-launch-of-transcon-tm-pt-asnd-20240207monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20240108monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-third-quarter-2023-financial-results-european-commission-decision--asnd-20231107monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-second-quarter-2023-financial-results-expect-to-resubmit-nda-to-fd-asnd-20230905monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20230620monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20230531monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2023-notice-is-hereby-given-that-the-annual-gener-asnd-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-first-quarter-2023-financial-results-focused-on-bringing-transcon--asnd-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-full-year-2022-results-transcon-pth-pdufa-date-of-asnd-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-41st-annual-j-p-morgan-healthcare-conference-asnd-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/transcon-cnp-accomplish-trial-topline-results-asnd-20221114monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-reports-third-quarter-2022-financial-results-skytrofa-u-s-revenue-more-tha-asnd-20221102monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-extraordinary-general-meeting-notice-is-hereby-given-that-an-extraordina-asnd-20220812monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-second-quarter-2022-financial-results-u-s-regulatory-submissio-asnd-20220810monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20220511monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-first-quarter-2022-financial-results-phase-3-pathway-trial-top-asnd-20220429monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2022-notice-is-hereby-given-that-the-annual-gener-asnd-20220502monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-announces-proposed-convertible-senior-notes-offering-asnd-20220323monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20220302monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-full-year-2021-financial-results-and-provides-a-business-updat-asnd-20220302monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20220110monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-virtual-r-d-program-update-asnd-20211214monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20211110monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-third-quarter-2021-financial-results-skytrofa-lonapegsomatropi-asnd-20211110monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-extraordinary-general-meeting-notice-is-hereby-given-that-an-extraordina-asnd-20211021monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20210827monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-second-quarter-2021-financial-results-announced-u-s-food-and-d-asnd-20210825monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20210527monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20210511monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2021-notice-is-hereby-given-that-the-annual-gener-asnd-20210430monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-full-year-2020-financial-results-preparations-for-potential-la-asnd-20210310monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20210111monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20201120monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20201112monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20200929monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20200827monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20200519monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2020-notice-is-hereby-given-that-the-annual-gener-asnd-20200505monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20200403monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-full-year-2019-financial-results-on-track-with-2020-corporate--asnd-20200401monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20200113monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20191118monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20190828monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20190626monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20190530monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2019-notice-is-hereby-given-that-the-annual-gener-asnd-20190501monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-full-year-2018-financial-results-rare-disease-endocrinology-pi-asnd-20190403monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20190107monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20181128monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-extraordinary-general-meeting-notice-is-hereby-given-that-an-extraordina-asnd-20181005monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20180829monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20180530monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2018-notice-is-hereby-given-that-the-annual-gener-asnd-20180501monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-full-year-2017-financial-results-rare-disease-endocrinology-pi-asnd-20180328monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20180108monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20171116monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20170818monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20170523monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2017-notice-is-hereby-given-that-the-annual-gener-asnd-20170426monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20170322monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-full-year-2016-financial-results-company-expanded-pipeline-and-asnd-20170322monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20170109monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20161130monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-special-note-regarding-forward-looking-statements-this-report-contains-asnd-20161018monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-special-note-regarding-forward-looking-statements-this-report-contains-asnd-20160930monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-this-presentation-contains-forward-looking-s-asnd-20160930monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20160831monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20160519monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2016-notice-is-hereby-given-that-the-annual-gener-asnd-20160426monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-full-year-2015-financial-results-copenhagen-denmark-asnd-20160414monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20151116monthly0.5https://www.biopharmawatch.com/news/ASND/a-phase-2-six-month-randomized-active-controlled-safety-and-efficacy-study-of-transcon-hgh-asnd-20151001monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20150825monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-asnd-20150518monthly0.5https://www.biopharmawatch.com/news/ASND/cautionary-note-on-forward-looking-statements-2-q2-2015-this-presentation-contains-forward-asnd-20150513monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2015-notice-is-hereby-given-that-the-annual-gener-asnd-20150330monthly0.5https://www.biopharmawatch.com/news/ASND/notice-to-convene-annual-general-meeting-2015-notice-is-hereby-given-that-the-annual-gener-asnd-20150327monthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-a-s-reports-full-year-2014-financial-results-conference-call-scheduled-for-asnd-20150325monthly0.5https://www.biopharmawatch.com/news/ASND/lbt-078-six-month-interim-safety-and-efficacy-of-different-dose-levels-of-transcon-hgh-adm-asnd-20150305monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-765-740-0314-or-tiffany-kanaga-elancoah-com-media-contact--elan-20260506monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-765-740-0314-or-tiffany-kanaga-elancoah-com-media-contact--elan-20260224monthly0.5https://www.biopharmawatch.com/news/ELAN/j-p-morgan-healthcare-conference-jeff-simmons-president-ceo-elan-20260113monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-450-elanco-circle-indianapolis-in-46221-for-immediate-release-investo-elan-20251209monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-765-740-0314-or-tiffany-kanaga-elancoah-com-media-contact--elan-20251105monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-765-740-0314-or-tiffany-kanaga-elancoah-com-media-contact--elan-20250807monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-765-740-0314-tiffany-kanaga-elancoah-com-media-contact-col-elan-20250528monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-765-740-0314-or-tiffany-kanaga-elancoah-com-media-contact--elan-20250507monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-765-740-0314-tiffany-kanaga-elancoah-com-media-contact-col-elan-20250317monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-765-740-0314-or-tiffany-kanaga-elancoah-com-media-contact--elan-20250225monthly0.5https://www.biopharmawatch.com/news/ELAN/j-p-morgan-healthcare-conference-elan-20250114monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20241112monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20241107monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20240808monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20240709monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20240508monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20240401monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20240226monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-media-contact-colleen-parr-de-elan-20240205monthly0.5https://www.biopharmawatch.com/news/ELAN/j-p-morgan-healthcare-conference-elan-20240109monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-media-c-elan-20240102monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20231107monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-media-c-elan-20231004monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20230807monthly0.5https://www.biopharmawatch.com/news/ELAN/season-solorio-765-316-0233-season-solorio-elancoah-com-investor-contact-kathryn-grissom-3-elan-20230713monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/reflect-the-revisions-to-previously-reported-financial-results-related-to-the-identified-i-elan-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/j-p-morgan-healthcare-conference-elan-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-elan-20221108monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-announces-changes-to-its-board-of-directors-scott-ferguson-steps-down-from-the-boar-elan-20220908monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20220808monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20220509monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-and-ginkgo-bioworks-launch-biomedit-a-new-animal-health-company-leveraging-microbio-elan-20220411monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20220329monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-kathryn-grissom-317-273-9284-or-kathryn-grissom-elancoah-com-media-contac-elan-20220224monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-dave-pugh-317-361-9892-or-david-pugh-elancoah-com-media-contact-colleen-p-elan-20211130monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-dave-pugh-317-361-9892-or-david-pugh-elancoah-com-media-contact-colleen-p-elan-20211105monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-302-897-0668-or-tiffany-kanaga-elancoah-com-media-contact--elan-20211005monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20210830monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-302-897-0668-or-tiffany-kanaga-elancoah-com-media-contact--elan-20210809monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20210616monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-1-302-897-0668-tiffany-kanaga-elancoah-com-media-contact-c-elan-20210604monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-302-897-0668-or-tiffany-kanaga-elancoah-com-media-contact--elan-20210507monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-302-897-0668-or-kanaga-tiffany-elanco-com-media-contact-co-elan-20210224monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-media-c-elan-20210222monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-draft-for-review-only-media-c-elan-20210126monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-media-c-elan-20210111monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-302-897-0668-or-kanaga-tiffany-elanco-com-media-contact-co-elan-20201215monthly0.5https://www.biopharmawatch.com/news/ELAN/cooperation-agreement-elan-20201213monthly0.5https://www.biopharmawatch.com/news/ELAN/media-colleen-parr-dekker-1-317-989-7011-colleen-parr-dekker-elanco-com-investor-relations-elan-20201130monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-302-897-0668-or-kanaga-tiffany-elanco-com-media-contact-co-elan-20201106monthly0.5https://www.biopharmawatch.com/news/ELAN/to-the-amended-form-8-k-ii-euro-amounts-are-converted-to-u-s-dollars-at-an-exchange-rate-o-elan-20201015monthly0.5https://www.biopharmawatch.com/news/ELAN/media-colleen-parr-dekker-1-317-989-7011-colleen-parr-dekker-elanco-com-elan-20200930monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20200803monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-tiffany-kanaga-302-897-0668-or-kanaga-tiffany-elanco-com-media-contact-co-elan-20200730monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-jim-greffet-317-383-9935-or-greffet-james-f-elanco-com-media-contact-coll-elan-20200507monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-media-colleen-parr-dekker-at--elan-20200420monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20200324monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-jim-greffet-317-383-9935-or-greffet-james-f-elanco-com-media-contact-coll-elan-20200219monthly0.5https://www.biopharmawatch.com/news/ELAN/media-colleen-parr-dekker-1-317-989-7011-colleen-parr-dekker-elanco-com-investor-relations-elan-20200204monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-media-c-elan-20200123monthly0.5https://www.biopharmawatch.com/news/ELAN/media-colleen-parr-dekker-1-317-989-7011-colleen-parr-dekker-elanco-com-investor-relations-elan-20200121monthly0.5https://www.biopharmawatch.com/news/ELAN/animal-health-business-of-bayer-aktiengesellschaft-combined-financial-statements-as-of-elan-20200121monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-jim-greffet-317-383-9935-greffet-james-f-elanco-com-media-contact-colleen-elan-20200110monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-media-c-elan-20191209monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-jim-greffet-317-383-9935-or-greffet-james-f-elanco-com-media-contact-coll-elan-20191106monthly0.5https://www.biopharmawatch.com/news/ELAN/media-colleen-parr-dekker-1-317-989-7011-colleen-parr-dekker-elanco-com-investor-relations-elan-20190930monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20190820monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-jim-greffet-317-383-9935-or-greffet-james-f-elanco-com-media-contact-coll-elan-20190813monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-media-colleen-parr-dekker-at--elan-20190718monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-jim-greffet-317-383-9935-or-greffet-james-f-elanco-com-media-contact-coll-elan-20190509monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20190426monthly0.5https://www.biopharmawatch.com/news/ELAN/investor-contact-jim-greffet-1-317-383-9935-greffet-james-f-elanco-com-media-contact-colle-elan-20190313monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20190208monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-strong-2018-fourth-quarter-and-full-year-results-confirms-201-elan-20190206monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-2500-innovation-way-greenfield-in-46140-for-immediate-release-investo-elan-20181218monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-strong-third-quarter-results-provides-financial-guidance-for--elan-20181106monthly0.5https://www.biopharmawatch.com/news/ELAN/colleen-parr-dekker-1-317-989-7011-parr-dekker-colleen-elanco-com-elanco-names-todd-s-youn-elan-20181030monthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-inc-to-acquire-talkspace-inc-industry-leading-virtual-behavioral-uhs-20260309monthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-inc-selected-hospital-statistics-for-the-three-months-ended-uhs-20240228monthly0.5https://www.biopharmawatch.com/news/UHS/separation-agreement-and-general-release-uhs-of-delaware-inc-uhs-or-employer-and-marvin-pe-uhs-20221207monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20200710monthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-inc-selected-hospital-statistics-for-the-three-months-ended-uhs-20190426monthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-inc-announces-retirement-of-debra-k-osteen-president-of-the-beha-uhs-20181206monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20170425monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20170228monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-uhs-20161208monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-uhs-20161205monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20161026monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20160726monthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-inc-announces-offering-of-senior-secured-notes-uhs-20160519monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20160502monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20160427monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20160225monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20151027monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20150730monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20150427monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20150226monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20141027monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-uhs-20140926monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20140724monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20140424monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20140227monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20131029monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20130725monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20130425monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-uhs-20130401monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20130228monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20121030monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-uhs-20121010monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-uhs-20120921monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20120726monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20120604monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20120426monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20120412monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20120227monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20111027monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20110727monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20110615monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20110426monthly0.5https://www.biopharmawatch.com/news/UHS/uhs-commences-exchange-offer-for-7-senior-notes-due-2018-uhs-20110414monthly0.5https://www.biopharmawatch.com/news/UHS/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-shar-uhs-20110401monthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-inc-amends-credit-agreement-and-increases-2011-earnings-guidance-uhs-20110316monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20110228monthly0.5https://www.biopharmawatch.com/news/UHS/universal-health-services-completes-acquisition-of-psychiatric-solutions-uhs-20101115monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20101027monthly0.5https://www.biopharmawatch.com/news/UHS/capitalization-the-following-table-sets-forth-our-capitalization-as-of-uhs-20100914monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-610-768-3300-uhs-20100914monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-uhs-20100908monthly0.5https://www.biopharmawatch.com/news/UHS/steve-filton-chief-financial-officer-uhs-20100726monthly0.5https://www.biopharmawatch.com/news/UHS/sources-and-uses-subsection-of-uhs-20100624monthly0.5https://www.biopharmawatch.com/news/UHS/j-p-morgan-securities-inc-270-park-avenue-new-york-new-york-10017-deutsche-bank-securities-uhs-20100615monthly0.5https://www.biopharmawatch.com/news/RVTY/execution-version-cusip-numbers-deal-76156eaa9-revolver-76156eab7-credit-agreement-dated-a-rvty-20250107monthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-announces-financial-results-for-the-fourth-quarter-and-full-year-of-2023-fourth-qu-rvty-20240201monthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-to-hold-earnings-call-on-thursday-rvty-20240109monthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-announces-financial-results-for-the-third-quarter-of-2023-revenue-of-671-million-6-rvty-20231030monthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-announces-financial-results-for-the-second-quarter-of-2023-revenue-of-709-million--rvty-20230801monthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-announces-financial-results-for-the-first-quarter-of-2023-revenue-of-675-million-3-rvty-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-and-full-year-of-2022-fourt-rvty-202302142023-02-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-to-hold-earnings-call-on-tuesday-rvty-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2022-third-quarter-revenu-rvty-20221108monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-to-hold-earnings-call-on-tuesday-rvty-20221017monthly0.5https://www.biopharmawatch.com/news/RVTY/employment-agreement-this-employment-agreement-the-agreement-effective-as-of-rvty-20220817monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2022-signs-agreement-wit-rvty-20220801monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2022-first-quarter-revenu-rvty-20220503monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-and-full-year-of-2021-4q-re-rvty-20220201monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-updates-fourth-quarter-outlook-to-hold-earnings-call-on-tuesday-rvty-20220111monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2021-revenue-of-1-17-bill-rvty-20211102monthly0.5https://www.biopharmawatch.com/news/RVTY/execution-version-published-cusip-numbers-deal-71404hal9-revolver-71404ham7-credit-agreeme-rvty-20210824monthly0.5https://www.biopharmawatch.com/news/RVTY/execution-version-term-loan-credit-agreement-dated-as-of-rvty-20210811monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-to-acquire-antibody-and-reagent-leader-biolegend-transformative-deal-significa-rvty-20210726monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2021-revenue-of-1-228-bi-rvty-20210726monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-provides-update-on-second-quarter-performance-and-schedules-earnings-call-for--rvty-20210624monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2021-revenue-of-1-308-bil-rvty-20210504monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-provides-first-quarter-update-and-schedules-earnings-call-for-tuesday-rvty-20210413monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-and-full-year-of-2020-4q-re-rvty-20210202monthly0.5https://www.biopharmawatch.com/news/RVTY/j-p-morgan-healthcare-conference-prahlad-singh-chief-executive-officer-rvty-20210111monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-updates-fourth-quarter-outlook-to-hold-earnings-call-on-tuesday-rvty-20210111monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-to-acquire-oxford-immunotec-global-plc-perkinelmer-to-acquire-oxford-immunotec-rvty-20210107monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2020-revenue-of-964-0-mil-rvty-20201028monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-updates-third-quarter-outlook-to-hold-earnings-call-on-wednesday-rvty-20201013monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2020-revenue-of-811-7-mi-rvty-20200728monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-updates-second-quarter-outlook-to-hold-earnings-call-on-tuesday-rvty-20200713monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2020-revenue-of-652-4-mil-rvty-20200505monthly0.5https://www.biopharmawatch.com/news/RVTY/time-vested-rsu-single-trigger-perkinelmer-inc-restricted-stock-unit-agreement-2019-stock--rvty-20200401monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-first-quarter-2020-financial-performance-update-rvty-20200309monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-and-full-year-2019-4q-reven-rvty-20200127monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2019-revenue-of-706-9-mil-rvty-20191030monthly0.5https://www.biopharmawatch.com/news/RVTY/amended-and-restated-employment-agreement-this-amended-and-restated-employment-agreement-t-rvty-20190821monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2019-revenue-of-722-5-mi-rvty-20190729monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2019-revenue-of-648-7-mil-rvty-20190425monthly0.5https://www.biopharmawatch.com/news/RVTY/rsu-board-perkinelmer-inc-restricted-stock-unit-agreement-2019-stock-incentive-plan-this-r-rvty-20190424monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-and-full-year-2018-fourth-q-rvty-20190131monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2018-gaap-revenue-growth--rvty-20181031monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2018-gaap-revenue-growth-rvty-20180801monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2018-first-quarter-2018-g-rvty-20180430monthly0.5https://www.biopharmawatch.com/news/RVTY/employment-agreement-this-employment-agreement-the-agreement-made-this-10th-day-of-april-2-rvty-20180413monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-and-full-year-2017-fourth-q-rvty-20180125monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2017-gaap-revenue-growth--rvty-20171102monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2017-gaap-and-adjusted-r-rvty-20170803monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2017-gaap-revenue-of-514--rvty-20170504monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-fourth-quarter-and-full-year-2016-the-company--rvty-20170202monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-inc-restricted-stock-agreement-under-2009-incentive-plan-this-agreement-made-a-rvty-20170127monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2016-gaap-revenue-of-548--rvty-20161107monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2016-revenue-of-573-mill-rvty-20160804monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2016-gaap-revenue-of-539--rvty-20160505monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-fourth-quarter-and-full-year-2015-fourth-quart-rvty-20160204monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2015-gaap-revenue-of-563--rvty-20151105monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2015-gaap-revenue-of-564-rvty-20150730monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2015-gaap-revenue-of-527--rvty-20150430monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-of-2014-revenue-growth-of-3-rvty-20150129monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2014-revenue-growth-of-4--rvty-20141030monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2014-revenue-growth-of-3-rvty-20140731monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2014-reported-and-organic-rvty-20140424monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-of-2013-revenue-growth-of-4-rvty-20140130monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2013-revenue-growth-of-3--rvty-20131030monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2013-revenue-growth-of-4-rvty-20130801monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2013-revenue-decline-of-1-rvty-20130425monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-fourth-quarter-of-2012-revenue-growth-of-6-rvty-20130131monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-third-quarter-of-2012-revenue-growth-of-13-rvty-20121025monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-second-quarter-of-2012-revenue-growth-of-9-rvty-20120802monthly0.5https://www.biopharmawatch.com/news/RVTY/perkinelmer-announces-financial-results-for-the-first-quarter-of-2012-revenue-of-511-milli-rvty-20120426monthly0.5https://www.biopharmawatch.com/news/EHC/polly-manuel-205-970-5912-media-encompasshealth-com-investor-relations-contact-mark-miller-ehc-20260514monthly0.5https://www.biopharmawatch.com/news/EHC/hillary-carnel-205-970-5912-hillary-carnel-encompasshealth-com-investor-relations-contact--ehc-20190909monthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-contacts-media-hillary-carnel-205-970-5912-hillary-carnel-encompasshealth-ehc-20190401monthly0.5https://www.biopharmawatch.com/news/EHC/encompass-health-contacts-media-hillary-carnel-205-767-9654-hillary-carnel-encompasshealth-ehc-20180315monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-approval-of-auvelity-dextromethorphan-hbr-and-bupropion--axsm-20260430monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-acquires-selective-pde10a-inhibitor-balipodect-for-the-treatment-of-sc-axsm-20260401monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2025-net-product-rev-axsm-20260112monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-up-axsm-20250804monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-availability-of-symbravo-meloxicam-and-rizatriptan-for-the-a-axsm-20250610monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-provides-update-on-the-new-drug-application-nda-for-axs-14-for-the-man-axsm-20250609monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-settles-sunosi-solriamfetol-patent-litigation-with-hetero-labs-ltd-axsm-20250527monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-enters-570-million-term-loan-and-revolving-credit-facility-with-blacks-axsm-20250513monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-upd-axsm-20250505monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-topline-results-of-paradigm-phase-3-proof-of-concept-trial-o-axsm-20250401monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-focus-phase-3-trial-of-solriamfetol-in-adults-with-attention-axsm-20250325monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-settles-sunosi-solriamfetol-patent-litigation-with-hikma-pharmaceutica-axsm-20250305monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-pre-nda-meeting-minutes-for-axs-05-in-alzheimer-s-diseas-axsm-20250303monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-axsm-20250218monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-settlement-agreement-resolving-auvelity-dextromethorphan-hbr-axsm-20250210monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-a-axsm-20250130monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2024-net-revenue-auv-axsm-20250113monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-successful-completion-and-results-of-phase-3-clinical-progra-axsm-20241230monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-in-encore-long-term-phase-3-axsm-20241126monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upd-axsm-20241112monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-acceptance-of-nda-resubmission-for-axs-07-for-the-acute--axsm-20240904monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reaches-agreement-to-dismiss-sunosi-solriamfetol-patent-litigation-wit-axsm-20240821monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-up-axsm-20240805monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-settles-sunosi-solriamfetol-patent-litigation-with-unichem-laboratorie-axsm-20240605monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-upd-axsm-20240506monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-engage-phase-3-trial-of-solriamfetol-for-the-treatment-of-bi-axsm-20240401monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-results-of-crescendo-narcolepsy-patient-survey-demonstrating-axsm-20240325monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-in-the-symphony-phase-3-tri-axsm-20240325monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-paradigm-phase-3-trial-of-solriamfetol-for-the-treatment-of--axsm-20240319monthly0.5https://www.biopharmawatch.com/news/AXSM/corporate-presentation-february-2024-certain-information-contained-in-this-presentation-ma-axsm-20240220monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provid-axsm-20240220monthly0.5https://www.biopharmawatch.com/news/AXSM/corporate-presentation-january-2024-certain-information-contained-in-this-presentation-may-axsm-20240108monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2023-net-revenue-and-axsm-20240104monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-hosts-solriamfetol-virtual-investor-event-with-expert-thought-leaders--axsm-20231207monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-upd-axsm-20231106monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-appoints-dr-sue-mahony-to-its-board-of-directors-axsm-20231011monthly0.5https://www.biopharmawatch.com/news/AXSM/corporate-presentation-august-2023-certain-information-contained-in-this-presentation-may--axsm-20230815monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-up-axsm-20230807monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-focus-phase-3-trial-of-solriamfetol-for-the-treatment-of-att-axsm-20230707monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-closing-of-public-offering-of-225-million-of-shares-of-commo-axsm-20230630monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-proposed-public-offering-of-common-stock-axsm-20230627monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2023-financial-results-and-corporate-update-auve-axsm-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provid-axsm-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-enters-into-license-agreement-with-pharmanovia-to-expand-commercializa-axsm-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-the-accord-phase-3-trial-axsm-20221128monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-upd-axsm-20221107monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-availability-of-auvelity-the-first-and-only-oral-nmda-recept-axsm-20221020monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-sunosi-solriamfetol-meets-primary-endpoint-demonstrating-imp-axsm-20221003monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-plans-to-resubmit-axs-07-nda-based-on-successful-fda-type-a--axsm-20220929monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-advance-2-phase-3-trial-of-axs-05-in-alzheimer-s-disease-agi-axsm-20220908monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-emerge-phase-3-open-label-trial-of-axs-07-for-the-acute-trea-axsm-20220901monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-approval-of-auvelity-tm-the-first-and-only-oral-nmda-rec-axsm-20220819monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-up-axsm-20220809monthly0.5https://www.biopharmawatch.com/news/AXSM/sunosi-solriamfetol-investor-update-axsm-20220628monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-new-data-from-the-gemini-trial-demonstrating-efficacy-of-axs--axsm-20220602monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-late-breaking-presentations-of-positive-results-of-the-evolv-axsm-20220601monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-publication-of-pivotal-gemini-phase-3-trial-of-axs-05-in-maj-axsm-20220531monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-publication-of-pivotal-ascend-phase-2-trial-of-axs-05-in-maj-axsm-20220518monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-completes-u-s-acquisition-of-sunosi-solriamfetol-for-excessive-daytime-axsm-20220509monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-upd-axsm-20220502monthly0.5https://www.biopharmawatch.com/news/AXSM/certain-identified-information-has-been-excluded-from-this-exhibit-because-it-is-not-mater-axsm-20220325monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-acquire-sunosi-from-jazz-pharmaceuticals-expanding-axsome-s-leaders-axsm-20220328monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provid-axsm-20220301monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-upd-axsm-20211108monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-expands-term-loan-facility-with-hercules-capital-to-300-million-100-mi-axsm-20211018monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-symphony-phase-3-trial-of-axs-12-in-narcolepsy-axsm-20210916monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-07-for-the-ac-axsm-20210914monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-provides-update-on-the-new-drug-application-for-axs-05-for-the-treatme-axsm-20210823monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-up-axsm-20210809monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-planned-nda-submission-for-axs-14-for-the-management-of-fibr-axsm-20210615monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-upd-axsm-20210510monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-f-axsm-20210426monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-provid-axsm-20210301monthly0.5https://www.biopharmawatch.com/news/AXSM/certain-information-contained-in-this-presentation-may-include-forward-looking-statements--axsm-20210224monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-positive-efficacy-and-safety-results-from-the-phase-3-moveme-axsm-20201231monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-positive-results-from-the-comet-si-trial-of-axs-05-in-patien-axsm-20201208monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-positive-results-from-the-comet-trd-trial-of-axs-05-in-patie-axsm-20201202monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-positive-efficacy-and-safety-results-from-phase-3-comet-long-axsm-20201201monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business-upd-axsm-20201105monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-225-million-term-loan-facility-with-hercules-capital-non-dil-axsm-20200929monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-new-data-from-momentum-phase-3-trial-with-axs-07-demonstratin-axsm-20200924monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-expedited-development-of-axs-12-for-the-treatment-of-narcole-axsm-20200921monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-corporate-presentation-september-2020-xa9-axsome-therapeutics-inc-certain-info-axsm-20200916monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-new-data-from-gemini-phase-3-trial-with-axs-05-demonstrating--axsm-20200914monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-completes-successful-fda-pre-nda-meeting-for-axs-07-for-the-acute-trea-axsm-20200820monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2020-financial-results-and-provides-business-up-axsm-20200810monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-12-for-the-treat-axsm-20200805monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-completes-successful-fda-pre-nda-meeting-for-axs-05-for-the-treatment--axsm-20200713monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-05-for-the-treat-axsm-20200626monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2020-financial-results-and-provides-business-upd-axsm-20200508monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-the-advance-1-pivotal-ph-axsm-20200427monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-07-achieves-both-co-primary-endpoints-and-prevents-migra-axsm-20200406monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-topline-results-of-the-stride-1-phase-3-trial-in-treatment-r-axsm-20200330monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-accelerates-completion-of-the-advance-1-phase-2-3-trial-of-axs-05-in-a-axsm-20200320monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-march-2020-xa9-axsome-therapeutics-inc-certain-information-contained-in-this-p-axsm-20200312monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-provid-axsm-20200312monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-completes-patient-enrollment-in-the-intercept-phase-3-trial-of-axs-07--axsm-20200220monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-completes-patient-randomization-in-the-stride-1-phase-3-trial-of-axs-0-axsm-20200122monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-enters-into-exclusive-license-agreement-with-pfizer-inc-for-pfizer-s-r-axsm-20200113monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-07-achieves-co-primary-and-key-secondary-endpoints-in-mo-axsm-20191230monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-closing-of-200-million-public-offering-of-common-stock-inclu-axsm-20191223monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-proposed-public-offering-of-common-stock-axsm-20191218monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-gemini-phase-3-trial-in--axsm-20191216monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-in-concert-phase-2-trial-in-axsm-20191203monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-november-2019-xa9-axsome-therapeutics-inc-certain-information-contained-in-thi-axsm-20191107monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2019-financial-results-and-provides-business-upd-axsm-20191107monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-results-of-mindset-physician-survey-affirming-unmet-need-and-axsm-20191028monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-continued-progress-in-clinical-development-of-axs-07-for-the-axsm-20191028monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-completes-patient-enrollment-in-the-concert-phase-2-trial-of-axs-12-in-axsm-20191021monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-completion-of-patient-enrollment-in-the-gemini-phase-3-trial-axsm-20191016monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-provide-update-on-continued-progress-at-the-2019-cantor-global-heal-axsm-20191002monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-positive-axs-07-phase-1-trial-results-at-the-19th-congress-of-axsm-20190905monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-appoints-david-marek-as-chief-commercial-officer-axsm-20190820monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2019-financial-results-and-provides-business-up-axsm-20190808monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-amends-silicon-valley-bank-loan-agreement-increasing-financial-flexibi-axsm-20190729monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-gemini-phase-3-trial-of-axs-05-in-major-depressive-disorder--axsm-20190624monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-provides-update-on-continued-progress-at-annual-stockholders-meeting-p-axsm-20190607monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2019-financial-results-and-provides-business-upd-axsm-20190509monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-expedited-development-and-pivotal-status-for-axs-05-in-the-t-axsm-20190506monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-phase-2-trial-in-smoking-axsm-20190415monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-05-for-the-treat-axsm-20190327monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-provid-axsm-20190314monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-secures-24-million-growth-capital-loan-facility-led-by-silicon-valley--axsm-20190306monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-momentum-phase-3-trial-of-axs-07-in-migraine-first-patient-e-axsm-20190304monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-agreement-under-special-protocol-assessment-spa-for-the-m-axsm-20190206monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-phase-2-trial-of-axs-12-in-narcolepsy-topline-results-antici-axsm-20190130monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-raises-23-3-million-under-existing-atm-facility-axsm-20190107monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-january-2019-axsome-therapeutics-inc-fls-forward-looking-statements-safe-harbo-axsm-20190107monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-phase-2-trial-in-major-d-axsm-20190107monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-provides-year-end-2018-clinical-update-fda-clearance-of-ind-received-f-axsm-20181227monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-positive-outcome-of-interim-analysis-of-advance-1-phase-2-3--axsm-20181210monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-expands-loan-agreement-with-silicon-valley-bank-providing-additional-g-axsm-20181127monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-completion-of-patient-enrollment-in-the-ascend-phase-2-trial-axsm-20181114monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-november-2018-axsome-therapeutics-inc-fls-forward-looking-statements-safe-harb-axsm-20181109monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2018-financial-results-and-provides-business-upd-axsm-20181109monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-october-2018-axsome-therapeutics-inc-fls-forward-looking-statements-safe-harbo-axsm-20181017monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-orphan-drug-designation-for-axs-12-for-the-treatment-of-n-axsm-20181017monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-12-for-the-treatment-of-narcolepsy-narcolepsy-is-a-debil-axsm-20181016monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-focus-on-growing-core-cns-portfolio-establishes-axsome-pain-and-pri-axsm-20181011monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-8-9-million-registered-direct-offering-axsm-20180928monthly0.5https://www.biopharmawatch.com/news/AXSM/exhibi-t-99-1-nasdaq-axsm-august-2018-2018-axsome-therapeutics-inc-fls-forward-looking-sta-axsm-20180808monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2018-financial-results-and-provides-business-up-axsm-20180808monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-phase-2-trial-of-axs-05-in-major-depressive-disorder-first-p-axsm-20180605monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2018-financial-results-and-provides-business-upd-axsm-20180508monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-positive-outcome-of-interim-analysis-of-stride-1-phase-3-tri-axsm-20180426monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-first-patient-enrolled-in-phase-2-clinical-trial-of-axs-05-i-axsm-20180423monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-appoints-nick-pizzie-cpa-mba-as-chief-financial-officer-axsm-20180419monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-provid-axsm-20180307monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-primary-endpoint-met-in-phase-1-trial-of-next-generation-pro-axsm-20180226monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-02-independent-data-monitoring-committee-recommends-cont-axsm-20180109monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-collaborates-with-world-leading-nicotine-addiction-research-center-for-axsm-20171214monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-9-5-million-registered-direct-offering-priced-at-the-market-axsm-20171201monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-07-for-the-treatment-of-migraine-axsm-20171128monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2017-financial-results-axsm-20171108monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-september-2017-2017-axsome-therapeutics-inc-forward-looking-statements-safe-ha-axsm-20170918monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-announces-create-1-interim-analysis-expected-year-end-2017-interim-analysis-results-axsm-20170907monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2017-financial-results-axsm-20170809monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-06-moseic-meloxicam-and-esomeprazole-meets-primaryendpoi-axsm-20170725monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-phase-2-3-trial-of-axs-05-for-alzheimer-s-disease-agitation--axsm-20170717monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-appoints-john-golubieski-as-chief-financial-officer-axsm-20170706monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-appoints-myrtle-potter-to-its-board-of-directors-axsm-20170619monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2017-financial-results-axsm-20170509monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-april-2017-2017-axsome-therapeutics-inc-fls-forward-looking-statements-safe-ha-axsm-20170331monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-full-exercise-of-underwriter-s-option-to-purchase-additional-axsm-20170329monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-proposed-public-offering-of-common-stock-axsm-20170320monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-march-2017-2017-axsome-therapeutics-inc-fls-forward-looking-statements-safe-ha-axsm-20170314monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-provid-axsm-20170307monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-fast-track-designation-for-axs-05-for-treatment-resistant-axsm-20170214monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-february-2017-2017-axsome-therapeutics-inc-fls-forward-looking-statements-safe-axsm-20170210monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-january-2017-2016-axsome-therapeutics-inc-fls-forward-looking-statements-safe--axsm-20170112monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-clearance-of-ind-for-phase-2-3-trial-of-axs-05-in-alzheim-axsm-20170103monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-third-quarter-2016-financial-results-axsm-20161114monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-enters-into-20-million-term-loan-agreement-with-silicon-valley-bank-axsm-20161110monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-transition-of-chief-medical-officer-axsm-20160902monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2016-financial-results-axsm-20160809monthly0.5https://www.biopharmawatch.com/news/AXSM/nasdaq-axsm-cantor-fitzgerald-2nd-annual-healthcare-conference-july-2016-2016-axsome-thera-axsm-20160713monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-first-quarter-2016-financial-results-axsm-20160511monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-fast-track-designation-for-axs-02-for-the-treatment-of-th-axsm-20160503monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-pre-ind-guidance-from-fda-for-axs-05-for-agitation-in-patient-axsm-20160420monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-axsm-20160324monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-phase-3-study-of-axs-05-for-treatment-resistant-depression-f-axsm-20160317monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-annouces-results-of-its-abvx-20260511monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-positive-phase-3-results-from-both-abtect-8-week-induction-trials-investi-abvx-20250722monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-results-of-its-abvx-20250606monthly0.5https://www.biopharmawatch.com/news/ABVX/trial-participant-baseline-characteristics-abtect-phase-3-vs-obefazimod-phase-2b-trial-par-abvx-20250425monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-annual-general-meeting-details-as-company-advances-toward-key-2025-value--abvx-20250422monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-achieves-key-milestone-in-phase-3-abtect-trial-enrollment-phase-3-abtect-trial-eval-abvx-20250109monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-a-change-to-the-composition-of-its-board-of-directors-abvx-20241223monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-establishes-an-at-the-market-atm-program-on-nasdaq-abvx-20241119monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-releases-the-results-of-its-abvx-20240530monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2026-results-raises-full-year-total-company-revenue-guidance-podd-20260506monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-initiates-voluntary-medical-device-correction-for-certain-omnipod-5-pods-in-the-u--podd-20260312monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2025-results-raises-full-year-revenue-and-margin-guidance-podd-20251106monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-appointment-of-robert-l-huffines-to-its-board-of-directors-podd-20251023monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-cfo-transition-flavia-pease-appointed-chief-financial-officer-acton-mass-podd-20250916monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2025-revenue-increase-of-32-9-year-over-year-31-3-constant--podd-20250807monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2025-revenue-increase-of-29-year-over-year-30-constant-curre-podd-20250508monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-appoints-ashley-mcevoy-president-and-ceo-expects-to-exceed-first-quarter-revenue-g-podd-20250428monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-pricing-of-senior-notes-due-2033-podd-20250318monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-proposed-financing-transactions-podd-20250318monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-full-year-2024-revenue-increase-of-22-and-fourth-quarter-2024-revenue-incr-podd-20250220monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-successfully-defends-its-intellectual-property-against-eoflow-co-in-u-s-district-c-podd-20241203monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2024-revenue-increase-of-26-year-over-year-25-constant-curre-podd-20241107monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2024-revenue-increase-of-23-year-over-year-raising-full-yea-podd-20240808monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-preliminary-second-quarter-2024-revenue-results-second-quarter-revenue-inc-podd-20240726monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2024-revenue-increase-of-23-year-over-year-raising-full-year-podd-20240509monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-appoints-ana-maria-chadwick-as-chief-financial-officer-podd-20240320monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-full-year-2023-revenue-increase-of-30-30-constant-currency-1-and-fourth-qu-podd-20240222monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-changes-to-board-of-directors-with-retirements-and-new-appointments-flav-podd-20240118monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2023-revenue-increase-of-27-year-over-year-25-constant-curre-podd-20231102monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-cfo-transition-reaffirms-guidance-for-third-quarter-and-fiscal-year-2023-podd-20231003monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2023-revenue-increase-of-32-year-over-year-32-constant-curr-podd-20230808monthly0.5https://www.biopharmawatch.com/news/PODD/united-states-district-court-district-of-massachusetts-insulet-corporation-plaintiff-case--podd-20230808monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-new-organizational-structure-to-drive-further-growth-structured-to-accel-podd-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2023-revenue-increase-of-21-year-over-year-23-constant-curre-podd-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-full-year-2022-revenue-increase-of-19-22-constant-currency-1-and-fourth-qu-podd-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-issues-a-nationwide-voluntary-medical-device-correction-for-the-omnipod-5-controll-podd-20221114monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2022-revenue-increase-of-24-year-over-year-29-constant-curre-podd-20221103monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2022-revenue-increase-of-14-year-over-year-18-constant-curr-podd-20220804monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-ceo-transition-director-jim-hollingshead-to-succeed-shacey-petrovic-as-p-podd-20220506monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2022-revenue-increase-of-17-year-over-year-podd-20220505monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-full-year-2021-revenue-increase-of-21-and-fourth-quarter-2021-revenue-incr-podd-20220223monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-board-appointment-of-elizabeth-weatherman-and-retirement-of-david-lemoin-podd-20220207monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-fda-clearance-of-its-omnipod-5-automated-insulin-delivery-system-first-t-podd-20220128monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2021-revenue-increase-of-18-year-over-year-acton-ma-podd-20211104monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-board-of-director-changes-with-appointment-of-luciana-borio-m-d-and-reti-podd-20211018monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2021-revenue-increase-of-16-year-over-year-acton-ma-podd-20210805monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2021-revenue-increase-of-27-year-over-year-acton-ma-podd-20210506monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-pricing-of-new-senior-secured-credit-facilities-podd-20210429monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-launch-of-syndication-of-new-credit-facilities-podd-20210419monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-full-year-2020-revenue-increase-of-23-and-fourth-quarter-2020-revenue-incr-podd-20210223monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2020-revenue-increase-of-22-year-over-year-includes-total-om-podd-20201104monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-appoints-wayne-a-i-frederick-m-d-to-board-of-directors-podd-20201020monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2020-revenue-increase-of-28-year-over-year-includes-total-o-podd-20200806monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-corporation-announces-pricing-of-500-million-public-offering-of-common-stock-podd-20200512monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-corporation-announces-plans-for-public-offering-of-common-stock-podd-20200512monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2020-revenue-increase-of-24-year-over-year-includes-total-om-podd-20200507monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-full-year-2019-revenue-of-738-2-million-an-increase-of-31-and-fourth-quart-podd-20200225monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2019-revenue-of-192-million-an-increase-of-27-year-over-year-podd-20191105monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-pricing-of-convertible-senior-notes-due-2026-podd-20190904monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-private-offering-of-convertible-senior-notes-podd-20190903monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2019-revenue-of-177-million-an-increase-of-43-year-over-yea-podd-20190805monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-appoints-jim-hollingshead-to-board-of-directors-podd-20190731monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2019-revenue-of-159-6-million-an-increase-of-29-year-over-ye-podd-20190502monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-fourth-quarter-2018-revenue-of-164-9-million-up-26-year-over-year-and-full-podd-20190225monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-appoints-corinne-nevinny-to-board-of-directors-acton-mass-business-wire-podd-20190128monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-appoints-wayde-mcmillan-chief-financial-officer-acton-mass-business-wire-podd-20190107monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2018-revenue-of-151-1-million-up-24-year-over-year-and-gross-podd-20181101monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-shacey-petrovic-president-and-coo-promoted-to-podd-20180914monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2018-revenue-of-124-3-million-up-13-year-over-year-and-gros-podd-20180802monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2018-revenue-of-123-6-million-up-21-year-over-year-and-gross-podd-20180503monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-fourth-quarter-revenue-of-130-5-million-up-26-and-gross-margin-up-210-basi-podd-20180221monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2017-financial-results-third-quarter-revenue-of-121-8-millio-podd-20171102monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-corporation-appoints-michael-r-minogue-and-james-c-mullen-to-board-of-directors-bi-podd-20170810monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2017-financial-results-second-quarter-revenue-of-109-8-mill-podd-20170803monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-to-assume-distribution-and-commercial-support-for-its-omnipod-system-in-europe-dir-podd-20170720monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2017-financial-results-first-quarter-revenue-of-101-7-millio-podd-20170508monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-fourth-quarter-and-full-year-2016-financial-results-fourth-quarter-revenue-podd-20170227monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2016-financial-results-third-quarter-revenue-of-94-9-million-podd-20161103monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-board-and-management-changes-patrick-sullivan-elected-chairman-of-the-bo-podd-20161019monthly0.5https://www.biopharmawatch.com/news/PODD/patient-protection-and-affordable-care-act-the-patient-protection-and-affordable-care-act--podd-20160906monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2016-financial-results-second-quarter-revenue-of-87-3-milli-podd-20160803monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reaffirms-second-quarter-and-full-year-2016-guidance-podd-20160503monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-first-quarter-2016-financial-results-first-quarter-revenue-of-81-2-million-podd-20160428monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-fourth-quarter-and-full-year-2015-financial-results-fourth-quarter-revenue-podd-20160225monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-appoints-david-a-lemoine-to-board-of-directors-new-independent-director-brings-ext-podd-20160209monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-to-divest-neighborhood-diabetes-supplies-business-signs-definitive-agreement-to-se-podd-20160202monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2015-financial-results-revenue-of-87-3-million-exceeds-expec-podd-20151105monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-second-quarter-2015-financial-results-revenue-of-75-6-million-exceeds-expe-podd-20150812monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-provides-update-regarding-release-of-second-quarter-results-company-reiterates-pre-podd-20150810monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-preliminary-second-quarter-2015-revenue-results-company-anticipates-second-podd-20150729monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-appoints-jessica-hopfield-phd-to-board-of-directors-addition-strengthens-the-board-podd-20150728monthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-organizational-changes-focus-on-operational-excellence-billerica-ma-podd-20150630monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-marni-kottle-biomarin-pharmaceutical-inc-biomarin-pharmaceut-bmrn-20260504monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-marni-kottle-biomarin-pharmaceutical-inc-biomarin-pharmaceut-bmrn-20260427monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-biomarin-pharmaceutical-inc-415-455-7558-erin-rau-biomarin-p-bmrn-20260212monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-erin-rau-biomarin-pharmaceutical-inc-biomarin-pharmaceutical-bmrn-20260129monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-traci-mccarty-biomarin-pharmaceutical-inc-415-455-7558-media-erin-rau-biomarin-p-bmrn-20260126monthly0.5https://www.biopharmawatch.com/news/BMRN/th-annual-j-p-morgan-healthcare-conference-alexander-hardy-greg-friberg-chief-executive-of-bmrn-20260112monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-contacts-amicus-contacts-traci-mccarty-investors-biomarin-pharmaceutical-inc-415--bmrn-20251219monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-contacts-inozyme-contacts-traci-mccarty-investors-stefan-riley-investors-biomarin-bmrn-20250516monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-marni-kottle-biomarin-pharmaceutical-inc-biomarin-pharmaceut-bmrn-20250501monthly0.5https://www.biopharmawatch.com/news/BMRN/efiled-mar-27-2024-12-01pm-edt-transaction-id-72616079-case-no-multi-case-in-the-court-of--bmrn-20240423monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-marni-kottle-biomarin-pharmaceutical-inc-biomarin-pharmaceut-bmrn-20231220monthly0.5https://www.biopharmawatch.com/news/BMRN/st-annual-j-p-morgan-ai0marin-healthcare-conference-bmrn-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20220427monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20220223monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-sells-priority-review-voucher-for-110-million-bmrn-20220209monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20211027monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20210728monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20210429monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20210225monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20201105monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20200804monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20200519monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20200511monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20200429monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20200226monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20191023monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20190801monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20190425monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20190215monthly0.5https://www.biopharmawatch.com/news/BMRN/th-37-annual-j-p-morgan-healthcare-conference-jean-jacques-bienaim-chairman-and-chief-exec-bmrn-20190108monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20181025monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20180802monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20180425monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20180222monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20171127monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20171026monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-offering-of-450-million-of-senior-subordinated-convertible-notes-due-20-bmrn-20170807monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20170802monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20170504monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20170413monthly0.5https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-debra-charlesworth-biomarin-pharmaceutical-inc-biomarin-phar-bmrn-20170223monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-gmab-20260616monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20260615monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-gmab-20260611monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20260529monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-gmab-20260512monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20260508monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-quarter-of-2026-gmab-20260507monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-a-s-share-capital-reduction-company-announcement-gmab-20260417monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20260414monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2026-company-annou-gmab-20260414monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20260401monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20260401monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20260330monthly0.5https://www.biopharmawatch.com/news/GMAB/passing-of-genmab-a-s-annual-general-meeting-company-announcement-at-genmab-a-s-annual-gen-gmab-20260319monthly0.5https://www.biopharmawatch.com/news/GMAB/completion-of-share-buy-back-program-company-announcement-gmab-20260316monthly0.5https://www.biopharmawatch.com/news/GMAB/correction-to-company-announcement-no-13-of-gmab-20260302monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-management-and-employees-and-grant-of-warrants-to-emplo-gmab-20260227monthly0.5https://www.biopharmawatch.com/news/GMAB/notice-to-convene-the-annual-general-meeting-of-genmab-a-s-company-announcement-genmab-a-s-gmab-20260218monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-topline-results-for-epcoritamab-duobody-cd3xcd20-from-phase-3-epcore-dlbc-gmab-20260116monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-portfolio-prioritization-update-company-announcement-genmab-to-discontinue-clinical-gmab-20251229monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20251201monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-gmab-20251120monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20251119monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-gmab-20251118monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-epkinly-epcoritamab-bysp-in-combination-with-rituximab-and-lenalidomide-a-gmab-20251118monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-nine-months-of-2025-gmab-20251106monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20250923monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-gmab-20250909monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-phase-3-epcore-fl-1-clinical-trial-met-dual-primary-endpoints-in-patients-gmab-20250807monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-second-quarter-of-2025-company-anno-gmab-20250716monthly0.5https://www.biopharmawatch.com/news/GMAB/completion-of-share-buy-back-program-company-announcement-gmab-20250630monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-gmab-20250623monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-gmab-20250617monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20250617monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-gmab-20250616monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-gmab-20250612monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-gmab-20250610monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-gmab-20250602monthly0.5https://www.biopharmawatch.com/news/GMAB/a-appendix-share-buy-back-programme-specification-for-may-19-23-2025-issuer-date-time-cet--gmab-20250527monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-gmab-20250520monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-company-announ-gmab-20250519monthly0.5https://www.biopharmawatch.com/news/GMAB/a-appendix-share-buy-back-programme-specification-for-may-5-9-2025-issuer-date-time-cet-qu-gmab-20250512monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-quarter-of-2025-gmab-20250508monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-gmab-20250505monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-to-submit-supplemental-biologics-license-application-sbla-to-u-s-food-and-drug-admi-gmab-20250502monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-gmab-20250428monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20250422monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2025-company-annou-gmab-20250415monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20250414monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-a-s-share-capital-reduction-company-announcement-copenhagen-denmark-gmab-20250410monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20250407monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20250401monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20250331monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-initiation-of-share-buy-back-program-company-announcement-repurchase-of-u-gmab-20250325monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-to-vigorously-defend-alleged-claims-of-trade-secret-misappropriation-by-abbvie-inc--gmab-20250322monthly0.5https://www.biopharmawatch.com/news/GMAB/constitution-of-the-board-of-directors-in-genmab-a-s-grant-of-restricted-stock-units-to-bo-gmab-20250312monthly0.5https://www.biopharmawatch.com/news/GMAB/passing-of-genmab-a-s-annual-general-meeting-company-announcement-at-genmab-a-s-annual-gen-gmab-20250312monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-johnson-johnson-decision-regarding-hexabody-cd38-company-announcement-joh-gmab-20250310monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20250304monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-management-and-employees-and-grant-of-warrants-to-emplo-gmab-20250228monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20250225monthly0.5https://www.biopharmawatch.com/news/GMAB/notice-to-convene-the-annual-general-meeting-of-genmab-a-s-company-announcement-genmab-a-s-gmab-20250213monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-2024-annual-report-table-of-contents-genmab-2024-annual-report-management-s-review--gmab-20250212monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20250123monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-2024-company-announcement-net-sales-gmab-20250122monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20241203monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20241203monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20241121monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-nine-months-of-2024-gmab-20241106monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-third-quarter-of-2024-company-annou-gmab-20241015monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-for-genmab-a-s-company-announcement-major-shareholder-annou-gmab-20241004monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20240926monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20240910monthly0.5https://www.biopharmawatch.com/news/GMAB/tepkinly-epcoritamab-receives-second-european-commission-approval-for-the-treatment-of-adu-gmab-20240819monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20240813monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-half-of-2024-gmab-20240808monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-updates-2024-financial-guidance-company-announcement-genmab-updates-its-2024-financ-gmab-20240808monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-takes-full-control-of-acasunlimab-development-program-company-announcement-genmab-t-gmab-20240805monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-second-quarter-of-2024-company-anno-gmab-20240717monthly0.5https://www.biopharmawatch.com/news/GMAB/epcoritamab-tepkinly-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-relap-gmab-20240628monthly0.5https://www.biopharmawatch.com/news/GMAB/completion-of-share-buy-back-program-company-announcement-copenhagen-denmark-gmab-20240627monthly0.5https://www.biopharmawatch.com/news/GMAB/epkinly-epcoritamab-bysp-approved-by-u-s-fda-for-patients-with-relapsed-or-refractory-r-r--gmab-20240627monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240624monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20240618monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240618monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20240612monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20240611monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240610monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240603monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240527monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-completes-acquisition-of-profoundbio-company-announcement-genmab-has-completed-acqu-gmab-20240521monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240521monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240513monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20240507monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240506monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-quarter-of-2024-gmab-20240502monthly0.5https://www.biopharmawatch.com/news/GMAB/tivdak-tisotumab-vedotin-tftv-receives-u-s-fda-approval-to-treat-recurrent-or-metastatic-c-gmab-20240430monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240429monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-genmab-company-announcement-copenha-gmab-20240422monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2024-company-annou-gmab-20240416monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240415monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240408monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of-profoundbio-compan-gmab-20240403monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240402monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240325monthly0.5https://www.biopharmawatch.com/news/GMAB/completion-of-share-buy-back-program-company-announcement-copenhagen-denmark-gmab-20240318monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-initiation-of-share-buy-back-program-company-announcement-repurchase-of-u-gmab-20240315monthly0.5https://www.biopharmawatch.com/news/GMAB/constitution-of-the-board-of-directors-in-genmab-a-s-grant-of-restricted-stock-units-to-bo-gmab-20240313monthly0.5https://www.biopharmawatch.com/news/GMAB/passing-of-genmab-a-s-annual-general-meeting-company-announcement-at-genmab-a-s-annual-gen-gmab-20240313monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240311monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20240304monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240304monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20240302monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20240229monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20240227monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240226monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20240223monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-management-and-employees-and-grant-of-warrants-to-emplo-gmab-20240223monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20240219monthly0.5https://www.biopharmawatch.com/news/GMAB/notice-to-convene-the-annual-general-meeting-of-genmab-a-s-company-announcement-genmab-a-s-gmab-20240216monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-initiation-of-share-buy-back-program-company-announcement-repurchase-of-u-gmab-20240214monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-2023-annual-report-table-of-contents-management-s-review-our-2030-vision-2-chair-s--gmab-20240214monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-2023-company-announcement-net-sales-gmab-20240123monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-decision-in-arbitration-appeal-under-license-agreement-with-janssen-compa-gmab-20240123monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20240103monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20231205monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-board-members-and-employees-and-grant-of-warrants-to-em-gmab-20231121monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20231109monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-nine-months-of-2023-gmab-20231107monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-third-quarter-of-2023-company-annou-gmab-20231017monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20230928monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-european-commission-approval-of-tepkinly-epcoritamab-for-adults-with-rela-gmab-20230925monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20230912monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-and-seagen-announce-that-tivdak-tisotumab-vedotin-tftv-met-its-primary-endpoint-of--gmab-20230904monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20230815monthly0.5https://www.biopharmawatch.com/news/GMAB/x200b-x200b-genmab-announces-financial-results-for-the-first-half-of-2023-x200b-gmab-20230803monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-updates-2023-financial-guidance-company-announcement-copenhagen-denmark-gmab-20230728monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-abbvie-receives-positive-chmp-opinion-for-epcoritamab-tepkinly-for-the-tr-gmab-20230721monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-second-quarter-of-2023-company-anno-gmab-20230720monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-and-abbvie-announce-positive-topline-results-from-phase-1-2-epcore-nhl-1-trial-eval-gmab-20230628monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcem-ent--gmab-20230620monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20230608monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20230601monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20230523monthly0.5https://www.biopharmawatch.com/news/GMAB/epkinly-epcoritamab-bysp-approved-by-u-s-food-and-drug-administration-as-the-first-and-onl-gmab-20230519monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-quarter-of-2023-gmab-202305102023-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-to-file-appeal-in-its-second-arbitration-under-license-agreement-with-janssen-compa-gmab-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-initial-resolution-of-its-second-arbitration-under-license-agreement-with-gmab-202304212023-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2023-company-annou-gmab-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/completion-of-share-buy-back-program-company-announcement-copenhagen-denmark-gmab-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/constitution-of-the-board-of-directors-in-genmab-a-s-grant-of-restricted-stock-units-to-ma-gmab-202303292023-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/passing-of-genmab-a-s-annual-general-meeting-company-announcement-at-genmab-a-s-annual-gen-gmab-202303292023-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-202303202023-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-202303132023-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-copenhagen-denmark-gmab-202302282023-02-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-management-and-employees-and-grant-of-warrants-to-emplo-gmab-202302242023-02-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/notice-to-convene-the-annual-general-meeting-of-genmab-a-s-company-announcement-genmab-a-s-gmab-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-initiation-of-share-buy-back-program-company-announcement-repurchase-of-u-gmab-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-2022-annual-report-table-of-contents-management-s-review-our-vision-2-chair-s-state-gmab-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-202301242023-01-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-2022-company-announcement-net-sales-gmab-202301242023-01-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/correction-to-company-announcement-no-1-of-gmab-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20221214monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20221213monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20221123monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-board-members-and-employees-and-grant-of-warrants-to-em-gmab-20221121monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20221115monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20221114monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-nine-months-of-2022-gmab-20221109monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-improves-its-2022-financial-guidance-company-announcement-genmab-improves-its-2022--gmab-20221103monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-the-third-quarter-of-2022-company-a-gmab-20221018monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20221005monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20220927monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20220920monthly0.5https://www.biopharmawatch.com/news/GMAB/completion-of-share-buy-back-program-company-announcement-copenhagen-denmark-gmab-20220901monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220829monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20220824monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220822monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20220817monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20220816monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220815monthly0.5https://www.biopharmawatch.com/news/GMAB/x200b-x200b-genmab-announces-financial-results-for-the-first-half-of-2022-x200b-gmab-20220810monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-improves-its-2022-financial-guidance-company-announcement-genmab-improves-its-2022--gmab-20220808monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220808monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20220802monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220801monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220725monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20220720monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-the-second-quarter-of-2022-company--gmab-20220719monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-that-abbvie-will-submit-marketing-authorization-application-to-european-m-gmab-20220718monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220718monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20220711monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220711monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20220705monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220704monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20220701monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-to-submit-biologics-license-application-to-u-s-food-and-drug-administration-for-epc-gmab-20220630monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20220627monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20220623monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20220620monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-initiation-of-share-buy-back-program-company-announcement-repurchase-of-u-gmab-20220617monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-commences-new-arbitration-under-license-agreement-with-janssen-company-announcement-gmab-20220609monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20220609monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20220601monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20220517monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-quarter-of-2022-gmab-20220511monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2022-company-annou-gmab-20220419monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-and-abbvie-announce-topline-results-for-epcoritamab-duobody-cd3xcd20-from-phase-1-2-gmab-20220413monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-the-initial-resolution-of-its-arbitration-with-janssen-relating-to-their--gmab-20220408monthly0.5https://www.biopharmawatch.com/news/GMAB/constitution-of-the-board-of-directors-in-genmab-a-s-grant-of-restricted-stock-units-to-th-gmab-20220329monthly0.5https://www.biopharmawatch.com/news/GMAB/passing-of-genmab-a-s-annual-general-meeting-company-announcement-at-genmab-a-s-annual-gen-gmab-20220329monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-the-nomination-of-a-new-member-of-the-company-s-board-of-directors-compan-gmab-20220314monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-management-and-employees-and-grant-of-warrants-to-emplo-gmab-20220225monthly0.5https://www.biopharmawatch.com/news/GMAB/notice-to-convene-the-annual-general-meeting-of-genmab-a-s-company-announcement-genmab-a-s-gmab-20220224monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20220222monthly0.5https://www.biopharmawatch.com/news/GMAB/12-31-2021-fy-false-p5y-0-0225-0-p5y-p1y-p5y-3-genmab-a-s-6-k-2021-12-31-0001434265-gmab-r-gmab-20220216monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20220126monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20220125monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-2021-company-announcement-net-sales-gmab-20220125monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20220104monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20211214monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-board-members-and-employees-and-grant-of-warrants-to-em-gmab-20211122monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20211116monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-nine-months-of-2021-gmab-20211110monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-improves-its-2021-financial-guidance-company-announcement-genmab-improves-its-2021--gmab-20211104monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-the-third-quarter-of-2021-company-a-gmab-20211019monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20211007monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20210921monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-and-seagen-announce-fda-accelerated-approval-for-tivdak-tm-tisotumab-vedotin-tftv-i-gmab-20210920monthly0.5https://www.biopharmawatch.com/news/GMAB/the-board-of-directors-shall-receive-an-annual-remuneration-the-size-of-which-shall-be-sta-gmab-20210817monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20210817monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-half-of-2021-gmab-20210811monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20210721monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-the-second-quarter-of-2021-company--gmab-20210721monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20210706monthly0.5https://www.biopharmawatch.com/news/GMAB/completion-of-share-buy-back-program-company-announcement-copenhagen-denmark-gmab-20210701monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210628monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20210622monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-that-janssen-has-received-european-marketing-authorizations-for-darzalex--gmab-20210622monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210621monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210616monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210614monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210610monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210607monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210531monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210525monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-that-janssen-has-received-positive-chmp-opinion-recommending-darzalex-dar-gmab-20210521monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210521monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210519monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210517monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210512monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20210511monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210510monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210507monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-quarter-of-2021-gmab-20210505monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210503monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210503monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210426monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2021-company-annou-gmab-20210420monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210419monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210406monthly0.5https://www.biopharmawatch.com/news/GMAB/constitution-of-the-board-of-directors-in-genmab-a-s-and-grant-of-restricted-stock-units-a-gmab-20210413monthly0.5https://www.biopharmawatch.com/news/GMAB/passing-of-genmab-a-s-annual-general-meeting-company-announcement-at-genmab-a-s-annual-gen-gmab-20210413monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210412monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-and-seagen-announce-u-s-fda-filing-acceptance-for-priority-review-of-tisotumab-vedo-gmab-20210409monthly0.5https://www.biopharmawatch.com/news/GMAB/a-appendix-share-buy-back-programme-specification-for-march-29-to-31-2021-43-2029-xcse-202-gmab-20210406monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-european-marketing-authorization-for-kesimpta-ofatumumab-in-relapsing-mul-gmab-20210330monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210329monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210322monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210315monthly0.5https://www.biopharmawatch.com/news/GMAB/notice-to-convene-the-annual-general-meeting-of-genmab-a-s-company-announcement-genmab-a-s-gmab-20210309monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210308monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210307monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20210302monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-in-connection-with-share-buy-back-program-company-announcement-copenhagen-den-gmab-20210301monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-management-and-employees-and-grant-of-warrants-to-emplo-gmab-20210226monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210225monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-initiation-of-share-buy-back-program-company-announcement-repurchase-of-u-gmab-20210223monthly0.5https://www.biopharmawatch.com/news/GMAB/a-delivering-on-our-commitment-2020-annual-report-genmab-a-s-cvr-no-21-02-38-84-table-of-c-gmab-20210223monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-appointment-of-tahamtan-ahmadi-to-newly-created-position-of-chief-medical-gmab-20210222monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-and-seagen-submit-tisotumab-vedotin-biologics-license-application-to-the-u-s-fda-fo-gmab-20210210monthly0.5https://www.biopharmawatch.com/news/GMAB/chmp-issues-positive-opinion-recommending-ofatumumab-in-relapsing-multiple-sclerosis-compa-gmab-20210129monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20210128monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210127monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-2020-net-sales-of-darzalex-daratumumab-company-announcement-net-sales-of--gmab-20210126monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-that-janssen-has-been-granted-u-s-fda-approval-for-darzalex-faspro-daratu-gmab-20210115monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-achieves-usd-40-million-milestone-in-collaboration-with-abbvie-company-announcement-gmab-20210113monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20210105monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-board-members-and-employees-and-grant-of-warrants-to-em-gmab-20201215monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-enapotamab-vedotin-update-company-announcement-genmab-will-not-advance-th-gmab-20201124monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20201110monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-phase-3-study-evaluating-epcoritamab-in-patients-with-relapsed-or-refract-gmab-20201105monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-nine-months-of-2020-gmab-20201104monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-ifm-hovon-and-janssen-achieve-positive-topline-results-in-second-part-of--gmab-20201021monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-daratumumab-for-third-quarter-of-2020-company-annou-gmab-20201013monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20201007monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20200930monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20200929monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-commences-binding-arbitration-of-two-matters-under-license-agreement-with-janssen-c-gmab-20200922monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-janssen-granted-u-s-fda-approval-for-darzalex-daratumumab-in-combination--gmab-20200820monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-plan-to-transition-arzerra-ofatumumab-to-an-oncology-access-program-for-c-gmab-20200820monthly0.5https://www.biopharmawatch.com/news/GMAB/u-s-fda-approves-kesimpta-ofatumumab-in-relapsing-multiple-sclerosis-company-announcement--gmab-20200820monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20200818monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-half-of-2020-gmab-20200812monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-european-myeloma-network-and-janssen-achieve-positive-topline-results-fro-gmab-20200731monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20200720monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-for-the-second-quarter-of-2020-company-announcement-gmab-20200716monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20200707monthly0.5https://www.biopharmawatch.com/news/GMAB/major-shareholder-announcement-company-announcement-major-shareholder-announcement-for-gen-gmab-20200703monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20200630monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-very-favorable-topline-results-from-phase-2-clinical-trial-of-tisotumab-v-gmab-20200629monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-and-abbvie-announce-broad-oncology-collaboration-company-announcement-xb7-genmab-an-gmab-20200610monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-european-marketing-authorization-for-the-subcutaneous-formulation-of-darz-gmab-20200604monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-company-announcement-c-gmab-20200603monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-positive-topline-results-in-phase-iii-andromeda-study-of-daratumumab-in-l-gmab-20200528monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20200512monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-quarter-of-2020-gmab-20200506monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-u-s-fda-approval-of-subcutaneous-formulation-of-daratumumab-darzalex-fasp-gmab-20200501monthly0.5https://www.biopharmawatch.com/news/GMAB/chmp-issues-positive-opinion-recommending-subcutaneous-formulation-of-daratumumab-for-the--gmab-20200430monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-xae-daratumumab-for-first-quarter-of-2020-company-a-gmab-20200414monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20200401monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20200331monthly0.5https://www.biopharmawatch.com/news/GMAB/constitution-of-the-board-of-directors-in-genmab-a-s-grant-of-restricted-stock-units-to-th-gmab-20200326monthly0.5https://www.biopharmawatch.com/news/GMAB/passing-of-genmab-a-s-annual-general-meeting-company-announcement-xb7-at-genmab-a-s-annual-gmab-20200326monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-a-s-provides-update-to-annual-general-meeting-media-release-copenhagen-denmark-gmab-20200312monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-appointment-of-anthony-mancini-to-newly-created-position-of-chief-operati-gmab-20200310monthly0.5https://www.biopharmawatch.com/news/GMAB/notice-to-convene-the-annual-general-meeting-of-genmab-a-s-company-announcement-xb7-genmab-gmab-20200227monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20200226monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20200225monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-board-of-directors-chairman-to-step-down-company-announcement-copenhagen-denmark-gmab-20200221monthly0.5https://www.biopharmawatch.com/news/GMAB/innovating-antibodies-improving-lives-annual-report-2019-genmab-a-s-cvr-no-21-02-38-84-tab-gmab-20200219monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-2019-net-sales-figures-for-darzalex-xae-daratumumab-and-achievement-of-us-gmab-20200122monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-european-marketing-authorization-for-darzalex-xae-daratumumab-in-combinat-gmab-20200120monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20200102monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20191220monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-and-curevac-enter-strategic-partnership-to-develop-mrna-based-antibody-therapeutics-gmab-20191219monthly0.5https://www.biopharmawatch.com/news/GMAB/chmp-issues-positive-opinion-recommending-darzalex-xae-daratumumab-in-combination-with-bor-gmab-20191213monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20191205monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-to-board-members-management-and-employees-and-grant-of-war-gmab-20191205monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-achieves-usd-100-million-sales-milestone-in-darzalex-xae-daratumumab-collaboration--gmab-20191205monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-european-marketing-authorization-for-darzalex-xae-daratumumab-in-combinat-gmab-20191119monthly0.5https://www.biopharmawatch.com/news/GMAB/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees--gmab-20191112monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20191112monthly0.5https://www.biopharmawatch.com/news/GMAB/interim-report-for-the-nine-months-ended-gmab-20191106monthly0.5https://www.biopharmawatch.com/news/GMAB/david-eatwell-to-retire-as-chief-financial-officer-of-genmab-company-announcement-xb7-davi-gmab-20191030monthly0.5https://www.biopharmawatch.com/news/GMAB/chmp-issues-positive-opinion-recommending-darzalex-xae-daratumumab-in-combination-with-len-gmab-20191018monthly0.5https://www.biopharmawatch.com/news/GMAB/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-copenhagen-denmark-gmab-20191011monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-net-sales-of-darzalex-xae-daratumumab-for-third-quarter-of-2019-company-a-gmab-20191015monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20191001monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-u-s-fda-approval-of-darzalex-xae-daratumumab-in-combination-with-bortezom-gmab-20190926monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-positive-topline-results-in-phase-iii-study-of-daratumumab-in-combination-gmab-20190913monthly0.5https://www.biopharmawatch.com/news/GMAB/detailed-results-from-the-phase-iii-asclepios-i-ii-studies-of-ofatumumab-in-patients-with--gmab-20190913monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-s-partner-for-ofatumumab-novartis-reports-that-ofatumumab-demonstrates-superiority--gmab-20190830monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-approval-of-darzalex-xae-daratumumab-in-frontline-multiple-myeloma-in-jap-gmab-20190822monthly0.5https://www.biopharmawatch.com/news/GMAB/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise-company-announcement-c-gmab-20190820monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-financial-results-for-the-first-half-of-2019-and-updates-2019-financial-g-gmab-20190814monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-the-closing-of-over-allotment-option-in-initial-public-offering-of-americ-gmab-20190723monthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-announces-the-completion-of-its-initial-public-offering-of-american-depositary-shar-gmab-20190722monthly0.5https://www.biopharmawatch.com/news/FMS/bad-homburg-v-d-h-he-fms-20260528monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-sven-jacobse-fms-20260521monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20260505monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-hof-saale-isin-de0005785802-wkn-578580-isin-us3580291066-cusip-3-fms-20260414monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20260224monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-is-continuing-its-share-buyback-program-in-an-accelerated-manner-fms-20260109monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20251210monthly0.5https://www.biopharmawatch.com/news/FMS/not-for-release-publication-or-distribution-directly-or-indirectly-in-or-into-the-united-s-fms-20251117monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20251104monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20251001monthly0.5https://www.biopharmawatch.com/news/FMS/kirsten-stratton-t-1-781-929-8096-kirsten-stratton-freseniusmedicalcare-com-christine-pete-fms-20250918monthly0.5https://www.biopharmawatch.com/news/FMS/bad-homburg-v-d-h-he-fms-20250811monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20250805monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-resolves-share-buyback-program-with-a-total-volume-of-eur-1-bill-fms-20250617monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-emanuela-car-fms-20250604monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-sven-jacobse-fms-20250522monthly0.5https://www.biopharmawatch.com/news/FMS/countermotions-submitted-by-the-association-of-critical-shareholders-dachverband-der-kriti-fms-20250514monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20250506monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-fresenius-medical-care-ag-hof-saale-isin-de0005785802-wkn-578580-i-fms-20250410monthly0.5https://www.biopharmawatch.com/news/FMS/not-for-distribution-in-or-into-or-to-any-person-located-or-resident-in-the-united-states--fms-20250408monthly0.5https://www.biopharmawatch.com/news/FMS/not-for-distribution-in-or-into-or-to-any-person-located-or-resident-in-the-united-states--fms-20250402monthly0.5https://www.biopharmawatch.com/news/FMS/not-for-release-publication-or-distribution-directly-or-indirectly-in-or-into-the-united-s-fms-20250401monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20250225monthly0.5https://www.biopharmawatch.com/news/FMS/fme-media-contact-christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcar-fms-20250224monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20241220monthly0.5https://www.biopharmawatch.com/news/FMS/notice-relating-to-eur-500-000-000-1-500-bonds-2018-2025-xs1854532949-eur-600-000-000-0-62-fms-20241218monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-fresenius-medical-care-ag-hof-isin-de0005785802-wkn-578580-isin-us-fms-20241212monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20241105monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20240730monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20240523monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20240516monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20240507monthly0.5https://www.biopharmawatch.com/news/FMS/8764-fresenius-medical-register-vif-proof-2-annual-general-meeting-of-fresenius-medical-ca-fms-20240503monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-hof-saale-isin-de0005785802-wkn-578580-isin-us3580291066-cusip-3-fms-20240328monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20240313monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20240305monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-6066-770-christine-peters-freseniusmedicalcare-com-contact-for-a-fms-20240220monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-emanuela-car-fms-20240208monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-160-60-66-770-christine-peters-freseniusmedicalcare-com-contact-for--fms-20240205monthly0.5https://www.biopharmawatch.com/news/FMS/christine-peters-t-49-151-215-275-19-christine-peters-freseniusmedicalcare-com-contact-for-fms-20240108monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-hof-notification-of-impending-merger-pursuant-to-section-62-3-se-fms-20231207monthly0.5https://www.biopharmawatch.com/news/FMS/commercial-register-b-of-the-local-court-of-hof-company-number-hrb-6841-page-1-of-1-retrie-fms-20231130monthly0.5https://www.biopharmawatch.com/news/FMS/ad-hoc-release-fresenius-medical-care-ag-co-kgaa-favorable-settlement-agreement-with-u-s-g-fms-20231121monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-hof-isin-de0005785802-wkn-578580-isin-us3580291066-cusip-fms-20231113monthly0.5https://www.biopharmawatch.com/news/FMS/leif-heussen-t-49-6172-608-4030-leif-heussen-fresenius-com-contact-for-analysts-and-invest-fms-20231101monthly0.5https://www.biopharmawatch.com/news/FMS/adhoc-release-fresenius-medical-care-ag-co-kgaa-raises-outlook-for-operating-income-in-fis-fms-20231101monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-hof-isin-de0005785802-wkn-578580-isin-us3580291066-cusip-fms-20230906monthly0.5https://www.biopharmawatch.com/news/FMS/leif-heussen-t-49-6172-608-4030-leif-heussen-fresenius-com-contact-for-analysts-and-invest-fms-20230802monthly0.5https://www.biopharmawatch.com/news/FMS/steffen-rinas-t-49-6172-608-6698-steffen-rinas-fresenius-com-contact-for-analysts-and-inve-fms-20230714monthly0.5https://www.biopharmawatch.com/news/FMS/steffen-rinas-t-49-6172-608-6698-steffen-rinas-fresenius-com-contact-for-analysts-and-inve-fms-20230710monthly0.5https://www.biopharmawatch.com/news/FMS/content-statement-of-earnings-page-2-segment-information-page-3-balance-sheet-page-4-cash--fms-20230602monthly0.5https://www.biopharmawatch.com/news/FMS/filed-by-fresenius-medical-care-ag-co-kgaa-commission-file-no-001-32749-pursuant-to-rules--fms-20230605monthly0.5https://www.biopharmawatch.com/news/FMS/leif-heussen-t-49-6172-608-4030-leif-heussen-fresenius-com-contact-for-analysts-and-invest-fms-20230516monthly0.5https://www.biopharmawatch.com/news/FMS/leif-heussen-t-49-6172-608-4030-leif-heussen-fresenius-com-contact-for-analysts-and-invest-fms-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-register-vif-proof-3-annual-general-meeting-of-fresenius-medical-care-ag-fms-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FMS/invitation-to-the-annual-general-meeting-t-u-es-day-1-6-m-ay-2023-invitation-03-invitation-fms-202303302023-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FMS/martin-kunze-t-49-6172-608-2115-martin-kunze-fresenius-com-contact-for-analysts-and-invest-fms-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FMS/martin-kunze-t-49-6172-608-2115-martin-kunze-fresenius-com-contact-for-analysts-and-invest-fms-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FMS/ad-hoc-announcement-according-to-art-17-1-mar-february-9-th-2023-fresenius-medical-care-ag-fms-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FMS/ad-hoc-announcement-according-to-art-17-1-mar-media-contact-steffen-rinas-t-49-6172-608-66-fms-20221206monthly0.5https://www.biopharmawatch.com/news/FMS/ad-hoc-announcement-according-to-art-17-1-mar-media-contact-matthias-link-t-49-6172-609-28-fms-20221031monthly0.5https://www.biopharmawatch.com/news/FMS/not-for-release-publication-or-distribution-directly-or-indirectly-in-or-into-the-united-s-fms-20220912monthly0.5https://www.biopharmawatch.com/news/FMS/martin-kunze-t-49-6172-608-2115-martin-kunze-fresenius-com-contact-for-analysts-and-invest-fms-20220824monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20220802monthly0.5https://www.biopharmawatch.com/news/FMS/ad-hoc-announcement-according-to-art-17-1-mar-media-contact-matthias-link-t-49-6172-609-28-fms-20220728monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-holdings-inc-and-subsidiaries-consolidated-financial-statements-fms-20220517monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20220512monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20220504monthly0.5https://www.biopharmawatch.com/news/FMS/ad-hoc-announcement-according-to-art-17-1-mar-media-contact-matthias-link-t-49-6172-609-28-fms-20220503monthly0.5https://www.biopharmawatch.com/news/FMS/invitation-to-the-annual-general-meeting-fresenius-medical-care-ag-co-kgaa-hof-an-der-saal-fms-20220330monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20220321monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20220223monthly0.5https://www.biopharmawatch.com/news/FMS/martin-kunze-t-49-6172-609-2115-martin-kunze-fresenius-com-contact-for-analysts-and-invest-fms-20211201monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20211102monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20210730monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20210702monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20210520monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20210514monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20210506monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-holdings-inc-and-subsidiaries-consolidated-financial-statements-fms-20210504monthly0.5https://www.biopharmawatch.com/news/FMS/annual-general-meeting-of-fresenius-medical-care-ag-co-kgaa-to-be-held-fms-20210503monthly0.5https://www.biopharmawatch.com/news/FMS/invitation-to-the-annual-general-meeting-fresenius-medical-care-ag-co-kgaa-hof-an-der-saal-fms-20210407monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20210224monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20210201monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20201029monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20201008monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20200910monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20200827monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20200730monthly0.5https://www.biopharmawatch.com/news/FMS/invitation-to-the-annual-general-meeting-fresenius-medical-care-ag-co-kgaa-hof-an-der-saal-fms-20200717monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20200521monthly0.5https://www.biopharmawatch.com/news/FMS/not-for-release-publication-or-distribution-directly-or-indirectly-in-or-into-the-united-s-fms-20200519monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-holdings-inc-and-subsidiaries-consolidated-financial-statements-dec-fms-20200519monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20200506monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-608-2115-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20200221monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20200219monthly0.5https://www.biopharmawatch.com/news/FMS/not-for-release-publication-or-distribution-directly-or-indirectly-in-or-into-the-united-s-fms-20191120monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fmc-ag-com-contact-for-analysts-and-investo-fms-20191029monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190827monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190730monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-group-matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com--fms-20190710monthly0.5https://www.biopharmawatch.com/news/FMS/martin-kunze-t-49-6172-609-2115-martin-kunze-fresenius-com-contact-for-analysts-and-invest-fms-20190614monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190523monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190516monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190502monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-holdings-inc-and-subsidiaries-consolidated-financial-statements-fms-20190430monthly0.5https://www.biopharmawatch.com/news/FMS/annual-general-meeting-2-0-1-9-invitation-to-the-annual-general-meeting-on-16-may-2019-fre-fms-20190410monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190329monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-fresenius-medical-care-north--fms-20190226monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-608-2115-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190221monthly0.5https://www.biopharmawatch.com/news/FMS/ad-hoc-announcement-according-media-contact-to-art-17-1-mar-matthias-link-t-49-6172-609-28-fms-20190220monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190129monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20190102monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20181206monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20181107monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20181029monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20181016monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20180731monthly0.5https://www.biopharmawatch.com/news/FMS/not-for-release-publication-or-distribution-directly-or-indirectly-in-or-into-the-united-s-fms-20180704monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-holdings-inc-and-subsidiaries-consolidated-financial-statements-fms-20180629monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20180628monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-fresen-fms-20180611monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20180503monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20180421monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-register-vif-proof-2-ordinary-general-meeting-of-fresenius-medical-care--fms-20180419monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-invitation-to-the-annual-general-meeting-fresenius-medical-care-ag-fms-20180403monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20180227monthly0.5https://www.biopharmawatch.com/news/FMS/ad-hoc-announcement-according-to-art-17-1-mar-media-contact-matthias-link-t-49-6172-609-28-fms-20180226monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20171222monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20171212monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20171127monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20171102monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-fresenius-medical-care-north--fms-20171027monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20170928monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20170801monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20170712monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20170608monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20170512monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-t-49-6172-609-2872-matthias-link-fresenius-com-contact-for-analysts-and-inve-fms-20170503monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-invitation-to-the-annual-general-meeting-fresenius-medical-care-ag-fms-20170411monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-dr-dominik-heger-head-of-investor-relations-corporate-communications-freseni-fms-20170405monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-register-vif-proof-3-ordinary-general-meeting-of-fresenius-medical-care--fms-20170411monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-invitation-to-the-annual-general-meeting-fresenius-medical-care-ag-fms-20170330monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-dr-dominik-heger-head-of-investor-relations-corporate-communications-freseni-fms-20170222monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-dr-dominik-heger-head-of-investor-relations-corporate-communications-freseni-fms-20170131monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-dr-dominik-heger-head-of-investor-relations-corporate-communications-freseni-fms-20170126monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-cms-tro-release-update-fms-20170113monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-dr-dominik-heger-head-of-investor-relations-corporate-communications-freseni-fms-20170113monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-impact-of-potential-regulation-change-centers-for-medicare-and-medi-fms-20170109monthly0.5https://www.biopharmawatch.com/news/FMS/announcement-fresenius-medical-care-will-focus-on-ifrs-reporting-and-discontinue-u-s-gaap--fms-20161201monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-third-quarter-2016-fms-20161027monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-second-quarter-half-year-2016-fms-20160801monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-register-vif-proof-6-ordinary-general-meeting-of-fresenius-medical-care--fms-20160411monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-invitation-to-the-annual-general-meeting-fresenius-medical-care-ag-fms-20160401monthly0.5https://www.biopharmawatch.com/news/FMS/joachim-weith-senior-vice-president-corporate-communications-governmental-affairs-freseniu-fms-20160311monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20160225monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20160217monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20160128monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20150921monthly0.5https://www.biopharmawatch.com/news/FMS/this-announcement-is-being-filed-as-a-matter-of-record-only-it-is-not-intended-for-publica-fms-20150520monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-corporate-communications-fresenius-medical-care-else-kr-ner-stra-e-1-61352-b-fms-20150519monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-plan-vif-proof-7-ordinary-general-meeting-of-fresenius-medical-care-ag-c-fms-20150416monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-convening-of-th-fms-20150407monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20141127monthly0.5https://www.biopharmawatch.com/news/FMS/oliver-maier-investor-news-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20141113monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20141024monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20141022monthly0.5https://www.biopharmawatch.com/news/FMS/this-announcement-is-being-filed-as-a-matter-of-record-only-it-is-not-intended-for-publica-fms-20141009monthly0.5https://www.biopharmawatch.com/news/FMS/this-announcement-is-being-filed-as-a-matter-of-record-only-it-is-not-intended-for-publica-fms-20140916monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20140627monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-corporate-communications-fresenius-medical-care-else-kr-ner-stra-e-1-61352-b-fms-20140515monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-vif-proof-2-ordinary-general-meeting-of-fresenius-medical-care-ag-co-kga-fms-20140414monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20140404monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-convening-of-th-fms-20140402monthly0.5https://www.biopharmawatch.com/news/FMS/corporate-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner--fms-20140312monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20140226monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-reports-full-year-2013-results-and-provides-outlook-for-2014-fresen-fms-20140225monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20131105monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20130730monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-isin-de0005785802-securities-identifica-fms-20130703monthly0.5https://www.biopharmawatch.com/news/FMS/matthias-link-corporate-communications-fresenius-medical-care-else-kr-ner-stra-e-1-61352-b-fms-20130516monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20130430monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-common-proof-7-ordinary-general-meeting-of-fresenius-medical-care-ag-co-kgaa-dat-fms-20130418monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-convening-of-th-fms-20130408monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20130404monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20130314monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20130227monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20121221monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20121213monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20121210monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20121031monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20120917monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20120801monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20120627monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-oliver-maier-head-of-investor-relations-fresenius-medical-care-else-kr-ner-s-fms-20120503monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-else-kr-ner-stra-e-1-61352-bad-homburg-ger-fms-20120426monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-shareholder-motions-all-counter-motions-and-proposals-fo-fms-20120406monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-else-kr-ner-stra-e-1-61352-bad-homburg-ger-fms-20120402monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-convening-of-th-fms-20120329monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20120309monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20120229monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20120227monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20120224monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20120221monthly0.5https://www.biopharmawatch.com/news/FMS/unassociated-document-contact-fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-s-fms-20120118monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20120117monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20111220monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20111102monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20111010monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20110908monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20110818monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20110802monthly0.5https://www.biopharmawatch.com/news/FMS/unassociated-document-contact-fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-s-fms-20110701monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-isin-de0005785802-wkn-578580-isin-de000-fms-20110512monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20110504monthly0.5https://www.biopharmawatch.com/news/FMS/supplemental-information-in-this-letter-1-fmc-ag-co-kgaa-the-company-we-or-our-refer-to-fr-fms-20110411monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-convening-of-th-fms-20110401monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-oliver-maier-else-kr-ner-str-1-phone-49-6172-609-2601-61-fms-20110224monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-61352-fms-20110127monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-61352-fms-20110121monthly0.5https://www.biopharmawatch.com/news/FMS/press-release-fresenius-medical-care-north-america-initiates-voluntary-recall-of-combiset--fms-20110114monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-61352-fms-20110104monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-61352-fms-20101201monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-61352-fms-20101102monthly0.5https://www.biopharmawatch.com/news/FMS/unassociated-document-fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-e-fms-20101001monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-d-613-fms-20100826monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-61352-fms-20100803monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-61352-fms-20100723monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-d-613-fms-20100504monthly0.5https://www.biopharmawatch.com/news/FMS/supplemental-information-as-a-foreign-private-issuer-under-the-rules-and-regulations-of-th-fms-20100413monthly0.5https://www.biopharmawatch.com/news/FMS/convenience-translation-fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-invitation-to-o-fms-20100326monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20100225monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20100114monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20100111monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-d-613-fms-20091209monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20091103monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20090804monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20090430monthly0.5https://www.biopharmawatch.com/news/FMS/supplemental-information-as-a-foreign-private-issuer-under-the-rules-and-regulations-of-th-fms-20090406monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-invitation-to-ordinary-general-meeting--fms-20090324monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-d-613-fms-20090310monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20090223monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20090219monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20081104monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20080916monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20080730monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20080717monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20080430monthly0.5https://www.biopharmawatch.com/news/FMS/supplemental-information-as-a-foreign-private-issuer-under-the-rules-and-regulations-of-th-fms-20080418monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-invitation-to-ordinary-general-meeting--fms-20080407monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20080407monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20080402monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20080220monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20071129monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20071031monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-d-613-fms-20070802monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20070626monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20070618monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-news-investor-relations-else-kr-ner-str-1-d-613-fms-20070615monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20070502monthly0.5https://www.biopharmawatch.com/news/FMS/exhibit-1-fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-invitation-to-ordinary-genera-fms-20070402monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20070321monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20070222monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20070201monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20070116monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20070109monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-investor-relations-investor-news-else-kr-ner-str-1-d-613-fms-20060803monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20060602monthly0.5https://www.biopharmawatch.com/news/FMS/investor-news-fresenius-medical-care-ag-co-kgaa-investor-relations-else-kr-ner-str-1-d-613-fms-20060503monthly0.5https://www.biopharmawatch.com/news/FMS/graphic-omitted-fresenius-medical-care-investor-news-fresenius-medical-care-ag-co-kgaa-inv-fms-20060407monthly0.5https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-ag-co-kgaa-hof-an-der-saale-invitation-to-ordinary-general-meeting--fms-20060407monthly0.5https://www.biopharmawatch.com/news/FMS/graphic-omitted-fresenius-medical-care-investor-news-fresenius-medical-care-ag-co-kgaa-inv-fms-20060331monthly0.5https://www.biopharmawatch.com/news/FMS/graphic-omitted-fresenius-medical-care-press-release-contact-contact-oliver-maier-heinz-sc-fms-20060315monthly0.5https://www.biopharmawatch.com/news/FMS/graphic-omitted-fresenius-medical-care-investor-news-fresenius-medical-care-ag-co-kgaa-inv-fms-20060228monthly0.5https://www.biopharmawatch.com/news/FMS/graphic-omitted-fresenius-medical-care-investor-news-fresenius-medical-care-ag-co-kgaa-inv-fms-20060222monthly0.5https://www.biopharmawatch.com/news/FMS/graphic-omitted-fresenius-medical-care-investor-news-fresenius-medical-care-ag-co-kgaa-inv-fms-20060215monthly0.5https://www.biopharmawatch.com/news/FMS/graphic-omitted-fresenius-medical-care-investor-news-fresenius-medical-care-ag-co-kgaa-inv-fms-20060213monthly0.5https://www.biopharmawatch.com/news/BTSG/leigh-white-leigh-white-brightspringhealth-com-502-630-7412-brightspring-health-services-c-btsg-20260331monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-third-quarter-2025-financial-results-and-increase-btsg-20251028monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-preliminary-third-quarter-2025-financial-results--btsg-20251020monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-second-quarter-2025-financial-results-and-increas-btsg-20250801monthly0.5https://www.biopharmawatch.com/news/BTSG/item-7-management-s-discussion-and-analysis-of-financial-condition-and-results-of-operatio-btsg-20250610monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-first-quarter-2025-financial-results-and-increase-btsg-20250502monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-fourth-quarter-and-full-year-2024-financial-resul-btsg-20250306monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-announces-promotion-of-jennifer-phipps-to-chief-financial-btsg-20250305monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-enters-into-definitive-agreement-to-divest-community-livi-btsg-20250121monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-announced-refinancing-of-term-loan-b-louisville-kentucky-btsg-20241211monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-third-quarter-2024-financial-results-and-increase-btsg-20241101monthly0.5https://www.biopharmawatch.com/news/BTSG/leigh-white-leigh-white-brightspringhealth-com-502-630-7412-brightspring-health-services-i-btsg-20240930monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-second-quarter-2024-financial-results-and-increas-btsg-20240802monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-first-quarter-2024-financial-results-and-increase-btsg-20240502monthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-financial-results-for-fourth-quarter-and-full-yea-btsg-20240229monthly0.5https://www.biopharmawatch.com/news/PRAX/document-praxis-precision-medicines-highlights-2025-corporate-strategy-and-business-priori-prax-20250112monthly0.5https://www.biopharmawatch.com/news/PRAX/relutrigine-embold-phase-2-study-topline-results-prax-20240903monthly0.5https://www.biopharmawatch.com/news/PRAX/document-unaudited-selected-financial-data-amounts-in-thousands-except-share-and-per-share-prax-20231128monthly0.5https://www.biopharmawatch.com/news/PRAX/document-prax-20230303monthly0.5https://www.biopharmawatch.com/news/PRAX/document-prax-20220810monthly0.5https://www.biopharmawatch.com/news/PRAX/document-praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-a-prax-20220228monthly0.5https://www.biopharmawatch.com/news/PRAX/page-1-confidential-corporate-overview-january-2-0-2-2-page-1-page-2-confidential-forward--prax-20220110monthly0.5https://www.biopharmawatch.com/news/PRAX/movementdisor-movement-disorder-day-friday-december-17-2021-2-this-presentation-may-contai-prax-20211217monthly0.5https://www.biopharmawatch.com/news/PRAX/document-praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-20-prax-20211103monthly0.5https://www.biopharmawatch.com/news/PRAX/document-praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2-prax-20210816monthly0.5https://www.biopharmawatch.com/news/PRAX/document-praxis-precision-medicines-appoints-tim-kelly-as-chief-financial-officer-prax-20210525monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-adds-neurology-expertise-to-board-of-directors-with-appointment-prax-20210429monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-adds-development-expertise-to-board-of-directors-with-appointme-prax-20210415monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-y-prax-20210317monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-cfo-transition-prax-20201201monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-update-on-prax-114-ind-submission-for-the-treatment-of-prax-20201117monthly0.5https://www.biopharmawatch.com/news/PRAX/from-fda-hhs-gov-sent-friday-prax-20201106monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20260507monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20260205monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20260107monthly0.5https://www.biopharmawatch.com/news/ARWR/document-arwr-20260106monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20251125monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20251118monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20250911monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20250902monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20250807monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20250512monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20250415monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20250210monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20241126monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20240808monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20240509monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20240206monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20231129monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20221128monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20220804monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20220510monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20220425monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20220202monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20211220monthly0.5https://www.biopharmawatch.com/news/ARWR/in-the-court-of-chancery-of-the-state-of-delaware-j-s-eppers-2005-revocable-trust-john-epp-arwr-20211216monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20211122monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20210805monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20210621monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20210504monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20210204monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20201123monthly0.5https://www.biopharmawatch.com/news/ARWR/takeda-and-arrowhead-collaborate-to-co-develop-and-co-commercialize-aro-aat-for-alpha-1-an-arwr-20201008monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20200805monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20200507monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20200205monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20191125monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20190805monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20190508monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20190207monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20181211monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20181004monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20180807monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20180508monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20180209monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20171212monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20170803monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20170503monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20170206monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20161214monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20161108monthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-arrowhead-amgen-collaboration-prepared-remarks-arwr-20160929monthly0.5https://www.biopharmawatch.com/news/ARWR/amgen-and-arrowhead-pharmaceuticals-announce-two-cardiovascular-collaborations-amgen-to-re-arwr-20160929monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20160809monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20160510monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20160209monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20151214monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20150804monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20150511monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20150209monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20141125monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20141008monthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-reports-fiscal-2014-third-quarter-financial-results-and-provides-update-on-arc-5-arwr-20140812monthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-reports-fiscal-2014-second-quarter-financial-results-conference-call-today-at-4--arwr-20140506monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20140204monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20131218monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20131008monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20130807monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20130509monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20130429monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20130213monthly0.5https://www.biopharmawatch.com/news/ARWR/investor-subscription-agreement-this-investor-subscription-agreement-this-agreement-is-ent-arwr-20130130monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-press-release-arwr-20121220monthly0.5https://www.biopharmawatch.com/news/ARWR/investor-subscription-agreement-this-investor-subscription-agreement-this-agreement-is-ent-arwr-20121212monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20120813monthly0.5https://www.biopharmawatch.com/news/ARWR/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-arwr-20120810monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20120508monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20120209monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20111220monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20110808monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20110512monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20110210monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20101222monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20100812monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20100513monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20100322monthly0.5https://www.biopharmawatch.com/news/ARWR/press-release-arwr-20100211monthly0.5https://www.biopharmawatch.com/news/CYTK/forward-looking-statements-this-presentation-contains-forward-looking-statements-for-purpo-cytk-20260505monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-proposed-private-placement-of-550-0-million-of-convertible-senior-n-cytk-20250916monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-related-to-aficamten-at-the-european-society-of-cardiology--cytk-20250902monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-primary-results-from-maple-hcm-presented-at-the-european-society-of-cytk-20250902monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-second-quarter-2025-financial-results-and-provides-business-update-re-cytk-20250807monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-first-quarter-2025-financial-results-and-provides-business-update-pdu-cytk-20250506monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-fourth-quarter-2024-financial-results-and-provides-business-update-co-cytk-20250227monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-second-quarter-2024-financial-results-type-b-meeting-held-with-fda-re-cytk-20240808monthly0.5https://www.biopharmawatch.com/news/CYTK/as-we-had-previously-stated-throughout-2023-cytokinetics-engaged-in-business-development-d-cytk-20240605monthly0.5https://www.biopharmawatch.com/news/CYTK/empowering-muscle-empowering-lives-forward-looking-statements-this-presentation-contains-f-cytk-20240522monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-primary-results-from-sequoia-hcm-presented-in-late-breaking-clinica-cytk-20240513monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-first-quarter-2024-financial-results-primary-results-and-two-addition-cytk-20240508monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-fourth-quarter-2023-financial-results-topline-results-from-sequoia-hc-cytk-20240227monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-third-quarter-2023-financial-results-on-track-for-topline-results-fro-cytk-20231102monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-all-rights-reserved-cytokinetics-and-the-c-shaped-logo-are-registered-tradema-cytk-20231019monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-second-quarter-2023-financial-results-completed-enrollment-in-sequoia-cytk-20230803monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-in-patients-with-non-obstructive-hcm-from-cohort-4-of-redwo-cytk-20230520monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-first-quarter-2023-financial-results-sequoia-hcm-nearing-completion-o-cytk-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-fourth-quarter-2022-financial-results-company-received-complete-respo-cytk-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/compensation-information-for-the-company-s-named-executive-officers-robert-i-blum-presiden-cytk-202302242023-02-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/forward-looking-statements-this-presentation-contains-forward-looking-statements-for-purpo-cytk-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-third-quarter-2022-financial-results-advisory-committee-meeting-to-re-cytk-20221103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-second-quarter-2022-financial-results-advisory-committee-meeting-to-r-cytk-20220804monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-cytk-20220629monthly0.5https://www.biopharmawatch.com/news/CYTK/program-to-begin-at-8-30-am-et-n-o-t-f-o-r-p-r-o-m-ot-io-n-a-l-u-s-e-f-o-r-i-n-v-e-s-t-o-r-cytk-20211007monthly0.5https://www.biopharmawatch.com/news/CYTK/forward-looking-statements-this-presentation-contains-forward-looking-statements-for-purpo-cytk-20210719monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-first-quarter-2026-results-sales-from-continuing-operations-of-2-7-billion--bax-20260430monthly0.5https://www.biopharmawatch.com/news/BAX/executive-summary-management-and-board-of-directors-andrew-hider-appointed-as-president-an-bax-20260319monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-cfo-transition-joel-grade-to-depart-as-baxter-cfo-anita-zielinski-named-i-bax-20260316monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-fourth-quarter-2025-results-fourth-quarter-sales-from-continuing-operations-bax-20260213monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-increase-in-maximum-tender-cap-for-1-915-senior-notes-due-2027-bax-20251119monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-tender-offers-for-2026-notes-and-2027-bax-20251119monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-third-quarter-2025-results-third-quarter-sales-from-continuing-operations-o-bax-20251030monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-second-quarter-2025-results-second-quarter-sales-from-continuing-operations-bax-20250731monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-appoints-andrew-hider-chief-executive-officer-deerfield-ill-july-7-2025-baxter-inte-bax-20250707monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-first-quarter-2025-results-first-quarter-sales-from-continuing-operations-o-bax-20250501monthly0.5https://www.biopharmawatch.com/news/BAX/stockholder-engagement-1-baxter-international-inc-march-2025-sa-f-e-ha-r-bo-r-stat-ement-2-bax-20250314monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-fourth-quarter-and-full-year-2024-results-fourth-quarter-sales-from-continu-bax-20250220monthly0.5https://www.biopharmawatch.com/news/BAX/unaudited-pro-forma-condensed-consolidated-financial-information-on-bax-20250206monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-ceo-retirement-and-appointment-of-coo-jos-joe-e-almeida-to-retire-as-chai-bax-20250203monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-third-quarter-2024-results-baxter-third-quarter-2024-sales-totaled-3-85-bil-bax-20241108monthly0.5https://www.biopharmawatch.com/news/BAX/supplemental-historical-financial-information-n-o-v-e-m-b-e-r-7-2-0-24-1-2-non-gaap-financ-bax-20241107monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-provides-update-on-north-cove-n-c-facility-and-hurricane-helene-relief-plans-for-co-bax-20240930monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-appoints-jeffrey-a-craig-to-its-board-addition-of-mr-craig-complements-current-boar-bax-20240909monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-definitive-agreement-to-divest-its-vantive-kidney-care-segment-to-carlyle-bax-20240813monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-second-quarter-2024-results-second-quarter-sales-from-continuing-operations-bax-20240806monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-first-quarter-2024-results-first-quarter-sales-from-continuing-operations-o-bax-20240502monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-fourth-quarter-and-full-year-2023-results-fourth-quarter-sales-from-continu-bax-20240208monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-third-quarter-2023-results-third-quarter-revenue-from-continuing-operations-bax-20231102monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-updates-to-its-board-of-directors-addition-of-stephen-h-rusckowski-comple-bax-20230821monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-second-quarter-2023-results-second-quarter-revenues-increased-3-on-a-report-bax-20230727monthly0.5https://www.biopharmawatch.com/news/BAX/saf-e-h-ar-b-o-r-s-tat-e-m-e-n-t-2baxter-international-this-presentation-includes-forward--bax-20230706monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-appoints-william-ampofo-to-its-board-addition-of-mr-ampofo-complements-and-expands--bax-20230629monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-signs-definitive-agreement-to-divest-its-biopharma-solutions-business-to-advent-int-bax-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-first-quarter-2023-results-first-quarter-revenue-of-3-65-billion-decreased--bax-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-fourth-quarter-and-full-year-2022-results-fourth-quarter-sales-of-3-9-billi-bax-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-strategic-actions-to-enhance-operational-effectiveness-accelerate-innovat-bax-202301062023-01-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-third-quarter-2022-results-third-quarter-revenue-of-3-8-billion-increased-1-bax-20221027monthly0.5https://www.biopharmawatch.com/news/BAX/fall-stockholder-engagement-baxter-international-inc-october-2022-safe-harbor-statement-th-bax-20220930monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-second-quarter-2022-results-second-quarter-revenue-of-3-75-billion-increase-bax-20220728monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-highlights-business-strategies-and-innovation-at-2022-investor-conference-company-t-bax-20220525monthly0.5https://www.biopharmawatch.com/news/BAX/unaudited-pro-forma-condensed-combined-financial-information-on-bax-20220428monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-first-quarter-2022-results-first-quarter-revenue-of-3-7-billion-increased-2-bax-20220428monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-ba-bax-20220217monthly0.5https://www.biopharmawatch.com/news/BAX/unaudited-pro-forma-condensed-combined-financial-information-on-bax-20211213monthly0.5https://www.biopharmawatch.com/news/BAX/unaudited-pro-forma-condensed-combined-financial-information-on-bax-20211115monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-ba-bax-20211028monthly0.5https://www.biopharmawatch.com/news/BAX/october-2021-baxter-international-inc-fall-shareholder-engagement-2-this-presentation-incl-bax-20211018monthly0.5https://www.biopharmawatch.com/news/BAX/baxter-lauren-russ-224-948-5353-media-baxter-com-hillrom-howard-karesh-312-819-7268-howard-bax-20210902monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-ba-bax-20210729monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-ba-bax-20210429monthly0.5https://www.biopharmawatch.com/news/BAX/document-baxter-international-inc-net-sales-by-segment-unaudited-in-millions-years-ended-d-bax-20210426monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-b-bax-20210216monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-ba-bax-20210204monthly0.5https://www.biopharmawatch.com/news/BAX/th-annual-j-p-morgan-healthcare-conference-jos-joe-e-almeida-chairman-chief-executive-offi-bax-20210111monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-b-bax-20201029monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-ba-bax-20201029monthly0.5https://www.biopharmawatch.com/news/BAX/august-2019-fall-shareholder-engagement-baxter-international-inc-october-2020-safe-harbor--bax-20200928monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-ba-bax-20200730monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3020-ba-bax-20200415monthly0.5https://www.biopharmawatch.com/news/BAX/safe-harbor-statement-this-presentation-includes-forward-looking-statements-concerning-bax-bax-20200421monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-b-bax-20200317monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-b-bax-20191231monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-b-bax-20191122monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-2304-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-b-bax-20191024monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-ba-bax-20190725monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-ba-bax-20190425monthly0.5https://www.biopharmawatch.com/news/BAX/steve-brett-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-ba-bax-20190131monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-b-bax-20181206monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-b-bax-20181031monthly0.5https://www.biopharmawatch.com/news/BAX/bill-rader-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-bax-bax-20180726monthly0.5https://www.biopharmawatch.com/news/BAX/bill-rader-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-bax-bax-20180426monthly0.5https://www.biopharmawatch.com/news/BAX/bill-rader-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-bax-bax-20180201monthly0.5https://www.biopharmawatch.com/news/BAX/bill-rader-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-bax-bax-20171025monthly0.5https://www.biopharmawatch.com/news/BAX/bill-rader-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-bax-bax-20170726monthly0.5https://www.biopharmawatch.com/news/BAX/bill-rader-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-bax-bax-20170717monthly0.5https://www.biopharmawatch.com/news/BAX/bill-rader-224-948-5353-media-baxter-com-investor-contact-clare-trachtman-224-948-3085-bax-bax-20170426monthly0.5https://www.biopharmawatch.com/news/BAX/bill-rader-224-948-5353-investor-contact-clare-trachtman-224-948-3085-baxter-appoints-dr-s-bax-20170208monthly0.5https://www.biopharmawatch.com/news/BAX/stacey-eisen-224-948-5353-investor-contact-clare-trachtman-224-948-3085-baxter-reports-201-bax-20170201monthly0.5https://www.biopharmawatch.com/news/BAX/deborah-spak-224-948-2349-investor-contact-clare-trachtman-224-948-3085-baxter-reports-thi-bax-20161025monthly0.5https://www.biopharmawatch.com/news/BAX/deborah-spak-224-948-2349-investor-contact-clare-trachtman-224-948-3085-baxter-reports-sec-bax-20160726monthly0.5https://www.biopharmawatch.com/news/BAX/deborah-spak-224-948-2349-investor-contact-clare-trachtman-224-948-3085-baxter-reports-fir-bax-20160426monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-chief-financial-officer-transition-michael-g-knell-co-crl-20250916monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-governance-updates-and-strategic-review-to-enhance-lo-crl-20250507monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2023-results-and-provide-crl-20240214monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-third-quarter-2023-results-third-quarter-revenue-of-1-crl-20231108monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-second-quarter-2023-results-second-quarter-revenue-of-crl-20230809monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-first-quarter-2023-results-first-quarter-revenue-of-1-crl-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2022-results-and-provide-crl-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-third-quarter-2022-results-third-quarter-revenue-of-9-crl-20221102monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-second-quarter-2022-results-second-quarter-revenue-of-crl-20220803monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-first-quarter-2022-results-first-quarter-revenue-of-9-crl-20220504monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2021-results-fourth-quar-crl-20220216monthly0.5https://www.biopharmawatch.com/news/CRL/aex991xcrljpm2022present-every-step-of-the-way-2022-charles-river-laboratories-internation-crl-20220111monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-third-quarter-2021-results-third-quarter-revenue-of-8-crl-20211103monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-second-quarter-2021-results-second-quarter-revenue-of-crl-20210804monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-international-inc-amended-and-restated-employment-agreement-thi-crl-20210518monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-first-quarter-2021-results-first-quarter-revenue-of-8-crl-20210504monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-planned-offering-of-1-crl-20210308monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-to-acquire-cognate-bioservices-to-create-a-premier-scientific-p-crl-20210217monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2020-results-and-provide-crl-20210217monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-third-quarter-2020-results-third-quarter-revenue-of-7-crl-20201029monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-second-quarter-2020-results-second-quarter-revenue-of-crl-20200805monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-first-quarter-2020-results-first-quarter-revenue-of-7-crl-20200507monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2019-results-and-provide-crl-20200211monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-third-quarter-2019-results-third-quarter-revenue-of-6-crl-20191106monthly0.5https://www.biopharmawatch.com/news/CRL/excerpts-from-the-preliminary-offering-memorandum-dated-crl-20191021monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-second-quarter-2019-results-second-quarter-revenue-of-crl-20190731monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-first-quarter-2019-results-first-quarter-revenue-of-6-crl-20190507monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-signs-binding-offer-to-acquire-citoxlab-further-strengthens-cha-crl-20190213monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2018-results-and-provide-crl-20190213monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-third-quarter-2018-results-third-quarter-revenue-of-5-crl-20181107monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-second-quarter-2018-results-from-continuing-operation-crl-20180808monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-first-quarter-2018-results-from-continuing-operations-crl-20180510monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-refinancing-of-credit-facilities-and-offering-of-500-crl-20180326monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-to-acquire-mpi-research-enhances-charles-river-s-position-as-a--crl-20180213monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2017-results-from-contin-crl-20180213monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-third-quarter-2017-results-from-continuing-operations-crl-20171109monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-second-quarter-2017-results-from-continuing-operation-crl-20170809monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-first-quarter-2017-results-from-continuing-operations-crl-20170510monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-fourth-quarter-and-full-year-2016-results-from-contin-crl-20170214monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-third-quarter-2016-results-from-continuing-operations-crl-20161102monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-second-quarter-2016-results-from-continuing-operation-crl-20160803monthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-announces-first-quarter-2016-results-from-continuing-operations-crl-20160504monthly0.5https://www.biopharmawatch.com/news/KRYS/document-krystal-biotech-announces-fourth-quarter-and-full-year-2025-financial-and-operati-krys-20260217monthly0.5https://www.biopharmawatch.com/news/KRYS/document-krystal-biotech-announces-third-quarter-2025-financial-and-operating-results-97-8-krys-20251103monthly0.5https://www.biopharmawatch.com/news/KRYS/document-krystal-biotech-announces-second-quarter-2025-financial-and-operating-results-96--krys-20250804monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-first-patient-dosed-in-phase-1-2-trial-of-kb801-for-the-treatmen-krys-20250709monthly0.5https://www.biopharmawatch.com/news/KRYS/document-krystal-biotech-announces-first-quarter-2025-financial-and-operating-results-vyju-krys-20250506monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-european-commission-approval-of-vyjuvek-for-the-treatment-of-dys-krys-20250428monthly0.5https://www.biopharmawatch.com/news/KRYS/document-krystal-biotech-announces-fourth-quarter-and-full-year-2024-financial-and-operati-krys-20250219monthly0.5https://www.biopharmawatch.com/news/KRYS/document-krystal-biotech-announces-third-quarter-2024-financial-results-and-provides-busin-krys-20241104monthly0.5https://www.biopharmawatch.com/news/KRYS/subjects-also-reported-improvements-in-wrinkles-that-increased-from-the-first-to-second-fo-krys-20240828monthly0.5https://www.biopharmawatch.com/news/KRYS/document-krystal-biotech-announces-second-quarter-2024-financial-results-and-provides-busi-krys-20240805monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-first-quarter-2024-financial-results-and-provides-business-updat-krys-20240506monthly0.5https://www.biopharmawatch.com/news/KRYS/years-ended-december-31-in-thousands-except-shares-and-per-share-data-2023-2022-change-rev-krys-20240226monthly0.5https://www.biopharmawatch.com/news/KRYS/nine-months-ended-krys-20231106monthly0.5https://www.biopharmawatch.com/news/KRYS/six-months-ended-krys-20230807monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-pipeline-expansion-into-oncology-and-fda-acceptance-of-ind-appli-krys-20230726monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-160-million-private-placement-equity-financing-pittsburgh-krys-20230522monthly0.5https://www.biopharmawatch.com/news/KRYS/updated-risk-factors-risks-related-to-our-business-we-have-limited-experience-as-a-commerc-krys-20230519monthly0.5https://www.biopharmawatch.com/news/KRYS/document-krystal-biotech-announces-first-quarter-2023-financial-results-and-operational-hi-krys-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-clinical-data-on-topical-application-of-b-vec-to-the-eye-to-trea-krys-202304232023-04-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-appoints-catherine-mazzacco-to-board-of-directors-krys-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-fourth-quarter-and-full-year-2022-financial-results-and-operatio-krys-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-first-quarter-2022-financial-results-and-reports-updates-on-oper-krys-20220509monthly0.5https://www.biopharmawatch.com/news/KRYS/this-presentation-contains-forward-looking-statements-that-involve-substantial-risks-and-u-krys-20220328monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-settlement-with-periphagen-inc-pittsburgh-krys-20220315monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-appoints-jing-marantz-md-phd-mba-as-chief-business-officer-and-rand-suther-krys-20220118monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-positive-topline-results-from-gem-3-pivotal-trial-of-vyjuvek-in--krys-20211129monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-third-quarter-2021-financial-results-and-provides-update-on-operat-krys-20211108monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-second-quarter-2021-financial-results-and-provides-update-on-opera-krys-20210809monthly0.5https://www.biopharmawatch.com/news/KRYS/jeune-aesthetics-announces-initiation-of-dosing-in-efficacy-cohort-of-kb301-phase-1-trial--krys-20210802monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-provides-update-on-the-clinical-trial-evaluating-topical-kb105-for-the-tre-krys-20210701monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-first-quarter-2021-financial-results-and-provides-update-on-operat-krys-20210510monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-launch-of-jeune-a-gene-based-aesthetics-company-and-initial-phas-krys-20210324monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-provides-update-on-operational-progress-and-reports-fourth-quarter-and-ful-krys-20210301monthly0.5https://www.biopharmawatch.com/news/KRYS/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-krys-20210107monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-appoints-dr-chris-mason-and-dr-jing-marantz-to-its-board-of-directors-pitt-krys-20210104monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-third-quarter-2020-financial-results-and-provides-update-on-operat-krys-20201109monthly0.5https://www.biopharmawatch.com/news/KRYS/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-krys-20201001monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-second-quarter-2020-financial-results-and-provides-update-on-opera-krys-20200810monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-positive-interim-results-from-phase-1-2-clinical-trial-of-kb105--krys-20200514monthly0.5https://www.biopharmawatch.com/news/KRYS/in-vitro-pharmacology-of-kb407-an-hsv-1-based-gene-therapy-vector-for-the-treatment-of-cys-krys-20200512monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-first-quarter-2020-financial-results-and-provides-update-on-operat-krys-20200504monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-2019-financial-results-and-business-progress-phase-3-trial-of-b-ve-krys-20200310monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-change-in-financial-leadership-pittsburgh-krys-20200225monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-third-quarter-2019-financial-and-operating-results-alignment-with--krys-20191104monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-final-update-from-phase-1-2-clinical-trial-of-kb103-bercolagene--krys-20191029monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-second-quarter-2019-financial-and-operating-results-fda-grants-rma-krys-20190805monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-positive-results-from-phase-2-clinical-trial-gem-2-study-of-kb10-krys-20190624monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-first-quarter-2019-financial-results-and-provides-corporate-update-krys-20190506monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-2018-financial-results-and-business-progress-topline-data-from-pha-krys-20190312monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-strengthens-board-of-directors-with-appointment-of-julian-s-gangolli-pittsburgh-krys-20190304monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-third-quarter-2018-financial-results-and-provides-corporate-update-krys-20181105monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-closing-of-public-offering-of-common-stock-and-exercise-in-full--krys-20181023monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-commencement-of-60-0-million-public-offering-of-common-stock-pit-krys-20181017monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-positive-interim-results-from-placebo-controlled-phase-1-2-clini-krys-20181015monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-inc-stock-purchase-agreement-this-stock-purchase-agreement-the-agreement-i-krys-20180816monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-first-quarter-2018-financial-results-and-provides-corporate-update-krys-20180507monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-that-kb103-received-clearance-from-rac-review-and-announces-third--krys-20171113monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-pricing-of-upsized-initial-public-offering-pittsburgh-pennsylvan-krys-20170919monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-the-election-of-william-k-dan-hsic-20260522monthly0.5https://www.biopharmawatch.com/news/HSIC/1-more-for-immediate-release-henry-schein-reports-first-quarter-2026-financial-results-x25-hsic-20260505monthly0.5https://www.biopharmawatch.com/news/HSIC/1-more-for-immediate-release-henry-schein-reports-fourth-quarter-and-full-year-2025-financ-hsic-20260224monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-names-frederick-m-lowery-as-chief-executive-officer-industry-veteran-brings-m-hsic-20260112monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-provides-update-on-ceo-search-process-melville-n-y-hsic-20251223monthly0.5https://www.biopharmawatch.com/news/HSIC/1-more-for-immediate-release-henry-schein-reports-record-third-quarter-2025-financial-resu-hsic-20251104monthly0.5https://www.biopharmawatch.com/news/HSIC/august-5-2025-exhibit991-1-more-for-immediate-release-henry-schein-reports-second-quarter--hsic-20250805monthly0.5https://www.biopharmawatch.com/news/HSIC/stanley-m-bergman-to-retire-as-henry-schein-s-chief-executive-officer-at-the-end-of-2025-m-hsic-20250715monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-completion-of-strategic-investment-by-kkr-and-appointment-of-dan-da-hsic-20250502monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-1q-2025-quarterly-8-k-exhibit991-1-more-for-immediate-release-henry-schein-re-hsic-20250505monthly0.5https://www.biopharmawatch.com/news/HSIC/february-25-2025-exhibit991-1-more-for-immediate-release-henry-schein-reports-fourth-quart-hsic-20250225monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-strategic-investment-by-kkr-board-changes-and-provides-preliminary--hsic-20250129monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-november-5-2024-exhibit991-1-more-for-immediate-release-henry-schein-reports-third-q-hsic-20241105monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-august-6-2024-exhibit991-1-more-for-immediate-release-henry-schein-reports-second-qu-hsic-20240806monthly0.5https://www.biopharmawatch.com/news/HSIC/may-7-2024-exhibit991-1-more-for-immediate-release-henry-schein-reports-solid-first-quarte-hsic-20240507monthly0.5https://www.biopharmawatch.com/news/HSIC/february-27-2024-exhibit991-1-more-for-immediate-release-henry-schein-reports-fourth-quart-hsic-20240227monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-receipt-of-deficiency-notice-from-nasdaq-regarding-requirement-to-t-hsic-20231116monthly0.5https://www.biopharmawatch.com/news/HSIC/november-13-2023-exhibit991-1-more-for-immediate-release-henry-schein-reports-third-quarte-hsic-20231113monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-to-webcast-third-quarter-2023-conference-call-and-provide-an-update-on-its-fu-hsic-20231102monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-provides-information-on-cybersecurity-incident-melville-new-york-on-saturday--hsic-20231016monthly0.5https://www.biopharmawatch.com/news/HSIC/august-7-2023-exhibit991-1-more-for-immediate-release-henry-schein-reports-solid-second-qu-hsic-20230807monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-enhances-liquidity-position-with-new-750-million-credit-facility-amends-exist-hsic-20230713monthly0.5https://www.biopharmawatch.com/news/HSIC/may-9-2023-exhibit991-1-more-for-immediate-release-henry-schein-reports-first-quarter-2023-hsic-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-inc-to-detail-strategic-plan-and-long-term-hsic-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSIC/february-16-2023-exhibit991-1-more-for-immediate-release-henry-schein-reports-fourth-quart-hsic-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSIC/november-1-2022-exhibit991-1-more-for-immediate-release-henry-schein-reports-record-non-ga-hsic-20221101monthly0.5https://www.biopharmawatch.com/news/HSIC/august-2-2022-exhibit991-1-more-for-immediate-release-henry-schein-reports-record-second-q-hsic-20220802monthly0.5https://www.biopharmawatch.com/news/HSIC/may-3-2022-exhibit991-1-more-for-immediate-release-henry-schein-reports-record-first-quart-hsic-20220503monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-retirement-of-chief-administrative-officer-and-appoints-chief-opera-hsic-20220404monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-inc-4q-2021-quarterly-8-k-for-immediate-release-henry-schein-reports-record-n-hsic-20220215monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-retirement-of-chief-financial-officer-and-related-succession-plan-c-hsic-20220105monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-appoints-scott-serota-to-board-of-directors-former-president-and-ceo-of-blue--hsic-20211208monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-inc-3q-2021-quarterly-8-k-for-immediate-release-henry-schein-reports-record-t-hsic-20211102monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-new-1-hsic-20210823monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-inc-2q-2021-quarterly-8-k-for-immediate-release-henry-schein-reports-record-s-hsic-20210803monthly0.5https://www.biopharmawatch.com/news/HSIC/may-4-2021-exhibit991-1-more-for-immediate-release-henry-schein-reports-record-first-quart-hsic-20210504monthly0.5https://www.biopharmawatch.com/news/HSIC/february-17-2021-exhibit991-1-more-for-immediate-release-henry-schein-reports-fourth-quart-hsic-20210217monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-two-new-directors-mohamad-ali-and-deborah-derby-appointed-as-board--hsic-20210210monthly0.5https://www.biopharmawatch.com/news/HSIC/november-2-2020-exhibit991-1-more-for-immediate-release-henry-schein-reports-record-third--hsic-20201102monthly0.5https://www.biopharmawatch.com/news/HSIC/august-4-2020-for-immediate-release-henry-schein-reports-second-quarter-2020-financial-res-hsic-20200804monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-amends-and-extends-financing-facilities-company-amends-and-extends-350-millio-hsic-20200625monthly0.5https://www.biopharmawatch.com/news/HSIC/may-5-2020-for-immediate-release-henry-schein-reports-first-quarter-2020-financial-results-hsic-20200505monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-enhances-liquidity-position-with-new-credit-facility-totaling-700-million-com-hsic-20200420monthly0.5https://www.biopharmawatch.com/news/HSIC/february-20-2020-for-immediate-release-henry-schein-reports-record-fourth-quarter-2019-fin-hsic-20200220monthly0.5https://www.biopharmawatch.com/news/HSIC/november-5-2019-for-immediate-release-henry-schein-reports-record-third-quarter-2019-finan-hsic-20191105monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-to-be-dismissed-from-summit-county-opioid-litigation-company-to-make-donation-hsic-20191021monthly0.5https://www.biopharmawatch.com/news/HSIC/august-6-2019-for-immediate-release-henry-schein-reports-record-second-quarter-2019-financ-hsic-20190806monthly0.5https://www.biopharmawatch.com/news/HSIC/may-7-2019-for-immediate-release-henry-schein-reports-record-first-quarter-2019-financial--hsic-20190507monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-february-20-2019-for-immediate-release-henry-schein-reports-record-fourth-quarter-an-hsic-20190220monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-november-6-2018-for-immediate-release-henry-schein-reports-record-third-quarter-2018-hsic-20181106monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-anticipates-settling-proposed-class-action-litigation-company-expects-to-reco-hsic-20180830monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-august-6-2018-for-immediate-release-henry-schein-reports-record-second-quarter-2018--hsic-20180806monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-may-8-2018-for-immediate-release-henry-schein-reports-record-first-quarter-2018-fina-hsic-20180508monthly0.5https://www.biopharmawatch.com/news/HSIC/safe-harbor-statement-forward-looking-statements-in-accordance-with-the-safe-harbor-provis-hsic-20180423monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-february-20-2018-for-immediate-release-henry-schein-reports-record-fourth-quarter-an-hsic-20180220monthly0.5https://www.biopharmawatch.com/news/HSIC/can-you-comment-on-the-ftc-complaint-that-alleges-henry-schein-benco-and-patterson-violate-hsic-20180213monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-november-6-2017-for-immediate-release-henry-schein-reports-record-third-quarter-fina-hsic-20171106monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-2-for-1-stock-split-trading-on-a-split-adjusted-basis-to-begin-hsic-20170816monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-august-8-2017-for-immediate-release-henry-schein-reports-record-second-quarter-finan-hsic-20170808monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-may-9-2017-for-immediate-release-henry-schein-reports-record-first-quarter-financial-hsic-20170509monthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-announces-new-750-hsic-20170419monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-february-21-2017-for-immediate-release-henry-schein-reports-record-fourth-quarter-an-hsic-20170221monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-november-2-2016-for-immediate-release-henry-schein-reports-record-third-quarter-fina-hsic-20161102monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-august-4-2016-hsic-20160804monthly0.5https://www.biopharmawatch.com/news/HSIC/dated-may-3-2016-for-immediate-release-henry-schein-reports-record-first-quarter-results-a-hsic-20160503monthly0.5https://www.biopharmawatch.com/news/SNN/life-unlimited-annual-report-2025-1-these-non-ifrs-financial-measures-are-explained-and-re-snn-20260316monthly0.5https://www.biopharmawatch.com/news/SNN/annual-report-2024-life-unlimited-contents-5-810m-group-revenue-37-5-xa2-unchanged-dividen-snn-20250310monthly0.5https://www.biopharmawatch.com/news/SNN/life-unlimited-annual-report-2023-contents-our-performance-strategic-report-our-performanc-snn-20240311monthly0.5https://www.biopharmawatch.com/news/SNN/securities-and-exchange-commission-snn-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/stock-exchange-announcement-for-media-and-investors-only-issued-9-june-2026-london-uk-gsk--nuvl-20260609monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-ontarget-2026-operating-plan-progress-and-outlines-key-anticipated-2026-nuvl-20260114monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-pipeline-and-business-achievements-reiterates-key-anticipated-mileston-nuvl-20250807monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-outlines-recent-pipeline-and-business-progress-reiterates-key-anticipated-milesto-nuvl-20250508monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-outlines-pipeline-and-business-progress-reiterates-key-anticipated-milestones-and-nuvl-20250227monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-details-strategy-to-seek-first-potential-approval-in-2026-and-outlines-key-antici-nuvl-20250113monthly0.5https://www.biopharmawatch.com/news/NUVL/restricted-stock-unit-award-agreement-performance-vesting-for-company-employees-under-the--nuvl-20241209monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-corporate-and-pipeline-achievements-reiterates-key-anticipated-milesto-nuvl-20241112monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-pricing-of-upsized-public-offering-of-common-stock-cambridge-mass-septe-nuvl-20240918monthly0.5https://www.biopharmawatch.com/news/NUVL/one-broadway-14-th-floor-cambridge-ma-02142-nuvalent-com-nuvalent-highlights-presentation--nuvl-20240914monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-pipeline-progress-reiterates-key-anticipated-milestones-and-reports-se-nuvl-20240808monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-pipeline-progress-reiterates-key-anticipated-milestones-and-reports-fi-nuvl-20240509monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-pipeline-progress-reiterates-key-anticipated-milestones-and-reports-fo-nuvl-20240227monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-x201c-ontarget-2026-x201d-operating-plan-and-key-anticipated-milestones-nuvl-20240108monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-corporate-and-pipeline-achievements-and-reports-third-quarter-2023-fin-nuvl-20231114monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-pricing-of-public-offering-of-common-stock-nuvl-20231016monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-reports-preliminary-phase-1-clinical-data-from-alkove-1-trial-that-support-best-i-nuvl-20231013monthly0.5https://www.biopharmawatch.com/news/NUVL/preliminary-phase-1-dose-escalation-data-from-alkove-1-trial-of-nvl-655-demonstrated-activ-nuvl-20231004monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-pipeline-progress-and-reports-second-quarter-2023-financial-results-co-nuvl-20230810monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-anticipated-timing-of-preliminary-phase-1-dose-escalation-data-for-nvl--nuvl-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-pipeline-and-business-progress-and-reports-fourth-quarter-and-full-yea-nuvl-202303162023-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-reviews-corporate-and-pipeline-achievements-and-reports-third-quarter-2022-financ-nuvl-20221110monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-pricing-of-public-offering-of-common-stock-nuvl-20221031monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-reports-preliminary-phase-1-clinical-data-from-arros-1-trial-that-support-best-in-nuvl-20221028monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-execution-across-pipeline-of-novel-kinase-inhibitors-and-reports-secon-nuvl-20220810monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-pipeline-and-business-progress-and-reports-first-quarter-2022-financia-nuvl-20220512monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-reports-pipeline-and-business-progress-and-fourth-quarter-and-full-year-2021-fina-nuvl-20220329monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-reports-pipeline-progress-and-third-quarter-2021-financial-results-arros-1-clinic-nuvl-20211110monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-business-and-program-highlights-and-reports-second-quarter-2021-financi-nuvl-20210908monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-signs-exclusive-u-s-agreement-with-japan-bcg-laboratory-for-the-tokyo-strain-o-ibrx-20260516monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-addresses-fda-correspondence-and-reaffirms-commitment-to-advertising-complianc-ibrx-20260406monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-strengthens-balance-sheet-with-100-million-of-financing-transactions-including-ibrx-20260331monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-continued-execution-and-sales-momentum-with-113-million-of-preliminary-ibrx-20251231monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-receives-conditional-marketing-authorization-recommendation-from-the-european--ibrx-20251212monthly0.5https://www.biopharmawatch.com/news/IBRX/driven-by-strong-demand-immunitybio-reports-467-year-to-date-unit-growth-and-75-million-in-ibrx-20251105monthly0.5https://www.biopharmawatch.com/news/IBRX/united-states-district-court-southern-district-of-california-in-re-immunitybio-inc-shareho-ibrx-20250808monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-q2-earnings-release-reflecting-60-increase-in-revenue-in-q2-2025-with--ibrx-20250805monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-millio-ibrx-20250725monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-doubled-net-revenue-and-150-unit-growth-in-q1-2025-with-continued-stro-ibrx-20250512monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-requests-an-urgent-meeting-with-fda-to-address-the-change-in-the-agency-s-unam-ibrx-20250505monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-fda-submissions-of-supplemental-bla-for-nmibc-papillary-disease-and--ibrx-20250331monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-execution-of-75-million-equity-financing-with-an-institutional-inves-ibrx-20250408monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-sales-momentum-unit-growth-since-permanent-j-code-issuance-j9028-in-ja-ibrx-20250303monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-inc-announces-pricing-of-public-offering-of-common-stock-culver-city-calif-bus-ibrx-20241211monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-inc-announces-proposed-public-offering-of-common-stock-culver-city-calif-busin-ibrx-20241210monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-completes-anktiva-s-post-approval-enrollment-of-the-100-th-patient-in-bcg-unre-ibrx-20241119monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-third-quarter-2024-financial-results-ibrx-20241112monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bc-ibrx-20240422monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-320-million-investment-by-oberland-capital-with-210-million-funded-a-ibrx-20240102monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-470-million-equity-and-debt-financing-from-founder-dr-patrick-soon-s-ibrx-20230911monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-execution-of-40-million-equity-financing-with-institutional-investor-ibrx-20230720monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-execution-of-50-million-equity-financing-with-multiple-institutional-ibrx-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-157-million-financing-from-nant-and-institutional-investor-financing-ibrx-20221212monthly0.5https://www.biopharmawatch.com/news/IBRX/nasdaq-ibrx-overview-presentation-november-2022-11-14-22-1-forward-looking-statements-this-ibrx-20221115monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-completes-acquisition-of-athenex-s-interest-in-dunkirk-new-york-advanced-biote-ibrx-20220215monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-expands-manufacturing-capacity-with-state-of-the-art-manufacturing-plant-in-ne-ibrx-20220112monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-completion-of-470-million-post-merger-financing-to-fund-late-stage-c-ibrx-20211220monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-announces-positive-durable-responses-in-bcg-unresponsive-bladder-cancer-patien-ibrx-20210913monthly0.5https://www.biopharmawatch.com/news/IBRX/fda-authorizes-immunitybio-study-of-anktiva-and-pd-l1-t-hank-to-increase-effectiveness-of--ibrx-20210615monthly0.5https://www.biopharmawatch.com/news/IBRX/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-ibrx-20210604monthly0.5https://www.biopharmawatch.com/news/IBRX/index-to-immunitybio-consolidated-financial-statements-page-report-of-independent-auditors-ibrx-20210422monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-appoints-dr-linda-maxwell-and-ceo-richard-adcock-to-board-of-directors-ibrx-20210401monthly0.5https://www.biopharmawatch.com/news/IBRX/this-press-release-contains-forward-looking-statements-within-the-meaning-of-the-private-s-ibrx-20210310monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-and-nantkwest-complete-merger-creates-leading-immunotherapy-and-cell-therapy-c-ibrx-20210309monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-appoints-john-brennan-and-wesley-clark-to-board-of-directors-ibrx-20210224monthly0.5https://www.biopharmawatch.com/news/IBRX/this-presentation-contains-forward-looking-statements-relating-to-the-proposed-transaction-ibrx-20210113monthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-and-nantkwest-to-merge-creating-a-leading-immunotherapy-and-cell-therapy-compa-ibrx-20201221monthly0.5https://www.biopharmawatch.com/news/IBRX/nantkwest-names-richard-adcock-chief-executive-officer-experienced-six-sigma-healthcare-ex-ibrx-20201026monthly0.5https://www.biopharmawatch.com/news/IBRX/business-the-following-summary-highlights-selected-information-about-us-this-summary-is-no-ibrx-20200624monthly0.5https://www.biopharmawatch.com/news/IBRX/johnson-fistel-llp-frank-j-johnson-sbn-174882-655-west-broadway-suite-1400-san-diego-ca-92-ibrx-20190610monthly0.5https://www.biopharmawatch.com/news/IBRX/cheryl-cohen-appointed-to-nantkwest-s-board-of-directors-culver-city-ca-ibrx-20190606monthly0.5https://www.biopharmawatch.com/news/IBRX/nantkwest-names-angela-wilson-chief-financial-officer-culver-city-california-ibrx-20151117monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-full-year-2025-record-revenue-of-1-4-billion-and-reiterates-strong-2026-f-halo-20260217monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-pricing-of-private-offering-of-650-million-of-converti-halo-20251106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-acquire-elektrofi-expanding-our-offerings-in-innovative-drug-delivery-and-stre-halo-20251001monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-2025-financial-guidance-ranges-and-reports-strong-first-quarter-2025-resul-halo-20250506monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-full-year-2024-record-revenue-of-1-015-billion-and-exceeds-its-financial--halo-20250218monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reiterates-2024-financial-guidance-and-raises-2025-and-multi-year-financial-guida-halo-20250108monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2024-financial-and-operating-results-total-revenue-increase-halo-20241031monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2024-financial-and-operating-results-total-revenue-of-231--halo-20240806monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2024-financial-and-operating-results-revenue-increased-21-y-halo-20240507monthly0.5https://www.biopharmawatch.com/news/HALO/document-halozyme-reports-fourth-quarter-and-full-year-2023-financial-and-operating-result-halo-20240220monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2023-financial-and-operating-results-royalty-revenue-increa-halo-20231106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2023-financial-and-operating-results-revenue-increased-45--halo-20230808monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2023-financial-and-operating-results-revenue-increased-38-y-halo-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-update-on-licensee-co-formulation-patent-hearing-in-europe-company-antic-halo-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results-fourth--halo-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/document-halozyme-provides-2023-financial-guidance-and-outlook-2023-total-revenue-guidance-halo-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2022-financial-and-operating-results-third-quarter-revenue--halo-20221108monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-upsize-and-pricing-of-private-offering-of-625-million--halo-20220815monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2022-financial-and-operating-results-closed-antares-pharma-halo-20220809monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-completes-antares-pharma-acquisition-halo-20220524monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2022-results-first-quarter-revenue-of-117-3-million-represe-halo-20220510monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-acquire-antares-pharma-to-create-a-specialty-product-and-drug-delivery-leader--halo-20220413monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-2021-and-full-year-results-reports-fourth-quarter-revenue--halo-20220222monthly0.5https://www.biopharmawatch.com/news/HALO/document-halozyme-appoints-new-chief-financial-officer-halo-20220202monthly0.5https://www.biopharmawatch.com/news/HALO/document-halozyme-provides-2022-financial-guidance-and-outlook-2022-revenue-guidance-of-53-halo-20220110monthly0.5https://www.biopharmawatch.com/news/HALO/document-halo-20211213monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2021-results-record-quarterly-royalties-in-the-third-quarte-halo-20211102monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2021-results-raising-2021-revenue-guidance-to-425-445-mill-halo-20210809monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2021-results-first-quarter-revenue-of-89-0-million-up-from--halo-20210510monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-pricing-of-private-offering-of-700-million-of-converti-halo-20210224monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-2020-results-and-full-year-2020-results-reports-fourth-qua-halo-20210223monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme2021-jpmxfi-39th-annual-j-p-morgan-healthcare-conference-dr-helen-torley-president-halo-20210113monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-2021-financial-guidance-highlighted-by-strong-revenue-and-eps-growth-202-halo-20210111monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2020-results-and-raises-full-year-2020-guidance-reports-thi-halo-20201102monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-significant-recent-achievements-and-second-quarter-2020-results-reports-f-halo-20200810monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2020-results-darzalex-faspro-tm-utilizing-enhanze-technolog-halo-20200511monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-full-year-2019-results-halozyme-reiterates-2020-guidan-halo-20200224monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-pricing-of-private-offering-of-400-million-of-converti-halo-20191113monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2019-results-total-revenues-increase-81-to-46-2-million-com-halo-20191112monthly0.5https://www.biopharmawatch.com/news/HALO/presentation-2019-wells-fargo-healthcare-conference-building-a-premier-oncology-biotech-dr-halo-20190904monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2019-results-total-revenues-increase-11-to-39-1-million-co-halo-20190806monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2019-results-revenue-of-56-9-million-compared-to-30-9-milli-halo-20190507monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-full-year-2018-results-enhanze-technology-licensed-to--halo-20190221monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-2019-pipeline-update-and-financial-guidance-at-37-th-annual-jp-morgan-he-halo-20190109monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-change-in-primary-endpoint-for-halo-301-to-overall-survival-fda-agrees--halo-20181126monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2018-financial-results-enhanze-licensed-to-roche-for-up-to--halo-20181106monthly0.5https://www.biopharmawatch.com/news/HALO/forward-looking-statements-all-of-the-statements-in-this-presentation-that-are-not-stateme-halo-20180905monthly0.5https://www.biopharmawatch.com/news/HALO/robert-h-uhl-managing-director-westwicke-partners-llc-858-356-5932-robert-uhl-westwicke-co-halo-20180807monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20180510monthly0.5https://www.biopharmawatch.com/news/HALO/to-such-form-8-k-board-recommendation-and-vote-required-as-our-board-of-directors-continue-halo-20180322monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20180220monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20180109monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20171107monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20170808monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halo-20170518monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20170509monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20170228monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20170109monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20161107monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halo-20160901monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20160809monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20160608monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20160509monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halo-20160307monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-halozym-halo-20160229monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-for-imm-halo-20160126monthly0.5https://www.biopharmawatch.com/news/HALO/th-annual-j-p-morgan-healthcare-conference-platforms-for-growth-building-a-premier-oncolog-halo-20160112monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-for-imm-halo-20160111monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-858-704-8122-ir-halozyme-com-chris-burton-858-704-8352-ir-halozyme-com-for-imm-halo-20160104monthly0.5https://www.biopharmawatch.com/news/HALO/jim-mazzola-halozyme-therapeutics-858-704-8122-ir-halozyme-com-halozyme-reports-third-quar-halo-20151109monthly0.5https://www.biopharmawatch.com/news/HALO/schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-jim-mazzola-halozyme-th-halo-20150810monthly0.5https://www.biopharmawatch.com/news/HALO/schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-jim-mazzola-halozyme-th-halo-20150805monthly0.5https://www.biopharmawatch.com/news/HALO/schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-jim-mazzola-halozyme-th-halo-20150605monthly0.5https://www.biopharmawatch.com/news/HALO/schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-jim-mazzola-halozyme-th-halo-20150511monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-media--halo-20150302monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-media--halo-20150112monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-media--halo-20150107monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-media--halo-20141110monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-media--halo-20140811monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-media--halo-20140512monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme-com-media--halo-20140227monthly0.5https://www.biopharmawatch.com/news/HALO/investor-and-media-contact-schond-greenway-halozyme-therapeutics-858-704-8352-ir-halozyme--halo-20140203monthly0.5https://www.biopharmawatch.com/news/HALO/hill-knowlton-strategies-halo-20140113monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-david-ramsay-halozyme-therapeutics-858-704-8260-ir-halozyme-com-media-con-halo-20131217monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-david-ramsay-halozyme-therapeutics-858-704-8260-ir-halozyme-com-media-con-halo-20131108monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-david-ramsay-halozyme-therapeutics-858-704-8260-ir-halozyme-com-media-con-halo-20130807monthly0.5https://www.biopharmawatch.com/news/HALO/gynoid-lipodystrophy-cellulite-a-phase-1-2-vehicle-controlled-study-to-evaluate-safety-tol-halo-20130703monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-names-david-a-ramsay-chief-financial-officer-halo-20130523monthly0.5https://www.biopharmawatch.com/news/HALO/hill-knowlton-strategies-halo-20130508monthly0.5https://www.biopharmawatch.com/news/HALO/investor-contact-kurt-gustafson-halozyme-therapeutics-858-704-8272-ir-halozyme-com-media-c-halo-20130225monthly0.5https://www.biopharmawatch.com/news/HALO/safe-harbor-all-of-the-statements-in-this-presentation-that-are-not-statements-of-historic-halo-20121002monthly0.5https://www.biopharmawatch.com/news/HALO/media-investor-contact-anne-erickson-executive-director-halozyme-therapeutics-858-704-8264-halo-20120309monthly0.5https://www.biopharmawatch.com/news/HALO/media-investor-contact-anne-erickson-executive-director-halozyme-therapeutics-858-704-8264-halo-20120209monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-thinking-outside-the-cell-tm-j-p-morgan-healthcare-conference-halo-20120111monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2025-results-minneapolis-tech-20250806monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2025-results-minneapolis-tech-20250507monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2025-results-minneapolis-tech-20250205monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2025-results-minneapolis-tech-20241030monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2024-results-minneapolis-tech-20240807monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2024-results-minneapolis-tech-20240501monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-appoints-dr-judith-klimovsky-to-board-of-directors-minneapolis-tech-20240430monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2024-results-minneapolis-tech-20240201monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-appointment-of-matthew-f-mcmanus-as-president-diagnostics-and-genomic-tech-20240105monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2024-results-minneapolis-tech-20231031monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-tech-20231019monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2023-results-minneapolis-tech-20230808monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-tech-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-tech-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2023-results-minneapolis-tech-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-retirement-appointment-of-general-counsel-minneapolis-tech-202301312023-01-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2023-results-minneapolis-tech-20221101monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-tech-20220804monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2022-results-minneapolis-tech-20220504monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2017-results-minneapolis-tech-20170808monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2017-results-minneapolis-tech-20170502monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2017-results-minneapolis-tech-20170207monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2017-results-minneapolis-tech-20161031monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2016-results-minneapolis-tech-20160817monthly0.5https://www.biopharmawatch.com/news/TECH/minneapolis-mn-tech-20160801monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-agreement-to-acquire-advanced-cell-diagnostics-minneapolis-tech-20160706monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2016-results-minneapolis-tech-20160503monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2016-results-minneapolis-tech-20160202monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-minneapolis-tech-20151029monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2016-results-minneapolis-tech-20151028monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2015-results-minneapolis-tech-20150806monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-corporation-agrees-to-acquire-cliniqa-corporation-minneapolis-tech-20150605monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2015-results-minneapolis-may-5th-2015-bio-techne--tech-20150505monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2015-results-minneapolis-tech-20150203monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-agreement-to-acquire-cyvek-minneapolis-tech-20141104monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2015-results-minneapolis-tech-20141028monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-and-full-year-2014-results-minneapolis-tech-20140811monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-proteinsimple-acquisition-completion-minneapolis-tech-20140801monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-agreement-to-acquire-novus-biologicals-minneapolis-tech-20140702monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-agreement-to-acquire-proteinsimple-minneapolis-tech-20140617monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-the-appointment-of-harold-wiens-to-the-board-of-directors-minneapolis-tech-20140515monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-unaudited-third-quarter-and-nine-month-fiscal-year-2014-results-minnea-tech-20140428monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-investment-in-cyvek-inc-minneapolis-tech-20140404monthly0.5https://www.biopharmawatch.com/news/TECH/techne-corporation-announces-appointment-of-james-t-hippel-as-chief-financial-officer-minn-tech-20140206monthly0.5https://www.biopharmawatch.com/news/TECH/techne-corporation-announces-acquisition-agreement-minneapolis-tech-20130618monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2026-financial-results-bio-20260430monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2025-financial-results-bio-20260212monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2025-financial-results-bio-20251029monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-laboratories-inc-co-founder-and-director-emeritus-alice-schwartz-passes-away-bio-20250929monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2025-financial-results-bio-20250731monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-appoints-rajat-mehta-executive-vice-president-global-commercial-operations-bio-20250728monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2025-financial-results-bio-20250501monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2024-financial-results-bio-20250213monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2024-financial-results-bio-20241030monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-appoints-jon-divincenzo-president-chief-operating-officer-bio-20240820monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2024-financial-results-bio-20240801monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2024-financial-results-bio-20240507monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-announces-life-science-group-management-changes-bio-20240426monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-s-chief-operating-officer-andrew-last-to-retire-bio-20240410monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-appoints-roop-k-lakkaraju-executive-vice-president-chief-financial-officer-bio-20240320monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2023-financial-results-bio-20240215monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2023-financial-results-bio-20231026monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2023-financial-results-bio-20230803monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2023-financial-results-hercules-calif-bio-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2022-financial-results-bio-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2022-financial-results-bio-20221027monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2022-financial-results-hercules-calif-bio-20220728monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2022-financial-results-bio-20220428monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-announces-closing-of-1-2-billion-aggregate-senior-notes-offering-bio-20220302monthly0.5https://www.biopharmawatch.com/news/BIO/f-e-b-r-u-a-r-y-2-5-2-0-2-2-bio-rad-investor-laboratories-inc-day-2022-forward-looking-sta-bio-20220225monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2021-financial-results-bio-20220210monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2021-financial-results-bio-20211028monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2021-financial-results-bio-20210729monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2021-financial-results-bio-20210429monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2020-financial-results-bio-20210211monthly0.5https://www.biopharmawatch.com/news/BIO/outlook-2021-2023-bio-rad-laboratories-inc-bio-20201210monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2020-financial-results-bio-20201029monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2020-financial-results-bio-20200730monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2020-financial-results-bio-20200506monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2019-financial-results-bio-20200213monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2019-financial-results-bio-20191031monthly0.5https://www.biopharmawatch.com/news/BIO/corrected-press-release-bio-rad-reports-second-quarter-2019-financial-results-bio-20190827monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2019-financial-results-bio-20190801monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2019-financial-results-bio-20190508monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-appoints-andrew-last-as-executive-vice-president-and-chief-operating-officer-bio-20190422monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-names-ilan-daskal-executive-vice-president-and-chief-financial-officer-bio-20190402monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-laboratories-inc-receives-expected-nyse-notice-regarding-late-form-10-k-filing-bio-20190325monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2018-financial-results-bio-20190228monthly0.5https://www.biopharmawatch.com/news/BIO/christine-tsingos-announces-plans-to-retire-as-cfo-of-bio-rad-laboratories-inc-effective-bio-20190103monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2018-financial-results-bio-20181101monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2018-financial-results-bio-20180807monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2018-financial-results-bio-20180508monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-laboratories-inc-receives-expected-nyse-notice-regarding-late-form-10-k-filing-bio-20180322monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2017-financial-results-bio-20180227monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-authorizes-new-250-million-share-repurchase-program-bio-20171128monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2017-financial-results-bio-20171102monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2017-financial-results-bio-20170803monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2017-financial-results-bio-20170504monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2016-financial-results-bio-20170223monthly0.5https://www.biopharmawatch.com/news/BIO/to-all-record-holders-and-beneficial-owners-of-the-common-stock-of-bio-rad-laboratories-in-bio-20161227monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-currency-neutral-revenue-growth-of-9-1-percent-bio-20161101monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2016-financial-results-bio-20160803monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2016-currency-neutral-revenue-growth-of-nearly-4-percent-her-bio-20160505monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2015-financial-results-bio-20160225monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2015-financial-results-hercules-ca-bio-20151103monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2015-financial-results-hercules-ca-bio-20150806monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2015-financial-results-hercules-ca-bio-20150505monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2014-financial-results-hercules-ca-bio-20150226monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2014-financial-results-hercules-ca-bio-20141104monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-laboratories-resolves-foreign-corrupt-practices-act-matters-with-u-s-government-fu-bio-20141103monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-appoints-john-goetz-as-chief-operating-officer-and-announces-other-executive-appoi-bio-20141001monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2014-financial-results-hercules-ca-bio-20140805monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-announces-the-appointment-of-new-board-member-hercules-ca-bio-20140725monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2014-financial-results-hercules-ca-bio-20140506monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2013-financial-results-hercules-ca-bio-20140227monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2013-financial-results-hercules-ca-bio-20131107monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2013-financial-results-hercules-ca-bio-20130806monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2013-financial-results-hercules-ca-bio-20130507monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2012-financial-results-hercules-ca-bio-20130226monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2012-financial-results-hercules-ca-bio-20121106monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-2012-financial-results-hercules-ca-bio-20120807monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-first-quarter-2012-financial-results-hercules-ca-bio-20120501monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-fourth-quarter-and-full-year-2011-financial-results-hercules-ca-bio-20120223monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-announces-the-appointment-of-new-board-member-hercules-ca-bio-20111101monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-revenue-growth-of-more-than-9-percent-hercules-ca-bio-20111101monthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-reports-second-quarter-revenue-growth-of-11-5-percent-hercules-ca-bio-20110802monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-the-closing-of-its-acquisition-of-bright-healthcare-s-californ-moh-20240102monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-amends-terms-for-acquisition-of-bright-healthcare-s-california-medicare--moh-20231218monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-the-closing-of-its-acquisition-of-my-choice-wisconsin-long-bea-moh-20230905monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-of-new-mexico-receives-notification-of-intent-to-award-new-medicaid-cont-moh-20230814monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-to-acquire-bright-healthcare-s-california-medicare-business-transaction--moh-20230630monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-promotions-of-two-senior-executives-long-beach-calif-business--moh-202305162023-05-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-of-indiana-recommended-for-mltss-award-long-beach-calif-business-wire-moh-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-the-closing-of-its-acquisition-of-agewell-new-york-s-managed-l-moh-20221003monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-selected-for-nebraska-medicaid-managed-care-program-long-beach-calif-bus-moh-20220926monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-wins-iowa-medicaid-contract-long-beach-calif-business-wire-moh-20220831monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-to-acquire-my-choice-wisconsin-transaction-expands-molina-s-medicaid-man-moh-20220713monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-pricing-of-750-million-of-senior-notes-due-2032-long-beach-cal-moh-20211101monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-proposed-offering-of-750-million-of-senior-notes-due-2032-long-moh-20211101monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-signs-ceo-joe-zubretsky-to-new-employment-agreement-long-beach-calif-bus-moh-20210909monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-wins-ohio-medicaid-contracts-long-beach-calif-business-wire-moh-20210413monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-inc-jp-morgan-healthcare-conference-joe-zubretsky-president-and-chief-ex-moh-20210114monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-the-closing-of-its-acquisition-of-magellan-complete-care-long--moh-20210104monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-cfo-transition-with-retirement-of-tom-tran-in-2021-mark-keim-t-moh-20201119monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-closing-of-offering-of-650-million-of-3-875-senior-notes-due-2-moh-20201117monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-pricing-of-650-million-of-senior-notes-due-2030-long-beach-cal-moh-20201102monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-proposed-offering-of-650-million-of-senior-notes-due-2030-long-moh-20201102monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-to-acquire-affinity-health-plan-represents-excellent-fit-with-existing-p-moh-20200929monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-closing-of-offering-of-800-million-of-4-375-senior-notes-due-2-moh-20200602monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-wins-kentucky-medicaid-contract-long-beach-calif-business-wire-moh-20200529monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-pricing-of-offering-of-800-million-of-senior-notes-due-2028-lo-moh-20200528monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-proposed-offering-of-800-million-of-senior-notes-due-2028-long-moh-20200528monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-reports-first-quarter-2020-financial-results-reaffirms-2020-earnings-gui-moh-20200430monthly0.5https://www.biopharmawatch.com/news/MOH/molina-expands-executive-leadership-team-with-key-hires-and-appointments-new-executives-wi-moh-20200109monthly0.5https://www.biopharmawatch.com/news/MOH/molina-to-acquire-nextlevel-health-partners-expands-illinois-presence-with-cook-county-mem-moh-20200106monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-inc-announces-500-million-common-stock-repurchase-program-long-beach-cal-moh-20191213monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-inc-investor-day-2019-moh-20190530monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-agreement-with-infosys-to-improve-information-technology-infra-moh-20190206monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-inc-j-p-morgan-healthcare-conference-joe-zubretskypresident-chief-execut-moh-20190107monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-renews-agreement-with-cvs-caremark-for-pharmacy-benefit-management-long--moh-20190103monthly0.5https://www.biopharmawatch.com/news/MOH/unaudited-pro-forma-condensed-consolidated-financial-statements-the-following-unaudited-pr-moh-20181019monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-completes-sale-of-medicaid-management-information-systems-business-to-dx-moh-20181001monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-notice-of-redemption-of-1-625-convertible-senior-notes-long-be-moh-20180711monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-of-puerto-rico-awarded-contract-for-island-wide-medicaid-managed-care-pr-moh-20180709monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-reaches-agreement-with-dxc-technology-to-sell-medicaid-management-inform-moh-20180627monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-awarded-florida-medicaid-managed-care-contracts-long-beach-calif-busines-moh-20180618monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-inc-investor-day-2018-moh-20180531monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-elects-richard-zoretic-to-board-of-directors-long-beach-calif-business-w-moh-20180529monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-selected-for-medicaid-contract-awards-in-all-eight-regions-of-the-state--moh-20180524monthly0.5https://www.biopharmawatch.com/news/MOH/thomas-l-tran-named-new-chief-financial-officer-of-molina-healthcare-as-joseph-w-white-ann-moh-20180524monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-pricing-of-synthetic-exchange-transaction-long-beach-calif-bus-moh-20180306monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-resignation-of-john-molina-from-the-board-of-directors-long-be-moh-20180226monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-chief-operating-officer-terry-bayer-to-retire-long-beach-calif-business--moh-20180111monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-resignation-of-dr-j-mario-molina-from-the-board-of-directors-l-moh-20171213monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-pricing-of-synthetic-exchange-transaction-long-beach-calif-bus-moh-20171207monthly0.5https://www.biopharmawatch.com/news/MOH/juan-jos-orellana-laura-murray-investor-relations-public-relations-562-435-3666-562-506-92-moh-20171010monthly0.5https://www.biopharmawatch.com/news/MOH/exhibit-news-release-contact-juan-jos-orellana-investor-relations-562-435-3666-ext-111143--moh-20170606monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-pricing-of-offering-moh-20170522monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-announces-leadership-changes-cao-joseph-w-white-named-interim-ceo-and-ap-moh-20170502monthly0.5https://www.biopharmawatch.com/news/MOH/molina-healthcare-reports-first-quarter-2017-results-long-beach-calif-business-wire-moh-20170502monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2026-financial-results-bio.b-20260430monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2025-financial-results-bio.b-20260212monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2025-financial-results-bio.b-20251029monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-laboratories-inc-co-founder-and-director-emeritus-alice-schwartz-passes-away-bio.b-20250929monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2025-financial-results-bio.b-20250731monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-appoints-rajat-mehta-executive-vice-president-global-commercial-operations-bio.b-20250728monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2025-financial-results-bio.b-20250501monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2024-financial-results-bio.b-20250213monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2024-financial-results-bio.b-20241030monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-appoints-jon-divincenzo-president-chief-operating-officer-bio.b-20240820monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2024-financial-results-bio.b-20240801monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2024-financial-results-bio.b-20240507monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-announces-life-science-group-management-changes-bio.b-20240426monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-s-chief-operating-officer-andrew-last-to-retire-bio.b-20240410monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-appoints-roop-k-lakkaraju-executive-vice-president-chief-financial-officer-bio.b-20240320monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2023-financial-results-bio.b-20240215monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2023-financial-results-bio.b-20231026monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2023-financial-results-bio.b-20230803monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2023-financial-results-hercules-calif-bio.b-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2022-financial-results-bio.b-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2022-financial-results-bio.b-20221027monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2022-financial-results-hercules-calif-bio.b-20220728monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2022-financial-results-bio.b-20220428monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-announces-closing-of-1-2-billion-aggregate-senior-notes-offering-bio.b-20220302monthly0.5https://www.biopharmawatch.com/news/BIO.B/f-e-b-r-u-a-r-y-2-5-2-0-2-2-bio-rad-investor-laboratories-inc-day-2022-forward-looking-sta-bio.b-20220225monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2021-financial-results-bio.b-20220210monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2021-financial-results-bio.b-20211028monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2021-financial-results-bio.b-20210729monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2021-financial-results-bio.b-20210429monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2020-financial-results-bio.b-20210211monthly0.5https://www.biopharmawatch.com/news/BIO.B/outlook-2021-2023-bio-rad-laboratories-inc-bio.b-20201210monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2020-financial-results-bio.b-20201029monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2020-financial-results-bio.b-20200730monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2020-financial-results-bio.b-20200506monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2019-financial-results-bio.b-20200213monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2019-financial-results-bio.b-20191031monthly0.5https://www.biopharmawatch.com/news/BIO.B/corrected-press-release-bio-rad-reports-second-quarter-2019-financial-results-bio.b-20190827monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2019-financial-results-bio.b-20190801monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2019-financial-results-bio.b-20190508monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-appoints-andrew-last-as-executive-vice-president-and-chief-operating-officer-bio.b-20190422monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-names-ilan-daskal-executive-vice-president-and-chief-financial-officer-bio.b-20190402monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-laboratories-inc-receives-expected-nyse-notice-regarding-late-form-10-k-filing-bio.b-20190325monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2018-financial-results-bio.b-20190228monthly0.5https://www.biopharmawatch.com/news/BIO.B/christine-tsingos-announces-plans-to-retire-as-cfo-of-bio-rad-laboratories-inc-effective-bio.b-20190103monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2018-financial-results-bio.b-20181101monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2018-financial-results-bio.b-20180807monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2018-financial-results-bio.b-20180508monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-laboratories-inc-receives-expected-nyse-notice-regarding-late-form-10-k-filing-bio.b-20180322monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2017-financial-results-bio.b-20180227monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-authorizes-new-250-million-share-repurchase-program-bio.b-20171128monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2017-financial-results-bio.b-20171102monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2017-financial-results-bio.b-20170803monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2017-financial-results-bio.b-20170504monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2016-financial-results-bio.b-20170223monthly0.5https://www.biopharmawatch.com/news/BIO.B/to-all-record-holders-and-beneficial-owners-of-the-common-stock-of-bio-rad-laboratories-in-bio.b-20161227monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-currency-neutral-revenue-growth-of-9-1-percent-bio.b-20161101monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2016-financial-results-bio.b-20160803monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2016-currency-neutral-revenue-growth-of-nearly-4-percent-her-bio.b-20160505monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2015-financial-results-bio.b-20160225monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2015-financial-results-hercules-ca-bio.b-20151103monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2015-financial-results-hercules-ca-bio.b-20150806monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2015-financial-results-hercules-ca-bio.b-20150505monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2014-financial-results-hercules-ca-bio.b-20150226monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2014-financial-results-hercules-ca-bio.b-20141104monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-laboratories-resolves-foreign-corrupt-practices-act-matters-with-u-s-government-fu-bio.b-20141103monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-appoints-john-goetz-as-chief-operating-officer-and-announces-other-executive-appoi-bio.b-20141001monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2014-financial-results-hercules-ca-bio.b-20140805monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-announces-the-appointment-of-new-board-member-hercules-ca-bio.b-20140725monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2014-financial-results-hercules-ca-bio.b-20140506monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2013-financial-results-hercules-ca-bio.b-20140227monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2013-financial-results-hercules-ca-bio.b-20131107monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2013-financial-results-hercules-ca-bio.b-20130806monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2013-financial-results-hercules-ca-bio.b-20130507monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2012-financial-results-hercules-ca-bio.b-20130226monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-2012-financial-results-hercules-ca-bio.b-20121106monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-2012-financial-results-hercules-ca-bio.b-20120807monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-first-quarter-2012-financial-results-hercules-ca-bio.b-20120501monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-fourth-quarter-and-full-year-2011-financial-results-hercules-ca-bio.b-20120223monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-announces-the-appointment-of-new-board-member-hercules-ca-bio.b-20111101monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-third-quarter-revenue-growth-of-more-than-9-percent-hercules-ca-bio.b-20111101monthly0.5https://www.biopharmawatch.com/news/BIO.B/bio-rad-reports-second-quarter-revenue-growth-of-11-5-percent-hercules-ca-bio.b-20110802monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quarter-ended-imvt-20250811monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-imvt-20250529monthly0.5https://www.biopharmawatch.com/news/IMVT/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-for-the-imvt-20250114monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-provides-development-updates-and-reports-financial-results-for-the-quarter-ende-imvt-20241107monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-provides-update-on-graves-disease-development-program-high-dose-batoclimab-achi-imvt-20240909monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-and-provides-corporate-updates-for-the-quarter-ended-imvt-20240806monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-imvt-20240529monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-and-provides-corporate-updates-for-the-quarter-ended-imvt-20240212monthly0.5https://www.biopharmawatch.com/news/IMVT/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-for-the-imvt-20240109monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-positive-initial-phase-2-results-for-batoclimab-in-graves-disease-imvt-20231220monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-positive-imvt-1402-initial-600-mg-mad-results-that-confirm-best-in-cl-imvt-20231128monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-and-provides-corporate-updates-for-the-quarter-ended-imvt-20231109monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-positive-initial-imvt-1402-phase-1-sad-and-300-mg-subcutaneous-mad-re-imvt-20230926monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-and-provides-corporate-updates-for-the-quarter-ended-imvt-20230810monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-imvt-20230522monthly0.5https://www.biopharmawatch.com/news/IMVT/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-for-the-imvt-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-and-recent-business-updates-for-the-quarter-ended-imvt-202302032023-02-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-for-the-imvt-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-for-the-imvt-20221208monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-and-recent-business-updates-for-the-quarter-ended-imvt-20221104monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-pricing-of-75-0-million-underwritten-offering-of-common-stock-new-yor-imvt-20221004monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-imvt-1402-a-next-generation-anti-fcrn-in-animal-studies-deep-igg-lowe-imvt-20220928monthly0.5https://www.biopharmawatch.com/news/IMVT/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-for-the-imvt-20220907monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-and-recent-business-updates-for-the-quarter-ended-imvt-20220805monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-achieves-alignment-with-fda-on-plans-for-phase-3-clinical-trials-of-batoclimab--imvt-20220608monthly0.5https://www.biopharmawatch.com/news/IMVT/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-for-the-imvt-20220330monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-for-the-quarter-ended-imvt-20220204monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-imvt-20220107monthly0.5https://www.biopharmawatch.com/news/IMVT/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-for-the-imvt-20220105monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-provides-regulatory-update-regarding-initiation-of-phase-3-trial-for-batoclimab-imvt-20211230monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-the-stifel-2021-virtual-healthcare-conference-imvt-20211112monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-for-the-quarter-ended-imvt-20211105monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-participate-in-roivant-r-d-day-2021-imvt-20210927monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-appoints-renee-barnett-as-chief-financial-officer-ms-barnett-brings-a-wealth-of-imvt-20210915monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-for-the-quarter-ended-imvt-20210809monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-receives-200-million-strategic-investment-from-roivant-sciences-proceeds-will-f-imvt-20210802monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-for-the-quarter-and-nine-months-ended-imvt-20210216monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-voluntary-pause-in-clinical-dosing-of-imvt-1401-imvt-20210202monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-for-the-quarter-and-six-months-ended-imvt-20201112monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-positive-topline-results-from-multi-center-placebo-controlled-phase-2-imvt-20200825monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-for-the-quarter-ended-imvt-20200812monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-for-the-quarter-and-fiscal-year-ended-imvt-20200629monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-redemption-of-warrants-and-achievement-of-first-earnout-milestone-und-imvt-20200514monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-positive-clinical-results-from-ongoing-phase-2a-proof-of-concept-stud-imvt-20200330monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-for-the-quarter-and-nine-months-ending-imvt-20200214monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-sciences-ltd-closes-transaction-with-health-sciences-acquisitions-corporation-c-imvt-20191219monthly0.5https://www.biopharmawatch.com/news/IMVT/health-sciences-acquisitions-corporation-sets-date-for-special-meeting-of-stockholders-to--imvt-20191202monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-initiates-dosing-in-ascend-go-2-a-phase-2b-trial-of-imvt-1401-in-patients-with--imvt-20191125monthly0.5https://www.biopharmawatch.com/news/IMVT/corporate-overview-november-2019-imvt-20191114monthly0.5https://www.biopharmawatch.com/news/IMVT/graves-ophthalmopathy-go-or-thyroid-eye-disease-is-an-autoimmune-disease-mediated-by-patho-imvt-20191112monthly0.5https://www.biopharmawatch.com/news/IMVT/this-report-is-prepared-solely-imvt-20191029monthly0.5https://www.biopharmawatch.com/news/IMVT/o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-imvt-20191015monthly0.5https://www.biopharmawatch.com/news/IMVT/health-sciences-acquisitions-corporation-and-immunovant-to-host-joint-conference-call-for--imvt-20191008monthly0.5https://www.biopharmawatch.com/news/IMVT/chardan-advises-health-sciences-acquisitions-corporation-on-merger-with-immunovant-imvt-20191003monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-merge-with-health-sciences-acquisitions-corporation-creating-new-publicly-li-imvt-20191002monthly0.5https://www.biopharmawatch.com/news/IMVT/health-sciences-acquisitions-corporation-index-to-financial-statement-report-of-independen-imvt-20190514monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business--pcvx-20250225monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-third-quarter-2024-financial-results-and-provides-business-update-company--pcvx-20241105monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-positive-topline-data-from-phase-1-2-study-of-vax-31-its-31-valent-pneumoc-pcvx-20240903monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-second-quarter-2024-financial-results-and-provides-business-update-vax-31--pcvx-20240806monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-first-quarter-2024-financial-results-and-provides-business-update-vax-31-a-pcvx-20240508monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business--pcvx-20240227monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-third-quarter-2023-financial-results-and-provides-business-update-complete-pcvx-20231106monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-second-quarter-2023-financial-results-and-provides-business-update-advance-pcvx-20230808monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-first-quarter-2023-financial-results-and-provides-business-update-positive-pcvx-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-positive-data-from-phase-2-study-of-its-24-valent-pneumococcal-conjugate-v-pcvx-202304172023-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business--pcvx-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-third-quarter-2022-financial-results-and-provides-business-update-vaxcyte--pcvx-20221107monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-positive-topline-data-from-phase-1-2-proof-of-concept-study-of-its-24-vale-pcvx-20221024monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-second-quarter-2022-financial-results-and-provides-business-update-complet-pcvx-20220808monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-first-quarter-2022-financial-results-and-provides-business-update-company--pcvx-20220509monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business--pcvx-20220228monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-third-quarter-2021-financial-results-and-provides-business-update-company--pcvx-20211110monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-second-quarter-2021-financial-results-and-provides-business-update-pcvx-20210811monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-first-quarter-2021-financial-results-and-provides-business-update-pcvx-20210511monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business--pcvx-20210329monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-third-quarter-2020-financial-results-and-provides-business-update-foster-c-pcvx-20201112monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-second-quarter-2020-financial-results-and-provides-business-update-foster--pcvx-20200812monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-opt-pcvx-20200616monthly0.5https://www.biopharmawatch.com/news/GKOS/disclaimer-all-statements-other-than-statements-of-historical-facts-included-in-this-prese-gkos-20260504monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-clewis-glaukos-com-glaukos-gkos-20260429monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-march-2026-about-glaukos-2-xa9-2026-glaukos-corporation-disclaimer-a-gkos-20260302monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20260217monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-contact-chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0-gkos-20260113monthly0.5https://www.biopharmawatch.com/news/GKOS/november-2025-investor-presentation-disclaimer-all-statements-other-than-statements-of-his-gkos-20251110monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20251029monthly0.5https://www.biopharmawatch.com/news/GKOS/august-2025-investor-presentation-disclaimer-all-statements-other-than-statements-of-histo-gkos-20250812monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20250730monthly0.5https://www.biopharmawatch.com/news/GKOS/may-2025-investor-presentation-disclaimer-all-statements-other-than-statements-of-historic-gkos-20250514monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20250430monthly0.5https://www.biopharmawatch.com/news/GKOS/march-2025-investor-presentation-disclaimer-all-statements-other-than-statements-of-histor-gkos-20250312monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20250220monthly0.5https://www.biopharmawatch.com/news/GKOS/january-2025-investor-presentation-disclaimer-all-statements-other-than-statements-of-hist-gkos-20250114monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-november-2024-disclaimer-all-statements-other-than-statements-of-his-gkos-20241115monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20241104monthly0.5https://www.biopharmawatch.com/news/GKOS/notice-of-full-redemption-glaukos-corporation-2-75-convertible-senior-notes-due-2027-cusip-gkos-20241011monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-august-2024-disclaimer-all-statements-other-than-statements-of-histo-gkos-20240809monthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-corporation-condensed-consolidated-statements-of-operations-unaudited-in-thousands-gkos-20240802monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20240731monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20240614monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-may-2024-disclaimer-all-statements-other-than-statements-of-historic-gkos-20240520monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20240501monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-february-2024-disclaimer-all-statements-other-than-statements-of-his-gkos-20240228monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20240221monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-contact-chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0-gkos-20240109monthly0.5https://www.biopharmawatch.com/news/GKOS/glaucoma-stefanie-tuck-978-390-1394-stefanie-jpa-com-investor-contact-chris-lewis-vice-pre-gkos-20231214monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20231101monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-august-2023-disclaimer-all-statements-other-than-statements-of-histo-gkos-20230818monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20230802monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-may-2023-disclaimer-all-statements-other-than-statements-of-historic-gkos-20230517monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-march-2023-disclaimer-all-statements-other-than-statements-of-histor-gkos-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-january-2023-disclaimer-all-statements-other-than-statements-of-hist-gkos-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-november-2022-2-xa9-2022-glaukos-corporation-disclaimer-all-statemen-gkos-20221115monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20221102monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-september-2022-2-xa9-2022-glaukos-corporation-disclaimer-all-stateme-gkos-20220907monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20220803monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-may-2022-2-2022-glaukos-corporation-disclaimer-all-statements-other--gkos-20220523monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20220504monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-march-2022-2-xa9-2022-glaukos-corporation-disclaimer-all-statements--gkos-20220302monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-vice-president-investor-relations-corporate-affairs-949-481-0510-clewis-glauko-gkos-20220222monthly0.5https://www.biopharmawatch.com/news/GKOS/cassandra-dump-619-971-1887-cassy-pascalecommunications-com-investor-contact-chris-lewis-v-gkos-20220207monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-january-2022-2-xa9-2022-glaukos-corporation-disclaimer-all-statement-gkos-20220111monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-sr-director-investor-relations-corporate-strategy-development-949-481-0510-cle-gkos-20211220monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2021-glaukos-corporation-investor-relations-presentation-november-2021-2-xa9-2021-glau-gkos-20211122monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-sr-director-investor-relations-corporate-strategy-development-949-481-0510-cle-gkos-20211104monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2021-glaukos-corporation-august-2021-2-xa9-2021-glaukos-corporation-disclaimer-all-sta-gkos-20210818monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-sr-director-investor-relations-corporate-strategy-development-949-481-0510-cle-gkos-20210805monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-sr-director-investor-relations-corporate-strategy-development-949-481-0510-cle-gkos-20210505monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2021-glaukos-corporation-march-2021-2-xa9-2021-glaukos-corporation-disclaimer-all-stat-gkos-20210304monthly0.5https://www.biopharmawatch.com/news/GKOS/cassandra-dump-619-971-1887-cassy-pascalecommunications-com-investor-contact-chris-lewis-d-gkos-20210301monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20210225monthly0.5https://www.biopharmawatch.com/news/GKOS/cassandra-dump-619-971-1887-cassy-pascalecommunications-com-investor-contact-chris-lewis-d-gkos-20210113monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2020-glaukos-corporation-1-november-2020-2-xa9-2020-glaukos-corporation-disclaimer-all-gkos-20201110monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20201105monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20200806monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20200608monthly0.5https://www.biopharmawatch.com/news/GKOS/financial-statements-of-avedro-report-of-independent-registered-public-accounting-firm-to--gkos-20200608monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2020-glaukos-corporation-1-may-2020-2-xa9-2020-glaukos-corporation-disclaimer-all-stat-gkos-20200511monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20200507monthly0.5https://www.biopharmawatch.com/news/GKOS/gkos-exh99-1-for-immediate-release-investor-contact-chris-lewis-director-investor-relation-gkos-20200409monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-contact-chris-lewis-director-investor-relations-corporate-development-strategy-94-gkos-20200324monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2020-glaukos-corporation-1-march-2020-2-xa9-2020-glaukos-corporation-disclaimer-all-st-gkos-20200306monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20200227monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2020-glaukos-corporation-1-january-2020-2-xa9-2020-glaukos-corporation-disclaimer-all--gkos-20200115monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20191121monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2019-glaukos-corporation-1-november-2019-transforming-ophthalmology-acquisition-of-2-x-gkos-20191017monthly0.5https://www.biopharmawatch.com/news/GKOS/gkos-ex99-1-for-immediate-release-contact-chris-lewis-director-investor-relations-corporat-gkos-20191106monthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-and-avedro-announce-definitive-acquisition-agreement-gkos-20190808monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2019-glaukos-corporation-1-gkos-20190807monthly0.5https://www.biopharmawatch.com/news/GKOS/gkos-ex99-1-for-immediate-release-contact-chris-lewis-director-investor-relations-corporat-gkos-20190807monthly0.5https://www.biopharmawatch.com/news/GKOS/gkos-ex99-1-for-immediate-release-media-contact-cassandra-dump-619-971-1887-cassy-pascalec-gkos-20190619monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2019-glaukos-corporation-1-may-2019-2-xa9-2019-glaukos-corporation-all-statements-othe-gkos-20190513monthly0.5https://www.biopharmawatch.com/news/GKOS/gkos-ex99-1-for-immediate-release-contact-chris-lewis-director-investor-relations-corporat-gkos-20190508monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2019-glaukos-corporation-1-march-2019-2-xa9-2019-glaukos-corporation-all-statements-ot-gkos-20190312monthly0.5https://www.biopharmawatch.com/news/GKOS/gkos-ex99-1-for-immediate-release-contact-chris-lewis-director-investor-relations-corporat-gkos-20190227monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2019-glaukos-corporation-1-january-2019-2-xa9-2019-glaukos-corporation-all-statements--gkos-20190108monthly0.5https://www.biopharmawatch.com/news/GKOS/xa9-2018-glaukos-corporation-1-november-2018-2-xa9-2018-glaukos-corporation-all-statements-gkos-20181116monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20181107monthly0.5https://www.biopharmawatch.com/news/GKOS/september-2018-1-xa9-2018-glaukos-corporation-1-disclaimer-all-statements-other-than-state-gkos-20180905monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20180802monthly0.5https://www.biopharmawatch.com/news/GKOS/may-2018-1-xa9-2018-glaukos-corporation-1-disclaimer-all-statements-other-than-statements--gkos-20180515monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20180509monthly0.5https://www.biopharmawatch.com/news/GKOS/cassandra-dump-619-971-1887-cassy-pascalecommunications-com-investor-contact-chris-lewis-d-gkos-20180414monthly0.5https://www.biopharmawatch.com/news/GKOS/march-2018-1-xa9-2018-glaukos-corporation-1-disclaimer-all-statements-other-than-statement-gkos-20180301monthly0.5https://www.biopharmawatch.com/news/GKOS/chris-lewis-director-investor-relations-corporate-strategy-development-949-481-0510-clewis-gkos-20180228monthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-xae-transforming-glaucoma-therpy-january-2018-1-xa9-2018-glaukos-corporation-1-dis-gkos-20180110monthly0.5https://www.biopharmawatch.com/news/GKOS/november-2017-1-xa9-2017-glaukos-corporation-1-disclaimer-all-statements-other-than-statem-gkos-20171109monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-481-0361-saronson-glaukos-com-glaukos-corporation-gkos-20171107monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-481-0361-saronson-glaukos-com-glaukos-to-outline--gkos-20170914monthly0.5https://www.biopharmawatch.com/news/GKOS/august-2017-xa9-2017-glaukos-corporation-2-xa9-2017-glaukos-corporation-disclaimer-all-sta-gkos-20170809monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-481-0361-saronson-glaukos-com-glaukos-corporation-gkos-20170802monthly0.5https://www.biopharmawatch.com/news/GKOS/may-2017-xa9-2017-glaukos-corporation-2-xa9-2017-glaukos-corporation-disclaimer-all-statem-gkos-20170515monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-cor-gkos-20170503monthly0.5https://www.biopharmawatch.com/news/GKOS/march-2017-2017-glaukos-corporation-2-2017-glaukos-corporation-disclaimer-all-statements-o-gkos-20170310monthly0.5https://www.biopharmawatch.com/news/GKOS/as-of-02242017-for-immediate-release-contact-sheree-aronson-vp-investor-relations-949-367--gkos-20170301monthly0.5https://www.biopharmawatch.com/news/GKOS/cassandra-dump-619-971-1887-cassy-pascalecommunications-com-investor-contact-sheree-aronso-gkos-20170206monthly0.5https://www.biopharmawatch.com/news/GKOS/cassandra-dump-619-971-1887-cassy-pascalecommunications-com-investor-contact-sheree-aronso-gkos-20170201monthly0.5https://www.biopharmawatch.com/news/GKOS/january-2017-2-disclaimer-all-statements-other-than-statements-of-historical-facts-include-gkos-20170110monthly0.5https://www.biopharmawatch.com/news/GKOS/growth-strategies-establishing-migs-as-oag-standard-of-care-01020304-increase-us-istentsec-gkos-20161129monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-cor-gkos-20161110monthly0.5https://www.biopharmawatch.com/news/GKOS/august-2016-2-disclaimer-all-statements-other-than-statements-of-historical-facts-included-gkos-20160804monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-cor-gkos-20160801monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-ann-gkos-20160714monthly0.5https://www.biopharmawatch.com/news/GKOS/june-2016-2016-glaukos-corporation-2-2016-glaukos-corporation-disclaimer-all-statements-ot-gkos-20160606monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-cor-gkos-20160503monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-ann-gkos-20160414monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-cor-gkos-20160301monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-pro-gkos-20160112monthly0.5https://www.biopharmawatch.com/news/GKOS/investor-presentation-december-2-4-2015-2-all-statements-other-than-statements-of-historic-gkos-20151202monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-cor-gkos-20151110monthly0.5https://www.biopharmawatch.com/news/GKOS/sheree-aronson-vp-investor-relations-949-367-9600-ext-371-saronson-glaukos-com-glaukos-cor-gkos-20150812monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-full-results-for-q1-2026-q1-2026-results-in-line-with-pre-announcement-net--qgen-20260506monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-exceeds-q4-2025-outlook-driven-by-growth-pillars-q4-2025-net-sales-of-540-million-4-qgen-20260204monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-details-for-completion-of-synthetic-share-repurchase-of-up-to-approximate-qgen-20251222monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-exceeds-q3-2025-outlook-raises-fy-2025-adj-eps-target-announces-parse-acquisition-a-qgen-20251104monthly0.5https://www.biopharmawatch.com/news/QGEN/not-for-release-publication-or-distribution-into-or-in-the-united-states-canada-australia--qgen-20250828monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-exceeds-outlook-for-q2-2025-with-solid-growth-and-improved-profitability-q2-2025-re-qgen-20250805monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-election-of-stephen-rusckowski-as-chairman-of-supervisory-board-stephen-h-qgen-20250626monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-delivers-solid-q1-2025-results-exceeding-outlook-will-seek-shareholder-approval-to--qgen-20250507monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-delivers-strong-preliminary-q1-2025-results-exceeding-outlook-and-raises-full-year--qgen-20250406monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-delivers-solid-q4-2024-growth-ahead-of-outlook-q4-2024-net-sales-of-521-million-2-a-qgen-20250205monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-details-for-completion-of-synthetic-share-repurchase-of-up-to-approximate-qgen-20250116monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-return-approximately-300-million-to-shareholders-through-a-synthetic-share-repur-qgen-20250112monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-delivers-solid-q3-2024-growth-ahead-of-outlook-increases-full-year-2024-adjusted-ep-qgen-20241106monthly0.5https://www.biopharmawatch.com/news/QGEN/the-bonds-are-not-intended-to-be-offered-sold-or-otherwise-made-available-to-and-should-no-qgen-20240904monthly0.5https://www.biopharmawatch.com/news/QGEN/not-for-release-publication-or-distribution-into-or-in-the-united-states-canada-australia--qgen-20240903monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-delivers-solid-performance-and-exceeds-outlook-for-q2-2024-q2-2024-net-sales-of-496-qgen-20240731monthly0.5https://www.biopharmawatch.com/news/QGEN/notice-of-the-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-the-annua-qgen-20240802monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-2028-strategy-for-solid-profitable-growth-hosts-capital-markets-day-event-qgen-20240617monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-discontinue-neumodx-integrated-pcr-testing-system-support-customers-during-trans-qgen-20240606monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-results-for-q1-2024-ahead-of-outlook-on-track-to-achieve-full-year-2024-gui-qgen-20240429monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-details-for-completion-of-synthetic-share-repurchase-of-up-to-approximate-qgen-20240118monthly0.5https://www.biopharmawatch.com/news/QGEN/document-qiagen-announces-plans-to-return-approximately-300-million-to-shareholders-capita-qgen-20240107monthly0.5https://www.biopharmawatch.com/news/QGEN/notice-of-the-annual-general-meeting-of-shareholders-qgen-20231101monthly0.5https://www.biopharmawatch.com/news/QGEN/news-thermo-fisher-media-contact-information-karen-kirkwood-phone-781-622-1306-e-mail-kare-qgen-20200716monthly0.5https://www.biopharmawatch.com/news/QGEN/confidential-and-privileged-execution-version-business-combination-agreement-between-therm-qgen-20200306monthly0.5https://www.biopharmawatch.com/news/QGEN/news-for-immediate-release-thermo-fisher-media-contact-information-karen-kirkwood-phone-78-qgen-20200303monthly0.5https://www.biopharmawatch.com/news/QGEN/table-of-contents-qgen-20120426monthly0.5https://www.biopharmawatch.com/news/QGEN/table-of-contents-qgen-20110201monthly0.5https://www.biopharmawatch.com/news/QGEN/table-of-contents-qgen-20101109monthly0.5https://www.biopharmawatch.com/news/QGEN/table-of-contents-qgen-20100504monthly0.5https://www.biopharmawatch.com/news/QGEN/table-of-contents-qgen-20090811monthly0.5https://www.biopharmawatch.com/news/QGEN/table-of-contents-qgen-20090210monthly0.5https://www.biopharmawatch.com/news/QGEN/information-qiagen-investors-dr-solveigh-m-hler-011-49-2103-29-11710-media-dr-thomas-theur-qgen-20070730monthly0.5https://www.biopharmawatch.com/news/QGEN/information-qiagen-investors-dr-solveigh-m-hler-inside-the-us-240-686-2222-international-4-qgen-20070723monthly0.5https://www.biopharmawatch.com/news/QGEN/peer-m-schatz-chief-executive-officer-qiagen-n-v-49-2103-29-11702-e-mail-peer-schatz-qiage-qgen-20040804monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-closure-of-bothell-seattle-facility-decision-expected-to-increase-qiagen--qgen-20030514monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-4th-annual-ubs-warburg-global-life-sciences-conference-venlo-the--qgen-20021115monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-affymetrix-enter-into-supply-agreement-for-nucleic-acid-purification-solutions--qgen-20020830monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-provides-update-on-business-outlook-venlo-the-netherlands-qgen-20020703monthly0.5https://www.biopharmawatch.com/news/QGEN/dex99-txt-press-release-qiagen-logo-contacts-peer-m-schatz-noonan-russo-presence-chief-fin-qgen-20020701monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-opens-north-american-headquarters-in-montgomery-county-maryland-venlo-the-netherlan-qgen-20020531monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-release-of-first-quarter-2026-financial-results-and-provides-corporat-celc-20260514monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-s-phase-3-viktoria-1-trial-achieves-primary-endpoint-with-clinically-meaningful-i-celc-20260501monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-appoints-charles-romp-to-its-board-of-directors-minneapolis-celc-20260212monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-completion-of-submission-of-its-new-drug-application-to-the-u-s-fda-for-celc-20251117monthly0.5https://www.biopharmawatch.com/news/CELC/detailed-results-from-pik3ca-wild-type-cohort-of-phase-3-viktoria-1-trial-presented-at-202-celc-20251020monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-upsized-senior-secured-term-loan-facility-of-500-million-with-innovatus-celc-20250909monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-second-quarter-2025-financial-results-and-provides-corporate-update-r-celc-20250814monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-announces-pricing-of-concurrent-public-offerings-of-2-750-convertible-senior--celc-20250730monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-announces-concurrent-public-offerings-of-convertible-senior-notes-due-2031-an-celc-20250728monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-clinically-meaningful-improvement-in-both-progression-free-survival-pfs-celc-20250728monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-first-quarter-2025-financial-results-and-provides-corporate-update-th-celc-20250514monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corp-celc-20250331monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-third-quarter-financial-results-and-provides-corporate-update-the-pik-celc-20241114monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-second-quarter-financial-results-and-provides-corporate-update-announ-celc-20240814monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-pricing-of-underwritten-common-stock-offering-minneapolis-celc-20240530monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-announces-plan-to-initiate-a-phase-3-clinical-trial-for-gedatolisib-as-first--celc-20240530monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-first-quarter-financial-results-and-provides-corporate-update-the-pha-celc-20240515monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corp-celc-20240327monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-third-quarter-2023-financial-results-and-provides-corporate-updates-r-celc-20231113monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-announces-50-million-private-placement-minneapolis-mn-celc-20231018monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-plan-to-conduct-phase-1b-2-clinical-trial-in-metastatic-castration-resi-celc-20230822monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-second-quarter-2023-financial-results-and-provides-corporate-updates--celc-20230810monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-first-quarter-2023-financial-results-and-provides-corporate-updates-p-celc-202305152023-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corp-celc-202303232023-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-third-quarter-2022-financial-results-and-provides-corporate-update-co-celc-20221110monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-appoints-polly-murphy-d-v-m-ph-d-to-board-of-directors-seasoned-executive-brings--celc-20220914monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-second-quarter-2022-financial-results-and-provides-corporate-update-g-celc-20220811monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-announces-100-million-private-placement-proceeds-to-advance-clinical-developm-celc-20220516monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-first-quarter-2022-financial-results-and-business-updates-entered-int-celc-20220516monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-reports-fourth-quarter-and-full-year-2021-financial-results-pivotal-phase-3-t-celc-20220323monthly0.5https://www.biopharmawatch.com/news/CELC/to-celcuity-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-celc-20211108monthly0.5https://www.biopharmawatch.com/news/CELC/to-celcuity-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-celc-20210809monthly0.5https://www.biopharmawatch.com/news/CELC/to-celcuity-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-celc-20210630monthly0.5https://www.biopharmawatch.com/news/CELC/to-celcuity-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-celc-20210510monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-worldwide-licensing-agreement-with-pfizer-to-develop-and-commercialize--celc-20210408monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-proposed-public-offering-of-common-celc-20210224monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-business-h-celc-20210216monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-third-quarter-2020-financial-results-and-recent-business-highlights-new-c-celc-20201109monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-second-quarter-2020-financial-results-and-recent-business-highlights-pres-celc-20200810monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-first-quarter-2020-financial-results-and-recent-business-highlights-s-ign-celc-20200507monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-fourth-quarter-and-full-year-2019-financial-results-minneapolis-minnesota-celc-20200312monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-presents-results-at-the-2019-san-antonio-breast-cancer-symposium-evaluating-a-sub-celc-20191211monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-appointment-of-richard-buller-to-board-of-directors-minneapolis-minneso-celc-20191205monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-third-quarter-2019-financial-results-minneapolis-minnesota-x2014-celc-20191107monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-second-quarter-2019-financial-results-minneapolis-minnesota-celc-20190808monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-appointment-of-leo-furcht-to-board-of-directors-minneapolis-minnesota-celc-20190520monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-first-quarter-2019-financial-results-minneapolis-minnesota-celc-20190507monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-fourth-quarter-and-full-year-2018-financial-results-minneapolis-minnesota-celc-20190226monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-third-quarter-2018-financial-results-minneapolis-minnesota-celc-20181113monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-second-quarter-2018-financial-results-minneapolis-minnesota-celc-20180809monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-first-quarter-2018-financial-results-minneapolis-minnesota-celc-20180514monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-fourth-quarter-and-full-year-2017-financial-results-minneapolis-minnesota-celc-20180315monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-third-quarter-fiscal-2017-financial-results-minneapolis-minnesota-celc-20171113monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-pricing-of-initial-public-offering-celc-20170920monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20260615monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20260512monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20260505monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20260225monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20260212monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-x2-alks-20260112monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20260106monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-plc-announces-increased-offer-to-acquire-avadel-pharmaceuticals-plc-not-for-relea-alks-20251119monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20251112monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20251028monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20251022monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20250912monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20250908monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20250729monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20250721monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20250501monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20250212monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-x2-alks-20250113monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-x2-alks-20241202monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20241024monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-note-regarding-forward-looking-statements-certain-statements-se-alks-20241009monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20240724monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20240501monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20240409monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20240307monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20240215monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-x2-alks-20240108monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-60-alks-20231214monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-301-32-alks-20231115monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20231031monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20231025monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20231023monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-marisa-borgasano-1-7-alks-20230830monthly0.5https://www.biopharmawatch.com/news/ALKS/ale-alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-78-alks-20230726monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20230606monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-files-preliminary-proxy-statement-and-provides-update-on-annual-director-nominati-alks-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alex-alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-7-alks-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alex-alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-7-alks-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-fo-alks-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/ale-alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-78-alks-20221102monthly0.5https://www.biopharmawatch.com/news/ALKS/alex-alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-7-alks-20220727monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-announces-results-of-annual-general-meeting-of-shareholders-all-board-nominees-ov-alks-20220707monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20220526monthly0.5https://www.biopharmawatch.com/news/ALKS/alex-alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-7-alks-20220427monthly0.5https://www.biopharmawatch.com/news/ALKS/alex-alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-7-alks-20220216monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-fo-alks-20220111monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20211119monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20211108monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20211027monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20210728monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-marisa-borgasano-1-7-alks-20210601monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20210520monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20210430monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20210428monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-and-non-gaap-financial-information-certain-statements-set-forth-alks-20210325monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20210211monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-fo-alks-20210111monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-60-alks-20210106monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-60-alks-20201210monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-eva-stroynowski-1-78-alks-20201117monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20201029monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-marisa-borgasano-1-7-alks-20201009monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-katie-joyce-1-781-24-alks-20200729monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-eva-stroynowski-1-78-alks-20200429monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-eva-stroynowski-1-78-alks-20200213monthly0.5https://www.biopharmawatch.com/news/ALKS/th-annual-j-p-morgan-healthcare-conference-alks-20200115monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-eva-stroynowski-1-78-alks-20191125monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-eva-stroynowski-1-78-alks-20191118monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20191030monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-eva-stroynowski-1-78-alks-20191023monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-matthew-henson-1-781-alks-20190913monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20190730monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-matthew-henson-1-781-alks-20190725monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-gretchen-murphy-1-78-alks-20190715monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-matthew-henson-1-781-alks-20190425monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-matthew-henson-1-781-alks-20190408monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-matthew-henson-1-781-alks-20190214monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-for-media-sherry-feldberg-1-78-alks-20190201monthly0.5https://www.biopharmawatch.com/news/ALKS/forward-looking-statements-certain-statements-set-forth-in-this-presentation-constitute-fo-alks-20190102monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-eva-stroynowski-1-781-609-6823-sandy-coombs-1-781-609-6377-alks-20181129monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-eva-stroynowski-1-781-609-6823-sandy-coombs-1-781-609-6377-alks-20181101monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-eva-stroynowski-1-781-609-6823-alks-20181023monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-eva-stroynowski-1-781-609-6823-alks-20180726monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-eva-stroynowski-1-781-609-6823-sandy-coombs-1-781-609-6377-alks-20180702monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-eva-stroynowski-1-781-609-6823-alks-20180426monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-eva-stroynowski-1-781-609-6823-sandy-coombs-1-781-609-6377-alks-20180416monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-eva-stroynowski-1-781-609-6823-sandy-coombs-1-781-609-6377-alks-20180402monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-eva-stroynowski-1-781-609-6823-sandy-coombs-1-781-609-6377-alks-20180301monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-eva-stroynowski-1-781-609-6823-alks-20180214monthly0.5https://www.biopharmawatch.com/news/ALKS/relevant-slides-from-alkermes-plc-s-presentation-at-the-j-p-morgan-healthcare-conference-i-alks-20180109monthly0.5https://www.biopharmawatch.com/news/ALKS/biogen-contacts-for-investors-matt-calistri-1-781-464-2442-for-media-matt-fearer-1-781-464-alks-20171127monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-eva-stroynowski-1-781-609-6823-alks-20171026monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-eva-stroynowski-1-781-609-6823-alks-20170727monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-eva-stroynowski-1-781-609-6823-sandy-coombs-1-781-609-6377-alks-20170629monthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-contacts-for-investors-sandy-coombs-1-781-609-6377-eva-stroynowski-1-781-609-6823-alks-20170427monthly0.5https://www.biopharmawatch.com/news/HQY/conduent-incorporated-100-campus-drive-florham-park-n-j-07932-www-conduent-com-conduent-s--hqy-20230919monthly0.5https://www.biopharmawatch.com/news/HQY/healthequity-completes-further-acquisition-expands-hsa-market-share-health-plan-relationsh-hqy-20211101monthly0.5https://www.biopharmawatch.com/news/HQY/fifth-third-bank-hsas-moving-to-healthequity-draper-utah-globe-newswire-hqy-20210427monthly0.5https://www.biopharmawatch.com/news/HQY/healthequity-expands-commuter-offering-with-luum-acquisition-adds-options-beyond-monthly-t-hqy-20210308monthly0.5https://www.biopharmawatch.com/news/HQY/copyright-2020-healthequity-inc-all-rights-reserved-investor-update-hqy-20200707monthly0.5https://www.biopharmawatch.com/news/HQY/healthequity-completes-acquisition-of-wageworks-announces-80-100-million-investment-in-rem-hqy-20190830monthly0.5https://www.biopharmawatch.com/news/HQY/healthequity-and-wageworks-announce-hsr-clearance-draper-utah-and-san-mateo-california-glo-hqy-20190730monthly0.5https://www.biopharmawatch.com/news/HQY/unaudited-pro-forma-combined-condensed-financial-information-of-healthequity-on-hqy-20190626monthly0.5https://www.biopharmawatch.com/news/HQY/wageworks-inc-and-subsidiaries-index-to-consolidated-financial-statements-page-reports-of--hqy-20190708monthly0.5https://www.biopharmawatch.com/news/HQY/healthequity-to-acquire-wageworks-accelerating-market-wide-transition-to-hsas-delivers-sus-hqy-20190627monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-55-msa-20260505monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20260504monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20260226monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20260211monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20251028monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20250813monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20250804monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20250507monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20250429monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20250313monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20250212monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20241023monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20240724monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20240605monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20240513monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20240429monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-55-msa-20240222monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20240214monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20231024monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20230731monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-55-msa-20230626monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-msa-media-contact-mark-deasy-1-412-559-81-msa-20230531monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20230501monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20230215monthly0.5https://www.biopharmawatch.com/news/MSA/unaudited-pro-forma-condensed-consolidated-financial-statements-on-msa-20230105monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20221026monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20220727monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20220427monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20220217monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20211027monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20210728monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-contact-mark-deasy-412-559-8154-inv-msa-20210524monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20210428monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20210218monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20201028monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-412-559-81-msa-20200729monthly0.5https://www.biopharmawatch.com/news/MSA/msa-safety-announces-strong-first-quarter-results-msa-20200429monthly0.5https://www.biopharmawatch.com/news/MSA/item-1a-risk-factors-pandemics-or-disease-outbreaks-such-as-covid-19-may-cause-unfavorable-msa-20200320monthly0.5https://www.biopharmawatch.com/news/MSA/msa-announces-fourth-quarter-and-full-year-2019-results-msa-20200219monthly0.5https://www.biopharmawatch.com/news/MSA/msa-safety-announces-third-quarter-results-msa-20191023monthly0.5https://www.biopharmawatch.com/news/MSA/douglas-mcclaine-announces-plans-to-retire-from-msa-msa-20191003monthly0.5https://www.biopharmawatch.com/news/MSA/msa-announces-second-quarter-results-msa-20190724monthly0.5https://www.biopharmawatch.com/news/MSA/exhibit-for-immediate-release-from-msa-safety-incorporated-ticker-msa-nyse-media-contact-m-msa-20190521monthly0.5https://www.biopharmawatch.com/news/MSA/msa-announces-first-quarter-results-msa-20190424monthly0.5https://www.biopharmawatch.com/news/MSA/msa-safety-to-acquire-industrial-internet-of-things-solution-provider-sierra-monitor-corpo-msa-20190329monthly0.5https://www.biopharmawatch.com/news/MSA/msa-announces-fourth-quarter-and-full-year-2018-results-msa-20190220monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-724-741-85-msa-20181024monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-724-741-85-msa-20180725monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-contact-mark-deasy-724-741-8570-inv-msa-20180515monthly0.5https://www.biopharmawatch.com/news/MSA/msa-announces-record-first-quarter-results-msa-20180423monthly0.5https://www.biopharmawatch.com/news/MSA/msa-announces-fourth-quarter-and-full-year-2017-results-msa-20180220monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-contact-mark-deasy-724-741-8570-inv-msa-20171101monthly0.5https://www.biopharmawatch.com/news/MSA/msa-announces-third-quarter-results-msa-20171019monthly0.5https://www.biopharmawatch.com/news/MSA/msa-announces-second-quarter-results-msa-20170803monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-contact-mark-deasy-724-741-8570-inv-msa-20170628monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-724-741-85-msa-20170425monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-724-741-85-msa-20170223monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-724-74-msa-20170215monthly0.5https://www.biopharmawatch.com/news/MSA/unaudited-reportable-segment-information-is-presented-in-the-following-tables-in-thousands-msa-20160503monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-724-74-msa-20150901monthly0.5https://www.biopharmawatch.com/news/MSA/from-msa-safety-incorporated-ticker-msa-nyse-media-relations-contact-mark-deasy-724-741-85-msa-20150513monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-proposed-public-offering-watertown-mass-kymr-20251208monthly0.5https://www.biopharmawatch.com/news/KYMR/kt-621-oral-stat6-degrader-phase-1b-results-1-agenda-introduction-justine-koenigsberg-vice-kymr-20251208monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-positive-results-from-broaden-phase-1b-clinical-trial-of-kt--kymr-20251208monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2025-financial-results-and-provides-a-busines-kymr-20250731monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-proposed-public-offering-watertown-mass-kymr-20250625monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-sanofi-irak4-collaboration-update-sanofi-to-advance-kymera-s-kymr-20250625monthly0.5https://www.biopharmawatch.com/news/KYMR/gilead-info-jessica-smith-media-public-affairs-gilead-com-jacquie-ross-investors-investor--kymr-20250625monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-positive-first-in-human-results-from-phase-1-healthy-volunte-kymr-20250602monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-quarter-2025-financial-results-and-provides-a-business-kymr-20250509monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-prov-kymr-20250227monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-outlines-key-2025-objectives-and-strategy-to-advance-industry-leading--kymr-20250114monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-third-quarter-2024-financial-results-and-provides-a-business-kymr-20241031monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-proposed-public-offering-watertown-mass-kymr-20240819monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2024-financial-results-and-provides-a-busines-kymr-20240807monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-announces-expansion-of-kt-474-sar444656-hs-and-ad-phase-2-studies-following-interim-kymr-20240708monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-quarter-2024-financial-results-and-provides-a-business-kymr-20240502monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-prov-kymr-20240222monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-proposed-public-offering-watertown-mass-kymr-20240104monthly0.5https://www.biopharmawatch.com/news/KYMR/immunology-r-d-day-kymr-20240104monthly0.5https://www.biopharmawatch.com/news/KYMR/r-d-day-highlights-kymera-s-immunology-strategy-and-emerging-pipeline-of-novel-first-in-cl-kymr-20240104monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-new-clinical-data-from-the-phase-1-trial-of-stat3-degrader--kymr-20231102monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-third-quarter-2023-financial-results-and-provides-a-business-kymr-20231102monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2023-financial-results-and-provides-a-busines-kymr-20230803monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-appoints-jeremy-chadwick-ph-d-as-chief-operating-officer-watertown-mass-kymr-20230522monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-quarter-2023-financial-results-and-provides-a-business-kymr-20230504monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and-prov-kymr-20230223monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-shares-key-2023-goals-to-support-its-evolution-into-a-fully-integrated-kymr-20230110monthly0.5https://www.biopharmawatch.com/news/KYMR/kt-474-hs-and-ad-clinical-data-and-oncology-pipeline-update-c-o-m-p-a-n-y-w-e-b-c-a-s-t-kymr-20221214monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-announces-positive-results-from-phase-1-clinical-trial-evaluating-kt-474-in-patient-kymr-20221214monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-third-quarter-2022-financial-results-and-provides-a-business-kymr-20221103monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-hold-investor-webcast-on-december-14-to-share-clinical-data-from-kt-kymr-20221013monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-announces-150-million-private-placement-equity-financing-watertown-mass-kymr-20220819monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2022-financial-results-and-provides-a-busines-kymr-20220809monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-inc-consolidated-statements-of-operations-in-thousands-except-share-an-kymr-20220503monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-prov-kymr-20220224monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-discloses-new-kt-474-clinical-data-unveils-new-development-program-provides-oncolog-kymr-20211216monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-third-quarter-2021-financial-results-and-provides-a-business-kymr-20211110monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-positive-data-demonstrating-robust-irak4-degradation-and-firs-kymr-20211027monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2021-financial-results-and-provides-a-busines-kymr-20210806monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-positive-interim-results-from-single-ascending-dose-phase-1--kymr-20210628monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-quarter-2021-financial-results-and-provides-a-business-kymr-20210506monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-prov-kymr-20210311monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-in-human-dose-in-phase-1-trial-of-kt-474-a-first-in-cl-kymr-20210302monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-key-2021-goals-and-milestones-to-support-its-evolution-into--kymr-20210112monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-third-quarter-2020-financial-results-and-provides-business-u-kymr-20201105monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-the-addition-of-diagnostics-industry-leader-jack-phillips-to-its-board-of-brkr-20251208monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2025-financial-results-x2022-q3-2025-revenues-of-860-5-millio-brkr-20251103monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2025-financial-results-x2022-q2-2025-revenues-of-797-4-milli-brkr-20250804monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-second-quarter-2025-preliminary-results-plans-to-hold-q2-earnings-confere-brkr-20250721monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-and-10x-genomics-reach-global-settlement-of-patent-litigation-billerica-massachuset-brkr-20250514monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2025-financial-results-x2022-q1-2025-revenues-of-801-4-millio-brkr-20250507monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-first-quarter-2025-preliminary-revenue-billerica-massachusetts-x2014-brkr-20250411monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-laura-francis-to-its-board-of-directors-brkr-20250221monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-full-year-2024-financial-results-x2022-q4-2024-revenues--brkr-20250213monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2024-financial-results-x2022-q3-2024-revenues-of-864-4-millio-brkr-20241105monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2024-financial-results-x2022-q2-2024-revenues-of-800-7-milli-brkr-20240806monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-public-offering-of-common-stock-brkr-20240529monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2024-financial-results-x2022-q1-2024-revenues-of-721-7-millio-brkr-20240502monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-completes-acquisition-of-molecular-diagnostics-innovator-elitech-x2022-elitech-is-a-brkr-20240502monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-to-acquire-the-nanostring-business-in-an-asset-deal-nanostring-is-an-established-le-brkr-20240422monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-full-year-2023-financial-results-x2022-q4-2023-revenues--brkr-20240213monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2023-financial-results-x2022-q3-2023-revenues-of-742-8-millio-brkr-20231102monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2023-financial-results-x2022-q2-2023-revenues-of-681-9-milli-brkr-20230803monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-new-two-year-share-repurchase-authorization-of-up-to-500-million-board-de-brkr-20230515monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2023-financial-results-x2022-q1-2023-revenues-of-685-3-millio-brkr-20230504monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-fiscal-year-2022-financial-results-x2022-q4-2022-revenue-brkr-20230209monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2022-financial-results-x2022-q3-2022-reported-revenue-growth--brkr-20221103monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2022-financial-results-x2022-q2-2022-reported-revenue-growth-brkr-20220803monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-financial-results-x2022-q1-2022-revenue-growth-of-7-3-year-ov-brkr-20220504monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-philip-ma-to-its-board-of-directors-brkr-20220316monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-fiscal-year-2021-financial-results-q4-2021-revenues-683--brkr-20220211monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2021-financial-results-q3-2021-revenues-of-608-9-million-up-1-brkr-20211101monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2021-financial-results-q2-2021-revenue-growth-of-34-4-year-o-brkr-20210802monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-updates-fy-2021-guidance-and-provides-medium-term-outlook-at-virtual-investor-day-brkr-20210617monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-new-two-year-share-repurchase-authorization-of-up-to-500-million-board-al-brkr-20210513monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2021-financial-results-q1-2021-revenue-growth-of-30-8-year-ov-brkr-20210505monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-first-quarter-2021-preliminary-revenue-brkr-20210413monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-fiscal-year-2020-financial-results-q4-2020-revenues-up-4-brkr-20210216monthly0.5https://www.biopharmawatch.com/news/BRKR/the-field-allows-up-to-17-characters-brkr-20201102monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-bonnie-h-anderson-to-its-board-of-directors-brkr-20200908monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2020-financial-results-covid-19-disruption-and-softer-demand-brkr-20200803monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2020-financial-results-q1-2020-revenue-decline-of-8-1-year-ov-brkr-20200506monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-final-fourth-quarter-and-fiscal-year-2019-financial-results-q4-2019-reven-brkr-20200327monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-receives-notification-from-nasdaq-related-to-delayed-annual-report-on-form-10-k-brkr-20200305monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2019-financial-results-q3-19-revenue-growth-of-11-7-and-organ-brkr-20191031monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2019-financial-results-q2-19-revenue-growth-of-10-5-and-orga-brkr-20190801monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-new-300-million-share-repurchase-authorization-and-quarterly-dividend-brkr-20190510monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2019-financial-results-q1-2019-revenue-growth-of-6-9-year-ove-brkr-20190502monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-fiscal-year-2018-financial-results-q4-2018-revenue-growt-brkr-20190211monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2018-financial-results-brkr-20181101monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2018-financial-results-brkr-20180802monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-appoints-gerald-herman-as-chief-financial-officer-brkr-20180606monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2018-financial-results-brkr-20180503monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-gerald-herman-as-interim-chief-financial-officer-brkr-20180314monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-resignation-of-chief-financial-officer-and-appointment-of-principal-accou-brkr-20180221monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-fiscal-year-2017-financial-results-brkr-20180208monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2017-financial-results-brkr-20171102monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2017-financial-results-brkr-20170803monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-new-225-million-share-repurchase-program-and-quarterly-dividend-brkr-20170512monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2017-financial-results-brkr-20170503monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-fiscal-year-2016-financial-results-brkr-20170213monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-bruker-drives-profitable-growth-and-margin-expansion-by-enabling-scient-brkr-20170109monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2016-financial-results-brkr-20161102monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2016-financial-results-brkr-20160802monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2016-financial-results-brkr-20160504monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-appoints-anthony-mattacchione-as-chief-financial-officer-brkr-20160222monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-fiscal-year-2015-financial-results-fiscal-year-2015-fy-1-brkr-20160210monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-robert-rosenthal-to-board-of-directors-brkr-20151116monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-new-225-million-share-repurchase-program-brkr-20151113monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2015-financial-results-company-reports-solid-organic-revenue--brkr-20151104monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-ren-lenggenhager-as-biospin-group-president-brkr-20151013monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-mr-john-ornell-to-board-of-directors-brkr-20150820monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-names-dr-hermann-requardt-to-board-of-directors-former-ceo-of-siemens-healthcare-br-brkr-20150807monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2015-financial-results-brkr-20150805monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-resignation-of-chief-financial-officer-and-appointment-of-interim-chief-f-brkr-20150520monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2015-financial-results-brkr-20150506monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-full-year-2014-financial-results-brkr-20150219monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-third-quarter-2014-financial-results-brkr-20141106monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-second-quarter-2014-financial-results-brkr-20140806monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-first-quarter-2014-financial-results-brkr-20140507monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-and-full-year-2013-financial-results-brkr-20140218monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-announces-the-appointment-of-dr-gilles-martin-to-its-board-of-directors-brkr-20140113monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-third-quarter-2013-financial-results-brkr-20131101monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-second-quarter-2013-financial-results-company-s-financial-resul-brkr-20130731monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-first-quarter-2013-financial-results-brkr-20130502monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-fourth-quarter-and-full-year-2012-financial-results-company-del-brkr-20130219monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-financial-results-for-the-third-quarter-of-2012-brkr-20121105monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-financial-results-for-the-second-quarter-and-first-half-of-2012-brkr-20120731monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-preliminary-second-quarter-2012-revenue-and-eps-as-well-as-planned-earnin-brkr-20120724monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-appoints-charles-f-wagner-jr-as-executive-vice-president-and-new-chief--brkr-20120607monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-energy-supercon-technologies-best-inc-investor-presentation-may-2012-best-is-a-whol-brkr-20120507monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-first-quarter-2012-financial-results-brkr-20120501monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-to-release-first-quarter-2012-financial-results-on-brkr-20120424monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-financial-results-for-the-fourth-quarter-and-full-year-2011-brkr-20120222monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-nasdaq-brkr-30th-annual-j-p-morgan-healthcare-conference-brkr-20120109monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-financial-results-for-the-third-quarter-of-2011-brkr-20111027monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-william-j-knight-as-chief-financial-officer-billerica-mass-business-wire-brkr-20110914monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-nasdaq-brkr-jefferies-field-trip-investor-presentation-brkr-20110808monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-financial-results-for-the-second-quarter-and-first-half-year-of-brkr-20110803monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-announces-cfo-transition-brkr-20110602monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-first-quarter-2011-financial-results-brkr-20110428monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-financial-results-for-the-fourth-quarter-and-full-year-2010-brkr-20110223monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-board-meeting-brkr-20110112monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-financial-results-for-the-third-quarter-of-2010-brkr-20101028monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-completes-acquisition-of-the-atomic-force-microscopy-and-optical-industrial-metrolo-brkr-20101007monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-energy-supercon-technologies-inc-files-registration-statement-for-initial-public-of-brkr-20100903monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-agreement-to-acquire-veeco-s-scanning-probe-microscopy-spm-and-optical-in-brkr-20100816monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-elects-charles-wagner-as-independent-director-billerica-mass-business-w-brkr-20100803monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-financial-results-for-the-second-quarter-and-first-half-year-of-brkr-20100728monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-first-quarter-2010-financial-results-brkr-20100429monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-and-agilent-technologies-announce-agreement-for-bruker-to-acquire-certain-varian-in-brkr-20100309monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-record-financial-results-for-the-fourth-quarter-and-full-year-2-brkr-20100225monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-announces-management-promotions-and-strong-fourth-quarter-2009-preliminary-operatin-brkr-20100204monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-brkr-28th-j-p-morgan-healthcare-conference-brkr-20100113monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-appoints-william-j-knight-to-chief-operating-officer-and-brian-p-monaha-brkr-20091109monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-third-quarter-2009-financial-results-brkr-20091029monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-brkr-presentation-at-thomas-weisel-partners-healthcare-conference-2009-brkr-20090911monthly0.5https://www.biopharmawatch.com/news/BRKR/japan-special-supplementary-budget-ssb-initial-global-stimulus-orders-for-10m-received-1-j-brkr-20090825monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-second-quarter-2009-financial-results-brkr-20090729monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-brkr-overview-company-presentation-brkr-20090617monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-brkr-overview-goldman-sachs-30th-global-healthcare-conference-brkr-20090609monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-brkr-overview-bank-of-america-merrill-lynch-2009-health-care-conference-brkr-20090512monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-first-quarter-2009-results-brkr-20090430monthly0.5https://www.biopharmawatch.com/news/BRKR/copyright-2009-bruker-corporation-all-rights-reserved-1-bruker-corporation-brkr-overview-j-brkr-20090416monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-reports-financial-results-for-the-fourth-quarter-and-full-year-2008-200-brkr-20090303monthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-corporation-brkr-presentation-at-27th-j-p-morgan-healthcare-conference-brkr-20090114monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-completes-acquisition-of-life-molecular-imaging-and-appoints-dr-ludger-dinkelborg-lnth-20250722monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-first-quarter-2025-financial-results-and-provides-business-update-worldwi-lnth-20250507monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-completes-acquisition-of-evergreen-theragnostics-lnth-20250401monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-fourth-quarter-and-full-year-2024-financial-performance-worldwide-revenue-lnth-20250226monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-appoints-phuong-khanh-p-k-morrow-m-d-as-new-board-member-lnth-20250130monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-st-lnth-20250128monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-acquire-life-molecular-imaging-for-an-upfront-payment-of-350-million-to-accele-lnth-20250113monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-share-repurchase-program-lnth-20241120monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-third-quarter-2024-financial-results-worldwide-revenue-of-378-7-million-a-lnth-20241106monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-appoints-julie-eastland-as-new-board-member-lnth-20240905monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-second-quarter-2024-financial-results-second-quarter-2024-worldwide-reven-lnth-20240731monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-acquires-global-rights-to-life-molecular-imaging-s-novel-therapeutic-and-diagnost-lnth-20240627monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-executive-appointments-to-accelerate-innovation-jeffrey-s-humphrey-md-a-lnth-20240515monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-first-quarter-2024-financial-results-first-quarter-2024-worldwide-revenue-lnth-20240502monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-fourth-quarter-and-full-year-2023-financial-results-worldwide-revenue-of--lnth-20240222monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-ceo-succession-plan-lantheus-board-member-and-pharmaceutical-industry-v-lnth-20240123monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-preliminary-fiscal-year-2023-revenue-full-year-2023-worldwide-revenue-exp-lnth-20240109monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-third-quarter-2023-financial-results-worldwide-revenue-of-319-9-million-f-lnth-20231102monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-second-quarter-2023-financial-results-worldwide-revenue-of-321-7-million--lnth-20230803monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-first-quarter-2023-financial-results-worldwide-revenue-of-300-8-million-f-lnth-20230504monthly0.5https://www.biopharmawatch.com/news/LNTH/burlington-road-bedford-ma-01730-800-362-2668-www-lantheus-com-lantheus-announces-two-key--lnth-20230317monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-fourth-quarter-and-full-year-2022-financial-results-worldwide-revenue-of--lnth-20230223monthly0.5https://www.biopharmawatch.com/news/LNTH/burlington-road-bedford-ma-01730-800-362-2668-www-lantheus-com-lantheus-announces-acquisit-lnth-20230206monthly0.5https://www.biopharmawatch.com/news/LNTH/safe-harbor-statements-2023-lantheus-all-rights-reserved-cautionary-statement-regarding-fo-lnth-20230111monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-closing-of-strategic-collaboration-and-exclusive-license-agreements-for-lnth-20221220monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-announces-pricing-of-offering-of-500-million-convertible-senior-note-lnth-20221206monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-announces-proposed-offering-of-500-million-convertible-senior-notes--lnth-20221205monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-reports-t-lnth-20221103monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-reports-s-lnth-20220804monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-announces-lnth-20220615monthly0.5https://www.biopharmawatch.com/news/LNTH/welcome-opening-remarks-mark-kinarney-senior-director-investor-relations-safe-harbor-and-n-lnth-20220517monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20220429monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-announces-lnth-20220301monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20220224monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20211104monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20210728monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-receives--lnth-20210527monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20210504monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-announces-lnth-20210401monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-reports-f-lnth-20210225monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20201209monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20201203monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20201118monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20201105monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20200930monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20200730monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-completes-merger-with-progenics-north-billerica-mass-and-new-york-business-wire-lnth-20200622monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-stockholders-approve-share-issuance-for-merger-with-progenics-lnth-20200616monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20200430monthly0.5https://www.biopharmawatch.com/news/LNTH/velan-capital-agrees-to-support-merger-of-lantheus-and-progenics-north-billerica-mass-and--lnth-20200414monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-for-immediate-rele-lnth-20200409monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-and-progenics-reschedule-their-respective-special-meetings-of-stockholders-for-pr-lnth-20200402monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20200225monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-and-progenics-agree-to-amended-transaction-terms-combination-to-create-robust-por-lnth-20200220monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-announces-lnth-20200203monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20200127monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20200106monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-releases-comprehensive-strategic-plan-for-progenics-lantheus-value-creating-visio-lnth-20191107monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20191031monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-acquire-progenics-to-form-a-leading-precision-diagnostics-imaging-and-therapeu-lnth-20191002monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20190725monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20190430monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-for-immediate-rele-lnth-20190325monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20190219monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20181030monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-appoints-robert-j-marshall-jr-as-chief-financial-officer-and-treasurer-n-lnth-20180820monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20180801monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20180502monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20180227monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-for-release-4-02-p-lnth-20170801monthly0.5https://www.biopharmawatch.com/news/LNTH/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-lnth-20170616monthly0.5https://www.biopharmawatch.com/news/LNTH/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-lnth-20170505monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-for-release-4-02-p-lnth-20170502monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-and-ge-healthcare-announce-the-signing-of-a-definitive-license-agreement-for-worl-lnth-20170425monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-refinancing-of-its-debt-facility-increases-available-liquidity-positive-lnth-20170330monthly0.5https://www.biopharmawatch.com/news/LNTH/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-lnth-20170315monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-lantheus-holdings--lnth-20170221monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-and-ge-healthcare-announce-the-signing-of-a-term-sheet-for-worldwide-dev-lnth-20170221monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-immediate-release--lnth-20170126monthly0.5https://www.biopharmawatch.com/news/LNTH/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-lnth-20161117monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-for-release-4-02-p-lnth-20161101monthly0.5https://www.biopharmawatch.com/news/LNTH/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-lnth-20160913monthly0.5https://www.biopharmawatch.com/news/LNTH/meara-murphy-978-671-8508-lantheus-holdings-announces-divestiture-of-its-australian-radiop-lnth-20160811monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-for-release-4-02-lnth-20160804monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-contacts-meara-mur-lnth-20160503monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-contact-meara-murp-lnth-20160328monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-for-immediate-rele-lnth-20160308monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-for-release-4-02-p-lnth-20160222monthly0.5https://www.biopharmawatch.com/news/LNTH/treble-cove-road-north-billerica-ma-01862-800-362-2668-www-lantheus-com-contact-meara-murp-lnth-20160113monthly0.5https://www.biopharmawatch.com/news/CNTA/uk-employment-agreement-this-employment-agreement-this-agreement-is-made-by-and-between-ce-cnta-20260107monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-150-000-000-proposed-public-offering-of-american-deposi-cnta-20240911monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-announces-positive-interim-phase-1-clinical-data-with-its-novel-orexin-receptor-2-cnta-20240910monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-strengthens-executive-leadership-with-appointment-of-john-crowley-cnta-20240610monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-100-million-proposed-public-offering-of-american-deposi-cnta-20240423monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-preclinical-data-supporting-orx750-s-potential-as-a-bes-cnta-20231025monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-busines-cnta-20220516monthly0.5https://www.biopharmawatch.com/news/CNTA/document-centessa-pharmaceuticals-doses-first-subject-in-global-phase-3-action-study-of-li-cnta-20220224monthly0.5https://www.biopharmawatch.com/news/CNTA/document-centessa-pharmaceuticals-initiates-global-phase-3-action-study-of-lixivaptan-in-a-cnta-20211214monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-demonstrates-proof-of-mechanism-from-first-three-pimz-subjects-do-cnta-20211101monthly0.5https://www.biopharmawatch.com/news/CNTA/document-centessa-pharmaceuticals-announces-300-million-financing-agreement-with-oberland--cnta-20211004monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-positive-phase-2-part-a-52-week-data-of-zumilokibart-apg777--apge-20260323monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-positive-interim-results-from-phase-1b-trial-of-zumilokibart-apge-20260106monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-inc-condensed-consolida-ted-statement-of-operations-unaudited-in-thous-apge-20250811monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-provides-business-update-pipeline-progress-and-reports-first-quarter-2-apge-20250512monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-full-year-2024-financial-result-apge-20250303monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-first-patient-dosed-in-part-b-of-phase-2-apex-trial-of-apg77-apge-20250203monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-first-participants-dosed-in-phase-1-clinical-trial-of-apg333-apge-20241210monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-highlights-progress-and-best-in-class-potential-of-novel-biologic-prog-apge-20241202monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-third-quarter-2024-financial-re-apge-20241112monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-results-up-to-9-months-from-phase-1-trial-of-apg777-its-nove-apge-20241024monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-first-participants-dosed-in-phase-1-clinical-trial-of-apg990-apge-20240819monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-second-quarter-2024-financial-r-apge-20240812monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-expands-board-of-directors-with-the-appointment-of-lisa-bollinger-md-s-apge-20240528monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-announces-dosing-of-first-patient-in-phase-2-atopic-dermatitis-trial-of-apg777-a-no-apge-20240515monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-highlights-pipeline-progress-and-reports-first-quarter-2024-financial--apge-20240513monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-first-participants-dosed-in-phase-1-trial-of-apg808-its-nove-apge-20240325monthly0.5https://www.biopharmawatch.com/news/APGE/apg777-phase-1-data-march-2024-xa9-apogee-therapeutics-inc-2-disclaimers-and-forward-looki-apge-20240305monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-fourth-quarter-and-full-year-20-apge-20240305monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-highlights-corporate-progress-and-reports-third-quarter-2023-financial-results-phas-apge-20231113monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-highlights-corporate-progress-and-reports-second-quarter-2023-financial-results-345-apge-20230828monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-appoints-mark-c-mckenna-healthcare-veteran-and-former-chairman-preside-apge-20230821monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-announces-first-participants-dosed-ahead-of-schedule-in-phase-1-trial-of-apg777-its-apge-20230807monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20260617monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20260325monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20260219monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20260122monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20251231monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-financial-results-oncology-development-progra-cort-20251104monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20250910monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-financial-results-and-provides-corporate-upd-cort-20250731monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20250714monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-financial-results-and-provides-corporate-upda-cort-20250505monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20250331monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20250303monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2024-audited-financial-results-cort-20250226monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20241230monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-financial-results-positive-results-from-phase-cort-20241030monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-financial-results-and-provides-corporate-upd-cort-20240729monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-financial-results-and-provides-corporate-upda-cort-20240501monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-financial-results-and-provides-corporate-upd-cort-20240215monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-communications-corcept-com-www-corcept-c-cort-20240108monthly0.5https://www.biopharmawatch.com/news/CORT/investor-inquiries-ir-corcept-com-media-inquiries-corceptcommunications-corcept-com-www-co-cort-20240102monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-financial-results-and-provides-corporate-upda-cort-20231101monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-financial-results-and-provides-corporate-upd-cort-20230802monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-financial-results-and-provides-corporate-upda-cort-20230503monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2022-audited-financial-results-cort-20230228monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-investor-relations-ir-corcept-com-www-corcept-com-c-orcept-t-herapeut-cort-20230213monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-investor-relations-ir-corcept-com-www-corcept-com-c-orcept-t-herapeut-cort-20221208monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-financial-results-and-provides-corporate-upda-cort-20221103monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-financial-results-and-provides-corporate-upd-cort-20220803monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-financial-results-and-provides-corporate-upda-cort-20220505monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2021-audited-financial-results-cort-20220215monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-investor-relations-ir-corcept-com-www-corcept-com-corcep-cort-20211208monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-financial-results-and-provides-corporate-upda-cort-20211103monthly0.5https://www.biopharmawatch.com/news/CORT/investor-relations-ir-corcept-com-www-corcept-com-w-illiam-g-uyer-to-join-c-orcept-as-c-hi-cort-20210812monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-financial-results-and-provides-corporate-upd-cort-20210729monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-settles-patent-litigation-with-sun-pharmaceutical-menlo-park-calif-cort-20210615monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-joshua-m-murray-to-board-of-directors-menlo-park-calif-cort-20210610monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-provides-clinical-update-and-announces-first-quarter-2021-financial-r-cort-20210506monthly0.5https://www.biopharmawatch.com/news/CORT/christopher-s-james-md-director-investor-relations-corcept-therapeutics-650-684-8725-cjame-cort-20210301monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2020-audited-financial-results-cort-20210223monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-full-year-2020-preliminary-selected-financia-cort-20210208monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-gillian-m-cannon-phd-to-board-of-directors-menlo-park-calif-cort-20201123monthly0.5https://www.biopharmawatch.com/news/CORT/u-s-patent-trial-and-appeals-board-affirms-validity-of-all-claims-of-corcept-s-u-s-patent--cort-20201118monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2020-financial-results-and-provides-corporate-cort-20201103monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2020-financial-results-and-provides-corporat-cort-20200804monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2020-financial-results-and-provides-corporate-cort-20200504monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-gregg-alton-to-board-of-directors-menlo-park-calif-cort-20200312monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2019-audited-financial-results-cort-20200220monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2019-preliminary-selected-fina-cort-20200130monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2019-financial-results-and-provides-corporate-cort-20191107monthly0.5https://www.biopharmawatch.com/news/CORT/christopher-s-james-md-director-investor-relations-corcept-therapeutics-650-684-8725-cjame-cort-20190918monthly0.5https://www.biopharmawatch.com/news/CORT/charles-robb-chief-financial-officer-corcept-therapeutics-650-688-8783-crobb-corcept-com-w-cort-20190205monthly0.5https://www.biopharmawatch.com/news/CORT/charles-robb-chief-financial-officer-corcept-therapeutics-650-688-8783-crobb-corcept-com-w-cort-20170501monthly0.5https://www.biopharmawatch.com/news/CORT/charles-robb-chief-financial-officer-corcept-therapeutics-650-688-8783-crobb-corcept-com-w-cort-20160802monthly0.5https://www.biopharmawatch.com/news/CORT/charles-robb-chief-financial-officer-corcept-therapeutics-650-688-8783-crobb-corcept-com-w-cort-20160628monthly0.5https://www.biopharmawatch.com/news/GRFS/exv99w1-grifols-to-acquire-talecris-biotherapeutics-creating-a-world-leading-provider-of-l-grfs-20100607monthly0.5https://www.biopharmawatch.com/news/PTGX/company-overview-dinesh-v-patel-ph-d-president-ceo-ptgx-20260112monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-third-quarter-2025-financial-results-and-provides-corporate-update-fol-ptgx-20251106monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-second-quarter-2025-financial-results-and-provides-corporate-update-nd-ptgx-20250806monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-first-quarter-2025-financial-results-and-provides-corporate-update-pos-ptgx-20250506monthly0.5https://www.biopharmawatch.com/news/PTGX/icotrokinra-clinical-study-results-demonstrate-its-potential-to-shift-treatment-paradigm-a-ptgx-20250308monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-and-takeda-announce-positive-topline-results-from-phase-3-verify-study-of-rusf-ptgx-20250303monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corpo-ptgx-20250221monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-announces-positive-topline-results-from-phase-3-iconic-studies-of-icotrokinra--ptgx-20241118monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-third-quarter-2024-financial-results-and-provides-corporate-update-top-ptgx-20241107monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-second-quarter-2024-financial-results-and-provides-corporate-update-jn-ptgx-20240806monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-first-quarter-2024-financial-results-and-provides-corporate-update-ent-ptgx-20240507monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corpo-ptgx-20240227monthly0.5https://www.biopharmawatch.com/news/PTGX/jp-morgan-42-nd-annual-healthcare-conference-dinesh-v-ptgx-20240116monthly0.5https://www.biopharmawatch.com/news/PTGX/company-overview-dinesh-v-patel-ph-d-president-ceo-ptgx-20240108monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-third-quarter-2023-financial-results-and-provides-corporate-update-fiv-ptgx-20231102monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-second-quarter-2023-financial-results-and-provides-corporate-update-po-ptgx-20230803monthly0.5https://www.biopharmawatch.com/news/PTGX/company-overview-dinesh-v-patel-ph-d-president-ceo-ptgx-20230704monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-first-quarter-2023-financial-results-and-provides-corporate-update-ann-ptgx-20230504monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-p-ptgx-20230315monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-third-quarter-2022-financial-results-and-provides-corporate-update-con-ptgx-20221108monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-second-quarter-2022-financial-results-and-provides-corporate-update-co-ptgx-20220804monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-first-quarter-2022-financial-results-and-provides-corporate-update-ini-ptgx-20220504monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-announces-topline-data-from-phase-2-ideal-study-of-pn-943-in-ulce-ptgx-20220425monthly0.5https://www.biopharmawatch.com/news/PTGX/company-overview-dinesh-v-patel-phd-president-ceo-april-2022-forward-looking-statements-2--ptgx-20220413monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-c-ptgx-20220228monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corpora-ptgx-20211103monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-fda-clinical-hold-on-rusfertide-clinical-development-prog-ptgx-20210917monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-second-quarter-2021-financial-results-and-recent-company--ptgx-20210804monthly0.5https://www.biopharmawatch.com/news/PTGX/pn-943-ptg-200-pn-232-pn-235-rusfertide-ptg-300-ptg-100-dinesh-v-patel-phd-president-ceo-j-ptgx-20210614monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-first-quarter-2021-financial-results-and-provides-corporate-update-ptgx-20210504monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-c-ptgx-20210310monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-third-quarter-financial-results-and-provides-corporate-up-ptgx-20201104monthly0.5https://www.biopharmawatch.com/news/PTGX/ptg-300-opportunity-update-dinesh-v-patel-phd-president-ceo-1-ptgx-20200911monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-second-quarter-financial-results-and-provides-corporate-u-ptgx-20200806monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-first-quarter-financial-results-and-provides-corporate-up-ptgx-20200507monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-thera-ptgx-20200310monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-announces-preliminary-phase-2-results-with-hepcidin-mimetic-ptg-3-ptgx-20191203monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-third-quarter-2019-financial-results-preliminary-phase-2--ptgx-20191106monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-second-quarter-2019-financial-results-initial-phase-2-res-ptgx-20190807monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-first-quarter-2019-financial-results-ptg-200-collaboratio-ptgx-20190508monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-preli-ptgx-20190312monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-announces-new-development-candidate-pn-10943-for-the-treatment-of-ptgx-20181127monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-third-quarter-2018-financial-results-and-provides-corpora-ptgx-20181106monthly0.5https://www.biopharmawatch.com/news/PTGX/ptg-100-an-oral-gut-restricted-peptide-47-antagonist-induces-clinical-and-histologic-remis-ptgx-20181022monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-second-quarter-2018-financial-results-ptgx-20180807monthly0.5https://www.biopharmawatch.com/news/PTGX/dinesh-v-patel-phd-president-ceo-ptgx-20180806monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-first-quarter-2018-financial-results-newark-ca-ptgx-20180509monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-fourth-quarter-and-year-end-2017-financial-results-protag-ptgx-20180307monthly0.5https://www.biopharmawatch.com/news/PTGX/company-overview-dinesh-v-patel-phd-president-ceo-january-2018-forward-looking-statements--ptgx-20180108monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-third-quarter-2017-financial-results-and-provides-corpora-ptgx-20171106monthly0.5https://www.biopharmawatch.com/news/PTGX/risk-factors-investing-in-our-common-stock-involves-a-high-degree-of-risk-you-should-consi-ptgx-20171013monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-second-quarter-2017-financial-results-and-business-highli-ptgx-20170808monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-first-quarter-2017-financial-results-milpitas-ca-ptgx-20170510monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-fourth-quarter-and-year-end-2016-financial-results-phase--ptgx-20170307monthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-reports-third-quarter-2016-financial-results-and-provides-corpora-ptgx-20161114monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20260505monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20260224monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20260106monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20251028monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20250729monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20250429monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20250220monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20241112monthly0.5https://www.biopharmawatch.com/news/RGEN/safe-harbor-this-report-contains-forward-looking-information-within-the-meaning-of-the-pri-rgen-20240918monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20240730monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20240613monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20240501monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20240319monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20240221monthly0.5https://www.biopharmawatch.com/news/RGEN/execution-version-rgen-20231206monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20231031monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-rgen-20231002monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20230926monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-rgen-20230912monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20230802monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20230502monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-acquire-flexbiosys-inc-rgen-20230412monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20230222monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20230209monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20221101monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20220802monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20220526monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20220427monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20220217monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-acquistion-of-bioflex-solutions-rgen-20211216monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20211028monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20210916monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20210727monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20210504monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20210224monthly0.5https://www.biopharmawatch.com/news/RGEN/source-repligen-corporation-rgen-20201207monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20201105monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20201027monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20200730monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20200629monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20200615monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20200506monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20200227monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20200220monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20191031monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20190801monthly0.5https://www.biopharmawatch.com/news/RGEN/source-repligen-corporation-rgen-20190719monthly0.5https://www.biopharmawatch.com/news/RGEN/source-repligen-corporation-rgen-20190715monthly0.5https://www.biopharmawatch.com/news/RGEN/c-technologies-inc-financial-statements-three-months-ended-march-31-2019-and-2018-and-inde-rgen-20190715monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20190509monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20190429monthly0.5https://www.biopharmawatch.com/news/RGEN/c-technologies-inc-financial-statements-years-ended-december-31-2018-and-2017-and-independ-rgen-20190429monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20190426monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20190221monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20181101monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20180802monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20180508monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20180222monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20171109monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20170803monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20170627monthly0.5https://www.biopharmawatch.com/news/RGEN/spectrum-inc-table-of-contents-page-s-report-of-independent-auditors-2-combined-balance-sh-rgen-20170626monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20170623monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20170504monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20170222monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20161215monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20161103monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20160804monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20160518monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20160505monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20160404monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20160225monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20151105monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20150915monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20150806monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-repl-rgen-20150507monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20150313monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20150123monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20150108monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20141106monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20140811monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20140715monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20140612monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20140603monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20140508monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20140506monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20140306monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20140121monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20131119monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20131107monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20130801monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20130502monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20130307monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20130103monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20121108monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20120921monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20120802monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20120622monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20120507monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-for-immediate-release-repligen-corporation-41-seyon-street-building-1-suite-100--rgen-20120503monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20120426monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20120316monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20120305monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20120221monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20111221monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20111028monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20111027monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20111004monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-fiscal-year-2012-financial-results-rgen-20110727monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-for-immediate-release-repligen-corporation-41-seyon-street-building-1-suite-100--rgen-20110609monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-for-immediate-release-repligen-corporation-41-seyon-street-building-1-suite-100--rgen-20110421monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-fiscal-year-2011-financial-results-rgen-20110209monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-fiscal-year-2011-financial-results-rgen-20101102monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20100805monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20100609monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20100416monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20100204monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20100128monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts-02453-tele-rgen-20091105monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-repligen-corporation-41-seyon-street-building-1-suite-100-waltham-massachusetts--rgen-20090825monthly0.5https://www.biopharmawatch.com/news/RGEN/repli-gen-for-immediate-release-repligen-corporation-41-seyon-street-building-1-suite-100--rgen-20090806monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-41-seyon-street-repli-gen-building-1-suite-100-waltham-massachusetts--rgen-20090611monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-for-immediate-release-repligen-corporation-41-seyon-street-building-1-suite-100-w-rgen-20090205monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-topline-results-from-phase-3-emanate-trial-four-substudie-rytm-20260316monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2025-financial-results-and-business-update-s-rytm-20250805monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-oral-mc4r-agonist-bivamelagon-achieved-statistically-sign-rytm-20250709monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2025-financial-results-and-business-update-fi-rytm-20250507monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-pivotal-phase-3-transcend-trial-meets-primary-endpoint-wi-rytm-20250407monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reacquires-licensing-rights-to-imcivree-setmelanotide-in-china-with-rytm-20250320monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-bus-rytm-20250226monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2024-net-product-rytm-20250110monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-third-quarter-2024-financial-results-and-business-update-th-rytm-20241105monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2024-financial-results-and-business-update-s-rytm-20240806monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-rhythm-pharmaceuticals-reports-first-quarter-2024-financial-results-rytm-20240507monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-secures-150-million-in-convertible-preferred-stock-financing-procee-rytm-20240401monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-2023-financial-results-and-business-update-f-rytm-20240222monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-third-quarter-2023-financial-results-and-business-update-th-rytm-20231107monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2023-financial-results-and-business-update-s-rytm-20230801monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2023-financial-results-and-business-update-st-rytm-20230502monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-imcivre-rytm-20230301monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-all-rights-reserved-january-2023-rhythm-pharmaceuticals-transfo-rytm-20230109monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-third-quarter-2022-financial-results-and-business-update-u--rytm-20221108monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2022-financial-results-and-business-update-r-rytm-20220802monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2022-financial-results-and-business-update-pa-rytm-20220503monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-all-rights-reserved-april-2022-rhythm-pharmaceuticals-targeting-rytm-20220406monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-prepara-rytm-20220301monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-third-quarter-2021-financial-results-u-s-and-eu-regulatory--rytm-20211102monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2021-financial-results-received-european-com-rytm-20210803monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2021-financial-results-first-u-s-commercial-s-rytm-20210503monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-receive-rytm-20210301monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-all-rights-reserved-february-2021-rhythm-pharmaceuticals-target-rytm-20210203monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-third-quarter-2020-financial-results-nda-for-setmelanotide--rytm-20201102monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2020-financial-results-appointed-david-meeke-rytm-20200803monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-on-trac-rytm-20200302monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-all-rights-reserved-rhythm-pharmaceuticals-inc-all-rights-reser-rytm-20200110monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-leadership-transition-keith-gottesdiener-m-d-to-step-down-rytm-20200106monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-late-breaking-data-from-phase-3-trials-of-setmelanotide-i-rytm-20191104monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-third-quarter-2019-financial-results-announced-positive-top-rytm-20191101monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-proposed-public-offering-boston-ma-rytm-20191015monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-provides-update-on-research-and-development-programs-four-new-mc4r--rytm-20190925monthly0.5https://www.biopharmawatch.com/news/RYTM/under-embargo-until-wednesday-august-7-2019-at-7-01am-edt-rhythm-pharmaceuticals-announces-rytm-20190807monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-positive-opinion-by-the-european-medicines-agency-on-orph-rytm-20190729monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2019-financial-results-launched-uncovering-r-rytm-20190729monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-appointment-of-stuart-arbuckle-to-its-board-of-directors--rytm-20190724monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2019-financial-results-announced-updated-clin-rytm-20190503monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-promising-clinical-data-in-mc4r-pathway-heterozygous-obes-rytm-20190328monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-boston--rytm-20190308monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-outline-expected-2019-milestones-and-review-updated-clinical-dat-rytm-20190104monthly0.5https://www.biopharmawatch.com/news/RYTM/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-the--rytm-20181109monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-third-quarter-2018-financial-results-presented-updated-data-rytm-20181109monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2018-financial-results-completed-pivotal-enr-rytm-20180808monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2018-financial-results-u-s-food-and-drug-admi-rytm-20180514monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-licensing-agreement-with-takeda-for-the-development-and-c-rytm-20180402monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results-continu-rytm-20180312monthly0.5https://www.biopharmawatch.com/news/RYTM/confidential-rhythm-announces-preliminary-data-from-phase-2-study-of-setmelanotide-for-tre-rytm-20171031monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-closing-of-initial-public-offering-and-full-exercise--rytm-20171010monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-u-mirm-20260506monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-announces-additional-private-placement-financing-with-tcgx-foster-ci-mirm-20251219monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-enters-into-definitive-agreement-to-acquire-bluejay-therapeutics-exp-mirm-20251208monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-business-u-mirm-20251104monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business--mirm-20250806monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-u-mirm-20250507monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-fourth-quarter-and-year-end-2024-financial-results-and-provi-mirm-20250226monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-announces-preliminary-unaudited-2024-net-product-sales-and-cash-bala-mirm-20250113monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-u-mirm-20241112monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-business--mirm-20240807monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-business-u-mirm-20240508monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-fourth-quarter-and-year-end-2023-financial-results-and-provi-mirm-20240228monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-announces-preliminary-unaudited-2023-net-revenue-and-provides-corpor-mirm-20240108monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-business-u-mirm-20231102monthly0.5https://www.biopharmawatch.com/news/MIRM/refer-to-mirum-pharmaceuticals-inc-summary-of-risks-associated-with-our-business-an-invest-mirm-20231013monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-completes-acquisition-of-bile-acid-product-portfolio-for-treatment-o-mirm-20230905monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-business--mirm-20230803monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-enters-agreement-to-acquire-bile-acid-product-portfolio-for-the-trea-mirm-20230717monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-business-u-mirm-20230504monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-announces-proposed-convertible-senior-notes-offering-foster-city-cal-mirm-20230412monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-announces-preliminary-unaudited-first-quarter-2023-financial-results-mirm-20230412monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-fourth-quarter-and-year-end-2022-financial-results-and-provi-mirm-20230308monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-announces-preliminary-unaudited-livmarli-2022-net-revenue-and-provid-mirm-20230109monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-business-u-mirm-20221109monthly0.5https://www.biopharmawatch.com/news/MIRM/positive-topline-data-announced-from-mirum-s-livmarli-phase-3-march-study-in-progressive-f-mirm-20221024monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-business--mirm-20220804monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-appoints-saira-ramasastry-to-board-of-directors-mirm-20220606monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-business-u-mirm-20220505monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-fourth-quarter-and-year-end-2021-financial-results-and-provi-mirm-20220309monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-provides-business-update-and-highlights-key-2022-corporate-milestone-mirm-20211231monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-business-u-mirm-20211115monthly0.5https://www.biopharmawatch.com/news/MIRM/u-s-fda-approves-livmarli-maralixibat-as-the-first-and-only-approved-medication-for-the-tr-mirm-20210929monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-appoints-biotechnology-executive-william-c-fairey-to-its-board-of-di-mirm-20210819monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-business--mirm-20210805monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-appoints-veteran-biotechnology-executive-carol-l-brosgart-m-d-to-boa-mirm-20210607monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-business-u-mirm-20210506monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-fourth-quarter-and-year-end-2020-results-and-provides-busine-mirm-20210309monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-provides-corporate-update-completion-of-maralixibat-rolling-nda-targ-mirm-20210112monthly0.5https://www.biopharmawatch.com/news/MIRM/certain-information-in-this-document-identified-by-brackets-has-been-omitted-because-it-is-mirm-20201208monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-provides-third-quarter-2020-financial-results-and-business-update-an-mirm-20201112monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-announces-second-quarter-2020-financial-results-and-provides-clinica-mirm-20200806monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides-business-u-mirm-20200507monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and-prov-mirm-20200312monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-promotes-ian-clements-to-chief-financial-officer-foster-city-calif-mirm-20200114monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-third-quarter-financial-results-and-provides-corporate-updat-mirm-20191106monthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-second-quarter-financial-results-and-provides-corporate-upda-mirm-20190828monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-announces-potential-best-in-class-spy002-anti-tl1a-part-a-induction-results-from-sky-syre-20260615monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provide-syre-20260219monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-poised-for-transformational-2026-with-six-expected-proof-of-concept-rea-syre-20260112monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-up-syre-20250805monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-syre-20250227monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-highlights-2025-priorities-and-robust-pipeline-of-upcoming-clinical-rea-syre-20241231monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-positive-interim-results-from-phase-1-healthy-volunteer-trial-syre-20241112monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-upd-syre-20241107monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-expected-acceleration-of-spy003-il-23p19-clinical-timelines-a-syre-20241014monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-up-syre-20240807monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-appoints-accomplished-biopharma-leader-dr-sandra-milligan-to-its-board--syre-20240515monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-upd-syre-20240509monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-180-million-private-placement-syre-20240318monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-syre-20240229monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-180-million-private-placement-syre-20231207monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-name-change-to-spyre-therapeutics-appoints-ceo-and-additi-syre-20231128monthly0.5https://www.biopharmawatch.com/news/SYRE/item-7-management-s-discussion-and-analysis-of-financial-condition-and-results-of-operatio-syre-20231115monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-syre-20231109monthly0.5https://www.biopharmawatch.com/news/SYRE/corporate-overview-24-october-2023-disclosures-the-information-contained-in-this-presentat-syre-20231024monthly0.5https://www.biopharmawatch.com/news/SYRE/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-of-aegle-syre-20231010monthly0.5https://www.biopharmawatch.com/news/SYRE/disclosures-the-information-contained-in-this-presentation-has-been-prepared-by-aeglea-bio-syre-20230908monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-expands-executive-leadership-team-with-appointment-of-industry-vete-syre-20230905monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-second-quarter-2023-financial-results-acquisition-of-spyre--syre-20230811monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-sale-of-pegzilarginase-to-immedica-pharma-global-rights-t-syre-20230727monthly0.5https://www.biopharmawatch.com/news/SYRE/disclosures-the-information-contained-in-this-presentation-has-been-prepared-by-spyre-ther-syre-20230623monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-acquisition-of-spyre-therapeutics-acquisition-of-spyre-an-syre-20230622monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-first-quarter-2023-financial-results-39-8-million-of-cash-a-syre-20230511monthly0.5https://www.biopharmawatch.com/news/SYRE/forward-looking-statements-2023-aeglea-biotherapeutics-this-presentation-by-aeglea-biother-syre-20230425monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-interim-results-from-ongoing-phase-1-2-clinical-trial-of--syre-20230412monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-pro-syre-20230302monthly0.5https://www.biopharmawatch.com/news/SYRE/forward-looking-statements-2023-aeglea-biotherapeutics-this-presentation-and-the-accompany-syre-20230109monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-third-quarter-2022-financial-results-and-provides-program-u-syre-20221103monthly0.5https://www.biopharmawatch.com/news/SYRE/reimagining-the-potential-of-human-enzyme-therapeutics-corporate-overview-september-2022-n-syre-20220906monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-second-quarter-2022-financial-results-and-provides-program--syre-20220804monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-first-quarter-2022-financial-results-and-provides-program-u-syre-20220505monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-presents-additional-data-from-peace-phase-3-study-of-pegzilarginase-syre-20220411monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-pro-syre-20220308monthly0.5https://www.biopharmawatch.com/news/SYRE/forward-looking-statements-2022-aeglea-biotherapeutics-external-2-this-presentation-and-th-syre-20220105monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-achievement-of-primary-endpoint-in-phase-3-study-of-pegzi-syre-20211206monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-third-quarter-2021-financial-results-and-corporate-highligh-syre-20211104monthly0.5https://www.biopharmawatch.com/news/SYRE/company-logo-forward-looking-statements-2021-aeglea-biotherapeutics-external-2-this-presen-syre-20210909monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-second-quarter-2021-financial-results-and-corporate-highlig-syre-20210805monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-first-quarter-2021-financial-results-and-corporate-highligh-syre-20210510monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-cor-syre-20210318monthly0.5https://www.biopharmawatch.com/news/SYRE/forward-looking-statements-2020-aeglea-biotherapeutics-external-2-this-presentation-and-th-syre-20210105monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-third-quarter-2020-financial-results-and-corporate-highligh-syre-20201105monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-second-quarter-2020-financial-results-and-corporate-highlig-syre-20200810monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-1-year-data-for-pegzilarginase-in-patients-with-arginase--syre-20200526monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-first-quarter-2020-financial-results-and-corporate-highligh-syre-20200507monthly0.5https://www.biopharmawatch.com/news/SYRE/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-syre-20200408monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-highlig-syre-20200224monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-submits-cta-application-for-its-novel-engineered-human-enzyme-desig-syre-20200113monthly0.5https://www.biopharmawatch.com/news/SYRE/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-syre-20191203monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-third-quarter-2019-financial-results-and-corporate-highligh-syre-20191106monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-positive-20-dose-data-for-pegzilarginase-in-patients-with-syre-20190903monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-second-quarter-2019-financial-results-and-corporate-highlig-syre-20190806monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-first-quarter-2019-financial-results-and-corporate-highligh-syre-20190507monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-new-positive-phase-1-2-data-for-pegzilarginase-in-patient-syre-20190407monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-cor-syre-20190307monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-design-of-pivotal-phase-3-peace-trial-evaluating-pegzilar-syre-20181211monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-reports-third-quarter-2018-financial-results-and-recent-corporate-h-syre-20181108monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-positive-interim-clinical-data-for-pegzilarginase-in-adva-syre-20181022monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-new-positive-interim-clinical-data-and-improvements-in-di-syre-20181017monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-positive-interim-clinical-data-and-completion-of-enrollme-syre-20180904monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-provides-corporate-update-and-reports-second-quarter-2018-financial-syre-20180809monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-provides-corporate-update-and-reports-first-quarter-2018-financial--syre-20180508monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-prices-public-offering-of-common-stock-syre-20180418monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-presents-new-phase-1-2-trial-data-demonstrating-clinically-relevant-syre-20180412monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-provides-key-clinical-data-update-from-phase-1-2-trial-in-arginase--syre-20180313monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-provides-corporate-update-and-reports-third-quarter-2017-financial--syre-20171107monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-provides-corporate-update-and-reports-second-quarter-2017-financial-syre-20170809monthly0.5https://www.biopharmawatch.com/news/SYRE/resignation-letter-syre-20170718monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-prices-public-offering-of-common-stock-austin-texas-syre-20170606monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-provides-corporate-update-and-reports-first-quarter-2017-financial--syre-20170509monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year--syre-20170323monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-provides-corporate-update-and-reports-third-quarter-2016-financial--syre-20161109monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-second-quarter-2016-financial-results-austin-texas-syre-20160809monthly0.5https://www.biopharmawatch.com/news/SYRE/aeglea-biotherapeutics-announces-first-quarter-2016-financial-results-austin-texas-syre-20160519monthly0.5https://www.biopharmawatch.com/news/SYRE/targeting-chronic-lymphocytic-leukemia-by-interfering-glutathione-synthesis-using-a-novel--syre-20160419monthly0.5https://www.biopharmawatch.com/news/SYRE/abstract-1042-development-of-aeb1102-an-engineered-human-arginase-1-for-patients-with-soli-syre-20160418monthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-third-quarter-2025-financial-results-and-provides-business-updates-x20-cgon-20251114monthly0.5https://www.biopharmawatch.com/news/CGON/attacking-bladder-cancer-for-a-better-tomorrow-disclaimer-and-forward-looking-statements-w-cgon-20250909monthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-first-quarter-2025-financial-results-and-provides-business-updates-upd-cgon-20250513monthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-announces-best-in-disease-durability-data-in-bond-003-cohort-c-and-promising-e-cgon-20250428monthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-2024-year-end-financial-results-and-provides-business-updates-cretosti-cgon-20250328monthly0.5https://www.biopharmawatch.com/news/CGON/cretostimogene-grenadenorepvec-data-continues-to-demonstrate-best-in-class-durability-of-r-cgon-20250324monthly0.5https://www.biopharmawatch.com/news/CGON/groundbreaking-cretostimogene-grenadenorepvec-monotherapy-data-demonstrates-sustained-dura-cgon-20241205monthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-third-quarter-2024-financial-results-and-provides-business-updates-lat-cgon-20241112monthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-second-quarter-2024-financial-results-and-provides-business-updates-x2-cgon-20240808monthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-to-present-positive-final-results-from-phase-2-core-001-study-of-cretostimogen-cgon-20240524monthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-first-quarter-2024-financial-results-and-provides-business-updates-cre-cgon-20240509monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-update-on-issuance-of-full-year-2026-guidance-on-iclr-20260107monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-provides-update-on-vaccine-study-on-iclr-20250303monthly0.5https://www.biopharmawatch.com/news/ICLR/document-third-amendment-to-credit-agreement-this-third-amendment-to-the-credit-agreement--iclr-20240425monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-schedules-fourth-quarter-and-full-year-2023-earnings-conference-call-dublin-busin-iclr-20240130monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-issues-financial-guidance-for-full-year-2024-highlights-full-year-2024-revenue-guidan-iclr-20240109monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-42-nd-annual-j-p-morgan-healthcare-conference-dublin-business-w-iclr-20240104monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-secures-upgraded-credit-rating-from-moody-s-investors-service-dublin-business-wire-iclr-20231207monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-upcoming-investor-conferences-dublin-business-wire-iclr-20231108monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2023-results-highlights-net-business-wins-in-the-quarter-of-2-5-iclr-20231025monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-secures-upgraded-credit-rating-from-s-p-global-ratings-dublin-business-wire-iclr-20231012monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-schedules-third-quarter-2023-earnings-conference-call-dublin-business-wire-iclr-20230921monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-baird-global-healthcare-conference-dublin-business-wire-iclr-20230906monthly0.5https://www.biopharmawatch.com/news/ICLR/second-amendment-to-credit-agreement-this-second-amendment-to-the-credit-agreement-referre-iclr-20230728monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20230726monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2023-results-highlights-net-business-wins-in-the-quarter-of-2--iclr-20230726monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-annual-general-meeting-of-shareholders-to-be-held-on-iclr-20230705monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-schedules-second-quarter-2023-earnings-conference-call-dublin-business-wire-iclr-20230627monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-set-to-join-russell-3000-index-dublin-business-wire-iclr-20230626monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-attend-upcoming-investor-conferences-dublin-business-wire-iclr-20230531monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-releases-its-2022-icon-cares-esg-report-dublin-business-wire-iclr-20230516monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2023-results-highlights-net-business-wins-in-the-quarter-of-2-4-iclr-20230426monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-schedules-first-quarter-2023-earnings-conference-call-dublin-business-wire-iclr-20230329monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-upcoming-investor-conferences-dublin-business-wire-iclr-20230227monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2022-results-highlights-net-business-wins-in-the-iclr-20230222monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-schedules-fourth-quarter-2022-earnings-conference-call-dublin-business-wire-iclr-20230126monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-issues-financial-guidance-for-full-year-2023-highlights-full-year-2023-revenue-guidan-iclr-20230110monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-41-st-annual-j-p-morgan-healthcare-conference-dublin-ireland-bu-iclr-20230103monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-2022-evercore-isi-healthconx-conference-dublin-business-wire-iclr-20221123monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2022-results-highlights-net-business-wins-in-the-quarter-of-2-3-iclr-20221102monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-schedules-third-quarter-2022-earnings-conference-call-dublin-business-wire-iclr-20220926monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-releases-its-2021-esg-report-dublin-business-wire-iclr-20220906monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-2022-wells-fargo-healthcare-conference-dublin-business-wire-iclr-20220831monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20220727monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2022-results-highlights-net-business-wins-in-the-quarter-of-2--iclr-20220727monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-schedules-second-quarter-2022-earnings-conference-call-dublin-business-wire-iclr-20220621monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-h-c-wainwright-global-investment-conference-and-the-jefferies-h-iclr-20220523monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-bofa-securities-2022-healthcare-conference-dublin-business-wire-iclr-20220503monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2022-results-highlights-record-net-business-wins-in-the-quarter-iclr-20220427monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-webcast-analyst-day-meeting-dublin-business-wire-iclr-20220310monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2021-results-highlights-record-net-business-wins-iclr-20220222monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-2022-citi-healthcare-conference-dublin-business-wire-iclr-20220217monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-issues-financial-guidance-for-full-year-2022-highlights-full-year-2022-revenue-guidan-iclr-20220112monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-40-th-annual-jp-morgan-healthcare-conference-dublin-ireland-bus-iclr-20220105monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-releases-environmental-social-and-governance-report-the-report-looks-to-the-future-of-iclr-20211122monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-30th-annual-credit-suisse-healthcare-conference-and-the-4th-ann-iclr-20211105monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2021-results-highlights-record-net-business-wins-in-the-quarter-iclr-20211103monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-wells-fargo-16th-annual-healthcare-conference-and-the-baird-glo-iclr-20210902monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2021-results-highlights-record-net-business-wins-in-the-quarte-iclr-20210721monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20210721monthly0.5https://www.biopharmawatch.com/news/ICLR/credit-agreement-dated-as-of-iclr-20210701monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-pricing-of-senior-secured-notes-dublin-business-wire-iclr-20210617monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-extraordinary-general-meeting-d-iclr-20210615monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-private-offering-of-senior-secured-notes-dublin-ireland-iclr-20210614monthly0.5https://www.biopharmawatch.com/news/ICLR/unaudited-pro-forma-condensed-combined-financial-information-on-iclr-20210614monthly0.5https://www.biopharmawatch.com/news/ICLR/disclaimer-cautionary-note-regarding-forward-looking-statementsthis-presentation-contains--iclr-20210608monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-jefferies-virtual-healthcare-conference-and-the-william-blair-4-iclr-20210525monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-bofa-securities-2021-virtual-healthcare-conference-and-the-ubs--iclr-20210505monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2021-results-highlights-record-net-business-wins-in-the-quarter-iclr-20210428monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-barclays-global-healthcare-conference-and-the-keybanc-capital-m-iclr-20210309monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-acquire-pra-health-sciences-creating-a-world-leader-in-healthcare-intelligence-and-iclr-20210224monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2020-results-highlights-record-net-business-wins-iclr-20210224monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-39-th-annual-jp-morgan-healthcare-conference-dublin-ireland-bus-iclr-20210107monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-releases-first-environmental-social-and-governance-report-dublin-business-wire-iclr-20201111monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-the-29th-annual-credit-suisse-virtual-healthcare-conference-and-eve-iclr-20201030monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2020-results-highlights-record-net-business-wins-in-the-quarter-iclr-20201021monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-wells-fargo-2020-virtual-global-healthcare-conference-and-baird-202-iclr-20200902monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20200722monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2020-results-highlights-robust-net-business-wins-in-the-quarte-iclr-20200722monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-jefferies-virtual-healthcare-conference-dublin-business-wire-iclr-20200527monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-ubs-virtual-global-healthcare-conference-dublin-business-wire-iclr-20200513monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2020-results-highlights-net-business-wins-in-the-quarter-of-867-iclr-20200422monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-signs-new-service-agreement-with-pfizer-dublin-business-wire-iclr-20200403monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-barclays-global-healthcare-conference-2020-dublin-business-wire-iclr-20200303monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-medpass-international-acquisition-expands-icon-s-global-medical-device-and-d-iclr-20200219monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2019-results-highlights-net-business-wins-in-the-iclr-20200219monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-issues-financial-guidance-for-full-year-2020-highlights-full-year-2020-revenue-guidan-iclr-20200114monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-38th-annual-j-p-morgan-healthcare-conference-and-issue-financial-gu-iclr-20200113monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-evercore-isi-2nd-annual-healthconx-conference-dublin-business-wire-iclr-20191127monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-jefferies-2019-london-healthcare-conference-dublin-business-wire-iclr-20191114monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-s-acquisition-of-symphony-clinical-research-acquisition-enhances-icon-s-ability-to-of-iclr-20191023monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2019-results-highlights-record-net-business-wins-in-the-quarter-iclr-20191023monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-to-present-at-baird-s-2019-global-healthcare-conference-dublin-business-wire-iclr-20190903monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2019-results-highlights-net-business-wins-including-pass-throu-iclr-20190724monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-the-appointment-of-ms-julie-o-neill-to-board-of-directors-and-confirms-the--iclr-20190724monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20190724monthly0.5https://www.biopharmawatch.com/news/ICLR/notice-of-annual-general-meeting-to-be-held-on-23-july-2019-icon-plc-the-company-or-icon-t-iclr-20190610monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-s-acquisition-of-medinova-research-acquisition-enhances-icon-s-patient-access-in-euro-iclr-20190523monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2019-results-highlights-net-business-wins-including-pass-throug-iclr-20190501monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-present-at-the-barclays-global-healthcare-conference-on-iclr-20190312monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2018-results-highlights-record-net-business-wins-iclr-20190220monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-issues-financial-guidance-for-full-year-2019-highlights-full-year-2019-revenue-guidan-iclr-20190108monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-present-at-evercore-isi-healthconx-conference-2018-on-iclr-20181128monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-present-at-jefferies-2018-london-healthcare-conference-on-iclr-20181114monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2018-results-highlights-excluding-the-impact-of-asc-606-record--iclr-20181024monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-sell-side-analyst-day-meeting-on-iclr-20180910monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-confirms-retirement-of-co-founder-dr-ronan-lambe-dublin-business-wire-iclr-20180727monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2018-results-highlights-excluding-the-impact-of-asc-606-record-iclr-20180725monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20180725monthly0.5https://www.biopharmawatch.com/news/ICLR/notice-of-annual-general-meeting-to-be-held-on-24-july-2018-icon-plc-the-company-or-icon-t-iclr-20180612monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2018-results-highlights-excluding-the-impact-of-asc-606-net-bus-iclr-20180502monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2017-results-highlights-quarter-4-gross-business-iclr-20180215monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-issues-financial-guidance-for-full-year-2018-highlights-full-year-2018-revenue-guidan-iclr-20180109monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-appointment-of-ms-joan-garahy-to-board-of-directors-dublin-business-wire-iclr-20171117monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2017-results-highlights-record-gross-and-net-business-wins-of-6-iclr-20171026monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-appointment-of-mr-eugene-mccague-to-board-of-directors-dublin-business-wire-iclr-20171004monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-mapi-group-expands-icon-s-leadership-in-health-outcomes-research-and-commerc-iclr-20170727monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2017-results-highlights-record-net-business-wins-of-563-millio-iclr-20170727monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20170726monthly0.5https://www.biopharmawatch.com/news/ICLR/notice-of-annual-general-meeting-to-be-held-on-25-july-2017-icon-plc-the-company-or-icon-t-iclr-20170623monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2017-results-highlights-record-net-business-wins-of-521-million-iclr-20170427monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2016-results-highlights-quarter-4-gross-business-iclr-20170216monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-issues-financial-guidance-for-full-year-2017-highlights-full-year-2017-revenue-guidan-iclr-20170109monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-unaudited-interim-financial-statements-for-the-interim-period-1-january-2016-to-3-iclr-20161221monthly0.5https://www.biopharmawatch.com/news/ICLR/cro-an-oifig-um-chlaru-cuideachtai-companies-regristration-office-b7-variation-of-company--iclr-20161027monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-appointment-of-mr-ronan-murphy-to-board-of-directors-dublin-business-wire-iclr-20161024monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-executive-leadership-transition-mr-ciaran-murray-to-transition-to-chairman--iclr-20161020monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2016-results-highlights-net-business-wins-of-510-million-net-bo-iclr-20161020monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-completes-the-acquisition-of-clinical-research-management-inc-acquisition-extends-ico-iclr-20160919monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2016-results-highlights-record-net-business-wins-of-502-millio-iclr-20160726monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20160725monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-acquire-clinical-research-management-inc-acquisition-extends-icon-s-presence-in-th-iclr-20160630monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-service-agreement-with-pfizer-dublin-business-wire-iclr-20160610monthly0.5https://www.biopharmawatch.com/news/ICLR/notice-of-annual-general-meeting-to-be-held-on-22-july-2016-icon-plc-the-company-or-icon-t-iclr-20160610monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2016-results-highlights-backlog-of-business-up-9-year-on-year-t-iclr-20160426monthly0.5https://www.biopharmawatch.com/news/ICLR/mr-thomas-lynch-notifies-icon-of-his-retirement-as-chairman-and-that-he-will-not-stand-for-iclr-20160329monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2015-results-and-issues-2016-earnings-guidance-h-iclr-20160223monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-secures-investment-grade-credit-ratings-dublin-business-wire-iclr-20160105monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-announces-private-placement-of-us-350-000-000-of-senior-notes-dublin-business-wir-iclr-20151216monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-pmg-research-inc-acquisition-enhances-icon-s-site-and-patient-engagement-cap-iclr-20151207monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-the-appointment-of-dr-steve-cutler-to-board-of-directors-dublin-business-wi-iclr-20151125monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2015-highlights-gross-business-wins-of-518-million-representing-iclr-20151027monthly0.5https://www.biopharmawatch.com/news/ICLR/b7-companies-registration-office-cro-variation-of-company-capital-as-prescribed-under-sect-iclr-20151014monthly0.5https://www.biopharmawatch.com/news/ICLR/cro-an-oifig-um-chlaru-cuideachtai-companies-registration-office-variation-of-company-capi-iclr-20151002monthly0.5https://www.biopharmawatch.com/news/ICLR/crio-an-oifig-um-chlaru-cuideachtai-f-7-i-l-companies-registration-offlce-1-variation-of-c-iclr-20150904monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-unaudited-interim-financial-statements-for-the-interim-period-from-1-january-2015-iclr-20150827monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2015-highlights-gross-business-wins-of-571-million-representin-iclr-20150728monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20150727monthly0.5https://www.biopharmawatch.com/news/ICLR/notice-of-annual-general-meeting-to-be-held-on-24-july-2015-icon-plc-the-company-or-icon-t-iclr-20150612monthly0.5https://www.biopharmawatch.com/news/ICLR/shares-01-06-2015-date-effective-description-of-change-company-name-cro-an-oifig-um-chalar-iclr-20150609monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2015-highlights-quarter-1-net-revenue-increased-11-year-on-year-iclr-20150428monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-completes-acquisition-of-medimedia-pharma-solutions-extends-icon-s-leadership-in-comm-iclr-20150302monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-and-full-year-2014-results-and-issues-2015-earnings-guidance-h-iclr-20150225monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-acquire-medimedia-pharma-solutions-extends-icon-s-leadership-in-commercialisation--iclr-20150202monthly0.5https://www.biopharmawatch.com/news/ICLR/form-no-28-b7-certificate-no-145835-companies-acts-1963-to-2013-notice-of-consolidation-an-iclr-20141218monthly0.5https://www.biopharmawatch.com/news/ICLR/form-no-28-b7-certificate-no-145835-companies-acts-1963-to-2013-notice-of-consolidation-an-iclr-20141024monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2014-and-increases-earnings-guidance-highlights-third-quarter-f-iclr-20141022monthly0.5https://www.biopharmawatch.com/news/ICLR/form-no-28-b7-certificate-no-145835-companies-acts-1963-to-2013-notice-of-consolidation-an-iclr-20140926monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-announces-completion-of-40-million-share-buyback-and-a-further-share-buyback-prog-iclr-20140919monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20140730monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2014-and-increases-earnings-guidance-highlights-second-quarter-iclr-20140730monthly0.5https://www.biopharmawatch.com/news/ICLR/notice-of-annual-general-meeting-to-be-held-on-29-july-2014-icon-plc-the-company-or-icon-t-iclr-20140619monthly0.5https://www.biopharmawatch.com/news/ICLR/form-no-28-b7-certificate-no145835-companies-acts-1963-to-2013-notice-of-consolidation-and-iclr-20140606monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-webcast-analyst-day-meeting-dublin-business-wire-iclr-20140509monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-completes-acquisition-of-aptiv-solutions-dublin-business-wire-iclr-20140508monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2014-highlights-first-quarter-fiscal-2014-quarter-1-net-revenue-iclr-20140430monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-appointment-of-dr-hugh-brady-to-board-of-directors-dublin-business-wire-iclr-20140430monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-acquire-aptiv-solutions-acquisition-enhances-icon-s-capabilities-in-adaptive-and-m-iclr-20140331monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-appointment-of-ms-mary-pendergast-to-board-of-directors-dublin-business-wir-iclr-20140220monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-2013-revenue-of-345-million-up-15-year-on-year-and-eps-of-53c--iclr-20140220monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-announces-resignation-of-a-director-on-iclr-20140124monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-third-quarter-2013-revenue-of-340-million-up-19-year-on-year-eps-of-45c-and-r-iclr-20131024monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2013-revenue-of-334-million-up-21-year-on-year-non-gaap-eps-of-iclr-20130725monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20130723monthly0.5https://www.biopharmawatch.com/news/ICLR/mr-justin-levis-iss-20850-king-farm-boulevard-rockville-md-20850-11-july-2013-icon-plc-ann-iclr-20130711monthly0.5https://www.biopharmawatch.com/news/ICLR/notice-of-annual-general-meeting-to-be-held-on-22-july-2013-icon-plc-the-company-or-icon-t-iclr-20130617monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2013-revenue-of-317-million-up-26-year-on-year-and-non-gaap-eps-iclr-20130425monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-appointment-of-professor-william-hall-to-board-of-directors-dublin-business-iclr-20130221monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-2012-revenue-of-300-million-up-24-year-on-year-eps-of-34c-and--iclr-20130219monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-the-commencement-of-direct-trading-on-nasdaq-dublin-business-wire-iclr-20130205monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-to-acquire-clinical-trial-services-division-of-cross-country-healthcare-inc-acquisiti-iclr-20130204monthly0.5https://www.biopharmawatch.com/news/ICLR/mr-thomas-lynch-elected-as-chairman-of-icon-plc-dublin-business-wire-iclr-20121221monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-extraordinary-general-meeting-r-iclr-20121218monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-provides-2013-financial-guidance-ahead-of-investor-day-in-new-york-dublin-busines-iclr-20121203monthly0.5https://www.biopharmawatch.com/news/ICLR/dr-bruce-given-notifies-icon-that-he-will-not-seek-a-further-term-as-chairman-of-the-board-iclr-20121129monthly0.5https://www.biopharmawatch.com/news/ICLR/notice-of-extraordinary-general-meeting-to-be-held-on-17-december-2012-icon-plc-the-compan-iclr-20121123monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-publication-of-egm-circular-in-respect-of-proposed-conversion-to-direct-lis-iclr-20121116monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-q3-revenue-of-286-million-eps-of-29c-and-net-new-business-of-450-million-nasd-iclr-20121101monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-and-subsidiaries-interim-financial-statements-six-months-ended-30-june-2012-regis-iclr-20120830monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2012-revenue-up-19-to-277-million-and-non-gaap-eps-of-21c-nasd-iclr-20120724monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20120720monthly0.5https://www.biopharmawatch.com/news/ICLR/july-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120702monthly0.5https://www.biopharmawatch.com/news/ICLR/june-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120627monthly0.5https://www.biopharmawatch.com/news/ICLR/june-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120621monthly0.5https://www.biopharmawatch.com/news/ICLR/june-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120619monthly0.5https://www.biopharmawatch.com/news/ICLR/dear-shareholders-the-market-trends-that-were-evident-during-2010-accelerated-during-2011--iclr-20120614monthly0.5https://www.biopharmawatch.com/news/ICLR/june-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120614monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-peter-gray-to-retire-from-icon-board-of-directors-dublin-business-wire-iclr-20120612monthly0.5https://www.biopharmawatch.com/news/ICLR/june-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120612monthly0.5https://www.biopharmawatch.com/news/ICLR/june-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120608monthly0.5https://www.biopharmawatch.com/news/ICLR/june-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120606monthly0.5https://www.biopharmawatch.com/news/ICLR/june-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2-iclr-20120601monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120531monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120529monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120525monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120523monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120521monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-p-l-c-and-subsidiaries-annual-report-year-ended-31-december-2011-registered-number-14-iclr-20120518monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120518monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120516monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120511monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120509monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120504monthly0.5https://www.biopharmawatch.com/news/ICLR/may-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-20-iclr-20120501monthly0.5https://www.biopharmawatch.com/news/ICLR/st-quarter-results-dublin-business-wire-iclr-20120424monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-pricespective-leading-value-strategy-consultancy-deepens-icon-s-pricing-and--iclr-20120228monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-fourth-quarter-2011-revenue-of-243m-up-5-year-on-year-and-eps-of-0-07-backlog-iclr-20120216monthly0.5https://www.biopharmawatch.com/news/ICLR/january-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-novembe-iclr-20120117monthly0.5https://www.biopharmawatch.com/news/ICLR/january-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-novembe-iclr-20120110monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-selected-by-shire-plc-s-specialty-pharmaceuticals-division-as-global-strategic-partne-iclr-20120109monthly0.5https://www.biopharmawatch.com/news/ICLR/january-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-novembe-iclr-20120106monthly0.5https://www.biopharmawatch.com/news/ICLR/january-2012-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-novembe-iclr-20120104monthly0.5https://www.biopharmawatch.com/news/ICLR/december-2011-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-novemb-iclr-20111230monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-dr-anthony-murphy-to-retire-from-board-of-directors-dublin-business-wire-iclr-20111227monthly0.5https://www.biopharmawatch.com/news/ICLR/december-2011-icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-novemb-iclr-20111228monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111220monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111216monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111214monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-beijingwits-medical-consulting-ltd-acquisition-strengthens-icon-s-presence-c-iclr-20111213monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111212monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111209monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111207monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111205monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111202monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111130monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111128monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-purchase-of-own-securities-further-to-the-announcement-on-22-november-2011-of-a-s-iclr-20111125monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-commencement-of-share-repurchase-programme-dublin-business-wire-iclr-20111122monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-names-new-global-head-of-clinical-research-services-experienced-industry-executive-dr-iclr-20111101monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-q3-revenue-growth-of-7-to-241-million-and-net-new-business-of-431-million-nas-iclr-20111027monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-peter-gray-to-retire-as-ceo-ciaran-murray-named-as-his-successor-and-appoin-iclr-20110907monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-selected-as-a-preferred-provider-for-early-phase-clinical-development-by-bristol-myer-iclr-20110830monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-second-quarter-2011-net-new-business-of-310-million-revenue-of-233-million-an-iclr-20110720monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-vote-in-favour-of-all-resolutions-at-its-annual-general-meeting-dublin-b-iclr-20110719monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-firecrest-clinical-acquisition-enables-icon-to-enhance-investigator-site-per-iclr-20110714monthly0.5https://www.biopharmawatch.com/news/ICLR/dear-shareholders-and-stakeholders-overview-the-challenging-market-conditions-that-prevail-iclr-20110617monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-selected-by-pfizer-as-a-global-strategic-partner-for-clinical-research-and-developmen-iclr-20110526monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-first-quarter-2011-revenue-up-5-to-229-million-and-eps-of-21c-highlights-firs-iclr-20110421monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-full-year-2010-revenue-of-900m-and-eps-of-1-44-highlights-full-year-2010-and--iclr-20110224monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-oxford-outcomes-leading-international-health-outcomes-consultancy-to-become--iclr-20110114monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-revenues-of-225-million-up-2-on-prior-year-nasdaq-iclr-isin-ie0005711209-dubl-iclr-20101129monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-p-l-c-and-subsidiaries-annual-report-year-ended-31-december-2009-registered-number-14-iclr-20100930monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-revenues-up-2-and-strong-new-business-wins-highlights-second-quarter-2010-net-iclr-20100727monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-shareholders-pass-all-resolutions-at-its-annual-general-meeting-dublin-business-wire-iclr-20100720monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-extends-agm-proxy-return-deadline-for-holders-of-american-depositary-shares-dublin-bu-iclr-20100708monthly0.5https://www.biopharmawatch.com/news/ICLR/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-iclr-20100616monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-solid-first-quarter-with-eps-up-6-year-on-year-highlights-first-quarter-fisca-iclr-20100427monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-full-year-2009-eps-growth-of-18-and-announces-revenue-and-eps-guidance-for-20-iclr-20100225monthly0.5https://www.biopharmawatch.com/news/ICLR/dr-john-climax-announces-his-retirement-as-chairman-of-icon-plc-dr-bruce-given-elected-to--iclr-20091217monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-receives-warning-letter-relating-to-two-studies-dublin-business-wire-iclr-20091204monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-14-increase-in-eps-and-raises-earnings-guidance-for-2009-highlights-third-qua-iclr-20091021monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-22-increase-in-eps-and-strong-cash-flows-nasdaq-iclr-isin-ie0005711209-highli-iclr-20090722monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-results-of-annual-general-meeting-dublin-business-wire-iclr-20090723monthly0.5https://www.biopharmawatch.com/news/ICLR/letter-to-shareholders-of-icon-plc-dublin-business-wire-iclr-20090709monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-veeda-laboratories-limited-expands-icon-s-biomarker-and-immunoassay-capabili-iclr-20090709monthly0.5https://www.biopharmawatch.com/news/ICLR/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-iclr-20090617monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-full-year-2008-revenue-growth-of-37-operating-income-growth-of-44-and-eps-gro-iclr-20090223monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-issues-financial-guidance-for-2009-and-updates-guidance-for-2008-nasdaq-iclr-isin-ie0-iclr-20090109monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-acquires-remaining-30-stake-in-beacon-bioscience-inc-dublin-ireland-business-wire-iclr-20090108monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-guidance-date-for-2009-dublin-ireland-business-wire-iclr-20081215monthly0.5https://www.biopharmawatch.com/news/ICLR/lilly-selects-icon-to-manage-its-clinical-data-management-business-outside-the-us-dublin-i-iclr-20081118monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-acquires-prevalere-life-sciences-inc-expands-bioanalytical-and-immunoassay-capabiliti-iclr-20081114monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-35-increase-in-revenue-and-45-increase-in-operating-income-highlights-third-q-iclr-20081021monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-completion-of-stock-split-dublin-ireland-business-wire-icon-nasdaq-iclr-isi-iclr-20080808monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-ads-payment-date-and-nasdaq-ex-date-for-stock-split-dublin-ireland-business-iclr-20080731monthly0.5https://www.biopharmawatch.com/news/ICLR/letter-to-shareholders-of-icon-plc-dear-all-in-response-to-the-negative-voting-recommendat-iclr-20080710monthly0.5https://www.biopharmawatch.com/news/ICLR/letter-to-shareholders-of-icon-plc-dear-all-following-feedback-from-some-of-our-shareholde-iclr-20080709monthly0.5https://www.biopharmawatch.com/news/ICLR/letter-to-shareholders-of-icon-plc-dear-all-we-are-disappointed-to-note-that-in-its-recent-iclr-20080708monthly0.5https://www.biopharmawatch.com/news/ICLR/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-iclr-20080625monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-announces-appointment-of-professor-dermot-kelleher-to-the-board-of-directors-nasd-iclr-20080529monthly0.5https://www.biopharmawatch.com/news/ICLR/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-iclr-20070716monthly0.5https://www.biopharmawatch.com/news/ICLR/chairman-dr-john-climax-icon-corporate-dev-president-bill-taaffe-ceo-peter-gray-cfo-ciaran-iclr-20070302monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-raises-2006-guidance-and-issues-financial-guidance-for-2007-highlights-2006-revenue-g-iclr-20070110monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-american-depositary-shares-representing-ordinary-shares-par-value-0-06-per-share--iclr-20060801monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-files-registration-statement-for-american-depositary-shares-dublin-ireland-iclr-20060419monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-record-net-new-business-awards-of-140-million-and-a-20-increase-in-eps-for-th-iclr-20060111monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-10-increase-in-net-revenues-and-eps-of-45-cents-nasdaq-iclr-highlights-first--iclr-20050927monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-announces-new-appointments-dublin-ireland-monday-iclr-20050830monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-10-increase-in-net-revenues-and-eps-of-42-cents-nasdaq-iclr-highlights-fourth-iclr-20050802monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-a-9-increase-in-net-revenues-eps-of-0-41-and-net-new-business-awards-of-120-m-iclr-20050106monthly0.5https://www.biopharmawatch.com/news/ICLR/icon-reports-strong-results-with-24-increase-in-operating-income-in-first-quarter-fy-2005--iclr-20040928monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-first-quarter-2026-results-raises-guidance-based-on-strong-performan-blco-20260429monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-fourth-quarter-and-full-year-2025-results-provides-2026-guidance-del-blco-20260218monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-completes-refinancing-of-outstanding-term-b-loans-blco-20260102monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-two-board-of-directors-appointments-blco-20251217monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-refinancing-of-outstanding-term-b-loans-blco-20251212monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-to-highlight-company-transformation-and-growth-strategy-at-investor-day-blco-20251113monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-third-quarter-2025-results-revenue-of-1-281-billion-gaap-net-loss-at-blco-20251029monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-second-quarter-2025-results-revenue-of-1-278-billion-gaap-net-loss-a-blco-20250730monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-closing-of-upsized-675-million-senior-secured-notes-offering-and-par-blco-20250626monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-pricing-of-upsized-senior-secured-notes-offering-blco-20250618monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-launch-of-senior-secured-notes-offering-and-refinancing-of-credit-ag-blco-20250610monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-first-quarter-2025-results-revenue-of-1-137-billion-gaap-net-loss-at-blco-20250430monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-fourth-quarter-and-full-year-2024-results-provides-2025-guidance-fou-blco-20250219monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-third-quarter-2024-results-revenue-of-1-196-billion-gaap-net-income--blco-20241030monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-second-quarter-2024-results-revenue-of-1-216-billion-gaap-net-loss-a-blco-20240731monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-first-quarter-2024-results-revenue-of-1-099-billion-gaap-net-loss-at-blco-20240501monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-appointment-of-karen-l-ling-to-board-of-directors-richard-de-schutte-blco-20240228monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-fourth-quarter-and-full-year-2023-results-and-provides-2024-guidance-blco-20240221monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-third-quarter-2023-results-and-raises-full-year-2023-guidance-revenu-blco-20231101monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-completes-acquisition-of-xiidra-poised-for-significant-growth-in-prescription--blco-20230929monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-pricing-of-senior-secured-notes-offering-blco-20230914monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-announces-launch-of-proposed-financing-for-acquisition-of-blco-20230911monthly0.5https://www.biopharmawatch.com/news/BLCO/independent-auditors-report-to-management-of-novartis-pharma-ag-report-on-the-audit-of-the-blco-20230906monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contacts-media-contacts-george-gadkowski-t-j-crawford-george-gadkowski-bausch-com-blco-20230802monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-will-acquire-xiidra-acquisition-represents-significant-opportunity-for-growth--blco-20230630monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contacts-media-contacts-allison-ryan-lainie-keller-allison-ryan-bausch-com-lainie-blco-20230601monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contacts-media-contacts-arthur-shannon-lainie-keller-arthur-shannon-bausch-com-la-blco-20230503monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bausch-com-lain-blco-20230412monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contacts-media-contacts-arthur-shannon-lainie-keller-arthur-shannon-bausch-com-la-blco-20230222monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bausch-com-lain-blco-20230215monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contacts-media-contacts-arthur-shannon-lainie-keller-arthur-shannon-bausch-com-la-blco-20221102monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contacts-media-contacts-arthur-shannon-lainie-keller-arthur-shannon-bausch-com-la-blco-20220804monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bausch-com-lain-blco-20220720monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contacts-media-contacts-arthur-shannon-lainie-keller-arthur-shannon-bausch-com-la-blco-20220623monthly0.5https://www.biopharmawatch.com/news/BLCO/investor-contacts-media-contacts-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth--blco-20220608monthly0.5https://www.biopharmawatch.com/news/BLCO/bausch-lomb-corporation-a-business-of-bausch-health-companies-inc-index-to-condensed-conso-blco-20220517monthly0.5https://www.biopharmawatch.com/news/SRRK/as-of-today-and-should-not-be-relied-upon-as-representing-its-views-as-of-any-subsequent-d-srrk-20260112monthly0.5https://www.biopharmawatch.com/news/SRRK/ir-scholarrock-com-917-439-0374-media-contact-molly-macleod-media-scholarrock-com-802-579--srrk-20251114monthly0.5https://www.biopharmawatch.com/news/SRRK/fda-issues-complete-response-letter-crl-for-apitegromab-as-a-treatment-for-patients-with-s-srrk-20250923monthly0.5https://www.biopharmawatch.com/news/SRRK/other-current-assets-24-113-13-887-total-current-assets-319-126-451-165-other-assets-20-91-srrk-20250806monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-positive-phase-2-embraze-trial-results-demonstrating-statistically-si-srrk-20250618monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-first-quarter-2025-financial-results-and-highlights-business-progress-srrk-20250514monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-appoints-david-l-hallal-as-chief-executive-officer-also-announces-addition-of-srrk-20250428monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-full-year-2024-financial-results-and-highlights-business-progress-sub-srrk-20250227monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-the-appointment-of-industry-leader-lisa-wyman-as-chief-technical-an-srrk-20250129monthly0.5https://www.biopharmawatch.com/news/SRRK/xa9-2025-scholar-rock-inc-all-rights-reserved-forward-looking-statements-various-statement-srrk-20250114monthly0.5https://www.biopharmawatch.com/news/SRRK/xa9-2024-scholar-rock-inc-all-rights-reserved-forward-looking-statements-various-statement-srrk-20250113monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-third-quarter-2024-financial-results-and-highlights-business-progress-srrk-20241112monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-srrk-20241007monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-apitegromab-meets-primary-endpoint-in-phase-3-sapphire-study-in-patie-srrk-20241007monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-second-quarter-2024-financial-results-and-highlights-business-progres-srrk-20240808monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-s-subsequent-filings-with-the-securities-and-exchange-commission-any-forward--srrk-20240624monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-presents-new-data-from-srk-181-phase-1-dragon-trial-at-asco-2024-annual-meeti-srrk-20240603monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-initiation-of-phase-2-embraze-trial-of-apitegromab-in-obesity-and-n-srrk-20240522monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-first-quarter-2024-financial-results-and-highlights-business-progress-srrk-20240507monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-full-year-2023-financial-results-and-highlights-business-progress-piv-srrk-20240319monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-the-addition-of-katie-peng-to-its-board-of-directors-and-promotes-m-srrk-20240215monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-inc-all-rights-reserved-advancing-new-possibilities-for-patients-42nd-annual--srrk-20240108monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-third-quarter-2023-financial-results-and-highlights-business-progress-srrk-20231107monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-proposed-public-offering-of-common-stock-cambridge-mass-business-wi-srrk-20231011monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-to-advance-antimyostatin-program-to-develop-novel-therapies-for-cardiometabol-srrk-20231011monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-second-quarter-2023-financial-results-and-highlights-business-progres-srrk-20230809monthly0.5https://www.biopharmawatch.com/news/SRRK/new-36-month-apitegromab-extension-data-reinforce-long-term-substantial-and-sustained-impr-srrk-20230629monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-first-quarter-2023-financial-results-and-highlights-business-progress-srrk-20230509monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-the-addition-of-richard-brudnick-to-its-board-of-directors-cambridg-srrk-20230410monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-full-year-2022-financial-results-and-highlights-business-progress-enr-srrk-20230307monthly0.5https://www.biopharmawatch.com/news/SRRK/deep-insightsadvancingimpactful-medicines-january-2023-disclaimers-various-statements-in-t-srrk-20230109monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-third-quarter-2022-financial-results-and-highlights-business-progress-srrk-20221114monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-appoints-jing-l-marantz-m-d-ph-d-m-b-a-as-chief-medical-officer-dr-marantz-br-srrk-20221109monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-appoints-jay-backstrom-m-d-m-p-h-to-be-its-next-chief-executive-officer-dr-ba-srrk-20220920monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-second-quarter-2022-financial-results-and-highlights-business-progres-srrk-20220808monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-the-addition-of-srinivas-akkaraju-m-d-ph-d-to-its-board-of-director-srrk-20220726monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-205-million-registered-direct-offering-cambridge-mass-business-wire-srrk-20220617monthly0.5https://www.biopharmawatch.com/news/SRRK/positive-phase-2-topaz-trial-extension-data-demonstrate-sizable-and-sustained-motor-functi-srrk-20220617monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-first-quarter-2022-financial-results-and-updates-strategic-priorities-srrk-20220516monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-full-year-2021-financial-results-and-highlights-business-progress-pro-srrk-20220307monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-provides-corporate-update-and-highlights-priorities-for-2022-initiated-phase--srrk-20220110monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-design-of-phase-3-sapphire-clinical-trial-evaluating-apitegromab-in-srrk-20211130monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-third-quarter-2021-financial-results-and-highlights-business-progress-srrk-20211109monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-second-quarter-2021-financial-results-and-highlights-business-progres-srrk-20210810monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-leadership-change-nagesh-mahanthappa-ph-d-mba-scholar-rock-s-foundi-srrk-20210803monthly0.5https://www.biopharmawatch.com/news/SRRK/apitegromab-positioned-to-be-the-potential-next-transformative-therapy-for-patients-suffer-srrk-20210615monthly0.5https://www.biopharmawatch.com/news/SRRK/deep-insights-impactful-medicines-may-2021-disclaimers-various-statements-in-this-presenta-srrk-20210526monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-first-quarter-2021-financial-results-and-highlights-business-progress-srrk-20210513monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-positive-12-month-top-line-results-from-the-topaz-phase-2-clinical--srrk-20210406monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-the-addition-of-joshua-reed-to-its-board-of-directors-cambridge-mas-srrk-20210318monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-full-year-2020-financial-results-and-highlights-business-progress-top-srrk-20210309monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-third-quarter-2020-financial-results-and-highlights-business-progress-srrk-20201109monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-proposed-public-offering-of-common-stock-srrk-20201027monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-positive-proof-of-concept-data-from-topaz-phase-2-trial-interim-ana-srrk-20201027monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-secures-50-million-debt-facility-with-silicon-valley-bank-and-oxford-finance--srrk-20201019monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-second-quarter-2020-financial-results-and-highlights-business-progres-srrk-20200807monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-appoints-tony-kingsley-as-president-and-ceo-nagesh-mahanthappa-ph-d-mba-compa-srrk-20200714monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-appoints-tony-kingsley-to-its-board-of-directors-proven-leader-with-extensive-srrk-20200521monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-first-quarter-2020-financial-results-and-highlights-business-progress-srrk-20200507monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-full-year-2019-financial-results-and-highlights-business-progress-ini-srrk-20200312monthly0.5https://www.biopharmawatch.com/news/SRRK/january-2020-deep-insights-impactful-medicines-srrk-20200113monthly0.5https://www.biopharmawatch.com/news/SRRK/november-2019-from-new-insights-to-new-medicines-srrk-20191119monthly0.5https://www.biopharmawatch.com/news/SRRK/f-r-o-mn-e-wi-n-s-i-ghtst-on-e-wm-e-d-i-ci-ne-s-june-2019-disclaimers-various-statements-i-srrk-20190624monthly0.5https://www.biopharmawatch.com/news/SRRK/march-2019-from-new-insights-to-new-medicines-srrk-20190313monthly0.5https://www.biopharmawatch.com/news/SRRK/august-2018-from-new-insights-to-new-medicines-srrk-20180813monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-pricing-of-350-0-million-underwritten-public-offering-of-american-dep-blte-20251201monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-inc-condensed-consolidated-balance-sheets-amounts-in-thousands-of-us-dollars-ex-blte-20251201monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-proposed-underwritten-public-offering-of-american-depositary-shares-blte-20251201monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-second-quarter-2025-financial-results-and-provides-blte-20250811monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-registered-direct-offering-of-15-million-the-offering-was-to-a-single-blte-20250806monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-completion-of-enrollment-in-the-pivotal-global-phase-3-phoenix-trial--blte-20250702monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-fda-granting-of-breakthrough-therapy-designation-for-tinlarebant-for--blte-20250521monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-first-quarter-2025-financial-results-and-provides-corporate-update-foll-blte-20250514monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-results-of-2025-general-meeting-blte-20250415monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-inc-notice-of-annual-general-meeting-of-shareholders-to-be-held-on-april-15-202-blte-20250318monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-availability-of-annual-report-on-form-20-f-through-company-website-blte-20250317monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corpor-blte-20250317monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-interim-analysis-results-from-the-pivotal-global-phase-3-dragon-trial-blte-20250226monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-registered-direct-offering-of-15-million-blte-20250205monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update-do-blte-20241112monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-appointment-of-hendrik-p-n-scholl-md-ma-as-chief-medical-officer-dr-s-blte-20240901monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-second-quarter-2024-financial-results-and-provides-a-corporate-update-t-blte-20240812monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update-tinl-blte-20240514monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-25-million-registered-direct-offering-san-diego-april-25-2024-belite--blte-20240426monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-pmda-submission-of-tinlarebant-for-stargardt-disease-clinical-trial-i-blte-20240322monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-availability-of-annual-report-on-form-20-f-through-company-website-blte-20240311monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corpor-blte-20240312monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-third-quarter-2023-operational-highlights-and-financial-results-complet-blte-20231114monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-presents-results-from-a-24-month-phase-2-study-of-tinlarebant-in-childhood-onse-blte-20231106monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-second-quarter-2023-operational-highlights-and-financial-results-comple-blte-20230809monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-completes-enrollment-in-pivotal-global-phase-3-dragon-trial-evaluating-oral-tin-blte-20230724monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-pricing-of-30-million-underwritten-public-offering-of-american-deposi-blte-20230530monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-proposed-underwritten-public-offering-of-american-depositary-shares-a-blte-20230530monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-first-quarter-2023-operational-highlights-and-financial-results-in-18-m-blte-20230511monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-presented-18-month-interim-data-from-a-24-month-phase-2-study-of-tinlarebant-in-blte-20230425monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-full-year-2022-operational-highlights-and-financial-results-12-month-in-blte-20230403monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-finalizes-phase-3-clinical-trial-plans-for-advanced-dry-amd-treatment-with-tinl-blte-20221118monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-presented-12-month-interim-results-of-lbs-008-phase-1b-2-study-in-adolescent-st-blte-20221001monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-receives-approval-of-lbs-008-phase-3-clinical-trial-in-china-lbs-008-aka-tinlar-blte-20220916monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-initiates-pivotal-phase-3-clinical-trial-of-lbs-008-in-stargardt-disease-in-the-blte-20220822monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-first-half-2022-operational-highlights-and-financial-results-lbs-008-ak-blte-20220811monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-submits-investigational-new-drug-blte-20220719monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-partial-exercise-of-over-allotment-option-in-initial-public-offering-blte-20220512monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-receives-fda-fast-track-designation-for-lbs-008-lbs-008-aka-tinlarebant-is-the--blte-20220503monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2026-financial-res-cogt-20260505monthly0.5https://www.biopharmawatch.com/news/COGT/peak-trial-bezuclastinib-sunitinib-in-gastrointestinal-stromal-tumors-gist-top-line-result-cogt-20251110monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2025-financial-re-cogt-20250805monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-top-line-results-achieving-statistical-significance--cogt-20250707monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-secures-up-to-400-million-in-non-dilutive-financing-facility-provides-a-cogt-20250611monthly0.5https://www.biopharmawatch.com/news/COGT/jefferies-global-healthcare-conference-cogt-20250605monthly0.5https://www.biopharmawatch.com/news/COGT/xfeff-cogent-biosciences-reports-first-quarter-2025-financial-results-three-registration-d-cogt-20250506monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-fourth-quarter-and-full-year-202-cogt-20250225monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2024-financial-res-cogt-20241112monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-phase-3-peak-trial-in-patients-with-gastrointestinal-stromal--cogt-20240903monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2024-financial-re-cogt-20240806monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-fda-meeting-and-alignment-on-ms2d2-a-novel-patient-r-cogt-20240627monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-first-quarter-2024-financial-results-summit-peak-and-apex-regis-cogt-20240507monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-fourth-quarter-and-full-year-202-cogt-20240226monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-oversubscribed-225-million-private-placement-pro-forma-cash-c-cogt-20240214monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2023-financial-res-cogt-20231102monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2023-financial-re-cogt-20230808monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2023-financial-res-cogt-20230509monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-fourth-quarter-and-full-year-202-cogt-20230314monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-updated-clinical-data-from-ongoing-phase-2-apex-tria-cogt-20221211monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2022-financial-res-cogt-20221114monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2022-financial-re-cogt-20220809monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-fu-cogt-20220616monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-initial-clinical-data-from-ongoing-phase-2-apex-tria-cogt-20220610monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2022-financial-res-cogt-20220510monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-provides-corporate-updates-fourth-quarter-and-full-year-2021-financial--cogt-20220315monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-provides-corporate-updates-and-reports-third-quarter-2021-financial-res-cogt-20211110monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-provides-corporate-updates-and-reports-second-quarter-2021-financial-re-cogt-20210816monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-provides-corporate-updates-and-reports-first-quarter-2021-financial-res-cogt-20210512monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-fourth-quarter-2020-and-full-year-2020-financial-results-cgt948-cogt-20210316monthly0.5https://www.biopharmawatch.com/news/COGT/developing-precision-therapies-for-genetically-defined-diseases-corporate-presentation-q4--cogt-20201130monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-third-quarter-2020-financial-results-and-provides-corporate-upd-cogt-20201109monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-appoints-andrew-robbins-as-chief-executive-officer-seasoned-executive-w-cogt-20201026monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-announces-company-name-change-to-cogent-biosciences-highlights-recent-sc-cogt-20201005monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-transfers-boxr-cell-based-therapy-technology-to-sotio-transaction-focuse-cogt-20200831monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-second-quarter-2020-financial-results-and-provides-corporate-upd-cogt-20200811monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-inc-announces-acquisition-of-kiq-llc-acquisition-includes-lead-clinical--cogt-20200706monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-first-quarter-financial-results-and-provides-corporate-updates-c-cogt-20200511monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-cogt-20200326monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-announces-common-stock-purchase-agreement-for-up-to-25-million-with-linc-cogt-20200320monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-implements-strategic-restructuring-to-prioritize-efforts-on-boxr1030-for-cogt-20200302monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-provides-updates-to-its-phase-1-trial-of-actr707-for-her2-solid-tumor-ca-cogt-20200129monthly0.5https://www.biopharmawatch.com/news/COGT/forward-looking-statements-and-risk-factors-this-presentation-and-the-accompanying-oral-co-cogt-20200113monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-announces-new-data-at-the-american-society-of-hematology-ash-annual-meet-cogt-20191207monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-third-quarter-2019-financial-results-progress-towards-focusing-o-cogt-20191112monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-presents-preclinical-data-for-boxr1030-at-the-society-for-immunotherapy--cogt-20191105monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-announces-strategic-focus-on-developing-best-in-class-cellular-therapies-cogt-20191104monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-second-quarter-2019-financial-results-and-provides-corporate-upd-cogt-20190812monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-announces-new-appointments-to-its-board-of-directors-cogt-20190729monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-announces-regulatory-update-from-phase-1-trial-with-actr087-cogt-20190702monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-strengthens-and-expands-leadership-team-matthew-osborne-appointed-as-chi-cogt-20190613monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-first-quarter-2019-financial-results-and-provides-business-updat-cogt-20190513monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-cogt-20190328monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-corporate-presentation-th-cowen-and-company-39-annual-healthcare-confere-cogt-20190307monthly0.5https://www.biopharmawatch.com/news/COGT/forward-looking-statements-and-risk-factors-this-presentation-and-the-accompanying-oral-co-cogt-20190107monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-announces-transition-of-chief-financial-officer-cambridge-ma-cogt-20190103monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-presents-preliminary-results-from-ongoing-phase-1-study-attck-17-01-at-t-cogt-20181201monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-third-quarter-2018-financial-results-and-provides-business-updat-cogt-20181112monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-second-quarter-2018-financial-results-and-provides-business-upda-cogt-20180813monthly0.5https://www.biopharmawatch.com/news/COGT/unum-therapeutics-reports-first-quarter-2018-financial-results-and-provides-business-updat-cogt-20180514monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-result-ptct-20260507monthly0.5https://www.biopharmawatch.com/news/PTCT/significant-business-effects-including-the-effects-of-industry-market-economic-political-o-ptct-20260428monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-f-ptct-20260219monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-update-at-j-p-morgan-annual-healthcare-conference-strong-sephien-ptct-20260112monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial-resul-ptct-20250807monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-approval-of-sephience-sepiapterin-for-the-treatment-of-chil-ptct-20250728monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2025-financial-result-ptct-20250506monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc518-pivot-hd-study-achieves-primary-endpoint-study-met-primary-endpoint-with-dose-depen-ptct-20250505monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-regulatory-update-on-translarna-ataluren-in-europe-warren-n-j-ptct-20250328monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-f-ptct-20250227monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-update-on-commercial-performance-and-r-d-pipeline-at-43-rd-annua-ptct-20250113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-enters-into-a-global-license-and-collaboration-agreement-with-novartis-fo-ptct-20241202monthly0.5https://www.biopharmawatch.com/news/PTCT/words-guidance-plan-anticipate-believe-estimate-expect-intend-may-target-potential-will-wo-ptct-20241127monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-result-ptct-20241107monthly0.5https://www.biopharmawatch.com/news/PTCT/chmp-maintains-negative-opinion-on-translarna-reexamination-opinion-to-be-reviewed-by-euro-ptct-20241018monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-second-quarter-2024-financial-resul-ptct-20240808monthly0.5https://www.biopharmawatch.com/news/PTCT/chmp-issues-negative-opinion-on-translarna-following-european-commission-request-for-revie-ptct-20240628monthly0.5https://www.biopharmawatch.com/news/PTCT/interim-pivot-hd-results-demonstrate-evidence-of-favorable-cns-biomarker-and-clinical-effe-ptct-20240620monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-european-commission-returns-translarna-opinion-to-chmp-for-re-e-ptct-20240520monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-result-ptct-20240425monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2023-f-ptct-20240229monthly0.5https://www.biopharmawatch.com/news/PTCT/chmp-issues-negative-opinion-for-renewal-of-conditional-marketing-authorization-for-transl-ptct-20240125monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-an-update-on-commercial-progress-and-r-d-pipeline-at-42nd-annual-ptct-20240108monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-financial-results-thi-ptct-20231026monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-evrysdi-royalty-agreement-with-royalty-pharma-for-up-to-1-5-bil-ptct-20231019monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-announces-further-strategic-prioritization-and-associated-reduction-in-workforce-trans-ptct-20230928monthly0.5https://www.biopharmawatch.com/news/PTCT/chmp-delivers-opinion-on-translarna-for-conversion-to-full-authorization-conference-call-t-ptct-20230915monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-second-quarter-financial-results-se-ptct-20230803monthly0.5https://www.biopharmawatch.com/news/PTCT/patient-living-with-pku-ptct-20230719monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-shares-positive-interim-data-from-pivot-hd-clinical-trial-in-huntington-s-ptct-20230621monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-strategic-pipeline-prioritization-preclinical-and-early-researc-ptct-20230523monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-aphenity-trial-achieved-primary-endpoint-with-sepiapterin-in-pk-ptct-20230517monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-first-quarter-financial-results-f-ptct-20230427monthly0.5https://www.biopharmawatch.com/news/PTCT/stuart-peltz-ph-d-rare-disease-pioneer-to-retire-as-chief-executive-officer-of-ptc-therape-ptct-20230324monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-fourth-quarter-and-full-year-2022-ptct-20230221monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-an-update-on-commercial-progress-and-r-d-pipeline-at-41st-annual-ptct-20230109monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-third-quarter-financial-results-t-ptct-20221027monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-strategic-financing-collaboration-with-blackstone-with-up-to-1--ptct-20221027monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-provides-update-on-ongoing-global-pivot-hd-trial-for-ptc518-ptct-20221018monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-2022-corporate-presentation-september-2022-forward-looking-statements-this-presentatio-ptct-20220907monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-second-quarter-financial-results--ptct-20220804monthly0.5https://www.biopharmawatch.com/news/PTCT/translarna-x2122-ataluren-study-041-topline-results21stjune-2022-forward-looking-statement-ptct-20220621monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-william-blair-growth-stock-conference-matthew-klein-m-d-chief-operating-o-ptct-20220609monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-first-quarter-financial-results-1-ptct-20220503monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-fourth-quarter-and-full-year-2021-ptct-20220222monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-an-update-on-commercial-progress-and-r-d-pipeline-at-40-th-annua-ptct-20220110monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-2021-corporate-deck-updated-ptct-20211130monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-third-quarter-2021-financial-resu-ptct-20211028monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc518-huntington-s-disease-program-update-ptct-20210923monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-second-quarter-2021-financial-res-ptct-20210729monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-a-corporate-update-and-reports-first-quarter-2021-financial-resu-ptct-20210504monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc518-huntington-s-disease-deep-dive-april-15th-2021-forward-looking-statements-this-pres-ptct-20210415monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-inc-summary-consolidated-balance-sheets-in-thousands-except-share-data-ptct-20210225monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-call-to-review-results-from-its-study-of-translarna-ataluren-in-p-ptct-20210204monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-update-on-r-d-pipeline-and-commercial-progress-at-39-th-annual-j-ptct-20210111monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-third-quarter-2020-financial-results-and-provides-a-corporate-upd-ptct-20201029monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-acquire-censa-pharmaceuticals-acquisition-diversifies-and-strengthens--ptct-20200506monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides--ptct-20200302monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-2020-jp-morgan-healthcare-conference-stuart-w-peltz-ph-d-ceo-forwar-lookingstatement-t-ptct-20200117monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-highlights-pipeline-progress-at-2020-j-p-mo-ptct-20200113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-pricing-of-public-offering-of-common-stock-ptct-20190918monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-expands-presence-in-new-jersey-by-securing-ptct-20190805monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides--ptct-20190228monthly0.5https://www.biopharmawatch.com/news/PTCT/to-ptc-s-current-report-on-form-8-k-filed-on-ptct-20190107monthly0.5https://www.biopharmawatch.com/news/PTCT/to-ptc-s-current-report-on-form-8-k-filed-on-ptct-20181218monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-successfully-completes-acquisition-of-agilis-biotherapeutics-ptct-20180823monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-acquire-agilis-biotherapeutics-expands-and-diversifies-current-pipelin-ptct-20180719monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-formal-dispute-resolution-request-decision-from-the-fda-s-office-ptct-20180220monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-s-actual-results-performance-or-achievements-could-differ-materially-from-those-expres-ptct-20180127monthly0.5https://www.biopharmawatch.com/news/PTCT/jpmpresentation2018-ptct-20180110monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-outlines-2018-strategic-priorities-ptct-20180108monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-third-quarter-2017-financial-results-and-provides-corporate-updat-ptct-20171102monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-complete-response-letter-for-ataluren-s-nda-ptct-20171025monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-second-quarter-2017-financial-results-and-provides-corporate-upda-ptct-20170808monthly0.5https://www.biopharmawatch.com/news/PTCT/ppmdpresentation-accessing-emflaza-deflazacort-for-duchenne-muscular-dystrophy-ppmd-2017-c-ptct-20170629monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-executive-promotions-ptct-20170605monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-completes-acquisition-of-emflaza-for-the-treatment-of-duchenne-muscular-d-ptct-20170420monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-departure-of-chief-financial-officer-shane-kovacs-ptct-20170410monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-agreement-to-acquire-emflaza-for-the-treatment-of-duchenne-musc-ptct-20170316monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-results-from-pivotal-phase-3-clinical-trial-of-ataluren-in-pati-ptct-20170302monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-outlines-2017-strategic-priorities-ptct-20170109monthly0.5https://www.biopharmawatch.com/news/TFX/lawrence-keusch-vice-president-investor-relations-and-strategy-development-610-948-2836-fo-tfx-20260601monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-leadership-transition-stuart-randle-appointed-interim-president-and-ceo-tfx-20260108monthly0.5https://www.biopharmawatch.com/news/TFX/the-release-accompanying-slides-and-replay-webcast-are-available-online-at-www-teleflex-co-tfx-20240222monthly0.5https://www.biopharmawatch.com/news/TFX/the-release-accompanying-slides-and-replay-webcast-are-available-online-at-www-teleflex-co-tfx-20230504monthly0.5https://www.biopharmawatch.com/news/TFX/document-tfx-20220224monthly0.5https://www.biopharmawatch.com/news/TFX/lawrence-keusch-vice-president-investor-relations-and-strategy-development-610-948-2836-tfx-20210729monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20210429monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20210225monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20201029monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20200730monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-investor-relations-610-948-2836-for-immediate-r-tfx-20200521monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20200430monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20200220monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20191031monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20190801monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20190502monthly0.5https://www.biopharmawatch.com/news/TFX/to22120198kresupple-schedule-of-segment-revenues-three-months-ended-increase-decrease-tfx-20190221monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20190221monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20181101monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20180802monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-investor-relations-610-948-2836-teleflex-incorp-tfx-20180511monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20180503monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20180222monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-investor-relations-610-948-2836-for-immediate-r-tfx-20171116monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20171102monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20171002monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20170905monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20170803monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20170504monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20170223monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20170217monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-enters-into-separate-privately-negotiated-agreements-with-certain-of-its-converti-tfx-20161215monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-to-acquire-vascular-solutions-tfx-20161202monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20161027monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20160728monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-investor-relations-610-948-2836-for-immediate-r-tfx-20160511monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20160428monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-enters-into-separate-privately-negotiated-agreements-with-certain-of-its-converti-tfx-20160317monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20160225monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-are-available-tfx-20151029monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20150730monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20150521monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20150430monthly0.5https://www.biopharmawatch.com/news/TFX/to22020158kreq-1-teleflex-incorporated-fourth-quarter-2014-earnings-conference-call-1-conf-tfx-20150220monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20150220monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-are-available-tfx-20141029monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20141029monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-are-available-tfx-20140730monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20140730monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20140516monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-and-subsidiaries-segment-net-revenues-years-ended-tfx-20140516monthly0.5https://www.biopharmawatch.com/news/TFX/proposal-2-approval-of-2014-stock-incentive-plan-on-tfx-20140508monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-are-available-tfx-20140430monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20140430monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-are-available-tfx-20140221monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20140221monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20131217monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-are-available-tfx-20131030monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20131030monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-second-quarter-2013-earnings-conference-call-1-conference-call-logis-tfx-20130731monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20130731monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-available-onl-tfx-20130430monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20130430monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-fourth-quarter-full-year-2012earnings-conference-call-1-conference-c-tfx-20130221monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20130221monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20121213monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-available-onl-tfx-20121031monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20121031monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-available-onl-tfx-20120731monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20120731monthly0.5https://www.biopharmawatch.com/news/TFX/conference-call-logistics-the-release-accompanying-slides-and-replay-webcast-available-onl-tfx-20120501monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20120501monthly0.5https://www.biopharmawatch.com/news/TFX/this-presentation-and-our-discussion-contain-forward-looking-information-and-statements-in-tfx-20120314monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-fourth-quarter-full-year-2011-2012-outlook-earnings-conference-call--tfx-20120223monthly0.5https://www.biopharmawatch.com/news/TFX/jake-elguicze-treasurer-and-vice-president-of-investor-relations-610-948-2836-tfx-20120223monthly0.5https://www.biopharmawatch.com/news/PACS/document-pacs-nyse-notice-press-release-pacs-group-announces-receipt-of-notice-of-late-fil-pacs-20241126monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-first-quarter-2026-results-net-sales-of-1-581-million-net-income-of-43-mil-avtr-20260429monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-third-quarter-2025-results-net-sales-of-1-62-billion-decrease-of-5-net-los-avtr-20251029monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-second-quarter-2025-results-net-sales-of-1-68-billion-decrease-of-1-organi-avtr-20250801monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-announces-emmanuel-ligner-as-next-president-and-ceo-seasoned-executive-with-proven-avtr-20250721monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-first-quarter-2025-results-net-sales-of-1-58-billion-decrease-of-6-organic-avtr-20250425monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-fourth-quarter-and-full-year-2024-results-fourth-quarter-2024-net-sales-of-avtr-20250207monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-third-quarter-2024-results-net-sales-of-1-71-billion-decrease-of-0-3-organ-avtr-20241025monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-second-quarter-2024-results-net-sales-of-1-70-billion-decrease-of-2-4-orga-avtr-20240726monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-first-quarter-2024-results-net-sales-of-1-68-billion-decrease-of-5-6-organ-avtr-20240426monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-fourth-quarter-and-full-year-2023-results-fourth-quarter-2023-net-sales-of-avtr-20240214monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-hosts-investor-day-announces-new-strategic-operating-model-to-drive-growth-and-pro-avtr-20231207monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-third-quarter-2023-results-net-sales-of-1-72-billion-decrease-of-7-3-core--avtr-20231027monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-second-quarter-2023-results-net-sales-of-1-74-billion-decrease-of-8-7-core-avtr-20230728monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-names-r-brent-jones-as-chief-financial-officer-radnor-pa-avtr-20230713monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-announces-cfo-transition-radnor-pa-avtr-20230515monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-first-quarter-2023-results-net-sales-of-1-78-billion-decrease-of-8-7-core--avtr-20230428monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-fourth-quarter-and-full-year-2022-results-fourth-quarter-net-sales-of-1-80-avtr-20230203monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-third-quarter-2022-results-net-sales-of-1-86-billion-increase-of-1-2-core--avtr-20221028monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-second-quarter-2022-results-net-sales-of-1-91-billion-increase-of-2-8-core-avtr-20220728monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-first-quarter-2022-results-net-sales-of-1-95-billion-increase-of-9-2-organ-avtr-20220428monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-fourth-quarter-and-full-year-2021-results-fourth-quarter-net-sales-of-1-91-avtr-20220203monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-third-quarter-2021-results-net-sales-of-1-83-billion-increase-of-14-3-orga-avtr-20211028monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-announces-offering-of-senior-notes-radnor-pa-avtr-20211019monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-second-quarter-2021-results-net-sales-of-1-86-billion-increase-of-25-7-org-avtr-20210729monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-first-quarter-2021-results-revenue-of-1-79-billion-increase-of-17-5-organi-avtr-20210428monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-fourth-quarter-and-full-year-2020-results-business-highlights-q4-revenue-o-avtr-20210203monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-announces-upsizing-and-pricing-of-offering-of-650-0-million-of-senior-first-lien-n-avtr-20201030monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-announces-offering-of-senior-first-lien-notes-avtr-20201028monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-announces-upsizing-and-pricing-of-offering-of-2-0-billion-equivalent-of-senior-not-avtr-20200707monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-announces-offering-of-senior-notes-radnor-pa-avtr-20200707monthly0.5https://www.biopharmawatch.com/news/AVTR/index-to-financial-statements-vwr-corporation-glossary-2-audited-consolidated-financial-st-avtr-20200518monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-first-quarter-2020-results-revenue-of-1-52-billion-increase-of-2-6-organic-avtr-20200429monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-fourth-quarter-and-full-year-2019-results-net-sales-1-52-billion-net-incom-avtr-20200207monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-third-quarter-2019-results-net-sales-of-1-50-billion-net-income-of-22-1-mi-avtr-20191105monthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-second-quarter-2019-results-net-sales-of-1-53-billion-up-4-6-on-an-organic-avtr-20190806monthly0.5https://www.biopharmawatch.com/news/NNNN/anbio-biotechnology-friedrich-ebert-anlage-35-37-60327-frankfurt-am-main-germany-proxy-sta-nnnn-20260427monthly0.5https://www.biopharmawatch.com/news/NNNN/anbio-biotechnology-announced-unaudited-financial-results-for-the-six-months-ended-nnnn-20251230monthly0.5https://www.biopharmawatch.com/news/NNNN/anbio-biotechnology-announces-closing-of-initial-public-offering-frankfurt-am-main-germany-nnnn-20250220monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-announces-inclusion-in-the-s-p-smallcap-600-index-morrisville-n-c-lqda-20260608monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-first-quarter-2026-financial-results-yutrepia-treprostinil-in-lqda-20260430monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provi-lqda-20260305monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-announces-preliminary-full-year-2025-yutrepia-net-sales-and-corporate-lqda-20260109monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-third-quarter-2025-financial-results-and-provides-corporate-u-lqda-20251103monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-second-quarter-2025-financial-results-and-provides-corporate--lqda-20250812monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-receives-50-million-from-healthcare-royalty-hcrx-following-first-commercial-sale--lqda-20250623monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-schedules-first-commercial-shipment-of-yutrepia-treprostinil-inhalation-powder-fo-lqda-20250523monthly0.5https://www.biopharmawatch.com/news/LQDA/u-s-fda-approves-liquidia-s-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulm-lqda-20250523monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-provides-update-on-litigation-filed-by-united-therapeutics-new-litiga-lqda-20250512monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-first-quarter-2025-financial-results-and-provides-corporate-u-lqda-20250508monthly0.5https://www.biopharmawatch.com/news/LQDA/item-8-financial-statements-and-supplementary-data-liquidia-corporation-financial-statemen-lqda-20250508monthly0.5https://www.biopharmawatch.com/news/LQDA/district-court-dismisses-dispute-filed-by-united-therapeutics-against-liquidia-court-will--lqda-20250505monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-announces-fda-acceptance-of-new-drug-application-resubmission-for-yut-lqda-20250328monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-full-year-2024-financial-results-and-provides-corporate-updat-lqda-20250319monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-strengthens-financial-position-by-amending-healthcare-royalty-agreeme-lqda-20250318monthly0.5https://www.biopharmawatch.com/news/LQDA/certain-identified-information-has-been-excluded-from-this-exhibit-because-it-is-not-mater-lqda-20241126monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-third-quarter-2024-financial-results-and-provides-corporate-u-lqda-20241113monthly0.5https://www.biopharmawatch.com/news/LQDA/united-states-supreme-court-declines-to-review-rulings-that-invalidate-united-therapeutics-lqda-20241007monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-and-pharmosa-biopharm-expand-collaboration-to-develop-sustained-release-inhaled-t-lqda-20241002monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-announces-raise-of-67-5-million-from-new-common-stock-financings-and--lqda-20240911monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-files-litigation-to-challenge-regulatory-exclusivity-blocking-access-to-yutrepia--lqda-20240816monthly0.5https://www.biopharmawatch.com/news/LQDA/u-s-fda-grants-tentative-approval-of-yutrepia-treprostinil-inhalation-powder-for-patients--lqda-20240819monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-second-quarter-2024-financial-results-and-provides-corporate--lqda-20240807monthly0.5https://www.biopharmawatch.com/news/LQDA/district-court-issues-favorable-ruling-and-denies-united-therapeutics-request-to-block-yut-lqda-20240603monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-first-quarter-2024-financial-results-and-provides-corporate-u-lqda-20240513monthly0.5https://www.biopharmawatch.com/news/LQDA/update-on-favorable-legal-and-regulatory-outcomes-clearing-path-for-potential-fda-approval-lqda-20240401monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-full-year-2023-financial-results-and-provides-corporate-updat-lqda-20240313monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-provides-update-on-new-drug-application-for-yutrepia-treprostinil-inh-lqda-20240125monthly0.5https://www.biopharmawatch.com/news/LQDA/confidential-information-liquidia-corporation-announces-updates-to-operations-leadership-m-lqda-20240119monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-provides-update-on-clinical-pipeline-targeting-pah-and-ph-ild-lqda-20240105monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-announces-100-million-in-new-financings-agreed-to-75-0-million-sale-o-lqda-20240104monthly0.5https://www.biopharmawatch.com/news/LQDA/u-s-federal-circuit-affirms-earlier-ptab-decision-to-invalidate-all-claims-of-united-thera-lqda-20231220monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-announces-pricing-of-public-offering-of-common-stock-lqda-20231212monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-third-quarter-2023-financial-results-and-provides-corporate-u-lqda-20231107monthly0.5https://www.biopharmawatch.com/news/LQDA/fda-accepts-submission-to-add-ph-ild-to-yutrepia-label-sets-pdufa-goal-date-of-lqda-20230925monthly0.5https://www.biopharmawatch.com/news/LQDA/united-therapeutics-corporation-files-lawsuit-alleging-infringement-of-tyvaso-patent-alrea-lqda-20230906monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-second-quarter-2023-financial-results-and-provides-corporate--lqda-20230810monthly0.5https://www.biopharmawatch.com/news/LQDA/confidential-information-liquidia-submits-amendment-to-add-ph-ild-indication-to-tentativel-lqda-20230727monthly0.5https://www.biopharmawatch.com/news/LQDA/u-s-federal-circuit-affirms-all-district-court-rulings-in-patent-litigation-infringement-c-lqda-20230724monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-and-pharmosa-biopharm-announce-collaboration-for-sustained-release-in-lqda-20230628monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-first-quarter-2023-financial-results-and-provides-corporate-u-lqda-20230504monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-and-gsk-restructure-license-to-print-technology-for-inhaled-applications-new-agre-lqda-20230403monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-full-year-2022-financial-results-and-provides-corporate-updat-lqda-20230316monthly0.5https://www.biopharmawatch.com/news/LQDA/patent-trial-and-appeal-board-ptab-reaffirms-decision-to-invalidate-all-claims-of-united-t-lqda-20230202monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-enters-into-a-revenue-interest-financing-agreement-with-healthcare-royalty-for-up-lqda-20230109monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-announces-collaboration-to-develop-a-new-infusion-pump-for-subcutaneous-delivery--lqda-20221205monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-reports-third-quarter-2022-financial-results-and-provides-corporate-update-compan-lqda-20221108monthly0.5https://www.biopharmawatch.com/news/LQDA/precedential-opinion-panel-denies-united-therapeutics-request-for-review-of-793-inter-part-lqda-20221027monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-provides-update-on-hatch-waxman-litigation-and-to-host-call-on-lqda-20220901monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-receives-favorable-ruling-in-inter-partes-review-against-united-therapeutics-pate-lqda-20220719monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-announces-proposed-offering-of-common-stock-morrisville-n-c-lqda-20220412monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-reports-full-year-2021-financial-results-and-provides-corporate-updat-lqda-20220317monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-re-finances-debt-facility-with-silicon-valley-bank-to-increase-to-40-0-million-mo-lqda-20220107monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-announces-chief-executive-officer-transition-morrisville-n-c-lqda-20220103monthly0.5https://www.biopharmawatch.com/news/LQDA/stipulation-of-partial-judgment-in-favor-of-liquidia-filed-in-hatch-waxman-litigation-morr-lqda-20211229monthly0.5https://www.biopharmawatch.com/news/LQDA/fda-grants-tentative-approval-for-liquidia-s-yutrepia-treprostinil-inhalation-powder-first-lqda-20211108monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-receives-favorable-ruling-in-inter-partes-review-against-united-therapeutics-pate-lqda-20211008monthly0.5https://www.biopharmawatch.com/news/LQDA/fda-completes-on-site-pre-approval-inspection-of-liquidia-s-morrisville-north-carolina-fac-lqda-20210818monthly0.5https://www.biopharmawatch.com/news/LQDA/u-s-patent-trial-and-trademark-appeal-board-decides-to-institute-inter-partes-review-of-un-lqda-20210811monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-announces-fda-acceptance-of-new-drug-application-resubmission-for-liq861-treprost-lqda-20210602monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-announces-generic-treprostinil-injection-now-also-available-for-subcutaneous-rout-lqda-20210524monthly0.5https://www.biopharmawatch.com/news/LQDA/confidential-information-until-released-liquidia-reports-first-quarter-2021-financial-resu-lqda-20210513monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-resubmits-new-drug-application-for-liq861-treprostinil-inhalation-powder-for-the--lqda-20210510monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-announces-21-7-million-private-placement-lqda-20210413monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-419-davis-drive-suite-100-morrisville-nc-27560-www-liquidia-com-liqui-lqda-20210330monthly0.5https://www.biopharmawatch.com/news/LQDA/corporation-reports-full-year-2020-lqda-20210323monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-419-davis-drive-suite-100-morrisville-nc-27560-www-liquidia-com-liqui-lqda-20210302monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-419-davis-drive-suite-100-morrisville-nc-27560-media-release-www-liqu-lqda-20201214monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-technologies-inc-419-davis-drive-suite-100-morrisville-nc-27560-media-release-www-lqda-20201130monthly0.5https://www.biopharmawatch.com/news/LQDA/liquidia-technologies-inc-419-davis-drive-suite-100-morrisville-nc-27560-media-release-www-lqda-20201125monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-second-quarter-2023-financial-results-tgtx-20230801monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-first-quarter-2023-financial-results--tgtx-20230501monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-fourth-quarter-and-year-end-2022-fina-tgtx-20230228monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-fda-approval-of-briumvi-ublituximab-xiiy-briumvi-is-the-first-an-tgtx-20221229monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-third-quarter-2022-financial-results--tgtx-20221110monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-second-quarter-2022-financial-results-tgtx-20220808monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-voluntary-withdrawal-of-the-bla-snda-for-u2-to-treat-patients-wi-tgtx-20220418monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-fourth-quarter-and-year-end-2021-fina-tgtx-20220301monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-regulatory-update-company-to-host-conference-call-today-tuesday-tgtx-20211130monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-third-quarter-2021-financial-results--tgtx-20211104monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-second-quarter-2021-financial-results-tgtx-20210802monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-first-quarter-2021-financial-results--tgtx-20210510monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-positive-results-from-the-ultimate-i-ii-phase-3-trials-of-ublitu-tgtx-20210416monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-fourth-quarter-and-year-end-2020-fina-tgtx-20210302monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-fda-accelerated-approval-of-ukoniq-umbralisib-ukoniq-is-approved-tgtx-20210208monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-positive-topline-results-from-the-ultimate-i-ii-phase-3-studies--tgtx-20201210monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-triple-combination-data-presentations-at-the-at-the-62nd-america-tgtx-20201207monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-third-quarter-2020-financial-results--tgtx-20201109monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-highlights-data-selected-for-presentation-at-the-62nd-american-society-of--tgtx-20201105monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-second-quarter-2020-financial-results-tgtx-20200810monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-first-quarter-2020-financial-results--tgtx-20200511monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-positive-topline-results-from-the-unity-cll-phase-3-study-evalua-tgtx-20200505monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-bolsters-board-of-directors-with-the-appointment-of-sagar-lonial-md-new-yo-tgtx-20200429monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-fourth-quarter-and-year-end-2019-fina-tgtx-20200303monthly0.5https://www.biopharmawatch.com/news/TGTX/form-of-securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreem-tgtx-20191226monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-oral-presentation-of-umbralisib-ublituximab-and-venetoclax-tripl-tgtx-20191209monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-third-quarter-2019-financial-results--tgtx-20191112monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-positive-results-from-the-unity-nhl-phase-2b-pivotal-trial-evalu-tgtx-20191028monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-presents-data-for-ublituximab-at-the-35-th-annual-congress-of-the-european-tgtx-20190912monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-second-quarter-2019-financial-results-tgtx-20190809monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-provides-business-update-and-reports-first-quarter-2019-financial-results--tgtx-20190510monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-long-term-follow-up-data-from-the-phase-2-trial-of-ublituximab-i-tgtx-20190507monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-reports-positive-interim-data-from-unity-nhl-phase-2b-trial-evaluating-umb-tgtx-20190401monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-positive-outcome-from-unity-nhl-phase-2b-pivotal-trial-evaluatin-tgtx-20190228monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-receives-breakthrough-therapy-designation-from-the-u-s-food-and-drug-admin-tgtx-20190122monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-oral-presentation-of-follow-up-data-from-the-triple-combinat-tgtx-20181203monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-provides-business-update-and-reports-third-quarter-2018-financial-resu-tgtx-20181109monthly0.5https://www.biopharmawatch.com/news/TGTX/untitled-document-tg-therapeutics-inc-announces-final-phase-2-multiple-sclerosis-data-pres-tgtx-20181011monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-update-regarding-unity-cll-phase-3-trial-conference-call-to-be-h-tgtx-20180925monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-provides-business-update-and-reports-second-quarter-2018-financial-res-tgtx-20180807monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-presents-phase-2-data-evaluating-umbralisib-in-cll-patients-intolerant-tgtx-20180618monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-clinical-and-preclinical-data-presentations-at-the-23-rd-con-tgtx-20180615monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-umbralisib-clinical-data-presentation-at-the-54th-annual-mee-tgtx-20180604monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-provides-business-update-and-reports-first-quarter-2018-financial-resu-tgtx-20180508monthly0.5https://www.biopharmawatch.com/news/TGTX/untitled-document-tg-therapeutics-inc-announces-updated-results-from-the-ongoing-phase-2-s-tgtx-20180424monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-fourth-quarter-and-year-end-2017-financial-results-and-busin-tgtx-20180308monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-inc-announces-preclinical-clinical-data-presentations-at-the-59--tgtx-20171211monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-provides-business-update-and-reports-third-quarter-2017-financial-resu-tgtx-20171108monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-inc-announces-updated-results-from-the-ongoing-phase-2-study-of--tgtx-20171026monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-provides-update-on-fda-meeting-for-genuine-phase-3-trial-follow--tgtx-20171016monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-announces-completion-of-target-enrollment-in-the-unity-cll-phase-tgtx-20170905monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-inc-announces-successful-outcome-from-the-first-pre-planned-inte-tgtx-20170810monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-provides-business-update-and-reports-second-quarter-2017-financial-res-tgtx-20170809monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-announces-special-protocol-assessment-spa-agreement-with-the-fda-tgtx-20170801monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-inc-announces-follow-up-data-for-combination-of-tgr-1202-umbrali-tgtx-20170614monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-announces-positive-data-from-phase-3-genuine-trial-of-tg-1101-in-tgtx-20170603monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-inc-announces-successful-outcome-from-pre-planned-interim-analys-tgtx-20170523monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-provides-business-update-and-reports-first-quarter-2017-financial-resu-tgtx-20170505monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-announces-preliminary-results-from-ongoing-phase-2-study-of-tg-1-tgtx-20170428monthly0.5https://www.biopharmawatch.com/news/TGTX/blueprint-tg-therapeutics-inc-announces-fourth-quarter-and-year-end-2016-financial-results-tgtx-20170310monthly0.5https://www.biopharmawatch.com/news/TGTX/untitled-document-tg-therapeutics-announces-positive-topline-data-from-phase-3-genuine-stu-tgtx-20170306monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-double-triple-combination-therapy-data-presentations-at-the--tgtx-20161206monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-preclinical-data-presentations-for-tgr-1202-at-the-58-th-ame-tgtx-20161205monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-provides-business-update-and-reports-third-quarter-2016-financial-resu-tgtx-20161107monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-amends-the-genuine-phase-3-clinical-trial-to-accelerate-study-completi-tgtx-20161013monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-second-quarter-2016-financial-results-and-business-update-in-tgtx-20160808monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-long-term-follow-up-of-tgr-1202-demonstrates-a-differentiate-tgtx-20160606monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-first-quarter-2016-financial-results-and-business-update-inv-tgtx-20160510monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-fourth-quarter-and-year-end-2015-financial-results-and-busin-tgtx-20160307monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-common-stock-par-value-0-001-per-share-amended-and-restated-at-market--tgtx-20151231monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-data-presentations-at-the-57-th-american-society-of-hematolo-tgtx-20151206monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-third-quarter-2015-financial-results-and-business-update-inv-tgtx-20151109monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-special-protocol-assessment-spa-agreement-with-the-fda-for-the-f-tgtx-20150917monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-second-quarter-2015-financial-results-and-business-update-in-tgtx-20150810monthly0.5https://www.biopharmawatch.com/news/TGTX/updated-results-from-phase-2-clinical-trial-of-tg-1101-ublituximab-in-combination-with-ibr-tgtx-20150618monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-presentations-of-its-proprietary-combination-of-tg-1101-plus-tgtx-20150531monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-first-quarter-2015-financial-results-and-business-update-inv-tgtx-20150505monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-fourth-quarter-and-year-end-2014-financial-results-and-busin-tgtx-20150312monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-appointment-of-kenneth-hoberman-to-board-of-directors-tgtx-20141217monthly0.5https://www.biopharmawatch.com/news/TGTX/interim-data-from-phase-1-dose-escalation-clinical-trial-of-tgr-1202-the-once-daily-pi3k-d-tgtx-20141206monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-third-quarter-2014-financial-results-and-business-update-inv-tgtx-20141111monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-special-protocol-assessment-spa-agreement-with-the-fda-for-its-f-tgtx-20140915monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-novel-combination-of-tg-1101-ublituximab-and-tgr-1202-demonstrates-compell-tgtx-20140721monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-second-quarter-2014-financial-results-and-business-update-in-tgtx-20140722monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-tg-1101-ublituximab-in-combination-with-ibrutinib-demonstrates-compelling--tgtx-20140613monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-presentation-of-single-agent-data-for-both-tg-1101-and-tgr-1-tgtx-20140530monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-first-quarter-2014-financial-results-and-business-update-inv-tgtx-20140513monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-fourth-quarter-and-year-end-2013-financial-results-and-busin-tgtx-20140306monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-presentation-of-encouraging-clinical-activity-of-tgr-1202-in-tgtx-20131209monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-comments-on-unusual-trading-activity-new-york-ny-tgtx-20131028monthly0.5https://www.biopharmawatch.com/news/TGTX/presentation-nasdaq-tgtx-september-2013-this-presentation-contains-forward-looking-stateme-tgtx-20130927monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-second-quarter-2013-financial-results-and-business-update-in-tgtx-20130802monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-presentation-of-interim-results-from-its-phase-i-ii-clinical-tgtx-20130603monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-approved-for-listing-on-the-nasdaq-capital-market-new-york-ny-tgtx-20130528monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-first-quarter-2013-financial-results-and-business-update-inv-tgtx-20130514monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-fourth-quarter-and-year-end-2012-financial-results-and-busin-tgtx-20130313monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-poster-presentation-highlights-for-ublituximab-tg-1101-and-t-tgtx-20121210monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-announces-exclusive-licensing-agreement-with-ildong-pharmaceutical-co-ltd--tgtx-20121115monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-inc-announces-third-quarter-2012-financial-results-and-business-update-inv-tgtx-20121109monthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-and-rhizen-pharmaceuticals-announce-global-agreement-for-development-and-c-tgtx-20120816monthly0.5https://www.biopharmawatch.com/news/TGTX/unassociated-document-manhattan-pharmaceuticals-achieves-ariston-merger-milestone-ast-915--tgtx-20110131monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-announces-entry-into-settlement-and-release-agreement-with-nordi-tgtx-20110104monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-awarded-245k-grant-under-the-u-s-qualified-therapeutic-discovery-tgtx-20101108monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-announces-private-placement-final-close-at-3-0-million-new-york--tgtx-20100414monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-completes-merger-transaction-with-ariston-pharmaceuticals-new-yo-tgtx-20100312monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-completes-2-5-million-financing-new-york-ny-mar-4-2010-manhattan-tgtx-20100305monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-provides-corporate-update-on-hedrin-and-management-restructuring-tgtx-20090616monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-completes-1-million-financing-new-york-ny-nov-25-2008-manhattan--tgtx-20081119monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-announces-amendment-of-joint-venture-deal-with-nordic-biotech-co-tgtx-20080613monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-to-voluntarily-withdraw-its-american-stock-exchange-common-stock-tgtx-20080228monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-announces-joint-venture-with-nordic-biotech-for-lead-product-hed-tgtx-20080205monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-names-mary-c-spellman-m-d-as-head-of-dermatology-and-drug-develo-tgtx-20080103monthly0.5https://www.biopharmawatch.com/news/TGTX/pipeline-update-tgtx-20071003monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-receives-notification-from-amex-of-non-compliance-with-certain-listing-standards-tgtx-20070918monthly0.5https://www.biopharmawatch.com/news/TGTX/news-from-contact-douglas-abel-president-chief-executive-officer-manhattan-pharmaceuticals-tgtx-20070710monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-acquires-hedrin-for-the-treatment-of-head-lice-new-york-june-27--tgtx-20070702monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-announces-license-agreement-and-expanded-pipeline-company-acquir-tgtx-20070409monthly0.5https://www.biopharmawatch.com/news/TGTX/michael-g-mcguinness-chief-financial-officer-manhattan-pharmaceuticals-inc-212-582-3950-th-tgtx-20070323monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-receives-notification-from-amex-of-non-compliance-of-certain-listing-standards-n-tgtx-20070112monthly0.5https://www.biopharmawatch.com/news/TGTX/source-manhattan-pharmaceuticals-inc-manhattan-pharmaceuticals-reports-update-on-clinical--tgtx-20060428monthly0.5https://www.biopharmawatch.com/news/TGTX/dr-harris-is-a-fellow-of-the-american-college-of-physicians-the-royal-college-of-physician-tgtx-20060201monthly0.5https://www.biopharmawatch.com/news/TGTX/source-manhattan-pharmaceuticals-inc-manhattan-pharmaceuticals-raises-11-9-million-in-priv-tgtx-20050830monthly0.5https://www.biopharmawatch.com/news/TGTX/manhattan-pharmaceuticals-acquires-tarpan-therapeutics-monday-april-4-8-30-am-et-douglas-a-tgtx-20050404monthly0.5https://www.biopharmawatch.com/news/TGTX/source-manhattan-pharmaceuticals-inc-manhattan-pharmaceuticals-inc-to-merge-with-tarpan-th-tgtx-20050105monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-first-quarter-2026-results-xfeff-full-che-20260423monthly0.5https://www.biopharmawatch.com/news/CHE/item-991-press-release-for-amended-restated-credit-facility-xfeff-contact-michael-d-witzem-che-20260413monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-fourth-quarter-2025-results-xfeff-cin-che-20260225monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-third-quarter-2025-results-xfeff-cinc-che-20251028monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-second-quarter-2025-results-and-annou-che-20250729monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-for-immediate-release-513-762-6714-xfeff-chemed-to-report-second-quarte-che-20250627monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-first-quarter-2025-results-xfeff-xfef-che-20250423monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-fourth-quarter-2024-results-xfeff-cin-che-20250226monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-third-quarter-2024-results-xfeff-cinc-che-20241029monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-second-quarter-2024-results-xfeff-cin-che-20240724monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-first-quarter-2024-results-xfeff-cinc-che-20240424monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-michael-d-witzeman-513-762-6-714-xfeff-xfeff-vitas-to-buy-hospice-assets-of--che-20240313monthly0.5https://www.biopharmawatch.com/news/CHE/michael-d-witzeman-513-762-6714-xfeff-chemed-reports-fourth-quarter-2023-results-xfeff-xfe-che-20240227monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-michael-d-witzeman-513-762-6-714-xfeff-xfeff-chemed-corporation-announces-th-che-20231218monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-michael-d-witzeman-513-762-6-714-xfeff-xfeff-chemed-corporation-announces-th-che-20231103monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-chemed-reports-third-quarter-2023-results-x2013-incre-che-20231025monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-chemed-reports-second-quarter-2023-results-xfeff-cincinnati-che-20230726monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-david-p-william-s-513-762-6901-chemed-reports-first-quarter-2023-results-xfe-che-20230426monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-david-p-william-s-513-762-6901-xfeff-chemed-reports-fourth-quarter-2022-resu-che-20230223monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-david-p-william-s-513-762-6901-xfeff-chemed-reports-third-quarter-2022-resul-che-20221031monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-david-p-william-s-513-762-6901-xfeff-chemed-reports-second-quarter-2022-resu-che-20220727monthly0.5https://www.biopharmawatch.com/news/CHE/item-99-1-press-release-for-amended-restated-credit-facility-taxonomy2022-xfeff-xfeff-xfef-che-20220629monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-david-p-william-s-513-762-6901-xfeff-chemed-reports-first-quarter-2022-resul-che-20220426monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-david-p-william-s-513-762-6901-xfeff-chemed-reports-fourth-quarter-2021-resu-che-20220224monthly0.5https://www.biopharmawatch.com/news/CHE/xfeff-contact-david-p-william-s-513-762-6901-xfeff-chemed-reports-third-quarter-2021-resul-che-20211028monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-chemed-reports-second-quarter-2021-results-x2013-full-che-20210727monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-chemed-reports-first-quarter-2021-results-xfeff-cinci-che-20210427monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-chemed-reports-fourth-quarter-2020-results-xfeff-xfef-che-20210223monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-chemed-reports-third-quarter-2020-results-xfeff-xfeff-che-20201029monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-chemed-reports-second-quarter-2020-results-xfeff-cinc-che-20200729monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-xfeff-chemed-reports-first-quarter-2020-results-xfeff-che-20200428monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-williams-513-762-6901-xfeff-chemed-corporation-announces-virtual-2020-annual-stock-che-20200422monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-williams-513-762-6901-xfeff-chemed-corporation-s-board-of-directors-authorizes-an--che-20200313monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-xfeff-chemed-reports-fourth-quarter-2019-results-xfef-che-20200218monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-william-s-513-762-6901-xfeff-chemed-reports-third-quarter-2019-results-xfeff-cinci-che-20191029monthly0.5https://www.biopharmawatch.com/news/CHE/david-p-williams-513-762-6901-xfeff-chemed-corporation-releases-updated-guidance-xfeff-cin-che-20190805monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-second-quarter-2019-results-cincinnati-business-wire-che-20190725monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-first-quarter-2019-results-cincinnati-business-wire-che-20190429monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-s-board-of-directors-authorizes-an-additional-150-million-for-stock-rep-che-20190225monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-fourth-quarter-2018-results-cincinnati-business-wire-che-20190220monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-third-quarter-2018-results-earnings-guidance-increased-cincinnati-business--che-20181029monthly0.5https://www.biopharmawatch.com/news/CHE/roto-rooter-buys-five-northern-california-franchises-acquisition-is-the-company-s-largest--che-20181001monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-second-quarter-2018-results-earnings-guidance-increased-cincinnati-business-che-20180725monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-announces-a-five-year-450-million-amended-and-restated-credit-agreement-che-20180621monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-first-quarter-2018-results-cincinnati-business-wire-che-20180419monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-s-board-of-directors-authorizes-an-additional-150-million-for-stock-rep-che-20180306monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-fourth-quarter-2017-results-cincinnati-business-wire-che-20180214monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-settles-doj-litigation-no-admission-or-determination-of-wrongdoing-cincinnati-busin-che-20171031monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-third-quarter-2017-results-increases-full-year-guidance-cincinnati-business-che-20171026monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-second-quarter-2017-results-earnings-guidance-increased-cincinnati-business-che-20170725monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-first-quarter-2017-results-cincinnati-business-wire-che-20170426monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-s-board-of-directors-authorizes-an-additional-100-million-for-stock-rep-che-20170313monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-fourth-quarter-2016-results-cincinnati-business-wire-che-20170215monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-third-quarter-2016-results-cincinnati-business-wire-che-20161026monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-second-quarter-2016-results-raises-full-year-earnings-guidance-cincinnati-b-che-20160725monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-announces-the-retirement-of-timothy-s-o-toole-cincinnati-business-wire-che-20160608monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-first-quarter-2016-results-cincinnati-business-wire-che-20160428monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-s-board-of-directors-authorizes-an-additional-100-million-for-stock-rep-che-20160314monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-fourth-quarter-2015-results-cincinnati-business-wire-che-20160217monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-third-quarter-2015-results-cincinnati-business-wire-che-20151022monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-second-quarter-2015-results-increases-2015-earnings-guidance-cincinnati-bus-che-20150723monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-first-quarter-2015-results-cincinnati-business-wire-che-20150428monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-s-board-of-directors-authorizes-an-additional-100-million-for-stock-rep-che-20150313monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-fourth-quarter-2014-results-cincinnati-business-wire-che-20150217monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-third-quarter-2014-results-cincinnati-business-wire-che-20141030monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-second-quarter-2014-results-cincinnati-business-wire-che-20140723monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-announces-a-five-year-450-million-amended-and-restated-credit-agreement-che-20140701monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-first-quarter-2014-results-cincinnati-business-wire-che-20140429monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-s-board-of-directors-authorizes-an-additional-100-million-for-stock-rep-che-20140221monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-fourth-quarter-2013-results-cincinnati-business-wire-che-20140217monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-third-quarter-2013-results-cincinnati-business-wire-che-20131028monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-second-quarter-2013-results-cincinnati-business-wire-che-20130718monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-reports-first-quarter-2013-results-reaffirms-full-year-2013-earnings-guidance-cinci-che-20130418monthly0.5https://www.biopharmawatch.com/news/CHE/chemed-corporation-s-board-of-directors-authorizes-an-additional-100-million-for-stock-rep-che-20130220monthly0.5https://www.biopharmawatch.com/news/DNTH/forward-looking-statements-certain-statements-in-this-presentation-other-than-purely-histo-dnth-20260612monthly0.5https://www.biopharmawatch.com/news/DNTH/forward-looking-statements-certain-statements-in-this-presentation-other-than-purely-histo-dnth-20260326monthly0.5https://www.biopharmawatch.com/news/DNTH/forward-looking-statements-certain-statements-in-this-presentation-other-than-purely-histo-dnth-20260112monthly0.5https://www.biopharmawatch.com/news/DNTH/forward-looking-statements-certain-statements-in-this-presentation-other-than-purely-histo-dnth-20251103monthly0.5https://www.biopharmawatch.com/news/DNTH/forward-looking-statements-certain-statements-in-this-presentation-other-than-purely-histo-dnth-20251016monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q2-financial-res-dnth-20250807monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q1-financial-res-dnth-20250512monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q4-and-fy-2024-f-dnth-20250311monthly0.5https://www.biopharmawatch.com/news/DNTH/forward-looking-statements-certain-statements-in-this-presentation-x201c-presentation-x201-dnth-20241212monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-financial-res-dnth-20241107monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q2-financial-res-dnth-20240808monthly0.5https://www.biopharmawatch.com/news/DNTH/forward-looking-statements-certain-statements-in-this-presentation-x201c-presentation-x201-dnth-20240606monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q1-financial-res-dnth-20240509monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q4-and-fy2023-fi-dnth-20240321monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-230-million-private-placement-new-york-and-dnth-20240122monthly0.5https://www.biopharmawatch.com/news/DNTH/to-the-company-s-current-report-on-form-8-k-filed-with-the-sec-on-dnth-20240108monthly0.5https://www.biopharmawatch.com/news/DNTH/index-to-fi-nan-cial-statements-in-connection-with-the-closing-of-the-merger-as-defined-be-dnth-20231221monthly0.5https://www.biopharmawatch.com/news/DNTH/to-the-company-s-form-8-k-a-filed-on-dnth-20231109monthly0.5https://www.biopharmawatch.com/news/DNTH/is-a-part-for-a-more-detailed-description-of-the-process-for-seeking-fast-track-designatio-dnth-20230921monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-announces-completion-of-merger-with-dianthus-therapeutics-and-impleme-dnth-20230912monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-and-dianthus-therapeutics-announce-merger-agreement-merger-to-create--dnth-20230503monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-adopts-limited-duration-stockholder-rights-plan-cambridge-ma-dnth-20230331monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-to-explore-strategic-alternatives-cambridge-ma-dnth-20230202monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-voluntarily-pauses-the-mgta-117-phase-1-2-dose-escalation-clinical-tr-dnth-20230125monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-provides-update-for-mgta-117-phase-1-2-dose-escalation-clinical-trial-dnth-20221220monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-presents-positive-mgta-117-clinical-data-at-the-american-society-of-h-dnth-20221213monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-third-quarter-financial-results-and-recent-program-highlights-dnth-20221103monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-appoints-michael-vasconcelles-m-d-to-the-board-of-directors-cambridge-dnth-20220817monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-second-quarter-financial-results-and-recent-program-highlight-dnth-20220804monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-first-quarter-financial-results-early-clinical-observations-f-dnth-20220516monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-focuses-r-d-and-operational-spending-reduces-workforce-and-extends-ca-dnth-20220414monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-recen-dnth-20220308monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-highlights-recent-pipeline-progress-and-milestone-expectations-for-20-dnth-20220110monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-third-quarter-financial-results-and-program-highlights-positi-dnth-20211104monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-second-quarter-financial-results-and-recent-program-highlight-dnth-20210805monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-announces-86-4-million-common-stock-investment-from-multiple-investor-dnth-20210512monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-first-quarter-financial-results-and-recent-program-highlights-dnth-20210506monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-recen-dnth-20210303monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-highlights-recent-progress-and-expected-timing-of-2021-milestones-inc-dnth-20210111monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-appoints-steve-mahoney-as-chief-financial-and-operating-officer-dnth-20201109monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-recent-business-highlights-and-third-quarter-financial-result-dnth-20201105monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-recent-business-highlights-and-second-quarter-financial-resul-dnth-20200806monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-launches-proposed-public-offering-cambridge-mass-business-wire-dnth-20200624monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-recent-business-highlights-and-first-quarter-financial-result-dnth-20200507monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-names-john-davis-jr-m-d-m-p-h-m-s-head-of-research-and-development-dnth-20200417monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-provides-business-update-mgta-117-conditioning-adc-based-program-on-t-dnth-20200416monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-recen-dnth-20200303monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-advances-conditioning-platform-and-clinical-programs-highlights-recen-dnth-20200113monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-third-quarter-2019-financial-results-and-recent-business-high-dnth-20191113monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-second-quarter-2019-financial-results-and-recent-business-hig-dnth-20190808monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-appoints-anne-mcgeorge-to-board-of-directors-dnth-20190624monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-first-quarter-2019-financial-results-and-recent-business-high-dnth-20190509monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-launches-proposed-public-offering-dnth-20190429monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-recen-dnth-20190319monthly0.5https://www.biopharmawatch.com/news/DNTH/forward-looking-statements-this-presentation-contains-forward-looking-statements-and-infor-dnth-20190107monthly0.5https://www.biopharmawatch.com/news/DNTH/employment-agreement-this-employment-agreement-agreement-is-made-by-and-between-magenta-th-dnth-20181119monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-recent-operational-progress-and-third-quarter-2018-financial--dnth-20181108monthly0.5https://www.biopharmawatch.com/news/DNTH/magenta-therapeutics-reports-recent-operational-progress-and-second-quarter-2018-financial-dnth-20180809monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-establishes-clinical-proof-of-concept-for-lb2501-a-potential-first-in-class-legn-20260615monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-ph-legn-20260602monthly0.5https://www.biopharmawatch.com/news/LEGN/disclaimer-2-this-presentation-has-been-prepared-by-legend-biotech-corporation-legend-biot-legn-20260114monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporate-presentation-june-2025-legn-20250606monthly0.5https://www.biopharmawatch.com/news/LEGN/international-trade-policies-including-tariffs-sanctions-and-trade-barriers-may-adversely--legn-20250513monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-2101-cottontail-lane-somerset-new-jersey-08873-proxy-statement--legn-20250512monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporate-presentation-january-14-2025-legn-20250114monthly0.5https://www.biopharmawatch.com/news/LEGN/december-18-2024-lori-macomber-re-transition-agreement-dear-lori-this-letter-sets-forth-th-legn-20241223monthly0.5https://www.biopharmawatch.com/news/LEGN/voting-results-of-2024-annual-general-meeting-at-legend-biotech-corporation-s-the-company--legn-20241021monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-2101-cottontail-lane-somerset-new-jersey-08873-proxy-statement--legn-20240920monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporate-presentation-this-presentation-is-for-investor-relations-purposes-legn-20240109monthly0.5https://www.biopharmawatch.com/news/LEGN/patient-reported-outcomes-from-the-cartitude-4-study-showed-clinically-meaningful-improvem-legn-20231211monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-exclusive-global-license-agreement-for-certain-car-t-therapies-ta-legn-20231113monthly0.5https://www.biopharmawatch.com/news/LEGN/voting-results-of-2023-annual-general-meeting-at-legend-biotech-corporation-s-the-company--legn-20230921monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-2101-cottontail-lane-somerset-new-jersey-08873-proxy-statement--legn-20230821monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-submission-of-supplemental-application-to-the-u-s-fda-for-expande-legn-20230606monthly0.5https://www.biopharmawatch.com/news/LEGN/ciltacabtagene-autoleucel-cilta-cel-reduced-risk-of-disease-progression-or-death-by-74-vs--legn-20230605monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-submission-to-the-european-medicines-agency-for-expanded-use-of-c-legn-20230525monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-first-quarter-2023-results-and-recent-highlights-new-and-updated-da-legn-20230518monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-demonstrate-progress-in-advancing-potential-treatment-options-for-patien-legn-20230516monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-announces-pricing-of-registered-direct-offering-of-us-350-milli-legn-20230508monthly0.5https://www.biopharmawatch.com/news/LEGN/background-cartitude-4-is-a-global-phase-3-randomized-controlled-trial-nct04181827-of-cilt-legn-20230421monthly0.5https://www.biopharmawatch.com/news/LEGN/certain-information-contained-in-this-document-marked-by-brackets-has-been-omitted-because-legn-20230414monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-establishes-strategic-advisory-board-somerset-n-j-business-wire-legn-20230403monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-full-year-2022-results-and-recent-highlights-cartitude-4-a-phase-3--legn-20230330monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-phase-3-cartitude-4-study-of-carvykti-ciltacabtagene-autoleucel-h-legn-20230127monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-notification-of-delinquency-from-the-nasdaq-stock-market-llc-some-legn-20230109monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-acceptance-of-its-new-drug-application-for-ciltacabtagene-autoleu-legn-20230102monthly0.5https://www.biopharmawatch.com/news/LEGN/preclinical-phase-1-gastric-esophageal-pancreatict-claudin-18-2-auto-logous-nct04467853-rr-legn-20221208monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-fda-clearance-of-ind-application-for-lb2102-in-extensive-stage-sm-legn-20221121monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-participation-in-upcoming-investor-conferences-somerset-n-j-busin-legn-20221104monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-shares-updated-data-from-comprehensive-cilta-cel-clinical-development-progr-legn-20221103monthly0.5https://www.biopharmawatch.com/news/LEGN/voting-results-of-2022-annual-general-meeting-at-legend-biotech-corporation-s-the-company--legn-20221014monthly0.5https://www.biopharmawatch.com/news/LEGN/carvykti-ciltacabtagene-autoleucel-receives-approval-from-japan-s-ministry-of-health-labou-legn-20220927monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-2101-cottontail-lane-somerset-new-jersey-08873-proxy-statement--legn-20220916monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-2022-r-d-day-on-monday-legn-20220915monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-participation-in-upcoming-investor-conferences-somerset-n-j-busin-legn-20220819monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-preliminary-results-for-the-six-months-ended-legn-20220805monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-appoints-three-new-directors-and-elects-new-chairman-of-the-board-somerset--legn-20220804monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-announces-pricing-of-public-offering-somerset-nj-legn-20220726monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-announces-proposed-public-offering-somerset-nj-legn-20220725monthly0.5https://www.biopharmawatch.com/news/LEGN/certain-information-contained-in-this-document-marked-by-brackets-has-been-omitted-because-legn-20220707monthly0.5https://www.biopharmawatch.com/news/LEGN/longer-term-data-from-cartitude-program-continue-to-show-deep-and-durable-responses-with-c-legn-20220604monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-u-s-fda-clearance-of-ind-application-for-solid-tumor-car-t-lb1908-legn-20220603monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-investors-at-the-2022-american-society-of-clinical-oncology-asco-an-legn-20220531monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-first-quarter-2022-financial-results-and-recent-highlights-the-u-s--legn-20220601monthly0.5https://www.biopharmawatch.com/news/LEGN/carvykti-ciltacabtagene-autoleucel-granted-conditional-approval-by-the-european-commission-legn-20220526monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-highlight-continued-progress-in-the-treatment-of-multiple-myeloma-with-u-legn-20220518monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-appoints-lori-macomber-as-chief-financial-officer-somerset-n-j-business-wir-legn-20220509monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-participation-in-upcoming-investor-conferences-somerset-n-j-busin-legn-20220506monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-achieves-milestone-under-collaboration-agreement-with-janssen-biotech-inc-f-legn-20220421monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-appointment-of-global-head-of-research-and-early-development-some-legn-20220401monthly0.5https://www.biopharmawatch.com/news/LEGN/carvykti-ciltacabtagene-autoleucel-receives-positive-chmp-opinion-for-the-treatment-of-pat-legn-20220325monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-high-legn-20220318monthly0.5https://www.biopharmawatch.com/news/LEGN/carvykti-ciltacabtagene-autoleucel-bcma-directed-car-t-therapy-receives-u-s-fda-approval-f-legn-20220228monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-preliminary-results-for-the-year-ended-legn-20220218monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-fda-clinical-hold-of-its-phase-1-clinical-trial-for-lb1901-somers-legn-20220215monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-achieves-milestone-payments-in-bcma-car-t-collaboration-with-janssen-somers-legn-20220211monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-participate-in-the-40-th-annual-j-p-morgan-healthcare-conference-somerse-legn-20220104monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-appointment-of-dr-ying-huang-to-the-board-of-directors-somerset-n-legn-20211230monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-announces-pricing-of-public-offering-somerset-nj-legn-20211216monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-announces-proposed-public-offering-somerset-nj-legn-20211214monthly0.5https://www.biopharmawatch.com/news/LEGN/two-year-analysis-of-cartitude-1-shows-early-durable-and-deepening-responses-of-ciltacabta-legn-20211213monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-hybrid-kol-event-detailing-cartitude-data-from-the-63-rd-american-s-legn-20211207monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-submission-of-new-drug-application-to-japanese-regulatory-authori-legn-20211206monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-third-quarter-2021-financial-results-and-recent-highlights-enrollme-legn-20211116monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-showcases-updated-and-new-data-from-comprehensive-bcma-car-t-cilta-cel-prog-legn-20211104monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-extension-of-pdufa-date-for-cilta-cel-somerset-n-j-business-wire-legn-20211101monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-r-d-day-on-legn-20210922monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-begins-phase-1-clinical-trial-in-the-us-to-evaluate-investigational-anti-cd-legn-20210913monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-participate-in-the-19th-annual-morgan-stanley-global-healthcare-conferen-legn-20210830monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-second-quarter-2021-financial-results-and-recent-highlights-investi-legn-20210823monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-advancement-of-global-manufacturing-infrastructure-new-cell-thera-legn-20210622monthly0.5https://www.biopharmawatch.com/news/LEGN/voting-results-of-2021-annual-general-meeting-at-legend-biotech-corporation-s-the-company--legn-20210609monthly0.5https://www.biopharmawatch.com/news/LEGN/june-2021-disclaimer-this-presentation-has-been-prepared-by-legend-biotech-corporation-leg-legn-20210609monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-new-and-updated-data-for-investigational-bcma-car-t-ciltacabtagen-legn-20210601monthly0.5https://www.biopharmawatch.com/news/LEGN/u-s-food-and-drug-administration-grants-bcma-car-t-cilta-cel-priority-review-for-the-treat-legn-20210526monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-present-at-the-jefferies-virtual-healthcare-conference-somerset-n-j-busi-legn-20210525monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-first-quarter-2021-financial-results-and-recent-highlights-rolling--legn-20210518monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-compelling-new-and-updated-data-from-bcma-car-t-program-at-upcoming-legn-20210512monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-2101-cottontail-lane-somerset-new-jersey-08873-proxy-statement--legn-20210505monthly0.5https://www.biopharmawatch.com/news/LEGN/forward-looking-statements-although-not-all-forward-looking-statements-contain-these-ident-legn-20210430monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-fourth-quarter-and-full-year-2020-financial-results-and-business-up-legn-20210318monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-fourth-quarter-and-full-year-2020-earnings-conference-call-somers-legn-20210310monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-preliminary-results-for-the-year-ended-legn-20210219monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-bcma-car-t-therapy-cilta-cel-accepted-for-accelerated-assessment--legn-20210201monthly0.5https://www.biopharmawatch.com/news/LEGN/disclaimer-this-presentation-has-been-prepared-by-legend-biotech-corporation-legend-biotec-legn-20210111monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-initiation-of-rolling-submission-of-biologics-license-application-legn-20201221monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-added-to-the-nasdaq-biotechnology-index-somerset-n-j-legn-20201214monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-fda-clearance-of-the-ind-for-lb1901-an-investigational-autologous-legn-20201214monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-phase-1b-2-study-data-of-cilta-cel-an-investigational-bcma-car-t--legn-20201205monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-appointment-of-dr-patrick-casey-to-the-board-of-directors-somerse-legn-20201203monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-virtual-investor-kol-event-reviewing-latest-cartitude-1-data-from-t-legn-20201124monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-new-appointment-to-the-board-of-directors-and-resignation-of-dr-f-legn-20201123monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-third-quarter-2020-financial-results-somerset-n-j-business-wire-legn-20201116monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-leadership-transition-ye-sally-wang-appointed-chairwoman-of-the-b-legn-20201109monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-ash-2020-data-presentations-for-ciltacabtagene-autoleucel-cilta-c-legn-20201105monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-names-current-chief-financial-officer-ying-huang-as-interim-ceo-legn-20200921monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-second-quarter-2020-financial-results-somerset-n-j-business-wire-legn-20200828monthly0.5https://www.biopharmawatch.com/news/LEGN/the-china-center-for-drug-evaluation-national-medical-products-administration-has-recommen-legn-20200805monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-preliminary-results-for-first-half-of-2020-legn-20200802monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-chief-executive-officer-transition-somerset-n-j-business-wire-legn-20200802monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-results-of-ordinary-and-extraordinary-shareholders-meeting-all-r-stvn-20260526monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-first-quarter-2026-financial-results-conference-call-thursday-stvn-20260507monthly0.5https://www.biopharmawatch.com/news/STVN/published-on-stvn-20260511monthly0.5https://www.biopharmawatch.com/news/STVN/q1-2026-financial-results-safe-harbor-statement-forward-looking-statements-this-presentati-stvn-20260507monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-stvn-20260507monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-fourth-quarter-and-full-year-2025-financial-results-conference-call--stvn-20260304monthly0.5https://www.biopharmawatch.com/news/STVN/q4-and-fy-2025-financial-results-safe-harbor-statement-forward-looking-statements-this-pre-stvn-20260304monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-december-31-for-the-ye-stvn-20260304monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-third-quarter-2025-financial-results-conference-call-thursday-stvn-20251106monthly0.5https://www.biopharmawatch.com/news/STVN/q3-2025-financial-results-safe-harbor-statement-forward-looking-statements-this-presentati-stvn-20251106monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-september-30-for-the-n-stvn-20251106monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-second-quarter-2025-results-conference-call-tuesday-stvn-20250805monthly0.5https://www.biopharmawatch.com/news/STVN/q2-2025-financial-results-safe-harbor-statement-forward-looking-statements-this-presentati-stvn-20250805monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-june-30-for-the-six-mo-stvn-20250805monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-results-of-ordinary-shareholders-meeting-stvn-20250610monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-first-quarter-2025-results-conference-call-tuesday-stvn-20250508monthly0.5https://www.biopharmawatch.com/news/STVN/q1-2025-financial-results-safe-harbor-statement-forward-looking-statements-this-presentati-stvn-20250508monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-stvn-20250508monthly0.5https://www.biopharmawatch.com/news/STVN/published-on-stvn-20250411monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-fourth-quarter-and-year-end-2024-conference-call-thursday-stvn-20250306monthly0.5https://www.biopharmawatch.com/news/STVN/q4-and-fy-2024-financial-results-safe-harbor-statement-forward-looking-statements-this-pre-stvn-20250306monthly0.5https://www.biopharmawatch.com/news/STVN/amounts-may-not-add-due-to-rounding-stevanatogroup-com-stevanato-group-s-p-a-ph-39-049-931-stvn-20250306monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-third-quarter-2024-earnings-call-tuesday-stvn-20241105monthly0.5https://www.biopharmawatch.com/news/STVN/q3-2024-financial-results-safe-harbor-statement-forward-looking-statements-this-presentati-stvn-20241105monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-september-30-for-the-n-stvn-20241105monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-second-quarter-2024-earnings-call-tuesday-stvn-20240806monthly0.5https://www.biopharmawatch.com/news/STVN/q2-2024-financial-results-safe-harbor-statement-forward-looking-statements-this-presentati-stvn-20240806monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-june-30-for-the-six-mo-stvn-20240806monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-appoints-franco-stevanato-chief-executive-officer-succeeding-franco-moro-stvn-20240528monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-results-of-annual-general-meeting-all-resolutions-proposed-to-sh-stvn-20240524monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-first-quarter-2024-earnings-call-thursday-stvn-20240509monthly0.5https://www.biopharmawatch.com/news/STVN/published-on-stvn-20240514monthly0.5https://www.biopharmawatch.com/news/STVN/q1-2024-financial-results-safe-harbor-statement-forward-looking-statements-this-presentati-stvn-20240509monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-stvn-20240509monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-closing-of-upsized-public-offering-of-ordinary-shares-and-exerci-stvn-20240326monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-pricing-of-upsized-public-offering-of-ordinary-shares-stvn-20240321monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-public-offering-of-ordinary-shares-stvn-20240320monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-fourth-quarter-and-year-end-2023-financial-results-earnings-call-thu-stvn-20240307monthly0.5https://www.biopharmawatch.com/news/STVN/q4-and-fy-2023-financial-results-safe-harbor-statement-forward-looking-statements-this-pre-stvn-20240307monthly0.5https://www.biopharmawatch.com/news/STVN/free-cash-flow-amounts-in-x20ac-millions-for-the-three-months-ended-december-31-for-the-ye-stvn-20240307monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-third-quarter-2023-financial-results-conference-call-tuesday-stvn-20231031monthly0.5https://www.biopharmawatch.com/news/STVN/forward-looking-statements-this-presentation-may-include-forward-looking-statements-the-wo-stvn-20231031monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-third-quarter-2023-financial-results-reiterates-full-year-2023-gui-stvn-20231031monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-voting-results-from-its-extraordinary-general-meeting-piombino-d-stvn-20231005monthly0.5https://www.biopharmawatch.com/news/STVN/lisa-miles-x-investor-relations-senior-vice-president-welcome-capital-markets-day-stvn-20230927monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-extraordinary-shareholders-meeting-stvn-20230915monthly0.5https://www.biopharmawatch.com/news/STVN/published-on-stvn-20230824monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-second-quarter-2023-financial-results-conference-call-friday-stvn-20230728monthly0.5https://www.biopharmawatch.com/news/STVN/summary-of-resolutions-passed-at-annual-general-meeting-on-stvn-20230802monthly0.5https://www.biopharmawatch.com/news/STVN/forward-looking-statements-this-presentation-may-include-forward-looking-statements-the-wo-stvn-20230728monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-second-quarter-2023-financial-results-reiterates-full-year-2023-re-stvn-20230728monthly0.5https://www.biopharmawatch.com/news/STVN/published-on-stvn-20230524monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-first-quarter-2023-financial-results-conference-call-thursday-stvn-20230504monthly0.5https://www.biopharmawatch.com/news/STVN/forward-looking-statements-this-presentation-may-include-forward-looking-statements-the-wo-stvn-20230504monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-first-quarter-2023-financial-results-reiterates-full-year-2023-gui-stvn-20230504monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-fourth-quarter-and-fiscal-year-2022-financial-results-conference-cal-stvn-20230302monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-fourth-quarter-and-fiscal-year-2022-financial-results-establishes--stvn-20230302monthly0.5https://www.biopharmawatch.com/news/STVN/forward-looking-statements-this-presentation-may-include-forward-looking-statements-the-wo-stvn-20230302monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-third-quarter-2022-financial-results-conference-call-tuesday-stvn-20221108monthly0.5https://www.biopharmawatch.com/news/STVN/forward-looking-statements-this-presentation-may-include-forward-looking-statements-the-wo-stvn-20221108monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-third-quarter-2022-financial-results-piombino-dese-italy-x2013-stvn-20221108monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-second-quarter-financial-results-conference-call-thursday-stvn-20220804monthly0.5https://www.biopharmawatch.com/news/STVN/safe-harbor-statement-forward-looking-statements-this-presentation-contains-certain-forwar-stvn-20220804monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-second-quarter-2022-financial-results-raises-fiscal-2022-guidance--stvn-20220804monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-voting-results-from-its-annual-general-meeting-stvn-20220602monthly0.5https://www.biopharmawatch.com/news/STVN/transcript-0800-138-2636-conferencingservice-netroadshow-com-www-incommglobal-com-stevanat-stvn-20220513monthly0.5https://www.biopharmawatch.com/news/STVN/safe-harbor-statement-forward-looking-statements-this-presentation-contains-certain-forwar-stvn-20220510monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-first-quarter-2022-financial-results-the-company-is-maintaining-it-stvn-20220510monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-s-p-a-ordinary-and-extraordinary-shareholders-meeting-on-stvn-20220506monthly0.5https://www.biopharmawatch.com/news/STVN/published-on-stvn-20220412monthly0.5https://www.biopharmawatch.com/news/STVN/service-incommglobal-com-transcript-www-incommglobal-com-stevanato-group-full-year-results-stvn-20220311monthly0.5https://www.biopharmawatch.com/news/STVN/safe-harbor-statement-forward-looking-statements-this-presentation-contains-certain-forwar-stvn-20220308monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-record-2021-revenue-of-843-9-million-establishes-full-year-2022-gu-stvn-20220308monthly0.5https://www.biopharmawatch.com/news/STVN/service-incommglobal-com-transcript-www-incommglobal-com-stevanato-q3-earnings-call-tuesda-stvn-20211115monthly0.5https://www.biopharmawatch.com/news/STVN/safe-harbor-statement-forward-looking-statements-this-presentation-contains-certain-forwar-stvn-20211109monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-reports-strong-third-quarter-2021-revenue-and-financial-results-and-update-stvn-20211109monthly0.5https://www.biopharmawatch.com/news/STVN/transcript-0800-138-2636-service-incommglobal-com-www-incommglobal-com-stevanato-earnings--stvn-20210824monthly0.5https://www.biopharmawatch.com/news/STVN/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-w-stvn-20210819monthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-announces-second-quarter-2021-financial-results-establishes-full-year-2021-stvn-20210819monthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-cai-20260226monthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-reports-third-quarter-2025-financial-results-and-increases-2025-revenu-cai-20251105monthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-reports-second-quarter-2025-financial-results-cai-20250812monthly0.5https://www.biopharmawatch.com/news/HIMS/document-hims-hers-completes-acquisition-of-eucalyptus-advancing-its-position-as-the-world-hims-20260602monthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-health-inc-announces-proposed-convertible-senior-notes-offering-to-support-inter-hims-20260518monthly0.5https://www.biopharmawatch.com/news/HIMS/document-hims-hers-announces-strategic-shift-for-us-weight-loss-business-starting-with-a-n-hims-20260309monthly0.5https://www.biopharmawatch.com/news/HIMS/hims-hers-health-inc-announces-proposed-convertible-senior-notes-offering-to-accelerate-gl-hims-20250508monthly0.5https://www.biopharmawatch.com/news/HIMS/c-onsolidated-f-inancial-s-tatements-hims-inc-and-subsidiaries-years-ended-hims-20220204monthly0.5https://www.biopharmawatch.com/news/SHC/could-adversely-affect-our-ability-to-raise-additional-capital-limit-our-ability-to-react--shc-20251231monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-strong-second-quarter-and-first-half-2025-results-q2-2025-net-revenu-shc-20250808monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-first-quarter-2025-results-q1-2025-net-revenues-increased-2-6-to-255-shc-20250501monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-fourth-quarter-and-full-year-2024-results-provides-2025-outlook-2024-shc-20250227monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-chairman-and-ceo-presents-at-43rd-annual-j-p-morgan-healthcare-conference-cl-shc-20250114monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-appoints-vincent-k-petrella-as-lead-independent-director-cleveland-o-shc-20250106monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-to-share-next-chapter-of-growth-at-2024-investor-day-cleveland-oh-shc-20241120monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-third-quarter-and-year-to-date-2024-results-q3-2024-net-revenues-of--shc-20241105monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-second-quarter-and-first-half-2024-results-q2-2024-net-revenues-of-2-shc-20240805monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-first-quarter-2024-results-q1-2024-net-revenues-increased-12-5-to-24-shc-20240502monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-fourth-quarter-and-full-year-2023-results-provides-2024-outlook-2023-shc-20240227monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-chairman-and-ceo-presents-at-42-nd-annual-j-p-morgan-healthcare-conference-c-shc-20240109monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-third-quarter-and-year-to-date-2023-results-q3-2023-net-revenues-of--shc-20231101monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-second-quarter-and-first-half-2023-results-q2-2023-net-revenues-of-2-shc-20230803monthly0.5https://www.biopharmawatch.com/news/SHC/document-sotera-health-announces-jon-lyons-as-new-senior-vice-president-and-chief-financia-shc-20230626monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-first-quarter-2023-results-q1-2023-net-revenues-of-221-million-decre-shc-20230503monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-amends-and-upsizes-revolving-credit-facility-cleveland-oh-shc-20230321monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-fourth-quarter-and-full-year-2022-results-provides-2023-outlook-q4-2-shc-20230228monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-closes-on-500-million-term-loan-b-financing-cleveland-oh-shc-20230223monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-confirms-preliminary-2022-full-year-guidance-in-conjunction-with-incremental-shc-20230213monthly0.5https://www.biopharmawatch.com/news/SHC/document-sotera-health-announces-settlement-of-ethylene-oxide-litigation-in-illinois-settl-shc-20230109monthly0.5https://www.biopharmawatch.com/news/SHC/document-sotera-health-chairman-and-ceo-presents-at-41-st-annual-j-p-morgan-healthcare-con-shc-20230109monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-third-quarter-and-year-to-date-2022-results-q3-2022-net-revenues-of--shc-20221102monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-second-quarter-and-first-half-2022-results-q2-2022-net-revenues-of-2-shc-20220804monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-second-quarter-2022-earnings-release-date-names-michael-f-biehl-as-shc-20220720monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-departure-of-chief-financial-officer-scott-leffler-shc-20220519monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-first-quarter-2022-results-q1-2022-net-revenues-of-237-million-incre-shc-20220505monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-fourth-quarter-and-full-year-2021-results-provides-2022-outlook-q4-2-shc-20220301monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-third-quarter-and-year-to-date-2021-results-q3-2021-net-revenues-of--shc-20211110monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-second-quarter-and-first-half-2021-results-increases-2021-outlook-q2-shc-20210812monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-first-quarter-2021-results-q1-2021-net-revenues-of-212-million-incre-shc-20210513monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-fourth-quarter-and-full-year-2020-results-provides-2021-outlook-q4-2-shc-20210309monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-successful-repricing-of-its-first-lien-term-loan-facility-clevelan-shc-20210120monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-preliminary-fourth-quarter-and-full-year-2020-revenue-cleveland-oh-shc-20210111monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-debt-pay-down-and-expansion-of-revolving-credit-facility-cleveland-shc-20201218monthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-inc-condensed-balance-sheets-unaudited-as-of-march-31-as-of-december-31-in-tho-mane-20260512monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-reports-second-quarter-2025-financial-results-business-update-x2013-phase-3-azetukal-xene-20250811monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-reports-first-quarter-2025-financial-results-and-provides-business-update-x2013-phas-xene-20250512monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-reports-fourth-quarter-full-year-2024-financial-results-and-business-update-x2013-ph-xene-20250227monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-reports-q3-2024-financial-results-and-business-update-x2013-phase-3-epilepsy-program-xene-20241112monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-reports-q2-2024-financial-results-and-business-update-x2013-phase-3-epilepsy-program-xene-20240808monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate--xene-20240509monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-prov-xene-20240229monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-topline-results-from-phase-2-proof-of-concept-x-nova-clini-xene-20231127monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-update-on-partnered-program-with-neurocrine-biosciences-pha-xene-20231109monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-corporate--xene-20231108monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-corporate-xene-20230809monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-expands-leadership-on-its-board-of-directors-with-appointments-of-gi-xene-20230808monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-corporate--xene-20230509monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-prov-xene-20230301monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporate--xene-20221108monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-strengthens-leadership-team-with-appointment-of-andrea-difabio-as-ch-xene-20221107monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-corporate-xene-20220809monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-positive-outcome-of-end-of-phase-2-meeting-with-the-fda-xe-xene-20220621monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corporate--xene-20220510monthly0.5https://www.biopharmawatch.com/news/XENE/craig-colosso-relationship-management-american-stock-transfer-trust-company-llc-brooklyn-n-xene-20220310monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2021-financial-results-and-provides-corporate-update-confere-xene-20220301monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-collaboration-with-neurocrine-biosciences-achieves-15-0-mi-xene-20220112monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-corporate--xene-20211110monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-positive-topline-results-from-phase-2b-x-tole-clinical-tri-xene-20211004monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-collaboration-with-neurocrine-biosciences-achieves-10-0-mi-xene-20210908monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-strengthens-leadership-team-with-appointment-of-dr-christopher-kenne-xene-20210823monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corporate-xene-20210811monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate--xene-20210511monthly0.5https://www.biopharmawatch.com/news/XENE/craig-colosso-relationship-management-american-stock-transfer-trust-company-llc-brooklyn-n-xene-20210312monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2020-financial-results-and-provides-corporate-update-xen1101-xene-20210301monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-milestone-opportunities-and-planned-leadership-transiti-xene-20210114monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-corporate--xene-20201105monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-appoints-dr-chris-von-seggern-as-chief-commercial-officer-burnaby-br-xene-20200817monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides-corporate-xene-20200806monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides-corporate--xene-20200521monthly0.5https://www.biopharmawatch.com/news/XENE/craig-colosso-relationship-management-american-stock-transfer-trust-company-llc-brooklyn-n-xene-20200311monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2019-financial-results-and-provides-corporate-update-xenon-s-xene-20200309monthly0.5https://www.biopharmawatch.com/news/XENE/neurocrine-biosciences-and-xenon-pharmaceuticals-announce-agreement-to-develop-first-in-cl-xene-20191202monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-corporate--xene-20191105monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2019-financial-results-and-provides-corporate-xene-20190806monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2019-financial-results-and-provides-corporate--xene-20190507monthly0.5https://www.biopharmawatch.com/news/XENE/craig-colosso-relationship-manager-american-stock-transfer-trust-company-llc-charlotte-nor-xene-20190313monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2018-financial-results-and-provides-corporate-update-multipl-xene-20190306monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-corporate--xene-20181106monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-enters-into-agreement-to-buy-out-milestones-and-royalties-related-to-its-xen1101-pro-xene-20180910monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-expands-ion-channel-neurology-pipeline-with-addition-of-xen496-a-phase-3-ready-potas-xene-20180907monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-announces-positive-xen1101-pharmacodynamic-data-from-phase-1b-tms-study-xen1101-demo-xene-20180829monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2018-financial-results-and-provides-corporate-xene-20180807monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-presents-xen901-phase-1-clinical-update-and-supporting-pre-clinical-data-at-14th-eil-xene-20180515monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-corporate--xene-20180508monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-confirms-closing-of-transaction-with-teva-and-announces-preferred-sh-xene-20180328monthly0.5https://www.biopharmawatch.com/news/XENE/craig-colosso-relationship-manager-american-stock-transfer-trust-company-llc-charlotte-nor-xene-20180315monthly0.5https://www.biopharmawatch.com/news/XENE/dr-ernesto-aycardi-joins-xenon-pharmaceuticals-as-chief-medical-officer-changes-to-senior--xene-20180313monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2017-financial-results-and-provides-corporate-update-two-nov-xene-20180307monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-milestones-for-2018-burnaby-british-columbia-xene-20180108monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-corporate--xene-20171107monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-corporate-xene-20170803monthly0.5https://www.biopharmawatch.com/news/XENE/teva-and-xenon-announce-phase-ii-study-of-topical-tv-45070-in-patients-with-post-herpetic--xene-20170627monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2017-financial-results-and-provides-corporate--xene-20170509monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-expands-ion-channel-neurology-pipeline-with-acquisition-of-new-potassium-channel-mod-xene-20170426monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-xen801-did-not-meet-efficacy-endpoints-in-phase-2-clinical-xene-20170324monthly0.5https://www.biopharmawatch.com/news/XENE/deana-fuhriman-senior-relationship-manager-american-stock-transfer-trust-company-llc-seatt-xene-20170309monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2016-financial-results-and-provides-corporate-update-burnaby-xene-20170308monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2016-financial-results-and-provides-corporate--xene-20161103monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-appoints-dawn-svoronos-to-its-board-of-directors-burnaby-british-col-xene-20160927monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2016-financial-results-and-provides-corporate-xene-20160803monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2016-financial-results-and-provides-corporate--xene-20160510monthly0.5https://www.biopharmawatch.com/news/XENE/joshua-p-mcginn-cep-senior-vice-president-western-region-relationship-management-american--xene-20160309monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2015-financial-results-and-provides-corporate-update-signifi-xene-20160308monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-proposed-convertible-senior-notes-offering-zug-switzerland-a-crsp-20260310monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-crsp-20260212monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2025-financial-res-crsp-20250804monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-first-quarter-2025-financial-results-and-announces-positive-t-crsp-20250506monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-transition-of-chief-operating-officer-zug-switzerland-and-bo-crsp-20250326monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-crsp-20250211monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2024-financial-resu-crsp-20241105monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2024-financial-res-crsp-20240805monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2024-financial-resu-crsp-20240508monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2023-crsp-20240221monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2023-financial-resu-crsp-20231031monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-leadership-transition-crispr-therapeutics-co-founder-rodger--crsp-20230907monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2023-financial-res-crsp-20230807monthly0.5https://www.biopharmawatch.com/news/CRSP/fda-accepts-biologics-license-applications-for-exagamglogene-autotemcel-exa-cel-for-severe-crsp-20230609monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2023-financial-resu-crsp-20230508monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-complete-submission-of-rolling-biologics-license-applicatio-crsp-20230403monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-departure-of-board-member-zug-switzerland-and-boston-mass-crsp-20230329monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-announce-licensing-agreement-to-accelerate-development-of-v-crsp-20230327monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-transition-of-chief-financial-officer-zug-switzerland-and-bo-crsp-20230313monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2022-crsp-20230221monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2022-financial-resu-crsp-20221101monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-planned-transition-of-chief-operating-officer-zug-switzerlan-crsp-20221027monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-announce-global-exa-cel-regulatory-submissions-for-sickle-c-crsp-20220927monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2022-financial-res-crsp-20220808monthly0.5https://www.biopharmawatch.com/news/CRSP/the-presentation-and-other-related-materials-may-contain-a-number-of-x201c-forward-looking-crsp-20220621monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-present-new-data-on-more-patients-with-longer-follow-up-tre-crsp-20220611monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-the-appointment-of-phuong-khanh-morrow-m-d-facp-as-chief-med-crsp-20220516monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-oral-presentation-of-new-clinical-data-on-anti-cd70-allogene-crsp-20220512monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2022-financial-resu-crsp-20220509monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2021-crsp-20220215monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-rmat-designation--crsp-20211122monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2021-financial-resu-crsp-20211103monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-transition-of-chief-financial-officer-zug-switzerland-and-crsp-20211014monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-reports-positive-results-from-its-phase-1-carbon-trial-of-ctx110-in-re-crsp-20211012monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2021-financial-res-crsp-20210729monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-present-new-data-in-22-patients-with-greater-than-3-months--crsp-20210611monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2021-financial-resu-crsp-20210427monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-pharmaceuticals-and-crispr-therapeutics-amend-collaboration-for-development-manufac-crsp-20210420monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2020-crsp-20210216monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-present-new-data-for-investigational-crispr-cas9-gene-editi-crsp-20201205monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-cas9-gene-editing-therapy-ctx001-for-severe-hemoglobinopathies-accepted-for-plenary-crsp-20201104monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2020-financial-resu-crsp-20201028monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-reports-positive-top-line-results-from-its-phase-1-carbon-trial-of-ctx-crsp-20201021monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2020-financial-res-crsp-20200727monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-proposed-public-offering-of-common-shares-zug-switzerland-an-crsp-20200629monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-announce-new-clinical-data-for-investigational-gene-editing-crsp-20200612monthly0.5https://www.biopharmawatch.com/news/CRSP/new-data-for-investigational-crispr-cas9-gene-editing-therapy-ctx001-for-severe-hemoglobin-crsp-20200514monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-pharmaceuticals-announce-fda-regenerative-medicine-advanced-crsp-20200511monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2020-financial-resu-crsp-20200428monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-proposes-changes-to-the-board-of-directors-zug-switzerland-and-crsp-20200226monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2019-crsp-20200212monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-proposed-public-offering-of-common-shares-zug-switzerland-an-crsp-20191119monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-announce-positive-safety-and-efficacy-data-from-first-two-p-crsp-20191119monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2019-financial-resu-crsp-20191028monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2019-financial-res-crsp-20190729monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-expands-into-new-disease-areas-and-enhances-gene-editing-capabilities-through-expan-crsp-20190606monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2019-financial-resu-crsp-20190429monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-announce-progress-in-clinical-development-programs-for-the--crsp-20190225monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2018-crsp-20190225monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2018-financial-resu-crsp-20181107monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-announce-fda-has-lifted-the-clinical-hold-on-the-investigat-crsp-20181010monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-proposed-public-offering-of-common-shares-zug-switzerland-an-crsp-20180919monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-viacyte-announce-strategic-collaboration-to-develop-gene-edited-st-crsp-20180917monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-intellia-therapeutics-and-caribou-biosciences-provide-update-on-u-s-fe-crsp-20180910monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-second-quarter-2018-financial-res-crsp-20180807monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-provide-update-on-fda-review-of-investigational-new-drug-ap-crsp-20180530monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2018-financial-resu-crsp-20180508monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2017-crsp-20180308monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-proposed-public-offering-of-common-shares-zug-switzerland-an-crsp-20180103monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-appointment-of-dr-rodger-novak-as-chairman-of-the-board-zug--crsp-20171221monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-to-co-develop-and-co-commercialize-ctx001-as-crispr-cas9-ge-crsp-20171212monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-submits-first-clinical-trial-application-for-a-crispr-gene-edited-ther-crsp-20171207monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-appointment-of-michael-tomsicek-as-chief-financial-officer-z-crsp-20171113monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-third-quarter-2017-financial-results-and-provides-business-u-crsp-20171108monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-new-data-on-allogeneic-crispr-based-car-t-program-and-host--crsp-20171107monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-promotion-of-samarth-kulkarni-ph-d-to-chief-executive-office-crsp-20171002monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-second-quarter-2017-financial-results-and-provides-business--crsp-20170810monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-appoints-dr-tony-w-ho-to-head-research-development-zug-switzerland-and-crsp-20170801monthly0.5https://www.biopharmawatch.com/news/CRSP/confidential-clia-draft-for-planned-release-tuesday-25-july-at-4-30-pm-eastern-time-crispr-crsp-20170725monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-patent-for-crispr-cas-genome-editing-in-china-patent-include-crsp-20170619monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-appoints-james-r-kasinger-as-general-counsel-crispr-continues-to-add-t-crsp-20170607monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-reports-financial-results-for-the-three-months-ended-crsp-20170511monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-appoints-samarth-kulkarni-ph-d-as-president-expanding-role-beyond-chie-crsp-20170504monthly0.5https://www.biopharmawatch.com/news/CRSP/intellia-therapeutics-and-crispr-therapeutics-announce-u-s-patent-covering-crispr-cas9-rib-crsp-20170426monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-intellia-therapeutics-caribou-biosciences-and-ers-genomics-announce-ap-crsp-20170413monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-european-patent-for-crispr-cas-gene-editing-patent-to-includ-crsp-20170328monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-intellia-therapeutics-caribou-biosciences-and-ers-genomics-provide-upd-crsp-20170215monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-intellia-therapeutics-caribou-biosciences-and-ers-genomics-announce-gl-crsp-20161216monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-first-quarter-2026-financial-results-first-quarter-performance-dri-lgnd-20260507monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-lgnd-20260427monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-fourth-quarter-and-full-year-2025-financial-results-robust-financi-lgnd-20260226monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-third-quarter-2025-financial-results-and-raises-guidance-third-qua-lgnd-20251106monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-announces-proposed-offering-of-400-million-of-convertible-senior-notes-due-2030-lgnd-20250811monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-second-quarter-2025-financial-results-and-raises-guidance-second-q-lgnd-20250807monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-first-quarter-2025-financial-results-first-quarter-performance-dri-lgnd-20250508monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-fourth-quarter-and-full-year-2024-financial-results-robust-financi-lgnd-20250227monthly0.5https://www.biopharmawatch.com/news/LGND/document-for-immediate-release-ligand-leads-75-million-royalty-financing-in-castle-creek-b-lgnd-20250225monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-third-quarter-2024-financial-results-and-raises-2024-guidance-thir-lgnd-20241107monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-second-quarter-2024-financial-results-conference-call-at-4-30-p-m--lgnd-20240806monthly0.5https://www.biopharmawatch.com/news/LGND/document-for-immediate-release-ligand-to-acquire-apeiron-biologics-ag-for-100-million-acqu-lgnd-20240708monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-first-quarter-2024-financial-results-conference-call-begins-at-4-3-lgnd-20240507monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-fourth-quarter-and-full-year-2023-financial-results-conference-cal-lgnd-20240227monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-third-quarter-2023-financial-results-raising-2023-guidance-investo-lgnd-20231108monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-second-quarter-2023-financial-results-conference-call-begins-at-4--lgnd-20230808monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-first-quarter-2023-financial-results-2023-financial-guidance-raise-lgnd-20230504monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-fourth-quarter-and-full-year-2022-financial-results-2023-financial-lgnd-20230222monthly0.5https://www.biopharmawatch.com/news/LGND/1-amounts-represent-non-cash-debt-related-costs-that-are-calculated-in-accordance-with-the-lgnd-20221107monthly0.5https://www.biopharmawatch.com/news/LGND/for-the-six-months-ended-lgnd-20221104monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-announces-record-date-and-details-for-distribution-for-omniab-spin-off-emeryville-c-lgnd-20221003monthly0.5https://www.biopharmawatch.com/news/LGND/1-amounts-represent-non-cash-debt-related-costs-that-are-calculated-in-accordance-with-the-lgnd-20220808monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-pharmaceuticals-incorporated-lha-investor-relations-simon-latimer-bruce-voss-invest-lgnd-20220629monthly0.5https://www.biopharmawatch.com/news/LGND/analyst-teach-in-lgnd-20220621monthly0.5https://www.biopharmawatch.com/news/LGND/1-amounts-represent-non-cash-debt-related-costs-that-are-calculated-in-accordance-with-the-lgnd-20220504monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-spin-off-its-omniab-business-through-merger-with-avista-public-acquisition-corp--lgnd-20220323monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-fourth-quarter-and-full-year-2021-financial-results-conference-cal-lgnd-20220217monthly0.5https://www.biopharmawatch.com/news/LGND/1-amounts-represent-non-cash-debt-related-costs-that-are-calculated-in-accordance-with-the-lgnd-20211109monthly0.5https://www.biopharmawatch.com/news/LGND/1-amounts-represent-non-cash-debt-related-costs-that-are-calculated-in-accordance-with-the-lgnd-20210729monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-pharmaceuticals-appoints-dr-jennifer-cochran-to-its-board-of-directors-eme-lgnd-20210714monthly0.5https://www.biopharmawatch.com/news/LGND/1-amounts-represent-non-cash-debt-related-costs-that-are-calculated-in-accordance-with-the-lgnd-20210503monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-reports-fourth-quarter-and-full-year-2020-financial-results-raises-2021-fi-lgnd-20210203monthly0.5https://www.biopharmawatch.com/news/LGND/document-ligand-and-gsk-enter-global-collaboration-and-license-agreement-leveraging-icagen-lgnd-20201221monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-divest-vernalis-research-operations-consideration-includes-25-million-cash-payme-lgnd-20201012monthly0.5https://www.biopharmawatch.com/news/LGND/contingent-value-rights-agreement-this-contingent-value-rights-agreement-this-agreement-da-lgnd-20200930monthly0.5https://www.biopharmawatch.com/news/LGND/tender-and-support-agreement-this-tender-and-support-agreement-this-agreement-is-entered-i-lgnd-20200810monthly0.5https://www.biopharmawatch.com/news/LGND/document-contacts-ligand-pharmaceuticals-incorporated-lha-investor-relations-patrick-o-bri-lgnd-20200402monthly0.5https://www.biopharmawatch.com/news/LGND/document-contacts-ligand-pharmaceuticals-incorporated-lha-investor-relations-patrick-o-bri-lgnd-20200211monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-appoints-pharmaceutical-executive-sarah-boyce-to-its-board-of-directors-lgnd-20191016monthly0.5https://www.biopharmawatch.com/news/LGND/investor-conference-call-lgnd-20190305monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-second-quarter-2018-financial-results-lgnd-20180806monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-first-quarter-2018-financial-results-lgnd-20180508monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-third-quarter-2017-financial-results-lgnd-20171109monthly0.5https://www.biopharmawatch.com/news/LGND/forward-looking-statements-lgnd-20161114monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-third-quarter-2016-financial-results-lgnd-20161103monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-announces-multi-program-ltp-technology-licensing-agreement-lgnd-20160729monthly0.5https://www.biopharmawatch.com/news/LGND/certain-material-indicated-by-an-asterisk-has-been-omitted-from-this-document-pursuant-to--lgnd-20151125monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-pharmaceuticals-incorporated-lha-todd-pettingill-bruce-voss-investors-ligand-com-bv-lgnd-20150602monthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-strengthens-leadership-team-to-support-long-term-growth-and-sharehold-alhc-20260512monthly0.5https://www.biopharmawatch.com/news/ALHC/legal-disclaimer-forward-looking-statements-this-presentation-contains-forward-looking-sta-alhc-20240108monthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-reports-first-quarter-2021-financial-results-orange-calif-alhc-20210517monthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-announces-closing-of-initial-public-offering-orange-calif-alhc-20210330monthly0.5https://www.biopharmawatch.com/news/NAMS/investor-presentation-as-of-nams-20260302monthly0.5https://www.biopharmawatch.com/news/NAMS/corporate-presentation-nams-20250902monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financial-results-nams-20250806monthly0.5https://www.biopharmawatch.com/news/NAMS/welcome-to-r-d-day-nams-20250611monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-first-quarter-financial-results--nams-20250508monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-late-breaking-data-from-broadway-and-tandem-pivotal-studies--nams-20250507monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-appoints-adele-gulfo-to-its-board-of-directors-naarden-the-netherlands-nams-20250417monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-full-year-2024-financial-results-and-provides-corporate-update-nams-20250226monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-highlights-2024-achievements-and-outlines-2025-strategic-priorities-ad-nams-20250110monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-commencement-of-300-million-public-offering-of-ordinary-shar-nams-20241210monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-positive-topline-data-from-pivotal-phase-3-broadway-clinical-nams-20241210monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-positive-topline-data-from-pivotal-phase-3-tandem-clinical-t-nams-20241120monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-presents-additional-data-from-pivotal-phase-3-brooklyn-clinical-trial--nams-20241118monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-third-quarter-financial-results--nams-20241106monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financial-results-nams-20240807monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-positive-topline-data-from-pivotal-phase-3-brooklyn-clinical-nams-20240729monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-appointments-of-mark-c-mckenna-and-wouter-joustra-to-its-boa-nams-20240718monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-issuance-of-composition-of-matter-patent-for-obicetrapib-by--nams-20240611monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-first-quarter-financial-results--nams-20240509monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-the-appointment-of-juliette-audet-as-chief-business-officer--nams-20240401monthly0.5https://www.biopharmawatch.com/news/NAMS/0-121-2-13-1-141-2-55-01-6-01-3-121-52-55-01-74-62-340-1-6-0-2-1-0-7-2-2-5-340-1-2-121-084-nams-20240304monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-full-year-2023-financial-results-and-provides-corporate-update-nams-20240228monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-commencement-of-public-offering-of-ordinary-shares-and-pre-f-nams-20240213monthly0.5https://www.biopharmawatch.com/news/NAMS/january-2024-disclaimer-this-presentation-together-with-oral-statements-made-in-connection-nams-20240122monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-appoints-william-h-lewis-j-d-m-b-a-as-chair-of-its-board-of-directors--nams-20240108monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-2024-strategic-priorities-positioned-for-three-phase-3-trial-nams-20240104monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-third-quarter-2023-financial-hig-nams-20231113monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-appointment-of-ian-somaiya-as-chief-financial-officer-naarde-nams-20231023monthly0.5https://www.biopharmawatch.com/news/NAMS/september-2023-disclaimer-this-presentation-together-with-oral-statements-made-in-connecti-nams-20230925monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-initial-data-from-phase-2a-clinical-trial-evaluating-obicetr-nams-20230921monthly0.5https://www.biopharmawatch.com/news/NAMS/new-insights-on-cetp-inhibition-from-genetic-research-and-clinical-trials-john-j-p-kastele-nams-20230828monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-appointment-of-william-bj-jones-formerly-of-biohaven-pharmac-nams-20230814monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-2023-financial-hi-nams-20230807monthly0.5https://www.biopharmawatch.com/news/NAMS/condensed-consolidated-statements-of-profit-or-loss-unaudited-for-the-six-months-ended-jun-nams-20230807monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-completes-enrollment-in-pivotal-phase-3-broadway-clinical-trial-evalua-nams-20230725monthly0.5https://www.biopharmawatch.com/news/NAMS/our-business-overview-newamsterdam-pharma-company-n-v-we-us-our-or-the-company-is-a-clinic-nams-20230606monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-presents-full-data-from-phase-2-rose2-trial-evaluating-obicetrapib-in--nams-20230605monthly0.5https://www.biopharmawatch.com/news/NAMS/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-shareholde-nams-20230531monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-to-present-full-data-from-rose2-at-nla-scientific-sessions-2023-newamsterdam--nams-20230523monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-first-quarter-financial-highligh-nams-20230508monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-completes-enrollment-in-pivotal-phase-3-brooklyn-clinical-trial-evalua-nams-20230424monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-appoints-janneke-van-der-kamp-to-its-board-of-directors-naarden-the-ne-nams-20230403monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-full-year-2022-financial-results-and-provides-corporate-update-nams-20230331monthly0.5https://www.biopharmawatch.com/news/NAMS/march-2023-disclaimer-this-presentation-together-with-oral-statements-made-in-connection-h-nams-20230307monthly0.5https://www.biopharmawatch.com/news/NAMS/february-2023-disclaimer-this-presentation-together-with-oral-statements-made-in-connectio-nams-20230214monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-appoints-john-w-smither-to-its-board-of-directors-naarden-the-netherla-nams-20230206monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-announces-positive-results-from-rose2-phase-2-trial-evaluating-obicetrapib-in-nams-20230117monthly0.5https://www.biopharmawatch.com/news/NAMS/january-2023-disclaimer-this-presentation-together-with-oral-statements-made-in-connection-nams-20230109monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-announces-appointment-of-david-topper-as-chief-financial-officer-naarden-the--nams-20221219monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-debuts-as-publicly-traded-company-focused-on-developing-obicetrapib-a--nams-20221122monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-provides-corporate-update-arcalyst-rilonacept-2025-net-product-rev-knsa-20260112monthly0.5https://www.biopharmawatch.com/news/KNSA/corporate-presentation-september-2025-forward-looking-statements-2-this-presentation-toget-knsa-20250903monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-second-quarter-2025-financial-results-and-recent-portfolio-knsa-20250729monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-first-quarter-2025-financial-results-and-recent-portfolio--knsa-20250429monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-re-knsa-20250225monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-preliminary-2024-net-product-revenue-and-provides-2025-net-knsa-20250113monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-third-quarter-2024-financial-results-and-recent-portfolio--knsa-20241029monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-second-quarter-2024-financial-results-and-recent-portfolio-knsa-20240723monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-first-quarter-2024-financial-results-and-recent-portfolio--knsa-20240423monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-announces-development-indication-for-abiprubart-abiprubart-phase-2-knsa-20240402monthly0.5https://www.biopharmawatch.com/news/KNSA/from-kiniksa-pharmaceuticals-ltd-to-the-holders-of-common-shares-of-the-company-knsa-20240329monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-re-knsa-20240228monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-provides-corporate-update-arcalyst-rilonacept-2023-net-product-rev-knsa-20240104monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-third-quarter-2023-financial-results-and-recent-portfolio--knsa-20231031monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-second-quarter-2023-financial-results-and-recent-portfolio-knsa-20230725monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-re-knsa-20230228monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-provides-corporate-and-portfolio-update-arcalyst-rilonacept-q4-202-knsa-20230109monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporat-knsa-20221101monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-corpora-knsa-20220803monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corporat-knsa-20220503monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-pr-knsa-20220222monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-provides-corporate-update-and-outlines-anticipated-2022-milestones-arcalyst-full-y-knsa-20220110monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-reports-third-quarter-2021-financial-results-and-recent-portfolio--knsa-20211101monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-second-quarter-2021-financial-results-and-recent-corporate-and-portfolio-a-knsa-20210803monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-first-quarter-2021-financial-results-and-recent-corporate-and-portfolio-ac-knsa-20210504monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-fourth-quarter-and-full-year-2020-financial-results-and-corporate-and-pipe-knsa-20210223monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-highlights-corporate-priorities-and-expected-2021-milestones-pdufa-goal-date-of-knsa-20210111monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-third-quarter-2020-financial-results-and-highlights-recent-pipeline-and-co-knsa-20201105monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-announces-new-data-from-phase-2-trial-of-mavrilimumab-in-giant-cell-arteritis-to-b-knsa-20201026monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-second-quarter-2020-financial-results-and-highlights-recent-pipeline-and-c-knsa-20200730monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-announces-positive-data-from-phase-3-trial-of-rilonacept-in-recurrent-pericarditis-knsa-20200629monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-first-quarter-2020-financial-results-and-highlights-recent-corporate-and-p-knsa-20200428monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-announces-phase-2-clinical-trial-of-vixarelimab-kpl-716-in-prurigo-nodularis-meets-knsa-20200422monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-recent--knsa-20200226monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-announces-pipeline-progress-and-reiterates-2020-clinical-data-readouts-enrollment--knsa-20200113monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-third-quarter-2019-financial-results-and-highlights-recent-corporate-and-p-knsa-20191028monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-second-quarter-2019-financial-results-and-highlights-recent-corporate-and--knsa-20190812monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-first-quarter-2019-financial-results-and-highlights-recent-corporate-and-p-knsa-20190502monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-fourth-quarter-and-full-year-2018-financial-results-and-highlights-recent--knsa-20190307monthly0.5https://www.biopharmawatch.com/news/KNSA/every-second-counts-january-2019-forward-looking-statements-this-presentation-together-wit-knsa-20190128monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-third-quarter-2018-financial-results-and-pipeline-progress-rilonacept-pivo-knsa-20181101monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-presents-kpl-716-clinical-data-at-the-27-th-european-academy-of-dermatology-and-ve-knsa-20180915monthly0.5https://www.biopharmawatch.com/news/KNSA/th-eadv-congress-late-breaker-abstract-kpl-716-c001-phase-1a-1b-authors-zamaneh-mikhak-1-j-knsa-20180913monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-reports-second-quarter-2018-financial-results-and-pipeline-progress-rilonacept-adv-knsa-20180806monthly0.5https://www.biopharmawatch.com/news/OPCH/extraordinary-care-that-changes-lives-2026-option-care-health-inc-all-rights-reserved-opti-opch-20260512monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-fourth-quarter-and-full-year-2025-banno-opch-20260224monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-preliminary-fourth-quarter-full-year-2025-financial-results-a-opch-20260112monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-third-quarter-ended-september-30-20-opch-20251030monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-chief-financial-officer-transition-mike-shapiro-to-step-down--opch-20250820monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-second-quarter-ended-june-30-2025-b-opch-20250730monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-first-quarter-ended-march-31-2025-b-opch-20250429monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-reports-financial-results-for-fourth-quarter-and-full-year-2024-bannock-opch-20250226monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-preliminary-financial-results-for-fourth-quarter-and-full-yea-opch-20250113monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-third-quarter-ended-september-30-20-opch-20241030monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-second-quarter-ended-june-30-2024-b-opch-20240731monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-first-quarter-ended-march-31-2024-b-opch-20240423monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-reports-financial-results-for-fourth-quarter-and-full-year-2023-bannock-opch-20240222monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-third-quarter-ended-september-30-20-opch-20231025monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-second-quarter-ended-june-30-2023-b-opch-20230727monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-confirms-termination-of-merger-agreement-with-amedisys-highlights-stren-opch-20230626monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-and-amedisys-to-combine-creating-a-leading-independent-platform-for-hom-opch-20230503monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-first-quarter-ended-march-31-2023-b-opch-20230503monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-reports-financial-results-for-fourth-quarter-and-full-year-2022-opch-20230223monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-third-quarter-ended-september-30-20-opch-20221027monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-second-quarter-ended-june-30-2022-b-opch-20220727monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-first-quarter-ended-march-31-2022-b-opch-20220428monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-reports-financial-results-for-fourth-quarter-and-full-year-2021-opch-20220223monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-third-quarter-ended-september-30-20-opch-20211104monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-pricing-of-offering-of-500-million-4-375-opch-20211022monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-offering-of-500-opch-20211020monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-preliminary-financial-results-for-the-third-quarter-ended-sep-opch-20211020monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-second-quarter-ended-june-30-2021-b-opch-20210803monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-first-quarter-ended-march-31-2021-b-opch-20210506monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-fourth-quarter-and-full-year-2020-and-p-opch-20210311monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-issuance-of-250-opch-20210121monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-third-quarter-ended-september-30-20-opch-20201103monthly0.5https://www.biopharmawatch.com/news/OPCH/unaudited-pro-forma-combined-financial-statements-on-opch-20200626monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-the-first-quarter-and-provides-an-updat-opch-20200507monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-announces-financial-results-for-fourth-quarter-and-full-year-2019-and-a-opch-20200305monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-completes-opch-20200203monthly0.5https://www.biopharmawatch.com/news/OPCH/granted-in-the-court-of-chancery-of-the-state-of-delaware-erik-schmidt-on-behalf-of-himsel-opch-20191227monthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-receives-anticipated-nasdaq-notice-intends-to-request-appeals-hearing-a-opch-20190813monthly0.5https://www.biopharmawatch.com/news/OPCH/hc-group-holdings-ii-inc-quarterly-report-for-the-quarterly-period-ended-opch-20190807monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-announces-shareholder-approval-of-merger-with-option-care-denver-co-opch-20190802monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-second-quarter-2019-financial-results-denver-co-opch-20190730monthly0.5https://www.biopharmawatch.com/news/OPCH/key-members-of-bioscrip-s-leadership-team-to-continue-in-executive-roles-with-combined-com-opch-20190613monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-first-quarter-2019-financial-results-denver-co-opch-20190502monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-inc-provides-merger-update-denver-co-opch-20190423monthly0.5https://www.biopharmawatch.com/news/OPCH/home-and-alternate-site-infusion-therapy-providers-bioscrip-and-option-care-to-merge-creat-opch-20190315monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-fourth-quarter-and-full-year-2018-financial-results-denver-co-opch-20190315monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-third-quarter-2018-financial-results-denver-co-opch-20181106monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-comments-on-implementation-of-medicare-home-infusion-transition-benefit-reaffirmi-opch-20181101monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-appoints-john-mcmahon-as-chief-accounting-officer-denver-opch-20181022monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-second-quarter-2018-financial-results-denver-co-opch-20180807monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-first-quarter-2018-financial-results-denver-co-opch-20180510monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-fourth-quarter-and-full-year-2017-financial-results-denver-co-opch-20180308monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-announces-additions-to-senior-leadership-team-appoints-harriet-booker-as-senior-v-opch-20171128monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-third-quarter-2017-financial-results-net-revenue-of-198-7-million-includi-opch-20171102monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-second-quarter-2017-financial-results-net-revenue-of-218-1-million-includ-opch-20170809monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-announces-new-senior-credit-facility-agreement-will-immediately-improve-capital-s-opch-20170629monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-first-quarter-2017-financial-opch-20170504monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-announces-cfo-transition-appoints-stephen-m-deitsch-as-senior-vice-president-chie-opch-20170420monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-announces-meeting-with-investors-company-expects-improved-profitability-following-opch-20170327monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-fourth-quarter-and-full-year-2016-financial-results-q4-consolidated-reven-opch-20170303monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-raises-approximately-5-million-in-private-placement-of-common-stock-denver-opch-20170302monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-announces-amendment-to-credit-opch-20170109monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-inc-all-rights-reserved-bank-meeting-proposed-amendment-to-credit-agreement-2012--opch-20161214monthly0.5https://www.biopharmawatch.com/news/OPCH/jeffrey-m-kreger-chief-financial-officer-720-697-5200-jeffrey-kreger-bioscrip-com-bioscrip-opch-20161107monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-completes-acquisition-of-home-solutions-denver-opch-20160909monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-and-home-solutions-enter-into-amended-asset-purchase-agreement-to-expedite-closin-opch-20160902monthly0.5https://www.biopharmawatch.com/news/OPCH/jeffrey-m-kreger-chief-financial-officer-720-697-5200-jeffrey-kreger-bioscrip-com-bioscrip-opch-20160812monthly0.5https://www.biopharmawatch.com/news/OPCH/jeffrey-m-kreger-chief-financial-officer-720-697-5200-jeffrey-kreger-bioscrip-com-bioscrip-opch-20160808monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-opch-20160622monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-opch-20160616monthly0.5https://www.biopharmawatch.com/news/OPCH/jeffrey-m-kreger-bioscrip-chief-financial-officer-720-697-5200-jeffrey-kreger-bioscrip-com-opch-20160616monthly0.5https://www.biopharmawatch.com/news/OPCH/jeffrey-m-kreger-bioscrip-chief-financial-officer-720-697-5200-jeffrey-kreger-bioscrip-com-opch-20160613monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-inc-1600-broadway-suite-950-denver-colorado-80202-720-697-5200-notice-of-action-w-opch-20160601monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-bioscrip-re-opch-20160505monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-bioscrip-re-opch-20160302monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-bioscrip-pr-opch-20160119monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-for-immedia-opch-20151104monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-inc-and-subsidiaries-unaudited-pro-forma-consolidated-financial-information-pbm-b-opch-20150827monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-for-immedia-opch-20150810monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-for-immedia-opch-20150728monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-for-immedia-opch-20150619monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-for-immedia-opch-20150618monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-for-immedia-opch-20150610monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-for-immedia-opch-20150507monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-bioscrip-ap-opch-20150427monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-bioscrip-ra-opch-20150309monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-for-immedia-opch-20150302monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-sharon-ster-opch-20150209monthly0.5https://www.biopharmawatch.com/news/OPCH/lisa-wilson-in-site-communications-inc-t-212-452-2793-e-lwilson-insitecony-com-bioscrip-an-opch-20150204monthly0.5https://www.biopharmawatch.com/news/OPCH/hai-tran-chief-financial-officer-bioscrip-952-979-3768-for-immediate-release-bioscrip-repo-opch-20141105monthly0.5https://www.biopharmawatch.com/news/OPCH/hai-tran-chief-financial-officer-bioscrip-952-979-3768-bioscrip-reports-second-quarter-201-opch-20140806monthly0.5https://www.biopharmawatch.com/news/OPCH/hai-tran-chief-financial-officer-bioscrip-952-979-3768-opch-20140718monthly0.5https://www.biopharmawatch.com/news/OPCH/hai-tran-chief-financial-officer-bioscrip-952-979-3768-bioscrip-stockholders-elect-new-ind-opch-20140514monthly0.5https://www.biopharmawatch.com/news/OPCH/hai-tran-chief-financial-officer-bioscrip-952-979-3768-or-lisa-wilson-in-site-communicatio-opch-20140508monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-completes-sale-of-home-health-services-business-to-lhc-group-elmsford-ny-opch-20140401monthly0.5https://www.biopharmawatch.com/news/OPCH/hai-tran-chief-financial-officer-bioscrip-952-979-3768-bioscrip-reports-fourth-quarter-201-opch-20140226monthly0.5https://www.biopharmawatch.com/news/OPCH/announces-pricing-of-8-875-senior-notes-due-2021-opch-20140211monthly0.5https://www.biopharmawatch.com/news/OPCH/to-credit-agreement-this-amendment-is-made-and-entered-into-as-of-december-23-2013-by-and--opch-20140203monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-reports-third-quarter-2013-financial-results-elmsford-ny-opch-20131106monthly0.5https://www.biopharmawatch.com/news/OPCH/final-reminder-for-bioscrip-2013-investor-day-rsvp-requested-to-attend-elmsford-ny-opch-20130923monthly0.5https://www.biopharmawatch.com/news/OPCH/bioscrip-completes-acquisition-of-carepoint-home-infusion-business-elmsford-ny-opch-20130826monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-first-quarter-2026-financial-results-q1-2026-net-revenue-of-723-million-gaa-amrx-20260422monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-str-amrx-20260422monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-second-quarter-2025-financial-results-q2-2025-net-revenue-of-725-million-ga-amrx-20250805monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-first-quarter-2025-financial-results-q1-2025-net-revenue-of-695-million-gaa-amrx-20250502monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-2024-performa-amrx-20250228monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-third-quarter-2024-financial-results-q3-2024-net-revenue-of-702-million-gaa-amrx-20241108monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-receives-u-s-fda-approval-for-ipx203-for-treatment-of-parkinson-s-disease-to-be-lau-amrx-20240807monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-first-quarter-2024-financial-results-q1-2024-net-revenue-of-659-million-gaa-amrx-20240503monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-fourth-quarter-and-full-year-2023-financial-results-full-year-2023-performa-amrx-20240301monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-announces-move-to-nasdaq-nasdaq-move-will-be-effective-on-amrx-20231215monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-third-quarter-2023-financial-results-q3-2023-net-revenue-of-620-million-gaa-amrx-20231107monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-second-quarter-2023-financial-results-q2-2023-net-revenue-of-599-million-ga-amrx-20230804monthly0.5https://www.biopharmawatch.com/news/AMRX/in-the-court-of-chancery-of-the-state-of-delaware-russell-thiele-and-jeffrey-edelman-deriv-amrx-20230519monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-first-quarter-2023-financial-results-q1-2023-net-revenue-of-558-million-gaa-amrx-20230505monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-fourth-quarter-and-full-year-2022-financial-results-q4-2022-net-revenue-of--amrx-20230302monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-third-quarter-2022-financial-results-q3-2022-net-revenue-of-546-million-gaa-amrx-20221104monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-appoints-gustavo-pesquin-as-executive-vice-president-chief-commercial-officer-speci-amrx-20220906monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-second-quarter-2022-financial-results-q2-2022-net-revenue-of-559-million-ga-amrx-20220805monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-appoints-deborah-m-autor-to-board-of-directors-adds-new-independent-director-with-d-amrx-20220803monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-first-quarter-2022-financial-results-q1-2022-net-revenue-of-498-million-gaa-amrx-20220504monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-fourth-quarter-and-full-year-2021-financial-results-q4-2021-net-revenue-of--amrx-20220302monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-acquires-saol-therapeutics-baclofen-franchise-expands-amneal-s-neurology-presence-i-amrx-20220105monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-third-quarter-2021-financial-results-q3-2021-net-revenue-of-529-million-gaa-amrx-20211103monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-second-quarter-2021-financial-results-q2-2021-net-revenue-of-535-million-ga-amrx-20210809monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-first-quarter-2021-financial-results-q1-2021-net-revenue-of-493-million-gaa-amrx-20210507monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-completes-acquisition-of-kashiv-specialty-pharmaceuticals-bridgewater-new-jersey-amrx-20210405monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-fourth-quarter-and-full-year-2020-financial-results-q4-2020-net-revenue-of--amrx-20210226monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-to-acquire-substantially-all-of-kashiv-specialty-pharmaceuticals-bridgewater-new-je-amrx-20210111monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-third-quarter-2020-financial-results-q3-2020-net-revenue-of-519-million-gaa-amrx-20201106monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-second-quarter-2020-financial-results-q2-2020-net-revenue-of-465-million-ga-amrx-20200806monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-first-quarter-2020-financial-results-q1-2020-net-revenue-of-499-million-gaa-amrx-20200511monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-pharmaceuticals-appoints-tasos-konidaris-as-senior-vice-president-chief-financial-o-amrx-20200311monthly0.5https://www.biopharmawatch.com/news/AMRX/todd-branning-908-280-6019-amneal-reports-fourth-quarter-and-full-year-2019-financial-resu-amrx-20200226monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-appoints-jeff-george-john-kiely-and-shlomo-yanai-to-board-of-directors-three-indepe-amrx-20191216monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-to-acquire-majority-interest-in-avkare-enhancing-access-to-growing-federal-healthca-amrx-20191210monthly0.5https://www.biopharmawatch.com/news/AMRX/mark-donohue-908-409-6718-amneal-reports-third-quarter-2019-financial-results-q3-2019-net--amrx-20191106monthly0.5https://www.biopharmawatch.com/news/AMRX/the-reader-is-cautioned-not-to-rely-on-these-forward-looking-statements-amrx-20190805monthly0.5https://www.biopharmawatch.com/news/AMRX/the-reader-is-cautioned-not-to-rely-on-these-forward-looking-statements-amrx-20190509monthly0.5https://www.biopharmawatch.com/news/AMRX/targeting-up-to-50-new-generic-product-launches-in-2019-amrx-20190228monthly0.5https://www.biopharmawatch.com/news/AMRX/dated-january-4-2019-exhibit-contact-mark-donohue-908-409-6718-amneal-names-david-a-buchen-amrx-20190104monthly0.5https://www.biopharmawatch.com/news/AMRX/integration-of-amneal-and-impax-nearing-completion-on-track-to-achieve-more-than-200-milli-amrx-20181107monthly0.5https://www.biopharmawatch.com/news/AMRX/integration-of-amneal-and-impax-advancing-ahead-of-schedule-on-track-to-achieve-more-than--amrx-20180809monthly0.5https://www.biopharmawatch.com/news/AMRX/impax-laboratories-llc-announces-results-of-tender-offer-for-2-00-convertible-senior-notes-amrx-20180605monthly0.5https://www.biopharmawatch.com/news/AMRX/we-make-healthy-possible-ubs-global-healthcare-conference-focused-on-rob-stewart-growth-pr-amrx-20180521monthly0.5https://www.biopharmawatch.com/news/AMRX/mark-donohue-215-558-4526-amneal-and-impax-complete-business-combination-creates-diversifi-amrx-20180507monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-plc-historical-recast-of-segment-data-unaudited-livn-20240501monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-announces-early-retirement-of-450-million-term-loan-and-executes-125-million-revo-livn-20210816monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-prices-offering-of-ordinary-shares-london-livn-20210803monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-announces-offering-of-ordinary-shares-london-livn-20210802monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-completes-initial-closing-of-heart-valve-business-to-gyrus-capital-additional-loc-livn-20210601monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-announces-board-appointment-and-board-leadership-changes-london-livn-20201207monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-and-gyrus-capital-enter-into-agreement-for-the-purchase-of-heart-valve-business-l-livn-20201203monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-announces-pricing-of-private-offering-of-250-million-of-3-00-cash-exchangeable-se-livn-20200612monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-announces-proposed-private-offering-of-250-million-of-cash-exchangeable-senior-no-livn-20200611monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-fourth-quarter-and-full-year-2019-results-london-livn-20200226monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-preliminary-unaudited-first-quarter-2019-revenue-results-london-livn-20190405monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-preliminary-unaudited-first-quarter-2019-livn-20190405monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-announces-settlement-agreement-to-resolve-certain-litigation-in-the-u-s-livn-20190329monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-recognizes-final-decision-from-the-u-s-centers-for-medicare-medicaid-services-reg-livn-20190215monthly0.5https://www.biopharmawatch.com/news/LIVN/n-ews-release-livanova-comments-on-the-u-s-centers-for-medicare-medicaid-services-reconsid-livn-20180530monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-completes-sale-of-cardiac-rhythm-management-business-to-microport-scientific-corp-livn-20180430monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-completes-acquisition-of-tandemlife-london-livn-20180404monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-to-acquire-imthera-medical-inc-livn-20180116monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-to-acquire-imthera-medical-inc-company-will-enter-obstructive-sleep-apnea-space-e-livn-20171205monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-enters-into-binding-letter-of-intent-to-sell-its-cardiac-rhythm-management-busine-livn-20171120monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-to-explore-strategic-options-for-cardiac-rhythm-management-business-franchise-lon-livn-20170914monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-plc-announces-chief-financial-officer-resignation-london-livn-20170331monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-fourth-quarter-and-full-year-2016-results-london-livn-20170301monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-third-quarter-2016-results-london-livn-20161102monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-second-quarter-2016-results-london-livn-20160803monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-plc-names-chief-operating-officer-london-livn-20160801monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-plc-names-andrea-l-saia-to-its-board-of-directors-london-livn-20160728monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-plc-sets-operating-model-and-supporting-organization-london-livn-20160706monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-first-quarter-2016-results-london-livn-20160504monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-2015-annual-and-fourth-quarter-financial-results-provides-fiscal-2016-gui-livn-20160224monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-receives-regulatory-approval-in-japan-for-kora-250-world-s-smallest-full-body-mri-livn-20160128monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-plc-announces-management-change-london-livn-20160113monthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-plc-announces-approval-of-perceval-london-livn-20160111monthly0.5https://www.biopharmawatch.com/news/LIVN/sorin-warning-letter-ex99-1-htm-livn-20160105monthly0.5https://www.biopharmawatch.com/news/LIVN/sorin-and-cyberonics-announce-appointment-of-livanova-s-chief-financial-officer-milan-ital-livn-20150910monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and--crnx-20260226monthly0.5https://www.biopharmawatch.com/news/CRNX/january-2026-beyond-building-innovation-the-premier-to-impact-endocrinology-business-j-p-m-crnx-20251231monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-crnx-20260105monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-fda-approval-of-palsonify-tm-paltusotine-for-the-treatment-of-adults-w-crnx-20250925monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-busin-crnx-20250807monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-to-showcase-the-next-generation-of-endocrinology-innovation-at-endo-2025-with-ei-crnx-20250630monthly0.5https://www.biopharmawatch.com/news/CRNX/this-presentation-contains-forward-looking-statements-crinetics-pharmaceuticals-inc-x201c--crnx-20250626monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-busine-crnx-20250508monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and--crnx-20250227monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-tobin-schilke-as-chief-financial-officer-san-diego-x201-crnx-20250224monthly0.5https://www.biopharmawatch.com/news/CRNX/safe-harbor-statement-this-presentation-contains-forward-looking-statements-crinetics-phar-crnx-20250114monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-positive-topline-results-from-phase-2-trial-of-atumelnant-in-congenita-crnx-20250110monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-isabel-kalofonos-as-chief-commercial-officer-san-diego--crnx-20241216monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-fda-acceptance-of-new-drug-application-for-paltusotine-for-adult-patie-crnx-20241209monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-busine-crnx-20241112monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-crnx-20241008monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-submits-new-drug-application-for-paltusotine-for-the-treatment-of-acromegaly-san-crnx-20240926monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-busin-crnx-20240808monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-positive-initial-findings-at-endo-2024-for-atumelnant-in-two-ongoing-o-crnx-20240603monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-early-release-of-endo-2024-late-breaking-abstracts-crnx-20240522monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-busine-crnx-20240509monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-advancements-from-atumelnant-crn04894-and-paltusotine-crnx-20240508monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-once-daily-oral-paltusotine-achieved-the-primary-and-all-secondary-endpoints-in--crnx-20240319monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-positive-topline-results-from-phase-2-trial-of-paltusotine-for-the-tre-crnx-20240312monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-oversubscribed-350-million-private-placement-crnx-20240228monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and--crnx-20240228monthly0.5https://www.biopharmawatch.com/news/CRNX/nd-42-annual-j-p-morgan-healthcare-conference-ja-nua-ry-9-2-02-4-safe-harbor-statement-thi-crnx-20240108monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-positive-initial-findings-from-ongoing-open-label-phase-2-study-of-pal-crnx-20231218monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-inc-condensed-consolidated-financial-statement-data-in-thousands-crnx-20231107monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-crnx-20230911monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-once-daily-oral-paltusotine-achieved-the-primary-and-all-secondary-endpoints-in--crnx-20230911monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-inc-condensed-consolidated-financial-statement-data-in-thousands-crnx-20230808monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-inc-condensed-consolidated-financial-statement-data-in-thousands-crnx-20230504monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-inc-condensed-consolidated-financial-statement-data-in-thousands-crnx-20230228monthly0.5https://www.biopharmawatch.com/news/CRNX/safe-harbor-statement-this-presentation-contains-forward-looking-statements-crinetics-phar-crnx-20230109monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-provides-update-on-crn04777-program-crnx-20221128monthly0.5https://www.biopharmawatch.com/news/CRNX/three-months-ended-september-30-nine-months-ended-september-30-statements-of-operations-da-crnx-20221114monthly0.5https://www.biopharmawatch.com/news/CRNX/investors-media-corey-davis-lifesci-advisors-llc-cdavis-lifesciadvisors-com-212-915-2577-a-crnx-20221013monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-dana-pizzuti-m-d-as-chief-development-officer-crnx-20221003monthly0.5https://www.biopharmawatch.com/news/CRNX/858-450-6464-investors-media-corey-davis-lifesci-advisors-llc-cdavis-lifesciadvisors-com-2-crnx-20220812monthly0.5https://www.biopharmawatch.com/news/CRNX/this-presentation-contains-forward-looking-statements-crinetics-cautions-you-that-statemen-crnx-20220525monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corpor-crnx-20220512monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-underwritten-common-stock-offering-crnx-20220412monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-x201-crnx-20220330monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-caren-deardorf-to-board-of-directors-crnx-20220314monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-expands-executive-team-with-appointment-of-james-hassard-as-chie-crnx-20220301monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-adds-board-member-with-global-rare-disease-expertise-with-appoin-crnx-20220105monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-corpor-crnx-20211105monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-crnx-20211020monthly0.5https://www.biopharmawatch.com/news/CRNX/this-presentation-contains-forward-looking-statements-crinetics-cautions-you-that-statemen-crnx-20210915monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-expands-executive-team-with-addition-of-jeff-knight-as-chief-ope-crnx-20210902monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corpo-crnx-20210810monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-inc-stock-purchase-agreement-this-stock-purchase-agreement-the-a-crnx-20210728monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corpor-crnx-20210506monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-crnx-20210407monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-2021-clinical-plans-and-reports-fourth-quarter-and-ful-crnx-20210330monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-corpor-crnx-20201106monthly0.5https://www.biopharmawatch.com/news/CRNX/this-presentation-contains-forward-looking-statements-all-statements-other-than-statements-crnx-20201026monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-rare-disease-executive-camille-l-bedrosian-m-d-to-board-crnx-20200903monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides-corpo-crnx-20200807monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides-corpor-crnx-20200508monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-crnx-20200414monthly0.5https://www.biopharmawatch.com/news/CRNX/safe-harbor-statement-this-presentation-contains-forward-looking-statements-all-statements-crnx-20200406monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and--crnx-20200309monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-corpor-crnx-20191112monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2019-financial-results-and-provides-corpo-crnx-20190813monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-stephanie-okey-to-board-of-directors-crnx-20190716monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2019-financial-results-and-provides-corpor-crnx-20190513monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and--crnx-20190313monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-corpor-crnx-20181113monthly0.5https://www.biopharmawatch.com/news/CRNX/this-presentation-contains-forward-looking-statements-all-statements-other-than-statements-crnx-20181001monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2018-financial-results-and-provides-corpo-crnx-20180830monthly0.5https://www.biopharmawatch.com/news/TVTX/equity-incentive-plan-adopted-by-the-board-of-directors-tvtx-20260521monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-announces-proposed-convertible-senior-notes-offering-to-refinance-2029-convertible-tvtx-20260511monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20260504monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20260219monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20260112monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20251030monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20250806monthly0.5https://www.biopharmawatch.com/news/TVTX/equity-incentive-plan-adopted-by-the-board-of-directors-tvtx-20250516monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20250501monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20250220monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20250113monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-proposed-public-offering-of-common-stock-tvtx-20241107monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20241031monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20240801monthly0.5https://www.biopharmawatch.com/news/TVTX/equity-incentive-plan-adopted-by-the-board-of-directors-tvtx-20240513monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20240506monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20240215monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-888-969-7879-888-969-7879-ir-travere-com-mediarelations-travere-com-traver-tvtx-20240108monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-naomi-eichenbaum-nivi-nehra-vice-president-investor-relations-vice-preside-tvtx-20231107monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-naomi-eichenbaum-nivi-nehra-vice-president-investor-relations-vice-preside-tvtx-20230803monthly0.5https://www.biopharmawatch.com/news/TVTX/equity-incentive-plan-adopted-by-the-board-of-directors-tvtx-20230522monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-naomi-eichenbaum-nivi-nehra-vice-president-investor-relations-vice-preside-tvtx-20230504monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-proposed-public-offering-of-common-stock-tvtx-20230227monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-naomi-eichenbaum-nivi-nehra-vice-president-investor-relations-vice-preside-tvtx-20230223monthly0.5https://www.biopharmawatch.com/news/TVTX/naomi-eichenbaum-vice-president-investor-relations-ir-travere-com-888-969-7879-travere-the-tvtx-20230109monthly0.5https://www.biopharmawatch.com/news/TVTX/investors-media-naomi-eichenbaum-nivi-nehra-vice-president-investor-relations-vice-preside-tvtx-20221027monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20220804monthly0.5https://www.biopharmawatch.com/news/TVTX/equity-incentive-plan-adopted-by-the-board-of-directors-tvtx-20220512monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20220505monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-announces-proposed-convertible-senior-notes-offering-tvtx-20220308monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20220224monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20220110monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20211028monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20210729monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20210506monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20210210monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20210111monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20201105monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-retrophi-tvtx-20200608monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-vice-president-investor-relations-corporate-communications-888-969--tvtx-20200113monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-2018-equity-incentive-plan-adopted-by-the-board-of-directors-tvtx-20190513monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-vice-president-investor-relations-corporate-communications-760-260-8600-ir-tvtx-20190107monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-vice-president-investor-relations-corporate-communications-760-260-8600-ir-tvtx-20190103monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-announces-proposed-convertible-senior-notes-offering-tvtx-20180904monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-2018-equity-incentive-plan-adopted-by-the-board-of-directors-tvtx-20180510monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-vice-president-investor-relations-corporate-communications-760-260-8600-ir-tvtx-20180108monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-2015-equity-incentive-plan-adopted-by-the-board-of-directors-tvtx-20170518monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-director-investor-relations-646-630-7519-ir-retrophin-com-retrophin-tvtx-20170109monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-director-investor-relations-646-564-3680-ir-retrophin-com-retrophin-tvtx-20160719monthly0.5https://www.biopharmawatch.com/news/TVTX/r-etrophin-i-nc-2015-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-irectors-a-pril--tvtx-20160519monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-senior-director-investor-relations-646-564-3680-ir-retrophin-com-retrophin-tvtx-20160503monthly0.5https://www.biopharmawatch.com/news/TVTX/chris-cline-cfa-director-investor-relations-646-564-3680-ir-retrophin-com-retrophin-report-tvtx-20160225monthly0.5https://www.biopharmawatch.com/news/TVTX/retirement-and-transition-agreement-this-retirement-and-transition-agreement-agreement-is--tvtx-20160202monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-chris-cline-cfa-director-investor-relations-646-564-3680-ir-retrophin-com-re-tvtx-20160111monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-chris-cline-cfa-director-investor-relations-646-564-3680-ir-retrophin-com-re-tvtx-20151103monthly0.5https://www.biopharmawatch.com/news/TVTX/united-states-district-court-southern-district-of-new-york-x-retrophin-inc-case-no-plainti-tvtx-20150817monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-chris-cline-cfa-director-investor-relations-646-564-3680-ir-retrophin-com-re-tvtx-20150804monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-executive-designated-officer-annual-bonus-plan-plan-objective-the-purpose-of-tvtx-20150729monthly0.5https://www.biopharmawatch.com/news/TVTX/r-etrophin-i-nc-2015-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-irectors-a-pril--tvtx-20150611monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-chris-cline-cfa-manager-investor-relations-646-564-3680-ir-retrophin-com-ret-tvtx-20150511monthly0.5https://www.biopharmawatch.com/news/TVTX/retrophin-inc-chris-cline-cfa-manager-investor-relations-646-564-3680-ir-retrophin-com-ret-tvtx-20150401monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-record-first-quarter-financial-results-and-revises-upwards-2026-imaging-cen-rdnt-20260511monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-2025-results-including-record-revenue-and-adjusted-ebitda-1--rdnt-20260302monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-names-four-leaders-to-expanded-executive-roles-bench-of-veteran-leaders-elevated-to-rdnt-20260107monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-with-record-quarterly-revenue-and-adjusted--rdnt-20251110monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-with-record-quarterly-revenue-and-adjusted-rdnt-20250811monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-s-wholly-owned-subsidiary-deephealth-completes-acquisition-of-icad-acquisition-cont-rdnt-20250717monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-secures-100-million-incremental-term-loan-to-fund-acquisitions-and-corporate-initia-rdnt-20250611monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-and-revises-upwards-2025-financial-guidance-rdnt-20250512monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-inc-to-acquire-icad-inc-to-accelerate-ai-powered-early-detection-and-diagnosis-of-b-rdnt-20250416monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-2024-results-including-record-revenue-and-adjusted-ebitda-1--rdnt-20250305monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-secures-commitments-to-amend-its-credit-facility-resulting-in-0-25-reduction-in-int-rdnt-20241122monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-with-record-quarterly-revenue-and-adjusted--rdnt-20241112monthly0.5https://www.biopharmawatch.com/news/RDNT/jefferies-investor-update-rdnt-20241010monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-inc-announces-the-appointment-of-kees-wesdorp-as-president-and-chief-executive-offi-rdnt-20240912monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-with-record-quarterly-revenue-and-adjusted-rdnt-20240809monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-with-record-first-quarter-revenue-adjusted--rdnt-20240508monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-closing-of-its-previously-announced-term-loan-and-revolving-credit-facili-rdnt-20240418monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-pricing-and-upsizing-of-its-previously-announced-term-loan-and-revolving--rdnt-20240411monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-a-proposed-refinancing-of-its-term-loan-and-revolving-credit-facility-rdnt-20240403monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-proposed-200-rdnt-20240307monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-2023-results-including-record-revenue-and-adjusted-ebitda-1--rdnt-20240229monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-and-revises-upwards-2023-financial-guidance-rdnt-20231108monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-with-record-quarterly-revenue-and-adjusted-rdnt-20230809monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-with-record-first-quarter-revenue-and-adjus-rdnt-20230511monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-2022-results-including-record-revenue-and-adjusted-ebitda-1--rdnt-20230228monthly0.5https://www.biopharmawatch.com/news/RDNT/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-mark-stolper-executive-vice-president-and-chief--rdnt-20221110monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-and-revises-2022-financial-guidance-ranges--rdnt-20221109monthly0.5https://www.biopharmawatch.com/news/RDNT/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-mark-stolper-executive-vice-president-and-chief--rdnt-20220812monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-and-reaffirms-2022-financial-guidance-rang-rdnt-20220809monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-with-record-revenue-and-adjusted-ebitda-1-f-rdnt-20220509monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-2021-results-and-releases-2022-financial-guidance-revenue-in-rdnt-20220301monthly0.5https://www.biopharmawatch.com/news/RDNT/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-mark-stolper-executive-vice-president-and-chief--rdnt-20220128monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-completes-the-acquisitions-of-aidence-holding-b-v-and-quantib-b-v-to-address-opport-rdnt-20220124monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-and-revises-upward-2021-financial-guidance--rdnt-20211108monthly0.5https://www.biopharmawatch.com/news/RDNT/revenue-increased-75-2-to-an-all-time-quarterly-record-of-333-9-million-in-the-second-quar-rdnt-20210809monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-including-record-first-quarter-revenue-adju-rdnt-20210510monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-the-closing-of-its-previously-announced-refinancing-transaction-rdnt-20210426monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-a-proposed-refinancing-transaction-for-its-611-million-senior-secured-ter-rdnt-20210406monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-results-with-record-revenue-and-adjusted-ebitda-and-releases-rdnt-20210308monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-demonstrating-strong-recovery-from-the-covi-rdnt-20201109monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-expands-its-revolving-credit-facility-to-195-million-rdnt-20200831monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-as-a-result-of-taking-immediate-expense-an-rdnt-20200810monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-and-announces-strong-liquidity-position-as--rdnt-20200511monthly0.5https://www.biopharmawatch.com/news/RDNT/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-dr-howard-g-berger-president-and-chief-executive-rdnt-20200313monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-record-fourth-quarter-and-full-year-2019-results-and-releases-2020-financia-rdnt-20200312monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-and-reaffirms-previously-announced-2019-gui-rdnt-20191112monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-and-increases-financial-guidance-levels-re-rdnt-20190808monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-including-record-revenue-and-adjusted-ebitd-rdnt-20190509monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-record-fourth-quarter-and-full-year-2018-results-and-releases-2019-financia-rdnt-20190314monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-and-reaffirms-previously-announced-2018-gui-rdnt-20181109monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-to-include-record-revenue-and-reaffirms-gu-rdnt-20180809monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-severe-weather-in-the-northeast-impacted-to-rdnt-20180509monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-record-fourth-quarter-and-full-year-2017-results-and-releases-2018-financia-rdnt-20180308monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-and-reaffirms-previously-announced-2017-gui-rdnt-20171109monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-the-completion-of-an-amendment-to-its-first-lien-credit-facilities-and-th-rdnt-20170822monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-to-include-record-revenue-and-ebitda-the-a-rdnt-20170808monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-inc-2006-equity-incentive-plan-amended-and-restated-as-of-rdnt-20170613monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-and-reaffirms-2017-guidance-ranges-total-ne-rdnt-20170510monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-record-fourth-quarter-and-full-year-2016-results-and-releases-2017-financia-rdnt-20170314monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-amendment-to-first-lien-credit-facilities-rdnt-20170202monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-and-reaffirms-previously-announced-2016-gui-rdnt-20161109monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-and-reaffirms-previously-announced-2016-gu-rdnt-20160809monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-the-closing-of-amended-and-restated-602-5-million-first-lien-credit-facil-rdnt-20160701monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-a-proposed-refinancing-of-its-444-8-million-senior-secured-first-lien-ter-rdnt-20160602monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-announces-its-first-health-system-joint-ven-rdnt-20160510monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-and-full-year-2015-results-and-releases-2016-financial-guida-rdnt-20160314monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-third-quarter-financial-results-total-net-revenue-revenue-increased-13-2-to-rdnt-20151109monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-expands-its-new-york-city-metropolitan-area-presence-through-the-acquisition-of-dia-rdnt-20151016monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-second-quarter-financial-results-and-reaffirms-previously-announced-2015-gu-rdnt-20150810monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-and-adjusts-upwards-2015-guidance-ranges-de-rdnt-20150511monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-secures-additional-75-million-as-part-of-its-existing-senior-secured-credit-facilit-rdnt-20150430monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-and-record-full-year-2014-results-and-releases-2015-financia-rdnt-20150316monthly0.5https://www.biopharmawatch.com/news/RDNT/press-release-dated-rdnt-20141106monthly0.5https://www.biopharmawatch.com/news/RDNT/99-1-press-release-dated-rdnt-20140808monthly0.5https://www.biopharmawatch.com/news/RDNT/press-release-dated-rdnt-20140509monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-redemption-of-remaining-10-3-8-senior-notes-and-satisfaction-and-discharg-rdnt-20140425monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-expiration-of-its-tender-offer-and-consent-solicitation-for-its-10-3-8-se-rdnt-20140404monthly0.5https://www.biopharmawatch.com/news/RDNT/second-amendment-agreement-dated-as-of-rdnt-20140325monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-announces-completion-of-its-previously-announced-senior-debt-refinancing-and-receip-rdnt-20140325monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-commences-tender-offer-and-consent-solicitation-for-10-3-8-senior-notes-due-2018-rdnt-20140307monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-proposed-refinancing-transaction-rdnt-20140306monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-and-full-year-2013-results-releases-2014-financial-guidance--rdnt-20140303monthly0.5https://www.biopharmawatch.com/news/RDNT/press-release-dated-rdnt-20131216monthly0.5https://www.biopharmawatch.com/news/RDNT/99-1-press-release-dated-rdnt-20131111monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-and-reaffirms-2013-full-year-guidance-servi-rdnt-20130510monthly0.5https://www.biopharmawatch.com/news/RDNT/first-amendment-agreement-dated-as-of-rdnt-20130403monthly0.5https://www.biopharmawatch.com/news/RDNT/issued-by-radnet-inc-on-rdnt-20130320monthly0.5https://www.biopharmawatch.com/news/RDNT/press-release-dated-rdnt-20130312monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-enters-the-new-york-city-marketplace-through-the-acquisition-of-lenox-hill-radiolog-rdnt-20130102monthly0.5https://www.biopharmawatch.com/news/RDNT/press-release-dated-rdnt-20121109monthly0.5https://www.biopharmawatch.com/news/RDNT/credit-and-guaranty-agreement-dated-as-of-rdnt-20121010monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-launches-a-refinancing-of-its-senior-credit-facilities-rdnt-20120918monthly0.5https://www.biopharmawatch.com/news/RDNT/press-release-dated-rdnt-20120809monthly0.5https://www.biopharmawatch.com/news/RDNT/99-1-press-release-dated-rdnt-20120510monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-record-full-year-2011-and-fourth-quarter-results-and-releases-2012-financia-rdnt-20120308monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-quarterly-financial-results-and-reaffirms-2011-full-year-guidance-revenue-w-rdnt-20111109monthly0.5https://www.biopharmawatch.com/news/RDNT/99-1-for-immediate-release-radnet-acquires-the-united-states-imaging-operations-of-cml-hea-rdnt-20111108monthly0.5https://www.biopharmawatch.com/news/RDNT/press-release-dated-rdnt-20110809monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-first-quarter-financial-results-and-reaffirms-2011-full-year-guidance-reven-rdnt-20110510monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-completes-the-previously-announced-acquisition-of-imaging-centers-in-maryland-from--rdnt-20110408monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-record-2010-fourth-quarter-results-and-releases-2011-financial-guidance-for-rdnt-20110309monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-to-acquire-imaging-centers-in-maryland-from-diagnostic-health-corporation-rdnt-20110307monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-completes-the-previously-announced-acquisition-of-imaging-on-call-rdnt-20110104monthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-to-enter-the-teleradiology-and-remote-interpretation-business-through-the-acquisiti-rdnt-20101222monthly0.5https://www.biopharmawatch.com/news/OSCR/oscar-health-inc-news-release-oscar-health-prices-upsized-355-000-000-convertible-senior-s-oscr-20250916monthly0.5https://www.biopharmawatch.com/news/OSCR/oscar-health-inc-news-release-oscar-health-launches-proposed-convertible-senior-subordinat-oscr-20250915monthly0.5https://www.biopharmawatch.com/news/OSCR/oscar-health-inc-ir-hioscar-com-news-release-oscar-health-inc-announces-that-mark-bertolin-oscr-20231120monthly0.5https://www.biopharmawatch.com/news/OSCR/oscar-health-inc-ir-hioscar-com-news-release-oscar-health-delivers-historic-growth-issues--oscr-20220127monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-second-quarter-2026-financial-results-record-revenue-of-11-twst-20260504monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-first-quarter-2026-financial-results-record-revenue-of-103-twst-20260202monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-fourth-quarter-and-full-year-fiscal-2025-financial-results-twst-20251114monthly0.5https://www.biopharmawatch.com/news/TWST/document-twist-bioscience-appoints-trynka-shineman-blake-to-board-of-directors-south-san-f-twst-20250806monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-third-quarter-2025-financial-results-record-revenue-of-96--twst-20250804monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-second-quarter-2025-financial-results-record-revenue-of-92-twst-20250505monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-first-quarter-2025-financial-results-record-revenue-of-88--twst-20250203monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-fourth-quarter-and-full-year-fiscal-2024-financial-results-twst-20241118monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-third-quarter-2024-financial-results-record-revenue-of-81--twst-20240802monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-second-quarter-2024-financial-results-record-revenue-of-75-twst-20240502monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-first-quarter-2024-financial-results-record-revenue-of-71--twst-20240202monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-appoints-adam-laponis-as-chief-financial-officer-south-san-francisco-twst-20240105monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-fourth-quarter-and-full-year-fiscal-2023-financial-results-twst-20231117monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-third-quarter-2023-financial-results-record-revenue-of-63--twst-20230804monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-appoints-robert-werner-as-chief-accounting-officer-twst-20230523monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-second-quarter-2023-financial-results-record-revenue-of-60-twst-20230505monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-first-quarter-2023-financial-results-revenue-of-54-2m-in-1-twst-20230203monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-fourth-quarter-and-full-year-fiscal-2022-financial-results-twst-20221118monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-addresses-misleading-short-seller-report-twist-to-report-fiscal-q4-and-fu-twst-20221115monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-promotes-patrick-finn-ph-d-to-president-and-chief-operating-officer-dr-fi-twst-20221026monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-fiscal-third-quarter-2022-financial-results-record-revenue-of-56--twst-20220805monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-second-quarter-2022-financial-results-record-revenue-of-48-1m-in--twst-20220505monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-announces-promotions-and-changes-to-executive-leadership-team-twst-20220421monthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-reports-first-quarter-2022-financial-results-record-revenues-of-42m-incre-twst-20220204monthly0.5https://www.biopharmawatch.com/news/IRTC/three-months-ended-irtc-20260430monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-continue-irtc-20260219monthly0.5https://www.biopharmawatch.com/news/IRTC/three-months-ended-september-30-nine-months-ended-irtc-20251030monthly0.5https://www.biopharmawatch.com/news/IRTC/three-months-ended-june-30-six-months-ended-irtc-20250731monthly0.5https://www.biopharmawatch.com/news/IRTC/adjusted-net-income-loss-reconciliation-net-loss-as-reported-1-1-333-38-699-113-289-123-40-irtc-20250220monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-in-thous-irtc-20241030monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-unaudite-irtc-20240801monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-unaudite-irtc-20240502monthly0.5https://www.biopharmawatch.com/news/IRTC/dealer-name-and-address-march-2024-to-irhythm-technologies-inc-699-8-th-street-suite-600-s-irtc-20240308monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-prices-upsized-offering-of-575-0-million-of-1-50-convertible-senior-notes-due-2029-irtc-20240307monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-announces-proposed-offering-of-450-0-million-of-convertible-senior-notes-san-franc-irtc-20240304monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-in-thous-irtc-20240222monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-shares-preliminary-fourth-quarter-2023-highlights-and-business-update-irtc-20240108monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-unaudite-irtc-20231102monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-unaudite-irtc-20230803monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-unaudite-irtc-20230504monthly0.5https://www.biopharmawatch.com/news/IRTC/reconciliation-of-gaap-to-non-gaap-financial-information-three-months-ended-december-31-ye-irtc-20230223monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-unaudite-irtc-20221101monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-unaudite-irtc-20220805monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-gaap-to-non-gaap-financial-information-unaudite-irtc-20220505monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-amendment-to-term-loan-agreement-provides-enhanced-credit-f-irtc-20220329monthly0.5https://www.biopharmawatch.com/news/IRTC/document-irhythm-technologies-announces-kevin-king-to-retire-from-board-of-directors-irtc-20220314monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-net-loss-to-adjusted-ebitda-unaudited-in-thousa-irtc-20220223monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-net-loss-to-adjusted-ebitda-unaudited-in-thousa-irtc-20211104monthly0.5https://www.biopharmawatch.com/news/IRTC/document-irhythm-technologies-announces-changes-to-its-board-of-directors-karen-ling-appoi-irtc-20211012monthly0.5https://www.biopharmawatch.com/news/IRTC/document-irhythm-technologies-names-quentin-blackford-president-and-chief-executive-office-irtc-20210913monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-net-loss-to-adjusted-ebitda-unaudited-in-thousa-irtc-20210805monthly0.5https://www.biopharmawatch.com/news/IRTC/the-company-also-reiterated-its-second-quarter-2021-guidance-of-approximately-4-sequential-irtc-20210601monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-net-loss-to-adjusted-ebitda-unaudited-in-thousa-irtc-20210506monthly0.5https://www.biopharmawatch.com/news/IRTC/the-first-quarter-2021-financial-results-included-in-this-release-are-preliminary-and-ther-irtc-20210412monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-net-loss-to-adjusted-ebitda-unaudited-in-thousa-irtc-20210225monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-provides-statement-on-medicare-administrative-contractor-mac-novitas--irtc-20210129monthly0.5https://www.biopharmawatch.com/news/IRTC/cardioverter-defibrillator-and-cardiac-resynchronization-businesses-he-also-led-the-compan-irtc-20201214monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-comments-on-centers-for-medicare-and-medicaid-services-2021-medicare--irtc-20201202monthly0.5https://www.biopharmawatch.com/news/IRTC/leigh-salvo-saige-smith-415-937-5404-262-289-7065-investors-irhythmtech-com-irhythm-highwi-irtc-20201116monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-reconciliation-of-net-loss-to-adjusted-ebitda-unaudited-in-thousa-irtc-20201105monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-condensed-consolidated-statements-of-operations-unaudited-in-thou-irtc-20200807monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-comments-on-the-centers-for-medicare-and-medicaid-services-2021-propo-irtc-20200804monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-cfo-transition-irtc-20200604monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-condensed-consolidated-statements-of-operations-unaudited-in-thou-irtc-20200507monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-the-appointment-of-renee-budig-to-its-board-of-directors-irtc-20200423monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-update-on-covid-19-impact-and-response-announces-preliminar-irtc-20200409monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-consolidated-statements-of-operations-in-thousands-except-share-a-irtc-20200227monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-files-quarterly-report-on-form-10-q-for-third-quarter-2019-and-update-irtc-20191223monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-receives-notification-of-deficiency-from-nasdaq-related-to-delayed-qu-irtc-20191119monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-condensed-consolidated-statements-of-operations-unaudited-in-thou-irtc-20191105monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-announces-collaboration-with-verily-to-develop-health-management-solutions-for-atr-irtc-20190904monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-condensed-consolidated-statements-of-operations-and-comprehensive-irtc-20190507monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-fourth-quarter-and-full-year-2018-financial-results-and-pro-irtc-20190212monthly0.5https://www.biopharmawatch.com/news/IRTC/irtc-ex991-17-pptx-htm-j-p-morgan-healthcare-conference-january-2019-certain-data-in-this--irtc-20190109monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-third-quarter-financial-results-irtc-20181030monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-second-quarter-financial-results-irtc-20180801monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-names-karim-karti-as-chief-operating-officer-irtc-20180627monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-appoints-ucla-and-cedars-sinai-professor-c-noel-bairey-merz-m-d-to-it-irtc-20180410monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-fourth-quarter-and-full-year-2017-financial-results-and-pro-irtc-20180214monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-third-quarter-2017-financial-results-and-raises-guidance-fo-irtc-20171101monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-condensed-consolidated-statements-of-operations-unaudited-in-thou-irtc-20170802monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-names-uc-berkeley-faculty-member-bruce-g-bodaken-and-duke-university--irtc-20170719monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-first-quarter-2017-financial-results-raises-guidance-for-fu-irtc-20170503monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-inc-condensed-consolidated-statements-of-operations-and-comprehensive-irtc-20170215monthly0.5https://www.biopharmawatch.com/news/IRTC/irhythm-technologies-announces-third-quarter-2016-financial-results-and-provides-full-year-irtc-20161205monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260613monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260610monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260605monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260603monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260601monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260530monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260528monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260518monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260516monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260512monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260429monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260424monthly0.5https://www.biopharmawatch.com/news/RDY/exhibits-99-1-dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-03-rdy-20260416monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260414monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260407monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260326monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260324monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260321monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260317monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260313monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260310monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260306monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260227monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260224monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260218monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260212monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260209monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260202monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260127monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260124monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260121monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20251231monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260114monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260110monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260108monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20260101monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251223monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251216monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251212monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251209monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251202monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251126monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251124monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251118monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251114monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251110monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251030monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251025monthly0.5https://www.biopharmawatch.com/news/RDY/securities-and-exchange-commission-rdy-20251024monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20251024monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251021monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20251013monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250922monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250918monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250916monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250913monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250910monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250906monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250904monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250902monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250829monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250826monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250820monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250813monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250808monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250730monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250725monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250723monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20250723monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250721monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250718monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250715monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250702monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250630monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250623monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250620monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250614monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250611monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250607monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250605monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250603monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250528monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250524monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250520monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250517monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250515monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250510monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyd-erabad-500-034-telangana-i-rdy-20250424monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250416monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250414monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250404monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250322monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250313monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250307monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250228monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250225monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250214monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250212monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250206monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250204monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250202monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250129monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250124monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20250123monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250122monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250109monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20250107monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241227monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241223monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241220monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241206monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241203monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241201monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241126monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241120monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241114monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241111monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241106monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20241105monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241104monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241029monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241021monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241014monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241010monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241008monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241005monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20241002monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240930monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240927monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240922monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240920monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240916monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240912monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240910monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240906monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240831monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240829monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240823monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240814monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240812monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240807monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240805monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240801monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240729monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20240727monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20240729monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240727monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240724monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240718monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240712monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240710monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-0-34-telangana-i-rdy-20240704monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-0-34-telangana-i-rdy-20240702monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240628monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240621monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240614monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240612monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240610monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240607monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240604monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240602monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240531monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240529monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240524monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240522monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240517monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240515monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240513monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240508monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240506monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240503monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240430monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240425monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240423monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240420monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240418monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240413monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240410monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240405monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240327monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240322monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240319monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240315monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240313monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240301monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240228monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240226monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240222monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240217monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240214monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240212monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240210monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240205monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240202monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240131monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20240130monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20240130monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240129monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240119monthly0.5https://www.biopharmawatch.com/news/RDY/national-stock-exchange-of-india-ltd-rdy-20240116monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240116monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240105monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20240103monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231229monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231214monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231212monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231209monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231206monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231201monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231121monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231117monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231110monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231107monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231028monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20231030monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20231027monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231026monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231016monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231012monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20231009monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230928monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230922monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230919monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratores-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-ind-rdy-20230919monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230916monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230907monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230905monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230829monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230824monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230814monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230810monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230808monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230804monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230731monthly0.5https://www.biopharmawatch.com/news/RDY/national-stock-exchange-of-india-ltd-rdy-20230728monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230727monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddys-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-ind-rdy-20230726monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20230727monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20230726monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230720monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230717monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230715monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230712monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230705monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230701monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230623monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratorie-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-ind-rdy-20230623monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230619monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230616monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230614monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230612monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230605monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230531monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230522monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230515monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230512monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230510monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratorie-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-ind-rdy-20230510monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230505monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230422monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230407monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230323monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230320monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230316monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230311monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230228monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230216monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230208monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230203monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230130monthly0.5https://www.biopharmawatch.com/news/RDY/securities-and-exchange-commission-rdy-20230127monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230126monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20230125monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20230125monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230120monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230113monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20230106monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221229monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221227monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221223monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221219monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221217monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221206monthly0.5https://www.biopharmawatch.com/news/RDY/national-stock-exchange-of-india-ltd-rdy-20221128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221122monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221116monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221103monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221101monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221029monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20221028monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20221028monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221021monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221013monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20221011monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220928monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220922monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220920monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220917monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220910monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220907monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220825monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220806monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220803monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220801monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20220801monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220729monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20220728monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20220728monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220727monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220722monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220713monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220711monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220708monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220706monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220629monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220624monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220621monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220617monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220614monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220609monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220603monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220527monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220524monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220520monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20220519monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220511monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220425monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220422monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220420monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220408monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220405monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220401monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220329monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220317monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220228monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220225monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220221monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220214monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220211monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220209monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220203monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220207monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220201monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220129monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20220128monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20220128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220118monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220110monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20220107monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20211228monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20211218monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20211210monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20211108monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20211105monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20211105monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20211030monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20211029monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20211019monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20211015monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20211007monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210924monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210922monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210909monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210907monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210904monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210902monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210831monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210809monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210804monthly0.5https://www.biopharmawatch.com/news/RDY/please-find-enclosed-a-press-release-on-rdy-20210803monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210802monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210728monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20210727monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-rdy-20210727monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-foreign-private-issuer-pursuant-rdy-20210727monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210707monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210703monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210630monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210628monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210625monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210622monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210615monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210603monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210523monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210519monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210515monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-contact-8-2-337-road-no-3-banjara-hills-investor-relations-med-rdy-20210514monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210511monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210508monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210430monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210423monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210413monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210407monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210401monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210329monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210319monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210310monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210301monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210222monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210219monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210217monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20210203monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210202monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210131monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20210129monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210127monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210115monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210111monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20210108monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201229monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201218monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201209monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201201monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201119monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201112monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201029monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20201029monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20201028monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201022monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201020monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201017monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201012monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201005monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201003monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20201001monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200927monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200923monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200917monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200909monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200907monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200903monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200828monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200819monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200817monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200811monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200730monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20200729monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20200729monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200727monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200720monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200714monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200707monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200701monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200627monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200625monthly0.5https://www.biopharmawatch.com/news/RDY/securities-and-exchange-commission-rdy-20200623monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200619monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200617monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200613monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200610monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200530monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200528monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200521monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20200520monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200516monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200508monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200506monthly0.5https://www.biopharmawatch.com/news/RDY/the-secretary-executive-director-rdy-20200501monthly0.5https://www.biopharmawatch.com/news/RDY/the-secretary-executive-director-rdy-20200429monthly0.5https://www.biopharmawatch.com/news/RDY/please-find-enclosed-a-press-release-on-dr-rdy-20200427monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200414monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200409monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200327monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200323monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200320monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200317monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200314monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200312monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200305monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200228monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200220monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200216monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200214monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200212monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200207monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20200131monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20200127monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200113monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200110monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20200103monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191231monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191227monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191206monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191204monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191202monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191130monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191125monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191122monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191111monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191104monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20191101monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-contact-8-2-337-road-no-3-banjara-hills-investor-relations-med-rdy-20191101monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191101monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191026monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191023monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191014monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20191005monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190926monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190924monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190916monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190912monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190906monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190821monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190819monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190809monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190801monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190726monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190730monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20190729monthly0.5https://www.biopharmawatch.com/news/RDY/investor-relations-media-relations-dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-h-rdy-20190729monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190723monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190720monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190712monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190710monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190708monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190703monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190627monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190625monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190622monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190614monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190612monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190610monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190607monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190603monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190530monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20190517monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190517monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190515monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190506monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190402monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190419monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190417monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190415monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190413monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190329monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190327monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190324monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190322monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190314monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190222monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190220monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190216monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190212monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190208monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20190201monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20190201monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190131monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190124monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190115monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190111monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190107monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20190103monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181227monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181224monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181215monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181211monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181128monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181120monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181116monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181112monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181102monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-boa-rdy-20181101monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181030monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-contact-8-2-337-road-no-3-banjara-hills-investor-relations-med-rdy-20181026monthly0.5https://www.biopharmawatch.com/news/RDY/dr-raddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181025monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181015monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181009monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181003monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20181001monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180925monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180912monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180823monthly0.5https://www.biopharmawatch.com/news/RDY/review-report-of-independent-registered-public-accounting-firm-to-board-of-directors-and-s-rdy-20180806monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180727monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-contact-8-2-337-road-no-3-banjara-hills-investor-relations-med-rdy-20180726monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180720monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180714monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180711monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180709monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180707monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180705monthly0.5https://www.biopharmawatch.com/news/RDY/notice-237-notice-of-annual-general-meeting-notice-is-hereby-given-that-the-34th-annual-ge-rdy-20180706monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180702monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180629monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180623monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180619monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180616monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabed-500-034-telangana-in-rdy-20180614monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180612monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180609monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180605monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180602monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180525monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20180522monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180425monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180414monthly0.5https://www.biopharmawatch.com/news/RDY/dr-r-eddy-s-l-aboratories-l-td-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-rdy-20180410monthly0.5https://www.biopharmawatch.com/news/RDY/dr-r-eddy-s-l-aboratories-l-td-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-rdy-20180402monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180329monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180326monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180316monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180312monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180309monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180225monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180219monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-shar-rdy-20180202monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180202monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-contact-8-2-337-road-no-3-banjara-hills-investor-relations-med-rdy-20180125monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180124monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180120monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180116monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180106monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20180102monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20171227monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20171221monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20171219monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20171211monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20171201monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20171129monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20171102monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-the-board-of-directors-and-shareho-rdy-20171108monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20171031monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-rood-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20171012monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20170929monthly0.5https://www.biopharmawatch.com/news/RDY/aurigene-a-wholly-owned-subsidiary-of-dr-reddy-s-and-curis-announce-ca-170-program-update--rdy-20170912monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-announces-the-launch-of-bupropion-hydrochloride-extended-release-t-rdy-20170906monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170901monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170828monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170821monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170810monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-the-board-of-directors-and-shareho-rdy-20170808monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170728monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20170728monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170721monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20170717monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-limited-notice-of-annual-general-meeting-notice-is-hereby-given-th-rdy-20170707monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170615monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170613monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-announces-the-launch-of-bivalirudin-for-injection-in-the-u-s-marke-rdy-20170606monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-limited-to-present-at-the-jefferies-2017-global-healthcare-confere-rdy-20170606monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-announces-usfda-approval-for-the-launch-of-doxorubicin-hydrochlori-rdy-20170517monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20170512monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20170427monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20170426monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20170425monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170403monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170321monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20170221monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-the-board-of-directors-and-shareho-rdy-20170210monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20170204monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-to-release-q3-fy17-results-on-rdy-20170124monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-announces-the-launch-of-nystatin-and-triamcinolone-acetonide-cream-rdy-20170110monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20170110monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-the-board-of-directors-and-shareho-rdy-20161110monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-announces-new-strategic-deal-with-gland-pharma-in-the-u-s-market-h-rdy-20161026monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20161025monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relation-s-media-relation-s-8-2-337-road-no-3-banjara-rdy-20161010monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20161011monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-launches-nitroglycerin-sublingual-tablets-usp-in-the-u-s-market-hy-rdy-20160829monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-the-board-of-directors-and-shareho-rdy-20160812monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-completes-acquisition-of-product-portfolio-from-teva-hyderabad-india-rdy-20160803monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20160718monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20160726monthly0.5https://www.biopharmawatch.com/news/RDY/ref-ii-ca-com-20939-2016-rdy-20160622monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-limited-announces-filing-of-annual-report-on-form-20-f-hyderabad-i-rdy-20160624monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20160606monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20160617monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20160525monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-to-acquire-product-portfolio-from-teva-for-us-market-hyderabad-india-rdy-20160611monthly0.5https://www.biopharmawatch.com/news/RDY/hyderabad-india-and-princeton-nj-usa-rdy-20160601monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-enters-the-branded-consumer-health-arena-through-the-acquisition-of-six-otc-bra-rdy-20160525monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-investor-relations-media-relations-8-2-337-road-no-3-banjara-h-rdy-20160512monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20160511monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20160418monthly0.5https://www.biopharmawatch.com/news/RDY/zembrace-tm-symtouch-tm-sumatriptan-injection-3-mg-approved-by-the-fda-in-january-2016-for-rdy-20160419monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-limited-registered-office-8-2-337-road-no-3-banjara-hills-hyderaba-rdy-20160413monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20160407monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20160402monthly0.5https://www.biopharmawatch.com/news/RDY/hyderabad-india-rdy-20160331monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-and-xenoport-enter-into-a-u-s-licensing-agreement-for-xp23829-hyde-rdy-20160328monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-limited-q3-fy16-earnings-call-transcript-page-1-of-21-dr-reddy-s-l-rdy-20160314monthly0.5https://www.biopharmawatch.com/news/RDY/hyderabad-india-rdy-20160311monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20160301monthly0.5https://www.biopharmawatch.com/news/RDY/nse-drreddy-bse-500124-nyse-rdy-the-board-of-directors-of-the-company-in-their-meeting-hel-rdy-20160217monthly0.5https://www.biopharmawatch.com/news/RDY/hyderabad-india-princeton-nj-usa-rdy-20160201monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20160209monthly0.5https://www.biopharmawatch.com/news/RDY/hyderabad-india-princeton-nj-usa-rdy-20160129monthly0.5https://www.biopharmawatch.com/news/RDY/report-of-independent-registered-public-accounting-firm-the-board-of-directors-and-shareho-rdy-20160209monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20160108monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500-034-telangana-in-rdy-20151208monthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddy-s-laboratories-ltd-8-2-337-road-no-3-banjara-hills-hyderabad-500034-telangana-ind-rdy-20151130monthly0.5https://www.biopharmawatch.com/news/INDV/first-amendment-to-note-purchase-agreement-this-first-amendment-to-note-purchase-agreement-indv-20260121monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-provides-full-year-2026-financial-guidance-and-business-update-total-net-revenue--indv-20260108monthly0.5https://www.biopharmawatch.com/news/INDV/this-document-is-important-and-requires-your-immediate-attention-part-ii-of-this-document--indv-20251114monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-inclusion-in-the-u-s-russell-2000-and-3000-indexes-richmond-va-indv-20250630monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-appoints-tony-kingsley-to-the-board-of-directors-richmond-va-indv-20250624monthly0.5https://www.biopharmawatch.com/news/INDV/investor-presentation-june-2025-for-investor-relations-purposes-only-i-n-v-e-s-t-o-r-p-r-e-indv-20250602monthly0.5https://www.biopharmawatch.com/news/INDV/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-market--indv-20250602monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-result-of-annual-general-meeting-agm-indv-20250508monthly0.5https://www.biopharmawatch.com/news/INDV/document-indv-20250220monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20241210monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-total-voting-rights-and-capital-in-accordance-with-the-fca-s-disc-indv-20241201monthly0.5https://www.biopharmawatch.com/news/INDV/note-purchase-agreement-rbp-global-holdings-limited-the-issuer-which-is-an-indirect-wholly-indv-20241104monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-responds-to-publication-of-a-letter-by-oaktree-capital-management-to-the-board-of-indv-20241108monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-completes-refinance-of-secured-term-loan-enhances-liquidity-and-financial-flexibi-indv-20241105monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20241105monthly0.5https://www.biopharmawatch.com/news/INDV/document-indv-20241024monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240903monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-total-voting-rights-and-capital-in-accordance-with-the-fca-s-disc-indv-20240901monthly0.5https://www.biopharmawatch.com/news/INDV/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-the-market--indv-20240725monthly0.5https://www.biopharmawatch.com/news/INDV/document-indv-20240725monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240723monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20240628monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20240624monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240620monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240617monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-participate-in-upcoming-investor-events-slough-uk-and-richmond-va-indv-20240516monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-result-of-annual-general-meeting-agm-indv-20240509monthly0.5https://www.biopharmawatch.com/news/INDV/document-indv-20240425monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240412monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240410monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-announce-q1-2024-results-and-host-webcast-on-april-25-th-slough-uk-and-richmon-indv-20240408monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240408monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240328monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240326monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-notification-and-public-disclosure-of-transactions-by-persons-dis-indv-20240315monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-notification-and-public-disclosure-of-transactions-by-persons-dis-indv-20240312monthly0.5https://www.biopharmawatch.com/news/INDV/securities-and-exchange-commission-indv-20240313monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20240312monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-notification-and-public-disclosure-of-transactions-by-persons-dis-indv-20240305monthly0.5https://www.biopharmawatch.com/news/INDV/document-indv-20240222monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240202monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-total-voting-rights-and-capital-in-accordance-with-the-fca-s-disc-indv-20240201monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240129monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-director-pdmr-shareholdings-correction-the-following-amendment-ha-indv-20240125monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240112monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240110monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240108monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20240103monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20231208monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-indv-20231206monthly0.5https://www.biopharmawatch.com/news/INDV/document-indv-20231109monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-participate-in-upcoming-investor-events-slough-uk-and-richmond-va-indv-20230906monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-reaches-agreement-with-end-payor-class-to-resolve-their-antitrust-multi-district--indv-20230821monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-total-voting-rights-and-capital-in-accordance-with-the-fca-s-disc-indv-20230801monthly0.5https://www.biopharmawatch.com/news/INDV/document-the-information-contained-within-this-announcement-is-deemed-by-the-company-to-co-indv-20230727monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20230726monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20230724monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20230710monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20230705monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-the-company-indivior-plc-confirms-that-jerome-lande-non-executive-director-ha-indv-20230630monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20230629monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-announce-q2-and-h1-2023-results-on-july-27-th-slough-uk-and-richmond-va-indv-20230627monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-indv-20230621monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20230616monthly0.5https://www.biopharmawatch.com/news/INDV/tr-1-standard-form-for-notification-of-major-holdings-1-issuer-details-isin-gb00bn4ht335-i-indv-20230614monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-commence-trading-on-nasdaq-company-to-ring-opening-bell-june-14-to-bring-aware-indv-20230612monthly0.5https://www.biopharmawatch.com/news/OGN/felicia-bisaro-investor-contacts-jennifer-halchak-646-703-1807-201-275-2711-kate-vossen-re-ogn-20260430monthly0.5https://www.biopharmawatch.com/news/OGN/felicia-bisaro-investor-contacts-jennifer-halchak-646-703-1807-201-275-2711-kate-vossen-re-ogn-20260212monthly0.5https://www.biopharmawatch.com/news/OGN/felicia-bisaro-investor-contacts-jennifer-halchak-646-703-1807-201-275-2711-kate-vossen-re-ogn-20251110monthly0.5https://www.biopharmawatch.com/news/OGN/felicia-bisaro-investor-contacts-jennifer-halchak-646-703-1807-201-275-2711-kate-vossen-re-ogn-20251027monthly0.5https://www.biopharmawatch.com/news/OGN/felicia-bisaro-investor-contacts-jennifer-halchak-646-703-1807-201-275-2711-kate-vossen-re-ogn-20250805monthly0.5https://www.biopharmawatch.com/news/OGN/us-food-and-drug-administration-fda-grants-interchangeability-designation-to-samsung-bioep-ogn-20250527monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-kate-vossen-732-675-8448-201--ogn-20250501monthly0.5https://www.biopharmawatch.com/news/OGN/felicia-bisaro-investor-contacts-jennifer-halchak-646-703-1807-201-275-2711-kate-vossen-73-ogn-20250415monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-201-275-2711-kate-vossen-rene-ogn-20250213monthly0.5https://www.biopharmawatch.com/news/OGN/felicia-bisaro-investor-contacts-jennifer-halchak-646-703-1807-201-275-2711-kim-hamilton-9-ogn-20241105monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-201-275-2711-kate-vossen-rene-ogn-20241031monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-201-275-2711-kate-vossen-rene-ogn-20240806monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-201-275-2711-kate-vossen-rene-ogn-20240502monthly0.5https://www.biopharmawatch.com/news/OGN/the-field-allows-up-to-17-characters-ogn-20240215monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-201-275-2711-kate-vossen-alex-ogn-20231102monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-201-275-2711-kate-vossen-alex-ogn-20230808monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-201-275-2711-kate-vossen-alex-ogn-20230504monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-201-275-2711-kate-vossen-alex-ogn-20230216monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-kate-vossen-732-675-8448-201--ogn-20221103monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-kate-vossen-732-675-8448-201--ogn-20220804monthly0.5https://www.biopharmawatch.com/news/OGN/organon-co-moderator-ali-kevin-ogn-20220505monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-kate-vossen-732-675-8448-201--ogn-20220505monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-kate-vossen-732-675-8448-201--ogn-20220217monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-kate-vossen-732-675-8448-201--ogn-20211112monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-kate-vossen-732-675-8448-201--ogn-20210812monthly0.5https://www.biopharmawatch.com/news/OGN/organon-recommends-stockholders-reject-below-market-mini-tender-offer-by-trc-capital-inves-ogn-20210629monthly0.5https://www.biopharmawatch.com/news/OGN/karissa-peer-investor-contacts-jennifer-halchak-614-314-8094-kate-vossen-732-675-8448-201--ogn-20210603monthly0.5https://www.biopharmawatch.com/news/MMED/minimed-delivers-strong-fourth-quarter-and-full-fiscal-year-2026-financial-results-provide-mmed-20260603monthly0.5https://www.biopharmawatch.com/news/MMED/minimed-announces-closing-of-initial-public-offering-northridge-ca-mmed-20260309monthly0.5https://www.biopharmawatch.com/news/MMSI/summary-of-merit-medical-systems-inc-2026-equity-incentive-plan-the-following-is-a-brief-d-mmsi-20260519monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20260430monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20260224monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-appoints-f-ann-millner-as-chair-of-the-board-and-announces-projected-prelimi-mmsi-20260108monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-provides-update-on-u-s-reimbursement-and-commercial-strategies-for-wrapsody--mmsi-20251113monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20251030monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20250730monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-names-martha-aronson-as-new-president-and-chief-executive-officer-fred-lampr-mmsi-20250630monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20250520monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20250424monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20250225monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-wrapsody-investor-conference-call-remarks-operator-please-standby-we-mmsi-20250128monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20250114monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-1-801-432-2864-sarah-comstock-merit-com-me-mmsi-20241216monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20241101monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20240918monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20240801monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20240701monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-shareholders-elect-silvia-m-perez-as-new-director-experienced-healthcare-vet-mmsi-20240516monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-executive-leadership-team-update-joe-wright-appointed-president-expands-deep-mmsi-20240515monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20240430monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20240228monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20240108monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-pricing-of-upsized-private-offering-of-650-0-million-of-3-00-conve-mmsi-20231206monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-proposed-private-placement-of-550-million-of-convertible-senior-no-mmsi-20231204monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20231026monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20230725monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-sarah-comstock-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20230608monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-new-five-year-senior-secured-credit-agreement-credit-agreement-inc-mmsi-20230607monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20230426monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20230222monthly0.5https://www.biopharmawatch.com/news/MMSI/in-the-united-states-district-court-district-of-utah-steffen-maute-derivatively-on-behalf--mmsi-20221102monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20221026monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20220727monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20220427monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-chief-operating-officer-transition-ronald-a-frost-to-retire-after--mmsi-20220421monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20220224monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20211123monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20211028monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20210729monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20210429monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20210224monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20201110monthly0.5https://www.biopharmawatch.com/news/MMSI/pr-media-inquiries-teresa-johnson-merit-medical-investor-inquiries-mike-piccinino-cfa-irc--mmsi-20201028monthly0.5https://www.biopharmawatch.com/news/MMSI/judy-wagner-patrick-mccarty-corporate-communications-investor-relations-1-801-208-4793-1-8-mmsi-20200729monthly0.5https://www.biopharmawatch.com/news/MMSI/statements-contained-in-this-release-which-are-not-purely-historical-including-without-lim-mmsi-20200715monthly0.5https://www.biopharmawatch.com/news/MMSI/statements-contained-in-this-release-which-are-not-purely-historical-including-without-lim-mmsi-20200423monthly0.5https://www.biopharmawatch.com/news/MMSI/statements-contained-in-this-release-which-are-not-purely-historical-including-without-lim-mmsi-20200403monthly0.5https://www.biopharmawatch.com/news/MMSI/statements-contained-in-this-release-which-are-not-purely-historical-including-without-lim-mmsi-20200224monthly0.5https://www.biopharmawatch.com/news/MMSI/statements-contained-in-this-release-which-are-not-purely-historical-including-without-lim-mmsi-20191121monthly0.5https://www.biopharmawatch.com/news/MMSI/statements-contained-in-this-release-which-are-not-purely-historical-including-without-lim-mmsi-20191030monthly0.5https://www.biopharmawatch.com/news/MMSI/results-or-outcomes-to-be-materially-different-from-those-expressed-or-implied-by-the-forw-mmsi-20180725monthly0.5https://www.biopharmawatch.com/news/MMSI/the-assets-to-be-acquired-are-soft-tissue-core-needle-biopsy-products-currently-sold-by-bd-mmsi-20171116monthly0.5https://www.biopharmawatch.com/news/MMSI/results-or-outcomes-to-be-materially-different-from-those-expressed-or-implied-by-the-forw-mmsi-20170322monthly0.5https://www.biopharmawatch.com/news/MMSI/date-march-2017-contact-anne-marie-wright-vice-president-corporate-communications-phone-80-mmsi-20170320monthly0.5https://www.biopharmawatch.com/news/MMSI/west-merit-parkway-south-jordan-ut-84095-telephone-801-253-1600-fax-801-253-1688-press-rel-mmsi-20150305monthly0.5https://www.biopharmawatch.com/news/MMSI/west-merit-parkway-south-jordan-ut-84095-telephone-801-253-1600-fax-801-253-1688-press-rel-mmsi-20140303monthly0.5https://www.biopharmawatch.com/news/MMSI/west-merit-parkway-south-jordan-ut-84095-telephone-801-253-1600-fax-801-253-1688-press-rel-mmsi-20131007monthly0.5https://www.biopharmawatch.com/news/MMSI/west-merit-parkway-south-jordan-ut-84095-telephone-801-253-1600-fax-801-253-1688-press-rel-mmsi-20110721monthly0.5https://www.biopharmawatch.com/news/MMSI/west-merit-parkway-south-jordan-ut-84095-telephone-801-253-1600-fax-801-253-1688-press-rel-mmsi-20110616monthly0.5https://www.biopharmawatch.com/news/MMSI/west-merit-parkway-south-jordan-ut-84095-telephone-801-253-1600-fax-801-253-1688-press-rel-mmsi-20110421monthly0.5https://www.biopharmawatch.com/news/MMSI/west-merit-parkway-south-jordan-ut-84095-telephone-801-253-1600-fax-801-253-1688-press-rel-mmsi-20110414monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-sale-of-sevasemten-for-up-to-2-65-billion-strengthening-ba-ewtx-20260601monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-first-quarter-2026-financial-results-and-advances-clinical-p-ewtx-20260507monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-with-str-ewtx-20260226monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-to-its-boar-ewtx-20251120monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-appointment-of-michael-nofi-as-chief-financial-officer-and-ewtx-20251110monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-hig-ewtx-20251106monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-hi-ewtx-20250807monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-first-quarter-2025-financial-results-and-recent-business-hig-ewtx-20250508monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-pricing-of-200-million-underwritten-offering-of-common-sto-ewtx-20250402monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-positive-top-line-results-from-phase-2-cirrus-hcm-four-wee-ewtx-20250402monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-rece-ewtx-20250303monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-positive-topline-results-from-the-canyon-phase-2-trial-of--ewtx-20241216monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-hig-ewtx-20241107monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-second-quarter-2024-financial-results-and-recent-business-hi-ewtx-20240808monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-first-quarter-2024-financial-results-and-recent-business-hig-ewtx-20240509monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-appoints-arlene-morris-to-its-board-of-directors-boulder-colo-ewtx-20240507monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-rece-ewtx-20240222monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-pricing-of-240-million-underwritten-offering-of-common-sto-ewtx-20240119monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-third-quarter-2023-financial-results-and-recent-business-hig-ewtx-20231109monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-hi-ewtx-20230810monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-first-quarter-2023-financial-results-and-recent-business-hig-ewtx-20230511monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-appoints-industry-veteran-jonathan-c-fox-m-d-ph-d-facc-to-its-board--ewtx-20230306monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-rece-ewtx-20230223monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-third-quarter-2022-financial-results-announced-positive-6-mo-ewtx-20221103monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-fda-authorization-for-phase-2-clinical-trial-of-edg-5506-f-ewtx-20220907monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-second-quarter-2022-financial-results-announced-positive-2-m-ewtx-20220804monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-first-quarter-2022-financial-results-completed-enrollment-of-ewtx-20220511monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-announce-ewtx-20220224monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-positive-topline-results-from-the-edg-5506-phase-1b-clinic-ewtx-20220105monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-third-quarter-2021-financial-results-announced-positive-topl-ewtx-20211110monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-positive-topline-results-from-the-edg-5506-phase-1-multipl-ewtx-20211028monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-second-quarter-2021-financial-results-continued-to-advance-a-ewtx-20210809monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-first-quarter-2021-financial-results-and-recent-highlights-c-ewtx-20210513monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-announces-closing-of-initial-public-offering-and-exercise-in-full-of-ewtx-20210330monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-preliminary-full-year-2023-results-acquisition-of-c2i-genomics-to-add-m-vcyt-20240108monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-appoints-rebecca-chambers-as-executive-vice-president-and-chief-financial-officer-vcyt-20210712monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-to-acquire-haliodx-positioning-for-global-cancer-diagnostics-growth-fueling-growt-vcyt-20210601monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-pricing-of-upsized-public-offering-of-7-432-433-shares-of-common-stock--vcyt-20210204monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-to-acquire-decipher-biosciences-further-solidifies-global-leadership-in-different-vcyt-20210203monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-pricing-of-public-offering-of-6-000-000-shares-of-common-stock-south-sa-vcyt-20200804monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-third-quarter-2019-financial-results-and-business-progress-revenue-grew-vcyt-20191022monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-second-quarter-2019-financial-results-revenue-grew-32-to-30-1-million-g-vcyt-20190730monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-pricing-of-public-offering-of-5-500-000-shares-of-common-stock-south-sa-vcyt-20190502monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-third-quarter-2018-financial-results-revenue-grew-34-percent-and-genomi-vcyt-20181029monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-pricing-of-public-offering-of-5-000-000-shares-of-common-stock-south-sa-vcyt-20180725monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-second-quarter-2018-financial-results-revenue-up-24-to-22-8-million-com-vcyt-20180723monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-first-quarter-2018-financial-results-grew-revenue-by-22-to-20-0-million-vcyt-20180501monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-fourth-quarter-and-full-year-2017-financial-results-provides-2018-finan-vcyt-20180227monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-strategic-realignment-and-new-appointments-to-advance-commercial-growth-vcyt-20180108monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-third-quarter-2017-financial-results-reports-revenue-of-17-5-million-fo-vcyt-20171106monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-second-quarter-2017-financial-results-reports-25-revenue-growth-to-18-4-vcyt-20170731monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-appointment-of-kevin-k-gordon-and-other-changes-to-its-board-of-directo-vcyt-20161213monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-that-cms-will-maintain-historic-medicare-reimbursement-rate-for-the-afi-vcyt-20161122monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-appoints-keith-kennedy-as-chief-financial-officer-vcyt-20161121monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-pricing-of-public-offering-of-5-000-000-shares-of-common-stock-vcyt-20161102monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-proposed-public-offering-of-common-stock-south-san-francisco-calif-nove-vcyt-20161101monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-releases-statement-on-cms-s-final-2017-gapfill-rate-for-the-afirma-gene-expressio-vcyt-20160930monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-second-quarter-2016-financial-results-vcyt-20160803monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-first-quarter-2016-financial-results-revenue-increased-21-and-afirma-ge-vcyt-20160505monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-fourth-quarter-and-full-year-2015-financial-results-provides-2016-finan-vcyt-20160310monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-names-tina-s-nova-ph-d-to-its-board-of-directors-vcyt-20151116monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-third-quarter-2015-financial-results-revenue-grew-25-and-afirma-gec-tes-vcyt-20151105monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-statement-on-cms-s-preliminary-2016-clinical-laboratory-fee-schedule-and-proposed-vcyt-20150927monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-second-quarter-2015-financial-results-revenue-increased-37-compared-to--vcyt-20150813monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-announces-first-quarter-2015-financial-results-first-quarter-revenue-increased-50-vcyt-20150514monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-inc-announces-40-million-private-placement-south-san-francisco-calif-vcyt-20150423monthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-inc-announces-fourth-quarter-and-full-year-2014-financial-results-provides-2015-f-vcyt-20150319monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-up-vktx-20260429monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provide-vktx-20260211monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-up-vktx-20251022monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-positive-top-line-results-from-phase-2-venture-oral-dosing-t-vktx-20250819monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-u-vktx-20250723monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-up-vktx-20250423monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-signs-broad-manufacturing-agreement-with-cordenpharma-to-support-comme-vktx-20250311monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provide-vktx-20250205monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-new-data-from-vk2735-obesity-program-at-obesityweek-2024-up-to-vktx-20241104monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-up-vktx-20241023monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-u-vktx-20240724monthly0.5https://www.biopharmawatch.com/news/VKTX/tim-brons-media-415-675-7402-tbrons-vidasp-com-vktx-20240604monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-up-vktx-20240424monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-results-from-phase-1-clinical-trial-of-oral-tablet-formulati-vktx-20240326monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-closing-of-public-offering-of-common-stock-including-full-ex-vktx-20240304monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-pricing-of-550-million-public-offering-of-common-stock-san-d-vktx-20240228monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-positive-top-line-results-from-phase-2-venture-trial-of-dual-vktx-20240227monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and-provide-vktx-20240207monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-up-vktx-20231025monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-u-vktx-20230726monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-up-vktx-20230426monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-vktx-20230403monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-pricing-of-250-million-public-offering-of-common-stock-san-d-vktx-20230329monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-oral-formulation-of--vktx-20230328monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-results-from-phase-1-clinical-trial-of-dual-glp-1-gip-recept-vktx-20230328monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2022-financial-results-and-provide-vktx-20230208monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corporate-up-vktx-20221026monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corporate-u-vktx-20220727monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corporate-up-vktx-20220427monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-and-provide-vktx-20220209monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate-up-vktx-20211103monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate-u-vktx-20210728monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2021-financial-results-and-provides-corporate-up-vktx-20210428monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-and-provide-vktx-20210217monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corporate-up-vktx-20201028monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2020-financial-results-and-provides-corporate-u-vktx-20200729monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2020-financial-results-and-provides-corporate-up-vktx-20200430monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2019-financial-results-and-provides-corporate-up-vktx-20191105monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2019-financial-results-and-provides-corporate-u-vktx-20190801monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-appoints-kathy-rouan-ph-d-to-board-of-directors-vktx-20190702monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2019-financial-results-and-provides-corporate-up-vktx-20190502monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2018-financial-results-and-provide-vktx-20190313monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2018-financial-results-and-provides-corporate-up-vktx-20181107monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-pricing-of-175-8-million-public-offering-of-common-stock-vktx-20180920monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-positive-top-line-results-from-phase-2-study-of-vk2809-in-pa-vktx-20180918monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2018-financial-results-and-provides-corporate-u-vktx-20180809monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-closing-of-public-offering-of-common-stock-vktx-20180612monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-pricing-of-67-5-million-public-offering-of-common-stock-vktx-20180607monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2018-financial-results-and-provides-corporate-up-vktx-20180509monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2017-financial-results-and-provide-vktx-20180307monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-closing-of-public-offering-of-common-stock-vktx-20180206monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-stock-vktx-20180202monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-closing-of-public-offering-of-common-stock-vktx-20171211monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-pricing-of-12-8-million-public-offering-of-common-stock-vktx-20171206monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-positive-top-line-results-from-phase-2-study-of-vk5211-in-pa-vktx-20171128monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2017-financial-results-and-provides-corporate-up-vktx-20171108monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-purchase-agreements-for-up-to-16-25-million-with-lincoln-par-vktx-20170929monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2017-financial-results-and-provides-corporate-u-vktx-20170809monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-appoints-charles-a-rowland-jr-to-board-of-directors-vktx-20170706monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-4-3-million-registered-direct-offering-vktx-20170614monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2017-financial-results-and-provides-corporate-up-vktx-20170510monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2016-financial-results-and-provide-vktx-20170321monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2016-financial-results-and-provides-corporate-up-vktx-20161110monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-doses-first-patient-in-phase-2-clinical-trial-of-vk2809-in-patients-wi-vktx-20161004monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-enters-into-12-5-million-common-stock-purchase-agreement-with-aspire-c-vktx-20160825monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-second-quarter-2016-financial-results-and-provides-corporate-u-vktx-20160810monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-first-quarter-2016-financial-results-and-provides-corporate-up-vktx-20160510monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-full-exercise-of-over-allotment-option-vktx-20160502monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-closing-of-public-offering-of-common-stock-and-warrants-vktx-20160413monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-warrants-vktx-20160408monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2015-financial-results-and-provide-vktx-20160308monthly0.5https://www.biopharmawatch.com/news/VKTX/forward-looking-statements-this-presentation-contains-statements-about-our-future-expectat-vktx-20160111monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-third-quarter-2015-financial-results-and-provides-corporate-up-vktx-20151105monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-initiates-phase-2-trial-of-vk5211-in-patients-recovering-from-hip-frac-vktx-20151103monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-completes-safety-tolerability-and-pharmacokinetic-study-of-vk5211-a-se-vktx-20151020monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-inc-announces-chairman-appointment-vktx-20150604monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-inc-announces-full-exercise-of-over-allotment-option-vktx-20150529monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-first-quarter-2026-business-updates-and-financial-results-robust-monotherap-eras-20260511monthly0.5https://www.biopharmawatch.com/news/ERAS/we-caution-you-that-this-presentation-contains-forward-looking-statements-all-statements-o-eras-20260112monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-in-thous-eras-20250812monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-first-quarter-2025-business-updates-and-financial-results-early-entry-of-ra-eras-20250513monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-fourth-quarter-and-full-year-2024-business-updates-and-financial-results-po-eras-20250320monthly0.5https://www.biopharmawatch.com/news/ERAS/we-caution-you-that-this-presentation-contains-forward-looking-statements-all-statements-o-eras-20250113monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-third-quarter-2024-business-updates-and-financial-results-positive-prelimin-eras-20241112monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-second-quarter-2024-business-updates-and-financial-results-in-licensed-pote-eras-20240812monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-pricing-of-underwritten-offering-of-common-stock-eras-20240516monthly0.5https://www.biopharmawatch.com/news/ERAS/on-a-journey-to-erase-cancer-erasca-investor-update-may-2024-disclaimer-forward-looking-st-eras-20240516monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-first-quarter-2024-business-updates-and-financial-results-median-os-of-13-1-eras-20240508monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-45-million-oversubscribed-private-placement-financing-funding-from-new-an-eras-20240327monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-inc-consolidated-statements-of-operations-and-comprehensive-loss-in-thousands-excep-eras-20240327monthly0.5https://www.biopharmawatch.com/news/ERAS/we-caution-you-that-this-presentation-contains-forward-looking-statements-all-statements-o-eras-20240109monthly0.5https://www.biopharmawatch.com/news/ERAS/dated-november-9-2023-ex-99-erasca-reports-third-quarter-2023-financial-results-and-busine-eras-20231109monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-second-quarter-2023-financial-results-and-business-updates-significant-prog-eras-20230810monthly0.5https://www.biopharmawatch.com/news/ERAS/we-caution-you-that-this-presentation-contains-forward-looking-statements-all-statements-o-eras-20230605monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-first-quarter-2023-financial-results-and-business-updates-publication-of-pr-eras-20230515monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-fourth-quarter-2022-and-full-year-2022-financial-results-and-business-updat-eras-20230323monthly0.5https://www.biopharmawatch.com/news/ERAS/anticipated-key-milestones-updated-eras-20230208monthly0.5https://www.biopharmawatch.com/news/ERAS/we-caution-you-that-this-presentation-contains-forward-looking-statements-all-statements-o-eras-20230109monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-pricing-of-underwritten-offering-of-common-stock-eras-20221209monthly0.5https://www.biopharmawatch.com/news/ERAS/on-a-journey-to-erase-cancer-erasca-corporate-presentation-december-2022-disclaimer-forwar-eras-20221209monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-third-quarter-2022-financial-results-and-business-updates-positive-prelimin-eras-20221109monthly0.5https://www.biopharmawatch.com/news/ERAS/we-caution-you-that-this-presentation-contains-forward-looking-statements-all-statements-o-eras-20220907monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-second-quarter-2022-financial-results-and-business-updates-initial-phase-1b-eras-20220811monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-first-quarter-2022-financial-results-and-business-updates-presented-compell-eras-20220512monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-fourth-quarter-2021-financial-results-and-business-updates-five-ongoing-cli-eras-20220324monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-third-quarter-2021-financial-results-and-business-updates-strong-execution--eras-20211110monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-second-quarter-2021-financial-results-and-business-updates-successfully-clo-eras-20210826monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-acn-616-620-369-55-flemington-road-north-melbourne-victoria--tlx-20260414monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-acn-616-620-369-55-flemington-road-north-melbourne-victoria--tlx-20241119monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-acn-616-620-369-55-flemington-road-north-melbourne-victoria--tlx-20241114monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-first-quarter-2026-financial-results-txg-20260507monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-announces-preliminary-select-fourth-quarter-and-full-year-2025-results-txg-20260111monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-third-quarter-2025-financial-results-txg-20251106monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-second-quarter-2025-financial-results-txg-20250807monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-first-quarter-2025-financial-results-txg-20250508monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-announces-preliminary-select-fourth-quarter-and-full-year-2024-results-fy-2024--txg-20250112monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-third-quarter-2024-financial-results-txg-20241029monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-announces-preliminary-select-third-quarter-2024-results-txg-20241009monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-second-quarter-2024-financial-results-txg-20240808monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-first-quarter-2024-financial-results-txg-20240430monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-announces-preliminary-fourth-quarter-and-full-year-2023-results-txg-20240108monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-third-quarter-2023-financial-results-txg-20231102monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-second-quarter-2023-financial-results-txg-20230803monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-wins-permanent-injunction-against-nanostring-s-cosmx-products-10x-genomics-is-s-txg-20230517monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-first-quarter-2023-financial-results-txg-20230503monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-third-quarter-2022-financial-results-txg-20221102monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-second-quarter-2022-financial-results-txg-20220808monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-announces-preliminary-second-quarter-2022-revenue-txg-20220714monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-first-quarter-2022-financial-results-q1-2022-revenue-growth-of-8-over-p-txg-20220504monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-third-quarter-2021-financial-results-q3-2021-revenue-growth-of-74-over--txg-20211103monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-second-quarter-2021-financial-results-q2-2021-revenue-growth-of-170-ove-txg-20210804monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-signs-global-patent-cross-license-agreement-with-bio-rad-agreement-to-cross-lic-txg-20210727monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-first-quarter-2021-financial-results-q1-2021-revenue-growth-of-47-over--txg-20210505monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-third-quarter-2020-financial-results-txg-20201110monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-advances-into-emerging-field-of-in-situ-analysis-with-two-acquisitions-signs-ag-txg-20201005monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-second-quarter-2020-financial-results-txg-20200811monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-first-quarter-2020-financial-results-txg-20200511monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-provides-covid-19-business-impact-update-and-response-provides-preliminary-reve-txg-20200409monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-full-y-txg-20200218monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-reports-third-quarter-2019-financial-results-and-provides-2019-revenue-guidance-txg-20191107monthly0.5https://www.biopharmawatch.com/news/TXG/x-genomics-announces-closing-of-initial-public-offering-and-exercise-in-full-of-the-underw-txg-20190916monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-fourth-quarter-2025-results-and-provides-fiscal-year-2026-guidance-icui-20260219monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-second-quarter-2025-results-and-updates-its-fiscal-year-2025-guidanc-icui-20250807monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-third-quarter-2024-results-and-updates-its-fiscal-year-2024-guidance-icui-20241112monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-second-quarter-2024-results-and-updates-its-fiscal-year-2024-guidanc-icui-20240807monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-first-quarter-2024-results-icui-20240507monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-fourth-quarter-2023-results-and-provides-fiscal-year-2024-guidance-icui-20240227monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-third-quarter-2023-results-icui-20231106monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-second-quarter-2023-results-and-narrows-fiscal-year-2023-guidance-ra-icui-20230807monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-first-quarter-2023-results-icui-20230508monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-fourth-quarter-2022-results-and-provides-fiscal-year-2023-guidance-icui-20230227monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-third-quarter-2022-results-the-company-reaffirms-2022-fiscal-year-gu-icui-20221107monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-second-quarter-2022-results-company-updated-fy-2022-guidance-icui-20220808monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-first-quarter-2022-results-icui-20220509monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-fourth-quarter-2021-results-and-provides-fiscal-year-2022-guidance-icui-20220224monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-third-quarter-2021-results-icui-20211103monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-to-acquire-smiths-medical-icui-20210908monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-second-quarter-2021-results-company-updated-fy-2021-guidance-icui-20210804monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-first-quarter-2021-results-icui-20210506monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-fourth-quarter-2020-results-and-provides-fiscal-year-2021-guidan-icui-20210225monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-third-quarter-2020-results-and-updates-fiscal-year-2020-guidance-icui-20201105monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-second-quarter-2020-results-icui-20200810monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-first-quarter-2020-results-and-updates-fiscal-year-2020-guidance-icui-20200507monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-fourth-quarter-2019-results-icui-20200227monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-third-quarter-2019-results-icui-20191111monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-second-quarter-2019-results-company-updates-fy-2019-guidance-icui-20190807monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-cfo-announces-intention-to-retire-from-cfo-role-after-close-of-fy19-icui-20190708monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-first-quarter-2019-results-icui-20190509monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-fourth-quarter-2018-results-icui-20190228monthly0.5https://www.biopharmawatch.com/news/ICUI/pfizer-infusion-systems-a-business-unit-of-pfizer-inc-combined-statements-of-income-loss-a-icui-20181115monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-third-quarter-2018-results-company-modifies-fy-2018-guidance-and-icui-20181108monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-second-quarter-2018-results-company-updates-fy-2018-guidance-icui-20180809monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-first-quarter-2018-results-icui-20180509monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-fourth-quarter-and-fiscal-year-2017-results-company-updates-fy-2-icui-20180301monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-third-quarter-2017-results-company-updates-fy-2017-guidance-and--icui-20171109monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-second-quarter-2017-results-icui-20170809monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-announces-first-quarter-2017-results-icui-20170510monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-icui-20170105monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-icui-20161006monthly0.5https://www.biopharmawatch.com/news/ICUI/buy-out-agreement-this-buy-out-agreement-dated-as-of-icui-20150930monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2025-financial-results-and-operating-overview-acad-20251105monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2025-financial-results-and-operating-overvie-acad-20250806monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2025-financial-results-and-operating-overview-acad-20250507monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-ope-acad-20250226monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2024-financial-results-and-operating-overview-acad-20241106monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2024-financial-results-and-operating-overvie-acad-20240806monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2024-financial-results-and-operating-overview-acad-20240508monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-ope-acad-20240227monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2023-financial-results-and-operating-overview-acad-20231102monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2023-financial-results-and-operating-overvie-acad-20230802monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-acquires-ex-north-american-rights-to-trofinetide-and-global-rights--acad-20230713monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2023-financial-results-and-operating-overview-acad-20230508monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-ope-acad-20230228monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2022-financial-results-3q22-net-sales-of-130--acad-20221102monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2022-financial-results-2q22-net-sales-of-134-acad-20220808monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2022-financial-results-1q22-net-sales-of-115--acad-20220504monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-full-ye-acad-20220228monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-announces-plan-for-a-resubmission-of-its-supplemental-new-drug-appl-acad-20211220monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-announces-promotion-of-mark-schneyer-to-executive-vice-president-ch-acad-20211214monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavend-acad-20211206monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2021-financial-results-3q21-net-sales-of-131--acad-20211108monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2021-financial-results-2q21-net-sales-of-115-acad-20210804monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2021-financial-results-1q21-net-sales-of-106--acad-20210505monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-receives-complete-response-letter-from-u-s-fda-for-supplemental-new-acad-20210405monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-provides-regulatory-update-on-supplemental-new-drug-application-for-acad-20210308monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-full-ye-acad-20210224monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2020-financial-results-3q20-net-sales-of-120--acad-20201104monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-acquires-cersci-therapeutics-adds-novel-pain-program-to-portfolio-f-acad-20200825monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2020-financial-results-2q20-net-sales-of-110-acad-20200805monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-announces-u-s-fda-accepted-for-filing-the-supplemental-new-drug-application-for-nup-acad-20200720monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-2004-employee-stock-purchase-plan-adopted-by-the-board-of-direc-acad-20200629monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2020-financial-results-1q20-net-sales-of-90-1-acad-20200507monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-full-ye-acad-20200226monthly0.5https://www.biopharmawatch.com/news/ACAD/forward-looking-statement-this-presentation-contains-forward-looking-statements-these-stat-acad-20200113monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2019-financial-results-3q19-net-sales-grew-to-acad-20191030monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-announces-proposed-public-offering-of-common-stock-acad-20190917monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for-positive--acad-20190909monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2019-financial-results-2q19-net-sales-grew-t-acad-20190731monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-p-harmaceuticals-i-nc-2010-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-ire-acad-20190628monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2019-financial-results-1q19-net-sales-grew-to-acad-20190501monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-fourth--acad-20190226monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-announces-proposed-public-offering-of-common-stock-acad-20181126monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2018-financial-results-third-quarter-net-sale-acad-20181106monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-announces-positive-top-line-results-from-phase-2-clarity-trial-of-p-acad-20181031monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2018-financial-results-second-quarter-net-sa-acad-20180808monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-p-harmaceuticals-i-nc-2010-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-ire-acad-20180608monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2018-financial-results-strong-performance-for-acad-20180504monthly0.5https://www.biopharmawatch.com/news/ACAD/blueprint-acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-resul-acad-20180227monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2017-financial-results-third-quarter-net-sale-acad-20171107monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2017-financial-results-second-quarter-net-sa-acad-20170808monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-p-harmaceuticals-i-nc-2010-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-ire-acad-20170613monthly0.5https://www.biopharmawatch.com/news/ACAD/blueprint-acadia-pharmaceuticals-reports-first-quarter-2017-financial-results-acad-20170509monthly0.5https://www.biopharmawatch.com/news/ACAD/blueprint-acadia-pharmaceuticals-reports-financial-results-for-the-fourth-quarter-and-year-acad-20170228monthly0.5https://www.biopharmawatch.com/news/ACAD/secconnect-com-acadia-pharmaceuticals-announces-positive-top-line-results-from-phase-ii-st-acad-20161220monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-third-quarter-2016-financial-results-nuplazid-net-product-s-acad-20161107monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-second-quarter-2016-financial-results-quarter-highlighted-b-acad-20160804monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-p-harmaceuticals-i-nc-2004-e-mployee-s-tock-p-urchase-p-lan-a-dopted-by-the-b-oard--acad-20160610monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2016-financial-results-acad-20160505monthly0.5https://www.biopharmawatch.com/news/ACAD/fda-approves-acadia-pharmaceuticals-nuplazid-pimavanserin-the-first-drug-approved-for-the--acad-20160429monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-description-of-executive-officer-annual-incentive-cash-compensa-acad-20160318monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-lisa-barthelemy-senior-director-investor-relations-858-558-2871-acad-20160229monthly0.5https://www.biopharmawatch.com/news/ACAD/company-overview-company-overview-we-are-a-biopharmaceutical-company-focused-on-the-develo-acad-20160105monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-management-severance-benefit-plan-section-1-introduction-the-ac-acad-20151210monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-lisa-barthelemy-director-of-investor-relations-858-558-2871-aca-acad-20151105monthly0.5https://www.biopharmawatch.com/news/ACAD/employment-agreement-this-amended-and-restated-executive-employment-agreement-the-agreemen-acad-20150901monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-steve-davis-interim-chief-executive-officer-lisa-barthelemy-dir-acad-20150806monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-p-harmaceuticals-i-nc-2010-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-ire-acad-20150619monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-steve-davis-interim-chief-executive-officer-lisa-barthelemy-dir-acad-20150507monthly0.5https://www.biopharmawatch.com/news/ACAD/investor-contacts-acadia-pharmaceuticals-inc-steve-davis-interim-chief-executive-officer-l-acad-20150311monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-steve-davis-executive-vice-president-chief-financial-officer-an-acad-20150226monthly0.5https://www.biopharmawatch.com/news/ACAD/investor-contacts-acadia-pharmaceuticals-inc-steve-davis-executive-vice-president-chief-fi-acad-20141110monthly0.5https://www.biopharmawatch.com/news/ACAD/secconnect-com-investor-contacts-acadia-pharmaceuticals-inc-uli-hacksell-ph-d-chief-execut-acad-20140902monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-steve-davis-executive-vice-president-chief-financial-officer-an-acad-20140805monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-uli-hacksell-ph-d-chief-executive-officer-lisa-barthelemy-direc-acad-20140506monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-description-of-executive-officer-annual-incentive-cash-compensa-acad-20140311monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20140227monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20131106monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20130806monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-p-harmaceuticals-i-nc-2010-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-ire-acad-20130612monthly0.5https://www.biopharmawatch.com/news/ACAD/lease-11085-torreyana-road-hcp-torreyana-llc-a-delaware-limited-liability-company-as-landl-acad-20130605monthly0.5https://www.biopharmawatch.com/news/ACAD/text-omitted-and-filed-separately-with-the-securities-and-exchange-commission-confidential-acad-20130531monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20130514monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20130507monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20130312monthly0.5https://www.biopharmawatch.com/news/ACAD/securities-purchase-agreement-this-s-ecurities-p-urchase-a-greement-this-agreement-dated-a-acad-20121212monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20121212monthly0.5https://www.biopharmawatch.com/news/ACAD/investor-contacts-acadia-pharmaceuticals-inc-uli-hacksell-ph-d-chief-executive-officer-tho-acad-20121127monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20121105monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20120808monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20120508monthly0.5https://www.biopharmawatch.com/news/ACAD/at-the-market-issuance-sales-agreement-dated-march-30-2012-by-and-between-acadia-pharmaceu-acad-20120330monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20120306monthly0.5https://www.biopharmawatch.com/news/ACAD/secconnect-com-contact-acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president--acad-20111109monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20110810monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20110510monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20110310monthly0.5https://www.biopharmawatch.com/news/ACAD/securities-purchase-agreement-this-s-ecurities-p-urchase-a-greement-this-agreement-dated-a-acad-20110109monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20101109monthly0.5https://www.biopharmawatch.com/news/ACAD/amendment-no-1-to-common-stock-purchase-agreement-this-amendment-no-1-to-the-common-stock--acad-20100921monthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-inc-thomas-h-aasen-executive-vice-president-chief-financial-officer-acad-20100809monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates-beam-20260507monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-announces-beam-20260224monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-sets-strategic-priorities-for-its-genetic-disease-and-hematology-franchi-beam-20260111monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-updates-beam-20251104monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-second-quarter-2025-financial-results-and-provides-update-on-bea-beam-20250805monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-first-quarter-2025-financial-results-and-recent-business-highlig-beam-20250506monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-pricing-of-underwritten-offering-cambridge-mass-beam-20250310monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-positive-initial-data-for-beam-302-in-the-phase-1-2-trial-in-a-beam-20250310monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-reiterate-beam-20250225monthly0.5https://www.biopharmawatch.com/news/BEAM/precision-genetic-medicines-through-base-editing-nasdaq-beam-january-2025-cautionary-note--beam-20241231monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-new-data-from-beacon-phase-1-2-clinical-trial-of-beam-101-in-s-beam-20241208monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-appointment-of-sravan-emany-as-chief-financial-officer-cambrid-beam-20241206monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-expands-its-board-of-directors-with-appointment-of-chirfi-guindo-global--beam-20241204monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-to-present-data-across-hematology-franchise-including-first-clinical-dat-beam-20241105monthly0.5https://www.biopharmawatch.com/news/BEAM/q3-financial-results-ash-abstracts-investor-webcast-beam-20241105monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-third-quarter-2024-financial-results-and-progress-across-priorit-beam-20241105monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-pipeline-updates-and-second-quarter-2024-financial-results-u-s-f-beam-20240806monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-transition-of-chief-financial-officer-cambridge-mass-beam-20240715monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-pipeline-updates-and-first-quarter-2024-financial-results-dosing-beam-20240507monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and-reiterate-beam-20240227monthly0.5https://www.biopharmawatch.com/news/BEAM/precision-genetic-medicines-through-base-editing-january-2024-nasdaq-beam-cautionary-note--beam-20240108monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-appoints-biotech-executive-christi-shaw-to-its-board-of-directors-beam-20231214monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-pipeline-and-business-updates-and-third-quarter-2023-financial-r-beam-20231108monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-announces-agreement-for-lilly-to-acquire-beam-s-opt-in-rights-to-verve-therapeutics-b-beam-20231031monthly0.5https://www.biopharmawatch.com/news/BEAM/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-beam-20231019monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-pipeline-updates-and-second-quarter-2023-financial-results-beaco-beam-20230808monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-pipeline-updates-and-first-quarter-2023-financial-results-focuse-beam-20230510monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-fourth-quarter-and-year-end-2022-financial-results-and-reiterate-beam-20230228monthly0.5https://www.biopharmawatch.com/news/BEAM/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-beam-20230109monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-portfolio-progress-and-reports-third-quarter-2022-financial-re-beam-20221107monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-pipeline-and-business-highlights-and-reports-second-quarter-20-beam-20220809monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-fda-clinical-hold-on-beam-201-ind-application-beam-20220801monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-pipeline-and-business-highlights-and-reports-first-quarter-202-beam-20220509monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-pipeline-and-business-highlights-planned-2022-milestones-and-fou-beam-20220228monthly0.5https://www.biopharmawatch.com/news/BEAM/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-beam-20220110monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-provides-business-and-pipeline-updates-and-reports-third-quarter-2021-fi-beam-20211108monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-provides-business-and-pipeline-updates-and-reports-second-quarter-2021-f-beam-20210810monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-presents-lnp-formulation-data-at-asgct-and-reports-first-quarter-2021-fi-beam-20210511monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-business-and-pipeline-progress-and-reports-fourth-quarter-and--beam-20210315monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-acquisition-of-guide-therapeutics-guidetx-s-proprietary-lnp-sc-beam-20210223monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-inc-announces-260-million-common-stock-investment-from-multiple-investor-beam-20210119monthly0.5https://www.biopharmawatch.com/news/BEAM/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-beam-20210112monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-business-and-pipeline-progress-and-reports-third-quarter-2020--beam-20201110monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-announces-first-development-candidates-for-sickle-cell-disease-and-repor-beam-20200812monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-additional-data-at-asgct-annual-meeting-and-first-quarter-2020-f-beam-20200512monthly0.5https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-reports-business-updates-and-full-year-2019-financial-results-successful-beam-20200330monthly0.5https://www.biopharmawatch.com/news/ITGR/integer-holdings-corporation-announces-preliminary-unaudited-sales-results-and-acquisition-itgr-20240110monthly0.5https://www.biopharmawatch.com/news/ITGR/first-amendment-to-credit-agreement-itgr-20230130monthly0.5https://www.biopharmawatch.com/news/ITGR/historical-financial-information-2017-by-quarter-and-total-year-5-periods-2018-by-1st-quar-itgr-20180730monthly0.5https://www.biopharmawatch.com/news/ITGR/integer-completes-divestiture-of-its-advanced-surgical-and-orthopedics-product-lines-frisc-itgr-20180702monthly0.5https://www.biopharmawatch.com/news/ITGR/itgr-2017-16-07-press-release-ceo-exhibit-investor-relations-amy-wakeham-ir-integer-net-21-itgr-20170717monthly0.5https://www.biopharmawatch.com/news/ITGR/investor-relations-amy-wakeham-ir-integer-net-214-618-4978-media-relations-kelly-butler-ke-itgr-20170327monthly0.5https://www.biopharmawatch.com/news/ITGR/exhibit-investor-relations-amy-wakeham-ir-integer-net-214-618-4978-for-immediate-release-m-itgr-20170227monthly0.5https://www.biopharmawatch.com/news/ITGR/lake-region-medical-holdings-inc-unaudited-condensed-consolidated-balance-sheets-in-thousa-itgr-20160428monthly0.5https://www.biopharmawatch.com/news/ITGR/anthony-borowicz-tborowicz-greatbatch-com-tel-716-759-5809-itgr-20160314monthly0.5https://www.biopharmawatch.com/news/ITGR/greatbatch-inc-itgr-20160229monthly0.5https://www.biopharmawatch.com/news/ITGR/greatbatch-inc-itgr-20160111monthly0.5https://www.biopharmawatch.com/news/ITGR/elizabeth-cowell-ecowell-greatbatch-com-tel-214-618-4982-media-contact-christopher-knospe--itgr-20151027monthly0.5https://www.biopharmawatch.com/news/ITGR/greatbatch-announces-pricing-of-360-million-of-9-125-senior-notes-due-2023-itgr-20151020monthly0.5https://www.biopharmawatch.com/news/ITGR/greatbatch-announces-private-offering-of-360-million-of-senior-notes-in-connection-with-it-itgr-20151013monthly0.5https://www.biopharmawatch.com/news/ITGR/accellent-inc-consolidated-financial-statements-as-of-and-for-the-years-ended-itgr-20150917monthly0.5https://www.biopharmawatch.com/news/ITGR/greatbatch-inc-provides-preliminary-2014-results-and-2015-guidance-itgr-20150115monthly0.5https://www.biopharmawatch.com/news/ITGR/greatbatch-inc-reports-2013-fourth-quarter-and-full-year-results-frisco-texas-business-wir-itgr-20140224monthly0.5https://www.biopharmawatch.com/news/ITGR/jp-morgan-conference-january-13-16-2014-greatbatch-team-thomas-j-hook-president-ceo-michae-itgr-20140113monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-announces-chief-operating-officer-tenured-leader-brings-40-years-of-senior-livin-bkd-20251118monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-appoints-nick-stengle-as-ceo-proven-executive-brings-extensive-experience-in-sen-bkd-20251002monthly0.5https://www.biopharmawatch.com/news/BKD/form-of-base-capped-call-confirmation-dealer-address-2021-to-brookdale-senior-living-inc-1-bkd-20210928monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-prices-offering-of-200-million-convertible-senior-notes-due-2026-nashville-tenn-bkd-20210928monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-to-offer-200-million-convertible-senior-notes-due-2026-nashville-tenn-bkd-20210927monthly0.5https://www.biopharmawatch.com/news/BKD/pressreleaseda-brookdale-completes-previously-announced-sale-of-a-majority-stake-in-its-ho-bkd-20210701monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-enters-into-definitive-agreement-to-sell-a-majority-stake-in-its-home-health-hos-bkd-20210224monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-announces-multi-part-transaction-with-ventas-significantly-improves-brookdale-s--bkd-20200727monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-enters-into-mutually-beneficial-agreements-with-hcp-unlocks-value-from-sale-of-u-bkd-20191001monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-announces-fourth-quarter-and-full-year-2016-results-fourth-quarter-2016-and-rece-bkd-20170213monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-announces-third-quarter-2016-results-board-authorizes-100-million-share-repurcha-bkd-20161101monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-announces-second-quarter-2016-results-nashville-tenn-bkd-20160808monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-investors-ross-roadman-615-564-8104-rroadman-brookdale-com-bro-bkd-20160509monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-announces-leadership-changes-bkd-20160301monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-investors-ross-roadman-615-564-8104-rroadman-brookdale-com-bro-bkd-20160208monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-investors-ross-roadman-615-564-8104-rroadman-brookdale-com-bro-bkd-20151104monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-announces-changes-to-its-executive-leadership-team-labeed-diab-named-as-coo-and--bkd-20151102monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-investors-ross-roadman-615-564-8104-rroadman-brookdale-com-bro-bkd-20150924monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-investors-ross-roadman-615-564-8104-rroadman-brookdale-com-bro-bkd-20150803monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-announces-leadership-changes-mark-ohlendorf-president-and-chief-financial-office-bkd-20150622monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-investors-ross-roadman-615-564-8104-media-julie-davis-615-564--bkd-20150507monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-appoints-mark-parrell-and-lee-wielansky-to-board-of-directors-sandell-supports-b-bkd-20150424monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-confirms-receipt-of-director-nominations-no-shareholder-action-required-at-this--bkd-20150316monthly0.5https://www.biopharmawatch.com/news/BKD/statements-include-but-are-not-limited-to-the-risk-associated-with-the-current-global-econ-bkd-20150206monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-investors-ross-roadman-615-564-8104-media-julie-davis-615-564--bkd-20150204monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-investors-ross-roadman-615-564-8104-media-julie-davis-615-564--bkd-20150126monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-expands-and-extends-credit-facility-nashville-tenn-bkd-20141222monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-corporate-overview-selected-financial-information-as-of-bkd-20141216monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-inc-ross-roadman-615-564-8104-brookdale-announces-third-quarter-20-bkd-20141105monthly0.5https://www.biopharmawatch.com/news/BKD/brookdale-and-hcp-complete-previously-disclosed-creation-of-1-2-billion-ccrc-joint-venture-bkd-20140902monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-fourth-quarter-and-full-year-2025-financial-results-sold-more-than-185-000-g-gral-20260219monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-second-quarter-2025-financial-results-q2-u-s-galleri-revenue-grew-21-year-ov-gral-20250812monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-first-quarter-2025-financial-results-q1-u-s-galleri-revenue-grew-22-year-ove-gral-20250513monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-fourth-quarter-and-full-year-2024-financial-results-sold-more-than-137-000-g-gral-20250220monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-third-quarter-2024-financial-results-galleri-revenue-grew-52-year-over-year--gral-20241112monthly0.5https://www.biopharmawatch.com/news/GRAL/document-news-release-grail-appoints-sarah-krevans-to-board-of-directors-gral-20241021monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-second-quarter-2024-financial-results-and-provides-a-strategic-update-second-gral-20240813monthly0.5https://www.biopharmawatch.com/news/GRAL/information-statement-grail-llc-1525-o-brien-drive-menlo-park-california-94025-common-stoc-gral-20240603monthly0.5https://www.biopharmawatch.com/news/NHC/nhc-announces-25-million-stock-repurchase-program-for-release-nhc-20170809monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20170804monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20170510monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20170215monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20170210monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20161108monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-november-3-2016-nhc-20161104monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20160930monthly0.5https://www.biopharmawatch.com/news/NHC/nhc-announces-25-million-stock-repurchase-program-for-release-nhc-20160809monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20160808monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-august-5-2016-nhc-20160808monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20160504monthly0.5https://www.biopharmawatch.com/news/NHC/gerald-coggin-sr-nhc-20160503monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-february-19-2016-nhc-20160222monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-february-12-2016-nhc-20160212monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-november-5-2015-nhc-20151106monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-october-7-2015-nhc-20151008monthly0.5https://www.biopharmawatch.com/news/NHC/national-healthcare-corporation-nhc-20151002monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-august-6-2015-nhc-20150807monthly0.5https://www.biopharmawatch.com/news/NHC/nhc-announces-25-million-stock-repurchase-programs-for-release-nhc-20150511monthly0.5https://www.biopharmawatch.com/news/NHC/gerald-coggin-sr-nhc-20150508monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-february-20-2015-nhc-20150220monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-november-6-2014-nhc-20141106monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-october-23-2014-nhc-20141023monthly0.5https://www.biopharmawatch.com/news/NHC/nhc-announces-25-million-stock-repurchase-program-for-release-nhc-20140812monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20140806monthly0.5https://www.biopharmawatch.com/news/NHC/gerald-coggin-sr-nhc-20140509monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-march-5-2014-nhc-20140305monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-february-24-2014-nhc-20140225monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-february-12-2014-nhc-20140212monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-november-5-2013-nhc-20131106monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20131023monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-september-3-2013-nhc-20130903monthly0.5https://www.biopharmawatch.com/news/NHC/nhc-announces-25-million-stock-repurchase-program-for-release-nhc-20130805monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20130801monthly0.5https://www.biopharmawatch.com/news/NHC/gerald-coggin-sr-nhc-20130509monthly0.5https://www.biopharmawatch.com/news/NHC/john-k-lines-senior-vp-and-general-counsel-phone-615-890-2020-nhc-announces-settlements-in-nhc-20130502monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-february-15-2013-nhc-20130215monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-december-28-2012-nhc-20130102monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20121206monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-october-31-2012-nhc-20121031monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20121025monthly0.5https://www.biopharmawatch.com/news/NHC/nhc-announces-25-million-stock-repurchase-program-nhc-20120806monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-august-1-2012-nhc-20120802monthly0.5https://www.biopharmawatch.com/news/NHC/for-release-nhc-20120503monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-high-tngx-20260513monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development--tngx-20260415monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-high-tngx-20251104monthly0.5https://www.biopharmawatch.com/news/TNGX/disclaimer-and-safe-harbor-statement-certain-statements-in-this-presentation-may-be-consid-tngx-20251023monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-hig-tngx-20250805monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-high-tngx-20250512monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-tngx-20250227monthly0.5https://www.biopharmawatch.com/news/TNGX/the-next-wave-of-targeted-therapies-in-oncology-corporate-overview-january-2025-1-disclaim-tngx-20250113monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-high-tngx-20241106monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-hig-tngx-20240807monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-discontinuation-of-tng348-program-the-phase-1-2-clinical-tria-tngx-20240523monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-high-tngx-20240508monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-tngx-20240318monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-high-tngx-20231108monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-80-million-private-placement-financing-tngx-20230810monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-hig-tngx-20230807monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-high-tngx-20230509monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provide-tngx-20230327monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-appointment-of-adam-crystal-m-d-ph-d-as-president-of-research-tngx-20230228monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-high-tngx-20221110monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-hig-tngx-20220810monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-high-tngx-20220511monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provide-tngx-20220328monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-high-tngx-20211109monthly0.5https://www.biopharmawatch.com/news/TNGX/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-of-t-tngx-20210813monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-and-bctg-acquisition-corp-announce-merger-agreement-to-create-publicly--tngx-20210414monthly0.5https://www.biopharmawatch.com/news/TNGX/bctg-acquisition-corp-report-of-independent-registered-public-accounting-firm-f-2-balance--tngx-20200908monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-first-quarter-2026-financial-results-delivered-q1-2026-to-cprx-20260511monthly0.5https://www.biopharmawatch.com/news/CPRX/angelini-pharma-to-acquire-catalyst-pharmaceuticals-for-4-1-billion-usd-3-5-billion-euros--cprx-20260422monthly0.5https://www.biopharmawatch.com/news/CPRX/safe-harbor-this-presentation-contains-forward-looking-statements-that-are-subject-to-a-nu-cprx-20260112monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-settlement-of-firdapse-amifampridine-patent-litigation--cprx-20250825monthly0.5https://www.biopharmawatch.com/news/CPRX/lambert-eaton-myasthenic-syndrome-lems-antibody-testing-and-treatment-recommendations-adde-cprx-20250806monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-half-2025-financial-resul-cprx-20250807monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-daniel-curran-md-to-its-board-of-directors-cprx-20250804monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-appointment-of-william-t-andrews-md-facp-as-chief-medic-cprx-20250602monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-record-first-quarter-2025-financial-results-and-provides--cprx-20250507monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-health-canada-s-acceptance-of-agamree-new-drug-submissi-cprx-20250408monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2024-financial-result-cprx-20250227monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-sub-licensee-dydo-pharma-launched-firdapse-in-japan-cprx-20250121monthly0.5https://www.biopharmawatch.com/news/CPRX/improving-the-lives-of-patients-with-rare-diseases-nasdaq-cprx-j-p-morgan-healthcare-confe-cprx-20250113monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-settlement-of-firdapse-amifampridine-patent-litigation--cprx-20250108monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-strong-third-quarter-2024-financial-results-and-provides--cprx-20241107monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-sub-licensee-dydo-pharma-received-approval-to-commercia-cprx-20240924monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-strong-second-quarter-2024-financial-results-and-provides-cprx-20240808monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-enters-into-an-exclusive-license-supply-and-commercialization-agr-cprx-20240724monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-u-s-fda-approval-for-increased-maximum-daily-dose-for-cprx-20240530monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-solid-first-quarter-2024-financial-results-and-provides-b-cprx-20240508monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-agamree-now-commercially-available-in-the-u-s-for-the-t-cprx-20240313monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-strong-fourth-quarter-and-full-year-2023-financial-result-cprx-20240229monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-publication-of-santhera-pharmaceutical-s-vision-dmd-vam-cprx-20240221monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-announces-closing-of-public-offering-of-common-stock-cprx-20240109monthly0.5https://www.biopharmawatch.com/news/CPRX/safe-harbor-this-presentation-contains-forward-looking-statements-that-are-subject-to-a-nu-cprx-20240108monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-cprx-20240104monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-firdapse-new-drug-application-submitted-in-japan-by-par-cprx-20231218monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-appointment-of-michael-w-kalb-as-chief-financial-office-cprx-20231204monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-strong-third-quarter-2023-financial-results-and-corporate-cprx-20231109monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-two-new-u-s-patent-allowances-for-firdapse-new-patents-f-cprx-20231102monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-fda-approval-of-agamree-vamorolone-for-duchenne-muscular--cprx-20231026monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-richard-j-daly-as-chief-executive-officer-patrick-j-mcen-cprx-20231019monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fda-acceptance-of-the-supplemental-new-drug-application-cprx-20231013monthly0.5https://www.biopharmawatch.com/news/CPRX/safe-harbor-this-presentation-contains-forward-looking-statements-that-are-subject-to-a-nu-cprx-20230926monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-strong-second-quarter-2023-financial-results-and-provides-cprx-20230810monthly0.5https://www.biopharmawatch.com/news/CPRX/patrick-j-mcenany-announces-intention-to-retire-as-ceo-of-catalyst-pharmaceuticals-by-year-cprx-20230725monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-acquires-exclusive-north-american-license-for-vamorolone-for-duch-cprx-20230721monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-license-north-american-rights-to-vamorolone-for-duchenne-muscu-cprx-20230620monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-positive-momentum-in-second-quarter-2023-reaffirms-full-y-cprx-20230601monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-tamar-thompson-to-its-board-of-directors-cprx-20230530monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-record-first-quarter-2023-results-achieving-98-total-reve-cprx-20230510monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-advances-snda-submission-plans-to-increase-indicated-maximum-dose-cprx-20230509monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-p-cprx-20230316monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-preliminary-fourth-quarter-and-full-year-2022-total-reven-cprx-20230207monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-completes-the-acquisition-of-u-s-rights-to-fycompa-perampanel-cii-cprx-20230125monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-comments-on-fda-s-announcement-of-its-position-on-orphan-drug-exc-cprx-20230123monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-notified-of-abbreviated-new-drug-application-filing-for-cprx-20230123monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-acquire-u-s-commercial-rights-to-fycompa-perampanel-ciii-from--cprx-20221219monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-record-third-quarter-2022-financial-results-and-provides--cprx-20221110monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-for-f-cprx-20220929monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-delivers-strong-second-quarter-2022-financial-results-with-record-cprx-20220809monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-settlement-of-u-s-patent-litigation-and-resolution-of-l-cprx-20220712monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-record-first-quarter-2022-financial-results-and-provides--cprx-20220511monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-p-cprx-20220317monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-and-kye-pharmaceuticals-announce-a-second-favorable-canadian-fede-cprx-20220311monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-further-strengthens-firdapse-u-s-patent-portfolio-three-new-paten-cprx-20220302monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-preliminary-fourth-quarter-and-full-year-2021-total-reven-cprx-20220207monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-that-the-fda-marketing-approval-previously-granted-for-ru-cprx-20220203monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-issuance-of-mandate-by-the-u-s-court-of-appeals-for-the-cprx-20220128monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-11th-circuit-court-of-appeals-denial-of-jacobus-pharmac-cprx-20220110monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-dydo-pharma-initiation-of-a-phase-3-study-for-firdapse--cprx-20211206monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-third-quarter-2021-financial-results-continued-strong-fin-cprx-20211110monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-positive-decision-from-appeals-court-that-supports-orpha-cprx-20210930monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-mary-coleman-as-vice-president-head-of-investor-relation-cprx-20210816monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-second-quarter-2021-financial-results-and-provides-corp-cprx-20210809monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-issuance-of-u-s-patent-11-060-128-a-method-of-use-paten-cprx-20210719monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-expands-leadership-team-with-appointment-of-preethi-sundaram-ph-d-cprx-20210706monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-exclusive-license-and-supply-agreement-with-dydo-pharma-cprx-20210628monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-pharmaceutical-executive-molly-harper-to-its-board-of-di-cprx-20210629monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-comments-on-recent-decision-by-health-canada-to-re-issue-an-noc-f-cprx-20210628monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-s-and-kye-pharmaceuticals-lawsuit-in-canadian-federal-court-q-cprx-20210603monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-first-quarter-2021-financial-results-and-provides-busin-cprx-20210510monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-40-million-share-repurchase-program-cprx-20210322monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fourth-quarter-and-year-end-2020-financial-results-and--cprx-20210315monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-strategic-plan-for-product-portfolio-expansion-for-long-cprx-20210106monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-third-quarter-2020-financial-results-and-provides-busin-cprx-20201110monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-filing-of-patent-infringement-actions-against-jacobus-p-cprx-20201019monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-issuance-of-u-s-patent-for-firdapse-issued-patent-is-th-cprx-20201006monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-ruling-on-lawsuit-against-the-fda-and-intent-to-appeal-cprx-20200929monthly0.5https://www.biopharmawatch.com/news/CPRX/kye-pharmaceuticals-and-catalyst-pharmaceuticals-challenge-health-canada-s-decision-to-ove-cprx-20200826monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-and-kye-pharmaceuticals-announce-agreement-to-make-firdapse-amifa-cprx-20200818monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-notice-of-allowance-of-a-u-s-patent-application-for-met-cprx-20200811monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-second-quarter-2020-financial-results-and-provides-busi-cprx-20200810monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-firdapse-amifampridine-phosphate-receives-marketing-approval-in-c-cprx-20200806monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-change-to-a-virtual-meeting-format-for-the-2020-annual--cprx-20200803monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-jeffrey-del-carmen-as-chief-commercial-officer-pete-curr-cprx-20200623monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-first-quarter-2020-financial-results-and-provides-corpo-cprx-20200511monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-provides-update-on-impact-of-covid-19-pandemic-on-its-business-ac-cprx-20200408monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-fourth-quarter-and-year-end-2019-financial-results-and-pr-cprx-20200316monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-david-ailinger-as-vice-president-business-development-cprx-20200204monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-pre-announces-estimated-firdapse-revenues-and-provides-updates-on-cprx-20200106monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-corpora-cprx-20191112monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-top-line-results-of-cms-001-a-phase-3-trial-of-firdapse-cprx-20191030monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-comments-on-trading-in-its-common-stock-and-on-its-capital-re-cprx-20190923monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-determines-not-to-proceed-with-previously-announced-public-of-cprx-20190913monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-second-quarter-2019-financial-results-and-provides-corp-cprx-20190807monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-files-federal-lawsuit-against-u-s-food-and-drug-administration-co-cprx-20190612monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-expansion-of-firdapse-license-to-include-japan-cprx-20190530monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-first-quarter-2019-financial-results-and-provides-corpo-cprx-20190513monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fourth-quarter-and-year-end-2018-financial-results-and--cprx-20190318monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-definitive-agreement-with-endo-for-vigabatrin-tablets-cprx-20181218monthly0.5https://www.biopharmawatch.com/news/CPRX/commercial-launch-of-firdapse-december-13-2018-confirmation-13685524-page-1-catalyst-pharm-cprx-20181217monthly0.5https://www.biopharmawatch.com/news/CPRX/fda-approves-firdapse-amifampridine-for-the-treatment-of-lambert-eaton-myasthenic-syndrome-cprx-20181129monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-third-quarter-2018-financial-results-and-provides-corpo-cprx-20181107monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-expands-commercial-leadership-team-augments-medical-affairs-team--cprx-20180806monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-daniel-j-brennan-as-chief-commercial-officer-cprx-20180613monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fda-acceptance-of-nda-and-priority-review-status-for-fi-cprx-20180529monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-first-quarter-2018-financial-results-and-provides-corpo-cprx-20180509monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-enrollment-of-first-patient-in-phase-3-trial-of-firdaps-cprx-20180419monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-submission-of-new-drug-application-for-firdapse-for-tre-cprx-20180329monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fourth-quarter-and-year-end-2017-financial-results-and--cprx-20180314monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-plans-to-resubmit-new-drug-application-for-firdapse-pos-cprx-20180212monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-announces-closing-of-previously-announced-public-offering-cprx-20171130monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-cprx-20171127monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-positive-top-line-results-from-second-phase-3-clinical--cprx-20171127monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-phase-2-study-of-firdapse-in-ambulatory-patients-with-s-cprx-20171121monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-third-quarter-2017-financial-results-and-provides-corpo-cprx-20171108monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-completes-enrollment-in-second-phase-3-trial-of-firdapse-in-patie-cprx-20171031monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-provides-update-on-the-status-of-its-firdapse-development-activit-cprx-20170830monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-second-quarter-2017-financial-results-and-provides-corp-cprx-20170809monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-first-quarter-2017-financial-results-and-provides-corpo-cprx-20170510monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fourth-quarter-and-year-end-2016-financial-results-and--cprx-20170315monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-positive-data-from-investigator-sponsored-trial-of-fird-cprx-20170315monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-first-patient-enrolled-in-second-phase-3-trial-of-firda-cprx-20161215monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-provides-update-on-its-clinical-trial-for-patients-with-congenita-cprx-20161208monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-third-quarter-2016-financial-results-and-provides-corpo-cprx-20161109monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-special-protocol-assessment-spa-from-the-fda-for-second--cprx-20161031monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-publication-of-cpp-115-clinical-efficacy-data-for-infan-cprx-20160919monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fda-orphan-drug-designation-of-firdapse-for-the-treatme-cprx-20160902monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-second-quarter-2016-financial-results-and-provides-prod-cprx-20160809monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-agreement-with-fda-on-confirmatory-phase-3-study-protoc-cprx-20160613monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-reduction-in-workforce-as-part-of-operating-expense-man-cprx-20160517monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-first-quarter-2016-financial-results-and-provides-corpo-cprx-20160510monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-provides-regulatory-update-on-firdapse-cprx-20160426monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fourth-quarter-and-year-end-2015-financial-results-comp-cprx-20160315monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-refusal-to-file-letter-from-the-fda-on-its-nda-for-firda-cprx-20160217monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-initiation-of-investigator-sponsored-study-of-firdapse--cprx-20160208monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-completes-nda-submission-to-fda-for-firdapse-for-the-treatment-of-cprx-20151217monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-top-line-results-in-phase-1-b-trial-of-cpp-115-cprx-20151216monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-third-quarter-2015-financial-results-and-provides-corpo-cprx-20151109monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-notice-of-allowance-of-a-u-s-patent-application-for-the-cprx-20151013monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-a-clinical-trial-for-pediatric-patients-with-congenital-cprx-20151006monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-intent-to-develop-a-generic-equivalent-of-sabril-one-ti-cprx-20150909monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-paul-j-merrigan-as-chief-commercial-officer-cprx-20150817monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-second-quarter-2015-financial-results-and-provides-corp-cprx-20150810monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-initiates-rolling-nda-submission-for-firdapse-for-the-treatment-o-cprx-20150722monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-dr-gary-ingenito-as-chief-medical-officer-cprx-20150630monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-encouraging-top-line-results-in-proof-of-concept-trial--cprx-20150624monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-names-richard-j-daly-interim-chief-commercial-officer-former-top--cprx-20150528monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-first-quarter-2015-financial-results-and-provides-corpo-cprx-20150511monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-oral-presentation-of-firdapse-phase-3-trial-data-at-ame-cprx-20150414monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fourth-quarter-and-year-end-2014-financial-results-cprx-20150316monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-fda-orphan-drug-designation-of-firdapse-for-treatment-o-cprx-20150305monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-appointment-of-richard-j-daly-and-donald-a-denkhaus-to--cprx-20150219monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-closing-of-previously-announced-public-offe-cprx-20150209monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-commencement-of-public-offering-of-common-s-cprx-20150203monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-encouraging-pre-nda-meeting-with-the-fda-for-firdapse-a-cprx-20150202monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-provides-an-update-of-2015-goals-for-its-product-portfolio-pre-nd-cprx-20150112monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-david-d-muth-executive-vice-president-chief-commercial-o-cprx-20150105monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-the-passing-of-hubert-e-huckel-co-founder-and-director-cprx-20141216monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-notice-of-allowance-of-u-s-patent-application-for-the-r-cprx-20141124monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-third-quarter-2014-financial-results-cprx-20141114monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-proposed-settlement-of-pending-securities-class-action--cprx-20141104monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-positive-top-line-phase-3-data-from-pivotal-firdapse-cl-cprx-20140929monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-david-d-muth-as-executive-vice-president-corporate-devel-cprx-20140904monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-initiates-phase-1-b-safety-and-tolerance-study-for-cpp-11-cprx-20140902monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-second-quarter-2014-financial-results-cprx-20140814monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-provides-updates-on-progress-of-phase-3-firdapse-study-in-cprx-20140811monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-first-quarter-2014-financial-results-and-provid-cprx-20140516monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-announces-initiation-of-an-expanded-access-program-to-provide-firdapse-at-no-cost-cprx-20140423monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-closing-of-previously-announced-public-offe-cprx-20140408monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-commencement-of-public-offering-of-common-s-cprx-20140402monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-announces-completion-of-enrollment-in-pivotal-phase-3-trial-of-firdapse-tm-in-pat-cprx-20140401monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-expands-executive-leadership-team-to-support-the-commerci-cprx-20140328monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-recommendation-of-data-monitoring-committee-to--cprx-20140325monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-fourth-quarter-and-year-end-2013-financial-resu-cprx-20140319monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-successful-completion-of-type-b-breakthrough-ther-cprx-20140106monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-publication-of-preclinical-proof-of-principle-o-cprx-20131118monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-third-quarter-2013-financial-results-cprx-20131114monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-updates-on-its-development-activities-for-firdapse-cprx-20131029monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20131015monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-mcenany-melody-carey-catalyst-pharmaceutical-partn-cprx-20130910monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130905monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130827monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130815monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130802monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130627monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130625monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130516monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130402monthly0.5https://www.biopharmawatch.com/news/CPRX/for-further-information-contact-patrick-j-mcenany-melody-carey-catalyst-pharmaceutical-par-cprx-20130327monthly0.5https://www.biopharmawatch.com/news/CON/concentra-announces-closing-of-pivot-onsite-innovations-acquisition-addison-texas-concentr-con-20250602monthly0.5https://www.biopharmawatch.com/news/CON/concentra-announces-signing-of-definitive-agreement-to-acquire-pivot-onsite-innovations-ad-con-20250331monthly0.5https://www.biopharmawatch.com/news/CON/concentra-announces-preliminary-2024-financial-results-agreement-to-acquire-nova-medical-c-con-20250122monthly0.5https://www.biopharmawatch.com/news/CON/xa9-2024-concentra-inc-all-rights-reserved-investor-presentation-november-2024-xa9-2024-co-con-20241112monthly0.5https://www.biopharmawatch.com/news/CON/concentra-group-holdings-parent-inc-announces-results-for-its-third-quarter-ended-con-20241031monthly0.5https://www.biopharmawatch.com/news/CON/concentra-group-holdings-parent-inc-announces-results-for-its-second-quarter-ended-con-20240801monthly0.5https://www.biopharmawatch.com/news/ORKA/recent-developments-certain-financial-and-operating-data-for-first-quarter-2026-while-we-h-orka-20260430monthly0.5https://www.biopharmawatch.com/news/ORKA/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-stoc-orka-20241114monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-200-million-private-placement-orka-20240912monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-closing-of-merger-with-arca-biopharma-and-previously-announce-orka-20240903monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-provides-update-regarding-special-dividend-amount-in-connection-with-the-pr-orka-20240826monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-1-for-12-reverse-stock-split-in-connection-with-the-proposed-merg-orka-20240823monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-declares-special-dividend-in-connection-with-the-proposed-merger-with-oruka-orka-20240816monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2024-financial-results-and-provides-corporate-upda-orka-20240801monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2024-financial-results-and-provides-corporate-updat-orka-20240425monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-and-oruka-therapeutics-announce-merger-agreement-merger-to-create-a-company-orka-20240403monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-2023-financial-results-x2022-company-is-currently-engaged-in-a-st-orka-20240201monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2023-financial-results-x2022-company-is-currently-e-orka-20231018monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2023-financial-results-x2022-company-is-currently--orka-20230721monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2023-financial-results-x2022-company-is-currently-e-orka-20230424monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-2022-financial-results-and-provides-corporate-update-x2022-compan-orka-20230224monthly0.5https://www.biopharmawatch.com/news/ORKA/james-flynn-joins-arca-biopharma-board-of-directors-westminster-co-orka-20221219monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2022-financial-results-company-is-currently-engaged-orka-20221028monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2022-financial-results-company-is-currently-engage-orka-20220802monthly0.5https://www.biopharmawatch.com/news/ORKA/jacob-ma-weaver-joins-arca-biopharma-board-of-directors-westminster-co-orka-20220621monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-retains-ladenburg-thalmann-to-support-strategic-options-review-westminster--orka-20220505monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2022-financial-results-company-is-currently-engaged-orka-20220502monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-establishes-special-committee-of-the-board-of-directors-westminster-co-orka-20220418monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-reports-topline-results-for-aspen-covid-19-phase-2b-clinical-trial-for-the--orka-20220331monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-2021-financial-results-and-provides-corporate-update-topline-data-orka-20220314monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-completion-of-enrollment-in-phase-2b-aspen-covid-19-clinical-tria-orka-20211202monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2021-financial-results-and-provides-corporate-updat-orka-20211102monthly0.5https://www.biopharmawatch.com/news/ORKA/aspen-covid-19-data-and-safety-monitoring-committee-recommends-continuing-phase-2b-clinica-orka-20211028monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-enrollment-of-first-international-patient-in-phase-2b-clinical-tr-orka-20210916monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-submission-of-pct-patent-application-for-the-treatment-of-coronav-orka-20210809monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2021-financial-results-and-provides-corporate-upda-orka-20210804monthly0.5https://www.biopharmawatch.com/news/ORKA/gencaro-atrial-fibrillation-phase-2b-results-selected-for-publication-in-circulation-arrhy-orka-20210728monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-provides-update-on-aspen-covid-19-phase-2b-clinical-trial-evaluating-rnapc2-orka-20210713monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-rnapc2-covid-19-patent-assignment-agreement-provides-exclusive-wo-orka-20210707monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2021-financial-results-and-provides-corporate-updat-orka-20210511monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-c-jeff-dekker-to-be-appointed-chief-financial-officer-westminster-orka-20210503monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-2020-financial-results-and-provides-corporate-update-topline-data-orka-20210318monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical-trial-orka-20201215monthly0.5https://www.biopharmawatch.com/news/ORKA/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-design-orka-20201123monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2020-financial-results-and-provides-corporate-updat-orka-20201102monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-fda-approval-of-ind-application-for-ab201-as-a-potential-treatmen-orka-20201007monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-submission-of-ind-application-to-u-s-fda-for-ab201-as-a-potential-orka-20200921monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-completion-of-fda-pre-ind-consultation-under-coronavirus-treatmen-orka-20200812monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2020-financial-results-and-provides-corporate-upda-orka-20200805monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-closing-of-6-1-million-registered-direct-offering-westminster-co-orka-20200603monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-9-4-million-registered-direct-offering-westminster-co-orka-20200601monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-ab201-development-program-for-treatment-of-covid-19-associated-co-orka-20200528monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2020-financial-results-and-provides-corporate-updat-orka-20200506monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-fiscal-year-2019-financial-results-and-provides-corporate-update--orka-20200218monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2019-financial-results-and-provides-corporate-updat-orka-20191106monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2019-financial-results-and-provides-corporate-upda-orka-20190801monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2019-financial-results-and-provides-corporate-updat-orka-20190508monthly0.5https://www.biopharmawatch.com/news/ORKA/safe-harbor-statement-this-presentation-contains-forward-looking-statements-for-purposes-o-orka-20190405monthly0.5https://www.biopharmawatch.com/news/ORKA/safe-harbor-statement-this-presentation-contains-forward-looking-statements-for-purposes-o-orka-20190320monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-fiscal-year-2018-financial-results-and-provides-corporate-update--orka-20190227monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-fda-agreement-for-a-single-phase-3-clinical-trial-to-support-appr-orka-20190220monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-updates-special-protocol-assessment-request-to-fda-for-gencaro-phase-3-atri-orka-20181220monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2018-financial-results-and-provides-corporate-updat-orka-20181114monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-submits-special-protocol-assessment-request-to-fda-for-gencaro-phase-3-atri-orka-20180918monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2018-financial-results-and-provides-corporate-upda-orka-20180809monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-positive-outcome-of-end-of-phase-2-meeting-with-fda-on-gencaro-de-orka-20180731monthly0.5https://www.biopharmawatch.com/news/ORKA/genetic-af-phase-2b-clinical-trial-results-presented-in-late-breaking-presentation-at-euro-orka-20180529monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2018-financial-results-and-provides-corporate-updat-orka-20180508monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-and-medtronic-extend-gencaro-clinical-trial-collaboration-agreement-westmin-orka-20180423monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-fiscal-year-2017-financial-results-and-provides-corporate-update--orka-20180322monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-reports-topline-phase-2b-results-for-genetic-af-clinical-trial-gencaro-demo-orka-20180226monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-completion-of-genetic-af-phase-2b-clinical-trial-genetic-af-evalu-orka-20180108monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-issuance-of-european-patent-for-treating-cardiovascular-diseases--orka-20171116monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2017-financial-results-and-provides-business-update-orka-20171109monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-completion-of-enrollment-for-genetic-af-phase-2b-clinical-trial-g-orka-20170816monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-genetic-af-data-and-safety-monitoring-board-recommendation-to-com-orka-20170809monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2017-financial-results-and-provides-business-updat-orka-20170803monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-database-lock-for-genetic-af-phase-2b-interim-efficacy-analysis-d-orka-20170620monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2017-financial-results-and-provides-business-update-orka-20170515monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-200-th-patient-randomized-into-the-genetic-af-seamless-design-pha-orka-20170426monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-fiscal-year-2016-financial-results-and-provides-business-update-g-orka-20170321monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-175-th-patient-randomized-into-the-genetic-af-phase-2b-3-clinical-orka-20170306monthly0.5https://www.biopharmawatch.com/news/ORKA/anders-hove-md-joins-arca-biopharma-board-of-directors-westminster-co-orka-20170221monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-150-th-patient-randomized-into-the-genetic-af-phase-2b-3-clinical-orka-20170118monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2016-financial-results-and-provides-business-update-orka-20161114monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-randomization-of-first-european-patients-in-genetic-af-phase-2b-3-orka-20161006monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-100-th-patient-randomized-into-the-genetic-af-phase-2b-3-clinical-orka-20160818monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2016-financial-results-and-provides-business-updat-orka-20160809monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-first-quarter-2016-financial-results-and-provides-business-update-orka-20160511monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-75-th-patient-enrolled-in-genetic-af-phase-2b-3-clinical-trial-ge-orka-20160418monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-fiscal-year-2015-financial-results-and-provides-business-update-g-orka-20160317monthly0.5https://www.biopharmawatch.com/news/ORKA/genetic-af-clinical-trial-for-prevention-of-atrial-fibrillation-enrolls-50-th-patient-enro-orka-20160112monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-third-quarter-2015-financial-results-and-provides-business-update-orka-20151112monthly0.5https://www.biopharmawatch.com/news/ORKA/gencaro-tm-potential-efficacy-preventing-atrial-flutter-in-heart-failure-paper-to-be-prese-orka-20150909monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-second-quarter-2015-operating-results-and-provides-update-on-rece-orka-20150811monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-37-million-private-placement-proceeds-to-support-advancement-of-b-orka-20150611monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-receives-fda-fast-track-designation-for-gencaro-tm-atrial-fibrillation-deve-orka-20150413monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-provides-genetic-af-clinical-trial-update-genetic-af-trial-evaluating-genca-orka-20150316monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-patent-issuance-for-methods-and-compositions-of-s-isomer-formulat-orka-20150204monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-activation-of-first-canadian-genetic-af-clinical-trial-site-clini-orka-20141211monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-receives-fda-orphan-drug-designation-for-rnapc2-as-a-potential-treatment-fo-orka-20141210monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-management-transitions-westminster-co-orka-20141201monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-health-canada-acceptance-of-genetic-af-clinical-trial-application-orka-20140818monthly0.5https://www.biopharmawatch.com/news/ORKA/robert-e-conway-elected-chairman-of-arca-biopharma-board-of-directors-westminster-co-orka-20140609monthly0.5https://www.biopharmawatch.com/news/ORKA/dan-mitchell-joins-arca-biopharma-board-of-directors-westminster-co-february-12-2014-arca--orka-20140212monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-proposed-public-offering-of-common-stock-and-warrants-westminster-orka-20140203monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-to-present-at-biotech-showcase-2014-westminster-co-orka-20140107monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-us-fda-acceptance-of-gencaro-ind-application-for-the-treatment-of-orka-20131204monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-resignation-from-board-of-directors-westminster-co-orka-20131121monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-clinical-trial-agreement-for-genetic-af-trial-gencaro-potentially-orka-20131106monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-ind-submission-to-us-fda-for-gencaro-for-the-treatment-of-atrial--orka-20131029monthly0.5https://www.biopharmawatch.com/news/ORKA/robert-e-conway-appointed-to-arca-biopharma-board-of-directors-broomfield-co-orka-20130904monthly0.5https://www.biopharmawatch.com/news/ORKA/raymond-l-woosley-m-d-ph-d-appointed-to-arca-biopharma-board-of-directors-broomfield-co-orka-20130730monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-additions-to-genetic-af-leadership-team-team-will-oversee-executi-orka-20130722monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-provides-business-update-genetic-af-trial-evaluating-gencaro-as-potential-t-orka-20130717monthly0.5https://www.biopharmawatch.com/news/ORKA/christopher-d-ozeroff-senior-vice-president-and-general-counsel-720-940-2100-gencaro-tm-po-orka-20130606monthly0.5https://www.biopharmawatch.com/news/ORKA/arca-biopharma-announces-pricing-of-20-million-equity-offering-broomfield-co-orka-20130530monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-investor-relations-advisory-solutions-720-940-2163-derek-cole-arcabiopharma-com-orka-20130506monthly0.5https://www.biopharmawatch.com/news/ORKA/safe-harbor-statement-2-this-presentation-contains-forward-looking-statements-for-purposes-orka-20130423monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-of-investor-relations-720-940-2100-arca-biopharma-and-medtronic--orka-20130422monthly0.5https://www.biopharmawatch.com/news/ORKA/christopher-d-ozeroff-senior-vice-president-and-general-counsel-720-940-2100-unmet-medical-orka-20130206monthly0.5https://www.biopharmawatch.com/news/ORKA/christopher-d-ozeroff-senior-vice-president-and-general-counsel-720-940-2100-new-adaptive--orka-20130129monthly0.5https://www.biopharmawatch.com/news/ORKA/christopher-d-ozeroff-senior-vice-president-and-general-counsel-720-940-2100-gencaro-tm-ef-orka-20130103monthly0.5https://www.biopharmawatch.com/news/ORKA/christopher-d-ozeroff-senior-vice-president-and-general-counsel-720-940-2100-gencaro-tm-ca-orka-20121212monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20120816monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20120326monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20120119monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20111230monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20111222monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20111116monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20111111monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20110526monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20110503monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20110418monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20110415monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20101104monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20101007monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20100517monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20100513monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20100401monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20100326monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20100317monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20100120monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20100111monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20091222monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20091123monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20091116monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20090701monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20090601monthly0.5https://www.biopharmawatch.com/news/ORKA/derek-cole-vice-president-investor-relations-corporate-communications-720-940-2163-derek-c-orka-20090225monthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-reports-fourth-quarter-and-full-year-2025-financial-results-san-francisco-cal-hnge-20260210monthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-announces-250-million-share-repurchase-program-san-francisco-california-x2013-hnge-20251112monthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-reports-third-quarter-2025-financial-results-san-francisco-california-x2013-hnge-20251104monthly0.5https://www.biopharmawatch.com/news/HNGE/hinge-health-reports-second-quarter-2025-financial-results-san-francisco-california-x2013-hnge-20250805monthly0.5https://www.biopharmawatch.com/news/KLRA/kailera-reports-first-quarter-2026-financial-results-and-provides-clinical-data-updates-x2-klra-20260526monthly0.5https://www.biopharmawatch.com/news/DYN/advancing-clinically-validated-platform-toward-commercialization-44th-annual-j-p-morgan-he-dyn-20260112monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-pricing-of-upsized-350-0-million-public-offering-of-common-sto-dyn-20251209monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-highli-dyn-20250728monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-fda-breakthrough-therapy-designation-for-dyne-101-and-updated--dyn-20250617monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-first-quarter-2025-financial-results-and-recent-business-highlig-dyn-20250508monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-b-dyn-20250227monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-new-clinical-data-showing-compelling-impact-on-multiple-measures-dyn-20250110monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-upda-dyn-20241112monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-new-clinical-data-from-phase-1-2-deliver-trial-of-dyne-251-in--dyn-20240903monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-second-quarter-2024-financial-results-and-recent-business-highli-dyn-20240812monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-pricing-of-325-5-million-public-offering-of-common-stock-dyn-20240521monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-new-clinical-data-from-achieve-trial-of-dyne-101-in-dm1-and-de-dyn-20240520monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-first-quarter-2024-financial-results-and-recent-business-highlig-dyn-20240502monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-b-dyn-20240305monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-pricing-of-300-million-public-offering-of-common-stock-dyn-20240104monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-positive-initial-clinical-data-from-achieve-trial-in-dm1-patie-dyn-20240103monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-third-quarter-2023-financial-results-and-provides-update-on-sign-dyn-20231030monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-second-quarter-2023-financial-results-and-business-highlights-on-dyn-20230803monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-first-quarter-2023-financial-results-and-business-highlights-on--dyn-20230511monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-business-dyn-20230302monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-third-quarter-2022-financial-results-and-business-highlights-dyn-dyn-20221103monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-second-quarter-2022-financial-results-and-business-highlights-in-dyn-20220804monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-first-quarter-2022-financial-results-and-business-highlights-ini-dyn-20220502monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-h-dyn-20220310monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-third-quarter-2021-financial-results-and-business-highlights-rob-dyn-20211104monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-second-quarter-2021-financial-results-and-business-highlights-on-dyn-20210805monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-first-quarter-2021-financial-results-and-business-highlights-on--dyn-20210506monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-h-dyn-20210304monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-third-quarter-2020-financial-results-and-recent-highlights-succe-dyn-20201105monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-third-quarter-2025-financial-results-and-provides-a-pipeline-upd-rcus-20251028monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-second-quarter-2025-financial-results-and-provides-a-pipeline-up-rcus-20250806monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-first-quarter-2025-financial-results-and-provides-a-pipeline-upd-rcus-20250506monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-rcus-20250225monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-third-quarter-2024-financial-results-and-provides-a-pipeline-upd-rcus-20241106monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-second-quarter-2024-financial-results-and-provides-a-pipeline-up-rcus-20240808monthly0.5https://www.biopharmawatch.com/news/RCUS/arc-9-a-randomized-study-to-evaluate-etrumadenant-based-treatment-combinations-in-previous-rcus-20240523monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-first-quarter-2024-financial-results-and-provides-a-pipeline-upd-rcus-20240508monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-rcus-20240221monthly0.5https://www.biopharmawatch.com/news/RCUS/gilead-contacts-jacquie-ross-investors-investor-relations-gilead-com-meaghan-smith-media-p-rcus-20240129monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-third-quarter-2023-financial-results-and-provides-a-pipeline-upd-rcus-20231107monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-second-quarter-2023-financial-results-and-provides-a-pipeline-up-rcus-20230807monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-first-quarter-2023-financial-results-and-provides-a-pipeline-upd-rcus-20230509monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-rcus-20230228monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-third-quarter-2022-financial-results-and-provides-a-pipeline-upd-rcus-20221102monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-second-quarter-2022-financial-results-and-provides-a-pipeline-up-rcus-20220803monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-first-quarter-2022-financial-results-and-provides-a-pipeline-upd-rcus-20220509monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-rcus-20220223monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-third-quarter-2021-financial-results-and-provides-an-update-on-o-rcus-20211108monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-second-quarter-2021-financial-results-and-provides-operational-h-rcus-20210805monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-chief-medical-officer-transitions-to-role-at-gilead-sciences-kartik-krishnan-m-d-ph--rcus-20210719monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-first-quarter-2021-financial-results-and-provides-operational-hi-rcus-20210505monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-rcus-20210224monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-third-quarter-2020-financial-results-and-corporate-updates-com-rcus-20201105monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-second-quarter-2020-financial-results-and-corporate-updates-es-rcus-20200806monthly0.5https://www.biopharmawatch.com/news/RCUS/certain-information-has-been-omitted-because-it-is-both-not-material-and-would-be-competit-rcus-20200713monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-first-quarter-2020-financial-results-and-corporate-updates-pre-rcus-20200505monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-s-covid-19-statement-despite-the-ongoing-situation-with-covid-19-we-continue-to-see--rcus-20200407monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-fourth-quarter-and-full-year-2019-financial-results-and-corpor-rcus-20200305monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-third-quarter-2019-financial-results-and-recent-corporate-upda-rcus-20191105monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-second-quarter-2019-financial-results-and-recent-corporate-upd-rcus-20190806monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-first-quarter-2019-financial-results-and-recent-corporate-upda-rcus-20190502monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-fourth-quarter-and-full-year-2018-financial-results-and-recent-rcus-20190305monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-third-quarter-2018-financial-results-and-recent-corporate-upda-rcus-20181108monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-second-quarter-2018-financial-results-and-recent-corporate-upd-rcus-20180806monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-that-taiho-pharmaceutical-has-exercised-its-option-to-develop--rcus-20180712monthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-first-quarter-2018-financial-results-and-recent-corporate-upda-rcus-20180509monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-reports-first-quarter-2026-financial-results-and-highlights-recent-achievements-lat-alms-20260514monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-envudeucitinib-delivers-leading-skin-clearance-among-next-generation-oral-plaque-ps-alms-20260106monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-reports-third-quarter-2025-financial-results-and-highlights-recent-progress-alms-20251113monthly0.5https://www.biopharmawatch.com/news/ALMS/transform-therapies-reimagine-lives-september-2025-corporate-presentation-2-xa9-alumis-for-alms-20250903monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-completes-merger-with-acelyrin-establishes-leading-clinical-stage-biopharma-company-alms-20250521monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-reports-first-quarter-2025-financial-results-and-highlights-recent-achievements-alms-20250514monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-and-acelyrin-announce-amended-merger-agreement-acelyrin-stockholders-to-receive-inc-alms-20250421monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-and-kaken-pharmaceutical-announce-collaboration-and-licensing-agreement-for-esk-001-alms-20250325monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-reports-year-end-2024-financial-results-and-highlights-recent-achievements-presente-alms-20250319monthly0.5https://www.biopharmawatch.com/news/ALMS/transform-therapies-reimagine-lives-march-2025-corporate-presentation-supplemental-materia-alms-20250318monthly0.5https://www.biopharmawatch.com/news/ALMS/late-breaking-esk-001-phase-2-ole-data-presented-at-2025-aad-annual-meeting-demonstrate-ro-alms-20250308monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-and-acelyrin-reaffirm-strategic-and-financial-rationale-of-proposed-merger-combined-alms-20250304monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-and-acelyrin-to-merge-creating-a-late-stage-clinical-biopharma-company-dedicated-to-alms-20250206monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-reports-third-quarter-2024-financial-results-and-highlights-recent-achievements-pre-alms-20241113monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-reports-second-quarter-2024-financial-results-and-highlights-recent-development-and-alms-20240813monthly0.5https://www.biopharmawatch.com/news/DNLI/biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122-dnl151-in--dnli-20260521monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-busine-dnli-20260226monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-key-anticipated-milestones-and-priorities-for-2026-including-dnli-20260106monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-wa-dnli-20251210monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-second-quarter-2025-financial-results-and-business-highlights--dnli-20250811monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-fda-acceptance-and-priority-review-of-biologics-license-appl-dnli-20250707monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-initiation-of-bla-filing-for-accelerated-approval-of-tividen-dnli-20250402monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-busine-dnli-20250227monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-key-anticipated-2025-milestones-and-priorities-to-further-ad-dnli-20250113monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-topline-results-for-regimen-g-evaluating-eif2b-agonist-dnl34-dnli-20250106monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-third-quarter-2024-financial-results-and-business-highlights-s-dnli-20241106monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-second-quarter-2024-financial-results-and-business-highlights--dnli-20240801monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-first-quarter-2024-financial-results-and-business-highlights-s-dnli-20240507monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-busine-dnli-20240227monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-key-anticipated-2024-milestones-and-priorities-to-further-ad-dnli-20240108monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-third-quarter-2023-financial-results-and-business-highlights-s-dnli-20231107monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-second-quarter-2023-financial-results-and-business-highlights--dnli-20230808monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-robust-reduction-in-neurofilament-light-nfl-with-dnl310-etv--dnli-20230620monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-first-quarter-2023-financial-results-and-business-highlights-dnli-20230508monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-busine-dnli-20230227monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-key-anticipated-2023-milestones-for-its-therapeutic-portfoli-dnli-20230109monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-third-quarter-2022-financial-results-and-business-highlights-dnli-20221103monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-pricing-of-275-million-public-offering-of-common-stock-dnli-20221019monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-proposed-offering-of-common-stock-dnli-20221018monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-second-quarter-2022-financial-results-and-business-highlights-dnli-20220808monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-first-quarter-2022-financial-results-and-business-highlights-dnli-20220505monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-appoints-alexander-schuth-as-chief-operating-and-financial-officer-as--dnli-20220315monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-busine-dnli-20220228monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-continued-progress-in-dnl310-etv-ids-program-for-mps-ii-hunt-dnli-20220210monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-appointment-of-erik-harris-to-board-of-directors-dnli-20220207monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-progression-and-expansion-of-broad-therapeutic-portfolio-for-dnli-20220110monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-strategic-partner-takeda-exercises-option-to-co-develop-and--dnli-20211117monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-third-quarter-2021-financial-results-and-business-highlights-dnli-20211104monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-second-quarter-2021-financial-results-and-business-highlights-dnli-20210804monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-positive-interim-data-from-phase-1-2-study-with-etv-ids-dnl3-dnli-20210725monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-first-quarter-2021-financial-results-and-business-highlights-dnli-20210503monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-full-year-2020-financial-results-and-business-highlights-dnli-20210225monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-positive-three-month-data-from-phase-1-2-study-with-etv-ids-dn-dnli-20210212monthly0.5https://www.biopharmawatch.com/news/DNLI/in-the-court-of-chancery-of-the-state-of-delaware-john-solak-derivatively-on-behalf-of-den-dnli-20210205monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-appointment-of-nancy-thornberry-to-board-of-directors-dnli-20210111monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-first-human-biomarker-proof-of-concept-for-its-transport-veh-dnli-20201110monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-third-quarter-2020-financial-results-and-business-highlights-dnli-20201105monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-closing-of-collaboration-and-share-purchase-agreements-with--dnli-20201007monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-second-quarter-2020-financial-results-and-business-highlights-dnli-20200807monthly0.5https://www.biopharmawatch.com/news/DNLI/biogen-and-denali-to-collaborate-on-lrrk2-program-for-parkinson-s-disease-and-certain-tv-p-dnli-20200806monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-first-quarter-2020-financial-results-and-provides-covid-19-res-dnli-20200507monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-provides-pipeline-and-business-update-in-response-to-the-covid-19-pand-dnli-20200402monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-full-year-2019-financial-results-and-business-highlights-dnli-20200227monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-pricing-of-public-offering-of-common-stock-dnli-20200128monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-proposed-offering-of-common-stock-dnli-20200127monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-broad-pipeline-progress-including-positive-results-from-its--dnli-20200114monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-third-quarter-2019-financial-results-and-business-highlights-dnli-20191106monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-second-quarter-2019-financial-results-and-business-highlights-dnli-20190806monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-first-quarter-2019-financial-results-dnli-20190508monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-full-year-2018-financial-results-and-business-highlights-dnli-20190312monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-positive-clinical-results-with-its-lead-ripk1-inhibitor-mole-dnli-20181119monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-third-quarter-2018-financial-results-and-business-highlights-a-dnli-20181108monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-broad-collaboration-with-sanofi-to-develop-ripk1-inhibitors--dnli-20181101monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-second-quarter-2018-financial-results-dnli-20180809monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-positive-clinical-results-from-lrrk2-inhibitor-program-for-p-dnli-20180801monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-early-exercise-of-its-option-to-acquire-f-star-gamma-dnli-20180530monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-reports-first-quarter-2018-financial-results-dnli-20180511monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-first-in-human-dosing-of-its-ripk1-inhibitor-clinical-progra-dnli-20180319monthly0.5https://www.biopharmawatch.com/news/DNLI/takeda-and-denali-therapeutics-collaborate-to-develop-and-commercialize-therapies-for-neur-dnli-20180105monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-closing-of-initial-public-offering-including-full-exercise-o-dnli-20171212monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights--gpcr-20260507monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-positive-topline-data-from-phase-2-access-ii-trial-with-onc-gpcr-20260316monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-rec-gpcr-20260226monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-positive-topline-gpcr-20251208monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-second-quarter-2025-financial-results-and-recent-highlights-gpcr-20250806monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-first-quarter-2025-financial-results-and-recent-highlights--gpcr-20250508monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-rec-gpcr-20250227monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-announces-selection-of-lead-oral-small-molecule-amylin-receptor-ago-gpcr-20241217monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-third-quarter-2024-financial-results-and-recent-highlights--gpcr-20241113monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-strengthens-executive-team-with-promotion-of-blai-coll-m-d-ph-d-to--gpcr-20240917monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-second-quarter-2024-financial-results-and-recent-highlights-gpcr-20240808monthly0.5https://www.biopharmawatch.com/news/GPCR/as-of-the-date-of-this-current-report-structure-therapeutics-inc-the-company-updates-and-s-gpcr-20240603monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-positive-topline-data-from-its-phase-2a-obesity-study-and-c-gpcr-20240603monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-first-quarter-2024-financial-results-and-recent-highlights--gpcr-20240509monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-rec-gpcr-20240308monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-provides-comprehensive-gsbr-1290-program-update-including-clinicall-gpcr-20231218monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-third-quarter-2023-financial-results-and-recent-highlights--gpcr-20231114monthly0.5https://www.biopharmawatch.com/news/GPCR/share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-dated-as-of-gpcr-20230929monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-announces-positive-results-from-phase-1b-clinical-study-of-oral-glp-gpcr-20230929monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-second-quarter-2023-financial-results-and-recent-highlights-gpcr-20230810monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-first-quarter-2023-financial-results-and-recent-highlights--gpcr-20230511monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-rec-gpcr-20230330monthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-appoints-adrian-mitchell-as-chief-financial-officer-wrby-20260209monthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-partners-with-google-to-develop-intelligent-eyewear-ai-powered-glasses-will-b-wrby-20250520monthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-announces-update-regarding-conversion-of-shares-of-class-b-common-stock-to-sh-wrby-20210928monthly0.5https://www.biopharmawatch.com/news/WRBY/warby-parker-releases-financial-guidance-for-the-third-quarter-and-fiscal-year-2021-and-fi-wrby-20210921monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-78-hae-20260605monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-jo-hae-20260507monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-jo-hae-20260205monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-olga-guyette-vp-investor-relations-treasury-781-356-9763-olga-guyette-ha-hae-20260109monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-jo-hae-20251106monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-jo-hae-20250807monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-jo-hae-20250508monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-olga-guyette-vice-president-investor-relations-treasury-781-356-9763-olg-hae-20250303monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-jo-hae-20250206monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-78-hae-20250114monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-78-hae-20241203monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-jo-hae-20241107monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-vice-president-investor-relations-treasury-jo-hae-20240808monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-olga-guyette-sr-director-investor-relations-treasury-david-trenk-manager-hae-20240522monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh--hae-20240509monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-olga-guyette-sr-director-investor-relations-treasury-781-356-9763-olga-g-hae-20240401monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-olga-guyette-sr-director-investor-relations-treasury-781-356-9763-olga-g-hae-20240305monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh--hae-20240208monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-olga-guyette-sr-director-investor-relations-treasury-781-356-9763-olga-g-hae-20231212monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh--hae-20231102monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-olga-guyette-sr-director-investor-relations-treasury-781-356-9763-olga-g-hae-20231010monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh--hae-20230808monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-olga-guyette-sr-director-investor-relations-treasury-781-356-9763-olga-g-hae-20230807monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh--hae-20230511monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh--hae-20230207monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh-g-hae-20221107monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh-g-hae-20220810monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-sr-director-investor-relations-treasury-josh-g-hae-20220510monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-olga-guyette-director-investor-relations-781-356-9763-olga-guyette-haemon-hae-20220321monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-josh-gitelson-dire-hae-20220208monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-josh-gitelson-dire-hae-20211109monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-josh-gitelson-dire-hae-20210811monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-carla-burigatto-vp-hae-20210513monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-olga-guyette-director-investor-relations-781-356-9763-olga-guyette-haemon-hae-20210419monthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-prices-435-0-million-convertible-senior-notes-offering-boston-hae-20210302monthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-announces-proposed-convertible-senior-notes-offering-boston-hae-20210301monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-carla-burigatto-vp-hae-20210202monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-olga-guyette-director-investor-relations-781-356-9763-olga-guyette-haemon-hae-20210120monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-carla-burigatto-vp-hae-20201104monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-carla-burigatto-vp-hae-20200804monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-carla-burigatto-vp-hae-20200505monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-media-contact-olga-guyette-director-investor-relations-carla-burigatto-vp-hae-20200204monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy20-q2-investor-contact-media-contact-olga-guyette-sr-mgr-investor-relat-hae-20191101monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy20-q1-investor-contacts-media-contact-gerry-gould-vp-investor-relations-hae-20190806monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contacts-media-contact-gerry-gould-vp-investor-relations-781-356-9402-gerry-gould-hae-20190722monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy19-q4-investor-contacts-media-contact-gerry-gould-vp-investor-relations-hae-20190507monthly0.5https://www.biopharmawatch.com/news/HAE/investor-contact-gerry-gould-vp-investor-relations-781-356-9402-gerry-gould-haemonetics-co-hae-20190429monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy19-q3-investor-contacts-media-contact-gerry-gould-vp-investor-relations-hae-20190205monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy19-q2-investor-contact-media-contact-gerry-gould-vp-investor-relations--hae-20181106monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy19-q1-investor-contact-media-contact-gerry-gould-vp-investor-relations--hae-20180807monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy18-q4-investor-contact-media-contact-gerry-gould-vp-investor-relations--hae-20180508monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy18-q3-investor-contact-media-contact-gerry-gould-vp-investor-relations--hae-20180206monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy18-q2-investor-contact-media-contact-gerry-gould-vp-investor-relations--hae-20171107monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy18-q1-investor-contact-gerry-gould-vp-investor-relations-781-356-9402-g-hae-20170807monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy17-q4-investor-contact-gerry-gould-vp-investor-relations-781-356-9402-g-hae-20170508monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy17-q3-investor-contact-gerry-gould-vp-investor-relations-781-356-9402-g-hae-20170206monthly0.5https://www.biopharmawatch.com/news/HAE/earnings-release-fy17-q2-investor-contact-gerry-gould-vp-investor-relations-781-356-9402-g-hae-20161107monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20160801monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-investor-contact-date-hae-20160509monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20160502monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20160201monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20151104monthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-pre-announces-2-nd-quarter-results-revises-fiscal-year-2016-guidance-and-sets--hae-20151005monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20150727monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20150427monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20140428monthly0.5https://www.biopharmawatch.com/news/HAE/arctender-news-release-for-release-contact-date-hae-20140324monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20140127monthly0.5https://www.biopharmawatch.com/news/HAE/ex-1-99-2-ex99101122014hemexcelpress-htm-exhibit-ex99101122014hemexcelpressrelease-for-rel-hae-20140112monthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-corporation-financial-summary-unaudited-data-in-thousands-except-per-share-dat-hae-20130503monthly0.5https://www.biopharmawatch.com/news/HAE/for-release-contact-date-hae-20130501monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-first-quarter-2026-financial-results-strong-first-quarter-performanc-prva-20260507monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-third-quarter-2025-financial-results-very-strong-third-quarter-and-y-prva-20251106monthly0.5https://www.biopharmawatch.com/news/PRVA/would-could-should-and-variations-of-such-terms-and-similar-expressions-and-references-to--prva-20250923monthly0.5https://www.biopharmawatch.com/news/PRVA/financial-and-operational-impact-of-our-compliance-with-various-complex-and-changing-feder-prva-20250829monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-second-quarter-2025-financial-results-very-strong-first-half-perform-prva-20250807monthly0.5https://www.biopharmawatch.com/news/PRVA/does-not-undertake-any-obligation-to-update-or-revise-any-forward-looking-statements-wheth-prva-20250708monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-first-quarter-2025-financial-results-strong-first-quarter-performanc-prva-20250508monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-fourth-quarter-and-full-year-2024-financial-results-all-2024-operati-prva-20250227monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-third-quarter-2024-financial-results-strong-execution-across-all-bus-prva-20241107monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-second-quarter-2024-financial-results-strong-execution-across-all-bu-prva-20240808monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-first-quarter-2024-financial-results-practice-collections-7-4-compar-prva-20240509monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-fourth-quarter-and-full-year-2023-financial-results-achieved-all-202-prva-20240227monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-appoints-edward-c-fargis-as-general-counsel-arlington-va-prva-20240129monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-third-quarter-2023-financial-results-announces-new-market-entry-in-s-prva-20231103monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-second-quarter-2023-financial-results-practice-collections-13-7-comp-prva-20230803monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-announces-changes-to-board-of-directors-distinguished-healthcare-leader-dave-prva-20230731monthly0.5https://www.biopharmawatch.com/news/PRVA/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-fo-prva-20230508monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-first-quarter-2023-financial-results-practice-collections-17-3-compa-prva-20230504monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-announces-leadership-succession-current-president-and-coo-parth-mehrotra-nam-prva-20230412monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-fourth-quarter-2022-financial-results-fy-2022-financial-results-at-o-prva-20230228monthly0.5https://www.biopharmawatch.com/news/PRVA/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-fo-prva-20221121monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-announces-change-to-its-board-of-directors-arlington-va-prva-20221115monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-third-quarter-2022-financial-results-results-and-outlook-reflect-str-prva-20221110monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-second-quarter-2022-financial-results-updated-guidance-reflects-stro-prva-20220811monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-first-quarter-2022-financial-results-updated-financial-guidance-refl-prva-20220512monthly0.5https://www.biopharmawatch.com/news/PRVA/nancy-cocozza-joins-privia-health-s-board-of-directors-arlington-va-prva-20220331monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-fourth-quarter-2021-financial-results-fy-2021-financial-results-abov-prva-20220323monthly0.5https://www.biopharmawatch.com/news/PRVA/investorpresentatio-proprietary-and-confidential-j-p-morgan-healthcare-conference-prva-20220110monthly0.5https://www.biopharmawatch.com/news/PRVA/jeff-sherman-joins-privia-health-as-chief-financial-officer-arlington-va-prva-20220106monthly0.5https://www.biopharmawatch.com/news/PRVA/empowering-physicians-transforming-healthcare-piper-sandler-value-based-care-webinar-prva-20211221monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-third-quarter-2021-financial-results-raises-full-year-2021-guidance--prva-20211108monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-second-quarter-2021-financial-results-arlington-va-prva-20210809monthly0.5https://www.biopharmawatch.com/news/PRVA/dr-jaewon-ryu-joins-privia-health-s-board-of-directors-arlington-va-prva-20210630monthly0.5https://www.biopharmawatch.com/news/PRVA/priviainvesto-proprietary-and-confidential-investor-presentation-june-2021-empowering-phys-prva-20210527monthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-reports-first-quarter-2021-financial-results-arlington-va-prva-20210527monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-first-quarter-2026-financial-results-and-recent-business-achieveme-tars-20260506monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-bus-tars-20260223monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-third-quarter-2025-financial-results-and-recent-business-achieveme-tars-20251104monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-second-quarter-2025-financial-results-and-recent-business-achievem-tars-20250806monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-first-quarter-2025-financial-results-and-recent-business-achieveme-tars-20250501monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-proposed-100-0-million-public-offering-tars-20250312monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-strong-fourth-quarter-and-full-year-2024-financial-results-and-rec-tars-20250225monthly0.5https://www.biopharmawatch.com/news/TARS/the-future-of-eye-care-begins-here-january-2025-matt-an-xdemvy-patient-forward-looking-sta-tars-20250113monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-third-quarter-and-year-to-date-2024-financial-results-and-recent-b-tars-20241113monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-second-quarter-and-year-to-date-2024-financial-results-and-recent--tars-20240808monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-first-quarter-2024-financial-results-and-recent-business-achieveme-tars-20240508monthly0.5https://www.biopharmawatch.com/news/TARS/disease-prevention-xdemvy-lotilaner-ophthalmic-solution-0-25-is-fda-approved-in-the-united-tars-20240423monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-proposed-100-0-million-public-offering-tars-20240229monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-strong-fourth-quarter-and-full-year-2023-financial-results-and-rec-tars-20240227monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-third-quarter-2023-financial-results-and-recent-business-achieveme-tars-20231109monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-second-quarter-2023-financial-results-and-recent-business-achievem-tars-20230810monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-proposed-100-0-million-underwritten-public-offering-of-shares-of-its-comm-tars-20230731monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-first-quarter-2023-financial-results-and-recent-business-achieveme-tars-20230509monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-full-year-2022-financial-results-and-recent-business-achievements--tars-20230313monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-third-quarter-2022-financial-results-and-recent-business-achieveme-tars-20221109monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-second-quarter-2022-financial-results-and-recent-business-achievem-tars-20220811monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-reports-first-quarter-2022-financial-results-and-recent-business-achieveme-tars-20220510monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-proposed-50-million-underwritten-public-offering-of-shares-of-its-common--tars-20220502monthly0.5https://www.biopharmawatch.com/news/TARS/legal-disclaimer-this-presentation-contains-forward-looking-statements-that-involve-risks--tars-20220502monthly0.5https://www.biopharmawatch.com/news/TARS/tp-03-met-all-primary-and-secondary-endpoints-again-in-saturn-2-with-a-complete-resolution-tars-20220502monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-pharmaceuticals-inc-reports-full-year-2021-financial-results-and-recent-bu-tars-20220314monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-appoints-elizabeth-yeu-m-d-a-nationally-recognized-ophthalmologist-and-eye-tars-20220104monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-pharmaceuticals-inc-reports-third-quarter-2021-financial-results-and-recen-tars-20211109monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-appoints-pharmaceutical-and-healthcare-industry-leader-rosemary-tars-20210812monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-pharmaceuticals-inc-reports-second-quarter-2021-financial-results-and-prov-tars-20210805monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-announces-positive-results-of-saturn-1-pivotal-trial-evaluating-tars-20210621monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-pharmaceuticals-inc-reports-first-quarter-2021-financial-results-and-provi-tars-20210511monthly0.5https://www.biopharmawatch.com/news/TARS/legal-disclaimer-this-presentation-contains-forward-looking-statements-that-involve-risks--tars-20210409monthly0.5https://www.biopharmawatch.com/news/TARS/document-tarsus-pharmaceuticals-inc-reports-full-year-2020-financial-results-and-business--tars-20210331monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-and-lianbio-announce-strategic-partnership-to-develop-and-commercia-tars-20210329monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-appoints-wendy-yarno-to-board-of-directors-tars-20201119monthly0.5https://www.biopharmawatch.com/news/TARS/legal-disclaimer-this-presentation-contains-forward-looking-statements-that-involve-risks--tars-20201117monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-first-quarter-2026-financial-results-and-corporate-updates-fda--rlay-20260505monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-data-from-zovegalisib-fulvestrant-at-the-phase-3-dose-of-400m-rlay-20260316monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-outline-rlay-20260226monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-second-quarter-2025-financial-results-and-corporate-updates-pre-rlay-20250807monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-first-quarter-2025-financial-results-and-corporate-updates-cash-rlay-20250505monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-corpora-rlay-20250226monthly0.5https://www.biopharmawatch.com/news/RLAY/disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-rlay-20250113monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-updated-interim-data-for-rly-2608-fulvestrant-demonstrating-c-rlay-20241211monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-highlights-r-rlay-20241106monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-proposed-public-offering-of-common-stock-rlay-20240909monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-positive-interim-data-for-rly-2608-demonstrating-clinically-m-rlay-20240909monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-second-quarter-2024-financial-results-and-corporate-highlights--rlay-20240806monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-clinical-trial-collaboration-with-pfizer-to-evaluate-atirmoci-rlay-20240605monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-first-quarter-2024-financial-results-and-corporate-highlights-a-rlay-20240502monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-corpora-rlay-20240222monthly0.5https://www.biopharmawatch.com/news/RLAY/disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-rlay-20240108monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-third-quarter-2023-financial-results-and-corporate-highlights-r-rlay-20231102monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-initial-rly-4008-lirafugratinib-data-demonstrating-durable-re-rlay-20231012monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-second-quarter-2023-financial-results-and-corporate-highlights--rlay-20230808monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-full-dose-escalation-data-for-rly-4008-data-from-fgfri-na-ve--rlay-20230525monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-first-quarter-2023-financial-results-and-corporate-highlights-p-rlay-20230504monthly0.5https://www.biopharmawatch.com/news/RLAY/disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-rlay-20230418monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-corpora-rlay-20230223monthly0.5https://www.biopharmawatch.com/news/RLAY/jpm-presentation-january-2023-disclaimer-this-presentation-contains-forward-looking-statem-rlay-20230109monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-third-quarter-2022-financial-results-and-corporate-highlights-s-rlay-20221103monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-proposed-public-offering-of-common-stock-cambridge-ma-rlay-20220912monthly0.5https://www.biopharmawatch.com/news/RLAY/late-breaking-data-presented-at-esmo-congress-2022-demonstrate-potential-of-rly-4008-to-tr-rlay-20220911monthly0.5https://www.biopharmawatch.com/news/RLAY/hollebecque-esmo-2022-rly-4008-lba-final-efficacy-of-rly-4008-a-highly-selective-fgfr2-inh-rlay-20220908monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-second-quarter-2022-financial-results-and-corporate-highlights--rlay-20220804monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-discloses-anticipated-registrational-path-for-rly-4008-in-cholangiocarc-rlay-20220627monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-first-quarter-2022-financial-results-and-corporate-highlights-i-rlay-20220505monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-corpora-rlay-20220224monthly0.5https://www.biopharmawatch.com/news/RLAY/disclaimer-this-presentation-contains-forward-looking-statements-and-information-about-our-rlay-20220110monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-third-quarter-2021-financial-results-and-recent-corporate-highl-rlay-20211110monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-proposed-public-offering-of-common-stock-cambridge-ma-rlay-20211011monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-preclinical-data-that-support-rly-2608-as-the-first-known-all-rlay-20211007monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-corporate-updates-and-reports-second-quarter-2021-financial-r-rlay-20210812monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-first-quarter-2021-financial-results-cambridge-ma-rlay-20210513monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-extends-leadership-in-integrating-computational-and-experimental-approa-rlay-20210416monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-operati-rlay-20210325monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-a-worldwide-license-and-collaboration-agreement-with-genentec-rlay-20201214monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-third-quarter-2020-financial-results-cambridge-ma-rlay-20201112monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-reports-second-quarter-2020-financial-results-cambridge-ma-rlay-20200827monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-fourth-quarter-and-full-year-2025-financial-results-and-provide-arqt-20260225monthly0.5https://www.biopharmawatch.com/news/ARQT/media-amanda-sheldon-head-of-corporate-communications-media-arcutis-com-investors-brian-sc-arqt-20251208monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-outlines-strategy-for-driving-sustainable-growth-and-announces-third-quar-arqt-20251028monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-second-quarter-2025-financial-results-and-provides-business-upd-arqt-20250806monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-first-quarter-2025-financial-results-and-provides-business-upda-arqt-20250506monthly0.5https://www.biopharmawatch.com/news/ARQT/document-for-immediate-release-arcutis-announces-chief-financial-officer-transition-arqt-20250410monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-fourth-quarter-and-full-year-2024-financial-results-and-provide-arqt-20250225monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-preliminary-unaudited-fourth-quarter-product-revenue-and-full-y-arqt-20241231monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-third-quarter-2024-financial-results-and-provides-business-upda-arqt-20241106monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-second-quarter-2024-financial-results-and-provides-business-upd-arqt-20240814monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-first-quarter-2024-financial-results-and-provides-business-upda-arqt-20240514monthly0.5https://www.biopharmawatch.com/news/ARQT/not-historical-facts-are-forward-looking-statements-these-statements-are-based-on-the-comp-arqt-20240410monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-fourth-quarter-and-full-year-2023-financial-results-and-provide-arqt-20240227monthly0.5https://www.biopharmawatch.com/news/ARQT/toxc-option-exchange-offer-arqt-20240111monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-third-quarter-2023-financial-results-and-provides-business-upda-arqt-20231103monthly0.5https://www.biopharmawatch.com/news/ARQT/8xk-corporate-overview-2-copyright-2023-arcutis-biotherapeutics-inc-presentation-designed--arqt-20230930monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-second-quarter-2023-financial-results-and-provides-business-upd-arqt-20230808monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-first-quarter-2023-financial-results-and-provides-business-upda-arqt-20230509monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-fourth-quarter-and-full-year-2022-financial-results-and-provide-arqt-20230228monthly0.5https://www.biopharmawatch.com/news/ARQT/8xk-corporate-overview-2-copyright-2022-arcutis-biotherapeutics-inc-presentation-designed--arqt-20221216monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-third-quarter-2022-financial-results-and-provides-business-upda-arqt-20221108monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-acquisition-of-ducentis-biotherapeutics-ltd-leverages-arcutis-deep-derma-arqt-20220907monthly0.5https://www.biopharmawatch.com/news/ARQT/document-exhibit-1-1-arcutis-announces-appointment-of-neha-krishnamohan-to-board-of-direct-arqt-20220902monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-second-quarter-2022-financial-results-and-provides-business-upd-arqt-20220804monthly0.5https://www.biopharmawatch.com/news/ARQT/corporate-overview-2-copyright-2022-arcutis-biotherapeutics-inc-presentation-designed-for--arqt-20220802monthly0.5https://www.biopharmawatch.com/news/ARQT/8xk692022-arcutis-announces-positive-topline-results-from-stratum-pivotal-phase-3-trial-of-arqt-20220606monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-first-quarter-2022-financial-results-and-provides-business-upda-arqt-20220505monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-fourth-quarter-and-full-year-2021-financial-results-and-provide-arqt-20220222monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-biotherapeutics-secures-225-million-in-non-dilutive-debt-financing-from-s-arqt-20211223monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-third-quarter-2021-financial-results-and-provides-business-upda-arqt-20211104monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-second-quarter-2021-financial-results-and-provides-business-upd-arqt-20210805monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-first-quarter-2021-financial-results-and-provides-business-upda-arqt-20210504monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-fourth-quarter-and-full-year-2020-financial-results-and-provide-arqt-20210216monthly0.5https://www.biopharmawatch.com/news/ARQT/8xk-dermis-1-dermis-2-phase-3-plaque-psoriasis-topline-data-review-february-2021-legal-dis-arqt-20210201monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-topline-data-from-phase-2b-study-of-arq-154-topical-roflumilast-arqt-20201123monthly0.5https://www.biopharmawatch.com/news/ARQT/document-arcutis-announces-third-quarter-2020-financial-results-and-provides-business-upda-arqt-20201105monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-appointment-of-terrie-curran-to-board-of-directors-westlake-village-ca-arqt-20201104monthly0.5https://www.biopharmawatch.com/news/ARQT/seborrheic-dermatitis-september-2020-legal-disclaimers-this-presentation-and-the-accompany-arqt-20200929monthly0.5https://www.biopharmawatch.com/news/ARQT/preliminary-data-from-long-term-safety-study-support-chronic-use-of-arq-151-topical-roflum-arqt-20200731monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-quarter-2020-financial-results-and-provides-business-update-multip-arqt-20200512monthly0.5https://www.biopharmawatch.com/news/ARQT/halley-e-gilbert-appointed-to-arcutis-board-of-directors-westlake-village-ca-arqt-20200427monthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-reports-fourth-quarter-and-full-year-2025-financial-results-rai-grdn-20260311monthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-reports-third-quarter-2025-financial-results-raises-full-year-g-grdn-20251110monthly0.5https://www.biopharmawatch.com/news/GRDN/smarter-growth-better-service-disclaimers-forward-looking-statements-this-presentation-inc-grdn-20250918monthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-reports-second-quarter-2025-financial-results-raises-full-year--grdn-20250811monthly0.5https://www.biopharmawatch.com/news/GRDN/smarter-growth-better-service-investor-day-grdn-20250618monthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-inc-reports-first-quarter-2025-financial-results-atlanta-grdn-20250512monthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-inc-reports-fourth-quarter-and-full-year-2024-financial-results-grdn-20250326monthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-inc-announces-preliminary-fourth-quarter-and-full-year-2024-res-grdn-20250303monthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-inc-reports-third-quarter-2024-financial-results-atlanta-busine-grdn-20241112monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20260507monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20260225monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20251106monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20250807monthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-lfst-20250514monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20250507monthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-appoints-dave-bourdon-as-ceo-ken-burdick-named-executive-chairman-ryan-mcgroart-lfst-20250227monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20250227monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20241107monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20240808monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20240509monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-finance-investor-relations-602-767-2100-investor-relations-lifestanc-lfst-20240228monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20231108monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20230809monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20230510monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20230308monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20221108monthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-health-appoints-j-michael-bruff-as-new-business-tranformation-officer-lfst-20221103monthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-health-appoints-ken-burdick-as-ceo-and-chairman-founding-ceo-and-chairman-micha-lfst-20220908monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20220809monthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-health-names-danish-qureshi-as-chief-operating-officer-effective-july-1-2022-gw-lfst-20220523monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20220509monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20220310monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-602-767-2100-investor-relations-lifestance-com-li-lfst-20211108monthly0.5https://www.biopharmawatch.com/news/LFST/monica-prokocki-vp-of-investor-relations-425-279-8500-investorrelations-lifestance-com-lif-lfst-20210811monthly0.5https://www.biopharmawatch.com/news/IDYA/hla-human-leukocyte-antigen-mos-median-overall-survival-mpfs-median-progression-free-survi-idya-20260601monthly0.5https://www.biopharmawatch.com/news/IDYA/certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-are-forward-l-idya-20260112monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-condensed-balance-sheet-data-in-thousands-september-30-idya-20251104monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-condensed-balance-sheet-data-in-thousands-june-30-idya-20250805monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-condensed-balance-sheet-data-in-thousands-march-31-idya-20250506monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-condensed-balance-sheet-data-in-thousands-december-31-idya-20250213monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-enters-exclusive-license-with-hengrui-pharma-for-shr-4849-a-novel-phase-idya-20241229monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-third-quarter-2024-financial-results-and-provides-business--idya-20241104monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-late-breaker-oral-presentation-of-ide397-phase-1-expansion-re-idya-20241004monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-second-quarter-2024-financial-results-and-provides-business-idya-20240806monthly0.5https://www.biopharmawatch.com/news/IDYA/intellectual-property-and-other-matters-that-could-affect-the-sufficiency-of-existing-cash-idya-20240731monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-condensed-bal-ance-sheet-data-in-thousands-march-31-idya-20240507monthly0.5https://www.biopharmawatch.com/news/IDYA/about-ideaya-biosciences-ideaya-is-a-precision-medicine-oncology-company-committed-to-the--idya-20240220monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-condensed-bal-ance-sheet-data-in-thousands-december-31-idya-20240220monthly0.5https://www.biopharmawatch.com/news/IDYA/under-the-clinical-study-collaboration-and-supply-agreement-gilead-will-provide-drug-suppl-idya-20231204monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-condensed-bal-ance-sheet-data-in-thousands-idya-20231107monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-condensed-bal-ance-sheet-data-in-thousands-idya-20230810monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-expands-clinical-trial-collaboration-and-supply-agreements-with-pfizer-to-support-r-idya-20230516monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-first-quarter-2023-financial-results-and-provides-business--idya-20230509monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-2022-financial-results-and-provides-business-update-x2022-s-idya-20230307monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-third-quarter-2022-financial-results-and-provides-business--idya-20221108monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-second-quarter-2022-financial-results-and-provides-business-idya-20220815monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-clinical-trial-collaboration-with-amgen-to-evaluate-mat2a-prmt5-synthetic-idya-20220727monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-first-quarter-2022-financial-results-and-provides-business--idya-20220510monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-catherine-mackey-ph-d-to-its-board-of-directors-dr-mackey-form-idya-20220406monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-2021-financial-results-and-provides-business-update-strong--idya-20220315monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-third-quarter-2021-financial-results-and-provides-business--idya-20211115monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-second-quarter-2021-financial-results-and-provides-business-idya-20210810monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-first-quarter-2021-financial-results-and-provides-business--idya-20210510monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-fourth-quarter-2020-financial-results-and-provides-business-idya-20210323monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-susan-l-kelley-m-d-an-industry-veteran-in-medical-oncology-and-idya-20210217monthly0.5https://www.biopharmawatch.com/news/IDYA/nasdaq-idya-certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-a-idya-20210111monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-third-quarter-2020-financial-results-and-provides-business--idya-20201112monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-and-pfizer-expand-clinical-trial-collaboration-and-supply-agreement-to-evaluate-cli-idya-20200924monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-second-quarter-2020-financial-results-and-provides-business-idya-20200812monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-hsr-clearance-of-gsk-strategic-partnership-in-synthetic-lethality-and-clo-idya-20200804monthly0.5https://www.biopharmawatch.com/news/IDYA/exibhit-99-1-ideaya-appoints-garret-hampton-ph-d-to-the-board-of-directors-an-industry-lea-idya-20200630monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-and-gsk-announce-a-broad-partnership-in-synthetic-lethality-an-emerging-field-in-pr-idya-20200616monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-first-quarter-2020-financial-results-and-provides-business--idya-20200512monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-fourth-quarter-2019-financial-results-and-provides-business-idya-20200324monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-and-cancer-research-uk-announce-expanded-research-collaboration-for-par-idya-20200311monthly0.5https://www.biopharmawatch.com/news/IDYA/company-logo-safe-harbor-statement-certain-statements-in-this-presentation-and-the-accompa-idya-20200113monthly0.5https://www.biopharmawatch.com/news/IDYA/exibhit-99-1-ideaya-biosciences-appoints-wendy-yarno-to-its-board-of-directors-south-san-f-idya-20191218monthly0.5https://www.biopharmawatch.com/news/IDYA/phase-1-2-clinical-trial-data-for-ide196-presented-at-society-for-melanoma-research-congre-idya-20191120monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-third-quarter-2019-financial-results-and-provides-business--idya-20191113monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-second-quarter-2019-financial-results-and-provides-business-idya-20190812monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-closing-of-initial-public-offering-and-full-exercise-of-under-idya-20190528monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-a-business-updat-elvn-20260507monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-second-quarter-financial-results-and-provides-a-business-upda-elvn-20250813monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-a-business-updat-elvn-20250514monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-elvn-20250313monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-third-quarter-financial-results-and-provides-a-business-updat-elvn-20241113monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-second-quarter-financial-results-and-provides-a-business-upda-elvn-20240813monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-a-business-updat-elvn-20240514monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-announces-positive-proof-of-concept-data-from-phase-1-clinical-trial--elvn-20240411monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-third-quarter-2023-financial-results-and-provides-a-business--elvn-20231109monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-second-quarter-2023-financial-results-and-highlights-recent-c-elvn-20230810monthly0.5https://www.biopharmawatch.com/news/ELVN/financial-statements-and-supplementary-data-index-to-financial-statements-enliven-therapeu-elvn-20230623monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-highlights-business-achievements-and-reports-first-quarter-2023-finan-elvn-20230511monthly0.5https://www.biopharmawatch.com/news/ELVN/to-the-amended-8-k-quantitative-and-qualitative-disclosures-about-market-risks-interest-ra-elvn-20230321monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-closes-merger-with-imara-and-private-placement-of-165-million-elvn-20230223monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-inc-amended-and-restated-2020-equity-incentive-plan-1-purpose-the-purpose-of-this-am-elvn-20230222monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-inc-and-imara-inc-announce-definitive-merger-agreement-transcript-of--elvn-20221013monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-and-imara-announce-merger-agreement-merger-to-create-nasdaq-listed-cl-elvn-20221013monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-reports-full-year-2021-financial-results-and-business-highlights-completed-enrollmen-elvn-20220315monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-reports-third-quarter-2021-financial-results-and-business-highlights-interim-analysi-elvn-20211109monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-reports-second-quarter-2021-financial-results-and-business-highlights-accelerated-en-elvn-20210806monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-announces-launch-of-proposed-public-offering-elvn-20210713monthly0.5https://www.biopharmawatch.com/news/ELVN/forward-looking-statements-and-disclaimer-this-presentation-may-contain-forward-looking-st-elvn-20210713monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-presents-clinical-data-on-imr-687-in-sickle-cell-disease-at-the-european-hematology--elvn-20210611monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-reports-first-quarter-2021-financial-results-and-business-highlights-on-track-to-rep-elvn-20210511monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-reports-full-year-2020-financial-results-and-business-highlights-significant-progres-elvn-20210305monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-reports-third-quarter-2020-financial-results-and-business-highlights-patient-dosing--elvn-20201105monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-reports-second-quarter-2020-financial-results-and-business-highlights-initiated-phas-elvn-20200814monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-reports-first-quarter-2020-financial-results-and-business-highlights-strengthened-bo-elvn-20200507monthly0.5https://www.biopharmawatch.com/news/ELVN/imara-strengthens-board-of-directors-with-appointment-of-edward-r-conner-m-d-industry-lead-elvn-20200423monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-fda-acceptance-of-nda-for-lorundrostat-for-treatment-of-a-mlys-20260309monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-provides-corporate-update-and-announces-participation-in-upcoming-l-mlys-20260106monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporat-mlys-20250812monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-positive-topline-results-from-phase-2-explore-ckd-trial-o-mlys-20250617monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-mlys-20250512monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-late-breaking-data-from-advance-htn-pivotal-trial-of-loru-mlys-20250329monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-proposed-public-offering-of-common-stock-radnor-pa-mlys-20250310monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-positive-topline-results-from-launch-htn-and-advance-htn--mlys-20250310monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-pro-mlys-20250212monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-completes-enrollment-in-explore-ckd-phase-2-trial-of-lorundrostat-f-mlys-20250204monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-phase-2-clinical-trial-of-lorundrostat-for-obstructive-sl-mlys-20250108monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-mlys-20241111monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-completes-enrollment-ahead-of-schedule-in-launch-htn-the-second-piv-mlys-20241030monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-completes-target-enrollment-in-pivotal-advance-htn-trial-of-lorundr-mlys-20240925monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporat-mlys-20240813monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-mlys-20240509monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-pro-mlys-20240321monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-120-million-private-placement-financing-radnor-pa-mlys-20240208monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-appoints-minji-kim-ph-d-as-chief-business-officer-radnor-pa-mlys-20240104monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-first-subject-dosed-in-launch-htn-the-second-pivotal-tria-mlys-20231221monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-further-defines-endotype-specific-targeted-approach-to-treatment-of-mlys-20231111monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-mlys-20231107monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-presents-new-post-hoc-analysis-from-target-htn-phase-2-trial-of-lor-mlys-20231102monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporat-mlys-20230807monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-expansion-of-planned-phase-2-trial-of-lorundrostat-alone--mlys-20230717monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-mlys-20230515monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-pro-mlys-20230315monthly0.5https://www.biopharmawatch.com/news/IRON/bitopertin-regulatory-update-february-2026-disclaimer-and-fls-this-presentation-contains-x-iron-20260217monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-receives-complete-response-letter-from-fda-for-bitopertin-for-the-treatment--iron-20260213monthly0.5https://www.biopharmawatch.com/news/IRON/disclaimer-and-fls-this-presentation-contains-x201c-forward-looking-statements-x201d-withi-iron-20251208monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-provides-update-on-hematology-portfolio-and-outlines-near-term-business-obje-iron-20250929monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-second-quarter-2025-financial-results-and-provides-business-update-x-iron-20250807monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-first-quarter-2025-financial-results-and-provides-business-update-x2-iron-20250507monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-bus-iron-20250227monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-w-iron-20250121monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-successful-type-c-meeting-with-fda-for-bitopertin-in-erythropoieti-iron-20250121monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-highlights-recent-achievements-across-hematology-portfolio-and-key-business--iron-20250110monthly0.5https://www.biopharmawatch.com/news/IRON/disclaimer-and-fls-this-presentation-contains-x201c-forward-looking-statements-x201d-withi-iron-20241209monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-third-quarter-2024-financial-results-and-provides-business-update-co-iron-20241112monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-secures-200-million-in-non-dilutive-debt-financing-from-hercules-capital-inc-iron-20241108monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-successful-end-of-phase-2-meeting-with-fda-for-bitopertin-in-eryth-iron-20241104monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presents-positive-data-from-sad-cohorts-of-a-phase-1b-trial-in-patients-with-iron-20241025monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-second-quarter-2024-financial-results-and-provides-business-update-p-iron-20240808monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-underwritten-offering-of-common-stock-watertown-mass-iron-20240614monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presents-positive-clinical-data-across-portfolio-at-the-european-hematology--iron-20240614monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-first-quarter-2024-financial-results-and-provides-business-update-pr-iron-20240509monthly0.5https://www.biopharmawatch.com/news/IRON/disc-reports-topline-results-from-phase-2-aurora-study-of-bitopertin-in-patients-with-eryt-iron-20240401monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-bus-iron-20240321monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-expands-leadership-team-with-appointment-of-industry-veteran-pamela-stephens-iron-20240226monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-strengthens-leadership-team-with-appointment-of-seasoned-industry-executive--iron-20240207monthly0.5https://www.biopharmawatch.com/news/IRON/disc-presents-positive-updated-results-from-phase-2-beacon-study-of-bitopertin-and-other-p-iron-20231211monthly0.5https://www.biopharmawatch.com/news/IRON/disc-presents-initial-positive-data-from-ongoing-phase-1b-2-trial-of-disc-0974-in-patients-iron-20231211monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-third-quarter-2023-financial-results-and-provides-business-update-co-iron-20231109monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-65-th-american-soci-iron-20231102monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-planned-departure-of-chief-financial-officer-joanne-bryce-iron-20231023monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-second-quarter-2023-financial-results-and-provides-business-update-p-iron-20230811monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-w-iron-20230612monthly0.5https://www.biopharmawatch.com/news/IRON/disc-presents-positive-initial-data-from-phase-2-beacon-trial-of-bitopertin-in-patients-wi-iron-20230609monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-first-quarter-2023-financial-results-and-provides-business-update-tw-iron-20230515monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-full-year-2022-financial-results-and-provides-business-update-comple-iron-20230331monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-62-5-million-financing-led-by-bain-capital-life-sciences-to-advanc-iron-20230214monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-exclusive-licensing-agreement-with-mabwell-therapeutics-for-novel--iron-20230120monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-completion-of-merger-with-gemini-therapeutics-the-combined-company-iron-20221229monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-receives-fda-orphan-drug-designation-for-bitopertin-for-the-treatment-of-ery-iron-20221227monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-several-presentations-across-hematology-portfolio-at-the-64th-amer-iron-20221213monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-initiates-aurora-a-phase-2-clinical-study-of-bitopertin-in-adults-with-eryth-iron-20221031monthly0.5https://www.biopharmawatch.com/news/IRON/confidential-conference-call-transcript-gemini-therapeutics-and-disc-medicine-merger-agree-iron-20220810monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-and-disc-medicine-announce-merger-agreement-merger-to-create-nasdaq-li-iron-20220810monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-reports-2021-financial-results-remote-first-company-mass-iron-20220310monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-provides-corporate-update-remote-first-company-mass-iron-20220228monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-provides-gem103-program-update-iron-20220110monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-upd-iron-20211115monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-announces-poster-presentation-at-aao-2021-iron-20211112monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-announces-corporate-restructuring-to-prioritize-late-stage-clinical-de-iron-20211006monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-up-iron-20210812monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-announces-initial-data-from-its-ongoing-phase-2a-study-of-gem103-in-pa-iron-20210622monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-upd-iron-20210513monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-appoints-samuel-barone-m-d-as-chief-medical-officer-iron-20210412monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-reports-full-year-2020-financial-results-and-provides-business-update--iron-20210329monthly0.5https://www.biopharmawatch.com/news/IRON/unaudited-pro-forma-combined-financial-information-the-following-unaudited-pro-forma-combi-iron-20210211monthly0.5https://www.biopharmawatch.com/news/IRON/fs-development-corp-announces-effectiveness-of-registration-statement-for-proposed-busines-iron-20210119monthly0.5https://www.biopharmawatch.com/news/IRON/gemini-therapeutics-and-fs-development-corp-announce-merger-agreement-creating-publicly-li-iron-20201015monthly0.5https://www.biopharmawatch.com/news/IRON/fs-development-corp-report-of-independent-registered-public-accounting-firm-f-2-balance-sh-iron-20200814monthly0.5https://www.biopharmawatch.com/news/IRON/fs-development-corp-sponsored-by-foresite-capital-announces-pricing-of-upsized-105-million-iron-20200812monthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-reports-f-irst-quarter-202-6-financial-results-and-raises-full-year-2026-guidanc-htfl-20260514monthly0.5https://www.biopharmawatch.com/news/HTFL/xfeff-heartflow-reports-fourth-quarter-and-full-year-2025-financial-results-m-ountain-view-htfl-20260318monthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-investor-presentation-january-2026-xfeff-disclaimers-forward-looking-statements--htfl-20260112monthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-reports-third-quarter-2025-financial-results-initiates-full-year-2025-revenue-gu-htfl-20251112monthly0.5https://www.biopharmawatch.com/news/VERA/primary-endpoint-upcr-reduction-interim-analysis-set-ias-included-the-first-203-randomized-vera-20251106monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-second-quarter-2025-financial-resul-vera-20250805monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-atacicept-achieved-46-proteinuria-reduction-in-origin-phase-3--vera-20250602monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-first-quarter-2025-financial-result-vera-20250506monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-f-vera-20250226monthly0.5https://www.biopharmawatch.com/news/VERA/j-p-morgan-healthcare-conference-vera-20250113monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-third-quarter-2024-financial-result-vera-20241107monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of-atacice-vera-20241026monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-expanded-atacicept-development-program-in-multiple-autoimmune--vera-20241002monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-second-quarter-2024-financial-resul-vera-20240808monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-first-quarter-2024-financial-result-vera-20240509monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2023-f-vera-20240320monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-presents-positive-72-week-data-showing-egfr-stabilization-in-the-phase-2-vera-20240125monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-appointment-of-industry-veterans-robert-brenner-m-d-as-chief-m-vera-20240108monthly0.5https://www.biopharmawatch.com/news/VERA/corporate-presentation-january-2024-2023-vera-therapeutics-inc-forward-looking-statements--vera-20240108monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-third-quarter-financial-results-x20-vera-20231109monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-second-quarter-financial-results-x2-vera-20230810monthly0.5https://www.biopharmawatch.com/news/VERA/corporate-presentation-june-2023-2023-vera-therapeutics-inc-forward-looking-statements-dis-vera-20230620monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-first-quarter-financial-results-x20-vera-20230511monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2022-f-vera-20230328monthly0.5https://www.biopharmawatch.com/news/VERA/forward-looking-statements-disclaimer-this-material-has-been-made-available-to-you-with-th-vera-20230130monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inc-phase-2b-clinical-trial-week-24-results-january-2023-forward-looking-vera-20221223monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-third-quarter-2022-financial-result-vera-20221109monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-second-quarter-2022-financial-resul-vera-20220810monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-first-quarter-2022-financial-result-vera-20220516monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-x2022-phase--vera-20220324monthly0.5https://www.biopharmawatch.com/news/VERA/subject-to-risks-and-uncertainties-actual-results-may-differ-materially-from-those-express-vera-20211217monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate-upda-vera-20211110monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate-upd-vera-20210816monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-first-quarter-2021-financial-results-and-provides-corporate-upda-vera-20210624monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-announces-proposed-public-offering-of-common-stock-imnm-20251215monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-imnm-20251215monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-third-quarter-2025-financial-results-and-provides-business-update-imnm-20251106monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-second-quarter-2025-financial-results-and-provides-business-update-8-6-20-imnm-20250806monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-first-quarter-2025-financial-results-and-provides-business-update-5-12-20-imnm-20250512monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-full-year-2024-financial-results-and-provides-business-update-3-19-2025-t-imnm-20250319monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-announces-proposed-public-offering-of-common-stock-imnm-20250129monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-third-quarter-2024-financial-results-and-provides-business-update-11-13-2-imnm-20241113monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-inc-2024-inducement-plan-effective-as-of-october-3-2024-1-general-a-eligible-awar-imnm-20241008monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-second-quarter-2024-financial-results-and-provides-business-update-08-12--imnm-20240812monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-first-quarter-2024-financial-results-and-provides-business-update-integra-imnm-20240514monthly0.5https://www.biopharmawatch.com/news/IMNM/filed-with-immunome-s-current-report-on-form-8-k-with-securities-and-exchange-commission-s-imnm-20240328monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-completes-acquisition-of-al102-a-phase-3-asset-for-the-treatment-of-desmoid-tumor-imnm-20240326monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-s-business-overview-we-are-a-biopharmaceutical-company-focused-on-the-development-imnm-20240205monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-to-acquire-al102-a-phase-3-asset-for-the-treatment-of-desmoid-tumors-from-ayala-p-imnm-20240206monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-corporate-presentation-imnm-20240111monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-exclusively-licenses-zentalis-ror1-antibody-drug-conjugate-and-proprietary-techno-imnm-20240108monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-corporate-presentation-imnm-20231115monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-third-quarter-2023-financial-results-completed-merger-with-morphimmune-an-imnm-20231109monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-and-morphimmune-announce-successful-completion-of-merger-with-125-million-pipe-to-imnm-20231004monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-second-quarter-2023-financial-results-exton-pa-imnm-20230809monthly0.5https://www.biopharmawatch.com/news/IMNM/morphimmune-and-immunome-combined-corporate-presentation-july-2023-morphimmune-immunome-2--imnm-20230705monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-and-morphimmune-announce-definitive-merger-agreement-and-simultaneous-private-pla-imnm-20230629monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-first-quarter-2023-financial-results-exton-pa-imnm-20230505monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-fourth-quarter-and-full-year-2022-financial-results-exton-pa-imnm-20230316monthly0.5https://www.biopharmawatch.com/news/IMNM/harnessing-the-power-of-the-human-memory-b-cell-january-2023-immunome-inc-665-stockton-dri-imnm-20230130monthly0.5https://www.biopharmawatch.com/news/IMNM/abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-t-imnm-20230106monthly0.5https://www.biopharmawatch.com/news/IMNM/harnessing-the-power-of-the-human-memory-b-cell-january-2023-immunome-inc-665-stockton-dri-imnm-20230106monthly0.5https://www.biopharmawatch.com/news/IMNM/harnessing-the-human-cell-the-power-of-memory-b-imnm-20221115monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-third-quarter-2022-financial-results-exton-pa-imnm-20221114monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-second-quarter-2022-financial-results-exton-pa-imnm-20220805monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-s-covid-19-cocktail-retains-neutralizing-activity-against-the-most-prevalent-omic-imnm-20220706monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-announces-initiation-of-phase-1b-study-of-imm-bcp-01-for-the-treatment-of-covid-1-imnm-20220609monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-announces-data-demonstrating-covid-19-antibody-cocktail-potently-clears-omicron-b-imnm-20220519monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-first-quarter-2022-financial-results-exton-pa-imnm-20220512monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-fourth-quarter-and-full-year-2021-financial-results-immunome-receives-saf-imnm-20220328monthly0.5https://www.biopharmawatch.com/news/IMNM/fda-lifts-clinical-hold-on-immunome-s-imm-bcp-01-ind-application-for-the-treatment-of-covi-imnm-20220311monthly0.5https://www.biopharmawatch.com/news/IMNM/harnessing-the-power-of-the-human-memory-b-cell-imnm-20220208monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-provides-update-on-investigational-new-drug-application-for-imm-bcp-01-for-the-tr-imnm-20220110monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-announces-submission-of-an-investigational-new-drug-ind-application-for-imm-bcp-0-imnm-20211129monthly0.5https://www.biopharmawatch.com/news/IMNM/harnessing-the-human-memory-b-cell-response-to-develop-antibody-based-therapeutics-imnm-20211015monthly0.5https://www.biopharmawatch.com/news/IMNM/harnessing-the-human-memory-b-cell-response-to-develop-antibody-based-therapeutics-imnm-20210921monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-antibody-cocktail-imm-bcp-01-neutralizes-sars-cov-2-lambda-and-delta-plus-variant-imnm-20210907monthly0.5https://www.biopharmawatch.com/news/IMNM/copyright-2021-immunome-inc-all-rights-reserved-harnessing-the-human-memory-b-cell-respons-imnm-20210720monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-appoints-franklyn-g-prendergast-m-d-ph-d-to-board-of-directors-dr-prendergast-is--imnm-20210617monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-announces-additional-4-3-million-award-by-dod-following-positive-preclinical-test-imnm-20210520monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-first-quarter-2021-financial-results-imm-bcp-01-selected-antibody-cocktai-imnm-20210512monthly0.5https://www.biopharmawatch.com/news/IMNM/copyright-2021-immunome-inc-all-rights-reserved-harnessing-the-human-memory-b-cell-respons-imnm-20210422monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-announces-27-million-private-placement-exton-pa-imnm-20210426monthly0.5https://www.biopharmawatch.com/news/IMNM/copyright-2021-immunome-inc-all-rights-reserved-harnessing-the-human-memory-b-cell-respons-imnm-20210329monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-fourth-quarter-and-full-year-2020-financial-results-provides-corporate-up-imnm-20210325monthly0.5https://www.biopharmawatch.com/news/IMNM/copyright-2021-immunome-inc-all-rights-reserved-harnessing-the-human-memory-b-cell-respons-imnm-20210314monthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-third-quarter-2020-financial-results-and-significant-progress-completed-4-imnm-20201117monthly0.5https://www.biopharmawatch.com/news/IMNM/developing-antibody-based-therapeutics-by-unlocking-the-human-memory-b-cell-response-immun-imnm-20201026monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-preliminary-fourth-quarter-and-full-year-2025-results-f-adpt-20260112monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-second-quarter-2025-financial-results-seattle-adpt-20250805monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-first-quarter-2025-financial-results-seattle-adpt-20250501monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-fourth-quarter-and-full-year-2024-financial-results-seatt-adpt-20250211monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-third-quarter-2024-financial-results-seattle-adpt-20241107monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-second-quarter-2024-financial-results-seattle-adpt-20240801monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-first-quarter-2024-financial-results-seattle-adpt-20240507monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-provides-strategic-review-update-and-announces-preliminary-first--adpt-20240402monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-fourth-quarter-and-full-year-2023-financial-results-seatt-adpt-20240214monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-third-quarter-2023-financial-results-and-provides-busines-adpt-20231109monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-second-quarter-2023-financial-results-seattle-adpt-20230802monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-fda-acceptance-of-genentech-s-investigational-new-drug--adpt-20230509monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-first-quarter-2023-financial-results-seattle-adpt-20230503monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-fourth-quarter-and-full-year-2022-financial-results-seatt-adpt-20230214monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-third-quarter-2022-financial-results-seattle-adpt-20221103monthly0.5https://www.biopharmawatch.com/news/ADPT/solutions-and-extensive-global-team-resources-to-help-build-world-class-healthcare-compani-adpt-20220912monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-second-quarter-2022-financial-results-seattle-adpt-20220803monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-first-quarter-2022-financial-results-seattle-adpt-20220504monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-fourth-quarter-and-full-year-2021-financial-results-seatt-adpt-20220215monthly0.5https://www.biopharmawatch.com/news/ADPT/business-strategies-use-of-capital-results-of-operations-and-financial-position-and-plans--adpt-20220110monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-third-quarter-2021-financial-results-seattle-adpt-20211103monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-second-quarter-2021-financial-results-seattle-adpt-20210804monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-first-quarter-2021-financial-results-seattle-adpt-20210505monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-strengthens-expertise-and-diversity-of-board-of-directors-with-ap-adpt-20210317monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-fourth-quarter-and-full-year-2020-financial-results-seatt-adpt-20210224monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-third-quarter-2020-financial-results-seattle-adpt-20201110monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-second-quarter-2020-financial-results-seattle-adpt-20200810monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-proposed-public-offering-of-common-stock-adpt-20200714monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-first-quarter-2020-financial-results-seattle-adpt-20200512monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-and-microsoft-launch-virtual-immunerace-study-to-inform-novel-cov-adpt-20200505monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-fourth-quarter-and-full-year-2019-financial-results-seatt-adpt-20200226monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-announces-proposed-public-offering-of-common-stock-adpt-20200121monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-receives-expanded-medicare-coverage-of-clonoseq-for-monitoring-mr-adpt-20200108monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-corporation-reports-third-quarter-2019-financial-results-seattle-adpt-20191112monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-enters-partnership-with-illumina-to-develop-distributable-ivd-tes-adpt-20190924monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-corporation-reports-second-quarter-2019-financial-results-seattle-adpt-20190813monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-executes-lease-for-new-100-000-square-foot-corporate-headquarters-adpt-20190807monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-receives-new-york-state-clep-approval-for-clonoseq-to-detect-and--adpt-20190731monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-pricing-of-initial-public-offering-adpt-20190626monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-second-quarter-2025-financial-results-andover-mass-x2013-tmdx-20250730monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-first-quarter-2025-financial-results-andover-mass-x2013-tmdx-20250508monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-fourth-quarter-and-full-year-2024-financial-results-andover-mass-x2013-tmdx-20250227monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-202-tmdx-20241202monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2024-financial-results-andover-mass-x2013-tmdx-20241028monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-second-quarter-2024-financial-results-andover-mass-x2013-tmdx-20240731monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-first-quarter-2024-financial-results-andover-mass-x2013-tmdx-20240430monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-fourth-quarter-and-full-year-2023-financial-results-andover-mass-x2013-tmdx-20240226monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2023-financial-results-andover-mass-x2013-tmdx-20231106monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-completes-acquisition-of-summit-aviation-andover-mass-tmdx-20230816monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-second-quarter-2023-financial-results-andover-mass-x2013-tmdx-20230803monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-first-quarter-2023-financial-results-andover-mass-x2013-tmdx-20230501monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-fourth-quarter-and-full-year-2022-financial-results-andover-mass-x2013-tmdx-20230222monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2022-financial-results-net-revenue-of-25-7-million-compr-tmdx-20221103monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-second-quarter-2022-financial-results-accelerated-commercial-momentum--tmdx-20220801monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-first-quarter-2022-financial-results-andover-mass-tmdx-20220503monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-fourth-quarter-and-full-year-2021-financial-results-andover-mass-tmdx-20220223monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-condensed-consolidated-balance-sheets-in-thousands-unaudited-tmdx-20211109monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-inc-press-release-tmdx-20210929monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-inc-press-release-tmdx-20210907monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-condensed-consolidated-balance-sheets-in-thousands-unaudited-tmdx-20210805monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-positive-fda-advisory-committee-vote-for-the-ocs-liver-system-panel--tmdx-20210714monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-first-quarter-2021-financial-results-andover-mass-tmdx-20210504monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-positive-fda-advisory-committee-vote-for-ocs-heart-system-panel-vote-tmdx-20210406monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-condensed-consolidated-balance-sheets-in-thousands-unaudited-decembe-tmdx-20210302monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2020-financial-results-andover-mass-tmdx-20201104monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-first-quarter-2020-financial-results-andover-mass-tmdx-20200506monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-provides-covid-19-pandemic-update-and-announces-preliminary-financial-results--tmdx-20200413monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-fourth-quarter-and-full-year-2019-financial-results-andover-mass-tmdx-20200302monthly0.5https://www.biopharmawatch.com/news/TMDX/dbd-donors-cautionary-note-regarding-forward-looking-statements-this-presentation-contains-tmdx-20200113monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2019-financial-results-andover-mass-tmdx-20191106monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-second-quarter-2019-financial-results-andover-mass-tmdx-20190807monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-first-quarter-2019-financial-results-andover-mass-tmdx-20190611monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-the-second-fda-pma-approval-for-its-ocs-lung-system-allowing-access--tmdx-20190603monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-first-quarter-2025-financial-resu-kod-20250514monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-fourth-quarter-and-full-year-2024-kod-20250327monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-third-quarter-2024-financial-resu-kod-20241114monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-second-quarter-2024-financial-res-kod-20240814monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-first-quarter-2024-financial-resu-kod-20240515monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-fourth-quarter-and-full-year-2023-kod-20240328monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-third-quarter-2023-financial-results-and-recent-business-highlig-kod-20231114monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-second-quarter-2023-financial-results-and-recent-business-highli-kod-20230814monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-first-quarter-2023-financial-results-and-recent-business-highlig-kod-20230515monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-fourth-quarter-and-full-year-2022-financial-results-and-recent-b-kod-20230328monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-third-quarter-2022-financial-results-and-recent-business-highlig-kod-20221109monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-second-quarter-2022-financial-results-and-recent-business-highli-kod-20220809monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-first-quarter-2022-financial-results-and-recent-business-highlig-kod-20220510monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-fourth-quarter-and-full-year-2021-financial-results-and-recent-b-kod-20220301monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-third-quarter-2021-financial-results-and-recent-business-highlig-kod-20211109monthly0.5https://www.biopharmawatch.com/news/KOD/summary-of-the-ltpip-overview-below-is-an-overview-of-the-ltpip-which-is-intended-as-a-sum-kod-20211015monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-new-long-term-performance-incentive-plan-pay-for-performance-pro-kod-20210901monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-second-quarter-2021-financial-results-and-recent-business-highli-kod-20210809monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-first-quarter-2021-financial-results-and-recent-business-highlig-kod-20210510monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-fourth-quarter-and-full-year-2020-financial-results-and-recent-b-kod-20210301monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-third-quarter-2020-financial-results-and-recent-business-highlig-kod-20201109monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-second-quarter-2020-financial-results-and-recent-business-highli-kod-20200810monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-first-quarter-2020-financial-results-and-recent-business-highlig-kod-20200511monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-fourth-quarter-and-full-year-2019-financial-results-and-recent-b-kod-20200316monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-third-quarter-2019-financial-results-and-recent-business-highlig-kod-20191112monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-safety-efficacy-and-durability-data-from-ongoing-phase-1b-study--kod-20191011monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-second-quarter-2019-financial-results-and-recent-business-highli-kod-20190814monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-positive-interim-data-from-ongoing-phase-1b-clinical-study-of-ks-kod-20190727monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-first-quarter-2019-financial-results-and-recent-business-highlig-kod-20190515monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-fourth-quarter-and-full-year-2018-financial-results-and-recent-b-kod-20190328monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-third-quarter-2018-financial-results-and-recent-business-highlig-kod-20181116monthly0.5https://www.biopharmawatch.com/news/DFTX/corporate-presentation-may-2026-this-presentation-the-x201c-presentation-x201d-has-been-pr-dftx-20260519monthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates-emerge-dftx-20260226monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeli-dftx-20260113monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-q3-2025-financial-results-and-business-updates-anticipated-topline-data-re-dftx-20251106monthly0.5https://www.biopharmawatch.com/news/DFTX/mind-medicine-mindmed-inc-announces-proposed-public-offering-dftx-20251029monthly0.5https://www.biopharmawatch.com/news/DFTX/corporate-presentation-october-2025-2-this-presentation-the-presentation-has-been-prepared-dftx-20251029monthly0.5https://www.biopharmawatch.com/news/DFTX/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomi-dftx-20250904monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-q2-2025-financial-results-and-business-updates-strong-enrollment-continues-dftx-20250731monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-strengthens-executive-team-with-appointment-of-brandi-roberts-cpa-as-chief-financi-dftx-20250527monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-first-quarter-2025-financial-results-and-recent-business-updates-dosed-fir-dftx-20250508monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-first-patient-dosed-in-phase-3-emerge-study-of-mm120-in-major-depressive-dftx-20250415monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-up-dftx-20250306monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm12-dftx-20250130monthly0.5https://www.biopharmawatch.com/news/DFTX/corporate-presentation-january-2025-corporate-presentation-january-2025-this-presentation--dftx-20250113monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxi-dftx-20241216monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-third-quarter-2024-financial-results-and-business-updates-on-track-to-init-dftx-20241107monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-second-quarter-2024-financial-results-and-business-updates-completed-end-o-dftx-20240813monthly0.5https://www.biopharmawatch.com/news/DFTX/mind-medicine-mindmed-inc-announces-proposed-public-offering-dftx-20240809monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalize-dftx-20240620monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-first-quarter-2024-financial-results-and-business-updates-announced-positi-dftx-20240508monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-voluntary-delisting-from-cboe-canada-all-common-shares-will-remain-liste-dftx-20240401monthly0.5https://www.biopharmawatch.com/news/DFTX/mind-medicine-mindmed-inc-announces-pricing-of-underwritten-offering-of-common-shares-and--dftx-20240307monthly0.5https://www.biopharmawatch.com/news/DFTX/mm120-for-generalized-anxiety-disorder-gad-phase-2b-full-topline-data-odt-pk-bridging-stud-dftx-20240307monthly0.5https://www.biopharmawatch.com/news/DFTX/thursday-march-7-2023-6-00-am-est-mindmed-receives-fda-breakthrough-therapy-designation-an-dftx-20240307monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-2023-financial-results-and-business-updates-announced-statistically-signif-dftx-20240228monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-business-update-and-anticipated-milestones-for-2024-recently-announced-s-dftx-20240108monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-an-dftx-20231214monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-third-quarter-2023-financial-results-and-business-highlights-x2013-topline-dftx-20231102monthly0.5https://www.biopharmawatch.com/news/DFTX/company-logo-mindmed-investor-presentation-august-2023-disclaimer-this-presentation-the-x2-dftx-20230814monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-second-quarter-2023-financial-results-and-business-highlights-x2013-toplin-dftx-20230803monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-investor-presentation-investor-day-2023-mm-120-for-generalized-anxiety-disorder-di-dftx-20230620monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-adjourns-annual-general-meeting-of-shareholders-meeting-will-resume-on-wednesday-dftx-20230615monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-to-present-data-on-the-preclinical-activity-of-mm-402-at-the-american-society-of-c-dftx-20230524monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-enrollment-milestone-in-phase-2b-trial-of-mm-120-in-generalized-anxiety--dftx-20230517monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-first-quarter-2023-financial-results-and-business-highlights-x2013-key-mm--dftx-20230504monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-files-preliminary-proxy-statement-for-2023-annual-meeting-presents-highly-qualifie-dftx-20230418monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-collaborators-announce-positive-topline-data-from-phase-2-trial-of-lysergide-lsd-i-dftx-20230414monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-full-year-2022-financial-results-and-business-highlights-x2013-company-pos-dftx-20230309monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-provides-corporate-update-and-2023-outlook-company-positioned-for-key-mm-120-phase-dftx-20230109monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-third-quarter-2022-financial-results-and-business-highlights-x2013-phase-2-dftx-20221110monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-proposed-public-offering-of-common-shares-new-york-dftx-20220927monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-compliance-with-nasdaq-listing-requirements-dftx-20220914monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-completes-1-for-15-reverse-share-split-common-shares-will-begin-trading-on-a-split-dftx-20220829monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-second-quarter-2022-financial-results-and-business-highlights-x2013-phase--dftx-20220811monthly0.5https://www.biopharmawatch.com/news/DFTX/corporate-overview-july-2022-3-corporate-overview-july-2022-4-dftx-20220721monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-first-quarter-2022-financial-results-and-business-highlights-advanced-clin-dftx-20220516monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase--dftx-20220511monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-corporate-over-april-2022-disclaimer-this-presentation-the-presentation-has-been-p-dftx-20220426monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-reports-full-year-2021-financial-results-and-business-highlights-fda-cleared-mindm-dftx-20220328monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-transition-of-dftx-20220325monthly0.5https://www.biopharmawatch.com/news/DFTX/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder-fda-clearan-dftx-20220125monthly0.5https://www.biopharmawatch.com/news/DFTX/stephen-hurst-resigns-from-mindmed-board-of-directors-dftx-20220107monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-transitions-to-management-team-bradford-cross-chief-technology-officer-t-dftx-20211229monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-provides-status-update-on-ind-for-phase-2b-trial-of-lsd-for-the-treatment-of-gener-dftx-20211221monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director-mr-barrow-previousl-dftx-20211214monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-enrolling-patients-in-dftx-20211217monthly0.5https://www.biopharmawatch.com/news/DFTX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-mind-medicine-mind-dftx-20211213monthly0.5https://www.biopharmawatch.com/news/DFTX/for-immediate-release-dftx-20211209monthly0.5https://www.biopharmawatch.com/news/DFTX/notice-of-change-of-auditor-pursuant-to-national-instrument-51-102-of-the-canadian-securit-dftx-20211201monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-to-participate-at-the-benzinga-global-small-cap-conference-dftx-20211202monthly0.5https://www.biopharmawatch.com/news/DFTX/to-present-at-h-c-dftx-20211201monthly0.5https://www.biopharmawatch.com/news/DFTX/ehhibit-99-1-for-immediate-release-dftx-20211116monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cas-dftx-20211115monthly0.5https://www.biopharmawatch.com/news/DFTX/mind-medicine-mindmed-inc-condensed-consolidated-interim-financial-statements-expressed-in-dftx-20211112monthly0.5https://www.biopharmawatch.com/news/DFTX/for-immediate-release-dftx-20211112monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-appoints-dr-dftx-20211105monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-expands-its-drug-development-pipeline-with-launch-of-r-mdma-dftx-20211026monthly0.5https://www.biopharmawatch.com/news/DFTX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-mind-medicine-mind-dftx-20210929monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-appointment-of-andreas-krebs-and-carol-vallone-as-directors-and-transiti-dftx-20210930monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-and-bioxcel-therapeutics-publish-an-international-patent-application-describing-a--dftx-20210902monthly0.5https://www.biopharmawatch.com/news/DFTX/for-immediate-release-dftx-20210824monthly0.5https://www.biopharmawatch.com/news/DFTX/for-immediate-release-dftx-20210817monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-millio-dftx-20210813monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-discover-develop-deploy-www-mindmed-co-psychedelic-inspired-medicines-august-2021--dftx-20210813monthly0.5https://www.biopharmawatch.com/news/DFTX/mind-medicine-mindmed-inc-condensed-consolidated-interim-financial-statements-expressed-in-dftx-20210813monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-appoints-dr-robert-dworkin-to-scientific-advisory-board-new-york-ny-dftx-20210810monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technol-dftx-20210803monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt-new-york-ny-dftx-20210728monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-chosen-to-participate-in-cowen-s-psychedelics-novel-mechanisms-in-neuropsychiatry--dftx-20210712monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-partnership-with-datavant-a-leading-health-data-connectivity-company-new-dftx-20210708monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-appoints-mgh-psychiatrist-in-chief-dr-maurizio-fava-to-scientific-advisory-board-n-dftx-20210623monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-m-d-to-scientific-advisory-board-n-dftx-20210617monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-chief-executive-officer-transition-new-york-ny-dftx-20210609monthly0.5https://www.biopharmawatch.com/news/DFTX/mind-medicine-mindmed-inc-the-corporation-annual-and-special-meeting-of-shareholders-repor-dftx-20210527monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to--dftx-20210526monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposo-dftx-20210524monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-the-approval-of-mescaline-study-basel-switzerland-dftx-20210520monthly0.5https://www.biopharmawatch.com/news/DFTX/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of--dftx-20210518monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-receives-fda-type-c-meeting-response-for-project-lucy-phase-2b-clinical-trial-mind-dftx-20210517monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-bolsters-management-team-appoints-peter-mack-phd-as-vice-president-of-pharmaceutic-dftx-20210513monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics-new-york-dftx-20210505monthly0.5https://www.biopharmawatch.com/news/DFTX/notice-of-annual-and-special-meeting-and-management-information-circular-with-respect-to-t-dftx-20210428monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-begins-trading-on-nasdaq-new-york-ny-dftx-20210427monthly0.5https://www.biopharmawatch.com/news/DFTX/mindmed-to-commence-trading-on-nasdaq-new-york-ny-dftx-20210423monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2026-financial-results-burlington-ma-lmat-20260505monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2025-financial-results-burlington-ma-lmat-20260225monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2025-financial-results-burlington-ma-lmat-20251106monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-prices-150-million-convertible-senior-notes-boston-ma-lmat-20241216monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-proposed-convertible-senior-notes-offering-boston-ma-lmat-20241216monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-preliminary-q3-2018-results-burlington-ma-lmat-20181004monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-clot-management-business-from-applied-medical-lmat-20180926monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2018-record-sales-27-0mm-5-record-eps-0-43-86-burlington-ma-lmat-20180726monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2018-sales-26-0mm-8-eps-0-19-17-burlington-ma-lmat-20180425monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-divests-general-surgery-product-lines-lmat-20180405monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2017-record-sales-26-2mm-12-record-op-income-6-3mm-62-burlington-ma-lmat-20180221monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2017-sales-24-8mm-7-record-eps-0-25-49-burlington-ma-lmat-20171026monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2017-record-sales-25-8-mm-15-record-eps-0-23-69-burlington-ma-lmat-20170727monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2017-record-sales-24-1-mm-19-net-income-3-2-mm-49-burlington-ma-lmat-20170426monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2016-record-sales-23-3-mm-14-op-income-3-9-mm-27-burlington-ma-lmat-20170221monthly0.5https://www.biopharmawatch.com/news/LMAT/lmat-investment-highlights-89-6mm-sales-in-2016-14-reported-growth-12-organic-growth-16-9m-lmat-20161110monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-restore-flow-allografts-lmat-20161110monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2016-record-sales-23-2-mm-22-record-op-income-5-3-mm-61-burlington-ma-lmat-20161026monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2016-record-sales-22-4mm-13-record-op-income-3-8mm-35-5-0mm-share-repurchase-b-lmat-20160727monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2016-sales-20-3mm-7-op-inc-3-3mm-43-burlington-ma-lmat-20160502monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-appoints-daniel-cancelmi-to-board-of-directors-wade-d-miquelon-to-retire-achc-20260312monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-appoints-todd-young-as-chief-financial-officer-young-brings-25-years-of--achc-20251007monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-announces-launch-of-500-million-senior-notes-offering-franklin-tenn-achc-20250305monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-third-quarter-2023-results-and-updates-guidance-ranges-to-reflec-achc-20231102monthly0.5https://www.biopharmawatch.com/news/ACHC/gretchen-hommrich-vice-president-investor-relations-615-861-6000-acadia-healthcare-welcome-achc-20231026monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-second-quarter-2023-results-and-raises-2023-guidance-company-sig-achc-20230727monthly0.5https://www.biopharmawatch.com/news/ACHC/gretchen-hommrich-vice-president-investor-relations-615-861-6000-acadia-healthcare-appoint-achc-20230601monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-first-quarter-2023-results-company-affirms-full-year-2023-guidan-achc-20230426monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-fourth-quarter-2022-results-company-provides-full-year-and-first-achc-20230227monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-provides-business-outlook-ahead-of-investor-day-franklin-tenn-business-w-achc-20221207monthly0.5https://www.biopharmawatch.com/news/ACHC/correcting-and-replacing-acadia-healthcare-reports-third-quarter-2022-results-same-facilit-achc-20221031monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-third-quarter-2022-results-same-facility-revenue-increases-10-2--achc-20221031monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-second-quarter-2022-results-and-raises-2022-guidance-franklin-te-achc-20220727monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-names-r-david-kelly-to-board-of-directors-adds-financial-advisory-and-re-achc-20220629monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-first-quarter-2022-results-franklin-tenn-business-wire-achc-20220503monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-announces-christopher-hunter-as-new-chief-executive-officer-franklin-ten-achc-20220401monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-fourth-quarter-2021-results-company-provides-full-year-and-first-achc-20220228monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-third-quarter-2021-results-same-facility-revenue-grows-7-9-frank-achc-20211028monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-announces-retirement-of-chief-executive-officer-franklin-tenn-business-w-achc-20211005monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-second-quarter-2021-results-and-increases-2021-guidance-franklin-achc-20210802monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-first-quarter-2021-results-and-increases-2021-guidance-revenue-g-achc-20210429monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-fourth-quarter-2020-results-company-provides-full-year-and-first-achc-20210225monthly0.5https://www.biopharmawatch.com/news/ACHC/gretchen-hommrich-director-investor-relations-615-861-6000-acadia-healthcare-announces-def-achc-20201230monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-third-quarter-2020-results-company-provides-fourth-quarter-2020--achc-20201029monthly0.5https://www.biopharmawatch.com/news/ACHC/gretchen-hommrich-director-investor-relations-615-861-6000-acadia-healthcare-names-former--achc-20201028monthly0.5https://www.biopharmawatch.com/news/ACHC/gretchen-hommrich-director-investor-relations-615-861-6000-acadia-healthcare-announces-lau-achc-20200929monthly0.5https://www.biopharmawatch.com/news/ACHC/gretchen-hommrich-director-investor-relations-615-861-6000-acadia-healthcare-announces-lau-achc-20200610monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-first-quarter-2020-results-withdraws-full-year-2020-guidance-due-achc-20200504monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-provides-business-update-franklin-tenn-business-wire-achc-20200319monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-fourth-quarter-2019-results-company-provides-full-year-and-first-achc-20200227monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-names-senior-healthcare-investment-banker-jason-bernhard-to-board-of-dir-achc-20191217monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-third-quarter-2019-revenue-of-777-3-million-eps-of-0-48-and-adju-achc-20191105monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-second-quarter-2019-revenue-of-789-4-million-eps-of-0-55-and-adj-achc-20190730monthly0.5https://www.biopharmawatch.com/news/ACHC/update-on-strategic-priorities-and-initiatives-conference-call-achc-20190530monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-first-quarter-2019-revenue-of-760-6-million-eps-of-0-34-and-adju-achc-20190430monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-fourth-quarter-2018-results-provides-full-year-and-first-quarter-achc-20190228monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-announces-ceo-transition-debbie-osteen-named-chief-executive-officer-rep-achc-20181217monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-third-quarter-eps-of-0-53-and-adjusted-eps-of-0-55-revenue-incre-achc-20181105monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-second-quarter-eps-of-0-67-and-adjusted-eps-of-0-70-revenue-incr-achc-20180730monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-first-quarter-revenue-of-742-2-million-eps-of-0-58-and-adjusted--achc-20180501monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-fourth-quarter-revenue-of-724-5-million-eps-of-0-80-and-adjusted-achc-20180221monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-third-quarter-financial-results-produces-u-s-same-facility-reven-achc-20171024monthly0.5https://www.biopharmawatch.com/news/ACHC/gretchen-hommrich-director-investor-relations-615-861-6000-achc-20170510monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-first-quarter-gaap-eps-of-0-40-and-adjusted-eps-of-0-46-affirms--achc-20170425monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-fourth-quarter-gaap-eps-of-0-48-and-adjusted-eps-of-0-59-establi-achc-20170223monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-completes-previously-announced-sale--achc-20161130monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-third-quarter-financial-results-consistent-with-previously-annou-achc-20161101monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-signs-definitive-agreement-for-sale--achc-20161018monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-second-quarter-gaap-eps-of-0-65-and-adjusted-eps-of-0-73-up-28-1-achc-20160729monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-update-on-the-u-k-s-competition-and-markets-authority--achc-20160714monthly0.5https://www.biopharmawatch.com/news/ACHC/unaudited-pro-forma-condensed-combined-financial-information-the-tables-below-set-forth-th-achc-20160520monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-names-vicky-gregg-former-ceo-of-blue-achc-20160519monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-27-9-growth-in-first-quarter-adjusted-eps-to-0-55-on-revenue-of--achc-20160428monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-company-inc-reconciliation-of-net-income-attributable-to-acadia-healthca-achc-20160226monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-reports-28-3-growth-in-fourth-quarte-achc-20160216monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-prices-390-million-senior-unsecured--achc-20160204monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-announces-proposed-390-million-senio-achc-20160202monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-announces-closing-of-equity-offering-achc-20160112monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-announces-proposed-offering-of-10-00-achc-20160105monthly0.5https://www.biopharmawatch.com/news/ACHC/unaudited-pro-forma-condensed-combined-financial-information-the-tables-below-set-forth-th-achc-20151231monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-third-quarter-adjusted-eps-increases-34-8-to-0-62-on-revenue-of-479-7-mi-achc-20151103monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-announces-results-of-cash-tender-off-achc-20150921monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-prices-275-million-add-on-offering-o-achc-20150914monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-78-1-growth-in-second-quarter-adjusted-eps-to-0-57-revenue-more--achc-20150804monthly0.5https://www.biopharmawatch.com/news/ACHC/crc-health-group-inc-consolidated-financial-statements-as-of-and-for-the-year-ended-achc-20150702monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-announces-closing-of-equity-offering-achc-20150511monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-announces-proposed-offering-of-4-500-achc-20150504monthly0.5https://www.biopharmawatch.com/news/ACHC/unaudited-pro-forma-condensed-combined-financial-information-the-tables-below-set-forth-th-achc-20150504monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-first-quarter-adjusted-eps-increases-53-6-to-0-43-revenue-grows-81-6-inc-achc-20150428monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-reports-growth-of-58-6-in-fourth-qua-achc-20150211monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-prices-375-million-senior-unsecured--achc-20150205monthly0.5https://www.biopharmawatch.com/news/ACHC/unaudited-pro-forma-condensed-combined-financial-information-the-tables-below-set-forth-th-achc-20150128monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-reports-third-quarter-adjusted-earni-achc-20141029monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-second-quarter-adjusted-eps-increase-of-23-1-to-0-32-on-20-5-gro-achc-20140729monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-completes-previously-announced-purch-achc-20140702monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-prices-300-million-senior-unsecured--achc-20140617monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-announces-pricing-of-offering-of-7-7-achc-20140611monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-announces-commencement-of-consent-so-achc-20140609monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-signs-definitive-agreement-to-purcha-achc-20140603monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-reports-33-3-growth-in-first-quarter-adjusted-eps-to-0-28-on-24-9-increa-achc-20140429monthly0.5https://www.biopharmawatch.com/news/ACHC/brent-turner-president-615-861-6000-acadia-healthcare-reports-52-6-increase-in-fourth-quar-achc-20140219monthly0.5https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-third-quarter-adjusted-eps-increases-to-0-30-from-0-17-as-adjusted-incom-achc-20131029monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-election-of-denice-torres-to-its-board-of-directors-hampton-cldx-20250606monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-proposed-public-offering-of-common-stock-hampton-n-j-cldx-20240228monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-proposed-public-offering-of-common-stock-cldx-20231107monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-appointment-of-rita-jain-m-d-to-board-of-directors-hampton--cldx-20230221monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-proposed-public-offering-of-common-stock-hampton-n-j-cldx-20210712monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-appoints-freddy-a-jimenez-esq-as-senior-vice-president-and-general-counsel-hampton-cldx-20210104monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-proposed-public-offering-of-common-stock-hampton-n-j-cldx-20200615monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-appoints-diane-c-young-m-d-as-senior-vice-president-chief-medical-off-cldx-20190624monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-appoints-margo-heath-chiozzi-m-d-as-senior-vice-president-regulatory--cldx-20171003monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-departure-of-chief-medical-officer-hampton-n-j-cldx-20170912monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-additions-to-the-board-of-directors-and-senior-management-t-cldx-20170616monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-appointment-to-board-of-directors-hampton-n-j-cldx-20170301monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-appointment-to-board-of-directors-hampton-n-j-cldx-20161214monthly0.5https://www.biopharmawatch.com/news/CLDX/theresa-lavallee-ph-d-joins-celldex-therapeutics-senior-management-team-hampton-n-j-cldx-20161205monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-completes-acquisition-of-kolltan-pharmaceuticals-hampton-n-j-cldx-20161129monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-expands-antibody-and-immuno-oncology-portfolio-with-the-acquisition-of-kolltan-pha-cldx-20161101monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-appoints-elizabeth-crowley-as-chief-product-development-officer-hampton-n-j-cldx-20160811monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-prices-public-offering-of-common-stock-hampton-nj-cldx-20150225monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-year-end-2014-results-conference-call-scheduled-for-8-0-cldx-20150224monthly0.5https://www.biopharmawatch.com/news/CLDX/bristol-myers-squibb-and-celldex-therapeutics-announce-clinical-trial-collaboration-to-eva-cldx-20140514monthly0.5https://www.biopharmawatch.com/news/CLDX/sarah-cavanaugh-vice-president-of-investor-relations-corp-communications-celldex-therapeut-cldx-20131204monthly0.5https://www.biopharmawatch.com/news/CLDX/rindopepimut-society-for-neuro-oncology-sno-2014-update-cldx-20131125monthly0.5https://www.biopharmawatch.com/news/CLDX/sarah-cavanaugh-vice-president-of-investor-relations-corp-communications-celldex-therapeut-cldx-20131124monthly0.5https://www.biopharmawatch.com/news/CLDX/sarah-cavanaugh-vice-president-of-investor-relations-corp-communications-celldex-therapeut-cldx-20130502monthly0.5https://www.biopharmawatch.com/news/CLDX/management-to-host-conference-call-to-discuss-results-and-provide-2013-outlook-today-thurs-cldx-20130307monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-pricing-of-90-million-public-offering-of-common-stock-cldx-20130205monthly0.5https://www.biopharmawatch.com/news/CLDX/corporate-presentation-january-2013-forward-looking-statement-this-communication-contains--cldx-20130107monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2012-financial-results-needham-mass-business-wire-cldx-20121101monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2012-financial-results-management-to-host-conference-call-t-cldx-20120810monthly0.5https://www.biopharmawatch.com/news/CLDX/anthony-s-marucci-avery-w-catlin-for-media-president-and-ceo-chief-financial-officer-brad--cldx-20120523monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2012-financial-results-needham-mass-business-wire-cldx-20120503monthly0.5https://www.biopharmawatch.com/news/CLDX/management-to-host-conference-call-to-discuss-results-and-provide-2012-outlook-cldx-20120307monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-prices-public-offering-of-common-stock-cldx-20120224monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2011-financial-results-company-preparing-for-initiation-of-r-cldx-20111102monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2011-financial-results-and-announces-finalization-of-rindop-cldx-20110803monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-expands-senior-management-team-with-appointment-of-cldx-20110706monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-prices-public-offering-of-common-stock-cldx-20110518monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2011-financial-results-needham-mass-business-wire-cldx-20110504monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-fiscal-2010-financial-results-management-to-host-confer-cldx-20110303monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2010-financial-results-needham-mass-business-wire-cldx-20101102monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2010-financial-results-management-to-host-conference-call-t-cldx-20100804monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2010-financial-results-needham-mass-business-wire-cldx-20100504monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-fiscal-2009-financial-results-management-to-host-confer-cldx-20100304monthly0.5https://www.biopharmawatch.com/news/CLDX/for-immediate-release-cldx-20100216monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-reports-third-quarter-and-nine-month-2009-financial-results-needham-m-cldx-20091104monthly0.5https://www.biopharmawatch.com/news/CLDX/for-immediate-release-cldx-20090930monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-appointment-of-larry-ellberger-as-chairman-of-the-board-nee-cldx-20090904monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-and-six-month-2009-financial-results-conference-call-wednes-cldx-20090805monthly0.5https://www.biopharmawatch.com/news/CLDX/asco-abstract-no-2021-embargoed-until-saturday-may-30-2009-at-8-00-a-m-edt-pfizer-and-cell-cldx-20090530monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-inc-enhances-precision-targeted-immunotherapy-platform-with-the-acqui-cldx-20090529monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2009-financial-results-conference-call-tuesday-may-5-at-9-00-cldx-20090505monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-fiscal-2008-financial-results-conference-call-friday-fe-cldx-20090227monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-and-nine-month-financial-results-conference-call-wednesday-n-cldx-20081105monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-immunotherapeutics-announces-name-cldx-20080929monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-reports-second-quarter-and-six-month-financial-results-conference-call-wednesday-aug-cldx-20080806monthly0.5https://www.biopharmawatch.com/news/CLDX/embargoed-until-10-15-am-cdt-on-monday-june-2-2008-pfizer-inc-vanessa-aristede-212-733-378-cldx-20080602monthly0.5https://www.biopharmawatch.com/news/CLDX/for-immediate-release-cldx-20080416monthly0.5https://www.biopharmawatch.com/news/CLDX/for-immediate-release-cldx-20080307monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-reports-fourth-quarter-and-fiscal-2007-financial-results-needham-mass-business-wire--cldx-20080227monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-appeals-delisting-notification-from-nasdaq-needham-ma-cldx-20080109monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-immunotherapeutics-reports-third-quarter-and-nine-month-financial-results-needham-ma-cldx-20071031monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-immunotherapeutics-inc-and-celldex-therapeutics-schedule-joint-teleconference-for-mo-cldx-20071022monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-receives-approval-to-transfer-securities-to-the-nasdaq-capital-market-needham-mass-b-cldx-20070830monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-receives-nasdaq-deficiency-notice-relating-to-market-value-needham-mass-business-wir-cldx-20070821monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-immunotherapeutics-reports-second-quarter-and-six-month-financial-results-needham-ma-cldx-20070802monthly0.5https://www.biopharmawatch.com/news/CLDX/avant-receives-nasdaq-deficiency-notice-relating-to-minimum-bid-price-needham-mass-busines-cldx-20070710monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jess-rowlands--rare-20260505monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jess-rowlands--rare-20260212monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-provides-financial-and-business-updates-at-j-p-morgan-annual-healthcare-confere-rare-20251231monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-ultragenyx-reports-t-rare-20251104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-ultragenyx-reports-s-rare-20250805monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-ultragenyx-reports-f-rare-20250506monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-ultragenyx-reports-f-rare-20250213monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-carolyn-wang-m-rare-20250112monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-ultragenyx-reports-t-rare-20241105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-ultragenyx-reports-s-rare-20240801monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-ultragenyx-reports-f-rare-20240502monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-ultragenyx-reports-f-rare-20240215monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-carolyn-wang-m-rare-20240107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20231102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-mereo-biopharma-announce-interim-phase-2-data-from-phase-2-3-orbit-study-de-rare-20231014monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20230803monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-howard-horn-as-chief-financial-officer-and-executive-vice-president-co-rare-20230712monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patients-dosed-in-phase-3-program-evaluating-setrusumab-ux143-f-rare-20230706monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-mereo-biopharma-announce-positive-data-from-the-ongoing-phase-2-3-orbit-stu-rare-20230605monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20230504monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20230216monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20230106monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20221102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20220728monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-genetx-provide-program-update-on-gtx-102-for-angelman-syndrome-including-pr-rare-20220718monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-sale-of-a-portion-of-future-north-american-royalties-on-crysvita-buro-rare-20220714monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-acquires-global-rights-to-aav-gene-therapy-abo-102-for-sanfilippo-syndrome-type-rare-20220505monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20220505monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-ir-ultragenyx-com-media-jeff-blake-med-rare-20220210monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-preliminary-2021-revenue-and-2022-revenue-guidance-for-crysvita-in-ultr-rare-20220110monthly0.5https://www.biopharmawatch.com/news/RARE/regeneron-and-ultragenyx-collaborate-to-commercialize-evkeeza-evinacumab-outside-the-unite-rare-20220107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-415-475-6370-ir-ultragenyx-com-media-c-rare-20211102monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-first-patient-dosed-in-canada-in-phase-1-2-clinical-trial-o-rare-20211007monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-fda-has-removed-clinical-hold-on-phase-1-2-clinical-study-o-rare-20210927monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-joshua-higa-415-475-6370-media-carolyn-wang-415-22-rare-20210802monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-receive-approval-from-u-k-regulatory-agency-to-begin-clinical-study--rare-20210610monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-receive-clearance-from-health-canada-to-begin-clinical-study-of-gtx--rare-20210519monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-multi-year-durability-data-from-ongoing-phase-1-2-gene-thera-rare-20210514monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-joshua-higa-415-475-6370-ultragenyx-reports--rare-20210504monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-joshua-higa-415-475-6370-ultragenyx-reports--rare-20210211monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-fda-clearance-of-investigational-new-drug-ind-application-for-ux701-a-rare-20210121monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-preliminary-2020-revenue-and-2021-revenue-guidance-for-crysvita-in-ultr-rare-20210111monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-investors-media-joshua-higa-415-475-6370-ultragenyx-announces-progress-across-b-rare-20210108monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-mereo-biopharma-announce-collaboration-and-license-agreement-for-setrusumab-rare-20201217monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-presentation-of-phase-1-2-data-on-investigational-gtx-102-i-rare-20201205monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-joshua-higa-415-475-6370-ultragenyx-reports--rare-20201027monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-positive-interim-phase-1-2-data-on-investigational-gtx-102--rare-20201026monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-solid-biosciences-announce-strategic-collaboration-to-develop-and-commercia-rare-20201023monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-joshua-higa-415-475-6370-ultragenyx-appoints-rare-20200902monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-joshua-higa-415-475-6370-ultragenyx-reports--rare-20200730monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-u-s-fda-approval-of-dojolvi-ux007-triheptanoin-the-first-fda-approved-rare-20200630monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-u-s-fda-approval-of-crysvita-burosumab-for-the-treatme-rare-20200618monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20200515monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20200513monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20200506monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-enters-into-strategic-partnership-with-daiichi-sankyo-for-gene-therapy-manufact-rare-20200331monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20200213monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20200113monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20200109monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20191105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20190904monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-partnership-with-genetx-to-advance-treatment-for-angelman-syndrome-pr-rare-20190814monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20190801monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-arcturus-therapeutics-expand-existing-research-collaboration-and-license-ag-rare-20190619monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20190506monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20190221monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20190219monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20190104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20181114monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20181105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-expands-leadership-team-and-appoints-dr-wladimir-hogenhuis-as-chief-operating-o-rare-20180917monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-approval-of-mepsevii-vestronidase-alfa-in-europe-for-the-treatment-of-rare-20180827monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-second-quarter-2018-financial-results-conference-call-rare-20180802monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20180802monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20180507monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-fda-approval-of-crysvita-burosumab-twza-for-the-treatm-rare-20180417monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20180307monthly0.5https://www.biopharmawatch.com/news/RARE/kyowa-kirin-and-ultragenyx-announce-crysvita-burosumab-receives-conditional-marketing-auth-rare-20180223monthly0.5https://www.biopharmawatch.com/news/RARE/unaudited-pro-forma-condensed-combined-financial-information-the-following-unaudited-pro-f-rare-20180221monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20180220monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-sel-rare-20171218monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-burosumab-receives-positive-chmp-opinion-for-the-treat-rare-20171215monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-ann-rare-20171115monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-danielle-keatley-415-475-6876-ultragenyx-rep-rare-20171102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-415-483-8257-contact-kyowa-hakk-rare-20171010monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-acquire-dimension-therapeutics-ultragenyx-enters-into-definitive-agreement-t-rare-20171003monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-comments-on-dimension-therapeutics-announcement-that-ultragenyx-s-offer-is-a-su-rare-20171002monthly0.5https://www.biopharmawatch.com/news/RARE/rare-jpm-2017-fall-biotech-conference-call-series-rare-20170922monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-proposes-to-acquire-dimension-therapeutics-for-5-50-per-share-in-cash-rare-20170918monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-415-483-8257-ultragenyx-announc-rare-20170822monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-415-483-8257-ultragenyx-reports-rare-20170727monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-reports-rare-20170504monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-reports-rare-20170216monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-announc-rare-20161111monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-reports-rare-20161107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-reports-rare-20160808monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-announc-rare-20160714monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-reports-rare-20160509monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-reports-rare-20160225monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-ryan-martins-844-758-7273-ultragenyx-reports-rare-20151109monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-robert-anstey-844-758-7273-ultragenyx-report-rare-20150813monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-media-robert-anstey-844-758-7273-ultragenyx-report-rare-20150511monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-completes-acquisition-of-breathe-right-tarrytown-n-y-pbh-20260615monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2026-results-announces-acquisition-of-laco-pbh-20260513monthly0.5https://www.biopharmawatch.com/news/PBH/m-a-r-c-h-2-0-2-6-a-c-q-u-i-s-i-t-i-o-n-a-n-n-o-u-n-c-e-m-e-n-t-safe-harbor-disclosure-2-t-pbh-20260320monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-third-quarter-and-year-to-date-fiscal-2026-result-pbh-20260205monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-second-quarter-and-first-half-fiscal-2026-results-pbh-20251106monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2026-first-quarter-results-revenue-of-249--pbh-20250807monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-record-fiscal-2025-revenue-and-earnings-revenue-o-pbh-20250508monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-record-third-quarter-results-and-raises-full-year-pbh-20250206monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-expands-cfo-christine-sacco-s-role-to-include-chief-opera-pbh-20250106monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-second-quarter-and-first-half-fiscal-2025-results-pbh-20241107monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-first-quarter-fiscal-2025-results-revenue-of-267--pbh-20240808monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-year-2024-results-revenue-of-277-0-million-pbh-20240514monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-third-quarter-fiscal-2024-results-revenue-of-282--pbh-20240208monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-second-quarter-fiscal-2024-results-revenue-of-286-pbh-20231102monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-first-quarter-fiscal-2024-results-revenue-of-279--pbh-20230803monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-record-fiscal-year-2023-revenue-of-285-9-million--pbh-20230504monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-third-quarter-results-revenue-of-275-5-million-in-pbh-20230202monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-second-quarter-results-and-reaffirms-outlook-for--pbh-20221103monthly0.5https://www.biopharmawatch.com/news/PBH/f-i-r-s-t-q-u-a-r-t-e-r-f-y-2-3-r-e-s-u-l-t-s-safe-harbor-disclosure-this-presentation-con-pbh-20220804monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-record-results-for-fiscal-2022-company-exceeds-fu-pbh-20220505monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2022-third-quarter-results-revenue-of-274--pbh-20220203monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2022-second-quarter-results-record-revenue-pbh-20211104monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2022-first-quarter-results-revenue-was-269-pbh-20210805monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-completes-acquisition-of-theratears-announces-first-quarter-f-pbh-20210701monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-announces-agreement-to-expand-eye-care-offering-with-acquisition-of-theratears-ac-pbh-20210527monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2021-fourth-quarter-and-record-full-year-r-pbh-20210506monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2021-third-quarter-results-revenue-was-238-pbh-20210204monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2021-second-quarter-results-revenue-was-23-pbh-20201105monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2021-first-quarter-results-revenue-was-229-pbh-20200806monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2020-fourth-quarter-and-full-year-results--pbh-20200507monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-announces-new-25-million-share-repurchase-program-partici-pbh-20200302monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2020-third-quarter-and-year-to-date-result-pbh-20200206monthly0.5https://www.biopharmawatch.com/news/PBH/icr-conference-january-13-th-2020-icr-conference-2020-2-safe-harbor-disclosure-this-presen-pbh-20200113monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2020-second-quarter-and-year-to-date-resul-pbh-20191031monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2020-first-quarter-results-revenue-232-2-m-pbh-20190801monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2019-fourth-quarter-and-full-year-results--pbh-20190509monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2019-third-quarter-results-revenue-was-241-pbh-20190207monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-updates-third-quarter-and-fiscal-2019-guidance-announces--pbh-20190114monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2019-second-quarter-results-revenue-was-23-pbh-20181101monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-pbh-20180802monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-announces-strategic-sale-of-household-cleaning-business-trans-pbh-20180702monthly0.5https://www.biopharmawatch.com/news/PBH/william-blair-growth-stock-conference-2-safe-harbor-disclosure-this-presentation-contains--pbh-20180613monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-2018-fourth-quarter-and-full-year-results-prov-pbh-20180510monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-2018-third-quarter-results-revenue-increased-2-pbh-20180201monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-2018-second-quarter-results-reaffirms-fiscal-2-pbh-20171102monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-2018-first-quarter-results-reaffirms-fiscal-20-pbh-20170803monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-2017-fourth-quarter-and-full-year-results-prov-pbh-20170511monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-third-quarter-fiscal-2017-results-q3-revenues-up-8-3--pbh-20170202monthly0.5https://www.biopharmawatch.com/news/PBH/transaction-overview-on-pbh-20170112monthly0.5https://www.biopharmawatch.com/news/PBH/to-our-form-8-k-dated-pbh-20170110monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-announces-agreement-to-acquire-c-b-fleet-company-adds-leading-brand-to-wom-pbh-20161222monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-completes-sale-of-dermoplast-to-moberg-pharma-ab-licenses-mas-pbh-20161207monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-second-quarter-fiscal-2017-results-q2-revenues-up-4-4-pbh-20161103monthly0.5https://www.biopharmawatch.com/news/PBH/for-release-on-monday-september-12-th-prestige-brands-holdings-inc-appoints-christine-sacc-pbh-20160912monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-first-quarter-fiscal-2017-revenues-up-9-1-to-209-6-mi-pbh-20160804monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-completes-divestiture-of-three-brands-to-moberg-pharma-ab-tar-pbh-20160707monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-to-sell-three-brands-to-moberg-pharma-ab-prestige-to-release--pbh-20160630monthly0.5https://www.biopharmawatch.com/news/PBH/safe-harbor-disclosure-this-presentation-contains-certain-forward-looring-statements-withi-pbh-20160525monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-2016-fourth-quarter-and-full-year-results-comp-pbh-20160512monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-announces-pricing-of-350-million-senior-notes-tarrytown-ny-pbh-20160216monthly0.5https://www.biopharmawatch.com/news/PBH/dean-siegal-914-524-6819-2-pbh-20160216monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-completes-acquisition-of-dentek-holdings-inc-tarrytown-ny-bus-pbh-20160208monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-2016-third-quarter-and-year-to-date-results-cl-pbh-20160204monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-announces-agreement-to-acquire-dentek-holdings-inc-acquisition-will-add-sc-pbh-20151123monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-record-second-quarter-fiscal-2016-revenues-up-13-7-to-pbh-20151105monthly0.5https://www.biopharmawatch.com/news/PBH/about-prestige-brands-holdings-inc-the-company-markets-and-distributes-brand-name-over-the-pbh-20151028monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-record-first-quarter-fiscal-2016-revenues-up-31-9-to--pbh-20150806monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-record-fiscal-2015-fourth-quarter-and-full-year-resul-pbh-20150514monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-announces-ron-lombardi-to-succeed-matt-mannelly-as-president-and-chief-exe-pbh-20150422monthly0.5https://www.biopharmawatch.com/news/PBH/to-our-form-8-k-filed-with-the-sec-on-pbh-20150226monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-third-quarter-2015-and-year-to-date-results-re-pbh-20150205monthly0.5https://www.biopharmawatch.com/news/PBH/non-gaap-financial-measures-we-define-non-gaap-adjusted-ebitda-as-earnings-before-income-l-pbh-20141212monthly0.5https://www.biopharmawatch.com/news/PBH/accompanying-form-8-k-filed-pbh-20141118monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-second-quarter-revenue-up-8-6-integration-of-insight--pbh-20141106monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-completes-purchase-of-insight-pharmaceuticals-corporation-tar-pbh-20140903monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-first-quarter-fiscal-2015-revenues-of-145-7-million-u-pbh-20140807monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fourth-quarter-fiscal-2014-results-provides-outlook-f-pbh-20140515monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-completes-purchase-of-hydralyte-for-its-australian-subsidiary-pbh-20140501monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-announces-agreement-to-acquire-insight-pharmaceuticals-adds-new-platform-i-pbh-20140425monthly0.5https://www.biopharmawatch.com/news/PBH/for-release-7am-et-tuesday-pbh-20140415monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-fiscal-third-quarter-nine-month-results-results-impac-pbh-20140206monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-announces-initial-results-of-tender-offer-and-consent-solicit-pbh-20131217monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-announces-offering-of-400-million-senior-note-s-tarrytown-ny-pbh-20131203monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-record-second-quarter-revenue-of-168-4-million-record-pbh-20131107monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-record-first-quarter-eps-of-0-40-vs-0-29-up-37-9-reve-pbh-20130801monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-record-fourth-quarter-revenues-up-15-3-and-eps-of-0-3-pbh-20130516monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-50-8-revenue-increase-record-earnings-for-third-quart-pbh-20130207monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-53-4-revenue-increase-record-earnings-for-second-quar-pbh-20121101monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-record-revenue-increase-of-54-for-first-quarter-fisca-pbh-20120807monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-completes-purchase-of-debrox-and-gly-oxide-from-gsk-finalizin-pbh-20120402monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-expects-to-report-revenue-growth-of-approximately-38-and-adjusted-eps-of-a-pbh-20120322monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-comments-on-genomma-lab-s-intention-to-nominate-directors-irvington-n-y-pbh-20120315monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-rejects-unsolicited-proposal-from-genomma-lab-irvington-ny-pbh-20120312monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-adopts-stockholder-rights-plan-irvington-ny-pbh-20120227monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reacts-to-unsolicited-non-binding-highly-conditional-letter-f-pbh-20120221monthly0.5https://www.biopharmawatch.com/news/PBH/for-release-on-pbh-20120131monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-announces-pricing-of-250-million-senior-note-s-due-2020-irvin-pbh-20120124monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-inc-announces-offering-of-290-million-senior-notes-irvington-ny-pbh-20120118monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-signs-definitive-agreements-with-gsk-to-acquire-17-consumer-o-pbh-20111220monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-third-quarter-nine-months-fiscal-2011-results-for-the-pbh-20110209monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-reports-second-quarter-six-months-fiscal-2011-results-for-the-pbh-20101104monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-inc-announces-100-pbh-20101022monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-announces-agreement-to-acquire-blacksmith-brands-irvington-n-y-pbh-20100920monthly0.5https://www.biopharmawatch.com/news/PBH/unassociated-document-prestige-brands-holdings-inc-reports-fiscal-first-quarter-2011-resul-pbh-20100805monthly0.5https://www.biopharmawatch.com/news/PBH/prestige-brands-holdings-inc-announces-appointment-of-matthew-mannelly-as-chief-executive--pbh-20090903monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2025-financial-results-a-supn-20260212monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2025-financial-results-net-sales-of-qelbree-increased-31-supn-20250805monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2025-financial-results-and-host-confer-supn-20250722monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filings-for-qelbree-rockville-md-supn-20250528monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2025-financial-results-first-quarter-2025-net-sales-of-qe-supn-20250506monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2025-financial-results-and-host-confere-supn-20250423monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fourth-quarter-and-full-year-2024-financial-results-fourth-quarter-2024-supn-20250225monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-topline-results-from-phase-2b-study-in-adults-with-treatment-resistant--supn-20250218monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-host-conference-call-and-webcast-on-supn-20250211monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fda-approval-of-onapgo-apomorphine-hydrochloride-for-parkinson-s-diseas-supn-20250204monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-label-update-for-non-stimulant-adhd-treatment-qelbree-including-new-pha-supn-20250127monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2024-financial-results-net-sales-of-qelbree-increased-68--supn-20241104monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-host-conference-call-and-webcast-on-supn-20241021monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-promising-data-from-open-label-phase-2a-study-of-spn-820-in-adults-with-supn-20241017monthly0.5https://www.biopharmawatch.com/news/SUPN/document-supernus-pharmaceuticals-to-host-webcast-to-review-open-label-phase-2a-study-of-s-supn-20241010monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-spn-830-apomorphine-infusion-device-nda-accepted-for-review-by-fda-pduf-supn-20240819monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2024-financial-results-net-sales-of-qelbree-increased-92-supn-20240806monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-resubmits-nda-for-spn-830-apomorphine-infusion-device-rockville-md-supn-20240801monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2024-financial-results-and-host-confer-supn-20240723monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-promising-interim-data-from-ongoing-open-label-phase-2a-study-of-spn-81-supn-20240523monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-host-webcast-to-review-interim-data-from-ongoing-open-label-ph-supn-20240509monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2024-financial-results-net-sales-of-qelbree-increased-75--supn-20240508monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2024-financial-results-and-host-confere-supn-20240424monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-regulatory-update-for-spn-830-rockville-md-supn-20240408monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fourth-quarter-and-full-year-2023-financial-results-fourth-quarter-2023-supn-20240227monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2023-financial-results-a-supn-20240213monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-wins-infringement-and-validity-case-on-trokendi-xr-against-torrent-rockville-md-supn-20240205monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2023-financial-results-raises-full-year-2023-adjusted-ope-supn-20231108monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-spn-830-apomorphine-infusion-device-nda-accepted-for-review-by-fda-pduf-supn-20231102monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-third-quarter-2023-financial-results-and-host-confere-supn-20231025monthly0.5https://www.biopharmawatch.com/news/SUPN/xa9-2023-supernus-pharmaceuticals-inc-all-rights-reserved-supernus-pharmaceuticals-r-d-day-supn-20231018monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-resubmits-nda-for-spn-830-apomorphine-infusion-device-rockville-md-supn-20231009monthly0.5https://www.biopharmawatch.com/news/SUPN/bethany-l-sensenig-joins-supernus-board-of-directors-rockville-md-supn-20230821monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2023-financial-results-qelbree-net-product-sales-growth--supn-20230808monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2023-financial-results-and-host-confer-supn-20230724monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2023-financial-results-first-quarter-2023-total-revenues--supn-20230509monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2023-financial-results-and-host-confere-supn-20230426monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-repayment-of-convertible-notes-rockville-md-supn-20230403monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fourth-quarter-and-full-year-2022-financial-results-full-year-2022-tota-supn-20230228monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-enters-into-150-million-credit-facility-rockville-md-supn-20230214monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2022-financial-results-a-supn-20230210monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2022-financial-results-third-quarter-2022-total-revenues--supn-20221108monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-third-quarter-2022-financial-results-and-host-confere-supn-20221025monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-regulatory-update-on-spn-830-rockville-md-supn-20221010monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2022-financial-results-second-quarter-2022-total-revenue-supn-20220804monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2022-financial-results-and-host-confer-supn-20220726monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-inc-all-rights-reserved-1-supernus-pharmaceuticals-jefferies-heal-supn-20220609monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2022-financial-results-first-quarter-2022-total-revenues--supn-20220509monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2022-financial-results-and-host-confere-supn-20220504monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fda-approval-of-qelbree-for-the-treatment-of-adhd-in-adults-first-novel-supn-20220429monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-reports-final-audited-fourth-quarter-and-full-year-2021-financial-results-annual--supn-20220413monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-update-on-filing-of-annual-report-and-reiterates-full-year-2022-financia-supn-20220404monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-notifies-nasdaq-regarding-non-compliance-with-listing-requirement-and-expectation-supn-20220317monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-preliminary-fourth-quarter-and-full-year-2021-financial-results-prelimi-supn-20220228monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-provide-preliminary-fourth-quarter-and-full-year-2021-financial-results-and-ho-supn-20220222monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-resubmits-nda-for-spn-830-apomorphine-infusion-device-rockville-md-supn-20211208monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-targeted-in-ransomware-incident-the-attack-had-no-significant-imp-supn-20211124monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-completes-acquisition-of-adamas-pharmaceuticals-acquisition-stren-supn-20211124monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2021-financial-results-total-revenues-for-the-first-nine--supn-20211104monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-announce-third-quarter-2021-financial-results-and-host-conference-call-on-supn-20211028monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-acquire-adamas-pharmaceuticals-strengthening-its-cns-product-p-supn-20211011monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-qelbree-snda-for-adult-indication-accepted-for-review-by-supn-20210902monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2021-financial-results-second-quarter-2021-total-revenue-supn-20210804monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-second-quarter-2021-financial-results-conference-call-rockville-md-supn-20210722monthly0.5https://www.biopharmawatch.com/news/SUPN/qelbree-viloxazine-extended-release-capsules-a-new-non-controlled-substance-now-available--supn-20210524monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2021-financial-results-first-quarter-2021-total-revenues--supn-20210505monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-supn-20210504monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-first-quarter-2021-financial-results-conference-call-rockville-md-supn-20210427monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fda-approval-of-qelbree-spn-812-for-the-treatment-of-adhd-qelbree-vilox-supn-20210402monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fourth-quarter-and-full-year-2020-financial-results-full-year-2020-tota-supn-20210225monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-fourth-quarter-and-full-year-2020-financial-results-conference-call-rockv-supn-20210224monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-fda-notice-assigning-early-april-2021-pdufa-date-for-spn-812-supn-20210222monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-resubmits-new-drug-application-for-spn-812-for-the-treatment-of-adhd-in-pediatric-supn-20210208monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-positive-results-from-phase-iii-study-for-spn-812-in-adults-with-adhd-m-supn-20201222monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-regulatory-update-for-spn-812-and-spn-830-rockville-md-supn-20201109monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2020-financial-results-q3-2020-total-revenues-of-155-1-mi-supn-20201103monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-third-quarter-results-earnings-conference-call-rockville-md-supn-20201027monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-appoints-james-kelly-as-chief-financial-officer-greg-patrick-to-r-supn-20201005monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-submits-nda-for-spn-830-for-continuous-treatment-of-on-off-episodes-in-adults-wit-supn-20200914monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-morgan-stanley-18-th-annual-global-healthcare-conference-rockvi-supn-20200909monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-wells-fargo-virtual-health-care-conference-rockville-md-supn-20200902monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2020-financial-results-total-revenue-of-126-7-million-in-supn-20200819monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-preliminary-second-quarter-2020-revenue-second-quarter-total-revenue-is-supn-20200811monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-apotex-for-infringement-of-oxtellar-xr-patents-rockville-md-supn-20200626monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-completes-acquisition-of-cns-portfolio-from-us-worldmeds-creates-leading-cns-port-supn-20200609monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-jefferies-virtual-health-care-conference-rockville-md-supn-20200527monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-oxtellar-supn-20200515monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2020-financial-results-first-quarter-total-revenue-of-95--supn-20200507monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-acquire-cns-portfolio-from-us-worldmeds-expands-and-strengthens-neurology-port-supn-20200429monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-first-quarter-results-earnings-conference-call-rockville-md-supn-20200424monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-and-navitor-announce-development-and-option-agreement-for-orally-active-mtorc1-ac-supn-20200421monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-business-update-rockville-md-supn-20200330monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fourth-quarter-and-full-year-2019-financial-results-fourth-quarter-and--supn-20200227monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-fourth-quarter-and-full-year-2019-results-earnings-conference-call-rockvi-supn-20200211monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fda-acceptance-for-review-of-new-drug-application-for-spn-812-for-the-t-supn-20200121monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2020-j-p-morgan-healthcare-conference-rockville-md-supn-20200108monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-update-on-results-from-phase-iii-study-p301-of-spn-810-for-treatment-of--supn-20191209monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-submits-new-drug-application-for-spn-812-for-the-treatment-of-adhd-spn-812-viloxa-supn-20191111monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2019-financial-results-and-topline-data-from-phase-iii-st-supn-20191105monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-third-quarter-2019-earnings-conference-call-rockville-md-supn-20191024monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2019-cantor-global-healthcare-conference-rockville-md-supn-20190925monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-september-healthcare-conferences-rockville-md-supn-20190826monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2019-financial-results-total-revenue-of-104-7-million-a--supn-20190806monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-second-quarter-2019-earnings-conference-call-rockville-md-supn-20190723monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-jefferies-2019-global-healthcare-conference-rockville-md-supn-20190529monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2019-financial-results-total-revenue-of-85-5-million-and--supn-20190507monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-first-quarter-2019-earnings-conference-call-rockville-md-supn-20190424monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-webcast-of-investor-day-on-supn-20190404monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-hosts-conference-call-to-present-topline-results-of-final-phase-iii-study-for-spn-supn-20190327monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2019-cowen-health-care-conference-rockville-md-supn-20190306monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-record-full-year-2018-financial-results-fourth-quarter-2018-total-reven-supn-20190226monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-fourth-quarter-and-full-year-2018-earnings-conference-call-rockville-md-supn-20190212monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-positive-results-from-phase-iii-study-for-spn-812-in-adolescents-with-a-supn-20181220monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fda-approval-of-snda-to-expand-oxtellar-xr-label-to-include-monotherapy-supn-20181214monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-schedules-conference-call-to-present-topline-results-of-two-phase-iii-studies-for-supn-20181205monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-three-november-healthcare-conferences-rockville-md-supn-20181107monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2018-financial-results-and-record-quarterly-revenue-total-supn-20181106monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-third-quarter-2018-earnings-conference-call-rockville-md-supn-20181024monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2018-cantor-fitzgerald-global-healthcare-conference-rockville-m-supn-20180920monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-acquire-biscayne-neurotherapeutics-adds-phase-1-novel-epilepsy-development-pro-supn-20180913monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-wins-appeal-on-oxtellar-xr-against-twi-second-appeal-win-against-generic-filers-r-supn-20180906monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-september-2018-wells-fargo-healthcare-conference-rockville-md-supn-20180829monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2018-financial-results-and-record-quarterly-revenue-tota-supn-20180807monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-second-quarter-2018-earnings-conference-call-rockville-md-supn-20180725monthly0.5https://www.biopharmawatch.com/news/SUPN/dr-carrolee-barlow-m-d-ph-d-joins-supernus-board-of-directors-rockville-md-supn-20180627monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2018-jefferies-healthcare-conference-rockville-md-supn-20180530monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2018-financial-results-and-record-quarterly-revenue-total-supn-20180508monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-first-quarter-2018-earnings-conference-call-rockville-md-supn-20180424monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-pricing-of-350-million-private-offering-of-0-625-convertible-senior-not-supn-20180315monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-management-march-2018-presentation-2018-supernus-pharmaceuticals--supn-20180314monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2018-cowen-health-care-conference-rockville-md-supn-20180306monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-record-full-year-2017-financial-results-exceeding-operating-earnings-gu-supn-20180227monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-fourth-quarter-and-full-year-2017-earnings-conference-call-rockville-md-supn-20180212monthly0.5https://www.biopharmawatch.com/news/SUPN/exhib-it-99-1-supernus-to-present-at-the-2018-j-p-morgan-healthcare-conference-rockville-m-supn-20180102monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-three-november-healthcare-conferences-rockville-md-supn-20171108monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2017-financial-results-third-quarter-net-product-sales-we-supn-20171106monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-third-quarter-2017-earnings-conference-call-rockville-md-supn-20171024monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-update-on-spn-810-phase-iii-clinical-trials-rockville-md-supn-20170918monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-defeats-second-generic-challenger-to-oxtellar-xr-federal-court-finds-supernus-pat-supn-20170815monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-record-second-quarter-2017-financial-results-second-quarter-net-product-supn-20170802monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-second-quarter-2017-earnings-conference-call-rockville-md-supn-20170719monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-that-its-partner-shire-receives-fda-approval-for-mydayis-for-adhd-rockv-supn-20170621monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-jefferies-healthcare-conference-rockville-md-supn-20170601monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2017-financial-results-net-product-sales-were-56-4-millio-supn-20170509monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-first-quarter-2017-earnings-conference-call-rockville-md-supn-20170426monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-final-fda-approval-for-trokendi-xr-for-migraine-prophylaxis-in-adults-an-supn-20170405monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-settlement-with-actavis-on-trokendi-xr-patent-litigation-rockville-md-supn-20170307monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-settlement-with-zydus-on-trokendi-xr-patent-litigation-rockville-md-supn-20170306monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-record-fourth-quarter-and-full-year-2016-financial-results-fourth-quart-supn-20170228monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-fourth-quarter-and-full-year-2016-earnings-conference-call-rockville-md-supn-20170213monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-eighth-u-s-patent-protecting-trokendi-supn-20170208monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-seventh-u-s-patent-protecting-trokendi-supn-20170130monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-files-form-10-q-for-third-quarter-2016-and-is-now-current-with-all-financial-fili-supn-20170123monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2017-j-p-morgan-healthcare-conference-rockville-md-supn-20170103monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-wins-appeal-case-on-oxtellar-xr-u-s-court-of-appeals-affirms-district-court-s-dec-supn-20161212monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-nasdaq-non-compliance-notice-rockville-md-supn-20161117monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-three-november-healthcare-conferences-rockville-md-supn-20161107monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-schedules-conference-call-to-present-results-of-phase-iib-clinical-trial-of-spn-8-supn-20161010monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-fda-tentative-approval-for-expanded-label-of-trokendi-xr-to-include-migr-supn-20160819monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-resignation-of-dr-james-barrett-from-board-of-directors-charles-w-newha-supn-20160812monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2016-financial-results-second-quarter-2016-product-presc-supn-20160802monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-second-quarter-2016-earnings-conference-call-rockville-md-supn-20160720monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-seventh-u-s-patent-protecting-oxtellar-supn-20160622monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-update-on-trokendi-xr-migraine-snda-and-reiterates-guidance-rockville-md-supn-20160616monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-sixth-u-s-patent-protecting-oxtellar-supn-20160602monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-june-jefferies-healthcare-conference-rockville-md-supn-20160524monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-enters-into-partial-settlement-agreement-with-actavis-on-oxtellar-supn-20160510monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2016-financial-results-first-quarter-2016-product-prescri-supn-20160503monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-first-quarter-2016-earnings-conference-call-rockville-md-supn-20160419monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-record-fourth-quarter-and-full-year-2015-financial-results-net-product--supn-20160302monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-fourth-quarter-and-full-year-2015-earnings-conference-call-rockville-md-supn-20160218monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-prevails-in-oxtellar-xr-anda-litigation-a-federal-court-finds-supernus-patents-va-supn-20160208monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-attend-guggenheim-securities-boston-healthcare-conference-rockville-md-supn-20151202monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-distribution-of-common-stock-by-supn-20151112monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-investor-conferences-rockville-md-supn-20151109monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2015-financial-results-and-raises-2015-guidance-third-qua-supn-20151103monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fda-acceptance-of-snda-to-add-migraine-to-trokendi-xr-label-rockville-m-supn-20151022monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-third-quarter-2015-earnings-conference-call-rockville-md-supn-20151020monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-fifth-u-s-patent-protecting-oxtellar-xr-rockville-md-supn-20150902monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-attend-fbr-healthcare-conference-on-september-9-th-rockville-md-supn-20150827monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2015-financial-results-second-quarter-product-prescripti-supn-20150804monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-second-quarter-2015-earnings-conference-call-rockville-md-supn-20150720monthly0.5https://www.biopharmawatch.com/news/SUPN/exhibi-99-1-supernus-announces-distribution-of-common-stock-by-supn-20150617monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-webcast-of-investor-day-on-supn-20150610monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-june-jefferies-healthcare-conference-rockville-md-supn-20150519monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2015-financial-results-net-product-sales-for-the-first-qu-supn-20150505monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-first-quarter-2015-earnings-conference-call-rockville-md-supn-20150421monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-sixth-u-s-patent-protecting-trokendi-xr-rockville-md-supn-20150402monthly0.5https://www.biopharmawatch.com/news/SUPN/georges-gemayel-ph-d-joins-supernus-board-of-directors-rockville-md-supn-20150323monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fourth-quarter-and-full-year-2014-results-cash-flow-positive-for-the-fo-supn-20150310monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-fourth-quarter-and-full-year-2014-earnings-conference-call-rockville-md-supn-20150217monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-par-for-infringement-of-trokendi-xr-patents-rockville-md-supn-20150116monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-trokendi-xr-rockville-md-supn-20141209monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-zydus-for-infringement-of-trokendi-xr-patents-rockville-md-supn-20141121monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2014-results-the-company-raises-revenue-guidance-from-app-supn-20141111monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-investor-conferences-rockville-md-supn-20141104monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-third-quarter-2014-earnings-conference-call-rockville-md-supn-20141029monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-trokendi-supn-20141014monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-actavis-for-infringement-of-trokendi-xr-patents-rockville-md-supn-20141002monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-business-update-rockville-md-supn-20140922monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-fourth-us-patent-protecting-oxtellar-xr-rockville-md-supn-20140904monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-trokendi-xr-rockville-md-supn-20140821monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-fda-fast-track-designation-for-spn-810-rockville-md-supn-20140814monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2014-results-second-quarter-combined-net-product-revenue-supn-20140812monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-second-quarter-2014-earnings-conference-call-rockville-md-supn-20140729monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-2-million-milestone-for-united-therapeutics-launch-of-orenitram-rockvill-supn-20140520monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2014-results-first-quarter-product-prescriptions-as-repor-supn-20140512monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-first-quarter-2014-earnings-conference-call-rockville-md-supn-20140429monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fourth-quarter-and-full-year-2013-results-product-prescriptions-filled--supn-20140312monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-fourth-quarter-and-full-year-2013-earnings-conference-call-rockville-md-supn-20140225monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-publication-of-phase-iii-study-prosper-results-on-oxtellar-xr-rockville-supn-20140203monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-first-use-patents-protecting-spn-812-as-a-novel-non-stimula-supn-20140127monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-malavika-william-mwilliam-establishmentlabs-com-establishment-labs--esta-20260506monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20260224monthly0.5https://www.biopharmawatch.com/news/ESTA/document-esta-20260114monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20251231monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20250807monthly0.5https://www.biopharmawatch.com/news/ESTA/investorsday-investor-day-welcome-agenda-topic-presenter-moderator-welcome-logistics-agend-esta-20250612monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20250507monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20250410monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20250226monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20250113monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20241107monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20240806monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20240508monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20240228monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-announces-50-million-private-placement-and-preliminary-unaudited-financ-esta-20240112monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20231107monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20230808monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20230508monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-announces-preliminary-unaudited-results-for-first-quarter-2023-esta-20230424monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-notes-presentation-of-3-year-results-from-motiva-u-s-ide-study-at-the-a-esta-20230420monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20230227monthly0.5https://www.biopharmawatch.com/news/ESTA/presentationmateria-founder-ceo-establishment-labs-juan-jos-eacute-chac-oacute-n-quir-oacu-esta-20230111monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20230109monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20221107monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20220808monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20220509monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20220301monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20220110monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20211213monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20211210monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20211109monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20210729monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20210715monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20210712monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-announces-pratip-dastidar-has-joined-the-company-as-head-of-global-oper-esta-20210518monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20210505monthly0.5https://www.biopharmawatch.com/news/ESTA/investor-media-contact-raj-denhoy-415-828-1044-rdenhoy-establishmentlabs-com-establishment-esta-20210310monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-hosts-investor-event-for-its-motiva-mia-system-for-minimally-invasive-a-esta-20210209monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-preliminary-results-for-fourth-quarter-and-fiscal-year-2020-pre-esta-20201231monthly0.5https://www.biopharmawatch.com/news/ESTA/motiva-ergonomix2-platform-and-motiva-mia-implant-receive-ce-mark-commercial-launch-of-erg-esta-20201214monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-preliminary-third-quarter-revenue-and-cash-balance-22-million-t-esta-20200930monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-finalizes-distribution-agreement-with-puregraft-esta-20200925monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-announces-transition-to-a-direct-sales-force-in-italy-esta-20200806monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-record-first-quarter-2020-financial-results-esta-20200507monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-fourth-quarter-and-full-year-2019-financial-results-esta-20200316monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-third-quarter-2019-financial-results-esta-20191112monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-second-quarter-2019-financial-results-esta-20190813monthly0.5https://www.biopharmawatch.com/news/ESTA/estainvestordaysbtmjune2-roberto-de-mezerville-chief-technology-officer-investor-day-costa-esta-20190619monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-announces-additional-financing-and-improved-terms-with-amendment-to-exi-esta-20190617monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-announces-appointment-of-lisa-gersh-to-board-of-directors-esta-20190606monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-first-quarter-2019-financial-results-esta-20190515monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-fourth-quarter-and-full-year-2018-financial-results-esta-20190320monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-third-quarter-2018-financial-results-esta-20181113monthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-announces-transition-to-a-direct-sales-force-in-germany-and-spain-durin-esta-20181004monthly0.5https://www.biopharmawatch.com/news/NKTR/week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-de-nktr-20260420monthly0.5https://www.biopharmawatch.com/news/NKTR/efficacy-and-safety-of-rezpegaldesleukin-a-selective-regulatory-t-cell-inducing-interleuki-nktr-20250918monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-second-quarter-2025-financial-results-nktr-20250807monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-pricing-of-100-million-public-offering-nktr-20250701monthly0.5https://www.biopharmawatch.com/news/NKTR/rezolve-ad-phase-2b-study-of-rezpegaldesleukin-meets-primary-and-key-secondary-endpoints-i-nktr-20250624monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2025-financial-results-nktr-20250508monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-nktr-20250312monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-clinical-trial-agreement-to-evaluate-rezpegaldesleukin-in-patients-with-n-nktr-20250224monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-third-quarter-2024-financial-results-nktr-20241107monthly0.5https://www.biopharmawatch.com/news/NKTR/final-confidential-press-release-for-issuance-monday-november-4-2024-at-5-30am-pt-7-30-am--nktr-20241104monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-second-quarter-2024-financial-results-nktr-20240808monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2024-financial-results-nktr-20240509monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-nktr-20240304monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-third-quarter-2023-financial-results-nktr-20231107monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-second-quarter-2023-financial-results-nktr-20230808monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2023-financial-results-nktr-20230509monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-it-will-regain-full-rights-to-rezpegaldesleukin-rezpeg-nktr--nktr-20230427monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-strategic-reprioritization-and-cost-restructuring-plan-pipel-nktr-20230417monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-issues-statement-confirming-that-it-does-not-hold-any-cash-deposits-or-nktr-20230311monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2022-financial-results-nktr-20230228monthly0.5https://www.biopharmawatch.com/news/NKTR/phase-2-island-study-of-rezpeg-in-sle-topline-data-results-nktr-20230223monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-third-quarter-2022-financial-results-nktr-20221103monthly0.5https://www.biopharmawatch.com/news/NKTR/not-for-release-publication-or-distribution-in-whole-or-in-part-in-into-or-from-any-jurisd-nktr-20221011monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-second-quarter-2022-financial-results-nktr-20220804monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2022-financial-results-nktr-20220505monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-strategic-reorganization-plan-and-corporate-outlook-company--nktr-20220425monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-and-bristol-myers-squibb-announce-update-on-clinical-development-program-for-bempeg-nktr-20220414monthly0.5https://www.biopharmawatch.com/news/NKTR/bristol-myers-squibb-and-nektar-announce-update-on-phase-3-pivot-io-001-trial-evaluating-b-nktr-20220314monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-nktr-20220228monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-third-quarter-2021-financial-results-nktr-20211104monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-second-quarter-2021-financial-results-nktr-20210805monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2021-financial-results-nktr-20210506monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-nktr-20210225monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-third-quarter-2020-financial-results-nktr-20201105monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-second-quarter-2020-financial-results-nktr-20200806monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2020-financial-results-nktr-20200507monthly0.5https://www.biopharmawatch.com/news/NKTR/a-letter-from-our-president-ceo-howard-robin-updated-nktr-20200401monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2019-financial-results-nktr-20200227monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-nktr-20191106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2019-company-to-ho-nktr-20190808monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-first-quarter-of-2019-nktr-20190508monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-preliminary-immune-activation-safety-and-clinical-activity-da-nktr-20190301monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2018-financial-results-nktr-20190228monthly0.5https://www.biopharmawatch.com/news/NKTR/clinical-data-presented-from-pivot-02-study-of-bempegaldesleukin-nktr-214-with-nivolumab-i-nktr-20190215monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-third-quarter-of-2018-nktr-20181107monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2018-nktr-20180808monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-first-quarter-of-2018-nktr-20180510monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2017-financial-results-nktr-20180301monthly0.5https://www.biopharmawatch.com/news/NKTR/bristol-myers-squibb-and-nektar-therapeutics-announce-global-development-commercialization-nktr-20180214monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-third-quarter-of-2017-nktr-20171107monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-appoints-biotechnology-executive-jeff-ajer-as-new-board-member-nktr-20170921monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2017-nktr-20170808monthly0.5https://www.biopharmawatch.com/news/NKTR/lilly-and-nektar-therapeutics-announce-alliance-to-develop-and-commercialize-nktr-358-a-no-nktr-20170724monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-topline-data-from-human-abuse-potential-study-for-nktr-181-a-first-in-cla-nktr-20170718monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-first-quarter-of-2017-nktr-20170509monthly0.5https://www.biopharmawatch.com/news/NKTR/meets-primary-and-secondary-endpoints-in-phase-3-nktr-20170320monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2016-financial-results-nktr-20170301monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-third-quarter-of-2016-nktr-20161103monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-public-offering-of-shares-of-common-stock-nktr-20161017monthly0.5https://www.biopharmawatch.com/news/NKTR/bristol-myers-squibb-and-nektar-therapeutics-announce-oncology-clinical-collaboration-to-e-nktr-20160927monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2016-nktr-20160803monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-executive-management-promotions-john-nicholson-named-senior--nktr-20160602monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-first-quarter-of-2016-nktr-20160503monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2015-financial-results-nktr-20160301monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-third-quarter-of-2015-nktr-20151105monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-closes-direct-private-placement-with-tpg-special-situations-partners-of-250-million-nktr-20151006monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2015-nktr-20150805monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-first-quarter-of-2015-nktr-20150430monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2014-financial-results-nktr-20150224monthly0.5https://www.biopharmawatch.com/news/NKTR/federal-register-vol-80-no-15-friday-nktr-20150123monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-third-quarter-2025-financial-results-and-recent-corporate-updates-zocilu-zlab-20251106monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-second-quarter-2025-financial-results-and-recent-corporate-updates-total-zlab-20250807monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-first-quarter-2025-financial-results-and-recent-corporate-updates-total--zlab-20250508monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-fourth-quarter-and-full-year-2024-financial-results-and-recent-corporate-zlab-20250227monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares-shanghai-zlab-20241114monthly0.5https://www.biopharmawatch.com/news/ZLAB/updated-risk-factors-risks-related-to-our-business-and-industry-we-our-employees-and-our-c-zlab-20241113monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-third-quarter-2024-financial-results-and-recent-corporate-updates-strong-zlab-20241112monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-second-quarter-2024-financial-results-and-recent-corporate-updates-net-p-zlab-20240806monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-first-quarter-2024-financial-results-and-recent-corporate-updates-net-pr-zlab-20240508monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-full-year-2023-financial-results-and-recent-corporate-updates-total-prod-zlab-20240227monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-third-quarter-2023-financial-results-and-recent-corporate-updates-total--zlab-20231107monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-second-quarter-2023-financial-results-and-corporate-updates-total-produc-zlab-20230807monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-first-quarter-2023-financial-results-and-corporate-updates-total-product-zlab-20230509monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-full-year-2022-financial-results-and-recent-corporate-updates-total-reve-zlab-20230301monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-michel-vounatsos-to-its-board-of-directors-shanghai-and-zlab-20230109monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-third-quarter-2022-financial-results-and-corporate-updates-revenue-of-57-zlab-20221110monthly0.5https://www.biopharmawatch.com/news/ZLAB/seagen-and-zai-lab-announce-regional-strategic-collaboration-and-license-agreement-for-tiv-zlab-20220927monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-second-quarter-2022-financial-results-and-corporate-updates-key-pipeline-zlab-20220810monthly0.5https://www.biopharmawatch.com/news/ZLAB/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--zlab-20220531monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-first-quarter-2022-financial-results-and-corporate-updates-company-to-ho-zlab-20220511monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-the-appointment-of-josh-smiley-as-chief-operating-officer-shanghai-san-f-zlab-20220315monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-financial-results-and-corporate-updates-for-twelve-months-ended-zlab-20220301monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-nda-acceptance-of-margetuximab-for-patients-with-pretreated-metastatic-h-zlab-20220106monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-promotion-of-harald-reinhart-m-d-to-president-and-head-of-global-develop-zlab-20211222monthly0.5https://www.biopharmawatch.com/news/ZLAB/china-nmpa-approves-nuzyra-as-a-category-1-innovative-drug-for-the-treatment-of-patients-w-zlab-20211216monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-inclusion-of-zejula-niraparib-in-china-s-national-reimbursement-drug-lis-zlab-20211203monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-richard-gaynor-md-to-its-board-of-directors-shanghai-san-francisco-and-zlab-20211122monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-blueprint-medicines-announce-strategic-collaboration-and-license-agreement-for-zlab-20211106monthly0.5https://www.biopharmawatch.com/news/ZLAB/zl-1102-zai-lab-s-internally-developed-novel-human-vh-antibody-fragment-achieved-proof-of--zlab-20211020monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-entasis-therapeutics-announce-positive-topline-results-for-sulbactam-durlobact-zlab-20211019monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-scott-morrison-to-its-board-of-directors-shanghai-san-francisco-and-cambr-zlab-20211018monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-second-quarter-2021-financial-results-and-corporate-updates-company-to-h-zlab-20210810monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-macrogenics-enter-into-broad-strategic-collaboration-to-develop-and-commercial-zlab-20210616monthly0.5https://www.biopharmawatch.com/news/ZLAB/mirati-therapeutics-and-zai-lab-enter-into-a-collaboration-to-develop-and-commercialize-ad-zlab-20210601monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-reports-first-quarter-2021-financial-results-company-to-host-conference-call-and-w-zlab-20210510monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-partner-novocure-announces-update-on-phase-3-pivotal-lunar-trial-of-tumor-treating-zlab-20210413monthly0.5https://www.biopharmawatch.com/news/ZLAB/china-nmpa-approves-qinlock-ripretinib-for-treatment-of-advanced-gastrointestinal-stromal--zlab-20210331monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-financial-results-for-second-half-and-full-year-2020-company-to-host-con-zlab-20210301monthly0.5https://www.biopharmawatch.com/news/ZLAB/turning-point-and-zai-lab-broaden-collaboration-zai-lab-secures-exclusive-right-to-develop-zlab-20210111monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-and-zai-lab-announce-strategic-collaboration-for-efgartigimod-in-greater-china-coll-zlab-20210106monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-inclusion-of-zejula-niraparib-in-china-s-national-reimbursement-drug-lis-zlab-20201229monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-cullinan-oncology-announce-strategic-collaboration-and-license-agreement-for-c-zlab-20201228monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-alan-sandler-m-d-as-president-head-of-global-development-oncology-shangha-zlab-20201201monthly0.5https://www.biopharmawatch.com/news/ZLAB/hong-kong-exchanges-and-clearing-limited-the-stock-exchange-of-hong-kong-limited-and-hong--zlab-20201022monthly0.5https://www.biopharmawatch.com/news/ZLAB/hong-kong-exchanges-and-clearing-limited-the-stock-exchange-of-hong-kong-limited-the-hong--zlab-20201009monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-closing-of-hong-kong-secondary-listing-shanghai-and-zlab-20200928monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-pricing-of-hong-kong-secondary-listing-shanghai-and-zlab-20200922monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-launches-hong-kong-secondary-listing-shanghai-and-zlab-20200916monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-limited-index-to-consolidated-financial-statements-x200b-x200b-x200b-x200b-page-x2-zlab-20200911monthly0.5https://www.biopharmawatch.com/news/ZLAB/of-our-report-on-form-6-k-furnished-to-the-sec-on-zlab-20200911monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-nmpa-approval-of-zejula-niraparib-for-first-line-maintenance-treatment-o-zlab-20200910monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-f-ty-edmondson-as-chief-legal-officer-shanghai-and-zlab-20200817monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-financial-results-for-six-months-ended-zlab-20200813monthly0.5https://www.biopharmawatch.com/news/ZLAB/china-nmpa-accepts-nda-submission-of-ripretinib-for-advanced-gastrointestinal-stromal-tumo-zlab-20200720monthly0.5https://www.biopharmawatch.com/news/ZLAB/turning-point-therapeutics-and-zai-lab-announce-exclusive-license-agreement-for-repotrecti-zlab-20200707monthly0.5https://www.biopharmawatch.com/news/ZLAB/china-nmpa-approves-optune-for-the-treatment-of-newly-diagnosed-and-recurrent-glioblastoma-zlab-20200513monthly0.5https://www.biopharmawatch.com/news/ZLAB/regeneron-and-zai-lab-announce-regional-strategic-collaboration-for-regn1979-cd20xcd3-bisp-zlab-20200408monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-financial-results-for-full-year-ended-zlab-20200319monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-acceptance-of-snda-submission-of-zejula-niraparib-for-first-line-mainten-zlab-20200316monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-closing-of-public-offering-of-american-depositary-shares-and-full-exerci-zlab-20200127monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares-zlab-20200122monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-proposed-public-offering-of-american-depositary-shares-zlab-20200121monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-lonnie-moulder-to-board-of-directors-zlab-20200114monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-nmpa-approval-of-zejula-niraparib-in-china-as-maintenance-therapy-for-pa-zlab-20191227monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-financial-results-and-corporate-update-for-the-six-months-ended-zlab-20190903monthly0.5https://www.biopharmawatch.com/news/ZLAB/incyte-and-zai-lab-announce-collaboration-and-license-agreement-for-incmga0012-in-greater--zlab-20190702monthly0.5https://www.biopharmawatch.com/news/ZLAB/deciphera-pharmaceuticals-inc-and-zai-lab-limited-announce-an-exclusive-license-agreement--zlab-20190611monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-valeria-fantin-ph-d-as-chief-scientific-officer-appointment-of-industry-v-zlab-20190603monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares-zlab-20190502monthly0.5https://www.biopharmawatch.com/news/ZLAB/legal-opinion-to-zai-lab-limited-4560-jinke-road-bldg-1-4f-pudong-shanghai-people-s-republ-zlab-20190501monthly0.5https://www.biopharmawatch.com/news/ZLAB/shanghai-china-zlab-20190501monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-financial-results-and-corporate-update-for-full-year-2018-zai-lab-to-hos-zlab-20190307monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-acceptance-of-nda-submission-of-zejula-niraparib-in-mainland-china-by-th-zlab-20181212monthly0.5https://www.biopharmawatch.com/news/ZLAB/macrogenics-and-zai-lab-announce-exclusive-collaboration-and-license-agreement-to-develop--zlab-20181129monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-approval-of-zejula-niraparib-for-patients-with-relapsed-ovarian-cancer-i-zlab-20181022monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-industry-leader-tao-fu-as-president-chief-operating-officer-expands-us-pr-zlab-20180927monthly0.5https://www.biopharmawatch.com/news/ZLAB/novocure-and-zai-lab-announce-strategic-collaboration-with-a-license-agreement-for-tumor-t-zlab-20180912monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares-zlab-20180906monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-proposed-public-offering-of-american-depositary-shares-zlab-20180903monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-financial-results-and-corporate-progress-for-the-six-months-ended-zlab-20180830monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-appoints-professor-kai-xian-chen-ph-d-to-its-board-of-directors-zlab-20180814monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-expands-commercial-leadership-team-appoints-william-liang-as-chief-commercial-offi-zlab-20180605monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-reports-full-year-2017-financial-results-and-corporate-update-zai-lab-to-host-conf-zlab-20180502monthly0.5https://www.biopharmawatch.com/news/ZLAB/entasis-therapeutics-and-zai-lab-announce-exclusive-license-agreement-in-asia-pacific-and--zlab-20180425monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-limited-to-announce-full-year-2017-financial-results-zlab-20180424monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-limited-appoints-billy-cho-as-chief-financial-officer-zlab-20180305monthly0.5https://www.biopharmawatch.com/news/ZLAB/disclaimer-this-presentation-includes-forward-looking-statements-beliefs-or-opinions-inclu-zlab-20180108monthly0.5https://www.biopharmawatch.com/news/ZLAB/five-prime-therapeutics-and-zai-lab-announce-exclusive-license-agreement-for-fpa144-anti-f-zlab-20171219monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-third-quarter-2025-financial-results-transformation-i-eye-20251105monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-second-quarter-2025-financial-results-accelerated-ini-eye-20250806monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-first-quarter-2025-financial-results-successful-execu-eye-20250507monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-appoints-alex-wilkes-as-ceo-reade-fahs-to-assume-executive-chairman-positi-eye-20250429monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-appoints-jim-mcgrann-and-michael-nicholson-to-board-of-directors-enters-in-eye-20250317monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-announces-leadership-changes-cfo-to-depart-following-transition-period-ele-eye-20250116monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-third-quarter-2024-financial-results-results-reflect--eye-20241106monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-announces-repurchase-of-218-million-of-convertible-notes-and--eye-20240808monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-second-quarter-2024-financial-results-announces-new-a-eye-20240807monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-appoints-caitlin-zulla-to-board-of-directors-adds-healthcare-and-financial-eye-20240801monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-first-quarter-2024-financial-results-first-quarter-20-eye-20240508monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-appoints-susan-o-farrell-to-board-of-directors-brings-additional-financial-eye-20240208monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-announces-repurchase-of-100-million-of-convertible-notes-dulu-eye-20231110monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-third-quarter-2023-financial-results-net-revenue-of-5-eye-20231109monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-second-quarter-2023-financial-results-net-revenue-of--eye-20230810monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-first-quarter-2023-financial-results-net-revenue-of-5-eye-20230511monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-third-quarter-2022-financial-results-net-revenue-decr-eye-20221110monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-second-quarter-2022-financial-results-updates-fiscal--eye-20220811monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-first-quarter-2022-financial-results-updates-fiscal-2-eye-20220510monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-fourth-quarter-and-fiscal-2021-financial-results-expa-eye-20220228monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-increases-share-repurchase-authorization-to-100-million-dulut-eye-20211129monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-third-quarter-2021-financial-results-updates-fiscal-2-eye-20211110monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-second-quarter-2021-financial-results-raises-fiscal-2-eye-20210812monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-first-quarter-2021-financial-results-raises-fiscal-20-eye-20210513monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-fourth-quarter-and-fiscal-2020-financial-results-dulu-eye-20210303monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-appoints-jose-armario-to-board-of-directors-brings-additional-business-ope-eye-20210204monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-third-quarter-2020-financial-results-net-revenue-incr-eye-20201105monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-appoints-susan-somersille-johnson-to-board-of-directors-addition-brings-wo-eye-20201026monthly0.5https://www.biopharmawatch.com/news/EYE/naomi-kelman-appointed-to-national-vision-s-board-of-directors-duluth-ga-eye-20200914monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-second-quarter-2020-financial-results-net-revenue-dec-eye-20200806monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-extends-long-standing-partnership-with-walmart-inc-duluth-ga-eye-20200720monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-reports-first-quarter-2020-financial-results-net-revenue-incr-eye-20200507monthly0.5https://www.biopharmawatch.com/news/EYE/in-the-company-s-form-8-k-filing-today-for-supplemental-tables-providing-reconciliations-f-eye-20200226monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20191107monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20190806monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20190724monthly0.5https://www.biopharmawatch.com/news/EYE/kristina-gross-national-vision-inc-kristina-gross-nationalvision-com-470-448-2355-investor-eye-20190719monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20190509monthly0.5https://www.biopharmawatch.com/news/EYE/of-form-8-k-filed-on-eye-20190227monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20190227monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20181113monthly0.5https://www.biopharmawatch.com/news/EYE/kristina-gross-national-vision-holdings-inc-kristina-gross-nationalvision-com-470-448-2355-eye-20180910monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20180814monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20180515monthly0.5https://www.biopharmawatch.com/news/EYE/national-vision-holdings-inc-eye-20180308monthly0.5https://www.biopharmawatch.com/news/EYE/kristina-gross-national-vision-holdings-inc-kristina-gross-nationalvision-com-470-448-2355-eye-20180123monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-appoints-christoph-brackmann-as-chief-financial-officer-root-switzerland-novocure-nvcr-20241030monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-and-zai-lab-announce-ef-31-phase-2-pilot-study-evaluating-tumor-treating-fields-t-nvcr-20220603monthly0.5https://www.biopharmawatch.com/news/NVCR/prospects-for-regulatory-approval-manufacturing-development-and-capabilities-market-prospe-nvcr-20200813monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-announces-fourth-quarter-and-full-year-2019-preliminary-net-revenues-and-provides-nvcr-20200113monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-second-quarter-2019-financial-results-and-provides-company-update-quarter-nvcr-20190725monthly0.5https://www.biopharmawatch.com/news/NVCR/cms-establishes-2019-monthly-fee-schedule-amount-for-optune-st-helier-jersey-novocure-nasd-nvcr-20190719monthly0.5https://www.biopharmawatch.com/news/NVCR/medicare-releases-final-local-coverage-determination-providing-coverage-of-optune-for-newl-nvcr-20190718monthly0.5https://www.biopharmawatch.com/news/NVCR/fda-approves-the-novottf-100l-system-in-combination-with-chemotherapy-for-the-treatment-of-nvcr-20190524monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-first-quarter-2019-financial-results-and-provides-company-update-quarterl-nvcr-20190502monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-s-chief-science-officer-retires-after-17-years-of-service-st-helier-jersey-novocu-nvcr-20190321monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-company--nvcr-20190228monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-announces-fourth-quarter-and-full-year-2018-operating-statistics-preliminary-net--nvcr-20190107monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-third-quarter-2018-financial-results-and-provides-company-update-quarterl-nvcr-20181025monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-and-zai-lab-announce-strategic-collaboration-with-a-license-agreement-for-tumor-t-nvcr-20180912monthly0.5https://www.biopharmawatch.com/news/NVCR/acordova-novocure-com-212-767-7558-nvcr-20180906monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-second-quarter-2018-financial-results-and-provides-company-update-quarter-nvcr-20180726monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-appoints-pritesh-shah-as-chief-commercial-officer-with-extensive-experience-in-on-nvcr-20180706monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-announces-changes-to-its-board-of-directors-former-medivation-ceo-dr-david-t-hung-nvcr-20180606monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-first-quarter-2018-financial-results-and-provides-company-update-2-009-ac-nvcr-20180426monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-positive-top-line-results-from-stellar-phase-2-pilot-trial-in-mesotheliom-nvcr-20180417monthly0.5https://www.biopharmawatch.com/news/NVCR/consolidated-balance-sheets-usd-in-thousands-except-share-data-december-31-u-s-dollars-in--nvcr-20180222monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-announces-fourth-quarter-and-full-year-2017-operating-statistics-and-preliminary--nvcr-20171231monthly0.5https://www.biopharmawatch.com/news/NVCR/consolidated-balance-sheets-usd-in-thousands-except-share-data-september-30-nvcr-20171026monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-policy-on-recoupment-of-incentive-compensation-effective-as-of-july-26-20-nvcr-20170801monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-second-quarter-2017-financial-results-and-provides-company-update-1-460-a-nvcr-20170727monthly0.5https://www.biopharmawatch.com/news/NVCR/martin-j-madden-joins-novocure-board-of-directors-st-helier-jersey-novocure-today-announce-nvcr-20170512monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-early-termination-of-hsr-waiting-period-for-astria-acquisition-bcrx-20251203monthly0.5https://www.biopharmawatch.com/news/BCRX/voting-and-support-agreement-among-biocryst-pharmaceuticals-inc-and-certain-stockholders-o-bcrx-20251014monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-provides-update-on-strategy-pipeline-and-outlook-bcrx-20180711monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-announces-termination-of-merger-agreement-with-idera-pharmaceutic-bcrx-20180710monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2017-financial-results-updates-investors-reg-bcrx-20180227monthly0.5https://www.biopharmawatch.com/news/BCRX/execution-version-voting-and-support-agreement-this-voting-and-support-agreement-this-agre-bcrx-20180121monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-trvi-20260317monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-pricing-of-100-million-underwritten-offering-of-common-stock--trvi-20250603monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-upda-trvi-20250508monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-trvi-20250318monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-company-updates-ahead-of-14th-annual-lifesci-partners-corpora-trvi-20250108monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-pricing-of-50-million-underwritten-offering-new-haven-conn-trvi-20241216monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upda-trvi-20241106monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-appointment-of-james-v-cassella-ph-d-as-chief-development-off-trvi-20240930monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-upd-trvi-20240808monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-upda-trvi-20240507monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and-provides-trvi-20240320monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-third-quarter-2023-financial-results-and-provides-business-up-trvi-20231109monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-second-quarter-2023-financial-results-and-provides-business-u-trvi-20230810monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-first-quarter-2023-financial-results-and-provides-business-up-trvi-20230511monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-fourth-quarter-and-year-end-2022-financial-results-and-provid-trvi-20230316monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-third-quarter-2022-financial-results-and-provides-business-up-trvi-20221110monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-pricing-of-55-million-public-offering-new-haven-conn-trvi-20220923monthly0.5https://www.biopharmawatch.com/news/TRVI/corporate-presentation-september-2022-forward-looking-statement-disclaimer-statements-cont-trvi-20220919monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-second-quarter-2022-financial-results-and-business-update-rep-trvi-20220811monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-first-quarter-2022-financial-results-and-business-update-acce-trvi-20220512monthly0.5https://www.biopharmawatch.com/news/TRVI/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-trvi-20220406monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-fourth-quarter-and-year-end-2021-financial-results-and-busine-trvi-20220317monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-third-quarter-2021-financial-results-and-business-update-phas-trvi-20211110monthly0.5https://www.biopharmawatch.com/news/TRVI/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-trvi-20211015monthly0.5https://www.biopharmawatch.com/news/TRVI/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-trvi-20210930monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-second-quarter-2021-financial-results-and-business-update-pha-trvi-20210812monthly0.5https://www.biopharmawatch.com/news/TRVI/statements-contained-in-this-presentation-and-oral-statements-made-regarding-the-subject-o-trvi-20210709monthly0.5https://www.biopharmawatch.com/news/TRVI/first-a-mendment-to-loan-and-security-agreement-this-first-amendment-to-loan-and-security--trvi-20210707monthly0.5https://www.biopharmawatch.com/news/TRVI/purchase-agreement-this-purchase-agreement-the-agreement-dated-as-of-trvi-20210618monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-first-quarter-2021-financial-results-and-business-update-phas-trvi-20210513monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-third-quarter-2020-financial-results-and-business-update-pris-trvi-20201111monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-second-quarter-2020-financial-results-and-business-update-ann-trvi-20200813monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-election-of-dominick-c-colangelo-to-board-of-directors-season-trvi-20200630monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-first-quarter-2020-financial-results-and-corporate-update-sam-trvi-20200507monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-fourth-quarter-and-year-end-2019-financial-results-and-corpor-trvi-20200316monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-election-of-james-v-cassella-ph-d-to-board-of-directors-seaso-trvi-20200218monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-third-quarter-2019-financial-results-and-recent-business-deve-trvi-20191114monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-second-quarter-2019-financial-results-and-recent-business-dev-trvi-20190812monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-first-quarter-2019-financial-results-and-recent-business-deve-trvi-20190613monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2025-ala-axgn-20260112monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-fda-approval-of-biologics-license-application-for-avance-acellular-nerve--axgn-20251203monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-provides-update-on-fda-review-timeline-for-avance-nerve-graft-fda-pdufa-goal-da-axgn-20250825monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-second-quarter-2025-financial-results-raises-full-year-revenue-guidance-axgn-20250805monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-condensed-consolidated-statements-of-cash-flows-unaudited-three-months-ended-axgn-20250508monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-new-leadership-appointments-the-board-of-directors-appoints-michael-d-axgn-20240809monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-organizational-updates-preliminary-second-quarter-revenue-and-reaffir-axgn-20220718monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-william-burke-to-board-of-directors-burke-brings-25-years-of-global-fi-axgn-20220711monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-recon-sm-clinical-study-completes-subject-follow-up-recon-is-a-pivotal-study-suppor-axgn-20210901monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2020-alachua-axgn-20210111monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-third-quarter-2020-financial-results-alachua-fl-axgn-20201029monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-paul-g-thomas-to-board-of-directors-healthcare-veteran-brings-30-years-axgn-20200930monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-second-quarter-2020-financial-results-alachua-fl-axgn-20200805monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-recon-sm-clinical-study-completes-target-enrollment-of-220-subjects-recon-is-a-pivo-axgn-20200722monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-new-seven-year-financing-agreement-with-oberland-capital-and-provides-pre-axgn-20200701monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-planned-retirement-of-greg-freitag-and-appoints-brad-ottinger-as-gene-axgn-20200601monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-first-quarter-2020-financial-results-alachua-fl-x2013-axgn-20200506monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-preliminary-revenue-for-the-first-quarter-2020-provides-business-update-axgn-20200423monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-fourth-quarter-and-full-year-2019-financial-results-alachua-fl-x2013-axgn-20200224monthly0.5https://www.biopharmawatch.com/news/AXGN/this-press-release-contains-x201c-forward-looking-x201d-statements-as-defined-in-the-priva-axgn-20200113monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2019-third-quarter-financial-results-alachua-fl-x2013-axgn-20191106monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2019-second-quarter-financial-results-second-quarter-revenue-of-26-7-mi-axgn-20190806monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2019-first-quarter-financial-results-first-quarter-revenue-of-23-3-mill-axgn-20190508monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-new-members-to-board-of-directors-quentin-s-blackford-executive-vice-p-axgn-20190502monthly0.5https://www.biopharmawatch.com/news/AXGN/inflammation-in-the-surgical-bed-along-with-these-core-surgical-products-axogen-also-offer-axgn-20190422monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2018-fourth-quarter-and-full-year-2018-financial-results-fourth-quarter-axgn-20190226monthly0.5https://www.biopharmawatch.com/news/AXGN/sensory-grip-and-pinch-function-evaluating-effective-treatment-interventions-and-providing-axgn-20190122monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-recon-xae-study-update-study-supports-company-s-planned-biologic-license--axgn-20190115monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-pre-announces-financial-and-operational-results-q4-revenue-of-at-least-23-4-mil-axgn-20190107monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2018-third-quarter-financial-results-q3-revenue-of-22-7-million-represe-axgn-20181029monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-angelo-g-scopelianos-ph-d-as-vice-president-research-and-development-a-axgn-20180904monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2018-second-quarter-financial-results-q2-revenue-of-20-6-million-repres-axgn-20180801monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-lisa-n-colleran-to-board-of-directors-health-care-industry-veteran-bri-axgn-20180710monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-proposed-public-offering-of-common-stock-alachua-fl-axgn-20180507monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2018-first-quarter-financial-results-record-q1-revenue-of-17-3-million--axgn-20180430monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2017-fourth-quarter-and-full-year-financial-results-record-q4-revenue-o-axgn-20180228monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-preannounces-estimated-fourth-quarter-and-full-year-2017-revenue-q4-revenue-wil-axgn-20180108monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2017-third-quarter-financial-results-record-q3-revenue-of-16-0-million--axgn-20171101monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2017-second-quarter-financial-results-record-q2-revenue-of-15-2-million-axgn-20170802monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-jon-gingrich-chief-commercial-officer-alachua-fl-x2013-axgn-20170717monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2017-first-quarter-financial-results-record-q1-revenue-of-12-2-million--axgn-20170504monthly0.5https://www.biopharmawatch.com/news/AXGN/2016-fourth-quarter-and-full-year-financial-results-axgn-20170222monthly0.5https://www.biopharmawatch.com/news/AXGN/axgn-current-folio-ex99-1-20170109-exihibit-99-1-axogen-inc-preannounces-estimated-fourth--axgn-20170109monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-axgn-20161102monthly0.5https://www.biopharmawatch.com/news/AXGN/axgn-ex99-1-exibit-99-1-axogen-inc-announces-the-refinancing-of-its-debt-facility-new-agre-axgn-20161026monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-proposed-public-offering-of-common-stock-alachua-fl-axgn-20161006monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-amy-wendell-to-board-of-directors-former-covidien-senior-executive-bri-axgn-20160919monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-financial-results-for-second-quarter-2016-second-quarter-revenues-of-10-axgn-20160803monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-first-quarter-revenue-increases-64-over-prior-year-to-8-1-million-alachua-fl-x2-axgn-20160504monthly0.5https://www.biopharmawatch.com/news/AXGN/axgn-ex99-1-axogen-inc-reports-record-revenue-results-record-annual-revenue-of-27-3-3-mill-axgn-20160229monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-third-quarter-revenue-exceeds-8-million-revenue-increased-74-5-gross-profit-mar-axgn-20151105monthly0.5https://www.biopharmawatch.com/news/AXGN/essex-woodlands-fund-ix-acquires-significant-position-in-axogen-inc-investment-of-17-5-mil-axgn-20150826monthly0.5https://www.biopharmawatch.com/news/AXGN/strong-operatin-g-momentum-leads-to-axogen-inc-s-first-ever-6-million-quarter-revenue-incr-axgn-20150806monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-chief-marketing-officer-named-ceo-of-privately-held-life-sciences-company-plan--axgn-20150619monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-61-revenue-growth-for-the-2014-fourth-quarter-axgn-fourth-quarter-reven-axgn-20150305monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-prices-public-offering-of-common-stock-nerve-repair-company-prices-public-offer-axgn-20150205monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-preliminary-fourth-quarter-and-full-year-revenue-nerve-repair-company-axgn-20150204monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-58-third-quarter-revenue-growth-quarterly-record-revenue-of-4-67-millio-axgn-20141113monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-47-second-quarter-revenue-growth-quarterly-record-revenue-of-4-2-millio-axgn-20140804monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-46-first-quarter-revenue-growth-quarterly-revenues-exceeds-3-million-fo-axgn-20140430monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-46-fourth-quarter-and-42-full-year-2013-revenue-growth-company-reports--axgn-20140306monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20260612monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20260610monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20260528monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20260522monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-rockville-md-and-aapg-20260512monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-aapg-20260501monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20260401monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20260316monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20260311monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-outlined-its-global-innovation-strategy-during-presentation-at-44-th-annu-aapg-20260114monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-announces-ind-clearance-by-the-u-s-food-and-drug-administration-for-btk-d-aapg-20260106monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20251226monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-to-present-at-44-th-annual-j-p-morgan-healthcare-conference-rockville-md--aapg-20251217monthly0.5https://www.biopharmawatch.com/news/AAPG/ash-2025-updated-data-for-ascentage-pharma-s-olverembatinib-in-second-line-cml-cp-showing--aapg-20251208monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-presents-pivotal-china-registrational-study-data-for-lisaftoclax-in-oral--aapg-20251206monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-announces-global-registrational-phase-iii-study-of-olverembatinib-in-firs-aapg-20251204monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-to-host-webcast-highlighting-key-data-from-ash-2025-rockville-md-and-aapg-20251201monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20251128monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-announces-publication-of-olverembatinib-phase-ib-safety-efficacy-and-nove-aapg-20251124monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-in-december-2025-ro-aapg-20251119monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-in-october-2025-roc-aapg-20251007monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-in-september-2025-r-aapg-20250825monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250808monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250714monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250717monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-announces-pricing-of-top-up-placement-rockville-md-and-aapg-20250714monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250710monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250708monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250627monthly0.5https://www.biopharmawatch.com/news/AAPG/eha-2025-multiple-studies-report-encouraging-data-of-olverembatinib-in-ph-all-rockville-md-aapg-20250615monthly0.5https://www.biopharmawatch.com/news/AAPG/thirteen-studies-of-ascentage-pharma-s-assets-including-olverembatinib-and-lisaftoclax-sel-aapg-20250609monthly0.5https://www.biopharmawatch.com/news/AAPG/live-from-asco-2025-ascentage-pharma-releases-promising-clinical-data-on-alrizomadlin-mono-aapg-20250602monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-announces-clinical-data-of-lisaftoclax-which-shows-therapeutic-potential--aapg-20250522monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250520monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-presents-results-from-five-preclinical-studies-at-2025-american-associati-aapg-20250428monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-to-present-data-from-two-clinical-studies-at-2025-asco-annual-meeting-inc-aapg-20250423monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250421monthly0.5https://www.biopharmawatch.com/news/AAPG/pelcitoclax-apg-1252-apg-2449-apg-5918-lisaftoclax-apg-2575-alrizomadlin-apg-115-incorpora-aapg-20250417monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250408monthly0.5https://www.biopharmawatch.com/news/AAPG/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--aapg-20250331monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-reports-full-year-2024-unaudited-financial-results-and-business-updates-r-aapg-20250327monthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-to-present-five-preclinical-studies-from-innovative-pipeline-at-american--aapg-20250325monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-outlines-2026-strategic-priorities-x2022-topline-data-from-chapter-3-a-pivotal-s-phvs-20260112monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-positive-topline-data-from-rapide-3-pivotal-study-confirming-potential-phvs-20251203monthly0.5https://www.biopharmawatch.com/news/PHVS/execution-version-pharvaris-n-v-registration-rights-agreement-this-registration-rights-agr-phvs-20250902monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-second-quarter-2025-financial-results-and-provides-business-update-x2022-phvs-20250812monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-annual-meeting-of-shareholders-zug-switzerland-phvs-20250610monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-first-quarter-2025-financial-results-and-provides-business-update-x2022--phvs-20250513monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-busines-phvs-20250407monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-outlines-2025-strategic-priorities-x2022-initiated-chapter-3-the-pivotal-phase-3-phvs-20250113monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-third-quarter-2024-financial-results-and-highlights-recent-business-upda-phvs-20241113monthly0.5https://www.biopharmawatch.com/news/PHVS/amendment-2-to-the-license-agreement-entered-into-by-analyticon-discovery-gmbh-and-pharvar-phvs-20240920monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-data-at-the-bradykinin-symposium-2024-phvs-20240905monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-second-quarter-2024-financial-results-and-provides-business-update-x2022-phvs-20240814monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-annual-meeting-of-shareholders-zug-switzerland-phvs-20240611monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-highlights-properties-of-deucrictibant-in-data-presentations-at-recent-congresse-phvs-20240604monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-first-quarter-2024-financial-results-and-provides-business-update-x2022--phvs-20240508monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-busines-phvs-20240410monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-extraordinary-meeting-of-shareholders-zug-switzerland-phvs-20240216monthly0.5https://www.biopharmawatch.com/news/PHVS/execution-version-pharvaris-n-v-registration-rights-agreement-this-registration-rights-agr-phvs-20240205monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-fda-lifting-of-the-clinical-hold-of-deucrictibant-for-the-prophylactic-phvs-20240122monthly0.5https://www.biopharmawatch.com/news/PHVS/corporate-presentation-january-2024-pioneering-science-for-patient-choice-exhibit-99-2-phvs-20240108monthly0.5https://www.biopharmawatch.com/news/PHVS/disclaimer-this-presentation-contains-certain-x201c-forward-x2010-looking-statements-x201d-phvs-20231130monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-third-quarter-2023-financial-results-and-provides-business-update-x2022--phvs-20231102monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-second-quarter-2023-financial-results-and-provides-business-update-x2022-phvs-20230807monthly0.5https://www.biopharmawatch.com/news/PHVS/material-united-states-federal-income-tax-and-dutch-tax-considerations-the-information-pre-phvs-20230627monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-fda-removal-of-clinical-hold-of-deucrictibant-for-the-on-demand-treatm-phvs-20230626monthly0.5https://www.biopharmawatch.com/news/PHVS/subscription-agreement-pharvaris-n-v-emmy-noetherweg-2-2333-bk-leiden-the-netherlands-ladi-phvs-20230616monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-annual-meeting-of-shareholders-zug-switzerland-phvs-20230601monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-first-quarter-2023-financial-results-and-provides-business-update-x2022--phvs-20230508monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-busines-phvs-20230405monthly0.5https://www.biopharmawatch.com/news/PHVS/disclaimer-this-presentation-may-contain-certain-x201c-forward-x2010-looking-statements-x2-phvs-20230308monthly0.5https://www.biopharmawatch.com/news/PHVS/disclaimer-this-presentation-may-contain-certain-x201c-forward-x2010-looking-statements-x2-phvs-20230214monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-provides-regulatory-clinical-and-corporate-updates-phvs-20230109monthly0.5https://www.biopharmawatch.com/news/PHVS/rapide-1-phase-2-top-line-data-phvs-20221208monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-positive-top-line-phase-2-data-from-rapide-1-study-of-phvs416-for-the--phvs-20221208monthly0.5https://www.biopharmawatch.com/news/PHVS/pioneering-science-for-patient-choice-november-2022-ex-99-1-disclaimer-this-presentation-m-phvs-20221101monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-second-quarter-2022-financial-results-and-provides-business-update-forma-phvs-20220912monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-fda-clinical-hold-on-pha121-clinical-trials-in-the-u-s-zug-switzerland-phvs-20220822monthly0.5https://www.biopharmawatch.com/news/PHVS/pioneering-science-for-patient-choice-july-2022-2022-2022-disclaimer-this-presentation-may-phvs-20220713monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-annual-meeting-of-shareholders-zug-switzerland-phvs-20220614monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-appoints-joan-schmidt-j-d-as-chief-legal-officer-x2022-pharvaris-executive-team--phvs-20220511monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-first-quarter-2022-financial-results-and-provides-business-highlights-ta-phvs-20220511monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-busines-phvs-20220329monthly0.5https://www.biopharmawatch.com/news/PHVS/pioneering-science-for-patient-choice-january-2022-2022-2022-disclaimer-this-presentation--phvs-20211231monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-changes-to-its-board-of-directors-zug-switzerland-phvs-20211222monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-changes-to-its-board-of-directors-zug-switzerland-phvs-20211207monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-third-quarter-2021-financial-results-and-provides-business-highlights-ra-phvs-20211110monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-second-quarter-2021-financial-results-and-provides-business-highlights-r-phvs-20210730monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-t-phvs-20210701monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-annual-meeting-of-shareholders-zug-switzerland-phvs-20210611monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-first-quarter-2021-financial-results-and-provides-business-highlights-ra-phvs-20210526monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-appoints-wim-souverijns-ph-d-as-chief-community-engagement-commercial-officer-in-phvs-20210512monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-full-year-2020-financial-results-and-provides-business-highlights-rapide-phvs-20210503monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-full-year-2020-financial-results-and-provides-business-highlights-rapide-phvs-20210429monthly0.5https://www.biopharmawatch.com/news/NBTX/pdmr-notifications-exhibit991december1st-2025dd1072320-fr0011341205-dd190222-01-d-cembre-2-nbtx-20251201monthly0.5https://www.biopharmawatch.com/news/NBTX/k-1-exhibit9916kfiling-july2-htm-6-k-exhibit9916kfiling-july2-2025dd1045711-fr0011341205-d-nbtx-20250702monthly0.5https://www.biopharmawatch.com/news/NBTX/amf-declaration-exhibit991may272025-part-2025dd1039917-fr0011341205-dd187700-27-mai-2025-i-nbtx-20250527monthly0.5https://www.biopharmawatch.com/news/NBTX/amf-attestation-exhibit991may272025-2025dd1039719-fr0011341205-dd187665-26-mai-2025-inform-nbtx-20250527monthly0.5https://www.biopharmawatch.com/news/NBTX/amf-declaration-exhibit991may152025-2025dd1038006-fr0011341205-dd187429-15-mai-2025-inform-nbtx-20250515monthly0.5https://www.biopharmawatch.com/news/NBTX/amf-attestation-exhibit991april142025-2025dd1031953-fr0011341205-dd187019-14-avril-2025-in-nbtx-20250414monthly0.5https://www.biopharmawatch.com/news/NBTX/amf-attestation-exhibit991april102025-2025dd1031083-fr0011341205-dd186943-09-avril-2025-in-nbtx-20250410monthly0.5https://www.biopharmawatch.com/news/NBTX/pdmr-notifications-pursuant-to-mar-exhibit991december16-0-1-2-3-4-25-678-9-9-7-a-b88-9c8d--nbtx-20241216monthly0.5https://www.biopharmawatch.com/news/NBTX/pdmr-notifications-pursuant-to-mar-exhibit991pdmrnotificati-0-1-2-3-4-25-678-9-9-7-a-b88-9-nbtx-20241212monthly0.5https://www.biopharmawatch.com/news/NBTX/to-the-company-s-report-on-form-6-k-furnished-to-the-sec-on-nbtx-20230926monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-voting-rights-and-shares-capital-of-the-company-in-accordance-with-articles-l-2-nbtx-20221010monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-reports-financial-results-for-the-first-half-of-20-nbtx-20220928monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-half-year-2022-financial-results-on-nbtx-20220922monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-establishes-recommended-dose-for-planned-registrational-study-evaluating-nbtxr3-nbtx-20220921monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-agreement-in-principle-to-restructure-existing-loan-agreement-with-eu-nbtx-20220912monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-voting-rights-and-shares-capital-of-the-company-in-accordance-with-articles-l-2-nbtx-20220908monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-and-lianbio-announce-first-patient-enrolled-in-asia-in-phase-3-nanoray-312-tria-nbtx-20220907monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-co-founder-and-ceo-laurent-levy-named-to-2022-pharmavoice-100-list-of-most-insp-nbtx-20220906monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-during-the-h-c-wainwright-global-investment-conference-in-september--nbtx-20220831monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-voting-rights-and-shares-capital-of-the-company-in-accordance-with-articles-l-2-nbtx-20220809monthly0.5https://www.biopharmawatch.com/news/NBTX/half-year-report-on-the-nanobiotix-liquidity-contract-with-gilbert-dupont-paris-cambridge--nbtx-20220713monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-voting-rights-and-shares-capital-of-the-company-in-accordance-with-articles-l-2-nbtx-20220708monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20220609monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-new-data-featuring-nbtxr3-plus-chemoradiation-and-in-the-preoperative-setting-s-nbtx-20220605monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-nbtx-20220602monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-first-quarter-operational-and-financial-update-on-track-to-activate-fi-nbtx-20220519monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-during-the-jefferies-healthcare-conference-in-june-2022-paris-cambri-nbtx-20220517monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-participate-in-two-upcoming-investor-conferences-paris-cambridge-mass-busine-nbtx-20220511monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20220510monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-first-quarter-2022-financial-results-on-nbtx-20220504monthly0.5https://www.biopharmawatch.com/news/NBTX/new-data-featuring-nanobiotix-lead-product-candidate-nbtxr3-to-be-presented-at-the-2022-as-nbtx-20220502monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobotix-new-preclinical-immunotherapy-data-show-boosted-anti-tumor-immune-activation-via-nbtx-20220411monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-filing-of-the-2021-universal-registration-document-and-the-2021-annua-nbtx-20220408monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20220407monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-reports-full-year-2021-financial-results-new-data--nbtx-20220330monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-full-year-2021-financial-results-on-nbtx-20220316monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20220308monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20220210monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-publication-of-new-clinical-case-study-highlighting-first-patient-exp-nbtx-20220209monthly0.5https://www.biopharmawatch.com/news/NBTX/operating-and-financial-review-and-prospects-unless-otherwise-indicated-or-the-context-oth-nbtx-20220204monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-publication-of-new-preclinical-immunotherapy-data-showcasing-the-comb-nbtx-20220126monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20220111monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-corporate-update-and-highlights-key-2022-milestone-targets-evaluation--nbtx-20220110monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-patient-enrolled-in-nanoray-312-global-phase-iii-registrational-nbtx-20220105monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-participation-at-three-virtual-investor-conferences-in-january-2022-p-nbtx-20220104monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20211208monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-4th-annual-evercore-isi-healthconx-conference-paris-cambridge-nbtx-20211117monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-new-preclinical-data-highlighting-nbtxr3-immune-priming-and-checkpoin-nbtx-20211109monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20211108monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-participate-in-a-fireside-chat-at-the-jefferies-london-healthcare-conference-nbtx-20211103monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-18-1-month-median-overall-survival-for-41-evaluable-elderly-and-frail-nbtx-20211024monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-third-quarter-operational-and-financial-update-published-preclinical-d-nbtx-20210930monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-nbtx-20211008monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-first-survival-data-from-priority-head-and-neck-cancer-program-among-nbtx-20211006monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-red-journal-publication-of-preclinical-data-showing-radioenhancer-nbt-nbtx-20210928monthly0.5https://www.biopharmawatch.com/news/NBTX/statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital-as-of-augu-nbtx-20210909monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-reports-financial-results-for-the-first-half-of-20-nbtx-20210908monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-h-c-wainwright-23-rd-annual-global-investment-conference-pari-nbtx-20210907monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-second-quarter-operational-and-financial-update-presented-updated-resu-nbtx-20210630monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-host-virtual-kol-event-discussing-potential-first-in-class-radioenhancer-nbt-nbtx-20210607monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-reports-new-data-for-potential-first-in-class-radioenhancer-nbtxr3-in-combinati-nbtx-20210604monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-the-appointment-of-bart-van-rhijn-as-chief-financial-officer-and-memb-nbtx-20210601monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-participate-in-fireside-chat-at-the-jefferies-virtual-healthcare-conference--nbtx-20210526monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-the-appointment-of-dr-gary-phillips-as-chairman-of-the-nanobiotix-sup-nbtx-20210525monthly0.5https://www.biopharmawatch.com/news/NBTX/correction-to-release-dated-nbtx-20210519monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-updated-results-from-priority-pathways-in-head-and-neck-cancer-and-im-nbtx-20210519monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-ubs-global-healthcare-virtual-conference-paris-cambridge-mass-nbtx-20210512monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-partners-with-lianbio-to-develop-and-commercialize-potential-first-in-class-rad-nbtx-20210511monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-quarter-operational-and-financial-updates-expanded-clinical-dat-nbtx-20210430monthly0.5https://www.biopharmawatch.com/news/NBTX/annual-general-combined-meeting-of-the-shareholders-on-april-28th-2021-at-17-00-cet-attend-nbtx-20210428monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-four-posters-including-updates-from-priority-head-and-neck-cancer-an-nbtx-20210428monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-a-limited-liability-company-with-an-executive-board-and-a-supervisory-board-soc-nbtx-20210414monthly0.5https://www.biopharmawatch.com/news/NBTX/time-sensitive-materials-depositary-s-notice-of-combined-general-meeting-of-nanobiotix-s-a-nbtx-20210326monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-filing-of-2020-universal-registration-document-and-2020-annual-report-nbtx-20210407monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-reports-full-year-2020-financial-results-and-highlights-operational-progress-su-nbtx-20210317monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-and-pharmaengine-mutually-agree-to-conclude-collaboration-paris-cambridge-mass--nbtx-20210304monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-h-c-wainwright-global-life-sciences-conference-paris-cambridg-nbtx-20210303monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-preclinical-data-presented-at-first-aacr-virtual-special-conference-on-radiatio-nbtx-20210302monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-2020-q4-and-annual-revenues-strong-cash-position-of-119-2m-as-of-nbtx-20210226monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-patient-injected-with-nbtxr3-in-esophageal-cancer-first-patient-nbtx-20210128monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-subsidiary-curadigm-secures-new-collaboration-agreement-with-sanofi-focused-on--nbtx-20210125monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-positive-first-results-for-novel-nbtxr3-in-rectal-cancer-study-at-asc-nbtx-20210115monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-key-development-milestones-for-2021-after-successful-nasdaq-initial-p-nbtx-20210108monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-first-quarter-2026-financial-results-and-recent-highlights-advanc-tyra-20260513monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-hi-tyra-20260302monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-third-quarter-2025-financial-results-and-highlights-dosed-first-p-tyra-20251105monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-second-quarter-2025-financial-results-and-highlights-dosed-first--tyra-20250814monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-first-quarter-2025-financial-results-and-highlights-beach301-stud-tyra-20250508monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlight-tyra-20250327monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights-reported-posi-tyra-20241107monthly0.5https://www.biopharmawatch.com/news/TYRA/today-s-participants-and-agenda-agenda-introduction-todd-interim-surf301-tyra-300-results--tyra-20241025monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-second-quarter-2024-financial-results-and-highlights-surf301-ph1--tyra-20240807monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-first-quarter-2024-financial-results-and-highlights-tyra-300-on-t-tyra-20240509monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlight-tyra-20240319monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-inc-announces-200-million-private-placement-financing-tyra-20240202monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-third-quarter-2023-financial-results-and-highlights-enrollment-an-tyra-20231107monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-first-quarter-2023-financial-results-and-highlights-surf301-phase-tyra-20230504monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-highlight-tyra-20230322monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-third-quarter-2022-financial-results-and-highlights-pipeline-on-t-tyra-20221103monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-second-quarter-2022-financial-results-and-highlights-ind-clearanc-tyra-20220804monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-first-quarter-2022-financial-results-and-highlights-pipeline-on-t-tyra-20220505monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-highlight-tyra-20220303monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-reports-third-quarter-2021-financial-results-and-highlights-successful-co-tyra-20211103monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20260430monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20260302monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20260219monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20251124monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20251030monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20250902monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20250731monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20250501monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20250220monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20241203monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20241118monthly0.5https://www.biopharmawatch.com/news/SEM/cautionary-note-regarding-forward-looking-statements-this-offering-memorandum-contains-for-sem-20241118monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20241106monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20241031monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20240801monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20240630monthly0.5https://www.biopharmawatch.com/news/SEM/select-medical-holdings-corporation-and-concentra-sem-20240627monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20240502monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20240222monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20231102monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20230907monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20230803monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20230630monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20230504monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20230223monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20221103monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20220804monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20220505monthly0.5https://www.biopharmawatch.com/news/SEM/sele-ct-med-ical-hold-ing-s-c-orp-o-r-a-tion-sele-ct-med-ical-ho-l-d-ing-s-c-orp-ora-tion--sem-20220304monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20220224monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20211231monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20211104monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20211102monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20210805monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20210506monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20210416monthly0.5https://www.biopharmawatch.com/news/SEM/s-e-l-e-c-tm-e-d-i-c-a-lh-o-l-d-i-n-g-sc-o-r-p-o-r-a-t-i-o-n-a-year-of-resilience-220-a-n--sem-20210305monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20210225monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20201029monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20200730monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20200430monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20200420monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20200403monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20200331monthly0.5https://www.biopharmawatch.com/news/SEM/s-e-l-e-c-tm-e-d-i-c-a-lh-o-l-d-i-n-g-sc-o-r-p-o-r-a-t-i-o-n-a-focus-on-quality-a-n-n-u-a--sem-20200304monthly0.5https://www.biopharmawatch.com/news/SEM/j-p-morgan-global-high-yield-leveraged-finance-conference-february-24-26-2020-2-forward-lo-sem-20200224monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20200220monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20200127monthly0.5https://www.biopharmawatch.com/news/SEM/select-medical-corporation-closes-private-sem-20191211monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-corporation-ann-sem-20191205monthly0.5https://www.biopharmawatch.com/news/SEM/forward-looking-statements-this-offering-memorandum-contains-forward-looking-statements-wi-sem-20191205monthly0.5https://www.biopharmawatch.com/news/SEM/the-field-allows-up-to-17-characters-sem-20191203monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20191031monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20190801monthly0.5https://www.biopharmawatch.com/news/SEM/news-r-e-l-e-a-s-e-for-immediate-release-4714-gettysburg-road-mechanicsburg-pa-17055-nyse--sem-20190801monthly0.5https://www.biopharmawatch.com/news/SEM/news-r-e-l-e-a-s-e-for-immediate-release-4714-gettysburg-road-mechanicsburg-pa-17055-nyse--sem-20190729monthly0.5https://www.biopharmawatch.com/news/SEM/forward-looking-statements-this-offering-memorandum-contains-forward-looking-statements-wi-sem-20190729monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20190722monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20190502monthly0.5https://www.biopharmawatch.com/news/SEM/s-e-l-e-c-tm-e-d-i-c-a-lh-o-l-d-i-n-g-sc-o-r-p-o-r-a-t-i-o-n-partners-in-post-acute-care-a-sem-20190306monthly0.5https://www.biopharmawatch.com/news/SEM/j-p-morgan-global-high-yield-leveraged-finance-conference-sem-20190225monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20190221monthly0.5https://www.biopharmawatch.com/news/SEM/th-annual-j-p-morgan-healthcare-conference-sem-20190107monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20190104monthly0.5https://www.biopharmawatch.com/news/SEM/amendment-2-to-select-medical-holdings-corporation-2016-equity-incentive-plan-pursuant-to--sem-20190104monthly0.5https://www.biopharmawatch.com/news/SEM/amendment-i-to-select-medical-holdings-corporation-2016-equity-incentive-plan-pursuant-to--sem-20181211monthly0.5https://www.biopharmawatch.com/news/SEM/bank-of-america-merrill-lynch-leveraged-finance-conference-december-4-5-2018-forward-looki-sem-20181204monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20181101monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20180930monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20180802monthly0.5https://www.biopharmawatch.com/news/SEM/deutsche-bank-43rd-annual-health-care-conference-may-8-2018-forward-looking-statements-thi-sem-20180503monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20180503monthly0.5https://www.biopharmawatch.com/news/SEM/regular-basis-thank-you-for-making-how-well-i-ve-come-back-and-all-the-tough-love-along-th-sem-20180308monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20180221monthly0.5https://www.biopharmawatch.com/news/SEM/select-medical-and-dignity-health-announce-completion-of-transaction-to-combine-concentra--sem-20180201monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20180108monthly0.5https://www.biopharmawatch.com/news/SEM/bank-of-america-merrill-lynch-leveraged-finance-conference-november-28-30-2017-forward-loo-sem-20171129monthly0.5https://www.biopharmawatch.com/news/SEM/concentra-november-2017-0-this-presentation-may-contain-forward-looking-statements-based-o-sem-20171122monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20171102monthly0.5https://www.biopharmawatch.com/news/SEM/select-medical-and-dignity-health-announce-signing-of-a-definitive-agreement-to-combine-co-sem-20171023monthly0.5https://www.biopharmawatch.com/news/SEM/deutsche-bank-leveraged-finance-conference-october-3-2017-forward-looking-statements-this--sem-20171003monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20170803monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20170504monthly0.5https://www.biopharmawatch.com/news/SEM/s-e-l-e-c-tm-e-d-i-c-a-lh-o-l-d-i-n-g-sc-o-r-p-o-r-a-t-i-o-n-20-years-of-growth-a-n-n-u-a--sem-20170308monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20170223monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20170221monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20170127monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20170106monthly0.5https://www.biopharmawatch.com/news/SEM/bank-of-america-merrill-lynch-2016-leveraged-finance-conference-sem-20161129monthly0.5https://www.biopharmawatch.com/news/SEM/news-r-e-l-e-a-s-e-for-immediate-release-4714-gettysburg-road-mechanicsburg-pa-17055-nyse--sem-20161103monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20160804monthly0.5https://www.biopharmawatch.com/news/SEM/bank-of-america-merrill-lynch-healthcare-conference-may-10-12-2016-forward-looking-stateme-sem-20160505monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20160505monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20160331monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20160304monthly0.5https://www.biopharmawatch.com/news/SEM/s-e-l-e-c-tm-e-d-i-c-a-lh-o-l-d-i-n-g-sc-o-r-p-o-r-a-t-i-o-n-a-year-of-growth-a-n-n-u-a-lr-sem-20160302monthly0.5https://www.biopharmawatch.com/news/SEM/j-p-morgan-global-high-yield-leveraged-finance-conference-february-29-2016-forward-looking-sem-20160229monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20160225monthly0.5https://www.biopharmawatch.com/news/SEM/news-r-e-l-e-a-s-e-for-immediate-release-4714-gettysburg-road-mechanicsburg-pa-17055-nyse--sem-20160218monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20160125monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20160111monthly0.5https://www.biopharmawatch.com/news/SEM/lender-presentation-december-2015-transaction-overview-select-medical-corporation-select-o-sem-20151202monthly0.5https://www.biopharmawatch.com/news/SEM/bank-of-america-merrill-lynch-2015-leveraged-finance-conference-sem-20151203monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20151030monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20150807monthly0.5https://www.biopharmawatch.com/news/SEM/investor-presentation-july-2015-improving-quality-of-life-forward-looking-statements-this--sem-20150724monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-government-declines-to-interve-sem-20150619monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20150601monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-corporation-s-p-sem-20150520monthly0.5https://www.biopharmawatch.com/news/SEM/investor-presentation-may-2015-forward-looking-statements-this-presentation-may-contain-fo-sem-20150520monthly0.5https://www.biopharmawatch.com/news/SEM/bank-of-america-merrill-lynch-2015-health-care-conference-forward-looking-statements-this--sem-20150512monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20150430monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-corporation-ann-sem-20150323monthly0.5https://www.biopharmawatch.com/news/SEM/select-medical-holdings-corporation-investing-for-growth-2014-annual-report-select-medical-sem-20150304monthly0.5https://www.biopharmawatch.com/news/SEM/j-p-morgan-global-high-yield-leveraged-finance-conference-forward-looking-statements-this--sem-20150223monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20150220monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20150109monthly0.5https://www.biopharmawatch.com/news/SEM/bank-of-america-merrill-lynch-2014-leveraged-finance-conference-sem-20141202monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20141031monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20140808monthly0.5https://www.biopharmawatch.com/news/SEM/bank-of-america-merrill-lynch-2014-health-care-conference-sem-20140514monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-holdings-corpor-sem-20140502monthly0.5https://www.biopharmawatch.com/news/SEM/4714-gettysburg-road-mechanicsburg-pa-17055-nyse-symbol-sem-select-medical-corporation-clo-sem-20140311monthly0.5https://www.biopharmawatch.com/news/AHG/akso-health-group-room-8201-4-4-a-2nd-floor-qiantongyuan-building-no-44-moscow-road-qianwa-ahg-20260320monthly0.5https://www.biopharmawatch.com/news/AHG/akso-health-group-and-subsidiaries-unaudited-condensed-consolidated-balance-sheets-express-ahg-20260210monthly0.5https://www.biopharmawatch.com/news/AHG/akso-health-group-and-subsidiaries-unaudited-condensed-consolidated-balance-sheets-express-ahg-20250328monthly0.5https://www.biopharmawatch.com/news/AHG/securities-purchase-agreement-this-securities-purchase-agreement-the-agreement-is-dated-as-ahg-20241108monthly0.5https://www.biopharmawatch.com/news/AHG/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-april-30-2024-dear-sharehol-ahg-20240326monthly0.5https://www.biopharmawatch.com/news/AHG/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-dated-as-o-ahg-20240308monthly0.5https://www.biopharmawatch.com/news/AHG/securities-purchase-agreement-this-securities-purchase-agreement-the-agreement-is-dated-as-ahg-20240122monthly0.5https://www.biopharmawatch.com/news/AHG/akso-health-group-and-subsidiaries-unaudited-condensed-consolidated-balance-sheets-express-ahg-20240103monthly0.5https://www.biopharmawatch.com/news/AHG/securities-purchase-agreement-this-securities-purchase-agreement-the-agreement-is-dated-as-ahg-20231117monthly0.5https://www.biopharmawatch.com/news/AHG/securities-purchase-agreement-this-securities-purchase-agreement-the-agreement-is-dated-as-ahg-20231002monthly0.5https://www.biopharmawatch.com/news/AHG/share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-made-and-entered--ahg-20230510monthly0.5https://www.biopharmawatch.com/news/AHG/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-june-19-2023-dear-sharehold-ahg-20230518monthly0.5https://www.biopharmawatch.com/news/AHG/x200b-akso-health-group-and-subsidiaries-unaudited-condensed-consolidated-balance-sheets-e-ahg-20230216monthly0.5https://www.biopharmawatch.com/news/AHG/akso-health-group-room-515-floor-5-jia-no-92-4-to-24-jianguo-road-chaoyang-district-beijin-ahg-20221012monthly0.5https://www.biopharmawatch.com/news/AHG/akso-health-group-room-515-floor-5-jia-no-92-4-to-24-jianguo-road-chaoyang-district-beijin-ahg-20220607monthly0.5https://www.biopharmawatch.com/news/AHG/akso-health-group-room-515-floor-5-jia-no-92-4-to-24-jianguo-road-chaoyang-district-beijin-ahg-20220411monthly0.5https://www.biopharmawatch.com/news/AHG/akso-health-group-reports-u-naudited-financial-results-for-first-half-of-fiscal-year-2022--ahg-20211215monthly0.5https://www.biopharmawatch.com/news/AHG/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-december-3-2021-dear-shareh-ahg-20211103monthly0.5https://www.biopharmawatch.com/news/AHG/amendment-to-securities-purchase-agreement-this-amendment-to-securities-purchase-agreement-ahg-20210913monthly0.5https://www.biopharmawatch.com/news/AHG/employment-agreement-this-employment-agreement-the-agreement-or-amendment-is-entered-into--ahg-20210901monthly0.5https://www.biopharmawatch.com/news/AHG/securities-purchase-agreement-this-securities-purchase-agreement-the-agreement-is-dated-as-ahg-20210728monthly0.5https://www.biopharmawatch.com/news/AHG/xiaobai-maimai-inc-room-515-floor-5-jia-no-92-4-to-24-jianguo-road-chaoyang-district-beiji-ahg-20210714monthly0.5https://www.biopharmawatch.com/news/AHG/xiaobai-maimai-announces-the-closing-of-p2p-disposition-agreement-beijing-china-ahg-20201230monthly0.5https://www.biopharmawatch.com/news/AHG/x-iaobai-maimai-reports-u-n-audited-financial-results-for-first-half-of-fiscal-year-2021-b-ahg-20201221monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-the-disposition-of-p2p-business-to-focus-on-developing-social-e-commerc-ahg-20201216monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-hold-annual-general-meeting-on-ahg-20201106monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-launches-elite-influencers-program-on-xiaobai-maimai-beijing-china-ahg-20200925monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-regains-compliance-with-nasdaq-minimum-bid-price-requirement-beijing-china-ahg-20200904monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-upgrades-social-e-commerce-platform-xiaobai-maimai-beijing-china-ahg-20200813monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-ads-ratio-change-beijing-china-ahg-20200810monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-u-n-audited-financial-results-for-second-quarter-and-first-half-of-fiscal-ahg-20200612monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-launches-social-e-commerce-platform-xiaobai-maimai-beijing-china-ahg-20200528monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-delay-earnings-release-for-first-half-of-fiscal-year-2020-beijing-ahg-20200401monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-changes-to-board-of-directors-beijing-ahg-20200117monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-appoints-new-independent-registered-public-accounting-firm-beijing-china-ahg-20191230monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-receives-nasdaq-notification-regarding-minimum-bid-price-compliance-beijing-ahg-20191219monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-works-on-applying-for-micro-lending-license-to-further-diversify-business-beijing-ahg-20191210monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-s-connection-to-real-time-monitoring-system-aids-timely-compliance-beijing-ahg-20191112monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-hold-annual-general-meeting-on-ahg-20191028monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-u-n-audited-f-irst-quarter-of-fiscal-year-20-20-financial-results-beijing-ahg-20190918monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-report-unaudited-first-quarter-fiscal-year-2020-financial-results-on-ahg-20190911monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-regulators-decision-to-include-p2p-platforms-in-central-bank-s-credit-system-a-po-ahg-20190910monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-management-changes-beijing-ahg-20190830monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-backed-musketeer-completes-registration-for-its-p2p-platform-in-indonesia-beijing-ahg-20190814monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-launch-consumer-installment-financing-platform-beijing-ahg-20190701monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-u-n-audited-f-ou-rth-quarter-and-fiscal-year-2019-financial-results-beiji-ahg-20190618monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-completes-key-step-in-compliance-process-beijing-ahg-20190613monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-report-fourth-quarter-and-fiscal-year-2019-financial-results-on-ahg-20190604monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-s-founder-and-chairman-xiaobo-an-assumes-ceo-role-beijing-ahg-20190520monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-issues-us-20-million-senior-unsecured-note-to-majik-fund-ahg-20190329monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-u-n-audited-third-quarter-of-fiscal-year-2019-financial-results-beijing-c-ahg-20190228monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-report-third-quarter-fiscal-year-2019-financial-results-on-ahg-20190214monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-begins-sharing-credit-data-with-baihang-credit-beijing-ahg-20190123monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-provides-detailed-rebuttal-to-baseless-allegations-made-by-short-seller-beijing-j-ahg-20190118monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-signs-investor-insurance-coverage-agreement-with-shanxi-zhengxuan-finance-guarant-ahg-20190118monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-diversifies-funding-sources-by-partnering-with-bohai-international-trust-beijing-ahg-20190111monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-provides-details-on-strategic-investment-in-a-subsidiary-of-phoenix-finance-beiji-ahg-20190108monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-result-of-annual-general-meeting-of-shareholders-beijing-ahg-20181228monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-partners-with-kunming-aotou-to-diversify-funding-sources-beijing-ahg-20181226monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-strategic-investment-to-expand-its-funding-sources-beijing-ahg-20181210monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-us-25-million-share-repurchase-program-beijing-ahg-20181210monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-u-n-audited-second-quarter-of-fiscal-year-2019-financial-results-beijing-ahg-20181203monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-hold-annual-general-meeting-on-ahg-20181126monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-report-second-quarter-fiscal-year-2019-financial-results-on-ahg-20181119monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-changes-in-its-independent-registered-public-accounting-firm-beijing-ahg-20181116monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-custodian-bank-jiangxi-bank-passes-compliance-evaluation-beijing-ahg-20181112monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-help-support-emissions-reduction-beijing-ahg-20181016monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-completes-submission-of-p2p-compliance-self-inspection-report-beijing-ahg-20181015monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-u-n-audited-f-irst-quarter-of-fiscal-year-2019-financial-results-beijing-ahg-20180925monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-report-first-quarter-fiscal-year-2019-financial-results-on-ahg-20180828monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-acquires-equity-stake-in-indonesian-online-lending-platform-musketeer-beijing-ahg-20180814monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-further-strengthens-risk-control-system-to-better-protect-investors-beijing-ahg-20180810monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-files-annual-report-on-form-20-f-for-fiscal-year-2018-beijing-ahg-20180730monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-declares-cash-dividend-beijing-china-ahg-20180723monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-joins-nandu-finance-digital-union-to-aid-transformation-of-china-financial-servic-ahg-20180620monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-u-n-audited-f-ou-rth-quarter-and-fiscal-year-2018-financial-results-beiji-ahg-20180615monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-to-report-fourth-quarter-and-fiscal-year-2018-financial-results-on-ahg-20180604monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-announces-appointment-of-chief-marketing-officer-beijing-ahg-20180530monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-attends-lendit-fintech-usa-2018-beijing-ahg-20180412monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-opens-sales-call-center-in-hefei-beijing-china-ahg-20180313monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-third-quarter-of-fiscal-year-2018-financial-results-beijing-china-ahg-20180213monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-signs-aggregate-rmb1-billion-in-line-of-credit-agreements-with-ping-an-and-xiamen-ahg-20180131monthly0.5https://www.biopharmawatch.com/news/AHG/hexindai-reports-second-quarter-of-fiscal-year-2018-financial-results-beijing-china-ahg-20171205monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-announces-positive-phase-1-data-for-nbd1-stabilizers-sion-719-and-sion-sion-20250604monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-phase-1-ma-sion-20250320monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-third-quarter-fiscal-year-2026-financial-results-x2022-fiscal-third-quarter-neog-20260409monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-2026-results-x2022-revenue-of-224-7-million-a-decrease-of--neog-20260108monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-appointment-of-bryan-riggsbee-as-chief-financial-officer-neog-20251030monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-first-quarter-2026-results-x2022-revenue-of-209-2-million-x2022-net-incom-neog-20251009monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-board-transition-with-appointment-of-avi-pelossof-and-the-retirement-of-w-neog-20250814monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-fourth-quarter-2025-results-x2022-revenue-of-225-5-million-x2022-net-loss-neog-20250729monthly0.5https://www.biopharmawatch.com/news/NEOG/william-blair-growth-stock-conference-neog-20250604monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-board-transition-with-appointment-of-andrea-wainer-and-retirement-of-jame-neog-20250513monthly0.5https://www.biopharmawatch.com/news/NEOG/petrifilm-at-neogen-neog-20250422monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-ceo-transition-board-has-formed-search-committee-and-engaged-leading-exec-neog-20250409monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-2025-results-x2022-revenue-of-221-0-million-x2022-net-loss--neog-20250409monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-refinancing-of-term-loan-and-revolving-credit-facility-lansing-mich-neog-20250407monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-preliminary-1-second-quarter-2025-results-x2022-revenue-of-231-3-million--neog-20250110monthly0.5https://www.biopharmawatch.com/news/NEOG/piper-sandler-healthcare-conference-neog-20241204monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-first-quarter-2025-results-x2022-revenue-of-217-0-million-x2022-net-loss--neog-20241010monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-the-appointment-of-new-board-member-neog-20241001monthly0.5https://www.biopharmawatch.com/news/NEOG/wells-fargo-healthcare-conference-neog-20240905monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-fourth-quarter-2024-results-x2022-revenue-of-236-8-million-x2022-net-loss-neog-20240730monthly0.5https://www.biopharmawatch.com/news/NEOG/william-blair-growth-stock-conference-neog-20240604monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-2024-results-x2022-revenue-of-228-8-million-x2022-net-loss--neog-20240409monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-2024-results-x2022-revenue-of-229-6-million-x2022-net-loss-neog-20240109monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-first-quarter-2024-results-x2022-revenue-of-229-0-million-an-increase-of--neog-20231010monthly0.5https://www.biopharmawatch.com/news/NEOG/wells-fargo-healthcare-conference-neog-20230907monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-fourth-quarter-2023-results-x2022-revenue-of-241-8-million-an-increase-of-neog-20230727monthly0.5https://www.biopharmawatch.com/news/NEOG/william-blair-growth-stock-conference-neog-20230606monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-2023-results-x2022-revenue-of-218-3-million-an-increase-of--neog-20230330monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-2023-results-revenue-of-230-0-million-up-76-2-over-the-pri-neog-20230105monthly0.5https://www.biopharmawatch.com/news/NEOG/disclaimer-forward-looking-statements-this-presentation-includes-forward-looking-statement-neog-20221130monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-chief-financial-officer-517-372-9200-squinlan-neogen-com-neogen-announces-fi-neog-20220927monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-completes-3m-food-safety-business-merger-combination-creates-an-innovative-leader-i-neog-20220901monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-shareholders-approve-all-proposals-required-for-combination-with-3m-s-food-safety-b-neog-20220817monthly0.5https://www.biopharmawatch.com/news/NEOG/to-the-current-report-on-form-8-k-to-which-this-document-is-attached-as-an-exhibit-the-sum-neog-20220812monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-chief-financial-officer-517-372-9200-squinlan-neogen-com-neogen-announces-re-neog-20220726monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-pricing-of-350-0-million-senior-notes-offering-and-entry-into-800-0-milli-neog-20220707monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-chief-financial-officer-517-372-9200-squinlan-neogen-com-neogen-announces-th-neog-20220324monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-chief-financial-officer-517-372-9200-squinlan-neogen-com-neogen-announces-se-neog-20211221monthly0.5https://www.biopharmawatch.com/news/NEOG/joint-announcement-press-release-neogen-to-combine-3m-s-food-safety-business-with-its-exis-neog-20211214monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-chief-financial-officer-517-372-9200-squinlan-neogen-com-neogen-announces-re-neog-20210921monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-and-chief-financial-officer-517-372-9200-squinlan-neogen-com--neog-20210720monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-announces-2-for-1-stock-split-neog-20210512monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-third-quar-neog-20210323monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-chief-financial-officer-neogen-corporation-517-372-9200-papesh-retires-from--neog-20210302monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-cfo-neogen-corporation-517-372-9200-neogen-reports-second-quarter-results-neog-20201222monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-first-quarter-results-neog-20200922monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-fiscal-202-neog-20200721monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-herbert-resigns-as-neogen-neog-20200410monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-third-quar-neog-20200324monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-second-qua-neog-20191223monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-fiscal-201-neog-20190723monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-third-quar-neog-20190326monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-neogen-vice-president-cfo-517-372-9200-neogen-names-lilly-vp-of-internati-neog-20190109monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-second-qua-neog-20181220monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-first-quarter-results-neog-20180925monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-fiscal-201-neog-20180717monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-neogen-vice-president-cfo-517-372-9200-hagedorn-named-neogen-vp-of-food-s-neog-20180406monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-third-quar-neog-20180322monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-record-rev-neog-20180103monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-517-372-9200-neogen-announces-4-for-3-stock-split-neog-20171208monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-announces-bradley-retirement-neog-20171206monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-neogen-vice-president-and-cfo-517-372-9200-neogen-announces-management-ch-neog-20170922monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-21-net-income-increase-neog-20170919monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-record-revenues-and-ea-neog-20170718monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-24-increase-in-net-inc-neog-20170321monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-neogen-vice-president-cfo-517-372-9200-neogen-announces-senestech-agreeme-neog-20170124monthly0.5https://www.biopharmawatch.com/news/NEOG/steve-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-reports-23-increas-neog-20161221monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-neogen-vice-president-cfo-517-372-9200-fischer-resigns-as-neogen-director-neog-20161214monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-12-revenue-increase-neog-20160927monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-record-revenues-and-ea-neog-20160719monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-neogen-vice-president-cfo-517-372-9200-crowder-resigns-as-neogen-director-neog-20160418monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-12-increase-in-net-inc-neog-20160323monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-16-increase-in-net-inc-neog-20151221monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-11-revenue-increase-neog-20150921monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-record-revenues-and-ea-neog-20150721monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-ceo-adopts-10b5-1-trading-plan-neog-20150327monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-13-increase-in-net-inc-neog-20150326monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-26-increase-in-net-inc-neog-20141218monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-names-neog-20141204monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-517-372-9200-neogen-reports-13-net-income-increase-neog-20140922monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-517-372-9200-neogen-comments-on-senestech-neog-20140724monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-517-372-9200-neogen-reports-19-increase-in-annual-reve-neog-20140722monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-coo-resigns-neog-20140718monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-third-quarter-results-neog-20140325monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-and-cfo-517-372-9200-neogen-reports-second-quarter-results-neog-20131219monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-neogen-vp-cfo-517-372-9200-neogen-announces-3-for-2-stock-split-neog-20131003monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-517-372-9200-neogen-reports-18-revenue-increase-neog-20130924monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-517-372-9200-neogen-reports-21-increase-in-annual-net--neog-20130723monthly0.5https://www.biopharmawatch.com/news/NEOG/steven-j-quinlan-vice-president-cfo-neogen-corporation-517-372-9200-neogen-announces-bohan-neog-20130610monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-full-year-2022-business-results-02-21-2023-total-revenue-of-485-million--abcl-20230221monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-q3-2022-business-results-11-08-2022-total-revenue-of-101-million-compare-abcl-20221108monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-q2-2022-business-update-august-9-2022-copyright-abcellera-disclaimer-q2-2022-bus-abcl-20220809monthly0.5https://www.biopharmawatch.com/news/ABCL/lilly-to-supply-an-additional-150-000-doses-of-abcellera-discovered-antibody-bebtelovimab--abcl-20220629monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-q1-2022-business-results-05-10-2022-total-revenue-of-317-million-compare-abcl-20220510monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-full-year-2021-business-results-02-24-2022-total-revenue-of-375-million--abcl-20220224monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-discovered-antibody-bebtelovimab-receives-u-s-fda-emergency-use-authorization-fo-abcl-20220211monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-announces-changes-to-its-board-of-directors-12-7-2021-vancouver-british-columbia-abcl-20211207monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-announces-the-appointment-of-neil-aubuchon-as-chief-commercial-officer-12-02-202-abcl-20211202monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-q3-2021-business-results-11-09-2021-total-revenue-of-6-million-compared--abcl-20211109monthly0.5https://www.biopharmawatch.com/news/ABCL/lilly-to-supply-614-000-additional-doses-of-abcellera-discovered-bamlanivimab-together-wit-abcl-20211104monthly0.5https://www.biopharmawatch.com/news/ABCL/lilly-to-supply-the-eu-and-eea-with-up-to-220-000-doses-of-bamlanivimab-together-with-etes-abcl-20210923monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-acquires-tetragenetics-enhancing-capabilities-to-generate-antibodies-against-hig-abcl-20210913monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-q2-2021-business-results-08-12-2021-total-revenue-of-28-million-up-from--abcl-20210812monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-appoints-neil-berkley-as-chief-business-officer-07-13-2021-vancouver-british-col-abcl-20210713monthly0.5https://www.biopharmawatch.com/news/ABCL/a-abcellera-reports-q1-2021-business-results-total-revenue-of-203-million-up-from-5-millio-abcl-20210513monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-q1-2021-business-results-total-revenue-of-203-million-up-from-5-million--abcl-20210513monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-and-gilead-sciences-announce-new-multi-year-multi-target-antibody-discovery-coll-abcl-20210401monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-full-year-2020-business-results-total-revenue-of-233-million-1-in-2020-u-abcl-20210329monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-share-repurchase-program-of-up-to-125-million-of-its-common-stock-vanc-zyme-20260514monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-first-quarter-2026-financial-resu-zyme-20260507monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-zyme-20260302monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-outlines-strategic-priorities-and-outlook-for-2026-positive-phase-3-herizon-gea--zyme-20251231monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-strategic-initiative-to-optimize-value-of-licensed-products-by-buildin-zyme-20251118monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-positive-herizon-gea-01-phase-3-results-supporting-ziihera-zanidatamab-zyme-20251117monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-third-quarter-2025-financial-resu-zyme-20251104monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-decision-to-discontinue-clinical-development-of-zw171-a-mesothelin-dir-zyme-20250902monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-strengthens-board-of-directors-with-appointments-of-greg-ciongoli-and-robert-e-l-zyme-20250811monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-second-quarter-2025-financial-res-zyme-20250807monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-nmpa-approval-of-zanidatamab-in-china-for-adults-with-previously-treat-zyme-20250530monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-first-quarter-2025-financial-resu-zyme-20250508monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-zyme-20250305monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-appointment-of-oleg-nodelman-to-board-of-directors-vancouver-british-c-zyme-20250218monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-outlines-strategic-priorities-and-outlook-for-2025-and-2026-investigational-new--zyme-20241231monthly0.5https://www.biopharmawatch.com/news/ZYME/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previ-zyme-20241121monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-third-quarter-2024-financial-resu-zyme-20241031monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-share-repurchase-program-of-up-to-60-million-of-its-common-stock-zymew-zyme-20240801monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-second-quarter-2024-financial-res-zyme-20240801monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-leone-patterson-as-chief-business-and-financial-officer-vancouver-briti-zyme-20240725monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-first-quarter-2024-financial-resu-zyme-20240502monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-appointment-of-dr-neil-gallagher-to-its-board-of-directors-vancouver-b-zyme-20240328monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-fourth-quarter-and-full-year-2023-financial-results-reported-45-zyme-20240306monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-appointment-of-dr-alessandra-cesano-to-its-board-of-directors-vancouve-zyme-20240208monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-outlines-strategic-priorities-and-outlook-for-2024-and-2025-company-well-positio-zyme-20231231monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-50-million-private-placement-to-ecor1-capital-proceeds-expected-to-ext-zyme-20231226monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-third-quarter-2023-financial-resu-zyme-20231107monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-new-director-nominee-vancouver-british-columbia-zyme-20231016monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-second-quarter-2023-financial-res-zyme-20230810monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-new-director-vancouver-british-columbia-zyme-20230629monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-departure-of-neil-klompas-president-and-chief-operating-officer-vancou-zyme-20230518monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-first-quarter-2023-financial-resu-zyme-20230508monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-data-from-multiple-preclinical-and-clinical-development-programs-at-zyme-20230418monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-appointment-of-derek-j-miller-to-its-board-of-directors-vancouver-brit-zyme-20230410monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-fourth-quarter-and-full-year-2022-financial-results-2022-was-a--zyme-20230307monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-on-key-strategic-priorities-and-outlook-for-2023-provi-zyme-20221231monthly0.5https://www.biopharmawatch.com/news/ZYME/jazz-pharmaceuticals-and-zymeworks-announce-jazz-has-confirmed-opt-in-and-advances-partner-zyme-20221221monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-positive-topline-data-in-the-pivotal-herizon-btc-01-trial-of-zanidatam-zyme-20221219monthly0.5https://www.biopharmawatch.com/news/ZYME/new-clinical-data-for-zanidatamab-in-her2-hr-metastatic-breast-cancer-presented-today-at-2-zyme-20221209monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-transfer-stock-listing-to-nasdaq-vancouver-british-columbia-zyme-20221205monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-expiration-of-hart-scott-rodino-waiting-period-for-zanidatamab-license-zyme-20221129monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-provides-corporate-update-and-reports-third-quarter-2022-financial-resu-zyme-20221108monthly0.5https://www.biopharmawatch.com/news/ZYME/jazz-pharmaceuticals-and-zymeworks-announce-exclusive-license-agreement-to-develop-and-com-zyme-20221019monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-presents-rap-219-focal-onset-seizure-phase-2a-follow-up-period-result-rapp-20260421monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provi-rapp-20260310monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-reports-second-quarter-2025-financials-and-provides-business-update-x-rapp-20250807monthly0.5https://www.biopharmawatch.com/news/RAPP/investor-analyst-day-rapp-20250602monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-reports-first-quarter-2025-financials-and-provides-business-update-x2-rapp-20250508monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-rapp-20250311monthly0.5https://www.biopharmawatch.com/news/RAPP/corporate-overview-march-2025-disclaimer-this-presentation-contains-forward-looking-statem-rapp-20250303monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-announces-new-phase-1-data-further-supporting-rap-219-s-transformativ-rapp-20250109monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update-x2022-b-rapp-20241107monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-reports-second-quarter-financials-and-provides-business-update-x2022--rapp-20240808monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-updates-to-timelines-for-the-completion-of-enrollment-and-a-p-stok-20260113monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-and-biogen-present-data-that-further-support-the-disease-modifying-pote-stok-20251205monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-upda-stok-20251104monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-upd-stok-20250812monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-and-biogen-announce-first-patient-dosed-in-phase-3-emperor-study-of-zor-stok-20250811monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-and-biogen-announce-presentation-of-data-from-studies-of-zorevunersen-a-stok-20250710monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-nasdaq-stok-june-2025-cop-copy-yr-ri-ig-gh-ht-t-2-20-02-25-5-s-st-toke--stok-20250604monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-upda-stok-20250513monthly0.5https://www.biopharmawatch.com/news/STOK/ex-99-1-stoke-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-stok-20250318monthly0.5https://www.biopharmawatch.com/news/STOK/biogen-and-stoke-therapeutics-enter-into-collaboration-to-develop-and-commercialize-zorevu-stok-20250218monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-alignment-with-global-regulatory-agencies-and-plans-to-initia-stok-20250107monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-receives-fda-breakthrough-therapy-designation-for-zorevunersen-for-the--stok-20241204monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-third-quarter-financial-results-and-provides-business-updates-x-stok-20241105monthly0.5https://www.biopharmawatch.com/news/STOK/in-the-court-of-chancery-of-the-state-of-delaware-gerald-j-alsid-derivatively-on-behalf-of-stok-20240820monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-second-quarter-financial-results-and-provides-business-updates--stok-20240807monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-first-quarter-financial-results-and-provides-business-updates-x-stok-20240506monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-pricing-of-upsized-125-million-public-offering-stok-20240327monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-landmark-new-data-that-support-the-potential-for-stk-001-to-b-stok-20240325monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-x2013-as-of-stok-20240325monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-nasdaq-stok-edward-m-kaye-m-d-chief-executive-officer-nd-42-annual-j-p--stok-20240110monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-presents-data-from-multiple-studies-of-children-and-adolescents-with-dr-stok-20231201monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-third-quarter-financial-results-and-provides-business-updates-x-stok-20231107monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-appoints-ian-smith-to-its-board-of-directors-mr-smith-brings-significan-stok-20230920monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-second-quarter-financial-results-and-provides-business-updates--stok-20230807monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-positive-new-safety-efficacy-data-from-patients-treated-with--stok-20230725monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-first-quarter-financial-results-and-provides-business-updates-x-stok-20230504monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-that-fda-will-allow-the-administration-of-a-higher-single-dos-stok-20230315monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provide-stok-20230306monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-nasdaq-stok-edward-m-kaye-m-d-chief-executive-officer-st-41-annual-j-p--stok-20230110monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-presents-data-from-a-combined-interim-analysis-of-the-phase-1-2a-monarc-stok-20221202monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-third-quarter-financial-results-and-provides-business-updates-c-stok-20221114monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-second-quarter-financial-results-and-provides-business-updates--stok-20220808monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-first-quarter-financial-results-and-provides-business-updates-2-stok-20220510monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provide-stok-20220310monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-nasdaq-stok-edward-m-kaye-m-d-chief-executive-officer-th-40-annual-j-p--stok-20220110monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-presents-data-from-the-phase-1-2a-monarch-study-of-stk-001-in-children--stok-20211203monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-third-quarter-financial-results-and-provides-business-updates-c-stok-20211108monthly0.5https://www.biopharmawatch.com/news/STOK/agenda-introduction-eric-rojas-head-of-investor-relations-disease-overview-patient-need-an-stok-20210921monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-second-quarter-financial-results-and-provides-business-updates--stok-20210810monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-first-quarter-financial-results-and-provides-business-updates-e-stok-20210510monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-full-year-2020-financial-results-and-provides-business-updates--stok-20210309monthly0.5https://www.biopharmawatch.com/news/STOK/disclaimer-copyright-2021-stoke-therapeutics-this-presentation-has-been-prepared-by-stoke--stok-20210205monthly0.5https://www.biopharmawatch.com/news/STOK/disclaimer-copyright-2021-stoke-therapeutics-this-presentation-has-been-prepared-by-stoke--stok-20201231monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-pricing-of-97-5-million-public-offering-stok-20201119monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-third-quarter-financial-results-and-provides-business-updates-c-stok-20201112monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-appointment-of-garry-e-menzel-ph-d-to-its-board-of-directors--stok-20200817monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-second-quarter-financial-results-and-provides-business-updates--stok-20200810monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-publication-of-data-in-the-journal-nature-communications-that-stok-20200709monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-appoints-julie-anne-smith-to-its-board-of-directors-ms-smith-brings-sig-stok-20200604monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-first-quarter-financial-results-and-provides-business-updates-c-stok-20200515monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-presents-preclinical-data-that-demonstrate-in-vitro-and-in-vivo-target--stok-20200512monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-full-year-2019-financial-results-and-provides-business-updates--stok-20200323monthly0.5https://www.biopharmawatch.com/news/STOK/disclaimer-copyright-2020-stoke-therapeutics-inc-all-rights-reserved-this-presentation-has-stok-20200113monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-presents-preclinical-data-from-studies-of-stk-001-that-showed-improveme-stok-20191207monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-third-quarter-2019-financial-results-and-provides-business-upda-stok-20191112monthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-reports-second-quarter-2019-financial-results-and-provides-business-upd-stok-20190814monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobr-nrix-20260611monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and--nrix-20260607monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a--nrix-20260408monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2025-financial-result-nrix-20260128monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-outlines-2026-goals-and-objectives-for-advancing-bexobrutideg-and-its-p-nrix-20260112monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-250-0-million-registered-offering-of-common-stock-nrix-20251022monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a--nrix-20251009monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-second-quarter-2025-financial-results-and-provides-a-nrix-20250709monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-first-quarter-2025-financial-results-and-provides-a--nrix-20250408monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-provi-nrix-20250128monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-outlines-2025-goals-and-objectives-for-advancement-of-its-ro-nrix-20250113monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-presents-new-positive-data-from-phase-1a-1b-clinical-trial-o-nrix-20241209monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-third-quarter-fiscal-2024-financial-results-and-prov-nrix-20241011monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-second-quarter-fiscal-2024-financial-results-and-pro-nrix-20240711monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-pricing-of-upsized-175-0-million-public-offering-nrix-20240411monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-first-quarter-fiscal-2024-financial-results-and-prov-nrix-20240410monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-announces-u-s-fda-lifts-partial-clinical-hold-on-nx-2127-pha-nrix-20240311monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2023-financial-result-nrix-20240215monthly0.5https://www.biopharmawatch.com/news/NRIX/important-notice-and-disclaimers-this-presentation-contains-statements-that-relate-to-futu-nrix-20240108monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-logo-nurix-therapeutics-presents-positive-clinical-data-from-its-novel-bruton-s-tyro-nrix-20231211monthly0.5https://www.biopharmawatch.com/news/NRIX/leader-in-targeted-protein-modulation-nurix-therapeutics-blazing-a-new-path-in-medicine-in-nrix-20231113monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-partial-clinical-hold-for-nx-2127-phase-1-trial-currently-enr-nrix-20231101monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-third-quarter-fiscal-2023-financial-results-and-provides-a-corp-nrix-20231012monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-second-quarter-fiscal-2023-financial-results-and-provides-a-cor-nrix-20230713monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-first-quarter-fiscal-2023-financial-results-and-provides-a-corp-nrix-20230413monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and-provi-nrix-20230209monthly0.5https://www.biopharmawatch.com/news/NRIX/leader-in-targeted-protein-modulation-nurix-therapeutics-blazing-a-new-path-in-medicine-in-nrix-20230109monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-positive-clinical-results-from-its-novel-btk-degrader-nx-2127--nrix-20221212monthly0.5https://www.biopharmawatch.com/news/NRIX/leader-in-targeted-protein-modulation-the-first-btk-degraders-in-hematologic-malignancies--nrix-20221026monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-third-quarter-fiscal-2022-financial-results-and-provides-a-corp-nrix-20221006monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-leading-industry-strategist-edward-c-saltzman-to-its-board-of--nrix-20220914monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-55-million-registered-direct-offering-nrix-20220707monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-fiscal-second-quarter-2022-financial-results-and-provides-a-cor-nrix-20220707monthly0.5https://www.biopharmawatch.com/news/NRIX/leader-in-targeted-protein-modulation-nurix-therapeutics-blazing-a-new-path-in-medicine-r--nrix-20220526monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-fiscal-first-quarter-2022-financial-results-and-provides-a-corp-nrix-20220407monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2021-financial-results-and-provi-nrix-20220127monthly0.5https://www.biopharmawatch.com/news/NRIX/important-notice-and-disclaimers-this-presentation-contains-information-relating-to-nurix--nrix-20220110monthly0.5https://www.biopharmawatch.com/news/NRIX/important-notice-and-disclaimers-this-presentation-contains-information-relating-to-nurix--nrix-20211027monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-third-quarter-fiscal-2021-financial-results-and-provides-a-corp-nrix-20211014monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-expands-its-board-of-directors-with-the-addition-of-two-industry-leader-nrix-20210930monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-second-quarter-fiscal-2021-financial-results-and-provides-a-cor-nrix-20210713monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentation-of-preclinical-data-from-nx-5948-program-demonst-nrix-20210602monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-industry-leader-clay-siegall-ph-d-to-its-board-of-directors-nrix-20210601monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-first-quarter-fiscal-2021-financial-results-and-provides-a-corp-nrix-20210413monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2020-financial-results-and-provi-nrix-20210216monthly0.5https://www.biopharmawatch.com/news/NRIX/disclosures-all-authors-of-this-presentation-are-current-or-former-employees-and-sharehold-nrix-20201207monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-appointment-of-robert-tjian-as-chairman-of-scientific-advisor-nrix-20201026monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-third-quarter-fiscal-2020-financial-results-and-provides-a-corp-nrix-20201014monthly0.5https://www.biopharmawatch.com/news/NRIX/important-notice-and-disclaimers-this-presentation-contains-forward-looking-statements-and-nrix-20201014monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-financial-results-for-the-three-months-ended-auph-20260507monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-acquire-kezar-life-sciences-for-6-955-in-cash-per-share-plus-a--auph-20260330monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-management-transition-rockville-maryland-and-auph-20260323monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-nine-months-ended-auph-20251104monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-six-months-ended-auph-20250731monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-positive-results-from-phase-1-study-of-aritinercept-aur200-single-doses--auph-20250630monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-financial-results-for-the-three-months-ended-auph-20250512monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-twelve-months-ended-auph-20250227monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-third-quarter-and-nine-months-2024-financial-and-operation-auph-20241107monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-board-restructuring-peter-greenleaf-president-and-chief-executive-office-auph-20240912monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-second-quarter-and-six-months-2024-financial-and-operation-auph-20240801monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-discloses-2023-year-end-financial-and-operational-results-announces-corporate-acti-auph-20240215monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-third-quarter-and-nine-months-2023-financial-and-operation-auph-20231102monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-second-quarter-and-six-months-2023-financial-and-operation-auph-20230803monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-reports-first-quarter-2023-financial-and-operational-results-34-4--auph-20230504monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-promising-topline-data-from-renal-biopsy-sub-study-of-th-auph-20230405monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2022-financial-results-and-company-updates-28-auph-20230228monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-and-nine-months-2022-financial-and-operational-results-net-r-auph-20221031monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-and-six-months-2022-financial-and-operational-results-net-r-auph-20220804monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-2022-financial-and-operational-results-21-6-million-in-net-r-auph-20220510monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2021-financial-results-and-company-updates-23-auph-20220228monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-and-nine-months-2021-financial-results-and-company-updates-1-auph-20211103monthly0.5https://www.biopharmawatch.com/news/AUPH/confidential-riptide-aurinia-collaboration-license-agreement-between-aurinia-pharmaceutica-auph-20210816monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-and-six-months-2021-financial-results-and-recent-operationa-auph-20210805monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-delisting-from-the-toronto-stock-exchange-victoria-briti-auph-20210716monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-licensing-partner-otsuka-filed-initial-marketing-authorization-applicati-auph-20210625monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-addition-of-dr-brinda-balakrishnan-to-the-board-of-directors-victoria-br-auph-20210614monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-2021-financial-results-and-recent-operational-highlights-qua-auph-20210506monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-operational-auph-20210224monthly0.5https://www.biopharmawatch.com/news/AUPH/item-8-executive-officer-for-further-information-please-contact-mr-joseph-m-miller-chief-f-auph-20201229monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-collaboration-and-licensing-agreement-with-otsuka-pharmaceutical-co-ltd--auph-20201217monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-and-lonza-announce-exclusive-agreement-for-dedicated-voclosporin-manufacturing-cap-auph-20201215monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635-c-4-victo-auph-20201120monthly0.5https://www.biopharmawatch.com/news/AUPH/financial-statements-third-quarter-ended-auph-20201110monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-2020-financial-results-and-recent-operational-highlights-u-s-auph-20201110monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-presents-integrated-time-to-renal-response-data-from-the-aura-lv-and-aurora-trials-auph-20201109monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-outcome-of-audrey-clinical-trial-in-dry-eye-syndrome-the-trial-did-not-a-auph-20201102monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-european-investigator-initiated-trial-to-evaluate-antiviral-activity-of--auph-20201027monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-presents-voclosporin-efficacy-and-pharmacokinetic-data-from-integrated-analysis-of-auph-20201022monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-launch-of-lupus-nephritis-disease-state-awareness-initia-auph-20201014monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-new-employment-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vict-auph-20201002monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclospori-auph-20200928monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-new-employment-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vict-auph-20200904monthly0.5https://www.biopharmawatch.com/news/AUPH/financial-statements-second-quarter-ended-auph-20200811monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-2020-financial-results-and-recent-operational-highlights-u--auph-20200811monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20200721monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-public-offering-of-common-shares-victoria-british-columbia-business-wire-auph-20200722monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-u-s-food-and-drug-administration-acceptance-of-the-filing-of-new-drug-ap-auph-20200721monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-completes-patient-enrollment-into-the-audrey-phase-2-3-clinical-trial-of-voclospor-auph-20200622monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-presents-additional-aurora-pivotal-trial-safety-data-at-the-era-edta-virtual-congr-auph-20200609monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-presents-aurora-pivotal-trial-subgroup-analysis-at-the-eular-2020-e-congress-all-p-auph-20200605monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-results-of-annual-general-meeting-victoria-british-columbia-business-wir-auph-20200603monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-completes-submission-of-new-drug-application-to-the-u-s-food-drug-administration-f-auph-20200526monthly0.5https://www.biopharmawatch.com/news/AUPH/financial-statements-first-quarter-ended-auph-20200514monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-2020-financial-results-and-recent-operational-highlights-cas-auph-20200514monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-appoints-joe-miller-as-chief-financial-officer-dennis-bourgeault-to-retire-after-m-auph-20200427monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-appoints-industry-veteran-timothy-p-walbert-to-its-board-of-directors-victoria-bri-auph-20200420monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-aurora-phase-3-clinical-data-for-voclosporin-in-lupus-nephritis-to-be-pr-auph-20200318monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-establishes-u-s-commercial-operations-center-in-rockville-maryland-auph-20200317monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-initiates-rolling-submission-of-a-new-drug-application-to-the-u-s--auph-20200316monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-launches-resource-kit-for-people-living-with-lupus-nephritis-and-partners-with-nat-auph-20200312monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2019-financial-results-and-operational-highli-auph-20200305monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-appoints-max-colao-as-chief-commercial-officer-and-expands-u-s-commercial-leadersh-auph-20200225monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20191209monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-closes-us-191-7-million-public-offering-of-common-shares-and-full-exercise-of-unde-auph-20191212monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-prices-us-166-7-million-public-offering-of-common-shares-victoria-british-columbia-auph-20191209monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-public-offering-of-common-shares-victoria-british-columbia-business-wire-auph-20191209monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-positive-aurora-phase-3-trial-results-demonstrating-voclosporin-superior-auph-20191205monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-preclinical-voclosporin-data-at-2020-keystone-symposia-conference-voclo-auph-20191203monthly0.5https://www.biopharmawatch.com/news/AUPH/financial-statements-third-quarter-ended-auph-20191114monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-2019-financial-results-and-recent-operational-highlights-con-auph-20191114monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-updates-to-the-board-of-directors-victoria-british-columbia-business-wir-auph-20191113monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-completes-voclosporin-drug-drug-interaction-study-demonstrating-no-clinically-sign-auph-20191107monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-initiation-of-patient-dosing-in-phase-2-3-audrey-clinical-trial-for-dry--auph-20191031monthly0.5https://www.biopharmawatch.com/news/AUPH/financial-statements-second-quarter-ended-auph-20190806monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-2019-financial-results-and-operational-highlights-fully-enr-auph-20190806monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-further-strengthening-of-the-senior-management-team-max-donley-appointed-auph-20190718monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-shareholders-elect-all-eight-directors-at-2019-annual-general-meeting-shareholders-auph-20190626monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reminds-shareholders-to-vote-the-yellow-proxy-prior-to-june-24-deadline-shareholde-auph-20190621monthly0.5https://www.biopharmawatch.com/news/AUPH/leading-independent-proxy-advisors-recommend-aurinia-shareholders-vote-the-yellow-proxy-ca-auph-20190619monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-issues-letter-to-shareholders-highlights-the-company-s-strong-progress-advancement-auph-20190607monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-upcoming-annual-general-meeting-of-shareholders-special--auph-20190531monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-statements-of-financial-positio-auph-20190514monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-2019-financial-results-and-recent-operational-highlights-con-auph-20190514monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-recognizes-world-lupus-day-and-lupus-awareness-month-with-activities-focused-on-ra-auph-20190510monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-further-strengthens-its-board-of-directors-with-the-appointment-of-dr-daniel-bille-auph-20190430monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-appointment-of-peter-greenleaf-as-chief-executive-officer-and-board-dire-auph-20190411monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2018-financial-results-and-operational-highli-auph-20190319monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-recognizes-world-kidney-day-and-national-kidney-month-with-new-activities-focused--auph-20190314monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-closes-at-the-market-facility-victoria-british-columbia-business-wire-auph-20190227monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-receives-notice-of-allowance-from-the-us-patent-and-trademark-office-for-claims-di-auph-20190225monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-voclosporin-ophthalmic-solution-demonstrates-statistically-superior-effi-auph-20190122monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-establishes-at-the-market-facility-victoria-british-columbia-auph-20181130monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-statements-of-financial-positio-auph-20181108monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-financial-results-clinical-highlights-and-corporate-developm-auph-20181108monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-completes-enrollment-of-aurora-its-phase-3-clinical-trial-for-the-treatment-of-lup-auph-20180925monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-statements-of-financial-positio-auph-20180809monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-financial-results-and-operational-highlights-aurora-phase-i-auph-20180809monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-initiates-phase-2-clinical-trial-for-voclosporin-ophthalmic-solution-for-the-treat-auph-20180711monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-initiates-clinical-trials-broadening-the-development-of-voclosporin-first-lupus-ne-auph-20180625monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-results-of-annual-general-meeting-victoria-british-columbia-business-wir-auph-20180622monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-statements-of-financial-positio-auph-20180510monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-financial-results-and-operational-highlights-aurora-phase-ii-auph-20180510monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2017-financial-results-and-operational-highli-auph-20180315monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-enhances-research-development-and-scientific-expertise-with-the-appointment-of-mic-auph-20180222monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-enhances-commercial-and-business-development-expertise-with-the-appointment-of-jos-auph-20180208monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-files-new-preliminary-base-shelf-prospectus-to-replace-expired-bas-auph-20180104monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-financial-statements-unaudited--auph-20171114monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-2017-financial-results-and-provides-operational-highlights-a-auph-20171114monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-expand-renal-franchise-with-novel-indications-and-launches-development-program--auph-20171020monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-host-r-d-day-and-webcast-on-october-20-th-in-new-york-ny-presentations-will-hig-auph-20170919monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-webcast-at-upcoming-investor-conferences-victoria-british-columbia-business-wir-auph-20170905monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-financial-statements-unaudited--auph-20170810monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-2017-financial-results-and-provides-operational-highlights--auph-20170810monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-resolves-temporary-non-compliance-with-nasdaq-s-audit-committee-composition-rule-v-auph-20170712monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-results-of-annual-general-meeting-victoria-british-columbia-business-wir-auph-20170622monthly0.5https://www.biopharmawatch.com/news/AUPH/voclosporin-remission-data-from-the-phase-iib-aura-lv-study-highlighted-at-eular-2017-pati-auph-20170616monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-presents-additional-data-from-phase-iib-aura-lv-study-demonstrating-stable-renal-f-auph-20170605monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-doses-first-patient-in-aurora-phase-3-clinical-trial-of-voclosporin-in-lupus-nephr-auph-20170517monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-notice-of-annual-general-meeting-of-shareholders-notice-is-her-auph-20170519monthly0.5https://www.biopharmawatch.com/news/AUPH/financial-statements-first-quarter-ended-march-31-2017-q1-17-financial-statements-first-qu-auph-20170515monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-2017-financial-results-announces-initiation-of-phase-iii-aur-auph-20170515monthly0.5https://www.biopharmawatch.com/news/AUPH/pharma-industry-veteran-dr-george-milne-joins-aurinia-s-board-of-directors-victoria-britis-auph-20170509monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-at-bloom-burton-co-healthcare-conference-victoria-british-columbia-busi-auph-20170426monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-releases-additional-48-week-data-from-the-aura-lv-study-during-late-breaking-sessi-auph-20170420monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-completes-licensing-deal-with-merck-animal-health-for-its-nanomicellar-formulation-auph-20170417monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-host-investor-event-and-webcast-on-april-20-th-in-orlando-fl-victoria-british-c-auph-20170410monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-development-plans-for-voclosporin-in-europe-and-japan-single-phase-iii-t-auph-20170406monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-highlights-48-week-data-from-open-label-aurion-study-at-12-th-international-congre-auph-20170327monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20170313monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-closes-us-173-1-million-public-offering-of-common-shares-and-full-exercise-of-unde-auph-20170320monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-presentation-at-12-th-international-congress-on-sle-lupus-2017-the-7-th--auph-20170316monthly0.5https://www.biopharmawatch.com/news/AUPH/execution-version-underwriting-agreement-22-300-000-common-shares-aurinia-pharmaceuticals--auph-20170314monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-prices-us-150-5-million-public-offering-of-common-shares-victoria-british-columbia-auph-20170314monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-public-offering-of-common-shares-victoria-british-columbia-business-wire-auph-20170313monthly0.5https://www.biopharmawatch.com/news/AUPH/manufacturing-collaboration-and-services-agreement-the-agreement-by-and-between-lonza-ltd--auph-20170309monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2016-financial-results-and-recent-operational-auph-20170309monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-acceptance-of-voclosporin-late-breaking-presentation-at-the-national-kid-auph-20170306monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20170301monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-at-cowen-and-company-37-th-annual-healthcare-conference-victoria-britis-auph-20170302monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-voclosporin-meets-48-week-remission-endpoints-achieving-highest-complete-auph-20170301monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20170206monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-results-from-japanese-phase-i-ethnic-bridging-study-for-voclosporin-data-auph-20170214monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-selects-worldwide-clinical-trials-as-its-cro-for-phase-3-lupus-nephritis-trial-sin-auph-20170127monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-appointment-of-company-founder-dr-richard-m-glickman-as-its-new-chief-ex-auph-20170206monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-participate-in-upcoming-conferences-canaccord-genuity-rare-dise-auph-20170126monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20161222monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-closes-us-28-million-financing-victoria-british-columbia-business-wire-auph-20161228monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-us-25-0-million-bought-deal-financing-victoria-british-columbia-business-auph-20161222monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-long-term-manufacturing-collaboration-agreement-with-lonza-for-clinical--auph-20161219monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-confirms-receipt-of-fda-end-of-phase-2-meeting-minutes-minutes-are-consistent-with-auph-20161213monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-appointment-of-biotech-industry-leader-jeffry-randall-to-its-board-of-di-auph-20161212monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-highlights-renal-function-data-from-global-phase-iib-aura-study-of-voclosporin-for-auph-20161121monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-highlights-speed-of-remission-from-global-phase-iib-aura-study-of-voclosporin-in-l-auph-20161116monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-stifel-2016-healthcare-conference-victoria-british-c-auph-20161110monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20161102monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-establishes-at-the-market-facility-victoria-british-columbia-auph-20161109monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20161109monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-financial-statements-unaudited--auph-20161107monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-2016-financial-results-and-operational-highlights-aura-first-auph-20161104monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-plans-for-single-phase-iii-clinical-trial-for-voclosporin-in-the-treatme-auph-20161102monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-acceptance-of-late-breaking-voclosporin-abstracts-for-oral-presentation--auph-20161024monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-2016-bio-investor-forum-in-san-francisco-on-auph-20161011monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-releases-open-label-aurion-data-demonstrating-increased-remission-rates-over-time--auph-20161006monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-that-voclosporin-achieves-primary-and-all-pre-specified-secondary-endpoi-auph-20160929monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-leerink-partners-roundtable-series-in-new-york-auph-20160928monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-host-lupus-nephritis-ln-breakfast-and-webcast-on-september-30-t-auph-20160921monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-2016-rodman-renshaw-18-th-annual-global-investme-auph-20160907monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20160815monthly0.5https://www.biopharmawatch.com/news/AUPH/clinical-trial-update-aurinia-pharmaceuticals-announces-voclosporin-meets-primary-endpoint-auph-20160815monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-voclosporin-meets-primary-endpoint-in-phase-iib-aura-lv--auph-20160815monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-financial-statements-unaudited--auph-20160805monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-2016-financial-results-and-operational-highlights-completed-auph-20160805monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20160722monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-host-lupus-nephritis-expert-breakfast-and-webcast-on-august-4th-auph-20160728monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-establishes-at-the-market-facility-victoria-british-columbia-auph-20160722monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-appointment-of-head-of-communications-advocacy-victoria-british-columbia-auph-20160711monthly0.5https://www.biopharmawatch.com/news/AUPH/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurinia-pharmaceut-auph-20160615monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-24-week-remission-rates-from-the-first-seven-patients-in-its-open-label--auph-20160628monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-closing-of-us-7-million-private-placement-victoria-british-columbia-busi-auph-20160622monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-private-placement-victoria-british-columbia-business-wire-auph-20160615monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-results-of-annual-general-meeting-victoria-british-columbia-business-wir-auph-20160609monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-presentations-at-the-european-renal-association-european-dialysis-and-tr-auph-20160512monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-2016-financial-results-and-operational-highlights-enrollment-auph-20160511monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-financial-statements-unaudited--auph-20160511monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-initiates-first-clinical-study-of-voclosporin-for-japan-study-has-potential-to-red-auph-20160509monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-notice-of-annual-general-meeting-of-shareholders-notice-is-her-auph-20160503monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-2016-bloom-burton-co-healthcare-investor-confere-auph-20160428monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-appointment-of-new-chief-executive-officer-appointment-enhances-commerci-auph-20160411monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-result-from-data-and-safety-monitoring-board-for-its-phase-2b-study-in-l-auph-20160329monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2015-financial-results-and-recent-operational-auph-20160318monthly0.5https://www.biopharmawatch.com/news/AUPH/aurina-receives-fda-fast-track-designation-for-voclosporin-for-the-treatment-of-lupus-neph-auph-20160302monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-36-th-annual-cowan-health-care-conference-victor-auph-20160229monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-host-conference-call-webcast-to-review-results-from-the-aurion-study-conference-auph-20160211monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-preliminary-topline-data-from-its-open-label-aurion-study-in-lupus-nephr-auph-20160208monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-attend-two-upcoming-investor-conferences-source-capital-group-2-auph-20160204monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-18-th-annual-bio-ceo-investor-conference-victori-auph-20160202monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-canaccord-genuity-rare-disease-and-bio-pharma-on-auph-20160129monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-completion-of-patient-enrollment-in-its-phase-2b-aura-lv-study-in-lupus--auph-20160119monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-outcome-from-data-and-safety-monitoring-board-for-its-ph-auph-20151124monthly0.5https://www.biopharmawatch.com/news/AUPH/interim-condensed-consolidated-financial-statements-unaudited-aurinia-pharmaceuticals-inc--auph-20151113monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-2015-financial-results-victoria-british-columbia-business-wi-auph-20151113monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-14-th-annual-bio-investor-forum-victoria-british-auph-20151019monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-filing-of-preliminary-base-shelf-prospectus-victoria-bri-auph-20150917monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-2015-rodman-renshaw-17th-annual-global-investmen-auph-20150902monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-2015-financial-results-victoria-british-columbia-business-w-auph-20150811monthly0.5https://www.biopharmawatch.com/news/AUPH/interim-condensed-consolidated-financial-statements-unaudited-expressed-in-thousands-of-un-auph-20150811monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-canaccord-genuity-35-th-annual-growth-conference-auph-20150806monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-results-of-annual-general-meeting-victoria-british-columbia-business-wir-auph-20150527monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-2015-ubs-global-health-care-conference-victoria--auph-20150519monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-interim-condensed-consolidated-financial-statements-unaudited--auph-20150515monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-2015-financial-results-and-restatement-of-2014-financial-sta-auph-20150515monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-host-lupus-nephritis-opinion-leader-meeting-and-webcast-on-may--auph-20150423monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2014-financial-results-and-highlights-initiat-auph-20150330monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-change-to-its-board-of-directors-victoria-british-columbia-business-wire-auph-20150306monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-cowen-and-company-35-th-annual-health-care-conferenc-auph-20150226monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-initiate-an-open-label-clinical-study-to-investigate-the-impact-auph-20150209monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-recently-granted-nanomicellar-formulation-patents-in-jap-auph-20150203monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-bio-ceo-investor-conference-victoria-british-col-auph-20150129monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-2014-financial-results-victoria-british-columbia-auph-20141112monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-host-lupus-opinion-leader-meeting-and-webcast-on-october-23-in--auph-20141021monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-begin-trading-on-the-nasdaq-global-market-victoria-british-colu-auph-20140902monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-inc-news-release-aurinia-reports-second-quarter-2014-financial-res-auph-20140814monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-adds-financial-expertise-to-its-board-of-directors-victoria-bc-july-29-th-2014-aur-auph-20140729monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-at-the-bio-international-convention-victoria-auph-20140623monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-initiates-phase-2b-clinical-trial-of-voclosporin-to-treat-lupus-ne-auph-20140626monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-alterity-therape-athe-20260319monthly0.5https://www.biopharmawatch.com/news/ATHE/march-2026-asx-announcement-unmarketable-parcel-sale-facility-alterity-therapeutics-limite-athe-20260316monthly0.5https://www.biopharmawatch.com/news/ATHE/january-2026-appendix-4c-q2-fy26-quarterly-cash-flow-report-corporate-update-phase-2-data--athe-20260130monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-athe-20260115monthly0.5https://www.biopharmawatch.com/news/ATHE/january-2026-corporate-presentation-forward-looking-statements-2-this-presentation-may-con-athe-20260113monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20260107monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-alter-athe-20260107monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-athe-20251124monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3z-final-director-s-interest-notice-rule-3-19a-3-appendix-3z-final-director-s-int-athe-20251124monthly0.5https://www.biopharmawatch.com/news/ATHE/results-of-2025-annual-general-meeting-melbourne-australia-and-san-francisco-usa-21-novemb-athe-20251121monthly0.5https://www.biopharmawatch.com/news/ATHE/ceo-s-presentation-dr-david-stamler-21-november-2025-forward-looking-statements-2-this-pre-athe-20251121monthly0.5https://www.biopharmawatch.com/news/ATHE/chairman-s-address-2025-annual-general-meeting-good-morning-everyone-thank-you-for-joining-athe-20251121monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-21-november-2025-alterity-therapeutics-announces-board-changes-to-support-athe-20251121monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-13-november-2025-disclosure-under-takeovers-panel-guidance-note-20-equity-athe-20251113monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q1-fy26-quarterly-cash-flow-report-highlights-new-analysis-of-ath434-201-doubl-athe-20251031monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-the-company-abn-37-080-699-065-21-october-2025-alterity-ther-athe-20251021monthly0.5https://www.biopharmawatch.com/news/ATHE/form-604-corporations-act-2001-section-671b-notice-of-change-of-interests-of-substantial-h-athe-20251015monthly0.5https://www.biopharmawatch.com/news/ATHE/september-2025-asx-announcement-date-of-agm-and-closing-date-for-director-nominations-alte-athe-20250923monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20250917monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-alter-athe-20250917monthly0.5https://www.biopharmawatch.com/news/ATHE/form-604-corporations-act-2001-section-671b-notice-of-change-of-interests-of-substantial-h-athe-20250917monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250915monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-15-september-2025-notice-under-section-708a-5-e-of-the-corporations-act-t-athe-20250915monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-alterity-therape-athe-20250908monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-4-september-2025-alterity-therapeutics-limited-asx-ath-trading-halt-tr-athe-20250904monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-filed-form-20-f-and-xbrl-data-with-the-sec-melbourne-australia-and-s-athe-20250902monthly0.5https://www.biopharmawatch.com/news/ATHE/rules-4-7-3-and-4-10-3-appendix-4g-key-to-disclosures-corporate-governance-council-princip-athe-20250902monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250822monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-athe-20250815monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-4-august-2025-attached-for-the-information-of-the-market-are-asx-s-que-athe-20250804monthly0.5https://www.biopharmawatch.com/news/ATHE/july-2025-corporate-presentation-forward-looking-statements-2-this-presentation-may-contai-athe-20250731monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q4-fy25-quarterly-cash-flow-report-highlights-granted-u-s-fda-fast-track-desig-athe-20250730monthly0.5https://www.biopharmawatch.com/news/ATHE/page-1-of-2-15-july-2001-form-604-corporations-act-2001-section-671b-notice-of-change-of-i-athe-20250728monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-publication-on-novel-mri-endpoint-from-the-biomuse-natural-athe-20250724monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250721monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250717monthly0.5https://www.biopharmawatch.com/news/ATHE/july-2025-by-email-melissa-kostopoulos-asx-com-au-melissa-kostopoulos-adviser-listings-com-athe-20250714monthly0.5https://www.biopharmawatch.com/news/ATHE/page-1-of-2-15-july-2001-form-604-corporations-act-2001-section-671b-notice-of-change-of-i-athe-20250707monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-athe-20250703monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-alter-athe-20250630monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-provide-corporate-update-in-fireside-chat-melbourne-australia-and-athe-20250623monthly0.5https://www.biopharmawatch.com/news/ATHE/page-1-of-2-15-july-2001-form-604-corporations-act-2001-section-671b-notice-of-change-of-i-athe-20250523monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-prominently-featured-at-the-international-msa-congress-ath434-phase--athe-20250512monthly0.5https://www.biopharmawatch.com/news/ATHE/page-1-of-2-15-july-2001-form-604-corporations-act-2001-section-671b-notice-of-change-of-i-athe-20250512monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-multiple-oral-and-poster-presentations-to-be-featured-at-t-athe-20250509monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-granted-u-s-fda-fast-track-designation-for-ath434-to-treat-multiple--athe-20250505monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q3-fy25-quarterly-cash-flow-report-highlights-reported-positive-topline-data-f-athe-20250430monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20250429monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presents-ath434-201-phase-2-clinical-trial-results-at-european-msa-s-athe-20250428monthly0.5https://www.biopharmawatch.com/news/ATHE/as-at-date-16-apr-2025-top-holders-grouped-report-alterity-therapeutics-limited-security-c-athe-20250422monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250422monthly0.5https://www.biopharmawatch.com/news/ATHE/david-stamler-md-ceo-april-2025-forward-looking-statements-this-presentation-may-contain-s-athe-20250422monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-the-company-options-prospectus-this-prospect-athe-20250417monthly0.5https://www.biopharmawatch.com/news/ATHE/topline-data-from-a-randomized-double-blind-placebo-controlled-phase-2-study-of-ath434-in--athe-20250410monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presents-encouraging-new-data-from-its-ath434-phase-2-trial-in-multi-athe-20250410monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20250410monthly0.5https://www.biopharmawatch.com/news/ATHE/page-1-of-2-15-july-2001-form-604-corporations-act-2001-section-671b-notice-of-change-of-i-athe-20250408monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-completion-of-placement-melbourne-australia-and-san-franci-athe-20250407monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-07-april-2025-notice-under-section-708a-5-e-of-the-corporations-act-this--athe-20250407monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250407monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-deliver-an-oral-presentation-of-the-positive-ath434-phase-2-trial-athe-20250403monthly0.5https://www.biopharmawatch.com/news/ATHE/disclosure-of-proxy-votes-alterity-therapeutics-limited-extraordinary-general-meeting-mond-athe-20250331monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-completes-last-patient-visit-in-ath434-202-open-label-phase-2-trial--athe-20250327monthly0.5https://www.biopharmawatch.com/news/ATHE/page-1-of-2-form-605-corporations-act-2001-section-671b-notice-of-ceasing-to-be-a-substant-athe-20250325monthly0.5https://www.biopharmawatch.com/news/ATHE/form-603-corporations-act-2001-section-671b-notice-of-initial-substantial-holder-to-compan-athe-20250314monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250314monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4d-half-year-ended-31-december-2024-name-of-entity--athe-20250228monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-alterity-therape-athe-20250224monthly0.5https://www.biopharmawatch.com/news/ATHE/form-604-corporations-act-2001-section-671b-notice-of-change-of-interests-of-substantial-h-athe-20250219monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250217monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-17-february-2025-notice-under-section-708a-5-e-of-the-corporations-act-th-athe-20250218monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-alterity-therape-athe-20250210monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-raises-a-40-0-million-in-placement-funds-to-be-used-primarily-to-adv-athe-20250210monthly0.5https://www.biopharmawatch.com/news/ATHE/form-603-corporations-act-2001-section-671b-notice-of-initial-substantial-holder-to-compan-athe-20250206monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-6-february-2025-alterity-therapeutics-limited-asx-ath-trading-halt-des-athe-20250206monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-05-february-2025-disclosure-under-takeovers-panel-guidance-note-20-equity-athe-20250205monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-04-february-2025-notice-under-section-708a-5-e-of-the-corporations-act-th-athe-20250204monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250130monthly0.5https://www.biopharmawatch.com/news/ATHE/ath434-201-phase-2-topline-results-athe-20250130monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-28-january-2025-alterity-therapeutics-limited-asx-ath-trading-halt-des-athe-20250128monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q2-fy25-quarterly-cash-flow-report-highlig-hts-topline-data-for-ath434-201-ran-athe-20250124monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20250122monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-issues-shareholder-newsletter-highlighting-pipeline-advances-and-key-athe-20250121monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20250106monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-athe-20241230monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-completes-last-patient-visit-in-ath434-201-phase-2-clinical-trial-in-athe-20241204monthly0.5https://www.biopharmawatch.com/news/ATHE/results-of-2024-annual-general-meeting-melbourne-australia-and-san-francisco-usa-22-novemb-athe-20241122monthly0.5https://www.biopharmawatch.com/news/ATHE/david-stamler-md-ceo-agm-22-november-2024-forward-looking-statements-this-presentation-may-athe-20241122monthly0.5https://www.biopharmawatch.com/news/ATHE/chairman-s-address-2024-annual-general-meeting-good-morning-everyone-and-thank-you-for-joi-athe-20241122monthly0.5https://www.biopharmawatch.com/news/ATHE/change-of-company-secretary-melbourne-australia-and-san-francisco-usa-19-november-2024-alt-athe-20241119monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-on-tracking-the-progression-of-multiple-syste-athe-20241112monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-new-publication-describing-novel-mechanism-of-action-for-a-athe-20241106monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q1-fy25-quarterly-cash-flow-report-highlights-topline-data-for-ath434-201-rand-athe-20241031monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-notice-of-annual-general-meeting-and-explana-athe-20241023monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-participate-in-a-fireside-chat-at-the-2024-maxim-healthcare-virtu-athe-20241015monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-of-new-data-describing-neuroprotection-of-ath-athe-20241011monthly0.5https://www.biopharmawatch.com/news/ATHE/change-of-share-registry-melbourne-australia-and-san-francisco-usa-4-october-2024-alterity-athe-20241004monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-raises-profile-with-multiple-data-presentations-at-the-international-athe-20241002monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-appoints-abby-macnish-niven-as-chief-financial-officer-melbourne-aus-athe-20240930monthly0.5https://www.biopharmawatch.com/news/ATHE/rules-4-7-3-and-4-10-3-appendix-4g-key-to-disclosures-corporate-governance-council-princip-athe-20240926monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-corporate-governance-statement-30-june-2024-this-corporate-g-athe-20240926monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-annual-report-athe-20240926monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-deliver-multiple-oral-and-poster-presentations-at-the-internation-athe-20240923monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20240920monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-alter-athe-20240902monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-preliminary-final-report-30-june-2024-2-alte-athe-20240829monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-alter-athe-20240801monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q4-fy24-quarterly-cash-flow-report-highlights-positive-interim-data-reported-f-athe-20240731monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-at-mst-financial-webinar-melbourne-australia-and-san-fran-athe-20240724monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-19-july-2024-notice-under-section-708a-5-e-of-the-corporations-act-this-n-athe-20240719monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20240719monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-alterity-therape-athe-20240718monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-reports-positive-interim-data-from-ath434-202-phase-2-clinical-trial-athe-20240717monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-15-july-2024-alterity-therapeutics-limited-asx-ath-trading-halt-descri-athe-20240715monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-athe-20240628monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-at-the-mst-access-hidden-gems-in-life-sciences-webinar-me-athe-20240613monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-host-webcast-today-on-new-data-from-the-biomuse-natural-history-s-athe-20240531monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-alter-athe-20240521monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-phase-2-data-monitoring-committee-recommends-continuing-clinical-tri-athe-20240509monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q3-fy24-quarterly-cash-flow-report-highlights-ath434-201-phase-2-baseline-data-athe-20240430monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20240429monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presents-new-data-demonstrating-potential-of-ath434-to-treat-rare-ne-athe-20240429monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-parkinson-s-disease-and-multiple-system-atrophy-data-featured-at-the-athe-20240417monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20240415monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-the-company-options-prospectus-this-prospect-athe-20240412monthly0.5https://www.biopharmawatch.com/news/ATHE/results-of-extraordinary-general-meeting-melbourne-australia-and-san-francisco-usa-12-apri-athe-20240412monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-receives-a-3-9-million-research-development-tax-incentive-refund-mel-athe-20240326monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-notice-of-extraordinary-general-meeting-and--athe-20240315monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-4-march-2024-notice-under-section-708a-5-e-of-the-corporations-act-this-n-athe-20240304monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-alter-athe-20240304monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4d-half-year-ended-31-december-2023-name-of-entity--athe-20240229monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-proposed-issue-of-securities-announcement-summary-entity-name-alterity-therape-athe-20240223monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-raises-3-25-m-aud-in-placement-company-now-fully-funded-through-data-athe-20240223monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-22-february-2024-alterity-therapeutics-limited-asx-ath-trading-halt-de-athe-20240222monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-new-data-at-the-upcoming-american-academy-of-neurology-20-athe-20240220monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-phase-2-data-monitoring-committee-recommends-continuing-clinical-tri-athe-20240206monthly0.5https://www.biopharmawatch.com/news/ATHE/application-for-quotation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20240202monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-announcement--athe-20240202monthly0.5https://www.biopharmawatch.com/news/ATHE/not-for-release-to-us-wire-services-or-distribution-in-the-united-states-alterity-therapeu-athe-20240202monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q2-fy24-quarterly-cash-flow-report-highlights-completed-enrollment-in-for-ath4-athe-20240131monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-issues-shareholder-letter-highlighting-pipeline-advances-and-key-upc-athe-20240122monthly0.5https://www.biopharmawatch.com/news/ATHE/application-for-quotation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20240118monthly0.5https://www.biopharmawatch.com/news/ATHE/confidential-appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-cha-athe-20240111monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-launches-security-purchase-plan-spp-with-continued-support-from-inst-athe-20240111monthly0.5https://www.biopharmawatch.com/news/ATHE/not-for-release-to-us-wire-services-or-distribution-in-the-united-states-alterity-therapeu-athe-20240110monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-8-january-2024-notice-under-section-708a-5-e-of-the-corporations-act-this-athe-20240108monthly0.5https://www.biopharmawatch.com/news/ATHE/not-for-release-to-us-wire-services-or-distribution-in-the-united-states-alterity-therapeu-athe-20240108monthly0.5https://www.biopharmawatch.com/news/ATHE/application-for-quotation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20240108monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-announcement--athe-20240108monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-update-summary-entity-name-alterity-therapeutics-limited-anno-athe-20240105monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-shareholder-approval-of-tranche-two-placement-and-security-athe-20240102monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-the-company-prospectus-an-offer-for-the-issu-athe-20240102monthly0.5https://www.biopharmawatch.com/news/ATHE/results-of-extraordinary-general-meeting-melbourne-australia-and-san-francisco-usa-29-dece-athe-20231229monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-announcement--athe-20231221monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-appoints-phillip-hains-as-chief-financial-officer-melbourne-australi-athe-20231221monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-update-summary-entity-name-alterity-therapeutics-limited-anno-athe-20231218monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-grants-listing-rule-waiver-addendum-to-the-notice-of-extraordinary-general-meeting-29--athe-20231211monthly0.5https://www.biopharmawatch.com/news/ATHE/virtual-access-to-extraordinary-general-meeting-29-december-2023-melbourne-australia-and-s-athe-20231208monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-reports-positive-efficacy-data-for-ath434-in-a-primate-model-of-park-athe-20231203monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-notice-of-extraordinary-general-meeting-and--athe-20231130monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-cessation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20231130monthly0.5https://www.biopharmawatch.com/news/ATHE/application-for-quotation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20231129monthly0.5https://www.biopharmawatch.com/news/ATHE/results-of-annual-general-meeting-melbourne-australia-and-san-francisco-usa-29-november-20-athe-20231129monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-nasdaq-athe-asx-ath-david-stamler-md-ceo-november-2023-forward-looki-athe-20231129monthly0.5https://www.biopharmawatch.com/news/ATHE/not-for-release-to-us-wire-services-or-distribution-in-the-united-states-alterity-complete-athe-20231129monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-29-november-2023-notice-under-section-708a-5-e-of-the-corporations-act-th-athe-20231129monthly0.5https://www.biopharmawatch.com/news/ATHE/chairman-s-address-2023-annual-general-meeting-good-morning-all-and-thank-you-for-joining--athe-20231129monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-of-novel-biomarker-data-for-evaluation-of-mul-athe-20231127monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20231122monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-nasdaq-athe-asx-ath-d-av-i-d-s-ta-ml-e-r-m-d-ceo-no-ve-mb-e-r-2023-f-athe-20231122monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-raises-4-8m-aud-in-placement-funds-to-be-used-primarily-to-advance-o-athe-20231122monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-20-november-2023-alterity-therapeutics-limited-asx-ath-trading-halt-de-athe-20231120monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-of-new-data-demonstrating-novel-mechanisms-of-athe-20231116monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-completes-enrolment-in-ath434-201-phase-2-clinical-trial-in-multiple-athe-20231108monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-notice-of-annual-general-meeting-and-explana-athe-20231031monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q1-fy24-quarterly-cash-flow-report-highlights-participant-screening-closed-for-athe-20231030monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-cessation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20230913monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4e-audited-financial-report-for-the-year-ended-30-j-athe-20230831monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-corporate-governance-statement-30-june-2023-this-corporate-g-athe-20230831monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presents-new-data-on-multiple-system-atrophy-a-rare-parkinsonian-dis-athe-20230831monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-granted-new-composition-of-matter-patent-in-europe-for-neurodegenera-athe-20230823monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-rare-disease-natural-history-study-to-be-featured-at-the-internation-athe-20230822monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-receives-a-4-74-million-research-development-tax-incentive-refund-me-athe-20230815monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q4-fy23-quarterly-cash-flow-report-highlights-ath434-201-phase-2-study-on-trac-athe-20230731monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-phase-2-data-monitoring-committee-recommends-continuing-clinical-tri-athe-20230726monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-n-as-d-a-q-a-t-h-e-as-x-a-t-h-d-av-i-d-s-t-a-ml-er-m-d-ceo-jun-e-202-athe-20230622monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-in-mst-access-rare-diseases-rich-returns-forum-on-22-june-athe-20230621monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-initiates-second-phase-2-study-in-rare-parkinsonian-disorder-ath434--athe-20230530monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-enrolls-first-patient-in-australia-in-ath434-global-phase-2-clinical-athe-20230510monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q3-fy23-quarterly-cash-flow-report-highlights-continued-expansion-of-ath434-ph-athe-20230427monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presents-promising-wearable-sensor-data-from-the-biomuse-natural-his-athe-20230426monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-cessation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20230411monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-enrols-first-patient-in-the-united-kingdom-in-ath434-phase-2-clinica-athe-20230404monthly0.5https://www.biopharmawatch.com/news/ATHE/application-for-quotation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20230316monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-16-march-2023-notice-under-section-708a-5-e-of-the-corporations-act-this--athe-20230316monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-enrolls-first-patient-in-the-u-s-in-ath434-phase-2-clinical-trial-in-athe-20230316monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20230315monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-granting-of-new-composition-of-matter-patent-and-exclusive-athe-20230314monthly0.5https://www.biopharmawatch.com/news/ATHE/investor-webinar-presentation-melbourne-australia-and-san-francisco-usa-9-march-2023-alter-athe-20230309monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-enrolls-first-patient-in-italy-in-ath434-phase-2-clinical-trial-in-m-athe-20230308monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4d-half-year-ended-31-december-2022-name-of-entity--athe-20230228monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-receives-regulatory-authorization-in-france-and-austria-to-proceed-w-athe-20230217monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-cessation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20230201monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q2-fy23-quarterly-cash-flow-report-highlights-expanded-participation-in-ath434-athe-20230131monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-s-ath434-prevents-loss-of-brain-cells-in-parkinson-s-disease-animal-model-indepen-athe-20230130monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-launches-ath434-phase-2-clinical-trial-in-italy-for-the-treatment-of-athe-20230125monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-launches-ath434-phase-2-clinical-trial-in-the-united-states-for-the--athe-20230109monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-1-for-10-reverse-ads-split-consolidation-melbourne-austral-athe-20230109monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-participate-in-the-sachs-associates-6-th-annual-neuroscience-inno-athe-20230103monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-allowance-of-new-composition-of-matter-patent-by-the-unite-athe-20221229monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20221215monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-cessation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20221215monthly0.5https://www.biopharmawatch.com/news/ATHE/constitution-of-alterity-therapeutics-limited-acn-080-699-065-amended-by-special-resolutio-athe-20221116monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-ath-nasdaq-athe-results-of-annual-general-meeting-friday-11-th-no-athe-20221114monthly0.5https://www.biopharmawatch.com/news/ATHE/chairman-s-address-2022-annual-general-meeting-good-morning-all-and-thank-you-for-joining--athe-20221114monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-nasdaq-athe-asx-ath-david-stamler-md-ceo-november-2022-forward-looki-athe-20221114monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-of-data-from-the-biomuse-natural-history-stud-athe-20221107monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q1-fy23-quarterly-cash-flow-report-first-patient-dosed-in-phase-2-clinical-tri-athe-20221028monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-of-mri-data-from-the-biomuse-natural-history--athe-20221024monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-launches-ath434-phase-2-clinical-trial-in-australia-for-the-treatmen-athe-20221013monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-notice-of-annual-general-meeting-and-explana-athe-20221013monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-of-wearable-sensor-data-from-the-biomuse-natu-athe-20220926monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-23-september-2022-notice-under-section-708a-5-e-of-the-corporations-act-t-athe-20220923monthly0.5https://www.biopharmawatch.com/news/ATHE/application-for-quotation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20220923monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20220921monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-receives-u-s-fda-approval-for-investigational-new-drug-application-f-athe-20220920monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-filed-form-20-f-and-xbrl-data-with-sec-melbourne-australia-and-san-f-athe-20220901monthly0.5https://www.biopharmawatch.com/news/ATHE/rules-4-7-3-and-4-10-3-appendix-4g-key-to-disclosures-corporate-governance-council-princip-athe-20220831monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4e-preliminary-final-report-for-the-year-ended-30-j-athe-20220831monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-launches-ath434-phase-2-clinical-trial-for-the-treatment-of-patients-athe-20220825monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-granted-extension-by-nasdaq-to-regain-compliance-minimum-bid-price-r-athe-20220824monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q4-fy22-quarterly-cash-flow-report-phase-2-clinical-trial-for-ath434-commences-athe-20220722monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-doses-first-patient-in-ath434-phase-2-clinical-trial-in-multiple-sys-athe-20220706monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-receives-a-4-1-million-r-d-tax-incentive-refund-melbourne-australia-and-san-franc-athe-20220630monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-cessation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20220627monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-regulatory-authorization-to-proceed-with-ath434-phase-2-cl-athe-20220623monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-at-the-at-virtualinvestorconferences-com-life-sciences-in-athe-20220621monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-at-the-gcff-virtual-conference-2022-investing-in-healthca-athe-20220614monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-launches-ath434-phase-2-clinical-trial-for-the-treatment-of-patients-athe-20220603monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-participate-in-the-benchmark-company-healthcare-house-call-confer-athe-20220526monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q3-fy22-quarterly-cash-flow-report-melbourne-australia-and-san-francisco-usa-2-athe-20220502monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-regulatory-authorization-to-proceed-with-ath434-phase-2-cl-athe-20220427monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-of-biomuse-data-at-the-american-academy-of-ne-athe-20220407monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-participate-in-the-sachs-associates-5-th-annual-neuroscience-inno-athe-20220315monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-nasda-q-a-t-he-asx-a-t-h-d-avi-d-s-ta-m-le-r-m-d-ceo-ma-r-c-h-2022-f-athe-20220307monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-at-the-34-th-annual-roth-conference-melbourne-australia-a-athe-20220307monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4d-half-year-ended-31-december-2021-name-of-entity--athe-20220228monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-receives-non-compliance-notice-regarding-nasdaq-minimum-bid-price-re-athe-20220228monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-publication-demonstrating-that-ath434-is-neuroprotective-i-athe-20220128monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q2-fy22-quarterly-cash-flow-report-highlights-nz-s-regulator-medsafe-authorize-athe-20220127monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-granted-new-us-patent-for-compounds-for-neurodegenerative-diseases-i-athe-20220106monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-melbo-athe-20220105monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3z-final-director-s-interest-notice-rule-3-19a-3-appendix-3z-final-director-s-int-athe-20220105monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-cessation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20220105monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-resignation-of-non-executive-directors-melbourne-australia-athe-20220104monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-cessation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20211215monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-first-regulatory-authorization-to-proceed-with-ath434-phas-athe-20211214monthly0.5https://www.biopharmawatch.com/news/ATHE/notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-announcement--athe-20211209monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-participate-in-two-upcoming-investor-conferences-melbourne-austra-athe-20211122monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-ath-results-of-annual-general-meeting-friday-12-th-november-2021--athe-20211112monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-nasdaq-a-the-as-x-a-th-agm-ceo-address-2021-davi-d-stamle-r-md-ceo-1-athe-20211112monthly0.5https://www.biopharmawatch.com/news/ATHE/chairman-s-address-2021-annual-general-meeting-i-am-pleased-to-present-my-chairman-s-addre-athe-20211112monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-presentation-of-ath434-at-the-american-autonomic-society-v-athe-20211109monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-new-publications-providing-further-evidence-of-the-potenti-athe-20211104monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q1-fy22-quarterly-cash-flow-report-highlights-new-details-on-ath34-phase-2-cli-athe-20211029monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-expanded-ath434-phase-2-clinical-development-program-clini-athe-20211019monthly0.5https://www.biopharmawatch.com/news/ATHE/abn-37-080-699-065-notice-of-annual-general-meeting-and-explanatory-memorandum-alterity-th-athe-20211012monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-announces-presentation-of-biomarker-data-at-the-international-parkinson-and-movem-athe-20210920monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4e-preliminary-final-report-for-the-year-ended-30-j-athe-20210903monthly0.5https://www.biopharmawatch.com/news/ATHE/rules-4-7-3-and-4-10-3-appendix-4g-key-to-disclosures-corporate-governance-council-princip-athe-20210903monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-filed-form-20-f-and-xbrl-data-with-sec-melbourne-australia-and-san-f-athe-20210903monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-new-us-patent-to-expand-its-portfolio-of-compounds-for-neu-athe-20210804monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q4-fy21-quarterly-cash-flow-report-highlights-positive-guidance-from-european--athe-20210730monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-publication-of-data-demonstrating-ath434-is-neuroprotectiv-athe-20210715monthly0.5https://www.biopharmawatch.com/news/ATHE/application-for-quotation-of-securities-announcement-summary-entity-name-alterity-therapeu-athe-20210705monthly0.5https://www.biopharmawatch.com/news/ATHE/asx-announcement-notice-under-section-708a-5-of-the-corporations-act-asx-code-ath-this-not-athe-20210706monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20210702monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-granted-a-new-us-patent-targeting-major-neurodegenerative-diseases-i-athe-20210701monthly0.5https://www.biopharmawatch.com/news/ATHE/european-union-regulatory-guidance-for-ath434-phase-2-clinical-trial-highlights-alterity-r-athe-20210623monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-nasdaq-a-the-asx-a-t-h-jun-e-2021-davi-d-stamle-r-md-ceo-forward-loo-athe-20210617monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-at-the-mst-access-australian-micro-small-caps-conference--athe-20210616monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q3-fy21-quarterly-cash-flow-report-highlights-michael-j-fox-foundation-grants--athe-20210429monthly0.5https://www.biopharmawatch.com/news/ATHE/ath434-protects-brain-cells-and-improves-motor-function-in-parkinsonian-disorder-oral-pres-athe-20210421monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-3-10-3a-3-10-3b-3-10-3c-appendix-3g-notification-of-issue-conversion-or-payment-up-of-athe-20210420monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-ceo-dr-david-stamler-presents-to-us-investors-at-the-hc-wainwright-global-life-sc-athe-20210310monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-to-present-at-the-7th-international-congress-of-multiple-system-atrophy-melbourne-athe-20210226monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4d-half-year-ended-31-december-2020-name-of-entity--athe-20210225monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-half-year-results-and-investor-webcast-notification-melbourne-australia-and-san-f-athe-20210219monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-2-7-appendix-2a-application-for-quotation-of-securities-information-or-documents-not--athe-20210211monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20210210monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-funding-from-michael-j-fox-foundation-for-ath434-dose-opti-athe-20210209monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q2-fy21-quarterly-cash-flow-report-highlights-dr-david-stamler-appointed-ceo-g-athe-20210128monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-participates-in-world-s-largest-virtual-healthcare-conference-jp-morgan-melbourne-athe-20210111monthly0.5https://www.biopharmawatch.com/news/ATHE/dr-david-stamler-appointed-ceo-melbourne-australia-and-san-francisco-usa-7-january-2021-th-athe-20210107monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-and-uniquest-partner-to-reverse-bacterial-resistance-to-antibiotics-new-commercia-athe-20201221monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-presents-at-finance-news-network-investor-event-melbourne-australia-and-san-franc-athe-20201202monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-3-10-3a-3-10-3b-3-10-3c-appendix-3g-notification-of-issue-conversion-or-payment-up-of-athe-20201124monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-2-7-appendix-2a-application-for-quotation-of-securities-information-or-documents-not--athe-20201124monthly0.5https://www.biopharmawatch.com/news/ATHE/constitution-of-alterity-therapeutics-limited-acn-080-699-065-as-adopted-by-a-special-reso-athe-20201119monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-ath-results-of-annual-general-meeting-wednesday-18-th-november-20-athe-20201118monthly0.5https://www.biopharmawatch.com/news/ATHE/chairman-s-address-2020-annual-general-meeting-while-the-world-responds-and-adjusts-to-the-athe-20201118monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-announces-approval-of-us-patent-for-next-generation-compounds-to-treat-neurodegen-athe-20201116monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q1-fy21-quarterly-cash-flow-report-highlights-continued-scientific-and-clinica-athe-20201030monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-commences-enrolling-multiple-system-atrophy-patients-in-biomuse-study-melbourne-a-athe-20201027monthly0.5https://www.biopharmawatch.com/news/ATHE/not-for-release-to-us-wire-services-or-distribution-in-the-united-states-alterity-complete-athe-20201023monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-2-7-appendix-2a-application-for-quotation-of-securities-information-or-documents-not--athe-20201023monthly0.5https://www.biopharmawatch.com/news/ATHE/abn-37-080-699-065-notice-of-annual-general-meeting-and-explanatory-memorandum-alterity-th-athe-20201020monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20201016monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-12-october-2020-alterity-therapeutics-limited-asx-ath-trading-halt-2-2-athe-20201013monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20200921monthly0.5https://www.biopharmawatch.com/news/ATHE/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-athe-20200903monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-filed-form-20-f-and-xbrl-data-with-sec-melbourne-australia-and-san-f-athe-20200916monthly0.5https://www.biopharmawatch.com/news/ATHE/rules-4-7-3-and-4-10-31-appendix-4g-key-to-disclosures-corporate-governance-council-princi-athe-20200909monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-2020-annual-report-contents-alterity-therapeutics-limited-ac-athe-20200909monthly0.5https://www.biopharmawatch.com/news/ATHE/annual-report-melbourne-australia-and-san-francisco-usa-9th-september-2020-alterity-therap-athe-20200909monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-ath-results-of-general-meeting-thursday-3rd-september-2020-the-co-athe-20200903monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-acn-080-699-065-appendix-4e-preliminary-final-report-30-june-athe-20200831monthly0.5https://www.biopharmawatch.com/news/ATHE/abn-37-080-699-065-notice-of-general-meeting-and-explanatory-memorandum-alterity-therapeut-athe-20200804monthly0.5https://www.biopharmawatch.com/news/ATHE/new-data-independently-confirms-and-extends-laboratory-findings-and-expands-safety-profile-athe-20200804monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q4-fy20-quarterly-cash-flow-report-highlights-fda-provides-guidance-for-ath434-athe-20200730monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-2-7-appendix-2a-application-for-quotation-of-securities-information-or-documents-not--athe-20200702monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20200701monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-meeting-with-us-fda-provides-development-pathway-for-ath434-melbourn-athe-20200630monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-2-7-appendix-2a-application-for-quotation-of-securities-information-or-documents-not--athe-20200526monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20200522monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presents-data-on-ath434-to-the-american-academy-of-neurology-melbour-athe-20200521monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q3-fy20-quarterly-cash-flow-report-highlights-european-commission-designated-o-athe-20200430monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-qualifies-for-temporary-relief-from-nasdaq-regarding-minimum-bid-price-requiremen-athe-20200422monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-2a-application-for-quotation-of-securities-information-or-documents-not-available-athe-20200327monthly0.5https://www.biopharmawatch.com/news/ATHE/proposed-issue-of-securities-announcement-summary-entity-name-alterity-therapeutics-limite-athe-20200326monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-limited-appendix-4d-half-year-ended-31-december-2019-name-of-entity--athe-20200227monthly0.5https://www.biopharmawatch.com/news/ATHE/interim-consolidated-financial-statements-of-alterity-therapeutics-limited-and-subsidiarie-athe-20200227monthly0.5https://www.biopharmawatch.com/news/ATHE/receives-non-compliance-notice-regarding-nasdaq-athe-20200207monthly0.5https://www.biopharmawatch.com/news/ATHE/4c-q2-fy20-quarterly-cash-flow-report-athe-20200131monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-2-7-3-10-3-3-10-4-3-10-5-athe-20200117monthly0.5https://www.biopharmawatch.com/news/ATHE/receives-a-4-8-million-r-d-tax-incentive-refund-athe-20200115monthly0.5https://www.biopharmawatch.com/news/ATHE/upcoming-release-of-warrants-from-voluntary-athe-20191211monthly0.5https://www.biopharmawatch.com/news/ATHE/results-of-annual-general-meeting-athe-20191126monthly0.5https://www.biopharmawatch.com/news/ATHE/address-2019-annual-general-meeting-athe-20191126monthly0.5https://www.biopharmawatch.com/news/ATHE/jfif-6-6-424-lddl-z-6-6-424-lddl-z-v-16-athe-20191126monthly0.5https://www.biopharmawatch.com/news/ATHE/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-athe-20191121monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-agm-investor-conference-call-athe-20191120monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-s-lead-drug-candidate-athe-20191118monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-q1-fy20-quarterly-athe-20191030monthly0.5https://www.biopharmawatch.com/news/ATHE/of-annual-general-meeting-and-explanatory-memorandum-athe-20191025monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-presents-clinical-data-on-pbt434-athe-20190924monthly0.5https://www.biopharmawatch.com/news/ATHE/to-present-at-the-janney-healthcare-conference-in-new-york-athe-20190909monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-filed-form-20-f-athe-20190903monthly0.5https://www.biopharmawatch.com/news/ATHE/4e-preliminary-final-report-athe-20190830monthly0.5https://www.biopharmawatch.com/news/ATHE/rules-4-7-3-and-4-10-3-1-appendix-4g-key-to-disclosures-corporate-governance-council-princ-athe-20190830monthly0.5https://www.biopharmawatch.com/news/ATHE/upcoming-release-of-shares-from-voluntary-athe-20190805monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-exhibit-1-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-app-athe-20190801monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-quarterly-report-exhibit-1-appendix-4c-q4-fy19-quarterly-cash-flow-report-high-athe-20190731monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-successful-completion-of-phase-1-clinical-trial-exhibit-1--athe-20190729monthly0.5https://www.biopharmawatch.com/news/ATHE/interim-consolidated-financial-statements-of-prana-biotechnology-limited-and-subsidiaries--athe-20190228monthly0.5https://www.biopharmawatch.com/news/ATHE/market-announcement-24-december-2018-prana-biotechnology-limited-asx-pbt-trading-halt-desc-athe-20181227monthly0.5https://www.biopharmawatch.com/news/ATHE/pbt434-data-to-be-presented-at-the-international-congress-of-parkinson-s-disease-and-movem-athe-20180709monthly0.5https://www.biopharmawatch.com/news/ATHE/first-volunteers-dosed-in-phase-i-clinical-trial-of-pbt434-prana-s-lead-therapy-for-parkin-athe-20180704monthly0.5https://www.biopharmawatch.com/news/ATHE/interim-consolidated-financial-statements-of-prana-biotechnology-limited-and-subsidiaries--athe-20180228monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-commences-research-collaboration-with-takeda-for-the-treatment-of-parkinson-s-diseas-athe-20170718monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-s-pbt434-lowers-alpha-synuclein-and-prevents-neurodegeneration-scientific-journal-ac-athe-20170703monthly0.5https://www.biopharmawatch.com/news/ATHE/change-of-address-melbourne-june-26-th-2017-in-accordance-with-listing-rule-3-14-the-compa-athe-20170626monthly0.5https://www.biopharmawatch.com/news/ATHE/david-stamler-as-chief-medical-officer-to-lead-clinical-development-athe-20170605monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-biotechnology-s-anti-parkinsonian-compound-pbt434-presented-at-13-th-international-c-athe-20170330monthly0.5https://www.biopharmawatch.com/news/ATHE/interim-consolidated-financial-statements-of-prana-biotechnology-limited-and-subsidiaries--athe-20170224monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-receives-approval-for-12-month-open-label-extension-study-in-alzheimer-s-disease-mel-athe-20130816monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-completes-phase-2-huntington-disease-trial-with-pbt2-melbourne-athe-20130816monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-prepares-for-next-steps-in-the-pbt2-development-path-to-market-and-commercialization-athe-20130816monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-doses-first-patient-in-pbt2-alzheimer-s-extension-study-melbourne-monday-29-th-july--athe-20130816monthly0.5https://www.biopharmawatch.com/news/ATHE/securities-and-exchange-commission-athe-20121212monthly0.5https://www.biopharmawatch.com/news/ATHE/further-information-prana-s-pbt2-clinical-trials-cited-as-most-advanced-in-addressing-neur-athe-20120920monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-monday-17-athe-20120918monthly0.5https://www.biopharmawatch.com/news/ATHE/medical-science-has-made-a-significant-number-of-breakthroughs-over-the-past-century-the-a-athe-20090928monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-secures-6-million-additional-financing-provides-greater-opportunity-to-advance-prana-athe-20090909monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-athe-20090430monthly0.5https://www.biopharmawatch.com/news/ATHE/jfif-c-1-3-mqypdx-egc-c-cb8bcccccccccccccccccccccccccccccccccccccccccccccccccc-0-1a-qa-q-2-athe-20090304monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4d-interim-financial-report-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-b-athe-20090218monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-athe-20090130monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20081204monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-thursday--athe-20081204monthly0.5https://www.biopharmawatch.com/news/ATHE/results-of-annual-general-meeting-28-th-of-november-2008-prana-biotechnology-limited-asx-p-athe-20081201monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20081117monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-monday-17-athe-20081117monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-athe-20081031monthly0.5https://www.biopharmawatch.com/news/ATHE/notice-of-annual-general-meeting-incorporating-explanatory-memorandum-and-proxy-form-to-be-athe-20081020monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-friday-17-athe-20081017monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20081017monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-wednesday-athe-20081015monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-announces-filing-of-annual-report-dated-athe-20080925monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20080903monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-wednesday-athe-20080903monthly0.5https://www.biopharmawatch.com/news/ATHE/unassociated-document-appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-app-athe-20080827monthly0.5https://www.biopharmawatch.com/news/ATHE/unassociated-document-company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corp-athe-20080827monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-athe-20080731monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20080731monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-co-founding-scientist-professor-rudolph-tanzi-addressed-u-s-senate-special-committee-athe-20080708monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20080626monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-wednesday-athe-20080626monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20080612monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20080609monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-monday-2--athe-20080606monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-biotechnology-ltd-acn-080-699-065-annexure-to-notice-of-change-of-interests-of-subst-athe-20080528monthly0.5https://www.biopharmawatch.com/news/ATHE/jfif-c-1-3-mqypdx-egc-c-cb8bcccccccccccccccccccccccccccccccccccccccccccccccccc-0-1a-qa-q-2-athe-20080528monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-athe-20080527monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-tuesday-2-athe-20080527monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-announces-7-million-placement-to-fund-research-programs-additional-investment-from-e-athe-20080521monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-thursday--athe-20080515monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-athe-20080314monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corporations-act-friday-14-athe-20080314monthly0.5https://www.biopharmawatch.com/news/ATHE/company-announcement-prana-responds-to-press-comments-on-visits-by-pharmaceutical-executiv-athe-20080304monthly0.5https://www.biopharmawatch.com/news/ATHE/v105115-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-athe-20080228monthly0.5https://www.biopharmawatch.com/news/ATHE/v105113-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-athe-20080227monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-announces-success-in-phase-iia-clinical-trial-of-pbt2-in-early-alzheimer-s-disease-p-athe-20080226monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-athe-20080131monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-announces-completion-of-phase-iia-trial-of-pbt2-in-alzheimer-s-disease-patients-resu-athe-20080102monthly0.5https://www.biopharmawatch.com/news/ATHE/th-of-december-2007-prana-biotechnology-limited-asx-pbt-results-of-annual-general-meeting--athe-20071220monthly0.5https://www.biopharmawatch.com/news/ATHE/unassociated-document-appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-app-athe-20071024monthly0.5https://www.biopharmawatch.com/news/ATHE/unassociated-document-company-announcement-asx-pbt-notice-under-section-708a-5-of-the-corp-athe-20071024monthly0.5https://www.biopharmawatch.com/news/ATHE/page-1-of-2-15-july-2001-form-604-corporations-act-2001-section-671b-notice-of-change-of-i-athe-20071022monthly0.5https://www.biopharmawatch.com/news/ATHE/wang2-jfif-c-1-3-mqypdx-egc-c-cb8bcccccccccccccccccccccccccccccccccccccccccccccccccc-1a-athe-20070831monthly0.5https://www.biopharmawatch.com/news/ATHE/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-athe-20070730monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-biotechnology-presents-new-key-findings-on-pbt2-pbt2-alters-biomarkers-and-rapidly-i-athe-20070606monthly0.5https://www.biopharmawatch.com/news/ATHE/v074599-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-athe-20070511monthly0.5https://www.biopharmawatch.com/news/ATHE/corresponding-period-half-year-ended-31-december-2005-athe-20070228monthly0.5https://www.biopharmawatch.com/news/ATHE/dosing-commenced-in-phase-iia-pbt2-trial-of-alzheimer-s-patients-screening-of-patients-und-athe-20061219monthly0.5https://www.biopharmawatch.com/news/ATHE/prana-biotechnology-co-founding-scientist-receives-grand-hamdan-international-award-for-me-athe-20061219monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20260429monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20260218monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20260123monthly0.5https://www.biopharmawatch.com/news/BHC/bausch-lomb-completes-refinancing-of-outstanding-term-b-loans-bhc-20260102monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-garen-sarafian-ir-bauschhealth-com-877-281-6642-toll-free-media-contact-k-bhc-20251223monthly0.5https://www.biopharmawatch.com/news/BHC/bausch-lomb-announces-refinancing-of-outstanding-term-b-loans-bhc-20251212monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-garen-sarafian-ir-bauschhealth-com-877-281-6642-toll-free-media-contact-k-bhc-20251124monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20251029monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20250815monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20250730monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20250724monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20250710monthly0.5https://www.biopharmawatch.com/news/BHC/bausch-lomb-announces-closing-of-upsized-675-million-senior-secured-notes-offering-and-par-bhc-20250626monthly0.5https://www.biopharmawatch.com/news/BHC/bausch-lomb-announces-pricing-of-upsized-senior-secured-notes-offering-bhc-20250618monthly0.5https://www.biopharmawatch.com/news/BHC/bausch-lomb-announces-launch-of-senior-secured-notes-offering-and-refinancing-of-credit-ag-bhc-20250610monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20250430monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-garen-sarafian-ir-bauschhealth-com-877-281-6642-toll-free-media-contact-k-bhc-20250414monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20250219monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20241030monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20240801monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-katie-savastano-ir-bauschhealth-com-corporat-bhc-20240719monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-garen-sarafian-kevin-wiggins-ir-bauschhealth-com-corporate--bhc-20240502monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contacts-media-contact-solebury-strategic-communications-kevin-wiggins-ir-bauschh-bhc-20240222monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contacts-kevin-wiggins-ir-bauschhealth-com-corporate-communications-bhc-20240201monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contacts-media-contact-lisa-wilson-kevin-wiggins-ir-bauschhealth-com-corporate-co-bhc-20231102monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-mark-maico-ir-bauschhealth-com-908-541-2102-877-281-6642-toll-free-media--bhc-20230929monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contacts-media-contact-john-o-connor-kevin-wiggins-ir-bauschhealth-com-corporate--bhc-20230918monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contacts-john-o-connor-ir-bauschhealth-com-908-541-2973-media-contact-kevin-wiggi-bhc-20230911monthly0.5https://www.biopharmawatch.com/news/BHC/independent-auditors-report-to-management-of-novartis-pharma-ag-report-on-the-audit-of-the-bhc-20230906monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contacts-media-contact-john-o-connor-kevin-wiggins-ir-bauschhealth-com-corporate--bhc-20230803monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-mark-maico-kevin-wiggins-ir-bauschhealth-com-corporate-comm-bhc-20230707monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-mark-maico-kevin-wiggins-ir-bausckhealth-com-coporate-commu-bhc-20230630monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-mark-maico-kevin-wiggins-ir-bauschhealth-com-corporate-comm-bhc-20230504monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-kevin-wiggins-ir-bauschhealth-com-corporate-communications--bhc-20230301monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-mark-maico-kevin-wiggins-ir-bauschhealth-com-corporate-comm-bhc-20230223monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contacts-christina-cheng-kevin-wiggins-ir-bauschhealth-com-corporat-bhc-20221129monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-christina-cheng-kevin-wiggins-ir-bauschhealth-com-corporate-bhc-20221103monthly0.5https://www.biopharmawatch.com/news/BHC/document-investor-contact-media-contacts-christina-cheng-kevin-wiggins-ir-bauschhealth-com-bhc-20220928monthly0.5https://www.biopharmawatch.com/news/BHC/document-investor-contact-media-contacts-christina-cheng-kevin-wiggins-ir-bauschhealth-com-bhc-20220914monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contacts-christina-cheng-kevin-wiggins-ir-bauschhealth-com-corporat-bhc-20220830monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contacts-christina-cheng-kevin-wiggins-ir-bauschhealth-com-corporat-bhc-20220822monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-christina-cheng-kevin-wiggins-ir-bauschhealth-com-corporate-bhc-20220809monthly0.5https://www.biopharmawatch.com/news/BHC/document-investor-contact-media-contacts-christina-cheng-kevin-wiggins-ir-bauschhealth-com-bhc-20220728monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-christina-cheng-christina-cheng-bauschhealth-com-514-856-3855-877-281-664-bhc-20220623monthly0.5https://www.biopharmawatch.com/news/BHC/agenda-2-3-4-1-call-to-order-procedural-matters-voting-items-and-results-management-presen-bhc-20220621monthly0.5https://www.biopharmawatch.com/news/BHC/of-our-form-8-k-filed-on-bhc-20220511monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-christina-cheng-lainie-keller-christina-cheng-bauschhealth--bhc-20220510monthly0.5https://www.biopharmawatch.com/news/BHC/redacted-certain-identified-information-indicated-by-has-been-excluded-from-the-exhibit-be-bhc-20220428monthly0.5https://www.biopharmawatch.com/news/BHC/redacted-certain-identified-information-indicated-by-has-been-excluded-from-the-exhibit-be-bhc-20220330monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20220223monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20220127monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20220118monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20220113monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20211102monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20211021monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210803monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-arthur-shannon-arthur-shannon-bauschhealth-com-514-856-3855-877-281-6642--bhc-20210621monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210607monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210524monthly0.5https://www.biopharmawatch.com/news/BHC/revenues-our-revenues-were-8-601-million-and-8-380-million-for-2019-and-2018-respectively--bhc-20210504monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210504monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210427monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210331monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210311monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210224monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20210112monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20201118monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20201103monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20201008monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20200806monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20200511monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20200507monthly0.5https://www.biopharmawatch.com/news/BHC/annual-meeting-of-shareholders-bhc-20200428monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20200219monthly0.5https://www.biopharmawatch.com/news/BHC/th-annual-j-p-morgan-healthcare-conference-bhc-20200113monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20191217monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20191104monthly0.5https://www.biopharmawatch.com/news/BHC/investor-media-contact-arthur-shannon-arthur-shannon-bauschhealth-com-514-856-3855-877-281-bhc-20190806monthly0.5https://www.biopharmawatch.com/news/BHC/investor-media-contact-arthur-shannon-arthur-shannon-bauschhealth-com-514-856-3855-877-281-bhc-20190523monthly0.5https://www.biopharmawatch.com/news/BHC/investor-media-contact-arthur-shannon-arthur-shannon-bauschhealth-com-514-856-3855-877-281-bhc-20190509monthly0.5https://www.biopharmawatch.com/news/BHC/investor-media-contact-arthur-shannon-arthur-shannon-bauschhealth-com-514-856-3855-877-281-bhc-20190506monthly0.5https://www.biopharmawatch.com/news/BHC/this-presentation-contains-forward-looking-information-and-statements-within-the-meaning-o-bhc-20190430monthly0.5https://www.biopharmawatch.com/news/BHC/investor-media-contact-arthur-shannon-arthur-shannon-bauschhealth-com-514-856-3855-877-281-bhc-20190308monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20190222monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20190220monthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-enters-into-definitive-stalking-horse-agreement-to-acquire-substantially-all-bhc-20181212monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20181127monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20181107monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contacts-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-c-bhc-20181024monthly0.5https://www.biopharmawatch.com/news/BHC/has-been-revised-from-the-item-7-management-s-discussion-and-analysis-of-financial-conditi-bhc-20180810monthly0.5https://www.biopharmawatch.com/news/BHC/investor-contact-media-contact-arthur-shannon-lainie-keller-arthur-shannon-bauschhealth-co-bhc-20180807monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20180601monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20180517monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-qu-bec-h7l-4a8-phone-514-744-679-bhc-20180508monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20180312monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-qu-bec-h7l-4a8-phone-514-744-679-bhc-20180228monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20171215monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20171204monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20171114monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-qu-bec-h7l-4a8-phone-514-744-679-bhc-20171107monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20171016monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20171002monthly0.5https://www.biopharmawatch.com/news/BHC/excerpts-from-the-preliminary-offering-memorandum-dated-bhc-20171002monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-qu-bec-h7l-4a8-phone-514-744-679-bhc-20170808monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20170619monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20170608monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20170509monthly0.5https://www.biopharmawatch.com/news/BHC/valeant-announces-the-early-results-of-tender-offers-for-its-6-75-senior-notes-due-2018-bhc-20170320monthly0.5https://www.biopharmawatch.com/news/BHC/information-elif-mcdonald-elif-mcdonald-valeant-com-514-856-3855-877-281-6642-toll-free-me-bhc-20170310monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20170309monthly0.5https://www.biopharmawatch.com/news/BHC/information-elif-mcdonald-elif-mcdonald-valeant-com-514-856-3855-877-281-6642-toll-free-me-bhc-20170306monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20170228monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20170109monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20170104monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20161212monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20161108monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20160822monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20160809monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20160728monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20160607monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20160520monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20160509monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20160429monthly0.5https://www.biopharmawatch.com/news/BHC/of-valeant-pharmaceuticals-international-inc-dated-april-22-2016-ex99-1-htm-international--bhc-20160425monthly0.5https://www.biopharmawatch.com/news/BHC/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-bhc-20160413monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-tm-announces-pricing-of-underwritten-offering-of-common-stock-bedford-m-ocul-20250930monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2025-financial-results-and-business-highlights-o-ocul-20250805monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2025-results-and-business-highlights-axpaxli-sol--ocul-20250505monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-full-year-2024-results-and-business-highligh-ocul-20250303monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2024-results-and-business-highlights-sol-1-expect-ocul-20241114monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inc-amendment-no-4-to-2019-inducement-stock-incentive-plan-ocular-thera-ocul-20241004monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2024-results-sol-r-axpaxli-repeat-dosing-study-i-ocul-20240807monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2024-results-recent-leadership-appointments-put-o-ocul-20240507monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inc-amendment-no-3-to-2019-inducement-stock-incentive-plan-ocular-thera-ocul-20240416monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-full-year-2023-results-leadership-appointmen-ocul-20240311monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inc-announces-325-0-million-private-placement-bedford-ma-ocul-20240222monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-tm-announces-pricing-of-public-offering-of-common-stock-ocul-20231213monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-provides-third-quarter-2023-financial-results-and-corporate-update-fda--ocul-20231107monthly0.5https://www.biopharmawatch.com/news/OCUL/transformative-investigational-tyrosine-kinase-inhibitor-therapy-for-retinal-vascular-dise-ocul-20231004monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-provides-second-quarter-2023-financial-results-and-corporate-update-dex-ocul-20230807monthly0.5https://www.biopharmawatch.com/news/OCUL/month-10-analysis-presented-at-angiogenesis-2023-month-7-analysis-presented-at-aao-2022-1--ocul-20230612monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-provides-first-quarter-2023-financial-results-and-corporate-update-12-m-ocul-20230508monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-provides-fourth-quarter-and-year-end-2022-results-and-corporate-update--ocul-20230306monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-provides-2022-year-end-corporate-update-and-reviews-expected-2023-miles-ocul-20230106monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2022-financial-results-and-business-update-announ-ocul-20221107monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2022-financial-results-and-business-update-inter-ocul-20220808monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2022-financial-results-and-business-update-dexten-ocul-20220509monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-year-end-2021-financial-results-and-business-ocul-20220228monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2021-financial-results-and-business-update-dexten-ocul-20211108monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2021-financial-results-and-business-update-dexte-ocul-20210719monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-second-quarter-2021-preliminary-net-product-revenue-of-11-7-m-ocul-20210722monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2021-financial-results-and-business-update-dexten-ocul-20210505monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-year-end-2020-financial-results-and-business-ocul-20210311monthly0.5https://www.biopharmawatch.com/news/OCUL/cohort-1-n-6-until-month-9-cohort-2-n-7-until-month-9-n-6-for-month-11-n-6-for-month-12-n--ocul-20210129monthly0.5https://www.biopharmawatch.com/news/OCUL/otx-tic-an-intracameral-hydrogel-based-travoprost-implant-to-treat-patients-with-glaucoma--ocul-20210120monthly0.5https://www.biopharmawatch.com/news/OCUL/transforming-drug-delivery-leveraging-a-novel-technology-platform-nasdaq-ocul-antony-matte-ocul-20210111monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-proposed-public-offering-of-common-stock-ocul-20201214monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2020-financial-results-and-business-update-octobe-ocul-20201105monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-proposed-public-offering-of-common-stock-ocul-20201013monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-preliminary-net-product-revenue-of-5-8-million-to-5-9-million-ocul-20201007monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2020-financial-results-and-business-update-newly-ocul-20200807monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-presents-at-the-12-th-annual-ophthalmology-innovation-summit-ois-dexten-ocul-20200717monthly0.5https://www.biopharmawatch.com/news/OCUL/nasdaq-ocul-transforming-drug-delivery-leveraging-a-novel-technology-platform-antony-matte-ocul-20200716monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-proposed-public-offering-of-common-stock-ocul-20200519monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2020-financial-results-and-business-update-presen-ocul-20200508monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-provides-business-update-and-response-to-covid-19-global-pandemic-bedfo-ocul-20200413monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-year-end-2019-financial-results-and-business-ocul-20200312monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-preliminary-fourth-quarter-2019-net-product-revenue-and-provi-ocul-20200303monthly0.5https://www.biopharmawatch.com/news/OCUL/if-the-study-eye-was-given-other-iop-lowering-medication-the-iop-value-was-removed-from-th-ocul-20200207monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2019-financial-results-and-business-update-over-7-ocul-20191112monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2019-financial-results-and-business-update-comme-ocul-20190807monthly0.5https://www.biopharmawatch.com/news/OCUL/otx-tp-phase-3-trial-topline-efficacy-results-mean-intraocular-pressure-diurnal-timepoints-ocul-20190606monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2019-financial-results-and-business-update-dexten-ocul-20190510monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inc-settles-litigation-with-mati-therapeutics-inc-bedford-mass-business-ocul-20190430monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-year-end-2018-financial-results-and-business-ocul-20190307monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2018-financial-results-and-business-update-dexten-ocul-20181107monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-receives-fda-warning-letter-related-to-resure-sealant-bedford-mass-busi-ocul-20181019monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2018-financial-results-and-business-update-dexte-ocul-20180807monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2018-financial-results-and-business-update-target-ocul-20180508monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-year-end-2017-financial-results-and-business-ocul-20180308monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-proposed-public-offering-of-common-stock-ocul-20180124monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-provides-legal-update-ocul-20171222monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2017-financial-results-and-provides-corporate-upd-ocul-20171107monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2017-financial-results-and-provides-corporate-up-ocul-20170808monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2017-financial-results-pdufa-target-action-date-o-ocul-20170505monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-full-year-2016-financial-results-pdufa-targe-ocul-20170310monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inc-announces-public-offering-of-common-stock-ocul-20170123monthly0.5https://www.biopharmawatch.com/news/OCUL/overview-of-ocular-therapeutix-we-are-a-biopharmaceutical-company-focused-on-the-developme-ocul-20161130monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2016-financial-results-and-provides-corporate-upd-ocul-20161109monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2016-financial-results-and-provides-corporate-up-ocul-20160809monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-receives-complete-response-letter-from-fda-for-its-nda-for-dextenza-for-ocul-20160725monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-topline-results-of-second-phase-3-clinical-trial-of-dextenza--ocul-20160606monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-first-quarter-2016-financial-results-and-provides-corporate-upd-ocul-20160510monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-tm-reports-fourth-quarter-and-full-year-2015-financial-results-pdufa-ta-ocul-20160310monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2015-financial-results-advances-in-clinical-progr-ocul-20151110monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-tm-reports-second-quarter-2015-financial-results-clinical-programs-adva-ocul-20150810monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-tm-announces-plans-to-proceed-with-an-nda-submission-for-otx-dp-for-tre-ocul-20150515monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-fourth-quarter-and-full-year-2014-financial-results-both-primar-ocul-20150310monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-third-quarter-2014-financial-results-completed-enrollment-for-s-ocul-20141112monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-second-quarter-2014-financial-results-bedford-mass-business-w-ocul-20140828monthly0.5https://www.biopharmawatch.com/news/ATAI/unaudited-pro-forma-condensed-combined-financial-information-introduction-on-atai-20260306monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-busin-atai-20260306monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-appoints-michael-faerm-as-chief-financial-officer-new-york-united-states-febru-atai-20260219monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-provides-update-and-outlook-for-2026-ahead-of-j-p-morgan-healthcare-conference-atai-20260108monthly0.5https://www.biopharmawatch.com/news/PLSE/taxonomy2022-pulse-biosciences-reports-third-quarter-202-2-financial-results-xfeff-hayward-plse-20221110monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-strategic-change-of-focus-in-support-of-significant-additional-plse-20220920monthly0.5https://www.biopharmawatch.com/news/PLSE/taxonomy2022-pulse-biosciences-reports-second-quarter-202-2-financial-results-xfeff-haywar-plse-20220810monthly0.5https://www.biopharmawatch.com/news/PLSE/taxonomy2022-pulse-biosciences-inc-announces-the-closing-of-its-rights-offering-xfeff-hayw-plse-20220609monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-announces-preliminary-results-for-its-rights-offering-xfeff-hayward--plse-20220526monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-announces-changes-to-its-rights-offering-xfeff-hayward-calif-busines-plse-20220519monthly0.5https://www.biopharmawatch.com/news/PLSE/p-ulse-biosciences-reports-first-quarter-2022-financial-results-xfeff-hayward-calif-busine-plse-20220511monthly0.5https://www.biopharmawatch.com/news/PLSE/the-terms-and-conditions-of-the-rights-offering-are-set-forth-in-the-company-s-prospectus--plse-20220504monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-announces-rights-offering-hayward-calif-business-wire-plse-20220414monthly0.5https://www.biopharmawatch.com/news/PLSE/p-ulse-biosciences-reports-fourth-quarter-full-year-2021-financial-results-xfeff-hayward-c-plse-20220331monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-the-appointment-of-kevin-danahy-as-chief-commercial-officer-ha-plse-20220214monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-provides-an-update-on-recent-fda-510-k-submission-hayward-calif-business-plse-20220208monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-preliminary-fourth-quarter-and-full-year-2021-financial-and-op-plse-20220111monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-reports-third-quarter-2021-financial-results-xfeff-hayward-calif-busines-plse-20211115monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-xfeff-pulse-biosciences-appoints-laureen-debuono-to-its-board-of-directors-xfeff-hay-plse-20211006monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-xfeff-pulse-biosciences-announces-appointment-of-mitchell-e-levinson-as-chief-strate-plse-20210819monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-reports-second-quarter-2021-financial-results-xfeff-hayward-calif-busine-plse-20210809monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-50-million-private-placement-hayward-calif-business-wire-x2013-plse-20210701monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-health-canada-approval-for-cellfx-xae-system-xfeff-company-to--plse-20210609monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-reports-first-quarter-2021-financial-results-xfeff-hayward-calif-busines-plse-20210510monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-reports-fourth-quarter-and-full-year-2020-financial-results-xfeff-haywar-plse-20210222monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-announces-at-the-market-equity-offering-program-plse-20210204monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-fda-clearance-for-the-cellfx-xae-system-xfeff-cellfx-system-de-plse-20210203monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-ce-mark-approval-for-cellfx-xae-system-xfeff-cellfx-system-del-plse-20210125monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-announces-redemption-of-warrants-xfeff-plse-20210105monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-reports-third-quarter-2020-financial-results-xfeff-hayward-calif-busines-plse-20201109monthly0.5https://www.biopharmawatch.com/news/PLSE/p-ulse-biosciences-reports-second-quarter-2020-financial-results-xfeff-hayward-calif-busin-plse-20200810monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-appoints-richard-van-den-broek-to-board-of-directors-xfeff-hayward-c-plse-20200806monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-announces-closing-of-30-million-rights-offering-plse-20200616monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-plse-20200608monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-plse-20200514monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-reports-first-quarter-2020-financial-results-xfeff-hayward-calif-b-plse-20200511monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-announces-updated-structure-dates-and-pricing-terms-for-rights-offer-plse-20200501monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-files-registration-statement-for-rights-offering-plse-20200406monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-report-fourth-quarter-and-full-year-2019-financial-results-xfeff-x-plse-20200316monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-provides-update-on-fda-510-k-submission-for-the-cellfx-system-in-dermato-plse-20200214monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarterly-investor-conference-call-xfeff-conference-call-today-at--plse-20191107monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarterly-investor-conference-call-xfeff-conference-call-today-at--plse-20190808monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-xfeff-c-o-broadridg-e-corpor-a-t-e-issue-r-solution-s-inc-p-o-box-1342-brentwood-ny--plse-20190531monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarterly-investor-conference-call-xfeff-conference-call-today-at--plse-20190430monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-xfeff-pulse-biosciences-appoints-mitchell-levinson-to-board-of-directors-hayward-cal-plse-20190319monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarterly-investor-conference-call-xfeff-first-patient-treated-in--plse-20190207monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-announces-two-appointments-focused-on-cellfx-tm-commercialization--plse-20190117monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-inc-announces-closing-of-its-45-million-rights-offering-xfeff-hayw-plse-20181214monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-inc-announces-over-subscription-pricing-and-preliminary-results-fo-plse-20181206monthly0.5https://www.biopharmawatch.com/news/PLSE/forward-looking-statements-this-investor-overview-provided-by-pulse-biosciences-inc-contai-plse-20181120monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-announces-commencement-of-rights-offering-hayward-calif-business-wir-plse-20181119monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-inc-announces-record-date-subscription-pricing-a-nd-expiration-dat-plse-20181107monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarterly-investor-conference-call-xfeff-conference-call-today-at--plse-20181030monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-files-registration-statement-for-rights-offering-xfeff-hayward-cal-plse-20181025monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarterly-investor-conference-call-xfeff-conference-call-today-at--plse-20180731monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarterly-investor-conference-call-xfeff-conference-call-today-at--plse-20180508monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarterly-investor-conference-call-xfeff-c-onference-call-today-at-plse-20180316monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-quarterly-investor-conference-call-xfeff-investor-conference-call-today--plse-20171107monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-transition-of-board-of-directors-e-xtend-s-a-ppreciation-to-re-plse-20171103monthly0.5https://www.biopharmawatch.com/news/PLSE/p-ulse-biosciences-announces-30-million-private-placement-hayward-calif-business-wire-sept-plse-20170922monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-announces-withdrawal-and-planned-resubmission-of-510-k-application-plse-20170908monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-quarter-l-y-investor-and-analyst-conference-call-investor-conference-cal-plse-20170727monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quarter-l-y-investor-conference-call-investor-conference-call-toda-plse-20170504monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quartery-investor-conference-call-investor-conference-call-today-a-plse-20170314monthly0.5https://www.biopharmawatch.com/news/PLSE/02-10-pulse-biosciences-announces-healthcare-executives-and-entrepreneurs-robert-duggan-an-plse-20170210monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-quartery-nano-pulse-stimulation-nps-update-investor-conference-cal-plse-20161114monthly0.5https://www.biopharmawatch.com/news/PLSE/xfeff-pulse-biosciences-provides-overview-of-corporate-strategy-and-updates-on-clinical-de-plse-20160907monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-amtagvi-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-au-iova-20260603monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-highlights-positive-first-quarter-2026-results-business-achievemen-iova-20260507monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-2026-iovance-biotherapeutics-inc-corporate-overview-january-20-iova-20260109monthly0.5https://www.biopharmawatch.com/news/IOVA/xa9-2025-iovance-biotherapeutics-inc-xa9-2025-iovance-biotherapeutics-inc-corporate-overvi-iova-20250829monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-corleen-roche-as-chief-financial-officer-iova-20250715monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-financial-results-and-corporate-updates-for-first-quarter--iova-20250508monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-financial-results-and-corporate-updates-for-fourth-quarter-iova-20250227monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-dan-kirby-as-chief-commercial-officer-iova-20250210monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-2024-iovance-biotherapeutics-inc-corporate-overview-november-2-iova-20241108monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-financial-results-and-corporate-updates-for-third-quarter--iova-20241107monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-2024-iovance-biotherapeutics-inc-corporate-overview-august-202-iova-20240731monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-financial-results-and-corporate-updates-for-second-quarter-iova-20240808monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-submits-marketing-authorization-application-to-european-medicines--iova-20240628monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-2024-iovance-biotherapeutics-inc-corporate-overview-iova-20240531monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-in-frontline-advanced-melanoma-at-asco-202-iova-20240523monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-first-quarter-2024-financial-results-and-corporate-updates-iova-20240509monthly0.5https://www.biopharmawatch.com/news/IOVA/leo-shumacher-derivatively-on-behalf-of-iovance-biotherapeutics-inc-plaintiff-v-iain-dukes-iova-20240403monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-fda-has-lifted-clinical-hold-on-the-iov-lun-202-registra-iova-20240304monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-2024-iovance-biotherapeutics-inc-corporate-overview-iova-20240228monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-co-iova-20240228monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-pricing-of-211-million-underwritten-offering-of-comm-iova-20240220monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-amtagvi-tm-lifileucel-receives-u-s-fda-accelerated-approval-for-advanced-melanom-iova-20240216monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-2024-iovance-biotherapeutics-inc-corporate-overview-iova-20240125monthly0.5https://www.biopharmawatch.com/news/IOVA/2024-iovance-biotherapeutics-inc-iova-20240108monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-program-update-for-ln-145-in-non-small-cell-lun-iova-20231227monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-third-quarter-and-year-to-date-2023-financial-results-and--iova-20231107monthly0.5https://www.biopharmawatch.com/news/IOVA/u-s-food-and-drug-administration-updates-prescription-drug-user-fee-act-pdufa-action-date--iova-20230915monthly0.5https://www.biopharmawatch.com/news/IOVA/adam-schoenfeld-memorial-sloan-kettering-cancer-center-new-york-ny-usa-1-multicenter-phase-iova-20230818monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-second-quarter-and-first-half-2023-financial-results-and-c-iova-20230808monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-closing-of-172-5-million-common-stock-public-offering-of-iova-20230713monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-proposed-public-offering-of-common-stock-iova-20230710monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-regulatory-and-clinical-updates-for-til-therapy-in-advan-iova-20230710monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-u-s-food-and-drug-administration-acceptance-of-the-biolo-iova-20230530monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-first-quarter-2023-financial-results-and-corporate-updates-iova-20230509monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-completes-biologics-license-application-bla-submission-for-lifileu-iova-20230324monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-co-iova-20230228monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-provides-corporate-clinical-and-regulatory-updates-acquisition-of--iova-20230123monthly0.5https://www.biopharmawatch.com/news/IOVA/xa9-2023-iovance-biotherapeutics-inc-xa9-2023-iovance-biotherapeutics-inc-corporate-overvi-iova-20230111monthly0.5https://www.biopharmawatch.com/news/IOVA/privileged-and-confidential-iovance-biotherapeutics-provides-update-on-biologics-license-a-iova-20221118monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-third-quarter-and-year-to-date-2022-financial-results-and--iova-20221103monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-initiates-biologics-license-application-bla-submission-for-lifileu-iova-20220825monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-second-quarter-and-first-half-2022-financial-results-and-c-iova-20220804monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-wendy-l-dixon-ph-d-to-board-of-directors-iova-20220613monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-positive-clinical-data-for-lifileucel-in-advanced-melano-iova-20220526monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-corporate-overview-may-2022-1-2-forward-looking-statements-202-iova-20220513monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-first-quarter-2022-financial-results-and-corporate-updates-iova-20220505monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-regulatory-and-clinical-updates-for-lifileucel-in-melano-iova-20220405monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-co-iova-20220224monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-raj-k-puri-m-d-ph-d-to-join-leadership-team-iova-20220110monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-third-quarter-and-year-to-date-2021-financial-results-and--iova-20211104monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-second-quarter-and-first-half-2021-financial-results-and-c-iova-20210805monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-2-iova-20210629monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-provides-regulatory-update-for-lifileucel-potency-assays-iova-20210518monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-first-quarter-2021-financial-results-and-corporate-updates-iova-20210506monthly0.5https://www.biopharmawatch.com/news/IOVA/tumor-infiltrating-lymphocyte-cell-therapy-for-treatment-of-solid-tumors-april-2021-2021-i-iova-20210412monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-igor-bilinsky-as-chief-operating-officer-iova-20210315monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-co-iova-20210225monthly0.5https://www.biopharmawatch.com/news/IOVA/tumor-infiltrating-lymphocyte-cell-therapy-for-treatment-of-solid-tumors-january-2021-2021-iova-20210107monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-jean-marc-bellemin-as-chief-financial-officer-iova-20201214monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-third-quarter-and-year-to-date-2020-financial-results-and--iova-20201105monthly0.5https://www.biopharmawatch.com/news/IOVA/title-safety-and-efficacy-of-tumor-infiltrating-lymphocytes-til-ln-145-in-combination-with-iova-20201014monthly0.5https://www.biopharmawatch.com/news/IOVA/investigating-the-power-of-tumor-infiltrating-lymphocytes-for-treatment-of-cancer-october--iova-20201005monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-second-quarter-2020-financial-results-and-provides-a-corpo-iova-20200806monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-closing-of-603-7-million-common-stock-public-offerin-iova-20200602monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-proposed-public-offering-of-common-stock-iova-20200527monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-reports-pivotal-cohort-4-data-for-tumor-infiltrating-lymphocyte-til-therapy-lifile-iova-20200527monthly0.5https://www.biopharmawatch.com/news/IOVA/investigating-the-power-of-tumor-infiltrating-lymphocytes-for-treatment-of-cancer-may-2020-iova-20200522monthly0.5https://www.biopharmawatch.com/news/IOVA/in-the-united-states-district-court-for-the-district-of-delaware-x-in-re-iovance-biotherap-iova-20200508monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-first-quarter-2020-financial-results-and-provides-a-corpor-iova-20200505monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-pr-iova-20200225monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-third-quarter-and-september-year-to-date-2019-financial-re-iova-20191104monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-second-quarter-2019-financial-results-and-provides-corpora-iova-20190801monthly0.5https://www.biopharmawatch.com/news/IOVA/july-2019-2019-iovance-biotherapeutics-inc-iova-20190702monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-athena-countouriotis-m-d-to-board-of-directors-iova-20190611monthly0.5https://www.biopharmawatch.com/news/IOVA/june-2019-2019-iovance-biotherapeutics-inc-corporate-presentation-this-presentation-contai-iova-20190603monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-breakthrough-therapy-designation-for-ln-145-for-treatmen-iova-20190522monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-updates-to-tumor-infiltrating-lymphocyte-til-therapy-cli-iova-20190515monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-first-quarter-2019-financial-results-and-provides-corporat-iova-20190507monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-pr-iova-20190227monthly0.5https://www.biopharmawatch.com/news/IOVA/corporate-presentation-january-2019-this-presentation-contains-forward-looking-statements--iova-20190107monthly0.5https://www.biopharmawatch.com/news/IOVA/clinical-program-update-november-9-2018-2018-iovance-biotherapeutics-this-presentation-con-iova-20181109monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-third-quarter-2018-financial-results-and-provides-corporat-iova-20181106monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-closing-of-252-million-common-stock-public-offering--iova-20181017monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-proposed-public-offering-of-common-stock-iova-20181011monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-results-from-fda-end-of-phase-2-meeting-and-provides-updat-iova-20181011monthly0.5https://www.biopharmawatch.com/news/IOVA/corporate-presentation-september-2018-2018-iovance-biotherapeutics-inc-this-presentation-c-iova-20180905monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-second-quarter-2018-financial-results-and-provides-corpora-iova-20180806monthly0.5https://www.biopharmawatch.com/news/IOVA/corporate-presentation-june-2018-2018-iovance-biotherapeutics-inc-this-presentation-contai-iova-20180607monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-first-quarter-2018-financial-results-and-provides-corporat-iova-20180510monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-pr-iova-20180312monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-michael-weiser-m-d-ph-d-to-its-board-of-directors-industr-iova-20180301monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-closing-of-172-5-million-common-stock-public-offerin-iova-20180129monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-public-offering-of-common-stock-iova-20180124monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-preliminary-phase-2-data-for-til-treatment-in-head-and-n-iova-20180124monthly0.5https://www.biopharmawatch.com/news/IOVA/corporate-presentation-january-2018-2018-iovance-biotherapeutics-inc-this-presentation-con-iova-20180108monthly0.5https://www.biopharmawatch.com/news/IOVA/analyst-day-iova-20171213monthly0.5https://www.biopharmawatch.com/news/IOVA/novel-cryopreserved-tumor-infiltrating-lymphocytes-ln-144-administered-to-patients-with-me-iova-20171113monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-third-quarter-2017-financial-results-company-to-host-confe-iova-20171031monthly0.5https://www.biopharmawatch.com/news/IOVA/manufacturing-tour-at-wuxi-apptec-iova-20171026monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-closing-of-57-5-million-common-stock-public-offering-iova-20170925monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-public-offering-of-common-stock-iova-20170919monthly0.5https://www.biopharmawatch.com/news/IOVA/corporate-presentation-september-2017-2017-iovance-biotherapeutics-this-presentation-conta-iova-20170911monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-fda-fast-track-designation-for-ln-144-for-treatment-of-a-iova-20170831monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-timothy-morris-as-chief-financial-officer-iova-20170808monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-second-quarter-2017-financial-results-company-to-host-conf-iova-20170801monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-inc-changes-name-to-iovance-biotherapeutics-inc-name-change-reflects--iova-20170628monthly0.5https://www.biopharmawatch.com/news/IOVA/corporate-presentation-june-2017-2017-lion-biotechnologies-this-presentation-contains-forw-iova-20170605monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-reports-first-quarter-2017-financial-results-company-to-host-conferen-iova-20170501monthly0.5https://www.biopharmawatch.com/news/IOVA/corporate-presentation-april-2017-2017-lion-biotechnologies-this-presentation-contains-for-iova-20170421monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-strategic-alliance-with-md-anderson-cancer-center-to-conduc-iova-20170419monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-reports-fourth-quarter-and-full-year-2016-financial-results-and-provi-iova-20170307monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-reports-third-quarter-2016-financial-results-and-provides-corporate-u-iova-20161104monthly0.5https://www.biopharmawatch.com/news/IOVA/corporate-presentation-october-2016-2016-lion-biotechnologies-this-presentation-contains-f-iova-20161103monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-second-quarter-2016-financial-results-company-appointed-new-iova-20160808monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-annual-meeting-rescheduled-new-york-ny-iova-20160608monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-closing-of-100-million-private-financing-new-york-ny-iova-20160608monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-appoints-maria-fardis-ph-d-as-ceo-dr-fardis-brings-extensive-experien-iova-20160603monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-first-quarter-2016-financial-results-iova-20160509monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-2015-fourth-quarter-and-year-end-financial-results-new-york-iova-20160310monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-third-quarter-2015-financial-results-new-york-ny-iova-20151105monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-obtains-exclusive-license-from-nih-to-develop-and-commercialize-til-i-iova-20151007monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-second-quarter-2015-financial-results-new-york-ny-iova-20150810monthly0.5https://www.biopharmawatch.com/news/IOVA/biotechnologies-announces-pricing-of-secondary-iova-20150504monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-public-offering-of-common-stock-los-angeles-ca-iova-20150225monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-appoints-ryan-maynard-director-and-chair-of-audit-committee-los-angel-iova-20150217monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-pricing-of-underwritten-common-stock-offering-released-on-iova-20141217monthly0.5https://www.biopharmawatch.com/news/IOVA/the-issuance-of-a-patent-is-not-conclusive-as-to-its-validity-or-enforceability-and-it-is--iova-20141217monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-announces-management-change-company-remains-on-track-to-achieve-strat-iova-20141112monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-names-elma-hawkins-president-and-chief-operating-officer-los-angeles--iova-20140820monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-enters-clinical-trial-grant-agreement-with-moffitt-cancer-center-gran-iova-20140730monthly0.5https://www.biopharmawatch.com/news/IOVA/lion-biotechnologies-lead-program-with-national-cancer-institute-demonstrates-positive-res-iova-20140407monthly0.5https://www.biopharmawatch.com/news/IOVA/ir-contact-gitanjali-jain-ogawa-the-trout-group-llc-646-378-2949-gogawa-troutgroup-com-lio-iova-20140203monthly0.5https://www.biopharmawatch.com/news/IOVA/investor-contact-lha-don-markley-dmarkley-lhai-com-310-691-7100-lion-biotechnologies-compl-iova-20131106monthly0.5https://www.biopharmawatch.com/news/IOVA/investor-contact-lha-don-markley-senior-vice-president-dmarkley-lhai-com-310-691-7100-lion-iova-20131031monthly0.5https://www.biopharmawatch.com/news/IOVA/investor-contact-lha-don-markley-senior-vice-president-dmarkley-lhai-com-310-691-7100-gene-iova-20130808monthly0.5https://www.biopharmawatch.com/news/IOVA/investor-contact-lha-anne-marie-fields-senior-vice-president-afields-lhai-com-212-838-3777-iova-20130725monthly0.5https://www.biopharmawatch.com/news/IOVA/of-genesis-biopharma-inc-issued-may-7-2012-investor-contact-lha-anne-marie-fields-senior-v-iova-20120507monthly0.5https://www.biopharmawatch.com/news/IOVA/investor-contact-lha-anne-marie-fields-senior-vice-president-afields-lhai-com-212-838-3777-iova-20120322monthly0.5https://www.biopharmawatch.com/news/IOVA/unassociated-document-investor-contact-lha-anne-marie-fields-senior-vice-president-afields-iova-20120109monthly0.5https://www.biopharmawatch.com/news/IOVA/unassociated-document-investor-contact-lha-anne-marie-fields-senior-vice-president-afields-iova-20111011monthly0.5https://www.biopharmawatch.com/news/IOVA/unassociated-document-investor-contact-lippert-heilshorn-associates-inc-don-markley-dmarkl-iova-20110810monthly0.5https://www.biopharmawatch.com/news/IOVA/unassociated-document-investor-contact-lippert-heilshorn-associates-inc-don-markley-dmarkl-iova-20110721monthly0.5https://www.biopharmawatch.com/news/IOVA/investor-contact-lippert-heilshorn-associates-inc-don-markley-dmarkley-lhai-com-310-691-71-iova-20110718monthly0.5https://www.biopharmawatch.com/news/IOVA/unassociated-document-investor-contact-lippert-heilshorn-associates-inc-don-markley-dmarkl-iova-20110613monthly0.5https://www.biopharmawatch.com/news/IOVA/unassociated-document-investor-contact-lippert-heilshorn-associates-inc-don-markley-dmarkl-iova-20110317monthly0.5https://www.biopharmawatch.com/news/IOVA/investor-contact-lippert-heilshorn-associates-inc-don-markley-dmarkley-lhai-com-310-691-71-iova-20110223monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-kasandra-h-rossi-executive-vice-president-chief-financial-officer-tre-md-20260505monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-kasandra-h-rossi-executive-vice-president-chief-financial-officer-tre-md-20260219monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-kasandra-h-rossi-executive-vice-president-chief-financial-officer-tre-md-20251103monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-kasandra-h-rossi-executive-vice-president-chief-financial-officer-tre-md-20250818monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-kasandra-h-rossi-executive-vice-president-chief-financial-officer-tre-md-20250805monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-kasandra-rossi-executive-vice-president-chief-financial-officer-and-t-md-20250701monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-kasandra-h-rossi-executive-vice-president-chief-financial-officer-tre-md-20250506monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20250220monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20250113monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20241101monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20240806monthly0.5https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-inc-nyse-md-supplemental-disclosure-md-20240530monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20240507monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20240220monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20231102monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20230803monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20230504monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20230502monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20230217monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20221215monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20221103monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20220804monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20220621monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20220428monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20220217monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20220214monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20211028monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20210806monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20210507monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20210218monthly0.5https://www.biopharmawatch.com/news/MD/unaudited-pro-forma-consolidated-financial-information-overview-on-md-20201215monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20201106monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20200910monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20200825monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20200730monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-senior-vice-president-finance-and-strategy-954-384-0175-md-20200713monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20200605monthly0.5https://www.biopharmawatch.com/news/MD/unaudited-pro-forma-condensed-consolidated-financial-information-overview-on-md-20200506monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20200507monthly0.5https://www.biopharmawatch.com/news/MD/north-american-partners-in-anesthesia-napa-acquires-american-anesthesiology-from-mednax-in-md-20200506monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20200325monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20200220monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20191101monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20191010monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20190801monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20190502monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20190328monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20190207monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20181101monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20180904monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20180802monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20180430monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20180208monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20171101monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20170728monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20170504monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20170420monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20170207monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20161107monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20161027monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20160728monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20160428monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20160204monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20151029monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20150730monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20150518monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20150430monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20150312monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20150129monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20141215monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20140731monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-charles-lynch-vice-president-strategy-and-investor-relations-954-384--md-20140501monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-company-contact-vivian-lopez-blanco-954-384-0175-x-5020-chief-financi-md-20140130monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-company-contact-vivian-lopez-blanco-954-384-0175-x-5020-chief-financi-md-20131205monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-company-contact-vivian-lopez-blanco-954-384-0175-x-5020-chief-financi-md-20131031monthly0.5https://www.biopharmawatch.com/news/MD/mednax-reports-2013-second-quarter-eps-of-1-37-board-authorizes-share-repurchase-program-f-md-20130730monthly0.5https://www.biopharmawatch.com/news/MD/mednax-reports-2013-first-quarter-eps-of-1-10-expects-second-quarter-2013-eps-of-1-32-to-1-md-20130502monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-1-32-per-share-for-2012-fourth-quarter-2012-net-income-increases-by-over-10-e-md-20130131monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-david-t-parker-vice-president-investor-relations-corporate-communicat-md-20121120monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-1-32-per-share-for-2012-third-quarter-exceeds-third-quarter-earnings-guidance-md-20121101monthly0.5https://www.biopharmawatch.com/news/MD/mednax-exceeds-second-quarter-earnings-guidance-earns-1-22-per-share-for-2012-second-quart-md-20120731monthly0.5https://www.biopharmawatch.com/news/MD/mednax-reports-2012-first-quarter-eps-of-98-cents-fort-lauderdale-fla-business-wire-md-20120503monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-1-19-per-share-for-2011-fourth-quarter-2011-net-income-increases-by-over-13-n-md-20120202monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-1-19-per-share-for-2011-third-quarter-expects-fourth-quarter-eps-of-1-15-to-1-md-20111101monthly0.5https://www.biopharmawatch.com/news/MD/for-more-information-david-t-parker-vice-president-investor-relations-corporate-communicat-md-20111024monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-1-15-per-share-for-2011-second-quarter-expects-third-quarter-eps-of-1-15-to-1-md-20110802monthly0.5https://www.biopharmawatch.com/news/MD/mednax-s-2011-first-quarter-eps-grows-by-16-percent-to-94-cents-expects-second-quarter-eps-md-20110503monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-1-12-per-share-for-2010-fourth-quarter-expects-2011-first-quarter-eps-growth--md-20110203monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-1-06-non-gaap-for-2010-third-quarter-expects-fourth-quarter-eps-of-1-10-to-1--md-20101102monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-1-04-per-share-in-2010-second-quarter-generates-91-7-million-of-cash-flow-fro-md-20100803monthly0.5https://www.biopharmawatch.com/news/MD/mednax-reports-2010-first-quarter-non-gaap-eps-of-82-cents-expects-second-quarter-eps-of-1-md-20100503monthly0.5https://www.biopharmawatch.com/news/MD/mednax-reports-gaap-eps-of-1-07-for-2009-fourth-quarter-fort-lauderdale-fla-business-wire-md-20100205monthly0.5https://www.biopharmawatch.com/news/MD/mednax-reports-2009-third-quarter-eps-of-1-03-fort-lauderdale-fla-business-wire-md-20091102monthly0.5https://www.biopharmawatch.com/news/MD/mednax-earns-93-cents-per-share-in-2009-second-quarter-expects-third-quarter-eps-of-94-cen-md-20090804monthly0.5https://www.biopharmawatch.com/news/MD/mednax-reports-2009-first-quarter-eps-of-74-cents-expects-second-quarter-eps-of-84-to-90-c-md-20090507monthly0.5https://www.biopharmawatch.com/news/WGS/genedx-names-mark-gardner-president-to-lead-its-next-phase-of-scale-and-growth-former-ques-wgs-20260616monthly0.5https://www.biopharmawatch.com/news/WGS/genedx-reports-first-quarter-2026-financial-results-and-updates-full-year-outlook-reported-wgs-20260504monthly0.5https://www.biopharmawatch.com/news/WGS/genedx-reports-first-quarter-2023-financial-results-and-business-highlights-generated-40-7-wgs-20230509monthly0.5https://www.biopharmawatch.com/news/WGS/net-decrease-increase-in-cash-cash-equivalents-and-restricted-cash-263-166-282-509-3-954-c-wgs-20230314monthly0.5https://www.biopharmawatch.com/news/WGS/wgsinvestordec-41st-annual-jpmorgan-healthcare-conference-wgs-20230112monthly0.5https://www.biopharmawatch.com/news/WGS/sema4-appoints-healthcare-and-diagnostics-industry-veteran-kevin-feeley-as-chief-financial-wgs-20220826monthly0.5https://www.biopharmawatch.com/news/WGS/sema4-announces-the-completion-of-the-genedx-acquisition-and-a-streamlined-leadership-stru-wgs-20220502monthly0.5https://www.biopharmawatch.com/news/WGS/sema4-reports-third-quarter-2021-financial-results-and-business-highlights-36-increase-in--wgs-20211115monthly0.5https://www.biopharmawatch.com/news/WGS/sema4-reports-second-quarter-2021-financial-results-and-business-highlights-85-test-volume-wgs-20210816monthly0.5https://www.biopharmawatch.com/news/WGS/sema4-closes-transaction-with-cm-life-sciences-debuts-as-publicly-traded-ai-driven-genomic-wgs-20210722monthly0.5https://www.biopharmawatch.com/news/WGS/sema4-a-disruptive-ai-driven-genomic-clinical-data-platform-company-to-combine-with-cm-lif-wgs-20210210monthly0.5https://www.biopharmawatch.com/news/WGS/cm-life-sciences-inc-announces-separate-trading-of-its-shares-of-class-a-common-stock-and--wgs-20201026monthly0.5https://www.biopharmawatch.com/news/WGS/index-to-financial-statement-audited-financial-statement-for-cm-life-sciences-inc-page-rep-wgs-20200904monthly0.5https://www.biopharmawatch.com/news/WGS/cm-life-sciences-inc-sponsored-by-affiliates-of-casdin-capital-and-corvex-management-annou-wgs-20200901monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-sovleplenib-eslim-02-phase-iii-data-in-warm-antibody-autoimmune-hemoly-hcm-20260612monthly0.5https://www.biopharmawatch.com/news/HCM/block-admission-application-hong-kong-shanghai-florham-park-nj-friday-june-5-2026-hutchmed-hcm-20260605monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting-hong-kon-hcm-20260522monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-innovent-jointly-announce-nmpa-approval-for-elunate-fruquintinib-in-combinati-hcm-20260521monthly0.5https://www.biopharmawatch.com/news/HCM/annual-general-meeting-held-on-may-1-2-202-6-poll-results-hong-kong-shanghai-florham-park--hcm-20260512monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-thursday-hcm-20260430monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-nda-acceptance-in-china-with-priority-review-status-and-breakthrough-de-hcm-20260429monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-data-to-be-presented-at-aacr-annual-meeting-2026-hong-kong-shanghai-fl-hcm-20260409monthly0.5https://www.biopharmawatch.com/news/HCM/2025-annual-report-and-notice-of-annual-general-hcm-20260409monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-iii-trial-of-hmpl-760-in-patients-with-relapsed-refractory-diffus-hcm-20260323monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-mo-hcm-20260316monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-we-hcm-20260311monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-update-on-licensed-oncology-product-tazverik-in-china-hong-kong-shangha-hcm-20260309monthly0.5https://www.biopharmawatch.com/news/HCM/intended-r-etirement-of-independent-non-executive-director-and-changes-of-composition-of-b-hcm-20260306monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-reports-2025-full-year-results-and-business-updates-geographic-expansion-driving--hcm-20260305monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-global-trial-of-pi3k-pikk-egfr-attc-candidate-hmpl-a580-in-patients-wit-hcm-20260304monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2025-final-results-hong-kong-shanghai-florham-park-nj-friday-hcm-20260206monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-publication-of-phase-iii-sachi-results-in-the-lancet-first-randomized--hcm-20260114monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-positive-topline-results-of-phase-iii-part-of-eslim-02-trial-of-sovlepl-hcm-20260107monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-iii-stage-of-the-ongoing-trial-of-the-combination-of-surufatinib--hcm-20260105monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20251231monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-nda-acceptance-in-china-with-priority-review-status-for-savolitinib-for-hcm-20251230monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-monday-hcm-20251229monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-global-clinical-development-of-attc-candidate-hmpl-a251-in-patients-wit-hcm-20251217monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-expanded-coverage-on-national-reimbursement-drug-list-and-inclusion-in--hcm-20251208monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2-hcm-20251127monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-enrollment-completed-of-saffron-global-phase-iii-trial-of-orpathys-and--hcm-20251105monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-pipeline-and-business-progress-at-r-d-updates-event-hutchmed-unveils-i-hcm-20251103monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-hmpl-a251-data-presented-at-the-aacr-nci-eortc-international-conferenc-hcm-20251023monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-tu-hcm-20251021monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-frusica-2-registration-trial-data-to-be-presented-at-the-2025-esmo-con-hcm-20251013monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-esmo-congress-2025-hong-kong-shan-hcm-20251002monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-tuesday-hcm-20250930monthly0.5https://www.biopharmawatch.com/news/HCM/save-the-date-hutchmed-to-present-r-d-updates-on-hcm-20250912monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-world-conference-of-lung-can-hcm-20250905monthly0.5https://www.biopharmawatch.com/news/HCM/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--hcm-20250825monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-completes-patient-enrollment-of-sanovo-phase-iii-trial-of-orpathys-and-tagrisso-c-hcm-20250820monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-reports-2025-interim-results-indications-expansion-driving-growth-and-attc-platfo-hcm-20250807monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2025-half-year-financial-results-hong-kong-shanghai-florham-park-nj-t-hcm-20250703monthly0.5https://www.biopharmawatch.com/news/HCM/update-on-joint-corporate-brokers-in-london-hong-kong-shanghai-florham-park-nj-wednesday-j-hcm-20250702monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-monday-hcm-20250630monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-and-awards-under-long-term-incentive-plan-hcm-20250609monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-innovent-jointly-announce-nda-acceptance-in-china-for-fruquintinib-combinatio-hcm-20250605monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-sachi-phase-iii-study-data-presented-at-the-2025-asco-annual-meeting-t-hcm-20250602monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-friday-hcm-20250530monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-asco-annual-meeting-hong-kon-hcm-20250523monthly0.5https://www.biopharmawatch.com/news/HCM/annual-general-meeting-held-on-hcm-20250513monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-data-to-be-presented-at-aacr-annual-meeting-2025-hong-kong-shanghai-fl-hcm-20250424monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-completes-patient-enrollment-of-a-phase-ii-registration-study-of-savolitinib-in-g-hcm-20250422monthly0.5https://www.biopharmawatch.com/news/HCM/2024-annual-report-and-notice-of-annual-hcm-20250407monthly0.5https://www.biopharmawatch.com/news/HCM/extraordinary-general-meeting-held-on-hcm-20250331monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-nmpa-conditional-approval-for-tazverik-tazemetostat-for-the-treatment-o-hcm-20250321monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-savolitinib-savannah-phase-ii-and-other-data-at-european-lung-cancer-c-hcm-20250320monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-reports-2024-full-year-results-and-provides-business-updates-65-oncology-products-hcm-20250319monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-innovent-jointly-announce-that-the-frusica-2-phase-ii-iii-study-of-fruquintin-hcm-20250319monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-fr-hcm-20250314monthly0.5https://www.biopharmawatch.com/news/HCM/notice-of-extraordinary-general-meeting-hong-kong-shanghai-florham-park-nj-thursday-hcm-20250313monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-that-it-has-completed-enrollment-of-a-phase-ii-registration-study-of-fa-hcm-20250306monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-appointment-of-independent-non-executive-director-and-member-of-board-c-hcm-20250305monthly0.5https://www.biopharmawatch.com/news/HCM/overseas-regulatory-announcement-update-on-transaction-hutchmed-china-limited-hutchmed-not-hcm-20250302monthly0.5https://www.biopharmawatch.com/news/HCM/overseas-regulatory-announcement-update-on-transaction-hutchmed-china-limited-hutchmed-not-hcm-20250228monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2024-final-results-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20250219monthly0.5https://www.biopharmawatch.com/news/HCM/overseas-regulatory-announcement-disposal-transaction-hutchmed-china-limited-hutchmed-note-hcm-20250128monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-nmpa-full-approval-for-orpathys-savolitinib-in-china-for-patients-with--hcm-20250114monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-us-608-million-divestment-of-non-core-joint-venture-hutchmed-continues--hcm-20250102monthly0.5https://www.biopharmawatch.com/news/HCM/appointment-of-cavendish-as-joint-corporate-broker-in-london-hong-kong-shanghai-florham-pa-hcm-20241231monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-monday-hcm-20241230monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-receive-milestone-payment-from-takeda-following-first-european-reimbursement-f-hcm-20241213monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-breakthrough-therapy-designation-in-china-for-orpathys-and-tagrisso-com-hcm-20241212monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-innovent-jointly-announce-nmpa-conditional-approval-for-elunate-fruquintinib--hcm-20241203monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-continued-inclusion-of-orpathys-savolitinib-in-the-national-reimburseme-hcm-20241128monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-launch-by-takeda-of-fruzaqla-fruquintinib-in-japan-launch-follows-appro-hcm-20241122monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-appointment-of-independent-non-executive-director-and-member-of-board-c-hcm-20241120monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-2024-ash-annual-meeting-and-the-2-hcm-20241106monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-thursday-hcm-20241031monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-mo-hcm-20241021monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-that-tagrisso-plus-orpathys-demonstrated-high-clinically-meaningful-res-hcm-20241016monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-japan-approval-for-fruzaqla-fruquintinib-received-by-takeda-approval-ba-hcm-20240924monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-esmo-congress-2024-and-the-2024-world-hcm-20240909monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-friday-hcm-20240830monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20240822monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-host-expert-call-to-discuss-immune-thrombocytopenia-hong-kong-shanghai-florham-hcm-20240821monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-and-awards-under-long-term-incentive-plan-hcm-20240805monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-reports-2024-interim-results-and-provides-business-updates-hong-kong-shanghai-flo-hcm-20240731monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-nda-acceptance-in-china-for-tazemetostat-for-the-treatment-of-relapsed--hcm-20240705monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-friday-hcm-20240628monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2024-half-year-financial-results-hong-kong-shanghai-florham-park-nj-w-hcm-20240626monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-european-commission-approval-for-fruzaqla-fruquintinib-received-by-take-hcm-20240621monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-publication-of-phase-iii-eslim-01-results-in-the-lancet-haematology-pu-hcm-20240617monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-i-trial-of-menin-inhibitor-hmpl-506-in-patients-with-hematologica-hcm-20240531monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-publication-of-phase-iii-frutiga-results-in-nature-medicine-updated-su-hcm-20240603monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-friday-hcm-20240531monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-presentations-at-the-2024-asco-annual-meeting-hong-kong-shanghai-florh-hcm-20240524monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-sovleplenib-phase-iii-eslim-01-study-and-hematological-malignancy-prog-hcm-20240517monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-ii-iii-trial-of-the-combination-of-surufatinib-and-camrelizumab-f-hcm-20240508monthly0.5https://www.biopharmawatch.com/news/HCM/annual-general-meeting-held-on-may-1-0-202-4-poll-results-hong-kong-shanghai-florham-park--hcm-20240510monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-appointment-of-independent-non-executive-director-and-member-of-board-c-hcm-20240508monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-positive-chmp-opinion-for-fruquintinib-in-previously-treated-metastatic-hcm-20240426monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-mo-hcm-20240422monthly0.5https://www.biopharmawatch.com/news/HCM/2023-annual-report-and-notice-of-annual-general-meeting-hcm-20240408monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-data-to-be-presented-at-aacr-congress-202-4-hong-kong-shanghai-florham-hcm-20240408monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-innovent-jointly-announce-nda-acceptance-in-china-for-fruquintinib-combinatio-hcm-20240402monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-savolitinib-snda-accepted-in-china-for-treatment-na-ve-or-previously-tr-hcm-20240328monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-registration-stage-of-the-eslim-02-phase-ii-iii-trial-of-sovleplenib-fo-hcm-20240320monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-and-awards-under-long-term-incentive-plan-hcm-20240314monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-tu-hcm-20240305monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-reports-2023-full-year-results-and-provides-business-updates-revenue-grew-97-102--hcm-20240228monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-presentation-of-phase-iii-data-on-fruquintinib-in-second-line-gastric--hcm-20240207monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-that-inmagene-exercises-option-to-license-two-drug-candidates-as-part-o-hcm-20240202monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2023-final-results-hong-kong-shanghai-florham-park-nj-thursday-hcm-20240201monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-receives-elunate-fruquintinib-marketing-approval-in-hong-kong-for-treatment-of-me-hcm-20240130monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-nda-acceptance-in-china-for-sovleplenib-for-the-treatment-of-primary-im-hcm-20240111monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-friday-hcm-20231229monthly0.5https://www.biopharmawatch.com/news/HCM/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--hcm-20231221monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-that-it-has-completed-enrollment-of-a-phase-ii-iii-trial-of-fruquintini-hcm-20231213monthly0.5https://www.biopharmawatch.com/news/HCM/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--hcm-20231207monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-2023-esmo-asia-and-esmo-immuno-oncolo-hcm-20231201monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-thursday-hcm-20231130monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-that-takeda-receives-u-s-fda-approval-of-fruzaqla-fruquintinib-for-prev-hcm-20231109monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-tu-hcm-20231024monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-esmo-congress-2023-hong-kong-shanghai-hcm-20231016monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-friday-hcm-20230929monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-hong-kong-shanghai-florham-park-nj-thursday-hcm-20230914monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-completes-patient-enrollment-of-a-bridging-study-of-tazemetostat-in-patients-with-hcm-20230912monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-thursday-hcm-20230831monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-receives-breakthrough-therapy-designation-in-china-for-savolitinib-for-gastric-ca-hcm-20230829monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-that-the-sovleplenib-phase-iii-eslim-01-study-met-its-primary-endpoint--hcm-20230821monthly0.5https://www.biopharmawatch.com/news/HCM/exercise-of-share-options-by-a-director-hong-kong-shanghai-florham-park-nj-monday-hcm-20230807monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-reports-2023-interim-results-and-provides-business-updates-strong-execution-on-st-hcm-20230731monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-receives-breakthrough-therapy-designation-in-china-for-fruquintinib-combination-w-hcm-20230720monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-changes-to-board-of-directors-and-technical-committee-ms-ling-yang-to-r-hcm-20230713monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-i-study-of-its-novel-shp2-inhibitor-hmpl-415-for-advanced-maligna-hcm-20230710monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-thursday-hcm-20230629monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2023-half-year-financial-results-hong-kong-shanghai-florham-park-nj-m-hcm-20230626monthly0.5https://www.biopharmawatch.com/news/HCM/takeda-and-hutchmed-announce-marketing-authorization-application-of-fruquintinib-for-previ-hcm-20230615monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-presentations-for-hematological-malignancy-programs-at-the-2023-eha-an-hcm-20230609monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-awards-under-long-term-incentive-plan-and-share-options-under-share-option-scheme-hcm-20230605monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20230531monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-presentations-at-the-2023-asco-annual-meeting-hong-kong-shanghai-florh-hcm-20230525monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20230517monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-board-of-directors-and-board-committee-membership-hong-kong-shanghai-fl-hcm-20230512monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-appointment-of-independent-non-executive-director-and-member-of-board-c-hcm-20230510monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-friday-hcm-20230428monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-fr-hcm-20230421monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-nda-acceptance-in-china-for-fruquintinib-in-second-line-gastric-cancer--hcm-20230418monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-presentations-at-american-association-for-cancer-research-annual-meeti-hcm-20230412monthly0.5https://www.biopharmawatch.com/news/HCM/annual-report-and-notice-of-annual-general-meeting-hong-kong-shanghai-florham-park-nj-tues-hcm-20230411monthly0.5https://www.biopharmawatch.com/news/HCM/securities-and-exchange-commission-hcm-20230411monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-registration-phase-enrollments-of-hmpl-453-for-ihcc-and-savolitinib-for-hcm-20230404monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-completes-rolling-submission-of-nda-to-u-s-fda-for-fruquintinib-for-the-treatment-hcm-20230331monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-closing-of-fruquintinib-license-to-takeda-outside-china-hong-kong-shang-hcm-20230314monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20230308monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-mo-hcm-20230306monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-reports-2022-full-year-results-and-provides-business-updates-landmark-licensing-d-hcm-20230228monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-completes-patient-enrollment-of-phase-ii-registration-trial-of-amdizalisib-in-fol-hcm-20230227monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2022-final-results-hong-kong-shanghai-florham-park-nj-tuesday-hcm-20230131monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-license-to-takeda-to-develop-and-commercialize-fruquintinib-outside-chi-hcm-20230123monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-agreement-with-nhsa-for-inclusion-of-orpathys-in-the-national-reimburse-hcm-20230119monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-completes-patient-enrollment-of-eslim-01-a-phase-iii-trial-of-sovleplenib-in-prim-hcm-20230103monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-friday-hcm-20221230monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-rolling-submission-of-nda-to-u-s-fda-for-fruquintinib-for-the-treatment-hcm-20221219monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-strategy-to-focus-on-late-stage-pipeline-regulatory-approvals-repriorit-hcm-20221115monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-positive-topline-result-in-fruquintinib-phase-iii-frutiga-study-in-seco-hcm-20221114monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-a-phase-ii-iii-trial-of-fruquintinib-in-combination-with-sintilimab-for-hcm-20221027monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-fr-hcm-20221021monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-a-phase-ii-iii-trial-of-sovleplenib-for-warm-antibody-autoimmune-hemoly-hcm-20221010monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-friday-hcm-20220930monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-and-awards-under-long-term-incentive-plan-hcm-20220913monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-phase-iii-fresco-2-mrct-data-summary-of-fruquintinib-in-refractory-met-hcm-20220908monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-fruquintinib-mrct-fresco-2-data-to-be-presented-at-the-upcoming-esmo-c-hcm-20220823monthly0.5https://www.biopharmawatch.com/news/HCM/inmagene-and-hutchmed-announce-first-participant-in-global-phase-i-trial-of-img-004-san-di-hcm-20220809monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-that-fruquintinib-global-phase-iii-fresco-2-study-has-met-its-primary-e-hcm-20220808monthly0.5https://www.biopharmawatch.com/news/HCM/x200b-hutchmed-reports-2022-interim-results-and-provides-business-updates-oncology-immunol-hcm-20220801monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-a-bridging-study-of-tazemetostat-in-patients-with-relapsed-refractory-f-hcm-20220801monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-i-trial-of-anti-cd47-monoclonal-antibody-hmpl-a83-in-patients-wit-hcm-20220715monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-first-presentation-of-results-of-the-savannah-global-phase-ii-trial-of-hcm-20220713monthly0.5https://www.biopharmawatch.com/news/HCM/inmagene-and-hutchmed-announce-first-participants-in-global-phase-i-trial-of-img-007-san-d-hcm-20220706monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-thursday-hcm-20220630monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20220629monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2022-half-year-financial-results-hong-kong-shanghai-florham-park-nj-m-hcm-20220627monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-tazverik-approved-to-be-used-in-hainan-pilot-zone-in-china-hong-kong-sh-hcm-20220601monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-awards-under-long-term-incentive-plan-and-share-options-under-share-option-scheme-hcm-20220523monthly0.5https://www.biopharmawatch.com/news/HCM/appointment-of-non-executive-director-hong-kong-shanghai-florham-park-nj-monday-hcm-20220516monthly0.5https://www.biopharmawatch.com/news/HCM/hong-kong-exchanges-and-clearing-limited-and-the-stock-exchange-of-hong-kong-limited-take--hcm-20220502monthly0.5https://www.biopharmawatch.com/news/HCM/annual-general-meeting-held-on-hcm-20220427monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-th-hcm-20220421monthly0.5https://www.biopharmawatch.com/news/HCM/update-on-status-under-holding-foreign-companies-accountable-act-hong-kong-shanghai-florha-hcm-20220331monthly0.5https://www.biopharmawatch.com/news/HCM/annual-report-and-notice-of-annual-general-meeting-hong-kong-shanghai-florham-park-nj-wedn-hcm-20220323monthly0.5https://www.biopharmawatch.com/news/HCM/update-on-status-under-holding-foreign-companies-accountable-act-hong-kong-shanghai-florha-hcm-20220311monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-we-hcm-20220309monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-receives-a-us-15-million-milestone-from-astrazeneca-for-initiating-start-up-activ-hcm-20220307monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-reports-2021-full-year-results-and-provides-business-updates-oncology-immunology--hcm-20220303monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-retirement-of-ceo-and-appointment-of-new-ceo-hong-kong-shanghai-florham-hcm-20220303monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-receives-approval-to-commercialize-elunate-in-macau-first-homegrown-innovative-me-hcm-20220301monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-announce-2021-final-results-hong-kong-shanghai-florham-park-nj-monday-hcm-20220207monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-ib-ii-study-of-hmpl-453-in-combination-with-chemotherapy-or-torip-hcm-20220204monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-a-phase-i-trial-of-hmpl-653-in-patients-with-advanced-malignant-solid-t-hcm-20220120monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-fruquintinib-clinical-data-to-be-presented-at-the-2022-asco-gastrointe-hcm-20220119monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20220118monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-receives-break-through-therapy-designation-in-china-for-hmpl-523-for-treatment-of-hcm-20220112monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-i-study-of-btk-inhibitor-hmpl-760-in-patients-with-previously-tre-hcm-20220110monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-friday-hcm-20211231monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-included-in-ftse-russell-indexes-hong-kong-shanghai-florham-park-nj-monday-hcm-20211220monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-and-awards-under-long-term-incentive-plan-hcm-20211214monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-hmpl-523-clinical-data-presented-at-the-2021-ash-annual-meeting-hong-k-hcm-20211214monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-surufatinib-and-toripalimab-combination-clinical-data-being-presented--hcm-20211210monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-completes-planned-enrollment-of-fresco-2-a-global-phase-iii-trial-of-fruquintinib-hcm-20211206monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-agreement-with-nhsa-for-continued-inclusion-of-elunate-and-addition-of--hcm-20211203monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-tuesday-hcm-20211130monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-astrazeneca-initiate-sachi-phase-iii-trial-of-orpathys-and-tagrisso-combinati-hcm-20211124monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-hmpl-523-clinical-data-to-be-presented-at-the-2021-ash-annual-meeting--hcm-20211108monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-astrazeneca-initiate-sameta-global-phase-iii-trial-of-savolitinib-in-combinat-hcm-20211101monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-friday-hcm-20211029monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-eslim-01-a-phase-iii-trial-of-hmpl-523-in-patients-with-immune-thromboc-hcm-20211028monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-awards-under-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-wednesda-hcm-20211020monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-thursday-hcm-20210930monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-closing-of-divestment-of-non-core-otc-joint-venture-hong-kong-shanghai--hcm-20210929monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-surtori-01-a-phase-iii-trial-of-sulanda-in-combination-with-tuoyi-in-th-hcm-20210921monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-a-japan-bridging-study-to-support-surufatinib-registration-for-advanced-hcm-20210920monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-receives-breakthrough-therapy-designation-in-china-for-amdizalisib-hmpl-689-for-t-hcm-20210913monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-astrazeneca-initiate-sanovo-phase-iii-trial-of-orpathys-and-tagrisso-combinat-hcm-20210908monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-selection-of-its-shares-in-the-shanghai-hong-kong-and-shenzhen-hong-kon-hcm-20210906monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-and-awards-under-long-term-incentive-plan-hcm-20210901monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-tuesday-hcm-20210831monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-a-phase-ib-ii-trial-of-fruquintinib-in-combination-with-tislelizumab-in-hcm-20210826monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-selected-as-constituent-of-certain-hang-seng-indexes-hong-kong-shanghai-florham-p-hcm-20210823monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-epizyme-announce-strategic-collaboration-to-develop-and-commercialize-tazveri-hcm-20210809monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-friday-hcm-20210730monthly0.5https://www.biopharmawatch.com/news/HCM/x200b-hutchmed-reports-2021-interim-results-and-provides-business-updates-elunate-xae-in-m-hcm-20210728monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-and-astrazeneca-initiate-phase-ii-trial-of-orpathys-in-patients-with-met-amplifie-hcm-20210728monthly0.5https://www.biopharmawatch.com/news/HCM/hong-kong-exchanges-and-clearing-limited-the-stock-exchange-of-hong-kong-limited-the-stock-hcm-20210723monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-s-marketing-authorization-application-for-surufatinib-submitted-and-validated-by--hcm-20210716monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20210714monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-first-commercial-sale-of-orpathys-in-china-triggering-a-us-25-million-m-hcm-20210713monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-full-exercise-of-the-over-allotment-option-of-the-global-offering-hong--hcm-20210712monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-i-trials-of-novel-erk-inhibitor-hmpl-295-in-patients-with-advance-hcm-20210706monthly0.5https://www.biopharmawatch.com/news/HCM/u-s-fda-accepts-filing-of-hutchmed-s-nda-for-surufatinib-for-the-treatment-of-advanced-neu-hcm-20210702monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-the-closing-of-the-global-offering-and-the-primary-listing-in-hong-kong-hcm-20210630monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-hong-kong-shanghai-florham-park-nj-tuesday-hcm-20210629monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-pricing-of-global-offering-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20210623monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-announces-nmpa-approval-of-surufatinib-sulanda-in-china-for-advanced-pancreatic-n-hcm-20210618monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-launches-hong-kong-initial-public-offering-hong-kong-shanghai-florham-park-nj-fri-hcm-20210618monthly0.5https://www.biopharmawatch.com/news/HCM/titled-unaudited-first-quarter-2021-financial-information-of-our-report-on-form-6-k-furnis-hcm-20210621monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-china-limited-condensed-consolidated-balance-sheets-as-of-hcm-20210621monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-asco21-virtual-scientifi-hcm-20210520monthly0.5https://www.biopharmawatch.com/news/HCM/save-the-date-hutchmed-to-host-company-update-on-r-d-commercial-and-asco-data-for-analysts-hcm-20210517monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-to-attend-upcoming-investor-conferences-hong-kong-shanghai-florham-park-nj-friday-hcm-20210507monthly0.5https://www.biopharmawatch.com/news/HCM/change-of-company-name-hong-kong-shanghai-florham-park-nj-tuesday-hcm-20210504monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-phase-ii-registration-study-of-hmpl-689-in-patients-with-follicular-lym-hcm-20210429monthly0.5https://www.biopharmawatch.com/news/HCM/results-of-annual-general-meeting-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20210428monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-fr-hcm-20210423monthly0.5https://www.biopharmawatch.com/news/HCM/notification-of-dilution-of-voting-rights-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20210414monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20210408monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20210331monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-international-phase-i-trials-of-idh1-2-dual-inhibitor-in-patients-with--hcm-20210329monthly0.5https://www.biopharmawatch.com/news/HCM/annual-report-and-notice-of-annual-general-meeting-hong-kong-shanghai-florham-park-nj-frid-hcm-20210326monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-enters-agreement-to-divest-non-core-otc-joint-venture-for-us-169-million-allows-f-hcm-20210324monthly0.5https://www.biopharmawatch.com/news/HCM/hutchmed-initiates-a-phase-ib-ii-trial-of-surufatinib-in-combination-with-tislelizumab-in--hcm-20210324monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hong-kong-shanghai-florham-park-nj-we-hcm-20210310monthly0.5https://www.biopharmawatch.com/news/HCM/hutchison-china-meditech-limited-reports-2020-full-year-results-and-provides-business-upda-hcm-20210304monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2020-final-results-hong-kong-shanghai-florham-park-nj-wednesday-hcm-20210203monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-savolitinib-clinical-data-to-be-presented-at-virtual-wclc-hong-kong-sha-hcm-20210114monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-and-inmagene-announce-strategic-partnership-to-develop-and-commercialize-portfolio-hcm-20210111monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-london-thursday-hcm-20201231monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-rolling-submission-of-nda-to-u-s-fda-for-surufatinib-for-the-treatment-o-hcm-20201228monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-present-at-the-39-th-annual-jp-morgan-healthcare-conference-hong-kong-shanghai--hcm-20201222monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-tuesday-december-15-20-20-hutchiso-hcm-20201214monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-monday-hcm-20201130monthly0.5https://www.biopharmawatch.com/news/HCM/notification-of-dilution-of-voting-rights-london-friday-hcm-20201127monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20201117monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-hmpl-689-clinical-data-to-be-presented-at-the-62-nd-ash-annual-meeting--hcm-20201105monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-attend-upcoming-industry-and-investor-virtual-conferences-hong-kong-shanghai-fl-hcm-20201030monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20201030monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-wednesday-hcm-20200930monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-surufatinib-phase-iii-results-in-neuroendocrine-tumors-at-esmo-2020-and-hcm-20200921monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-second-nda-acceptance-in-china-for-surufatinib-in-pancreatic-neuroendocr-hcm-20200917monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-fresco-2-a-global-phase-iii-trial-of-fruquintinib-in-metastatic-colorect-hcm-20200904monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-ii-trial-of-hmpl-453-in-patients-with-advanced-intrahepatic-chol-hcm-20200903monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20200828monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-clinical-data-to-be-presented-at-the-upcoming-esmo-virtual-congress-202-hcm-20200824monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-hong-kong-shanghai-florham-park-nj-wednes-hcm-20200811monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-plans-to-submit-marketing-authorization-application-for-surufatinib-following-scie-hcm-20200810monthly0.5https://www.biopharmawatch.com/news/HCM/x200b-chi-med-reports-2020-interim-results-and-provides-updates-on-key-clinical-programs-x-hcm-20200730monthly0.5https://www.biopharmawatch.com/news/HCM/block-admission-application-london-thursday-hcm-20200730monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-s-nda-for-savolitinib-in-non-small-cell-lung-cancer-granted-priority-review-in-chi-hcm-20200728monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-i-trial-of-idh1-2-dual-inhibitor-in-patients-with-hematological--hcm-20200724monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20200708monthly0.5https://www.biopharmawatch.com/news/HCM/notification-of-dilution-of-voting-rights-london-tuesday-hcm-20200707monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-london-monday-hcm-20200629monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2020-half-year-financial-results-london-friday-hcm-20200626monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20200625monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-fruquintinib-granted-u-s-fda-fast-track-designation-for-metastatic-color-hcm-20200618monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-us-95-million-guangzhou-land-compensation-agreement-london-tuesday-hcm-20200609monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-the-continuation-of-phase-iii-frutiga-study-of-fruquintinib-in-second-li-hcm-20200604monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-plans-to-submit-nda-for-surufatinib-following-pre-nda-meeting-with-the-u-s-fda-lon-hcm-20200601monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-nda-acceptance-in-china-for-savolitinib-in-the-treatment-of-non-small-ce-hcm-20200529monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-and-beigene-enter-into-clinical-collaboration-to-evaluate-combinations-of-surufati-hcm-20200526monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-clinical-data-to-be-presented-at-the-upcoming-asco20-virtual-scientific-hcm-20200514monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-attend-upcoming-investor-conferences-london-monday-hcm-20200511monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-wednesday-hcm-20200429monthly0.5https://www.biopharmawatch.com/news/HCM/results-of-annual-general-meeting-london-monday-hcm-20200427monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-presentations-of-surufatinib-at-the-upcoming-aacr-virtual-annual-meetin-hcm-20200422monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-awards-under-long-term-incentive-plan-and-share-options-under-share-option-scheme-hcm-20200421monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-surufatinib-granted-u-s-fda-fast-track-designations-for-the-treatment-of-hcm-20200417monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-ii-trial-of-hmpl-453-in-patients-with-advanced-malignant-mesothe-hcm-20200331monthly0.5https://www.biopharmawatch.com/news/HCM/annual-report-and-notice-of-annual-general-meeting-london-wednesday-hcm-20200325monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-london-monday-hcm-20200309monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-reports-2019-full-year-results-and-provides-updates-on-key-clinical-programs-compa-hcm-20200303monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2019-final-results-on-tuesday-hcm-20200225monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-updated-phase-ii-savolitinib-imfinzi-xae-combination-data-in-advanced-p-hcm-20200210monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20200206monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2019-final-results-london-friday-hcm-20200131monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20200129monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20200123monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20200121monthly0.5https://www.biopharmawatch.com/news/HCM/hutchison-china-meditech-limited-condensed-consolidated-balance-sheets-in-us-000-except-sh-hcm-20200121monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-that-surufatinib-phase-iii-sanet-p-study-has-already-achieved-its-primar-hcm-20200120monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-ii-trial-of-surufatinib-in-combination-with-tuoyi-in-patients-wi-hcm-20200113monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-present-at-the-38-th-annual-jp-morgan-healthcare-conference-london-monday-hcm-20200106monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-london-tuesday-hcm-20191231monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-s-new-drug-application-for-surufatinib-in-non-pancreatic-neuroendocrine-tumors-gra-hcm-20191220monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-thursday-hcm-20191212monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-s-elunate-xae-fruquintinib-capsules-included-in-the-national-reimbursement-drug-li-hcm-20191128monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-surufatinib-granted-fda-orphan-drug-designation-for-pancreatic-neuroendo-hcm-20191125monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-nda-acceptance-in-china-for-surufatinib-in-non-pancreatic-neuroendocrine-hcm-20191111monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-publication-of-phase-ii-data-showing-promising-efficacy-for-savolitinib-hcm-20191017monthly0.5https://www.biopharmawatch.com/news/HCM/innovent-and-chi-med-expand-global-collaboration-to-evaluate-the-combination-of-sintilimab-hcm-20191010monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-an-international-phase-i-ib-trial-of-hmpl-523-in-patients-with-advanced--hcm-20191004monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20191003monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20190930monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-monday-hcm-20190930monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-discuss-surufatinib-phase-iii-and-u-s-phase-i-ib-efficacy-and-safety-data-prese-hcm-20190929monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-presentation-of-clinical-data-from-the-successful-sanet-ep-phase-iii-tr-hcm-20190925monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-oral-presentations-at-2019-csco-annual-meeting-london-wednesday-hcm-20190918monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-an-international-phase-i-ib-trial-of-hmpl-689-in-patients-with-advanced--hcm-20190903monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20190830monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-i-trial-of-hmpl-523-in-patients-with-immune-thrombocytopenia-itp-hcm-20190823monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20190820monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-reports-2019-interim-results-and-provides-updates-on-key-clinical-programs-financi-hcm-20190730monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20190730monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2019-half-year-financial-results-london-wednesday-hcm-20190703monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-london-friday-hcm-20190628monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20190628monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-that-surufatinib-phase-iii-sanet-ep-study-has-met-its-primary-endpoint-a-hcm-20190614monthly0.5https://www.biopharmawatch.com/news/HCM/block-admission-applications-and-total-voting-rights-london-wednesday-hcm-20190612monthly0.5https://www.biopharmawatch.com/news/HCM/hutchison-china-meditech-limited-condensed-consolidated-balance-sheets-in-us-000-except-sh-hcm-20190606monthly0.5https://www.biopharmawatch.com/news/HCM/results-of-extraordinary-general-meeting-london-wednesday-hcm-20190529monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-wednesday-hcm-20190522monthly0.5https://www.biopharmawatch.com/news/HCM/notice-of-extraordinary-general-meeting-and-shareholders-circular-london-friday-hcm-20190503monthly0.5https://www.biopharmawatch.com/news/HCM/results-of-annual-general-meeting-london-wednesday-hcm-20190424monthly0.5https://www.biopharmawatch.com/news/HCM/business-overview-we-are-an-innovative-commercial-stage-biopharmaceutical-company-based-in-hcm-20190415monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-iib-iii-trial-of-surufatinib-in-patients-with-unresectable-or-me-hcm-20190329monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-oral-presentations-on-savolitinib-lung-cancer-programs-at-aacr-annual-m-hcm-20190328monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-london-monday-hcm-20190325monthly0.5https://www.biopharmawatch.com/news/HCM/annual-report-and-notice-of-annual-general-meeting-london-thursday-hcm-20190321monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-reports-2018-full-year-results-and-provides-updates-on-key-clinical-programs-londo-hcm-20190311monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-preliminary-phase-ii-savolitinib-imfinzi-xae-combination-data-in-advanc-hcm-20190212monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2018-final-results-london-friday-hcm-20190208monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-present-at-the-37-th-annual-jp-morgan-healthcare-conference-london-monday-hcm-20190107monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-london-monday-hcm-20181231monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-amendment-to-the-2013-license-collaboration-agreement-on-fruquintinib-wi-hcm-20181220monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20181214monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20181130monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-enters-into-multiple-collaborations-to-evaluate-combinations-of-surufatinib-and-fr-hcm-20181129monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-first-commercial-launch-of-fruquintinib-capsules-elunate-xae-london-mond-hcm-20181126monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-phase-iii-faluca-trial-results-for-fruquintinib-in-third-line-advanced-n-hcm-20181116monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-wednesday-hcm-20181031monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-monday-hcm-20181022monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-i-trial-of-hmpl-523-in-combination-with-azacitidine-in-elderly-p-hcm-20181018monthly0.5https://www.biopharmawatch.com/news/HCM/appointment-of-hsbc-bank-plc-as-joint-corporate-broker-in-london-london-friday-hcm-20181005monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-the-approval-of-fruquintinib-capsules-for-previously-treated-colorectal--hcm-20180905monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20180831monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-tuesday-hcm-20180807monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-reports-2018-interim-results-and-updates-shareholders-on-key-clinical-programs-fin-hcm-20180727monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-ib-ii-proof-of-concept-trial-of-sulfatinib-in-pancreatic-neuroen-hcm-20180723monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2018-half-year-financial-results-london-friday-hcm-20180629monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-thursday-hcm-20180607monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-presents-further-fruquintinib-fresco-trial-data-at-asco-2018-annual-meeting-x2013--hcm-20180604monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-thursday-hcm-20180531monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-present-at-bank-of-america-merrill-lynch-annual-health-care-conference-london-f-hcm-20180511monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-monday-hcm-20180430monthly0.5https://www.biopharmawatch.com/news/HCM/results-of-annual-general-meeting-london-friday-hcm-20180427monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-monday-hcm-20180423monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-thursday-hcm-20180329monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-london-wednesday-hcm-20180328monthly0.5https://www.biopharmawatch.com/news/HCM/annual-report-and-notice-of-annual-general-meeting-london-monday-hcm-20180326monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-wednesday-hcm-20180321monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-share-options-under-share-option-scheme-london-tuesday-hcm-20180320monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-monday-hcm-20180319monthly0.5https://www.biopharmawatch.com/news/HCM/hutchison-china-meditech-limited-chi-med-reports-final-results-for-the-year-ended-hcm-20180312monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-ib-ii-proof-of-concept-trial-of-epitinib-in-glioblastoma-in-chin-hcm-20180306monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-completes-enrollment-of-527-patients-in-pivotal-phase-iii-faluca-trial-with-fruqui-hcm-20180213monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2017-final-results-london-monday-hcm-20180205monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-london-friday-hcm-20171229monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-fruquintinib-u-s-clinical-trials-london-friday-hcm-20171215monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-hcm-20171101monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-the-closing-of-u-s-public-offering-of-american-depositary-shares-adss-ra-hcm-20171030monthly0.5https://www.biopharmawatch.com/news/HCM/not-for-release-publication-or-distribution-in-whole-or-in-part-in-or-into-or-from-any-jur-hcm-20171027monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-pricing-of-u-s-public-offering-of-adss-raising-us-262-million-on-nasdaq--hcm-20171025monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-proposed-offering-of-adss-london-tuesday-hcm-20171024monthly0.5https://www.biopharmawatch.com/news/HCM/tr-1-notification-of-major-interest-in-shares-i-1-identity-of-the-issuer-or-the-underlying-hcm-20171019monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-and-astrazeneca-s-savolitinib-shows-encouraging-clinical-activity-in-second-line-e-hcm-20171017monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-reports-preliminary-phase-ii-data-on-fruquintinib-combination-in-first-line-lung-c-hcm-20171016monthly0.5https://www.biopharmawatch.com/news/HCM/appointment-of-director-london-thursday-hcm-20171012monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20170929monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-thursday-hcm-20170831monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-i-clinical-trial-of-selective-pi3k-x3b4-inhibitor-hmpl-689-in-ly-hcm-20170829monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-tuesday-hcm-20170822monthly0.5https://www.biopharmawatch.com/news/HCM/directors-share-dealing-london-friday-hcm-20170818monthly0.5https://www.biopharmawatch.com/news/HCM/directors-share-dealing-london-tuesday-hcm-20170815monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-thursday-hcm-20170810monthly0.5https://www.biopharmawatch.com/news/HCM/directors-share-dealing-london-monday-hcm-20170807monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-reports-2017-interim-results-and-updates-shareholders-on-key-clinical-programs-lon-hcm-20170731monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20170630monthly0.5https://www.biopharmawatch.com/news/HCM/astrazeneca-plc-x201c-astrazeneca-x201d-lon-sto-nyse-azn-hutchison-china-meditech-limited--hcm-20170629monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-i-ii-clinical-trial-of-novel-fgfr-inhibitor-hmpl-453-in-china-lo-hcm-20170622monthly0.5https://www.biopharmawatch.com/news/HCM/directors-share-dealing-london-friday-hcm-20170616monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-submits-new-drug-application-to-cfda-for-fruquintinib-in-advanced-colorectal-cance-hcm-20170612monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-highlights-phase-iii-fruquintinib-data-in-oral-presentation-at-asco-chicago-monday-hcm-20170605monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-presents-clinical-data-at-asco-2017-annual-meeting-x2013-fresco-phase-iii-trial-re-hcm-20170518monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20170428monthly0.5https://www.biopharmawatch.com/news/HCM/results-of-annual-general-meeting-london-thursday-hcm-20170427monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-presented-pre-clinical-data-for-fruquintinib-and-sulfatinib-at-the-american-associ-hcm-20170407monthly0.5https://www.biopharmawatch.com/news/HCM/london-friday-march-31-2017-for-information-purposes-hutchison-china-meditech-limited-chi--hcm-20170331monthly0.5https://www.biopharmawatch.com/news/HCM/vesting-of-awards-under-the-long-term-incentive-plan-hcm-20170329monthly0.5https://www.biopharmawatch.com/news/HCM/annual-report-and-notice-of-annual-general-meeting-london-monday-hcm-20170327monthly0.5https://www.biopharmawatch.com/news/HCM/london-friday-march-24-2017-hutchison-china-meditech-limited-chi-med-or-the-company-aim-na-hcm-20170324monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-host-r-d-briefings-on-march-29-30-2017-hcm-20170321monthly0.5https://www.biopharmawatch.com/news/HCM/grant-of-awards-under-long-term-incentive-plan-hcm-20170316monthly0.5https://www.biopharmawatch.com/news/HCM/hutchison-china-meditech-limited-chi-med-reports-final-results-for-the-year-ended-december-hcm-20170313monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-presented-sulfatinib-neuroendocrine-tumors-phase-ib-ii-results-at-the-14th-annual--hcm-20170310monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-announces-positive-top-line-results-for-fresco-its-phase-iii-pivotal-registration--hcm-20170303monthly0.5https://www.biopharmawatch.com/news/HCM/london-tuesday-february-28-2017-hutchison-china-meditech-limited-chi-med-or-the-company-ai-hcm-20170228monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-a-phase-ii-study-of-savolitinib-in-pulmonary-sarcomatoid-carcinoma-hcm-20170221monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-and-astrazeneca-present-savolitinib-papillary-renal-cell-carcinoma-phase-ii-result-hcm-20170214monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2016-final-results-london-monday-hcm-20170206monthly0.5https://www.biopharmawatch.com/news/HCM/change-of-directors-london-wednesday-hcm-20170201monthly0.5https://www.biopharmawatch.com/news/HCM/change-of-directors-london-monday-hcm-20170116monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-hmpl-523-clinical-trials-in-hematological-cancer-in-china-london-tuesday-hcm-20170110monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20161230monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-london-thursday-hcm-20161229monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-tuesday-hcm-20161220monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-wednesday-hcm-20161214monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-presents-pre-clinical-data-for-selective-syk-inhibitor-hmpl-523-at-the-2016-americ-hcm-20161206monthly0.5https://www.biopharmawatch.com/news/HCM/london-wednesday-november-30-2016-for-information-purposes-hutchison-china-meditech-limite-hcm-20161130monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-present-data-from-proof-of-concept-clinical-trials-for-fruquintinib-and-epitini-hcm-20161123monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-presents-phase-i-clinical-data-for-selective-syk-inhibitor-hcm-20161114monthly0.5https://www.biopharmawatch.com/news/HCM/london-tuesday-november-1-2016-hutchison-china-meditech-limited-chi-med-aim-nasdaq-hcm-has-hcm-20161101monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-commercial-platform-joint-venture-receives-us-59-5-million-land-compensation-payme-hcm-20161031monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-wednesday-october-12-2016-hutchison-china-meditech-limited-hcm-20161007monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-share-dealing-london-tuesday-august-9-2016-hutchison-china-meditech-limited-chi-hcm-20160804monthly0.5https://www.biopharmawatch.com/news/HCM/hutchison-china-meditech-limited-chi-med-reports-interim-results-for-the-six-months-ended-hcm-20160802monthly0.5https://www.biopharmawatch.com/news/HCM/astrazeneca-plc-astrazeneca-hutchison-china-meditech-limited-chi-med-lon-sto-nyse-azn-aim--hcm-20160801monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-to-announce-2016-half-year-financial-results-london-tuesday-hcm-20160705monthly0.5https://www.biopharmawatch.com/news/HCM/blocklisting-six-monthly-return-london-wednesday-hcm-20160629monthly0.5https://www.biopharmawatch.com/news/HCM/savolitinib-global-phase-ii-trial-initiated-in-egfr-mutant-non-small-cell-lung-cancer-init-hcm-20160621monthly0.5https://www.biopharmawatch.com/news/HCM/block-admission-london-wednesday-june-15-2016-hutchison-china-meditech-limited-chi-med-aim-hcm-20160616monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-tuesday-hcm-20160531monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-completes-enrollment-of-416-patients-in-pivotal-phase-iii-fresco-trial-with-fruqui-hcm-20160516monthly0.5https://www.biopharmawatch.com/news/HCM/total-voting-rights-london-friday-hcm-20160429monthly0.5https://www.biopharmawatch.com/news/HCM/results-of-annual-general-meeting-london-wednesday-hcm-20160427monthly0.5https://www.biopharmawatch.com/news/HCM/hutchison-china-meditech-limited-announces-exercise-of-overallotment-option-london-wednesd-hcm-20160413monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-first-in-human-clinical-trial-of-novel-pi3k-inhibitor-hmpl-689-london-tu-hcm-20160407monthly0.5https://www.biopharmawatch.com/news/HCM/director-s-shareholding-london-tuesday-march-29-2016-hutchison-china-meditech-limited-chi--hcm-20160325monthly0.5https://www.biopharmawatch.com/news/HCM/incorporated-in-the-cayman-islands-with-limited-liability-aim-code-hcm-15-march-2016-dear--hcm-20160324monthly0.5https://www.biopharmawatch.com/news/HCM/chi-med-initiates-sulfatinib-phase-iii-registration-study-in-pancreatic-neuroendocrine-tum-hcm-20160321monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-shareholders-adopt-all-resolutions-proposed-by-the-board-of-directors-at-the-ann-lkft-20260428monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-in-cla-lkft-20260331monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-publishes-2025-annual-report-and-announces-annual-and-extraordinary-shareholders-lkft-20260326monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-half-year-2025-financial-results-and-provides-second-quarter-business-up-lkft-20250724monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-publishes-2024-annual-report-and-announces-annual-shareholders-meeting-mechelen--lkft-20250327monthly0.5https://www.biopharmawatch.com/news/LKFT/certain-confidential-portions-of-this-exhibit-have-been-omitted-and-replaced-with-such-ide-lkft-20250212monthly0.5https://www.biopharmawatch.com/news/LKFT/exhibit-ex99-1-galapagos-reports-half-year-2024-financial-results-and-provides-second-quar-lkft-20240801monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-publishes-2023-annual-report-and-announces-annual-and-extraordinary-shareholders-lkft-20240329monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-announces-first-half-year-2023-financial-results-half-year-2023-key-financials-g-lkft-20230804monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-publishes-2022-annual-report-and-announces-annual-shareholders-meeting-publicati-lkft-20230327monthly0.5https://www.biopharmawatch.com/news/LKFT/j-p-morgan-healthcare-conference-lkft-20230109monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-announces-strategy-to-accelerate-innovation-and-reports-strong-third-quarter-202-lkft-20221107monthly0.5https://www.biopharmawatch.com/news/LKFT/first-key-steps-in-pipeline-rebuild-and-strong-commercial-progress-in-h1-2022-first-half-y-lkft-20220808monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-demonstrates-regulatory-and-commercial-progress-in-q1-2022-first-three-months-20-lkft-20220506monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-publishes-2021-annual-report-and-announces-extraordinary-and-annual-shareholders-lkft-20220325monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-commercial-and-operational-progress-at-q3-financial-results-first-nine-m-lkft-20211108monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-h1-financial-results-with-refocused-pipeline-and-operational-progress-fi-lkft-20210805monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-refocuses-pipeline-and-rightsizes-operations-first-three-months-2021-financial-r-lkft-20210511monthly0.5https://www.biopharmawatch.com/news/LKFT/publication-of-the-annual-report-and-invitation-to-the-ordinary-shareholders-meeting-meche-lkft-20210325monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-q3-2020-results-first-nine-months-2020-financial-results-group-revenues--lkft-20201109monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-solid-h1-2020-progress-first-half-year-2020-financial-results-o-group-re-lkft-20200806monthly0.5https://www.biopharmawatch.com/news/LKFT/on-track-for-clinical-read-outs-and-commercial-readiness-in-2020-first-three-month-2020-fi-lkft-20200511monthly0.5https://www.biopharmawatch.com/news/LKFT/publication-of-the-annual-report-and-invitation-to-the-ordinary-and-extraordinary-sharehol-lkft-20200327monthly0.5https://www.biopharmawatch.com/news/LKFT/solid-third-quarter-2019-performance-with-strong-balance-sheet-for-continued-r-d-growth-fi-lkft-20191025monthly0.5https://www.biopharmawatch.com/news/LKFT/invitation-to-the-special-and-extraordinary-shareholders-meetings-mechelen-belgium-20-sept-lkft-20190920monthly0.5https://www.biopharmawatch.com/news/LKFT/gilead-and-galapagos-complete-closing-of-their-transformative-research-and-development-col-lkft-20190823monthly0.5https://www.biopharmawatch.com/news/LKFT/strong-clinical-progress-in-h1-and-transformative-collaboration-with-gilead-announced-xb7--lkft-20190725monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-on-historic-first-quarter-2019-key-q1-2019-results-group-revenues-of-40--lkft-20190426monthly0.5https://www.biopharmawatch.com/news/LKFT/publication-of-the-annual-report-and-invitation-to-the-annual-shareholders-meeting-nominat-lkft-20190401monthly0.5https://www.biopharmawatch.com/news/LKFT/hallmark-third-quarter-2018-and-annual-r-d-update-at-galapagos-first-nine-months-financial-lkft-20181026monthly0.5https://www.biopharmawatch.com/news/LKFT/productive-first-half-year-at-galapagos-xb7-first-half-year-financial-results-o-group-reve-lkft-20180802monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-first-quarter-2018-results-key-q1-2018-results-group-revenues-of-44-8-mi-lkft-20180427monthly0.5https://www.biopharmawatch.com/news/LKFT/publication-of-the-annual-report-and-invitation-to-the-annual-shareholders-meeting-mechele-lkft-20180323monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-q3-clinical-success-with-glpg1690-and-mor106-highlights-strength-of-deep-pipelin-lkft-20171030monthly0.5https://www.biopharmawatch.com/news/LKFT/solid-financials-support-r-d-progress-first-half-year-financial-results-revenues-73-0-m-an-lkft-20170731monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-reports-first-quarter-2017-results-key-q1-2017-results-group-revenues-more-than--lkft-20170428monthly0.5https://www.biopharmawatch.com/news/LKFT/galapagos-announces-launch-of-proposed-public-offering-mechelen-belgium-17-april-2017-22-1-lkft-20170418monthly0.5https://www.biopharmawatch.com/news/LKFT/march-2017-22-00-cet-publication-of-the-annual-report-and-invitation-to-the-annual-and-ext-lkft-20170323monthly0.5https://www.biopharmawatch.com/news/LKFT/robust-progress-in-q3-2016-lkft-20161109monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-28-july-2016-22-00-cet-focus-on-filgotinib-and-cystic-fibrosis-first-lkft-20160801monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-23-june-2016-7-30-cet-invitation-to-the-special-and-extraordinary-sh-lkft-20160629monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-19-january-2016-22-40-cet-galapagos-and-gilead-complete-closing-of-t-lkft-20160119monthly0.5https://www.biopharmawatch.com/news/LKFT/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2015-11-12-16-56-17-lkft-20151113monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-25-september-2015-16-45-cet-galapagos-to-advance-filgotinib-to-phase-lkft-20150928monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-10-august-2015-22-00-cet-darwin-2-24-week-monotherapy-data-in-ra-con-lkft-20150812monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-5-august-2015-22-00-cet-galapagos-on-track-to-deliver-on-pipeline-in-lkft-20150806monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-29-july-2015-galapagos-selective-jak1-inhibitor-filgotinib-meets-key-lkft-20150731monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-19-june-2015-galapagos-raises-4-4-million-through-warrant-exercises--lkft-20150624monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-18-june-2015-galapagos-completes-recruitment-for-origin-phase-2-tria-lkft-20150619monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-15-june-2015-abbvie-and-galapagos-present-cystic-fibrosis-corrector--lkft-20150616monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-10-june-2015-galapagos-darwin-1-and-2-studies-have-completed-24-week-lkft-20150611monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-26-may-2015-galapagos-receives-transparency-notifications-mechelen-b-lkft-20150514monthly0.5https://www.biopharmawatch.com/news/LKFT/regulated-information-18-may-2015-galapagos-announces-full-exercise-of-underwriters-option-lkft-20150514monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-private-placement-of-250-0-million-of-convertible-senior-notes-sndx-20260604monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-first-quarter-2026-financial-results-and-provides-business-update-x2022-tot-sndx-20260430monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-u-sndx-20260226monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-preliminary-2025-financial-highlights-and-provides-business-updates-at-the--sndx-20260112monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-third-quarter-2025-financial-results-and-provides-business-update-x2022-45--sndx-20251024monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-second-quarter-2025-financial-results-and-provides-business-update-x2022-28-sndx-20250804monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-appoints-dr-nicholas-botwood-as-head-of-research-and-development-an-sndx-20250512monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-first-quarter-2025-financial-results-and-provides-business-update-x2022-20--sndx-20250505monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-u-sndx-20250303monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-fda-approval-of-revuforj-revumenib-the-first-and-only-menin-inhibitor-to--sndx-20241115monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-positive-pivotal-topline-results-from-relapsed-or-refractory-mnpm1-aml-co-sndx-20241112monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update-x2013-new-sndx-20241105monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-second-quarter-2024-financial-results-and-provides-clinical-and-business-up-sndx-20240801monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-appoints-aleksandra-rizo-m-d-ph-d-to-the-board-of-directors-sndx-20240515monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-clinical--sndx-20240508monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-appointment-of-steven-closter-as-chief-commercial-officer-x2013-steven-cl-sndx-20240318monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-pro-sndx-20240227monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-closing-of-public-offering-of-common-stock-and-exercise-in-full-of-the-un-sndx-20231219monthly0.5https://www.biopharmawatch.com/news/SNDX/incyte-and-syndax-present-additional-data-from-positive-agave-201-trial-at-ash-plenary-ses-sndx-20231210monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-clinical--sndx-20231102monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-pivotal-augment-101-trial-of-revumenib-in-relapsed-refractory-kmt2ar-acut-sndx-20231002monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-clinical-sndx-20230803monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-and-incyte-announce-positive-topline-results-from-the-pivotal-agave-201-trial-of-ax-sndx-20230724monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-clinical--sndx-20230508monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-appointment-of-neil-gallagher-m-d-ph-d-as-president-head--sndx-20230330monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-pro-sndx-20230228monthly0.5https://www.biopharmawatch.com/news/SNDX/estimate-intend-and-similar-expressions-as-well-as-other-words-or-expressions-referencing--sndx-20221214monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-appointment-of-steve-sabus-as-chief-commercial-officer-sndx-20221202monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-clinical--sndx-20221103monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-clinical-sndx-20220808monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-appointment-of-keith-a-goldan-as-chief-financial-officer-sndx-20220613monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-clinical--sndx-20220509monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-fourth-quarter-2021-financial-results-and-provides-clinical-sndx-20220301monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-transition-of-michael-a-metzger-to-chief-executive-office-sndx-20220203monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-updated-positive-data-demonstrating-broad-activity-and-to-sndx-20211211monthly0.5https://www.biopharmawatch.com/news/SNDX/unless-the-context-indicates-otherwise-references-to-syndax-the-company-we-us-our-and-simi-sndx-20211209monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-and-incyte-announce-global-collaboration-to-develop-and-commerciali-sndx-20210927monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-appoints-martin-h-huber-m-d-to-its-board-of-directors-sndx-20210915monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-sndx-20210809monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-clinical--sndx-20210511monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-fourth-quarter-2020-financial-results-and-provides-clinical-sndx-20210308monthly0.5https://www.biopharmawatch.com/news/SNDX/unless-the-context-indicates-otherwise-references-to-syndax-the-company-we-us-our-and-simi-sndx-20201206monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-clinical--sndx-20201102monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides-clinical-sndx-20200806monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-s-cautionary-note-on-forward-looking-statements-this-press-release-contains-forward-sndx-20200707monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides-clinical--sndx-20200507monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-pricing-of-public-offering-of-common-stock-sndx-20200430monthly0.5https://www.biopharmawatch.com/news/SNDX/unless-the-context-indicates-otherwise-references-to-syndax-the-company-we-us-our-and-simi-sndx-20200427monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-fourth-quarter-2019-financial-results-and-provides-clinical-sndx-20200303monthly0.5https://www.biopharmawatch.com/news/SNDX/whether-as-a-result-of-new-information-future-events-or-otherwise-company-overview-we-are--sndx-20200204monthly0.5https://www.biopharmawatch.com/news/SNDX/forward-looking-statements-forward-looking-statements-contained-in-this-press-release-incl-sndx-20191210monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-clinical--sndx-20191107monthly0.5https://www.biopharmawatch.com/news/SNDX/sndx-ex991-6-pptx-htm-corporate-presentation-october-2019-determined-to-realize-a-future-i-sndx-20191007monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-second-quarter-2019-financial-results-and-provides-clinical-sndx-20190807monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2019-financial-results-and-provides-clinical--sndx-20190506monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-fourth-quarter-2018-financial-results-and-provides-clinical-sndx-20190307monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical--sndx-20181105monthly0.5https://www.biopharmawatch.com/news/SNDX/tel-212-600-1902-sndx-g-sndx-20180926monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-second-quarter-2018-financial-results-and-provides-clinical-sndx-20180807monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical--sndx-20180508monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-fourth-quarter-2017-financial-results-and-provides-clinical-sndx-20180305monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-clinical--sndx-20171107monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-expands-pipeline-with-exclusive-worldwide-license-to-allergan-s-portfolio-of-menin--sndx-20171017monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-dosing-of-first-patient-in-pivotal-trial-of-entinostat-for-the-treatment--sndx-20171005monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-clinical-sndx-20170810monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2017-financial-results-and-provides-clinical--sndx-20170508monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-adds-biopharmaceutical-industry-leader-keith-a-katkin-to-board-of-d-sndx-20170404monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-fourth-quarter-and-year-end-2016-financial-results-and-prov-sndx-20170302monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-appoints-richard-p-shea-as-chief-financial-officer-sndx-20170209monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-third-quarter-2016-financial-results-and-provides-business--sndx-20161110monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-second-quarter-2016-financial-results-and-provides-business-sndx-20160809monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-expands-pipeline-with-exclusive-worldwide-license-agreement-for-ucb-s-colony-stimul-sndx-20160706monthly0.5https://www.biopharmawatch.com/news/SNDX/entinostat-data-to-be-highlighted-at-the-american-society-of-clinical-oncology-asco-2016-sndx-20160518monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-first-quarter-2016-financial-results-and-provides-business--sndx-20160516monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-third-quarter-2025-financial-results-and-highlights-recent-p-vrdn-20251031monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-highlights-recent-progress-and-reports-second-quarter-2025-financial-vrdn-20250806monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-collaboration-and-license-agreement-with-kissei-pharmaceut-vrdn-20250730monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-positive-long-term-durability-data-from-the-veligrotug-pha-vrdn-20250520monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-highlights-recent-progress-and-reports-first-quarter-2025-financial--vrdn-20250506monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-appoints-jeff-ajer-to-its-board-of-directors-mr-ajer-was-most-recent-vrdn-20250407monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-highlights-recent-progress-and-reports-fourth-quarter-and-full-year--vrdn-20250227monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-positive-topline-results-from-veligrotug-phase-3-thrive-2--vrdn-20241216monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-third-quarter-2024-financial-results-and-recent-progress-inc-vrdn-20241112monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-positive-topline-results-from-veligrotug-vrdn-001-phase-3--vrdn-20240910monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-highlights-recent-progress-and-reports-second-quarter-2024-financial-vrdn-20240808monthly0.5https://www.biopharmawatch.com/news/VRDN/corporate-presentation-july-2024-cautionary-note-regarding-forward-looking-statements-this-vrdn-20240715monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-highlights-recent-progress-and-reports-first-quarter-2024-financial--vrdn-20240508monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-highlights-recent-progress-and-reports-fourth-quarter-and-full-year--vrdn-20240227monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-present-key-2024-corporate-priorities-at-j-p-morgan-healthcare-co-vrdn-20240108monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-positive-clinical-data-in-healthy-volunteer-study-and-sele-vrdn-20231218monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate--vrdn-20231113monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-appoints-new-chief-executive-officer-unveils-next-generation-fcrn-in-vrdn-20231030monthly0.5https://www.biopharmawatch.com/news/VRDN/corporate-overview-july-2023-cautionary-note-regarding-forward-looking-statements-this-pre-vrdn-20230717monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-vrdn-001-in-patie-vrdn-20230710monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-prov-vrdn-20230308monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-appoints-scott-myers-as-president-and-chief-executive-officer-transition-highligh-vrdn-20230206monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-low-dose-vrdn-001-vrdn-20230108monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corporate-vrdn-20220815monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corporate--vrdn-20220512monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-prov-vrdn-20220310monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate--vrdn-20211104monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate-vrdn-20210811monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-vrdn-20210726monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-appoints-jennifer-moses-vrdn-20210715monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-first-quarter-2021-financial-results-and-provides-corporate--vrdn-20210506monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-2020-financial-results-and-provides-corporate-updates-progre-vrdn-20210325monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-enters-into-license-agreement-with-xencor-for-use-of-xtend-antibody-technology-for-vrdn-20201217monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-reports-third-quarter-2020-financial-results-and-provides-corporate-updates-recent-vrdn-20201112monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-inc-announces-acquisition-of-viridian-therapeutics-inc-vrdn-20201028monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announces-internal-review-of-preliminary-topline-data-for-the-phase-2-solar-clinic-vrdn-20201005monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announces-leadership-transition-and-review-of-strategic-alternatives-lee-rauch-app-vrdn-20200914monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-reports-second-quarter-2020-financial-results-and-provides-business-updates-progre-vrdn-20200805monthly0.5https://www.biopharmawatch.com/news/VRDN/cobomarsen-receives-orphan-drug-designation-from-the-u-s-fda-for-the-treatment-of-t-cell-l-vrdn-20200723monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announces-encouraging-preclinical-safety-and-efficacy-data-for-its-next-generation-vrdn-20200622monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-to-host-a-key-opinion-leader-call-on-idiopathic-pulmonary-fibrosis-on-tuesday-june-vrdn-20200616monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-reports-first-quarter-2020-financial-results-and-provides-corporate-update-new-atl-vrdn-20200507monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-reports-fourth-quarter-and-full-year-2019-financial-results-completed-enrollment-o-vrdn-20200311monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announces-pricing-of-15-0-vrdn-20200207monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announces-major-changes-to-company-s-strategy-expecting-topline-data-in-q3-2020-fr-vrdn-20191211monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-reports-third-quarter-2019-results-and-provides-corporate-update-announced-positiv-vrdn-20191107monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announces-new-clinical-data-showing-mrg-110-positively-impacted-tissue-repair-and--vrdn-20191016monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-reports-second-quarter-2019-results-regains-global-rights-to-mrg-110-and-announces-vrdn-20190807monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-presents-preclinical-data-in-pulmonary-fibrosis-using-second-generation-microrna-2-vrdn-20190521monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announce-s-first-quarter-2019-financial-results-and-provides-corporate-update-init-vrdn-20190508monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-announces-new-data-supporting-the-potential-use-of-remlarsen-to-preve-vrdn-20190429monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announces-new-clinical-data-for-cobomarsen-in-atll-patients-at-the-19th-annual-htl-vrdn-20190426monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announce-s-fourth-quarter-and-full-year-2018-financial-results-and-provides-2019-o-vrdn-20190313monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-to-present-new-cobomarsen-clinical-trial-data-for-adult-t-cell-leukem-vrdn-20181220monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-announces-final-safety-biodistribution-and-clinical-efficacy-data-fro-vrdn-20181202monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-announces-the-presentation-of-data-from-preclinical-studies-demonstra-vrdn-20181001monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-reports-second-quarter-2018-financial-results-and-provides-corporate--vrdn-20180807monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-and-the-leukemia-lymphoma-society-enter-into-an-agreement-to-facilita-vrdn-20180806monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-announces-initiation-of-phase-2-clinical-trial-of-mrg-201-vrdn-20180710monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-to-present-first-cobomarsen-phase-1-clinical-trial-data-from-patients-vrdn-20180604monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-reports-first-quarter-2018-financial-results-and-provides-corporate-u-vrdn-20180509monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-announces-new-interim-data-from-phase-1-clinical-trial-of-cobomarsen--vrdn-20180508monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-announces-initiation-of-second-phase-1-clinical-trial-of-mrg-110-vrdn-20180501monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-announces-new-data-showing-administration-of-mrg-110-improved-tissue--vrdn-20180427monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-announces-initiation-of-phase-1-clinical-trial-of-mrg-110-vrdn-20180327monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-provi-vrdn-20180314monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-vrdn-20180208monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-presents-new-data-from-phase-1-clinical-trial-of-mrg-106-in-mycosis-f-vrdn-20180202monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-presents-new-interim-clinical-data-expanding-on-previous-data-suggest-vrdn-20171204monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-reports-third-quarter-2017-financial-results-and-provides-corporate-u-vrdn-20171108monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-presents-new-clinical-data-suggesting-positive-impact-from-systemical-vrdn-20171013monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-presents-new-mrg-201-preclinical-data-for-inhaled-microrna-29-mimic-t-vrdn-20170911monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-reports-second-quarter-2017-financial-results-and-provides-corporate--vrdn-20170811monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-to-present-mrg-106-phase-1-clinical-trial-data-at-the-international-c-vrdn-20170608monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-presents-new-data-from-phase-1-clinical-trial-evaluating-mrg-106-in-s-vrdn-20170605monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-receives-eu-orphan-medicinal-product-designation-for-mrg-106-for-the--vrdn-20170524monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-reports-first-quarter-2017-financial-results-and-provides-corporate-u-vrdn-20170510monthly0.5https://www.biopharmawatch.com/news/VRDN/servier-and-miragen-extend-collaboration-for-the-research-development-and-commercializatio-vrdn-20170503monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-provides-corporate-update-boulder-co-vrdn-20170331monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-completes-merger-with-signal-genetics-and-concurrent-40-7-million-equ-vrdn-20170213monthly0.5https://www.biopharmawatch.com/news/VRDN/signal-announces-results-of-special-meeting-carlsbad-ca-vrdn-20170210monthly0.5https://www.biopharmawatch.com/news/VRDN/signal-genetics-sets-date-for-special-meeting-of-stockholders-carlsbad-california-vrdn-20170109monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-expands-executive-leadership-team-paul-rubin-m-d-joins-as-executive-v-vrdn-20161129monthly0.5https://www.biopharmawatch.com/news/VRDN/signal-genetics-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement-carls-vrdn-20161128monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-announces-presentation-of-mrg-106-clinical-data-at-american-society-o-vrdn-20161103monthly0.5https://www.biopharmawatch.com/news/VRDN/signal-genetics-and-miragen-therapeutics-investor-conference-call-vrdn-20161101monthly0.5https://www.biopharmawatch.com/news/VRDN/miragen-therapeutics-and-signal-genetics-sign-merger-agreement-merger-to-create-clinical-s-vrdn-20161031monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-march-31-vcel-20260507monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20260226monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20260113monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-september-vcel-20251106monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-june-30-vcel-20250731monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-march-31-vcel-20250508monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20250227monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20250114monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-september-vcel-20241107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20240826monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20240815monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-june-30-vcel-20240801monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-march-31-vcel-20240508monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20240229monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20240109monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-september-vcel-20231108monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20230920monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-june-30-vcel-20230802monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-in-thousands-unaudited-march-31-vcel-20230510monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20230223monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-preliminary-fourth-quarter-and-full-year-2022-financial-results-and-acce-vcel-20230110monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20221229monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-unaudited-amounts-in-thousands-s-vcel-20221109monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-unaudited-amounts-in-thousands-j-vcel-20220803monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-condensed-consolidated-balance-sheets-unaudited-amounts-in-thousands-m-vcel-20220504monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20220224monthly0.5https://www.biopharmawatch.com/news/VCEL/advanced-therapies-for-the-sports-medicine-and-severe-burn-care-markets-corporate-presenta-vcel-20211231monthly0.5https://www.biopharmawatch.com/news/VCEL/reconciliation-of-reported-net-income-loss-gaap-to-adjusted-ebitda-non-gaap-measure-unaudi-vcel-20211109monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20210804monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20210629monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20210602monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20210505monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20210224monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20210212monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20210125monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20210111monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20201105monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20201014monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20200916monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20200805monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20200709monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-submission-of-biologics-license-application-to-the-fda-for-nexobrid-for--vcel-20200630monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20200505monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20200402monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20200225monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20191105monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20190806monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20190507monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20190226monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20181106monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20180806monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-veri-vcel-20180530monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20180508monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20180305monthly0.5https://www.biopharmawatch.com/news/VCEL/company-presentation-january-2018-safe-harbor-this-presentation-contains-forward-looking-s-vcel-20180108monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-enters-into-expanded-25-million-debt-facilities-with-silicon-valley-vcel-20171207monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20171107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20170809monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-licenses-product-portfolio-to-innovative-cellular-therapeutics-for-distribution-in-vcel-20170510monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20170510monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20170310monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20161216monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20161214monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20161114monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20161107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5554-www--vcel-20160912monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20160808monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20160510monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5668-www--vcel-20160405monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20160328monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20160314monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-588-5555-f-617-588-5668-www--vcel-20160310monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20160307monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20160222monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20160104monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20151208monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20151113monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20151026monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20150812monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20150514monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20150323monthly0.5https://www.biopharmawatch.com/news/VCEL/company-presentation-january-2015-safe-harbor-this-presentation-contains-forward-looking-s-vcel-20150112monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20150107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-64-sidney-street-cambridge-ma-02139-t-617-252-7999-f-617-252-7550-www--vcel-20141124monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-reports-third-quarter-2014-financial-results-conference-call-today-at--vcel-20141113monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-announces-plans-to-change-name-to-vericel-corporation-and-move-headqua-vcel-20141009monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-vcel-20140917monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-announces-pricing-of-public-offering-of-common-stock-vcel-20140911monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-reports-second-quarter-2014-financial-results-u-s-commercial-business--vcel-20140814monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-domino-s-farms-lobby-k-24-frank-lloyd-wright-drive-ann-arbor-mi-48105--vcel-20140616monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-domino-s-farms-lobby-k-24-frank-lloyd-wright-drive-ann-arbor-mi-48105--vcel-20140604monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-domino-s-farms-lobby-k-24-frank-lloyd-wright-drive-ann-arbor-mi-48105--vcel-20140602monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-domino-s-farms-lobby-k-24-frank-lloyd-wright-drive-ann-arbor-mi-48105--vcel-20140421monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-announces-appointments-of-dr-ross-tubo-as-chief-scientific-officer-and-dr-david-re-vcel-20140401monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-enters-into-15-million-equity-commitment-with-lincoln-park-capital-vcel-20140127monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-reports-third-quarter-and-nine-month-2013-financial-results-conference-vcel-20131112monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-announces-one-for-twenty-reverse-stock-split-vcel-20131010monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-inc-announces-pricing-of-public-offering-of-common-stock-and-warrants-vcel-20130813monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-announces-amendment-of-series-b-preferred-stock-certificate-of-designa-vcel-20130812monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-reports-second-quarter-and-first-half-2013-financial-results-conferenc-vcel-20130807monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-reports-first-quarter-2013-financial-results-conference-call-today-at--vcel-20130508monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-the-future-of-cell-therapy-april-2013-safe-harbor-this-presentation-co-vcel-20130423monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-domino-s-farms-lobby-k-24-frank-lloyd-wright-drive-ann-arbor-mi-48105--vcel-20130327monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-domino-s-farms-lobby-k-24-frank-lloyd-wright-drive-ann-arbor-mi-48105--vcel-20130306monthly0.5https://www.biopharmawatch.com/news/VCEL/aastrom-biosciences-domino-s-farms-lobby-k-24-frank-lloyd-wright-drive-ann-arbor-mi-48105--vcel-20121212monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2025-financial-results-and-recent-corporate-d-srpt-20251103monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-strategic-restructuring-and-pipeline-prioritization-plan-to-srpt-20250716monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-rec-srpt-20250226monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-net-product-rev-srpt-20250113monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2023-net-product-rev-srpt-20240108monthly0.5https://www.biopharmawatch.com/news/SRPT/this-presentation-contains-x201c-forward-looking-statements-x201d-any-statements-that-are--srpt-20230622monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fda-approval-of-elevidys-the-first-gene-therapy-to-treat-du-srpt-20230622monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-gene-therapy-srp-9001-shows-statistically-significant-functional-impr-srpt-20220110monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-preliminary-financial-results-for-the-third-quarter-ended-srpt-20210930monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-initiate-part-b-of-momentum-study-of-srp-5051-in-patients-with-duc-srpt-20210927monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-investigational-gene-therapy-for-the-treatment-of-duchenne-muscular-d-srpt-20210518monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-reports-positive-clinical-results-from-phase-2-momentum-study-of-srp--srpt-20210503monthly0.5https://www.biopharmawatch.com/news/SRPT/forward-looking-statements-this-presentation-contains-forward-looking-statements-any-state-srpt-20210111monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-top-line-results-for-part-1-of-study-102-evaluating-srp-900-srpt-20210107monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-provides-program-update-for-srp-9001-its-investigational-gene-therapy-srpt-20200909monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-positive-expression-and-functional-data-from-the-srp-9003-g-srpt-20200608monthly0.5https://www.biopharmawatch.com/news/SRPT/some-see-slow-and-steady-scientific-progress-we-see-a-revolution-doug-ingram-president-and-srpt-20200113monthly0.5https://www.biopharmawatch.com/news/SRPT/and-then-advance-our-srp-9003-program-along-with-our-other-five-lgmd-programs-as-rapidly-a-srpt-20191004monthly0.5https://www.biopharmawatch.com/news/SRPT/letter-and-find-an-expeditious-pathway-forward-for-the-approval-of-golodirsen-and-our-imme-srpt-20190820monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-comments-on-erroneous-submission-to-us-fda-adverse-event-reporting-sy-srpt-20190808monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-positive-expression-results-from-the-casimersen-srp-4045-ar-srpt-20190328monthly0.5https://www.biopharmawatch.com/news/SRPT/forward-looking-statements-this-presentation-contains-forward-looking-statements-any-state-srpt-20190325monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-350-000-000-public-offering-of-common-stock-srpt-20190305monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-2018-and-full-year-2018-financial-results-an-srpt-20190227monthly0.5https://www.biopharmawatch.com/news/SRPT/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-srpt-20181231monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-500-000-000-public-offering-of-common-stock-srpt-20181107monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-consolidated-balance-sheets-unaudited-in-thousands-except-share-a-srpt-20181024monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-that-at-the-23-rd-international-congress-of-the-world-muscl-srpt-20181003monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-that-at-its-first-r-d-day-jerry-mendell-m-d-presented-posit-srpt-20180619monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2018-financial-results-and-recent-corporate-d-srpt-20180503monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-plan-to-submit-a-new-drug-application-nda-for-accelerated-a-srpt-20180312monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-2017-and-full-year-2017-financial-results-an-srpt-20180301monthly0.5https://www.biopharmawatch.com/news/SRPT/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-srpt-20171231monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-offering-of-375-million-of-convertible-senior-note-srpt-20171107monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2017-financial-results-and-recent-corporate-d-srpt-20171025monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-250-million-public-offering-of-common-stock-cambri-srpt-20170724monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2017-financial-results-and-recent-corporate--srpt-20170719monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-secures-100-million-in-debt-financing-srpt-20170718monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-biomarin-pharmaceutical-inc-announce-execution-of-a-global-settle-srpt-20170718monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-douglas-s-ingram-as-president-and-chief-executive-officer-mr-srpt-20170628monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2017-financial-results-and-recent-corporate-d-srpt-20170427monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2016-financial-results-and-rec-srpt-20170228monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-agrees-to-sale-of-priority-review-voucher-for-125m-sale-of-prv-provid-srpt-20170221monthly0.5https://www.biopharmawatch.com/news/SRPT/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-srpt-20170110monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2016-financial-results-and-recent-corporate-d-srpt-20161027monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-summit-enter-into-exclusive-license-and-collaboration-agreement-f-srpt-20161004monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-public-offering-of-common-stock-cambridge-ma-srpt-20160921monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-favorable-uspto-decisions-in-exon-51-and-exon-53-compositio-srpt-20160920monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fda-accelerated-approval-of-exondys-51-eteplirsen-injection-srpt-20160919monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2016-financial-results-and-recent-corporate--srpt-20160719monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-offering-cambridge-mass-business-wire-srpt-20160608monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fda-request-for-dystrophin-data-prior-to-making-a-decision--srpt-20160606monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2016-financial-results-and-recent-corporate-d-srpt-20160505monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2015-financial-results-and-rec-srpt-20160225monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2015-financial-results-and-recent-corporate-d-srpt-20151105monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-public-offering-of-common-stock-cambridge-ma-srpt-20151005monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-investor-update-srpt-20151001monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2015-financial-results-and-recent-corporate--srpt-20150806monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-secures-40-million-in-debt-financing-cambridge-mass-business-wire-srpt-20150629monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2015-financial-results-and-recent-corporate-d-srpt-20150507monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-edward-kaye-m-d-as-interim-ceo-company-on-track-with-clinica-srpt-20150401monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2014-financial-results-and-rec-srpt-20150226monthly0.5https://www.biopharmawatch.com/news/SRPT/realizing-the-potential-of-rna-based-technology-jp-morgan-healthcare-conference-january-15-srpt-20150112monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2014-financial-results-and-recent-corporate-d-srpt-20141106monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-regulatory-update-on-eteplirsen-updated-and-additional-guid-srpt-20141027monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2014-financial-results-and-recent-corporate--srpt-20140807monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-appointment-of-john-hodgman-as-interim-chairman-board-of-di-srpt-20140731monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-and-media-contact-jim-baker-617-274-4010-jbaker-sarepta-com-sarepta-thera-srpt-20140522monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-and-media-contact-jim-baker-617-274-4010-jbaker-sarepta-com-sarepta-thera-srpt-20140508monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-public-offering-of-common-stock-cambridge-ma-srpt-20140422monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-contact-erin-cox-617-274-4014-ecox-sarepta-com-sarepta-media-contact-jim--srpt-20140421monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-contact-erin-cox-857-242-3714-ecox-sarepta-com-sarepta-media-contact-jim--srpt-20140227monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-contact-erin-cox-857-242-3714-ecox-sarepta-com-sarepta-media-contact-jim--srpt-20140109monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-contact-erin-cox-857-242-3714-ecox-sarepta-com-sarepta-media-contact-jim--srpt-20131112monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-contact-erin-cox-857-242-3714-ecox-sarepta-com-sarepta-media-contact-jim--srpt-20130808monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-plans-to-submit-new-drug-application-to-fda-for-eteplirsen--srpt-20130724monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-contact-erin-cox-857-242-3714-ecox-sarepta-com-sarepta-media-contact-jim--srpt-20130703monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-contact-erin-cox-857-242-3714-ecox-sareptatherapeutics-com-sarepta-media--srpt-20130509monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-contact-erin-cox-1-857-242-3714-ecox-sareptatherapeutics-com-sarepta-medi-srpt-20130411monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-and-media-contact-erin-cox-425-354-5140-ecox-sareptatherapeutics-com-sare-srpt-20121212monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-and-media-contact-erin-cox-425-354-5140-ecox-sareptatherapeutics-com-sare-srpt-20121107monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-and-media-contact-erin-cox-425-354-5140-ecox-sareptatherapeutics-com-sare-srpt-20121105monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-and-media-contact-erin-cox-425-354-5140-ecox-sareptatherapeutics-com-sare-srpt-20121003monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-and-media-contact-erin-cox-425-354-5140-ecox-sareptatherapeutics-com-sare-srpt-20120904monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-investor-and-media-contact-erin-cox-425-354-5140-ecox-sareptatherapeutics-com-sare-srpt-20120807monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-erin-cox-425-354-5140-ecox-sareptatherapeutics-com-avi-biop-srpt-20120712monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-erin-cox-425-354-5140-ecox-avibio-com-avi-biopharma-receive-srpt-20120601monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-investor-and-media-contact-erin-cox-425-354-5140-ecox-avibio-com-avi-biopharma-announc-srpt-20120510monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-erin-cox-425-354-5140-ecox-avibio-com-avi-media-contact-dav-srpt-20120425monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-investor-and-media-contact-erin-cox-425-354-5140-ecox-avibio-com-avi-media-contact-dav-srpt-20120402monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-investor-and-media-contact-erin-cox-425-354-5140-ecox-avibio-com-avi-media-contact-dav-srpt-20120301monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-erin-cox-425-354-5140-ecox-avibio-com-avi-media-contact-dav-srpt-20111214monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-investor-and-media-contact-erin-cox-425-354-5140-ecox-avibio-com-avi-media-contact-dav-srpt-20111103monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-investor-and-media-contact-david-schull-russo-partners-858-717-2310-or-212-845-4271-da-srpt-20110804monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-david-a-walsey-senior-director-investor-relations-corporate-srpt-20110609monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-david-a-walsey-senior-director-investor-relations-corporate-srpt-20110606monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-david-a-walsey-senior-director-investor-relations-corporate-srpt-20110505monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-david-a-walsey-senior-director-investor-relations-corporate-srpt-20110406monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-david-a-walsey-senior-director-investor-relations-corporate-srpt-20110401monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-david-a-walsey-senior-director-investor-relations-corporate-srpt-20110328monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-david-a-walsey-senior-director-investor-relations-corporate-srpt-20110310monthly0.5https://www.biopharmawatch.com/news/SRPT/avi-media-and-investor-contact-david-a-walsey-senior-director-investor-relations-corporate-srpt-20101213monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-guides-to-over-1-billion-in-wakix-revenue-in-2026-advancing-robust-lat-hrmy-20260112monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-q3-2025-financial-results-recently-raised-2025-revenue--hrmy-20251104monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-preannounces-strong-q3-2025-wakix-performance-raises-2025-hrmy-20251023monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-provides-update-from-its-phase-3-reconnect-study-of-zyn002-in-fragile--hrmy-20250924monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-q2-2025-financial-results-and-reaffirms-2025-revenue-gu-hrmy-20250805monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-presents-preclinical-data-demonstrating-significant-wake-promoting-and-hrmy-20250611monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-q1-2025-financial-results-highlights-advancement-of-its-hrmy-20250506monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-2024-financial-results-and-reiterates-2025-net-revenue--hrmy-20250225monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-2024-revenues-provides-2025-revenue-guidance-and-highli-hrmy-20250113monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-third-quarter-2024-financial-results-and-highlights-cat-hrmy-20241029monthly0.5https://www.biopharmawatch.com/news/HRMY/copyright-xa9-2024-harmony-biosciences-all-rights-reserved-investor-day-2024-hrmy-20241001monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-second-quarter-2024-financial-results-and-advances-pito-hrmy-20240806monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-first-quarter-financial-results-and-acceleration-of-its-hrmy-20240430monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-busine-hrmy-20240222monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-preliminary-unaudited-fourth-quarter-and-full-year-2023-net-product-re-hrmy-20240108monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-appoints-peter-anastasiou-to-its-board-of-directors-hrmy-20231108monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-strong-third-quarter-2023-financial-results-continued-strong-g-hrmy-20231031monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-announces-topline-data-from-phase-3-intune-study-evaluating-pitolisant-hrmy-20231013monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-completes-acquisition-of-zynerba-pharmaceuticals-and-expands-pipeline--hrmy-20231011monthly0.5https://www.biopharmawatch.com/news/HRMY/execution-version-schedule-a-subject-securities-common-shares-company-restricted-stock-awa-hrmy-20230814monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-second-quarter-2023-financial-results-and-business-updates-wak-hrmy-20230801monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-enters-into-185-million-term-loan-facility-financing-further-strengthe-hrmy-20230727monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-first-quarter-2023-financial-results-and-business-updates-waki-hrmy-20230502monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-announces-j-effrey-m-dayno-m-d-appointed-president-chief-executive-off-hrmy-20230424monthly0.5https://www.biopharmawatch.com/news/HRMY/the-forward-looking-statements-made-in-this-press-release-any-such-forward-looking-stateme-hrmy-20230329monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-busine-hrmy-20230221monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-appoints-jeffrey-dayno-hrmy-20230106monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-third-quarter-2022-financial-results-and-business-updates-waki-hrmy-20221101monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-second-quarter-2022-financial-results-and-business-updates-wak-hrmy-20220802monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-first-quarter-2022-financial-results-and-business-updates-waki-hrmy-20220503monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-busine-hrmy-20220228monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-third-quarter-2021-financial-results-and-business-updates-waki-hrmy-20211109monthly0.5https://www.biopharmawatch.com/news/HRMY/conference-call-transcript-harmony-biosciences-holdings-inc-earnings-conference-call-secon-hrmy-20210810monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-first-quarter-2021-results-and-business-updates-wakix-pitolisa-hrmy-20210511monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-fourth-quarter-and-full-year-2020-financial-results-and-busine-hrmy-20210325monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-to-be-added-to-russell-2000-and-russell-3000-indexes-plymouth-meeting--hrmy-20201217monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-enrolls-first-patient-in-phase-2-trial-evaluating-pitolisant-for-exces-hrmy-20201215monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-reports-third-quarter-2020-financial-results-and-business-updates-waki-hrmy-20201112monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-appoints-mark-graf-and-eric-motley-to-its-board-of-directors-plymouth--hrmy-20201111monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-receives-fda-approval-for-expanded-use-of-wakix-pitolisant-for-the-tre-hrmy-20201014monthly0.5https://www.biopharmawatch.com/news/NTLA/confidential-intellia-therapeutics-reports-positive-phase-3-results-in-hereditary-angioede-ntla-20260427monthly0.5https://www.biopharmawatch.com/news/NTLA/amendment-no-2-ntla-20260302monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-legal-disclaimer-this-presentation-contains-forward-looking-statemen-ntla-20260109monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-positive-longer-term-phase-1-data-for-nexiguran-ziclumeran-ntla-20250925monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2025-financial-results-and-highlights-recen-ntla-20250807monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-positive-three-year-data-from-phase-1-trial-of-lonvoguran--ntla-20250615monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-announces-positive-two-year-follow-up-data-from-ongoing-phase-1-study-of-nexigura-ntla-20250518monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2025-financial-results-and-highlights-recent-ntla-20250508monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-hi-ntla-20250227monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-anticipated-2025-milestones-and-strategic-reorganization-t-ntla-20250109monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran-ziclu-ntla-20241116monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2024-financial-results-and-highlights-recent-ntla-20241107monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-presents-positive-results-from-the-phase-2-study-of-ntla-2002-an-investigational--ntla-20241024monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2024-financial-results-and-highlights-recen-ntla-20240808monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-cfo-transition-ntla-20240626monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-brian-goff-to-its-board-of-directors-ntla-20240614monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2024-financial-results-and-highlights-recent-ntla-20240509monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-publication-of-positive-interim-phase-1-data-for-ntla-2002-ntla-20240415monthly0.5https://www.biopharmawatch.com/news/NTLA/amendment-no-1-ntla-20240223monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-hi-ntla-20240222monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-publication-of-positive-interim-phase-1-data-for-ntla-2002-ntla-20240131monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-highlights-its-three-year-strategic-priorities-and-anticipated-2024--ntla-20240104monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2023-financial-results-and-highlights-recent-ntla-20231109monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-presents-new-interim-data-from-the-ongoing-phase-1-study-of-ntla-2001-at-the-4-th-ntla-20231102monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application--ntla-20231018monthly0.5https://www.biopharmawatch.com/news/NTLA/regeneron-and-intellia-announce-expanded-research-collaboration-to-develop-crispr-based-th-ntla-20231003monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2023-financial-results-and-highlights-recen-ntla-20230803monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-new-positive-clinical-data-from-phase-1-study-of-ntla-2002-ntla-20230611monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-retirement-of-jean-fran-ois-formela-m-d-from-its-board-of--ntla-20230605monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2023-financial-results-and-highlights-recent-ntla-20230504monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-bill-chase-to-its-board-of-directors-ntla-20230417monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application--ntla-20230302monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and-hi-ntla-20230223monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-highlights-strategic-priorities-and-anticipated-2023-key-milestones--ntla-20230105monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-new-interim-data-from-first-in-human-study-of-ntla-2002-for-ntla-20221112monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-presents-updated-interim-data-from-the-cardiomyopathy-arm-of-ongoing-phase-1-stud-ntla-20221105monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-recent-ntla-20221103monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-and-regeneron-announce-initial-data-from-the-cardiomyopathy-arm-of-ongoing-phase--ntla-20220916monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2022-financial-results-and-highlights-recen-ntla-20220804monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-and-regeneron-present-updated-interim-data-from-phase-1-study-of-crispr-based-ntl-ntla-20220624monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2022-financial-results-and-highlights-recent-ntla-20220505monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-and-regeneron-announce-updated-phase-1-data-demonstrating-a-single-dose-of-ntla-2-ntla-20220228monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-hi-ntla-20220224monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-acquisition-of-rewrite-therapeutics-rewrite-therapeutics-p-ntla-20220203monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-highlights-strategic-priorities-and-anticipated-development-mileston-ntla-20220106monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2021-financial-results-and-highlights-recent-ntla-20211104monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2021-financial-results-and-highlights-recen-ntla-20210805monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-and-regeneron-announce-landmark-clinical-data-showing-deep-reduction-in-disease-c-ntla-20210626monthly0.5https://www.biopharmawatch.com/news/NTLA/blackstone-life-sciences-cellex-cell-professionals-and-intellia-therapeutics-launch-new-ca-ntla-20210622monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2021-financial-results-plan-to-report-initia-ntla-20210506monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-georgia-keresty-ph-d-m-p-h-to-board-of-directors-ntla-20210412monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-expect-ntla-20210225monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-highlights-strategic-priorities-and-anticipated-development-mileston-ntla-20210107monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-proposed-public-offering-of-common-stock-ntla-20201130monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-doses-first-patient-in-landmark-crispr-cas9-clinical-trial-of-ntla-2-ntla-20201109monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2020-financial-results-on-track-to-dose-firs-ntla-20201105monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-authorization-to-initiate-phase-1-clinical-trial-of-ntla-20-ntla-20201019monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-john-f-crowley-to-board-of-directors-ntla-20201005monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2020-financial-results-submitted-first-regu-ntla-20200806monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-proposed-public-offering-of-common-stock-ntla-20200601monthly0.5https://www.biopharmawatch.com/news/NTLA/regeneron-and-intellia-therapeutics-expand-collaboration-to-develop-crispr-cas9-based-trea-ntla-20200601monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2020-financial-results-on-track-to-submit-an-ntla-20200507monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-on-tra-ntla-20200227monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-highlights-recent-progress-and-anticipated-2020-milestones-on-track--ntla-20200109monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2019-financial-results-on-track-to-submit-in-ntla-20191031monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2019-financial-results-and-company-update-n-ntla-20190801monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2019-financial-results-and-company-update-re-ntla-20190502monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2018-financial-results-confir-ntla-20190227monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-fred-cohen-m-d-to-board-of-directors-ntla-20190124monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-legal-disclaimer-this-presentation-contains-forward-looking-statemen-ntla-20190107monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-and-novartis-expand-cell-therapy-collaboration-to-pursue-crispr-cas9-ntla-20181206monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2018-financial-results-and-corporate-develop-ntla-20181031monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2018-financial-results-continued-to-progres-ntla-20180801monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2018-financial-results-new-ceo-puts-in-vivo--ntla-20180501monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2017-financial-results-initia-ntla-20180314monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-john-leonard-m-d-president-and-chief-executive-officer-dr-leon-ntla-20171218monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-pricing-of-public-offering-of-common-stock-ntla-20171101monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2017-financial-results-first-company-to-demo-ntla-20171031monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2017-financial-results-in-non-human-primate-ntla-20170801monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-moncef-slaoui-ph-d-and-frank-verwiel-m-d-to-its-board-of-direc-ntla-20170724monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2017-financial-results-first-to-demonstrate--ntla-20170502monthly0.5https://www.biopharmawatch.com/news/NTLA/crispr-therapeutics-intellia-therapeutics-caribou-biosciences-and-ers-genomics-announce-ap-ntla-20170413monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2016-financial-results-first--ntla-20170314monthly0.5https://www.biopharmawatch.com/news/NTLA/crispr-therapeutics-intellia-therapeutics-caribou-biosciences-and-ers-genomics-provide-upd-ntla-20170215monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-financial-results-for-third-quarter-2016-first-company-to-re-ntla-20161101monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-financial-results-for-second-quarter-2016-advancing-propriet-ntla-20160804monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-closing-of-initial-public-offering-underwriters-exercise-o-ntla-20160511monthly0.5https://www.biopharmawatch.com/news/MESO/this-presentation-includes-forward-looking-statements-and-forecasts-that-relate-to-future--meso-20260610monthly0.5https://www.biopharmawatch.com/news/MESO/other-fees-to-non-executive-directors-were-us-156-048-consulting-payments-to-non-executive-meso-20260430monthly0.5https://www.biopharmawatch.com/news/MESO/about-chronic-low-back-pain-back-pain-is-the-leading-cause-of-disability-in-americans-unde-meso-20260429monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-terms-01-01-20-meso-20260417monthly0.5https://www.biopharmawatch.com/news/MESO/about-mesoblast-intellectual-property-mesoblast-has-a-strong-and-extensive-global-intellec-meso-20260415monthly0.5https://www.biopharmawatch.com/news/MESO/inflammatory-bowel-disease-rexlemestrocel-l-is-being-developed-for-heart-failure-and-chron-meso-20260408monthly0.5https://www.biopharmawatch.com/news/MESO/about-parent-project-muscular-dystrophy-parent-project-muscular-dystrophy-ppmd-a-leading-p-meso-20260408monthly0.5https://www.biopharmawatch.com/news/MESO/about-mesoblast-manufacturing-the-company-s-proprietary-manufacturing-processes-yield-indu-meso-20260331monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-terms-appendix-meso-20260323monthly0.5https://www.biopharmawatch.com/news/MESO/forward-looking-statements-this-press-release-includes-forward-looking-statements-that-rel-meso-20260318monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3ydrge-rule-3-19a-2-appendix-3y-change-of-director-s-interest-notice-information-o-meso-20260313monthly0.5https://www.biopharmawatch.com/news/MESO/maappointment-dr-teresa-montagut-appointed-as-clinical-development-and-medical-affairs-hea-meso-20260312monthly0.5https://www.biopharmawatch.com/news/MESO/h12026results-ryoncil-profits-underpinning-substantial-growth-pipeline-financial-results-a-meso-20260227monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20260227monthly0.5https://www.biopharmawatch.com/news/MESO/webcastnoticef-mesoblast-financial-results-and-corporate-update-webcast-new-york-usa-febru-meso-20260220monthly0.5https://www.biopharmawatch.com/news/MESO/ryoncileindatt-high-survival-rates-with-ryoncil-in-eind-program-emphasize-importance-of-ea-meso-20260212monthly0.5https://www.biopharmawatch.com/news/MESO/appendix4cq2fy-ryoncil-net-revenues-increase-for-the-quarter-to-us-30m-activity-report-for-meso-20260129monthly0.5https://www.biopharmawatch.com/news/MESO/realworldexper-real-world-commercial-experience-with-ryoncil-shows-84-survival-of-children-meso-20260127monthly0.5https://www.biopharmawatch.com/news/MESO/fdaconfirmspat-fda-acknowledges-effects-on-pain-intensity-favor-rexlemestrocel-l-confirms--meso-20260119monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3h3g-appendix-3h-notification-of-cessation-of-securities-appendix-3h-notification--meso-20260115monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3y2a3g-appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equi-meso-20260113monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3y-lco-appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-meso-20260113monthly0.5https://www.biopharmawatch.com/news/MESO/ryoncilsalesde-ryoncil-sales-increase-60-in-december-quarter-to-us-35-1m-strong-balance-sh-meso-20260109monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3h3y-appendix-3h-notification-of-cessation-of-securities-appendix-3h-notification--meso-20260106monthly0.5https://www.biopharmawatch.com/news/MESO/boardupdate-mesoblast-announces-changes-to-board-of-directors-leadership-roles-new-york-us-meso-20260102monthly0.5https://www.biopharmawatch.com/news/MESO/debtrefinancea-mesoblast-retires-senior-debt-with-non-dilutive-lower-cost-five-year-credit-meso-20251230monthly0.5https://www.biopharmawatch.com/news/MESO/app3y-gregoryg-gregory-george-rule-3-19a-2-appendix-3y-change-of-director-s-interest-notic-meso-20251229monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-meso-20251218monthly0.5https://www.biopharmawatch.com/news/MESO/references-footnotes-1-ramteke-hd-et-al-comparative-efficacy-and-safety-of-ruxolitinib-and-meso-20251212monthly0.5https://www.biopharmawatch.com/news/MESO/differences-may-be-material-and-adverse-forward-looking-statements-include-but-are-not-lim-meso-20251204monthly0.5https://www.biopharmawatch.com/news/MESO/resultsofagm-25-november-2025-mesoblast-limited-msb-results-of-annual-general-meeting-held-meso-20251126monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-ryoncil-remestemcel-l-rknd-for-the-treatment-of-steroid-refractory-acute-graft-meso-20251125monthly0.5https://www.biopharmawatch.com/news/MESO/about-mesoblast-intellectual-property-mesoblast-has-a-strong-and-extensive-global-intellec-meso-20251124monthly0.5https://www.biopharmawatch.com/news/MESO/about-mesoblast-manufacturing-the-company-s-proprietary-manufacturing-processes-yield-indu-meso-20251117monthly0.5https://www.biopharmawatch.com/news/MESO/fdameetingonre-mesoblast-to-meet-with-fda-next-month-to-discuss-rexlemestrocel-l-and-opioi-meso-20251104monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3y3g-appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-t-meso-20251029monthly0.5https://www.biopharmawatch.com/news/MESO/to-the-company-s-post-effective-amendment-to-the-registration-statement-on-form-s-8-file-n-meso-20251028monthly0.5https://www.biopharmawatch.com/news/MESO/q1fy26appendix-ryoncil-net-revenues-increase-69-in-second-quarter-post-launch-activity-rep-meso-20251022monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3g-appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-s-meso-20251014monthly0.5https://www.biopharmawatch.com/news/MESO/ryoncilsalesup-ryoncil-revenues-increase-66-in-second-quarter-post-launch-melbourne-austra-meso-20251007monthly0.5https://www.biopharmawatch.com/news/MESO/ryoncilcmsj-co-ryoncil-receives-j-code-from-medicare-medicaid-services-cms-facilitating-re-meso-20251003monthly0.5https://www.biopharmawatch.com/news/MESO/actual-results-levels-of-activity-performance-or-achievements-to-differ-materially-from-an-meso-20250929monthly0.5https://www.biopharmawatch.com/news/MESO/levels-of-activity-performance-or-achievements-expressed-or-implied-by-these-forward-looki-meso-20250915monthly0.5https://www.biopharmawatch.com/news/MESO/drggeorgeappen-gregory-george-rule-3-19a-2-appendix-3y-change-of-director-s-interest-notic-meso-20250915monthly0.5https://www.biopharmawatch.com/news/MESO/chronic-low-back-pain-clbp-10-billion-addressable-market-additional-potential-multi-billio-meso-20250829monthly0.5https://www.biopharmawatch.com/news/MESO/for-more-information-please-contact-corporate-communications-investors-paul-hughes-t-61-3--meso-20250827monthly0.5https://www.biopharmawatch.com/news/MESO/in-july-mesoblast-held-a-type-b-meeting-with-fda-for-ryoncil-to-discuss-a-pivotal-trial-in-meso-20250630monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3h-notification-of-cessation-of-securities-appendix-3h-notification-of-cessation--meso-20250715monthly0.5https://www.biopharmawatch.com/news/MESO/forward-looking-statements-this-press-release-includes-forward-looking-statements-that-rel-meso-20250701monthly0.5https://www.biopharmawatch.com/news/MESO/inflammatory-bowel-disease-rexlemestrocel-l-is-being-developed-for-heart-failure-and-chron-meso-20250612monthly0.5https://www.biopharmawatch.com/news/MESO/ryoncilfdaexcl-fda-provides-seven-years-of-orphan-drug-exclusive-approval-for-ryoncil-melb-meso-20250514monthly0.5https://www.biopharmawatch.com/news/MESO/held-under-mesoblast-s-regenerative-medicines-advanced-therapy-rmat-designation-for-revasc-meso-20250430monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-has-locations-in-australia-the-united-states-and-singapore-and-is-listed-on-the--meso-20250429monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-terms-01-01-20-meso-20250424monthly0.5https://www.biopharmawatch.com/news/MESO/actual-results-levels-of-activity-performance-or-achievements-to-differ-materially-from-an-meso-20250417monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3h-notification-of-cessation-of-securities-appendix-3h-notification-of-cessation--meso-20250415monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-terms-appendix-meso-20250409monthly0.5https://www.biopharmawatch.com/news/MESO/forward-looking-statements-this-press-release-includes-forward-looking-statements-that-rel-meso-20250404monthly0.5https://www.biopharmawatch.com/news/MESO/about-mesoblast-manufacturing-the-company-s-proprietary-manufacturing-processes-yield-indu-meso-20250331monthly0.5https://www.biopharmawatch.com/news/MESO/about-mesoblast-manufacturing-the-company-s-proprietary-manufacturing-processes-yield-indu-meso-20250327monthly0.5https://www.biopharmawatch.com/news/MESO/ryoncilpublica-ryoncil-product-information-now-available-in-all-four-major-drug-pricing-co-meso-20250313monthly0.5https://www.biopharmawatch.com/news/MESO/cautionary-note-regarding-forward-looking-statements-this-presentation-includes-forward-lo-meso-20250313monthly0.5https://www.biopharmawatch.com/news/MESO/research-and-development-programs-mesoblast-s-ability-to-advance-product-candidates-into-e-meso-20250312monthly0.5https://www.biopharmawatch.com/news/MESO/material-and-adverse-forward-looking-statements-include-but-are-not-limited-to-statements--meso-20250307monthly0.5https://www.biopharmawatch.com/news/MESO/as-a-medical-scientist-with-unique-operational-experience-having-built-a-start-up-company--meso-20250228monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20250227monthly0.5https://www.biopharmawatch.com/news/MESO/and-patent-applications-are-expected-to-provide-commercial-protection-extending-through-to-meso-20250225monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-is-committed-to-developing-additional-cell-therapies-for-distinct-indications-ba-meso-20250214monthly0.5https://www.biopharmawatch.com/news/MESO/other-fees-to-non-executive-directors-were-us-295-803-consulting-payments-to-non-executive-meso-20250131monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-2a-application-for-quotation-of-securities-appendix-2a-application-for-quotation--meso-20250124monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-raises-new-capital-for-commercial-launch-of-ryoncil-not-for-release-to-us-wire-s-meso-20250113monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-terms-appendix-meso-20241223monthly0.5https://www.biopharmawatch.com/news/MESO/what-is-ryoncil-remestemcel-l-ryoncil-is-an-allogeneic-bone-marrow-derived-mesenchymal-str-meso-20241220monthly0.5https://www.biopharmawatch.com/news/MESO/including-any-future-decision-that-the-fda-may-make-on-the-bla-for-remestemcel-l-for-pedia-meso-20241220monthly0.5https://www.biopharmawatch.com/news/MESO/about-hypoplastic-left-heart-syndrome-hlhs-hlhs-is-a-severe-congenital-heart-disease-in-wh-meso-20241209monthly0.5https://www.biopharmawatch.com/news/MESO/about-revascor-rexlemestrocel-l-in-heart-disease-revascor-is-an-allogeneic-preparation-of--meso-20241204monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3z-final-director-s-interest-notice-see-chapter-19-for-defined-terms-appendix-3z--meso-20241118monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-meso-20241113monthly0.5https://www.biopharmawatch.com/news/MESO/revascor-rexlemestrocel-l-for-pediatric-congenital-heart-disease-hypoplastic-left-heart-sy-meso-20241101monthly0.5https://www.biopharmawatch.com/news/MESO/to-the-company-s-post-effective-amendment-to-the-registration-statement-on-form-s-8-file-n-meso-20241018monthly0.5https://www.biopharmawatch.com/news/MESO/the-convertible-notes-will-be-unsecured-and-be-subordinated-to-the-company-s-two-existing--meso-20241001monthly0.5https://www.biopharmawatch.com/news/MESO/o-ongoing-kol-engagement-with-greatest-experience-using-ryoncil-at-highest-volume-centers--meso-20240829monthly0.5https://www.biopharmawatch.com/news/MESO/chronic-heart-failure-with-reduced-ejection-fraction-hfref-and-persistent-inflammation-fda-meso-20240801monthly0.5https://www.biopharmawatch.com/news/MESO/in-addition-results-of-a-4-year-survival-study-performed-by-the-center-for-international-b-meso-20240725monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-has-locations-in-australia-the-united-states-and-singapore-and-is-listed-on-the--meso-20240723monthly0.5https://www.biopharmawatch.com/news/MESO/survival-at-1-year-51-at-2-years-and-49-survival-through-4-years-in-children-with-expected-meso-20240710monthly0.5https://www.biopharmawatch.com/news/MESO/intellectual-property-on-its-product-candidates-and-mesoblast-s-ability-to-successfully-de-meso-20240702monthly0.5https://www.biopharmawatch.com/news/MESO/the-initiation-timing-progress-and-results-of-mesoblast-s-preclinical-and-clinical-studies-meso-20240604monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-terms-appendix-meso-20240510monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-terms-appendix-meso-20240503monthly0.5https://www.biopharmawatch.com/news/MESO/cardiovascular-pediatric-congenital-heart-disease-during-the-quarter-fda-granted-mesoblast-meso-20240501monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3y-cha-appendix-3y-change-of-director-s-interest-notice-see-chapter-19-for-defined-meso-20240417monthly0.5https://www.biopharmawatch.com/news/MESO/appendix2a-app-appendix-2a-application-for-quotation-of-securities-appendix-2a-application-meso-20240416monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3h-not-appendix-3h-notification-of-cessation-of-securities-appendix-3h-notificatio-meso-20240415monthly0.5https://www.biopharmawatch.com/news/MESO/fdanotifiescli-00876702-united-states-food-drug-administration-fda-notifies-mesoblast-that-meso-20240325monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3b-appendix-3b-proposed-issue-of-securities-appendix-3b-proposed-issue-of-securiti-meso-20240321monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-successfully-completes-placement-and-accelerated-entitlement-offer-melbourne-aus-meso-20240313monthly0.5https://www.biopharmawatch.com/news/MESO/about-revascor-rexlemestrocel-l-in-heart-disease-revascor-is-an-allogeneic-preparation-of--meso-20240312monthly0.5https://www.biopharmawatch.com/news/MESO/hy1fy24results-mesoblast-reports-financial-results-and-operational-update-for-half-year-en-meso-20240228monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20240229monthly0.5https://www.biopharmawatch.com/news/MESO/immediate-surgery-after-birth-the-prognosis-is-dismal-with-hlhs-overall-being-responsible--meso-20240221monthly0.5https://www.biopharmawatch.com/news/MESO/the-results-from-the-blinded-randomized-placebo-controlled-prospective-trial-of-revascor-c-meso-20240201monthly0.5https://www.biopharmawatch.com/news/MESO/beneficial-to-children-with-hlhs-including-neovascularization-anti-fibrosis-anti-apoptosis-meso-20240123monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-no-meso-20240115monthly0.5https://www.biopharmawatch.com/news/MESO/adrratiochange-00876702-mesoblast-modifies-ratio-for-american-depositary-receipt-program-m-meso-20240105monthly0.5https://www.biopharmawatch.com/news/MESO/forward-looking-statements-this-press-release-includes-forward-looking-statements-that-rel-meso-20240105monthly0.5https://www.biopharmawatch.com/news/MESO/fda-hlhsannoun-00876702-mesoblast-files-for-orphan-drug-and-pediatric-rare-disease-designa-meso-20231126monthly0.5https://www.biopharmawatch.com/news/MESO/bmtctnannounce-00876702-mesoblast-partners-with-blood-and-marrow-transplant-clinical-trial-meso-20231121monthly0.5https://www.biopharmawatch.com/news/MESO/appendix4c-00876702-appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2-meso-20231030monthly0.5https://www.biopharmawatch.com/news/MESO/appendix4gandc-rules-4-7-3-and-4-10-3-asx-listing-rules-appendix-4g-current-at-17-7-2020-p-meso-20231030monthly0.5https://www.biopharmawatch.com/news/MESO/appendix3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-no-meso-20231016monthly0.5https://www.biopharmawatch.com/news/MESO/mspooner3z-appendix-3z-final-director-s-interest-notice-see-chapter-19-for-defined-terms-1-meso-20231003monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-has-locations-in-australia-the-united-states-and-singapore-and-is-listed-on-the--meso-20230926monthly0.5https://www.biopharmawatch.com/news/MESO/regupdatextyp-key-outcomes-from-fda-type-a-meeting-and-mesoblast-next-steps-to-achieve-ryo-meso-20230920monthly0.5https://www.biopharmawatch.com/news/MESO/annualreport-mesoblast-reports-financial-results-and-operational-update-for-fiscal-year-en-meso-20230830monthly0.5https://www.biopharmawatch.com/news/MESO/about-steroid-refractory-acute-graft-versus-host-disease-acute-gvhd-occurs-in-approximatel-meso-20230804monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-has-locations-in-australia-the-united-states-and-singapore-and-is-listed-on-the--meso-20230801monthly0.5https://www.biopharmawatch.com/news/MESO/this-appendix-is-available-as-an-online-form-appendix-3g-notification-of-issue-conversion--meso-20230712monthly0.5https://www.biopharmawatch.com/news/MESO/document-appendix-99-1-appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appen-meso-20230613monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-director-philip-r-krause-m-d-appointed-to-strategic-advisory-role-melbourne-aust-meso-20230604monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-operational-and-financial-highlights-for-quarter-ended-march-31-2023-mel-meso-20230525monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-activity-report-mesoblast-financial-and-operational-highlights-for-q-meso-20230503monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-completes-private-placement-new-york-usa-meso-20230425monthly0.5https://www.biopharmawatch.com/news/MESO/fda-schedules-pre-license-inspection-of-remestemcel-l-manufacturing-biologics-license-appl-meso-20230323monthly0.5https://www.biopharmawatch.com/news/MESO/this-appendix-is-available-as-an-online-form-only-use-this-form-if-the-online-version-is-n-meso-20230316monthly0.5https://www.biopharmawatch.com/news/MESO/fda-accepts-mesoblast-s-resubmission-of-the-biologic-license-application-for-remestemcel-l-meso-20230307monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-operational-and-financial-highlights-for-quarter-ended-december-31-2022--meso-20230227monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20230228monthly0.5https://www.biopharmawatch.com/news/MESO/remestemcel-l-clinical-and-potency-studies-presented-at-premier-meeting-of-transplantation-meso-20230216monthly0.5https://www.biopharmawatch.com/news/MESO/fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-for-rexlemestrocel-l-in-meso-20230208monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-activity-report-mesoblast-operational-and-financial-highlights-for-q-meso-20230201monthly0.5https://www.biopharmawatch.com/news/MESO/cautionary-note-regarding-forward-looking-statements-this-presentation-includes-forward-lo-meso-20230118monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-and-oaktree-extend-availability-period-of-undrawn-tranches-of-financing-facility-meso-20221222monthly0.5https://www.biopharmawatch.com/news/MESO/this-appendix-is-available-as-an-online-form-only-use-this-form-if-the-online-version-is-n-meso-20221207monthly0.5https://www.biopharmawatch.com/news/MESO/children-treated-with-remestemcel-l-show-long-term-survival-through-four-years-in-steroid--meso-20221122monthly0.5https://www.biopharmawatch.com/news/MESO/change-to-proposed-amendment-to-the-constitution-regarding-virtual-meetings-melbourne-aust-meso-20221114monthly0.5https://www.biopharmawatch.com/news/MESO/rules-4-7-3-and-4-10-3-appendix-4g-key-to-disclosures-corporate-governance-council-princip-meso-20221107monthly0.5https://www.biopharmawatch.com/news/MESO/notification-of-cessation-of-securities-announcement-summary-entity-name-mesoblast-limited-meso-20221014monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-submits-new-information-to-fda-ind-file-in-response-to-items-in-the-crl-to-the-r-meso-20221002monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-99-1-appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-ch-meso-20220923monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-meso-20220914monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-operational-highlights-for-fiscal-year-ended-june--meso-20220831monthly0.5https://www.biopharmawatch.com/news/MESO/jane-bell-joins-mesoblast-board-melbourne-australia-august-18-and-new-york-usa-meso-20220817monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-completes-us-45-million-private-placement-to-major-shareholders-melbourne-austra-meso-20220808monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-activity-report-mesoblast-operational-and-financial-highlights-for-q-meso-20220805monthly0.5https://www.biopharmawatch.com/news/MESO/only-use-this-form-if-the-online-version-is-not-available-rule-3-10-3e-appendix-3h-notific-meso-20220721monthly0.5https://www.biopharmawatch.com/news/MESO/release-authorized-by-the-chief-executive-for-more-information-please-contact-corporate-co-meso-20220714monthly0.5https://www.biopharmawatch.com/news/MESO/regulatory-or-public-perceptions-and-market-acceptance-surrounding-the-use-of-stem-cell-ba-meso-20220617monthly0.5https://www.biopharmawatch.com/news/MESO/survival-outcomes-in-covid-19-ards-patients-treated-with-remestemcel-l-melbourne-australia-meso-20220530monthly0.5https://www.biopharmawatch.com/news/MESO/the-potential-for-mesoblast-s-product-candidates-if-any-are-approved-to-be-withdrawn-from--meso-20220523monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-activity-report-mesoblast-operational-and-financial-highlights-for-q-meso-20220503monthly0.5https://www.biopharmawatch.com/news/MESO/only-use-this-form-if-the-online-version-is-not-available-rule-3-10-3e-appendix-3h-notific-meso-20220420monthly0.5https://www.biopharmawatch.com/news/MESO/appointment-of-joint-company-secretary-melbourne-australia-april-6-and-new-york-usa-meso-20220406monthly0.5https://www.biopharmawatch.com/news/MESO/philip-r-krause-m-d-former-fda-deputy-chief-for-vaccines-joins-mesoblast-board-melbourne-a-meso-20220323monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3z-final-director-s-interest-notice-rule-3-19a-3-appendix-3z-final-director-s-int-meso-20220301monthly0.5https://www.biopharmawatch.com/news/MESO/consolidated-income-statement-three-months-ended-december-31-six-months-ended-december-31--meso-20220228monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20220225monthly0.5https://www.biopharmawatch.com/news/MESO/rapid-improvement-and-remission-in-patients-with-refractory-ulcerative-colitis-and-crohn-s-meso-20220220monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-appoints-dr-eric-rose-as-chief-medical-officer-melbourne-australia-february-2-an-meso-20220201monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-activity-report-mesoblast-prepares-for-resubmission-of-biologics-lic-meso-20220130monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-participate-in-edison-group-s-global-healthcare-open-house-virtual-conference-meso-20220124monthly0.5https://www.biopharmawatch.com/news/MESO/only-use-this-form-if-the-online-version-is-not-available-rule-3-10-3a-3-10-3b-3-10-3c-3-1-meso-20220121monthly0.5https://www.biopharmawatch.com/news/MESO/single-dose-of-mesoblast-s-allogeneic-cell-therapy-provides-durable-pain-reduction-for-at--meso-20220111monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-update-following-meeting-with-fda-s-otat-on-remestemcel-l-for-children--meso-20211230monthly0.5https://www.biopharmawatch.com/news/MESO/fda-s-otat-in-agreement-with-12-month-reduction-in-pain-as-primary-endpoint-for-chronic-lo-meso-20211215monthly0.5https://www.biopharmawatch.com/news/MESO/update-on-novartis-agreement-melbourne-australia-december-14-and-new-york-usa-meso-20211213monthly0.5https://www.biopharmawatch.com/news/MESO/rexlemestrocel-l-shows-greatest-treatment-benefit-on-major-adverse-cardiovascular-events-i-meso-20211205monthly0.5https://www.biopharmawatch.com/news/MESO/chairman-s-address-to-shareholders-2021-mesoblast-annual-general-meeting-2021-has-been-a-r-meso-20211202monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-and-oaktree-capital-enter-into-refinancing-and-expansion-of-senior-debt-facility-meso-20211121monthly0.5https://www.biopharmawatch.com/news/MESO/late-breaking-presentation-at-american-heart-association-annual-meeting-of-landmark-phase--meso-20211114monthly0.5https://www.biopharmawatch.com/news/MESO/rules-4-7-3-and-4-10-3-appendix-4g-key-to-disclosures-corporate-governance-council-princip-meso-20211109monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-activity-report-financial-and-operational-highlights-for-quarter-end-meso-20211104monthly0.5https://www.biopharmawatch.com/news/MESO/this-appendix-is-available-as-an-online-form-appendix-99-1-only-use-this-form-if-the-onlin-meso-20211019monthly0.5https://www.biopharmawatch.com/news/MESO/rexlemestrocel-l-phase-3-trial-results-in-chronic-heart-failure-selected-as-late-breaking--meso-20211006monthly0.5https://www.biopharmawatch.com/news/MESO/consolidated-income-statement-year-ended-june-30-in-u-s-dollars-in-thousands-except-per-sh-meso-20210901monthly0.5https://www.biopharmawatch.com/news/MESO/management-changes-post-financial-year-end-melbourne-australia-august-10-and-new-york-usa-meso-20210809monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-activity-report-mesoblast-operational-and-financial-highlights-for-q-meso-20210803monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-presents-respiratory-function-results-of-covid-19-ards-trial-at-pulmonary-diseas-meso-20210715monthly0.5https://www.biopharmawatch.com/news/MESO/only-use-this-form-if-the-online-version-is-not-available-rule-3-10-3a-3-10-3b-3-10-3c-3-1-meso-20210709monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-update-on-program-for-chronic-low-back-pain-due-to-degenerative-disc-di-meso-20210630monthly0.5https://www.biopharmawatch.com/news/MESO/consolidated-income-statement-three-months-ended-march-31-nine-months-ended-march-31-in-u--meso-20210604monthly0.5https://www.biopharmawatch.com/news/MESO/improved-outcomes-in-inflammatory-lung-disease-with-remestemcel-l-published-in-respiratory-meso-20210524monthly0.5https://www.biopharmawatch.com/news/MESO/remestemcel-l-reduces-mortality-in-patients-less-than-65-years-old-with-moderate-severe-co-meso-20210429monthly0.5https://www.biopharmawatch.com/news/MESO/initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-interest-no-meso-20210408monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-operational-highlights-and-upcoming-milestones-melbourne-australia-march-31-and--meso-20210330monthly0.5https://www.biopharmawatch.com/news/MESO/philip-j-facchina-chief-strategy-officer-and-principal-of-surgcenter-development-joins-mes-meso-20210328monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-closes-us-110-a-138-million-financing-led-by-us-strategic-investor-group-melbour-meso-20210308monthly0.5https://www.biopharmawatch.com/news/MESO/please-fill-in-and-submit-as-a-pdf-announcement-rule-2-7-appendix-2a-application-for-quota-meso-20210305monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-completes-us-110-a-138-million-financing-led-by-us-strategic-investor-group-melb-meso-20210301monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20210302monthly0.5https://www.biopharmawatch.com/news/MESO/positive-outcomes-of-first-children-treated-with-remestemcel-l-for-multisystem-inflammator-meso-20210216monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-phase-3-trial-shows-that-a-single-injection-of-rexlemestrocel-l-hyaluronic-acid--meso-20210210monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-activity-report-mesoblast-operational-and-financial-highlights-for-q-meso-20210201monthly0.5https://www.biopharmawatch.com/news/MESO/single-dose-of-rexlemestrocel-l-provides-substantial-and-durable-reduction-in-heart-attack-meso-20210110monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-update-on-covid-19-ards-trial-melbourne-australia-december-18-and-new-york-usa-meso-20201217monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-topline-results-from-phase-3-trial-of-rexlemestrocel-l-for-advanced-chr-meso-20201214monthly0.5https://www.biopharmawatch.com/news/MESO/fda-grants-fast-track-designation-for-remestemcel-l-in-the-treatment-of-acute-respiratory--meso-20201201monthly0.5https://www.biopharmawatch.com/news/MESO/chairman-s-address-to-shareholders-2020-mesoblast-annual-general-meeting-this-has-been-an--meso-20201201monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-enters-global-collaboration-for-development-manufacture-and-commercialization-of-meso-20201119monthly0.5https://www.biopharmawatch.com/news/MESO/second-interim-analysis-of-clinical-outcomes-after-135-patients-results-in-recommendation--meso-20201110monthly0.5https://www.biopharmawatch.com/news/MESO/update-on-remestemcel-l-for-the-treatment-of-covid-19-ards-and-steroid-refractory-acute-gv-meso-20201028monthly0.5https://www.biopharmawatch.com/news/MESO/key-to-disclosures-corporate-governance-council-principles-and-recommendations-rules-4-7-3-meso-20201029monthly0.5https://www.biopharmawatch.com/news/MESO/randomized-controlled-study-using-direct-injection-of-remestemcel-l-into-inflamed-gut-of-p-meso-20201022monthly0.5https://www.biopharmawatch.com/news/MESO/randomized-controlled-phase-3-trial-of-remestemcel-l-for-reduced-mortality-in-covid-19-acu-meso-20201012monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-complete-response-letter-from-the-fda-for-biologics-license-application-meso-20201002monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-wins-2020-fierce-biotech-innovation-of-the-year-award-for-remestemcel-l-melbourn-meso-20200914monthly0.5https://www.biopharmawatch.com/news/MESO/please-fill-in-and-submit-as-a-pdf-announcement-rule-2-7-appendix-2a-application-for-quota-meso-20200916monthly0.5https://www.biopharmawatch.com/news/MESO/data-safety-monitoring-board-recommends-continuation-of-remestemcel-l-phase-3-trial-in-cov-meso-20200904monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-ethics-approval-to-treat-covid-19-patients-in-australia-melbourne-austr-meso-20200902monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-substantial-operational-progress-and-financial-results-for-the-year-ende-meso-20200827monthly0.5https://www.biopharmawatch.com/news/MESO/please-fill-in-and-submit-as-a-pdf-announcement-rule-2-7-appendix-2a-application-for-quota-meso-20200825monthly0.5https://www.biopharmawatch.com/news/MESO/u-s-fda-advisory-committee-votes-nine-to-one-in-favor-of-remestemcel-l-ryoncil-for-efficac-meso-20200814monthly0.5https://www.biopharmawatch.com/news/MESO/update-on-scheduled-fda-advisory-committee-meeting-melbourne-australia-meso-20200811monthly0.5https://www.biopharmawatch.com/news/MESO/please-fill-in-and-submit-as-a-pdf-announcement-rule-2-7-appendix-2a-application-for-quota-meso-20200810monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-remestemcel-l-update-and-quarterly-activity-report-melbourne-australia-meso-20200730monthly0.5https://www.biopharmawatch.com/news/MESO/fda-advisory-committee-sets-review-date-for-mesoblast-s-remestemcel-l-in-pediatric-steroid-meso-20200721monthly0.5https://www.biopharmawatch.com/news/MESO/july-2020-issue-to-kentgrove-capital-in-connection-with-the-kentgrove-capital-equity-facil-meso-20200710monthly0.5https://www.biopharmawatch.com/news/MESO/expanded-access-protocol-initiated-for-compassionate-use-of-remestemcel-l-in-children-with-meso-20200706monthly0.5https://www.biopharmawatch.com/news/MESO/please-fill-in-and-submit-as-a-pdf-announcement-rule-2-7-appendix-2a-application-for-quota-meso-20200702monthly0.5https://www.biopharmawatch.com/news/MESO/please-fill-in-and-submit-as-a-pdf-announcement-rule-3-10-3a-3-10-3b-3-10-3c-appendix-3g-n-meso-20200626monthly0.5https://www.biopharmawatch.com/news/MESO/please-fill-in-and-submit-as-a-pdf-announcement-rule-2-7-appendix-2a-application-for-quota-meso-20200618monthly0.5https://www.biopharmawatch.com/news/MESO/remestemcel-l-improves-respiratory-and-functional-outcomes-in-patients-with-inflammatory-l-meso-20200601monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-strong-financial-position-and-substantial-operational-progress-for-the-p-meso-20200528monthly0.5https://www.biopharmawatch.com/news/MESO/clinical-outcomes-using-ryoncil-remestemcel-l-in-children-and-adults-with-severe-inflammat-meso-20200525monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-successfully-completes-financing-to-scale-up-manufacturing-of-remestemcel-l-for--meso-20200513monthly0.5https://www.biopharmawatch.com/news/MESO/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-meso-20200506monthly0.5https://www.biopharmawatch.com/news/MESO/phase-2-3-randomized-controlled-trial-of-remestemcel-l-in-300-patients-with-covid-19-acute-meso-20200430monthly0.5https://www.biopharmawatch.com/news/MESO/survival-in-covid-19-patients-with-moderate-severe-acute-respiratory-distress-syndrome-tre-meso-20200424monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-positive-clinical-outcomes-using-remestemcel-l-in-patients-with-infla-meso-20200417monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-partners-with-the-cardiothoracic-surgical-trials-network-established-by-the-u-s--meso-20200409monthly0.5https://www.biopharmawatch.com/news/MESO/fda-clears-investigational-new-drug-application-for-mesoblast-to-use-remestemcel-l-in-pati-meso-20200406monthly0.5https://www.biopharmawatch.com/news/MESO/clinical-outcomes-of-mesoblast-s-cell-therapy-in-end-stage-ischemic-heart-failure-presente-meso-20200330monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-meso-20200325monthly0.5https://www.biopharmawatch.com/news/MESO/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-meso-20200320monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-evaluate-anti-inflammatory-cell-therapy-remestemcel-l-for-treatment-of-covid--meso-20200310monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20200228monthly0.5https://www.biopharmawatch.com/news/MESO/clinically-meaningful-outcomes-using-remestemcel-l-in-patients-with-chronic-graft-versus-h-meso-20200220monthly0.5https://www.biopharmawatch.com/news/MESO/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-meso-20200214monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-submits-completed-biologics-license-application-for-ryoncil-to-us-fda-melbourne--meso-20200203monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-quarterly-cash-flow-report-continued-revenue-growth-in-japan-provides-framework--meso-20200129monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-presents-commercial-plans-at-2020-biotech-showcase-in-san-francisco-announces-ry-meso-20200114monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-submits-clinical-efficacy-and-safety-data-to-fda-in-rolling-biologics-license-ap-meso-20200102monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-phase-3-trial-of-revascor-in-advanced-chronic-heart-failure-surpasses-the-numb-meso-20191217monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-meso-20191212monthly0.5https://www.biopharmawatch.com/news/MESO/interview-with-mesoblast-chairman-joseph-r-swedish-2019-meso-20191127monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-finanical-results-for-the-quarter-ended-september-30-2019-continued-increase-in--meso-20191126monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-quarterly-cash-flow-report-strong-balance-sheet-for-first-product-commercializat-meso-20191031monthly0.5https://www.biopharmawatch.com/news/MESO/appointment-of-joint-company-secretary-new-york-usa-and-melbourne-australia-meso-20191029monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-and-lonza-enter-into-agreement-for-commercial-manufacture-of-mesoblast-s-potenti-meso-20191017monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3b-new-issue-announcement-quotation-agreement-1-quotation-of-our-additional-secur-meso-20191010monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-completes-successful-institutional-capital-raising-of-a-75-million-melbourne-aus-meso-20191003monthly0.5https://www.biopharmawatch.com/news/MESO/september-2019-chronic-low-back-pain-associated-with-degenerative-disc-disease-a-major-unm-meso-20191003monthly0.5https://www.biopharmawatch.com/news/MESO/gr-nenthal-and-mesoblast-enter-strategic-partnership-for-europe-and-latin-america-to-devel-meso-20190911monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-2019-full-year-results-strong-operational-progress-and-continued-growth--meso-20190830monthly0.5https://www.biopharmawatch.com/news/MESO/fda-provides-guidance-on-clinical-pathway-to-marketing-application-for-revascor-in-end-sta-meso-20190827monthly0.5https://www.biopharmawatch.com/news/MESO/remestemcel-l-to-be-evaluated-as-treatment-for-chronic-graft-versus-host-disease-in-planne-meso-20190814monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-appoints-leading-pharmaceutical-industry-executive-as-chief-medical-officer-melb-meso-20190812monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-quarterly-cash-flow-report-record-revenues-from-japan-product-sales-for-the-peri-meso-20190731monthly0.5https://www.biopharmawatch.com/news/MESO/circulation-research-special-article-highlights-potential-of-mesoblast-cell-therapy-in-tre-meso-20190725monthly0.5https://www.biopharmawatch.com/news/MESO/new-issue-announcement-step-4-subtract-e-from-a-x-d-to-calculate-remaining-placement-capac-meso-20190717monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-virtual-symposium-with-key-opinion-leader-highlighting-acute-graft-versu-meso-20190617monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-and-jcr-pharmaceuticals-expand-japan-license-agreement-to-use-of-mesenchymal-ste-meso-20190611monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-operational-highlights-for-the-period-ended-march--meso-20190531monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-initiates-rolling-submission-of-biologics-license-application-bla-to-u-s-fda-for-meso-20190530monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-keynote-presentations-to-feature-at-2019-annual-meeting-of-the-international-soc-meso-20190523monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-at-2019-rbc-capital-markets-global-healthcare-conference-new-york-usa-meso-20190522monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20190506monthly0.5https://www.biopharmawatch.com/news/MESO/fda-agrees-to-rolling-review-of-mesoblast-s-biologic-license-application-for-its-cell-ther-meso-20190416monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-at-upcoming-global-life-science-conference-in-london-new-york-usa-and-meso-20190405monthly0.5https://www.biopharmawatch.com/news/MESO/memorandum-of-understanding-for-confirmatory-trial-to-support-marketing-approval-of-revasc-meso-20190327monthly0.5https://www.biopharmawatch.com/news/MESO/u-s-healthcare-leader-joseph-r-swedish-appointed-mesoblast-chairman-new-york-usa-and-melbo-meso-20190322monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-features-at-upcoming-u-s-investor-conferences-new-york-usa-and-melbourne-austral-meso-20190313monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20190222monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-operational-highlights-for-the-first-half-ended-de-meso-20190221monthly0.5https://www.biopharmawatch.com/news/MESO/final-patient-dosed-in-mesoblast-phase-3-trial-of-revascor-cell-therapy-for-advanced-heart-meso-20190219monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20190205monthly0.5https://www.biopharmawatch.com/news/MESO/hercules-capital-provides-us-15m-from-existing-facility-for-mesoblast-to-accelerate-produc-meso-20190114monthly0.5https://www.biopharmawatch.com/news/MESO/new-issue-announcement-step-4-subtract-e-from-a-x-d-to-calculate-remaining-placement-capac-meso-20190114monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-at-2019-biotech-showcase-in-san-francisco-new-york-usa-and-melbourne--meso-20181224monthly0.5https://www.biopharmawatch.com/news/MESO/meetings-held-with-fda-support-mesoblast-s-planned-regulatory-filing-for-commercialization-meso-20181213monthly0.5https://www.biopharmawatch.com/news/MESO/chairman-s-address-to-the-mesoblast-2018-annual-general-meeting-welcome-to-the-mesoblast-2-meso-20181130monthly0.5https://www.biopharmawatch.com/news/MESO/tasly-and-mesoblast-initiate-development-and-regulatory-activities-for-mpc-150-im-heart-fa-meso-20181126monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-first-quarter-ended-september-30-2018-financial-results-and-operational--meso-20181116monthly0.5https://www.biopharmawatch.com/news/MESO/clinically-meaningful-outcome-in-nih-trial-of-mpc-150-im-for-heart-failure-lvad-recipients-meso-20181111monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20181107monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-expands-partnership-with-jcr-pharmaceuticals-for-treatment-of-wound-healing-in-e-meso-20181024monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-and-tasly-pharmaceutical-group-complete-transaction-for-strategic-cardiovascular-meso-20181012monthly0.5https://www.biopharmawatch.com/news/MESO/trial-results-of-mesoblast-cell-therapy-in-end-stage-heart-failure-selected-as-late-breaki-meso-20181002monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-heart-failure-cell-therapy-for-children-featured-at-regenerative-symposium-for-c-meso-20180925monthly0.5https://www.biopharmawatch.com/news/MESO/tasly-pharmaceutical-group-receives-all-necessary-approvals-for-transaction-with-mesoblast-meso-20180917monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-fourth-quarter-and-full-year-2018-financial-results-and-operational-high-meso-20180830monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20180802monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-meso-20180724monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-enters-into-strategic-cardiovascular-alliance-for-china-with-tasly-pharmaceutica-meso-20180717monthly0.5https://www.biopharmawatch.com/news/MESO/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-meso-20180713monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-meso-20180705monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-is-committed-to-bringing-to-market-disruptive-cellular-medicines-to-treat-seriou-meso-20180628monthly0.5https://www.biopharmawatch.com/news/MESO/key-day-100-survival-outcomes-of-phase-3-trial-for-acute-graft-versus-host-disease-present-meso-20180620monthly0.5https://www.biopharmawatch.com/news/MESO/u-s-healthcare-leader-joseph-r-swedish-joins-mesoblast-board-new-york-usa-meso-20180618monthly0.5https://www.biopharmawatch.com/news/MESO/financial-results-and-operational-highlights-for-the-third-quarter-ended-march-31-2018-mel-meso-20180531monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-partners-with-cartherics-to-develop-off-the-shelf-cell-based-immunotherapies-for-meso-20180528monthly0.5https://www.biopharmawatch.com/news/MESO/may-2018-the-manager-company-notices-section-asx-limited-level-4-north-tower-rialto-towers-meso-20180518monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-phase-3-trial-results-for-acute-graft-versus-host-disease-presented-at-2018-inte-meso-20180508monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20180504monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-clinical-program-update-for-mpc-150-im-in-patients-with-chronic-heart-failure-ne-meso-20180418monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-phase-3-cell-therapy-trial-for-chronic-low-back-pain-completes-enrollment-new-yo-meso-20180329monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-enters-into-us-75-million-non-dilutive-credit-facility-funds-to-advance-commerci-meso-20180307monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20180301monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-operational-highlights-and-financial-results-for-the-half-year-ended-december-31-meso-20180228monthly0.5https://www.biopharmawatch.com/news/MESO/cautionary-note-regarding-forward-looking-statements-this-presentation-includes-forward-lo-meso-20180227monthly0.5https://www.biopharmawatch.com/news/MESO/primary-endpoint-successfully-achieved-in-mesoblast-s-phase-3-cell-therapy-trial-for-acute-meso-20180222monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20180207monthly0.5https://www.biopharmawatch.com/news/MESO/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-meso-20180125monthly0.5https://www.biopharmawatch.com/news/MESO/cautionary-note-regarding-forward-looking-statements-this-presentation-includes-forward-lo-meso-20180118monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-fda-regenerative-medicine-advanced-therapy-designation-for-its-cell-the-meso-20171221monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-phase-3-trial-in-children-with-acute-graft-versus-host-disease-completes-enrol-meso-20171220monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-grants-tigenix-an-exclusive-global-patent-license-to-use-adipose-derived-mesench-meso-20171214monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-named-global-technology-leader-in-cell-therapy-industry-new-york-usa-meso-20171207monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-operational-highlights-and-financial-results-for-the-first-quarter-ended-septemb-meso-20171115monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-presents-corporate-update-at-26-th-annual-credit-suisse-healthcare-conference-ne-meso-20171109monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20171101monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4g-key-to-disclosures-corporate-governance-council-principles-and-recommendations-meso-20171018monthly0.5https://www.biopharmawatch.com/news/MESO/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-meso-20171010monthly0.5https://www.biopharmawatch.com/news/MESO/clinical-trial-of-mesoblast-s-cell-therapy-in-end-stage-heart-failure-patients-completes-e-meso-20170928monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-presents-corporate-updates-at-global-healthcare-conferences-new-york-usa-and-mel-meso-20170925monthly0.5https://www.biopharmawatch.com/news/MESO/not-for-release-or-distribution-in-the-united-states-mesoblast-successfully-completes-a-50-meso-20170915monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-meso-20170907monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-successfully-completes-institutional-entitlement-offer-for-fully-underwritten-a--meso-20170829monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-outlines-potential-pathway-to-accelerated-market-entry-for-mpc-150-im-in-advance-meso-20170823monthly0.5https://www.biopharmawatch.com/news/MESO/positive-trial-results-of-mesoblast-cell-therapy-in-post-traumatic-osteoarthritis-publishe-meso-20170816monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20170803monthly0.5https://www.biopharmawatch.com/news/MESO/july-2017-the-manager-company-notices-section-asx-limited-level-4-north-tower-rialto-tower-meso-20170717monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-rheumatoid-arthritis-trial-results-presented-at-eular-annual-european-congress-o-meso-20170622monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-operational-highlights-and-financial-results-for-the-period-ended-march-31-2017--meso-20170525monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-meso-20170505monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20170503monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-a-3-7-million-from-australian-government-for-research-and-development-a-meso-20170406monthly0.5https://www.biopharmawatch.com/news/MESO/fda-clears-heart-disease-trial-at-harvard-s-boston-children-s-hospital-using-mesoblast-s-c-meso-20170404monthly0.5https://www.biopharmawatch.com/news/MESO/independent-data-monitoring-committee-initiates-process-for-interim-analysis-of-mes-oblast-meso-20170331monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-raises-us-40-million-new-york-usa-and-melbourne-australia-meso-20170327monthly0.5https://www.biopharmawatch.com/news/MESO/durable-three-year-outcomes-in-degenerative-disc-disease-after-a-single-injection-of-mesob-meso-20170315monthly0.5https://www.biopharmawatch.com/news/MESO/fda-grants-fast-track-designation-for-mesoblast-s-cell-therapy-in-children-with-acute-graf-meso-20170307monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20170228monthly0.5https://www.biopharmawatch.com/news/MESO/published-study-results-show-that-mesoblast-cells-administered-intravenously-significantly-meso-20170213monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20170203monthly0.5https://www.biopharmawatch.com/news/MESO/cautionary-note-regarding-forward-looking-statements-this-presentation-includes-forward-lo-meso-20170117monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-at-35-th-annual-j-p-morgan-healthcare-conference-melbourne-australia--meso-20170111monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-a-29-6-million-following-share-issue-to-mallinckrodt-new-york-usa-and-m-meso-20170109monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-and-mallinckrodt-enter-into-equity-purchase-agreement-to-exclusively-negotiate-d-meso-20161223monthly0.5https://www.biopharmawatch.com/news/MESO/united-states-congress-legislates-new-accelerated-approval-pathway-for-regenerative-advanc-meso-20161209monthly0.5https://www.biopharmawatch.com/news/MESO/md-anderson-cancer-center-and-national-institutes-of-health-to-fund-clinical-trial-combini-meso-20161206monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-announces-successful-interim-futility-analysis-in-phase-3-trial-for-acute-graft--meso-20161114monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-corporate-update-and-financial-results-for-the-first-quarter-ended-sept-meso-20161115monthly0.5https://www.biopharmawatch.com/news/MESO/rule-4-7b-appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-introduce-meso-20161103monthly0.5https://www.biopharmawatch.com/news/MESO/corporate-governance-statement-mesoblast-limited-the-company-or-mesoblast-and-its-board-of-meso-20161026monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-named-2016-cell-therapy-company-of-the-year-at-frost-sullivan-asia-pacific-best--meso-20161018monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-japan-strategy-highlighted-at-australia-japan-business-council-annual-meeting-ne-meso-20161012monthly0.5https://www.biopharmawatch.com/news/MESO/phase-2-trial-results-of-mesoblast-s-cell-therapy-in-diabetic-kidney-disease-published-new-meso-20161006monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-appoints-bill-burns-former-chief-executive-of-roche-pharmaceuticals-as-vice-chai-meso-20160901monthly0.5https://www.biopharmawatch.com/news/MESO/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-meso-20160826monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-strengthens-key-united-states-patent-portfolio-for-the-treatment-of-rheumatic-di-meso-20160817monthly0.5https://www.biopharmawatch.com/news/MESO/phase-2-trial-results-of-mesoblast-s-cell-therapy-show-dose-related-improvements-in-biolog-meso-20160810monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-meso-20160802monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-update-on-heart-failure-trial-and-funding-of-clinical-operations-highli-meso-20160701monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-update-on-global-heart-failure-program-key-points-mesoblast-regains-wor-meso-20160613monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-6-2-million-from-australian-government-for-research-and-development-act-meso-20160524monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-for-period-ended-31-march-2016-and-provides-corporate--meso-20160510monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-meso-20160429monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-19-april-2016-corporate-headquarters-level-38-55-coll-meso-20160422monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-cell-therapy-shows-disease-modifying-effects-on-knee-osteoarthritis-clinical-res-meso-20160404monthly0.5https://www.biopharmawatch.com/news/MESO/key-united-states-patent-granted-for-cell-based-treatment-of-rheumatoid-arthritis-and-othe-meso-20160325monthly0.5https://www.biopharmawatch.com/news/MESO/new-mesoblast-cell-targeting-technology-shows-potential-to-induce-durable-reversal-of-type-meso-20160317monthly0.5https://www.biopharmawatch.com/news/MESO/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-meso-20160226monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-cell-therapy-shows-clinical-benefit-in-first-cohort-of-patients-with-biologic-re-meso-20160217monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-abn-68-109-431-870-and-controlled-entities-mesoblast-group-half-year-inf-meso-20160216monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-rule-4-7b-a-meso-20160201monthly0.5https://www.biopharmawatch.com/news/MESO/cautionary-note-regarding-forward-looking-statements-this-presentation-includes-forward-lo-meso-20160119monthly0.5https://www.biopharmawatch.com/news/MESO/phase-3-heart-failure-trial-size-to-be-substantially-reduced-following-fda-discussions-new-meso-20160112monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-strategic-update-and-reports-on-first-quarter-financial-results-materia-meso-20151216monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-meso-20151204monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-meso-20151130monthly0.5https://www.biopharmawatch.com/news/MESO/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-meso-20151125monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-first-quarter-2026-financial-results-and-provides-business-update-ach-nuvb-20260504monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-preliminary-fourth-quarter-and-full-year-2025-financial-results-and-p-nuvb-20251231monthly0.5https://www.biopharmawatch.com/news/NUVB/forward-looking-statements-certain-statements-included-in-this-presentation-this-presentat-nuvb-20251126monthly0.5https://www.biopharmawatch.com/news/NUVB/driven-by-science-focused-on-life-november-2025-forward-looking-statements-certain-stateme-nuvb-20251103monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-third-quarter-2025-financial-results-and-provides-business-update-suc-nuvb-20251103monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-second-quarter-2025-financial-results-and-provides-business-update-re-nuvb-20250807monthly0.5https://www.biopharmawatch.com/news/NUVB/forward-looking-statements-certain-statements-included-in-this-presentation-this-presentat-nuvb-20250611monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-first-quarter-2025-financial-results-and-provides-business-update-new-nuvb-20250507monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-busi-nuvb-20250306monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-third-quarter-2024-financial-results-and-provides-business-update-sub-nuvb-20241106monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-second-quarter-2024-financial-results-and-provides-business-update-ef-nuvb-20240805monthly0.5https://www.biopharmawatch.com/news/NUVB/anheart-therapeutics-ltd-incorporated-in-the-cayman-islands-with-limited-liability-report--nuvb-20240620monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-first-quarter-2024-financial-results-and-provides-business-update-acq-nuvb-20240514monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-to-acquire-anheart-therapeutics-in-all-stock-transaction-acquisition-transfor-nuvb-20240325monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-busi-nuvb-20240229monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-third-quarter-2023-financial-results-and-provides-business-update-pha-nuvb-20231102monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-second-quarter-2023-financial-results-and-provides-business-update-en-nuvb-20230803monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-first-quarter-2023-financial-results-and-provides-business-update-enr-nuvb-20230504monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-busi-nuvb-20230315monthly0.5https://www.biopharmawatch.com/news/NUVB/in-the-court-of-chancery-of-the-state-of-delaware-in-re-nuvation-bio-inc-c-a-no-2023-verif-nuvb-20230302monthly0.5https://www.biopharmawatch.com/news/NUVB/forward-looking-statements-certain-statements-included-in-this-presentation-this-presentat-nuvb-20221223monthly0.5https://www.biopharmawatch.com/news/NUVB/privileged-and-confidential-nuvation-bio-reports-third-quarter-2022-financial-results-and--nuvb-20221103monthly0.5https://www.biopharmawatch.com/news/NUVB/privileged-and-confidential-nuvation-bio-reports-second-quarter-2022-financial-results-and-nuvb-20220804monthly0.5https://www.biopharmawatch.com/news/NUVB/privileged-and-confidential-nuvation-bio-announces-discontinuation-of-nuv-422-clinical-dev-nuvb-20220801monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-first-quarter-2022-financial-results-and-provides-business-update-nuv-nuvb-20220509monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-busi-nuvb-20220228monthly0.5https://www.biopharmawatch.com/news/NUVB/forward-looking-statements-certain-statements-included-in-this-presentation-this-presentat-nuvb-20220110monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-third-quarter-2021-financial-results-and-provides-business-update-enr-nuvb-20211110monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-second-quarter-2021-financial-results-and-provides-business-update-on-nuvb-20210812monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-reports-first-quarter-2021-financial-results-and-provides-business-update-ong-nuvb-20210517monthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-and-panacea-announce-business-combination-agreement-creating-a-publicly-liste-nuvb-20201021monthly0.5https://www.biopharmawatch.com/news/NUVB/panacea-acquisition-corp-announces-the-separate-trading-of-its-shares-of-class-a-common-st-nuvb-20200821monthly0.5https://www.biopharmawatch.com/news/NUVB/panacea-acquisition-corp-index-to-financial-statements-page-report-of-independent-register-nuvb-20200706monthly0.5https://www.biopharmawatch.com/news/NUVB/panacea-acquisition-corp-announces-pricing-of-125-000-000-initial-public-offering-nuvb-20200630monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-first-quarter-2026-ahco-20260505monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-fourth-quarter-and-full-year-2025-results-and-provides-2026-ahco-20260224monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-third-quarter-2025-ahco-20251104monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-second-quarter-2025-ahco-20250805monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-for-immediate-release-adapthealth-corp-partners-with-a-ahco-20250805monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-first-quarter-2025-ahco-20250506monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-fourth-quarter-and-full-year-2024-results-and-provides-2025-ahco-20250225monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-third-quarter-2024-ahco-20241105monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-for-immediate-release-adapthealth-appoints-diana-nole-to-board-of-directo-ahco-20241017monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-jason-clemens-cfa-chief-financial-officer-investor-relations-icr-westwick-ahco-20240916monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-jason-clemens-cfa-chief-financial-officer-ir-adapthealth-com-adapthealth--ahco-20240826monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-second-quarter-2024-ahco-20240806monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-first-quarter-2024-ahco-20240507monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-fourth-quarter-and-full-year-2023-results-and-provides-initial--ahco-20240227monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-third-quarter-2023-ahco-20231107monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-second-quarter-2023-ahco-20230808monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-appoints-crispin-teufel-as-new-chief-executive-officer-ahco-20230627monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-announces-stephen-griggs-will-step-down-as-ceo-at-the-end-of-second-quarter-bo-ahco-20230509monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-first-quarter-2023-ahco-20230509monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-fourth-quarter-and-full-year-2022-results-and-updates-2023-ahco-20230227monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-provides-full-year-2023-guidance-and-preliminary-commentary-on-fourth-quarter--ahco-20230110monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-third-quarter-2022-results-and-updates-2022-ahco-20221108monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-reports-second-quarter-2022-results-ahco-20220809monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-reports-first-quarter-2022-results-updates-2022-guidance-and-announces-200-mil-ahco-20220510monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-pricing-of-add-on-sgry-20251211monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-reports-fourth-quarter-and-full-year-2021-results-and-updates-2022-guidance-ahco-20220224monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-announces-third-quarter-2021-financial-results-raises-full-year-2021-guidance--ahco-20211104monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-appointment-of-greg-belinfanti-as-director-plymouth-meeting-pa-ahco-20210930monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-add-on-sgry-20251211monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-announces-proposed-offering-of-550-million-senior-notes-due-2030-plymouth-meet-ahco-20210810monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-second-quarter-2021-financial-results-plymouth-meeting-pa-ahco-20210805monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2025-sgry-20251110monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-appoints-stephen-griggs-chief-executive-officer-plymouth-meeting-pa-ahco-20210614monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-first-quarter-2021-financial-results-plymouth-meeting-pa-ahco-20210506monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2025-results-reaffirms-full-year-2025-sgry-20250805monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-s-board-of-directors-statement-on-co-chief-executive-officer-luke-mcgee-p-ahco-20210413monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-fourth-quarter-and-full-year-2020-financial-results-plymouth-me-ahco-20210304monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-closes-previously-announced-acquisition-of-aerocare-holdings-inc-plymouth-ahco-20210201monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-announces-proposed-offering-of-500-million-senior-notes-due-2029-plymouth-meet-ahco-20201214monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-acquisition-of-national-hme-provider-aerocare-holdings-inc-and--ahco-20201201monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-ahco-20201104monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-and-bain-capital-conclude-discussions-board-reaffirms-its-confidence--sgry-20250617monthly0.5https://www.biopharmawatch.com/news/AHCO/for-immmediate-release-adapthealth-corp-appoints-frank-j-mullen-as-chief-accounting-office-ahco-20200921monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-second-quarter-2020-financial-results-plymouth-meeting-pa-ahco-20200804monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-appoints-david-s-williams-iii-to-board-of-directors-plymouth-meeting-pa-ahco-20200730monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2025-results-reaffirms-full-year-2025-sgry-20250512monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-announces-proposed-offering-of-300-0-million-senior-notes-due-2028-plymouth-me-ahco-20200714monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-closes-previously-announced-acquisitions-of-solara-medical-supplies-and-activs-ahco-20200702monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2024-results-sets-2025-sgry-20250303monthly0.5https://www.biopharmawatch.com/news/AHCO/solara-medical-supplies-llc-consolidated-financial-statements-as-of-december-31-2019-and-2-ahco-20200618monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-expands-into-diabetes-segment-with-accretive-acquisition-of-leading-distributo-ahco-20200526monthly0.5https://www.biopharmawatch.com/news/AHCO/for-immmediate-release-adapthealth-corp-appoints-jason-a-clemens-cfa-as-chief-financial-of-ahco-20200521monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-confirms-receipt-of-non-binding-acquisition-proposal-from-bain-capita-sgry-20250128monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-first-quarter-2020-financial-results-plymouth-meeting-pa-ahco-20200505monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-ahco-20200225monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-acquires-patient-care-solutions-business-from-mckesson-corporation-names--ahco-20200103monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-names-laura-l-forese-sgry-20250113monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-to-acquire-north-carolina-based-advanced-home-care-ahco-20191209monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-signs-definitive-agreement-to-acquire-patient-care-solutions-business-from-mck-ahco-20191122monthly0.5https://www.biopharmawatch.com/news/AHCO/investor-november-2019-presentation-disclaimer-disclaimers-and-other-important-information-ahco-20191108monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2024-sgry-20241112monthly0.5https://www.biopharmawatch.com/news/AHCO/selected-historical-financial-information-of-adapthealth-the-following-table-shows-selecte-ahco-20191114monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-corp-announces-third-quarter-2019-financial-results-for-its-adapthealth-holdin-ahco-20191113monthly0.5https://www.biopharmawatch.com/news/SGRY/year-to-date-operating-cash-flows-were-123-5-million-compared-to-126-6-million-in-the-prio-sgry-20240806monthly0.5https://www.biopharmawatch.com/news/AHCO/dfb-adapthealth-investor-presentation-october-2019-disclaimer-disclaimers-and-other-import-ahco-20191022monthly0.5https://www.biopharmawatch.com/news/AHCO/dfb-healthcare-acquisitions-corp-and-adapthealth-holdings-llc-announce-amendments-to-merge-ahco-20191015monthly0.5https://www.biopharmawatch.com/news/AHCO/dfb-healthcare-acquisitions-corp-announces-record-date-for-special-meeting-of-shareholders-ahco-20191010monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2024-results-raises-full-year-2024-sgry-20240507monthly0.5https://www.biopharmawatch.com/news/AHCO/investor-presentation-ahco-20191003monthly0.5https://www.biopharmawatch.com/news/AHCO/dfb-adapthealth-investor-presentation-september-2019-disclaimer-disclaimers-and-other-impo-ahco-20190917monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-sgry-20240326monthly0.5https://www.biopharmawatch.com/news/AHCO/adapthealth-to-become-a-public-company-via-business-combination-with-dfb-healthcare-adapth-ahco-20190708monthly0.5https://www.biopharmawatch.com/news/AHCO/dfb-healthcare-acquisitions-corp-report-of-independent-registered-public-accounting-firm-f-ahco-20180221monthly0.5https://www.biopharmawatch.com/news/AHCO/dfb-healthcare-acquisitions-corp-announces-pricing-of-250-million-initial-public-offering-ahco-20180216monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2023-results-sets-2024-sgry-20240226monthly0.5https://www.biopharmawatch.com/news/SGRY/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-sgry-20231218monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-sgry-20231206monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2023-sgry-20231107monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2023-sgry-20230801monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2023-sgry-20230501monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2022-results-sets-2023-sgry-20230301monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2022-sgry-20221108monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2022-results-revenue-increased-13-3-from-the-sgry-20220802monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2022-results-revenues-increased-16-4-to-596-2-sgry-20220503monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2021-results-raises-2022-guida-sgry-20220228monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-reaffirms-2021-and-2022-full-year-guidance-david-t-doherty-to-assume-role-sgry-20220110monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2021-sgry-20211102monthly0.5https://www.biopharmawatch.com/news/SGRY/investor-presentation-august-2021-2021-surgery-partners-confidential-proprietary-informati-sgry-20210817monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2021-sgry-20210804monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2021-sgry-20210505monthly0.5https://www.biopharmawatch.com/news/SGRY/lender-presentation-april-2021-2-legal-disclaimer-forward-looking-statements-this-presenta-sgry-20210331monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2020-sgry-20210310monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2020-sgry-20201104monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2020-sgry-20200805monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-pricing-of-incremental-note-offering-surgery-partners-inc-n-sgry-20200724monthly0.5https://www.biopharmawatch.com/news/SGRY/legal-disclaimer-forward-looking-statements-this-presentation-contains-forward-looking-sta-sgry-20200722monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2020-sgry-20200511monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2019-sgry-20200305monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-executive-promotions-wayne-s-deveydt-appointed-to-executive-sgry-20200113monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2019-sgry-20191105monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2019-sgry-20190807monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2019-sgry-20190508monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-nasdaq-sgry-surgery-partners-today-announced-that-its-wholly-owned-su-sgry-20190329monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-nasdaq-sgry-surgery-partners-today-announced-that-its-wholly-owned-su-sgry-20190325monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2018-results-same-store-volume-sgry-20190313monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-announces-appointment-of-eric-evans-as-executive-vice-president-and-chief-sgry-20190211monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2018-results-near-term-results-reflect-ongoin-sgry-20181107monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-closing-of-new-180-million-incremental-term-loan-sgry-20181024monthly0.5https://www.biopharmawatch.com/news/SGRY/lender-presentation-october-2018-legal-disclaimer-forward-looking-statements-statements-co-sgry-20181011monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2018-results-strategic-initiatives-begin-to--sgry-20180809monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2018-results-quarterly-highlights-reflect-sig-sgry-20180509monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-announces-appointment-of-thomas-cowhey-as-chief-financial-officer-sgry-20180312monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2017-sgry-20180301monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-announces-executive-leadership-transitions-david-kretschmer-appointed-chi-sgry-20180129monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-announces-appointment-of-wayne-s-deveydt-as-chief-executive-officer-commi-sgry-20180108monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-50-0-sgry-20171215monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2017-results-integration-with-national-surgic-sgry-20171108monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-provides-update-on-2017-third-quarter-results-sgry-20171031monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-announces-appointment-of-clifford-adlerz-as-interim-chief-executive-offic-sgry-20170907monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-completes-acquisition-of-national-surgical-healthcare-combination-creates-sgry-20170831monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2017-results-transaction-with-national-surgi-sgry-20170808monthly0.5https://www.biopharmawatch.com/news/SGRY/summary-unaudited-pro-forma-condensed-combined-financial-information-the-following-summary-sgry-20170619monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-new-appointments-to-the-board-of-directors-sgry-20170605monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-receipt-of-requisite-consents-and-expiration-of-its-consent-sgry-20170525monthly0.5https://www.biopharmawatch.com/news/SGRY/bridge-presentation-may-2017-legal-disclaimer-this-document-has-been-prepared-solely-for-u-sgry-20170509monthly0.5https://www.biopharmawatch.com/news/SGRY/consent-solicitation-statement-surgery-center-holdings-inc-solicitation-of-consents-relati-sgry-20170518monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-to-acquire-national-surgical-healthcare-from-irving-place-capital-combina-sgry-20170510monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2017-results-revenues-increase-7-2-over-prior-sgry-20170509monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2016-results-fourth-quarter-re-sgry-20170309monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2016-results-revenues-increase-18-over-prior--sgry-20161109monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-appoints-teresa-deluca-m-d-to-the-board-of-directors-sgry-20160930monthly0.5https://www.biopharmawatch.com/news/SGRY/corrected-surgery-partners-inc-announces-second-quarter-2016-results-revenues-increase-24--sgry-20160810monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-second-quarter-2016-results-revenues-increase-24-over-prior-sgry-20160809monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-first-quarter-2016-results-revenues-increase-19-over-prior--sgry-20160505monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-announces-pricing-of-400-million-senior-note-offering-sgry-20160329monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-announces-proposed-400-million-senior-note-offering-sgry-20160318monthly0.5https://www.biopharmawatch.com/news/SGRY/name-number-of-shares-of-restricted-stock-date-of-grant-s-urgery-p-artners-i-nc-2015-o-mni-sgry-20160315monthly0.5https://www.biopharmawatch.com/news/SGRY/executive-summary-surgery-partners-inc-surgery-partners-or-the-company-is-a-leading-surgic-sgry-20160314monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-fourth-quarter-and-full-year-2015-results-fourth-quarter-re-sgry-20160310monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-appoints-brent-turner-to-the-board-of-directors-sgry-20151230monthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-inc-announces-third-quarter-2015-results-revenues-increase-214-over-prior-sgry-20151112monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-preliminary-full-year-2025-unaudited-total-revenue-and-provides-b-adma-20260112monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-second-quarter-2025-financial-results-and-provides-business-updat-adma-20250806monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-first-quarter-2025-financial-results-and-provides-business-update-adma-20250507monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides--adma-20250303monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-realizing-the-potential-of-specialty-biologicswith-groundbreaking-immunotec-adma-20250113monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-preliminary-full-year-2024-revenue-and-provides-business-update-f-adma-20250113monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-partial-paydown-of-senior-term-loan-credit-facility-cash-on-hand--adma-20241220monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-third-quarter-2024-financial-results-and-provides-business-update-adma-20241107monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-partial-paydown-of-revolving-credit-facility-cash-on-hand-utilize-adma-20240814monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-second-quarter-2024-financial-results-and-provides-business-updat-adma-20240808monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-realizing-the-potential-of-specialty-biologicswith-groundbreaking-immunotec-adma-20240517monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-first-quarter-2024-financial-results-and-provides-business-update-adma-20240509monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-fda-approvals-of-extended-room-temperature-storage-conditions-for-adma-20240311monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-realizing-the-potential-of-specialty-biologicswith-groundbreaking-immunotec-adma-20240305monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-cfo-transition-executive-search-initiated-for-cfo-replacement-ram-adma-20240228monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-fourth-quarter-and-full-year-2023-financial-results-and-provides--adma-20240228monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-successfully-implements-innovative-ai-program-named-admalytics-admalytics-c-adma-20240221monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-realizing-the-potential-of-specialty-biologicswith-groundbreaking-immunotec-adma-20240108monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-preliminary-fourth-quarter-2023-revenue-and-provides-business-upd-adma-20240108monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-135-million-non-dilutive-refinancing-of-credit-facilities-with-ar-adma-20231218monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-fda-approval-for-bivigam-in-the-pediatric-patient-setting-for-tho-adma-20231212monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biocenters-receives-fda-approval-for-its-tenth-plasma-collection-center-located-in-la-adma-20231116monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-third-quarter-2023-financial-results-and-provides-business-update-adma-20231108monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-second-quarter-2023-financial-results-and-provides-business-updat-adma-20230809monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biocenters-receives-fda-approval-for-its-ninth-plasma-collection-center-located-in-da-adma-20230719monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-first-quarter-2023-financial-results-and-provides-business-update-adma-20230510monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-amendment-to-credit-agreement-reduces-nominal-interest-rate-by-1--adma-20230502monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-fourth-quarter-and-full-year-2022-financial-results-and-provides--adma-20230323monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biocenters-receives-fda-approval-for-its-eighth-plasma-collection-center-located-in-h-adma-20230208monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-preliminary-fourth-quarter-and-full-year-2022-revenues-and-provid-adma-20230117monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-closing-of-69-million-public-offering-including-full-exercise-of--adma-20221209monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-public-offering-for-60-million-of-common-stock-ramsey--adma-20221209monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-preliminary-fourth-quarter-2022-revenue-estimate-fourth-quarter-2-adma-20221206monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-third-quarter-2022-financial-results-and-provides-business-update-adma-20221109monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biocenters-receives-fda-approval-for-its-seventh-plasma-collection-center-located-in--adma-20221031monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-second-quarter-2022-financial-results-and-provides-business-updat-adma-20220810monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biocenters-receives-fda-approval-for-its-sixth-plasma-collection-center-located-in-my-adma-20220627monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-first-quarter-2022-financial-results-and-provides-business-update-adma-20220511monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-fda-approval-of-extended-shelf-life-for-asceniv-bivigam-from-24-t-adma-20220325monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-fourth-quarter-and-full-year-2021-financial-results-and-provides--adma-20220324monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biocenters-receives-fda-approval-for-its-fifth-plasma-collection-center-located-in-co-adma-20220307monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-record-preliminary-fourth-quarter-and-full-year-2021-revenues-and-adma-20220119monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biocenters-receives-fda-approval-for-its-fourth-plasma-collection-center-located-in-g-adma-20220118monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-adopts-limited-duration-stockholder-rights-plan-ramsey-n-j-and-adma-20211221monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-update-on-global-intellectual-property-portfolio-extends-existing--adma-20211209monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-realizing-the-potential-of-plasma-derived-therapieswith-groundbreaking-immu-adma-20211201monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-advances-plasma-collection-center-expansion-plans-with-opening-of-new-facil-adma-20211116monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-record-third-quarter-2021-financial-results-and-highlights-recent-p-adma-20211110monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-closing-of-57-5-million-public-offering-including-full-exercise-o-adma-20211025monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-public-offering-for-50-million-of-common-stock-ramsey--adma-20211021monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-strengthens-its-board-of-directors-with-the-appointment-of-young-t-kwon-ph--adma-20211018monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-fda-approval-for-adma-biocenters-plasma-collection-facility-in-mar-adma-20210816monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-commercial-availability-of-expanded-vial-size-offerings-for-bivig-adma-20210809monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-record-second-quarter-2021-financial-results-and-highlights-recent--adma-20210811monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-successful-completion-of-fda-pre-approval-manufacturing-facility--adma-20210720monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2021-financial-results-and-highlights-recent-company--adma-20210512monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-fda-approval-for-increased-ivig-production-scale-adma-increases-to-adma-20210428monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-fourth-quarter-and-full-year-2020-financial-results-achieved-full-y-adma-20210325monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-fda-approval-for-adma-biocenters-plasma-collection-facility-in-kno-adma-20210201monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-unique-permanent-j-code-for-asceniv-ramsey-n-j-and-adma-20210126monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-preliminary-fourth-quarter-and-full-year-2020-revenues-and-provid-adma-20210119monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-unique-temporary-c-code-and-pass-through-payment-status-for-asceni-adma-20210104monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-adopts-limited-duration-stockholder-rights-plan-ramsey-n-j-and-adma-20201216monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-enters-into-100-million-credit-facility-loan-amendment-with-perceptive-advi-adma-20201209monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2020-financial-results-and-business-highlights-genera-adma-20201105monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-highlights-launch-of-covid-19-immunorank-neutralization-micro-elisa-assay-t-adma-20200903monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-business-highlights-and-second-quarter-2020-financial-results-gener-adma-20200805monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-opens-its-newest-adma-biocenters-plasma-collection-facility-ramsey-n-j-and--adma-20200706monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-jefferies-virtual-healthcare-conference-ramsey-n-j-and-adma-20200527monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-commences-collection-of-covid-19-plasma-from-recovered-patients-ramsey-n-j--adma-20200521monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2020-financial-results-and-highlights-recent-company--adma-20200506monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights--adma-20200312monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-closing-of-full-exercise-of-underwriters-option-to-purchase-addit-adma-20200224monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-bionj-2020-innovator-award-for-asceniv-ramsey-nj-and-adma-20200211monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-proposed-75-million-public-offering-of-common-stock-ramsey-n-j-an-adma-20200207monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-preliminary-fourth-quarter-and-full-year-2019-revenues-and-provid-adma-20200109monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-enters-into-a-manufacturing-and-supply-agreement-to-produce-and-sell-plasma-adma-20200107monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-added-to-nasdaq-biotechnology-index-ramsey-n-j-and-adma-20191217monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-jefferies-2019-london-healthcare-conference-ramsey-n-j-and-adma-20191113monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2019-financial-results-and-highlights-recent-company--adma-20191106monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-named-company-of-the-year-by-bioflorida-ramsey-n-j-and-boca-raton-fl-adma-20191022monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-first-commercial-sales-of-asceniv-ramsey-n-j-and-boca-raton-fl-adma-20191021monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-publication-of-an-article-describing-the-manufacturing-process-op-adma-20191017monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-data-presented-at-idweek-2019-ramsey-n-j-and-boca-raton-fl-adma-20191007monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-poster-presentation-at-idweek-2019-ramsey-n-j-and-boca-raton-fl-adma-20191003monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-2019-cantor-global-healthcare-conference-ramsey-n-j-and-boca--adma-20190923monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-commercial-relaunch-and-its-first-commercial-sales-of-bivigam-ram-adma-20190822monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-second-quarter-and-first-half-2019-financial-results-ramsey-n-j-and-adma-20190808monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-fda-approval-for-license-transfers-for-bivigam-and-nabi-hb-all-asp-adma-20190708monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-upcoming-investor-conferences-jefferies-2019-healthcare-confe-adma-20190529monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-closing-of-51-75-million-public-offering-and-full-exercise-of-und-adma-20190521monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-proposed-45-million-public-offering-of-common-stock-ramsey-n-j-an-adma-20190515monthly0.5https://www.biopharmawatch.com/news/ADMA/fda-approves-prior-approval-supplement-for-bivigam-adma-announces-it-will-commence-commerc-adma-20190510monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2019-financial-results-ramsey-n-j-and-boca-raton-fl-adma-20190508monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-elects-to-draw-down-27-5-million-in-capital-from-existing-perceptive-adviso-adma-20190503monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-granted-u-s-patent-for-treatment-and-prevention-of-pneumococcal-infections--adma-20190417monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-receives-department-of-health-and-human-services-u-s-license-ramsey-n-j-and-boca-rato-adma-20190402monthly0.5https://www.biopharmawatch.com/news/ADMA/fda-approves-asceniv-a-novel-intravenous-immune-globulin-approved-for-use-in-the-treatment-adma-20190401monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-full-year-2018-financial-results-ramsey-n-j-and-boca-raton-fl-adma-20190313monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-upcoming-investor-conferences-raymond-james-40-th-annual-inst-adma-20190225monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-enters-into-72-5-million-loan-facility-with-perceptive-advisors-provides-fu-adma-20190212monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-regulatory-update-on-bivigam-pas-submissions-call-adma-20181220monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-regulatory-update-on-bivigam-pas-submissions-fda-issues-complete-r-adma-20181219monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-regulatory-update-for-bivigam-fda-pdufa-action-anticipated-ramsey--adma-20181219monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2018-financial-results-ramsey-n-j-and-boca-raton-fl-adma-20181108monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-pdufa-date-for-ri-002-resubmission-of-biologics-license-applicatio-adma-20181017monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-regulatory-update-for-bivigam-ramsey-n-j-and-boca-raton-fl-adma-20181011monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biocenters-receives-fda-approval-for-third-plasma-collection-center-ramsey-nj-mariett-adma-20181003monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-resubmits-biologics-license-application-for-ri-002-ramsey-nj-adma-20181001monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-fda-compliance-status-for-its-manufacturing-facility-has-improved-f-adma-20180905monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-20-th-annual-rodman-renshaw-global-investment-conference--adma-20180827monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-second-quarter-2018-financial-results-key-regulatory-manufacturing--adma-20180810monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-successful-close-out-of-its-april-2018-fda-compliance-inspection-fd-adma-20180726monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-pdufa-date-for-bivigam-regulatory-submission-prior-approval-supple-adma-20180726monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-added-to-the-russell-3000-and-russell-2000-indexes-ramsey-n-j-and-adma-20180625monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-closing-of-40m-public-offering-ramsey-n-j-and-adma-20180612monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-proposed-public-offering-of-common-stock-ramsey-n-j-and-adma-20180607monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-granted-u-s-patent-for-treating-respiratory-infections-fourth-patent-issued-adma-20180516monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-retires-approximately-8-6-million-shares-previously-issued-to-biotest-capit-adma-20180514monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-the-release-of-its-first-commercial-batch-of-nabi-hb-manufactured-adma-20180424monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-full-year-2017-financial-results-ramsey-n-j-and-boca-raton-fl-adma-20180305monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-files-biologics-license-application-for-its-third-plasma-collection-center-adma-bioce-adma-20171211monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-further-enhances-intellectual-property-portfolio-through-newly-issued-u-s-p-adma-20171115monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-closing-of-42m-follow-on-offering-ramsey-n-j-adma-20171113monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-follow-on-offering-ramsey-n-j-adma-20171109monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-corporate-update-and-reports-third-quarter-2017-financial-results--adma-20171103monthly0.5https://www.biopharmawatch.com/news/ADMA/marathon-asset-management-and-adma-biologics-complete-30-million-debt-refinancing-new-debt-adma-20171011monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-corporate-update-and-reports-second-quarter-2017-financial-results-adma-20170811monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-strengthens-patent-portfolio-through-newly-issued-u-s-patent-for-immunother-adma-20170731monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-corporate-timeline-and-activities-update-to-stockholders-ramsey-n--adma-20170627monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-completes-acquisition-of-biotest-s-therapy-business-unit-assets-transaction-adma-20170606monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-stockholders-vote-to-approve-acquisition-of-certain-assets-from-biotest-pha-adma-20170530monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-jefferies-2017-healthcare-conference-ramsey-n-j-adma-20170525monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-corporate-update-and-reports-first-quarter-2017-financial-results--adma-20170512monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-reports-year-end-2016-financial-results-accomplishmen-adma-20170224monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-filed-by-adma-biologics-inc-pursuant-to-rule-14a-12-under-the-securi-adma-20170123monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2016-results-ramsey-n-j-adma-20161110monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-20160909monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-second-quarter-2016-results-ramsey-n-j-adma-20160812monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-complete-response-letter-from-fda-for-pending-biologics-license-ap-adma-20160729monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2016-results-company-announces-recent-accomplishments-adma-20160513monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-announces-pricing-of-public-offering-of-common-stock--adma-20160428monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-announces-proposed-public-offering-of-common-stock-ra-adma-20160427monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-year-end-2015-financial-results-accomplishments-and-upcoming-milest-adma-20160323monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2015-results-ramsey-n-j-adma-20151110monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-20150909monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-second-quarter-2015-results-provides-corporate-update-and-anticipat-adma-20150811monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-secures-up-to-21-million-loan-commitment-from-oxford-finance-ramsey-n-j-adma-20150622monthly0.5https://www.biopharmawatch.com/news/ADMA/charter-2-e613828-ex99-1-htm-unassociated-document-adma-20150624monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2015-results-provides-corporate-update-and-anticipate-adma-20150512monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-public-offering-of-common-stock-ramsey-n-j-adma-20150313monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-year-end-2014-results-and-upcoming-milestones-ramsey-n-j-adma-20150309monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-20150302monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-20141211monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2014-financial-and-operational-results-ramsey-n-j-adma-20141110monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-reports-second-quarter-2014-financial-and-operational-adma-20140811monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2014-financial-and-operational-results-ramsey-n-j-adma-20140512monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-year-end-2013-results-ramsey-n-j-adma-20140328monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-secures-up-to-15-million-loan-commitment-from-hercules-technology-growth-ca-adma-20140227monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-expands-plasma-collection-operations-of-adma-biocenters-ramsey-n-j-norcross-adma-20140203monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-20131209monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-reports-third-quarter-2013-financial-and-operational--adma-20131112monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-inc-announces-pricing-of-initial-public-offering-rams-adma-20131017monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-reports-second-quarter-2013-financial-and-operational-adma-20130812monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-reports-first-quarter-2013-financial-and-operational--adma-20130514monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-commences-pivotal-phase-iii-clinical-study-of-ri-002--adma-20130307monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-reports-2012-year-end-financial-and-operational-resul-adma-20130306monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-20130107monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-reports-2012-third-quarter-results-hackensack-n-j-adma-20121113monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-20120911monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-reports-2012-second-quarter-results-hackensack-n-j-adma-20120814monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-consolidated-financial-statements-unassociated-document-adma-biologics--adma-20120622monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-appoints-brian-lenz-as-chief-financial-officer-hacken-adma-20120503monthly0.5https://www.biopharmawatch.com/news/ADMA/unassociated-document-adma-biologics-inc-and-subsidiary-index-page-report-of-independent-r-adma-20120424monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-financial-statements-unassociated-document-adma-biologics-inc-and-subsi-adma-20120329monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-and-subsidiary-a-development-stage-enterprise-index-page-report-of-inde-adma-20120213monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20250505monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-finn-partners-chief-financial-officer-6-adus-20250311monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20250224monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-finn-partners-chief-financial-officer-6-adus-20241202monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20241104monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20240805monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-finn-partners-chief-financial-officer-6-adus-20240626monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-finn-partners-chief-financial-officer-6-adus-20240610monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20240506monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-finn-partners-chief-financial-officer-6-adus-20240423monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20240226monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20231030monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-finn-partners-chief-financial-officer-6-adus-20230801monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-finn-partners-chief-financial-officer-6-adus-20230629monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20230501monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-finnpartners-chief-financial-officer-61-adus-20230301monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20230227monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-finn-partners-a-adus-20221031monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-announces-passing-of-director-steven-geringer-adus-20220913monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-cci-finn-partne-adus-20220801monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-executive-vice-president-chief-financial-officer-addus-homecare-corporation-4-adus-20220502monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-cci-finn-partne-adus-20220224monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-cci-finn-partne-adus-20211101monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-cci-finn-partners-chief-financial-offic-adus-20210802monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20210503monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-corporate-commu-adus-20210225monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20210111monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20201204monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20201111monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-corporate-commu-adus-20201102monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20200810monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-corporate-commu-adus-20200515monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20200504monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-corporate-commu-adus-20200320monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20200317monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20200227monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-chief-financial-officer-corporate-commu-adus-20191104monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20191001monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20190826monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20190805monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20190724monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20190506monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20190408monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20190304monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-dru-anderson-executive-vice-president-corporate-communications-inc-chief-fina-adus-20181105monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20180806monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20180507monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20180501monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20180402monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20180305monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20171106monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20170807monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20170731monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20170508monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-executive-vice-president-chief-financial-officer-addus-homecare-corporation-4-adus-20170504monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20170306monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-chief-financial-officer-corporate-com-adus-20170104monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-corporate-communications-inc-chief-fi-adus-20161107monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-chief-financial-officer-addus-homecar-adus-20161019monthly0.5https://www.biopharmawatch.com/news/ADUS/brian-w-poff-scott-brittain-executive-vice-president-chief-financial-officer-corporate-com-adus-20160801monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-version-employment-and-non-competition-agreement-this-employment-and-non-competi-adus-20160601monthly0.5https://www.biopharmawatch.com/news/ADUS/separation-agreement-this-separation-agreement-and-general-release-this-agreement-is-being-adus-20160527monthly0.5https://www.biopharmawatch.com/news/ADUS/e-xecution-c-opy-consent-and-amendment-no-2-to-second-amended-and-restated-credit-and-guar-adus-20160524monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-version-employment-and-non-competition-agreement-this-employment-and-non-competi-adus-20160510monthly0.5https://www.biopharmawatch.com/news/ADUS/don-klink-scott-brittain-chief-financial-officer-corporate-communications-inc-addus-homeca-adus-20160502monthly0.5https://www.biopharmawatch.com/news/ADUS/don-klink-scott-brittain-chief-financial-officer-corporate-communications-inc-addus-homeca-adus-20160307monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-version-employment-and-non-competition-agreement-this-employment-and-non-competi-adus-20160229monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-version-employment-and-non-competition-agreement-this-employment-and-non-competi-adus-20160225monthly0.5https://www.biopharmawatch.com/news/ADUS/don-klink-chief-financial-officer-addus-homecare-630-296-3400-investorrelations-addus-com--adus-20160218monthly0.5https://www.biopharmawatch.com/news/ADUS/don-klink-scott-brittain-chief-financial-officer-corporate-communications-inc-addus-homeca-adus-20160208monthly0.5https://www.biopharmawatch.com/news/ADUS/don-klink-scott-brittain-chief-financial-officer-corporate-communications-inc-addus-homeca-adus-20160118monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-version-second-amended-and-restated-credit-and-guaranty-agreement-among-addus-he-adus-20151110monthly0.5https://www.biopharmawatch.com/news/ADUS/don-klink-chief-financial-officer-addus-homecare-corporation-630-296-3400-investorrelation-adus-20151102monthly0.5https://www.biopharmawatch.com/news/ADUS/don-klink-scott-brittain-chief-financial-officer-corporate-communications-inc-630-296-3400-adus-20151022monthly0.5https://www.biopharmawatch.com/news/ADUS/don-klink-scott-brittain-chief-financial-officer-corporate-communications-inc-addus-homeca-adus-20150803monthly0.5https://www.biopharmawatch.com/news/ADUS/employment-and-non-competition-agreement-this-employment-and-non-competition-agreement-thi-adus-20150430monthly0.5https://www.biopharmawatch.com/news/ADUS/dennis-meulemans-scott-brittain-chief-financial-officer-corporate-communications-inc-addus-adus-20150305monthly0.5https://www.biopharmawatch.com/news/ADUS/serving-families-at-home-since-1979-the-pre-acute-solution-to-the-post-acute-problem-jp-mo-adus-20150112monthly0.5https://www.biopharmawatch.com/news/ADUS/dennis-meulemans-scott-brittain-chief-financial-officer-corporate-communications-inc-addus-adus-20150105monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-copy-employment-and-non-competition-agreement-this-employment-and-non-competitio-adus-20141215monthly0.5https://www.biopharmawatch.com/news/ADUS/dennis-meulemans-scott-brittain-chief-financial-officer-corporate-communications-inc-addus-adus-20141030monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-sm-homecare-coordinated-personal-home-care-a-pre-acute-solution-to-the-post-acute-pr-adus-20140811monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-630-296-3400-email-dmeulem-adus-20140731monthly0.5https://www.biopharmawatch.com/news/ADUS/coordinated-personal-home-care-a-pre-acute-solution-to-the-post-acute-problemsm-jefferies--adus-20140604monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-announces-the-acquisition-of-aid-assist-at-home-adus-20140602monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20140501monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-appoints-michael-earley-to-board-of-directors-palatine-il-adus-20140401monthly0.5https://www.biopharmawatch.com/news/ADUS/addussm-homecare-coordinated-personal-home-care-a-pre-acute-solution-to-the-post-acute-pro-adus-20140317monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20140312monthly0.5https://www.biopharmawatch.com/news/ADUS/for-more-information-adus-20140113monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-announces-the-closing-of-its-previously-announced-purchase-of-fifteen-offic-adus-20131206monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20131107monthly0.5https://www.biopharmawatch.com/news/ADUS/coordinated-personal-home-care-a-pre-acute-solution-to-the-post-acute-problemsm-avondalepa-adus-20130814monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20130801monthly0.5https://www.biopharmawatch.com/news/ADUS/forward-looking-statements-the-following-information-contains-or-may-be-deemed-to-contain--adus-20130514monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20130502monthly0.5https://www.biopharmawatch.com/news/ADUS/first-amendment-to-amended-and-restated-bylaws-of-addus-homecare-corporation-this-first-am-adus-20130429monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20130301monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20130222monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20130220monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20130207monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20121101monthly0.5https://www.biopharmawatch.com/news/ADUS/separation-agreement-and-general-release-this-separation-agreement-and-general-release-thi-adus-20120921monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-dual-advantagetm-integrated-personal-home-health-care-a-pre-acute-solution-to-the-po-adus-20120906monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20120802monthly0.5https://www.biopharmawatch.com/news/ADUS/employment-and-non-competition-agreement-this-employment-and-non-competition-agreement-thi-adus-20120618monthly0.5https://www.biopharmawatch.com/news/ADUS/mission-statement-it-is-the-primary-mission-of-addus-healthcare-to-improve-the-health-and--adus-20120613monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20120503monthly0.5https://www.biopharmawatch.com/news/ADUS/note-execution-of-this-adoption-agreement-creates-a-legal-liability-of-the-employer-with-s-adus-20120401monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-dennis-meulemans-chief-financial-officer-phone-847-303-5300-email-dmeulem-adus-20120301monthly0.5https://www.biopharmawatch.com/news/ADUS/amendment-no-2-to-employment-and-non-competition-agreement-this-amendment-no-2-to-employme-adus-20111117monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-amy-glynn-nick-laudico-the-ruth-group-phone-646-536-7023-7030-email-aglyn-adus-20111103monthly0.5https://www.biopharmawatch.com/news/ADUS/mission-statement-it-is-the-primary-mission-of-addus-healthcare-to-improve-the-health-and--adus-20110927monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-amy-glynn-nick-laudico-the-ruth-group-phone-646-536-7023-7030-email-aglyn-adus-20110804monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-version-amendment-no-4-to-loan-and-security-agreement-this-amendment-no-4-to-loa-adus-20110726monthly0.5https://www.biopharmawatch.com/news/ADUS/amendment-no-1-to-employment-and-non-competition-agreement-this-amendment-no-1-to-employme-adus-20110718monthly0.5https://www.biopharmawatch.com/news/ADUS/employment-and-non-competition-agreement-this-employment-and-non-competition-agreement-thi-adus-20110623monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-version-joinder-consent-and-amendment-no-3-to-loan-and-security-agreement-this-j-adus-20110524monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-corporation-and-subsidiaries-condensed-consolidated-statements-of-income-an-adus-20110505monthly0.5https://www.biopharmawatch.com/news/ADUS/in-the-circuit-court-of-cook-county-illinois-county-department-chancery-division-paul-wes--adus-20110413monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-amy-glynn-nick-laudico-the-ruth-group-phone-646-536-7023-7030-email-aglyn-adus-20110303monthly0.5https://www.biopharmawatch.com/news/ADUS/employment-and-non-competition-agreement-this-employment-and-non-competition-agreement-thi-adus-20110105monthly0.5https://www.biopharmawatch.com/news/ADUS/employment-and-non-competition-agreement-this-employment-and-non-competition-agreement-thi-adus-20101129monthly0.5https://www.biopharmawatch.com/news/ADUS/separation-agreement-waiver-and-general-release-this-separation-agreement-and-general-rele-adus-20101130monthly0.5https://www.biopharmawatch.com/news/ADUS/a-addus-homecare-corporation-and-subsidiaries-condensed-consolidated-statements-of-income--adus-20101104monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-amy-glynn-nick-laudico-the-ruth-group-phone-646-536-7023-7030-email-aglyn-adus-20101021monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-appoints-r-dirk-allison-to-board-of-directors-veteran-in-healthcare-service-adus-20101021monthly0.5https://www.biopharmawatch.com/news/ADUS/separation-agreement-and-general-release-this-separation-agreement-and-general-release-the-adus-20100907monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-announces-strategic-management-changes-chief-financial-officer-resigns-to-p-adus-20100826monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-amy-glynn-nick-laudico-the-ruth-group-phone-646-536-7023-7030-email-aglyn-adus-20100805monthly0.5https://www.biopharmawatch.com/news/ADUS/joinder-consent-and-amendment-no-2-to-loan-and-security-agreement-this-joinder-consent-and-adus-20100726monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-nick-laudico-amy-glynn-the-ruth-group-phone-646-536-7030-7023-email-nlaud-adus-20100513monthly0.5https://www.biopharmawatch.com/news/ADUS/consent-and-amendment-no-1-to-loan-and-security-agreement-this-consent-and-amendment-no-1--adus-20100318monthly0.5https://www.biopharmawatch.com/news/ADUS/addus-homecare-appoints-wayne-b-lowell-to-board-of-directors-palatine-il-adus-20100105monthly0.5https://www.biopharmawatch.com/news/ADUS/investor-contact-carol-ruth-amy-glynn-the-ruth-group-phone-646-536-7004-7023-email-cruth-t-adus-20091112monthly0.5https://www.biopharmawatch.com/news/ADUS/execution-version-loan-and-security-agreement-by-and-among-fifth-third-bank-an-ohio-bankin-adus-20091102monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-board-transition-rxrx-20260430monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-second-quarter-2025-financial-results-and-provides-business-update-compa-rxrx-20250805monthly0.5https://www.biopharmawatch.com/news/RXRX/forward-looking-statements-this-document-contains-information-that-includes-or-is-based-up-rxrx-20250708monthly0.5https://www.biopharmawatch.com/news/RXRX/corporate-deck-june-2025-important-information-this-presentation-of-recursion-pharmaceutic-rxrx-20250610monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-first-quarter-2025-financial-results-and-provides-business-update-pipeli-rxrx-20250505monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-bolsters-board-of-directors-with-former-fda-principal-deputy-commissioner-dr-nam-rxrx-20250318monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-fourth-quarter-and-fiscal-year-2024-financ-rxrx-20250228monthly0.5https://www.biopharmawatch.com/news/RXRX/closingdeck-november-2024-decoding-biology-to-radically-improve-lives-this-presentation-of-rxrx-20241120monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-third-quarter-2024-financial-results-multi-rxrx-20241106monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-fda-clearance-of-investigational-new-drug-application-for-rec-1245-a-p-rxrx-20241002monthly0.5https://www.biopharmawatch.com/news/RXRX/rxrxsept2024-september-2024-decoding-biology-to-radically-improve-lives-this-presentation--rxrx-20240903monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-and-exscientia-enter-definitive-agreement-to-create-a-global-technology-enabled--rxrx-20240808monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-proposed-offering-of-class-a-common-stock-rxrx-20240626monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-gives-guidance-on-seven-clinical-readouts-within-18-months-and-partnership-updat-rxrx-20240624monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-first-quarter-2024-financial-results-on-tr-rxrx-20240509monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-fourth-quarter-and-fiscal-year-2023-financ-rxrx-20240227monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-and-enamine-to-generate-and-design-enriched-compound-libraries-for-global-drug-d-rxrx-20231220monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-third-quarter-2023-financial-results-enter-rxrx-20231109monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-completion-of-phase-1-study-for-rec-3964-for-clostridioides-difficile--rxrx-20230905monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-second-quarter-2023-financial-results-depl-rxrx-20230808monthly0.5https://www.biopharmawatch.com/news/RXRX/experimental-scale-up-to-millions-of-wet-lab-experiments-weekly-and-massive-computational--rxrx-20230712monthly0.5https://www.biopharmawatch.com/news/RXRX/june2023deck-early-june-2023-this-presentation-and-any-accompanying-discussion-and-documen-rxrx-20230613monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-first-quarter-2023-financial-results-enter-rxrx-20230508monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-enters-into-agreements-to-acquire-cyclica-and-valence-to-bolster-chemistry-and-g-rxrx-20230508monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-fourth-quarter-and-fiscal-year-2022-financ-rxrx-20230227monthly0.5https://www.biopharmawatch.com/news/RXRX/downloaddayslides-breakfast-8-30-9-30-am-welcome-tina-larson-president-coo-r-martin-chavez-rxrx-20230125monthly0.5https://www.biopharmawatch.com/news/RXRX/decoding-biology-to-radically-improve-lives-recursion-jp-morgan-healthcare-conference-janu-rxrx-20230110monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-third-quarter-2022-financial-results-initi-rxrx-20221108monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-150-million-private-placement-to-new-and-existing-investors-led-by-kin-rxrx-20221025monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-initiates-two-additional-clinical-trials-for-a-total-of-four-in-2022-recursion-i-rxrx-20220913monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-second-quarter-2022-financial-results-acti-rxrx-20220809monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-initiation-of-phase-2-3-trial-for-the-treatment-of-nf2-mutated-meningi-rxrx-20220620monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-first-quarter-2022-financial-results-enrol-rxrx-20220510monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-is-granted-fast-track-designation-for-rec-4881-for-the-potential-treatment-of-fa-rxrx-20220411monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-fourth-quarter-and-fiscal-year-2021-financ-rxrx-20220323monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-enrollment-of-first-patient-in-phase-2-trial-for-the-treatment-of-cere-rxrx-20220318monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-updated-guidance-on-clinical-trial-starts-rxrx-20220303monthly0.5https://www.biopharmawatch.com/news/RXRX/th-january-10-2022-2-this-presentation-and-any-accompanying-discussion-or-documents-may-co-rxrx-20220110monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-transformational-collaboration-with-roche-and-genentech-in-neuroscienc-rxrx-20211207monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-and-bayer-expand-fibrosis-collaboration-to-include-inferential-search-capabiliti-rxrx-20211206monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-third-quarter-2021-financials-received-fas-rxrx-20211110monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-is-granted-fda-fast-track-designation-for-rec-2282-for-the-potential-treatment-o-rxrx-20211007monthly0.5https://www.biopharmawatch.com/news/RXRX/this-presentation-and-any-accompanying-discussion-or-documents-may-contain-information-tha-rxrx-20210909monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-second-quarter-2021-financials-and-provides-business-updates-expanded-th-rxrx-20210813monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-therapeutics-advisory-board-chaired-by-joseph-miletich-md-phd-therapeu-rxrx-20210713monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-first-quarter-2021-financials-and-provides-business-updates-strengthened-rxrx-20210512monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-pharmaceuticals-announces-closing-of-initial-public-offering-rxrx-20210421monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-first-quarter-2026-financial-results-and-business-update-glue-20260507monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-pricing-of-300-million-underwritten-public-offering-glue-20260108monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-second-quarter-2025-financial-results-and-business-updat-glue-20250807monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-first-quarter-2025-financial-results-and-business-update-glue-20250508monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-fourth-quarter-2024-financial-results-and-provides-corpo-glue-20250320monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-provides-corporate-update-and-key-anticipated-milestones-for-2025--glue-20241231monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-provides-development-progress-update-for-ongoing-mrt-2359-phase-1--glue-20241205monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-third-quarter-2024-financial-results-and-provides-corpor-glue-20241107monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-global-license-agreement-with-novartis-to-advance-t-and--glue-20241028monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-second-quarter-2024-financial-results-and-provides-corpo-glue-20240808monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-provides-development-progress-updates-on-mrt-2359-and-mrt-6160-ong-glue-20240627monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-leadership-team-promotions-glue-20240530monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-pricing-of-100-million-underwritten-public-offering-glue-20240516monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-first-quarter-2024-financial-results-and-provides-corpor-glue-20240509monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-the-departure-of-owen-wallace-ph-d-chief-scientific-offi-glue-20240502monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and--glue-20240314monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-provides-corporate-update-and-key-anticipated-milestones-for-2024--glue-20240110monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-third-quarter-2023-financial-results-and-provides-corpor-glue-20231109monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-25-million-registered-direct-offering-priced-at-the-mark-glue-20231026monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-strategic-collaboration-with-roche-to-discover-novel-mol-glue-20231017monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-second-quarter-2023-financial-results-and-provides-corpo-glue-20230810monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-first-quarter-2023-financial-results-and-provides-corpor-glue-20230511monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and--glue-20230316monthly0.5https://www.biopharmawatch.com/news/GLUE/from-serendipity-to-rational-design-taking-molecular-glue-degraders-to-new-heights-january-glue-20230109monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-reports-third-quarter-2022-financial-results-and-business-updates--glue-20221110monthly0.5https://www.biopharmawatch.com/news/GLUE/mrt-2359-kol-webinar-hosted-by-cowen-glue-20221024monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-reports-second-quarter-2022-financial-results-and-business-updates-glue-20220811monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-reports-first-quarter-2022-financial-results-and-business-updates--glue-20220511monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-bu-glue-20220329monthly0.5https://www.biopharmawatch.com/news/GLUE/these-materials-include-express-and-implied-forward-looking-statements-including-forward-l-glue-20220110monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-first-development-candidate-and-reports-third-quarter-20-glue-20211110monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-pipel-glue-20210812monthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-announces-pricing-of-150-million-public-offering-london-new-york-business-cmps-20260220monthly0.5https://www.biopharmawatch.com/news/CMPS/investorpresen-1-compass-pathways-comp360-phase-3-program-topline-results-comp005-comp006-cmps-20260217monthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-appoints-dr-jeffrey-jonas-to-board-of-directors-london-new-york-cmps-20251029monthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-announces-pricing-of-underwritten-offering-london-and-new-york-cmps-20250110monthly0.5https://www.biopharmawatch.com/news/CMPS/document-compass-pathways-board-chair-and-co-founder-george-goldsmith-and-co-founder-ekate-cmps-20240328monthly0.5https://www.biopharmawatch.com/news/CMPS/these-risks-uncertainties-and-other-factors-include-among-others-our-plans-to-transition-t-cmps-20231207monthly0.5https://www.biopharmawatch.com/news/CMPS/future-developments-or-otherwise-these-forward-looking-statements-are-based-on-compass-s-c-cmps-20231026monthly0.5https://www.biopharmawatch.com/news/CMPS/these-risks-uncertainties-and-other-factors-include-among-others-market-risks-and-other-ma-cmps-20230918monthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-announces-up-to-285-million-private-placement-financing-joined-by-leading-cmps-20230816monthly0.5https://www.biopharmawatch.com/news/CMPS/document-compass-pathways-secures-term-loan-facility-for-up-to-50-million-from-hercules-ca-cmps-20230705monthly0.5https://www.biopharmawatch.com/news/CMPS/this-press-release-contains-forward-looking-statements-within-the-meaning-of-the-private-s-cmps-20230531monthly0.5https://www.biopharmawatch.com/news/CMPS/compassinvesto-transforming-mental-health-care-cmps-20230419monthly0.5https://www.biopharmawatch.com/news/CMPS/compassinvesto-transforming-mental-health-care-january-2023-2-compass-pathways-plc-2023-ca-cmps-20230106monthly0.5https://www.biopharmawatch.com/news/CMPS/quarterly-report-on-form-10-q-and-in-other-reports-we-have-filed-with-the-u-s-securities-a-cmps-20220719monthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-announces-positive-topline-results-from-groundbreaking-phase-iib-trial-of-cmps-20211109monthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-to-launch-phase-ii-trial-of-comp360-psilocybin-therapy-for-post-traumatic-cmps-20211104monthly0.5https://www.biopharmawatch.com/news/CMPS/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstra-cmps-20211021monthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-is-granted-new-us-patent-for-crystalline-psilocybin-london-uk-19-october--cmps-20211019monthly0.5https://www.biopharmawatch.com/news/CMPS/document-new-england-journal-of-medicine-publishes-exploratory-study-showing-signals-of-po-cmps-20210415monthly0.5https://www.biopharmawatch.com/news/CMPS/document-compass-pathways-granted-two-us-patents-london-uk-23-march-2021-compass-pathways--cmps-20210323monthly0.5https://www.biopharmawatch.com/news/CMPS/document-compass-pathways-plc-announces-financial-results-and-business-highlights-for-four-cmps-20210312monthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-2021-transforming-mental-health-care-compass-pathways-plc-february-2021-c-cmps-20210209monthly0.5https://www.biopharmawatch.com/news/ANIP/a-ni-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2025-financial-results-an-anip-20260227monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-highlights-significant-growth-in-2025-provides-2026-financial-guidance-anip-20260112monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-board-transition-patrick-d-walsh-steps-down-as-chairman-and--anip-20251201monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-third-qu-arter-2025-financial-results-and-raises-2025-g-anip-20251107monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-second-qu-arter-2025-financial-results-and-raises-2025--anip-20250808monthly0.5https://www.biopharmawatch.com/news/ANIP/newdayinvestor-new-day-clinical-trial-results-anip-20250723monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-results-from-new-day-clinical-trial-of-iluvien-for-use-in-pa-anip-20250723monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-first-quarter-2025-financial-results-and-raises-2025-gu-anip-20250509monthly0.5https://www.biopharmawatch.com/news/ANIP/document-ani-pharmaceuticals-announces-buyout-of-royalty-obligation-for-iluvien-and-anip-20250318monthly0.5https://www.biopharmawatch.com/news/ANIP/document-ani-pharmaceuticals-announces-fda-approval-for-expansion-of-iluvien-label-iluvien-anip-20250314monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2024-financial-results-and-anip-20250228monthly0.5https://www.biopharmawatch.com/news/ANIP/investordeck20-2025-ani-pharmaceuticals-inc-1-guggenheim-smid-cap-biotech-conference-anip-20250205monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-provides-preliminary-fourth-quarter-and-2024-financial-results-and-pre-anip-20250113monthly0.5https://www.biopharmawatch.com/news/ANIP/investordeck11-2024-ani-pharmaceuticals-inc-1-jefferies-healthcare-conference-anip-20241120monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-third-quarter-2024-financial-res-ults-and-raises-2024-g-anip-20241108monthly0.5https://www.biopharmawatch.com/news/ANIP/document-unaudited-pro-forma-condensed-combined-financial-information-on-anip-20240916monthly0.5https://www.biopharmawatch.com/news/ANIP/document-for-immediate-release-ani-pharmaceuticals-inc-completes-acquisition-of-alimera-sc-anip-20240916monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-closes-316-25-million-convertible-senior-notes-offering-including--anip-20240813monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-prices-upsized-275-0-million-convertible-senior-notes-offering-pri-anip-20240807monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-announces-proposed-convertible-senior-notes-offering-princeton-n-j-anip-20240807monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-second-quarter-2024-financial-results-and-raises-2024-guidance-anip-20240806monthly0.5https://www.biopharmawatch.com/news/ANIP/document-for-immediate-release-ani-pharmaceuticals-to-further-expand-rare-disease-business-anip-20240624monthly0.5https://www.biopharmawatch.com/news/ANIP/investordeckju-2024-ani-pharmaceuticals-inc-1-june-2024-2024-ani-pharmaceuticals-inc-2-dis-anip-20240605monthly0.5https://www.biopharmawatch.com/news/ANIP/investordeckma-2024-ani-pharmaceuticals-inc-1-capital-one-1st-annual-biotech-biopharma-dis-anip-20240514monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-first-quarter-2024-financial-results-and-reiterates-202-anip-20240510monthly0.5https://www.biopharmawatch.com/news/ANIP/investordeckap-2024-ani-pharmaceuticals-inc-1-april-2024-2024-ani-pharmaceuticals-inc-2-di-anip-20240417monthly0.5https://www.biopharmawatch.com/news/ANIP/20240312-2024-ani-pharmaceuticals-inc-1-march-2024-2024-ani-pharmaceuticals-inc-2-disclaim-anip-20240229monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-fourth-quarter-and-record-full-year-2023-financial-results-and-anip-20240229monthly0.5https://www.biopharmawatch.com/news/ANIP/investordeckja-2023-ani-pharmaceuticals-inc-1-january-2024-2023-ani-pharmaceuticals-inc-2--anip-20240108monthly0.5https://www.biopharmawatch.com/news/ANIP/investordeckno-2023-ani-pharmaceuticals-inc-1-jefferies-london-healthcare-conference-novem-anip-20231115monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-third-quarter-2023-financial-results-and-raises-full-ye-anip-20231108monthly0.5https://www.biopharmawatch.com/news/ANIP/pressrelease10-for-immediate-release-ani-pharmaceuticals-announces-fda-approval-and-commer-anip-20231002monthly0.5https://www.biopharmawatch.com/news/ANIP/investorpresen-2023-ani-pharmaceuticals-inc-1-investor-presentation-september-2023-2023-an-anip-20230912monthly0.5https://www.biopharmawatch.com/news/ANIP/investorpresen-2023-ani-pharmaceuticals-inc-1-investor-presentation-september-2023-2023-an-anip-20230907monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-1-2023-ani-pharmaceuticals-inc-1-investor-presentation-august-2023-anip-20230830monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-appoints-healthcare-executive-matthew-j-leonard-to-its-board-of-direct-anip-20230823monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-second-quarter-2023-financial-results-and-raises-full-y-anip-20230809monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-1-2023-ani-pharmaceuticals-inc-1-jefferies-healthcare-conference-j-anip-20230609monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-including-full-ex-anip-20230516monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-pricing-of-75-million-public-offering-of-common-stock-baudet-anip-20230512monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-proposed-public-offering-of-common-stock-baudette-minn-busin-anip-20230511monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-first-quarter-2023-financial-results-and-raises-full-ye-anip-20230508monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-fourth-quarter-financial-results-and-achieves-full-year-anip-20230309monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-anip-20221109monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-third-quarter-2022-financial-results-reports-record-net-revenu-anip-20221109monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-second-quarter-2022-financial-results-reports-record-net-reven-anip-20220808monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-consolidation-of-manufacturing-network-capturing-operational-anip-20220602monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-appoints-experienced-commercial-leader-renee-p-tannenbaum-pharm-d-mba--anip-20220322monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-results-strong-foundation-in-anip-20220315monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-210-main-street-west-baudette-mn-56623-https-www-anipharmaceutical-anip-20220124monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-completes-acquisition-of-novitium-pharma-significantly-enhancing-r-d-c-anip-20211126monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-baudette-minnes-anip-20211103monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-third-quarter-2021-results-third-quarter-2021-net-revenues-of--anip-20211101monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-second-quarter-2021-results-second-quarter-2021-net-revenues-o-anip-20210806monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-inc-1-2021-ani-pharmaceuticals-inc-1-jefferies-healthcare-conference-j-anip-20210604monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-2021-results-first-quarter-2021-net-revenues-of--anip-20210507monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-n-anip-20210406monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-to-acquire-novitium-pharma-strengthening-r-d-engine-and-expanding-gene-anip-20210309monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-results-company-positioned-f-anip-20210309monthly0.5https://www.biopharmawatch.com/news/ANIP/about-ani-ani-pharmaceuticals-inc-is-an-integrated-specialty-pharmaceutical-company-develo-anip-20210217monthly0.5https://www.biopharmawatch.com/news/ANIP/the-field-allows-up-to-17-characters-anip-20201105monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-appoints-experienced-pharmaceutical-executives-jeanne-thoma-and-antoni-anip-20200806monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-second-quarter-2020-results-second-quarter-2020-net-revenues-o-anip-20200806monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-names-nikhil-lalwani-as-president-and-chief-executive-officer-accompli-anip-20200803monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-provides-update-on-recent-regulatory-filing-baudette-minnesota-anip-20200601monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-2020-results-and-appoints-interim-ceo-for-the-fi-anip-20200507monthly0.5https://www.biopharmawatch.com/news/ANIP/nasdaq-anip-ani-pharmaceuticals-schedules-conference-call-to-discuss-first-quarter-2020-fi-anip-20200430monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-receives-refusal-to-file-letter-from-fda-for-cortrophin-gel-baudette-minnesota-anip-20200429monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-announces-upcoming-departure-of-ceo-baudette-minnesota-anip-20200414monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-full-year-and-fourth-quarter-2019-results-provides-2020-guidan-anip-20200227monthly0.5https://www.biopharmawatch.com/news/ANIP/nasdaq-anip-ani-pharmaceuticals-schedules-conference-call-to-discuss-fourth-quarter-and-ye-anip-20200220monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-acquisition-of-commercial-and-pipeline-generic-products-from-anip-20200109monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20191203monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-to-present-at-evercore-isi-2nd-annual-healthconx-conference-baudette-m-anip-20191126monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-third-quarter-results-for-the-third-quarter-2019-net-revenues--anip-20191106monthly0.5https://www.biopharmawatch.com/news/ANIP/nasdaq-anip-ani-pharmaceuticals-schedules-conference-call-to-discuss-third-quarter-and-yea-anip-20191030monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-second-quarter-results-anip-20190807monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-second-quarter-and-year-to-date-2-anip-20190731monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-to-present-at-raymond-james-life-sciences-and-medtech-conference-anip-20190612monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-2019-results-and-reaffirms-guidance-anip-20190509monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-first-quarter-2019-financial-resu-anip-20190502monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20190227monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-full-year-and-fourth-quarter-2018-results-and-provides--anip-20190227monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-fourth-quarter-and-year-to-date-2-anip-20190220monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-secures-refinancing-for-convertible-debt-due-december-2019-and-enters--anip-20181227monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-third-quarter-and-year-to-date-2018-results-and-reaffirms-guid-anip-20181106monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-third-quarter-and-year-to-date-20-anip-20181030monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20180807monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-second-quarter-and-year-to-date-2018-results-and-updates-guida-anip-20180807monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-second-quarter-and-year-to-date-2-anip-20180801monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20180516monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-2018-results-and-reaffirms-guidance-anip-20180508monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-first-quarter-2018-financial-resu-anip-20180501monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20180307monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-full-year-results-reports-fourth-quarter-2017-results-a-anip-20180227monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-fourth-quarter-and-full-year-2017-anip-20180220monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-acquires-four-ndas-from-astrazeneca-for-46-5-million-anip-20171229monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-third-quarter-and-year-to-date-2017-results-and-narrows-anip-20171102monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-third-quarter-and-year-to-date-20-anip-20171026monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20170808monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-second-quarter-and-year-to-date-2017-results-and-reaffi-anip-20170803monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-second-quarter-and-year-to-date-2-anip-20170727monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20170619monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20170606monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-results-and-year-to-date-2017-highlights-and-rea-anip-20170504monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-first-quarter-2017-financial-resu-anip-20170427monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20170223monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-full-year-2016-results-and-fourth-quarter-results-and-provides-anip-20170302monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-acquires-inderal-xl-and-innopran-anip-20170224monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-for-fourth-quarter-and-full-year-2016-financ-anip-20170216monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20161103monthly0.5https://www.biopharmawatch.com/news/ANIP/exhbit-99-1-ani-pharmaceuticals-reports-record-third-quarter-results-and-year-to-date-2016-anip-20161103monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-third-quarter-and-year-to-date-20-anip-20161027monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20160804monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20160811monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-second-quarter-results-and-increases-full-year-2016-gui-anip-20160804monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-to-discuss-second-quarter-and-year-to-date-2-anip-20160728monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-to-present-at-the-ubs-global-healthcare-conference-anip-20160518monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-enters-three-year-30-million-asset-based-line-of-credit-with-citizens--anip-20160513monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-results-and-year-to-date-2016-highlights-and-rea-anip-20160505monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-announces-appointment-of-stephen-p-carey-as-vice-president-and-chief-financial-officer-anip-20160427monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-closes-acquisition-of-inderal-la-assets-anip-20160404monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-agrees-to-acquire-inderal-la-assets-from-cranford-pharmaceuticals-anip-20160311monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-to-present-at-28th-annual-roth-conference-anip-20160309monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-fourth-quarter-and-full-year-2015-results-and-provides-2016-gu-anip-20160223monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-for-fourth-quarter-and-full-year-2015-financ-anip-20160216monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20160111monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-presents-at-oppenheimer-26th-annual-healthcare-conference-anip-20151208monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20151110monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-third-quarter-and-year-to-date-2015-results-and-highlights-for-anip-20151103monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-for-third-quarter-and-year-to-date-2015-fina-anip-20151027monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-appoints-peter-a-lankau-to-its-board-of-directors-anip-20151013monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-to-acquire-two-ndas-from-merck-for-75-million-transaction-highlights-c-anip-20150921monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-second-quarter-and-year-to-date-2015-results-and-highlights-fo-anip-20150804monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-for-second-quarter-and-year-to-date-2015-fin-anip-20150728monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-acquires-22-generic-drug-products-from-teva-pharmaceuticals-for-25-mil-anip-20150713monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-presents-at-the-ubs-global-healthcare-conference-anip-20150515monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-first-quarter-2015-financial-results-for-the-first-quarter-201-anip-20150505monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-for-first-quarter-2015-financial-results-anip-20150428monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-presents-at-14th-annual-needham-healthcare-conference-anip-20150407monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20150227monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2014-financial-results-for-anip-20150219monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-for-fourth-quarter-and-full-year-2014-financ-anip-20150212monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-appointment-of-dr-david-sullivan-to-vp-of-quality-operations-anip-20150203monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-presents-at-oppenheimer-25th-annual-healthcare-conference-anip-20141211monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-closing-of-3-00-convertible-senior-notes-and-full-exercise-o-anip-20141210monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-announces-pricing-of-upsized-125-million-convertible-notes-offering-anip-20141205monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20141110monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-third-quarter-2014-financial-results-and-year-to-date-h-anip-20141103monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-for-third-quarter-2014-financial-results-bau-anip-20141027monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-generic-and-branded-prescription-drug-produ-anip-20140911monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-reports-second-quarter-2014-financial-results-and-year-to-date-highlights-recognized-n-anip-20140804monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-acquires-vancocin-capsules-and-additional-vancomycin-assets-from-shire-anip-20140801monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-schedules-conference-call-for-second-quarter-2014-financial-results-anip-20140728monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-acquires-lithobid-extended-release-tablets-from-noven-therapeutics-anip-20140701monthly0.5https://www.biopharmawatch.com/news/ANIP/a-specialty-pharmaceutical-company-nasdaq-anip-high-potency-drugs-narcotic-drugs-rx-liquid-anip-20140529monthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-net-revenues-of-10-9-million-eps-of-0-33-and-adjusted-n-anip-20140505monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-takes-legal-action-to-protect-patient-access-to-deramiocel-for-duche-capr-20260507monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-establishment-of-new-pdufa-date-for-deramiocel-bla-deramio-capr-20260310monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-pricing-of-150-million-public-offering-of-common-stock-capr-20251205monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-nasdaq-capr-capr-20251203monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-topline-results-from-pivotal-phase-3-hope-3-study-capr-20251203monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-capr-20250811monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-provides-regulatory-update-on-deramiocel-bla-for-duchenne-muscular-d-capr-20250711monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate--capr-20250513monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-prov-capr-20250319monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-fda-acceptance-and-priority-review-of-its-biologics-licens-capr-20250304monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-completes-submission-of-biologics-license-application-to-the-u-s-fda-capr-20250102monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate--capr-20241113monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-pricing-of-approximately-75-million-public-offering-of-com-capr-20241017monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-initiation-of-rolling-submission-of-biologics-license-appl-capr-20241009monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-intent-to-file-biologics-license-application-for-full-appr-capr-20240924monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-signs-binding-term-sheet-with-nippon-shinyaku-for-european-expansion-capr-20240917monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-capr-20240807monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate--capr-20240513monthly0.5https://www.biopharmawatch.com/news/CAPR/x4-x189-x18c-x15d-x16f-x200b-x3ee-x3f5-x355-x200b-x3ee-x3ec-x3ee-x3f0-e-x102-x190-x11a-x10-capr-20240429monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-prov-capr-20240229monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-continuation-of-phase-3-hope-3-trial-of-cap-1002-in-duchen-capr-20231211monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate--capr-20231114monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-23-million-registered-direct-offering-capr-20230929monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-type-b-meeting-with-the-fda-to-discuss-pathway-to-capr-20230929monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-appoints-michael-kelliher-to-board-of-directors-capr-20230906monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-capr-20230807monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-appointment-of-philip-j-gotwals-ph-d-to-its-board-of-direc-capr-20230724monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-appointment-of-paul-auwaerter-m-d-to-its-board-of-director-capr-20230713monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate--capr-20230511monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-prov-capr-20230315monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-nippon-shinyaku-enter-partnership-for-exclusive-commercializatio-capr-20230216monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corporate--capr-20221110monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corporate-capr-20220810monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-first-patient-dosed-in-pivotal-phase-3-study-of-cap-1002-f-capr-20220719monthly0.5https://www.biopharmawatch.com/news/CAPR/hope-2-open-label-extension-1-year-data-results-trial-conducted-by-capricor-national-pi-cr-capr-20220629monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corporate--capr-20220510monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-prov-capr-20220310monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-nippon-shinyaku-enter-partnership-for-exclusive-commercializatio-capr-20220125monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate--capr-20211109monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-final-data-from-its-phase-2-hope-2-trial-in-patie-capr-20210924monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate-capr-20210812monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-the-appointment-of-karimah-es-sabar-to-its-board-of-direct-capr-20210727monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2021-financial-results-and-provides-corporate--capr-20210513monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-signs-exclusive-worldwide-license-agreement-with-johns-hopkins-unive-capr-20210429monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-prov-capr-20210311monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corporate--capr-20201112monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-preclinical-data-for-multivalent-exosome-mrna-vac-capr-20201109monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2020-financial-results-and-provides-corporate-capr-20200806monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-q1-earnings-call-and-corporate-update-1-capr-20200514monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2020-financial-results-and-provides-corporate--capr-20200514monthly0.5https://www.biopharmawatch.com/news/CAPR/a-study-of-cap-1002-in-ambulatory-and-non-ambulatory-patients-with-duchenne-muscular-dystr-capr-20200513monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-positive-top-line-final-results-from-hope-2-study-in-patients-with-duch-capr-20200513monthly0.5https://www.biopharmawatch.com/news/CAPR/new-capricor-data-reports-100-percent-survival-in-critical-covid-19-patients-treated-with--capr-20200429monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-prov-capr-20200318monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-developing-transformative-therapies-from-bench-to-bedside-nasdaq-capr-20200311monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-closing-of-5-1-million-offering-priced-at-the-market-capr-20191219monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-pricing-of-5-1-million-offering-priced-at-the-market-capr-20191217monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-corporate-investor-presentation-december-2019-capr-20191217monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-corporate-investor-presentation-november-2019-capr-20191114monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2019-financial-results-and-provides-recent-cor-capr-20191107monthly0.5https://www.biopharmawatch.com/news/CAPR/a-study-of-cap-1002-in-ambulatory-and-non-ambulatory-patients-with-duchenne-muscular-dystr-capr-20191007monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2019-financial-results-and-provides-corporate-capr-20190806monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-hope-2-data-update-conference-call-capr-20190715monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-results-from-its-interim-analysis-in-the-hope-2-t-capr-20190715monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2019-financial-results-and-provides-corporate--capr-20190513monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-prov-capr-20190328monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-resumes-dosing-of-enrolled-patients-in-hope-2-clinical-trial-for-duchenne-muscula-capr-20190206monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-positive-outcomes-from-comprehensive-multidisciplinary-meeting-with-fda-capr-20190122monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2018-financial-results-and-provides-corporate--capr-20181113monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2018-financial-results-and-provides-corporate-capr-20180809monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2018-financial-results-and-provides-corporate--capr-20180510monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-may-2018-forward-looking-statements-2-statements-in-this-presentation-regardin-capr-20180504monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-presents-fourth-quarter-and-full-year-2017-financial-results-and-corporate-update-capr-20180314monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-inc-kol-lunch-on-dmd-key-opinion-leaders-lunch-to-discuss-the-emerging-clinical-p-capr-20180309monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-duchenne-capr-20180205monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-december-2017-capr-20171219monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-condensed-consolidated-balance-sheets-unaudited-assets-capr-20171212monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application--capr-20171129monthly0.5https://www.biopharmawatch.com/news/CAPR/significant-improvements-reported-in-duchenne-muscular-dystrophy-patients-treated-with-cap-capr-20171115monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2017-financial-results-and-provides-update-on--capr-20171108monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-presents-positive-six-month-results-in-duchenne-muscular-dystrophy-a-capr-20171004monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-october-2017-capricor-therapeutics-forward-looking-statements-2-statements-in--capr-20171003monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2017-financial-results-and-provides-corporate-capr-20170810monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-retains-full-rights-to-cap-1002-as-janssen-biotech-inc-decides-not-t-capr-20170706monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-june-2017-a-translational-m-edicine-c-ompany-capr-20170607monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2017-financial-results-and-provides-corporate--capr-20170515monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-provides-update-on-allstar-trial-unlikely-to-achieve-primary-efficac-capr-20170512monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-private-placement-of-common-stock-investors-include-cedars-capr-20170508monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-capr-20170425monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-six-month-results-from-the-randomized-phase-i-ii--capr-20170425monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-prov-capr-20170315monthly0.5https://www.biopharmawatch.com/news/CAPR/corporate-overview-february-2017-a-translational-medicine-company-nasdaq-capr-2-this-prese-capr-20170213monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2016-financial-results-and-provides-corporate--capr-20161110monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-a-translational-medicine-company-www-capricor-com-investor-presentation-octobe-capr-20161005monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-closing-of-public-offerings-raising-approximately-10-0-mil-capr-20160921monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-pricing-of-offerings-of-common-stock-capr-20160916monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2016-financial-results-and-provides-clinical--capr-20160815monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-a-translational-medicine-company-www-capricor-com-investor-presentation-june-2-capr-20160622monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-provides-corporate-update-and-reports-first-quarter-2016-financial-r-capr-20160512monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-and-busi-capr-20160317monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-4-million-registered-direct-offering-capr-20160315monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-the-first-patient-with-duchenne-muscular-dystrophy-related-capr-20160222monthly0.5https://www.biopharmawatch.com/news/CAPR/nasdaq-capr-december-2015-transformative-therapies-from-bench-to-bedside-2-forward-looking-capr-20151210monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2015-business-financial-highlights-positive-si-capr-20151112monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2015-business-financial-highlights-company-to-capr-20150813monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2015-financial-business-highlights-company-to--capr-20150512monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-uplisting-to-nasdaq-capital-market-nasdaq-trading-of-capr--capr-20150305monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-condensed-consolidated-balance-sheets-unaudited-capr-20150206monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-7-million-private-placement-of-common-stock-institutional--capr-20150204monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-10-million-private-placement-of-common-stock-investors-inc-capr-20150112monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-pre-clinical-data-for-cardiosphere-derived-cells--capr-20141118monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-third-quarter-2014-financial-business-highlights-announced-p-capr-20141112monthly0.5https://www.biopharmawatch.com/news/CAPR/transformative-therapies-from-bench-to-bedside-corporate-presentation-november-2014-non-co-capr-20141106monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-acquisition-of-intellectual-property-rights-to-family-of-n-capr-20141014monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-plans-to-pursue-clinical-program-for-the-treatment-of-duchenne-muscular-capr-20141006monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-presents-safety-and-preliminary-efficacy-results-from-allstar-phase-i-clinical-tr-capr-20140918monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-second-quarter-2014-financial-business-highlights-reports-en-capr-20140813monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-encouraging-results-from-phase-i-allstar-trial-phase-ii-trial-underway--capr-20140716monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-enters-into-exclusive-license-with-cedars-sinai-medical-center-for-e-capr-20140506monthly0.5https://www.biopharmawatch.com/news/CAPR/december-31-2012-and-2011-capr-20140124monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-and-nile-therapeutics-complete-merger-to-form-capricor-therapeutics-inc-common-st-capr-20131121monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-and-nile-therapeutics-announce-merger-agreement-capricor-therapeutics-inc-will-em-capr-20130708monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-promotes-darlene-horton-m-d-to-chief-executive-officer-and-director-capr-20120806monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-inc-to-raise-2-5-million-in-private-placement-capr-20110621monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20110228monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20101203monthly0.5https://www.biopharmawatch.com/news/CAPR/b-capr-20100727monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20100604monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20100507monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20100422monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20090925monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20090813monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20090327monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-announces-information-in-compliance-with-nasdaq-marketplace-rule-4350-an-capr-20090319monthly0.5https://www.biopharmawatch.com/news/CAPR/press-release-capr-20090309monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-announces-focus-on-cd-np-for-acute-heart-failure-and-termination-of-2ntx-capr-20090122monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-announces-positive-results-from-phase-1b-safety-and-pharmacodynamics-stu-capr-20081212monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-announces-positive-interim-data-from-phase-2a-study-of-cd-np-in-patients-capr-20081015monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-reports-2007-fourth-quarter-and-full-year-financial-results-on-thursday-capr-20080313monthly0.5https://www.biopharmawatch.com/news/CAPR/hsiao-dee-lieu-m-d-f-a-c-c-named-vp-of-clinical-research-of-nile-therapeutics-monday-febru-capr-20080227monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-announces-dosing-of-first-heart-failure-patient-in-phase-ib-study-of-cd--capr-20080207monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-appoints-pedro-granadillo-to-board-of-directors-capr-20071018monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-announces-positive-phase-1a-results-of-cd-np-a-selective-npr-b-agonist-i-capr-20071015monthly0.5https://www.biopharmawatch.com/news/CAPR/nile-therapeutics-inc-completes-20-million-financing-and-reverse-merger-with-smi-products--capr-20070921monthly0.5https://www.biopharmawatch.com/news/PVLA/issued-by-palvella-therapeutics-inc-on-may-20-2026-ex-99-1-palvella-therapeutics-presents--pvla-20260520monthly0.5https://www.biopharmawatch.com/news/PVLA/issued-by-palvella-therapeutics-inc-on-may-15-2026-ex-99-1-palvella-therapeutics-announces-pvla-20260515monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate--pvla-20260507monthly0.5https://www.biopharmawatch.com/news/PVLA/ex-palvella-therapeutics-corporate-presentation-april-2026-first-in-disease-therapies-for--pvla-20260407monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-upda-pvla-20260331monthly0.5https://www.biopharmawatch.com/news/PVLA/corporate-presentation-on-phase-3-selva-study-of-qtorin-dated-february-24-2026-first-in-di-pvla-20260224monthly0.5https://www.biopharmawatch.com/news/PVLA/issued-by-palvella-therapeutics-inc-on-february-24-2026-ex-99-1-palvella-therapeutics-anno-pvla-20260224monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-corporate-presentation-january-2026-first-in-disease-therapies-for-p-pvla-20260129monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-corporate-presentation-january-2026-first-in-disease-therapies-for-p-pvla-20260112monthly0.5https://www.biopharmawatch.com/news/PVLA/first-in-disease-therapies-for-patients-with-rare-skin-diseases-phase-2-toiva-topline-data-pvla-20251215monthly0.5https://www.biopharmawatch.com/news/PVLA/first-in-disease-therapies-for-patients-with-rare-skin-diseases-qtorin-pitavastatin-develo-pvla-20251105monthly0.5https://www.biopharmawatch.com/news/PVLA/first-in-disease-therapies-for-patients-with-rare-genetic-skin-diseases-corporate-presenta-pvla-20250903monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-pvla-20250814monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate--pvla-20250515monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-reports-full-year-2024-financial-results-and-provides-corporate-upda-pvla-20250331monthly0.5https://www.biopharmawatch.com/news/PVLA/this-press-release-contains-forward-looking-statements-as-that-term-is-defined-in-section--pvla-20190312monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-announces-pricing-of-its-public-offering-boston-ma-marketwired-02-1-pvla-20180216monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-announces-public-offering-of-common-stock-boston-ma-marketwired-02--pvla-20180213monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-appoints-james-geraghty-as-chairman-of-the-board-of-directors-bosto-pvla-20171121monthly0.5https://www.biopharmawatch.com/news/PVLA/forward-looking-statements-statements-in-this-presentation-that-are-not-descriptions-of-hi-pvla-20171114monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-financial-results-for-the-third-quarter-ended-pvla-20171108monthly0.5https://www.biopharmawatch.com/news/PVLA/klinikum-rechts-der-isar-technische-universit-t-m-nchen-safety-tolerability-and-pharmacody-pvla-20170918monthly0.5https://www.biopharmawatch.com/news/PVLA/forward-looking-statements-statements-in-this-presentation-that-are-not-descriptions-of-hi-pvla-20170911monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-financial-results-for-the-second-quarter-ended-pvla-20170810monthly0.5https://www.biopharmawatch.com/news/PVLA/klinikum-rechts-der-isar-a-phase-ib-study-investigating-the-safety-tolerability-technische-pvla-20170605monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-appoints-james-geraghty-to-its-board-of-directors-boston-ma-marketw-pvla-20170522monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-financial-results-for-the-first-quarter-ended-pvla-20170511monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-and-astrazeneca-collaborate-to-develop-and-commercialize-anticalin--pvla-20170503monthly0.5https://www.biopharmawatch.com/news/PVLA/preclinical-toxicology-and-pharmacology-for-the-4-1bb-her2-bispecific-prs-343-a-first-in-c-pvla-20170404monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-full-year-2016-financial-results-and-corporate-update-compa-pvla-20170322monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-inc-nasdaq-pirs-27th-annual-oppenheimer-healthcare-conference-steph-pvla-20170322monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-signs-1st-partnership-for-anemia-drug-prs-080-granting-exclusive-option-in-japan-to-pvla-20170227monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-announces-management-transition-boston-ma-pvla-20170207monthly0.5https://www.biopharmawatch.com/news/PVLA/forward-looking-statements-non-confidential-statements-in-this-presentation-that-are-not-d-pvla-20170109monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-and-servier-forge-strategic-immuno-oncology-co-development-alliance-pvla-20170105monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-financial-results-and-provides-corporate-update-for-the-thi-pvla-20161109monthly0.5https://www.biopharmawatch.com/news/PVLA/costimulatory-t-cell-engagement-by-prs-343-a-cd137-4-1bb-her2-bispecific-leads-to-tumor-gr-pvla-20161024monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-appoints-christopher-kiritsy-to-its-board-of-directors-mr-kiritsy-b-pvla-20160922monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-financial-results-and-provides-corporate-update-for-the-sec-pvla-20160811monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-appoints-julian-adams-ph-d-to-its-board-of-directors-dr-adams-bring-pvla-20160726monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-announces-closing-of-16-5-million-private-placement-boston-ma-pvla-20160608monthly0.5https://www.biopharmawatch.com/news/PVLA/forward-looking-statements-non-confidential-statements-in-this-presentation-that-are-not-d-pvla-20160608monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-announces-16-5-million-private-placement-boston-ma-pvla-20160603monthly0.5https://www.biopharmawatch.com/news/PVLA/background-cd137-4-1bb-is-a-key-costimulatory-immunoreceptor-and-a-member-of-the-tnf-recep-pvla-20160418monthly0.5https://www.biopharmawatch.com/news/PVLA/forward-looking-statements-statements-in-this-presentation-that-are-not-descriptions-of-hi-pvla-20160111monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-announces-first-cancer-immunotherapy-collaboration-agreement-with-r-pvla-20151208monthly0.5https://www.biopharmawatch.com/news/PVLA/forward-looking-statements-statements-in-this-presentation-that-are-not-descriptions-of-hi-pvla-20151208monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-presents-clinical-data-for-its-hepcidin-antagonist-program-prs-080--pvla-20151207monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-collaborator-daiichi-sankyo-doses-first-subject-in-a-phase-1-clinic-pvla-20151119monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-financial-results-for-the-third-quarter-ended-pvla-20151112monthly0.5https://www.biopharmawatch.com/news/PVLA/forward-looking-statements-statements-in-this-presentation-that-are-not-descriptions-of-hi-pvla-20151105monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-collaborator-presents-promising-preclinical-data-on-tetraspecific-i-pvla-20150915monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-strenghtens-senior-management-team-and-establishes-us-headquarters--pvla-20150902monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-appoints-louis-a-matis-m-d-pvla-20150818monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-financial-results-for-the-second-quarter-ended-pvla-20150813monthly0.5https://www.biopharmawatch.com/news/PVLA/non-confidential-forward-looking-statements-2-statements-in-this-presentation-that-are-not-pvla-20150519monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-appoints-immuno-oncology-expert-holbrook-kohrt-m-d-ph-d-to-spearhea-pvla-20150514monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-first-quarter-2015-financial-results-company-to-host-an-inv-pvla-20150514monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-appoints-former-celgene-and-sanofi-executive-jean-pierre-bizzari-m--pvla-20150512monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-reports-full-year-2014-financial-results-and-provides-corporate-upd-pvla-20150326monthly0.5https://www.biopharmawatch.com/news/PVLA/non-confidential-forward-looking-statements-2-non-confidential-statements-in-this-presenta-pvla-20150309monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-pharmaceuticals-inc-completes-private-placement-raises-13-6m-freising-germany-pvla-20141223monthly0.5https://www.biopharmawatch.com/news/PVLA/pieris-ag-table-of-contents-report-of-independent-registered-public-accounting-firm-2-bala-pvla-20141218monthly0.5https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-appoints-biotechnology-leader-jennifer-jarrett-as-president-and-chief--dmra-20260323monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-announces-name-change-to-damora-therapeutics-with-mission-to-fundamentally-redefin-dmra-20260310monthly0.5https://www.biopharmawatch.com/news/DMRA/company-logo-disclaimers-the-information-contained-in-this-presentation-has-been-prepared--dmra-20260112monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-announces-acquisition-of-damora-therapeutics-acquisition-of-damora-and-concurrent--dmra-20251110monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-strengthens-board-of-directors-with-appointment-of-dr-amy-wechsler-boston-dmra-20241015monthly0.5https://www.biopharmawatch.com/news/DMRA/unaudited-pro-forma-condensed-consolidated-financial-statements-on-dmra-20241007monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-presents-updated-clinical-data-at-esmo-congress-2023-and-provides-update-on-phase--dmra-20231023monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-announces-plans-to-explore-strategic-alternatives-boston-ma-dmra-20230926monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-announces-topline-results-from-phase-2b-galactic-1-trial-of-gb0139-for-the-treatme-dmra-20230815monthly0.5https://www.biopharmawatch.com/news/DMRA/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-gal-dmra-20230106monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-to-present-topline-data-from-gulliver-2-clinical-trial-showing-gb1211-reduced-sign-dmra-20221031monthly0.5https://www.biopharmawatch.com/news/DMRA/gb2064-shows-reduction-in-fibrosis-of-the-bone-marrow-in-patients-with-myelofibrosis-valid-dmra-20220929monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-publishes-results-showing-safety-and-efficacy-of-the-gb0139-inhaled-galectin-3-inh-dmra-20220127monthly0.5https://www.biopharmawatch.com/news/DMRA/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-dmra-20220105monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-announces-outcome-of-data-safety-monitoring-board-interim-review-of-phase-2b-galac-dmra-20210315monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-appoints-anne-prener-to-its-board-of-directors-boston-dmra-20210108monthly0.5https://www.biopharmawatch.com/news/DMRA/first-in-class-small-molecule-anti-fibrotic-and-anti-cancer-agents-january-2021-forward-lo-dmra-20210105monthly0.5https://www.biopharmawatch.com/news/DMRA/galecto-appoints-experienced-healthcare-executive-jayson-dallas-to-board-of-directors-has--dmra-20201123monthly0.5https://www.biopharmawatch.com/news/OCS/investor-relations-lifesci-advisors-corey-davis-ph-d-cdavis-lifesciadvisors-com-media-rela-ocs-20260601monthly0.5https://www.biopharmawatch.com/news/OCS/ms-sylvia-cheung-cfo-sylvia-cheung-oculis-com-investor-relations-lifesci-advisors-corey-da-ocs-20260514monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20260511monthly0.5https://www.biopharmawatch.com/news/OCS/approach-to-drive-precision-medicine-in-dry-eye-disease-ded-and-privosegtor-a-breakthrough-ocs-20260421monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-consolidated-financial-statements-table-of-contents-report-of-the-statut-ocs-20260304monthly0.5https://www.biopharmawatch.com/news/OCS/uncertainties-and-other-factors-that-may-cause-actual-results-to-differ-materially-from-th-ocs-20260303monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20251110monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-accelerates-privosegtor-into-registrational-trials-in-acute-optic-neuritis-pioneeri-ocs-20251006monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20250821monthly0.5https://www.biopharmawatch.com/news/OCS/maximum-value-of-equity-based-compensation-for-three-members-of-the-executive-committee-un-ocs-20250605monthly0.5https://www.biopharmawatch.com/news/OCS/investor-relations-lifesci-advisors-corey-davis-ph-d-cdavis-lifesciadvisors-com-media-rela-ocs-20250509monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20250508monthly0.5https://www.biopharmawatch.com/news/OCS/about-oculis-oculis-is-a-global-biopharmaceutical-company-nasdaq-ocs-xice-ocs-purposefully-ocs-20250311monthly0.5https://www.biopharmawatch.com/news/OCS/results-to-differ-materially-from-those-that-we-expected-and-or-those-expressed-or-implied-ocs-20250214monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-positive-ocs-05-phase-2-acuity-trial-in-acute-optic-neuritis-met-primary--ocs-20250106monthly0.5https://www.biopharmawatch.com/news/OCS/securities-and-exchange-commission-ocs-20241129monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20241107monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20240827monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-positive-topline-results-of-phase-2b-relief-trial-with-licaminlimab-desig-ocs-20240610monthly0.5https://www.biopharmawatch.com/news/OCS/statements-are-subject-to-risks-uncertainties-and-other-factors-that-may-cause-actual-resu-ocs-20240531monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20240508monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-invitation-to-the-annual-general-meeting-ocs-20240429monthly0.5https://www.biopharmawatch.com/news/OCS/about-oculis-oculis-is-a-global-biopharmaceutical-company-nasdaq-ocs-purposefully-driven-t-ocs-20240422monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-completion-of-oversubscribed-59-million-registered-direct-offering-and-su-ocs-20240411monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q4-and-full-year-2023-financial-results-and-update-on-company-progress-x202-ocs-20240228monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20231115monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-unaudited-condensed-consolidated-interim-financial-statements-table-of-c-ocs-20230829monthly0.5https://www.biopharmawatch.com/news/OCS/ocs-01-first-investigational-eye-drop-for-front-and-back-of-the-eye-met-both-primary-endpo-ocs-20230808monthly0.5https://www.biopharmawatch.com/news/OCS/these-slides-and-the-accompanying-oral-presentation-contain-forward-looking-statements-and-ocs-20230712monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-partial-exercise-of-underwriters-option-to-purchase-additional-ordinary-s-ocs-20230613monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-pricing-of-40-25-million-public-offering-of-ordinary-shares-zug-switzerla-ocs-20230531monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-launch-of-proposed-public-offering-of-ordinary-shares-zug-switzerland-and-ocs-20230530monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-positive-top-line-results-from-diamond-stage-1-phase-3-trial-in-diabetic--ocs-20230522monthly0.5https://www.biopharmawatch.com/news/OCS/rethinking-ophthalmology-ocs-20230413monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-us-public-listing-on-nasdaq-closing-of-business-combination-with-european-ocs-20230303monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-upda-tsha-20260319monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-fda-breakthrough-therapy-designation-and-provides-positive-tsha-20251002monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-second-quarter-2025-financial-results-and-provides-corporate-tsha-20250812monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-proposed-public-offering-of-common-stock-and-pre-funded-wa-tsha-20250528monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-pivotal-part-b-trial-design-details-for-tsha-102-in-rett-s-tsha-20250528monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2025-financial-results-and-provides-corporate--tsha-20250515monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-full-year-2024-financial-results-and-provides-corporate-upda-tsha-20250226monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-third-quarter-2024-financial-results-and-provides-corporate--tsha-20241113monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-second-quarter-2024-financial-results-and-provides-corporate-tsha-20240812monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-pre-funded--tsha-20240626monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-proposed-public-offering-of-common-stock-and-pre-funded-wa-tsha-20240625monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-positive-clinical-data-across-adult-and-pediatric-patients-tsha-20240618monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2024-financial-results-and-provides-corporate--tsha-20240514monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-full-year-2023-financial-results-and-provides-corporate-and--tsha-20240319monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-first-pediatric-patient-dosed-with-tsha-102-in-reveal-phas-tsha-20240110monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-third-quarter-2023-financial-results-and-provides-corporate--tsha-20231114monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-second-patient-dosed-with-tsha-102-in-the-reveal-phase-1-2-tsha-20230926monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-provides-update-on-tsha-120-program-in-giant-axonal-neuropathy-gan-f-tsha-20230919monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-fast-track-designation-granted-by-u-s-fda-for-tsha-102-in--tsha-20230824monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-initial-clinical-data-from-first-adult-rett-syndrome-patient-tsha-20230814monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-positive-recommendation-from-independent-data-monitoring-c-tsha-20230731monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-provides-clinical-updates-for-investigational-programs-tsha-120-in-g-tsha-20230628monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-first-patient-dosed-with-tsha-102-in-the-reveal-phase-1-2--tsha-20230605monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-presents-preclinical-data-on-tsha-102-for-rett-syndrome-demonstratin-tsha-20230519monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2023-financial-results-and-provides-corporate--tsha-20230511monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-fourth-quarter-and-full-year-2022-financial-results-and-prov-tsha-20230328monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-provides-update-on-tsha-120-program-in-giant-axonal-neuropathy-and-a-tsha-20230131monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-executive-leadership-changes-chair-of-the-board-of-directo-tsha-20221216monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-third-quarter-2022-financial-results-and-provides-corporate--tsha-20221108monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-announces-pricing-of-public-offering-of-common-stock-dallas-tsha-20221026monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-proposed-public-offering-of-common-stock-dallas-tsha-20221025monthly0.5https://www.biopharmawatch.com/news/TSHA/astellas-and-taysha-gene-therapies-announce-strategic-investment-to-support-development-of-tsha-20221024monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-second-quarter-2022-financial-results-and-provides-corporate-tsha-20220811monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2022-financial-results-and-provides-corporate--tsha-20220516monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-fourth-quarter-and-full-year-2021-financial-results-and-prov-tsha-20220331monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-positive-clinical-efficacy-and-safety-data-for-high-dose-coh-tsha-20220131monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-positive-initial-biomarker-data-for-tsha-101-the-first-bic-tsha-20220127monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-third-quarter-2021-financial-results-and-provides-corporate--tsha-20211110monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-announces-exclusive-option-from-utsw-to-license-worldwide-rights-to-clinical-stage--tsha-20211005monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-second-quarter-2021-financial-results-and-provides-corporate-tsha-20210816monthly0.5https://www.biopharmawatch.com/news/TSHA/legal-disclosure-forward-looking-statements-this-presentation-contains-forward-looking-sta-tsha-20210629monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2021-financial-results-and-provides-a-corporat-tsha-20210511monthly0.5https://www.biopharmawatch.com/news/TSHA/bringing-new-cures-to-life-corporate-presentation-april-2021-legal-disclosure-forward-look-tsha-20210414monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-acquires-exclusive-worldwide-rights-to-clinical-stage-aav9-gene-ther-tsha-20210412monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-collaboration-to-advance-next-generation-mini-gene-payload-tsha-20210309monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-third-quarter-2020-financial-results-and-provides-business-u-tsha-20210305monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reports-full-year-2020-financial-results-and-provides-a-corporate-up-tsha-20210303monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-collaborations-to-advance-next-generation-mini-gene-payloa-tsha-20210209monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-highlights-strategic-priorities-and-provides-2021-business-outlook-e-tsha-20210201monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-receives-rare-pediatric-disease-and-orphan-drug-designations-for-tsh-tsha-20210119monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-queen-s-university-s-receipt-of-clinical-trial-application-tsha-20201221monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-new-cgmp-gene-therapy-manufacturing-facility-approximately-tsha-20201217monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-receives-rare-pediatric-disease-and-orphan-drug-designations-for-tsh-tsha-20201203monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-adds-industry-leading-gene-therapy-executives-to-board-of-directors--tsha-20201124monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-bolsters-manufacturing-capacity-through-partnership-with-catalent-pa-tsha-20201105monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-receives-rare-pediatric-disease-designation-and-orphan-drug-designat-tsha-20201027monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-receives-rare-pediatric-disease-designation-and-orphan-drug-designat-tsha-20201014monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-partners-with-invitae-to-enable-rapid-access-to-genetic-testing-and--tsha-20200923monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2025-financial-results-highlights-recent-company-progress-g-inva-20251105monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2025-financial-results-highlights-recent-company-progress--inva-20250806monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2025-financial-results-highlights-recent-company-progress-c-inva-20250507monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-and-full-year-2024-financial-results-highlights-recent-com-inva-20250226monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2024-financial-results-highlights-recent-company-progress-c-inva-20241106monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2024-financial-results-highlights-recent-company-progress--inva-20240731monthly0.5https://www.biopharmawatch.com/news/INVA/corporate-presentation-may-2024-forward-looking-statements-the-information-in-this-present-inva-20240513monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2024-financial-results-highlights-recent-company-progress-c-inva-20240508monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-and-full-year-2023-financial-results-highlights-recent-com-inva-20240229monthly0.5https://www.biopharmawatch.com/news/INVA/zoliflodacin-phase-3-clinical-trial-topline-data-inva-20231102monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2023-financial-results-and-highlights-recent-company-progre-inva-20231101monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-appoints-stephen-basso-as-chief-financial-officer-inva-20230825monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2023-financial-results-and-highlights-recent-company-progr-inva-20230802monthly0.5https://www.biopharmawatch.com/news/INVA/corporate-presentation-may-2023-forward-looking-statementsthe-information-in-this-presenta-inva-20230524monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2023-financial-results-and-highlights-recent-company-progre-inva-20230509monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-announces-retirement-of-board-chairman-burlingame-calif-business-wir-e-innoviva-i-inva-20230501monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-2022-financial-results-and-highlights-recent-company-progr-inva-20230228monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2022-financial-results-and-highlights-recent-company-progre-inva-20221109monthly0.5https://www.biopharmawatch.com/news/INVA/item-1a-risk-factors-the-information-presented-below-supplements-the-risk-factors-set-fort-inva-20220823monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progr-inva-20220727monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-sells-15-economic-stake-in-theravance-respiratory-company-to-royalty-pharma-for-a-inva-20220713monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-completes-acquisition-of-entasis-therapeutics-burlingame-calif-business-wire-inva-20220711monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-to-acquire-la-jolla-pharmaceutical-company-acquisition-to-strengthen-innoviva-s-i-inva-20220711monthly0.5https://www.biopharmawatch.com/news/INVA/execution-version-tender-and-support-agreement-this-tender-and-support-agreement-this-agre-inva-20220523monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2022-financial-results-royalties-increased-by-5-to-93-5-mil-inva-20220427monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-announces-proposed-offering-of-200-million-of-convertible-senior-notes-proceeds-e-inva-20220302monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-2021-financial-results-royalties-increased-by-18-to-111-1--inva-20220209monthly0.5https://www.biopharmawatch.com/news/INVA/corporate-presentation-december-2021-forward-looking-statements-the-information-in-this-pr-inva-20211213monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2021-financial-results-royalties-increased-by-10-to-101-3-m-inva-20211027monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2021-financial-results-royalties-increased-by-44-to-104-3--inva-20210728monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2021-financial-results-royalties-increased-by-8-to-89-0-mil-inva-20210428monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-2020-financial-results-royalties-increased-by-18-to-93-9-m-inva-20210203monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2020-financial-results-royalties-increased-by-33-to-92-2-mi-inva-20201028monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2020-financial-results-royalties-increased-by-7-to-72-4-mi-inva-20200729monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2020-financial-results-total-net-revenue-increased-by-43-to-inva-20200429monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-announces-change-of-location-of-annual-meeting-of-stockholders-to-be-held-on-apri-inva-20200331monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-2019-financial-results-total-net-revenue-decreased-by-4-9--inva-20200205monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2019-financial-results-total-net-revenue-increased-by-7-to--inva-20191030monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2019-financial-results-total-net-revenue-decreased-by-4-to-inva-20190724monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2019-financial-results-total-net-revenue-increased-by-5-to--inva-20190501monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-2018-financial-results-total-net-revenue-rose-15-to-79-9-m-inva-20190206monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2018-financial-results-total-net-revenue-rose-26-8-to-61-7--inva-20181031monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2018-financial-results-total-net-revenue-rose-14-6-to-67-1-inva-20180726monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-names-geoffrey-hulme-as-interim-principal-executive-officer-hulme-to-execute-capi-inva-20180522monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2018-financial-results-royalties-earned-rose-28-to-55-8-mil-inva-20180426monthly0.5https://www.biopharmawatch.com/news/INVA/issued-inva-20180424monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-record-fourth-quarter-and-full-year-2017-financial-results-royalties-earn-inva-20180208monthly0.5https://www.biopharmawatch.com/news/INVA/issued-26-january-2018-london-uk-and-brisbane-calif-lse-announcement-gsk-announces-chmp-po-inva-20180126monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-and-sarissa-implement-court-order-appoints-george-bickerstaff-iii-and-odysseas-ko-inva-20171219monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2017-financial-results-and-provides-business-updates-royalt-inva-20171025monthly0.5https://www.biopharmawatch.com/news/INVA/issued-19-september-2017-london-uk-gsk-and-innoviva-report-positive-headline-results-from--inva-20170920monthly0.5https://www.biopharmawatch.com/news/INVA/issued-18-september-2017-london-uk-lse-announcement-trelegy-ellipta-approved-as-the-first--inva-20170919monthly0.5https://www.biopharmawatch.com/news/INVA/issued-15-september-2017-london-uk-lse-announcement-trelegy-ellipta-once-daily-single-inha-inva-20170915monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-completes-refinancing-of-its-9-2029-non-recourse-notes-closes-250-million-term-b--inva-20170821monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-inc-announces-closing-of-175-million-offering-of-2-50-convertible-senior-notes-an-inva-20170807monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-inc-prices-offering-of-175-million-of-2-50-convertible-senior-notes-inva-20170801monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-announces-proposed-offering-of-175-million-of-convertible-senior-notes-inva-20170731monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-strong-second-quarter-2017-financial-results-royalties-earned-up-73-and-n-inva-20170726monthly0.5https://www.biopharmawatch.com/news/INVA/relvar-ellipta-significantly-improved-asthma-control-in-salford-lung-study-patients-compar-inva-20170505monthly0.5https://www.biopharmawatch.com/news/INVA/in-the-court-of-chancery-of-the-state-of-delaware-sarissa-capital-domestic-fund-lp-sarissa-inva-20170501monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2017-financial-results-royalties-earned-in-q1-2017-of-43-7--inva-20170427monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-announces-50-million-partial-royalty-notes-redemption-accelerated-notes-redemptio-inva-20170410monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-files-preliminary-proxy-materials-for-2017-annual-meeting-current-board-s-strateg-inva-20170307monthly0.5https://www.biopharmawatch.com/news/INVA/issued-thursday-23-february-2017-london-uk-lse-announcement-positive-results-for-relvar-el-inva-20170223monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-and-full-year-2016-financial-results-2016-royalties-earned-inva-20170209monthly0.5https://www.biopharmawatch.com/news/INVA/gsk-files-regulatory-submission-in-european-union-for-once-daily-closed-triple-combination-inva-20161202monthly0.5https://www.biopharmawatch.com/news/INVA/relvar-ellipta-100-25-mcg-gains-approval-in-japan-for-use-in-patients-with-copd-london-and-inva-20161201monthly0.5https://www.biopharmawatch.com/news/INVA/issued-monday-21-november-2016-london-uk-lse-announcement-gsk-files-regulatory-submission--inva-20161121monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-third-quarter-2016-financial-results-q3-2016-royalty-revenue-earned-up-11-inva-20161027monthly0.5https://www.biopharmawatch.com/news/INVA/pa4629-single-inhaler-triple-therapy-ics-lama-laba-in-patients-with-advanced-copd-results--inva-20160906monthly0.5https://www.biopharmawatch.com/news/INVA/positive-results-from-the-copd-salford-lung-study-published-in-the-nejm-and-presented-at-e-inva-20160904monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-second-quarter-2016-financial-results-royalty-revenues-rose-157-compared--inva-20160728monthly0.5https://www.biopharmawatch.com/news/INVA/issued-monday-20-june-2016-london-uk-lse-announcement-fulfil-study-shows-superiority-of-cl-inva-20160620monthly0.5https://www.biopharmawatch.com/news/INVA/regulatory-update-on-us-filing-plans-for-closed-triple-combination-therapy-ff-umec-vi-in-p-inva-20160602monthly0.5https://www.biopharmawatch.com/news/INVA/salford-lung-study-results-show-copd-patients-treated-with-relvar-ellipta-achieve-superior-inva-20160524monthly0.5https://www.biopharmawatch.com/news/INVA/new-york-presbyterian-hospital-weil-cornell-medical-center-new-york-ny-usa-2university-of--inva-20160518monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-first-quarter-2016-financial-results-including-royalty-revenues-of-27-4-m-inva-20160428monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-march-2016-safe-harbor-2-2016-innoviva-this-presentation-contains-certain-forward-inva-20160308monthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-and-full-year-2015-financial-results-company-reports-its-f-inva-20160203monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-inc-announces-name-change-to-innoviva-inc-south-san-francisco-calif-inva-20160108monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-reports-third-quarter-2015-financial-results-us-breo-ellipta-sales-up-by-more-t-inva-20151028monthly0.5https://www.biopharmawatch.com/news/INVA/effect-of-umeclidinium-vilanterol-umec-vi-on-inspiratory-capacity-total-lung-capacity-rati-inva-20150928monthly0.5https://www.biopharmawatch.com/news/INVA/issued-thursday-24-september-2015-london-uk-and-south-san-francisco-ca-usa-lse-announcemen-inva-20150924monthly0.5https://www.biopharmawatch.com/news/INVA/issued-8-september-2015-london-uk-and-south-san-francisco-ca-usa-lse-announcement-gsk-and--inva-20150908monthly0.5https://www.biopharmawatch.com/news/INVA/issued-6th-august-2015-mississauga-gsk-receives-approval-for-breo-ellipta-for-the-treatmen-inva-20150806monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-reports-second-quarter-2015-financial-results-theravance-declares-a-0-25-per-sh-inva-20150729monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-inc-appoints-michael-faerm-as-chief-business-officer-inva-20150713monthly0.5https://www.biopharmawatch.com/news/INVA/can-dual-long-acting-bronchodilator-therapy-prevent-clinically-important-deteriorations-in-inva-20150520monthly0.5https://www.biopharmawatch.com/news/INVA/the-effect-of-reducing-lung-hyperinflation-with-fluticasone-furoate-vilanterol-on-cardiac--inva-20150518monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-reports-first-quarter-2015-financial-results-theravance-declares-a-0-25-per-sha-inva-20150506monthly0.5https://www.biopharmawatch.com/news/INVA/issued-thursday-30-april-2015-london-uk-and-south-san-francisco-ca-usa-lse-announcement-fd-inva-20150430monthly0.5https://www.biopharmawatch.com/news/INVA/issued-19-march-2015-london-uk-and-south-san-francisco-ca-usa-gsk-and-theravance-announce--inva-20150320monthly0.5https://www.biopharmawatch.com/news/INVA/efficacy-and-safety-of-once-daily-umeclidinium-added-to-fluticasone-furoate-vilanterol-in--inva-20141028monthly0.5https://www.biopharmawatch.com/news/INVA/efficacy-and-safety-of-umeclidinium-vilanterol-umec-vi-once-daily-od-vs-fluticasone-salmet-inva-20141027monthly0.5https://www.biopharmawatch.com/news/INVA/umeclidinium-vilanterol-umec-vi-once-daily-od-vs-fluticasone-salmeterol-combination-fsc-tw-inva-20140908monthly0.5https://www.biopharmawatch.com/news/INVA/for-healthcare-professional-media-only-issued-9-july-2014-sydney-australia-anoro-ellipta-u-inva-20140709monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-inc-and-theravance-biopharma-inc-announce-completion-of-separation-of-late-stag-inva-20140605monthly0.5https://www.biopharmawatch.com/news/INVA/a-nicholls-m-d-ph-d-theravance-inc-901-gateway-blvd-south-san-francisco-ca-94080-phone-650-inva-20140521monthly0.5https://www.biopharmawatch.com/news/INVA/efficacy-and-safety-of-once-daily-fluticasone-furoate-vilanterol-ff-vi-and-ff-over-12-week-inva-20140520monthly0.5https://www.biopharmawatch.com/news/INVA/poster-board-no-411-bronchodilator-response-to-the-long-acting-bronchodilator-combination--inva-20140520monthly0.5https://www.biopharmawatch.com/news/INVA/poster-406-aps-2014-tampa-fl-rvickery-theravance-com-axelopran-phase-2b-study-demonstrates-inva-20140502monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-announces-positive-results-from-a-phase-2-study-of-td-9855-in-patients-with-fib-inva-20140430monthly0.5https://www.biopharmawatch.com/news/INVA/for-medical-media-issued-22-april-2014-sydney-australia-breo-ellipta-fluticasone-furoate-v-inva-20140422monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-closes-private-placement-of-450-million-of-9-non-recourse-notes-supporting-stra-inva-20140421monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-announces-update-to-planned-separation-of-late-stage-partnered-respiratory-asse-inva-20140303monthly0.5https://www.biopharmawatch.com/news/INVA/anoro-ellipta-approved-for-copd-treatment-in-canada-approved-as-a-new-once-daily-dual-bron-inva-20131223monthly0.5https://www.biopharmawatch.com/news/INVA/for-medical-and-trade-media-08-01-14-london-uk-the-first-once-daily-ics-laba-treatment-for-inva-20140108monthly0.5https://www.biopharmawatch.com/news/INVA/the-efficacy-and-safety-of-inhaled-fluticasone-furoate-ff-vilanterol-vi-in-asian-patients--inva-20131113monthly0.5https://www.biopharmawatch.com/news/INVA/poster-no-ps108-efficacy-and-safety-of-once-daily-fluticasone-furoate-vilanterol-200-25mcg-inva-20131112monthly0.5https://www.biopharmawatch.com/news/INVA/poster-no-p3640-efficacy-and-safety-of-umeclidinium-vilanterol-compared-with-umeclidinium--inva-20130910monthly0.5https://www.biopharmawatch.com/news/INVA/poster-no-p760-long-term-safety-and-tolerability-of-umeclidinium-vilanterol-and-umeclidini-inva-20130909monthly0.5https://www.biopharmawatch.com/news/INVA/medicines-that-make-a-difference-nasdaq-thrx-inva-20130905monthly0.5https://www.biopharmawatch.com/news/INVA/breo-ellipta-approved-for-copd-treatment-in-canada-mississauga-on-inva-20130710monthly0.5https://www.biopharmawatch.com/news/INVA/qualitative-assessment-of-a-two-strip-dry-powder-inhaler-ellipta-for-copd-and-asthma-poste-inva-20130624monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-inc-calls-for-redemption-of-172-5-million-of-3-convertible-subordinated-notes-d-inva-20130604monthly0.5https://www.biopharmawatch.com/news/INVA/poster-no-g16-effect-of-fluticasone-furoate-ff-vilanterol-vi-compared-with-vi-on-copd-exac-inva-20130521monthly0.5https://www.biopharmawatch.com/news/INVA/poster-no-806-once-daily-od-fluticasone-furoate-vilanterol-100-25mcg-ff-vi-compared-with-t-inva-20130520monthly0.5https://www.biopharmawatch.com/news/INVA/long-acting-bronchodilators-and-arterial-stiffness-in-patients-with-copd-poster-no-225-d-b-inva-20130520monthly0.5https://www.biopharmawatch.com/news/INVA/poster-376-aps2013-new-orleans-la-rvickery-theravance-com-td-1211-demonstrates-tolerabilit-inva-20130510monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-announces-closing-of-public-offering-of-287-5-inva-20130124monthly0.5https://www.biopharmawatch.com/news/INVA/theravance-announces-pricing-of-convertible-subordinated-notes-offering-company-has-also-e-inva-20130117monthly0.5https://www.biopharmawatch.com/news/BHVN/about-biohaven-biohaven-is-a-biopharmaceutical-company-focused-on-the-discovery-developmen-bhvn-20260527monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-second-quarter-2025-financial-results-and-recent-business-developments-ca-bhvn-20250811monthly0.5https://www.biopharmawatch.com/news/BHVN/sections-titled-risk-factors-and-management-s-discussion-and-analysis-of-financial-conditi-bhvn-20250515monthly0.5https://www.biopharmawatch.com/news/BHVN/expected-timing-commencement-and-outcomes-of-biohaven-s-planned-and-ongoing-clinical-trial-bhvn-20250428monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-spinocerebel-bhvn-20240923monthly0.5https://www.biopharmawatch.com/news/BHVN/development-timing-and-potential-marketing-approval-and-commercialization-of-development-c-bhvn-20230728monthly0.5https://www.biopharmawatch.com/news/BHVN/investor-contact-jennifer-porcelli-vice-president-investor-relations-jennifer-porcelli-bio-bhvn-20230531monthly0.5https://www.biopharmawatch.com/news/BHVN/januaryinvesto-41st-annual-j-p-morgan-healthcare-conference-vlad-coric-m-d-chairman-and-ch-bhvn-20230110monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-reports-first-quarter-2026-financial-results-and-corporate-highlights-resu-mbx-20260507monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-successful-end-of-phase-2-fda-meeting-and-provides-phase-3-devel-mbx-20260309monthly0.5https://www.biopharmawatch.com/news/MBX/and-drug-administration-and-comparable-foreign-regulatory-authorities-risks-related-to-est-mbx-20251231monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-reports-second-quarter-2025-financial-results-and-recent-corporate-highlig-mbx-20250807monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-ind-submission-of-mbx-4291-its-long-acting-glp1-gip-receptor-co--mbx-20250616monthly0.5https://www.biopharmawatch.com/news/MBX/disclaimer-this-presentation-includes-forward-looking-statements-all-statements-other-than-mbx-20250609monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-reports-first-quarter-2025-financial-results-and-recent-corporate-highligh-mbx-20250512monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-veteran-pharmaceutical-executive-steve-hoerter-to-board-of-direct-mbx-20250407monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-cor-mbx-20250317monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-positive-phase-1-topline-results-for-mbx-1416-for-the-treatment--mbx-20250107monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-update--mbx-20241107monthly0.5https://www.biopharmawatch.com/news/IMTX/minutes-of-the-annual-general-meeting-of-shareholders-of-immatics-n-v-june-18-2026-edward--imtx-20260618monthly0.5https://www.biopharmawatch.com/news/IMTX/convening-notice-of-the-annual-general-meeting-of-immatics-n-v-this-is-the-convening-notic-imtx-20260602monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynec-imtx-20260530monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-interim-condensed-consolidated-financial-statements-for-the-imtx-20260512monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-four-upcoming-oral-presentations-across-its-clinical-cell-therapy-and-b-imtx-20260421monthly0.5https://www.biopharmawatch.com/news/IMTX/prame-directed-cell-therapy-using-immatics-tcr-induces-deep-and-durable-remission-in-pedia-imtx-20260417monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2025-financial-results-and-business-update-anzu-cel-anzutresg-imtx-20260305monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-not-for-further-reproduction-or-distribution-immatics-not-for-further-reproductio-imtx-20260112monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-presents-ima203cd8-prame-cell-therapy-data-from-ongoing-dose-escalation-and-shows-imtx-20251211monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-125-million-underwritten-offering-houston-texas-and-tuebingen-germany-imtx-20251205monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-interim-condensed-consolidated-financial-statements-for-the-imtx-20251117monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-achieves-clinical-proof-of-concept-of-its-next-generation-tcr-bispecific-tcer-pip-imtx-20251112monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-amie-krause-as-chief-people-officer-houston-texas-and-tuebingen-germany-imtx-20251027monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-highlights-compelling-anti-tumor-activity-of-anzu-cel-prame-cell-therapy-in-metas-imtx-20251020monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-venkat-ramanan-as-chief-financial-officer-houston-texas-and-tuebingen-ge-imtx-20251001monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-interim-condensed-consolidated-financial-statements-for-the-imtx-20250813monthly0.5https://www.biopharmawatch.com/news/IMTX/minutes-of-the-annual-general-meeting-of-shareholders-of-immatics-n-v-june-18-2025-edward--imtx-20250618monthly0.5https://www.biopharmawatch.com/news/IMTX/convening-notice-of-the-annual-general-meeting-of-immatics-n-v-this-is-the-convening-notic-imtx-20250602monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima203-prame-cell-therapy-data-presented-at-2025-asco-annual-meeting-continues-to-imtx-20250531monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-interim-condensed-consolidated-financial-statements-for-the-imtx-20250513monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2024-financial-results-and-business-update-randomized-control-imtx-20250327monthly0.5https://www.biopharmawatch.com/news/IMTX/delivering-the-power-of-t-cells-to-cancer-patients-immatics-not-for-further-reproduction-o-imtx-20250113monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-interim-condensed-consolidated-financial-statements-for-the-imtx-20241118monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-multiple-presentations-at-the-39-th-annual-meeting-of-the-society-for-i-imtx-20241108monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-proposed-150-million-public-offering-houston-texas-and-tuebingen-german-imtx-20241010monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-updated-phase-1b-clinical-data-on-actengine-ima203-tcr-t-targeting-pram-imtx-20241010monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-presents-clinical-proof-of-concept-data-from-ongoing-phase-1-dose-escalation-tria-imtx-20240916monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-interim-condensed-consolidated-financial-statements-for-the-imtx-20240813monthly0.5https://www.biopharmawatch.com/news/IMTX/minutes-of-the-annual-general-meeting-of-shareholders-of-immatics-n-v-june-20-2024-edward--imtx-20240620monthly0.5https://www.biopharmawatch.com/news/IMTX/convening-notice-of-the-annual-general-meeting-of-immatics-n-v-this-is-the-convening-notic-imtx-20240603monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-interim-condensed-consolidated-financial-statements-for-the-imtx-20240514monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2023-financial-results-and-corporate-update-interim-clinical--imtx-20240321monthly0.5https://www.biopharmawatch.com/news/IMTX/p-r-e-s-s-r-e-l-e-a-s-e-immatics-announces-proposed-public-offering-houston-texas-and-tueb-imtx-20240117monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-interim-condensed-consolidated-financial-statements-for-the-imtx-20231114monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-reports-interim-clinical-data-from-actengine-ima203-and-ima203cd8-tcr-t-monothera-imtx-20231108monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-actengin-imtx-20231024monthly0.5https://www.biopharmawatch.com/news/IMTX/moderna-and-immatics-announce-strategic-multi-platform-collaboration-to-develop-innovative-imtx-20230911monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-imtx-20230817monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-initiates-phase-1-2-clinical-trial-to-evaluate-prame-tcr-bispecific-ima402-in-pat-imtx-20230810monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-35-million-equity-investment-from-bristol-myers-squibb-tuebingen-german-imtx-20230724monthly0.5https://www.biopharmawatch.com/news/IMTX/minutes-of-the-annual-general-meeting-of-shareholders-of-immatics-n-v-june-20-2023-edward--imtx-20230620monthly0.5https://www.biopharmawatch.com/news/IMTX/convening-notice-of-the-annual-general-meeting-of-immatics-n-v-this-is-the-convening-notic-imtx-20230526monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-imtx-20230516monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-reports-interim-clinical-data-from-ongoing-phase-1b-cohort-a-monotherapy-with-act-imtx-20230502monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-first-bristol-myers-squibb-opt-in-of-tcr-t-candidate-from-ongoing-multi-imtx-20230501monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2022-financial-results-and-corporate-update-actengine-ima203--imtx-20230321monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-not-for-further-reproduction-or-distribution-delivering-the-power-of-t-cells-to-c-imtx-20230109monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-imtx-20221117monthly0.5https://www.biopharmawatch.com/news/IMTX/next-generation-tcr-bispecifics-tcer-targeting-peptide-hla-antigens-for-the-treatment-of-p-imtx-20221110monthly0.5https://www.biopharmawatch.com/news/IMTX/delivering-the-power-of-t-cells-to-cancer-patients-immatics-not-for-further-reproduction-o-imtx-20221018monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-110-million-underwritten-offering-of-ordinary-shares-houston-texas-and--imtx-20221010monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-reports-interim-clinical-data-update-on-actengine-ima203-tcr-t-monotherapy-target-imtx-20221010monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-presents-comprehensive-preclinical-data-set-for-tcr-bispecific-candidate-ima402-t-imtx-20220910monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-first-cancer-patient-treated-with-second-generation-actengine-tcr-t-can-imtx-20220823monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-imtx-20220809monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-not-for-further-reproduction-or-distribution-immatics-corporate-presentation-imtx-20220630monthly0.5https://www.biopharmawatch.com/news/IMTX/minutes-of-the-annual-general-meeting-of-shareholders-of-immatics-n-v-june-13-2022-edward--imtx-20220614monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-and-editas-medicine-enter-strategic-research-collaboration-and-licensing-agreemen-imtx-20220607monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-imtx-20220602monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-and-bristol-myers-squibb-expand-strategic-alliance-to-develop-gamma-delta-allogen-imtx-20220602monthly0.5https://www.biopharmawatch.com/news/IMTX/convening-notice-of-the-annual-general-meeting-of-immatics-n-v-this-is-the-convening-notic-imtx-20220527monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-first-patient-treated-with-actengine-ima203-tcr-t-in-combination-with-c-imtx-20220518monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-initiates-phase-1-clinical-trial-to-evaluate-lead-tcr-bispecific-ima401-in-patien-imtx-20220510monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2021-financial-results-and-corporate-update-ima203-tcr-t-cand-imtx-20220323monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-and-bristol-myers-squibb-enter-into-global-exclusive-license-for-immatics-tcr-bis-imtx-20211214monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-imtx-20211116monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-not-for-further-reproduction-or-distribution-actengine-ima200-tcr-t-programs-inte-imtx-20211109monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-to-present-update-on-lead-actengine-program-ima203-targeting-prame-at-the-society-imtx-20211101monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-imtx-20211028monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-imtx-20210810monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-not-for-further-reproduction-or-distribution-unlocking-immunotherapies-for-solid--imtx-20210715monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-n-v-annual-general-meeting-of-shareholders-imtx-20210617monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-changes-to-its-board-of-directors-tuebingen-germany-and-houston-texas-m-imtx-20210526monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-imtx-20210518monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-presents-preclinical-proof-of-concept-data-for-tcr-bispecifics-program-ima402-tar-imtx-20210511monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-not-for-further-reproduction-or-distribution-unlocking-immunotherapies-for-solid--imtx-20210401monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2020-financial-results-and-corporate-update-phase-1a-data-upd-imtx-20210330monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-presents-data-update-on-dose-escalation-from-ongoing-actengine-cell-therapy-progr-imtx-20210317monthly0.5https://www.biopharmawatch.com/news/IMTX/forward-looking-statement-this-presentation-presentation-is-provided-by-immatics-n-v-immat-imtx-20210106monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-imtx-20201202monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-arnd-christ-as-chief-financial-officer-tuebingen-germany-and-houston-tex-imtx-20201001monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-biotech-executive-eliot-forster-to-board-of-directors-tuebingen-germany--imtx-20200915monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-provides-update-on-ima204-actengine-cell-therapy-program-targeting-the-tumor-micr-imtx-20200910monthly0.5https://www.biopharmawatch.com/news/IMTX/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-imtx-20200903monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-european-clinical-expansion-of-its-adoptive-cell-therapy-programs-first-imtx-20200818monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-extends-cell-therapy-manufacturing-collaboration-with-uthealth-extension-of-colla-imtx-20200806monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-completion-of-business-combination-and-listing-on-nasdaq-the-business-c-imtx-20200701monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-delivers-fourth-quarter-and-full-year-net-sales-growth-net-sales-and-adjusted-eb-hlf-20260218monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-delivers-q3-net-sales-increase-above-guidance-midpoint-north-america-returns-to--hlf-20251105monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-q2-net-sales-near-guidance-midpoint-q2-adjusted-ebitda-1-exceeds-guidanc-hlf-20250806monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-q1-net-sales-at-midpoint-of-guidance-range-net-sales-growth-excluding-fx-hlf-20250430monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-q4-net-sales-at-high-end-of-guidance-q4-and-full-year-net-sales-growth-e-hlf-20250219monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-third-quarter-2024-results-net-sales-in-line-with-expectations-adjusted--hlf-20241030monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-second-quarter-2024-results-adjusted-ebitda-1-exceeds-guidance-raised-fu-hlf-20240731monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-year-over-year-net-sales-growth-for-second-consecutive-quarter-raises-fu-hlf-20240501monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-completes-1-6-billion-senior-secured-refinancing-includes-1-2-billion-senior-sec-hlf-20240412monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-announces-pricing-of-upsized-800-million-aggregate-principal-amount-of-senior-se-hlf-20240405monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-announces-proposed-offering-of-700-million-aggregate-principal-amount-of-senior--hlf-20240401monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-announces-cfo-transition-initiates-guidance-for-first-quarter-and-full-year-2024-hlf-20240320monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-year-over-year-net-sales-growth-in-fourth-quarter-2023-los-angeles-busin-hlf-20240214monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-third-quarter-2023-results-los-angeles-business-wire-hlf-20231101monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-second-quarter-2023-results-los-angeles-business-wire-hlf-20230802monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-first-quarter-2023-results-los-angeles-business-wire-hlf-20230502monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-full-year-and-fourth-quarter-2022-results-los-angeles-business-hlf-20230214monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-ceo-michael-o-johnson-agrees-to-1-salary-and-removing-interim-title-lo-hlf-20221227monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-pricing-of-250-million-aggregate-principal-amount-of-convert-hlf-20221207monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-proposed-offering-of-250-million-aggregate-principal-amount--hlf-20221205monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-third-quarter-2022-results-withdraws-full-year-2022-guidance-a-hlf-20221031monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-exceeds-second-quarter-2022-expectations-and-reaffirms-full-year-2022--hlf-20220802monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-first-quarter-2022-results-and-updates-full-year-2022-guidan-hlf-20220503monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-full-year-record-results-for-the-second-consecutive-year-ann-hlf-20220223monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-third-quarter-2021-results-and-on-track-for-another-record-yea-hlf-20211102monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-revises-third-quarter-and-full-year-2021-guidance-los-angeles-business-hlf-20210913monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-fourth-straight-quarter-of-year-over-year-double-digit-net-sal-hlf-20210803monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-closing-of-600-million-senior-notes-at-rate-of-4-875-los-ang-hlf-20210520monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-pricing-of-upsized-600-million-senior-notes-offering-to-rede-hlf-20210507monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-proposed-offering-of-500-million-of-senior-notes-to-redeem-e-hlf-20210506monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-raises-full-year-2021-guidance-rep-or-ts-r-ecord-first-quarter-net-sal-hlf-20210504monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-record-breaking-2020-net-sales-with-14-growth-versus-prior-yea-hlf-20210217monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-record-breaking-quarterly-net-sales-with-22-growth-versus-prio-hlf-20201105monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-record-breaking-quarterly-net-sales-results-los-angeles-august-hlf-20200806monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-a-self-tender-offer-seeking-to-purchase-up-to-750-million-of-hlf-20200713monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-closing-of-600-million-senior-note-offering-los-angeles-busi-hlf-20200529monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-pricing-of-senior-note-offering-los-angeles-business-wire-hlf-20200521monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-offering-of-600-million-of-senior-notes-los-angeles-business-hlf-20200519monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-largest-volume-point-quarter-in-company-history-los-angeles-bu-hlf-20200507monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-record-breaking-full-year-2019-volume-point-results-incoming-c-hlf-20200218monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-record-breaking-quarterly-volume-point-results-and-provides-in-hlf-20191029monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-reports-results-with-net-sales-growth-in-four-of-our-six-regions-los-a-hlf-20190801monthly0.5https://www.biopharmawatch.com/news/HLF/after-a-record-breaking-year-in-2018-herbalife-nutrition-reports-highest-first-quarter-vol-hlf-20190502monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-achieves-double-digit-net-sales-growth-in-2018-and-updates-growth-proj-hlf-20190219monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-michael-o-johnson-will-reassume-the-role-of-chief-executive--hlf-20190108monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-achieves-net-sales-growth-of-15-in-the-third-quarter-establishes-new-1-hlf-20181030monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-closing-of-1-25-billion-credit-facility-and-400-hlf-20180816monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-pricing-of-400-million-aggregate-principal-amount-of-senior--hlf-20180809monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-announces-proposed-offering-of-400-million-aggregate-principal-amount--hlf-20180806monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-achieves-net-sales-growth-of-12-in-the-second-quarter-with-all-time-re-hlf-20180801monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-nutrition-exceeds-first-quarter-net-sales-guidance-exceeds-high-end-of-reported--hlf-20180503monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-announces-self-tender-offer-seeking-to-purchase-up-to-600-million-of-its-common--hlf-20180418monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-announces-pricing-of-550-million-aggregate-principal-amount-of-convertible-senio-hlf-20180321monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-announces-proposed-offering-of-500-million-aggregate-principal-amount-of-convert-hlf-20180320monthly0.5https://www.biopharmawatch.com/news/HLF/investor-contact-jennifer-butler-eric-monroe-vp-media-relations-director-investor-relation-hlf-20180222monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-provides-preliminary-volume-point-results-for-the-fourth-quarter-2017-los-angele-hlf-20180108monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-third-quarter-2017-results-provides-initial-full-year-2018-guidance-thir-hlf-20171102monthly0.5https://www.biopharmawatch.com/news/HLF/as-part-of-herbalife-nutrition-s-self-tender-offer-the-company-updates-guidance-for-third--hlf-20171002monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-announces-self-tender-offer-seeking-to-purchase-up-to-600-million-of-its-outstan-hlf-20170821monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-second-quarter-2017-results-exceeds-updated-reported-and-adjusted-eps-gu-hlf-20170801monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-exceeds-first-quarter-2017-reported-and-adjusted-eps-guidance-first-quarter-2017-hlf-20170504monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-reports-record-full-year-2016-worldwide-volume-number-of-preferred-members-in-th-hlf-20170223monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-ltd-announces-closing-of-1-45-hlf-20170215monthly0.5https://www.biopharmawatch.com/news/HLF/confidential-information-memorandum-herbalife-nutrition-public-1-325-000-000-senior-secure-hlf-20170120monthly0.5https://www.biopharmawatch.com/news/HLF/investor-contact-jennifer-butler-alan-quan-vp-media-relations-vp-investor-relations-213-74-hlf-20161101monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-ltd-announces-record-second-quarter-2016-volume-results-second-quarter-2016-volu-hlf-20160803monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-and-the-federal-trade-commission-reach-settlement-agreement-settlement-does-not--hlf-20160715monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-ltd-announces-first-quarter-2016-results-and-raises-full-year-adjusted-guidance--hlf-20160505monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-ltd-announces-fourth-quarter-and-full-year-2015-results-fourth-quarter-adjusted--hlf-20160225monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-responds-to-the-dismissal-of-abdul-awad-v-herbalife-ltd-et-al-hlf-20151125monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-ltd-announces-third-quarter-2015-results-raises-adjusted-full-year-guidance-and--hlf-20151103monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-ltd-announces-second-quarter-2015-results-and-raises-full-year-guidance-second-q-hlf-20150805monthly0.5https://www.biopharmawatch.com/news/HLF/may-14-2015-herbalife-responds-to-court-s-final-approval-of-bostick-class-action-settlemen-hlf-20150518monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-ltd-announces-first-quarter-2015-results-and-raises-full-year-guidance-first-qua-hlf-20150505monthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-ltd-announces-fourth-quarter-and-full-year-2014-results-and-2015-earnings-guidan-hlf-20150226monthly0.5https://www.biopharmawatch.com/news/VIR/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-tar-vir-20260223monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2025-financial-resul-vir-20251105monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-second-quarter-2025-financial-resu-vir-20250806monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-preliminary-24-week-post-end-of-treatment-data-for-tobevibart--vir-20250509monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-first-quarter-2025-financial-resul-vir-20250507monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024--vir-20250226monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-encouraging-safety-and-efficacy-data-in-ongoing-dose-escalatio-vir-20250108monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-upda-vir-20241031monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-closing-of-exclusive-worldwide-license-agreement-with-sanofi-f-vir-20240909monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-reports-second-quarter-2024-financial-results-and-announces-strategic-re-vir-20240801monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-receives-fda-ind-clearance-and-fast-track-designation-for-tobevibart-and-vir-20240626monthly0.5https://www.biopharmawatch.com/news/VIR/tobevibart-monotherapy-and-combination-therapy-with-elebsiran-achieved-high-virologic-resp-vir-20240605monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-first-quarter-2024-financial-resul-vir-20240502monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-nomination-of-norbert-bischofberger-ph-d-and-ramy-farid-ph-d-t-vir-20240418monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2023--vir-20240222monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2023-financial-resul-vir-20231102monthly0.5https://www.biopharmawatch.com/news/VIR/document-exhibit-99-1-vir-biotechnology-provides-corporate-update-and-reports-second-quart-vir-20230803monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-vir-20230504monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-vir-20230223monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-vir-20221103monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-awarded-u-s-government-contract-to-support-pandemic-preparedness-for-inf-vir-20221004monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-vir-20220809monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-vir-20220505monthly0.5https://www.biopharmawatch.com/news/VIR/us-food-and-drug-administration-revises-emergency-use-authorization-for-sotrovimab-due-to--vir-20220325monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2021--vir-20220224monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2021-financial-resul-vir-20211104monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-second-quarter-2021-financial-resu-vir-20210805monthly0.5https://www.biopharmawatch.com/news/VIR/legal-disclaimers-2021-vir-biotechnology-inc-forward-looking-statements-statements-in-this-vir-20210625monthly0.5https://www.biopharmawatch.com/news/VIR/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorizatio-vir-20210526monthly0.5https://www.biopharmawatch.com/news/VIR/correction-ema-issues-positive-scientific-opinion-on-gsk-and-vir-biotechnology-s-sotrovima-vir-20210521monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-first-quarter-2021-financial-resul-vir-20210506monthly0.5https://www.biopharmawatch.com/news/VIR/legal-disclaimers-2021-vir-biotechnology-inc-forward-looking-statements-statements-in-this-vir-20210413monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2020--vir-20210225monthly0.5https://www.biopharmawatch.com/news/VIR/gsk-and-vir-biotechnology-expand-coronavirus-collaboration-to-advance-new-therapeutics-for-vir-20210217monthly0.5https://www.biopharmawatch.com/news/VIR/initial-data-from-ongoing-phase-1-trial-of-vir-3434-for-chronic-hepatitis-b-virus-infectio-vir-20210126monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2020-financial-resul-vir-20201110monthly0.5https://www.biopharmawatch.com/news/VIR/a-w-o-r-l-d-w-i-t-h-o-u-t-i-n-f-e-c-t-i-o-u-s-d-i-s-e-a-s-e-vir-biotechnology-inc-h-c-wain-vir-20200916monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-second-quarter-2020-financial-resu-vir-20200811monthly0.5https://www.biopharmawatch.com/news/VIR/confidential-execution-copy-29-july-2020-assignment-and-novation-agreement-this-assignment-vir-20200729monthly0.5https://www.biopharmawatch.com/news/VIR/business-summary-business-summary-our-mission-is-to-create-a-world-without-infectious-dise-vir-20200619monthly0.5https://www.biopharmawatch.com/news/VIR/certain-confidential-information-contained-in-this-document-marked-by-has-been-omitted-bec-vir-20200619monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-and-biogen-execute-agreement-to-manufacture-sars-cov-2-antibodies-for-po-vir-20200529monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-first-quarter-2020-financial-resul-vir-20200512monthly0.5https://www.biopharmawatch.com/news/VIR/release-date-10-april-2020-samsung-biologics-and-vir-biotechnology-enter-into-agreement-fo-vir-20200410monthly0.5https://www.biopharmawatch.com/news/VIR/for-media-and-investors-only-issued-vir-20200406monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2019--vir-20200326monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-identifies-two-antibodies-that-bind-to-the-spike-protein-of-2019-ncov-ne-vir-20200212monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-applying-multiple-platforms-to-address-public-health-risk-from-wuhan-cor-vir-20200122monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2019-financial-resul-vir-20191119monthly0.5https://www.biopharmawatch.com/news/AGIO/document-agios-reports-first-quarter-2026-financial-results-and-provides-business-update-m-agio-20260429monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-outlines-2026-strategic-priorities-and-key-milestones-to-accelerate-rare-disease-por-agio-20260112monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-second-quarter-2025-financial-results-and-provides-business-update-12-5-mill-agio-20250731monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-first-quarter-2025-financial-results-and-recent-business-highlights-u-s-regu-agio-20250501monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-high-agio-20250213monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-key-2025-milestones-for-innovative-rare-disease-portfolio-fda-accepted-agi-agio-20250113monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-third-quarter-2024-financial-results-completed-enrol-agio-20241031monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-second-quarter-2024-financial-results-reported-posit-agio-20240801monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-905-million-purchase-agreement-for-vorasidenib-royalty-royalty-pharma-to-a-agio-20240528monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-first-quarter-2024-financial-results-topline-data-re-agio-20240502monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-business-high-agio-20240215monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-key-anticipated-2024-milestones-across-rare-disease-portfolio-industry-lea-agio-20240108monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-third-quarter-2023-financial-results-first-patient-d-agio-20231102monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-second-quarter-2023-financial-results-announced-posi-agio-20230803monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-first-quarter-2023-financial-results-on-track-for-py-agio-20230504monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2022-financial-results-completed-enrollment-in--agio-20230223monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-unveils-2023-2026-value-driving-catalysts-enabling-company-s-vision-to-transform-pat-agio-20230108monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-tsveta-milanova-as-chief-commercial-officer-agio-20221206monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-third-quarter-2022-financial-results-u-s-pyrukynd-mi-agio-20221103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-and-sagard-healthcare-partners-announce-131-8-million-purchase-agreement-for-tibsovo-agio-20221027monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-cecilia-jones-as-chief-financial-officer-agio-20220919monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-second-quarter-2022-financial-results-generated-3-1--agio-20220804monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-brian-goff-as-chief-executive-officer-current-ceo-jackie-fouse-ph-d-to-tran-agio-20220712monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-first-quarter-2022-financial-results-received-u-s-fd-agio-20220505monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2021-financial-results-received-fda-approval-of-agio-20220224monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-third-quarter-2021-financial-results-received-fda-pr-agio-20211103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-second-quarter-2021-financial-results-completed-regu-agio-20210729monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-positive-results-from-phase-2-study-of-mitapivat-in-non-transfusion-depende-agio-20210611monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-first-quarter-2021-financial-results-data-from-activ-agio-20210429monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-closing-of-oncology-business-sale-to-servier-agios-receives-1-8-billion-in-agio-20210401monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-shareholders-approve-sale-of-oncology-business-to-servier-agio-20210325monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2020-financial-results-strong-commercial-execut-agio-20210225monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-inc-index-to-consolidated-financial-statements-report-of-independent-agio-20210129monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-phase-3-activate-t-trial-of-mitapivat-achieved-primary-endpoint-in-adults--agio-20210126monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-highlights-2021-milestones-to-accelerate-and-expand-its-genetically-defined-disease--agio-20210111monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-focus-on-developing-and-commercializing-innovative-treatments-for-genetically-def-agio-20201221monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-updated-data-from-phase-1-study-of-mitapivat-first-in-class-pkr-activator--agio-20201207monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-the-phase-3-activate-trial-of-mitapivat-achieved-its-primary-endpoint-in-a-agio-20201201monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-third-quarter-2020-financial-results-third-quarter-t-agio-20201105monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-final-overall-survival-data-from-phase-3-claridhy-study-of-tibsovo-ivoside-agio-20200921monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-jonathan-biller-as-chief-financial-officer-head-of-legal-and-corporate-affa-agio-20200908monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-second-quarter-2020-financial-results-second-quarter-agio-20200730monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-and-royalty-pharma-announce-255-million-purchase-agreement-for-idhifa-royalty-royalt-agio-20200612monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-data-from-the-phase-1-dose-escalation-study-of-vorasidenib-in-patie-agio-20200529monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-first-quarter-2020-financial-results-and-provides-update-on-business-operati-agio-20200430monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2019-financial-results-fourth-quarter-tibsovo-n-agio-20200213monthly0.5https://www.biopharmawatch.com/news/AGIO/forward-looking-statements-this-presentation-and-various-remarks-we-make-during-this-prese-agio-20200113monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-agios-2025-strategic-vision-and-highlights-2020-milestones-in-2025-company-agio-20200112monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-establishes-proof-of-concept-for-mitapivat-in-non-transfusion-dependent-thalassemia--agio-20191208monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-new-pharmacodynamic-and-response-data-from-both-cohorts-of-the-perioperativ-agio-20191122monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-pricing-of-256-million-public-offering-of-common-stock-agio-20191107monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-third-quarter-2019-financial-results-tibsovo-net-rev-agio-20191031monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-data-from-single-agent-dose-escalation-arm-of-phase-1-study-of-ag-270-a-mat-agio-20191027monthly0.5https://www.biopharmawatch.com/news/AGIO/data-from-agios-phase-3-claridhy-trial-of-tibsovo-demonstrates-significant-improvement-in--agio-20190930monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-publication-of-data-for-mitapivat-from-core-and-extension-phases-of-the-dr-agio-20190904monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-second-quarter-2019-financial-results-strong-topline-agio-20190801monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-data-from-phase-1-studies-of-tibsovo-ivosidenib-in-newly-diagnosed--agio-20190603monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-the-randomized-phase-3-claridhy-trial-of-tibsovo-ivosidenib-achieved-its-p-agio-20190515monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-approval-of-supplemental-new-drug-application-snda-for-tibsovo-as-mono-agio-20190502monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-business-highlights-and-first-quarter-2019-financial-results-commercial-orga-agio-20190502monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2018-financial-results-strong-launch-of-tibsovo-agio-20190201monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-highlights-key-2019-initiatives-to-broaden-potential-for-late-stage-cancer-and-rare--agio-20190107monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-updated-data-from-phase-1-study-of-ivosidenib-or-enasidenib-in-combination-agio-20181203monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-data-from-phase-1-dose-escalation-study-of-ag-881-in-patients-with--agio-20181116monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-third-quarter-2018-financial-results-supplemental-new-drug-application-submi-agio-20181101monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-chief-executive-officer-succession-plan-david-schenkein-m-d-agios-long-tim-agio-20180905monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-second-quarter-2018-financial-results-tibsovo-launch-underway-post-fda-appro-agio-20180802monthly0.5https://www.biopharmawatch.com/news/AGIO/fda-grants-approval-of-tibsovo-the-first-oral-targeted-therapy-for-adult-patients-with-rel-agio-20180720monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-and-cstone-pharmaceuticals-announce-exclusive-collaboration-and-license-agreement-to-agio-20180626monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-data-from-phase-1-dose-escalation-study-of-ag-881-in-patients-with-idh-muta-agio-20180601monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-provides-business-update-on-discovery-research-strategy-and-pipeline-progress-on-cli-agio-20180504monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2017-financial-results-all-2017-key-milestones--agio-20180214monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-pricing-of-475-million-public-offering-of-common-stock-agio-20180118monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-outlines-key-2018-priorities-expanding-clinical-and-research-programs-to-drive-long--agio-20180108monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-data-from-drive-pk-study-demonstrating-ag-348-is-well-tolerated-and-agio-20171210monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-phase-1-data-from-dose-expansion-cohort-of-ivosidenib-ag-120-in-pat-agio-20171117monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-third-quarter-2017-financial-results-idhifa-approval-for-idh2m-r-r-aml-valid-agio-20171101monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-second-quarter-2017-financial-results-idhifa-enasidenib-granted-approval-fro-agio-20170808monthly0.5https://www.biopharmawatch.com/news/AGIO/fda-grants-approval-of-idhifa-the-first-oral-targeted-therapy-for-adult-patients-with-rela-agio-20170801monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-updated-data-from-fully-enrolled-drive-pk-study-demonstrating-ag-348-s-pot-agio-20170624monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-phase-1-data-from-dose-escalation-and-expansion-cohorts-of-ag-120-ivosideni-agio-20170603monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-first-quarter-2017-financial-results-idhifa-enasidenib-granted-priority-revi-agio-20170504monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-pricing-of-250-million-public-offering-of-common-stock-agio-20170418monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-mtap-pathway-research-program-as-development-program-and-development-candi-agio-20170313monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2016-financial-results-and-highlights-key-2017--agio-20170216monthly0.5https://www.biopharmawatch.com/news/AGIO/forward-looking-statements-this-presentation-and-various-remarks-we-make-during-this-prese-agio-20170109monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-provides-update-on-pkr-program-development-of-second-pkr-activator-ag-519-discontinu-agio-20161215monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-new-data-from-ag-348-and-ag-519-demonstrating-potential-for-first-disease--agio-20161204monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-phase-1-data-from-dose-expansion-cohorts-of-ag-120-in-patients-with-idh1-m-agio-20161118monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-third-quarter-2016-financial-results-and-reviews-recent-progress-in-idh-and--agio-20161103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-pricing-of-150-million-public-offering-of-common-stock-agio-20160914monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-andrew-hirsch-as-chief-financial-officer-cambridge-ma-agio-20160816monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-second-quarter-2016-financial-results-data-from-pkr-activators-at-eha-demons-agio-20160804monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-initial-data-from-phase-1-study-of-ag-519-in-healthy-volunteers-data-demonst-agio-20160609monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-and-celgene-establish-new-collaboration-in-metabolic-immuno-oncology-and-amend-certa-agio-20160517monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-first-quarter-2016-financial-results-five-abstracts-accepted-for-presentatio-agio-20160505monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2015-financial-results-and-highlights-key-2016--agio-20160218monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-steve-hoerter-as-chief-commercial-officer-agio-20160208monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-in-2016-jpmorgan-healthcare-conference-agio-20160111monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-data-from-ongoing-phase-1-trial-of-ag-120-showing-durable-responses-in-pat-agio-20151207monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-data-from-dose-escalation-phase-1-study-of-ag-120-in-patients-with-idh1-mu-agio-20151108monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-third-quarter-2015-financial-results-new-ag-221-and-ag-120-data-in-solid-tum-agio-20151105monthly0.5https://www.biopharmawatch.com/news/AGIO/what-s-possible-at-agios-agio-20151016monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-second-quarter-2015-financial-results-and-provides-updates-on-clinical-devel-agio-20150806monthly0.5https://www.biopharmawatch.com/news/STAA/reconciliation-of-non-gaap-financial-measure-constant-currency-sales-in-000-s-unaudited-th-staa-20260513monthly0.5https://www.biopharmawatch.com/news/STAA/reconciliation-of-non-gaap-financial-measure-constant-currency-sales-in-000-s-unaudited-th-staa-20260303monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-preliminary-results-of-special-meeting-of-stockholders-staar-inte-staa-20260106monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-expiration-of-go-shop-period-no-competing-acquisition-proposals-r-staa-20251208monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-amendments-to-alcon-merger-agreement-30-day-go-shop-period-to-act-staa-20251107monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-2025-results-staa-20251105monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-sets-new-record-date-and-postpones-staar-special-meeting-of-stockholders-in-staa-20251027monthly0.5https://www.biopharmawatch.com/news/STAA/alcon-and-staar-surgical-announce-adjournment-of-staar-special-meeting-of-stockholders-gen-staa-20251023monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-preliminary-net-sales-results-for-third-quarter-2025-staa-20251020monthly0.5https://www.biopharmawatch.com/news/STAA/additional-information-about-the-merger-and-where-to-find-it-this-presentation-relates-to--staa-20250916monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-second-quarter-2025-results-staa-20250806monthly0.5https://www.biopharmawatch.com/news/STAA/alcon-agrees-to-acquire-staar-surgical-staar-surgical-is-a-leader-in-refractive-surgery-us-staa-20250805monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-appointment-of-deborah-andrews-as-chief-financial-officer-forms-c-staa-20250625monthly0.5https://www.biopharmawatch.com/news/STAA/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-staa-20250604monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-30-million-share-repurchase-authorization-staa-20250516monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-first-quarter-2025-results-china-icl-procedure-trends-improving-tar-staa-20250507monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-changes-to-board-of-directors-lake-forest-ca-x2013-staa-20250424monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-realignment-of-leadership-structure-warren-foust-named-president--staa-20250317monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-leadership-transition-stephen-c-farrell-appointed-ceo-to-succeed--staa-20250226monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-fiscal-year-2024-results-net-sales-of-313-9-mill-staa-20250211monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-to-host-fourth-quarter-and-fiscal-year-2024-earnings-conference-call-and-we-staa-20250113monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-2024-results-net-sales-up-10-to-88-6-million-driven-b-staa-20241030monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-second-quarter-2024-results-record-quarterly-net-sales-of-99-0-mill-staa-20240807monthly0.5https://www.biopharmawatch.com/news/STAA/all-statements-that-are-not-statements-of-historical-fact-are-forward-looking-statements-i-staa-20240612monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-first-quarter-2024-results-evo-icl-continues-to-outpace-refractive--staa-20240507monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-preliminary-net-sales-for-first-quarter-2024-total-net-sales-in-e-staa-20240404monthly0.5https://www.biopharmawatch.com/news/STAA/all-statements-that-are-not-statements-of-historical-fact-are-forward-looking-statements-i-staa-20240318monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-adds-arthur-butcher-and-wei-jiang-to-board-of-directors-staa-20240312monthly0.5https://www.biopharmawatch.com/news/STAA/february-26-2024-9-15pm-staa-oq-q4-2023-staar-surgical-co-earnings-call-february-26-2024-9-staa-20240226monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-fiscal-year-2023-results-generates-double-digit--staa-20240226monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-preliminary-results-for-fourth-quarter-and-fiscal-2023-net-sales--staa-20240108monthly0.5https://www.biopharmawatch.com/news/STAA/lilian-zhou-appointed-to-staar-surgical-board-of-directors-staa-20231204monthly0.5https://www.biopharmawatch.com/news/STAA/all-statements-that-are-not-statements-of-historical-fact-are-forward-looking-statements-i-staa-20231116monthly0.5https://www.biopharmawatch.com/news/STAA/november-01-2023-8-30pm-staa-oq-q3-2023-staar-surgical-co-earnings-call-patrick-f-williams-staa-20231102monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-2023-results-net-sales-of-80-3-million-icl-sales-of-8-staa-20231101monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-vision-2026-staar-surgical-investor-day-september14-2023-nasdaq-staa-agenda-staa-20230914monthly0.5https://www.biopharmawatch.com/news/STAA/investor-presentation-staar-surgical-nasdaq-staa-august-2023-forward-looking-statements-al-staa-20230809monthly0.5https://www.biopharmawatch.com/news/STAA/refinitiv-streetevents-edited-transcript-staa-oq-q2-2023-staar-surgical-co-earnings-call-e-staa-20230802monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-second-quarter-2023-results-record-icl-sales-of-93-1million-up-19-y-staa-20230802monthly0.5https://www.biopharmawatch.com/news/STAA/company-name-staar-surgical-company-staa-event-william-blair-43rd-annual-growth-stock-conf-staa-20230606monthly0.5https://www.biopharmawatch.com/news/STAA/all-statements-that-are-not-statements-of-historical-fact-are-forward-looking-statements-i-staa-20230606monthly0.5https://www.biopharmawatch.com/news/STAA/may-03-2023-8-30pm-staa-oq-q1-2023-staar-surgical-co-earnings-call-c-o-r-p-o-r-a-t-e-p-a-r-staa-20230503monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-first-quarter-2023-results-q1-2023-net-sales-of-73-5-million-icl-sa-staa-20230503monthly0.5https://www.biopharmawatch.com/news/STAA/magda-michna-ph-d-chief-clinical-regulatory-and-medical-affairs-officer-staar-surgical-com-staa-20230329monthly0.5https://www.biopharmawatch.com/news/STAA/all-statements-that-are-not-statements-of-historical-fact-are-forward-looking-statements-i-staa-20230314monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-fiscal-year-2022-results-icl-unit-growth-up-33-y-staa-20230221monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-preliminary-sales-for-fourth-quarter-and-fiscal-2022-icl-unit-growt-staa-20230109monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-ceo-caren-mason-to-retire-tom-frinzi-appointed-new-ceo-ophthalmic-industry--staa-20221219monthly0.5https://www.biopharmawatch.com/news/STAA/november-02-2022-8-30pm-staa-oq-q3-2022-staar-surgical-co-earnings-call-c-o-r-p-o-r-a-t-e--staa-20221102monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-net-sales-of-76-million-up-30-y-y-icl-units-up-40-y-y-staa-20221102monthly0.5https://www.biopharmawatch.com/news/STAA/august-10-2022-8-30pm-staa-oq-q2-2022-staar-surgical-co-earnings-call-c-o-r-p-o-r-a-t-e-p--staa-20220810monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-record-second-quarter-net-sales-of-81-1-million-up-30-y-y-icl-units-staa-20220810monthly0.5https://www.biopharmawatch.com/news/STAA/all-statements-that-are-not-statements-of-historical-fact-are-forward-looking-statements-i-staa-20220607monthly0.5https://www.biopharmawatch.com/news/STAA/may-04-2022-8-30pm-staa-oq-q1-2022-staar-surgical-co-earnings-call-d-i-s-c-l-a-i-m-e-r-ref-staa-20220506monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-record-first-quarter-net-sales-of-63-2-million-up-25-y-y-evo-visian-staa-20220504monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-first-implants-of-evo-visian-icl-in-the-u-s-announces-program-of--staa-20220406monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-u-s-fda-approval-of-evo-visian-implantable-collamer-lenses-evo-le-staa-20220328monthly0.5https://www.biopharmawatch.com/news/STAA/february-23-2022-9-30pm-staa-oq-q4-2021-staar-surgical-co-earnings-call-caren-l-mason-staa-staa-20220224monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-full-year-2021-results-staa-20220223monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-investor-presentation-nasdaq-staa-february-2022-all-statements-that-are-not-staa-20220201monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-preliminary-fourth-quarter-and-full-year-2021-results-achieves-40-staa-20220110monthly0.5https://www.biopharmawatch.com/news/STAA/refinitiv-streetevents-www-refinitiv-com-contact-us-2021-refinitiv-all-rights-reserved-rep-staa-20211104monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-net-sales-of-58-4-million-up-24-y-y-third-quarter-icl-staa-20211103monthly0.5https://www.biopharmawatch.com/news/STAA/forward-looking-statements-all-statements-that-are-not-statements-of-historical-fact-are-f-staa-20210810monthly0.5https://www.biopharmawatch.com/news/STAA/august-04-2021-8-30pm-staa-oq-q2-2021-staar-surgical-co-earnings-call-caren-l-mason-staar--staa-20210805monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-record-second-quarter-net-sales-of-62-4-million-up-77-y-y-and-incre-staa-20210804monthly0.5https://www.biopharmawatch.com/news/STAA/forward-looking-statements-all-statements-that-are-not-statements-of-historical-fact-are-f-staa-20210527monthly0.5https://www.biopharmawatch.com/news/STAA/kick-in-the-gear-here-and-then-the-follow-up-would-be-specifically-on-the-us-and-eu-implan-staa-20210506monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-record-first-quarter-2021-net-sales-of-50-8-million-up-44-y-y-first-staa-20210505monthly0.5https://www.biopharmawatch.com/news/STAA/thank-you-operator-and-thanks-everyone-for-your-participation-on-our-call-today-we-look-fo-staa-20210225monthly0.5https://www.biopharmawatch.com/news/STAA/consolidated-statements-of-cash-flows-in-000-s-unaudited-three-months-ended-twelve-months--staa-20210224monthly0.5https://www.biopharmawatch.com/news/STAA/elizabeth-yeu-m-d-and-k-peony-yu-m-d-appointed-to-staar-surgical-board-of-directors-staa-20210126monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-preliminary-fourth-quarter-and-full-year-2020-results-net-sales-a-staa-20210110monthly0.5https://www.biopharmawatch.com/news/STAA/sure-just-as-a-reminder-bruce-last-year-we-switched-from-our-normal-sequential-growth-quar-staa-20201105monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-2020-results-staa-20201104monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-completion-of-patient-enrollment-in-evo-implantable-lens-us-clini-staa-20200914monthly0.5https://www.biopharmawatch.com/news/STAA/forward-looking-statements-all-statements-in-this-presentation-that-are-not-statements-of--staa-20200902monthly0.5https://www.biopharmawatch.com/news/STAA/forward-looking-statements-all-statements-in-this-presentation-that-are-not-statements-of--staa-20200811monthly0.5https://www.biopharmawatch.com/news/STAA/so-thank-you-for-your-participation-on-our-call-today-we-look-forward-to-speaking-with-man-staa-20200807monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-second-quarter-2020-results-staa-20200805monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-introduces-evo-viva-presbyopia-correcting-lens-see-young-again-receives-ce--staa-20200707monthly0.5https://www.biopharmawatch.com/news/STAA/patrick-f-williams-appointed-chief-financial-officer-of-staar-surgical-deborah-andrews-to--staa-20200706monthly0.5https://www.biopharmawatch.com/news/STAA/forward-looking-statements-all-statements-in-this-presentation-that-are-not-statements-of--staa-20200602monthly0.5https://www.biopharmawatch.com/news/STAA/dr-gil-kliman-and-tom-frinzi-appointed-to-staar-surgical-board-of-directors-staa-20200601monthly0.5https://www.biopharmawatch.com/news/STAA/productivity-and-we-know-we-will-have-the-inventory-necessary-for-demand-as-we-see-it-goin-staa-20200507monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-first-quarter-2020-results-staa-20200506monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-provides-covid-19-business-update-staa-20200413monthly0.5https://www.biopharmawatch.com/news/STAA/caren-mason-president-chief-executive-officer-director-staar-surgical-the-edof-toric-pilot-staa-20200227monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-full-year-2019-results-staa-20200226monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-the-evo-implantable-lens-us-clinical-trial-is-underway-with-1st-p-staa-20200204monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-preliminary-fourth-quarter-net-sales-growth-of-25-achieves-33-icl-u-staa-20200113monthly0.5https://www.biopharmawatch.com/news/STAA/staar-cfo-to-retire-in-2020-deborah-andrews-plans-to-retire-after-24-years-with-the-compan-staa-20191218monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-fda-ide-clinical-study-approval-evo-evo-visian-implantable-collam-staa-20191211monthly0.5https://www.biopharmawatch.com/news/STAA/forward-looking-statements-all-statements-in-this-presentation-that-are-not-statements-of--staa-20191108monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-results-staa-20191030monthly0.5https://www.biopharmawatch.com/news/STAA/release-see-staar-s-annual-report-on-form-10-k-for-the-year-ended-staa-20190827monthly0.5https://www.biopharmawatch.com/news/STAA/forward-looking-statements-all-statements-in-this-presentation-that-are-not-statements-of--staa-20190807monthly0.5https://www.biopharmawatch.com/news/STAA/yes-i-mean-if-you-look-at-the-calendarization-of-sales-last-year-you-are-going-to-see-simi-staa-20190801monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-reconciliation-of-non-gaap-financial-measure-constant-currency-sale-staa-20190731monthly0.5https://www.biopharmawatch.com/news/STAA/staa-ex991-16-pptx-htm-staar-surgical-nasdaq-staa-www-staar-com-www-discoverevo-com-invest-staa-20190605monthly0.5https://www.biopharmawatch.com/news/STAA/forward-looking-statements-all-statements-in-this-presentation-that-are-not-statements-of--staa-20190515monthly0.5https://www.biopharmawatch.com/news/STAA/welcoming-a-ubs-investor-bus-tour-at-our-lake-forest-headquarters-on-may-16th-and-we-look--staa-20190503monthly0.5https://www.biopharmawatch.com/news/STAA/reconciliation-of-non-gaap-financial-measure-in-000-s-unaudited-three-months-ended-staa-20190501monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-nasdaq-staa-investor-presentation-staa-20190228monthly0.5https://www.biopharmawatch.com/news/STAA/presentation-operator-good-day-ladies-and-gentlemen-thank-you-for-standing-by-welcome-to-t-staa-20190221monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-full-year-2018-results-fourth-quarter-icl-sales--staa-20190221monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-nasdaq-staa-investor-presentation-january-17-2019-staa-20190117monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-nasdaq-staa-investor-presentation-staa-20190107monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-expects-fourth-quarter-icl-sales-to-rise-42-china-units-nearly-double-u-s-m-staa-20190107monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-nasdaq-staa-investor-presentation-november-2018-staa-20181106monthly0.5https://www.biopharmawatch.com/news/STAA/presentation-operator-good-day-ladies-and-gentlemen-thank-you-for-standing-by-welcome-to-t-staa-20181031monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-icl-sales-up-46-company-raises-outlook-for-full-year-2018-monrovia-ca-staa-20181031monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-approval-by-the-fda-of-the-visian-toric-icl-for-the-correction-of-staa-20180913monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-nasdaq-staa-staa-20180822monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-canaccord-growth-conference-nasdaq-staa-staa-20180808monthly0.5https://www.biopharmawatch.com/news/STAA/operator-good-day-ladies-and-gentlemen-thank-you-for-standing-by-welcome-to-the-staar-surg-staa-20180801monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-icl-sales-up-67-company-raises-outlook-for-2018-monrovia-ca-staa-20180801monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-resolution-of-fda-warning-letter-monrovia-ca-staa-20180620monthly0.5https://www.biopharmawatch.com/news/STAA/may-02-2018-4-30pm-edt-q1-2018-staar-surgical-co-earnings-call-presentation-operator-good--staa-20180502monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-first-quarter-2018-results-revenue-increases-33-percent-on-accelera-staa-20180502monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-investor-presentation-nasdaq-staa-march-2018-evolution-in-visual-fr-staa-20180313monthly0.5https://www.biopharmawatch.com/news/STAA/operator-good-day-ladies-and-gentlemen-thank-you-for-standing-by-welcome-to-the-staar-surg-staa-20180228monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-full-year-2017-results-monrovia-ca-staa-20180228monthly0.5https://www.biopharmawatch.com/news/STAA/a-leading-developer-manufacturer-and-marketer-of-premium-implantable-lenses-for-refractive-staa-20180108monthly0.5https://www.biopharmawatch.com/news/STAA/a-leading-developer-manufacturer-and-marketer-of-premium-implantable-lenses-for-refractive-staa-20171116monthly0.5https://www.biopharmawatch.com/news/STAA/operator-good-day-ladies-and-gentlemen-thank-you-for-standing-by-welcome-to-the-staar-surg-staa-20171108monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-2017-results-monrovia-ca-staa-20171108monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-appoints-scott-d-barnes-m-d-as-chief-medical-officer-distinguished-ophthalm-staa-20171002monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-names-deborah-andrews-as-cfo-surindra-mann-joins-staar-as-vice-president-gl-staa-20170928monthly0.5https://www.biopharmawatch.com/news/STAA/investor-presentation-nasdaq-staa-september-2017-evolution-in-visual-freedom-building-a-fo-staa-20170920monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-and-seoul-busan-balgeunsesang-eye-clinic-announce-strategic-cooperation-agr-staa-20170815monthly0.5https://www.biopharmawatch.com/news/STAA/investor-presentation-nasdaq-staa-august-2017-evolution-in-visual-freedom-building-a-found-staa-20170808monthly0.5https://www.biopharmawatch.com/news/STAA/operator-good-day-ladies-and-gentlemen-thank-you-for-standing-by-welcome-to-the-staar-surg-staa-20170802monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-second-quarter-2017-results-monrovia-ca-staa-20170802monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-ce-mark-approval-for-the-evo-visian-icl-with-aspheric-edof-optic--staa-20170511monthly0.5https://www.biopharmawatch.com/news/STAA/operator-good-day-ladies-and-gentlemen-thank-you-for-standing-by-welcome-to-the-staar-surg-staa-20170503monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-first-quarter-2017-results-monrovia-ca-staa-20170503monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-names-deborah-andrews-interim-cfo-steve-brown-resignation-effective-staa-20170405monthly0.5https://www.biopharmawatch.com/news/STAA/brian-moore-staar-surgical-company-evc-group-ir-thank-you-vince-good-afternoon-everyone-th-staa-20170303monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-staa-20170302monthly0.5https://www.biopharmawatch.com/news/STAA/investor-presentation-january-10-11-2017-evolution-in-visual-freedom-staa-nasdaq-building--staa-20170110monthly0.5https://www.biopharmawatch.com/news/STAA/edited-transcript-staa-q3-2016-staar-surgical-co-earnings-call-event-date-time-november-03-staa-20161103monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-staa-20161103monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-approval-by-health-canada-of-its-evo-visian-icl-toric-lens-specif-staa-20160922monthly0.5https://www.biopharmawatch.com/news/STAA/leading-refractive-surgery-provider-eyeq-vision-private-ltd-gurgaon-india-and-staar-surgic-staa-20160915monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-strategic-cooperation-agreement-with-world-eye-hospital-group-wit-staa-20160907monthly0.5https://www.biopharmawatch.com/news/STAA/c-anaccord-g-rowth-c-onference-a-ugust-10-2016-evolution-in-visual-freedom-1-building-a-fo-staa-20160810monthly0.5https://www.biopharmawatch.com/news/STAA/transcript-staa-q2-2016-staar-surgical-co-earnings-call-event-date-time-august-03-2016-04--staa-20160803monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-second-quarter-2016-results-monrovia-ca-staa-20160803monthly0.5https://www.biopharmawatch.com/news/STAA/j-efferies-h-ealthcare-conference-j-une-10-2016-evolution-in-visual-freedom-building-a-fou-staa-20160610monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-announces-approval-by-health-canada-of-its-evo-visian-icl-for-surgeons-and--staa-20160513monthly0.5https://www.biopharmawatch.com/news/STAA/transcript-of-staa-earnings-conference-call-staa-20160511monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-first-quarter-2016-results-monrovia-ca-staa-20160511monthly0.5https://www.biopharmawatch.com/news/STAA/edited-transcript-of-staa-earnings-conference-call-or-presentation-2-mar-16-4-30pm-et-corp-staa-20160303monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-full-year-2015-results-monrovia-ca-staa-20160302monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-and-aier-eye-hospital-group-announce-strategic-cooperation-agreement-agreem-staa-20160216monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-company-and-memira-holding-announce-cooperation-agreement-for-memira-s-eye--staa-20160209monthly0.5https://www.biopharmawatch.com/news/STAA/investor-update-january-11-12-2016-1-nasdaq-staa-all-statements-in-this-presentation-that--staa-20160111monthly0.5https://www.biopharmawatch.com/news/STAA/stephen-c-farrell-appointed-to-staar-surgical-board-of-directors-company-also-reports-adop-staa-20151217monthly0.5https://www.biopharmawatch.com/news/STAA/event-name-q3-2015-staar-surgical-co-earnings-call-event-date-2015-10-28-4-30-pm-et-presen-staa-20151028monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-2015-results-monrovia-ca-staa-20151028monthly0.5https://www.biopharmawatch.com/news/STAA/william-p-wall-appointed-to-staar-surgical-board-of-directors-monrovia-ca-staa-20150902monthly0.5https://www.biopharmawatch.com/news/STAA/dr-keith-holliday-named-vice-president-research-and-development-for-staar-surgical-monrovi-staa-20150806monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-second-quarter-2015-results-monrovia-ca-staa-20150729monthly0.5https://www.biopharmawatch.com/news/STAA/dr-jon-k-hayashida-named-vice-president-global-clinical-and-medical-affairs-for-staar-surg-staa-20150723monthly0.5https://www.biopharmawatch.com/news/STAA/nasdaq-staa-may-7-th-1-all-statements-in-this-presentation-that-are-not-statements-of-hist-staa-20150429monthly0.5https://www.biopharmawatch.com/news/STAA/corporate-participants-brian-moore-evc-group-ir-caren-mason-staar-surgical-president-ceo-s-staa-20150501monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-first-quarter-2015-results-monrovia-ca-staa-20150429monthly0.5https://www.biopharmawatch.com/news/STAA/j-steven-roush-cpa-appointed-to-staar-surgical-board-of-directors-monrovia-ca-staa-20150421monthly0.5https://www.biopharmawatch.com/news/STAA/thomson-reuters-streetevents-edited-transcript-staa-q4-2014-staar-surgical-co-earnings-cal-staa-20150303monthly0.5https://www.biopharmawatch.com/news/STAA/caren-mason-appointed-president-ceo-of-staar-surgical-company-accomplished-leader-brings-b-staa-20150303monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-fourth-quarter-and-full-year-2014-results-total-sales-of-16-6-milli-staa-20150225monthly0.5https://www.biopharmawatch.com/news/STAA/nasdaq-staa-staa-20141120monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-third-quarter-results-total-sales-increase-to-18-2m-from-17-1m-in-q-staa-20141030monthly0.5https://www.biopharmawatch.com/news/STAA/louis-silverman-appointed-to-staar-surgical-board-of-directors-appointment-of-healthcare-i-staa-20140915monthly0.5https://www.biopharmawatch.com/news/STAA/thomson-reuters-streetevents-edited-transcript-staa-q2-2014-staar-surgical-co-earnings-cal-staa-20140801monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-10-second-quarter-revenue-growth-total-sales-increased-to-20-0m-fro-staa-20140730monthly0.5https://www.biopharmawatch.com/news/STAA/caren-mason-elected-to-staar-s-board-of-directors-stockholders-approve-all-proposals-at-co-staa-20140610monthly0.5https://www.biopharmawatch.com/news/STAA/visian-icl-fastest-growing-refractive-technology-in-the-world-nasdaq-staa-staa-20140507monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-12-first-quarter-2014-revenue-growth-total-sales-of-20-2m-increased-staa-20140428monthly0.5https://www.biopharmawatch.com/news/STAA/visian-icl-fastest-growing-refractive-technology-in-the-world-non-deal-roadshow-april-2014-staa-20140416monthly0.5https://www.biopharmawatch.com/news/STAA/visian-icl-fastest-growing-refractive-technology-in-the-world-sidoti-eighteenth-annual-eme-staa-20140317monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-15-fourth-quarter-revenue-growth-and-13-full-year-2013-total-sales--staa-20140226monthly0.5https://www.biopharmawatch.com/news/STAA/kathryn-tunstall-appointed-to-staar-surgical-board-of-directors-appointment-expands-board--staa-20140130monthly0.5https://www.biopharmawatch.com/news/STAA/visian-icl-fastest-growing-refractive-technology-in-the-world-january-2014-nasdaq-staa-all-staa-20140113monthly0.5https://www.biopharmawatch.com/news/STAA/visian-icl-fastest-growing-refractive-technology-in-the-world-december-2013-nasdaq-staa-al-staa-20131202monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-continued-momentum-staa-20131030monthly0.5https://www.biopharmawatch.com/news/STAA/stephen-p-brown-appointed-chief-financial-officer-at-staar-surgical-company-deborah-andrew-staa-20130909monthly0.5https://www.biopharmawatch.com/news/STAA/visian-icl-fastest-growing-refractive-technology-in-the-world-staa-20130814monthly0.5https://www.biopharmawatch.com/news/STAA/investors-media-evc-group-evc-group-douglas-sherk-415-652-9100-chris-gale-646-201-5431-lei-staa-20130731monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-gains-regulatory-approvals-for-visian-icl-with-centraflow-technology-in-kor-staa-20130617monthly0.5https://www.biopharmawatch.com/news/STAA/nasdaq-staa-visian-icl-fastest-growing-technology-in-the-world-may-2013-forward-looking-st-staa-20130507monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-strong-first-quarter-2013-financial-results-total-sales-of-18-milli-staa-20130501monthly0.5https://www.biopharmawatch.com/news/STAA/nasdaq-staa-fastest-growing-refractive-technology-in-t-he-world-april-2013-forward-looking-staa-20130410monthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-provides-preliminary-first-quarter-revenue-results-visian-icl-revenue-incre-staa-20130408monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-names-ryan-stafford-general-counsel-and-senior-vice-president-of-human-re-ufpt-20260604monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-announces-strong-q1-results-newburyport-mass-ufpt-20260504monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-announces-record-2025-results-newburyport-mass-ufpt-20260224monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-announces-strong-q3-2025-results-newburyport-mass-ufpt-20251103monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2022-welcome-investors-august-2025-ufpt-20250821monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2022-welcome-investors-june-2025-ufpt-20250610monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2022-welcome-investors-august-2024-ufpt-20240826monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2022-welcome-investors-june-2024-ufpt-20240611monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2022-welcome-investors-november-2023-ufpt-20231128monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2022-welcome-investors-august-2023-ufpt-20230821monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2022-welcome-investors-june-2023-ufpt-20230613monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2022-welcome-investors-march-2023-ufpt-20230321monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-november-16-2022-ufpt-20221115monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-september-21-2022-ufpt-20220920monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-june-16-2022-ufpt-20220614monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-september-2021-ufpt-20210921monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-august-2021-ufpt-20210825monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-june-2021-ufpt-20210615monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-march-2021-ufpt-20210323monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-november-2020-ufpt-20201117monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-august-2020-ufpt-20200825monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-november-20-2019-draft-11-13-2019-2-50pm-ufpt-20191115monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-august-28-2019-ufpt-20190826monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-june-12-2019-ufpt-20190610monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-november-14-2018-ufpt-20181113monthly0.5https://www.biopharmawatch.com/news/UFPT/welcome-investors-august-29-2018-ufpt-20180828monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-100-hale-street-contact-ron-lataille-newburyport-ma-0195-ufpt-20160802monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-100-hale-street-contact-ron-lataille-newburyport-ma-0195-ufpt-20160504monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-100-hale-street-contact-ron-lataille-newburyport-ma-0195-ufpt-20160301monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-contact-ron-lataille-978-ufpt-20151216monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20151104monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20150804monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-announces-stock-repurchase-program-ufpt-20150616monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20150505monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20150303monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20141104monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20140805monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20140506monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20140227monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-tel-978-352-2200-172-east-main-street-www-ufpt-com-georgetown-ma-0183-ufpt-20131105monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20130917monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20130801monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20130503monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20130228monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-tel-978-352-2200-172-east-main-street-www-ufpt-com-georgetown-ma-0183-ufpt-20121101monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-tel-978-352-2200-172-east-main-street-www-ufpt-com-georgetown-ma-0183-ufpt-20120802monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20120503monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-www-ufpt-com-172-east-main-street-contact-ron-lataille-georgetown-ma--ufpt-20120223monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20111103monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20110803monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20110504monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20110223monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20101103monthly0.5https://www.biopharmawatch.com/news/UFPT/ufp-technologies-inc-172-east-main-street-georgetown-ma-01833-usa-tel-978-352-2200-www-ufp-ufpt-20100803monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-leadership-transition-albert-a-manzone-appointed-interim-president-and-c-prgo-20260608monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reconciliation-of-non-gaap-measures-select-consolidated-information-qu-prgo-20260422monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-second-quarter-2025-financial-results-from-continuing-operations-company-a-prgo-20250806monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-proposed-divestiture-of-dermacosmetics-business-for-up-to-327-million-pr-prgo-20250714monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-strategic-organizational-update-to-drive-sustainable-growth-and-performa-prgo-20250701monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-global-operations-and-supply-chain-leadership-transition-ron-janish-evp--prgo-20250604monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-first-quarter-2025-financial-results-from-continuing-operations-advancing--prgo-20250507monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-fourth-quarter-fiscal-year-2024-financial-results-from-continuing-operatio-prgo-20250227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-third-quarter-2024-financial-results-from-continuing-operations-company-de-prgo-20241106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-closing-of-a-senior-notes-offering-by-its-finance-subsidiary-perrigo-prgo-20240917monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-second-quarter-2024-financial-results-from-continuing-operations-delivered-prgo-20240802monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-divestment-of-hra-pharma-rare-diseases-business-dublin-ireland-prgo-20240710monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-first-quarter-2024-financial-results-from-continuing-operations-delivered--prgo-20240507monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-fourth-quarter-fiscal-year-2023-financial-results-from-continuing-operatio-prgo-20240227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-early-results-of-cash-tender-offer-for-notes-dublin-prgo-20231129monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-cash-tender-offer-for-notes-dublin-prgo-20231110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-third-quarter-fiscal-year-2023-financial-results-from-continuing-operation-prgo-20231107monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-second-quarter-fiscal-year-2023-financial-results-from-continuing-operatio-prgo-20230808monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-chief-executive-officer-retirement-and-succession-plan-dublin-ireland-prgo-20230509monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-first-quarter-fiscal-year-2023-financial-results-from-continuing-operation-prgo-20230509monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-fourth-quarter-fiscal-year-2022-financial-results-from-continuing-operatio-prgo-20230228monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-third-quarter-fiscal-year-2022-financial-results-from-continuing-operation-prgo-20221108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-second-quarter-fiscal-year-2022-financial-results-from-continuing-operatio-prgo-20220809monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-first-quarter-fiscal-year-2022-financial-results-from-continuing-operation-prgo-20220511monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-planned-leadership-succession-mr-eduardo-g-bezerra-named-evp-chief-finan-prgo-20220511monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-the-acquisition-of-hra-pharma-dublin-ireland-prgo-20220502monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-expected-transaction-close-date-of-hra-pharma-dublin-ireland-prgo-20220428monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-closing-of-2-6-billion-senior-secured-credit-facilities-dublin-ireland-prgo-20220420monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-launch-of-private-notes-offering-dublin-ireland-prgo-20220404monthly0.5https://www.biopharmawatch.com/news/PRGO/non-gaap-disclosure-the-following-provides-a-reconciliation-of-pro-forma-ebitda-and-pro-fo-prgo-20220328monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-fourth-quarter-fiscal-year-2021-financial-results-from-continuing-operatio-prgo-20220301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-third-quarter-2021-financial-results-from-continuing-operations-major-stra-prgo-20211110monthly0.5https://www.biopharmawatch.com/news/PRGO/for-release-perrigo-to-acquire-leading-consumer-self-care-company-hra-pharma-transaction-w-prgo-20210908monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-second-quarter-2021-financial-results-from-continuing-operations-fiscal-20-prgo-20210811monthly0.5https://www.biopharmawatch.com/news/PRGO/unaudited-pro-forma-financial-information-in-millions-except-share-information-on-prgo-20210706monthly0.5https://www.biopharmawatch.com/news/PRGO/for-release-perrigo-reports-first-quarter-2021-financial-results-from-continuing-operation-prgo-20210511monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-fourth-quarter-fiscal-year-2020-financial-results-consumer-transformation--prgo-20210301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-third-quarter-2020-financial-results-consolidated-third-quarter-net-sales--prgo-20201104monthly0.5https://www.biopharmawatch.com/news/PRGO/for-release-perrigo-company-plc-reports-second-quarter-2020-financial-results-consolidated-prgo-20200805monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-closing-of-a-senior-notes-offering-by-its-finance-subsidiary-perrigo-prgo-20200619monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-first-quarter-2020-financial-results-reports-record-first-quar-prgo-20200430monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-preliminary-unaudited-first-quarter-2020-net-sales-and-provides-first-qu-prgo-20200407monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-fourth-quarter-fiscal-year-2019-financial-results-reports-reco-prgo-20200227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-provide-self-care-transformation-update-at-j-p-morgan-healthcare-conference-ann-prgo-20200114monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-third-quarter-2019-financial-results-continues-successful-tran-prgo-20191106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-second-quarter-2019-financial-results-reaffirms-outlook-progre-prgo-20190808monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-selected-segment-information-quarters-and-fiscal-year-2016-in-millions-prgo-20190508monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-first-quarter-2019-financial-results-begins-consumer-self-care-prgo-20190508monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-2018-fourth-quarter-and-full-year-financial-results-full-year--prgo-20190227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-third-quarter-2018-financial-results-realized-third-quarter-20-prgo-20181108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-second-quarter-2018-financial-results-realized-second-quarter--prgo-20180809monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-first-quarter-2018-financial-results-realized-first-quarter-20-prgo-20180508monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-fourth-quarter-calendar-year-2017-financial-results-fourth-qua-prgo-20180301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-select-preliminary-unaudited-calendar-year-2017-financial-resu-prgo-20180227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-third-quarter-2017-financial-results-delivered-third-quarter-2-prgo-20171109monthly0.5https://www.biopharmawatch.com/news/PRGO/exhibit-for-immediate-release-perrigo-company-plc-reports-second-quarter-2017-financial-re-prgo-20170810monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-early-tender-results-for-cash-tender-offer-dublin-prgo-20170614monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-forthcoming-retirement-of-ceo-john-hendrickson-dublin-ireland-prgo-20170605monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-1-400-000-000-cash-tender-offer-for-certain-notes-dublin-prgo-20170531monthly0.5https://www.biopharmawatch.com/news/PRGO/exhibit-for-immediate-release-perrigo-company-plc-files-first-quarter-2017-form-10-q-and-r-prgo-20170531monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-selected-consolidated-information-quarters-and-calendar-year-to-date-2-prgo-20170523monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-files-2016-form-10-k-with-restated-financial-statements-reports-fourth-quarter-and-prgo-20170523monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-restatement-of-previously-issued-forms-10-k-and-10-q-financial-statement-prgo-20170425monthly0.5https://www.biopharmawatch.com/news/PRGO/dublin-ireland-february-27-2017-perrigo-company-plc-nyse-tase-prgo-a-leading-global-provid-prgo-20170227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-selected-segment-information-quarters-and-calendar-year-to-date-2016-i-prgo-20170110monthly0.5https://www.biopharmawatch.com/news/PRGO/exhibit-for-immediate-release-perrigo-company-plc-reports-third-quarter-2016-financial-res-prgo-20161107monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-second-quarter-2016-financial-results-delivered-second-quarter-prgo-20160810monthly0.5https://www.biopharmawatch.com/news/PRGO/correcting-and-replacing-gaap-net-loss-on-consolidated-statement-of-operations-for-first-q-prgo-20160512monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-first-quarter-2016-financial-results-delivered-record-first-qu-prgo-20160512monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-the-pricing-of-a-senior-notes-offering-by-its-finance-subsid-prgo-20160308monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-proposed-public-offering-of-senior-notes-of-its-finance-subs-prgo-20160307monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-record-fourth-quarter-calendar-year-net-sales-and-adjusted-net-prgo-20160218monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-increases-2016-full-year-adjusted-earnings-per-share-guidance-expects--prgo-20160111monthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-announces-u-s-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conventional-ch-inbx-20260615monthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-first-quarter-2025-financial-results-san-diego-ca-inbx-20250514monthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-fourth-quarter-and-fiscal-year-2024-financial-results-san-diego-ca-inbx-20250317monthly0.5https://www.biopharmawatch.com/news/INBX/document-inhibrx-biosciences-announces-preliminary-data-from-the-phase-1-trial-of-ozekibar-inbx-20250121monthly0.5https://www.biopharmawatch.com/news/INBX/document-inhibrx-biosciences-announces-loan-agreement-with-oxford-finance-san-diego-ca-inbx-20250113monthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-biosciences-reports-third-quarter-2024-financial-results-san-diego-ca-inbx-20241114monthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-biosciences-reports-second-quarter-2024-financial-results-and-recent-corporate-hig-inbx-20240813monthly0.5https://www.biopharmawatch.com/news/INBX/table-of-contents-inhibrx-biosciences-inc-11025-n-torrey-pines-road-suite-140-la-jolla-cal-inbx-20240524monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-publication-of-phase-2a-postpartum-depression-results-dublin-ireland-ghrs-20260604monthly0.5https://www.biopharmawatch.com/news/GHRS/apparent-sadness-reported-sadness-concentration-difficulty-lassitude-inability-to-feel-mea-ghrs-20260521monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-unaudited-condensed-consolidated-interim-statement-of-comprehensive-loss-t-ghrs-20260514monthly0.5https://www.biopharmawatch.com/news/GHRS/notice-of-annual-general-meeting-to-be-held-on-25-june-2026-gh-research-plc-the-company-or-ghrs-20260513monthly0.5https://www.biopharmawatch.com/news/GHRS/exploring-the-therapeutic-potential-of-mebufotenin-gh001-across-depressive-disorders-acnp--ghrs-20260115monthly0.5https://www.biopharmawatch.com/news/GHRS/gh001-improves-illness-severity-anxiety-symptoms-and-quality-of-life-in-patients-with-trea-ghrs-20260113monthly0.5https://www.biopharmawatch.com/news/GHRS/figure-3-double-blind-part-madrs-suicidality-item-10-responses-at-baseline-and-day-8-gh001-ghrs-20260108monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-to-announce-ind-status-for-gh001-dublin-ghrs-20260102monthly0.5https://www.biopharmawatch.com/news/GHRS/gh001-improves-illness-severity-anxiety-symptoms-and-quality-of-life-in-patients-with-trea-ghrs-20251124monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-unaudited-condensed-consolidated-interim-statement-of-comprehensive-loss-t-ghrs-20251106monthly0.5https://www.biopharmawatch.com/news/GHRS/suicidal-ideation-and-behavior-in-patients-with-treatment-resistant-depression-treated-wit-ghrs-20251017monthly0.5https://www.biopharmawatch.com/news/GHRS/long-term-data-for-gh001-in-patients-with-treatment-resistant-depression-wies-aw-j-cuba-a--ghrs-20251014monthly0.5https://www.biopharmawatch.com/news/GHRS/event-n-any-teae-18-5-83-3-mild-15-5-83-3-moderate-2-2-33-3-severe-1-1-16-7-treatment-rela-ghrs-20250909monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-unaudited-condensed-consolidated-interim-statement-of-comprehensive-loss-t-ghrs-20250807monthly0.5https://www.biopharmawatch.com/news/GHRS/notice-of-annual-general-meeting-to-be-held-on-31-july-2025-gh-research-plc-the-company-or-ghrs-20250618monthly0.5https://www.biopharmawatch.com/news/GHRS/safety-and-efficacy-of-gh001-in-treatment-resistant-depression-results-from-a-phase-2b-dou-ghrs-20250527monthly0.5https://www.biopharmawatch.com/news/GHRS/safety-and-efficacy-of-gh001-in-treatment-resistant-depression-results-from-a-phase-2b-dou-ghrs-20250521monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-unaudited-condensed-consolidated-interim-statement-of-comprehensive-loss-t-ghrs-20250508monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-reports-full-year-2024-financial-results-and-provides-business-updates-phase-2-ghrs-20250227monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-proposed-public-offering-dublin-ireland-ghrs-20250203monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-primary-endpoint-met-in-phase-2b-trial-with-gh001-in-trd-demonstrati-ghrs-20250122monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-to-provide-update-on-phase-2b-trial-with-gh001-in-trd-dublin-ireland-ghrs-20250131monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-primary-endpoint-met-in-two-phase-2a-poc-trials-with-gh001-and-compl-ghrs-20250110monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-unaudited-condensed-consolidated-interim-statement-of-comprehensive-income-ghrs-20241114monthly0.5https://www.biopharmawatch.com/news/GHRS/09-2024-1-review-of-ongoing-phase-2b-treatment-resistant-depression-clinical-trial-gh001-t-ghrs-20240920monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-appointment-of-dr-velichka-villy-valcheva-to-chief-executive-officer-ghrs-20240903monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-unaudited-condensed-consolidated-interim-statement-of-comprehensive-income-ghrs-20240903monthly0.5https://www.biopharmawatch.com/news/GHRS/notice-of-annual-general-meeting-to-be-held-on-27-june-2024-gh-research-plc-the-company-or-ghrs-20240515monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-unaudited-condensed-consolidated-interim-statement-of-comprehensive-income-ghrs-20240503monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-reports-full-year-2023-financial-results-and-provides-business-updates-phase-2-ghrs-20240229monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-grant-of-european-patent-covering-all-mebufotenin-5-meo-dmt-and-mebu-ghrs-20240118monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-nasdaq-ghrs-january-2024-corporate-presentation-1-this-presentation-has-be-ghrs-20240105monthly0.5https://www.biopharmawatch.com/news/GHRS/unaudited-condensed-consolidated-interim-statement-of-comprehensive-income-three-months-en-ghrs-20231109monthly0.5https://www.biopharmawatch.com/news/GHRS/concentration-nm-mebufotenin-psilocin-dmt-determination-of-inhibition-constants-for-three--ghrs-20231006monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-provides-updates-and-guidance-on-its-clinical-development-program-for-gh001-in-ghrs-20230929monthly0.5https://www.biopharmawatch.com/news/GHRS/unaudited-condensed-consolidated-interim-statement-of-comprehensive-income-three-months-en-ghrs-20230823monthly0.5https://www.biopharmawatch.com/news/GHRS/notice-of-annual-general-meeting-to-be-held-on-31-august-2023-gh-research-plc-the-company--ghrs-20230719monthly0.5https://www.biopharmawatch.com/news/GHRS/exhibi-99-1-unaudited-condensed-consolidated-interim-financial-statements-for-the-three-mo-ghrs-20230511monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-reports-full-year-2022-financial-results-and-provides-business-updates-ghrs-20230302monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-provides-business-updates-and-highlights-key-upcoming-milestones-initial-appro-ghrs-20230109monthly0.5https://www.biopharmawatch.com/news/GHRS/unaudited-condensed-consolidated-interim-statement-of-comprehensive-income-three-months-en-ghrs-20221110monthly0.5https://www.biopharmawatch.com/news/GHRS/introduction-current-established-treatments-for-depression-are-slow-acting-often-taking-se-ghrs-20221014monthly0.5https://www.biopharmawatch.com/news/GHRS/a-phase-1-2-trial-of-gh001-a-vaporized-5-methoxy-n-n-dimethyltryptamine-formulation-inpati-ghrs-20220921monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-plc-unaudited-condensed-consolidated-interim-statement-of-comprehensive-income-ghrs-20220823monthly0.5https://www.biopharmawatch.com/news/GHRS/notice-of-annual-general-meeting-to-be-held-on-22-september-2022-gh-research-plc-the-compa-ghrs-20220811monthly0.5https://www.biopharmawatch.com/news/GHRS/a-phase-1-2-trial-of-gh001-a-vaporized-5-methoxy-n-n-dimethyltryptamine-formulation-inpati-ghrs-20220531monthly0.5https://www.biopharmawatch.com/news/GHRS/unaudited-condensed-consolidated-interim-financial-statements-for-the-three-months-ended-m-ghrs-20220518monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-reports-full-year-2021-financial-results-and-provides-business-updates-dublin--ghrs-20220328monthly0.5https://www.biopharmawatch.com/news/GHRS/corporate-presentationgh-research-plc-nasdaq-ghrs-gh-research-march-2022-2022-gh-research--ghrs-20220304monthly0.5https://www.biopharmawatch.com/news/GHRS/unaudited-condensed-consolidated-interim-financial-statements-for-the-three-and-nine-month-ghrs-20211206monthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-successful-outcome-of-the-phase-2-part-of-its-phase-1-2-clinical-tri-ghrs-20211206monthly0.5https://www.biopharmawatch.com/news/GHRS/corporate-presentation-gh-research-plc-nasdaq-ghrs-gh-research-october-2021-2021-gh-resear-ghrs-20211026monthly0.5https://www.biopharmawatch.com/news/GHRS/unaudited-condensed-consolidated-interim-financial-statements-for-the-three-and-six-months-ghrs-20210923monthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-reports-second-quarter-2025-financial-results-and-recent-highlights-mze7-maze-20250812monthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-reports-first-quarter-2025-financial-results-and-reiterates-upcoming-mil-maze-20250514monthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-h-maze-20250331monthly0.5https://www.biopharmawatch.com/news/BCAX/fighting-cancer-with-precision-and-power-corporate-presentation-january-2025-2024-2025-bic-bcax-20250113monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upd-bcax-20241112monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-first-quarter-2026-financial-results-x2022-topline-data-rea-amlx-20260507monthly0.5https://www.biopharmawatch.com/news/AMLX/march-2026-we-have-an-audacious-mission-to-develop-novel-therapies-for-diseases-with-high--amlx-20260324monthly0.5https://www.biopharmawatch.com/news/AMLX/january-2026-we-have-an-audacious-mission-to-develop-novel-therapies-for-diseases-with-hig-amlx-20260108monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-third-quarter-2025-financial-results-x2022-completion-of-re-amlx-20251106monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-second-quarter-2025-financial-results-x2022-completion-of-r-amlx-20250807monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-first-quarter-2025-financial-results-x2022-pivotal-phase-3--amlx-20250508monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-x2022-p-amlx-20250304monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-third-quarter-2024-financial-results-x2022-on-track-to-init-amlx-20241107monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-second-quarter-2024-financial-results-x2022-expanded-pipeli-amlx-20240808monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-first-quarter-2024-financial-results-x2d7-company-plans-to--amlx-20240509monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrio-albrioza-from-the-mar-amlx-20240404monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-announces-topline-results-from-global-phase-3-phoenix-trial-of-amx0-amlx-20240308monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-x2022-r-amlx-20240222monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-third-quarter-2023-financial-results-x2d7-third-quarter-202-amlx-20231109monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-second-quarter-2023-financial-results-x2d7-second-quarter-2-amlx-20230810monthly0.5https://www.biopharmawatch.com/news/AMLX/progressive-supranuclear-palsy-psp-investor-and-analyst-conference-call-amlx-20230726monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-receives-chmp-negative-opinion-on-its-conditional-marketing-authori-amlx-20230623monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-first-quarter-2023-financial-results-x2d7-first-quarter-202-amlx-20230511monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-x2022-f-amlx-20230313monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-third-quarter-2022-financial-results-x2d7-relyvrio-sodium-p-amlx-20221110monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-announces-fda-approval-of-relyvrio-for-the-treatment-of-als-relyvri-amlx-20220929monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results-albrioza-also-known-a-amlx-20220811monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-announces-fda-plan-to-reconvene-advisory-committee-to-review-amx003-amlx-20220705monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-announces-health-canada-approval-of-albrioza-for-the-treatment-of-a-amlx-20220613monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-receives-notification-of-pdufa-date-extension-for-amx0035-for-the-t-amlx-20220603monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-first-quarter-2022-financial-results-x2d7-final-stages-of-c-amlx-20220512monthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-reports-full-year-2021-financial-results-x2d7-preparations-underway-amlx-20220331monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-presentation-exhibit-anab-20200115monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-pricing-of-public-offering-of-common-stock-anab-20180925monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-positive-topline-data-from-phase-2a-proof-of-concept-clinical-trial-of--anab-20180924monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-positive-top-line-proof-of-concept-data-for-anb020-in-moderate-to-sev-anab-20180326monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-appointment-of-j-anthony-ware-m-d-to-board-of-directors-san-diego-aug-anab-20170824monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-first-quarter-2017-financial-results-and-provides-pipeline-update-top-anab-20170511monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-2016-operating-results-and-pipeline-progress-data-from-ongoing-anb020-anab-20170308monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-second-quarter-financial-results-and-provides-a-business-update-kimmtra-imcr-20250807monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update-kimmtrak-imcr-20250507monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-a-busi-imcr-20250226monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-strategic-priorities-at-43-rd-annual-j-p-morgan-healthcare-conference-imcr-20250110monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-appoints-travi-s-coy-previously-a-non-executive-director-as-its-evp-chief-finan-imcr-20250101monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-third-quarter-financial-results-and-provides-a-business-update-kimmtrak-imcr-20241106monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-phase-1-data-of-brenetafusp-an-immtac-bispecific-targeting-prame-in-pa-imcr-20240916monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-transition-of-chief-financial-officer-oxfordshire-england-conshohocke-imcr-20240829monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-second-quarter-financial-results-and-provides-a-business-update-kimmtra-imcr-20240808monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-updated-phase-1-data-of-brenetafusp-imc-f106c-an-immtac-bispecific-targ-imcr-20240531monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-converts-phase-2-3-tebe-am-clinical-trial-into-registrational-phase-3-trial-eva-imcr-20240530monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update-kimmtrak-imcr-20240508monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-a-busi-imcr-20240228monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-prices-upsized-convertible-senior-notes-offering-oxfordshire-england-conshohock-imcr-20240130monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-proposed-convertible-senior-notes-offering-oxfordshire-england-consho-imcr-20240129monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-strategic-priorities-and-pipeline-expansion-ahead-of-42-nd-annual-j-p-imcr-20231231monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-holdings-plc-unaudited-condensed-consolidated-interim-financial-statements-unau-imcr-20231107monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-holdings-plc-unaudited-condensed-consolidated-interim-financial-statements-unau-imcr-20230810monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-additional-ctdna-data-from-the-kimmtrak-phase-3-trial-at-asco-early-on-imcr-20230605monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-holdings-plc-unaudited-condensed-consolidated-interim-financial-statements-unau-imcr-20230510monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-new-kimmtrak-data-confirming-association-between-early-ctdna-reduction-imcr-20230418monthly0.5https://www.biopharmawatch.com/news/IMCR/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-imcr-20230418monthly0.5https://www.biopharmawatch.com/news/IMCR/forward-looking-statements-this-letter-contains-forward-looking-statements-within-the-mean-imcr-20230302monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-2022-financial-results-and-provides-business-update-kimmtrak-tebentafus-imcr-20230301monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-initial-phase-1-safety-and-pharmacodynamic-activity-data-with-first-s-imcr-20230222monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-strategic-priorities-including-pipeline-expansion-for-2023-2024-kimmt-imcr-20230111monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-ovarian-cancer-expansion-data-for-immtac-candidate-imc-c103c-targeting-imcr-20221208monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-and-gadeta-announce-agreement-to-develop-first-gamma-delta-tcr-immtac-for-solid-imcr-20221202monthly0.5https://www.biopharmawatch.com/news/IMCR/index-to-unaudited-condensed-consolidated-interim-financial-statements-page-unaudited-cond-imcr-20221118monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-new-biomarker-analysis-for-kimmtrak-tebentafusp-tebn-in-metastatic-uve-imcr-20221114monthly0.5https://www.biopharmawatch.com/news/IMCR/index-to-unaudited-condensed-consolidated-interim-financial-statements-page-unaudited-cond-imcr-20221109monthly0.5https://www.biopharmawatch.com/news/IMCR/cautionary-note-regarding-forward-looking-statements-this-exhibit-contains-forward-looking-imcr-20220909monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-promising-initial-phase-1-data-for-first-off-the-shelf-tcr-therapy-tar-imcr-20220909monthly0.5https://www.biopharmawatch.com/news/IMCR/index-to-unaudited-condensed-consolidated-interim-financial-statements-page-unaudited-cond-imcr-20220810monthly0.5https://www.biopharmawatch.com/news/IMCR/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-made-an-imcr-20220715monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-dosing-of-first-patient-with-immtav-bispecific-for-hiv-imc-m113v-t-ce-imcr-20220711monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-the-presentation-of-initial-data-from-the-phase-1-immtav-trial-for-ch-imcr-20220627monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-appoints-siddharth-kaul-to-its-board-of-directors-oxfordshire-england-conshohoc-imcr-20220608monthly0.5https://www.biopharmawatch.com/news/IMCR/the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-australian-therapeutic-goo-imcr-20220608monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-clinical-trial-collaboration-with-sanofi-to-evaluate-sanofi-s-product-imcr-20220603monthly0.5https://www.biopharmawatch.com/news/IMCR/index-to-unaudited-condensed-consolidated-interim-financial-statements-page-unaudited-cond-imcr-20220511monthly0.5https://www.biopharmawatch.com/news/IMCR/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-imcr-20220414monthly0.5https://www.biopharmawatch.com/news/IMCR/european-commission-approves-kimmtrak-tebentafusp-for-the-treatment-of-unresectable-or-met-imcr-20220404monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-full-year-2021-financial-results-and-provides-business-update-kimmtrak--imcr-20220303monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-fda-approval-of-kimmtrak-tebentafusp-tebn-for-the-treatment-of-unrese-imcr-20220126monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-initial-phase-1-data-of-immtac-candidate-imc-c103c-targeting-mage-a4--imcr-20211207monthly0.5https://www.biopharmawatch.com/news/IMCR/index-to-unaudited-condensed-consolidated-interim-financial-statements-page-unaudited-cond-imcr-20211110monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-that-u-s-food-and-drug-administration-and-european-medicines-agency-a-imcr-20210824monthly0.5https://www.biopharmawatch.com/news/IMCR/index-to-unaudited-condensed-consolidated-interim-financial-statements-page-unaudited-cond-imcr-20210811monthly0.5https://www.biopharmawatch.com/news/IMCR/index-to-unaudited-condensed-consolidated-interim-financial-statements-page-unaudited-cond-imcr-20210512monthly0.5https://www.biopharmawatch.com/news/SNDA/financial-statements-index-to-consolidated-financial-statements-cnl-healthcare-properties--snda-20260513monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-fourth-quarter-and-full-year-2025-results-dallas-texas--snda-20260311monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-completes-1-8-billion-strategic-merger-with-cnl-healthcare-properties-snda-20260311monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-third-quarter-2025-results-dallas-te-xas-november-10-20-25--snda-20251110monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-strategic-merger-with-cnl-healthcare-properties-inc-in-a-st-snda-20251105monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-second-quarter-2025-results-dallas-te-xas-august-11-20-25-s-snda-20250811monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-closes-two-previously-announced-senior-living-asset-acquisitions-completes-purchase-snda-20250609monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-first-quarter-2025-results-dallas-te-xas-may-12-20-25-sonid-snda-20250512monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-fourth-quarter-and-full-year-2024-results-snda-20250317monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-announces-latest-asset-acquisition-and-closing-of-fannie-mae-maturity-modifications-snda-20250106monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-third-quarter-2024-results-dallas-te-xas-november-13-20-24--snda-20241113monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-announces-general-counsel-transition-snda-20241028monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-continues-to-execute-on-its-accretive-growth-plan-and-upsizes-its-revolver-complete-snda-20241003monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-public-offering-of-common-stock-snda-20240815monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-second-quarter-2024-results-dallas-te-xas-august-12-20-24-s-snda-20240812monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-enhances-executive-team-and-board-to-support-company-growth-max-levy-appointed-chie-snda-20240510monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-first-quarter-2024-results-dallas-te-xas-may-10-20-24-sonid-snda-20240510monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-fourth-quarter-and-full-year-2023-results-snda-20240327monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-47-75-million-equity-raise-to-fund-discounted-debt-purchase-snda-20240206monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-third-quarter-2023-results-dallas-te-xas-november-14-20-snda-20231114monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-completion-of-loan-modifications-with-fannie-mae-and-update-snda-20231010monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-second-quarter-2023-results-dallas-te-xas-augu-st-14-2--snda-20230814monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-strengthens-financial-position-and-enhances-leadership-team-to-positi-snda-20230705monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-first-quarter-2023-results-dallas-te-xas-snda-20230511monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-fourth-quarter-and-full-year-2022-results-snda-20230330monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-third-quarter-2022-results-dallas-te-xas-snda-20221114monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-second-quarter-2022-results-dallas-te-xas-snda-20220812monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-leadership-transition-ceo-kim-lody-to-step-down-after-eight-snda-20220804monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-names-tim-cober-as-chief-accounting-officer-dallas-snda-20220624monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-first-quarter-2022-results-dallas-te-xas-snda-20220523monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-announces-two-new-hires-to-strengthen-its-finance-and-accounting-team-snda-20220504monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-names-kevin-detz-chief-financial-officer-deepens-sonida-s-leadership--snda-20220413monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-announces-fourth-quarter-and-full-year-2021-results-snda-20220418monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-inc-to-extend-timing-of-fourth-quarter-and-full-year-earnings-release-snda-20220330monthly0.5https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-completes-80-million-refinancing-addressing-all-debt-maturities-throu-snda-20220310monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-announces-third-quarter-2021-results-dallas-snda-20211110monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-announces-closing-of-financing-transaction-with-conversant-capital-n-snda-20211103monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-affirms-special-meeting-vote-results-approving-conversant-capital-in-snda-20211028monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-shareholders-approve-amended-investment-agreement-with-conversant-ca-snda-20211027monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-announces-move-to-virtual-special-meeting-of-stockholders-dallas-snda-20211013monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-enters-into-amended-and-restated-investment-agreement-with-conversan-snda-20211001monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-announces-postponement-of-special-meeting-of-stockholders-dallas-snda-20210928monthly0.5https://www.biopharmawatch.com/news/SNDA/form-of-letter-to-brokers-dealers-banks-and-other-nominees-capital-senior-living-corporati-snda-20210910monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-files-definitive-proxy-statement-and-issues-letter-to-shareholders-d-snda-20210831monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-announces-key-dates-for-rights-offering-dallas-snda-20210830monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-announces-second-quarter-2021-results-dallas-snda-20210812monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-announces-strategic-investment-from-conversant-capital-and-proposed--snda-20210722monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-announces-first-quarter-2021-results-dallas-snda-20210513monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-announces-fourth-quarter-and-full-year-2020-results-dall-snda-20210331monthly0.5https://www.biopharmawatch.com/news/SNDA/forward-looking-statements-forward-looking-statements-the-forward-looking-statements-in-th-snda-20210228monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-announces-1-for-15-snda-20201209monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-chendricks-snda-20201105monthly0.5https://www.biopharmawatch.com/news/SNDA/for-further-information-contact-september-21-2020-susan-j-turkell-303-766-4343-sturkell-ca-snda-20200921monthly0.5https://www.biopharmawatch.com/news/SNDA/forward-looking-statements-non-gaap-financial-measures-forward-looking-statements-the-forw-snda-20200818monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-chendricks-snda-20200806monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-chendricks-snda-20200521monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-chendricks-snda-20200416monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-chendricks-snda-20200331monthly0.5https://www.biopharmawatch.com/news/SNDA/carey-hendrickson-chief-financial-officer-972-770-5600-chendrickson-capitalsenior-com-capi-snda-20200211monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-chendricks-snda-20191107monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-972-770-5600-chendrickson-capit-snda-20190910monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-chendricks-snda-20190808monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-chendricks-snda-20190509monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-press-cont-snda-20190228monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-appoints-kimberly-lody-as-president-and-ceo-20-year-healthcare-indus-snda-20190108monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20181106monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-announces-retirement-of-larry-cohen-as-vice-chairman-and-ceo-board-i-snda-20180822monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20180731monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20180501monthly0.5https://www.biopharmawatch.com/news/SNDA/special-issue-brief-flu-prevention-and-response-planning-by-brett-lee-and-colleen-honnors--snda-20180228monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20180227monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20171101monthly0.5https://www.biopharmawatch.com/news/SNDA/forward-looking-statements-the-forward-looking-statements-in-this-presentation-are-subject-snda-20170905monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20170801monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20170710monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20170502monthly0.5https://www.biopharmawatch.com/news/SNDA/support-agreement-this-support-agreement-dated-snda-20170307monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20170228monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-mourns-the-passing-of-president-and-coo-keith-johannesse-snda-20161221monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20161101monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20160802monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20160503monthly0.5https://www.biopharmawatch.com/news/SNDA/agreement-this-agreement-dated-snda-20160318monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20160225monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20160114monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20151103monthly0.5https://www.biopharmawatch.com/news/SNDA/investor-analyst-day-agenda-9-00-am-transformation-of-capital-senior-living-and-executing--snda-20151008monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20150804monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-p-hendrickson-chief-financial-officer-phone-1-972-770-5600-capital-sen-snda-20150505monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-p-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immedia-snda-20150226monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20150129monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-p-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immedia-snda-20141104monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-p-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immedia-snda-20140805monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-carey-hendrickson-chief-financial-officer-phone-1-972-770-5600-for-immediate-snda-20140701monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-ralph-a-beattie-chief-financial-officer-phone-1-972-770-5600-for-immediate-r-snda-20140506monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-ralph-a-beattie-chief-financial-officer-phone-1-972-770-5600-for-immediate-r-snda-20140428monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-ralph-a-beattie-chief-financial-officer-phone-1-972-770-5600-for-immediate-r-snda-20140227monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-ralph-a-beattie-chief-financial-officer-phone-1-972-770-5600-for-immediate-r-snda-20131104monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-ralph-a-beattie-chief-financial-officer-phone-1-972-770-5600-for-immediate-r-snda-20130805monthly0.5https://www.biopharmawatch.com/news/SNDA/press-contact-ralph-a-beattie-chief-financial-officer-phone-1-972-770-5600-for-immediate-r-snda-20130528monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-for-immediate-release-contact-ralph-a-beattie-972-770-56-snda-20130506monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-for-immediate-release-contact-ralph-a-beattie-972-770-56-snda-20130306monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-for-immediate-release-contact-ralph-a-beattie-972-770-56-snda-20121221monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-for-immediate-release-contact-ralph-a-beattie-972-770-56-snda-20121107monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-for-immediate-release-contact-ralph-a-beattie-972-770-56-snda-20121024monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-for-immediate-release-contact-ralph-a-beattie-972-770-56-snda-20120801monthly0.5https://www.biopharmawatch.com/news/SNDA/ralph-a-beattie-972-770-5600-capital-senior-living-corporation-reports-first-quarter-2012--snda-20120502monthly0.5https://www.biopharmawatch.com/news/SNDA/capital-senior-living-corporation-for-immediate-release-contact-ralph-a-beattie-972-770-56-snda-20120402monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-first-quarter-2026-financial-results-q1-net-sales-grew-19-year-over-cdre-20260511monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-fourth-quarter-and-full-year-2025-financial-results-generated-annua-cdre-20260310monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-third-quarter-2025-financial-results-grew-quarterly-net-sales-42-an-cdre-20251104monthly0.5https://www.biopharmawatch.com/news/CDRE/acquisition-overview-cdre-20251029monthly0.5https://www.biopharmawatch.com/news/CDRE/investor-day-cdre-20251008monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-second-quarter-2025-financial-results-increased-quarterly-net-sales-cdre-20250805monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-first-quarter-2025-financial-results-capitalizes-on-continued-stron-cdre-20250506monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-fourth-quarter-and-full-year-2024-financial-results-achieved-annual-cdre-20250311monthly0.5https://www.biopharmawatch.com/news/CDRE/acquisition-overview-carr-s-engineering-division-cdre-20250116monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-third-quarter-2024-financial-results-favorable-market-trends-contin-cdre-20241106monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-second-quarter-2024-financial-results-grew-quarterly-net-sales-19-a-cdre-20240809monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-first-quarter-2024-financial-results-achieves-record-quarterly-net--cdre-20240507monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-fourth-quarter-and-full-year-2023-financial-results-achieved-annual-cdre-20240305monthly0.5https://www.biopharmawatch.com/news/CDRE/acquisition-overview-alpha-safety-february-2024-t-ogether-w-e-s-ave-l-ives-2-forward-looki-cdre-20240220monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-third-quarter-2023-financial-results-increased-quarterly-revenue-ne-cdre-20231108monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-second-quarter-2023-financial-results-achieved-revenue-net-income-g-cdre-20230808monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-first-quarter-2023-financial-results-achieved-revenue-net-income-an-cdre-20230509monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-fourth-quarter-and-full-year-2022-financial-results-generated-recor-cdre-20230315monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-third-quarter-2022-financial-results-achieved-net-income-and-adjust-cdre-20221110monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-second-quarter-2022-financial-results-exceeds-pricing-growth-target-cdre-20220811monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-announces-pricing-of-public-primary-and-secondary-offering-of-common-stock-cdre-20220609monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-announces-launch-of-public-primary-and-secondary-offering-of-common-stock-cdre-20220607monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-first-quarter-2022-financial-results-completes-second-accretive-acq-cdre-20220512monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-fourth-quarter-2021-financial-results-generated-record-full-year-ne-cdre-20220310monthly0.5https://www.biopharmawatch.com/news/CDRE/cadre-holdings-reports-third-quarter-2021-financial-results-expanded-gross-profit-margin-a-cdre-20211202monthly0.5https://www.biopharmawatch.com/news/PGEN/us-fda-approval-of-papzimeos-pgen-20250818monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-79-0-million-private-placement-offering-of-convertible-preferred-stock--pgen-20241227monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-third-quarter-2024-financial-results-and-business-updates-completed-pre-b-pgen-20241114monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-second-quarter-and-first-half-2024-financial-results-and-business-updates-pgen-20240814monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-strategically-prioritizes-portfolio-to-focus-on-first-potential-gene-therapy-laun-pgen-20240806monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-first-quarter-2024-financial-results-and-business-updates-pivotal-phase-2-pgen-20240514monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-full-year-2023-financial-results-and-business-updates-significant-progres-pgen-20240319monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-highlights-pipeline-updates-to-be-presented-at-the-42nd-annual-j-p-morgan-healthc-pgen-20240108monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-third-quarter-2023-financial-results-and-progress-of-clinical-programs-ba-pgen-20231109monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-second-quarter-and-first-half-2023-financial-results-and-provides-update--pgen-20230809monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-first-quarter-2023-financial-results-and-business-updates-positive-phase--pgen-20230510monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-fourth-quarter-and-full-year-2022-financial-results-and-business-updates--pgen-20230306monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-positive-phase-1-dose-escalation-and-expansion-cohort-data-for-investig-pgen-20230124monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-provides-pipeline-and-corporate-updates-at-the-41st-annual-j-p-morgan-healthcare--pgen-20230112monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-third-quarter-2022-financial-results-and-progress-of-clinical-programs-co-pgen-20221109monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-names-rutul-r-shah-chief-operating-officer-germantown-md-pgen-20220921monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-completes-sale-of-non-healthcare-subsidiary-trans-ova-genetics-pgen-20220822monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-second-quarter-and-first-half-2022-financial-results-enrollment-complete--pgen-20220808monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-enters-into-agreement-to-divest-non-healthcare-subsidiary-trans-ova-genetics-pgen-20220705monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-first-quarter-2022-financial-results-and-business-updates-fast-track-desi-pgen-20220509monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-fourth-quarter-and-full-year-2021-financial-results-2021-clinical-milesto-pgen-20220301monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-achieves-significant-clinical-progress-for-ultracar-t-and-adenoverse-therapies-50-pgen-20211104monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-appoints-harry-thomasian-jr-as-chief-financial-officer-germantown-md-pgen-20211012monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-second-quarter-and-first-half-2021-financial-results-company-to-provide-c-pgen-20210809monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-first-quarter-2021-financial-results-company-on-track-to-achieve-stated-2-pgen-20210510monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-departure-of-chief-financial-officer-commences-search-for-new-cfo-germa-pgen-20210330monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-fourth-quarter-and-full-year-2020-financial-results-company-successfully--pgen-20210301monthly0.5https://www.biopharmawatch.com/news/PGEN/forward-looking-statements-some-of-the-statements-made-in-this-presentation-are-forward-lo-pgen-20210113monthly0.5https://www.biopharmawatch.com/news/PGEN/internal-confidential-precigen-reports-third-quarter-2020-and-year-to-date-financial-resul-pgen-20201109monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-merck-kgaa-darmstadt-germany-increases-ownership-position-through-exerc-pgen-20201009monthly0.5https://www.biopharmawatch.com/news/PGEN/event-name-precigen-second-quarter-2020-financial-results-conference-call-event-date-monda-pgen-20200810monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-second-quarter-and-first-half-2020-financial-results-announced-proprietar-pgen-20200810monthly0.5https://www.biopharmawatch.com/news/PGEN/may-06-2020-8-15pm-gmt-q1-2020-precigen-inc-earnings-call-corporate-participants-helen-sab-pgen-20200512monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-first-quarter-2020-financial-results-achieves-significant-progress-in-str-pgen-20200506monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-fourth-quarter-and-year-end-2019-financial-results-company-completed-seri-pgen-20200302monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-completes-series-of-transactions-to-solidify-healthcare-focus-company-on-track-to-pgen-20200203monthly0.5https://www.biopharmawatch.com/news/PGEN/forward-looking-statements-precigen-inc-is-a-subsidiary-of-intrexon-corporation-nasdaq-xon-pgen-20200102monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-to-achieve-175m-cash-goal-appoints-helen-sabzevari-phd-as-new-president-and-ceo-a-pgen-20200102monthly0.5https://www.biopharmawatch.com/news/PGEN/forward-looking-statements-precigen-inc-is-a-subsidiary-of-intrexon-corporation-nasdaq-xon-pgen-20191112monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-reports-third-quarter-2019-financial-results-tightened-focus-on-healthcare-and-on-pgen-20191112monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-reports-second-quarter-and-first-half-2019-financial-results-quarterly-gaap-reven-pgen-20190808monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-reports-first-quarter-2019-financial-results-quarterly-gaap-revenues-of-23-3-mill-pgen-20190509monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-reports-2018-fourth-quarter-and-year-end-financial-results-quarterly-gaap-revenue-pgen-20190228monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-company-update-helen-sabzevari-phd-president-precigen-7-january-2019-forward-look-pgen-20190107monthly0.5https://www.biopharmawatch.com/news/PGEN/forward-looking-statements-today-s-business-updates-introduction-to-precigen-s-near-term-r-pgen-20181226monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-and-merck-kgaa-darmstadt-germany-announce-agreement-realizing-precigen-s-vision-f-pgen-20181220monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-third-quarter-2018-financial-results-quarterly-gaap-revenues-of-32-4-mi-pgen-20181108monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-transfer-of-stock-listing-to-nasdaq-ticker-symbol-to-remain-pgen-20180912monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-business-update-and-conference-call-germantown-md-pgen-20180809monthly0.5https://www.biopharmawatch.com/news/PGEN/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-au-pgen-20180703monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-first-quarter-2018-financial-results-quarterly-gaap-revenues-of-43-8-mi-pgen-20180510monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-fourth-quarter-and-full-year-2017-financial-results-quarterly-gaap-reve-pgen-20180301monthly0.5https://www.biopharmawatch.com/news/PGEN/construction-of-powerful-gene-expression-programs-drives-efficacy-control-of-gene-expressi-pgen-20180110monthly0.5https://www.biopharmawatch.com/news/PGEN/actobio-therapeutics-introduction-a-new-class-of-microbe-based-biopharmaceuticals-actobiot-pgen-20180108monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-corporation-annual-ceo-letter-germantown-md-pgen-20180102monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-key-management-appointments-germantown-md-pgen-20171127monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-third-quarter-2017-financial-results-quarterly-gaap-revenues-of-46-0-mi-pgen-20171109monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-second-quarter-and-first-half-2017-financial-results-quarterly-gaap-rev-pgen-20170809monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-integrates-leading-adenoviral-gene-delivery-technology-with-completion-of-genvec--pgen-20170616monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-first-quarter-2017-financial-results-quarterly-gaap-revenues-of-53-7-mi-pgen-20170510monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-appoints-vinita-gupta-leading-pharma-executive-to-its-board-of-directors-germanto-pgen-20170427monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-creates-precigen-inc-and-accelerates-strategic-review-of-structural-options-relat-pgen-20170310monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-fourth-quarter-and-full-year-2016-financial-results-quarterly-gaap-reve-pgen-20170301monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-to-acquire-genvec-to-expand-industry-leading-gene-delivery-platform-genvec-s-aden-pgen-20170124monthly0.5https://www.biopharmawatch.com/news/PGEN/forward-looking-statements-safe-harbor-statement-some-of-the-statements-made-in-this-prese-pgen-20170106monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-third-quarter-2016-financial-results-quarterly-gaap-revenues-of-49-0-mi-pgen-20161109monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-second-quarter-and-first-half-2016-financial-results-quarterly-revenues-pgen-20160809monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-appoints-dr-andrew-j-last-as-chief-operating-officer-germantown-md-pgen-20160808monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-and-ziopharm-amend-exclusive-channel-collaborations-to-improve-alignment-as-progr-pgen-20160630monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-retirement-of-samuel-broder-m-d-head-of-health-sector-broder-continuing-pgen-20160606monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-appoints-geno-germano-to-new-role-of-president-germantown-md-may-1-7-201-6-intrex-pgen-20160517monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-first-quarter-2016-financial-results-quarterly-revenues-of-43-4-million-pgen-20160510monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-establishes-crop-protection-enterprise-intrexon-crop-protection-intended-to-becom-pgen-20160504monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-realigns-responsibilities-augments-team-germantown-md-pgen-20160321monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-fourth-quarter-and-full-year-2015-financial-results-quarterly-revenues--pgen-20160229monthly0.5https://www.biopharmawatch.com/news/PGEN/forward-looking-statements-safe-harbor-statement-some-of-the-statements-made-in-this-prese-pgen-20160113monthly0.5https://www.biopharmawatch.com/news/PGEN/forward-looking-statements-special-note-regarding-forward-looking-statements-some-of-the-m-pgen-20151112monthly0.5https://www.biopharmawatch.com/news/PGEN/intrexon-announces-third-quarter-2015-financial-results-quarterly-revenues-of-53-4-million-pgen-20151109monthly0.5https://www.biopharmawatch.com/news/PGEN/ziopharm-intrexon-graft-versus-host-disease-exclusive-channel-collaboration-september-28-2-pgen-20150928monthly0.5https://www.biopharmawatch.com/news/PGEN/environmentally-friendly-insect-control-solutions-tackle-growing-global-health-and-agricul-pgen-20150908monthly0.5https://www.biopharmawatch.com/news/PGEN/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-au-pgen-20150821monthly0.5https://www.biopharmawatch.com/news/URGN/developing-innovative-medicines-to-treat-urothelial-cancers-january-2025-disclaimers-this--urgn-20250114monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights-includi-urgn-20241106monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ahead-of-schedule-to-complete-ugn-102-nda-submission-and-reports-2024-second-urgn-20240813monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-commencement-of-public-offering-of-ordinary-shares-and-pre-funded--urgn-20240617monthly0.5https://www.biopharmawatch.com/news/URGN/new-horizons-in-bladder-cancer-ugn-102-duration-of-response-results-from-the-envision-stud-urgn-20240613monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-date-for-envision-data-new-long-term-jelmyto-durability-data-and-r-urgn-20240513monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-delivers-double-digit-jelmyto-growth-and-prepares-for-the-next-phase-of-the--urgn-20240314monthly0.5https://www.biopharmawatch.com/news/URGN/developing-innovative-medicines-to-treat-urothelial-cancers-march-2024-for-investor-audien-urgn-20240304monthly0.5https://www.biopharmawatch.com/news/URGN/developing-innovative-medicines-to-treat-urothelial-cancers-february-2024-for-investor-aud-urgn-20240207monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-third-quarter-2023-financial-results-continued-strong-growth-with-je-urgn-20231114monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-record-jelmyto-quarterly-sales-and-recent-corporate-developments-bot-urgn-20230810monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-announces-120-million-private-placement-of-ordinary-shares-princeton-n-j-urgn-20230727monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-meets-revenue-goal-reports-first-quarter-2023-financial-results-and-recent-c-urgn-20230511monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-highest-revenue-quarter-and-significant-full-year-2022-growth-and-re-urgn-20230316monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-third-quarter-2022-financial-results-and-recent-corporate-developmen-urgn-20221110monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-second-quarter-2022-financial-results-and-recent-corporate-developme-urgn-20220811monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-first-quarter-2022-financial-results-and-recent-corporate-developmen-urgn-20220510monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-corpo-urgn-20220321monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-third-quarter-2021-financial-results-and-recent-corporate-developmen-urgn-20211115monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-second-quarter-2021-financial-results-and-recent-corporate-developme-urgn-20210804monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-strong-preliminary-jelmyto-sales-for-second-quarter-2021-73-growth-i-urgn-20210714monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-first-quarter-2021-financial-results-and-recent-corporate-developmen-urgn-20210513monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-corpo-urgn-20210318monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-75-million-of-non-dilutive-funding-from-rtw-investments-rtw-invest-urgn-20210318monthly0.5https://www.biopharmawatch.com/news/URGN/forward-looking-statements-this-investor-presentation-contains-forward-looking-statements--urgn-20210111monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-third-quarter-2020-financial-results-and-recent-corporate-developmen-urgn-20201109monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-update-on-the-phase-2-trial-of-an-rtgel-hydrogel-formulation-in-co-urgn-20200827monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-second-quarter-2020-financial-results-and-recent-corporate-developme-urgn-20200810monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-third-quarter-2019-financial-results-and-recent-corporate-developmen-urgn-20191112monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-reports-positive-data-from-two-important-studies-ugn-101-olympus-pivotal-trial-in-l-urgn-20190924monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-second-quarter-2019-financial-results-and-recent-corporate-developme-urgn-20190809monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-first-quarter-2019-financial-results-and-recent-corporate-developmen-urgn-20190509monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-report-fourth-quarter-and-full-year-2018-financial-results-on-track-to-co-urgn-20190228monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-pricing-of-public-offering-of-ordinary-shares-new-york-business-wi-urgn-20190123monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-proposed-public-offering-of-ordinary-shares-new-york-business-wire-urgn-20190122monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-positive-results-of-ugn-101-from-pivotal-phase-3-olympus-trial-for-urgn-20190108monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-condensed-consolidated-balance-sheets-u-s-dollars-in-thousands-except-sh-urgn-20181113monthly0.5https://www.biopharmawatch.com/news/URGN/fda-grants-breakthrough-therapy-designation-btd-for-urogen-pharma-s-ugn-101-for-the-treatm-urgn-20181030monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-condensed-consolidated-balance-sheets-u-s-dollars-in-thousands-except-sh-urgn-20180814monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-appoints-peter-p-pfreundschuh-as-chief-financial-officer-life-sciences-veter-urgn-20180808monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-appoints-shawn-cline-tomasello-to-its-board-of-directors-tomasello-is-a-reno-urgn-20180710monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-stephen-mullennix-as-interim-chief-financial-officer-and-jason-pat-urgn-20180605monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-condensed-consolidated-balance-sheets-u-s-dollars-in-thousands-except-sh-urgn-20180515monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-9-ha-ta-asiya-street-ra-anana-4365007-israel-urgn-20180425monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-presentation-of-results-from-interim-analysis-of-pivotal-phase-3-o-urgn-20180403monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-reports-fourth-quarter-and-full-year-2017-financial-results-presentation-of-mitogel-urgn-20180315monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-strengthens-management-team-with-the-appointment-of-stephen-mullennix-as-chi-urgn-20180214monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-9-ha-ta-asiya-street-ra-anana-4365007-israel-urgn-20180110monthly0.5https://www.biopharmawatch.com/news/URGN/this-presentation-and-the-accompanying-oral-presentation-by-urogen-pharma-ltd-urogen-conta-urgn-20180108monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-expands-clinical-development-leadership-team-mark-schoenberg-m-d-named-chief-urgn-20171212monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-condensed-consolidated-balance-sheets-u-s-dollars-in-thousands-except-sh-urgn-20171114monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-first-patient-enrolled-in-allergan-phase-2-clinical-trial-of-rtgel-urgn-20171106monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-appoints-former-kite-pharma-chief-operating-officer-cynthia-m-butitta-to-its-urgn-20171102monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-receives-fda-fast-track-designation-for-mitogel-for-the-treatment-of-upper-t-urgn-20170829monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-condensed-consolidated-balance-sheets-u-s-dollars-in-thousands-except-sh-urgn-20170814monthly0.5https://www.biopharmawatch.com/news/URGN/investigational-new-drug-application-for-rtgel-tm-in-combination-with-botox-for-the-treatm-urgn-20170719monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-appoints-fred-e-cohen-md-to-its-board-of-directors-ra-anana-israel-new-york--urgn-20170516monthly0.5https://www.biopharmawatch.com/news/NVAX/xa9-2026-novavax-all-rights-reserved-1-novavax-corporate-presentation-john-c-jacobs-presid-nvax-20260112monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-completes-u-s-marketing-authorization-transfer-to-sanofi-for-nuvaxovid-triggering--nvax-20251104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-continues-to-deliver-on-sanofi-partnership-completing-nuvaxovid-eu-marketing-autho-nvax-20251007monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-s-nuvaxovid-2025-2026-formula-covid-19-vaccine-approved-in-the-u-s-nuvaxovid-is-th-nvax-20250827monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-convertible-debt-refinancing-refinancing-extends-maturity-of-most-existi-nvax-20250820monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-s-covid-19-influenza-combination-and-stand-alone-influenza-vaccine-candidates-show-nvax-20250611monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-changes-to-board-of-directors-james-young-phd-retires-as-chair-of-the-bo-nvax-20250311monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-corporate-presentation-march-2025-2025-novavax-all-rights-reserved-2-cautionary-no-nvax-20250304monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-corporate-presentation-january-2025-2025-novavax-all-rights-reserved-2-cautionary--nvax-20250113monthly0.5https://www.biopharmawatch.com/news/NVAX/investor-presentation-xa9-2024-novavax-all-rights-reserved-1-nasdaq-nvax-november-2024-2-c-nvax-20241120monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand-alone--nvax-20241111monthly0.5https://www.biopharmawatch.com/news/NVAX/update-on-novavax-s-covid-19-influenza-combination-and-stand-alone-influenza-phase-3-trial-nvax-20241016monthly0.5https://www.biopharmawatch.com/news/NVAX/investor-presentation-1-2024-novavax-all-rights-reserved-nasdaq-nvax-june-2024-2-cautionar-nvax-20240606monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2024-financial-results-and-operational-highlights-announces--nvax-20240510monthly0.5https://www.biopharmawatch.com/news/NVAX/j-p-morgan-42-nd-annual-healthcare-conference-1-2024-novavax-all-rights-reserved-nasdaq-nv-nvax-20240108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-makes-changes-to-executive-leadership-team-to-enhance-focus-on-delivery-of-strateg-nvax-20231117monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-2023-2024-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s-this--nvax-20231003monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-full-year-2022-financial-results-and-operational-highli-nvax-20230228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-names-john-c-jacobs-as-new-president-chief-executive-officer-current-president-ceo-nvax-20230109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2022-financial-results-and-operational-highlights-achieved-t-nvax-20221108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-rick-rodgers-to-board-of-directors-gaithersburg-md-nvax-20221101monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2022-financial-results-and-operational-highlights-received--nvax-20220808monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2022-financial-results-and-operational-highlights-achieved-r-nvax-20220509monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-all-rights-reserved-update-on-novavax-investigational-n-anoflu-vaccine-and-covid-1-nvax-20220420monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-full-year-2021-financial-results-and-operational-highli-nvax-20220228monthly0.5https://www.biopharmawatch.com/news/NVAX/forward-looking-statements-are-based-on-current-expectations-and-assumptions-and-currently-nvax-20220210monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-all-rights-reserved-j-p-morgan-40-th-annual-healthcare-conference-nasdaq-nvax-janu-nvax-20220110monthly0.5https://www.biopharmawatch.com/news/NVAX/european-commission-grants-conditional-marketing-authorization-for-novavax-covid-19-vaccin-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2021-financial-results-and-operational-highlights-received-e-nvax-20211104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-files-for-authorization-of-its-covid-19-vaccine-in-the-united-kingdom-filing-marks-nvax-20211027monthly0.5https://www.biopharmawatch.com/news/NVAX/nasdaq-nvax-september-2021-corporate-overview-and-investor-deck-2-novavax-com-safe-harbor--nvax-20210909monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-biopharmaceutical-veterans-jim-kelly-as-chief-financial-officer-and-nasir-nvax-20210816monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2021-financial-results-and-operational-highlights-filed-reg-nvax-20210805monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and-100-protection-against-moder-nvax-20210614monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2021-financial-results-and-operational-highlights-significan-nvax-20210510monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-full-year-2020-financial-results-and-operational-highli-nvax-20210301monthly0.5https://www.biopharmawatch.com/news/NVAX/nasdaq-nvax-january-2021-j-p-morgan-39-th-annual-healthcare-conference-virtual-2-novavax-c-nvax-20210111monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-vaccine-industry-expert-margaret-g-mcglynn-to-board-of-directors-gaithers-nvax-20201209monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2020-financial-and-operational-results-advanced-clinical-dev-nvax-20201109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-biopharmaceutical-industry-veteran-gregg-alton-to-board-of-directors-gait-nvax-20201103monthly0.5https://www.biopharmawatch.com/news/NVAX/nasdaq-nvax-september-10-2020-corporate-overview-and-investor-deck-nvax-20200910monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2020-financial-and-operational-results-announced-positive-p-nvax-20200810monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-raise-200-million-from-private-placement-with-ra-capital-gaithersburg-md-nvax-20200615monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-biotechnology-veteran-david-mott-to-board-of-directors-gaithersburg-md-nvax-20200616monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-expands-large-scale-global-manufacturing-capacity-novavax-acquires-praha-vaccines--nvax-20200527monthly0.5https://www.biopharmawatch.com/news/NVAX/nvx-cov2373-vaccine-for-covid-19-dr-gregory-glenn-world-vaccine-congress-webcast-13-may-20-nvax-20200511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-receive-up-to-388-million-funding-from-cepi-for-covid-19-vaccine-development-an-nvax-20200511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2020-financial-results-cepi-increases-investment-up-to-388-m-nvax-20200511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nanoflu-achieves-all-primary-endpoints-in-phase-3-clinical-trial-trial-also-achiev-nvax-20200324monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-full-year-2019-financial-results-nanoflu-top-line-data--nvax-20200311monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2019-financial-results-nanoflu-pivotal-phase-3-clinical-tria-nvax-20191107monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2019-financial-results-agreement-with-the-fda-on-phase-3-no-nvax-20190807monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-catalent-announce-closing-of-strategic-partnership-gaithersburg-md-nvax-20190731monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-catalent-biologics-enter-strategic-partnership-allowing-catalent-biologics-to--nvax-20190627monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2019-financial-results-company-to-host-conference-call-today-nvax-20190502monthly0.5https://www.biopharmawatch.com/news/NVAX/phase-3-and-beyond-the-rsv-f-nanoparticle-vaccine-for-infants-via-maternal-immunization-pr-nvax-20190416monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-year-end-2018-financial-results-company-to-host-confere-nvax-20190318monthly0.5https://www.biopharmawatch.com/news/NVAX/prepare-trial-topline-results-february-28-2019-nvax-20190228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2018-financial-results-company-to-host-conference-call-today-nvax-20181107monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-rachel-king-to-board-of-directors-gaithersburg-md-nvax-20181101monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2018-financial-results-novavax-delivers-on-key-milestones-s-nvax-20180808monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2018-financial-results-gaithersburg-md-nvax-20180509monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-proposed-public-offering-of-common-stock-gaithersburg-md-nvax-20180411monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-provides-corporate-update-and-report-of-fourth-quarter-and-year-end-2017-financial-nvax-20180314monthly0.5https://www.biopharmawatch.com/news/NVAX/j-p-nvax-20180108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2017-financial-results-gaithersburg-md-nvax-20171107monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-leadership-change-gaithersburg-md-nvax-20171013monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2017-financial-results-gaithersburg-md-nvax-20170808monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-topline-data-from-phase-2-older-adult-trial-and-provides-path-f-nvax-20170724monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2017-financial-results-gaithersburg-md-nvax-20170508monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-year-end-2016-financial-results-gaithersburg-md-nvax-20170227monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2016-financial-results-announces-corporate-restructuring-and-nvax-20161109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-topline-rsv-f-vaccine-data-from-two-clinical-trials-in-older-adults-topl-nvax-20160915monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2016-financial-results-gaithersburg-md-nvax-20160809monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2016-financial-results-gaithersburg-md-nvax-20160504monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-year-end-2015-financial-results-gaithersburg-md-nvax-20160229monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2015-financial-nvax-20151109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-grant-of-up-to-89-million-to-support-development-of-rsv-f-vaccine-to-pro-nvax-20150929monthly0.5https://www.biopharmawatch.com/news/NVAX/analyst-investor-meeting-september-2015-safe-harbor-statement-certain-information-containe-nvax-20150929monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2015-financial-results-gaithersburg-md-nvax-20150810monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-gail-boudreaux-to-board-gaithersburg-md-nvax-20150618monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2015-financial-results-gaithersburg-md-nvax-20150507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-proposed-public-offering-of-common-stock-gaithersburg-md-nvax-20150324monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-year-end-2014-financial-results-gaithersburg-md-nvax-20150226monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2014-financial-results-gaithersburg-md-nvax-20141105monthly0.5https://www.biopharmawatch.com/news/NVAX/announces-barda-exercise-of-contract-option-nvax-20140924monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2014-financial-results-gaithersburg-md-nvax-20140806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-exercise-of-option-to-purchase-additional-shares-and-closing-of-public-o-nvax-20140611monthly0.5https://www.biopharmawatch.com/news/NVAX/launch-press-release-novavax-announces-proposed-public-offering-of-common-stock-gaithersbu-nvax-20140604monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2014-financial-results-gaithersburg-md-nvax-20140507monthly0.5https://www.biopharmawatch.com/news/NVAX/barclay-a-phillips-svp-chief-financial-officer-and-treasurer-novavax-inc-240-268-2000-nova-nvax-20140310monthly0.5https://www.biopharmawatch.com/news/NVAX/barclay-a-phillips-svp-chief-financial-officer-and-treasurer-novavax-inc-240-268-2000-nova-nvax-20140227monthly0.5https://www.biopharmawatch.com/news/NVAX/barclay-a-phillips-svp-chief-financial-officer-and-treasurer-novavax-inc-240-268-2000-nova-nvax-20130927monthly0.5https://www.biopharmawatch.com/news/NVAX/barclay-a-phillips-svp-chief-financial-officer-and-treasurer-novavax-inc-240-268-2000-nova-nvax-20130924monthly0.5https://www.biopharmawatch.com/news/NVAX/john-a-herrmann-vp-general-counsel-and-secretary-novavax-inc-240-268-2000-novavax-acquires-nvax-20130822monthly0.5https://www.biopharmawatch.com/news/NVAX/john-a-herrmann-vp-general-counsel-and-secretary-novavax-inc-240-268-2000-novavax-and-isco-nvax-20130708monthly0.5https://www.biopharmawatch.com/news/NVAX/barclay-phillips-svp-chief-financial-officer-and-treasurer-novavax-inc-240-268-2000-novava-nvax-20130702monthly0.5https://www.biopharmawatch.com/news/NVAX/john-herrmann-vp-general-counsel-and-corporate-secretary-novavax-inc-240-268-2000-novavax--nvax-20130624monthly0.5https://www.biopharmawatch.com/news/NVAX/uppsala-17-june-2013-novavax-to-make-initial-form-s-4-registration-statement-filing-iscono-nvax-20130617monthly0.5https://www.biopharmawatch.com/news/NVAX/irrevocable-undertaking-this-irrevocable-undertaking-agreement-the-agreement-has-been-made-nvax-20130604monthly0.5https://www.biopharmawatch.com/news/NVAX/frederick-w-driscoll-vp-chief-financial-officer-and-treasurer-novavax-inc-240-268-2000-nov-nvax-20130507monthly0.5https://www.biopharmawatch.com/news/NVAX/frederick-w-driscoll-vp-chief-financial-officer-and-treasurer-novavax-inc-240-268-2000-nov-nvax-20121023monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-appointment-of-damien-mcdonald-as-chief-executive-officer-damien-mcdonald-enov-20250402monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-planned-ceo-succession-process-wilmington-de-enov-20250226monthly0.5https://www.biopharmawatch.com/news/ENOV/forward-looking-statements-this-presentation-includes-forward-looking-statements-including-enov-20241231monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-has-provided-in-this-presentation-financial-information-that-has-not-been-prepared--enov-20240108monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-completes-acquisition-of-limacorporate-s-p-a-wilmington-de-enov-20240103monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-business-segment-leadership-transition-plan-brady-r-shirley-current-presi-enov-20231205monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-corporation-announces-pricing-of-private-offering-of-400-million-of-3-875-convertib-enov-20231020monthly0.5https://www.biopharmawatch.com/news/ENOV/kpmg-s-p-a-revisione-e-organizzazione-contabile-piazza-salvemini-20-35131-padova-pd-telefo-enov-20231019monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-acquire-limacorporate-s-p-a-creating-a-high-growth-global-reconstruction-leader--enov-20230925monthly0.5https://www.biopharmawatch.com/news/ENOV/matt-trerotola-chief-executive-officer-ben-berry-chief-financial-officer-forward-looking-s-enov-20230912monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-board-leadership-transition-ceo-matt-trerotola-to-be-named-chair-and-dire-enov-20230315monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-chief-financial-officer-transition-plan-wilmington-delaware-enov-20220630monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-first-quarter-2022-adjusted-stand-alone-results-increased-stand-alone-sal-enov-20220510monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-formerly-colfax-completes-spin-off-of-esab-corporation-wilmington-de-enov-20220405monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-expected-completion-date-of-enov-20220314monthly0.5https://www.biopharmawatch.com/news/ENOV/forward-looking-statement-and-non-gaap-disclaimer-this-document-has-been-prepared-by-colfa-enov-20220314monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-board-of-directors-for-enovis-the-post-spinoff-medical-technology-company-enov-20220311monthly0.5https://www.biopharmawatch.com/news/ENOV/executive-employment-agreement-this-employment-agreement-agreement-is-entered-into-as-of-t-enov-20220225monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-plans-for-reverse-stock-split-wilmington-de-enov-20211230monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-corporation-investor-day-enov-20210311monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-intention-to-separate-into-two-independent-public-companies-will-create-f-enov-20210304monthly0.5https://www.biopharmawatch.com/news/ENOV/philip-okala-appointed-to-colfax-board-of-directors-annapolis-junction-md-enov-20210222monthly0.5https://www.biopharmawatch.com/news/ENOV/investor-day-december-2019-forward-looking-statements-non-gaap-disclaimer-the-following-in-enov-20191218monthly0.5https://www.biopharmawatch.com/news/ENOV/liam-kelly-appointed-to-colfax-board-of-directors-annapolis-junction-md-enov-20191211monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-agreement-to-sell-its-air-and-gas-handling-business-to-kps-capital-partne-enov-20190516monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-completes-acquisition-of-djo-global-inc-schedules-2019-outlook-conference-call-anna-enov-20190225monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-pricing-of-6-000-senior-notes-due-2024-and-6-375-senior-notes-due-2026-enov-20190131monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-offering-of-senior-notes-enov-20190128monthly0.5https://www.biopharmawatch.com/news/ENOV/supplemental-financial-and-operating-information-regarding-the-company-and-djo-dated-enov-20190128monthly0.5https://www.biopharmawatch.com/news/ENOV/ernst-young-llp-tel-1-858-535-7200-suite-1600-fax-1-858-535-7777-4365-executive-drive-ey-c-enov-20190107monthly0.5https://www.biopharmawatch.com/news/ENOV/execution-copy-credit-agreement-dated-as-of-enov-20181217monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-to-acquire-djo-global-for-3-15-billion-in-cash-djo-is-global-orthopedics-leader-str-enov-20181119monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-completes-sale-of-fluid-handling-business-annapolis-junction-md-enov-20171211monthly0.5https://www.biopharmawatch.com/news/ENOV/investor-day-november-2017-2-forward-looking-statements-these-slides-and-accompanying-oral-enov-20171129monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-sale-of-its-fluid-handling-business-to-circor-annapolis-junction-md-enov-20170925monthly0.5https://www.biopharmawatch.com/news/ENOV/didier-teirlinck-appointed-to-colfax-board-of-directors-enov-20170919monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-pricing-of-3-250-senior-notes-due-2025-enov-20170412monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-offering-of-senior-notes-and-preliminary-trends-for-the-first-quarter-of--enov-20170407monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-names-shyam-kambeyanda-as-president-esab-enov-20160418monthly0.5https://www.biopharmawatch.com/news/ENOV/colfax-announces-clay-kiefaber-to-retire-as-ceo-of-esab-business-enov-20151117monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-appoints-dave-caspers-as-ceo-mr-caspers-brings-decades-of-operational-expert-ardt-20260602monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-first-quarter-2026-results-brentwood-tenn-ardt-20260505monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-fourth-quarter-2025-results-brentwood-tenn-ardt-20260304monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-announces-50-million-share-repurchase-program-authorization-brentwood-tenn-ardt-20251118monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-third-quarter-2025-results-brentwood-tenn-ardt-20251112monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-announces-successful-amendment-and-extension-of-term-loan-facility-brentwood-tenn-ardt-20250922monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-second-quarter-2025-results-brentwood-tenn-ardt-20250805monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-first-quarter-2025-results-brentwood-tenn-ardt-20250506monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-appoints-robert-demichiei-to-board-of-directors-brentwood-tenn-ardt-20250403monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-announces-appointment-of-chief-operating-officer-and-senior-leadership-promo-ardt-20250331monthly0.5https://www.biopharmawatch.com/news/ARDT/brentwood-tenn-ardt-20250226monthly0.5https://www.biopharmawatch.com/news/ARDT/jpmpresentatio-january-2025-investor-presentation-important-disclaimers-forward-looking-st-ardt-20250113monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-third-quarter-2024-results-brentwood-tenn-ardt-20241106monthly0.5https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-second-quarter-2024-results-brentwood-tenn-ardt-20240814monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-contact-matt-buckhalter-chief-financial-officer-ir-aveanna-com-avah-20260528monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-presentation-may-2026-disclaimers-and-forward-looking-statements-this-investor-pr-avah-20260515monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-presentation-march-2026-disclaimers-and-forward-looking-statements-this-investor--avah-20260319monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-fourth-quarter-and-full-year-2025-financial-results--avah-20260319monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-agreement-to-acquire-family-first-homecare-atlanta-g-avah-20260312monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-llc-name-title-executive-name-avah-20260220monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-presentation-november-2025-disclaimers-and-forward-looking-statements-this-invest-avah-20251107monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-third-quarter-financial-results-and-revised-2025-out-avah-20251106monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-preliminary-third-quarter-financial-results-atlanta--avah-20251021monthly0.5https://www.biopharmawatch.com/news/AVAH/disclaimers-and-forward-looking-statements-this-investor-presentation-this-presentation-x2-avah-20250929monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-announces-successful-debt-refinancing-atlanta-georgia-avah-20250918monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-presentation-august-2025-disclaimers-and-forward-looking-statements-this-investor-avah-20250808monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-second-quarter-financial-results-and-revised-2025-ou-avah-20250807monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-completes-acquisition-of-thrive-skilled-pediatric-care-atlanta-avah-20250604monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-presentation-may-2025-disclaimers-and-forward-looking-statements-this-investor-pr-avah-20250509monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-first-quarter-financial-results-and-revised-2025-out-avah-20250508monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-agreement-to-acquire-thrive-skilled-pediatric-care-a-avah-20250403monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-presentation-march-2025-disclaimers-and-forward-looking-statements-this-investor--avah-20250313monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-fourth-quarter-and-full-year-2024-financial-results--avah-20250313monthly0.5https://www.biopharmawatch.com/news/AVAH/disclaimers-and-forward-looking-statements-this-investor-presentation-this-presentation-x2-avah-20241108monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-third-quarter-2024-financial-results-and-revised-202-avah-20241107monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-appointment-of-new-director-atlanta-georgia-avah-20241104monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-agreement-to-extend-its-revolving-credit-facility-at-avah-20241004monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-presentation-august-2024-disclaimers-and-forward-looking-statements-this-investor-avah-20240809monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-second-quarter-2024-financial-results-and-revised-20-avah-20240808monthly0.5https://www.biopharmawatch.com/news/AVAH/investor-presentation-june-2024-disclaimers-and-forward-looking-statements-this-investor-p-avah-20240531monthly0.5https://www.biopharmawatch.com/news/AVAH/disclaimers-and-forward-looking-statements-this-investor-presentation-this-presentation-x2-avah-20240510monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-first-quarter-2024-financial-results-and-revised-202-avah-20240509monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-fourth-quarter-2023-financial-results-and-2024-outlo-avah-20240314monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-appointment-of-chief-financial-officer-atlanta-georg-avah-20231211monthly0.5https://www.biopharmawatch.com/news/AVAH/disclaimers-and-forward-looking-statements-this-investor-presentation-this-presentation-x2-avah-20231114monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-third-quarter-2023-financial-results-x2022-revenue-w-avah-20231109monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-second-quarter-2023-financial-results-x2022-revenue--avah-20230810monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-agreement-to-extend-its-175-million-securitization-f-avah-20230804monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-announces-resignation-of-chief-financial-officer-announces-corresponding-appointme-avah-20230615monthly0.5https://www.biopharmawatch.com/news/AVAH/disclaimers-and-forward-looking-statements-this-investor-presentation-this-presentation-x2-avah-20230522monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-first-quarter-2023-financial-results-x2022-revenue-i-avah-20230511monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-fourth-quarter-and-full-year-2022-financial-results--avah-20230316monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-ceo-transition-and-reaffirms-fy-2022-revenue-and-adj-avah-20221213monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-third-quarter-2022-financial-results-atlanta-georgia-avah-20221109monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-second-quarter-2022-financial-results-atlanta-georgi-avah-20220810monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-preliminary-second-quarter-2022-results-updated-full-avah-20220719monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-first-quarter-2022-financial-results-x2022-revenue-i-avah-20220511monthly0.5https://www.biopharmawatch.com/news/AVAH/disclaimers-and-forward-looking-statements-this-investor-presentation-this-presentation-an-avah-20220427monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-fourth-quarter-and-full-year-2021-financial-results--avah-20220328monthly0.5https://www.biopharmawatch.com/news/AVAH/disclaimers-and-forward-looking-statements-this-investor-presentation-this-presentation-an-avah-20211129monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-third-quarter-2021-financial-results-third-quarter-2-avah-20211115monthly0.5https://www.biopharmawatch.com/news/AVAH/disclaimers-and-forward-looking-statements-this-investor-presentation-this-presentation-an-avah-20210823monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-second-quarter-2021-financial-results-revenue-increa-avah-20210811monthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-holdings-announces-first-quarter-2021-financial-results-revenue-increas-avah-20210525monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-reports-second-quarter-fiscal-2026-financial-results-kmts-20251211monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-reports-fourth-quarter-and-fiscal-year-2025-financial-results-kmts-20250715monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-reports-third-quarter-fiscal-2025-financial-results-kmts-20250414monthly0.5https://www.biopharmawatch.com/news/QURE/leadership-in-gene-therapy-january-2026-2-disclaimer-this-presentation-contains-forward-lo-qure-20260113monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-provides-regulatory-update-on-amt-130-for-huntington-s-disease-lexington-ma-and-am-qure-20251204monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2025-financial-results-and-highlights-of-recent-company-p-qure-20250729monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-provides-regulatory-update-on-amt-130-for-huntington-s-disease-alignment-with-fda--qure-20250602monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2025-financial-results-and-highlights-of-recent-company-pr-qure-20250509monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2024-financial-results-and-highlights-recent-company-progress-announced--qure-20250227monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-its-public-offering-lexington-ma-and-amsterdam-the-netherland-qure-20250108monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway-for-a-qure-20241210monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-dosing-of-first-patient-in-gentle-phase-i-iia-clinical-trial-of-amt-260--qure-20241121monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-third-quarter-2024-financial-results-and-highlights-recent-company-progr-qure-20241105monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-dosing-of-first-patient-in-phase-i-ii-clinical-trial-of-amt-162-for-the--qure-20241015monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-orphan-drug-designation-granted-to-amt-191-for-the-treatment-of-fabry-di-qure-20240923monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-dosing-of-first-patient-in-phase-i-iia-clinical-trial-of-amt-191-for-the-qure-20240815monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2024-financial-results-and-provides-company-update-announ-qure-20240801monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-closing-of-sale-of-manufacturing-facility-to-genezen-uniqure-maintains-p-qure-20240723monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-positive-interim-data-update-demonstrating-slowing-of-disease-progressio-qure-20240709monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-sale-of-commercial-manufacturing-facility-to-genezen-proposed-divestitur-qure-20240701monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-investiga-qure-20240603monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2024-financial-results-and-highlights-recent-company-progr-qure-20240507monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2023-financial-results-and-highlights-recent-company-progress-presented--qure-20240228monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-update-on-phase-i-ii-clinical-trials-of-amt-130-gene-therapy-for-the-tre-qure-20231219monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-third-quarter-2023-financial-results-and-highlights-recent-company-progr-qure-20231107monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-strategic-reorganization-to-reduce-operating-expenses-and-support-advanc-qure-20231005monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2023-financial-results-and-highlights-recent-company-prog-qure-20230801monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-achievement-of-100-million-milestone-related-to-hemophilia-b-gene-therap-qure-20230620monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-sale-of-royalty-interest-in-hemgenix-for-up-to-400-million-uniqure-to-re-qure-20230515monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2023-financial-results-and-highlights-recent-company-progr-qure-20230509monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2022-financial-results-and-highlights-recent-company-progress-achieved-u-qure-20230227monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-the-european-commission-approval-of-the-first-gene-therapy-for-adults-wi-qure-20230221monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-and-apic-bio-enter-into-global-licensing-agreement-for-apb-102-a-clinical-stage-ge-qure-20230131monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-positive-chmp-opinion-for-etranacogene-dezaparvovec-gene-therapy-for-adu-qure-20221216monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-approval-of-first-gene-therapy-for-adults-with-hemophilia-b-historic-qure-20221122monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-third-quarter-2022-financial-results-and-highlights-recent-company-progr-qure-20221102monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2022-financial-results-and-highlights-recent-company-prog-qure-20220808monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-acceptance-of-biologics-license-application-for-etranacogene-dezapar-qure-20220524monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2022-financial-results-and-highlights-recent-company-progr-qure-20220502monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-completion-of-patient-enrollment-in-the-first-two-cohorts-of-its-phase-i-qure-20220321monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2021-financial-results-and-highlights-recent-company-progress-data-from--qure-20220225monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-dosing-of-first-patients-in-european-open-label-clinical-trial-of-amt-13-qure-20220207monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-clinical-update-on-first-patients-in-phase-i-ii-clinical-trial-of-amt-13-qure-20211216monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-and-csl-behring-announce-primary-endpoint-achieved-in-hope-b-pivotal-trial-of-etra-qure-20211209monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-third-quarter-2021-financial-results-and-highlights-recent-company-progr-qure-20211025monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2021-financial-results-and-highlights-recent-company-prog-qure-20210726monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-acquire-corlieve-therapeutics-and-advance-its-gene-therapy-program-to-treat-tem-qure-20210622monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2021-financial-results-and-highlights-recent-company-progr-qure-20210510monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-closing-of-commercialization-and-license-agreement-with-csl-behring-upfr-qure-20210507monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-removes-clinical-hold-on-hemophilia-b-gene-therapy-program-lexington-qure-20210426monthly0.5https://www.biopharmawatch.com/news/QURE/un-iqure-announces-completion-of-enrollment-in-first-cohort-of-phase-i-ii-clinical-trial-o-qure-20210405monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-findings-from-reported-case-of-hepatocellular-carcinoma-hcc-in-hemophili-qure-20210326monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2020-financial-results-and-highlights-recent-company-progress-six-patien-qure-20210301monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-positive-recommendation-from-data-safety-monitoring-board-of-phase-i-ii--qure-20210204monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-clinical-update-on-hemophilia-b-gene-therapy-program-company-to-hold-con-qure-20201221monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-late-breaking-data-from-the-hope-b-pivotal-trial-of-etranacogene-dezaparv-qure-20201208monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-two-year-follow-up-data-from-the-phase-iib-study-of-etranacogene-dezapar-qure-20201207monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-positive-top-line-data-from-the-hope-b-pivotal-trial-of-etranacogene-dez-qure-20201119monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-third-quarter-2020-financial-results-and-highlights-recent-company-progr-qure-20201027monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-appointment-of-ricardo-dolmetsch-ph-d-as-president-research-development--qure-20200826monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2020-financial-results-and-highlights-recent-company-prog-qure-20200730monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-license-agreement-with-csl-behring-to-commercialize-hemophilia-b-gene-th-qure-20200624monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-two-patients-treated-in-phase-i-ii-clinical-trial-of-amt-130-for-t-qure-20200619monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-new-preclinical-data-in-sca3-fabry-disease-and-hemophilia-a-at-the-asgct--qure-20200514monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2020-financial-results-and-highlights-recent-company-progr-qure-20200429monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-achievement-of-target-patient-dosing-in-hope-b-pivotal-trial-of-amt-061--qure-20200326monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2019-financial-results-and-highlights-recent-company-progress-patient-do-qure-20200302monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-the-allowance-of-new-patent-providing-further-protection-of-the-padua-an-qure-20191105monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-its-public-offering-lexington-ma-and-amsterdam-the-netherland-qure-20190905monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-achievement-of-planned-enrollment-in-hope-b-pivotal-trial-of-amt-061-etr-qure-20190903monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-leadership-promotions-and-executive-transition-lexington-ma-and-amsterda-qure-20190820monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2019-results-and-highlights-recent-company-progress-prese-qure-20190729monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-36-weeks-of-follow-up-data-from-phase-iib-study-of-amt-061-and-long-term-qure-20190706monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-strengthens-intellectual-property-portfolio-with-granted-patent-claims-covering-am-qure-20190522monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-updated-clinical-data-from-phase-iib-study-of-amt-061-in-patients-with-h-qure-20190510monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-featured-presentations-of-new-data-on-spinocerebellar-ataxia-type-3-at-t-qure-20190507monthly0.5https://www.biopharmawatch.com/news/QURE/annual-report-2018-uniqure-n-v-amsterdam-qure-20190503monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-new-preclinical-data-in-hemophilia-a-and-fabry-disease-in-oral-presentat-qure-20190502monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2019-results-and-highlights-recent-company-progress-presen-qure-20190429monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-receives-fda-fast-track-designation-for-amt-130-gene-therapy-for-the-treatment-of--qure-20190408monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2018-financial-results-and-highlights-recent-company-progress-initiated--qure-20190228monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-new-preclinical-data-on-amt-130-at-the-chdi-s-14-th-annual-huntington-s-d-qure-20190227monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-updated-clinical-data-from-phase-iib-study-of-amt-061-in-patients-with-h-qure-20190208monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-patient-treated-in-hope-b-pivotal-trial-of-amt-061-in-patients-wit-qure-20190204monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-clearance-of-investigational-new-drug-application-for-amt-130-in-hun-qure-20190122monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-long-term-clinical-data-from-ongoing-phase-i-ii-trial-of-amt-060-and-con-qure-20181203monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-highlights-pipeline-expansion-and-advancements-in-technology-at-research-developme-qure-20181119monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-initial-topline-data-from-dose-confirmation-study-of-amt-061-in-patients-qure-20181115monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-third-quarter-2018-financial-results-and-highlights-company-progress-lex-qure-20181106monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2018-financial-results-and-highlights-company-progress-pa-qure-20180808monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-new-appointments-to-its-board-of-directors-lexington-mass-and-amsterdam--qure-20180613monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-its-public-offering-lexington-ma-and-amsterdam-the-netherland-qure-20180502monthly0.5https://www.biopharmawatch.com/news/QURE/annual-report-2017-uniqure-n-v-amsterdam-qure-20180430monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2017-financial-results-and-recent-company-progress-on-track-to-begin-piv-qure-20180314monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-closing-of-its-public-offering-lexington-ma-and-amsterdam-the-netherland-qure-20171027monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-its-public-offering-lexington-ma-and-amsterdam-the-netherland-qure-20171024monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-hemophilia-b-gene-therapy-program-to-enter-pivotal-study-with-fix-padua--qure-20171019monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-company-presentations-at-upcoming-october-conferences-lexington-mass-and-qure-20171002monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-second-quarter-2017-financial-results-and-recent-company-progress-advanc-qure-20170808monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-leadership-team-appointments-and-nominations-to-its-board-of-directors-s-qure-20170807monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-reaquires-development-and-commercialization-rights-for-its-gene-therapy-candidate--qure-20170731monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-updated-long-term-clinical-data-from-ongoing-phase-i-ii-trial-of-amt-060-qure-20170710monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-appointment-of-steven-l-zelenkofske-as-chief-medical-officer-lexington-m-qure-20170606monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2017-financial-results-and-highlights-recent-company-progr-qure-20170509monthly0.5https://www.biopharmawatch.com/news/QURE/annual-report-2016-uniqure-n-v-amsterdam-qure-20170414monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-it-will-not-seek-marketing-authorization-renewal-for-glybera-in-europe-m-qure-20170420monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-2016-financial-results-and-provides-update-on-company-progress-lexington-qure-20170315monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-breakthrough-therapy-designation-for-amt-060-in-hemophilia-b-lexingt-qure-20170130monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-matthew-kapusta-as-chief-executive-officer-lexington-ma-and-amsterdam-the-qure-20161219monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-clinical-data-from-second-dose-cohort-of-amt-060-in-ongoing-phase--qure-20161205monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-financial-results-for-third-quarter-2016-and-provides-update-on-company--qure-20161122monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-completes-strategic-review-to-refocus-its-pipeline-reduce-operating-costs-and-deli-qure-20161115monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-management-and-board-changes-lexington-ma-and-amsterdam-the-netherlands-qure-20160922monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-receives-nasdaq-deficiency-letter-related-to-board-composition-lexington-ma-and-am-qure-20160916monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-financial-results-for-second-quarter-2016-and-update-on-company-progress-qure-20160825monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-updated-clinical-data-in-patients-with-severe-hemophilia-b-demonstrating--qure-20160727monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-first-quarter-2016-amsterdam-the-netherlands-qure-20160531monthly0.5https://www.biopharmawatch.com/news/QURE/annual-report-2015-uniqure-n-v-amsterdam-qure-20160509monthly0.5https://www.biopharmawatch.com/news/QURE/notice-to-convene-the-annual-general-meeting-of-shareholders-of-uniqure-n-v-to-be-held-at--qure-20160509monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-preclinical-data-on-aav-re-administration-regulated-gene-expression-and-t-qure-20160509monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-fourth-quarter-and-financial-year-2015-amsterdam-the-netherl-qure-20160404monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-preliminary-topline-results-from-low-dose-cohort-in-hemophilia-b-phase-i-qure-20160107monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-dan-soland-as-chief-executive-officer-amsterdam-the-netherlands-qure-20151218monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-financial-results-for-third-quarter-2015-and-provides-update-on-product--qure-20151130monthly0.5https://www.biopharmawatch.com/news/QURE/positive-topline-results-announced-from-phase-i-ii-trial-in-sanfilippo-b-syndrome-patients-qure-20150919monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-financial-results-for-second-quarter-2015-amsterdam-the-netherlands-qure-20150827monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-receipt-of-53-million-from-bristol-myers-squibb-for-target-selection-pay-qure-20150810monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-financial-results-for-first-quarter-2015-amsterdam-the-netherlands-qure-20150611monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-closing-of-strategic-collaboration-with-bristol-myers-squibb-to-develop--qure-20150526monthly0.5https://www.biopharmawatch.com/news/QURE/annual-report-2014-uniqure-n-v-amsterdam-qure-20150501monthly0.5https://www.biopharmawatch.com/news/QURE/notice-to-convene-the-annual-general-meeting-of-shareholders-of-uniqure-n-v-to-be-held-at--qure-20150506monthly0.5https://www.biopharmawatch.com/news/QURE/execution-copy-uniqure-n-v-3-000-000-ordinary-shares-nominal-value-0-05-per-share-qure-20150409monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-closing-of-follow-on-public-offering-amsterdam-the-netherlands-qure-20150415monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-follow-on-public-offering-amsterdam-the-netherlands-qure-20150409monthly0.5https://www.biopharmawatch.com/news/QURE/the-following-risk-factor-on-page-14-of-uniqure-s-2014-annual-report-on-form-20-f-filed-wi-qure-20150409monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-launch-of-follow-on-public-offering-amsterdam-qure-20150407monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-fourth-quarter-and-financial-year-2014-amsterdam-the-netherl-qure-20150406monthly0.5https://www.biopharmawatch.com/news/QURE/bristol-myers-squibb-and-uniqure-enter-into-exclusive-strategic-collaboration-to-develop-g-qure-20150406monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-management-s-discussion-and-analysis-of-financial-condition-and-results-of-ope-qure-20150303monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-matthew-kapusta-as-chief-financial-officer-company-announces-changes-in-s-qure-20150109monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-the-third-quarter-of-2014-amsterdam-the-netherlands-qure-20141201monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-unaudited--qure-20140902monthly0.5https://www.biopharmawatch.com/news/QURE/chiesi-and-uniqure-provide-update-on-glybera-launch-amsterdam-the-netherlands-and-parma-it-qure-20140804monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-secures-additional-10m-venture-loan-from-hercules-capital-restructured-venture-deb-qure-20140701monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-index-to-consolidated-financial-statements-page-unaudited-condensed-consolidat-qure-20140606monthly0.5https://www.biopharmawatch.com/news/QURE/notice-to-convene-the-annual-general-meeting-of-shareholders-of-uniqure-n-v-to-be-held-at--qure-20140520monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-changes-in-management-team-amsterdam-the-netherlands-qure-20140409monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-financial-year-2013-amsterdam-the-netherlands-qure-20140326monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-announces-positive-topline-results-from-its-phase-2-clinical-trial-of-sonelokimab-mltx-20260223monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-announces-positive-outcome-from-type-b-meeting-with-u-s-fda-an-mltx-20260108monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-announces-positive-regulatory-feedback-from-both-fda-and-ema-o-mltx-20240610monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-announces-significant-improvements-with-nanobody-sonelokimab-over-24-weeks-in-act-mltx-20240310monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-announces-positive-feedback-from-both-fda-and-ema-on-regulator-mltx-20240226monthly0.5https://www.biopharmawatch.com/news/MLTX/document-exh-ibit-99-1-moonlake-immunotherapeutics-announces-landmark-phase-2-results-for--mltx-20231105monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-announces-the-full-dataset-from-its-24-week-mira-clinical-tria-mltx-20231016monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-second-quarter-2023-financial-results-and-provides-a-b-mltx-20230810monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-achieves-landmark-milestone-with-positive-phase-2-results-for--mltx-20230625monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-ag-announces-closing-of-business-combination-with-helix-acquis-mltx-20220405monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-ag-and-helix-acquisition-corp-announce-business-combination-ag-mltx-20211004monthly0.5https://www.biopharmawatch.com/news/MLTX/helix-acquisition-corp-index-to-financial-statement-page-report-of-independent-registered--mltx-20201022monthly0.5https://www.biopharmawatch.com/news/MLTX/helix-acquisition-corp-announces-pricing-of-100-million-initial-public-offering-boston-ma-mltx-20201019monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-highlights-business-progress-and-reports-first-quarter-2026-financial-results-com-sepn-20260511monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-highlights-pipeline-progress-and-reports-fourth-quarter-and-full-year-2025-financ-sepn-20260309monthly0.5https://www.biopharmawatch.com/news/SEPN/pioneering-a-new-era-of-gpcr-drug-discovery-j-p-morgan-healthcare-conference-2026-january--sepn-20260112monthly0.5https://www.biopharmawatch.com/news/SEPN/forward-looking-statements-this-presentation-contains-express-or-implied-forward-looking-s-sepn-20250903monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-highlights-business-progress-and-reports-second-quarter-2025-financial-results-ad-sepn-20250811monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-highlights-business-progress-and-reports-first-quarter-2025-financial-results-ann-sepn-20250515monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-and-novo-nordisk-to-collaborate-on-oral-small-molecule-medicines-for-obesity-and--sepn-20250514monthly0.5https://www.biopharmawatch.com/news/SEPN/forward-looking-statements-this-presentation-contains-express-or-implied-forward-looking-s-sepn-20250303monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-announces-discontinuation-of-sep-786-phase-1-clinical-trial-and-plans-to-advance--sepn-20250218monthly0.5https://www.biopharmawatch.com/news/SEPN/pioneering-a-new-era-of-gpcr-drug-discovery-j-p-morgan-healthcare-conference-2025-january--sepn-20250113monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-expands-leadership-with-appointment-of-industry-veteran-gil-labrucherie-as-chief--sepn-20250106monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-reports-third-quarter-2024-financial-results-and-recent-business-highlights-deep--sepn-20241120monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2026-financial-results-and-provides-business-update-q1-2026--ardx-20260430monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business--ardx-20260219monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-second-quarter-2025-financial-results-and-provides-business-update-company-ardx-20250804monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2025-financial-results-and-provides-business-update-company--ardx-20250501monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business--ardx-20250220monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2024-financial-results-and-provides-business-update-ibsrela--ardx-20241031monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-second-quarter-2024-financial-results-and-provides-business-update-ibsrela-ardx-20240801monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2024-financial-results-and-provides-business-update-company--ardx-20240502monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business--ardx-20240222monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2023-financial-results-and-updates-2023-u-s-ibsrela-net-sale-ardx-20231017monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-second-quarter-2023-financial-results-and-provides-2023-ibsrela-net-sales--ardx-20230802monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2023-financial-results-and-provides-business-update-continue-ardx-20230417monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business--ardx-20230302monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2022-financial-results-and-recent-business-highlights-confer-ardx-20221103monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-second-quarter-2022-financial-results-and-recent-business-highlights-confe-ardx-20220804monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2022-financial-results-and-recent-business-highlights-confer-ardx-20220505monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-highlights--ardx-20220228monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2021-financial-results-fremont-calif-and-ardx-20211112monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-second-quarter-2021-financial-results-fremont-calif-ardx-20210813monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2021-financial-results-and-recent-business-highlights-fremon-ardx-20210506monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-highlights--ardx-20210308monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2020-financial-results-and-business-highlights-tenapanor-nda-ardx-20201105monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-second-quarter-2020-financial-results-and-recent-business-highlights-submi-ardx-20200806monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2020-financial-results-and-recent-business-highlights-compan-ardx-20200507monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-fourth-quarter-and-full-year-2019-financial-results-and-recent-highlights-ardx-20200306monthly0.5https://www.biopharmawatch.com/news/ARDX/forward-looking-statements-to-the-extent-that-statements-contained-in-this-presentation-ar-ardx-20191203monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2019-financial-results-and-recent-highlights-phreedom-clinic-ardx-20191106monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-second-quarter-2019-financial-results-and-recent-business-highlights-ampli-ardx-20190809monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2019-financial-results-and-recent-business-highlights-two-pi-ardx-20190507monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-fourth-quarter-2018-financial-results-and-recent-highlights-xf0b7-company--ardx-20190306monthly0.5https://www.biopharmawatch.com/news/ARDX/to-the-extent-that-statements-contained-in-this-presentation-are-not-descriptions-of-histo-ardx-20190107monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2018-financial-results-and-recent-highlights-tenapanor-secon-ardx-20181107monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-second-quarter-2018-financial-results-and-recent-highlights-operating-runw-ardx-20180807monthly0.5https://www.biopharmawatch.com/news/ARDX/risk-factors-investing-in-our-common-stock-involves-a-high-degree-of-risk-before-deciding--ardx-20180514monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2018-financial-results-and-recent-business-highlights-on-tra-ardx-20180508monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-2017-financial-results-and-appoints-industry-veteran-jan-lundberg-ph-d-to--ardx-20180314monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2017-operating-results-and-clinical-progress-ardx-20171107monthly0.5https://www.biopharmawatch.com/news/ARDX/to-the-extent-that-statements-contained-in-this-presentation-are-not-descriptions-of-histo-ardx-20171011monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-focuses-resources-on-late-stage-programs-and-reports-second-quarter-2017-operation-ardx-20170809monthly0.5https://www.biopharmawatch.com/news/ARDX/forward-looking-statements-to-the-extent-that-statements-contained-in-this-presentation-ar-ardx-20170622monthly0.5https://www.biopharmawatch.com/news/ARDX/the-intersection-of-breakthrough-science-and-better-health-ardelyx-jpmorgan-2017-annual-he-ardx-20170109monthly0.5https://www.biopharmawatch.com/news/ARDX/ardenwood-blvd-fremont-ca-94555-510-745-1700-tele-www-ardelyx-com-ardelyx-reports-third-qu-ardx-20161107monthly0.5https://www.biopharmawatch.com/news/ARDX/ardenwood-blvd-fremont-ca-94555-510-745-1700-tele-510-745-0493-fax-www-ardelyx-com-ardelyx-ardx-20160808monthly0.5https://www.biopharmawatch.com/news/ARDX/ardenwood-blvd-fremont-ca-94555-510-745-1700-tele-510-745-0493-fax-www-ardelyx-com-ardelyx-ardx-20160509monthly0.5https://www.biopharmawatch.com/news/ARDX/ardenwood-blvd-fremont-ca-94555-510-745-1700-tele-510-745-0493-fax-www-ardelyx-com-ardelyx-ardx-20160304monthly0.5https://www.biopharmawatch.com/news/ARDX/ardenwood-blvd-fremont-ca-94555-510-745-1700-tele-510-745-0493-fax-www-ardelyx-com-ardelyx-ardx-20151112monthly0.5https://www.biopharmawatch.com/news/HCSG/the-company-entered-into-a-second-amendment-dated-hcsg-20260407monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reconciliations-of-non-gaap-financial-measures-unaudited-rec-hcsg-20260211monthly0.5https://www.biopharmawatch.com/news/HCSG/cash-flow-from-operations-includes-a-31-8-million-benefit-related-to-the-erc-1-2-3-balance-hcsg-20251022monthly0.5https://www.biopharmawatch.com/news/HCSG/cash-flow-from-operations-was-reported-at-28-8-million-after-adjusting-for-the-20-3-millio-hcsg-20250723monthly0.5https://www.biopharmawatch.com/news/HCSG/conference-call-and-upcoming-events-the-company-will-host-a-conference-call-on-wednesday-hcsg-20250423monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reconciliations-of-non-gaap-financial-measures-unaudited-rec-hcsg-20250212monthly0.5https://www.biopharmawatch.com/news/HCSG/upcoming-events-and-conference-call-the-company-will-be-participating-in-the-ubs-global-he-hcsg-20241023monthly0.5https://www.biopharmawatch.com/news/HCSG/november-2027-additionally-the-company-repurchased-263-500-shares-or-3-0-million-of-its-co-hcsg-20240724monthly0.5https://www.biopharmawatch.com/news/HCSG/revenue-was-423-4-million-in-line-with-the-company-s-expectations-of-420-0-million-to-430--hcsg-20240424monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reconciliations-of-non-gaap-financial-measures-unaudited-rec-hcsg-20240214monthly0.5https://www.biopharmawatch.com/news/HCSG/housekeeping-laundry-and-dining-nutrition-segment-revenues-were-190-9-million-and-220-5-mi-hcsg-20231025monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-q2-2023-results-robust-new-business-pipeline-sets-st-hcsg-20230726monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-q1-2023-results-continues-positive-business-momentum-hcsg-20230426monthly0.5https://www.biopharmawatch.com/news/HCSG/ted-wahl-well-i-think-the-ultimate-lever-are-the-ongoing-positive-trends-related-to-labor--hcsg-20230216monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-condensed-consolidated-balance-sheets-unaudited-in-thousands-hcsg-20230215monthly0.5https://www.biopharmawatch.com/news/HCSG/conference-call-and-upcoming-events-the-company-will-host-a-conference-call-on-wednesday-hcsg-20221019monthly0.5https://www.biopharmawatch.com/news/HCSG/to-our-customers-so-on-behalf-of-matt-and-all-of-us-at-healthcare-services-group-i-wanted--hcsg-20220720monthly0.5https://www.biopharmawatch.com/news/HCSG/conference-call-and-upcoming-events-the-company-will-host-a-conference-call-on-wednesday-hcsg-20220720monthly0.5https://www.biopharmawatch.com/news/HCSG/inquiries-regarding-the-settlement-or-the-derivative-action-should-be-addressed-in-writing-hcsg-20220617monthly0.5https://www.biopharmawatch.com/news/HCSG/dividend-the-company-s-board-of-directors-declared-a-quarterly-cash-dividend-of-0-2125-per-hcsg-20220420monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-condensed-consolidated-balance-sheets-unaudited-in-thousands-hcsg-20220209monthly0.5https://www.biopharmawatch.com/news/HCSG/cash-outflow-from-operations-for-the-quarter-was-23-1-million-and-was-impacted-by-a-16-0-m-hcsg-20211020monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-announces-conclusion-of-sec-matter-bensalem-pa-hcsg-20210824monthly0.5https://www.biopharmawatch.com/news/HCSG/second-quarter-results-revenue-for-the-quarter-was-398-2-million-with-housekeeping-laundry-hcsg-20210721monthly0.5https://www.biopharmawatch.com/news/HCSG/dividend-share-repurchase-the-company-s-board-of-directors-declared-a-quarterly-cash-divid-hcsg-20210421monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-announces-leadership-updates-bensalem-pa-hcsg-20201111monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-provides-update-on-first-quarter-results-bensalem-pa-hcsg-20180416monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20161011monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20160712monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2016-inc-hcsg-20160412monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-and-year-ended-december-hcsg-20160202monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-increases-fourth-quarter-cash-dividend-provides-update-on-20-hcsg-20160126monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20151013monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20150714monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2015-inc-hcsg-20150414monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-and-year-ended-december-hcsg-20150203monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-increases-fourth-quarter-2014-cash-dividend-bensalem-pa-hcsg-20150127monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-provides-update-on-insurance-programs-and-related-charges-an-hcsg-20141014monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20140708monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2014-inc-hcsg-20140408monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-and-year-ended-december-hcsg-20140204monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-increases-fourth-quarter-2013-cash-dividend-provides-update--hcsg-20140128monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-appoints-general-counsel-secretary-provides-update-on-captiv-hcsg-20131219monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20131008monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20130716monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-announces-asset-purchase-agreement-with-platinum-health-serv-hcsg-20130715monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20121009monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20120710monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2012-and-hcsg-20120410monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-announces-independent-lead-director-independent-director-nominee-hcsg-20120331monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-and-year-ended-december-hcsg-20120207monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-declares-increased-fourth-quarter-2011-cash-dividend-bensale-hcsg-20120124monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20111011monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20110712monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2011-and-hcsg-20110412monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-and-year-ended-december-hcsg-20110207monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-declares-fourth-quarter-2010-cash-dividend-bensalem-pa-hcsg-20110125monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20101012monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20100713monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2010-ben-hcsg-20100413monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-and-year-ended-december-hcsg-20100209monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-declares-fourth-quarter-2009-cash-dividend-bensalem-pa-hcsg-20100129monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20091013monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20090714monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2009-dec-hcsg-20090414monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-and-year-ended-december-hcsg-20090210monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-declares-fourth-quarter-2008-cash-dividend-bensalem-pa-hcsg-20090120monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20081014monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20080715monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2008-and-hcsg-20080415monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-and-year-ended-december-hcsg-20080212monthly0.5https://www.biopharmawatch.com/news/HCSG/issued-by-healthcare-services-group-inc-exv99w1-healthcare-services-group-inc-declares-fou-hcsg-20080122monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-nine-months-ended-septembe-hcsg-20071016monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-and-six-months-ended-june-30-2-hcsg-20070717monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-reports-results-for-the-three-months-ended-march-31-2007-and-hcsg-20070417monthly0.5https://www.biopharmawatch.com/news/HCSG/dated-february-13-2007-exv99w1-healthcare-services-group-inc-reports-record-results-for-th-hcsg-20070214monthly0.5https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-inc-declares-fourth-quarter-2006-cash-dividend-bensalem-pa-hcsg-20070123monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-reports-full-year-2025-financial-results-topline-global-pivotal-phase-3-avbp-20260305monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-reports-third-quarter-2025-financial-results-final-phase-1b-results-pre-avbp-20251110monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-announces-positive-interim-firmonertinib-monotherapy-data-from-global-phase-1b-st-avbp-20250623monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-reports-first-quarter-2025-financial-results-completed-enrollment-in-gl-avbp-20250512monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-appoints-merdad-parsey-m-d-ph-d-to-its-board-of-directors-avbp-20250428monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-reports-full-year-2024-financial-results-first-clinical-data-demonstrat-avbp-20250303monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-enters-exclusive-license-with-lepu-biopharma-for-mrg007-an-antibody-dru-avbp-20250121monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-reports-third-quarter-2024-financial-results-robust-firmonertinib-monot-avbp-20241114monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-announces-positive-proof-of-concept-global-phase-1b-interim-data-for-firmonertini-avbp-20240909monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-reports-second-quarter-2024-financial-results-clinical-proof-of-concept-avbp-20240814monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-appoints-kristine-peterson-to-its-board-of-directors-newton-square-pa-april-22-20-avbp-20240709monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-announces-a-multi-target-adc-collaboration-with-alphamab-collaboration-will-lever-avbp-20240605monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-appoints-john-hohneker-m-d-to-its-board-of-directors-avbp-20240516monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-reports-first-quarter-2024-financial-results-presented-preclinical-firm-avbp-20240508monthly0.5https://www.biopharmawatch.com/news/AVBP/kristine-peterson-to-its-board-of-directors-avbp-20240422monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-reports-full-year-2023-financial-results-company-progresses-the-develop-avbp-20240328monthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-u-mplt-20260514monthly0.5https://www.biopharmawatch.com/news/MPLT/xfeff-this-presentation-and-any-accompanying-oral-commentary-have-been-prepared-by-mapligh-mplt-20260109monthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-reports-third-quarter-financial-results-and-highlights-corporate-pro-mplt-20251204monthly0.5https://www.biopharmawatch.com/news/MPLT/form-of-share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-entered-i-mplt-20251026monthly0.5https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-reports-first-quarter-2026-financial-results-completed-initial-public-o-coag-20260521monthly0.5https://www.biopharmawatch.com/news/AVLN/avalyn-completes-target-enrollment-in-phase-2b-mist-trial-of-ap01-inhaled-pirfenidone-for--avln-20260617monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-c-zbio-20260316monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-reports-third-quarter-2025-financial-results-and-provides-corporate-update-zbio-20251112monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-positive-results-from-phase-2-moonstone-trial-of-obexelimab-in-r-zbio-20251027monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-and-innocare-pharma-announce-license-agreement-granting-zenas-rights-for-t-zbio-20251008monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-and-royalty-pharma-enter-into-obexelimab-funding-agreement-for-up-to-300-m-zbio-20250902monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-reports-second-quarter-2025-financial-results-and-provides-corporate-updat-zbio-20250812monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-corporate-presentation-june-2025-enabling-patients-with-autoimmune-disease-zbio-20250604monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-reports-first-quarter-2025-financial-results-and-provides-corporate-update-zbio-20250515monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-key-2024-accomplishments-and-2025-business-objectives-to-support-zbio-20250205monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-corporate-presentation-december-2024-enabling-patients-with-autoimmune-dis-zbio-20241202monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update-zbio-20241112monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-preliminary-unaudited-revenue-results-for-the-fourth-insp-20260112monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-preliminary-results-for-the-fourth-quarter-and-full--insp-20250113monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-preliminary-results-for-second-quarter-of-2024-and-u-insp-20240729monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-preliminary-results-for-the-fourth-quarter-and-full--insp-20240108monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-appointment-of-seasoned-medical-device-executive-myr-insp-20231228monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-preliminary-results-for-the-fourth-quarter-and-full--insp-20230109monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-preliminary-results-for-the-fourth-quarter-and-full--insp-20220104monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-positive-coverage-policy-issued-by-anthem-for-inspir-insp-20210520monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-provides-first-quarter-and-full-year-2020-update-insp-20200413monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-first-quarter-2019-financial-results-and-increases-2-insp-20190507monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-fourth-quarter-and-full-year-2018-financial-results-insp-20190226monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-third-quarter-2018-financial-results-and-updates-201-insp-20181106monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-to-have-significant-presence-at-american-academy-of-otolaryngo-insp-20181002monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-s-company-presentation-september-2018-nyse-insp-disclaimer-thi-insp-20180905monthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-inc-announces-second-quarter-2018-financial-results-insp-20180807monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-first-quarter-2026-financial-results-and-provides-corporate-u-sls-20260511monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-announces-exercise-of-existing-warrants-held-by-a-current-insti-sls-20250911monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-second-quarter-2025-financial-results-and-provides-corporate--sls-20250812monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-first-quarter-2025-financial-results-and-provides-corporate-u-sls-20250513monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-full-year-2024-financial-results-and-provides-corporate-updat-sls-20250320monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-announces-25-million-registered-direct-offering-priced-at-the-m-sls-20250128monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-positive-outcome-of-interim-analysis-for-its-pivotal-phase--sls-20250123monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-triggers-interim-analysis-in-phase-3-regal-trial-of-gps-in-acute-myel-sls-20241210monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-third-quarter-2024-financial-results-and-provides-corporate-u-sls-20241113monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-second-quarter-2024-financial-results-and-provides-corporate--sls-20240813monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-21-0-million-registered-direct-offering-priced-at-a-premium-sls-20240731monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-first-quarter-2024-financial-results-and-provides-corporate-u-sls-20240514monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-full-year-2023-financial-results-and-provides-corporate-updat-sls-20240328monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-announces-20-million-registered-direct-offering-and-concurrent--sls-20240315monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-executive-leadership-reorganization-and-prioritization-of-commercializati-sls-20240308monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-of-9-0-million-public-offering-1-4-2024-sls-20240104monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-third-quarter-2023-financial-res-sls-20231109monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-4-million-registered-direct-offering-priced-at-the-market-u-sls-20231031monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-initial-topline-phase-2a-data-of-sls009-in-acute-myeloid-leukemi-sls-20231016monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-update-on-phase-3-regal-clinical-trial-for-galinpepimut-s-in-sls-20231012monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-second-quarter-2023-financial-re-sls-20230810monthly0.5https://www.biopharmawatch.com/news/SLS/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-tara-sobierajski-senior-manager-client-success-l-sls-20230601monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-first-quarter-2023-financial-res-sls-20230511monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-full-year-2022-financial-results-and-provides-business-update-sls-20230316monthly0.5https://www.biopharmawatch.com/news/SLS/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-sls-20230224monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-phase-1-data-with-cdk9-inhibitor-gfh009-monotherapy-in-patients--sls-20221213monthly0.5https://www.biopharmawatch.com/news/SLS/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-allison-soss-investor-relations-kcsa-strategic-c-sls-20221115monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-third-quarter-2022-financial-res-sls-20221114monthly0.5https://www.biopharmawatch.com/news/SLS/investor-symposium-on-galinpepimut-s-sls-20220915monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-election-of-katherine-bach-kalin-to-its-board-of-directors--sls-20220816monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-second-quarter-2022-financial-re-sls-20220811monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-first-quarter-2022-financial-results-and-provides-business-up-sls-20220512monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-inc-business-update-and-first-quarter-2022-highlights-call-sls-20220406monthly0.5https://www.biopharmawatch.com/news/SLS/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-sls-20220401monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-third-quarter-2021-financial-results-and-provides-business-up-sls-20211112monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-settlement-of-derivative-litigation-sls-20210923monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-second-quarter-2021-financial-results-and-provides-business-u-sls-20210812monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-inc-shareholder-update-call-sls-20210603monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-first-quarter-2021-financial-results-and-provides-business-up-sls-20210513monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update-sls-20210323monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-highlights-2020-business-and-clinical-progress-and-2021-milestones-ph-sls-20201231monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-promising-initial-clinical-data-for-galinpepimut-s-gps-in-combination-wit-sls-20201221monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-pricing-of-16-2-million-registered-direct-offering-sls-20201213monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-and-3d-medicines-announce-exclusive-license-agreement-for-development-sls-20201207monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-third-quarter-2020-financial-res-sls-20201113monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-second-quarter-2020-financial-re-sls-20200813monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-9-2-million-private-placement-priced-at-the-market-proceeds-sls-20200804monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-first-quarter-2020-financial-results-and-provides-business-up-sls-20200514monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-full-year-2019-financial-results-and-provides-business-update-sls-20200313monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-pricing-of-6-5-million-registered-direct-offering-priced-at-the-market-sls-20200109monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-third-quarter-2019-financial-res-sls-20191115monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-second-quarter-2019-financial-re-sls-20190814monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-of-15-million-public-offering-6-14-2019-sls-20190614monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-first-quarter-2019-financial-res-sls-20190515monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-2018-financial-results-and-provides-business-update-sls-20190322monthly0.5https://www.biopharmawatch.com/news/SLS/in-its-current-report-on-form-8-k-filed-on-sls-20190226monthly0.5https://www.biopharmawatch.com/news/SLS/in-its-current-report-on-form-8-k-filed-on-sls-20181115monthly0.5https://www.biopharmawatch.com/news/SLS/may-contain-forward-looking-statements-that-reflect-our-current-views-with-respect-to-our--sls-20180718monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-corporate-highlights-advancements-for-its-cancer-immunotherap-sls-20180416monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-10-700-000-private-placement-financing-will-support-advance-sls-20180307monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-inc-stockholders-approve-business-combination-with-sellas-life-sciences-g-sls-20171229monthly0.5https://www.biopharmawatch.com/news/SLS/galena-will-adjourn-special-meeting-until-friday-sls-20171214monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-third-quarter-2017-financial-results-sls-20171109monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-enters-into-a-clinical-trial-collaboration-and-supply-agreement-with-merck-co-inc-k-sls-20171002monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-completion-of-enrollment-in-two-neuvax-nelipepimut-s-clinical-t-sls-20170928monthly0.5https://www.biopharmawatch.com/news/SLS/mm-252-galinpepimut-s-a-wilms-tumor-protein-1-wt1-targeting-immuno-oncology-treatment-indu-sls-20170914monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-and-biovascular-inc-reaffirm-gale-401-partnership-san-ramon-california-sls-20170911monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-second-quarter-2017-financial-results-sls-20170814monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-enters-into-merger-agreement-with-sellas-life-sciences-group-merger-to-cr-sls-20170808monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-first-quarter-2017-financial-results-sls-20170510monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-fourth-quarter-and-year-end-2016-financial-results-and-provides-a-sls-20170315monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-board-of-directors-appoints-stephen-f-ghiglieri-as-interim-chief-executiv-sls-20170221monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-the-resignation-of-its-president-and-chief-executive-officer-an-sls-20170131monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-third-quarter-2016-financial-results-and-provides-a-corporate-upd-sls-20161109monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-appoints-stephen-f-sls-20161103monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-second-quarter-2016-financial-results-and-provides-a-corporate-up-sls-20160809monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-pricing-of-registered-direct-offering-san-ramon-california-sls-20160708monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-discontinues-neuvax-nelipepimut-s-phase-3-present-interim-analysis-based--sls-20160629monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-appoints-mary-ann-gray-ph-d-to-its-board-of-directors-sls-20160426monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-fourth-quarter-and-year-end-2015-financial-results-and-provides-a-sls-20160310monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-proposed-settlement-of-derivative-litigation-sls-20160216monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-proposed-public-offering-of-common-stock-and-warrants-san-ramon-sls-20160106monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-a-change-to-its-board-of-directors-sls-20151224monthly0.5https://www.biopharmawatch.com/news/SLS/this-press-release-contains-forward-looking-statements-within-the-meaning-of-the-private-s-sls-20151218monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-departure-of-chief-financial-officer-sls-20151211monthly0.5https://www.biopharmawatch.com/news/SLS/k-exhibit-99-1-galena-biopharma-inc-index-to-consolidated-financial-statements-and-other-f-sls-20151204monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-completes-divestiture-of-abstral-fentanyl-sublingual-tablets-as-part-of-s-sls-20151120monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-third-quarter-2015-financial-results-and-sls-20151109monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-appoints-bijan-nejadnik-m-d-as-executive-vice-president-and-chief-medical-sls-20151030monthly0.5https://www.biopharmawatch.com/news/SLS/gale-2015-08-06-ex99-1-galena-biopharma-reports-second-quarter-2015-financial-results-comp-sls-20150729monthly0.5https://www.biopharmawatch.com/news/SLS/gale-2015-05-07-ex99-1-galena-biopharma-reports-first-quarter-2015-financial-results-compl-sls-20150507monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-proposed-public-offering-of-common-stock-and-warrants-portland--sls-20150312monthly0.5https://www.biopharmawatch.com/news/SLS/gale-2015-03-05-ex99-1-galena-biopharma-reports-fourth-quarter-and-year-end-2014-financial-sls-20150305monthly0.5https://www.biopharmawatch.com/news/SLS/gale-2015-02-09-ex99-1-galena-biopharma-enrolls-700-th-patient-in-neuvax-nelipepimut-s-pha-sls-20150209monthly0.5https://www.biopharmawatch.com/news/SLS/11-20-2014-galena-biopharma-inc-announces-purchase-agreement-for-up-to-55-0-million-with-l-sls-20141118monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-third-quarter-2014-results-sls-20141103monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-appoints-mark-w-schwartz-ph-d-as-president-and-chief-executive-officer-po-sls-20140821monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-second-quarter-2014-results-sls-20140811monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-enters-into-definitive-agreement-to-license-sls-20140722monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-first-quarter-2014-results-sls-20140506monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-fourth-quarter-and-year-end-2013-results-sls-20140317monthly0.5https://www.biopharmawatch.com/news/SLS/dr-reddy-s-partnership-galena-biopharma-and-dr-reddy-s-announce-strategic-partnership-for--sls-20140114monthly0.5https://www.biopharmawatch.com/news/SLS/mills-pharma-acquisition-press-release-galena-biopharma-acquires-mills-pharmaceuticals-llc-sls-20140113monthly0.5https://www.biopharmawatch.com/news/SLS/gale-2013-09-30-ex99-1-galena-biopharma-reports-third-quarter-2013-results-portland-oregon-sls-20131106monthly0.5https://www.biopharmawatch.com/news/SLS/closing-press-release-galena-biopharma-announces-closing-of-public-offering-of-common-stoc-sls-20130918monthly0.5https://www.biopharmawatch.com/news/SLS/public-offering-announcement-galena-biopharma-announces-proposed-public-offering-of-common-sls-20130912monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-second-quarter-2013-financial-results-galena-to-generate-sales-re-sls-20130808monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-first-quarter-2013-financial-results-lead-product-neuvax-nelipepi-sls-20130509monthly0.5https://www.biopharmawatch.com/news/SLS/william-l-ashton-joins-galena-biopharma-s-board-of-directors-lake-oswego-oregon-sls-20130501monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-acquires-abstral-fentanyl-sublingual-tablets-in-u-s-a-novel-best-in-class-sls-20130318monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-year-end-2012-financial-results-operating-loss-from-continuing-op-sls-20130312monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-pricing-of-public-offering-of-common-stock-and-warrants-lake-os-sls-20121218monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-public-offering-of-common-stock-and-warrants-lake-oswego-oregon-sls-20121217monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-signature-of-commercialization-partnership-with-teva-for-israel-sls-20121204monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-third-quarter-2012-financial-results-lake-oswego-oregon-sls-20121113monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-second-quarter-2012-financial-results-lake-oswego-oregon-sls-20120814monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-first-quarter-2012-financial-results-lake-oswego-oregon-sls-20120514monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-exercise-of-underwriters-over-allotment-option-and-closing-of-1-sls-20120416monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-announces-public-offering-of-common-stock-lake-oswego-oregon-sls-20120404monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-fourth-quarter-and-2011-financial-results-and-provides-business-u-sls-20120328monthly0.5https://www.biopharmawatch.com/news/SLS/securities-and-exchange-commission-sls-20120123monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-enters-into-exchange-agreements-with-warrant-holders-agreement-simplifies-sls-20111206monthly0.5https://www.biopharmawatch.com/news/SLS/galena-biopharma-reports-third-quarter-2011-financial-results-and-provides-business-update-sls-20111114monthly0.5https://www.biopharmawatch.com/news/SLS/rxi-pharmaceuticals-to-strengthen-strategic-focus-by-separating-into-two-publicly-traded-c-sls-20110926monthly0.5https://www.biopharmawatch.com/news/SLS/rxi-pharmaceuticals-licenses-novel-targeted-cancer-vaccine-for-gynecological-cancers-vacci-sls-20110921monthly0.5https://www.biopharmawatch.com/news/SLS/rxi-pharmaceuticals-provides-update-and-reports-financial-results-for-q2-2011-neuvax-e75-m-sls-20110815monthly0.5https://www.biopharmawatch.com/news/SLS/rxi-pharmaceuticals-strengthens-neuvax-tm-e75-patent-portfolio-rxi-acquires-patent-rights--sls-20110713monthly0.5https://www.biopharmawatch.com/news/SLS/rxi-pharmaceuticals-reports-financial-results-for-the-first-quarter-of-2011-acquisition-an-sls-20110517monthly0.5https://www.biopharmawatch.com/news/SLS/rxi-pharmaceuticals-announces-public-offering-of-common-stock-and-warrants-sls-20110414monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-results-updates-financial-guidance--pahc-20260506monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-regulatory-framework-change-in-brazil-for-antim-pahc-20260427monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-results-updates-financial-guidance-pahc-20260204monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-leadership-transition-jack-bendheim-to-assume-t-pahc-20251218monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-results-updates-financial-guidance--pahc-20251105monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-results-provides-f-pahc-20250827monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20250729monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-results-updates-financial-guidance--pahc-20250507monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-results-updates-financial-guidance-pahc-20250205monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-the-appointment-of-joyce-j-lee-to-its-board-of--pahc-20250123monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-results-updates-financial-guidance--pahc-20241106monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-completes-acquisition-of-zoetis-medicated-feed-additive-p-pahc-20241031monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-results-provides-f-pahc-20240828monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20240730monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-results-updates-financial-guidance--pahc-20240508monthly0.5https://www.biopharmawatch.com/news/PAHC/zoetis-to-sell-medicated-feed-additive-portfolio-to-phibro-animal-health-parsippany-nj-and-pahc-20240428monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-results-updates-financial-guidance-pahc-20240207monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-results-updates-financial-guidance--pahc-20231108monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20231106monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-chief-financial-officer-changes-teaneck-n-j-pahc-20230905monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-results-provides-f-pahc-20230830monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20230725monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-and-year-to-date-results-teaneck-n--pahc-20230503monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20230501monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-results-teaneck-n-j-pahc-20230208monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-the-appointment-of-alejandro-bernal-to-its-boar-pahc-20230206monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-results-revised-guidance-teaneck-n--pahc-20221109monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20221107monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-results-provides-f-pahc-20220824monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20220725monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-results-provides-revised-financial--pahc-20220504monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20220502monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-results-provides-revised-financial-pahc-20220209monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20220207monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-welcomes-fda-hearing-on-mecadox-teaneck-nj-pahc-20220112monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-results-teaneck-n-j-pahc-20211102monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20211101monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-results-provides-f-pahc-20210825monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20210726monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-and-year-to-date-results-teaneck-n--pahc-20210506monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20210503monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-550-million-debt-refinancing-teaneck-n-j-pahc-20210422monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-results-teaneck-n-j-pahc-20210203monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20210201monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-results-teaneck-n-j-pahc-20201104monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20201102monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-chief-financial-officer-changes-teaneck-n-j-pahc-20200917monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-results-provides-g-pahc-20200826monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20200727monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reiterates-safety-of-mecadox-teaneck-nj-pahc-20200717monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-results-teaneck-n-j-pahc-20200507monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20200504monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-results-teaneck-n-j-pahc-20200203monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-results-presents-f-pahc-20190827monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-acquires-business-of-osprey-biotechnics-inc-teaneck-n-j-pahc-20190801monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20190729monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-results-teaneck-n-j-pahc-20190506monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-results-teaneck-n-j-pahc-20190206monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-results-updates-financial-guidance--pahc-20181106monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20181105monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-results-presents-f-pahc-20180827monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20180730monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-teaneck-n-j-pahc-20180507monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-and-updated-annual-financial-guida-pahc-20180205monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-teaneck-n-j-pahc-20171106monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-teaneck-n-j-pahc-20170830monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20170724monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-teaneck-n-j-pahc-20170508monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-teaneck-n-j-pahc-20170206monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-first-quarter-teaneck-n-j-pahc-20161109monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20161107monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-teaneck-n-j-pahc-20160829monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20160725monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-gerald-carlson-retirement-larry-miller-promotio-pahc-20160531monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-pahc-20160509monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reiterates-safety-of-mecadox-teaneck-n-j-pahc-20160408monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-teaneck-n-j-pahc-20160209monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-pahc-20160208monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-closing-of-acquisition-pahc-20160125monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-to-acquire-business-of-pahc-20160112monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-pahc-20151109monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-fiscal-year-teaneck-n-j-pahc-20150909monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-pahc-20150727monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-teaneck-n-j-pahc-20150511monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-second-quarter-teaneck-n-j-pahc-20150210monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-pahc-20150209monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-announces-entry-into-collaboration-agreement-license-agre-pahc-20150122monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-pahc-20141112monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-pahc-20141110monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-fourth-quarter-and-annual-results-teaneck-n-j-pahc-20140916monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-teaneck-n-j-pahc-20140728monthly0.5https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-reports-third-quarter-results-teaneck-n-j-pahc-20140513monthly0.5https://www.biopharmawatch.com/news/PAHC/for-release-immediately-for-additional-information-contact-richard-g-johnson-chief-financi-pahc-20060801monthly0.5https://www.biopharmawatch.com/news/PAHC/for-release-immediately-for-additional-information-contact-richard-g-johnson-chief-financi-pahc-20060714monthly0.5https://www.biopharmawatch.com/news/PAHC/y22885aexv99w1-txt-press-release-for-release-immediately-for-additional-information-contac-pahc-20060630monthly0.5https://www.biopharmawatch.com/news/PAHC/for-release-immediately-for-additional-information-contact-richard-g-johnson-chief-financi-pahc-20050505monthly0.5https://www.biopharmawatch.com/news/PAHC/for-additional-information-contact-richard-g-johnson-chief-financial-officer-201-329-7300--pahc-20050309monthly0.5https://www.biopharmawatch.com/news/PAHC/for-release-immediately-for-additional-information-contact-richard-g-johnson-chief-financi-pahc-20050228monthly0.5https://www.biopharmawatch.com/news/PAHC/y05870exv99w1-txt-press-release-for-release-immediately-for-additional-information-contact-pahc-20050215monthly0.5https://www.biopharmawatch.com/news/PAHC/for-release-immediately-for-additional-information-contact-richard-g-johnson-chief-financi-pahc-20041118monthly0.5https://www.biopharmawatch.com/news/PAHC/consent-solicitation-statement-phibro-animal-health-corporation-solicitation-of-consents-r-pahc-20041118monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-bayer-to-e-olma-20260526monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-appoints-prakash-raman-ph-d-to-board-of-directors-olma-20260429monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-x-olma-20260316monthly0.5https://www.biopharmawatch.com/news/OLMA/advancing-medicines-for-breast-cancer-and-beyond-corporate-overview-january-2025-forward-l-olma-20251231monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-second-quarter-2025-financial-and-operating-results-x2022-selected--olma-20250811monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-first-quarter-2025-financial-and-operating-results-x2022-pivotal-ph-olma-20250513monthly0.5https://www.biopharmawatch.com/news/OLMA/forward-looking-statements-this-presentation-contains-forward-looking-statements-made-purs-olma-20250305monthly0.5https://www.biopharmawatch.com/news/OLMA/forward-looking-statements-this-presentation-contains-forward-looking-statements-made-purs-olma-20241231monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-fda-clearance-of-investigational-new-drug-application-for-op-3136-olma-20241209monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-new-clinical-trial-collaboration-and-supply-agreement-with-novart-olma-20241202monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-third-quarter-2024-financial-results-and-provides-corporate-update--olma-20241112monthly0.5https://www.biopharmawatch.com/news/OLMA/advancing-medicines-for-breast-cancer-and-beyond-corporate-overview-september-2024-forward-olma-20240927monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-second-quarter-2024-financial-results-and-provides-corporate-update-olma-20240806monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-promising-new-data-for-palazestrant-in-combination-with-ribocicli-olma-20240515monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-first-quarter-2024-financial-results-and-provides-corporate-update--olma-20240508monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-co-olma-20240311monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-jp-morgan-conference-january-2024-forward-looking-statements-this-presentat-olma-20240108monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-nominates-op-3136-an-orally-bioavailable-kat6-inhibitor-as-a-development-ca-olma-20240108monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-sabcs-december-2023-presentation-olma-20231206monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-palazestrant-demonstrates-attractive-combinability-with-cdk4-6-in-olma-20231206monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-third-quarter-2023-financial-results-and-provides-corporate-update--olma-20231107monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-positive-phase-2-monotherapy-clinical-study-results-for-palazestr-olma-20231023monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-appoints-oncology-biotech-executive-scott-garland-to-board-of-directors-mr--olma-20231017monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-expansion-of-collaboration-agreement-with-novartis-amended-clinic-olma-20231010monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-combined-financing-for-up-to-180-million-130-million-equity-priva-olma-20230905monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-second-quarter-2023-financial-results-and-provides-corporate-update-olma-20230808monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-op-1250-continues-to-demonstrate-attractive-combinability-with-cd-olma-20230511monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-first-quarter-2023-financial-results-and-provides-corporate-update--olma-20230512monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-st-olma-20230309monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-third-quarter-2022-financial-results-and-provides-corporate-update--olma-20221108monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-second-quarter-2022-financial-results-and-provides-corporate-update-olma-20220809monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-first-quarter-2022-financial-results-and-provides-corporate-update--olma-20220509monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-co-olma-20220228monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-third-quarter-2021-financial-results-and-provides-corporate-update--olma-20211110monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-second-quarter-2021-financial-results-and-provides-corporate-update-olma-20210810monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-first-quarter-2021-financial-results-and-provides-corporate-update--olma-20210511monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-co-olma-20210317monthly0.5https://www.biopharmawatch.com/news/ASTH/m-e-d-i-c-a-r-e-m-e-d-i-c-a-i-d-c-o-m-m-e-r-c-i-al-o-th-e-r-t-h-i-r-d-p-a-r-t-i-es-f-u-l-l-asth-20260512monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-first-quarter-2026-results-company-to-host-conference-call-on-t-asth-20260507monthly0.5https://www.biopharmawatch.com/news/ASTH/php-holdings-llc-rhode-island-market-condensed-combined-and-consolidated-financial-stateme-asth-20260330monthly0.5https://www.biopharmawatch.com/news/ASTH/investor-presentation-march-2026-2-forward-looking-statements-this-presentation-contains-f-asth-20260304monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-fourth-quarter-and-year-end-2025-results-company-to-host-confer-asth-20260302monthly0.5https://www.biopharmawatch.com/news/ASTH/investor-presentation-january-2026-2-forward-looking-statements-this-presentation-contains-asth-20260112monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-third-quarter-2025-results-company-to-host-conference-call-on-t-asth-20251106monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-second-quarter-2025-results-company-to-host-conference-call-on--asth-20250807monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-announces-closing-of-prospect-health-acquisition-asth-20250702monthly0.5https://www.biopharmawatch.com/news/ASTH/x2022-x2022-x2022-x2022-x2022-asth-20250604monthly0.5https://www.biopharmawatch.com/news/ASTH/e-2019-2020-2021-2022-2023-2024-2025e-x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-2019-asth-20250513monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-first-quarter-2025-results-company-to-host-conference-call-on-t-asth-20250508monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-consolidated-balance-sheets-in-thousands-except-share-and-per-share-dat-asth-20250314monthly0.5https://www.biopharmawatch.com/news/ASTH/investor-presentation-march-2025-2-forward-looking-statements-this-presentation-contains-f-asth-20250310monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-fourth-quarter-and-year-end-2024-results-company-to-host-confer-asth-20250227monthly0.5https://www.biopharmawatch.com/news/ASTH/x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-asth-20250114monthly0.5https://www.biopharmawatch.com/news/ASTH/x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-asth-20241114monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-announces-definitive-agreement-to-acquire-certain-businesses-and-assets-of--asth-20241108monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-third-quarter-2024-results-company-to-host-conference-call-on-t-asth-20241107monthly0.5https://www.biopharmawatch.com/news/ASTH/x2022-x2022-x2022-x2022-x2022-x2022-x2022-x2022-asth-20240904monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-second-quarter-2024-results-company-to-host-conference-call-on--asth-20240807monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-enters-definitive-agreement-to-acquire-collaborative-health-systems-asth-20240725monthly0.5https://www.biopharmawatch.com/news/ASTH/may-2024-powered-by-technology-built-by-doctors-for-patients-2-forward-looking-statements--asth-20240515monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-first-quarter-2024-results-company-to-host-conference-call-on-t-asth-20240507monthly0.5https://www.biopharmawatch.com/news/ASTH/march-2024-powered-by-technology-built-by-doctors-for-patients-2-forward-looking-statement-asth-20240311monthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-inc-reports-fourth-quarter-and-year-end-2023-results-company-to-host-confer-asth-20240227monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-january-2024-powered-by-technology-built-by-doctors-for-patients-f-asth-20240110monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-november-2023-powered-by-technology-built-by-doctors-for-patients--asth-20231130monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-reports-third-quarter-2023-results-company-to-host-conference--asth-20231107monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-announces-definitive-agreement-to-acquire-assets-of-community--asth-20231107monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-september-2023-powered-by-technology-built-by-doctors-for-patients-asth-20230913monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-reports-second-quarter-2023-results-company-to-host-conference-asth-20230807monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-announces-partnership-with-intracare-to-advance-value-based-ca-asth-20230731monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-signs-definitive-agreement-to-acquire-assets-of-texas-independ-asth-20230712monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-june-2023-powered-by-technology-built-by-doctors-for-patients-this-asth-20230607monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-first-quarter-2023-results-company-to-host-co-asth-20230508monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-fourth-quarter-and-year-end-2022-results-comp-asth-20230224monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-announces-share-repurchase-program-asth-20221215monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-nasdaq-ameh-powered-by-technology-built-by-doctors-for-patients-th-asth-20221104monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-third-quarter-2022-results-raises-revenue-net-asth-20221104monthly0.5https://www.biopharmawatch.com/news/ASTH/corporateprese-apollo-medical-holdings-october-2022-powered-by-technology-built-by-doctors-asth-20221012monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-expands-into-nevada-and-texas-with-acquisition-of-val-asth-20221005monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-announces-affiliate-s-entry-into-agreement-to-acquire-asth-20220926monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-second-quarter-2022-results-company-to-host-c-asth-20220804monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-first-quarter-2022-results-company-to-host-co-asth-20220505monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-march-2022-powered-by-technology-built-by-doctors-for-patients-thi-asth-20220314monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-fourth-quarter-and-year-end-2021-results-comp-asth-20220224monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-announces-acquisition-of-value-based-care-technology-platform--asth-20220127monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-january-2022-powered-by-technology-built-by-doctors-for-patients-t-asth-20220112monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-announces-affiliate-s-entry-into-agreement-to-acquire-jade-hea-asth-20211221monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-appoints-weili-dai-and-j-lorraine-estradas-to-its-board-of-dir-asth-20211220monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-nasdaq-ameh-november-2021-powered-by-technology-asth-20211108monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-third-quarter-2021-results-raises-full-year-2-asth-20211104monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-announces-signing-of-agreement-to-purchase-the-remain-asth-20211103monthly0.5https://www.biopharmawatch.com/news/ASTH/document-clinigence-holdings-announces-the-completion-of-a-3-million-strategic-equity-inve-asth-20210923monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-nasdaq-ameh-september-2021-powered-by-technology-built-by-doctors--asth-20210909monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-announces-closing-of-caipa-mso-strategic-investment-a-asth-20210831monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-second-quarter-2021-results-raises-full-year--asth-20210805monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-nasdaq-ameh-june-2021-powered-by-technology-built-by-doctors-for-p-asth-20210622monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-announces-successful-completion-of-debt-refinancing-reducing-a-asth-20210617monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-announces-purchase-of-controlling-interests-in-sun-clinical-la-asth-20210602monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-nasdaq-ameh-may-2021-powered-by-technology-built-by-doctors-for-pa-asth-20210518monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-reports-first-quarter-2021-results-company-to-host-conference--asth-20210505monthly0.5https://www.biopharmawatch.com/news/ASTH/a-leader-in-integrated-healthcare-management-and-delivery-powered-by-technology-built-by-d-asth-20210407monthly0.5https://www.biopharmawatch.com/news/ASTH/a-leader-in-integrated-healthcare-management-and-delivery-powered-by-technology-built-by-d-asth-20210311monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-reports-fourth-quarter-and-year-end-2020-results-highlighted-b-asth-20210310monthly0.5https://www.biopharmawatch.com/news/ASTH/a-leader-in-integrated-healthcare-management-and-delivery-powered-by-technology-built-by-d-asth-20210216monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-promotes-chief-technology-officer-brandon-sim-to-chie-asth-20210209monthly0.5https://www.biopharmawatch.com/news/ASTH/a-leader-in-integrated-healthcare-management-and-delivery-powered-by-technology-built-by-d-asth-20201216monthly0.5https://www.biopharmawatch.com/news/ASTH/a-leader-in-integrated-healthcare-management-and-delivery-powered-by-technology-asth-20201112monthly0.5https://www.biopharmawatch.com/news/ASTH/document-apollo-medical-holdings-inc-reports-third-quarter-2020-results-raises-full-year-2-asth-20201104monthly0.5https://www.biopharmawatch.com/news/ASTH/investorpresen-investor-presentation-september-2020-forward-looking-statements-this-presen-asth-20200910monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-asth-20200807monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-asth-20200527monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-asth-20200312monthly0.5https://www.biopharmawatch.com/news/ASTH/investor-presentation-january-2020-2-forward-looking-statements-this-presentation-contains-asth-20200114monthly0.5https://www.biopharmawatch.com/news/ASTH/c-o-r-r-e-c-t-i-o-n-apollo-medical-holdings-inc-in-the-news-release-apollo-medical-holding-asth-20191108monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-adds-approximately-145-000-members-by-entering-into-new-management-asth-20191002monthly0.5https://www.biopharmawatch.com/news/ASTH/cantor-fitzgerald-global-healthcare-conference-october-2019-2-forward-looking-statements-t-asth-20191003monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-the-appointment-of-matthew-mazdyasni-to-its-board-of-dir-asth-20190930monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-the-closing-of-its-inaugural-290-million-syndicated-cred-asth-20190911monthly0.5https://www.biopharmawatch.com/news/ASTH/this-press-release-contains-forward-looking-statements-within-the-meaning-of-the-private-s-asth-20190905monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-reports-revenue-of-130-0-million-for-the-second-quarter-of-2019-al-asth-20190809monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-acquisition-of-alpha-care-medical-group-alhambra-ca-pr-n-asth-20190604monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-signing-of-agreements-with-independent-practice-associat-asth-20190513monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-reports-46-revenue-increase-for-2018-alhambra-ca-and-glendale-ca-p-asth-20190318monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-the-appointment-of-linda-marsh-and-john-chiang-to-its-bo-asth-20190117monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-that-apa-aco-generated-12-96-million-in-gross-savings-in-asth-20181221monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-reports-72-revenue-increase-year-over-year-for-the-third-quarter-o-asth-20181114monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-reports-51-revenue-increase-year-over-year-for-the-2nd-quarter-of--asth-20180814monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-the-appointment-of-ernest-a-bates-m-d-and-j-mario-molina-asth-20180626monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-appointment-of-new-chief-financial-officer-alhambra-ca-a-asth-20180606monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-reports-46-revenue-growth-year-over-year-for-the-1st-quarter-of-20-asth-20180515monthly0.5https://www.biopharmawatch.com/news/ASTH/promissory-note-5-000-000-asth-20170213monthly0.5https://www.biopharmawatch.com/news/ASTH/apollomed-announces-that-apa-aco-inc-has-been-chosen-as-a-next-generation-accountable-care-asth-20170119monthly0.5https://www.biopharmawatch.com/news/ASTH/execution-agreement-and-plan-of-merger-by-and-among-apollo-medical-holdings-inc-apollo-acq-asth-20161221monthly0.5https://www.biopharmawatch.com/news/ASTH/employment-agreement-this-employment-agreement-this-agreement-is-made-and-entered-into-as--asth-20161220monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-appoints-mihir-shah-as-chief-financial-officer-glendale-ca-pr-news-asth-20160725monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-receives-5-million-equity-investment-from-network-medical-manageme-asth-20160331monthly0.5https://www.biopharmawatch.com/news/ASTH/medical-holdings-announces-the-appointment-of-asth-20160119monthly0.5https://www.biopharmawatch.com/news/ASTH/the-following-unaudited-pro-forma-condensed-consolidated-balance-sheet-shall-not-be-deemed-asth-20151119monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-the-completion-of-a-10-million-strategic-equity-investme-asth-20151019monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-changes-to-its-board-of-directors-and-cfo-position-glend-asth-20150925monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-reports-strong-fiscal-2014-first-quarter-results-net-revenues-clim-asth-20130614monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-launch-of-new-operating-unit-maverick-medical-group-glen-asth-20130605monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-the-appointment-of-david-g-schmidt-to-its-board-of-direc-asth-20130522monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-announces-record-fiscal-year-end-results-glendale-ca-pr-newswire-asth-20130503monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-announces-appointment-of-mark-a-meyers-to-its-board-of-directo-asth-20121017monthly0.5https://www.biopharmawatch.com/news/ASTH/of-apollo-medical-holdings-inc-dated-march-7-2012-asth-20120307monthly0.5https://www.biopharmawatch.com/news/ASTH/ameh-ob-otcbb-asth-20110216monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-2010-equity-incentive-plan-1-purposes-of-the-plan-the-purposes-asth-20100304monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-inc-announces-completion-of-1-25-million-private-placement-of-conv-asth-20091016monthly0.5https://www.biopharmawatch.com/news/ASTH/apollo-medical-holdings-appoints-noel-dewinter-chief-financial-officer-glendale-california-asth-20080911monthly0.5https://www.biopharmawatch.com/news/ASTH/report-of-independent-registered-public-accounting-firm-board-of-directors-and-stockholder-asth-20080619monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-first-quarter-2026-financial-results-atrc-20260506monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-fourth-quarter-2025-and-full-year-2025-financial-results-atrc-20260217monthly0.5https://www.biopharmawatch.com/news/ATRC/provides-financial-outlook-for-2026-atrc-20260112monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-third-quarter-2025-financial-results-raises-financial-outlook-for-2025-atrc-20251029monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-second-quarter-2025-financial-results-raises-financial-outlook-for-2025-atrc-20250729monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-first-quarter-2025-financial-results-atrc-20250429monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-all-rights-reserved-2-forward-looking-statements-and-non-gaap-financial-measu-atrc-20250326monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-fourth-quarter-2024-and-full-year-2024-financial-results-atrc-20250212monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-preliminary-results-for-fourth-quarter-and-full-year-2024-atrc-20250113monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-third-quarter-2024-financial-results-atrc-20241029monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-second-quarter-2024-financial-results-atrc-20240730monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-first-quarter-2024-financial-results-atrc-20240501monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-fourth-quarter-2023-and-full-year-2023-financial-results-atrc-20240215monthly0.5https://www.biopharmawatch.com/news/ATRC/provides-financial-outlook-for-2024-atrc-20240108monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-appoints-shlomi-nachman-to-the-board-of-directors-atrc-20240104monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-third-quarter-2023-financial-results-atrc-20231101monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-second-quarter-2023-financial-results-atrc-20230725monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-first-quarter-2023-financial-results-atrc-20230502monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-fourth-quarter-2022-and-full-year-2022-financial-results-atrc-20230221monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-preliminary-results-for-fourth-quarter-and-full-year-2022-atrc-20230109monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-third-quarter-2022-financial-results-atrc-20221101monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-second-quarter-2022-financial-results-atrc-20220802monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-first-quarter-2022-financial-results-atrc-20220503monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-launches-encompass-clamp-a-part-of-isolator-synergy-ablation-system-atrc-20220412monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-fourth-quarter-2021-and-full-year-2021-financial-results-atrc-20220215monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-preliminary-results-for-fourth-quarter-and-full-year-2021-atrc-20220110monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-third-quarter-2021-financial-results-atrc-20211103monthly0.5https://www.biopharmawatch.com/news/ATRC/a-ugust-4-2021-xfeff-atricure-reports-second-quarter-20-2-1-financial-results-mason-ohio-a-atrc-20210804monthly0.5https://www.biopharmawatch.com/news/ATRC/june-15-202-1-xfeff-xfeff-atricure-names-two-new-members-to-the-board-of-directors-xfeff-m-atrc-20210615monthly0.5https://www.biopharmawatch.com/news/ATRC/april-2-9-20-2-1-xfeff-atricure-s-epi-sense-system-approved-by-fda-for-treatment-of-long-s-atrc-20210429monthly0.5https://www.biopharmawatch.com/news/ATRC/april-27-2021-xfeff-atricure-reports-first-quarter-20-2-1-financial-results-mason-ohio-apr-atrc-20210427monthly0.5https://www.biopharmawatch.com/news/ATRC/april-8-202-1-xfeff-xfeff-atricure-names-b-kristine-johnson-board-chair-xfeff-mason-ohio-x-atrc-20210408monthly0.5https://www.biopharmawatch.com/news/ATRC/february-23-2021-xfeff-atricure-reports-fourth-quarter-20-20-and-full-year-20-20-financial-atrc-20210223monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-january-1-1-20-2-1-xfeff-atricure-reports-preliminary-results--atrc-20210111monthly0.5https://www.biopharmawatch.com/news/ATRC/annual-reports-on-form-10-k-and-quarterly-reports-on-form-10-q-which-contain-risk-factors-atrc-20201105monthly0.5https://www.biopharmawatch.com/news/ATRC/than-those-expressed-in-our-forward-looking-statements-visit-http-www-atricure-com-fls-as--atrc-20200806monthly0.5https://www.biopharmawatch.com/news/ATRC/july-28-20-20-xfeff-atricure-reports-second-quarter-20-20-financial-results-xb7-w-orldwide-atrc-20200728monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-announces-proposed-public-offering-of-common-stock-mason-ohio-business-wire-atrc-20200511monthly0.5https://www.biopharmawatch.com/news/ATRC/may-8-20-20-xfeff-atricure-announces-results-from-converge-ide-clinical-trial-xfeff-r-esul-atrc-20200508monthly0.5https://www.biopharmawatch.com/news/ATRC/april-29-20-20-xfeff-atricure-reports-first-quarter-20-20-financial-results-xb7-w-orldwide-atrc-20200409monthly0.5https://www.biopharmawatch.com/news/ATRC/april-13-2020-xfeff-atricure-announces-converge-ide-trial-results-accepted-for-late-breaki-atrc-20200413monthly0.5https://www.biopharmawatch.com/news/ATRC/april-9-2020-xfeff-atricure-announces-preliminary-financial-results-for-first-quarter-2020-atrc-20200409monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-fourth-quarter-2019-and-full-year-2019-financial-results-atrc-20200218monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-january-13-20-20-xfeff-atricure-reports-preliminary-results-fo-atrc-20200113monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-names-two-industry-veterans-to-board-of-directors-atrc-20191204monthly0.5https://www.biopharmawatch.com/news/ATRC/october-30-201-9-xfeff-atricure-reports-third-quarter-201-9-financial-results-xb7-w-orldwi-atrc-20191030monthly0.5https://www.biopharmawatch.com/news/ATRC/for-immediate-release-atrc-20190813monthly0.5https://www.biopharmawatch.com/news/ATRC/definitive-agreement-to-acquire-sentreheart-atrc-20190811monthly0.5https://www.biopharmawatch.com/news/ATRC/july-30-201-9-xfeff-atricure-reports-second-quarter-201-9-financial-results-xb7-w-orldwide-atrc-20190730monthly0.5https://www.biopharmawatch.com/news/ATRC/april-2-5-201-9-xfeff-atricure-reports-first-quarter-201-9-financial-results-xb7-w-orldwid-atrc-20190425monthly0.5https://www.biopharmawatch.com/news/ATRC/february-28-201-9-xfeff-xfeff-atricure-reports-fourth-quarter-and-full-year-2018-financial-atrc-20190228monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-january-7-201-9-xfeff-atricure-reports-preliminary-results-for-atrc-20190107monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-third-quarter-2018-financial-results-atrc-20181101monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-and-its-business-can-be-found-in-atricure-s-annual-report-on-form-10-k-and-quarte-atrc-20181003monthly0.5https://www.biopharmawatch.com/news/ATRC/august-1-2018-xfeff-atricure-reports-second-quarter-2018-financial-results-updates-2018-fi-atrc-20180801monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-reports-first-quarter-2018-financial-results-atrc-20180426monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-atrc-20180226monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-february-20-201-8-atric-ure-names-scott-drake-board-chairman-r-atrc-20180220monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-january-8-201-8-xfeff-atricure-reports-preliminary-results-for-atrc-20180108monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-november-1-2017-xfeff-atricure-reports-third-quarter-2017-fina-atrc-20171101monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-july-27-2017-xfeff-atricure-reports-second-quarter-2017-financ-atrc-20170727monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-xfeff-xfeff-for-immediate-release-atrc-20170504monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-xfeff-for-immediate-release-atrc-20170321monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-february-28-2017-xfeff-atricure-reports-fourth-quarter-and-ful-atrc-20170228monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-atrc-20170109monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-for-immediate-release-november-11-2016-xfeff-atricure-names-sven-wehrwein-to-its-boa-atrc-20161114monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-xfeff-contact-atricure-inc-andy-wade-senior-vice-president-and-chief-financial-offic-atrc-20161027monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-xfeff-contact-atricure-inc-andy-wade-senior-vice-president-and-chief-financial-offic-atrc-20160804monthly0.5https://www.biopharmawatch.com/news/ATRC/xfeff-xfeff-contact-atricure-inc-andy-wade-senior-vice-president-and-chief-financial-offic-atrc-20160428monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-senior-vice-president-and-chief-financial-officer-513-755-4564-awad-atrc-20160223monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-senior-vice-president-and-chief-financial-officer-513-755-45-64-awa-atrc-20160111monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-senior-vice-president-and-chief-financial-officer-513-755-4564-awad-atrc-20151027monthly0.5https://www.biopharmawatch.com/news/ATRC/october-13-2015-atricure-completes-acquisition-of-ncontact-west-chester-ohio-x2013-october-atrc-20151014monthly0.5https://www.biopharmawatch.com/news/ATRC/october-4-2015-atricure-enters-into-definitive-agreement-to-acquire-ncontact-an-nounces-pr-atrc-20150930monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-senior-vice-president-and-chief-financial-officer-513-755-4564-awad-atrc-20150728monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-senior-vice-president-and-chief-financial-officer-513-755-4564-awad-atrc-20150429monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-senior-vice-president-and-chief-financial-officer-513-755-4564-awad-atrc-20150223monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-senior-vice-president-and-chief-financial-officer-513-755-4564-awad-atrc-20150114monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20150112monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20141030monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20140724monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20140424monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20140227monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20140212monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20140109monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20140102monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20131219monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20131029monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20130903monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20130801monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20130502monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20130311monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20130228monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-and-chief-financial-officer-513-755-4564-awade-atric-atrc-20130115monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-andy-wade-vice-president-finance-513-755-4564-awade-atricure-com-investor-rel-atrc-20130107monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-investor-relations-andy-wade-lynn-pieper-vice-president-finance-westwicke-par-atrc-20121101monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-third-quarter-2025-financial-results-organizational-restructu-mrvi-20251106monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-first-quarter-2025-financial-results-san-diego-calif-mrvi-20250512monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-fourth-quarter-and-full-year-2024-financial-results-schedules-mrvi-20250320monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-appoints-r-andrew-eckert-as-chairman-of-the-board-of-directors-carl-h-mrvi-20241205monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-third-quarter-2024-financial-results-announces-agreement-to-a-mrvi-20241107monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-second-quarter-2024-financial-results-continued-focus-on-prod-mrvi-20240807monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-appoints-trey-martin-to-board-of-directors-maravai-announces-the-appo-mrvi-20240729monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-first-quarter-2024-financial-results-continued-focus-on-produ-mrvi-20240508monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-fourth-quarter-and-full-year-2023-financial-results-continued-mrvi-20240222monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-third-quarter-2023-financial-results-announces-realignment-to-mrvi-20231107monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-second-quarter-2023-financial-results-continued-focus-on-expa-mrvi-20230807monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-completion-of-planned-ceo-leadership-transition-william-tre-mrvi-20230727monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-appointment-of-new-director-to-the-board-mrvi-20230720monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-first-quarter-2023-financial-results-continued-focus-on-expan-mrvi-20230508monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-fourth-quarter-and-full-year-2022-financial-results-base-busi-mrvi-20230222monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-updated-ceo-leadership-transition-plans-maravai-announces-p-mrvi-20221201monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-third-quarter-2022-financial-results-updates-revenue-adjusted-mrvi-20221102monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-temporarily-reinstates-carl-hull-as-ceo-amidst-pending-noncompetition-mrvi-20221019monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-second-quarter-2022-financial-results-record-first-half-reven-mrvi-20220804monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-first-quarter-2022-financial-results-affirms-revenue-guidance-mrvi-20220505monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-updat-mrvi-20220223monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-third-quarter-financial-results-updates-2021-financial-guidan-mrvi-20211110monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-second-quarter-financial-results-and-updates-2021-mrvi-20210810monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-first-quarter-financial-results-and-updates-2021-mrvi-20210510monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-preliminary-unaudited-first-quarter-revenues-and-income-fro-mrvi-20210331monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-fourth-quarter-and-full-year-2020-financial-results-and-initi-mrvi-20210302monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-mrvi-20201124monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-reports-first-quarter-2026-financial-results-announces-regular-quarte-irmd-20260501monthly0.5https://www.biopharmawatch.com/news/IRMD/i-r-adimed-announces-special-cash-dividend-of-0-50-per-share-orlando-florida-irmd-20251208monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-reports-record-second-quarter-2025-financial-results-announces-regula-irmd-20250801monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-and-full-year-of-2024-financial-results-and--irmd-20250213monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-reports-preliminary-unaudited-record-fourth-quarter-and-full-year-202-irmd-20250110monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-of-2024-financial-results-and-the-declaration-irmd-20241031monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-of-2024-financial-results-and-the-declaratio-irmd-20240801monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-uplisting-to-the-nasdaq-global-market-trading-to-commence-e-irmd-20240607monthly0.5https://www.biopharmawatch.com/news/IRMD/amendment-to-susi-llc-lease-agreement-tids-amendment-to-susi-llc-lease-agreement-this-amen-irmd-20240529monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-of-2024-financial-results-and-the-declaration-irmd-20240502monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-of-2023-and-full-year-of-2023-financial-resu-irmd-20240208monthly0.5https://www.biopharmawatch.com/news/IRMD/i-r-adimed-corporation-announces-establishment-of-a-quarterly-dividend-of-0-15-per-share-a-irmd-20231212monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2023-financial-results-reports-record-revenue-irmd-20231103monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2023-financial-results-reports-record-revenu-irmd-20230803monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-named-a-2023-best-small-company-in-america-by-forbes-winter-springs-f-irmd-20230510monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2023-financial-results-reports-record-revenue-irmd-20230504monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-and-full-year-2022-financial-results-and-ann-irmd-20230202monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-preliminary-financial-results-for-fourth-quarter-2022-repor-irmd-20230118monthly0.5https://www.biopharmawatch.com/news/IRMD/i-r-adimed-corporation-announces-third-quarter-2022-financial-results-revenue-was-13-4-mil-irmd-20221103monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-withdraws-510-k-with-plans-to-resubmit-after-further-discussions-with-irmd-20221010monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-appointment-of-hilda-scharen-guivel-to-board-of-directors-w-irmd-20221006monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2022-financial-results-reports-second-quarte-irmd-20220729monthly0.5https://www.biopharmawatch.com/news/IRMD/i-r-adimed-names-john-f-glenn-chief-financial-officer-winter-springs-florida-irmd-20220526monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-first-quarter-2022-financial-results-reports-first-quarter-irmd-20220429monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-executive-transition-winter-springs-florida-irmd-20220428monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-announces-special-1-00-per-share-cash-dividend-winter-springs-florida-irmd-20220207monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-2021-financial-results-reports-fourth-quarte-irmd-20220204monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2021-financial-results-reports-third-quarter--irmd-20211029monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-second-quarter-2021-financial-results-reports-second-quart-irmd-20210730monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-first-quarter-2021-financial-results-reports-first-quarter-irmd-20210430monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-2020-financial-results-reports-fourth-quarte-irmd-20210204monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-third-quarter-2020-financial-results-reports-third-quarter-irmd-20201030monthly0.5https://www.biopharmawatch.com/news/IRMD/e-xhibit-99-1-iradimed-corporation-announces-second-quarter-2020-financial-results-reports-irmd-20200730monthly0.5https://www.biopharmawatch.com/news/IRMD/i-r-adimed-corporation-names-roger-susi-as-president-and-chief-executive-officer-winter-sp-irmd-20200529monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2020-financial-results-reports-first-quarter--irmd-20200430monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-withdraws-2020-financial-guidance-due-to-uncertainties-from-the-effec-irmd-20200407monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-retirement-of-francis-casey-and-the-appointment-of-steven-k-irmd-20200226monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-2019-financial-results-reports-fourth-quarte-irmd-20200206monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-retirement-of-brent-johnson-and-the-appointment-of-marybeth-irmd-20200107monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-completes-ce-mark-renewal-process-for-its-mri-compatible-patient-vita-irmd-20191212monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-third-quarter-2019-financial-results-reports-third-quarter-irmd-20191030monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-resolves-warning-letter-related-to-its-infusion-pump-system-winter-s-irmd-20191008monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-second-quarter-2019-financial-results-reports-second-quart-irmd-20190730monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-first-quarter-2019-financial-results-reports-first-quarter-irmd-20190430monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-fourth-quarter-2018-financial-results-reports-fourth-quart-irmd-20190206monthly0.5https://www.biopharmawatch.com/news/IRMD/irad-ime-d-corporation-expects-minor-impact-to-2019-revenue-after-temporarily-suspending-s-irmd-20190122monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-third-quarter-2018-financial-results-reports-third-quarter-irmd-20181030monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-second-quarter-2018-financial-results-reports-second-quart-irmd-20180731monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-first-quarter-2018-financial-results-reports-first-quarter-irmd-20180430monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-2017-financial-results-reports-fourth-quarte-irmd-20180206monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-2018-annual-and-first-quarter-financial-guidance-announces--irmd-20180122monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-third-quarter-2017-financial-results-reports-third-quarter-irmd-20171030monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fda-510-k-clearance-of-mri-compatible-patient-vital-signs-m-irmd-20171026monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-second-quarter-2017-financial-results-reports-second-quart-irmd-20170728monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-first-quarter-2017-financial-results-reports-first-quarter-irmd-20170428monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-names-john-mccreery-chief-operating-officer-winter-springs-florida-irmd-20170330monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-fourth-quarter-2016-financial-results-reports-fourth-quart-irmd-20170206monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-2017-annual-and-first-quarter-financial-guidance-announces-irmd-20170118monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-third-quarter-2016-financial-results-reports-third-quarter-irmd-20161028monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-revises-financial-guidance-for-the-third-quarter-and-full-year-2016--irmd-20161004monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-second-quarter-2016-financial-results-revenue-grows-29-7-c-irmd-20160729monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-appointment-of-jonathan-kennedy-to-its-board-of-directors--irmd-20160628monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-provides-regulatory-update-provides-regulatory-update-on-the-status--irmd-20160609monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-first-quarter-2016-financial-results-revenue-grows-28-2-co-irmd-20160429monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-mourns-the-death-of-board-member-serge-novovich-winter-springs-flori-irmd-20160419monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-provides-regulatory-update-and-schedules-first-quarter-conference-ca-irmd-20160401monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-changes-to-its-board-of-directors-winter-springs-florida-irmd-20160329monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-fourth-quarter-2015-financial-results-revenue-grows-145-5--irmd-20160205monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-10-million-share-repurchase-program-winter-springs-florida-irmd-20160128monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-2016-annual-and-first-quarter-financial-guidance-announces-irmd-20160111monthly0.5https://www.biopharmawatch.com/news/IRMD/i-r-adimed-corporation-announces-pricing-of-secondary-offering-of-common-stock-winter-spri-irmd-20151218monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-third-quarter-2015-financial-results-revenue-grows-114-9-c-irmd-20151030monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-second-quarter-2015-financial-results-revenue-grows-62-com-irmd-20150730monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2015-financial-results-reports-first-quarter--irmd-20150430monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-2014-financial-results-reports-fourth-quarte-irmd-20150205monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-resumes-domestic-distribution-of-ders-option-winter-springs-florida-irmd-20150128monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-announces-2015-annual-and-first-quarter-financial-guidance-announces-irmd-20150112monthly0.5https://www.biopharmawatch.com/news/IRMD/i-radimed-corporation-resumes-domestic-distribution-of-infusion-pumps-winter-springs-flori-irmd-20141222monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2014-financial-results-reports-revenue-growth-irmd-20141030monthly0.5https://www.biopharmawatch.com/news/IRMD/department-of-health-and-human-services-food-and-drug-administration-florida-district-555--irmd-20140818monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2014-financial-results-reports-revenue-growt-irmd-20140812monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-scott-galovan-avanos-medical-inc-investor-relations-avanos-com-m-avns-20260414monthly0.5https://www.biopharmawatch.com/news/AVNS/year-ended-avns-20260414monthly0.5https://www.biopharmawatch.com/news/AVNS/sec-carefully-and-in-their-entirety-when-they-become-available-as-they-will-contain-import-avns-20260226monthly0.5https://www.biopharmawatch.com/news/AVNS/earnings-release-document-investor-contact-scott-galovan-avanos-medical-inc-470-562-2692-i-avns-20260224monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-scott-galovan-avanos-medical-inc-470-562-2692-investor-relations-avns-20251105monthly0.5https://www.biopharmawatch.com/news/AVNS/document-avanos-medical-acquires-nexus-medical-to-strengthen-nutrition-and-medication-deli-avns-20250915monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-scott-galovan-avanos-medical-inc-470-562-2692-investor-relations-avns-20250805monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-scott-galovan-avanos-medical-inc-470-562-2692-investor-relations-avns-20250506monthly0.5https://www.biopharmawatch.com/news/AVNS/document-media-contact-katrine-kubis-avanos-medical-inc-corporatecommunications-avanos-com-avns-20250317monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20250226monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20241030monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20240731monthly0.5https://www.biopharmawatch.com/news/AVNS/for-further-information-investor-contact-michael-greiner-avanos-medical-inc-investor-relat-avns-20240701monthly0.5https://www.biopharmawatch.com/news/AVNS/for-further-information-investor-contact-michael-greiner-avanos-medical-inc-investor-relat-avns-20240513monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20240502monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20240220monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20240104monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20231101monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20230809monthly0.5https://www.biopharmawatch.com/news/AVNS/avnsform8k-6202023xex991-investor-day-avns-20230620monthly0.5https://www.biopharmawatch.com/news/AVNS/not-relate-solely-to-historical-or-current-facts-and-can-generally-be-identified-by-the-us-avns-20230608monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20230503monthly0.5https://www.biopharmawatch.com/news/AVNS/with-this-new-appointment-the-avanos-board-now-comprises-six-directors-five-of-whom-are-in-avns-20230306monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20230221monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20230111monthly0.5https://www.biopharmawatch.com/news/AVNS/investor-contact-michael-greiner-avanos-medical-inc-investor-relations-avanos-com-media-co-avns-20221114monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20221102monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20220809monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20220504monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20220223monthly0.5https://www.biopharmawatch.com/news/AVNS/in-more-than-90-countries-for-more-information-visit-www-avanos-com-and-follow-avanos-medi-avns-20211215monthly0.5https://www.biopharmawatch.com/news/AVNS/statements-include-all-statements-that-do-not-relate-solely-to-historical-or-current-facts-avns-20211213monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20211102monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-michael-greiner-avanos-medical-inc-470-562-2692-investor-relatio-avns-20210803monthly0.5https://www.biopharmawatch.com/news/AVNS/investor-contact-dave-crawford-avanos-medical-inc-470-448-5177-investor-relations-avanos-c-avns-20210712monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-dave-crawford-avanos-medical-inc-470-448-5177-investor-relations-avns-20210507monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-dave-crawford-avanos-medical-inc-470-448-5177-investor-relations-avns-20210218monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-dave-crawford-avanos-medical-inc-470-448-5177-investor-relations-avns-20201103monthly0.5https://www.biopharmawatch.com/news/AVNS/investor-contact-dave-crawford-avanos-medical-inc-470-448-5177-investor-relations-avanos-c-avns-20200831monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-dave-crawford-avanos-medical-inc-470-448-5177-investor-relations-avns-20200804monthly0.5https://www.biopharmawatch.com/news/AVNS/document-investor-contact-dave-crawford-avanos-medical-inc-470-448-5177-investor-relations-avns-20200506monthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-inc-avns-20200225monthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-appoints-michael-c-avns-20200101monthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-inc-avns-20191105monthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-inc-avns-20190806monthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-inc-avns-20190507monthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-inc-avns-20190226monthly0.5https://www.biopharmawatch.com/news/AVNS/investor-contact-dave-crawford-avanos-medical-inc-470-448-5177-investor-relations-avanos-c-avns-20181106monthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-inc-avns-20180807monthly0.5https://www.biopharmawatch.com/news/AVNS/investor-contact-dave-crawford-halyard-health-inc-470-448-5177-investor-relations-hyh-com--avns-20180601monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20180502monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20180227monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20171101monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20170802monthly0.5https://www.biopharmawatch.com/news/AVNS/levels-from-third-party-payors-a-significant-increase-in-product-liability-claims-the-impa-avns-20170623monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20170502monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20170227monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20161102monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20160803monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20160504monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-announces-agreement-to-acquire-corpak-medsystems-acquisition-enhances-halya-avns-20160411monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-avns-20151103monthly0.5https://www.biopharmawatch.com/news/AVNS/hyh2q2015form8kex99-1-investor-contact-dave-crawford-halyard-health-inc-470-448-5177-inves-avns-20150804monthly0.5https://www.biopharmawatch.com/news/AVNS/hyh1q2015form8kex99-1-investor-contact-dave-crawford-halyard-health-inc-470-448-5177-inves-avns-20150504monthly0.5https://www.biopharmawatch.com/news/AVNS/halyard-health-inc-selected-business-segment-data-unaudited-percentage-change-net-sales-vs-avns-20150304monthly0.5https://www.biopharmawatch.com/news/AVNS/jessica-van-derven-halyard-health-1-770-587-8709-jessica-vanderven-hyh-com-laura-weitzenho-avns-20141103monthly0.5https://www.biopharmawatch.com/news/AVNS/legal-disclaimer-legal-disclaimer-preliminary-financial-results-this-presentation-contains-avns-20140930monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-positive-update-on-restoraation-2-trial-wve-006-galnac-rna-ed-wve-20260518monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-strategic-priorities-for-2026-at-the-44-th-annual-j-p-morgan-wve-20251231monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20251117monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announced-positive-target-engagement-data-from-inlight-clinical-trial-o-wve-20251029monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20250924monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20250805monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2025-financial-results-and-provides-business-upd-wve-20250730monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2025-financial-results-and-provides-business-upda-wve-20250508monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-positive-data-from-forward-53-clinical-trial-in-dmd-including-wve-20250326monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-wve-20250304monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20250113monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20241120monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2024-financial-results-and-provides-business-upda-wve-20241112monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-growing-pipeline-at-research-day-including-inhbe-sirna-progr-wve-20241030monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-first-ever-therapeutic-rna-editing-in-humans-achieved-in-rest-wve-20241016monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20241001monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-prices-upsized-200-million-public-offering-of-ordinary-shares-and-pre-f-wve-20240925monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-positive-interim-data-from-forward-53-clinical-trial-evaluati-wve-20240924monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2024-financial-results-and-provides-business-upd-wve-20240808monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-positive-results-from-phase-1b-2a-select-hd-trial-with-first--wve-20240625monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2024-financial-results-and-provides-business-upda-wve-20240509monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-wve-20240306monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20240108monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20231215monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-prices-100-million-public-offering-of-ordinary-shares-wve-20231207monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20231109monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2023-financial-results-and-provides-business-upda-wve-20231109monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20231002monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-growth-strategy-for-building-the-leading-rna-medicines-compa-wve-20230928monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20230905monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2023-financial-results-and-provides-business-upd-wve-20230803monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-topline-results-from-phase-1b-2a-focus-c9-study-of-wve-004-fo-wve-20230523monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2023-financial-results-and-provides-business-upda-wve-20230503monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provide-wve-20230322monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20230109monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-provides-positive-update-on-proof-of-concept-study-for-wve-n531-in-duch-wve-20221219monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-and-gsk-announce-collaboration-to-drive-discovery-and-development-of-ol-wve-20221213monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20221115monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2022-financial-results-and-provides-business-upda-wve-20221110monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20221004monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-therapeutic-potential-for-wve-006-for-alpha-1-antitrypsin-de-wve-20220928monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-positive-update-from-phase-1b-2a-select-hd-trial-with-initial-wve-20220920monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20220817monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2022-financial-results-and-provides-business-upd-wve-20220811monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-pricing-of-70-0-million-underwritten-offering-wve-20220614monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2022-financial-results-and-provides-business-upda-wve-20220512monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-positive-update-to-ongoing-phase-1b-2a-focus-c9-study-driven--wve-20220404monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provide-wve-20220303monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20220110monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2021-financial-results-and-provides-business-upda-wve-20211110monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-and-takeda-amend-cns-collaboration-amendment-to-ongoing-collaboration-a-wve-20211018monthly0.5https://www.biopharmawatch.com/news/WVE/analyst-investor-research-webcast-wve-20210928monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20210910monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2021-financial-results-and-provides-business-upd-wve-20210805monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2021-financial-results-and-provides-business-upda-wve-20210513monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20210401monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-provides-update-on-phase-1b-2a-precision-hd-trials-mhtt-results-from-pr-wve-20210329monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2020-financial-results-and-provide-wve-20210304monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20210111monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20201112monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2020-financial-results-and-provides-business-upda-wve-20201109monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20201001monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-prices-100-million-public-offering-of-ordinary-shares-wve-20200923monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-proposed-public-offering-of-ordinary-shares-wve-20200922monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20200909monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20200825monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2020-financial-results-and-provides-business-upd-wve-20200810monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2020-financial-results-and-provides-business-upda-wve-20200511monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2019-financial-results-and-provide-wve-20200302monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20200113monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-topline-data-and-addition-of-higher-dose-cohort-in-ongoing-ph-wve-20191230monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-discontinuation-of-suvodirsen-development-for-duchenne-muscul-wve-20191216monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2019-financial-results-and-provides-business-upda-wve-20191105monthly0.5https://www.biopharmawatch.com/news/WVE/welcome-paul-bolno-md-mba-president-and-ceo-wave-life-sciences-forward-looking-statements--wve-20191007monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-expands-board-of-directors-with-three-new-appointments-new-independent--wve-20190905monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2019-financial-results-and-provides-business-upd-wve-20190729monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20190605monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2019-financial-results-and-provides-business-upda-wve-20190510monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-suvodirsen-phase-1-safety-and-tolerability-data-and-phase-2-3-wve-20190416monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2018-financial-results-and-provide-wve-20190301monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-prices-150-million-public-offering-of-ordinary-shares-wve-20190124monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-proposed-public-offering-of-ordinary-shares-wve-20190123monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20190103monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-positive-phase-1-results-for-wve-210201-in-duchenne-muscular--wve-20181206monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2018-financial-results-and-provides-business-upda-wve-20181109monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20181009monthly0.5https://www.biopharmawatch.com/news/WVE/acknowledgements-disclosures-all-wave-life-sciences-employees-prof-gregory-verdine-co-foun-wve-20181003monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20181002monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20180911monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2018-financial-results-and-provides-business-upd-wve-20180809monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2018-financial-results-and-provides-business-upda-wve-20180509monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20180410monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20180402monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20180326monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2017-financial-results-and-provide-wve-20180312monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-and-takeda-form-global-strategic-collaboration-to-advance-therapies-for-wve-20180220monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-corporate-presentation-wve-20180105monthly0.5https://www.biopharmawatch.com/news/WVE/preclinical-data-for-wve-3972-01-supporting-als-and-ftd-programs-robert-brown-jr-dphil-md--wve-20171210monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2017-financial-results-and-provides-business-upda-wve-20171109monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20170918monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2017-financial-results-and-provides-business-upd-wve-20170809monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2017-financial-results-and-provides-business-upda-wve-20170510monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-prices-public-offering-of-4-166-667-ordinary-shares-cambridge-mass-busi-wve-20170412monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-proposed-public-offering-of-ordinary-shares-cambridge-mass-bu-wve-20170411monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2016-financial-results-and-provide-wve-20170316monthly0.5https://www.biopharmawatch.com/news/WVE/forward-looking-statements-this-document-contains-forward-looking-statements-all-statement-wve-20170106monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-appoints-christian-henry-to-its-board-of-directors-wve-20161110monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-third-quarter-2016-financial-results-and-provides-business-upda-wve-20161109monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-appoints-keith-regnante-as-chief-financial-officer-wve-20160817monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-second-quarter-2016-financial-results-and-provides-business-upd-wve-20160815monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-first-quarter-2016-financial-results-and-provides-business-upda-wve-20160516monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-enters-collaboration-with-pfizer-to-develop-genetically-targeted-therap-wve-20160505monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-reports-fourth-quarter-and-full-year-2015-financial-results-and-provide-wve-20160330monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-appoints-jennifer-browne-as-president-and-chief-operating-officer-denver-innv-20260512monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-third-quarter-ended-march-31-2025-denv-innv-20260505monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-second-quarter-ended-december-31-2025--innv-20260203monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-first-quarter-ended-september-30-2025--innv-20251104monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-june-30--innv-20250909monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-third-quarter-ended-march-31-2025-denv-innv-20250506monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-second-quarter-ended-december-31-2024--innv-20250204monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-first-quarter-ended-september-30-2024--innv-20241105monthly0.5https://www.biopharmawatch.com/news/INNV/document-innovage-appoints-michael-scarbrough-as-new-president-and-chief-operating-officer-innv-20241104monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-june-30--innv-20240910monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-holding-corp-announces-5-0-innv-20240610monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-third-quarter-ended-march-31-2024-denv-innv-20240507monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-second-quarter-ended-december-31-2023--innv-20240206monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-first-quarter-ended-september-30-2023--innv-20231107monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-june-30--innv-20230912monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-strengthens-board-with-appointment-of-new-independent-director-denver-innv-20230814monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-names-ben-adams-as-new-chief-financial-officer-denver-innv-20230705monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-third-quarter-ended-march-31-2023-denv-innv-20230509monthly0.5https://www.biopharmawatch.com/news/INNV/final-sanction-removed-at-innovage-sacramento-pace-center-enabling-new-participant-enrollm-innv-20230501monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-diversifies-board-of-directors-with-new-independent-director-denver-innv-20230330monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-names-christine-bent-as-chief-operations-officer-denver-innv-20230301monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-second-quarter-ended-december-31-2022--innv-20230207monthly0.5https://www.biopharmawatch.com/news/INNV/state-and-federal-regulators-lift-sanctions-at-innovage-s-colorado-pace-centers-denver-co-innv-20230123monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-release-of-cms-sanction-in-sacramento-center-denver-co-innv-20221122monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-first-quarter-ended-september-30-2022--innv-20221108monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-year-and-fourth-quarter-ended-june-30--innv-20220913monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-appoints-james-carlson-to-the-board-as-non-executive-chairman-denver-innv-20220630monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-third-quarter-ended-march-31-2022-denv-innv-20220510monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-second-quarter-ended-december-31-2021--innv-20220209monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-innv-20220103monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-audit-sanctions-in-colorado-and-withdraws-guidance-denver-innv-20211223monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-appoints-patrick-blair-as-president-denver-innv-20211112monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-first-quarter-ended-september-30-2021--innv-20211109monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-year-and-fourth-quarter-ended-june-30--innv-20210921monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-financial-results-for-the-fiscal-third-quarter-ended-march-31-2021-denv-innv-20210510monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-exercise-of-underwriters-option-to-purchase-additional-shares-denver-co-innv-20210312monthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-pricing-of-initial-public-offering-denver-co-innv-20210303monthly0.5https://www.biopharmawatch.com/news/IART/document-integra-lifesciences-announces-leadership-transition-stuart-essig-appointed-as-in-iart-20260505monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-first-quarter-2026-financial-results-pr-iart-20260505monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-fourth-quarter-and-full-year-2025-finan-iart-20260226monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-third-quarter-2025-financial-results-pr-iart-20251030monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-second-quarter-2025-financial-results-p-iart-20250731monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-first-quarter-2025-financial-results-pr-iart-20250505monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-fourth-quarter-and-full-year-2024-finan-iart-20250225monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-third-quarter-2024-financial-results-pr-iart-20241104monthly0.5https://www.biopharmawatch.com/news/IART/projecteaglep-integra-lifesciences-announces-appointment-of-mojdeh-poul-as-president-and-c-iart-20241104monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-second-quarter-2024-financial-results-p-iart-20240729monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-first-quarter-2024-financial-results-pr-iart-20240506monthly0.5https://www.biopharmawatch.com/news/IART/pressreleasex-integra-lifesciences-announces-leadership-transition-plan-jan-de-witte-to-re-iart-20240228monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-fourth-quarter-and-full-year-2023-finan-iart-20240228monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-third-quarter-2023-financial-results-pr-iart-20231025monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-second-quarter-2023-financial-results-p-iart-20230726monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-first-quarter-2023-financial-results-pr-iart-20230426monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provi-iart-20230222monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-third-quarter-2022-financial-results-pr-iart-20221026monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-second-quarter-2022-financial-results-p-iart-20220727monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-first-quarter-2022-financial-results-pr-iart-20220427monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-fourth-quarter-and-full-year-2021-finan-iart-20220223monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-third-quarter-2021-financial-results-th-iart-20211102monthly0.5https://www.biopharmawatch.com/news/IART/document-integra-lifesciences-announces-jan-de-witte-as-president-and-chief-executive-offi-iart-20211028monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-integra-lifesciences-reports-second-quarter-2021-financial-results-r-iart-20210728monthly0.5https://www.biopharmawatch.com/news/IART/document-integra-lifesciences-hosts-virtual-investor-day-princeton-new-jersey-iart-20210520monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-investor-relations-contacts-michael-beaulieu-director-investor-relat-iart-20210428monthly0.5https://www.biopharmawatch.com/news/IART/document-news-release-contact-investor-relations-michael-beaulieu-director-investor-relati-iart-20210218monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2020-financial-results-iart-20201028monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2020-financial-results-iart-20200810monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2020-financial-results-iart-20200507monthly0.5https://www.biopharmawatch.com/news/IART/investor-relations-sravan-emany-sr-vice-president-strategy-treasury-investor-relations-609-iart-20200219monthly0.5https://www.biopharmawatch.com/news/IART/integra-announces-pricing-of-convertible-senior-notes-princeton-n-j-iart-20200204monthly0.5https://www.biopharmawatch.com/news/IART/integra-announces-amendment-and-extension-of-credit-facility-and-private-placement-of-conv-iart-20200203monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2019-financial-results-iart-20191024monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2019-financial-results-iart-20190724monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2019-financial-results-iart-20190424monthly0.5https://www.biopharmawatch.com/news/IART/investor-relations-sravan-emany-sr-vice-president-strategy-treasury-investor-relations-609-iart-20190221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2018-financial-results-iart-20181031monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2018-financial-results-iart-20180725monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-prices-public-offering-of-common-stock-plainsboro-new-jersey-iart-20180509monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-proposed-public-offering-of-common-stock-plainsboro-new-jer-iart-20180509monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-amendment-and-extension-of-credit-facility-plainsboro-new-j-iart-20180507monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2018-financial-results-iart-20180425monthly0.5https://www.biopharmawatch.com/news/IART/investor-relations-michael-beaulieu-609-750-2827-michael-beaulieu-integralife-com-media-la-iart-20180227monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2017-financial-results-iart-20171026monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-definitive-agreement-to-sell-certain-neurosurgery-assets-to-iart-20170911monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2017-financial-results-iart-20170726monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2017-financial-results-iart-20170426monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investor-relations-angela-steinway-609-936-2268--iart-20170404monthly0.5https://www.biopharmawatch.com/news/IART/investor-relations-angela-steinway-609-936-2268-angela-steinway-integralife-com-michael-be-iart-20170223monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-plans-to-acquire-the-codman-neurosurgery-business-from-johnson-johnso-iart-20170215monthly0.5https://www.biopharmawatch.com/news/IART/jan-2017-integra-lifesciences-holdings-corp-iart-acquisition-of-derma-sciences-inc-by-inte-iart-20170112monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-acquire-derma-sciences-inc-and-announces-preliminary-fourth-quarte-iart-20170111monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-approval-of-two-for-one-stock-split-iart-20161222monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investor-relations-angela-steinway-609-936-2268--iart-20161207monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2016-financial-results-iart-20161027monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2016-financial-results-iart-20160728monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2016-financial-results-iart-20160427monthly0.5https://www.biopharmawatch.com/news/IART/investor-relations-angela-steinway-609-936-2268-angela-steinway-integralife-com-michael-be-iart-20160225monthly0.5https://www.biopharmawatch.com/news/IART/this-news-release-contains-forward-looking-statements-within-the-meaning-of-the-private-se-iart-20151103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investor-relations-angela-steinway-609-936-2268--iart-20150901monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-unaudited-pro-forma-consolidated-financial-infor-iart-20150803monthly0.5https://www.biopharmawatch.com/news/IART/q2-2015-earnings-release-news-release-contact-investor-relations-angela-steinway-609-936-2-iart-20150730monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investor-relations-angela-steinway-609-936-2268--iart-20150720monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-unaudited-pro-forma-consolidated-financial-infor-iart-20150701monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investor-relations-angela-steinway-609-936-2268--iart-20150628monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investor-relations-angela-steinway-609-936-2268--iart-20150609monthly0.5https://www.biopharmawatch.com/news/IART/kirt-stephenson-future-chairman-of-seaspine-s-board-of-directors-said-we-are-pleased-to-ha-iart-20150430monthly0.5https://www.biopharmawatch.com/news/IART/q1-2015-earnings-release-news-release-contact-investor-relations-angela-steinway-609-936-2-iart-20150430monthly0.5https://www.biopharmawatch.com/news/IART/historical-segment-revenue-new-segments-2012-2014-new-reporting-segments-information-2-in--iart-20150413monthly0.5https://www.biopharmawatch.com/news/IART/investor-relations-angela-steinway-609-936-2268-angela-steinway-integralife-com-integra-li-iart-20150224monthly0.5https://www.biopharmawatch.com/news/IART/food-and-drug-administration-466-fernandez-juncos-avenue-san-juan-puerto-rico-00901-teleph-iart-20150114monthly0.5https://www.biopharmawatch.com/news/IART/this-news-release-contains-forward-looking-statements-within-the-meaning-of-the-private-se-iart-20141103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investors-angela-steinway-609-936-2268-angela-st-iart-20141027monthly0.5https://www.biopharmawatch.com/news/IART/to-manufacture-and-ship-sufficient-quantities-of-its-products-to-meet-its-customers-demand-iart-20140805monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investor-relations-angela-steinway-609-936-2268--iart-20140709monthly0.5https://www.biopharmawatch.com/news/IART/part-ii-item-6-selected-financial-data-the-information-set-forth-below-should-be-read-in-c-iart-20140620monthly0.5https://www.biopharmawatch.com/news/CDNA/united-states-district-court-northern-district-of-california-jeffrey-edelman-jaysen-steven-cdna-20251218monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-repurchase-of-5-of-outstanding-shares-board-of-directors-authorizes-new-5-cdna-20250603monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-preliminary-fourth-quarter-and-full-year-2024-results-fourth-quarter-reve-cdna-20250113monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-financial-results-for-third-quarter-2024-third-quarter-2024-fin-cdna-20241015monthly0.5https://www.biopharmawatch.com/news/CDNA/final-press-release-for-newswire-issue-thursday-9-12-24-7-01-am-et-caredx-appoints-keith-k-cdna-20240912monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-appoints-john-w-hanna-as-its-new-president-and-chief-executive-officer-brisbane-ca-cdna-20240416monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-appoints-bryan-riggsbee-to-its-board-of-directors-cdna-20240311monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-revenue-results-for-fourth-quarter-and-full-year-2023-brisbane--cdna-20240109monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-ceo-transition-board-establishes-office-of-the-ceo-conducts-search-for-su-cdna-20231101monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-revenue-results-for-fourth-quarter-and-full-year-2022-cdna-20230109monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-completes-orderly-management-transition-cdna-20211101monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-names-longtime-patient-advocate-art-torres-to-board-of-directors-torres-adds-expert-cdna-20210915monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-appoints-dr-hannah-valantine-to-its-board-of-directors-dr-valantine-brings-deep-tra-cdna-20210630monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-names-ankur-dhingra-as-new-chief-financial-officer-cdna-20210311monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-pricing-of-public-offering-of-common-stock-cdna-20210120monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-third-quarter-2020-results-cdna-20201029monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-pricing-of-public-offering-of-common-stock-cdna-20200610monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-first-quarter-2020-revenue-and-provides-business-update-in-resp-cdna-20200408monthly0.5https://www.biopharmawatch.com/news/CDNA/chris-cournoyer-joins-caredx-board-of-directors-cournoyer-brings-deep-digital-expertise-to-cdna-20190827monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-second-quarter-2019-results-allosure-momentum-drives-76-second-quarter-reve-cdna-20190801monthly0.5https://www.biopharmawatch.com/news/CDNA/grace-col-n-succeeds-amy-abernethy-on-the-caredx-board-col-n-brings-expertise-to-grow-pati-cdna-20190702monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-first-quarter-2019-results-allosure-momentum-drives-85-first-quarter-revenu-cdna-20190508monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-agrees-to-acquire-ottr-complete-transplant-management-ottr-acquisition-will-enable--cdna-20190425monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-accuses-natera-of-false-advertising-claims-that-mislead-medical-personnel-and-trans-cdna-20190410monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-files-patent-infringement-lawsuit-against-natera-caredx-protects-innovation-in-tran-cdna-20190326monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-fourth-quarter-and-fy-2018-results-allosure-launch-momentum-drives-88-fourt-cdna-20190306monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-fourth-quarter-and-full-year-2018-financial-results-cdna-20190107monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-director-dr-amy-abernethy-resigns-board-seat-to-become-principal-deputy-commissione-cdna-20181217monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-strengthens-executive-leadership-team-with-the-appointment-of-reginald-seeto-mb-bs--cdna-20181126monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-full-repayment-of-its-outstanding-debt-recent-equity-financing-leads-to-s-cdna-20181126monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwrit-cdna-20181116monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-pricing-of-public-offering-of-common-stock-cdna-20181113monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-third-quarter-results-allosure-launch-momentum-drives-74-revenue-growth-cdna-20181108monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-second-quarter-results-allosure-launch-momentum-drives-48-revenue-growth-cdna-20180809monthly0.5https://www.biopharmawatch.com/news/CDNA/flatiron-health-cmo-cso-joins-caredx-board-of-directors-amy-abernethy-adds-clinical-expert-cdna-20180628monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-first-quarter-results-allosure-launch-momentum-drives-21-revenue-growth-fur-cdna-20180510monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-closes-debt-refinancing-15-million-term-loan-with-perceptive-advisors-cdna-20180418monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-fourth-quarter-and-fy2017-financial-results-47-transplantation-centers-offe-cdna-20180322monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-refinance-debt-with-perceptive-advisors-balance-sheet-to-be-simplified-with-sing-cdna-20180301monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-fourth-quarter-and-fy2017-financial-results-32-transplantation--cdna-20180108monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-further-simplifies-its-balance-sheet-cdna-20171115monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-third-quarter-2017-financial-results-cdna-20171109monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-closing-of-public-offering-of-common-stock-including-full-exercise-of-und-cdna-20171010monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-pricing-of-upsized-public-offering-of-common-stock-cdna-20171005monthly0.5https://www.biopharmawatch.com/news/CDNA/moldx-sets-allosure-reimbursement-at-2017-allomap-level-80-of-kidney-transplant-patients-w-cdna-20170926monthly0.5https://www.biopharmawatch.com/news/JBIO/disclaimers-forward-looking-statements-certain-statements-contained-in-or-made-orally-duri-jbio-20260601monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides--jbio-20260306monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-updat-jbio-20251113monthly0.5https://www.biopharmawatch.com/news/JBIO/financial-statements-jade-biosciences-inc-condensed-consolidated-balance-sheets-unaudited--jbio-20250514monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-completes-closing-of-merger-with-aerovate-therapeutics-and-previously-ann-jbio-20250428monthly0.5https://www.biopharmawatch.com/news/JBIO/company-overview-april-2025-nasdaq-jbio-disclaimers-forward-looking-statements-certain-sta-jbio-20250429monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-stockholders-approve-proposed-merger-with-jade-biosciences-and-all-r-jbio-20250421monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-declares-special-cash-dividend-in-connection-with-the-proposed-merge-jbio-20250409monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-range-of-expected-cash-dividend-in-connection-with-the-pro-jbio-20250407monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-and-jade-biosciences-announce-merger-agreement-merger-to-create-a-co-jbio-20241031monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-to-explore-strategic-alternatives-jbio-20240708monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-24-week-topline-results-from-the-phase-2b-portion-of-impah-jbio-20240617monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-first-quarter-financial-results-and-business-highlights-to-jbio-20240513monthly0.5https://www.biopharmawatch.com/news/JBIO/meaningfully-improving-the-lives-of-patients-with-rare-cardiopulmonary-disease-targeting-t-jbio-20240327monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-full-year-2023-financial-results-and-business-highlights-t-jbio-20240325monthly0.5https://www.biopharmawatch.com/news/JBIO/meaningfully-improving-the-lives-of-patients-with-rare-cardiopulmonary-disease-targeting-t-jbio-20240108monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-simultaneous-completion-of-enrollment-in-phase-2b-portion--jbio-20231120monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-third-quarter-financial-results-and-business-highlights-jbio-20231113monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-second-quarter-financial-results-and-business-highlights-jbio-20230814monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-appoints-habib-dable-to-its-board-of-directors-jbio-20230711monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-first-quarter-financial-results-and-business-highlights-to-jbio-20230515monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-full-year-2022-financial-results-and-business-highlights-p-jbio-20230329monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-appoints-donald-santel-to-its-board-of-directors-jbio-20230123monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-third-quarter-2022-financial-results-jbio-20221114monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-second-quarter-2022-financial-results-jbio-20220815monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-first-quarter-2022-financial-results-jbio-20220516monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-full-year-2021-financial-results-initiated-impahct-a-globa-jbio-20220330monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-initiation-of-impahct-phase-2b-phase-3-trial-of-av-101-in--jbio-20211215monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-third-quarter-2021-financial-results-jbio-20211115monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-announces-second-quarter-2021-financial-results-jbio-20210816monthly0.5https://www.biopharmawatch.com/news/JBIO/aerovate-therapeutics-appoints-allison-dorval-to-its-board-of-directors-boston-jbio-20210719monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-fourth-quarter-and-full-year-2025-financial-results-full-year-2025-total-reve-atec-20260224monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-select-preliminary-financial-results-for-2025-and-provides-2026-outlook-ful-atec-20260112monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-mourns-passing-of-board-member-jeffrey-p-rydin-atec-20251107monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-third-quarter-2025-financial-results-and-raises-full-year-guidance-x2022-tota-atec-20251030monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-second-quarter-2025-financial-results-and-raises-full-year-guidance-surgical--atec-20250731monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-first-quarter-2025-financial-results-and-raises-full-year-guidance-surgical-r-atec-20250501monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-prices-upsized-350-0-million-convertible-senior-notes-offering-atec-20250304monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-proposed-convertible-senior-notes-offering-atec-20250303monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-2024-total-reve-atec-20250226monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-select-preliminary-financial-results-for-2024-and-provides-2025-outlook-ful-atec-20250113monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-third-quarter-2024-financial-results-and-raises-full-year-guidance-surgical-r-atec-20241030monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-second-quarter-2024-financial-results-and-raises-full-year-guidance-surgical--atec-20240731monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-first-quarter-2024-financial-results-and-raises-full-year-guidance-total-reve-atec-20240507monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-corporate-high-atec-20240227monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-record-preliminary-revenue-results-for-2023-and-2024-revenue-guidance-full--atec-20240108monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-third-quarter-2023-financial-results-and-raises-full-year-2023-adjusted-ebitd-atec-20231106monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-pricing-of-public-offering-of-common-stock-atec-20231024monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-proposed-public-offering-of-common-stock-atec-20231024monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-enhances-board-with-renowned-spine-prowess-dave-demski-appointed-to-board-of-director-atec-20231017monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-preliminary-third-quarter-2023-revenue-results-and-raises-full-year-revenue-atec-20231016monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-second-quarter-2023-financial-results-and-raises-full-year-2023-revenue-and-a-atec-20230803monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-first-quarter-2023-financial-results-total-revenue-grew-54-to-109-million-inc-atec-20230504monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-60-million-underwritten-offering-atec-20230419monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-record-fourth-quarter-and-full-year-2022-financial-results-and-recent-corpora-atec-20230228monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-select-preliminary-financial-2022-results-2023-guidance-and-closing-of-flex-atec-20230109monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-third-quarter-2022-financial-results-total-revenue-grew-43-to-90-million-incl-atec-20221103monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-second-quarter-2022-financial-results-and-increases-full-year-revenue-guidanc-atec-20220804monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-to-host-investor-day-today-atec-20220525monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-first-quarter-2022-financial-results-and-increases-full-year-revenue-guidance-atec-20220505monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-corporate-high-atec-20220301monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-preliminary-2021-revenue-results-and-2022-guidance-full-year-2021-u-s-organ-atec-20220110monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-third-quarter-financial-results-and-recent-corporate-highlights-total-revenue-atec-20211104monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-provides-business-update-atec-20210928monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-prices-upsized-275-0-million-convertible-senior-notes-offering-carls-atec-20210805monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-proposed-convertible-senior-notes-offering-carlsbad-califo-atec-20210804monthly0.5https://www.biopharmawatch.com/news/ATEC/carlsbad-california-global-newswire-atec-20210804monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-second-quarter-financial-results-and-recent-corporate-highlights-organic-reve-atec-20210803monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-appoints-beth-altman-to-board-of-directors-atec-20210726monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-select-preliminary-second-quarter-2021-financial-results-second-quarter-202-atec-20210712monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-appoints-marie-meynadier-ph-d-to-board-of-directors-atec-20210621monthly0.5https://www.biopharmawatch.com/news/ATEC/strong-success-of-the-tender-offer-initiated-by-alphatec-holdings-for-common-shares-and-oc-atec-20210513monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-first-quarter-financial-results-and-recent-corporate-highlights-u-s-revenue-g-atec-20210506monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-preliminary-first-quarter-2021-revenue-results-and-provides-corporate-updat-atec-20210408monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-corporate-high-atec-20210304monthly0.5https://www.biopharmawatch.com/news/ATEC/any-forward-looking-statements-whether-as-a-result-of-new-information-future-events-or-oth-atec-20210112monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-continues-to-advance-clinical-prowess-with-renewed-agreement-to-acquire-eos-imaging-i-atec-20201216monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-third-quarter-2020-financial-results-and-recent-corporate-highlights-u-s-reve-atec-20201105monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-preliminary-third-quarter-2020-financial-results-third-quarter-u-s-revenue--atec-20201007monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-second-quarter-2020-financial-results-and-recent-corporate-highlights-u-s-rev-atec-20200806monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-first-quarter-2020-financial-results-and-recent-corporate-highlights-new-prod-atec-20200511monthly0.5https://www.biopharmawatch.com/news/ATEC/about-eos-imaging-based-in-paris-eos-imaging-is-a-global-medical-device-company-that-devel-atec-20200427monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-fourth-quarter-and-full-year-2019-financial-results-u-s-revenue-grew-nearly-3-atec-20200305monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-agreement-to-acquire-eos-imaging-accelerates-revenue-by-creating-significan-atec-20200228monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-announces-preliminary-2019-revenue-results-and-2020-revenue-outlook-x2022-full-year-2-atec-20200113monthly0.5https://www.biopharmawatch.com/news/ATEC/atec-reports-third-quarter-2019-financial-results-and-recent-corporate-highlights-third-qu-atec-20191030monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-pricing-of-public-offering-of-common-stock-atec-20190731monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-proposed-public-offering-of-common-stock-atec-20190730monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-reports-second-quarter-2019-financial-results-and-corporate-highlights-full-year--atec-20190724monthly0.5https://www.biopharmawatch.com/news/ATEC/described-in-the-forward-looking-statements-the-company-cautions-investors-that-there-can--atec-20190627monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-reports-first-quarter-2019-financial-results-and-corporate-highlights-strong-earl-atec-20190509monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-reports-fourth-quarter-and-full-year-2018-financial-results-secures-additio-atec-20190307monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-2018-preliminary-revenue-results-2019-revenue-outlook-and-senior-leader-atec-20190107monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-reports-third-quarter-2018-financial-results-and-corporate-highlights-atec-20181108monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-reports-second-quarter-2018-financial-results-atec-20180802monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-reports-first-quarter-2018-financial-results-and-recent-corporate-highlights-atec-20180510monthly0.5https://www.biopharmawatch.com/news/ATEC/safeop-surgical-inc-financial-statements-with-independent-auditor-s-report-year-ended-atec-20180416monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-reports-fourth-quarter-and-full-year-2017-financial-results-atec-20180308monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-preliminary-fourth-quarter-and-full-year-2017-revenue-and-corporate-upd-atec-20180108monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-reports-third-quarter-2017-financial-results-significant-progress-wi-atec-20171109monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-preliminary-third-quarter-2017-financial-results-and-corporate-updates-atec-20171024monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-accelerates-business-transformation-with-additional-spine-experienced-leadership--atec-20171002monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-reports-second-quarter-2017-financial-results-substantial-improvemen-atec-20170810monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-reports-first-quarter-2017-financial-results-atec-20170511monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-18-9-million-private-placement-proceeds-to-support-corporate-g-atec-20170323monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-fourth-quarter-and-full-year-2016-financial-results-atec-20170315monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-jeffrey-g-black-as-chief-financial-officer-financial-executive-wit-atec-20170306monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-board-and-executive-leadership-changes-experienced-orthopedics-atec-20161212monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-company-updates-company-names-chairman-leslie-h-cross-as-inter-atec-20160915monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-completes-sale-of-international-business-to-globus-medical-substantially-atec-20160901monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-sale-of-international-business-to-globus-medical-atec-20160726monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-reconciliation-of-geographic-segment-revenues-and-gross-profit-in-th-atec-20160315monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-third-quarter-2015-revenue-and-financial-results-carlsbad-ca-atec-20151103monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-second-quarter-2015-revenue-and-financial-results-carlsbad-ca-atec-20150804monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-dalton-henry-investor-relations-analyst-ir-conmed-com-conmed-corporatio-cnmd-20260617monthly0.5https://www.biopharmawatch.com/news/CNMD/j-p-morgan-44-th-annual-healthcare-conference-pat-j-beyer-president-and-chief-executive-of-cnmd-20260112monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-toddgarner-conmed-com-conmed-corp-cnmd-20251205monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-toddgarner-conmed-com-conmed-corpor-cnmd-20250909monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-toddgarner-conmed-com-martha-aronso-cnmd-20250707monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20250430monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20250225monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20250205monthly0.5https://www.biopharmawatch.com/news/CNMD/j-p-morgan-43rd-annual-healthcare-conference-forward-looking-information-this-presentation-cnmd-20250113monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20241030monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20241004monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20240731monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20240424monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20240131monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20231025monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20230726monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20230426monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20230202monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20221115monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20221026monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-com--cnmd-20220809monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-com--cnmd-20220801monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20220727monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-com--cnmd-20220613monthly0.5https://www.biopharmawatch.com/news/CNMD/confidential-news-release-contact-conmed-corporation-todd-garner-chief-financial-officer-7-cnmd-20220601monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-com--cnmd-20220531monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20220504monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20220126monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20211027monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-co-cnmd-20210728monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-727-214-2975-toddgarner-conmed-com--cnmd-20210428monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20210127monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20201028monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20200729monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20200429monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20200420monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20200316monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-co-cnmd-20200129monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20191030monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-w-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-co-cnmd-20190923monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20190731monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20190618monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20190424monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20190211monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-announces-pricing-of-300-million-offering-of-convertible-senior-notes-u-cnmd-20190124monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20190123monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-announces-definitive-agreement-to-acquire-buffalo-filter-llc-transaction-adds-categ-cnmd-20181213monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20181101monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20180801monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20180425monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-todd-garner-chief-financial-officer-315-624-3317-toddgarner-conmed-com--cnmd-20180131monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-advisor-to-chief-financial-officer-315-624-3202-conmed-c-cnmd-20180102monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20171102monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20170726monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20170426monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-conmed-corporation--cnmd-20170411monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20170201monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20161027monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20160727monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20160427monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-conmed-corporation--cnmd-20160223monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20160127monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-conmed-completes-ac-cnmd-20160104monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-conmed-announces-de-cnmd-20151116monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-a-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed--cnmd-20151021monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed-co-cnmd-20150721monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-adds-two-health-care-executives-to-its-board-of-directors-utica-new-yor-cnmd-20150701monthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-corporation-luke-pomilio-chief-financial-officer-315-624-3202-lukepomilio-conmed-co-cnmd-20150422monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-first-quarter-2026-financial-results-first-quarter-2026-and-selected-high-hrow-20260511monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-closing-of-acquisition-of-melt-pharmaceuticals-hrow-20251118monthly0.5https://www.biopharmawatch.com/news/HROW/imprimisrx-announces-leadership-changes-frank-mullery-appointed-chief-executive-officer-of-hrow-20251006monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-offering-of-250-0-million-senior-unsecured-notes-due-2030-announces-commi-hrow-20250908monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-second-quarter-2025-financial-results-second-quarter-2025-and-recent-sele-hrow-20250811monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-enters-into-commercialization-agreement-with-samsung-bioepis-for-ophthalmology-bios-hrow-20250717monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-acquires-u-s-commercial-rights-to-byqlovi-clobetasol-propionate-ophthalmic-suspensi-hrow-20250609monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-first-quarter-2025-financial-results-first-quarter-2025-and-recent-select-hrow-20250508monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-fourth-quarter-and-year-end-2024-audited-financial-results-fourth-quarter-hrow-20250327monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-provides-fourth-quarter-and-year-end-2024-unaudited-preliminary-financial-results-a-hrow-20250317monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-third-quarter-2024-financial-results-third-quarter-2024-and-recent-select-hrow-20241114monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-second-quarter-2024-financial-results-second-quarter-2024-and-recent-sele-hrow-20240807monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-first-quarter-2024-financial-results-first-quarter-2024-and-recent-select-hrow-20240513monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-fourth-quarter-and-year-end-2023-financial-results-full-year-2023-highlig-hrow-20240319monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-licenses-canadian-rights-to-apotex-for-five-branded-ophthalmic-pharmaceutical-produ-hrow-20240215monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-new-appointments-to-its-board-of-directors-hrow-20240129monthly0.5https://www.biopharmawatch.com/news/HROW/melt-pharmaceuticals-provides-corporate-update-nashville-tenn-hrow-20240103monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-third-quarter-2023-financial-results-third-quarter-2023-and-recent-select-hrow-20231113monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-second-quarter-2023-financial-results-second-quarter-2023-and-recent-sele-hrow-20230809monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-prices-60-million-public-offering-of-common-stock-hrow-20230719monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-provides-select-preliminary-second-quarter-2023-financial-guidance-hrow-20230718monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-first-quarter-2023-financial-results-first-quarter-2023-and-recent-select-hrow-20230511monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-new-100-million-secured-credit-facility-with-oaktree-hrow-20230328monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-fourth-quarter-and-year-end-2022-financial-results-2022-and-recent-highli-hrow-20230323monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-closes-acquisition-of-u-s-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence-an-hrow-20230123monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-secures-capital-to-close-recently-announced-acquisition-announces-pricing-of-35-mil-hrow-20221216monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-proposed-offering-of-100-million-of-senior-notes-due-2027-and-bb-rating-f-hrow-20221214monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-enters-into-agreement-to-acquire-exclusive-u-s-rights-to-ilevro-nevanac-vigamox-max-hrow-20221214monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-announces-third-quarter-2022-financial-results-selected-recent-highlights-fda-appro-hrow-20221114monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-sells-non-ophthalmic-compounding-business-hrow-20221005monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-second-quarter-2022-financial-results-revenues-increase-for-eighth-hrow-20220809monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-first-quarter-2022-financial-results-seventh-consecutive-quarter-o-hrow-20220505monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-fourth-quarter-and-year-end-2021-financial-results-sixth-consecuti-hrow-20220310monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-acquires-u-s-commercial-rights-to-four-branded-eye-drops-expands-and-strengt-hrow-20211220monthly0.5https://www.biopharmawatch.com/news/HROW/eyepoint-pharmaceuticals-and-harrow-health-s-imprimisrx-announce-expanded-u-s-commercial-a-hrow-20211207monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-third-quarter-2021-financial-results-revenues-reach-record-levels--hrow-20211109monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-provides-13-5-million-senior-secured-loan-to-melt-pharmaceuticals-melt-expec-hrow-20210902monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-acquires-ophthalmic-surgical-drug-candidate-from-wakamoto-pharmaceutical-co--hrow-20210818monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-second-quarter-2021-financial-results-fourth-consecutive-quarter-o-hrow-20210810monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-acquires-patented-ophthalmic-surgical-drug-candidate-from-sintetica-new-drug-hrow-20210727monthly0.5https://www.biopharmawatch.com/news/HROW/surface-ophthalmics-announces-25-million-private-round-of-fundraising-proceeds-from-the-ca-hrow-20210721monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-pricing-of-17-5-million-aggregate-principal-amount-offering-of-8-6-hrow-20210614monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-offering-of-17-5-million-of-8-625-senior-notes-due-2026-and-bb-rat-hrow-20210614monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-record-first-quarter-2021-financial-results-highlights-for-first-q-hrow-20210511monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-raises-approximately-11-million-in-sale-of-series-b-preferred-stock-hrow-20210505monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-pricing-of-50-million-offering-of-senior-notes-due-2026-hrow-20210415monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-preliminary-first-quarter-2021-financial-results-hrow-20210414monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-fourth-quarter-and-year-end-2020-financial-results-company-s-prior-hrow-20210308monthly0.5https://www.biopharmawatch.com/news/HROW/melt-pharmaceuticals-completes-phase-1-study-for-sublingual-non-opioid-pain-and-sedation-d-hrow-20210209monthly0.5https://www.biopharmawatch.com/news/HROW/surface-ophthalmics-announces-first-patient-dosed-in-phase-ii-trial-for-surf-200-for-acute-hrow-20210204monthly0.5https://www.biopharmawatch.com/news/HROW/surface-ophthalmics-announces-first-patient-dosed-in-landmark-head-to-head-phase-ii-trial--hrow-20210127monthly0.5https://www.biopharmawatch.com/news/HROW/surface-ophthalmics-announces-positive-top-line-results-from-phase-ii-trial-for-surf-201-b-hrow-20210121monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-publishes-third-quarter-2020-letter-to-stockholders-nashville-tn-november-9--hrow-20201117monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-publishes-third-quarter-2020-letter-to-stockholders-nashville-tn-november-9--hrow-20201109monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-publishes-second-quarter-2020-letter-to-stockholders-nashville-tn-hrow-20200810monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-publishes-first-quarter-2020-letter-to-stockholders-nashville-tn-hrow-20200511monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-publishes-fourth-quarter-2019-letter-to-stockholders-nashville-tn-hrow-20200313monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-publishes-third-quarter-letter-to-stockholders-nashville-tn-hrow-20191113monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-second-quarter-2019-results-consolidated-quarterly-revenues-reach--hrow-20190814monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-renegotiated-debt-facility-with-swk-holdings-san-diego-ca-hrow-20190529monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-first-quarter-2019-financial-results-san-diego-ca-hrow-20190509monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-fourth-quarter-2018-financial-results-san-diego-ca-hrow-20190312monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-11-million-series-a-financing-for-melt-pharmaceuticals-subsidiary--hrow-20190205monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-inc-completes-name-change-to-harrow-health-inc-harrow-health-inc--hrow-20181231monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-third-quarter-2018-results-san-diego-ca-hrow-20181113monthly0.5https://www.biopharmawatch.com/news/HROW/eton-pharmaceuticals-announces-pricing-of-initial-public-offering-hrow-20181112monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-second-quarter-2018-results-san-diego-ca-hrow-20180806monthly0.5https://www.biopharmawatch.com/news/HROW/eton-pharma-reports-positive-top-line-results-from-phase-iii-trial-of-em-100-ophthalmic-so-hrow-20180724monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-first-quarter-2018-results-san-diego-ca-hrow-20180515monthly0.5https://www.biopharmawatch.com/news/HROW/surface-pharmaceuticals-inc-announces-20-million-series-a-financing-from-flying-l-partners-hrow-20180515monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-fourth-quarter-2017-results-san-diego-ca-hrow-20180308monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-third-quarter-2017-results-san-diego-ca-hrow-20171114monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-second-quarter-2017-financial-results-san-diego-ca-hrow-20170810monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-16-million-debt-facility-with-swk-holdings-san-diego-ca-hrow-20170720monthly0.5https://www.biopharmawatch.com/news/HROW/eton-pharmaceuticals-announces-20-million-series-a-financing-proceeds-to-support-the-devel-hrow-20170620monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-first-quarter-2017-financial-results-san-diego-ca-hrow-20170510monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-and-sightlife-surgical-sign-agreement-for-national-launch-of-seru-hrow-20170502monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-and-precision-lens-sign-agreement-to-expand-imprimis-ophthalmic-p-hrow-20170418monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-acquires-exclusive-license-to-patented-ophthalmic-formulation-for-hrow-20170406monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-to-raise-3-1-million-in-registered-direct-offering-san-diego-cali-hrow-20170322monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-fourth-quarter-and-year-end-2016-financial-results-san--hrow-20170321monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-begins-dispensing-from-fda-registered-503b-outsourcing-facility-i-hrow-20170216monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-9-8-million-private-placement-of-units-san-diego-calif-hrow-20161219monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-third-quarter-2016-financial-results-san-diego-calif-hrow-20161114monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-second-quarter-2016-financial-results-san-diego-ca-hrow-20160815monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-2-million-equipment-sale-leaseback-agreement-with-essex-hrow-20160811monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-first-quarter-2016-financial-results-and-provides-busin-hrow-20160512monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-fourth-quarter-and-year-end-2015-financial-results-and--hrow-20160323monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-san-diego-ca-hrow-20160310monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2015-financial-hrow-20160303monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-third-quarter-2015-financial-results-and-provides-busin-hrow-20151112monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-preliminary-revenue-for-third-quarter-2015-san-diego-ca-hrow-20151020monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-signs-license-agreement-to-bring-proprietary-compounded-ophthalmi-hrow-20150812monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-first-quarter-2015-financial-results-and-provides-busin-hrow-20150513monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-15-million-term-loan-agreement-with-life-sciences-alter-hrow-20150512monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-fourth-quarter-and-year-end-2014-financial-results-and--hrow-20150312monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-two-key-leadership-promotions-john-saharek-appointed-to-hrow-20150202monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-signs-agreement-to-acquire-pcab-accredited-pharmacy-in-california-hrow-20141202monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-reports-on-third-quarter-2014-financial-results-and-provides-upda-hrow-20141112monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-enters-into-license-agreement-for-patented-urology-formulation-pa-hrow-20141029monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-announces-second-quarter-2014-financial-results-and-provides-oper-hrow-20140813monthly0.5https://www.biopharmawatch.com/news/HROW/jen-carroll-jcarroll-imprimispharma-com-858-704-4587-imprimis-pharmaceuticals-announces-ac-hrow-20140211monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-inc-a-unique-approach-to-505-b-2-july-2013-mark-l-baum-c-e-o-1-sa-hrow-20130723monthly0.5https://www.biopharmawatch.com/news/HROW/josh-berg-imprimis-pharmaceuticals-inc-858-704-4041-for-immediate-release-imprimis-pharmac-hrow-20130617monthly0.5https://www.biopharmawatch.com/news/HROW/executive-summary-imprimis-pharmaceuticals-inc-nasdaq-immy-who-we-are-imprimis-pharmaceuti-hrow-20130522monthly0.5https://www.biopharmawatch.com/news/HROW/mark-l-baum-imprimis-pharmaceuticals-inc-858-433-2800-for-immediate-release-imprimis-pharm-hrow-20130208monthly0.5https://www.biopharmawatch.com/news/HROW/imprimis-pharmaceuticals-closes-7-95m-financing-and-provides-progress-report-to-shareholde-hrow-20120427monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-reports-third-quarter-and-year-to-date-2010-results-hrow-20101108monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-appoints-john-n-bonfiglio-ph-d-as-chief-executive-officer-and-pre-hrow-20101021monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-reports-second-quarter-and-year-to-date-2010-results-hrow-20100812monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-inc-june-2010-safe-harbor-statement-the-company-cautions-you-that-hrow-20100617monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-reports-first-quarter-2010-results-hrow-20100513monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-closes-1-million-debt-financing-company-provides-update-on-recent-hrow-20100408monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-announces-management-reorganization-hrow-20100218monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-inc-symbol-tdlp-ob-october-2009-2-safe-harbor-statement-the-compa-hrow-20091026monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-announces-positive-phase-3-study-results-for-lead-topical-pain-dr-hrow-20091006monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-appoints-mr-lynn-swann-pro-football-hall-of-famer-abc-sports-broa-hrow-20081124monthly0.5https://www.biopharmawatch.com/news/HROW/dated-june-16-2008-contact-john-lomoro-chief-financial-officer-transdel-pharmaceuticals-in-hrow-20080616monthly0.5https://www.biopharmawatch.com/news/HROW/dated-may-15-2008-contact-john-lomoro-chief-financial-officer-transdel-pharmaceuticals-inc-hrow-20080515monthly0.5https://www.biopharmawatch.com/news/HROW/unassociated-document-contact-john-lomoro-chief-financial-officer-transdel-pharmaceuticals-hrow-20080424monthly0.5https://www.biopharmawatch.com/news/HROW/transdel-pharmaceuticals-appoints-mr-anthony-s-thornley-to-its-board-of-directors-la-jolla-hrow-20071106monthly0.5https://www.biopharmawatch.com/news/HROW/trans-pharma-corporation-a-development-stage-company-financial-statements-for-the-years-en-hrow-20070921monthly0.5https://www.biopharmawatch.com/news/PNTG/the-pennant-group-inc-announces-completion-of-spin-off-from-the-ensign-group-inc-pntg-20191001monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-completes-acquisition-of-azstarys-from-corium-therapeutics-adds-highly-complemen-coll-20260512monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-2026-financial-results-and-highlights-recent-company-progr-coll-20260507monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-acquire-azstarys-from-corium-therapeutics-strengthening-position-in-adhd-and--coll-20260319monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-fourth-quarter-and-full-year-2025-financial-results-coll-20260226monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2026-financial-guidance-and-business-update-product-revenues-net-expect-coll-20260108monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-2025-financial-results-and-highlights-recent-company-progr-coll-20250508monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-record-fourth-quarter-and-full-year-2024-financial-results-generated-rec-coll-20250227monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2025-financial-guidance-and-business-update-product-revenues-net-expect-coll-20250108monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-record-third-quarter-2024-financial-results-generated-record-q3-24-net-r-coll-20241107monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-completes-acquisition-of-ironshore-therapeutics-adds-commercial-product-jornay-p-coll-20240904monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-second-quarter-2024-financial-results-generated-q2-24-net-revenue-of-145-coll-20240808monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-acquire-ironshore-therapeutics-expanding-into-neurology-adds-commercial-produ-coll-20240729monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-obtains-six-month-extension-of-u-s-pediatric-exclusivity-for-nucynta-franchise-coll-20240613monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-2024-financial-results-generated-q1-24-net-revenue-of-144--coll-20240509monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-inc-announces-redemption-of-outstanding-2-625-convertible-senior--coll-20240411monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-record-fourth-quarter-and-full-year-2023-financial-results-generated-rec-coll-20240222monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2024-financial-guidance-product-revenues-net-expected-in-the-range-of-5-coll-20240103monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-2023-financial-results-q3-23-net-revenue-of-136-7-million--coll-20231107monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-extension-of-nucynta-regulatory-exclusivity-through-july-2026-coll-20230824monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-record-1h-23-net-revenue-of-280-3-million-up-35-year-over-year-q2-23-net-coll-20230803monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-2023-financial-results-generated-record-net-revenue-of-144-coll-20230504monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-fourth-quarter-and-full-year-2022-financial-results-generated-record-qua-coll-20230223monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-inc-prices-upsized-210-0-million-convertible-senior-notes-offerin-coll-20230207monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-fourth-quarter-and-full-year-2022-preliminary-financial-results-result-coll-20230206monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2023-financial-guidance-product-revenues-net-expected-in-the-range-of-5-coll-20230104monthly0.5https://www.biopharmawatch.com/news/COLL/appeals-court-affirms-validity-of-collegium-s-belbuca-patents-ruling-bars-anda-filer-alvog-coll-20221222monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-2022-financial-results-generated-record-net-revenue-of-127-coll-20221103monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-second-quarter-2022-financial-results-generated-record-net-revenue-of-12-coll-20220804monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-2022-financial-results-generated-net-revenue-of-83-8-milli-coll-20220510monthly0.5https://www.biopharmawatch.com/news/COLL/april-2022-nasdaq-coll-corporate-presentation-investor-presentation-forward-looking-statem-coll-20220413monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2022-financial-guidance-total-product-revenues-expected-in-the-range-of-coll-20220405monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-completes-the-acquisition-of-coll-20220322monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-fourth-quarter-and-full-year-2021-financial-results-bdsi-acquisition-exp-coll-20220224monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-acquire-biodelivery-sciences-broadening-pain-portfolio-expected-to-be-immedia-coll-20220214monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-settlement-framework-to-resolve-pending-opioid-related-litigation-coll-20211228monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-fiscal-2021-results-board-of-directors-has-authorized-25-m-coll-20211104monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-strong-q2-results-with-cash-balance-growing-to-over-200-million-xtampza--coll-20210805monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-inc-corporate-overview-june-2021-forward-looking-statements-this--coll-20210602monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-record-quarterly-revenue-of-87-7-million-net-income-of-15-7-million-and--coll-20210506monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-record-full-year-2020-revenue-of-310-0-million-2020-first-full-year-of-p-coll-20210225monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2021-financial-guidance-xtampza-er-revenues-expected-in-the-range-of-15-coll-20210106monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-net-income-of-11-3-million-in-the-third-quarter-of-2020-strengthened-for-coll-20201105monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-settlement-with-teva-resolving-xtampza-er-patent-litigation-coll-20200930monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-appoints-rita-balice-gordon-to-its-board-of-directors-coll-20200925monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-net-income-of-8-1-million-in-the-second-quarter-of-2020-non-gaap-net-inc-coll-20200805monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-2020-profitability-x2013-achieves-gaap-profitability-with--coll-20200507monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-full-year-2019-revenue-of-296-7-million-2019-revenue-growth-of-6-driven--coll-20200227monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-closing-of-the-nucynta-franchise-acquisition-collegium-announces-closi-coll-20200213monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-acquire-u-s-rights-to-nucynta-franchise-financially-transformative-acquisitio-coll-20200206monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2020-financial-guidance-xtampza-er-revenues-expected-in-the-range-of-15-coll-20200107monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-2019-financial-results-new-exclusive-formulary-wins-announ-coll-20191106monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-second-quarter-2019-financial-results-xtampza-er-net-product-revenues-we-coll-20190807monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-2019-financial-results-xtampza-er-net-product-revenues-of--coll-20190508monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-fourth-quarter-and-full-year-2018-financial-results-xtampza-er-prescript-coll-20190227monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-full-year-2019-financial-guidance-xtampza-er-revenue-expected-in-the-ra-coll-20190107monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-financial-results-net-product-revenues-were-70-2-million-f-coll-20181108monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-second-quarter-financial-results-and-provides-corporate-update-net-reven-coll-20180808monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-ceo-succession-joseph-ciaffoni-promoted-to-ceo-and-appointed-to-board--coll-20180604monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-financial-results-and-provides-corporate-update-net-revenu-coll-20180509monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-fourth-quarter-financial-results-and-provides-corporate-update-xtampza-e-coll-20180307monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-closing-of-agreement-to-license-rights-to-commercialize-nucynta-franch-coll-20180110monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-license-rights-to-commercialize-nucynta-franchise-establishes-collegium-as-a--coll-20171204monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-financial-results-and-provides-corporate-update-xtampza-er-coll-20171108monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-second-quarter-financial-results-and-provides-corporate-update-collegium-coll-20170809monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-the-appointment-of-joseph-ciaffoni-as-chief-operating-officer-coll-20170530monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-financial-results-and-provides-corporate-update-xtampza-er-coll-20170510monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-fourth-quarter-financial-results-and-provides-corporate-update-xtampza-e-coll-20170309monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-financial-results-and-provides-corporate-update-broadened--coll-20161110monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-prices-public-offering-of-80-million-of-common-stock-coll-20161026monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-proposed-public-offering-of-common-stock-coll-20161025monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-second-quarter-financial-results-and-provides-corporate-update-received--coll-20160810monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-licenses-the-u-s-rights-to-onsolis-from-biodelivery-sciences-breakthrough-cancer-coll-20160511monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-first-quarter-financial-results-and-provides-corporate-update-coll-20160510monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-2015-financial-results-and-provides-corporate-update-coll-20160315monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-appoints-ted-schroeder-to-board-of-directors-coll-20160125monthly0.5https://www.biopharmawatch.com/news/COLL/united-states-district-court-district-of-massachusetts-purdue-pharma-l-p-the-p-f-laborator-coll-20151228monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-financial-results-and-provides-corporate-update-coll-20151112monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-second-quarter-financial-results-and-provides-corporate-update-coll-20150812monthly0.5https://www.biopharmawatch.com/news/XERS/communication-are-therefore-cautioned-not-to-place-undue-reliance-on-these-forward-looking-xers-20260611monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-first-quarter-2026-financial-results-total-product-revenue-increas-xers-20260507monthly0.5https://www.biopharmawatch.com/news/XERS/document-xeris-biopharma-subsidiaries-file-recorlev-patent-infringement-lawsuit-four-orang-xers-20260226monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-posts-record-financial-results-for-the-third-quarter-2025-total-product-re-xers-20251106monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-record-financial-results-for-the-second-quarter-2025-and-raises-fu-xers-20250807monthly0.5https://www.biopharmawatch.com/news/XERS/copyright-2021-2025-xeris-pharmaceuticals-inc-all-rights-reserved-welcome-and-agenda-allis-xers-20250603monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-record-first-quarter-2025-financial-results-total-revenue-increase-xers-20250508monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-delivers-record-fourth-quarter-and-full-year-2024-results-and-announces-20-xers-20250306monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-appoints-anh-nguyen-md-mba-as-chief-medical-officer-kenneth-johnson-pharmd-svp-globa-xers-20250224monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-third-quarter-2024-financial-results-achieved-record-total-revenue-xers-20241108monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-xeris-biopharma-reports-second-quarter-2024-financial-results-achieved-revenue-of-48-xers-20240808monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-announces-ceo-succession-plan-john-shannon-president-and-chief-operating-o-xers-20240708monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-first-quarter-2024-financial-results-and-recent-events-q1-2024-tot-xers-20240509monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-eve-xers-20240306monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-third-quarter-2023-financial-results-achieved-record-revenue-of-48-xers-20231109monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-announces-private-convertible-note-exchange-transactions-chicago-il-xers-20230927monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-second-quarter-2023-financial-results-achieved-record-revenue-of-3-xers-20230808monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-first-quarter-2023-financial-results-achieved-first-quarter-total--xers-20230509monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-2-xers-20230308monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-third-quarter-2022-financial-results-and-recent-events-achieved-re-xers-20221109monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-announces-positive-topline-phase-1-clinical-data-of-its-investigational-su-xers-20221020monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-second-quarter-financial-results-and-upcoming-events-achieved-reco-xers-20220810monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-first-quarter-financial-results-and-upcoming-events-launched-recor-xers-20220511monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-eve-xers-20220310monthly0.5https://www.biopharmawatch.com/news/XERS/consolidated-financial-statements-strongbridge-biopharma-plc-xers-20220128monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-provides-business-update-and-reaffirms-2021-guidance-preliminary-2021-full-xers-20220101monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-enters-into-agreement-for-30-million-private-placement-chicago-il-xers-20220103monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-reports-third-quarter-2021-financial-results-and-other-highlights-acquisit-xers-20211110monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-preliminary-unaudited-fourth-quarter-2025-revenue-growth-o-f-at--bfly-20260115monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-third-quarter-2025-financial-results-delivered-quarterly-revenue-bfly-20251031monthly0.5https://www.biopharmawatch.com/news/BFLY/document-butterfly-network-appoints-john-doherty-as-chief-financial-officer-seasoned-finan-bfly-20251009monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-second-quarter-2025-financial-results-delivered-highest-quarterl-bfly-20250801monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-first-quarter-2025-financial-results-delivered-on-quarterly-reve-bfly-20250502monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-fourth-quarter-2024-financial-results-delivered-record-annual-an-bfly-20250228monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-announces-pricing-of-75-6-million-public-offering-of-common-stock-1-29-2-bfly-20250131monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-announces-proposed-public-offering-of-common-stock-1-29-2025-burlington--bfly-20250129monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-preliminary-unaudited-fourth-quarter-2024-revenue-growth-of-appr-bfly-20250108monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-third-quarter-2024-financial-results-delivered-quarterly-revenue-bfly-20241101monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-second-quarter-2024-financial-results-reports-record-quarterly-r-bfly-20240801monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-first-quarter-2024-financial-results-achieves-14-revenue-growth--bfly-20240501monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-fourth-quarter-2023-financial-results-completed-cost-savings-and-bfly-20240228monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-third-quarter-2023-financial-results-delivers-on-multiple-growth-bfly-20231102monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-second-quarter-2023-financial-results-reports-reorganization-wit-bfly-20230803monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-first-quarter-2023-financial-results-reports-revenue-in-line-wit-bfly-20230511monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-names-joseph-m-devivo-as-president-and-chief-executive-officer-health-te-bfly-20230424monthly0.5https://www.biopharmawatch.com/news/BFLY/granted-in-the-court-of-chancery-of-the-state-of-delaware-in-re-butterfly-network-inc-c-a--bfly-20230317monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-fourth-quarter-2022-financial-results-progress-on-key-initiative-bfly-20230228monthly0.5https://www.biopharmawatch.com/news/BFLY/in-the-court-of-chancery-of-the-state-of-delaware-in-re-butterfly-network-inc-c-a-no-2023--bfly-20230224monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-third-quarter-2022-financial-results-record-revenue-with-momentu-bfly-20221103monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-second-quarter-2022-financial-results-record-revenue-with-moment-bfly-20220803monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-first-quarter-2022-financial-results-solid-revenue-growth-driven-bfly-20220505monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-names-heather-getz-as-chief-financial-officer-health-tech-executive-brin-bfly-20220420monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-fourth-quarter-and-full-year-2021-financial-results-full-year-20-bfly-20220328monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-inc-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-2-bfly-20220328monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-third-quarter-2021-financial-results-year-over-year-revenue-grow-bfly-20220328monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-announces-key-appointments-to-the-board-and-management-dr-erica-schwartz-bfly-20220328monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-second-quarter-2021-financial-results-strong-revenue-growth-driv-bfly-20220328monthly0.5https://www.biopharmawatch.com/news/BFLY/legacy-butterfly-bfly-operations-inc-formerly-known-as-butterfly-network-inc-unaudited-qua-bfly-20220328monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-first-quarter-2021-financial-results-strong-revenue-growth-drive-bfly-20220328monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-fourth-quarter-and-full-year-2021-financial-results-full-year-20-bfly-20220228monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-inc-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-2-bfly-20220111monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-third-quarter-2021-financial-results-year-over-year-revenue-grow-bfly-20211115monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-announces-key-appointments-to-the-board-and-management-dr-erica-schwartz-bfly-20210909monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-second-quarter-2021-financial-results-strong-revenue-growth-driv-bfly-20210809monthly0.5https://www.biopharmawatch.com/news/BFLY/legacy-butterfly-bfly-operations-inc-formerly-known-as-butterfly-network-inc-unaudited-qua-bfly-20210617monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-reports-first-quarter-2021-financial-results-strong-revenue-growth-drive-bfly-20210513monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-inc-reports-2020-financial-results-strong-year-over-year-revenue-growth--bfly-20210329monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-inc-further-strengthens-management-and-board-with-key-additions-stacey-p-bfly-20210311monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-a-global-leader-in-democratizing-medical-imaging-closes-business-combina-bfly-20210216monthly0.5https://www.biopharmawatch.com/news/BFLY/unaudited-pro-forma-condensed-combined-financial-information-defined-terms-included-below--bfly-20210216monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-inc-and-longview-acquisition-corp-announce-dr-todd-fruchterman-to-become-bfly-20210125monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-a-global-leader-in-democratizing-medical-imaging-to-be-listed-on-nyse-th-bfly-20201120monthly0.5https://www.biopharmawatch.com/news/BFLY/longview-acquisition-corp-announces-the-separate-trading-of-its-shares-of-class-a-common-s-bfly-20200713monthly0.5https://www.biopharmawatch.com/news/BFLY/longview-acquisition-corp-pro-forma-balance-sheet-actual-as-of-bfly-20200702monthly0.5https://www.biopharmawatch.com/news/BFLY/longview-acquisition-corp-pro-forma-balance-sheet-actual-as-of-bfly-20200526monthly0.5https://www.biopharmawatch.com/news/BFLY/longview-acquisition-corp-index-to-financial-statements-page-report-of-independent-registe-bfly-20200526monthly0.5https://www.biopharmawatch.com/news/EVO/directors-dealings-16-june-2026-17-46-notification-and-public-disclosure-of-transactions-b-evo-20260617monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-dr-sarah-fakih-evp-head-of-global-communications-an-evo-20260501monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-announces-new-nomination-to-board-of-directors-nomination-of-dr-wolfgang-hofmann-as-evo-20260429monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-announces-chief-financial-officer-transition-paul-hitchin-to-step-down-as-of-evo-20260424monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-announces-fourth-quarter-and-full-year-2025-results-foundation-for-profitable-growt-evo-20260408monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-nominates-dieter-weinand-as-supervisory-board-chairman-strengthens-supervisory-boar-evo-20260407monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-announces-horizon-next-inflection-in-its-strategic-transformation-to-accelerate-gro-evo-20260310monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-5-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b12-evo-20260116monthly0.5https://www.biopharmawatch.com/news/EVO/stimmrechtsmitteilung-seite-1-5-hamburg-22419-manfred-eigen-campus-essener-bogen-7-529900f-evo-20260113monthly0.5https://www.biopharmawatch.com/news/EVO/just-evotec-biologics-receives-grant-for-ai-driven-optimization-of-monoclonal-antibody-dev-evo-20260108monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-4-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b12-evo-20260106monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b12-evotec-s-evo-20260102monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-appoints-dr-sarah-fakih-as-evp-head-of-global-communications-and-investor-relations-evo-20260101monthly0.5https://www.biopharmawatch.com/news/EVO/announcement-pursuant-to-article-5-1-a-of-regulation-eu-no-596-2014-in-conjunction-with-ar-evo-20251106monthly0.5https://www.biopharmawatch.com/news/EVO/interim-statement-9m-2025-highlights-change-in-revenue-mix-aligned-with-new-strategy-for-l-evo-20251105monthly0.5https://www.biopharmawatch.com/news/EVO/in-a-landmark-industry-transaction-evotec-signs-agreement-with-sandoz-resulting-in-payment-evo-20251105monthly0.5https://www.biopharmawatch.com/news/EVO/interim-statement-6m-2025-highlights-changing-revenue-mix-aligned-with-new-strategy-for-su-evo-20250730monthly0.5https://www.biopharmawatch.com/news/EVO/disclosure-of-an-inside-information-acc-to-article-17-mar-of-the-regulation-eu-no-596-2014-evo-20250730monthly0.5https://www.biopharmawatch.com/news/EVO/disclosure-of-an-inside-information-acc-to-article-17-mar-of-the-regulation-eu-no-596-2014-evo-20250721monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-se-results-of-the-annual-general-meeting-2025-all-agenda-items-adopted-under-the-to-evo-20250603monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-evp-head-of-global-investor-relations--evo-20250506monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-se-unveils-new-strategy-and-provides-2025-guidance-bolstered-by-strong-q4-2024-resu-evo-20250417monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-announces-change-in-management-board-laetitia-rouxel-steps-down-as-chief-financial--evo-20250417monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-announces-change-in-management-board-dr-craig-johnstone-steps-down-as-chief-operati-evo-20241129monthly0.5https://www.biopharmawatch.com/news/EVO/disclosure-of-an-inside-information-acc-to-article-17-mar-of-the-regulation-eu-no-596-2014-evo-20241122monthly0.5https://www.biopharmawatch.com/news/EVO/disclosure-of-an-inside-information-acc-to-article-17-mar-of-the-regulation-eu-no-596-2014-evo-20241115monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-evp-head-of-global-investor-relations--evo-20241106monthly0.5https://www.biopharmawatch.com/news/EVO/interim-statement-6m-2024-for-further-information-please-contact-volker-braun-evp-head-of--evo-20240814monthly0.5https://www.biopharmawatch.com/news/EVO/disclosure-of-an-inside-information-acc-to-article-17-mar-of-the-regulation-eu-no-596-2014-evo-20240806monthly0.5https://www.biopharmawatch.com/news/EVO/results-of-the-annual-general-meeting-2024-most-agenda-items-adopted-with-great-majority-a-evo-20240610monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-evp-head-of-global-investor-relations--evo-20240522monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-se-appoints-dr-christian-wojczewski-as-chief-executive-officer-23-apr-2024-20-38-ce-evo-20240423monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-4-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b12-evo-20240408monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-announces-ceo-transition-hamburg-germany-evotec-se-frankfurt-stock-exchange-evt-mda-evo-20240103monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-svp-head-of-global-investor-relations--evo-20231108monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-svp-head-of-global-investor-relations--evo-20230829monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-provides-update-on-financial-impact-of-cyber-attack-hamburg-germany-evotec-se-frank-evo-20230727monthly0.5https://www.biopharmawatch.com/news/EVO/page-2-12-6-total-positions-of-voting-rights-attached-to-shares-total-of-7-a-of-voting-rig-evo-20230621monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-11-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b1-evo-20230512monthly0.5https://www.biopharmawatch.com/news/EVO/just-evotec-biologics-enters-strategic-biosimilars-partnership-with-sandoz-hamburg-germany-evo-20230509monthly0.5https://www.biopharmawatch.com/news/EVO/cyber-attack-on-evotec-07-apr-2023-15-10-cet-cest-the-issuer-is-solely-responsible-for-the-evo-20230407monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-5-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b12-evo-20230405monthly0.5https://www.biopharmawatch.com/news/EVO/march-2023-ad-hoc-release-according-to-article-17-mar-of-the-regulation-eu-no-596-2014-evo-evo-20230328monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-se-laetitia-rouxel-to-succeed-enno-spillner-as-chief-financial-officer-07-02-2023-0-evo-20230207monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-4-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b12-evo-20221116monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-svp-head-of-global-investor-relations--evo-20221109monthly0.5https://www.biopharmawatch.com/news/EVO/stimmrechtsmitteilung-seite-1-3-hamburg-22419-manfred-eigen-campus-essener-bogen-7-529900f-evo-20221006monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-svp-head-of-global-investor-relations--evo-20220811monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-4-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b12-evo-20220624monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-se-reports-results-of-annual-general-meeting-2022-all-agenda-items-adopted-with-the-evo-20220623monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-11-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b1-evo-20220609monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-11-hamburg-22419-essener-bogen-7-529900f9ki6oyito9b1-evo-20220607monthly0.5https://www.biopharmawatch.com/news/EVO/notification-of-major-holdings-page-1-3-hamburg-22419-manfred-eigen-campus-essener-bogen-7-evo-20220603monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-svp-global-head-of-investor-relations--evo-20220510monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-and-bristol-myers-squibb-extend-and-expand-strategic-partnership-hamburg-germany-ev-evo-20220510monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-se-fiscal-year-2021-results-setting-the-pace-on-the-data-driven-r-d-autobahn-to-cur-evo-20220412monthly0.5https://www.biopharmawatch.com/news/EVO/evotec-se-bayer-discontinues-clinical-development-candidate-eliapixant-bay1817080-evotec-r-evo-20220204monthly0.5https://www.biopharmawatch.com/news/EVO/for-further-information-please-contact-volker-braun-svp-global-head-of-investor-relations--evo-20211112monthly0.5https://www.biopharmawatch.com/news/EVO/table-of-contents-evo-20101116monthly0.5https://www.biopharmawatch.com/news/EVO/table-of-contents-evo-20100514monthly0.5https://www.biopharmawatch.com/news/EVO/table-of-contents-evo-20091112monthly0.5https://www.biopharmawatch.com/news/EVO/table-of-contents-evo-20090812monthly0.5https://www.biopharmawatch.com/news/EVO/table-of-contents-evo-20090506monthly0.5https://www.biopharmawatch.com/news/EVO/table-of-contents-evo-20090331monthly0.5https://www.biopharmawatch.com/news/EVO/table-of-contents-evo-20090309monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-full-data-from-cohort-3-of-placebo-controlled-phase-1-cli-crvs-20250604monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2025-financial-r-crvs-20250508monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-data-from-cohort-2-of-placebo-controlled-phase-1-clinical-crvs-20250113monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-interim-data-from-placebo-controlled-phase-1-clinical-tri-crvs-20241218monthly0.5https://www.biopharmawatch.com/news/CRVS/immunobiology-and-clinical-activity-of-cpi-006-an-anti-cd73-antibody-with-immunomodulating-crvs-20191108monthly0.5https://www.biopharmawatch.com/news/CRVS/immunobiology-preliminary-safety-and-efficacy-of-cpi-006-an-anti-cd73-antibody-with-immune-crvs-20190603monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-interim-results-demonstrating-anti-tumor-activity-of-cpi--crvs-20170605monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-preliminary-phase-1-1b-clinical-data-with-lead-checkpoint-crvs-20161111monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-third-quarter-financial-results-and-provides-business-upd-crvs-20161103monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-biomarker-findings-from-phase-1-1b-study-of-lead-oral-che-crvs-20161010monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-preclinical-and-preliminary-clinical-biomarker-data-of-le-crvs-20160925monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-second-quarter-financial-results-and-provides-business-up-crvs-20160804monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-first-quarter-2016-financial-results-burlingame-calif-crvs-20160505monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-results-of-preclinical-studies-demonstrating-enhanced-imm-crvs-20160419monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-french-soci-t-anonyme-with-a-board-of-d-iva-20260612monthly0.5https://www.biopharmawatch.com/news/IVA/copyright-xa9-2026-betanxt-inc-or-its-affiliates-all-rights-reserved-styleipc-instructions-iva-20260603monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20260522monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20251107monthly0.5https://www.biopharmawatch.com/news/IVA/copyright-xa9-2025-betanxt-inc-or-its-affiliates-all-rights-reserved-styleipc-instructions-iva-20251030monthly0.5https://www.biopharmawatch.com/news/IVA/free-translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-dir-iva-20251020monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-s-a-a-joint-stock-company-soci-t-anonyme-with-a-share-capital-of-1-391-512-74-eu-iva-20250929monthly0.5https://www.biopharmawatch.com/news/IVA/subscription-agreement-for-absas-pfw-bsas-inventiva-s-a-50-rue-de-dijon-21121-daix-france--iva-20250505monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20250502monthly0.5https://www.biopharmawatch.com/news/IVA/copyright-xa9-2025-betanxt-inc-or-its-affiliates-all-rights-reserved-styleipc-instructions-iva-20250424monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20250411monthly0.5https://www.biopharmawatch.com/news/IVA/subscription-agreement-for-t1-bis-shares-pre-funded-warrants-inventiva-s-a-50-rue-de-dijon-iva-20241216monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-french-soci-t-anonyme-with-a-board-of-d-iva-20241126monthly0.5https://www.biopharmawatch.com/news/IVA/copyright-xa9-2024-betanxt-inc-or-its-affiliates-all-rights-reserved-styleipc-instructions-iva-20241114monthly0.5https://www.biopharmawatch.com/news/IVA/free-translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-dir-iva-20241104monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-s-a-a-joint-stock-company-soci-t-anonyme-with-a-share-capital-of-524-771-88-euro-iva-20241015monthly0.5https://www.biopharmawatch.com/news/IVA/subscription-agreement-for-t1-shares-pre-funded-warrants-inventiva-s-a-50-rue-de-dijon-211-iva-20241015monthly0.5https://www.biopharmawatch.com/news/IVA/royalty-certificate-subscription-agreement-inventiva-50-rue-de-dijon-21121-daix-france-the-iva-20240716monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-french-soci-t-anonyme-with-a-board-of-d-iva-20240605monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20240513monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-s-a-a-joint-stock-company-soci-xe9-t-xe9-anonyme-with-a-share-capital-of-517-528-iva-20231003monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-s-a-a-joint-stock-company-soci-xe9-t-xe9-anonyme-with-a-share-capital-of-517-528-iva-20230928monthly0.5https://www.biopharmawatch.com/news/IVA/subscription-agreement-inventiva-50-rue-de-dijon-21121-daix-france-the-undersigned-the-sub-iva-20230831monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-french-soci-t-anonyme-with-a-board-of-d-iva-20230505monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-sa-vif-proof-3-ordinary-and-extraordinary-general-meeting-of-inventiva-s-a-date-iva-20230425monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20230417monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20230106monthly0.5https://www.biopharmawatch.com/news/IVA/please-separate-carefully-at-the-perforation-and-return-just-this-portion-in-the-envelope--iva-20230103monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20221219monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-provides-an-update-on-the-development-of-cedirogant-by-abbvie-daix-france-long-i-iva-20221031monthly0.5https://www.biopharmawatch.com/news/IVA/certain-confidential-information-contained-in-this-exhibit-indicated-by-has-been-omitted-p-iva-20220921monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-and-sino-biopharm-announce-licensing-and-collaboration-agreement-to-develop-and--iva-20220922monthly0.5https://www.biopharmawatch.com/news/IVA/update-on-inventiva-s-cash-position-and-on-the-finance-documentation-with-the-european-inv-iva-20220705monthly0.5https://www.biopharmawatch.com/news/IVA/results-of-the-votes-of-the-combined-shareholders-meeting-of-iva-20220519monthly0.5https://www.biopharmawatch.com/news/IVA/description-of-the-share-repurchase-program-authorised-by-the-ordinary-general-meeting-of--iva-20220519monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-secures-a-50-million-credit-facility-from-the-european-investment-bank-this-cred-iva-20220516monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20220502monthly0.5https://www.biopharmawatch.com/news/IVA/combined-general-meeting-of-iva-20220428monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-sa-vif-proof-3-ordinary-and-extraordinary-general-meeting-of-inventiva-s-a-date-iva-20220425monthly0.5https://www.biopharmawatch.com/news/IVA/translation-for-information-purpose-only-inventiva-soci-t-anonyme-with-a-board-of-director-iva-20220411monthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-s-a-index-to-unaudited-interim-condensed-consolidated-financial-statements-page--iva-20210802monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-nasdaq-clov-first-quarter-2026-supplemental-q-a-clov-20260518monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-reports-first-quarter-2026-results-business-highlights-delivered-positive-ga-clov-20260506monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-announces-departure-of-chief-financial-officer-and-appointment-of-interim-ch-clov-20260401monthly0.5https://www.biopharmawatch.com/news/CLOV/axex991x4q25supplemental-clover-health-nasdaq-clov-fourth-quarter-2025-supplemental-q-a-clov-20260306monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-reports-fourth-quarter-full-year-2025-results-provides-full-year-2026-guidan-clov-20260226monthly0.5https://www.biopharmawatch.com/news/CLOV/pressreleasedatedj-clover-health-announces-53-growth-in-medicare-advantage-membership-duri-clov-20260101monthly0.5https://www.biopharmawatch.com/news/CLOV/axex991xcphperformanceup-clov-20251210monthly0.5https://www.biopharmawatch.com/news/CLOV/axex991x3q25supplemental-clover-health-nasdaq-clov-third-quarter-2025-supplemental-q-a-clov-20251112monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-reports-third-quarter-2025-results-business-highlights-generates-third-quart-clov-20251104monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-announces-chelsea-clinton-to-step-down-from-board-following-eight-y-clov-20251031monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-comments-on-2026-medicare-advantage-star-ratings-and-trajectory-for-clov-20251009monthly0.5https://www.biopharmawatch.com/news/CLOV/a8-kxex991x8112025-clov-20250811monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-reports-second-quarter-2025-results-delivering-strong-sustainable-g-clov-20250805monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-nasdaq-clov-first-quarter-2025-shareholder-q-a-clov-20250514monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-reports-first-quarter-2025-results-and-improves-full-year-2025-guid-clov-20250506monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-announces-changes-to-board-of-directors-thomas-l-tran-will-become-c-clov-20250422monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-reports-fourth-quarter-and-full-year-2024-results-provides-full-yea-clov-20250227monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-reports-27-growth-in-medicare-advantage-membership-surpassing-100-0-clov-20250101monthly0.5https://www.biopharmawatch.com/news/CLOV/document-thomas-l-tran-former-chief-financial-officer-of-molina-healthcare-joins-clover-he-clov-20240822monthly0.5https://www.biopharmawatch.com/news/CLOV/judgmentapprovings-united-states-district-court-middle-district-of-tennessee-yuechuan-sun--clov-20240711monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-regains-compliance-with-nasdaq-minimum-bid-price-requirement-clov-20240626monthly0.5https://www.biopharmawatch.com/news/CLOV/document-cms-improves-star-ratings-to-3-5-stars-for-clover-health-ppo-medicare-advantage-p-clov-20240614monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-announces-counterpart-health-a-new-saas-and-tech-enabled-services-s-clov-20240529monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-appoints-healthcare-technology-veteran-peter-kuipers-as-chief-finan-clov-20240422monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-provides-notice-associated-with-previously-disclosed-settlement-of--clov-20240404monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-announces-agreement-to-settle-derivative-litigation-resolving-all-r-clov-20230622monthly0.5https://www.biopharmawatch.com/news/CLOV/document-clover-health-announces-business-transformation-initiatives-to-accelerate-path-to-clov-20230417monthly0.5https://www.biopharmawatch.com/news/CLOV/document-dr-anna-loengard-joins-clover-health-board-of-directors-clov-20221130monthly0.5https://www.biopharmawatch.com/news/CLOV/dr-carladenise-armbrister-edwards-joins-clover-health-board-of-directors-clov-20220726monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-investments-corp-announces-redemption-of-all-outstanding-warrants-clov-20210722monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-today-announces-that-joe-wagner-chief-financial-officer-will-leave-the-compa-clov-20210715monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-reports-first-quarter-2021-financial-results-record-revenue-of-over-200-mill-clov-20210517monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-investments-corp-and-subsidiaries-consolidated-balance-sheets-selected-metri-clov-20210301monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-reports-full-year-2020-financial-results-grew-total-revenue-46-year-over-yea-clov-20210301monthly0.5https://www.biopharmawatch.com/news/CLOV/in-response-to-short-seller-firm-s-questions-andrew-still-baxter-18-min-read-from-vivek-ga-clov-20210205monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-believes-in-accessible-and-affordable-healthcare-for-everyone-a-cap-on-costs-0-low--clov-20210127monthly0.5https://www.biopharmawatch.com/news/CLOV/selected-unaudited-pro-forma-condensed-combined-financial-information-the-following-select-clov-20210112monthly0.5https://www.biopharmawatch.com/news/CLOV/social-capital-hedosophia-holdings-corp-iii-to-trade-on-nasdaq-in-connection-with-its-prop-clov-20201214monthly0.5https://www.biopharmawatch.com/news/CLOV/source-cms-kaiser-family-foundation-l-e-k-6-source-cms-kaiser-family-foundation-l-e-k-77-d-clov-20201119monthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-a-next-generation-medicare-advantage-insurer-announces-plans-to-become-publi-clov-20201006monthly0.5https://www.biopharmawatch.com/news/CLOV/social-capital-hedosophia-holdings-corp-iii-index-to-financial-statement-page-report-of-in-clov-20200424monthly0.5https://www.biopharmawatch.com/news/CLOV/social-capital-hedosophia-holdings-corp-iii-announces-pricing-of-upsized-720-million-initi-clov-20200421monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-table-d--tndm-20260507monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-announces-proposed-private-placement-of-convertible-notes-tndm-20260223monthly0.5https://www.biopharmawatch.com/news/TNDM/4-in-the-first-quarter-of-2025-the-company-included-an-adjustment-for-ipr-d-expense-in-its-tndm-20260219monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-announces-appointment-of-sandra-beaver-to-board-of-directors-tndm-20251112monthly0.5https://www.biopharmawatch.com/news/TNDM/4-in-the-first-quarter-of-2025-the-company-included-an-adjustment-for-ipr-d-expense-in-its-tndm-20251106monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-table-d--tndm-20250806monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20250430monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20250226monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20241106monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20240801monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20240502monthly0.5https://www.biopharmawatch.com/news/TNDM/about-tandem-diabetes-care-inc-tandem-diabetes-care-a-global-insulin-delivery-and-diabetes-tndm-20240311monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20240221monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20231101monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20230803monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20230503monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20230222monthly0.5https://www.biopharmawatch.com/news/TNDM/forward-looking-statements-this-press-release-contains-forward-looking-statements-within-t-tndm-20221231monthly0.5https://www.biopharmawatch.com/news/TNDM/forward-looking-statements-this-press-release-contains-forward-looking-statements-within-t-tndm-20221213monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20221102monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20220803monthly0.5https://www.biopharmawatch.com/news/TNDM/about-tandem-diabetes-care-inc-tandem-diabetes-care-inc-a-global-insulin-delivery-and-diab-tndm-20220616monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-reconciliation-of-gaap-versus-non-gaap-financial-results-unaudite-tndm-20220504monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-table-e-reconciliation-of-gaap-versus-non-gaap-financial-results--tndm-20220222monthly0.5https://www.biopharmawatch.com/news/TNDM/in-addition-to-the-t-connect-mobile-app-being-the-first-to-receive-fda-clearance-on-both-i-tndm-20220216monthly0.5https://www.biopharmawatch.com/news/TNDM/reconciliation-of-gaap-versus-non-gaap-financial-results-in-thousands-three-months-ended-s-tndm-20211103monthly0.5https://www.biopharmawatch.com/news/TNDM/reconciliation-of-gaap-versus-non-gaap-financial-results-in-thousands-three-months-ended-j-tndm-20210804monthly0.5https://www.biopharmawatch.com/news/TNDM/reconciliation-of-gaap-versus-non-gaap-financial-results-in-thousands-three-months-ended-tndm-20210505monthly0.5https://www.biopharmawatch.com/news/TNDM/reconciliation-of-gaap-versus-non-gaap-financial-results-in-thousands-three-months-ended-d-tndm-20210224monthly0.5https://www.biopharmawatch.com/news/TNDM/about-tandem-diabetes-care-inc-tandem-diabetes-care-inc-www-tandemdiabetes-com-is-a-medica-tndm-20201214monthly0.5https://www.biopharmawatch.com/news/TNDM/reconciliation-of-gaap-versus-non-gaap-financial-results-in-thousands-three-months-ended-s-tndm-20201105monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20200729monthly0.5https://www.biopharmawatch.com/news/TNDM/reconciliation-of-gaap-versus-non-gaap-financial-results-in-thousands-three-months-ended-j-tndm-20200730monthly0.5https://www.biopharmawatch.com/news/TNDM/the-t-connect-mobile-app-is-intended-to-be-a-secondary-display-for-compatible-tandem-diabe-tndm-20200625monthly0.5https://www.biopharmawatch.com/news/TNDM/about-tandem-diabetes-care-inc-tandem-diabetes-care-inc-www-tandemdiabetes-com-is-a-medica-tndm-20200618monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20200604monthly0.5https://www.biopharmawatch.com/news/TNDM/include-for-base-capped-call-2-include-for-additional-capped-call-3-include-for-base-cappe-tndm-20200515monthly0.5https://www.biopharmawatch.com/news/TNDM/reconciliation-of-gaap-versus-non-gaap-financial-results-in-thousands-three-months-ended-tndm-20200430monthly0.5https://www.biopharmawatch.com/news/TNDM/reconciliation-of-gaap-versus-non-gaap-financial-results-in-thousands-three-months-ended-d-tndm-20200224monthly0.5https://www.biopharmawatch.com/news/TNDM/1-as-measured-by-cgm-2-if-glucose-alerts-and-cgm-readings-do-not-match-symptoms-or-expecta-tndm-20191213monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-condensed-consolidated-statements-of-operations-in-thousands-exce-tndm-20191104monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-condensed-consolidated-statements-of-operations-in-thousands-exce-tndm-20190801monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-reports-positive-results-from-two-studies-of-the-t-slim-x2-insulin-pu-tndm-20190609monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20190430monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20190226monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20190103monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20181101monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-increases-2018-sales-guidance-and-provides-estimated-third-quarter-sa-tndm-20180925monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-announces-full-repayment-of-outstanding-crg-debt-san-diego-tndm-20180808monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180807monthly0.5https://www.biopharmawatch.com/news/TNDM/about-tandem-diabetes-care-inc-tandem-diabetes-care-inc-www-tandemdiabetes-com-is-a-medica-tndm-20180803monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180730monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-announces-fda-approval-of-t-slim-x2-insulin-pump-with-basal-iq-techno-tndm-20180621monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-receives-ce-mark-for-t-slim-x2-insulin-pump-san-diego-tndm-20180430monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180426monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180410monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180301monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180213monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180209monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180109monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20180103monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20171207monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20171026monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20171012monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20171009monthly0.5https://www.biopharmawatch.com/news/TNDM/ex-99-1-media-contact-steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-con-tndm-20170828monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20170727monthly0.5https://www.biopharmawatch.com/news/TNDM/for-the-three-months-ended-march-31-201-7-the-impact-of-the-upgrade-program-was-as-follows-tndm-20170427monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20170323monthly0.5https://www.biopharmawatch.com/news/TNDM/ex-99-1-media-contact-steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-con-tndm-20170308monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-to-draw-down-35-million-under-existing-term-loan-facility-with-tndm-20161129monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20161101monthly0.5https://www.biopharmawatch.com/news/TNDM/steve-sabicer-714-907-6264-ssabicer-thesabicergroup-com-investor-contact-susan-morrison-85-tndm-20161024monthly0.5https://www.biopharmawatch.com/news/DBVT/ch-tillon-france-dbvt-20260430monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2025-financial-results-and-business-update-continued-ad-dbvt-20260326monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-highlights-additional-data-from-successful-phase-3-vitesse-study-at-the-a-dbvt-20260302monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-166-7-million-in-gross-proceeds-following-the-full-exercise-of--dbvt-20260120monthly0.5https://www.biopharmawatch.com/news/DBVT/ch-tillon-france-dbvt-20251216monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-philina-lee-ph-d-to-board-of-directors-dbv-techn-dbvt-20251030monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-third-quarter-2025-financial-results-dbv-closes-q3-2025-with-a-ca-dbvt-20251028monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-resignation-of-board-member-dbv-technologies-euronext-dbv-isin--dbvt-20250918monthly0.5https://www.biopharmawatch.com/news/DBVT/ch-tillon-france-dbvt-20250905monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-second-quarter-and-half-year-2025-financial-results-dbv-technolog-dbvt-20250729monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-first-subject-screened-in-comfort-toddlers-supplemental-safety--dbvt-20250625monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-first-quarter-2025-financial-results-dbv-technologies-euronext-db-dbvt-20250430monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-financing-of-up-to-306-9-million-284-5-million-to-advance-viask-dbvt-20250331monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-secures-agreement-with-fda-on-safety-exposure-data-required-for-biologics-dbvt-20250323monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-positive-3-year-results-from-epitope-phase-3-open-label-extensi-dbvt-20250108monthly0.5https://www.biopharmawatch.com/news/DBVT/ch-tillon-france-december-11-th-2024-dbv-confirms-alignment-with-u-s-fda-on-accelerated-ap-dbvt-20241211monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-plan-to-implement-ads-ratio-change-dbv-technologies-euronext-db-dbvt-20241112monthly0.5https://www.biopharmawatch.com/news/DBVT/ch-tillon-france-dbvt-20241106monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-announces-positive-regulatory-updates-for-the-viaskin-peanut-patch-in-the-united-state-dbvt-20241022monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-completes-screening-for-the-vitesse-phase-3-clinical-trial-in-q3-2024-dbv-dbvt-20240923monthly0.5https://www.biopharmawatch.com/news/DBVT/ch-tillon-france-dbvt-20240730monthly0.5https://www.biopharmawatch.com/news/DBVT/ch-tillon-france-dbvt-20240531monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-plan-to-implement-ads-ratio-change-dbv-technologies-euronext-db-dbvt-20240517monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20240507monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2023-annual-report-on-form-10-k-and-universal-registr-dbvt-20240308monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20240307monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20231109monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-receives-requested-feedback-from-fda-on-protocol-design-elements-for-comf-dbvt-20231031monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20231016monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20230731monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-new-england-journal-of-medicine-publication-of-phase-3-epitope--dbvt-20230511monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-first-quarter-2023-financial-results-dbv-closes-q1-2023-with-cash-dbvt-20230504monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-outlines-regulatory-path-for-viaskin-peanut-in-children-1-3-years-after-r-dbvt-20230331monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-first-patient-screened-in-vitesse-phase-3-clinical-trial-in-pea-dbvt-20230307monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20230302monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-fda-has-lifted-partial-clinical-hold-on-vitesse-phase-3-pivotal-dbvt-20221223monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-third-quarter-financial-results-and-business-update-dbv-closes-q3-dbvt-20221103monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20221003monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-clinical-update-on-vitesse-phase-3-trial-dbv-technologies-eurone-dbvt-20220922monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-initiation-of-phase-3-study-vitesse-using-the-modified-viaskin--dbvt-20220907monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20220801monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20220609monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20220607monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-establishes-an-at-the-market-atm-program-on-nasdaq-dbv-technologies-euron-dbvt-20220502monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20220502monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20220309monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2021-financial-results-and-recent-business-updates-mvp--dbvt-20220303monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-update-on-investigational-viaskin-peanut-dbv-technologies-s-a-eu-dbvt-20211220monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20211026monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20210802monthly0.5https://www.biopharmawatch.com/news/DBVT/communiqu-de-presse-montrouge-france-le-3-mai-7-h-30-cest-2021-dbv-technologies-annonce-se-dbvt-20210503monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-timothy-e-morris-to-board-of-directors-dbv-techn-dbvt-20210330monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20210326monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2020-financial-results-and-recent-business-developments-dbvt-20210316monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-update-on-investigational-viaskin-peanut-for-children-ages-4-11--dbvt-20210114monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20210107monthly0.5https://www.biopharmawatch.com/news/DBVT/unaudited-interim-condensed-statement-of-consolidated-financial-position-amounts-in-thousa-dbvt-20201228monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20200909monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20200731monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-the-launch-of-a-proposed-global-offering-of-ordinary-shares-whi-dbvt-20200130monthly0.5https://www.biopharmawatch.com/news/DBVT/content-i-interim-condensed-consolidated-financial-statements-for-the-nine-months-ended-se-dbvt-20200129monthly0.5https://www.biopharmawatch.com/news/DBVT/unlocking-the-powerful-immune-properties-of-the-skin-to-offer-innovative-treatments-to-pat-dbvt-20200113monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-positive-three-year-long-term-data-from-the-people-phase-iii-open-dbvt-20200109monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20191008monthly0.5https://www.biopharmawatch.com/news/DBVT/content-i-first-half-2019-interim-condensed-consolidated-financial-statements-2-ii-managem-dbvt-20190927monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-the-launch-of-a-proposed-global-offering-of-ordinary-shares-whi-dbvt-20190403monthly0.5https://www.biopharmawatch.com/news/DBVT/index-to-financial-statements-page-annual-financial-statements-for-the-years-ended-dbvt-20190401monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-publication-of-detailed-phase-iii-trial-results-evaluating-vias-dbvt-20190222monthly0.5https://www.biopharmawatch.com/news/DBVT/safe-harbor-this-presentation-contains-forward-looking-statements-including-but-not-limite-dbvt-20190107monthly0.5https://www.biopharmawatch.com/news/DBVT/unaudited-interim-condensed-statement-of-consolidated-financial-position-thousands-of-euro-dbvt-20181213monthly0.5https://www.biopharmawatch.com/news/DBVT/safe-harbor-this-presentation-contains-forward-looking-statements-including-but-not-limite-dbvt-20181129monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-closing-of-global-offering-and-full-exercise-of-underwriters-op-dbvt-20180322monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20171128monthly0.5https://www.biopharmawatch.com/news/DBVT/montrouge-france-dbvt-20171120monthly0.5https://www.biopharmawatch.com/news/DBVT/unaudited-interim-condensed-statement-of-consolidated-financial-position-amounts-in-thousa-dbvt-20171117monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-limited-company-with-share-capital-of-2-466-883-80-registered-office-177--dbvt-20170531monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20170524monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20170502monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20170428monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20170405monthly0.5https://www.biopharmawatch.com/news/DBVT/unaudited-interim-condensed-statement-of-consolidated-financial-position-amounts-in-thousa-dbvt-20161220monthly0.5https://www.biopharmawatch.com/news/DBVT/interim-condensed-statement-of-consolidated-financial-position-amounts-in-euros-06-30-2015-dbvt-20160107monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20151112monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20151022monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150901monthly0.5https://www.biopharmawatch.com/news/DBVT/report-by-the-board-of-directors-notice-of-extraordinary-general-meeting-on-september-21-2-dbvt-20150820monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150720monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150715monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150630monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150623monthly0.5https://www.biopharmawatch.com/news/DBVT/key-scientific-data-demonstrating-that-epicutaneous-administration-may-reactivate-protecti-dbvt-20150610monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150608monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150602monthly0.5https://www.biopharmawatch.com/news/DBVT/bagneux-france-dbvt-20150520monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150505monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150429monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150415monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150409monthly0.5https://www.biopharmawatch.com/news/DBVT/bagneux-france-dbvt-20150325monthly0.5https://www.biopharmawatch.com/news/DBVT/securities-and-exchange-commission-dbvt-20150310monthly0.5https://www.biopharmawatch.com/news/DBVT/bagneux-france-dbvt-20150224monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-topline-financial-results-for-full-year-2014-bagneux-france-jan-dbvt-20150129monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-organizational-update-dbvt-20150108monthly0.5https://www.biopharmawatch.com/news/DBVT/additional-contribution-to-the-liquidity-agreement-with-natixis-dbvt-20141218monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-initiates-phase-i-ii-clinical-trial-with-viaskin-milk-for-the-treatment-o-dbvt-20141120monthly0.5https://www.biopharmawatch.com/news/CRON/document-cronos-to-enter-the-netherlands-with-acquisition-of-europe-s-largest-adult-use-ca-cron-20251209monthly0.5https://www.biopharmawatch.com/news/CRON/document-cronos-group-announces-streamlined-operating-structure-to-improve-cash-flow-plans-cron-20230531monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-reports-2023-first-quarter-results-industry-leading-balance-sheet-with-836-mi-cron-20230509monthly0.5https://www.biopharmawatch.com/news/CRON/financial-results-in-thousands-of-usd-three-months-ended-december-31-change-year-ended-dec-cron-20230228monthly0.5https://www.biopharmawatch.com/news/CRON/financial-results-in-thousands-of-usd-three-months-ended-september-30-change-nine-months-e-cron-20221107monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-announces-strategic-investment-in-pharmacann-a-leading-u-s-cannabis-company-i-cron-20210614monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-and-ginkgo-bioworks-amend-agreement-to-accelerate-commercialization-of-cultur-cron-20210604monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-announces-expanded-leadership-structure-to-drive-next-phase-of-growth-30-year-cron-20200909monthly0.5https://www.biopharmawatch.com/news/CRON/notice-to-reader-as-of-cron-20200330monthly0.5https://www.biopharmawatch.com/news/CRON/exhibit-notice-to-reader-cronos-group-inc-cronos-group-or-the-company-has-restated-its-una-cron-20200330monthly0.5https://www.biopharmawatch.com/news/CRON/exhibit-cronos-group-inc-amended-and-restated-condensed-interim-unaudited-consolidated-fin-cron-20200330monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-unaudited-condensed-interim-consolidated-financial-statements-for-the-thr-cron-20191112monthly0.5https://www.biopharmawatch.com/news/CRON/form-51-102f3-material-change-report-1-name-and-address-of-company-cronos-group-inc-720-ki-cron-20190905monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-unaudited-condensed-interim-consolidated-financial-statements-for-the-thr-cron-20190808monthly0.5https://www.biopharmawatch.com/news/CRON/execution-version-membership-interest-purchase-agreement-by-and-among-cronos-group-inc-red-cron-20190801monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-the-corporation-annual-meeting-of-shareholders-held-on-cron-20190619monthly0.5https://www.biopharmawatch.com/news/CRON/notice-of-meeting-and-management-information-circular-for-the-annual-meeting-of-shareholde-cron-20190528monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-unaudited-condensed-interim-consolidated-financial-statements-for-the-thr-cron-20190509monthly0.5https://www.biopharmawatch.com/news/CRON/execution-version-investor-rights-agreement-by-and-between-cronos-group-inc-and-altria-gro-cron-20190308monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-report-of-voting-results-special-meeting-of-shareholders-held-on-thursday-cron-20190221monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-closing-of-65-million-credit-facility-toronto-cron-20190123monthly0.5https://www.biopharmawatch.com/news/CRON/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-cron-20190118monthly0.5https://www.biopharmawatch.com/news/CRON/execution-version-subscription-agreement-by-and-among-cronos-group-inc-altria-summit-llc-a-cron-20181207monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-c-2-4-billion-strategic-investment-from-altria-group-inc-provid-cron-20181207monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-confirms-discussions-regarding-potential-investment-by-altria-group-toronto-cron-20181203monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-third-quarter-2018-results-increased-revenues-186-and-kilograms-cron-20181113monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-unaudited-condensed-interim-consolidated-financial-statements-for-the-thr-cron-20181113monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-to-hold-third-quarter-2018-earnings-conference-call-toronto-cron-20181019monthly0.5https://www.biopharmawatch.com/news/CRON/canada-makes-history-and-cronos-group-inc-looks-forward-with-enthusiasm-toronto-cron-20181017monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-partners-with-technion-research-development-foundation-for-cannabinoid-ba-cron-20181015monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-launches-new-recreational-brand-spinach-toronto-cron-20180913monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-and-ginkgo-bioworks-announce-a-landmark-partnership-to-produce-cultured-canna-cron-20180904monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-unveils-platform-in-cron-20180829monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-provincial-supply-agreements-toronto-cron-20180821monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-second-quarter-2018-results-increased-sales-428-year-over-year--cron-20180814monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-unaudited-condensed-interim-consolidated-financial-statements-for-the-thr-cron-20180814monthly0.5https://www.biopharmawatch.com/news/CRON/cura-goes-international-with-cronos-group-inc-toronto-cron-20180809monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-capacity-expansion-with-premier-greenhouse-expert-toronto-cron-20180718monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-to-hold-second-quarter-2018-earnings-conference-call-toronto-cron-20180717monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-the-corporation-report-of-voting-results-annual-and-special-meeting-of-sh-cron-20180628monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-results-of-vote-for-election-of-directors-toronto-cron-20180628monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-exclusive-distribution-agreement-with-delfarma-in-poland-toront-cron-20180625monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-australia-is-granted-manufacturing-license-toronto-cron-20180619monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-sets-date-for-2018-annual-and-special-meeting-of-shareholders-toronto-cron-20180608monthly0.5https://www.biopharmawatch.com/news/CRON/notice-of-meeting-and-management-information-circular-for-the-annual-and-special-meeting-o-cron-20180529monthly0.5https://www.biopharmawatch.com/news/CRON/change-of-auditor-reporting-package-notice-of-change-of-auditor-pursuant-to-national-instr-cron-20180518monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-to-up-list-and-begin-trading-on-toronto-stock-exchange-toronto-cron-20180522monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-appoints-lead-director-engages-investor-relations-agency-and-grants-optio-cron-20180518monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-first-quarter-2018-results-q1-2018-total-sales-of-2-9-million-u-cron-20180515monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-unaudited-condensed-interim-consolidated-financial-statements-for-the-thr-cron-20180515monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-to-hold-conference-call-on-first-quarter-2018-financial-results-toronto-cron-20180509monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-fourth-quarter-and-fiscal-year-2017-results-q4-2017-sales-of-1--cron-20180430monthly0.5https://www.biopharmawatch.com/news/CRON/by-law-no-5-repealing-and-replacing-by-law-no-3-and-by-law-no-4-a-by-law-relating-generall-cron-20180430monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-to-hold-conference-call-on-fourth-quarter-and-fiscal-year-2017-financial--cron-20180427monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-announces-closing-of-previously-announced-100-million-bought-deal-toronto-cron-20180406monthly0.5https://www.biopharmawatch.com/news/CRON/c-o-r-r-e-c-t-i-o-n-from-source-cronos-group-inc-in-the-news-release-cronos-group-inc-anno-cron-20180321monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-100-million-bought-deal-toronto-cron-20180321monthly0.5https://www.biopharmawatch.com/news/CRON/cannabis-giants-join-forces-in-cross-border-venture-toronto-cron-20180319monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-reports-first-quarter-2026-financial-results-and-provides-business-update-xf06c-q-mnkd-20260506monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-acquire-scpharmaceuticals-accelerating-revenue-growth-and-emerging-as-a-patien-mnkd-20250822monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-second-quarter-2025-financial-results-and-provides-business-u-mnkd-20250806monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-first-quarter-2025-financial-results-and-provides-business-up-mnkd-20250508monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-mnkd-20250226monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2024-third-quarter-financial-results-and-provides-business-up-mnkd-20241107monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2024-second-quarter-financial-results-provides-clinical-devel-mnkd-20240807monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2024-first-quarter-financial-results-provides-clinical-develo-mnkd-20240508monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2023-fourth-quarter-and-full-year-financial-results-provides--mnkd-20240227monthly0.5https://www.biopharmawatch.com/news/MNKD/purchase-and-sale-agreement-dated-as-of-mnkd-20231227monthly0.5https://www.biopharmawatch.com/news/MNKD/certain-confidential-information-contained-in-this-document-marked-by-has-been-omitted-bec-mnkd-20231227monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2023-third-quarter-financial-results-conference-call-to-begin-mnkd-20231107monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2023-second-quarter-financial-results-conference-call-to-begi-mnkd-20230807monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2023-first-quarter-financial-results-conference-call-to-begin-mnkd-20230510monthly0.5https://www.biopharmawatch.com/news/MNKD/lauren-sabella-joins-mannkind-as-executive-vice-president-mnkd-20230327monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2022-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20230223monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2022-third-quarter-financial-results-conference-call-to-begin-mnkd-20221108monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2022-second-quarter-financial-results-conference-call-to-begi-mnkd-20220809monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-s-technosphere-inhalation-platform-utilized-in-fda-approved-tyvaso-dpi-tyvaso-dpi-mnkd-20220524monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2022-first-quarter-financial-results-conference-call-to-begin-mnkd-20220505monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2021-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20220224monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2021-third-quarter-financial-results-conference-call-to-begin-mnkd-20211109monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2021-second-quarter-financial-results-conference-call-to-begi-mnkd-20210811monthly0.5https://www.biopharmawatch.com/news/MNKD/certain-confidential-information-contained-in-this-document-marked-by-has-been-omitted-bec-mnkd-20210525monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2021-first-quarter-financial-results-conference-call-to-begin-mnkd-20210512monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-amendment-no-7-to-credit-and-security-agreement-this-amendment-no-7-to-c-mnkd-20210426monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-amendment-no-6-to-credit-and-security-agreement-this-amendment-no-6-to-c-mnkd-20210305monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2020-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20210225monthly0.5https://www.biopharmawatch.com/news/MNKD/omnibus-joinder-and-amendment-no-5-to-credit-and-security-agreement-and-amendment-no-1-to--mnkd-20201230monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-expands-its-pipeline-with-the-acquisition-of-qrumpharma-inc-lead-investigational--mnkd-20201207monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-amendment-no-3-credit-and-security-agreement-this-amendment-no-3-to-cred-mnkd-20201201monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2020-third-quarter-financial-results-conference-call-to-begin-mnkd-20201104monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-amendment-no-2-credit-and-security-agreement-this-amendment-no-2-to-cred-mnkd-20200825monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2020-second-quarter-financial-results-conference-call-to-begi-mnkd-20200805monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2020-first-quarter-financial-results-conference-call-to-begin-mnkd-20200506monthly0.5https://www.biopharmawatch.com/news/MNKD/note-date-4-9-2020-note-amount-4-872-860-borrower-mannkind-corporation-lender-jpmorgan-cha-mnkd-20200415monthly0.5https://www.biopharmawatch.com/news/MNKD/jennifer-grancio-appointed-to-mannkind-board-of-directors-mnkd-20200324monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2019-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20200225monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-amendment-no-1-credit-and-security-agreement-this-amendment-no-1-to-cred-mnkd-20191218monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-appoints-tony-hooper-to-its-board-of-directors-mnkd-20191121monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2019-third-quarter-preliminary-financial-results-conference-c-mnkd-20191106monthly0.5https://www.biopharmawatch.com/news/MNKD/certain-confidential-information-contained-in-this-document-marked-by-has-been-omitted-bec-mnkd-20190806monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2019-second-quarter-financial-results-and-recent-business-hig-mnkd-20190807monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-exchange-agreement-this-exchange-agreement-this-agreement-dated-as-of-mnkd-20190718monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-eleventh-amendment-to-facility-agreement-this-eleventh-amendment-to-faci-mnkd-20190618monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2019-first-quarter-financial-results-conference-call-to-begin-mnkd-20190506monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-fourth-quarter-and-year-end-2018-earnings-call-conference-call-to-beg-mnkd-20190226monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-commencement-of-public-offering-westlake-village-ca-mnkd-20181219monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-appoints-christine-mundkur-to-its-board-of-directors-mnkd-20181127monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2018-third-quarter-financial-results-conference-call-to-begin-mnkd-20181101monthly0.5https://www.biopharmawatch.com/news/MNKD/united-therapeutics-and-mannkind-announce-closing-of-license-and-collaboration-agreement-r-mnkd-20181016monthly0.5https://www.biopharmawatch.com/news/MNKD/tenth-amendment-to-facility-agreement-this-tenth-amendment-to-facility-agreement-this-amen-mnkd-20180926monthly0.5https://www.biopharmawatch.com/news/MNKD/ninth-amendment-to-facility-agreement-this-ninth-amendment-to-facility-agreement-this-amen-mnkd-20180905monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2018-second-quarter-financial-results-conference-call-to-begi-mnkd-20180802monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-exchange-and-eighth-amendment-to-facility-agreement-this-exchange-and-ei-mnkd-20180712monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-exchange-and-seventh-amendment-to-facility-agreement-this-exchange-and-s-mnkd-20180608monthly0.5https://www.biopharmawatch.com/news/MNKD/exchange-agreement-the-undersigned-for-itself-and-on-behalf-of-the-beneficial-owner-listed-mnkd-20180525monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2018-first-quarter-financial-results-conference-call-to-begin-mnkd-20180509monthly0.5https://www.biopharmawatch.com/news/MNKD/form-of-securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-mnkd-20180405monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-the-security-represented-by-this-certificate-and-the-common-stock-issuab-mnkd-20180312monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2017-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20180227monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-fifth-amendment-to-facility-agreement-this-fifth-amendment-to-facility-a-mnkd-20180115monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2017-third-quarter-financial-results-conference-call-to-begin-mnkd-20171107monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-fourth-amendment-to-facility-agreement-this-fourth-amendment-to-facility-mnkd-20171023monthly0.5https://www.biopharmawatch.com/news/MNKD/form-of-securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-mnkd-20171010monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-61-million-registered-direct-offering-of-common-stock-mnkd-20171010monthly0.5https://www.biopharmawatch.com/news/MNKD/exchange-agreement-the-investor-enters-into-this-exchange-agreement-this-agreement-with-ma-mnkd-20170929monthly0.5https://www.biopharmawatch.com/news/MNKD/one-casper-street-danbury-ct-06810-main-203-798-8000-fax-203-798-7740-www-mannkindcorp-com-mnkd-20170712monthly0.5https://www.biopharmawatch.com/news/MNKD/agreement-this-agreement-this-agreement-is-entered-into-as-of-mnkd-20170627monthly0.5https://www.biopharmawatch.com/news/MNKD/exchange-agreement-this-exchange-agreement-this-agreement-dated-as-of-mnkd-20170418monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-change-of-control-agreement-this-change-of-control-agreement-this-agr-mnkd-20170406monthly0.5https://www.biopharmawatch.com/news/MNKD/rose-alinaya-svp-finance-661-775-5300-ralinaya-mannkindcorp-com-mannkind-corporation-repor-mnkd-20170316monthly0.5https://www.biopharmawatch.com/news/MNKD/agreement-of-purchase-and-sale-and-joint-escrow-instructions-this-agreement-of-purchase-an-mnkd-20170106monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2016-third-quarter-financial-results-conference-call-to-begin-mnkd-20161109monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2016-second-quarter-financial-results-conference-call-to-begi-mnkd-20160808monthly0.5https://www.biopharmawatch.com/news/MNKD/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-mnkd-20160509monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-common-stock-par-value-0-01-per-share-at-market-issuance-sales-agreem-mnkd-20160426monthly0.5https://www.biopharmawatch.com/news/MNKD/matthew-j-pfeffer-chief-executive-officer-661-775-5300-mpfeffer-mannkindcorp-com-mannkind--mnkd-20160314monthly0.5https://www.biopharmawatch.com/news/MNKD/january-05-2016-4-30pm-est-mnkd-mannkind-corp-announces-termination-of-license-and-collabo-mnkd-20160105monthly0.5https://www.biopharmawatch.com/news/MNKD/one-casper-street-danbury-ct-06810-main-203-798-8000-fax-203-798-7740-www-mannkindcorp-com-mnkd-20151221monthly0.5https://www.biopharmawatch.com/news/MNKD/stock-purchase-agreement-this-stock-purchase-agreement-this-agreement-is-entered-into-as-o-mnkd-20151112monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-common-stock-par-value-0-01-per-share-amendment-no-1-to-at-the-market-mnkd-20150904monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-stock-and-note-exchange-agreements-with-holders-of-outstanding-5-75-sen-mnkd-20150729monthly0.5https://www.biopharmawatch.com/news/MNKD/execution-version-senior-secured-revolving-promissory-note-for-value-received-and-subject--mnkd-20140929monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-fda-approval-of-afrezza-a-novel-rapid-acting-inhaled-insuli-mnkd-20140627monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2013-third-quarter-financial-results-conference-call-to-begin-mnkd-20131104monthly0.5https://www.biopharmawatch.com/news/MNKD/a-cknowledgement-and-a-greement-this-acknowledgment-and-agreement-this-agreement-is-made-a-mnkd-20131031monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-fda-acknowledgement-of-resubmission-of-new-drug-application-for-afrezza-mnkd-20131030monthly0.5https://www.biopharmawatch.com/news/MNKD/matthew-pfeffer-chief-financial-officer-661-775-5300-mpfeffer-mannkindcorp-com-media-inqui-mnkd-20131014monthly0.5https://www.biopharmawatch.com/news/MNKD/frequently-asked-questions-about-the-affinity-1-and-affinity-2-trials-i-mnkd-20130826monthly0.5https://www.biopharmawatch.com/news/MNKD/august-14-2013-8-00pm-mnkd-q2-2013-mannkind-earnings-clinical-trial-results-conference-cal-mnkd-20130814monthly0.5https://www.biopharmawatch.com/news/MNKD/matthew-pfeffer-chief-financial-officer-661-775-5300-mpfeffer-mannkindcorp-com-mannkind-re-mnkd-20130814monthly0.5https://www.biopharmawatch.com/news/MNKD/e-xecution-v-ersion-facility-agreement-this-agreement-dated-as-of-mnkd-20130701monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2013-first-quarter-financial-results-conference-call-to-begin-mnkd-20130509monthly0.5https://www.biopharmawatch.com/news/AVR/results-for-announcement-to-the-market-name-of-entity-anteris-technologies-global-corp-atg-avr-20260227monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-presents-data-from-100-duravr-thv-patients-at-pcr-london-valves-minne-avr-20251117monthly0.5https://www.biopharmawatch.com/news/AVR/results-for-announcement-to-the-market-name-of-entity-anteris-technologies-global-corp-atg-avr-20251113monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-announces-first-patients-treated-in-duravr-thv-global-pivotal-trial-t-avr-20251028monthly0.5https://www.biopharmawatch.com/news/AVR/october-2025-nasdaq-avr-asx-avr-disclaimer-this-presentation-has-been-prepared-by-anteris--avr-20251024monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-global-corp-announces-postponement-of-special-meeting-of-stockholders-avr-20250904monthly0.5https://www.biopharmawatch.com/news/AVR/results-for-announcement-to-the-market-name-of-entity-anteris-technologies-global-corp-atg-avr-20250812monthly0.5https://www.biopharmawatch.com/news/AVR/waiver-from-asx-listing-rule-7-1-minneapolis-united-states-and-brisbane-australia-7-august-avr-20250807monthly0.5https://www.biopharmawatch.com/news/AVR/asx-quarterly-results-announcement-name-of-entity-anteris-technologies-global-corp-atgc-ar-avr-20250514monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-reaches-clinical-milestone-100-patients-treated-with-duravr-thv-minne-avr-20250331monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-reports-one-year-patient-outcomes-for-duravr-thv-new-class-biomimetic-tavr-demonst-avr-20250321monthly0.5https://www.biopharmawatch.com/news/AVR/results-announcement-name-of-entity-anteris-technologies-global-corp-arbn-677-960-235-repo-avr-20250313monthly0.5https://www.biopharmawatch.com/news/AVR/asx-announcement-15-january-2025-partial-exercise-of-over-allotment-option-and-end-of-stab-avr-20250115monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-conference-call-transcript-usph-20260507monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-jason-curtis-interim-chief-financial-officer-email-jcurtis-usph-c-usph-20260506monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20260415monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-2026-objective-long-term-incentive-plan-for-senior-management-obj-usph-20260309monthly0.5https://www.biopharmawatch.com/news/USPH/disclaimer-2-forward-looking-statements-this-presentation-contains-forward-looking-stateme-usph-20260309monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-conference-call-transcript-usph-20260226monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20260225monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-strategic-alliance-with-nyu-langone-health-houston-tx-usph-20260202monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-the-acquisition-of-an-eight-clinic-physical-therapy-managem-usph-20260105monthly0.5https://www.biopharmawatch.com/news/USPH/disclaimer-2-forward-looking-statements-this-presentation-contains-forward-looking-stateme-usph-20251118monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-conference-call-transcript-usph-20251106monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20251105monthly0.5https://www.biopharmawatch.com/news/USPH/disclaimer-2-forward-looking-statements-this-presentation-contains-forward-looking-stateme-usph-20250812monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-conference-call-transcript-usph-20250807monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20250806monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-the-acquisition-of-a-three-clinic-physical-therapy-practice-usph-20250801monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-dual-listing-on-nyse-texas-houston-tx-usph-20250528monthly0.5https://www.biopharmawatch.com/news/USPH/disclaimer-2-forward-looking-statements-this-presentation-contains-forward-looking-stateme-usph-20250513monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-conference-call-transcript-usph-20250508monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20250507monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-the-acquisition-of-an-outpatient-home-care-physical-and-spe-usph-20250430monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-2025-objective-long-term-incentive-plan-for-senior-management-obj-usph-20250326monthly0.5https://www.biopharmawatch.com/news/USPH/disclaimer-2-forward-looking-statements-this-presentation-contains-forward-looking-stateme-usph-20250307monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-the-acquisition-of-a-three-clinic-physical-therapy-practice-usph-20250303monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20250226monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20241202monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20241112monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-conference-call-transcript-usph-20241106monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20241105monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20241031monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20241007monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240903monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240821monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-conference-call-transcript-usph-20240814monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240813monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240703monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240605monthly0.5https://www.biopharmawatch.com/news/USPH/first-amendment-to-third-amended-and-restated-employment-agreement-this-first-amendment-to-usph-20240531monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240530monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240509monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240507monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240501monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240401monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240311monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240308monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-2024-objective-long-term-incentive-plan-for-senior-management-obj-usph-20240306monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-fourth-quarter-and-year-ended-usph-20240301monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240228monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20240109monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20231109monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20231107monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20231101monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20231002monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230822monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230816monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230808monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230801monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230707monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230531monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230523monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230516monthly0.5https://www.biopharmawatch.com/news/USPH/investor-presentation-may-2023-disclaimer-2-forward-looking-statements-this-presentation-c-usph-20230511monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230504monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20230302monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230306monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230301monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230222monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20230111monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20221130monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20221115monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20221107monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20221102monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20221017monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20221003monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220908monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220901monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220823monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220804monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-p-hendrickson-chief-financial-officer-email-chendrickson-us-usph-20220621monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220616monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220603monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220505monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-physical-therapy-shareholder-these-past-two-years-have-been-nothing-if-not-exciti-usph-20220404monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220401monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20220314monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220224monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220110monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20220103monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20211201monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20211119monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20211112monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20211105monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20211001monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20210917monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20210902monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20210823monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20210805monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20210707monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-chris-reading-chief-exe-usph-20210701monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20210614monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-email-chendrickson-usph-usph-20210526monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-chris-reading-chief-exe-usph-20210506monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-usph-20210405monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-chris-reading-chief-exe-usph-20210401monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20210317monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-chris-reading-chief-exe-usph-20210310monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-chris-reading-chief-exe-usph-20210308monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-chris-reading-chief-exe-usph-20210225monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-carey-hendrickson-chief-financial-officer-chris-reading-chief-exe-usph-20201201monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20201105monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20201001monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20200922monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20200806monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20200804monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-physical-therapy-shareholder-2019-seems-like-a-lifetime-ago-already-so-much-has-h-usph-20200626monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-amended-and-restated-objective-long-term-incentive-plan-for--usph-20200529monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20200521monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20200303monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20200227monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20191114monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20191108monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20191001monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190923monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190826monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190808monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190701monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190606monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190529monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190520monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190502monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190411monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-physical-therapy-shareholder-over-these-past-16-years-i-have-noticed-that-my-shar-usph-20190405monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190325monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190314monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190311monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20190304monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20190307monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20181107monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20181102monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180904monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180823monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180802monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180531monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180521monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180516monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180504monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180501monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20180409monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-physical-therapy-shareholder-this-year-will-mark-15-years-that-our-executive-team-usph-20180405monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180313monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180308monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180302monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20180209monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20180109monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20171110monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20171102monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170925monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170920monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-2017-credit-suisse-under-followed-opportunities-con-usph-20170911monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170825monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-second-quarter-and-six-months-2017-results-company-declares-0-usph-20170803monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-nine-clinic-group-acquisition-houston-business-wire-usph-20170705monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-first-quarter-results-houston-business-wire-usph-20170629monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170607monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-2016-results-provides-2017-earnings-guidance-houston-business-usph-20170607monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-acquisition-houston-business-wire-usph-20170601monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170531monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170510monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-provides-update-on-form-10-k-filing-and-announces-increase-in-quarter-usph-20170331monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20170324monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170323monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170316monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20170103monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20161201monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20161110monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20161103monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160908monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160825monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160804monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160623monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160603monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160518monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160509monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160505monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160428monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-physical-therapy-shareholder-in-2015-our-team-of-dedicated-professionals-further--usph-20160407monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160303monthly0.5https://www.biopharmawatch.com/news/USPH/second-amendment-to-amended-and-restated-credit-agreement-this-second-amendment-to-amended-usph-20160111monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20160104monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20151204monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-southwest-ideas-investor-conference-houston-busines-usph-20151116monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-stephens-2015-fall-investment-conference-houston-bu-usph-20151106monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-third-quarter-and-first-nine-months-2015-results-company-decl-usph-20151105monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-rodman-renshaw-17th-annual-global-investment-confer-usph-20150904monthly0.5https://www.biopharmawatch.com/news/USPH/first-amendment-to-amended-and-restated-credit-agreement-this-first-amendment-to-amended-a-usph-20150831monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-second-quarter-and-first-six-months-2015-results-company-decl-usph-20150806monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-completes-another-acquisition-company-surpasses-500-clinic-mark-houst-usph-20150701monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-2015-east-coast-ideas-investor-conference-houston-b-usph-20150529monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-ubs-global-healthcare-conference-houston-business-w-usph-20150512monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-conf-usph-20150507monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-first-quarter-2015-results-company-declares-15-per-share-quar-usph-20150507monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-makes-acquisition-houston-business-wire-usph-20150501monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-physical-therapy-shareholder-in-2014-our-team-of-dedicated-partners-and-staff-alo-usph-20150409monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20150323monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-record-earnings-raises-dividend-and-provides-2015-earnings-gu-usph-20150305monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-makes-nine-clinic-group-acquisition-houston-business-wire-usph-20150202monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-sidoti-company-llc-emerging-growth-institutional-in-usph-20150107monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-oppenheimer-25-th-annual-healthcare-conference-hous-usph-20141205monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-stephens-fall-investment-conference-houston-busines-usph-20141111monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-third-quarter-results-houston-business-wire-usph-20141106monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-investment-and-m-a-healthcare-conference-houston-busine-usph-20141014monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-new-board-member-houston-business-wire-usph-20140827monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-record-results-and-raises-2014-earnings-guidance-houston-busi-usph-20140807monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-makes-acquisition-houston-business-wire-usph-20140804monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-jefferies-2014-global-healthcare-conference-houston-usph-20140529monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-ubs-global-healthcare-conference-houston-business-w-usph-20140520monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-bank-of-america-merrill-lynch-2014-healthcare-confe-usph-20140512monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-first-quarter-2014-results-company-declares-quarterly-dividen-usph-20140508monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-makes-13-clinic-acquisition-houston-business-wire-usph-20140501monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-physical-therapy-shareholder-the-past-year-has-been-filled-with-challenges-as-wel-usph-20140411monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-objective-long-term-incentive-plan-for-senior-management-for-usph-20140321monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-sidoti-eighteenth-annual-emerging-growth-institutio-usph-20140313monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-2013-results-company-increases-quarterly-dividend-by-20-and-i-usph-20140306monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20131216monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-completes-12-clinic-acquisition-houston-business-wire-usph-20131210monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-larry-mcafee-chief-financial-officer-chris-reading-chief-executiv-usph-20131206monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-oppenheimer-24-th-annual-healthcare-conference-hous-usph-20131206monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-stephens-fall-investment-conference-houston-busines-usph-20131111monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-third-quarter-and-nine-months-results-company-declares-quarte-usph-20131107monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-sells-remaining-piece-of-discontinued-physician-services-business-hou-usph-20131001monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-second-quarter-and-six-months-2013-results-company-declares-q-usph-20130808monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-jefferies-2013-global-healthcare-conference-houston-usph-20130530monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-announces-acquisition-of-five-clinic-therapy-practice-houston-busines-usph-20130528monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-38-th-annual-dbaccess-health-care-conference-housto-usph-20130523monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-2013-ubs-global-healthcare-conference-houston-busin-usph-20130516monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-reports-first-quarter-2013-results-announces-acquisition-quarterly-di-usph-20130509monthly0.5https://www.biopharmawatch.com/news/USPH/dear-u-s-physical-therapy-shareholder-your-company-had-another-solid-year-of-growth-in-ear-usph-20130408monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-inc-usph-long-term-incentive-plan-for-senior-management-for-2013-ltip-usph-20130327monthly0.5https://www.biopharmawatch.com/news/USPH/u-s-physical-therapy-to-present-at-the-sidoti-seventeenth-annual-emerging-growth-research--usph-20130314monthly0.5https://www.biopharmawatch.com/news/AORT/than-100-countries-worldwide-for-additional-information-about-artivion-visit-our-website-w-aort-20260518monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-executive-vice-president-phone-3-aort-20260507monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20260212monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-executive-vice-president-laine-m-aort-20251106monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20250807monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20250528monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20250514monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20250505monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20250224monthly0.5https://www.biopharmawatch.com/news/AORT/document-for-immediate-release-contacts-artivion-gilmartin-group-llc-lance-a-berry-brian-j-aort-20241209monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20241107monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20240808monthly0.5https://www.biopharmawatch.com/news/AORT/document-for-immediate-release-contacts-artivion-inc-lance-a-berry-executive-vice-presiden-aort-20240701monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20240506monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-lance-a-berry-brian-johnston-laine-morgan-executive-vice-pres-aort-20240215monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20231206monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20231102monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20230803monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20230504monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20230216monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20221103monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20220929monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20220923monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-gilmartin-group-llc-d-ashley-lee-brian-johnston-lynn-lewis-executive-vice-preside-aort-20220804monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-artivion-d--aort-20220505monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-xfeff-xfeff-artivion-d-ashley-lee-executive-vic-aort-20220217monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-for-immediate-release-contacts-xfeff-xfeff-631-807-1986-cryolife-d-ashley-lee--aort-20220120monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-cryolife-d--aort-20211104monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-n-e-w-s-r-e-l-e-a-s-e-xfeff-for-immediate-release-xfeff-contacts-xfeff-cryolife-d-as-aort-20210922monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-cryolife-d--aort-20210729monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-cryolife-d--aort-20210429monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-xfeff-xfeff-cryolife-d-ashley-lee-executive-vic-aort-20210211monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-cryolife-d--aort-20201104monthly0.5https://www.biopharmawatch.com/news/AORT/cryolife-d-ashley-lee-executive-vice-president-chief-financial-officer-and-chief-operating-aort-20200902monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-cryolife-d--aort-20200730monthly0.5https://www.biopharmawatch.com/news/AORT/cryolife-d-ashley-lee-executive-vice-president-chief-financial-officer-and-chief-operating-aort-20200619monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-cryolife-d--aort-20200430monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-contacts-xfeff-xfeff-cryolife-d-ashley-lee-executive-vice-president-chief-financial--aort-20200401monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-cryolife-d--aort-20200213monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-cryolife-inc-and-subsidiaries-financial-highlights-in-thousands-except-per-share-dat-aort-20191030monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-contacts-xfeff-phone-770-419-3355-cryolife-d-ashley-lee-executive-vice-president-chi-aort-20190911monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-phone-770-419-3355-lynn-lewis-xfeff-cryolife-d--aort-20190730monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-xfeff-contacts-xfeff-xfeff-cryolife-gilmartin-group-llc-d-ashl-aort-20190430monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-cryolife-gilmartin-group-llc--aort-20190214monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-cryolife-gilmartin-group-llc--aort-20181101monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-xfeff-cryolife-inc-gilmartin--aort-20181016monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-xfeff-cryolife-gilmartin-grou-aort-20180807monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-xfeff-for-immediate-release-contacts-xfeff-phone-770-419-3355-cryolife-the-rut-aort-20180620monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-cryolife-the-ruth-group-d-ashley-le-aort-20180503monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-cryolife-the-ruth-group-d-ash-aort-20180308monthly0.5https://www.biopharmawatch.com/news/AORT/cryolife-d-ashley-lee-executive-vice-president-chief-financial-officer-and-chief-operating-aort-20171201monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-xfeff-cryolife-the-ruth-group-aort-20171031monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-for-immediate-release-contacts-xfeff-cryolife-the-ruth-group-d-ashley-lee-zack-kubow-aort-20171011monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-for-immediate-release-contacts-xfeff-phone-770-419-3355-cryolife-the-ruth-grou-aort-20170929monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-cryolife-the-ruth-group-d-ash-aort-20170725monthly0.5https://www.biopharmawatch.com/news/AORT/xfeff-xfeff-for-immediate-release-xfeff-contacts-xfeff-cryolife-the-ruth-group-d-ashley-le-aort-20170427monthly0.5https://www.biopharmawatch.com/news/EYPT/tanner-kaufman-fticonsulting-com-jenni-lu-fticonsulting-com-media-helen-o-gorman-fti-consu-eypt-20260514monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-inc-and-subsidiaries-consolidated-statements-of-operations-unaudited-in-thousands-eypt-20260506monthly0.5https://www.biopharmawatch.com/news/EYPT/legal-disclaimers-various-statements-made-in-this-presentation-are-forward-looking-within--eypt-20260413monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-inc-and-subsidiaries-consolidated-statements-of-operations-in-tho-eypt-20260304monthly0.5https://www.biopharmawatch.com/news/EYPT/green-room-communications-direct-850-384-2833-eyepointmedia-grcomms-com-eypt-20260302monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-corporate-update-and-anticipated-pivotal-milestones-for-2026-x2013-phase--eypt-20260107monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-positive-recommendation-from-independent-data-safety-monitoring-committ-eypt-20251119monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-second-quarter-2025-financial-results-and-highlights-recent-corporate-dev-eypt-20250806monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-completes-enrollment-of-pivotal-phase-3-trials-for-duravyu-in-wet-age-related-mac-eypt-20250729monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-completes-enrollment-in-the-pivotal-phase-3-lugano-trial-of-duravyu-tm-for-the-tr-eypt-20250527monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-first-quarter-2025-financial-results-and-highlights-recent-corporate-deve-eypt-20250507monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlights-recent-eypt-20250305monthly0.5https://www.biopharmawatch.com/news/EYPT/the-leader-in-sustained-release-drug-delivery-for-retinal-disease-2025-eyepoint-pharmaceut-eypt-20250304monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-positive-six-month-results-for-the-phase-2-verona-clinical-trial-of-dur-eypt-20250205monthly0.5https://www.biopharmawatch.com/news/EYPT/legal-disclaimers-2025-eyepoint-pharmaceuticals-inc-all-rights-reserved-various-statements-eypt-20250113monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-appoints-renowned-retina-specialist-and-industry-pioneer-reginald-j-sanders-m-d-f-eypt-20250108monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-first-patient-dosed-in-second-global-phase-3-lucia-clinical-trial-of-du-eypt-20241204monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-third-quarter-2024-financial-results-and-highlights-recen-eypt-20241107monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-proposed-public-offering-of-common-stock-eypt-20241028monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-positive-interim-16-week-data-for-ongoing-phase-2-veron-eypt-20241028monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-global-phase-3-lugano-clinical-t-eypt-20241024monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-esteemed-industry-leader-fred-hassan-to-board-of-directo-eypt-20240904monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-second-quarter-2024-financial-results-and-highlights-rece-eypt-20240807monthly0.5https://www.biopharmawatch.com/news/EYPT/legal-disclaimers-2024-eyepoint-pharmaceuticals-inc-all-rights-reserved-various-statements-eypt-20240626monthly0.5https://www.biopharmawatch.com/news/EYPT/legal-disclaimers-2024-eyepoint-pharmaceuticals-inc-all-rights-reserved-various-statements-eypt-20240528monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-first-quarter-2024-financial-results-and-highlights-recen-eypt-20240508monthly0.5https://www.biopharmawatch.com/news/EYPT/fda-regulatory-approval-of-duravyu-and-eyp-2301-the-success-of-current-and-future-license--eypt-20240506monthly0.5https://www.biopharmawatch.com/news/EYPT/consider-any-forward-looking-statements-our-forward-looking-statements-speak-only-as-of-th-eypt-20240304monthly0.5https://www.biopharmawatch.com/news/EYPT/legal-disclaimers-2023-eyepoint-pharmaceuticals-inc-all-rights-reserved-various-statements-eypt-20231231monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-proposed-public-offering-of-common-stock-eypt-20231204monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eypt-20231204monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-statements-2023-eyepoint-pharmaceuticals-inc-all-rights-reserved-various-s-eypt-20231109monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-third-quarter-2023-financial-results-and-highlights-recen-eypt-20231101monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-strengthens-board-and-executive-leadership-team-stuart-duty-appoi-eypt-20231016monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-statements-various-statements-made-in-this-presentation-are-forward-lookin-eypt-20230913monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-positive-masked-safety-update-for-lead-product-candidate--eypt-20230901monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-second-quarter-2023-financial-results-and-highlights-rece-eypt-20230802monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-presents-interim-masked-safety-data-and-patient-baseline-characte-eypt-20230727monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-statements-various-statements-made-in-this-presentation-are-forward-lookin-eypt-20230630monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-chief-executive-officer-transition-x2013-jay-s-duker-m--eypt-20230710monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-completes-enrollment-in-phase-2-pavia-clinical-trial-of-eyp-1901--eypt-20230605monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-sale-of-yutiq-to-alimera-sciences-inc-for-82-5-million--eypt-20230518monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-first-quarter-2023-financial-results-and-highlights-recen-eypt-20230503monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-completes-enrollment-in-oversubscribed-phase-2-davio-2-clinical-t-eypt-20230327monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-h-eypt-20230302monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-enters-lease-agreement-for-the-construction-of-a-commercial-manuf-eypt-20230123monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-statements-various-statements-made-in-this-presentation-are-forward-lookin-eypt-20230101monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-provides-business-update-and-key-2023-clinical-timelines-x2013-to-eypt-20221231monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-statements-various-statements-made-in-this-presentation-are-forward-lookin-eypt-20221116monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-third-quarter-2022-financial-results-and-highlights-recen-eypt-20221102monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-clinical-trial-of--eypt-20220929monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-statements-various-statements-made-in-this-presentation-are-forward-lookin-eypt-20220928monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-second-quarter-2022-financial-results-and-highlights-rece-eypt-20220803monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-investor-day-to-highlight-eyp-1901-and-durasert-technology-develo-eypt-20220630monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-karen-zaderej-to-board-of-directors-eypt-20220711monthly0.5https://www.biopharmawatch.com/news/EYPT/various-statements-made-in-this-presentation-are-forward-looking-within-the-meaning-of-the-eypt-20220513monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-first-quarter-2022-financial-results-and-highlights-recen-eypt-20220504monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-h-eypt-20220212monthly0.5https://www.biopharmawatch.com/news/EYPT/employee-eyepoint-pharma-board-of-directors-sesen-bio-hubble-tx-consultant-aura-bio-financ-eypt-20220214monthly0.5https://www.biopharmawatch.com/news/EYPT/various-statements-made-in-this-presentation-are-forward-looking-within-the-meaning-of-the-eypt-20220101monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-michael-c-pine-as-chief-corporate-development-and-strate-eypt-20220110monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-2022-clinical-plans-and-highlights-recent-corporate-and-eypt-20211231monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-and-harrow-health-s-imprimisrx-announce-expanded-u-s-commercial-a-eypt-20211210monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-proposed-public-offering-of-common-stock-eypt-20211116monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-positive-interim-safety-and-efficacy-data-from-phase-1-da-eypt-20211113monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-third-quarter-2021-financial-results-and-highlights-recen-eypt-20211103monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-jay-s-duker-m-d-as-chief-operating-officer-eypt-20211101monthly0.5https://www.biopharmawatch.com/news/EYPT/various-statements-made-in-this-presentation-are-forward-looking-and-are-inherently-subjec-eypt-20210817monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-second-quarter-2021-financial-results-and-highlights-rece-eypt-20210804monthly0.5https://www.biopharmawatch.com/news/EYPT/various-statements-made-in-this-presentation-are-forward-looking-and-are-inherently-subjec-eypt-20210602monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-first-quarter-2021-financial-results-and-highlights-recen-eypt-20210505monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-h-eypt-20210304monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-1-clinical-trial-of-eyp-19-eypt-20210128monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-provides-business-update-and-preliminary-fourth-quarter-and-full--eypt-20201231monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-15-7-million-equity-investment-by-asia-partner-ocumensi-eypt-20210103monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-16-5-million-monetization-of-iluvien-royalty-with-swk-h-eypt-20201218monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-third-quarter-2020-financial-results-and-highlights-recen-eypt-20201031monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-amendment-to-crg-debt-facility-modifying-2020-and-2021--eypt-20201008monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-preliminary-net-product-revenue-for-third-quarter-2020--eypt-20201007monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-various-statements-made-in-this-presentation-are-forward-looking-and-are-i-eypt-20200831monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-receives-9-5-million-in-upfront-cash-from-ocumension-therapeutics-eypt-20200820monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-second-quarter-2020-financial-results-and-highlights-rece-eypt-20200805monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-expands-executive-leadership-team-with-the-appointment-of-jay-s-d-eypt-20200713monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-first-quarter-2020-financial-results-and-highlights-recen-eypt-20200506monthly0.5https://www.biopharmawatch.com/news/EYPT/silicon-valley-bank-u-s-small-business-administration-paycheck-protection-program-note-sba-eypt-20200428monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-provides-covid-19-pandemic-business-operations-update-proactive-e-eypt-20200401monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and-h-eypt-20200305monthly0.5https://www.biopharmawatch.com/news/EYPT/various-statements-made-in-this-presentation-are-forward-looking-and-are-inherently-subjec-eypt-20200220monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-signs-exclusive-license-agreement-with-equinox-science-to-develop-eypt-20200203monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2019-revenues--eypt-20200123monthly0.5https://www.biopharmawatch.com/news/EYPT/safe-harbor-statements-under-the-private-securities-litigation-act-of-1995-various-stateme-eypt-20191231monthly0.5https://www.biopharmawatch.com/news/EYPT/safe-harbor-statements-under-the-private-securities-litigation-act-of-1995-various-stateme-eypt-20191127monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-amendment-to-crg-debt-facility-watertown-ma-eypt-20191119monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-george-o-elston-as-chief-financial-officer-and-head-of-c-eypt-20191119monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-third-quarter-2019-financial-results-and-highlights-recen-eypt-20191107monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-safe-harbor-statements-under-the-private-securities-litigation-act-of-1995-eypt-20190822monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-second-quarter-2019-financial-results-and-highlights-rece-eypt-20190807monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-wendy-dicicco-cpa-to-board-of-directors-ms-dicicco-is-a--eypt-20190715monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-first-quarter-2019-financial-results-and-highlights-recen-eypt-20190508monthly0.5https://www.biopharmawatch.com/news/EYPT/forward-looking-safe-harbor-statements-under-the-private-securities-litigation-act-of-1995-eypt-20190401monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fiscal-period-ended-eypt-20190314monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-secures-up-to-60-million-debt-facility-provides-support-for-the-p-eypt-20190213monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-david-guyer-m-d-to-board-of-directors-dr-guyer-is-a-succ-eypt-20190128monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-provides-2019-commercial-update-dexycu-tm-commercial-launch-now-e-eypt-20190103monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fiscal-first-quarter-2019-financial-results-and-highlight-eypt-20181106monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-john-landis-ph-d-m-s-to-board-of-directors-seasoned-phar-eypt-20181030monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-fluocinolone-acetonide-intravitrea-eypt-20181015monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fiscal-2018-fourth-quarter-full-year-financial-results-an-eypt-20180928monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer-seasoned-financia-eypt-20180801monthly0.5https://www.biopharmawatch.com/news/EYPT/introduction-our-business-we-are-a-specialty-biopharmaceutical-company-committed-to-develo-eypt-20180611monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fiscal-third-quarter-2018-results-completed-substantive-s-eypt-20180508monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-announces-transformative-acquisition-of-icon-bioscience-inc-and-growth-capita-eypt-20180329monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-announces-fda-acceptance-for-filing-of-new-drug-application-nda-for-durasert-three-eypt-20180319monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-second-quarter-fy2018-results-continues-to-achieve-milestones-and-tim-eypt-20180207monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-builds-momentum-during-first-quarter-fy18-continues-operating-milestone-execu-eypt-20171107monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-achieves-significant-milestones-throughout-fy-2017-reports-fourth-quarter-and-eypt-20170911monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-out-licenses-emea-rights-for-durasert-three-year-treatment-for-posterior-segment-u-eypt-20170710monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-enhances-board-of-directors-with-election-of-veteran-healthcare-executive-kristine-eypt-20170628monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-submits-marketing-authorization-application-maa-for-approval-of-durasert-three-yea-eypt-20170622monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-s-durasert-three-year-treatment-for-posterior-segment-uveitis-successfully-achieve-eypt-20170613monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fiscal-2017-third-quarter-results-key-milestones-on-track-eu-and-us-c-eypt-20170504monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fiscal-2017-second-quarter-and-first-half-results-eu-and-u-s-2017-reg-eypt-20170207monthly0.5https://www.biopharmawatch.com/news/EYPT/seasoned-ophthalmology-executive-deb-jorn-joins-psivida-to-focus-on-corporate-and-commerci-eypt-20161107monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fiscal-2017-first-quarter-results-and-provides-update-on-corporate-ob-eypt-20161107monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-implements-leadership-change-nancy-lurker-named-as-president-and-ceo-watertown-ma-eypt-20160915monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-provides-company-update-and-reports-fourth-quarter-and-fy-2016-eypt-20160912monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-announces-plan-to-consolidate-all-research-and-development-in-current-u-s-fac-eypt-20160715monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-provides-company-update-and-reports-third-quarter-fy-2016-eypt-20160505monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-provides-company-update-and-reports-second-quarter-fy-2016-eypt-20160208monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-announces-proposed-public-offering-of-common-stock-watertown-mass-eypt-20160106monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-s-medidur-meets-primary-efficacy-endpoint-in-phase-3-trial-high-statistical-signif-eypt-20151222monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-provides-company-update-and-reports-first-quarter-fy-2016-eypt-20151105monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-provides-company-update-and-reports-fourth-quarter-and-fy-2015-eypt-20150909monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-third-quarter-fy-2015-results-clear-fda-regulatory-path-for-medidur-f-eypt-20150508monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-second-quarter-fy-2015-eypt-20150205monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-first-quarter-fy-2015-eypt-20141107monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fda-approval-of-iluvien-for-diabetic-macular-edema-psivida-earns-25-m-eypt-20140930monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fourth-quarter-and-fy-2014-eypt-20140909monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-third-quarter-2014-results-now-plans-to-seek-us-approval-of-medidur-f-eypt-20140513monthly0.5https://www.biopharmawatch.com/news/EYPT/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-eypt-20140313monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-second-quarter-2014-eypt-20140207monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fda-labeling-discussions-for-iluvien-for-dme-eypt-20131218monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-first-quarter-2014-eypt-20131112monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-reports-complete-response-letter-from-fda-for-iluvien-watertown-ma-eypt-20131018monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fourth-quarter-and-fiscal-year-2013-eypt-20130925monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-announces-proposed-public-offering-of-common-stock-watertown-massachusetts-eypt-20130718monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-third-quarter-fiscal-year-2013-eypt-20130513monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-reports-updates-on-iluvien-for-planned-resubmission-to-fda-and-european-launch-eypt-20130322monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-second-quarter-fiscal-year-2013-eypt-20130206monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-first-quarter-fiscal-year-2013-eypt-20121108monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fourth-quarter-and-fiscal-year-2012-eypt-20120924monthly0.5https://www.biopharmawatch.com/news/EYPT/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-eypt-20120801monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-alimera-s-intention-to-resubmit-application-to-fda-for-iluvien-in-dme-eypt-20120801monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-receives-fda-clearance-for-pivotal-trials-for-injectable-sustained-release-mi-eypt-20120719monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-s-eypt-20120718monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-third-quarter-ended-march-31-2012-watertown-ma-eypt-20120509monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-announces-positive-outcome-to-european-decentralized-procedure-for-approval-o-eypt-20120228monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-second-quarter-ended-december-31-2011-watertown-ma-eypt-20120208monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-first-quarter-ended-september-30-2011-watertown-ma-eypt-20111107monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fourth-quarter-and-fiscal-year-2011-eypt-20110912monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-announces-opening-of-investigator-sponsored-trial-for-injectable-sustained-release-eypt-20110912monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-third-quarter-ended-march-31-2011-watertown-ma-eypt-20110510monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-announces-new-safety-and-efficacy-data-from-phase-3-eypt-20110503monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-second-quarter-ended-december-31-2010-watertown-ma-eypt-20110209monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-announces-positive-results-from-the-36-month-readout-of-completed-phase-3-eypt-20110203monthly0.5https://www.biopharmawatch.com/news/EYPT/rodman-renshaw-letterhead-eypt-20110118monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-first-quarter-ended-september-30-2010-watertown-ma-eypt-20101105monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-fourth-quarter-and-fiscal-year-2010-financial-results-iluvien-nda-fil-eypt-20100922monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-third-quarter-fiscal-year-2010-financial-results-15-2m-received-from--eypt-20100512monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-second-quarter-ended-december-31-2009-watertown-ma-eypt-20100211monthly0.5https://www.biopharmawatch.com/news/EYPT/iluvien-clinical-development-program-and-certain-risk-factors-relating-to-the-iluvien-clin-eypt-20091223monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-first-quarter-ended-september-30-2009-watertown-ma-eypt-20091112monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-fourth-quarter-and-fiscal-year-ended-june-30-2009-wat-eypt-20090924monthly0.5https://www.biopharmawatch.com/news/EYPT/psivida-corp-reports-results-for-the-third-quarter-ended-march-31-2009-iluvien-nda-filing--eypt-20090513monthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-results-p-lmri-20260302monthly0.5https://www.biopharmawatch.com/news/LMRI/stockholders-agreement-by-and-among-lumexa-imaging-holdings-inc-and-the-entities-named-in--lmri-20251212monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-inc-amended-and-restated-2014-equity-incentive-plan-amended-and-restated-by--kura-20260604monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-highlights-recent-accomplishments-preliminary-komzifti-revenue-and-anticipat-kura-20260112monthly0.5https://www.biopharmawatch.com/news/KURA/k-ura-o-ncology-i-nc-2023-i-nducement-o-ption-p-lan-a-dopted-by-the-b-oard-of-d-irectors-d-kura-20251016monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2025-financial-results-x2013-fda-priority-review-of-n-kura-20250807monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20250618monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-inc-amended-and-restated-2014-equity-incentive-plan-amended-and-restated-by--kura-20250606monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20250525monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2025-financial-results-x2013-nda-submitted-in-1q-2025--kura-20250501monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2024-financial-results-x2013-komet-001--kura-20250226monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20250205monthly0.5https://www.biopharmawatch.com/news/KURA/k-ura-o-ncology-i-nc-2023-i-nducement-o-ption-p-lan-a-dopted-by-the-b-oard-of-d-irectors-d-kura-20241220monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2024-financial-results-x2013-topline-results-from-regi-kura-20241107monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2024-financial-results-x2013-topline-data-from-regist-kura-20240808monthly0.5https://www.biopharmawatch.com/news/KURA/qq-x201c-restricted-stock-award-agreement-x201d-means-a-written-agreement-between-the-comp-kura-20240607monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2024-financial-results-x2013-breakthrough-therapy-desi-kura-20240502monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2023-financial-results-x2013-positive-p-kura-20240227monthly0.5https://www.biopharmawatch.com/news/KURA/developing-precision-medicines-for-the-treatment-of-cancer-preliminary-data-from-komet-007-kura-20240130monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-oversubscribed-150-million-private-placement-funding-from-existing-kura-20240124monthly0.5https://www.biopharmawatch.com/news/KURA/k-ura-o-ncology-i-nc-2023-i-nducement-o-ption-p-lan-a-dopted-by-the-b-oard-of-d-irectors-d-kura-20231222monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2023-financial-results-x2013-completion-of-enrollment--kura-20231102monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2023-financial-results-x2013-enrollment-in-registrati-kura-20230803monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-commencement-of-public-offering-of-common-stock-and-pre-funded-war-kura-20230613monthly0.5https://www.biopharmawatch.com/news/KURA/this-presentation-contains-forward-looking-statements-such-statements-include-but-are-not--kura-20230612monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-inc-amended-and-restated-2014-equity-incentive-plan-amended-and-restated-by--kura-20230602monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2023-financial-results-x2013-evolving-data-from-phase--kura-20230510monthly0.5https://www.biopharmawatch.com/news/KURA/background-the-menin-and-histone-lysine-n-methyltransferase-2a-kmt2a-protein-complex-is-an-kura-20230419monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2022-financial-results-x2013-phase-1-da-kura-20230223monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20221231monthly0.5https://www.biopharmawatch.com/news/KURA/update-on-a-phase-1-2-first-in-human-study-of-the-menin-kmt2a-mll-inhibitor-ziftomenib-ko--kura-20221103monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2022-financial-results-x2013-abstract-reporting-update-kura-20221103monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-financing-transactions-with-bristol-myers-squibb-and-hercules-capi-kura-20221103monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2022-financial-results-x2013-recommended-phase-2-dose-kura-20220803monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2022-financial-results-x2013-enrollment-completed-in-p-kura-20220504monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2021-financial-results-x2013-patient-en-kura-20220224monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2021-financial-results-continued-enrollment-in-phase-1-kura-20211104monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2021-financial-results-first-patients-dosed-in-phase--kura-20210805monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-helen-collins-m-d-to-board-of-directors-kura-20210729monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-carol-schafer-to-board-of-directors-kura-20210604monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2021-financial-results-menin-inhibitor-ko-539-continue-kura-20210506monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2020-financial-results-preliminary-clin-kura-20210224monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-commencement-of-public-offering-of-common-stock-kura-20201207monthly0.5https://www.biopharmawatch.com/news/KURA/this-presentation-contains-forward-looking-statements-such-statements-include-but-are-not--kura-20201207monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2020-financial-results-preliminary-data-from-first-in--kura-20201105monthly0.5https://www.biopharmawatch.com/news/KURA/abstract-accepted-for-oral-presentation-at-the-62nd-american-society-of-hematology-annual--kura-20201104monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2020-financial-results-anticipate-preliminary-data-pr-kura-20200806monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-overall-survival-data-from-phase-2-trial-of-tipifarnib-in-hras-mutan-kura-20200529monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-commencement-of-public-offering-of-common-stock-kura-20200505monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2020-financial-results-enhanced-focus-on-tipifarnib-in-kura-20200504monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-receives-fast-track-designation-for-tipifarnib-in-t-cell-lymphomas-second-fa-kura-20200303monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2019-financial-results-registration-dir-kura-20200225monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20200113monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-receives-fast-track-designation-for-tipifarnib-in-hras-mutant-hnscc-and-prov-kura-20191216monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-clinical-and-regulatory-updates-for-tipifarnib-in-angioimmunoblastic-kura-20191208monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2019-financial-results-and-provides-corporate-update-u-kura-20191105monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-durable-anti-tumor-activity-in-phase-2-trial-of-tipifarnib-in-hras-m-kura-20191029monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-expands-board-of-directors-with-appointment-of-diane-parks-accomplished-exec-kura-20191015monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-positive-phase-2-trial-of-tipifarnib-in-hras-mutant-urothelial-car-kura-20190903monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-appointment-of-kathleen-ford-as-chief-operating-officer-appointmen-kura-20190812monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2019-financial-results-and-provides-corporate-update--kura-20190801monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-commencement-of-public-offering-of-common-stock-kura-20190618monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-positive-phase-2-trial-of-tipifarnib-in-peripheral-t-cell-lymphoma-kura-20190614monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2019-financial-results-and-highlights-upcoming-milesto-kura-20190507monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2018-financial-results-registration-dir-kura-20190305monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20190107monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-proof-of-concept-in-angioimmunoblastic-t-cell-lymphoma-validation--kura-20181202monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-adds-commercial-veteran-mary-szela-to-board-of-directors-ms-szela-brings-exp-kura-20181108monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2018-financial-results-and-provides-corporate-update-r-kura-20181105monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-presents-update-on-positive-phase-2-trial-of-tipifarnib-in-hras-mutant-hnscc-kura-20181022monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2018-financial-results-and-provides-corporate-update--kura-20180806monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-marc-grasso-m-d-as-chief-financial-officer-and-chief-business-offic-kura-20180731monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-commencement-of-public-offering-of-common-stock-kura-20180627monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-chief-operating-officer-expands-clinical-development-team-as-compan-kura-20180620monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2018-financial-results-and-provides-corporate-update-r-kura-20180508monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-provides-regulatory-update-on-tipifarnib-and-reports-fourth-quarter-and-full-kura-20180312monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2017-financial-results-and-provides-corporate-update-m-kura-20171107monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20170907monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-commencement-of-public-offering-of-common-stock-kura-20170809monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2017-financial-results-and-provides-update-on-tipifar-kura-20170807monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20170614monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2017-operational-and-financial-results-management-to-h-kura-20170515monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2016-operational-and-financial-results--kura-20170314monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20170306monthly0.5https://www.biopharmawatch.com/news/KURA/company-overview-we-are-a-clinical-stage-biopharmaceutical-company-committed-to-realizing--kura-20170127monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-steven-stein-m-d-to-board-of-directors-kura-20170103monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-third-quarter-2016-financial-results-management-to-host-webcast-and--kura-20161107monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-second-quarter-2016-financial-results-promising-clinical-activity-ob-kura-20160810monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20160616monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-quarter-2016-financial-results-kura-20160511monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-fourth-quarter-and-full-year-2015-operational-and-financial-results--kura-20160317monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20160210monthly0.5https://www.biopharmawatch.com/news/KURA/description-of-our-business-overview-we-are-a-clinical-stage-biopharmaceutical-company-dis-kura-20151020monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-thomas-malley-to-board-of-directors-kura-20151014monthly0.5https://www.biopharmawatch.com/news/KURA/forward-looking-statements-this-presentation-contains-forward-looking-statements-such-stat-kura-20150811monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-inc-financial-statements-contents-report-of-independent-registered-public-ac-kura-20150312monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-savara-inc-all-rights-reserved-savara-inc-savara-or-the-company-caut-svra-20260109monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-pricing-of-130-0-million-public-offering-of-common-stock-and-pre-funded-svra-20251029monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-75m-royalty-funding-agreement-with-rtw-to-support-the-potential-launch-of-svra-20251029monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-savara-inc-all-rights-reserved-savara-inc-savara-or-the-company-caut-svra-20250902monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-receives-refusal-to-file-rtf-letter-from-the-u-s-food-and-drug-administration-fda-f-svra-20250527monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-enters-into-non-dilutive-debt-financing-for-up-to-200m-with-hercules-capital-includ-svra-20250326monthly0.5https://www.biopharmawatch.com/news/SVRA/corporate-overview-developing-new-therapies-for-rare-respiratory-diseases-january-2025-sav-svra-20250113monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-pricing-of-100-0-svra-20240628monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-molgramostim-nebulizer-solution-molgramostim-achieved-statistical-signifi-svra-20240626monthly0.5https://www.biopharmawatch.com/news/SVRA/corporate-overview-developing-new-therapies-for-rare-respiratory-diseases-january-2024-saf-svra-20240105monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-pricing-of-80-million-underwritten-offering-of-common-stock-and-pre-funde-svra-20230713monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-all-rights-reserved-safe-harbor-statement-savara-inc-savara-or-the-company-caut-svra-20230608monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-all-rights-reserved-safe-harbor-statement-savara-inc-savara-or-the-company-caut-svra-20220110monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-savara-inc-savara-or-the-company-cautions-you-that-statements-in-thi-svra-20210316monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-savara-inc-savara-or-the-company-cautions-you-that-statements-in-thi-svra-20210119monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-provides-pipeline-and-business-update-announces-phase-3-avail-trial-missed-primary--svra-20201210monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-senior-management-changes-rob-neville-resigns-as-chairman-and-chief-execu-svra-20200911monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-second-quarter-2020-financial-results-and-provides-business-update-announce-svra-20200806monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-first-quarter-2020-financial-results-and-provides-business-update-company-a-svra-20200507monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-fourth-quarter-year-end-2019-financial-results-and-provides-business-update-svra-20200312monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-granted-breakthrough-therapy-designation-for-molgradex-for-the-treatment-of-autoimm-svra-20191230monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-private-placement-of-26-8-million-with-total-potential-proceeds-of-75-0-svra-20191220monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-third-quarter-2019-financial-results-and-provides-business-update-company-i-svra-20191107monthly0.5https://www.biopharmawatch.com/news/SVRA/disclosures-the-impala-trial-was-sponsored-by-savara-pharmaceuticals-i-receive-grant-fundi-svra-20191002monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-second-quarter-2019-financial-results-and-provides-business-update-molgrade-svra-20190808monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-results-of-impala-a-phase-3-study-of-molgradex-for-the-treatment-of-autoi-svra-20190612monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-first-quarter-2019-financial-results-and-provides-business-update-top-line--svra-20190509monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-business-u-svra-20190313monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-second-quarter-2018-financial-results-and-provides-positive-business-update-svra-20180809monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-provides-positive-update-on-development-and-commercial-preparations-of-molgradex-in-svra-20180725monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-first-quarter-2018-financial-results-and-provides-business-update-molgradex-svra-20180509monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-business-u-svra-20180314monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-savara-inc-savara-or-the-company-cautions-you-that-statements-in-thi-svra-20180212monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-third-quarter-2017-financial-results-and-provides-business-update-anticipat-svra-20171108monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-expansion-of-molgradex-development-to-include-treatment-of-nontuberculous-svra-20171024monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-second-quarter-2017-financial-results-and-provides-business-update-on-track-svra-20170809monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-closing-of-merger-with-mast-therapeutics-commences-trading-on-nasdaq-capi-svra-20170428monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statements-forward-looking-statements-savara-cautions-you-that-statements-in-t-svra-20170424monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-announces-possible-adjournment-of-special-stockholders-meeting-to-solici-svra-20170420monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-reminds-stockholders-to-vote-for-the-proposed-merger-with-savara-x2022-of-the-votes-r-svra-20170417monthly0.5https://www.biopharmawatch.com/news/SVRA/leading-independent-proxy-advisory-firms-iss-and-glass-lewis-recommend-mast-therapeutics-s-svra-20170411monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-and-savara-announce-approval-to-list-common-stock-on-the-nasdaq-capital--svra-20170410monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-sets-date-for-special-meeting-of-stockholders-to-vote-on-proposed-merger-svra-20170316monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-fourth-quarter-and-full-year-2016-svra-20170306monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statements-forward-looking-statements-savara-cautions-you-that-statements-in-t-svra-20170306monthly0.5https://www.biopharmawatch.com/news/SVRA/shareholder-update-q4-shareholder-brief-wednesday-svra-20170125monthly0.5https://www.biopharmawatch.com/news/SVRA/event-name-mast-savara-conference-call-event-date-svra-20170109monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-and-savara-sign-merger-agreement-proposed-merger-creates-specialty-pharm-svra-20170109monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-third-quarter-2016-financial-results-conference-call-scheduled-t-svra-20161108monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-this-presentation-includes-forward-looking-statements-about-our-busi-svra-20161019monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-this-presentation-includes-forward-looking-statements-about-our-busi-svra-20160912monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-this-presentation-includes-forward-looking-statements-about-our-busi-svra-20160907monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-this-presentation-includes-forward-looking-statements-about-our-busi-svra-20160809monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-second-quarter-2016-svra-20160809monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-first-quarter-2016-financial-results-and-recent-highlights-compl-svra-20160506monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-fourth-quarter-and-full-year-2015-svra-20160314monthly0.5https://www.biopharmawatch.com/news/SVRA/safe-harbor-statement-this-presentation-includes-forward-looking-statements-about-our-busi-svra-20160307monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-announces-amendment-to-loan-and-security-agreement-with-hercules-capital-svra-20160229monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-announces-positive-top-line-results-from-phase-2a-study-of-air001-in-pat-svra-20160201monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-air001-selected-by-the-heart-failure-clinical-research-network-for-evalu-svra-20160201monthly0.5https://www.biopharmawatch.com/news/SVRA/forward-looking-statements-this-presentation-includes-forward-looking-statements-about-our-svra-20160111monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-provides-business-update-enrollment-in-largest-ever-interventional-phase-svra-20160107monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-third-quarter-2015-financial-results-conference-call-scheduled-t-svra-20151112monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-announces-amendment-to-loan-and-security-agreement-with-hercules-technology-growth-ca-svra-20150930monthly0.5https://www.biopharmawatch.com/news/SVRA/forward-looking-statements-this-presentation-includes-forward-looking-statements-about-our-svra-20150915monthly0.5https://www.biopharmawatch.com/news/SVRA/forward-looking-statements-this-presentation-includes-forward-looking-statements-about-our-svra-20150903monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-second-quarter-2015-financial-results-conference-call-scheduled--svra-20150812monthly0.5https://www.biopharmawatch.com/news/SVRA/mstx-ex991-201507216-pptx-htm-nyse-mkt-mstx-corporate-overview-svra-20150721monthly0.5https://www.biopharmawatch.com/news/SVRA/mstx-ex991-2015062554-pptx-htm-nyse-mkt-mstx-corporate-overview-svra-20150625monthly0.5https://www.biopharmawatch.com/news/SVRA/forward-looking-statements-this-presentation-includes-forward-looking-statements-about-our-svra-20150519monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-first-quarter-2015-svra-20150511monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-fourth-quarter-and-full-year-2014-svra-20150324monthly0.5https://www.biopharmawatch.com/news/SVRA/nyse-mkt-mstx-corporate-overview-march-2-2015-forward-looking-statements-this-presentation-svra-20150302monthly0.5https://www.biopharmawatch.com/news/SVRA/nyse-mkt-mstx-2-forward-looking-statements-this-presentation-includes-forward-looking-stat-svra-20150209monthly0.5https://www.biopharmawatch.com/news/SVRA/nyse-mkt-mstx-2-forward-looking-statements-this-presentation-includes-forward-looking-stat-svra-20150203monthly0.5https://www.biopharmawatch.com/news/SVRA/nyse-mkt-mstx-2-forward-looking-statements-this-presentation-includes-forward-looking-stat-svra-20150112monthly0.5https://www.biopharmawatch.com/news/SVRA/bio-investor-forum-brandi-l-roberts-cfo-svra-20141007monthly0.5https://www.biopharmawatch.com/news/SVRA/nyse-mkt-mstx-rodman-renshaw-16th-annual-investment-conference-brian-m-culley-ceo-svra-20140909monthly0.5https://www.biopharmawatch.com/news/SVRA/nyse-mkt-mstx-canaccord-genuity-34th-annual-growth-conference-brian-m-culley-ceo-svra-20140814monthly0.5https://www.biopharmawatch.com/news/SVRA/nyse-mkt-mstx-corporate-overview-brian-m-culley-ceo-svra-20140605monthly0.5https://www.biopharmawatch.com/news/SVRA/a-brief-history-of-mst-188-definitions-rheothrx-a-first-generation-product-with-unpurified-svra-20140509monthly0.5https://www.biopharmawatch.com/news/SVRA/nyse-mkt-mstx-corporate-overview-brian-m-culley-ceo-svra-20140326monthly0.5https://www.biopharmawatch.com/news/SVRA/mast-therapeutics-reports-fourth-quarter-and-full-year-2013-svra-20140326monthly0.5https://www.biopharmawatch.com/news/SVRA/corporate-overview-svra-20140224monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-svra-20111111monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-completes-acquisition-of-synthrx-san-diego-svra-20110411monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-pharmaceuticals-announces-capital-raise-of-22-5-svra-20110107monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-svra-20100503monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-announces-6-month-stability-data-results-for-anx-530-san-diego-svra-20100503monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-to-resubmit-anx-530-nda-in-the-fourth-quarter-of-2010-san-diego-svra-20100427monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-svra-20100104monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-pharmaceuticals-submits-anx-530-new-drug-application-san-diego-svra-20100104monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-svra-20091006monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-svra-20090805monthly0.5https://www.biopharmawatch.com/news/SVRA/adventrx-svra-20090629monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-approximately-94-6-million-public-offering-and-concurrent-pri-lxrx-20260129monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-2023-financial-results-and-provides-busines-lxrx-20240311monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-125-million-public-offering-and-concurrent-private-placement--lxrx-20230601monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-proposed-public-offering-of-common-stock-the-woodlands-texas-lxrx-20220727monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-offering-of-common-stock-the-woodlands-texas-lxrx-20201211monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-receives-fast-track-designation-from-the-fda-for-lx9211-for-diabet-lxrx-20201211monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-2-nd-quarter-financial-results-provides-clinical-pipeline--lxrx-20150807monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2015-first-quarter-f-lxrx-20150429monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-common-stock-offering-the-woodlands-texas-lxrx-20141120monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2014-third-quarter-f-lxrx-20141104monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2014-second-quarter--lxrx-20140807monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2014-first-quarter-f-lxrx-20140508monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2013-first-quarter-f-lxrx-20130510monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2012-fourth-quarter--lxrx-20130221monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-on-clinical-program-status-and-2012-third-quarter-results--lxrx-20121106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-common-stock-offering-the-woodlands-texas-lxrx-20121018monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-on-clinical-program-status-and-2012-second-quarter-results-lxrx-20120731monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-on-clinical-program-status-and-2012-first-quarter-results--lxrx-20120503monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2011-fourth-quarter--lxrx-20120222monthly0.5https://www.biopharmawatch.com/news/LXRX/instructions-for-use-of-lexicon-pharmaceuticals-inc-subscription-rights-certificate-and-el-lxrx-20111122monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-on-clinical-program-status-and-2011-third-quarter-results--lxrx-20111101monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-on-clinical-program-status-and-2011-second-quarter-results-lxrx-20110809monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-on-clincial-program-status-and-2011-first-quarter-results--lxrx-20110503monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2010-third-quarter-f-lxrx-20101105monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2010-second-quarter--lxrx-20100809monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2010-first-quarter-r-lxrx-20100510monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-common-stock-in-public-offering-the-woodlands-texas-lxrx-20100316monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-adss-admitted-to-trade-on-nasdaq-under-the-symbol-phar-u-s-sec-de-phar-20201223monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-announces-proposed-offering-of-275-million-convertible-senior-notes-neo-20260615monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-appoints-dr-marjorie-green-to-board-of-directors-neo-20250624monthly0.5https://www.biopharmawatch.com/news/NEO/key-2021-financial-highlights-and-accomplishm-nts-increased-consolidated-venue-by-9-y-r-ov-neo-20220414monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-announces-ceo-departure-and-initiates-ceo-search-board-appoints-executive-chai-neo-20220328monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-completes-inivata-acquisition-combining-best-in-class-liquid-biopsy-technology-neo-20210618monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-to-acquire-inivata-combining-best-in-class-liquid-biopsy-technology-with-leadi-neo-20210505monthly0.5https://www.biopharmawatch.com/news/NEO/key-2020-financial-highlights-and-accomplishments-our-common-purpose-we-save-lives-by-impr-neo-20210415monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-agrees-to-acquire-trapelo-health-clinical-decision-support-to-enable-precision-neo-20210324monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-announces-pricing-of-public-offerings-of-common-stock-and-convertible-senior-n-neo-20210106monthly0.5https://www.biopharmawatch.com/news/NEO/only-by-means-of-the-prospectus-for-the-notes-offering-and-the-prospectus-supplement-and-t-neo-20200429monthly0.5https://www.biopharmawatch.com/news/NEO/genoptix-business-and-otherwise-implement-its-business-plan-as-well-as-additional-factors--neo-20190628monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-announces-pricing-on-public-offering-of-common-stock-neo-20190521monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomicsinvestor-investor-presentation-april-2019-forward-looking-statements-this-prese-neo-20190502monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-appoints-dr-lawrence-m-weiss-as-chief-scientific-officer-ft-myers-florida-neo-20181210monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-announces-pricing-on-secondary-offering-of-common-stock-by-selling-stockholder-neo-20181212monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-announces-secondary-offering-of-common-stock-by-selling-stockholder-ft-myers-f-neo-20181211monthly0.5https://www.biopharmawatch.com/news/NEO/historical-consolidated-financial-information-independent-auditors-report-to-the-board-of--neo-20181210monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-announces-pricing-on-public-offering-of-common-stock-neo-20180810monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-announces-proposed-public-offering-of-common-stock-ft-myers-florida-neo-20180806monthly0.5https://www.biopharmawatch.com/news/NEO/ppd-and-neogenomics-forming-global-strategic-alliance-for-pathology-and-molecular-testing--neo-20180601monthly0.5https://www.biopharmawatch.com/news/NEO/supplemental-information-impact-of-asu-606-adoption-in-thousands-for-the-year-ended-neo-20180525monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-revenue-of-67-8-mi-neo-20180221monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-revenue-of-63-1-mi-neo-20171025monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-announces-preliminary-quar-neo-20171012monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-record-revenue-of--neo-20170725monthly0.5https://www.biopharmawatch.com/news/NEO/meeting-agenda-may-25th-8-00-8-30am-annual-shareholders-meeting-analyst-investor-day-prese-neo-20170525monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-15-volume-growth-a-neo-20170426monthly0.5https://www.biopharmawatch.com/news/NEO/transcript-of-neogenomics-inc-fourth-quarter-and-full-year-2016-financial-results-neo-20170222monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-122-revenue-growth-neo-20170222monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-closes-150-million-senior--neo-20161222monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-142-revenue-growth-neo-20161026monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-159-revenue-growth-neo-20160726monthly0.5https://www.biopharmawatch.com/news/NEO/forward-looking-statements-this-presentation-contains-statements-which-constitute-forward--neo-20160608monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-condensed-consolidated-statements-of-cash-flows-unaudited-in-thousands-for-neo-20160428monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-condensed-consolidated-statements-of-cash-flows-unaudited-in-thousands-for-neo-20160301monthly0.5https://www.biopharmawatch.com/news/NEO/forward-looking-statements-this-presentation-contains-statements-which-constitute-forward--neo-20151223monthly0.5https://www.biopharmawatch.com/news/NEO/forward-looking-statements-this-presentation-contains-statements-which-constitute-forward--neo-20151217monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-amends-strategic-alliance--neo-20151028monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-signs-definitive-agreement-neo-20151021monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-18-revenue-growth--neo-20150723monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-27-revenue-growth--neo-20150428monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-record-revenue-of--neo-20150224monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-raises-revenue-guidance-to-neo-20150122monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-38-increase-in-rev-neo-20141030monthly0.5https://www.biopharmawatch.com/news/NEO/charter-of-the-compliance-committee-of-the-board-of-directors-of-neogenomics-inc-the-corpo-neo-20141014monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-announces-closing-of-recen-neo-20140822monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-announces-pricing-of-32-2--neo-20140815monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-record-revenues-of-neo-20140717monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-completes-acquisition-of-p-neo-20140708monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-revenue-of-18-2-mi-neo-20140423monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-record-revenue-of--neo-20140219monthly0.5https://www.biopharmawatch.com/news/NEO/covance-central-laboratories-and-neogenomics-enter-into-exclusive-alliance-to-provide-comp-neo-20131118monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-record-revenue-of--neo-20131023monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-revenue-of-15-6-mi-neo-20130731monthly0.5https://www.biopharmawatch.com/news/NEO/mission-to-improve-patient-care-through-exceptional-cancer-genetic-diagnostic-services-vis-neo-20130509monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-record-quarterly-r-neo-20130425monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-announces-pricing-of-9-5-m-neo-20130228monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-reports-181-increase-in-ad-neo-20130214monthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-inc-press-release-for-immediate-release-neogenomics-announces-nasdaq-capital-m-neo-20121206monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-susan-salka-experienced-healthcare-executive-to-its-board-of-direc-tdoc-20260330monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-fourth-quarter-and-full-year-2025-results-tdoc-20260225monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-michael-smith-experienced-insurance-and-financial-services-executi-tdoc-20260218monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-third-quarter-2025-results-tdoc-20251029monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-announces-chief-financial-officer-transition-provides-preliminary-third-qua-tdoc-20251023monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-second-quarter-2025-results-tdoc-20250729monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-first-quarter-2025-results-purchase-ny-tdoc-20250430monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-full-year-and-fourth-quarter-2024-results-purchase-ny-tdoc-20250226monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-third-quarter-2024-results-purchase-ny-tdoc-20241030monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-second-quarter-2024-results-purchase-ny-tdoc-20240731monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-names-chuck-divita-as-ceo-experienced-healthcare-leader-to-head-global-virt-tdoc-20240610monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-first-quarter-2024-results-purchase-ny-tdoc-20240425monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-board-of-directors-announces-leadership-transition-jason-gorevic-to-depart--tdoc-20240405monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-fourth-quarter-and-full-year-2023-results-fourth-quarter-2023-reven-tdoc-20240220monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-third-quarter-2023-results-third-quarter-2023-revenue-grows-8-year--tdoc-20231024monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-leading-healthcare-and-hospitals-executive-eric-evans-to-board-of--tdoc-20230920monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-second-quarter-2023-results-second-quarter-2023-revenue-grows-10-ye-tdoc-20230725monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-first-quarter-2023-results-first-quarter-2023-revenue-grows-11-year-tdoc-20230426monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-fourth-quarter-and-full-year-2022-results-fourth-quarter-revenue-gr-tdoc-20230222monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-names-laizer-kornwasser-as-president-enterprise-growth-global-markets-purch-tdoc-20221024monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-third-quarter-2022-results-third-quarter-revenue-grows-17-year-over-tdoc-20221026monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-second-quarter-2022-results-second-quarter-revenue-grows-18-year-ov-tdoc-20220727monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-names-mike-waters-as-chief-operating-officer-purchase-ny-tdoc-20220725monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-first-quarter-2022-results-first-quarter-revenue-grows-25-year-over-tdoc-20220427monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-fourth-quarter-and-full-year-2021-results-fourth-quarter-revenue-gr-tdoc-20220222monthly0.5https://www.biopharmawatch.com/news/TDOC/this-presentation-contains-and-our-officers-may-make-x201c-forward-looking-x201d-statement-tdoc-20211118monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-third-quarter-2021-results-third-quarter-revenue-grows-81-year-over-tdoc-20211027monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-second-quarter-2021-results-raises-full-year-revenue-guidance-secon-tdoc-20210727monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-first-quarter-2021-results-purchase-ny-tdoc-20210428monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-fourth-quarter-and-full-year-2020-results-q4-revenue-grows-145-year-tdoc-20210224monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-completes-merger-with-livongo-combination-creates-the-global-leader-in-whol-tdoc-20201030monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-announces-shareholder-approvals-in-merger-with-livongo-tdoc-20201029monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-third-quarter-2020-results-year-over-year-q3-revenue-grows-109-to-2-tdoc-20201028monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-and-livongo-file-definitive-proxy-statement-special-meetings-to-be-held-on-tdoc-20200916monthly0.5https://www.biopharmawatch.com/news/TDOC/transforming-healthcare-across-the-continuum-of-care-september-2020-creates-the-global-lea-tdoc-20200903monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-and-livongo-merge-to-create-new-standard-in-global-healthcare-delivery-acce-tdoc-20200805monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-second-quarter-2020-results-year-over-year-q2-revenue-grows-85-to-2-tdoc-20200729monthly0.5https://www.biopharmawatch.com/news/TDOC/teladoc-health-completes-acquisition-tdoc-20200701monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-third-quarter-2025-financial-results-and-business-highlights-x2-janx-20251106monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-second-quarter-2025-financial-results-and-business-highlights-x-janx-20250807monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-first-quarter-2025-financial-results-and-business-highlights-x2-janx-20250508monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-busines-janx-20250227monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-announces-proposed-public-offering-janx-20241203monthly0.5https://www.biopharmawatch.com/news/JANX/janux-announces-doses-selected-for-phase-1b-expansion-trials-supported-by-encouraging-effi-janx-20241202monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-third-quarter-2024-financial-results-and-business-highlights-x2-janx-20241106monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-second-quarter-2024-financial-results-and-business-highlights-x-janx-20240807monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-announces-updates-to-board-of-directors-x2022-the-appointment-of-eric-d-janx-20240722monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-first-quarter-2024-financial-results-and-business-highlights-x2-janx-20240507monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-busines-janx-20240308monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-announces-proposed-public-offering-of-common-stock-janx-20240227monthly0.5https://www.biopharmawatch.com/news/JANX/janux-announces-encouraging-safety-and-efficacy-data-in-ongoing-dose-escalation-trials-for-janx-20240226monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-third-quarter-2023-financial-results-and-business-highlights-x2-janx-20231107monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-second-quarter-2023-financial-results-and-business-highlights-p-janx-20230808monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-announces-pricing-of-60-million-underwritten-offering-of-common-stock-a-janx-20230717monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-announces-positive-interim-clinical-data-from-phase-1a-dose-escalation--janx-20230717monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-first-quarter-2023-financial-results-and-business-highlights-fi-janx-20230509monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-busines-janx-20230310monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-third-quarter-2022-financial-results-and-business-highlights-fi-janx-20221110monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-appoints-winston-kung-to-board-of-directors-janx-20220922monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-second-quarter-2022-financial-results-and-business-highlights-i-janx-20220809monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-first-quarter-2022-financial-results-and-business-highlights-in-janx-20220510monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2021--janx-20220318monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-business-highlights-and-third-quarter-2021-financial-results-co-janx-20211109monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-second-quarter-2021-financial-results-successful-222-9-million--janx-20210810monthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-under-janx-20210615monthly0.5https://www.biopharmawatch.com/news/PHAT/florham-park-n-j-phat-20260107monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2025-financial--phat-20260107monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-busines-phat-20250807monthly0.5https://www.biopharmawatch.com/news/PHAT/terrie-curran-chief-executive-officer-phathom-pharmaceuticals-inc-100-campus-drive-suite-1-phat-20250606monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-phat-20250501monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-pr-phat-20250306monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-phat-20241107monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-pricing-of-130-million-offering-of-common-stock-and-pre--phat-20240819monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-busines-phat-20240808monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-business-phat-20240509monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-pr-phat-20240307monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-third-quarter-2023-results-and-recent-business-updates-voq-phat-20231109monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-second-quarter-2023-results-prior-approval-supplement-pas--phat-20230810monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-proposed-public-offering-of-common-stock-florham-park-n--phat-20230523monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-first-quarter-2023-results-phat-20230510monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-pr-phat-20230228monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-business-phat-20221108monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-placement-of-the-remaining-40-million-in-non-dilutive-ca-phat-20221101monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-busines-phat-20220802monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-first-quarter-2022-results-and-provides-recent-clinical-re-phat-20220510monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-revenue-interest-financing-agreement-for-up-to-260-milli-phat-20220504monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-hi-phat-20220301monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-third-quarter-2021-results-and-provides-key-clinical-regul-phat-20211108monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-second-quarter-2021-results-and-provides-update-regarding--phat-20210810monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-mourns-the-loss-of-chairman-and-founder-tadataka-tachi-yamada-phat-20210805monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-first-quarter-2021-results-and-provides-recent-business-up-phat-20210511monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-hi-phat-20210330monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-proposed-public-offering-of-2-250-000-shares-of-common-s-phat-20201215monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-third-quarter-2020-results-and-provides-update-on-phase-3--phat-20201110monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-second-quarter-2020-results-florham-park-n-j-phat-20200806monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-first-quarter-2020-results-florham-park-n-j-phat-20200512monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-clinical--phat-20200319monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-corporat-phat-20191125monthly0.5https://www.biopharmawatch.com/news/INMD/tavor-building-sha-ar-yokneam-p-o-inmd-20220210monthly0.5https://www.biopharmawatch.com/news/INMD/inmode-reports-third-quarter-2019-record-revenue-of-40-million-reflects-growth-of-57-year--inmd-20191105monthly0.5https://www.biopharmawatch.com/news/INMD/inmode-reports-second-quarter-2019-financial-results-record-quarterly-revenue-of-38-8-mill-inmd-20190813monthly0.5https://www.biopharmawatch.com/news/INMD/final-inmode-ltd-announces-closing-of-initial-public-offering-inmd-20190812monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-q4-2025-and-full-year-2025-financial-results-alvo-20260319monthly0.5https://www.biopharmawatch.com/news/ALVO/execution-version-amendment-no-2-to-term-loan-credit-agreement-this-amendment-no-2-to-term-alvo-20250728monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-the-outcome-of-the-offering-in-connection-with-the-company-s-listing-on-alvo-20250527monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-record-preliminary-results-for-revenues-and-ebitda-for-the-second-quart-alvo-20240701monthly0.5https://www.biopharmawatch.com/news/ALVO/cautionary-note-regarding-forward-looking-statements-this-exhibit-contains-forward-looking-alvo-20240614monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-provides-u-s-regulatory-update-on-avt02-a-high-concentration-interchangeable-bios-alvo-20230920monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-unaudited-condensed-consolidated-interim-financial-statements-as-of-30-june-2023--alvo-20230907monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-changes-to-the-leadership-team-reykjavik-iceland-alvo-20230905monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-unaudited-condensed-consolidated-interim-financial-statements-as-of-30-june-2023--alvo-20230831monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-or-its-partners-to-gain-approval-from-regulators-for-planned-clinical-studies-stu-alvo-20230801monthly0.5https://www.biopharmawatch.com/news/ALVO/important-factors-that-could-cause-or-contribute-to-such-differences-include-risks-relatin-alvo-20230724monthly0.5https://www.biopharmawatch.com/news/ALVO/certain-identified-information-has-been-excluded-from-this-exhibit-because-it-is-both-not--alvo-20230712monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-provides-regulatory-update-on-second-biologics-license-application-for-avt02-alvo-20230628monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-teva-secure-u-s-license-date-for-avt04-a-proposed-biosimilar-to-stelara-accor-alvo-20230613monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-soci-t-anonyme-gesellschaftssitz-9-rue-de-bitbourg-l-1273-luxembourg-r-c-s-luxemb-alvo-20230606monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-five-proposed-bio-alvo-20230524monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-financial-results-for-first-three-months-of-2023-and-provides-business-up-alvo-20230519monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-soci-t-anonyme-si-ge-social-9-rue-de-bitbourg-l-1273-luxembourg-grand-duch-de-lux-alvo-20230505monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-initiates-confirmatory-patient-study-for-avt05-a-proposed-biosimilar-for-simponi--alvo-20230504monthly0.5https://www.biopharmawatch.com/news/ALVO/sarah-tanksley-joins-board-of-directors-for-alvotech-hf-and-sandra-casaca-appointed-chief--alvo-20230420monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-provides-regulatory-update-on-avt02-biologics-license-application-reykjavik-icela-alvo-20230413monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-increase-in-number-of-own-shares-reykjavik-iceland-alvo-20230328monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-financial-results-for-full-year-2022-and-provides-business-update-full-ye-alvo-20230301monthly0.5https://www.biopharmawatch.com/news/ALVO/settlement-of-alvotech-private-share-placement-completed-reykjavik-iceland-alvo-20230210monthly0.5https://www.biopharmawatch.com/news/ALVO/ema-confirms-acceptance-of-application-for-avt04-a-proposed-biosimilar-to-stelara-ustekinu-alvo-20230209monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimila-alvo-20230206monthly0.5https://www.biopharmawatch.com/news/ALVO/table-of-contents-1-general-description-3-2-risk-factors-6-3-summary-of-main-terms-of-the--alvo-20230207monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-bioventure-announce-approval-of-avt02-adalimumab-as-simlandi-in-saudi-arabia--alvo-20230124monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-completes-137-million-private-share-placement-reykjavik-iceland-alvo-20230123monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-s-a-inside-information-alvotech-initiates-proposed-private-share-placement-to-pro-alvo-20230120monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-initiates-pharmacokinetic-study-for-avt05-a-proposed-biosimilar-for-simponi-and-s-alvo-20230111monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-teva-announce-acceptance-of-u-s-biologics-license-application-for-avt04-a-pro-alvo-20230106monthly0.5https://www.biopharmawatch.com/news/ALVO/update-on-u-s-regulatory-status-of-avt02-alvotech-s-proposed-high-concentration-interchang-alvo-20221222monthly0.5https://www.biopharmawatch.com/news/ALVO/correction-to-total-amount-in-announcement-about-private-placement-published-2022-12-16-09-alvo-20221216monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-publishes-prospectus-related-to-the-admission-to-trading-and-listing-on-nasdaq-ic-alvo-20221206monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-submits-its-application-for-admission-of-the-company-s-shares-to-trading-on-nasda-alvo-20221201monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-secures-financing-facilities-of-approximately-136-million-existing-senior-bonds-u-alvo-20221116monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-financial-results-for-first-nine-months-of-2022-and-provides-business-upd-alvo-20221116monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-participate-in-upcoming-jefferies-london-healthcare-conference-in-november-rey-alvo-20221026monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-jamp-pharma-expand-exclusive-partnership-adding-two-biosimilar-candidates-for-alvo-20221019monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-s-partner-submits-application-for-marketing-approval-of-first-biosimilar-candidat-alvo-20221017monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-appoints-sarah-tanksley-as-chief-quality-officer-reykjavik-iceland-alvo-20221011monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-stada-increase-access-to-adalimumab-for-patients-in-switzerland-with-the-laun-alvo-20220922monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-update-on-initial-avt02-biologics-license-application-reykjavik-iceland-alvo-20220905monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-unaudited-condensed-consolidated-interim-financial-statements-as-of-30-june-2022--alvo-20220831monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-corporate-sustainability-participation-and-discloses-esg-data-covering--alvo-20220829monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-initiates-confirmatory-patient-study-for-avt03-a-proposed-biosimilar-for-prolia-a-alvo-20220825monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-report-first-six-months-and-second-quarter-2022-financial-results-on-alvo-20220815monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-s-board-of-directors-approves-plan-to-prepare-for-listing-on-nasdaq-main-market-i-alvo-20220812monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-initiates-a-pharmacokinetic-study-for-avt03-a-proposed-biosimilar-for-prolia-and--alvo-20220720monthly0.5https://www.biopharmawatch.com/news/ALVO/published-2022-07-15-10-00-00-cest-alvotech-s-a-interim-information-filing-of-preliminary--alvo-20220718monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-soci-t-anonyme-registered-office-9-rue-de-bitbourg-l-1273-luxembourg-r-c-s-luxemb-alvo-20220714monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-initiates-patient-study-for-avt06-a-proposed-biosimilar-for-eylea-avt06-is-the-th-alvo-20220707monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-soci-t-anonyme-registered-office-9-rue-de-bitbourg-l-1273-luxembourg-r-c-s-luxemb-alvo-20220705monthly0.5https://www.biopharmawatch.com/news/ALVO/supplement-dated-22-june-2022-to-the-company-description-dated-21-june-2022-incorporated-i-alvo-20220615monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-debuts-on-nasdaq-first-north-growth-market-becoming-first-dual-listed-icelandic-c-alvo-20220622monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-company-description-june-2022-listing-of-shares-on-nasdaq-first-north-iceland-tab-alvo-20220621monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-a-global-pureplay-biosimilars-company-to-debut-on-nasdaq-under-the-ticker-alvo-on-alvo-20220615monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-stockholders-have-elected-all-three-of-the-company-s-director-pcrx-20260609monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-announces-pricing-of-250-0-million-aggregate-principal-amount-of-2--pcrx-20240510monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-announces-proposed-offering-of-250-0-million-aggregate-principal-am-pcrx-20240508monthly0.5https://www.biopharmawatch.com/news/PCRX/document-for-immediate-release-news-release-pacira-appoints-frank-d-lee-as-chief-executive-pcrx-20231221monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-leadership-succession-plan-david-stack-to-retire-as-chairman--pcrx-20230926monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-repayment-and-termination-of-term-loan-b-facility-using-proce-pcrx-20230403monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-departure-of-yvonne-greenstreet-from-board-of-directors-tampa-pcrx-20230322monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-closing-of-375-million-five-year-term-loan-b-provides-additio-pcrx-20211209monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-completes-acquisition-of-flexion-therapeutics-and-strengthens-leadershi-pcrx-20211119monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-acquire-flexion-therapeutics-further-expanding-leadership-position-i-pcrx-20211011monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-second-quarter-2020-financial-results-and-business-update-expar-pcrx-20200806monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-announces-proposed-offering-of-300-0-million-aggregate-principal-am-pcrx-20200706monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-total-revenue-of-75-5-million-for-second-quarter-of-pcrx-20200706monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-conclusion-of-exparel-agreement-with-depuy-synthes-orthopedic-pcrx-20200702monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-full-year-2019-preliminary-revenue-of-421-0-million-pcrx-20200109monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-former-johnson-johnson-executive-max-reinhardt-as-president-re-pcrx-20190619monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-completes-acquisition-of-myoscience-advancing-leadership-in-non-opioid-pain-managem-pcrx-20190409monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-acquire-myoscience-adding-fda-approved-iovera-system-for-non-opioid-pain-control-pcrx-20190305monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-reports-preliminary-2018-net-exparel-sales-of-331-million-exparel-sales-exceed-uppe-pcrx-20190103monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-reports-preliminary-2017-revenues-of-286-6-million-exparel-sales-of-pcrx-20180104monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-announces-promotions-of-scott-braunstein-md-to-chief-operating-officer-and-richard--pcrx-20171207monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-and-tela-bio-announce-equity-agreement-pacira-to-invest-up-to-25-mi-pcrx-20171025monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-announces-resignation-of-james-scibetta-parsippany-n-j-pcrx-20170523monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-announces-proposed-offering-of-300-million-aggregate-principal-amou-pcrx-20170306monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-announces-collaboration-with-depuy-synthes-to-support-promotion-edu-pcrx-20170125monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-reports-preliminary-2016-revenues-of-276-4-million-exparel-net--pcrx-20170106monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-reports-estimated-full-year-2015-total-revenue-of-249-0-million-par-pcrx-20160107monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-announces-favorable-resolution-with-u-s-food-and-drug-administratio-pcrx-20151215monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-seeks-court-injunction-to-defend-its-rights-to-share-information-ab-pcrx-20150908monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-reports-second-quarter-2015-financial-results-conference-call-t-pcrx-20150730monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-reports-first-quarter-exparel-revenues-of-56-0-million-and-firs-pcrx-20150430monthly0.5https://www.biopharmawatch.com/news/PCRX/draft-release-for-immediate-release-pacira-receives-complete-response-letter-from-fda-for--pcrx-20150302monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-reports-2014-financial-results-company-will-host-conference-cal-pcrx-20150224monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-reports-estimated-fourth-quarter-total-revenue-of-61-8-million--pcrx-20150108monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-reports-third-quarter-exparel-revenue-of-50-2-million-and-third-pcrx-20141030monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-reports-second-quarter-2014-results-exparel-revenue-up-31-over--pcrx-20140731monthly0.5https://www.biopharmawatch.com/news/PCRX/not-for-immediate-release-pacira-pharmaceuticals-inc-reports-first-quarter-exparel-revenue-pcrx-20140501monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-parsippany-n-j-pcrx-20140408monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-announces-fda-approval-of-additional-manufacturing-suite-for-pcrx-20140331monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-pharmaceuticals-inc-reports-2013-financial-results-fourth-quarter-exparel-revenues--pcrx-20140225monthly0.5https://www.biopharmawatch.com/news/TALK/may-29-2026-talkspace-stockholders-vote-to-approve-acquisition-by-uhs-new-york-ny-talk-20260529monthly0.5https://www.biopharmawatch.com/news/TALK/voting-agreement-this-voting-agreement-this-agreement-dated-as-of-talk-20260309monthly0.5https://www.biopharmawatch.com/news/TALK/universal-health-services-inc-to-acquire-talkspace-inc-industry-leading-virtual-behavioral-talk-20260309monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-fourth-quarter-and-full-year-2025-results-4q-2025-total-revenue-grew-2-talk-20260219monthly0.5https://www.biopharmawatch.com/news/TALK/disclaimer-this-presentation-contains-certain-forward-looking-statements-within-the-meanin-talk-20260115monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-third-quarter-2025-results-3q-2025-total-revenue-grew-25-year-over-yea-talk-20251030monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-acquires-wisdo-health-to-expand-ai-powered-social-health-and-peer-support-soluti-talk-20251006monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-second-quarter-2025-results-2q-2025-total-revenue-grew-18-year-over-ye-talk-20250805monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-first-quarter-2025-results-1q-2025-total-revenue-grew-15-year-over-yea-talk-20250506monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-fourth-quarter-and-full-year-2024-results-full-year-2024-total-revenue-talk-20250220monthly0.5https://www.biopharmawatch.com/news/TALK/quality-mental-health-care-for-all-jon-cohen-m-d-ceo-ian-harris-cfo-2025-jp-morgan-healthc-talk-20250115monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-third-quarter-2024-results-3q-2024-total-revenue-grew-23-year-over-yea-talk-20241029monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-second-quarter-2024-results-2q-2024-total-revenue-grew-29-year-over-ye-talk-20240806monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-first-quarter-2024-results-1q-2024-total-revenue-grew-36-year-over-yea-talk-20240507monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-fourth-quarter-and-full-year-2023-results-4q-2023-payor-revenue-grew-1-talk-20240222monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-appointment-of-two-new-independent-directors-new-york-dec-5-2023-globe-talk-20231201monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-third-quarter-2023-results-b2b-payor-revenue-grew-132-year-over-year-3-talk-20231102monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-second-quarter-2023-results-b2b-payor-revenue-grew-135-year-over-year--talk-20230727monthly0.5https://www.biopharmawatch.com/news/TALK/after-negotiating-the-principal-terms-of-the-settlement-plaintiffs-counsel-and-defendants--talk-20230725monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-first-quarter-2023-results-b2b-payor-sessions-grew-90-year-over-year-1-talk-20230502monthly0.5https://www.biopharmawatch.com/news/TALK/granted-in-the-court-of-chancery-of-the-state-of-delaware-in-re-talkspace-inc-c-a-no-2023--talk-20230317monthly0.5https://www.biopharmawatch.com/news/TALK/in-the-court-of-chancery-of-the-state-of-delaware-in-re-talkspace-inc-c-a-no-2023-verified-talk-20230307monthly0.5https://www.biopharmawatch.com/news/TALK/fourth-quarter-earnings-presentation-talk-20230222monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-fourth-quarter-and-fiscal-year-2022-results-b2b-payor-sessions-grew-56-talk-20230221monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-jon-cohen-m-d-as-next-chief-executive-officer-talk-20221108monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-reports-2022-third-quarter-and-nine-months-results-strong-acceleration-in-b2b-re-talk-20221108monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-reports-2022-second-quarter-and-first-half-results-second-quarter-and-first-half-talk-20220808monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-reports-2022-first-quarter-results-revenue-grew-11-year-over-year-to-30-million--talk-20220503monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-reports-2021-full-year-and-fourth-quarter-results-revenue-grew-49-in-2021-to-114-talk-20220222monthly0.5https://www.biopharmawatch.com/news/TALK/january-13th-2022-talkspace-accessible-high-quality-mental-healthcare-doug-braunstein-inte-talk-20211231monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-announces-ceo-transition-plan-co-founders-oren-and-roni-frank-step-down-from-the-talk-20211115monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-reports-third-quarter-2021-financial-results-net-revenue-grew-23-year-over-year--talk-20211115monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-reports-second-quarter-2021-results-q2-net-revenue-grew-73-year-over-year-to-app-talk-20210809monthly0.5https://www.biopharmawatch.com/news/TALK/have-the-meanings-ascribed-to-them-in-the-current-report-on-form-8-k-the-form-8-k-filed-wi-talk-20210623monthly0.5https://www.biopharmawatch.com/news/TALK/hudson-executive-investment-corp-stockholders-approve-business-combination-with-talkspace--talk-20210617monthly0.5https://www.biopharmawatch.com/news/TALK/hudson-executive-investment-corp-announces-filing-of-definitive-proxy-statement-and-sets-talk-20210601monthly0.5https://www.biopharmawatch.com/news/TALK/talkspace-to-merge-with-hudson-executive-investment-corp-forming-the-only-publicly-traded--talk-20210113monthly0.5https://www.biopharmawatch.com/news/TALK/hudson-executive-investment-corp-announces-the-separate-trading-of-its-class-a-common-stoc-talk-20200730monthly0.5https://www.biopharmawatch.com/news/TALK/index-to-financial-statements-page-report-of-independent-registered-public-accounting-firm-talk-20200611monthly0.5https://www.biopharmawatch.com/news/TALK/hudson-executive-investment-corp-announces-pricing-of-upsized-360-million-initial-public-o-talk-20200609monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-first-quarter-2026-results-strong-first-quarter-performance-reinforces-con-ftre-20260505monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-third-quarter-2025-results-for-the-three-months-ended-ftre-20251105monthly0.5https://www.biopharmawatch.com/news/FTRE/about-fortrea-fortrea-nasdaq-ftre-is-a-leading-global-provider-of-clinical-development-sol-ftre-20250922monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-second-quarter-2025-results-for-the-three-months-ended-ftre-20250806monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-adopts-limited-duration-stockholder-rights-plan-board-committed-to-protecting-long-ftre-20250612monthly0.5https://www.biopharmawatch.com/news/FTRE/cautionary-statement-regarding-forward-looking-statements-this-press-release-contains-forw-ftre-20250611monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-first-quarter-2025-results-for-the-three-months-ended-ftre-20250512monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-announces-ceo-stepping-down-peter-m-neupert-fortrea-s-lead-independent-director-wi-ftre-20250512monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-fourth-quarter-and-full-year-2024-results-issues-full-year-2025-guidance-f-ftre-20250303monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-to-add-erin-l-russell-to-board-of-directors-fortrea-and-starboard-enter-into-coope-ftre-20250221monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-third-quarter-2024-results-for-the-three-months-ended-ftre-20241108monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-second-quarter-2024-results-for-the-three-months-ended-ftre-20240812monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-appoints-robert-parks-as-chief-accounting-officer-durham-n-c-ftre-20240711monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-completes-divestiture-of-endpoint-clinical-and-patient-access-businesses-to-arsena-ftre-20240604monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-appoints-machelle-sanders-to-board-of-directors-durham-n-c-ftre-20240516monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-first-quarter-2024-results-for-the-three-months-ended-ftre-20240513monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-fourth-quarter-and-full-year-2023-results-issues-full-year-2024-guidance-f-ftre-20240311monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-previews-j-p-morgan-healthcare-conference-updates-fortrea-nasdaq-ftre-a-leading-gl-ftre-20240108monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-third-quarter-2023-results-for-the-three-months-ended-ftre-20231113monthly0.5https://www.biopharmawatch.com/news/FTRE/updated-august-24-2023-fortrea-reports-second-quarter-2023-results-and-provides-full-year--ftre-20230824monthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-second-quarter-2023-results-company-and-provides-full-year-2023-guidance-f-ftre-20230814monthly0.5https://www.biopharmawatch.com/news/FTRE/south-main-street-burlington-north-carolina-27215-united-states-adam-schechter-chairman-pr-ftre-20230615monthly0.5https://www.biopharmawatch.com/news/FTRE/document-for-immediate-release-labcorp-contacts-media-rachael-valdez-336-436-8263-media-la-ftre-20230612monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-fourth-quarter-and-year-end-2025-financial-results-portfolio-progress-and--annx-20260330monthly0.5https://www.biopharmawatch.com/news/ANNX/stopping-neuroinflammation-at-its-source-th-44-annual-j-p-morgan-healthcare-conference-jan-annx-20260114monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-accelerating-next-generation-targeted-immunotherapy-platform-for-treatment-of-neur-annx-20260112monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-second-quarter-2025-financial-results-portfolio-progress-and-key-anticipat-annx-20250814monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-first-quarter-2025-financial-results-portfolio-progress-and-key-anticipate-annx-20250512monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-fourth-quarter-and-year-end-2024-financial-results-portfolio-progress-and--annx-20250303monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-provides-2025-outlook-with-strong-momentum-accelerating-into-breakthrough-year-anx-annx-20250113monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-expands-board-of-directors-with-appointment-of-commercial-executive-william-bj-jon-annx-20250110monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-positive-topline-results-from-real-world-evidence-study-comparing-anx005-annx-20241216monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-third-quarter-2024-portfolio-and-financial-results-and-key-anticipated-mil-annx-20241114monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-presents-phase-2-vision-preservation-data-with-anx007-in-dry-amd-patients-with-les-annx-20241021monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-second-quarter-2024-portfolio-and-financial-results-and-key-anticipated-mi-annx-20240812monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-provides-update-on-archer-ii-global-registrational-program-in-geographic-atrophy-p-annx-20240805monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-presented-additional-positive-phase-3-results-for-anx005-c1q-targeted-immunotherap-annx-20240625monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-pricing-of-125-million-underwritten-public-offering-annx-20240605monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-positive-topline-results-from-pivotal-phase-3-trial-for-first-in-class-c-annx-20240604monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-first-quarter-2024-financial-results-and-key-anticipated-milestones-multip-annx-20240513monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-presents-new-neuroprotection-data-showing-anx007-protects-vision-and-vision-associ-annx-20240507monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-fourth-quarter-and-year-end-2023-financial-results-and-key-anticipated-mil-annx-20240326monthly0.5https://www.biopharmawatch.com/news/ANNX/virtual-r-d-day-annx-20240301monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-outlines-2024-priorities-with-late-stage-clinical-milestones-across-upstream-compl-annx-20240107monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-pricing-of-125-0-million-underwritten-public-offering-of-common-stock-annx-20231220monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-outlines-global-registrational-program-for-anx007-in-geographic-atrophy-with-fda-a-annx-20231220monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-significant-progress-with-its-priority-programs-and-third-quarter-2023-fin-annx-20231113monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-annx-20231024monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-clinical-and-regulatory-progress-for-anx005-pivotal-program-in-guillain--annx-20231010monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-highlights-recent-pipeline-and-business-progress-and-reports-second-quarter-2023-f-annx-20230807monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-strengthens-leadership-team-with-appointment-of-jamie-dananberg-m-d-as-annx-20230727monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-topline-data-from-archer-phase-2-trial-of-anx007-in-geographic-atrophy-demonstrate-annx-20230524monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-first-quarter-2023-financial-results-and-highlights-recent-pipeline-progre-annx-20230508monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-fourth-quarter-and-year-end-2022-financial-results-and-reiterates-anticipa-annx-20230306monthly0.5https://www.biopharmawatch.com/news/ANNX/game-changing-medicines-for-complement-mediated-diseases-january-2023-nasdaq-annx-1-forwar-annx-20230109monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-appoints-industry-veteran-dr-rick-artis-as-chief-scientific-officer-to-support-the-annx-20230106monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-third-quarter-2022-financial-results-and-plans-to-provide-updates-on-compl-annx-20221103monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-highlights-business-and-portfolio-progress-and-key-anticipated-milesto-annx-20220808monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-130-million-private-placement-financing-annx-20220708monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-reports-phase-2-clinical-trial-results-demonstrating-upstream-classica-annx-20220607monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-highlights-portfolio-progress-and-key-anticipated-milestones-and-repor-annx-20220509monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-completes-enrollment-in-archer-phase-2-trial-of-novel-c1q-inhibitor-an-annx-20220407monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-announces-program-highlights-and-reports-fourth-quarter-and-full-year--annx-20220301monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-appoints-bettina-m-cockroft-m-d-to-its-board-of-directors-annx-20220120monthly0.5https://www.biopharmawatch.com/news/ANNX/th-annual-j-p-morgan-healthcare-conference-january-11-2022-forward-looking-statements-this-annx-20220110monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-reports-promising-interim-phase-2-data-showing-improvement-in-clinical-annx-20220104monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-announces-business-and-program-highlights-and-reports-third-quarter-20-annx-20211109monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-further-strengthens-its-executive-leadership-team-with-appointment-of--annx-20211004monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-reports-second-quarter-2021-financial-results-and-provides-mid-year-bu-annx-20210816monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-broadens-autoimmune-franchise-with-advancement-of-third-anti-c1q-product-candidate-annx-20210722monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-provides-business-update-and-reports-first-quarter-2021-financial-resu-annx-20210517monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-reports-fourth-quarter-and-full-year-2020-financial-results-with-recen-annx-20210325monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-welcomes-william-h-carson-m-d-to-the-board-of-directors-thomas-g-wiggans-appointed-annx-20210208monthly0.5https://www.biopharmawatch.com/news/ANNX/stopping-classical-complement-at-the-start-treating-diseases-of-the-body-brain-and-eye-com-annx-20210111monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-reports-third-quarter-2020-financial-results-and-recent-business-highl-annx-20201116monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-reports-second-quarter-2020-financial-results-and-recent-highlights-co-annx-20200908monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates--oric-20260504monthly0.5https://www.biopharmawatch.com/news/ORIC/rinzimetostat-dose-optimization-data-update-oric-20260331monthly0.5https://www.biopharmawatch.com/news/ORIC/enozertinib-oric-114-program-update-oric-20251206monthly0.5https://www.biopharmawatch.com/news/ORIC/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-oric-20251113monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-clinical-an-oric-20251113monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-125-million-private-placement-financing-financing-led-by-sr-oric-20250528monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-first-quarter-2025-financial-results-and-operational-updates--oric-20250505monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-focused-registrational-clinical-development-plans-for-lead--oric-20250225monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-opera-oric-20250218monthly0.5https://www.biopharmawatch.com/news/ORIC/company-overview-january-2025-forward-looking-statements-this-presentation-contains-forwar-oric-20250113monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-third-quarter-2024-financial-results-and-operational-updates--oric-20241112monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-second-quarter-2024-financial-results-and-operational-updates-oric-20240812monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-first-quarter-2024-financial-results-and-operational-updates--oric-20240506monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-opera-oric-20240311monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-125-million-private-placement-financing-funding-from-new-an-oric-20240122monthly0.5https://www.biopharmawatch.com/news/ORIC/company-overview-january-2024-forward-looking-statements-this-presentation-contains-forwar-oric-20231231monthly0.5https://www.biopharmawatch.com/news/ORIC/initial-phase-1-dose-escalation-data-for-oric-533-in-relapsed-refractory-multiple-myeloma--oric-20231211monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-third-quarter-2023-financial-results-and-operational-updates--oric-20231106monthly0.5https://www.biopharmawatch.com/news/ORIC/initial-phase-1-dose-escalation-data-of-oric-114-in-patients-with-egfr-and-her2-exon-20-mu-oric-20231021monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-second-quarter-2023-financial-results-and-operational-updates-oric-20230810monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-85-million-private-placement-financing-oric-20230626monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-first-quarter-2023-financial-results-and-operational-updates--oric-20230508monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-opera-oric-20230316monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-provides-corporate-update-and-highlights-key-upcoming-milestones-init-oric-20230109monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-clinical-development-collaboration-with-pfizer-for-oric-533-oric-20221221monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-third-quarter-2022-financial-results-and-operational-update-i-oric-20221107monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-second-quarter-2022-financial-results-and-operational-update--oric-20220811monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-first-quarter-2022-financial-results-and-operational-update-t-oric-20220509monthly0.5https://www.biopharmawatch.com/news/ORIC/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-oric-20220321monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-opera-oric-20220321monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-provides-corporate-update-and-highlights-key-upcoming-milestones-oric-oric-20220110monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-appoints-angie-you-ph-d-to-its-board-of-directors-south-san-francisco-oric-20211110monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-third-quarter-2021-financial-results-and-operational-update-i-oric-20211108monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-initial-clinical-data-from-phase-1b-trial-of-oric-101-in-com-oric-20211007monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-appoints-steven-l-hoerter-to-its-board-of-directors-south-san-francis-oric-20210816monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-second-quarter-2021-financial-results-and-operational-update--oric-20210810monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-fda-clearance-of-ind-application-for-oric-533-a-highly-pote-oric-20210628monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-initial-clinical-data-being-presented-at-asco-from-phase-1b-t-oric-20210602monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-first-quarter-2021-financial-results-and-operational-update-l-oric-20210506monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-opera-oric-20210323monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-provides-corporate-update-and-highlights-key-2021-milestones-lead-pro-oric-20210111monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-third-quarter-2020-financial-and-operational-update-expanded--oric-20201105monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-expands-precision-oncology-pipeline-with-exclusive-license-to-brain-p-oric-20201019monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-second-quarter-2020-financial-and-operational-update-lead-pro-oric-20200805monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-appoints-lori-kunkel-m-d-to-its-board-of-directors-oric-20200609monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-first-quarter-2020-financial-and-operational-results-successf-oric-20200520monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-closing-of-initial-public-offering-and-full-exercise-of-und-oric-20200428monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-second-quarter-2023-financial-results-total-q2-revenue-of-12--eton-20230810monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-receives-complete-response-letter-crl-for-dehydrated-alcohol-injectio-eton-20230628monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-first-quarter-2023-financial-results-product-sales-and-royalt-eton-20230511monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-commercial-availability-of-betaine-anhydrous-for-oral-solut-eton-20230510monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-fourth-quarter-2022-financial-results-q4-2022-revenue-of-8-5--eton-20230316monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-rare-disease-product-candidate-et-600-produc-eton-20230315monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fda-acceptance-of-nda-response-for-dehydrated-alcohol-injec-eton-20230111monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-2022-financial-results-eton-20221110monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-fda-approved-rare-disease-product-betaine-an-eton-20220913monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-second-quarter-2022-financial-results-eton-20220811monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-sale-of-hospital-products-eton-sold-its-rights-in-biorphen--eton-20220624monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-first-quarter-2022-financial-results-eton-20220512monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-appoints-james-gruber-as-chief-financial-officer-eton-20220411monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fda-approval-of-cysteine-hydrochloride-injection-eton-20220411monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-fourth-quarter-2021-financial-results-fourth-quarter-2021-rev-eton-20220316monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-and-xgen-pharmaceuticals-djb-announce-commercial-launch-of-rezipres-e-eton-20220314monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-and-ani-pharmaceuticals-announce-commercial-availability-of-carglumic-eton-20211220monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-financial-results-eton-20211115monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-co-promotion-agreement-with-tolmar-pharmaceuticals-for-alki-eton-20211115monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-inc-and-azurity-pharmaceuticals-inc-announce-fda-approval-of-eprontia-eton-20211108monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-approved-orphan-drug-product-carglumic-acid--eton-20211028monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-second-quarter-financial-results-eton-20210816monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-acquires-u-s-and-canadian-rights-to-zeneo-hydrocortisone-autoinjector-eton-20210615monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fda-approval-of-rezipres-ephedrine-hydrochloride-injection-eton-20210615monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-receives-complete-response-letter-from-u-s-fda-for-dehydrated-alcohol-eton-20210528monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-record-revenue-and-earnings-first-quarter-2021-revenue-of-11--eton-20210513monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-appointment-of-jenn-adams-to-its-board-of-directors-eton-20210317monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fourth-quarter-and-full-year-2020-financial-results-eton-20210316monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-sale-of-neurology-portfolio-eton-to-receive-up-to-45-millio-eton-20210208monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-eton-20210114monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acceptance-for-filing-of-new-drug-application-for-topiramat-eton-20201217monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-availability-of-orphan-drug-alkindi-sprinkle-hydrocortisone-eton-20201124monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-closing-of-public-offering-eton-20201016monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acceptance-for-filing-of-new-drug-application-for-zonisamid-eton-20201015monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-proposed-public-offering-of-common-stock-eton-20201013monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acceptance-for-filing-of-new-drug-application-for-orphan-dr-eton-20201008monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-submits-new-drug-application-to-the-fda-for-topiramate-oral-solution--eton-20201006monthly0.5https://www.biopharmawatch.com/news/ETON/pharmaceuticals-announces-fda-approval-of-orphan-drug-alkindi-sprinkle-hydrocortisone-as-r-eton-20200929monthly0.5https://www.biopharmawatch.com/news/ETON/eton-investor-and-media-contact-david-krempa-dkrempa-etonpharma-com-612-387-3740-bausch-he-eton-20200925monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-provides-update-on-the-fda-review-of-em-100-eton-20200916monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-appointment-of-ingrid-hoos-as-senior-vice-president-of-scie-eton-20200831monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-second-quarter-2020-financial-results-eton-20200812monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-provides-update-on-the-fda-review-of-em-100-eton-20200811monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-submits-new-drug-application-to-the-fda-for-zonisamide-oral-suspensio-eton-20200730monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-submits-new-drug-application-to-the-fda-for-orphan-drug-dehydrated-al-eton-20200727monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-first-quarter-2020-financial-results-eton-20200514monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-confirms-first-to-file-patent-challenge-on-elcys-cysteine-hydrochlori-eton-20200507monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-appointment-of-paul-stickler-as-senior-vice-president-of-sa-eton-20200504monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-u-s-marketing-rights-to-pediatric-orphan-dru-eton-20200330monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-positive-study-results-for-et-101-topiramate-oral-solution-re-eton-20200317monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fourth-quarter-and-full-year-2019-financial-results-eton-20200305monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-provides-update-on-et-105-program-eton-20200219monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-and-xellia-pharmaceuticals-announce-biorphen-phenylephrine-hcl-co-pro-eton-20200121monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-commercial-availability-of-biorphen-phenylephrine-hci-injec-eton-20191202monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-third-quarter-financial-results-and-highlights-business-pro-eton-20191114monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-u-s-fda-approval-of-biorphen-phenylephrine-hci-injection-bi-eton-20191022monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-positive-results-from-clinical-study-report-of-et-104-et-10-eton-20190819monthly0.5https://www.biopharmawatch.com/news/ETON/eton-announces-second-quarter-financial-results-and-highlights-business-progress-et-203-nd-eton-20190806monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-et-105-et-105-as-eton-20190801monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-provides-update-on-em-100-program-eton-20190712monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-licensing-of-lamotrigine-new-drug-application-and-provides--eton-20190613monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-first-quarter-2019-financial-results-and-highlights-business--eton-20190507monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-highl-eton-20190325monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-t-cell-engager-cgem-20260606monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2-cgem-20260310monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-highlights-anticipated-2026-milestones-cgem-20251231monthly0.5https://www.biopharmawatch.com/news/CGEM/corporate-overview-september-2025-important-notice-and-disclaimers-this-presentation-conta-cgem-20250904monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial--cgem-20250807monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-first-quarter-2025-financial-r-cgem-20250508monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2-cgem-20250227monthly0.5https://www.biopharmawatch.com/news/CGEM/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-me-cgem-20250128monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-r-cgem-20241107monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-receives-u-s-fda-clearance-of-investigational-new-drug-application-f-cgem-20241016monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-receives-approval-to-initiate-its-global-phase-1-clinical-trial-of-c-cgem-20240917monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-second-quarter-2024-financial--cgem-20240808monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-announces-positive-initial-data-from-pivotal-phase-2b-rezilient1-stu-cgem-20240601monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-present-first-data-for-cln-619-a-novel-anti-mica-b-antibody-in-co-cgem-20240523monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-r-cgem-20240515monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-announces-oversubscribed-280-million-private-placement-financing-inc-cgem-20240416monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2023--cgem-20240314monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-third-quarter-2023-financial-resul-cgem-20231108monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-second-quarter-2023-financial-resu-cgem-20230810monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-first-monotherapy-clinical-data-for-cln-619-a-novel-anti-mica-cgem-20230525monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-first-quarter-2023-financial-resul-cgem-20230511monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022--cgem-20230309monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-licenses-u-s-rights-to-the-first-clinical-stage-b7h4-x-4-1bb-bispecific--cgem-20230213monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-third-quarter-2022-financial-resul-cgem-20221114monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-significantly-increases-ownership-stake-in-its-mica-subsidiary-which-hol-cgem-20221025monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-second-quarter-2022-financial-resu-cgem-20220810monthly0.5https://www.biopharmawatch.com/news/CGEM/unaudited-pro-forma-financial-information-on-june-21-2022-cullinan-oncology-inc-cullinan-c-cgem-20220627monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-first-quarter-2022-financial-resul-cgem-20220516monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-and-taiho-pharmaceutical-announce-strategic-collaboration-to-jointly-dev-cgem-20220512monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2021--cgem-20220317monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-updated-phase-1-2a-data-for-cln-081-in-nsclc-egfr-exon-20-pati-cgem-20211216monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-third-quarter-2021-financial-resul-cgem-20211109monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-appoints-nadim-ahmed-as-chief-executive-officer-ahmed-s-appointment-brin-cgem-20211018monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-provides-corporate-update-and-reports-second-quarter-2021-financial-resu-cgem-20210810monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-phase-1-2a-interim-data-for-cullinan-pearl-s-cln-081-in-nsclc--cgem-20210604monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-first-quarter-2021-financial-results-continued-advancement-of-br-cgem-20210514monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-full-year-2020-financial-results-and-business-highlights-pipelin-cgem-20210330monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-management-inc-announces-business-update-cgem-20210222monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-fourth-quarter-2025-business-highlights-and-financial-results-conferen-opk-20260226monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-third-quarter-2025-business-highlights-and-financial-results-conferenc-opk-20251029monthly0.5https://www.biopharmawatch.com/news/OPK/labcorp-completes-acquisition-of-select-assets-of-bioreference-health-s-innovative-oncolog-opk-20250915monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-second-quarter-2025-business-highlights-and-financial-results-conferen-opk-20250731monthly0.5https://www.biopharmawatch.com/news/OPK/uexif-mm-k-1-2-i-adobe-photoshop-cs6-windows-2025-opk-20250115monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-s-modex-therapeutics-enters-into-exclusive-worldwide-license-and-coll-opk-20230308monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-reports-fourth-quarter-2022-business-highlights-and-financial-results-opk-20230223monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-reports-third-quarter-2022-business-highlights-and-financial-results--opk-20221108monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-reports-2022-second-quarter-business-highlights-and-financial-results-opk-20220804monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-reports-2022-first-quarter-business-highlights-and-financial-results--opk-20220509monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-reports-2021-fourth-quarter-business-highlights-and-financial-results-opk-20220224monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-reports-2021-third-quarter-business-highlights-and-financial-results--opk-20211028monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-reports-2020-fourth-quarter-business-highlights-and-financial-results-opk-20210218monthly0.5https://www.biopharmawatch.com/news/OPK/13x21-january-2021-nasdaq-opk-january-2021-2-this-presentation-contains-forward-looking-st-opk-20210113monthly0.5https://www.biopharmawatch.com/news/OPK/document-opko-health-reports-2020-third-quarter-business-highlights-and-financial-results--opk-20201029monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-2020-second-quarter-business-highlights-and-financial-results-opk-20200730monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-2020-first-quarter-business-highlights-and-financial-results-opk-20200506monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-2019-fourth-quarter-business-highlights-and-financial-results-opk-20200226monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-2019-third-quarter-business-highlights-and-financial-results-opk-20191105monthly0.5https://www.biopharmawatch.com/news/OPK/a8khghctpex991-long-term-safety-of-a-once-weekly-somatrogon-hgh-ctp-4-year-results-of-a-ph-opk-20190923monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-2019-second-quarter-business-highlights-and-financial-results-opk-20190807monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-2019-first-quarter-business-highlights-and-financial-results-opk-20190507monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-2018-fourth-quarter-business-highlights-and-financial-results-opk-20190227monthly0.5https://www.biopharmawatch.com/news/OPK/and-our-consolidated-financial-statements-and-the-related-notes-thereto-effective-opk-20190129monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-and-opko-s-ceo-and-chairman-dr-opk-20181227monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-third-quarter-2018-financial-results-conference-call-begins-today-at-4-opk-20181109monthly0.5https://www.biopharmawatch.com/news/OPK/exhibit-lippert-heilshorn-associates-moderator-miriam-miller-08-07-18-4-30-p-m-et-confirma-opk-20180807monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-second-quarter-2018-financial-results-opk-20180807monthly0.5https://www.biopharmawatch.com/news/OPK/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-that-t-opk-20180606monthly0.5https://www.biopharmawatch.com/news/OPK/client-id-77-thomson-reuters-streetevents-preliminary-transcript-opk-q4-2017-opko-health-i-opk-20180301monthly0.5https://www.biopharmawatch.com/news/OPK/thomson-reuters-streetevents-www-streetevents-com-contact-us-2017-thomson-reuters-all-righ-opk-20171108monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-2017-third-quarter-highlights-and-financial-results-rayaldee-total-pre-opk-20171108monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-enters-into-exclusive-agreement-with-japan-tobacco-to-develop-and-commercializ-opk-20171012monthly0.5https://www.biopharmawatch.com/news/OPK/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-that-t-opk-20170907monthly0.5https://www.biopharmawatch.com/news/OPK/this-presentation-contains-forward-looking-statements-as-that-term-is-defined-under-the-pr-opk-20170615monthly0.5https://www.biopharmawatch.com/news/OPK/diagnostics-pharmaceuticals-for-large-markets-with-unmet-needs-january-2017-nasdaq-opk-for-opk-20170101monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-financial-third-quarter-operating-results-consolidated-revenue-increas-opk-20161107monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-completes-acquisition-of-transition-therapeutics-miami-opk-20160831monthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-reports-improved-financial-and-operating-results-net-income-was-15-5-million-a-opk-20160808monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-first-quarter-2026-financial-results-and-business-updates-annou-sana-20260511monthly0.5https://www.biopharmawatch.com/news/SANA/this-presentation-contains-forward-looking-statements-about-sana-biotechnology-inc-the-x20-sana-20260114monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-second-quarter-2025-financial-results-and-business-updates-pres-sana-20250811monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-first-quarter-2025-financial-results-and-business-updates-prese-sana-20250508monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-fourth-quarter-and-full-year-2024-financial-results-and-busines-sana-20250317monthly0.5https://www.biopharmawatch.com/news/SANA/corporate-presentation-january-2025-cautionary-note-regarding-forward-looking-statements-t-sana-20250113monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates-conti-sana-20241108monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-second-quarter-2024-financial-results-and-business-updates-cont-sana-20240808monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-first-quarter-2024-financial-results-and-business-updates-goal--sana-20240508monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-fourth-quarter-and-full-year-2023-financial-results-and-busines-sana-20240229monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-pricing-of-upsized-public-offering-seattle-feb-08-202-4-globe-sana-20240208monthly0.5https://www.biopharmawatch.com/news/SANA/overview-we-were-founded-on-the-belief-that-engineered-cells-will-be-one-of-the-most-impor-sana-20240207monthly0.5https://www.biopharmawatch.com/news/SANA/this-presentation-contains-forward-looking-statements-about-sana-biotechnology-inc-the-com-sana-20240109monthly0.5https://www.biopharmawatch.com/news/SANA/this-presentation-contains-forward-looking-statements-about-sana-biotechnology-inc-the-com-sana-20231211monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-third-quarter-2023-financial-results-and-business-updates-enrol-sana-20231108monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-increased-focus-on-hypoimmune-related-pipeline-with-the-poten-sana-20231010monthly0.5https://www.biopharmawatch.com/news/SANA/this-presentation-contains-forward-looking-statements-about-sana-biotechnology-inc-the-x20-sana-20230913monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-second-quarter-2023-financial-results-and-business-updates-enro-sana-20230803monthly0.5https://www.biopharmawatch.com/news/SANA/this-presentation-contains-forward-looking-statements-about-sana-biotechnology-inc-the-x20-sana-20230607monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-first-quarter-2023-financial-results-and-business-updates-ind-c-sana-20230508monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-the-appointment-of-two-pioneers-in-drug-discovery-and-develop-sana-20230410monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-fourth-quarter-and-full-year-2022-financial-results-and-busines-sana-20230316monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-fda-clearance-of-investigational-new-drug-application-for-sc2-sana-20230126monthly0.5https://www.biopharmawatch.com/news/SANA/this-presentation-contains-forward-looking-statements-about-sana-biotechnology-inc-the-com-sana-20230110monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-third-quarter-2022-financial-results-and-business-updates-expec-sana-20221102monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-second-quarter-2022-financial-results-and-business-updates-expe-sana-20220804monthly0.5https://www.biopharmawatch.com/news/SANA/this-presentation-contains-forward-looking-statements-about-sana-biotechnology-inc-the-com-sana-20220614monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-plan-to-relocate-manufacturing-to-bothell-washington-along-wi-sana-20220601monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-first-quarter-2022-financial-results-and-business-updates-plans-sana-20220510monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-fourth-quarter-and-full-year-2021-financial-results-and-busines-sana-20220316monthly0.5https://www.biopharmawatch.com/news/SANA/this-presentation-contains-forward-looking-statements-about-sana-biotechnology-inc-the-com-sana-20220111monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-third-quarter-2021-financial-results-and-business-updates-annou-sana-20211108monthly0.5https://www.biopharmawatch.com/news/SANA/and-clinical-and-regulatory-development-plans-and-timing-expectations-the-use-and-utility--sana-20211019monthly0.5https://www.biopharmawatch.com/news/SANA/cautionary-note-regarding-forward-looking-statements-this-presentation-contains-forward-lo-sana-20210913monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-second-quarter-2021-financial-results-and-business-updates-pres-sana-20210804monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-first-quarter-2021-financial-results-and-business-updates-prese-sana-20210505monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-reports-fourth-quarter-and-2020-financial-results-and-business-updates--sana-20210324monthly0.5https://www.biopharmawatch.com/news/EVMN/role-of-mrgprx2-in-migraine-evmn-20260413monthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-evmn-20260305monthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-announces-125-million-private-placement-palo-alto-ca-and-new-york-ny-evmn-20260212monthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-reports-third-quarter-2025-financial-results-and-provides-business-update-three-p-evmn-20251211monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-receives-fda-clearance-to-complete-enrollment-in-regain-recurrent-glioblastoma-t-drts-20260611monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-and-tolmar-announce-strategic-collaboration-to-bring-alpha-dart-therapy-to-u-s-u-drts-20260603monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-strong-overall-survival-results-from-alpha-dart-pancreatic-cancer-stud-drts-20260601monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-first-quarter-2026-financial-results-and-provides-corporate-update-gro-drts-20260518monthly0.5https://www.biopharmawatch.com/news/DRTS/revolutionary-alpha-emitters-radiotherapy-brain-tumors-1-2-this-presentation-together-with-drts-20260511monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-host-conference-call-to-discuss-interim-results-from-first-three-patients-tre-drts-20260508monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-completes-patient-enrollment-in-its-u-s-pivotal-skin-cancer-study-advancing-towa-drts-20260508monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-upcoming-podium-presentation-at-the-ahns-12-th-international-conferenc-drts-20260505monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-full-year-2025-financial-results-and-provides-corporate-update-tremend-drts-20260309monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-reports-new-positive-results-in-two-upcoming-presentations-at-asco-gi-2026-sympo-drts-20260106monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-the-j-p-morgan-2026-healthcare-conference-the-overview-presentatio-drts-20251218monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-successfully-treats-first-patient-in-its-u-s-trial-for-patients-with-recurrent-g-drts-20251209monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-third-quarter-2025-financial-results-and-provides-corporate-update-alp-drts-20251120monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-ltd-interim-consolidated-financial-statements-as-of-june-30-2025-u-s-dol-drts-20250811monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-first-quarter-2025-financial-results-and-provides-corporate-update-int-drts-20250519monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-may-investor-conferences-jerusalem-drts-20250506monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-receives-fda-approval-to-initiate-a-trial-for-patients-with-recurrent-glioblasto-drts-20250402monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-full-year-2024financial-results-and-provides-corporate-update-interim--drts-20250312monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-march-investor-conferences-jerusalem-drts-20250227monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-receives-medical-device-single-audit-program-mdsap-certification-jerusalem-drts-20250224monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-fda-approval-of-ide-supplement-to-expand-pilot-trial-of-alpha-dart-to--drts-20250127monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-cornerstone-interim-data-across-multiple-clinical-trials-to-be-shared--drts-20250127monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-upcoming-presentation-of-new-data-at-2025-asco-gi-symposium-and-at-com-drts-20241218monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-appointment-of-maya-netser-to-its-board-of-directors-board-member-meir-drts-20241217monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-the-43-rd-annual-j-p-morgan-healthcare-conference-the-overview-pre-drts-20241211monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-ladenburg-s-oncology-innovators-investors-symposium-jerusalem--drts-20241206monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-up-drts-20241119monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-citi-s-2024-global-healthcare-conference-and-piper-sandler-s-3-drts-20241113monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-acceptance-into-fda-s-total-product-life-cycle-advisory-program-to-acc-drts-20241021monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-treats-first-patient-with-recurrent-lung-cancer-jerusalem-drts-20241010monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-investigator-initiated-st-drts-20240920monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-the-h-c-wainwright-26-th-annual-global-investment-conference-t-drts-20240822monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-second-quarter-2024-financial-results-and-provides-corporate-u-drts-20240814monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-ltd-interim-consolidated-financial-statements-as-of-june-30-2024-u-s-dol-drts-20240814monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-publication-in-cancers-journal-of-long-term-safety-and-efficacy-data-i-drts-20240625monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-the-jefferies-global-healthcare-conference-jerusalem-drts-20240521monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-first-quarter-2024-financial-results-and-provides-corporate-up-drts-20240520monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-alpha-dart-treatment-of-first-patient-with-liver-metastases-of-colorec-drts-20240513monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-presents-preclinical-data-demonstrating-abscopal-immune-effect-in-pancreatic-mur-drts-20240506monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-may-investor-conferences-jerusalem-drts-20240501monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-the-jefferies-radiopharma-innovation-summit-jerusalem-drts-20240325monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-full-year-2023-financial-results-and-provides-corporate-update-drts-20240307monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-barclays-26-th-annual-global-healthcare-conference-jerusalem-drts-20240226monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-the-42-nd-annual-j-p-morgan-healthcare-conference-the-overview-pre-drts-20231220monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-sidoti-small-cap-conference-jerusalem-drts-20231129monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-highly-promising-interim-results-from-safety-and-feasibility-trial-of--drts-20231128monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-submits-to-japanese-pmda-for-pre-market-approval-of-alpha-dart-in-patients-with--drts-20231120monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-third-quarter-2023-financial-results-and-provides-corporate-up-drts-20231116monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-november-investor-conferences-jerusalem-drts-20231101monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-enters-into-long-term-lease-of-site-in-new-hampshire-for-second-u-s-manufacturin-drts-20231030monthly0.5https://www.biopharmawatch.com/news/DRTS/former-u-s-commissioner-of-food-and-drug-administration-stephen-m-hahn-m-d-appointed-to-al-drts-20231024monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-treats-first-patient-with-advanced-inoperable-pancreatic-cancer-at-israel-s-hada-drts-20230914monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-ltd-interim-consolidated-financial-statements-as-of-june-30-2023-u-s-dol-drts-20230828monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-second-quarter-2023-financial-results-and-provides-corporate-u-drts-20230828monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-to-participate-in-september-investor-conferences-jerusalem-drts-20230824monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-robust-long-term-safety-and-efficacy-data-from-multiple-clinical-trial-drts-20230817monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-to-present-at-the-emerging-growth-conference-on-august-9-th-2023-jerusal-drts-20230802monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-to-participate-in-june-investor-conferences-jerusalem-drts-20230524monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-first-quarter-2023-financial-results-and-provides-corporate-up-drts-20230523monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-to-present-at-guggenheim-radiopharmaceuticals-day-jerusalem-drts-20230503monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-and-the-jgh-announce-alpha-dart-treatment-of-first-patient-in-its-advanced-pancr-drts-20230403monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-to-present-at-jefferies-radiopharma-innovation-summit-jerusalem-drts-20230329monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-confirms-no-direct-exposure-to-silicon-valley-bank-jerusalem-drts-20230312monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-full-year-2022-financial-results-and-provides-corporate-update-drts-20230309monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-alpha-dart-treatment-of-first-two-patients-in-its-pivotal-multicenter--drts-20230308monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-grant-of-expanded-radioactive-license-and-final-pre-clinical-laborator-drts-20230303monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-health-canada-authorization-for-alpha-dart-clinical-trial-for-the-trea-drts-20230301monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-citi-s-2023-healthcare-services-medtech-tools-hcit-conference--drts-20230221monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-biotech-showcase-and-participate-in-lifesci-advisors-corporate-acc-drts-20221213monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-third-quarter-2022-financial-results-and-provides-corporate-up-drts-20221122monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-upcoming-november-investor-conferences-jerusalem-drts-20221109monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-multiple-corporate-updates-ahead-of-2022-annual-meeting-of-the-america-drts-20221021monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-the-acceptance-in-major-peer-reviewed-journals-international-journal-o-drts-20220908monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-appoints-industry-veteran-peter-melnyk-as-chief-commercial-officer-jerusalem-drts-20220901monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-to-participate-in-upcoming-september-investor-conferences-jerusalem-drts-20220830monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-second-quarter-2022-financial-results-and-provides-corporate-u-drts-20220825monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-and-mim-software-announce-collaboration-for-alpha-dart-treatment-planning-jerusa-drts-20220822monthly0.5https://www.biopharmawatch.com/news/DRTS/nasdaq-drts-revolutionary-alpha-emitters-radiotherapy-kol-investor-event-1-this-presentati-drts-20220718monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-hosting-key-opinion-leader-meeting-on-alpha-dart-clinical-trials-jerusalem-drts-20220705monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-treatment-of-first-prostate-cancer-patient-with-alpha-dart-jerusalem-drts-20220622monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-receipt-of-radioactive-license-to-allow-production-in-main-manufacturi-drts-20220616monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-pivotal-study-of-alpha-da-drts-20220608monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-resignation-of-gary-leibler-from-its-board-of-directors-jerusalem-drts-20220607monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-first-quarter-2022-financial-results-and-provides-corporate-up-drts-20220526monthly0.5https://www.biopharmawatch.com/news/DRTS/first-alpha-dart-patients-treated-in-france-as-part-of-alpha-dart-multicenter-skin-cancer--drts-20220523monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-announces-full-year-2021-financial-results-and-provides-corporate-update-drts-20220328monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-ltd-appoints-ruth-alon-to-its-board-of-directors-jerusalem-drts-20220321monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-first-quarter-2026-financial-and-operational-results-received-fda-breakth-mgtx-20260514monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-the-acquisition-of-botaretigene-sparoparvovec-bota-vec-for-the-treatmen-mgtx-20260416monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-positive-three-year-data-from-the-phase-1-aquax-clinical-study-of-aav-h-mgtx-20260416monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-fda-breakthrough-therapy-designation-for-aav2-haqp1-for-the-treatment-o-mgtx-20260326monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-third-quarter-2025-financial-and-operational-results-entered-into-broad-s-mgtx-20251113monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-enters-into-strategic-collaboration-with-eli-lilly-and-company-to-develop-and-com-mgtx-20251110monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-second-quarter-2025-financial-and-operational-results-gained-alignment-wi-mgtx-20250814monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-first-quarter-2025-financial-and-operational-results-announced-strategic--mgtx-20250513monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-aav-gad-f-mgtx-20250509monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-enters-into-a-strategic-collaboration-with-hologen-ai-to-expedite-phase-3-develop-mgtx-20250313monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-aav2-haqp-mgtx-20241209monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-third-quarter-2024-financial-and-operational-results-and-recent-busines-mgtx-20241113monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-positive-data-from-randomized-sham-controlled-clinical-bridging-study-o-mgtx-20241015monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-50-million-offering-of-ordinary-shares-led-by-sanofi-and-reports-second-mgtx-20240812monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-first-quarter-2024-financial-and-operational-results-positive-data-from-t-mgtx-20240509monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-fourth-quarter-and-full-year-2023-financial-and-operational-results-and-r-mgtx-20240314monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-50-million-milestone-from-janssen-pharmaceuticals-meiragtx-to-receive-5-mgtx-20240213monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-asset-purchase-agreement-involving-its-aav-rpgr-collaboration-for-up-to-mgtx-20231221monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-third-quarter-2023-financial-and-operational-results-received-strategic-mgtx-20231114monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-30-million-strategic-investment-from-sanofi-company-pursuing-multiple-a-mgtx-20231030monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-second-quarter-2023-financial-and-operational-results-phase-3-lumeos-clin-mgtx-20230810monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-first-quarter-2023-financial-and-operational-results-raised-approximately-mgtx-20230511monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-fourth-quarter-and-full-year-2022-financial-and-operational-results-annou-mgtx-20230314monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-third-quarter-2022-financial-and-operational-results-and-receives-25-mill-mgtx-20221110monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-second-quarter-2022-financial-and-operational-results-recent-positive-top-mgtx-20220811monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-financing-agreement-with-perceptive-advisors-for-up-to-100-million-secu-mgtx-20220803monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-first-quarter-2022-financial-and-operational-results-phase-3-lumeos-clini-mgtx-20220512monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-appoints-debra-yu-md-to-board-of-directors-london-and-mgtx-20220427monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-fourth-quarter-and-full-year-2021-financial-and-operational-results-phase-mgtx-20220310monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-positive-preliminary-data-from-the-aquax-phase-1-clinical-trial-of-aav--mgtx-20211207monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-third-quarter-2021-financial-and-operational-results-london-and-mgtx-20211110monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-second-quarter-2021-financial-and-operational-results-london-and-mgtx-20210811monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-first-quarter-2021-financial-and-operational-results-london-and-mgtx-20210511monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-fourth-quarter-and-full-year-2020-financial-and-operational-results-prepa-mgtx-20210311monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-to-present-clinical-program-update-for-aav-haqp1-treatment-of-radiation-induced-x-mgtx-20201217monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-investigational-gene-therapy-continues-to-demonstrate-statistically-sig-mgtx-20201113monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-third-quarter-2020-financial-results-meiragtx-preparing-to-initiate-phase-mgtx-20201105monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-nine-month-data-from-phase-1-2-trial-of-aav-rpgr-demonstrating-signific-mgtx-20201003monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-second-quarter-2020-financial-results-positive-initial-data-from-phase-1--mgtx-20200806monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-positive-clinical-data-demonstrating-treatment-with-aav-rpgr-investigat-mgtx-20200717monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-first-quarter-2020-financial-results-london-and-mgtx-20200507monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-full-year-2019-financial-results-london-and-mgtx-20200311monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-third-quarter-2019-financial-results-london-and-mgtx-20191107monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-second-quarter-2019-financial-results-and-provides-corporate-update-londo-mgtx-20190807monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-first-quarter-2019-financial-results-and-provides-corporate-update-positi-mgtx-20190514monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-appoints-nicole-seligman-to-board-of-directors-london-and-mgtx-20190510monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-full-year-2018-financial-results-london-and-mgtx-20190326monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-80-million-private-placement-of-ordinary-shares-london-and-mgtx-20190227monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-appoints-martin-indyk-ph-d-to-board-of-directors-london-and-mgtx-20190221monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-enters-into-strategic-collaboration-with-janssen-to-develop-and-commercialize-gen-mgtx-20190131monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-third-quarter-2018-financial-results-and-provides-corporate-update-london-mgtx-20181108monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-announces-acquisition-of-vector-neurosciences-gains-phase-2-gene-therapy-program--mgtx-20181009monthly0.5https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-second-quarter-2018-financial-results-and-provides-corporate-update-londo-mgtx-20180808monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-first-quarter-2026-financial-results-first-quarter-acv-of-28-million-r-sdgr-20260505monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-third-quarter-2025-financial-results-third-quarter-total-revenue-of-54-sdgr-20251105monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-second-quarter-2025-financial-results-second-quarter-total-revenue-of--sdgr-20250806monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-strong-first-quarter-2025-financial-results-first-quarter-total-revenu-sdgr-20250507monthly0.5https://www.biopharmawatch.com/news/SDGR/supreme-court-of-the-state-of-new-york-county-of-new-york-arnat-abzhanov-derivatively-on-b-sdgr-20250411monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-strong-fourth-quarter-and-full-year-2024-financial-results-achieved-20-sdgr-20250226monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-third-quarter-2024-financial-results-schr-dinger-to-receive-150-millio-sdgr-20241112monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-strong-second-quarter-2024-financial-results-second-quarter-total-reve-sdgr-20240731monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-first-quarter-2024-financial-results-first-quarter-total-revenue-of-36-sdgr-20240501monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-strong-fourth-quarter-and-full-year-2023-financial-results-achieved-fo-sdgr-20240228monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-third-quarter-2023-financial-results-delivers-third-quarter-total-reve-sdgr-20231101monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-second-quarter-2023-financial-results-announces-ind-clearance-for-cdc7-sdgr-20230802monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-strong-first-quarter-2023-financial-results-delivered-first-quarter-to-sdgr-20230504monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-strong-fourth-quarter-and-full-year-2022-financial-results-delivered-3-sdgr-20230228monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-third-quarter-2022-financial-results-total-revenue-growth-of-24-percen-sdgr-20221103monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-second-quarter-2022-financial-results-software-revenue-of-30-0-million-sdgr-20220804monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-ouml-dinger-inc-2022-equity-incentive-plan-1-purpose-the-purpose-of-this-2022-equity--sdgr-20220616monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-first-quarter-2022-financial-results-software-revenue-of-3-3-1-million-sdgr-20220504monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-financial-results-for-the-fourth-quarter-and-full-year-2021-delivered--sdgr-20220224monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-third-quarter-2021-financial-results-and-provides-company-update-third-sdgr-20211110monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-second-quarter-2021-financial-results-and-provides-company-update-seco-sdgr-20210812monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-first-quarter-2021-financial-results-and-provides-company-update-first-sdgr-20210511monthly0.5https://www.biopharmawatch.com/news/SDGR/transforming-discovery-of-therapeutics-and-materials-sdgr-20210323monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-financial-results-for-the-fourth-quarter-and-full-year-2020-and-provid-sdgr-20210304monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-inc-reports-third-quarter-2020-financial-results-and-business-update-total-rev-sdgr-20201112monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-inc-reports-second-quarter-2020-financial-results-and-business-updates-total-r-sdgr-20200810monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-ouml-dinger-transforming-discovery-of-therapeutics-and-materials-cautionary-note-and--sdgr-20200612monthly0.5https://www.biopharmawatch.com/news/SDGR/schr-dinger-reports-first-quarter-2020-financial-results-and-recent-business-updates-total-sdgr-20200513monthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer-lbrx-20251112monthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-reports-3q-2025-financial-results-and-recent-corporate-updates-lbrx-20251106monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-reports-third-quarter-2025-financial-results-total-revenue-of-700-million-excl-qdel-20251105monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-announces-appointment-of-two-independent-directors-to-its-board-veteran-health-qdel-20241210monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-corporation-announces-pricing-of-secondary-offering-of-common-stock-by-the-car-qdel-20241119monthly0.5https://www.biopharmawatch.com/news/QDEL/about-quidelortho-corporation-quidelortho-corporation-nasdaq-qdel-is-a-world-leader-in-in--qdel-20240507monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-reports-second-quarter-2023-financial-results-highligh-ts-second-quarter-reven-qdel-20230808monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-reports-first-quarter-2023-financial-results-highligh-ts-first-quarter-revenue-qdel-20230503monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-reports-fourth-quarter-and-full-year-2022-financial-results-highlights-fourth--qdel-20230215monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles-lead-indepe-qdel-20221212monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-reports-third-quarter-2022-financial-results-highlights-revenue-of-783-8-milli-qdel-20221102monthly0.5https://www.biopharmawatch.com/news/QDEL/ranked-among-the-world-s-largest-in-vitro-diagnostics-ivd-providers-with-more-than-120-yea-qdel-20221012monthly0.5https://www.biopharmawatch.com/news/QDEL/among-others-could-cause-actual-results-to-differ-from-those-set-forth-in-the-forward-look-qdel-20220805monthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-reports-second-quarter-2022-financial-results-highlights-revenue-of-613-4-mill-qdel-20220804monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-end-amph-20260226monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-announces-exclusive-license-agreement-with-nanjing-hanxin-pharma-amph-20260112monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20251106monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-bolsters-proprietary-pipeline-through-exclusive-licensing-agreem-amph-20250812monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20250807monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20250507monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-end-amph-20250227monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-september-3-amph-20241106monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june-30-20--amph-20240807monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-additional-50-million-increase-to-its-share-buyback-program-amph-20240604monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20240508monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-end-amph-20240228monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-september-3-amph-20231108monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-announces-proposed-private-offering-of-300-0-million-of-converti-amph-20230911monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june-30-20--amph-20230808monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-completes-acquisition-of-baqsimi-from-lilly-amph-20230630monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-march-31-20-amph-20230509monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-end-amph-20230228monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-september-3-amph-20221107monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june-30-20--amph-20220808monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-march-31-20-amph-20220509monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-end-amph-20220310monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-september-3-amph-20211108monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june-30-20--amph-20210809monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-end-amph-20210315monthly0.5https://www.biopharmawatch.com/news/AMPH/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-amph-20210112monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-2015-equity-incentive-plan-1-purposes-of-the-plan-the-purpos-amph-20201106monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-september-3-amph-20201106monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june-30-20--amph-20200806monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20200507monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-announces-simplification-of-management-structure-rancho-cuca-amph-20200413monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-end-amph-20200312monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20191107monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20190807monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-announces-settlement-in-litigation-with-momenta-and-sandoz-r-amph-20190619monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20190509monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-end-amph-20190312monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20181108monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-announces-reintroduction-of-primatene-xae-mist-primatene-xae-amph-20181107monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20180808monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-expansion-of-amphastar-nanjing-pharmaceuticals-inc-rancho-cucamonga-ca-amph-20180709monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20180509monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-final-judgment-in-the-patent-litigation-against-momenta-pharmaceutical-amph-20180321monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-fiscal-year-e-amph-20180312monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20171108monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20170809monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-jury-verdict-in-patent-litigation-against-momenta-pharmaceuticals-inc--amph-20170724monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20170508monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-fiscal-year-e-amph-20170313monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-receives-complete-response-letter-for-primatene-xae-mist-rancho--amph-20161227monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-amph-20161108monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june-30-201-amph-20160808monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-purchases-international-medication-systems-uk-limited-from-u-amph-20160804monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-f-irst-quarter-ended-m-arch-31-amph-20160509monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-amph-20160314monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-net-revenues-of-63-9-m-illion-for-the-t-hird-quarter-end-amph-20151112monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-notice-of-annual-general-meeting-of-drug-20260603monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-date-drug-20260602monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-jefferies-global-healthcare-conference-new-york-cit-drug-20260526monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20260520monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20260213monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-announces-closing-of-us-175-million-pub-drug-20260109monthly0.5https://www.biopharmawatch.com/news/DRUG/to-the-company-s-annual-report-on-form-40-f-for-the-fiscal-year-ended-drug-20260109monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-pricing-of-upsized-us-175-million-public-offering-of-co-drug-20260107monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-launch-of-us-100-million-public-offering-new-york-city-drug-20260106monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-positive-topline-results-from-phase-2-clinical-trial-of-drug-20260106monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-to-announce-topline-results-for-bmb-101-phase-2-trial-in-absence-seizures-and-drug-20260106monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-for-immediate-release-bright-minds-biosciences-expands-scientifi-drug-20251106monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-initiates-new-prader-willi-syndrome-pws-program-kol-event-schedul-drug-20251106monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-for-immediate-release-bright-minds-biosciences-to-present-at-upc-drug-20251030monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-bmb-201-outperforms-sumatriptan-in-validated-preclinica-drug-20250904monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20250815monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20250811monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-2025-jefferies-global-healthcare-conference-new-drug-20250528monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-featured-speakers-for-its-absence-epilepsy-virtual-r-d--drug-20250520monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-positive-findings-from-its-dba-2-mouse-model-study-eval-drug-20250513monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-host-virtual-r-d-day-on-drug-20250429monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-expands-scientific-advisory-board-to-include-renowned-leaders-in--drug-20250304monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-participate-at-three-healthcare-conferences-in-march-new-york--drug-20250224monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20250214monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-appoints-pharmaceutical-leader-stephen-collins-m-d-ph-d-as-chief--drug-20250107monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-for-immediate-release-bright-minds-biosciences-to-present-data-a-drug-20241121monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-closes-us-35-million-non-brokered-priva-drug-20241104monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-and-firefly-neuroscience-to-collaborate-after-the-breakthrough-st-drug-20241021monthly0.5https://www.biopharmawatch.com/news/DRUG/not-for-distribution-to-u-s-newswire-services-or-for-release-publication-distribution-or-d-drug-20241018monthly0.5https://www.biopharmawatch.com/news/DRUG/unaware-of-any-material-changes-vancouver-british-columbia-drug-20241015monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-initiates-the-breakthrough-study-a-phase-2-trial-of-bmb-101-in-ab-drug-20240912monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20240815monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20240517monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-510-burrard-st-3rd-floor-vancouver-bc-v6c-3b9-www-computershare--drug-20240517monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20240213monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-closing-of-non-brokered-private-placement-fully-subscribed-by-manag-drug-20231222monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-not-for-distribution-to-u-s-newswire-services-or-for-release-pub-drug-20231206monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20230815monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-positive-qeeg-quantitative-electroencephalogram-data-fr-drug-20230808monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-positive-topline-data-for-its-first-in-human-phase-1-st-drug-20230720monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-effective-date-of-share-consolidation-vancouver-british-columbia-drug-20230711monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-proposed-share-consolidation-vancouver-british-columbia-drug-20230622monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20230515monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-receives-a-favorable-written-opinion-from-the-international-searc-drug-20230419monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-provides-clinical-program-updates-and-outlines-anticipated-milest-drug-20230227monthly0.5https://www.biopharmawatch.com/news/DRUG/not-for-distribution-to-u-s-newswire-services-or-for-release-publication-distribution-or-d-drug-20230217monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-receipt-of-nasdaq-deficiency-letter-regarding-independe-drug-20230208monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20230207monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-resignation-of-board-member-vancouver-bc-drug-20230109monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-drug-20230127monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-this-news-release-is-intended-for-distribution-in-canada-only-an-drug-20221202monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-this-news-release-is-intended-for-distribution-in-canada-only-an-drug-20221128monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-appoints-drug-development-executive-mark-a-smith-m-d-ph-d-as-chie-drug-20221123monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-appointment-of-doug-williamson-to-board-of-directors-no-drug-20220907monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-initiates-dosing-in-phase-i-clinical-trial-of-bmb-101-for-dravet--drug-20220831monthly0.5https://www.biopharmawatch.com/news/DRUG/prospectus-supplement-dated-august-25-2022-to-the-short-form-base-shelf-prospectus-dated-j-drug-20220829monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-pricing-of-overnight-marketed-offering-of-units-not-for-distributio-drug-20220823monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-overnight-marketed-offering-of-units-this-news-release-is-intended--drug-20220822monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-comments-on-recent-trading-activity-vancouver-bc-drug-20220818monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20220815monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20220516monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-host-key-opinion-leader-symposium-on-dravet-syndrome-review-of-drug-20220512monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-establishes-scientific-advisory-board-comprising-five-preeminent--drug-20220502monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-host-symposium-on-therapeutic-developments-with-in-dravet-synd-drug-20220419monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-successful-completion-of-28-day-toxicology-studies-and--drug-20220314monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-v-drug-20220308monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20220215monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-h-c-wainwright-bioconnect-conference-vancouver--drug-20220104monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-provides-scientific-update-on-its-novel-5-ht-2a-psychedelic-progr-drug-20211130monthly0.5https://www.biopharmawatch.com/news/DRUG/dated-november-3-2021-for-immediate-release-bright-minds-biosciences-commences-trading-on--drug-20211103monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-to-present-at-the-ld-micro-main-event-s-drug-20211006monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-for-immediate-release-bright-minds-biosciences-provides-scientif-drug-20210922monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-minds-biosciences-inc-condensed-interim-consolidated-fina-drug-20210917monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-bright-min-ds-biosciences-to-present-at-the-virtual-h-c-wainwrig-drug-20210908monthly0.5https://www.biopharmawatch.com/news/DRUG/filed-by-newsfilecorp-com-for-immediate-release-bright-minds-biosciences-bmb-proprietary-5-drug-20210818monthly0.5https://www.biopharmawatch.com/news/XNCR/xncr-20260504xexx991-designing-proteins-delivering-medicines-results-from-phase-1-study-of-xncr-20260505monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-highlights-corporate-priorities-and-2026-pipeline-milestones-pasadena-calif-xncr-20260108monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2025-financial-results-pasadena-calif-xncr-20251105monthly0.5https://www.biopharmawatch.com/news/XNCR/xncr-2025x1024xexx991-initial-results-from-ongoing-dose-escalation-study-of-xmab819-oncolo-xncr-20251024monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2025-financial-results-pasadena-calif-xncr-20250806monthly0.5https://www.biopharmawatch.com/news/XNCR/investigational-indicates-supports-and-similar-terms-or-by-express-or-implied-discussions--xncr-20250731monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2025-financial-results-recent-interim-phase-1-study-results-f-xncr-20250507monthly0.5https://www.biopharmawatch.com/news/XNCR/xncr-20250429xexx991-interim-results-from-first-in-human-study-of-xmab942-tl1a-pipeline-up-xncr-20250429monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-appoints-todd-simpson-to-board-of-directors-pasadena-calif-xncr-20250313monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2024-financial-results-pasadena-calif-business-xncr-20250227monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2024-financial-results-pasadena-calif-xncr-20241106monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-announces-upcoming-change-to-board-of-directors-pasadena-calif-xncr-20241004monthly0.5https://www.biopharmawatch.com/news/XNCR/document-xencor-announces-closing-of-public-offering-including-full-exercise-of-underwrite-xncr-20240912monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-announces-proposed-public-offering-of-common-stock-xncr-20240910monthly0.5https://www.biopharmawatch.com/news/XNCR/document-xencor-announces-xmab-drug-candidates-in-autoimmune-disease-with-near-term-clinic-xncr-20240909monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2024-financial-results-xncr-20240805monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-regains-cd20-x-cd3-bispecific-t-cell-engager-pasadena-calif-xncr-20240613monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2024-financial-results-xncr-20240509monthly0.5https://www.biopharmawatch.com/news/XNCR/statements-of-historical-fact-and-can-generally-be-identified-by-the-use-of-words-such-as--xncr-20240409monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2023-financial-results-xncr-20240227monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2023-financial-results-royalty-transaction-generates-215-mill-xncr-20231107monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-sells-portion-of-royalties-and-milestones-from-ultomiris-and-monjuvi-to-omers-life--xncr-20231107monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-announces-planned-retirement-of-chief-financial-officer-john-kuch-pasadena-calif-xncr-20231026monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-appoints-barbara-j-xncr-20230919monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2023-financial-results-management-to-host-conference-call-at-xncr-20230803monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2023-financial-results-management-to-host-conference-call-at--xncr-20230508monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-appoints-nancy-valente-m-d-as-chief-development-officer-xncr-20230426monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2022-financial-results-xncr-20230223monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2022-financial-results-xmab564-engineered-il-2-cytokine-is-we-xncr-20221107monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-is-a-clinical-stage-biopharmaceutical-company-developing-engineered-antibodies-and--xncr-20220909monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2022-financial-results-management-to-host-conference-call-at-xncr-20220803monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2022-financial-results-management-to-host-conference-call-at--xncr-20220505monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2021-financial-results-management-to-host-conf-xncr-20220223monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-thirds-quarter-2021-financial-results-and-announces-encouraging-preliminary-xncr-20211108monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-enters-global-collaboration-and-license-agreement-with-janssen-to-advance-plamotama-xncr-20211004monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2021-financial-results-management-to-host-conference-call-at-xncr-20210804monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2021-financial-results-management-to-host-conference-call-at--xncr-20210505monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2020-financial-results-management-to-host-conf-xncr-20210223monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-enters-collaboration-with-janssen-with-aim-to-discover-novel-cd28-bispecific-antibo-xncr-20201207monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2020-financial-results-management-to-host-conference-call-at--xncr-20201105monthly0.5https://www.biopharmawatch.com/news/XNCR/preliminary-safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity-of-xmab20717-a-xncr-20201014monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2020-financial-results-management-to-host-conference-call-at-xncr-20200804monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2020-financial-results-management-to-host-conference-call-at--xncr-20200507monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2019-financial-results-management-to-host-conf-xncr-20200224monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-appoints-dagmar-rosa-bjorkeson-to-board-of-directors-monrovia-calif-xncr-20191220monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2019-financial-results-management-to-host-conference-call-at--xncr-20191105monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2019-financial-results-management-to-host-conference-call-at-xncr-20190806monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2019-financial-results-management-to-host-conference-call-at--xncr-20190509monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-announces-closing-of-research-collaboration-and-license-agreement-with-genentech-xncr-20190308monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2018-financial-results-initial-data-from-phase-xncr-20190225monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-to-develop-and-commercialize-novel-il-15-immune-activating-cytokines-with-genentech-xncr-20190205monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-appoints-ellen-g-feigal-m-d-to-board-of-directors-xncr-20181108monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2018-financial-results-initial-data-from-phase-1-dose-escalat-xncr-20181105monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2018-financial-results-dosed-the-first-patient-in-duet-2-pha-xncr-20180806monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2018-financial-results-introduced-xmab-il15-bispecific-antibo-xncr-20180507monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-inc-announces-proposed-public-offering-of-common-stock-xncr-20180319monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2017-financial-results-broadening-tumor-microe-xncr-20180227monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-appoints-richard-ranieri-to-board-of-directors-monrovia-calif-xncr-20171219monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2017-financial-results-and-provides-clinical-pipeline-update--xncr-20171107monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2017-financial-results-management-to-host-conference-call-to-xncr-20170807monthly0.5https://www.biopharmawatch.com/news/XNCR/second-amendment-to-lease-this-second-amendment-to-lease-this-amendment-is-made-and-effect-xncr-20170705monthly0.5https://www.biopharmawatch.com/news/XNCR/office-lease-by-and-between-prii-high-bluffs-llc-a-delaware-limited-liability-company-and--xncr-20170626monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-inc-1q17-earnings-conference-call-script-tuesday-xncr-20170509monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2017-financial-results-phase-1-data-from-subcutaneous-adminis-xncr-20170509monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-appoints-kevin-gorman-ph-d-to-its-board-of-directors-monrovia-calif-xncr-20170417monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-announces-bruce-l-a-carter-ph-d-chairman-of-the-board-of-directors-will-not-stand-f-xncr-20170306monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2016-financial-results-reported-promising-prel-xncr-20170228monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-inc-announces-proposed-public-offering-of-common-stock-xncr-20161130monthly0.5https://www.biopharmawatch.com/news/XNCR/preliminary-data-from-on-going-igg4-rd-phase-2-trial-patients-shows-encouraging-early-resp-xncr-20161130monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2016-financial-results-xncr-20161102monthly0.5https://www.biopharmawatch.com/news/XNCR/equity-distribution-program-40-000-000-xencor-inc-common-stock-xncr-20160919monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2016-financial-results-expanded-bispecific-oncology-pipeline-xncr-20160802monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-announces-strategic-collaboration-for-bispecific-programs-including-xmab-14045-and--xncr-20160628monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2016-financial-results-monrovia-ca-xncr-20160502monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2015-financial-results-monrovia-calif-xncr-20160307monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-announces-change-to-board-of-directors-xncr-20160111monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2015-financial-results-and-pipeline-update-monrovia-calif-xncr-20151103monthly0.5https://www.biopharmawatch.com/news/XNCR/amgen-and-xencor-announce-strategic-collaboration-in-cancer-immunotherapy-and-inflammation-xncr-20150916monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2015-financial-and-operating-results-xncr-20150804monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2015-financial-and-operating-results-monrovia-calif-xncr-20150504monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-inc-announces-proposed-public-offering-of-common-stock-xncr-20150223monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2014-financial-results-conference-call-to-be-h-xncr-20150219monthly0.5https://www.biopharmawatch.com/news/XNCR/lease-between-bf-monrovia-llc-a-california-limited-liability-company-as-landlord-and-xenco-xncr-20150101monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-third-quarter-2014-financial-results-conference-call-today-at-4-30-p-m-est--xncr-20141110monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-second-quarter-2014-financial-results-conference-call-today-at-4-30-p-m-edt-xncr-20140731monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-appoints-kurt-gustafson-to-board-of-directors-promotes-john-desjarlais-to-chief-sci-xncr-20140715monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-first-quarter-2014-financial-results-conference-call-today-at-4-30-p-m-edt--xncr-20140514monthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2013-financial-results-conference-call-to-be-h-xncr-20140319monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-march-31-december-31-in--absi-20260507monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-consolidated-balance-sheets-december-31-december-31-in-thousands-except--absi-20260324monthly0.5https://www.biopharmawatch.com/news/ABSI/program-he-leaves-behind-a-legacy-of-innovation-that-will-continue-to-guide-our-mission-as-absi-20260306monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-september-30-december-31-absi-20251112monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-june-30-december-31-in-t-absi-20250812monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-announces-proposed-public-offering-of-common-stock-vancouver-wa-absi-20250724monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-march-31-december-31-in--absi-20250513monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-condensed-consolidated-balance-sheets-december-31-december-31-in-thousan-absi-20250318monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-september-30-december-31-absi-20241112monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-june-30-december-31-in-t-absi-20240814monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-march-31-december-31-in--absi-20240514monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-condensed-consolidated-balance-sheets-december-31-december-31-in-thousan-absi-20240321monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-announces-proposed-public-offering-of-common-stock-vancouver-wa-absi-20240227monthly0.5https://www.biopharmawatch.com/news/ABSI/availability-of-other-information-about-absci-investors-and-others-should-note-that-we-rou-absi-20231220monthly0.5https://www.biopharmawatch.com/news/ABSI/well-as-discussions-of-potential-risks-uncertainties-and-other-important-factors-in-our-su-absi-20231204monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-september-30-december-31-absi-20231114monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-june-30-december-31-in-t-absi-20230814monthly0.5https://www.biopharmawatch.com/news/ABSI/about-absci-absci-is-a-generative-ai-drug-creation-company-that-combines-ai-with-scalable--absi-20230606monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-unaudited-condensed-consolidated-balance-sheets-march-31-december-31-in--absi-20230515monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-condensed-consolidated-balance-sheets-december-31-december-31-in-thousan-absi-20230330monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-condensed-consolidated-balance-sheets-unaudited-september-30-december-31-absi-20221109monthly0.5https://www.biopharmawatch.com/news/ABSI/availability-of-other-information-about-absci-investors-and-others-should-note-that-we-rou-absi-20221102monthly0.5https://www.biopharmawatch.com/news/ABSI/goal-estimates-expects-progress-and-intends-or-similar-expressions-we-intend-these-forward-absi-20221004monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-condensed-consolidated-balance-sheets-unaudited-june-30-december-31-in-t-absi-20220811monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-condensed-consolidated-balance-sheets-unaudited-march-31-december-31-in--absi-20220511monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-consolidated-balance-sheets-unaudited-december-31-december-31-in-thousan-absi-20220322monthly0.5https://www.biopharmawatch.com/news/ABSI/website-that-may-be-accessed-from-our-website-shall-not-be-deemed-incorporated-by-referenc-absi-20220107monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-condensed-consolidated-balance-sheets-unaudited-september-30-december-31-absi-20211109monthly0.5https://www.biopharmawatch.com/news/ABSI/absci-corporation-condensed-consolidated-balance-sheets-unaudited-june-30-december-31-in-t-absi-20210907monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-q1-2026-financial-results-and-provides-business-update-posit-ctmx-20260507monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-2025-financial-results-and-provides-business-update-announce-ctmx-20260316monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-second-quarter-2025-financial-results-and-provides-business--ctmx-20250807monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-quarter-2025-financial-results-and-provides-business-u-ctmx-20250512monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-2024-financial-results-and-provides-business-update-continue-ctmx-20250306monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upd-ctmx-20241107monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-up-ctmx-20240808monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-positive-initial-phase-1a-dose-escalation-data-for-monothera-ctmx-20240508monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-upd-ctmx-20240508monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-2023-financial-results-and-provides-business-update-cx-904-egf-ctmx-20240311monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-upd-ctmx-20231107monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-up-ctmx-20230808monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-upd-ctmx-20230509monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-full-year-2022-financial-results-and-provides-business-update--ctmx-20230327monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-upd-ctmx-20221108monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-up-ctmx-20220804monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-upd-ctmx-20220505monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provid-ctmx-20220301monthly0.5https://www.biopharmawatch.com/news/CTMX/2022-cytomx-therapeutics-inc-ctmx-20220110monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-third-quarter-2021-financial-results-and-provides-business-u-ctmx-20211104monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-second-quarter-2021-financial-results-and-provides-business--ctmx-20210805monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-quarter-2021-financial-results-and-provides-business-u-ctmx-20210506monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-prov-ctmx-20210224monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-third-quarter-2020-financial-results-and-provides-business-u-ctmx-20201105monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-second-quarter-2020-financial-results-and-provides-business--ctmx-20200806monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-quarter-2020-financial-results-and-provides-business-u-ctmx-20200507monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-full-year-2019-financial-results-and-provides-business-updat-ctmx-20200227monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-third-quarter-2019-financial-results-company-to-host-a-confe-ctmx-20191107monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-second-quarter-2019-financial-results-and-provides-business--ctmx-20190807monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-quarter-2019-financial-results-company-to-host-a-confe-ctmx-20190509monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-elaine-v-jones-ph-d-to-board-of-directors-ctmx-20190422monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-full-year-2018-financial-results-company-to-host-a-conferenc-ctmx-20190227monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-2019-research-and-development-day-highlights-clinical-data-from-lead-p-ctmx-20190226monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-changes-to-its-board-of-directors-president-and-ceo-sean-mcc-ctmx-20181220monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-third-quarter-2018-financial-results-esmo-presentations-supp-ctmx-20181106monthly0.5https://www.biopharmawatch.com/news/CTMX/forward-looking-statements-special-note-regarding-forward-looking-statements-this-presenta-ctmx-20181022monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-second-quarter-2018-financial-results-presentation-of-first--ctmx-20180808monthly0.5https://www.biopharmawatch.com/news/CTMX/forward-looking-statements-special-note-regarding-forward-looking-statements-this-presenta-ctmx-20180516monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-quarter-2018-financial-results-initial-clinical-data-f-ctmx-20180509monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-full-year-2017-financial-results-and-provides-operational-up-ctmx-20180307monthly0.5https://www.biopharmawatch.com/news/CTMX/forward-looking-statements-special-note-regarding-forward-looking-statements-this-presenta-ctmx-20180108monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-fda-acceptance-of-investigational-new-drug-application-for-c-ctmx-20171128monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-third-quarter-2017-financial-results-and-operational-progress-ctmx-20171107monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-charles-s-fuchs-m-d-mph-to-board-of-directors-ctmx-20171024monthly0.5https://www.biopharmawatch.com/news/CTMX/amgen-and-cytomx-therapeutics-announce-strategic-collaboration-in-immuno-oncology-companie-ctmx-20171003monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-second-quarter-2017-financial-results-and-mid-year-update-webcast-confere-ctmx-20170807monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-achieves-development-milestone-in-strategic-oncology-collaboration-with-abbvie-for--ctmx-20170629monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-the-first-patient-treated-in-phase-1-2-proclaim-cx-2009-trial-ctmx-20170628monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-first-quarter-2017-financial-results-ctmx-20170505monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-marion-mccourt-to-board-of-directors-ctmx-20170330monthly0.5https://www.biopharmawatch.com/news/CTMX/bristol-myers-squibb-and-cytomx-therapeutics-extend-worldwide-collaboration-to-discover-pr-ctmx-20170320monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-full-year-2016-financial-results-ctmx-20170302monthly0.5https://www.biopharmawatch.com/news/CTMX/forward-looking-statements-special-note-regarding-forward-looking-statements-this-presenta-ctmx-20161231monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-u-s-fda-clearance-of-investigational-new-drug-application-for-phase-1-2-c-ctmx-20161214monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-selection-by-bristol-myers-squibb-of-first-clinical-candidate-probody-fro-ctmx-20161213monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-fourth-target-selection-by-bristol-myers-squibb-under-strategic-oncology--ctmx-20161205monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-third-quarter-2016-financial-results-and-provides-pipeline-u-ctmx-20161103monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-second-quarter-2016-financial-results-ctmx-20160803monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-john-a-scarlett-m-d-to-board-of-directors-south-san-francisco-ctmx-20160613monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-first-quarter-2016-financial-results-ctmx-20160506monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-and-abbvie-announce-strategic-collaboration-for-probody-drug-conjugates-companies-t-ctmx-20160421monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-year-end-2015-financial-results-ctmx-20160307monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-third-target-selection-by-bristol-myers-squibb-triggering-milestone-miles-ctmx-20160120monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-reports-third-quarter-2015-financial-results-ctmx-20151123monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-opti-ctmx-20151014monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2026-financial-results-and-provides-corpora-tbph-20260507monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-p-tbph-20260319monthly0.5https://www.biopharmawatch.com/news/TBPH/e-xhibit-99-1-theravance-biopharma-reports-phase-3-cypress-study-did-not-meet-primary-endp-tbph-20260303monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-theravance-the-cross-star-logo-and-medicines-that-make-a-difference-a-tbph-20260112monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-theravance-the-cross-star-logo-and-medicines-that-make-a-difference-a-tbph-20251208monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2025-financial-results-and-provides-corpor-tbph-20250812monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-approval-of-yupelri-revefenacin-by-china-s-nmpa-yupelri-app-tbph-20250626monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-sells-remaining-royalty-interest-in-trelegy-ellipta-to-gsk-for-22-tbph-20250602monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2025-financial-results-and-provides-corpora-tbph-20250508monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-record-fourth-quarter-and-full-year-2024-financial-result-tbph-20250226monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2024-financial-results-and-announces-initia-tbph-20241112monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-theravance-the-cross-star-logo-and-medicines-that-make-a-difference-a-tbph-20240910monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2024-financial-results-and-provides-busine-tbph-20240730monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2024-financial-results-and-provides-busines-tbph-20240513monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2023-financial-results-and-p-tbph-20240226monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-results-from-the-phase-4-yupelri-pifr-2-study-in-patients-w-tbph-20240105monthly0.5https://www.biopharmawatch.com/news/TBPH/page-1-of-3-theravance-biopharma-inc-announces-appointment-of-jeremy-grant-to-board-of-dir-tbph-20231221monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2023-financial-results-and-provides-busines-tbph-20231107monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-theravance-the-cross-star-logo-and-medicines-that-make-a-difference-a-tbph-20230912monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2023-financial-results-and-provides-busine-tbph-20230807monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2023-financial-results-and-provides-busines-tbph-20230508monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-theravance-the-cross-star-logo-and-medicines-that-make-a-difference-a-tbph-20230417monthly0.5https://www.biopharmawatch.com/news/TBPH/continued-transformation-positions-theravance-biopharma-for-value-creation-the-board-and-m-tbph-20230228monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-strategic-actions-and-reports-fourth-quarter-full-year--tbph-20230227monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-highlights-2022-accomplishments-and-2023-key-targets-strategic-pr-tbph-20230109monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2022-financial-results-provides-business-up-tbph-20221107monthly0.5https://www.biopharmawatch.com/news/TBPH/ampreloxetine-data-in-neurogenic-orthostatic-hypotension-to-be-presented-at-the-33-rd-inte-tbph-20221102monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-theravance-the-cross-star-logo-and-medicines-that-make-a-difference-a-tbph-20220912monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2022-financial-results-and-provides-busine-tbph-20220720monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-sell-trelegy-ellipta-royalty-interests-to-royalty-pharma-for-appro-tbph-20220713monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2022-financial-results-and-provides-busines-tbph-20220505monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-results-from-study-0170-a-second-phase-3-study-of-ampre-tbph-20220404monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2021-financial-results-and-p-tbph-20220223monthly0.5https://www.biopharmawatch.com/news/TBPH/jp-morgan-healthcare-conference-tbph-20220113monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2021-financial-results-and-provides-busines-tbph-20211103monthly0.5https://www.biopharmawatch.com/news/TBPH/consulting-agreement-effective-tbph-20210930monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-strategic-actions-to-focus-on-respiratory-disease-portf-tbph-20210914monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-top-line-results-from-phase-2b-dose-finding-induction-s-tbph-20210823monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2021-financial-results-and-provides-busine-tbph-20210803monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-proposed-public-offering-of-ordinary-shares-dublin-irel-tbph-20210624monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-top-line-results-from-phase-2-study-of-nezulcitinib-in--tbph-20210621monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2021-financial-results-and-provides-busines-tbph-20210504monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2020-financial-results-and-p-tbph-20210223monthly0.5https://www.biopharmawatch.com/news/TBPH/jp-morgan-healthcare-conference-tbph-20210113monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2020-financial-results-and-provides-busines-tbph-20201105monthly0.5https://www.biopharmawatch.com/news/TBPH/corporate-overview-september-2020-theravance-biopharma-theravance-the-cross-star-logo-and--tbph-20200914monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2020-financial-results-and-provides-busine-tbph-20200806monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2020-financial-results-and-provides-busines-tbph-20200506monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-responds-to-covid-19-pandemic-by-advancing-td-0903-to-treat-hospitali-tbph-20200409monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-closing-of-private-placement-of-400-million-non-recourse-no-tbph-20200302monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2019-financial-results-and-p-tbph-20200224monthly0.5https://www.biopharmawatch.com/news/TBPH/summary-overview-theravance-biopharma-inc-theravance-biopharma-is-a-diversified-biopharmac-tbph-20200213monthly0.5https://www.biopharmawatch.com/news/TBPH/corporate-presentation-january-2020-theravance-the-cross-star-logo-and-medicines-that-make-tbph-20200113monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-pfizer-inc-enter-global-license-agreement-for-skin-targeted-local-tbph-20191223monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2019-financial-results-and-provides-busines-tbph-20191105monthly0.5https://www.biopharmawatch.com/news/TBPH/the-field-allows-up-to-17-characters-tbph-20190909monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-nasdaq-tbph-investor-presentation-tbph-20190904monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2019-financial-results-and-provides-busine-tbph-20190731monthly0.5https://www.biopharmawatch.com/news/TBPH/efficacy-durability-and-safety-of-ampreloxetine-a-norepinephrine-reuptake-inhibitor-given--tbph-20190618monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-nasdaq-tbph-investor-presentation-evercore-isi-webinar-tbph-20190614monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2019-financial-results-and-provides-busines-tbph-20190507monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2018-financial-results-and-p-tbph-20190226monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-nasdaq-tbph-investor-presentation-january-2019-theravance-the-cro-tbph-20190107monthly0.5https://www.biopharmawatch.com/news/TBPH/consulting-agreement-effective-tbph-20190102monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-closing-of-private-placement-of-250-million-of-9-non-recour-tbph-20181203monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-receive-fda-approval-for-yupelri-tm-revefenacin-in-adults-w-tbph-20181109monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2018-financial-results-and-provides-busines-tbph-20181106monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2018-financial-results-and-provides-busine-tbph-20180801monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2018-financial-results-and-provides-busines-tbph-20180508monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2018-financial-results-on-tbph-20180501monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2017-financial-results-and-p-tbph-20180227monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-enters-global-collaboration-with-janssen-for-td-1473-in-inflammatory--tbph-20180207monthly0.5https://www.biopharmawatch.com/news/TBPH/investor-presentation-january-2018-theravance-biopharma-inc-nasdaq-tbph-cautionary-stateme-tbph-20180108monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2017-financial-results-and-provides-busines-tbph-20171107monthly0.5https://www.biopharmawatch.com/news/TBPH/investor-presentation-august-2017-theravance-biopharma-inc-nasdaq-tbph-cautionary-statemen-tbph-20170809monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2017-financial-results-and-provides-busine-tbph-20170808monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-encouraging-data-from-first-cohort-of-patients-in-phase-1b-cl-tbph-20170808monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-positive-top-line-results-from-phase-2b-study-of-velusetrag-tbph-20170802monthly0.5https://www.biopharmawatch.com/news/TBPH/script-used-in-the-previously-announced-theravance-biopharma-inc-conference-call-held-tbph-20170509monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2017-financial-results-and-provides-busines-tbph-20170509monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2016-financial-results-and-p-tbph-20170227monthly0.5https://www.biopharmawatch.com/news/TBPH/investor-presentation-january-2017-theravance-biopharma-inc-nasdaq-tbph-cautionary-stateme-tbph-20170109monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2016-financial-results-and-provides-busines-tbph-20161108monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-proposed-public-offerings-of-100-million-of-ordinary-shares-tbph-20161026monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-positive-results-including-biomarker-data-from-phase-1-mult-tbph-20161025monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-announce-positive-results-from-two-pivotal-phase-3-studies--tbph-20161020monthly0.5https://www.biopharmawatch.com/news/TBPH/investor-presentation-september-2016-theravance-biopharma-inc-nasdaq-tbph-cautionary-state-tbph-20160907monthly0.5https://www.biopharmawatch.com/news/TBPH/gi-targeted-jak-inhibition-for-ulcerative-colitis-dr-brett-haumann-chief-medical-officer-u-tbph-20160614monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-closing-of-public-offering-of-its-ordinary-shares-dublin-ir-tbph-20160504monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-proposed-public-offering-of-its-ordinary-shares-theravance--tbph-20160502monthly0.5https://www.biopharmawatch.com/news/TBPH/cowen-and-company-36th-annual-health-care-conference-march-2016-theravance-biopharma-inc-n-tbph-20160309monthly0.5https://www.biopharmawatch.com/news/TBPH/investor-presentation-january-2016-theravance-biopharma-inc-nasdaq-tbph-under-the-safe-har-tbph-20151231monthly0.5https://www.biopharmawatch.com/news/TBPH/woodford-investment-management-to-make-55-tbph-20151026monthly0.5https://www.biopharmawatch.com/news/TBPH/investor-presentation-september-2015-theravance-biopharma-inc-nasdaq-tbph-theravance-the-c-tbph-20150909monthly0.5https://www.biopharmawatch.com/news/TBPH/investor-relations-presentation-august-2015-theravance-biopharma-inc-nasdaq-tbph-rick-e-wi-tbph-20150819monthly0.5https://www.biopharmawatch.com/news/TBPH/wedbush-pacgrow-healthcare-conference-tbph-20150812monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-nasdaq-tbph-rick-e-winningham-chief-executive-officer-bank-of-ame-tbph-20150512monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-announces-pricing-of-22-million-registered-direct-offering-seattle-wa-omer-20250725monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2023-financial-results-conference-call-today-at--omer-20230809monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2023-financial-results-conference-call-today-at-4-omer-20230509monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2022-financial-results-conference-c-omer-20230313monthly0.5https://www.biopharmawatch.com/news/OMER/l-omeros-corporation-receives-200-million-milestone-payment-from-rayner-surgical-omidria-r-omer-20230206monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2022-financial-results-conference-call-today-at-4-omer-20221109monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2022-financial-results-conference-call-today-at--omer-20220809monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2022-financial-results-conference-call-today-at-4-omer-20220510monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2021-financial-results-conference-c-omer-20220301monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-completes-sale-of-omidria-franchise-to-rayner-surgical-seattle-omer-20211223monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-agreement-to-sell-omidria-franchise-to-rayner-surgical-in-a-transaction-v-omer-20211202monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2021-financial-results-conference-call-today-at-4-omer-20211109monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-receives-complete-response-letter-from-fda-for-biologics-license-application-for-na-omer-20211018monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-provides-regulatory-update-on-biologics-license-application-for-narsoplimab-in-the--omer-20211001monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2021-financial-results-conference-call-today-at--omer-20210809monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-extension-of-fda-review-period-for-narsoplimab-in-hsct-tma-pdufa-date-is-omer-20210520monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2021-financial-results-conference-call-today-at-4-omer-20210510monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2020-financial-results-conference-c-omer-20210301monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2020-financial-results-seattle-wa-omer-20201109monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-pricing-of-public-offerings-6-900-000-shares-of-common-stock-210-000-000--omer-20200812monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2020-financial-results-seattle-wa-omer-20200810monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2020-financial-results-x2013-conference-call-toda-omer-20200511monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2019-financial-results-x2013-confer-omer-20200302monthly0.5https://www.biopharmawatch.com/news/OMER/omer-ex991-omeros-corporation-appoints-former-amazon-treasurer-kurt-zumwalt-to-board-of-di-omer-20200211monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-pricing-of-upsized-public-offering-of-common-stock-seattle-business-wire-omer-20191205monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2019-financial-results-x2013-conference-call-toda-omer-20191112monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2019-financial-results-x2013-conference-call-tod-omer-20190808monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2019-financial-results-conference-call-today-at-4-omer-20190509monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2018-financial-results-conference-c-omer-20190301monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-appoints-thomas-f-bumol-ph-d-to-board-of-directors-former-lilly-biotech-omer-20190212monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-announces-record-high-quarterly-revenue-results-for-the-fourth-quarter--omer-20190114monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2018-financial-results-conference-call-friday-nov-omer-20181108monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2018-financial-results-conference-call-today-at--omer-20180809monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-settlement-of-infringement-suit-against-anda-filer-lupin-lupin-confirms-v-omer-20180524monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2018-financial-results-conference-call-today-at-4-omer-20180510monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2017-financial-results-conference-c-omer-20180301monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2017-financial-results-conference-call-today-at-4-omer-20171109monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-settlement-of-infringement-suit-against-anda-filer-par-par-confirms-valid-omer-20171005monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-responds-to-statnews-com-story-seattle-wa-omer-20170823monthly0.5https://www.biopharmawatch.com/news/OMER/e-xhibit-99-1-omeros-announces-pricing-of-public-offering-of-common-stock-seattle-wa-omer-20170815monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-data-show-continued-improvement-in-patients-with-iga-nephropathy-treated-with-oms72-omer-20170814monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2017-financial-results-conference-call-today-at--omer-20170808monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2017-financial-results-conference-call-today-at-4-omer-20170510monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2016-financial-results-conference-c-omer-20170316monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2016-financial-results-conference-call-today-at-4-omer-20161109monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-pricing-of-public-offering-of-common-stock-seattle-wa-omer-20160811monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2016-financial-results-conference-call-today-at--omer-20160809monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2016-financial-results-conference-call-today-at-9-omer-20160510monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2015-financial-results-conference-c-omer-20160307monthly0.5https://www.biopharmawatch.com/news/OMER/disclosure-of-omidria-post-launch-study-findings-to-occur-at-hawaiian-eye-and-retina-confe-omer-20160115monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2015-financial-results-conference-call-today-at-4-omer-20151109monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2015-financial-results-conference-call-today-at--omer-20150810monthly0.5https://www.biopharmawatch.com/news/OMER/rajiv-shah-m-d-appointed-to-omeros-board-of-directors-seattle-wa-omer-20150617monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-exclusive-license-agreement-for-omeros-arthroscopic-product-oms103-u-s-sa-omer-20150616monthly0.5https://www.biopharmawatch.com/news/OMER/omidria-receives-positive-opinion-from-european-medicines-agency-s-committee-for-medicinal-omer-20150522monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2015-financial-results-omidria-now-widely-availab-omer-20150511monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2014-financial-results-4q-2014-net--omer-20150316monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-prices-75-million-public-offering-of-common-stock-and-pre-funded-warrants-seattle-w-omer-20150129monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2014-financial-results-omidria-u-s-commercial-lau-omer-20141110monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2014-financial-results-fda-approval-of-omidria-r-omer-20140811monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-receives-fda-approval-of-omidria-for-use-in-cataract-and-other-intraocular-lens-rep-omer-20140602monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2014-financial-results-secures-additional-50-4-mi-omer-20140512monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-prices-35-0-million-public-offering-of-common-stock-seattle-omer-20140314monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2013-financial-results-4q-2013-net--omer-20140313monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2013-financial-results-obtains-additional-17-4-mi-omer-20131107monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-settles-insurance-litigation-omeros-to-receive-12-5-million-seattle-omer-20131003monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-submits-oms302-marketing-authorization-application-to-european-medicines-agency-eur-omer-20130910monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2013-financial-results-seattle-wa-omer-20130809monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-submits-new-drug-application-to-u-s-fda-for-oms302-submission-of-european-marketing-omer-20130801monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-16-2-million-registered-direct-offering-of-common-stock-seattle-wa-omer-20130509monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2013-financial-results-seattle-wa-omer-20130510monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2012-financial-results-seattle-wa-omer-20130318monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-positive-oms302-safety-data-in-phase-3-clinical-trial-market-launch-expec-omer-20130122monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-reports-oms103hp-phase-3-clinical-trial-results-second-meniscectomyphase-3-clinical-omer-20121227monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2012-financial-results-seattle-wa-omer-20121109monthly0.5https://www.biopharmawatch.com/news/OMER/arnold-c-hanish-elected-to-board-of-directors-of-omeros-seattle-wa-omer-20120927monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2012-financial-results-seattle-wa-omer-20120807monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-prices-30-million-public-offering-of-common-stock-seattle-wa-omer-20120627monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2012-financial-results-seattle-wa-omer-20120510monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2011-financial-results-seattle-wa-m-omer-20120316monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-ophthalmology-product-oms302-achieves-primary-and-secondary-endpoints-in-phase-3-cl-omer-20120313monthly0.5https://www.biopharmawatch.com/news/OMER/biomed-realty-trust-inc-rick-howe-senior-director-corporate-communications-858-207-5859-co-omer-20120201monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2011-financial-results-seattle-wa-omer-20111108monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-second-quarter-2011-financial-results-seattle-wa-omer-20110809monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-first-quarter-2011-financial-results-seattle-wa-may-10-201-1-om-omer-20110510monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-reports-outcome-of-phase-3-trials-of-oms103hp-webcast-conference-call-scheduled-for-omer-20110331monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2010-financial-results-seattle-wa-omer-20110315monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-expansion-of-exclusive-license-to-pde7-inhibitors-from-daiichi-sankyo-pro-omer-20110222monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-completion-of-acquisition-of-assay-for-gpcr-program-seattle-wa-omer-20101123monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2010-financial-results-seattle-wa-omer-20101104monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-receives-20-million-from-vulcan-capital-and-5-million-grant-award-from-washington-s-omer-20101025monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-reports-second-quarter-2010-financial-results-seattle-wa-omer-20100810monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-secures-40-omer-20100729monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-reports-first-quarter-2010-financial-results-seattle-wa-omer-20100512monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-fourth-quarter-and-year-end-2009-financial-results-company-also-omer-20100331monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-licenses-pde7-compounds-for-parkinson-s-disease-program-seattle-washington-omer-20100309monthly0.5https://www.biopharmawatch.com/news/OMER/daniel-k-spiegelman-elected-to-board-of-directors-of-omeros-seattle-washington-omer-20091209monthly0.5https://www.biopharmawatch.com/news/OMER/omeros-corporation-reports-third-quarter-2009-financial-results-and-development-highlights-omer-20091119monthly0.5https://www.biopharmawatch.com/news/VOR/telitacicept-receives-nmpa-conditional-approval-for-the-treatment-of-iga-nephropathy-in-ch-vor-20260608monthly0.5https://www.biopharmawatch.com/news/VOR/global-science-one-purpose-44th-annual-j-p-morgan-healthcare-conference-january-2026-forwa-vor-20260112monthly0.5https://www.biopharmawatch.com/news/VOR/global-science-one-purpose-48-week-phase-3-clinical-trial-data-from-china-for-telitacicept-vor-20251028monthly0.5https://www.biopharmawatch.com/news/VOR/forward-looking-statement-this-presentation-the-presentation-contains-forward-looking-stat-vor-20250902monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-qing-zuraw-m-d-as-chief-development-officer-vor-20250717monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-veteran-biotech-executive-sandy-mahatme-as-chief-financial-officer-and-ch-vor-20250710monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-enters-into-exclusive-global-license-agreement-with-remegen-for-late-stage-autoimm-vor-20250625monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-exploration-of-strategic-alternatives-to-maximize-shareholder-value-vor-20250508monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-life-sciences-and-technology-investor-and-entrepreneur-mr-erez-kalir-to-i-vor-20250108monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-55-6-million-private-placement-intend-to-announce-updated-clinical-data--vor-20241227monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-provides-clinical-update-further-validating-approach-of-using-shielded-transplants-vor-20241209monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-seasoned-healthcare-institutional-investor-han-choi-m-d-ll-m-as-chief-fin-vor-20240930monthly0.5https://www.biopharmawatch.com/news/VOR/new-clinical-data-validates-vor-bio-s-approach-of-using-shielded-transplants-to-deliver-ta-vor-20240905monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-accomplished-oncology-and-cancer-immunotherapy-r-d-executive-fouad-namoun-vor-20240502monthly0.5https://www.biopharmawatch.com/news/VOR/this-presentation-the-presentation-contains-forward-looking-statements-within-the-meaning--vor-20240105monthly0.5https://www.biopharmawatch.com/news/VOR/multiple-clinical-and-preclinical-presentations-at-ash-2023-highlight-vor-bio-s-novel-ehsc-vor-20231102monthly0.5https://www.biopharmawatch.com/news/VOR/successful-primary-engraftment-of-trem-cel-in-first-five-aml-patients-demonstrates-promise-vor-20230609monthly0.5https://www.biopharmawatch.com/news/VOR/first-aml-patient-transplanted-with-vor-bio-s-trem-cel-demonstrated-durable-engraftment-th-vor-20230216monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-prices-underwritten-offering-of-common-stock-and-concurrent-private-placement-for--vor-20221207monthly0.5https://www.biopharmawatch.com/news/VOR/first-aml-patient-successfully-transplanted-with-vor-bio-s-investigational-trem-cel-vor33--vor-20221207monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-build-out-state-of-the-art-clinical-manufacturing-facility-capable-of-supporting-mu-vor-20210617monthly0.5https://www.biopharmawatch.com/news/VOR/vor-biopharma-closes-over-200m-initial-public-offering-including-full-exercise-of-option-t-vor-20210209monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights-accelerat-spry-20250813monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-reports-first-quarter-2025-financial-results-and-highlights-progress-i-spry-20250514monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-spry-20250320monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-preliminary-fourth-quarter-2024-financial-results-and-2025-o-spry-20250115monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-upd-spry-20241113monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-update-neffy-approval-spry-20240812monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-provides-business-highlights-and-reports-second-quarter-2024-financial-spry-20240806monthly0.5https://www.biopharmawatch.com/news/SPRY/forward-looking-statements-statements-in-this-presentation-that-are-not-purely-historical--spry-20240628monthly0.5https://www.biopharmawatch.com/news/SPRY/forward-looking-statements-statements-in-this-presentation-that-are-not-purely-historical--spry-20240510monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-highlights-neffy-regulatory-progress-and-reports-first-quarter-2024-fi-spry-20240509monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2023-spry-20240321monthly0.5https://www.biopharmawatch.com/news/SPRY/neffy-investor-day-spry-20240307monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-business-upd-spry-20231109monthly0.5https://www.biopharmawatch.com/news/SPRY/forward-looking-statements-this-presentation-contains-forward-looking-statements-which-inc-spry-20230925monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-reports-second-quarter-2023-financial-results-and-provides-business-updates-ars-contin-spry-20230810monthly0.5https://www.biopharmawatch.com/news/SPRY/forward-looking-statements-this-presentation-contains-forward-looking-statements-which-inc-spry-20230516monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-highlights-progress-and-reports-first-quarter-2023-financial-results-f-spry-20230515monthly0.5https://www.biopharmawatch.com/news/SPRY/fda-briefing-document-nda-bla-214697-drug-name-ars-1-intranasal-epinephrine-applicant-ars--spry-20230511monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-highlights-progress-and-reports-fourth-quarter-and-full-year-2022-fina-spry-20230323monthly0.5https://www.biopharmawatch.com/news/SPRY/the-first-no-needle-no-injection-solution-for-type-i-allergic-reactions-q1-2023-1-forward--spry-20230313monthly0.5https://www.biopharmawatch.com/news/SPRY/forward-looking-statements-this-presentation-contains-forward-looking-statements-which-inc-spry-20230214monthly0.5https://www.biopharmawatch.com/news/SPRY/forward-looking-statements-this-presentation-contains-forward-looking-statements-which-inc-spry-20221206monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-closes-merger-with-silverback-therapeutics-over-280-million-in-combine-spry-20221108monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-inc-announces-the-fda-s-acceptance-of-ars-pharmaceuticals-nda-for--spry-20221021monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-and-ars-pharmaceuticals-announce-merger-transaction-to-support-pot-spry-20220721monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-spry-20220512monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-updates-strategic-priorities-and-reports-fourth-quarter-and-full-y-spry-20220331monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-spry-20211110monthly0.5https://www.biopharmawatch.com/news/SPRY/forward-looking-statements-and-disclaimers-any-reproduction-or-distribution-of-this-presen-spry-20210916monthly0.5https://www.biopharmawatch.com/news/SPRY/title-results-of-an-ongoing-phase-1-1b-study-of-sbt6050-as-monotherapy-and-combined-with-p-spry-20210913monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-reports-second-quarter-2021-financial-results-and-provides-busines-spry-20210812monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-reports-first-quarter-2021-financial-results-seattle-spry-20210513monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-re-spry-20210329monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-announces-the-appointment-of-dr-maria-koehler-to-its-board-of-dire-spry-20210315monthly0.5https://www.biopharmawatch.com/news/SPRY/silverback-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of--spry-20201208monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-third-quarter-2025-financial-results-and-recent-business-highlig-anro-20251112monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-announces-50-million-private-placement-financing-financing-led-by-percep-anro-20251020monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-second-quarter-2025-financial-results-and-recent-business-highli-anro-20250813monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-identifies-biomarker-and-reports-positive-pharmacodynamic-results-from-e-anro-20250626monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-announces-acquisition-of-novel-dopamine-agonist-combination-product-cand-anro-20250603monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-first-quarter-2025-financial-results-and-recent-business-highlig-anro-20250514monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-full-year-2024-financial-results-and-recent-business-highlights--anro-20250320monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-announces-favorable-outcome-from-interim-analysis-of-alto-300-phase-2b-m-anro-20250212monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-third-quarter-2024-financial-results-and-recent-business-highlig-anro-20241112monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-topline-results-from-a-phase-2b-trial-evaluating-alto-100-as-a-t-anro-20241022monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-second-quarter-2024-financial-results-and-recent-business-highli-anro-20240813monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-first-quarter-2024-financial-results-and-recent-business-highlig-anro-20240514monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-full-year-2023-financial-results-and-recent-business-highlights--anro-20240229monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-quarter-financial-results-q1-reported-revenue-of-132-1-million-inc-bvs-20260506monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-third-quarter-financial-results-q3-reported-revenue-of-138-7-million-was-bvs-20251104monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-second-quarter-financial-results-q2-reported-revenue-of-147-7-million-de-bvs-20250806monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-quarter-financial-results-q1-reported-revenue-of-123-9-million-dec-bvs-20250506monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-fourth-quarter-and-full-year-2024-financial-results-accelerated-fourth-bvs-20250311monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-completes-divestiture-of-its-advanced-rehabilitation-business-to-accelmed-partne-bvs-20250102monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-third-quarter-financial-results-q3-revenue-advanced-by-15-0-fourth-strai-bvs-20241105monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-divestiture-of-its-advanced-rehabilitation-business-to-accelmed-partne-bvs-20241001monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-second-quarter-financial-results-q2-revenue-advanced-by-10-3-organic-gro-bvs-20240806monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-quarter-financial-results-raises-full-year-2024-financial-guidance-bvs-20240507monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-fourth-quarter-and-full-year-2023-financial-results-accelerated-fourth-bvs-20240312monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-names-robert-claypoole-as-president-and-chief-executive-officer-seasoned-leader--bvs-20231219monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-third-quarter-financial-results-raises-full-year-2023-financial-guidance-bvs-20231107monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-second-quarter-financial-results-introduces-full-year-2023-financial-gui-bvs-20230808monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-completes-divestiture-of-its-wound-business-bvs-20230523monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-quarter-financial-results-durham-nc-bvs-20230516monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-divestiture-of-its-wound-business-durham-n-c-bvs-20230510monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-fourth-quarter-and-full-year-2022-financial-results-durham-nc-bvs-20230331monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-issues-revised-third-quarter-results-updates-full-year-2022-financial-guidance-d-bvs-20221121monthly0.5https://www.biopharmawatch.com/news/BVS/document-bioventus-files-for-extension-to-file-form-10-q-for-the-period-ended-bvs-20221116monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-third-quarter-results-updates-full-year-2022-financial-guidance-durham-n-bvs-20221108monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-second-quarter-results-updates-full-year-2022-financial-guidance-durham--bvs-20220811monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-quarter-results-reaffirms-full-year-2022-financial-guidance-durham-bvs-20220510monthly0.5https://www.biopharmawatch.com/news/BVS/news-bioventus-announces-preliminary-first-quarter-net-sales-and-adjusted-bvs-20220426monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-fourth-quarter-and-full-year-2021-financial-results-introduces-full-year-bvs-20220310monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-preliminary-fourth-quarter-and-full-year-2021-revenue-durham-nc-bvs-20220111monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-third-quarter-results-updates-full-year-2021-financial-guidance-durham-n-bvs-20211109monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-4721-emperor-blvd-suite-100-durham-nc-27703-usa-news-bioventus-completes-the-acq-bvs-20211029monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-and-misonix-stockholders-approve-the-acquisition-of-misonix-by-bioventus-durham--bvs-20211026monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-second-quarter-results-updates-full-year-2021-financial-guidance-durham--bvs-20210810monthly0.5https://www.biopharmawatch.com/news/BVS/execution-version-voting-and-support-agreement-this-voting-and-support-agreement-this-agre-bvs-20210729monthly0.5https://www.biopharmawatch.com/news/BVS/document-bioventus-inc-reports-preliminary-second-quarter-net-sales-updates-full-year-2021-bvs-20210729monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-reports-first-quarter-results-updates-full-year-2021-financial-guidance-durh-bvs-20210512monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-4721-emperor-blvd-suite-100-durham-nc-27703-usa-news-bioventus-acquires-bioness--bvs-20210330monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-reports-fourth-quarter-and-full-year-2020-financial-results-introduces-full--bvs-20210325monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-reports-full-year-2025-financial-results-and-provides-business-updates-from-th-bioa-20260324monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-announces-pricing-of-upsized-115-0-million-public-offering-bioa-20260121monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-reports-third-quarter-2025-financial-results-and-provides-business-updates-fir-bioa-20251106monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-reports-second-quarter-2025-financial-results-and-provides-business-updates-or-bioa-20250806monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-reports-first-quarter-2025-financial-results-and-provides-business-updates-x25-bioa-20250506monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-reports-full-year-2024-financial-results-and-provides-business-updates-from-th-bioa-20250320monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-unaudited-condensed-consolidated-balance-sheets-in-thousands-september-30-bioa-20241107monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-reports-first-quarter-2026-results-returns-to-positive-comp-growth-in-q1-validating--woof-20260603monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-reports-fourth-quarter-and-full-year-2025-results-delivers-profitability-ahead-of-ou-woof-20260311monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-announces-completion-of-refinancing-and-glenn-murphy-s-transition-to-chairman-woof-20260202monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-announces-pricing-of-its-600-000-000-offering-of-senior-secured-notes-woof-20260122monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-announces-650-000-000-offering-of-senior-secured-notes-woof-20260121monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-announces-launch-of-debt-refinancing-transaction-reaffirms-fourth-quarter-and-full-f-woof-20260112monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-reports-third-quarter-2025-financial-results-upwardly-revises-fiscal-2025-earnings-o-woof-20251125monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-reports-second-quarter-2025-financial-results-raises-fiscal-2025-earnings-outlook-sa-woof-20250828monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-to-present-at-goldman-sachs-global-retailing-conference-on-woof-20250821monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-tina-romani-lisa-stark-investorrelations-petco-com-lisa-woof-20250605monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-tina-romani-lisa-stark-investorrelations-petco-com-lisa-woof-20250326monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-strengthens-leadership-team-with-appointment-of-three-proven-executives-sabrina-simm-woof-20250218monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-investorrelations-petco-com-media-relations-lisa-stark-petco-com-for-im-woof-20241205monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-investorrelations-petco-com-media-relations-benjamin-thiele-long-benjam-woof-20240910monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-names-joel-d-anderson-as-chief-executive-officer-30-year-retail-industry-veteran-nam-woof-20240717monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-health-wellness-company-inc-announces-evolution-of-leadership-team-appoints-james-ro-woof-20240528monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-investorrelations-petco-com-benjamin-thiele-long-benjam-woof-20240522monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-health-wellness-company-inc-announces-appointment-of-glenn-murphy-as-executive-chair-woof-20240514monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-cathy-yao-cathy-yao-petco-com-media-relations-benjamin-thiele-long-benj-woof-20240313monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-to-participate-in-the-ubs-global-consumer-and-retail-conference-woof-20240226monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-investorrelations-petco-com-benjamin-thiele-long-benjam-woof-20231129monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-cathy-yao-benjamin-thiele-long-cathy-yao-petco-com-benj-woof-20230915monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-cathy-yao-benjamin-thiele-long-cathy-yao-petco-com-benj-woof-20230908monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-cathy-yao-benjamin-thiele-long-cathy-yao-petco-com-benj-woof-20230824monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-health-wellness-company-inc-woof-20230524monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-health-wellness-company-inc-woof-20230322monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-to-participate-in-the-25-th-annual-needham-growth-conference-woof-20230104monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-updates-time-for-participation-in-morgan-stanley-global-consumer-retail-conference-woof-20221202monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-to-participate-in-the-morgan-stanley-global-consumer-retail-conference-woof-20221201monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-health-wellness-company-inc-reports-third-quarter-earnings-x2022-comparable-sales-gr-woof-20221130monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-to-present-at-goldman-sachs-29-th-annual-global-retailing-conference-woof-20220906monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-investorrelations-petco-com-media-relations-benjamin-thiele-long-benjam-woof-20220824monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-evolves-organizational-design-to-enable-next-phase-of-growth-woof-20220809monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-investorrelations-petco-com-benjamin-thiele-long-benjam-woof-20220524monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-health-wellness-company-inc-announces-long-term-strategic-priorities-as-it-shapes-th-woof-20220323monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-kristy-moser-ventura-olvera-kristine-moser-petco-com-ve-woof-20220308monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-health-and-wellness-company-inc-to-host-inaugural-investor-day-on-woof-20220302monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-the-retail-leader-in-premium-fresh-frozen-expands-unique-partnership-with-justfoodfo-woof-20220301monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-appoints-digital-strategy-leader-iris-yen-as-board-advisor-and-observer-woof-20211206monthly0.5https://www.biopharmawatch.com/news/WOOF/media-relations-investor-relations-ventura-olvera-kristy-moser-ventura-olvera-petco-com-kr-woof-20211206monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-kristy-moser-ventura-olvera-kristine-moser-petco-com-ve-woof-20211119monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-kristy-moser-kristine-moser-petco-com-media-relations-ventura-olvera-ve-woof-20211118monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-kristy-moser-ventura-olvera-kristine-moser-petco-com-ve-woof-20210915monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-kristy-moser-ventura-olvera-kristine-moser-petco-com-ve-woof-20210908monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-health-and-wellness-company-inc-appoints-brian-larose-as-chief-financial-officer-lar-woof-20210819monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-kristy-moser-ventura-olvera-kristine-moser-petco-com-ve-woof-20210819monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-kristy-moser-ventura-olvera-kristine-moser-petco-com-ve-woof-20210614monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-kristy-moser-kristine-moser-petco-com-media-relations-ventura-olvera-ve-woof-20210609monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-kristy-moser-ventura-olvera-kristine-moser-petco-com-ve-woof-20210520monthly0.5https://www.biopharmawatch.com/news/WOOF/investor-relations-media-relations-kristy-moser-ventura-olvera-kristine-moser-petco-com-ve-woof-20210318monthly0.5https://www.biopharmawatch.com/news/WOOF/petco-announces-successful-completion-of-debt-refinancing-transaction-solidifying-its-capi-woof-20210305monthly0.5https://www.biopharmawatch.com/news/CBLL/30-2025-rebecca-robertson-board-chair-ceribell-360-n-pastoria-avenue-sunnyvale-ca-94085-us-cbll-20251231monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-receives-fda-510-k-clearance-for-first-of-its-kind-delirium-monitoring-solution-n-cbll-20251209monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-receives-fda-510-k-clearance-for-use-of-clarity-x24c7-algorithm-for-neonates-beco-cbll-20251124monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-reports-second-quarter-2025-financial-results-cbll-20250805monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-reports-first-quarter-2025-financial-results-cbll-20250508monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-reports-fourth-quarter-and-full-year-2024-financial-results-sunnyvale-calif-x2013-cbll-20250225monthly0.5https://www.biopharmawatch.com/news/CBLL/corporate-presentation-january-2025-forward-looking-statement-this-presentation-contains-f-cbll-20250113monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-reports-third-quarter-2024-financial-results-sunnyvale-ca-x2013-cbll-20241112monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-be-acquired-by-archimed-esperion-shareholders-to-receive-3-16-per-share-in-cas-espr-20260501monthly0.5https://www.biopharmawatch.com/news/ESPR/structure-and-function-of-aclyi-fully-enables-rational-drug-design-and-the-opportunity-to--espr-20251104monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-proposed-public-offering-of-common-stock-espr-20251007monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-corporate-presentation-xa9-2025-esperion-therapeutics-inc-all-rights-reserved-oct-espr-20251007monthly0.5https://www.biopharmawatch.com/news/ESPR/about-esperion-therapeutics-esperion-therapeutics-inc-is-a-commercial-stage-biopharmaceuti-espr-20250401monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-210-espr-20241213monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-monetization-of-european-royalties-and-concurrent-payoff-and-terminatio-espr-20240628monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-proposed-public-offering-of-common-stock-espr-20240118monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-presents-results-from-clear-outcomes-primary-prevention-analysis-at-83-rd-america-espr-20230624monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-56-7-million-registered-direct-offering-priced-at-the-market-under-nasd-espr-20230320monthly0.5https://www.biopharmawatch.com/news/ESPR/landmark-clear-outcomes-study-demonstrates-nexletol-bempedoic-acid-tablet-is-the-only-ldl--espr-20230306monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-company--espr-20230221monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-outlines-upcoming-milestones-and-announces-preliminary-fourth-quarter-2022-financ-espr-20230108monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-ben-halladay-chief-financial-officer-espr-20221116monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-third-quarter-2022-financial-results-and-provides-company-update-clear-ou-espr-20221101monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-second-quarter-2022-financial-results-and-provides-company-update-achieve-espr-20220802monthly0.5https://www.biopharmawatch.com/news/ESPR/statements-forward-looking-statements-involve-risks-and-uncertainties-that-could-cause-esp-espr-20220601monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-first-quarter-2022-financial-results-and-provides-company-update-unpreced-espr-20220503monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-the-appointment-of-stephen-rocamboli-to-its-board-of-directors-espr-20220428monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-company--espr-20220222monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-preliminary-fourth-quarter-2021-financial-results-and-clear-outcomes-pro-espr-20220111monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-benjamin-o-looker-as-general-counsel-addition-to-management-team-brings--espr-20220104monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-proposed-public-offering-espr-20211202monthly0.5https://www.biopharmawatch.com/news/ESPR/ben-church-bchurch-esperion-com-734-864-6774-esperion-reports-third-quarter-2021-financial-espr-20211102monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-the-appointment-of-seth-h-z-fischer-to-its-board-of-directors-espr-20211101monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-agreement-to-exchange-15-million-in-principal-amount-of-its-4-00-conver-espr-20211025monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-plan-for-transformative-long-term-growth-optimizes-organizational-struc-espr-20211018monthly0.5https://www.biopharmawatch.com/news/ESPR/kaitlyn-brosco-esperion-corporateteam-esperion-com-esperion-reports-second-quarter-2021-fi-espr-20210803monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-joanne-micale-foody-md-facc-faha-as-chief-medical-officer-espr-20210628monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-sheldon-koenig-as-president-and-ceo-mr-koenig-has-30-years-of-commercial-espr-20210517monthly0.5https://www.biopharmawatch.com/news/ESPR/kaitlyn-brosco-esperion-corporateteam-esperion-com-esperion-reports-first-quarter-2021-fin-espr-20210504monthly0.5https://www.biopharmawatch.com/news/ESPR/ben-church-esperion-corporateteam-esperion-com-esperion-expands-partnership-with-daiichi-s-espr-20210426monthly0.5https://www.biopharmawatch.com/news/ESPR/kaitlyn-brosco-esperion-corporateteam-esperion-com-esperion-reports-fourth-quarter-and-ful-espr-20210223monthly0.5https://www.biopharmawatch.com/news/ESPR/kaitlyn-brosco-esperion-corporateteam-esperion-com-esperion-reports-preliminary-fourth-qua-espr-20210113monthly0.5https://www.biopharmawatch.com/news/ESPR/false000143486800014348682020-12-162020-12-16-espr-20201216monthly0.5https://www.biopharmawatch.com/news/ESPR/ben-church-esperion-bchurch-esperion-com-734-864-6774-esperion-appoints-sheldon-koenig-as--espr-20201215monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-private-offering-of-200-0-million-of-convertible-senior-subordinated-no-espr-20201110monthly0.5https://www.biopharmawatch.com/news/ESPR/kaitlyn-brosco-esperion-investorrelations-esperion-com-esperion-reports-third-quarter-2020-espr-20201102monthly0.5https://www.biopharmawatch.com/news/ESPR/ben-church-esperion-734-864-6774-bchurch-esperion-com-esperion-reports-second-quarter-2020-espr-20200810monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20200622monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20200506monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20200420monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-april-2020-corporate-overview-safe-harbor-forward-looking-statements-this-present-espr-20200330monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20200406monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-fda-approval-of-the-nexlizet-bempedoic-acid-and-ezetimibe-tablet-an-ora-espr-20200226monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20200221monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20200131monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20191106monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20190829monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20190808monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20190626monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20190508monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20190506monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20190228monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20190104monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20181101monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-top-line-results-from-final-pivotal-phase-3-study-of-bempedoic-espr-20181028monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-top-line-results-from-pivotal-phase-3-bempedoic-acid-ezetimibe-espr-20180827monthly0.5https://www.biopharmawatch.com/news/ESPR/investor-contact-alex-schwartz-esperion-734-249-3386-aschwartz-esperion-com-media-contact--espr-20180802monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-alex-schwartz-esperio-espr-20180523monthly0.5https://www.biopharmawatch.com/news/ESPR/exhib-it-99-1-study-1-pivotal-phase-1002-040-3-long-term-safety-study-supplemental-materia-espr-20180508monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-audrey-gross-w20-grou-espr-20180502monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-audrey-gross-w2o-grou-espr-20180327monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-audrey-gross-w2o-grou-espr-20180307monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-audrey-gross-w20-grou-espr-20180220monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20171107monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20170808monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20170726monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20170626monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20170504monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20170320monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20170307monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20170222monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20170108monthly0.5https://www.biopharmawatch.com/news/ESPR/audrey-gross-w2o-group-212-301-7214-agross-w2ogroup-com-investor-contact-mindy-lowe-esperi-espr-20161103monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20161013monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-12-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-th-espr-20160804monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20160628monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20160504monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20160225monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20160112monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20151105monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20150928monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20150817monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20150806monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20150728monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20150707monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-barbara-ryan-clermont-espr-20150507monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20150317monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20150305monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20150202monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20141110monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-mindy-lowe-esperion-t-espr-20141014monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-announces-positive-top-line-phase-2b-results-for-etc-1002-an-investi-espr-20141001monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-jordan-kohnstam-westw-espr-20140812monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-investor-contact-jordan-kohnstam-westw-espr-20140512monthly0.5https://www.biopharmawatch.com/news/ESPR/elliot-fox-w2o-group-212-257-6724-efox-w2ogroup-com-esperion-therapeutics-provides-etc-100-espr-20140305monthly0.5https://www.biopharmawatch.com/news/ESPR/media-and-investor-contact-denise-powell-brewlife-510-703-9491-dpowell-brewlife-com-esperi-espr-20131106monthly0.5https://www.biopharmawatch.com/news/ESPR/jessica-volchok-brewlife-310-774-3423-jvolchok-brewlife-com-esperion-therapeutics-announce-espr-20131030monthly0.5https://www.biopharmawatch.com/news/ESPR/denise-powell-brewlife-510-703-9491-dpowell-brewlife-com-esperion-therapeutics-announces-p-espr-20130903monthly0.5https://www.biopharmawatch.com/news/ESPR/media-and-investor-contact-denise-powell-brewlife-510-703-9491-dpowell-brewlife-com-esperi-espr-20130812monthly0.5https://www.biopharmawatch.com/news/SGP/amended-all-statements-in-this-press-release-that-are-not-purely-historical-are-forward-lo-sgp-20260309monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2025-financial-results-and-recent-business-highlig-gern-20251105monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2025-financial-results-and-recent-business-highli-gern-20250806monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2025-financial-results-and-recent-business-highlig-gern-20250507monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-b-gern-20250226monthly0.5https://www.biopharmawatch.com/news/GERN/corporate-presentation-our-mission-is-to-change-lives-by-changing-the-course-of-blood-canc-gern-20241231monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2024-financial-results-and-recent-business-highlig-gern-20241107monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2024-financial-results-and-business-highlights-u--gern-20240808monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-fda-approval-of-rytelo-imetelstat-a-first-in-class-telomerase-inhibitor-fo-gern-20240607monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2024-financial-results-and-business-highlights-gern-20240502monthly0.5https://www.biopharmawatch.com/news/GERN/risk-factor-summary-below-is-a-summary-of-material-factors-that-make-an-investment-in-our--gern-20240319monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-fda-oncologic-drugs-advisory-committee-votes-in-favor-of-the-clinical-bene-gern-20240314monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-business-highlights-and-fourth-quarter-and-full-year-2023-financ-gern-20240228monthly0.5https://www.biopharmawatch.com/news/GERN/company-logo-enhancing-the-lives-of-patients-with-hematologic-malignancies-corporate-prese-gern-20231231monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-business-highlights-and-third-quarter-2023-financial-results-ime-gern-20231102monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-business-highlights-and-second-quarter-2023-financial-results-su-gern-20230803monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2023-financial-results-and-business-highlights-pla-gern-20230511monthly0.5https://www.biopharmawatch.com/news/GERN/nd-annual-needham-virtual-healthcare-conference-slides-gern-20230420monthly0.5https://www.biopharmawatch.com/news/GERN/in-the-court-of-chancery-of-the-state-of-delaware-in-re-geron-corporation-stockholder-deri-gern-20230317monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-full-year-2022-financial-results-and-upcoming-gern-20230316monthly0.5https://www.biopharmawatch.com/news/GERN/by-these-cautionary-statements-company-overview-summary-we-are-a-late-stage-biopharmaceuti-gern-20230104monthly0.5https://www.biopharmawatch.com/news/GERN/in-the-court-of-chancery-of-the-state-of-delaware-in-re-geron-corporation-stockholder-deri-gern-20221221monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2022-financial-results-and-upcoming-expected-miles-gern-20221103monthly0.5https://www.biopharmawatch.com/news/GERN/stipulation-and-agreement-of-settlement-dated-gern-20220902monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20220811monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20220509monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20220310monthly0.5https://www.biopharmawatch.com/news/GERN/january-2022-gern-20220110monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20211109monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20210816monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20210510monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20210311monthly0.5https://www.biopharmawatch.com/news/GERN/january-2021-gern-20210108monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20201105monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20200806monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20200528monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20200402monthly0.5https://www.biopharmawatch.com/news/GERN/dated-march-12-2020-geron-corporation-reports-fourth-quarter-and-full-year-2019-financial--gern-20200312monthly0.5https://www.biopharmawatch.com/news/GERN/january-2020-gern-20200113monthly0.5https://www.biopharmawatch.com/news/GERN/dated-gern-20191218monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20191106monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20190801monthly0.5https://www.biopharmawatch.com/news/GERN/geron-provides-imetelstat-program-update-conference-call-scheduled-for-9-00-a-m-et-today-gern-20190516monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20190502monthly0.5https://www.biopharmawatch.com/news/GERN/dated-march-7-2019-geron-corporation-reports-fourth-quarter-and-full-year-2018-financial-r-gern-20190307monthly0.5https://www.biopharmawatch.com/news/GERN/january-2019-gern-20190107monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20181101monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20180927monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20180731monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20180510monthly0.5https://www.biopharmawatch.com/news/GERN/p-ress-r-elease-d-ated-m-arch-16-2018-geron-corporation-reports-fourth-quarter-and-annual--gern-20180316monthly0.5https://www.biopharmawatch.com/news/GERN/january-2018-gern-20180108monthly0.5https://www.biopharmawatch.com/news/GERN/dated-december-12-2017-geron-reports-imetelstat-presentations-at-american-society-of-hemat-gern-20171212monthly0.5https://www.biopharmawatch.com/news/GERN/p-ress-r-elease-d-ated-n-ovember-1-2017-geron-corporation-reports-third-quarter-2017-finan-gern-20171101monthly0.5https://www.biopharmawatch.com/news/GERN/dated-november-1-2017-geron-announces-presentations-at-american-society-of-hematology-annu-gern-20171101monthly0.5https://www.biopharmawatch.com/news/GERN/p-ress-r-elease-d-ated-a-ugust-9-2017-geron-corporation-reports-second-quarter-2017-financ-gern-20170809monthly0.5https://www.biopharmawatch.com/news/GERN/dated-gern-20170731monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20170509monthly0.5https://www.biopharmawatch.com/news/GERN/dated-gern-20170410monthly0.5https://www.biopharmawatch.com/news/GERN/stipulation-and-agreement-of-settlement-richard-w-gonnello-admitted-pro-hac-vice-megan-m-s-gern-20170303monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20170301monthly0.5https://www.biopharmawatch.com/news/GERN/january-2017-gern-20170109monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20161103monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20160912monthly0.5https://www.biopharmawatch.com/news/GERN/summary-notice-of-proposed-settlement-robbins-arroyo-llp-brian-j-robbins-190264-craig-w-sm-gern-20160825monthly0.5https://www.biopharmawatch.com/news/GERN/dated-august-3-2016-gern-20160803monthly0.5https://www.biopharmawatch.com/news/GERN/p-ress-r-elease-d-ated-m-ay-5-2016-geron-corporation-reports-first-quarter-2016-financial--gern-20160505monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20160225monthly0.5https://www.biopharmawatch.com/news/GERN/january-2016-gern-20160111monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20151105monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20150805monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20150430monthly0.5https://www.biopharmawatch.com/news/GERN/of-geron-s-current-report-on-form-8-k-filed-on-gern-20150303monthly0.5https://www.biopharmawatch.com/news/GERN/january-2015-gern-20150112monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-early-hsr-clearance-for-global-strategic-collaboration-with-janssen-menlo--gern-20141216monthly0.5https://www.biopharmawatch.com/news/GERN/stifel-2014-gern-20141118monthly0.5https://www.biopharmawatch.com/news/GERN/risk-factors-our-business-is-subject-to-various-risks-and-uncertainties-that-may-have-a-ma-gern-20141113monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-removal-of-full-clinical-hold-on-imetelstat-ind-2014-third-quarter-and-yea-gern-20141103monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2014-financial-results-conference-call-scheduled--gern-20140811monthly0.5https://www.biopharmawatch.com/news/GERN/dated-june-12-2014-geron-reports-removal-of-partial-clinical-hold-on-myelofibrosis-ist-men-gern-20140612monthly0.5https://www.biopharmawatch.com/news/GERN/jefferies-2014-gern-20140602monthly0.5https://www.biopharmawatch.com/news/GERN/dated-gern-20140509monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2014-financial-results-conference-call-scheduled-f-gern-20140501monthly0.5https://www.biopharmawatch.com/news/GERN/dated-march-20-2014-geron-reports-myelofibrosis-ist-placed-on-partial-clinical-hold-patien-gern-20140320monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-ind-clinical-hold-affecting-clinical-trials-of-imetelstat-in-essential-thr-gern-20140312monthly0.5https://www.biopharmawatch.com/news/GERN/forward-looking-statements-this-current-report-on-form-8-k-or-form-8-k-contains-forward-lo-gern-20140130monthly0.5https://www.biopharmawatch.com/news/GERN/slides-presented-at-ash-2013-gern-20131210monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20131107monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2013-financial-results-provides-update-on-investi-gern-20130808monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20130425monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20130312monthly0.5https://www.biopharmawatch.com/news/GERN/j-p-morgan-healthcare-conference-2013-presentation-gern-20130107monthly0.5https://www.biopharmawatch.com/news/GERN/to-geron-s-current-report-on-form-8-k-filed-on-gern-20121009monthly0.5https://www.biopharmawatch.com/news/GERN/risk-factors-our-business-is-subject-to-various-risks-including-those-described-below-you--gern-20121009monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20120917monthly0.5https://www.biopharmawatch.com/news/GERN/dated-september-10-2012-geron-provides-update-on-imetelstat-clinical-development-program-c-gern-20120910monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-2012-second-quarter-financial-results-and-events-gern-20120731monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20120502monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20120307monthly0.5https://www.biopharmawatch.com/news/GERN/jpmorgan-2012-presentation-gern-20120111monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20120105monthly0.5https://www.biopharmawatch.com/news/GERN/a-tribute-to-alex-barkas-palo-alto-calif-business-wire-gern-20111123monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-2011-third-quarter-financial-results-and-events-menlo-park-calif-gern-20111103monthly0.5https://www.biopharmawatch.com/news/GERN/press-release-dated-gern-20110929monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-2011-second-quarter-financial-results-and-events-menlo-park-cali-gern-20110728monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-2011-first-quarter-financial-results-and-highlights-menlo-park-c-gern-20110427monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-annual-2010-financial-results-summary-of-2010-gern-20110224monthly0.5https://www.biopharmawatch.com/news/GERN/geron-appoints-david-greenwood-president-interim-ceo-and-director-new-leadership-structure-gern-20110209monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-announces-closing-of-its-public-offering-of-common-stock-menlo-park-cali-gern-20101210monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-announces-the-pricing-of-its-public-offering-of-common-stock-menlo-park--gern-20101207monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-announces-proposed-public-offering-of-common-stock-menlo-park-calif-busi-gern-20101206monthly0.5https://www.biopharmawatch.com/news/GERN/geron-expands-clinical-oncology-pipeline-with-license-and-collaboration-agreements-with-an-gern-20101206monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-2010-third-quarter-financial-results-and-events-menlo-park-calif-gern-20101028monthly0.5https://www.biopharmawatch.com/news/GERN/geron-initiates-clinical-trial-of-human-embryonic-stem-cell-based-therapy-in-patients-with-gern-20101011monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-proceed-with-first-human-clinical-trial-of-embryonic-stem-cell-based-therapy-gero-gern-20100730monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-2010-second-quarter-financial-results-and-events-menlo-park-cali-gern-20100729monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-2010-first-quarter-financial-results-and-highlights-menlo-park-c-gern-20100428monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-annual-2009-financial-results-and-highlights--gern-20100225monthly0.5https://www.biopharmawatch.com/news/GERN/of-geron-corporation-dated-gern-20100115monthly0.5https://www.biopharmawatch.com/news/GERN/geron-and-fda-reach-agreement-on-clinical-hold-company-and-regulatory-agency-define-path-t-gern-20091030monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-2009-third-quarter-financial-results-and-events-menlo-park-calif-gern-20091029monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-direct-equity-issuance-proceeds-to-be-invested-in-viagen-inc-gern-20090910monthly0.5https://www.biopharmawatch.com/news/GERN/geron-s-ind-for-spinal-cord-injury-placed-on-hold-menlo-park-calif-business-wire-gern-20090818monthly0.5https://www.biopharmawatch.com/news/SSII/we-build-advanced-affordable-and-accessible-surgical-robotic-solutions-ss-innovations-inte-ssii-20260531monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-announces-completion-of-world-s-longest-distance-robotic-telesurgery-cardia-ssii-20260604monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-demonstrates-long-distance-telesurgery-capabilities-at-royal-australian-col-ssii-20260507monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-unveils-cutting-edge-surgical-robotic-technologies-at-smrsc-2026-innovation-ssii-20260423monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-to-host-smrsc-2026-in-new-delhi-india-from-april-9-11-2026-conference-to-un-ssii-20260407monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-ssi-mantra-surgical-robotic-system-approved-for-telesurgeries-in-indonesia--ssii-20260318monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-reports-fourth-quarter-and-full-year-2025-financial-results-strong-growth-i-ssii-20260310monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-appoints-milan-rao-as-global-chief-operating-officer-and-chief-financial-of-ssii-20260108monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-develops-new-instruments-to-advance-robotic-surgery-in-large-underserved-pa-ssii-20260106monthly0.5https://www.biopharmawatch.com/news/SSII/we-build-advanced-affordable-and-accessible-surgical-robotic-solutions-ss-innovations-inte-ssii-20251106monthly0.5https://www.biopharmawatch.com/news/SSII/we-build-advanced-affordable-and-accessible-surgical-robotic-solutions-ss-innovations-inte-ssii-20250930monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-surpasses-milestone-of-100-installations-of-the-ssi-mantra-surgical-robotic-ssii-20250715monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-announces-completion-of-world-s-first-robotic-telesurgery-for-weight-loss-w-ssii-20250710monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-announces-successful-completion-of-first-robotic-cardiac-surgery-in-the-wes-ssii-20250616monthly0.5https://www.biopharmawatch.com/news/SSII/we-build-advanced-affordable-and-accessible-surgical-robotic-solutions-ss-innovations-inte-ssii-20250603monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-to-ring-the-nasdaq-opening-bell-on-tuesday-ssii-20250603monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-surpasses-milestone-of-4-000-robotic-surgeries-successfully-performed-with--ssii-20250527monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-reports-first-quarter-2025-financial-results-record-quarterly-revenue-of-5--ssii-20250514monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-to-submit-de-novo-application-to-the-fda-for-the-ssi-mantra-3-surgical-robo-ssii-20250508monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-reiterates-guidance-for-first-quarter-2025-and-provides-commentary-on-secon-ssii-20250505monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-announces-chief-financial-officer-transition-fort-lauderdale-fl-ssii-20250502monthly0.5https://www.biopharmawatch.com/news/SSII/fort-lauderdale-fl-ssii-20250424monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-achieves-significant-milestones-in-2024-the-company-s-award-winning-ssi-man-ssii-20250331monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-inc-achieves-another-milestone-by-successfully-performing-ove-ssii-20250327monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-unveils-india-s-first-mobile-tele-surgical-unit-at-smrsc-2025-fort-lauderda-ssii-20250313monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-launches-the-2nd-global-robotic-surgery-conference-smrsc-2025-ssii-20250307monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-performs-world-s-first-robotic-cardiac-telesurgeries-with-its-ssii-20250113monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-announces-completion-of-bdo-audit-process-and-issues-update-on-plans-for-na-ssii-20241211monthly0.5https://www.biopharmawatch.com/news/SSII/india-s-first-cdsco-certified-robotic-system-for-telesurgery-ssi-mantra-leads-the-way-ss-i-ssii-20241210monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-marks-a-milestone-with-first-robotic-cardiac-surgery-in-indonesia-ss-innova-ssii-20241127monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-welcomes-mr-tim-adams-leader-in-the-health-care-industry-to-board-tim-adams-ssii-20240930monthly0.5https://www.biopharmawatch.com/news/SSII/revolutionizing-surgery-ss-innovations-international-inc-celebrates-2-000-procedures-with--ssii-20240923monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-conducts-interactive-meeting-with-the-center-for-devices-and-radiological-h-ssii-20240911monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-welcomes-father-of-surgical-robotics-dr-fredric-moll-to-board-dr-moll-found-ssii-20240910monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-inc-announces-first-mantra-surgical-robotic-system-sale-in-so-ssii-20240903monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-issues-update-on-status-of-audit-process-and-trading-market-for-common-stoc-ssii-20240830monthly0.5https://www.biopharmawatch.com/news/SSII/ssi-mantra-3-an-advanced-surgical-robotic-2024-ss-innovations-international-inc-confidenti-ssii-20240731monthly0.5https://www.biopharmawatch.com/news/SSII/meet-the-latest-innovation-in-robotic-surgery-the-ssi-mantra-3-new-disruptive-system-with--ssii-20240718monthly0.5https://www.biopharmawatch.com/news/SSII/ssi-mantra-expands-global-footprint-nepal-s-first-surgical-robot-set-to-transform-healthca-ssii-20240709monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-designated-outstanding-company-finalist-for-surgical-robotics-industry-awar-ssii-20240617monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-ssi-mantra-surgical-robotic-system-approved-for-use-in-indonesia-fort-laude-ssii-20240611monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-engages-bdo-as-its-new-auditor-ss-innovations-believes-that-the-selection-o-ssii-20240531monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-ssi-mantra-surgical-robotic-system-used-to-perform-100-cardiac-surgeries-si-ssii-20240521monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-achieves-pediatric-milestone-with-first-infant-pyeloplasty-using-ssi-mantra-ssii-20240429monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-announces-q1-2024-company-updates-significant-milestones-achi-ssii-20240422monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-ssi-mantra-surgical-robotic-system-used-to-perform-mitral-valve-replacement-ssii-20240312monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-demonstrates-groundbreaking-telesurgery-platform-at-company-s-first-multi-s-ssii-20240201monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-announces-filing-of-pre-submission-application-to-the-center-for-devices-an-ssii-20240126monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-partners-with-india-s-leading-medical-equipment-supplier-medikabazaar-colla-ssii-20240125monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-achieves-significant-milestones-in-2023-company-s-award-winning-ssi-mantra--ssii-20240108monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-announces-strategic-partnership-with-surgical-lab-for-distribution-in-afric-ssii-20231226monthly0.5https://www.biopharmawatch.com/news/SSII/s-u-d-h-i-r-s-r-i-v-a-s-t-a-v-a-i-n-n-o-v-a-t-i-o-n-s-p-v-t-l-t-d-c-o-n-f-i-d-e-n-t-i-a-l--ssii-20231204monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-ssi-mantra-robotic-surgical-system-crosses-500-successful-pro-ssii-20231127monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-appoints-dr-sonia-shokeen-as-head-of-quality-and-regulatory-affairs-dr-shok-ssii-20231030monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-enters-licensing-agreement-with-johns-hopkins-university-company-s-flagship-ssii-20231012monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-recognized-on-national-news-as-india-celebrates-independence-day-news-chann-ssii-20230817monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-and-dr-frederic-moll-to-deliver-keynote-presentation-at-the-moneyshow-inves-ssii-20230808monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-begins-fda-and-ce-regulatory-approval-processes-for-ssi-mantra-flagship-sur-ssii-20230802monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-inc-to-present-at-the-emerging-growth-conference-on-wednesday-ssii-20230712monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-inc-s-s-i-n-n-o-v-a-t-i-o-n-s-i-n-t-e-r-n-a-t-i-o-n-a-l-i-n-c-ssii-20230606monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-inc-provides-business-update-celebrates-achievement-of-signif-ssii-20230530monthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-international-inc-f-k-a-avra-medical-robotics-inc-commences-trading-under-s-ssii-20230515monthly0.5https://www.biopharmawatch.com/news/SSII/avra-medical-robotics-announces-closing-of-merger-with-cardioventures-announces-management-ssii-20230419monthly0.5https://www.biopharmawatch.com/news/SSII/avra-medical-robotics-inc-otc-avmr-becomes-current-in-its-sec-filing-status-for-immediate--ssii-20221201monthly0.5https://www.biopharmawatch.com/news/SSII/avra-medical-robotics-inc-otcmkts-avmr-2020-year-end-ceo-update-letter-to-shareholders-and-ssii-20210309monthly0.5https://www.biopharmawatch.com/news/SSII/we-further-remind-you-that-avra-files-quarterly-annual-and-other-periodic-reports-with-the-ssii-20190131monthly0.5https://www.biopharmawatch.com/news/SSII/avra-medical-robotics-inc-updates-shareholders-and-the-investment-community-with-respect-t-ssii-20170927monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-first-quarter-2026-financial-results-and-business-highlights-phas-aura-20260511monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-business--aura-20260330monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-second-quarter-2025-financial-results-and-business-highlights-con-aura-20250813monthly0.5https://www.biopharmawatch.com/news/AURA/may-2025-innovating-the-future-of-cancer-care-to-cure-patients-and-preserve-organ-function-aura-20250516monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-first-quarter-2025-financial-results-and-business-highlights-firs-aura-20250515monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-business--aura-20250324monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-third-quarter-2024-financial-results-and-business-highlights-posi-aura-20241112monthly0.5https://www.biopharmawatch.com/news/AURA/multiple-clinical-complete-responses-demonstrated-following-single-low-dose-administration-aura-20241017monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-positive-phase-2-end-of-study-results-evaluating-bel-sar-as-a-fir-aura-20240912monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-second-quarter-2024-financial-results-and-business-highlights-com-aura-20240808monthly0.5https://www.biopharmawatch.com/news/AURA/corporate-presentation-june-2024-legal-disclosure-this-presentation-contains-forward-looki-aura-20240604monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-first-quarter-2024-financial-results-and-business-highlights-cont-aura-20240509monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-business--aura-20240327monthly0.5https://www.biopharmawatch.com/news/AURA/legal-disclosure-this-presentation-contains-forward-looking-statements-all-of-which-are-qu-aura-20240108monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-third-quarter-2023-financial-results-and-provides-clinical-develo-aura-20231109monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-receives-fda-agreement-under-special-protocol-assessment-spa-for-compass--aura-20231106monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-strengthens-and-expands-leadership-team-with-key-appointments-j-jill-hopk-aura-20231002monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-second-quarter-2023-financial-results-and-provides-clinical-devel-aura-20230809monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-first-quarter-2023-financial-results-and-provides-clinical-develo-aura-20230511monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides--aura-20230315monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-announces-positive-interim-phase-2-safety-and-efficacy-data-of-belzupacap-aura-20230216monthly0.5https://www.biopharmawatch.com/news/AURA/legal-disclosure-this-presentation-contains-forward-looking-statements-all-of-which-are-qu-aura-20230106monthly0.5https://www.biopharmawatch.com/news/AURA/legal-disclosure-this-presentation-contains-forward-looking-statements-all-of-which-are-qu-aura-20221130monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-third-quarter-2022-financial-results-and-provides-clinical-develo-aura-20221110monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-announces-interim-phase-2-data-evaluating-suprachoroidal-administration-o-aura-20221003monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-announces-first-patient-dosed-in-phase-1-study-evaluating-belzupacap-saro-aura-20220928monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-second-quarter-2022-financial-results-and-provides-clinical-devel-aura-20220811monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-receives-fda-fast-track-designation-for-belzupacap-sarotalocan-au-011-for-aura-20220630monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-topline-data-from-a-retrospective-study-of-belzupacap-sarotalocan-aura-20220622monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-announces-publication-of-preclinical-data-of-the-combination-of-vdcs-with-aura-20220526monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-first-quarter-2022-financial-results-and-provides-clinical-develo-aura-20220512monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides--aura-20220323monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-reports-third-quarter-2021-financial-results-and-provides-clinical-develo-aura-20211124monthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-announces-the-appointment-of-pedro-j-beltran-phd-as-chief-executive-officer-idan-elme-bbot-20260422monthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-reports-fourth-quarter-and-full-year-2025-financial-results-and-update-on-corporate-p-bbot-20260305monthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-announces-new-clinical-data-advancing-its-portfolio-of-three-innovative-and-different-bbot-20260107monthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-reports-third-quarter-2025-financial-results-and-update-on-corporate-progress-bbot-de-bbot-20251112monthly0.5https://www.biopharmawatch.com/news/BBOT/index-to-unaudited-condensed-financial-statements-theras-inc-page-unaudited-condensed-fina-bbot-20250813monthly0.5https://www.biopharmawatch.com/news/BBOT/helix-acquisition-corp-ii-retains-more-than-60-of-trust-account-after-redemptions-in-conne-bbot-20250806monthly0.5https://www.biopharmawatch.com/news/BBOT/helix-acquisition-corp-ii-and-bridgebio-oncology-therapeutics-announce-effectiveness-of-re-bbot-20250711monthly0.5https://www.biopharmawatch.com/news/BBOT/bridgebio-oncology-therapeutics-bbot-and-helix-acquisition-corp-ii-announce-business-combi-bbot-20250228monthly0.5https://www.biopharmawatch.com/news/BBOT/helix-acquisition-corp-ii-index-to-financial-statement-page-report-of-independent-register-bbot-20240213monthly0.5https://www.biopharmawatch.com/news/BBOT/helix-acquisition-corp-ii-announces-pricing-of-upsized-160-million-initial-public-offering-bbot-20240209monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-accelerates-next-phase-of-global-growth-and-market-leadership-tilray-advance-tlry-20260415monthly0.5https://www.biopharmawatch.com/news/TLRY/in-the-court-of-chancery-of-the-state-of-delaware-nabil-salama-individually-and-on-behalf--tlry-20241106monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-announces-at-the-market-tlry-20240517monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-completes-accretive-acquisition-of-hexo-corp-leading-the-next-evolution-of-c-tlry-20230622monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20220728monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-announces-closing-of-transaction-with-hexo-laying-groundwork-for-the-next-ev-tlry-20220712monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-announces-enhancements-to-accretive-strategic-transaction-with-hexo-amended--tlry-20220614monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-announces-definitive-agreement-with-hexo-corp-related-to-hexo-s-senior-secur-tlry-20220412monthly0.5https://www.biopharmawatch.com/news/TLRY/april-6-2022-tilray-brands-inc-reports-third-quarter-fiscal-year-2022-financial-results-pr-tlry-20220406monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-announces-proposed-agreement-for-strategic-alliance-with-hexo-corp-tilray-to-tlry-20220303monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20220110monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20211007monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-stockholders-approve-proposal-to-increase-authorized-shares-at-special-meeting-prov-tlry-20210910monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-announces-adjournment-of-special-meeting-of-stockholders-to-september-10-2021-votes-tlry-20210819monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-acquires-majority-position-in-amended-medmen-convertible-notes-investment-provides--tlry-20210817monthly0.5https://www.biopharmawatch.com/news/TLRY/filed-with-the-original-report-the-prior-exhibit-the-prior-exhibit-included-among-other-th-tlry-20210730monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-announces-adjournment-of-special-meeting-of-stockholders-to-august-19-2021-prelimin-tlry-20210729monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20210728monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-aphria-announce-closing-of-transaction-that-creates-the-new-tilray-a-global-cannabi-tlry-20210505monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-board-of-directors-announces-approval-of-amendment-to-company-s-bylaws-aphria-and-t-tlry-20210416monthly0.5https://www.biopharmawatch.com/news/TLRY/special-meeting-of-tilray-inc-stockholders-adjourned-to-tlry-20210415monthly0.5https://www.biopharmawatch.com/news/TLRY/united-states-district-court-southern-district-of-new-york-patricia-violini-case-no-plaint-tlry-20210326monthly0.5https://www.biopharmawatch.com/news/TLRY/unaudited-pro-forma-condensed-combined-financial-statements-of-tilray-unaudited-pro-forma--tlry-20210225monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20210217monthly0.5https://www.biopharmawatch.com/news/TLRY/aphria-and-tilray-combine-to-create-largest-global-cannabis-company-with-pro-forma-revenue-tlry-20201216monthly0.5https://www.biopharmawatch.com/news/TLRY/form-of-exchange-agreement-november-2020-tilray-inc-1100-maughan-rd-nanaimo-bc-canada-v9x--tlry-20201124monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20201109monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20200810monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20200511monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-inc-announces-pricing-of-its-90-4-million-registered-offering-march-13-2020-8-00-am-tlry-20200313monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20200302monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-inc-completes-merger-with-privateer-holdings-inc-tlry-20191213monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20191112monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-inc-and-privateer-holdings-inc-sign-definitive-agreement-to-extend-lock-up-and-prov-tlry-20190909monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20190829monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20190813monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-inc-and-privateer-holdings-inc-sign-letter-of-intent-to-extend-lock-up-and-provide--tlry-20190610monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20190514monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20190318monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-and-authentic-brands-group-sign-global-revenue-sharing-agreement-to-develop-and-mar-tlry-20190115monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-signs-global-collaboration-agreement-with-leading-pharmaceutical-company-nanaimo-b--tlry-20181219monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20181113monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-inc-upsizes-and-prices-offering-of-us-450-million-convertible-senior-notes-nanaimo--tlry-20181004monthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-inc-announces-proposed-private-placement-of-400-million-of-convertible-senior-notes-tlry-20181003monthly0.5https://www.biopharmawatch.com/news/TLRY/press-release-tlry-20180828monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-dsgn-20260309monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-highlights-momentum-across-lead-genetac-programs-and-reports-first-qua-dsgn-20250507monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-highlights-progress-across-lead-genetac-programs-and-reports-fourth-qu-dsgn-20250310monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-announces-third-quarter-2024-financial-results-and-reviews-near-term-m-dsgn-20241107monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-announces-second-quarter-2024-financial-results-and-reviews-near-term--dsgn-20240805monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-announces-first-quarter-2024-financial-results-and-highlights-upcoming-dsgn-20240508monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-outlines-progress-across-genetac-platform-and-announces-fourth-quarter-dsgn-20240319monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-reports-third-quarter-2023-financial-results-and-plans-for-a-comprehen-dsgn-20231113monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-provides-pipeline-update-and-reports-second-quarter-2023-financial-res-dsgn-20230814monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-provides-pipeline-updates-and-reports-first-quarter-2023-financial-res-dsgn-20230509monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-highlights-pipeline-progress-and-reports-fourth-quarter-and-full-year--dsgn-20230314monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-highlights-pipeline-progress-and-upcoming-milestones-and-reports-third-dsgn-20221103monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-highlights-upcoming-milestones-and-reports-second-quarter-2022-financi-dsgn-20220808monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-highlights-clinical-and-research-progress-and-reports-first-quarter-20-dsgn-20220509monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-reports-pipeline-and-business-progress-and-fourth-quarter-and-full-yea-dsgn-20220310monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-reports-pipeline-progress-and-third-quarter-2021-results-clinical-init-dsgn-20211109monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-reports-genetac-portfolio-progress-and-second-quarter-2021-results-pre-dsgn-20210809monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-announces-business-highlights-and-reports-first-quarter-2021-financial-dsgn-20210510monthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-unde-dsgn-20210330monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-second-quarter-2025-financial-results-and-business-update-pi-allo-20250813monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2025-financial-results-and-business-update-piv-allo-20250513monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-busi-allo-20250313monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-third-quarter-2024-financial-results-and-business-update-cem-allo-20241107monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-second-quarter-2024-financial-results-and-business-update-ce-allo-20240807monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2024-financial-results-and-business-update-cem-allo-20240513monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-busi-allo-20240314monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-third-quarter-2023-financial-results-and-business-update-pre-allo-20231102monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-second-quarter-2023-financial-results-and-business-update-pr-allo-20230802monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2023-financial-results-and-business-update-enr-allo-20230503monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-prov-allo-20230228monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-third-quarter-2022-financial-results-and-announces-investor--allo-20221102monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-second-quarter-2022-financial-results-u-s-fda-clearance-on-p-allo-20220809monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2022-financial-results-pivotal-phase-2-alpha2--allo-20220504monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-prov-allo-20220223monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-third-quarter-2021-financial-results-and-business-update-new-allo-20211104monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-second-quarter-2021-financial-results-cd19-program-highlight-allo-20210804monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2021-financial-results-cd19-program-highlights-allo-20210505monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-corp-allo-20210225monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-third-quarter-2020-financial-results-enrollment-ongoing-in-p-allo-20201104monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-second-quarter-2020-financial-results-initial-phase-1-result-allo-20200805monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-commencement-of-public-offering-of-common-stock-allo-20200601monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2020-financial-results-oral-presentation-of-in-allo-20200506monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-initial--allo-20200227monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-third-quarter-2019-financial-results-initiated-allo-715-phas-allo-20191105monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-second-quarter-2019-financial-results-allo-501-phase-1-alpha-allo-20190807monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2019-financial-results-initiated-allo-501-phas-allo-20190507monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-phase-1--allo-20190308monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-un-allo-20181015monthly0.5https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-announces-first-quarter-2026-financial-results-and-provides-b-trax-20260514monthly0.5https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-debuts-on-nasdaq-to-advance-therapies-for-autoimmune-diseases-trax-20260420monthly0.5https://www.biopharmawatch.com/news/TRAX/dear-anaptys-and-future-first-tracks-bio-shareholders-in-september-2025-we-announced-our-i-trax-20260326monthly0.5https://www.biopharmawatch.com/news/ABUS/case-no-abus-20260220monthly0.5https://www.biopharmawatch.com/news/ABUS/case-no-abus-20260206monthly0.5https://www.biopharmawatch.com/news/ABUS/genevant-arbutus-lnp-litigation-lindsay-androski-special-counsel-genevant-ceo-arbutus-matt-abus-20251211monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-third-quarter-2025-financial-results-and-provides-corporate-update-abus-20251113monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-2025-corporate-and-financial-update-abus-20250113monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-imdusiran-achieves-functional-cure-in-chbv-patients-when-combined-with-a-short-cou-abus-20241115monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-third-quarter-2024-financial-results-and-provides-corporate-update-abus-20241106monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-second-quarter-2024-financial-results-and-provides-corporate-update-abus-20240801monthly0.5https://www.biopharmawatch.com/news/ABUS/treatment-with-arbutus-imdusiran-and-vtp-300-achieves-statistical-significance-in-lowering-abus-20240606monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-imdusiran-with-short-course-interferon-achieves-sustained-undetectable-hbsag-a-nec-abus-20240605monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-first-quarter-2024-financial-results-and-provides-corporate-update-abus-20240502monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2023-financial-results-and-provides-corporate--abus-20240229monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-2024-corporate-objectives-and-provides-financial-update-abus-20240108monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-and-barinthus-bio-present-preliminary-data-from-phase-2a-clinical-trial--abus-20231109monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-third-quarter-2023-financial-results-and-provides-corporate-update-abus-20231107monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-pipeline-updates-and-dosing-of-the-first-subject-in-the-phase-1a-1b-clin-abus-20230911monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-second-quarter-2023-financial-results-and-corporate-update-abus-20230803monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-first-quarter-2023-financial-results-and-corporate-update-abus-20230504monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2022-financial-results-and-corporate-update-abus-20230302monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-2023-corporate-objectives-and-provides-financial-update-abus-20230105monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-third-quarter-2022-financial-results-and-provides-corporate-update-abus-20221109monthly0.5https://www.biopharmawatch.com/news/ABUS/nasdaq-abus-www-arbutusbio-com-november-4-2022-aasld-data-presentation-abus-20221104monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-new-data-on-ab-729-ab-836-and-ab-101-at-the-easl-international-liver-cong-abus-20220627monthly0.5https://www.biopharmawatch.com/news/ABUS/nasdaq-abus-www-arbutusbio-com-may-24-2022-corporate-presentation-abus-20220524monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-first-quarter-2022-financial-results-and-provides-corporate-update-abus-20220505monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2021-financial-results-and-provides-corporate--abus-20220303monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-2022-corporate-objectives-and-provides-financial-update-abus-20220124monthly0.5https://www.biopharmawatch.com/news/ABUS/preliminary-data-shows-that-arbutus-capsid-inhibitor-ab-836-is-generally-safe-and-well-tol-abus-20211201monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-new-data-on-ab-729-in-late-breaker-poster-presentation-at-aasld-the-live-abus-20211112monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-third-quarter-2021-financial-results-and-provides-corporate-update-abus-20211104monthly0.5https://www.biopharmawatch.com/news/ABUS/corporate-presentation-october-2021-nasdaq-abus-www-arbutusbio-com-nasdaq-abus-www-arbutus-abus-20211008monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-second-quarter-2021-financial-results-and-provides-corporate-update-abus-20210805monthly0.5https://www.biopharmawatch.com/news/ABUS/corporate-presentation-july-2021-nasdaq-abus-www-arbutusbio-com-abus-20210714monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-new-data-on-ab-729-and-ab-836-programs-with-presentation-of-five-abstrac-abus-20210628monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-first-quarter-2021-financial-results-and-provides-corporate-update-abus-20210505monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-receives-regulatory-approval-to-initiate-a-phase-1a-1b-clinical-trial-with-ab-836--abus-20210316monthly0.5https://www.biopharmawatch.com/news/ABUS/corporate-presentation-february-2021-nasdaq-abus-www-arbutusbio-com-abus-20210201monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-2021-corporate-objectives-and-provides-financial-update-abus-20210125monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-presentation-of-phase-1a-1b-clinical-trial-results-for-ab-729-in-chronic-abus-20201116monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-ab-729-90-mg-single-dose-week-12-data-in-chronic-hepatitis-b-subjects-de-abus-20200915monthly0.5https://www.biopharmawatch.com/news/ABUS/deck8k-corporate-presentation-august-2020-nasdaq-abus-www-arbutusbio-com-forward-looking-s-abus-20200731monthly0.5https://www.biopharmawatch.com/news/ABUS/forward-looking-statements-and-information-this-press-release-contains-forward-looking-sta-abus-20200518monthly0.5https://www.biopharmawatch.com/news/ABUS/implied-by-the-forward-looking-statements-contained-herein-known-risk-factors-include-amon-abus-20200326monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2019-financial-results-confirms-2020-corporate-abus-20200305monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-third-quarter-2019-financial-results-and-provides-corporate-update-confere-abus-20191106monthly0.5https://www.biopharmawatch.com/news/ABUS/singularly-focused-on-hbv-august-2019-nasdaq-abus-www-arbutusbio-com-forward-looking-state-abus-20190809monthly0.5https://www.biopharmawatch.com/news/ABUS/singularly-on-hbv-may-2019-focused-nasdaq-abus-www-arbutusbio-com-forward-looking-statemen-abus-20190520monthly0.5https://www.biopharmawatch.com/news/ABUS/singularly-focused-on-hbv-corporate-overview-february-2019-nasdaq-abus-www-arbutusbio-com--abus-20190214monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-closing-of-the-second-tranche-of-a-116m-strategic-investment-from-roivan-abus-20180116monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-receive-116-million-strategic-investment-from-roivant-sciences-cash-to-provide--abus-20171002monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-planned-executive-departure-vancouver-british-columbia-and-doylestown-pa-abus-20160421monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-announces-completion-of-underwritten-public-offering-of-common-shares-for-immediat-abus-20150325monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-announces-pricing-of-underwritten-public-offering-of-common-shares-for-immediate-r-abus-20150320monthly0.5https://www.biopharmawatch.com/news/ABUS/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2015-02-11-11-57-36-abus-20150211monthly0.5https://www.biopharmawatch.com/news/ABUS/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2015-01-26-18-06-11-abus-20150128monthly0.5https://www.biopharmawatch.com/news/ABUS/agreement-and-plan-of-merger-and-reorganization-abus-20150112monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-material-change-report-form-51-102f3-1-name-and-addres-abus-20140113monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20131114monthly0.5https://www.biopharmawatch.com/news/ABUS/execution-copy-3-750-000-common-shares-tekmira-pharmaceuticals-corporation-incorporated-un-abus-20131017monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20130812monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20130514monthly0.5https://www.biopharmawatch.com/news/ABUS/cross-license-agreement-by-and-among-alnylam-pharmaceuticals-inc-tekmira-pharmaceuticals-c-abus-20130117monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-material-change-report-form-51-102f3-1-name-and-addres-abus-20121112monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20121113monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20120814monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20120515monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-material-change-report-form-51-102f3-1-name-and-addres-abus-20120229monthly0.5https://www.biopharmawatch.com/news/ABUS/schedule-a-tekmira-secures-3-million-financing-financial-guidance-updated-cash-runway-furt-abus-20111221monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20111108monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20110811monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-2011-omnibus-share-compensation-plan-as-approved-by-the-board-of-directors-on-abus-20110711monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-material-change-report-form-51-102f3-1-name-and-addres-abus-20110629monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-closes-5-1-million-public-offering-for-immediate-release-abus-20110616monthly0.5https://www.biopharmawatch.com/news/ABUS/agency-agreement-abus-20110610monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-prices-public-offering-abus-20110609monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-announces-proposed-public-offering-abus-20110608monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-material-change-report-form-51-102f3-1-name-and-addres-abus-20110606monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-pharmaceuticals-corporation-unaudited-interim-condensed-consolidated-financial-sta-abus-20110510monthly0.5https://www.biopharmawatch.com/news/ABUS/tekmira-and-the-national-cancer-institute-publish-promising-data-demonstrating-the-anti-tu-abus-20110421monthly0.5https://www.biopharmawatch.com/news/RLMD/unlocking-life-changing-therapies-october-2025-c-o-r-po-r-at-e-o-ver-vi-e-w-2025-relmada-a-rlmd-20251104monthly0.5https://www.biopharmawatch.com/news/RLMD/unlocking-life-changing-therapies-september-2025-c-o-r-po-r-at-e-o-ver-vi-e-w-2025-relmada-rlmd-20250917monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-presents-positive-initial-phase-2-ndv-01-data-at-aua2025-90-of-patien-rlmd-20250428monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-reports-fourth-quarter-and-full-year-2024-results-and-provides-busine-rlmd-20250327monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-licenses-phase-2-bladder-cancer-candidate-ndv-01-from-trigone-pharma--rlmd-20250325monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-acquires-potential-therapy-for-tourette-syndrome-from-asarina-pharma--rlmd-20250206monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-discontinue-the-reliance-ii-and-relight-phase-3-studies-of-rel-101-rlmd-20241209monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-reports-that-data-monitoring-committee-dmc-assessment-indicates-that--rlmd-20241204monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-20-rlmd-20240319monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-company-well-positioned-for-a-pivotal-2024--rlmd-20240104monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-third-quarter-2023-financial-re-rlmd-20231108monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-present-new-preclinical-data-on-its-psilocybin-program-at-aasld-th-rlmd-20231011monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-the-treatment-of-cns-disorders-october-10-th-2023-2023-relmada-rlmd-20231010monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-the-treatment-of-cns-disorders-october-4-th-2023-2023-relmada--rlmd-20231004monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-the-treatment-of-cns-disorders-august-10-th-2023-2023-relmada--rlmd-20230810monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-second-quarter-2023-financial-r-rlmd-20230808monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-the-treatment-of-cns-disorders-may-15-th-2023-202-3-relmada-al-rlmd-20230515monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2023-financial-re-rlmd-20230511monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-the-treatment-of-cns-disorders-april-19th-2023-2023-relmada-al-rlmd-20230419monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-20-rlmd-20230323monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-inc-2222-ponce-de-leon-blvd-3-rd-floor-coral-gables-fl-33134-rlmd-20230112monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-cns-therapeutic-expert-cedric-o-gorman-md-as-chief-medical-o-rlmd-20230109monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-top-line-results-from-phase-3-reliance-i-trial-for-rel-1017-rlmd-20221207monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-treatment-of-cns-disorders-november-11th-2022-i-nasdaq-rlmd-1--rlmd-20221114monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-third-quarter-2022-financial-re-rlmd-20221110monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-top-line-results-from-phase-3-reliance-iii-trial-for-rel-10-rlmd-20221013monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-completion-of-treatment-in-company-s-registrational-phase-3-rlmd-20220920monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2022-financial-re-rlmd-20220505monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-20-rlmd-20220323monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-treatment-of-cns-disorders-rlmd-20220307monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-top-line-results-of-study-evaluating-rel-1017-vs-ketamine-f-rlmd-20220223monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-publication-of-rel-1017-phase-2-study-results-in-the-americ-rlmd-20211222monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-treatment-of-cns-disorders-rlmd-20211123monthly0.5https://www.biopharmawatch.com/news/RLMD/targeting-major-advances-in-treatment-of-cns-disorders-november-2021-i-nasdaq-rlmd-1-discl-rlmd-20211115monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-regulatory-and-development-updates-on-ongoing-late-stage-cli-rlmd-20211004monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-20-rlmd-20210323monthly0.5https://www.biopharmawatch.com/news/RLMD/abstract-to-be-presented-at-the-aspet-annual-meeting-at-experimental-biology-on-april-27-t-rlmd-20210315monthly0.5https://www.biopharmawatch.com/news/RLMD/we-have-recently-initiated-two-separate-human-abuse-potential-studies-rel-1017-120-and-rel-rlmd-20210315monthly0.5https://www.biopharmawatch.com/news/RLMD/corporate-presentation-i-targeting-major-advances-in-treatment-of-cns-disorders-december-2-rlmd-20201214monthly0.5https://www.biopharmawatch.com/news/RLMD/corporate-presentation-i-targeting-major-advances-in-treatment-of-cns-disorders-november-2-rlmd-20201116monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-expands-r-d-team-appoints-paolo-manfredi-m-d-as-acting-chief-scientif-rlmd-20201027monthly0.5https://www.biopharmawatch.com/news/RLMD/corporate-presentation-i-targeting-major-advances-in-treatment-of-cns-disorders-june-2020--rlmd-20200603monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-strengthens-board-rlmd-20191226monthly0.5https://www.biopharmawatch.com/news/RLMD/cautionary-note-regarding-forward-looking-statements-this-current-report-on-form-8-k-this--rlmd-20191203monthly0.5https://www.biopharmawatch.com/news/RLMD/jfif-c-7-01444-9-82-w-4-g-t-w-4-g-t-gc-lj-h-5-rlmd-20191021monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-inc-audited-financial-statements-as-of-rlmd-20191018monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-inc-proforma-balance-sheet-rlmd-20191001monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-inc-proforma-balance-sheet-rlmd-20190718monthly0.5https://www.biopharmawatch.com/news/RLMD/ticker-symbol-otcqb-rlmd-innovations-in-central-nervous-system-diseases-rlmd-20180404monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-acquires-global-rights-to-develop-and-market-dextromethadone-for-trea-rlmd-20180117monthly0.5https://www.biopharmawatch.com/news/RLMD/therapeutics-announces-settlement-of-legal-action-with-laidlaw-company-rlmd-20170518monthly0.5https://www.biopharmawatch.com/news/RLMD/jeffrey-s-rugg-esq-bar-10978-jrugg-bhfs-com-maximilien-d-fetaz-esq-bar-12737-mfetaz-bhfs-c-rlmd-20160912monthly0.5https://www.biopharmawatch.com/news/RLMD/therapeutics-announces-results-of-annual-meeting-of-stockholders-rlmd-20151230monthly0.5https://www.biopharmawatch.com/news/RLMD/brownstein-hyatt-farber-schreck-llp-100-north-city-parkway-suite-1600-las-vegas-nv-89106-7-rlmd-20151222monthly0.5https://www.biopharmawatch.com/news/RLMD/pharmaceutical-industry-leader-james-dolan-joins-relmada-therapeutics-advisory-team-former-rlmd-20151214monthly0.5https://www.biopharmawatch.com/news/RLMD/brownstein-hyatt-farber-schreck-llp-100-north-city-parkway-suite-1600-las-vegas-nv-89106-7-rlmd-20151211monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-additional-information-regarding-positive-topline-results-f-rlmd-20151210monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-positive-topline-results-for-proof-of-concept-study-with-bu-rlmd-20151210monthly0.5https://www.biopharmawatch.com/news/RLMD/brownstein-hyatt-farber-schreck-llp-100-north-city-parkway-suite-1600-las-vegas-nv-89106-7-rlmd-20151209monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-strengthens-its-board-of-directors-with-the-appointment-of-maged-shen-rlmd-20151112monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-responds-to-13d-filing-by-laidlaw-rlmd-20151105monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-management-promotions-company-expands-roles-for-seasoned-in-rlmd-20151005monthly0.5https://www.biopharmawatch.com/news/RLMD/jfif-zexif-mm-j-q-q-q-c-c-e-rlmd-20150923monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-charles-j-casamento-to-its-board-of-directors-seasoned-execu-rlmd-20150716monthly0.5https://www.biopharmawatch.com/news/RLMD/lease-agreement-agreement-of-lease-between-gp-275-owner-llc-landlord-and-relmada-therapeut-rlmd-20150609monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-reinforces-balance-sheet-with-15-2-million-from-exercise-of-warrants--rlmd-20141016monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-inc-provides-its-first-corporate-update-as-a-public-company-material--rlmd-20140909monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-inc-completes-name-change-and-announces-new-ticker-the-company-s-new--rlmd-20140806monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-successfully-completes-offerings-totaling-28-million-in-connection-wi-rlmd-20140616monthly0.5https://www.biopharmawatch.com/news/RLMD/the-unaudited-pro-forma-information-below-gives-effect-to-the-share-exchange-between-camp--rlmd-20140527monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-third-quarter-2025-financial-results-and-provides-update-on-insp-sldb-20251031monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-pricing-of-underwritten-offering-sldb-20250218monthly0.5https://www.biopharmawatch.com/news/SLDB/february-2025-sgt-003-inspire-duchenne-data-update-2025-solid-biosciences-cautionary-note--sldb-20250211monthly0.5https://www.biopharmawatch.com/news/SLDB/forward-looking-statement-this-presentation-contains-forward-looking-statements-within-the-sldb-20240108monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-ind-clearance-by-fda-for-duchenne-muscular-dystrophy-gene-ther-sldb-20231114monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-bio-sciences-ignite-dmd-phase-i-ii-study-of-sgt-001-microdystrophin-gene-therapy-for-sldb-20230320monthly0.5https://www.biopharmawatch.com/news/SLDB/forward-looking-statement-this-presentation-contains-forward-looking-statements-within-the-sldb-20221231monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-closing-of-acquisition-of-aavantibio-and-concurrent-75-million-sldb-20221205monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-inc-amended-and-restated-2020-equity-incentive-plan-1-purpose-the-purpos-sldb-20221201monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-business-update-call-sldb-20220930monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-acquisition-of-aavantibio-and-concurrent-75-million-private-pl-sldb-20220930monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-second-quarter-2022-business-update-and-financial-results-trans-sldb-20220811monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-updated-corporate-strategy-to-develop-sgt-001-and-sgt-003-pipe-sldb-20220427monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-outlines-its-strategic-priorities-for-2022-and-announces-corporate-updat-sldb-20220110monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-second-quarter-2021-business-update-and-financial-results-clini-sldb-20210816monthly0.5https://www.biopharmawatch.com/news/SLDB/exhibit-a-amendment-no-1-to-2020-stock-incentive-plan-the-2020-stock-incentive-plan-the-pl-sldb-20210617monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-first-quarter-2021-business-update-and-financial-results-patien-sldb-20210514monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-pricing-of-public-offering-of-common-stock-sldb-20210318monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-positive-interim-efficacy-and-safety-data-from-the-ongoing-ignit-sldb-20210315monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-90-million-private-placement-cambridge-ma-sldb-20201211monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-third-quarter-2020-financial-results-and-provides-business-updat-sldb-20201105monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-inc-2020-equity-incentive-plan-1-purpose-the-purpose-of-this-2020-equity-sldb-20200618monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-sldb-20200312monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-second-quarter-2019-financial-results-and-provides-business-upda-sldb-20190814monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-60-million-private-placement-with-new-and-existing-investors-c-sldb-20190726monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-first-quarter-2019-financial-results-and-provides-business-updat-sldb-20190513monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-fourth-quarter-and-fiscal-year-2018-financial-results-and-provid-sldb-20190313monthly0.5https://www.biopharmawatch.com/news/SLDB/forward-looking-statements-this-presentation-includes-forward-looking-statements-within-th-sldb-20190108monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-third-quarter-2018-financial-results-and-provides-business-updat-sldb-20181113monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-second-quarter-2018-financial-results-and-provides-business-upda-sldb-20180810monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-first-quarter-2018-financial-results-and-provides-business-updat-sldb-20180510monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-full-year-2017-financial-results-and-provides-corporate-update-c-sldb-20180329monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-second-quarter-2025-and-raises-2025-guidance-sibn-20250804monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-first-quarter-2025-and-updates-2025-guidance-sibn-20250505monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-record-financial-results-for-the-fourth-quarter-2024-and-issues-2025-g-sibn-20250224monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-2024-fourth-qua-sibn-20250113monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-third-quarter-2024-and-updates-guidance-expe-sibn-20241112monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-second-quarter-2024-increases-2024-revenue-g-sibn-20240805monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-first-quarter-2024-annual-guidance-increased-sibn-20240506monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-record-fourth-quarter-and-full-year-2023-financial-results-and-issues--sibn-20240226monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-2023-fiscal-yea-sibn-20240108monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-record-financial-results-for-the-third-quarter-2023-and-raises-annual--sibn-20231106monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-second-quarter-2023-and-increases-annual-gui-sibn-20230807monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-first-quarter-2023-and-increases-annual-guid-sibn-20230501monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-fourth-quarter-and-full-year-2022-financial-results-and-issues-2023-gu-sibn-20230227monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-2022-fourth-qua-sibn-20230109monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-third-quarter-2022-and-updates-guidance-sibn-20221107monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-financial-results-for-the-second-quarter-2022-sibn-20220808monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-first-quarter-2022-financial-results-sibn-20220509monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-fourth-quarter-and-full-year-2021-financial-results-and-issues-2022-re-sibn-20220228monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-revenue-for-the-fourth-quarter-and-full-year-2021-preliminary-2021-reven-sibn-20220110monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-third-quarter-2021-financial-results-and-updates-2021-financial-guidan-sibn-20211108monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-second-quarter-2021-financial-results-and-announces-exclusive-coverage-sibn-20210802monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-first-quarter-2021-financial-results-and-reiterates-2021-financial-gui-sibn-20210503monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-fourth-quarter-and-full-year-2020-financial-results-and-issues-2021-fi-sibn-20210308monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-senior-leadership-changes-and-record-quarterly-revenue-laura-francis-to--sibn-20210107monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-third-quarter-2020-financial-results-and-2020-revenue-guidance-sibn-20201102monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-reports-preliminary-unaudited-revenue-for-the-third-quarter-2020-and-provides-full-sibn-20201008monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-second-quarter-2020-financial-results-sibn-20200803monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-first-quarter-2020-financial-results-sibn-20200504monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-provides-business-update-in-response-to-covid-19-pandemic-sibn-20200402monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-fourth-quarter-and-full-year-2019-financial-results-reiterates-full-ye-sibn-20200309monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-third-quarter-2019-financial-results-and-updates-full-year-2019-revenu-sibn-20191111monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-second-quarter-2019-financial-results-sibn-20190806monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-first-quarter-2019-financial-results-sibn-20190508monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-fourth-quarter-and-full-year-2018-financial-results-provides-full-year-sibn-20190307monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-reports-third-quarter-2018-financial-results-sibn-20181129monthly0.5https://www.biopharmawatch.com/news/NUTX/document-nutex-health-reports-first-quarter-2026-financial-results-houston-tx-prnewswire-a-nutx-20260430monthly0.5https://www.biopharmawatch.com/news/NUTX/document-nutex-health-reports-2025-financial-results-and-announces-second-stock-repurchase-nutx-20260305monthly0.5https://www.biopharmawatch.com/news/NUTX/document-nutex-health-reports-september-30-2025-third-quarter-and-year-to-date-financial-r-nutx-20251119monthly0.5https://www.biopharmawatch.com/news/NUTX/document-nutex-health-reports-june-30-2025-second-quarter-and-year-to-date-financial-resul-nutx-20251118monthly0.5https://www.biopharmawatch.com/news/NUTX/document-nutex-health-reports-restated-first-quarter-2025-financial-results-total-revenue--nutx-20251118monthly0.5https://www.biopharmawatch.com/news/NUTX/document-nutex-health-reports-restated-2024-financial-results-full-year-2024-highlights-to-nutx-20251118monthly0.5https://www.biopharmawatch.com/news/NUTX/document-nutex-health-provides-corporate-update-significant-year-over-year-growth-in-patie-nutx-20250930monthly0.5https://www.biopharmawatch.com/news/NUTX/forward-looking-statements-certain-statements-and-information-included-in-this-press-relea-nutx-20250922monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-first-quarter-2025-financial-results-total-revenue-of-211-8-million-v-nutx-20250513monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-2024-hi-nutx-20250331monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-issues-no-surprises-act-nsa-arbitration-update-houston-nutx-20250205monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-third-quarter-and-year-to-date-nutx-20241107monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-second-quarter-and-six-months-ended-nutx-20240808monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-first-quarter-2024-financial-results-total-revenue-of-67-5-million-fo-nutx-20240509monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-fourth-quarter-and-full-year-2023-financial-results-total-revenue-of--nutx-20240328monthly0.5https://www.biopharmawatch.com/news/NUTX/risk-factors-as-of-the-date-of-this-current-report-the-company-updates-and-supplements-the-nutx-20240124monthly0.5https://www.biopharmawatch.com/news/NUTX/s-t-r-i-c-t-l-y-p-r-i-v-a-t-e-a-n-d-c-o-n-f-i-d-e-n-t-i-a-l-s-t-r-i-c-t-l-y-p-r-i-v-a-t-e--nutx-20240111monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-third-quarter-2023-financial-results-net-revenue-of-62-7-million-net--nutx-20231109monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-announces-the-acquisition-of-population-health-associates-and-managed-care-in-nutx-20230822monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-second-quarter-2023-financial-results-net-revenue-of-58-9-million-com-nutx-20230809monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-first-quarter-2023-financial-results-net-revenue-of-56-3-million-net--nutx-20230515monthly0.5https://www.biopharmawatch.com/news/NUTX/s-t-r-i-c-t-l-y-p-r-i-v-a-t-e-a-n-d-c-o-n-f-i-d-e-n-t-i-a-l-s-t-r-i-c-t-l-y-p-r-i-v-a-t-e--nutx-20230502monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-announces-that-it-has-entered-into-a-100-million-pre-paid-advance-agreement-w-nutx-20230411monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-announces-change-to-its-board-of-directors-houston-tx-prnewswire-april-5-2023-nutx-20230405monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-inc-reports-fourth-quarter-and-full-year-2022-financial-results-total-revenue-nutx-20230302monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-inc-investor-presentation-nutx-20230228monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-to-present-at-the-41-st-annual-j-p-morgan-healthcare-conference-houston-tx-pr-nutx-20221221monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-third-quarter-2022-financial-results-and-announces-common-stock-purch-nutx-20221122monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-provides-corporate-update-houston-tx-prnewswire-nutx-20221010monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-reports-second-quarter-2022-financial-results-ebitda-of-5-4-million-for-the-s-nutx-20220822monthly0.5https://www.biopharmawatch.com/news/NUTX/to-this-filing-for-a-detailed-description-of-the-revisions-as-of-and-for-the-year-ended-nutx-20220616monthly0.5https://www.biopharmawatch.com/news/NUTX/nutex-health-announces-the-appointment-of-jon-bates-as-its-new-chief-financial-officer-hou-nutx-20220610monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-and-nutex-health-announce-completion-of-merger-and-listing-on-the-nasd-nutx-20220401monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-announces-results-of-2022-special-meeting-of-stockholders-ft-lauderdal-nutx-20220317monthly0.5https://www.biopharmawatch.com/news/NUTX/agreement-and-plan-of-merger-by-and-among-nutex-health-holdco-llc-clinigence-holdings-inc--nutx-20211123monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-announces-the-acquisition-of-procare-health-ft-lauderdale-fl-prnewswir-nutx-20211021monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-announces-the-signing-of-a-binding-letter-of-intent-to-acquire-procare-nutx-20210521monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-announces-the-successful-acquisitions-of-accountable-healthcare-americ-nutx-20210302monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-provides-strategic-update-atlanta-ga-businesswire-nutx-20200715monthly0.5https://www.biopharmawatch.com/news/NUTX/from-mark-fawcett-sent-saturday-nutx-20200627monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-and-accountable-healthcare-america-provide-new-update-to-shareholders--nutx-20200603monthly0.5https://www.biopharmawatch.com/news/NUTX/lawrence-schimmel-m-d-facs-nutx-20200516monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-and-accountable-healthcare-america-sign-letter-of-intent-to-merge-atla-nutx-20191112monthly0.5https://www.biopharmawatch.com/news/NUTX/clinigence-holdings-inc-goes-public-via-a-reverse-merger-with-igambit-inc-atlanta-ga-busin-nutx-20191031monthly0.5https://www.biopharmawatch.com/news/NUTX/igambit-and-clinigence-holdings-announce-transformational-merger-smithtown-ny-and-atlanta--nutx-20190809monthly0.5https://www.biopharmawatch.com/news/NUTX/igambit-inc-and-clinigence-holdings-inc-sign-letter-of-intent-for-merger-smithtown-n-y-nutx-20190627monthly0.5https://www.biopharmawatch.com/news/NUTX/john-salerno-chairman-amendment-1-letter-of-intent-to-purchase-personal-and-confidential-t-nutx-20180907monthly0.5https://www.biopharmawatch.com/news/NUTX/winpoint-health-llc-and-igambit-inc-sign-letter-of-intent-for-igambit-inc-to-acquire-winpo-nutx-20180619monthly0.5https://www.biopharmawatch.com/news/NUTX/during-the-past-several-months-some-significant-events-have-occurred-at-igambit-nutx-20170726monthly0.5https://www.biopharmawatch.com/news/NUTX/converted-by-edgarwiz-igambit-announces-sale-of-arcmail-technologies-and-6-000-000-liabili-nutx-20170705monthly0.5https://www.biopharmawatch.com/news/NUTX/converted-by-edgarwiz-igambit-announces-dr-benedict-s-maniscalco-joins-its-advisory-board--nutx-20170508monthly0.5https://www.biopharmawatch.com/news/NUTX/converted-by-edgarwiz-igambit-announces-acquisition-of-cybercare-health-network-inc-press--nutx-20170406monthly0.5https://www.biopharmawatch.com/news/NUTX/converted-by-edgarwiz-igambit-announces-acquisition-of-hubcentrix-inc-a-leading-provider-o-nutx-20170215monthly0.5https://www.biopharmawatch.com/news/NUTX/converted-by-edgarwiz-hubcentrix-inc-and-igambit-inc-sign-letter-of-intent-for-igambit-inc-nutx-20160826monthly0.5https://www.biopharmawatch.com/news/NUTX/converted-by-edgarwiz-encountercare-and-igambit-inc-sign-letter-of-intent-for-igambit-inc--nutx-20160815monthly0.5https://www.biopharmawatch.com/news/NUTX/converted-by-edgarwiz-igambit-announces-sale-of-gotham-subsidiary-press-release-igambit-in-nutx-20151111monthly0.5https://www.biopharmawatch.com/news/NUTX/converted-by-edgarwiz-igambit-files-form-8-k-announces-execution-of-letter-of-intent-to-ac-nutx-20150513monthly0.5https://www.biopharmawatch.com/news/NUTX/letter-of-resignation-john-waters-converted-by-edgarwiz-nutx-20130426monthly0.5https://www.biopharmawatch.com/news/NUTX/on-acquisition-converted-by-edgarwiz-igambit-acquires-assets-and-operations-of-igx-global--nutx-20121231monthly0.5https://www.biopharmawatch.com/news/NUTX/source-igambit-inc-nutx-20120404monthly0.5https://www.biopharmawatch.com/news/NUTX/source-igambit-inc-nutx-20111117monthly0.5https://www.biopharmawatch.com/news/NUTX/source-igambit-inc-nutx-20110817monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-select-preliminary-fourth-quarter-and-full-year-2025-results-and-recent-psnl-20260108monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-2025-financial-results-company-advances-win-in-mrd-strate-psnl-20251104monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-second-quarter-2025-financial-results-strong-q2-clinical-momentum-with--psnl-20250805monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-first-quarter-2025-financial-results-clinical-test-volume-of-2-184-incr-psnl-20250506monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-revenue-o-psnl-20250227monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-preliminary-fourth-quarter-and-full-year-2024-revenue-full-year-revenue-psnl-20250107monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-2024-financial-results-41-year-over-year-increase-in-reve-psnl-20241106monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-and-tempus-announce-expanded-collaboration-tempus-invests-36-million-by-exercis-psnl-20240816monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-second-quarter-2024-financial-results-strong-revenue-growth-of-35-year--psnl-20240807monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-first-quarter-2024-financial-results-raises-full-year-revenue-guidance--psnl-20240508monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-fourth-quarter-and-full-year-2023-financial-results-fremont-calif-x2013-psnl-20240228monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-preliminary-fourth-quarter-and-full-year-2023-revenue-and-cash-balance--psnl-20240105monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-2023-financial-results-increased-third-quarter-revenue-23-psnl-20231107monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-second-quarter-2023-financial-results-fremont-calif-x2013-psnl-20230808monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-first-quarter-2023-financial-results-fremont-calif-x2013-psnl-20230503monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-fourth-quarter-and-full-year-2022-financial-results-fremont-calif-x2013-psnl-20230223monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-preliminary-fourth-quarter-and-full-year-2022-revenue-fremont-calif-x20-psnl-20230104monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-2022-financial-results-menlo-park-calif-x2013-psnl-20221102monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-second-quarter-2022-financial-results-psnl-20220803monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-first-quarter-2022-financial-results-psnl-20220504monthly0.5https://www.biopharmawatch.com/news/PSNL/diagnostic-industry-veteran-karin-eastham-to-chair-personalis-board-of-directors-personali-psnl-20220324monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-fourth-quarter-and-full-year-2021-financial-results-psnl-20220224monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-preliminary-fourth-quarter-and-full-year-2021-revenue-psnl-20220106monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-2021-financial-results-psnl-20211104monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-second-quarter-2021-financial-results-psnl-20210804monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-first-quarter-2021-financial-results-psnl-20210505monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-fourth-quarter-and-full-year-2020-financial-results-psnl-20210225monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-preliminary-fourth-quarter-2020-revenue-psnl-20210111monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-2020-financial-results-psnl-20201105monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-second-quarter-2020-financial-results-psnl-20200806monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-first-quarter-2020-financial-results-psnl-20200507monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-fourth-quarter-and-full-year-2019-financial-results-psnl-20200325monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-2019-financial-results-psnl-20191113monthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-second-quarter-2019-financial-results-psnl-20190813monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-inc-2021-equity-incentive-plan-adopted-by-the-compensation-committee-of-the-boar-clym-20260608monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-first-quarter-2026-financial-results-and-provides-business-updates-robus-clym-20260507monthly0.5https://www.biopharmawatch.com/news/CLYM/confidential-climb-bio-hosts-budoprutug-r-d-spotlight-event-highlighting-topline-subcutane-clym-20260505monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-announces-pipeline-progress-and-strategic-priorities-for-2026-first-patients-dos-clym-20260108monthly0.5https://www.biopharmawatch.com/news/CLYM/in-the-superior-court-of-the-state-of-delaware-climb-bio-inc-plaintiff-v-c-a-no-ccld-alumi-clym-20251231monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-second-quarter-2025-financial-results-and-provides-business-updates-clin-clym-20250812monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-first-quarter-2025-financial-results-and-provides-business-updates-clini-clym-20250514monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-business-clym-20250325monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-third-quarter-2024-financial-results-and-business-highlights-appointed-d-clym-20241112monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-provide-budoprutug-development-strategy-and-corporate-update-at-virtual-inves-clym-20241015monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-inc-condensed-consolidated-balance-sheets-in-thousands-unaudited-clym-20240814monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-the-closing-of-its-acquisition-of-tenet-medicines-and-concurr-clym-20240627monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-agreement-to-acquire-tenet-medicines-and-concurrent-120-milli-clym-20240411monthly0.5https://www.biopharmawatch.com/news/CLYM/summary-of-proposed-terms-for-transaction-between-eliem-therapeutics-inc-and-target-form-o-clym-20240319monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-plans-to-explore-strategic-alternatives-seattle-and-cambridge-clym-20230720monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-first-quarter-financial-results-and-business-highlights-present-clym-20230511monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-fourth-quarter-and-year-end-financial-results-and-business-high-clym-20230306monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-provides-strategic-update-and-announces-leadership-transition-clym-20230209monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-third-quarter-financial-and-business-highlights-positioned-to-i-clym-20221114monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-provides-update-on-pipeline-progress-company-is-positioned-to-initiate--clym-20221005monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-second-quarter-financial-and-business-highlights-initiated-phas-clym-20220815monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-first-quarter-financial-and-business-highlights-seattle-and-cam-clym-20220516monthly0.5https://www.biopharmawatch.com/news/CLYM/clinical-stage-neurology-company-focused-on-neuronal-excitability-disorders-corporate-pres-clym-20220328monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-fourth-quarter-and-year-end-financial-and-business-highlights-c-clym-20220307monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-third-quarter-financial-and-business-highlights-advanced-etx-15-clym-20211108monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-second-quarter-financial-results-on-track-to-advance-two-clinic-clym-20210913monthly0.5https://www.biopharmawatch.com/news/EIKN/q2-company-update-june-2026-disclaimer-any-statements-made-in-this-presentation-that-are-n-eikn-20260601monthly0.5https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provi-eikn-20260330monthly0.5https://www.biopharmawatch.com/news/AMN/of-the-company-s-current-report-on-form-8-k-filed-on-amn-20251106monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-launches-400-0-million-offering-of-senior-notes-dallas-amn-20250922monthly0.5https://www.biopharmawatch.com/news/AMN/document-amn-healthcare-announces-second-quarter-2025-results-quarterly-revenue-of-658-mil-amn-20250807monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-first-quarter-2025-results-quarterly-revenue-of-690-million-gaap--amn-20250508monthly0.5https://www.biopharmawatch.com/news/AMN/of-the-company-s-current-report-on-form-8-k-filed-on-amn-20250220monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-third-quarter-2024-results-quarterly-revenue-of-688-million-gaap--amn-20241107monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-appoints-brian-scott-as-cfo-and-coo-seasoned-healthcare-executive-brings-ro-amn-20241003monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-cfo-transition-jeffrey-knudson-to-step-down-as-cfo-following-comp-amn-20241001monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-second-quarter-2024-results-quarterly-revenue-of-741-million-gaap-amn-20240808monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-first-quarter-2024-results-quarterly-revenue-of-821-million-gaap--amn-20240509monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-fourth-quarter-and-full-year-2023-results-quarterly-revenue-of-81-amn-20240215monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-third-quarter-2023-results-quarterly-revenue-of-853-million-gaap--amn-20231102monthly0.5https://www.biopharmawatch.com/news/AMN/date-monday-amn-20231023monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-second-quarter-2023-results-quarterly-revenue-of-991-million-gaap-amn-20230803monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-first-quarter-2023-results-quarterly-revenue-of-1-126-billion-gaa-amn-20230504monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-fourth-quarter-and-full-year-2022-results-quarterly-revenue-of-1--amn-20230216monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-third-quarter-2022-results-quarterly-revenue-of-1-139-billion-gaa-amn-20221103monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-selects-cary-grace-as-president-and-chief-executive-officer-grace-will-succ-amn-20221031monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-second-quarter-2022-results-quarterly-revenue-of-1-427-billion-ga-amn-20220804monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-services-inc-announces-250-million-share-repurchase-program-dallas-amn-20220615monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-first-quarter-2022-results-quarterly-revenue-of-1-553-billion-gaa-amn-20220505monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-ceo-susan-salka-intends-to-retire-by-end-of-year-dallas-amn-20220310monthly0.5https://www.biopharmawatch.com/news/AMN/document-amn-healthcare-announces-fourth-quarter-and-full-year-2021-results-quarterly-reve-amn-20220217monthly0.5https://www.biopharmawatch.com/news/AMN/document-amn-healthcare-announces-third-quarter-2021-results-quarterly-revenue-of-878-mill-amn-20211104monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-names-jeffrey-r-knudson-as-chief-financial-officer-dallas-amn-20211014monthly0.5https://www.biopharmawatch.com/news/AMN/document-amn-healthcare-announces-second-quarter-2021-results-quarterly-revenue-of-857-mil-amn-20210805monthly0.5https://www.biopharmawatch.com/news/AMN/document-amn-healthcare-announces-first-quarter-2021-results-quarterly-revenue-of-886-mill-amn-20210506monthly0.5https://www.biopharmawatch.com/news/AMN/document-amn-healthcare-announces-fourth-quarter-and-full-year-2020-results-quarterly-reve-amn-20210218monthly0.5https://www.biopharmawatch.com/news/AMN/document-amn-healthcare-announces-third-quarter-2020-results-quarterly-revenue-of-552-mill-amn-20201105monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-launches-325-0-million-offering-of-senior-notes-dallas-amn-20201005monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-launches-150-million-offering-of-senior-notes-dallas-and-amn-20200810monthly0.5https://www.biopharmawatch.com/news/AMN/certain-supplemental-financial-information-introduction-as-part-of-our-preliminary-offerin-amn-20200810monthly0.5https://www.biopharmawatch.com/news/AMN/document-amn-healthcare-announces-second-quarter-2020-results-quarterly-revenue-of-608-mil-amn-20200806monthly0.5https://www.biopharmawatch.com/news/AMN/for-a-discussion-of-additional-risk-factors-and-a-more-complete-discussion-of-some-of-the--amn-20200511monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-to-hold-virtual-2020-annual-meeting-of-shareholders-dallas-and-amn-20200403monthly0.5https://www.biopharmawatch.com/news/AMN/for-a-discussion-of-additional-risk-factors-and-a-more-complete-discussion-of-some-of-the--amn-20200213monthly0.5https://www.biopharmawatch.com/news/AMN/annual-report-on-form-10-k-for-the-year-ended-december-31-2018-our-subsequent-quarterly-re-amn-20191031monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-launches-300-million-offering-of-senior-notes-dallas-and-amn-20190926monthly0.5https://www.biopharmawatch.com/news/AMN/certain-supplemental-financial-information-introduction-our-historical-financial-statement-amn-20190926monthly0.5https://www.biopharmawatch.com/news/AMN/for-a-discussion-of-additional-risk-factors-and-a-more-complete-discussion-of-some-of-the--amn-20190806monthly0.5https://www.biopharmawatch.com/news/AMN/for-a-discussion-of-additional-risk-factors-and-a-more-complete-discussion-of-some-of-the--amn-20190502monthly0.5https://www.biopharmawatch.com/news/AMN/for-a-discussion-of-additional-risk-factors-and-a-more-complete-discussion-of-some-of-the--amn-20190214monthly0.5https://www.biopharmawatch.com/news/AMN/this-press-release-contains-forward-looking-statements-within-the-meaning-of-section-27a-o-amn-20181031monthly0.5https://www.biopharmawatch.com/news/AMN/this-press-release-contains-forward-looking-statements-within-the-meaning-of-section-27a-o-amn-20180802monthly0.5https://www.biopharmawatch.com/news/AMN/randle-reece-director-investor-relations-866-861-3229-amn-healthcare-announces-first-quart-amn-20180503monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-completes-two-acquisitions-medpartners-expands-amn-s-leadership-in-mid-reve-amn-20180409monthly0.5https://www.biopharmawatch.com/news/AMN/randle-reece-director-investor-relations-866-861-3229-amn-healthcare-announces-fourth-quar-amn-20180215monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-new-revolving-credit-facility-amn-20180212monthly0.5https://www.biopharmawatch.com/news/AMN/randle-reece-director-investor-relations-866-861-3229-amn-healthcare-announces-third-quart-amn-20171102monthly0.5https://www.biopharmawatch.com/news/AMN/brian-scott-chief-financial-officer-chief-accounting-officer-866-861-3229-amn-healthcare-a-amn-20170803monthly0.5https://www.biopharmawatch.com/news/AMN/neil-thomas-senior-director-investor-relations-866-861-3229-amn-healthcare-announces-first-amn-20170504monthly0.5https://www.biopharmawatch.com/news/AMN/neil-thomas-senior-director-investor-relations-866-861-3229-amn-healthcare-announces-fourt-amn-20170216monthly0.5https://www.biopharmawatch.com/news/AMN/david-erdman-director-investor-relations-866-861-3229-amn-healthcare-announces-third-quart-amn-20161103monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-launches-300-million-offering-of-senior-notes-san-diego-amn-20160919monthly0.5https://www.biopharmawatch.com/news/AMN/david-erdman-director-investor-relations-866-861-3229-amn-healthcare-announces-second-quar-amn-20160804monthly0.5https://www.biopharmawatch.com/news/AMN/david-erdman-director-investor-relations-866-861-3229-amn-healthcare-announces-first-quart-amn-20160505monthly0.5https://www.biopharmawatch.com/news/AMN/brian-m-scott-chief-financial-officer-866-861-3229-amn-healthcare-announces-fourth-quarter-amn-20160218monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-completes-the-acquisition-of-b-e-smith-expands-leadership-position-in-healt-amn-20160104monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-to-acquire-b-e-smith-expands-leadership-position-in-healthcare-workforce-so-amn-20151117monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-third--amn-20151104monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-second-amn-20150804monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-first--amn-20150506monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-full-y-amn-20150219monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-completes-the-acquisition-of-onward-healthcare-locum-leaders-medefis-expand-amn-20150109monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-to-acquire-onward-healthcare-locum-leaders-medefis-expands-leadership-posit-amn-20141217monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-third--amn-20141030monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-second-amn-20140731monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-first--amn-20140501monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-fourth-amn-20140220monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-third--amn-20131031monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-second-amn-20130801monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-first--amn-20130502monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-fourth-amn-20130221monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-third--amn-20121101monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-second-amn-20120802monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-first--amn-20120503monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-full-y-amn-20120308monthly0.5https://www.biopharmawatch.com/news/AMN/wendy-newman-wendy-newman-amnhealthcare-com-858-720-6202-sean-ebner-joins-amn-healthcare-a-amn-20120227monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-completes-sale-o-amn-20120130monthly0.5https://www.biopharmawatch.com/news/AMN/amy-c-chang-vice-president-investor-relations-866-861-3229-amn-healthcare-announces-third--amn-20111103monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-second-quarter-2011-results-amn-20110804monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-first-quarter-2011-results-amn-20110505monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-announces-fourth-quarter-2010-results-amn-20110308monthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-services-names-brian-m-scott-chief-financial-officer-san-diego-amn-20110104monthly0.5https://www.biopharmawatch.com/news/AMN/unaudited-pro-forma-condensed-combined-consolidated-financial-statement-in-thousands-excep-amn-20101123monthly0.5https://www.biopharmawatch.com/news/AVTX/forward-looking-statements-this-presentation-may-include-forward-looking-statements-made-p-avtx-20260112monthly0.5https://www.biopharmawatch.com/news/AVTX/forward-looking-statements-this-presentation-may-include-forward-looking-statements-made-p-avtx-20251202monthly0.5https://www.biopharmawatch.com/news/AVTX/forward-looking-statements-this-presentation-may-include-forward-looking-statements-made-p-avtx-20250929monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-appoints-kevin-r-lind-to-the-board-of-directors-wayne-pa-avtx-20250922monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-first-quarter-2025-financial-results-and-recent-business-updates-mike-heffer-avtx-20250512monthly0.5https://www.biopharmawatch.com/news/AVTX/forward-looking-statements-this-presentation-may-include-forward-looking-statements-made-p-avtx-20250508monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-appoints-michael-heffernan-as-chairman-of-the-board-wayne-avtx-20250326monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-2024-financial-results-and-recent-business-updates-topline-data-from-phase-2-avtx-20250320monthly0.5https://www.biopharmawatch.com/news/AVTX/forward-looking-statements-this-presentation-may-include-forward-looking-statements-made-p-avtx-20250113monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer-wayne-avtx-20250102monthly0.5https://www.biopharmawatch.com/news/AVTX/forward-looking-statements-this-presentation-may-include-forward-looking-statements-made-p-avtx-20241205monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-receives-69-4-million-in-proceeds-from-the-full-exercise-of-private-pla-avtx-20241112monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-third-quarter-2024-financial-results-and-recent-business-updates-dosed-first-avtx-20241107monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment-o-avtx-20241008monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-second-quarter-2024-financial-results-and-provides-business-updates-expects--avtx-20240812monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-appointment-of-dr-mittie-doyle-as-chief-medical-officer-wayne-avtx-20240716monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-active-ind-for-avtx-009-an-anti-il-1-mab-to-treat-hidradeniti-avtx-20240709monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-appointment-of-paul-varki-as-chief-legal-officer-wayne-pa-and-avtx-20240624monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-first-quarter-2024-financial-results-and-provides-business-updates-topline-r-avtx-20240513monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-2023-financial-results-and-provides-business-updates-acquired-avtx-009-phase-avtx-20240329monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-acquires-anti-il-1-mab-and-announces-private-placement-financing-of-up-to-185-millio-avtx-20240328monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-encourages-stockholders-to-vote-for-the-reverse-stock-split-annual-meeting-has-been--avtx-20231207monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-third-quarter-2023-financial-results-and-provides-business-updates-successfu-avtx-20231109monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-completes-divestiture-of-avtx-800-series-wayne-avtx-20231031monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-successfully-eliminates-35-million-debt-paving-the-way-for-future-growt-avtx-20230926monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-enters-into-agreement-to-divest-avtx-800-series-wayne-avtx-20230912monthly0.5https://www.biopharmawatch.com/news/AVTX/copyright-2023-avalo-therapeutics-all-rights-reserved-this-presentation-may-include-forwar-avtx-20230911monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-second-quarter-2023-financial-results-and-provides-business-updates-announce-avtx-20230803monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-announces-topline-data-from-phase-2-peak-trial-for-avtx-002-quisovalimab-in-patients-avtx-20230626monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-first-quarter-2023-financial-results-and-provides-business-updates-topline-d-avtx-20230504monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-2022-financial-results-and-provides-business-updates-completed-enrollment-of-avtx-20230329monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inc-announces-proposed-public-offering-of-common-stock-and-warrants-way-avtx-20230202monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-announces-it-has-completed-targeted-enrollment-of-80-patients-in-phase-2-peak-trial--avtx-20230117monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-third-quarter-2022-financial-results-and-provides-business-updates-topline-d-avtx-20221107monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-board-changes-wayne-avtx-20220811monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-second-quarter-2022-financial-results-and-provides-business-updates-transfer-avtx-20220804monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-transfers-anti-il-18-antibody-avtx-007-camoteskimab-to-apollo-therapeut-avtx-20220801monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-first-patient-dosed-in-the-phase-2-peak-trial-of-avtx-002-for-avtx-20220518monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-first-quarter-2022-financial-results-and-business-updates-reaffirms-mil-avtx-20220505monthly0.5https://www.biopharmawatch.com/news/AVTX/avtxxirxdeckxfina-1-copyright-2022-avalo-therapeutics-all-rights-reserved-avalo-is-a-leadi-avtx-20220316monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-reports-2021-financial-results-and-provides-business-updates-dr-garry-n-avtx-20220302monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-leadership-transition-promotes-dr-garry-neil-to-chief-executi-avtx-20220217monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-positive-phase-1b-results-for-avtx-002-in-moderate-to-severe-crohn-s-disease-avtx-20220106monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-appoints-two-new-independent-directors-to-its-board-wayne-avtx-20211206monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-reports-third-quarter-2021-financial-results-and-provides-business-updates-topline-p-avtx-20211109monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inc-announces-proposed-public-offering-of-common-stock-wayne-pa-and-roc-avtx-20210914monthly0.5https://www.biopharmawatch.com/news/AVTX/copyright-2021-avalo-therapeutics-inc-all-rights-reserved-innovation-driven-by-compassion--avtx-20210909monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inc-announces-corporate-name-change-from-cerecor-inc-name-change-unders-avtx-20210826monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-second-quarter-2021-financial-results-and-provides-business-updates-announ-avtx-20210802monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-announces-positive-initial-phase-1b-results-for-cerc-002-in-moderate-to-severe-cro-avtx-20210726monthly0.5https://www.biopharmawatch.com/news/AVTX/risks-related-to-our-financial-position-raising-funds-through-lending-arrangements-may-res-avtx-20210702monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-licenses-immune-checkpoint-program-from-sanford-burnham-prebys-further-expanding-p-avtx-20210623monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-enters-into-35-million-debt-financing-agreement-with-horizon-technology-finance-an-avtx-20210607monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-first-quarter-2021-financial-results-and-provides-business-updates-announc-avtx-20210513monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-announces-new-worldwide-license-agreement-with-kyowa-kirin-for-anti-light-antibody-avtx-20210329monthly0.5https://www.biopharmawatch.com/news/AVTX/forward-looking-statements-this-presentation-may-include-forward-looking-statements-made-p-avtx-20210317monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-2020-financial-results-and-provides-business-updates-announced-cerc-002-si-avtx-20210308monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-appoints-schond-l-greenway-as-chief-financial-officer-announces-inducement-grant-u-avtx-20210301monthly0.5https://www.biopharmawatch.com/news/AVTX/c-erecor-inc-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-ro-avtx-20210107monthly0.5https://www.biopharmawatch.com/news/AVTX/forward-looking-statements-this-presentation-may-include-forward-looking-statements-made-p-avtx-20210107monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-announces-successful-proof-of-concept-data-for-cerc-002-a-unique-light-neutralizin-avtx-20210105monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-third-quarter-2020-financial-results-and-provides-business-update-on-track-avtx-20201109monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-appoints-gilla-kaplan-ph-d-to-the-board-of-directors-rockville-md-and-chesterbrook-avtx-20201012monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-second-quarter-2020-financial-results-and-business-update-generated-net-pr-avtx-20200806monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-inc-announces-proposed-public-offering-of-common-stock-rockville-md-avtx-20200608monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in-covid-19-induced-ards-company-to-in-avtx-20200528monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-and-myriad-genetics-announce-that-levels-of-light-a-novel-cytokine-were-highly-cor-avtx-20200526monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-q1-2020-results-and-update-significantly-improved-cash-position-and-balanc-avtx-20200507monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-announces-changes-to-board-of-directors-appoints-sol-j-barer-ph-d-as-chairman-of-t-avtx-20200424monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-2019-results-avtx-20200311monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-and-aevi-genomic-medicine-complete-merger-cerecor-emerges-as-a-leading-biopharmace-avtx-20200203monthly0.5https://www.biopharmawatch.com/news/AVTX/unaudited-pro-forma-condensed-combined-financial-information-the-following-unaudited-pro-f-avtx-20191209monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-to-acquire-aevi-genomic-medicine-expands-clinical-stage-pipeline-further-positioni-avtx-20191205monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-third-quarter-2019-results-sale-of-pediatric-portfolio-in-a-deal-valued-in-avtx-20191114monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-closes-deal-to-sell-pediatric-portfolio-rockville-md-avtx-20191104monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-to-sell-pediatric-portfolio-to-aytu-bioscience-deal-valued-in-excess-of-32-million-avtx-20191014monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-second-quarter-2019-results-positive-final-results-with-cerc-301-in-noh-fi-avtx-20190808monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-appoints-keith-schmidt-to-its-board-of-directors-rockville-md-avtx-20190612monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-first-quarter-2019-results-positive-interim-results-from-the-phase-l-study-avtx-20190509monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-announces-leadership-changes-rockville-md-avtx-20190411monthly0.5https://www.biopharmawatch.com/news/AVTX/january-2019-cerecor-corporate-highlights-cerecor-inc-forward-looking-statements-this-pres-avtx-20190118monthly0.5https://www.biopharmawatch.com/news/AVTX/corporatehighlights-30th-annualpiperjaffray-healthcare-conference-lottenew-yorkpalace-new--avtx-20181127monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-third-quarter-2018-results-baltimore-marketwired-avtx-20181113monthly0.5https://www.biopharmawatch.com/news/AVTX/corporate-overview-oppenheimer-fall-summit-focused-on-specialty-pharma-rare-disease-compan-avtx-20180927monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-to-acquire-ichorion-therapeutics-transaction-worth-approximately-26-5-million-in-s-avtx-20180925monthly0.5https://www.biopharmawatch.com/news/AVTX/th-annual-global-investment-conference-sponsored-by-h-c-wainwright-september-4-6-2018-1-fo-avtx-20180905monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-second-quarter-2018-financial-results-baltimore-marketwired-avtx-20180809monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-appoints-simon-pedder-to-its-board-of-directors-baltimore-md-avtx-20180409monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-appoints-peter-greenleaf-as-chief-executive-officer-baltimore-md-avtx-20180328monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-to-acquire-avadel-pharmaceuticals-pediatric-assets-transaction-is-immediately-accr-avtx-20180212monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-acquires-trx-pharmaceuticals-addition-of-commercial-franchise-signals-strategic-sh-avtx-20171117monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-inc-reports-second-quarter-2017-financial-results-cash-position-improved-by-sale-o-avtx-20170814monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-inc-closes-5-0-million-private-placement-use-of-proceeds-to-advance-development-of-avtx-20170428monthly0.5https://www.biopharmawatch.com/news/AVTX/securities-and-exchange-commission-avtx-20170314monthly0.5https://www.biopharmawatch.com/news/AVTX/risk-factors-investing-in-our-common-stock-involves-a-high-degree-of-risk-before-you-decid-avtx-20170130monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-announces-at-the-market-equity-offering-program-baltimore-marketwired-avtx-20170127monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-announces-top-line-results-from-cerc-501-phase-2-study-for-nicotine-withdrawal-avtx-20161205monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-reports-top-line-data-from-cerc-301-phase-2-study-for-major-depressive-disorder-avtx-20161129monthly0.5https://www.biopharmawatch.com/news/AVTX/cerecor-inc-reports-third-quarter-2016-financial-results-baltimore-x2014-marketwired-x2014-avtx-20161108monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-first-quarter-2026-results-delivered-q1-2026-revenue-of-83-7-mi-cstl-20260506monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-fourth-quarter-and-full-year-2025-results-2025-total-test-repor-cstl-20260226monthly0.5https://www.biopharmawatch.com/news/CSTL/cstlq42025prel-2026-castle-biosciences-1-empowering-people-informing-care-decisions-prelim-cstl-20260113monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-second-quarter-2025-results-delivered-q2-2025-revenue-of-86-mil-cstl-20250804monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-first-quarter-2025-results-q1-2025-revenue-increased-21-over-q1-cstl-20250505monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-fourth-quarter-and-full-year-2024-results-full-year-2024-revenu-cstl-20250227monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-third-quarter-2024-results-q3-2024-revenue-increased-39-over-q3-cstl-20241104monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-second-quarter-2024-results-q2-2024-revenue-increased-74-over-q-cstl-20240805monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-first-quarter-2024-results-q1-2024-revenue-increased-74-over-q1-cstl-20240502monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-fourth-quarter-and-full-year-2023-results-full-year-2023-revenu-cstl-20240228monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-third-quarter-2023-results-q3-2023-revenue-increased-66-over-q3-cstl-20231102monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-second-quarter-2023-results-q2-2023-revenue-increased-44-over-q-cstl-20230802monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-first-quarter-2023-results-q1-2023-revenue-increased-57-over-q1-cstl-20230503monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-fourth-quarter-and-full-year-2022-results-full-year-2022-revenu-cstl-20230228monthly0.5https://www.biopharmawatch.com/news/CSTL/document-castle-biosciences-announces-third-quarter-2022-results-q3-2022-revenue-grew-by-5-cstl-20221102monthly0.5https://www.biopharmawatch.com/news/CSTL/document-castle-biosciences-reports-second-quarter-2022-results-q2-2022-revenue-increased--cstl-20220808monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-inc-unaudited-pro-forma-condensed-combined-financial-information-the-fo-cstl-20220603monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-first-quarter-2022-results-q1-2022-revenue-increased-18-over-q1-cstl-20220509monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-fourth-quarter-and-full-year-2021-results-full-year-2021-revenu-cstl-20220228monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-third-quarter-2021-results-q3-2021-revenue-grew-by-54-over-th-cstl-20211108monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-second-quarter-2021-results-q2-2021-revenues-of-22-8-million--cstl-20210809monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-first-quarter-2021-results-q1-2021-revenues-of-22-8-million-c-cstl-20210510monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-fourth-quarter-and-full-year-2020-results-full-year-2020-reve-cstl-20210308monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-commencement-of-proposed-public-offering-of-common-stock-cstl-20201214monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-third-quarter-2020-results-q3-2020-revenues-of-15-2-million-q-cstl-20201109monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-second-quarter-2020-results-q2-2020-revenues-of-12-7-million--cstl-20200810monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-first-quarter-2020-results-q1-2020-decisiondx-melanoma-test-r-cstl-20200511monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-fourth-quarter-and-full-year-2019-results-q4-2019-recognized--cstl-20200310monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-preliminary-fourth-quarter-and-full-year-2019-performance-res-cstl-20200109monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-inc-q3-2019-earnings-cstl-20191111monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-third-quarter-2019-results-q3-2019-decisiondx-melanoma-test-rep-cstl-20191111monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-second-quarter-2019-results-q2-2019-decisiondx-melanoma-test-re-cstl-20190903monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-closing-of-initial-public-offering-and-full-exercise-of-under-cstl-20190729monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-first-irwd-20260507monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-achieves-2025-f-irwd-20260225monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-maintains-fy-2025-financial-guidance-and-announces-fy-2026-financ-irwd-20260102monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-third-quarter-2025-results-raises-full-year-2025-f-irwd-20251110monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-second-quarter-2025-results-maintains-full-year-2025-fina-irwd-20250807monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-first-quarter-2025-results-on-track-to-achieve-fy-2025-fi-irwd-20250507monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reiterates-full-year-2025-linzess-u-s-net-sales-guidance-and-rais-irwd-20250425monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-clinical-and-regulatory-update-on-apraglutide-feedback-f-irwd-20250414monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-announces-receipt-of-nasdaq-non-compliance-notification-regarding-irwd-20250327monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-results-achieves-2024-f-irwd-20250227monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-third-quarter-2024-results-linzess-iinaclotide-eutrx-pres-irwd-20241107monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-second-quarter-2024-results-linzess-iinaclotide-eutrx-pre-irwd-20240808monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-first-quarter-2024-results-reported-positive-topline-resu-irwd-20240509monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-results-achieves-2023-f-irwd-20240215monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-maintains-fy-2023-financial-guidance-and-announces-fy-2024-financ-irwd-20240108monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-third-quarter-2023-results-linzess-iinaclotide-eutrx-pres-irwd-20231109monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-second-quarter-2023-results-raises-full-year-2023-linzess-irwd-20230808monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-and-vectivbio-announce-the-completion-of-the-tender-offer-for-vectivbio-shares-bo-irwd-20230629monthly0.5https://www.biopharmawatch.com/news/IRWD/execution-version-privileged-and-confidential-form-of-tender-and-support-agreement-this-te-irwd-20230521monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-first-quarter-2023-results-maintains-full-year-2023-finan-irwd-20230504monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-results-2022-gaap-and-n-irwd-20230216monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-update-on-fy-2022-financial-guidance-and-announces-fy-20-irwd-20230109monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-third-quarter-2022-results-maintains-full-year-202-irwd-20221103monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-second-quarter-2022-results-maintains-full-year-guidance--irwd-20220804monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-first-quarter-2022-results-maintains-full-year-2022-finan-irwd-20220505monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-results-linzess-linaclo-irwd-20220217monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-update-on-fy-2021-financial-guidance-and-announces-fy-20-irwd-20220110monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-third-quarter-2021-results-and-provides-corporate-develop-irwd-20211104monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-second-quarter-2021-results-raises-full-year-guida-irwd-20210805monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-first-quarter-2021-results-linzess-iinaclotide-u-s-net-sa-irwd-20210506monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-results-exceeding-or-me-irwd-20210217monthly0.5https://www.biopharmawatch.com/news/IRWD/this-presentation-contains-forward-looking-statements-investors-are-cautioned-not-to-place-irwd-20210111monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-appoints-jay-p-shepard-to-board-of-directors-irwd-20201203monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-third-quarter-2020-results-and-increases-full-year-irwd-20201105monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-second-quarter-2020-results-delivered-gaap-net-income-of--irwd-20200806monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-fourth-quarter-and-full-year-2019-results-exceedin-irwd-20200213monthly0.5https://www.biopharmawatch.com/news/IRWD/j-p-morgan-38-th-annual-healthcare-conference-ironwood-pharmaceuticals-january-2020-2-forw-irwd-20200113monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-third-quarter-2019-results-raises-full-year-2019-guidance-irwd-20191031monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-and-astrazeneca-amend-linzess-linaclotide-collaboration-in-china--irwd-20190918monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-second-quarter-2019-results-generated-12-million-in-gaap--irwd-20190730monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-to-establish-new-headquarters-in-downtown-boston-new-location-des-irwd-20190613monthly0.5https://www.biopharmawatch.com/news/IRWD/estimated-discontinued-operations-1q-2019-irwd-20190514monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-first-quarter-2019-results-announces-positive-2019-adjust-irwd-20190502monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-completes-separation-of-cyclerion-therapeutics-and-becomes-a-gast-irwd-20190401monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2018-investor-update-grew-2-irwd-20190213monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-announces-board-of-directors-for-ironwood-and-cyclerion-effective-irwd-20190124monthly0.5https://www.biopharmawatch.com/news/IRWD/j-p-morgan-healthcare-conference-january-7-10-2019-forward-looking-statements-this-present-irwd-20190107monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-announces-chief-executive-officers-to-lead-ironwood-and-cyclerion-irwd-20190104monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-third-quarter-2018-investor-update-linzess-linaclotide-u-irwd-20181106monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-second-quarter-2018-investor-update-second-quarter-reven-irwd-20180806monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-first-quarter-2018-investor-update-first-quarter-revenue-irwd-20180501monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2017-investor-update-genera-irwd-20180215monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-strengthens-executive-leadership-team-william-huyett-appointed-to-irwd-20171128monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-third-quarter-2017-investor-update-ironwood-revenue-grew-irwd-20171102monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-announces-leadership-change-irwd-20170906monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-second-quarter-2017-investor-update-linzess-linaclotide--irwd-20170803monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-first-quarter-2017-investor-update-linzess-linaclotide-u-irwd-20170508monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2016-investor-update-ironwo-irwd-20170221monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-appoints-amy-schulman-to-board-of-directors-irwd-20170104monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-third-quarter-2016-investor-update-ironwood-revenue-incr-irwd-20161103monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-closes-150-million-debt-refinancing-proceeds-will-be-used-to-redeem-all-outstandi-irwd-20160926monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-second-quarter-2016-investor-update-ironwood-revenue-inc-irwd-20160804monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-first-quarter-2016-investor-update-progress-across-prior-irwd-20160509monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-enters-into-u-s-licensing-agreement-with-astrazeneca-for-lesinura-irwd-20160426monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-appoints-andrew-dreyfus-to-board-of-directors-irwd-20160407monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2015-investor-update-key-ad-irwd-20160218monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-details-strategy-to-build-top-performing-commercial-biotechnology-irwd-20160111monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-third-quarter-2015-investor-update-linzess-linaclotide-p-irwd-20151103monthly0.5https://www.biopharmawatch.com/news/IRWD/allergan-investors-lisa-defrancesco-862-261-7152-media-mark-marmur-u-s-862-261-7558-janet--irwd-20151027monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-second-quarter-2015-investor-update-linzess-linaclotide--irwd-20150805monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-first-quarter-2015-investor-update-linzess-linaclotide-u-irwd-20150505monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-appoints-lawrence-olanoff-m-d-ph-d-to-board-of-directors-irwd-20150416monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-fourth-quarter-2014-investor-update-u-s-linzess-linaclot-irwd-20150212monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-third-quarter-2014-investor-update-strong-linzess-linacl-irwd-20141104monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-appoints-two-new-senior-executives-to-support-continued-growth-as-a-leader-in-gas-irwd-20140902monthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-provides-second-quarter-2014-investor-update-36-growth-in-total-l-irwd-20140804monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-a-acrs-20260507monthly0.5https://www.biopharmawatch.com/news/ACRS/clinical-pipeline-update-ati-052-full-sad-mad-results-ati-2138-potential-mechanistically-c-acrs-20260428monthly0.5https://www.biopharmawatch.com/news/ACRS/corporate-overview-january-2026-empowering-patients-through-therapeutic-innovation-2-any-s-acrs-20260112monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-interim-results-of-phase-1a-trial-of-anti-tslp-il--acrs-20260106monthly0.5https://www.biopharmawatch.com/news/ACRS/patient-focused-innovation-developing-therapeutic-franchises-to-address-gaps-in-important--acrs-20251014monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate--acrs-20250807monthly0.5https://www.biopharmawatch.com/news/ACRS/ati-2138-phase-2a-top-line-results-acrs-20250729monthly0.5https://www.biopharmawatch.com/news/ACRS/corporate-overview-june-2025-empowering-patients-through-therapeutic-innovation-2-disclaim-acrs-20250630monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-u-acrs-20250508monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-acrs-20250227monthly0.5https://www.biopharmawatch.com/news/ACRS/i-n-v-e-s-t-o-r-p-r-e-s-e-n-t-a-t-i-o-n-corporate-overview-january-2025-2-disclaimer-and-c-acrs-20250113monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-exclusive-global-license-agreement-with-biosion-inc-adding--acrs-20241118monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2024-financial-results-and-provides-a-corporate-acrs-20241106monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2024-financial-results-and-provides-a-corporat-acrs-20240807monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-sale-of-olumiant-royalties-and-milestones-to-omers-life-sci-acrs-20240716monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2024-financial-results-and-provides-a-corporate-acrs-20240507monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provi-acrs-20240227monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-leadership-changes-and-strategic-business-review-douglas-ma-acrs-20240116monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-provides-corporate-update-ati-1777-phase-2a-trial-results-published-i-acrs-20231219monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2023-aclaris-therapeutics-inc-all-rights-reserved-xa9-copyright-2020-aclaris-acrs-20231113monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2023-financial-results-and-provides-a-corporate-acrs-20231106monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-results-from-phase-1-multiple-ascending-dose-trial-acrs-20230918monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2023-financial-results-and-provides-a-corporat-acrs-20230807monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2023-financial-results-and-provides-a-corporate-acrs-20230508monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2023-aclaris-therapeutics-inc-all-rights-reserved-xa9-copyright-2020-aclaris-acrs-20230414monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-preliminary-topline-data-from-12-week-phase-2a-study-of-ora-acrs-20230306monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provi-acrs-20230223monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2020-aclaris-therapeutics-inc-all-rights-reserved-xx-xa9-copyright-2023-acla-acrs-20230109monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2022-financial-results-and-provides-a-corporate-acrs-20221108monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2022-financial-results-and-provides-a-corporat-acrs-20220803monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2022-financial-results-and-provides-a-corporate-acrs-20220510monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provi-acrs-20220224monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2020-aclaris-therapeutics-inc-all-rights-reserved-xx-xa9-copyright-2021-acla-acrs-20211207monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2021-financial-results-and-provides-a-corporate-acrs-20211102monthly0.5https://www.biopharmawatch.com/news/ACRS/united-states-district-court-southern-district-of-new-york-in-re-aclaris-therapeutics-inc--acrs-20210827monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2021-financial-results-and-provides-a-corporat-acrs-20210805monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-proposed-public-offering-of-common-stock-wayne-pa-acrs-20210608monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2020-aclaris-therapeutics-inc-all-rights-reserved-xx-xa9-copyright-2021-acla-acrs-20210608monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2021-financial-results-and-provides-a-corporate-acrs-20210507monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-provi-acrs-20210225monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-proposed-public-offering-of-common-stock-wayne-pa-acrs-20210119monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2021-aclaris-therapeutics-inc-all-rights-reserved-pp-us-0544-01-21-ati-450-r-acrs-20210119monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2020-financial-results-and-provides-a-corporate-acrs-20201104monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2020-aclaris-therapeutics-inc-all-rights-reserved-xx-xa9-copyright-2020-acla-acrs-20200915monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2020-financial-results-and-provides-r-d-and-bu-acrs-20200807monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2020-aclaris-therapeutics-inc-all-rights-reserved-pp-us-0484-06-20-ati-450-a-acrs-20200617monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2020-aclaris-therapeutics-inc-all-rights-reserved-xx-xa9-copyright-2020-acla-acrs-20200527monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2020-aclaris-therapeutics-inc-all-rights-reserved-xx-xa9-copyright-2020-acla-acrs-20200515monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2020-financial-results-and-provides-r-d-and-bus-acrs-20200507monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-secures-11-million-term-loan-facility-wayne-pa-x2013-acrs-20200331monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-provi-acrs-20200225monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2020-aclaris-therapeutics-inc-all-rights-reserved-xa9-copyright-2020-aclaris-acrs-20200113monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-appointment-of-vincent-milano-to-board-of-directors-wayne-p-acrs-20200108monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2019-aclaris-therapeutics-inc-all-rights-reserved-xa9-copyright-2019-aclaris-acrs-20191203monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2019-aclaris-therapeutics-inc-all-rights-reserved-xa9-copyright-2019-aclaris-acrs-20191121monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2019-financial-results-and-provides-business-hi-acrs-20191107monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-divestiture-of-rhofade-xae-wayne-pa-x2013-acrs-20191010monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2019-aclaris-therapeutics-all-rights-reserved-empowering-patients-through-re-acrs-20190927monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-new-strategic-direction-xb7-completion-of-strategic-review--acrs-20190905monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2019-financial-results-provides-business-strat-acrs-20190808monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-phase-2-clinical-trial-of-ati-501-oral-in-patients-with-alo-acrs-20190730monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-appointment-of-maxine-gowen-to-board-of-directors-wayne-pa--acrs-20190703monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-6-month-results-from-a-phase-2-open-label-clinical-acrs-20190617monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2019-aclaris-therapeutics-inc-all-rights-reserved-xa9-copyright-2019-aclaris-acrs-20190605monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2019-financial-results-and-provides-update-on-c-acrs-20190508monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2019-aclaris-therapeutics-inc-all-rights-reserved-xa9-copyright-2019-aclaris-acrs-20190404monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-provi-acrs-20190318monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-provides-update-on-oral-and-topical-jak-1-3-inhibitor-clinical-trials-acrs-20181217monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-closes-acquisition-of-rhofade-xae-oxymetazoline-hydrochloride-cream-1-acrs-20181203monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2018-financial-results-and-provides-update-on-c-acrs-20181106monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-acquire-worldwide-rights-to-rhofade-xae-from-allergan-wayne-pa-acrs-20181015monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2018-financial-results-and-provides-update-on--acrs-20180803monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2018-financial-results-and-provides-update-on-c-acrs-20180508monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-appointment-of-bryan-reasons-as-a-director-and-chairman-of--acrs-20180424monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-provi-acrs-20180312monthly0.5https://www.biopharmawatch.com/news/ACRS/company-overview-dr-neal-walker-president-and-ceo-january-2018-xa9-copyright-2018-aclaris--acrs-20180108monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-receives-fda-approval-for-eskata-x2122-hydrogen-peroxide-topical-solu-acrs-20171215monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2017-financial-results-management-to-host-confe-acrs-20171107monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-r-d-and-investor-day-acrs-20171004monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-appointment-of-andrew-schiff-to-board-of-directors-malvern-pa-x2013-acrs-20170809monthly0.5https://www.biopharmawatch.com/news/ACRS/ex-99-1-aclaris-therapeutics-reports-second-quarter-2017-financial-results-management-to-h-acrs-20170808monthly0.5https://www.biopharmawatch.com/news/ACRS/acrs-ex-99-1-aclaris-therapeutics-acquires-confluence-life-sciences-inc-expands-pipeline-o-acrs-20170808monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2017-financial-results-management-to-host-confe-acrs-20170509monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-provi-acrs-20170315monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-appointment-of-andrew-powell-to-board-of-directors-malvern-pa-x2013-acrs-20170126monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-top-line-phase-3-results-for-a-101-in-treating-seb-acrs-20161115monthly0.5https://www.biopharmawatch.com/news/ACRS/release-aclaris-therapeutics-reports-third-quarter-2016-financial-results-management-to-ho-acrs-20161103monthly0.5https://www.biopharmawatch.com/news/ACRS/xa9-copyright-2016-aclaris-therapeutics-all-rights-reserved-a-1-company-overview-1-dr-neal-acrs-20160913monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2016-financial-results-management-to-host-conf-acrs-20160811monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-appointment-of-bill-humphries-to-board-of-directors-malvern-pa-x2013-aug-acrs-20160804monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2016-financial-results-management-to-host-confe-acrs-20160511monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-acquires-worldwide-rights-to-compounds-and-key-intellectual-property--acrs-20160328monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2015-operating-and-financial-res-acrs-20160323monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2015-financial-results-malvern-pa-acrs-20151118monthly0.5https://www.biopharmawatch.com/news/BWAY/from-an-innovative-technology-to-a-fast-growing-arr-company-investor-deck-may-2026-nasdaq--bway-20260513monthly0.5https://www.biopharmawatch.com/news/BWAY/from-an-innovative-technology-to-a-fast-growing-arr-company-investor-deck-march-2026-nasda-bway-20260317monthly0.5https://www.biopharmawatch.com/news/BWAY/advanced-noninvasive-neurostimulation-treatments-for-mental-health-disorders-investor-deck-bway-20251112monthly0.5https://www.biopharmawatch.com/news/BWAY/a-new-era-in-brain-disorder-treatment-corporate-presentation-nasdaq-tase-bway-august-2025-bway-20250813monthly0.5https://www.biopharmawatch.com/news/BWAY/hartum-street-bynet-building-3rd-floor-bway-20211117monthly0.5https://www.biopharmawatch.com/news/BWAY/brainsway-ltd-condensed-interim-consolidated-financial-statements-as-of-september-30-2020--bway-20210222monthly0.5https://www.biopharmawatch.com/news/BWAY/brainsway-ltd-announces-pricing-of-initial-public-offering-of-2-5-million-american-deposit-bway-20190416monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-first-quarter-2026-financial-results-and-raises-2026-revenue-gu-npce-20260512monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-fourth-quarter-and-full-year-2025-financial-results-and-reitera-npce-20260303monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-third-quarter-2025-financial-results-and-increases-2025-revenue-npce-20251104monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-second-quarter-2025-financial-results-and-increases-2025-revenu-npce-20250812monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-strategic-cfo-transition-appoints-patrick-f-williams-as-chief-financia-npce-20250624monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-first-quarter-2025-financial-results-reported-record-quarterly--npce-20250513monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-provides-update-on-tariff-status-minimal-expected-impact-to-operations-and-finan-npce-20250414monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-refocusing-of-product-portfolio-beginning-of-wind-down-of-stereo-eeg-s-npce-20250402monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-fourth-quarter-and-full-year-2024-financial-results-record-quar-npce-20250304monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-completes-repurchase-of-5-3-million-shares-of-its-common-stock-from-kck-ltd-moun-npce-20250220monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-issues-2025-financial-guidance-targets-2025-revenue-guidance-of-92-million-to-96-npce-20250128monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2024-an-npce-20250108monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-third-quarter-2024-financial-results-and-increases-2024-revenue-npce-20241112monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-second-quarter-2024-financial-results-and-increases-2024-revenu-npce-20240813monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-first-quarter-2024-financial-results-and-provides-corporate-upd-npce-20240508monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-announces-record-full-year-2023-revenue-of-65-4-million-revenue-increas-npce-20240305monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2023-an-npce-20240108monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-third-quarter-2023-financial-results-and-increases-full-year-20-npce-20231106monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-second-quarter-2023-financial-results-and-increases-full-year-2-npce-20230808monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-first-quarter-2023-financial-results-and-increases-full-year-20-npce-20230504monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-fourth-quarter-full-year-2022-financial-results-mountain-view-c-npce-20230302monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-revenue-and-ap-npce-20230109monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-third-quarter-2022-financial-results-and-provides-a-business-up-npce-20221108monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-second-quarter-2022-financial-results-and-provides-a-business-u-npce-20220811monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-first-quarter-2022-financial-results-mountain-view-calif-npce-20220512monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-fourth-quarter-full-year-2021-financial-results-mountain-view-c-npce-20220310monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-preliminary-unaudited-fourth-quarter-and-full-year-2021-revenue-mounta-npce-20220111monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-third-quarter-2021-financial-results-mountain-view-calif-npce-20211110monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-second-quarter-2021-financial-results-mountain-view-calif-npce-20210812monthly0.5https://www.biopharmawatch.com/news/NPCE/document-neuropace-reports-first-quarter-2021-financial-results-and-provides-2021-financia-npce-20210603monthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-reports-full-year-2025-financial-results-and-confirms-2026-outlook-cash-and-cash-in-agmb-20260424monthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-announces-launch-of-initial-public-offering-agmb-20260202monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-first-quarter-2026-financial-results-and-provides-business-update-pr-caba-20260514monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-presents-preconditioning-free-clinical-data-and-automated-manufacturing-tran-caba-20260514monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-this-presentation-including-any-printed-or-electronic-copy-of-these-slides-the--caba-20260420monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-2026-strategic-priorities-registrational-myositis-trial-actively-e-caba-20260112monthly0.5https://www.biopharmawatch.com/news/CABA/corporate-presentation-october-2025-disclaimer-this-presentation-including-any-printed-or--caba-20251029monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-presents-positive-clinical-data-and-development-updates-for-rese-cel-at-acr--caba-20251024monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-presents-first-rese-cel-data-with-no-preconditioning-demonstrating-biologic--caba-20250930monthly0.5https://www.biopharmawatch.com/news/CABA/corporate-presentation-september-2025-disclaimer-this-presentation-including-any-printed-o-caba-20250827monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-second-quarter-2025-financial-results-and-provides-business-update-x-caba-20250731monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-new-rese-cel-safety-and-efficacy-data-in-patients-with-myositis-lu-caba-20250530monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-2027-rese-cel-bla-submission-anticipated-in-myositis-following-rec-caba-20250509monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-bus-caba-20250314monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-updated-clinical-data-demonstrating-deepening-clinical-responses-a-caba-20250213monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20250218monthly0.5https://www.biopharmawatch.com/news/CABA/corporate-presentation-january-2025-2025-cabaletta-bio-all-rights-reserved-disclaimer-the--caba-20241231monthly0.5https://www.biopharmawatch.com/news/CABA/caba-201-clinical-and-translational-data-from-the-reset-phase-1-2-trials-november-2024-202-caba-20241112monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-third-quarter-2024-financial-results-and-provides-business-update-x2-caba-20241114monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20241004monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-second-quarter-2024-financial-results-and-provides-business-update-n-caba-20240805monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20240612monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-first-quarter-2024-financial-results-and-provides-business-update-no-caba-20240515monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-bus-caba-20240321monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-fda-granted-orphan-drug-designation-to-caba-201-for-treatment-of-s-caba-20240320monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-fda-granted-orphan-drug-designation-to-caba-201-for-treatment-of-m-caba-20240201monthly0.5https://www.biopharmawatch.com/news/CABA/corporate-presentation-january-2024-2024-cabaletta-bio-all-rights-reserved-disclaimer-the--caba-20240108monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-third-quarter-2023-financial-results-and-provides-business-update-in-caba-20231109monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-receives-fda-clearance-of-caba-201-ind-application-for-treatment-of-generali-caba-20231106monthly0.5https://www.biopharmawatch.com/news/CABA/corporate-presentation-october-2023-2023-cabaletta-bio-all-rights-reserved-disclaimer-the--caba-20231002monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20230905monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-and-wuxi-advanced-therapies-announce-expansion-of-gmp-manufacturing-agreemen-caba-20230822monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-second-quarter-2023-financial-results-and-provides-business-update-r-caba-20230810monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-appoints-global-commercial-leader-shawn-tomasello-to-board-of-directors-ms-t-caba-20230724monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-closing-of-100-million-public-offering-of-common-stock-including-f-caba-20230522monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-pricing-of-public-offering-of-common-stock-philadelphia-caba-20230517monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20230509monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-receives-fda-clearance-of-ind-application-for-caba-201-for-treatment-of-myos-caba-20230516monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-first-quarter-2023-financial-results-and-provides-business-update-in-caba-20230511monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-american-society-of-gene-and-cell-therapy-26th-annual-meet-caba-20230502monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20230501monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20230331monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-bus-caba-20230316monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20230306monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20230109monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-35-million-offering-philadelphia-caba-20221208monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20221208monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-third-quarter-2022-financial-results-and-provides-business-update-ph-caba-20221110monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20221011monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20220912monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-data-at-the-31st-eadv-congress-and-provides-update-on-descaartes--caba-20220829monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-second-quarter-2022-financial-results-and-provides-business-update-p-caba-20220811monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20220518monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-first-quarter-2022-financial-results-and-provides-business-update-de-caba-20220512monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-dsg3-caart-clinical-data-and-musk-caart-preclinical-data-at-upcom-caba-20220502monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-bus-caba-20220317monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20220314monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20220303monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20220108monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20211212monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-third-quarter-2021-financial-results-and-provides-business-update-do-caba-20211031monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20210817monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-second-quarter-2021-financial-results-and-provides-business-update-c-caba-20210805monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-appoints-biopharmaceutical-leader-scott-brun-m-d-to-board-of-directors-dr-br-caba-20210628monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20210603monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-first-quarter-2021-financial-results-and-provides-new-pipeline-updat-caba-20210430monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20210406monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-a-b-caba-20210316monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-third-quarter-2020-financial-results-and-provides-business-update-ph-caba-20201110monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-second-quarter-2020-financial-results-and-provides-business-update-p-caba-20200806monthly0.5https://www.biopharmawatch.com/news/CABA/disclaimer-the-following-presentation-including-any-printed-or-electronic-copy-of-these-sl-caba-20200603monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-expansion-of-sponsored-research-agreement-with-the-university-of-p-caba-20200528monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-first-quarter-2020-financial-results-and-provides-business-update-ph-caba-20200512monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-bus-caba-20200330monthly0.5https://www.biopharmawatch.com/news/CABA/the-following-presentation-including-any-printed-or-electronic-copy-of-these-slides-the-ta-caba-20200220monthly0.5https://www.biopharmawatch.com/news/CABA/fda-grants-dsg3-caart-orphan-drug-designation-for-the-treatment-of-pemphigus-vulgaris-phil-caba-20200129monthly0.5https://www.biopharmawatch.com/news/CABA/the-following-presentation-including-any-printed-or-electronic-copy-of-these-slides-the-ta-caba-20200110monthly0.5https://www.biopharmawatch.com/news/CADL/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-cadl-20260514monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-proposed-100-million-public-offering-cadl-20260219monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-100m-royalty-funding-agreement-with-rtw-to-support-the-poten-cadl-20260219monthly0.5https://www.biopharmawatch.com/news/CADL/research-development-day-virtual-event-cadl-20251205monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-second-quarter-2025-financial-results-and-recent-corporate-hig-cadl-20250814monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-15-million-registered-direct-offering-of-common-stock-cadl-20250624monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-charles-schoch-as-chief-financial-officer-interim-cfo-elevate-cadl-20250623monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-maha-radhakrishnan-m-d-to-its-board-of-directors-appointment--cadl-20250606monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-ca-cadl-20250528monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-presents-positive-phase-3-can-2409-results-in-localized-prostate-cance-cadl-20250522monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-first-quarter-2025-financial-results-and-recent-corporate-high-cadl-20250513monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-oral-presentation-of-positive-phase-3-can-2409-results-in-lo-cadl-20250423monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-both-prolonged-median-overall-survival-and-long-tail-of-surviv-cadl-20250327monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-cadl-20250313monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-positive-final-survival-data-from-randomized-controlled-phas-cadl-20250225monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-provides-corporate-update-and-highlights-strong-pipeline-momentum-and--cadl-20241231monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-80-million-proposed-public-offering-cadl-20241212monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-can-2409-achieved-primary-endpoint-in-phase-3-prostate-cance-cadl-20241211monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-high-cadl-20241114monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-showcases-innovative-cancer-therapy-candidates-at-16th-annual-internat-cadl-20241028monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-second-quarter-2024-financial-results-and-recent-corporate-hig-cadl-20240813monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-prolonged-overall-survival-in-phase-2-clinical-trial-of-can-24-cadl-20240523monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-first-quarter-2024-financial-results-and-recent-corporate-high-cadl-20240514monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-upcoming-presentations-at-the-2024-asco-annual-meeting-cadl-20240425monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-receives-fda-orphan-drug-designation-for-can-2409-for-the-treatment-of-cadl-20240411monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-presents-preclinical-data-at-aacr-on-immunotherapy-candidate-for-induc-cadl-20240409monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-positive-interim-data-from-randomized-phase-2-clinical-trial-cadl-20240404monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-cadl-20240328monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-an-upcoming-presentation-at-the-aacr-annual-meeting-unveilin-cadl-20240305monthly0.5https://www.biopharmawatch.com/news/CADL/can-3110-receives-fda-fast-track-designation-for-treatment-of-recurrent-high-grade-glioma-cadl-20240213monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-receives-fda-fast-track-designation-for-can-x2011-2409-in-pancreatic-c-cadl-20231212monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-third-quarter-2023-financial-results-and-recent-corporate-high-cadl-20231109monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-presents-preclinical-data-from-its-enlighten-discovery-platform-at-sit-cadl-20231103monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-initial-positive-interim-data-from-randomized-phase-2-clinic-cadl-20231103monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-nature-publication-showing-extended-survival-associated-with-cadl-20231018monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-encouraging-initial-survival-data-from-phase-2-clinical-trial--cadl-20230926monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-second-quarter-2023-financial-results-and-recent-corporate-hig-cadl-20230810monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-it-expects-to-report-topline-data-from-its-phase-2-clinical--cadl-20230613monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-experienced-manufacturing-leader-nicoletta-loggia-phd-rph-to--cadl-20230608monthly0.5https://www.biopharmawatch.com/news/CADL/can-3110-a-novel-oncolytic-virus-engineered-for-enhanced-activity-and-safety-hsv-1-enginee-cadl-20230519monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-first-quarter-2023-financial-results-and-recent-corporate-high-cadl-20230511monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-receives-fda-fast-track-designation-for-can-x2011-2409-in-non-small-ce-cadl-20230417monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-cadl-20230330monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-r-d-day-presentations-spotlight-its-advanced-pipeline-and-capabilities-cadl-20221206monthly0.5https://www.biopharmawatch.com/news/CADL/research-development-day-virtual-cadl-20221206monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-host-virtual-r-d-day-on-cadl-20221129monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-oral-presentation-of-updated-data-from-its-phase-1-clinical--cadl-20221118monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-late-breaking-oral-presentation-at-sitc-annual-meeting-with--cadl-20221111monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-third-quarter-2022-financial-results-and-recent-corporate-high-cadl-20221110monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-two-executive-leadership-appointments-jason-a-amello-joins-c-cadl-20220907monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-second-quarter-2022-financial-results-and-recent-corporate-hig-cadl-20220805monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-three-new-members-to-its-board-of-directors-gary-nabel-md-phd-cadl-20220801monthly0.5https://www.biopharmawatch.com/news/CADL/breakfast-event-during-asco-2022-annual-meeting-nasdaq-cadl-tipping-the-balance-in-favor-o-cadl-20220606monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-release-of-initial-data-on-can-2409-in-a-phase-2-clinical-tr-cadl-20220526monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-first-quarter-2022-financial-results-and-recent-corporate-high-cadl-20220512monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-cadl-20220329monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-25-million-non-dilutive-debt-financing-agreement-with-silico-cadl-20220301monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-dr-francesca-barone-as-chief-scientific-officer-cadl-20220203monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-third-quarter-2021-financial-results-and-recent-corporate-high-cadl-20211112monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-reports-second-quarter-2021-financial-results-and-recent-corporate-hig-cadl-20210908monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-closing-of-initial-public-offering-including-the-partial-exe-cadl-20210817monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mollie-cond-hstm-20210726monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mollie-cond-hstm-20210426monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mollie-cond-hstm-20210222monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-healthstream-615-301-3237-mollie-condra-healthstream-com-health-hstm-20210119monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-healthstream-615-301-3237-mollie-condra-healthstream-com-health-hstm-20201210monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-for-immediate-release-contact-mollie-condra-ph-d-healthstream-615--hstm-20201203monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-for-immediate-release-contact-mollie-condra-ph-d-healthstream-615--hstm-20201130monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mollie-cond-hstm-20201026monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-healthstream-615-301-3237-mollie-condra-healthstream-com-health-hstm-20201012monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mollie-cond-hstm-20200727monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mollie-cond-hstm-20200427monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-healthstream-615-301-3237-mollie-condra-healthstream-com-health-hstm-20200313monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-healthstream-615-301-3237-mollie-condra-healthstream-com-health-hstm-20200309monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mollie-cond-hstm-20200218monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-for-immediate-release-contact-mollie-condra-ph-d-healthstream-615--hstm-20191216monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mollie-cond-hstm-20191021monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-healthstream-615-301-3237-mollie-condra-healthstream-com-scott--hstm-20190925monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-interim-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mol-hstm-20190722monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-healthstream-615-301-3237-mollie-condra-healthstream-com-health-hstm-20190627monthly0.5https://www.biopharmawatch.com/news/HSTM/scott-a-roberts-interim-chief-financial-officer-615-301-3182-ir-healthstream-com-media-mol-hstm-20190422monthly0.5https://www.biopharmawatch.com/news/HSTM/gerard-m-hayden-jr-chief-financial-officer-615-301-3163-ir-healthstream-com-media-mollie-c-hstm-20190219monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-for-immediate-release-contact-mollie-condra-ph-d-healthstream-615--hstm-20190110monthly0.5https://www.biopharmawatch.com/news/HSTM/gerard-m-hayden-jr-chief-financial-officer-615-301-3163-ir-healthstream-com-media-mollie-c-hstm-20181022monthly0.5https://www.biopharmawatch.com/news/HSTM/gerard-m-hayden-jr-chief-financial-officer-615-301-3163-ir-healthstream-com-media-mollie-c-hstm-20180723monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-healthstream-615-301-3237-mollie-condra-healthstream-com-health-hstm-20180516monthly0.5https://www.biopharmawatch.com/news/HSTM/healthstream-inc-unaudited-pro-forma-condensed-consolidated-financial-information-on-hstm-20180212monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-vice-president-investor-relations-communications-healthstream-i-hstm-20170626monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-mollie-condra-ph-d-vice-president-investor-relations-communications-healthstream-i-hstm-20170301monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-media-contact-for-immediate-release-healthstream-inc-mollie-condra-hstm-20160808monthly0.5https://www.biopharmawatch.com/news/HSTM/within-the-current-report-on-form-8-k-a-filed-with-the-sec-on-hstm-20150911monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-for-immediate-release-contact-gerard-m-hayden-jr-chief-financial-o-hstm-20150528monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-for-immediate-release-contact-gerard-m-hayden-jr-chief-financial-o-hstm-20150521monthly0.5https://www.biopharmawatch.com/news/HSTM/contact-gerard-m-hayden-jr-chief-financial-officer-615-301-3163-ir-healthstream-com-mollie-hstm-20150518monthly0.5https://www.biopharmawatch.com/news/HSTM/to-this-form-8-k-this-discussion-contains-forward-looking-statements-that-involve-risks-an-hstm-20150518monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-for-immediate-release-contact-mollie-condra-ph-d-healthstream-615--hstm-20150316monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-for-immediate-release-contact-mollie-condra-ph-d-healthstream-615--hstm-20150213monthly0.5https://www.biopharmawatch.com/news/HSTM/p-r-e-s-s-r-e-l-e-a-s-e-media-contact-for-immediate-release-healthstream-inc-mollie-condra-hstm-20141009monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-reports-first-quarter-2026-financial-results-and-corporate-update-q1-2026-net-revenu-zvra-20260506monthly0.5https://www.biopharmawatch.com/news/ZVRA/document-zevra-therapeutics-sells-sdx-portfolio-to-commave-therapeutics-for-50-million-com-zvra-20260316monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-reports-fourth-quarter-and-full-year-2025-financial-results-q4-net-revenue-of-34-1-m-zvra-20260309monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-inc-appoints-alicia-secor-to-board-of-directors-announces-retirement-of-zvra-20251202monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-inc-announces-cfo-transition-celebration-fl-zvra-20251120monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-reports-third-quarter-2025-financial-results-and-corporate-update-2025-eps-of-0-01-q-zvra-20251105monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-reports-second-quarter-2025-financial-results-and-corporate-update-q2-2025-net-reven-zvra-20250812monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-announces-closing-of-sale-of-rare-pediatric-disease-priority-review-voucher-for-150--zvra-20250407monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-enters-agreement-to-sell-its-rare-pediatric-disease-priority-review-vou-zvra-20250227monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-completes-acquisition-of-acer-therapeutics-in-its-journey-to-become-a-l-zvra-20231120monthly0.5https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-to-acquire-acer-therapeutics-expanding-its-rare-disease-portfolio-and-a-zvra-20230831monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-strategic-acquisition-of-arimoclomol-from-orphazyme-expanding-its-rare--zvra-20220516monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-pricing-of-50-million-public-offering-of-common-stock-and-warrants-and--zvra-20210108monthly0.5https://www.biopharmawatch.com/news/ZVRA/executive-compensation-our-chief-executive-officer-and-two-of-our-other-most-highly-compen-zvra-20201231monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-debt-restructuring-with-deerfield-and-delaware-street-capital-principal-zvra-20191218monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-provides-updates-regarding-its-board-of-directors-zvra-20190920monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-entry-into-definitive-collaboration-and-license-agreement-for-its-adhd--zvra-20190904monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-reports-second-quarter-2019-results-zvra-20190813monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-reports-first-quarter-2019-results-zvra-20190514monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-reports-q4-and-fy-2018-results-zvra-20190228monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-zvra-20181108monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-pricing-of-public-offering-of-common-stock-coralville-ia-zvra-20181005monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-proposed-public-offering-of-common-stock-coralville-ia-zvra-20181004monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-zvra-20180809monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-reports-fourth-quarter-and-year-end-2017-results-zvra-20180329monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-fda-approval-of-apadaz-benzhydrocodone-and-acetaminophen-for-the-short--zvra-20180223monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-reports-third-quarter-2017-results-and-provides-corporate-update-zvra-20171109monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-fdrr-process-completion-and-resubmission-of-the-apadaz-nda-fda-has-assi-zvra-20170912monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-second-quarter-2017-results-conference-call-and-live-audio-webcast-wi-zvra-20170810monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-preliminary-results-from-kp415-pharmacokinetic-single-and-multiple-dose-zvra-20170810monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-strengthens-adhd-prodrug-pipeline-with-development-of-kp484-a-new-super-extended--zvra-20170628monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-first-quarter-2017-results-conference-call-and-live-audio-webcast-wit-zvra-20170523monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-first-quarter-2017-results-conference-call-and-live-audio-webcast-wit-zvra-20170510monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-fourth-quarter-and-year-end-2016-results-conference-call-and-live-aud-zvra-20170309monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-reports-positive-data-from-phase-1-intranasal-pharmacokinetic-study-of-kp511-an-i-zvra-20170109monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-s-kp415-an-investigational-prodrug-of-d-methylphenidate-completes-phase-1-proof-o-zvra-20161214monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-third-quarter-2016-results-conference-call-and-live-audio-webcast-wit-zvra-20161109monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-announces-licensing-agreement-with-acura-pharmaceuticals-for-aversion-abuse-deter-zvra-20161018monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-ndrs-presentation-09-21-16-zvra-20160921monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-provides-corporate-and-clinical-updat-e-conference-call-and-live-audio-webcas-zvra-20160915monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-second-quarter-2016-results-conference-call-and-live-audio-webcast-sc-zvra-20160810monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-s-prodrug-of-hydromorphone-kp511-demonstrates-comparable-oral-pharmacokinetics-to-zvra-20160628monthly0.5https://www.biopharmawatch.com/news/ZVRA/fda-issues-complete-response-letter-for-apadaz-tm-new-drug-application-coralville-ia-zvra-20160613monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-files-nda-amendment-request-with-fda-for-apadaz-tm-discussions-on-going-with-fda--zvra-20160609monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-first-quarter-2016-results-conference-call-and-live-audio-webcast-sch-zvra-20160512monthly0.5https://www.biopharmawatch.com/news/ZVRA/statement-regarding-fda-advisory-committee-meeting-on-kempharm-s-abuse-deterrent-product-c-zvra-20160505monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-q4-and-year-end-2015-results-conference-call-and-live-audio-webcast-s-zvra-20160310monthly0.5https://www.biopharmawatch.com/news/ZVRA/fda-grants-priority-review-to-kempharm-for-kp201-apap-nda-if-approved-kp201-apap-could-bec-zvra-20160210monthly0.5https://www.biopharmawatch.com/news/ZVRA/to-kempharm-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-zvra-20160209monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-expands-pain-therapy-pipeline-with-discovery-of-kp746-novel-prodrug-of-oxymor-zvra-20151230monthly0.5https://www.biopharmawatch.com/news/ZVRA/unless-the-context-otherwise-requires-we-use-the-terms-kempharm-the-company-we-us-and-our--zvra-20151218monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-submits-nda-for-kp201-apap-and-requests-priority-review-from-the-fda-if-approved--zvra-20151215monthly0.5https://www.biopharmawatch.com/news/ZVRA/cautionary-note-regarding-presentation-information-this-presentation-contains-forward-look-zvra-20151208monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-q3-2015-results-conference-call-and-live-audio-webcast-scheduled-for--zvra-20151112monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-completes-human-abuse-liability-program-for-kp201-apap-results-from-second-in-zvra-20151021monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-reports-positive-data-demonstrating-tamper-resistant-properties-of-kp201-apap-res-zvra-20150930monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-expands-its-abuse-deterrent-opioid-pipeline-with-new-acetaminophen-free-immediate-zvra-20150924monthly0.5https://www.biopharmawatch.com/news/ZVRA/cautionary-note-regarding-presentation-information-this-presentation-has-been-prepared-by--zvra-20150918monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-announces-positive-data-from-intranasal-human-abuse-liability-study-of-kp201--zvra-20150813monthly0.5https://www.biopharmawatch.com/news/ZVRA/cautionary-note-regarding-presentation-information-this-presentation-contains-forward-look-zvra-20150812monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-announces-changes-to-senior-leadership-to-target-strategic-opportunities-rust-zvra-20150625monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-management-presentation-zvra-20150616monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-positive-data-from-oral-human-abuse-liability-clinical-trial-of-kp201-zvra-20150611monthly0.5https://www.biopharmawatch.com/news/ZVRA/kempharm-inc-reports-q1-2015-results-conference-call-and-live-audio-webcast-scheduled-for--zvra-20150520monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2026-financial-results-minneapolis-mn-tcmd-20260504monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-strengthens-board-of-directors-with-appointment-of-andrea-pearson-minneapo-tcmd-20260309monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2025-financial-results-tcmd-20260217monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2025-financial-results-minneapolis-mn-tcmd-20251103monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2025-financial-results-minneapolis-m-tcmd-20250804monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2025-financial-results-minneapolis-mn-tcmd-20250505monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2024-financial-results-tcmd-20250218monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-appoints-laura-king-to-board-of-directors-minneapolis-tcmd-20250113monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2024-financial-results-authorizes-sha-tcmd-20241104monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2024-financial-results-minneapolis-m-tcmd-20240805monthly0.5https://www.biopharmawatch.com/news/TCMD/united-states-district-court-district-of-delaware-jack-weaver-derivatively-on-behalf-of-ta-tcmd-20240705monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2024-financial-results-reaffirms-full-tcmd-20240506monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-ceo-transition-and-preliminary-first-quarter-2024-revenue-ceo-da-tcmd-20240423monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2023-financial-results-tcmd-20240220monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2023-financial-results-updates-full-y-tcmd-20231106monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-appoints-vindell-washington-m-d-to-board-of-directors-minneapolis-tcmd-20231002monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2023-financial-results-updates-full--tcmd-20230807monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-appoints-sherri-ferstler-as-senior-vice-president-of-sales-minneapolis-tcmd-20230718monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2023-financial-results-raises-full-ye-tcmd-20230508monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-appoints-elaine-birkemeyer-as-chief-financial-officer-minneapolis-mn-tcmd-20230314monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-announces-proposed-public-offering-of-common-stock-minneapo-tcmd-20230223monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2022-financial-results-tcmd-20230221monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-appoints-carmen-volkart-to-board-of-directors-minneapolis-tcmd-20230105monthly0.5https://www.biopharmawatch.com/news/TCMD/november-2022investor-presentationnasdaq-tcmd-tactile-medical-2thispresentationcontainsfor-tcmd-20221129monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2022-financial-results-raises-full-ye-tcmd-20221107monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2022-financial-results-raises-full-y-tcmd-20220801monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2022-financial-results-reaffirms-full-tcmd-20220502monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2021-financial-results-tcmd-20220222monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-qui-tam-lawsuit-dropped-by-plaintiff-minneapolis-mn-tcmd-20220218monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-new-appointments-to-board-of-directors-appoints-valerie-asbury-a-tcmd-20220105monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2021-financial-results-updates-full-y-tcmd-20211108monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-acquisition-of-afflovest-further-expands-the-company-s-position--tcmd-20210908monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2021-financial-results-updates-full--tcmd-20210802monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2021-financial-results-reaffirms-full-tcmd-20210503monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-appoints-eric-pauls-as-senior-vice-president-of-sales-minneapolis-tcmd-20210420monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2020-financial-results-tcmd-20210223monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-additions-to-board-of-directors-appointment-of-sheri-dodd-and-de-tcmd-20210105monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2020-financial-results-provides-updat-tcmd-20201102monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2020-financial-results-second-quarte-tcmd-20200803monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-announces-appointment-of-daniel-l-reuvers-as-president-and--tcmd-20200521monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2020-financial-results-first-quarter--tcmd-20200504monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-preliminary-first-quarter-2020-revenue-results-with-tcmd-20200406monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2019-financial-results-tcmd-20200226monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-preliminary-full-year-and-fourth-quarter-2019-reven-tcmd-20200113monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2019-financial-results-updates-2019-o-tcmd-20191104monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2019-financial-results-updates-2019--tcmd-20190805monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2019-financial-results-updates-2019-o-tcmd-20190506monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2018-financial-results-tcmd-20190228monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-preliminary-full-year-and-fourth-quarter-2018-reven-tcmd-20190107monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reconciliation-of-net-income-to-non-gaap-adjusted-ebitda-un-tcmd-20181105monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-license-agreement-for-certain-intellectual-property-of-sun-scien-tcmd-20181017monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2018-financial-results-updates-2018--tcmd-20180806monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-chief-financial-officer-transition-appoints-brent-a-moen-as-chie-tcmd-20180806monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reconciliation-of-net-loss-to-non-gaap-adjusted-ebitda-unau-tcmd-20180507monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reconciliation-of-net-income-to-non-gaap-adjusted-ebitda-un-tcmd-20180226monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-preliminary-full-year-and-fourth-quarter-2017-reven-tcmd-20180108monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2017-financial-results-updates-2017-o-tcmd-20171107monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-appointment-of-raymond-huggenberger-to-board-of-directors-minnea-tcmd-20170920monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-pricing-of-secondary-offering-of-common-stock-minneapolis-tcmd-20170913monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2017-financial-results-updates-2017--tcmd-20170807monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-medical-announces-appointment-of-cheryl-pegus-to-board-of-directors-minneapolis-tcmd-20170801monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-first-quarter-2017-financial-results-updates-2017-o-tcmd-20170508monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2016-financial-results-tcmd-20170227monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-preliminary-full-year-and-fourth-quarter-2016-reven-tcmd-20170109monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-third-quarter-2016-financial-results-and-updates-fi-tcmd-20161110monthly0.5https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-inc-reports-second-quarter-2016-financial-results-and-introduce-tcmd-20160907monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-fourth-quarter-and-full-year-2025-financial-results-and-rec-tecx-20260226monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-third-quarter-2025-financial-results-and-recent-business-hi-tecx-20251106monthly0.5https://www.biopharmawatch.com/news/TECX/tx45-phase-1b-part-b-ph-hfref-data-release-single-dose-hemodynamic-trial-o-c-t-o-b-e-r-202-tecx-20251030monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-second-quarter-2025-financial-results-and-recent-business-h-tecx-20250807monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-presents-complete-results-for-positive-phase-1b-clinical-trial-of-tx4-tecx-20250517monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-first-quarter-2025-financial-results-and-recent-business-hi-tecx-20250508monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-fourth-quarter-and-full-year-2024-financial-results-and-rec-tecx-20250320monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-announces-185-million-private-placement-tecx-20250203monthly0.5https://www.biopharmawatch.com/news/TECX/tx45-phase-1b-ph-hfpef-interim-data-release-for-single-dose-hemodynamic-trial-january-2025-tecx-20250130monthly0.5https://www.biopharmawatch.com/news/TECX/innovating-gpcr-targeted-therapies-to-reach-large-untapped-market-opportunities-january-20-tecx-20250113monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-third-quarter-2024-financial-results-and-recent-business-hi-tecx-20241107monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-favorable-phase-1a-safety-tolerability-and-pk-pd-results-fo-tecx-20240919monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-second-quarter-2024-financial-results-and-recent-business-h-tecx-20240814monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-us-ind-clearance-for-lead-program-tx45-tx45-is-an-fc-relaxi-tecx-20240730monthly0.5https://www.biopharmawatch.com/news/TECX/transforming-and-innovating-the-discovery-and-development-of-novel-class-leading-gpcr-targ-tecx-20240626monthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-announces-closing-of-merger-with-avrobio-as-well-as-concurrent-privat-tecx-20240621monthly0.5https://www.biopharmawatch.com/news/TECX/transforming-the-discovery-of-novel-gpcr-targeted-therapies-j-a-n-u-a-r-y-2-0-2-4-disclaim-tecx-20240130monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-and-tectonic-therapeutic-announce-merger-combined-company-to-be-nasdaq-listed-clin-tecx-20240130monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-to-explore-strategic-alternatives-cambridge-mass-business-wire-tecx-20230712monthly0.5https://www.biopharmawatch.com/news/TECX/unaudited-pro-forma-financial-information-on-tecx-20230612monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-agreement-to-sell-cystinosis-gene-therapy-program-for-87-5-million-all-c-tecx-20230522monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-positive-data-from-phase-1-2-clinical-trial-of-investigational-gene-ther-tecx-20230518monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-first-quarter-2023-financial-results-and-provides-business-update-on-track-tecx-20230511monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-leadership-transition-current-cfo-erik-ostrowski-named-interim-ceo-repla-tecx-20230501monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and-provides-busines-tecx-20230323monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-new-positive-clinical-data-and-outlines-clinical-development-plan-follow-tecx-20221207monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-third-quarter-2022-financial-results-and-provides-business-update-patient--tecx-20221108monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-second-quarter-2022-financial-results-and-provides-business-update-present-tecx-20220809monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20220629monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20220506monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-preclinical-gene-therapy-data-for-pompe-disease-at-american-society-of-g-tecx-20220518monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-positive-data-from-phase-1-2-clinical-trial-of-investigational-gene-therap-tecx-20220517monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-first-quarter-2022-financial-results-and-provides-business-update-phase-1--tecx-20220510monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-fourth-quarter-and-fiscal-year-2021-financial-results-and-provides-busines-tecx-20220317monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-interim-data-from-phase-1-2-clinical-trial-of-investigational-gene-therapy-tecx-20220209monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reprioritizes-pipeline-programs-fabry-disease-program-to-be-deprioritized-shifting-tecx-20220104monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-third-quarter-2021-financial-results-and-provides-business-update-provided-tecx-20211104monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-new-interim-safety-data-across-investigational-gene-therapies-for-fabry-an-tecx-20211019monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20210809monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-second-quarter-2021-financial-results-and-provides-business-update-u-s-foo-tecx-20210805monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20210617monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-first-quarter-2021-financial-results-and-provides-business-update-held-mee-tecx-20210513monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-provides-regulatory-update-on-investigational-avr-rd-01-for-fabry-disease-anticipa-tecx-20210503monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20210323monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-fourth-quarter-and-fiscal-year-2020-financial-results-and-provides-busines-tecx-20210318monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-100-kidney-substrate-reduction-at-12-months-post-gene-therapy-in-first-p-tecx-20210208monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20210111monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-proposed-public-offering-of-common-stock-tecx-20201119monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20201112monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-new-positive-clinical-data-and-preclinical-data-as-well-as-expanded-lead-tecx-20201117monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-third-quarter-2020-financial-results-and-provides-business-update-expanded-tecx-20201105monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-appoints-dr-gail-farfel-to-its-board-of-directors-tecx-20201021monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20201006monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-expands-lentiviral-gene-therapy-pipeline-with-program-for-hunter-syndrome-investig-tecx-20201005monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-second-quarter-2020-financial-results-and-provides-business-update-new-dat-tecx-20200806monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-new-patients-dosed-in-gaucher-disease-and-cystinosis-clinical-trials-fir-tecx-20200706monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20200616monthly0.5https://www.biopharmawatch.com/news/TECX/pompe-program-team-3-25-2020-nsg-study-what-s-important-now-monthly-report-niek-van-til-is-tecx-20200514monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20200427monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-1q-2020-financial-results-and-provides-business-update-three-oral-presenta-tecx-20200507monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20200403monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-outlines-response-to-covid-19-and-current-assessment-of-business-impact-patient-id-tecx-20200330monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-fourth-quarter-and-fiscal-year-2019-financial-results-and-provides-busines-tecx-20200316monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-proposed-public-offering-of-common-stock-tecx-20200212monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-presents-positive-initial-data-for-its-investigational-cystinosis-program-and-plat-tecx-20200210monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20200113monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-inc-reports-third-quarter-2019-financial-results-and-provides-business-update-dosi-tecx-20191107monthly0.5https://www.biopharmawatch.com/news/TECX/disclaimer-this-presentation-has-been-prepared-by-avrobio-inc-avrobio-for-informational-pu-tecx-20191007monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-reports-second-quarter-2019-financial-results-and-provides-business-update-reporte-tecx-20190808monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-proposed-public-offering-of-common-stock-cambridge-mass-tecx-20190716monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-87-substrate-reduction-in-first-kidney-biopsy-and-additional-positive-da-tecx-20190715monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-inc-reports-first-quarter-2019-financial-results-and-provides-business-update-regu-tecx-20190513monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-inc-announces-fda-clearance-of-investigational-new-drug-application-for-avr-rd-01--tecx-20190429monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-inc-reports-fourth-quarter-and-fiscal-year-2018-financial-results-and-provides-bus-tecx-20190325monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-inc-announces-updated-clinical-data-from-ongoing-phase-1-and-phase-2-studies-for-a-tecx-20190206monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-inc-appoints-philip-j-vickers-to-its-board-of-directors-industry-leader-brings-glo-tecx-20190107monthly0.5https://www.biopharmawatch.com/news/TECX/s-avrobio-inc-expands-and-strengthens-leadership-team-with-four-senior-management-hires-bi-tecx-20181218monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-inc-reports-third-quarter-2018-financial-results-and-provides-business-update-duri-tecx-20181113monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-announces-updated-clinical-data-for-avr-rd-01-gene-therapy-in-fabry-disease-first--tecx-20181001monthly0.5https://www.biopharmawatch.com/news/TECX/avrobio-inc-reports-second-quarter-2018-financial-results-and-provides-business-update-com-tecx-20180809monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-second-quarter-2025-financial-results-and-provides-business-updates-prme-20250807monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-breakthrough-clinical-data-showing-rapid-restoration-of-dhr-posit-prme-20250519monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-first-quarter-2025-financial-results-and-provides-business-updates--prme-20250508monthly0.5https://www.biopharmawatch.com/news/PRME/delivering-on-the-promise-of-prime-editing-corporate-presentation-march-2025-1-forward-loo-prme-20250318monthly0.5https://www.biopharmawatch.com/news/PRME/delivering-on-the-promise-of-prime-editing-jp-morgan-healthcare-conference-january-2024-1--prme-20240108monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-bu-prme-20230309monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-st-41-annual-j-p-morgan-healthcare-conference-january-2023-1-forward-lookin-prme-20230109monthly0.5https://www.biopharmawatch.com/news/BBNX/ada-investor-analyst-event-june-2025-bbnx-20250623monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-closing-of-234-6-million-initial-public-offering-and-full-exercise--bbnx-20250131monthly0.5https://www.biopharmawatch.com/news/KYTX/are-based-on-the-current-expectations-of-kyverna-s-management-team-and-speak-only-as-of-th-kytx-20260518monthly0.5https://www.biopharmawatch.com/news/KYTX/statements-in-this-press-release-include-without-limitation-those-related-to-kyverna-s-nex-kytx-20260504monthly0.5https://www.biopharmawatch.com/news/KYTX/highlighting-new-data-from-our-neuroimmunology-franchise-at-aan-kytx-20260422monthly0.5https://www.biopharmawatch.com/news/KYTX/need-for-any-immunotherapies-for-sps-to-become-the-first-and-only-approved-treatment-for-s-kytx-20260422monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-presents-longer-term-phase-2-data-for-miv-cel-in-generalized-myasthenia-gravis-at--kytx-20260422monthly0.5https://www.biopharmawatch.com/news/KYTX/advisor-to-google-ventures-general-atlantic-vida-ventures-longwood-fund-and-the-one-mind-f-kytx-20260224monthly0.5https://www.biopharmawatch.com/news/KYTX/possibility-that-the-past-track-records-of-kyverna-and-its-personnel-may-not-be-repeated-o-kytx-20260203monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-provides-corporate-update-and-outlines-2026-strategic-priorities-at-t-kytx-20260112monthly0.5https://www.biopharmawatch.com/news/KYTX/topline-data-kysa-8-registrational-trial-of-miv-cel-kyv-101-in-stiff-person-syndrome-sps-kytx-20251215monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-positive-topline-data-from-registrational-kysa-8-trial-of-m-kytx-20251215monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial-res-kytx-20251112monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-secures-up-to-150-million-in-non-dilutive-financing-from-oxford-finan-kytx-20251103monthly0.5https://www.biopharmawatch.com/news/KYTX/this-presentation-contains-forward-looking-statements-that-are-based-on-management-s-belie-kytx-20251029monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-positive-interim-phase-2-data-from-kysa-6-study-of-kyv-101--kytx-20251029monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-provides-business-update-and-reports-second-quarter-2025-financial-re-kytx-20250812monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-provides-business-update-and-reports-third-quarter-2024-financial-res-kytx-20241113monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-appoints-mert-aktar-to-its-board-of-directors-enriches-board-s-expert-kytx-20241021monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-leadership-update-warner-biddle-appointed-as-chief-executiv-kytx-20240916monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-provides-business-update-and-reports-second-quarter-2024-financial-re-kytx-20240812monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-s-kyv-101-receives-u-s-fda-rmat-designation-for-kyv-101-in-the-treatment-of-patien-kytx-20240715monthly0.5https://www.biopharmawatch.com/news/KYTX/time-session-title-presenter-8-15-8-20-welcome-and-introduction-peter-maag-phd-kyverna-the-kytx-20240614monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-provides-business-update-and-reports-first-quarter-2024-financial-res-kytx-20240514monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-provides-business-update-and-reports-full-year-2023-financial-results-kytx-20240326monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-and-limmatech-enter-into-a-strategic-partnership-to-accelerate-the-development-of--valn-20240801monthly0.5https://www.biopharmawatch.com/news/VALN/ex-1-2-exhibit9912023-q1xresultsx-htm-ex-1-document-valneva-se-campus-bio-ouest-6-rue-alai-valn-20230504monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-full-year-2022-results-and-provides-corporate-updates-valn-20230323monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-nine-month-2022-results-and-provides-corporate-updates-total-nine-month-re-valn-20221110monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-campus-bio-ouest-6-rue-alain-bombard-44800-saint-herblain-france-valneva-announ-valn-20220929monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-campus-bio-ouest-6-rue-alain-bombard-44800-saint-herblain-france-valneva-establ-valn-20220815monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-consolidated-financial-statements-2022-1-consolidated-financial-statements-2022-valn-20220812monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-campus-bio-ouest-6-rue-alain-bombard-44800-saint-herblain-france-valneva-report-valn-20220812monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-initiates-heterologous-booster-trial-of-inactivated-covid-19-vaccine-candidate-valn-20220505monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-full-year-2021-results-and-provides-corporate-updates-valn-20220325monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candi-valn-20211018monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-h1-2021-financial-results-and-provides-business-update-valn-20210810monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-the-availability-of-documentation-for-its-combined-general-meeting-to-be-valn-20210603monthly0.5https://www.biopharmawatch.com/news/VALN/to-participate-in-the-world-s-first-covid-19-vaccine-booster-trial-in-the-uk-valn-20210521monthly0.5https://www.biopharmawatch.com/news/CRMD/not-for-distribution-without-the-prior-written-permission-of-cormedix-therapeutics-corpora-crmd-20260302monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-announces-preliminary-fourth-quarter-and-full-year-2025-results-and--crmd-20260108monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-2025-financial-results-and-provides-business-update-q2-crmd-20250807monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-proposed-public-offering-of-common-stock-berkeley-heights-nj-crmd-20250626monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-customer-implementation-berkeley-heights-nj-crmd-20250623monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-2025-financial-results-and-provides-business-update-q1--crmd-20250506monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-preliminary-first-quarter-2025-results-and-raises-h1-2025-net-sales-crmd-20250408monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-busi-crmd-20250325monthly0.5https://www.biopharmawatch.com/news/CRMD/issued-by-cormedix-inc-dated-january-7-2025-e-xhibit-99-1-cormedix-inc-announces-prelimina-crmd-20250107monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-and-nine-month-2024-financial-results-and-provides-busi-crmd-20241030monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-and-six-month-2024-financial-results-and-provides-busi-crmd-20240814monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-2024-financial-results-and-provides-business-update-con-crmd-20240509monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-busi-crmd-20240312monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-commercial-and-reimbursement-updates-berkeley-heights-nj-crmd-20240130monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-fda-approval-of-defencath-to-reduce-the-incidence-of-catheter-relat-crmd-20231115monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-and-nine-month-2023-financial-results-and-provides-busi-crmd-20231114monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-and-six-month-2023-financial-results-and-provides-busi-crmd-20230808monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-be-crmd-20230628monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-fda-acceptance-of-resubmission-of-new-drug-application-for-defencat-crmd-20230621monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-resubmission-of-new-drug-application-for-defencath-berkeley-heights-crmd-20230516monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-2023-financial-results-and-provides-business-update-con-crmd-20230515monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-regulatory-manufacturing-and-reimbursement-updates-berkeley-heights-crmd-20230426monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-appointment-of-robert-a-stewart-to-its-board-of-directors-berkeley--crmd-20230417monthly0.5https://www.biopharmawatch.com/news/CRMD/dated-march-30-2023-exhbit-99-1-cormedix-inc-reports-fourth-quarter-and-full-year-2022-fin-crmd-20230330monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-regulatory-and-manufacturing-updates-berkeley-heights-nj-crmd-20230302monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-2022-financial-results-and-provides-business-update-con-crmd-20221110monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-and-six-month-2022-financial-results-and-provides-busi-crmd-20220811monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-regulatory-and-manufacturing-updates-berkeley-heights-nj-crmd-20220808monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-2022-financial-results-and-provides-business-update-con-crmd-20220512monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-busi-crmd-20220329monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-fda-acceptance-of-resubmission-of-new-drug-application-for-defencat-crmd-20220328monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-the-appointment-of-chief-executive-officer-joseph-todisco-to-join-c-crmd-20220317monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-resubmission-of-new-drug-application-for-defencath-berkeley-heights-crmd-20220228monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-2021-financial-results-and-provides-business-update-con-crmd-20211109monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-regulatory-update-berkeley-heights-nj-crmd-20210907monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-and-six-month-2021-financial-results-and-provides-busi-crmd-20210812monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-appointment-of-chief-commercial-officer-thomas-nusbickel-to-join-co-crmd-20210513monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-2021-financial-results-and-provides-business-update-con-crmd-20210513monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-has-meeting-with-fda-on-defencath-catheter-lock-solution-nda-berkeley-heights-nj-crmd-20210414monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-busi-crmd-20210330monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-receives-complete-response-letter-from-fda-for-defencath-catheter-lock-solution-b-crmd-20210301monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-begin-trading-on-the-nasdaq-stock-exchange-berkeley-heights-nj-crmd-20210121monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-fda-decision-that-advisory-committee-meeting-for-new-drug-applicati-crmd-20201118monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-2020-financial-results-and-provides-business-update-con-crmd-20201105monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-appoints-greg-duncan-to-its-board-of-directors-seasoned-industry-veteran-with-dec-crmd-20201102monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-appoints-paulo-costa-to-its-board-of-directors-seasoned-industry-veteran-with-dec-crmd-20200917monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-fda-acceptance-for-filing-and-priority-review-of-new-drug-applicati-crmd-20200831monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-and-six-month-2020-financial-results-and-provides-busi-crmd-20200810monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-pricing-of-20m-public-offering-of-common-stock-berkeley-heights-nj-crmd-20200728monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-submission-of-defencath-new-drug-application-priority-review-of-nda-r-crmd-20200708monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-appointment-of-chief-financial-officer-berkeley-heights-nj-crmd-20200511monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-2020-financial-results-and-provides-business-update-con-crmd-20200511monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-completes-sale-of-5-5-million-of-nol-tax-benefits-through-new-jersey-technology-b-crmd-20200422monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-busi-crmd-20200316monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-approved-to-sell-5-5-million-of-nol-tax-benefits-through-the-new-jersey-economic--crmd-20200203monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-fda-grant-of-rolling-review-of-neutrolin-new-drug-application-berke-crmd-20200203monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-a-change-to-its-senior-leadership-berkeley-heights-nj-crmd-20191106monthly0.5https://www.biopharmawatch.com/news/CRMD/completes-successful-cmc-interaction-with-the-fda-crmd-20191016monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-exchange-agreement-with-its-largest-investor-berkeley-heights-nj-crmd-20190814monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-and-six-month-2019-financial-results-and-provides-busi-crmd-20190813monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-receives-encouraging-fda-feedback-on-neutrolin-xae-lock-it-100-data-company-compl-crmd-20190709monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-2019-financial-results-and-provides-business-update-con-crmd-20190513monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-completes-sale-of-5-4-million-of-nol-tax-benefits-through-new-jersey-economic-dev-crmd-20190417monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-notified-of-compliance-with-nyse-american-crmd-20190411monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-confirms-previously-announced-one-for-five-reverse-stock-split-berkeley-heights-n-crmd-20190325monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-appointment-of-phoebe-mounts-as-executive-vice-president-and-genera-crmd-20190321monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2018-financial-results-announces-reverse-crmd-20190314monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-appoints-alan-w-dunton-m-d-to-board-of-directors-berkeley-heights-nj-x2013-crmd-20190304monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-fda-meeting-update-cleared-to-request-approval-under-lpad-fda-to-re-crmd-20190214monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-ann-ounces-topline-analysis-of-the-full-data-set-of-phase-3-lock-it-100-study-crmd-20190130monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-highly-statistically-significant-topline-results-for-neutrolin-xae--crmd-20190117monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-resignation-of-member-of-its-board-of-directors-berkeley-heights-nj-crmd-20190116monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-closing-of-7-5-million-senior-secured-convertible-debt-financing-berkel-crmd-20190103monthly0.5https://www.biopharmawatch.com/news/CRMD/blueprint-exhibit-9-9-1-cormedix-receives-approval-to-sell-5-4-million-of-nol-tax-benefits-crmd-20181210monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-financial-results-and-provides-business-update-conferen-crmd-20181114monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance-berkeley--crmd-20180831monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-financial-results-and-provides-business-update-lock-it-crmd-20180814monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-positive-results-of-its-neutrolin-xae-phase-3-lock-it-100-study-bas-crmd-20180725monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-completes-review-and-source-verification-of-phase-3-lock-it-100-data-for-neut-crmd-20180620monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-receives-a-continued-listing-standard-notice-from-the-nyse-american-berkeley--crmd-20180619monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-progress-on-lock-it-100-data-review-and-appoints-paul-chew-as-consult-crmd-20180529monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-financial-results-and-provides-business-update-x25cf-an-crmd-20180515monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-revises-timeline-and-announces-changes-to-lock-it-100-study-management-berkeley-h-crmd-20180427monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-busi-crmd-20180319monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-provides-update-on-its-financing-plans-in-connection-with-its-ongoing-lock-it-crmd-20180227monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-granted-orphan-drug-designation-for-taurolidine-for-treatment-of-neuroblastom-crmd-20180226monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-achieves-target-number-of-events-in-its-lock-it-100-study-of-neutrolin-xae-fo-crmd-20180220monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-common-stock-purchase-by-company-directors-and-executive-management-crmd-20171120monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-enters-into-5-million-combined-securities-purchase-and-backstop-agreement-wit-crmd-20171109monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-financial-results-and-provides-business-update-conferen-crmd-20171109monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-financial-results-and-provides-business-update-confere-crmd-20170809monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-appoints-gary-gelbfish-m-d-to-board-of-directors-current-director-myron-kapla-crmd-20170807monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-provides-update-on-neutrolin-xae-ongoing-phase-3-clinical-trial-following-fav-crmd-20170802monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-provides-comprehensive-pipeline-update-during-research-and-development-day-li-crmd-20170712monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-appoints-mehmood-khan-m-d-and-steven-lefkowitz-to-its-board-of-directors-gary-crmd-20170626monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-changes-to-board-of-directors-bedminster-nj-x2013-crmd-20170612monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-financial-results-and-provides-business-update-conferen-crmd-20170510monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-closing-of-public-offering-of-common-stock-and-warrants-and-underwr-crmd-20170503monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-10-million-underwritten-public-offering-bedminster-nj-x2013-crmd-20170427monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-update-on-neutrolin-xae-phase-3-lock-it-100-clinical-trial-bedminster-crmd-20170420monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2016-financial-results-and-provides-busi-crmd-20170317monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-new-appointments-to-senior-leadership-team-robert-w-cook-internatio-crmd-20170201monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-2016-financial-results-and-provides-business-updates-co-crmd-20161110monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-appoints-khoso-baluch-as-chief-executive-officer-bedminster-nj-x2013-october--crmd-20161003monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-second-quarter-2016-financial-results-and-provides-business-updates-c-crmd-20160805monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-secures-first-research-collaboration-in-the-medical-device-space-with-luna-innova-crmd-20160629monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-first-quarter-2016-financial-results-conference-call-today-at-9-00-a--crmd-20160511monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-appoints-myron-kaplan-to-board-of-directors-bedminster-nj-x2013-crmd-20160502monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2015-financial-results-conference-call-s-crmd-20160316monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-2015-year-in-review-and-2016-objectives-dear-shareholders-and-investors-bedmi-crmd-20160222monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-enrollment-and-dosing-of-first-patient-in-phase-3-neutrolin-trial-in-he-crmd-20151214monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-janet-m-dillione-will-join-board-of-directors-bedminster-n-j-crmd-20150806monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-decision-to-initiate-neutrolin-phase-3-clinical-study-strategic-pro-crmd-20150717monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-join-russell-global-and-russell-3000-indexes-bedminster-n-j-crmd-20150622monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-receives-positive-feedback-from-fda-for-neutrolin-clinical-trial-protocol-for-crmd-20150617monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-presents-data-from-neutrolin-post-marketing-surveillance-study-at-two-medical-con-crmd-20150423monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-institutes-program-to-reduce-neutrolin-cost-of-goods-reports-on-strategic-review--crmd-20150409monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-provides-multiple-strategic-business-updates-cormedix-inc-engages-evercore-as-crmd-20150304monthly0.5https://www.biopharmawatch.com/news/CRMD/fda-grants-qidp-designation-to-neutrolin-cormedix-inc-s-lead-product-candidate-in-the-u-s--crmd-20150129monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-receives-fast-track-designation-for-neutrolin-bridgewater-n-j-crmd-20150115monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-2014-year-in-review-dear-shareholders-and-investors-cormedix-inc-is-providing-crmd-20150112monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-finalizes-first-middle-east-neutrolin-sales-distribution-agreement-in-the-kin-crmd-20141223monthly0.5https://www.biopharmawatch.com/news/CRMD/neutrolin-label-expansion-approved-in-germany-bridgewater-n-j-crmd-20141203monthly0.5https://www.biopharmawatch.com/news/CRMD/27-14-cormedix-receives-approval-from-fda-to-initiate-a-clinical-trial-for-neutrolin-in-th-crmd-20141024monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-fda-ind-filing-for-neutrolin-in-united-states-bridgewater-n-j-crmd-20140925monthly0.5https://www.biopharmawatch.com/news/CRMD/neutrolin-label-expansion-approved-for-the-european-union-bridgewater-n-j-crmd-20140922monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-amends-and-restates-outstanding-securities-to-remove-provisions-causing-derivativ-crmd-20140916monthly0.5https://www.biopharmawatch.com/news/CRMD/fda-accepts-cormedix-inc-pivotal-phase-3-study-protocol-signs-business-collaboration-in-so-crmd-20140814monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-finalizes-pivotal-phase-3-study-protocol-for-crmd-20140623monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-notified-of-nyse-mkt-listing-deficiency-bridgewater-n-j-crmd-20140523monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-announce-first-quarter-2014-results-on-crmd-20140515monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-welcomes-additional-board-members-bridgewater-n-j-crmd-20140407monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-registered-direct-offering-bridgewater-n-j-crmd-20140304monthly0.5https://www.biopharmawatch.com/news/CRMD/investor-contact-the-ruth-group-lee-roth-tel-646-536-7012-lroth-theruthgroup-com-media-con-crmd-20140113monthly0.5https://www.biopharmawatch.com/news/CRMD/investor-contact-the-ruth-group-lee-roth-tel-646-536-7012-lroth-theruthgroup-com-media-con-crmd-20140110monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-raise-2-000-000-in-follow-on-offering-bridgewater-n-j-crmd-20140108monthly0.5https://www.biopharmawatch.com/news/CRMD/investor-contact-the-ruth-group-lee-roth-tel-646-536-7012-lroth-theruthgroup-com-media-con-crmd-20131223monthly0.5https://www.biopharmawatch.com/news/CRMD/investor-contact-the-ruth-group-lee-roth-tel-646-536-7012-lroth-theruthgroup-com-media-con-crmd-20131212monthly0.5https://www.biopharmawatch.com/news/CRMD/drives-everything-we-do-company-overview-nyse-mkt-crmd-december-2013-2013-cormedix-2-forwa-crmd-20131203monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-closes-3-000-000-preferred-stock-offerings-as-a-result-meets-nyse-mkt-continu-crmd-20131023monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-reports-receipt-of-european-patent-office-decision-to-allow-prosl-patent-to-proce-crmd-20130905monthly0.5https://www.biopharmawatch.com/news/CRMD/nyse-mkt-crmd-august-2013-company-overview-2013-cormedix-inc-2-forward-looking-statements--crmd-20130826monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-reports-second-quarter-2013-results-also-reports-board-and-officer-appointments-c-crmd-20130815monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-granted-extension-of-nyse-mkt-listing-bridgewater-new-jersey-crmd-20130715monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-receives-ce-mark-for-neutrolin-catheter-lock-solution-drug-device-shown-to-preven-crmd-20130705monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-granted-extension-of-nyse-mkt-listing-bridgewater-new-jersey-crmd-20130531monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-granted-extension-of-nyse-mkt-listing-bridgewater-new-jersey-crmd-20130422monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-notified-of-nyse-mkt-listing-deficiency-also-defers-license-milestone-payment-bri-crmd-20130411monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-reports-year-end-2012-financial-results-bridgewater-new-jersey-crmd-20130327monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-granted-extension-of-nyse-mkt-listing-bridgewater-new-jersey-crmd-20130207monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-signs-sales-and-marketing-agreement-crmd-20130116monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-changes-in-executive-team-bridgewater-new-jersey-crmd-20121224monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-final-closing-of-2012-financing-bridgewater-new-jersey-crmd-20121114monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-initial-close-on-financing-and-extension-granted-to-regain-compliance-with-nyse-a-crmd-20120925monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-granted-extension-of-nyse-amex-listing-compliance-plan-approved-bridgewater-new-j-crmd-20120702monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-provides-an-update-on-ce-marking-process-for-neutrolin-in-the-eu-commercial-launc-crmd-20120614monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-strengthens-management-team-with-addition-of-randy-milby-as-chief-operating-offic-crmd-20120503monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-receives-nyse-amex-notice-of-delisting-for-non-compliance-bridgewater-nj-crmd-20120424monthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-reports-first-quarter-2026-ctnm-20260505monthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-reports-fourth-quarter-2025-financial-results-affirms-key-clinical--ctnm-20260305monthly0.5https://www.biopharmawatch.com/news/PROK/this-presentation-includes-x201c-forward-looking-statements-x201d-within-the-meaning-of-th-prok-20260202monthly0.5https://www.biopharmawatch.com/news/PROK/this-presentation-includes-x201c-forward-looking-statements-x201d-within-the-meaning-of-th-prok-20260112monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-second-quarter-2025-financial-results-and-provides-regulatory-and-clinic-prok-20250812monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-first-quarter-2025-financial-results-and-business-highlights-x2022-full--prok-20250512monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-full-year-2024-financial-results-and-business-highlights-x2022-significa-prok-20250317monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-third-quarter-2024-financial-results-along-with-regulatory-and-clinical--prok-20241112monthly0.5https://www.biopharmawatch.com/news/PROK/this-presentation-includes-x201c-forward-looking-statements-x201d-within-the-meaning-of-th-prok-20240903monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-business-updates-and-second-quarter-2024-financial-results-x2022-reporte-prok-20240809monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-pricing-of-its-upsized-130-million-public-offering-of-class-a-ordinary-prok-20240611monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-positive-interim-regen-007-phase-2-trial-data-and-provides-clinical-an-prok-20240610monthly0.5https://www.biopharmawatch.com/news/PROK/rmcl-002-final-analysis-developing-solutions-for-dialysis-prevention-may-2024-this-present-prok-20240529monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-business-updates-and-first-quarter-2024-financial-results-x2022-final-re-prok-20240510monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-key-leadership-appointments-strengthening-clinical-and-technical-opera-prok-20240325monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-full-year-2023-financial-results-and-recent-corporate-highlights-winston-prok-20240321monthly0.5https://www.biopharmawatch.com/news/PROK/corporate-presentation-january-2024-developing-solutions-for-dialysis-prevention-react-ren-prok-20240126monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-third-quarter-financial-results-winston-salem-n-c-prok-20231114monthly0.5https://www.biopharmawatch.com/news/PROK/rmcl-002-interim-results-updates-prok-20231114monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-a-step-closer-to-potential-dialysis-prevention-react-renal-autologous-cell-thera-prok-20230911monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-second-quarter-financial-results-and-recent-corporate-highlights-winston-prok-20230810monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-closing-of-purchase-of-manufacturing-facility-in-greensboro-nc-winston-prok-20230718monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-purchase-of-manufacturing-facility-in-greensboro-nc-winston-salem-n-c-prok-20230613monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-first-quarter-financial-results-and-recent-corporate-highlights-winston--prok-20230511monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-fourth-quarter-financial-results-and-recent-corporate-highlights-winston-prok-20230328monthly0.5https://www.biopharmawatch.com/news/PROK/forward-looking-statements-this-presentation-includes-x201c-forward-looking-statements-x20-prok-20230306monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-publication-of-trial-design-for-phase-2-multicenter-clinical-trial-of--prok-20230110monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-a-step-closer-to-potential-dialysis-prevention-react-renal-autologous-cell-thera-prok-20230110monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-third-quarter-2022-financial-results-and-recent-corporate-highlights-win-prok-20221114monthly0.5https://www.biopharmawatch.com/news/PROK/renal-autologous-cell-therapy-september-2022-a-step-closer-to-potential-dialysis-preventio-prok-20220908monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-corp-reports-second-quarter-2022-financial-results-and-provides-business-update--prok-20220811monthly0.5https://www.biopharmawatch.com/news/PROK/revolutionary-chronic-kidney-disease-therapeutics-company-prokidney-to-list-on-the-nasdaq--prok-20220712monthly0.5https://www.biopharmawatch.com/news/PROK/social-capital-suvretta-holdings-corp-iii-announces-reconvened-extraordinary-general-meeti-prok-20220708monthly0.5https://www.biopharmawatch.com/news/PROK/social-capital-suvretta-holdings-corp-iii-index-to-financial-statement-report-of-independe-prok-20220610monthly0.5https://www.biopharmawatch.com/news/PROK/renal-autologous-cell-therapy-a-step-closer-to-potential-dialysis-prevention-prok-20220428monthly0.5https://www.biopharmawatch.com/news/PROK/revolutionary-chronic-kidney-disease-therapeutics-company-prokidney-to-become-publicly-tra-prok-20220118monthly0.5https://www.biopharmawatch.com/news/PROK/social-capital-suvretta-holdings-corp-iii-index-to-financial-statement-report-of-independe-prok-20210702monthly0.5https://www.biopharmawatch.com/news/PROK/social-capital-suvretta-holdings-corp-iii-announces-pricing-of-upsized-220-000-000-initial-prok-20210630monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-preliminary-fourth-quarter-and-full-year-2025-product-revenue--cers-20260111monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-results-for-third-quarter-2025-and-raises-full-year-202-cers-20251106monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-second-quarter-2025-financial-results-second-quarter-total-rev-cers-20250805monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-first-quarter-2025-financial-results-first-quarter-2025-produc-cers-20250501monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-full-year-and-fourth-quarter-2024-financial-results-full-year--cers-20250220monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-preliminary-fourth-quarter-and-full-year-2024-product-revenue--cers-20250113monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-third-quarter-2024-financial-results-third-quarter-and-first-n-cers-20241030monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-provides-updates-on-intercept-red-blood-cell-programs-in-the-u-s-and-eur-cers-20241016monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-second-quarter-2024-financial-results-and-increases-full-year--cers-20240801monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-appointment-of-dean-gregory-to-board-of-directors-concord-ca-cers-20240702monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-first-quarter-2024-financial-results-first-quarter-product-rev-cers-20240502monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-positive-topline-results-for-the-phase-3-clinical-trial-of-the-cers-20240319monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-fourth-quarter-and-full-year-2023-financial-results-sequential-cers-20240305monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-preliminary-fourth-quarter-and-full-year-2023-product-revenue--cers-20240108monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-third-quarter-2023-financial-results-concord-ca-cers-20231102monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-second-quarter-2023-financial-results-concord-ca-cers-20230802monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-first-quarter-2023-financial-results-reiterating-full-year-202-cers-20230504monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-fourth-quarter-and-full-year-2022-financial-results-str-cers-20230228monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-preliminary-fourth-quarter-and-full-year-2022-product-revenue--cers-20230109monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-third-quarter-financial-results-total-revenue-of-46-3-million--cers-20221103monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-another-record-quarter-and-reiterates-full-year-2022-product-r-cers-20220804monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-appointment-of-hua-shan-md-phd-to-board-of-directors-concord-c-cers-20220705monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-first-quarter-2022-financial-results-and-increases-full-year-2-cers-20220505monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-fourth-quarter-and-full-year-2021-financial-results-str-cers-20220222monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-preliminary-fourth-quarter-and-full-year-2021-product-r-cers-20220110monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-third-quarter-2021-financial-results-and-raises-full-ye-cers-20211102monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-second-quarter-2021-financial-results-and-raises-full-y-cers-20210803monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-first-quarter-2021-financial-results-and-raises-full-year-prod-cers-20210504monthly0.5https://www.biopharmawatch.com/news/CERS/to-cerus-current-report-on-form-8-k-filed-with-the-sec-on-cers-20210225monthly0.5https://www.biopharmawatch.com/news/CERS/to-cerus-current-report-on-form-8-k-filed-with-the-sec-on-cers-20210111monthly0.5https://www.biopharmawatch.com/news/CERS/by-these-cautionary-statements-also-these-forward-looking-statements-represent-our-estimat-cers-20201211monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-third-quarter-2020-results-concord-ca-cers-20201029monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-second-quarter-2020-results-concord-ca-cers-20200804monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-first-quarter-2020-results-concord-ca-cers-20200505monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-strategic-organizational-changes-vivek-jayaraman-promoted-to-c-cers-20200302monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-fourth-quarter-and-full-year-2019-financial-results-con-cers-20200220monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-preliminary-fourth-quarter-and-full-year-2019-product-revenue--cers-20200128monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-third-quarter-2019-results-concord-ca-cers-20191030monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-second-quarter-2019-results-concord-ca-cers-20190801monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-first-quarter-2019-results-concord-ca-cers-20190507monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-record-fourth-quarter-and-full-year-2018-results-concord-ca-cers-20190226monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-announces-preliminary-fourth-quarter-and-full-year-2018-product-revenue-2019-product-cers-20190107monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-reports-third-quarter-2018-results-product-revenue-increases-43-compared-cers-20181101monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-to-provide-update-to-development-programs-and-outline-growth-strategy-at-2018-instit-cers-20181016monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-appoints-eric-bjerkholt-to-board-of-directors-concord-ca-cers-20181009monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-appoints-timothy-l-moore-to-board-of-directors-concord-ca-cers-20180906monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-reports-second-quarter-2018-results-product-revenue-increases-62-compare-cers-20180802monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-reports-first-quarter-2018-results-concord-ca-cers-20180508monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-reports-record-fourth-quarter-and-year-end-2017-results-concord-ca-cers-20180308monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-preliminary-product-revenue-results-for-fourth-quarter-and-ful-cers-20180108monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-reports-third-quarter-2017-results-concord-ca-cers-20171102monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-reports-second-quarter-2017-results-concord-ca-cers-20170803monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-green-vice-president-finance-and-chief-financial-officer-cerus-corporation-925-288-6-cers-20170503monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-green-vice-president-finance-and-chief-financial-officer-cerus-corporation-925-288-6-cers-20170307monthly0.5https://www.biopharmawatch.com/news/CERS/stacey-lea-os-associate-director-investor-and-public-relations-cerus-corporation-925-288-6-cers-20161103monthly0.5https://www.biopharmawatch.com/news/CERS/stacey-lea-os-associate-director-investor-and-public-relations-cerus-corporation-925-288-6-cers-20160804monthly0.5https://www.biopharmawatch.com/news/CERS/stacey-lea-os-associate-director-investor-and-public-relations-cerus-corporation-925-288-6-cers-20160503monthly0.5https://www.biopharmawatch.com/news/CERS/stacey-lea-os-associate-director-investor-and-public-relations-cerus-corporation-925-288-6-cers-20160308monthly0.5https://www.biopharmawatch.com/news/CERS/stacey-lea-os-associate-director-investor-and-public-relations-cerus-corporation-925-288-6-cers-20151105monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20150806monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20150505monthly0.5https://www.biopharmawatch.com/news/CERS/to-cerus-current-report-on-form-8-k-filed-with-the-sec-on-cers-20150226monthly0.5https://www.biopharmawatch.com/news/CERS/by-these-cautionary-statements-also-these-forward-looking-statements-represent-our-estimat-cers-20150105monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20141104monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20140731monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20140501monthly0.5https://www.biopharmawatch.com/news/CERS/frank-witney-joins-cerus-board-of-directors-concord-calif-business-wire-cers-20140325monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-moderator-lainie-corten-02-25-14-4-15-p-m-et-confirmation-29781713-page--cers-20140225monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20140225monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20131029monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20130730monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cfo-cerus-corporation-925-288-6138-cerus-corporation--cers-20130228monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cao-cerus-corporation-925-288-6138-cerus-corporation--cers-20121107monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cao-cerus-corporation-925-288-6138-cerus-corporation--cers-20120802monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cao-cerus-corporation-925-288-6138-cerus-corporation--cers-20120501monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cao-cerus-corporation-925-288-6138-cerus-corporation--cers-20120228monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cao-cerus-corporation-925-288-6138-cerus-corporation--cers-20111101monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cao-cerus-corporation-925-288-6138-cerus-corporation--cers-20110728monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-announces-changes-to-board-of-directors-concord-calif-business-wire-cers-20110629monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-lainie-corten-vice-president-finance-cao-director-global-communications-925--cers-20110428monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-appoints-william-obi-greenman-as-president-and-chief-executive-officer-concord-calif-cers-20110420monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-vice-president-finance-cao-925-288-6138-lainie-corten-director-global-commun-cers-20110303monthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-prices-public-offering-of-common-stock-and-warrants-cers-20101110monthly0.5https://www.biopharmawatch.com/news/CERS/kevin-d-green-jason-spark-vice-president-finance-cao-canale-communications-cerus-corporati-cers-20101028monthly0.5https://www.biopharmawatch.com/news/GYRE/a-fully-integrated-biopharmaceutical-company-focused-on-fibrosis-inflammatory-diseases-and-gyre-20260602monthly0.5https://www.biopharmawatch.com/news/GYRE/a-fully-integrated-biopharmaceutical-company-focused-on-fibrosis-inflammatory-diseases-and-gyre-20260514monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update-q1-2026--gyre-20260507monthly0.5https://www.biopharmawatch.com/news/GYRE/developing-anti-fibrotic-therapeutics-for-chronic-organ-diseases-h-c-wainwright-global-inv-gyre-20250910monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-reports-second-quarter-2025-and-year-to-date-financial-results-and-provi-gyre-20250811monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-hydronidone-met-the-primary-endpoint-and-demonstrated-statistically-sign-gyre-20250522monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-updat-gyre-20250509monthly0.5https://www.biopharmawatch.com/news/GYRE/corporate-presentation-april-2025-developing-anti-fibrotic-therapeutics-for-chronic-organ--gyre-20250428monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-gyre-20250317monthly0.5https://www.biopharmawatch.com/news/GYRE/gni-group-ltd-2160-fy2024-consolidated-financial-results-the-following-information-was-ori-gyre-20250214monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-announces-the-appointment-of-ping-zhang-to-board-of-directors-gyre-20250106monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-reports-third-quarter-2024-and-year-to-date-financial-results-and-provid-gyre-20241113monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-reports-second-quarter-2024-and-year-to-date-financial-results-and-provi-gyre-20240813monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-announces-appointment-of-david-m-epstein-ph-d-to-board-of-directors-gyre-20240808monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-pharmaceuticals-receives-ind-approval-from-china-s-nmpa-to-evaluate-f230-for-the-trea-gyre-20240530monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-updat-gyre-20240509monthly0.5https://www.biopharmawatch.com/news/GYRE/notification-of-conclusion-of-license-agreement-by-gyre-pharmaceuticals-co-gni-group-the-c-gyre-20240507monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-reports-full-year-2023-financial-results-and-provides-business-update-da-gyre-20240326monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-expands-board-of-directors-with-appointment-of-rodney-l-nussbaum-gyre-20240321monthly0.5https://www.biopharmawatch.com/news/GYRE/the-following-information-was-originally-prepared-and-published-by-gni-group-ltd-in-japane-gyre-20240214monthly0.5https://www.biopharmawatch.com/news/GYRE/quarterly-report-3q-of-23rd-fiscal-period-gyre-20231114monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-presents-poster-at-the-american-association-for-the-study-of-liver-disea-gyre-20231113monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-gyre-20231030monthly0.5https://www.biopharmawatch.com/news/GYRE/beijing-continent-pharmaceuticals-co-ltd-pages-unaudited-interim-condensed-consolidated-fi-gyre-20230814monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-corporate-presentation-20-march-2023-2-catalyst-biosciences-cautionar-gyre-20230321monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-provides-corporate-update-gyre-20230228monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-completes-first-steps-in-reverse-merger-plan-acquires-f351-a-phase-3--gyre-20221227monthly0.5https://www.biopharmawatch.com/news/GYRE/privileged-and-confidential-prepared-at-the-direction-of-counsel-catalyst-biosciences-inc--gyre-20220825monthly0.5https://www.biopharmawatch.com/news/GYRE/execution-version-cooperation-agreement-this-cooperation-agreement-this-agreement-is-made--gyre-20220818monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-second-quarter-2022-operating-financial-results-gyre-20220815monthly0.5https://www.biopharmawatch.com/news/GYRE/execution-version-confidential-agreement-this-agreement-the-agreement-is-made-and-entered--gyre-20220731monthly0.5https://www.biopharmawatch.com/news/GYRE/certain-identified-information-has-been-excluded-from-the-exhibit-because-it-is-both-i-not-gyre-20220627monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-sells-complement-portfolio-for-60-million-gyre-20220523monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-first-quarter-2022-operating-financial-results-gyre-20220509monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-fourth-quarter-and-year-end-2021-operating-financial-results--gyre-20220331monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-receives-rare-pediatric-disease-designation-for-cb-4332-for-the-treat-gyre-20220125monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-forward-looking-statements-certain-information-contained-in-this-pres-gyre-20220112monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-change-in-corporate-strategy-reports-third-quarter-2021-ope-gyre-20211112monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-chief-financial-officer-transition-gyre-20211013monthly0.5https://www.biopharmawatch.com/news/GYRE/fda-grants-catalyst-biosciences-orphan-drug-designation-for-marzaa-for-the-treatment-of-fa-gyre-20210928monthly0.5https://www.biopharmawatch.com/news/GYRE/forward-looking-statements-certain-information-contained-in-this-presentation-and-statemen-gyre-20210928monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-appointment-of-jeanne-jew-to-its-board-of-directors-seasone-gyre-20210908monthly0.5https://www.biopharmawatch.com/news/GYRE/nasdaq-cbio-catalyst-biosciences-corporate-overview-7-september-2021-catalystbiosciences-c-gyre-20210907monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-second-quarter-2021-operating-financial-results-and-provides--gyre-20210805monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-first-patient-screened-for-cfi-deficiency-in-its-cb-4332-sc-gyre-20210722monthly0.5https://www.biopharmawatch.com/news/GYRE/nasdaq-cbio-harnessing-the-catalytic-power-of-proteases-complement-r-d-day-19-july-2021-ca-gyre-20210719monthly0.5https://www.biopharmawatch.com/news/GYRE/target-the-complement-cascade-to-maximize-the-success-of-your-ards-therapeutic-catalyst-bi-gyre-20210716monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-receives-fda-fast-track-designation-for-subcutaneous-marzaa-for-the-t-gyre-20210628monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-first-patient-dosed-in-marzeptacog-alfa-activated-phase-1-2-gyre-20210518monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-first-quarter-2021-operating-financial-results-and-provides-a-gyre-20210506monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-first-patient-dosed-in-pivotal-phase-3-registration-study-o-gyre-20210505monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-fourth-quarter-and-full-year-2020-operating-financial-results-gyre-20210304monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-forward-looking-statements-certain-information-contained-in-this-pres-gyre-20210303monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-pricing-of-public-offering-of-common-stock-gyre-20210127monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-forward-looking-statements-certain-information-contained-in-this-pres-gyre-20210126monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-proposed-public-offering-of-common-stock-gyre-20210126monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-overview-kol-introduction-catalyst-s-complement-program-virtual-compl-gyre-20201214monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-receives-fda-fast-track-designation-for-subcutaneous-marzaa-for-the-t-gyre-20201202monthly0.5https://www.biopharmawatch.com/news/GYRE/nasdaq-cbio-catalyst-biosciences-corporate-overview-17-november-2020-catalystbiosciences-c-gyre-20201105monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-third-quarter-2020-operating-financial-results-and-provides-a-gyre-20201105monthly0.5https://www.biopharmawatch.com/news/GYRE/nasdaq-cbio-catalyst-biosciences-corporate-overview-17-september-2020-catalystbiosciences--gyre-20200917monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-second-quarter-2020-operating-financial-results-and-provides--gyre-20200806monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-proposed-public-offering-of-common-stock-gyre-20200617monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-corporate-overview-18-june-2020-1-nasdaq-cbio-forward-looking-stateme-gyre-20200618monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-appoints-clinton-musil-as-chief-financial-officer-gyre-20200615monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-first-quarter-2020-operating-financial-results-and-provides-a-gyre-20200511monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-fourth-quarter-and-full-year-2019-operating-financial-results-gyre-20200220monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-proposed-public-offering-of-common-stock-gyre-20200212monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-corporate-overview-7-february-2020-forward-looking-statements-nasdaq--gyre-20200207monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-addition-of-geoffrey-shiu-fei-ling-m-d-and-sharon-tetlow-to-gyre-20200115monthly0.5https://www.biopharmawatch.com/news/GYRE/forward-looking-statements-this-presentation-includes-forward-looking-statements-that-invo-gyre-20200108monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-global-license-and-collaboration-agreement-to-develop-pegyl-gyre-20191219monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-third-quarter-2019-operating-financial-results-and-provides-a-gyre-20191107monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-provides-dalca-phase-2b-trial-update-two-subjects-have-successfully-c-gyre-20191003monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-transition-of-chief-financial-officer-gyre-20190829monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-second-quarter-2019-operating-financial-results-and-provides--gyre-20190801monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-first-quarter-2019-operating-financial-results-and-provides-a-gyre-20190502monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-receives-orphan-designation-from-the-european-commission-for-marzepta-gyre-20190401monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-fourth-quarter-and-full-year-2018-operating-financial-results-gyre-20190307monthly0.5https://www.biopharmawatch.com/news/GYRE/forward-looking-statements-1-2-october-2018-nassim-usman-ph-d-president-ceo-this-presentat-gyre-20181218monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-third-quarter-operating-financial-results-and-provides-a-corp-gyre-20181101monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-updated-positive-interim-data-at-the-2018-hemophilia-drug-d-gyre-20180815monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-second-quarter-operating-financial-results-and-provides-corpo-gyre-20180802monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-positive-interim-data-from-a-phase-2-3-study-of-marzeptacog-gyre-20180718monthly0.5https://www.biopharmawatch.com/news/GYRE/forward-looking-statements-this-presentation-includes-forward-looking-statements-that-invo-gyre-20180621monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-provides-update-on-cb-2679d-isu304-factor-ix-clinical-program-in-hemo-gyre-20180618monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-first-quarter-operating-financial-results-and-provides-corpor-gyre-20180503monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-korean-ministry-of-food-and-drug-safety-approves-addition-o-gyre-20180412monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-the-calling-of-remaining-warrants-and-conversion-of-remaini-gyre-20180305monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-inc-consolidated-statements-of-operations-in-thousands-except-shares--gyre-20180302monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-pricing-of-public-offering-of-common-stock-gyre-20180213monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-proposed-public-offering-of-common-stock-gyre-20180212monthly0.5https://www.biopharmawatch.com/news/GYRE/forward-looking-statements-this-presentation-includes-forward-looking-statements-that-invo-gyre-20180212monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-positive-top-line-data-from-phase-1-2-study-of-subcutaneous-gyre-20180209monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-initiates-phase-2-3-trial-of-marzeptacog-alfa-activated-for-prophylax-gyre-20180104monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-pricing-of-public-offering-of-common-stock-gyre-20171220monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-proposed-public-offering-of-common-stock-gyre-20171219monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-acceleration-of-phase-1-2-trial-of-cb-2679d-isu304-in-indiv-gyre-20171218monthly0.5https://www.biopharmawatch.com/news/GYRE/phase1-2-trial-of-subcutaneously-administered-factor-ix-variant-cb-2679d-isu304-pharmacoki-gyre-20171211monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-inc-condensed-consolidated-statements-of-operations-in-thousands-exce-gyre-20171102monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-the-appointment-of-industry-veteran-andrea-hunt-to-its-boar-gyre-20171026monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-inc-condensed-consolidated-statements-of-operations-in-thousands-exce-gyre-20170803monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-inc-condensed-consolidated-statements-of-operations-in-thousands-exce-gyre-20170511monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-pricing-of-18-million-underwritten-public-offering-gyre-20170407monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-inc-consolidated-statements-of-operations-in-thousands-except-shares--gyre-20170308monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-1-for-15-reverse-stock-split-gyre-20170210monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-inc-condensed-consolidated-statements-of-operations-in-thousands-exce-gyre-20161103monthly0.5https://www.biopharmawatch.com/news/GYRE/r-r-presentation-sept-13-2016-cbio-ex991-22-pptx-htm-catalyst-biosciences-non-confidential-gyre-20160914monthly0.5https://www.biopharmawatch.com/news/GYRE/intentions-expectations-and-projections-disclosed-in-the-forward-looking-statements-variou-gyre-20160909monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-reports-second-quarter-2016-financial-results-and-provides-corporate--gyre-20160804monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-and-cmc-biologics-announce-manufacturing-agreement-for-catalyst-s-nex-gyre-20160524monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-announces-appointments-of-chief-medical-officer-and-vice-president-of-gyre-20160418monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-exceptional-science-essential-medicines-company-overview-december-201-gyre-20151224monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-names-andrew-hetherington-as-vice-president-of-manufacturing-operatio-gyre-20150928monthly0.5https://www.biopharmawatch.com/news/GYRE/catalyst-biosciences-completes-merger-with-targacept-and-creates-a-protease-based-hemostas-gyre-20150820monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-announces-stockholder-approval-of-proposals-related-to-merger-with-catalyst-bios-gyre-20150818monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-declares-pre-closing-dividend-in-connection-with-its-merger-with-catalyst-biosci-gyre-20150804monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-and-catalyst-biosciences-amend-definitive-merger-agreement-winston-salem-nc-and--gyre-20150514monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-announces-negative-top-line-results-from-exploratory-study-of-tc-6499-in-diabeti-gyre-20150416monthly0.5https://www.biopharmawatch.com/news/GYRE/thomson-reuters-streetevents-edited-transcript-trgt-targacept-inc-and-catalyst-biosciences-gyre-20150306monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-and-catalyst-biosciences-enter-definitive-merger-agreement-creating-a-protease-b-gyre-20150305monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-reports-third-quarter-2014-financial-results-winston-salem-north-carolina-gyre-20141105monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-reports-second-quarter-2014-financial-results-winston-salem-north-carolina-gyre-20140806monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-to-discontinue-tc-5214-overactive-bladder-program-winston-salem-nc-gyre-20140728monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-phase-2b-clinical-trial-in-alzheimer-s-disease-does-not-show-superiority-of-tc-1-gyre-20140714monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-reports-first-quarter-2014-financial-results-winston-salem-north-carolina-gyre-20140507monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-reports-fourth-quarter-and-2013-financial-results-winston-salem-north-carolina-gyre-20140213monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-announces-negative-top-line-results-from-phase-2b-clinical-trial-of-tc-5619-in-s-gyre-20131216monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-reports-third-quarter-2013-financial-results-winston-salem-north-carolina-gyre-20131105monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-reports-second-quarter-2013-financial-results-winston-salem-north-carolina-gyre-20130806monthly0.5https://www.biopharmawatch.com/news/GYRE/targacept-reports-first-quarter-2013-financial-results-winston-salem-north-carolina-gyre-20130507monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-ctkb-20260226monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-preliminary-fourth-quarter-and-full-year-2025-revenue-results--ctkb-20260112monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-second-quarter-2025-financial-results-ctkb-20250806monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-first-quarter-2025-financial-results-ctkb-20250508monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-ctkb-20250227monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-preliminary-full-year-2024-revenue-results-ctkb-20250115monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-third-quarter-2024-financial-results-ctkb-20241105monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-second-quarter-2024-financial-results-ctkb-20240806monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-first-quarter-2024-financial-results-ctkb-20240508monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-names-william-mccombe-chief-financial-officer-experienced-executive-with-ctkb-20240319monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-ctkb-20240228monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-preliminary-full-year-2023-revenue-results-ctkb-20240108monthly0.5https://www.biopharmawatch.com/news/CTKB/safe-harbor-statement-this-presentation-contains-forward-looking-statements-within-the-mea-ctkb-20231128monthly0.5https://www.biopharmawatch.com/news/CTKB/q3-2023-earnings-call-event-details-date-2023-11-07-company-cytek-biosciences-inc-ticker-c-ctkb-20231109monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-third-quarter-2023-financial-results-ctkb-20231107monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-second-quarter-2023-financial-results-ctkb-20230808monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-first-quarter-2023-financial-results-ctkb-20230509monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-2022-revenue-ctkb-20230228monthly0.5https://www.biopharmawatch.com/news/CTKB/c-ytek-b-iosciences-to-a-cquire-f-low-c-ytometry-and-i-maging-b-usiness-from-d-ia-s-orin-s-ctkb-20230213monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-third-quarter-2022-financial-results-third-quarter-revenue-grew--ctkb-20221109monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-names-chris-williams-chief-operating-officer-experienced-biotech-pharmac-ctkb-20221031monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-second-quarter-2022-financial-results-second-quarter-revenue-gre-ctkb-20220810monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-first-quarter-2022-financial-results-first-quarter-revenue-grew--ctkb-20220511monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-2021-revenue-ctkb-20220223monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-third-quarter-2021-financial-results-third-quarter-total-revenue-ctkb-20211108monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-second-quarter-2021-financial-results-ctkb-20210902monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2026-financial-results-and-business-update-initiation-of-alt-20260430monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-that-pemvidutide-achieved-key-measures-of-success-at-48-weeks-in-impac-alt-20251219monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2025-financial-results-and-business-update-positive-dat-alt-20250812monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-topline-results-from-the-impact-phase-2b-trial-of-pemvidutide-alt-20250626monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2025-financial-results-and-business-update-top-line-data-alt-20250513monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-a-bus-alt-20250227monthly0.5https://www.biopharmawatch.com/news/ALT/seasoned-biopharmaceutical-industry-executives-teri-lawver-and-jerry-durso-appointed-to-al-alt-20250225monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-third-quarter-2024-financial-results-and-provides-a-business-update-en-alt-20241112monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-life-sciences-industry-veteran-greg-weaver-as-chief-financial-officer-g-alt-20241111monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2024-financial-results-and-provides-a-business-update-r-alt-20240808monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-mourns-passing-of-chief-financial-officer-richard-eisenstadt-gaithersburg-md-alt-20240626monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2024-financial-results-and-provides-a-business-update-en-alt-20240509monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-lean-mass-preservation-data-for-pemvidutide-and-reports-fourt-alt-20240327monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-topline-results-from-momentum-48-week-phase-2-obesity-trial-o-alt-20231130monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-third-quarter-2023-financial-results-and-provides-a-business-update-to-alt-20231107monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2023-financial-results-and-provides-a-business-update-t-alt-20230810monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2023-financial-results-and-provides-a-business-update-in-alt-20230511monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-former-gsk-executive-catherine-angell-sohn-pharm-d-to-its-board-of-dire-alt-20230327monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-results-from-week-24-interim-analysis-of-pemvidutide-momentum-alt-20230321monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-fourth-quarter-and-full-year-2022-financial-results-and-provides-a-bus-alt-20230228monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-topline-results-from-24-week-12-week-extension-trial-of-pemvi-alt-20221220monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-third-quarter-2022-financial-results-and-provides-a-business-update-to-alt-20221110monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-significant-reductions-in-liver-fat-content-and-body-weight-in-12-week-alt-20220914monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2022-financial-results-and-provides-a-business-update-t-alt-20220811monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2022-financial-results-and-provides-a-corporate-update-m-alt-20220512monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-a-corpo-alt-20220315monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-richard-eisenstadt-as-chief-financial-officer-gaithersburg-md-alt-20211213monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-third-quarter-2021-financial-results-and-provides-a-corporate-update-e-alt-20211109monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-results-from-12-week-phase-1-clinical-trial-of-alt-801-pemvid-alt-20210928monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2021-financial-results-and-provides-a-corporate-update--alt-20210810monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-update-on-adcovid-tm-phase-1-clinical-trial-adcovid-was-well-tolerated-alt-20210629monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-interim-data-from-alt-801-phase-1-trial-in-overweight-and-obe-alt-20210616monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2021-financial-results-and-provides-a-corporate-update-d-alt-20210517monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-reports-data-from-its-phase-1b-clinical-trial-of-nasoshield-gaithersburg-md-alt-20210401monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-expands-adcovid-manufacturing-collaboration-with-lonza-lonza-to-commission-a-ded-alt-20210312monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-financial-results-for-the-year-ended-alt-20210225monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-provides-an-update-on-its-investigational-new-drug-application-for-a-phase-1-adc-alt-20201223monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-third-quarter-2020-financial-results-and-provides-a-business-update-ga-alt-20201109monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2020-financial-results-and-provides-a-business-update-alt-20200811monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-gaith-alt-20200713monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-and-the-university-of-alabama-at-birmingham-uab-announce-positive-preclinical-re-alt-20200713monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-launches-clinical-trial-of-t-covid-tm-an-investigational-intranasal-immune-modul-alt-20200601monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2020-financial-results-and-provides-a-business-update-alt-20200513monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-former-pfizer-and-gsk-executive-diane-jorkasky-m-d-to-its-board-of-dire-alt-20200512monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-financial-results-for-the-year-ended-alt-20200327monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-third-quarter-2019-financial-results-and-provides-a-business-update-co-alt-20191113monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-3-7-million-in-additional-barda-funding-to-advance-nasoshield-clinical-alt-20190821monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2019-financial-results-and-provides-a-business-update-c-alt-20190813monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-closing-of-acquisition-of-spitfire-pharma-inc-gaithersburg-md-alt-20190715monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-signs-definitive-agreement-to-acquire-spitfire-pharma-inc-adding-nash-drug-candi-alt-20190709monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-will-brown-as-chief-financial-officer-alt-20190612monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2019-financial-results-and-provides-a-business-update-co-alt-20190514monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-financial-results-for-the-year-ended-alt-20190401monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-14-million-registered-direct-offering-alt-20190308monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-clinical-program-updates-and-plans-for-pipeline-expansion-alt-20190308monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-vipin-k-garg-ph-d-as-its-new-president-and-chief-executive-officer-gait-alt-20181127monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-third-quarter-2018-financial-results-and-provides-corporate-update-alt-20181113monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-25-million-registered-direct-offering-gaithersburg-md-alt-20181008monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-4-9-million-registered-direct-offering-of-common-stock-gaithersburg-md-alt-20180924monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-awarded-2-5-million-in-additional-barda-funding-to-support-nasoshield-developmen-alt-20180924monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-additional-positive-data-from-its-phase-2a-study-of-nasovax-intranasal-alt-20180904monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-initial-single-dose-data-from-its-nasoshield-phase-1-study-studies-fun-alt-20180831monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2018-financial-results-and-provides-corporate-update-co-alt-20180815monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-restructures-financing-agreement-with-substantially-all-of-the-remaining-series--alt-20180712monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-restructures-financing-agreement-alt-20180622monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-quarter-2018-financial-results-and-provides-corporate-update-con-alt-20180515monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-financial-results-for-the-year-ended-alt-20180329monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-third-quarter-2017-financial-results-and-provides-corporate-update-ini-alt-20171109monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-closes-series-b-preferred-stock-offering-gaithersburg-md-alt-20170821monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-14-7-million-series-b-preferred-stock-offering-gaithersburg-md-alt-20170817monthly0.5https://www.biopharmawatch.com/news/ALT/supplemental-disclosures-relating-to-altimmune-inc-company-overview-altimmune-inc-a-delawa-alt-20170817monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-second-quarter-2017-financial-results-and-provides-corporate-update-co-alt-20170810monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-promotes-dr-sybil-tasker-to-chief-medical-officer-gaithersburg-md-alt-20170516monthly0.5https://www.biopharmawatch.com/news/ALT/matthew-duffy-investor-relations-212-915-0685-matthew-lifesciadvisors-com-for-immediate-re-alt-20170504monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2568-mcarey-rxir-com-pharmathene-re-alt-20170503monthly0.5https://www.biopharmawatch.com/news/ALT/for-pharmathene-inc-contact-for-altimmune-inc-melody-carey-matthew-duffy-investor-relation-alt-20170426monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2568-mcarey-rxir-com-pharmathene-re-alt-20170314monthly0.5https://www.biopharmawatch.com/news/ALT/merger-overview-january-2017-forward-looking-statement-disclosure-any-statements-made-in-t-alt-20170201monthly0.5https://www.biopharmawatch.com/news/ALT/for-pharmathene-inc-contact-for-altimmune-inc-melody-a-carey-bill-enright-investor-relatio-alt-20170119monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2571-mcarey-rxir-com-pharmathene-re-alt-20161104monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2571-mcarey-rxir-com-pharmathene-re-alt-20160804monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2571-mcarey-rxir-com-pharmathene-re-alt-20160509monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2571-mcarey-rxir-com-pharmathene-re-alt-20160311monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2571-mcarey-rxir-com-pharmathene-ad-alt-20151125monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2571-mcarey-rxir-com-pharmathene-re-alt-20151106monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2571-mcarey-rxir-com-pharmathene-re-alt-20150805monthly0.5https://www.biopharmawatch.com/news/ALT/melody-carey-rx-communications-group-llc-phone-917-322-2571-mcarey-rxir-com-pharmathene-re-alt-20150507monthly0.5https://www.biopharmawatch.com/news/ALT/melody-a-carey-rx-communications-group-llc-917-322-2571-mcarey-rxir-com-pharmathene-report-alt-20150309monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-delaw-alt-20150107monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20141106monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20140910monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20140804monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20140508monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-alt-20140407monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20140311monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-alt-20131216monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-alt-20131202monthly0.5https://www.biopharmawatch.com/news/ALT/theraclone-provides-update-on-barda-funding-proposal-for-tcn-032-for-serious-and-pandemic--alt-20131127monthly0.5https://www.biopharmawatch.com/news/ALT/an-important-reminder-dear-pharmathene-stockholder-as-you-know-we-are-holding-a-special-me-alt-20131119monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20131107monthly0.5https://www.biopharmawatch.com/news/ALT/theraclone-sciences-monoclonal-antibody-candidate-pgt121-suppresses-hiv-in-simian-models-o-alt-20131104monthly0.5https://www.biopharmawatch.com/news/ALT/turning-the-human-repertoire-s-most-potent-antibodies-into-superior-therapeutics-bio-inves-alt-20131008monthly0.5https://www.biopharmawatch.com/news/ALT/theraclone-sciences-presents-positive-data-from-phase-1-trial-of-therapeutic-antibody-for--alt-20130911monthly0.5https://www.biopharmawatch.com/news/ALT/theraclone-sciences-announces-initiation-of-phase-2a-trial-of-tcn-202-for-the-prevention-o-alt-20130910monthly0.5https://www.biopharmawatch.com/news/ALT/rodman-renshaw-annual-global-investment-conference-september-9-2013-alt-20130909monthly0.5https://www.biopharmawatch.com/news/ALT/for-pharmathene-inc-stacey-jurchison-phone-410-269-2610-stacey-jurchison-pharmathene-com-f-alt-20130909monthly0.5https://www.biopharmawatch.com/news/ALT/theraclone-sciences-announces-universal-therapeutic-antibody-for-influenza-a-demonstrates--alt-20130908monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20130906monthly0.5https://www.biopharmawatch.com/news/ALT/thomson-reuters-streetevents-edited-transcript-pip-q2-2013-pharmathene-inc-earnings-confer-alt-20130808monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20130807monthly0.5https://www.biopharmawatch.com/news/ALT/for-pharmathene-inc-stacey-jurchison-phone-410-269-2610-stacey-jurchison-pharmathene-com-f-alt-20130801monthly0.5https://www.biopharmawatch.com/news/ALT/fda-lifts-clinical-hold-on-pharmathene-s-sparvax-anthrax-vaccine-program-annapolis-md-alt-20130530monthly0.5https://www.biopharmawatch.com/news/ALT/delaware-supreme-court-affirms-lower-court-s-ruling-that-siga-technologies-breached-its-co-alt-20130526monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20130508monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-com-alt-20130313monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-com-alt-20121106monthly0.5https://www.biopharmawatch.com/news/ALT/rodman-renshaw-14-th-annual-healthcare-conference-alt-20120910monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20120807monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20120508monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20120403monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20120308monthly0.5https://www.biopharmawatch.com/news/ALT/unassociated-document-for-immediate-release-contact-stacey-jurchison-pharmathene-inc-phone-alt-20111109monthly0.5https://www.biopharmawatch.com/news/ALT/stacey-jurchison-pharmathene-inc-phone-410-269-2610-stacey-jurchison-pharmathene-com-pharm-alt-20110926monthly0.5https://www.biopharmawatch.com/news/ALT/unassociated-document-pharmathene-reports-second-quarter-2011-financial-and-operating-resu-alt-20110810monthly0.5https://www.biopharmawatch.com/news/ALT/unassociated-document-for-immediate-release-contact-stacey-jurchison-pharmathene-inc-phone-alt-20110610monthly0.5https://www.biopharmawatch.com/news/ALT/unassociated-document-for-immediate-release-contact-stacey-jurchison-pharmathene-inc-phone-alt-20110511monthly0.5https://www.biopharmawatch.com/news/ALT/unassociated-document-for-immediate-release-contact-stacey-jurchison-pharmathene-inc-phone-alt-20110328monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-therapeutics-inc-condensed-consolidated-statements-of-operations-information-unaudi-engn-20260615monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-full-year-2025-financial-results-and-provides-business-update-completed-enr-engn-20251218monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-announces-pricing-of-130-million-public-offering-of-common-shares-and-pre-funded-wa-engn-20251112monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-to-host-conference-call-to-provide-update-on-pivotal-cohort-of-legend-trial-boston--engn-20251110monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-appoints-hussein-sweiti-m-d-msc-as-chief-medical-officer-bladder-cancer-development-engn-20250930monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-third-quarter-2025-financial-results-and-provides-business-update-achieved--engn-20250911monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-announces-board-and-leadership-appointments-to-support-commercial-readiness-philip--engn-20250708monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-second-quarter-2025-financial-results-and-provides-business-update-addition-engn-20250612monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-announces-the-resignation-of-its-chief-medical-officer-boston-and-montreal-engn-20250604monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-first-quarter-2025-financial-results-and-provides-business-update-additiona-engn-20250310monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-full-year-2024-financial-results-and-provides-a-business-update-bla-filing--engn-20241219monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-announces-60-million-private-placement-financing-boston-and-montreal-engn-20241025monthly0.5https://www.biopharmawatch.com/news/ENGN/recent-quarterly-report-on-form-10-q-for-the-fiscal-quarter-ended-engn-20241021monthly0.5https://www.biopharmawatch.com/news/ENGN/detalimogene-demonstrates-71-complete-response-rate-at-any-time-in-preliminary-analysis-of-engn-20240926monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-third-quarter-2024-financial-results-and-provides-a-business-update-company-engn-20240910monthly0.5https://www.biopharmawatch.com/news/ENGN/non-viral-genetic-medicine-corporate-presentation-september-2024-cautionary-statement-rega-engn-20240905monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-announces-appointment-of-ron-cooper-as-chief-executive-officer-ron-cooper-succeeds--engn-20240724monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-second-quarter-2024-financial-results-and-provides-a-business-update-compan-engn-20240614monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-first-quarter-2024-financial-results-and-recent-corporate-progress-pivotal--engn-20240311monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-announces-oversubscribed-200-million-private-placement-financing-financing-included-engn-20240214monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-full-year-2023-financial-results-and-recent-operational-progress-achieved-p-engn-20240129monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-appoints-lota-s-zoth-cpa-as-member-of-the-board-of-directors-boston-mass-and-montre-engn-20231219monthly0.5https://www.biopharmawatch.com/news/ENGN/engene-appoints-ryan-daws-as-chief-financial-officer-boston-mass-and-montreal-canada-engn-20231129monthly0.5https://www.biopharmawatch.com/news/ENGN/unaudited-pro-forma-condensed-combined-financial-information-the-following-unaudited-pro-f-engn-20231031monthly0.5https://www.biopharmawatch.com/news/ARVN/presentationj-arvn-20260602monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-second-quarter-2025-financial-results-and-provides-corporate-update-submit-arvn-20250806monthly0.5https://www.biopharmawatch.com/news/ARVN/developed-as-a-potential-monotherapy-for-er-her2-advanced-or-metastatic-breast-cancer-with-arvn-20250606monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-first-quarter-2025-financial-results-and-provides-corporate-update-reporte-arvn-20250501monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-forward-looking-statements-this-press-release-contains-forward-looking-statements--arvn-20250311monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-arvn-20250211monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-initial-phase-1b-data-from-the-tactive-u-sub-study-of-vepdeges-arvn-20241210monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-third-quarter-2024-financial-results-and-provides-corporate-update-on-trac-arvn-20241030monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-second-quarter-2024-financial-results-and-provides-corporate-update-comple-arvn-20240730monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-first-quarter-2024-financial-results-and-provides-corporate-update-continu-arvn-20240507monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-arvn-20240227monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-oversubscribed-350-million-private-placement-arvn-20231127monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-third-quarter-2023-financial-results-and-provides-corporate-update-enrollm-arvn-20231107monthly0.5https://www.biopharmawatch.com/news/ARVN/castrate-resistant-prostate-cancer-and-we-are-prioritizing-the-initiation-of-a-phase-3-cli-arvn-20231023monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-second-quarter-2023-financial-results-and-provides-corporate-update-enroll-arvn-20230808monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-first-quarter-2023-financial-results-and-provides-corporate-update-multipl-arvn-20230505monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-arvn-20230223monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-third-quarter-2022-financial-results-and-provides-corporate-update-on-trac-arvn-20221108monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-second-quarter-2022-financial-results-and-provides-corporate-update-arvn-20220804monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-first-quarter-2022-financial-results-and-provides-corporate-update-arvn-20220505monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporate-arvn-20220228monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-protac-protein-degrader-bavdegalutamide-arv-110-continues-to-demonstrate-clinical--arvn-20220217monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-new-data-from-completed-phase-1-dose-escalation-and-ongoing-phase-2-arde-arvn-20220214monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-protac-protein-degrader-arv-471-continues-to-demonstrate-encou-arvn-20211210monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-third-quarter-2021-financial-results-and-provides-corporate-update-arvn-20211103monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-second-quarter-2021-financial-results-and-provides-corporate-update-arvn-20210805monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-global-collaboration-to-develop-and-commercialize-protac-prote-arvn-20210722monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-first-quarter-2021-financial-results-and-provides-corporate-update-arvn-20210504monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-corporate-arvn-20210301monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-inc-announces-pricing-of-400-million-public-offering-of-common-stock-arvn-20201215monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-releases-interim-clinical-data-further-demonstrating-the-powerful-potential-of-pro-arvn-20201214monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-third-quarter-2020-financial-results-and-provides-corporate-update-first-p-arvn-20201105monthly0.5https://www.biopharmawatch.com/news/ARVN/most-b-cell-lymphomas-are-dependent-on-constitutive-or-deregulated-expression-of-bcl6-a-tr-arvn-20201014monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-second-quarter-2020-financial-results-and-provides-corporate-update-arvn-20200804monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-releases-updated-dose-escalation-data-from-clinical-trial-of-protac-protein-degrad-arvn-20200529monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-first-quarter-2020-financial-results-and-provides-a-corporate-update-arvn-20200428monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-corporate-arvn-20200316monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-inc-announces-pricing-of-public-offering-of-common-stock-arvn-20191106monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-third-quarter-2019-financial-results-and-provides-corporate-update-arvn-20191104monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-presents-a-platform-update-including-initial-data-from-the-first-two-clinical-tria-arvn-20191023monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-second-quarter-2019-financial-results-and-provides-corporate-update-arvn-20190805monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-first-quarter-financial-results-and-provides-corporate-update-initiated-pa-arvn-20190508monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-corporate-arvn-20190326monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-provides-business-update-and-2026-outlook-preliminary-fourth-quarter-2025-total-reve-rigl-20260112monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-second-quarter-2025-financial-results-and-provides-business-update-second-qu-rigl-20250805monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-first-quarter-2025-financial-results-and-provides-business-update-first-quar-rigl-20250506monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-settlement-agreement-resolving-tavalisse-fostamatinib-disodium-hexahydrate-rigl-20250327monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-up-rigl-20250304monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-provides-business-update-and-2025-outlook-preliminary-fourth-quarter-2024-total-reve-rigl-20250113monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-highlights-initial-data-from-ongoing-phase-1b-study-evaluating-r289-in-lr-mds-at-the-rigl-20241209monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-third-quarter-2024-financial-results-and-provides-business-update-third-quar-rigl-20241107monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-second-quarter-2024-financial-results-and-provides-business-update-second-qu-rigl-20240806monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-reverse-stock-split-south-san-francisco-calif-june-25-2024-prnewswire-rige-rigl-20240627monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-first-quarter-2024-financial-results-and-provides-business-update-first-quar-rigl-20240507monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-up-rigl-20240305monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-preliminary-fourth-quarter-2023-total-reven-rigl-20240108monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-third-quarter-2023-financial-results-and-provides-business-update-third-quar-rigl-20231107monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-second-quarter-2023-financial-results-and-provides-business-update-second-qu-rigl-20230801monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-first-quarter-2023-financial-results-and-provides-business-update-first-quar-rigl-20230502monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-up-rigl-20230307monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-rezlidhia-u-s-fda-approval-and-commercial-l-rigl-20230109monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-u-s-fda-approval-of-rezlidhia-olutasidenib-for-the-treatment-of-adult-pati-rigl-20221201monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-third-quarter-2022-financial-results-and-provides-business-update-fda-review-rigl-20221103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-top-line-results-from-focus-phase-3-clinical-trial-of-fostamatinib-in-high-rigl-20221101monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-provides-update-on-plans-for-snda-for-waiha-program-following-fda-feedback-announces-rigl-20221010monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-second-quarter-2022-financial-results-and-provides-business-update-second-qu-rigl-20220802monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-top-line-results-from-forward-phase-3-clinical-trial-of-fostamatinib-in-pa-rigl-20220608monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-first-quarter-2022-financial-results-and-provides-business-update-first-quar-rigl-20220503monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business-up-rigl-20220301monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-tavalisse-preliminary-2021-net-product-sale-rigl-20220110monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-third-quarter-2021-financial-results-and-provides-business-update-completed--rigl-20211102monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-update-on-covid-19-program-fda-declines-to-issue-emergency--rigl-20210813monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-first-quarter-2021-financial-results-and-provides-business-update-reported-p-rigl-20210505monthly0.5https://www.biopharmawatch.com/news/RIGL/positive-topline-data-shows-fostamatinib-meets-primary-endpoint-of-safety-in-phase-2-clini-rigl-20210413monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-up-rigl-20210302monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-tavalisse-preliminary-2020-net-product-sale-rigl-20210111monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-third-quarter-2020-financial-results-and-provides-business-update-third-quar-rigl-20201105monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-second-quarter-2020-financial-results-provides-business-update-and-overviews-rigl-20200804monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-first-quarter-2020-financial-rigl-20200505monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-business-up-rigl-20200227monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-rigl-20200113monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-receives-positive-chmp-opinion-for-fostamatinib-disodium-hexahydrate-for-adult-patie-rigl-20191115monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2019-financial-results-net-sales-of-tavalisse-increased-15-q-rigl-20191105monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-prior-to-investor-analyst-call-tavalisse-ne-rigl-20191023monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2019-financial-results-and-provides-business-update-tavalis-rigl-20190806monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2019-financial-results-and-provides-company-update-tavalisse-rigl-20190507monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-company-upd-rigl-20190228monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-reports-1-794-total-bottles-of-tavalisse-tm-rigl-20190107monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2018-financial-results-and-provides-company-update-reports-t-rigl-20181106monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2018-financial-results-and-provides-company-update-1-8-mill-rigl-20180808monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2018-financial-results-and-provides-company-update-rigel-exp-rigl-20180501monthly0.5https://www.biopharmawatch.com/news/RIGL/completely-and-with-the-understanding-that-our-actual-future-results-may-be-materially-dif-rigl-20180417monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2017-financial-results-and-provides-company-up-rigl-20180306monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-provide-business-review-and-updated-phase-2-results-for-fostamatinib-in-aiha-at-t-rigl-20180104monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-departure-of-chief-financial-officer-launches-search-for-chief-financial-o-rigl-20171215monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2017-financial-results-and-provides-company-update-conferenc-rigl-20171107monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2017-financial-results-and-provides-company-update-conferen-rigl-20170801monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2017-financial-results-and-provides-company-update-conferenc-rigl-20170502monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-2016-and-year-end-2016-financial-results-and-provides-compa-rigl-20170307monthly0.5https://www.biopharmawatch.com/news/RIGL/completely-and-with-the-understanding-that-our-actual-future-results-may-be-materially-dif-rigl-20170130monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2016-financial-results-and-provides-company-update-conferenc-rigl-20161101monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-results-from-the-second-fit-phase-3-study-and-the-long-term-open-label-ext-rigl-20161020monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-restructures-to-focus-on-fostamatinib-commercialization-hires-eldon-mayer-as-first-c-rigl-20160915monthly0.5https://www.biopharmawatch.com/news/RIGL/logo-rigel-conference-call-fit-phase-3-study-in-itp-rigl-20160830monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2016-financial-results-and-provides-portfolio-update-confer-rigl-20160802monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2016-financial-results-conference-call-and-webcast-today-at--rigl-20160503monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2015-financial-results-conference-call-and-web-rigl-20160308monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-names-anne-marie-duliege-m-d-m-s-as-chief-medical-officer-elliott-grossbard-m-d-reti-rigl-20160308monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2015-financial-results-conference-call-and-webcast-today-at--rigl-20151103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2015-financial-results-conference-call-and-webcast-today-at-rigl-20150804monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2015-financial-results-conference-call-and-webcast-today-at--rigl-20150507monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2014-financial-results-south-san-francisco-cal-rigl-20150303monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-33-rd-annual-j-p-morgan-healthcare-conference-earns-5-75m-mileston-rigl-20150108monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-executive-management-changes-james-m-gower-retires-raul-rodriguez-named-ce-rigl-20141124monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2014-financial-results-south-san-francisco-calif-rigl-20141104monthly0.5https://www.biopharmawatch.com/news/RIGL/r348-did-not-meet-endpoints-in-phase-2-dry-eye-study-rigel-reiterates-clinical-focus-on-fo-rigl-20140813monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2014-financial-results-rigl-20140805monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2014-financial-results-south-san-francisco-calif-rigl-20140507monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2013-financial-results-south-san-francisco-cal-rigl-20140304monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-will-present-clinical-product-portfolio-update-at-j-p-morgan-healthcare-conference-e-rigl-20140110monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2013-financial-results-south-san-francisco-calif-rigl-20131105monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-s-r343-did-not-meet-primary-endpoint-in-asthma-study-rigl-20130826monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2013-financial-results-rigl-20130806monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20130604monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2013-financial-results-south-san-francisco-calif-rigl-20130507monthly0.5https://www.biopharmawatch.com/news/RIGL/astrazeneca-announces-top-line-results-from-oskira-1-phase-3-study-of-fostamatinib-in-rheu-rigl-20130405monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2012-financial-results-south-san-francisco-cal-rigl-20130305monthly0.5https://www.biopharmawatch.com/news/RIGL/astrazeneca-announces-top-line-results-of-oskira-4-phase-iib-study-of-fostamatinib-as-a-mo-rigl-20121213monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2012-financial-results-south-san-francisco-calif-rigl-20121106monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-pricing-of-public-offering-of-common-stock-south-san-francisco-calif-rigl-20121003monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2012-financial-results-south-san-francisco-calif-rigl-20120807monthly0.5https://www.biopharmawatch.com/news/RIGL/certificate-of-amendment-to-amended-and-restated-certificate-of-incorporation-of-rigel-pha-rigl-20120529monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2012-financial-results-south-san-francisco-calif-rigl-20120501monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2011-financial-results-south-san-francisco-cal-rigl-20120306monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2011-financial-results-south-san-francisco-calif-rigl-20111101monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2011-financial-results-south-san-francisco-calif-rigl-20110802monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-financial-results-south-san-francisco-calif-rigl-20110503monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2010-financial-results-south-san-francisco-cal-rigl-20110301monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2010-financial-results-south-san-francisco-calif-rigl-20101102monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2010-financial-results-south-san-francisco-calif-rigl-20100803monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-names-raul-rodriguez-president-ryan-maynard-and-dolly-vance-promoted-rigl-20100601monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2010-financial-results-south-san-francisco-calif-rigl-20100504monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2009-financial-results-south-san-francisco-cal-rigl-20100302monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20091103monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20090804monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20090723monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20090709monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2009-financial-results-south-san-francisco-calif-rigl-20090505monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20090224monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20090203monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20081103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2008-financial-results-south-san-francisco-calif-aug-5-prne-rigl-20080812monthly0.5https://www.biopharmawatch.com/news/RIGL/veterans-blvd-south-san-francisco-ca-94080-main-phone-650-624-1100-fax-650-624-1101-http-w-rigl-20080506monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fourth-quarter-and-year-end-2007-financial-results-rigl-20080212monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-pricing-of-public-offering-of-common-stock-rigl-20080131monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-s-r788-demonstrates-significant-improvement-in-rheumatoid-arthritis-in-phase-2-clini-rigl-20071213monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-r788-raises-platelet-counts-in-immune-thrombocytopenic-purpura-itp-patients-in-phase-rigl-20071109monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-third-quarter-2007-financial-results-south-san-francisco-calif-nov-6-rigel-rigl-20071106monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-quarter-2007-financial-results-rigl-20070807monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-2007-financial-results-south-san-francisco-calif-rigl-20070510monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-pricing-of-150-million-underwritten-offering-of-common-stock-immx-20260521monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-95-complete-response-rate-in-interim-update-from-relapsed-refrac-immx-20260521monthly0.5https://www.biopharmawatch.com/news/IMMX/california-institute-for-regenerative-medicine-awards-funding-for-car-t-nxc-201-u-s-al-amy-immx-20240725monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-in-licenses-nxc-201-bcma-targeted-next-generation-car-t-therapy-demonstrat-immx-20221214monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-announces-positive-imx-110-phase-1b-2a-interim-clinical-trial-safety-data-demonst-immx-20220119monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-imx-110-produced-50-positive-response-rate-in-first-line-therapy-resistant-cancer-immx-20220112monthly0.5https://www.biopharmawatch.com/news/IMMX/u-s-food-and-drug-administration-approves-immix-biopharma-rare-pediatric-disease-designati-immx-20220103monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-inc-announces-pricing-of-initial-public-offering-immx-20211215monthly0.5https://www.biopharmawatch.com/news/MDXG/forth-in-the-forward-looking-statements-any-forward-looking-statements-speak-only-as-of-th-mdxg-20260416monthly0.5https://www.biopharmawatch.com/news/MDXG/earningscallpresent-financial-results-conference-call-mdxg-20250226monthly0.5https://www.biopharmawatch.com/news/MDXG/investor-presentation-january-2025-disclaimer-cautionary-statements-this-presentation-incl-mdxg-20250114monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-cautionary-statements-this-presentation-includes-forward-looking-statements-for-mdxg-20241118monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-third-quarter-2024-operating-and-financial-results-net-sales-of-84-millio-mdxg-20241030monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-second-quarter-2024-operating-and-financial-results-net-sales-of-87-milli-mdxg-20240731monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-first-quarter-2024-operating-and-financial-results-net-sales-of-85-millio-mdxg-20240430monthly0.5https://www.biopharmawatch.com/news/MDXG/document-mimedx-announces-appointment-of-two-new-independent-directors-marietta-ga-mdxg-20240304monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-fourth-quarter-and-full-year-2023-operating-and-financial-results-net-sal-mdxg-20240228monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-improved-capital-structure-with-new-senior-secured-credit-facilities-and--mdxg-20240122monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-conversion-of-outstanding-series-b-convertible-preferred-stock-to-common--mdxg-20231228monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-in-upcoming-investor-conferences-marietta-ga-mdxg-20231113monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-third-quarter-2023-operating-and-financial-results-third-consecutive-quar-mdxg-20231030monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-upcoming-investor-conferences-marietta-ga-mdxg-20230905monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-second-quarter-2023-operating-and-financial-results-records-second-quarte-mdxg-20230801monthly0.5https://www.biopharmawatch.com/news/MDXG/document-mimedx-appoints-doug-rice-as-chief-financial-officer-company-adds-seasoned-medtec-mdxg-20230705monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-strategic-realignment-increases-focus-on-wound-surgical-business-expected-mdxg-20230620monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-first-quarter-2023-operating-and-financial-results-first-quarter-net-sale-mdxg-20230502monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-chief-financial-officer-transition-executive-search-underway-marietta-ga-mdxg-20230323monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-fourth-quarter-and-full-year-2022-operating-and-financial-results-reports-mdxg-20230228monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-appoints-joseph-h-capper-as-chief-executive-officer-and-director-highly-experienced-mdxg-20230130monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-cautionary-statements-some-of-the-information-and-statements-contained-in-this--mdxg-20230109monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-appoints-ricci-s-whitlow-as-chief-operating-officer-mimedx-bolsters-management-team-mdxg-20230103monthly0.5https://www.biopharmawatch.com/news/MDXG/a-pioneer-leader-in-placental-biologics-investor-presentation-november-2022-disclaimer-cau-mdxg-20221130monthly0.5https://www.biopharmawatch.com/news/MDXG/a-pioneer-leader-in-placental-biologics-investor-presentation-november-2022-disclaimer-cau-mdxg-20221117monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-third-quarter-2022-operating-and-financial-results-third-quarter-net-sale-mdxg-20221102monthly0.5https://www.biopharmawatch.com/news/MDXG/mdxgcanaccord081022-1-a-transformational-placental-biologics-company-canaccord-genuity-42n-mdxg-20220810monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-second-quarter-2022-operating-and-financial-results-second-quarter-net-sa-mdxg-20220803monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-cautionary-statements-this-presentation-includes-forward-looking-statements-for-mdxg-20220524monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-cautionary-statements-this-presentation-includes-forward-looking-statements-for-mdxg-20220510monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-first-quarter-2022-operating-and-financial-results-first-quarter-net-sale-mdxg-20220504monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-comments-on-prescience-point-s-recent-filing-shareholders-urged-to-support-mimedx-b-mdxg-20220429monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-cautionary-statements-this-presentation-includes-forward-looking-statements-for-mdxg-20220322monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-fourth-quarter-and-full-year-2021-operating-and-financial-results-fourth--mdxg-20220228monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-cautionary-statements-this-presentation-includes-forward-looking-statements-for-mdxg-20211207monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-cautionary-statements-this-presentation-includes-forward-looking-statements-for-mdxg-20211122monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-third-quarter-2021-operating-and-financial-results-third-quarter-net-sale-mdxg-20211103monthly0.5https://www.biopharmawatch.com/news/MDXG/advancing-regenerative-medicine-treatment-through-placental-science-raymond-james-human-he-mdxg-20210623monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-reminds-shareholders-to-pre-register-for-the-upcoming-virtual-2021-annual-meeting-o-mdxg-20210526monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-cautionary-statements-important-cautionary-statement-this-presentation-includes-mdxg-20210512monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-files-definitive-proxy-materials-and-mails-letter-to-shareholders-highlighting-acti-mdxg-20210503monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-first-quarter-2021-financial-and-operating-results-first-quarter-net-sale-mdxg-20210429monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-last-patients-last-visits-in-three-late-stage-musculoskeletal-trials-with-mdxg-20210419monthly0.5https://www.biopharmawatch.com/news/MDXG/important-cautionary-statement-this-presentation-contains-forward-looking-statements-actua-mdxg-20210310monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-fourth-quarter-and-full-year-2020-financial-and-operating-results-fourth--mdxg-20210309monthly0.5https://www.biopharmawatch.com/news/MDXG/innovating-treatments-through-advanced-placental-science-january-11-14-2021-2021-j-p-morga-mdxg-20210111monthly0.5https://www.biopharmawatch.com/news/MDXG/important-cautionary-statement-this-presentation-contains-forward-looking-statements-inves-mdxg-20201120monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-third-quarter-2020-financial-results-third-quarter-net-sales-of-64-3-mill-mdxg-20201105monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-relisting-on-nasdaq-marietta-ga-mdxg-20201030monthly0.5https://www.biopharmawatch.com/news/MDXG/united-states-district-court-northern-district-of-georgia-atlanta-division-in-re-mimedx-gr-mdxg-20201022monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-concludes-enrollment-for-phase-2b-study-of-osteoarthritis-oa-of-the-knee-research-a-mdxg-20200921monthly0.5https://www.biopharmawatch.com/news/MDXG/important-cautionary-statement-this-presentation-contains-forward-looking-statements-inves-mdxg-20200921monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-concludes-enrollment-for-phase-3-plantar-fasciitis-trial-research-in-plantar-fascii-mdxg-20200917monthly0.5https://www.biopharmawatch.com/news/MDXG/disclaimer-this-presentation-contains-summarized-information-concerning-the-company-and-th-mdxg-20200831monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-welcomes-robert-b-stein-m-d-ph-d-to-head-revitalized-r-d-efforts-pharmaceutical-and-mdxg-20200810monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-adds-rohit-kashyap-ph-d-to-leadership-team-as-executive-vice-president-and-chief-co-mdxg-20200728monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-filing-of-2019-annual-report-annual-report-on-form-10-k-includes-audited--mdxg-20200706monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-provides-update-on-payment-protection-program-loan-company-is-repaying-loan-in-full-mdxg-20200508monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-appointment-of-william-l-phelan-as-chief-accounting-officer-marietta-ga-mdxg-20200505monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-additional-access-to-capital-and-financing-includes-approval-of-paycheck--mdxg-20200421monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-settlement-of-va-pricing-investigation-settlement-recognizes-company-s-co-mdxg-20200406monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-names-peter-m-carlson-as-chief-financial-officer-marietta-ga-mdxg-20200319monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-filing-of-2018-annual-report-annual-report-on-form-10-k-includes-audited--mdxg-20200317monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-provides-update-regarding-timing-of-restatement-company-expects-to-file-2018-annual-mdxg-20191212monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-resignation-of-board-member-mr-luis-a-aguilar-resigned-effective-mdxg-20190919monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-agreement-regarding-2019-and-2020-shareholder-meetings-marietta-ga-mdxg-20190808monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-urges-shareholders-to-vote-today-for-all-of-the-board-s-highly-qualified-nominees-o-mdxg-20190617monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-highlights-skills-and-experience-of-director-nominees-company-urges-shareholders-to-mdxg-20190613monthly0.5https://www.biopharmawatch.com/news/MDXG/leading-independent-proxy-advisory-firm-glass-lewis-joins-iss-and-egan-jones-in-recommendi-mdxg-20190612monthly0.5https://www.biopharmawatch.com/news/MDXG/leading-independent-proxy-advisory-firms-iss-and-egan-jones-recommend-that-mimedx-sharehol-mdxg-20190611monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-issues-additional-information-to-shareholders-company-urges-shareholders-to-vote-th-mdxg-20190610monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-issues-new-presentation-for-investors-in-advance-of-2018-annual-meeting-illustrates-mdxg-20190605monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-comprehensive-board-refreshment-plan-in-cooperation-with-prescience-point-mdxg-20190530monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-bdo-as-the-company-s-new-independent-registered-public-accounting-firm-ma-mdxg-20190528monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-conclusion-of-audit-committee-s-independent-investigation-investigation-r-mdxg-20190523monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-appoints-timothy-r-wright-as-chief-executive-officer-healthcare-industry-veteran-to-mdxg-20190509monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-board-approval-of-long-range-strategic-plan-organization-focused-on-execu-mdxg-20190411monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-organizational-realignment-program-plan-will-improve-cost-structure-and-i-mdxg-20181205monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-adopts-limited-duration-shareholder-rights-plan-in-response-to-delisting-from-nasda-mdxg-20181107monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-receives-nasdaq-delisting-notification-company-remains-focused-on-delivering-operat-mdxg-20181107monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-nasdaq-listing-extension-marietta-georgia-mdxg-20180920monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-provides-update-on-previously-announced-senior-executive-separations-board-and-comp-mdxg-20180920monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-receipt-of-nasdaq-letter-company-will-request-hearing-with-nasdaq-hearing-mdxg-20180726monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-leadership-changes-and-corporate-actions-pete-petit-resigns-as-chairman-a-mdxg-20180702monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-reports-unreviewed-first-quarter-revenue-exceeds-upper-end-of-its-guidance-company--mdxg-20180426monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-expectation-to-exceed-the-92-million-top-end-of-first-quarter-revenue-gui-mdxg-20180315monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-receives-notice-of-filing-delinquency-from-nasdaq-marietta-georgia-mdxg-20180302monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-postpones-release-of-its-fourth-quarter-and-fiscal-year-2017-financial-results-mari-mdxg-20180220monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-releases-preliminary-2017-revenue-of-324-5-millio-mdxg-20180107monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-forecasts-2018-revenue-to-be-in-the-range-of-383--mdxg-20171213monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-results-for-the-third-quarter-of-mdxg-20171026monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-third-quarter-revenues-of-84-6-million--mdxg-20171010monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-completes-divestiture-of-its-stability-biologics--mdxg-20171002monthly0.5https://www.biopharmawatch.com/news/MDXG/exhibit-press-release-contact-michael-senken-phone-770-651-9100-mimedx-announces-its-expec-mdxg-20170905monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-logo-press-release-contact-michael-senken-phone-770-651-9100-mimedx-signs-definitiv-mdxg-20170818monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-results-for-the-second-quarter-o-mdxg-20170726monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-that-its-second-quarter-revenue-exceeds-the-guidance-range-q2-2017-revenu-mdxg-20170713monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-agreement-with-avkare-expires-as-planned-following-completion-of-contract-wind-down-mdxg-20170705monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-results-for-first-quarter-of-201-mdxg-20170428monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-first-quarter-2017-revenue-to-exceed-high-end-of-guidance-q1-2017-revenue-mdxg-20170413monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-the-addition-of-luis-a-aguilar-to-its-board-of-directors-newest-mimedx-bo-mdxg-20170319monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-2016-record-results-marietta-georgia-mdxg-20170223monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-fourth-quarter-2016-revenue-in-upper-range-of-guidance-246-8-million-full-year-2016-mdxg-20170109monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-third-quarter-2016-results-company-exce-mdxg-20161027monthly0.5https://www.biopharmawatch.com/news/MDXG/third-quarter-2016-revenue-highlights-mdxg-20161010monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-second-quarter-2016-results-company-exc-mdxg-20160726monthly0.5https://www.biopharmawatch.com/news/MDXG/second-quarter-2016-revenue-highlights-mdxg-20160711monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-first-quarter-2016-results-company-reco-mdxg-20160425monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-first-quarter-of-2016-revenue-results-53-4-million-q1-2016-revenue-is-31--mdxg-20160410monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-2015-record-results-company-records-rev-mdxg-20160223monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-signs-definitive-agreement-to-acquire-stability-biologics-company-issues-revised-gu-mdxg-20160110monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-exceeds-fourth-quarter-and-full-year-2015-revenue-consensus-187-3-million-full-year-mdxg-20160110monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-results-for-third-quarter-of-201-mdxg-20151029monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-third-quarter-record-revenue-is-49-million-nine-m-mdxg-20151012monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mdxg-20150806monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-results-for-second-quarter-of-20-mdxg-20150730monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-results-for-first-quarter-of-201-mdxg-20150427monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-reports-record-first-quarter-2015-revenue-of-40-8-mdxg-20150413monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-2014-record-revenue-and-first-full-year-mdxg-20150226monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-exceeds-fourth-quarter-and-full-year-2014-revenue-mdxg-20150112monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-10-miillion-increase-to-stock-repurchas-mdxg-20150106monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-comments-on-recent-fda-draft-guidance-on-minimal--mdxg-20141230monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-achieves-record-revenue-and-records-first-operati-mdxg-20141030monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-third-quarter-revenue-of-33-5-million-exceeds-upp-mdxg-20141013monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-correction-mimedx-group-inc-in-the-news-release-mimedx-a-mdxg-20140728monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-10-million-stock-repurchase-program-mar-mdxg-20140512monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-quarterly-results-revenue-increa-mdxg-20140425monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-first-quarter-revenue-exceeded-upper-end-of-guida-mdxg-20140407monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-2013-results-company-increases-s-mdxg-20140226monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-prices-34-0-million-public-offering-of-common-sto-mdxg-20131211monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-group-announces-proposed-public-offering-of-commo-mdxg-20131209monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-third-quarter-results-marietta-g-mdxg-20131030monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-to-exceed-high-end-of-third-quarter-guidance-mari-mdxg-20131016monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mdxg-20130904monthly0.5https://www.biopharmawatch.com/news/MDXG/event-id-5129761-culture-en-us-event-name-q2-2013-mimedx-group-inc-earnings-conference-cal-mdxg-20130806monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-mimedx-announces-record-second-quarter-results-marietta--mdxg-20130731monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-770-651-9100-marietta-ga-mdxg-20130715monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-678-384-6720-mimedx-secures-a-3-0-million-revolving-line-of-credit-wi-mdxg-20130520monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-678-384-6720-mimedx-announces-record-first-quarter-2013-mdxg-20130501monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-678-384-6720-mimedx-group-inc-announces-listing-on-the-nasdaq-capital-mdxg-20130425monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-678-384-6720-mimedx-announces-2012-mdxg-20130307monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-678-384-6720-mdxg-20121029monthly0.5https://www.biopharmawatch.com/news/MDXG/michael-senken-phone-678-384-6720-mdxg-20120910monthly0.5https://www.biopharmawatch.com/news/CBIO/document-kelun-biotech-and-crescent-biopharma-announce-strategic-partnership-to-develop-an-cbio-20251204monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-stockholders-approve-proposed-merger-with-crescent-biopharma-and-all-related-cbio-20250605monthly0.5https://www.biopharmawatch.com/news/CBIO/january-2025-crescent-biopharma-overview-2-disclaimer-this-presentation-is-for-information-cbio-20250113monthly0.5https://www.biopharmawatch.com/news/CBIO/november-2024-crescent-biopharma-overview-2-disclaimer-this-presentation-is-for-informatio-cbio-20241107monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-announces-national-cancer-institute-phase-2-3-study-of-uproleselan-did-not-m-cbio-20241029monthly0.5https://www.biopharmawatch.com/news/CBIO/about-glycomimetics-inc-glycomimetics-is-a-late-clinical-stage-biotechnology-company-disco-cbio-20240730monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-announces-comprehensive-results-from-pivotal-phase-3-study-of-uproleselan-in-cbio-20240604monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-announces-results-of-pivotal-phase-3-study-of-uproleselan-in-relapsed-refrac-cbio-20240506monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-full-year-20-cbio-20240327monthly0.5https://www.biopharmawatch.com/news/CBIO/x2022-to-the-extent-that-statements-contained-in-this-presentation-are-not-descriptions-of-cbio-20240301monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-third-quarter-2023-topline-resu-cbio-20231103monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-second-quarter-2023-topline-res-cbio-20230802monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-first-quarter-2023-pivotal-phas-cbio-20230503monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-year-end-202-cbio-20230329monthly0.5https://www.biopharmawatch.com/news/CBIO/xa9-2021-glycomimetics-inc-all-rights-reserved-glycobiology-based-therapeutics-transformin-cbio-20230302monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-third-quarter-2022-u-s-food-and-cbio-20221109monthly0.5https://www.biopharmawatch.com/news/CBIO/xa9-2021-glycomimetics-inc-all-rights-reserved-glycobiology-based-therapeuticstransforming-cbio-20221004monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-second-quarter-2022-u-s-food-an-cbio-20220803monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-first-quarter-2022-mid-year-202-cbio-20220428monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-full-year-20-cbio-20220303monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-third-quarter-2021-significant--cbio-20211102monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-second-quarter-2021-completion--cbio-20210805monthly0.5https://www.biopharmawatch.com/news/CBIO/g-lycomimetics-reports-highlights-and-financial-results-for-first-quarter-2021-glycomimeti-cbio-20210503monthly0.5https://www.biopharmawatch.com/news/CBIO/g-lycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-full-year-2-cbio-20210302monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-promotes-dr-eric-feldman-to-chief-medical-officer-rockville-md-cbio-20210223monthly0.5https://www.biopharmawatch.com/news/CBIO/g-lycomimetics-reports-highlights-and-financial-results-for-third-quarter-2020-enrollment--cbio-20201106monthly0.5https://www.biopharmawatch.com/news/CBIO/g-lycomimetics-reports-highlights-and-financial-results-for-second-quarter-2020-enrollment-cbio-20200731monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-operational-highlights-and-financial-results-for-first-quarter-2020--cbio-20200501monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-highlights-and-financial-results-for-fourth-quarter-and-year-end-201-cbio-20200228monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-and-apollomics-announce-exclusive-collaboration-and-license-agreement-to-dev-cbio-20200106monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-third-quarter-2019-financial-results-and-recent-operational-developm-cbio-20191107monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-top-line-results-from-pfizer-s-phase-3-clinical-trial-evaluating-riv-cbio-20190805monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-second-quarter-2019-financial-results-and-recent-operational-highlig-cbio-20190801monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-first-quarter-2019-results-and-recent-operational-highlights-xb7-enr-cbio-20190502monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-fourth-quarter-and-year-end-2018-results-xb7-initiated-first-company-cbio-20190306monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-announces-transition-plan-for-board-of-directors-xb7-current-board-member-ti-cbio-20190305monthly0.5https://www.biopharmawatch.com/news/CBIO/scott-jackson-veteran-biopharmaceutical-executive-cbio-20181128monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-third-quarter-2018-results-and-highlights-recent-company-achievement-cbio-20181102monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-second-quarter-2018-results-and-highlights-recent-company-achievemen-cbio-20180809monthly0.5https://www.biopharmawatch.com/news/CBIO/innovation-today-healing-tomorrow-july-2018-corporate-overview-nasdaq-glyc-glycomimetics-i-cbio-20180725monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-first-quarter-2018-results-xb7-based-on-guidance-from-the-us-food-an-cbio-20180503monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-announces-proposed-public-offering-of-common-stock-rockville-md-business-wir-cbio-20180319monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-fourth-quarter-and-year-end-2017-results-xb7-in-an-oral-presentation-cbio-20180306monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-program-updates-and-third-quarter-2017-restults-ongoing-discussions--cbio-20171108monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-program-updates-and-second-quarter-2017-restults-xb7-fda-granted-bre-cbio-20170803monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-cbio-20170612monthly0.5https://www.biopharmawatch.com/news/CBIO/unless-the-context-otherwise-requires-we-use-the-terms-glycomimetics-the-company-we-us-and-cbio-20170525monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-program-updates-and-first-quarter-2017-results-xb7-completed-enrollm-cbio-20170508monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-appoints-scott-koenig-of-macrogenics-cbio-20170313monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-fourth-quarter-and-year-end-2016-results-cbio-20170301monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-third-quarter-2016-results-and-progress-in-clinical-development-cbio-20161104monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-second-quarter-2016-results-rockville-md-cbio-20160804monthly0.5https://www.biopharmawatch.com/news/CBIO/unless-the-context-otherwise-requires-we-use-the-terms-x201c-glycomimetics-x201d-the-x201c-cbio-20160617monthly0.5https://www.biopharmawatch.com/news/CBIO/the-treatment-of-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-aml-remains-a-cbio-20160610monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-first-quarter-2016-cbio-20160504monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-appoints-immunogen-ceo-daniel-junius-to-board-of-directors-gaithersburg-md-m-cbio-20160321monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-fourth-quarter-and-year-end-2015-cbio-20160229monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-third-quarter-2015-results-rockville-md-november-12-2015-x2013-glyco-cbio-20151112monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-second-quarter-2015-cbio-20150806monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-first-quarter-2015-cbio-20150505monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-provides-update-on-pfizer-s-plans-to-intitiate-phase-3-trial-with-rivipansel-cbio-20150407monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-fourth-quarter-and-year-end-2014-results-year-end-cash-and-cash-equi-cbio-20150316monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-third-quarter-2014-cbio-20141031monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-announces-a-delay-in-the-initiation-of-the-phase-3-cbio-20140926monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-second-quarter-2014-cbio-20140731monthly0.5https://www.biopharmawatch.com/news/CBIO/source-glycomimetics-contact-brian-hahn-email-bhahn-glycomimetics-com-phone-240-243-1207-g-cbio-20140710monthly0.5https://www.biopharmawatch.com/news/CBIO/glycomimetics-reports-first-quarter-2014-cbio-20140508monthly0.5https://www.biopharmawatch.com/news/CBIO/31-2014-glycomimetics-reports-fourth-quarter-and-year-end-2013-results-gaithersburg-md-bus-cbio-20140404monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements-po-xoma-20260318monthly0.5https://www.biopharmawatch.com/news/XOMA/corporate-presentation-the-royalty-aggregator-nasdaq-common-xoma-for-biotech-nasdaq-perpet-xoma-20260302monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-announces-cfo-transition-xoma-20260112monthly0.5https://www.biopharmawatch.com/news/XOMA/corporate-presentation-the-royalty-aggregator-nasdaq-common-xoma-for-biotech-nasdaq-perpet-xoma-20260112monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-results-and-highlights-xoma-20250813monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-reports-first-quarter-2025-financial-results-and-highlights-business-achievem-xoma-20250513monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlights-bu-xoma-20250317monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-acquires-pulmokine-for-20-million-adding-the-royalty-and-milestone-interest-i-xoma-20241202monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities-xoma-20241107monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-significantly-expands-its-royalty-and-milestone-portfolio-with-the-addition-o-xoma-20241022monthly0.5https://www.biopharmawatch.com/news/XOMA/zevra-s-miplyffa-arimoclomol-receives-approval-from-u-s-food-and-drug-administration-for-u-xoma-20240923monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-reports-second-quarter-2024-financial-results-and-highlights-recent-activitie-xoma-20240813monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-first-quarter-2024-financial-results-and-highlights-recent-activities-earned--xoma-20240509monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-adds-economic-interests-in-three-first-in-category-assets-to-its-royalty-and-mileston-xoma-20240430monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-earns-9-million-milestone-as-fda-grants-accelerated-approval-to-day-one-s-ojemda-tm-t-xoma-20240425monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlights-recent-and-xoma-20240308monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-enters-into-agreement-to-acquire-kinnate-biopharma-for-between-2-3352-and-2-5879-in-c-xoma-20240216monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-announces-stock-repurchase-program-of-up-to-50-million-balanced-capital-allocation-st-xoma-20240102monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-raises-up-to-140-million-in-non-dilutive-non-recourse-financing-from-funds-managed-by-xoma-20231219monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-third-quarter-2023-financial-results-and-highlights-upcoming-events-expected--xoma-20231107monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-second-quarter-2023-financial-results-and-provides-update-on-its-royalty-mone-xoma-20230808monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-first-quarter-2023-financial-results-and-provides-update-on-the-acceleration--xoma-20230509monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-full-year-2022-financial-results-and-provides-update-to-the-acceleration-of-i-xoma-20230309monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-third-quarter-2022-financial-results-and-highlights-recent-operational-events-xoma-20221103monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-second-quarter-2022-financial-results-and-highlights-recent-operational-event-xoma-20220804monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-first-quarter-2022-financial-results-and-highlights-recent-operational-events-xoma-20220505monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-full-year-2021-financial-results-and-highlights-recent-operational-events-ear-xoma-20220308monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-third-quarter-2021-financial-results-and-highlights-recent-operational-events-xoma-20211104monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-second-quarter-2021-financial-results-and-highlights-recent-operational-event-xoma-20210805monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-first-quarter-2021-financial-results-and-highlights-recent-operational-events-xoma-20210506monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-fourth-quarter-and-full-year-2020-financial-results-and-operating-highlights--xoma-20210310monthly0.5https://www.biopharmawatch.com/news/XOMA/disclaimers-certain-statements-in-this-presentation-are-forward-looking-statements-within--xoma-20210105monthly0.5https://www.biopharmawatch.com/news/XOMA/disclaimers-certain-statements-in-this-presentation-are-forward-looking-statements-within--xoma-20201211monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-highlights-recent-royalty-asset-portfolio-developments-and-reports-third-quarter-2020-xoma-20201105monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-earns-25-million-milestone-payment-as-anti-tgf-antibody-enters-phase-2-clinical-study-xoma-20201028monthly0.5https://www.biopharmawatch.com/news/XOMA/corporate-presentation-a-royalty-aggregation-company-august-2020-nasdaq-xoma-1-disclaimers-xoma-20200811monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-second-quarter-2020-financial-results-partners-continue-to-advance-clinical-a-xoma-20200806monthly0.5https://www.biopharmawatch.com/news/XOMA/disclaimers-certain-statements-in-this-presentation-are-forward-looking-statements-within--xoma-20200113monthly0.5https://www.biopharmawatch.com/news/XOMA/form-of-instructions-as-to-use-of-xoma-corporation-subscription-rights-certificates-consul-xoma-20191202monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-announces-proposed-rights-offering-rights-offering-will-be-available-to-all-sharehold-xoma-20191120monthly0.5https://www.biopharmawatch.com/news/XOMA/disclaimers-certain-statements-in-this-presentation-are-forward-looking-statements-within--xoma-20190311monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-fourth-quarter-and-full-year-2018-financial-results-and-operating-highlights--xoma-20190307monthly0.5https://www.biopharmawatch.com/news/XOMA/certain-statements-in-this-presentation-are-forward-looking-statements-within-the-meaning--xoma-20190107monthly0.5https://www.biopharmawatch.com/news/XOMA/form-of-instructions-as-to-use-of-xoma-corporation-subscription-rights-certificates-consul-xoma-20181119monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-announces-proposed-rights-offering-rights-offering-will-be-available-to-all-sharehold-xoma-20181107monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-third-quarter-2018-financial-results-xoma-20181107monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-royalty-interest-position-from-agenus-on-seven-assets-being-developed-by-mer-xoma-20180921monthly0.5https://www.biopharmawatch.com/news/XOMA/corporate-presentation-with-over-35-years-of-discovery-activity-xoma-currently-has-over-th-xoma-20180814monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-first-quarter-2018-financial-results-current-cash-balance-sufficient-to-fund--xoma-20180509monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-business-upd-xoma-20180307monthly0.5https://www.biopharmawatch.com/news/XOMA/forward-looking-statements-certain-statements-in-this-presentation-are-forward-looking-sta-xoma-20180108monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-third-quarter-2017-financial-results-validated-business-strategy-with-transfo-xoma-20171106monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-second-quarter-2017-financial-results-executing-new-corporate-strategy-levera-xoma-20170808monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-first-quarter-2017-financial-results-established-new-corporate-strategy-lever-xoma-20170509monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-fourth-quarter-and-full-year-2016-financial-results-actions-taken-in-2016-set-xoma-20170316monthly0.5https://www.biopharmawatch.com/news/XOMA/cowen-company-37th-annual-health-care-conference-nasdaq-xoma-xoma-20170307monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-announces-up-to-22-million-generated-from-sale-of-royalty-streams-from-two-license-ag-xoma-20161221monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-announces-pricing-of-40-0-million-registered-offering-of-common-stock-and-warrants-xoma-20141209monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-2013-operational-highlights-and-fourth-quarter-and-full-year-2013-financial-r-xoma-20140304monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-announces-perindopril-and-amlodipine-fixed-dose-combination-meets-primary-endpoint-in-xoma-20121120monthly0.5https://www.biopharmawatch.com/news/XOMA/company-and-investor-contact-ashleigh-barreto-510-204-7482-barreto-xoma-com-juliane-snowde-xoma-20121003monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-announces-pricing-of-39-2-million-public-offering-of-common-stock-and-warrants-xoma-20120306monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-u-s-rights-to-perindopril-franchise-and-establishes-commercial-operations-be-xoma-20120117monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-secures-10-million-term-loan-xoma-20120103monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-appoints-john-varian-as-chief-executive-officer-berkeley-ca-xoma-20120105monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-provides-company-update-and-announces-sl-325-a-first-in-class-death-receptor-sttk-20241001monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-updated-positive-interim-data-from-the-phase-1b-dose-expansion-cli-sttk-20240614monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-appointment-of-clay-siegall-ph-d-and-kate-sasser-ph-d-to-its-board-sttk-20240304monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-positive-initial-topline-data-from-ongoing-phase-1-a-b-dose-expans-sttk-20231213monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-changes-to-its-board-of-directors-shattuck-labs-appoints-new-board-sttk-20211028monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2026-financial-results-and-business-highlights-net-cash-pro-prta-20260507monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-up-to-100-million-share-repurchase-plan-prta-20260227monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-financia-prta-20260219monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2025-financial-results-and-business-highlights-net-cash-use-prta-20251106monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-provides-update-on-prx012-and-announces-results-from-the-phase-1-ascent-clinical--prta-20250827monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-that-novo-nordisk-will-advance-coramitug-formerly-prx004-into-phase-3-d-prta-20250806monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2025-financial-results-and-business-highlights-net-cash-us-prta-20250804monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-s-partner-roche-to-advance-prasinezumab-into-phase-iii-development-for-early-stag-prta-20250615monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-phase-3-affirm-al-clinical-trial-for-birtamimab-in-patients-with-al-amy-prta-20250523monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2025-financial-results-and-business-highlights-net-cash-use-prta-20250508monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-financia-prta-20250220monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2024-financial-results-and-business-highlights-net-cash-use-prta-20241112monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2024-financial-results-and-business-highlights-net-cash-pr-prta-20240808monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2024-financial-results-and-business-highlights-net-cash-use-prta-20240508monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-financia-prta-20240215monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-provides-updates-on-prx012-prx123-birtamimab-and-portfolio-programs-updates-on-pr-prta-20240108monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2023-financial-results-and-business-highlights-net-cash-pro-prta-20231102monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2023-financial-results-and-business-highlights-net-cash-us-prta-20230803monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2023-financial-results-and-business-highlights-net-cash-use-prta-20230504monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-financia-prta-20230223monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-achievement-of-40-million-clinical-milestone-payment-from-novo-nordisk--prta-20221121monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2022-financial-results-and-business-highlights-net-cash-use-prta-20221103monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2022-financial-results-and-business-highlights-net-cash-us-prta-20220808monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2022-financial-results-and-business-highlights-net-cash-use-prta-20220505monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-receives-fda-fast-track-designation-for-prx012-a-next-generation-anti-amyloid-bet-prta-20220426monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-fda-clearance-of-ind-for-prx012-a-subcutaneous-anti-amyloid-beta-antibo-prta-20220328monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-financia-prta-20220217monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2021-financial-results-and-business-highlights-net-cash-pro-prta-20211104monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2021-financial-results-and-business-highlights-net-cash-pr-prta-20210805monthly0.5https://www.biopharmawatch.com/news/PRTA/more-information-please-visit-the-company-s-website-at-www-prothena-com-and-follow-the-com-prta-20210712monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2021-financial-results-and-provides-updated-financial-guida-prta-20210511monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-financia-prta-20210211monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2020-financial-results-and-provides-r-d-update-net-cash-use-prta-20201104monthly0.5https://www.biopharmawatch.com/news/PRTA/roche-and-prothena-will-advance-prasinezumab-into-late-stage-clinical-development-study-in-prta-20201020monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2020-financial-results-and-provides-r-d-update-net-cash-us-prta-20200806monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2020-financial-results-and-provides-r-d-update-and-updated--prta-20200506monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-financia-prta-20200212monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2019-financial-results-and-provides-r-d-update-net-cash-use-prta-20191105monthly0.5https://www.biopharmawatch.com/news/PRTA/dear-colleagues-i-m-writing-to-let-you-know-that-wagner-has-decided-to-leave-prothena-for--prta-20190924monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2019-financial-results-and-provides-r-d-update-net-cash-us-prta-20190806monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2019-financial-results-and-provides-r-d-update-net-cash-use-prta-20190507monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-results-from-the-phase-3-vital-amyloidosis-study-of-neod001-birtamimab-in-prta-20190418monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-financia-prta-20190214monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2018-financial-results-and-provides-r-d-update-net-cash-use-prta-20181106monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2018-financial-results-and-provides-r-d-update-net-loss-wa-prta-20180807monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2018-financial-results-and-provides-r-d-update-net-cash-use-prta-20180508monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-discontinues-development-of-neod001-for-al-amyloidosis-phase-2b-pronto-study-did--prta-20180423monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-global-neuroscience-research-development-collaboration-with-celgene-for-prta-20180320monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-financia-prta-20180214monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2017-financial-results-and-provides-r-d-update-net-cash-use-prta-20171107monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-results-from-phase-1b-multiple-ascending-dose-study-of-prx003-in-patients-prta-20170928monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2017-financial-results-and-provides-r-d-update-net-cash-us-prta-20170808monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2017-financial-results-and-provides-r-d-update-net-cash-use-prta-20170509monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2016-financial-results-and-provides-financia-prta-20170214monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-results-from-phase-1b-study-of-prx002-demonstrating-robust-antibody-cns-p-prta-20161109monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2016-financial-results-and-provides-r-d-update-net-cash-use-prta-20161101monthly0.5https://www.biopharmawatch.com/news/PRTA/in-memoriam-friend-scientific-innovator-and-leader-dr-dale-b-schenk-has-passed-away-prta-20160930monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-president-and-ceo-dr-prta-20160926monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2016-financial-results-provides-r-d-update-net-cash-used-i-prta-20160802monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-presents-new-data-from-phase-1-2-study-of-neod001-demonstrating-improvements-in-t-prta-20160705monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2016-financial-results-and-provides-r-d-update-net-cash-use-prta-20160503monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2015-financial-results-provides-financial-gu-prta-20160218monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2015-financial-results-and-provides-r-d-update-net-cash-use-prta-20151102monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-initiate-pronto-a-global-trial-of-neod001-in-patients-with-al-amyloidosis-with-prta-20151015monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2015-financial-results-and-provides-r-d-update-net-cash-us-prta-20150804monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-addition-of-seasoned-executive-to-board-of-directors-prta-20150629monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2015-financial-results-and-provides-r-d-update-net-cash-use-prta-20150505monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2014-financial-results-and-provides-2015-fin-prta-20150305monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-receives-fda-fast-track-designation-for-neod001-a-monoclonal-antibody-for-the-tre-prta-20141215monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-initiates-neod001-global-phase-3-registrational-trial-based-on-positive-results-i-prta-20141202monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2014-financial-results-and-r-d-progress-net-cash-used-in-op-prta-20141103monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2014-financial-results-and-r-d-progress-completion-of-succ-prta-20140804monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-2014-financial-results-and-provides-r-d-updates-encouraging-prta-20140505monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-clinical-data-to-be-presented-at-the-international-symposium-on-amyloid-prta-20140318monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2013-financial-results-and-provides-research-prta-20140306monthly0.5https://www.biopharmawatch.com/news/PRTA/regulation-we-anticipate-that-if-we-commercialize-any-products-the-u-s-market-will-be-our--prta-20140127monthly0.5https://www.biopharmawatch.com/news/PRTA/roche-and-prothena-enter-into-worldwide-collaboration-to-co-develop-and-co-promote-antibod-prta-20131211monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-third-quarter-2013-financial-results-prta-20131112monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2013-prta-20130812monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-prta-20130722monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-financial-results-phase-1-clinical-trial-initiated-in-april-prta-20130514monthly0.5https://www.biopharmawatch.com/news/PRTA/first-patient-dosed-in-phase-i-study-of-prothena-s-therapeutic-antibody-for-treatment-of-a-prta-20130423monthly0.5https://www.biopharmawatch.com/news/PRTA/to-the-company-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commiss-prta-20130328monthly0.5https://www.biopharmawatch.com/news/PRTA/to-our-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-on-prta-20130320monthly0.5https://www.biopharmawatch.com/news/PRTA/information-statement-prothena-corporation-plc-ordinary-shares-par-value-0-01-per-share-th-prta-20121214monthly0.5https://www.biopharmawatch.com/news/AQST/project-academy-corporate-presentation-strictly-confidential-do-not-distribute-disclaimer--aqst-20250815monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-aqst-20250811monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business--aqst-20250513monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-pro-aqst-20250305monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business--aqst-20241105monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-aqst-20240807monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business--aqst-20240508monthly0.5https://www.biopharmawatch.com/news/AQST/therapeutics-announces-proposed-public-offering-of-common-stock-aqst-20240321monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-full-year-2023-financial-results-and-provides-business-upda-aqst-20240306monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business--aqst-20231107monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-completes-45-million-debt-refinancing-warren-n-j-november-x-2023-aq-aqst-20231102monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-aqst-20230808monthly0.5https://www.biopharmawatch.com/news/AQST/advancing-medicines-solving-problems-improving-lives-corporate-presentation-june-2023-1-di-aqst-20230629monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business--aqst-20230503monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-fourth-quarter-full-year-2022-financial-results-and-provide-aqst-20230308monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-business-update-and-outlines-key-2023-objectives-anticipat-aqst-20230124monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business--aqst-20221102monthly0.5https://www.biopharmawatch.com/news/AQST/wainwrightpresenta-advancing-medicines-solving-problems-improving-lives-advancing-medicine-aqst-20220913monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-aqst-20220803monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-announces-8-5-million-registered-direct-offering-warren-n-j-jun-aqst-20220608monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-ceo-transition-daniel-barber-current-chief-operating-offi-aqst-20220517monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business--aqst-20220504monthly0.5https://www.biopharmawatch.com/news/AQST/releasexlincolnpar-aquestive-therapeutics-announces-common-stock-purchase-agreement-for-up-aqst-20220413monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-full-year-2021-results-exceeding-revenue-and-ebitda-guidanc-aqst-20220308monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-presented-positive-topline-phase-1-results-for-aqst-109-epinephrine-aqst-20220301monthly0.5https://www.biopharmawatch.com/news/AQST/aqst109epiphastpre-source-aquestive-therapeutics-inc-aqst-20211213monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-third-quarter-2021-financial-results-provides-business-upda-aqst-20211102monthly0.5https://www.biopharmawatch.com/news/AQST/document-aquestive-therapeutics-reports-positive-topline-data-from-phase-1-pharmacokinetic-aqst-20211025monthly0.5https://www.biopharmawatch.com/news/AQST/document-aquestive-therapeutics-reaches-agreement-to-extend-principal-payments-due-under-c-aqst-20211006monthly0.5https://www.biopharmawatch.com/news/AQST/document-aquestive-therapeutics-negotiates-six-month-extension-to-aqst-20210809monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2021-financial-results-provides-business-upd-aqst-20210803monthly0.5https://www.biopharmawatch.com/news/AQST/document-aquestive-therapeutics-announces-fda-acceptance-of-new-drug-application-nda-resub-aqst-20210721monthly0.5https://www.biopharmawatch.com/news/AQST/document-aquestive-therapeutics-resubmits-new-drug-application-for-libervant-diazepam-bucc-aqst-20210624monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business--aqst-20210505monthly0.5https://www.biopharmawatch.com/news/AQST/anaphylaxis-and-epinephriner-d-day-aqst-20210325monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-pro-aqst-20210309monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reaffirms-near-term-nda-resubmission-for-libervant-diazepam-buccal--aqst-20210225monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-strengthens-board-of-directors-with-appointments-of-julie-krop-m-d--aqst-20210209monthly0.5https://www.biopharmawatch.com/news/AQST/mitsubishi-tanabe-pharma-america-and-aquestive-therapeutics-announce-u-s-licensing-and-sup-aqst-20210121monthly0.5https://www.biopharmawatch.com/news/AQST/january-2021-aquestive-therapeuticscorporate-presentation-forward-looking-statement-2-this-aqst-20210108monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-business-update-resubmitted-revised-dosing-regimen-for-lib-aqst-20210107monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-departure-of-chief-financial-officer-and-appointment-of-i-aqst-20201216monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-first-milestone-payment-from-kynmobi-monetization-receives-aqst-20201123monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-completes-fda-type-a-meeting-on-libervant-fda-confirms-issues-ident-aqst-20201118monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business--aqst-20201104monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-complete-response-letter-from-fda-for-libervant-diazepam-b-aqst-20200925monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-fda-fast-track-designation-for-aqst-108-sublingual-film-fo-aqst-20200810monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2020-financial-results-and-provides-business-aqst-20200805monthly0.5https://www.biopharmawatch.com/news/AQST/the-fly-interview-q-a-keith-kendall-president-and-ceo-of-aquestive-therapeutics-1-last-mon-aqst-20200702monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-files-ind-for-pharmacokinetic-clinical-trials-of-aqst-108-sublingua-aqst-20200629monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-advances-royalty-monetization-plan-as-sunovion-pharmaceuticals-apom-aqst-20200521monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2020-financial-results-and-provides-business--aqst-20200506monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-rec-aqst-20200311monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-u-s-food-and-drug-administration-filing-acceptance-of-new-aqst-20200210monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-fda-confirmed-505-b-2-pathway-for-aqst-108-sublingual-fil-aqst-20200206monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-fda-response-to-citizen-s-petition-warren-nj-aqst-20200112monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-exceeds-top-end-of-guidance-range-for-preliminary-unaudited-full-ye-aqst-20191231monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-proposed-public-offering-of-common-stock-warren-nj-aqst-20191210monthly0.5https://www.biopharmawatch.com/news/AQST/investor-and-analyst-update-on-libervant-aqst-20191209monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-completes-rolling-submission-of-new-drug-application-nda-to-u-s-foo-aqst-20191202monthly0.5https://www.biopharmawatch.com/news/AQST/unreliable-absorption-with-rectal-administration-of-diazepam-gary-slatko-1-stephen-wargack-aqst-20191126monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film-warren-n-j-aqst-20191125monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-licenses-riluzole-oral-film-to-zambon-for-development-and-commercia-aqst-20191113monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-third-quarter-2019-financial-results-and-raises-2019-guidan-aqst-20191106monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reaffirms-full-year-2019-revenue-guidance-and-will-announce-third-q-aqst-20191016monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-successful-completion-of-phase-1-trial-for-aqst-108-subli-aqst-20190930monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2019-financial-results-and-recent-business-h-aqst-20190807monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-completes-70-million-debt-refinancing-warren-nj-aqst-20190715monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2019-financial-results-and-recent-business-hi-aqst-20190508monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-reports-fourth-quarter-and-full-year-2018-financial-results-and-aqst-20190314monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-end-of-year-business-update-including-progress-of-its-prop-aqst-20181220monthly0.5https://www.biopharmawatch.com/news/AQST/business-updatedecember-2018-2-forward-looking-statements-certain-statements-in-this-prese-aqst-20181212monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-third-quarter-2018-financial-results-and-recent-business-hi-aqst-20181106monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-completion-of-the-diazepam-buccal-film-adult-epilepsy-mon-aqst-20181024monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2018-financial-results-and-recent-business-h-aqst-20180904monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-closing-of-exercise-of-underwriters-over-allotment-option-aqst-20180815monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-names-sandy-costa-as-chairman-of-the-board-of-directors-warren-nj-aqst-20180813monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-closing-of-initial-public-offering-aqst-20180727monthly0.5https://www.biopharmawatch.com/news/UPB/this-presentation-contains-forward-looking-statements-within-the-meaning-of-section-27a-of-upb-20260211monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-reports-first-quarter-2025-financial-results-and-accelerates-guidance-on-all--upb-20250506monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-busine-upb-20250312monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-reports-third-quarter-2024-financial-results-and-recent-business-highlights-x-upb-20241107monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-first-quarter-2026-financial-results-first-quarter-revenue-grew-16-year-o-cyrx-20260504monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-fourth-quarter-and-full-year-2025-financial-results-fy-2025-revenue-incre-cyrx-20260303monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-third-quarter-2025-financial-results-third-quarter-revenue-increased-15-y-cyrx-20251104monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-second-quarter-2025-financial-results-second-quarter-revenue-increased-14-cyrx-20250805monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-completes-cryopdp-divestiture-and-commences-strategic-partnership-with-dhl-group-cyrx-20250612monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-first-quarter-2025-financial-results-commercial-cell-gene-therapy-revenue-cyrx-20250507monthly0.5https://www.biopharmawatch.com/news/CYRX/dhl-group-acquires-cryopdp-from-cryoport-to-strengthen-dhl-health-logistics-dhl-to-acquire-cyrx-20250331monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-fourth-quarter-and-full-year-2024-financial-results-fy-2024-revenue-of-22-cyrx-20250304monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-third-quarter-2024-financial-results-q3-2024-life-sciences-services-reven-cyrx-20241107monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-second-quarter-2024-financial-results-revenue-improved-sequentially-acros-cyrx-20240806monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-200-million-repurchase-program-and-the-repurchase-of-160-million-of-con-cyrx-20240806monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-first-quarter-2024-financial-results-q1-2024-revenue-of-54-6-million-9-ye-cyrx-20240507monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-fourth-quarter-and-full-year-2023-financial-results-fy-2023-revenue-of-23-cyrx-20240312monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-third-quarter-2023-financial-results-third-quarter-2023-commercial-cell-a-cyrx-20231108monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-second-quarter-2023-financial-results-second-quarter-revenue-of-57-millio-cyrx-20230809monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-certain-preliminary-results-for-second-quarter-updates-2023-revenue-exp-cyrx-20230712monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-first-quarter-2023-results-record-revenue-of-63-million-representing-20-g-cyrx-20230504monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-fourth-quarter-and-full-year-2022-results-2022-revenue-reached-a-record-2-cyrx-20230223monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-results-for-the-third-quarter-2022-third-quarter-revenue-of-60-5-million--cyrx-20221103monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-results-for-the-second-quarter-2022-record-revenue-of-64-2-million-for-th-cyrx-20220804monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-first-quarter-2022-results-revenue-of-52-3-million-provides-full-year-202-cyrx-20220505monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-authorizes-100-million-repurchase-program-management-presenting-at-upcoming-inves-cyrx-20220311monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-fourth-quarter-and-full-year-2021-results-2021-annual-revenue-grew-to-222-cyrx-20220224monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-provides-positive-update-on-mve-biological-solution-s-new-prague-facility-product-cyrx-20220209monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-fire-damage-at-mve-s-new-prague-facility-cyrx-20220131monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-inc-prices-upsized-350-0-million-convertible-senior-notes-offering-nashville-tenn-cyrx-20211109monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-inc-announces-proposed-convertible-senior-notes-offering-nashville-tennessee-pr-n-cyrx-20211108monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-record-third-quarter-and-nine-months-revenue-for-2021-third-quarter-reven-cyrx-20211104monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-record-second-quarter-2021-revenue-record-revenue-for-second-quarter-of-2-cyrx-20210805monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-revenue-climbs-to-53-3-million-for-first-quarter-2021-revenue-increased-445-compa-cyrx-20210504monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-appointment-of-linda-baddour-to-its-board-of-directors-ms-baddour-bring-cyrx-20210303monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-record-results-for-full-year-2020-fourth-quarter-revenue-increased-423-to-cyrx-20210301monthly0.5https://www.biopharmawatch.com/news/CYRX/blackstone-converts-51-million-of-cryoport-series-c-preferred-stock-into-common-stock-cyrx-20210208monthly0.5https://www.biopharmawatch.com/news/CYRX/you-should-be-aware-that-these-statements-are-projections-or-estimates-as-to-future-events-cyrx-20210120monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-inc-all-rights-reserved-cyrx-nasdaq-2021-cryoport-inc-all-rights-reserved-forward-cyrx-20201231monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-2020-third-quarter-results-acquired-mve-biological-solutions-and-cryopdp--cyrx-20201105monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-completes-acquisitions-of-mve-biological-solutions-and-cryopdp-cryoport-fortifies-cyrx-20201001monthly0.5https://www.biopharmawatch.com/news/CYRX/science-cyrx-20200825monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-expands-global-supply-chain-platform-by-signing-agreement-to-acquire-cryopdp-acqu-cyrx-20200821monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-2020-second-quarter-results-revenue-from-commercial-therapies-increased-3-cyrx-20200806monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-inc-announces-proposed-convertible-senior-notes-offering-nashville-tennessee-prne-cyrx-20200519monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-revenue-grows-47-for-first-quarter-2020-revenue-from-commercial-therapies-increas-cyrx-20200507monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-record-revenue-for-fiscal-year-2019-revenue-grows-73-year-over-year-reven-cyrx-20200305monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-preliminary-fourth-quarter-and-full-year-2019-revenue-2019-revenue-grow-cyrx-20191231monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-revenue-grows-81-for-third-quarter-2019-cryoport-now-supports-425-clinical-trials-cyrx-20191107monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-authorizes-share-repurchase-program-and-presenting-at-upcoming-investor-conferenc-cyrx-20191009monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-revenue-grows-83-for-second-quarter-2019-cryoport-now-supports-413-clinical-trial-cyrx-20190808monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-proposed-public-offering-of-common-stock-cyrx-20190619monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-expands-into-biostorage-through-the-acquisition-of-cryogene-acquisition-is-expect-cyrx-20190514monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-revenue-grows-65-for-first-quarter-2019-commercial-revenue-rises-to-25-of-total-b-cyrx-20190502monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-64-growth-for-fiscal-year-2018-cryoport-now-supports-357-clinical-trials--cyrx-20190307monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-appoints-daniel-m-hancock-to-board-of-directors-cyrx-20190107monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-25-million-investment-from-petrichor-healthcare-capital-management-cyrx-20181217monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-56-revenue-growth-for-fiscal-year-ended-cyrx-20180306monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-revenue-up-52-for-the-second-quarter-of-2017-driven-by-biopharma-biopharma-revenu-cyrx-20170808monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-proposed-public-offering-of-common-stock-cyrx-20170327monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-completes-warrant-tender-offer-irvine-ca-cyrx-20161103monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-continues-to-climb-reporting-34-revenue-growth-for-the-first-quarter-of-fiscal-ye-cyrx-20160815monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-50-revenue-growth-for-fiscal-year-2016-company-is-now-supporting-first-co-cyrx-20160627monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-successfully-completes-its-rights-offering-irvine-ca-cyrx-20160621monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-50-revenue-growth-for-the-third-quarter-of-fiscal-year-2016-company-adds--cyrx-20160208monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-revenues-climb-74-for-the-second-quarter-of-fiscal-year-2016-company-adds-over-16-cyrx-20151116monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-appoints-robert-hariri-md-phd-to-its-board-of-directors-conference-call-scheduled-cyrx-20151001monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-record-revenues-for-fourth-quarter-and-fiscal-year-2015-strong-performanc-cyrx-20150519monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-record-results-grows-revenue-by-50-for-the-first-nine-months-of-fiscal-20-cyrx-20150205monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-appoints-richard-j-berman-to-its-board-of-directors-lake-forest-ca-cyrx-20150112monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-increases-revenue-by-65-for-the-first-six-months-of-fiscal-2015-revenue-growth-dr-cyrx-20141112monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-92-revenue-growth-for-first-quarter-of-fiscal-2015-expanded-customer-base-cyrx-20140731monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-appointment-of-ramkumar-mandalam-ph-d-to-board-of-directors-mandalam-to-cyrx-20140616monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-reports-fourth-consecutive-quarter-of-triple-digit-year-over-year-revenue-growth--cyrx-20140519monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-elects-edward-zecchini-to-board-of-directors-lake-forest-calif-september-16-2013--cyrx-20130917monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-doubles-revenues-for-fiscal-2013-sales-growth-continues-to-ramp-in-fiscal-2014-cyrx-20130606monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-appoints-richard-rathmann-to-board-of-directors-cyrx-20130401monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-appoints-jerrell-shelton-as-president-and-chief-executive-officer-cyrx-20121105monthly0.5https://www.biopharmawatch.com/news/CYRX/jerrell-shelton-to-join-cryoport-s-board-of-directors-cyrx-20121022monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-cyrx-20120920monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-cyrx-20120329monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-closes-private-placement-with-purchase-agreements-for-5-0-cyrx-20120217monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-names-robert-stefanovich-as-chief-financial-officer-sales-team-bolstered-with-eas-cyrx-20110628monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-names-karen-m-muller-to-board-of-directors-cyrx-20110531monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-closes-first-round-of-private-placement-with-purchase-agreements-for-4-4-cyrx-20110207monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-cyrx-20100908monthly0.5https://www.biopharmawatch.com/news/CYRX/cryoport-announces-the-addition-of-john-h-bonde-to-its-board-of-directors-lake-forest-ca-cyrx-20100112monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-private-financing-term-loan-and-private-placement-of-conver-kids-20240805monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-acquisition-of-boston-orthotics-prosthetics-combined-organi-kids-20240108monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-proposed-offering-of-common-stock-and-pre-funded-warrants-kids-20220810monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-deal-to-acquire-pega-medical-expands-portfolio-of-trauma-an-kids-20220614monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-acquisition-of-md-orthopaedics-expands-portfolio-with-a-pat-kids-20220404monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-proposed-public-offering-of-common-stock-kids-20200617monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-kids-20200401monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-divestiture-of-the-vilex-adult-business-kids-20200106monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-proposed-public-offering-of-common-stock-kids-20191210monthly0.5https://www.biopharmawatch.com/news/KIDS/a123117123118v-vilex-in-tennessee-inc-and-affiliate-combined-financial-statements-years-en-kids-20190820monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-june-2019-mark-throdahl-ceo-fred-hite-cfo-disclaimer-forward-looking--kids-20190605monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-announces-acquisition-of-vilex-and-novel-external-fixation-technology-the--kids-20190605monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-pricing-of-offering-of-common-stock-kids-20181207monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-closing-of-59-8-million-initial-public-offering-warsaw-in-kids-20171016monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-first-quarter-2026-financial-results-and-provides-business-u-achv-20260512monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-up-to-354-million-private-placement-180-million-financing--achv-20260416monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-second-quarter-2025-financial-results-provides-updates-on-cy-achv-20250807monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-proposed-underwritten-public-offering-seattle-wash-and-van-achv-20250626monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-first-quarter-2025-financial-results-and-highlights-updates--achv-20250513monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-fourth-quarter-and-year-end-2024-and-p-achv-20250311monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-positive-outcome-of-second-data-safety-monitoring-committe-achv-20250210monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides-corpor-achv-20241107monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-second-quarter-2024-and-provides-corpo-achv-20240813monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-first-quarter-2024-and-provides-corpor-achv-20240509monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-fourth-quarter-and-year-end-2023-and-p-achv-20240328monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-pricing-of-up-to-124-2-million-registered-direct-offering--achv-20240229monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-third-quarter-and-provides-corporate-u-achv-20231109monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-second-quarter-2023-and-provides-corpo-achv-20230815monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-pricing-of-16-5-million-registered-direct-offering-seattle-achv-20230525monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-statistically-significant-smoking-cessation-benefit-for-cyti-achv-20230523monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-first-quarter-2023-and-provides-corpor-achv-20230509monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-refresh-to-board-of-directors-seattle-wash-and-vancouver-b-achv-20230330monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-fourth-quarter-and-year-end-2022-and-p-achv-20230316monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-private-placement-of-18-9-million-seattle-wash-and-vancouv-achv-20221115monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-third-quarter-2022-and-provides-corporate-update-com-achv-20221114monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-second-quarter-2022-and-provides-corporate-update-co-achv-20220811monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-first-quarter-2022-and-provides-corporate-update-com-achv-20220512monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-successful-statistically-significant-smoking-cessation-res-achv-20220427monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-reports-financial-results-for-fourth-quarter-and-year-end-2021-and-p-achv-20220310monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-third-quarter-2021-and-provides-update-on-cytisinicl-achv-20211109monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-second-quarter-2021-and-provides-corporate-update-se-achv-20210812monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-proposed-underwritten-public-offering-seattle-wash-and-van-achv-20210524monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-first-quarter-2021-and-provides-corporate-update-sea-achv-20210513monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-appointment-of-dr-bridget-martell-and-dr-cindy-jacobs-to-b-achv-20210315monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-fourth-quarter-and-year-end-2020-and-provides-corpor-achv-20210311monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-third-quarter-2020-and-provides-corporate-and-cytisi-achv-20201112monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-second-quarter-2020-and-provides-update-on-cytisinic-achv-20200806monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-pricing-of-6-million-registered-direct-offering-seattle-wa-achv-20200629monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-first-quarter-2020-and-provides-update-on-cytisinicl-achv-20200514monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-private-placement-of-1-9-million-seattle-wash-and-vancouve-achv-20200430monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-fourth-quarter-and-year-end-2019-and-provides-update-achv-20200313monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-pricing-of-12-million-underwritten-public-offering-seattle-achv-20191217monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-third-quarter-2019-and-provides-update-on-cytisinicl-achv-20191106monthly0.5https://www.biopharmawatch.com/news/ACHV/background-cytisine-is-a-naturally-occurring-substance-extracted-from-cytisus-laburnum-gol-achv-20190913monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-second-quarter-2019-and-provides-cytisinicline-clini-achv-20190808monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-statistically-significant-improvement-in-quit-rates-for-si-achv-20190611monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-first-quarter-2019-and-provides-cytisinicline-clinic-achv-20190515monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-year-end-2018-and-provides-cytisinicline-clinical-de-achv-20190314monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-third-quarter-2018-and-provides-cytisinicline-cytisi-achv-20181107monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-announces-pricing-of-5-6-million-registered-direct-offering-seattle-wash-and-vanco-achv-20181001monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-announces-results-of-clinical-study-demonstrating-similar-bioavailability-for-a-ne-achv-20180927monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-second-quarter-2018-and-provides-cytisine-clinical-d-achv-20180808monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-pricing-of-12-million-underwritten-public-offering-seattle-achv-20180615monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-inc-announces-reverse-stock-split-seattle-wash-and-vancouver-british-achv-20180523monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-reports-financial-results-for-first-quarter-2018-seattle-wash-and-vancouver-britis-achv-20180509monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-announces-recent-highlights-and-reports-year-end-2017-financial-results-bothell-wa-achv-20180301monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-announces-preliminary-data-from-cytisine-phase-i-ii-multi-dose-pharmacokinetic-and-achv-20180220monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-announces-expansion-of-partnership-with-the-university-of-bristol-for-next-generat-achv-20180124monthly0.5https://www.biopharmawatch.com/news/ACHV/consolidated-statements-of-loss-in-thousands-except-per-share-and-share-data-unaudited-thr-achv-20171109monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-announces-share-purchase-agreement-with-lincoln-park-capital-fund-llc-bothell-wash-achv-20170914monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-announces-fda-acceptance-of-the-investigational-new-drug-application-ind-for-cytis-achv-20170810monthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-and-oncogenex-pharmaceuticals-announce-form-s-4-registration-stateme-achv-20170613monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-first-quarter-2017-bothell-wa--achv-20170515monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-year-end-2016-bothell-wa-and-v-achv-20170223monthly0.5https://www.biopharmawatch.com/news/ACHV/this-presentation-contains-forward-looking-statements-including-but-not-limited-to-stateme-achv-20170106monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-and-achieve-life-science-inc-announce-definitive-merger-agre-achv-20170105monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-third-quarter-2016-bothell-wa--achv-20161110monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-positive-survival-results-from-apatorsen-phase-2-borealis-2-trial-in-m-achv-20161025monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-results-from-the-phase-3-enspirit-trial-of-custirsen-in-non-small-cell-achv-20161013monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-results-from-the-phase-3-affinity-trial-of-custirsen-in-men-with-metas-achv-20160816monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-second-quarter-2016-pivotal-ph-achv-20160804monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-first-quarter-2016-anticipated-achv-20160512monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-year-end-2015-conference-call--achv-20160309monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-reduction-in-force-to-extend-cash-runway-and-align-operations-with-cli-achv-20160204monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-update-on-phase-2-spruce-trial-in-previously-untreated-metastatic-non--achv-20160120monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-phase-3-affinity-trial-with-custirsen-continues-following-interim-anal-achv-20151201monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-third-quarter-2015-conference--achv-20151112monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-phase-2-rainier-results-in-previously-untreated-metastatic-pancreatic--achv-20150923monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-second-quarter-2015-conference-achv-20150813monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-custirsen-phase-3-enspirit-trial-continues-following-completion-of-fin-achv-20150713monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-first-quarter-2015-conference--achv-20150514monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-share-purchase-agreement-with-lincoln-park-capital-fund-llc-funds-to-h-achv-20150430monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-regains-rights-to-custirsen-from-teva-bothell-wash-and-vancouver-british-columbi-achv-20150427monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-fourth-quarter-and-year-end-20-achv-20150326monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-to-regain-rights-to-custirsen-from-teva-bothell-wa-and-vancouver-bc-achv-20141230monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-results-from-the-phase-2-borealis-1-trial-of-apatorsen-in-the-treatmen-achv-20141219monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-third-quarter-2014-conference--achv-20141030monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-second-quarter-2014-conference-achv-20140807monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-announces-pricing-of-24-million-underwritten-registered-direct-o-achv-20140626monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-first-quarter-2014-conference--achv-20140430monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-top-line-survival-results-of-phase-3-synergy-trial-evaluating-custirse-achv-20140428monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-fourth-quarter-and-year-end-20-achv-20140311monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-third-quarter-2013-and-address-achv-20131107monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-provides-clinical-development-program-overview-and-reports-f-achv-20130808monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-provides-clinical-development-program-overview-and-reports-f-achv-20130502monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-provides-update-on-clinical-development-program-and-reports--achv-20130307monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-provides-clinical-development-update-and-reports-financial-r-achv-20121108monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-second-quarter-and-first-half-2012-financial-results-achv-20120802monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-and-reviews-clinical-development-h-achv-20120503monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-announces-full-exercise-of-overallotment-option-by-underwrit-achv-20120323monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-prices-50-million-public-offering-bothell-washington-and-van-achv-20120316monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-bothell-w-achv-20120315monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-fourth-quarter-and-year-end-20-achv-20120308monthly0.5https://www.biopharmawatch.com/news/ACHV/clinical-data-on-ogx-427-presented-at-the-asco-2012-genitourinary-cancers-symposium-provid-achv-20120202monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-reports-financial-results-for-third-quarter-2011-and-highlights--achv-20111103monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-second-quarter-2011-and-provid-achv-20110804monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-first-quarter-2011-and-provide-achv-20110509monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-reports-financial-results-for-fourth-quarter-and-year-end-20-achv-20110310monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-names-michelle-burris-executive-vice-president-operations-and-ch-achv-20101108monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-reports-third-quarter-financial-results-conference-call-on-thursday-achv-20101104monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-closes-50-million-public-offering-bothell-wa-and-vancouver-achv-20101022monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-prices-50-million-public-offering-bothell-wa-and-vancouver-achv-20101019monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-inc-announces-proposed-public-offering-bothell-wa-and-vancouver-achv-20101018monthly0.5https://www.biopharmawatch.com/news/ACHV/journal-of-clinical-oncology-publishes-data-from-randomized-phase-2-custirsen-trial-random-achv-20101015monthly0.5https://www.biopharmawatch.com/news/ACHV/teva-and-oncogenex-announce-initiation-of-second-phase-3-trial-of-custirsen-in-men-with-me-achv-20100930monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-announces-initiation-of-a-phase-2-trial-evaluating-ogx-427-treat-achv-20100927monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-adds-david-v-smith-to-the-board-of-directors-bothell-wa-and-vancouver-bc-achv-20100810monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-reports-second-quarter-financial-results-conference-call-on-thursday-achv-20100805monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-announces-initiation-of-a-phase-3-trial-in-men-with-metastatic-p-achv-20100621monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-announces-final-results-from-phase-1-trial-evaluating-ogx-427-as-achv-20100607monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-reports-first-quarter-financial-results-conference-call-on-thursday-achv-20100506monthly0.5https://www.biopharmawatch.com/news/ACHV/data-from-oncogenex-pharmaceuticals-product-candidate-ogx-427-to-be-presented-at-the-ameri-achv-20100325monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-adds-biopharmaceutical-industry-veterans-to-the-board-of-directors-bothell-wa-an-achv-20100324monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-reports-financial-results-for-fourth-quarter-and-fiscal-year-2009-and-provides-o-achv-20100308monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-departure-of-chief-financial-officer-bothell-wa-and-vancouver-bc-achv-20100225monthly0.5https://www.biopharmawatch.com/news/ACHV/the-european-medicines-agency-is-in-overall-agreement-with-oncogenex-pharmaceuticals-devel-achv-20100225monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-announces-that-a-randomized-investigator-sponsored-phase-2-study-evaluating-ogx--achv-20100106monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-reports-third-quarter-2009-financial-results-conference-call-on-thursday-achv-20091105monthly0.5https://www.biopharmawatch.com/news/ACHV/fda-grants-additional-fast-track-designation-for-ogx-011-in-combination-with-first-line-ch-achv-20091006monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-expands-clinical-development-of-ogx-427-with-a-phase-1-clinical-trial-in-bladder-achv-20090813monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-reports-second-quarter-2009-financial-results-conference-call-on-thursday-achv-20090806monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-completes-9-5-million-registered-direct-offering-achv-20090724monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-to-raise-9-5-million-through-sale-of-common-stock-bothell-wa-and-achv-20090720monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-files-shelf-registration-statement-bothell-wa-and-vancouver-achv-20090626monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-completes-amendment-to-phase-3-special-protocol-assessment-for-c-achv-20090624monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-announces-ogx-011-treatment-provides-survival-benefit-in-randomi-achv-20090530monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-pharmaceuticals-announces-release-of-two-asco-abstracts-impact-of-ogx-011-on-sur-achv-20090514monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-reports-first-quarter-financial-results-conference-call-on-thursday-achv-20090507monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-receives-confirmation-from-fda-on-the-design-of-a-second-phase-3-trial-evaluatin-achv-20090428monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-reports-financial-results-for-fourth-quarter-and-fiscal-year-2008-and-provides-o-achv-20090311monthly0.5https://www.biopharmawatch.com/news/ACHV/oncogenex-provides-update-on-two-year-survival-data-from-ongoing-phase-1-2-clinical-trial--achv-20090123monthly0.5https://www.biopharmawatch.com/news/AUTL/autoluannualreporta-registered-number-11185179-england-wales-annual-report-and-financial-s-autl-20260609monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr140526-autolus-therapeutics-reports-first-quarter-2026-financial-results-and-b-autl-20260514monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-announces-initiative-to-support-operational-efficiency-and-cost-reduc-autl-20260429monthly0.5https://www.biopharmawatch.com/news/AUTL/allinvestoreventap-spotlight-on-the-acute-lymphoblastic-leukemia-all-business-autl-20260408monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr270326-autolus-therapeutics-reports-fourth-quarter-and-full-year-2025-financia-autl-20260327monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr120126-autolus-therapeutics-announces-preliminary-unaudited-fourth-quarter-and-autl-20260112monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr011225-1-autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors-l-autl-20251201monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr121125-autolus-therapeutics-reports-third-quarter-2025-financial-results-and-b-autl-20251112monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr120825-autolus-therapeutics-reports-second-quarter-2025-financial-results-and--autl-20250812monthly0.5https://www.biopharmawatch.com/news/AUTL/autolusannualreport-statement-of-liabilities-parent-company-autl-20250602monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr080525-autolus-therapeutics-reports-first-quarter-2025-financial-results-and-b-autl-20250508monthly0.5https://www.biopharmawatch.com/news/AUTL/patient-enrollment-delays-or-otherwise-autolus-ability-to-successfully-demonstrate-the-saf-autl-20250320monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991cp130125-developing-next-generation-programmed-t-cell-therapies-january-2025-aut-autl-20250113monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr121124-autolus-therapeutics-reports-third-quarter-2024-financial-results-and-b-autl-20241112monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr081124-1-autolus-therapeutics-announces-fda-approval-of-aucatzyl-obecabtagene--autl-20241108monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991cp260924-developing-next-generation-programmed-t-cell-therapies-september-2024-a-autl-20240926monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr190924-1-autolus-therapeutics-announces-appointment-of-matthias-will-m-d-as-ch-autl-20240919monthly0.5https://www.biopharmawatch.com/news/AUTL/autlex-991pr080824-autolus-therapeutics-reports-second-quarter-2024-financial-results-and--autl-20240808monthly0.5https://www.biopharmawatch.com/news/AUTL/registered-number-11185179-england-wales-annual-report-and-financial-statements-for-the-ye-autl-20240605monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-announces-delay-to-its-first-quarter-2024-earnings-release-and-confer-autl-20240513monthly0.5https://www.biopharmawatch.com/news/AUTL/ectranscript150324-event-id-138235356103-event-name-q4-2023-autolus-therapeutics-plc-earni-autl-20240315monthly0.5https://www.biopharmawatch.com/news/AUTL/disclaimer-developing-next-generation-programmed-t-cell-therapies-these-slides-contain-for-autl-20240213monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-announces-pricing-of-underwritten-offering-london-8-february-2024-autolus-therapeu-autl-20240208monthly0.5https://www.biopharmawatch.com/news/AUTL/biontech-and-autolus-announce-strategic-car-t-cell-therapy-collaboration-to-advance-pipeli-autl-20240208monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-14-autl-20231102monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-15-autl-20230803monthly0.5https://www.biopharmawatch.com/news/AUTL/annualreportandacco-autl-20230707monthly0.5https://www.biopharmawatch.com/news/AUTL/annualreportandacco-autl-20230606monthly0.5https://www.biopharmawatch.com/news/AUTL/pressreleasedatedj-autolus-therapeutics-presents-positive-results-from-pivotal-phase-2-fel-autl-20230602monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-12-autl-20230504monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-announces-partial-exercise-of-underwriters-option-to-purchase-additional-adss-lond-autl-20221213monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-announces-pricing-of-public-offering-london-8-december-2022-autolus-therapeutics-p-autl-20221213monthly0.5https://www.biopharmawatch.com/news/AUTL/taxation-the-following-summary-contains-a-description-of-material-u-k-and-u-s-federal-inco-autl-20221208monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-13-autl-20221121monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-13-autl-20221103monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-13-autl-20220804monthly0.5https://www.biopharmawatch.com/news/AUTL/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-autl-20220601monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-10-autl-20220505monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-announces-retirement-of-chief-financial-officer-and-succession-plan-a-autl-20220110monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-announces-the-appointment-of-dr-william-d-young-as-a-non-executive-di-autl-20211115monthly0.5https://www.biopharmawatch.com/news/AUTL/securities-purchase-agreement-this-s-ecurities-p-urchase-a-greement-this-agreement-is-made-autl-20211106monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-18-autl-20211103monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-announces-the-appointment-of-john-h-johnson-as-non-executive-chairman-autl-20210915monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-17-autl-20210805monthly0.5https://www.biopharmawatch.com/news/AUTL/annual-report-and-accounts-autl-20210630monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-14-autl-20210506monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-announces-appointment-of-martin-murphy-as-non-executive-chairman-lond-autl-20210419monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-announces-proposed-public-offering-in-the-united-states-london-8-february-2021-aut-autl-20210211monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-presents-compelling-auto1-data-from-allcar-phase-1-study-in-adult-acu-autl-20201207monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-16-autl-20201105monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-presents-additional-data-on-auto3-in-dlbcl-during-the-esmo-virtual-co-autl-20200918monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-announces-changes-to-its-board-and-management-team-autl-20200827monthly0.5https://www.biopharmawatch.com/news/AUTL/of-this-report-on-form-6-k-15-autl-20200806monthly0.5https://www.biopharmawatch.com/news/AUTL/index-to-condensed-consolidated-financial-statements-condensed-consolidated-balance-sheets-autl-20200507monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-presents-encouraging-additional-data-showcasing-clinical-progress-of--autl-20200130monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-announces-proposed-public-offering-in-the-united-states-london-22-january-2020-aut-autl-20200124monthly0.5https://www.biopharmawatch.com/news/AUTL/index-to-condensed-consolidated-financial-statements-condensed-consolidated-balance-sheets-autl-20191107monthly0.5https://www.biopharmawatch.com/news/AUTL/index-to-condensed-consolidated-financial-statements-condensed-consolidated-balance-sheets-autl-20190808monthly0.5https://www.biopharmawatch.com/news/AUTL/index-to-condensed-consolidated-financial-statements-condensed-consolidated-balance-sheets-autl-20190514monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-announces-pricing-of-public-offering-london-10-april-2019-autolus-therapeutics-plc-autl-20190411monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-announces-proposed-public-offering-in-the-united-states-london-uk-autl-20190408monthly0.5https://www.biopharmawatch.com/news/AUTL/initial-results-from-autolus-therapeutics-allcar19-phase-1-2-trial-in-adult-acute-lymphobl-autl-20190402monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-unveils-expanded-next-generation-technology-and-pipeline-and-provides-autl-20190326monthly0.5https://www.biopharmawatch.com/news/AUTL/annual-report-and-accounts-autl-20190315monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-reports-financial-and-operational-results-for-the-transition-period-f-autl-20190225monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-presents-initial-auto3-clinical-data-from-phase-1-2-clinical-trials-i-autl-20181202monthly0.5https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-plc-formerly-autolus-therapeutics-limited-balance-sheet-unaudited-exp-autl-20180926monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-announces-name-change-to-faeth-therapeutics-focused-on-advancing-pi-fth-20260615monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-inc-unaudited-pro-forma-condensed-financial-information-on-fth-20260521monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-fth-20260515monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-upd-fth-20260330monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-announces-acquisition-of-faeth-therapeutics-and-200-million-concurr-fth-20260218monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-third-quarter-2025-financial-results-boston-ma-fth-20251114monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-announces-initiation-of-strategic-review-to-maximize-shareholder-va-fth-20251030monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-new-clinical-results-highlighting-durable-progression-free--fth-20251017monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-second-quarter-2025-financial-results-and-provides-corporat-fth-20250805monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-first-quarter-2025-financial-results-and-updates-on-clinica-fth-20250506monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-full-year-2024-financial-results-and-update-on-clinical-pro-fth-20250328monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-favorable-preliminary-dose-expansion-data-for-solnerstotug--fth-20250327monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-hi-fth-20241114monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-second-quarter-2024-financial-results-and-recent-business-h-fth-20240806monthly0.5https://www.biopharmawatch.com/news/FTH/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-fth-20240603monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation-study-fth-20240523monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-first-quarter-2024-financial-results-and-recent-business-hi-fth-20240509monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-full-year-2023-financial-results-and-recent-business-highli-fth-20240228monthly0.5https://www.biopharmawatch.com/news/FTH/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-fth-20240104monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-third-quarter-2023-financial-results-and-recent-business-hi-fth-20231107monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-favorable-clinical-data-for-sns-101-at-2023-sitc-annual-mee-fth-20231103monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-second-quarter-2023-financial-results-and-recent-business-h-fth-20230803monthly0.5https://www.biopharmawatch.com/news/FTH/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-fth-20230627monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-first-quarter-2023-financial-results-and-recent-business-hi-fth-20230509monthly0.5https://www.biopharmawatch.com/news/FTH/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-fth-20230420monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-full-year-2022-financial-results-and-recent-business-highli-fth-20230328monthly0.5https://www.biopharmawatch.com/news/FTH/disclaimer-this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-w-fth-20230313monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-adopts-stockholder-rights-agreement-boston-ma-fth-20230307monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-signs-cooperative-research-and-development-agreement-crada-with-the-fth-20230206monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-provides-update-on-strategic-priorities-closes-boston-research-site-fth-20221208monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-presents-preclinical-data-at-the-37-th-society-for-immunotherapy-of-fth-20221110monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-third-quarter-2022-financial-results-and-recent-business-hi-fth-20221108monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista--fth-20220930monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-announces-new-preclinical-data-demonstrating-favorable-pharmacokine-fth-20220831monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-second-quarter-2022-financial-results-and-recent-business-h-fth-20220809monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-first-quarter-2022-financial-results-and-recent-business-hi-fth-20220510monthly0.5https://www.biopharmawatch.com/news/FTH/robert-pierce-md-world-vaccine-congress-2022-washington-dc-sns-101-a-unique-tumor-selectiv-fth-20220420monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-full-year-2021-financial-results-and-business-highlights-re-fth-20220310monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-appoints-william-ringo-mba-as-chair-of-board-of-directors-brings-de-fth-20220309monthly0.5https://www.biopharmawatch.com/news/FTH/training-the-immune-system-to-fight-cancer-john-k-celebi-mba-president-chief-executive-off-fth-20220110monthly0.5https://www.biopharmawatch.com/news/FTH/this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-we-us-and-is-fth-20211206monthly0.5https://www.biopharmawatch.com/news/FTH/vista-science-symposium-fth-20211116monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-third-quarter-2021-results-and-recent-business-highlights-s-fth-20211109monthly0.5https://www.biopharmawatch.com/news/FTH/this-presentation-has-been-prepared-by-sensei-biotherapeutics-inc-the-company-we-us-and-is-fth-20210908monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-second-quarter-2021-results-and-highlights-recent-in-vivo-d-fth-20210804monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-announces-prioritization-of-next-generation-multi-antigenic-immunop-fth-20210628monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-first-quarter-2021-results-and-provides-business-update-imm-fth-20210512monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-appoints-jessie-m-english-ph-d-to-its-board-of-directors-entreprene-fth-20210405monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-reports-full-year-2020-results-and-provides-business-update-success-fth-20210325monthly0.5https://www.biopharmawatch.com/news/FTH/sensei-biotherapeutics-announces-closing-of-initial-public-offering-boston-ma-and-rockvill-fth-20210210monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-new-ov329-data-and-indication-expansion-phase-1-clearance-for--ovid-20260318monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-phase-1-results-for-the-first-ever-direct-activator-of-potassium-ovid-20251218monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-business-updates-and-first-quarter-2025-financial-results-toplin-ovid-20250513monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-business-updates-and-fourth-quarter-and-full-year-2024-financial-ovid-20250311monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-and-graviton-bioscience-announce-topline-data-from-a-phase-1-clinical-tr-ovid-20240701monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-on-takeda-s-announcement-of-phase-3-topline-study-results-for-so-ovid-20240617monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-business-updates-and-first-quarter-2024-financial-results-takeda-ovid-20240514monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-business-updates-fourth-quarter-and-full-year-2023-financial-res-ovid-20240308monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-third-quarter-2023-financial-results-and-corporate-updates-recei-ovid-20231103monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-and-ligand-pharmaceuticals-enter-into-a-30-million-agreement-for-a-13-in-ovid-20231018monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-r-d-day-october-2-2023-dawn-of-the-neurotherapeutics-era-dr-jeremy-levin-ceo-chairman-ovid-20231002monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-second-quarter-2023-financial-results-and-corporate-updates-comp-ovid-20230804monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-first-quarter-2023-financial-results-and-corporate-updates-initi-ovid-20230505monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-collaboration-with-graviton-bioscience-proven-developers-of-se-ovid-20230501monthly0.5https://www.biopharmawatch.com/news/OVID/long-term-safety-efficacy-findings-from-soticlestat-open-label-extension-study-presented-b-ovid-20230427monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-business-update-fourth-quarter-and-full-year-2022-financial-resu-ovid-20230313monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-third-quarter-2022-financial-results-and-corporate-highlights-ov-ovid-20221108monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-second-quarter-2022-financial-results-and-corporate-highlights-a-ovid-20220809monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-first-quarter-2022-financial-results-and-corporate-highlights-x2-ovid-20220510monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-business-update-fourth-quarter-and-full-year-2021-financial-resu-ovid-20220315monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-expands-epilepsy-franchise-with-novel-kcc2-activators-exclusive-license--ovid-20220103monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-third-quarter-2021-business-update-corporate-highlights-and-fina-ovid-20211110monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-ovid-20210818monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-second-quarter-2021-financial-results-and-corporate-highlights-c-ovid-20210816monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-2021-ovid-therapeutics-inc-all-rights-reserved--ovid-20210623monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-2021-ovid-therapeutics-inc-all-rights-reserved--ovid-20210518monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-first-quarter-2021-financial-results-and-provides-corporate-upda-ovid-20210513monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-2021-ovid-therapeutics-inc-all-rights-reserved--ovid-20210419monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-provides-update-on-ov101-program-and-the-prioritization-of-its-resources-completed-so-ovid-20210419monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-2021-ovid-therapeutics-inc-all-rights-reserved--ovid-20210409monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-closing-of-agreement-with-takeda-for-global-development-and-co-ovid-20210330monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-provides-cor-ovid-20210315monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-2021-ovid-therapeutics-inc-all-rights-reserved--ovid-20210303monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-phase-3-neptune-clinical-trial-of-ov101-for-the-treatment-of-a-ovid-20201201monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corporate-upda-ovid-20201112monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-ovid-20201022monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-provides-soticlestat-ov935-tak-935-results-from-arcade-and-endymion-stud-ovid-20200930monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-pricing-of-50-million-offering-of-common-stock-ovid-20200825monthly0.5https://www.biopharmawatch.com/news/OVID/phase-2-elektra-study-of-soticlestat-tak-935-ov935-meets-primary-endpoint-reducing-seizure-ovid-20200825monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-second-quarter-2020-financial-results-and-provides-corporate-upd-ovid-20200810monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-receives-fda-rare-pediatric-disease-designation-for-ov101-for-the-treatm-ovid-20200619monthly0.5https://www.biopharmawatch.com/news/OVID/jeremy-levin-dphil-mb-bchir-chairman-chief-executive-officer-ovid-therapeutics-welcome-dis-ovid-20200617monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-first-quarter-2020-financial-results-and-provides-corporate-upda-ovid-20200507monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-initial-data-with-soticlestat-in-cdkl5-deficiency-disorder-and-ovid-20200330monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-ovid-20200313monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-provides-cor-ovid-20200311monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-ovid-20200302monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-provides-2020-update-in-preparation-for-multiple-clinical-data-readouts--ovid-20200107monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-third-quarter-2019-financial-results-and-recent-progress-announc-ovid-20191108monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-senior-management-promotions-in-preparation-for-multiple-data--ovid-20191101monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-pricing-of-32-5-million-of-securities-in-concurrent-public-off-ovid-20191004monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-ovid-20190923monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-first-patient-randomized-in-pivotal-phase-3-neptune-trial-of-o-ovid-20190912monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-ovid-20190909monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-nasdaq-ovid-is-a-new-york-based-biopharmaceutical-company-using-its-bold-ovid-20190807monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-receives-orphan-drug-designation-from-the-european-commission-for-ov101--ovid-20190702monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-ovid-20190627monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-initiates-pivotal-phase-3-clinical-trial-in-angelman-syndrome-multiple-d-ovid-20190627monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-host-r-d-day-on-ovid-20190618monthly0.5https://www.biopharmawatch.com/news/OVID/certain-confidential-information-contained-in-this-document-marked-by-brackets-is-omitted--ovid-20190515monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-first-quarter-2019-financial-results-remains-on-track-for-all-pr-ovid-20190507monthly0.5https://www.biopharmawatch.com/news/OVID/investors-investor-relations-public-relations-ovid-therapeutics-inc-irpr-ovidrx-com-alex-g-ovid-20190328monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-senior-management-changes-to-align-expertise-with-advancing-cl-ovid-20190328monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-appointment-of-pharmaceutical-veteran-thomas-perone-as-senior--ovid-20190321monthly0.5https://www.biopharmawatch.com/news/OVID/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-ovid-20190311monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-ovid-20190307monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-pricing-of-30-million-of-securities-in-concurrent-public-offer-ovid-20190220monthly0.5https://www.biopharmawatch.com/news/OVID/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-ovid-20190219monthly0.5https://www.biopharmawatch.com/news/OVID/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-ovid-20190107monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-outlines-2019-clinical-and-business-priorities-ov101-in-angelman-syndrom-ovid-20190104monthly0.5https://www.biopharmawatch.com/news/OVID/collaboration-with-takeda-pharmaceutical-company-limited-for-the-treatment-of-rare-develop-ovid-20181217monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-plans-to-move-into-a-phase-3-trial-in-pediatric-patients-based-ovid-20181206monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-third-quarter-2018-financial-results-and-highlights-recent-clini-ovid-20181108monthly0.5https://www.biopharmawatch.com/news/OVID/about-angelman-syndrome-angelman-syndrome-is-a-genetic-disorder-that-is-characterized-by-a-ovid-20181025monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-ex991-91-pptx-htm-corporate-presentation-cantor-fitzgerald-global-healthcare-conferen-ovid-20181001monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-second-quarter-2018-financial-results-and-highlights-recent-clin-ovid-20180809monthly0.5https://www.biopharmawatch.com/news/OVID/agenda-speakers-agenda-item-lora-pike-senior-director-ir-pr-welcome-jeremy-levin-dphil-mb--ovid-20180806monthly0.5https://www.biopharmawatch.com/news/OVID/about-ov101-ov101-gaboxadol-is-believed-to-be-the-only-delta-selective-gaba-a-receptor-ago-ovid-20180806monthly0.5https://www.biopharmawatch.com/news/OVID/takeda-and-ovid-therapeutics-expand-clinical-program-for-tak-935-ov935-with-three-new-stud-ovid-20180718monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-initiation-of-phase-2-rocket-clinical-trial-to-evaluate-ov101--ovid-20180711monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-first-quarter-2018-financial-results-and-corporate-progress-data-ovid-20180508monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-corporat-ovid-20180329monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-tak-935-ov935-has-received-orphan-drug-designation-from-u-s-fd-ovid-20171205monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-ov101-shows-comparable-pk-profile-in-phase-1-study-of-adolesce-ovid-20171128monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-third-quarter-2017-financial-results-and-corporate-progress-ovid-20171109monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-positive-preclinical-ov101-data-demonstrating-behavioral-impro-ovid-20171016monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-receives-orphan-drug-designation-from-the-u-s-fda-for-ov101-for-treatmen-ovid-20171010monthly0.5https://www.biopharmawatch.com/news/OVID/forward-looking-statements-this-presentation-contains-projections-for-ovid-therapeutics-in-ovid-20170815monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-second-quarter-2017-financial-results-and-corporate-progress-ovid-20170810monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-barbara-g-duncan-to-its-board-of-directors-ms-duncan-to-serve-a-ovid-20170614monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-first-quarter-2017-financial-results-and-recent-corporate-progre-ovid-20170613monthly0.5https://www.biopharmawatch.com/news/OVID/forward-looking-statements-this-presentation-contains-projections-for-ovid-therapeutics-in-ovid-20170609monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-first-quarter-2026-financial-results-operational-highlights-and-expected-upcom-fdmt-20260507monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-full-year-2025-financial-results-operational-highlights-and-expected-upcoming--fdmt-20260318monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-third-quarter-2025-financial-results-operational-highlights-and-expected-upcom-fdmt-20251110monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-second-quarter-2025-financial-results-operational-highlights-and-expected-upco-fdmt-20250811monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-first-quarter-2025-financial-results-operational-highlights-and-expected-upcom-fdmt-20250508monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-full-year-2024-financial-results-operational-highlights-and-expected-upcoming--fdmt-20250228monthly0.5https://www.biopharmawatch.com/news/FDMT/legal-disclaimer-this-presentation-contains-forward-looking-statements-that-involve-substa-fdmt-20250110monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-third-quarter-2024-financial-results-operational-highlights-and-expected-upcom-fdmt-20241113monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-second-quarter-2024-financial-results-and-operational-highlights-x2022-announc-fdmt-20240808monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-first-quarter-2024-financial-results-and-operational-highlights-x2022-announce-fdmt-20240509monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-full-year-2023-financial-results-and-operational-highlights-x2022-presented-po-fdmt-20240229monthly0.5https://www.biopharmawatch.com/news/FDMT/dmt-reports-third-quarter-2023-financial-results-and-operational-highlights-x2022-rapidly--fdmt-20231109monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-second-quarter-2023-financial-results-and-operational-hig-fdmt-20230809monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-first-quarter-2023-financial-results-and-operational-high-fdmt-20230510monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-full-year-2022-financial-results-and-operational-highligh-fdmt-20230315monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-third-quarter-2022-financial-results-interim-clinical-tri-fdmt-20221103monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-second-quarter-2022-financial-results-and-provides-4d-310-fdmt-20220811monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corpora-fdmt-20220512monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-full-year-2021-financial-results-and-operational-highligh-fdmt-20220328monthly0.5https://www.biopharmawatch.com/news/FDMT/harnessing-the-power-of-directed-evolution-for-targeted-gene-therapies-corporate-presentat-fdmt-20220111monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-financial-results-for-the-third-quarter-of-2021-and-provi-fdmt-20211110monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-financial-results-for-the-second-quarter-of-2021-and-prov-fdmt-20210812monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-announces-rare-disease-ophthalmology-product-candidate-portfolio--fdmt-20210624monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-financial-results-for-the-first-quarter-of-2021-and-provi-fdmt-20210513monthly0.5https://www.biopharmawatch.com/news/FDMT/d-molecular-therapeutics-reports-financial-results-for-the-year-ended-fdmt-20210325monthly0.5https://www.biopharmawatch.com/news/MCTA/charming-medical-limited-and-its-subsidiaries-unaudited-interim-condensed-consolidated-bal-mcta-20260331monthly0.5https://www.biopharmawatch.com/news/MCTA/charming-medical-limited-announces-full-exercise-of-representative-s-over-allotment-option-mcta-20251028monthly0.5https://www.biopharmawatch.com/news/MCTA/charming-medical-limited-announces-pricing-of-initial-public-offering-and-listing-on-nasda-mcta-20251021monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-positive-interim-results-from-phase-1b-clinical-studies-of-lo-asmb-20251208monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-second-quarter-2025-financial-results-and-recent-updates-x201-asmb-20250806monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-positive-topline-results-from-phase-1b-clinical-trial-of-next-asmb-20250625monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-first-quarter-2025-financial-results-and-recent-updates-x2013-asmb-20250508monthly0.5https://www.biopharmawatch.com/news/ASMB/ass-embly-biosciences-reports-year-end-2024-financial-results-and-recent-highlights-x2013--asmb-20250320monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-positive-interim-phase-1a-results-from-clinical-trial-evaluat-asmb-20250220monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-interim-phase-1b-results-from-clinical-trial-evaluating-next--asmb-20241226monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-third-quarter-2024-financial-results-and-recent-updates-x2022-asmb-20241107monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-positive-interim-phase-1a-results-from-clinical-trial-evaluat-asmb-20240923monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-second-quarter-2024-financial-results-and-recent-updates-x202-asmb-20240808monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-12-6-million-in-equity-financings-funding-supports-advancem-asmb-20240617monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-first-quarter-2024-financial-results-and-recent-highlights-x2-asmb-20240508monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-fourth-quarter-and-year-end-2023-financial-results-and-recent-asmb-20240328monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-effective-date-of-reverse-stock-split-x2013-assembly-bio-co-asmb-20240212monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-third-quarter-2023-financial-results-and-recent-updates-estab-asmb-20231108monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-second-quarter-2023-financial-results-and-recent-updates-herp-asmb-20230809monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-first-quarter-2023-financial-results-and-recent-highlights-he-asmb-20230504monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-additional-promising-data-from-phase-1a-clinical-trial-eval-asmb-20230418monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-provides-update-on-its-core-inhibitor-pipeline-reports-fourth-quarter-asmb-20230322monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-nominates-first-herpesvirus-development-candidate-abi-5366-a-long-act-asmb-20230215monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-promising-interim-results-from-two-clinical-trials-evaluati-asmb-20221219monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-third-quarter-2022-financial-results-and-recent-highlights-an-asmb-20221108monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-bio-announces-retirement-of-john-g-mchutchison-ao-md-as-ceo-and-appoints-current--asmb-20221005monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-second-quarter-2022-financial-results-and-recent-highlights-asmb-20220809monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-program-reprioritization-and-organizational-update-disconti-asmb-20220720monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-first-quarter-2022-financial-results-and-recent-highlights-asmb-20220512monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-fourth-quarter-and-year-end-2021-financial-results-and-recent-asmb-20220310monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-outlines-anticipated-2022-pipeline-development-milestones-asmb-20220104monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-third-quarter-2021-financial-results-and-recent-highlights-asmb-20211104monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-bio-announces-decision-to-discontinue-clinical-development-of-abi-h2158-decision--asmb-20210901monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-second-quarter-2021-financial-results-and-recent-highlights-asmb-20210805monthly0.5https://www.biopharmawatch.com/news/ASMB/nobel-laureate-dr-michael-houghton-appointed-to-assembly-biosciences-board-of-directors-es-asmb-20210720monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-first-quarter-2021-financial-results-and-recent-updates-asmb-20210506monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-and-arbutus-biopharma-initiate-phase-2-clinical-trial-of-triple-combi-asmb-20210226monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-fourth-quarter-and-year-end-2020-financial-results-and-recent-asmb-20210225monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-wind-down-microbiome-program-company-will-prioritize-resources-to--asmb-20201208monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-and-door-pharmaceuticals-sign-collaboration-and-option-agreement-to-d-asmb-20201116monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-third-quarter-2020-financial-results-and-business-update-asmb-20201105monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-appoints-gina-consylman-to-board-of-directors-asmb-20201020monthly0.5https://www.biopharmawatch.com/news/ASMB/section-27a-of-the-securities-act-of-1933-and-section-21e-of-the-securities-exchange-act-o-asmb-20200827monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-second-quarter-2020-financial-results-and-recent-highlights-asmb-20200805monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-and-beigene-announce-license-and-collaboration-agreement-in-china-for-asmb-20200720monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-updates-on-corporate-progress-and-first-quarter-2020-financia-asmb-20200507monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-fourth-quarter-and-year-end-2019-financial-results-asmb-20200304monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-proposed-public-offering-of-common-stock-asmb-20191211monthly0.5https://www.biopharmawatch.com/news/ASMB/agenda-and-speakers-on-today-s-call-agenda-introductions-and-safe-harbor-overview-of-asmb--asmb-20191112monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-third-quarter-2019-financial-results-and-recent-highlights-asmb-20191107monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-second-quarter-2019-financial-results-and-recent-highlights-asmb-20190805monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-first-quarter-2019-financial-results-and-recent-highlights-asmb-20190509monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-changes-to-senior-leadership-team-asmb-20190502monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-fourth-quarter-and-year-end-2018-financial-results-asmb-20190228monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-third-quarter-2018-financial-results-and-provides-hbv-progr-asmb-20181108monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-second-quarter-2018-financial-results-abi-h0731-phase-2a-cl-asmb-20180808monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-proposed-underwritten-offering-of-common-stock-indianapolis-asmb-20180710monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-initiates-two-phase-2a-trials-of-abi-h0731-for-the-treatment-of-hepat-asmb-20180709monthly0.5https://www.biopharmawatch.com/news/ASMB/r-d-day-hepatitis-b-program-asmb-20180620monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-first-quarter-2018-financial-results-indianapolis-and-asmb-20180507monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-additions-to-management-team-and-board-of-directors-accompl-asmb-20180312monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-appoints-sue-mahony-phd-to-board-of-directors-indianapolis-asmb-20171218monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-proposed-underwritten-offering-of-common-stock-indianapolis-asmb-20171101monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-inc-corporate-presentation-asmb-20170926monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-selects-next-generation-cpam-candidate-for-advancement-into-clinical--asmb-20170925monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-inc-corporate-presentation-asmb-20170907monthly0.5https://www.biopharmawatch.com/news/ASMB/allergan-assembly-investors-investors-lisa-defrancesco-lauren-glaser-862-261-7152-415-521--asmb-20170109monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-inc-asmb-20170109monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-inc-corporate-presentation-november-2016-cautionary-note-r-egarding-f-asmb-20161109monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-nasdaq-asmb-february-2016-rbc-capital-markets-2016-healthcare-confere-asmb-20160224monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-nasdaq-asmb-january-2016-c-autionary-note-regarding-forward-looking-s-asmb-20160112monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-appoints-biotech-veteran-alan-j-lewis-to-board-of-directors-indianapo-asmb-20151221monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-discusses-mechanism-of-action-of-its-hbv-antiviral-program-at-2nd-anr-asmb-20150519monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-proposed-public-offering-of-common-stock-asmb-20150318monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-february-2015-1-forward-looking-statements-this-presentation-contains-asmb-20150224monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-senior-management-changes-assembly-co-founder-derek-small-n-asmb-20150217monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-15-75-million-registered-direct-offering-new-york-new-york-asmb-20141001monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-august-2014-this-presentation-contains-forward-looking-statements-reg-asmb-20140813monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-provides-update-on-status-of-ven-307-new-york-new-york-july-25-2014-a-asmb-20140730monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-becomes-assembly-biosciences-as-stockholders-approve-merger-with-assem-asmb-20140711monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-to-merge-with-assembly-pharmaceuticals-new-company-assembly-bioscience-asmb-20140519monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-receives-date-for-type-b-pre-nda-meeting-with-fda-for-dolizem-diltiaze-asmb-20140404monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-announces-results-from-second-pivotal-phase-3-trial-of-diltiazem-cream-asmb-20140212monthly0.5https://www.biopharmawatch.com/news/ASMB/forward-looking-statements-this-material-contains-estimates-and-forward-looking-statements-asmb-20140108monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-completes-enrollment-of-second-pivotal-phase-3-trial-of-diltiazem-crea-asmb-20131125monthly0.5https://www.biopharmawatch.com/news/ASMB/forward-looking-statements-this-material-contains-estimates-and-forward-looking-statements-asmb-20131125monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-announces-positive-results-from-clinical-dermal-safety-and-pharmacokin-asmb-20130911monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-announces-full-exercise-of-overallotment-option-by-underwriters-new-yo-asmb-20130207monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-announces-20-million-financing-new-york-ny-asmb-20130130monthly0.5https://www.biopharmawatch.com/news/ASMB/forward-looking-statements-this-material-contains-estimates-and-forward-looking-statements-asmb-20130122monthly0.5https://www.biopharmawatch.com/news/ASMB/this-material-contains-estimates-and-forward-looking-statements-the-words-believe-may-migh-asmb-20130107monthly0.5https://www.biopharmawatch.com/news/ASMB/this-material-contains-estimates-and-forward-looking-statements-the-words-believe-may-migh-asmb-20121113monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-receives-fda-written-feedback-targets-nda-filing-for-diltiazem-ven-307-asmb-20121105monthly0.5https://www.biopharmawatch.com/news/ASMB/slide-presentation-1-this-material-contains-estimates-and-forward-looking-statements-the-w-asmb-20120905monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-announces-results-from-pivotal-phase-3-trial-of-iferanserin-ven-309-in-asmb-20120625monthly0.5https://www.biopharmawatch.com/news/ASMB/russell-h-ellison-md-msc-chief-executive-officer-and-chairman-of-the-board-1-this-material-asmb-20120516monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-announces-positive-results-from-pivotal-phase-3-trial-of-diltiazem-ven-asmb-20120514monthly0.5https://www.biopharmawatch.com/news/ASMB/russell-h-ellison-md-msc-chief-executive-officer-and-chairman-of-the-board-1-this-material-asmb-20120507monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-completes-enrollment-of-pivotal-phase-3-trial-of-iferanserin-ven-309-i-asmb-20120430monthly0.5https://www.biopharmawatch.com/news/ASMB/russell-h-ellison-md-msc-chief-executive-officer-and-chairman-of-the-board-1-this-material-asmb-20120305monthly0.5https://www.biopharmawatch.com/news/ASMB/this-material-contains-estimates-and-forward-looking-statements-the-words-believe-may-migh-asmb-20120213monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-announces-publication-of-prior-phase-2b-study-on-the-safety-and-efficacy-of-iferan-asmb-20120113monthly0.5https://www.biopharmawatch.com/news/ASMB/this-material-contains-estimates-and-forward-looking-statements-the-words-believe-may-migh-asmb-20120109monthly0.5https://www.biopharmawatch.com/news/ASMB/this-material-contains-estimates-and-forward-looking-statements-the-words-believe-may-migh-asmb-20111114monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-to-announce-3q-2011-financial-results-clinical-update-and-omnibus-mark-asmb-20111109monthly0.5https://www.biopharmawatch.com/news/ASMB/this-material-contains-estimates-and-forward-looking-statements-the-words-believe-may-migh-asmb-20110912monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-announces-exercise-of-underwriters-over-allotment-option-and-closing-o-asmb-20110719monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-biosciences-announces-pricing-of-its-underwritten-registered-offering-of-common-st-asmb-20110714monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-receives-spa-response-from-fda-and-will-update-and-file-the-first-pivotal-trial-pr-asmb-20110622monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-receives-notice-of-allowance-for-u-s-patent-for-ven-307-u-s-patent-office-allows-c-asmb-20110526monthly0.5https://www.biopharmawatch.com/news/ASMB/unassociated-document-asmb-20110318monthly0.5https://www.biopharmawatch.com/news/ASMB/this-material-contains-estimates-and-forward-looking-statements-as-defined-by-the-private--asmb-20110214monthly0.5https://www.biopharmawatch.com/news/ASMB/ventrus-completes-clinical-development-staffing-asmb-20110201monthly0.5https://www.biopharmawatch.com/news/ASMB/underwriters-exercise-over-allotment-option-for-ventrus-biosciences-initial-public-offerin-asmb-20110107monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-agrees-to-acquire-bako-diagnostics-and-stratadx-proposed-acquisition-will-flgt-20251222monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-third-quarter-2025-financial-results-x2022-revenue-of-84-1-million-growing-flgt-20251107monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-shares-preliminary-data-from-poster-presentation-at-esmo-2025-conference-flgt-20251020monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-second-quarter-2025-financial-results-x2022-core-revenue-of-81-7-million-g-flgt-20250801monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-first-quarter-2025-financial-results-x2022-core-revenue-of-73-5-million-gr-flgt-20250502monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-fourth-quarter-and-full-year-2024-financial-results-x2022-full-year-total--flgt-20250228monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-third-quarter-2024-financial-results-x2022-total-revenue-of-71-7-million-x-flgt-20241108monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-second-quarter-2024-financial-results-x2022-total-revenue-of-71-0-million--flgt-20240802monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-first-quarter-2024-financial-results-x2022-total-revenue-of-64-5-million-x-flgt-20240503monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-fourth-quarter-and-full-year-2023-financial-results-x2022-full-year-2023-t-flgt-20240228monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-third-quarter-2023-financial-results-x2022-core-revenue-of-66-million-repr-flgt-20231103monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-second-quarter-2023-financial-results-x2022-total-revenue-of-68-million-x2-flgt-20230804monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-first-quarter-2023-financial-results-x2022-total-revenue-of-66-2-million-x-flgt-20230505monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-fourth-quarter-and-full-year-2022-financial-results-x2022-full-year-2022-t-flgt-20230228monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-expands-board-of-directors-with-addition-of-reggie-groves-temple-city-california-x-flgt-20230103monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-third-quarter-2022-financial-results-x2022-revenue-totals-105-7-m-flgt-20221107monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-second-quarter-2022-financial-results-x2022-revenue-totals-125-3--flgt-20220804monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-first-quarter-2022-financial-results-x2022-revenue-totals-320-3-m-flgt-20220503monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-agrees-to-acquire-inform-diagnostics-and-provides-preliminary-first-quart-flgt-20220418monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-fourth-quarter-and-full-year-2021-financial-results-full-year-202-flgt-20220223monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-third-quarter-financial-results-revenue-grows-124-year-over-year--flgt-20211109monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-second-quarter-financial-results-x2022-revenue-grows-790-year-ove-flgt-20210809monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-record-first-quarter-financial-results-first-quarter-2021-results-flgt-20210506monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-record-fourth-quarter-and-full-year-2020-financial-results-fourth-flgt-20210304monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-announces-increase-to-full-year-2020-guidance-to-300-million-flgt-20201123monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-record-third-quarter-2020-financial-results-and-raises-full-year--flgt-20201109monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-record-second-quarter-2020-financial-results-second-quarter-2020--flgt-20200804monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-first-quarter-2020-financial-results-first-quarter-2020-results-x-flgt-20200504monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-fourth-quarter-and-full-year-2019-financial-results-fourth-quarte-flgt-20200310monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-announces-proposed-public-offering-of-common-stock-flgt-20191113monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-third-quarter-2019-financial-results-third-quarter-2019-results-x-flgt-20191104monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-second-quarter-2019-financial-results-second-quarter-2019-results-flgt-20190805monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-names-linda-marsh-to-board-of-directors-flgt-20190805monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-first-quarter-2019-financial-results-first-quarter-2019-results-x-flgt-20190507monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-fourth-quarter-and-full-year-2018-financial-results-fourth-quarte-flgt-20190228monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-third-quarter-2018-financial-results-third-quarter-2018-results-x-flgt-20181106monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-second-quarter-2018-financial-results-second-quarter-2018-results-flgt-20180806monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-first-quarter-2018-financial-results-first-quarter-2018-results-x-flgt-20180507monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-fourth-quarter-and-full-year-2017-financial-results-fourth-quarte-flgt-20180228monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-third-quarter-2017-financial-results-x2022-revenue-of-4-5-million-flgt-20171106monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-second-quarter-2017-financial-results-x2022-revenue-grows-17-year-flgt-20170807monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-first-quarter-2017-financial-results-x2022-revenue-grows-54-year--flgt-20170508monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-fourth-quarter-and-full-year-2016-financial-results-fourth-quarte-flgt-20170227monthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-reports-financial-results-for-the-third-quarter-of-2016-revenue-grows-72--flgt-20161103monthly0.5https://www.biopharmawatch.com/news/FULC/fast-track-and-orphan-drug-designation-from-the-fda-for-the-treatment-of-scd-to-learn-more-fulc-20260601monthly0.5https://www.biopharmawatch.com/news/FULC/january-2026-disclaimer-and-notice-this-presentation-contains-x201c-forward-looking-statem-fulc-20260112monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-pricing-of-upsized-175-0-million-public-offering-of-common--fulc-20251210monthly0.5https://www.biopharmawatch.com/news/FULC/august-2025-disclaimer-and-notice-this-presentation-contains-x201c-forward-looking-stateme-fulc-20250828monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-second-fulc-20250729monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-first--fulc-20250501monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-fourth-fulc-20250225monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-third--fulc-20241113monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-topline-results-from-phase-3-reach-clinical-trial-of-losmap-fulc-20240912monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-second-fulc-20240731monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-first--fulc-20240513monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-fourth-fulc-20240227monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-third--fulc-20231107monthly0.5https://www.biopharmawatch.com/news/FULC/ftx-6058-f-o-r-s-i-c-k-l-e-c-e-l-l-d-i-s-e-a-s-e-program-update-f-u-l-c-r-u-m-t-h-e-r-a-p--fulc-20230822monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-second-fulc-20230803monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-the-fi-fulc-20230515monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-the-fo-fulc-20230309monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-fulc-20230117monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-proposed-public-offering-of-common-stock-fulc-20230117monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-provides-business-update-and-2023-outlook-ftx-6058-granted-fast-track-fulc-20230104monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-third-quarter-2022-financial-fulc-20221108monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-proposed-public-offering-of-common-stock-fulc-20220815monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-second-quarter-2022-financial-results-and-business-update-x-fulc-20220811monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-first-quarter-2022-financial-r-fulc-20220509monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2-fulc-20220303monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-upcoming-milestones-to-support-its-mission-of-treating-the--fulc-20220110monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-esther-rajavelu-as-chief-financial-officer-fulc-20220104monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-sonja-l-banks-to-its-board-of-directors-fulc-20211117monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-third-quarter-2021-financial-r-fulc-20211104monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-pricing-of-125-million-public-offering-of-common-stock-fulc-20210811monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-second-quarter-2021-financial--fulc-20210810monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-first-quarter-2021-financial-r-fulc-20210506monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-judith-a-dunn-ph-d-as-president-of-research-and-development-fulc-20210324monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2-fulc-20210304monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-pricing-of-public-offering-of-common-stock-fulc-20210119monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-third-quarter-2020-financial-r-fulc-20201110monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-second-quarter-2020-financial--fulc-20200811monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-evaluate-losmapimod-as-potential-treatment-for-covid-19-investigat-fulc-20200610monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-first-quarter-2020-financial-r-fulc-20200513monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2-fulc-20200305monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-katina-dorton-to-its-board-of-directors-fulc-20200106monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-third-quarter-2019-financial-results-and-recent-business-high-fulc-20191114monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announced-results-of-phase-1-clinical-trial-of-losmapimod-in-fshd-dat-fulc-20191004monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-second-quarter-2019-financial-results-and-recent-business-hig-fulc-20190826monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-eprx-20260529monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-consolidated-financial-statements-for-the-three-months-ended--eprx-20260512monthly0.5https://www.biopharmawatch.com/news/EPRX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-eupraxia-pharmaceu-eprx-20260220monthly0.5https://www.biopharmawatch.com/news/EPRX/execution-version-eupraxia-pharmaceuticals-inc-6-428-574-common-shares-without-par-value-p-eprx-20260218monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-consolidated-financial-statements-for-the-three-and-nine-mont-eprx-20251104monthly0.5https://www.biopharmawatch.com/news/EPRX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-eupraxia-pharmaceu-eprx-20250924monthly0.5https://www.biopharmawatch.com/news/EPRX/execution-version-eupraxia-pharmaceuticals-inc-12-727-273-common-shares-without-par-value--eprx-20250922monthly0.5https://www.biopharmawatch.com/news/EPRX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-eupraxia-pharmaceu-eprx-20250919monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-consolidated-financial-statements-for-the-three-and-six-month-eprx-20250813monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-eprx-20250602monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-consolidated-financial-statements-for-the-three-months-ended--eprx-20250506monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-reports-fourth-quarter-2024-financial-results-victoria-b-c-eprx-20250320monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-positive-data-from-resolve-phase-1b-2a-trial-of-ep-104g-eprx-20250225monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-cfo-succession-bruce-cousins-is-retiring-and-former-cfo-eprx-20250218monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-s-diffusphere-technology-demonstrates-targeted-drug-release-while-minimizing-syst-eprx-20241120monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-at-american-college-of-rheumatology-convergence-2024-a-eprx-20241114monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-ceo-dr-james-helliwell-to-participate-in-webinar-event-eosinophil-eprx-20241115monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-positive-data-from-fifth-cohort-of-resolve-phase-1b-2a--eprx-20241112monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-consolidated-financial-statements-for-the-three-and-nine-mont-eprx-20241107monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-that-it-has-closed-a-non-brokered-private-placement-of--eprx-20241031monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-at-american-college-of-gastroenterology-annual-scienti-eprx-20241028monthly0.5https://www.biopharmawatch.com/news/EPRX/lancet-rheumatology-publishes-phase-2b-data-on-eupraxia-pharmaceuticals-ep-104iar-for-the--eprx-20241015monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-at-united-european-gastroenterology-week-2024-victoria-eprx-20241010monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-strengthens-senior-management-team-victoria-b-c-eprx-20241002monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-at-20th-isde-world-congress-for-esophageal-diseases-vi-eprx-20240919monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-data-from-resolve-phase-1b-2a-trial-of-ep-104gi-for-tre-eprx-20240911monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-at-the-h-c-wainwright-26-th-annual-global-investment-c-eprx-20240904monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-consolidated-financial-statements-for-the-three-and-six-month-eprx-20240807monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-new-c-12-million-convertible-debt-facility-the-company--eprx-20240802monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-at-controlled-release-society-2024-annual-meeting-and--eprx-20240708monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-ceo-dr-james-helliwell-to-participate-in-webinar-event-exploring--eprx-20240703monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-voting-results-from-annual-general-and-special-meeting--eprx-20240606monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-data-from-the-phase-2-springboard-study-in-osteoarthri-eprx-20240605monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-expansion-of-resolve-phase-1b-2a-trial-of-ep-104gi-for--eprx-20240523monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-host-virtual-kol-event-on-ep-104gi-clinical-development-progra-eprx-20240522monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-new-positive-data-from-resolve-phase-1b-2a-trial-of-ep--eprx-20240521monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-notice-of-annual-general-and-special-meeting-of-shareholders--eprx-20240515monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-initial-results-from-ongoing-phase-1b-study-of-ep-104g-eprx-20240514monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-inc-consolidated-financial-statements-for-the-three-months-ended-eprx-20240508monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-gastrointestinal-clinical-advisory-board-advisory-board-eprx-20240502monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-upcoming-presentations-at-the-osteoarthritis-research-s-eprx-20240411monthly0.5https://www.biopharmawatch.com/news/EPRX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-eupraxia-pharmaceu-eprx-20240405monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-at-bloom-burton-co-healthcare-investor-conference-vict-eprx-20240408monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-begins-trading-on-nasdaq-today-victoria-b-c-eprx-20240405monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-begin-trading-on-nasdaq-on-eprx-20240405monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-reports-fourth-quarter-and-2023-financial-results-victoria-b-c-eprx-20240401monthly0.5https://www.biopharmawatch.com/news/EPRX/form-51-102f3-material-change-report-item-1-name-and-address-of-company-eupraxia-pharmaceu-eprx-20240315monthly0.5https://www.biopharmawatch.com/news/EPRX/not-for-dissemination-in-the-united-states-or-through-u-s-newswire-services-eupraxia-pharm-eprx-20240315monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-pricing-of-overnight-marketed-offering-of-30-million-no-eprx-20240312monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-overnight-marketed-offering-of-approximately-30-million-eprx-20240311monthly0.5https://www.biopharmawatch.com/news/ANGO/j-p-morgan-44th-annual-healthcare-conference-ango-20260114monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-reports-fiscal-year-2026-second-quarter-financial-results-continued-double-d-ango-20260106monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-reports-fiscal-year-2026-first-quarter-financial-results-med-tech-growth-of--ango-20251002monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-reports-strong-fiscal-year-2025-fourth-quarter-and-full-year-financial-resul-ango-20250715monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-event-shaping-the-future-of-cardiovascular-care-innovative-technologies-improved--ango-20250402monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-reports-fiscal-year-2025-third-quarter-financial-results-latham-n-y-business-ango-20250402monthly0.5https://www.biopharmawatch.com/news/ANGO/j-p-morgan-43rd-annual-healthcare-conference-ango-20250116monthly0.5https://www.biopharmawatch.com/news/ANGO/edit-title-1-2-2-notice-regarding-forward-looking-statements-this-presentation-contains-fo-ango-20250108monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-reports-fiscal-year-2025-second-quarter-financial-results-latham-n-y-busines-ango-20250108monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-reports-fiscal-year-2025-first-quarter-financial-results-latham-n-y-business-ango-20241003monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20240716monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-and-subsidiaries-pro-forma-consolidated-income-statements-in-thousands-e-ango-20240716monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20240404monthly0.5https://www.biopharmawatch.com/news/ANGO/j-p-morgan-healthcare-conference-ango-20240111monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20240105monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20231004monthly0.5https://www.biopharmawatch.com/news/ANGO/stephen-trowbridge-saleem-cheeks-518-795-1408-518-795-1174-strowbridge-angiodynamics-com-s-ango-20230724monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20230712monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-unaudited-pro-forma-condensed-consolidated-financial-statements-angiodyn-ango-20230614monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20230608monthly0.5https://www.biopharmawatch.com/news/ANGO/needham-company-22nd-annual-virtual-healthcare-conference-ango-20230417monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20230330monthly0.5https://www.biopharmawatch.com/news/ANGO/raymond-james-44th-annual-institutional-investors-conference-ango-20230306monthly0.5https://www.biopharmawatch.com/news/ANGO/j-p-morgan-healthcare-conference-ango-20230112monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20230105monthly0.5https://www.biopharmawatch.com/news/ANGO/2022-angiodynamics-piper-sandler-healthcare-conference-jim-clemmer-president-ceo-stephen-t-ango-20221130monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20221006monthly0.5https://www.biopharmawatch.com/news/ANGO/2022-angiodynamics-canaccord-growth-conference-stephen-trowbridge-evp-cfo-1-2-notice-regar-ango-20220810monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20220712monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20220407monthly0.5https://www.biopharmawatch.com/news/ANGO/2022-angiodynamics-needham-healthcare-conferencejim-clemmer-president-ceo-stephen-trowbrid-ango-20220110monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20220106monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20210930monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-technology-day-july-2021-agenda-9-30-10-50-am-et-business-presentations-angiodyna-ango-20210713monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20210713monthly0.5https://www.biopharmawatch.com/news/ANGO/2021-angiodynamics-the-ubs-2021-virtual-global-healthcare-conference-jim-clemmer-president-ango-20210525monthly0.5https://www.biopharmawatch.com/news/ANGO/2021-angiodynamics-the-20th-annual-needham-virtual-healthcare-conferencejim-clemmer-presid-ango-20210412monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20210330monthly0.5https://www.biopharmawatch.com/news/ANGO/2021-angiodynamics-barclays-global-healthcare-conferencejim-clemmer-president-ceostephen-t-ango-20210309monthly0.5https://www.biopharmawatch.com/news/ANGO/2021-angiodynamics-23rd-annual-needham-virtual-growth-conference-jim-clemmer-president-ceo-ango-20210111monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-second-quarter-2021-earnings-presentation-ango-20210107monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20210107monthly0.5https://www.biopharmawatch.com/news/ANGO/2020-angiodynamics-canaccord-genuity2020-medical-technologies-diagnostics-forum-2-forward--ango-20201119monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20200929monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20200716monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-stephen-trowbridge-executive-vice-president-cfo-518-795-ango-20200407monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-stephen-trowbridge-518-795-1408-strowbridge-angiodynamics-com-angiodynam-ango-20200206monthly0.5https://www.biopharmawatch.com/news/ANGO/j-p-ango-20200116monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-stephen-trowbridge-518-795-1408-strowbridge-angiodynamics-com-angiodynam-ango-20191022monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-michael-c-greiner-executive-vice-president-cfo-518-795--ango-20191003monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-first-quarter-2019-earnings-presentation-ango-20180927monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-michael-c-greiner-executive-vice-president-cfo-518-795--ango-20180927monthly0.5https://www.biopharmawatch.com/news/ANGO/wells-fargo-securities-healthcare-conference-ango-20180906monthly0.5https://www.biopharmawatch.com/news/ANGO/presentation-dated-july-11-2018-angiodynamics-fourth-quarter-2018-earnings-presentation-ango-20180711monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-michael-c-greiner-executive-vice-president-cfo-518-795--ango-20180711monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-third-quarter-2018-earnings-presentationmarch-29-2018-ango-20180329monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-michael-c-greiner-executive-vice-president-cfo-518-795--ango-20180329monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-michael-greiner-executive-vice-president-cfo-518-795-18-ango-20180124monthly0.5https://www.biopharmawatch.com/news/ANGO/j-p-morgan-healthcare-conference-angiodynamics-investor-presentation-ango-20180110monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-second-quarter-2018-earnings-presentationjanuary-4th-2018-2-forward-looking--ango-20180104monthly0.5https://www.biopharmawatch.com/news/ANGO/investor-contact-angiodynamics-inc-michael-greiner-executive-vice-president-cfo-518-795-18-ango-20180104monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1418-cstefanik-angiodynamics-com-fti-consulting-ango-20170928monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-and-subsidiaries-consolidated-income-statements-in-thousands-except-per--ango-20170804monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1418-cstefanik-angiodynamics-com-fti-consulting-ango-20170718monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1418-cstefanik-angiodynamics-com-fti-consulting-ango-20170330monthly0.5https://www.biopharmawatch.com/news/ANGO/j-p-morgan-healthcare-conferencejim-clemmer-ceomichael-greiner-cfo-ango-20170110monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1418-cstafanik-angiodynamics-com-fti-consulting-ango-20170106monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-announces-new-senior-credit-facilities-and-new-share-repurchase-program-new--ango-20161109monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1418-cstefanik-angiodynamics-com-fti-consulting-ango-20161005monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-appoints-michael-c-greiner-as-new-chief-financial-officer-greiner-brings-mor-ango-20160725monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1418-cstefanik-angiodynamics-com-fti-consulting-ango-20160713monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1418-cstefanik-angiodynamics-com-fti-consulting-ango-20160407monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-appoints-james-c-clemmer-as-new-president-and-chief-executive-officer-clemme-ango-20160404monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1418-cstefanik-angiodynamics-com-evc-group-inc--ango-20160107monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-caitlin-stefanik-518-795-1400-x-1418-cstefanik-angiodynamics-com-evc-gro-ango-20151109monthly0.5https://www.biopharmawatch.com/news/ANGO/q1-fy2016-financial-results-presentation-ango-20151014monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x-1981-mfrost-angiodynamics-com-evc-group-in-ango-20151008monthly0.5https://www.biopharmawatch.com/news/ANGO/ubs-2015-smid-cap-one-on-one-conference-mark-frost-executive-vice-president-cfo-ango-20150805monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-reports-fiscal-2015-fourth-quarter-and-full-year-financial-results-ango-20150717monthly0.5https://www.biopharmawatch.com/news/ANGO/needham-company-14-th-annual-healthcare-conference-joseph-m-devivo-president-ceo-mark-fros-ango-20150414monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20150409monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20150108monthly0.5https://www.biopharmawatch.com/news/ANGO/november-2014-joseph-m-devivo-president-ceo-mark-frost-executive-vice-president-cfo-forwar-ango-20141118monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-and-subsidiaries-consolidated-income-statements-as-revised-1-in-thousand-ango-20141114monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20141009monthly0.5https://www.biopharmawatch.com/news/ANGO/presentation-slides-an31248225-ex99-1-htm-joseph-m-devivo-president-and-ceo-august-2014-an-ango-20140814monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20140723monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20140409monthly0.5https://www.biopharmawatch.com/news/ANGO/joseph-m-devivo-president-and-ceo-january-2014-angiodynamics-the-angiodynamics-logo-and-ot-ango-20140115monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20140109monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20131010monthly0.5https://www.biopharmawatch.com/news/ANGO/mark-frost-executive-vice-president-and-cfo-august-2013-angiodynamics-the-angiodynamics-lo-ango-20130814monthly0.5https://www.biopharmawatch.com/news/ANGO/presentation-slides-for-the-ubs-global-healthcare-conference-an20130521-ex99-1-htm-joseph--ango-20130521monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20130408monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-mark-frost-cfo-800-772-6446-x1981-mfrost-angiodynamics-com-evc-group-inc-ango-20130308monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-the-angiodynamics-logo-and-other-trademarks-displayed-in-this-presentation-a-ango-20130123monthly0.5https://www.biopharmawatch.com/news/ANGO/draft-v5-investor-relations-contacts-media-contact-evc-group-inc-jamar-ismail-robert-jones-ango-20121217monthly0.5https://www.biopharmawatch.com/news/ANGO/evc-group-inc-jamar-ismail-robert-jones-415-568-9348-646-201-5447-jismail-evcgroup-com-bjo-ango-20121119monthly0.5https://www.biopharmawatch.com/news/ANGO/summary-description-of-the-angiodynamics-inc-2004-stock-and-incentive-award-plan-as-amende-ango-20121025monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20121008monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20120712monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20120522monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20120515monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20120404monthly0.5https://www.biopharmawatch.com/news/ANGO/acquisition-of-navilyst-medical-investor-conference-call-ango-20120131monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20120125monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20120105monthly0.5https://www.biopharmawatch.com/news/ANGO/summary-of-the-stock-and-incentive-award-plan-an24485839-ex99-1-htm-exhbit-99-1-summary-de-ango-20111020monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20111006monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20110922monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20110816monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20110714monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20110613monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20110405monthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-inc-d-joseph-gersuk-cfo-800-772-6446-x1608-jgersuk-angiodynamics-com-evc-gro-ango-20110125monthly0.5https://www.biopharmawatch.com/news/NGNE/comparable-to-the-earnings-per-share-information-for-the-post-merger-period-the-earnings-p-ngne-20240318monthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-announces-expansion-and-plans-for-more-rapid-patient-enrollment-of-rett-syndrome-ngne-20240304monthly0.5https://www.biopharmawatch.com/news/NGNE/to-the-company-s-current-report-on-form-8-k-filed-with-the-sec-on-ngne-20231219monthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-doses-first-patients-in-phase-1-2-trial-of-ngn-401-for-the-treatment-of-female-p-ngne-20231130monthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-and-neoleukin-announce-definitive-merger-agreement-proposed-merger-to-create-nas-ngne-20230718monthly0.5https://www.biopharmawatch.com/news/NGNE/document-ex-99-1-neoleukin-therapeutics-provides-strategic-update-and-announces-restructur-ngne-20230308monthly0.5https://www.biopharmawatch.com/news/NGNE/document-ex-99-1-neoleukin-therapeutics-announces-third-quarter-2022-financial-results-and-ngne-20221114monthly0.5https://www.biopharmawatch.com/news/NGNE/document-ex-99-1-neoleukin-therapeutics-announces-second-quarter-2022-financial-results-pr-ngne-20220809monthly0.5https://www.biopharmawatch.com/news/NGNE/document-neoleukin-therapeutics-to-host-second-quarter-2022-financial-results-conference-c-ngne-20220727monthly0.5https://www.biopharmawatch.com/news/NGNE/document-neoleukin-therapeutics-announces-first-quarter-2022-financial-results-and-corpora-ngne-20220509monthly0.5https://www.biopharmawatch.com/news/NGNE/document-neoleukin-therapeutics-announces-year-end-2021-financial-results-and-corporate-up-ngne-20220301monthly0.5https://www.biopharmawatch.com/news/NGNE/corporate-presentation-november-2021-forward-looking-statements-certain-of-the-statements--ngne-20211116monthly0.5https://www.biopharmawatch.com/news/NGNE/document-neoleukin-therapeutics-announces-third-quarter-2021-financial-results-and-corpora-ngne-20211104monthly0.5https://www.biopharmawatch.com/news/NGNE/disclosures-hui-ling-yen-phd-received-donation-from-saiba-ag-and-has-performed-contract-re-ngne-20210929monthly0.5https://www.biopharmawatch.com/news/NGNE/document-neoleukin-therapeutics-announces-second-quarter-2021-financial-results-provides-c-ngne-20210805monthly0.5https://www.biopharmawatch.com/news/NGNE/forward-looking-statements-certain-of-the-statements-made-in-these-slides-and-the-accompan-ngne-20210602monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-first-quarter-2021-financial-results-and-corporate-update-ngne-20210512monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-year-end-2020-financial-results-anticipating-first-patien-ngne-20210325monthly0.5https://www.biopharmawatch.com/news/NGNE/forward-looking-statements-certain-of-the-statements-made-in-these-slides-and-the-accompan-ngne-20210111monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-third-quarter-2020-financial-results-and-corporate-update-ngne-20201109monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-second-quarter-2020-financial-results-provides-corporate--ngne-20200812monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-pricing-of-76-2-million-public-offering-seattle-ngne-20200702monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-first-quarter-2020-financial-results-and-provides-busines-ngne-20200506monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-year-end-financial-results-nl-201-ind-submission-expected-ngne-20200312monthly0.5https://www.biopharmawatch.com/news/NGNE/de-novo-proteins-for-immunotherapy-january-2020-forward-looking-statements-certain-of-the--ngne-20200113monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-pricing-of-75-0-million-public-offering-ngne-20191217monthly0.5https://www.biopharmawatch.com/news/NGNE/forward-looking-statements-certain-of-the-statements-made-in-these-slides-and-the-accompan-ngne-20191205monthly0.5https://www.biopharmawatch.com/news/NGNE/neoleukin-therapeutics-announces-corporate-update-and-third-quarter-2019-financial-results-ngne-20191113monthly0.5https://www.biopharmawatch.com/news/NGNE/description-of-neoleukin-s-business-overview-following-the-closing-of-our-acquisition-of-n-ngne-20190805monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-and-neoleukin-therapeutics-announce-merger-agreement-combined-comp-ngne-20190806monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-third-quarter-2018-financial-results-vancouver-british-c-ngne-20181107monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-second-quarter-2018-financial-results-vancouver-british--ngne-20180808monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-announces-topline-results-of-phase-3-leadership-301-clinical-trial-in-interstitial-ngne-20180627monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-initiation-of-proship-phase-2-proof-of-concept-clinical--ngne-20180611monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-first-quarter-2018-financial-results-vancouver-british-c-ngne-20180508monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-year-end-2017-financial-results-vancouver-british-columb-ngne-20180312monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-r-d-day-ngne-20180209monthly0.5https://www.biopharmawatch.com/news/NGNE/forward-looking-statements-safe-harbor-this-presentation-and-the-accompanying-oral-comment-ngne-20180108monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-third-quarter-2017-financial-results-vancouver-british-c-ngne-20171108monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-second-quarter-2017-financial-results-conference-call-up-ngne-20170808monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-first-quarter-2017-financial-results-vancouver-british-c-ngne-20170509monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-year-end-2016-financial-results-conference-call-update-t-ngne-20170309monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-third-quarter-2016-financial-results-vancouver-british-c-ngne-20161109monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-initiates-patient-dosing-in-leadership-301-phase-3-clinical-trial--ngne-20160906monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-second-quarter-2016-financial-results-conference-call-up-ngne-20160804monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-first-quarter-2016-financial-results-vancouver-british-c-ngne-20160510monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-year-end-2015-financial-results-advancing-to-first-phase-ngne-20160314monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-announces-update-on-development-program-for-aqx-1125-following-meeting-with-fda-va-ngne-20160111monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-reports-third-quarter-2015-financial-results-vancouver-british-col-ngne-20151110monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-results-from-phase-2-kinship-trial-with-aqx-1125-in-pati-ngne-20151102monthly0.5https://www.biopharmawatch.com/news/NGNE/targeted-therapeutics-for-inflammatory-disease-r-d-day-ngne-20151007monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-presents-at-2015-international-society-for-the-study-of-bps-conference-responder-a-ngne-20150918monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-positive-results-from-secondary-endpoints-from-phase-2-l-ngne-20150806monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-q2-2015-conference-call-leadership-secondary-endpoint-update-aqx-1125-in-bps-ic-aq-ngne-20150806monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-results-from-flagship-trial-with-aqx-1125-in-chronic-obs-ngne-20150709monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-results-from-leadership-trial-with-aqx-1125-in-patients--ngne-20150625monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-first-quarter-2015-financial-results-vancouver-british-c-ngne-20150512monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-completes-enrollment-in-the-phase-2-kinship-trial-of-aqx-1125-in-a-ngne-20150504monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-year-end-2014-financial-results-vancouver-british-columb-ngne-20150316monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-completes-enrollment-in-the-phase-2-leadership-trial-of-aqx-1125-i-ngne-20150302monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-completes-enrollment-in-the-phase-2-flagship-trial-of-aqx-1125-in--ngne-20150202monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-initiates-patient-dosing-in-the-phase-2-clinical-trial-of-aqx-1125-ngne-20141230monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-appointment-of-mr-david-c-mitchell-as-vice-president-glo-ngne-20141209monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-third-quarter-2014-financial-results-vancouver-british-c-ngne-20141104monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-second-quarter-2014-financial-results-conference-call-at-ngne-20140811monthly0.5https://www.biopharmawatch.com/news/NGNE/aquinox-pharmaceuticals-announces-first-quarter-2014-financial-results-vancouver-british-c-ngne-20140513monthly0.5https://www.biopharmawatch.com/news/XOMAO/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-xomao-20260427monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements-po-xomao-20260318monthly0.5https://www.biopharmawatch.com/news/XOMAO/corporate-presentation-the-royalty-aggregator-nasdaq-common-xoma-for-biotech-nasdaq-perpet-xomao-20260302monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-announces-cfo-transition-xomao-20260112monthly0.5https://www.biopharmawatch.com/news/XOMAO/corporate-presentation-the-royalty-aggregator-nasdaq-common-xoma-for-biotech-nasdaq-perpet-xomao-20260112monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-announces-closing-of-transaction-to-acquire-mural-oncology-plc-xomao-20251205monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-reports-third-quarter-and-year-to-date-2025-financial-results-and-highlights--xomao-20251112monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-results-and-highlights-xomao-20250813monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-reports-first-quarter-2025-financial-results-and-highlights-business-achievem-xomao-20250513monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlights-bu-xomao-20250317monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-acquires-pulmokine-for-20-million-adding-the-royalty-and-milestone-interest-i-xomao-20241202monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities-xomao-20241107monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-significantly-expands-its-royalty-and-milestone-portfolio-with-the-addition-o-xomao-20241022monthly0.5https://www.biopharmawatch.com/news/XOMAO/zevra-s-miplyffa-arimoclomol-receives-approval-from-u-s-food-and-drug-administration-for-u-xomao-20240923monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-royalty-reports-second-quarter-2024-financial-results-and-highlights-recent-activitie-xomao-20240813monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-first-quarter-2024-financial-results-and-highlights-recent-activities-earned--xomao-20240509monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-adds-economic-interests-in-three-first-in-category-assets-to-its-royalty-and-mileston-xomao-20240430monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-earns-9-million-milestone-as-fda-grants-accelerated-approval-to-day-one-s-ojemda-tm-t-xomao-20240425monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlights-recent-and-xomao-20240308monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-enters-into-agreement-to-acquire-kinnate-biopharma-for-between-2-3352-and-2-5879-in-c-xomao-20240216monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-announces-stock-repurchase-program-of-up-to-50-million-balanced-capital-allocation-st-xomao-20240102monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-raises-up-to-140-million-in-non-dilutive-non-recourse-financing-from-funds-managed-by-xomao-20231219monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-third-quarter-2023-financial-results-and-highlights-upcoming-events-expected--xomao-20231107monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-second-quarter-2023-financial-results-and-provides-update-on-its-royalty-mone-xomao-20230808monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-first-quarter-2023-financial-results-and-provides-update-on-the-acceleration--xomao-20230509monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-full-year-2022-financial-results-and-provides-update-to-the-acceleration-of-i-xomao-20230309monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-third-quarter-2022-financial-results-and-highlights-recent-operational-events-xomao-20221103monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-second-quarter-2022-financial-results-and-highlights-recent-operational-event-xomao-20220804monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-first-quarter-2022-financial-results-and-highlights-recent-operational-events-xomao-20220505monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-full-year-2021-financial-results-and-highlights-recent-operational-events-ear-xomao-20220308monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-third-quarter-2021-financial-results-and-highlights-recent-operational-events-xomao-20211104monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-second-quarter-2021-financial-results-and-highlights-recent-operational-event-xomao-20210805monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-first-quarter-2021-financial-results-and-highlights-recent-operational-events-xomao-20210506monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-fourth-quarter-and-full-year-2020-financial-results-and-operating-highlights--xomao-20210310monthly0.5https://www.biopharmawatch.com/news/XOMAO/disclaimers-certain-statements-in-this-presentation-are-forward-looking-statements-within--xomao-20210105monthly0.5https://www.biopharmawatch.com/news/XOMAO/disclaimers-certain-statements-in-this-presentation-are-forward-looking-statements-within--xomao-20201211monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-highlights-recent-royalty-asset-portfolio-developments-and-reports-third-quarter-2020-xomao-20201105monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-earns-25-million-milestone-payment-as-anti-tgf-antibody-enters-phase-2-clinical-study-xomao-20201028monthly0.5https://www.biopharmawatch.com/news/XOMAO/corporate-presentation-a-royalty-aggregation-company-august-2020-nasdaq-xoma-1-disclaimers-xomao-20200811monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-second-quarter-2020-financial-results-partners-continue-to-advance-clinical-a-xomao-20200806monthly0.5https://www.biopharmawatch.com/news/XOMAO/disclaimers-certain-statements-in-this-presentation-are-forward-looking-statements-within--xomao-20200113monthly0.5https://www.biopharmawatch.com/news/XOMAO/form-of-instructions-as-to-use-of-xoma-corporation-subscription-rights-certificates-consul-xomao-20191202monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-announces-proposed-rights-offering-rights-offering-will-be-available-to-all-sharehold-xomao-20191120monthly0.5https://www.biopharmawatch.com/news/XOMAO/disclaimers-certain-statements-in-this-presentation-are-forward-looking-statements-within--xomao-20190311monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-fourth-quarter-and-full-year-2018-financial-results-and-operating-highlights--xomao-20190307monthly0.5https://www.biopharmawatch.com/news/XOMAO/certain-statements-in-this-presentation-are-forward-looking-statements-within-the-meaning--xomao-20190107monthly0.5https://www.biopharmawatch.com/news/XOMAO/form-of-instructions-as-to-use-of-xoma-corporation-subscription-rights-certificates-consul-xomao-20181119monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-announces-proposed-rights-offering-rights-offering-will-be-available-to-all-sharehold-xomao-20181107monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-third-quarter-2018-financial-results-xomao-20181107monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-acquires-royalty-interest-position-from-agenus-on-seven-assets-being-developed-by-mer-xomao-20180921monthly0.5https://www.biopharmawatch.com/news/XOMAO/corporate-presentation-with-over-35-years-of-discovery-activity-xoma-currently-has-over-th-xomao-20180814monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-first-quarter-2018-financial-results-current-cash-balance-sufficient-to-fund--xomao-20180509monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-business-upd-xomao-20180307monthly0.5https://www.biopharmawatch.com/news/XOMAO/forward-looking-statements-certain-statements-in-this-presentation-are-forward-looking-sta-xomao-20180108monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-third-quarter-2017-financial-results-validated-business-strategy-with-transfo-xomao-20171106monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-second-quarter-2017-financial-results-executing-new-corporate-strategy-levera-xomao-20170808monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-first-quarter-2017-financial-results-established-new-corporate-strategy-lever-xomao-20170509monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-fourth-quarter-and-full-year-2016-financial-results-actions-taken-in-2016-set-xomao-20170316monthly0.5https://www.biopharmawatch.com/news/XOMAO/cowen-company-37th-annual-health-care-conference-nasdaq-xoma-xomao-20170307monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-announces-up-to-22-million-generated-from-sale-of-royalty-streams-from-two-license-ag-xomao-20161221monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-announces-pricing-of-40-0-million-registered-offering-of-common-stock-and-warrants-xomao-20141209monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-reports-2013-operational-highlights-and-fourth-quarter-and-full-year-2013-financial-r-xomao-20140304monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-announces-perindopril-and-amlodipine-fixed-dose-combination-meets-primary-endpoint-in-xomao-20121120monthly0.5https://www.biopharmawatch.com/news/XOMAO/company-and-investor-contact-ashleigh-barreto-510-204-7482-barreto-xoma-com-juliane-snowde-xomao-20121003monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-announces-pricing-of-39-2-million-public-offering-of-common-stock-and-warrants-xomao-20120306monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-acquires-u-s-rights-to-perindopril-franchise-and-establishes-commercial-operations-be-xomao-20120117monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-secures-10-million-term-loan-xomao-20120103monthly0.5https://www.biopharmawatch.com/news/XOMAO/xoma-appoints-john-varian-as-chief-executive-officer-berkeley-ca-xomao-20120105monthly0.5https://www.biopharmawatch.com/news/CATX/redefining-oncology-treatment-with-next-generation-radiopharmaceuticals-engineering-the-al-catx-20260601monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-to-present-data-from-all-clinical-programs-at-the-2026-asco-annua-catx-20260522monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-1q-2026-results-x-catx-20260511monthly0.5https://www.biopharmawatch.com/news/CATX/agenda-engineering-the-alpha-advantage-in-targeted-oncology-optimizing-the-entire-system-e-catx-20260504monthly0.5https://www.biopharmawatch.com/news/CATX/percent-change-in-sum-of-diameters-from-baseline-0-1-2-3-4-5-0-8-16-24-32-40-48-56-64-72-8-catx-20260420monthly0.5https://www.biopharmawatch.com/news/CATX/redefining-oncology-treatment-with-next-generation-radiopharmaceuticals-why-radiotherapy-w-catx-20260401monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-full-year-2025-re-catx-20260316monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-announces-pricing-of-175-million-underwritten-offering-of-common--catx-20260202monthly0.5https://www.biopharmawatch.com/news/CATX/redefining-oncology-treatment-with-next-generation-radiopharmaceuticals-why-radiotherapy-w-catx-20260202monthly0.5https://www.biopharmawatch.com/news/CATX/redefining-oncology-treatment-with-next-generation-radiopharmaceuticals-why-radiotherapy-w-catx-20260114monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-business-updates-and-strategic-priorities-ahead-of-prese-catx-20260114monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-x3b1-net-in-its-ongoin-catx-20260109monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-developing-the-next-generation-of-targeted-therapies-higher-potency-catx-20251201monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-3q-2025-results-x-catx-20251110monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-november-2025-nyse-american-catx-this-presentation-contains-forward-catx-20251106monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-presents-updated-interim-data-from-its-ongoing-phase-1-2a-clinica-catx-20251020monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-developing-the-next-generation-of-targeted-therapies-higher-potency-catx-20251001monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-appoints-biotech-veteran-joel-sendek-as-chief-financial-officer-d-catx-20250904monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-appoints-maya-martinez-davis-to-board-of-directors-seattle-x2013-catx-20250903monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-developing-the-next-generation-of-targeted-therapies-higher-potency-catx-20250902monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2025-results-x-catx-20250813monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-developing-the-next-generation-of-targeted-therapies-higher-potency-catx-20250801monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-july-2025-nyse-american-catx-this-presentation-contains-forward-loo-catx-20250703monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-commences-recruitment-for-212-pb-vmt-x3b1-net-in-the-third-dose-e-catx-20250621monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-developing-the-next-generation-of-targeted-therapies-higher-potency-catx-20250603monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-highlights-updated-interim-data-from-its-ongoing-phase-1-2a-clini-catx-20250602monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-1q-2025-results-x-catx-20250512monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-developing-the-next-generation-of-targeted-therapies-higher-potency-catx-20250501monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-announces-first-patient-dosed-with-psv359-in-a-phase-1-2a-study-i-catx-20250429monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-announces-first-patient-dosed-with-212-pb-vmt01-monotherapy-at-1--catx-20250411monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-full-year-2024-re-catx-20250326monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-announces-first-patient-dosed-with-212-pb-vmt01-in-combination-wi-catx-20250317monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-developing-the-next-generation-of-targeted-therapies-radiopharmaceu-catx-20250304monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-february-2025-nyse-american-catx-this-presentation-contains-forward-catx-20250203monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-continues-to-pursue-dose-escalation-of-212-pb-vmt-x3b1-net-in-its-catx-20250124monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-business-updates-and-strategic-priorities-ahead-of-prese-catx-20241231monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-appoints-juan-graham-mba-as-chief-financial-officer-seattle-washi-catx-20250106monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-december-2024-nyse-american-catx-this-presentation-contains-forward-catx-20241204monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-to-pursue-dose-escalation-of-212-pb-vmt-x3b1-net-in-its-ongoing-p-catx-20241121monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-november-2024-nyse-american-catx-this-presentation-contains-forward-catx-20241115monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-fiscal-3q-2024-re-catx-20241112monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-to-advance-investigation-of-potential-first-in-class-radiopharmac-catx-20241011monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-granted-fast-track-designation-for-vmt01-for-the-diagnosis-and-tr-catx-20240905monthly0.5https://www.biopharmawatch.com/news/CATX/corporate-presentation-august-2024-nyse-catx-legal-disclaimers-this-presentation-contains--catx-20240813monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-fiscal-2q-2024-re-catx-20240812monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-announces-1-for-10-reverse-stock-split-seattle-washington-x2013-catx-20240611monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-announces-pricing-of-80-million-underwritten-offering-of-common-s-catx-20240524monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-to-present-at-the-society-of-nuclear-medicine-and-molecular-imagi-catx-20240520monthly0.5https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-reports-fiscal-q1-2024-re-catx-20240515monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-the-resignation-of-chairman-and-ceo-thomas-lavoy-industry-veteran-lori-wo-catx-20180605monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-fourth-quarter-fiscal-2017-revenue-of-1-37-million-22-fourth-quarter-over-catx-20170928monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-appointment-of-mark-austin-as-controller-principal-accounting-and-financi-catx-20170707monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-third-quarter-fiscal-2017-financial-results-revenue-increased-7-this-quar-catx-20170510monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-final-court-approval-of-class-action-settlement-settlement-fully-funded-b-catx-20170309monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-second-quarter-fiscal-2017-financial-results-management-continues-to-expe-catx-20170208monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-first-quarter-fiscal-2017-financial-results-management-continues-to-expec-catx-20161108monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-enters-into-agreement-to-settle-class-action-shareholder-litigation-final-settl-catx-20160927monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-fourth-quarter-and-year-end-fiscal-2016-financial-results-management-pres-catx-20160908monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-third-quarter-fiscal-2016-financial-results-and-early-conclusions-from-on-catx-20160510monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-reports-second-quarter-fiscal-2016-financial-results-12-revenue-growth-in-the-2-nd--catx-20160210monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-appoints-thomas-lavoy-as-ceo-to-take-office-on-february-15-richland-wa-catx-20160114monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-chairman-and-ceo-dwight-babcock-to-retire-tom-lavoy-elected-new-chairman-bill-cavan-catx-20160107monthly0.5https://www.biopharmawatch.com/news/CATX/first-quarter-fiscal-2016-financial-results-catx-20151110monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-9-revenue-increase-for-fiscal-year-2015-spurred-by-41-revenue-growth-in-catx-20150915monthly0.5https://www.biopharmawatch.com/news/CATX/appointment-of-new-director-catx-20150622monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-third-quarter-results-institutional-interest-on-the-rise-following-rece-catx-20150518monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-second-quarter-results-published-reports-confirm-cesium-131-is-a-true-s-catx-20150218monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-first-quarter-results-7-revenue-growth-in-prostate-cancer-cases-quarter-catx-20141117monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-fiscal-year-2014-results-reports-growing-list-of-major-accomplishments--catx-20140930monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-third-quarter-results-sales-continue-to-all-study-sites-beyond-planned--catx-20140516monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-prices-registered-direct-offering-of-common-stock-richland-wa-catx-20140321monthly0.5https://www.biopharmawatch.com/news/CATX/inc-catx-20140218monthly0.5https://www.biopharmawatch.com/news/CATX/fda-clears-isoray-s-liquid-cesium-cesitrex-for-use-with-gliasite-in-treating-glioblastomas-catx-20140107monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-first-quarter-results-13-revenue-growth-in-brain-lung-and-other-non-pro-catx-20131115monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-fiscal-year-2013-results-non-prostate-revenues-up-to-17-of-total-revenu-catx-20130930monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-contact-350-hills-street-suite-106-dwight-babcock-richland-wa-99354-chairman-ce-catx-20130828monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-third-quarter-results-28-increase-in-third-quarter-revenues-over-second-catx-20130515monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-second-quarter-results-14-of-revenue-attributed-to-non-prostate-cases-f-catx-20130214monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-first-quarter-results-garnering-new-cancer-treatment-revenues-remains-t-catx-20121114monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-fiscal-year-2012-results-non-prostate-revenues-up-75-to-14-of-total-rev-catx-20120928monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-financing-of-3-5-million-to-advance-its-gliasite-and-new-emerging-cancer--catx-20120716monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-inc-reports-third-quarter-results-significant-growth-in-non-prostate-sales-realized-catx-20120515monthly0.5https://www.biopharmawatch.com/news/CATX/sharon-schultz-tel-301-351-0109-email-schultzpr-mchsi-com-isoray-inc-reports-performance-f-catx-20120215monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-contact-sharon-schultz-tel-301-351-0109-email--catx-20111115monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-contact-sharon-schultz-tel-301-351-0109-email--catx-20111103monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-contact-sharon-schultz-tel-301-351-0109-email--catx-20111013monthly0.5https://www.biopharmawatch.com/news/CATX/sharon-schultz-tel-301-351-0109-email-schultzpr-mchsi-com-isoray-inc-reports-improved-perf-catx-20110928monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-contact-sharon-schultz-tel-301-351-0109-email--catx-20110607monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-contact-sharon-schultz-tel-301-351-0109-email--catx-20110516monthly0.5https://www.biopharmawatch.com/news/CATX/sharon-schultz-tel-301-351-0109-email-schultzpr-mchsi-com-isoray-inc-announces-second-quar-catx-20110215monthly0.5https://www.biopharmawatch.com/news/CATX/sharon-schultz-tel-301-351-0109-email-schultzpr-mchsi-com-isoray-inc-announces-financing-c-catx-20101122monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-contact-dwight-babcock-tel-520-240-4840-email--catx-20101116monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-contact-dwight-babcock-ceo-520-240-4840-dbabcock-isoray-com-isoray-i-catx-20100928monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-contact-sharon-schultz-tel-301-351-0109-email--catx-20100623monthly0.5https://www.biopharmawatch.com/news/CATX/brachytherapy-an-initial-report-catx-20100512monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-catx-20100217monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-press-releases-news-release-for-catx-20100216monthly0.5https://www.biopharmawatch.com/news/CATX/for-release-catx-20091116monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-news-release-for-catx-20090924monthly0.5https://www.biopharmawatch.com/news/CATX/for-release-catx-20090518monthly0.5https://www.biopharmawatch.com/news/CATX/for-release-catx-20090218monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-release-catx-20081113monthly0.5https://www.biopharmawatch.com/news/CATX/brachytherapy-an-initial-report-catx-20080820monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-release-catx-20080513monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-release-catx-20080227monthly0.5https://www.biopharmawatch.com/news/CATX/for-release-catx-20080211monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-catx-20071108monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-for-immediate-release-catx-20070328monthly0.5https://www.biopharmawatch.com/news/CATX/brachytherapy-an-initial-report-catx-20070323monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-isoray-incorporated-isry-ob-presentation-at-the-roth-capital-partner-catx-20060907monthly0.5https://www.biopharmawatch.com/news/CATX/isoray-announces-preliminary-fiscal-year-2006-results-and-projected-first-quarter-2007-sal-catx-20060906monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-isoray-announces-1st-round-of-institutional-financing-led-by-microca-catx-20060818monthly0.5https://www.biopharmawatch.com/news/CATX/unassociated-document-isoray-announces-record-seed-orders-and-resulting-impact-on-cash-res-catx-20060621monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-s-a-soci-t-anonyme-6-rue-jean-monnet-l-2180-luxembourg-grand-duchy-of-luxembourg-r-c--auna-20260527monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-1q26-financial-results-strong-top-line-growth-and-cash-flow-performance-con-auna-20260519monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-reports-preliminary-key-performance-indicators-for-the-first-quarter-ended-auna-20260331monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-4q25-and-fy25-financial-results-auna-closes-fy-2025-with-strong-performance-auna-20260310monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-and-essalud-finalize-addendum-to-commence-construction-of-torre-trecca-in-lima-which--auna-20260226monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-3q25-financial-results-auna-delivers-solid-financial-and-operating-performa-auna-20251120monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-strategic-collaboration-with-sojitz-to-expand-healthcare-access-in-latin-am-auna-20251120monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-completion-of-us-765-million-debt-refinancing-through-successful-issuance-o-auna-20251107monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-successful-pricing-of-8-750-senior-secured-notes-due-2032-luxembourg-auna-20251104monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-s-a-announces-early-results-of-its-cash-tender-offer-and-related-consent-solicitation-auna-20251103monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-proposed-offering-of-senior-secured-notes-due-2032-luxembourg-auna-20251028monthly0.5https://www.biopharmawatch.com/news/AUNA/of-our-report-on-form-6-k-a-which-was-furnished-to-the-sec-on-auna-20251028monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-s-a-and-subsidiaries-condensed-consolidated-interim-financial-statements-auna-20251028monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-a-auna-20251020monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-continues-to-increase-oncomexico-network-s-nationwide-presence-through-partnerships-w-auna-20250924monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-2q25-financial-results-adjusted-ebitda-increases-5-fxn-yoy-with-all-segment-auna-20250819monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-common-shares-begin-trading-on-the-lima-stock-exchange-to-strengthen-company-s-region-auna-20250716monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-provides-an-update-from-its-controlling-shareholder-enfoca-regarding-its-sponsor-leve-auna-20250630monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-s-a-soci-t-anonyme-6-rue-jean-monnet-l-2180-luxembourg-grand-duchy-of-luxembourg-r-c--auna-20250519monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-pricing-of-additional-10-000-senior-secured-notes-due-2029-luxembourg-auna-20250507monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-proposed-offering-of-additional-10-000-senior-secured-notes-due-2029-monter-auna-20250506monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-the-filing-of-its-form-20-f-for-fiscal-year-2024-luxembourg-business-wire-a-auna-20250411monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-4q24-and-fy-2024-financial-results-adjusted-ebitda-increases-20-1-fxn-in-fy-auna-20250310monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-signs-exclusive-five-year-agreement-with-leading-oncology-group-to-strengthen-oncolog-auna-20250307monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-the-successful-redemption-of-its-6-500-senior-secured-notes-due-2025-with-t-auna-20241223monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-appoints-teresa-gutierrez-and-guadalupe-phillips-to-its-board-of-directors-monterrey--auna-20241219monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-s-a-soci-t-anonyme-6-rue-jean-monnet-l-2180-luxembourg-grand-duchy-of-luxembourg-r-c--auna-20241202monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-3q24-financial-results-adjusted-ebitda-increases-23-yoy-fxn-maintaining-str-auna-20241119monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-appoints-executive-vice-president-strategy-and-equity-capital-markets-reinforcing-its-auna-20240903monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-2q24-financial-results-adjusted-ebitda-increases-31-yoy-consolidating-stron-auna-20240821monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-s-a-soci-t-anonyme-6-rue-jean-monnet-l-2180-luxembourg-grand-duchy-of-luxembourg-r-c--auna-20240717monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-s-a-separate-financial-statements-auna-20240703monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-1q24-financial-results-revenue-increases-20-yoy-to-s-1-076-million-with-ope-auna-20240522monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-reporting-dates-for-first-quarter-2024-financial-results-luxembourg-grand-d-auna-20240508monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-provides-business-update-related-to-colombian-operations-colombia-s-healthcare-servic-auna-20240415monthly0.5https://www.biopharmawatch.com/news/AUNA/auna-announces-pricing-of-initial-public-offering-of-us-360-million-gross-proceeds-of-clas-auna-20240321monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-provides-update-on-financial-reporting-and-announces-fourth-quarter-and-fisc-cgc-20260515monthly0.5https://www.biopharmawatch.com/news/CGC/this-news-release-constitutes-a-designated-news-release-for-the-purposes-of-canopy-growth--cgc-20260316monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-third-quarter-fiscal-2026-financial-results-delivers-double-digit-ne-cgc-20260206monthly0.5https://www.biopharmawatch.com/news/CGC/this-news-release-constitutes-a-designated-news-release-for-the-purposes-of-canopy-growth--cgc-20260108monthly0.5https://www.biopharmawatch.com/news/CGC/this-news-release-constitutes-a-designated-news-release-for-the-purposes-of-canopy-growth--cgc-20251215monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-second-quarter-fiscal-2026-financial-results-company-continues-to-st-cgc-20251107monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-appoints-tom-stewart-as-chief-financial-officer-appointment-finalizes-cfo-tr-cgc-20250917monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-establishes-new-us-200-million-at-the-market-program-to-strengthen-the-compa-cgc-20250829monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-first-quarter-fiscal-2026-financial-results-cannabis-revenue-increas-cgc-20250808monthly0.5https://www.biopharmawatch.com/news/CGC/this-news-release-constitutes-a-designated-news-release-for-the-purposes-of-canopy-growth--cgc-20250729monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-appoints-tom-stewart-as-interim-chief-financial-officer-appointment-reflects-cgc-20250709monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-fourth-quarter-and-fiscal-year-2025-financial-results-canada-cannabi-cgc-20250530monthly0.5https://www.biopharmawatch.com/news/CGC/this-news-release-constitutes-a-designated-news-release-for-the-purposes-of-canopy-growth--cgc-20250401monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-third-quarter-fiscal-year-2025-financial-results-strong-holiday-sale-cgc-20250207monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-acreage-confirm-canopy-usa-s-completed-acquisition-of-acreage-canopy-usa-cgc-20241209monthly0.5https://www.biopharmawatch.com/news/CGC/this-news-release-constitutes-a-designated-news-release-for-the-purposes-of-canopy-growth--cgc-20241126monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-second-quarter-fiscal-year-2025-financial-results-storz-bickel-net-r-cgc-20241108monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-further-improves-balance-sheet-with-early-prepayment-to-reduce-term-loan-by--cgc-20241017monthly0.5https://www.biopharmawatch.com/news/CGC/this-news-release-constitutes-a-designated-news-release-for-the-purposes-of-canopy-growth--cgc-20240816monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-first-quarter-fiscal-year-2025-financial-results-focus-on-profitable-cgc-20240809monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-exercise-of-acreage-options-paving-the-way-for-acquisition-by-cano-cgc-20240604monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-fourth-quarter-and-fiscal-year-2024-financial-results-q4-fy2024-net--cgc-20240530monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-financing-to-further-strengthen-balance-sheet-including-approximat-cgc-20240503monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-cbi-conversion-to-exchangeable-shares-and-newly-constituted-board--cgc-20240418monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-results-of-special-meeting-of-shareholders-shareholders-overwhelmi-cgc-20240415monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-third-quarter-fiscal-year-2024-financial-results-achieves-third-quar-cgc-20240209monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-upsized-us-35-million-private-placement-cgc-20240118monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-effective-date-of-share-consolidation-shares-will-be-consolidated--cgc-20231213monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-second-quarter-fiscal-year-2024-financial-results-strong-execution-d-cgc-20231109monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-completes-sale-of-hershey-drive-facility-facility-sold-to-hershey-canada-inc-cgc-20231002monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-private-placement-of-up-to-us-50-million-cgc-20230918monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-cease-funding-biosteel-business-unit-furthering-business-transformation-a-cgc-20230914monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-enters-into-an-agreement-for-the-sale-of-hershey-drive-facility-in-smiths-fa-cgc-20230817monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-first-quarter-fiscal-year-2024-financial-results-net-revenue-in-q1-f-cgc-20230809monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-enhances-financial-flexibility-and-delevers-company-balance-sheet-by-437-mil-cgc-20230714monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-equitization-of-c-12-5-million-of-notes-due-in-july-2023-cgc-20230630monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-fourth-quarter-and-fiscal-year-2023-financial-results-business-trans-cgc-20230622monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-refinancing-of-c-100-million-of-notes-due-2023-smiths-falls-ontari-cgc-20230414monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-us-150-cgc-20230221monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-third-quarter-fiscal-year-2023-financial-results-and-announces-canad-cgc-20230209monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-completes-divestiture-of-canadian-retail-operations-transaction-supports-the-cgc-20230103monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-reports-second-quarter-fiscal-year-2023-financial-results-cgc-20221109monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-fast-track-entry-into-the-u-s-cannabis-market-creation-of-u-s-holding-com-cgc-20221025monthly0.5https://www.biopharmawatch.com/news/CGC/project-fission-press-release-canopy-growth-announces-divestiture-of-canadian-retail-opera-cgc-20220927monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-reports-first-quarter-fiscal-year-2023-financial-results-continu-cgc-20220805monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-exchanges-with-holders-of-approximately-us-198-million-of-converti-cgc-20220629monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-reports-fourth-quarter-and-fiscal-year-2022-financial-results-co-cgc-20220527monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-plan-to-acquire-jetty-extracts-broadens-canopy-growth-s-portfolio--cgc-20220518monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-cost-reduction-actions-to-accelerate-path-to-profitability-strateg-cgc-20220426monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-leadership-appointments-and-addition-of-strategic-executive-resour-cgc-20220331monthly0.5https://www.biopharmawatch.com/news/CGC/s-m-i-t-hs-f-a-ll-s-on-february-9-2-0-22-pr-n-ew-s-w-i-r-e-c-a-n-op-y-g-r-o-w-t-h-c-o-r-po-cgc-20220209monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-divests-pharmaceutical-c3-cannabinoid-compound-company-sale-supports-the-com-cgc-20211215monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-changes-to-executive-management-team-changes-are-designed-to-drive-cgc-20211119monthly0.5https://www.biopharmawatch.com/news/CGC/s-m-i-t-hs-f-a-ll-s-on-november-5-2-0-21-pr-n-ew-s-w-i-r-e-c-a-n-op-y-g-r-o-w-t-h-c-o-r-po-cgc-20211105monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-plan-to-acquire-wana-brands-the-1-cannabis-edibles-brand-in-north--cgc-20211014monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-first-quarter-fiscal-2022-cgc-20210806monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-completes-acquisition-of-supreme-acquisition-solidifies-canopy-growth-s-lead-cgc-20210623monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-fourth-quarter-and-fiscal-year-2021-financial-results-achieves-37-re-cgc-20210601monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-acquire-the-supreme-cannabis-company-toronto-and-cgc-20210408monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-us-750-million-term-loan-financing-provides-further-balance-sheet--cgc-20210318monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-closing-of-plan-of-arrangement-involving-riv-capital-canopy-growth-cgc-20210223monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-third-quarter-fiscal-2021-financial-results-business-transformation--cgc-20210209monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-plan-of-arrangement-with-canopy-rivers-canopy-growth-to-receive-ex-cgc-20201221monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-changes-to-canadian-operations-cgc-20201209monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-second-quarter-fiscal-2021-financial-results-achieved-record-quarter-cgc-20201109monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-acreage-implement-amended-arrangement-cgc-20200923monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-first-quarter-fiscal-2021-financial-results-transformation-strategy--cgc-20200810monthly0.5https://www.biopharmawatch.com/news/CGC/notice-to-reader-as-of-cgc-20200710monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-acreage-holdings-agree-to-modify-plan-of-arrangement-as-canopy-growth-s-u-s--cgc-20200625monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-full-year-and-4th-quarter-fiscal-2020-financial-results-provides-str-cgc-20200529monthly0.5https://www.biopharmawatch.com/news/CGC/constellation-brands-exercises-warrants-to-acquire-shares-in-canopy-growth-reinforcing-con-cgc-20200501monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-changes-to-global-operations-to-drive-strategic-focus-these-action-cgc-20200416monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-changes-to-its-board-of-directors-terry-yanofsky-and-david-lazzara-cgc-20200401monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-temporarily-close-corporate-owned-retail-amid-response-to-covid-19-cgc-20200317monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-terrascend-canada-enter-debt-financing-arrangement-canopy-growth-complet-cgc-20200311monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-production-optimization-plan-in-canada-the-company-announces-the-c-cgc-20200304monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-third-quarter-fiscal-2020-financial-results-generated-124-million-ne-cgc-20200214monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-condensed-interim-consolidated-financial-statements-unaudited-fo-cgc-20200214monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-announce-third-quarter-fiscal-2020-financial-results-cgc-20200207monthly0.5https://www.biopharmawatch.com/news/CGC/tweed-collective-accepting-project-applications-to-support-communities-across-canada-appli-cgc-20200123monthly0.5https://www.biopharmawatch.com/news/CGC/judy-schmeling-appointed-as-chair-of-the-canopy-growth-board-of-directors-and-jim-sabia-ap-cgc-20200122monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-revises-beverage-launch-timeline-cgc-20200117monthly0.5https://www.biopharmawatch.com/news/CGC/ten-tokyo-smoke-licensee-retail-cannabis-stores-to-open-in-ontario-in-early-2020-cgc-20200106monthly0.5https://www.biopharmawatch.com/news/CGC/form-51-102f3-material-change-report-item-1-name-and-address-of-company-canopy-growth-corp-cgc-20191208monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-introduces-first-free-a-line-of-branded-hemp-derived-cbd-products-to-the-u-s-cgc-20191212monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-david-klein-as-new-chief-executive-officer-mark-zekulin-to-step-do-cgc-20191209monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-provides-update-on-2-0-product-rollout-cgc-20191206monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-awarded-for-corporate-culture-and-marketing-excellence-cgc-20191202monthly0.5https://www.biopharmawatch.com/news/CGC/tweed-collective-seeks-community-initiatives-across-canada-cgc-20191202monthly0.5https://www.biopharmawatch.com/news/CGC/five-new-tokyo-smoke-licensee-retail-locations-advance-in-ontario-public-process-cgc-20191128monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-outlines-cannabis-2-0-portfolio-cgc-20191127monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-expands-investor-relations-team-with-appointment-of-wall-street-equity-resea-cgc-20191126monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-receives-health-canada-licence-for-state-of-the-art-beverage-facility-canopy-cgc-20191125monthly0.5https://www.biopharmawatch.com/news/CGC/bc-centre-on-substance-use-hosts-inaugural-cannabis-science-symposium-vancouver-cgc-20191125monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-comments-on-class-securities-litigation-cgc-20191121monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-reports-second-quarter-fiscal-2020-financial-results-cgc-20191114monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-condensed-interim-consolidated-financial-statements-unaudited-fo-cgc-20191114monthly0.5https://www.biopharmawatch.com/news/CGC/canadian-icons-come-together-canopy-growth-and-drake-launch-new-cannabis-wellness-company--cgc-20191107monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-announce-second-quarter-fiscal-2020-financial-results-cgc-20191105monthly0.5https://www.biopharmawatch.com/news/CGC/fashion-meets-flower-with-holt-renfrew-x-tokyo-smoke-holiday-collaboration-toronto-and-van-cgc-20191101monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-therapeutics-and-tree-of-knowledge-announce-partnership-to-educate-and-support-he-cgc-20191030monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-launches-27th-retail-banner-location-welcome-tokyo-smoke-brandon-manitoba-cgc-20191018monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-completes-previously-announced-acquisition-of-beckley-canopy-therapeutics-sm-cgc-20191015monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-sale-of-stake-in-auscann-the-companies-will-continue-to-collaborat-cgc-20191015monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-new-chair-of-the-board-of-directors-cgc-20191010monthly0.5https://www.biopharmawatch.com/news/CGC/tweed-terracycle-celebrate-over-one-million-pieces-of-cannabis-packaging-collected-for-rec-cgc-20191009monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-purchase-of-majority-stake-in-biosteel-sports-nutrition-inc-smiths-cgc-20191002monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-therapeutics-announces-donation-to-support-research-and-education-initiatives-led-cgc-20190926monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-election-of-board-of-directors-cgc-20190917monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-receives-key-extraction-licence-cgc-20190820monthly0.5https://www.biopharmawatch.com/news/CGC/notice-of-meeting-and-management-information-circular-for-the-annual-general-meeting-of-sh-cgc-20190816monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-drives-revenue-with-94-increase-in-recreational-dried-cannabis-sales-in-firs-cgc-20190814monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-condensed-interim-consolidated-financial-statements-unaudited-fo-cgc-20190814monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-strengthens-position-as-global-cannabis-research-leader-by-entering-agreemen-cgc-20190809monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-greenlane-announce-exclusive-distribution-partnership-for-storz-bickel-v-cgc-20190808monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-therapeutics-announces-strategic-patient-support-and-education-partnership-with-m-cgc-20190808monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-notice-notice-is-hereby-given-that-a-special-meeting-the-meeting-cgc-20190801monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-announce-first-quarter-fiscal-2020-financial-results-cgc-20190730monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-therapeutics-partners-with-canadian-mental-health-association-s-not-myself-today--cgc-20190710monthly0.5https://www.biopharmawatch.com/news/CGC/form-51-102f3-material-change-report-item-1-name-and-address-of-company-canopy-growth-corp-cgc-20190702monthly0.5https://www.biopharmawatch.com/news/CGC/form-51-102f3-material-change-report-item-1-name-and-address-of-corporation-canopy-growth--cgc-20190627monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-leadership-transition-bruce-linton-to-step-down-as-co-ceo-and-cano-cgc-20190703monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-acreage-implement-previously-announced-plan-of-arrangement-smiths-falls--cgc-20190627monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-acquisition-of-keyleaf-life-sciences-to-support-long-term-major-sc-cgc-20190626monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-adds-substantial-production-capacity-in-canada-after-receiving-licence-for-n-cgc-20190624monthly0.5https://www.biopharmawatch.com/news/CGC/acreage-obtains-final-order-for-plan-of-arrangement-with-canopy-growth-and-confirms-record-cgc-20190621monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-consolidated-financial-statements-for-the-years-ended-march-31-2-cgc-20190621monthly0.5https://www.biopharmawatch.com/news/CGC/tweed-joins-pride-toronto-to-support-progress-champion-diversity-and-celebrate-love-smiths-cgc-20190621monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-reports-fourth-quarter-and-fiscal-2019-results-with-annual-sales-cgc-20190621monthly0.5https://www.biopharmawatch.com/news/CGC/special-meeting-of-shareholders-of-canopy-growth-corporation-the-company-cgc-20190619monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-shareholder-approval-in-connection-with-the-proposed-acquisition-o-cgc-20190619monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-provides-update-on-international-operations-and-activities-company-enters-mu-cgc-20190617monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-acreage-holdings-remind-shareholders-to-vote-for-canopy-growth-s-plan-to-cgc-20190617monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-announce-fourth-quarter-and-fiscal-year-2019-financial-results-cgc-20190607monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-therapeutics-provides-update-on-its-global-clinical-research-program-and-unveils--cgc-20190605monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-subsidiary-and-canopy-rivers-portfolio-company-vert-mirabel-now-fully-licens-cgc-20190528monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-collaborates-with-parent-action-on-drugs-to-launch-digital-cannabis-educatio-cgc-20190528monthly0.5https://www.biopharmawatch.com/news/CGC/execution-version-first-amendment-to-arrangement-agreement-this-amendment-is-made-as-of-cgc-20190515monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-acreage-holdings-announce-filing-of-management-information-circulars-rel-cgc-20190523monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-acquires-established-skincare-and-well-being-company-this-works-london-based-cgc-20190522monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-appoints-mike-lee-as-acting-chief-financial-officer-the-company-and-board-of-cgc-20190521monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-offtake-agreement-with-pharmhouse-cgc-20190509monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-introduces-spectrum-therapeutics-cgc-20190507monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-acquires-germany-s-c3-cannabinoid-compound-company-founded-by-top-global-her-cgc-20190502monthly0.5https://www.biopharmawatch.com/news/CGC/form-51-102f3-material-change-report-item-1-name-and-address-of-corporation-canopy-growth--cgc-20190418monthly0.5https://www.biopharmawatch.com/news/CGC/new-york-hemp-industrial-park-update-canopy-growth-will-transform-the-appropriately-spotle-cgc-20190429monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-plan-to-acquire-leading-u-s-multi-state-cannabis-operator-acreage--cgc-20190418monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-cannabis-and-the-arthritis-society-team-up-to-launch-arthritis-talks-a-national-s-cgc-20190425monthly0.5https://www.biopharmawatch.com/news/CGC/tweed-and-terracycle-team-up-to-take-cannabis-packaging-recycling-program-across-canada-cgc-20190422monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-expands-european-footprint-acquires-spanish-licensed-cannabis-producer-cafin-cgc-20190416monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-join-the-s-p-tsx-60-index-cgc-20190412monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-cannabis-announces-partnership-with-carp-toronto-and-cgc-20190412monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-welcomes-houseplant-to-the-family-vancouver-cgc-20190327monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-receives-new-health-canada-licence-in-atlantic-canada-that-will-boost-output-cgc-20190325monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-acquires-hemp-company-to-accelerate-expansion-in-the-united-states-hemp-pion-cgc-20190321monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-multi-year-extraction-agreement-with-victoria-based-hollyweed-nort-cgc-20190320monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-dna-genetics-extend-and-expand-relationship-smiths-falls-on-and-cgc-20190319monthly0.5https://www.biopharmawatch.com/news/CGC/nhl-alumni-association-teams-up-with-canopy-growth-to-research-concussions-and-cannabinoid-cgc-20190302monthly0.5https://www.biopharmawatch.com/news/CGC/media-advisory-nhl-alumni-association-neeka-healthcare-canada-and-canopy-growth-team-up-fo-cgc-20190301monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-sequential-brands-group-announce-collaboration-on-cbd-product-developmen-cgc-20190228monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-names-cannabis-trailblazer-hilary-black-as-chief-advocacy-officer-cgc-20190225monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-appoints-dr-danial-schecter-as-director-global-medical-services-cgc-20190222monthly0.5https://www.biopharmawatch.com/news/CGC/alimentation-couche-tard-and-canopy-growth-to-support-cannabis-retail-in-london-ontario-la-cgc-20190221monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-amended-and-restated-management-s-discussion-and-analysis-of-the-cgc-20190221monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-files-amended-and-restated-third-quarter-md-a-cgc-20190220monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-reports-third-quarter-fiscal-2019-financial-results-gross-sales--cgc-20190214monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-condensed-interim-consolidated-financial-statements-unaudited-fo-cgc-20190215monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-inject-30-million-in-additional-capital-into-canopy-rivers-inc-cgc-20190207monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-biomedical-uk-opens-new-chapter-for-medicinal-cannabis-industry-cgc-20190121monthly0.5https://www.biopharmawatch.com/news/CGC/european-update-spectrum-cannabis-enters-uk-poland-high-quality-medical-cannabis-available-cgc-20190121monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-announce-third-quarter-fiscal-2019-financial-results-cgc-20190115monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-receives-new-york-state-hemp-licence-and-will-establish-u-s-based-commercial-cgc-20190114monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-latam-starting-the-year-strong-opening-new-markets-supporting-education-and-achievi-cgc-20190109monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-outlines-its-cbd-advantage-cgc-20190108monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-comments-on-the-farm-bill-cgc-20181220monthly0.5https://www.biopharmawatch.com/news/CGC/explanatory-note-this-amended-and-restated-business-acquisition-report-the-amended-and-res-cgc-20181220monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-multi-year-extraction-agreement-with-valens-groworks-cgc-20181213monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-announces-final-results-of-its-offer-to-purchase-convertible-not-cgc-20181206monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-acquires-storz-bickel-transaction-brings-together-world-s-most-technological-cgc-20181206monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-canopy-rivers-announce-completion-of-terrascend-restructuring-toronto-cgc-20181130monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-equity-investment-supply-deal-and-strategic-partnership-with-48nor-cgc-20181203monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-completes-strategic-extract-supply-agreement-with-medipharm-labs-smiths-fall-cgc-20181129monthly0.5https://www.biopharmawatch.com/news/CGC/battelle-and-canopy-growth-announce-strategic-collaboration-to-advance-cannabis-research-c-cgc-20181127monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-completes-ebbu-asset-acquisition-cgc-20181126monthly0.5https://www.biopharmawatch.com/news/CGC/professor-of-cannabis-science-announced-to-research-the-role-of-cannabis-in-opioid-overdos-cgc-20181123monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-cannabis-joins-cannabis-standard-the-evidence-based-medical-cannabis-formulary-fo-cgc-20181120monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-reports-second-quarter-fiscal-2019-financial-results-the-company-cgc-20181114monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-condensed-interim-consolidated-financial-statements-unaudited-fo-cgc-20181115monthly0.5https://www.biopharmawatch.com/news/CGC/form-51-102f4-business-acquisition-report-item-1-identity-of-company-1-1-name-and-address--cgc-20181114monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-brink-s-announce-partnership-cgc-20181108monthly0.5https://www.biopharmawatch.com/news/CGC/fundamental-change-notice-notice-of-right-to-convert-notice-of-make-whole-fundamental-chan-cgc-20181102monthly0.5https://www.biopharmawatch.com/news/CGC/constellation-brands-5-billion-cad-4-billion-usd-investment-in-canopy-growth-closes-follow-cgc-20181101monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-cannabis-welcomes-jwc-dried-cannabis-products-to-its-online-platform-diversified--cgc-20181101monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-issues-shares-to-acquire-stake-in-manitoba-retail-business-october-25-th-201-cgc-20181025monthly0.5https://www.biopharmawatch.com/news/CGC/caitlin-o-hara-media-relations-caitlin-ohara-canopygrowth-com-613-291-3239-about-tweed-twe-cgc-20181030monthly0.5https://www.biopharmawatch.com/news/CGC/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-cgc-20181024monthly0.5https://www.biopharmawatch.com/news/CGC/form-51-102f3-material-change-report-item-1-name-and-address-of-company-canopy-growth-corp-cgc-20181024monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-celebrates-history-and-the-legalization-of-recreational-cannabis-in-canada-s-cgc-20181017monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-introduces-lbs-brand-to-canada-cgc-20181016monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-announce-second-quarter-fiscal-2019-financial-results-cgc-20181015monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-acquire-assets-of-colorado-based-hemp-innovator-ebbu-cgc-20181015monthly0.5https://www.biopharmawatch.com/news/CGC/notice-of-change-of-auditor-to-kpmg-llp-and-to-deloitte-llp-cc-ontario-securities-commissi-cgc-20181004monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-increases-licensed-platform-4-3-million-square-feet-now-licensed-across-cana-cgc-20181009monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-completes-first-legal-medical-cannabis-export-from-canada-to-the-united-stat-cgc-20181009monthly0.5https://www.biopharmawatch.com/news/CGC/notice-regarding-forward-looking-statements-this-news-release-contains-forward-looking-sta-cgc-20181009monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-provides-comments-on-ontario-retail-bc-production-first-recreational-shipmen-cgc-20180927monthly0.5https://www.biopharmawatch.com/news/CGC/organigram-canopy-growth-partner-in-newfoundland-and-labrador-by-signing-supply-agreement--cgc-20180920monthly0.5https://www.biopharmawatch.com/news/CGC/approval-matters-votes-for-votes-for-votes-against-votes-against-the-transaction-resolutio-cgc-20180927monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-shareholders-approve-5b-cad-4b-usd-investment-by-constellation-brands-cgc-20180926monthly0.5https://www.biopharmawatch.com/news/CGC/another-exciting-step-towards-legalization-tweed-retail-is-coming-to-manitoba-cgc-20180924monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-filing-of-early-warning-report-in-connection-with-closing-of-canop-cgc-20180919monthly0.5https://www.biopharmawatch.com/news/CGC/notice-to-holders-canopy-growth-corporation-4-25-convertible-senior-notes-due-2023-cusip-n-cgc-20180919monthly0.5https://www.biopharmawatch.com/news/CGC/form-51-102f4-business-acquisition-report-item-1-identity-of-company-1-1-name-and-address--cgc-20180919monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-hiku-announce-closing-of-acquisition-smiths-falls-on-and-toronto-cgc-20180905monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-receives-amended-licences-from-health-canada-new-automated-distribution-cent-cgc-20180821monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-secures-over-100-cgc-20180820monthly0.5https://www.biopharmawatch.com/news/CGC/or-at-all-and-other-factors-and-uncertainties-disclosed-from-time-to-time-in-constellation-cgc-20180815monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-reports-first-quarter-fiscal-2019-financial-results-continued-re-cgc-20180815monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-condensed-interim-consolidated-financial-statements-unaudited-fo-cgc-20180815monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-extends-existing-commercial-agreement-cgc-20180814monthly0.5https://www.biopharmawatch.com/news/CGC/spectrum-cannabis-introduces-first-of-its-kind-catalyst-peer-mentorship-program-cgc-20180810monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-further-consolidation-of-latin-america-assets-with-full-acquisitio-cgc-20180809monthly0.5https://www.biopharmawatch.com/news/CGC/caitlin-o-hara-media-relations-caitlin-ohara-canopygrowth-com-613-291-3239-about-tweed-twe-cgc-20180809monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-announces-revised-schedule-for-first-quarter-fiscal-2019-cgc-20180807monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-strengthens-commitment-to-cannabis-based-cgc-20180807monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-to-announce-first-quarter-fiscal-2019-cgc-20180801monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-announces-results-of-special-shareholder-meeting-acquisition-of--cgc-20180731monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-acquire-hiku-brands-to-strengthen-retail-and-brand-portfolio-cgc-20180710monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-calls-new-brunswick-home-company-plans-to-create-136-high-quality-local-jobs-cgc-20180706monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-introduces-latin-american-subsidiary-canopy-latam-and-announces-the-acquisit-cgc-20180705monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-enters-supply-agreement-with-the-alberta-gaming-liquor-cgc-20180705monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-acquires-outstanding-shares-in-bc-tweed-joint-venture-july-5-2018-smiths-fal-cgc-20180706monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-applauds-health-canada-s-approach-to-cannabis-regulation-cgc-20180628monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-president-and-co-ceo-mark-zekulin-named-to-canada-s-top-40-under-40-cgc-20180627monthly0.5https://www.biopharmawatch.com/news/CGC/dated-june-27-2018-ex-99-1-canopy-growth-corporation-reports-fourth-quarter-and-fiscal-yea-cgc-20180627monthly0.5https://www.biopharmawatch.com/news/CGC/building-the-west-coast-team-and-welcoming-kirk-tousaw-and-mat-beren-to-the-canopy-growth--cgc-20180625monthly0.5https://www.biopharmawatch.com/news/CGC/execution-version-canopy-growth-corporation-glas-trust-company-llc-as-u-s-trustee-and-comp-cgc-20180620monthly0.5https://www.biopharmawatch.com/news/CGC/major-operational-milestones-for-spectrum-cannabis-in-europe-cgc-20180625monthly0.5https://www.biopharmawatch.com/news/CGC/caitlin-o-hara-media-relations-caitlin-ohara-canopygrowth-com-613-291-3239-investor-relati-cgc-20180625monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-announces-exercise-and-closing-of-over-allotment-option-cgc-20180622monthly0.5https://www.biopharmawatch.com/news/CGC/and-now-this-cgc-20180620monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-completes-c-500-cgc-20180620monthly0.5https://www.biopharmawatch.com/news/CGC/forward-looking-statement-this-news-release-contains-forward-looking-statements-within-the-cgc-20180620monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-corporation-announces-offering-of-c-400-0-million-of-convertible-senior-note-cgc-20180613monthly0.5https://www.biopharmawatch.com/news/CGC/medical-cannabis-leadership-from-canopy-growth-and-subsidiary-spectrum-cannabis-clinical-t-cgc-20180612monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-and-molecular-science-corp-announce-collaboration-to-advance-cannabis-testin-cgc-20180607monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-to-fund-professorship-of-cannabis-science-at-university-of-british-columbia--cgc-20180606monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-five-retail-locations-in-saskatchewan-tweed-online-store-to-serve--cgc-20180601monthly0.5https://www.biopharmawatch.com/news/CGC/organizations-in-the-medical-cannabis-industry-in-recognition-of-his-work-on-behalf-of-med-cgc-20180601monthly0.5https://www.biopharmawatch.com/news/CGC/dr-mark-ware-joins-canopy-growth-corporation-as-chief-medical-officer-may-28-th-2018-smith-cgc-20180530monthly0.5https://www.biopharmawatch.com/news/CGC/vert-is-growing-again-health-canada-grants-licence-to-vert-mirabel-cgc-20180527monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-growth-announces-inaugural-trading-date-on-the-new-york-stock-exchange-cgc-20180523monthly0.5https://www.biopharmawatch.com/news/CGC/canopy-rivers-pitch-day-micro-cannabis-macro-impact-invites-cannabis-entrepreneurs-to-shar-cgc-20180516monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-closing-for-130-0-million-of-6-75-convertible-senior-notes-includes-f-ocgn-20260514monthly0.5https://www.biopharmawatch.com/news/OCGN/excerpts-from-preliminary-offering-memorandum-overview-we-are-a-biotechnology-company-focu-ocgn-20260504monthly0.5https://www.biopharmawatch.com/news/OCGN/in-the-court-of-chancery-of-the-state-of-delaware-in-re-ocugen-inc-c-a-no-2026-verified-pe-ocgn-20260304monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-20-million-registered-direct-offering-of-common-stock-and-warrants-ma-ocgn-20250808monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-second-quarter-2025-financial-results-conference-call-ocgn-20250801monthly0.5https://www.biopharmawatch.com/news/OCGN/carisma-therapeutics-and-orthocellix-enter-into-definitive-merger-agreement-to-create-comp-ocgn-20250623monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-signing-of-binding-term-sheet-for-the-license-of-ocu400-modifier-gene-ocgn-20250605monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn20250509ex991-ocugen-provides-business-update-with-first-quarter-2025-financial-result-ocgn-20250509monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-fourth-quarter-and-full-year-2024-financial-results-c-ocgn-20250305monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-secures-30-million-in-debt-funding-malvern-pa-ocgn-20241107monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-third-quarter-2024-financial-results-conference-call--ocgn-20241108monthly0.5https://www.biopharmawatch.com/news/OCGN/courageous-innovation-dedicated-to-bringing-game-changing-gene-cell-therapies-and-vaccines-ocgn-20240813monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-second-quarter-2024-financial-results-conference-call-ocgn-20240808monthly0.5https://www.biopharmawatch.com/news/OCGN/web-8-4-24-1-09-pm-https-distribute-notified-com-preview-pnrarticlepreview-r-7184972-l-eng-ocgn-20240804monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-proposed-public-offering-of-common-stock-ocgn-20240731monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-first-quarter-2024-financial-results-conference-call--ocgn-20240514monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-u-s-fda-clearance-of-ind-amendment-to-initiate-ocu400-phase-3-clinica-ocgn-20240408monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-certain-financials-for-the-year-ending-2023-conferenc-ocgn-20240402monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-appoints-huma-qamar-md-mph-as-chief-medical-officer-malvern-pa-ocgn-20240318monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20240221xex991-courageous-innovation-clinical-showcase-ocgn-20240221monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-gains-fda-alignment-on-key-aspects-of-ocu400-modifier-gene-therapy-pivotal-phase-3--ocgn-20231221monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20231109xex991-courageous-innovation-dedicated-to-bringing-game-changing-gene-cell-th-ocgn-20231109monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-third-quarter-2023-financial-results-conference-call--ocgn-20231109monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-mucosal-vaccine-candidate-ocu500-selected-by-nih-niaid-project-nextgen-for-inclusio-ocgn-20231010monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-positive-clinical-study-update-from-the-phase-1-2-trial-of-ocu400-a-modif-ocgn-20230913monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20230822xex991-2-improved-visual-outcomes-and-quality-of-life-gene-x-gene-m-cell-nr2e-ocgn-20230822monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-second-quarter-2023-financial-results-conference-call-ocgn-20230821monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20230605xex991-bio-corporate-presentation-quan-vu-cfo-cbo-bio-international-2023-2-2b-ocgn-20230605monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20230505xex991-courageous-innovation-may-2023-nasdaq-ocgn-forward-looking-statements--ocgn-20230505monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-first-quarter-2023-financial-results-conference-call--ocgn-20230505monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-positive-preliminary-safety-and-efficacy-results-from-the-phase-1-2-trial-ocgn-20230414monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20230313xex991-courageous-innovation-march-2023-nasdaq-ocgn-forward-looking-statement-ocgn-20230313monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-fourth-quarter-and-full-year-2022-financial-results-c-ocgn-20230228monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20230206xex991-courageous-innovation-february-2023-nasdaq-ocgn-forward-looking-statem-ocgn-20230206monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20230109xex991-courageous-innovation-january-2023-nasdaq-ocgn-forward-looking-stateme-ocgn-20230109monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-positive-top-line-data-for-covid-19-vaccine-candidate-covaxin-bbv152-in-p-ocgn-20230109monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leb-ocgn-20221215monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20221108xex991-courageous-innovation-november-2022-nasdaq-ocgn-forward-looking-statem-ocgn-20221108monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-third-quarter-2022-financial-results-conference-call-and-w-ocgn-20221108monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20221101xex991-long-term-outlook-shankar-musunuri-phd-mba-chairman-of-the-board-ceo-c-ocgn-20221101monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunolog-ocgn-20220914monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220826xex991-courageous-innovation-august-2022-nasdaq-ocgn-forward-looking-statemen-ocgn-20220826monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220817xex991-courageous-innovation-august-2022-nasdaq-ocgn-forward-looking-statemen-ocgn-20220817monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220816xex991-courageous-innovation-august-2022-nasdaq-ocgn-forward-looking-statemen-ocgn-20220816monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-second-quarter-2022-financial-results-conference-call-and--ocgn-20220805monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-new-cell-therapy-program-following-fda-regenerative-medicine-advanced-the-ocgn-20220524monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-fda-removes-clinical-hold-on-phase-2-3-clinical-trial-for-covaxin-bbv152--ocgn-20220523monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-first-quarter-2022-financial-results-conference-call-a-ocgn-20220506monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220420xex991-courageous-innovation-april-2022-nasdaq-ocgn-forward-looking-statement-ocgn-20220420monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-provides-update-on-its-phase-2-3-study-of-covaxin-bbv152-malvern-pa-ocgn-20220412monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220404xex991-courageous-innovation-march-2022-nasdaq-ocgn-forward-looking-statement-ocgn-20220404monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220311xex991-a-biotech-company-focused-on-discovering-developing-and-commercializin-ocgn-20220311monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-an-update-on-its-covaxin-pediatric-2-18-emergency-use-authorization-eua-re-ocgn-20220304monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-fourth-quarter-and-full-year-2021-financial-results-c-ocgn-20220225monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220222xex991-taking-science-to-new-heights-for-patients-february-2022-nasdaq-ocgn-1-ocgn-20220222monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-u-s-fda-lifts-clinical-hold-on-the-submission-of-its-investigational--ocgn-20220218monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220214xex991-taking-science-to-new-heights-for-patients-february-2022-nasdaq-ocgn-1-ocgn-20220214monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220202xex991-taking-science-to-new-heights-for-patients-february-2022-nasdaq-ocgn-1-ocgn-20220202monthly0.5https://www.biopharmawatch.com/news/OCGN/covaxin-bbv152-booster-shown-to-neutralize-both-omicron-and-delta-variants-of-sars-cov-2-b-ocgn-20220112monthly0.5https://www.biopharmawatch.com/news/OCGN/covaxin-bbv152-booster-dose-study-demonstrates-robust-immune-responses-and-long-term-safet-ocgn-20220108monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20220106xex991-taking-science-to-new-heights-for-patients-january-2022-nasdaq-ocgn-1--ocgn-20220106monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-partner-bharat-biotech-announces-positive-immunogenicity-and-safety-data-from-covax-ocgn-20211230monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20211215xex991-taking-science-to-new-heights-for-patients-december-2021-nasdaq-ocgn-1-ocgn-20211215monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-u-s-fda-acceptance-of-investigational-new-drug-application-to-initiat-ocgn-20211209monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-provides-an-update-on-its-investigational-new-drug-application-with-u-s-fda-to--ocgn-20211126monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20211115xex991-taking-science-to-new-heights-for-patients-november-2021-nasdaq-ocgn-1-ocgn-20211111monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20211109xex991-taking-science-to-new-heights-for-patients-november-2021-nasdaq-ocgn-1-ocgn-20211109monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-third-quarter-2021-financial-results-conference-call-a-ocgn-20211109monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-submission-of-investigational-new-drug-application-with-u-s-fda-to-in-ocgn-20211108monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-submission-of-emergency-use-authorization-request-to-the-us-fda-for-i-ocgn-20211105monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20211102xex991-taking-science-to-new-heights-for-patients-november-2021-nasdaq-ocgn-1-ocgn-20211102monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-submission-of-investigational-new-drug-application-with-u-s-fda-to-in-ocgn-20211027monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20210908xex991-taking-science-to-new-heights-for-patients-september-2021-nasdaq-ocgn--ocgn-20210908monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-second-quarter-2021-financial-results-conference-call--ocgn-20210806monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20210720xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-an-ocgn-20210707monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-initiation-of-rolling-submission-to-health-canada-for-ocgn-20210715monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20210709xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-an-ocgn-20210707monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-s-covid-19-vaccine-co-development-partner-bharat-biotech-shares-phase-3-results-dem-ocgn-20210702monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-pursue-a-bla-path-in-the-us-for-its-covid-19-vaccine-candidate-company-intends-t-ocgn-20210610monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20210519xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-an-ocgn-20210519monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20210507xex991cd-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases--ocgn-20210507monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-first-quarter-2021-financial-results-conference-call-a-ocgn-20210507monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-s-covid-19-vaccine-co-development-partner-bharat-biotech-shares-second-interim-resu-ocgn-20210421monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20210331xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-an-ocgn-20210331monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-full-year-2020-financial-results-conference-call-and-w-ocgn-20210318monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20200305xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-an-ocgn-20210305monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-s-covid-19-vaccine-co-development-partner-bharat-biotech-shares-phase-3-interim-res-ocgn-20210303monthly0.5https://www.biopharmawatch.com/news/OCGN/european-commission-grants-ocugen-orphan-medicinal-product-designation-for-gene-therapy-pr-ocgn-20210223monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20200205xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-an-ocgn-20210121monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-regains-compliance-with-nasdaq-bid-price-rule-malvern-pa-ocgn-20210108monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20210105xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-an-ocgn-20210105monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-and-bharat-biotech-to-co-develop-covaxin-a-whole-virion-inactivated-covid-19-vaccin-ocgn-20201222monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20201106xex991cd-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases--ocgn-20201106monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-third-quarter-2020-financial-results-first-gene-therap-ocgn-20201106monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20201020xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-na-ocgn-20201020monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-engages-kemwell-biopharma-for-cgmp-manufacture-of-ocu200-paves-the-way-towards-gett-ocgn-20201006monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20200817xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-na-ocgn-20200817monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-second-quarter-2020-financial-results-two-additional-o-ocgn-20200814monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-receives-fourth-fda-orphan-drug-designation-for-the-same-product-ocu400-aav-nr2e3-g-ocgn-20200810monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20200804xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-na-ocgn-20200804monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-granted-fda-orphan-drug-designation-for-ocu400-aav-hnr2e3-gene-therapy-for-the-trea-ocgn-20200727monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20200716xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-na-ocgn-20200716monthly0.5https://www.biopharmawatch.com/news/OCGN/ocgn-20200603xex991-our-mission-is-to-develop-gene-therapies-to-cure-blindness-diseases-na-ocgn-20200603monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-discontinue-phase-3-ogvhd-trial-breakthrough-modifier-gene-therapy-platform-cont-ocgn-20200601monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-first-quarter-2020-financial-results-100-of-planned-en-ocgn-20200508monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-completion-of-50-of-enrollment-of-its-phase-3-clinical-trial-for-ocular-g-ocgn-20191209monthly0.5https://www.biopharmawatch.com/news/OCGN/forward-looking-statement-this-presentation-contains-forward-looking-statements-that-invol-ocgn-20191126monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-third-quarter-2019-financial-highlights-conference-cal-ocgn-20191101monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-warrant-restructuring-reduced-series-c-warrant-shares-to-20-million-from--ocgn-20191106monthly0.5https://www.biopharmawatch.com/news/OCGN/to-the-form-8-k-of-ocugen-inc-previously-known-as-histogeniccs-filed-with-the-securities-a-ocgn-20190930monthly0.5https://www.biopharmawatch.com/news/OCGN/developing-innovative-therapies-to-address-rare-diseases-and-underserved-nasdaq-ocgn-eye-c-ocgn-20190930monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-completion-of-its-merger-with-histogenics-to-create-nasdaq-listed-clinica-ocgn-20191001monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-announces-approval-of-merger-by-stockholders-at-special-meeting-ocgn-20190926monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-adjournment-of-its-special-meeting-to-thursday-september-ocgn-20190912monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-ocgn-20190911monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-and-ocugen-enter-into-definitive-merger-agreement-to-create-nasdaq-listed-clin-ocgn-20190408monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-and-fda-conclude-discussions-regarding-neocart-phase-3-clinical-trial-data-and-ocgn-20181221monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-and-fda-continue-to-discuss-neocart-phase-3-ocgn-20181129monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-third-quarter-2018-financial-and-operating-results-histo-ocgn-20181108monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-and-fda-to-continue-discussions-on-neocart-phase-3-ocgn-20181101monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-ocgn-20181004monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-to-meet-with-fda-to-discuss-neocart-phase-3-ocgn-20180926monthly0.5https://www.biopharmawatch.com/news/OCGN/disclaimer-regarding-forward-looking-statements-this-presentation-includes-statements-that-ocgn-20180905monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-second-quarter-2018-financial-and-operating-results-top--ocgn-20180809monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-restorative-cell-therapies-for-active-living-investor-day-ocgn-20180619monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-first-quarter-2018-financial-and-operating-results-top-l-ocgn-20180510monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-the-appointment-of-susan-washer-to-its-board-of-director-ocgn-20180418monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-financial-and-operating-results-for-the-fourth-quarter-a-ocgn-20180315monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-pricing-of-underwritten-registered-direct-offering-of-2--ocgn-20180122monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-and-medinet-co-ltd-enter-into-licensing-agreement-for-development--ocgn-20171221monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-third-quarter-2017-financial-and-operating-results-top-l-ocgn-20171109monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-promotes-stephen-kennedy-to-executive-vice-president-ocgn-20171012monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-second-quarter-2017-financial-and-operating-results-comp-ocgn-20170810monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-completes-enrollment-for-phase-3-clinical-trial-of-neocart-to-treat-knee-carti-ocgn-20170627monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-first-quarter-2017-financial-and-operating-results-neoca-ocgn-20170511monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-announces-agreement-with-the-japan-pharmaceuticals-and-medical-devices-agency--ocgn-20170508monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-financial-and-operating-results-for-the-fourth-quarter-a-ocgn-20170316monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-third-quarter-2016-financial-and-operating-results-neoca-ocgn-20161110monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-provides-neocart-phase-3-clinical-trial-enrollment-update-75-of-pa-ocgn-20161024monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-closes-30-0-ocgn-20160929monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-30-0-ocgn-20160916monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-second-quarter-2016-financial-and-operating-results-neoc-ocgn-20160811monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-first-quarter-2016-financial-and-operating-results-neoca-ocgn-20160512monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-acquires-neocart-development-and-commercialization-rights-for-japa-ocgn-20160510monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-financial-and-operating-results-for-the-fourth-quarter-a-ocgn-20160310monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-provides-neocart-phase-3-clinical-trial-enrollment-update-50-of-pa-ocgn-20160202monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-amendment-to-neocart-phase-3-clinical-trial-enrollment-c-ocgn-20151221monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-third-quarter-2015-financial-and-operating-results-compl-ocgn-20151112monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-second-quarter-2015-financial-and-operating-results-cont-ocgn-20150812monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-appointment-of-stephen-kennedy-to-chief-technology-offic-ocgn-20150730monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-dr-gloria-matthews-as-chief-medical-officer-globally-rec-ocgn-20150715monthly0.5https://www.biopharmawatch.com/news/OCGN/forward-looking-statements-various-statements-in-this-release-are-forward-looking-statemen-ocgn-20150622monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-first-quarter-2015-ocgn-20150514monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-fourth-quarter-and-full-year-2014-ocgn-20150226monthly0.5https://www.biopharmawatch.com/news/OCGN/histogenics-corporation-announces-the-appointment-of-david-gill-to-its-board-of-directors--ocgn-20150202monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-announces-first-quarter-2026-financial-results-irvine-calif-sbc-sbc-20260514monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-announces-fourth-quarter-and-full-year-2025-financial-results-q4-eps-more-than-sbc-20260327monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-accelerates-global-expansion-with-strategic-investment-and-alliance-with-a-lea-sbc-20260105monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-announces-capital-strategy-effectiveness-of-form-s-3-registration-statement-an-sbc-20251231monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-announcement-of-final-results-of-tender-offer-for-waqoo-inc-sha-sbc-20251213monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-announces-third-quarter-2025-financial-results-irvine-calif-sbc-sbc-20251114monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-announces-commencement-of-tender-offer-for-shares-of-waqoo-inc-tokyo-jap-sbc-20251113monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-announces-second-quarter-2025-financial-results-sbc-20250813monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-acquires-mb-career-lounge-jun-clinic-joins-the-group-strengthening-compe-sbc-20250717monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-added-to-membership-of-russell-3000-index-irvine-calif-sbc-medical-group-holdi-sbc-20250630monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-announces-first-quarter-2025-financial-results-irvine-calif-sbc-20250515monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-inc-announces-fourth-quarter-and-full-year-2024-financial-resul-sbc-20250328monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-announces-its-purchase-of-bitcoin-tokyo-business-wire-sbc-medic-sbc-20250218monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-inc-reports-third-quarter-2024-financial-results-irvine-califor-sbc-20241113monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-incorporated-index-to-financial-statements-page-consolidated-ba-sbc-20240920monthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-incorporated-a-medical-services-healthcare-company-announced-si-sbc-20230202monthly0.5https://www.biopharmawatch.com/news/SBC/pono-capital-two-inc-announces-the-separate-trading-of-its-class-a-common-stock-and-warran-sbc-20220923monthly0.5https://www.biopharmawatch.com/news/SBC/pono-capital-two-inc-index-to-financial-statement-report-of-independent-registered-public--sbc-20220809monthly0.5https://www.biopharmawatch.com/news/SBC/pono-capital-two-inc-announces-pricing-of-100-000-000-initial-public-offering-honolulu-haw-sbc-20220804monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolicdysfunction-with-novel-therapeutics-april-2026-april-2026-2-forward-loo-sgmt-20260427monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-sgmt-20260311monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolicdysfunction-with-novel-therapies-to-treat-mash-acne-cancer-december-202-sgmt-20251218monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolicdysfunction-with-novel-therapies-to-treat-mash-acne-cancer-october-2025-sgmt-20251023monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-second-quarter-2025-financial-results-and-provides-corporate-u-sgmt-20250813monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-positive-phase-3-results-for-denifanstat-for-the-treatment-o-sgmt-20250604monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-first-quarter-2025-financial-results-and-provides-corporate-up-sgmt-20250508monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-full-year-2024-financial-results-and-provides-corporate-update-sgmt-20250312monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-clearance-of-ind-for-fasn-inhibitor-tvb-3567-to-be-developed-sgmt-20250311monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-m-ash-acne-cancer-february-2-sgmt-20250214monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-m-ash-acne-cancer-january-20-sgmt-20250102monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-up-sgmt-20241114monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-second-quarter-2024-financial-results-and-provides-corporate-u-sgmt-20240801monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-m-ash-acne-cancer-july-2024--sgmt-20240702monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-presents-data-from-itt-and-f3-patient-population-in-phase-2b-fascinate-sgmt-20240613monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-presents-data-from-itt-and-f3-patient-population-in-phase-2b-fascinate-sgmt-20240606monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-m-ash-acne-and-cancer-may-20-sgmt-20240523monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-first-quarter-2024-financial-results-and-provides-corporate-up-sgmt-20240515monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-m-ash-acne-and-cancer-march--sgmt-20240325monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-pricing-of-public-offering-of-series-a-common-stock-01-25-20-sgmt-20240125monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-nash-acne-and-cancer-january-sgmt-20240122monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-nash-acne-and-cancer-decembe-sgmt-20231229monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-third-quarter-2023-financial-results-and-provides-corporate-up-sgmt-20231113monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-nash-acne-and-cancer-october-sgmt-20231023monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-nash-acne-and-cancer-septemb-sgmt-20230927monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-second-quarter-2023-financial-results-and-provides-corporate-u-sgmt-20230821monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-metabolic-dysfunction-with-novel-therapies-to-treat-nash-acne-and-cancer-august--sgmt-20230810monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-box-4081-rehovot-7670402-israel-noti-kmda-20260618monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-2026-financial-results-on-kmda-20260506monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-declares-cash-dividend-of-0-25-per-share-to-be-paid-in-accordance-with-an-adopted-a-kmda-20260311monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-a-10-14-million-extension-of-canadian-supply-tender-company-awarded-exten-kmda-20251218monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-compensation-policy-for-office-holders-1-purpose-this-compensation-policy-the-p-kmda-20251210monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-discontinuation-of-its-phase-3-inhaled-aat-clinical-trial-reiterates-2025-kmda-20251208monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-box-4081-rehovot-7670402-israel-dear-kmda-20251202monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-box-4081-rehovot-7670402-israel-noti-kmda-20251023monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-second-quarter-and-first-half-2025-financial-results-with-11-year-ov-kmda-20250813monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-first-quarter-2025-financial-results-with-year-over-year-top-line-gr-kmda-20250514monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-2025-financial-results-on-kmda-20250507monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-launch-of-a-comprehensive-post-marketing-research-program-for-cytogam-pro-kmda-20250505monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-updates-on-withholding-tax-procedures-on-previously-announced-special-cash-dividend-kmda-20250324monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-expansion-of-plasma-collection-operations-with-the-opening-of-new-site-in-kmda-20250319monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-declares-special-cash-dividend-of-0-20-per-share-company-reports-record-revenue-and-kmda-20250305monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-fourth-quarter-and-fiscal-year-2024-financial-results-on-kmda-20250226monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-a-25-million-3-year-contract-for-supply-of-kamrab-and-varizig-in-latin-am-kmda-20250122monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-affirms-2024-financial-guidance-and-announces-expected-continued-double-digit-profi-kmda-20250108monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-continued-profitable-growth-with-strong-third-quarter-and-nine-month-2024-f-kmda-20241113monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-third-quarter-and-nine-months-ended-kmda-20241106monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-present-at-the-stifel-2024-healthcare-conference-rehovot-israel-and-hoboken-nj-kmda-20241104monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-box-4081-rehovot-7670402-israel-noti-kmda-20241021monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-expansion-of-plasma-collection-operations-in-texas-with-the-opening-of-ne-kmda-20240923monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-second-quarter-and-first-half-2024-financial-results-with-year-over--kmda-20240814monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-second-quarter-and-first-half-ended-kmda-20240807monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-first-quarter-2024-financial-results-with-year-over-year-top-line-gr-kmda-20240508monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-2024-financial-results-and-host-conference-call-on-kmda-20240501monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-fiscal-year-and-fourth-quarter-2023-financial-results-and-provides-f-kmda-20240306monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-fourth-quarter-and-fiscal-year-2023-financial-results-and-provide-2024--kmda-20240228monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-its-largest-commercial-agreement-a-strategic-engagement-with-kedrion-for--kmda-20231206monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-x00a0-box-4081-rehovot-7670402-israe-kmda-20231113monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-significant-increase-in-sales-and-profitability-in-the-third-quarter-and-ni-kmda-20231113monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-third-quarter-and-first-nine-months-ended-kmda-20231108monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-recent-achievements-with-cytogam-including-availability-of-product-manufa-kmda-20231016monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-provides-corporate-update-on-its-israel-operations-rehovot-israel-and-hoboken-nj-kmda-20231010monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-shareholder-approval-and-planned-closing-of-60-million-private-placement--kmda-20230830monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-second-quarter-and-first-half-2023-financial-results-reiterates-2023-kmda-20230816monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-second-quarter-and-first-half-ended-kmda-20230809monthly0.5https://www.biopharmawatch.com/news/KMDA/respectively-to-our-report-on-form-x00a0-6-k-a-on-may-x00a0-24-2023-and-are-incorporated-h-kmda-20230713monthly0.5https://www.biopharmawatch.com/news/KMDA/ka-mada-announces-kedrion-exercised-its-option-for-two-year-extension-of-kedrab-distributi-kmda-20230712monthly0.5https://www.biopharmawatch.com/news/KMDA/share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-made-as-of-kmda-20230523monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-first-quarter-2023-financial-results-reiterates-revenue-and-profitab-kmda-20230524monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-chief-financial-officer-chaime-orlev-to-remain-in-role-and-appointment-of-kmda-20230524monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-60-million-private-placement-with-fimi-opportunity-funds-funding-to-suppo-kmda-20230524monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-2023-financial-results-and-host-conference-call-on-kmda-20230517monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-receipt-of-marketing-authorization-for-glassia-for-treatment-of-alpha-1-a-kmda-20230516monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-u-s-fda-approval-of-its-application-to-manufacture-cytogam-at-the-company-kmda-20230503monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-issues-2023-ceo-letter-to-shareholders-rehovot-israel-and-hoboken-nj-kmda-20230315monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-files-annual-report-for-the-year-ended-kmda-20230315monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-fiscal-year-and-fourth-quarter-2022-financial-results-and-provides-2-kmda-20230315monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-kmda-20230309monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-submission-of-application-to-the-u-s-fda-to-manufacture-cytogam-at-the-co-kmda-20230104monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-planned-transition-of-chief-financial-officer-rehovot-israel-and-hoboken--kmda-20221219monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-third-quarter-financial-results-demonstrating-successful-strategic-t-kmda-20221122monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-compensation-policy-for-executive-officers-1-purpose-this-compensation-policy-t-kmda-20221117monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-third-quarter-and-first-nine-months-ended-kmda-20221116monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-x00a0-box-4081-rehovot-7670402-israe-kmda-20221108monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-provides-update-on-recent-progress-achieved-in-ongoing-pivotal-phase-3-clinical-tri-kmda-20221107monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-present-at-the-credit-suisse-31st-annual-healthcare-conference-rehovot-israel-an-kmda-20221026monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-awarded-22-million-extension-of-canadian-supply-tender-awarded-extension-to-existin-kmda-20221019monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-second-quarter-and-first-half-2022-financial-results-significant-growth-dri-kmda-20220817monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-second-quarter-and-first-half-ended-kmda-20220810monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-resolution-the-labor-strike-at-the-company-s-manufacturing-facility-in-is-kmda-20220715monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-11-4-million-international-varizig-procurement-agreement-procurement-agre-kmda-20220706monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-strengthens-senior-leadership-team-furthering-commitment-as-a-fully-integrated-glob-kmda-20220615monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-host-a-virtual-analysts-and-investors-meeting-to-review-its-growth-catalysts-reh-kmda-20220601monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-first-quarter-2022-financial-results-reiterates-revenue-and-profitability-g-kmda-20220517monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-expansion-of-pivotal-phase-3-clinical-trial-of-inhaled-aat-to-additional--kmda-20220517monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-ended-kmda-20220511monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-the-company-nasdaq-tase-kmda-a-vertically-integrated-global-biopharmaceutical-c-kmda-20220426monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-issues-2022-ceo-letter-to-shareholders-kmda-20220315monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-files-annual-report-for-the-year-ended-kmda-20220315monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-fiscal-year-and-fourth-quarter-2021-financial-results-provides-revenue-and--kmda-20220315monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-expands-u-s-leadership-team-with-two-key-appointments-new-executives-to-strengthen--kmda-20220314monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-the-company-nasdaq-tase-kmda-a-plasma-derived-biopharmaceutical-company-today-a-kmda-20220303monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-fourth-quarter-and-fiscal-year-ended-kmda-20220302monthly0.5https://www.biopharmawatch.com/news/KMDA/to-a-report-of-foreign-private-issuer-on-form-6-k-furnished-by-the-company-to-the-u-s-secu-kmda-20211216monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-strategic-transformational-transaction-positioning-the-company-as-a-globa-kmda-20211122monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-third-quarter-and-first-nine-months-of-2021-financial-results-and-strategic-kmda-20211122monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-third-quarter-financial-results-and-host-conference-call-on-kmda-20211108monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-box-4081-rehovot-7670402-israel-noti-kmda-20211104monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-second-quarter-and-first-half-2021-financial-results-recent-achievements-an-kmda-20210811monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-second-quarter-and-first-half-2021-financial-results-and-host-conferenc-kmda-20210805monthly0.5https://www.biopharmawatch.com/news/KMDA/kedrion-and-kamada-announce-fda-approval-of-kedrab-label-update-confirming-safety-and-effe-kmda-20210602monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-first-quarter-2021-financial-results-recent-achievements-and-corporate-deve-kmda-20210512monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-ended-kmda-20210505monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-amendment-to-glassia-license-agreement-with-takeda-following-the-completi-kmda-20210407monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-top-line-results-from-its-phase-1-2-clinical-trial-of-its-plasma-derived--kmda-20210331monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-present-at-the-jefferies-global-plasma-summit-kmda-20210309monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-cent-kmda-20210303monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-files-annual-report-for-the-year-ended-kmda-20210224monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-fourth-quarter-and-fiscal-year-2020-financial-results-recent-achievements-a-kmda-20210210monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-fourth-quarter-and-fiscal-year-ended-kmda-20210203monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-acquires-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-i-kmda-20210201monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-enters-into-two-new-agreements-for-the-distribution-of-three-biosimilar-products-in-kmda-20210113monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-selected-as-a-winner-of-the-genesis-prize-foundation-and-start-up-nation-central-co-kmda-20210105monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-added-to-the-nasdaq-biotechnology-index-kmda-20201221monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-the-company-nasdaq-tase-kmda-a-plasma-derived-biopharmaceutical-company-today-a-kmda-20201214monthly0.5https://www.biopharmawatch.com/news/KMDA/to-a-report-of-foreign-private-issuer-on-form-6-k-furnished-by-the-company-to-the-u-s-secu-kmda-20201210monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-third-quarter-and-first-nine-months-of-2020-financial-results-recent-achiev-kmda-20201111monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-third-quarter-ended-kmda-20201104monthly0.5https://www.biopharmawatch.com/news/KMDA/to-our-report-on-form-6-k-on-kmda-20201029monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-supply-agreement-with-israeli-ministry-of-health-for-its-investigational--kmda-20201019monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-provides-update-on-2021-glassia-supply-to-takeda-kamada-expects-to-receive-25-milli-kmda-20201007monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-completion-of-enrollment-and-initial-interim-results-from-its-phase-1-2-c-kmda-20200908monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-and-kedrion-biopharma-announce-results-of-first-and-only-u-s-post-marketing-pediatr-kmda-20200819monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-changes-to-its-board-of-directors-lilach-asher-topilsky-a-director-on-the-kmda-20200812monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-second-quarter-and-first-six-months-of-2020-financial-results-recent-corpor-kmda-20200812monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-enrollment-of-first-patient-in-its-phase-1-2-clinical-trial-of-its-plasma-kmda-20200810monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-second-quarter-ended-kmda-20200805monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-availability-of-its-plasma-derived-hyperimmune-igg-therapy-for-coronaviru-kmda-20200617monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-first-quarter-2020-financial-results-and-highlights-recent-corporate-progre-kmda-20200518monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-ended-kmda-20200511monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-and-kedrion-biopharma-announce-global-collaboration-for-the-development-manufacturi-kmda-20200427monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-box-4081-rehovot-7670402-israel-noti-kmda-20200325monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-pl-kmda-20200311monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-files-annual-report-for-the-year-ended-kmda-20200226monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-2-holzman-street-weizmann-science-park-p-o-box-4081-rehovot-7670402-israel-noti-kmda-20200213monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-fourth-quarter-and-fiscal-year-2019-total-revenues-fo-kmda-20200212monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-fourth-quarter-and-fiscal-year-ended-kmda-20200205monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-25-million-private-placement-with-fimi-opportunity-fund-execution-of-secu-kmda-20200121monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-preliminary-revenue-for-fourth-quarter-and-full-year-2019-and-provides-fu-kmda-20200107monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-7-sapir-street-kiryat-weizmann-science-park-p-o-box-4081-ness-ziona-74140-israe-kmda-20130801monthly0.5https://www.biopharmawatch.com/news/KMDA/disclosure-for-debenture-holders-as-of-kmda-20130801monthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-ltd-c-o-po-box-309-ugland-house-grand-cayman-ky1-1104-cayman-islands-notice-o-anl-20251022monthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-reports-unaudited-first-half-2024-financial-results-and-highlights-recent-ope-anl-20240808monthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-ltd-to-present-encouraging-data-of-the-combination-of-an0025-and-definitive-c-anl-20240523monthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-announces-appointment-of-dr-archie-tse-as-the-head-of-research-development-si-anl-20240402monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-first-quarter-2026-financial-results-and-business-highlights-x2013-stro-20260514monthly0.5https://www.biopharmawatch.com/news/STRO/february-2026-nasdaq-stro-forward-looking-statements-this-presentation-and-the-accompanyin-stro-20260210monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-second-quarter-2025-financial-results-and-business-highlights-x201-stro-20250807monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-first-quarter-2025-financial-results-and-business-highlights-sharp-stro-20250508monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-inc-selected-statements-of-operations-financial-data-unaudited-in-thousand-stro-20250313monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-third-quarter-2024-financial-results-and-business-highlights-expec-stro-20241113monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-second-quarter-2024-financial-results-business-highlights-and-sele-stro-20240813monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-first-quarter-2024-financial-results-business-highlights-and-selec-stro-20240513monthly0.5https://www.biopharmawatch.com/news/STRO/ipsen-and-sutro-biopharma-announce-exclusive-global-licensing-agreement-for-an-adc-targeti-stro-20240402monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-inc-selected-statements-of-operations-financial-data-unaudited-in-thousand-stro-20240325monthly0.5https://www.biopharmawatch.com/news/STRO/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-stro-20231231monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-promotes-jane-chung-to-president-and-chief-operating-officer-stro-20231121monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-third-quarter-2023-financial-results-business-highlights-and-selec-stro-20231113monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-second-quarter-2023-financial-results-business-highlights-and-sele-stro-20230810monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-first-quarter-2023-financial-results-business-highlights-and-selec-stro-20230515monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-full-year-2022-financial-results-business-highlights-and-select-an-stro-20230330monthly0.5https://www.biopharmawatch.com/news/STRO/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-stro-20230109monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-third-quarter-2022-financial-results-business-highlights-and-selec-stro-20221108monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-second-quarter-2022-financial-results-business-highlights-and-anti-stro-20220808monthly0.5https://www.biopharmawatch.com/news/STRO/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-stro-20220628monthly0.5https://www.biopharmawatch.com/news/STRO/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-stro-20220616monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-first-quarter-2022-financial-results-business-highlights-and-antic-stro-20220509monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-full-year-2021-financial-results-business-highlights-and-anticipat-stro-20220228monthly0.5https://www.biopharmawatch.com/news/STRO/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-stro-20220110monthly0.5https://www.biopharmawatch.com/news/STRO/release-and-the-company-undertakes-no-obligation-to-revise-or-update-any-forward-looking-s-stro-20220105monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-third-quarter-2021-financial-results-business-highlights-and-antic-stro-20211110monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-second-quarter-2021-financial-results-business-highlights-and-anti-stro-20210809monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-additional-data-for-dose-escalation-phase-1-study-of-stro-002-to-stro-20210519monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-first-quarter-2021-financial-results-business-highlights-and-2021--stro-20210507monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-full-year-2020-financial-results-and-provides-business-highlights--stro-20210318monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-presents-data-from-ongoing-phase-1-dose-escalation-study-for-stro-001-for--stro-20201207monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-encouraging-interim-data-on-stro-002-phase-1-dose-escalation-stu-stro-20201203monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-third-quarter-2020-financial-results-and-provides-business-highlig-stro-20201105monthly0.5https://www.biopharmawatch.com/news/STRO/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-stro-20200909monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-second-quarter-2020-financial-results-and-provides-business-highli-stro-20200806monthly0.5https://www.biopharmawatch.com/news/STRO/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-stro-20200615monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-first-quarter-2020-financial-results-and-recent-business-highlight-stro-20200511monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-encouraging-interim-phase-1-clinical-data-for-a-dose-escalation--stro-20200420monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-full-year-2019-financial-results-and-recent-business-highlights-an-stro-20200316monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-third-quarter-2019-financial-results-and-recent-business-highlight-stro-20191029monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-presents-encouraging-preliminary-clinical-data-in-ongoing-phase-i-study-fo-stro-20191029monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-second-quarter-2019-financial-results-and-recent-business-highligh-stro-20190814monthly0.5https://www.biopharmawatch.com/news/STRO/summary-and-conclusions-1-stro-001-is-the-first-adc-generated-with-novel-cell-free-protein-stro-20190617monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-first-quarter-2019-financial-results-and-recent-business-highlight-stro-20190515monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-full-year-2018-financial-results-and-recent-business-highlights-an-stro-20190401monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-third-quarter-2018-financial-results-stro-001-received-orphan-drug-stro-20181114monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-first-quarter-2026-financial-results-first-quarter--ebs-20260430monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-fourth-quarter-and-full-year-2025-financial-result-ebs-20260226monthly0.5https://www.biopharmawatch.com/news/EBS/combating-public-health-threats-for-communities-around-the-world-th-44-annual-j-p-morgan-h-ebs-20260114monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-third-quarter-2025-financial-results-third-quarter-ebs-20251029monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-second-quarter-2025-financial-results-second-quart-ebs-20250806monthly0.5https://www.biopharmawatch.com/news/EBS/document-ex-99-1-united-states-district-court-district-of-maryland-in-re-emergent-biosolut-ebs-20250523monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-first-quarter-2025-financial-results-first-quarter-ebs-20250507monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-fourth-quarter-and-full-year-2024-financial-result-ebs-20250303monthly0.5https://www.biopharmawatch.com/news/EBS/this-presentation-includes-forward-looking-statements-within-the-meaning-of-the-private-se-ebs-20250115monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-third-quarter-2024-financial-results-third-quarter-ebs-20241106monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-closing-of-100-million-asset-backed-loan-facility-gaithers-ebs-20241002monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-successfully-refinances-debt-further-strengthens-financial-profile-n-ebs-20240903monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-second-quarter-2024-financial-results-second-quart-ebs-20240806monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-first-quarter-2024-financial-results-first-quarter-ebs-20240501monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-fourth-quarter-2023-financial-results-fourth-quart-ebs-20240306monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-third-quarter-2023-financial-results-third-quarter-ebs-20231108monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-financial-results-for-second-quarter-2023-reports--ebs-20230808monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-s-statement-regarding-its-amended-credit-agreement-gaithersburg-md-ebs-20230517monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-financial-results-for-first-quarter-2023-reports-q-ebs-20230509monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-financial-results-for-fourth-quarter-2022-reports--ebs-20230227monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-financial-results-for-third-quarter-2022-gaithersbu-ebs-20221108monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-financial-results-for-second-quarter-2022-reports-s-ebs-20220801monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-financial-results-for-first-quarter-2022-reports-q1-ebs-20220428monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-bioso-lutions-reports-financial-results-for-fourth-quarter-2021-reports--ebs-20220224monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-financial-results-for-third-quarter-2021-gaithersbu-ebs-20211104monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-financial-results-for-second-quarter-2021-reaffirms-ebs-20210729monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-financial-results-for-first-quarter-2021-revises-20-ebs-20210429monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-financial-results-for-fourth-quarter-and-full-year--ebs-20210218monthly0.5https://www.biopharmawatch.com/news/EBS/document-emergent-biosolutions-reports-financial-results-for-third-quarter-and-nine-months-ebs-20201105monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-successful-completion-of-offering-of-3-875-senior-unsecure-ebs-20200807monthly0.5https://www.biopharmawatch.com/news/EBS/ebs20200630exhibit99earn-emergent-biosolutions-reports-financial-results-for-second-quarte-ebs-20200730monthly0.5https://www.biopharmawatch.com/news/EBS/exhibit-emergent-biosolutions-reports-financial-results-for-first-quarter-2020-reaffirms-f-ebs-20200430monthly0.5https://www.biopharmawatch.com/news/EBS/exhibit-for-immediate-release-emergent-biosolutions-reports-financial-results-for-fourth-q-ebs-20200220monthly0.5https://www.biopharmawatch.com/news/EBS/exhibit-emergent-biosolutions-reports-financial-results-for-third-quarter-and-nine-months--ebs-20191106monthly0.5https://www.biopharmawatch.com/news/EBS/exhibit-emergent-biosolutions-reports-financial-results-for-second-quarter-and-six-months--ebs-20190801monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fourth-quarter-and-full-year-2018-ebs-20190221monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-preliminary-2018-financial-results-and-provides-2019-finan-ebs-20190107monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20190104monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-third-quarter-and-nine-months-of-2018--ebs-20181101monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-240-631-3280-burrowsr-ebsi-com-media-contacts-lynn-kieff-ebs-20181015monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20181004monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-joins-effort-to-combat-national-public-health-threat-from-opioid-ove-ebs-20180828monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-acquire-specialty-vaccines-company-paxvax-adds-two-revenue-genera-ebs-20180809monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-second-quarter-and-six-months-of-2018--ebs-20180802monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-first-quarter-2018-financial-results-reaffirms-full-year-201-ebs-20180503monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-executive-management-changes-that-enhance-execution-of-com-ebs-20180326monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fourth-quarter-and-twelve-months-2017-financial-results-reaf-ebs-20180222monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-preliminary-2017-financial-results-and-provides-2018-ebs-20180108monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20171114monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-third-quarter-and-nine-months-2017-financial-results-raises--ebs-20171102monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20171006monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20171003monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-second-quarter-and-six-months-2017-financial-results-reaffir-ebs-20170803monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-acquire-acam2000-business-from-sanofi-addition-of-acam2000-the-on-ebs-20170714monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-first-quarter-2017-financial-results-reaffirms-2017-ebs-20170504monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20170317monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20170109monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20161208monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20161108monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-third-quarter-and-nine-months-2016-ebs-20161107monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-barda-contract-for-advanced-development-and-delivery-of-nuth-ebs-20160930monthly0.5https://www.biopharmawatch.com/news/EBS/excerpts-from-the-information-statement-of-aptevo-therapeutics-inc-dated-ebs-20160722monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-second-quarter-and-six-months-2016-ebs-20160804monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-first-quarter-2016-financial-results-q1-2016-financial-perfo-ebs-20160505monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fourth-quarter-and-twelve-months-2015-financial-results-and--ebs-20160225monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-preliminary-2015-financial-results-provides-2016-financial-ebs-20160111monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-third-quarter-and-nine-months-2015-ebs-20151105monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-second-quarter-and-six-months-2015-financial-results-and-rea-ebs-20150806monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-301-795-1877-burrowsr--ebs-20150507monthly0.5https://www.biopharmawatch.com/news/EBS/investor-contact-robert-g-burrows-vice-president-investor-relations-240-631-3280-burrowsr--ebs-20150422monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fourth-quarter-and-twelve-months-2014-financial-results-and--ebs-20150305monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-preliminary-2014-financial-results-and-provides-2015-finan-ebs-20150111monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-third-quarter-and-nine-month-2014-ebs-20141106monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-first-quarter-2026-results-and-provides-update-fb102-recei-fbrx-20260514monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-third-quarter-2025-results-and-provides-update-three-clini-fbrx-20251114monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-results-and-provides-update-three-clinical-trial-readouts--fbrx-20250814monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-announces-pricing-of-75-million-public-offering-dallas-tx-june-24-2025-f-fbrx-20250626monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-announces-positive-data-in-fb102-celiac-disease-phase-1b-study-phase-2-c-fbrx-20250623monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-results-and-provides-update-dallas-tx-may-15-2025-forte-bi-fbrx-20250515monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-results-and-provides-clinical-update-dallas-tx-march-31-20-fbrx-20250404monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-forte-biosciences-dec-3-2024-1-cautionary-note-regarding-forward-looking-fbrx-20241203monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-oversubscribed-53-million-private-placement-from-leading-h-fbrx-20241120monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-third-quarter-2024-results-and-provides-business-update-da-fbrx-20241114monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-second-quarter-2024-results-and-provides-business-update-d-fbrx-20240814monthly0.5https://www.biopharmawatch.com/news/FBRX/in-the-court-of-chancery-of-the-state-of-delaware-camac-fund-lp-plaintiff-v-paul-a-wagner--fbrx-20240614monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-first-quarter-2024-results-and-provides-business-update-da-fbrx-20240513monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-2023-results-and-provides-business-update-dallas-tx-march--fbrx-20240318monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-25-million-financing-and-r-d-update-for-fb-102-fb-102-has--fbrx-20230801monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-full-year-2022-results-and-provides-business-update-fb-102-fbrx-20230331monthly0.5https://www.biopharmawatch.com/news/FBRX/mr-david-gryska-appointed-to-forte-biosciences-board-of-directors-addition-of-mr-david-gry-fbrx-20230112monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-third-quarter-2022-results-and-provides-business-update-fb-fbrx-20221114monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-second-quarter-2022-results-and-provides-business-update-f-fbrx-20220815monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-the-appointment-of-dr-hubert-chen-md-as-chief-scientific-o-fbrx-20220607monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-first-quarter-2022-results-and-provides-business-update-fo-fbrx-20220516monthly0.5https://www.biopharmawatch.com/news/FBRX/clinical-trial-of-fb-401-for-the-treatment-of-atopic-dermatitis-fails-to-meet-statistical--fbrx-20210902monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-first-quarter-2021-results-and-provides-a-general-business-fbrx-20210510monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-4q-and-full-year-2020-results-and-provides-a-general-busin-fbrx-20210324monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-topical-live-biotherapeutic-for-the-treatment-of-inflammatory-skin-disea-fbrx-20201110monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-third-quarter-2020-results-and-provides-general-business-u-fbrx-20201109monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-full-publication-of-phase-1-2-data-in-science-translationa-fbrx-20200909monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-audited-financial-statements-for-the-years-ended-fbrx-20200904monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-second-quarter-2020-results-and-provides-general-business--fbrx-20200810monthly0.5https://www.biopharmawatch.com/news/FBRX/certain-statements-contained-in-this-presentation-regarding-matters-that-are-not-historica-fbrx-20200626monthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inc-announces-closing-of-merger-with-tocagen-to-commence-trading-on-nasd-fbrx-20200616monthly0.5https://www.biopharmawatch.com/news/FBRX/san-diego-fbrx-20200423monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-fourth-quarter-and-full-year-2019-financial-results-definitive-merger-agre-fbrx-20200219monthly0.5https://www.biopharmawatch.com/news/FBRX/certain-statements-contained-in-this-presentation-regarding-matters-that-are-not-historica-fbrx-20200220monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-and-forte-biosciences-announce-merger-transaction-to-create-nasdaq-listed-company--fbrx-20200220monthly0.5https://www.biopharmawatch.com/news/FBRX/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-toc-fbrx-20191122monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-third-quarter-2019-financial-results-and-business-updates-fbrx-20191112monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-announces-restructuring-to-focus-on-clinical-development-toca-5-full-results-to-be-fbrx-20191003monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-second-quarter-2019-financial-results-and-business-updates-fbrx-20190808monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-first-quarter-2019-financial-and-business-results-fbrx-20190507monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-fourth-quarter-and-full-year-2018-financial-and-business-results-fbrx-20190227monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-announces-proposed-public-offering-of-common-stock-fbrx-20181211monthly0.5https://www.biopharmawatch.com/news/FBRX/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-toc-fbrx-20181212monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-third-quarter-2018-financial-and-business-results-fbrx-20181108monthly0.5https://www.biopharmawatch.com/news/FBRX/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-toc-fbrx-20181009monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-second-quarter-2018-financial-and-business-results-strong-execution-of-toc-fbrx-20180807monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-first-quarter-2018-financial-and-business-results-fbrx-20180510monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-and-apollobio-enter-license-agreement-to-develop-and-commercialize-toca-511-toca-f-fbrx-20180419monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-fourth-quarter-and-full-year-2017-financial-and-business-results-fbrx-20180308monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-third-quarter-2017-financial-and-business-results-san-diego-nov-8-2017-toc-fbrx-20171108monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-second-quarter-2017-financial-and-business-results-san-diego-aug-9-2017-to-fbrx-20170809monthly0.5https://www.biopharmawatch.com/news/FBRX/tocagen-reports-first-quarter-2017-financial-and-business-results-upsized-initial-public-o-fbrx-20170523monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-second-quarte-lyel-20250812monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-lyel-20250513monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-fourth-quarte-lyel-20250311monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-presents-positive-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-impt-31-lyel-20241209monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-third-quarter-lyel-20241107monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-completes-acquisition-of-immpact-bio-acquisition-strengthens-lyell-s-cl-lyel-20241031monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-acquire-immpact-bio-and-prioritizes-its-pipeline-to-focus-on-next-ge-lyel-20241024monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-second-quarte-lyel-20240807monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-dose-dependent-clinical-activity-from-phase-1-trial-of-lyl797-a-lyel-20240626monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-lyel-20240506monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-fourth-quarte-lyel-20240228monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-third-quarter-lyel-20231107monthly0.5https://www.biopharmawatch.com/news/LYEL/draft-jpm22-updated-12-14-21-lyell-immunopharma-lyel-20230911monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-second-quarte-lyel-20230808monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-lyel-20230504monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-fourth-quarte-lyel-20230228monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-appoints-lynn-seely-md-as-president-and-chief-executive-officer-lyel-20221215monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-recent-business-highlights-and-third-quarter-financial-results--lyel-20221108monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-fda-clearance-of-its-ind-for-lyl845-a-til-product-candidate-e-lyel-20221006monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-second-quarter-financial-results-and-business-highlights-cash-c-lyel-20220804monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-first-quarter-financial-results-and-business-highlights-cash-ca-lyel-20220510monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-fourth-quarter-and-full-year-2021-financial-results-and-busines-lyel-20220329monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-cgmp-qualification-of-lyfe-manufacturing-center-in-advance-of-lyel-20211215monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-third-quarter-2021-financial-results-and-business-highlights-x2-lyel-20211112monthly0.5https://www.biopharmawatch.com/news/LYEL/dear-colleagues-and-stockholders-i-am-writing-to-let-you-know-that-i-am-taking-a-temporary-lyel-20210930monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-reports-second-quarter-2021-financial-results-and-business-highlights-x-lyel-20210812monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-encouraging-camsirubicin-phase-1b-trial-update-patient-in-520-mg-m-2-coh-mnpr-20230601monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2023-financial-results-and-recent-developments--mnpr-20230511monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-result-of-interim-analysis-of-phase-2b-3-voice-trial-evaluating-validive-mnpr-20230327monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recen-mnpr-20230323monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-announce-expanded-radiopharma-program-positive-preclinical-results-a-mnpr-20230227monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-camsirubicin-clinical-program-update-improved-side-effect-profile-seen-t-mnpr-20230214monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-projected-timeline-of-upcoming-q1-2023-data-events-for-validive-camsirub-mnpr-20230126monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-successful-advancement-of-camsirubicin-phase-1b-clinical-trial-past-four-mnpr-20230118monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-promising-mnpr-202-data-from-ongoing-national-university-of-singapore-co-mnpr-20221212monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-encouraging-clinical-data-from-ongoing-camsirubicin-phase-1b-trial-mnpr-20221116monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-third-quarter-2022-financial-results-and-recent-program-devel-mnpr-20221110monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-completion-of-phase-2b-enrollment-and-commencement-of-phase-3-enrollment-mnpr-20221005monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-second-quarter-2022-financial-results-and-recent-program-deve-mnpr-20220811monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2022-financial-results-and-recent-program-devel-mnpr-20220512monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-recen-mnpr-20220324monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-clinical-and-preclinical-program-updates-validive-phase-2b-3-voice-trial-mnpr-20220215monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-advances-dosing-of-camsirubicin-to-higher-level-than-tested-in-any-previous-clinic-mnpr-20211208monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-third-quarter-2021-financial-results-and-recent-clinical-deve-mnpr-20211112monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-first-patient-dosed-in-phase-1b-trial-evaluating-camsirubicin-for-the-tr-mnpr-20211027monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-initiates-open-label-phase-1b-clinical-trial-evaluating-camsirubicin-in-patients-w-mnpr-20210916monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-expands-phase-2b-3-voice-clinical-trial-to-europe-trial-launch-in-europe-coincides-mnpr-20210913monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-second-quarter-2021-financial-results-and-recent-business-upd-mnpr-20210812monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-reaches-target-number-of-clinical-sites-in-phase-2b-portion-of-2b-3-validive-xae-v-mnpr-20210805monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-fda-clearance-to-proceed-with-camsirubicin-clinical-trial-targeting-adva-mnpr-20210803monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-appoints-oct-xe1-vio-costa-md-as-chief-medical-officer-mnpr-20210712monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-present-results-from-analysis-of-oropharyngeal-cancer-patients-in-completed-pha-mnpr-20210624monthly0.5https://www.biopharmawatch.com/news/MNPR/additional-exhibits-exh99-1q42019earningsrele-monopar-therapeutics-reports-fourth-quarter--mnpr-20200327monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report-beijin-sva-20260102monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-limited-press-release-antigua-court-makes-interim-order-giving-board-contr-sva-20251217monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal-beijing-sva-20251118monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-appointment-of-independent-auditor-beijing-the-board-of-directors-and-ma-sva-20251024monthly0.5https://www.biopharmawatch.com/news/SVA/newly-elected-directors-of-sinovac-hold-the-first-board-meeting-mr-andrew-y-yan-elected-ch-sva-20250710monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-board-of-directors-strongly-denounces-deceptive-and-illegal-claims-by-saif-and-the-sva-20250710monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-board-of-directors-announces-adjournment-of-special-meeting-of-shareholders-until--sva-20250709monthly0.5https://www.biopharmawatch.com/news/SVA/leading-independent-proxy-advisory-firm-iss-joins-glass-lewis-in-recommending-shareholders-sva-20250708monthly0.5https://www.biopharmawatch.com/news/SVA/leading-independent-proxy-advisory-firm-glass-lewis-recommends-sinovac-shareholders-vote-t-sva-20250702monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-board-of-directors-urges-shareholders-to-vote-the-white-proxy-card-against-the-mis-sva-20250630monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-board-of-directors-files-investor-presentation-outlining-decisive-actions-to-prote-sva-20250624monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-board-of-directors-files-definitive-proxy-materials-files-definitive-proxy-stateme-sva-20250619monthly0.5https://www.biopharmawatch.com/news/SVA/chairman-s-message-dear-shareholders-i-would-like-to-inform-you-that-a-2025-special-meetin-sva-20250618monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-board-of-directors-provides-update-on-special-dividend-payment-and-commitment-to-d-sva-20250617monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2024-annual-report-beijing-s-sva-20250516monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-notice-of-special-meeting-of-shareholders-notice-is-hereby-given-that--sva-20250520monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-record-and-distribution-dates-for-special-cash-dividend-beijing-sinovac--sva-20250430monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-decision-to-declare-cash-dividend-beijing-sinovac-biotech-ltd-nasdaq-sva-sva-20250401monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-new-board-member-and-chairman-of-the-audit-committee-beijing-sinovac-bio-sva-20250331monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-new-board-pursuant-to-privy-council-judgment-and-order-beijing-sinovac-b-sva-20250208monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-issues-statement-regarding-privy-council-judgment-beijing-sinovac-biotech-ltd-nasd-sva-20250116monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-half-of-2024-financial-results-sva-20240816monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-half-of-2023-financial-results-and-files-2023-annual-repo-sva-20240429monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-amends-shareholder-rights-plan-sva-20240221monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-on-the-clinical-trial-progress-of-its-anti-covid-19-antibody-sa55-injectio-sva-20230911monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-confirms-receipt-of-an-unsolicited-partial-tender-offer-sva-20230829monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-change-of-legal-representative-of-sinovac-beijing-sva-20230828monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-half-of-2023-financial-results-sva-20230815monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-half-of-2022-financial-results-and-files-2022-annual-repo-sva-20230501monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-amends-shareholder-rights-plan-sva-20230222monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-half-of-2022-financial-results-sva-20221229monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-varicella-vaccine-prequalified-by-who-sva-20221104monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-polio-vaccine-prequalified-by-sva-20220608monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-updates-the-status-under-holding-foreign-companies-accountable-act-sva-20220506monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-half-of-2021-financial-results-and-files-2021-annual-repo-sva-20220429monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-amends-shareholder-rights-plan-beijing-sva-20220222monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-half-of-2021-financial-results-sva-20211230monthly0.5https://www.biopharmawatch.com/news/SVA/antigua-court-of-appeal-rules-in-favor-of-sinovac-upholds-2018-judgment-current-sinovac-di-sva-20211209monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-beijing-settled-litigation-of-its-business-license-and-seals-beijing-sva-20211203monthly0.5https://www.biopharmawatch.com/news/SVA/preliminary-results-show-sinovac-s-covid-19-vaccine-demonstrates-good-safety-profile-among-sva-20211109monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-approval-on-sabin-strain-based-inactivated-polio-vaccine-sipv-to-support--sva-20210719monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-s-coronavac-used-on-child-population-in-china-good-antibody-levels-observed-after--sva-20210719monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-enters-into-agreement-to-supply-coronavac-to-sva-20210712monthly0.5https://www.biopharmawatch.com/news/SVA/the-lancet-infectious-diseases-published-data-from-sinovac-s-phase-i-ii-study-world-s-firs-sva-20210630monthly0.5https://www.biopharmawatch.com/news/SVA/world-health-organization-authorizes-sinovac-s-coronavac-for-emergency-use-beijing-sinovac-sva-20210602monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-fourth-quarter-2020-financial-results-and-files-2020-annual-repo-sva-20210422monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announced-buildup-of-two-billion-annual-capacity-of-its-covid-19-vaccine-beijing-sva-20210401monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-amends-shareholder-rights-plan-beijing-sva-20210222monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-for-conditional-market-authorization-of-covid-19-vaccine-in-china-beijing-sva-20210203monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-product-license-for-23-valent-pneumococcal-polysaccharide-vaccine-beijin-sva-20201209monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-secures-approximately-500-million-in-funding-for-covid-19-vaccine-development-beij-sva-20201207monthly0.5https://www.biopharmawatch.com/news/SVA/beijing-fourth-intermediate-people-s-court-issues-judgement-against-sinobioway-medicine-an-sva-20200928monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-s-coronavac-sars-cov-2-vaccine-vero-cell-inactivated-announces-approval-for-phase--sva-20200923monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-commences-phase-iii-clinical-trials-for-covid-19-vaccine-candidate-in-turkey-sva-20200922monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-quarter-2020-financial-results-beijing-business-wire-sino-sva-20200828monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-signs-agreement-with-bio-farma-indonesia-for-covid-19-vaccine-cooperation-sva-20200825monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-covid-19-vaccine-collaboration-with-butantan-receives-approval-from-brazilian-regu-sva-20200706monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2020-financial-results-sva-20200630monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-approval-from-china-for-its-quadrivalent-influenza-vaccine-beijing-busine-sva-20200624monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-positive-preliminary-results-of-phase-i-ii-clinical-trials-for-inactivat-sva-20200613monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-and-butantan-join-efforts-to-advance-the-clinical-development-of-an-inactivated-va-sva-20200611monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-secures-15-million-in-funding-to-accelerate-covid-19-vaccine-development-beijing-sva-20200522monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-comments-on-sec-findings-against-jiaqiang-chiang-li-and-1globe-capital-sec-order-f-sva-20200518monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-first-animal-study-results-of-vaccine-against-covid-19-published-in-scie-sva-20200506monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-fourth-quarter-2019-financial-results-and-files-2019-annual-repo-sva-20200430monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-commencement-of-phase-i-human-clinical-trial-for-vaccine-candidate-again-sva-20200417monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-approval-of-human-clinical-trial-for-a-vaccine-candidate-against-covid-1-sva-20200414monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-amends-shareholder-rights-plan-beijing-sva-20200221monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-approval-of-varicella-vaccine-for-prevention-of-varicella-zoster-virus-c-sva-20191227monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-third-quarter-2019-financial-results-sva-20191115monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-quarter-2019-financial-results-sva-20190815monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2019-financial-results-sva-20190710monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-half-of-2018-financial-results-and-files-2018-annual-repo-sva-20190429monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-positive-results-from-phase-iii-trial-of-a-sabin-strain-based-inactivate-sva-20190416monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-update-on-the-exchange-of-rights-for-common-and-series-b-preferred-shares-sva-20190412monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-press-release-sinovac-updates-exchange-mechanics-sinovac-update-on-the-exchange-of-sva-20190308monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-determines-trigger-event-occurred-under-rights-agreement-sinovac-board-of-director-sva-20190222monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-comments-on-antigua-and-barbuda-court-decision-denying-1globe-capital-s-claim-curr-sva-20181219monthly0.5https://www.biopharmawatch.com/news/SVA/haidian-district-people-s-court-in-beijing-issues-injunction-order-restraining-aihua-pan-f-sva-20181212monthly0.5https://www.biopharmawatch.com/news/SVA/hong-kong-high-court-issues-declaratory-orders-and-permanent-injunctive-relief-in-favor-of-sva-20181128monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-half-of-2018-financial-results-sva-20181108monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-granted-interim-injunctive-relief-regarding-filings-bearing-a-falsified-company-se-sva-20181022monthly0.5https://www.biopharmawatch.com/news/SVA/u-s-district-court-in-massachusetts-denies-1globe-s-motion-for-preliminary-injunction-to-e-sva-20181017monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-commences-legal-proceedings-to-nullify-filings-bearing-a-falsified-company-seal-an-sva-20181015monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-comments-on-unauthorized-use-of-falsified-sinovac-hong-kong-s-company-seal-and-sub-sva-20181009monthly0.5https://www.biopharmawatch.com/news/SVA/doj-closes-investigation-of-sinovac-beijing-sva-20180917monthly0.5https://www.biopharmawatch.com/news/SVA/sec-concludes-investigation-of-sinovac-beijing-sva-20180820monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-raises-86-73-million-through-private-placement-transaction-vivo-capital-and-advant-sva-20180703monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-motion-for-summary-judgment-on-rights-agreement-in-delaware-chancery-court-t-sva-20180626monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-2017-annual-report-on-form-20-f-and-reports-unaudited-second-half-audited-fu-sva-20180511monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-forced-to-temporarily-suspend-hepatitis-a-vaccine-production-line-due-to-disruptiv-sva-20180508monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-forced-to-temporarily-suspend-flu-vaccine-production-due-to-disruptive-actions-tak-sva-20180501monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-temporarily-blocks-access-to-its-websites-beijing-sva-20180430monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-delay-filing-of-2017-annual-report-on-form-20-f-following-actions-taken-by-the--sva-20180427monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-enters-into-amendment-to-amalgamation-agreement-for-going-private-transaction-beij-sva-20180427monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-resumes-production-and-operation-at-sinovac-beijing-s-quality-assurance-department-sva-20180423monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-preliminary-results-of-phase-iii-trial-on-sipv-beijing-sva-20180419monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-sets-the-record-straight-regarding-false-statements-by-shandong-sinobioway-biomedi-sva-20180418monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-enters-into-amendment-to-amalgamation-agreement-for-going-private-transaction-beij-sva-20180327monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-sets-the-record-straight-regarding-false-statements-by-unauthorized-third-parties--sva-20180315monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-amends-shareholder-rights-plan-beijing-sva-20180306monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-re-election-of-all-directors-at-annual-general-meeting-asks-delaware-cou-sva-20180306monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-holds-2017-annual-general-meeting-of-shareholders-beijing-sva-20180207monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-receives-positive-decision-on-its-hepatitis-a-vaccine-from-world-health-or-sva-20171222monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-cures-nasdaq-filing-deficiency-beijing-sva-20171201monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-half-of-2017-financial-results-sva-20171201monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-announces-update-on-nasdaq-matters-beijing-sva-20171130monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-2016-annual-report-on-form-20-f-and-reports-unaudited-fourth-quarter-2016-fi-sva-20171122monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-announces-request-hearing-before-nasdaq-hearings-panel-beijing-sva-20171108monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-announces-receipt-of-delisting-determination-letter-from-nasdaq-beijing-sva-20171103monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-announces-certain-updates-relating-to-delayed-filing-of-annual-report-on-f-sva-20170814monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-enters-into-definitive-agreement-for-going-private-transaction-beijing-sva-20170626monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-announces-receipt-of-nasdaq-letter-and-delayed-filing-of-annual-report-on--sva-20170516monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-amends-shareholder-rights-plan-beijing-sva-20170324monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-third-quarter-2016-financial-results-beijing-sva-20170208monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-responds-to-recent-report-sva-20161223monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-results-of-2016-annual-general-meeting-of-shareholders-beijing-sva-20161107monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-product-pipeline-news-sva-20161019monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-2016-annual-meeting-of-shareholders-beijing-sva-20160930monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-quarter-2016-financial-results-beijing-sva-20160823monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2016-financial-results-beijing-sva-20160526monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-special-committee-engages-financial-and-legal-advisors-beijing-sva-20160414monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-adopts-shareholder-rights-plan-and-declares-dividend-distribution-of-preferred-sha-sva-20160328monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-receipt-of-competing-non-binding-going-private-proposal-beijing-sva-20160204monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-receipt-of-a-preliminary-non-binding-proposal-to-acquire-the-company-and-sva-20160201monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-announces-issuance-of-gmp-certificate-for-ev71-vaccine-beijing-sva-20160128monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-obtains-clinical-trial-approval-for-sabin-ipv-candidate-beijing-sva-20160105monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-third-quarter-financial-results-conference-call-scheduled-for-th-sva-20151112monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-third-quarter-2015-unaudited-financial-results-b-sva-20151102monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-clinical-trial-approval-for-varicella-vaccine-candidate-beijing-sva-20151026monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-participate-in-morgan-stanley-global-healthcare-conference-beijing-sva-20150910monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-second-quarter-2015-unaudited-financial-results--sva-20150804monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2015-financial-results-conference-call-scheduled-f-sva-20150515monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-site-inspection-notification-for-ev71-vaccine-production-facilities-beiji-sva-20150514monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-participate-in-ubs-global-healthcare-conference-beijing-sva-20150512monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-first-quarter-2015-unaudited-financial-results-b-sva-20150507monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-2014-annual-report-on-form-20-f-beijing-sva-20150429monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-fourth-quarter-and-full-year-2014-financial-results-conference-c-sva-20150420monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-provides-updates-on-pipeline-vaccines-beijing-sva-20150415monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-participate-in-upcoming-investor-conferences-beijing-sva-20141117monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-tender-to-supply-inactivated-hepatitis-a-vaccine-healive-in-beijing-under-sva-20140819monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-quarter-financial-results-conference-call-scheduled-for-f-sva-20140815monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-2014-annual-meeting-of-shareholders-beijing-sva-20140714monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-favorable-reduction-in-value-added-tax-rate-beijing-sva-20140625monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-enters-technology-transfer-agreement-with-intravacc-to-develop-and-commercialize-s-sva-20140624monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-2013-annual-report-on-form-20-f-beijing-sva-20140416monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-clinical-trial-application-with-cfda-for-its-proprietary-vaccine-against-avi-sva-20140324monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-holds-2013-annual-general-meeting-of-shareholders-beijing-sva-20140127monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-2013-annual-meeting-of-shareholders-beijing-sva-20130816monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2013-financial-results-conference-call-scheduled-f-sva-20130528monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-beijing-obtains-china-gmp-certificate-under-the-new-gmp-guidelines-beijing-sva-20130524monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-appoints-ernst-young-hua-ming-llp-china-as-external-auditor-beijing-sva-20130515monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-preliminary-top-line-results-from-phase-iii-clinical-trial-for-ev71-vaccin-sva-20130503monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-third-quarter-2012-financial-results-conference-call-scheduled-f-sva-20121115monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-quarter-2012-financial-results-conference-call-scheduled--sva-20120928monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-beijing-cdc-tender-award-to-supply-seasonal-flu-vaccine-anflu-r-to-beijin-sva-20120926monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-holds-2012-annual-general-meeting-of-shareholders-beijing-sva-20120926monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-2012-annual-meeting-of-shareholders-beijing-sva-20120716monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-names-danny-chung-chief-financial-officer-beijing-sva-20120514monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2012-financial-results-conference-call-scheduled-f-sva-20120515monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-fourth-quarter-and-preliminary-full-year-2011-financial-results--sva-20120329monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-director-appointment-beijing-sva-20120329monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-nasdaq-deficiency-letter-regarding-audit-committee-requirement-press-rele-sva-20120124monthly0.5https://www.biopharmawatch.com/news/SVA/unassociated-document-sinovac-announces-resignation-of-chup-hung-mok-from-board-of-directo-sva-20120104monthly0.5https://www.biopharmawatch.com/news/SVA/unassociated-document-correction-sinovac-biotech-ltd-in-the-news-release-sinovac-reports-u-sva-20111208monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-quarter-2011-financial-results-conference-call-scheduled--sva-20110812monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-management-changes-chief-financial-officer-resigns-vice-president-of-sin-sva-20110805monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-holds-2011-annual-shareholders-meeting-press-release-source-sinovac-biotech-ltd-on-sva-20110714monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-positive-phase-i-clinical-trial-results-for-ev71-vaccine-candidate-against-sva-20110720monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2011-financial-results-conference-call-scheduled-f-sva-20110711monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-files-clinical-trial-applications-with-sfda-for-its-proprietary-pneumococc-sva-20110418monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-submits-clinical-trial-application-to-sfda-for-pneumococcal-conjugate-vacc-sva-20110418monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-positive-preliminary-phase-i-clinical-trial-results-for-ev71-vaccine-in-ad-sva-20110418monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-fourth-quarter-and-full-year-2010-financial-results-conference-call-schedu-sva-20110331monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-provides-preliminary-unaudited-fourth-quarter-2010-sales-range-beijing-sva-20110106monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-sfda-approval-to-commence-clinical-trials-for-inactivated-enterovirus-typ-sva-20101228monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-third-quarter-2010-financial-results-conference-call-scheduled-f-sva-20101115monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-preliminary-unaudited-third-quarter-2010-sales-range-and-revises-full-ye-sva-20101024monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-second-quarter-2010-financial-results-conference-call-scheduled--sva-20100816monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-holds-2010-annual-meeting-of-shareholders-beijing-sva-20100715monthly0.5https://www.biopharmawatch.com/news/SVA/important-reminder-sva-20100701monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-2010-annual-meeting-of-shareholders-beijing-sva-20100618monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2010-financial-results-conference-call-scheduled-f-sva-20100513monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-fourth-quarter-and-preliminary-full-year-2009-record-financial-r-sva-20100406monthly0.5https://www.biopharmawatch.com/news/SVA/english-translation-equity-joint-venture-contract-for-the-establishment-of-sinovac-dalian--sva-20100120monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-establishes-joint-venture-to-expand-human-use-vaccine-development-and-manufacturin-sva-20091127monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-third-quarter-2009-financial-results-conference-call-scheduled-m-sva-20091116monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-consolidated-financial-statements-expressed-in-u-s-dollars-unaudited-s-sva-20091118monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-transfer-stock-exchange-listing-to-nasdaq-global-market-beijing-nov-3-prnewswir-sva-20091104monthly0.5https://www.biopharmawatch.com/news/SVA/i-sinovac-reports-unaudited-second-quarter-2009-financial-results-conference-call-schedule-sva-20090930monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-first-quarter-2009-financial-results-conference-call-scheduled-f-sva-20090929monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-present-at-2009-ubs-global-life-sciences-conference-beijing-sept-16-prnewswire--sva-20090922monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-obtains-lot-release-certificate-for-its-first-batch-of-h1n1-vaccine-beijing-sept-8-sva-20090928monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-obtains-initial-order-of-h1n1-vaccine-from-chinese-central-government-beijing-sept-sva-20090915monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-obtains-production-license-for-h1n1-vaccine-beijing-sept-3-prnewswire-asia-sinovac-sva-20090928monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-supply-agreement-with-boryung-pharmaceutical-company-limited-in-south-ko-sva-20090928monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-s-h1n1-vaccine-passes-experts-evaluation-organized-by-sfda-beijing-aug-31-prnewswi-sva-20090928monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-wins-beijing-public-health-bureau-s-bid-to-supply-seasonal-flu-vaccine-anflu-r-to--sva-20090928monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-top-line-preliminary-results-of-h1n1-vaccine-clinical-trials-results-show--sva-20090817monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-2009-second-quarter-financial-results-beijing-au-sva-20090819monthly0.5https://www.biopharmawatch.com/news/SVA/revised-sinovac-provides-update-on-clinical-trial-for-h1n1-vaccine-trials-h1n1-vaccine-sho-sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-provides-update-on-clinical-trial-for-h1n1-vaccine-trials-h1n1-vaccine-shows-good--sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-initiates-dosing-in-human-clinical-trial-of-panflu-for-pandemic-influenza-a-h1n1-b-sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-adjourns-2008-annual-general-meeting-beijing-july-16-prnewswire-asia-sinovac-biote-sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-revised-approvals-for-panflu-extension-of-eligible-age-group-enables-sino-sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-china-s-first-influenza-a-h1n1-vaccine-order-beijing-june-19-prnewswire-a-sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-2008-annual-general-meeting-beijing-june-10-prnewswire-asia-sinovac-biot-sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-begins-the-production-of-influenza-a-h1n1-vaccine-on-monday-sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/china-s-vice-premier-li-keqiang-visits-sinovac-to-inspect-h1n1-vaccine-production-preparat-sva-20090827monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-files-annual-report-on-form-20-f-on-friday-sva-20090501monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-initiates-preparatory-activities-for-swine-flu-vaccine-on-thursday-sva-20090430monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-rmb-87-million-purchase-order-for-healive-from-china-s-ministry-of-public-sva-20090428monthly0.5https://www.biopharmawatch.com/news/SVA/c-o-r-r-e-c-t-i-o-n-sinovac-biotech-ltd-in-the-news-release-sinovac-reports-unaudited-full-sva-20090506monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-unaudited-full-year-2008-and-fourth-quarter-financial-results-conference-c-sva-20090506monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-fourth-quarter-and-full-year-2008-financial-resu-sva-20090506monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-co-ltd-sinovac-s-beijing-subsidiary-obtains-high-tech-enterprise-status-mo-sva-20090309monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-that-government-investigation-rules-out-healive-s-role-in-child-s-death--sva-20090108monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-named-to-zhongguancun-s-top-20-most-influential-brands-monday-december-22-8-00-am--sva-20081230monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-share-repurchase-program-tuesday-december-2-8-00-am-et-beijing-dec-2-prn-sva-20081204monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-releases-statement-on-healive-vaccine-suspension-tuesday-december-2-7-00-am-et-bei-sva-20081127monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-third-quarter-2008-unaudited-financial-results-conference-call-on-tuesday-sva-20081118monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-third-quarter-2008-financial-results-wednesday-sva-20081112monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-named-to-deloitte-technology-fast-50-china-monday-november-3-8-00-am-et-beijing-no-sva-20081031monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-participate-in-two-upcoming-investor-conferences-wednesday-october-29-8-00-am-e-sva-20081104monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-s-credit-rating-upgraded-to-aaz-second-highest-rating-obtains-10-million-rmb-comme-sva-20081009monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-launches-seasonal-influenza-vaccine-anflu-r-for-2008-2009-flu-season-wednesday-sep-sva-20081010monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-initiates-development-of-vaccine-against-hand-foot-and-mouth-disease-tuesday-septe-sva-20081008monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-increases-ownership-position-in-its-operating-subsidiary-sinovac-beijing-b-sva-20080922monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-holds-annual-general-meeting-beijing-september-18-sinovac-biotech-ltd-amex-sva-20081008monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-present-at-the-2008-ubs-global-life-sciences-conference-wednesday-september-17--sva-20080923monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-initiates-clinical-trials-for-inactivated-hepatitis-a-vaccine-in-ukraine-monday-se-sva-20081008monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-adjourns-annual-general-meeting-thursday-september-4-6-45-am-et-beijing-sept-4-xin-sva-20080904monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-present-at-the-susquehanna-financial-group-s-second-annual-beijing-management-s-sva-20080901monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-record-second-quarter-2008-unaudited-financial-results-conference-call-on--sva-20080813monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-schedules-2007-annual-meeting-of-shareholders-monday-august-11-8-00-am-sva-20080814monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-second-quarter-2008-financial-results-beijing-sva-20080807monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-initiates-phase-ii-volunteer-enrollment-for-split-viron-pandemic-influenza-h5n1-va-sva-20080702monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-healive-and-bilive-purchase-orders-from-provincial-cdcs-for-earthquake-di-sva-20080616monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-delivers-80-000-doses-of-bilive-to-gansu-earthquake-disaster-area-wednesday-june-1-sva-20080603monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-rmb-20-million-purchase-order-for-healive-from-china-s-ministry-of-health-sva-20080529monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-provides-support-to-china-s-ministry-of-health-to-aid-earthquake-victims-wednesday-sva-20080523monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-fourth-quarter-and-full-year-2007-financial-resu-sva-20080520monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-first-quarter-2008-unaudited-financial-results-friday-may-16-8-00-am-et-co-sva-20080516monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-host-conference-call-to-report-first-quarter-2008-financial-results-thursday-ma-sva-20080516monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-present-at-the-brean-murray-carret-co-all-cap-all-china-conference-and-the-roth-sva-20080509monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-holds-annual-general-meeting-thursday-april-10-8-00-am-et-beijing-april-10-sva-20080325monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-china-state-food-and-drug-administration-sfda-approval-for-pandemic-influ-sva-20080402monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-fourth-quarter-and-full-year-2007-financial-results-monday-march-31-1-00-a-sva-20080331monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-adjournment-of-annual-general-meeting-tuesday-march-25-3-00-am-et-beijin-sva-20080325monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-present-at-the-brean-murray-carret-co-fourth-investor-tour-of-china-beijing-sva-20080324monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-9-75-million-private-placement-beijing-sva-20080123monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-top-line-preliminary-phase-ii-results-of-pandemic-influenza-h5n1-whole-vir-sva-20071224monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-enters-purchase-agreement-with-beijing-public-health-bureau-for-anflu-sinovac-s-se-sva-20071101monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-present-at-2007-ubs-global-life-sciences-conference-monday-september-17-8-00-am-sva-20071101monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-commences-vaccination-on-volunteers-for-phase-ii-clinical-trial-on-pandemic-influe-sva-20071101monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-postponement-of-annual-general-meeting-monday-august-20-8-49-pm-et-beiji-sva-20071101monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-first-half-2007-financial-results-thursday-august-16-8-00-am-et-first-half-sva-20071101monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-commences-vaccination-of-volunteers-for-the-clinical-research-of-pandemic-influenz-sva-20070817monthly0.5https://www.biopharmawatch.com/news/SVA/semiannual-report-for-the-six-months-ended-sva-20070816monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-first-half-2007-financial-results-date-monday-august-13-8-00-am-et-beiji-sva-20070815monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-enters-exclusive-promotion-service-agreement-with-glaxosmithkline-china-investment-sva-20070803monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-annual-general-meeting-tuesday-july-31-8-00-am-et-beijing-july-31-xinhua-sva-20070802monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-receives-full-payment-for-heping-wang-s-obligations-friday-july-27-8-00-am-et-beij-sva-20070801monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-issues-corporate-update-friday-june-1-4-30-pm-et-beijing-june-1-xinhua-prnewswire--sva-20070801monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-commences-phase-ii-clinical-trials-for-pandemic-influenza-vaccine-h5n1-wednesday-m-sva-20070514monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-to-present-at-2007-ubs-global-generic-and-specialty-pharmaceuticals-conference-mon-sva-20070508monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-2006-financial-results-thursday-april-12-8-00-am-et-beijing-april-12-xinhu-sva-20070514monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-first-quarter-2007-unaudited-sales-thursday-april-12-8-00-am-et-beijing-ap-sva-20070514monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-2006-financial-results-date-monday-april-9-8-00-am-et-beijing-april-9-xi-sva-20070514monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-provides-update-on-study-of-third-dose-of-its-pandemic-influenza-vaccine-tuesday-m-sva-20070313monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-files-registration-documents-for-euvax-b-tm-with-sfda-loan-repayment-received-from-sva-20070212monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-schedules-investor-conference-call-for-sva-20070206monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-clarifies-position-on-restructuring-involving-its-chinese-subsidiary-wednesday-jan-sva-20070205monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-fourth-quarter-2006-unaudited-sales-and-provides-corporate-update-for-2007-sva-20070122monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-issues-corporate-update-tuesday-november-28-7-30-am-et-beijing-nov-28-xinhua-prnew-sva-20061130monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-engages-the-ruth-group-as-investor-relations-and-public-relations-coun-sva-20061018monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-announces-first-sales-of-its-seasonal-influenza-vaccine-anflu-tm-wedne-sva-20060929monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-announces-its-clinical-trial-results-of-a-pandemic-influenza-h5n1-vaccine-are-publ-sva-20060912monthly0.5https://www.biopharmawatch.com/news/SVA/preliminary-result-of-phase-i-clinical-trial-shows-that-sinovac-s-pandemic-influenza-vacci-sva-20060831monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-changes-its-contact-for-investor-relations-beijing-aug-1-xinhua-prnews-sva-20060731monthly0.5https://www.biopharmawatch.com/news/SVA/ludlow-capital-adds-sinovac-to-china-small-cap-index-beijing-july-19-xinhua-prnewswire-fir-sva-20060721monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-reports-fiscal-2005-results-beijing-july-14-xinhua-prnewswire-sinovac-biotech-ltd--sva-20060717monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-files-form-12b-25-with-the-u-s-securities-and-exchange-commission-beijing-sva-20060630monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-provides-administrative-updates-beijing-sva-20060616monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-completes-immunization-schedule-in-the-phase-i-clinical-trial-of-its-proprietary-a-sva-20060530monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-and-lg-life-sciences-ltd-announce-distribution-agreement-to-market-vac-sva-20060412monthly0.5https://www.biopharmawatch.com/news/SVA/to-the-form-s-8-which-was-filed-with-the-securities-and-exchange-commission-on-sva-20060302monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-announces-first-sales-of-its-proprietary-combined-hepatitis-a-b-vaccin-sva-20051109monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-and-lg-life-sciences-ltd-announce-their-letter-of-intent-for-collabora-sva-20050616monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-issues-corporate-update-beijing-sva-20050418monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-updates-on-its-avian-influenza-vaccine-development-beijing-sva-20050421monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-releases-financial-statements-for-the-third-quarter-and-nine-months-en-sva-20050217monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-completes-the-acquisition-of-an-additional-20-56-of-sinovac-beijing-op-sva-20050211monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-reports-2004-sales-growth-of-over-230-and-announces-1-475-million-priv-sva-20050110monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-signs-avian-flu-vaccine-co-development-agreement-with-china-centre-of--sva-20041216monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-enters-into-financial-advisory-agreement-with-credit-suisse-advisory-p-sva-20041221monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-phase-i-human-clinical-trial-shows-its-sars-vaccine-to-be-safe-and-to--sva-20041206monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-releases-financial-statements-for-first-six-months-of-2004-showing-sal-sva-20041122monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-issues-corporate-update-on-approval-of-its-hepatitis-a-b-vaccine-biliv-sva-20041118monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-updates-on-phase-i-human-clinical-testing-of-sars-vaccine-all-36-subje-sva-20041006monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-updates-on-phase-i-human-clinical-testing-of-sars-vaccine-all-36-subje-sva-20040916monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-has-received-over-us-1-million-in-government-research-funding-for-sars-sva-20040818monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-has-initiated-new-human-influenza-vaccine-r-d-project-and-is-expected--sva-20040323monthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-biotech-ltd-formerly-net-force-systems-inc-pro-forma-consolidated-financial-statem-sva-20040129monthly0.5https://www.biopharmawatch.com/news/SVA/net-force-systems-inc-signs-letter-of-intent-to-acquire-tangshan-yian-biological-engineeri-sva-20031031monthly0.5https://www.biopharmawatch.com/news/SVA/net-force-sva-20031029monthly0.5https://www.biopharmawatch.com/news/SVA/net-force-sva-20030926monthly0.5https://www.biopharmawatch.com/news/IPSC/unlocking-the-value-of-our-pipeline-for-t1d-january-2026-2-forward-looking-statements-this-ipsc-20260112monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-secures-oversubscribed-135-million-private-placement-financing-to-sup-ipsc-20260108monthly0.5https://www.biopharmawatch.com/news/IPSC/advancing-pipeline-of-transformative-cell-therapies-corporate-deck-x2013-december-2025-2-f-ipsc-20251212monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-appoints-accomplished-biotechnology-leaders-dr-han-lee-and-dr-martin--ipsc-20251209monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-u-ipsc-20250814monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-up-ipsc-20250515monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-full-year-2024-financial-results-and-provides-business-update-ipsc-20250319monthly0.5https://www.biopharmawatch.com/news/IPSC/january-2025-corporate-overview-2-forward-looking-statements-this-presentation-contains-fo-ipsc-20250113monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-up-ipsc-20241105monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-u-ipsc-20240808monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overview-july-2024-2-forward-looking-statements-this-presentation-contains-forwa-ipsc-20240708monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-presents-interim-results-from-phase-1-elipse-1-study-at-asco-2024-ann-ipsc-20240603monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-up-ipsc-20240509monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-strengthens-position-in-autoimmune-disease-with-strategic-pipeline-ex-ipsc-20240411monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overviewapril-2024-2-forward-looking-statements-this-presentation-contains-forwa-ipsc-20240411monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-presents-new-preclinical-data-highlighting-ipsc-derived-cell-therapy--ipsc-20240408monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-full-year-2023-financial-results-and-provides-business-update-ipsc-20240314monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-presents-initial-data-from-cnty-101-phase-1-elipse-1-trial-supporting-ipsc-20231209monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-receives-fda-clearance-of-ind-application-for-cnty-101-in-systemic-lu-ipsc-20231206monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-up-ipsc-20231109monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overview-aug-2023-2-forward-looking-statements-this-presentation-contains-forwar-ipsc-20231003monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-u-ipsc-20230809monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-up-ipsc-20230511monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overview-march-2023-2-forward-looking-statements-this-presentation-contains-forw-ipsc-20230320monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-full-year-2022-financial-results-and-provides-business-update-ipsc-20230316monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overviewjanuary-2023-2-forward-looking-statementsthis-presentation-contains-forw-ipsc-20230109monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overviewnovember-2022-2-forward-looking-statementsthis-presentation-contains-for-ipsc-20221130monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-up-ipsc-20221110monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overview-september-2022-2-forward-looking-statements-this-presentation-contains--ipsc-20220908monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-receives-study-may-proceed-notification-from-fda-for-cnty-101-the-fir-ipsc-20220825monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-u-ipsc-20220811monthly0.5https://www.biopharmawatch.com/news/IPSC/virtual-r-d-day-ipsc-20220613monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-up-ipsc-20220516monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-and-provid-ipsc-20220317monthly0.5https://www.biopharmawatch.com/news/IPSC/j-p-morgan-annual-healthcare-conference-january-2022-2-2-forward-looking-statements-this-p-ipsc-20220111monthly0.5https://www.biopharmawatch.com/news/IPSC/virtual-r-d-update-ipsc-20211216monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overview-november-2021-2-2-forward-looking-statements-this-presentation-contains-ipsc-20211118monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-up-ipsc-20211110monthly0.5https://www.biopharmawatch.com/news/IPSC/corporate-overview-october-2021-2-2-forward-looking-statements-this-presentation-contains--ipsc-20211013monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-reports-second-quarter-2021-financial-results-and-business-updates-co-ipsc-20210812monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates-zura-20260507monthly0.5https://www.biopharmawatch.com/news/ZURA/corporate-overview-zura-20260310monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-proposed-public-offering-of-class-a-ordinary-shares-and-pre-funded-warr-zura-20260224monthly0.5https://www.biopharmawatch.com/news/ZURA/corporate-overview-zura-20260211monthly0.5https://www.biopharmawatch.com/news/ZURA/corporate-overview-zura-20260112monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-third-quarter-2025-financial-results-and-recent-corporate-updates-continu-zura-20251113monthly0.5https://www.biopharmawatch.com/news/ZURA/advancing-dual-pathway-biologic-candidates-in-autoimmune-and-inflammatory-diseases-septemb-zura-20250904monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-to-participate-in-the-cantor-fitzgerald-global-healthcare-conference-henderson-ne-zura-20250820monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-second-quarter-2025-financial-results-and-recent-corporate-updates-initia-zura-20250814monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-chief-financial-officer-transition-henderson-nv-business-wire-zura-20250701monthly0.5https://www.biopharmawatch.com/news/ZURA/advancing-dual-pathway-biologic-candidates-addressing-unmet-needs-in-autoimmune-and-inflam-zura-20250604monthly0.5https://www.biopharmawatch.com/news/ZURA/at-the-jefferies-global-healthcare-conference-zura-20250527monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-launches-global-phase-2-tibushield-study-to-evaluate-tibulizumab-in-adults-with-h-zura-20250520monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-first-quarter-2025-financial-results-and-recent-corporate-updates-advance-zura-20250508monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-ltd-nasdaq-ticker-zura-advancing-dual-pathway-biologic-candidates-addressing-unme-zura-20250321monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-full-year-2024-financial-results-and-recent-corporate-updates-achieved-ke-zura-20250325monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-to-present-at-the-leerink-partners-global-healthcare-conference-henderson-nev-bus-zura-20250224monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-ltd-nasdaq-ticker-zura-advancing-dual-pathway-biologic-candidates-addressing-unme-zura-20250113monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-launches-global-phase-2-tibusure-study-to-evaluate-tibulizumab-in-adults-with-sys-zura-20241223monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-submission-of-protocol-to-u-s-food-and-drug-administration-for-the-phas-zura-20241114monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-third-quarter-2024-financial-results-and-recent-corporate-updates-expect--zura-20241107monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-to-participate-in-two-upcoming-investor-conferences-in-november-henderson-nev-bus-zura-20241030monthly0.5https://www.biopharmawatch.com/news/ZURA/xa9-2024-zura-bio-ltd-nasdaq-ticker-zura-three-unique-dual-pathway-biologics-clinically-va-zura-20240909monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-to-present-at-three-upcoming-investor-conferences-in-september-henderson-nev-zura-20240903monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-ltd-nasdaq-ticker-zura-three-unique-dual-pathway-biologics-clinically-validated-f-zura-20240814monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-second-quarter-2024-financial-results-and-recent-business-highlights-pres-zura-20240813monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-completes-exchange-offer-and-consent-solicitation-and-notice-to-exercise-right-to-zura-20240812monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-expiration-and-results-of-exchange-offer-and-consent-solicitation-relat-zura-20240809monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-commences-warrant-exchange-offer-and-consent-solicitation-henderson-nv-zura-20240712monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-presents-data-for-the-tibulizumab-zb-106-program-at-eular-2024-tibulizumab-zb-106-zura-20240614monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-forms-scientific-advisory-board-with-prominent-specialists-in-rheumatology-dermat-zura-20240606monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-to-present-data-exploring-the-expanded-potential-of-tibulizumab-zb-106-into-sjogr-zura-20240603monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-participation-in-june-investor-conferences-henderson-nev-zura-20240529monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-first-quarter-2024-financial-results-and-recent-business-highlights-ended-zura-20240509monthly0.5https://www.biopharmawatch.com/news/ZURA/xa9-2024-zura-bio-ltd-nasdaq-ticker-zura-advancing-clinical-outcomes-through-pioneering-du-zura-20240423monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-robert-lisicki-as-ceo-and-director-succeeds-founding-ceo-dr-someit-sidh-zura-20240408monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-full-year-2023-financial-results-business-highlights-and-appoints-robert--zura-20240328monthly0.5https://www.biopharmawatch.com/news/ZURA/xa9-2024-zura-bio-ltd-nasdaq-ticker-zura-building-the-next-immunology-leader-march-2024-xa-zura-20240311monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-participation-at-march-conferences-henderson-nev-zura-20240304monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-participation-at-february-investor-conferences-henderson-nev-zura-20240202monthly0.5https://www.biopharmawatch.com/news/ZURA/xa9-2024-zura-bio-ltd-nasdaq-ticker-zura-building-the-next-immunology-leader-42nd-annual-j-zura-20240111monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-continues-to-strengthen-leadership-with-appointment-of-robert-lisicki-as-presiden-zura-20240108monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-and-dermatology-su-zura-20240103monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-two-immunology-abstracts-presented-at-the-world-allergy-congress-in-ban-zura-20231204monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-appoints-arnout-ploos-van-amstel-to-its-board-of-directors-henderson-nev-zura-20231114monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-ltd-corporate-overview-last-updated-october-2023-building-the-next-immunology-lea-zura-20231025monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-enters-into-sponsored-research-agreement-with-benaroya-research-institute-benaroy-zura-20230912monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-reports-second-quarter-2023-financial-results-and-recent-business-highlights-focu-zura-20230814monthly0.5https://www.biopharmawatch.com/news/ZURA/building-the-next-immunology-leader-corporate-presentation-july-2023-2023-zura-bio-ltd-thi-zura-20230727monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-to-join-the-russell-2000-and-russell-3000-indexes-zura-20230623monthly0.5https://www.biopharmawatch.com/news/ZURA/building-the-next-immunology-leader-last-updated-june-2023-zurabio-corporate-overview-disc-zura-20230615monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-completes-approximately-80-million-financing-with-the-focus-on-advancing-zb-106-a-zura-20230606monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-80-million-financing-and-the-licensing-of-tibulizumab-zb-106-a-potentia-zura-20230427monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-announces-appointment-of-chief-scientific-officer-zura-20230414monthly0.5https://www.biopharmawatch.com/news/ZURA/summary-unaudited-pro-forma-condensed-combined-financial-information-the-following-summary-zura-20230324monthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-limited-announces-closing-of-business-combination-with-jatt-acquisition-corp-zura-zura-20230321monthly0.5https://www.biopharmawatch.com/news/ZURA/jatt-acquisition-corp-shareholders-approve-proposed-business-combination-with-zura-bio-lim-zura-20230316monthly0.5https://www.biopharmawatch.com/news/ZURA/jatt-acquisition-corp-announces-planned-transfer-of-listing-to-nasdaq-in-connection-with-i-zura-20230313monthly0.5https://www.biopharmawatch.com/news/ZURA/jatt-acquisition-corp-s-proposed-business-combination-with-zura-bio-limited-declared-effec-zura-20230216monthly0.5https://www.biopharmawatch.com/news/ZURA/jatt-acquisition-corp-and-zura-bio-limited-announce-definitive-business-combination-agreem-zura-20220617monthly0.5https://www.biopharmawatch.com/news/ZURA/jatt-acquisition-corp-report-of-independent-registered-public-accounting-firm-f-2-balance--zura-20210716monthly0.5https://www.biopharmawatch.com/news/ZURA/jatt-acquisition-corp-prices-120-million-initial-public-offering-new-york-new-york-zura-20210714monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-operati-lxeo-20260330monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-positive-interim-phase-i-ii-data-for-lx2020-for-the-treatment-lxeo-20260112monthly0.5https://www.biopharmawatch.com/news/LXEO/forward-looking-statements-this-presentation-contains-x201c-forward-looking-statements-x20-lxeo-20251007monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-reports-second-quarter-2025-financial-results-and-operational-highlight-lxeo-20250814monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-reports-first-quarter-2025-financial-results-and-operational-highlights-lxeo-20250512monthly0.5https://www.biopharmawatch.com/news/LXEO/forward-looking-statements-this-presentation-contains-x201c-forward-looking-statements-x20-lxeo-20250407monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-operati-lxeo-20250324monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-corporate-overview-lxeo-20250113monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-appoints-kyle-rasback-as-chief-financial-officer-new-york-x2013-lxeo-20241219monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-provides-update-on-cardiac-portfolio-and-reports-third-quarter-2024-fin-lxeo-20241113monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-positive-interim-data-for-lx1001-first-ever-gene-therapy-to-i-lxeo-20241030monthly0.5https://www.biopharmawatch.com/news/LXEO/forward-looking-statements-this-presentation-contains-x201c-forward-looking-statements-x20-lxeo-20241009monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-reports-second-quarter-2024-financial-results-and-operational-highlight-lxeo-20240812monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-positive-interim-phase-1-2-clinical-data-of-lx2006-for-the-tr-lxeo-20240715monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-appoints-tim-van-hauwermeiren-to-its-board-of-directors-new-york-x2013-lxeo-20240708monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-reports-first-quarter-2024-financial-results-and-operational-highlights-lxeo-20240509monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-license-agreement-to-accelerate-development-of-lx2006-for-the-lxeo-20240422monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-granted-fda-fast-track-designation-for-lx2006-an-aav-based-gene-therapy-lxeo-20240416monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-operati-lxeo-20240311monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-strengthens-clinical-development-leadership-with-new-executive-appointm-lxeo-20240205monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-granted-fda-fast-track-designation-and-orphan-drug-designation-for-lx20-lxeo-20231218monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-reports-third-quarter-2023-financial-results-and-operational-highlights-lxeo-20231211monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-fourth-quarter-and-full-year-2025-financial-results-announces-focu-dna-20260226monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-third-quarter-2025-financial-results-ginkgo-provides-an-update-on--dna-20251106monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-second-quarter-2025-financial-results-ginkgo-provides-an-update-on-dna-20250807monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-announces-appointment-of-steven-coen-as-chief-financial-officer-dna-20250521monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-first-quarter-2025-financial-results-ginkgo-provides-an-update-on--dna-20250506monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-fourth-quarter-and-full-year-2024-financial-results-ginkgo-provide-dna-20250225monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-third-quarter-2024-financial-results-ginkgo-provides-update-on-its-dna-20241112monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-second-quarter-2024-financial-results-ginkgo-provides-update-on-it-dna-20240808monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-receives-continued-listing-standard-notice-from-nyse-ginkgo-s-class-a-comm-dna-20240513monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-first-quarter-2024-financial-results-ginkgo-announces-several-init-dna-20240509monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-fourth-quarter-and-full-year-2023-financial-results-251-million-of-dna-20240229monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-provides-business-updates-at-j-p-morgan-healthcare-conference-expects-to-m-dna-20240110monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-third-quarter-2023-financial-results-ginkgo-added-21-new-cell-prog-dna-20231108monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biologic-dna-20230829monthly0.5https://www.biopharmawatch.com/news/DNA/to-ginkgo-s-current-report-on-form-8-k-filed-with-the-sec-on-dna-20230823monthly0.5https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-reports-second-quarter-2023-financial-results-ginkgo-added-21-new-cell-pro-dna-20230809monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2026-results-highlighting-steady-execution-following-spine--ofix-20260505monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-realigns-spine-leadership-to-strengthen-focus-and-execution-company-reports-preli-ofix-20260409monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-fin-ofix-20260224monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-third-quarter-2025-financial-results-lewisville-texas-x2014-ofix-20251104monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-second-quarter-2025-financial-results-lewisville-texas-x2014-ofix-20250805monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2025-financial-results-lewisville-texas-x2014-ofix-20250506monthly0.5https://www.biopharmawatch.com/news/OFIX/forward-looking-statements-this-news-release-may-include-forward-looking-statements-within-ofix-20250312monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-fourth-quarter-and-full-year-2024-results-and-provides-2025-financial-gui-ofix-20250225monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-third-quarter-2024-results-reiterates-full-year-2024-financial-guidance-a-ofix-20241107monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-second-quarter-2024-results-and-raises-full-year-2024-financial-guidance--ofix-20240806monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2024-results-recent-highlights-x2022-net-sales-of-188-6-mil-ofix-20240507monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-fourth-quarter-and-full-year-2023-results-recent-highlights-x2022-fourth--ofix-20240305monthly0.5https://www.biopharmawatch.com/news/OFIX/julie-andrews-begins-as-new-chief-financial-officer-at-orthofix-lewisville-texas-x2014-ofix-20240116monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-medical-inc-announces-preliminary-2023-fourth-quarter-and-full-year-net-sales-res-ofix-20240109monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-provides-executive-management-business-update-and-appoints-julie-andrews-as-chief-ofix-20240108monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-medical-inc-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-orthofix--ofix-20231212monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-medical-inc-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-orthofix--ofix-20231128monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-third-quarter-2023-results-x2022-in-november-2023-entered-into-a-new-four-ofix-20231108monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-leadership-changes-9-12-2023-catherine-burzik-appointed-interim-chief-e-ofix-20230913monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-second-quarter-2023-results-and-raises-revenue-and-adjusted-ebitda-guidan-ofix-20230808monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-medical-inc-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-orthofix--ofix-20230620monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2023-results-x2022-net-sales-of-175-2-million-an-increase-o-ofix-20230509monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-medical-reports-orthofix-and-seaspine-fourth-quarter-and-full-year-2022-results-l-ofix-20230306monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-medical-inc-announces-preliminary-seaspine-and-orthofix-2022-fourth-quarter-and-f-ofix-20230109monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-and-seaspine-announce-completion-of-merger-of-equals-to-create-a-leading-global-s-ofix-20230104monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-and-seaspine-announce-john-bostjancic-to-serve-as-cfo-for-combined-company-post-c-ofix-20221118monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-third-quarter-2022-results-x2022-net-sales-of-114-0-million-an-increase-o-ofix-20221103monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-preliminary-third-quarter-and-year-to-date-2022-net-sales-results-third-ofix-20221011monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-and-seaspine-to-combine-in-merger-of-equals-to-create-leading-global-spine-and-or-ofix-20221011monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-second-quarter-2022-results-x2022-net-sales-of-118-1-million-a-decrease-o-ofix-20220805monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2022-results-x2022-net-sales-of-106-4-million-an-increase-o-ofix-20220506monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-medical-inc-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-orthofix--ofix-20220408monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-fourth-quarter-and-fiscal-year-2021-results-fourth-quarter-net-sales-of-1-ofix-20220225monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-preliminary-2021-fourth-quarter-and-full-year-net-sales-results-fourth--ofix-20220110monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-appointment-of-thomas-a-west-to-board-of-directors-lewisville-texas-ofix-20211214monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-third-quarter-2021-results-net-sales-of-112-million-an-increase-of-1-3-ov-ofix-20211105monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-provides-business-update-lewisville-texas-ofix-20210929monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-appointment-of-wayne-burris-to-board-of-directors-lewisville-texas-ofix-20210923monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-second-quarter-2021-results-net-sales-of-121-million-up-66-compared-to-pr-ofix-20210806monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2021-results-net-sales-of-106-million-up-1-compared-to-prio-ofix-20210430monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-board-chair-transition-ron-matricaria-to-conclude-service-as-chairman-o-ofix-20210407monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-fourth-quarter-and-fiscal-year-2020-results-fourth-quarter-net-sales-of-1-ofix-20210226monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-preliminary-2020-fourth-quarter-and-full-year-net-sales-results-fourth--ofix-20210112monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-third-quarter-2020-results-x2022-net-sales-of-111-0-million-an-increase-o-ofix-20201105monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-and-neo-medical-announce-partnership-to-develop-and-market-single-use-spinal-solu-ofix-20200922monthly0.5https://www.biopharmawatch.com/news/OFIX/paul-gonsalves-joins-orthofix-as-president-of-global-extremities-business-lewisville-texas-ofix-20200914monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-second-quarter-2020-results-x2022-net-sales-of-73-1-million-a-decrease-of-ofix-20200806monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-election-of-jason-hannon-to-board-of-directors-lewisville-tx-ofix-20200608monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2020-results-x2022-net-sales-of-104-8-million-a-decrease-of-ofix-20200508monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-preliminary-first-quarter-2020-results-and-provides-business-update-lew-ofix-20200409monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-completes-acquisition-of-fitbone-limb-lengthening-system-lewisville-tx-ofix-20200326monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-fourth-quarter-and-fiscal-year-2019-financial-results-fourth-quarter-high-ofix-20200224monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-agreement-to-acquire-fitbone-limb-lengthening-system-transaction-expand-ofix-20200204monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-names-kevin-kenny-president-of-global-spine-business-lewisville-texas-ofix-20191205monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-appoints-jon-serbousek-as-president-and-chief-executive-officer-serbousek-succeed-ofix-20191101monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-third-quarter-2019-results-x2022-jon-serbousek-to-succeed-brad-mason-as-p-ofix-20191028monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-names-jon-serbousek-to-succeed-ceo-serbousek-to-succeed-brad-mason-upon-his-retir-ofix-20190806monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-second-quarter-2019-results-x2022-jon-serbousek-to-succeed-brad-mason-as--ofix-20190805monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2019-results-x2022-net-sales-of-109-1-million-an-increase-o-ofix-20190506monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-fourth-quarter-and-fiscal-2018-financial-results-ceo-announces-plans-to-r-ofix-20190225monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-medical-inc-3451-plano-parkway-lewisville-tx-75056-usa-214-937-2000-orthofix-com--ofix-20190207monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-preliminary-2018-fourth-quarter-and-full-year-net-sales-results-ofix-20190108monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-third-quarter-2018-financial-results-third-quarter-highlights-x2022-net-s-ofix-20181029monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-second-quarter-2018-financial-results-second-quarter-highlights-x2022-net-ofix-20180806monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-first-quarter-2018-financial-results-completes-acquisition-of-spinal-kine-ofix-20180430monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20180315monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20180313monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-fourth-quarter-and-fiscal-2017-financial-results-fourth-qua-ofix-20180226monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-preliminary-2017-fourth-quarter-and-full-year-net-sales-results-provide-ofix-20180109monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-third-quarter-2017-financial-results-third-quarter-highligh-ofix-20171030monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-second-quarter-2017-financial-results-second-quarter-highli-ofix-20170807monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-first-quarter-2017-financial-results-first-quarter-highligh-ofix-20170504monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-fourth-quarter-and-fiscal-2016-financial-results-fourth-qua-ofix-20170227monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20170118monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-preliminary-2016-fourth-quarter-and-full-year-net-sales-results-provide-ofix-20170110monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20161213monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-third-quarter-2016-financial-results-x2022-net-sales-of-98--ofix-20161031monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-second-quarter-2016-financial-results-net-sales-of-104-1-mi-ofix-20160801monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-first-quarter-2016-financial-results-first-quarter-highligh-ofix-20160428monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20160317monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-fourth-quarter-and-fiscal-2015-financial-results-fourth-qua-ofix-20160229monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-announces-preliminary-fourth-quarter-2015-and-full-year-net-sales-results-ofix-20160112monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-third-quarter-2015-financial-results-third-quarter-highligh-ofix-20151103monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-second-quarter-2015-financial-results-second-quarter-highli-ofix-20150804monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20150625monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-first-quarter-2015-financial-results-lewisville-texas-ofix-20150518monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-reports-fourth-quarter-and-fiscal-2014-financial-results-appoints-d-ofix-20150429monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20150324monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20150112monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20141124monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-provides-finance-and-restatement-update-company-continuing-to-finalize-audit-work-ofix-20140925monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20140922monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-updates-filing-status-plans-to-restate-prior-periods-financial-statements-company-ofix-20140819monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20140806monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-news-release-contact-mark-quick-investor-relations-tel-214-937--ofix-20140505monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20140507monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20140425monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20140327monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-appoints-ronald-a-matricaria-as-new-chairman-of-the-board-ofix-20140320monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-n-v-3451-plano-parkway-lewisville-tx-75056-usa-tel-214-937-2000-ort-ofix-20140324monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-receives-expected-nasdaq-notice-intends-to-request-a-hearing-before-nasdaq-hearin-ofix-20140212monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-provides-update-on-nasdaq-listing-status-intends-to-complete-its-financial-restat-ofix-20140205monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-appoints-kathleen-regan-as-interim-chair-of-the-board-ofix-20140123monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-appoints-dr-anthony-f-martin-to-its-board-of-directors-ofix-20131203monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-provides-update-regarding-nasdaq-listing-matters-lewisville-tx-ofix-20131122monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-appoints-two-new-independent-board-members-randy-thurman-named-chairman-expands-b-ofix-20131106monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-receives-expected-nasdaq-notice-related-to-late-filing-of-form-10-q-lewisville-tx-ofix-20130819monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-issues-financial-statement-non-reliance-statement-company-to-restate-financial-st-ofix-20130806monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-postpones-second-quarter-earnings-release-and-investor-conference-call-lewisville-ofix-20130729monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-realigns-business-units-to-support-future-growth-opportunities-and-announces-lead-ofix-20130620monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-announces-first-quarter-2013-results-board-of-directors-authorizes--ofix-20130508monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-appoints-emily-buxton-as-chief-financial-officer-ofix-20130404monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-appoints-brad-mason-as-president-and-chief-executive-officer-ofix-20130313monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-announces-4th-quarter-and-full-year-2012-results-q4-12-gross-profit-ofix-20130221monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-provides-preliminary-2012-results-ofix-20130107monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-concludes-bone-growth-stimulator-investigation-ofix-20121216monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-executes-final-settlement-agreement-related-to-the-investigation-of-blackstone-me-ofix-20121029monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-announces-3rd-quarter-2012-results-reported-operating-margin-of-19--ofix-20121024monthly0.5https://www.biopharmawatch.com/news/OFIX/brian-mccollum-to-lead-orthofix-spine-global-business-unit-ofix-20121016monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-comments-on-judge-s-ruling-ofix-20120906monthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-international-announces-2nd-quarter-2012-results-net-sales-were-119-5-million-up--ofix-20120726monthly0.5https://www.biopharmawatch.com/news/OFIX/in-the-united-states-district-court-for-the-eastern-district-of-texas-sherman-division-sec-ofix-20120710monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-update-on-phase-iii-clinical-trial-flamingo-01-glsi-20240214monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-inc-announces-partnership-with-baylor-college-of-medicine-for-its-p-glsi-20201113monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-inc-announces-pricing-of-initial-public-offering-stafford-tx-busine-glsi-20200924monthly0.5https://www.biopharmawatch.com/news/CYH/the-unaudited-pro-forma-condensed-consolidated-financial-information-is-subject-to-the-ass-cyh-20260601monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2026-results-cyh-20260421monthly0.5https://www.biopharmawatch.com/news/CYH/on-january-20-2026-chs-community-health-systems-inc-cyh-20260401monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-four-arkansas-hospitals-to-cyh-20260305monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-and-year-end-2025-results-cyh-20260218monthly0.5https://www.biopharmawatch.com/news/CYH/notes-thereto-should-be-read-in-conjunction-with-the-company-s-financial-statements-for-th-cyh-20260202monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-huntsville-alabama-hospita-cyh-20260120monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-appoints-kevin-hammons-chief-executive-officer-and-jason-johnson--cyh-20251210monthly0.5https://www.biopharmawatch.com/news/CYH/the-unaudited-pro-forma-condensed-consolidated-financial-information-is-subject-to-the-ass-cyh-20251202monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-ownership-interests-in-cla-cyh-20251030monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2025-results-cyh-20251023monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-early-tender-results-for-its-5-625-senior-secured-n-cyh-20250811monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-offering-of-1-500-million-of-senior-secured-notes-d-cyh-20250728monthly0.5https://www.biopharmawatch.com/news/CYH/tim-hingtgen-to-retire-as-chief-executive-officer-of-community-health-systems-kevin-hammon-cyh-20250723monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2025-results-cyh-20250723monthly0.5https://www.biopharmawatch.com/news/CYH/chs-announces-definitive-agreement-to-sell-select-outreach-laboratory-assets-to-labcorp-pa-cyh-20250722monthly0.5https://www.biopharmawatch.com/news/CYH/the-unaudited-pro-forma-condensed-consolidated-financial-information-is-subject-to-the-ass-cyh-20250701monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-early-tender-results-of-previously-announced-tender-cyh-20250507monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-commencement-of-cash-tender-offer-for-6-875-senior--cyh-20250423monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-sale-of-700-million-aggregate-principal-amount-of-1-cyh-20250423monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2025-results-cyh-20250423monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-ownership-interest-in-ceda-cyh-20250415monthly0.5https://www.biopharmawatch.com/news/CYH/the-unaudited-pro-forma-condensed-consolidated-financial-information-is-subject-to-the-ass-cyh-20250401monthly0.5https://www.biopharmawatch.com/news/CYH/the-unaudited-pro-forma-condensed-consolidated-financial-information-is-subject-to-the-ass-cyh-20250303monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-2024-results-cyh-20250218monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-north-carolina-hospital-to-cyh-20241211monthly0.5https://www.biopharmawatch.com/news/CYH/president-and-chief-financial-officer-anton-hie-615-465-7012-vice-president-x2013-investor-cyh-20241126monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-shorepoint-health-system-i-cyh-20241122monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2024-results-cyh-20241023monthly0.5https://www.biopharmawatch.com/news/CYH/medicine-surgical-services-cardiovascular-care-obstetrics-and-other-service-lines-clinical-cyh-20240911monthly0.5https://www.biopharmawatch.com/news/CYH/not-be-useful-in-predicting-the-impact-of-the-transactions-on-the-future-financial-conditi-cyh-20240801monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-three-pennsylvania-hospita-cyh-20240730monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2024-results-cyh-20240724monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-provides-update-regarding-lake-norman-regional-medical-center-cyh-20240619monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-pricing-of-1-225-0-million-tack-on-offering-of-10-8-cyh-20240521monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-tack-on-offering-of-1-125-0-million-10-875-senior-s-cyh-20240521monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-election-of-new-independent-director-franklin-tenn-cyh-20240507monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2024-results-cyh-20240424monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-cleveland-tennessee-hospit-cyh-20240418monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-2023-results-cyh-20240220monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-early-tender-results-for-its-8-000-senior-secured-n-cyh-20231226monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-pricing-of-upsized-offering-of-senior-secured-notes-cyh-20231211monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-offering-of-750-0-million-of-senior-secured-notes-d-cyh-20231211monthly0.5https://www.biopharmawatch.com/news/CYH/in-the-united-states-district-court-for-the-middle-district-of-tennessee-nashville-divisio-cyh-20231208monthly0.5https://www.biopharmawatch.com/news/CYH/the-unaudited-pro-forma-condensed-consolidated-financial-information-is-subject-to-the-ass-cyh-20231201monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2023-results-cyh-20231025monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-appointment-of-new-independent-director-franklin-te-cyh-20230913monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2023-results-cyh-20230802monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-three-florida-hospitals-to-cyh-20230724monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2023-results-cyh-20230501monthly0.5https://www.biopharmawatch.com/news/CYH/financial-statements-for-the-year-ended-december-31-2022-included-in-the-company-s-annual--cyh-20230403monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-definitive-agreement-to-sell-two-north-carolina-hospita-cyh-20230228monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contact-kevin-hammons-president-and-chief-financial-officer-615-465-7000-communit-cyh-20230215monthly0.5https://www.biopharmawatch.com/news/CYH/company-s-quarterly-report-on-form-10-q-filed-on-october-27-2022-and-the-company-s-financi-cyh-20230103monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-wayne-t-smith-to-retire-as-executive-chairman-of-th-cyh-20221202monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2022-results-cyh-20221026monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2022-results-cyh-20220727monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contact-kevin-hammons-president-and-chief-financial-officer-615-465-7000-communit-cyh-20220427monthly0.5https://www.biopharmawatch.com/news/CYH/thereto-the-consolidated-operating-results-for-the-three-months-and-year-ended-cyh-20220216monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-pricing-of-senior-secured-notes-due-2030-franklin-t-cyh-20220120monthly0.5https://www.biopharmawatch.com/news/CYH/risk-factors-risks-related-to-the-covid-19-pandemic-we-expect-the-covid-19-pandemic-to-con-cyh-20220113monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-offering-of-1-535-0-million-of-senior-secured-notes-cyh-20220120monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-mourns-the-death-of-lead-director-and-longtime-board-member-julia-cyh-20211210monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-that-ben-fordham-executive-vice-president-general-couns-cyh-20211208monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2021-results-cyh-20211027monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-appointment-of-new-independent-director-franklin-te-cyh-20210915monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2021-results-cyh-20210728monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-pricing-of-1-440-million-junior-priority-secured-no-cyh-20210504monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-offering-of-1-440-million-of-junior-priority-secure-cyh-20210504monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2021-results-cyh-20210428monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-and-year-end-2020-results-cyh-20210217monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-early-tender-results-for-its-junior-priority-secure-cyh-20210202monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-pricing-of-senior-secured-notes-due-2031-franklin-t-cyh-20210126monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-offering-of-1-095-billion-of-senior-secured-notes-d-cyh-20210126monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-pricing-of-1-775-billion-junior-priority-secured-no-cyh-20210119monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-offering-of-750-million-of-junior-priority-secured--cyh-20210119monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-early-tender-results-and-notice-of-redemption-for-i-cyh-20201228monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-pricing-of-2-8-billion-senior-secured-notes-frankli-cyh-20201211monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-offering-of-1-050-billion-of-senior-secured-notes-d-cyh-20201211monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-agrees-to-privately-negotiated-exchange-of-700-million-of-not-cyh-20201207monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-early-tender-results-of-and-amendment-to-previously-cyh-20201116monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-cash-tender-offers-for-up-to-400-0-million-aggregat-cyh-20201030monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-that-wayne-t-smith-will-transition-from-chief-execu-cyh-20201027monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2020-results-cyh-20201027monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2020-results-cyh-20200728monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2020-results-cyh-20200428monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-and-year-end-2019-results-cyh-20200219monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-kevin-j-hammons-ross-w-comeaux-executive-vice-president-vice-president-i-cyh-20200205monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-kevin-j-hammons-ross-w-comeaux-executive-vice-president-and-chief-financ-cyh-20200123monthly0.5https://www.biopharmawatch.com/news/CYH/kevin-hammons-named-chief-financial-officer-of-community-health-systems-franklin-tenn-cyh-20200102monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-that-chief-financial-officer-thomas-j-aaron-will-retire-cyh-20191212monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20191113monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20191029monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2019-results-cyh-20191029monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2019-results-cyh-20190805monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contact-thomas-j-aaron-executive-vice-president-and-chief-financial-officer-615-4-cyh-20190430monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-executive-vice-president-and-chief-financial-officer-615--cyh-20190227monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-and-year-end-2018-results-cyh-20190220monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-appointment-of-new-director-franklin-tenn-cyh-20181212monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2018-results-cyh-20181029monthly0.5https://www.biopharmawatch.com/news/CYH/global-settlement-resolves-u-s-department-of-justice-investigation-into-health-management--cyh-20180925monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2018-results-cyh-20180726monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20180627monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20180620monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-and-chief-financi-cyh-20180611monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20180606monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-and-chief-financi-cyh-20180604monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20180525monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20180523monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20180518monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20180505monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contacts-thomas-j-aaron-ross-w-comeaux-executive-vice-president-vice-president-in-cyh-20180501monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2018-results-cyh-20180501monthly0.5https://www.biopharmawatch.com/news/CYH/summarized-organizational-chart-guarantor-hospitals-91-non-guarantor-hospitals-with-equity-cyh-20180320monthly0.5https://www.biopharmawatch.com/news/CYH/this-presentation-has-been-prepared-for-the-exclusive-use-of-the-party-to-whom-community-h-cyh-20180315monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-and-year-end-2017-results-cyh-20180227monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-election-of-two-new-independent-directors-franklin--cyh-20171213monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2017-results-cyh-20171101monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-retirement-of-division-president-michael-portacci-frank-cyh-20171026monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2017-results-cyh-20170801monthly0.5https://www.biopharmawatch.com/news/CYH/exhibit-number-99-1-investor-contact-thomas-j-aaron-executive-vice-president-and-chief-fin-cyh-20170726monthly0.5https://www.biopharmawatch.com/news/CYH/thomas-j-aaron-named-chief-financial-officer-of-community-health-systems-franklin-tenn-cyh-20170516monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-completion-of-tack-on-offering-of-900-000-000-of-6--cyh-20170512monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2017-results-cyh-20170501monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-completion-of-offering-of-2-2-billion-of-6-250-seni-cyh-20170316monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-commencement-of-tender-offer-for-5-125-senior-secur-cyh-20170302monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-retirement-of-chief-financial-officer-w-larry-cash-will-cyh-20170222monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-and-year-end-2016-results-cyh-20170220monthly0.5https://www.biopharmawatch.com/news/CYH/united-states-district-court-middle-district-of-tennessee-nashville-division-in-re-communi-cyh-20161118monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contact-w-larry-cash-president-of-financial-services-and-chief-financial-officer--cyh-20161101monthly0.5https://www.biopharmawatch.com/news/CYH/exhibit-number-99-1-investor-contact-w-larry-cash-president-of-financial-services-and-chie-cyh-20161026monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-adopts-a-short-term-stockholder-protection-rights-agreement-f-cyh-20161003monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-that-tim-l-hingtgen-will-become-president-and-chief-ope-cyh-20160809monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2016-results-cyh-20160802monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-completes-spin-off-of-quorum-health-corporation-franklin-tenn-cyh-20160429monthly0.5https://www.biopharmawatch.com/news/CYH/information-regarding-why-the-company-believes-adjusted-ebitda-presents-useful-information-cyh-20160502monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-that-president-and-chief-operating-officer-david-l-mill-cyh-20160422monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-board-of-directors-approves-completion-of-the-spin-off-of-quorum--cyh-20160401monthly0.5https://www.biopharmawatch.com/news/CYH/quorum-health-corporation-announces-2016-financial-outlook-franklin-tenn-cyh-20160322monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contact-w-larry-cash-president-of-financial-services-and-chief-financial-officer--cyh-20160215monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-update-on-spin-off-of-quorum-health-corporation-schedul-cyh-20160107monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-appointment-of-new-independent-director-franklin-te-cyh-20151209monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-future-board-of-directors-and-names-additional-officers-cyh-20151120monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-new-share-repurchase-program-franklin-tenn-cyh-20151109monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-retirements-of-division-president-william-s-hussey-and--cyh-20151104monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contact-w-larry-cash-president-of-financial-services-and-chief-financial-officer--cyh-20151102monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contact-w-larry-cash-president-of-financial-services-and-chief-financial-officer--cyh-20151021monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-martin-d-smith-will-serve-as-executive-vice-president-f-cyh-20151020monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-files-form-10-registration-statement-for-spin-off-and-announces-q-cyh-20150904monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-announces-plans-to-spin-off-38-hospitals-and-quorum-health-resour-cyh-20150803monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2015-results-cyh-20150803monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2015-results-cyh-20150505monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-enters-into-amendment-of-its-existing-credit-agreement-frankl-cyh-20150309monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-2014-results-cyh-20150219monthly0.5https://www.biopharmawatch.com/news/CYH/investor-contact-w-larry-cash-executive-vice-president-and-chief-financial-officer-615-465-cyh-20150120monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-third-quarter-2014-results-cyh-20141103monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-launch-of-exchange-offers-for-5-125-senior-secured--cyh-20140926monthly0.5https://www.biopharmawatch.com/news/CYH/discontinued-operations-with-respect-to-these-hospitals-during-the-year-ended-cyh-20140917monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-second-quarter-2014-results-cyh-20140731monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-first-quarter-2014-results-cyh-20140506monthly0.5https://www.biopharmawatch.com/news/CYH/index-to-financial-statements-page-health-management-associates-inc-consolidated-financial-cyh-20140410monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-announces-amendments-to-accounts-receivable-securitization-pr-cyh-20140331monthly0.5https://www.biopharmawatch.com/news/CYH/cyh-announces-fourth-quarter-2013-results-cyh-20140218monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-completes-acquisition-of-health-management-associates-franklin-te-cyh-20140127monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-and-health-management-associates-receive-ftc-clearance-for-chs-s--cyh-20140122monthly0.5https://www.biopharmawatch.com/news/CYH/community-health-systems-inc-launches-credit-facility-financing-for-the-acquisition-of-hma-cyh-20140107monthly0.5https://www.biopharmawatch.com/news/CYH/exhibit-number-99-1-investor-contact-w-larry-cash-executive-vice-president-and-chief-finan-cyh-20140106monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20251117monthly0.5https://www.biopharmawatch.com/news/ENTA/this-presentation-contains-forward-looking-statements-concerning-our-business-operations-a-enta-20250929monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-positive-topline-results-from-its-phase-2b-study-of-zelicap-enta-20250929monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-files-patent-infringement-suit-against-pfizer-in-the-unified-patent-enta-20250820monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20250811monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20250512monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20250210monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-announces-positive-topline-results-from-first-in-pediatrics-phase-2-enta-20241209monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20241125monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-x2022-announ-enta-20240805monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-with-webcas-enta-20240506monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20240207monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20231120monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-with-confere-enta-20230807monthly0.5https://www.biopharmawatch.com/news/ENTA/company-logo-corporate-presentation-enta-20230607monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-with-confer-enta-20230508monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-announces-sale-of-a-portion-of-global-royalties-on-mavyret-u-s-mavi-enta-20230425monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20230207monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20221121monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20220808monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20220509monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20220208monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20211122monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20210805monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20210506monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20210208monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20201123monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20200804monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20200506monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-and-three-mo-enta-20200206monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20191121monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20190806monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20190507monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-and-three-mo-enta-20190206monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20181126monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20180807monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20180508monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20180207monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fourth-quarter-and-year-ended-enta-20171120monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20170807monthly0.5https://www.biopharmawatch.com/news/ENTA/correcting-and-replacing-enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-s-enta-20170509monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20170508monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20170208monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-announces-highlights-of-business-overview-and-update-on-its-researc-enta-20170106monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20161121monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20160808monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20160509monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20160208monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20151123monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20150806monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20150507monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20150205monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-announces-u-s-food-and-drug-administration-approves-abbvie-s-viekira-pak-ombitasvir-enta-20141219monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-en-enta-20141124monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-enta-20140811monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-enta-20140512monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-announces-new-drug-application-submission-to-the-u-s-fda-for-all-or-enta-20140422monthly0.5https://www.biopharmawatch.com/news/ENTA/pearl-iii-study-results-in-patients-with-chronic-hepatitis-c-presented-at-the-21-st-confer-enta-20140303monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-first-quarter-ended-enta-20140213monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-announces-results-from-four-all-oral-interferon-free-phase-3-studie-enta-20140131monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-announces-96-percent-svr-12-in-treatment-experienced-genotype-1-hep-enta-20131210monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-the-fiscal-fourth-quarter-and-year-en-enta-20131125monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-announces-96-percent-svr-12-in-sapphire-i-study-first-of-six-all-or-enta-20131118monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-the-third-fiscal-quarter-and-nine-mon-enta-20130812monthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-announces-financial-results-for-the-second-fiscal-quarter-and-six-m-enta-20130508monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-first-quarter-2026-financial-results-company-delivers-second-conse-eols-20260504monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-fourth-quarter-and-full-year-2025-financial-results-delivers-sixth-eols-20260303monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-net-reve-eols-20260109monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-third-quarter-2025-financial-results-total-net-revenue-of-69-0-mil-eols-20251105monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-the-appointment-of-tatjana-mitchell-as-chief-financial-officer-eols-20250908monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-second-quarter-2025-financial-results-and-provides-business-update-eols-20250805monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-departure-of-its-chief-financial-officer-eols-20250527monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-first-quarter-2025-results-global-net-revenue-of-68-5-million-for--eols-20250507monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-strengthens-balance-sheet-with-refinancing-reducing-cost-of-capital-and-ex-eols-20250505monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-record-fourth-quarter-and-full-year-2024-financial-results-reaffir-eols-20250304monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-net-reve-eols-20250121monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-third-quarter-2024-results-total-net-revenue-of-61-1-million-for-q-eols-20241106monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-second-quarter-2024-results-and-raises-full-year-revenue-guidance--eols-20240731monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-appointment-of-albert-g-white-iii-to-board-of-directors-eols-20240701monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-first-quarter-2024-results-and-provides-business-update-q1-2024-ne-eols-20240507monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-record-fourth-quarter-and-full-year-2023-financial-results-reaffir-eols-20240307monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-net-reve-eols-20240116monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-enters-into-licensing-agreement-with-symatese-to-exclusively-distribute-ne-eols-20231220monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-record-third-quarter-2023-financial-results-and-phase-ii-data-for--eols-20231107monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-second-quarter-2023-results-and-provides-business-update-q2-2023-n-eols-20230802monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-raises-full-year-revenue-guidance-on-record-second-quarter-2023-revenue-co-eols-20230727monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-first-quarter-2023-results-and-provides-business-update-q1-2023-ne-eols-20230509monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-up-eols-20230308monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-net-reve-eols-20230118monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-extends-term-of-credit-facility-with-pharmakon-advisors-second-tranche-of--eols-20221208monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-third-quarter-2022-results-and-provides-business-update-reported-s-eols-20221108monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-appoints-sandra-beaver-as-chief-financial-officer-eols-20220830monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-second-quarter-2022-results-and-provides-business-update-q2-2022-n-eols-20220802monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-first-quarter-2022-results-and-provides-business-update-q1-2022-ne-eols-20220510monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-retirement-of-chief-financial-officer-lauren-silvernail-eols-20220303monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-fourth-quarter-and-full-year-2021-results-and-provides-business-up-eols-20220303monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-preliminary-unaudited-fourth-quarter-and-full-year-2021-net-reve-eols-20220126monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-expands-board-of-directors-with-appointment-of-digital-and-beauty-innovato-eols-20220105monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-enters-into-125-million-credit-facility-with-pharmakon-advisors-initial-dr-eols-20211214monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-third-quarter-2021-results-and-provides-business-update-record-qua-eols-20211102monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-second-quarter-2021-results-and-provides-business-update-record-qu-eols-20210804monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-fourth-quarter-and-full-year-2020-results-and-provides-business-up-eols-20210324monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-strengthens-balance-sheet-through-a-25-5-million-cash-infusion-and-elimina-eols-20210323monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-promotion-of-crystal-muilenburg-to-chief-marketing-officer-newpo-eols-20210226monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-announces-preliminary-unaudited-fourth-quarter-and-full-year-2020-net-reve-eols-20210223monthly0.5https://www.biopharmawatch.com/news/EOLS/document-abbvie-evolus-and-medytox-announce-resolution-of-intellectual-property-litigation-eols-20210219monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-provides-update-on-united-states-international-trade-commission-itc-case-s-eols-20201216monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-third-quarter-2020-results-and-provides-business-update-q3-2020-ne-eols-20201029monthly0.5https://www.biopharmawatch.com/news/EOLS/document-evolus-reports-second-quarter-2020-results-and-provides-business-update-q2-2020-n-eols-20200810monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-provides-update-on-international-trade-commission-itc-case-eols-20200706monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-first-quarter-2020-results-and-provides-business-update-eols-20200511monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-fourth-quarter-and-full-year-2019-results-and-provides-business-update-eols-20200225monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-third-quarter-2019-financial-results-and-eols-20191104monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-second-quarter-2019-financial-results-eols-20190812monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-expands-board-of-directors-with-appointment-of-independent-directors-eols-20190715monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-first-quarter-2019-financial-results-eols-20190430monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-provides-regulatory-update-on-nuceiva-in-the-european-union-eols-20190401monthly0.5https://www.biopharmawatch.com/news/EOLS/provides-non-dilutive-financing-and-increased-flexibility-ahead-of-jeuveau-u-s-eols-20190318monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-third-quarter-2018-financial-results-eols-20181105monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-expands-role-of-chief-medical-officer-rui-avelar-md-with-appointment-as-head-of-r-d-eols-20180815monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-second-quarter-2018-financial-results-eols-20180802monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-inc-eols-20180718monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-appoints-veteran-healthcare-executive-lauren-silvernail-as-chief-financial-officer--eols-20180601monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-announces-progress-with-dwp-450-regulatory-submissions-eols-20180516monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-first-quarter-2018-financial-results-eols-20180510monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-appoints-allergan-aesthetics-head-as-president-and-chief-executive-officer-eols-20180506monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-inc-announces-pricing-of-initial-public-offering-of-common-stock-irvine-calif-eols-20180207monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-jpm-2026-presentation-click-to-edit-master-title-style-1-click-to-edit-repl-20260114monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-first-quarter-2026-financial-results-and-provides-corporate-updat-repl-20250807monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-end-2025-financial-results-and-provides-c-repl-20250522monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-third-quarter-2025-financial-results-and-provides-corporate-updat-repl-20250212monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-biologics-license-application-acceptance-and-priority-review-for-rp1-f-repl-20250121monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-proposed-public-offering-repl-20241125monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-rp1-biologics-lice-repl-20241121monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-second-quarter-2025-financial-results-and-provides-corporate-upda-repl-20241112monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-first-quarter-2025-financial-results-and-provides-corporate-updat-repl-20240808monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-100-million-private-placement-financing-led-by-a-life-sciences-focused-repl-20240613monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-positive-topline-primary-analysis-data-by-independent-central-review-f-repl-20240606monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-presents-positive-data-from-rp1-and-rp2-clinical-programs-at-the-2024-american-s-repl-20240603monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-ended-2024-financial-results-and-provides-repl-20240516monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-appointment-of-sushil-patel-to-ceo-and-executive-leadership-transition-repl-20240326monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-third-quarter-2024-financial-results-and-provides-corporate-updat-repl-20240208monthly0.5https://www.biopharmawatch.com/news/REPL/safe-harbor-any-statements-contained-herein-that-are-not-statements-of-historical-facts-ma-repl-20240108monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-shares-initial-primary-analysis-results-from-cerpass-clinical-trial-in-advanced--repl-20231205monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-second-quarter-2024-financial-results-and-provides-corporate-upda-repl-20231107monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-appointment-of-emily-hill-as-chief-financial-officer-woburn-ma-repl-20230919monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-first-quarter-2024-financial-results-and-provides-corporate-updat-repl-20230803monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-sander-slootweg-will-depart-from-its-board-of-directors-repl-20230720monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-appoints-veleka-r-peeples-dyer-to-its-board-of-directors-woburn-ma-repl-20230605monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-ended-2023-financial-results-and-provides-repl-20230518monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-third-quarter-financial-results-and-provides-corporate-update-str-repl-20230209monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-appoints-former-sanofi-u-s-commercial-oncology-head-chris-sarchi-as-chief-commer-repl-20230104monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-proposed-public-offering-boston-ma-repl-20221207monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-enters-into-clinical-collaboration-agreement-with-roche-for-the-development-of-r-repl-20221207monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-second-quarter-financial-results-and-provides-corporate-update-co-repl-20221103monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-secures-200-million-in-non-dilutive-debt-financing-from-hercules-capital-inc-wob-repl-20221007monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-first-quarter-financial-results-and-provides-corporate-update-tar-repl-20220804monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-the-departure-of-jason-rhodes-from-its-board-of-directors-woburn-ma-repl-20220603monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-ended-2022-financial-results-and-provides-repl-20220519monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-provides-new-clinical-data-broad-program-update-and-future-development-strategy--repl-20220330monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-third-fiscal-quarter-financial-results-and-provides-corporate-update-dat-repl-20220203monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-the-departure-of-dr-otello-stampacchia-from-its-board-of-directors-wob-repl-20220131monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-provides-2021-year-end-review-and-overview-of-expected-2022-milestones-cerpass-c-repl-20220110monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-appoints-christy-oliger-to-its-board-of-directors-woburn-ma-repl-20211202monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-second-quarter-financial-results-and-provides-corporate-update-rp-repl-20211104monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-first-quarter-financial-results-and-provides-corporate-update-upd-repl-20210806monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-provides-data-update-from-its-rp1-vusolimogene-oderparepvec-and-rp2-programs-and-repl-20210603monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-ended-2021-financial-results-and-provides-repl-20210520monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-appoints-tanya-lewis-as-chief-development-operations-officer-woburn-ma-repl-20210510monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-provides-a-regulatory-update-for-its-registration-directed-clinical-trials-evalu-repl-20210505monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-to-present-new-biomarker-pre-clinical-data-for-lead-oncolytic-immunotherapy-prog-repl-20210412monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-third-fiscal-quarter-financial-results-and-provides-corporate-update-rp1-repl-20210204monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-provides-2020-year-end-review-and-overview-of-expected-2021-milestones-rp1-data--repl-20210111monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-second-quarter-financial-results-and-provides-corporate-update-rp-repl-20201105monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-proposed-public-offering-boston-ma-repl-20201020monthly0.5https://www.biopharmawatch.com/news/REPL/next-generation-oncolytic-immunotherapy-next-generation-oncolytic-immunotherapy-safe-harbo-repl-20200930monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-appoints-tanya-lewis-to-the-board-of-directors-woburn-ma-repl-20201019monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-presentation-at-the-2020-society-for-immunotherapy-of-cancer-sitc-annu-repl-20201014monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-first-quarter-financial-results-and-provides-corporate-update-cli-repl-20200807monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-proposed-public-offering-boston-ma-repl-20200608monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-full-year-2020-financial-results-and-provides--repl-20200603monthly0.5https://www.biopharmawatch.com/news/REPL/next-generation-oncolytic-immunotherapy-next-generation-oncolytic-immunotherapy-data-updat-repl-20200603monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-appoints-dieter-weinand-as-chairman-and-paolo-pucci-to-the-board-of-directors-wo-repl-20200402monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-provides-2019-year-end-corporate-update-and-reviews-expected-2020-milestones-repl-20200113monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-the-evolution-of-its-management-team-as-it-advances-through-later-stag-repl-20200109monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-announces-proposed-public-offering-boston-ma-repl-20191112monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-second-fiscal-quarter-financial-results-and-provides-corporate-update-rp-repl-20191111monthly0.5https://www.biopharmawatch.com/news/REPL/nnexext-tggenenereraatitoionnoonnccoolylytitcic-imimmmuunnooththereraappyy-sitc-investor-e-repl-20191108monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-provides-update-on-rp1-clinical-development-program-in-cutaneous-squamous-cell-c-repl-20191015monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-first-fiscal-quarter-financial-results-and-provides-corporate-update-rp1-repl-20190814monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-fourth-fiscal-quarter-and-year-2019-financial-results-and-provides-corpo-repl-20190628monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-financial-results-for-the-third-fiscal-quarter-ended-december-31-and-pro-repl-20190214monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-financial-results-for-the-second-fiscal-quarter-ended-september-30-and-p-repl-20181114monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-reports-financial-results-for-the-first-fiscal-quarter-ended-june-30-and-provide-repl-20180830monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-first-quarter-2026-financial-results-and-provides-operational-u-bntc-20251114monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-provides-operational-updates-in-april-2025-the-sixth-and-final-subject-o-bntc-20250709monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-third-quarter-2025-financial-results-bntc-20250514monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-inc-announces-pricing-of-30-million-common-stock-offering-bntc-20250325monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-second-quarter-2025-financial-results-and-provides-operational--bntc-20250214monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-first-quarter-2025-financial-results-and-provides-operational-u-bntc-20241114monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-reports-positive-data-from-two-subjects-treated-with-low-dose-bb-301-in--bntc-20241012monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-full-year-2024-financial-results-and-provides-operational-updat-bntc-20240926monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-reports-continued-durable-improvements-in-the-radiographic-assessments-o-bntc-20240715monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-appointment-of-kishen-mehta-to-its-board-of-directors-bntc-20240701monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-third-quarter-2024-financial-results-and-provides-operational-u-bntc-20240513monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-oversubscribed-private-placement-financing-of-40-0-million-bntc-20240418monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-reports-positive-interim-clinical-trial-data-for-first-opmd-subject-trea-bntc-20240418monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-second-quarter-2024-financial-results-and-provides-operational--bntc-20240213monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-first-subject-dosed-in-phase-1b-2a-clinical-trial-for-gene-the-bntc-20231130monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-first-quarter-2024-financial-results-and-provides-operational-u-bntc-20231113monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-full-year-2023-financial-results-and-provides-operational-updat-bntc-20230921monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-inc-announces-pricing-of-30-million-underwritten-public-offering-bntc-20230808monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-1-for-17-reverse-stock-split-effective-bntc-20230726monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-receives-fda-clearance-of-the-ind-for-bb-301-for-the-treatment-of-oculop-bntc-20230626monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-third-quarter-2023-financial-results-and-provides-operational-u-bntc-20230515monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-second-quarter-2023-financial-results-and-provides-operational--bntc-20230213monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-enrolls-first-opmd-subject-into-the-clinical-development-program-bntc-20230123monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-first-quarter-2023-financial-results-and-provides-operational-u-bntc-20221110monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-inc-announces-pricing-of-18-million-underwritten-public-offering-bntc-20220912monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-full-year-2022-financial-results-and-provides-operational-updat-bntc-20220902monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-q3-2022-financial-results-bntc-20220516monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-discloses-q2-2022-financial-results-bntc-20220214monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-discloses-q1-2022-financial-results-bntc-20211115monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-provides-operational-update-and-releases-its-2021-fiscal-year-end-financ-bntc-20210920monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-7-5-million-bought-deal-offering-of-common-stock-bntc-20210427monthly0.5https://www.biopharmawatch.com/news/BNTC/interim-results-of-ind-enabling-large-animal-study-for-bb-301-february-2021-copyright-beni-bntc-20210224monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-pricing-of-10-0-million-public-offering-bntc-20201002monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-provides-operational-update-and-releases-its-2020-fiscal-year-end-financ-bntc-20200923monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-highligh-cccc-20250723monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-first-quarter-2025-financial-results-and-recent-business-highlight-cccc-20250507monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-bus-cccc-20250227monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-2025-milestones-across-clinical-portfolio-of-degrader-medicines--cccc-20250114monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-presents-cemsidomide-phase-1-data-at-the-american-society-for-hematology-a-cccc-20241208monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-appoints-accomplished-oncology-executive-steve-hoerter-to-board-of-directo-cccc-20241120monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlight-cccc-20241031monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-appoints-paige-mahaney-ph-d-as-chief-scientific-officer-and-announces-reti-cccc-20241016monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-appoints-veteran-biotechnology-leader-stephen-fawell-ph-d-to-board-of-dire-cccc-20240903monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-second-quarter-2024-financial-results-and-recent-business-highligh-cccc-20240801monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-appoints-ron-cooper-as-chairman-of-the-board-of-directors-cooper-brings-de-cccc-20240610monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-first-quarter-2024-financial-results-and-recent-business-highlight-cccc-20240508monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-strategic-discovery-research-collaboration-with-merck-kgaa-darms-cccc-20240304monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-bus-cccc-20240222monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-positive-data-from-cft7455-phase-1-trial-in-relapsed-refractory--cccc-20231212monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-license-and-research-collaboration-with-merck-to-discover-and-de-cccc-20231212monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-strengthens-board-of-directors-with-owen-hughes-appointment-owen-hughes-ac-cccc-20231120monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-third-quarter-2023-financial-results-and-recent-business-highlight-cccc-20231101monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-chief-financial-officer-succession-cccc-20230905monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-highligh-cccc-20230808monthly0.5https://www.biopharmawatch.com/news/CCCC/document-c4-therapeutics-appoints-leonard-reyno-m-d-as-chief-medical-officer-cccc-20230620monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-first-quarter-2023-financial-results-and-recent-business-highlight-cccc-20230504monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-bus-cccc-20230223monthly0.5https://www.biopharmawatch.com/news/CCCC/document-c4-therapeutics-announces-2023-strategic-priorities-to-advance-portfolio-of-targe-cccc-20230109monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-third-quarter-2022-financial-results-and-recent-business-highlight-cccc-20221103monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-second-quarter-2022-financial-results-and-recent-business-highligh-cccc-20220804monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-appoints-experienced-clinical-development-leaders-laura-bessen-m-d-and-don-cccc-20220802monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-evaluating-cft86-cccc-20220516monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-first-quarter-2022-financial-results-and-recent-business-highlight-cccc-20220505monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-presents-clinical-data-from-cohort-a-of-the-ongoing-phase-1-2-clinical-tri-cccc-20220408monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-appoints-utpal-koppikar-to-board-of-directors-utpal-koppikar-veteran-life--cccc-20220316monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-full-year-2021-financial-results-and-recent-business-highlights-da-cccc-20220224monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-2022-key-milestones-to-advance-targeted-protein-degradation-port-cccc-20220110monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-recent-business-highlights-and-third-quarter-2021-financial-result-cccc-20211110monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-recent-business-highlights-and-second-quarter-2021-financial-resul-cccc-20210811monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-presents-pre-clinical-data-on-cft7455-a-novel-ikzf1-3-degrader-for-the-tre-cccc-20210621monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-evaluating-cft74-cccc-20210614monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-presents-pre-clinical-data-on-cft8919-a-selective-degrader-of-egfr-l858r-a-cccc-20210607monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-to-advance-cft8919-a-selective-degrader-of-egfr-l858r-into-ind-enabling-st-cccc-20210526monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-appoints-lauren-white-as-chief-financial-officer-cccc-20210520monthly0.5https://www.biopharmawatch.com/news/CCCC/condensed-consolidated-balance-sheet-data-in-thousands-unaudited-cccc-20210513monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-recent-business-highlights-and-full-year-2020-financial-results-ph-cccc-20210311monthly0.5https://www.biopharmawatch.com/news/CCCC/forward-looking-statements-the-following-presentation-contains-forward-looking-statements--cccc-20210112monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-announces-key-2021-milestones-to-support-progress-toward-goal-of-four-clin-cccc-20210106monthly0.5https://www.biopharmawatch.com/news/CCCC/cccc-ex991-6-pptx-htm-corporate-presentation-november-2020-2020-c4-therapeutics-inc-forwar-cccc-20201119monthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-reports-business-highlights-and-third-quarter-2020-financial-results-stren-cccc-20201112monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-and-treeline-biosciences-announce-merger-agreement-combined-company-to-o-lab-20260608monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-preliminary-fourth-quarter-and-full-year-2025-revenue-prelimin-lab-20260108monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-second-quarter-2025-financial-results-lab-20250811monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-first-quarter-2025-financial-results-lab-20250506monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-fourth-quarter-and-full-year-2024-financial-results-lab-20250226monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-preliminary-fourth-quarter-and-full-year-2024-revenue-prelimin-lab-20250113monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-appoints-alex-kim-as-chief-financial-officer-lab-20241107monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-third-quarter-2024-financial-results-lab-20241030monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-1-unleashing-tools-to-accelerate-breakthroughs-in-human-health-investor--lab-20240905monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-senior-leadership-changes-alex-kim-chief-operating-officer-and-lab-20240731monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-second-quarter-2024-financial-results-delivered-revenue-of-37-2--lab-20240731monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-first-quarter-2024-financial-results-x2022-ahead-of-plan-on-oper-lab-20240508monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-operational-restructuring-plan-to-drive-long-term-profitable-g-lab-20240425monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-exchange-of-all-outstanding-series-b-convertible-preferred-sto-lab-20240318monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-fourth-quarter-and-full-year-2023-financial-results-x2022-achiev-lab-20240228monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-preliminary-fourth-quarter-and-full-year-2023-revenue-achievin-lab-20240108monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-stockholders-approve-merger-with-somalogic-lab-20240104monthly0.5https://www.biopharmawatch.com/news/LAB/glass-lewis-recommends-standard-biotools-stockholders-vote-for-all-proposals-relating-to-p-lab-20231229monthly0.5https://www.biopharmawatch.com/news/LAB/iss-recommends-standard-biotools-stockholders-vote-for-all-proposals-relating-to-proposed--lab-20231222monthly0.5https://www.biopharmawatch.com/news/LAB/investor-presentation-unlocking-value-in-a-fragmented-space-december-2023-legal-informatio-lab-20231219monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-and-somalogic-announce-date-for-special-meetings-of-stockholders-to-vote-lab-20231204monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-activating-strategy-to-become-a-diversified-leader-in-life-sciences-tool-lab-20231129monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-third-quarter-and-year-to-date-2023-financial-results-x2022-year-lab-20231107monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-and-somalogic-to-combine-in-all-stock-merger-creating-a-diversified-lead-lab-20231004monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-appoints-jeffrey-black-as-chief-financial-officer-and-announces-induceme-lab-20230515monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-first-quarter-2023-financial-results-net-cash-used-in-operating--lab-20230509monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-appointment-of-fenel-eloi-to-board-of-directors-lab-20230315monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-lab-20230214monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-provides-preliminary-fourth-quarter-2022-revenue-and-business-update-con-lab-20230109monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-authorizes-up-to-20-million-of-share-repurchases-lab-20221128monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-stockholders-approve-250-million-strategic-capital-infusion-lab-20220401monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-announces-support-agreement-with-caligan-partners-related-to-250-million-strategi-lab-20220401monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-adjourns-special-meeting-of-stockholders-until-lab-20220328monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-announces-250-million-strategic-capital-infusion-from-casdin-capital-and-viking-g-lab-20220124monthly0.5https://www.biopharmawatch.com/news/LAB/dr-ana-k-stankovic-md-phd-appointed-to-fluidigm-board-of-directors-lab-20201215monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-corporation-announces-proposed-private-offering-of-45-million-of-convertible-seni-lab-20191120monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-announces-q4-and-full-year-2016-lab-20170208monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-ended-december-lab-20170109monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-lab-20161103monthly0.5https://www.biopharmawatch.com/news/LAB/separation-agreement-and-release-this-separation-agreement-and-release-agreement-is-made-b-lab-20161024monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-announces-preliminary-third-quarter-2016-lab-20161012monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-appoints-new-president-and-chief-operating-officer-seasoned-life-science-industry-lab-20160804monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-lab-20160804monthly0.5https://www.biopharmawatch.com/news/LAB/fluidigm-lab-20160505monthly0.5https://www.biopharmawatch.com/news/CMPX/tovecimig-demonstrates-statistically-significant-benefit-in-companion-002-randomized-phase-cmpx-20260427monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-2025-second-quarter-financial-results-and-provides-corporate--cmpx-20250811monthly0.5https://www.biopharmawatch.com/news/CMPX/tovecimig-ctx-009-meets-primary-endpoint-in-the-ongoing-randomized-phase-2-3-study-in-pati-cmpx-20250401monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-positive-interim-phase-2-data-of-ctx-009-in-combination-with--cmpx-20220504monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-pricing-of-approximately-125-million-public-offering-of-com-cmpx-20211101monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-reports-the-advancement-of-ctx-009-a-bispecific-antibody-to-phase-2a-development-i-cmpx-20211101monthly0.5https://www.biopharmawatch.com/news/CMPX/ctx-009-abl001-es104-clinical-data-presented-today-at-the-new-drugs-on-the-horizon-plenary-cmpx-20211008monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-inc-to-acquire-trigr-therapeutics-inc-to-obtain-global-rights-to-tr00-cmpx-20210513monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-inc-provides-corporate-update-cambridge-mass-september-15th-2020-comp-cmpx-20200915monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-llc-and-subsidiary-consolidated-financial-statements-december-3-1-201-cmpx-20200623monthly0.5https://www.biopharmawatch.com/news/NATR/earnings-release-exhibit-for-immediate-release-nature-s-sunshine-products-reports-second-q-natr-20170808monthly0.5https://www.biopharmawatch.com/news/NATR/fourth-quarter-2016-financial-highlights-natr-20170307monthly0.5https://www.biopharmawatch.com/news/NATR/jbaty-press-release-exhibit-for-immediate-release-nature-s-sunshine-products-announces-new-natr-20161031monthly0.5https://www.biopharmawatch.com/news/NATR/earnings-release-exhibit-for-immediate-release-nature-s-sunshine-products-reports-second-q-natr-20160808monthly0.5https://www.biopharmawatch.com/news/NATR/fourth-quarter-2015-financial-highlights-natr-20160225monthly0.5https://www.biopharmawatch.com/news/NATR/cyber-security-threats-and-exposure-to-data-loss-its-reliance-on-its-information-technolog-natr-20160308monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-third-quarter-2015-financial-results-net-sales-revenue--natr-20151103monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-second-quarter-2015-financial-results-net-sales-revenue-natr-20150810monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-first-quarter-2015-financial-results-third-consecutive--natr-20150507monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-fourth-quarter-and-full-year-2014-financial-results-nsp-natr-20150225monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20150206monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20150202monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-third-quarter-2014-financial-results-fifth-consecutive--natr-20141105monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20141010monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-announces-closing-of-private-placement-and-joint-venture-agreement-with--natr-20140827monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-second-quarter-2014-financial-results-fourth-consecutiv-natr-20140806monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-announces-strategic-alliance-with-fosun-pharma-nature-s-sunshine-enters--natr-20140626monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-first-quarter-2014-financial-results-third-consecutive--natr-20140507monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-fourth-quarter-and-full-year-2013-financial-results-fou-natr-20140317monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20140206monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-third-quarter-2013-financial-results-third-quarter-net--natr-20131106monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-names-richard-strulson-as-executive-vice-president-general-coun-natr-20131003monthly0.5https://www.biopharmawatch.com/news/NATR/gregory-l-probert-appointed-chief-executive-officer-of-nature-s-natr-20131002monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20130906monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-second-quarter-financial-results-and-declares-special-o-natr-20130808monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20130508monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-reports-fourth-quarter-and-fiscal-year-financial-results-increa-natr-20130306monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20130201monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-sunshine-products-names-gregory-l-probert-executive-chairman-of-the-board-of-dire-natr-20121213monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20120801monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20120507monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20120223monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20111107monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20110803monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20110622monthly0.5https://www.biopharmawatch.com/news/NATR/nature-s-natr-20110506monthly0.5https://www.biopharmawatch.com/news/ADCT/corporate-presentation-january-2026-2-forward-looking-statements-this-presentation-and-any-adct-20251231monthly0.5https://www.biopharmawatch.com/news/ADCT/corporate-presentation-october-2025-forward-looking-statements-this-presentation-and-any-a-adct-20250930monthly0.5https://www.biopharmawatch.com/news/ADCT/jpmorgan-43-rd-annual-healthcare-conference-january-2025-2-forward-looking-statements-this-adct-20250113monthly0.5https://www.biopharmawatch.com/news/ADCT/corporate-presentation-2q-2024-2-forward-looking-statements-this-presentation-and-any-acco-adct-20240514monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-business-overview-cowen-conference-adct-20240305monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-provides-business-updates-zynlonta-1-4q-2023-net-sales-expected-to-be-16--adct-20240104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-receives-nyse-notice-of-non-compliance-with-continued-listing-standards-l-adct-20231107monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-update-adct-20231107monthly0.5https://www.biopharmawatch.com/news/ADCT/morgan-stanley-global-healthcare-conference-adct-20230911monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-updat-adct-20230808monthly0.5https://www.biopharmawatch.com/news/ADCT/articles-of-association-of-adc-therapeutics-sa-adc-therapeutics-ag-adc-therapeutics-ltd-st-adct-20230614monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-and-st-adct-20230509monthly0.5https://www.biopharmawatch.com/news/ADCT/to-the-shareholders-of-adc-therapeutics-sa-invitation-to-the-annual-general-meeting-date-a-adct-20230505monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-sa-biop-le-route-de-la-corniche-3b-1066-epalinges-switzerland-adct-20230202monthly0.5https://www.biopharmawatch.com/news/ADCT/ameet-mallik-ceo-adct-20230111monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-appoints-mohamed-zaki-as-chief-medical-officer-adct-20230103monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-41-st-annual-j-p-morgan-healthcare-conference-adct-20230104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-and-sobi-announce-european-commission-approval-of-zynlonta-loncastuximab--adct-20221221monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-appoints-jose-carmona-as-chief-financial-officer-adct-20221219monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-update-adct-20221108monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-adct-20221107monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-abstracts-accepted-for-presentation-at-the-64-th-ash-annual-mee-adct-20221103monthly0.5https://www.biopharmawatch.com/news/ADCT/igm-biosciences-and-adc-therapeutics-announce-clinical-collaboration-agreement-to-evaluate-adct-20221102monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-third-quarter-2022-financial-results-conference-call-on-adct-20221031monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-morgan-stanley-s-20-th-annual-global-healthcare-confere-adct-20220906monthly0.5https://www.biopharmawatch.com/news/ADCT/warrant-to-purchase-common-shares-of-adc-therapeutics-sa-no-w-df-adct-20220815monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-updat-adct-20220809monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-second-quarter-2022-financial-results-conference-call-on-adct-20220802monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-names-david-gilman-as-chief-business-strategy-officer-seasoned-life-scien-adct-20220613monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-present-at-the-jefferies-healthcare-conference-adct-20220601monthly0.5https://www.biopharmawatch.com/news/ADCT/to-the-shareholders-of-adc-therapeutics-sa-invitation-to-the-annual-general-meeting-date-a-adct-20220520monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-abstracts-to-be-presented-at-the-european-hematology-associatio-adct-20220512monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-update-adct-20220509monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-ceo-transition-co-founder-chris-martin-transitions-ceo-role-to--adct-20220509monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-present-at-the-bofa-securities-2022-healthcare-conference-adct-20220504monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-first-quarter-2022-financial-results-conference-call-on-adct-20220503monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-adct-20220317monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides--adct-20220303monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-cowen-s-42-nd-annual-health-care-conference-adct-20220301monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-fourth-quarter-and-year-end-2021-financial-results-conference-cal-adct-20220224monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-releases-its-inaugural-environmental-social-and-governance-report-report--adct-20220217monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-guggenheim-oncology-conference-adct-20220202monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-webcast-highlighting-its-adc-platform-and-solid-tumor-pipeline-on-adct-20220120monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-adct-20211109monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-abstracts-to-be-presented-at-the-63-rd-ash-annual-meeting-sever-adct-20211104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-update-adct-20211102monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-third-quarter-2021-financial-results-conference-call-on-adct-20211027monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-adct-20210923monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-morgan-stanley-s-19-th-annual-global-healthcare-confere-adct-20210909monthly0.5https://www.biopharmawatch.com/news/ADCT/certain-confidential-information-contained-in-this-document-marked-by-has-been-omitted-bec-adct-20210825monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-updat-adct-20210803monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-second-quarter-2021-financial-results-conference-call-on-adct-20210728monthly0.5https://www.biopharmawatch.com/news/ADCT/articles-of-association-of-adc-therapeutics-sa-adc-therapeutics-ag-adc-therapeutics-ltd-st-adct-20210611monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-presentations-at-the-16-th-annual-international-conference-on-m-adct-20210609monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-presents-updated-clinical-data-at-2021-asco-annual-meeting-zynlonta-lotis-adct-20210604monthly0.5https://www.biopharmawatch.com/news/ADCT/the-securities-represented-by-this-note-and-the-common-shares-issuable-upon-conversion-the-adct-20210517monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-adct-20210527monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-online-publication-of-camidanlumab-tesirine-phase-1-results-in--adct-20210526monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-presentations-at-the-2021-asco-annual-meeting-posters-to-highli-adct-20210519monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-receipt-of-50-million-second-tranche-of-convertible-credit-faci-adct-20210517monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-online-publication-of-lotis-2-results-in-the-lancet-oncology-re-adct-20210512monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-update-adct-20210506monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-zynlonta-loncastuximab-tesirine-lpyl-added-to-national-comprehensive-canc-adct-20210505monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-may-investor-conferences-adct-20210504monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-first-quarter-2021-financial-results-conference-call-on-adct-20210429monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-fda-approval-of-zynlonta-loncastuximab-tesirine-lpyl-in-relapse-adct-20210423monthly0.5https://www.biopharmawatch.com/news/ADCT/to-the-shareholders-of-adc-therapeutics-sa-invitation-to-the-annual-general-meeting-date-a-adct-20210414monthly0.5https://www.biopharmawatch.com/news/ADCT/overland-adct-biopharma-appoints-eric-koo-as-chief-executive-officer-senior-pharmaceutical-adct-20210406monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides-b-adct-20210318monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-fourth-quarter-and-year-end-2020-financial-results-conference-cal-adct-20210311monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-cowen-41-st-annual-health-care-conference-adct-20210225monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-guggenheim-healthcare-talks-2021-oncology-day-adct-20210205monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-completes-enrollment-in-pivotal-phase-2-clinical-trial-of-camidanlumab-te-adct-20210204monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-initiates-expanded-access-program-for-loncastuximab-tesirine-in-the-u-s-l-adct-20210107monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-sternir-virtual-corporate-access-event-lausanne-switzer-adct-20210104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-and-overland-pharmaceuticals-announce-formation-of-overland-adct-biopharm-adct-20201214monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-updated-clinical-data-on-lead-antibody-drug-conjugate-programs--adct-20201207monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-conference-call-highlighting-data-from-its-next-generation-antibo-adct-20201130monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-fda-accepts-biologics-license-application-and-grants-priority-r-adct-20201120monthly0.5https://www.biopharmawatch.com/news/ADCT/unaudited-ifrs-condensed-consolidated-interim-financial-statements-as-of-and-for-the-three-adct-20201112monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-present-at-the-stifel-2020-virtual-healthcare-conference-lausanne-swit-adct-20201110monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-third-quarter-2020-financial-results-conference-call-on-adct-20201105monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-eight-presentations-on-data-from-its-next-generation-antibody-d-adct-20201104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-first-patient-dosed-with-camidanlumab-tesirine-cami-in-combinat-adct-20201103monthly0.5https://www.biopharmawatch.com/news/ADCT/genmab-and-adc-therapeutics-announce-amended-agreement-for-camidanlumab-tesirine-cami-medi-adct-20201030monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-full-exercise-of-underwriters-option-to-purchase-additional-com-adct-20201009monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-pricing-of-public-offering-lausanne-switzerland-adct-20200923monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-proposed-public-offering-lausanne-switzerland-adct-20200921monthly0.5https://www.biopharmawatch.com/news/ADCT/ex-1-2-dp137015-ex9901-htm-adc-therapeutics-submits-biologics-license-application-to-the-u-adct-20200921monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-presentation-of-preliminary-findings-from-phase-1b-clinical-tri-adct-20200917monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-publication-highlighting-the-potential-of-camidanlumab-tesirine-adct-20200910monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-gives-notice-of-partial-waiver-of-restrictions-pursuant-to-finra-rule-513-adct-20200904monthly0.5https://www.biopharmawatch.com/news/ADCT/unaudited-ifrs-condensed-consolidated-interim-financial-statements-as-of-and-for-the-three-adct-20200818monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-report-second-quarter-2020-financial-results-on-adct-20200812monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-first-patient-dosed-in-pivotal-phase-2-portion-of-lotis-3-clini-adct-20200717monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-u-s-food-and-drug-administration-has-lifted-partial-clinical-ho-adct-20200706monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-maturing-data-from-pivotal-phase-2-clinical-trial-and-phase-1-2-adct-20200612monthly0.5https://www.biopharmawatch.com/news/ADCT/the-securities-represented-by-this-note-and-the-common-shares-issuable-upon-conversion-the-adct-20200519monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-first-quarter-fiscal-2026-results-same-center-sales-increas-airs-20260508monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-fourth-quarter-and-full-year-fiscal-2025-results-airs-20260406monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-fourth-quarter-and-full-year-fiscal-2025-results-airs-20260402monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-appoints-mike-doyle-as-non-executive-chairman-of-the-board-airs-20251117monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-third-quarter-fiscal-2025-results-airs-20251107monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-second-quarter-fiscal-2025-results-airs-20250801monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-announces-public-offering-of-common-stock-airs-20250609monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-first-quarter-fiscal-2025-results-and-full-year-guidance-airs-20250502monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-fourth-quarter-and-full-year-fiscal-2024-results-airs-20250314monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-updates-fiscal-year-2024-guidance-in-advance-of-its-participation-i-airs-20250113monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-names-yogi-jashnani-chief-executive-officer-airs-20241217monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-third-quarter-fiscal-2024-results-third-quarter-revenue-of--airs-20241108monthly0.5https://www.biopharmawatch.com/news/AIRS/document-airsculpt-technologies-announces-preliminary-third-quarter-2024-revenue-results-e-airs-20241024monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-announces-leadership-changes-airs-20240809monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-second-quarter-fiscal-2024-results-second-quarter-revenue-o-airs-20240809monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-for-first-quarter-earnings-airs-20240510monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-reports-double-digit-revenue-growth-for-the-fourth-quarter-and-full-airs-20240227monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-announces-third-quarter-2023-results-and-reaffirms-2023-guidance-airs-20231109monthly0.5https://www.biopharmawatch.com/news/AIRS/document-airsculpt-technologies-announces-strong-preliminary-third-quarter-2023-revenue-re-airs-20231005monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-announces-second-quarter-2023-results-and-reaffirms-2023-guidance-airs-20230811monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-announces-strong-preliminary-second-quarter-2023-revenue-reaffirms--airs-20230711monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-announces-first-quarter-2023-results-reaffirms-2023-guidance-and-an-airs-20230512monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-announces-fourth-quarter-2022-results-and-provides-2023-guidance-airs-20230310monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-inc-announces-executive-leadership-changes-reiterates-2022-revenue--airs-20230106monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-inc-announces-third-quarter-2022-results-airs-20221110monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-inc-announces-second-quarter-2022-results-and-authorizes-special-ca-airs-20220812monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-inc-announces-first-quarter-2022-results-airs-20220513monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-inc-announces-fourth-quarter-and-full-year-2021-results-airs-20220311monthly0.5https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-inc-announces-third-quarter-2021-results-airs-20211203monthly0.5https://www.biopharmawatch.com/news/GIX/gigcapital9-corp-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-rights--gix-20260319monthly0.5https://www.biopharmawatch.com/news/GIX/gigcapital9-corp-index-to-balance-sheet-and-notes-to-balance-sheet-report-of-independent-r-gix-20260128monthly0.5https://www.biopharmawatch.com/news/GIX/gigcapital9-corp-announces-pricing-of-220-000-000-initial-public-offering-palo-alto-ca-gix-20260126monthly0.5https://www.biopharmawatch.com/news/XFOR/this-presentation-including-any-printed-or-electronic-copy-of-these-slides-the-talks-given-xfor-20250501monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-reverse-stock-split-xfor-20250424monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-strategic-restructuring-to-drive-value-and-maximize-opportuni-xfor-20250206monthly0.5https://www.biopharmawatch.com/news/XFOR/forward-looking-statements-this-presentation-including-any-printed-or-electronic-copy-of-t-xfor-20240627monthly0.5https://www.biopharmawatch.com/news/XFOR/forward-looking-statements-this-presentation-including-any-printed-or-electronic-copy-of-t-xfor-20240507monthly0.5https://www.biopharmawatch.com/news/XFOR/forward-looking-statements-this-presentation-including-any-printed-or-electronic-copy-of-t-xfor-20240429monthly0.5https://www.biopharmawatch.com/news/XFOR/document-exhibit-99-1-x4-pharmaceuticals-announces-fda-approval-of-xolremdi-mavorixafor-ca-xfor-20240429monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-fda-acceptance-with-priority-review-of-u-s-nda-for-mavorixafo-xfor-20231031monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-appointment-of-industry-veteran-r-keith-woods-to-board-of-dir-xfor-20231018monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-65-million-private-placement-priced-at-the-market-x4-whim-pha-xfor-20230516monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-proposed-public-offering-boston-xfor-20221206monthly0.5https://www.biopharmawatch.com/news/XFOR/durability-safety-and-tolerability-of-mavorixafor-in-a-larger-cn-patient-population-we-ant-xfor-20220927monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-55-million-private-placement-financing-and-debt-facility-amen-xfor-20220630monthly0.5https://www.biopharmawatch.com/news/XFOR/document-ex-99-1-xfor-20220126monthly0.5https://www.biopharmawatch.com/news/XFOR/document-x4-pharmaceuticals-expands-board-of-directors-through-appointment-of-biopharmaceu-xfor-20201001monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-class-b-warrants-xfor-20191125monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-reports-third-quarter-2019-financial-results-and-recent-business-highli-xfor-20191107monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-reports-positive-data-from-phase-2a-trial-of-mavorixafor-in-combination-xfor-20190930monthly0.5https://www.biopharmawatch.com/news/XFOR/of-x4-pharmaceuticals-inc-s-formerly-arsanis-inc-amendment-no-1-to-the-current-report-on-f-xfor-20190809monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-initiates-pivotal-phase-3-clinical-trial-of-mavorixafor-for-the-treatme-xfor-20190626monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-prices-85-8-million-public-offering-of-common-stock-and-class-a-warrant-xfor-20190412monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-class-a-warrants-xfor-20190411monthly0.5https://www.biopharmawatch.com/news/XFOR/description-of-the-business-of-x4-pharmaceuticals-inc-overview-we-are-a-clinical-stage-bio-xfor-20190411monthly0.5https://www.biopharmawatch.com/news/XFOR/forward-looking-statements-certain-statements-in-this-presentation-particularly-statements-xfor-20190401monthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-completes-merger-with-arsanis-newly-nasdaq-listed-xfor-focused-on-the-d-xfor-20190313monthly0.5https://www.biopharmawatch.com/news/XFOR/arsanis-inc-and-x4-pharmaceuticals-inc-conference-call-tuesday-november-27-th-2018-arsanis-xfor-20181127monthly0.5https://www.biopharmawatch.com/news/XFOR/forward-looking-statements-certain-statements-in-this-communication-regarding-the-proposed-xfor-20181127monthly0.5https://www.biopharmawatch.com/news/XFOR/arsanis-reports-financial-results-for-third-quarter-2018-waltham-mass-and-xfor-20181109monthly0.5https://www.biopharmawatch.com/news/XFOR/arsanis-reports-financial-results-for-second-quarter-2018-waltham-mass-and-xfor-20180813monthly0.5https://www.biopharmawatch.com/news/XFOR/arsanis-provides-update-following-completion-of-planned-interim-analysis-of-phase-2-clinic-xfor-20180628monthly0.5https://www.biopharmawatch.com/news/XFOR/arsanis-reports-business-highlights-and-financial-results-for-first-quarter-2018-asn100-ph-xfor-20180510monthly0.5https://www.biopharmawatch.com/news/XFOR/arsanis-reports-financial-results-and-highlights-for-fourth-quarter-and-full-year-2017-com-xfor-20180309monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-p-1-800-388-4264-f-402-475-9061-nrchealth-com-contact-helen-hrdy-nrc-20250304monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20171107monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-karas-chief-fi-nrc-20170830monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20170801monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20170502monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20170214monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20161101monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20160802monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20160503monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20160209monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20151103monthly0.5https://www.biopharmawatch.com/news/NRC/kevin-karas-chief-financial-officer-national-research-corporation-800-388-4264-kkaras-nati-nrc-20151028monthly0.5https://www.biopharmawatch.com/news/NRC/kevin-karas-chief-financial-officer-national-research-corporation-800-388-4264-kkaras-nati-nrc-20151001monthly0.5https://www.biopharmawatch.com/news/NRC/nrc-announces-second-quarter-2015-results-nrc-20150804monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20150507monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20150210monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20141104monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20140506monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-karas-chief-fi-nrc-20140401monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20140211monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20131105monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20130806monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20130507monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20130212monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20121106monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20120807monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20120501monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20120214monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-kevin-r-karas-chief--nrc-20111101monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-patrick-e-beans-chie-nrc-20110802monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-patrick-e-beans-chie-nrc-20110705monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-patrick-e-beans-chie-nrc-20110503monthly0.5https://www.biopharmawatch.com/news/NRC/unassociated-document-1245-q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-c-nrc-20110208monthly0.5https://www.biopharmawatch.com/news/NRC/unassociated-document-1245-q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-c-nrc-20101102monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-patrick-e-beans-chie-nrc-20100803monthly0.5https://www.biopharmawatch.com/news/NRC/unassociated-document-1245-q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-c-nrc-20100504monthly0.5https://www.biopharmawatch.com/news/NRC/q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-contact-patrick-e-beans-chie-nrc-20100209monthly0.5https://www.biopharmawatch.com/news/NRC/unassociated-document-1245-q-street-lincoln-ne-68508-phone-402-475-2525-fax-402-475-9061-c-nrc-20091103monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-healthcare-announces-2026-share-repurchase-program-lafayette-la-vmd-20260304monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-healthcare-announces-completion-of-share-repurchase-program-lafayette-la-vmd-20250923monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-completes-acquisition-of-lehan-s-medical-equipment-anticipates-updating-it-vmd-20250702monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-healthcare-announces-share-repurchase-program-lafayette-la-vmd-20250609monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-executes-diversification-strategy-with-26-million-acquisition-of-home-equi-vmd-20250506monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-announces-acquisition-of-majority-interest-in-homemed-forging-partnership--vmd-20240402monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-to-centralize-market-for-common-shares-on-nasdaq-through-voluntary-delisti-vmd-20231207monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-announces-successful-completion-of-hmp-acquisition-lafayette-louisiana-vmd-20230601monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-accelerates-growth-through-acquisition-of-tennessee-based-home-medical-pro-vmd-20230418monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-wins-complete-overruling-of-appealed-oig-claims-resolving-multiyear-proces-vmd-20230123monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-announces-strategic-investment-in-population-health-sector-lafayette-louis-vmd-20230112monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-announces-new-senior-secured-credit-facilities-lafayette-louisiana-vmd-20221129monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-announces-executive-additions-to-lead-acquisition-growth-lafayette-louisia-vmd-20220801monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-announces-publication-of-peer-reviewed-nivh-study-finding-treatment-reduce-vmd-20220705monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-provides-update-concerning-successful-appeal-of-office-of-inspector-genera-vmd-20220516monthly0.5https://www.biopharmawatch.com/news/VMD/document-viemed-healthcare-comments-on-final-report-issued-by-office-of-inspector-general--vmd-20210524monthly0.5https://www.biopharmawatch.com/news/VMD/informationcircular-notice-of-annual-special-meeting-of-shareholders-to-be-held-on-june-11-vmd-20200506monthly0.5https://www.biopharmawatch.com/news/VMD/viemed-healthcare-announces-financial-results-for-second-quarter-2019-lafayette-louisiana-vmd-20190809monthly0.5https://www.biopharmawatch.com/news/VSTM/delivering-novel-therapies-for-ras-mapk-pathway-driven-cancers-c-o-r-p-o-r-a-t-e-p-r-e-s-e-vstm-20260507monthly0.5https://www.biopharmawatch.com/news/VSTM/delivering-novel-therapies-for-ras-mapk-pathway-driven-cancers-c-o-r-p-o-r-a-t-e-p-r-e-s-e-vstm-20260304monthly0.5https://www.biopharmawatch.com/news/VSTM/delivering-novel-therapies-for-ras-mapk-pathway-driven-cancers-corporate-presentation-janu-vstm-20260108monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-strategic-transition-plan-to-accelerate-next-phase-of-growth-j-vstm-20251215monthly0.5https://www.biopharmawatch.com/news/VSTM/part-ii-information-not-required-in-prospectus-item-14-other-expenses-of-issuance-and-dist-vstm-20251117monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-reports-third-quarter-2025-financial-results-and-highlights-recent-busin-vstm-20251104monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-encouraging-preliminary-data-from-ongoing-phase-1-2a-dose-esca-vstm-20251023monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-updated-data-from-partner-genfleet-therapeutics-phase-1-2-mono-vstm-20251019monthly0.5https://www.biopharmawatch.com/news/VSTM/delivering-novel-therapies-for-ras-mapk-pathway-driven-cancers-corporate-presentation-sept-vstm-20250908monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-late-breaking-abstract-from-partner-genfleet-therapeutics-stud-vstm-20250813monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-r-d-investor-event-asco-2025-vstm-20250602monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-updated-data-from-partner-genfleet-therapeutics-phase-1-study--vstm-20250602monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-positive-updated-results-from-ramp-205-evaluating-avutometinib-vstm-20250522monthly0.5https://www.biopharmawatch.com/news/VSTM/fda-approves-the-avmapki-fakzynja-combination-therapy-as-the-first-ever-treatment-for-adul-vstm-20250508monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-75-million-private-placement-boston-business-wire-vstm-20250425monthly0.5https://www.biopharmawatch.com/news/VSTM/delivering-novel-therapies-for-ras-mapk-pathway-driven-cancers-corporate-presentation-marc-vstm-20250320monthly0.5https://www.biopharmawatch.com/news/VSTM/delivering-novel-therapies-for-ras-mapk-pathway-driven-cancers-january-2025-corporate-pres-vstm-20250123monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-debt-refinancing-with-oberland-capital-and-strategic-commercia-vstm-20241231monthly0.5https://www.biopharmawatch.com/news/VSTM/in-collaboration-with-efficacy-and-safety-of-avutometinib-defactinib-in-recurrent-low-grad-vstm-20241017monthly0.5https://www.biopharmawatch.com/news/VSTM/part-ii-information-not-required-in-prospectus-item-14-other-expenses-of-issuance-and-dist-vstm-20240725monthly0.5https://www.biopharmawatch.com/news/VSTM/delivering-novel-therapies-in-ras-mapk-pathway-driven-cancers-june-2024-corporate-presenta-vstm-20240626monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-the-initiation-of-a-rolling-submission-of-nda-to-fda-seeking-a-vstm-20240524monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-positive-initial-interim-safety-and-efficacy-results-from-ramp-vstm-20240523monthly0.5https://www.biopharmawatch.com/news/VSTM/delivering-novel-therapies-in-ras-mapk-pathway-driven-cancers-april-2024-corporate-present-vstm-20240409monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-outlines-key-2024-strategic-priorities-and-upcoming-catalysts-for-advanc-vstm-20240129monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-presents-avutometinib-and-defactinib-combination-program-updates-at-the-5-th-annu-vstm-20230928monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-presentation-september-2023-2-disclaimers-this-presentation-includes-forward-loo-vstm-20230912monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-promotion-of-dan-paterson-to-chief-executive-officer-vstm-20230711monthly0.5https://www.biopharmawatch.com/news/VSTM/part-ii-information-not-required-in-prospectus-item-14-other-expenses-of-issuance-and-dist-vstm-20230621monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-presentation-june-2023-2-disclaimers-this-presentation-includes-forward-looking--vstm-20230608monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-reverse-stock-split-boston-ma-vstm-20230531monthly0.5https://www.biopharmawatch.com/news/VSTM/updated-data-from-part-a-of-verastem-oncology-s-ramp-201-trial-show-an-objective-response--vstm-20230525monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-outlines-key-2023-strategic-priorities-and-upcoming-catalysts-for-advanc-vstm-20230202monthly0.5https://www.biopharmawatch.com/news/VSTM/lgsoc-program-update-vstm-20230124monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-appoints-rob-gagnon-to-board-of-directors-boston-vstm-20221215monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-appoints-anil-kapur-to-board-of-directors-boston-vstm-20221020monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-presentation-october-2022-2-safe-harbor-statement-this-presentation-includes-for-vstm-20221004monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-comp-vstm-20220808monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-presentation-june-2022-2-safe-harbor-statement-this-presentation-includes-forwar-vstm-20220606monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-provides-financial-update-to-support-development-of-vs-6766-and-defactin-vstm-20220328monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-presentation-january-2022-2-safe-harbor-statement-this-presentation-includes-for-vstm-20220111monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-appoints-michelle-robertson-to-board-of-directors-boston-vstm-20211026monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-appoints-paul-bunn-m-d-and-lesley-solomon-to-board-of-directors-boston-b-vstm-20210624monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-presentation-may-2021-nasdaq-vstm-2-this-presentation-includes-forward-looking-s-vstm-20210526monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-presentation-february-2021-nasdaq-vstm-safe-harbor-statement-this-presentation-i-vstm-20210225monthly0.5https://www.biopharmawatch.com/news/VSTM/btig-kol-event-vstm-20201217monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-closing-of-copiktra-duvelisib-sale-to-secura-bio-verastem-now--vstm-20200930monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-presentation-of-updated-phase-1-2-frame-study-data-at-the-2-nd-vstm-20200916monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-signs-definitive-agreement-to-sell-copiktra-duvelisib-rights-to-secura-b-vstm-20200810monthly0.5https://www.biopharmawatch.com/news/VSTM/property-of-verastem-inc-1-addressing-ras-pathway-blockade-resistance-vs-6766-defactinib-c-vstm-20200427monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-appoints-john-h-johnson-to-its-board-of-directors-boston-ma-vstm-20200423monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-100-million-private-placement-offering-of-common-stock-to-prem-vstm-20200228monthly0.5https://www.biopharmawatch.com/news/VSTM/property-of-verastem-inc-1-corporate-overview-j-p-morgan-healthcare-conference-vstm-20200113monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-private-exchange-of-approximately-114-3-million-of-its-5-00-co-vstm-20191112monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-reports-third-quarter-2019-financial-results-and-recent-company-progress-vstm-20191029monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-appoints-brian-stuglik-as-chief-executive-officer-boston-ma-x2013-vstm-20190729monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-leadership-changes-vstm-20190620monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-amendment-to-refinance-hercules-loan-facility-new-terms-provid-vstm-20190423monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-executive-leadership-appointments-and-changes-gina-consylman-j-vstm-20181018monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-inc-5-00-convertible-senior-notes-due-2048-placement-agent-agreement-vstm-20181011monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-receives-fda-approval-of-copiktra-duvelisib-capsules-company-to-host-con-vstm-20180924monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-appoints-robert-e-gagnon-as-chief-financial-officer-boston-ma-vstm-20180829monthly0.5https://www.biopharmawatch.com/news/VSTM/purchase-agreement-this-purchase-agreement-this-agreement-is-dated-as-of-vstm-20180614monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-announces-increased-hercules-debt-facility-increases-borrowing-limit-to-50-millio-vstm-20180104monthly0.5https://www.biopharmawatch.com/news/VSTM/information-relating-to-part-ii-item-14-other-expenses-of-issuance-and-distribution-the-ex-vstm-20171218monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-pays-milestone-payment-to-infinity-pharmaceuticals-boston-ma-vstm-20171017monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-overview-nasdaq-vstm-september-18-2017-forward-looking-statements-this-presentat-vstm-20170919monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-expands-duvelisib-development-program-to-include-peripheral-t-cell-lymphoma-duvel-vstm-20170906monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-names-julie-b-feder-as-chief-financial-officer-boston-ma-vstm-20170711monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-appoints-eric-k-rowinsky-to-the-board-of-directors-boston-ma-vstm-20170502monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-licenses-duvelisib-from-infinity-pharmaceuticals-transaction-adds-complementary-l-vstm-20161102monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-announces-changes-to-its-board-of-directors-boston-ma-vstm-20160614monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-names-gregory-i-berk-md-as-chief-medical-officer-announces-additional-key-executi-vstm-20160418monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-reports-year-end-2015-financial-results-boston-ma-vstm-20160303monthly0.5https://www.biopharmawatch.com/news/VSTM/corporate-overview-nasdaq-vstm-vstm-20160107monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-reports-third-quarter-2015-financial-and-corporate-results-boston-business-wire-vstm-20151109monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-stops-enrollment-due-to-futility-in-the-command-study-of-vs-6063-for-the-treatmen-vstm-20150928monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-issues-statement-regarding-wclc-presentations-boston-ma-vstm-20150826monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-reports-year-end-2014-financial-results-command-interim-analysis-expected-second--vstm-20150310monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-provides-year-end-2014-update-and-outlook-for-2015-command-study-currently-on-tra-vstm-20150108monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-appoints-daniel-paterson-as-chief-operating-officer-boston-ma-vstm-20141218monthly0.5https://www.biopharmawatch.com/news/VSTM/dr-paul-a-friedman-joins-verastem-board-of-directors-cambridge-ma-vstm-20140512monthly0.5https://www.biopharmawatch.com/news/VSTM/timothy-j-barberich-joins-verastem-board-of-directors-cambridge-ma-vstm-20140311monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-reports-year-end-2013-financial-results-a-year-of-clinical-execution-three-small--vstm-20140306monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-acquires-rights-to-cancer-stem-cell-inhibitor-vs-4718-the-acquisition-reduces-mil-vstm-20140225monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-announces-proposed-public-offering-of-common-stock-cambridge-mass-business-wire-vstm-20130716monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-appoints-robert-forrester-as-chief-executive-officer-christoph-westphal-m-d-ph-d--vstm-20130606monthly0.5https://www.biopharmawatch.com/news/VSTM/jack-green-joins-verastem-as-chief-financial-officer-cambridge-ma-vstm-20130514monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-reports-year-end-2012-financial-results-advancing-clinical-development-programs-t-vstm-20130327monthly0.5https://www.biopharmawatch.com/news/VSTM/stephen-sherwin-m-d-joins-verastem-board-of-directors-cambridge-ma-vstm-20130306monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-promotes-chief-operating-officer-robert-forrester-to-president-vstm-20130122monthly0.5https://www.biopharmawatch.com/news/VSTM/alison-lawton-and-michael-kauffman-join-verastem-board-of-directors-vstm-20121126monthly0.5https://www.biopharmawatch.com/news/VSTM/louise-phanstiel-joins-verastem-board-of-directors-cambridge-mass-vstm-20120919monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-reports-second-quarter-2012-financial-and-corporate-results-cambridge-ma-vstm-20120813monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-acquires-clinical-stage-fak-inhibitor-from-pfizer-cambridge-ma-vstm-20120711monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-inc-reports-first-quarter-2012-financial-results-cambridge-ma-vstm-20120514monthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-inc-reports-year-end-2011-financial-results-cambridge-ma-vstm-20120314monthly0.5https://www.biopharmawatch.com/news/SRTA/strata-announces-closing-of-revolving-credit-facility-to-support-acquisition-strategy-exec-srta-20260205monthly0.5https://www.biopharmawatch.com/news/SRTA/strata-critical-medical-inc-appoints-will-cook-to-board-of-directors-new-york-new-york-srta-20251203monthly0.5https://www.biopharmawatch.com/news/SRTA/strata-critical-medical-inc-unaudited-pro-forma-condensed-consolidated-financial-statement-srta-20250829monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-announces-sale-of-passenger-division-to-joby-transitions-to-pure-play-medical-servic-srta-20250804monthly0.5https://www.biopharmawatch.com/news/SRTA/hereto-and-is-incorporated-by-reference-herein-d-exhibits-exhibit-no-description-2-1-agree-srta-20230213monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-to-acquire-three-urban-air-mobility-companies-creating-largest-helicopter-passenger--srta-20220519monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-acquires-exclusive-rights-to-helijet-s-scheduled-passenger-business-in-canada-flight-srta-20211202monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-air-mobility-appoints-reggie-love-to-board-of-directors-replacing-david-zaslav-new-y-srta-20210924monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-air-mobility-completes-acquisition-of-trinity-air-medical-inc-new-york-ny-and-phoeni-srta-20210917monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-air-mobility-announces-definitive-agreement-to-acquire-trinity-air-medical-creating--srta-20210909monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-air-mobility-reports-fiscal-third-quarter-ended-june-30-2021-financial-results-and-p-srta-20210816monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-air-mobility-reports-fiscal-second-quarter-ending-march-31-2021-financial-results-an-srta-20210517monthly0.5https://www.biopharmawatch.com/news/SRTA/unaudited-pro-forma-condensed-combined-financial-information-defined-terms-included-below--srta-20210513monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-to-begin-trading-today-on-the-nasdaq-stock-market-under-ticker-symbol-blde-new-york--srta-20210510monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-completes-business-combination-becoming-the-first-publicly-traded-urban-air-mobility-srta-20210510monthly0.5https://www.biopharmawatch.com/news/SRTA/experience-investment-corp-stockholders-approve-business-combination-with-blade-urban-air--srta-20210506monthly0.5https://www.biopharmawatch.com/news/SRTA/experience-investment-corp-announces-special-meeting-date-to-approve-proposed-business-com-srta-20210407monthly0.5https://www.biopharmawatch.com/news/SRTA/urban-air-mobility-additional-information-and-where-to-find-it-experience-investment-corp--srta-20210318monthly0.5https://www.biopharmawatch.com/news/SRTA/blade-to-be-listed-on-nasdaq-creating-the-only-publicly-traded-global-urban-air-mobility-c-srta-20201215monthly0.5https://www.biopharmawatch.com/news/SRTA/experience-investment-corp-announces-the-separate-trading-of-its-class-a-common-stock-and--srta-20191030monthly0.5https://www.biopharmawatch.com/news/SRTA/index-to-financial-statements-page-report-of-independent-registered-public-accounting-firm-srta-20190917monthly0.5https://www.biopharmawatch.com/news/SRTA/experience-investment-corp-announces-pricing-of-250-000-000-initial-public-offering-denver-srta-20190912monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-fourth-quarter-and-full-year-2025-financial-results-pacb-20260212monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-unaudited-pro-forma-consolidated-financial-statement-pacb-20260130monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-third-quarter-2025-financial-results-pacb-20251105monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-second-quarter-2025-financial-results-pacb-20250807monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-first-quarter-2025-financial-results-pacb-20250508monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-preliminary-first-quarter-2025-revenue-and-reiterates-2025-revenue-guidan-pacb-20250409monthly0.5https://www.biopharmawatch.com/news/PACB/jim-gibson-to-join-pacbio-as-chief-financial-officer-pacb-20250327monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-fourth-quarter-and-fiscal-year-2024-financial-results-pacb-20250213monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-appointment-of-chris-smith-to-board-of-directors-pacbio-to-leverage-chris-pacb-20250130monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-preliminary-fourth-quarter-and-full-year-revenue-commenced-shipment-of-th-pacb-20250114monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-third-quarter-2024-financial-results-pacb-20241107monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-a-private-convertible-exchange-transaction-of-459-million-principal-amoun-pacb-20241107monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-second-quarter-2024-financial-results-pacb-20240807monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-first-quarter-2024-financial-results-pacb-20240509monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-preliminary-first-quarter-2024-revenue-and-updates-2024-revenue-guidance--pacb-20240416monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-fourth-quarter-and-fiscal-year-2023-financial-results-pacb-20240215monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-record-preliminary-fourth-quarter-and-full-year-revenue-growing--pacb-20240108monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-third-quarter-2023-financial-results-pacb-20231030monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-appointment-of-david-meline-to-board-of-directors-former-cfo-of--pacb-20231016monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-second-quarter-2023-financial-results-menlo-park-calif-pacb-20230802monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-a-private-convertible-exchange-transaction-of-441-million-principal-amoun-pacb-20230626monthly0.5https://www.biopharmawatch.com/news/PACB/document-pacbio-announces-record-revenue-in-first-quarter-2023-menlo-park-calif-pacb-20230502monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-fourth-quarter-and-fiscal-year-2022-financial-results-menlo-park-calif-x2-pacb-20230216monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-pricing-of-upsized-public-offering-of-comm-pacb-20230124monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-record-orders-including-orders-for-76-revio-systems-received-in-the-fourt-pacb-20230109monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-third-quarter-2022-financial-results-menlo-park-calif-x2013-pacb-20221107monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-to-report-third-quarter-earnings-on-november-7-and-host-inaugural-investor-day-on-n-pacb-20221025monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-second-quarter-2022-financial-results-menlo-park-calif-x2013-pacb-20220803monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-first-quarter-2022-financial-results-menlo-park-calif-x2013-pacb-20220504monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-fourth-quarter-and-fiscal-year-2021-financial-results-menlo-park-calif-x2-pacb-20220215monthly0.5https://www.biopharmawatch.com/news/PACB/xfeff-pacbio-announces-record-preliminary-fourth-quarter-2021-revenue-new-sequencing-kits--pacb-20220111monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-third-quarter-2021-financial-results-menlo-park-calif-x2013-pacb-20211102monthly0.5https://www.biopharmawatch.com/news/PACB/and-broadly-enable-clinical-sequencing-the-potential-ability-of-a-combined-product-portfol-pacb-20210920monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-2021-financial-results-menl-pacb-20210803monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-signs-definitive-agreement-to-acquire-omniome-combination-aims-to-tran-pacb-20210720monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-first-quarter-2021-financial-results-menlo-pacb-20210429monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-nominates-dr-hannah-valantine-to-its-board-of-directors-pacb-20210427monthly0.5https://www.biopharmawatch.com/news/PACB/xfeff-pacific-biosciences-of-california-inc-announces-fourth-quarter-and-fiscal-year-2020--pacb-20210210monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-900-million-investment-from-softbank-to-support-growth-initi-pacb-20210210monthly0.5https://www.biopharmawatch.com/news/PACB/xfeff-pacific-biosciences-and-invitae-to-develop-ultra-high-throughput-clinical-whole-geno-pacb-20210113monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-preliminary-fourth-quarter-2020-revenue-me-pacb-20210111monthly0.5https://www.biopharmawatch.com/news/PACB/xfeff-pacific-biosciences-of-california-inc-announces-appointments-of-mark-van-oene-as-chi-pacb-20210108monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-pricing-of-public-offering-of-common-stock-pacb-20201110monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-2020-financial-results-xfeff-pacb-20201102monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-new-chief-financial-officer-pacb-20200914monthly0.5https://www.biopharmawatch.com/news/PACB/xfeff-xfeff-xfeff-pacific-biosciences-of-california-inc-announces-pricing-of-public-offeri-pacb-20200811monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-new-chief-executive-officer-christian-o-henry-named-chief-ex-pacb-20200807monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-2020-financial-results-menl-pacb-20200803monthly0.5https://www.biopharmawatch.com/news/PACB/xfeff-pacific-biosciences-announces-planned-retirement-of-ceo-dr-michael-hunkapiller-xfeff-pacb-20200610monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-first-quarter-20-20-financial-results-menl-pacb-20200506monthly0.5https://www.biopharmawatch.com/news/PACB/xfeff-xfeff-christian-henry-appointed-chairman-of-pacific-biosciences-board-of-directors-x-pacb-20200306monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-retirement-of-michael-phillips-svp-of-research-and-developme-pacb-20200207monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-fourth-quarter-and-annual-201-9-financial-results-annual-rev-pacb-20200206monthly0.5https://www.biopharmawatch.com/news/PACB/illumina-and-pacific-biosciences-announce-termination-of-merger-agreement-san-diego-pacb-20200102monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-201-9-financial-results-menl-pacb-20191107monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-201-9-financial-results-men-pacb-20190806monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-first-quarter-201-9-financial-results-menl-pacb-20190503monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-fourth-quarter-and-annual-201-8-financial-results-menlo-park-pacb-20190211monthly0.5https://www.biopharmawatch.com/news/PACB/illumina-to-acquire-pacific-biosciences-for-approximately-1-2-billion-broadening-access-to-pacb-20181101monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-201-8-financial-results-menl-pacb-20181101monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-pricing-of-public-offering-of-common-stock-pacb-20180911monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-201-8-financial-results-men-pacb-20180802monthly0.5https://www.biopharmawatch.com/news/PACB/henry-pacific-biosciences-appoints-christian-henry-to-board-of-directors-industry-veteran--pacb-20180731monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-favorable-outcome-in-uk-and-german-patent-litigation-against-pacb-20180508monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-f-irst-quarter-201-8-financial-results-xfe-pacb-20180502monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-pricing-of-public-offering-of-common-stock-pacb-20180213monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-fourth-quarter-and-annual-2017-financial-results-annual-prod-pacb-20180201monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-xfeff-condensed-consolidated-balance-sheets-unaudite-pacb-20180201monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-appoints-kathy-ordo-ez-as-chief-commercial-officer-pacb-20171102monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-2017-financial-results-produ-pacb-20171102monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-2017-financial-results-prod-pacb-20170802monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-pricing-of-public-offering-of-common-stock-pacb-20170615monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-first-quarter-2017-financial-results-produ-pacb-20170426monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-xfeff-condensed-consolidated-balance-sheets-unaudite-pacb-20170426monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-xfeff-consolidated-balance-sheets-unaudited-xfeff-xf-pacb-20170202monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-fourth-quarter-2016-financial-results-product-and-service-re-pacb-20170202monthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-announces-termination-of-agreement-with-roche-diagnostics-pacb-20161215monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-2016-financial-results-reven-pacb-20161102monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-2016-financial-results-prod-pacb-20160804monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-f-irst-quarter-201-6-financial-results-men-pacb-20160421monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-consolidated-balance-sheets-unaudited-december-31-in-pacb-20160203monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-fourth-quarter-2015-financial-results-menlo-park-calif-x2013-pacb-20160203monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-provides-update-on-launch-of-new-sequel-system-orders-received-for-49--pacb-20160111monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-condensed-consolidated-balance-sheets-unaudited-sept-pacb-20151022monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-201-5-financial-results-menl-pacb-20151022monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-launches-new-sequencing-platform-based-on-its-smrt-technology-sequel-x-pacb-20150930monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-201-5-financial-results-men-pacb-20150805monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-f-irst-quarter-201-5-financial-results-men-pacb-20150505monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-achieves-second-development-milestone-in-clinical-diagnostics-agreemen-pacb-20150505monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-consolidated-balance-sheets-unaudited-december-31-in-pacb-20150203monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-reports-fourth-quarter-201-4-financial-results-menlo-park-calif-x2013--pacb-20150203monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-appoints-kathy-ordo-xf1-ez-to-board-of-directors-industry-veteran-prev-pacb-20141218monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-condensed-consolidated-balance-sheets-unaudited-sept-pacb-20141023monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-reports-third-quarter-201-4-financial-results-menlo-park-calif-x2013-pacb-20141023monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-condensed-consolidated-balance-sheets-unaudited-june-pacb-20140724monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-reports-second-quarter-201-4-financial-results-menlo-park-calif-x2013--pacb-20140724monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-condensed-consolidated-balance-sheets-unaudited-marc-pacb-20140430monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-f-irst-quarter-201-4-financial-results-men-pacb-20140430monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-consolidated-balance-sheets-unaudited-december-31-in-pacb-20140204monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-fourth-quarter-2013-financial-results-menl-pacb-20140204monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-2013-financial-results-menlo-pacb-20131022monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-announces-agreement-with-roche-diagnostics-to-develop-and-supply-dna-s-pacb-20130925monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-2013-financial-results-menl-pacb-20130801monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-appoints-john-f-milligan-to-board-of-directors-gilead-sciences-executi-pacb-20130718monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-condensed-consolidated-balance-sheets-unaudited-in-t-pacb-20130423monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-first-quarter-2013-financial-results-menlo-pacb-20130423monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-completes-20-5-million-debt-financing-menlo-park-calif-pacb-20130205monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-consolidated-balance-sheets-unaudited-in-thousands-e-pacb-20130205monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-fourth-quarter-2012-financial-results-menl-pacb-20130205monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-2012-financial-results-menlo-pacb-20121025monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-appoints-lucy-shapiro-ph-d-to-board-of-directors-pacb-20120912monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-2012-financial-results-menl-pacb-20120726monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-names-david-botstein-ph-d-to-its-board-of-directors-pacb-20120723monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-first-quarter-2012-financial-results-menlo-pacb-20120501monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-financial-results-for-the-fourth-quarter-a-pacb-20120207monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-names-michael-w-hunkapiller-chief-executive-officer-pacb-20120106monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-third-quarter-financial-results-menlo-park-pacb-20111027monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-second-quarter-financial-results-menlo-par-pacb-20110804monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-inc-announces-first-quarter-financial-results-menlo-park-pacb-20110427monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-announces-fourth-quarter-and-fiscal-year-2010-operating--pacb-20110215monthly0.5https://www.biopharmawatch.com/news/PACB/pacific-biosciences-of-california-announces-third-quarter-of-2010-operating-results-menlo--pacb-20101130monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-select-preliminary-fourth-quarter-and-full-year-2025-financial-r-mygn-20251231monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-ben-wheeler-chief-financial-officer-mygn-20250818monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-second-quarter-2025-financial-results-raises-2025-revenue-guidance-mygn-20250731monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-new-200-million-credit-facility-mygn-20250731monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-first-quarter-2025-financial-results-updates-2025-financial-guidan-mygn-20250506monthly0.5https://www.biopharmawatch.com/news/MYGN/kate-schraml-investor-contact-matt-scalo-224-875-4493-801-584-3532-pr-myriad-com-matt-scal-mygn-20250224monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-board-of-directors-with-election-of-mark-s-davis-as-new-board-memb-mygn-20241210monthly0.5https://www.biopharmawatch.com/news/MYGN/megan-manzari-investor-contact-matt-scalo-385-318-3718-801-584-3532-megan-manzari-myriad-c-mygn-20241101monthly0.5https://www.biopharmawatch.com/news/MYGN/in-the-court-of-chancery-of-the-state-of-delaware-in-re-myriad-genetics-inc-stockholder-de-mygn-20240603monthly0.5https://www.biopharmawatch.com/news/MYGN/lambertcoo-myriad-genetics-promotes-nicole-lambert-to-chief-operating-officer-mygn-20211214monthly0.5https://www.biopharmawatch.com/news/MYGN/jared-maxwell-investor-contact-nathan-smith-801-505-5027-801-505-5067-jmaxwell-myriad-com--mygn-20210524monthly0.5https://www.biopharmawatch.com/news/MYGN/jared-maxwell-investor-contact-scott-gleason-801-505-5027-801-584-1143-jmaxwell-myriad-com-mygn-20201015monthly0.5https://www.biopharmawatch.com/news/MYGN/jared-maxwell-801-505-5027-jmaxwell-myriad-com-investor-contact-scott-gleason-801-584-1143-mygn-20200910monthly0.5https://www.biopharmawatch.com/news/MYGN/jared-maxwell-investor-contact-scott-gleason-801-505-5027-801-584-1143-jmaxwell-myriad-com-mygn-20200814monthly0.5https://www.biopharmawatch.com/news/MYGN/jared-maxwell-investor-contact-scott-gleason-801-505-5027-801-584-1143-jmaxwell-myriad-com-mygn-20200722monthly0.5https://www.biopharmawatch.com/news/MYGN/jared-maxwell-investor-contact-scott-gleason-801-505-5027-801-584-1143-jmaxwell-myriad-com-mygn-20200528monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20200505monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20200408monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20200323monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20200206monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20200206monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20191104monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20190925monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20190813monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20190507monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20190314monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20190205monthly0.5https://www.biopharmawatch.com/news/MYGN/forward-looking-statements-some-of-the-information-presented-here-today-may-contain-projec-mygn-20190104monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20181119monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20181106monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20180821monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20180731monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20180528monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20180508monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20180206monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20171107monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogersinvestor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgle-mygn-20171102monthly0.5https://www.biopharmawatch.com/news/MYGN/mygn-ex991-53-pptx-htm-91-87-forward-looking-statements-15m-patient-preventive-care-market-mygn-20170905monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20170808monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20170502monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20170207monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20161101monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-908-285-0248-801-584-1143-rrogers-myriad-com-sgl-mygn-20160901monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20160809monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20160803monthly0.5https://www.biopharmawatch.com/news/MYGN/forward-looking-statements-some-of-the-information-presented-here-today-may-contain-projec-mygn-20160630monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-908-285-0248-rrogers-myriad-com-investor-contact-scott-gleason-801-584-1143-sgl-mygn-20160629monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-908-285-0248-801-584-1143-rrogers-myriad-com-sgl-mygn-20160607monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-908-285-0248-801-584-1143-rrogers-myriad-com-sgl-mygn-20160531monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20160503monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20160202monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20151103monthly0.5https://www.biopharmawatch.com/news/MYGN/copyright-2015-myriad-genetics-inc-all-rights-reserved-www-myriad-com-forward-looking-stat-mygn-20150914monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20150811monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20150505monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-investor-contact-scott-gleason-801-584-3065-801-584-1143-rrogers-myriad-com-sgl-mygn-20150224monthly0.5https://www.biopharmawatch.com/news/MYGN/ron-rogers-801-584-3065-rrogers-myriad-com-investor-contact-scott-gleason-801-584-1143-sgl-mygn-20150203monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-first-quarter-2026-financial-results-and-provides-business-updates-new-imrx-20260515monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-busin-imrx-20260306monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-announces-25-million-private-placement-imrx-20250821monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-second-quarter-2025-financial-results-and-provides-business-updates-co-imrx-20250813monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-first-quarter-2025-financial-results-and-provides-business-updates-pro-imrx-20250505monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-busin-imrx-20250320monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-third-quarter-2024-financial-results-and-provides-business-updates-ann-imrx-20241113monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-second-quarter-2024-financial-results-and-provides-business-updates-en-imrx-20240806monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-first-quarter-2024-financial-results-and-provides-business-updates-rep-imrx-20240507monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-busin-imrx-20240301monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-third-quarter-2023-financial-results-and-provides-business-updates-dos-imrx-20231109monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-second-quarter-2023-financial-results-and-provides-business-updates-po-imrx-20230803monthly0.5https://www.biopharmawatch.com/news/IMRX/building-a-universal-ras-franchise-nasdaq-imrx-april-2023-investor-presentation-2023-corpo-imrx-20230331monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-busin-imrx-20230306monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-third-quarter-2022-financial-results-and-recent-business-highlights-re-imrx-20221110monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-second-quarter-2022-financial-results-and-recent-business-highlights-i-imrx-20220810monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-first-quarter-2022-financial-results-and-recent-business-highlights-in-imrx-20220510monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-busin-imrx-20220310monthly0.5https://www.biopharmawatch.com/news/IMRX/the-field-allows-up-to-17-characters-imrx-20220118monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-third-quarter-2021-financial-results-and-recent-business-highlights-su-imrx-20211109monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-reports-second-quarter-2021-financial-results-and-provides-business-updates-re-imrx-20210909monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-first-quarter-results-nus-20260507monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-appoints-chelsea-lantz-as-interim-chief-financial-officer-nus-20260320monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-appoints-chayce-clark-as-coo-clark-to-expand-on-his-responsibilities-as-chief-lega-nus-20260309monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2025-results-within-guidance-comp-nus-20260212monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-earnings-company-preparing-for-limited-introduct-nus-20251106monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-second-quarter-revenue-at-high-end-of-guidance-and-earnings-pe-nus-20250807monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-first-quarter-revenue-at-high-end-of-guidance-nus-20250508monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2024-results-above-company-revenu-nus-20250213monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-announces-strategic-transaction-of-mavely-for-250-million-nus-20250103monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-results-nus-20241107monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-second-quarter-results-nus-20240808monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-first-quarter-results-nus-20240508monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2023-results-above-company-guidan-nus-20240214monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-to-discuss-company-strategy-and-opportunities-at-icr-conference-compan-nus-20240108monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-2023-financial-results-nus-20231101monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-second-quarter-2023-financial-results-nus-20230801monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-appoints-james-d-thomas-as-chief-financial-officer-nus-20230727monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-first-quarter-2023-financial-results-company-reiterates-2023-g-nus-20230503monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-fourth-quarter-and-2022-financial-results-company-provides-ini-nus-20230215monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-financial-results-nus-20221102monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-second-quarter-financial-results-nus-20220804monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-provides-estimated-second-quarter-revenue-company-to-announce-full-sec-nus-20220707monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-first-quarter-financial-results-nus-20220504monthly0.5https://www.biopharmawatch.com/news/NUS/dear-shareholder-2021-was-another-year-filled-with-global-uncertainty-due-to-covid-related-nus-20220419monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-fourth-quarter-and-2021-financial-results-company-provides-ini-nus-20220216monthly0.5https://www.biopharmawatch.com/news/NUS/new-year-s-message-from-ceo-ryan-napierski-dear-nu-skin-team-what-a-year-2021-was-in-many--nus-20220105monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-2021-results-nus-20211103monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-provides-estimated-third-quarter-revenue-company-to-announce-full-thir-nus-20211004monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-42-percent-eps-growth-and-15-nus-20210804monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-record-first-quarter-2021-results-company-announces-first-quar-nus-20210505monthly0.5https://www.biopharmawatch.com/news/NUS/dear-shareholder-as-i-enter-my-final-year-as-ceo-of-nu-skin-i-reflect-on-a-year-unlike-any-nus-20210419monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-fourth-quarter-revenue-growth-of-28-percent-and-eps-growth-of--nus-20210210monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-2020-nus-20201104monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-estimated-third-quarter-revenue-significantly-above-previous-g-nus-20201001monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-second-quarter-2020-results-and-raises-2020-nus-20200805monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-estimated-second-quarter-revenue-above-previous-guidance-compa-nus-20200701monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-first-quarter-2020-nus-20200506monthly0.5https://www.biopharmawatch.com/news/NUS/dear-shareholder-in-my-2018-annual-report-letter-i-shared-details-of-nu-skin-s-long-term-b-nus-20200421monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-fourth-quarter-and-2019-results-and-provides-2020-nus-20200212monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-2019-nus-20191105monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-second-quarter-2019-nus-20190806monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-provides-estimated-second-quarter-results-and-updates-2019-nus-20190716monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-first-quarter-2019-nus-20190430monthly0.5https://www.biopharmawatch.com/news/NUS/dear-shareholder-two-years-ago-when-i-became-ceo-our-management-team-put-in-place-a-dynami-nus-20190424monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-fourth-quarter-and-2018-results-and-provides-2019-nus-20190213monthly0.5https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-strong-third-quarter-results-with-20-percent-revenue-growth-an-nus-20181107monthly0.5https://www.biopharmawatch.com/news/NUS/dated-august-2-2018-for-immediate-release-nu-skin-enterprises-reports-28-percent-second-qu-nus-20180802monthly0.5https://www.biopharmawatch.com/news/NUS/dated-april-26-2018-for-immediate-release-nu-skin-enterprises-reports-strong-first-quarter-nus-20180426monthly0.5https://www.biopharmawatch.com/news/NUS/letter-to-shareholders-dear-shareholder-the-past-year-has-been-one-of-growth-and-renewal-f-nus-20180425monthly0.5https://www.biopharmawatch.com/news/NUS/dated-february-15-2018-for-immediate-release-nu-skin-enterprises-reports-fourth-quarter-an-nus-20180215monthly0.5https://www.biopharmawatch.com/news/NUS/dated-november-1-2017-for-immediate-release-nu-skin-enterprises-reports-third-quarter-2017-nus-20171101monthly0.5https://www.biopharmawatch.com/news/NUS/dated-october-12-2017-for-immediate-release-for-immediate-release-nu-skin-enterprises-prov-nus-20171012monthly0.5https://www.biopharmawatch.com/news/NUS/dated-august-2-2017-for-immediate-release-nu-skin-enterprises-reports-second-quarter-2017--nus-20170802monthly0.5https://www.biopharmawatch.com/news/NUS/dated-may-3-2017-for-immediate-release-nu-skin-enterprises-reports-first-quarter-2017-nus-20170503monthly0.5https://www.biopharmawatch.com/news/NUS/letter-to-shareholders-dear-shareholder-it-is-an-honor-to-be-writing-my-first-shareholder--nus-20170327monthly0.5https://www.biopharmawatch.com/news/NUS/dated-february-16-2017-for-immediate-release-contacts-investors-scott-pond-801-345-2657-sp-nus-20170216monthly0.5https://www.biopharmawatch.com/news/NUS/dated-november-3-2016-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spo-nus-20161103monthly0.5https://www.biopharmawatch.com/news/NUS/dated-august-4-2016-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nus-20160804monthly0.5https://www.biopharmawatch.com/news/NUS/in-the-united-states-district-court-district-of-utah-central-division-in-re-nu-skin-enterp-nus-20160713monthly0.5https://www.biopharmawatch.com/news/NUS/dated-june-15-2016-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond--nus-20160615monthly0.5https://www.biopharmawatch.com/news/NUS/dated-april-28-2016-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nus-20160428monthly0.5https://www.biopharmawatch.com/news/NUS/letter-to-shareholders-dear-shareholder-we-are-pleased-to-share-our-2-0-15-annual-report-w-nus-20160412monthly0.5https://www.biopharmawatch.com/news/NUS/dated-february-11-2016-for-immediate-release-contacts-investors-scott-pond-801-345-2657-sp-nus-20160211monthly0.5https://www.biopharmawatch.com/news/NUS/dated-october-29-2015-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spo-nus-20151029monthly0.5https://www.biopharmawatch.com/news/NUS/q3-2015-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nuskin-com--nus-20151006monthly0.5https://www.biopharmawatch.com/news/NUS/dated-august-6-2015-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nus-20150806monthly0.5https://www.biopharmawatch.com/news/NUS/letter-to-stockholders-dear-stockholder-the-year-2014-marked-nu-skin-s-30th-anniversary-an-nus-20150512monthly0.5https://www.biopharmawatch.com/news/NUS/dated-may-6-2015-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nu-nus-20150506monthly0.5https://www.biopharmawatch.com/news/NUS/dated-february-5-2015-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spo-nus-20150205monthly0.5https://www.biopharmawatch.com/news/NUS/november-5-2014-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nus-nus-20141105monthly0.5https://www.biopharmawatch.com/news/NUS/dated-august-6-2014-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nus-20140806monthly0.5https://www.biopharmawatch.com/news/NUS/letter-to-shareholders-excerpted-from-the-nu-skin-enterprises-inc-2013-annual-report-to-sh-nus-20140501monthly0.5https://www.biopharmawatch.com/news/NUS/dated-may-6-2014-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nu-nus-20140506monthly0.5https://www.biopharmawatch.com/news/NUS/dated-march-3-2014-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond--nus-20140303monthly0.5https://www.biopharmawatch.com/news/NUS/dated-february-4-2014-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spo-nus-20140204monthly0.5https://www.biopharmawatch.com/news/NUS/release-by-nu-skin-china-dated-january-21-2014-1-2-3-1-2-3-dear-consumers-and-everyone-who-nus-20140121monthly0.5https://www.biopharmawatch.com/news/NUS/dated-january-16-2014-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spo-nus-20140116monthly0.5https://www.biopharmawatch.com/news/NUS/dated-october-22-2013-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spo-nus-20131022monthly0.5https://www.biopharmawatch.com/news/NUS/correction-to-press-release-dated-august-1-2013-for-immediate-release-contacts-investors-s-nus-20130801monthly0.5https://www.biopharmawatch.com/news/NUS/dated-august-1-2013-for-immediate-release-contacts-investors-scott-pond-801-345-2657-spond-nus-20130801monthly0.5https://www.biopharmawatch.com/news/NMRA/february-2026-guggenheim-emerging-outlook-biotech-summit-important-disclosures-this-presen-nmra-20260211monthly0.5https://www.biopharmawatch.com/news/NMRA/important-disclosures-this-presentation-contains-forward-looking-statements-about-neumora--nmra-20260112monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-u-nmra-20250806monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-up-nmra-20250512monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-nmra-20250303monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-leadership-transition-paul-l-berns-executive-chair-of-neumo-nmra-20250213monthly0.5https://www.biopharmawatch.com/news/NMRA/important-disclosures-this-presentation-contains-forward-looking-statements-about-neumora--nmra-20250113monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-data-from-koastal-1-study-of-navacaprant-in-major-depressive--nmra-20250102monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-up-nmra-20241112monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-u-nmra-20240806monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-up-nmra-20240507monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provi-nmra-20240307monthly0.5https://www.biopharmawatch.com/news/NMRA/j-p-morgan-healthcare-conference-january-2024-important-disclosures-this-presentation-cont-nmra-20240108monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-up-nmra-20231101monthly0.5https://www.biopharmawatch.com/news/PBYI/jfif-exif-mm-c-c-l-1a-qa-q-2-pbyi-20221208monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2021-financial-results-pbyi-20210805monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2021-financial-results-pbyi-20210506monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-financial-results-pbyi-20210225monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2020-financial-results-pbyi-20201105monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2020-financial-results-pbyi-20200806monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2020-financial-results-pbyi-20200507monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-financial-results-pbyi-20200220monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-j-p-morgan-2020-healthcare-conference-january-2020-copyright-2020-puma--pbyi-20200113monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2019-financial-results-pbyi-20191106monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2019-financial-results-pbyi-20190808monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2019-financial-results-pbyi-20190509monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-2018-financial-results-pbyi-20190228monthly0.5https://www.biopharmawatch.com/news/PBYI/robbins-arroyo-llp-brian-j-robbins-190264-brobbins-robbinsarroyo-com-kevin-a-seely-199982--pbyi-20181119monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2018-financial-results-pbyi-20181101monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2018-financial-results-pbyi-20180809monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2018-financial-results-pbyi-20180509monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-2017-financial-results-pbyi-20180301monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2017-financial-results-results-include-the-initia-pbyi-20171109monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2017-financial-results-pbyi-20170809monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2017-financial-results-pbyi-20170510monthly0.5https://www.biopharmawatch.com/news/PBYI/interim-5-year-dfs-in-patients-initiating-neratinib-treatment-less-than-1-year-after-compl-pbyi-20170301monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-2016-financial-results-pbyi-20170301monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-to-move-stock-exchange-listing-to-nasdaq-ticker-symbol-to-remain-pbyi-20161219monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2016-financial-results-pbyi-20161109monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2016-financial-results-pbyi-20160809monthly0.5https://www.biopharmawatch.com/news/PBYI/interim-5-year-analysis-of-idfs-data-from-phase-iii-extenet-trial-july-2016-copyright-2016-pbyi-20160722monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2016-financial-results-pbyi-20160510monthly0.5https://www.biopharmawatch.com/news/PBYI/event-and-censoring-rules-original-rule-invasive-disease-free-survival-idfs-events-were-de-pbyi-20160330monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-2015-financial-results-pbyi-20160229monthly0.5https://www.biopharmawatch.com/news/PBYI/an-open-label-study-to-characterize-the-incidence-and-severity-of-diarrhea-in-patients-wit-pbyi-20151223monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2015-financial-results-pbyi-20151109monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2015-financial-results-pbyi-20150810monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-phase-iii-trial-of-pb272-in-extended-adjuvant-breast-cancer-e-pbyi-20150601monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2015-financial-results-pbyi-20150511monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-expands-cohort-in-phase-ii-trial-of-pb272-in-her2-mutation-positive-can-pbyi-20150414monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-initiates-phase-ii-trial-of-pb272-in-early-stage-her2-positive-breast-c-pbyi-20150310monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-2014-financial-results-pbyi-20150302monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-positive-interim-pb272-neratinib-phase-ii-data-at-2014-ctrc-a-pbyi-20141212monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-updates-timeline-for-filing-new-drug-application-nda-filing-currently-a-pbyi-20141202monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-positive-top-line-results-from-pb272-phase-ii-trial-in-her2-p-pbyi-20141113monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2014-financial-results-pbyi-20141110monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-positive-initial-results-from-pb272-phase-ii-trial-in-her2-mu-pbyi-20140929monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2014-financial-results-pbyi-20140811monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-amendment-to-neratinib-licensing-agreement-with-pfizer-pbyi-20140722monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-presentation-of-positive-pb272-phase-ii-data-at-the-2014-asco-pbyi-20140601monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-expands-cohort-in-phase-ii-trial-of-pb272-neratinib-in-her2-mutation-po-pbyi-20140514monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2014-financial-results-pbyi-20140512monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-presentation-of-positive-pb272-phase-ii-data-from-i-spy-2-tri-pbyi-20140407monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-2013-financial-results-pbyi-20140303monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-positive-outcome-of-european-opposition-proceedings-patent-cl-pbyi-20140206monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-positive-top-line-data-from-i-spy-2-trial-neratinib-graduates-f-pbyi-20131204monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2013-financial-results-pbyi-20131112monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-initiates-phase-ii-trial-of-pb272-neratinib-in-her2-mutation-positive-s-pbyi-20131004monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-second-quarter-2013-financial-results-pbyi-20130806monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-initiates-phase-iii-trial-of-pb272-neratinib-in-her2-positive-metastati-pbyi-20130607monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-first-quarter-2013-financial-results-pbyi-20130509monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-fourth-quarter-and-full-year-2012-financial-results-pbyi-20130401monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-agreement-with-fda-on-special-protocol-assessment-for-phase-i-pbyi-20130220monthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-announces-upsizing-and-pricing-of-120-million-public-offering-of-common-pbyi-20121018monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-x2022-bre-lrmr-20260319monthly0.5https://www.biopharmawatch.com/news/LRMR/pro-march-2026-larimar-therapeutics-corporate-deck-forward-looking-statements-this-present-lrmr-20260309monthly0.5https://www.biopharmawatch.com/news/LRMR/pro-january-2026-larimar-therapeutics-corporate-deck-forward-looking-statements-this-prese-lrmr-20251231monthly0.5https://www.biopharmawatch.com/news/LRMR/pro-november-2025-larimar-therapeutics-corporate-deck-forward-looking-statements-this-pres-lrmr-20251110monthly0.5https://www.biopharmawatch.com/news/LRMR/pro-october-2025-larimar-therapeutics-corporate-deck-forward-looking-statements-this-prese-lrmr-20250930monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-second-quarter-2025-financial-results-x2022-initial-data-from-lrmr-20250814monthly0.5https://www.biopharmawatch.com/news/LRMR/this-presentation-contains-forward-looking-statements-that-are-based-on-the-beliefs-and-as-lrmr-20250623monthly0.5https://www.biopharmawatch.com/news/LRMR/pro-may-2025-larimar-therapeutics-corporate-deck-this-presentation-contains-forward-lookin-lrmr-20250505monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2025-financial-results-x2022-fda-stated-as-part-lrmr-20250430monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-provides-nomlabofusp-development-update-and-reports-fourth-quarter-an-lrmr-20250324monthly0.5https://www.biopharmawatch.com/news/LRMR/pro-january-2025-larimar-therapeutics-corporate-deck-exhibit-99-1-lrmr-20250110monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-positive-initial-data-from-ongoing-long-term-open-label-ext-lrmr-20241216monthly0.5https://www.biopharmawatch.com/news/LRMR/this-presentation-contains-forward-looking-statements-that-are-based-on-the-beliefs-and-as-lrmr-20241118monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-third-quarter-2024-operating-and-financial-results-x2022-noml-lrmr-20241030monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-second-quarter-2024-operating-and-financial-results-x2022-ope-lrmr-20240807monthly0.5https://www.biopharmawatch.com/news/LRMR/this-presentation-contains-forward-looking-statements-that-are-based-on-the-beliefs-and-as-lrmr-20240520monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-selected-by-fda-to-participate-in-start-pilot-program-for-nomlabofusp-lrmr-20240530monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-fda-has-removed-partial-clinical-hold-for-nomlabofusp-progr-lrmr-20240520monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2024-operating-and-financial-results-x2022-firs-lrmr-20240509monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2023-operating-and-financial-res-lrmr-20240314monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-the-dosing-of-the-first-patient-in-long-term-open-label-ext-lrmr-20240311monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-positive-top-line-data-from-phase-2-dose-exploration-study-fr-lrmr-20240212monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-third-quarter-2023-operating-and-financial-results-x2022-comp-lrmr-20231114monthly0.5https://www.biopharmawatch.com/news/LRMR/this-presentation-contains-forward-looking-statements-that-are-based-on-the-beliefs-and-as-lrmr-20230814monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-second-quarter-2023-operating-and-financial-results-x2022-ini-lrmr-20230810monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-receives-fda-clearance-to-proceed-to-50-mg-cohort-in-cti-1601-s-phase-lrmr-20230725monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-appoints-dr-rusty-clayton-as-chief-medical-officer-lrmr-20230717monthly0.5https://www.biopharmawatch.com/news/LRMR/june-2023-larimar-therapeutics-corporate-presentation-forward-looking-statements-this-pres-lrmr-20230601monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-preliminary-top-line-data-from-phase-2-trial-s-25-mg-cohort-s-lrmr-20230515monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2022-operating-and-financial-res-lrmr-20230314monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-appoints-dr-gopi-shankar-as-chief-development-officer-biologics-exper-lrmr-20230207monthly0.5https://www.biopharmawatch.com/news/LRMR/january-2023-larimar-therapeutics-corporate-presentation-forward-looking-statements-this-p-lrmr-20230109monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-third-quarter-2022-operating-and-financial-results-first-coho-lrmr-20221110monthly0.5https://www.biopharmawatch.com/news/LRMR/october-2022-larimar-therapeutics-corporate-presentation-forward-looking-statements-this-p-lrmr-20221020monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-fda-clearance-to-initiate-the-25-mg-cohort-of-a-phase-2-dos-lrmr-20220914monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-provides-updates-on-cti-1601-clinical-program-following-a-type-c-meet-lrmr-20220811monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2022-operating-and-financial-results-cti-1601-t-lrmr-20220512monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2021-operating-and-financial-res-lrmr-20220325monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-corporate-presentation-february-2022-1-forward-looking-statements-thi-lrmr-20220228monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-provides-update-on-cti-1601-clinical-program-bala-cynwyd-pa-lrmr-20220214monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-third-quarter-2021-operating-and-financial-results-bala-cynwy-lrmr-20211112monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-second-quarter-2021-operating-and-financial-results-reported--lrmr-20210812monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-corporate-presentation-july-2021-1-forward-looking-statements-this-pr-lrmr-20210701monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-corporate-presentation-june-2021-1-forward-looking-statements-this-pr-lrmr-20210614monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-fda-clinical-hold-on-cti-1601-and-termination-of-recently-ann-lrmr-20210525monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-receives-european-medicines-agency-priority-medicines-prime-designati-lrmr-20210520monthly0.5https://www.biopharmawatch.com/news/LRMR/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-are--lrmr-20210518monthly0.5https://www.biopharmawatch.com/news/LRMR/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-are--lrmr-20210511monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2021-operating-and-financial-results-topline-da-lrmr-20210511monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2020-operating-and-financial-res-lrmr-20210304monthly0.5https://www.biopharmawatch.com/news/LRMR/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-are--lrmr-20201208monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-third-quarter-2020-operating-and-financial-results-phase-1-tr-lrmr-20201110monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-second-quarter-2020-operating-and-financial-results-merger-be-lrmr-20200811monthly0.5https://www.biopharmawatch.com/news/LRMR/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-are--lrmr-20200806monthly0.5https://www.biopharmawatch.com/news/LRMR/of-larimar-s-amendment-no-1-to-the-current-report-on-form-8-k-filed-on-lrmr-20200626monthly0.5https://www.biopharmawatch.com/news/LRMR/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-are--lrmr-20200603monthly0.5https://www.biopharmawatch.com/news/LRMR/chondrial-therapeutics-and-zafgen-complete-merger-and-begin-operating-as-larimar-therapeut-lrmr-20200529monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-fourth-quarter-and-full-year-2019-financial-results-zafgen-and-chondrial-th-lrmr-20200305monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-and-chondrial-therapeutics-planned-definitive-merger-february-2020-forward-looking--lrmr-20200205monthly0.5https://www.biopharmawatch.com/news/LRMR/forward-looking-statements-additional-information-about-the-proposed-merger-and-where-to-f-lrmr-20200113monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-and-chondrial-therapeutics-announce-definitive-merger-agreement-creates-clinical-st-lrmr-20191218monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-third-quarter-2019-financial-results-evaluation-of-strategic-alternatives-o-lrmr-20191106monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-second-quarter-2019-operating-and-financial-results-agreement-reached-with--lrmr-20190808monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-regulatory-update-on-zgn-1061-received-fda-type-a-meeting-minutes-related-lrmr-20190530monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-first-quarter-2019-operating-and-financial-results-recently-announced-posit-lrmr-20190509monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-boston-lrmr-20190404monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-fourth-quarter-and-full-year-2018-operating-and-financial-results-and-provi-lrmr-20190311monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-positive-results-for-second-cohort-of-phase-2-clinical-trial-of-zgn-1061--lrmr-20190117monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-provides-update-on-investigational-new-drug-application-for-zgn-1061-boston-mass-lrmr-20181126monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-third-quarter-2018-operating-and-financial-results-zgn-1061-1-8-mg-cohort-f-lrmr-20181107monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-second-quarter-2018-operating-and-financial-results-phase-1-clinical-trial--lrmr-20180807monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-departure-of-president-and-chief-scientific-officer-dr-thomas-hughes-lrmr-20180802monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-proposed-offering-of-common-stock-lrmr-20180627monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-positive-full-results-in-phase-2-proof-of-concept-trial-of-zgn-1061-in-pa-lrmr-20180625monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-inc-appoints-industry-veteran-and-healthcare-policy-expert-dr-wendy-everett-to-its--lrmr-20180607monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-inc-expands-executive-leadership-team-with-appointment-of-brian-mcveigh-as-chief-bu-lrmr-20180530monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-first-quarter-2018-operating-and-financial-results-multiple-zgn-1061-abstra-lrmr-20180508monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-fourth-quarter-and-full-year-2017-financial-results-announces-positive-inte-lrmr-20180306monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-strong-clinical-progress-and-updates-outlook-for-2018-zgn-1061-phase-2-tria-lrmr-20180105monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-third-quarter-2017-financial-results-initiated-phase-2-clinical-trial-for-s-lrmr-20171107monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-appoints-jeffrey-hatfield-as-chief-executive-officer-thomas-hughes-ph-d-to-continue-lrmr-20171010monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-second-quarter-2017-financial-results-zgn-1061-phase-1-data-support-continu-lrmr-20170808monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-first-quarter-2017-financial-results-zgn-1061-phase-1-data-support-continue-lrmr-20170509monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-positive-topline-phase-1-data-for-zgn-1061-a-second-generation-metap2-inh-lrmr-20170504monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-fourth-quarter-and-full-year-2016-financial-results-on-track-to-complete-do-lrmr-20170309monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-third-quarter-2016-financial-results-advancing-phase-1-clinical-trial-of-zg-lrmr-20161109monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-second-quarter-2016-financial-results-boston-lrmr-20160804monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-refocuses-resources-on-development-of-differentiated-second-generation-metap2-inhib-lrmr-20160719monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-first-quarter-2016-financial-results-conference-call-scheduled-for-4-30-pm--lrmr-20160510monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-reports-fourth-quarter-and-full-year-2015-financial-results-conference-call-schedul-lrmr-20160309monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-adds-thomas-o-daniel-m-d-to-its-board-of-directors-boston-lrmr-20160308monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-s-phase-2b-trial-of-beloranib-in-severe-obesity-complicated-by-type-2-diabetes-achi-lrmr-20160218monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-s-pivotal-phase-3-trial-of-beloranib-in-prader-willi-syndrome-achieves-co-primary-e-lrmr-20160120monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-beloranib-ind-placed-on-complete-clinical-hold-boston-lrmr-20151202monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-provides-clinical-update-on-beloranib-boston-lrmr-20151202monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-third-quarter-2015-financial-results-company-to-host-conference-call-at-4-lrmr-20151110monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-beloranib-program-update-company-elects-to-proceed-with-data-analysis-for-lrmr-20151022monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-partial-clinical-hold-affecting-beloranib-trials-investor-conference-call-lrmr-20151016monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-announces-transition-of-board-of-directors-adds-significant-industry-leadership-exp-lrmr-20150928monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-inc-patricia-allen-chief-financial-officer-617-648-9792-fti-consulting-kimberly-ha--lrmr-20150811monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-inc-patricia-allen-chief-financial-officer-617-648-9792-fti-consulting-kimberly-ha--lrmr-20150512monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-inc-patricia-allen-chief-financial-officer-617-648-9792-fti-consulting-kimberly-ha--lrmr-20150319monthly0.5https://www.biopharmawatch.com/news/LRMR/media-investor-relations-contact-shauna-elkin-212-850-5613-shauna-elkin-fticonsulting-com--lrmr-20150107monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-inc-patricia-allen-chief-financial-officer-617-648-9792-fti-consulting-brian-ritchi-lrmr-20141111monthly0.5https://www.biopharmawatch.com/news/LRMR/zafgen-inc-patricia-allen-chief-financial-officer-617-648-9792-brian-ritchie-212-850-5683--lrmr-20140813monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20260507monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-reconciliation-of-reported-net-income-loss-gaap-to-adjusted-ebitda-non-dcth-20260226monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-preliminary-fourth-quarter-and-full-year-2025-financial-results--dcth-20260109monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20251104monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-preliminary-third-quarter-2025-financial-results-dcth-20251018monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20250806monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-issues-full-year-2025-guidance-2025-full-year-total-revenue-guidance-of-94-dcth-20250522monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20250508monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20250306monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results--dcth-20250113monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-additional-16-3-million-in-funding-from-series-e-and-e1-warrant--dcth-20241230monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20241108monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-preliminary-third-quarter-2024-revenue-results-10-million-quarte-dcth-20241017monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-positive-results-from-independent-study-on-liver-directed-th-dcth-20240828monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-promising-results-from-independent-study-on-repeated-hepatic-dcth-20240826monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20240805monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-appointment-of-bridget-martell-ma-md-to-delcath-s-board-of-direc-dcth-20240528monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20240514monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-consolidated-statements-of-operations-and-comprehensive-loss-unaudited-dcth-20240326monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-7-million-private-placement-dcth-20240315monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-appoints-martha-s-rook-as-chief-operating-officer-delcath-systems-inc-nasd-dcth-20240318monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-receives-permanent-j-code-j9248-for-hepzato-melphalan-hepatic-delivery-sys-dcth-20240131monthly0.5https://www.biopharmawatch.com/news/DCTH/corporate-presentation-nasdaq-dcth-january-2024-table-of-contents-forward-looking-statemen-dcth-20240108monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20231113monthly0.5https://www.biopharmawatch.com/news/DCTH/the-private-securities-litigation-reform-act-of-1995-provides-a-safe-harbor-for-forward-lo-dcth-20230906monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-fda-approval-of-hepzato-kit-for-the-treatment-of-adult-patie-dcth-20230815monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss-dcth-20230809monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dcth-20230621monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-sandra-pennell-as-senior-vice-president-of-finance-dcth-20230607monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-provides-business-update-and-reports-preliminary-first-quarter-2023-financ-dcth-20230512monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-up-to-85-million-financing-led-by-vivo-capital-with-participatio-dcth-20230327monthly0.5https://www.biopharmawatch.com/news/DCTH/corporate-presentation-nasdaq-dcth-dcth-20230326monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-new-drug-application-resubmission-for-hepzato-kit-dcth-20230214monthly0.5https://www.biopharmawatch.com/news/DCTH/the-private-securities-litigation-reform-act-of-1995-provides-a-safe-harbor-for-forward-lo-dcth-20230103monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-private-placement-of-6-2-million-dcth-20221208monthly0.5https://www.biopharmawatch.com/news/DCTH/corporate-presentation-nasdaq-dcth-september-2022-forward-looking-statements-the-private-s-dcth-20220912monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-closes-private-placement-of-5-0-million-dcth-20220720monthly0.5https://www.biopharmawatch.com/news/DCTH/corporate-presentation-nasdaq-dcth-june-2022-forward-looking-statements-the-private-securi-dcth-20220531monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-reports-first-quarter-2022-results-and-provides-business-update-new-york-d-dcth-20220511monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-reports-fourth-quarter-and-full-year-2021-results-and-provides-business-up-dcth-20220329monthly0.5https://www.biopharmawatch.com/news/DCTH/the-private-securities-litigation-reform-act-of-1995-provides-a-safe-harbor-for-forward-lo-dcth-20211202monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-third-quarter-2021-results-dcth-20211109monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-second-quarter-2021-results-dcth-20210810monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-first-quarter-2021-results-new-york-globe-newswire-delcath-s-dcth-20210512monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-fourth-quarter-2020-results-highlights-preliminary-positive--dcth-20210331monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-pricing-of-public-offering-of-common-stock-new-york-dcth-20201209monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-proposed-public-offering-of-common-stock-new-york-dcth-20201208monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-strengthens-executive-team-with-appointment-of-gerard-michel-as-chief-executive-of-dcth-20201001monthly0.5https://www.biopharmawatch.com/news/DCTH/limited-waiver-this-limited-waiver-dated-dcth-20200818monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-second-quarter-2020-results-dcth-20200813monthly0.5https://www.biopharmawatch.com/news/DCTH/system-for-delivery-and-filtration-of-melphalan-or-other-chemotherapeutic-agents-for-vario-dcth-20200219monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-1-for-700-reverse-stock-split-to-be-effective-on-dcth-20191224monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-ratio-for-reverse-stock-split-dcth-20191018monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-closes-9-5-million-private-placement-bringing-total-financial-amount-raise-dcth-20190819monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-9-5-million-private-placement-dcth-20190815monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-enhances-board-of-directors-with-appointment-of-commercial-leader-john-r-sylvester-dcth-20190729monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-closes-20-million-private-placement-dcth-20190717monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-20-million-private-placement-dcth-20190711monthly0.5https://www.biopharmawatch.com/news/DCTH/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-dcth-20190211monthly0.5https://www.biopharmawatch.com/news/DCTH/consolidated-financial-statements-report-of-grant-thornton-llp-independent-registered-publ-dcth-20181024monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-raises-8-1-million-from-shareholders-in-rights-offering-new-york-ny-dcth-20180927monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-delcath-investor-presentation-otcqb-dcth-march-2018-forward-looking-st-dcth-20180313monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-exit-from-convertible-note-new-york-dcth-20171229monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-enhances-board-of-directors-with-appointment-of-industry-veteran-dr-simon-pedder-d-dcth-20171120monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-agreement-for-extinguishment-of-convertible-notes-with-majority-holder-a-dcth-20170828monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-second-quarter-2017-financial-results-company-comments-on-consent-propos-dcth-20170808monthly0.5https://www.biopharmawatch.com/news/DCTH/shareholder-voting-instructions-as-set-forth-in-the-definitive-schedule-14a-filed-with-the-dcth-20170726monthly0.5https://www.biopharmawatch.com/news/DCTH/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-dcth-20170605monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-issues-letter-to-stockholders-new-york-dcth-20170427monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-this-presentation-contains-forward-looking--dcth-20170309monthly0.5https://www.biopharmawatch.com/news/DCTH/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-dcth-20170215monthly0.5https://www.biopharmawatch.com/news/DCTH/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-dcth-20170130monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-issues-letter-to-stockholders-new-york-dcth-20161018monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-prices-underwritten-public-offering-of-common-stock-and-warrants-dcth-20160930monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-issues-35-million-in-senior-convertible-notes-to-support-melphalan-hds-clinical-de-dcth-20160606monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-2015-fourth-quarter-and-full-year-financial-results-quarterly-and-yearly-dcth-20160321monthly0.5https://www.biopharmawatch.com/news/DCTH/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-dcth-20160122monthly0.5https://www.biopharmawatch.com/news/DCTH/first-amendment-to-the-series-b-warrant-of-delcath-systems-inc-this-first-amendment-to-the-dcth-20151125monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-this-presentation-contains-forward-looking--dcth-20151009monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-appoints-ceo-jennifer-simpson-to-board-of-directors-new-york-dcth-20151006monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-this-presentation-contains-forward-looking--dcth-20150903monthly0.5https://www.biopharmawatch.com/news/DCTH/united-states-district-court-southern-district-of-new-york-in-re-delcath-systems-inc-13-ci-dcth-20150831monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-this-presentation-contains-forward-looking--dcth-20150610monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-names-dr-jennifer-simpson-president-and-ceo-new-york-may-26-2015-delcath-systems-i-dcth-20150526monthly0.5https://www.biopharmawatch.com/news/DCTH/investor-presentation-nasdaq-dcth-april-2015-forward-looking-statements-this-presentation--dcth-20150414monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-2014-fourth-quarter-and-full-year-financial-results-new-york-dcth-20150310monthly0.5https://www.biopharmawatch.com/news/DCTH/investor-presentation-nasdaq-dcth-march-2015-2-delcath-systems-inc-forward-looking-stateme-dcth-20150310monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-prices-2-8-million-public-offering-of-common-stock-and-warrants-dcth-20150211monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-this-presentation-contains-forward-looking--dcth-20150202monthly0.5https://www.biopharmawatch.com/news/DCTH/investor-presentation-nasdaq-dcth-january-2015-2-delcath-systems-inc-forward-looking-state-dcth-20150112monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-strengthens-board-of-directors-with-new-appointments-industry-veterans-add-clinica-dcth-20141215monthly0.5https://www.biopharmawatch.com/news/DCTH/investor-presentation-nasdaq-dcth-november-2014-2-delcath-systems-inc-forward-looking-stat-dcth-20141118monthly0.5https://www.biopharmawatch.com/news/DCTH/thomson-reuters-streetevents-edited-transcript-dcth-q3-2014-delcath-systems-inc-earnings-c-dcth-20141031monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-2014-third-quarter-results-conference-call-and-webcast-today-at-4-30-p-m-e-dcth-20141105monthly0.5https://www.biopharmawatch.com/news/DCTH/jennifer-simpson-ph-d-appointed-interim-president-and-interim-ceo-of-delcath-systems-roger-dcth-20140915monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-2014-second-quarter-results-conference-call-and-webcast-today-at-4-30-p-m--dcth-20140806monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-2014-first-quarter-results-conference-call-and-webcast-today-at-4-30-p-m-e-dcth-20140507monthly0.5https://www.biopharmawatch.com/news/DCTH/thomson-reuters-streetevents-edited-transcript-dcth-q4-2013-delcath-systems-inc-earnings-c-dcth-20140317monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-2013-fourth-quarter-and-full-year-results-conference-call-and-webcast-toda-dcth-20140312monthly0.5https://www.biopharmawatch.com/news/DCTH/investor-presentation-ex99-1-htm-investor-presentation-nasdaq-dcth-january-2014-2-delcath--dcth-20131231monthly0.5https://www.biopharmawatch.com/news/DCTH/executive-security-agreement-parties-delcath-systems-inc-company-810-seventh-avenue-35-th--dcth-20131220monthly0.5https://www.biopharmawatch.com/news/DCTH/conference-call-transcript-ex99-1-htm-thomson-reuters-streetevents-edited-transcript-dcth--dcth-20131112monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-2013-third-quarter-results-conference-call-and-webcast-today-at-4-30-p-m-e-dcth-20131106monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-to-raise-approximately-7-5-million-new-york-ny-dcth-20131023monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-strategic-reorganzation-company-implements-plan-to-reduce-operat-dcth-20131004monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-board-of-directors-implements-leadership-transition-plan-jennifer-simpson--dcth-20130913monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-receives-complete-response-letter-from-fda-for-melblez-tm-kit-new-drug-application-dcth-20130912monthly0.5https://www.biopharmawatch.com/news/DCTH/investor-presentation-nasdaq-dcth-august-2013-2-delcath-systems-inc-forward-looking-statem-dcth-20130814monthly0.5https://www.biopharmawatch.com/news/DCTH/conference-call-transcript-ex99-1-htm-thomson-reuters-streetevents-edited-transcript-dcth--dcth-20130812monthly0.5https://www.biopharmawatch.com/news/DCTH/of-delcath-systems-inc-dated-august-6-2013-ex99-1-htm-delcath-reports-2013-second-quarter--dcth-20130806monthly0.5https://www.biopharmawatch.com/news/DCTH/william-m-appling-named-executive-vice-president-of-delcath-systems-company-continues-to-i-dcth-20130626monthly0.5https://www.biopharmawatch.com/news/DCTH/annual-shareholder-meeting-nasdaq-dcth-dcth-20130516monthly0.5https://www.biopharmawatch.com/news/DCTH/may-08-2013-08-30pm-gmt-dcth-q1-2013-delcath-systems-inc-earnings-conference-call-corporat-dcth-20130502monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-2013-first-quarter-results-conference-call-and-webcast-today-at-4-30-p-m-e-dcth-20130509monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-provides-update-on-fda-advisory-committee-meeting-on-melblez-tm-kit-queensbury-ny-dcth-20130502monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-private-securities-litigation-reform-act-of-dcth-20130430monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-expands-program-to-increase-efficiencies-and-reduce-cash-utilization-jennifer-simp-dcth-20130408monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-receives-notification-of-pdufa-date-extension-new-pdufa-goal-date-is-dcth-20130408monthly0.5https://www.biopharmawatch.com/news/DCTH/thomson-reuters-streetevents-edited-transcript-dcth-q4-2012-delcath-systems-inc-earnings-c-dcth-20130319monthly0.5https://www.biopharmawatch.com/news/DCTH/investor-presentation-nasdaq-dcth-march-2013-2-delcath-systems-inc-forward-looking-stateme-dcth-20130314monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-fourth-quarter-and-full-year-2012-results-conference-call-and-webcast-toda-dcth-20130314monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-private-securities-litigation-reform-act-of-dcth-20130304monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-private-securities-litigation-reform-act-of-dcth-20130212monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-private-securities-litigation-reform-act-of-dcth-20130107monthly0.5https://www.biopharmawatch.com/news/DCTH/forward-looking-statements-2-delcath-systems-inc-private-securities-litigation-reform-act--dcth-20121214monthly0.5https://www.biopharmawatch.com/news/DCTH/thomson-reuters-streetevents-edited-transcript-dcth-delcath-corporate-update-webinar-event-dcth-20121210monthly0.5https://www.biopharmawatch.com/news/DCTH/for-release-at-4-20pm-et-12-5-12-delcath-provides-update-on-nda-submission-for-its-chemosa-dcth-20121205monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-secures-a-35-million-committed-equity-financing-facility-with-terrapin-opportunity-dcth-20121205monthly0.5https://www.biopharmawatch.com/news/DCTH/thomson-reuters-streetevents-www-streetevents-com-contact-us-2012-thomson-reuters-all-righ-dcth-20121113monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-private-securities-litigation-reform-act-of-dcth-20121109monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-third-quarter-2012-financial-results-and-recent-operational-progress-confe-dcth-20121107monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-june-15-2013-dcth-20121101monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-this-presentation-contains-forward-looking--dcth-20120814monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-second-quarter-2012-dcth-20120807monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-second-quarter-2012-financial-results-and-highlights-recent-accomplishment-dcth-20120807monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announced-changes-to-board-of-directors-pharma-industry-veterans-laura-a-brege-and-dcth-20120709monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-exercise-of-underwriters-over-allotment-option-and-closing-of-23-million-dcth-20120531monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-this-presentation-contains-forward-looking--dcth-20120514monthly0.5https://www.biopharmawatch.com/news/DCTH/final-transcript-dcth-q1-2012-delcath-systems-inc-earnings-conference-call-may-08-2012-4-3-dcth-20120511monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-highlights-first-quarter-2012-and-recent-accomplishments-conference-call-and-webca-dcth-20120508monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-expands-global-marketing-team-with-key-pharma-oncology-hire-jennifer-simpson-appoi-dcth-20120326monthly0.5https://www.biopharmawatch.com/news/DCTH/thomson-reuters-streetevents-edited-transcript-dcth-q4-2011-delcath-systems-inc-earnings-c-dcth-20120314monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-highlights-fiscal-2011-fourth-quarter-and-full-year-results-and-recent-development-dcth-20120309monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-forward-looking-statements-this-presentation-contains-forward-looking--dcth-20120131monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-first-european-chemosat-procedures-procedures-conducted-at-european-inst-dcth-20120202monthly0.5https://www.biopharmawatch.com/news/DCTH/investor-presentation-nasdaq-dcth-november-2011-2-delcath-systems-inc-forward-looking-stat-dcth-20111118monthly0.5https://www.biopharmawatch.com/news/DCTH/final-transcript-1-final-transcript-dcth-20111107monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-fiscal-2011-third-quarter-results-and-recent-developments-quarterly-inve-dcth-20111107monthly0.5https://www.biopharmawatch.com/news/DCTH/fda-schedules-delcath-pre-new-dcth-20111026monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-updated-efficacy-results-from-phase-3-trial-of-chemosaturation-for-melan-dcth-20110923monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-expands-senior-management-team-graham-g-miao-appointed-chief-financial-officer-dav-dcth-20110926monthly0.5https://www.biopharmawatch.com/news/DCTH/positive-phase-2-trial-results-from-neuroendocrine-tumor-cohort-presented-at-cirse-chemosa-dcth-20110912monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-top-line-results-from-metastatic-colorectal-cohort-in-phase-ii-trial-of--dcth-20110901monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-first-quarter-2026-results-company-continues-to-mak-usna-20260505monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-fourth-quarter-and-full-year-2025-results-and-provi-usna-20260217monthly0.5https://www.biopharmawatch.com/news/USNA/document-kevin-guest-returns-to-usana-health-sciences-as-usna-20260108monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-third-quarter-2025-results-and-updates-full-year-ou-usna-20251022monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-provides-preliminary-third-quarter-results-usna-20251009monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-second-quarter-2025-results-and-reiterates-full-yea-usna-20250722monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-first-quarter-2025-results-and-reiterates-full-year-usna-20250422monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-fourth-quarter-and-full-year-2024-results-and-provi-usna-20250225monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-announces-strategic-acquisition-of-hiya-health-hiya-is-a-fa-usna-20241223monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-third-quarter-2024-results-usna-20241022monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-second-quarter-2024-results-usna-20240723monthly0.5https://www.biopharmawatch.com/news/USNA/document-usana-health-sciences-reports-first-quarter-2024-results-usna-20240430monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-fourth-quarter-and-fiscal-year-2023-results-salt-lake-city-b-usna-20240206monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-third-quarter-2023-results-salt-lake-city-business-wire-usna-20231024monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-second-quarter-net-sales-of-238-million-and-diluted-eps-of-0-usna-20230725monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-announces-plans-to-expand-into-india-salt-lake-city-business-wire-usna-20230504monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-first-quarter-net-sales-of-248-million-and-diluted-eps-of-0--usna-20230425monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-announces-ceo-transition-plan-salt-lake-city-business-wire-usna-20230213monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-fourth-quarter-and-fiscal-year-2022-results-salt-lake-city-b-usna-20230207monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-provides-preliminary-fiscal-year-2022-results-and-issues-initial-fis-usna-20230105monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-third-quarter-results-salt-lake-city-business-wire-usna-20221025monthly0.5https://www.biopharmawatch.com/news/USNA/j-scott-nixon-cpa-rejoins-usana-health-sciences-board-of-directors-salt-lake-city-business-usna-20220727monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-second-quarter-results-salt-lake-city-business-wire-usna-20220726monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-provides-preliminary-second-quarter-results-and-updates-fiscal-year--usna-20220706monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-first-quarter-results-salt-lake-city-business-wire-usna-20220426monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-fiscal-year-and-fourth-quarter-2021-results-salt-lake-city-b-usna-20220208monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-third-quarter-results-salt-lake-city-business-wire-usna-20211026monthly0.5https://www.biopharmawatch.com/news/USNA/xia-ding-named-to-usana-health-sciences-board-of-directors-salt-lake-city-business-wire-usna-20211012monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-provides-preliminary-third-quarter-results-and-updates-fiscal-year-2-usna-20210916monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-record-second-quarter-results-and-reiterates-growth-outlook--usna-20210727monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-first-quarter-results-salt-lake-city-business-wire-usna-20210427monthly0.5https://www.biopharmawatch.com/news/USNA/usana-announces-formation-of-board-sustainability-committee-salt-lake-city-business-wire-usna-20210216monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-finishes-strong-2020-with-14-5-fourth-quarter-net-sales-growth-and-3-usna-20210209monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-strong-third-quarter-growth-raises-full-year-2020-net-sales--usna-20201020monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-announces-appointment-of-john-t-fleming-to-board-of-directors-salt-l-usna-20200908monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-second-quarter-results-salt-lake-city-business-wire-usna-20200721monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-first-quarter-results-salt-lake-city-business-wire-usna-20200421monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-announces-increased-share-repurchase-authorization-to-130-million-sa-usna-20200205monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-fourth-quarter-and-full-year-2019-results-fourth-quarter-net-usna-20200204monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-announces-retirement-of-founder-and-chairman-myron-w-wentz-ph-d-from-usna-20191218monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-announces-appointment-of-timothy-wood-ph-d-to-board-of-directors-and-usna-20191024monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-third-quarter-2019-results-third-quarter-net-sales-of-260-6--usna-20191022monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-second-quarter-2019-results-second-quarter-net-sales-of-256--usna-20190702monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-provides-preliminary-second-quarter-results-and-updates-fiscal-year--usna-20190702monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-first-quarter-2019-results-results-in-line-with-preliminary--usna-20190430monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-provides-preliminary-first-quarter-net-sales-and-updates-fiscal-year-usna-20190402monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-record-full-year-2018-results-record-fiscal-year-net-sales-o-usna-20190205monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-announces-appointment-of-peggie-pelosi-to-board-of-directors-salt-la-usna-20181219monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-results-for-third-quarter-2018-updates-2018-outlook-board-in-usna-20181023monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-record-results-for-second-quarter-2018-increases-2018-outloo-usna-20180724monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-record-first-quarter-2018-net-sales-and-increases-2018-outlo-usna-20180424monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-record-fourth-quarter-and-full-year-2017-net-sales-record-fi-usna-20180206monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-provides-estimated-impact-of-u-s-tax-reform-salt-lake-city-business--usna-20180108monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-reports-third-quarter-financial-results-record-third-quarter-net-sal-usna-20171024monthly0.5https://www.biopharmawatch.com/news/USNA/usana-health-sciences-announces-appointment-of-j-scott-nixon-to-board-of-directors-salt-la-usna-20171005monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-receipt-of-fda-decision-letter-on-hetlioz-supplemental-new-vnda-20260108monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-fda-approval-of-nereus-tradipitant-for-the-prevention-of-v-vnda-20251230monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2025-financial-results-fanapt-q2-2025-net-pro-vnda-20250731monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2025-financial-results-fanapt-q1-2025-total-pr-vnda-20250507monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-q4-2024--vnda-20250213monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2024-financial-results-revenues-for-q3-2024-we-vnda-20241106monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-confirms-receipt-of-economically-identical-unsolicited-non-binding-p-vnda-20241014monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-declines-to-approve-vanda-s-marketing-application-for-tradipitant-in-gastroparesis-was-vnda-20240919monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2024-financial-results-revenues-for-q2-2024-w-vnda-20240731monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-board-of-directors-determines-that-recent-unsolicited-takeover-propo-vnda-20240619monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-confirms-receipt-of-revised-unsolicited-takeover-proposal-from-futur-vnda-20240613monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-confirms-receipt-of-unsolicited-non-binding-indication-of-interest-f-vnda-20240606monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-board-of-directors-determines-that-revised-unsolicited-takeover-prop-vnda-20240524monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2024-financial-results-revenues-for-q1-2024-we-vnda-20240508monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-confirms-receipt-of-revised-unsolicited-takeover-proposal-from-futur-vnda-20240507monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-adopts-limited-duration-stockholder-rights-plan-washington-vnda-20240417monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fanapt-iloperidone-receives-u-s-fda-approval-for-the-acute-treatment-vnda-20240402monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-fda-update-for-supplemental-nda-for-hetlioz-in-the-treatme-vnda-20240306monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-full-yea-vnda-20240207monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-fda-update-for-supplemental-nda-for-hetlioz-in-the-treatme-vnda-20240205monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-acquires-u-s-and-canadian-rights-to-ponvory-ponesimod-a-selective-s1-vnda-20231207monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2023-financial-results-total-revenues-in-the-f-vnda-20231108monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2023-financial-results-q2-2023-total-revenues-vnda-20230727monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-responds-to-ruling-in-hetlioz-anda-appeal-washington-vnda-20230510monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2023-financial-results-q1-2023-total-revenues--vnda-20230503monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-dr-tage-honor-to-its-board-of-directors-washington-vnda-20230317monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-q4-2022--vnda-20230208monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-provides-an-update-to-hetlioz-anda-litigation-appeal-federal-circuit-vnda-20221216monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-responds-to-ruling-in-hetlioz-anda-litigation-washington-vnda-20221213monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2022-financial-results-q3-2022-total-revenues--vnda-20221102monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2022-financial-results-q2-2022-total-revenues-vnda-20220803monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2022-financial-results-washington-vnda-20220505monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-full-yea-vnda-20220223monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-results-from-the-phase-iii-study-of-tradipitant-in-gastropar-vnda-20220204monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-settles-hetlioz-patent-litigation-with-vnda-20220114monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2021-financial-results-q3-2021-total-revenues--vnda-20211103monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2021-financial-results-q2-2021-total-revenues-vnda-20210728monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2021-financial-results-q1-2021-total-revenues--vnda-20210505monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-q4-2020--vnda-20210210monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-approves-hetlioz-tasimelteon-for-the-treatment-of-nighttime-sleep-disturbances-in-smit-vnda-20201201monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2020-financial-results-q3-2020-total-net-produ-vnda-20201028monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-interim-analysis-from-odyssey-study-shows-tradipitant-may-accelerate-vnda-20200818monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2020-financial-results-q2-2020-total-net-prod-vnda-20200805monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-agreement-with-fda-on-resubmission-of-the-application-for--vnda-20200513monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2020-financial-results-q1-2020-total-net-produ-vnda-20200506monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-reports-results-from-the-epione-study-of-tradipitant-in-the-treatment-of-pruritus-in-vnda-20200225monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-full-yea-vnda-20200225monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-stephen-ray-mitchell-to-board-of-directors-washington-vnda-20200219monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-comments-on-court-ruling-washington-vnda-20200131monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-wins-key-u-s-supreme-court-patent-ruling-on-fanapt-washington-vnda-20200113monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2019-financial-results-q3-2019-total-net-produ-vnda-20191106monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-anne-sempowski-ward-to-board-of-directors-washington-vnda-20191028monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fda-update-for-hetlioz-in-the-treatment-of-jet-lag-disorder-washingt-vnda-20190819monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2019-financial-results-q2-2019-total-net-prod-vnda-20190731monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fda-update-for-hetlioz-in-the-treatment-of-jet-lag-disorder-washingt-vnda-20190722monthly0.5https://www.biopharmawatch.com/news/VNDA/tradipitant-effective-in-preventing-motion-sickness-washington-vnda-20190716monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2019-financial-results-total-net-product-sales-vnda-20190501monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-phaedra-chrousos-to-board-of-directors-washington-vnda-20190424monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-2018-and-full-year-2018-financial-results-ful-vnda-20190213monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-takes-a-stand-against-unnecessary-animal-research-company-pursuing-l-vnda-20190205monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-positive-pivotal-study-results-for-hetlioz-tasimelteon-in-patients-with-sm-vnda-20181210monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-positive-phase-ii-study-results-for-tradipitant-in-patients-with-gastropar-vnda-20181203monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2018-financial-results-hetlioz-net-product-sal-vnda-20181107monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-wins-denial-of-petition-for-rehearing-on-fanapt-u-s-court-of-appeals-denies-petition-vnda-20180814monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2018-financial-results-total-net-product-sale-vnda-20180801monthly0.5https://www.biopharmawatch.com/news/VNDA/hetlioz-tasimelteon-effective-in-treating-jet-lag-during-transatlantic-travel-hetlioz-demo-vnda-20180523monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2018-financial-results-total-net-product-sales-vnda-20180502monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-wins-appeal-case-on-fanapt-u-s-court-of-appeals-affirms-district-court-s-decision-wa-vnda-20180413monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-prices-public-offering-of-common-stock-washington-vnda-20180315monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-proposes-public-offering-of-common-stock-washington-vnda-20180314monthly0.5https://www.biopharmawatch.com/news/VNDA/hetlioz-tasimelteon-demonstrates-efficacy-to-treat-jet-lag-disorder-in-an-8-hour-phase-adv-vnda-20180305monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-2017-and-full-year-2017-financial-results-ful-vnda-20180214monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-preliminary-fourth-quarter-and-full-year-2017-revenue-result-vnda-20180107monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2017-financial-results-total-net-product-sales-vnda-20171107monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-s-tradipitant-improves-itch-and-disease-severity-in-patients-with-atopic-dermatitis--vnda-20170913monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2017-financial-results-total-net-product-sale-vnda-20170802monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2017-financial-results-total-net-product-sales-vnda-20170502monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-2016-and-full-year-2016-financial-results-ful-vnda-20170215monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-preliminary-fourth-quarter-and-full-year-2016-revenue-result-vnda-20170109monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-settles-fanapt-patent-litigation-with-apotex-vanda-grants-apotex-a-l-vnda-20161207monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2016-financial-results-total-revenues-grew-to--vnda-20161102monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-settles-fanapt-patent-litigation-with-taro-vanda-grants-taro-a-licen-vnda-20161024monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-patents-found-valid-and-infringed-in-fanapt-anda-litigation-washington-vnda-20160825monthly0.5https://www.biopharmawatch.com/news/VNDA/hetlioz-is-now-available-for-the-treatment-of-non-24-hour-sleep-wake-disorder-in-germany-h-vnda-20160801monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2016-financial-results-hetlioz-net-product-sa-vnda-20160727monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-grants-fanapt-three-years-of-marketing-exclusivity-for-labeling-changes-relating-to-ma-vnda-20160615monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-fda-approval-of-the-fanapt-supplemental-new-drug-application-for-maintenan-vnda-20160526monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2016-financial-results-hetlioz-net-product-sal-vnda-20160504monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-2015-and-full-year-2015-financial-results-het-vnda-20160210monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-preliminary-fourth-quarter-and-full-year-2015-results-and-20-vnda-20160111monthly0.5https://www.biopharmawatch.com/news/VNDA/european-medicines-agency-accepts-fanaptum-iloperidone-marketing-authorization-application-vnda-20151222monthly0.5https://www.biopharmawatch.com/news/VNDA/kenneth-bate-joins-the-board-of-directors-of-vanda-pharmaceuticals-washington-vnda-20151218monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2015-financial-results-vanda-affirms-its-full--vnda-20151103monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-fda-has-accepted-for-review-the-fanapt-supplemental-new-drug-application-f-vnda-20150915monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2015-financial-results-hetlioz-u-s-net-produc-vnda-20150729monthly0.5https://www.biopharmawatch.com/news/VNDA/hetlioz-receives-european-commission-approval-for-the-treatment-of-non-24-hour-sleep-wake--vnda-20150707monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2015-financial-results-hetlioz-net-product-sal-vnda-20150506monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-receives-positive-chmp-opinion-for-hetlioz-tasimelteon-for-the-treatment-of-non-24-h-vnda-20150424monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-tradipitant-phase-ii-proof-of-concept-study-results-for-ch-vnda-20150304monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-2014-and-full-year-2014-financial-results-het-vnda-20150219monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-to-regain-us-and-canadian-rights-to-fanapt-vanda-and-novartis-agree-to-settle-arbitr-vnda-20141222monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-prices-public-offering-of-common-stock-washington-vnda-20141029monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-proposes-public-offering-of-common-stock-washington-vnda-20141028monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2014-financial-results-hetlioz-u-s-sales-grew--vnda-20141027monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2014-results-washington-vnda-20140807monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-2014-corporate-presentation-forward-looking-statements-2-all-wri-vnda-20140604monthly0.5https://www.biopharmawatch.com/news/VNDA/european-medicines-agency-accepts-hetlioz-tm-tasimelteon-marketing-authorization-applicati-vnda-20140603monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2014-results-washington-vnda-20140508monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-availability-of-hetlioz-tasimelteon-for-non-24-hour-sleep--vnda-20140409monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-2013-and-full-year-2013-results-washington-vnda-20140213monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-approves-hetlioz-tm-tasimelteon-for-the-treatment-of-non-24-hour-sleep-wake-disorder-n-vnda-20140131monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-advisory-committee-recommends-approval-of-hetlioz-for-the-treatment-of-non-24-hour-dis-vnda-20131114monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2013-results-washington-vnda-20131107monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-prices-public-offering-of-common-stock-washington-vnda-20130807monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-proposes-public-offering-of-common-stock-washington-vnda-20130806monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2013-results-washington-vnda-20130731monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-accepts-tasimelteon-new-drug-application-for-priority-review-in-the-treatment-of-non-2-vnda-20130729monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2013-results-washington-vnda-20130509monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-reports-successful-completion-of-pre-nda-meeting-with-fda-on-tasimelteon-for-the-tre-vnda-20130325monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-senior-communications-manager-vanda-pharmaceuticals-inc-202-734-3414-crist-vnda-20130212monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-phase-iib-iii-vnda-20130131monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-positive-results-in-the-second-phase-iii-study-reset-of-tasimelteon-for-th-vnda-20130123monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-positive-phase-iii-results-for-tasimelteon-in-the-treatment-of-non-24-hour-vnda-20121218monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-senior-communications-manager-vanda-pharmaceuticals-inc-202-734-3414-crist-vnda-20121107monthly0.5https://www.biopharmawatch.com/news/VNDA/tasimelteon-restores-daily-cortisol-rhythms-in-blind-patients-with-non-24-hour-disorder-wa-vnda-20121015monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-senior-communications-manager-vanda-pharmaceuticals-inc-202-734-3414-crist-vnda-20120802monthly0.5https://www.biopharmawatch.com/news/VNDA/michael-cola-joins-the-board-of-directors-of-vanda-pharmaceuticals-washington-dc-vnda-20120618monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-senior-communications-manager-vanda-pharmaceuticals-inc-202-734-3414-crist-vnda-20120508monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-acquires-rights-to-nk-1-receptor-antagonist-from-eli-lilly-and-compa-vnda-20120416monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-senior-communications-manager-vanda-pharmaceuticals-inc-240-599-4500-crist-vnda-20120214monthly0.5https://www.biopharmawatch.com/news/VNDA/initial-clinical-data-reveal-potential-of-tasimelteon-to-reset-the-body-clock-in-non-24-ho-vnda-20120126monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-senior-communications-manager-vanda-pharmaceuticals-inc-240-599-4500-crist-vnda-20111104monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-2011-corporate-presentation-forward-looking-statement-various-st-vnda-20110908monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-communications-manager-vanda-pharmaceuticals-inc-240-599-4500-cristina-mur-vnda-20110804monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-2011-corporate-presentation-forward-looking-statement-various-st-vnda-20110609monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-communications-manager-vanda-pharmaceuticals-inc-240-599-4500-cristina-mur-vnda-20110505monthly0.5https://www.biopharmawatch.com/news/VNDA/cristina-murphy-communications-manager-vanda-pharmaceuticals-inc-240-599-4500-cristina-mur-vnda-20110210monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-receives-positive-ruling-from-the-irs-rockville-md-vnda-20101115monthly0.5https://www.biopharmawatch.com/news/VNDA/not-for-immediate-release-company-contact-cristina-murphy-communications-manager-vanda-pha-vnda-20101103monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-vnda-20101007monthly0.5https://www.biopharmawatch.com/news/VNDA/not-for-immediate-release-company-contact-cristina-murphy-communications-manager-vanda-pha-vnda-20100805monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-adds-former-u-s-surgeon-general-steven-galson-to-its-board-of-direct-vnda-20100701monthly0.5https://www.biopharmawatch.com/news/VNDA/not-for-immediate-release-company-contact-cristina-murphy-communications-manager-vanda-pha-vnda-20100504monthly0.5https://www.biopharmawatch.com/news/VNDA/vincent-milano-to-join-the-board-of-directors-of-vanda-pharmaceuticals-rockville-md-vnda-20100420monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-date-of-annual-meeting-of-stockholders-rockville-md-march--vnda-20100310monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-cowen-healthcare-conference-vnda-20100309monthly0.5https://www.biopharmawatch.com/news/VNDA/stephanie-r-irish-acting-chief-financial-officer-vanda-pharmaceuticals-inc-240-599-4500-st-vnda-20100216monthly0.5https://www.biopharmawatch.com/news/VNDA/fanapt-launches-in-the-vnda-20100111monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-expiration-of-hart-scott-rodino-waiting-period-for-exclusi-vnda-20091201monthly0.5https://www.biopharmawatch.com/news/VNDA/not-for-immediate-release-company-contact-stephanie-r-irish-acting-chief-financial-officer-vnda-20091102monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-enters-into-an-exclusive-license-agreement-for-the-commercialization-vnda-20091012monthly0.5https://www.biopharmawatch.com/news/VNDA/stephanie-r-irish-acting-chief-financial-officer-vanda-pharmaceuticals-inc-240-599-4500-st-vnda-20090810monthly0.5https://www.biopharmawatch.com/news/VNDA/exv99w1-figure-1-schematic-representation-of-the-molecular-pathway-involved-in-regulation--vnda-20090609monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-date-of-annual-meeting-of-stockholders-rockville-md-may-29-vnda-20090529monthly0.5https://www.biopharmawatch.com/news/YDES/ydes-1-yd-bio-limited-architecting-the-modern-biotechnology-ecosystem-investment-deck-janu-ydes-20260115monthly0.5https://www.biopharmawatch.com/news/YDES/index-to-financial-statements-yd-bio-limited-unaudited-interim-financial-statements-page-c-ydes-20250930monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provi-avir-20260305monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-highlight-2026-strategic-priorities-at-the-44th-annual-j-p-morgan--avir-20260108monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business-u-avir-20250807monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-up-avir-20250514monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-appoints-howard-h-berman-to-board-of-directors-and-announces-share-re-avir-20250417monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-issues-statement-regarding-director-nominations-no-shareholder-action-avir-20250321monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-avir-20250306monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-highlight-2025-strategic-priorities-at-the-43rd-annual-j-p-morgan--avir-20250113monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-up-avir-20241107monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-business-u-avir-20240807monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-business-up-avir-20240514monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-provi-avir-20240228monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-business-up-avir-20231108monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-business-u-avir-20230808monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-business-up-avir-20230508monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-provi-avir-20230228monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-business-up-avir-20221107monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-business-u-avir-20220808monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-business-up-avir-20220510monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-provi-avir-20220228monthly0.5https://www.biopharmawatch.com/news/AVIR/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-avir-20220110monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-provides-clinical-and-corporate-update-and-reports-third-quarter-2021-avir-20211111monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-provides-clinical-and-corporate-update-and-reports-second-quarter-202-avir-20210812monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate-u-avir-20210513monthly0.5https://www.biopharmawatch.com/news/CV/capsovision-announces-510-k-submission-for-the-addition-of-ai-assisted-reading-module-in-c-cv-20251229monthly0.5https://www.biopharmawatch.com/news/CV/capsovision-reports-third-quarter-2025-financial-results-cv-20251113monthly0.5https://www.biopharmawatch.com/news/CV/capsovision-submits-breakthrough-device-designation-application-to-fda-for-pancreatic-canc-cv-20251110monthly0.5https://www.biopharmawatch.com/news/CV/capsovision-appoints-david-garcia-as-senior-vice-president-of-finance-seasoned-finance-exe-cv-20251103monthly0.5https://www.biopharmawatch.com/news/CV/capsovision-reports-second-quarter-2025-financial-results-cv-20250814monthly0.5https://www.biopharmawatch.com/news/CV/capsovision-announces-pricing-of-initial-public-offering-cv-20250701monthly0.5https://www.biopharmawatch.com/news/PRLD/balance-sheets-in-thousands-except-share-data-prld-20260512monthly0.5https://www.biopharmawatch.com/news/PRLD/selective-kat6a-degraders-and-jak2v617f-mutant-selective-inhibitors-new-approaches-to-clin-prld-20260415monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incorporated-balance-sheets-december-31-in-thousands-except-share-and-prld-20260310monthly0.5https://www.biopharmawatch.com/news/PRLD/investor-contact-robert-a-doody-jr-senior-vice-president-investor-relations-prelude-therap-prld-20260203monthly0.5https://www.biopharmawatch.com/news/PRLD/this-presentation-contains-x201c-forward-looking-x201d-statements-within-the-meaning-of-th-prld-20260109monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incorporated-balance-sheets-in-thousands-except-share-data-prld-20251112monthly0.5https://www.biopharmawatch.com/news/PRLD/investor-contact-robert-a-doody-jr-senior-vice-president-investor-relations-prelude-therap-prld-20251017monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incorporated-balance-sheets-in-thousands-except-share-data-prld-20250814monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incorporated-balance-sheets-in-thousands-except-share-data-prld-20250506monthly0.5https://www.biopharmawatch.com/news/PRLD/investor-contact-robert-a-doody-jr-senior-vice-president-investor-relations-prelude-therap-prld-20250425monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incorporated-balance-sheets-december-31-in-thousands-except-share-and-prld-20250310monthly0.5https://www.biopharmawatch.com/news/PRLD/investor-contact-robert-a-doody-jr-senior-vice-president-investor-relations-484-639-7235-r-prld-20241211monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incorporated-balance-sheets-in-thousands-except-share-data-prld-20241106monthly0.5https://www.biopharmawatch.com/news/PRLD/undertakes-no-obligation-to-revise-or-update-any-forward-looking-statements-to-reflect-eve-prld-20241024monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-smarca2-degrader-prt3789-demonstrated-promising-initial-clinical-acti-prld-20240913monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-publication-of-abstract-for-presentation-at-the-european-so-prld-20240909monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incorporated-balance-sheets-in-thousands-except-share-data-prld-20240812monthly0.5https://www.biopharmawatch.com/news/PRLD/corporate-presentation-june-2024-forward-looking-statements-this-presentation-contains-x20-prld-20240612monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incorporated-balance-sheets-unaudited-in-thousands-except-share-data-prld-20240507monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-full-year-2023-financial-results-and-outlines-key-objectives--prld-20240215monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-25-million-private-placement-wilmington-de-prld-20231211monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-announces-strategic-pipeline-progress-and-updates-including-its-partnership-with-a-prld-20231101monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-second-quarter-2023-financial-results-and-provides-corporat-prld-20230803monthly0.5https://www.biopharmawatch.com/news/PRLD/forward-looking-statements-this-presentation-contains-x201c-forward-looking-x201d-statemen-prld-20230601monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-launch-of-proposed-public-offering-wilmington-del-globe-new-prld-20230517monthly0.5https://www.biopharmawatch.com/news/PRLD/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-prld-20230517monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-first-quarter-2023-financial-results-and-operations-update--prld-20230508monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-full-year-2022-financial-results-and-provides-corporate-updat-prld-20230315monthly0.5https://www.biopharmawatch.com/news/PRLD/forward-looking-statements-this-presentation-contains-x201c-forward-looking-x201d-statemen-prld-20230214monthly0.5https://www.biopharmawatch.com/news/PRLD/forward-looking-statements-this-presentation-contains-x201c-forward-looking-x201d-statemen-prld-20230109monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-third-quarter-2022-financial-results-and-provides-business--prld-20221114monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-second-quarter-2022-financial-results-and-business-update-p-prld-20220809monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-first-quarter-2022-financial-results-and-operations-update--prld-20220510monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-full-year-2021-financial-results-significant-progress-achieve-prld-20220316monthly0.5https://www.biopharmawatch.com/news/PRLD/jane-huang-m-d-joins-prelude-therapeutics-as-president-and-chief-medical-officer-wilmingto-prld-20220309monthly0.5https://www.biopharmawatch.com/news/PRLD/precision-oncology-redefined-february-2022-forward-looking-statements-this-presentation-co-prld-20220216monthly0.5https://www.biopharmawatch.com/news/PRLD/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-prld-20220110monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-third-quarter-2021-financial-results-and-operations-update--prld-20211112monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-second-quarter-2021-financial-results-and-operations-update-prld-20210812monthly0.5https://www.biopharmawatch.com/news/PRLD/disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-prld-20210512monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-first-quarter-2021-financial-results-and-operations-update--prld-20210511monthly0.5https://www.biopharmawatch.com/news/PRLD/disclaimer-this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-prld-20210317monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-pro-prld-20210316monthly0.5https://www.biopharmawatch.com/news/PRLD/corporate-january-2021-presentation-disclaimer-this-presentation-contains-forward-looking--prld-20210104monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-third-quarter-2020-financial-results-completed-initial-publ-prld-20201110monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2026-financial-results-canton-mass-orgo-20260507monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-2025-financial-results-posts-record-reve-orgo-20260226monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-2025-financial-results-posts-record-reven-orgo-20251106monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2025-financial-results-canton-mass-orgo-20250807monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2025-financial-results-canton-mass-orgo-20250508monthly0.5https://www.biopharmawatch.com/news/ORGO/investor-presentation-march-2025-forward-looking-statements-other-important-cautions-this--orgo-20250327monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-2024-financial-results-canton-mass-orgo-20250227monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-expands-manufacturing-capacity-to-support-future-growth-orgo-20241122monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-130-million-private-placement-offering-of-series-a-co-orgo-20241112monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-2024-financial-results-canton-mass-orgo-20241112monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2024-financial-results-canton-mass-orgo-20240808monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2024-financial-results-canton-mass-orgo-20240509monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-announces-favorable-court-ruling-dismissing-securities-fraud-case-orgo-20240403monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-2023-and-fiscal-year-2023-financial-resu-orgo-20240229monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-2023-financial-results-canton-mass-orgo-20231109monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2023-financial-results-withdraws-fiscal--orgo-20230809monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2023-financial-results-canton-mass-orgo-20230510monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-2022and-fiscal-year-2022-financial-resul-orgo-20230301monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-2022-financial-results-canton-mass-orgo-20221109monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2022-financial-results-canton-mass-orgo-20220809monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2022-financial-results-canton-mass-orgo-20220510monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-appoints-michele-korfin-and-gilberto-quintero-ph-d-to-board-of-directors-orgo-20220505monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-and-fiscal-year-2021-financial-results-i-orgo-20220301monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-appoints-michael-j-driscoll-ed-d-to-board-of-directors-orgo-20220217monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-appoints-prathyusha-duraibabu-to-board-of-directors-orgo-20211122monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-and-first-nine-months-2021-financial-resu-orgo-20211109monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-and-first-half-2021-financial-results-ca-orgo-20210809monthly0.5https://www.biopharmawatch.com/news/ORGO/correcting-and-replacing-organogenesis-holdings-inc-reports-first-quarter-2021-financial-r-orgo-20210510monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2021-financial-results-canton-mass-orgo-20210510monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-and-fiscal-year-2020-financial-results-i-orgo-20210316monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-appoints-david-c-francisco-as-chief-financial-officer-orgo-20210216monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-preliminary-financial-results-for-fourth-quarter-and-fi-orgo-20210113monthly0.5https://www.biopharmawatch.com/news/ORGO/forward-looking-statements-and-other-important-cautions-industry-and-market-data-unless-th-orgo-20201210monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-and-nine-months-2020-financial-results-ca-orgo-20201109monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-preliminary-financial-results-for-third-quarter-2020-ca-orgo-20201014monthly0.5https://www.biopharmawatch.com/news/ORGO/corporate-presentation-september-2020-1-forward-looking-statements-and-other-important-cau-orgo-20200915monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-management-change-canton-mass-orgo-20200824monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-and-first-half-2020-financial-results-ca-orgo-20200810monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-preliminary-revenue-results-for-second-quarter-2020-can-orgo-20200715monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2020-financial-results-canton-mass-orgo-20200511monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-preliminary-revenue-results-for-first-quarter-2020-with-orgo-20200408monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-and-fiscal-year-2019-financial-results-i-orgo-20200309monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-preliminary-revenue-results-for-the-fourth-quarter-and--orgo-20200113monthly0.5https://www.biopharmawatch.com/news/ORGO/unless-the-context-indicates-otherwise-the-terms-organogenesis-company-we-us-and-our-refer-orgo-20191206monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-proposed-public-offering-of-class-a-common-stock-cant-orgo-20191119monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-and-nine-months-of-2019-financial-results-orgo-20191112monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-announces-completion-of-exchange-offer-and-plan-to-exchange-remaining-outsta-orgo-20190819monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-and-first-half-2019-financial-results-ca-orgo-20190809monthly0.5https://www.biopharmawatch.com/news/ORGO/unless-the-context-indicates-otherwise-the-terms-organogenesis-company-we-us-and-our-refer-orgo-20190522monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2019-financial-results-canton-mass-orgo-20190510monthly0.5https://www.biopharmawatch.com/news/ORGO/unless-the-context-indicates-otherwise-the-terms-organogenesis-company-we-us-and-our-refer-orgo-20190320monthly0.5https://www.biopharmawatch.com/news/ORGO/unless-the-context-indicates-otherwise-the-terms-organogenesis-company-we-us-and-our-refer-orgo-20190212monthly0.5https://www.biopharmawatch.com/news/ORGO/unless-the-context-indicates-otherwise-the-terms-organogenesis-company-we-us-and-our-refer-orgo-20190107monthly0.5https://www.biopharmawatch.com/news/ORGO/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-stoc-orgo-20181211monthly0.5https://www.biopharmawatch.com/news/ORGO/confidential-for-immediate-release-avista-healthcare-public-acquisition-corp-to-combine-wi-orgo-20180817monthly0.5https://www.biopharmawatch.com/news/ORGO/investor-december-presentation-2017-2017-envigo-disclaimer-this-presentation-the-presentat-orgo-20171212monthly0.5https://www.biopharmawatch.com/news/ORGO/confidential-avista-healthcare-public-acquisition-corp-to-combine-with-envigo-internationa-orgo-20170821monthly0.5https://www.biopharmawatch.com/news/ORGO/avista-healthcare-public-acquisition-corp-announces-the-separate-trading-of-its-class-a-or-orgo-20161129monthly0.5https://www.biopharmawatch.com/news/ORGO/avista-healthcare-public-acquisition-corp-report-of-independent-registered-public-accounti-orgo-20161014monthly0.5https://www.biopharmawatch.com/news/ORGO/avista-healthcare-public-acquisition-corp-announces-pricing-of-300-000-000-initial-public--orgo-20161010monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rese-fenc-20260518monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-acceptance-of-abstracts-at-the-2026-asco-annual-meeting-d-fenc-20260421monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-investigator-sponsored-study-to-be-conducted-by-universit-fenc-20260407monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-settlement-agreement-resolving-pedmark-patent-litigation--fenc-20260316monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-investigator-sponsored-trial-to-be-conducted-by-city-of-h-fenc-20251209monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-full-debt-redemption-research-triangle-park-nc-fenc-20251119monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-private-offering-of-common-shares-in-canada-research-tria-fenc-20251113monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-proposed-offering-of-common-shares-research-triangle-park-fenc-20251113monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-pro-fenc-20250310monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-pedmarqsi-ograve-positive-recommendation-by-nice-for-the--fenc-20241220monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-early-partial-repayment-of-its-outstanding-convertible-de-fenc-20241219monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-strengthens-executive-leadership-team-with-three-key-appointments-t-fenc-20241028monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-appoints-jeffrey-s-hackman-as-chief-executive-officer-and-director--fenc-20240805monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-first-quarter-2024-financial-results-on-fenc-20240509monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-full-year-and-fourth-quarter-2023-financial-results-and-pro-fenc-20240321monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement-to-commerciali-fenc-20240318monthly0.5https://www.biopharmawatch.com/news/FENC/pharmaceuticals-reports-preliminary-unaudited-net-revenue-for-fourth-quarter-and-full-year-fenc-20240306monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-preliminary-unaudited-net-revenue-for-fourth-quarter-and-fu-fenc-20240229monthly0.5https://www.biopharmawatch.com/news/FENC/fda-issues-reminder-of-non-substitution-of-pedmark-ograve-sodium-thiosulfate-injection-for-fenc-20240201monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-incremental-5-million-investment-from-petrichor-supports-strategic-discus-fenc-20231205monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-third-quarter-2023-financial-results-and-provides-busines-fenc-20231106monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-second-quarter-2023-financial-results-and-provides-busine-fenc-20230803monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-second-quarter-fenc-20230804monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-european-commission-marketing-authorization-for-pedmarqsi-fenc-20230606monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-receives-positive-chmp-opinion-for-pedmarqsi-sodium-thiosulfate-to--fenc-20230331monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-pedmark-sodium-thiosulfate-injection-receives-orphan-drug-fenc-20230131monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-updated-nccn-clinical-practice-guidelines-recommend-pedma-fenc-20230125monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-commercial-availability-of-pedmark-sodium-thiosulfate-inj-fenc-20221017monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-second-closing-of-20-million-investment-from-petrichor-un-fenc-20220926monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-fda-approval-of-pedmark-sodium-thiosulfate-injection-pedm-fenc-20220921monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-closes-first-5-million-investment-from-petrichor-under-the-terms-of-fenc-20220822monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-up-to-45-million-investment-from-petrichor-under-the-term-fenc-20220801monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-resubmits-new-drug-application-to-u-s-food-and-drug-adminstration-f-fenc-20220324monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-management-change-research-triangle-park-nc-fenc-20220131monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-its-new-drug-app-fenc-20211130monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-expects-to-receive-complete-response-letter-from-the-fda-for-its-ne-fenc-20211129monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-amendment-to-increase-existing-senior-debt-facility-resea-fenc-20210624monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-resubmission-for-p-fenc-20210622monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-resubmits-new-drug-application-to-u-s-food-and-drug-administration--fenc-20210528monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-issuance-of-u-s-patent-for-pedmark-tm-research-triangle-park-nc-fenc-20200921monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-its-new-drug-app-fenc-20200811monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-amendment-to-increase-existing-senior-debt-facility-resea-fenc-20200626monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-proposed-public-offering-of-common-shares-research-triangle-park-n-c-fenc-20200429monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-fda-filing-acceptance-and-priority-review-of-new-drug-app-fenc-20200413monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-issuance-of-u-s-patent-for-use-of-pedmark-tm-research-triangle-park-nc-fenc-20200305monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-receives-european-medicines-agency-validation-for-marketing-authori-fenc-20200228monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-fiscal-year-2019-financial-results-nda-new-d-fenc-20200214monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-completes-rolling-submission-of-new-drug-application-nda-to-u-s-foo-fenc-20200211monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-third-quarter-2019-financial-results-nda-new-fenc-20191112monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-appoints-jodi-a-cook-phd-to-its-board-of-directors-research-triangle-park-nc-fenc-20190924monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-appoints-shubh-goel-as-chief-commercial-officer-seasoned-commercial-leader-to-lead--fenc-20190909monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-second-quarter-2019-financial-results-antici-fenc-20190809monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-first-quarter-2019-financial-results-targeti-fenc-20190509monthly0.5https://www.biopharmawatch.com/news/FENC/university-avenue-8th-floor-date-fenc-20190418monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-fiscal-year-2018-financial-results-initiated-fenc-20190313monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-12-5-million-debt-financing-with-bridge-bank-research-tri-fenc-20190204monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-set-to-join-russell-3000-index-research-triangle-park-nc-fenc-20180611monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-receives-breakthrough-therapy-designation-by-fda-for-pedmark-resear-fenc-20180327monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-receives-fast-track-designation-by-fda-for-pedmark-research-triangl-fenc-20180321monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-proposed-public-offering-of-common-shares-research-triangle-park-n-c-fenc-20171207monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-positive-results-from-phase-3-siopel-6-study-on-pedmark-tm-sodium-thiosul-fenc-20171016monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-listing-on-the-nasdaq-capital-market-trading-on-nasdaq-un-fenc-20170913monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-7-6-million-private-placement-of-common-shares-led-by-venbio-select-advis-fenc-20170608monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-appointment-of-marco-brughera-to-the-board-of-directors-research-triangle-fenc-20160811monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-interim-results-of-siopel-6-study-on-sodium-thiosulfate-sts-presented-at--fenc-20160606monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-second-closing-of-private-placement-research-triangle-park-nc-fenc-20160516monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-5-0-million-private-fenc-20160411monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-new-chairman-of-the-board-research-triangle-park-nc-fenc-20151209monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-share-consolidation-name-change-and-trading-symbol-change-research-trian-fenc-20140903monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-results-from-two-sodium-thiosulfate-phase-3-studies-presented-at-the-50--fenc-20140602monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-appoints-two-independent-directors-research-triangle-park-nc-marketwire-fenc-20140428monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-two-sodium-thiosulfate-presentations-for-prevention-of-ototoxicity-in-ch-fenc-20140422monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-sodium-thiosulfate-clinical-study-update-research-triangle-park-nc-marke-fenc-20140227monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-closing-of-private-placement-research-triangle-park-nc-fenc-20131122monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-recent-developments-and-third-quarter-september-30-2013-financial-results--fenc-20131115monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-updated-guidance-for-sodium-thiosulfate-sts-results-research-triangle-pa-fenc-20131016monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-corporate-update-research-triangle-park-nc-fenc-20130815monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-feedback-from-the-fda-from-end-of-phase-2-meeting-research-triangle-park-n-fenc-20130523monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-completion-of-patient-enrollment-and-maintains-tsx-listing-status-resear-fenc-20130107monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-positive-preliminary-interim-phase-ii-results-for-eniluracil-plus-5-fluoro-fenc-20121209monthly0.5https://www.biopharmawatch.com/news/FENC/about-adherex-technologies-inc-adherex-technologies-inc-is-a-biopharmaceutical-company-foc-fenc-20120918monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-to-present-at-rodman-renshaw-fenc-20120905monthly0.5https://www.biopharmawatch.com/news/FENC/about-metastatic-breast-cancer-breast-cancer-is-the-second-leading-cause-of-cancer-related-fenc-20120109monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-meeting-with-fda-s-pediatric-subcommittee-of-the-oncologic-drugs-advisory--fenc-20111007monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-completion-of-reverse-stock-split-and-continuance-to-british-columbia-re-fenc-20110825monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-responds-to-stock-trading-activity-chapel-hill-nc-fenc-20101217monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-second-quarter-2010-financial-results-chapel-hill-nc-fenc-20100813monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-first-closing-of-private-placement-chapel-hill-nc-fenc-20100430monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-additional-financing-chapel-hill-nc-fenc-20100420monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-a-new-corporate-direction-for-the-company-research-triangle-park-nc-fenc-20090707monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-files-to-delist-from-the-amex-stock-continues-to-trade-on-tsx-research-triangle-pa-fenc-20090109monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-receives-amex-delisting-notice-implements-success-based-incentive-program-research-fenc-20081210monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-agreement-for-sts-phase-iii-data-research-triangle-park-nc-fenc-20080514monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-first-quarter-2008-financial-results-research-triangle-park-nc-fenc-20080513monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-third-quarter-2007-financial-results-research-triangle-park-nc-fenc-20071107monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-2006-fiscal-results-research-triangle-park-nc-fenc-20070326monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-completes-us-25-million-public-financing-research-triangle-park-nc-fenc-20070221monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-filing-of-final-prospectus-research-triangle-park-nc-fenc-20070214monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-equity-offering-up-to-us-25-million-minimum-of-us-10-million-in-gross-pr-fenc-20070119monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-buys-out-eniluracil-development-options-from-glaxosmithkline-research-triangle-par-fenc-20070118monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-third-quarter-2006-financial-results-research-triangle-park-nc-fenc-20061113monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-second-quarter-2006-financial-results-research-triangle-park-nc-fenc-20060809monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-first-quarter-2006-financial-results-research-triangle-park-nc-fenc-20060515monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-announces-us-6-5-million-private-placement-research-triangle-park-nc-fenc-20060504monthly0.5https://www.biopharmawatch.com/news/FENC/a-message-to-our-shareholders-this-past-year-was-highlighted-by-the-presentation-of-import-fenc-20060324monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-third-quarter-2005-financial-results-research-triangle-park-nc-fenc-20051107monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-second-quarter-2005-financial-results-research-triangle-park-nc-fenc-20050810monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-technologies-inc-annual-and-special-meeting-of-shareholders-fenc-20050606monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-first-quarter-2005-financial-results-research-triangle-park-nc-fenc-20050510monthly0.5https://www.biopharmawatch.com/news/FENC/chairman-s-letter-adherex-is-continuing-our-efforts-to-build-a-clinical-drug-development-e-fenc-20050318monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-reports-2004-six-month-fiscal-transition-results-research-triangle-park-nc-fenc-20050321monthly0.5https://www.biopharmawatch.com/news/FENC/adherex-logo-appears-here-press-release-adherex-receives-approval-for-amex-listing-trading-fenc-20041112monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-r-d-science-forum-ird-20260616monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-financial-results-for-first-quarter-2026-and-provides-corporate-up-ird-20260512monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-financial-results-for-full-year-2025-and-provides-corporate-update-ird-20260310monthly0.5https://www.biopharmawatch.com/news/IRD/delivering-on-the-promise-ofgene-therapy-for-rare-inherited-retinal-diseases-january-2026--ird-20260112monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-highlights-2025-progress-and-upcoming-2026-catalysts-multi-asset-pipeline-wi-ird-20260108monthly0.5https://www.biopharmawatch.com/news/IRD/final-for-globenewswire-opus-genetics-announces-23-million-registered-direct-offering-fina-ird-20251106monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-appoints-rob-gagnon-as-chief-financial-officer-ird-20250902monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-financial-results-for-second-quarter-2025-and-provides-corporate-u-ird-20250813monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapy-for-inhe-ird-20250723monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-oph-ird-20250626monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-awarded-non-dilutive-funding-from-the-rd-fund-to-support-preclinical-develop-ird-20250623monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-financial-results-for-first-quarter-2025-and-provides-corporate-up-ird-20250515monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-financial-results-for-full-year-2024-provides-update-on-the-compan-ird-20250331monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-financial-results-for-third-quarter-2024-and-provides-corporate-up-ird-20241112monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-acquisition-of-opus-genetics-acquisition-creates-a-leading-clini-ird-20241022monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-second-quarter-2024-and-provides-corporate-ird-20240813monthly0.5https://www.biopharmawatch.com/news/IRD/npdr-subset-analysis-of-zeta-1-phase-2-trial-a-moderate-to-severe-npdr-qualifying-subgroup-ird-20240510monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-first-quarter-2024-and-provides-corporate--ird-20240510monthly0.5https://www.biopharmawatch.com/news/IRD/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-ird-20240327monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-fourth-quarter-and-full-year-2023-and-prov-ird-20240308monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-strengthens-leadership-team-with-key-appointments-ash-jayagopal-ph-d-m-b-a-ird-20240214monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-appointment-of-joseph-schachle-m-b-a-as-chief-operating-officer--ird-20231127monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-third-quarter-2023-and-provides-corporate--ird-20231113monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-corporate-presentation-november-2023-this-presentation-contains-forward-looking-s-ird-20231102monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-appointment-of-george-magrath-m-d-m-b-a-m-s-as-chief-executive-o-ird-20231101monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-and-viatris-announce-fda-approval-of-ryzumvl-phentolamine-ophthalmic-solut-ird-20230927monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-second-quarter-2023-and-provides-corporate-ird-20230811monthly0.5https://www.biopharmawatch.com/news/IRD/restore-vision-clarity-ocuphire-corporate-presentation-august-2023-2-this-presentation-con-ird-20230801monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-first-quarter-2023-and-provides-corporate--ird-20230515monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-appoints-rick-rodgers-as-interim-chief-executive-officer-seasoned-operating-execu-ird-20230421monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-fourth-quarter-and-year-ended-2022-and-pro-ird-20230330monthly0.5https://www.biopharmawatch.com/news/IRD/zeta-1-apx3330-topline-results-investor-webcast-ird-20230125monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-submission-of-new-drug-application-to-fda-for-nyxol-eye-drops-fo-ird-20221206monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-enters-into-a-global-license-agreement-for-development-and-commercializati-ird-20221108monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-third-quarter-2022-and-provides-corporate--ird-20221104monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-kol-event-apx3330-ird-20221014monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-the-second-quarter-2022-and-provides-corpo-ird-20220812monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-corporate-presentation-ird-20220519monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-financial-results-for-first-quarter-2022-and-provides-corporate--ird-20220513monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-completes-last-clinical-trial-supporting-the-planned-2022-nda-submission-with-the-ird-20220428monthly0.5https://www.biopharmawatch.com/news/IRD/mira-3-phase-3-trial-results-conference-call-ird-20220329monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-financial-results-for-the-fourth-quarter-and-year-ended-2021-and-provid-ird-20220324monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-investor-r-d-day-ird-20220131monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-presenting-new-data-and-updates-on-apx3330-and-nyxol-clinical-programs-at-virtual-ird-20220131monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-provides-corporate-update-announcing-enrollment-completion-of-phase-3-nyxol-trial-ird-20220105monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-financial-results-for-the-third-quarter-2021-and-provides-corporate-upd-ird-20211112monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-financial-results-for-the-second-quarter-2021-and-provides-corporate-up-ird-20210812monthly0.5https://www.biopharmawatch.com/news/IRD/vega-1-phase-2-topline-results-conference-call-ird-20210630monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-closing-of-15-million-registered-direct-offering-priced-at-the-market-c-ird-20210608monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-15-million-registered-direct-offering-priced-at-the-market-under-nasdaq-ird-20210604monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-financial-results-for-the-first-quarter-2021-and-provides-corporate-upd-ird-20210507monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-financial-results-for-the-full-year-2020-and-provides-corporate-update-ird-20210310monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-corporate-presentation-january-2021-disclosures-and-forward-looking-statements-th-ird-20210106monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-completes-transactions-and-begins-trading-on-nasdaq-as-ocup-merger-complet-ird-20201106monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-announces-stockholder-approval-of-all-proposals-required-for-merger-ird-20201102monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-and-ocuphire-enter-into-definitive-merger-agreement-transaction-to-create-a-nasdaq--ird-20200617monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-reports-second-quarter-2019-financial-results-and-provides-update-o-ird-20190807monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-announces-move-to-nasdaq-company-will-trade-under-the-ticker-symbol-rexn-beginning--ird-20190529monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-and-biosense-global-announce-collaboration-and-license-agreement-for-rx-3117-in-gre-ird-20190416monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-effects-1-for-12-reverse-stock-split-rockville-md-ird-20190412monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-appoints-lara-s-sullivan-to-its-board-of-directors-rockville-md-ird-20190301monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-presents-updated-preliminary-data-on-rx-3117-in-pancreatic-cancer-at-the-2019-asco--ird-20190122monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-appoints-gil-price-to-its-board-of-directors-rockville-md-ird-20181203monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-announces-leadership-transition-douglas-swirsky-assumes-role-of-chi-ird-20181114monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-announces-clinical-collaboration-with-merck-to-evaluate-rx-5902-sup-ird-20180821monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-announces-collaboration-with-zhejiang-haichang-biotechnology-co-ltd-ird-20180208monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-announces-the-appointment-of-douglas-j-swirsky-as-president-and-chi-ird-20180104monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-announces-retirement-of-its-founder-chang-ahn-ph-d-from-the-board-o-ird-20170901monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-effects-1-for-10-reverse-stock-split-rockville-md-ird-20170505monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-announces-1-for-10-reverse-stock-split-rockville-md-ird-20170413monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-initiates-stage-2-of-phase-ib-iia-clinical-trial-of-rx-3117-in-rela-ird-20160912monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-strengthens-leadership-team-appoints-industry-veteran-lisa-nolan-ph-ird-20160711monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-reports-interim-clinical-data-for-archexin-at-the-14-th-internation-ird-20151105monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-presents-preliminary-clinical-data-for-supinoxin-and-rx-3117-oncolo-ird-20150928monthly0.5https://www.biopharmawatch.com/news/IRD/investor-presentation-september-2015-1-safe-harbor-statement-the-statements-that-follow-in-ird-20150910monthly0.5https://www.biopharmawatch.com/news/IRD/the-trout-group-llc-tricia-truehart-646-378-2953-ttruehart-troutgroup-com-rexahn-pharmaceu-ird-20150204monthly0.5https://www.biopharmawatch.com/news/IRD/the-trout-group-llc-tricia-truehart-646-378-2953-ttruehart-troutgroup-com-rexahn-pharmaceu-ird-20141203monthly0.5https://www.biopharmawatch.com/news/IRD/the-trout-group-llc-tricia-truehart-646-378-2953-ttruehart-troutgroup-com-rexahn-pharmaceu-ird-20140303monthly0.5https://www.biopharmawatch.com/news/IRD/january-2014-revolutionizing-the-treatment-of-cancer-2-safe-harbor-statement-the-statement-ird-20140114monthly0.5https://www.biopharmawatch.com/news/IRD/the-trout-group-llc-tricia-truehart-646-378-2953-ttruehart-troutgroup-com-rexahn-pharmaceu-ird-20130828monthly0.5https://www.biopharmawatch.com/news/IRD/the-trout-group-llc-tricia-truehart-646-378-2953-ttruehart-troutgroup-com-rexahn-pharmaceu-ird-20130724monthly0.5https://www.biopharmawatch.com/news/IRD/the-trout-group-llc-tricia-truehart-646-378-2953-ttruehart-troutgroup-com-rexahn-pharmaceu-ird-20130715monthly0.5https://www.biopharmawatch.com/news/IRD/michael-mason-allen-caron-inc-212-691-8087-michaelm-allencaron-com-constantine-theodoropul-ird-20130122monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-constantine-theodoropulos-base-pair-group-617-816-4637-constantine-base-ird-20121130monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-stephanie-ascher-stern-investor-relations-inc-212-362-1200-stephanie-st-ird-20120117monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-stephanie-ascher-stern-investor-relations-inc-212-362-1200-stephanie-st-ird-20111104monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-stephanie-ascher-stern-investor-relations-inc-212-362-1200-stephanie-st-ird-20110328monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-stephanie-ascher-stern-investor-relations-inc-212-362-1200-stephanie-st-ird-20110307monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-stephanie-ascher-stern-investor-relations-inc-212-362-1200-stephanie-st-ird-20110120monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-announces-the-appointment-of-peter-brandt-and-richard-kivel-to-boar-ird-20100913monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-stephanie-ascher-stern-investor-relations-inc-212-362-1200-stephanie-st-ird-20100630monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-stephanie-ascher-stern-investor-relations-inc-212-362-1200-stephanie-st-ird-20100628monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-stephanie-ascher-stern-investor-relations-inc-212-362-1200-stephanie-st-ird-20100413monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-industry-and-press-relations-jeffrey-goldberger-yemi-rose-constantine-t-ird-20091026monthly0.5https://www.biopharmawatch.com/news/IRD/jeffrey-goldberger-yemi-rose-kcsa-strategic-communications-212-896-1249-212-896-1233-jgold-ird-20091019monthly0.5https://www.biopharmawatch.com/news/IRD/jeffrey-goldberger-yemi-rose-kcsa-strategic-communications-212-896-1249-212-896-1233-jgold-ird-20090921monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-jeffrey-goldberger-yemi-rose-kcsa-strategic-communications-212-896-1249-ird-20090810monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-jeffrey-goldberger-yemi-rose-kcsa-strategic-communications-212-896-1249-ird-20090708monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-jeffrey-goldberger-yemi-rose-kcsa-strategic-communications-212-896-1249-ird-20090630monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-industry-and-press-relations-jeffrey-goldberger-yemi-rose-constantine-t-ird-20090608monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-industry-and-press-relations-jeffrey-goldberger-yemi-rose-constantine-t-ird-20090520monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-media-relations-jeffrey-goldberger-yemi-rose-constantine-theodoropulos--ird-20090505monthly0.5https://www.biopharmawatch.com/news/IRD/investor-relations-media-relations-jeffrey-goldberger-yemi-rose-constantine-theodoropulos--ird-20090414monthly0.5https://www.biopharmawatch.com/news/IRD/jeffrey-goldberger-yemi-rose-kcsa-strategic-communications-212-896-1249-212-896-1233-jgold-ird-20090227monthly0.5https://www.biopharmawatch.com/news/IRD/beth-bittle-communications-manager-240-268-5300-ext-307-rexahn-pharmaceuticals-appoints-ch-ird-20080714monthly0.5https://www.biopharmawatch.com/news/IRD/mark-kibong-lee-director-of-operations-240-268-5300-extension-313-rexahn-pharmaceuticals-r-ird-20080103monthly0.5https://www.biopharmawatch.com/news/IRD/at-rexahn-amanda-sawney-240-268-5300-ext-300-rexahn-pharmaceuticals-inc-appoints-dr-freddi-ird-20070615monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-completes-public-company-merger-ird-20050516monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-first-quarter-2026-results-record-revenue-achieved-including-25-o-clpt-20260513monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2025-results-record-revenue-and-irra-clpt-20260317monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-revenue-clpt-20260112monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-completes-acquisition-of-irras-acquisition-will-enhance-clearpoint-neuro--clpt-20251120monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-third-quarter-2025-results-site-readiness-continues-for-specializ-clpt-20251106monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-agreement-to-acquire-irras-acquisition-will-further-expand-the--clpt-20251106monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-second-quarter-2025-results-record-revenue-and-substantial-cash-i-clpt-20250812monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-first-quarter-2025-results-record-revenue-highlighted-by-70-growt-clpt-20250513monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2024-results-achieved-record-revenue-clpt-20250226monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-third-quarter-2024-results-achieved-record-revenue-and-growth-of--clpt-20241107monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-second-quarter-2024-results-second-quarter-revenue-growth-32-reco-clpt-20240807monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-first-quarter-2024-results-first-quarter-revenue-growth-41-record-clpt-20240507monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2023-results-release-includes-commen-clpt-20240312monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2023-preliminary-revenue-results-and-clpt-20240108monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-third-quarter-2023-results-biologics-drug-delivery-growing-55-q3--clpt-20231109monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-second-quarter-2023-results-biologics-drug-delivery-growing-40-co-clpt-20230808monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-first-quarter-2023-results-biologics-drug-delivery-growing-24-com-clpt-20230511monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2022-results-company-reports-record--clpt-20230301monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2022-preliminary-revenue-results-and-clpt-20230111monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-third-quarter-2022-results-company-reaffirms-2022-revenue-forecas-clpt-20221108monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-appointment-of-mazin-sabra-as-chief-operating-officer-clpt-20220920monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-second-quarter-2022-results-record-quarterly-revenue-achieved-com-clpt-20220809monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-first-quarter-2022-results-clpt-20220511monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2021-results-company-reports-record--clpt-20220301monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2021-preliminary-revenue-results-and-clpt-20220215monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-third-quarter-2021-results-record-revenue-achieved-company-reaffi-clpt-20211109monthly0.5https://www.biopharmawatch.com/news/CLPT/internationally-renowned-neurosurgeon-and-accomplished-researcher-dr-linda-m-liau-joins-cl-clpt-20211102monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-second-quarter-2021-results-record-case-volume-supported-clinical-clpt-20210810monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-appointment-of-lynnette-c-fallon-to-board-of-directors-clpt-20210715monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-executive-officer-and-director-stock-ownership-guidelines-as-adopted--clpt-20210625monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-record-revenue-in-first-quarter-2021-results-announces-fda-cleara-clpt-20210511monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-retirement-of-director-john-n-spencer-jr-clpt-20210413monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-fourth-quarter-and-full-year-2020-results-company-reports-record--clpt-20210304monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-appointment-of-r-john-fletcher-as-chairman-of-the-board-of--clpt-20210205monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-reports-record-revenue-in-preliminary-fourth-quarter-2020-results-irv-clpt-20210112monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-funding-of-additional-7-5m-of-existing-convertible-note-on--clpt-20201229monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-third-quarter-2020-results-revenue-reaches-a-record-3-5-million-i-clpt-20201110monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-transition-plan-for-new-chief-financial-officer-danilo-d-alessa-clpt-20200914monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-second-quarter-2020-results-revenue-reaches-2-5-million-amid-covi-clpt-20200812monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-first-quarter-2020-results-company-provides-update-on-effects-of--clpt-20200512monthly0.5https://www.biopharmawatch.com/news/CLPT/the-company-s-actual-results-are-described-in-the-risk-factors-section-of-the-company-s-an-clpt-20200417monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-provides-a-covid-19-pandemic-update-and-announces-preliminary-first-quart-clpt-20200416monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-2020-revenue-outlook-ahead-of-nasdaq-investor-presentation--clpt-20200214monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-53-increase-in-2019-revenue-fourth-quarter-revenue-grows-41-fifth-clpt-20200212monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-changes-corporate-name-to-clearpoint-neuro-inc-company-to-commence-t-clpt-20200212monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-closes-17-5-million-strategic-investment-from-ptc-therapeutics-inc-a-clpt-20200129monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-obtains-a-17-5-million-strategic-investment-from-ptc-therapeutics-in-clpt-20191231monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-announces-move-to-nasdaq-capital-market-clpt-20191126monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-reports-62-increase-in-2019-third-quarter-revenue-performance-marks-four-clpt-20191112monthly0.5https://www.biopharmawatch.com/news/CLPT/healthcare-veteran-kristine-johnson-to-join-mri-interventions-clpt-20190806monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-reports-58-increase-in-2019-second-quarter-revenue-record-2-6-million-qu-clpt-20190806monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-announces-uplisting-to-nyse-american-stock-will-trade-under-its-exis-clpt-20190703monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-closing-of-7-522-million-private-placement-irvine-ca-clpt-20190517monthly0.5https://www.biopharmawatch.com/news/CLPT/ptc-therapeutics-and-mri-interventions-announce-strategic-investment-4-million-equity-inve-clpt-20190509monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-reports-52-increase-in-first-quarter-revenue-record-2-5-million-quarterl-clpt-20190430monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-reports-36-increase-in-fourth-quarter-revenue-and-record-quarterly-clear-clpt-20190311monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-estimated-30-growth-driven-by-record-revenue-and-record-clearp-clpt-20190103monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-reports-record-clearpoint-cases-and-disposable-functional-neurosurgery-r-clpt-20181112monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-and-clinical-laserthermia-systems-cls-announce-collaboration-to-develop--clpt-20181017monthly0.5https://www.biopharmawatch.com/news/CLPT/investor-presentation-joe-burnett-president-ceo-june-2018-forward-looking-statements-state-clpt-20180927monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-retires-brainlab-debt-extends-2019-notes-by-18-months-irvine-ca-clpt-20180925monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-reports-second-quarter-results-biologics-trials-ce-mark-clearances-and-f-clpt-20180814monthly0.5https://www.biopharmawatch.com/news/CLPT/investor-presentation-joe-burnett-president-ceo-june-2018-forward-looking-statements-state-clpt-20180605monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-to-webcast-at-ld-micro-conference-clpt-20180604monthly0.5https://www.biopharmawatch.com/news/CLPT/first-quarter-results-mri-interventions-reports-first-quarter-results-new-strategic-initia-clpt-20180515monthly0.5https://www.biopharmawatch.com/news/CLPT/investor-presentation-joe-burnett-president-ceo-april-2018-2018-mri-interventions-inc-1-fo-clpt-20180410monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-reports-34-year-over-year-increase-in-functional-neurology-revenues--clpt-20180315monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-announces-record-629-clearpoint-cases-in-2017-2017-functional-neurol-clpt-20180206monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-reports-26-year-over-year-increase-in-third-quarter-procedures-gross-clpt-20171106monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-joseph-burnett-as-new-president-and-ceo-leadership-transition--clpt-20171009monthly0.5https://www.biopharmawatch.com/news/CLPT/investor-presentation-october-2017-2017-mri-interventions-inc-1-forward-looking-statements-clpt-20171003monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-reports-79-revenue-increase-and-record-treatments-in-second-quarter--clpt-20170801monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-record-second-quarter-clearpoint-system-procedures-and-a-79-ye-clpt-20170711monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-closing-of-13-25-million-private-placement-irvine-ca-clpt-20170530monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-13-25-million-private-placement-offering-transformative-for-th-clpt-20170525monthly0.5https://www.biopharmawatch.com/news/CLPT/healthcare-veteran-john-fletcher-joins-mri-interventions-board-of-directors-irvine-ca-may--clpt-20170511monthly0.5https://www.biopharmawatch.com/news/CLPT/investor-presentation-may-2017-2017-mri-interventions-inc-1-forward-looking-statements-sta-clpt-20170501monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-condensed-consolidated-statements-of-cash-flows-unaudited-for-the-th-clpt-20170427monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-license-and-collaboration-agreement-with-acoustic-medsystems-a-clpt-20170427monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-record-quarterly-revenue-record-clearpoint-system-procedures-i-clpt-20170406monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20170228monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20170124monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20161104monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-6-million-private-placement-includes-4-25-million-of-gross-cas-clpt-20160831monthly0.5https://www.biopharmawatch.com/news/CLPT/ticker-mric-investor-presentation-august-18-transforming-minimally-invasive-neurosurgery-b-clpt-20160818monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20160815monthly0.5https://www.biopharmawatch.com/news/CLPT/ticker-mric-investor-presentation-clpt-20160609monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20160428monthly0.5https://www.biopharmawatch.com/news/CLPT/ticker-mric-investor-presentation-clpt-20160323monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20160323monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-inc-announces-agreement-to-restructure-brainlab-ag-senior-secured-note-a-clpt-20160322monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20160107monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-5-3-million-private-placement-irvine-ca-clpt-20151215monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20151103monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20151001monthly0.5https://www.biopharmawatch.com/news/CLPT/ticker-mric-investor-presentation-september-2015-transforming-minimally-invasive-neurosurg-clpt-20150925monthly0.5https://www.biopharmawatch.com/news/CLPT/harold-a-hurwitz-chief-financial-officer-949-900-6833-for-immediate-release-mri-interventi-clpt-20150730monthly0.5https://www.biopharmawatch.com/news/CLPT/frank-grillo-chief-executive-officer-949-900-6833-mri-interventions-reports-2015-first-qua-clpt-20150430monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-new-chief-financial-officer-harold-a-hurwitz-brings-considerable-medical-clpt-20150317monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-reports-2014-clpt-20150305monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-10-2-million-private-placement-irvine-ca-clpt-20141219monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-third-quarter-2014-clpt-20141113monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-provides-perspective-on-third-quarter-as-frank-grillo-assumes-leadership-clpt-20141006monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-frank-grillo-intuitive-surgical-executive-to-become-ceo-and-ki-clpt-20140911monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-welcomes-pascal-e-r-girin-to-board-of-directors-newest-director-brings-a-clpt-20140903monthly0.5https://www.biopharmawatch.com/news/CLPT/dear-fellow-stockholders-on-the-heels-of-our-q2-2014-earnings-release-i-am-pleased-to-prov-clpt-20140820monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-second-quarter-2014-financial-results-reports-record-total-pro-clpt-20140807monthly0.5https://www.biopharmawatch.com/news/CLPT/mri-interventions-announces-first-quarter-2014-financial-results-reports-total-revenues-of-clpt-20140508monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-months-ended-sndl-20260429monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-nine-months-sndl-20251104monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-2025-annual-and-special-meeting-results-edmonton-ab-sndl-20250731monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-second-quarter-2025-financial-and-operational-results-the-company-delivers-po-sndl-20250731monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-six-months--sndl-20250731monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-second-quarter-2025-financial-results-on-sndl-20250711monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-notice-of-meeting-and-information-circular-dated-june-20-2025-for-the-annual-and--sndl-20250620monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-first-quarter-2025-financial-and-operational-results-the-company-delivers-rec-sndl-20250501monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-months-ended-sndl-20250501monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-launches-rise-rewards-loyalty-program-edmonton-ab-sndl-20250422monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f3-material-change-report-item-1-name-and-address-of-company-sndl-inc-sndl-101--sndl-20250409monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-first-quarter-2025-financial-results-on-sndl-20250415monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-listing-on-the-sndl-20250411monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-enters-into-agreement-to-acquire-cost-cannabis-and-t-cannabis-locations-from-1cm-edmo-sndl-20250409monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-fourth-quarter-and-full-year-2024-financial-and-operational-results-the-compa-sndl-20250318monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-fourth-quarter-2024-and-full-year-2024-financial-results-on-sndl-20250225monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-appoints-new-chief-information-officer-and-new-president-liquor-division-calgary-ab-sndl-20241121monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-renewal-of-share-repurchase-program-calgary-ab-sndl-20241114monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-third-quarter-2024-financial-and-operational-results-the-company-reports-reco-sndl-20241105monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-nine-months-sndl-20241105monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-emerges-as-canada-s-leading-producer-of-edibles-with-indiva-acquisition-calgary-ab-sndl-20241104monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-third-quarter-2024-financial-results-on-sndl-20241024monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f3-material-change-report-item-1-name-and-address-of-company-sndl-inc-sndl-300--sndl-20241021monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-successfully-completes-privatization-of-nova-and-welcomes-new-director-calgary-ab-sndl-20241021monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-departure-of-liquor-segment-president-calgary-ab-sndl-20240910monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-successful-bid-to-purchase-indiva-calgary-ab-sndl-20240829monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f3-material-change-report-item-1-name-and-address-of-company-sndl-inc-sndl-919--sndl-20240812monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-acquire-remaining-minority-interest-of-nova-cannabis-sndl-and-nova-execute-arrange-sndl-20240813monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-second-quarter-2024-financial-and-operational-results-the-company-reports-rec-sndl-20240801monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-six-months--sndl-20240801monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-2024-annual-general-meeting-results-calgary-ab-sndl-20240730monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-second-quarter-2024-financial-results-on-sndl-20240722monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-overheads-restructuring-project-and-operational-adjustments-calgary-ab-sndl-20240716monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-acquires-delta-9-cannabis-debt-ascends-to-senior-secured-creditor-status-calgary-ab-sndl-20240705monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-enters-into-a-stalking-horse-purchase-agreement-for-indiva-limited-s-business-and-ass-sndl-20240705monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-notice-of-meeting-and-information-circular-dated-june-21-2024-for-the-annual-meet-sndl-20240621monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-first-quarter-2024-financial-and-operational-results-the-company-reports-incr-sndl-20240509monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-complete-the-assignment-of-dutch-love-stores-to-nova-cannabis-this--sndl-20240509monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-months-ended-sndl-20240509monthly0.5https://www.biopharmawatch.com/news/SNDL/sunstream-usa-poised-to-acquire-cannabis-assets-calgary-ab-sndl-20240502monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-first-quarter-2024-financial-results-on-sndl-20240426monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-participate-in-upcoming-international-cannabis-conferences-calgary-ab-sndl-20240409monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-announce-assignment-of-dutch-love-stores-to-nova-cannabis-and-exten-sndl-20240402monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-full-year-and-fourth-quarter-2023-financial-and-operational-results-the-compa-sndl-20240321monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-year-end-and-fourth-quarter-2023-financial-results-on-sndl-20240301monthly0.5https://www.biopharmawatch.com/news/SNDL/termination-agreement-this-termination-agreement-the-agreement-is-made-as-of-sndl-20231117monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-remain-committed-to-partnership-following-the-termination-of-the-im-sndl-20231117monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-renewal-of-share-repurchase-program-calgary-ab-sndl-20231113monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-third-quarter-2023-financial-and-operational-results-and-achieves-positive-ne-sndl-20231113monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-nine-months-sndl-20231113monthly0.5https://www.biopharmawatch.com/news/SNDL/amendment-no-7-to-the-implementation-agreement-this-amendment-no-7-to-the-implementation-a-sndl-20231029monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-extend-outside-date-for-closing-of-the-strategic-partnership-calgar-sndl-20231030monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-third-quarter-2023-financial-results-on-sndl-20231027monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-streamlines-cannabis-operations-footprint-to-enhance-competitiveness-and-profitabilit-sndl-20231019monthly0.5https://www.biopharmawatch.com/news/SNDL/skymint-assets-acquired-from-receivership-sunstream-usa-builds-on-parallel-acquisition-cal-sndl-20231013monthly0.5https://www.biopharmawatch.com/news/SNDL/amendment-no-6-to-the-implementation-agreement-this-amendment-no-6-to-the-implementation-a-sndl-20230928monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-extend-outside-date-for-closing-of-the-strategic-partnership-calgar-sndl-20230928monthly0.5https://www.biopharmawatch.com/news/SNDL/sunstream-usa-launches-as-a-result-of-restructuring-of-parallel-calgary-ab-sndl-20230922monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-participate-in-upcoming-investor-and-cannabis-conferences-calgary-ab-sndl-20230918monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-s-wine-and-beyond-expands-reach-with-e-commerce-launch-calgary-ab-sndl-20230915monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-extend-outside-date-for-closing-of-the-strategic-partnership-calgar-sndl-20230824monthly0.5https://www.biopharmawatch.com/news/SNDL/amendment-no-5-to-the-implementation-agreement-this-amendment-no-5-to-the-implementation-a-sndl-20230823monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-second-quarter-2023-financial-and-operational-results-the-company-achieves-re-sndl-20230814monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-six-months--sndl-20230814monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-second-quarter-2023-financial-results-on-sndl-20230803monthly0.5https://www.biopharmawatch.com/news/SNDL/amendment-no-4-to-the-implementation-agreement-this-amendment-no-4-to-the-implementation-a-sndl-20230725monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-2023-annual-general-meeting-results-calgary-ab-sndl-20230727monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-extend-outside-date-for-closing-of-the-strategic-partnership-calgar-sndl-20230725monthly0.5https://www.biopharmawatch.com/news/SNDL/amendment-no-3-to-the-implementation-agreement-this-amendment-no-3-to-the-implementation-a-sndl-20230630monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-extend-outside-date-for-closing-of-the-strategic-partnership-calgar-sndl-20230630monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-files-early-warning-report-issued-pursuant-to-national-instrument-62-103-calgary-ab-sndl-20230622monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-notice-of-meeting-and-information-circular-dated-june-16-2023-for-the-annual-meet-sndl-20230620monthly0.5https://www.biopharmawatch.com/news/SNDL/amendment-no-2-to-the-implementation-agreement-this-amendment-no-2-to-the-implementation-a-sndl-20230616monthly0.5https://www.biopharmawatch.com/news/SNDL/form-62-103f1-required-disclosure-under-the-early-warning-requirements-item-1-security-and-sndl-20230612monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-files-early-warning-report-issued-pursuant-to-national-instrument-62-103-calgary-ab-sndl-20230609monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-appoints-new-chief-financial-officer-calgary-ab-sndl-20230606monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-provides-update-on-the-nova-cannabis-strategic-partnership-calgary-ab-sndl-20230601monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-first-quarter-2023-financial-and-operational-results-synergy-targets-related--sndl-20230515monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-months-ended-sndl-20230515monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-first-quarter-2023-financial-results-on-sndl-20230510monthly0.5https://www.biopharmawatch.com/news/SNDL/nova-cannabis-shareholders-vote-in-favour-of-strategic-partnership-with-sndl-20230505monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-full-year-and-fourth-quarter-2022-financial-and-operational-results-record-ne-sndl-20230424monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-granted-mcto-extension-calgary-ab-sndl-20230414monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-filing-of-annual-report-by-april-24-and-provides-bi-weekly-mcto-status-upda-sndl-20230413monthly0.5https://www.biopharmawatch.com/news/SNDL/certain-information-contained-in-this-document-marked-by-brackets-has-been-omitted-because-sndl-20230410monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-granted-sndl-20230403monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-enters-into-a-purchase-agreement-to-acquire-four-dutch-love-locations-calgary-ab-sndl-20230328monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-fourth-quarter-and-year-end-2022-financial-results-on-sndl-20230328monthly0.5https://www.biopharmawatch.com/news/SNDL/michigan-court-approves-order-for-the-appointment-of-receiver-over-skymint-assets-sunstrea-sndl-20230313monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-expands-its-wine-and-beyond-banner-into-saskatchewan-calgary-ab-sndl-20230303monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-cost-saving-measures-and-rightsizing-of-cannabis-operations-at-alberta-faci-sndl-20230213monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-expands-retail-network-via-conclusion-of-superette-group-s-ccaa-proceedings-calgary-a-sndl-20230207monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f3-material-change-report-item-1-name-and-address-of-company-sndl-inc-sndl-300--sndl-20230117monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-completes-acquisition-of-the-valens-company-creates-a-low-cost-vertically-integrated--sndl-20230117monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-nova-cannabis-announce-transformational-strategic-partnership-creating-a-sustaina-sndl-20221220monthly0.5https://www.biopharmawatch.com/news/SNDL/sunstream-bancorp-provides-senior-bridge-financing-to-parallel-calgary-ab-sndl-20221208monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-renewal-of-share-repurchase-program-calgary-ab-sndl-20221116monthly0.5https://www.biopharmawatch.com/news/SNDL/sunstream-bancorp-provides-follow-on-funding-to-sndl-20221115monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-third-quarter-2022-financial-and-operational-results-with-record-net-revenue--sndl-20221114monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-nine-months-sndl-20221114monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-acquires-zenabis-business-sndl-adds-low-cost-indoor-cultivation-with-international-ex-sndl-20221101monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-third-quarter-2022-financial-results-on-sndl-20221028monthly0.5https://www.biopharmawatch.com/news/SNDL/consolidated-financial-statements-years-ended-sndl-20220920monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-and-im-cannabis-complete-sndl-s-first-international-export-of-premium-dried-flower-fr-sndl-20220915monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-enters-into-a-bid-agreement-to-acquire-superette-assets-sndl-enters-into-an-agree-sndl-20220831monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f3-material-change-report-item-1-name-and-address-of-company-sndl-inc-sndl-or-t-sndl-20220822monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-announces-agreement-to-acquire-the-valens-company-to-create-leading-vertically-integr-sndl-20220822monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-reports-second-quarter-2022-financial-and-operational-results-calgary-ab-sndl-20220812monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-six-months--sndl-20220812monthly0.5https://www.biopharmawatch.com/news/SNDL/sndl-to-announce-second-quarter-2022-financial-results-on-sndl-20220803monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-results-of-its-annual-and-special-meeting-of-shareholders-and-details-of-sndl-20220725monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-adjournment-of-its-annual-and-special-meeting-of-shareholders-to-sndl-20220725monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-virtual-agm-reminder-calgary-ab-sndl-20220718monthly0.5https://www.biopharmawatch.com/news/SNDL/notice-of-annual-and-special-meeting-on-sndl-20220714monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-notice-of-meeting-and-information-circular-dated-june-21-2022-for-the--sndl-20220630monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-enters-into-a-bid-agreement-for-zenabis-global-inc-s-assets-sundial-enters-sndl-20220620monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f4-business-acquisition-report-item-1-identity-of-company-1-1-name-and-address--sndl-20220615monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-first-quarter-2022-financial-and-operational-results-calgary-ab-sndl-20220516monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-consolidated-interim-financial-statements-for-the-three-mont-sndl-20220516monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-announce-first-quarter-2022-financial-results-on-sndl-20220516monthly0.5https://www.biopharmawatch.com/news/SNDL/to-the-company-s-annual-report-on-form-40-f-with-the-securities-and-exchange-commission-se-sndl-20220502monthly0.5https://www.biopharmawatch.com/news/SNDL/letter-from-the-chief-executive-officer-reminiscences-of-a-cross-border-essential-worker-f-sndl-20220428monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-change-of-auditor-notice-to-british-columbia-securities-commission-alb-sndl-20220407monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-participate-in-the-benzinga-cannabis-capital-conference-calgary-ab-sndl-20220414monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-filing-of-annual-report-by-april-29-and-provides-bi-weekly-mcto--sndl-20220413monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-granted-sndl-20220401monthly0.5https://www.biopharmawatch.com/news/SNDL/form-62-103f1-required-disclosure-under-the-early-warning-requirements-item-1-security-and-sndl-20220330monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-completes-acquisition-of-alcanna-sundial-is-now-the-largest-private-sector-sndl-20220331monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-anticipated-closing-date-of-alcanna-acquisition-and-late-filing-of-annua-sndl-20220328monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-announce-year-end-and-fourth-quarter-2021-financial-results-on-sndl-20220310monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-extension-of-alcanna-arrangement-agreement-outside-date-calgary-ab-sndl-20220225monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-granted-a-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-rule-c-sndl-20220208monthly0.5https://www.biopharmawatch.com/news/SNDL/sunstream-opportunities-lp-receives-investment-grade-credit-rating-calgary-ab-sndl-20220124monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-and-alcanna-inc-announce-the-agreement-to-revised-consideration-under-the--sndl-20220106monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-reiterates-commitment-to-the-transaction-with-alcanna-and-announces-iss-su-sndl-20211208monthly0.5https://www.biopharmawatch.com/news/SNDL/sunstream-ivxx-investment-corp-announces-confidential-submission-of-draft-registration-sta-sndl-20211202monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-share-repurchase-program-calgary-ab-sndl-20211111monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-third-quarter-2021-financial-and-operational-results-calgary-ab-sndl-20211111monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-consolidated-interim-financial-statements-for-the-three-and--sndl-20211112monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-invites-investors-to-submit-questions-in-advance-of-the-third-quarter-2021-sndl-20211028monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-files-early-warning-report-issued-pursuant-to-national-instrument-62-103-calgary-a-sndl-20211020monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f3-material-change-report-item-1-name-and-address-of-company-sundial-growers-in-sndl-20211007monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-acquire-alcanna-inc-calgary-ab-sndl-20211007monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-files-early-warning-report-issued-pursuant-to-national-instrument-62-103-calgary-a-sndl-20210921monthly0.5https://www.biopharmawatch.com/news/SNDL/form-62-103f1-required-disclosure-under-the-early-warning-requirements-item-1-security-and-sndl-20210917monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-launches-first-canadian-caviar-cone-under-top-leaf-brand-sundial-leads-canadian-ma-sndl-20210916monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f3-material-change-report-item-1-name-and-address-of-the-company-sundial-grower-sndl-20210901monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-second-quarter-2021-financial-and-operational-results-calgary-ab-sndl-20210812monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-consolidated-interim-financial-statements-for-the-three-and--sndl-20210812monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-announce-second-quarter-2021-financial-results-on-sndl-20210804monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-completes-the-acquisition-of-spiritleaf-retail-cannabis-network-sundial-en-sndl-20210720monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-results-of-its-annual-general-meeting-of-shareholders-calgary-ab-sndl-20210709monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-increases-commitment-to-sunstream-bancorp-inc-by-350-million-calgary-ab-sndl-20210707monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-virtual-agm-reminder-calgary-ab-sndl-20210701monthly0.5https://www.biopharmawatch.com/news/SNDL/notice-of-annual-general-meeting-on-sndl-20210621monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-notice-of-meeting-and-information-circular-dated-june-7-2021-for-the-a-sndl-20210617monthly0.5https://www.biopharmawatch.com/news/SNDL/statement-of-sundial-growers-inc-regarding-receipt-of-letter-from-nasdaq-confirming-compli-sndl-20210615monthly0.5https://www.biopharmawatch.com/news/SNDL/statement-of-sundial-growers-inc-regarding-receipt-of-letter-from-nasdaq-concerning-non-co-sndl-20210525monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-first-quarter-2021-financial-and-operational-results-first-positive-quarte-sndl-20210511monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-consolidated-interim-financial-statements-for-the-three-mont-sndl-20210512monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-acquire-inner-spirit-holdings-and-spiritleaf-retail-cannabis-network-ca-sndl-20210505monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-files-early-warning-report-issued-pursuant-to-national-instrument-62-103-calgary-a-sndl-20210504monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-announce-first-quarter-2021-financial-results-on-sndl-20210503monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-increases-commitment-to-sunstream-bancorp-inc-calgary-ab-sndl-20210423monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-us-800-000-000-sndl-20210322monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-full-year-and-fourth-quarter-2020-financial-and-operational-results-calgar-sndl-20210317monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-and-saf-group-announce-strategic-capital-partnership-calgary-ab-sndl-20210315monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-announce-full-year-and-fourth-quarter-2020-financial-results-on-sndl-20210302monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-and-indiva-announce-closing-of-22-million-strategic-investment-brokered-private-pl-sndl-20210223monthly0.5https://www.biopharmawatch.com/news/SNDL/warrant-exercise-agreement-this-warrant-exercise-agreement-this-agreement-is-dated-as-of-sndl-20210219monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-issuance-of-new-warrants-and-us-89-1-million-proceeds-from-warrant-exerc-sndl-20210219monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-regains-compliance-with-nasdaq-minimum-bid-price-rule-calgary-ab-sndl-20210217monthly0.5https://www.biopharmawatch.com/news/SNDL/description-of-certain-risks-related-to-our-business-and-our-common-shares-investing-in-ou-sndl-20210216monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-and-indiva-announce-22-million-strategic-investment-brokered-private-placement-off-sndl-20210216monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-closing-of-its-us-74-5-million-registered-offering-calgary-ab-sndl-20210204monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-60-500-000-series-a-units-consisting-of-60-500-000-common-shares-and-w-sndl-20210202monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-closing-of-its-us-100-million-registered-offering-calgary-ab-sndl-20210202monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-us-74-5-million-registered-offering-and-full-utilization-of-shel-sndl-20210202monthly0.5https://www.biopharmawatch.com/news/SNDL/execution-copy-sundial-growers-inc-100-000-000-series-a-units-consisting-of-100-000-000-co-sndl-20210129monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-us-100-million-registered-offering-calgary-ab-sndl-20210129monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-us-400-000-000-sndl-20210120monthly0.5https://www.biopharmawatch.com/news/SNDL/certain-information-in-this-document-marked-by-brackets-has-been-omitted-pursuant-to-item--sndl-20210120monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-us-400-000-000-sndl-20210115monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-us-50-000-000-sndl-20210111monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-the-launch-of-premium-concentrates-products-under-its-top-leaf-brand-cal-sndl-20210111monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-provides-update-of-strategic-investment-calgary-ab-sndl-20210106monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-strategic-investment-calgary-ab-sndl-20201230monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-concentrates-licence-agreement-with-simply-solventless-calgary-ab-sndl-20201228monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-completion-of-financial-restructuring-and-debt-free-status-calgary-ab-sndl-20201221monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-50-million-prepayment-on-senior-secured-non-revolving-term-credit-facili-sndl-20201215monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-receives-approval-for-nasdaq-listing-transfer-to-allow-for-additional-180-day-comp-sndl-20201211monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-us-150-000-000-sndl-20201203monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-files-new-shelf-registration-statement-calgary-ab-sndl-20201204monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-elimination-of-senior-secured-second-lien-convertible-notes-calgary-ab-sndl-20201130monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-to-participate-in-2020-cowen-boston-cannabis-conference-calgary-ab-sndl-20201123monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-third-quarter-2020-financial-results-calgary-ab-sndl-20201111monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-consolidated-interim-financial-statements-for-the-three-and--sndl-20201112monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-expands-into-the-edible-market-with-choklat-collaboration-calgary-ab-sndl-20201109monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-announce-third-quarter-2020-financial-results-on-sndl-20201029monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-expands-brand-portfolio-presence-with-palmetto-available-coast-to-coast-calgary-ab-sndl-20201020monthly0.5https://www.biopharmawatch.com/news/SNDL/kpmg-llp-205-5th-avenue-sw-suite-3100-calgary-ab-t2p-4b9-tel-403-691-8000-fax-403-691-8008-sndl-20201013monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-to-participate-in-alliance-global-partners-virtual-event-calgary-ab-sndl-20200903monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-closing-of-its-us-20-million-registered-offering-calgary-ab-sndl-20200818monthly0.5https://www.biopharmawatch.com/news/SNDL/form-of-series-a-b-warrant-the-number-of-common-shares-issuable-upon-exercise-of-this-warr-sndl-20200814monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-pricing-of-its-us-20-million-registered-offering-sndl-20200814monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-consolidated-interim-financial-statements-for-the-three-and--sndl-20200814monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-second-quarter-2020-financial-results-calgary-ab-sndl-20200813monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-us-50-000-000-sndl-20200813monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-announce-second-quarter-2020-financial-results-on-sndl-20200730monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-to-participate-in-alliance-global-partners-virtual-event-calgary-ab-sndl-20200618monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-successful-amendments-with-senior-lenders-us-18-million-convertible-note-sndl-20200608monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-extension-of-credit-facility-waiver-agreements-calgary-sndl-20200601monthly0.5https://www.biopharmawatch.com/news/SNDL/form-51-102f3-material-change-report-item-1-name-and-address-of-the-company-sundial-grower-sndl-20200515monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-results-of-its-annual-general-and-special-meeting-of-shareholders-and-de-sndl-20200521monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-consolidated-interim-financial-statements-for-the-three-mont-sndl-20200515monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-first-quarter-2020-financial-results-calgary-sndl-20200515monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-enters-into-agreement-to-sell-bridge-farm-group-calgary-sndl-20200515monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-provides-update-on-senior-lender-discussions-calgary-sndl-20200512monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-extension-of-credit-facility-waiver-agreements-sundial-will-announce-q1--sndl-20200501monthly0.5https://www.biopharmawatch.com/news/SNDL/appendix-d-board-mandate-effective-as-and-from-sndl-20200424monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-change-to-its-board-of-directors-calgary-sndl-20200424monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-extension-of-credit-facility-waiver-agreements-calgary-sndl-20200415monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-operational-adjustments-to-adapt-to-current-market-conditions-and-improv-sndl-20200409monthly0.5https://www.biopharmawatch.com/news/SNDL/execution-version-waiver-and-agreement-to-sundial-growers-inc-the-borrower-re-credit-agree-sndl-20200331monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-fourth-quarter-and-full-year-2019-financial-results-and-provides-operati-sndl-20200330monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-reschedule-fourth-quarter-and-fiscal-full-year-2019-financial-results-t-sndl-20200330monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-reschedule-fourth-quarter-and-fiscal-full-year-2019-financial-results-t-sndl-20200313monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-announce-fourth-quarter-and-fiscal-full-year-2019-financial-results-on-sndl-20200303monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-departure-of-ceo-and-other-leadership-changes-and-optimization-initiativ-sndl-20200130monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-and-vir-pharmaceuticals-sign-medical-cannabis-supply-agreement-for-australian-chro-sndl-20200109monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-2020-launch-of-medical-cannabis-marketplace-calgary-sndl-20191219monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-new-board-member-bryan-pinney-calgary-sndl-20191218monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-new-board-member-calgary-sndl-20191128monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-added-to-the-nyse-arca-listed-etfmg-alternative-harvest-sndl-20191121monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-added-to-the-nyse-listed-the-advisorshares-pure-cannabis-etf-calgary-nov-20-2019-c-sndl-20191120monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-interim-consolidated-financial-statements-for-the-three-and--sndl-20191113monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-delivers-quarterly-net-revenue-of-33-5-million-representing-74-sequential-growth-t-sndl-20191113monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-date-and-time-changes-for-third-quarter-2019-earnings-call-and-w-sndl-20191108monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-added-to-the-nyse-listed-the-cannabis-sndl-20191107monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-moves-forward-with-expansion-into-prince-edward-island-calgary-sndl-20191031monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-report-third-quarter-2019-financial-results-on-sndl-20191030monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-and-crescita-sign-exclusive-partnership-to-develop-cannabis-and-hemp-topicals-calg-sndl-20191028monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-receives-sales-licence-for-cannabis-oil-products-calgary-sndl-20191024monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-management-transitions-calgary-sndl-20191023monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-to-present-at-benzinga-cannabis-capital-conference-calgary-sndl-20191021monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-responds-to-baseless-class-action-lawsuits-calgary-sndl-20191009monthly0.5https://www.biopharmawatch.com/news/SNDL/lock-up-agreement-this-lock-up-agreement-this-agreement-is-dated-as-of-the-30-th-day-of-se-sndl-20191003monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-introduces-palmetto-the-handy-cannabis-quality-meets-good-to-go-with-this-new-conv-sndl-20191003monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-voluntary-lock-up-by-directors-and-executive-officers-lock-up-covers-app-sndl-20191001monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-enters-atlantic-canada-with-first-shipment-to-nova-scotia-calgary-sndl-20190917monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-supplies-high-quality-cannabis-to-british-columbia-calgary-sndl-20190910monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-announces-up-to-140-million-corporate-credit-facilities-with-atb-financial-sndl-20190830monthly0.5https://www.biopharmawatch.com/news/SNDL/execution-version-registration-rights-agreement-this-registration-rights-agreement-is-made-sndl-20190829monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-joins-the-horizons-marijuana-life-sciences-index-sndl-20190827monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-market-expansion-continues-east-into-saskatchewan-calgary-sndl-20190821monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-cannabis-now-available-across-the-prairies-including-manitoba-calgary-sndl-20190821monthly0.5https://www.biopharmawatch.com/news/SNDL/august-19-2019-statement-from-sundial-sundial-is-aware-of-an-online-article-involving-a-co-sndl-20190819monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-inc-condensed-interim-consolidated-financial-statements-for-the-three-and--sndl-20190814monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-reports-second-quarter-results-as-operations-ramp-up-calgary-sndl-20190814monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-obtains-health-canada-approval-to-further-expand-production-capacity-and-allow-pro-sndl-20190812monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-growers-to-report-second-quarter-2019-financial-results-on-sndl-20190808monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-closing-of-initial-public-offering-calgary-sndl-20190806monthly0.5https://www.biopharmawatch.com/news/SNDL/sundial-announces-pricing-of-upsized-initial-public-offering-calgary-sndl-20190731monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2026-financial-results-and-operational-highlights-x2022-co-rgnx-20260514monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-fda-review-extension-of-bla-for-rgx-121-to-treat-patients-with-mps-ii--rgnx-20250818monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2025-financial-results-and-operational-highlights-x2022-r-rgnx-20250807monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-strategic-royalty-monetization-agreement-for-up-to-250-million-150-mil-rgnx-20250519monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2025-financial-results-and-recent-operational-highlights-x-rgnx-20250512monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-operation-rgnx-20250313monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-closing-of-strategic-partnership-with-nippon-shinyaku-for-mps-diseases-rgnx-20250304monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-nippon-shinyaku-announce-exclusive-partnership-to-develop-and-commercialize--rgnx-20250114monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-initiates-pivotal-phase-of-affinity-duchenne-trial-of-rgx-202-gene-therapy-and-r-rgnx-20241118monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2024-financial-results-and-recent-operational-updates-x202-rgnx-20241106monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-appoints-mitchell-chan-as-chief-financial-officer-x2022-life-sciences-veteran-mi-rgnx-20240917monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2024-financial-results-and-recent-operational-highlights--rgnx-20240801monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-leadership-transition-curran-simpson-chief-operating-officer-appointed-rgnx-20240612monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2024-financial-results-and-recent-operational-highlights-x-rgnx-20240508monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-pricing-of-upsized-public-offering-of-common-stock-and-pre-funded-warr-rgnx-20240306monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-operation-rgnx-20240227monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-updated-strategic-plans-and-third-quarter-2023-financial-results-x2022-rgnx-20231108monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2023-financial-results-and-recent-operational-highlights--rgnx-20230802monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2023-financial-results-and-recent-operational-highlights-c-rgnx-20230503monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-2022-and-full-year-2022-financial-results-and-recent-oper-rgnx-20230228monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-senior-leadership-promotions-curran-simpson-has-been-appointed-chief-o-rgnx-20230109monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2022-financial-results-and-recent-operational-highlights-c-rgnx-20221103monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2022-financial-results-and-recent-operational-highlights--rgnx-20220803monthly0.5https://www.biopharmawatch.com/news/RGNX/jennifer-zachary-joins-regenxbio-board-of-directors-rockville-md-rgnx-20220607monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2022-financial-results-and-recent-operational-highlights-c-rgnx-20220504monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-operation-rgnx-20220301monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-positive-interim-data-from-phase-ii-altitude-trial-of-rgx-314-for-the-t-rgnx-20220212monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-additional-positive-interim-data-from-phase-i-ii-trial-of-rgx-121-for-t-rgnx-20220209monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-additional-positive-interim-data-from-trials-of-rgx-314-in-wet-amd-and--rgnx-20211112monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-closing-of-eye-care-collaboration-agreement-with-abbvie-rockville-md-rgnx-20211109monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2021-financial-results-and-operational-highlights-announce-rgnx-20211102monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-positive-initial-data-from-phase-ii-altitude-trial-of-rgx-314-for-the-t-rgnx-20211009monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-positive-initial-data-from-phase-ii-aaviate-trial-of-rgx-314-for-the-tr-rgnx-20211001monthly0.5https://www.biopharmawatch.com/news/RGNX/abbvie-and-regenxbio-announce-eye-care-collaboration-abbvie-and-regenxbio-form-a-strategic-rgnx-20210913monthly0.5https://www.biopharmawatch.com/news/RGNX/dr-jean-bennett-and-george-migausky-join-regenxbio-board-of-directors-renowned-gene-therap-rgnx-20210907monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-enrollm-rgnx-20210809monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2021-financial-results-and-operational-highlights-enrollme-rgnx-20210505monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2020-financial-results-and-operational-high-rgnx-20210301monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-rgnx-20210108monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-update-on-rgx-314-and-pivotal-program-for-the-treatment-of-wet-amd-and-rgnx-20210105monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-agreement-to-monetize-portion-of-zolgensma-royalties-for-200-million-a-rgnx-20201222monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2020-financial-results-and-operational-highlights-x2022-rg-rgnx-20201104monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-receive-80-0-million-milestone-payment-from-novartis-ag-milestone-payment-bas-rgnx-20201027monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2020-financial-results-and-operational-highlights-x2022-r-rgnx-20200806monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2020-financial-results-and-operational-highlights-x2022-po-rgnx-20200507monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2019-financial-results-and-operational-high-rgnx-20200226monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-continued-progress-across-programs-in-year-end-2019-corporate-update-rgx-rgnx-20200109monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2019-financial-and-operating-results-and-recent-operationa-rgnx-20191105monthly0.5https://www.biopharmawatch.com/news/RGNX/key-takeaways-from-the-rgx-314-phase-i-iia-clinical-trial-for-wet-amd-cohorts-1-5-jeffrey--rgnx-20191009monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2019-financial-and-operating-results-and-additional-posit-rgnx-20190807monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2019-financial-and-operating-results-and-additional-positi-rgnx-20190507monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2018-financial-results-and-recent-operation-rgnx-20190221monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-continued-progress-across-programs-in-year-end-2018-corporate-update-rep-rgnx-20181231monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2018-financial-and-operating-results-and-announces-initiat-rgnx-20181107monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-abeona-therapeutics-announce-worldwide-exclusive-licenses-for-the-treatment--rgnx-20181105monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-rgnx-20180810monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2018-financial-and-operating-results-and-interim-data-fro-rgnx-20180808monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-receives-100-million-accelerated-license-payment-due-to-acquisition-of-avexis-by-rgnx-20180611monthly0.5https://www.biopharmawatch.com/news/RGNX/alexandra-glucksmann-joins-regenxbio-board-of-directors-dr-glucksmann-brings-25-years-of-r-rgnx-20180529monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2018-financial-results-and-recent-operational-highlights-x-rgnx-20180508monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2017-financial-results-and-recent-operation-rgnx-20180306monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-provides-year-end-2017-corporate-update-initiated-third-cohort-dosing-of-rgx-314-rgnx-20180104monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2017-financial-results-and-recent-operational-highlights-x-rgnx-20171108monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-responds-to-notification-of-a-superior-proposal-under-its-merger-agreement-with--rgnx-20171002monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-acquire-dimension-therapeutics-acquisition-will-add-two-lead-product-candidat-rgnx-20170825monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2017-financial-results-and-recent-operational-highlights--rgnx-20170808monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2017-financial-results-and-recent-operational-highlights-x-rgnx-20170509monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-full-exercise-and-closing-of-underwriters-option-to-purchase-additiona-rgnx-20170426monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-pricing-of-public-offering-of-common-stock-rockville-md-rgnx-20170321monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2016-financial-results-and-recent-operation-rgnx-20170307monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-provides-year-end-2016-corporate-update-filed-ind-for-rgx-314-phase-i-clinical-t-rgnx-20170106monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2016-financial-results-and-recent-operational-highlights-x-rgnx-20161109monthly0.5https://www.biopharmawatch.com/news/RGNX/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-rgnx-20160912monthly0.5https://www.biopharmawatch.com/news/RGNX/daniel-tass-appointed-to-regenxbio-board-of-directors-rockville-md-rgnx-20160816monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2016-financial-results-and-recent-operational-highlights--rgnx-20160809monthly0.5https://www.biopharmawatch.com/news/RGNX/fda-grants-rare-pediatric-disease-designation-to-regenxbio-s-rgx-121-gene-therapy-for-the--rgnx-20160802monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-provides-update-on-lead-gene-therapy-development-programs-phase-i-ii-clinical-tr-rgnx-20160705monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2016-financial-results-and-recent-operational-highlights-o-rgnx-20160505monthly0.5https://www.biopharmawatch.com/news/RGNX/preclinical-data-from-regenxbio-s-rgx-314-and-rgx-121-gene-therapy-programs-to-be-presente-rgnx-20160419monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2015-financial-results-and-recent-operation-rgnx-20160303monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-provides-year-end-2015-corporate-update-company-begins-2016-in-strong-financial--rgnx-20160107monthly0.5https://www.biopharmawatch.com/news/RGNX/fda-grants-rare-pediatric-disease-designation-to-regenxbio-s-rgx-111-gene-therapy-for-the--rgnx-20151230monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2015-results-closed-initial-public-offering-raising-145-2--rgnx-20151105monthly0.5https://www.biopharmawatch.com/news/RGNX/fda-grants-orphan-drug-designation-to-regenxbio-s-rgx-111-gene-therapy-for-the-treatment-o-rgnx-20151001monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2025-financial-results-seattle-wa-naut-20250731monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-first-quarter-2025-financial-results-seattle-wa-naut-20250429monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-fourth-quarter-and-fiscal-year-2024-financial-results-seatt-naut-20250227monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-third-quarter-2024-financial-results-seattle-wa-naut-20241029monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2024-financial-results-seattle-wa-naut-20240730monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-first-quarter-2024-financial-results-seattle-wa-naut-20240430monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-fourth-quarter-and-fiscal-year-2023-financial-results-seatt-naut-20240228monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-third-quarter-2023-financial-results-seattle-wa-naut-20231031monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2023-financial-results-seattle-wa-naut-20230802monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-first-quarter-2023-financial-results-seattle-wa-naut-20230502monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-fourth-quarter-and-fiscal-year-2022-financial-results-seatt-naut-20230223monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-third-quarter-2022-financial-results-seattle-wa-naut-20221101monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2022-financial-results-seattle-wa-naut-20220802monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-first-quarter-2022-financial-results-seattle-wa-naut-20220503monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-appoints-karen-akinsanya-ph-d-to-board-of-directors-schr-dinger-pre-naut-20220331monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-fourth-quarter-and-fiscal-year-2021-financial-results-seatt-naut-20220224monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-third-quarter-2021-financial-results-seattle-wa-naut-20211102monthly0.5https://www.biopharmawatch.com/news/NAUT/financial-information-nautilus-biotechnology-inc-unaudited-condensed-financial-statements--naut-20210610monthly0.5https://www.biopharmawatch.com/news/NAUT/arya-sciences-acquisition-corp-iii-announces-extraordinary-general-meeting-teleconference--naut-20210601monthly0.5https://www.biopharmawatch.com/news/NAUT/filed-by-arya-sciences-acquisition-corp-iii-pursuant-to-rule-425-under-the-securities-act--naut-20210407monthly0.5https://www.biopharmawatch.com/news/NAUT/next-gen-proteomics-company-nautilus-biotechnology-to-list-on-nasdaq-through-merger-with-a-naut-20210208monthly0.5https://www.biopharmawatch.com/news/NAUT/arya-sciences-acquisition-corp-iii-report-of-independent-registered-public-accounting-firm-naut-20200811monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-months-ended-siga-20260507monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-twelve-months-ended-siga-20260310monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-six-months-ended-siga-20250805monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-months-ended-siga-20250508monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-twelve-months-ended-siga-20250311monthly0.5https://www.biopharmawatch.com/news/SIGA/interim-results-from-stomp-study-of-siga-s-tecovirimat-in-treatment-of-mpox-announced-inte-siga-20241210monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-nine-months-ended-siga-20241107monthly0.5https://www.biopharmawatch.com/news/SIGA/topline-results-from-palm-007-study-of-siga-s-tecovirimat-in-treatment-of-mpox-released-pr-siga-20240815monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-six-months-ended-siga-20240801monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-u-s-government-procurement-order-of-113-million-for-oral-tpoxx-exercise-of--siga-20240719monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-months-ended-siga-20240507monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-twelve-months-ended-siga-20240312monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-appointment-of-diem-nguyen-ph-d-mba-as-new-chief-executive-officer-siga-20240122monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-nine-months-ended-siga-20231107monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-names-dr-jay-k-varma-as-evp-and-chief-medical-officer-siga-20230906monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-six-months-ended-siga-20230808monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-u-s-government-procurement-orders-of-approximately-138-million-for-oral-and-siga-20230728monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-months-ended-siga-20230504monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-declares-special-cash-dividend-of-0-45-per-share-siga-20230504monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-twelve-months-ended-siga-20230302monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-announces-planned-retirement-of-ceo-phil-gomez-in-2023-siga-board-of-dir-siga-20230117monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-nine-months-ended-siga-20221103monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-barda-exercise-of-procurement-options-valued-at-approximately-26-million-fo-siga-20220809monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-six-months-ended-siga-20220804monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-approximately-28-million-of-international-procurement-orders-for-oral-tpoxx-siga-20220712monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-months-ended-siga-20220505monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-declares-special-dividend-of-0-45-per-share-siga-20220505monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-twelve-months-ended-siga-20220303monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-third-quarter-and-nine-months-ended-siga-20211104monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-six-months-ended-siga-20210805monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-months-ended-siga-20210506monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-twelve-months-ended-siga-20210304monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-public-health-agency-of-canada-contract-award-to-purchase-up-to-approximate-siga-20210113monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-for-three-and-nine-months-ended-siga-20201105monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-reports-financial-results-for-three-and-six-months-ended-siga-20200806monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-reports-financial-results-for-the-first-quarter-of-2020-company-rece-siga-20200506monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-barda-exercise-of-contract-options-valued-at-101-3-million-for-the-procurem-siga-20200429monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-reports-financial-results-for-fiscal-year-2019-announces-expectation-siga-20200305monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-tpoxx-promotion-agreement-with-meridian-medical-technologies-inc-a-pfizer-c-siga-20190603monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-exercise-of-option-for-the-purchase-of-raw-materials-for-oral-tpoxx-manufac-siga-20190520monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-priority-review-voucher-transaction-totaling-80-million-siga-20181101monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-awarded-barda-contract-for-tpoxx-contract-valued-at-up-to-629-million-co-siga-20180910monthly0.5https://www.biopharmawatch.com/news/SIGA/united-states-bankruptcy-court-southern-district-of-new-york-x-in-re-chapter-11-case-no-si-siga-20161212monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-commencement-of-rights-offering-new-york-ny-business-wire-siga-technologies-siga-20161012monthly0.5https://www.biopharmawatch.com/news/SIGA/stephen-karotkin-weil-gotshal-manges-llp-767-fifth-avenue-new-york-new-york-10153-telephon-siga-20160912monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-data-safety-monitoring-board-dsmb-approval-to-complete-subject-enrollment-i-siga-20160808monthly0.5https://www.biopharmawatch.com/news/SIGA/stephen-karotkin-weil-gotshal-manges-llp-767-fifth-avenue-new-york-new-york-10153-telephon-siga-20160721monthly0.5https://www.biopharmawatch.com/news/SIGA/stephen-karotkin-weil-gotshal-manges-llp-767-fifth-avenue-new-york-new-york-10153-telephon-siga-20160708monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-that-delaware-supreme-court-affirms-court-of-chancery-opinion-new-york-busi-siga-20151224monthly0.5https://www.biopharmawatch.com/news/SIGA/united-states-bankruptcy-court-southern-district-of-new-york-x-in-re-chapter-11-case-no-si-siga-20151216monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-receives-nasdaq-delisting-notification-delisting-follows-litigation-rela-siga-20150320monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-appeals-judgment-of-delaware-court-o-f-siga-20150116monthly0.5https://www.biopharmawatch.com/news/SIGA/delaware-siga-20150107monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-files-for-chapter-11-reorganization-siga-20140916monthly0.5https://www.biopharmawatch.com/news/SIGA/delaware-supreme-court-reverses-equitable-payment-stream-to-pharmathene-and-remands-litiga-siga-20130526monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-delivers-first-courses-of-arestvyr-tm-under-barda-contract-siga-20130312monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-appoints-william-j-haynes-as-general-counsel-new-york-new-york-siga-20120604monthly0.5https://www.biopharmawatch.com/news/SIGA/chancery-court-issues-final-judgment-in-litigation-brought-by-pharmathene-new-york-siga-20120601monthly0.5https://www.biopharmawatch.com/news/SIGA/chancery-court-denies-motion-for-reconsideration-in-pharmathene-litigation-proceedings-con-siga-20111216monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-comments-on-court-ruling-in-pharmathene-litigation-new-york-new-york-siga-20110922monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-to-sell-1-7-million-courses-of-st-246-to-national-stockpile-under-modified-barda-cont-siga-20110627monthly0.5https://www.biopharmawatch.com/news/SIGA/dated-may-13-2011-exhibit99-1-htm-siga-technologies-awarded-u-s-government-contract-valued-siga-20110513monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-appoints-daniel-luckshire-as-chief-financial-officer-new-york-new-york-siga-20110211monthly0.5https://www.biopharmawatch.com/news/SIGA/moderator-this-conference-call-contains-or-implies-certain-forward-looking-statements-with-siga-20091214monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-raises-20-0-million-in-a-common-stock-offering-new-york-city-siga-20091210monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-approved-for-nasdaq-global-market-listing-new-york-new-york-siga-20090903monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-receives-additional-20-million-from-nih-for-st-246-antiviral-therapeutic-siga-20080918monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-awarded-55-million-by-federal-government-to-develop-broader-applications-siga-20080903monthly0.5https://www.biopharmawatch.com/news/SIGA/final-siga-technologies-inc-investor-update-conference-call-tuesday-siga-20070508monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-s-smallpox-drug-candidate-administered-to-critically-ill-human-patient-new-york-siga-20070319monthly0.5https://www.biopharmawatch.com/news/SIGA/tom-konatich-siga-technologies-inc-chief-financial-officer-acting-ceo-212-672-9100-siga-ap-siga-20070131monthly0.5https://www.biopharmawatch.com/news/SIGA/tom-konatich-siga-technologies-inc-chief-financial-officer-acting-ceo-212-672-9100-fda-app-siga-20061220monthly0.5https://www.biopharmawatch.com/news/SIGA/tom-konatich-siga-technologies-inc-chief-financial-officer-acting-ceo-212-672-9100-siga-an-siga-20061019monthly0.5https://www.biopharmawatch.com/news/SIGA/debbie-raskin-rubenstein-associates-inc-212-843-8028-draskin-rubenstein-com-siga-announces-siga-20061018monthly0.5https://www.biopharmawatch.com/news/SIGA/thomas-n-konatich-siga-technologies-inc-chief-financial-officer-acting-ceo-212-672-9100-si-siga-20061004monthly0.5https://www.biopharmawatch.com/news/SIGA/mr-thomas-konatich-chief-financial-officer-and-acting-chief-executive-officer-siga-technol-siga-20060828monthly0.5https://www.biopharmawatch.com/news/SIGA/mr-thomas-konatich-chief-financial-officer-and-acting-chief-executive-officer-siga-technol-siga-20060725monthly0.5https://www.biopharmawatch.com/news/SIGA/for-pharmathene-inc-stacey-jurchison-phone-410-571-8925-jurchisons-pharmathene-com-for-sig-siga-20060609monthly0.5https://www.biopharmawatch.com/news/SIGA/thomas-n-konatich-siga-technologies-inc-chief-financial-officer-212-672-9100-siga-reports--siga-20060403monthly0.5https://www.biopharmawatch.com/news/SIGA/for-siga-technologies-inc-thomas-n-konatich-phone-212-672-9100-tkonatich-siga-com-for-phar-siga-20060314monthly0.5https://www.biopharmawatch.com/news/SIGA/dr-bernard-kasten-siga-technologies-inc-chief-executive-officer-212-672-9100-siga-reports--siga-20060203monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-logo-contact-dr-bernard-kasten-siga-technologies-inc-chief-executive-officer-212-672--siga-20051213monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-contact-dr-bernard-l-kasten-siga-technologies-inc-ceo-bkasten-siga-com-212-672-9100-s-siga-20051103monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-contact-dr-bernard-l-kasten-siga-technologies-inc-ceo-bkasten-siga-com-212-672-9100-s-siga-20051006monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-contact-dr-bernard-l-kasten-siga-technologies-inc-ceo-bkasten-siga-com-212-672-9100-s-siga-20050928monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-contact-investor-contact-dr-bernard-kasten-dianne-will-siga-technologies-inc-willstar-siga-20050215monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-contact-investor-contact-dr-bernard-kasten-dianne-will-siga-technologies-inc-willstar-siga-20041124monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-contact-investor-contact-dr-bernard-kasten-dianne-will-siga-technologies-inc-willstar-siga-20041115monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-contact-investor-contact-dr-bernard-kasten-dianne-will-siga-technologies-inc-willstar-siga-20041025monthly0.5https://www.biopharmawatch.com/news/SIGA/investor-contact-dr-bernard-kasten-dianne-will-siga-technologies-inc-willstar-consultants--siga-20041005monthly0.5https://www.biopharmawatch.com/news/SIGA/investor-contact-thomas-n-konatich-dianne-will-chief-financial-officer-willstar-consultant-siga-20040914monthly0.5https://www.biopharmawatch.com/news/SIGA/investor-contact-thomas-n-konatich-dianne-will-chief-financial-officer-willstar-consultant-siga-20040825monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-preliminary-fourth-quarter-2025-revenue-and-recent-business-highlights-pre-ivvd-20260108monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-earns-fast-track-designation-for-vyd2311-a-vaccine-alternative-antibody-to-prevent-ivvd-20251223monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-proposed-public-offering-of-common-stock-ivvd-20251117monthly0.5https://www.biopharmawatch.com/news/IVVD/life-can-only-be-understood-backwards-but-it-must-be-lived-forwards-kierkegaard-invivyd-1-ivvd-20251030monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-paul-b-bolno-ivvd-20250924monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-proposed-public-offering-of-common-stock-ivvd-20250820monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-second-quarter-2025-financial-results-and-recent-business-highlights-pemga-ivvd-20250814monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-and-leading-researchers-form-spear-s-pike-p-rotein-e-limination-a-nd-r-ecovery-stu-ivvd-20250702monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-positive-full-phase-1-2-clinical-data-for-vyd2311-a-next-generation-covi-ivvd-20250626monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-first-quarter-2025-financial-results-and-recent-business-highlights-pemgar-ivvd-20250515monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-new-pipeline-discovery-program-focused-on-monoclonal-antibody-treatment--ivvd-20250512monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-30m-non-dilutive-loan-facility-with-silicon-valley-bank-ivvd-20250421monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-ajay-royan-founder-of-mithril-capital-to-its-board-of-directors-ivvd-20250326monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-recent-bu-ivvd-20250320monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-continued-neutralizing-activity-of-pemgarda-pemivibart-against-currently-ivvd-20250305monthly0.5https://www.biopharmawatch.com/news/IVVD/fda-declined-invivyd-s-request-to-expand-existing-emergency-use-authorization-of-pemgarda--ivvd-20250224monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-preliminary-fourth-quarter-2024-financial-results-strong-revenue-growth--ivvd-20250203monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-provides-another-positive-sars-cov-2-variant-data-analysis-to-satisfy-u-s-fda-s-ga-ivvd-20250127monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-continued-neutralizing-activity-of-pemgarda-pemivibart-against-dominant--ivvd-20250110monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-third-quarter-2024-financial-results-and-recent-business-highlights-q3-202-ivvd-20241114monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-preliminary-third-quarter-2024-results-withdraws-prior-financial-guidance--ivvd-20241029monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-provides-detailed-virology-data-and-analysis-of-sars-cov-2-structural-biology-pred-ivvd-20240923monthly0.5https://www.biopharmawatch.com/news/IVVD/corporate-overview-september-2024-2024-invivyd-inc-invivy-pemgar-and-the-ribbon-logos-are--ivvd-20240906monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-doses-first-participants-in-phase-1-clinical-trial-of-vyd2311-a-next-generation-mo-ivvd-20240904monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-continued-neutralizing-activity-of-pemgarda-pemivibart-against-dominant--ivvd-20240903monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-pemgarda-pemivibart-demonstrated-84-relative-risk-reduction-in-symptomat-ivvd-20240827monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-second-quarter-2024-financial-results-and-recent-business-highlights-pemga-ivvd-20240814monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-antiviral-activity-of-vyd222-pemivibart-against-sars-cov-2-kp-1-1-flirt--ivvd-20240614monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-the-appointment-of-timothy-lee-as-chief-commercial-officer-mr-lee-joins--ivvd-20240531monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-elects-two-new-independent-members-to-its-board-of-directors-ivvd-20240522monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-first-quarter-2024-financial-results-and-recent-business-highlights-launch-ivvd-20240509monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-pursue-rapid-immunobridging-pathway-to-potential-eua-for-treatment-of-covid-19--ivvd-20240509monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-ceo-transition-jeremy-gowler-appointed-interim-ivvd-20240412monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-provides-pemgarda-tm-launch-update-and-announces-2024-net-product-revenue-guidance-ivvd-20240404monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-full-year-2023-financial-results-and-recent-business-highlights-received-e-ivvd-20240328monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-fda-authorization-for-emergency-use-of-pemgarda-formerly-vyd222-for-pre--ivvd-20240325monthly0.5https://www.biopharmawatch.com/news/IVVD/index-to-consoli-dated-financial-statements-page-report-of-independent-registered-public-a-ivvd-20240209monthly0.5https://www.biopharmawatch.com/news/IVVD/corporate-overview-ivvd-20240108monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-submits-request-for-emergency-use-authorization-eua-to-u-s-fda-for-vyd222-for-the--ivvd-20240103monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-positive-initial-results-from-ongoing-canopy-phase-3-pivotal-clinical-tr-ivvd-20231218monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-third-quarter-2023-financial-results-and-recent-business-highlights-enroll-ivvd-20231109monthly0.5https://www.biopharmawatch.com/news/IVVD/corporate-overview-september-2023-2023-invivyd-inc-invivyd-and-the-invivyd-logo-are-tradem-ivvd-20230911monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-second-quarter-2023-financial-results-and-business-highlights-reported-pos-ivvd-20230810monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-appointment-of-sara-cotter-to-board-of-directors-waltham-mass-july-27-20-ivvd-20230727monthly0.5https://www.biopharmawatch.com/news/IVVD/corporate-overview-june-2023-2023-invivyd-inc-invivyd-and-the-invivyd-logo-are-trademarks--ivvd-20230629monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-first-quarter-2023-financial-results-and-business-highlights-completed-dos-ivvd-20230511monthly0.5https://www.biopharmawatch.com/news/IVVD/corporate-overview-may-2023-cautionary-note-regarding-forward-looking-statements-this-pres-ivvd-20230502monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-full-year-2022-financial-results-and-business-highlights-advancing-vyd222--ivvd-20230323monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-optimizes-development-efficiency-with-election-of-vyd222-for-near-term-clinical-ad-ivvd-20230306monthly0.5https://www.biopharmawatch.com/news/IVVD/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-ivvd-20230109monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-jeremy-gowler-as-chief-operating-and-commercial-officer-promotes-pete-sch-ivvd-20221206monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-partnership-with-population-health-partners-to-accelerate-clinical-devel-ivvd-20221117monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-third-quarter-2022-financial-results-and-business-highlights-novel-monoclo-ivvd-20221110monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-the-appointment-of-christine-lindenboom-to-board-of-directors-waltham-ma-ivvd-20221024monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-fred-driscoll-as-interim-chief-financial-officer-and-announces-resource-r-ivvd-20221013monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-announces-corporate-name-change-to-invivyd-new-name-reflects-company-f-ivvd-20220912monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-reports-second-quarter-2022-financial-results-and-business-highlights--ivvd-20220815monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-announces-results-of-annual-meeting-of-stockholders-and-evolution-of-the-board-of-d-ivvd-20220701monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-reports-first-quarter-2022-financial-results-532-2-million-in-total-ca-ivvd-20220513monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-announces-adg20-adintrevimab-is-the-first-monoclonal-antibody-to-meet--ivvd-20220330monthly0.5https://www.biopharmawatch.com/news/IVVD/amended-and-restated-employment-agreement-this-amended-and-restated-employment-agreement-a-ivvd-20220321monthly0.5https://www.biopharmawatch.com/news/IVVD/confidential-not-for-release-adagio-therapeutics-announces-david-hering-appointed-interim--ivvd-20220223monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-announces-ceo-succession-plan-waltham-ma-ivvd-20220218monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-summarizes-adg20-neutralizing-activity-against-sars-cov-2-variants-and-ivvd-20220112monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-reports-reduction-in-in-vitro-neutralizing-activity-of-adg20-against-o-ivvd-20211214monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-reports-that-none-of-the-mutations-present-in-sars-cov-2-variant-omicr-ivvd-20211129monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-announces-expansion-of-management-team-and-board-of-directors-to-suppo-ivvd-20211122monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-provides-update-for-adg20-covid-19-antibody-program-and-reports-third--ivvd-20211115monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-announces-new-in-vitro-data-highlighting-broad-and-potent-neutralizati-ivvd-20211019monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-announces-new-data-highlighting-the-potential-of-adg20-for-treatment-a-ivvd-20210929monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-provides-covid-19-antibody-program-updates-as-well-as-business-highlig-ivvd-20210920monthly0.5https://www.biopharmawatch.com/news/IVVD/adagio-therapeutics-announces-expansion-of-patient-population-in-global-phase-2-3-clinical-ivvd-20210910monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-first-quarter-2026-results-raises-full-year-2026-total-revenues-medi-agl-20260506monthly0.5https://www.biopharmawatch.com/news/AGL/practice-his-commitment-to-supporting-the-people-who-deliver-care-every-day-gives-me-great-agl-20260427monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-announces-reverse-stock-split-agl-20260318monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-fourth-quarter-and-full-year-fiscal-2025-results-issues-2026-guidanc-agl-20260225monthly0.5https://www.biopharmawatch.com/news/AGL/document-agilon-announces-receipt-of-notice-of-non-compliance-with-the-nyse-continued-list-agl-20251107monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-third-quarter-2025-results-and-re-establishes-full-year-outlook-cont-agl-20251104monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-second-quarter-2025-results-total-revenues-of-1-4-billion-in-the-sec-agl-20250804monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-first-quarter-2025-results-total-revenues-of-1-53-billion-in-the-fir-agl-20250506monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-fourth-quarter-and-full-year-fiscal-2024-results-revenue-increased-4-agl-20250225monthly0.5https://www.biopharmawatch.com/news/AGL/investorpresen-agl-20241119monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-third-quarter-2024-results-revenue-increased-28-to-1-45-billion-medi-agl-20241107monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-second-quarter-2024-results-revenue-increased-39-to-1-5-billion-medi-agl-20240806monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-names-jeff-schwaneke-new-chief-financial-officer-austin-tx-agl-20240605monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-first-quarter-2024-results-revenue-increased-52-to-1-6-billion-medic-agl-20240507monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-fourth-quarter-2023-results-revenue-increased-72-to-1-06-billion-in--agl-20240227monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-announces-chief-medical-officer-transition-austin-t-x-agl-20240208monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-announces-tim-bensley-to-retire-as-cfo-austin-tx-january-5-2024-agilon-healt-agl-20240105monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-provides-2023-guidance-update-initial-2024-view-revised-2023-expectations-an-agl-20240105monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-third-quarter-2023-results-revenue-increased-75-to-1-22-billion-medi-agl-20231102monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-second-quarter-2023-results-revenue-increased-71-to-1-15-billion-med-agl-20230803monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-names-silvana-battaglia-to-board-of-directors-longtime-human-resources-execu-agl-20230626monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-first-quarter-2023-results-revenue-increased-74-to-1-14-billion-and--agl-20230509monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-fourth-quarter-and-fiscal-year-2022-results-revenue-increased-49-to--agl-20230301monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-third-quarter-2022-results-revenue-increased-52-to-695-million-medic-agl-20221103monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-second-quarter-2022-results-revenue-increased-45-and-medicare-advant-agl-20220804monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-first-quarter-2022-results-revenue-growth-of-58-driven-by-51-growth--agl-20220505monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-fourth-quarter-and-fiscal-year-2021-results-revenue-growth-of-44-for-agl-20220303monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-third-quarter-2021-results-revenue-growth-of-47-driven-by-43-growth--agl-20211028monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-second-quarter-2021-results-long-beach-calif-x2013-agl-20210804monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-names-karen-mcloughlin-to-its-board-of-directors-long-beach-calif-x2013-agl-20210712monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-reports-first-quarter-2021-results-agl-20210526monthly0.5https://www.biopharmawatch.com/news/AGL/agilon-health-announces-closing-of-initial-public-offering-and-full-exercise-of-underwrite-agl-20210419monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-full-year-2025-financial-results-and-corporate-updates-first-z-abeo-20260317monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-2025-financial-results-and-corporate-updates-re-abeo-20250814monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-closes-sale-of-rare-pediatric-disease-priority-review-voucher-for-155--abeo-20250630monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-2025-financial-results-and-corporate-updates-rec-abeo-20250515monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-enters-into-agreement-to-sell-priority-review-voucher-for-155-million--abeo-20250512monthly0.5https://www.biopharmawatch.com/news/ABEO/u-s-fda-approves-zevaskyn-prademagene-zamikeracel-the-first-and-only-cell-based-gene-thera-abeo-20250429monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-full-year-2024-financial-results-provides-pz-cel-regulatory-up-abeo-20250320monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-upda-abeo-20241114monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-pz-cel-for-the-treatme-abeo-20241112monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-completes-pz-cel-biologics-license-application-resubmission-to-u-s-foo-abeo-20241029monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-appointment-of-bernhardt-zeiher-md-fccp-facp-and-eric-crombe-abeo-20240814monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-2024-financial-results-and-concludes-type-a-mee-abeo-20240812monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-2024-financial-results-and-recent-corporate-prog-abeo-20240515monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-pricing-of-75-million-underwritten-offering-of-common-stock--abeo-20240503monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-provides-regulatory-update-on-pz-cel-receives-fda-complete-response-le-abeo-20240423monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-full-year-2023-financial-results-and-announces-completion-of-f-abeo-20240318monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-50-million-credit-facility-cleveland-abeo-20240108monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-fda-accepts-and-grants-priority-review-for-pz-cel-biologics--abeo-20231127monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-third-quarter-2023-financial-results-and-corporate-development-abeo-20231113monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-2023-financial-results-on-track-for-biologics-l-abeo-20230808monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-closing-of-25-million-registered-direct-offering-priced-at-t-abeo-20230707monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-25-million-registered-direct-offering-priced-at-the-market-u-abeo-20230703monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-2023-financial-results-continues-to-make-progres-abeo-20230511monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-full-year-2022-financial-results-and-provides-corporate-update-abeo-20230329monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-third-quarter-2022-financial-results-following-positive-toplin-abeo-20221114monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-35-million-private-placement-financing-new-york-and-clevelan-abeo-20221103monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-2022-financial-results-disposition-of-mps-progr-abeo-20220811monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-regains-compliance-with-nasdaq-listing-requirements-new-york-and-cleve-abeo-20220720monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-granted-second-180-day-period-by-nasdaq-to-regain-compliance-with-mini-abeo-20220519monthly0.5https://www.biopharmawatch.com/news/ABEO/ultragenyx-acquires-global-rights-to-aav-gene-therapy-abo-102-for-sanfilippo-syndrome-type-abeo-20220505monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-2022-financial-results-disposition-of-mps-progra-abeo-20220513monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-pricing-of-25-million-private-placement-of-convertible-redee-abeo-20220429monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-strategy-update-and-2021-financial-results-eb-101-pivotal-ph-abeo-20220331monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-warrants-new--abeo-20211217monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-public-offering-of-common-stock-and-warrants-new-york-and-cl-abeo-20211216monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-third-quarter-financial-results-phase-3-viital-study-on-track--abeo-20211117monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-new-chairman-executive-leadership-promotions-and-key-talent-additions-for-abeo-20210921monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-financial-results-second-clinical-trial-site-ac-abeo-20210729monthly0.5https://www.biopharmawatch.com/news/ABEO/event-type-q1-2021-earnings-call-date-2021-05-25-company-abeona-therapeutics-inc-ticker-ab-abeo-20210526monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-financial-results-patient-enrollment-ongoing-for-abeo-20210518monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-two-industry-leaders-as-new-independent-members-to-its-board--abeo-20210419monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-appointment-of-two-new-independent-members-to-its-board-of-d-abeo-20210325monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-2020-financial-results-and-recent-operational-progress-fourt-abeo-20210324monthly0.5https://www.biopharmawatch.com/news/ABEO/new-positive-phase-1-2-interim-data-presented-at-world-symposium-shows-neurocognitive-deve-abeo-20210212monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-successful-type-b-meeting-with-fda-for-pivotal-phase-3-viita-abeo-20210125monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-third-quarter-financial-results-conference-call-scheduled-for--abeo-20201110monthly0.5https://www.biopharmawatch.com/news/ABEO/e-xhibit-99-1-abeona-therapeutics-announces-the-appointment-of-michael-amoroso-as-chief-op-abeo-20201027monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-board-of-directors-forms-special-committee-to-oversee-operations-devel-abeo-20201006monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-leadership-and-board-transitions-new-york-and-cleveland-abeo-20200928monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-financial-results-and-business-updates-addition-abeo-20200811monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-further-strengthens-board-with-appointment-of-two-new-independent-dire-abeo-20200617monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-financial-results-and-business-updates-first-pat-abeo-20200507monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-brian-pereira-and-shawn-tomasello-to-the-board-of-directors-c-abeo-20200421monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-busine-abeo-20200316monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-european-medicines-agency-prime-designation-for-abo-102-gene--abeo-20191220monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-new-yo-abeo-20191220monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-public-offering-of-common-stock-and-pre-funded-warrants-new--abeo-20191219monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-cleared-to-initiate-pivotal-phase-3-clinical-trial-evaluating-eb-101-g-abeo-20191209monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-third-quarter-2019-financial-results-and-business-updates-subm-abeo-20191112monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-provides-regulatory-update-ahead-of-pivotal-phase-3-clinical-trial-for-abeo-20190923monthly0.5https://www.biopharmawatch.com/news/ABEO/confidential-abeona-therapeutics-announces-strategic-review-company-engages-jefferies-llc--abeo-20190903monthly0.5https://www.biopharmawatch.com/news/ABEO/monsie-living-with-rdeb-corporate-presentation-august-2019-safe-harbor-statement-this-pres-abeo-20190814monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-2019-financial-results-and-business-updates-fiv-abeo-20190809monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-positive-interim-data-from-the-abo-102-phase-1-2-gene-therap-abeo-20190725monthly0.5https://www.biopharmawatch.com/news/ABEO/forward-looking-statement-this-press-release-contains-certain-statements-that-are-forward--abeo-20190510monthly0.5https://www.biopharmawatch.com/news/ABEO/actual-results-may-differ-materially-from-those-indicated-by-such-forward-looking-statemen-abeo-20190318monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-jo-o-siffert-m-d-chief-executive-officer-former-avexis-direct-abeo-20190211monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-strengthens-financial-leadership-with-new-executive-appointments-inter-abeo-20190108monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-2018-r-d-day-monsie-living-with-rdeb-2018-r-d-day-abeo-20181206monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-ceo-transition-dr-carsten-thiel-to-depart-company-immediatel-abeo-20181126monthly0.5https://www.biopharmawatch.com/news/ABEO/regenxbio-and-abeona-therapeutics-announce-worldwide-exclusive-licenses-for-the-treatment--abeo-20181105monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-2018-financial-results-and-business-highlights--abeo-20180809monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-leadership-appointments-with-max-colao-as-chief-commercial-o-abeo-20180726monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-2018-financial-results-and-business-highlights-i-abeo-20180511monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-carsten-thiel-ph-d-as-chief-executive-officer-company-strengt-abeo-20180402monthly0.5https://www.biopharmawatch.com/news/ABEO/a-global-phase-1-2-clinical-trial-of-systemic-gene-transfer-of-scaav9-u1a-hsgsh-for-mps-ii-abeo-20180209monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-closing-of-92-million-underwritten-public-offering-and-full-exercise-of-u-abeo-20171019monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-pricing-of-public-offering-of-common-stock-new-york-and-clev-abeo-20171016monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-public-offering-of-common-stock-new-york-and-cleveland-abeo-20171016monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-13-85m-grant-from-leading-sanfilippo-syndrome-foundations-for-clinical-de-abeo-20171016monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-q4-2016-financial-results-and-business-highlights-management-t-abeo-20170331monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-dismissal-of-securities-class-action-lawsuit-securities-clas-abeo-20170223monthly0.5https://www.biopharmawatch.com/news/ABEO/nasdaq-abeo-www-abeonatherapeutics-com-safe-harbor-statement-this-presentation-contains-ce-abeo-20170217monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-third-quarter-2016-financial-results-and-recent-clinical-hig-abeo-20161110monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-inc-announces-closing-of-its-underwritten-offering-of-common-stock-new-abeo-20161101monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-pricing-of-public-offering-of-common-stock-new-york-ny-and-c-abeo-20161027monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-public-offering-of-common-stock-new-york-ny-and-cleveland-oh-abeo-20161026monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-fast-track-designation-from-fda-for-abo-102-in-sanfilippo-sy-abeo-20161025monthly0.5https://www.biopharmawatch.com/news/ABEO/therapeutics-provides-update-from-abo-102-phase-1-2-mps-iiia-clinical-trial-at-abeo-20161021monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-second-quarter-2016-financial-results-and-recent-clinical-hi-abeo-20160816monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-eb-research-partnership-and-eb-medical-research-foundation-to-collabor-abeo-20160809monthly0.5https://www.biopharmawatch.com/news/ABEO/nasdaq-abeo-www-abeonatherapeutics-com-1-safe-harbor-statement-this-presentation-contains--abeo-20151201monthly0.5https://www.biopharmawatch.com/news/ABEO/announces-closing-of-upsized-15-5-million-equity-financing-with-institutional-investors-an-abeo-20150803monthly0.5https://www.biopharmawatch.com/news/ABEO/plasmatech-biopharmaceuticals-announces-name-change-to-abeona-therapeutics-to-reflect-broa-abeo-20150622monthly0.5https://www.biopharmawatch.com/news/ABEO/plasmatech-biopharmaceuticals-closes-abeona-therapeutics-acquisition-two-phase-1-2-clinica-abeo-20150518monthly0.5https://www.biopharmawatch.com/news/ABEO/plasmatech-biopharmaceuticals-closes-10-million-financing-proceeds-to-support-clinical-dev-abeo-20150511monthly0.5https://www.biopharmawatch.com/news/ABEO/nasdaq-ptbi-investor-presentation-this-presentation-contains-certain-statements-that-may-b-abeo-20150507monthly0.5https://www.biopharmawatch.com/news/ABEO/plasmatech-biopharmaceuticals-announces-agreement-to-acquire-abeona-therapeutics-llc-compa-abeo-20150506monthly0.5https://www.biopharmawatch.com/news/ABEO/plasmatech-news-plasmatech-biopharmaceuticals-announces-closing-of-upsized-7-million-priva-abeo-20150424monthly0.5https://www.biopharmawatch.com/news/ABEO/plasmatech-biopharmaceuticals-inc-logo-plasmatech-news-plasmatech-biopharmaceuticals-annou-abeo-20150402monthly0.5https://www.biopharmawatch.com/news/ABEO/company-overview-q1-2015-this-presentation-contains-certain-statements-that-may-be-forward-abeo-20150209monthly0.5https://www.biopharmawatch.com/news/ABEO/investor-presentation-january-2015-this-presentation-contains-certain-statements-that-may--abeo-20150106monthly0.5https://www.biopharmawatch.com/news/ABEO/entitled-plasma-tech-announces-closing-of-public-offering-unassociated-document-plasmatech-abeo-20141224monthly0.5https://www.biopharmawatch.com/news/ABEO/plasmatech-news-company-and-media-contact-harrison-wehner-president-cfo-plasmatech-biophar-abeo-20141218monthly0.5https://www.biopharmawatch.com/news/ABEO/investor-presentation-december-2014-this-presentation-contains-certain-statements-that-may-abeo-20141205monthly0.5https://www.biopharmawatch.com/news/ABEO/plasmatech-news-company-and-media-contact-christine-berni-vice-president-corporate-develop-abeo-20141024monthly0.5https://www.biopharmawatch.com/news/ABEO/investor-presentation-october-november-2014-10-24-14-final-version-this-presentation-conta-abeo-20141024monthly0.5https://www.biopharmawatch.com/news/ABEO/access-pharmaceuticals-announces-exclusive-global-plasma-therapeutics-license-new-manageme-abeo-20140922monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights-recent--rckt-20251106monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-fda-acceptance-of-bla-resubmission-of-kresladi-for-the-tr-rckt-20251014monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-fda-has-lifted-the-clinical-hold-on-the-pivotal-phase-2-t-rckt-20250820monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights-recent-rckt-20250807monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-strategic-corporate-reorganization-and-pipeline-prioritiz-rckt-20250724monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-rmat-designatio-rckt-20250717monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-provides-update-on-phase-2-clinical-trial-of-rp-a501-for-danon-dise-rckt-20250527monthly0.5https://www.biopharmawatch.com/news/RCKT/nvestor-de-i-ck-investor-deck-investor-deck-preliminary-data-from-phase-1-trial-of-rp-a601-rckt-20250515monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2025-financial-results-and-highlights-recent--rckt-20250508monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-hig-rckt-20250227monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-third-quarter-2024-financial-results-and-highlights-recent--rckt-20241107monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-second-quarter-2024-financial-results-and-highlights-recent-rckt-20240805monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-provides-regulatory-update-on-kresladi-tm-marnetegragene-autotemcel-rckt-20240628monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2024-financial-results-and-highlights-recent--rckt-20240506monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-appointment-of-aaron-ondrey-as-chief-financial-officer-an-rckt-20240326monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-hig-rckt-20240226monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-update-on-fda-review-timeline-of-kresladi-tm-marnetegrage-rckt-20240213monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-with-prio-rckt-20231002monthly0.5https://www.biopharmawatch.com/news/RCKT/s-e-e-k-i-n-g-g-e-n-e-t-h-e-r-a-p-y-c-u-r-e-s-rocket-pharmaceuticals-danon-disease-program-rckt-20230911monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-and-operational-rckt-20230227monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-rmat-designatio-rckt-20230207monthly0.5https://www.biopharmawatch.com/news/RCKT/investor-deck-investor-deck-investor-deck-41st-annual-j-p-morgan-healthcare-conference-com-rckt-20230109monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-provides-update-on-anticipated-registration-path-for-rp-a501-in-dan-rckt-20221222monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-completes-acquisition-of-renovacor-acquisition-further-extends-rock-rckt-20221201monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-third-quarter-2022-financial-results-and-highlights-recent--rckt-20221103monthly0.5https://www.biopharmawatch.com/news/RCKT/update-from-phase-1-trial-of-rp-a501-gene-therapy-treatment-for-danon-disease-rckt-20220930monthly0.5https://www.biopharmawatch.com/news/RCKT/execution-version-voting-agreement-this-voting-agreement-this-agreement-is-made-and-entere-rckt-20220920monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-second-quarter-2022-financial-results-and-highlights-recent-rckt-20220808monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-and-operational-rckt-20220224monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-third-quarter-2021-financial-results-and-highlights-recent--rckt-20211103monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-26-4-million-private-placement-cranbury-n-j-rckt-20210830monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-second-quarter-2021-financial-results-and-highlights-recent-rckt-20210809monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2021-financial-results-and-highlights-recent--rckt-20210510monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-private-exchange-transaction-regarding-its-outstanding-co-rckt-20200608monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-announces-private-exchange-transactions-regarding-outstanding-conve-rckt-20200211monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-and-regenxbio-announce-new-license-agreement-for-the-treatment-of-d-rckt-20181126monthly0.5https://www.biopharmawatch.com/news/RCKT/american-society-of-gene-cell-therapy-rckt-20180518monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-full-year-2017-financial-results-and-operational-highlights-rckt-20180306monthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-and-inotek-pharmaceuticals-complete-merger-transaction-strong-suppo-rckt-20180105monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-announces-filing-of-preliminary-proxy-statement-for-proposed-merger-rckt-20171012monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-announces-merger-agreement-with-rocket-pharmaceuticals-to-advance-p-rckt-20170912monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-second-quarter-2017-financial-results-and-opera-rckt-20170803monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-announces-top-line-results-of-phase-2-fixed-dose-combination-trial--rckt-20170710monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-first-quarter-2017-financial-results-and-operat-rckt-20170510monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-completes-patient-recruitment-in-phase-2-trial-of-a-fixed-dose-combination-fdc-of-t-rckt-20170411monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-fiscal-year-2016-financial-results-and-operatio-rckt-20170316monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-announces-top-line-results-for-matrx-1-first-phase-3-trial-of-trabodenoson-for-glau-rckt-20170103monthly0.5https://www.biopharmawatch.com/news/RCKT/november-2016-corporate-presentation-forward-looking-statements-this-presentation-contains-rckt-20161129monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-third-quarter-2016-financial-results-and-operat-rckt-20161109monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-appoints-timothy-barberich-to-board-of-directors-lexington-ma-rckt-20160929monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-announces-the-completion-of-the-recruitment-phase-of-matrx-1-the-fi-rckt-20160824monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-appoints-patrick-machado-jd-to-board-of-directors-lexington-ma-rckt-20160818monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-second-quarter-2016-financial-results-and-opera-rckt-20160810monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-announces-proposed-public-offering-of-50-million-of-convertible-sen-rckt-20160801monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-expands-intellectual-property-portfolio-with-combination-patent-cov-rckt-20160722monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-initiates-phase-2-dose-ranging-trial-of-a-fixed-dose-combination-of-rckt-20160712monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-first-quarter-2016-financial-results-and-operat-rckt-20160511monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-announces-changes-to-board-of-directors-pharmaceutical-industry-lea-rckt-20160404monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-fiscal-year-2015-financial-results-and-operatio-rckt-20160323monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-strengthens-patent-estate-for-lead-product-candidate-trabodenoson-rckt-20160309monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-appoints-carsten-boess-to-board-of-directors-lexington-mass-busines-rckt-20160112monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-third-quarter-2015-financial-results-and-operat-rckt-20151112monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-initiates-dosing-of-mat-rx-1-the-first-pivotal-phase-3-clinical-tri-rckt-20151016monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-appoints-gary-m-phillips-md-mba-to-board-of-directors-pharmaceutica-rckt-20151013monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-announces-closing-of-79-2-million-public-offering-inclu-rckt-20150818monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-announces-pricing-of-68-9-million-public-offering-lexin-rckt-20150812monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-corporation-reports-second-quarter-2015-financial-results-and-opera-rckt-20150806monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-announces-positive-end-of-phase-2-meeting-with-fda-and-phase-3-deve-rckt-20150723monthly0.5https://www.biopharmawatch.com/news/RCKT/inotek-pharmaceuticals-appoints-richard-n-spivey-pharmd-ph-d-to-board-of-directors-global--rckt-20150721monthly0.5https://www.biopharmawatch.com/news/RCKT/chris-erdman-781-235-3060-chris-macbiocom-com-company-contact-david-p-southwell-ceo-781-67-rckt-20150515monthly0.5https://www.biopharmawatch.com/news/RCKT/chris-erdman-781-235-3060-chris-macbiocom-com-company-contact-david-p-southwell-ceo-781-67-rckt-20150401monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-second-quarter-2025-financial-results-and-provides-business-update-daniel-srzn-20250808monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-first-quarter-2025-financial-results-and-provides-business-update-srzn-20250509monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-fourth-quarter-and-full-year-2024-financial-results-and-business-updates-srzn-20250331monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-an-oversubscribed-175-million-private-placement-of-securities-to-focus--srzn-20250324monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-third-quarter-2024-financial-results-and-business-update-substantial-enr-srzn-20241106monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-second-quarter-2024-financial-results-and-business-update-enrollment-ong-srzn-20240812monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-first-quarter-2024-financial-results-and-business-update-szn-043-phase-1-srzn-20240508monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-safety-pharmacodynamic-and-liver-function-data-for-szn-043-phase-1a-tri-srzn-20240401monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-third-quarter-2023-financial-results-expect-to-announce-data-from-szn-04-srzn-20231108monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-second-quarter-2023-financial-results-szn-043-phase-1a-clinical-trial-in-srzn-20230809monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-first-quarter-2023-financial-results-and-corporate-and-pipeline-updates--srzn-20230510monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-fourth-quarter-and-full-year-2022-financial-results-and-update-on-clinic-srzn-20230322monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-third-quarter-2022-financial-results-and-provides-corporate-update-srzn-20221114monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-second-quarter-2022-financial-results-x2022-phase-1-clinical-trials-of-sz-srzn-20220811monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-first-quarter-2022-financial-results-on-track-to-initiate-phase-1-clinica-srzn-20220511monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-fourth-quarter-and-full-year-2021-financial-results-on-track-to-initiate--srzn-20220324monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-third-quarter-2021-financial-results-product-candidates-szn-1326-and-szn--srzn-20211115monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-operating-inc-index-to-unaudited-condensed-interim-financial-statements-page-unau-srzn-20210817monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-debuts-as-publicly-traded-leader-in-wnt-biology-and-tissue-regeneration-srzn-20210811monthly0.5https://www.biopharmawatch.com/news/SRZN/new-surrozen-to-trade-on-nasdaq-as-srzn-20210730monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-and-consonance-hfw-acquisition-corp-announce-business-combination-creating-public-srzn-20210415monthly0.5https://www.biopharmawatch.com/news/SRZN/consonance-hfw-acquisition-corp-securities-to-commence-separate-trading-princeton-nj-srzn-20210107monthly0.5https://www.biopharmawatch.com/news/SRZN/index-to-financial-statement-audited-financial-statement-for-consonance-hfw-acquisition-co-srzn-20201123monthly0.5https://www.biopharmawatch.com/news/SRZN/consonance-hfw-acquisition-corp-announces-pricing-of-its-initial-public-offering-srzn-20201118monthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-reports-fourth-quarter-and-full-year-2025-financial-results-fourth-qu-si-20260310monthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-announces-strategic-partnership-with-ins-to-introduce-a-robotic-platf-si-20251203monthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-reports-third-quarter-2025-financial-results-and-increases-full-year--si-20251111monthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-reports-second-quarter-2025-financial-results-company-to-participate--si-20250909monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-inc-condensed-consolidated-st-ateme-nts-of-cash-flows-unaudited-in-thousands--pali-20260512monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-exercise-of-previously-issued-warrants-for-3-9-million-carlsbad-ca-pali-20250723monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-emil-chuang-mb-bs-fracp-to-its-board-of-directors-veteran-clinical-l-pali-20250709monthly0.5https://www.biopharmawatch.com/news/PALI/confidential-draft-not-for-immediate-release-palisade-bio-announces-pricing-of-5-million-u-pali-20241212monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-margery-fischbein-to-its-board-of-directors-wall-street-and-biotech--pali-20240507monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-4-million-private-placement-priced-at-the-market-under-nasdaq-rules-pali-20240502monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-development-overview-of-pali-2108-at-the-ibd-innovate-product-develo-pali-20240410monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-1-for-15-reverse-stock-split-carlsbad-ca-pali-20240403monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-year-end-2023-financial-results-and-provides-corporate-update-rapid-a-pali-20240327monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-provides-corporate-update-and-reiterates-guidance-company-announces-strategic-pali-20240213monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-exercise-of-previously-issued-warrants-for-2-5-million-carlsbad-ca-pali-20240130monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-positive-preclinical-data-of-lead-program-pali-2108-at-the-2024-cro-pali-20240129monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-gi-clinical-expert-and-biotech-entrepreneur-mitchell-jones-m-d-ph-d--pali-20230911monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-2-million-registered-direct-offering-of-common-stock-priced-at-mark-pali-20230907monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-transforms-gi-focused-pipeline-through-exclusive-worldwide-licensing-agreemen-pali-20230906monthly0.5https://www.biopharmawatch.com/news/PALI/bio-announces-6-million-registered-direct-offering-and-concurrent-private-placement-priced-pali-20230405monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-promotes-robert-mcrae-to-chief-operating-officer-mr-mcrae-is-an-industry-vete-pali-20230208monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-2-5-million-registered-direct-offering-and-concurrent-private-place-pali-20221230monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-provides-update-on-u-s-phase-2-study-evaluating-lb1148-for-post-surgical-abdo-pali-20221216monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-herbert-b-slade-md-faaaai-as-chief-medical-officer-established-acade-pali-20221118monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-reverse-stock-split-carlsbad-ca-pali-20221115monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-executive-leadership-transition-board-appoints-jd-finley-to-interim-pali-20221011monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-streamlines-operations-and-identifies-capital-efficiencies-to-focus-all-resou-pali-20220915monthly0.5https://www.biopharmawatch.com/news/PALI/forward-looking-statements-this-communication-contains-x201c-forward-looking-x201d-stateme-pali-20220816monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-2-0-million-registered-direct-offering-carlsbad-c-a-pali-20220506monthly0.5https://www.biopharmawatch.com/news/PALI/restoring-intestinal-barrier-health-corporate-presentation-may-2022-pali-nasdaq-palisadebi-pali-20220503monthly0.5https://www.biopharmawatch.com/news/PALI/restoring-intestinal-barrier-health-sages-2022-presentation-pali-20220316monthly0.5https://www.biopharmawatch.com/news/PALI/restoring-intestinal-barrier-health-corporate-presentation-february-2022-pali-nasdaq-palis-pali-20220224monthly0.5https://www.biopharmawatch.com/news/PALI/restoring-intestinal-barrier-health-corporate-presentation-january-2022-pali-nasdaq-palisa-pali-20220111monthly0.5https://www.biopharmawatch.com/news/PALI/restoring-intestinal-barrier-health-corporate-presentation-october-2021-pali-nasdaq-palisa-pali-20211028monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-inc-announces-sale-of-seneca-asset-nsi-189-for-the-treatment-of-central-nervo-pali-20211022monthly0.5https://www.biopharmawatch.com/news/PALI/restoring-intestinal-barrier-health-corporate-presentation-september-2021-pali-nasdaq-pali-pali-20210913monthly0.5https://www.biopharmawatch.com/news/PALI/restoring-intestinal-barrier-health-corporate-presentation-may-2021-pali-nasdaq-palisadebi-pali-20210601monthly0.5https://www.biopharmawatch.com/news/PALI/restoring-intestinal-barrier-health-corporate-presentation-april-2021-pali-nasdaq-palisade-pali-20210428monthly0.5https://www.biopharmawatch.com/news/PALI/nsi-566-stem-cell-programs-partnering-brief-pali-20200224monthly0.5https://www.biopharmawatch.com/news/PALI/seneca-biopharma-nasdaq-snca-partnering-opportunities-for-cns-diseases-pali-20200116monthly0.5https://www.biopharmawatch.com/news/PALI/seneca-biopharma-nasdaq-snca-nasdaq-listed-company-dedicated-to-developing-reduced-risk-in-pali-20191104monthly0.5https://www.biopharmawatch.com/news/PALI/exif-mm-i-1-2-i-adobe-photoshop-elements-11-0-windo-pali-20180705monthly0.5https://www.biopharmawatch.com/news/PALI/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2018-06-07-17-45-05-pali-20180608monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-com-corporate-overview-march-2018-1-pali-20180316monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-com-treatment-of-als-with-neural-stem-cells-cell-gene-therapy-world-1-karl-johe-pali-20180124monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-com-neuroscience-innovation-forum-january-7-2018-1-pali-20180109monthly0.5https://www.biopharmawatch.com/news/PALI/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2017-05-30-16-54-26-pali-20170531monthly0.5https://www.biopharmawatch.com/news/PALI/safe-harbor-statement-although-we-believe-that-we-have-a-reasonable-basis-for-each-forward-pali-20170419monthly0.5https://www.biopharmawatch.com/news/PALI/february-2017-corporate-clinical-overview-pali-20170227monthly0.5https://www.biopharmawatch.com/news/PALI/jfif-h-h-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2016-11-07-18-33-04-pali-20161108monthly0.5https://www.biopharmawatch.com/news/PALI/jfif-gexif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2016-06-23-13-24-56-pali-20160623monthly0.5https://www.biopharmawatch.com/news/PALI/exif-mm-1-2-i-adobe-photoshop-elements-11-0-windo-pali-20160610monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-announces-plan-of-reorganization-to-further-align-business-with-strategic-inten-pali-20160520monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-to-raise-1-08-million-pali-20160513monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-reports-fiscal-first-quarter-2016-results-and-business-update-germantown-md-pali-20160509monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-announces-proposed-public-offering-of-securities-germantown-md-pali-20160502monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-receives-nasdaq-notice-of-bid-price-deficiency-germantown-md-pali-20160421monthly0.5https://www.biopharmawatch.com/news/PALI/april-2016-corporate-presentation-neuralstem-inc-safe-harbor-statement-safe-harbor-stateme-pali-20160413monthly0.5https://www.biopharmawatch.com/news/PALI/march-15-2016-28-th-annual-roth-conference-pali-20160316monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-reports-fourth-quarter-and-year-end-2015-fiscal-results-and-business-update-fda-pali-20160314monthly0.5https://www.biopharmawatch.com/news/PALI/march-2016-corporate-presentation-neuralstem-inc-safe-harbor-statement-safe-harbor-stateme-pali-20160304monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-appoints-richard-daly-as-president-and-chief-executive-officer-germantown-md-pali-20160216monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-presented-cell-therapy-update-pali-20160127monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-s-preclinical-alzheimer-s-pali-20160111monthly0.5https://www.biopharmawatch.com/news/PALI/data-for-neuralstem-s-novel-nsi-189-molecule-in-major-depressive-disorder-published-in-mol-pali-20151208monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-reports-third-quarter-2015-financial-results-adds-depth-to-management-team-with-pali-20151109monthly0.5https://www.biopharmawatch.com/news/PALI/investigator-provides-phase-ii-update-on-als-cell-therapy-at-american-neurological-associa-pali-20150929monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-reports-second-quarter-2015-financial-results-germantown-md-pali-20150810monthly0.5https://www.biopharmawatch.com/news/PALI/us-district-court-rules-in-favor-of-neuralstem-pali-20150723monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-inc-announces-approval-for-listing-on-the-nasdaq-capital-market-germantown-md-pali-20150629monthly0.5https://www.biopharmawatch.com/news/PALI/preclinical-data-on-neuralstem-s-genetically-modified-hk532-igf-1-stem-cells-in-alzheimer--pali-20150626monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-pali-20150506monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-reports-first-quarter-2015-financial-results-and-provides-business-and-clinical-pali-20150508monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-reports-fiscal-2014-fourth-quarter-financial-and-year-end-pali-20150316monthly0.5https://www.biopharmawatch.com/news/PALI/barclay-s-global-healthcare-conference-pali-20150312monthly0.5https://www.biopharmawatch.com/news/PALI/the-17-th-annual-bio-ceo-investor-conference-pali-20150209monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-nsi-189-phase-ib-major-depression-disorder-neurogenic-biomarker-data-presented--pali-20141117monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-announces-publication-of-long-term-cell-survival-from-phase-i-nsi-566-als-study-pali-20141110monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-pali-20141107monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20141023monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20141009monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140922monthly0.5https://www.biopharmawatch.com/news/PALI/neural-stem-cell-technology-platform-cell-therapy-and-pharmaceuticals-september-2014-nyse--pali-20140911monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140808monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140804monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140618monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140523monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140508monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140512monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140416monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140328monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140317monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140310monthly0.5https://www.biopharmawatch.com/news/PALI/slide-presentation-pali-20140211monthly0.5https://www.biopharmawatch.com/news/PALI/planet-communications-media-relations-deanne-eagle-917-837-5866-mdc-group-investor-relatio-pali-20140114monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-747-222-7012-pali-20140113monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-mdc-group-investor-relations-susan-roush-747-222-pali-20140109monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-to-raise-19-65-pali-20140106monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20131112monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-747-222-7012-univ-pali-20131009monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130905monthly0.5https://www.biopharmawatch.com/news/PALI/slide-presentation-world-leader-in-neural-stem-cell-science-corporate-overview-september-2-pali-20130910monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20130809monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130801monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130528monthly0.5https://www.biopharmawatch.com/news/PALI/world-leader-in-neural-stem-cell-science-corporate-overview-may-2013-safe-harbor-statement-pali-20130523monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20130510monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130508monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130424monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130417monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20130405monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-secures-8-million-in-debt-pali-20130327monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130315monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130220monthly0.5https://www.biopharmawatch.com/news/PALI/world-leader-in-neural-stem-cell-science-corporate-overview-february-2013-safe-harbor-stat-pali-20130215monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20130114monthly0.5https://www.biopharmawatch.com/news/PALI/neural-stem-cell-technology-platform-cell-therapy-and-pharmaceuticals-january-2013-nyse-mk-pali-20130109monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20121109monthly0.5https://www.biopharmawatch.com/news/PALI/exhbit-99-01-contact-deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relati-pali-20121017monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20120927monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20120913monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20120906monthly0.5https://www.biopharmawatch.com/news/PALI/dated-august-14-2012-contact-deanne-eagle-media-relations-917-837-5866-susan-roush-investo-pali-20120814monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20120810monthly0.5https://www.biopharmawatch.com/news/PALI/neural-stem-cell-technology-platform-cell-therapy-and-pharmaceuticals-august-2012-nyse-mkt-pali-20120803monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20120725monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-firs-pali-20120625monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20120619monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20120605monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20120509monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20120329monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-four-pali-20120307monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20120206monthly0.5https://www.biopharmawatch.com/news/PALI/neural-stem-cell-technology-platform-for-cell-therapeutics-and-pharmaceuticals-nyse-amex-c-pali-20120112monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-neur-pali-20111227monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20111109monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20111024monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20111012monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20111004monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-dr-e-pali-20110927monthly0.5https://www.biopharmawatch.com/news/PALI/neural-stem-cell-technology-platform-cell-therapy-and-pharmaceuticals-nyse-amex-cur-2-neur-pali-20110913monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20110810monthly0.5https://www.biopharmawatch.com/news/PALI/neuralstem-awarded-department-of-defense-contract-for-brain-cancer-research-rockville-md-pali-20110803monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20110721monthly0.5https://www.biopharmawatch.com/news/PALI/deanne-eagle-media-relations-917-837-5866-susan-roush-investor-relations-818-222-8330-pali-20110714monthly0.5https://www.biopharmawatch.com/news/PALI/meg-mcelroy-shareholder-relations-301-366-4960-deanne-eagle-media-relations-917-837-5866-s-pali-20110620monthly0.5https://www.biopharmawatch.com/news/PALI/meg-mcelroy-shareholder-relations-301-366-4960-deanne-eagle-media-relations-917-837-5866-s-pali-20110614monthly0.5https://www.biopharmawatch.com/news/PALI/meg-mcelroy-shareholder-relations-301-366-4960-deanne-eagle-media-relations-917-837-5866-s-pali-20110607monthly0.5https://www.biopharmawatch.com/news/PALI/meg-mcelroy-shareholder-relations-301-366-4960-deanne-eagle-media-relations-917-837-5866-s-pali-20110510monthly0.5https://www.biopharmawatch.com/news/ELMD/dated-march-10-2025-for-immediate-release-electromed-inc-announces-share-repurchase-author-elmd-20250310monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-record-financial-performance-in-fiscal-2025-second-quarter-compan-elmd-20250211monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2025-first-quarter-financial-results-electromed-delivers-e-elmd-20241112monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-share-repurchase-authorization-new-prague-minn-business-wire-elec-elmd-20240911monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-record-fiscal-year-2024-financial-results-record-q4-and-full-year-elmd-20240827monthly0.5https://www.biopharmawatch.com/news/ELMD/investor-presentation-electromed-inc-investor-presentation-august-2024-nyse-american-elmd--elmd-20240807monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-record-revenue-in-fiscal-2024-third-quarter-growth-initiatives-dr-elmd-20240507monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-record-financial-performance-in-fiscal-2024-second-quarter-growth-elmd-20240213monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2024-first-quarter-financial-results-new-prague-minn-busin-elmd-20231107monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2023-fourth-quarter-and-full-year-financial-results-record-elmd-20230822monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-names-jim-cunniff-as-president-and-chief-executive-officer-healthcare-executive-elmd-20230605monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2023-third-quarter-results-quarterly-net-revenue-increase--elmd-20230509monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2023-second-quarter-results-growth-initiatives-help-drive--elmd-20230214monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2023-first-quarter-results-continued-momentum-on-key-growt-elmd-20221108monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-appoints-brad-nagel-as-chief-financial-officer-accomplished-medical-device--elmd-20221024monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2022-fourth-quarter-and-full-year-financial-results-record-elmd-20220823monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-election-of-andrew-summers-as-additional-independent-director-ele-elmd-20220725monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-third-quarter-financial-results-15-4-revenue-growth-while-continu-elmd-20220510monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-second-quarter-financial-results-record-quarterly-net-revenues-of-elmd-20220208monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2022-first-quarter-financial-results-record-quarterly-reve-elmd-20211109monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-nominations-of-kathy-tune-and-joe-galatowitsch-as-new-independent-elmd-20210927monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2021-fourth-quarter-and-full-year-financial-results-double-elmd-20210824monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-authorization-of-3-0-million-stock-repurchase-program-new-prague--elmd-20210527monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2021-third-quarter-financial-results-second-consecutive-qu-elmd-20210511monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2021-second-quarter-financial-results-11-1-net-revenue-gro-elmd-20210209monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2021-first-quarter-financial-results-16-4-sequential-reven-elmd-20201110monthly0.5https://www.biopharmawatch.com/news/ELMD/ceo-letter-to-shareholders-making-life-s-important-moments-possible-one-breath-at-a-time-t-elmd-20200929monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2020-fourth-quarter-and-full-year-financial-results-record-elmd-20200825monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-appoints-michael-j-maccourt-as-chief-financial-officer-new-prague-minnesota-elmd-20200518monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2020-third-quarter-financial-results-18-0-revenue-growth-f-elmd-20200512monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-cfo-transition-new-prague-minnesota-elmd-20200304monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2020-second-quarter-financial-results-net-income-of-1-2-mi-elmd-20200211monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2020-first-quarter-financial-results-net-income-of-1-0-mil-elmd-20191112monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2019-fourth-quarter-and-full-year-financial-results-fourth-elmd-20190827monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-names-john-erb-and-greg-fluet-to-its-board-of-directors-new-prague-minnesot-elmd-20190815monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2019-third-quarter-financial-results-new-prague-minnesota-elmd-20190507monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2019-second-quarter-financial-results-15-1-year-over-year--elmd-20190212monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2019-first-quarter-financial-results-15-4-year-over-year-i-elmd-20181113monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2018-fourth-quarter-financial-results-14-8-year-over-year--elmd-20180925monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2018-third-quarter-financial-results-new-prague-minnesota-elmd-20180508monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2018-second-quarter-financial-results-18-2-year-over-year--elmd-20180213monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2018-first-quarter-financial-results-16-5-year-over-year-i-elmd-20171107monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2017-fourth-quarter-financial-results-29-5-year-over-year--elmd-20170905monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2017-third-quarter-financial-results-13-5-year-over-year-i-elmd-20170515monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2017-second-quarter-financial-results-reports-record-reven-elmd-20170207monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-fiscal-2017-first-quarter-financial-results-boosts-r-d-investment-elmd-20161108monthly0.5https://www.biopharmawatch.com/news/ELMD/jeremy-brock-chief-financial-officer-electromed-inc-952-758-9299-investorrelations-electro-elmd-20160906monthly0.5https://www.biopharmawatch.com/news/ELMD/jeremy-brock-chief-financial-officer-electromed-inc-952-758-9299-investorrelations-electro-elmd-20160510monthly0.5https://www.biopharmawatch.com/news/ELMD/jeremy-brock-chief-financial-officer-electromed-inc-952-758-9299-investorrelations-electro-elmd-20160209monthly0.5https://www.biopharmawatch.com/news/ELMD/jeremy-brock-chief-financial-officer-electromed-inc-952-758-9299-investorrelations-electro-elmd-20151110monthly0.5https://www.biopharmawatch.com/news/ELMD/jeremy-brock-chief-financial-officer-electromed-inc-952-758-9299-investorrelations-electro-elmd-20150915monthly0.5https://www.biopharmawatch.com/news/ELMD/jeremy-brock-chief-financial-officer-electromed-inc-952-758-9299-investorrelations-electro-elmd-20150512monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20150210monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20141112monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20140923monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-kskarvan-electromed-com-952-758-9299-electromed-i-elmd-20140902monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-kskarvan-electromed-com-952-758-9299-electromed-i-elmd-20140522monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20140513monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20140211monthly0.5https://www.biopharmawatch.com/news/ELMD/kelly-lunder-manager-of-marketing-communications-klunder-electromed-com-952-758-0382-elect-elmd-20131230monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20131112monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20130925monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20130514monthly0.5https://www.biopharmawatch.com/news/ELMD/kathleen-skarvan-chief-executive-officer-electromed-inc-952-758-9299-kskarvan-electromed-c-elmd-20130213monthly0.5https://www.biopharmawatch.com/news/ELMD/stephen-h-craney-chairman-of-the-board-electromed-inc-507-452-5109-x-216-scraney-rellew-co-elmd-20121129monthly0.5https://www.biopharmawatch.com/news/ELMD/james-j-cassidy-ph-d-interim-chief-executive-officer-electromed-inc-952-758-9299-jcassidy--elmd-20121113monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-letterhead-elmd-20121105monthly0.5https://www.biopharmawatch.com/news/ELMD/james-j-cassidy-ph-d-interim-chief-executive-officer-electromed-inc-952-758-0376-jcassidy--elmd-20120924monthly0.5https://www.biopharmawatch.com/news/ELMD/james-j-cassidy-ph-d-interim-chief-executive-officer-electromed-inc-952-758-9299-jcassidy--elmd-20120514monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20120213monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20120117monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20111108monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20111019monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20110922monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20110912monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20110810monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20110726monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20110602monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20110512monthly0.5https://www.biopharmawatch.com/news/ELMD/robert-d-hansen-chairman-and-chief-executive-officer-electromed-inc-952-758-9299-bhansen-e-elmd-20110210monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-creating-superior-care-through-innovation-for-immediate-release-contact-rob-elmd-20101115monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-creating-superior-care-through-innovation-for-immediate-release-contacts-ro-elmd-20100929monthly0.5https://www.biopharmawatch.com/news/ELMD/electromed-inc-announces-pricing-of-initial-public-offering-new-prague-minnesota-elmd-20100813monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-upd-tenx-20260512monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-appoints-thomas-r-staab-ii-as-chief-financial-officer-mr-staab-has-over-tenx-20260422monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provide-tenx-20260310monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-upd-tenx-20251113monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-european-patent-office-intention-to-grant-patent-covering-use-tenx-20250916monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-up-tenx-20250813monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-upd-tenx-20250514monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-tenx-20250325monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-25-million-private-placement-tenx-20250305monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-second-quarter-2024-financial-results-and-provides-a-corporate--tenx-20240813monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-first-quarter-2024-financial-results-and-provides-a-corporate-u-tenx-20240514monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-provides-business-and-clinical-development-updates-with-full-year-2023--tenx-20240328monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-global-license-amendment-that-significantly-expands-rights-to-tenx-20240220monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-pricing-of-approximately-9-million-public-offering-tenx-20240208monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-enrolls-first-patient-in-phase-3-level-study-evaluating-tnx-103-oral-le-tenx-20240207monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-uspto-grants-notice-of-allowance-for-u-s-patent-application-s-tenx-20240206monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-reverse-stock-split-tenx-20231229monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-fda-clearance-of-ind-for-tnx-103-oral-levosimendan-for-the-tr-tenx-20231113monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-issued-u-s-patent-for-oral-levosimendan-in-pulmonary-hypertension-with--tenx-20230719monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-achieves-major-milestone-as-uspto-grants-notice-of-allowance-for-u-s-pa-tenx-20230531monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-provides-2023-business-update-company-to-prioritize-the-clinical-develo-tenx-20230412monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-announces-issuance-of-u-s-patent-covering-use-of-iv-levosimendan-in-pulmonary-hypert-tenx-20230322monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-pricing-of-approximately-15-6-million-public-offering-tenx-20230203monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-granted-notice-of-allowance-for-u-s-patent-application-covering-use-of-iv-levosimend-tenx-20230201monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-reverse-stock-split-morrisville-nc-tenx-20230104monthly0.5https://www.biopharmawatch.com/news/TENX/positive-data-presented-at-hfsa-annual-meeting-demonstrate-effects-of-oral-levosimendan-in-tenx-20221010monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-the-evaluation-of-strategic-alternatives-morrisville-n-c-tenx-20220915monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-successful-comparative-pharmacokinetic-study-of-tnx-201-for-t-tenx-20220523monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-8-million-pipe-offering-priced-at-the-market-under-nasdaq-rul-tenx-20220518monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-appoints-robyn-hunter-to-the-board-of-directors-morrisville-nc-tenx-20220131monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-january-2022-i-corporate-presentation-www-tenaxthera-com-nasdaq-tenx-di-tenx-20220124monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-granted-u-s-patent-for-the-subcutaneous-use-of-levosimendan-tnx-102-pro-tenx-20220112monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-provides-update-on-tnx-102-tnx-103-and-tnx-201-clinical-programs-receiv-tenx-20220104monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-ceo-transition-and-10-million-pipe-offering-priced-at-the-mar-tenx-20210707monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-continuation-of-board-refreshment-program-as-three-long-servi-tenx-20210407monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-inc-expands-board-of-directors-x25cf-new-board-appointments-strengthen--tenx-20210302monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-inc-announces-transformative-acquisition-of-ph-precision-med-x25cf-expa-tenx-20210119monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-gains-north-american-rights-to-oral-levosimendan-through-expanded-licen-tenx-20201015monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-expands-board-of-directors-with-the-appointment-of-two-new-directors-st-tenx-20200720monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-8-0-million-registered-direct-and-pipe-offerings-priced-at-th-tenx-20200706monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-reports-positive-results-from-phase-2-trial-of-levosimendan-in-patients-tenx-20200602monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-2-75-million-registered-direct-offering-priced-at-the-market--tenx-20200312monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-closing-of-10-million-underwritten-offering-morrisville-nc-tenx-20181211monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-appointment-of-anthony-a-ditonno-as-ceo-morrisville-nc-tenx-20180605monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-morrisvill-tenx-20180314monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-reverse-stock-split-morrisville-nc-tenx-20180223monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-provides-regulatory-update-on-levosimendan-morrisville-nc-tenx-20170728monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-review-of-strategic-alternatives-and-business-update-x2013-la-tenx-20170405monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-top-line-results-from-phase-3-levo-cts-trial-in-cardiac-surge-tenx-20170131monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-first-quarter-2016-financial-results-and-provides-corporate-u-tenx-20160519monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-provides-clinical-and-corporate-update-hosted-analyst-day-on-april-13-w-tenx-20150415monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-announces-fiscal-year-2014-financial-results-acquired-strategic-ass-tenx-20140729monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-inc-announces-the-appointment-of-industry-veteran-gerald-proehl-to--tenx-20140404monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-inc-provides-an-update-on-communication-with-the-fda-regarding-oxyc-tenx-20140303monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-closes-the-acquisition-of-phyxius-pharma-assets-related-to-levosime-tenx-20131114monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-receives-6-million-in-net-proceeds-from-warrant-exercises-morrisvil-tenx-20131108monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-prices-public-offering-with-gross-proceeds-of-5-4-million-morrisvil-tenx-20130722monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-svp-investor-relations-corporate-communications-oxygen-biotherapeutics-inc-9-tenx-20130516monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-svp-investor-relations-corporate-communications-oxygen-biotherapeutics-inc-9-tenx-20130510monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-inc-a-development-stage-enterprise-statements-of-operations-unaudit-tenx-20130319monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-corporate-communications-investor-relations-919-855-2112-oxygen-biotherapeut-tenx-20130222monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-svp-investor-relations-corporate-communications-919-855-2112-oxygen-biothera-tenx-20130211monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-vice-president-corporate-communications-investor-relations-919-855-2112-oxyg-tenx-20121217monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-svp-investor-relations-corporate-communications-919-855-2112-oxygen-biothera-tenx-20120919monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-vice-president-corporate-communications-investor-relations-919-855-2112-oxyg-tenx-20120828monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-senior-vice-president-corporate-communications-investor-relations-919-855-21-tenx-20120724monthly0.5https://www.biopharmawatch.com/news/TENX/the-securities-described-above-were-offered-by-the-company-pursuant-to-a-registration-stat-tenx-20120615monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-senior-vice-president-corporate-communications-investor-relations-919-855-21-tenx-20120315monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-vice-president-corporate-communications-investor-relations-919-855-2112-oxyg-tenx-20111216monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-corporate-communications-investor-relations-919-855-2112-oxygen-biotherapeut-tenx-20111209monthly0.5https://www.biopharmawatch.com/news/TENX/rene-a-eckert-c-o-oxygen-biotherapeutics-inc-one-copley-parkway-suite-490-morrisville-nort-tenx-20110930monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-corporate-communications-investor-relations-919-855-2112-oxygen-biotherapeut-tenx-20110919monthly0.5https://www.biopharmawatch.com/news/TENX/i-am-very-surprised-at-this-i-don-t-agree-and-do-not-accept-my-termination-and-i-request-t-tenx-20110826monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-ellen-corliss-vice-president-corporate-communications-investor-rela-tenx-20110824monthly0.5https://www.biopharmawatch.com/news/TENX/ellen-corliss-vice-president-corporate-communications-investor-relations-919-855-2112-oxyg-tenx-20110714monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-inc-announces-registered-direct-offering-of-5-million-in-common-sto-tenx-20100504monthly0.5https://www.biopharmawatch.com/news/TENX/oxygen-biotherapeutics-chairman-s-blog-march-2010-blog-in-this-blog-i-want-to-briefly-upda-tenx-20100308monthly0.5https://www.biopharmawatch.com/news/TENX/in-this-blog-i-want-to-briefly-address-the-recurring-question-about-updates-on-our-patient-tenx-20100219monthly0.5https://www.biopharmawatch.com/news/TENX/business-update-tenx-20081202monthly0.5https://www.biopharmawatch.com/news/TENX/the-private-securities-litigation-reform-act-of-1995-provides-a-safe-harbor-for-forward-lo-tenx-20081112monthly0.5https://www.biopharmawatch.com/news/TENX/synthetic-blood-8k-press-release-for-bob-larsen-synthetic-blood-international-inc-announce-tenx-20080324monthly0.5https://www.biopharmawatch.com/news/TENX/synthetic-blood-press-release-11-20-2007-company-contact-synthetic-blood-international-inc-tenx-20071120monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-reports-first-quarter-2026-financial-results-toi-20260507monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-reports-fourth-quarter-and-full-year-2025-financial-results-and-gui-toi-20260312monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-appoints-kim-tzoumakas-to-board-of-directors-toi-20260223monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-reaffirms-2025-guidance-and-provides-preliminary-2026-outlook-toi-20260112monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-announces-addition-of-board-member-mark-stolper-toi-20260105monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-announces-resignation-of-board-member-gabe-ling-toi-20251201monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-of-hope-innovation-l-y-2-the-oncology-institute-of-hope-innovation--toi-20251114monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-reports-third-quarter-2025-financial-results-and-increases-full-yea-toi-20251113monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-reports-second-quarter-2025-financial-results-and-reaffirms-full-ye-toi-20250813monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-announces-changes-to-board-of-directors-richard-barasch-to-retire-a-toi-20250813monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-of-hope-innovation-may-2025-this-presentation-is-being-furnished-so-toi-20250519monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-reports-first-quarter-2025-financial-results-and-reaffirms-full-yea-toi-20250514monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-announces-16-5-million-private-placement-toi-20250324monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-of-hope-innovation-q-february-2025-2-the-oncology-institute-of-hope-toi-20250324monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-reports-fourth-quarter-and-full-year-2024-financial-results-and-gui-toi-20250324monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-announces-amendment-to-facility-agreement-and-debt-paydown-toi-20250226monthly0.5https://www.biopharmawatch.com/news/TOI/the-oncology-institute-announces-cfo-transition-rob-carter-promoted-to-chief-financial-off-toi-20240923monthly0.5https://www.biopharmawatch.com/news/TOI/toitransitionpress-6-9-23-1-42-pm-the-oncology-institute-announces-leadership-transition-h-toi-20230612monthly0.5https://www.biopharmawatch.com/news/TOI/document-the-oncology-institute-announces-110-million-strategic-investment-by-deerfield-ma-toi-20220809monthly0.5https://www.biopharmawatch.com/news/TOI/toiinvestorpr-investor-presentation-march-2022-we-are-a-leading-value-based-oncology-care--toi-20220311monthly0.5https://www.biopharmawatch.com/news/TOI/globenewswire-covid-19-news-servicesv-contact-us-fran-ais-sign-in-by-notified-f-w-in-the-o-toi-20211115monthly0.5https://www.biopharmawatch.com/news/TOI/toi-parent-inc-table-of-contents-financial-statements-2-condensed-consolidated-balance-she-toi-20211118monthly0.5https://www.biopharmawatch.com/news/TOI/dfp-healthcare-acquisitions-corp-announces-special-meeting-date-to-approve-proposed-busine-toi-20211022monthly0.5https://www.biopharmawatch.com/news/TOI/the-leader-in-value-based-oncology-care-october-2021-analyst-day-presentation-disclaimer-a-toi-20211012monthly0.5https://www.biopharmawatch.com/news/TOI/dfp-healthcare-acquisitions-corp-announces-proposed-business-combination-with-the-oncology-toi-20210628monthly0.5https://www.biopharmawatch.com/news/TOI/dfp-healthcare-acquisitions-corp-announces-the-separate-trading-of-its-class-a-common-stoc-toi-20200501monthly0.5https://www.biopharmawatch.com/news/TOI/dfp-healthcare-acquisitions-corp-report-of-independent-registered-public-accounting-firm-f-toi-20200313monthly0.5https://www.biopharmawatch.com/news/TOI/dfp-healthcare-acquisitions-corp-announces-pricing-of-200-million-initial-public-offering-toi-20200310monthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-presents-additional-clinical-and-mechanistic-data-from-sab-142-phase-1-trial-in-ad-sabs-20260422monthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-miami-sabs-20260317monthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-announces-additional-phase-1-data-for-sab-142-in-adult-patients-with-established-a-sabs-20260310monthly0.5https://www.biopharmawatch.com/news/SABS/the-material-in-this-presentation-has-been-prepared-by-sab-biotherapeutics-inc-doing-busin-sabs-20251231monthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-provides-sab-142-clinical-trial-progress-update-at-the-european-association-for-th-sabs-20240909monthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-appoints-lucy-to-as-chief-financial-officer-sabs-20240731monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-departure-of-chief-financial-officer-sabs-20240530monthly0.5https://www.biopharmawatch.com/news/SABS/fda-provides-clearance-to-ind-application-for-type-1-diabetes-therapy-sab-142-by-sab-bioth-sabs-20240521monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-appoints-jay-skyler-md-to-the-board-of-directors-miami-sabs-20240506monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-reports-full-year-2023-operating-and-financial-results-sabs-20240329monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-executive-leadership-change-sabs-20240202monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-sabs-20240123monthly0.5https://www.biopharmawatch.com/news/SABS/forward-looking-statements-2-the-material-in-this-presentation-has-been-prepared-by-sab-bi-sabs-20240119monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-1-for-10-reverse-stock-split-sabs-20240102monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-commencement-of-the-human-phase-1-clinical-trial-with-sab-14-sabs-20231129monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-appoints-katie-ellias-to-the-board-of-directors-sabs-20231120monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-private-placement-of-up-to-130-million-to-advance-developmen-sabs-20231002monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-successfully-concludes-ind-enabling-glp-toxicology-study-for-sab-142-a-sabs-20230110monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-cmo-alexandra-kropotova-to-deliver-presentation-on-next-generation-bio-sabs-20230109monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-novel-diversitab-platform-proven-to-develop-anti-idiotype-antibodies-t-sabs-20230105monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-7-9-million-private-placement-of-common-stock-sabs-20221207monthly0.5https://www.biopharmawatch.com/news/SABS/experienced-management-team-christoph-bausch-phd-mba-evp-chief-operating-officer-20-years--sabs-20221121monthly0.5https://www.biopharmawatch.com/news/SABS/forward-looking-statements-2-the-material-in-this-presentation-has-been-prepared-by-sab-bi-sabs-20221107monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-exclusive-manufacturing-partnership-with-emergent-biosolutio-sabs-20221027monthly0.5https://www.biopharmawatch.com/news/SABS/experienced-management-team-christoph-bausch-phd-mba-evp-chief-operating-officer-20-years--sabs-20220923monthly0.5https://www.biopharmawatch.com/news/SABS/forward-looking-statements-2-the-material-in-this-presentation-has-been-prepared-by-sab-bi-sabs-20220711monthly0.5https://www.biopharmawatch.com/news/SABS/forward-looking-statements-2-the-material-in-this-presentation-has-been-prepared-by-sab-bi-sabs-20220705monthly0.5https://www.biopharmawatch.com/news/SABS/large-animal-genetic-engineering-summit-june-2022-2022-sab-biotherapeutics-inc-x2013-confi-sabs-20220607monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-appointment-of-alexandra-kropotova-m-d-as-chief-medical-offi-sabs-20220606monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-reports-third-quarter-2021-financial-results-and-provides-company-upda-sabs-20211122monthly0.5https://www.biopharmawatch.com/news/SABS/shall-have-the-meanings-ascribed-to-them-in-the-current-report-on-form-8-k-the-form-8-k-fi-sabs-20211028monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-and-big-cypress-merger-call-tuesday-22-nd-june-2021-sab-biotherapeutic-sabs-20210622monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-list-on-nasdaq-through-merger-with-big-cypress-acquisition-corp-adv-sabs-20210622monthly0.5https://www.biopharmawatch.com/news/SABS/big-cypress-acquisition-corp-announces-separate-trading-of-its-shares-of-common-stock-and--sabs-20210204monthly0.5https://www.biopharmawatch.com/news/SABS/big-cypress-acquisition-corp-report-of-independent-registered-public-accounting-firm-f-2-b-sabs-20210114monthly0.5https://www.biopharmawatch.com/news/SABS/big-cypress-acquisition-corp-announces-pricing-of-100-million-initial-public-offering-miam-sabs-20210111monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20260513monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-consolidated-statements-of-operations-and-comprehensive-loss-in-eldn-20260319monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20251114monthly0.5https://www.biopharmawatch.com/news/ELDN/x201c-targets-x201d-x201c-looks-forward-x201d-x201c-could-x201d-x201c-may-x201d-and-simila-eldn-20251107monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20250814monthly0.5https://www.biopharmawatch.com/news/ELDN/clinical-trials-expected-or-future-results-of-tegoprubart-trials-and-its-ability-to-preven-eldn-20250806monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20250514monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-consolidated-statements-of-operations-and-comprehensive-loss-in-eldn-20250320monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20241112monthly0.5https://www.biopharmawatch.com/news/ELDN/212-253-8881-jurban-berrypr-com-source-eledon-pharmaceuticals-eldn-20241030monthly0.5https://www.biopharmawatch.com/news/ELDN/forward-looking-statements-this-press-release-contains-forward-looking-statements-that-inv-eldn-20241029monthly0.5https://www.biopharmawatch.com/news/ELDN/investor-contact-stephen-jasper-gilmartin-group-858-525-2047-stephen-gilmartinir-com-media-eldn-20240814monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20240513monthly0.5https://www.biopharmawatch.com/news/ELDN/signaling-in-both-adaptive-and-innate-immune-cell-activation-and-function-positions-it-as--eldn-20240507monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-consolidated-statements-of-operations-and-comprehensive-loss-in-eldn-20240328monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20231109monthly0.5https://www.biopharmawatch.com/news/ELDN/attractive-target-for-non-lymphocyte-depleting-immunomodulatory-therapeutic-intervention-t-eldn-20231102monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20230810monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20230511monthly0.5https://www.biopharmawatch.com/news/ELDN/including-risks-related-to-the-private-placement-risks-relating-to-the-safety-and-efficacy-eldn-20230501monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-consolidated-statements-of-operations-and-comprehensive-loss-in-eldn-20230330monthly0.5https://www.biopharmawatch.com/news/ELDN/about-eledon-pharmaceuticals-and-tegoprubart-eledon-pharmaceuticals-is-a-clinical-stage-bi-eldn-20230109monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-third-quarter-2022-operating-and-financial-results-received-eldn-20221114monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensi-eldn-20220811monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-announces-positive-topline-results-from-phase-2a-trial-of-tegoprubart-demonstrating-eldn-20220531monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-first-quarter-2022-operating-and-financial-results-topline--eldn-20220512monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-operating-and-financial-r-eldn-20220324monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-third-quarter-2021-operating-and-financial-results-nearing--eldn-20211111monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-second-quarter-2021-operating-and-financial-results-receive-eldn-20210812monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-first-quarter-2021-operating-and-financial-results-continue-eldn-20210513monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-update-on-development-strategy-for-at-1501-in-renal-trans-eldn-20210426monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-announces-name-change-to-eledon-pharmaceuticals-provides-corporate-upda-eldn-20210105monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-announces-acquisition-of-anelixis-therapeutics-acquisition-includes-lea-eldn-20200914monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-first-quarter-2020-financial-results-eldn-20200515monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-data-from-t-eldn-20200317monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-third-quarter-2019-financial-results-management-to-participate--eldn-20191113monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-second-quarter-2019-financial-results-eldn-20190813monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-first-quarter-2019-financial-results-eldn-20190514monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-announces-10-7-million-registered-direct-offering-priced-at-the-market-eldn-20190430monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-announces-results-of-two-single-dose-phase-1-studies-of-op0201-op0201-w-eldn-20190422monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-provide-eldn-20190328monthly0.5https://www.biopharmawatch.com/news/ELDN/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-eldn-20190108monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-third-quarter-2018-financial-results-eldn-20181113monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-second-quarter-2018-financial-results-eldn-20180807monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-inc-consolidated-statements-of-operations-and-other-comprehensive-loss--eldn-20180511monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-inc-consolidated-statements-of-operations-and-other-comprehensive-loss--eldn-20180402monthly0.5https://www.biopharmawatch.com/news/ELDN/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-eldn-20171129monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-inc-condensed-consolidated-statements-of-cash-flows-unaudited-in-thousa-eldn-20171108monthly0.5https://www.biopharmawatch.com/news/ELDN/novus-therapeutics-reports-second-quarter-2017-results-eldn-20170809monthly0.5https://www.biopharmawatch.com/news/ELDN/tokai-pharmaceuticals-and-otic-pharma-enter-into-share-purchase-agreement-transaction-to-c-eldn-20161222monthly0.5https://www.biopharmawatch.com/news/ELDN/any-statements-contained-in-this-presentation-about-our-future-expectations-plans-and-pros-eldn-20160107monthly0.5https://www.biopharmawatch.com/news/ELDN/tokai-pharmaceuticals-announces-the-appointment-of-cheryl-cohen-former-medivation-chief-co-eldn-20150413monthly0.5https://www.biopharmawatch.com/news/ELDN/tokai-pharmaceuticals-reports-fourth-quarter-and-full-year-2014-financial-results-eldn-20150312monthly0.5https://www.biopharmawatch.com/news/ELDN/tokai-pharmaceuticals-provides-companion-diagnostic-update-armor3-sv-remains-on-track-to-b-eldn-20150112monthly0.5https://www.biopharmawatch.com/news/ELDN/stephen-buckley-jr-appointed-to-tokai-board-of-directors-cambridge-mass-business-wire-eldn-20150109monthly0.5https://www.biopharmawatch.com/news/ELDN/tokai-pharmaceuticals-reports-third-quarter-2014-financial-results-company-successfully-co-eldn-20141110monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-highlights-2025-accomplishments-and-strategic-priorities-for-2026-dos-bcyc-20260112monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-third-quarter-2025-financial-res-bcyc-20251030monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-strengthens-board-of-directors-with-new-appointments-roger-dansey-m-d-bcyc-20250908monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-second-quarter-2025-financial-re-bcyc-20250808monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-first-quarter-2025-financial-res-bcyc-20250501monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-presentation-of-additional-human-radiopharmaceutical-imagin-bcyc-20250429monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-new-board-and-key-clinical-leadership-appointments-felix-j--bcyc-20250327monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-202-bcyc-20250225monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-updated-topline-zelenectide-pevedotin-data-and-highlights-2-bcyc-20250113monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-data-updates-across-zelenectide-pevedotin-program-and-devel-bcyc-20241212monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-third-quarter-2024-financial-res-bcyc-20241031monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-first-human-imaging-data-from-european-association-of-nucle-bcyc-20241023monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-presents-updated-clinical-results-across-oncology-pipeline-at-esmo-co-bcyc-20240914monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-second-quarter-2024-financial-re-bcyc-20240806monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-first-quarter-2024-financial-res-bcyc-20240502monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-202-bcyc-20240220monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-provides-data-updates-for-three-clinical-programs-and-strategy-overvi-bcyc-20231214monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-third-quarter-2023-financial-res-bcyc-20231102monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-expedited-development-plan-for-bt8009-in-metastatic-bladder-bcyc-20230911monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate--bcyc-20230803monthly0.5https://www.biopharmawatch.com/news/BCYC/bayer-ag-communications-51368-leverkusen-germany-phone-49-214-30-1-www-bayer-com-en-media--bcyc-20230510monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-u-bcyc-20230504monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-enhances-leadership-team-with-key-appointments-santiago-arroyo-m-d-ph-bcyc-20230403monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-a-strategic-collaboration-with-novartis-to-discover-develop-bcyc-20230328monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provi-bcyc-20230228monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-phase-i-dose-escalation-results-from-ongoing-phase-i-ii-stu-bcyc-20230214monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-first-patient-dosed-in-bt8009-phase-ii-expansion-cohorts-an-bcyc-20221108monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corporate-u-bcyc-20221103monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-bt5528-phase-i-dose-escalation-results-in-patients-with-adv-bcyc-20220907monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corporate--bcyc-20220804monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-further-expansion-of-genentech-immuno-oncology-collaboratio-bcyc-20220712monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corporate-u-bcyc-20220505monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-interim-bt8009-phase-i-clinical-trial-results-at-the-2022-a-bcyc-20220411monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provi-bcyc-20220301monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-continued-clinical-progress-and-updates-to-management-team--bcyc-20220105monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate-u-bcyc-20211104monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-expansion-of-genentech-immuno-oncology-collaboration-genent-bcyc-20211026monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-interim-bt5528-phase-i-clinical-trial-results-and-prelimina-bcyc-20211007monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corporate--bcyc-20210805monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-enters-exclusive-license-and-collaboration-agreement-with-ionis-to-de-bcyc-20210713monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-first-quarter-2021-financial-results-and-provides-corporate-u-bcyc-20210506monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-significant-progress-across-multiple-therapeutic-programs-b-bcyc-20210330monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-provi-bcyc-20210311monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-pipeline-progress-update-bt1718-progressing-in-cancer-resea-bcyc-20210114monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v-cambr-bcyc-20201120monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corporate-u-bcyc-20201105monthly0.5https://www.biopharmawatch.com/news/BCYC/exhibt-99-1-bicycle-therapeutics-announces-gross-proceeds-of-50-0-million-from-its-at-the--bcyc-20201001monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-second-quarter-2020-financial-results-and-provides-corporate--bcyc-20200805monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-first-quarter-2020-financial-results-and-provides-corporate-u-bcyc-20200507monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-pipeline-progress-update-phase-i-dose-escalation-completed--bcyc-20200407monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-corpo-bcyc-20200310monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-exclusive-strategic-collaboration-with-genentech-to-develop-bcyc-20200225monthly0.5https://www.biopharmawatch.com/news/BCYC/constrained-peptides-unconstrained-thinking-november-2019-forward-looking-statements-nov-2-bcyc-20191107monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-third-quarter-2019-financial-results-and-corporate-update-bt7-bcyc-20191109monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-announces-presentation-of-updated-data-from-phase-i-iia-trial-evaluat-bcyc-20190928monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-second-quarter-2019-financial-results-and-provides-clinical-u-bcyc-20190808monthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-enhances-board-of-directors-bcyc-20190724monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-record-q1-2026-results-with-im8-revenue-reaching-a-record-16--pre-20260610monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-appoints-hudson-leogrande-founder-and-ceo-of-multi-billion-dollar-dtc-b-pre-20260604monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-preliminary-record-q1-2026-results-with-im8-revenue-growing-n-pre-20260514monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-executives-execute-second-consecutive-round-of-post-earnings-open-marke-pre-20260303monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-reports-record-q4-and-fy-2025-results-im8-achieves-120m-arr-1-in-12-mon-pre-20260218monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-appoints-renowned-longevity-expert-and-health-tech-ceo-dr-darshan-shah--pre-20260217monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-completes-70-million-insighta-sale-to-tencent-bolstering-balance-sheet--pre-20260218monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-reinforces-strategic-focus-on-im8-divests-europa-business-for-up-to-13--pre-20260106monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-provides-update-on-voluntary-warrant-exchange-program-reaching-86-7-par-pre-20260105monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-update-to-capital-allocation-strategy-ceases-bitcoin-purchase-pre-20251230monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-enters-into-warrant-exchange-agreements-with-warrant-holders-strengthen-pre-20251223monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-global-limited-unit-703-706-k11-atelier-king-s-road-728-king-s-road-qua-pre-20251211monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-executives-announce-open-market-share-purchases-totaling-approx-1-45-mi-pre-20251124monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-reports-record-third-quarter-2025-results-im8-on-track-for-120m-arr-1-b-pre-20251110monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-closing-of-approx-44-0-million-equity-offering-to-fuel-im8-s--pre-20251028monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-global-limited-announces-proposed-public-offering-charlotte-n-c-pre-20251024monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-global-limited-incorporated-in-the-cayman-islands-with-limited-liability-condens-pre-20251021monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-second-quarter-2025-financial-results-with-im8-on-track-to-ac-pre-20250912monthly0.5https://www.biopharmawatch.com/news/PRE/unaudited-pro-forma-condensed-financial-statements-these-unaudited-pro-forma-condensed-fin-pre-20250822monthly0.5https://www.biopharmawatch.com/news/PRE/document-exhibit-99-1-risk-factors-related-to-our-bitcoin-treasury-strategy-unless-the-con-pre-20250807monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-global-limited-the-company-notice-of-extraordinary-general-meeting-of-the-shareh-pre-20250718monthly0.5https://www.biopharmawatch.com/news/PRE/document-exhibit-99-1-risk-factors-related-to-our-bitcoin-treasury-strategy-unless-the-con-pre-20250717monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-becomes-first-healthcare-company-to-execute-aggressive-bitcoin-treasury-pre-20250618monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-divests-act-genomics-to-delta-electronics-as-part-of-up-to-us-71-78-mil-pre-20250618monthly0.5https://www.biopharmawatch.com/news/PRE/document-update-prenetics-announces-first-quarter-2025-financial-results-raises-fy2025-out-pre-20250612monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-first-quarter-2025-financial-results-raises-fy2025-outlook-cr-pre-20250612monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-fourth-quarter-and-full-year-2024-financial-results-provides--pre-20250305monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-global-limited-unit-703-706-k11-atelier-king-s-road-728-king-s-road-qua-pre-20241213monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-third-quarter-2024-financial-results-revenue-grew-59-4-to-7-8-pre-20241127monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-tencent-s-us-30-million-investment-in-insighta-strengthening--pre-20241015monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-second-quarter-2024-financial-results-cost-optimization-boost-pre-20241007monthly0.5https://www.biopharmawatch.com/news/PRE/index-page-no-independent-auditor-s-report-1-2-consolidated-financial-statements-balance-s-pre-20240927monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-acquisition-of-europa-sports-partners-in-strategic-expansion--pre-20240819monthly0.5https://www.biopharmawatch.com/news/PRE/docx-2024x07x11x21x-prenetics-nasdaq-health-sciences-company-partners-with-david-beckham-b-pre-20240711monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-nasdaq-health-sciences-company-partners-with-david-beckham-beckham-becomes-a-str-pre-20240711monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-first-quarter-2024-financial-results-first-quarter-revenue-in-pre-20240618monthly0.5https://www.biopharmawatch.com/news/PRE/document-prenetics-announces-fourth-quarter-and-full-year-2023-financial-results-pre-20240401monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-third-quarter-2023-financial-results-pre-20231120monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-global-limited-announces-reverse-stock-split-pre-20231113monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-global-limited-announces-reverse-stock-split-pre-20231101monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-second-quarter-2023-financial-results-pre-20230915monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-and-globally-renowned-scientist-prof-dennis-lo-establish-us-200m-joint-venture-i-pre-20230626monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-first-quarter-2023-financial-results-pre-20230605monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-fourth-quarter-and-full-year-2022-financial-results-new-business-strat-pre-20230501monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-fourth-quarter-and-full-year-2022-financial-results-new-business-strat-pre-20230314monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-formation-of-scientific-advisory-board-to-support-new-business-strateg-pre-20230302monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-dr-bayju-thakar-as-chief-executive-officer-of-prenetics-pre-20230119monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-owned-act-genomics-receives-fda-clearance-for-actonco-the-first-asia-based-compa-pre-20230110monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-acquires-act-genomics-creating-a-leader-in-comprehensive-cancer-genetics-and-pre-pre-20221216monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-us-20-million-stock-repurchase-program-and-inclusion-into-the-msci-glo-pre-20221130monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-record-third-quarter-2022-financial-results-and-raises-full-year-2022--pre-20221110monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-second-quarter-2022-financial-results-and-raises-full-year-adjusted-eb-pre-20220909monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-first-quarter-2022-financial-results-after-a-successful-listing-on-the-pre-20220606monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-rings-the-opening-bell-and-debuts-pre-20220519monthly0.5https://www.biopharmawatch.com/news/RZLT/positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism-rzlt-20260602monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetu-rzlt-20260501monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-second-quarter-fiscal-2026-financial-results-and-provides-business-update-rzlt-20260212monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-investor-event-ersodetug-development-program-rzlt-20251110monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-fourth-quarter-and-full-year-fiscal-2025-financial-results-and-provides-b-rzlt-20250917monthly0.5https://www.biopharmawatch.com/news/RZLT/baseline-demographics-and-disease-characteristics-were-consistent-with-published-epidemiol-rzlt-20250718monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-third-quarter-fiscal-2025-financial-results-and-provides-business-update--rzlt-20250513monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-announces-closing-of-underwritten-offering-new-york-business-wire-rzlt-20250425monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-pricing-of-offering-of-90-million-of-common-stock-and-pre-funded-warran-rzlt-20250423monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-positive-recommendation-after-independent-interim-analysis-of-phase-3-s-rzlt-20250423monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-second-quarter-fiscal-2025-financial-results-and-provides-business-update-rzlt-20250212monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-provides-update-on-its-phase-3-sunrize-study-of-ersodetug-for-the-treatment-of-hy-rzlt-20250204monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-film-transcript-ersodetug-is-an-investigational-drug-candidate-the-fda-has-not-de-rzlt-20250114monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-rzlt-20250107monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-first-quarter-fiscal-2025-financial-results-and-provides-business-update--rzlt-20241107monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-and-provides-b-rzlt-20240919monthly0.5https://www.biopharmawatch.com/news/RZLT/fda-lifts-partial-clinical-holds-on-rz358-for-the-treatment-of-congenital-hyperinsulinism--rzlt-20240909monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz-rzlt-20240805monthly0.5https://www.biopharmawatch.com/news/RZLT/topline-results-rz402-201-phase-2-study-in-patients-with-diabetic-macular-edema-dme-rzlt-20240628monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-exercise-of-underwriters-option-to-purchase-additional-shares-and-concu-rzlt-20240627monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-pricing-of-public-offering-of-60-million-of-common-stock-and-pre-funded-rzlt-20240613monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-positive-topline-results-from-phase-2-proof-of-concept-study-of-rz402-in--rzlt-20240521monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-third-quarter-fiscal-2024-financial-results-and-provides-business-update--rzlt-20240515monthly0.5https://www.biopharmawatch.com/news/RZLT/phase-2-rize-study-sub-analyses-to-be-presented-at-the-2024-pediatric-endocrine-society-an-rzlt-20240423monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-second-quarter-fiscal-2024-results-and-provides-business-update-phase-3-c-rzlt-20240213monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-receives-innovation-passport-designation-from-the-u-k-innovative-licensing-and-ac-rzlt-20240123monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-completes-enrollment-of-its-phase-2-study-in-diabetic-macular-edema-dme-plans-to--rzlt-20231213monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-first-quarter-fiscal-2024-results-redwood-city-calif-rzlt-20231113monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-receives-priority-medicines-prime-eligibility-from-european-medicines-agency-for--rzlt-20231017monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-further-evidence-of-rz358-s-efficacy-in-tumor-mediated-hyperinsulinism--rzlt-20231011monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-full-year-fiscal-2023-results-and-highlights-company-progress-planning-to-rzlt-20230914monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-initiate-a-pivotal-phase-3-study-of-rz358-in-participants-3-months-of-age-and--rzlt-20230627monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-third-quarter-fiscal-2023-results-and-highlights-company-progress-the-com-rzlt-20230511monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-second-quarter-fiscal-2023-results-and-highlights-company-progress-initia-rzlt-20230210monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-initiation-of-a-phase-2-study-of-rz402-in-patients-with-diabetic-macula-rzlt-20221215monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-first-quarter-fiscal-2023-results-and-highlights-company-progress-phase-2-rzlt-20221109monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-fourth-quarter-and-full-year-fiscal-2022-results-and-highlights-company-p-rzlt-20220915monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-third-quarter-fiscal-2022-financial-results-and-highlights-company-progre-rzlt-20220512monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-announces-closing-of-registered-direct-offering-rzlt-20220504monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-announces-aggregate-130-million-registered-direct-offering-and-concurrent-pri-rzlt-20220501monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-joins-the-rare-disease-company-coalition-rezolute-joins-group-aimed-at-helping-ad-rzlt-20220329monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hy-rzlt-20220323monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-positive-study-results-for-rz402-an-oral-pki-being-developed-for-dme-ph-rzlt-20220222monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-second-quarter-fiscal-2022-financial-results-and-highlights-company-progr-rzlt-20220209monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-first-quarter-fiscal-2022-financial-results-and-highlights-recent-company-rzlt-20211112monthly0.5https://www.biopharmawatch.com/news/RZLT/abstract-for-the-2021-asrs-meeting-title-a-phase-1-single-dose-study-of-rz402-a-novel-oral-rzlt-20211019monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-and-a--rzlt-20211012monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-presents-results-from-two-week-natural-history-study-in-congenital-hyperinsulinis-rzlt-20210922monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-fourth-quarter-and-full-year-fiscal-2021-financial-results-and-highlights-rzlt-20210915monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-initiation-of-dosing-in-the-second-cohort-of-its-phase-2b-trial-of-rz35-rzlt-20210909monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-initiation-of-multiple-ascending-dose-study-of-rz402-rezolute-s-oral-pk-rzlt-20210810monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-added-to-russell-microcap-index-rzlt-20210628monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-third-quarter-fiscal-2021-financial-results-and-highlights-recent-company-rzlt-20210517monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-positive-rz402-study-results-demonstrating-potential-for-once-daily-dos-rzlt-20210504monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-30-million-debt-financing-agreement-with-slr-capital-partners-rzlt-20210419monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-second-quarter-fiscal-2021-financial-results-rzlt-20210210monthly0.5https://www.biopharmawatch.com/news/RZLT/fda-clears-rezolute-s-ind-application-for-rz402-rz402-rzlt-20201203monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-uplisting-to-the-nasdaq-capital-market-trading-expected-to-begin-rzlt-20201109monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-41-million-private-placement-with-leading-investment-firms-and-prepares-rzlt-20201009monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-welcomes-pharmaceutical-industry-leader-philippe-fauchet-to-its-board-of-dire-rzlt-20200910monthly0.5https://www.biopharmawatch.com/news/RZLT/company-name-rezolute-inc-rzlt-event-canaccord-genuity-s-39th-annual-growth-conference-dat-rzlt-20190808monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-appointment-of-keith-vendola-as-chief-financial-officer-rzlt-20180516monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-appointment-of-congenital-hyperinsulinism-therapeutic-area-expert-dr-ch-rzlt-20180409monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-announces-appointment-of-hoyoung-huh-m-d-ph-d-as-vice-chairman-of-its-board-o-rzlt-20180404monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-announces-close-of-convertible-note-financing-rzlt-20180403monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-enters-into-common-stock-purchase-agreement-for-up-to-10-million-with-lincoln-rzlt-20171226monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-exclusive-license-agreement-for-a-phase-2-orphan-disease-therapy-with--rzlt-20171207monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-selection-of-lead-oral-plasma-kallikrein-inhibitor-candidates-for-the--rzlt-20171017monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-appoints-nektar-s-chief-financial-officer-to-its-board-of-directors-louisville-c-rzlt-20171009monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-appoints-dr-robert-bhisitkul-to-its-scientific-advisory-board-rzlt-20171004monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-and-activesite-pharmaceuticals-announce-license-and-development-agreement-for-pl-rzlt-20170807monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-first-patient-dosed-in-phase-1-clinical-study-of-ab101-louisville-co-m-rzlt-20170725monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-13-million-close-of-private-placement-transaction-and-plan-to-dose-fir-rzlt-20170717monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-files-investigational-new-drug-application-for-once-weekly-basal-insulin-ab101-l-rzlt-20170605monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-formally-engages-cro-for-the-conduct-of-its-phase-i-first-in-human-clinical-tria-rzlt-20170501monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-appoints-two-pharmaceutical-executives-to-its-board-of-directors-louisville-co-m-rzlt-20170322monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-offer-to-amend-warrants-to-purchase-shares-of-common-stock-louisville--rzlt-20161215monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-formation-of-subsidiary-and-plan-to-raise-capital-in-south-korea-compa-rzlt-20160922monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-12-million-private-placement-louisville-co-rzlt-20160629monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-preclinical-proof-of-concept-for-once-weekly-basal-insulin-ab101-in-di-rzlt-20160622monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-appointment-of-michael-deperro-as-vice-president-of-operations-louisvi-rzlt-20160106monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-first-close-of-private-placement-transaction-financing-round-led-by-in-rzlt-20151210monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-receives-notice-of-allowance-on-patent-covering-microsphere-drug-delivery-platfo-rzlt-20151117monthly0.5https://www.biopharmawatch.com/news/RZLT/investor-presentation-ex99-1-htm-exhib-it-99-1-rzlt-20150930monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-new-product-candidate-ab301-a-weekly-glp-1-agonist-and-basal-insulin-c-rzlt-20150916monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-appoints-david-f-welch-ph-d-to-its-board-of-directors-louisville-co-marketwired-rzlt-20150629monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-to-present-new-preclinical-data-at-the-american-diabetes-association-75-th-scien-rzlt-20150511monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-appointment-of-dr-hoyoung-huh-as-chairman-of-scientific-advisory-board-rzlt-20150108monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-completion-of-pk-pd-studies-of-ab101-in-two-species-ab101-positioned-t-rzlt-20150107monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-7-million-private-placement-louisville-co-rzlt-20150105monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-extinguishes-44-million-contingent-liability-louisville-co-rzlt-20141110monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-appoints-barry-sherman-m-d-to-its-board-of-directors-rzlt-20140714monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-appoints-c-ronald-kahn-m-d-to-its-scientific-advisory-board-rzlt-20140623monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-inc-establishes-manufacturing-and-laboratory-facility-in-colorado-menlo-park-ca-rzlt-20140512monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-inc-announces-1-for-6-reverse-stock-split-menlo-park-ca-rzlt-20140501monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-inc-announces-10m-million-private-placement-menlo-park-ca-rzlt-20140402monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-closing-of-bridge-financing-company-prepares-to-advance-innovative-lea-rzlt-20140116monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-granted-european-patent-allowance-for-method-of-preparing-site-specific-protein--rzlt-20130724monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-initiates-effort-to-raise-up-to-12-million-in-a-private-placement-menlo-park-ca-rzlt-20130701monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-appoints-two-industry-leaders-to-its-management-team-menlo-park-ca-february-19th-rzlt-20130131monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-announces-stock-ticker-symbol-change-to-antb-menlo-park-ca-february-8-th-2013-an-rzlt-20130208monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-inc-a-development-stage-enterprise-financial-statements-as-of-rzlt-20130206monthly0.5https://www.biopharmawatch.com/news/RZLT/antriabio-acquires-assets-of-pr-pharmaceuticals-and-announces-intent-to-merge-with-a-publi-rzlt-20130107monthly0.5https://www.biopharmawatch.com/news/UCFI/zhong-guo-liang-tou-group-limited-unaudited-consolidated-financial-statements-as-of-june-3-ucfi-20251006monthly0.5https://www.biopharmawatch.com/news/UCFI/iron-horse-acquisitions-postpones-business-combination-special-meeting-until-june-20-2025--ucfi-20250604monthly0.5https://www.biopharmawatch.com/news/UCFI/iron-horse-acquisitions-announces-business-combination-agreement-with-parent-of-zhong-guo--ucfi-20241002monthly0.5https://www.biopharmawatch.com/news/UCFI/iron-horse-acquisitions-corp-index-to-financial-statement-page-audited-balance-sheet-of-ir-ucfi-20231229monthly0.5https://www.biopharmawatch.com/news/UCFI/iron-horse-acquisitions-corp-announces-pricing-of-61-000-000-initial-public-offering-toluc-ucfi-20231227monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2025-financial-results-and-business-highlights--nvct-20250805monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-first-quarter-2025-financial-results-and-business-highlights-n-nvct-20250506monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-2024-financial-results-and-business-highlights-nxp800-phase-1b-nvct-20250225monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-proposed-public-offering-of-common-stock-nvct-20250204monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-third-quarter-2024-financial-results-and-business-highlights-c-nvct-20241105monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-orphan-drug-designation-granted-by-the-fda-for-nxp800-for-the-tr-nvct-20240829monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2024-financial-results-and-business-highlights-nvct-20240806monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-first-quarter-2024-financial-results-and-business-highlights-e-nvct-20240507monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-fiscal-year-2023-financial-results-and-business-highlights-nxp-nvct-20240305monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-third-quarter-2023-financial-results-and-business-highlights-p-nvct-20231108monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-initiation-of-the-nxp900-phase-1a-clinical-trial-nvct-20230912monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-orphan-drug-designation-granted-by-the-fda-to-nxp800-for-the-tre-nvct-20230817monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2023-financial-results-and-business-highlights--nvct-20230809monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-fda-clearance-of-nxp900-ind-nvct-20230515monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-first-quarter-2023-financial-results-and-business-highlights-p-nvct-20230510monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-fiscal-year-2022-financial-results-and-business-highlights-nxp-nvct-20230307monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-third-quarter-2022-financial-results-and-business-highlights-t-nvct-20221108monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2022-financial-results-and-business-highlights--nvct-20220805monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-announces-approximately-15-9-million-private-placement-nvct-20220727monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-first-quarter-2022-financial-results-and-business-highlights-d-nvct-20220510monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-reports-fiscal-year-2021-financial-results-and-business-highlights-com-nvct-20220322monthly0.5https://www.biopharmawatch.com/news/ZNTL/zntlcorporateprese-corporate-presentation-april-2026-nasdaq-zntl-2-zentalis-pharmaceutical-zntl-20260409monthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-appoints-james-b-bucher-jd-as-chief-legal-officer-and-corporate-s-zntl-20250826monthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-announces-intermittent-azenosertib-monotherapy-dosing-nearly-doubles-efficacy-ove-zntl-20230606monthly0.5https://www.biopharmawatch.com/news/ZNTL/smith-asco2023xznx-a-phase-1-2-dose-escalation-study-of-the-bcl-2-inhibitor-zn-d5-and-the--zntl-20230605monthly0.5https://www.biopharmawatch.com/news/ZNTL/document-zentalis-pharmaceuticals-reports-second-quarter-2021-financial-results-and-operat-zntl-20210812monthly0.5https://www.biopharmawatch.com/news/ZNTL/document-zentalis-pharmaceuticals-reports-first-quarter-2021-financial-results-and-operati-zntl-20210517monthly0.5https://www.biopharmawatch.com/news/ZNTL/document-zentalis-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-resu-zntl-20210325monthly0.5https://www.biopharmawatch.com/news/ZNTL/document-zentalis-pharmaceuticals-reports-third-quarter-2020-financial-results-and-operati-zntl-20201109monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-preliminary-q4-and-2025-financial-results-new-chief-financial-office-rxst-20260111monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-chief-financial-officer-transition-aliso-viejo-calif-nasdaq-rxst-rxst-20251222monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-third-quarter-2025-financial-results-aliso-viejo-calif-nasdaq-rxst-x20-rxst-20251105monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-second-quarter-2025-financial-results-aliso-viejo-calif-nasdaq-rxst-x2-rxst-20250807monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-appoints-raymond-w-cohen-to-its-board-of-directors-aliso-viejo-calif-nasdaq-rx-rxst-20250804monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-preliminary-second-quarter-2025-revenue-and-revised-2025-guidance-al-rxst-20250708monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-first-quarter-2025-financial-results-aliso-viejo-calif-nasdaq-rxst-x20-rxst-20250507monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-preliminary-first-quarter-2025-revenue-and-revised-2025-guidance-ali-rxst-20250402monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-fourth-quarter-and-full-year-2024-financial-results-reaffirms-2025-gui-rxst-20250225monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-an-rxst-20250112monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-third-quarter-2024-financial-results-aliso-viejo-calif-nasdaq-rxst-x20-rxst-20241107monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-second-quarter-2024-financial-results-aliso-viejo-calif-nasdaq-rxst-x2-rxst-20240805monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-pricing-of-public-offering-of-common-stock-aliso-viejo-calif-nasdaq--rxst-20240508monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-first-quarter-2024-financial-results-aliso-viejo-calif-nasdaq-rxst-x20-rxst-20240506monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-fourth-quarter-and-full-year-2023-financial-results-aliso-viejo-calif--rxst-20240228monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-financial-an-rxst-20240107monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-third-quarter-2023-financial-results-aliso-viejo-calif-nasdaq-rxst-x20-rxst-20231109monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-second-quarter-2023-financial-results-aliso-viejo-calif-nasdaq-rxst-x2-rxst-20230807monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-first-quarter-2023-financial-results-aliso-viejo-calif-nasdaq-rxst-x20-rxst-20230509monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-fourth-quarter-and-full-year-2022-financial-results-aliso-viejo-calif--rxst-20230306monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-pricing-of-public-offering-of-common-stock-aliso-viejo-calif-nasdaq--rxst-20230207monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-financial-an-rxst-20230108monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-third-quarter-2022-financial-results-aliso-viejo-calif-nasdaq-rxst-x20-rxst-20221107monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-files-shelf-registration-statement-and-announces-50-million-at-the-market-equi-rxst-20220808monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-second-quarter-2022-financial-results-aliso-viejo-calif-nasdaq-rxst-x2-rxst-20220808monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-first-quarter-2022-financial-results-aliso-viejo-calif-nasdaq-rxst-x20-rxst-20220505monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-reports-fourth-quarter-and-fiscal-year-2021-financial-results-aliso-viejo-cali-rxst-20220308monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-announces-preliminary-unaudited-fourth-quarter-and-full-year-2021-financial-an-rxst-20220109monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-inc-appoints-dr-tamara-r-fountain-m-d-and-shweta-singh-maniar-to-its-board-of-dire-rxst-20220104monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-reports-third-quarter-2021-financial-results-aliso-viejo-calif-nasdaq-rxst-x2013-rxst-20211110monthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-reports-second-quarter-2021-financial-results-aliso-viejo-calif-nasdaq-rxst-x2013-rxst-20210909monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-busine-lctx-20260512monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and--lctx-20260305monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-third-quarter-2025-financial-results-and-provides-busine-lctx-20251106monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-second-quarter-2025-financial-results-and-provides-busin-lctx-20250812monthly0.5https://www.biopharmawatch.com/news/LCTX/opregen-rg6501-36-month-visual-acuity-results-featured-at-clinical-trials-at-the-summit-20-lctx-20250623monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2025-financial-results-and-provides-busine-lctx-20250513monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and--lctx-20250310monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-announces-closing-of-second-tranche-of-previously-announced-regi-lctx-20250127monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-announces-pricing-of-up-to-66-million-registered-direct-offering-lctx-20241120monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-third-quarter-2024-financial-results-and-provides-busine-lctx-20241114monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-second-quarter-2024-financial-results-and-provides-busin-lctx-20240808monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2024-financial-results-and-provides-busine-lctx-20240509monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and--lctx-20240307monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-announces-14-0-lctx-20240206monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-third-quarter-2023-financial-results-and-provides-busine-lctx-20231109monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-second-quarter-2023-financial-results-and-provides-busin-lctx-20230810monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2023-financial-results-and-provides-busine-lctx-20230511monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and--lctx-20230309monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-third-quarter-2022-financial-results-and-provides-busine-lctx-20221110monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-second-quarter-2022-financial-results-and-provides-busin-lctx-20220811monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2022-financial-results-and-provides-busine-lctx-20220512monthly0.5https://www.biopharmawatch.com/news/LCTX/rg6501-opregen-phase-1-2a-clinical-results-support-the-potential-for-opregen-to-slow-stop--lctx-20220503monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and--lctx-20220310monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-establishes-exclusive-worldwide-collaboration-with-genentech-for-the-development-a-lctx-20211220monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-reports-fourth-case-of-retinal-tissue-restoration-with-opregen-four-patients-with--lctx-20211130monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-reports-third-quarter-2021-financial-results-and-highlights-progress-from-clinical-lctx-20211110monthly0.5https://www.biopharmawatch.com/news/LCTX/promising-new-opregen-clinical-data-featured-at-54-th-annual-retina-society-meeting-in-pod-lctx-20210930monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-reports-second-quarter-2021-financial-results-and-highlights-additional-progress-f-lctx-20210812monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-additional-cases-of-retinal-tissue-restoration-in-dry-am-lctx-20210601monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-reports-first-quarter-2021-financial-results-and-highlights-significant-progress-w-lctx-20210513monthly0.5https://www.biopharmawatch.com/news/LCTX/opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with--lctx-20210503monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and--lctx-20210311monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-presents-new-opregen-data-for-dry-amd-with-ga-at-2020-american-a-lctx-20201117monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-third-quarter-2020-financial-results-and-provides-busine-lctx-20201104monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-second-quarter-2020-financial-results-and-provides-updat-lctx-20200806monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2020-financial-results-and-provides-busine-lctx-20200507monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and--lctx-20200312monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-reports-third-quarter-2019-financial-results-and-provides-busine-lctx-20191112monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-presents-new-opregen-data-at-american-academy-of-ophthalmology-a-lctx-20191014monthly0.5https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-receives-ce-mark-approval-for-renevia-comparative-clinical-trial-lctx-20190919monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-second-quarter-2019-financial-results-and-provides-business-update-announc-lctx-20190808monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-first-quarter-2019-financial-results-and-provides-business-update-positive-lctx-20190509monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-presents-updated-data-from-opregen-phase-i-iia-clinical-study-at-the-association-f-lctx-20190502monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-present-scistar-clinical-study-top-line-data-at-the-26-lctx-20190426monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-business--lctx-20190314monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-provides-business-update-including-information-on-agex-oncocyte-and-lctx-20190214monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-and-asterias-biotherapeutics-enter-into-definitive-merger-agreement-to-create-lead-lctx-20181108monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-third-quarter-2018-financial-results-and-provides-business-update-industry-lctx-20181108monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-and-subsidiaries-unaudited-pro-forma-condensed-combined-balance-sheet-as-of-ju-lctx-20180831monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-second-quarter-results-and-recent-corporate-accomplishments-biotime-to-rec-lctx-20180802monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-first-quarter-results-and-recent-corporate-accomplishments-renevia-ce-mark-lctx-20180510monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-fourth-quarter-and-fiscal-2017-results-renevia-ce-mark-application-submitt-lctx-20180315monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-appoints-cavan-redmond-to-its-board-of-directors-former-ceo-of-webmd-former-genera-lctx-20180222monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-third-quarter-results-and-recent-corporate-accomplishments-over-40m-in-rec-lctx-20171109monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-positive-secondary-and-additional-positive-long-term-data-from-the-renev-lctx-20170926monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-second-quarter-results-and-recent-corporate-accomplishments-conference-cal-lctx-20170802monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-renevia-achieves-primary-endpoint-in-european-pivotal-trial-data-reinforce-renev-lctx-20170614monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-first-quarter-results-and-recent-corporate-accomplishments-conference--lctx-20170510monthly0.5https://www.biopharmawatch.com/news/LCTX/key-biotime-patents-upheld-by-european-patent-office-epo-rules-patents-for-opregen-are-val-lctx-20170328monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-fourth-quarter-and-fiscal-year-2016-financial-results-and-recent-corpo-lctx-20170316monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-closing-of-public-offering-of-common-stock-alameda-ca-jerusalem-lctx-20170215monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-pricing-of-public-offering-of-common-stock-alameda-ca-jerusalem-lctx-20170210monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-proposed-public-offering-of-common-stock-alameda-ca-jerusalem-lctx-20170209monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-third-quarter-results-and-recent-clinical-progress-initial-data-from-o-lctx-20161103monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-second-quarter-results-and-recent-corporate-accomplishments-therapeuti-lctx-20160809monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-full-exercise-and-closing-of-underwriters-over-allotment-option-alam-lctx-20160705monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-pricing-of-public-offering-of-common-stock-alameda-ca-lctx-20160616monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-proposed-public-offering-of-common-stock-alameda-ca-lctx-20160615monthly0.5https://www.biopharmawatch.com/news/LCTX/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-dan-l-lawrence-director-investor-relations-corpo-lctx-20160526monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-first-quarter-results-and-recent-corporate-accomplishments-first-cohor-lctx-20160510monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-and-asterias-sign-share-transfer-agreement-and-cross-license-agreement-for-pluripo-lctx-20160216monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-completes-distribution-of-approximately-4-75-million-shares-of-oncocyte-corporatio-lctx-20151231monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-when-issued-trading-of-subsidiary-oncocyte-corporation-in-connection-wit-lctx-20151230monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-record-date-distribution-ratio-and-distribution-date-for-distributio-lctx-20151211monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-the-appointment-of-life-sciences-industry-veteran-russell-skibsted-a-lctx-20151118monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-third-quarter-2015-results-and-recent-corporate-accomplishments-alamed-lctx-20151109monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-and-hepregen-corporation-form-ascendance-biotechnology-inc-to-address-the-in-v-lctx-20151106monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-oncocyte-corporation-files-form-10-registration-statement-for-planned-lctx-20151007monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-agrees-to-sell-5-1-million-of-equity-alameda-calif-business-wire-lctx-20151002monthly0.5https://www.biopharmawatch.com/news/LCTX/heraeus-medical-gmbh-and-biotime-subsidiary-orthocyte-corporation-enter-into-exclusive-wor-lctx-20150930monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-cell-cure-neurosciences-ltd-receives-fda-fast-track-designation-for-o-lctx-20150928monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-agrees-to-sell-up-to-20-7-million-of-common-shares-shares-to-be-sold-to-tase-i-lctx-20150925monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-agrees-to-sell-8-58-million-of-common-shares-alameda-calif-business-wire-lctx-20150914monthly0.5https://www.biopharmawatch.com/news/LCTX/the-wistar-institute-and-biotime-subsidiary-oncocyte-corporation-expand-agreement-to-devel-lctx-20150818monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-second-quarter-2015-results-and-recent-developments-alameda-calif-busi-lctx-20150810monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-the-issuance-of-27-new-patents-protecting-stem-cell-based-product-develo-lctx-20150810monthly0.5https://www.biopharmawatch.com/news/LCTX/oncocyte-s-collaborators-at-the-wistar-institute-present-positive-clinical-interim-results-lctx-20150519monthly0.5https://www.biopharmawatch.com/news/LCTX/oncocyte-corporation-completes-equity-financing-round-capital-to-fund-further-development--lctx-20150514monthly0.5https://www.biopharmawatch.com/news/LCTX/leading-theregenerative-medicine-revolution-may-2015nyse-mkt-btx-the-matters-discussed-in--lctx-20150501monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-cell-cure-neurosciences-ltd-awarded-1-6-million-grant-from-israel-s-o-lctx-20150513monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-first-quarter-2015-results-and-recent-corporate-accomplishments-alamed-lctx-20150511monthly0.5https://www.biopharmawatch.com/news/LCTX/cell-cure-neurosciences-announces-preclinical-efficacy-data-demonstrating-opregen-preserve-lctx-20150504monthly0.5https://www.biopharmawatch.com/news/LCTX/novel-strategies-for-the-scalable-manufacture-of-cellular-therapeutics-from-pluripotent-st-lctx-20150429monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-clinical-grade-stem-cells-from-subsidiary-es-cell-international-to-be-used-in-pl-lctx-20150427monthly0.5https://www.biopharmawatch.com/news/LCTX/human-embryonic-stem-cell-derived-clonal-brown-adipocyte-progenitors-hal-sternberg-david-l-lctx-20150421monthly0.5https://www.biopharmawatch.com/news/LCTX/positive-clinical-results-of-oncocyte-s-panc-dx-diagnostic-test-demonstrate-high-level-of--lctx-20150420monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-solutions-and-mount-sinai-national-jewish-health-respiratory-institute-launch-pilo-lctx-20150331monthly0.5https://www.biopharmawatch.com/news/LCTX/oncocyte-announces-availability-of-abstracts-with-new-clinical-data-from-studies-of-panc-d-lctx-20150320monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-reports-fourth-quarter-and-fiscal-year-end-2014-financial-results-and-recent-c-lctx-20150311monthly0.5https://www.biopharmawatch.com/news/LCTX/icahn-school-of-medicine-at-mount-sinai-and-lifemap-solutions-launch-asthma-study-for-ipho-lctx-20150309monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-first-patient-treated-in-pivotal-clinical-trial-of-renevia-for-hiv-assoc-lctx-20150224monthly0.5https://www.biopharmawatch.com/news/LCTX/leading-the-revolution-in-regenerative-medicine-nyse-mkt-btx-february-2015-safe-harbor-sta-lctx-20150224monthly0.5https://www.biopharmawatch.com/news/LCTX/subscription-agreement-this-subscription-agreement-this-agreement-is-made-as-of-lctx-20150204monthly0.5https://www.biopharmawatch.com/news/LCTX/oncocyte-to-present-cancer-diagnostic-clinical-study-data-at-aacr-annual-meeting-biotime-s-lctx-20150206monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-issuance-of-14-new-patents-in-the-fields-of-regenerative-medicine-stem-c-lctx-20150126monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-subsidiary-oncocyte-corporation-appoints-william-annett-to-its-board-of-directors--lctx-20150112monthly0.5https://www.biopharmawatch.com/news/LCTX/regenerative-medicine-through-pluripotencynyse-mkt-btx-january-2015-safe-harbor-statement--lctx-20150112monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-appoints-adi-mohanty-chief-operating-officer-executive-brings-proven-leadership-in-lctx-20141229monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-appoints-angus-c-russell-to-board-of-directors-alameda-calif-business-wire-lctx-20141215monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-host-investor-and-analyst-day-on-lctx-20141215monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-present-at-the-ld-micro-vii-conference-alameda-calif-business-wire-lctx-20141203monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-third-quarter-results-and-recent-progress-asterias-biotherapeutics-approve-lctx-20141110monthly0.5https://www.biopharmawatch.com/news/LCTX/shareholder-updatethe-regenerativemedicine-revolution-lctx-20141104monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-receives-authorization-to-begin-pivotal-human-clinical-trial-of-renevia-in-europe--lctx-20141104monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-cell-cure-neurosciences-receives-fda-authorization-to-initiate-phase--lctx-20141103monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-closes-31-million-financing-alameda-calif-business-wire-lctx-20141009monthly0.5https://www.biopharmawatch.com/news/LCTX/michael-h-mulroy-and-stephen-l-cartt-joining-biotime-board-of-directors-alameda-calif-busi-lctx-20141006monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-oncocyte-corporation-announces-completion-of-multi-site-clinical-stud-lctx-20141003monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-solutions-adds-chief-technology-officer-to-leadership-team-additional-experts-from-lctx-20141001monthly0.5https://www.biopharmawatch.com/news/LCTX/joseph-wagner-ph-d-chief-executive-officer-lctx-20140925monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-s-subsidiary-oncocyte-corporation-s-ceo-dr-joseph-wagner-to-present-at-btig-s--lctx-20140919monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-cell-cure-neurosciences-ltd-demonstrates-the-safety-and-efficacy-of-o-lctx-20140917monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-subsidiary-asterias-biotherapeutics-and-cancer-research-uk-and-cancer-research-tec-lctx-20140911monthly0.5https://www.biopharmawatch.com/news/LCTX/nyse-mkt-btx-rodman-renshaw16th-annual-globalinvestment-conference-lctx-20140910monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-dr-michael-d-west-to-present-at-rodman-renshaw-16th-annual-healthcare-conferen-lctx-20140909monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-collaborate-with-the-university-of-wisconsin-and-louvain-university-in-test-of--lctx-20140828monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-receives-fda-premarket-notification-clearance-for-premvia-510-k-alameda-calif-busi-lctx-20140812monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-second-quarter-2014-results-and-recent-developments-three-cancer-diagnos-lctx-20140812monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-subsidiary-oncocyte-corporation-expands-clinical-development-of-bladder-cancer-lctx-20140731monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-issuance-of-14-patents-in-the-fields-of-regenerative-medicine-and-cancer-lctx-20140714monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-subsidiary-asterias-biotherapeutics-raises-13-0-million-in-equity-financing-capita-lctx-20140617monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-subsidiary-asterias-biotherapeutics-announces-investment-by-ceo-ceo-pedro-lichting-lctx-20140617monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-subsidiary-asterias-biotherapeutics-appoints-former-pfizer-senior-executive-pedro--lctx-20140612monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-present-at-the-jefferies-2014-global-healthcare-conference-alameda-calif-busine-lctx-20140602monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-asterias-biotherapeutics-inc-announces-a-14-3-million-strategic-partn-lctx-20140530monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-asterias-biotherapeutics-inc-settles-patent-interference-proceedings--lctx-20140528monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-receives-iso-13485-certification-for-medical-devices-alameda-calif-business-wire-lctx-20140528monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-oncocyte-corporation-and-cornell-university-enter-license-agreement-t-lctx-20140527monthly0.5https://www.biopharmawatch.com/news/LCTX/asterias-biotherapeutics-inc-launches-new-website-asteriasbiotherapeutics-com-biotime-inc--lctx-20140521monthly0.5https://www.biopharmawatch.com/news/LCTX/asterias-biotherapeutics-inc-to-present-phase-i-clinical-data-at-the-17th-annual-meeting-o-lctx-20140513monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-first-quarter-2014-results-and-recent-developments-four-products-current-lctx-20140512monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-solutions-inc-to-develop-mobile-health-products-with-mount-sinai-s-icahn-school-of-lctx-20140507monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-raises-6-4-million-in-equity-financing-alameda-calif-business-wire-lctx-20140505monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-present-at-gtc-stem-cell-summit-2014-alameda-calif-business-wire-lctx-20140424monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-announces-board-membership-changes-and-management-and-board-changes-at-its-sub-lctx-20140414monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-present-at-13-th-annual-needham-healthcare-conference-alameda-calif-business-wi-lctx-20140407monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-present-at-regen-med-investor-day-march-26-in-new-york-alameda-calif-business-w-lctx-20140325monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-fourth-quarter-and-fiscal-year-end-2013-financial-results-and-recent-cor-lctx-20140317monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-raises-3-5-million-through-preferred-stock-offering-alameda-calif-business-wire-lctx-20140305monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-provides-financing-and-product-development-update-12-6-million-raised-since-lctx-20140303monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-dr-michael-west-to-present-at-9-th-annual-stem-cell-summit-alameda-calif-busin-lctx-20140218monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-subsidiary-oncocyte-corporation-initiates-clinical-development-of-bladder-canc-lctx-20140127monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-lifemap-sciences-announces-release-of-lifemap-discovery-version-1-5-w-lctx-20140117monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-results-of-clinical-safety-trial-of-renevia-renevia-appears-safe-and-well--lctx-20140113monthly0.5https://www.biopharmawatch.com/news/LCTX/asterias-biotherapeutics-inc-a-subsidiary-of-biotime-inc-leases-facilities-for-expanded-pr-lctx-20140102monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-cell-cure-neurosciences-ltd-awarded-1-7-million-grant-from-israel-s-o-lctx-20131223monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-isolation-of-novel-brain-associated-cells-from-human-embryonic-stem-cells--lctx-20131220monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-announces-release-of-genecards-version-3-11-new-r-lctx-20131206monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-ceo-dr-michael-west-to-moderate-session-on-mapping-the-cellular-basis-of-life-at-lctx-20131204monthly0.5https://www.biopharmawatch.com/news/LCTX/asterias-biotherapeutics-inc-files-registration-statement-for-underwritten-public-offering-lctx-20131202monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-dr-michael-west-to-present-at-11-th-annual-commercial-translation-of-regenerat-lctx-20131125monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-third-quarter-2013-financial-results-and-recent-corporate-accomplishment-lctx-20131112monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-to-provide-company-updates-during-investor-day-lctx-20131028monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-interim-results-on-renevia-clinical-safety-trial-enrollment-completed-in-f-lctx-20131028monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-organizes-new-esi-bio-division-to-develop-manufacture-and-market-the-company-s-cel-lctx-20131028monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-additional-products-in-development-based-on-hystem-technology-alameda-ca-lctx-20131004monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-signs-exclusive-agreement-with-jade-therapeutics-for-ophthalmic-drug-delivery-appl-lctx-20130919monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-receives-approval-to-begin-human-clinical-trials-of-renevia-alameda-calif-business-lctx-20130828monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-the-appointment-of-lesley-stolz-as-executive-vice-president-of-corporate-lctx-20130821monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-second-quarter-2013-financial-results-and-recent-corporate-accomplishmen-lctx-20130809monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-oncocyte-corporation-publishes-data-on-the-gene-fsip1-as-a-breast-can-lctx-20130805monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-dr-michael-west-to-present-at-the-case-western-reserve-university-6th-annual-r-lctx-20130716monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-appoints-henry-l-nordhoff-to-board-of-directors-alameda-calif-business-wire-lctx-20130612monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-closes-on-9-million-financing-alameda-calif-business-wire-lctx-20130607monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-inc-to-raise-9-million-in-registered-direct-offering-lctx-20130603monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-dr-michael-west-to-present-at-usc-minisymposium-musculoskeletal-development-an-lctx-20130520monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-appoints-franklin-berger-to-board-of-directors-alameda-calif-business-wire-lctx-20130514monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-cell-cure-neurosciences-ltd-awarded-1-5-million-grant-from-israel-s-o-lctx-20130513monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-first-quarter-2013-financial-results-and-recent-corporate-accomplishment-lctx-20130510monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-cfo-succession-plan-robert-w-peabody-to-become-cfo-on-lctx-20130430monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-announces-partnership-with-appistry-agreement-wil-lctx-20130423monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-enters-into-worldwide-license-agreement-with-ucla-to-develop-therapy-for-the-treat-lctx-20130419monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-adds-products-through-partnership-with-prospec-tany-technogene-biotime-su-lctx-20130410monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-announces-release-of-lifemap-discovery-tm-version-lctx-20130325monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-fourth-quarter-and-fiscal-year-end-2012-financial-results-and-recent-cor-lctx-20130318monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-to-present-at-25th-annual-roth-conference-alameda-calif-business-wire-lctx-20130313monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-appoints-stephen-c-farrell-to-board-of-directors-alameda-calif-business-wire-lctx-20130312monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-and-romulus-agree-to-accelerate-closing-date-for-second-tranche-of-5-million-finan-lctx-20130307monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-and-subsidiary-lifemap-sciences-announce-data-mining-collaboration-lifemap-science-lctx-20130304monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-reports-its-databases-currently-utilized-by-an-es-lctx-20130211monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-oncocyte-corporation-provides-an-update-on-the-development-of-the-nov-lctx-20130131monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-announces-publication-of-research-report-describi-lctx-20130130monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-dr-michael-west-to-present-at-scale-up-and-manufacturing-of-cell-based-therapi-lctx-20130118monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-submits-protocol-for-initiation-of-human-clinical-trials-of-renevia-in-europe-alam-lctx-20130110monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-inc-announces-the-release-of-malacards-version-1--lctx-20130109monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-signs-definitive-agreement-with-geron-regarding-stem-cell-assets-investor-commits--lctx-20130107monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-the-appointment-of-jeffrey-janus-as-vice-president-adds-senior-executive-lctx-20121220monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-reports-isolation-of-seven-diverse-cartilage-and-bone-cell-types-from-human-embryo-lctx-20121218monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-dr-michael-west-presents-product-development-update-at-world-stem-cell-summit--lctx-20121204monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-dr-michael-west-to-present-at-world-stem-cell-summit-2012-alameda-calif-busine-lctx-20121129monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-inc-launches-lifemap-discovery-a-database-of-huma-lctx-20121127monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-passing-of-director-abraham-e-cohen-alameda-calif-business-wire-lctx-20121126monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-signs-definitive-distribution-agreement-with-pros-lctx-20121120monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-a-subsidiary-of-biotime-announces-release-of-genecards-version-3-09-alame-lctx-20121119monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-non-binding-letter-of-intent-with-geron-regarding-stem-cell-assets-alame-lctx-20121115monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-and-subsidiary-lifemap-sciences-announce-the-launch-of-lifemap-bioreagents-portal--lctx-20121114monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-third-quarter-2012-financial-results-and-recent-corporate-accomplishment-lctx-20121109monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-and-subsidiary-cell-cure-neurosciences-ltd-announce-financing-alameda-calif-jerusa-lctx-20121107monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-subsidiary-orthocyte-corporation-announces-the-appointment-of-francois-binette-as--lctx-20121101monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-lifemap-sciences-inc-announces-the-launch-of-malacards-a-database-of--lctx-20121023monthly0.5https://www.biopharmawatch.com/news/LCTX/lifemap-sciences-inc-announces-addition-to-board-of-directors-and-provides-update-on-produ-lctx-20121019monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-forms-biotime-acquisition-corporation-subsidiary-will-seek-to-acquire-assets-and-b-lctx-20120928monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-ceo-michael-d-west-to-present-at-stem-cells-usa-regenerative-medicine-congress-201-lctx-20120919monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-obtains-expanded-license-to-hystem-technology-biotime-now-holds-exclusive-worldwid-lctx-20120827monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-and-oncocyte-corporation-publish-data-on-the-gene-col10a1-as-a-marker-and-potentia-lctx-20120816monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-announces-second-quarter-2012-financial-results-and-recent-corporate-accomplishmen-lctx-20120809monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-s-subsidiary-cell-cure-neurosciences-ltd-awarded-1-33-million-grant-from-israel-s--lctx-20120801monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-subsidiary-lifemap-sciences-inc-announces-financing-of-up-to-3-million-from-share--lctx-20120726monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-signs-agreements-with-jade-therapeutics-for-ophthalmological-drug-delivery-applica-lctx-20120717monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-and-subsidiary-lifemap-sciences-inc-announce-release-of-genecards-version-3-08-ala-lctx-20120523monthly0.5https://www.biopharmawatch.com/news/LCTX/biotime-completes-merger-of-xennex-inc-into-lifemap-sciences-inc-alameda-calif-business-wi-lctx-20120521monthly0.5https://www.biopharmawatch.com/news/LCTX/hystem-c-demonstrated-effective-when-formulated-with-human-heart-cells-and-transplanted-in-lctx-20120514monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-preliminary-2025-financial-highlights-and-operational-accomplishments-inc-amrn-20260108monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2025-financial-results-european-partnership-with-recordati-e-amrn-20250730monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-exclusive-license-and-supply-agreement-with-recordati-to-commercialize-va-amrn-20250624monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2025-financial-results-first-quarter-2025-performance-reflect-amrn-20250507monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-regains-compliance-with-nasdaq-minimum-bid-price-requirement-nasdaq-compliance-foll-amrn-20250429monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-confirms-effective-date-for-1-for-20-ads-ratio-change-action-taken-to-maintain-comp-amrn-20250409monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-appoints-jec-capital-partners-michael-torok-to-board-of-directors-dublin-ireland-an-amrn-20250407monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-financial-results-business-update-and-announces-important-co-amrn-20250312monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-appoints-peter-fishman-chief-financial-officer-fishman-previously-served-as-global--amrn-20241213monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2024-financial-results-and-provides-business-update-strong-ca-amrn-20241030monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2024-financial-results-and-provides-business-update-cash-pos-amrn-20240731monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-board-of-directors-announces-ceo-transition-board-appoints-aaron-berg-as-president--amrn-20240604monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2024-business-update-and-financial-results-new-vazkepa-patent-amrn-20240501monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-results-of-annual-general-meeting-of-shareholders-shareholders-approve-sh-amrn-20240418monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-update-on-vazkepa-icosapent-ethyl-intellectual-property-portfolio-in-europ-amrn-20240403monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-u-amrn-20240229monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-preliminary-fourth-quarter-2023-selected-financials-and-outlines-key-prior-amrn-20240110monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2023-financial-results-company-reported-total-net-revenues-of-amrn-20231101monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-appoints-jonathan-provoost-executive-vice-president-chief-legal-compliance-officer--amrn-20231031monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2023-financial-results-company-reported-total-net-revenues-o-amrn-20230802monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-implements-organizational-restructuring-to-strengthen-the-company-while-driving-pat-amrn-20230718monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2023-financial-results-and-provides-business-update-stable-re-amrn-20230503monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-names-aaron-berg-interim-president-chief-executive-officer-and-adds-oliver-o-connor-amrn-20230417monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-board-departures-dublin-ireland-and-amrn-20230306monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-u-amrn-20230301monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-preliminary-fourth-quarter-and-full-year-2022-revenue-and-cash-position-an-amrn-20230110monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-board-of-directors-announces-appointment-of-murray-w-stewart-dm-frcp-dr-stewart-bri-amrn-20230110monthly0.5https://www.biopharmawatch.com/news/AMRN/forward-looking-statements-disclaimer-this-presentation-contains-forward-looking-statement-amrn-20221116monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2022-financial-results-and-provides-business-update-u-s-busin-amrn-20221027monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-appoints-adam-berger-and-geraldine-murphy-to-board-of-directors-lars-ekman-and-patr-amrn-20221020monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-update-on-vazkepa-icosapent-ethyl-pricing-negotiations-in-germany-frankfur-amrn-20220819monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2022-financial-results-and-provides-business-update-company--amrn-20220803monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-comprehensive-cost-reduction-plan-to-address-market-dynamics-in-u-s-busin-amrn-20220606monthly0.5https://www.biopharmawatch.com/news/AMRN/board-changes-press-release-amarin-announces-appointment-of-new-directors-and-board-leader-amrn-20220519monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2022-financial-results-and-provides-business-update-initiated-amrn-20220504monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business-u-amrn-20220301monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-preliminary-2021-revenue-and-outlook-for-2022-dublin-ireland-and-bridgewat-amrn-20220110monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2021-financial-results-and-provides-business-update-launched--amrn-20211103monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-outlines-new-go-to-market-strategy-to-accelerate-vascepa-icosapent-ethyl-growth-in--amrn-20210922monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-and-six-month-2021-financial-results-and-provides-business-u-amrn-20210805monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2021-financial-results-and-provides-business-update-commercia-amrn-20210429monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-ceo-succession-plan-john-thero-to-retire-as-president-and-ceo-on-amrn-20210412monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-u-amrn-20210225monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-preliminary-2020-results-and-2021-outlook-unaudited-2020-total-net-revenue-amrn-20210107monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2020-financial-results-and-provides-business-update-total-rev-amrn-20201105monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-update-following-ruling-in-vascepa-anda-patent-litigation-dublin-ireland-a-amrn-20200903monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2020-financial-results-and-provides-update-on-operations-tot-amrn-20200804monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2020-financial-results-and-provides-update-on-operations-tota-amrn-20200430monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-comments-on-ruling-in-vascepa-anda-litigation-amrn-20200330monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-record-fourth-quarter-and-full-year-2019-financial-results-and-provides-upd-amrn-20200225monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-update-to-preliminary-2019-results-and-further-details-on-2020-outlook-una-amrn-20200107monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2019-financial-results-and-provides-update-on-operations-reco-amrn-20191105monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-notification-of-advisory-committee-meeting-planned-to-be-held-in-nove-amrn-20190808monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2019-financial-results-and-operational-update-record-total-r-amrn-20190731monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-400-000-000-public-offering-of-american-depositary-shares-bedminster-n-j--amrn-20190717monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-mid-2019-update-including-commercialization-plans-for-vascepa-and-updates--amrn-20190702monthly0.5https://www.biopharmawatch.com/news/AMRN/u-s-fda-grants-priority-review-for-vascepa-icosapent-ethyl-supplemental-new-drug-applicati-amrn-20190529monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2019-financial-results-and-provides-update-on-operations-tota-amrn-20190501monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-submits-supplemental-new-drug-application-snda-to-u-s-fda-seeking-new-indication-fo-amrn-20190328monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-record-fourth-quarter-and-full-year-2018-financial-results-and-provides-upd-amrn-20190227monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-preliminary-2018-results-and-2019-outlook-u-s-sales-force-increased-to-400-amrn-20190104monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-proposed-public-offering-of-american-depositary-shares-bedminster-n-j-and-amrn-20181126monthly0.5https://www.biopharmawatch.com/news/AMRN/vascepa-icosapent-ethyl-26-reduction-in-key-secondary-composite-endpoint-of-cardiovascular-amrn-20181110monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2018-financial-results-and-provides-update-on-operations-acti-amrn-20181101monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-mandatory-exchange-of-exchangeable-senior-notes-issued-in-january-2017-be-amrn-20181019monthly0.5https://www.biopharmawatch.com/news/AMRN/reduce-it-cardiovascular-outcomes-study-of-vascepa-icosapent-ethyl-capsules-met-primary-en-amrn-20180924monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2018-financial-results-and-provides-update-on-operations-red-amrn-20180801monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-and-mochida-announce-collaboration-on-future-development-of-epa-based-drug-products-amrn-20180612monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2018-financial-results-and-provides-update-on-operations-redu-amrn-20180502monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-promotion-of-aaron-berg-to-position-of-chief-commercial-officer-bedminste-amrn-20180423monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-updates-first-quarter-revenue-guidance-reiterates-full-year-guidance-and-updates-on-amrn-20180404monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-record-fourth-quarter-and-full-year-2017-financial-results-and-provides-upd-amrn-20180227monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-proposed-public-offering-of-american-depositary-shares-bedminster-n-j-and-amrn-20180129monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-preliminary-2017-results-and-provides-2018-outlook-unaudited-full-year-201-amrn-20180104monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2017-financial-results-and-provides-update-on-operations-reco-amrn-20171101monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2017-financial-results-and-provides-update-on-operations-rec-amrn-20170802monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2017-financial-results-and-provides-update-on-operations-pres-amrn-20170503monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-record-fourth-quarter-and-full-year-2016-financial-results-and-provides-upd-amrn-20170228monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-debt-restructuring-and-related-private-placement-of-exchangeable-senior-n-amrn-20170120monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-preliminary-2016-results-and-2017-outlook-unaudited-full-year-2016-net-pro-amrn-20170105monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-plc-one-new-change-london-ec4m-9af-england-dear-sirs-re-resignation-fro-amrn-20161216monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2016-financial-results-and-provides-update-on-operations-thir-amrn-20161103monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-reduce-it-cardiovascular-outcomes-study-of-vascepa-to-continue-as-planned-at-reco-amrn-20160912monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-mandatory-exchange-of-exchangeable-senior-notes-issued-in-may-2014-and-no-amrn-20160826monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-underwriters-exercise-of-option-to-purchase-additional-american-depositar-amrn-20160815monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-proposed-public-offering-of-american-depositary-shares-bedminster-n-j-and-amrn-20160810monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2016-financial-results-and-provides-update-on-operations-sec-amrn-20160804monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-appoints-michael-w-kalb-chief-financial-officer-bedminster-n-j-and-amrn-20160630monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2016-financial-results-and-provides-update-on-operations-prod-amrn-20160505monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-year-end-2015-financial-results-and-provides-update-on-o-amrn-20160225monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-preliminary-2015-net-product-sales-and-provides-2016-revenue-and-business-o-amrn-20160111monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2015-financial-results-and-provides-update-on-operations-redu-amrn-20151104monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2015-financial-results-and-provides-update-on-operations-red-amrn-20150806monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2015-financial-results-and-provides-update-on-operations-redu-amrn-20150508monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-52-8-million-private-placement-amrn-20150306monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-year-end-2014-financial-results-and-provides-update-on-o-amrn-20150303monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2014-financial-results-and-provides-update-on-operations-conf-amrn-20141106monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2014-financial-results-and-provides-update-on-operations-con-amrn-20140807monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-private-exchange-transactions-regarding-outstanding-senior-exchangeable-n-amrn-20140515monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2014-financial-results-and-provides-update-on-operations-conf-amrn-20140509monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-and-kowa-pharmaceuticals-america-inc-announce-u-s-co-promotion-agreement-for-vascep-amrn-20140331monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-year-end-2013-financial-results-and-provides-update-on-o-amrn-20140227monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-review-division-response-to-anchor-spa-agreement-reinstatement-reques-amrn-20140121monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2013-financial-results-and-provides-update-on-operations-amar-amrn-20131107monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2013-financial-results-and-provides-update-on-operations-con-amrn-20130808monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-public-offering-of-american-depositary-shares-bedminster-n-j-and-dublin-amrn-20130708monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-informed-by-fda-of-october-16-th-advisory-committee-date-in-connection-with-supplem-amrn-20130619monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2013-financial-results-and-provides-update-on-operations-conf-amrn-20130509monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-year-end-2012-financial-results-and-provides-update-on-o-amrn-20130228monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-100-million-non-equity-financing-and-vascepa-sales-force-hiring-while-con-amrn-20121206monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2012-financial-results-and-provides-update-on-operations-conf-amrn-20121108monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2012-financial-results-and-provides-update-on-operations-con-amrn-20120808monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-approval-of-vascepa-icosapent-ethyl-capsules-for-the-reduction-of-tri-amrn-20120726monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-first-quarter-2012-financial-results-and-provides-update-on-operations-conf-amrn-20120508monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-fourth-quarter-and-year-end-2011-financial-results-and-provides-update-on-o-amrn-20120229monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-appoints-dr-steven-ketchum-to-head-research-and-development-and-announc-amrn-20120216monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-plc-announces-offering-of-150-million-of-exchangeable-senior-notes-due--amrn-20120103monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-commences-2012-with-letter-to-shareholders-2012-priorities-outlined-bedminster-n-j--amrn-20120103monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-delays-announcement-of-fourth-quarter-and-full-year-2025-results-an-armp-20260319monthly0.5https://www.biopharmawatch.com/news/ARMP/corporate-presentation-deborah-birx-m-d-chief-executive-officer-h-c-wainwright-27-th-annua-armp-20250910monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-second-quarter-2025-results-and-provides-corporate-update-armp-20250812monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-first-quarter-2025-results-and-provides-corporate-update-armp-20250514monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-receives-4-65-million-of-additional-non-dilutive-award-funding-from-armp-20250501monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2024-results-and-provides-co-armp-20250320monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-10-million-secured-credit-agreement-with-innoviva-proceed-armp-20250312monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-encouraging-results-from-the-phase-2-tail-wind-study-of-i-armp-20241219monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-third-quarter-2024-results-and-provides-corporate-update-armp-20241113monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-the-completion-of-enrollment-of-its-phase-1b-2a-disarm-st-armp-20241112monthly0.5https://www.biopharmawatch.com/news/ARMP/phase-2-clinical-trials-evaluating-multi-phage-candidates-for-the-treatment-of-adults-with-armp-20240826monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-appointment-of-life-sciences-accounting-and-finance-veter-armp-20240815monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-second-quarter-2024-results-and-provides-corporate-update-armp-20240813monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-first-quarter-2024-results-and-provides-corporate-update-armp-20240507monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2023-results-and-provides-co-armp-20240321monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-35-million-secured-credit-agreement-with-innoviva-proceed-armp-20240304monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-third-quarter-2023-results-and-provides-corporate-update-armp-20231114monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-second-quarter-2023-results-and-provides-corporate-update-armp-20230814monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-new-financing-and-leadership-transition-to-accelerate-nov-armp-20230711monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-first-quarter-2023-results-and-provides-corporate-update-armp-20230511monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2022-results-and-provides-co-armp-20230316monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-positive-topline-data-from-phase-1b-2a-swarm-p-a-clinical-armp-20230306monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-closing-of-30-million-secured-convertible-credit-agreemen-armp-20230110monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-third-quarter-2022-results-and-provides-corporate-update-armp-20221109monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-second-quarter-2022-results-and-provides-corporate-update-armp-20220811monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-closing-of-second-and-final-tranche-of-45-million-private-armp-20220331monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-45-million-investment-to-support-advancement-of-the-compa-armp-20220209monthly0.5https://www.biopharmawatch.com/news/ARMP/brian-varnum-chief-executive-officer-steve-martin-chief-financial-officer-armp-20220105monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-enters-lease-to-build-state-of-the-art-r-d-and-gmp-manufacturing-facility-56-000-sq-armp-20211102monthly0.5https://www.biopharmawatch.com/news/ARMP/cystic-fibrosis-foundation-makes-equity-investment-in-armata-pharmaceuticals-funds-to-be-u-armp-20211028monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-second-quarter-results-and-provides-general-corporate-upd-armp-20210812monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-first-quarter-results-and-provides-general-corporate-upda-armp-20210513monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-closing-of-second-and-final-tranche-of-20-million-private-armp-20210317monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-20-million-investment-to-support-advancement-of-the-compa-armp-20210127monthly0.5https://www.biopharmawatch.com/news/ARMP/todd-patrick-chief-executive-officer-brian-varnum-president-and-chief-development-officer--armp-20210106monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-the-addition-of-robin-c-kramer-to-its-board-of-directors--armp-20201209monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-15-million-award-from-the-u-s-department-of-defense-dod-f-armp-20200617monthly0.5https://www.biopharmawatch.com/news/ARMP/todd-patrick-chief-executive-officer-brian-varnum-president-and-chief-development-officer--armp-20200428monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-closing-of-second-tranche-of-25-million-securities-purcha-armp-20200330monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2019-results-and-provides-ge-armp-20200319monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-up-to-5-million-therapeutics-development-award-from-the-c-armp-20200318monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-closing-of-first-tranche-of-recently-executed-25-million--armp-20200213monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-and-innoviva-announce-25-million-strategic-investment-to-support-ad-armp-20200128monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-expands-board-of-directors-with-the-appointment-of-research-and-dev-armp-20191010monthly0.5https://www.biopharmawatch.com/news/ARMP/todd-patrick-chief-executive-officer-ladenburg-thalmann-2019-healthcare-conference-new-yor-armp-20190924monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-development-of-new-synthetic-phage-candidate-targeting-ps-armp-20190912monthly0.5https://www.biopharmawatch.com/news/ARMP/key-opinion-leader-event-phage-based-therapeutics-for-the-treatment-of-antimicrobial-resis-armp-20190626monthly0.5https://www.biopharmawatch.com/news/ARMP/todd-patrick-chief-executive-officer-brian-varnum-president-and-chief-development-officer--armp-20190624monthly0.5https://www.biopharmawatch.com/news/ARMP/todd-patrick-chief-executive-officer-brian-varnum-president-and-chief-development-officer--armp-20190514monthly0.5https://www.biopharmawatch.com/news/ARMP/c3j-therapeutics-and-ampliphi-biosciences-announce-successful-completion-of-merger-and-for-armp-20190510monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20190508monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-c3j-therapeutics-conference-call-to-discuss-proposed-merger-script-armp-20190114monthly0.5https://www.biopharmawatch.com/news/ARMP/advancing-bacteriophage-therapeutics-for-patients-with-antibiotic-resistant-infections-armp-20190107monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-and-c3j-therapeutics-agree-to-merge-transaction-to-result-in-nyse-ame-armp-20190104monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-announces-presentation-of-positive-clinical-data-from-its-expanded-ac-armp-20181009monthly0.5https://www.biopharmawatch.com/news/ARMP/company-overview-we-are-a-clinical-stage-biotechnology-company-focused-on-precisely-target-armp-20180917monthly0.5https://www.biopharmawatch.com/news/ARMP/advancing-bacteriophage-therapeutics-for-patients-with-antibiotic-resistant-infections-com-armp-20180905monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20180809monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20180515monthly0.5https://www.biopharmawatch.com/news/ARMP/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-armp-20180320monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20180314monthly0.5https://www.biopharmawatch.com/news/ARMP/advancing-bacteriophage-therapeutics-for-patients-with-antibiotic-resistant-infections-bio-armp-20180108monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20171214monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20171114monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-2016-equity-incentive-plan-adopted-by-the-board-of-direct-armp-20170911monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20170814monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-first-amendment-to-common-stock-issuance-agreement-this-f-armp-20170627monthly0.5https://www.biopharmawatch.com/news/ARMP/developing-bacteriophage-therapies-for-patients-with-antibiotic-resistant-infections-armp-20170606monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20170515monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20170504monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20170501monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-amendment-to-offer-letter-agreement-this-amendment-to-off-armp-20170401monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-amp-armp-20170327monthly0.5https://www.biopharmawatch.com/news/ARMP/global-leader-in-bacteriophage-development-to-combat-infectious-diseases-january-2017-nyse-armp-20170109monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-announces-pricing-of-public-offering-of-common-stock-and-warrants-amp-armp-20161117monthly0.5https://www.biopharmawatch.com/news/ARMP/settlement-agreement-this-settlement-agreement-agreement-by-and-between-nrm-vii-holdings-i-armp-20161112monthly0.5https://www.biopharmawatch.com/news/ARMP/amendment-to-consulting-agreement-this-amendment-to-consulting-agreement-the-amendment-is--armp-20160927monthly0.5https://www.biopharmawatch.com/news/ARMP/company-overview-we-are-a-biotechnology-company-focused-on-the-discovery-development-and-c-armp-20160901monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-reports-second-quarter-2016-financial-results-and-provides-corporate--armp-20160815monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-announces-pricing-armp-20160601monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-pre-armp-20160512monthly0.5https://www.biopharmawatch.com/news/ARMP/julian-kirk-c-o-third-security-llc-the-governor-tyler-1881-grove-ave-radford-virginia-2414-armp-20160415monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-3579-valley-centre-drive-suite-100-san-diego-ca-92130-pre-armp-20160330monthly0.5https://www.biopharmawatch.com/news/ARMP/steve-martin-page-1-of-8-armp-20160118monthly0.5https://www.biopharmawatch.com/news/ARMP/a-global-leader-in-bacteriophage-development-to-combat-infectious-diseases-january-2016-st-armp-20160111monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-800-east-leigh-street-richmond-virginia-23219-press-relea-armp-20150807monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-800-east-leigh-street-richmond-va-23219-press-release-amp-armp-20150522monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-4870-sadler-road-glen-allen-virginia-23060-press-release--armp-20150430monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-biosciences-corporation-4870-sadler-road-glen-allen-virginia-23060-press-release--armp-20150310monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-provides-shareholder-update-bacteriophage-based-antibacterial-therapies-to-treat--armp-20150105monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-announces-departure-of-ceo-jeremy-curnock-cook-ampliphi-s-chairman-named-interim--armp-20140919monthly0.5https://www.biopharmawatch.com/news/ARMP/ampliphi-announces-appointment-of-new-board-member-richmond-va-us-ljubljana-slovenia-and-s-armp-20140522monthly0.5https://www.biopharmawatch.com/news/ARMP/targeted-genetics-corporation-reports-third-quarter-2009-armp-20091116monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-206-660-2588-sdbyars-comcast-net-targeted-geneti-armp-20090331monthly0.5https://www.biopharmawatch.com/news/ARMP/unassociated-document-targeted-genetics-realigns-product-development-priorities-and-implem-armp-20081202monthly0.5https://www.biopharmawatch.com/news/ARMP/unassociated-document-targeted-genetics-board-of-directors-appoints-b-g-susan-robinson-pre-armp-20081117monthly0.5https://www.biopharmawatch.com/news/ARMP/unassociated-document-targeted-genetics-board-of-directors-names-b-g-susan-robinson-as-pre-armp-20081110monthly0.5https://www.biopharmawatch.com/news/ARMP/targeted-genetics-reports-third-quarter-2008-financial-results-conference-call-today-at-5--armp-20081105monthly0.5https://www.biopharmawatch.com/news/ARMP/unassociated-document-targeted-genetics-reports-second-quarter-2008-financial-results-conf-armp-20080806monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-carolyn-wang-weisscomm-partners-weisscomm-partne-armp-20080530monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-weisscomm-partners-for-targeted-genetics-415-946-armp-20080507monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-weisscomm-partners-for-targeted-genetics-415-946-armp-20080328monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contacts-stacie-d-byars-carolyn-wang-director-communications-weisscomm--armp-20071203monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20071126monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20071031monthly0.5https://www.biopharmawatch.com/news/ARMP/unassociated-document-investor-and-media-contact-stacie-d-byars-director-communications-ta-armp-20070807monthly0.5https://www.biopharmawatch.com/news/ARMP/unassociated-document-logo-investor-and-media-contact-stacie-d-byars-director-communicatio-armp-20070806monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070726monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070724monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070628monthly0.5https://www.biopharmawatch.com/news/ARMP/targeted-genetics-announces-19-5-armp-20070622monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070604monthly0.5https://www.biopharmawatch.com/news/ARMP/logo-investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-c-armp-20070524monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contacts-marion-ferguson-celladon-corporation-858-366-4288-stacie-d-bya-armp-20070517monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070509monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070329monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070228monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070111monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20070108monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20061212monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20061113monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20061107monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20060830monthly0.5https://www.biopharmawatch.com/news/ARMP/targeted-genetics-enters-into-new-agreement-with-the-international-aids-vaccine-initiative-armp-20060628monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20060601monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-206-52-armp-20060502monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20060426monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20060316monthly0.5https://www.biopharmawatch.com/news/ARMP/exv99w1-investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetic-armp-20060314monthly0.5https://www.biopharmawatch.com/news/ARMP/stacie-d-byars-director-communications-targeted-genetics-corporation-206-521-7392-targeted-armp-20060310monthly0.5https://www.biopharmawatch.com/news/ARMP/exv99w1-investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetic-armp-20060309monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20060125monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20060118monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20051128monthly0.5https://www.biopharmawatch.com/news/ARMP/iavi-begins-first-phase-ii-preventive-hiv-vaccine-trial-in-south-africa-to-test-targeted-g-armp-20051114monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20051031monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20051011monthly0.5https://www.biopharmawatch.com/news/ARMP/targeted-genetics-logo-r-investor-and-media-contact-stacie-d-byars-director-communications-armp-20050901monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20050822monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20050728monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20050726monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-206-52-armp-20050426monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20050317monthly0.5https://www.biopharmawatch.com/news/ARMP/investor-and-media-contact-stacie-d-byars-director-communications-targeted-genetics-corpor-armp-20050303monthly0.5https://www.biopharmawatch.com/news/ARMP/targeted-genetics-corporation-stacie-byars-206-660-2588-targeted-genetics-announces-prelim-armp-20050222monthly0.5https://www.biopharmawatch.com/news/ARMP/targeted-genetics-corporation-stephanie-seiler-206-713-0124-targeted-genetics-and-celladon-armp-20050104monthly0.5https://www.biopharmawatch.com/news/ARMP/targeted-genetics-corporation-courtney-self-206-521-7392-targeted-genetics-reports-third-q-armp-20041104monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-inc-consolidated-statements-of-operations-unaudited-amounts-in-th-ccrn-20260507monthly0.5https://www.biopharmawatch.com/news/CCRN/document-cross-country-healthcare-announces-fourth-quarter-and-full-year-2025-ccrn-20260304monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-merger-agreement-with-aya-healthcare-terminated-cross-country-to--ccrn-20251204monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-inc-consolidated-statements-of-operations-unaudited-amounts-in-th-ccrn-20251112monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-inc-consolidated-statements-of-operations-unaudited-amounts-in-th-ccrn-20250806monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-inc-consolidated-statements-of-operations-unaudited-amounts-in-th-ccrn-20250507monthly0.5https://www.biopharmawatch.com/news/CCRN/customer-for-the-year-ended-ccrn-20250305monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-stockholders-approve-aya-healthcare-transaction-ccrn-20250228monthly0.5https://www.biopharmawatch.com/news/CCRN/aya-healthcare-to-acquire-cross-country-healthcare-for-approximately-615-million-in-cash-c-ccrn-20241204monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-inc-consolidated-statements-of-operations-unaudited-amounts-in-th-ccrn-20241106monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-inc-consolidated-statements-of-operations-unaudited-amounts-in-th-ccrn-20240731monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-benchmark-s-ccrn-20240503monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-inc-consolidated-statements-of-operations-unaudited-amounts-in-th-ccrn-20240501monthly0.5https://www.biopharmawatch.com/news/CCRN/e-impairment-charges-of-0-7-million-for-the-year-ended-ccrn-20240221monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2023-financial-results-boca-raton-fla-bus-ccrn-20231101monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-hold-third-quarter-2023-earnings-conference-call-on-wednesday-ccrn-20231010monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-16-th-annual-barrington-research-virtual-fall-inves-ccrn-20230814monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2023-financial-results-boca-raton-fla-bu-ccrn-20230802monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-hold-second-quarter-2023-earnings-conference-call-on-wednesday-ccrn-20230711monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-jefferies-2023-healthcare-conference-boca-raton-fla-ccrn-20230522monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2023-financial-results-boca-raton-fla-bus-ccrn-20230503monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-benchmark-healthcare-house-call-virtual-conference--ccrn-20230428monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-2023-bofa-healthcare-conference-boca-raton-fla-busi-ccrn-20230417monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-hold-first-quarter-2023-earnings-conference-call-on-wednesday-ccrn-20230410monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2022-financial-results-boc-ccrn-20230222monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-loop-capital-markets-2023-investor-conference-and-t-ccrn-20230213monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-hold-fourth-quarter-and-full-year-2022-earnings-conference-cal-ccrn-20230131monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-new-appointment-to-board-of-directors-boca-raton-fla-bu-ccrn-20230105monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-new-appointment-to-board-of-directors-boca-raton-fla-bu-ccrn-20221121monthly0.5https://www.biopharmawatch.com/news/CCRN/false000114110300011411032022-11-092022-11-09-cross-country-healthcare-to-attend-the-4-th--ccrn-20221109monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2022-financial-results-boca-raton-fla-bus-ccrn-20221102monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-credit-suisse-31-st-annual-healthcare-conference-bo-ccrn-20221013monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2022-earnings-release-date-and-conference-ccrn-20221010monthly0.5https://www.biopharmawatch.com/news/CCRN/investor-day-2022-cross-country-healthcare-ccrn-20220914monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-host-investor-day-on-ccrn-20220817monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-authorization-of-a-new-100-million-stock-repurchase-pro-ccrn-20220816monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-15-th-annual-barrington-research-virtual-fall-confe-ccrn-20220815monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2022-financial-results-boca-raton-fla-bu-ccrn-20220803monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2022-earnings-release-date-and-conferenc-ccrn-20220711monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-benchmark-2022-healthcare-house-call-virtual-confer-ccrn-20220513monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2022-financial-results-boca-raton-fla-bus-ccrn-20220504monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-2022-bofa-healthcare-conference-boca-raton-fla-busi-ccrn-20220418monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2022-earnings-release-date-and-conference-ccrn-20220412monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-welcomes-daniel-j-white-to-new-chief-commercial-officer-position--ccrn-20220407monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2021-financial-results-boc-ccrn-20220223monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-oppenheimer-s-32nd-annual-virtual-healthcare-confer-ccrn-20220217monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2021-earnings-release-date-ccrn-20220131monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-co-founder-and-ceo-kevin-clark-to-transition-to-chairma-ccrn-20220119monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-bofa-securities-virtual-home-care-2021-conference-b-ccrn-20211112monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2021-financial-results-boca-raton-fla-bus-ccrn-20211103monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-credit-suisse-30-th-annual-virtual-healthcare-confe-ccrn-20211015monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2021-earnings-release-date-and-conference-ccrn-20211007monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-14-th-annual-barrington-research-virtual-fall-inves-ccrn-20210816monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2021-financial-results-boca-raton-fla-bu-ccrn-20210804monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-change-in-conference-call-details-for-second-quarter-20-ccrn-20210730monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2021-earnings-release-date-and-conferenc-ccrn-20210714monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-completes-asset-acquisition-of-workforce-solutions-group-inc-and--ccrn-20210608monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-jefferies-2021-virtual-healthcare-conference-boca-r-ccrn-20210514monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-appoints-phillip-noe-as-chief-information-officer-boca-raton-fla--ccrn-20210510monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2021-financial-results-boca-raton-fla-bus-ccrn-20210505monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-2021-bofa-virtual-healthcare-conference-boca-raton--ccrn-20210420monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2021-earnings-release-date-and-conference-ccrn-20210414monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-sets-the-record-straight-on-vda-oc-indictment-report-doj-indictme-ccrn-20210331monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2020-financial-results-boc-ccrn-20210224monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-truist-securities-2021-technology-internet-services-ccrn-20210216monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2020-earnings-release-date-ccrn-20210129monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-new-executive-leadership-boca-raton-fla-business-wire-ccrn-20210125monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2020-financial-results-boca-raton-fla-bus-ccrn-20201104monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2020-earnings-release-date-and-conference-ccrn-20201021monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-credit-suisse-29th-annual-virtual-healthcare-confer-ccrn-20201020monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-morgan-stanley-2020-annual-global-healthcare-confer-ccrn-20200827monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2020-financial-results-boca-raton-fla-bu-ccrn-20200805monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2020-earnings-release-date-and-conferenc-ccrn-20200721monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-new-appointment-to-board-of-directors-boca-raton-fla-bu-ccrn-20200521monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-jefferies-2020-global-healthcare-conference-boca-ra-ccrn-20200520monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2020-financial-results-boca-raton-fla-bus-ccrn-20200507monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2020-earnings-release-date-and-conference-ccrn-20200421monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2019-financial-results-boc-ccrn-20200304monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-suntrust-robinson-humphrey-technology-internet-serv-ccrn-20200214monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2019-earnings-release-date-ccrn-20200212monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2019-financial-results-boca-raton-fla-bus-ccrn-20191105monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-new-120-million-senior-credit-facility-boca-raton-fla-b-ccrn-20191028monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-28-th-annual-credit-suisse-healthcare-conference-bo-ccrn-20191016monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2019-earnings-release-date-and-conference-ccrn-20191011monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2019-financial-results-boca-raton-fla-bu-ccrn-20190731monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2019-earnings-release-date-and-conferenc-ccrn-20190711monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-jefferies-2019-global-healthcare-conference-ccrn-20190513monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2019-financial-results-boca-raton-fla-bus-ccrn-20190501monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-names-stephen-a-saville-as-executive-vice-president-of-operations-ccrn-20190416monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2019-earnings-release-date-and-conference-ccrn-20190403monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2018-financial-results-boc-ccrn-20190227monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-barclays-global-healthcare-conference-and-oppenheim-ccrn-20190215monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2018-earnings-release-date-ccrn-20190213monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-names-kevin-clark-as-president-and-chief-executive-officer-boca-r-ccrn-20190116monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-j-p-morgan-s-37-th-annual-healthcare-conference-boca-ra-ccrn-20181213monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-acquires-american-personnel-inc-boca-raton-fla-business-wire-ccrn-20181205monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-suntrust-robinson-humphrey-2018-technology-services-ccrn-20181115monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2018-financial-results-boca-raton-fla-bus-ccrn-20181101monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-change-to-earnings-release-and-conference-call-date-for-ccrn-20181019monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-27-th-annual-credit-suisse-healthcare-conference-bo-ccrn-20181016monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2018-earnings-release-date-and-conference-ccrn-20181003monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-upcoming-retirement-of-ccrn-20180910monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-cantor-global-healthcare-conference-ccrn-20180906monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2018-financial-results-boca-raton-fla-bu-ccrn-20180801monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-elects-new-independent-director-ccrn-20180801monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2018-earnings-release-date-and-conferenc-ccrn-20180703monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2018-financial-results-boca-raton-fla-bus-ccrn-20180502monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-ubs-global-healthcare-conference-and-jefferies-2018-ccrn-20180501monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2018-earnings-release-date-and-conference-ccrn-20180404monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2017-financial-results-boc-ccrn-20180228monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-barclays-global-healthcare-conference-and-oppenheim-ccrn-20180220monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-organizational-changes-to-support-expanded-nationwide-p-ccrn-20180125monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-j-p-morgan-s-36th-annual-healthcare-conference-ccrn-20171211monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-suntrust-robinson-humphrey-2017-financial-technolog-ccrn-20171115monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2017-financial-results-ccrn-20171101monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-26th-annual-credit-suisse-healthcare-conference-ccrn-20171012monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2017-earnings-release-date-and-conference-ccrn-20171004monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2017-financial-results-completes-the-ren-ccrn-20170802monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2017-earnings-release-date-and-conferenc-ccrn-20170706monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-completes-acquisition-of-advantage-rn-reaffirms-second-quarter-20-ccrn-20170705monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-acquire-assets-of-advantage-rn-boca-raton-fla-x2014-business-w-ccrn-20170613monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-participate-in-the-benchmark-company-llc-one-on-one-investor-c-ccrn-20170511monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2017-financial-results-boca-raton-fla-bus-ccrn-20170503monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-ubs-global-healthcare-conference-boca-raton-fla-bus-ccrn-20170501monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2017-earnings-release-date-and-conference-ccrn-20170405monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2016-financial-results-boc-ccrn-20170301monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-barclays-global-healthcare-conference-and-oppenheim-ccrn-20170222monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2016-earnings-release-date-ccrn-20170203monthly0.5https://www.biopharmawatch.com/news/CCRN/vizient-inc-awards-cross-country-healthcare-three-year-contract-boca-raton-fla-business-wi-ccrn-20170112monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-j-p-morgan-s-35-th-healthcare-conference-boca-raton-fla-ccrn-20161215monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-acquires-rpo-business-boca-raton-fla-business-wire-ccrn-20161201monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2016-financial-results-boca-raton-fla-bus-ccrn-20161102monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-suntrust-humphrey-2016-business-government-services-ccrn-20161019monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2016-earnings-release-date-and-conference-ccrn-20161010monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2016-financial-results-boca-raton-fla-bu-ccrn-20160803monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-2016-avondale-partners-healthcare-1-1-conference-bo-ccrn-20160720monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2016-earnings-release-date-and-conferenc-ccrn-20160706monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-replaces-senior-credit-facility-boca-raton-fla-x2013-ccrn-20160622monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-cantor-fitzgerald-s-2-nd-annual-healthcare-conferen-ccrn-20160621monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-baird-2016-global-consumer-technology-services-conf-ccrn-20160517monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2016-financial-results-boca-raton-fla-bus-ccrn-20160504monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-the-ubs-global-healthcare-conference-boca-raton-fla-ccrn-20160502monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2016-earnings-release-date-and-conference-ccrn-20160406monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2015-financial-results-boc-ccrn-20160309monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2015-earnings-release-date-ccrn-20160211monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-the-oppenheimer-26-th-annual-healthcare-conference--ccrn-20151118monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2015-financial-results-boca-raton-fla-bus-ccrn-20151104monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-completes-acquisition-of-mediscan-boca-raton-fla-business-wire-ccrn-20151102monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-participate-in-j-p-morgan-ultimate-services-investor-conferenc-ccrn-20151022monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-acquire-mediscan-boca-raton-fla-business-wire-ccrn-20151019monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2015-earnings-release-date-and-conference-ccrn-20151008monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-completes-the-sale-of-its-education-business-boca-raton-fla-busin-ccrn-20150901monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2015-ccrn-20150805monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-agreement-to-sell-its-education-business-boca-raton-fla-ccrn-20150729monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-reprices-second-lien-loan-boca-raton-fla-business-wire-ccrn-20150722monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-second-quarter-2015-earnings-release-date-and-conferenc-ccrn-20150709monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-attend-the-cantor-fitzgerald-healthcare-conference-and-avondal-ccrn-20150619monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-inc-consolidated-statements-of-operations-unaudited-amounts-in-th-ccrn-20150506monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-participate-in-ubs-global-healthcare-conference-boca-raton-fla-ccrn-20150505monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2015-earnings-release-date-and-conference-ccrn-20150409monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2014-ccrn-20150304monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2014-earnings-release-date-ccrn-20150204monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-oppenheimer-healthcare-conference-boca-raton-fla-bu-ccrn-20141113monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-third-quarter-2014-ccrn-20141105monthly0.5https://www.biopharmawatch.com/news/CCRN/transcript-ccrn-20140807monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-schedules-second-quarter-2014-earnings-release-and-conference-cal-ccrn-20140707monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-jefferies-2014-global-healthcare-conference-boca-ra-ccrn-20140512monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2014-ccrn-20140507monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-bank-of-america-merrill-lynch-2014-health-care-conf-ccrn-20140422monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-schedules-first-quarter-2014-earnings-release-and-conference-call-ccrn-20140407monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-updated-fourth-quarter-full-year-2013-financial-results-ccrn-20140317monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-full-year-2013-financial-results-william-ccrn-20140305monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-barclays-global-healthcare-conference-and-sidoti-co-ccrn-20140218monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-announces-fourth-quarter-and-full-year-2013-earnings-release-date-ccrn-20140211monthly0.5https://www.biopharmawatch.com/news/CCRN/cross-country-healthcare-to-present-at-baird-s-2014-business-solutions-conference-ccrn-20140127monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-second-quarter-2025-financial-results-and-raises-full-year-2025-rev-sght-20250807monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-first-quarter-2025-financial-results-and-reaffirms-full-year-2025-r-sght-20250508monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-appoints-gary-burbach-to-its-board-of-directors-sght-20250422monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-initiates-f-sght-20250305monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-sght-20250114monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-third-quarter-2024-financial-results-and-updates-its-full-year-2024-sght-20241107monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-second-quarter-2024-financial-results-and-narrows-full-year-2024-fi-sght-20240801monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-first-quarter-2024-financial-results-and-reaffirms-full-year-2024-f-sght-20240502monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-successful-34-million-patent-infringement-verdict-against-alcon-a-sght-20240429monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-initiates-f-sght-20240307monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-closing-of-up-to-65-million-senior-secured-credit-facility-wi-sght-20240123monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-third-quarter-2023-financial-results-and-withdraws-guidance-for-ful-sght-20231107monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-appoints-matt-link-as-chief-commercial-officer-former-nuvasive-president-he-sght-20230911monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-second-quarter-2023-financial-results-and-reaffirms-guidance-for-fu-sght-20230803monthly0.5https://www.biopharmawatch.com/news/SGHT/delivering-the-power-of-sight-investor-presentation-may-2023-forward-looking-statements-th-sght-20230508monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-first-quarter-2023-financial-results-and-reaffirms-guidance-for-ful-sght-20230504monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-appoints-ali-bauerlein-as-chief-financial-officer-sght-20230403monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-fourth-quarter-and-full-year-2022-financial-results-sght-20230313monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-financial-sght-20230109monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-third-quarter-2022-financial-results-sght-20221110monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-introduces-the-sion-surgical-instrument-x2013-the-first-bladeless-device-us-sght-20220823monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-second-quarter-2022-financial-results-sght-20220811monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-first-quarter-2022-financial-results-sght-20220510monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-fourth-quarter-and-full-year-2021-financial-results-sght-20220324monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-preliminary-unaudited-fourth-quarter-and-full-year-2021-financial-sght-20220110monthly0.5https://www.biopharmawatch.com/news/SGHT/forward-looking-statements-this-presentation-together-with-other-statements-and-informatio-sght-20211130monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-third-quarter-2021-financial-results-sght-20211110monthly0.5https://www.biopharmawatch.com/news/SGHT/delivering-the-power-of-sight-investor-presentation-september-2021-1-forward-looking-state-sght-20210831monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-second-quarter-2021-financial-results-sght-20210812monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-pro-tara-20260310monthly0.5https://www.biopharmawatch.com/news/TARA/interim-data-presentation-from-the-advanced-2-trial-of-tara-002-in-bcg-na-ve-nmibc-patient-tara-20251203monthly0.5https://www.biopharmawatch.com/news/TARA/starborn-1-clinical-trial-interim-update-tara-20251119monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-second-quarter-2025-financial-results-and-provides-business-tara-20250811monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-first-quarter-2025-financial-results-and-provides-business--tara-20250508monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-positive-interim-results-demonstrating-durable-responses-in-tara-20250428monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-pro-tara-20250305monthly0.5https://www.biopharmawatch.com/news/TARA/corporate-presentation-january-2025-forward-looking-statements-2-2025-protara-therapeutics-tara-20250113monthly0.5https://www.biopharmawatch.com/news/TARA/protara-announces-proposed-public-offering-tara-20241209monthly0.5https://www.biopharmawatch.com/news/TARA/advanced-2-trial-interim-results-december-2024-forward-looking-statements-statements-conta-tara-20241205monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-third-quarter-2024-financial-results-and-provides-a-busines-tara-20241112monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-second-quarter-2024-financial-results-and-provides-a-busine-tara-20240806monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-first-quarter-2024-financial-results-and-provides-business--tara-20240502monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-alignment-with-fda-on-registrational-path-forward-for-iv-ch-tara-20240405monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-pro-tara-20240313monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-third-quarter-2023-financial-results-and-business-update-do-tara-20231103monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-second-quarter-2023-financial-results-and-business-update-d-tara-20230803monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-first-quarter-2023-financial-results-and-business-update-fa-tara-20230504monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-receives-regulatory-clearance-from-fda-to-commence-phase-2-starborn-1-tara-20230502monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-positive-preliminary-data-from-advanced-1-phase-1a-dose-esc-tara-20230428monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and-pro-tara-20230308monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-appointment-of-patrick-fabbio-as-chief-financial-officer-tara-20230130monthly0.5https://www.biopharmawatch.com/news/TARA/corporate-presentation-january-2023-forward-looking-statements-2-2023-protara-therapeutics-tara-20230105monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-third-quarter-2022-financial-results-and-business-overview--tara-20221103monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-second-quarter-2022-financial-results-and-business-overview-tara-20220809monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-departure-of-chief-financial-officer-new-york-tara-20220621monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-first-quarter-2022-financial-results-and-business-overview--tara-20220505monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-bus-tara-20220309monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-appointment-of-jathin-bandari-m-d-as-chief-medical-officer-tara-20220110monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-third-quarter-2021-financial-results-and-business-overview--tara-20211104monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-t-tara-20211012monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-second-quarter-2021-financial-results-and-business-overview-tara-20210805monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-appointment-of-jane-huang-m-d-to-board-of-directors-tara-20210610monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-provides-regulatory-update-for-tara-002-for-the-treatment-of-lymphati-tara-20210423monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-appointment-of-mart-n-sebastian-olivo-m-d-as-chief-medical--tara-20210419monthly0.5https://www.biopharmawatch.com/news/TARA/corporate-presentation-february-2021-forward-looking-statements-statements-contained-in-th-tara-20210205monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-appointment-of-cynthia-smith-to-board-of-directors-tara-20210202monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-proposed-concurrent-public-offerings-of-common-stock-and-pr-tara-20200921monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-provides-comparability-and-u-s-regulatory-updates-for-tara-002-suppor-tara-20200908monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-appointment-of-barry-p-flannelly-to-board-of-directors-tara-20200724monthly0.5https://www.biopharmawatch.com/news/TARA/artara-therapeutics-appoints-blaine-davis-as-chief-financial-officer-tara-20200211monthly0.5https://www.biopharmawatch.com/news/TARA/artara-therapeutics-completes-merger-transaction-with-proteon-therapeutics-shares-of-artar-tara-20200110monthly0.5https://www.biopharmawatch.com/news/TARA/artara-therapeutics-and-proteon-therapeutics-proposed-combination-webcast-tuesday-septembe-tara-20190924monthly0.5https://www.biopharmawatch.com/news/TARA/proteon-therapeutics-and-artara-therapeutics-agree-to-combine-transaction-to-create-nasdaq-tara-20190923monthly0.5https://www.biopharmawatch.com/news/TARA/proteon-therapeutics-announces-top-line-results-from-phase-3-patency-2-clinical-trial-of-v-tara-20190328monthly0.5https://www.biopharmawatch.com/news/TARA/exif-mm-1-2-i-adobe-photoshop-elements-11-0-windo-tara-20170322monthly0.5https://www.biopharmawatch.com/news/TARA/proteon-therapeutics-announces-top-line-data-from-phase-3-patency-1-clinical-trial-of-inve-tara-20161213monthly0.5https://www.biopharmawatch.com/news/TARA/proteon-therapeutics-appoints-scott-toner-as-senior-vice-president-of-marketing-tara-20150602monthly0.5https://www.biopharmawatch.com/news/TARA/proteon-therapeutics-announces-positive-long-term-results-from-phase-2-study-of-investigat-tara-20150327monthly0.5https://www.biopharmawatch.com/news/TARA/jfif-d-d-iexif-mm-b-j-1-r-2-i-d-d-adobe-photoshop-cs2-windows-2014-12-08-09-12-53-tara-20141208monthly0.5https://www.biopharmawatch.com/news/MGNX/candidates-in-ongoing-clinical-trials-the-company-s-ability-to-provide-manufacturing-servi-mgnx-20260504monthly0.5https://www.biopharmawatch.com/news/MGNX/more-information-please-see-the-company-s-website-at-www-macrogenics-com-macrogenics-the-m-mgnx-20260408monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-reports-2025-financial-results-and-highlights-upcoming-planned-data-disclosure-mgnx-20260309monthly0.5https://www.biopharmawatch.com/news/MGNX/301-251-5172-info-macrogenics-com-argot-partners-1-212-600-1902-macrogenics-argotpartners--mgnx-20260224monthly0.5https://www.biopharmawatch.com/news/MGNX/document-macrogenics-appoints-eric-risser-as-president-and-chief-executive-officer-rockvil-mgnx-20250813monthly0.5https://www.biopharmawatch.com/news/MGNX/expressions-or-by-discussions-of-strategy-constitute-forward-looking-statements-within-the-mgnx-20250610monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2025-financial-results-mgnx-20250513monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2024-financial-results-fully-enrolle-mgnx-20250320monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-third-quarter-2024-financial-results-str-mgnx-20241105monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-leadership-transition-scott-koenig-m-d-ph-d-to-step-down-as-presiden-mgnx-20241030monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study-of-vobra-du-mgnx-20240916monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-second-quarter-2024-financial-results-up-mgnx-20240806monthly0.5https://www.biopharmawatch.com/news/MGNX/statements-within-the-meaning-of-section-27a-of-the-securities-act-of-1933-and-section-21e-mgnx-20240730monthly0.5https://www.biopharmawatch.com/news/MGNX/the-regulatory-review-process-expectations-for-regulatory-approvals-expectations-of-future-mgnx-20240730monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-first-quarter-2024-financial-results-and-mgnx-20240509monthly0.5https://www.biopharmawatch.com/news/MGNX/clinical-trials-expected-timing-of-results-from-clinical-trials-discussions-with-regulator-mgnx-20240403monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2023-financial-results-presentation--mgnx-20240307monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-third-quarter-2023-financial-results-mgnx-20231106monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2023-financial-result-mgnx-20230809monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2023-financial-results-mgnx-20230509monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-earns-15-million-milestone-following-u-s-fda-approval-of-zynyz-retifanlimab-dl-mgnx-20230322monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-corporate-update-and-2022-financial-results-cash-runway-extended-thro-mgnx-20230315monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-sale-of-tzield-royalty-interest-for-up-to-200-million-rockville-md-mgnx-20230308monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-preliminary-clinical-results-from-single-arm-study-of-lorigerlimab-i-mgnx-20230213monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-appointment-of-dr-margaret-liu-and-meenu-chhabra-karson-to-board-of--mgnx-20230104monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-earns-60-million-milestone-with-u-s-fda-approval-of-teplizumab-rockville-m-d-mgnx-20221117monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-corporate-update-and-third-quarter-2022-financial-results-collaborati-mgnx-20221103monthly0.5https://www.biopharmawatch.com/news/MGNX/gilead-contacts-macrogenics-contact-jacquie-ross-investors-jim-karrels-senior-vice-preside-mgnx-20221017monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2022-financial-result-mgnx-20220808monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-closure-of-cp-mga271-06-study-evaluating-enoblituzumab-plus-checkpoi-mgnx-20220708monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-appointment-of-william-heiden-to-board-of-directors-rockville-md-mgnx-20220523monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2022-financial-results-mgnx-20220503monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2021-financial-results-initiating-ph-mgnx-20220224monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-third-quarter-2021-financial-results-mgnx-20211102monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2021-financial-result-mgnx-20210729monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2021-financial-results-mgnx-20210429monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2020-financial-results-margenza-appr-mgnx-20210225monthly0.5https://www.biopharmawatch.com/news/MGNX/cautionary-note-on-forward-looking-statements-any-statements-in-this-press-release-about-f-mgnx-20210211monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-third-quarter-2020-financial-results-mgnx-20201104monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2020-financial-result-mgnx-20200730monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-appoints-dr-stephen-eck-as-chief-medical-officer-rockville-md-mgnx-20200616monthly0.5https://www.biopharmawatch.com/news/MGNX/document-macrogenics-announces-preliminary-clinical-results-from-mgd013-and-mgc018-to-be-p-mgnx-20200513monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2020-financial-results-mgnx-20200505monthly0.5https://www.biopharmawatch.com/news/MGNX/document-macrogenics-to-host-its-annual-meeting-of-stockholders-in-virtual-format-rockvill-mgnx-20200428monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-departure-of-chief-medical-officer-rockville-md-mgnx-20200304monthly0.5https://www.biopharmawatch.com/news/MGNX/about-macrogenics-inc-macrogenics-is-a-clinical-stage-biopharmaceutical-company-focused-on-mgnx-20200225monthly0.5https://www.biopharmawatch.com/news/MGNX/www-macrogenics-com-macrogenics-the-macrogenics-logo-and-dart-are-trademarks-or-registered-mgnx-20191106monthly0.5https://www.biopharmawatch.com/news/MGNX/document-exhbit-99-1-macrogenics-announces-second-interim-overall-survival-data-from-phase-mgnx-20191022monthly0.5https://www.biopharmawatch.com/news/MGNX/thereon-and-similar-expressions-or-by-discussions-of-strategy-constitute-forward-looking-s-mgnx-20190731monthly0.5https://www.biopharmawatch.com/news/MGNX/about-macrogenics-inc-macrogenics-is-a-clinical-stage-biopharmaceutical-company-focused-on-mgnx-20190501monthly0.5https://www.biopharmawatch.com/news/MGNX/document-exhibi-t-99-1-macrogenics-provides-update-on-corporate-progress-and-2018-financia-mgnx-20190226monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-third-quarter-2017-financial-results-mgnx-20171108monthly0.5https://www.biopharmawatch.com/news/MGNX/incyte-and-macrogenics-announce-global-collaboration-and-licensing-agreement-for-anti-pd-1-mgnx-20171025monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-1-st-quarter-2017-financial-results--mgnx-20170503monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-third-quarter-2016-financial-results-mgnx-20161102monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2016-financial-result-mgnx-20160803monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2016-financial-results-mgnx-20160504monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2015-financial-results-eight-molecul-mgnx-20160229monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-third-quarter-2015-financial-results-mgnx-20151104monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-regains-european-and-other-regional-rights-to-enoblituzumab-servier-does-not-e-mgnx-20151028monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-closing-of-collaboration-and-license-agreement-with-janssen-to-devel-mgnx-20150127monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-enters-collaboration-and-license-agreement-with-janssen-to-develop-mgd011-for--mgnx-20141222monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-and-takeda-enter-strategic-alliance-to-develop-dart-for-treatment-of-autoimmun-mgnx-20140527monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2013-financial-results-six-immuno-on-mgnx-20140320monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-corporate-progress-update-and-third-quarter-2013-financial-results-ro-mgnx-20131112monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-closing-of-initial-public-offering-and-full-exercise-of-over-allotme-mgnx-20131016monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-second-quarter-2025-financial-results-and-provides-corporate-update-x-alxo-20250812monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-first-quarter-2025-financial-results-and-provides-corporate-update-x2-alxo-20250508monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corp-alxo-20250306monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-further-additions-to-leadership-team-and-board-of-directors-appoint-alxo-20250122monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-alan-sandler-m-d-as-chief-medical-officer-dr-sandler-brings-more-tha-alxo-20241114monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-third-quarter-2024-financial-results-and-provides-corporate-update-alxo-20241107monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-second-quarter-2024-financial-results-and-provides-corporate-update-alxo-20240808monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-alan-sandler-m-d-to-board-of-directors-x25aa-dr-sandler-brings-more--alxo-20240806monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-first-quarter-2024-financial-results-and-provides-corporate-update-alxo-20240509monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corp-alxo-20240307monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-third-quarter-2023-financial-results-and-provides-corporate-update-alxo-20231113monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-pricing-of-public-offering-alxo-20231005monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-positive-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacep-alxo-20231003monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-realigns-executive-leadership-team-jason-lettmann-appointed-as-chief-executiv-alxo-20230906monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-second-quarter-2023-financial-results-and-provides-clinical-program-u-alxo-20230810monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-first-quarter-2023-financial-results-and-provides-clinical-developmen-alxo-20230511monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-clin-alxo-20230309monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-scott-garland-to-its-board-of-directors-alxo-20221129monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-third-quarter-2022-financial-results-and-provides-clinical-developmen-alxo-20221108monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-enters-100-million-loan-facility-agreement-with-oxford-finance-and-silicon-va-alxo-20221031monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-second-quarter-2022-financial-results-and-provides-clinical-developme-alxo-20220808monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-first-quarter-2022-financial-results-an-d-provides-clinical-developme-alxo-20220509monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-itziar-canamasas-ph-d-to-its-board-of-directors-alxo-20220412monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-clin-alxo-20220228monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-third-quarter-2021-financial-results-and-provides-clinical-developmen-alxo-20211111monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-strengthens-immuno-oncology-pipeline-with-acquisition-of-scalmibio-acquisitio-alxo-20211007monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-second-quarter-2021-financial-results-and-provides-clinical-developme-alxo-20210812monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-first-quarter-2021-financial-results-and-provides-clinical-developmen-alxo-20210517monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-clin-alxo-20210318monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-appointment-of-sophia-randolph-m-d-ph-d-to-board-of-directors-alxo-20210315monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-third-quarter-2020-financial-results-and-provides-clinical-developmen-alxo-20201112monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-second-quarter-2020-financial-results-and-provides-operational-and-cl-alxo-20200827monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwr-alxo-20200721monthly0.5https://www.biopharmawatch.com/news/NAGE/document-niagen-bioscience-inc-reports-first-quarter-2026-financial-results-net-sales-incr-nage-20260506monthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-increases-share-repurchase-program-to-20-million-nage-20260319monthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-to-streamline-and-focus-its-operations-with-the-sale-of-chromadex-refere-nage-20260224monthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-acquires-core-nicotinamide-riboside-nr-patent-portfolio-from-queen-s-uni-nage-20251222monthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-announces-10-million-share-repurchase-program-nage-20251106monthly0.5https://www.biopharmawatch.com/news/NAGE/document-niagen-bioscience-inc-reports-third-quarter-2025-financial-results-and-reaffirms--nage-20251104monthly0.5https://www.biopharmawatch.com/news/NAGE/document-niagen-bioscience-inc-reports-second-quarter-2025-financial-results-and-increases-nage-20250806monthly0.5https://www.biopharmawatch.com/news/NAGE/document-niagen-bioscience-inc-reports-first-quarter-2025-financial-results-and-increases--nage-20250507monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-evolves-into-niagen-bioscience-marking-a-new-era-of-uncovering-the-potential-of--nage-20250319monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2024-results-full-year-net-sa-nage-20250304monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-third-quarter-2024-financial-results-total-net-sale-nage-20241031monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-second-quarter-2024-financial-results-total-net-sal-nage-20240807monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-first-quarter-2024-financial-results-total-net-sale-nage-20240508monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2023-results-fourth-quarter-n-nage-20240306monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-third-quarter-2023-financial-results-total-net-sale-nage-20231108monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-second-quarter-2023-financial-results-strong-quarte-nage-20230809monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-first-quarter-2023-financial-results-record-net-sal-nage-20230510monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2022-results-record-revenue-i-nage-20230308monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-third-quarter-2022-financial-results-total-net-sale-nage-20221102monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-first-quarter-2022-financial-results-total-net-sale-nage-20220512monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-fourth-quarter-and-fiscal-year-2021-results-total-n-nage-20220309monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-third-quarter-2021-financial-results-total-company--nage-20211103monthly0.5https://www.biopharmawatch.com/news/NAGE/document-chromadex-corporation-reports-second-quarter-2021-financial-results-tru-niagen-ne-nage-20210803monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-first-quarter-2021-financial-results-tru-niagen-xae-revenue--nage-20210506monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-2020-financial-results-revenue-for-the-three-month-period-en-nage-20210310monthly0.5https://www.biopharmawatch.com/news/NAGE/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-nage-20210220monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-third-quarter-2020-financial-results-revenue-for-the-three-m-nage-20201104monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-second-quarter-2020-financial-results-second-quarter-2020-hi-nage-20200806monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-amended-2017-equity-incentive-plan-adopted-by-the-board-of-directors-nage-20200622monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-first-quarter-2020-financial-results-first-quarter-2020-high-nage-20200511monthly0.5https://www.biopharmawatch.com/news/NAGE/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-nage-20200427monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-2019-financial-results-fourth-quarter-2019-highlights-vs-fou-nage-20200310monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-third-quarter-2019-financial-results-third-quarter-2019-high-nage-20191112monthly0.5https://www.biopharmawatch.com/news/NAGE/confidential-execution-version-registration-rights-agreement-this-registration-rights-agre-nage-20190815monthly0.5https://www.biopharmawatch.com/news/NAGE/confidential-execution-version-securities-purchase-agreement-this-securities-purchase-agre-nage-20190813monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-second-quarter-2019-financial-results-second-quarter-2019-ne-nage-20190807monthly0.5https://www.biopharmawatch.com/news/NAGE/omnibus-amendment-to-note-purchase-agreement-and-convertible-promissory-notes-this-omnibus-nage-20190630monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corp-and-nestl-xe9-health-science-enter-global-commercial-license-and-supply-agr-nage-20190514monthly0.5https://www.biopharmawatch.com/news/NAGE/execution-version-note-purchase-agreement-this-note-purchase-agreement-this-x201c-agreemen-nage-20190509monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-first-quarter-2019-financial-results-first-quarter-2019-net--nage-20190509monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-2018-financial-results-full-year-2018-net-revenues-increased-nage-20190307monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corp-and-nestl-xe9-health-science-enter-global-commercial-license-and-supply-agr-nage-20181220monthly0.5https://www.biopharmawatch.com/news/NAGE/presentation-untitled-document-nage-20181204monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-third-quarter-2018-financial-results-third-quarter-2018-net--nage-20181107monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-and-dartmouth-college-file-patent-infringement-lawsuit-against-elysium-health-nage-20180918monthly0.5https://www.biopharmawatch.com/news/NAGE/e-xhibit-99-1-chromadex-corporation-reports-second-quarter-2018-financial-results-second-q-nage-20180809monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-2017-equity-incentive-plan-adopted-by-the-board-of-directors-nage-20180628monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-first-quarter-2018-financial-results-first-quarter-2018-net--nage-20180510monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-appoints-frank-jaksch-as-executive-chairman-rob-fried-as-chief-executive-officer-nage-20180423monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-2017-financial-results-fourth-quarter-2017-net-revenues-incr-nage-20180308monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-reports-preliminary-2017-results-fourth-quarter-2017-net-revenues-ex-nage-20180212monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corporation-2017-equity-incentive-plan-adopted-by-the-board-of-directors-nage-20180123monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-reports-third-quarter-2017-financial-results-company-reports-third-quarter-2017--nage-20171109monthly0.5https://www.biopharmawatch.com/news/NAGE/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-nage-20171103monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-appoints-kevin-farr-as-new-nage-20171009monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-sells-its-analytical-testing-business-to-labcorp-to-accelerate-the-expansion-of--nage-20170823monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-announces-closing-of-third-and-final-tranche-of-the-25-million-strategic-investm-nage-20170821monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-reports-second-quarter-2017-financial-results-company-reports-revenue-of-5-3-mil-nage-20170810monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-announces-an-exclusive-worldwide-patent-license-and-research-agreement-with-the--nage-20170612monthly0.5https://www.biopharmawatch.com/news/NAGE/first-amendment-to-securities-purchase-agreement-this-first-amendment-to-securities-purcha-nage-20170524monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-reports-first-quarter-2017-financial-results-changes-in-q1-and-new-investor-set--nage-20170511monthly0.5https://www.biopharmawatch.com/news/NAGE/registration-rights-agreement-this-registration-rights-agreement-the-x201c-agreement-x201d-nage-20170429monthly0.5https://www.biopharmawatch.com/news/NAGE/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-nage-20170426monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-appoints-steven-d-rubin-j-d-to-its-board-of-directors-nage-20170328monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-reports-2016-record-revenue-as-ingredient-sales-grew-34-q4-total-revenue-increas-nage-20170316monthly0.5https://www.biopharmawatch.com/news/NAGE/a-letter-from-the-chromadex-chief-executive-officer-nage-20170223monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-expects-to-report-record-fourth-quarter-as-revenue-increased-approximately-29-q4-nage-20170214monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-reports-third-quarter-2016-financial-results-company-reports-revenue-of-21-2-mil-nage-20161110monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-establishes-5-million-credit-facility-with-bridge-bank-nage-20161108monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-appoints-kurt-gustafson-to-its-board-of-directors-nage-20161027monthly0.5https://www.biopharmawatch.com/news/NAGE/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33--nage-20160913monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-reports-record-revenue-as-ingredients-sales-climb-83-compared-to-previous-year-p-nage-20160811monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-names-former-chairman-ceo-of-the-quaker-oats-company-william-smithburg-to-its-bo-nage-20160607monthly0.5https://www.biopharmawatch.com/news/NAGE/resignation-letter-nage-20160513monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-approved-for-listing-on-the-nasdaq-capital-market-company-will-begin-trading-on--nage-20160421monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-announces-reverse-stock-split-as-company-seeks-to-list-its-common-stock-on-the-n-nage-20160412monthly0.5https://www.biopharmawatch.com/news/NAGE/investor-presentation-of-chromadex-corporation-ex99-1-htm-nage-20160315monthly0.5https://www.biopharmawatch.com/news/NAGE/a-letter-from-the-chromadex-chief-executive-officer-nage-20160106monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-enters-into-an-exclusive-joint-development-agreement-with-the-procter-gamble-com-nage-20151105monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-announces-2-000-000-registered-direct-offering-financing-increases-stockholder-e-nage-20151105monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-welcomes-business-media-executive-and-academy-award-winning-producer-rob-fried-t-nage-20150713monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-expands-patent-rights-to-pterostilbene-nage-20150604monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-announces-exclusive-worldwide-license-and-supply-agreement-for-anthocyanin-rich--nage-20150521monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-appoints-former-glaxosmithkline-executive-jeff-baxter-to-its-board-of-directors-nage-20150420monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-appoints-former-nestl-executive-steve-allen-as-chairman-company-reduces-number-o-nage-20150303monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-s-niagen-nicotinamide-riboside-meets-primary-endpoint-in-first-human-clinical-st-nage-20150211monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-receives-750-000-cash-from-previous-sale-of-its-bluscience-line-nage-20141203monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-licenses-exclusive-worldwide-patent-rights-from-the-university-of-mississippi-fo-nage-20141202monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-secures-5-0-million-in-growth-capital-financing-from-hercules-nage-20140930monthly0.5https://www.biopharmawatch.com/news/NAGE/university-of-california-irvine-completes-pterostilbene-study-for-prevention-of-skin-damag-nage-20140922monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-licenses-exclusive-patent-rights-from-dartmouth-college-for-pharmaceutical-use-o-nage-20140603monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-announces-62-million-ingredient-agreement-with-network-marketing-company-5linx-f-nage-20140106monthly0.5https://www.biopharmawatch.com/news/NAGE/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-nage-20131204monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-acquires-new-exclusive-worldwide-patent-rights-for-pteropure-pterostilbene-relat-nage-20130805monthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-supply-aggreement-this-agreement-the-agreement-is-made-and-entered-into-as-of-nage-20130709monthly0.5https://www.biopharmawatch.com/news/NAGE/htm-chromadex-adds-to-its-exclusive-worldwide-patent-rights-for-nicotinamide-riboside-nr-w-nage-20130308monthly0.5https://www.biopharmawatch.com/news/NAGE/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-nage-20121205monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-acquires-spherix-consulting-spherix-consulting-brings-technical-and-regulatory-s-nage-20121203monthly0.5https://www.biopharmawatch.com/news/NAGE/presentation-abstract-session-13-poster-session-ii-thursday-nage-20120920monthly0.5https://www.biopharmawatch.com/news/NAGE/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-nage-20120830monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-licenses-exclusive-patent-rights-for-nicotinamide-riboside-nr-vitamin-technologi-nage-20120716monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-corp-names-co-founder-frank-jaksch-ceo-president-nage-20120612monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-announces-management-changes-nage-20120217monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-to-raise-10-85m-in-sale-of-common-stock-nage-20120201monthly0.5https://www.biopharmawatch.com/news/NAGE/investor-presentation-ex99-1-htm-nage-20120127monthly0.5https://www.biopharmawatch.com/news/NAGE/irvine-calif-nage-20120123monthly0.5https://www.biopharmawatch.com/news/NAGE/investor-presentation-slides-ex99-1-htm-ex-99-1-http-investors-chromadex-com-phoenix-zhtml-nage-20110614monthly0.5https://www.biopharmawatch.com/news/NAGE/chromadex-receives-investment-from-the-frost-group-llc-capital-will-allow-chromadex-to-pur-nage-20100426monthly0.5https://www.biopharmawatch.com/news/SLN/inquiries-silence-therapeutics-plc-gem-hopkins-vp-head-of-ir-and-corporate-communications--sln-20260611monthly0.5https://www.biopharmawatch.com/news/SLN/xfeff-silence-therapeutics-highlights-recent-business-achievements-and-reports-first-quart-sln-20260507monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-leadership-changes-15-december-2025-london-silence-therapeu-sln-20251215monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-high-sln-20251106monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-completes-enrollment-in-sanreco-phase-2-study-of-divesiran-for-polycy-sln-20251023monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-hig-sln-20250807monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-reports-first-quarter-2025-financial-results-and-recent-business-high-sln-20250508monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-welcomes-tim-mcinerney-to-board-of-directors-mr-mcinerney-brings-over-sln-20250506monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-reports-full-year-2024-financial-results-and-provides-business-update-sln-20250227monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-presents-promising-phase-1-data-in-polycythemia-vera-patients-at-the--sln-20241209monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-presents-late-breaking-phase-2-zerlasiran-data-at-2024-american-heart-sln-20241118monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20241114monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20240815monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-positive-results-from-ongoing-sanreco-phase-1-study-of-dive-sln-20240627monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-achieves-2-million-research-milestone-payment-from-hansoh-pharma-coll-sln-20240624monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-positive-topline-48-week-data-from-phase-2-study-of-zerlasi-sln-20240620monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20240516monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-retirement-of-alistair-gray-from-board-of-directors-29-apri-sln-20240501monthly0.5https://www.biopharmawatch.com/news/SLN/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-sln-20240415monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-positive-topline-36-week-data-from-ongoing-phase-2-study-of-sln-20240313monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration--sln-20240223monthly0.5https://www.biopharmawatch.com/news/SLN/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-made-an-sln-20240202monthly0.5https://www.biopharmawatch.com/news/SLN/statements-made-in-this-announcement-relate-only-to-events-as-of-the-date-on-which-the-sta-sln-20231201monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20231114monthly0.5https://www.biopharmawatch.com/news/SLN/about-silence-therapeutics-silence-therapeutics-is-developing-a-new-generation-of-medicine-sln-20231101monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20230829monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20230816monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma--sln-20230711monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20230516monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration--sln-20230504monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-completes-enrollment-in-phase-2-study-of-zerlasiran-sln360-in-subject-sln-20230501monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head--sln-20230328monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-provides-sln360-and-sln124-clinical-program-updates-12-january-2023-l-sln-20230112monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20221110monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-presents-new-analysis-from-sln360-phase-1-single-dose-study-in-high-l-sln-20221107monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-preliminary-single-dose-results-from-sln124-phase-1-study-i-sln-20220929monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-pricing-of-underwritten-offering-london-sln-20220811monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20220811monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20220516monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-plc-notice-of-annual-general-meeting-15-the-agm-is-an-important-oppor-sln-20220516monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-achieves-2-million-research-milestone-in-hansoh-pharma-collaboration--sln-20220425monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-detailed-results-from-sln360-phase-1-study-in-high-lipoprot-sln-20220317monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-and-mallinckrodt-announce-submission-of-clinical-trial-application-fo-sln-20220317monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-appoints-craig-tooman-president-and-chief-executive-officer-mark-roth-sln-20220222monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-positive-topline-data-in-sln360-phase-1-single-ascending-do-sln-20220209monthly0.5https://www.biopharmawatch.com/news/SLN/new-data-from-sln124-healthy-volunteer-study-reinforce-broad-therapeutic-potential-in-hema-sln-20211213monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-plc-update-on-aim-delisting-26-november-2021-london-silence-therapeut-sln-20211126monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20211116monthly0.5https://www.biopharmawatch.com/news/SLN/results-of-general-meeting-1-november-2021-london-silence-therapeutics-plc-aim-sln-and-nas-sln-20211101monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-provides-mrnai-gold-platform-and-pipeline-updates-at-2021-r-d-day-ann-sln-20211021monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20211015monthly0.5https://www.biopharmawatch.com/news/SLN/silence-announces-proposed-cancellation-of-admission-of-its-ordinary-shares-to-trading-on--sln-20211015monthly0.5https://www.biopharmawatch.com/news/SLN/to-this-report-on-form-6-k-our-actual-results-may-differ-materially-from-those-contained-i-sln-20210812monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-reports-half-year-2021-results-full-enrollment-achieved-for-four-coho-sln-20210812monthly0.5https://www.biopharmawatch.com/news/SLN/results-of-annual-general-meeting-15-june-2021-london-silence-therapeutics-plc-aim-sln-and-sln-20210615monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-to-present-data-highlighting-broad-therapeutic-potential-for-sln124-a-sln-20210607monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-receives-remaining-40-million-from-astrazeneca-as-part-of-upfront-inv-sln-20210525monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-positive-data-from-gemini-phase-1-study-of-sln124-in-health-sln-20210429monthly0.5https://www.biopharmawatch.com/news/SLN/notice-of-annual-general-meeting-7-may-2021-london-silence-therapeutics-plc-aim-sln-and-na-sln-20210507monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-announces-first-patient-dosed-in-gemini-ii-phase-i-clinical-trial-for-sln-20210429monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-achieves-another-research-milestone-payment-from-mallinckrodt-collabo-sln-20210428monthly0.5https://www.biopharmawatch.com/news/SLN/purchase-of-american-depositary-shares-and-pdmr-dealings-19-th-april-2021-london-silence-t-sln-20210419monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-reports-full-year-2020-results-advancing-clinical-programmes-on-track-sln-20210330monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-and-mallinckrodt-initiate-work-on-third-target-as-part-of-ongoing-rna-sln-20210226monthly0.5https://www.biopharmawatch.com/news/SLN/and-proteins-most-people-have-some-lp-a-in-their-body-but-about-1-in-5-people-have-high-le-sln-20210217monthly0.5https://www.biopharmawatch.com/news/SLN/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-made-an-sln-20210204monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-appoints-craig-tooman-as-chief-financial-officer-6-january-2021-londo-sln-20210106monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-presents-positive-pre-clinical-data-for-sln360-for-the-treatment-of-e-sln-20201116monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-appoints-dr-marie-wikstr-m-lindholm-to-its-executive-leadership-team--sln-20201102monthly0.5https://www.biopharmawatch.com/news/SLN/the-information-contained-within-this-announcement-is-deemed-by-the-company-to-constitute--sln-20201008monthly0.5https://www.biopharmawatch.com/news/SLN/the-information-contained-within-this-announcement-is-deemed-by-the-company-to-constitute--sln-20200914monthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-provides-research-and-development-update-ind-approval-received-for-sl-sln-20200908monthly0.5https://www.biopharmawatch.com/news/EDIT/document-editas-medicine-reports-new-safety-and-efficacy-data-from-the-ruby-trial-of-reni--edit-20240614monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2023-results-and-business-updates-edit-20240228monthly0.5https://www.biopharmawatch.com/news/EDIT/availability-and-timing-of-results-from-preclinical-studies-and-clinical-trials-whether-in-edit-20231213monthly0.5https://www.biopharmawatch.com/news/EDIT/president-and-chief-medical-officer-editas-medicine-i-would-like-to-thank-the-clinical-tri-edit-20231211monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2023-results-and-business-updates-edit-20231103monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2023-results-and-business-updates-on-track-to-dos-edit-20230802monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-offering-of-common-stock-edit-20230614monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-positive-initial-edit-301-safety-and-efficacy-data-from-the-firs-edit-20230609monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2023-results-and-business-updates-company-to-provi-edit-20230505monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2022-results-and-business-updates-c-edit-20230222monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-positive-safety-and-efficacy-data-from-the-first-two-patients-tr-edit-20221206monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-clinical-data-demonstrating-proof-of-concept-of-edit-101-from-ph-edit-20221117monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2022-results-and-business-updates-dosed-second-pat-edit-20221102monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2022-results-and-business-updates-appointed-baiso-edit-20220803monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2022-results-and-business-updates-appointed-gilmor-edit-20220504monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2021-results-and-business-updates-e-edit-20220224monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2021-results-and-business-updates-edit-101-phase-1-edit-20211108monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-positive-initial-clinical-data-from-ongoing-phase-1-2-brilliance-edit-20210929monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2021-results-and-business-updates-enrolling-first-edit-20210804monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2021-results-and-update-strengthening-leadership-b-edit-20210505monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2020-results-and-update-strengthene-edit-20210225monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-appointment-of-james-c-mullen-as-chief-executive-officer-cindy-c-edit-20210208monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-pricing-of-offering-of-common-stock-edit-20210120monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2020-results-and-update-edit-101-for-lca10-brillia-edit-20201105monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2020-results-and-update-regained-full-control-of--edit-20200806monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-offering-of-common-stock-edit-20200623monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2020-results-and-update-patient-dosing-initiated-i-edit-20200507monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2019-results-and-update-announcemen-edit-20200226monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2019-results-and-update-amended-celgene-collaborat-edit-20191112monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2019-results-and-update-cynthia-cindy-collins-nam-edit-20190806monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2019-results-and-update-building-on-focus-in-oncol-edit-20190507monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2018-results-and-update-edit-101-fo-edit-20190228monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-chief-executive-officer-transition-katrine-bosley-to-step-down-a-edit-20190122monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2018-results-and-update-filed-ind-application-for--edit-20181107monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2018-results-and-update-allergan-exercises-option-edit-20180806monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2018-results-and-update-expanded-celgene-collabora-edit-20180503monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2017-results-and-update-edit-101-fo-edit-20180306monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-inc-announces-offering-of-common-stock-edit-20171205monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2017-results-and-update-edit-20171107monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2017-results-and-update-leber-congenital-amaurosi-edit-20170809monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2017-results-and-update-entered-strategic-r-d-alli-edit-20170515monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-inc-announces-pricing-of-90-million-offering-of-common-stock-edit-20170316monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2016-results-and-update-edit-20170307monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2016-results-and-update-edit-20161107monthly0.5https://www.biopharmawatch.com/news/EDIT/sublease-amendment-no-1-this-sublease-amendment-no-1-this-x201c-amendment-x201d-is-made-as-edit-20160902monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2016-results-and-update-exclusive-license-to-high-edit-20160809monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2016-results-and-update-advancing-pipeline-and-pla-edit-20160516monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-fourth-quarter-and-full-year-2015-financial-results-well-positione-edit-20160330monthly0.5https://www.biopharmawatch.com/news/EDIT/hurley-street-cambridge-ma-editas-medicine-inc-lease-agreement-this-lease-agreement-is-mad-edit-20160219monthly0.5https://www.biopharmawatch.com/news/TRDA/meet-andrew-and-jj-living-with-duchenne-muscular-dystrophy-corporate-presentation-may-2026-trda-20260519monthly0.5https://www.biopharmawatch.com/news/TRDA/j-p-morgan-healthcare-conference-nasdaq-trda-disclaimer-this-presentation-has-been-prepare-trda-20250115monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-100-million-registered-direct-offering-the-offering-was-led-trda-20240624monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-positive-preliminary-data-in-healthy-volunteers-from-phase-1--trda-20240624monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-promotes-nathan-j-dowden-to-president-with-a-proven-track-record-at-e-trda-20240103monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-updates-on-entr-601-44-in-duchenne-muscular-dystrophy-compa-trda-20231122monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-appoints-gina-chapman-to-its-board-of-directors-boston-trda-20230810monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-receives-authorization-in-the-united-kingdom-to-initiate-phase-1-clin-trda-20230801monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-clinical-hold-on-ind-application-for-entr-601-44-in-duchenn-trda-20221219monthly0.5https://www.biopharmawatch.com/news/TRDA/vertex-and-entrada-therapeutics-establish-collaboration-to-discover-and-develop-endosomal--trda-20221208monthly0.5https://www.biopharmawatch.com/news/TRDA/document-entrada-therapeutics-reports-third-quarter-2022-financial-results-on-track-to-sub-trda-20221107monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-first-quarter-2022-financial-results-second-clinical-candidat-trda-20220512monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-on-track--trda-20220315monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-third-quarter-2021-financial-results-successful-completion-of-trda-20211209monthly0.5https://www.biopharmawatch.com/news/FATE/transforming-the-lives-of-patients-liv-ing-with-autoimmun-e-diseases-and-c-ancer-making-ce-fate-20260604monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2025-financial-results-and-business-updates-first-fate-20250812monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-matthew-abernethy-m-b-a-to-its-board-of-directors-san-diego-ca-fate-20250530monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2025-financial-results-and-business-updates-additi-fate-20250513monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-business-fate-20250305monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-leadership-transition-bob-valamehr-ph-d-mba-to-become-presiden-fate-20241129monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates-initia-fate-20241112monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2024-financial-results-and-business-updates-enrol-fate-20240813monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-neely-mozaffarian-md-phd-facr-to-its-board-of-directors-san-die-fate-20240731monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2024-financial-results-and-business-updates-first--fate-20240509monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-first-lupus-patient-treated-in-phase-1-autoimmunity-study-of-o-fate-20240509monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-pricing-of-100-million-underwritten-offering-and-concurrent-pr-fate-20240319monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-business-fate-20240226monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2023-financial-results-and-business-updates-phase--fate-20231108monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2023-financial-results-and-business-updates-phase-fate-20230808monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2023-financial-results-and-business-updates-dose-e-fate-20230503monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-business-fate-20230228monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-termination-of-collaboration-agreement-with-janssen-pipeline-p-fate-20230105monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-exercise-by-ono-pharmaceutical-of-option-to-her2-targeted-car--fate-20221107monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2022-financial-results-and-highlights-operational--fate-20221103monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2022-financial-results-and-highlights-operational-fate-20220803monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-expansion-of-solid-tumor-collaboration-with-ono-pharmaceutical-fate-20220628monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2022-financial-results-and-highlights-operational--fate-20220504monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-highligh-fate-20220228monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-highlights-positive-durability-of-response-data-from-ft516-phase-1-study-fate-20211213monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2021-financial-results-and-highlights-operational--fate-20211104monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-operational-fate-20210804monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-yuan-xu-to-its-board-of-directors-san-diego-ca-fate-20210804monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2021-financial-results-and-highlights-operational--fate-20210505monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-retirement-of-chief-scientific-officer-after-12-years-of-servi-fate-20210325monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-2020-financial-results-and-highlights-operational-fate-20210224monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-proposed-public-offering-of-350-million-of-common-stock-fate-20210104monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2020-financial-results-and-highlights-operational--fate-20201105monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-edward-dulac-as-chief-financial-officer-san-diego-ca-fate-20200819monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2020-financial-results-and-highlights-operational-fate-20200805monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-proposed-public-offering-of-common-stock-fate-20200608monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2020-financial-results-and-highlights-operational--fate-20200511monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-changes-to-its-board-of-directors-san-diego-ca-fate-20200505monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-worldwide-collaboration-with-janssen-for-novel-ipsc-derived-ce-fate-20200402monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-2019-financial-results-and-operational-progress-w-fate-20200302monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2019-financial-results-and-highlights-operational--fate-20191105monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-proposed-public-offering-of-common-stock-fate-20190911monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2019-financial-results-and-highlights-operational-fate-20190806monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-the-appointment-of-dr-shefali-agarwal-to-its-board-of-director-fate-20190717monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2019-financial-results-and-highlights-operational--fate-20190507monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-the-appointment-of-karin-jooss-ph-d-to-its-board-of-directors--fate-20190318monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-highligh-fate-20190305monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2018-financial-results-and-highlights-operational--fate-20181101monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-proposed-public-offering-of-common-stock-san-diego-ca-fate-20180920monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-strategic-collaboration-with-ono-pharmaceutical-to-develop-off-fate-20180917monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-enters-into-exclusive-license-agreement-with-gladstone-institutes-for-cr-fate-20180913monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2018-financial-results-and-highlights-operational-fate-20180806monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-and-memorial-sloan-kettering-cancer-center-expand-scope-of-license-agree-fate-20180516monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2018-financial-results-and-highlights-operational--fate-20180510monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-highligh-fate-20180305monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-proposed-public-offering-of-common-stock-san-diego-ca-fate-20171212monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2017-financial-results-clinical-data-from-first-su-fate-20171101monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2017-financial-results-first-subject-treated-with-fate-20170814monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2017-financial-results-protmune-protect-safety-dat-fate-20170515monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-2016-financial-results-first-subject-treated-with-fate-20170316monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-private-financing-san-diego-ca-fate-20161122monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2016-financial-results-ind-filed-for-fate-nk100-ad-fate-20161107monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-and-memorial-sloan-kettering-cancer-center-launch-partnership-for-develo-fate-20160907monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2016-financial-results-opened-patient-enrollment--fate-20160808monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-10-3-million-common-stock-private-placement-san-diego-ca-fate-20160808monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2016-financial-results-phase-1-2-clinical-trial-of-fate-20160509monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-protmune-inv-fate-20160303monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2015-financial-results-pluripotent-cell-platform-f-fate-20151103monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-leadership-transition-scott-wolchko-a-fate-founder-to-succeed--fate-20151013monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2015-financial-results-interim-data-from-prohema--fate-20150805monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-proposed-public-offering-of-common-stock-san-diego-ca-fate-20150518monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2015-financial-results-strategic-research-collabor-fate-20150507monthly0.5https://www.biopharmawatch.com/news/FATE/juno-therapeutics-and-fate-therapeutics-announce-strategic-research-collaboration-to-impro-fate-20150506monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-year-end-2014-financial-results-favorable-phase-2-interim-data-f-fate-20150312monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-interim-data-from-ongoing-phase-2-puma-study-of-prohema-in-adu-fate-20141218monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-moderator-scott-wolchko-fate-20141111monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2014-financial-results-phase-1b-prompt-study-in-pe-fate-20141111monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-second-quarter-2014-financial-results-first-data-review-in-phase-fate-20140812monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-first-quarter-2014-financial-results-phase-2-puma-study-of-prohe-fate-20140513monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-fourth-quarter-and-full-year-2013-financial-results-phase-2-puma-fate-20140317monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-dr-robert-s-epstein-to-its-board-of-directors-fate-20140317monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-third-quarter-2013-financial-results-cleared-key-milestones-for--fate-20131113monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-board-of-directors-appoints-former-senior-vice-president-of-clinical--avxl-20260506monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-bus-avxl-20251125monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-regulatory-update-on-blarcamesine-for-early-alzheimer-s-dise-avxl-20251114monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2024-second-quarter-financial-results-and-provides-bus-avxl-20240509monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-2-73-blarcamesine-phase-2b-3-study-met-primary-and-key-secondary-endpoints-showing--avxl-20221201monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-change-of-auditor-to-grant-thornton-avxl-20220304monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-supplemental-information-on-anavex-2-73-blarcamesine-avatar--avxl-20220204monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-uplisting-to-the-nasdaq-global-select-market-avxl-20210927monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-50-million-registered-direct-offering-avxl-20210622monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2020-year-end-financial-results-and-clinical-program-u-avxl-20201228monthly0.5https://www.biopharmawatch.com/news/AVXL/proof-of-concept-controlled-phase-2-clinical-trial-data-evaluating-anavex-2-73-blarcamesin-avxl-20201106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-positive-results-from-proof-of-concept-controlled-phase-2-c-avxl-20201015monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-strengthens-management-team-and-board-of-directors-company-appoints-s-avxl-20180305monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-strengthens-board-of-directors-avxl-20170213monthly0.5https://www.biopharmawatch.com/news/AVXL/christopher-u-missling-ms-phd-mba-president-and-ceo-of-anavex-life-sciences-corp-dr-missli-avxl-20161021monthly0.5https://www.biopharmawatch.com/news/AVXL/jfif-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2016-06-23-21-55-09-4-avxl-20160623monthly0.5https://www.biopharmawatch.com/news/AVXL/jfif-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2016-05-06-18-58-50-4-avxl-20160506monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-prepares-for-uplisting-to-nasdaq-announces-reverse-stock--avxl-20151006monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-avxl-20150915monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-avxl-20150715monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-life-sciences-corp-consolidated-balance-sheets-assets-may-avxl-20150529monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-upgrades-to-otcqx-marketplace-new-york-ny-december-xx-201-avxl-20141212monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-appoints-senior-healthcare-and-pharmaceutical-executives--avxl-20140508monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-announces-10-million-private-placement-of-convertible-deb-avxl-20140313monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-safe-harbor-this-presentation-contains-forward-looking-statement-avxl-20131112monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-raises-2-6-million-in-private-placement-and-conversion-of-avxl-20130708monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-appoints-tom-skarpelos-as-director-vancouver-bc-avxl-20130109monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-appoints-robert-chisholm-as-cfo-vancouver-bc-avxl-20120626monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-announces-director-resignation-palo-alto-ca-avxl-20120327monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-closes-private-placement-portola-valley-ca-avxl-20120210monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-closes-private-placement-hoboken-nj-avxl-20111207monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-successfully-completes-a-phase-1-clinical-trial-for-anave-avxl-20111114monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-resignation-of-director-hoboken-nj-october-21-2011-anavex-life-sciences-c-avxl-20111021monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-appoints-dr-george-tidmarsh-as-executive-director-hoboken-avxl-20111012monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-announces-director-resignation-hoboken-nj-avxl-20110916monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-rapidly-advances-anavex-2-73-for-alzheimer-s-disease-phas-avxl-20110803monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-appoints-robert-chisholm-to-board-of-directors-hoboken-nj-avxl-20110513monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-arranges-for-convertible-debenture-hoboken-nj-may-9-2011-anavex-life-sciences-corp--avxl-20110420monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-arranges-for-convertible-debenture-hoboken-nj-avxl-20110506monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-first-in-human-dosing-commenced-in-anavex-2-73-clinical-t-avxl-20110420monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-appoints-dr-christopher-shackleton-as-an-advisor-hoboken--avxl-20110413monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-receives-approval-to-commence-phase-i-clinical-trial-in-a-avxl-20110315monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-appoints-dr-jeffrey-cummings-to-its-scientific-advisory-b-avxl-20110301monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-dr-rachelle-doody-to-scientific-advisory-board-hoboken-nj-february-23-2011-avxl-20110228monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-adds-dr-paul-aisen-to-scientific-advisory-board-hoboken-n-avxl-20110216monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-life-sciences-corp-amended-and-restated-2007-stock-option-avxl-20110208monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-strengthens-management-team-with-addition-of-vp-clinical-development-medical-affair-avxl-20110207monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-announces-private-placement-hoboken-new-jersey-avxl-20101130monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-insider-trading-policy-and-guidelines-with-respect-to-certain-tr-avxl-20100927monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-appoints-contract-research-organizations-to-initiate-phas-avxl-20100810monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-announces-results-of-annual-meeting-athens-greece-avxl-20100504monthly0.5https://www.biopharmawatch.com/news/AVXL/filed-by-newsfilecorp-com-anavex-provides-corporate-updates-athens-greece-avxl-20100409monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-a-consulting-agreement-and-closes-a-private-placement-athens-greece-avxl-20091124monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-closes-2-private-placements-for-290-000-u-s-2009-08-11-16-31-et-news-release-an-ano-avxl-20090811monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-convertible-loan-agreements-and-private-placement-athens-greece-avxl-20090626monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-dr-herv-de-kergrohen-as-ceo-to-lead-company-through-clinical-trials-and-fu-avxl-20090616monthly0.5https://www.biopharmawatch.com/news/AVXL/source-anavex-life-sciences-corp-anavex-further-strengthens-board-of-directors-tuesday-jun-avxl-20080605monthly0.5https://www.biopharmawatch.com/news/AVXL/source-anavex-life-sciences-corp-anavex-announces-appointment-of-oncology-specialist-to-bo-avxl-20080521monthly0.5https://www.biopharmawatch.com/news/AVXL/dated-december-17-2007-avxl-20071217monthly0.5https://www.biopharmawatch.com/news/AVXL/stock-option-plan-anavex-life-sciences-corp-2007-stock-option-plan-this-2007-stock-option--avxl-20070928monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corp-announces-its-preclinical-pipeline-of-novel-oncology-therapies-avxl-20070212monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corp-appoints-vp-business-development-and-vp-strategic-planning-ticke-avxl-20070209monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corp-ticker-symbol-avxl-british-columbia-canada-avxl-20070131monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corp-appointment-of-ceo-and-director-ticker-symbol-u-avxl-british-col-avxl-20070201monthly0.5https://www.biopharmawatch.com/news/AVXL/articles-of-merger-f-converted-by-s-created-by-bcl-technologies-inc-for-sec-filing-avxl-20070125monthly0.5https://www.biopharmawatch.com/news/AVXL/certificate-of-change-dean-heller-secretary-of-state-204-north-carson-street-suite-1-carso-avxl-20060609monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-ltd-amended-and-restated-articles-of-association-effective-as-of-janu-slgl-20180206monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-first-quarter-2026-results-washington-evh-20260507monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-fourth-quarter-2025-results-and-full-year-2025-results-washington-evh-20260224monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-third-quarter-2025-results-q3-2025-financial-results-ahead-of-expectatio-evh-20251106monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-strategic-divestiture-of-its-value-based-primary-care-business-evolent-c-evh-20250923monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-announces-pricing-of-oversubscribed-and-upsized-145-0-million-of-conver-evh-20250819monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-announces-proposed-offering-of-140-0-million-of-convertible-senior-note-evh-20250818monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-second-quarter-2025-results-washington-evh-20250807monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-reiterates-q2-and-full-year-guidance-for-adjusted-ebitda-notes-accelerating-2026-r-evh-20250620monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-first-quarter-2025-results-washington-evh-20250508monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-names-shawn-guertin-as-new-independent-nominee-for-election-to-its-board-of-direct-evh-20250422monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-fourth-quarter-and-full-year-2024-results-revenue-of-646-5-million-for-t-evh-20250220monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-changes-to-board-of-directors-richard-rick-jelinek-to-be-named-ch-evh-20250204monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-third-quarter-2024-results-revenue-of-621-4-million-an-increase-of-110-4-evh-20241107monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-second-quarter-2024-results-revenue-of-647-1-million-an-increase-of-178--evh-20240808monthly0.5https://www.biopharmawatch.com/news/EVH/document-evolent-signs-agreement-to-acquire-artificial-intelligence-utilization-management-evh-20240604monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-first-quarter-2024-results-revenue-of-639-7-million-an-increase-of-212-0-evh-20240509monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-consolidated-statements-of-operations-and-comprehensive-income-loss-una-evh-20240222monthly0.5https://www.biopharmawatch.com/news/EVH/document-evolent-adds-russell-glass-headspace-ceo-to-board-of-directors-washington-evh-20240214monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-announces-pricing-of-350-0-million-of-convertible-senior-notes-due-2029-evh-20231205monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-announces-proposed-offering-of-350-0-million-of-convertible-senior-note-evh-20231205monthly0.5https://www.biopharmawatch.com/news/EVH/combined-financial-statements-magellan-specialty-health-a-business-of-magellan-health-inc-evh-20231103monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-third-quarter-2023-results-washington-evh-20231102monthly0.5https://www.biopharmawatch.com/news/EVH/combined-financial-statements-magellan-specialty-health-a-business-of-magellan-health-inc-evh-20230926monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-announces-second-quarter-2023-results-washington-evh-20230802monthly0.5https://www.biopharmawatch.com/news/EVH/1-95b-2023-revenue-outlook-at-midpoint-39-1-revenue-cagr-q4-2019-q1-2023-190m1-2023-adjust-evh-20230523monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-first-quarter-2023-results-washington-evh-20230503monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-names-new-independent-nominee-for-election-to-board-of-directors-richard-je-evh-20230419monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-fourth-quarter-and-full-year-2022-results-washington-evh-20230222monthly0.5https://www.biopharmawatch.com/news/EVH/combined-financial-statements-magellan-specialty-health-a-business-of-magellan-health-inc-evh-20230123monthly0.5https://www.biopharmawatch.com/news/EVH/safe-harbor-statement-certain-statements-including-but-not-limited-to-estimates-of-adjuste-evh-20230111monthly0.5https://www.biopharmawatch.com/news/EVH/safe-harbor-statement-certain-statements-including-but-not-limited-to-estimates-of-adjuste-evh-20221117monthly0.5https://www.biopharmawatch.com/news/EVH/safe-harbor-statement-certain-statements-made-in-this-presentation-and-in-other-written-or-evh-20221110monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-third-quarter-2022-results-washington-evh-20221102monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-second-quarter-2022-results-announces-four-operating-partner-addi-evh-20220802monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-to-acquire-ipg-expected-to-accelerate-evolent-health-s-position-as-a-leadin-evh-20220629monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-first-quarter-2022-results-announces-two-operating-partner-additi-evh-20220504monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-fourth-quarter-and-full-year-2021-results-announces-four-new-part-evh-20220223monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-third-quarter-2021-results-washington-d-c-evh-20211103monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-agreement-to-acquire-vital-decisions-expanding-its-depth-and-brea-evh-20210804monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-first-quarter-2021-results-washington-d-c-evh-20210505monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-fourth-quarter-and-full-year-2020-results-washington-d-c-evh-20210225monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-enters-agreement-with-bright-healthcare-for-bright-healthcare-to-acquire-tr-evh-20210113monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-cooperation-agreement-with-engaged-capital-appoints-new-independe-evh-20201222monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-third-quarter-2020-results-washington-d-c-evh-20201105monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-second-quarter-2020-results-washington-d-c-evh-20200804monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-first-quarter-2020-results-washington-d-c-evh-20200507monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-fourth-quarter-and-full-year-2019-results-washington-d-c-evh-20200225monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-third-quarter-2019-results-washington-d-c-evh-20191105monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-second-quarter-2019-results-washington-d-c-evh-20190806monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-expands-partnership-with-passport-health-plan-to-support-medicaid-beneficia-evh-20190529monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-first-quarter-2019-results-washington-d-c-evh-20190507monthly0.5https://www.biopharmawatch.com/news/EVH/exhibit-evolent-health-globalhealth-and-kinderhook-industries-launch-true-health-to-suppor-evh-20190328monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-fourth-quarter-and-full-year-2018-results-evh-20190226monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-third-quarter-2018-results-washington-d-c-evh-20181106monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-announces-exercise-of-option-to-purchase-additional-convertible-senior--evh-20181023monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-evh-20181017monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-evh-20181016monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-completes-acquisition-of-new-century-health-washington-d-c-evh-20181002monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-to-acquire-new-century-health-expanding-its-specialty-care-management-capab-evh-20180912monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-second-quarter-2018-results-washington-d-c-evh-20180807monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-first-quarter-2018-results-evh-20180509monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-fourth-quarter-and-full-year-2017-results-evh-20180227monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-overview-january-2018-safe-harbor-statement-certain-statements-in-this-pres-evh-20180110monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-completes-acquisition-of-assets-from-new-mexico-health-connections-evh-20180102monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-and-premier-health-announce-termination-of-agreement-evh-20171208monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-third-quarter-2017-results-evh-20171102monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-proposed-expansion-of-relationships-in-illinois-and-new-mexico-wa-evh-20170927monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-second-quarter-2017-results-evh-20170807monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-first-quarter-2017-results-evh-20170509monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-fourth-quarter-and-full-year-2016-results-evh-20170228monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-evh-20161129monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-third-quarter-2016-results-evh-20161109monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-completes-acquisition-of-valence-health-evh-20161003monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-second-quarter-2016-results-evh-20160804monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-to-acquire-valence-health-extending-breadth-and-depth-evh-20160713monthly0.5https://www.biopharmawatch.com/news/EVH/sec-exhibit-evolent-health-announces-first-quarter-2016-results-washington-dc-evh-20160512monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-fourth-quarter-and-full-year-2015-results-evh-20160225monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-announces-third-quarter-2015-results-evh-20151105monthly0.5https://www.biopharmawatch.com/news/EVH/exhibit-evolent-health-elects-cheryl-scott-to-board-of-directors-washington-d-c-evh-20151103monthly0.5https://www.biopharmawatch.com/news/EVH/exhibit-evolent-health-elects-kenneth-a-samet-to-board-of-directors-washington-d-c-evh-20150902monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-800-north-glebe-road-500-arlington-virginia-22203-evolent-health-announ-evh-20150806monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-announces-closing-of-initial-public-offering-washington-d-c-evh-20150610monthly0.5https://www.biopharmawatch.com/news/EVH/evolent-health-inc-announces-pricing-of-initial-public-offering-washington-d-c-evh-20150604monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-2023-stock-incentive-plan-as-amended-by-amendment-no-1-1-purpose-t-akba-20250613monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-pricing-of-public-offering-of-common-stock-akba-20250319monthly0.5https://www.biopharmawatch.com/news/AKBA/presentation-unlocking-the-power-of-the-hypoxia-inducible-factor-hif-pathway-delivering-in-akba-20240108monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-receives-fda-acceptance-of-resubmission-to-nda-of-vadadustat-for-the-treatment-of-a-akba-20231025monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-announces-approval-of-vafseo-vadadustat-in-australia-and-provides-commercial-update-akba-20230926monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-high-akba-20230825monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-report-second-quarter-financial-results-by-akba-20230817monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-provides-update-on-form-10-q-filing-akebia-announces-late-filing-of-it-akba-20230811monthly0.5https://www.biopharmawatch.com/news/AKBA/document-akebia-therapeutics-completed-type-a-meeting-with-the-fda-and-expects-to-resubmit-akba-20230718monthly0.5https://www.biopharmawatch.com/news/AKBA/statements-in-this-presentation-regarding-akebia-therapeutics-inc-s-akebia-s-strategy-plan-akba-20230607monthly0.5https://www.biopharmawatch.com/news/AKBA/fda-provides-akebia-therapeutics-a-path-forward-for-vadadustat-fda-denies-formal-dispute-r-akba-20230530monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-enters-into-license-agreement-with-medice-arzneimittel-p-tter-gmbh-co--akba-20230525monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-akba-20230522monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-first-quarter-2023-financial-results-and-recent-business-highl-akba-20230508monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-akba-20230309monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-received-interim-response-from-the-fda-to-appeal-for-vadadustat-for-th-akba-20230221monthly0.5https://www.biopharmawatch.com/news/AKBA/statements-in-this-presentation-regarding-akebia-therapeutics-inc-s-akebia-s-strategy-plan-akba-20230109monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-third-quarter-2022-financial-results-and-recent-business-highl-akba-20221103monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-second-quarter-2022-financial-results-and-recent-business-high-akba-20220804monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-first-quarter-2022-financial-results-and-business-update-net-a-akba-20220509monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-receives-complete-response-letter-from-the-fda-for-vadadustat-for-the--akba-20220330monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-akba-20220301monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-amendment-of-license-agreement-with-vifor-pharma-in-preparat-akba-20220222monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-third-quarter-2021-financial-results-and-highlights-recent-com-akba-20211104monthly0.5https://www.biopharmawatch.com/news/AKBA/cautionary-note-on-forward-looking-statements-statements-in-this-presentation-regarding-ak-akba-20210909monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-recent-co-akba-20210805monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-and-otsuka-announce-fda-acceptance-for-filing-of-new-drug-application-for-vadadusta-akba-20210601monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-reports-first-quarter-2021-financial-results-and-highlights-recent-company-mileston-akba-20210510monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-submits-new-drug-application-nda-to-the-fda-for-vadadustat-for-the-treatment-of-ane-akba-20210330monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-u-akba-20210225monthly0.5https://www.biopharmawatch.com/news/AKBA/statements-in-this-presentation-regarding-akebia-s-strategy-plans-prospects-populations-th-akba-20210112monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-reports-third-quarter-2020-financial-results-and-recent-business-updates-presented--akba-20201105monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-top-line-results-from-its-pro-2-tect-global-phase-3-program--akba-20200903monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-reports-second-quarter-2020-financial-results-top-line-data-readout-of-global-phase-akba-20200810monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-announced-positive-top-line-results-from-global-phase-3-program-of-vadadustat-for-t-akba-20200505monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-hosts--akba-20200310monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-secures-100-million-non-dilutive-term-loan-financing-reports-third-quarter-2019-fin-akba-20191112monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-second-quarter-2019-financial-results-and-hosts-conference-cal-akba-20190808monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-dedicated-to-advancing-care-for-patients-with-kidney-disease-cautionar-akba-20190604monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-first-quarter-2019-financial-results-announces-full-enrollment-akba-20190509monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-preliminary-full-year-2018-financial-results-and-business-hi-akba-20190318monthly0.5https://www.biopharmawatch.com/news/AKBA/statements-in-this-presentation-regarding-akebia-s-strategy-plans-prospects-expectations-b-akba-20190107monthly0.5https://www.biopharmawatch.com/news/AKBA/voting-agreement-this-voting-agreement-this-agreement-is-made-and-entered-into-as-of-akba-20180628monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-names-rita-jain-m-d-as-chief-medical-officer-akba-20170525monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-and-vifor-pharma-announce-exclusive-license-agreement-to-provide-vadadustat-to-fres-akba-20170515monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-and-otsuka-expand-relationship-with-collaboration-to-develop-and-commercialize-vada-akba-20170425monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-appoints-scott-a-canute-to-its-board-of-directors-akba-20160802monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-245-first-street-suite-1100-cambridge-ma-02142-t-1-617-871-2098-f--akba-20160309monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-initiates-phase-3-pro-2-tect-program-achieved-all-corporate-objectives-for-2015-cam-akba-20160104monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-245-first-street-suite-1100-cambridge-ma-02142-t-1-617-871-2098-f--akba-20151006monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-245-first-street-suite-1100-cambridge-ma-02142-t-1-617-871-2098-f--akba-20150908monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-245-first-street-suite-1100-cambridge-ma-02142-t-1-617-871-2098-f--akba-20150811monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-announces-positive-top-line-results-from-its-phase-2b-study-of-akb-6548-in-non-dial-akba-20141027monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-245-first-street-suite-1100-cambridge-ma-02142-t-1-617-871-2098-f--akba-20140915monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-245-first-street-suite-1100-cambridge-ma-02142-t-1-617-871-2098-f--akba-20140806monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-245-first-street-suite-1100-cambridge-ma-02142-t-1-617-871-2098-f--akba-20140717monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-closing-of-private-placement-toronto-prof-20251230monthly0.5https://www.biopharmawatch.com/news/PROF/establishing-tulsa-pro-as-the-mainstream-treatment-option-for-personalized-prostate-ablati-prof-20250429monthly0.5https://www.biopharmawatch.com/news/PROF/form-51-102f3-material-change-report-1-name-and-address-of-company-profound-medical-corp-p-prof-20241206monthly0.5https://www.biopharmawatch.com/news/PROF/execution-version-profound-medical-corp-4-666-700-common-shares-prof-20241206monthly0.5https://www.biopharmawatch.com/news/PROF/bay-street-south-tower-suite-2800-toronto-on-647-499-2828-mintz-com-prof-20241205monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-third-quarter-2024-financial-results-prof-20241107monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-second-quarter-2024-financial-results-prof-20240808monthly0.5https://www.biopharmawatch.com/news/PROF/form-51-102f3-material-change-report-1-name-and-address-of-company-profound-medical-corp-p-prof-20231227monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-pricing-of-us-20-million-public-offering-of-common-shares-toron-prof-20231227monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-proposed-public-offering-of-common-shares-toronto-on-prof-20231227monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-at-the-market-offering-of-up-to-us-30-000-000-toronto-on-prof-20230906monthly0.5https://www.biopharmawatch.com/news/PROF/execution-copy-information-in-this-exhibit-identified-by-is-confidential-and-has-been-excl-prof-20230501monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-notice-of-annual-and-special-meeting-of-shareholders-to-be-held-on-m-prof-20220518monthly0.5https://www.biopharmawatch.com/news/PROF/form-51-102f3-material-change-report-1-name-and-address-of-company-profound-medical-corp-p-prof-20200721monthly0.5https://www.biopharmawatch.com/news/PROF/execution-version-profound-medical-corp-2-758-621-common-shares-prof-20200715monthly0.5https://www.biopharmawatch.com/news/PROF/nasdaq-prof-tsx-prn-corporate-presentation-prof-20200715monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-quarter-2020-financial-results-prof-20200507monthly0.5https://www.biopharmawatch.com/news/PROF/form-51-102f3-material-change-report-1-name-and-address-of-company-profound-medical-corp-p-prof-20200122monthly0.5https://www.biopharmawatch.com/news/PROF/execution-version-profound-medical-corp-2-950-000-common-shares-prof-20200122monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-third-quarter-2019-financial-results-prof-20191107monthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-2025-fourth-qu-carl-20260112monthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-reports-third-quarter-2025-financial-results-and-raises-full-year-guidance-third--carl-20251106monthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-reports-second-quarter-2025-financial-results-q2-25-revenue-of-12-1-million-99-yo-carl-20250828monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-third-quarter-2025-corporate-update-conference-call-12-november-2025-c-o--obio-20251113monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-corporate-overview-october-2025-nasdaq-obio-forward-looking-statements-th-obio-20251030monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-proposed-public-offering-obio-20250731monthly0.5https://www.biopharmawatch.com/news/OBIO/ligand-and-medtronic-commit-70-million-in-strategic-capital-to-orchestra-biomed-ligand-to--obio-20250731monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-receives-fda-breakthrough-device-designation-for-avim-therapy-breakthroug-obio-20250422monthly0.5https://www.biopharmawatch.com/news/OBIO/k-d-w-y-w-y-forward-looking-statements-this-presentation-has-been-prepared-for-information-obio-20250303monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-appointment-of-former-medtronic-svp-of-corporate-development-ch-obio-20250205monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-appointment-of-cardiovascular-device-industry-expert-john-mack--obio-20240730monthly0.5https://www.biopharmawatch.com/news/OBIO/cardiology-htn-co-principal-investigators-steering-committee-members-joann-lindenfeld-adva-obio-20240611monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-corporate-presentation-q1-2024-corporate-presentation-q1-2024-2-this-pres-obio-20240307monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-corporate-presentation-q4-2023-corporate-presentation-q4-2023-2-this-pres-obio-20231114monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-corporate-presentation-q4-2023-corporate-presentation-q4-2023-2-forward-l-obio-20231010monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-granted-fda-approval-of-ide-to-initiate-backbeat-pivotal-study-of-backbea-obio-20230919monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-corporate-presentation-q3-2023-2-corporate-presentation-q2-2023-forward-l-obio-20230713monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-corporate-presentation-q2-2023-corporate-presentation-q2-2023-2-forward-l-obio-20230712monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-appoints-bill-little-as-executive-vice-president-of-corporate-development-obio-20230607monthly0.5https://www.biopharmawatch.com/news/OBIO/bringing-medical-inn-vation-to-life-bringing-medical-inn-vation-to-life-orchestra-biomed-c-obio-20230608monthly0.5https://www.biopharmawatch.com/news/OBIO/index-to-consolidated-financial-statements-financial-statements-for-orchestra-biomed-inc-a-obio-20230324monthly0.5https://www.biopharmawatch.com/news/OBIO/bringing-medical-inn-vation-to-life-orchestra-biomed-corporate-presentation-q1-2023-forwar-obio-20230313monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-debuts-as-nasdaq-traded-company-with-lead-programs-targeting-hypertension-obio-20230126monthly0.5https://www.biopharmawatch.com/news/OBIO/bringing-medical-inn-vation-to-life-orchestra-biomed-corporate-presentation-july-2022-impo-obio-20220705monthly0.5https://www.biopharmawatch.com/news/OBIO/health-sciences-acquisitions-corporation-2-report-of-independent-registered-public-account-obio-20200806monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-fhtx-20260421monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-financial-update-for-2025-and-2026-strategic-outlook-fhd-909-fhtx-20260311monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-highlights-january-equity-financing-program-progress-and-strategic-ob-fhtx-20260113monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-second-quarter-2025-financial-and-corporate-update-fhd-909-l-fhtx-20250805monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2025-financial-and-corporate-update-fhd-909-ly-fhtx-20250514monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-on-selective-smarca2-inhibitor-fhd-909--fhtx-20250429monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-financial-update-for-2024-and-2025-strategic-outlook-first-i-fhtx-20250306monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-highlights-program-progress-and-strategic-objectives-for-2025-first-i-fhtx-20250113monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-update-on-fhd-286-clinical-development-program-and-strategic-fhtx-20241216monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-third-qu-arter-2024-financial-and-corporate-update-first-pat-fhtx-20241104monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-second-qu-arter-2024-financial-and-corporate-update-topline--fhtx-20240808monthly0.5https://www.biopharmawatch.com/news/FHTX/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-that-ar-fhtx-20240523monthly0.5https://www.biopharmawatch.com/news/FHTX/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-that-ar-fhtx-20240506monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-first-qu-arter-2024-financial-and-corporate-update-dose-esca-fhtx-20240506monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-strengthens-financial-leadership-with-appointment-of-kristian-humer-a-fhtx-20240416monthly0.5https://www.biopharmawatch.com/news/FHTX/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-all-sta-fhtx-20240409monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-financial-update-for-2023-and-2024-strategic-outlook-dose-es-fhtx-20240307monthly0.5https://www.biopharmawatch.com/news/FHTX/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-all-sta-fhtx-20240208monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-highlights-clinical-program-updates-and-research-progress-and-provide-fhtx-20240108monthly0.5https://www.biopharmawatch.com/news/FHTX/hans-vitzthum-lifesci-advisors-investors-hans-lifesciadvisors-com-fhtx-20240103monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-third-quarter-2023-financial-and-corporate-update-first-pati-fhtx-20231102monthly0.5https://www.biopharmawatch.com/news/FHTX/document-foghorn-therapeutics-announces-first-patient-dosed-in-phase-1-combination-study-o-fhtx-20230831monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-chief-medical-officer-succession-cambridge-mass-globe-newsw-fhtx-20230808monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-second-quarter-2023-financial-and-corporate-update-initiatin-fhtx-20230804monthly0.5https://www.biopharmawatch.com/news/FHTX/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-all-sta-fhtx-20230628monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2023-financial-and-corporate-update-data-from--fhtx-20230508monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-an-update-on-fhd-609-cambridge-mass-globe-newswire-fhtx-20230424monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-highlights-recent-clinical-and-research-progress-and-provides-strateg-fhtx-20230109monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-third-quarter-2022-financial-and-corporate-update-fhd-286-ph-fhtx-20221108monthly0.5https://www.biopharmawatch.com/news/FHTX/document-foghorn-therapeutics-announces-change-to-board-of-directors-foghorn-congratulates-fhtx-20220831monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-further-update-on-fhd-286-phase-i-study-in-relapsed-refracto-fhtx-20220823monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-second-quarter-2022-financial-and-corporate-update-fhtx-20220809monthly0.5https://www.biopharmawatch.com/news/FHTX/this-presentation-contains-forward-looking-statements-all-statements-other-than-statements-fhtx-20220519monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2022-corporate-update-foghorn-continues-to-adv-fhtx-20220509monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-full-year-2021-corporate-update-and-2022-outlook-initial-cli-fhtx-20220310monthly0.5https://www.biopharmawatch.com/news/FHTX/lilly-and-foghorn-announce-strategic-collaboration-for-novel-oncology-targets-using-foghor-fhtx-20211213monthly0.5https://www.biopharmawatch.com/news/FHTX/document-foghorn-therapeutics-provides-third-quarter-2021-corporate-update-first-patient-d-fhtx-20211109monthly0.5https://www.biopharmawatch.com/news/FHTX/document-exhibit-10-1-second-amendment-to-loan-and-security-agreement-this-second-amendmen-fhtx-20210830monthly0.5https://www.biopharmawatch.com/news/FHTX/document-foghorn-therapeutics-announces-first-patient-dosed-in-first-in-human-clinical-tri-fhtx-20210823monthly0.5https://www.biopharmawatch.com/news/FHTX/document-foghorn-therapeutics-provides-second-quarter-2021-corporate-update-first-patients-fhtx-20210810monthly0.5https://www.biopharmawatch.com/news/FHTX/july2021foghorninv-targeting-the-chromatin-regulatory-system-broadening-the-impact-of-prec-fhtx-20210714monthly0.5https://www.biopharmawatch.com/news/FHTX/finv2-9-00-9-10-a-m-9-10-9-25-a-m-9-25-9-45-a-m-9-45-10-05-a-m-10-05-10-20-a-m-10-20-10-30-fhtx-20210615monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-corporate-update-fhd-286-phase-1-data-anticipated-as-early-a-fhtx-20210318monthly0.5https://www.biopharmawatch.com/news/FHTX/targeting-the-chromatin-regulatory-system-a-product-platform-with-potential-to-impact-mill-fhtx-20210216monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-third-quarter-2020-financial-results-and-provides-corporate-fhtx-20201204monthly0.5https://www.biopharmawatch.com/news/CNTN/canton-strategic-holdings-inc-announces-authorization-of-share-repurchase-program-cntn-20260616monthly0.5https://www.biopharmawatch.com/news/CNTN/canton-strategic-holdings-reports-full-year-2025-financial-and-operational-results-first-a-cntn-20260331monthly0.5https://www.biopharmawatch.com/news/CNTN/canton-strategic-holdings-inc-chairman-and-ceo-mark-wendland-elected-to-canton-foundation--cntn-20260303monthly0.5https://www.biopharmawatch.com/news/CNTN/confidential-draft-tharimmune-inc-announces-corporate-rebrand-to-canton-strategic-holdings-cntn-20260218monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-inc-appoints-mark-wendland-chairman-of-the-board-and-names-angela-radkowski-chi-cntn-20260206monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-elects-jill-sommers-and-william-wiley-to-board-of-directors-new-directors-stren-cntn-20260202monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-announces-expanded-role-as-super-validator-on-canton-network-advances-digital-a-cntn-20260126monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-inc-announces-closing-of-55-million-underwritten-registered-direct-offering-cntn-20260122monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-inc-announces-pricing-of-55-million-underwritten-registered-offering-cntn-20260120monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-inc-appoints-jacob-asbury-as-chief-financial-officer-to-advance-canton-coin-tre-cntn-20251212monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-inc-closes-545-million-private-placement-to-establish-canton-coin-treasury-stra-cntn-20251106monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-inc-announces-private-placement-of-approximately-540-million-led-by-drw-and-lib-cntn-20251103monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-cntn-20250831monthly0.5https://www.biopharmawatch.com/news/CNTN/nancy-davis-visionary-philanthropist-and-founder-of-race-to-erase-ms-and-cure-addiction-no-cntn-20250805monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-announces-pricing-of-1-74-million-registered-direct-public-offering-of-common-s-cntn-20250723monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-announces-2-02-million-private-placement-to-advance-development-programs-bridge-cntn-20241206monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-acquires-global-license-and-partners-with-intract-pharma-to-develop-an-oral-for-cntn-20240916monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-announces-2-08-million-private-placement-bridgewater-n-j-accesswire-cntn-20240620monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-announces-1-for-15-reverse-stock-split-bridgewater-n-j-cntn-20240522monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-reports-positive-phase-1-data-on-th104-its-lead-therapeutic-candidate-for-chron-cntn-20231127monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-announces-1-for-25-reverse-stock-split-bridgewater-n-j-cntn-20231117monthly0.5https://www.biopharmawatch.com/news/CNTN/tharimmune-executes-exclusive-global-licensing-agreement-for-innovative-clinical-stage-ass-cntn-20231106monthly0.5https://www.biopharmawatch.com/news/CNTN/hillstream-biopharma-progressing-towards-acquiring-clinical-stage-asset-and-announces-corp-cntn-20230925monthly0.5https://www.biopharmawatch.com/news/CNTN/hillstream-biopharma-strengthens-its-board-of-directors-with-appointment-of-kelly-anderson-cntn-20230515monthly0.5https://www.biopharmawatch.com/news/CNTN/hillstream-biopharma-announces-proposed-public-offering-bridgewater-n-j-cntn-20230427monthly0.5https://www.biopharmawatch.com/news/CAMP/document-camp4-therapeutics-to-present-new-preclinical-data-demonstrating-cmp-002-improves-camp-20260514monthly0.5https://www.biopharmawatch.com/news/CAMP/document-camp4-reports-full-year-2025-financial-results-and-corporate-highlights-glp-toxic-camp-20260305monthly0.5https://www.biopharmawatch.com/news/CAMP/january2026co-camp-20260109monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-and-gsk-enter-strategic-collaboration-to-advance-rna-based-therapeutic-discoveries-c-camp-20251218monthly0.5https://www.biopharmawatch.com/news/CAMP/document-camp4-presents-translational-data-from-syngap1-related-disorders-program-showcasi-camp-20250516monthly0.5https://www.biopharmawatch.com/news/CAMP/document-camp4-reports-first-quarter-2025-financial-results-and-corporate-highlights-phase-camp-20250513monthly0.5https://www.biopharmawatch.com/news/CAMP/document-camp4-reports-full-year-2024-financial-results-and-provides-corporate-update-phas-camp-20250327monthly0.5https://www.biopharmawatch.com/news/CAMP/pioneering-a-new-class-of-rna-medicines-to-increase-targeted-gene-expression-corporate-ove-camp-20250107monthly0.5